PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Puppa, G; Arnoux, G; Sari, A; Kirsch, R				Puppa, Giacomo; Arnoux, Gregoire; Sari, Aysegul; Kirsch, Richard			Venous invasion detection in colorectal cancer specimens: risk assessment of modifying the dissection method using a tangential approach	JOURNAL OF CLINICAL PATHOLOGY			English	Letter							PROGNOSTIC-SIGNIFICANCE; CARCINOMA; SYSTEM; IMPACT; DEPTH		[Puppa, Giacomo; Arnoux, Gregoire] Geneva Univ Hosp, Dept Clin Pathol, CH-1211 Geneva, Switzerland; [Sari, Aysegul; Kirsch, Richard] Univ Toronto, Dept Pathol & Lab Med, Mt Sinai Hosp, Toronto, ON, Canada	Puppa, G (reprint author), Geneva Univ Hosp, Dept Clin Pathol, CH-1211 Geneva, Switzerland.	Giacomo.Puppa@hcuge.ch					Dawson H, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00354; Dirschmid K, 1996, HUM PATHOL, V27, P1227, DOI 10.1016/S0046-8177(96)90319-6; Dirschmid K, 2017, J CLIN PATHOL, V70, P551, DOI 10.1136/jclinpath-2017-204319; Dirschmid K, 2012, J CLIN PATHOL, V65, P619, DOI 10.1136/jclinpath-2011-200552; Kirsch R, 2017, HUM PATHOL, V67, P45, DOI 10.1016/j.humpath.2017.07.004; Kirsch R, 2013, AM J SURG PATHOL, V37, P200, DOI 10.1097/PAS.0b013e31826a92cd; Koukourakis MI, 2005, CLIN CANCER RES, V11, P8653, DOI 10.1158/1078-0432.CCR-05-1464; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Maughan NJ, 2007, BRIT J CANCER, V97, P1393, DOI 10.1038/sj.bjc.6604036; Messenger DE, 2012, HUM PATHOL, V43, P965, DOI 10.1016/j.humpath.2011.11.015; Roxburgh CSD, 2014, ANN SURG, V259, P1156, DOI 10.1097/SLA.0000000000000229; Shin R, 2012, DIS COLON RECTUM, V55, P1220, DOI 10.1097/DCR.0b013e31826fea6a; Shirouzu K, 2011, ANN SURG, V253, P704, DOI 10.1097/SLA.0b013e3182119331; Sternberg A, 1999, CANCER-AM CANCER SOC, V86, P782, DOI 10.1002/(SICI)1097-0142(19990901)86:5<782::AID-CNCR13>3.3.CO;2-I; Sternberg A, 2006, J CLIN PATHOL, V59, P207, DOI 10.1136/jcp.2004.023333; Tokoro T, 2009, HEPATO-GASTROENTEROL, V56, P124; Wittekind C, 2012, TNM SUPPLEMENT COMME	17	0	0	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	FEB	2018	71	2					186	188		10.1136/jclinpath-2017-204822			3	Pathology	Pathology	FT1RA	WOS:000422912700017	29212657				2019-10-28	
J	Gordetsky, J; Collingwood, R; Lai, WS; Pena, MDR; Rais-Bahrami, S				Gordetsky, Jennifer; Collingwood, Robin; Lai, Win Shun; Pena, Maria Del Carmen Rodriquez; Rais-Bahrami, Soroush			Second Opinion Expert Pathology Review in Bladder Cancer: Implications for Patient Care	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						urothelial carcinoma; cancer staging; cancer grading; radical cystectomy; bladder tumor	UROTHELIAL CARCINOMA; RADICAL CYSTECTOMY; IMPACT; DISCREPANCIES; MANAGEMENT; OUTCOMES; TUMORS	Objectives. To review bladder specimens referred to our facility for secondary review to determine the frequency and degree of changes in pathological diagnoses, which could affect patient care. Methods. A retrospective review of 246 bladder specimens sent to our pathology department for second opinion pathological review was performed. All consultation specimens were reviewed by a single genitourinary (GU)-subspecialized surgical pathologist. Any changes in the pathological grade, stage, or histological tumor type were noted as well as patient demographic data. Statistical analysis was performed to determine the frequency and type of discrepancies in diagnoses and determine any associations with patient demographic parameters. Results. Secondary pathology consultation of 246 bladder specimens from 233 patients were reviewed and compared with the primary diagnosis. The diagnosis was altered in 91/246 cases (37.0%). The number of cases reviewed per patient and specimen type was not associated with a change in diagnosis (P = .19; P = .1). Of the cases with a change in diagnosis, 8 (8.8%) changed malignancy status, 46 (50.5%) changed stage, 16 (17.6%) changed tumor type (ie, change from urothelial carcinoma to prostate adenocarcinoma), 16 (17.6%) changed histological variant subtype, and 14 (15.4%) changed grade. There was no association noted between age, gender, or race and changes in diagnosis (P = .53; P = .41; P = .70). Conclusions. Secondary pathology review with a GU-subspecialized surgical pathologist can change the stage, grade, or histological subtype on bladder biopsy and tumor resection specimens in more than one-third of cases. Age and gender were not associated with the frequency of change in diagnosis on consultation review.	[Gordetsky, Jennifer; Collingwood, Robin; Lai, Win Shun; Pena, Maria Del Carmen Rodriquez; Rais-Bahrami, Soroush] Univ Alabama Birmingham, Birmingham, AL USA	Gordetsky, J (reprint author), Univ Alabama Birmingham, Dept Pathol, NP 3550,1802 6th Ave South, Birmingham, AL 35249 USA.	jgordetsky@uabmc.edu					Amin MB, 2014, AM J SURG PATHOL, V38, pE20, DOI 10.1097/PAS.0000000000000240; Bruner JM, 1997, CANCER, V79, P796, DOI 10.1002/(SICI)1097-0142(19970215)79:4<796::AID-CNCR17>3.0.CO;2-V; Coblentz TR, 2001, CANCER, V91, P1284, DOI 10.1002/1097-0142(20010401)91:7<1284::AID-CNCR1130>3.0.CO;2-E; Donat SM, 2003, UROL CLIN N AM, V30, P765, DOI 10.1016/S0094-0143(03)00060-0; Gordetsky J, 2014, AM J SURG PATHOL, V38, P941, DOI 10.1097/PAS.0000000000000178; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Khazai L, 2015, J SURG ONCOL, V111, P192, DOI 10.1002/jso.23788; Kuroiwa K, 2010, J UROLOGY, V183, P952, DOI 10.1016/j.juro.2009.11.024; Lee MC, 2010, J UROLOGY, V183, P921, DOI 10.1016/j.juro.2009.11.049; Luchey AM, 2016, UROLOGY, V93, P130, DOI 10.1016/j.urology.2016.01.048; Middleton LP, 2014, J ONCOL PRACT, V10, P275, DOI 10.1200/JOP.2013.001204; Moch H, 2016, WHO CLASSIFICATION T; Moschini M, 2017, UROL ONCOL-SEMIN ORI, V35, P335, DOI 10.1016/j.urolonc.2016.12.006; Rais-Bahrami S, 2016, UROL ONCOL-SEMIN ORI, V34, P124, DOI 10.1016/j.urolonc.2015.08.018; Selman AE, 1999, OBSTET GYNECOL, V94, P302, DOI 10.1016/S0029-7844(99)00318-X; Sharma P, 2015, AM J CLIN PATHOL, V144, P289, DOI 10.1309/AJCPJTX8R6CVWSRW; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tomaszewski JE, 2000, AM J CLIN PATHOL, V114, P329, DOI 10.1093/ajcp/114.3.329; Van Der Meijden A, 2000, J UROLOGY, V164, P1533, DOI 10.1016/S0022-5347(05)67022-X; Wayment RO, 2011, UROL ONCOL-SEMIN ORI, V29, P194, DOI 10.1016/j.urolonc.2009.03.025; Westra WH, 2002, HEAD NECK-J SCI SPEC, V24, P684, DOI 10.1002/hed.10105; Xylinas E, 2013, EUR J CANCER, V49, P1889, DOI 10.1016/j.ejca.2013.02.001	22	4	4	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					12	17		10.1177/1066896917730903			6	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400002	28905666				2019-10-28	
J	Gupta, M; Suryawanshi, M; Kumar, R; Peedicayil, A				Gupta, Mayank; Suryawanshi, Mayur; Kumar, Ramani; Peedicayil, Abraham			Angioleiomyoma of Uterus: A Clinicopathologic Study of 6 Cases	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						angioleiomyoma; leiomyoma; endometrial stromal tumor; perivascular epithelioid cell tumor; myopericytoma	CERVICAL ANGIOLEIOMYOMA; UTERINE ANGIOLEIOMYOMA; LEIOMYOMA; VARIANT	Background and Objectives. Angioleiomyoma is a benign perivascular neoplasm commonly involving subcutaneous tissue of extremities, head, and trunk region. They rarely involve the female genital tract. This study analyses clinicopathological features of 6 cases of uterine angioleiomyoma. Methods. Routine sections of 6 cases were reviewed and immunohistochemical markers namely muscle-specific actin, h-caldesmon, desmin, CD10, WT-1, HMB-45, and melan-A were done. Results. Of the 6 cases, 4 cases had tumor involving the corpus and 2 cases had tumor in the cervix. Grossly, all tumors had a whorled and congested cut surface. Microscopic examination of all the cases revealed circumscribed neoplasms composed of interlacing fascicles of benign perivascular smooth muscle cells with evenly distributed slit-like blood vessels (solid variant) along with vessels exhibiting thick muscular walls with swirling pattern (venous variant). In only 2 cases many dilated vessels were seen (cavernous variant). Immunohistochemically, all cases were positive for muscle-specific actin, h-caldesmon, and desmin. All cases were negative for CD10 and WT-1 ruling out endometrial stromal tumor and were negative for HMB-45 and melan-A ruling out perivascular epithelioid cell tumor (both endometrial stromal tumor and perivascular epithelioid cell tumor have prominent vessels but have different histomorphology). In all cases, surgical excision was curative and there were no intraoperative or postoperative complications. Follow-up of all the cases has been unremarkable. Conclusion. As the World Health Organization has not included angioleiomyoma in the classification of mesenchymal tumors of uterine corpus and cervix, we recommend that it should be included in the classification.	[Gupta, Mayank; Suryawanshi, Mayur; Kumar, Ramani; Peedicayil, Abraham] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India	Gupta, M (reprint author), Christian Med Coll & Hosp, Dept Gen Pathol, 4th Floor,ASHA Bldg, Vellore 632004, Tamil Nadu, India.	gupta.mayank103@gmail.com	SOUNDRARAJAN, JOYSON/I-1779-2019				Agarwal S, 2009, J Gynecol Endosc Surg, V1, P116, DOI 10.4103/0974-1216.71609; Al-Sannaa GA, 2011, J OBSTET GYNAECOL, V31, P555, DOI 10.3109/01443615.2011.587052; Bouraoui S, 2010, GYNECOL OBSTET INVES, V70, P8, DOI 10.1159/000279310; Chung CP, 2012, INT UROGYNECOL J, V23, P1643, DOI 10.1007/s00192-012-1750-y; Culhaci N, 2006, PATHOL ONCOL RES, V12, P50, DOI 10.1007/BF02893432; Diwaker P, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.138127; DUHIG JT, 1959, ARCH PATHOL, V68, P424; Garg G, 2014, ARCH PATHOL LAB MED, V138, P1115, DOI 10.5858/arpa.2013-0315-RS; HACHISUGA T, 1984, CANCER, V54, P126, DOI 10.1002/1097-0142(19840701)54:1<126::AID-CNCR2820540125>3.0.CO;2-F; Hisaoka M, 2013, WHO CLASSIFICATION T, P118; Koleskas D, 2009, J OBSTET GYNAECOL, V29, P161, DOI 10.1080/01443610802633841; MAGNER D, 1961, AM J CLIN PATHOL, V35, P137; McCluggage WG, 2007, INT J SURG PATHOL, V15, P262, DOI 10.1177/1066896907302226; Morimoto N, 1973, MED J KAGOSHIMA U, V24, P663; Nucci MR, 2014, WHO CLASSIFICATION T, P198; Oliva E, 2014, WHO CLASSIFICATION T, P141; Rosai J., 2011, ROSAI ACKERMANS SURG, VVol. 2, P2163; Sharma Chanderdeep, 2014, J Pediatr Adolesc Gynecol, V27, pe69, DOI 10.1016/j.jpag.2013.07.002; TERADA S, 1993, ARCH GYNECOL OBSTET, V253, P51, DOI 10.1007/BF02770634; Weiss SW, 2008, BENIGN TUMORS SMOOTH, P520; Zaloudek CJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P453, DOI 10.1007/978-1-4419-0489-8_10	21	2	2	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					18	23		10.1177/1066896917731516			6	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400003	28905674				2019-10-28	
J	Fu, XG; Jiang, JH; Li, B; Tian, XY; Li, Z				Fu, Xinge; Jiang, Juhong; Li, Bin; Tian, Xiao-ying; Li, Zhi			Cecal Endometriosis With Intestinal Metaplasia Misdiagnosed as Neoplasm of the Cecum by Intraoperative Histological Examination	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						cecum; endometriosis; intestinal-type metaplasia; neoplasm; differential diagnosis	APPENDICEAL MUCINOUS NEOPLASM; PSEUDOMYXOMA PERITONEI; PERFORATION; PREGNANCY; DISEASE; TRACT	Appendiceal or cecal endometriosis with intestinal metaplasia is uncommon and may mimic mucinous tumors of the appendix. A 50-year-old woman was found incidentally to have an ileocecal lesion. In the intraoperative histological examination, a diagnosis of neoplasm of the cecum was made predominantly based on mucin extrusion with scattered lining mucinous epithelium. However, postoperative histological diagnosis of the lesion was cecal endometriosis with intestinal metaplasia as determined by thoroughly microscopic inspection and the presence of typical endometrial glands with surrounding endometrial-type stroma. There was no evidence of recurrence and pseudomyxoma peritonei after 1 year of follow-up. Overinterpretation of cytological atypia or mucin extrusion in endometriosis may lead to inappropriate surgical management. Therefore, in any ileocecal or appendiceal lesions with mucinous epithelia and mucin extrusions, removal of sufficient tissue from different portions of the lesion is essential for surgeons and pathologists to make a precise diagnosis in the intraoperative histological examination.	[Fu, Xinge; Jiang, Juhong] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Li, Bin; Li, Zhi] Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Tian, Xiao-ying] Hong Kong Baptist Univ, Kowloon Tong, Hong Kong, Peoples R China	Li, Z (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.	lizhi@mail.sysu.edu.cn					Carr NJ, 2010, WHO CLASSIFICATION T, P122; Clement PB, 2007, ADV ANAT PATHOL, V14, P241, DOI 10.1097/PAP.0b013e3180ca7d7b; Darvishzadeh A, 2016, ABDOM RADIOL, V41, P2380, DOI 10.1007/s00261-016-0956-8; Driman DK, 2000, AM J CLIN PATHOL, V113, P860; Emmanuel R, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-62; Fukunaga M, 1998, MODERN PATHOL, V11, P784; Jiang W, 2013, MODERN PATHOL, V26, P1270, DOI 10.1038/modpathol.2013.51; Kurogochi Takanori, 2012, J Med Case Rep, V6, P327, DOI 10.1186/1752-1947-6-327; Libbrecht L, 2012, VIRCHOWS ARCH, V461, P227, DOI 10.1007/s00428-012-1264-5; Mai KT, 1999, HISTOPATHOLOGY, V35, P368; Mandal S, 2008, ARCH GYNECOL OBSTET, V278, P265, DOI 10.1007/s00404-008-0579-6; Misdraji J, 2014, AM J SURG PATHOL, V38, P698, DOI 10.1097/PAS.0000000000000167; Mitchell A, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-39; NAKATANI Y, 1987, ACTA PATHOL JAPON, V37, P1685; Pisanu A, 2010, WORLD J GASTROENTERO, V16, P648, DOI 10.3748/wjg.v16.i5.648; Vyas M, 2017, PATHOL RES PRACT, V213, P39, DOI 10.1016/j.prp.2016.10.011; Yantiss RK, 2009, AM J SURG PATHOL, V33, P248, DOI 10.1097/PAS.0b013e31817ec31e; Yantiss RK, 2001, AM J SURG PATHOL, V25, P445, DOI 10.1097/00000478-200104000-00003	18	1	1	4	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					24	30		10.1177/1066896917727595			7	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400004	29070005				2019-10-28	
J	Heatley, N; Harrington, KJ; Thway, K				Heatley, Nicholas; Harrington, Kevin J.; Thway, Khin			Warthin Tumor-Like Mucoepidermoid Carcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						mucoepidermoid carcinoma; Warthin tumor; oncocytic variant; metaplastic; histological mimic; pathology; CRTC1-MAML2	IN-SITU-HYBRIDIZATION	Mucoepidermoid carcinoma (MEC) shows a wide morphologic spectrum, including epithelium with oncocytic or squamous metaplastic changes overlying a prominent cystic architecture, as well as tumor-associated lymphoid tissue. We illustrate a case of MEC of the parotid in a 17-year-old female, in which all these features occurred extensively, such that they accounted for almost the entire neoplasm, and closely mimicked Warthin tumor histologically. This highlights the need for diagnostic awareness of this particular morphologic variant of MEC, as patients could potentially be inappropriately discharged from follow-up if diagnosed with a benign neoplasm.	[Heatley, Nicholas; Harrington, Kevin J.; Thway, Khin] Royal Marsden Hosp, London, England; [Harrington, Kevin J.; Thway, Khin] Inst Canc Res, London, England	Thway, K (reprint author), Royal Marsden Hosp, Head & Neck Unit, 203 Fulham Rd, London SW3 6JJ, England.	khin.thway@rmh.nhs.uk			NIHR Royal Marsden/ICR Biomedical Research Centre	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: We acknowledge support from the NIHR Royal Marsden/ICR Biomedical Research Centre.	Garcia JJ, 2011, HUM PATHOL, V42, P2001, DOI 10.1016/j.humpath.2011.02.028; Ishibashi K, 2015, AM J SURG PATHOL, V39, P1479, DOI 10.1097/PAS.0000000000000507; Liao XY, 2016, RARE TUMORS, V8, P66, DOI 10.4081/rt.2016.6166	3	2	2	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					31	33		10.1177/1066896917724889			3	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400005	28793830				2019-10-28	
J	Prieto-Granada, CN; Stevens, T				Prieto-Granada, Carlos N.; Stevens, Todd			Multilocular Thymic Cyst With Mucinous Differentiation: A Mimicker of Thymic Mucoepidermoid Carcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							HYPERPLASIA		[Prieto-Granada, Carlos N.; Stevens, Todd] UAB, Birmingham, AL USA	Prieto-Granada, CN (reprint author), UAB, Dept Pathol, 619 19th St South, Birmingham, AL 35249 USA.	cprieto@uabmc.edu	Granada, Carlos N. Prieto/J-4665-2019	Granada, Carlos N. Prieto/0000-0002-5025-7539			Chaudhari J, 2015, ENDOCR PATHOL, V26, P45, DOI 10.1007/s12022-015-9355-x; Inui M, 2017, SURG CASE REP, V3, DOI 10.1186/s40792-016-0278-7; Izumi H, 2005, HUM PATHOL, V36, P841, DOI 10.1016/j.humpath.2005.05.004; Minato H, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0332-y; Moran CA, 2004, HISTOPATHOLOGY, V44, P64, DOI 10.1111/j.1365-2559.2004.01767.x; Moran CA, 1997, MODERN PATHOL, V10, P800; Nakamura S, 2012, AM J SURG PATHOL, V36, P1857, DOI 10.1097/PAS.0b013e31826320c4; Prieto-Granada CN, 2015, INT J SURG PATHOL, V23, P277, DOI 10.1177/1066896915576959; Roden AC, 2013, HUM PATHOL, V44, P2799, DOI 10.1016/j.humpath.2013.07.031; SUSTER S, 1991, HUM PATHOL, V22, P455, DOI 10.1016/0046-8177(91)90131-8	10	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					35	36		10.1177/1066896917709947			2	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400007	28508687				2019-10-28	
J	Renda, A; Vergani, C; Venturi, M; Ferrero, S; Del Gobbo, A				Renda, Anna; Vergani, Contardo; Venturi, Marco; Ferrero, Stefano; Del Gobbo, Alessandro			Diffuse Melanosis in Pericolic Lymph Nodes Associated With Laxative Abuse and Colorectal Cancer	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material									[Renda, Anna; Vergani, Contardo; Venturi, Marco; Ferrero, Stefano; Del Gobbo, Alessandro] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy; [Vergani, Contardo; Venturi, Marco; Ferrero, Stefano] Univ Milan, Milan, Italy	Del Gobbo, A (reprint author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Via Francesco Sforza 35, I-20122 Milan, Italy.	alessandro.delgobbo@policlinico.mi.it	Vergani, Contardo/P-4146-2016	Vergani, Contardo/0000-0002-6830-2692			Caire MT, 2014, ENDOSC INT OPEN, V2, pE191, DOI 10.1055/s-0034-1377175; Freeman HA, 2008, WORLD J GASTROENTERO, V14, P4296, DOI 10.3748/wjg.14.4296; Pranesh N, 2005, Ann R Coll Surg Engl, V87, pW1	3	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					37	38		10.1177/1066896917718346			2	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400008	28675973				2019-10-28	
J	Sancheti, S; Jain, S				Sancheti, Sankalp; Jain, Shivani			Liesegang Rings: Extremely Rare Structures in Malignant Lesions	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Editorial Material							CYST		[Sancheti, Sankalp] Homi Bhabha Canc Hosp, Tata Mem Ctr, Sangrur, Punjab, India; [Jain, Shivani] Manubhai Patel Dent Coll & Hosp, Vadodara, Gujarat, India	Sancheti, S (reprint author), Homi Bhabha Canc Hosp, Dept Pathol, Tata Mem Ctr, Sangrur 148001, Punjab, India.	sankalpsancheti123@rediff.com					BOSS JH, 1989, AM J SURG PATHOL, V13, P524, DOI 10.1097/00000478-198906000-00012; CLEMENT PB, 1989, INT J GYNECOL PATHOL, V8, P271, DOI 10.1097/00004347-198909000-00011; Cramer H, 1996, ACTA CYTOL, V40, P319, DOI 10.1159/000333760; Jain D, 2017, INT J SURG PATHOL, V25, P323, DOI 10.1177/1066896917697821; KATZ LBK, 1990, DIAGN CYTOPATHOL, V6, P197, DOI 10.1002/dc.2840060310; Perrotta PL, 1998, INT J GYNECOL PATHOL, V17, P358, DOI 10.1097/00004347-199810000-00010; SCHWARTZ DA, 1991, J REPROD MED, V36, P403; SNEIGE N, 1988, J LARYNGOL OTOL, V102, P730, DOI 10.1017/S0022215100106309; SNEIGE N, 1988, ACTA CYTOL, V32, P547; TUUR SM, 1987, AM J SURG PATHOL, V11, P598, DOI 10.1097/00000478-198708000-00003	10	1	1	1	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					39	40		10.1177/1066896917722389			2	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400009	28738748				2019-10-28	
J	Faye-Petersen, O; Sauder, A; Estrella, Y; Heller, DS				Faye-Petersen, Ona; Sauder, Adrienne; Estrella, Ydamis; Heller, Debra S.			Dichorionic Twins Discordant for Massive Perivillous Fibrinoid Deposition: Report of a Case and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						discordant twin growth; massive perivillous fibrinoid deposition; placental fibrinoid	MATERNAL FLOOR INFARCTION; FETAL-GROWTH; DEATH; DEHYDROGENASE; DEFINITIONS; PREGNANCY; PLACENTA; TIME	Massive perivillous fibrinoid deposition (MFD) and maternal floor infarction (MFI) are lesions of unknown etiology associated with poor perinatal outcomes, including fetal intrauterine growth restriction and neurodevelopmental injury, high risks of pregnancy loss, and recurrence in subsequent gestations. MFI comprises massive intervillous fibrinoid deposition concentrated at the maternal floor. MFD is a similar lesion but is diffuse within the parenchyma. MFD/MFI lesions represent a spectrum of severity of cloak-like perivillous fibrinoid deposition, and there is mounting evidence that, often, they represent sequelae of immune-mediated phenomena and/or an imbalance in factors that normally maintain the fluidity of blood in the maternal space. There are only a handful of reported instances of discordant MFD/MFI occurrence in twin placentas. We present a fourth such occurrence in a fused, dichorionic diamniotic twin placenta and submit that our dizygotic twin gestation case provides additional supportive evidence that immune-mediated mechanisms are involved in the formation of pathological accumulations of fibrinoid, at least in some cases.	[Faye-Petersen, Ona] Univ Alabama Birmingham, Birmingham, AL USA; [Sauder, Adrienne; Estrella, Ydamis; Heller, Debra S.] Rutgers New Jersey Med Sch, Newark, NJ USA	Heller, DS (reprint author), Rutgers New Jersey Med Sch, Dept Pathol, UH E158,185 South Orange Ave, Newark, NJ 07103 USA.	hellerds@njms.rutgers.edu					Bane AL, 2003, BJOG-INT J OBSTET GY, V110, P292, DOI 10.1016/S1470-0328(02)00919-4; Bendon RW, 1996, PEDIATR PATHOL LAB M, V16, P293, DOI 10.1080/107710496175778; Chaiworapongsa T, 2016, J MATERN-FETAL NEO M, V29, P855, DOI 10.3109/14767058.2015.1022864; Chang P, 2006, AM J PERINAT, V23, P125, DOI 10.1055/s-2006-931805; CLEWELL WH, 1983, AM J OBSTET GYNECOL, V147, P346, DOI 10.1016/0002-9378(83)91130-4; Faye-Petersen Ona Marie, 2013, Surg Pathol Clin, V6, P127, DOI 10.1016/j.path.2012.11.007; Feist H, 2015, PEDIATR DEVEL PATHOL, V18, P405, DOI 10.2350/15-02-1609-CR.1; GENEST DR, 1992, OBSTET GYNECOL, V80, P585; Grantz KL, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.04.044; Griffin AC, 2012, PEDIATR DEVEL PATHOL, V15, P368, DOI 10.2350/12-05-1198-OA.1; Gundogan F, 2010, FERTIL STERIL, V93, P397, DOI 10.1016/j.fertnstert.2008.12.144; Gupta N, 2004, J Obstet Gynaecol, V24, P579; Heller DS, 2016, PEDIATR DEVEL PATHOL, V19, P421, DOI 10.2350/15-10-1726-CR.1; Jacques SM, 2003, PEDIATR DEVEL PATHOL, V6, P226, DOI 10.1007/s10024-003-8089-9; Katzman PJ, 2002, PEDIATR DEVEL PATHOL, V5, P159, DOI 10.1007/s10024-001-0195-y; Khong TY, 2016, ARCH PATHOL LAB MED, V140, P698, DOI 10.5858/arpa.2015-0225-CC; Khong TY, 2000, HUM PATHOL, V31, P292; Makino A, 2004, FETAL DIAGN THER, V19, P261, DOI 10.1159/000076708; Matern D, 2001, MOL GENET METAB, V72, P265, DOI 10.1006/mgme.2000.3135; Min SJ, 2000, AM J OBSTET GYNECOL, V182, P1250, DOI 10.1067/mob.2000.104923; Perni SC, 2005, J PERINAT MED, V33, P27, DOI 10.1515/JPM.2005.004; Pinar H, 1996, PEDIATR PATHOL LAB M, V16, P901, DOI 10.1080/15513819609168713; Redline RW, 2003, HUM PATHOL, V34, P822, DOI 10.1016/S0046-8177(03)00288-0; Roifman M, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0238-x; Romero R, 2013, AM J REPROD IMMUNOL, V70, P285, DOI 10.1111/aji.12143; Sebire NJ, 2002, BJOG-INT J OBSTET GY, V109, P570, DOI 10.1111/j.1471-0528.2002.00077.x; Whitten AE, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.017	27	1	2	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					41	46		10.1177/1066896917720029			6	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400010	28691603				2019-10-28	
J	Caroppo, D; Salerno, G; Merolla, F; Mesolella, M; Ilardi, G; Pagliuca, F; De Dominicis, G; Califano, L; Ciancia, G; Russo, D; Mascolo, M				Caroppo, Danila; Salerno, Grazia; Merolla, Francesco; Mesolella, Massimo; Ilardi, Gennaro; Pagliuca, Francesca; De Dominicis, Gianfranco; Califano, Luigi; Ciancia, Giuseppe; Russo, Daniela; Mascolo, Massimo			Coexistent Squamous Cell Carcinoma and Granular Cell Tumor of Head and Neck Region: Report of Two Very Rare Cases and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						granular cell tumor; squamous cell carcinoma; head and neck region	MYOBLASTOMA; ESOPHAGUS; TONGUE; LARYNX	Granular cell tumor (GCT), a relatively rare neuroectodermal tumor occurring most often in the head and neck region, is not uncommonly associated with pseudoepitheliomatous hyperplasia of the overlying surface epithelium, which may be at times nonreadily distinguishable from well-differentiated squamous cell carcinoma (SCC). To the best of our knowledge, only a handful of coexisting SCC and GCT, mostly described in the esophagus, have been reported in (the current) literature so far. We herein report 2 new cases of coexisting GCT and SCC of the head and neck region, located, respectively, in larynx and tongue; comment on their clinical, imaging, and pathologic features; and discuss their management. In the present work, we also review the literature concerning this association to contribute to the head and neck pathologists' and surgeons' awareness regarding the possibility of this association for an adequate surgical excision and a better management of these patients.	[Caroppo, Danila; Ilardi, Gennaro; Pagliuca, Francesca; Ciancia, Giuseppe; Russo, Daniela; Mascolo, Massimo] Univ Naples Federico II, Pathol Sect, Dept Adv Biomed Sci, Naples, Italy; [Salerno, Grazia; Mesolella, Massimo] Univ Naples Federico II, Dept Neurosci, Ear Nose & Throat Sect, Naples, Italy; [Merolla, Francesco] Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy; [De Dominicis, Gianfranco] Hosp Cardarelli, AORN, Naples, Italy; [Califano, Luigi] Univ Naples Federico II, Dept Maxillofacial Surg, Naples, Italy	Merolla, F (reprint author), Univ Molise, Dept Med & Hlth Sci V Tiberio, I-86100 Campobasso, Italy.	francesco.merolla@unimol.it		Ilardi, Gennaro/0000-0002-9354-4087; Russo, Daniela/0000-0002-6961-3695			Abrikossoff A, 1926, VIRCHOWS ARCH A, V260, P215, DOI 10.1007/BF02078314; Al-Ahmadie H, 2002, ARCH PATHOL LAB MED, V126, P731; APARICIO SR, 1969, J PATHOL, V97, P339, DOI 10.1002/path.1710970221; Bedir Recep, 2015, Iran J Otorhinolaryngol, V27, P69; Caltabiano R, 2008, J CRANIOFAC SURG, V19, P1691, DOI 10.1097/SCS.0b013e31818973ad; Cambruzzi E, 2013, ABCD-ARQ BRAS CIR DI, V26, P156, DOI 10.1590/S0102-67202013000200020; Eandi JA, 2007, INT J UROL, V14, P862, DOI 10.1111/j.1442-2042.2007.01827.x; Fanburg-Smith JC, 1998, AM J SURG PATHOL, V22, P779, DOI 10.1097/00000478-199807000-00001; GOLDSTEIN A, 1971, ARCHIV OTOLARYNGOL, V94, P366; Isogai Keiki, 2005, Nihon Shokakibyo Gakkai Zasshi, V102, P1025; Kozminska J, 1995, Otolaryngol Pol, V49 Suppl 23, P244; LEHN E, 1981, J CHIR-PARIS, V118, P325; MANNION P, 1985, THORAX, V40, P551, DOI 10.1136/thx.40.7.551; Nasser H, 2011, PATHOL RES PRACT, V207, P164, DOI 10.1016/j.prp.2010.12.007; Perego P., 1995, Pathologica (Genoa), V87, P551; RADIN DR, 1987, AM J ROENTGENOL, V149, P863, DOI 10.2214/ajr.149.4.863-a; SaidAlNaief N, 1997, ARCH OTOLARYNGOL, V123, P543; Saito K, 2008, SURG TODAY, V38, P651, DOI 10.1007/s00595-007-3694-2; Sataloff RT, 2000, J VOICE, V14, P119, DOI 10.1016/S0892-1997(00)80102-2; Son Hee Young, 2012, Chonnam Med J, V48, P65, DOI 10.4068/cmj.2012.48.1.65; Vinco A, 2001, DIS ESOPHAGUS, V14, P262, DOI 10.1046/j.1442-2050.2001.00198.x; Weber CO, 1854, VIRCHOWS ARCH, P115	22	0	0	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					47	51		10.1177/1066896917724513			5	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400011	28783989				2019-10-28	
J	Garcia-Martos, M; Panizo-Santos, A				Garcia-Martos, Maria; Panizo-Santos, Angel			A Peculiar Form of Breast Fat Necrosis Simulating Hyaline Ring Granuloma (So-called Pulse Granuloma): A Rare Complication of Hyperparathyroidism	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						hyaline ring granuloma; pulse granuloma; breast; lipomembranous fat necrosis; hyperparathyroidism	CALCIPHYLAXIS; CAVITY	Pulse granuloma is a rare, foreign body inflammatory reaction that occurs mainly in the oral cavity. It is exceedingly rare elsewhere, with only isolated cases described in the literature. We report the case of a 79-year-old woman with a history of normocalcemic hyperparathyroidism who presented to our hospital with a painful 4-cm lump in the upper quadrantsupper outer quadrant of her left breast. The clinical and radiological (BIRADS-5) findings were indicative of a malignant lesion. However, core needle biopsy revealed features simulating hyaline ring granuloma (pulse granuloma-like). A definitive diagnosis of lipomembranous fat necrosis was made by identifying its characteristic histomorphology. Histopathological study is essential to establish an exact diagnosis since clinical and imaging features may mimic breast carcinoma. To our knowledge, this is the first reported case of a hyaline ring granuloma-like in the breast, which may represent a peculiar form of degenerative change of lipomembranous fat necrosis.	[Garcia-Martos, Maria] Hosp Univ Sureste, Madrid, Spain; [Panizo-Santos, Angel] Complejo Hosp Navarra, Calle Irunlarrea 3, Navarra 31008, Spain	Panizo-Santos, A (reprint author), Complejo Hosp Navarra, Calle Irunlarrea 3, Navarra 31008, Spain.	angel.panizo@gmail.com					BARKER BF, 1987, SEMIN DIAGN PATHOL, V4, P237; Coyne JD, 1996, HISTOPATHOLOGY, V28, P61, DOI 10.1046/j.1365-2559.1996.252292.x; Coyne JD, 2014, INT J SURG PATHOL, V22, P564, DOI 10.1177/1066896913513835; ELLABBAN NG, 1981, ORAL SURG ORAL MED O, V51, P509, DOI 10.1016/0030-4220(81)90011-6; Fabro Maurício, 2016, Radiol Bras, V49, P272, DOI 10.1590/0100-3984.2015.0058; Gupta A, 2016, HISTOPATHOLOGY, V68, P938, DOI 10.1111/his.12875; Haj Mahmoud, 2004, Breast J, V10, P504, DOI 10.1111/j.1075-122X.2004.21482.x; Ilkani R, 1997, SURGERY, V122, P967, DOI 10.1016/S0039-6060(97)90340-8; Karamurzin YS, 2009, HISTOPATHOLOGY, V54, P268, DOI 10.1111/j.1365-2559.2008.03208.x; Nambudripad R, 2008, INT J SURG PATHOL, V16, P96, DOI 10.1177/1066896907307233; Nowacki NB, 2015, AM J SURG PATHOL, V39, P84, DOI 10.1097/PAS.0000000000000308; Patetsios P, 2000, AM SURGEON, V66, P1056; Pawlowska M, 2015, CURR OPIN ENDOCRINOL, V22, P413, DOI 10.1097/MED.0000000000000198; Philipsen HP, 2010, CLIN ORAL INVEST, V14, P121, DOI 10.1007/s00784-009-0322-0; Rhee DD, 2006, ARCH PATHOL LAB MED, V130, P1839; Segura S, 2008, DERMATOL CLIN, V26, P509, DOI 10.1016/j.det.2008.05.002; Simsek GG, 2012, TURK J GASTROENTEROL, V23, P417, DOI 10.4318/tjg.2012.0362; Snow JL, 1996, AM J DERMATOPATH, V18, P151, DOI 10.1097/00000372-199604000-00007; TALACKO AA, 1988, INT J ORAL MAX SURG, V17, P343, DOI 10.1016/S0901-5027(88)80059-6; Tan Tanny SP, ANZ J SURG, DOI [10.1111/ans.13462., DOI 10.1111/ANS.13462]; Tuna MM, 2016, J BONE MINER METAB, V34, P331, DOI 10.1007/s00774-015-0673-3; Yeo NK, 2014, CLIN EXP OTORHINOLAR, V7, P334, DOI 10.3342/ceo.2014.7.4.334	22	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					52	55		10.1177/1066896917720031			4	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400012	28718332				2019-10-28	
J	Arriola, AGP; Taylor, BL; Ma, S; Malkowicz, SB; Lal, P				Arriola, Aileen Grace P.; Taylor, Benjamin L.; Ma, Sophia; Malkowicz, S. Bruce; Lal, Priti			Malignant Mixed Epithelial and Stromal Tumor of the Kidney With 2 Simultaneous Renal Carcinomas in a Male Patient: Case Report and Review of the Literature	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Review						malignant mixed epithelial and stromal tumor kidney	CYSTIC NEPHROMA; TRANSFORMATION; DIFFERENTIATION; ANGIOMYOLIPOMA; ENTITY; CELL	The majority of mixed epithelial and stromal tumors (MEST) of the kidney are benign entities found in female patients. Malignant MEST of the kidney is an extremely rare entity that often behaves clinically similar to an undifferentiated sarcoma. We report a case of a malignant MEST with synchronous papillary and clear cell renal cell carcinomas (RCCs) in a 61-year-old Caucasian man who presented with an incidental finding of a left renal mass on workup for back pain. The patient underwent a left radical nephrectomy, with histopathology confirming a malignant MEST, intimately associated papillary RCC, and separate adjacent focus of clear cell RCC.	[Arriola, Aileen Grace P.; Taylor, Benjamin L.; Ma, Sophia; Malkowicz, S. Bruce; Lal, Priti] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA	Lal, P (reprint author), Hosp Univ Penn, Dept Pathol & Lab Med, 3400 Spruce St, Philadelphia, PA 19104 USA.	Priti.Lal@uphs.upenn.edu					Adsay NV, 2000, AM J SURG PATHOL, V24, P958, DOI 10.1097/00000478-200007000-00007; Bisceglia M, 2003, ADV ANAT PATHOL, V10, P223, DOI 10.1097/00125480-200307000-00006; Chu PGG, 2009, VIRCHOWS ARCH, V455, P389, DOI 10.1007/s00428-009-0831-x; Farias JA, 2016, UROL ANNALS, V8, P114, DOI 10.4103/0974-7796.171493; Fine SW, 2006, AM J SURG PATHOL, V30, P593, DOI 10.1097/01.pas.0000194298.19839.b4; Jung SJ, 2008, HUM PATHOL, V39, P463, DOI 10.1016/j.humpath.2007.08.008; Kum JBJ, 2011, AM J SURG PATHOL, V35, P1114, DOI 10.1097/PAS.0b013e3182233fb6; Kuroda N, 2008, APMIS, V116, P1013, DOI 10.1111/j.1600-0463.2008.01063.x; Menendez CL, 2012, ANAL QUANT CYTOL, V34, P331; Michal M, 2000, PATHOL RES PRACT, V196, P275, DOI 10.1016/S0344-0338(00)80078-3; Michal M, 1998, PATHOL RES PRACT, V194, P445, DOI 10.1016/S0344-0338(98)80038-1; Mudaliar KM, 2014, INT J SURG PATHOL, V22, P266, DOI 10.1177/1066896913488823; Nakagawa T, 2004, HISTOPATHOLOGY, V44, P302, DOI 10.1111/j.1365-2559.2004.01782.x; Ozluk Y, 2015, ANAL QUANT CYTOPATHO, V37, P199; Shen SS, 2007, ARCH PATHOL LAB MED, V131, P1234; Sukov WR, 2007, HUM PATHOL, V38, P1432, DOI 10.1016/j.humpath.2007.03.022; Suzuki T, 2013, INT J UROL, V20, P448, DOI 10.1111/j.1442-2042.2012.03155.x; Svec A, 2001, VIRCHOWS ARCH, V439, P700, DOI 10.1007/s004280100518; Turbiner J, 2007, AM J SURG PATHOL, V31, P489, DOI 10.1097/PAS.0b013e31802bdd56; Vanecek T, 2017, APPL IMMUNOHISTO M M, V25, P117, DOI 10.1097/PAI.0000000000000262; Wei JG, 2015, INT J CLIN EXP PATHO, V8, P11760; Yang Y, 2005, VIRCHOWS ARCH, V447, P669, DOI 10.1007/s00428-005-1269-4; Yap YS, 2004, LANCET ONCOL, V5, P747, DOI 10.1016/S1470-2045(04)01651-1; Zhou M, 2009, AM J SURG PATHOL, V33, P72, DOI 10.1097/PAS.0b013e3181852105; Zou L, 2014, INT J CLIN EXP PATHO, V7, P2658	25	7	7	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					56	63		10.1177/1066896917720032			8	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400013	28697675				2019-10-28	
J	Chow, LTC; Chan, MHM; Wong, SKC				Chow, Louis Tsun Cheung; Chan, Michael Ho Ming; Wong, Simon Kwok Chuen			Functional Ulnar Nerve Paraganglioma: First Documented Occurrence in the Extremity With Hitherto Undescribed Associated Extensive Glomus Cell Hyperplasia and Tumorlet Formation	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						paraganglioma; glomus cell hyperplasia; glomus tumorlet; glomus tumor; ulnar nerve	THIGH	Extra-adrenal paraganglioma has never been described in the extremities. A 34-year-old woman complained of an enlarging mass in the right forearm for 18 months. Imaging showed a circumscribed vascular tumor attached to the ulnar nerve; biopsy revealed features of paraganglioma. The resected tumor consisted of zellballen pattern of chief cells staining positively for chromogranin with surrounding S100-positive sustentacular cells. The chief cells contained many neurosecretory granules and mitochondria, whereas the sustentacular cells contained a large amount of rough endoplasmic reticulum and some microfilaments. There was adjacent extensive glomus cell hyperplasia and tumorlet formation. The intraoperative blood pressure dropped abruptly on tumor removal. The serum normetanephrine level decreased from a preoperative level of 1987 pg/mL (normal < 149 pg/mL) to normal after operation. The patient admitted on questioning to a history of paroxysmal attacks of transient palpitation, hand tremors, and sweating; imaging showed no evidence of tumor in other parts of the body, and there was no family history of similar tumor; she remained well 33 months after the operation. This occurrence of functional ulnar nerve paraganglioma with the hitherto undescribed associated glomus cell hyperplasia and tumorlet formation attests to the probable existence of normal sympathetic paraganglia in the extremity and their intimate functional relationship with glomus bodies.	[Chow, Louis Tsun Cheung] Tuen Mun Hosp, Tuen Mun, Hong Kong, Peoples R China; [Chan, Michael Ho Ming; Wong, Simon Kwok Chuen] Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China	Chow, LTC (reprint author), Tuen Mun Hosp, Dept Clin Pathol, 23 Tsing Chung Koon Rd, Tuen Mun, Hong Kong, Peoples R China.	louistcchow@gmail.com					Beaton LI, 1941, Q B NW U MED SCHOOL, V15, P245; Brems H, 2009, CANCER RES, V69, P7393, DOI 10.1158/0008-5472.CAN-09-1752; BRUNCK H J, 1958, Frankf Z Pathol, V68, P643; Chow LTC, 2015, PATHOL RES PRACT, V211, P409, DOI 10.1016/j.prp.2014.10.014; Chow LTC, 2015, APMIS, V123, P350, DOI 10.1111/apm.12352; Chow LTC, 2014, ORTHOPEDICS, V37, pE940, DOI 10.3928/01477447-20140924-92; CHRISTOPHERSON WM, 1952, CANCER, V5, P100, DOI 10.1002/1097-0142(195201)5:1<100::AID-CNCR2820050112>3.0.CO;2-K; Dahir Kathryn McCrystal, 2004, Endocr Pract, V10, P424; Elshafie O, 2014, ENDOCRINOL DIAB META, DOI 10.1530/EDM-14-0051; GLENNER GG, 1974, ATLAS TUMOR PATHOLOG; JOHNSON RWP, 1957, BRIT J SURG, V44, P605, DOI 10.1002/bjs.18004418813; Kantorovich V, 2010, BEST PRACT RES CL EN, V24, P415, DOI 10.1016/j.beem.2010.04.001; KARNAUCHOW PN, 1957, LAB INVEST, V6, P368; MACFARLANE A, 1958, ARCH DIS CHILD, V33, P55, DOI 10.1136/adc.33.167.55; McNicol AM, 2006, ENDOCR PATHOL, V17, P131, DOI 10.1385/EP:17:2:131; Mehra S, 2005, ARCH PATHOL LAB MED, V129, P523; MORGAN RF, 1983, J HAND SURG-AM, V8, P283, DOI 10.1016/S0363-5023(83)80161-0; Ohkawara T, 2005, INTERNAL MED, V44, P1195, DOI 10.2169/internalmedicine.44.1195; RANDALL KJ, 1954, J PATHOL BACTERIOL, V67, P69, DOI 10.1002/path.1700670108; Sharma MC, 2005, CAN J OPHTHALMOL, V40, P640, DOI 10.1016/S0008-4182(05)80061-4; SMETANA H F, 1951, Mil Surg, V109, P330; Takahashi M, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.031708; Thareja S, 2015, J CUTAN PATHOL, V42, P285, DOI 10.1111/cup.12439; Turley AJ, 2005, EUR J CARDIO-THORAC, V28, P352, DOI 10.1016/j.ejcts.2005.04.038; van Roggen JFG, 1999, HISTOPATHOLOGY, V34, P474; Weiss SW, 2008, ENZINGER WEISSS SOFT, P989	26	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					64	72		10.1177/1066896917720750			9	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400014	28697655				2019-10-28	
J	Gupta, N; Kenan, S; Kahn, LB				Gupta, Neha; Kenan, Samuel; Kahn, Leonard B.			Synovial Sarcoma Mimicking Pleomorphic Hyalinizing Angiectatic Tumor of Soft Parts: A Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						synovial sarcoma; pleomorphic hyalinizing angiectatic tumor (PHAT); myxoinflammatory fibroblastic sarcoma (MIFS)	POTENTIAL DIAGNOSTIC PITFALL; MYXOFIBROSARCOMA; PHAT; FEATURES	Synovial sarcoma is a high-grade sarcoma commonly affecting young adults. The sites of involvement include soft tissue near joints, lung, pleura, mediastinum, larynx, kidney, and buttocks. Histologic types include monophasic, biphasic, and undifferentiated. We report a unique case of synovial sarcoma with low-grade histologic features mimicking pleomorphic hyalinizing angiectatic tumor (PHAT) with indolent behavior for a period of 10 years. The tumor showed angiectatic blood vessels with fibrinous cuffing, hypocellular and hypercellular spindle cell areas with rare mitoses, and focal atypia in a myxoid background. TLE1 was positive with SYT gene translocation detected on fluorescent in situ hybridization. Cases of myxoinflammatory fibroblastic sarcoma and myxofibrosarcoma have been reported as exhibiting histologic features of PHAT. However, to the best of our knowledge, cases of synovial sarcoma mimicking PHAT have not been reported.	[Gupta, Neha; Kahn, Leonard B.] Northwell Hlth, 6 Ohio Dr,Suite 202, New Hyde Pk, NY 11042 USA; [Kenan, Samuel] Northwell Hlth, Garden City, NY USA	Gupta, N (reprint author), Northwell Hlth, 6 Ohio Dr,Suite 202, New Hyde Pk, NY 11042 USA.	ngupta4@northwell.edu					CAGLE LA, 1987, CANCER, V59, P1810, DOI 10.1002/1097-0142(19870515)59:10<1810::AID-CNCR2820591021>3.0.CO;2-R; Capovilla M, 2006, AM J DERMATOPATH, V28, P276, DOI 10.1097/00000372-200606000-00053; Carter JM, 2014, AM J SURG PATHOL, V38, P1182, DOI 10.1097/PAS.0000000000000212; Changchien YC, 2014, PATHOL RES PRACT, V210, P1146, DOI 10.1016/j.prp.2014.04.016; Chu ZG, 2016, BMC MED IMAGING, V16, DOI 10.1186/s12880-016-0130-3; Ide F, 2004, J ORAL PATHOL MED, V33, P451, DOI 10.1111/j.1600-0714.2004.00211.x; Idrees MT, 2012, ANN DIAGN PATHOL, V16, P489, DOI 10.1016/j.anndiagpath.2011.03.010; Kazakov DV, 2007, PATHOL INT, V57, P281, DOI 10.1111/j.1440-1827.2007.02094.x; Kimura H, 2014, ANTICANCER RES, V34, P3105; Michal M, 2016, ANN DIAGN PATHOL, V20, P40, DOI 10.1016/j.anndiagpath.2015.10.006; Mitsuhashi T, 2005, AM J DERMATOPATH, V27, P322, DOI 10.1097/01.dad.0000171605.48186.31; Smith MEF, 1996, AM J SURG PATHOL, V20, P21, DOI 10.1097/00000478-199601000-00002; Spillane AJ, 2000, J CLIN ONCOL, V18, P3794, DOI 10.1200/JCO.2000.18.22.3794; Suzuki K, 2014, ONCOL LETT, V7, P1249, DOI 10.3892/ol.2014.1883; Tallarigo F, 2009, PATHOL RES PRACT, V205, P69, DOI 10.1016/j.prp.2008.07.010; Weiss SW, 2013, WHO CLASSIFICATION T, P200	16	0	0	0	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					73	77		10.1177/1066896917723463			5	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400015	28764610				2019-10-28	
J	Sciarra, A; Hessler, R; Godat, S; Fraga, M; Dromain, C; Duran, R; Halkic, N; Sempoux, C				Sciarra, Amedeo; Hessler, Roxane; Godat, Sebastien; Fraga, Montserrat; Dromain, Clarisse; Duran, Rafael; Halkic, Nermin; Sempoux, Christine			Heterotopic Gastric Mucosa in a Duplication Cyst of the Common Hepatic Duct Mimicking Cholangiocarcinoma	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						gastric heterotopia; common hepatic duct; cholangiocarcinoma; duplication cyst; liver fibrosis	BILE-DUCT; MECKELS-DIVERTICULUM; RECTUM; OBSTRUCTION; AMPULLA; VATER	Heterotopic gastric mucosa in biliary tract is a congenital anomaly that can prove significant clinical dilemmas. Here we report the case of a 28-year-old female patient presenting with jaundice, pruritus, and altered liver tests, with predominant cholestasis. Liver biopsy revealed histological changes suggesting large bile duct obstruction with advanced fibrosis. At imaging, common hepatic duct stricture due to an intraluminal enhancing mass was observed. Endoscopic retrograde cholangiopancreatography and upper echoendoscopy revealed a firm mass of the common hepatic duct with a complete obstruction, suspicious for cholangiocarcinoma. Fine-needle aspiration biopsy performed under echoendoscopic guidance revealed fundic type gastric mucosa. Despite histological result, radiological suspicion of malignancy together with advanced fibrosis prompted a segmental resection of biliary tract. At macroscopic examination, the common hepatic duct presented a focal pseudocystic appearance with a firm zone of subtotal stenosis. Histology revealed a duplication cyst lined by heterotopic fundic gastric mucosa. Heterotopic gastric mucosa of the biliary tract should be suspected in young patients without know risk factors for hepatobiliary malignancies. Imaging and careful histological examination are mandatory for optimal management. Liver fibrosis, secondary to chronic biliary obstruction may be a significant late complication.	[Sciarra, Amedeo; Hessler, Roxane; Godat, Sebastien; Fraga, Montserrat; Dromain, Clarisse; Duran, Rafael; Halkic, Nermin; Sempoux, Christine] Lausanne Univ Hosp, Lausanne, Switzerland; [Sciarra, Amedeo] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy	Sciarra, A (reprint author), Lausanne Univ Hosp, Inst Pathol, Rue Bugnon 25, CH-1011 Lausanne, Switzerland.	amedeo.sciarra@unimi.it		Sciarra, Amedeo/0000-0002-7550-0312; Dromain, Clarisse/0000-0002-2999-1958			AKERS DR, 1972, SURGERY, V71, P817; AUBREY DA, 1970, ARCH SURG-CHICAGO, V101, P628; BLUNDELL CR, 1982, AM J GASTROENTEROL, V77, P111; CHRISTENSEN WN, 1987, AM J SURG PATHOL, V11, P397, DOI 10.1097/00000478-198705000-00009; EVANS MM, 1990, SURGERY, V108, P96; FRIES M, 1984, ACTA RADIOL DIAGN, V25, P417, DOI 10.1177/028418518402500513; Fukuda S, 2013, SURG TODAY, V43, P91, DOI 10.1007/s00595-012-0221-x; Fukuda Y, 2001, HEPATO-GASTROENTEROL, V48, P1337; GORLIN RJ, 1964, J PEDIATR-US, V64, P604, DOI 10.1016/S0022-3476(64)80356-5; Hoang MP, 2001, MODERN PATHOL, V14, P1119, DOI 10.1038/modpathol.3880446; Iacopini F, 2016, GASTROENTEROL REP, V4, P196, DOI 10.1093/gastro/gow006; Jarry J, 2009, PANCREAS, V38, P351, DOI 10.1097/MPA.0b013e3181888feb; KALMAN PG, 1981, SURGERY, V89, P384; Kim J, 2012, J PEDIATR SURG, V47, pE5, DOI 10.1016/j.jpedsurg.2012.01.066; Kiratli PO, 2009, ANN NUCL MED, V23, P97, DOI 10.1007/s12149-008-0204-6; Madrid C, 2003, PEDIATR RADIOL, V33, P129, DOI 10.1007/s00247-002-0718-3; MARTINEZURRUTIA MJ, 1990, J PEDIATR SURG, V25, P356, DOI 10.1016/0022-3468(90)90088-Q; PICARD EJ, 1978, AM J DIG DIS, V23, P217, DOI 10.1007/BF01072320; SFAKIANAKIS GN, 1981, J NUCL MED, V22, P678; Wacrenier A, 2002, INT J PEDIATR OTORHI, V64, P65, DOI 10.1016/S0165-5876(02)00035-6; WELLING RE, 1970, ARCH SURG-CHICAGO, V101, P626; WOLFF M, 1971, AM J CLIN PATHOL, V55, P604; Wollschlaeger B, 1995, J Am Board Fam Pract, V8, P134	23	1	1	1	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					84	88		10.1177/1066896917727101			5	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400017	28830294				2019-10-28	
J	Fernandes, AM; Lakhe, MM; Pai, SA				Fernandes, Anisha M.; Lakhe, Maheshkumar M.; Pai, Sanjay A.			Toxoplasma Appendicitis: A Once-in-a-Lifetime Diagnosis!	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						misdiagnosis; tachyzoites; immunohistochemistry; serology; immunosuppression	RHEUMATOID-ARTHRITIS; METHOTREXATE; PATIENT	Toxoplasmosis is generally asymptomatic in immunocompetent individuals, but it can be life-threatening in immunocompromised patients. We present a case of a 62-year-old man with clinical features of acute appendicitis. Histology showed a transmural infiltrate of eosinophils. In addition, there were reactive lymphoid follicles with histiocytes in the submucosa and tachyzoites in the muscularis propria. Immunohistochemistry confirmed the diagnosis of toxoplasma appendicitis. Serological evaluation yielded negative results. Retrospective review of the history revealed that the patient was on long-term immunosuppressive therapy with methotrexate. The patient was treated with sulfamethoxazole-trimethoprim and is asymptomatic at 7-month follow-up. Toxoplasma appendicitis must be considered in the differential diagnosis of appendicitis in immunosuppressed patients.	[Fernandes, Anisha M.; Lakhe, Maheshkumar M.; Pai, Sanjay A.] Columbia Asia Referral Hosp, Bangalore 560055, Karnataka, India	Pai, SA (reprint author), Columbia Asia Referral Hosp, Bangalore 560055, Karnataka, India.	sanjayapai@gmail.com					Boyd WI, 1970, TXB PATHOLOGY, P820; Groopman J, 2004, NEW ENGL J MED, V351, P2043, DOI 10.1056/NEJMp048032; Horiuchi Kazuhiro, 2010, Rinsho Shinkeigaku, V50, P252; Lowe D, 2006, GASTROINTEST ENDOSC, V63, P341, DOI 10.1016/j.gie.2005.09.001; Merzianu Mihai, 2005, Arch Pathol Lab Med, V129, pe87; Montoya JG, 2004, LANCET, V363, P1965, DOI 10.1016/S0140-6736(04)16412-X; Montoya JG, 2002, J INFECT DIS, V185, pS73, DOI 10.1086/338827; OJO O S, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P245; PIRINGERKUCHINK.A, 1952, VERH DTSCH GES PATH, V36, P352; Pulivarthi S, 2015, INTERNAL MED, V54, P1433, DOI 10.2169/internalmedicine.54.3977; Robert-Gangneux F, 2012, CLIN MICROBIOL REV, V25, P264, DOI 10.1128/CMR.05013-11; ROSENTHAL GJ, 1988, J IMMUNOL, V141, P410; Wessels JAM, 2008, RHEUMATOLOGY, V47, P249, DOI 10.1093/rheumatology/kem279	13	0	0	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					89	92		10.1177/1066896917724888			4	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400018	28793826	Bronze			2019-10-28	
J	Son, HJ; Yu, IK; Kim, SM				Son, Hyun-Jin; Yu, In Kyu; Kim, Seong Min			Lymphoplasmacyte-Rich Meningioma With Atypical Angiomatous Feature and an Increased Deposition of IgG4-Positive Plasma Cells: An Unusual Case Report	INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY			English	Article						lymphoplasmacyte-rich meningioma; IgG4; odontoid process; clivus; angiomatous meningioma	IDIOPATHIC HYPERTROPHIC PACHYMENINGITIS; IGG4-RELATED SCLEROSING DISEASE; LYMPHOMA; RARE	Lymphoplasmacyte-rich meningioma (LPRM) is an extremely rare variant of meningioma, and a small percentage of LPRM may be associated with IgG4-related disease. To date, the coexistence of 2 rare meningioma variants consisting of LPRM and angiomatous meningioma within one neoplasm has not been reported in the literature. A 56-year-old woman presented with episodes of frequent and severe epistaxis that began 4 months ago. Initial magnetic resonance imaging showed localized, heterogeneous, and intermediate to high signal lesion at the odontoid process and clivus. In subsequent magnetic resonance images, the mass grew to the posterior nasopharyngeal wall, and compression to the medulla, and a suspicious enhancement of both distal vertebral arteries became evident even though there was 3 times of partial resection over 17 years. The tumor showed regional and temporal heterogeneity, and atypical features such as mitoses and a high proliferative index were also identified in the area of angiomatous meningioma in addition to LPRM with an increased deposition of IgG4-positive plasma cells within the neoplasm.	[Son, Hyun-Jin; Yu, In Kyu; Kim, Seong Min] Eulji Univ, Daejeon, South Korea	Son, HJ (reprint author), Eulji Univ Hosp, Dept Pathol, 95 Dunsanseo Ro, Daejeon 35233, South Korea.	shjpathol@eulji.ac.kr					Cha YJ, 2016, BRAIN TUMOR PATHOL, V33, P216, DOI 10.1007/s10014-016-0254-8; Cheuk W, 2008, AM J SURG PATHOL, V32, P1159, DOI 10.1097/PAS.0b013e31816148ad; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Divatia M, 2012, YONSEI MED J, V53, P15, DOI 10.3349/ymj.2012.53.1.15; Hasselblatt M, 2004, AM J SURG PATHOL, V28, P390, DOI 10.1097/00000478-200403000-00013; Hirunwiwatkul P, 2007, J NEURO-OPHTHALMOL, V27, P91, DOI 10.1097/WNO.0b013e31806773a5; Kubota T, 2010, J CLIN PATHOL, V63, P1059, DOI 10.1136/jcp.2010.082156; Lal A, 2014, BRAIN PATHOL, V24, P352, DOI 10.1111/bpa.12128; Majumdar K, 2013, CLIN NEUROPATHOL, V32, P122, DOI 10.5414/NP300517; Matsuo T, 2011, J CLIN EXP HEMATOP, V51, P125, DOI 10.3960/jslrt.51.125; Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M; Perry A, 1997, AM J SURG PATHOL, V21, P1455, DOI 10.1097/00000478-199712000-00008; Perry A, 1998, CANCER-AM CANCER SOC, V82, P2262, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2262::AID-CNCR23>3.0.CO;2-R; Sagaert X, 2010, NAT REV GASTRO HEPAT, V7, P336, DOI 10.1038/nrgastro.2010.58; Stone JH, 2012, SEMIN DIAGN PATHOL, V29, P177, DOI 10.1053/j.semdp.2012.08.002; Takeuchi S, 2014, J KOREAN NEUROSURG S, V55, P300, DOI 10.3340/jkns.2014.55.5.300	16	0	0	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1066-8969	1940-2465		INT J SURG PATHOL	Int. J. Surg. Pathol.	FEB	2018	26	1					93	97		10.1177/1066896917728103			5	Pathology; Surgery	Pathology; Surgery	FR9CF	WOS:000419370400019	28862040				2019-10-28	
J	Pastorello, RG; Costa, FD; Osorio, CABT; Makdissi, FBA; Bezerra, SM; De Brot, M; Campos, AHJFM; Soares, FA; Vassallo, J				Pastorello, Ricardo Garcia; Costa, Felipe D'Almeida; Osorio, Cynthia A. B. T.; Makdissi, Fabiana B. A.; Bezerra, Stephania Martins; de Brot, Marina; Campos, Antonio Hugo J. F. M.; Soares, Fernando Augusto; Vassallo, Jose			Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report	DIAGNOSTIC PATHOLOGY			English	Article						Lymphoma; Anaplastic large cell lymphoma; Anaplastic lymphoma kinase (ALK); Li-FRAUMENI syndrome; Breast implant	P53 GENE-MUTATIONS; DIAGNOSIS	Background: Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a rare malignancy, recently recognized as a provisional entity by the World Health Organization. Although increasing data have been published on this entity in recent years, a great number of patients and health professionals remain unaware of this diagnosis. Case presentation: We herein report the case of a 56-year-old female with Li-FRAUMENI syndrome who presented with late right-sided recurrent breast swelling after prophylactic adenomastectomy with implant reconstruction. Imaging scans revealed an heterogeneous mass adjacent to the implant fibrous capsule. A biopsy of the lesion rendered the diagnosis of a BIA-ALCL. Conclusions: This case presents similarities with previous reports, but also some particularities, which should be stressed in order to make the diagnosis the earliest possible. The most distinct feature is that this is the second report of BIA-ALCL arising in the setting of Li-FRAUMENI syndrome.	[Pastorello, Ricardo Garcia; Costa, Felipe D'Almeida; Osorio, Cynthia A. B. T.; Bezerra, Stephania Martins; de Brot, Marina; Campos, Antonio Hugo J. F. M.; Soares, Fernando Augusto; Vassallo, Jose] AC Camargo Canc Ctr, Dept Anat Pathol, 211 Prof Antonio Prudente St, BR-01509900 Sao Paulo, Brazil; [Makdissi, Fabiana B. A.] AC Camargo Canc Ctr, Dept Breast Surg, Sao Paulo, Brazil; [Soares, Fernando Augusto] Univ Sao Paulo, Dept Breast Surg, AC Camargo Canc Ctr, Sao Paulo, Brazil	Pastorello, RG (reprint author), AC Camargo Canc Ctr, Dept Anat Pathol, 211 Prof Antonio Prudente St, BR-01509900 Sao Paulo, Brazil.	ricardopastorello@hotmail.com	D'Almeida Costa, Felipe/Y-3841-2018; Bezerra, Stephania M/X-9260-2018; de Toledo Osorio, Cynthia Bueno/J-9282-2015; Campos, Antonio Hugo/AAB-9287-2019	de Toledo Osorio, Cynthia Bueno/0000-0002-7675-9780; Campos, Antonio Hugo/0000-0001-5322-7549			Adrada BE, 2014, BREAST CANCER RES TR, V147, P1, DOI 10.1007/s10549-014-3034-3; Barnes DM, P53 PROTEIN DETECTED; CESARMAN E, 1993, AM J PATHOL, V143, P845; Chai SM, 2014, DIAGN CYTOPATHOL, V42, P929, DOI 10.1002/dc.23152; Doren EL, 2017, PLAST RECONSTR SURG, V139, P1042, DOI 10.1097/PRS.0000000000003282; Fletcher CL, 2004, ARCH DERMATOL, V140, P449, DOI 10.1001/archderm.140.4.449; Gazzola A, 2014, THER ADV HEMATOL, V5, P35, DOI 10.1177/2040620713519729; Glenn MJ, 2017, NATL COMPR CANC NETW; Gualco G, 2009, APPL IMMUNOHISTO M M, V17, P301, DOI 10.1097/PAI.0b013e318195286d; Johnson L, 2017, EJSO-EUR J SURG ONC, V43, P1393, DOI 10.1016/j.ejso.2017.05.004; Kaartinen I, 2017, EJSO-EUR J SURG ONC, V43, P1385, DOI 10.1016/j.ejso.2017.05.021; Keech JA, 1997, PLAST RECONSTR SURG, V100, P554, DOI 10.1097/00006534-199708000-00065; Laurent C, 2016, ANN ONCOL, V27, P306, DOI 10.1093/annonc/mdv575; Lee YS, 2015, HISTOPATHOLOGY, V67, P925, DOI 10.1111/his.12737; Miranda RN, 2014, J CLIN ONCOL, V32, P114, DOI 10.1200/JCO.2013.52.7911; Rassidakis GZ, 2005, LEUKEMIA, V19, P1663, DOI 10.1038/sj.leu.2403840; Royds JA, 2006, CELL DEATH DIFFER, V13, P1017, DOI 10.1038/sj.cdd.4401913; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Ye X, 2014, MUTAT RES-REV MUTAT, V762, P123, DOI 10.1016/j.mrrev.2014.08.002	19	7	7	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 25	2018	13								10	10.1186/s13000-018-0688-x			6	Pathology	Pathology	FU2SE	WOS:000423699500001	29370815	DOAJ Gold, Green Published			2019-10-28	
J	Chang, S; Hirschowitz, S; Lu, DY; Montoya, RC; Vergara-Lluri, M; Moatamed, NA				Chang, Sue; Hirschowitz, Sharon; Lu, David Y.; Montoya, Rose C.; Vergara-Lluri, Maria; Moatamed, Neda A.			Fine-needle aspiration of a slowly enlarging neck mass in a 61-year-old woman: An interesting adult blue cell tumor in an unusual location	CYTOJOURNAL			English	Editorial Material							CARCINOMA; HEAD		[Chang, Sue] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA; [Hirschowitz, Sharon; Lu, David Y.; Moatamed, Neda A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Vergara-Lluri, Maria] Univ Southern Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA USA; [Montoya, Rose C.] Great River Hlth Syst, Dept Pathol, West Burlington, IA USA	Chang, S (reprint author), City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA.	suchang@coh.org; shirschowitz@mednet.ucla.edu; dylu@mednet.ucla.edu; rosecmontoya@gmail.com; maria.vergara-lluri@med.usc.edu; nmoatamed@mednet.ucla.edu		Moatamed, Neda/0000-0002-9986-8058			Basati M, 2013, CASE REP DERMATOL ME, V2013; Chan JK, 2013, DIAGNOSTIC HISTOPATH; Ghaderi Mahmoud, 2010, Ear Nose Throat J, V89, pE24; Goldblum JR, 2013, ENZINGER WEISSS SOFT; Kuwamoto S, 2011, HUM PATHOL, V42, P1063, DOI 10.1016/j.humpath.2011.01.020; Lastra RR, 2013, CYTOJOURNAL, V10, DOI 10.4103/1742-6413.120789; Simons SA, 2016, SEMIN DIAGN PATHOL, V33, P91, DOI 10.1053/j.semdp.2015.09.010; Wieczorek T. J., 2014, CYTOLOGY DIAGNOSTIC; Wong HH, 2010, ARCH PATHOL LAB MED, V134, P1711, DOI 10.1043/2009-0165-RSR2.1; Xu B, 2016, HUM PATHOL, V54, P193, DOI 10.1016/j.humpath.2016.04.002	10	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JAN 25	2018	15								1	10.4103/cytojournal.cytojournal_40_16			4	Pathology	Pathology	FZ0VC	WOS:000427290600001	29497454	DOAJ Gold, Green Published			2019-10-28	
J	Gupta, P; Agarwal, P; Ahuja, A; Durga, CK				Gupta, Prajwala; Agarwal, Poojan; Ahuja, Arvind; Durga, C. K.			Primary cutaneous non-Hodgkin's lymphoma, clinically mimicking a soft tissue sarcoma	CYTOJOURNAL			English	Article						Cutaneous lymphoma; diffuse large B-cell lymphoma; fine needle aspiration cytology; non-Hodgkin's lymphoma; sarcoma	B-CELL LYMPHOMA; CLASSIFICATION	Primary cutaneous B-cell lymphomas (PCBCL) are a heterogeneous group of neoplasms with distinct biology and clinical course when compared to their nodal counterparts. They usually present as violaceous, erythematous plaques, and nonulcerated nodules, which are confined to skin at the time of presentation. We present an unusual case of primary cutaneous diffuse large B-cell lymphoma, clinically mimicking a sarcoma. This case highlights the uncommon aggressive behavior and ulcerated type of nodular lesions seen in PCBCL and also revisits the cytomorphological findings of the same.	[Gupta, Prajwala; Agarwal, Poojan; Ahuja, Arvind] Dr Ram Manohar Lohia Hosp, PGIMER, Dept Pathol, New Delhi, India; [Durga, C. K.] Dr Ram Manohar Lohia Hosp, PGIMER, Dept Surg, New Delhi, India	Agarwal, P (reprint author), Dr Ram Manohar Lohia Hosp, PGIMER, Dept Pathol, New Delhi, India.	prajwala2000@yahoo.com; poojanagarwl@gmail.com; drarvindahuja@gmail.com; ckdurgarml@gmail.com	Ahuja, Arvind/F-3531-2015	Ahuja, Arvind/0000-0001-7003-5952			Armitage JO, 2005, CA-CANCER J CLIN, V55, P368, DOI 10.3322/canjclin.55.6.368; de Sousa ARD, 2011, AN BRAS DERMATOL, V86, P549, DOI 10.1590/S0365-05962011000300019; Hembury TA, 2002, AM J CLIN PATHOL, V117, P574; Kempf W, 2010, HISTOPATHOLOGY, V56, P57, DOI 10.1111/j.1365-2559.2009.03455.x; La Selva R, 2017, INDIAN J DERMATOL, V62, P146, DOI 10.4103/ijd.IJD_74_17; Lima M, 2015, AN BRAS DERMATOL, V90, P687, DOI 10.1590/abd1806-4841.20153638; Mandal S, 2007, ACTA CYTOL, V51, P853, DOI 10.1159/000325860; Suresh S, 2008, EUR RADIOL, V18, P2628, DOI 10.1007/s00330-008-1014-x; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502	9	0	0	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JAN 25	2018	15								2	10.4103/cytojournal.cytojournal_41_17			4	Pathology	Pathology	FZ0VC	WOS:000427290600002	29497455	DOAJ Gold, Green Published			2019-10-28	
J	Solmaz, OA				Solmaz, Ozgen Arslan			Diagnostic importance of CD56 with fine-needle aspiration cytology in suspected papillary thyroid carcinoma cases	CYTOJOURNAL			English	Article						CD56; fine-needle aspiration cytology; immunocytochemistry; suspicion; thyroid carcinoma	DIFFERENTIAL-DIAGNOSIS; SCIENCE CONFERENCE; BETHESDA SYSTEM; E-CADHERIN; NODULES; EXPRESSION; BIOPSIES; LESIONS; CANCER; HBME-1	Background: Palpable thyroid nodules can be found in 4%-7% of the adult population; however, < 5% of thyroid nodules are malignant. Immunohistochemical markers, such as CD56, can be used to make a differential diagnosis between benign and malignant lesions. To increase the accuracy of the diagnosis and distinguish the malignant aspirates from the benign ones, chose to evaluate CD56, which is normally found in benign thyroid tissue. Methods: A total of 53 fine-needle aspirate samples from patients diagnosed with suspected papillary thyroid carcinoma (PTC) were included prospectively. These aspirates were immunocytochemically stained for CD56. Results: In histopathological examination, the fine-needle aspiration cytopathology specimens suspicious for PTC (after undergoing surgery) showed that 32 (60.4%) were benign and 21 (39.6%) were malignant. Thirty-one of the benign cases (96.87%) were CD56-positive, whereas the last case (3.13%) was CD56-negative. Staining was not seen in any of the malignant cases. Conclusions: We believe that CD56 is an important marker in the definitive diagnosis of suspected PTC cases, with CD56-positivity being interpreted in favor of benignity.	[Solmaz, Ozgen Arslan] Elazig Training & Res Hosp, Dept Pathol, Elazig, Turkey	Solmaz, OA (reprint author), Elazig Training & Res Hosp, Dept Pathol, Elazig, Turkey.	ozgensolmaz_73@hotmail.com					Abd El Atti RM, 2012, J EGYPT NATL CANCER, V24, P175, DOI 10.1016/j.jnci.2012.10.002; Amrikachi M, 2001, ARCH PATHOL LAB MED, V125, P484; Baloch ZW, 2008, CYTOJOURNAL, V5, DOI 10.1186/1742-6413-5-6; Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830; Bizzarro T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132939; Bongiovanni M, 2012, ACTA CYTOL, V56, P333, DOI 10.1159/000339959; Borgohain R, 2014, IOSR J DENT MED SCI, V13, P46; Boyd LA, 1998, J AM COLL SURGEONS, V187, P494, DOI 10.1016/S1072-7515(98)00221-X; Ceyran AB, 2015, INT J CLIN EXP PATHO, V8, P3670; Chen H, 1997, J AM COLL SURGEONS, V184, P605; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Cramer H, 2000, CANCER CYTOPATHOL, V90, P325, DOI 10.1002/1097-0142(20001225)90:6<325::AID-CNCR1>3.3.CO;2-L; Dean DS, 2000, ENDOTEXT; El Demellawy D, 2009, PATHOL RES PRACT, V205, P303, DOI 10.1016/j.prp.2008.11.011; Erdogan-Durmus S, 2016, J RES MED SCI, V21; Fadda G, 2006, ACTA CYTOL, V50, P129, DOI 10.1159/000325920; GHARIB H, 1984, ANN INTERN MED, V101, P25, DOI 10.7326/0003-4819-101-1-25; GHARIB H, 1993, CLIN LAB MED, V13, P699, DOI 10.1016/S0272-2712(18)30434-7; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; KINI SR, 1980, ACTA CYTOL, V24, P511; Koss LG, 1984, ASPIRATION BIOPSY CY, P169; Kumar SK, 2013, SCHOLAR J APPL MED S, V1, P745; Nechifor-Boila A, 2014, ROM J MORPHOL EMBRYO, V55, P49; Ozolins A, 2012, MED LITH, V48, P507; Park WY, 2009, BASIC APPL PATHOLOGY, V2, P63; Pusztaszeri MP, 2014, CANCER CYTOPATHOL, V122, P666, DOI 10.1002/cncy.21441; Raj MD, 2010, ANZ J SURG, V80, P827, DOI 10.1111/j.1445-2197.2010.05343.x; Rossi ED, 2005, CANCER CYTOPATHOL, V105, P87, DOI 10.1002/cncr.21026; RUPP M, 1989, ACTA CYTOL, V33, P21; Sangalli G, 2006, CYTOPATHOLOGY, V17, P245, DOI 10.1111/j.1365-2303.2006.00335.x; Scarpino S, 2007, J PATHOL, V212, P411, DOI 10.1002/path.2183; Sharma C, 2008, ACTA CYTOL, V52, P56, DOI 10.1159/000325435; Sidawy MK, 1997, CANCER CYTOPATHOL, V81, P253, DOI 10.1002/(SICI)1097-0142(19970825)81:4<253::AID-CNCR7>3.0.CO;2-Q; ZEROMSKI J, 1992, CLIN EXP IMMUNOL, V89, P474	34	1	1	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0974-5963	1742-6413		CYTOJOURNAL	CytoJournal	JAN 25	2018	15								3	10.4103/cytojournal.cytojournal_42_17			6	Pathology	Pathology	FZ0VC	WOS:000427290600003	29497456	DOAJ Gold, Green Published			2019-10-28	
J	Percicote, AP; Mardegan, GL; Gugelmim, ES; Ioshii, SO; Kuczynski, AP; Nagashima, S; de Noronha, L				Percicote, Ana Paula; Mardegan, Gabriel Lazaretti; Gugelmim, Elizabeth Schneider; Ioshii, Sergio Ossamu; Kuczynski, Ana Paula; Nagashima, Seigo; de Noronha, Lucia			Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas	DIAGNOSTIC PATHOLOGY			English	Article						Nephroblastoma; Retinoic acid; CRABP2	WILMS-TUMORS REVEALS; CANCER; CELL; METABOLISM; TRANSPORT; RELAPSE; PROTEIN; GENES	Background: Nephroblastoma or Wilms tumor is the most frequent kidney cancer in children and accounts for 98% of kidney tumors in this age group. Despite favorable prognosis, a subgroup of these patients progresses to recurrence and death. The retinoic acid (RA) pathway plays a role in the chemoprevention and treatment of tumors due to its effects on cell differentiation and its antiproliferative, anti-oxidant, and pro-apoptotic activities. Reports describe abnormal cellular retinoic acid-binding protein 2 (CRABP2) expression in neoplasms and its correlation with prognostic factors and clinical and pathological characteristics. The aim of this study was to evaluate the immunohistochemical expression of retinoic acid receptor alpha (RARA) and CRABP2 in paraffin-embedded samples of nephroblastomas via semiquantitative and quantitative analyses and to correlate this expression with prognostic factors. Methods: Seventy-seven cases of nephroblastomas were selected from pediatric oncology services. The respective medical records and surgical specimens were reviewed. Three representative tumor samples and one non-tumor renal tissue sample were selected for the preparation of tissue microarrays (TMA). The Allred scoring system was used for semiquantitative immunohistochemical analyses, whereas a morphometric analysis of the stained area was employed for quantitative evaluation. The nonparametric Mann-Whitney test was used for comparisons between two groups, while the nonparametric Kruskal-Wallis test was used to compare three or more groups. Results: Immunopositivity for RARA and CRABP2 was observed in both the nucleus and cytoplasm. All histological components of the nephroblastoma (blastema, epithelium, and stroma) were positive for both markers. RARA, based on semiquantitative analyses, and CRABP2, bases on quantitative analyses, exhibited increased immunohistochemical expression in patients with metastasis, with p values of 0.0247 and 0.0128, respectively. These findings were similar to the results of the quantitative analysis of RARA expression, showing greater immunopositivity in tumor samples of patients subjected to pre-surgical chemotherapy. No significant correlation was found with the other variables studied, such as disease stage, anaplasia, risk group, histological type, nodal involvement, and clinical evolution. Conclusions: Semiquantitative and quantitative analyses of the markers RARA and CRABP2 indicate their potential as biomarkers for tumor progression and their participation in nephroblastoma tumorigenesis.	[Percicote, Ana Paula; Mardegan, Gabriel Lazaretti] Univ Fed Parana, Curitiba, Parana, Brazil; [Gugelmim, Elizabeth Schneider] Pequeno Principe Hosp, Anat Pathol Serv, Curitiba, Parana, Brazil; [Ioshii, Sergio Ossamu; de Noronha, Lucia] Univ Fed Parana, Dept Med Pathol, Curitiba, Parana, Brazil; [Ioshii, Sergio Ossamu; Nagashima, Seigo; de Noronha, Lucia] Pontificia Univ Catolica Parana, Sch Hlth, Curitiba, Parana, Brazil; [Kuczynski, Ana Paula] Pequeno Principe Hosp, Oncol Serv, Curitiba, Parana, Brazil	Percicote, AP (reprint author), Univ Fed Parana, Curitiba, Parana, Brazil.	appercicote@gmail.com	noronha, lucia/F-6339-2015	noronha, lucia/0000-0003-0310-7164			BLOMHOFF R, 1994, NUTR REV, V52, P13; Bushue N, 2010, ADV DRUG DELIVER REV, V62, P1285, DOI 10.1016/j.addr.2010.07.003; Chong DC, 2009, PEDIATR DEVEL PATHOL, V12, P211, DOI 10.2350/07-02-0229.1; Dome JS, 2015, J CLIN ONCOL, V33, P2999, DOI 10.1200/JCO.2015.62.1888; Favorskaya I, 2014, TUMOR BIOL, V35, P10295, DOI 10.1007/s13277-014-2348-4; Goto E, 2011, BLOOD, V118, P1600, DOI 10.1182/blood-2011-01-329433; Gupta A, 2008, EXP CELL RES, V314, P3663, DOI 10.1016/j.yexcr.2008.09.029; Gupta S, 2012, CLIN CANCER RES, V18, P280, DOI 10.1158/1078-0432.CCR-11-2165; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Honeyman JN, 2012, J PEDIATR SURG, V47, P1228, DOI 10.1016/j.jpedsurg.2012.03.030; Li WL, 2005, ONCOGENE, V24, P457, DOI 10.1038/sj.onc.1208228; Liebler S, 2004, AM J PHYSIOL-RENAL, V286, pF458, DOI 10.1152/ajprenal.00173.2003; Maschietto M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.105; Napoli JL, 1996, CLIN IMMUNOL IMMUNOP, V80, pS52, DOI 10.1006/clin.1996.0142; Noy N, 2000, BIOCHEM J, V348, P481, DOI 10.1042/0264-6021:3480481; Passeri D, 2016, J INVEST DERMATOL, V136, P1255, DOI 10.1016/j.jid.2016.01.039; Pritchard-Jones K, 2012, ANN ONCOL, V23, P2457, DOI 10.1093/annonc/mds025; Simoes MA, 2017, PATHOL RES PRACT, V213, P222, DOI 10.1016/j.prp.2016.12.011; Stiller CA, 1996, BRIT MED BULL, V52, P682; Theodosiou M, 2010, CELL MOL LIFE SCI, V67, P1423, DOI 10.1007/s00018-010-0268-z; Vreeland AC, 2014, MOL CELL BIOL, V34, P2135, DOI 10.1128/MCB.00281-14; Wang H, 2017, ONCOL LETT, V13, P2045, DOI 10.3892/ol.2017.5706; Wegert J, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-136; Zirn B, 2006, INT J CANCER, V118, P1954, DOI 10.1002/ijc.21564; Zirn B, 2005, ONCOGENE, V24, P5246, DOI 10.1038/sj.onc.1208725	25	2	3	1	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 22	2018	13								9	10.1186/s13000-018-0686-z			7	Pathology	Pathology	FX1MN	WOS:000425815700003	29378601	DOAJ Gold, Green Published			2019-10-28	
J	Cheng, N; Chen, JN; Pan, YH; Jiang, Y; Zhou, J; Shao, CK				Cheng, Na; Chen, Jianning; Pan, Yuhang; Jiang, Ye; Zhou, Jing; Shao, Chunkui			Splenic hamartoma with bizarre stromal cells: a case report and literature review	DIAGNOSTIC PATHOLOGY			English	Review						Spleen; Splenic hamartoma; Bizarre stromal cells; Immunohistochemistry	INFLAMMATORY MYOFIBROBLASTIC TUMOR; PRIMARY VASCULAR NEOPLASMS; NEEDLE-ASPIRATION BIOPSY; TUBEROUS SCLEROSIS; SPLEEN; EXPRESSION; FEATURES; PATIENT; ANGIOMA	Background: Splenic hamartoma is a rare benign vascular proliferative lesion composed of unorganized sinusoid-like channels lined with plump or flat endothelial cells and characterized by a CD8-positive immunophenotype of the lining cells. Scattered bizarre stromal cells can be found in some splenic hamartomas. The presence of splenic hamartoma with bizarre stromal cells is extremely rare and these bizarre cells make it possible to be regarded as a malignancy. Recognition of this rare histologic variant will help to avoid diagnostic confusion and overtreatment of this benign entity. Case presentation: We report a case of a 40-year-old man with occasional left-sided waist back pain. A splenic space-occupying lesion was detected by ultrasound and magnetic resonance imaging. Microscopically bizarre large cells were scattered throughout the splenic hamartoma. The cells exhibited atypical nuclei, scarcely visible cytoplasm, and vesicular chromatin, and they did not form expansile clusters and lacked mitotic activity. An immunohistochemical panel was performed. The bizarre cells strongly expressed vimentin, and the Ki-67 index was very low. The lesion was diagnosed as a splenic hamartoma with bizarre stromal cells. Conclusions: To the best of our knowledge, this is the first systematic review on a splenic hamartoma with bizarre stromal cells; only six cases have been described in the literature. Proper identification is important to secure adequate treatment.	[Cheng, Na; Chen, Jianning; Pan, Yuhang; Jiang, Ye; Zhou, Jing; Shao, Chunkui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China	Shao, CK (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.	shaochk@mail.sysu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81301694]	This work was supported by the National Natural Science Foundation of China (No. 81301694). The sponsors have no role in the study design, in the collection, analysis and interpretation of data, in the writing of the manuscript, and in the decision to submit the article for publication.	Abbott RM, 2004, RADIOGRAPHICS, V24, P1137, DOI 10.1148/rg.244045006; Abramowsky C, 2004, PEDIATR DEVEL PATHOL, V7, P231, DOI 10.1007/s10024-003-9097-5; Ali TZ, 2005, INT J SURG PATHOL, V13, P103, DOI 10.1177/106689690501300116; Arber DA, 1997, AM J SURG PATHOL, V21, P827, DOI 10.1097/00000478-199707000-00011; Cessna MH, 2002, MODERN PATHOL, V15, P931, DOI 10.1097/01.MP.0000026615.04130.1F; Chan JKC, 1997, CANCER, V79, P294; Cheuk W, 2005, AM J SURG PATHOL, V29, P109, DOI 10.1097/01.pas.0000146026.69082.68; Coffin CM, 2007, AM J SURG PATHOL, V31, P509, DOI 10.1097/01.pas.0000213393.57322.c7; COFFIN CM, 1995, AM J SURG PATHOL, V19, P859, DOI 10.1097/00000478-199508000-00001; Collins BT, 2008, ACTA CYTOL, V52, P347, DOI 10.1159/000325520; Conlon S, 2007, CYTOPATHOLOGY, V18, P200, DOI 10.1111/J.1365-2303.2006.00371.X; DARDEN JW, 1975, AM SURGEON, V41, P564; FALK S, 1989, HISTOPATHOLOGY, V14, P603, DOI 10.1111/j.1365-2559.1989.tb02201.x; Giovagnoni Andrea, 2005, Cancer Imaging, V5, P73, DOI 10.1102/1470-7330.2005.0002; Grogg KL, 2005, MODERN PATHOL, V18, P260, DOI 10.1038/modpathol.3800294; Harada S, 2008, ANN DIAGN PATHOL, V12, P212, DOI 10.1016/j.anndiagpath.2006.12.005; Lam KY, 1999, AUST NZ J SURG, V69, P422, DOI 10.1046/j.1440-1622.1999.01550.x; Laskin WB, 2005, AM J SURG PATHOL, V29, P1114; Lee H, 2009, ARCH PATHOL LAB MED, V133, P147, DOI 10.1043/1543-2165-133.1.147; Levy AD, 2004, RADIOLOGY, V230, P485, DOI 10.1148/radiol.2302030196; Ramdall RB, 2007, DIAGN CYTOPATHOL, V35, P137, DOI 10.1002/dc.20568; SILVERMAN ML, 1978, AM J CLIN PATHOL, V70, P224; VANHEERD.JA, 1967, ARCH SURG-CHICAGO, V95, P317; Yigit N, 2015, INT J HEMATOL, V101, P315, DOI 10.1007/s12185-015-1748-6; ZUKERBERG LR, 1991, HUM PATHOL, V22, P1258, DOI 10.1016/0046-8177(91)90108-2	25	1	1	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 22	2018	13								8	10.1186/s13000-018-0687-y			7	Pathology	Pathology	FX1MN	WOS:000425815700002	29378604	DOAJ Gold, Green Published			2019-10-28	
J	Graham, RP; Naini, BV; Shah, SS; Arnold, CA; Kannangai, R; Torbenson, MS; Lam-Himlin, DM				Graham, Rondell P.; Naini, Bita V.; Shah, Sejal S.; Arnold, Christina A.; Kannangai, Rajesh; Torbenson, Michael S.; Lam-Himlin, Dora M.			Treponema pallidum Immunohistochemistry is positive in human intestinal Spirochetosis	DIAGNOSTIC PATHOLOGY			English	Article						Intestinal spirochetosis; Treponema; Diarrhea; Brachyspira; Warthin-starry; B. Aalborgi; B. Pilosicoli	BRACHYSPIRA-PILOSICOLI; COLONIC SPIROCHETOSIS; AALBORGI	Background: Human intestinal spirochetosis (IS) has been recognized for decades, but whether it represents commensalism or a pathogenic process remains controversial. IS is diagnosed on routine stains with confirmation by silver stains but these stains are labor intensive and slow to read. We evaluated the Treponema pallidum immunostain as a diagnostic adjunct for IS. Methods: We retrieved biopsies from 33 patients with IS for this study. Each case was tested by Warthin-Starry (WS) and T. pallidum immunohistochemistry (IHC). Species specific genotyping was performed in 3 cases. Results: Patients with IS ranged from 22 to 82 years without gender predilection. IS involved normal (n = 15), and inflamed (n = 5) mucosa and colonic polyps (n = 13). Warthin-Starry and T. pallidum IHC were positive in all cases including both species of Brachyspira. Six (18%) symptomatic patients were treated for IS, and experienced resolution. In patients diagnosed with incidental IS on cancer screening (n = 5), follow up biopsies, without therapy, were negative for IS. T. pallidum IHC required 75 min less hands-on time than WS for performance and was faster to interpret. Conclusions: T. pallidum IHC can be used to confirm the diagnosis of IS and is easier to perform and faster to interpret than	[Graham, Rondell P.; Shah, Sejal S.; Torbenson, Michael S.] Mayo Clin, Div Anat Pathol, Dept Lab Med & Pathol, 200 First St SW, Rochester, MN 55905 USA; [Naini, Bita V.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, 10833 Le Conte Ave,Suite 27-061C7 CHS, Los Angeles, CA 90095 USA; [Arnold, Christina A.] Ohio State Univ, Dept Pathol, Wexner Med Ctr, 410 West 10th Ave, Columbus, OH 43210 USA; [Kannangai, Rajesh] Christian Med Coll & Hosp, Dept Clin Virol, Vellore 632004, Tamil Nadu, India; [Lam-Himlin, Dora M.] Mayo Clin, Div Anat Pathol, Dept Lab Med & Pathol, Scottsdale, AZ 85259 USA	Lam-Himlin, DM (reprint author), Mayo Clin, Div Anat Pathol, Dept Lab Med & Pathol, Scottsdale, AZ 85259 USA.	LamHimlin.Dora@mayo.edu	SOUNDRARAJAN, JOYSON/I-1779-2019	Graham, Rondell/0000-0002-8686-4867	Division of Anatomic Pathology, Mayo Clinic	This study was funded by the Division of Anatomic Pathology, Mayo Clinic.	Arnold CA, 2013, AM J SURG PATHOL, V37, P38, DOI 10.1097/PAS.0b013e31826a523e; Bait-Merabet Lilia, 2008, Ann Clin Microbiol Antimicrob, V7, P19, DOI 10.1186/1476-0711-7-19; COYNE JD, 1995, HISTOPATHOLOGY, V27, P377, DOI 10.1111/j.1365-2559.1995.tb01530.x; Escherich T., 1886, MUNCH MED WSCHR, V33, P815; Escherich T, 1886, MUNCH MED WSCHR, V33, P833; Esteve M, 2006, J GASTROEN HEPATOL, V21, P1326, DOI 10.1111/j.1440-1746.2006.04150.x; Graham R, 2016, LAB INVEST, V96, p173A; GUCCION JG, 1995, ULTRASTRUCT PATHOL, V19, P15, DOI 10.3109/01913129509014599; HOVINDHOUGEN K, 1982, J CLIN MICROBIOL, V16, P1127; Jensen TK, 2001, J CLIN MICROBIOL, V39, P4111, DOI 10.1128/JCM.39.11.4111-4118.2001; Korner M, 2003, INFECTION, V31, P341, DOI 10.1007/s15010-003-3145-y; Koteish A, 2003, AM J CLIN PATHOL, V120, P828, DOI 10.1039/G7U6BD85W4G3WJ0J; LEE JI, 1994, J MED MICROBIOL, V40, P365, DOI 10.1099/00222615-40-5-365; Padmanabhan V, 1996, PATHOLOGY, V28, P283, DOI 10.1080/00313029600169174; Palejwala AA, 2000, HISTOPATHOLOGY, V37, P284, DOI 10.1046/j.1365-2559.2000.01020-3.x; Prim N, 2011, J CLIN MICROBIOL, V49, P3697, DOI 10.1128/JCM.00680-11; Ruiz SJ, 2016, ARCH PATHOL LAB MED, V140, P1021, DOI 10.5858/arpa.2016-0004-LE; Smith JL, 2005, J FOOD PROTECT, V68, P1525, DOI 10.4315/0362-028X-68.7.1525; Tanahashi J, 2008, MODERN PATHOL, V21, P76, DOI 10.1038/modpathol.3800987; Tsinganou Efstathia, 2010, Ger Med Sci, V8, pDoc01, DOI 10.3205/000090; van Mook WNKA, 2004, EUR J GASTROEN HEPAT, V16, P83, DOI 10.1097/00042737-200401000-00013; Weisheit B, 2007, SCAND J GASTROENTERO, V42, P1422, DOI 10.1080/00365520701245629; Westerman LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052281; Willen R, 2006, HISTOPATHOLOGY, V49, P658, DOI 10.1111/j.1365-2559.2006.02565.x	24	1	1	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 22	2018	13								7	10.1186/s13000-017-0676-6			6	Pathology	Pathology	FX1MN	WOS:000425815700001	29378606	DOAJ Gold, Green Published			2019-10-28	
J	Hooper, JE; Richardson, H; Maters, AW; Carroll, KC; Pronovost, PJ				Hooper, Jody E.; Richardson, Hazel; Maters, Amelia W.; Carroll, Karen C.; Pronovost, Peter J.			The Association of Departmental Quality Infrastructure and Positive Change: A Pathology Department Illustration	ACADEMIC PATHOLOGY			English	Article						infrastructure; laboratory; patient safety; quality assurance; quality improvement	MANAGEMENT INFRASTRUCTURE	A vertically and horizontally well-integrated quality improvement team is essential for effective quality data collection and implementation of improvement measures. We outline the quality structure of a large academic pathology department and describe successful projects across multiple divisions made possible by this tightly integrated structure. The physician vice chair for quality organizes departmental quality efforts and provides representation at the hospital level. The department has an independent continuous quality improvement unit and each laboratory of the department has a staff quality improvement representative. Faculty and staff experts have interacted to produce improvements such as accurate container labeling, efficient triage of specimens, and reduction of unnecessary testing. Specialized task forces such as the Courier Task Force are producing concrete recommendations for process improvement. All phases of pathology patient care are represented by faculty and staff who are trained in quality improvement, and each position touches and communicates actively with levels above and below itself. The key to the department's approach has been the daily attention to quality efforts in all of its activities and the close association of faculty and staff to accomplish the goals of greater efficiency, safety, and cost savings.	[Hooper, Jody E.; Carroll, Karen C.; Pronovost, Peter J.] Johns Hopkins Univ, Dept Pathol, 600 North Wolfe St,Pathol B-106, Baltimore, MD 21287 USA; [Richardson, Hazel; Maters, Amelia W.] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA	Hooper, JE (reprint author), Johns Hopkins Univ, Dept Pathol, 600 North Wolfe St,Pathol B-106, Baltimore, MD 21287 USA.	jhooper9@jhmi.edu					de Graaf MT, 2011, J NEUROL, V258, P1507, DOI 10.1007/s00415-011-5970-8; Doran GT, 1981, MANAGE REV, V70, P35, DOI DOI 10.1177/004057368303900411; HOIBY EA, 1984, ACTA PATH MICRO IM B, V92, P73; Mathews SC, 2017, ACAD MED, V92, P608, DOI 10.1097/ACM.0000000000001380; MATSEN JM, 1976, HUM PATHOL, V7, P297, DOI 10.1016/S0046-8177(76)80040-8; Pronovost PJ, 2014, J HEALTH ORGAN MANAG, V28, P576, DOI 10.1108/JHOM-11-2013-0262	6	1	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2374-2895			ACAD PATHOL	Acad. Pathol.	JAN 18	2018	5								UNSP 2374289517744753	10.1177/2374289517744753			7	Pathology	Pathology	GH7WD	WOS:000433787300001	29376115	DOAJ Gold, Green Published			2019-10-28	
J	Liang, XL; Sun, J; Wu, HW; Luo, YF; Wang, LL; Lu, JL; Zhang, ZW; Guo, JC; Liang, ZY; Liu, TH				Liang, Xiaolong; Sun, Jian; Wu, Huanwen; Luo, Yufeng; Wang, Lili; Lu, Junliang; Zhang, Zhiwen; Guo, Junchao; Liang, Zhiyong; Liu, Tonghua			PD-L1 in pancreatic ductal adenocarcinoma: a retrospective analysis of 373 Chinese patients using an in vitro diagnostic assay	DIAGNOSTIC PATHOLOGY			English	Article						Pancreatic; PD-L1; Immunohistochemistry; Prognosis	CLINICAL-SIGNIFICANCE; CANCER; EXPRESSION; CARCINOMA; BLOCKADE; THERAPY; PATHWAY; TUMORS	Background: Programmed death ligand 1 (PD-L1) has shown potential as a therapeutic target in numerous solid tumors. Its prognostic significance has also been established in pancreatic ductal adenocarcinoma (PDAC). The present study aimed to explore PD-L1 expression in PDAC cases in a large Chinese cohort using an in vitro diagnostic (IVD) assay to provide further insight into the potential value of programmed cell death protein 1 (PD-1) as a therapeutic target. Methods: Three hundred seventy-three PDAC patients were retrospectively recruited in this study. Tissue microarray (TMA) blocks were made from available formalin-fixed and paraffin-embedded (FFPE) tumor and matched adjacent tissue specimens. We evaluated PD-L1 protein expression via immunohistochemistry (IHC) using a U.S. Food and Drug Administration (FDA)-approved IVD assay. The relationships between PD-L1 positivity and both clinicopathological characteristics and patient prognosis were analyzed. PD-1 expression and clinicopathological significance were also evaluated. Results: PD-L1 and PD-1 positivity were observed in 3.2% and 7.5% of cases, respectively. PD-L1 showed a predominantly membranous pattern in tumor cells, while no positive PD-L1 staining was observed in normal regions. Statistical analyses revealed that PD-L1 expression was associated with lymph node metastasis. PD-L1 positivity was a prognostic indicator of progression-free survival (PFS) and overall survival (OS) in univariate analyses, but only PFS remained statistically significant in multivariate analysis. PD-1 expression was detected in lymphocytes and was not associated with any clinicopathological feature except a history of pancreatitis. Conclusions: The PD-L1 positivity rate is low in PDAC when evaluated using a companion diagnostic assay. It remains an independent prognostic factor for poor PFS.	[Guo, Junchao] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China; [Liang, Xiaolong; Sun, Jian; Wu, Huanwen; Luo, Yufeng; Wang, Lili; Lu, Junliang; Zhang, Zhiwen; Guo, Junchao; Liang, Zhiyong; Liu, Tonghua] Chinese Acad Med Sci, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China; [Liang, Xiaolong; Sun, Jian; Wu, Huanwen; Luo, Yufeng; Wang, Lili; Lu, Junliang; Zhang, Zhiwen; Liang, Zhiyong; Liu, Tonghua] Peking Union Med Coll, Dept Pathol, Peking Union Med Coll Hosp, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China	Guo, JC (reprint author), Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China.; Guo, JC; Liang, ZY; Liu, TH (reprint author), Chinese Acad Med Sci, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China.; Liang, ZY; Liu, TH (reprint author), Peking Union Med Coll, Dept Pathol, Peking Union Med Coll Hosp, 1 Shuai Fu Yuan, Beijing 100730, Peoples R China.	gjcpumch@163.com; liangzhiyong1220@yahoo.com; Tonghua_liu@163.com	Wu, Huanwen/H-2888-2019	Sun, Jian/0000-0003-4997-2604	Chinese Academy of Medical Science Innovation Fund for Medical Science (CIFMS) [2016-I2M-1-002]	This study was supported by the Chinese Academy of Medical Science Innovation Fund for Medical Science (CIFMS, grant No. 2016-I2M-1-002).	Abdul Karim L, 2017, HISTOPATHOLOGY; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; Bosman FT, 2010, WHO CLASSIFICATION T; Botti G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020459; Boussiotis VA, 2016, NEW ENGL J MED, V375, P1767, DOI 10.1056/NEJMra1514296; Casadevall D, 2017, CLIN LUNG CANC; Chen Xiao-Ling, 2009, Ai Zheng, V28, P1328; Clark CE, 2009, CANCER LETT, V279, P1, DOI 10.1016/j.canlet.2008.09.037; Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963; Diana A, 2016, ONCOTARGET, V7, P40992, DOI 10.18632/oncotarget.10038; Dill EA, 2017, AM J SURG PATHOL, V41, P334, DOI 10.1097/PAS.0000000000000780; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Giraldo NA, 2017, CLIN CANC RES OFFICI; Igawa S, 2017, ONCOLOGY-BASEL, V92, P283, DOI 10.1159/000458412; Lu CW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw283; Lutz ER, 2014, CANCER IMMUNOL RES, V2, P616, DOI 10.1158/2326-6066.CIR-14-0027; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Ohigashi Y, 2005, CLIN CANCER RES, V11, P2947, DOI 10.1158/1078-0432.CCR-04-1469; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Soares KC, 2015, J IMMUNOTHER, V38, P1, DOI 10.1097/CJI.0000000000000062; Wang LH, 2010, CIVIL ENGINEERING IN CHINA - CURRENT PRACTICE AND RESEARCH REPORT, P34; Wang X, 2017, ONCOTARGET, DOI 10.18632/oncotarget.15254; Wang Y, 2017, ONCOTARGET, V8, P9354, DOI 10.18632/oncotarget.14069; Winograd R, 2015, CANCER IMMUNOL RES, V3, P399, DOI 10.1158/2326-6066.CIR-14-0215; Zhang JW, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0501-6	26	4	5	0	2	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 17	2018	13								5	10.1186/s13000-017-0678-4			8	Pathology	Pathology	FX1MJ	WOS:000425815200001	29378617	DOAJ Gold, Green Published			2019-10-28	
J	Masunaga, A; Ishibashi, F; Koh, E; Oide, T; Sekine, Y; Hiroshima, K				Masunaga, Atsuko; Ishibashi, Fumihiro; Koh, Eitetsu; Oide, Takashi; Sekine, Yasuo; Hiroshima, Kenzo			Possible relationship between fibrosis of IgG4-related thymitis and the profibrotic cytokines, transforming growth factor beta 1, interleukin 1 beta and interferon gamma: a case report	DIAGNOSTIC PATHOLOGY			English	Article						IgG4-related disease; Sclerosing mediastinitis; Thymitis; Transforming growth factor beta 1; Interleukin 1 beta; Interferon gamma; Regulatory T cells; Immunohistochemistry; Reverse transcription quantitative polymerase chain reaction	CYTOTOXIC T-LYMPHOCYTES; DISEASE; PATHOGENESIS; DIAGNOSIS; MECHANISM; CELLS	Background: IgG4-related disease often forms a mass and the affected lesion is clinically removed because the mass cannot be differentiated from a neoplasm. Affected lesions commonly occur in the pancreas, hepatobiliary tract, kidney, and retroperitoneum. However, the lesion rarely occurs in the thymus. A histological worldwide consensus of IgG4-related disease proposed that pathological diagnosis of IgG4-related disease should meet more than two of three major features: 1) dense lymphoplasmacytic infiltration with greater than 40% IgG4+/IgG+ plasma cells, 2) storiform fibrosis; and 3) obliterative phlebitis. Currently, fibrosis of IgG4-related disease is thought to be induced by profibrotic cytokines such as transforming growth factor beta 1 (TGFB1), interleukin 1 beta (IL1B) and interferon gamma (IFNG), which are secreted by regulatory T cells (Tregs) and CD4-positive cytotoxic T cells. However, it is unclear whether profibrotic cytokines are associated with the fibrosis seen in IgG4-related thymitis. Here we examined whether cytokines in the mass were increased compared with those in the surrounding thymus, and whether Tregs were present in the mass, using reverse transcription absolute quantitative polymerase chain reaction (RT-ab-qPCR) and immunohistochemistry. Case presentation: A 70-year-old Japanese man contracted IgG4-letated thymitis. Histological and immunohistochemical analyses demonstrated his mass had massive fibrosis with a focally storiform pattern and lymphoplasmacytic infiltration with 40% IgG4+/IgG+ plasma cells, but not obliterative phlebitis. The mass was surrounded by atrophic thymus. We diagnosed the mass as IgG4-related thymitis. Immunohistochemically, Tregs were scattered throughout the mass. RT-ab-qPCR showed that messenger RNA expressions of TGFB1, IL1B and IFNG in the mass were 270-, 158- and 5.5-fold higher than in the surrounding thymus. His serum IgG4 level after surgery was within the normal range (83.4 mg/dl soon after surgery, 89.3 mg/dl 2 weeks after surgery). Conclusions: Our results suggested the profibrotic cytokines TGFB1, IL1B and IFNG induce fibrosis and that Tregs might produce some of these cytokines in IgG4-related thymitis as well as in the other affected lesions of IgG4-related disease.	[Masunaga, Atsuko; Oide, Takashi; Hiroshima, Kenzo] Tokyo Womens Med Univ Yachiyo Med Ctr, Dept Pathol, 477-96 Owada Shinden, Chiba 2768524, Japan; [Masunaga, Atsuko] Showa Univ, Resp Dis Ctr, Northern Yokohama Hosp, Yokohama, Kanagawa, Japan; [Ishibashi, Fumihiro; Koh, Eitetsu; Sekine, Yasuo] Tokyo Womens Med Univ Yachiyo Med Ctr, Div Thorac Surg, Dept Surg, Chiba, Japan	Masunaga, A (reprint author), Tokyo Womens Med Univ Yachiyo Med Ctr, Dept Pathol, 477-96 Owada Shinden, Chiba 2768524, Japan.; Masunaga, A (reprint author), Showa Univ, Resp Dis Ctr, Northern Yokohama Hosp, Yokohama, Kanagawa, Japan.	masunaga.atsuko@twmu.ac.jp					Brito-Zeron P, 2014, AUTOIMMUN REV, V13, P1203, DOI 10.1016/j.autrev.2014.08.013; Chan G, 2015, WHO CLASSIFICATION T, pP209; Culver EL, 2012, J CLIN PATHOL, V65, P963, DOI 10.1136/jclinpath-2012-200932; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Fletcher CDM, 2015, WHO CLASSIFICATION T, pP291; Fox RI, 2015, ANN RHEUM DIS, V74, P1, DOI 10.1136/annrheumdis-2014-205476; Inoue M, 2007, GEN THORAC CARDIOVAS, V55, P431, DOI 10.1007/s11748-007-0154-2; Kawamura E, 2015, MOD RHEUMATOL, V25, P571, DOI 10.3109/14397595.2014.1001474; Liu X, 2015, AUTOPHAGY, INFECTION, AND THE IMMUNE RESPONSE, P1; Maehara T, 2017, ANN RHEUM DIS, V76, P377, DOI 10.1136/annrheumdis-2016-209139; Masunaga A, 2014, PATHOL INT, V64, P81, DOI 10.1111/pin.12138; Mattoo H, 2017, AUTOIMMUNITY, V50, P19, DOI 10.1080/08916934.2017.1280029; Mattoo H, 2016, J ALLERGY CLIN IMMUN, V138, P825, DOI 10.1016/j.jaci.2015.12.1330; Meng XJ, 2013, J CANCER RES THER, V9, P721, DOI 10.4103/0973-1482.126467; Okazaki K, 2014, GUT LIVER, V8, P462, DOI 10.5009/gnl14107; Stone JH, 2016, CLIN EXP RHEUMATOL, V34, pS66; Takeuchi A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00194; Uchida K, 2012, INT J RHEUMATOL, DOI 10.1155/2012/795026; Umehara H, 2017, MOD RHEUMATOL, V27, P381, DOI 10.1080/14397595.2017.1290911; Wallace ZS, 2015, ANN RHEUM DIS, V74, P190, DOI 10.1136/annrheumdis-2014-205233; Yi E, 2010, ARCH PATHOL LAB MED, V134, P417, DOI 10.1043/1543-2165-134.3.417; Zhang HY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-125	23	1	1	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 17	2018	13								6	10.1186/s13000-018-0684-1			6	Pathology	Pathology	FX1MJ	WOS:000425815200002	29439708	DOAJ Gold, Green Published			2019-10-28	
J	Bonaparte, E; Pesenti, C; Fontana, L; Falcone, R; Paganini, L; Marzorati, A; Ferrero, S; Nosotti, M; Mendogni, P; Bareggi, C; Sirchia, SM; Tabano, S; Bosari, S; Miozzo, M				Bonaparte, Eleonora; Pesenti, Chiara; Fontana, Laura; Falcone, Rossella; Paganini, Leda; Marzorati, Anna; Ferrero, Stefano; Nosotti, Mario; Mendogni, Paolo; Bareggi, Claudia; Sirchia, Silvia Maria; Tabano, Silvia; Bosari, Silvano; Miozzo, Monica			Molecular profiling of lung cancer specimens and liquid biopsies using MALDI-TOF mass spectrometry	DIAGNOSTIC PATHOLOGY			English	Article						Molecular diagnostics; MALDI-TOF mass spectrometry; Non-small cell lung cancer; Targeted therapy; Tumor genotyping	CIRCULATING TUMOR DNA; KINASE INHIBITORS; PLASMA DNA; PHASE-III; MUTATION; KRAS; CRIZOTINIB; TRIAL; CHEMOTHERAPY; RESISTANCE	Background: Identification of predictive molecular alterations in lung adenocarcinoma is essential for accurate therapeutic decisions. Although several molecular approaches are available, a number of issues, including tumor heterogeneity, frequent material scarcity, and the large number of loci to be investigated, must be taken into account in selecting the most appropriate technique. MALDI-TOF mass spectrometry (MS), which allows multiplexed genotyping, has been adopted in routine diagnostics as a sensitive, reliable, fast, and cost-effective method. Our aim was to test the reliability of this approach in detecting targetable mutations in non-small cell lung cancer (NSCLC). In addition, we also analyzed low-quality samples, such as cytologic specimens, that often, are the unique source of starting material in lung cancer cases, to test the sensitivity of the system. Methods: We designed a MS-based assay for testing 158 mutations in the EGFR, KRAS, BRAF, ALK, PIK3CA, ERBB2, DDR2, AKT, and MEK1 genes and applied it to 92 NSCLC specimens and 13 liquid biopsies from another subset of NSCLC patients. We also tested the sensitivity of the method to distinguish low represented mutations using serial dilutions of mutated DNA. Results: Our panel is able to detect the most common NSCLC mutations and the frequency of the mutations observed in our cohort was comparable to literature data. The assay identifies mutated alleles at frequencies of 2.5-10%. In addition, we found that the amount of DNA template was irrelevant to efficiently uncover mutated alleles present at high frequency. However, when using less than 10 ng of DNA, the assay can detect mutations present in at least 10% of the alleles. Finally, using MS and a commercial kit for RT-PCR we tested liquid biopsy from 13 patients with identified mutations in cancers and detected the mutations in 4 (MS) and in 5 samples (RT-PCR). Conclusions: MS is a powerful method for the routine predictive tests of lung cancer also using low quality and scant tissues. Finally, after appropriate validation and improvement, MS could represent a promising and cost-effective strategy for monitoring the presence and percentage of the mutations also in non-invasive sampling.	[Bonaparte, Eleonora; Pesenti, Chiara; Fontana, Laura; Falcone, Rossella; Paganini, Leda; Marzorati, Anna; Nosotti, Mario; Tabano, Silvia; Bosari, Silvano; Miozzo, Monica] Univ Milan, Dept Pathophysiol & Transplantat, Via Francesco Sforza 35, I-20122 Milan, Italy; [Bonaparte, Eleonora; Pesenti, Chiara; Paganini, Leda; Ferrero, Stefano; Tabano, Silvia; Bosari, Silvano; Miozzo, Monica] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Via Francesco Sforza 35, I-20122 Milan, Italy; [Ferrero, Stefano] Univ Milan, Dept Biomed Surg & Dent Sci, Med Sch, Via Francesco Sforza 35, I-20122 Milan, Italy; [Nosotti, Mario; Mendogni, Paolo] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Thorac Surg & Lung Transplantat Unit, Via Francesco Sforza 35, I-20122 Milan, Italy; [Bareggi, Claudia] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Oncol Unit, Via Francesco Sforza 35, I-20122 Milan, Italy; [Sirchia, Silvia Maria] Univ Milan, Med Genet, Dept Hlth Sci, Via Antonio di Rudini 8, I-20142 Milan, Italy	Tabano, S (reprint author), Univ Milan, Dept Pathophysiol & Transplantat, Via Francesco Sforza 35, I-20122 Milan, Italy.; Tabano, S (reprint author), Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Via Francesco Sforza 35, I-20122 Milan, Italy.	silvia.tabano@unimi.it	Sirchia, Silvia/AAB-2620-2019; Fontana, Laura/AAB-9869-2019; Bosari, Silvano/K-7744-2016	Fontana, Laura/0000-0001-9517-6997; Bosari, Silvano/0000-0002-9744-6951; Miozzo, Monica/0000-0002-6523-4575	Ministero della Salute, Regione Lombardia [RF-2011-02347106]	Ministero della Salute, Regione Lombardia (Ricerca Finalizzata 2011-2012, RF-2011-02347106 to Monica Miozzo). IRCCS Ca' Granda - Ospedale Maggiore Policlinico di Milano (Progetto a Concorso 2014-2015 to Mario Nosotti).	Arcila M, 2011, J MOL DIAGN, V13, P64, DOI 10.1016/j.jmoldx.2010.11.005; Cagle PT, 2011, ARCH PATHOL LAB MED, V135, P110, DOI 10.1043/2010-0567-RA.1; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; de Biase D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083607; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Fontana L, 2016, J NEUROPATHOL EXP NE; Heitzer E, 2015, CLIN CHEM, V61, P112, DOI 10.1373/clinchem.2014.222679; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Janne PA, 2015, BRIT J CANCER, V113, P199, DOI 10.1038/bjc.2015.215; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Jorge SE, 2015, LUNG CANCER, V90, P369, DOI 10.1016/j.lungcan.2015.10.028; Keedy VL, 2011, J CLIN ONCOL, V29, P2121, DOI 10.1200/JCO.2010.31.8923; Kriegsmann M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0364-3; Liu SV, 2014, EXPERT OPIN EMERG DR, V19, P51, DOI 10.1517/14728214.2014.873403; Louis DNOH, 2016, WHO HISTOLOGICAL CLA; Magliacane G, 2015, ONCOTARGET, V6, P30592, DOI 10.18632/oncotarget.5190; Nakamura T, 2011, J THORAC ONCOL, V6, P1639, DOI 10.1097/JTO.0b013e31822956e8; Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5; Perkins G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047020; Reck M, 2013, LANCET, V382, P709, DOI 10.1016/S0140-6736(13)61502-0; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806; Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766; Sirchia SM, 2016, EPIGENOMICS-UK, V8, P341, DOI 10.2217/epi.15.111; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Sorensen BS, 2014, CANCER-AM CANCER SOC, V120, P3896, DOI 10.1002/cncr.28964; Travis WD, 2015, WHO CLASSIFICATION T; Weber B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-294; Young EC, 2013, DIAGN MOL PATHOL, V22, P190, DOI 10.1097/PDM.0b013e318294936c	29	1	1	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 12	2018	13								4	10.1186/s13000-017-0683-7			9	Pathology	Pathology	FX1MF	WOS:000425814800001	29368620	DOAJ Gold, Green Published			2019-10-28	
J	Alessandrini, L; Clemente, N; Perin, T; Giorda, G; Canzonieri, V; Sopracordevole, F				Alessandrini, Lara; Clemente, Nicolo; Perin, Tiziana; Giorda, Giorgio; Canzonieri, Vincenzo; Sopracordevole, Francesco			Extramammary Paget disease of the vulva: immunohistochemical analysis of neoangiogenesis and epithelial-mesenchymal transition markers expression	DIAGNOSTIC PATHOLOGY			English	Article						Paget disease; Vulva; Neoangiogenesis; EMT; Microvessel density; HVD; AVD	ANTI-ANGIOGENESIS THERAPY; ENDOTHELIAL GROWTH-FACTOR; INTRAEPITHELIAL NEOPLASIA; MICROVESSEL DENSITY; E-CADHERIN; CANCER; PROGNOSIS; CARCINOMA; PROGRESSION; EXCISION	Background: Extra-mammary Paget's disease of the vulva (EMPDV) is an infrequent chronic disease that often recurs. The aim of the study was to assess the presence of neoangiogenesis and the expression of epithelial-mesenchymal transition (EMT) markers in EMPDV, and their potential correlation with stromal invasion. Methods: All the women consecutively treated for EMPDV at our Institute, between January 2011 and December 2014, were studied for neoangiogenesis, analysed by microvessel density (MVD) using antibodies against CD31 and CD34. Immunohistochemical expression of E-/N-cadherin, beta-catenin and SLUG was also evaluated. In each slide, three fields with the highest number of capillaries and small venules were identified at low power. In these three fields, the highest vessel density (HVD) and the average vessel density (AVD) at 200x and 400x magnification were counted. Immunohistochemical reactions for non-vascular markers were semiquantitatively scored by two pathologists, using a three-tier scale. Results: Seventeen cases of EMPDV (including 10 cases of invasive disease) were included. The AVD at 200x and 400x and the HVD at 400x magnification were significantly associated with invasive EMPDV (p = 0.02, 0.03, 0.03 respectively). No significant correlation between MVD, EMT-markers expression and risk of recurrence was detected. Conclusion: These results indicate that MVD, as a measure of neoangiogenesis, may be associated with histological progression of EMPDV. EMT could also be linked to an invasive potential of EMPDV but larger series are required to confirm this hypothesis.	[Alessandrini, Lara; Perin, Tiziana; Canzonieri, Vincenzo] IRCCS, Natl Canc Inst, CRO, Pathol Unit, Via Franco Gallini 2, I-33081 Aviano, Italy; [Clemente, Nicolo; Giorda, Giorgio; Sopracordevole, Francesco] IRCCS, Natl Canc Inst, CRO, Gynecol Oncol Unit, Aviano, Italy	Canzonieri, V (reprint author), IRCCS, Natl Canc Inst, CRO, Pathol Unit, Via Franco Gallini 2, I-33081 Aviano, Italy.	vcanzonieri@cro.it	Canzonieri, Vincenzo/AAA-7951-2019; Giorda, Giorgio/S-6803-2019; Canzonieri, Vincenzo/Z-5933-2019	Canzonieri, Vincenzo/0000-0001-6010-0976; Giorda, Giorgio/0000-0001-6386-3565; 			BancherTodesca D, 1997, GYNECOL ONCOL, V64, P496, DOI 10.1006/gyno.1996.4582; BEHRENDTZ H, 1994, INT J GYNECOL CANCER, V4, P1; Black D, 2007, GYNECOL ONCOL, V104, P547, DOI 10.1016/j.ygyno.2006.09.017; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; BOYER B, 1993, APMIS, V101, P257, DOI 10.1111/j.1699-0463.1993.tb00109.x; Crawford D, 1999, INT J GYNECOL PATHOL, V18, P351, DOI 10.1097/00004347-199910000-00010; Delport ES, 2013, AUSTRALAS J DERMATOL, V54, P9, DOI 10.1111/j.1440-0960.2012.00898.x; Edey KA, 2013, COCHRANE DB SYST REV, V10; Ellis PE, 2008, MODERN PATHOL, V21, P1192, DOI 10.1038/modpathol.2008.50; Ellis PE, 2012, J ONCOL, DOI 10.1155/2012/651507; Fanning J, 1999, AM J OBSTET GYNECOL, V180, P24, DOI 10.1016/S0002-9378(99)70143-2; Hotz B, 2007, CLIN CANCER RES, V13, P4769, DOI 10.1158/1078-0432.CCR-06-2926; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kurman RJ, 2014, WHO CLASSIFICATION T; Lascombe I, 2006, CLIN CANCER RES, V12, P2780, DOI 10.1158/1078-0432.CCR-05-2387; Li B, 2013, INT J CLIN EXP PATHO, V6, P1362; Lloyd J, 2000, J CLIN PATHOL, V53, P742, DOI 10.1136/jcp.53.10.742; MIETTINEN M, 1994, MODERN PATHOL, V7, P82; Nayha VV, 2007, ACTA OBSTET GYN SCAN, V86, P1392, DOI 10.1080/00016340701674303; Obermair A, 1996, GYNECOL ONCOL, V63, P204, DOI 10.1006/gyno.1996.0307; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Saravanamuthu J, 2003, GYNECOL ONCOL, V89, P251, DOI 10.1016/S0090-8258(03)00055-6; Shaco-Levy R, 2010, EUR J OBSTET GYN R B, V149, P86, DOI 10.1016/j.ejogrb.2009.11.003; Shojaei F, 2012, CANCER LETT, V320, P130, DOI 10.1016/j.canlet.2012.03.008; Siemerink MJ, 2013, J HISTOCHEM CYTOCHEM, V61, P101, DOI 10.1369/0022155412467635; Sopracordevole F, 2016, J LOW GENIT TRACT DI, V20, P184, DOI 10.1097/LGT.0000000000000191; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tebes S, 2002, AM J OBSTET GYNECOL, V187, P281, DOI 10.1067/mob.2002.125700; Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305; van der Linden M, 2016, CRIT REV ONCOL HEMAT, V101, P60, DOI 10.1016/j.critrevonc.2016.03.008; Xu XY, 2015, INT J CLIN EXP PATHO, V8, P3062	31	3	3	0	0	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 3	2018	13								2	10.1186/s13000-017-0680-x			8	Pathology	Pathology	FY2YY	WOS:000426684700001	29368628	DOAJ Gold, Green Published			2019-10-28	
J	Ito, S; Kitazawa, R; Haraguchi, R; Kondo, T; Ouchi, A; Ueda, Y; Kitazawa, S				Ito, Saki; Kitazawa, Riko; Haraguchi, Ryuma; Kondo, Takeshi; Ouchi, Ayaka; Ueda, Yasuo; Kitazawa, Sohei			Novel GLI3 variant causing overlapped Greig cephalopolysyndactyly syndrome (GCPS) and Pallister-Hall syndrome (PHS) phenotype with agenesis of gallbladder and pancreas	DIAGNOSTIC PATHOLOGY			English	Article						GLI3; Hedgehog; Greig cephalopolysyndactyly syndrome; Pallister-hall syndrome	SONIC HEDGEHOG; MUTATIONS; REPRESSOR; ASSOCIATION; EXPRESSION; LIMB	Background: A proper balance between the activator and the repressor form of GLI3, a zinc-finger transcription factor downstream of hedgehog signaling, is essential for proper development of various organs during development. Mutations in different domains of the GLI3 gene underlie several congenital diseases including Greig cephalopolysyndactyly syndrome (GCPS) and Pallister-Hall syndrome (PHS). Case presentation: Here, we describe the case of an overlapped phenotype of these syndromes with agenesis of the gallbladder and the pancreas, bearing a c.2155 C > T novel likely pathogenic variant of GLI3 gene by missense point mutation causing p.P719S at the proteolytic cleavage site. Conclusions: Although agenesis of the gallbladder and the pancreas is uncommon in GLI3 morphopathy, a slight difference in the gradient or the balance between activator and repressor in this case may hinder sophisticated spatial and sequential hedgehog signaling that is essential for proper development of gallbladder and pancreas from endodermal buds.	[Ito, Saki; Kitazawa, Riko; Haraguchi, Ryuma; Ouchi, Ayaka; Ueda, Yasuo; Kitazawa, Sohei] Ehime Univ, Grad Sch Med, Dept Mol Pathol, Toon City, Ehime 7910295, Japan; [Kitazawa, Riko; Ouchi, Ayaka; Ueda, Yasuo] Ehime Univ Hosp, Div Diagnost Pathol, Toon City, Ehime 7910295, Japan; [Kondo, Takeshi] Kobe Univ, Grad Sch Med, Div Legal Med, Kobe, Hyogo 6500017, Japan	Kitazawa, S (reprint author), Ehime Univ, Grad Sch Med, Dept Mol Pathol, Toon City, Ehime 7910295, Japan.	kitazawa@m.ehime-u.ac.jp	Kitazawa, Sohei/E-5602-2010	Kitazawa, Sohei/0000-0002-7466-7356	Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI)Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H05161, 15 K08426]	SK and RK receive research support from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI, # 16H05161 and 15 K08426, respectively).	Al-Qattan MM, 2017, CLIN GENET, V92, P457, DOI 10.1111/cge.12952; Biesecker LG, 1993, GENEREVIEWS; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Bok J, 2007, DEVELOPMENT, V134, P1713, DOI 10.1242/dev.000760; Cao T, 2013, DEV BIOL, V379, P221, DOI 10.1016/j.ydbio.2013.04.025; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Demurger F, 2015, EUR J HUM GENET, V23, P92, DOI 10.1038/ejhg.2014.62; Hall JG, 2016, GENE, V589, P100, DOI 10.1016/j.gene.2016.01.003; Krauss S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007471; Lei QB, 2004, DEVELOPMENT, V131, P3593, DOI 10.1242/dev.01230; Li JA, 2011, DEV DYNAM, V240, P766, DOI 10.1002/dvdy.22578; Marigo V, 1996, DEV BIOL, V180, P273, DOI 10.1006/dbio.1996.0300; McDonald-McGinn DM, 2010, AM J MED GENET A, V152A, P1654, DOI 10.1002/ajmg.a.33495; Motoyama Jun, 2006, Congenital Anomalies, V46, P123, DOI 10.1111/j.1741-4520.2006.00114.x; Qin JA, 2011, P NATL ACAD SCI USA, V108, P1456, DOI 10.1073/pnas.1011410108; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; SLACK JMW, 1995, DEVELOPMENT, V121, P1569; Teo AKK, 2016, STEM CELL REP, V6, P357, DOI 10.1016/j.stemcr.2016.01.007; VORTKAMP A, 1991, NATURE, V352, P539, DOI 10.1038/352539a0; WALTERHOUSE D, 1993, DEV DYNAM, V196, P91, DOI 10.1002/aja.1001960203; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wild A, 1997, HUM MOL GENET, V6, P1979, DOI 10.1093/hmg/6.11.1979	22	3	3	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 3	2018	13								1	10.1186/s13000-017-0682-8			4	Pathology	Pathology	FX1LQ	WOS:000425813200001	29368652	DOAJ Gold, Green Published			2019-10-28	
J	Sakai, Y; Imamura, Y				Sakai, Yasuhiro; Imamura, Yoshiaki			Case report: IgG4-related mass-forming thyroiditis accompanied by regional lymphadenopathy	DIAGNOSTIC PATHOLOGY			English	Article						IgG4-related disease; Mass-forming thyroiditis; Regional lymphadenopathy	IGG4-POSITIVE PLASMA-CELLS; SCLEROSING DISEASE; HASHIMOTOS-THYROIDITIS; INFLAMMATORY PSEUDOTUMOR; AUTOIMMUNE PANCREATITIS; SYSTEMIC-DISEASE; RESPECT; IGG4; FEATURES	Background: It has been recently accepted that IgG4-related thyroiditis is comparable to the Hashimoto and Riedel thyroiditis and Graves disease which are rich in IgG4-secreting plasma cells. Many physicians believe that in IgG4-related thyroiditis, the thyroid is entirely enlarged and diffusely affected, which is similar to conventional thyroiditis, but rarely ever accompanied by pseudoneoplastic mass formation as in IgG4-related disease in the other organs. This report introduces another pattern of IgG4-related thyroiditis as mass-forming thyroiditis and presents the occurrence of IgG4related regional lymphadenopathy as an unusual accompanying symptom. Case presentation: A 66-year-old woman presented with an approximately 2.5-cm mass in the right thyroidal lobe and regional lymph node swelling, which were preoperatively misinterpreted as thyroidal carcinoma. After lobectomy, histological examination was performed, revealing that the mass showed dense stromal fibrosis, lymphoplasmacytic infiltration, and effacement of thyroid follicles, while the background thyroidal tissue seemed to mimic lymphocytic thyroiditis without fibrosis. Immunohistochemistry revealed predominance of IgG4-secreting plasma cells among infiltrating lymphocytes independent of mass lesion or background tissue. In addition, the regional Delphian and paratracheal lymph nodes were swollen, histologically showing numerous IgG4-secreting plasma cell infiltrations in the interfollicular zone. Conclusions: IgG4-related mass-forming thyroiditis, which may be an extremely rare but recognizable pattern of IgG4-related thyroiditis, may be distinguishable from Hashimoto and Riedel thyroiditis, Graves disease, and thyroidal carcinoma. In addition, the regional IgG4-related lymphadenopathy, also possibly misdiagnosed as metastatic thyroidal carcinoma, may be a newly recognized manifestation of IgG4-related thyroiditis.	[Sakai, Yasuhiro] Univ Fukui, Dept Tumor Pathol, Fac Med Sci, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan; [Sakai, Yasuhiro; Imamura, Yoshiaki] Univ Fukui Hosp, Div Diagnost Pathol Surg Pathol, Eiheiji, Japan	Sakai, Y (reprint author), Univ Fukui, Dept Tumor Pathol, Fac Med Sci, 23-3 Matsuoka Shimoaizuki, Eiheiji, Fukui 9101193, Japan.; Sakai, Y (reprint author), Univ Fukui Hosp, Div Diagnost Pathol Surg Pathol, Eiheiji, Japan.	ya-sakai@u-fukui.ac.jp		Sakai, Yasuhiro/0000-0001-7210-9249			Carruthers MN, 2015, ANN RHEUM DIS, V74, P14, DOI 10.1136/annrheumdis-2013-204907; Cheuk W, 2008, AM J SURG PATHOL, V32, P671, DOI 10.1097/PAS.0b013e318157c068; Cheuk W, 2010, ADV ANAT PATHOL, V17, P303, DOI 10.1097/PAP.0b013e3181ee63ce; Cheuk W, 2009, AM J SURG PATHOL, V33, P1713, DOI 10.1097/PAS.0b013e3181b201de; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Dahlgren M, 2010, ARTHRIT CARE RES, V62, P1312, DOI 10.1002/acr.20215; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Hamano H, 2001, NEW ENGL J MED, V344, P732, DOI 10.1056/NEJM200103083441005; Kakudo K, 2012, ENDOCR J, V59, P273, DOI 10.1507/endocrj.EJ11-0309; Kamisawa T, 2003, AM J GASTROENTEROL, V98, P2811, DOI 10.1111/j.1572-0241.2003.08758.x; Kawano H, 2016, PATHOL INT, V66, P23, DOI 10.1111/pin.12364; Khosroshahi A, 2011, CURR OPIN RHEUMATOL, V23, P57, DOI 10.1097/BOR.0b013e3283418057; Kottahachchi D, 2016, EUR THYROID J, V5, P231, DOI 10.1159/000452623; Kumar V, 2015, ROBBINS COTRAN PATHO; Li YQ, 2012, MODERN PATHOL, V25, P1086, DOI 10.1038/modpathol.2012.68; Li YQ, 2011, CURR OPIN RHEUMATOL, V23, P102, DOI 10.1097/BOR.0b013e328341378c; Li YQ, 2010, J CLIN ENDOCR METAB, V95, P1309, DOI 10.1210/jc.2009-1794; Li YQ, 2009, PATHOL INT, V59, P636, DOI 10.1111/j.1440-1827.2009.02419.x; Masaki Y, 2014, J CLIN EXP HEMATOP, V54, P95, DOI 10.3960/jslrt.54.95; Miyoshi H, 2008, PANCREAS, V36, P133, DOI 10.1097/MPA.0b013e3181577553; Raess PW, 2015, ENDOCR PATHOL, V26, P170, DOI 10.1007/s12022-015-9368-5; Rollins-Raval MA, 2012, INT J SURG PATHOL, V20, P47, DOI 10.1177/1066896911420562; Yamamoto Motohisa, 2006, Mod Rheumatol, V16, P335; Zen Y, 2005, AM J SURG PATHOL, V29, P275, DOI 10.1097/01.pas.0000147399.10639.f5; Zen Y, 2007, MODERN PATHOL, V20, P884, DOI 10.1038/modpathol.3800836; Zen Y, 2007, HEPATOLOGY, V45, P1538, DOI 10.1002/hep.21697; Zen Y, 2009, AM J SURG PATHOL, V33, P1833, DOI 10.1097/PAS.0b013e3181b72882	27	1	1	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1746-1596			DIAGN PATHOL	Diagn. Pathol.	JAN 3	2018	13								3	10.1186/s13000-017-0681-9			5	Pathology	Pathology	FX1LT	WOS:000425813500001	29378608	DOAJ Gold, Green Published			2019-10-28	
J	Gupta, N; Carreon, CK; Sen, F; Farmer, P; Zhang, XM; Sheikh-Fayyaz, S; Haghi, N				Gupta, Neha; Carreon, Chrystalle Katte; Sen, Filiz; Farmer, Peter; Zhang, Xinmin; Sheikh-Fayyaz, Silvat; Haghi, Nina			CD5-Positive Intravascular Large B-Cell Lymphoma in a Patient with Wilson's Disease: Case Report and Review of the Literature	CASE REPORTS IN PATHOLOGY			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; RETROSPECTIVE ANALYSIS; NATURAL-HISTORY; MANAGEMENT	Intravascular large B-cell lymphoma (IVLBCL) is a rare extra-nodal B-cell lymphoma that proliferates within small/intermediate blood vessels and capillaries while sparing large blood vessels and organ parenchyma. Clinical presentation is highly variable and may include B symptoms, neurological deficits, and/or cutaneous findings. The diagnosis of IVLBCL is difficult due to multiorgan involvement and nonspecific symptoms. We describe the case of a 68-year-old male who presented with progressive weakness, confusion, and falls. He had a past medical history of liver cirrhosis secondary to Wilson's disease. Physical exam and laboratory results revealed a lethargic man with jaundice, hepatic encephalopathy, and abnormal liver/kidney function tests. He expired after a short hospital course in the setting of hepatic and renal failure. Postmortem examination revealed large neoplastic lymphoid cells involving multiple organ blood vessels; however skin and neurologic involvement was absent. The neoplastic cells demonstrated B-cells positive for CD5, rendering a diagnosis of IVLBCL. Our case represents the occurrence of IVLBCL with CD5-positivity in a patient with Wilson's disease, diagnosed at autopsy demonstrating the challenging nature of diagnosing IVLBCL.	[Gupta, Neha; Farmer, Peter; Zhang, Xinmin; Sheikh-Fayyaz, Silvat; Haghi, Nina] Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, 6 Ohio Dr,Suite 202, Lake Success, NY 11042 USA; [Carreon, Chrystalle Katte] Harvard Med Sch, Boston Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA; [Sen, Filiz] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA	Gupta, N (reprint author), Donald & Barbara Zucker Sch Med Hofstra Northwell, Dept Pathol & Lab Med, 6 Ohio Dr,Suite 202, Lake Success, NY 11042 USA.	ngupta4@northwell.edu					Bilgili SG, 2013, RENAL FAILURE, V35, P1163, DOI 10.3109/0886022X.2013.817277; Brunet V, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005985; Ferreri AJM, 2004, BRIT J HAEMATOL, V127, P173, DOI 10.1111/j.1365-2141.2004.05177.x; Fonkem E, 2014, CANCER MED-US, V3, P1010, DOI 10.1002/cam4.269; Klairmont MM, 2018, AM J CLIN PATHOL, V150, P18, DOI 10.1093/ajcp/aqy023; Linnik Y, 2018, INT J SURG PATHOL, V26, P428, DOI 10.1177/1066896918763282; Maeda S, 2014, PEDIATR INT, V56, P626, DOI 10.1111/ped.12313; Martusewicz-Boros M, 2007, J CLIN ONCOL, V25, P2137, DOI 10.1200/JCO.2007.10.7201; Masaki Y, 2009, INT J HEMATOL, V89, P600, DOI 10.1007/s12185-009-0304-7; Murase T, 2007, BLOOD, V109, P478, DOI 10.1182/blood-2006-01-021253; Nakamura S., 2016, WHO CLASSIFICATION T; PFLEGER L, 1959, Hautarzt, V10, P359; Ronny Faisal Mahmudul Huq, 2017, Autops Case Rep, V7, P30, DOI 10.4322/acr.2017.034; Sekiguchi N, 2013, INTERNAL MED, V52, P1903, DOI 10.2169/internalmedicine.52.0278; Shimada K, 2008, J CLIN ONCOL, V26, P3189, DOI 10.1200/JCO.2007.15.4278; Shimada K, 2010, CANCER SCI, V101, P1480, DOI 10.1111/j.1349-7006.2010.01555.x; Shimada K, 2009, LANCET ONCOL, V10, P895, DOI 10.1016/S1470-2045(09)70140-8; Singh D, 2016, CASE REP HEMATOL, DOI 10.1155/2016/6239416; Suehara Y, 2018, HAEMATOLOGICA, V103, pE241, DOI 10.3324/haematol.2017.178830; Yuce A, 2000, TURKISH J PEDIATR, V42, P256; Zuckerman D, 2006, ONCOLOGIST, V11, P496, DOI 10.1634/theoncologist.11-5-496	21	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5140586	10.1155/2018/5140586			5	Pathology	Pathology	HR1VC	WOS:000462922900001	30643658	DOAJ Gold, Green Published			2019-10-28	
J	McCarthy, MW; Walsh, TJ				McCarthy, Matthew W.; Walsh, Thomas J.			Galactomannan antigenemia as a biomarker for therapeutic response of invasive aspergillosis: implications for clinical trial design and patient care	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Aspergillosis; E1210; galactomannan; antigenemia; isavuconazole	AMPHOTERICIN-B; AGENT E1210; ANTIFUNGAL; ISAVUCONAZOLE; VORICONAZOLE; PHARMACODYNAMICS; ASP2397; INDEX	Introduction: Clinical trials for invasive pulmonary aspergillosis, a potentially lethal mold infection, are complex investigations that require protracted time and extensive resources, delaying the development of new antifungal agents for this important disease.Areas covered: In this paper, the authors examine a novel approach to study invasive pulmonary aspergillosis in humans, with a focus on the potentials and pitfalls of surrogate end points such as galactomannan antigenemia to evaluate therapeutic response to novel compounds.Expert commentary: The authors believe the use of serum galactomannan as a primary end point in clinical trials may allow for development studies that could be accomplished with fewer resources. It is widely appreciated that serum galactomannan values strongly correlate with outcome of invasive aspergillosis in patients with hematologic cancer and may be applicable to other at-risk patient populations.	[McCarthy, Matthew W.] New York Presbyterian Hosp, Div Gen Internal Med, Weill Cornell Med Coll, New York, NY USA; [Walsh, Thomas J.] New York Presbyterian Hosp, Weill Cornell Med Coll, Transplantat Oncol Infect Dis Program, Weill Cornell Med Coll, New York, NY USA	McCarthy, MW (reprint author), 525 East 68th St,Box 331, New York, NY 10065 USA.	mwm9004@med.cornell.edu					Arendrup MC, 2016, ANTIMICROB AGENTS CH, V60, P532, DOI 10.1128/AAC.02336-15; Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191; Ishii M, 2017, DRUG DISCOV THER, V11, P1, DOI 10.5582/ddt.2016.01080; Kovanda LL, 2017, CLIN INFECT DIS, V64, P1557, DOI 10.1093/cid/cix198; Kovanda LL, 2016, J ANTIMICROB CHEMOTH, V71, P1885, DOI 10.1093/jac/dkw098; Maertens JA, 2016, LANCET, V387, P760, DOI 10.1016/S0140-6736(15)01159-9; Marr KA, 2008, CLIN INFECT DIS, V46, P1423, DOI 10.1086/528715; McCarthy MW, 2017, J INFECT DIS, V216, pS474, DOI 10.1093/infdis/jix130; Miceli MH, 2008, CLIN INFECT DIS, V46, P1412, DOI 10.1086/528714; Nakamura I, 2017, J ANTIBIOT, V70, P45, DOI 10.1038/ja.2016.107; Neofytos D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129022; Nouer SA, 2011, CLIN INFECT DIS, V53, P671, DOI 10.1093/cid/cir441; Oliver JD, 2016, P NATL ACAD SCI US; Osherov N, 2016, MED MYCOL, V55, P1048; Osherov N, 2017, MED MYCOL, V55, P118, DOI 10.1093/mmy/myw060; Panthee S, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00373; Patterson TF, 2005, CLIN INFECT DIS, V41, P1448, DOI 10.1086/497126; Patterson TF, 2016, CLIN INFECT DIS, V63, pE1, DOI 10.1093/cid/ciw326; Pfaller MA, 2011, J ANTIMICROB CHEMOTH, V66, P2581, DOI 10.1093/jac/dkr342; Roilides E, 2016, LANCET INFECT DIS, V16, P761, DOI 10.1016/S1473-3099(16)00127-4; Watanabe N, 2012, ANTIMICROB AGENTS CH, V56, P960, DOI 10.1128/AAC.00731-11; Wiederhold NP, 2015, ANTIMICROB AGENTS CH, V59, P690, DOI 10.1128/AAC.03944-14; Zou MX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043347	23	2	2	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					601	604		10.1080/14737159.2018.1488589			4	Pathology	Pathology	GP3EX	WOS:000440725900003	29897826				2019-10-28	
B	McAloose, D; Colegrove, KM; Newton, AL		Terio, KA; McAloose, D; StLeger, J		McAloose, Denise; Colegrove, Kathleen M.; Newton, Alisa L.			Wildlife Necropsy	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter									[McAloose, Denise; Newton, Alisa L.] Wildlife Conservat Soc, Bronx, NY 10460 USA; [Colegrove, Kathleen M.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA	McAloose, D (reprint author), Wildlife Conservat Soc, Bronx, NY 10460 USA.						CDC, 2016, GUID DIS STER HEALTH; Eros C., 2007, PROCEDURES SALVAGE N; Farris S., 2013, NECROPSIES REPTILES; Foelix R. F., 2011, BIOL SPIDERS; Geering W., 2001, DISPOSAL PROCEDURE M; Harrison F., 1991, MICROSCOPIC ANATOMY; Hopkin S.P., 1992, BIOL MILLIPEDES; KELLY A, 2016, PREDICT OPERATING PR, P24; Lee C.-Y., 1979, SNAKE VENOMS, P1130; Munson L., 2000, CONSERVATION RES AFR; Polis G.A, 1990, BIOL SCORPIONS; PREDICT, 2016, PREDICT OPERATING PR, P29; PREDICT, 2016, PREDICT OPERATING PR, P47; Pugliares K., 2007, MARINE MAMMAL NECROP; Raverty S., 2014, KILLER WHALE NECROPS; Raverty S., 2018, CRC HDB MARINE MAMMA; Reingold AL, 1998, EMERG INFECT DIS, V4, P21, DOI 10.3201/eid0401.980104; Richmond JY, 2003, ILAR J, V44, P20, DOI 10.1093/ilar.44.1.20; Rideout Bruce A, 2012, Vet Clin North Am Exot Anim Pract, V15, P155, DOI 10.1016/j.cvex.2012.02.005; RUPPERT EE, 2003, INVERTEBRATE ZOOLOGY; Stoskopf MK, 1996, J ZOO WILDLIFE MED, V27, P1; Terrell Scott P., 2007, P219; UFl, 2017, SEA TURTL NECR BIOSP; Villarroel A., 2015, PRACTICAL CLIN EPIDE, P109, DOI [10.1002/9781119421382.ch7, DOI 10.1002/9781119421382.CH7.PP.109-119]; WHO, 2006, WMMR WEEKLY MORBIDIT, P23; WHO, 2004, LAB BIOS MAN, P1; Willis N. G., 2003, Compendium of technical items presented to the international committee or to regional commissions, 2003, P149; Woodford M., 2000, PROCEDURES WILDLIFE	28	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							1	+		10.1016/B978-0-12-805306-5.00001-8			1092	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300003					2019-10-28	
B	Viner, TC; Kagan, RA		Terio, KA; McAloose, D; StLeger, J		Viner, Tabitha C.; Kagan, Rebecca A.			Forensic Wildlife Pathology	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							BLUNT FORCE TRAUMA; ANTICOAGULANT RODENTICIDES; AVIAN MORTALITY; BONE-FRACTURES; GUNSHOT; CYANIDE; CHOLINESTERASE; ARTIFACTS; TOXICITY; NECROPSY		[Viner, Tabitha C.; Kagan, Rebecca A.] US Fish & Wildlife Serv, Ashland, OR 97520 USA	Viner, TC (reprint author), US Fish & Wildlife Serv, Ashland, OR 97520 USA.						Albert CA, 2010, ARCH ENVIRON CON TOX, V58, P451, DOI 10.1007/s00244-009-9402-z; [Anonymous], 2011, USE AVITROL BAITS PE; Asamura H, 2004, J FORENSIC SCI, V49, P592; Bakovic M, 2014, J FORENSIC SCI, V59, P1658, DOI 10.1111/1556-4029.12486; Behrensmeyer AK, 2003, PALEOBIOLOGY, V29, P52, DOI 10.1666/0094-8373(2003)029<0052:TAEOMA>2.0.CO;2; Birkle P, 2005, WATER ENVIRON RES, V77, P68, DOI 10.2175/106143005X41645; Bradley-Siemens N, 2016, VET PATHOL, V53, P988, DOI 10.1177/0300985816653170; Burns R.J., 1990, Proceedings of the Vertebrate Pest Conference, V14, P281; Campbell-Malone R, 2008, J ZOO WILDLIFE MED, V39, P37, DOI 10.1638/2006-0057.1; CHUPP NORMAN R., 1964, J WILDLIFE MANAGE, V28, P692, DOI 10.2307/3798784; CLARK DR, 1991, CALIF FISH GAME, V77, P61; Cryan PM, 2014, P NATL ACAD SCI USA, V111, P15126, DOI 10.1073/pnas.1406672111; Dalby O, 2010, J FORENSIC SCI, V55, P924, DOI 10.1111/j.1556-4029.2010.01370.x; DECINO TJ, 1966, J WILDLIFE MANAGE, V30, P249, DOI 10.2307/3797809; Denton JS, 2006, ARCH PATHOL LAB MED, V130, P1283; Dettmeyer RB, 2014, FORENSIC SCI MED PAT, V10, P401, DOI 10.1007/s12024-014-9536-9; Dettmeyer R. B., 2011, FORENSIC HISTOPATHOL; Di Maio VJM, 1999, GUNSHOT WOUNDS PRACT; Dolinak D, 2005, FORENSIC PATHOLOGY P; DRC-1339(Starlicide), 2001, DRC1339 USDA, P2; Eisemann J. D., 2003, USDA NATL WILDLIFE R, V211; Fenton TW, 2003, J FORENSIC SCI, V48, P274; FUKUTO TR, 1990, ENVIRON HEALTH PERSP, V87, P245; GREEN PD, 1980, CAN VET J, V21, P343; Haglund WD, 1997, FORENSIC TAPHONOMY P; HAIN JR, 1989, J FORENSIC SCI, V34, P691; Intarapanich NP, 2016, J FORENSIC SCI, V61, P993, DOI 10.1111/1556-4029.13074; JACOBS NA, 1988, BRIT J OPHTHALMOL, V72, P97, DOI 10.1136/bjo.72.2.97; Kagan RA, 2016, VET PATHOL, V53, P1030, DOI 10.1177/0300985816646431; Kagan R. A., 2014, AVIAN MORTALITY SOLA; Kahana T, 2005, FOREN PATHOL REV, V3, P443, DOI 10.1007/978-1-59259-910-3_13; Klippel WE, 2007, J FORENSIC SCI, V52, P765, DOI 10.1111/j.1556-4029.2007.00467.x; Knight M. W., 2013, SMALL ANIMAL TOXICOL, P853; LaDouceur EEB, 2015, J ZOO WILDLIFE MED, V46, P438, DOI 10.1638/2015-0026R.1; Lightsey JD, 2006, J ZOO WILDLIFE MED, V37, P262, DOI 10.1638/04-095.1; Litz JA, 2014, DIS AQUAT ORGAN, V112, P161, DOI 10.3354/dao02807; Longcore T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034025; Loss SR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101565; Loss SR, 2013, BIOL CONSERV, V168, P201, DOI 10.1016/j.biocon.2013.10.007; MCCRARY MD, 1986, J FIELD ORNITHOL, V57, P135; McEwen BJ, 2016, VET PATHOL, V53, P1049, DOI 10.1177/0300985815625757; Merck M., 2007, VET FORENSICS ANIMAL; Milroy CM, 1998, J CLIN PATHOL, V51, P525, DOI 10.1136/jcp.51.7.525; Mineau P, 2002, J WILDLIFE REHABIL, V25, P4; Murmann DC, 2006, J FORENSIC SCI, V51, P846, DOI 10.1111/j.1556-4029.2006.00166.x; Murphy M.J., 2013, SMALL ANIMAL TOXICOL, P435; Perez DB, 2012, AM J FOREN MED PATH, V33, P231, DOI 10.1097/PAF.0b013e318252e05f; Petrikovics I, 2011, BIOMARKERS, V16, P686, DOI 10.3109/1354750X.2011.626528; Poppenga RH, 2005, J WILDLIFE DIS, V41, P218, DOI 10.7589/0090-3558-41.1.218; Quatrehomme G, 1999, J FORENSIC SCI, V44, P568; Reeves NM, 2009, J FORENSIC SCI, V54, P523, DOI 10.1111/j.1556-4029.2009.01020.x; Ressel L, 2016, VET PATHOL, V53, P941, DOI 10.1177/0300985816653988; Roe WD, 2012, VET J, V194, P326, DOI 10.1016/j.tvjl.2012.03.028; Rollins KE, 2012, VET PATHOL, V49, P362, DOI 10.1177/0300985812436745; Salaramoli J, 2008, ASIAN J ANIM VET ADV, V3, P453, DOI 10.3923/ajava.2008.453.456; Saukko P, 2004, KNIGHTS FORENSIC PAT; Simonsen KP, 2011, J FORENSIC SCI, V56, P480, DOI 10.1111/j.1556-4029.2010.01668.x; STERNER RT, 1995, ARCH ENVIRON CON TOX, V28, P519; Stone WB, 2003, B ENVIRON CONTAM TOX, V70, P34, DOI 10.1007/s00128-002-0152-0; Stroud Richard K., 1996, P3; Trail PW, 2006, ENVIRON MANAGE, V38, P532, DOI 10.1007/s00267-005-0201-7; Tsokos M, 2005, FOREN PATHOL REV, V3, P183, DOI 10.1007/978-1-59259-910-3_5; USDA A, 2001, TECH NOT WILDL SERV, P4; Venn-Watson S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126538; Villar D, 2010, J VET DIAGN INVEST, V22, P313, DOI 10.1177/104063871002200229; Viner TC, 2014, FORENSIC SCI INT, V234, pE25, DOI 10.1016/j.forsciint.2013.10.033; Wheatley BP, 2008, J FORENSIC SCI, V53, P69, DOI 10.1111/j.1556-4029.2008.00593.x; Wieberg DAM, 2008, J FORENSIC SCI, V53, P1028, DOI 10.1111/j.1556-4029.2008.00801.x; WIEMEYER SN, 1986, J WILDLIFE DIS, V22, P538, DOI 10.7589/0090-3558-22.4.538; WOOTTON TA, 1979, ARCH ENVIRON CON TOX, V8, P457, DOI 10.1007/BF01056352	70	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							21	40		10.1016/B978-0-12-805306-5.00002-X			20	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300004					2019-10-28	
B	Rideout, B; Braun, J; Pessier, AP		Terio, KA; McAloose, D; StLeger, J		Rideout, Bruce; Braun, Josephine; Pessier, Allan P.			Laboratory Diagnostics	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							LONG-TERM STORAGE; MOLECULAR ANALYSIS; DECISION-MAKING; DNA; PRESERVATION; STRATEGIES; FIXATIVES; TISSUES; DISEASE; ERRORS		[Rideout, Bruce; Braun, Josephine] San Diego Zoo Global, Inst Conservat Res, Dis Invest, San Diego, CA 92112 USA; [Pessier, Allan P.] Washington State Univ, Pullman, WA 99164 USA	Rideout, B (reprint author), San Diego Zoo Global, Inst Conservat Res, Dis Invest, San Diego, CA 92112 USA.						Apweiler R, 2009, CYTOM PART A, V75A, P816, DOI 10.1002/cyto.a.20779; Barzon L, 2011, INT J MOL SCI, V12, P7861, DOI 10.3390/ijms12117861; Blooi M, 2013, J CLIN MICROBIOL, V51, P4173, DOI 10.1128/JCM.02313-13; Bornstein BH, 2001, J EVAL CLIN PRACT, V7, P97, DOI 10.1046/j.1365-2753.2001.00284.x; Chius CY, 2013, CURR OPIN MICROBIOL, V16, P468, DOI 10.1016/j.mib.2013.05.001; Croskerry P, 2003, ACAD MED, V78, P775, DOI 10.1097/00001888-200308000-00003; Croskerry P, 2002, ACAD EMERG MED, V9, P1184, DOI 10.1111/j.1553-2712.2002.tb01574.x; Elstein AS, 1999, ACAD MED, V74, P791, DOI 10.1097/00001888-199907000-00012; EVANS AS, 1976, YALE J BIOL MED, V49, P175; Friedrichs K., 2010, ASVCP QUAL ASSUR LAB, V2, P1; Goka K, 2009, MOL ECOL, V18, P4757, DOI 10.1111/j.1365-294X.2009.04384.x; Howat WJ, 2014, METHODS, V70, P12, DOI 10.1016/j.ymeth.2014.01.022; Jakobhoff R. M., 2014, MANUAL PROCEDURES WI, P1; Kothmaier H, 2011, ARCH PATHOL LAB MED, V135, P744, DOI 10.1043/2009-0676-OA.1; Lipkin WI, 2013, CURR OPIN VIROL, V3, P199, DOI 10.1016/j.coviro.2013.03.010; Michaud CL, 2011, J FORENSIC SCI, V56, P846, DOI 10.1111/j.1556-4029.2011.01771.x; Michaud V, 2007, J VIROL METHODS, V146, P257, DOI 10.1016/j.jviromet.2007.07.006; Moscoso H, 2007, AVIAN DIS, V51, P118, DOI 10.1637/0005-2086(2007)051[0118:FLIADT]2.0.CO;2; Moscoso H, 2006, AVIAN DIS, V50, P391, DOI 10.1637/7505-011306R.1; OIE, 2013, MAN DIAGN TESTS VACC, P10; Prento P, 1997, BIOTECH HISTOCHEM, V72, P273, DOI 10.3109/10520299709082252; Rajendram D, 2006, J MICROBIOL METH, V67, P582, DOI 10.1016/j.mimet.2006.05.010; SEUTIN G, 1991, CAN J ZOOL, V69, P82, DOI 10.1139/z91-013; Thrusfield M, 2007, VET EPIDEMIOLOGY; Veldhoen N, 2012, ECOTOX ENVIRON SAFE, V76, P23, DOI 10.1016/j.ecoenv.2011.10.005; Wayland M, 2001, ARCH ENVIRON CON TOX, V41, P491, DOI 10.1007/s002440010276; Zhang AH, 2012, ANAL BIOANAL CHEM, V404, P1239, DOI 10.1007/s00216-012-6117-1	27	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							41	53		10.1016/B978-0-12-805306-5.00003-1			13	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300005					2019-10-28	
B	Stacy, NI; Hollinger, C		Terio, KA; McAloose, D; StLeger, J		Stacy, Nicole I.; Hollinger, Charlotte			Introduction to Comparative Clinical Pathology	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Editorial Material; Book Chapter							POSTMORTEM BIOCHEMICAL-CHANGES; BLOOD FOLLOWING STORAGE; PROTEIN ELECTROPHORESIS; VITREOUS-HUMOR; ALBUMIN CONCENTRATION; REFERENCE INTERVALS; CYTOCHEMICAL CHARACTERISTICS; PLASMA ELECTROPHORESIS; SORBITOL DEHYDROGENASE; ARTIFACTUAL CHANGES		[Stacy, Nicole I.] Univ Florida, Gainesville, FL 32611 USA; [Hollinger, Charlotte] Wildlife Conservat Soc, Bronx, NY USA	Stacy, NI (reprint author), Univ Florida, Gainesville, FL 32611 USA.						Ackerman MR, 2012, PATHOLOGIC BASIS VET, P89; Agius C, 2003, J FISH DIS, V26, P499, DOI 10.1046/j.1365-2761.2003.00485.x; AKTAS M, 1994, RES VET SCI, V56, P30, DOI 10.1016/0034-5288(94)90192-9; Alleman AR, 1999, AM J VET RES, V60, P507; ALLEMAN AR, 1992, AM J VET RES, V53, P1645; Allender Matthew C., 2008, Veterinary Clinics of North America Exotic Animal Practice, V11, P463, DOI 10.1016/j.cvex.2008.03.006; ALTLAND PD, 1962, AM J PHYSIOL, V203, P1188; [Anonymous], 2013, SORBITOL DEHYDROGENA; Arnold JE, 2005, VET CLIN PATH, V34, P115, DOI 10.1111/j.1939-165X.2005.tb00023.x; Aronson PS, 2011, J AM SOC NEPHROL, V22, P1981, DOI 10.1681/ASN.2011040414; Bas S, 2004, DOMEST ANIM ENDOCRIN, V26, P99, DOI 10.1016/j.domaniend.2003.08.006; Belsey SL, 2016, J FORENSIC LEG MED, V41, P49, DOI 10.1016/j.jflm.2016.04.011; Bengis RG, 2014, REV SCI TECH OIE, V33, P593, DOI 10.20506/rst.33.2.2309; Bishop GT, 2016, J ZOO WILDLIFE MED, V47, P855; Boehlke C, 2015, ARCH ORAL BIOL, V60, P1162, DOI 10.1016/j.archoralbio.2015.05.008; Boulagnon C, 2011, CLIN CHEM LAB MED, V49, P1265, DOI 10.1515/CCLM.2011.638; Braun EJ, 2015, STURKIE'S AVIAN PHYSIOLOGY, 6TH EDITION, P285; Breidenbach A, 1998, VET RES, V29, P173; Bricker NK, 2012, VET CLIN PATH, V41, P353, DOI 10.1111/j.1939-165X.2012.00452.x; Brooks JW, 2016, VET PATHOL, V53, P929, DOI 10.1177/0300985816629720; Buzala M, 2017, LIVEST SCI, V195, P1, DOI 10.1016/j.livsci.2016.11.009; Campbell T., 2006, VET HEMATOLOGY CLIN, P463; Campbell TW, 2015, EXOTIC ANIMAL HEMATOLOGY AND CYTOLOGY, 4TH EDITION, P1, DOI 10.1002/9781118993705; Cerenius L, 2011, J INNATE IMMUN, V3, P3, DOI 10.1159/000322066; Clark P, 2002, VET CLIN PATH, V31, P90, DOI 10.1111/j.1939-165X.2002.tb00286.x; Collicutt NB, 2015, VET CLIN PATH, V44, P120, DOI 10.1111/vcp.12217; Cooper-Bailey K, 2011, VET CLIN PATH, V40, P316, DOI 10.1111/j.1939-165X.2011.00337.x; Cowell R., 2008, DIAGNOSTIC CYTOLOGY; Cray C, 1998, J AVIAN MED SURG, V12, P4; Cray C, 2007, VET CLIN PATH, V36, P64, DOI 10.1111/j.1939-165X.2007.tb00184.x; Cray C, 2015, J VET DIAGN INVEST, V27, P688, DOI 10.1177/1040638715607293; Dacke CG, 2015, STURKIE'S AVIAN PHYSIOLOGY, 6TH EDITION, P549; DAPOLLONIA S, 1980, CAN J FISH AQUAT SCI, V37, P163, DOI 10.1139/f80-021; Davidson CJ, 2003, J THROMB HAEMOST, V1, P1487, DOI 10.1046/j.1538-7836.2003.00334.x; Dawson DR, 2011, VET CLIN PATH, V40, P504, DOI 10.1111/j.1939-165X.2011.00359.x; Desprez I, 2017, J ZOO WILDLIFE MED, V48, P232, DOI 10.1638/2016-0102.1; Dieterlen-Lievre F., 1988, P257; Dittmer KE, 2011, VET PATHOL, V48, P389, DOI 10.1177/0300985810375240; DiVincenti L, 2013, VET CLIN PATH, V42, P19, DOI 10.1111/vcp.12017; Donaldson AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082011; Doolittle R F, 2009, Cold Spring Harb Symp Quant Biol, V74, P35, DOI 10.1101/sqb.2009.74.001; DOOLITTLE RF, 1962, AM J PHYSIOL, V203, P964; Doss GA, 2016, JAVMA-J AM VET MED A, V248, P901, DOI 10.2460/javma.248.8.901; Eckersall PD, 2008, CLINICAL BIOCHEMISTRY OF DOMESTIC ANIMALS, 6TH EDITION, P117; Emerson JA, 2013, VET QUART, V33, P191, DOI 10.1080/01652176.2013.880005; Erb HN, 2011, VET CLIN PATH, V40, P154, DOI 10.1111/j.1939-165X.2011.00315.x; Fisher Peter G., 2006, Veterinary Clinics of North America Exotic Animal Practice, V9, P69, DOI 10.1016/j.cvex.2005.10.002; Flatland B, 2014, VET CLIN PATH, V43, P475, DOI 10.1111/vcp.12199; Forzan MJ, 2017, VET CLIN PATH, V46, P11, DOI 10.1111/vcp.12452; Frankfurter G, 2012, J ZOO WILDLIFE MED, V43, P852, DOI 10.1638/2012-0076R.1; Friedrichs KR, 2012, VET CLIN PATH, V41, P441, DOI 10.1111/vcp.12006; Furlanello T, 2006, VET CLIN PATH, V35, P42, DOI 10.1111/j.1939-165X.2006.tb00087.x; Garner M., 2006, REPTILE MED SURG, P569; Gibbons P., 2007, SCI P ANN M ASS REPT, P69; Gimenez M, 2010, VET CLIN PATH, V39, P227, DOI 10.1111/j.1939-165X.2009.00204.x; GOLDSTEIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P879, DOI 10.1073/pnas.79.3.879; Groff J. M., 1999, VET CLIN N AM EXOTIC, V2, P741, DOI DOI 10.1016/S1094-9194(17)30120-2; Guddorf V, 2014, BERL MUNCH TIERARZTL, V127, P322, DOI 10.2376/0005-9366-127-322; Gupta A, 2014, JAVMA-J AM VET MED A, V244, P63, DOI 10.2460/javma.244.1.63; Hammerschlag N, 2006, MAR FRESHW BEHAV PHY, V39, P209, DOI 10.1080/10236240600815820; HANNA PE, 1990, CAN J VET RES, V54, P487; Harr KE, 2005, VET CLIN PATH, V34, P383, DOI 10.1111/j.1939-165X.2005.tb00065.x; Harr KE, 2002, VET CLIN PATH, V31, P140, DOI 10.1111/j.1939-165X.2002.tb00295.x; Harr KE, 2001, J AM VET MED ASSOC, V218, P915, DOI 10.2460/javma.2001.218.915; HARTMAN FA, 1964, BIOL BULL, V126, P83, DOI 10.2307/1539418; Harvey JW, 2007, J ZOO WILDLIFE MED, V38, P269, DOI 10.1638/1042-7260(2007)038[0269:CBIHMT]2.0.CO;2; Harvey JW, 2009, VET CLIN PATH, V38, P183, DOI 10.1111/j.1939-165X.2009.00113.x; Harvey JW, 2008, CLINICAL BIOCHEMISTRY OF DOMESTIC ANIMALS, 6TH EDITION, P173, DOI 10.1016/B978-0-12-370491-7.00007-6; Harvey JW, 2012, VET HEMATOLOGY DIAGN; Hildebrandt JP, 2001, ZOOL-ANAL COMPLEX SY, V104, P209, DOI 10.1078/0944-2006-00026; Hopper K, 2005, AM J VET RES, V66, P656, DOI 10.2460/ajvr.2005.66.656; Horney Barbara S., 1993, Vet Clin Pathol, V22, P5; Jackson DC, 2002, J PHYSIOL-LONDON, V543, P731, DOI 10.1113/jphysiol.2002.024729; Jacobsen E., 2007, INFECT DIS PATHOLOGY, P13; Johns JL, 2008, AM J VET RES, V69, P1067, DOI 10.2460/ajvr.69.8.1067; Kaye S, 2016, J ZOO WILDLIFE MED, V47, P397, DOI 10.1638/2015-0255.1; Keller KA, 2015, J AVIAN MED SURG, V29, P174, DOI 10.1647/2014-018; King J., 2002, NECROPSY BOOK; Koenigshof AM, 2012, VET CLIN PATH, V41, P63, DOI 10.1111/j.1939-165X.2011.00387.x; Kozaki N, 1998, J SURG RES, V79, P61, DOI 10.1006/jsre.1998.5357; LARSSON L, 1985, CLIN CHEM, V31, P169; Latimer K., 1994, AVIAN MED PRINCIPALS, P356; Lilliehook I, 2011, VET CLIN PATH, V40, P450, DOI 10.1111/j.1939-165X.2011.00353.x; Linn B. M., 1961, J EXP BIOL, V39, P67; Loof TG, 2011, J INNATE IMMUN, V3, P34, DOI 10.1159/000321641; Lowenstine Linda J., 2003, Toxicologic Pathology, V31, P92, DOI 10.1080/01926230390177668; Lumeij JT, 2008, CLINICAL BIOCHEMISTRY OF DOMESTIC ANIMALS, 6TH EDITION, P839, DOI 10.1016/B978-0-12-370491-7.00030-1; LUMEIJ JT, 1987, VET QUART, V9, P255, DOI 10.1080/01652176.1987.9694110; LUMEIJ JT, 1990, AVIAN PATHOL, V19, P255, DOI 10.1080/03079459008418678; LUMEIJ JT, 1985, AVIAN PATHOL, V14, P441, DOI 10.1080/03079458508436245; MacNeill AL, 2010, VET CLIN PATH, V39, P381, DOI 10.1111/j.1939-165X.2010.00247.x; Macrelli Roberto, 2013, Journal of Herpetological Medicine and Surgery, V23, P20; MCCLURE HM, 1972, FOLIA PRIMATOL, V18, P300, DOI 10.1159/000155485; McCoy MA, 2004, MAGNESIUM RES, V17, P137; MCLAUGHLIN BG, 1988, CAN J VET RES, V52, P476; McMichael M, 2012, TOP COMPANION ANIM M, V27, P40, DOI 10.1053/j.tcam.2012.07.005; Meinkoth JH, 2014, DIAGNOSTIC CYTOLOGY, P1; MONTALI RJ, 1988, J COMP PATHOL, V99, P1, DOI 10.1016/0021-9975(88)90101-6; Morey J., 2009, ENCY TIME SCI PHILOS, DOI [10.4135/9781412963961.N532, DOI 10.4135/9781412963961.N532]; Muller K, 2010, VET CLIN PATH, V39, P79, DOI 10.1111/j.1939-165X.2009.00177.x; Munson L., 2004, NECROPSY WILD ANIMAL; Musilova A, 2015, VET CLIN PATH, V44, P243, DOI 10.1111/vcp.12238; Nevill H, 2009, J EXOT PET MED, V18, P140, DOI 10.1053/j.jepm.2009.04.011; Nichols Donald K., 2001, P331; Noga E. J., 2010, FISH DIS DIAGNOSIS T; Osborne C. A., 1999, URINALYSIS CLIN GUID, P66201; Owens SD, 2003, VET CLIN PATH, V32, P114, DOI 10.1111/j.1939-165X.2003.tb00324.x; Ozer JS, 2010, NAT BIOTECHNOL, V28, P486, DOI 10.1038/nbt.1627; Parsons SDC, 2006, J COMP PATHOL, V134, P152, DOI 10.1016/j.jcpa.2005.09.008; PENNIALL R, 1975, P NATL ACAD SCI USA, V72, P5012, DOI 10.1073/pnas.72.12.5012; PEX JO, 1983, J FORENSIC SCI, V28, P594; Quality Assurance and Laboratory Standards Committee, 2009, PRINC QUAL ASS STAND; Quality Assurance and Laboratory Standards Committee, 2010, GUID DET REF INT VET; RADIN MJ, 1986, VET PATHOL, V23, P656, DOI 10.1177/030098588602300602; Raskin R, 2010, SCHALMS VET HEMATOLO, P1141; Raskin R., 2010, SCHALMS VET HEMATOLO, P797; Raskin R. E., 2015, CANINE FELINE CYTOLO; Reavill Drury, 2007, Veterinary Clinics of North America Exotic Animal Practice, V10, P207, DOI 10.1016/j.cvex.2006.11.002; Reimschuessel Renate, 1993, P160; Relford R, 2016, VET CLIN N AM-SMALL, V46, P941, DOI 10.1016/j.cvsm.2016.06.010; Ritter JM, 2009, VET PATHOL, V46, P1109, DOI 10.1354/vp.09-VP-0019-K-FL; ROBINSON AJ, 1969, SCIENCE, V166, P1420, DOI 10.1126/science.166.3911.1420; RODNAN GP, 1957, BLOOD, V12, P355, DOI 10.1182/blood.V12.4.355.355; Roman Y, 2009, VET CLIN PATH, V38, P206, DOI 10.1111/j.1939-165X.2009.00142.x; Roman Y, 2009, J WILDLIFE DIS, V45, P73, DOI 10.7589/0090-3558-45.1.73; Salam HA, 2012, ALEX J MED, V48, P335, DOI 10.1016/j.ajme.2012.05.004; Sarran Delphine, 2008, Aquatic Mammals, V34, P157, DOI 10.1578/AM.34.2.2008.157; Schmaier AA, 2011, BLOOD, V118, P3661, DOI 10.1182/blood-2011-02-338244; SCHONING P, 1980, J FORENSIC SCI, V25, P53; SCHONING P, 1980, J FORENSIC SCI, V25, P336; SCHONING P, 1980, J FORENSIC SCI, V25, P60; SCHULMAN FY, 1993, VET PATHOL, V30, P491, DOI 10.1177/030098589303000601; Sedlak TW, 2004, PEDIATRICS, V113, P1776, DOI 10.1542/peds.113.6.1776; Semba U, 1998, THROMB RES, V90, P31, DOI 10.1016/S0049-3848(97)00307-1; Smith SA, 2009, J VET EMERG CRIT CAR, V19, P3, DOI 10.1111/j.1476-4431.2009.00389.x; Soslau G, 2004, COMP BIOCHEM PHYS B, V138, P399, DOI 10.1016/j.cbpc.2004.05.004; Stacy Brian A., 2007, P257, DOI 10.1201/9781420004038.ch5; Stahl Scott J., 2003, Veterinary Clinics of North America Exotic Animal Practice, V6, P191, DOI 10.1016/S1094-9194(02)00054-3; Stanford M, 2007, VET REC, V161, P456, DOI 10.1136/vr.161.13.456; Stockham S, 2008, FUNDAMENTALS VET CLI; Stokol T, 2001, VET CLIN PATH, V30, P170, DOI 10.1111/j.1939-165X.2001.tb00427.x; Strik N., 2007, INFECT DIS PATHOLOGY, P175; Strindberg S, 2015, J AVIAN MED SURG, V29, P282, DOI 10.1647/2014-034; Sturkie P., 1983, AVIAN PHYSL, P281; Sutton R H, 1976, N Z Vet J, V24, P141, DOI 10.1080/00480169.1976.34304; Suzuki Yuzuru, 1992, Annual Review of Fish Diseases, V2, P149, DOI 10.1016/0959-8030(92)90061-2; Swain R, 2015, J FORENSIC LEG MED, V36, P144, DOI 10.1016/j.jflm.2015.09.017; Swenson CL, 2004, JAVMA-J AM VET MED A, V224, P1282, DOI 10.2460/javma.2004.224.1282; Tavares-Dias M., 2009, BRAZ J BIOSCI, V7, P205; Tavares-Dias M, 2007, VET CLIN PATH, V36, P49, DOI 10.1111/j.1939-165X.2007.tb00181.x; Thane K, 2017, J VET EMERG CRIT CAR, V27, P419, DOI 10.1111/vec.12610; Thierauf A, 2009, FORENSIC SCI INT, V192, P78, DOI 10.1016/j.forsciint.2009.08.001; Tornquist S., 2010, SCHALMS VET HEMATOLO, P910; Valli V., 2016, JUBB KENNEDY PALMERS, P171; Van Wettere Arnaud, 2007, Veterinary Clinics of North America Exotic Animal Practice, V10, P235, DOI 10.1016/j.cvex.2006.11.003; VIDYADARAN M K, 1979, Pertanika, V2, P101; Voituron Y, 2000, PHYSIOL BIOCHEM ZOOL, V73, P264, DOI 10.1086/316742; Webster KH, 2015, ECOTOXICOLOGY, V24, P1087, DOI 10.1007/s10646-015-1449-1; WEISS D.J., 2010, SCHALMS VET HEMATOLO; Westgard J., 2010, BASIC QC PRACTICES; Westgard J, 2008, BASIC METHOD VALIDAT; Weyand AC, 2014, CURR OPIN HEMATOL, V21, P418, DOI 10.1097/MOH.0000000000000075; Wiedner E, 2009, J ZOO WILDLIFE MED, V40, P659, DOI 10.1638/2008-0203.1; Wiinberg B, 2010, SEMIN THROMB HEMOST, V36, P747, DOI 10.1055/s-0030-1265291; Work T. M., 2000, USGS NATL WILDL HEAL, V30; Zabka T. S., 2005, IAAAM C P SEW AK; ZAPATA A, 1981, DEV COMP IMMUNOL, V5, P43, DOI 10.1016/S0145-305X(81)80006-7	167	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							55	115		10.1016/B978-0-12-805306-5.00004-3			61	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300006					2019-10-28	
B	Jones, MEB; Gasper, DJ; Mitchell, E		Terio, KA; McAloose, D; StLeger, J		Jones, Megan E. B.; Gasper, David J.; Mitchell (Nee Lane), Emily			Bovidae, Antilocapridae, Giraffidae, Tragulidae, Hippopotamidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							DES-PETITS-RUMINANTS; CONTAGIOUS CAPRINE PLEUROPNEUMONIA; NEOSPORA-CANINUM INFECTION; RANGING CHAMOIS RUPICAPRA; MALIGNANT CATARRHAL FEVER; BIGHORN SHEEP; MOUTH-DISEASE; WILD RUMINANTS; SABLE ANTELOPE; BOVINE TUBERCULOSIS		[Jones, Megan E. B.] San Diego Zoo Global, Inst Conservat Res, San Diego, CA 92112 USA; [Gasper, David J.] Pacific Zoo & Wildlife Diagnost, San Diego, CA USA; [Mitchell (Nee Lane), Emily] Natl Zool Gardens South Africa, Pretoria, South Africa; [Mitchell (Nee Lane), Emily] Univ Pretoria, Pretoria, South Africa	Jones, MEB (reprint author), San Diego Zoo Global, Inst Conservat Res, San Diego, CA 92112 USA.						ABUELZEIN EME, 1990, VET REC, V127, P309; Adetunji SA, 2018, J ZOO WILDLIFE MED, V49, P134, DOI 10.1638/2017-0059R1.1; Alasaad S, 2012, VET PARASITOL, V185, P359, DOI 10.1016/j.vetpar.2011.10.039; Alexandersen S, 2003, J COMP PATHOL, V129, P1, DOI 10.1016/S0021-9975(03)00041-0; Allsopp BA, 2015, REV SCI TECH OIE, V34, P557, DOI 10.20506/rst.34.2.2379; Anderson R. C, 2001, FILARIOID NEMATODES, P342; Arif A, 2007, J ZOO WILDLIFE MED, V38, P93, DOI 10.1638/05-097.1; Arnal M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061887; Arnal MC, 2004, J GEN VIROL, V85, P3653, DOI 10.1099/vir.0.80235-0; Arzt J, 2011, TRANSBOUND EMERG DIS, V58, P305, DOI 10.1111/j.1865-1682.2011.01236.x; Arzt J, 2011, TRANSBOUND EMERG DIS, V58, P291, DOI 10.1111/j.1865-1682.2011.01204.x; Auty H, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001828; Barrett T, 1999, ADV VIRUS RES, V53, P89, DOI 10.1016/S0065-3527(08)60344-9; Bengis R. G., 2012, ANTHRAX FREERANGING; BENIRSCHKE K, 1978, ACTA ZOOL PATHOL ANT, P63; Bertelsen M. F., 2015, FOWLERS ZOO WILD ANI; Besser TE, 2008, J CLIN MICROBIOL, V46, P423, DOI 10.1128/JCM.01931-07; Besser TE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110039; Besser TE, 2013, PREV VET MED, V108, P85, DOI 10.1016/j.prevetmed.2012.11.018; Besser TE, 2012, EMERG INFECT DIS, V18, P406, DOI 10.3201/eid1803.111554; Bishop R, 2004, PARASITOLOGY, V129, pS271, DOI 10.1017/S0031182003004748; BLEICH VC, 1990, J WILDLIFE DIS, V26, P372, DOI 10.7589/0090-3558-26.3.372; Boyce W, 1999, J WILDLIFE DIS, V35, P786, DOI 10.7589/0090-3558-35.4.786; Brothers PS, 2011, VET PARASITOL, V183, P160, DOI 10.1016/j.vetpar.2011.06.015; Bulmer W. S., 1971, Journal Wildl Dis, V7, P310; Cabezon O, 2010, J VET DIAGN INVEST, V22, P744, DOI 10.1177/104063871002200514; Carta T, 2013, RES VET SCI, V94, P191, DOI 10.1016/j.rvsc.2012.11.002; Cassirer EF, 2007, J WILDLIFE MANAGE, V71, P1080, DOI 10.2193/2006-002; Cassirer EF, 2013, J ANIM ECOL, V82, P518, DOI 10.1111/1365-2656.12031; Chaber AL, 2014, VET MICROBIOL, V173, P156, DOI 10.1016/j.vetmic.2014.07.003; Clauss M, 2007, J ZOO WILDLIFE MED, V38, P433, DOI 10.1638/06-032.1; Clemente L, 2008, VET REC, V163, P221, DOI 10.1136/vr.163.7.221; Clifford AB, 2004, J ZOOL, V264, P217, DOI 10.1017/S0952836904005540; Clyde Victoria L., 1998, American Association of Zoo Veterinarians Annual Conference Proceedings, V1998, P221; Cunningham AA, 2004, EMERG INFECT DIS, V10, P1044, DOI 10.3201/eid1006.030615; de Lisle GW, 2002, REV SCI TECH OIE, V21, P317, DOI 10.20506/rst.21.2.1339; DIERENFELD ES, 1988, J ZOO WILDLIFE MED, V19, P126, DOI 10.2307/20094869; Donahoe SL, 2015, INT J PARASITOL-PAR, V4, P216, DOI 10.1016/j.ijppaw.2015.04.002; Dubey JP, 2014, J PARASITOL, V100, P817, DOI 10.1645/13-467.1; Dubey J. P, 2001, TISSUE INHABITING PR, P478; DUBEY JP, 1982, J AM VET MED ASSOC, V181, P1263; Dubey JP, 2002, J PARASITOL, V88, P638, DOI 10.2307/3285468; Dudley JP, 2016, MAMMAL REV, V46, P191, DOI 10.1111/mam.12056; FAO and OIE, 2011, JOINT FAO OIE COMM G; Flach E, 2008, GASTROINTESTINAL NEM, P416; Flacke GL, 2016, ZOO BIOL, V35, P556, DOI 10.1002/zoo.21336; Fowler M. E., 1978, ZOO WILD ANIMAL MED; Fox KA, 2011, VET PATHOL, V48, P706, DOI 10.1177/0300985810383873; Fox KA, 2015, J WILDLIFE DIS, V51, P19, DOI 10.7589/2014-05-130; Fox R.I., 2001, European Journal of Veterinary Pathology, V7, P123, DOI 10.1054/ctnm.2001.0568; Frey R, 2011, J ANAT, V218, P566, DOI 10.1111/j.1469-7580.2011.01361.x; Frolich K, 2005, J WILDLIFE DIS, V41, P606; FURLEY CW, 1987, VET REC, V121, P443, DOI 10.1136/vr.121.19.443; Garretson PD, 2009, J ZOO WILDLIFE MED, V40, P131, DOI 10.1638/2007-0094.1; Gasper D, 2012, VET PATHOL, V49, P492, DOI 10.1177/0300985811429306; George JL, 2008, J WILDLIFE DIS, V44, P388, DOI 10.7589/0090-3558-44.2.388; Georgi J. R., 1990, PARASITOLOGY VETERIN; Giacometti M, 2002, J WILDLIFE DIS, V38, P297, DOI 10.7589/0090-3558-38.2.297; Githaka N, 2014, VET PARASITOL, V202, P180, DOI 10.1016/j.vetpar.2014.02.056; Godfroid J, 2013, REV SCI TECH OIE, V32, P27; Goossens E, 2006, J ZOO WILDLIFE MED, V37, P20, DOI 10.1638/05-041.1; Goossens E, 2005, VET PARASITOL, V127, P303, DOI 10.1016/j.vetpar.2004.10.013; GROOTENHUIS JG, 1980, RES VET SCI, V29, P219, DOI 10.1016/S0034-5288(18)32667-5; Guo J, 2004, VET MICROBIOL, V99, P81, DOI 10.1016/j.vetmic.2003.11.010; Gyimesi ZS, 2017, J ZOO WILDLIFE MED, V48, P933, DOI 10.1638/2016-0285.1; HADLOW WJ, 1962, J AM VET MED ASSOC, V141, P243; Haefele HJ, 2008, J ZOO WILDLIFE MED, V39, P266, DOI 10.1638/2007-0131R.1; Haenichen T, 2001, J ZOO WILDLIFE MED, V32, P459; Haigh JC, 2002, REV SCI TECH OIE, V21, P219, DOI 10.20506/rst.21.2.1331; Hang'ombe MB, 2012, TROP DOCT, V42, P136, DOI 10.1258/td.2012.110454; HEDGER RS, 1983, COMP IMMUNOL MICROB, V6, P209, DOI 10.1016/0147-9571(83)90012-7; Helmick K. E., 2007, P AM ASS ZOO VET, P92; Herder V, 2015, VET PATHOL, V52, P543, DOI 10.1177/0300985814549210; Hoberg E. P., 2001, GASTROINTESTINAL STR, P193; Hoby S, 2007, VET PARASITOL, V148, P341, DOI 10.1016/j.vetpar.2007.06.035; Hoefs M, 2001, J WILDLIFE DIS, V37, P39, DOI 10.7589/0090-3558-37.1.39; Holzwarth N, 2011, EUR J WILDLIFE RES, V57, P233, DOI 10.1007/s10344-010-0416-7; Holzwarth N, 2011, J VET DIAGN INVEST, V23, P333, DOI 10.1177/104063871102300223; Hooge J, 2015, INT J PARASITOL-PAR, V4, P239, DOI 10.1016/j.ijppaw.2015.04.004; Hugh-Jones ME, 2002, REV SCI TECH OIE, V21, P359, DOI 10.20506/rst.21.2.1336; IVERSON WO, 1982, KIDNEY INT, V22, P146, DOI 10.1038/ki.1982.146; JEFFREY M, 1988, VET PATHOL, V25, P398, DOI 10.1177/030098588802500514; Jenkins EJ, 2005, J WILDLIFE DIS, V41, P669, DOI 10.7589/0090-3558-41.4.669; JUNGE RE, 1992, J ZOO WILDLIFE MED, V23, P342; KEEP M E, 1973, Journal of the South African Veterinary Association, V44, P288; Kingdon J, 2013, MAMMALS AFRICA, VI; KINGSTON RS, 1982, J WILDLIFE DIS, V18, P381, DOI 10.7589/0090-3558-18.3.381; Kinne J, 2010, EPIDEMIOL INFECT, V138, P1211, DOI 10.1017/S0950268809991592; KIRKWOOD JK, 1994, VET REC, V135, P296, DOI 10.1136/vr.135.13.296; Knightly Felicia, 2003, Veterinary Clinics of North America Exotic Animal Practice, V6, P565, DOI 10.1016/S1094-9194(03)00037-9; Kocan A. A., 2001, BLOOD INHABITING PRO, P520; Kock ND, 1999, VET REC, V145, P527, DOI 10.1136/vr.145.18.527; Kock R., 2015, EMERGENCY RESPONSE S; Kock RA, 1999, VET REC, V145, P275, DOI 10.1136/vr.145.10.275; KOCK RA, 1986, J ZOO WILDLIFE MED, V17, P61, DOI 10.2307/20094796; Kock R, 2016, CONSERV SCI PRACT, P108; Koehler J, 2012, J ZOO WILDLIFE MED, V43, P629, DOI 10.1638/2011-0085R1.1; Kutz SJ, 2004, INTEGR COMP BIOL, V44, P109, DOI 10.1093/icb/44.2.109; Kutz SJ, 2012, ADV PARASIT, V79, P99, DOI 10.1016/B978-0-12-398457-9.00002-0; LANCE W, 1981, Journal of Wildlife Diseases, V17, P601; LANCE WR, 1983, J WILDLIFE DIS, V19, P165, DOI 10.7589/0090-3558-19.3.165; Lankester M. W., 2001, EXTRAPULMONARY LUNGW, P228; Lecu A., 2011, International Zoo Yearbook, V45, P183, DOI 10.1111/j.1748-1090.2011.00141.x; Lee DE, 2016, J WILDLIFE DIS, V52, P753, DOI 10.7589/2015-09-247; LINKE RP, 1986, VET PATHOL, V23, P63, DOI 10.1177/030098588602300110; Lloyd C, 2010, J ZOO WILDLIFE MED, V41, P83, DOI 10.1638/2009-0005.1; Maclachlan NJ, 2015, REV SCI TECH OIE, V34, P329, DOI 10.20506/rst.34.2.2360; Maclachlan NJ, 2009, J COMP PATHOL, V141, P1, DOI 10.1016/j.jcpa.2009.04.003; Mahapatra M, 2015, EMERG INFECT DIS, V21, P2230, DOI 10.3201/eid2112.150223; Mans BJ, 2015, INT J PARASITOL-PAR, V4, P104, DOI 10.1016/j.ijppaw.2014.12.006; Marco I, 2007, VET MICROBIOL, V120, P33, DOI 10.1016/j.vetmic.2006.10.007; Marco I, 2015, ANIM HEALTH RES REV, V16, P70, DOI 10.1017/S1466252315000055; MASBAKAL P, 1980, J WILDLIFE DIS, V16, P559, DOI 10.7589/0090-3558-16.4.559; Mauroy A, 2008, EMERG INFECT DIS, V14, P675, DOI 10.3201/eid1404.071416; Mayer D, 1997, J WILDLIFE DIS, V33, P413, DOI 10.7589/0090-3558-33.3.413; McAloose D, 2009, NAT REV CANCER, V9, P517, DOI 10.1038/nrc2665; McCurdy P, 2014, J ZOO WILDLIFE MED, V45, P906, DOI 10.1638/2014-0005.1; MEAGHER M, 1992, J WILDLIFE DIS, V28, P171, DOI 10.7589/0090-3558-28.2.171; Mengual-Chulia B, 2014, VET MICROBIOL, V172, P108, DOI 10.1016/j.vetmic.2014.05.006; Meyer LCR, 2008, J WILDLIFE DIS, V44, P404, DOI 10.7589/0090-3558-44.2.404; Michel AL, 2006, VET MICROBIOL, V112, P91, DOI 10.1016/j.vetmic.2005.11.035; Miller Michael W., 2001, P330, DOI 10.1002/9780470344880.ch20; Miller RE, 2015, FOWLERS ZOO WILD ANI; Murai A, 2007, VET PATHOL, V44, P204, DOI 10.1354/vp.44-2-204; Nees S, 2009, J ZOO WILDLIFE MED, V40, P529, DOI 10.1638/2007-0175.1; Nicholas R, 2008, MYCOPLASMA DISEASES OF RUMINANTS, P114, DOI 10.1079/9780851990125.0114; Nielsen SS, 2008, VET MICROBIOL, V129, P217, DOI 10.1016/j.vetmic.2007.12.011; Nijhof AM, 2005, J CLIN MICROBIOL, V43, P5907, DOI 10.1128/JCM.43.12.5907-5911.2005; Nishi JS, 2006, VET MICROBIOL, V112, P325, DOI 10.1016/j.vetmic.2005.11.013; Noon TH, 2002, J WILDLIFE DIS, V38, P172, DOI 10.7589/0090-3558-38.1.172; O'Toole D, 2014, VET PATHOL, V51, P437, DOI 10.1177/0300985813520435; Ogada DL, 2014, ANN NY ACAD SCI, V1322, P1, DOI 10.1111/nyas.12405; OIE, 2014, THEIL MAN DIAGN TEST; OIE, 2013, PEST PET RUM INF PES; OIE, 2016, SCRAP MAN DIAGN TEST; OIE, 2012, HAEM SEPT MAN DIAGN; OIE, 2014, CONT CAPR PLEUR; OIE, 2013, MAN DIAGN TESTS VACC; OIE, 2017, LUMP SKIN DIS MAN DI; OIE, 2015, BOV TUB MAN DIAGN; OIE, 2012, ANTHR MAN DIAGN TEST; Oosthuizen MC, 2008, J CLIN MICROBIOL, V46, P2247, DOI 10.1128/JCM.00167-08; Oosthuizen MC, 2009, VET PARASITOL, V163, P39, DOI 10.1016/j.vetpar.2009.03.045; Ortiz J, 2001, J HELMINTHOL, V75, P363, DOI 10.1017/S0022149X01000567; Osborne, 2009, MOST COMMON TYPE URO; Osborne CA, 2009, VET CLIN N AM-SMALL, V39, P65, DOI 10.1016/j.cvsm.2008.09.005; Ostrowski S, 2011, EMERG INFECT DIS, V17, P2338, DOI 10.3201/eid1712.110187; Oura CAL, 2011, VET PARASITOL, V175, P212, DOI 10.1016/j.vetpar.2010.10.032; Paterson Jessica, 2007, P115, DOI 10.1002/9780470376478.ch10; Pauling CD, 2016, INT J PARASITOL-PAR, V5, P312, DOI 10.1016/j.ijppaw.2016.11.001; PENCE DB, 1981, J WILDLIFE DIS, V17, P49, DOI 10.7589/0090-3558-17.1.49; Peter TF, 1999, J PARASITOL, V85, P468, DOI 10.2307/3285780; Peter TF, 2002, TRENDS PARASITOL, V18, P214, DOI 10.1016/S1471-4922(02)02251-1; Peter TF, 1998, J WILDLIFE DIS, V34, P567, DOI 10.7589/0090-3558-34.3.567; Peters M, 2001, VET PARASITOL, V97, P153, DOI 10.1016/S0304-4017(01)00401-0; Pinto AA, 2004, ANN NY ACAD SCI, V1026, P65, DOI 10.1196/annals.1307.008; PLETCHER JM, 1989, J ZOO WILDLIFE MED, V20, P465; Pospischil A, 2012, J WILDLIFE DIS, V48, P1074, DOI [10.7589/2011-10-298, 10.7589/2011-10-208]; Potter JS, 2005, J ZOO WILDLIFE MED, V36, P301, DOI 10.1638/03-097.1; Pybus MJ, 1996, J WILDLIFE DIS, V32, P614, DOI 10.7589/0090-3558-32.4.614; Raymond J. T., 2000, P AM ASS ZOO VET INT, P302; Reddacliff LA, 1997, J ZOO WILDLIFE MED, V28, P153; Renvoise E, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00324; Renwick AR, 2007, EPIDEMIOL INFECT, V135, P529, DOI 10.1017/S0950268806007205; Rhyan JC, 2013, REV SCI TECH OIE, V32, P127; Rideout B. A., 2012, DISORDERS NONDOMESTI, P201; RIDEOUT BA, 1989, VET PATHOL, V26, P129, DOI 10.1177/030098588902600205; RIEMANN H P, 1975, Journal of Wildlife Diseases, V11, P529; Rossiter Paul, 2001, P37, DOI 10.1002/9780470344880.ch2; Rudolph KM, 2007, J ZOO WILDLIFE MED, V38, P548, DOI 10.1638/2006-0027R.1; Salinas J, 2009, VET MICROBIOL, V135, P46, DOI 10.1016/j.vetmic.2008.10.001; Samuel W. M., 1975, CANADA J WILDL DIS, V11, P26; Sanderson S., 2008, P AM ASS ZOO VET, P232; Sanderson S., 2012, FOWLERS ZOO WILD ANI, V7, P573; Savini F, 2016, J WILDLIFE DIS, V52, P82, DOI 10.7589/2015-03-065; Schaftenaar W, 2002, REV SCI TECH OIE, V21, P613, DOI 10.20506/rst.21.3.1358; SCHMIDT RE, 1979, J WILDLIFE DIS, V15, P299, DOI 10.7589/0090-3558-15.2.299; Schoelkopf L, 2005, J WILDLIFE DIS, V41, P683, DOI 10.7589/0090-3558-41.4.683; Scott G. R., 1981, RINDERPEST, P18; Sedlak K, 2004, J ZOO WILDLIFE MED, V35, P530, DOI 10.1638/02-005.1; Sharma Anil Kumar, 2016, VirusDisease, V27, P198, DOI 10.1007/s13337-016-0316-x; Shen XY, 2012, J WILDLIFE DIS, V48, P542, DOI 10.7589/0090-3558-48.3.542; Shen XY, 2010, J WILDLIFE DIS, V46, P560, DOI 10.7589/0090-3558-46.2.560; Shivachandra S. B., 2011, Animal Health Research Reviews, V12, P67, DOI 10.1017/S146625231100003X; Sigurdson CJ, 2003, BRIT MED BULL, V66, P199, DOI 10.1093/bmb/66.1.199; Simmons HA, 2002, J WILDLIFE DIS, V38, P822, DOI 10.7589/0090-3558-38.4.822; Sleeman J. M., 2012, JOHNES DIS FREE RANG, P628; Sloan J. E. N., 1965, J ZOO WILDLIFE MED, V5, P24; Steyl Johan C.A, 2012, Onderstepoort j. vet. res., V79, P01; STOVER J, 1990, J ZOO WILDLIFE MED, V21, P295; Sundberg J. P., 2001, PAPILLOMAVIRUS INFEC, P223; SUNDBERG JP, 1983, J AM VET MED ASSOC, V183, P1333; SUZUKI Y, 1986, JPN J VET SCI, V48, P1278; SWEENEY RW, 1992, AM J VET RES, V53, P1312; Thomson GR, 2003, VIRUS RES, V91, P145, DOI 10.1016/S0168-1702(02)00263-0; THORNE ET, 1988, J WILDLIFE DIS, V24, P113, DOI 10.7589/0090-3558-24.1.113; TURNBULL PCB, 1991, VET REC, V128, P399, DOI 10.1136/vr.128.17.399; Uzal F. A., 2016, ALIMENTARY SYSTEM, P1; van Dyk E, 2011, J S AFR VET ASSOC, V82, P80; van Vuuren M, 2015, REV SCI TECH OIE, V34, P139, DOI 10.20506/rst.34.1.2350; Wamuyu L, 2015, PATHOGENS, V4, P626, DOI 10.3390/pathogens4030626; Warren JD, 2017, J ZOO WILDLIFE MED, V48, P179, DOI 10.1638/2016-0090.1; Weaver GV, 2013, J WILDLIFE DIS, V49, P759, DOI 10.7589/2012-11-276; Weiss RB, 2008, JAVMA-J AM VET MED A, V233, P1127, DOI 10.2460/javma.233.7.1127; WELLS SK, 1989, J ZOO WILDLIFE MED, V20, P291; Wessels ME, 2011, J ZOO WILDLIFE MED, V42, P149, DOI 10.1638/2010-0081.1; Whittington RJ, 2009, VET J, V179, P60, DOI 10.1016/j.tvjl.2007.08.023; Wiedner E, 2014, VET QUART, V34, P22, DOI 10.1080/01652176.2014.905881; Williams E. S., 2000, INFECT DIS WILD MAMM, P570; WILLIAMS ES, 1983, VET PATHOL, V20, P274, DOI 10.1177/030098588302000304; Williams JH, 2011, J S AFR VET ASSOC, V82, P97; Winkel A., 2008, P AM ASS ZOO VET, P38; Witte CL, 2009, J VET DIAGN INVEST, V21, P40, DOI 10.1177/104063870902100106; Wobeser G, 2009, CAN VET J, V50, P1169; Woc-Colburn M, 2010, J ZOO WILDLIFE MED, V41, P717, DOI 10.1638/2009-0195.1; Wolfe LL, 2010, J WILDLIFE DIS, V46, P1262, DOI 10.7589/0090-3558-46.4.1262; Wood ME, 2017, J WILDLIFE DIS, V53, P126, DOI 10.7589/2016-05-097; WOOLF A, 1973, Journal of Wildlife Diseases, V9, P12; YOUNG E, 1970, Onderstepoort Journal of Veterinary Research, V37, P79; Yu ZJ, 2013, EMERG INFECT DIS, V19, P2051, DOI 10.3201/eid1912.130067	220	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							117	+		10.1016/B978-0-12-805306-5.00005-5			17	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300007					2019-10-28	
B	Howerth, EW; Nemeth, NM; Ryser-Degiorgis, MP		Terio, KA; McAloose, D; StLeger, J		Howerth, Elizabeth W.; Nemeth, Nicole M.; Ryser-Degiorgis, Marie-Pierre			Cervidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							WHITE-TAILED DEER; MALIGNANT CATARRHAL FEVER; ELK CERVUS-ELAPHUS; MOOSE ALCES-ALCES; REINDEER RANGIFER-TARANDUS; EPIZOOTIC HEMORRHAGIC-DISEASE; CHRONIC WASTING DISEASE; DERMACENTOR-ALBIPICTUS ACARI; RED DEER; ODOCOILEUS-VIRGINIANUS		[Howerth, Elizabeth W.] Univ Georgia, Athens, GA 30602 USA; [Nemeth, Nicole M.] Univ Guelph, Guelph, ON, Canada; [Ryser-Degiorgis, Marie-Pierre] Univ Bern, Ctr Fish & Wildlife Hlth, Bern, Switzerland	Howerth, EW (reprint author), Univ Georgia, Athens, GA 30602 USA.						ABLER W A, 1975, Journal of Wildlife Diseases, V11, P76; Aguilar RF, 1999, J ZOO WILDLIFE MED, V30, P591; Aguirre AA, 1999, J WILDLIFE DIS, V35, P753, DOI 10.7589/0090-3558-35.4.753; Allan Sandra A., 2001, P18, DOI 10.1002/9780470377000.ch2; Allan Sandra A., 2001, P72, DOI 10.1002/9780470377000.ch4; Anderson RC, 1981, DIS PARASITES WHITE, V7, P266; AYROUD M, 1995, J WILDLIFE DIS, V31, P319, DOI 10.7589/0090-3558-31.3.319; Azorit C, 2012, J WILDLIFE DIS, V48, P77, DOI 10.7589/0090-3558-48.1.77; Baeten LA, 2007, J WILDLIFE DIS, V43, P309, DOI 10.7589/0090-3558-43.2.309; Barker I. K., 1980, The comparative pathology of zoo animals, P171; Bartlett SL, 2009, J ZOO WILDLIFE MED, V40, P152, DOI 10.1638/2008-0011.1; Baughman B, 2011, J VET DIAGN INVEST, V23, P965, DOI 10.1177/1040638711416621; Baumann CD, 2001, J WILDLIFE DIS, V37, P661, DOI 10.7589/0090-3558-37.4.661; Belser EH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120028; Benestad SL, 2016, VET RES, V47, DOI 10.1186/s13567-016-0375-4; Beringer J, 1996, J WILDLIFE MANAGE, V60, P373, DOI 10.2307/3802238; Bernstein JA, 2014, VET DERMATOL, V25, P487, DOI 10.1111/vde.12141; Bildfell RJ, 2010, J WILDLIFE DIS, V46, P33, DOI 10.7589/0090-3558-46.1.33; Birtles Richard, 2012, P363; Boes K.M., 2010, VET HEMATOLOGY, P918; Bojesen AM, 2007, J WILDLIFE DIS, V43, P345, DOI 10.7589/0090-3558-43.3.345; Broman E, 2002, WILDLIFE BIOL, V8, P219; Brooks JW, 2006, VET PATHOL, V43, P765, DOI 10.1354/vp.43-5-765; Bubenik A.B., 1994, Functional and Developmental Morphology, V4, P3; Bubenik GA, 2002, Z JAGDWISS, V48, P10, DOI 10.1007/BF02285353; Cantu A, 2007, J WILDLIFE DIS, V43, P504, DOI 10.7589/0090-3558-43.3.504; Chalmers G. A., 1982, Noninfectious diseases of wildlife, P84; Christodoulopoulos G, 2005, VET REC, V156, P115, DOI 10.1136/vr.156.4.115; Clark RG, 2011, NEW ZEAL VET J, V59, P261, DOI 10.1080/00480169.2011.596261; Clegg SR, 2015, J CLIN MICROBIOL, V53, P88, DOI 10.1128/JCM.02276-14; COGLEY TP, 1987, J WILDLIFE DIS, V23, P596, DOI 10.7589/0090-3558-23.4.596; Cohen BS, 2015, J WILDLIFE DIS, V51, P609, DOI 10.7589/2014-05-129; Colwell DD, 2008, J WILDLIFE DIS, V44, P687, DOI 10.7589/0090-3558-44.3.687; Colwell Douglas D., 2001, P46, DOI 10.1002/9780470377000.ch3; Cook WE, 2007, J WILDLIFE DIS, V43, P498, DOI 10.7589/0090-3558-43.3.498; Cooley AJ, 2008, J ZOO WILDLIFE MED, V39, P380, DOI 10.1638/2007-0181.1; Crawford TB, 2002, J AM VET MED ASSOC, V221, P843, DOI 10.2460/javma.2002.221.843; da Silveira JAG, 2011, VET PARASITOL, V177, P61, DOI 10.1016/j.vetpar.2010.10.044; das Neves CG, 2010, VET MICROBIOL, V143, P70, DOI 10.1016/j.vetmic.2010.02.015; Davidson William R., 2001, P455, DOI 10.1002/9780470344880.ch27; DAVIDSON WR, 1985, J WILDLIFE DIS, V21, P153, DOI 10.7589/0090-3558-21.2.153; DAVIDSON WR, 1990, J WILDLIFE DIS, V26, P460, DOI 10.7589/0090-3558-26.4.460; DAVIS JW, 1973, J WILDLIFE MANAGE, V37, P183, DOI 10.2307/3798902; De Bosschere H, 2007, VET J, V174, P665, DOI 10.1016/j.tvjl.2006.10.015; Degiorgis M. - P., 1997, P ANN C AM ASS ZOO V, P322; Deregt D, 2000, AM J VET RES, V61, P1614, DOI 10.2460/ajvr.2000.61.1614; Desch CE, 2010, J WILDLIFE DIS, V46, P585, DOI 10.7589/0090-3558-46.2.585; Desquesnes M, 2013, BIOMED RES INT, DOI 10.1155/2013/194176; Dierenfeld E. S., 1994, J NUTR, V124, p2579S; Donahoe SL, 2015, INT J PARASITOL-PAR, V4, P216, DOI 10.1016/j.ijppaw.2015.04.002; Dubey Jitender P., 2001, P478, DOI 10.1002/9780470377000.ch17d; Dubey JP, 2004, INT J PARASITOL, V34, P1273, DOI 10.1016/j.ijpara.2004.07.002; Ducrocq J, 2012, J WILDLIFE DIS, V48, P732, DOI 10.7589/0090-3558-48.3.732; Duszynski D. W., 2001, ENTERIC PROTOZOANS C, P416; EKKOMMONEN C, 1986, ACTA VET SCAND, V27, P299; Elmore SA, 2012, VECTOR-BORNE ZOONOT, V12, P1, DOI 10.1089/vbz.2011.0705; Elsmo B., 2014, 42 ANN SE VET PATH C; Erdelyi K, 2009, ACTA VET HUNG, V57, P337, DOI 10.1556/AVet.57.2009.2.14; Ferguson NM, 2008, J VET DIAGN INVEST, V20, P849, DOI 10.1177/104063870802000628; Fink M, 2015, EMERG INFECT DIS, V21, P464, DOI 10.3201/eid2103.141119; Fisher AC, 2013, VET PARASITOL, V197, P29, DOI 10.1016/j.vetpar.2013.04.037; Fitzgerald SD, 2013, VET PATHOL, V50, P488, DOI 10.1177/0300985812467472; Flueck WT, 2008, J WILDLIFE DIS, V44, P636, DOI 10.7589/0090-3558-44.3.636; Flueck Werner T, 2015, BMC Res Notes, V8, P330, DOI 10.1186/s13104-015-1291-9; Flueck WT, 2013, J WILDLIFE DIS, V49, P355, DOI 10.7589/2012-11-272; Forde T, 2015, CAN VET J, V56, P479; Foreyt W. J., 1981, Diseases and parasites of white-tailed deer., P237; FOREYT WJ, 1994, J WILDLIFE DIS, V30, P470, DOI 10.7589/0090-3558-30.3.470; Fox KA, 2015, J WILDLIFE DIS, V51, P166, DOI 10.7589/2014-03-067; Frank A, 2004, BIOL TRACE ELEM RES, V102, P143, DOI 10.1385/BTER:102:1-3:143; Frolich K., 1999, RANGIFER, V20, P83; Garcia-Lunar P, 2014, VET PARASITOL, V205, P434, DOI 10.1016/j.vetpar.2014.09.003; Garner B. C., 2010, SCHALMS VET HEMATOLO, P936; Garner BC, 2012, VET CLIN PATH, V41, P497, DOI 10.1111/j.1939-165x.2012.00475.x; Gaudie C, 2012, VET REC, V170, P369, DOI 10.1136/vr.e2543; Gavier-Widen D., 2012, INFECT DIS WILD MAMM, P266; Gelmetti D, 2010, J WILDLIFE DIS, V46, P961, DOI 10.7589/0090-3558-46.3.961; Gentes ML, 2007, J WILDLIFE DIS, V43, P758, DOI 10.7589/0090-3558-43.4.758; Giannitti F, 2012, J VET DIAGN INVEST, V24, P1068, DOI 10.1177/1040638712458784; GLINES MV, 1989, EXP APPL ACAROL, V6, P197, DOI 10.1007/BF01193980; GLOVER GJ, 1990, J WILDLIFE DIS, V26, P186, DOI 10.7589/0090-3558-26.2.186; Godfroid Jacques, 2012, P318; GOGAN PJP, 1988, J WILDLIFE DIS, V24, P656, DOI 10.7589/0090-3558-24.4.656; Gottdenker NL, 2012, J VET DIAGN INVEST, V24, P202, DOI 10.1177/1040638711425570; Haigh J, 2005, CAN VET J, V46, P507; Haley NJ, 2016, J CLIN MICROBIOL, V54, P1117, DOI 10.1128/JCM.02700-15; Hamir AN, 2002, VET REC, V151, P332, DOI 10.1136/vr.151.11.332; Han JI, 2009, J WILDLIFE DIS, V45, P1213, DOI 10.7589/0090-3558-45.4.1213; Han SS, 2014, J WILDLIFE DIS, V50, P259, DOI 10.7589/2013-07-163; Handeland K, 2010, J COMP PATHOL, V143, P29, DOI 10.1016/j.jcpa.2009.12.018; Handeland Kjell, 2012, P428; Hartfiel W., 1985, LANDWIRTSCHAFTLICHE, V1, P10; Hattel AL, 2004, J VET DIAGN INVEST, V16, P515, DOI 10.1177/104063870401600605; Hattel AL, 2007, J VET DIAGN INVEST, V19, P334, DOI 10.1177/104063870701900322; Hernandez J., 2014, SCI WORLD J, V2014, P8; Heuschele W. P., 2001, INFECT DIS WILD MAMM, P147; Hibler C. P., 1981, DIS PARASITES WHITE, P352; Hoff G.L., 1978, Advances in Veterinary Science and Comparative Medicine, V22, P111; Hofle U, 2004, NEW ZEAL VET J, V52, P44, DOI 10.1080/00480169.2004.36390; HOLMAN PJ, 1994, J WILDLIFE DIS, V30, P460, DOI 10.7589/0090-3558-30.3.460; Honess R., 1982, DIS WILDLIFE WYOMING, P231; Hoover CE, 2017, J VIROL, V91, DOI 10.1128/JVI.00077-17; HORNER GW, 1987, NEW ZEAL VET J, V35, P41, DOI 10.1080/00480169.1987.35376; HOWARD D R, 1976, Journal of Wildlife Diseases, V12, P143; Howe D. L., 1971, P335; Howe D. L., 1971, P343; Howerth Elizabeth W., 2001, P77, DOI 10.1002/9780470344880.ch3; HOWERTH EW, 1988, AM J VET RES, V49, P1906; HOWERTH EW, 1989, J WILDLIFE DIS, V25, P384, DOI 10.7589/0090-3558-25.3.384; HRUDKA F, 1983, CAN J ZOOL, V61, P1693, DOI 10.1139/z83-220; INGLIS DM, 1983, VET REC, V113, P182, DOI 10.1136/vr.113.8.182; Izdebska Joanna N., 2012, Annals of Parasitiology, V58, P161; Jellison W., 2001, PARASITIC DIS WILD M, P354; JENKS JA, 1986, J WILDLIFE DIS, V22, P286, DOI 10.7589/0090-3558-22.2.286; JOHNSON JL, 1983, J WILDLIFE DIS, V19, P279, DOI 10.7589/0090-3558-19.3.279; Jolley W., 1982, DIS WILDLIFE WYOMING, P107; Junge RE, 2000, J ZOO WILDLIFE MED, V31, P412; Karns GR, 2009, J WILDLIFE DIS, V45, P196, DOI 10.7589/0090-3558-45.1.196; KATZ J, 1994, J VET DIAGN INVEST, V6, P139, DOI 10.1177/104063879400600201; Kelly PA, 2015, VET PATHOL, V52, P193, DOI 10.1177/0300985814521246; KIERDORF H, 1992, ARCH ORAL BIOL, V37, P1091, DOI 10.1016/0003-9969(92)90042-7; Kierdorf U, 2004, ANAT REC PART A, V281A, P1352, DOI 10.1002/ar.a.20127; Kierdorf U, 2015, INT J PALEOPATHOL, V8, P42, DOI 10.1016/j.ijpp.2014.09.004; KING KA, 1984, J WILDLIFE MANAGE, V48, P267, DOI 10.2307/3808486; KINGSTON N, 1981, Journal of Wildlife Diseases, V17, P539; Kingston N., 1981, MISCELLANEOUS PUBLIC, P193; KISTNER TP, 1977, J WILDLIFE DIS, V13, P55, DOI 10.7589/0090-3558-13.1.55; Kleinschmidt S, 2012, RES VET SCI, V93, P1334, DOI 10.1016/j.rvsc.2012.03.008; Klieforth R, 2002, J CLIN MICROBIOL, V40, P3381, DOI 10.1128/JCM.40.9.3381-3390.2002; Kocan A. Alan, 2001, P520, DOI 10.1002/9780470377000.ch18a; Kocan A. Alan, 2001, P524, DOI 10.1002/9780470377000.ch18b; Konjevic D, 2011, J WILDLIFE DIS, V47, P393, DOI 10.7589/0090-3558-47.2.393; Kropatsch R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073734; Kuiken T, 1997, J WILDLIFE DIS, V33, P87, DOI 10.7589/0090-3558-33.1.87; LANCASTER WD, 1982, VIROLOGY, V123, P212, DOI 10.1016/0042-6822(82)90307-5; LANCE WR, 1983, J WILDLIFE DIS, V19, P165, DOI 10.7589/0090-3558-19.3.165; Lankester M. W., 2007, ECOLOGY MANAGEMENT N, P479; Lankester Murray W., 2001, P228, DOI 10.1002/9780470377000.ch9; Lapointe JM, 1999, ARCH VIROL, V144, P393, DOI 10.1007/s007050050512; Larsen RS, 2000, J ZOO WILDLIFE MED, V31, P236; LEADERWILLIAMS N, 1979, J REPROD FERTIL, V57, P127; Leighton Frederick A., 2001, P493; Leighton Frederick A., 2001, P489; Leighton Frederick A., 2001, P468, DOI 10.1002/9780470377000.ch17c; LEVINE S, 1987, VET PATHOL, V24, P207, DOI 10.1177/030098588702400302; Li H, 2000, J CLIN MICROBIOL, V38, P1313; Li H, 2014, ANNU REV ANIM BIOSCI, V2, P209, DOI 10.1146/annurev-animal-022513-114156; Li H, 2013, J ZOO WILDLIFE MED, V44, P484, DOI 10.1638/2012-0087R.1; Li H, 2011, INT J MOL SCI, V12, P6881, DOI 10.3390/ijms12106881; Li YQ, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-225; Linden A., 2012, INFECT DIS WILD MAMM, P281; Little SE, 1997, VET PATHOL, V34, P350, DOI 10.1177/030098589703400412; Mackintosh C, 2002, REV SCI TECH OIE, V21, P249, DOI 10.20506/rst.21.2.1341; Mackintosh CG, 2000, INFECT IMMUN, V68, P1620, DOI 10.1128/IAI.68.3.1620-1625.2000; Maclachlan NJ, 2009, J COMP PATHOL, V141, P1, DOI 10.1016/j.jcpa.2009.04.003; Madslien K, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-251; Madson DM, 2009, J WILDLIFE DIS, V45, P791, DOI 10.7589/0090-3558-45.3.791; MILLER F L, 1971, Journal of Wildlife Diseases, V7, P307; MILLER FL, 1971, J MAMMAL, V52, P164, DOI 10.2307/1378439; Miller MW, 2004, EMERG INFECT DIS, V10, P1003, DOI 10.3201/eid1006.040010; Monello R. J., 2015, J WILDLIFE DIS, V49, P270; Mossman H. W., 1987, VERTEBRATE FETAL MEM, P279; Munk BA, 2015, VET PATHOL, V52, P213, DOI 10.1177/0300985814528216; Mutinelli F, 2012, J VET MED SCI, V74, P527, DOI 10.1292/jvms.11-0385; Nemeth NM, 2014, VET PATHOL, V51, P633, DOI 10.1177/0300985813498783; Neumuller M, 2012, PARASITOL RES, V110, P135, DOI 10.1007/s00436-011-2462-9; NEWMAN J R, 1976, Journal of Wildlife Diseases, V12, P39; Nowak R. M., 1999, WALKERS MAMMALS WORL, V2, P1089; Nuvoli S, 2014, ITAL J ZOOL, V81, P457, DOI 10.1080/11250003.2014.942712; O'Toole D, 2014, VET PATHOL, V51, P437, DOI 10.1177/0300985813520435; Olias P, 2011, INFECT GENET EVOL, V11, P1564, DOI 10.1016/j.meegid.2011.08.006; Overy DP, 2016, EMERG INFECT DIS, V22, P1131, DOI 10.3201/eid2206.160081; Pajares G, 2009, ANIM REPROD SCI, V112, P190, DOI 10.1016/j.anireprosci.2008.04.018; Palmer MV, 2004, J VET DIAGN INVEST, V16, P475, DOI 10.1177/104063870401600522; Palmer MV, 2002, J WILDLIFE DIS, V38, P860, DOI 10.7589/0090-3558-38.4.860; PETERSON RO, 1988, J WILDLIFE DIS, V24, P461, DOI 10.7589/0090-3558-24.3.461; Pewsner M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170338; PLACKE ME, 1982, CAN J COMP MED, V46, P198; Plotka E. D., 1998, ENCY REPROD, V1, P842; Prestwood A. K., 1981, Diseases and parasites of white-tailed deer., P318; Pulford B, 2012, J WILDLIFE DIS, V48, P425, DOI 10.7589/0090-3558-48.2.425; Puraite I, 2016, FOLIA PARASIT, V63, DOI 10.14411/fp.2016.009; Pybus MJ, 2015, J WILDLIFE DIS, V51, P431, DOI 10.7589/2014-09-235; PYBUS MJ, 1984, VET PATHOL, V21, P425, DOI 10.1177/030098588402100409; Pyziel AM, 2013, PARASITOL RES, V112, P2083, DOI 10.1007/s00436-012-3262-6; Quinn ACD, 2014, J WILDLIFE DIS, V50, P250, DOI 10.7589/2012-07-174; Ramos CM, 2010, VET PARASITOL, V172, P214, DOI 10.1016/j.vetpar.2010.05.004; REHBINDER C, 1970, ACTA VET SCAND, V11, P338; Rehbinder C., 2014, MICROB ECOL HEALTH D, V16, P35; REID HW, 1986, VET REC, V118, P156; Ridler AL, 2012, NEW ZEAL VET J, V60, P146, DOI 10.1080/00480169.2011.638269; Robinson Anthony J., 2001, P179, DOI 10.1002/9780470344880.ch8; ROBINSON RM, 1967, J WILDLIFE MANAGE, V31, P455, DOI 10.2307/3798123; ROLLOR EA, 1993, J WILDLIFE DIS, V29, P618, DOI 10.7589/0090-3558-29.4.618; Ruder MG, 2015, VECTOR-BORNE ZOONOT, V15, P348, DOI 10.1089/vbz.2014.1703; Salaba O, 2013, PARASITOL RES, V112, P1661, DOI 10.1007/s00436-013-3322-6; SAMUEL WM, 1991, CAN J ZOOL, V69, P1255, DOI 10.1139/z91-176; Santos N, 2015, VET RES, V46, DOI 10.1186/s13567-015-0270-4; Sato Y, 1998, J VET MED SCI, V60, P981, DOI 10.1292/jvms.60.981; Scala C, 2014, J ZOO WILDLIFE MED, V45, P380, DOI 10.1638/2013-0274R1.1; Scandrett B, 2004, J WILDLIFE DIS, V40, P808, DOI 10.7589/0090-3558-40.4.808; Schares G, 2011, VET PARASITOL, V178, P208, DOI 10.1016/j.vetpar.2011.01.038; Schulz C, 2016, J GEN VIROL, V97, P2073, DOI 10.1099/jgv.0.000557; SHAW G E, 1973, Journal of Wildlife Diseases, V9, P311; Shilton CM, 2002, J ZOO WILDLIFE MED, V33, P73; SHOPE RE, 1958, J EXP MED, V108, P797, DOI 10.1084/jem.108.6.797; SHUPE JL, 1984, J AM VET MED ASSOC, V185, P1295; Sieber V., 2010, VET MED INT, V2010, P8; Simpson JW, 2011, VET REC, V169, DOI 10.1136/vr.100129; SNYDER SP, 1979, J WILDLIFE DIS, V15, P303, DOI 10.7589/0090-3558-15.2.303; SNYDER SP, 1979, J WILDLIFE DIS, V15, P307, DOI 10.7589/0090-3558-15.2.307; Soldati S, 2004, J VET MED A, V51, P280, DOI 10.1111/j.1439-0442.2004.00646.x; Sorden SD, 2000, J VET DIAGN INVEST, V12, P378, DOI 10.1177/104063870001200416; Speck S., 2012, INFECT DIS WILD MAMM, P442; Speck S., 2012, INFECT DIS WILD MAMM, P439; Spraker TR, 2015, J VET DIAGN INVEST, V27, P431, DOI 10.1177/1040638715593368; Spraker Terry R., 1993, P481; Stephens CP, 1997, AUST VET J, V75, P358, DOI 10.1111/j.1751-0813.1997.tb15715.x; Stubbe C., 2008, REWILD BIOL OKOLOGIE; Sundberg John P., 2001, P223, DOI 10.1002/9780470344880.ch11; SUNDBERG JP, 1981, CAN VET J, V22, P385; SUNDBERG JP, 1985, AM J VET RES, V46, P1145; SUNDBERG JP, 1981, J WILDLIFE DIS, V17, P251, DOI 10.7589/0090-3558-17.2.251; Takahasi M., 2008, NEOTROMBICULA NOGAMI, P55; Tate CM, 2013, TICKS TICK-BORNE DIS, V4, P110, DOI 10.1016/j.ttbdis.2012.09.005; Thorne E. Tom, 2001, P372, DOI 10.1002/9780470344880.ch22; TRAMONTIN RR, 1983, J AM VET MED ASSOC, V183, P1263; Tryland M, 2013, VET MICROBIOL, V162, P499, DOI 10.1016/j.vetmic.2012.10.039; Tryland M, 2009, J CLIN MICROBIOL, V47, P3707, DOI 10.1128/JCM.01198-09; Tuntasuvan D, 2000, VET PARASITOL, V89, P337, DOI 10.1016/S0304-4017(00)00236-3; Ulrich R, 2014, J WILDLIFE DIS, V50, P113, DOI 10.7589/2012-03-090; Useh NM, 2003, VET QUART, V25, P155, DOI 10.1080/01652176.2003.9695158; Vaatstra BL, 2014, NEW ZEAL VET J, V62, P96, DOI 10.1080/00480169.2013.840943; Vengust G, 2003, VET PARASITOL, V112, P51, DOI 10.1016/S0304-4017(02)00413-2; Vikoren T, 2006, J WILDLIFE DIS, V42, P797, DOI 10.7589/0090-3558-42.4.797; Wallach AD, 2008, J WILDLIFE DIS, V44, P693, DOI 10.7589/0090-3558-44.3.693; WELCH DA, 1991, CAN J ZOOL, V69, P2300, DOI 10.1139/z91-323; Wiegmann L, 2015, VET PARASITOL, V211, P16, DOI 10.1016/j.vetpar.2015.04.026; WILLIAMS ES, 1993, VET PATHOL, V30, P36, DOI 10.1177/030098589303000105; Williams ES, 2002, J WILDLIFE MANAGE, V66, P551, DOI 10.2307/3803123; WILLIAMS ES, 1985, J WILDLIFE DIS, V21, P430, DOI 10.7589/0090-3558-21.4.430; WOBESER G, 1975, Journal of Wildlife Diseases, V11, P116; WOBESER G, 1975, CAN VET J, V16, P3; Wobeser Gary, 2001, P487, DOI 10.1002/9780470344880.ch28; Wolfe BA, 1998, J AM VET MED ASSOC, V213, P1783; Wood J, 2013, J VET DIAGN INVEST, V25, P662, DOI 10.1177/1040638713501173; Woods Leslie W., 2001, P202, DOI 10.1002/9780470344880.ch9; Woods LW, 1997, J WILDLIFE DIS, V33, P801, DOI 10.7589/0090-3558-33.4.801; Woods LW, 1999, VET PATHOL, V36, P100, DOI 10.1354/vp.36-2-100; Woods LW, 1996, VET PATHOL, V33, P125, DOI 10.1177/030098589603300201; WORK TM, 1992, J WILDLIFE DIS, V28, P623, DOI 10.7589/0090-3558-28.4.623; Wunschmann A, 2015, J WILDLIFE DIS, V51, P157, DOI 10.7589/2014-02-037; Yoon BI, 1999, J ZOO WILDLIFE MED, V30, P456; ZARNKE RL, 1983, J WILDLIFE DIS, V19, P170, DOI 10.7589/0090-3558-19.3.170; Zimmerman TJ, 2004, J WILDLIFE DIS, V40, P145, DOI 10.7589/0090-3558-40.1.145	255	0	0	2	2	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							149	+		10.1016/B978-0-12-805306-5.00006-7			16	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300008					2019-10-28	
B	Agnew, D		Terio, KA; McAloose, D; StLeger, J		Agnew, Dalen			Camelidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							VIRAL DIARRHEA VIRUS; VENTRICULAR SEPTAL-DEFECT; LAMANEMA-CHAVEZI BECKLUND; ALPACAS VICUGNA-PACOS; NEW-WORLD CAMELIDS; DROMEDARY CAMEL; OVARIAN HYDROBURSITIS; PATHOLOGICAL FINDINGS; RESPIRATORY SYNDROME; COLLOID GOITER		[Agnew, Dalen] Michigan State Univ, Lansing, MI 48912 USA	Agnew, D (reprint author), Michigan State Univ, Lansing, MI 48912 USA.						Aboellail TA, 2013, J VET DIAGN INVEST, V25, P168, DOI 10.1177/1040638712471059; Abubakar MS, 2010, AFR J MICROBIOL RES, V4, P2479; ABUDAMIR H, 1990, BRIT VET J, V146, P219; Adney DR, 2016, EMERG INFECT DIS, V22, P1031, DOI [10.3201/eid2206.160192, 10.3201/2206.160192]; Al-Qarawi AA, 2001, DEUT TIERARZTL WOCH, V108, P172; Al-Qurawi AA, 2005, ANIM REPROD SCI, V87, P73, DOI 10.1016/j.anireprosci.2004.11.003; Ali A, 2012, THERIOGENOLOGY, V77, P1754, DOI 10.1016/j.theriogenology.2011.12.017; Ali A, 2011, THERIOGENOLOGY, V76, P492, DOI 10.1016/j.theriogenology.2011.02.028; Altmann D., 1976, 18TH INT S ERKR ZOOT, P127; Balamurugan V, 2013, INDIAN J VIROL, V24, P295, DOI 10.1007/s13337-013-0145-0; Bani-Ismail Z, 1999, J ZOO WILDLIFE MED, V30, P301; Benirschke K., 2008, COMP PLACENTATION; Carman S, 2005, J VET DIAGN INVEST, V17, P589, DOI 10.1177/104063870501700613; Caswell JL, 2016, JUBB KENNEDY PALMERS, P465, DOI DOI 10.1016/B978-0-7020-5318-4.00011-5; Cebra CK, 2007, JAVMA-J AM VET MED A, V230, P94, DOI 10.2460/javma.230.1.94; Cebra CK, 2009, VET CLIN N AM-FOOD A, V25, P339, DOI 10.1016/j.cvfa.2009.02.005; CEBRA CK, 1995, J VET INTERN MED, V9, P381, DOI 10.1111/j.1939-1676.1995.tb03297.x; Coster ME, 2010, VET OPHTHALMOL, V13, P53, DOI 10.1111/j.1463-5224.2009.00747.x; Crossley BM, 2012, VIRUSES-BASEL, V4, P3689, DOI 10.3390/v4123689; Crossley BM, 2010, J VET DIAGN INVEST, V22, P94, DOI 10.1177/104063871002200118; DECKER RA, 1979, J AM VET MED ASSOC, V175, P968; Dobey CL, 2014, J VET DIAGN INVEST, V26, P748, DOI 10.1177/1040638714553427; Dunkel B, 2004, J VET INTERN MED, V18, P365, DOI 10.1892/0891-6640(2004)18<365:EFWNFI>2.0.CO;2; Duraffour S, 2011, ANTIVIR RES, V92, P167, DOI 10.1016/j.antiviral.2011.09.003; ELSANOUSI SM, 1993, J VET MED A, V40, P525; Fowler M. E., 1985, California Veterinarian, V39, P10; FOWLER ME, 1992, J AM VET MED ASSOC, V201, P1609; Fowler ME, 2010, MEDICINE AND SURGERY OF CAMELIDS, 3RD EDITION, P1, DOI 10.1002/9781118785706; FOWLER ME, 2010, MED SURG S AM CAMELI, V3, P231; Fowler ME, 2010, MEDICINE AND SURGERY OF CAMELIDS, 3RD EDITION, P3; Fowler ME, 2010, MEDICINE AND SURGERY OF CAMELIDS, 3RD EDITION, P429; Fowler ME, 2010, MEDICINE AND SURGERY OF CAMELIDS, 3RD EDITION, P173; Fowler ME, 2010, MEDICINE AND SURGERY OF CAMELIDS, 3RD EDITION, P407; Gao SD, 2013, VET MICROBIOL, V163, P172, DOI 10.1016/j.vetmic.2012.12.015; Gauly M, 2005, J VET INTERN MED, V19, P756, DOI 10.1892/0891-6640(2005)19[756:BAPAOA]2.0.CO;2; GERROS TC, 1994, J AM VET MED ASSOC, V205, P179; Guimaraes AMS, 2012, J BACTERIOL, V194, P6312, DOI 10.1128/JB.01557-12; Henningson JN, 2013, VET PATHOL, V50, P308, DOI 10.1177/0300985812447827; Hilbe M, 2015, VET PATHOL, V52, P1202, DOI 10.1177/0300985814564978; House J A, 1991, J Vet Diagn Invest, V3, P137; HUSSEIN HS, 1987, J COMP PATHOL, V97, P293, DOI 10.1016/0021-9975(87)90093-4; Intisar KS, 2010, TROP ANIM HEALTH PRO, V42, P1203, DOI 10.1007/s11250-010-9549-7; Irwin JA, 2001, CAN VET J, V42, P805; Jacobsen B, 2010, J COMP PATHOL, V143, P203, DOI 10.1016/j.jcpa.2010.01.009; Jarvinen JAC, 2014, J VET DIAGN INVEST, V26, P178, DOI 10.1177/1040638713516626; Jones M, 2009, J VET INTERN MED, V23, P220, DOI 10.1111/j.1939-1676.2008.0219.x; Kapil S, 2009, VET CLIN N AM-FOOD A, V25, P323, DOI 10.1016/j.cvfa.2009.03.005; Khalafalla AI, 2010, ACTA TROP, V116, P161, DOI 10.1016/j.actatropica.2010.08.002; Kiupel M, 2003, J ZOO WILDLIFE MED, V34, P309, DOI 10.1638/01-081; Lamoureux JL, 2011, J VET DIAGN INVEST, V23, P312, DOI 10.1177/104063871102300218; Lee LC, 2012, CAN VET J, V53, P283; Martin JM, 2009, VET PATHOL, V46, P288, DOI 10.1354/vp.46-2-288; Mattson DE, 2006, JAVMA-J AM VET MED A, V228, P1762, DOI 10.2460/javma.228.11.1762; McKenna PB, 2009, NEW ZEAL VET J, V57, P395, DOI 10.1080/00480169.2009.64736; Milad KE, 2009, IRAQI J VET SCI S1, V23, P119; Moore CP, 1999, J ZOO WILDLIFE MED, V30, P423; Narnaware SD, 2015, TROP ANIM HEALTH PRO, V47, P1633, DOI 10.1007/s11250-015-0905-5; Nelson DD, 2016, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01415; Nolen-Walston R, 2007, J VET INTERN MED, V21, P846, DOI 10.1892/0891-6640(2007)21[846:EEEISA]2.0.CO;2; Oryan A, 2008, TROP BIOMED, V25, P30; Pillitteri CA, 2013, VET PATHOL, V50, P177, DOI 10.1177/0300985812442692; POWERS BE, 1990, J AM VET MED ASSOC, V197, P1157; REAGAN WJ, 1990, VET PATHOL, V27, P426, DOI 10.1177/030098589902700607; REBHUN WC, 1988, J AM VET MED ASSOC, V192, P953; Reed SK, 2007, AM J VET RES, V68, P879, DOI 10.2460/ajvr.68.8.879; RIBADU AY, 1991, BRIT VET J, V147, P290; RIDGE SE, 1995, AUST VET J, V72, P150, DOI 10.1111/j.1751-0813.1995.tb15040.x; Rosa FB, 2013, JAVMA-J AM VET MED A, V243, P645, DOI 10.2460/javma.243.5.645; Rosadio R, 2010, VET PARASITOL, V168, P116, DOI 10.1016/j.vetpar.2009.10.010; ROSYCHUK RAW, 1994, VET CLIN N AM-FOOD A, V10, P228, DOI 10.1016/S0749-0720(15)30557-0; Sakamoto K, 2004, J VET DIAGN INVEST, V16, P337, DOI 10.1177/104063870401600415; Sartin EA, 2004, J VET DIAGN INVEST, V16, P226, DOI 10.1177/104063870401600309; Schulman FY, 2003, VET PATHOL, V40, P103, DOI 10.1354/vp.40-1-103; Shapiro JL, 2005, CAN VET J, V46, P317; Simmons HA, 2005, J ZOO WILDLIFE MED, V36, P727, DOI 10.1638/03-040.1; Steffen DJ, 2014, J VET DIAGN INVEST, V26, P35, DOI 10.1177/1040638713509626; Stoughton WB, 2015, JAVMA-J AM VET MED A, V247, P300, DOI 10.2460/javma.247.3.300; Sumar J, 1989, DEFECTOS CONGENITOS; Tharwat M, 2012, CAN VET J, V53, P543; Tibary A, 2006, THERIOGENOLOGY, V66, P633, DOI 10.1016/j.theriogenology.2006.04.008; Tibary A, 2001, THERIOGENOLOGY, V56, P415, DOI 10.1016/S0093-691X(01)00573-8; Tornquist Susan J., 2012, P646; UNDERWOOD WJ, 1993, J VET DIAGN INVEST, V5, P117, DOI 10.1177/104063879300500130; Ure AE, 2011, J GEN VIROL, V92, P1769, DOI 10.1099/vir.0.031039-0; VALLENAS A, 1971, J MORPHOL, V134, P339; Valli V. E. O., 2016, PALMERS PATHOLOGY DO; VITOVEC J, 1982, VET PATHOL, V19, P331, DOI 10.1177/030098588201900315; Wernery U, 2006, VET REC, V158, P201, DOI 10.1136/vr.158.6.201; Wernery U, 2014, REV SCI TECH OIE, V33, P839, DOI 10.20506/rst.33.3.2322; Wernery U, 2012, REV SCI TECH OIE, V31, P907; Wernery U, 2012, REV SCI TECH OIE, V31, P899; Wernery U, 1991, Rev Elev Med Vet Pays Trop, V44, P147; Whitehead CE, 2009, VET CLIN N AM-FOOD A, V25, P385, DOI 10.1016/j.cvfa.2009.02.004; Whitehead CE, 2009, VET CLIN N AM-FOOD A, V25, P367, DOI 10.1016/j.cvfa.2009.03.002; Xu LH, 2012, GENE, V491, P256, DOI 10.1016/j.gene.2011.10.007; Younan M., 2012, TROPICAL ANIMAL HLTH, V48, P1277; Zakian A, 2016, TROP ANIM HEALTH PRO, V48, P1215, DOI 10.1007/s11250-016-1078-6	97	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							185	+		10.1016/B978-0-12-805306-5.00007-9			22	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300009					2019-10-28	
B	Martinez, MAJ; Gasper, DJ; Mucino, MDC; Terio, KA		Terio, KA; McAloose, D; StLeger, J		Jimenez Martinez, Maria Angeles; Gasper, David J.; Carmona Mucino, Maria del Carmen; Terio, Karen A.			Suidae and Tayassuidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							BOAR SUS-SCROFA; AFRICAN-SWINE-FEVER; EUROPEAN WILD BOARS; INFLUENZA-A VIRUS; BUSHPIGS POTAMOCHOERUS-LARVATUS; PORCINE CIRCOVIRUS TYPE-2; MYCOBACTERIUM-TUBERCULOSIS COMPLEX; WARTHOGS PHACOCHOERUS-AFRICANUS; CANINE-DISTEMPER VIRUS; PERFRINGENS TYPE-A		[Jimenez Martinez, Maria Angeles] Univ Complutense Madrid, Fac Vet, Madrid, Spain; [Gasper, David J.] Pacific Zoo & Wildlife Diagnost, San Diego, CA USA; [Carmona Mucino, Maria del Carmen] Africam Zoo Safari, Puebla, Mexico; [Terio, Karen A.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA	Martinez, MAJ (reprint author), Univ Complutense Madrid, Fac Vet, Madrid, Spain.		Terio, Karen/AAC-5376-2019				Alexandrov T, 2013, VET MICROBIOL, V166, P84, DOI 10.1016/j.vetmic.2013.05.016; Allan SA, 2001, J VECTOR ECOL, V26, P93; Anderson J, 1996, MANUAL DIAGNOSIS RIN; APPEL MJG, 1991, ARCH VIROL, V119, P147, DOI 10.1007/BF01314331; Artois M, 2002, REV SCI TECH OIE, V21, P287, DOI 10.20506/rst.21.2.1332; Barasona JA, 2016, EMERG INFECT DIS, V22, P2178, DOI 10.3201/eid2212.160677; Baroch JA, 2015, CAN J VET RES, V79, P74; Barrette RW, 2009, SCIENCE, V325, P204, DOI 10.1126/science.1172705; Batista JS, 2014, PESQUI VET BRASIL, V34, P1101, DOI 10.1590/S0100-736X2014001100012; Batista Jael Soares, 2008, Ciencia Animal Brasileira, V9, P170; Baums CG, 2007, APPL ENVIRON MICROB, V73, P711, DOI 10.1128/AEM.01800-06; Belem A. M. G., 2012, Bulletin of Animal Health and Production in Africa, V60, P199; BENIRSCHKE K, 1995, VET PATHOL, V32, P532, DOI 10.1177/030098589503200511; Berg F, 2006, PLOS GENET, V2, P1178, DOI 10.1371/journal.pgen.0020129; Biondo N, 2014, VET MICROBIOL, V168, P34, DOI 10.1016/j.vetmic.2013.10.010; Blome S, 2013, VIRUS RES, V173, P122, DOI 10.1016/j.virusres.2012.10.026; Blome S, 2012, EMERG INFECT DIS, V18, P708, DOI 10.3201/eid1804.111813; Boadella M, 2012, TRANSBOUND EMERG DIS, V59, P395, DOI 10.1111/j.1865-1682.2011.01285.x; Boadella M, 2011, J VET DIAGN INVEST, V23, P77, DOI 10.1177/104063871102300111; Bollo E, 2000, J VET MED B, V47, P337, DOI 10.1046/j.1439-0450.2000.00354.x; BOOMKER J, 1991, ONDERSTEPOORT J VET, V58, P195; Booyse DG, 2012, AFR ZOOL, V47, P169, DOI 10.3377/004.047.0105; Borba MR, 2011, MED MYCOL, V49, P172, DOI 10.3109/13693786.2010.510540; Breithaupt A, 2012, VET MICROBIOL, V159, P33, DOI 10.1016/j.vetmic.2012.03.021; Buxton D, 2002, TRENDS PARASITOL, V18, P546, DOI 10.1016/S1471-4922(02)02414-5; Cano-Manuel FJ, 2014, VET MICROBIOL, V174, P148, DOI 10.1016/j.vetmic.2014.06.017; Caswell J. L., 2016, KENNEDY PALMERP PATH, V3, P534; Chae JB, 2017, KOREAN J PARASITOL, V55, P185, DOI 10.3347/kjp.2017.55.2.185; Chiari M, 2014, EUR J WILDLIFE RES, V60, P187, DOI 10.1007/s10344-013-0763-2; Cho YY, 2015, J VET MED SCI, V77, P109, DOI 10.1292/jvms.14-0290; CLAXTON JR, 1992, VET PARASITOL, V41, P179, DOI 10.1016/0304-4017(92)90077-M; Closa-Sebastia F, 2011, EUR J WILDLIFE RES, V57, P977, DOI 10.1007/s10344-010-0491-9; Cole G, 2008, J ZOO WILDLIFE MED, V39, P663, DOI 10.1638/2008-0009.1; Comeaux JM, 2016, J WILDLIFE DIS, V52, P627, DOI 10.7589/2015-08-208; CORN JL, 1987, J WILDLIFE DIS, V23, P551, DOI 10.7589/0090-3558-23.4.551; CORNER LA, 1981, AUST VET J, V57, P537, DOI 10.1111/j.1751-0813.1981.tb00428.x; Craig LE, 2015, JUBB KENNEDY PALMERS, V1, P17; Crotti D., 2012, MICROBIOL MED, V27, P137; Csagola A, 2008, ACTA VET HUNG, V56, P139, DOI 10.1556/AVet.56.2008.1.15; Gerveno JMC, 2013, J VET DIAGN INVEST, V25, P297, DOI 10.1177/1040638713479348; Dardiri A. H., 1969, P 73 ANN M USAHA, P437; Das A, 2008, AFR J MICROBIOL RES, V2, P196; Diez-Delgado I, 2014, BIOMED RES INT, DOI 10.1155/2014/765715; Donahoe SL, 2015, INT J PARASITOL-PAR, V4, P216, DOI 10.1016/j.ijppaw.2015.04.002; Elbers ARW, 2003, VET REC, V153, P678, DOI 10.1136/vr.153.22.678; Ellis J, 2003, J VET DIAGN INVEST, V15, P364, DOI 10.1177/104063870301500411; Everett H, 2011, TRANSBOUND EMERG DIS, V58, P128, DOI 10.1111/j.1865-1682.2011.01202.x; Fernandez-de-Mera IG, 2003, VET PARASITOL, V115, P335, DOI 10.1016/S0304-4017(03)00211-5; Foni E, 2013, INFLUENZA OTHER RESP, V7, P16, DOI 10.1111/irv.12198; Fowler M. E., 2001, BIOL MED SURG S AM, P1; Fowler ME, 1996, REV SCI TECH OIE, V15, P141, DOI 10.20506/rst.15.1.913; Gabriel C, 2011, EMERG INFECT DIS, V17, P2342, DOI 10.3201/eid1712.110430; Gerber PF, 2012, J WILDLIFE DIS, V48, P230, DOI 10.7589/0090-3558-48.1.230; Gers S, 2011, TRANSBOUND EMERG DIS, V58, P135, DOI 10.1111/j.1865-1682.2010.01191.x; GLADNEY WJ, 1977, J MED ENTOMOL, V14, P85, DOI 10.1093/jmedent/14.1.85; Godfroid J, 2013, REV SCI TECH OIE, V32, P27; Gogin A, 2013, VIRUS RES, V173, P198, DOI 10.1016/j.virusres.2012.12.007; Gomez-Laguna J, 2010, J VET DIAGN INVEST, V22, P123, DOI 10.5533/2177-8264-201022303; Gortazar C, 2002, ANN NY ACAD SCI, V969, P210, DOI 10.1111/j.1749-6632.2002.tb04380.x; Gottdenker N., 2004, GRIZIMEKS ANIMAL LIF, V16, P291; Gruver KS, 1996, J WILDLIFE DIS, V32, P560, DOI 10.7589/0090-3558-32.3.560; Guenther S, 2008, J MICROBIOL METH, V75, P287, DOI 10.1016/j.mimet.2008.06.019; GUGLIELMONE AA, 1990, ANN PARASIT HUM COMP, V65, P145, DOI 10.1051/parasite/1990653145; Guinat C, 2016, VET REC, V178, DOI 10.1136/vr.103593; Haas C, 2015, SCHWEIZ ARCH TIERH, V157, P269, DOI 10.17236/sat00020; Hampson D., 2012, DIS SWINE, P680; HANNON PG, 1985, J WILDLIFE DIS, V21, P439, DOI 10.7589/0090-3558-21.4.439; Helcel J., 2016, EXTENSION, P14; HELLGREN E C, 1984, Journal of Wildlife Diseases, V20, P354; Herrera HM, 2008, PARASITOL RES, V103, P619, DOI 10.1007/s00436-008-1021-5; Hohloch C, 2015, BERL MUNCH TIERARZTL, V128, P200, DOI 10.2376/0005-9366-128-200; Horak IG, 2007, ONDERSTEPOORT J VET, V74, P231; HORAK IG, 1988, ONDERSTEPOORT J VET, V55, P145; HORAK IG, 1991, ONDERSTEPOORT J VET, V58, P281; Hotzel H, 2004, VET MICROBIOL, V103, P121, DOI 10.1016/j.vetmic.2004.06.009; Jacobson M, 2005, J VET MED B, V52, P386, DOI 10.1111/j.1439-0450.2005.00865.x; Jori F, 2013, VIRUS RES, V173, P212, DOI 10.1016/j.virusres.2012.10.005; Jori F, 2009, ECOHEALTH, V6, P296, DOI 10.1007/s10393-009-0248-7; Junker K, 2015, INT J PARASITOL-PAR, V4, P50, DOI 10.1016/j.ijppaw.2014.12.003; Kaden V, 2001, Z JAGDWISS, V47, P17, DOI 10.1007/BF02242410; Kaden V, 2008, VET MICROBIOL, V131, P123, DOI 10.1016/j.vetmic.2008.03.006; Kakati P., 2015, INT J RECENT SCI RES, V6, P4231; Kaufmann J, 2014, PARASITIC INFECTIONS; Kaupke A, 2017, EXP PARASITOL, V182, P22, DOI 10.1016/j.exppara.2017.09.020; KEIRANS JE, 1985, P ENTOMOL SOC WASH, V87, P489; Keuling O, 2013, EUR J WILDLIFE RES, V59, P805, DOI 10.1007/s10344-013-0733-8; KHIN T, 1981, ANN PARASIT HUM COMP, V56, P241; Kleiboeker Steven B., 2001, Animal Health Research Reviews, V2, P121; Kobinger GP, 2011, J INFECT DIS, V204, P200, DOI 10.1093/infdis/jir077; Koppel C, 2007, EUR J WILDLIFE RES, V53, P212, DOI 10.1007/s10344-006-0080-0; Kuhnert P, 2011, VET MICROBIOL, V152, P191, DOI 10.1016/j.vetmic.2011.04.026; Kuhnert P, 2014, VET MICROBIOL, V174, P261, DOI 10.1016/j.vetmic.2014.08.022; Kvac M, 2013, VET PARASITOL, V191, P218, DOI 10.1016/j.vetpar.2012.09.005; Lange M, 2014, PREV VET MED, V117, P317, DOI 10.1016/j.prevetmed.2014.08.012; Leak S. G. A., 1999, TSETSE BIOL ECOLOGY, P118; Leslie David M. Jr., 2015, Mammalian Species, P15, DOI 10.1093/mspecies/sev002; Levin M. L., 2016, MERCK VET MANUAL; Li M, 2017, J WILDLIFE DIS, V53, P642, DOI 10.7589/2016-08-199; Linhares MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119060; Link EK, 2017, J GEN VIROL, V98, P2113, DOI 10.1099/jgv.0.000868; Lipej Z, 2007, ACTA VET HUNG, V55, P389, DOI 10.1556/AVet.55.2007.3.13; LOCHMILLER RL, 1985, J WILDLIFE DIS, V21, P305, DOI 10.7589/0090-3558-21.3.305; LORD VR, 1991, J WILDLIFE DIS, V27, P477, DOI 10.7589/0090-3558-27.3.477; Lowenstein M., 1989, Angewandte Parasitologie, V30, P221; MacLachlan NJ, 2011, FENNER'S VETERINARY VIROLOGY, 4TH EDITION, P425, DOI 10.1016/B978-0-12-375158-4.00026-2; MacMillan AP, 1999, DIS SWINE, P385; Manning P. A., 1997, AGR RES SERVICE, V1849; Mansouri M, 2016, IRAN J PARASITOL, V11, P377; Margarido T. C. C., 2001, Biology, medicine, and surgery of South American wild animals, P377; Marinou KA, 2015, VET QUART, V35, P97, DOI 10.1080/01652176.2015.1022666; Marlow B. J. G., 1955, Journal of Mammalogy, V36, P147, DOI 10.2307/1375760; Marsh GA, 2011, J INFECT DIS, V204, pS804, DOI 10.1093/infdis/jir300; Martin-Hernando MP, 2007, TUBERCULOSIS, V87, P360, DOI 10.1016/j.tube.2007.02.003; de Castro AMMG, 2014, J WILDLIFE DIS, V50, P205, DOI 10.7589/2013-01-021; Masatani T, 2017, TICKS TICK-BORNE DIS, V8, P581, DOI 10.1016/j.ttbdis.2017.03.007; MATTHEE S, 2013, S AFRICA AFR, V48, P259; MAXIE M.D., 2007, JUBB KENNEDY PALMERS, V3, P1; Maxie M. G, 2016, PALMER PATHOLOGY DOM, V3, P404; McGregor GF, 2015, CAN VET J, V56, P839; Meng XJ, 2009, PHILOS T R SOC B, V364, P2697, DOI 10.1098/rstb.2009.0086; Mishra A.C., 1978, Bulletin of the Zoological Survey of India, V1, P167; Moennig V, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01211; Montagnaro S, 2010, J WILDLIFE DIS, V46, P316, DOI 10.7589/0090-3558-46.1.316; Muller T, 2011, ARCH VIROL, V156, P1691, DOI 10.1007/s00705-011-1080-2; Muller TF, 2001, AM J VET RES, V62, P252, DOI 10.2460/ajvr.2001.62.252; Naranjo V, 2008, VET MICROBIOL, V127, P1, DOI 10.1016/j.vetmic.2007.10.002; Nava S, 2009, SYST PARASITOL, V73, P161, DOI 10.1007/s11230-009-9191-9; Nemejc K, 2014, PARASITOL RES, V113, P761, DOI 10.1007/s00436-013-3707-6; Nemejc K, 2013, VET PARASITOL, V197, P504, DOI 10.1016/j.vetpar.2013.07.003; Nfon CK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061904; Nockler K, 2006, VET PARASITOL, V137, P364, DOI 10.1016/j.vetpar.2006.01.031; Noon TH, 2003, J WILDLIFE DIS, V39, P221, DOI 10.7589/0090-3558-39.1.221; Olinda RG, 2016, PESQUI VET BRASIL, V36, P516, DOI 10.1590/S0100-736X2016000600009; Olvera A, 2007, VET MICROBIOL, V125, P182, DOI 10.1016/j.vetmic.2007.05.003; Osorio J, 2013, RES VET SCI, V95, P861, DOI 10.1016/j.rvsc.2013.07.014; PAGE GR, 1992, J LEUKOCYTE BIOL, V52, P441; Pan YY, 2014, ARCH VIROL, V159, P1129, DOI 10.1007/s00705-012-1477-6; Parsons MB, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003529; Paulsen P, 2013, VET PARASITOL, V197, P384, DOI 10.1016/j.vetpar.2013.05.024; Penrith ML, 2011, TRANSBOUND EMERG DIS, V58, P187, DOI 10.1111/j.1865-1682.2011.01205.x; Perera HKK, 2013, EMERG INFECT DIS, V19, P481, DOI 10.3201/eid1903.120945; Phillips ND, 2009, VET MICROBIOL, V134, P294, DOI 10.1016/j.vetmic.2008.08.006; Pickering BS, 2018, TRANSBOUND EMERG DIS, V65, P77, DOI 10.1111/tbed.12606; Pietschmann J, 2016, BMC VET RES, V12, DOI 10.1186/s12917-015-0629-9; Pollock J. N, 1982, TSETSE BIOL SYSTEMAT, V1; Rahman H, 2005, REV SCI TECH OIE, V24, P959, DOI 10.20506/rst.24.3.1625; Rahman H, 2001, TROP ANIM HEALTH PRO, V33, P95, DOI 10.1023/A:1005229412814; Ramos VD, 2014, EXP APPL ACAROL, V64, P393, DOI 10.1007/s10493-014-9832-9; Ravamoana J., 2010, PARASITE VECTOR, V3, P2; Ravaomanana J, 2011, TRANSBOUND EMERG DIS, V58, P247, DOI 10.1111/j.1865-1682.2011.01207.x; Register K. B, 2012, DIS SWINE, P798; Reiner G, 2010, EUR J WILDLIFE RES, V56, P815, DOI 10.1007/s10344-010-0409-6; Reiner G, 2010, VET MICROBIOL, V145, P1, DOI 10.1016/j.vetmic.2010.02.028; Reiterova K, 2016, ACTA PARASITOL, V61, P255, DOI 10.1515/ap-2016-0035; Risco D, 2011, TRANSBOUND EMERG DIS, V58, P445, DOI 10.1111/j.1865-1682.2011.01234.x; Risco D, 2015, J ZOO WILDLIFE MED, V46, P370, DOI 10.1638/2014-0135R1.1; Risco D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110123; Risco D, 2013, J VET DIAGN INVEST, V25, P791, DOI 10.1177/1040638713504411; Robinson WF, 2015, PALMERP PATHOLOGY DO, P2; Rodriguez-Rivera LD, 2016, VECTOR-BORNE ZOONOT, V16, P765, DOI 10.1089/vbz.2016.2015; Roger F, 2001, EXP APPL ACAROL, V25, P263, DOI 10.1023/A:1010687502145; Romero CH, 1997, VET MICROBIOL, V55, P131, DOI 10.1016/S0378-1135(96)01307-7; Rossi S, 2005, EPIDEMIOL INFECT, V133, P559, DOI 10.1017/S0950268804003553; Round MC, 1968, CHECK LIST HELMINTH; Ruiz-Fons F, 2006, THERIOGENOLOGY, V65, P731, DOI 10.1016/j.theriogenology.2005.07.001; Ruiz-Fons F, 2017, TRANSBOUND EMERG DIS, V64, P68, DOI 10.1111/tbed.12369; Ryan UM, 2004, J PARASITOL, V90, P769, DOI 10.1645/GE-202R1; SAMSON K S, 1968, Bulletin of the Wildlife Disease Association, V4, P131; SAMUEL W M, 1970, Journal of Wildlife Diseases, V6, P16; del Rey VS, 2014, VET J, V200, P464, DOI 10.1016/j.tvjl.2014.03.013; Sanchez-Vizcaino JM, 2015, REV SCI TECH OIE, V34, P503, DOI 10.20506/rst.34.2.2375; Sanchez-Vizcaino JM, 2015, J COMP PATHOL, V152, P9, DOI 10.1016/j.jcpa.2014.09.003; Sato H, 2008, J HELMINTHOL, V82, P159, DOI 10.1017/S0022149X08936191; Sayama Y, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-82; Schulze C, 2003, DEUT TIERARZTL WOCH, V110, P426; Schulze C, 2010, BERL MUNCH TIERARZTL, V123, P359, DOI 10.2376/0005-9366-123-359; Seguel M, 2017, INT J PARASITOL-PAR, V6, P177, DOI 10.1016/j.ijppaw.2017.03.007; Seol B, 1998, VET REC, V143, P664; Shimizu T, 2016, JPN J VET RES, V64, P91; Shimoda H, 2017, J VET MED SCI, V79, P848, DOI 10.1292/jvms.17-0052; Shome BR, 2010, REV SCI TECH OIE, V29, P687, DOI 10.20506/rst.29.3.2010; Sibila M, 2010, VET MICROBIOL, V144, P214, DOI 10.1016/j.vetmic.2009.12.019; Silaghi C, 2014, VECTOR-BORNE ZOONOT, V14, P371, DOI 10.1089/vbz.2013.1495; Slodkowicz-Kowalska A, 2007, PARASITOL RES, V100, P505, DOI 10.1007/s00436-006-0303-z; Sofia M, 2008, J WILDLIFE DIS, V44, P864, DOI 10.7589/0090-3558-44.4.864; Solaymani-Mohammadi S, 2004, J WILDLIFE DIS, V40, P801, DOI 10.7589/0090-3558-40.4.801; Songer JG, 2005, J VET DIAGN INVEST, V17, P528, DOI 10.1177/104063870501700602; Stolte M, 1998, J EUKARYOT MICROBIOL, V45, P101, DOI 10.1111/j.1550-7408.1998.tb05076.x; Sugiyama H, 2015, JPN J INFECT DIS, V68, P536, DOI 10.7883/yoken.JJID.2015.280; Sutherland-Smith M., 2015, FOWLERS ZOO WILD ANI, P568; Thakur S, 2011, J WILDLIFE DIS, V47, P774, DOI 10.7589/0090-3558-47.3.774; Thompson H, 2009, VET REC, V165, P697; Thompson KA, 2015, J ZOO WILDLIFE MED, V46, P904, DOI 10.1638/2015-0079.1; TISCHER I, 1986, ARCH VIROL, V91, P271, DOI 10.1007/BF01314286; Touloudi A., 2015, VET REC OPEN, V28; Uni S, 2001, PARASITE, V8, P215, DOI 10.1051/parasite/2001083215; Uni S, 2015, PARASITOL INT, V64, P493, DOI 10.1016/j.parint.2015.07.001; Vadillo S, 2017, VET REC, V181, DOI 10.1136/vr.104348; van Wyk IC, 2011, ONDERSTEPOORT J VET, V78, P110, DOI 10.4102/ojvr.v78i1.308; Vengust G, 2006, J VET MED B, V53, P24, DOI 10.1111/j.1439-0450.2006.00899.x; Verin R, 2014, J WILDLIFE DIS, V50, P559, DOI 10.7589/2013-01-004; Vicente J, 2004, VET RES, V35, P243, DOI 10.1051/vetres:2004008; Vicente J, 2002, J WILDLIFE DIS, V38, P649, DOI 10.7589/0090-3558-38.3.649; Vicente JJ, 2000, MEM I OSWALDO CRUZ, V95, P849, DOI 10.1590/S0074-02762000000600017; Walker JB, 2005, GENUS RHIPICEPHALUS; Weingartl HM, 2013, DEV BIOLOGICALS, V135, P211, DOI 10.1159/000178495; Weingartl HM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00811; Wilber PG, 1996, J PARASITOL, V82, P624, DOI 10.2307/3283788; WOODALL PF, 1989, J WILDLIFE DIS, V25, P66, DOI 10.7589/0090-3558-25.1.66; Yamamoto K, 1999, RES VET SCI, V67, P301, DOI 10.1053/rvsc.1999.0311; Yu S., 1994, PARASITE VECTOR, V7, P70; Zamora MJ, 2015, VET PARASITOL, V210, P255, DOI 10.1016/j.vetpar.2015.04.004; Zupancic Z, 2002, J VET MED B, V49, P253, DOI 10.1046/j.1439-0450.2002.00562.x	213	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							207	+		10.1016/B978-0-12-805306-5.00008-0			13	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300010					2019-10-28	
B	Keel, MK; Terio, KA; McAloose, D		Terio, KA; McAloose, D; StLeger, J		Keel, M. Kevin; Terio, Karen A.; McAloose, Denise			Canidae, Ursidae, and Ailuridae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							FOX VULPES-VULPES; WOLVES CHRYSOCYON-BRACHYURUS; CANINE-DISTEMPER VIRUS; DOGS LYCAON-PICTUS; FATAL HEPATIC SARCOCYSTOSIS; BEARS URSUS-MARITIMUS; HEREDITARY HYPERPLASTIC GINGIVITIS; ANGIOSTRONGYLUS-VASORUM INFECTION; DETECT BOVINE TUBERCULOSIS; SALMON POISONING DISEASE		[Keel, M. Kevin] Univ Calif Davis, Davis, CA 95616 USA; [Terio, Karen A.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA; [McAloose, Denise] Wildlife Conservat Soc, Bronx, NY USA	Keel, MK (reprint author), Univ Calif Davis, Davis, CA 95616 USA.		Terio, Karen/AAC-5376-2019				Abd Rani PAM, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-141; ACTON AE, J ZOO WILDL MED, V31, P2; Agnarsson I, 2010, MOL PHYLOGENET EVOL, V54, P726, DOI 10.1016/j.ympev.2009.10.033; Al-Sabi MNS, 2014, VET PARASITOL, V205, P389, DOI 10.1016/j.vetpar.2014.07.002; Alencar NX, 1997, VET PARASITOL, V70, P279, DOI 10.1016/S0304-4017(96)01119-3; Federico RA, 2010, J ANIM VET ADV, V9, P1472; Alvarado-Rybak M, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1808-7; Anderson JL, 2007, J WILDLIFE DIS, V43, P302, DOI 10.7589/0090-3558-43.2.302; Appleton J. A., 2012, Immunity to parasitic infection, P275; Atwood T, 2015, J WILDLIFE DIS, V51, P48, DOI 10.7589/2013-11-301; Avelar Isabela de Oliveira, 2013, Brazilian Journal of Veterinary Pathology, V6, P111; BALACHANDRAN A, 1994, VET PATHOL, V31, P93, DOI 10.1177/030098589403100112; Banks M, 1999, VET REC, V145, P362, DOI 10.1136/vr.145.13.362; Barker Ian K., 2001, P131, DOI 10.1002/9780470344880.ch6; BAUMGARTNER W, 1995, VET MICROBIOL, V44, P201, DOI 10.1016/0378-1135(95)00013-Z; Beard PM, 1999, VET REC, V145, P612; Beck R, 2009, VET PARASITOL, V159, P304, DOI 10.1016/j.vetpar.2008.10.067; Bellan SE, 2012, J WILDLIFE DIS, V48, P371, DOI 10.7589/0090-3558-48.2.371; Berentsen AR, 2011, VET MICROBIOL, V151, P126, DOI 10.1016/j.vetmic.2011.02.035; Berny P, 2007, J VET PHARMACOL THER, V30, P93, DOI 10.1111/j.1365-2885.2007.00836.x; Berny PJ, 1997, CHEMOSPHERE, V35, P1817, DOI 10.1016/S0045-6535(97)00242-7; Bihr T, 1999, CAN VET J, V40, P555; BITTEGEKO SBPR, 1995, J AM ANIM HOSP ASSOC, V31, P42, DOI 10.5326/15473317-31-1-42; BLACKMORE DK, 1963, J COMP PATHOL THERAP, V73, P391, DOI 10.1016/S0368-1742(63)80041-7; Blume GR, 2014, J VET DIAGN INVEST, V26, P815, DOI 10.1177/1040638714554442; Boonmars T, 2005, PARASITOL RES, V97, P13, DOI 10.1007/s00436-005-1359-x; Bornstein Set, 2001, P107, DOI 10.1002/9780470377000.ch5; Bourque A, 2005, J WILDLIFE DIS, V41, P816, DOI 10.7589/0090-3558-41.4.816; BOUWMEESTER J, 1989, J ZOOL, V219, P123, DOI 10.1111/j.1469-7998.1989.tb02571.x; BOVEE KC, 1981, SCIENCE, V212, P919, DOI 10.1126/science.7233184; Brown P, 1996, J CHROMATOGR A, V754, P463, DOI 10.1016/S0021-9673(96)00311-1; Bruning-Fann CS, 2001, J WILDLIFE DIS, V37, P58, DOI 10.7589/0090-3558-37.1.58; Bruning-Fann CS, 1998, J WILDLIFE DIS, V34, P632, DOI 10.7589/0090-3558-47.632.636; Bumby MM, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1175-4; BUONAVOGLIA C, 1986, J VET MED B, V33, P597, DOI 10.1111/j.1439-0450.1986.tb00074.x; BUSH M, 1976, J AM VET MED ASSOC, V169, P959; BYMAN D, 1977, CAN J ZOOL, V55, P376, DOI 10.1139/z77-051; CANFIELD PC, 1990, J ZOO WILDLIFE MED, V21, P471; Cansi Edison Rogerio, 2012, Comparative Clinical Pathology, V21, P489, DOI 10.1007/s00580-012-1513-7; CANTILE C., 2016, JUBB KENNEDY PALMERS, V1, P250, DOI DOI 10.1016/B978-0-7020-5317-7.00004-7>; Carbyn L.N., 1982, P106; Cardoso L., 2015, J WILDLIFE DIS, V8; CARLSON BL, 1985, J WILDLIFE DIS, V21, P64, DOI 10.7589/0090-3558-21.1.64; CARON JR, 1996, NONINFECTIOUS DISEAS, P181; Carvalho Cory T. De, 1995, Revista Brasileira de Zoologia, V12, P627; Carvalho O., 2012, ADV VIROL, V2012, P10; Carvalho Tatiane F., 2015, Brazilian Journal of Veterinary Pathology, V8, P88; Cattet MRL, 2004, J WILDLIFE DIS, V40, P338, DOI 10.7589/0090-3558-40.2.338; Chesney RW, 2009, ADV EXP MED BIOL, V643, P325, DOI 10.1007/978-0-387-75681-3_33; Childs-Sanford SE, 2006, ZOO BIOL, V25, P369, DOI 10.1002/zoo.20095; Childs-Sanford SE, 2006, ZOO BIOL, V25, P87, DOI 10.1002/zoo.20078; Cho HS, 2006, J VET MED A, V53, P464, DOI 10.1111/j.1439-0442.2006.00873.x; Christoffersen M. L., 2013, Zoologische Mededelingen (Leiden), V87, P1; Chu PY, 2012, ANIM BIOL, V62, P95, DOI 10.1163/157075611X616941; Cirovic D, 2014, ACTA VET HUNG, V62, P481, DOI 10.1556/AVet.2014.021; Clancey N, 2010, J WILDLIFE DIS, V46, P615, DOI 10.7589/0090-3558-46.2.615; Clark JABJ, 2015, CAN VET J, V56, P408; CLARK LG, 1960, NATURE, V188, P1040, DOI 10.1038/1881040a0; Collins D., 2015, FOWLERS ZOO WILD ANI, P498; COLLY LP, 1992, J S AFR VET ASSOC, V63, P36; Conboy G, 2004, VET REC, V155, P16, DOI 10.1136/vr.155.1.16; Conboy GA, 1995, J ZOO WILDLIFE MED, V26, P597; CONLOGUE GJ, 1979, J WILDLIFE DIS, V15, P563, DOI 10.7589/0090-3558-15.4.563; Coonan TJ, 2005, SOUTHWEST NAT, V50, P32, DOI 10.1894/0038-4909(2005)050<0032:DOAIFS>2.0.CO;2; Costello CM, 2006, URSUS, V17, P186, DOI 10.2192/1537-6176(2006)17[186:OOADDI]2.0.CO;2; Cottrell WO, 2013, J WILDLIFE DIS, V49, P1024, DOI 10.7589/2013-02-027; Cracknell JM, 2009, VET REC, V164, P501, DOI 10.1136/vr.164.16.501; CREEL S, 1995, J ZOOL, V236, P199, DOI 10.1111/j.1469-7998.1995.tb04488.x; Cypher BL, 2017, J WILDLIFE DIS, V53, P46, DOI 10.7589/2016-05-098; DAVIDSON WR, 1992, J WILDLIFE DIS, V28, P581, DOI 10.7589/0090-3558-28.4.581; DAVIDSON WR, 1992, J WILDLIFE DIS, V28, P28, DOI 10.7589/0090-3558-28.1.28; Davies JL, 2011, J VET DIAGN INVEST, V23, P379, DOI 10.1177/104063871102300234; de Araujo JL, 2014, ACTA SCI VET, V42; de Quadros RM, 2015, J WILDLIFE DIS, V51, P787, DOI 10.7589/2014-08-194; Deem SL, 2005, J ZOO WILDLIFE MED, V36, P192, DOI 10.1638/04-076.1; Deem SL, 2000, J ZOO WILDLIFE MED, V31, P441; Delahay RJ, 2007, VET J, V173, P287, DOI 10.1016/j.tvjl.2005.11.011; Delaski KM, 2015, J ZOO WILDLIFE MED, V46, P779, DOI 10.1638/2014-0166.1; Derocher AE, 2012, POLAR BEARS COMPLETE; Desforges JPW, 2016, ENVIRON INT, V86, P126, DOI 10.1016/j.envint.2015.10.007; Dietz R, 2015, ENVIRON RES, V140, P45, DOI 10.1016/j.envres.2015.03.011; Donahue SW, 2006, J EXP BIOL, V209, P1630, DOI 10.1242/jeb.02185; Duarte FH, 2007, ARQ BRAS MED VET ZOO, V59, P1086, DOI 10.1590/S0102-09352007000400042; Dubey JP, 2008, J PARASITOL, V94, P496, DOI 10.1645/GE-1406.1; Dubey JP, 2008, VET PARASITOL, V153, P147, DOI 10.1016/j.vetpar.2008.01.030; Dubey JP, 2014, J ZOO WILDLIFE MED, V45, P454, DOI 10.1638/2013-0277.1; DUBEY JP, 1990, J WILDLIFE DIS, V26, P286, DOI 10.7589/0090-3558-26.2.286; DUBEY JP, 1994, VET PARASITOL, V51, P321, DOI 10.1016/0304-4017(94)90170-8; DUNSMORE JD, 1979, VET PARASITOL, V5, P275, DOI 10.1016/0304-4017(79)90017-7; DUNSMORE JD, 1972, AUST VET J, V48, P548, DOI 10.1111/j.1751-0813.1972.tb08007.x; Dykstra JA, 2012, J VET DIAGN INVEST, V24, P1125, DOI 10.1177/1040638712461788; East ML, 2008, J WILDLIFE DIS, V44, P45, DOI 10.7589/0090-3558-44.1.45; EFFRON M, 1977, JNCI-J NATL CANCER I, V59, P185, DOI 10.1093/jnci/59.1.185; Erdelyi K, 2014, TICKS TICK-BORNE DIS, V5, P281, DOI 10.1016/j.ttbdis.2013.11.003; Erken A., 1972, BIJDRAGEN TOT DIERKU, V42, P93; Farkas R, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-303; Faulkner CT, 2001, J PARASITOL, V87, P1174, DOI 10.1645/0022-3395(2001)087[1174:AGITIF]2.0.CO;2; Ferrantelli V, 2010, POL J VET SCI, V13, P465; Fiocchi A, 2016, ITAL J ZOOL, V83, P503, DOI 10.1080/11250003.2016.1249966; Fiorello CV, 2006, J ZOO WILDLIFE MED, V37, P130, DOI 10.1638/05-075.1; Fishman Z, 2004, VET PARASITOL, V119, P21, DOI 10.1016/j.vetpar.2003.08.012; Fitzgerald SD, 2008, J ZOO WILDLIFE MED, V39, P257, DOI 10.1638/2007-0071R.1; FOREYT WJ, 1987, J WILDLIFE DIS, V23, P412, DOI 10.7589/0090-3558-23.3.412; Fortin JS, 2014, ZOO BIOL, V33, P446, DOI 10.1002/zoo.21172; Foster GW, 2003, COMP PARASITOL, V70, P162, DOI 10.1654/4081; Franca RT, 2014, TICKS TICK-BORNE DIS, V5, P466, DOI 10.1016/j.ttbdis.2014.04.005; Fredo G, 2015, J WILDLIFE DIS, V51, P880, DOI 10.7589/2014-12-283; Freedholm D., 2013, J AM VET MED ASSOC, V243, P1; Fuehrer H. P., 2016, PLOS NEGLECT TROP D, V10, P1; Fugassa MH, 2015, ZOOTAXA, V4012, P271, DOI 10.11646/zootaxa.4012.2.3; Fuglei E, 1999, J COMP PHYSIOL B, V169, P361, DOI 10.1007/s003600050232; Fukui D, 2007, J COMP PATHOL, V137, P142, DOI 10.1016/j.jcpa.2007.05.004; Gabriel MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040163; Gabrielli S, 2010, VECTOR-BORNE ZOONOT, V10, P855, DOI 10.1089/vbz.2009.0182; Gabrielsen KM, 2015, ENVIRON RES, V136, P413, DOI 10.1016/j.envres.2014.09.019; Gaffney PM, 2016, VET PATHOL, V53, P637, DOI 10.1177/0300985815604725; Gai JJ, 2008, JAVMA-J AM VET MED A, V232, P586, DOI 10.2460/javma.232.4.586; Gamba CO, 2011, ARQ BRAS MED VET ZOO, V63, P1377, DOI 10.1590/S0102-09352011000600014; GARCELON DK, 1992, J WILDLIFE DIS, V28, P223, DOI 10.7589/0090-3558-28.2.223; Gardiner CH, 2006, ATLAS METAZOAN PARAS; Garner GW, 2000, POLAR BIOL, V23, P474, DOI 10.1007/s003000000108; Garner MM, 1997, J PARASITOL, V83, P523, DOI 10.2307/3284422; Gates M, 2014, J WILDLIFE DIS, V50, P896, DOI 10.7589/2013-10-283; Gavrilovic P, 2017, ACTA PARASITOL, V62, P880, DOI 10.1515/ap-2017-0107; Gerhold RW, 2007, J WILDLIFE DIS, V43, P734, DOI 10.7589/0090-3558-43.4.734; Gese EM, 1997, J WILDLIFE DIS, V33, P47, DOI 10.7589/0090-3558-33.1.47; Gherman CM, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2329-8; Giannitti F, 2012, VET PARASITOL, V186, P497, DOI 10.1016/j.vetpar.2011.11.006; Gjeltema JL, 2015, CASE REP VET MED, V2015, DOI [10.1155/2015/970742, DOI 10.1155/2015/970742]; Gormezano LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128520; GOSSELIN SJ, 1984, J AM VET MED ASSOC, V185, P1314; Green RG, 1942, J NUTR, V23, P165; Greene C, 2006, INFECT DIS DOG CAT, P25; Greenwood AD, 2012, CURR BIOL, V22, P1727, DOI 10.1016/j.cub.2012.07.035; GUNNARSSON E, 1991, J WILDLIFE DIS, V27, P105, DOI 10.7589/0090-3558-27.1.105; Guo L, 2013, ASIA PACIF MICROWAVE, P16, DOI 10.1109/APMC.2013.6695176; Gustayson L, 2015, ENVIRON RES, V138, P191, DOI 10.1016/j.envres.2015.02.011; HAGEN G, 1990, ACTA NEUROPATHOL, V80, P590, DOI 10.1007/BF00307625; Hajialilo E, 2015, IRAN J PUBLIC HEALTH, V44, P698; Hall ER, 1940, J DENT RES, V19, P103, DOI DOI 10.1177/00220345400190020101; Harish B., 2003, INDIAN J VET PATHOL, V27, P129; HARRIS S, 1977, J ARCHAEOL SCI, V4, P183, DOI 10.1016/0305-4403(77)90066-8; Helgason LB, 2013, ENVIRON TOXICOL CHEM, V32, P1784, DOI 10.1002/etc.2241; HELGEBOSTAD A, 1978, NORD VET MED, V30, P451; Hersteinsson P, 2007, POLAR BIOL, V30, P1047, DOI 10.1007/s00300-007-0264-4; Hervas J, 1996, VET REC, V139, P293, DOI 10.1136/vr.139.12.293; Highland MA, 2011, J VET DIAGN INVEST, V23, P764, DOI 10.1177/1040638711406976; HIMES EM, 1980, J AM VET MED ASSOC, V177, P825; Hirayama K, 1999, VET PATHOL, V36, P342, DOI 10.1354/vp.36-4-342; Hodzic A, 2016, VET PARASITOL, V223, P63, DOI 10.1016/j.vetpar.2016.04.016; HOLMES JC, 1968, CAN J ZOOLOG, V46, P1193, DOI 10.1139/z68-169; Honnold SP, 2010, J ZOO WILDLIFE MED, V41, P530, DOI 10.1638/2009-0090.1; Hostnik P, 2014, J WILDLIFE DIS, V50, P397, DOI 10.7589/2013-07-183; ISOGAI E, 1994, J WILDLIFE DIS, V30, P439, DOI 10.7589/0090-3558-30.3.439; ITAKURA C, 1979, JPN J VET SCI, V41, P561; Jager K, 2013, J COMP PATHOL, V148, P90; Jankowski G, 2012, J ZOO WILDLIFE MED, V43, P95, DOI 10.1638/2010-0222.1; Janovsky M, 1999, J WILDLIFE DIS, V35, P392, DOI 10.7589/0090-3558-35.2.392; JANSSEN DL, 1982, J AM VET MED ASSOC, V181, P1225; Jefferies R, 2009, PARASITOLOGY, V136, P107, DOI 10.1017/S0031182008005258; Jin YP, 2015, J WILDLIFE DIS, V51, P849, DOI 10.7589/2014-12-289; Kagan R, 2013, J WILDLIFE DIS, V49, P203, DOI 10.7589/2012-02-029; Kamine A, 2012, JPN J VET RES, V60, P5; Kat PW, 1996, J VET DIAGN INVEST, V8, P420, DOI 10.1177/104063879600800403; Kawabata A, 2008, J VET MED SCI, V70, P301, DOI 10.1292/jvms.70.301; Kearns K, 2000, J ZOO WILDLIFE MED, V31, P255; Kenny DE, 1999, J ZOO WILDLIFE MED, V30, P132; KHAN MA, 1991, J WILDLIFE DIS, V27, P248, DOI 10.7589/0090-3558-27.2.248; KINGSCOTE BF, 1986, J WILDLIFE DIS, V22, P475, DOI 10.7589/0090-3558-22.4.475; Kirk CM, 2010, ECOHEALTH, V7, P321, DOI 10.1007/s10393-010-0323-0; Officer K, 2014, J VET DIAGN INVEST, V26, P705, DOI 10.1177/1040638714547256; Knott KK, 2011, ENVIRON RES, V111, P1124, DOI 10.1016/j.envres.2011.08.009; Knowles S, 2017, J WILDLIFE DIS, V53, P925, DOI 10.7589/2016-11-247; KNUDTSON WU, 1980, J WILDLIFE DIS, V16, P465, DOI 10.7589/0090-3558-16.4.465; Kocan AA, 1999, J WILDLIFE DIS, V35, P86, DOI 10.7589/0090-3558-35.1.86; Kocan AA, 2000, J WILDLIFE DIS, V36, P149, DOI 10.7589/0090-3558-36.1.149; Kong F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097071; Kottwitz JJ, 2004, J AM ANIM HOSP ASSOC, V40, P501, DOI 10.5326/0400501; Kritsepi M, 1996, VET REC, V139, P600; LaDouceur EEB, 2014, J ZOO WILDLIFE MED, V45, P69, DOI 10.1638/2013-0071R.1; Laksono BM, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8080210; Lam L, 2013, J VET DIAGN INVEST, V25, P99, DOI 10.1177/1040638712472500; Lamglait B, 2015, J ZOO AQUAR RES, V3, P47; Langan J, 2000, J ZOO WILDLIFE MED, V31, P558; Lempp C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175469; LEWIN RA, 1979, NATURE, V278, P445, DOI 10.1038/278445a0; LIMA WS, 1994, J HELMINTHOL, V68, P87, DOI 10.1017/S0022149X00013547; Lin RC, 2005, VET SURG, V34, P358, DOI 10.1111/j.1532-950X.2005.00055.x; Little SE, 1998, J WILDLIFE DIS, V34, P620, DOI 10.7589/0090-3558-34.3.620; Loeffler IK, 2009, ANIM WELFARE, V18, P225; Lohse J, 2002, MED VET ENTOMOL, V16, P133, DOI 10.1046/j.1365-2915.2002.00355.x; Loots AK, 2017, J GEN VIROL, V98, P311, DOI 10.1099/jgv.0.000666; Luppi MM, 2008, VET PARASITOL, V155, P146, DOI 10.1016/j.vetpar.2008.04.024; Lynch M, 2002, J ZOO WILDLIFE MED, V33, P263; Ma HY, 2015, PARASITE, V22, DOI 10.1051/parasite/2015030; Magi M, 2015, J HELMINTHOL, V89, P506, DOI 10.1017/S0022149X1400025X; Mainka S. A., 1993, J ZOO WILDLIFE MED, V24, P425; Mandara MT, 2007, VET PATHOL, V44, P713, DOI 10.1354/vp.44-5-713; Martin-Atance P, 2005, J WILDLIFE DIS, V41, P435, DOI 10.7589/0090-3558-41.2.435; Masenga E.H., 2013, International Journal of Biodiversity and Conservation, V5, P367; Matos AC, 2016, TRANSBOUND EMERG DIS, V63, pE313, DOI 10.1111/tbed.12306; Matos AC, 2014, VECTOR-BORNE ZOONOT, V14, P531, DOI 10.1089/vbz.2013.1500; Matos AC, 2014, J ZOO WILDLIFE MED, V45, P775, DOI 10.1638/2014-0010.1; Matsuda K, 2010, J VET MED SCI, V72, P1213, DOI 10.1292/jvms.10-0034; McAloose D, 2012, J ZOO WILDLIFE MED, V43, P950, DOI 10.1638/2012-0068R.1; McCall JW, 2008, ADV PARASIT, V66, P193, DOI 10.1016/S0065-308X(08)00204-2; MCCUE PM, 1988, J WILDLIFE DIS, V24, P274, DOI 10.7589/0090-3558-24.2.274; Mcgee ME, 2008, BONE, V42, P396, DOI 10.1016/j.bone.2007.10.010; Mech Boitani, 2003, WOLVES BEHAV ECOLOGY; MEIER JE, 1982, J ZOO ANIM MED, V13, P107, DOI 10.2307/20094591; Millan J., 2014, PESQUI VET BRASIL, V109, P1041; Millan J, 2008, J WILDLIFE DIS, V44, P701, DOI 10.7589/0090-3558-44.3.701; Millan J, 2009, VECTOR-BORNE ZOONOT, V9, P549, DOI 10.1089/vbz.2008.0081; Millan J, 2009, VET J, V182, P114, DOI 10.1016/j.tvjl.2008.04.005; Miller DL, 2007, J ZOO WILDLIFE MED, V38, P492, DOI 10.1638/2007-0002.1; MILLER RE, 1985, J AM VET MED ASSOC, V187, P1256; Mol JPS, 2015, VET PARASITOL, V212, P86, DOI 10.1016/j.vetpar.2015.08.024; Morandi F, 2014, VET REC, V174, P228, DOI 10.1136/vr.g1802; Moresco A, 2013, J ZOO WILDLIFE MED, V44, pS26, DOI 10.1638/1042-7260-44.4S.S26; Moriarty ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144271; MORRISON EE, 1979, J WILDLIFE DIS, V15, P557, DOI 10.7589/0090-3558-15.4.557; MUNSON L, 1991, J ZOO WILDLIFE MED, V22, P125; Muthupalani S, 2014, MOL GENET METAB, V111, P513, DOI 10.1016/j.ymgme.2014.02.002; Mylniczenko ND, 2005, J ZOO WILDLIFE MED, V36, P346, DOI 10.1638/03-118.1; Neiffer DL, 2002, J ZOO WILDLIFE MED, V33, P242; Nevarez A, 2005, J VET DIAGN INVEST, V17, P486, DOI 10.1177/104063870501700516; OGDEN JA, 1981, SKELETAL RADIOL, V7, P43, DOI 10.1007/BF00347171; OKADA HM, 1987, VET PATHOL, V24, P180, DOI 10.1177/030098588702400212; Okajima M, 2007, VET REC, V161, P206, DOI 10.1136/vr.161.6.206; Pal M., 1997, ZOO PRINT, V12, P13; Paradiso J. L., 1966, Mammalia, V30, P120, DOI 10.1515/mamm.1966.30.1.120; Pas A, 2008, J PARASITOL, V94, P976, DOI 10.1645/GE-1492.1; Pate M, 2016, VET J, V208, P93, DOI 10.1016/j.tvjl.2015.10.004; Patterson-Kane JC, 2009, J VET DIAGN INVEST, V21, P270, DOI 10.1177/104063870902100219; PENCE DB, 1983, J PARASITOL, V69, P1100, DOI 10.2307/3280873; Perpinan D, 2011, J VET DIAGN INVEST, V23, P817, DOI 10.1177/1040638711407876; Phair KA, 2012, J ZOO WILDLIFE MED, V43, P162, DOI 10.1638/2010-0210.1; Pizzi R, 2011, VET REC, V169, DOI 10.1136/vr.d4985; Pozio E, 2007, VET PARASITOL, V149, P3, DOI 10.1016/j.vetpar.2007.07.002; Pozio E, 2016, VET PARASITOL, V231, P97, DOI 10.1016/j.vetpar.2016.03.021; Randall DA, 2004, EMERG INFECT DIS, V10, P2214, DOI 10.3201/eid1012.040080; Rattner BA, 2009, ECOTOXICOLOGY, V18, P773, DOI 10.1007/s10646-009-0354-x; Reid HL, 2005, J ZOO WILDLIFE MED, V36, P523, DOI 10.1638/04-043.1; Rinas MA, 2009, VET PARASITOL, V164, P347, DOI 10.1016/j.vetpar.2009.05.006; Romero B, 2008, VET MICROBIOL, V132, P87, DOI 10.1016/j.vetmic.2008.04.032; Rupprecht Charles E., 2001, P3, DOI 10.1002/9780470344880.ch1; SADIGHIAN A, 1969, J PARASITOL, V55, P372, DOI 10.2307/3277413; SAMUEL WM, 1978, CAN J ZOOL, V56, P2614, DOI 10.1139/z78-351; SAMUEL WM, 1978, J WILDLIFE DIS, V14, P165, DOI 10.7589/0090-3558-14.2.165; Sanchez C., 2012, NASAL CARCINOMA MEXI; Schlanser JR, 2014, J VET MED SCI, V76, P901, DOI 10.1292/jvms.13-0567; SCHMITT SM, 1987, J WILDLIFE DIS, V23, P162, DOI 10.7589/0090-3558-23.1.162; Schonbauer M., 1984, Verhandlungsbericht des Internationalen Symposiums uber die Erkrankungen der Zootiere, V26, P131; Schrenzel MD, 2008, EMERG INFECT DIS, V14, P1616, DOI 10.3201/eid1410.080703; Schulze C, 2008, DEUT TIERARZTL WOCH, V115, P471, DOI 10.2376/0341-6593-115-471; Scialfa E, 2013, J WILDLIFE DIS, V49, P168, DOI 10.7589/2011-07-219; Seeley KE, 2016, J ZOO WILDLIFE MED, V47, P83, DOI 10.1638/2014-0198.1; SEESEE FM, 1983, J WILDLIFE DIS, V19, P54, DOI 10.7589/0090-3558-19.1.54; Segovia JM, 2001, J HELMINTHOL, V75, P183; Shamsi S, 2017, INT J PARASITOL-PAR, V6, P271, DOI 10.1016/j.ijppaw.2017.08.008; Shokri H, 2016, J MYCOL MED, V26, P170, DOI 10.1016/j.mycmed.2016.04.007; Singh R, 2010, INDIAN J ANIM SCI, V80, P961; Soares JF, 2014, VET PARASITOL, V202, P156, DOI 10.1016/j.vetpar.2014.02.058; Solano-Gallego L, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1596-0; Sonne C, 2005, ENVIRON HEALTH PERSP, V113, P1569, DOI 10.1289/ehp.8038; Sonne C, 2008, CHEMOSPHERE, V71, P1214, DOI 10.1016/j.chemosphere.2007.12.028; Sonne C, 2006, ENVIRON TOXICOL CHEM, V25, P1551, DOI 10.1897/05-487R1.1; Sonne C, 2012, ENVIRON INT, V48, P143, DOI 10.1016/j.envint.2012.07.002; Sonne C, 2009, ENVIRON RES, V109, P702, DOI 10.1016/j.envres.2009.04.008; Sorensen KK, 2005, RES VET SCI, V78, P161, DOI 10.1016/j.rvsc.2004.07.010; Soulsbury CD, 2007, MAMMAL REV, V37, P278, DOI 10.1111/j.1365-2907.2007.00101.x; Dias RGS, 2012, J ZOO WILDLIFE MED, V43, P674, DOI 10.1638/2012-0005R.1; Souza TD, 2014, VET PARASITOL, V200, P233, DOI 10.1016/j.vetpar.2013.12.025; Spratt DM, 2015, INT J PARASITOL-PAR, V4, P178, DOI 10.1016/j.ijppaw.2015.02.006; Stallknecht David E., 2001, P164; Steenkamp G, 1999, J Vet Dent, V16, P65; Stenvinkel P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072934; Storms TN, 2004, J ZOO WILDLIFE MED, V35, P82, DOI 10.1638/03-033; Tenorio MD, 2011, J ZOO WILDLIFE MED, V42, P608; THORNTON J E, 1974, Journal of Wildlife Diseases, V10, P232; TURNBULL PCB, 1991, VET REC, V128, P399, DOI 10.1136/vr.128.17.399; Van Pelt R.W., 1974, Journal Wildl Dis, V10, P47; vanHeerden J, 1996, J S AFR VET ASSOC, V67, P141; VANHEERDEN J, 1989, J WILDLIFE DIS, V25, P70, DOI 10.7589/0090-3558-25.1.70; VANHEERDEN J, 1986, S AFR J WILDL RES, V16, P7; VANHEERDEN J, 1995, J S AFR VET ASSOC, V66, P18; VAVRA J, 1971, J PARASITOL, V57, P923, DOI 10.2307/3277832; VerCauteren KC, 2008, EMERG INFECT DIS, V14, P1862, DOI 10.3201/eid1412.071181; Verocai GG, 2013, J WILDLIFE DIS, V49, P422, DOI 10.7589/2012-07-186; Vickers T.W., 2015, PLOS ONE, V10, P1; Vieira FM, 2008, ZOOTAXA, P1; VOIPIO P, 1990, ANN ZOOL FENN, V27, P21; Waner T, 1999, VET PARASITOL, V82, P121, DOI 10.1016/S0304-4017(99)00002-3; Way JG, 2006, CAN FIELD NAT, V120, P478, DOI 10.22621/cfn.v120i4.360; Weissengruber GE, 2001, J ANAT, V198, P309, DOI 10.1046/j.1469-7580.2001.19830309.x; Williams BM, 2014, PARASITOL RES, V113, P911, DOI 10.1007/s00436-013-3722-7; Witmer G, 2010, J WILDLIFE DIS, V46, P368, DOI 10.7589/0090-3558-46.2.368; WOBESER G, 1992, J WILDLIFE DIS, V28, P268, DOI 10.7589/0090-3558-28.2.268; Woodroffe R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030099; Woods Leslie W., 2001, P202, DOI 10.1002/9780470344880.ch9; WU Z, 2008, PARASITE VECTOR, P28, DOI DOI 10.3141/2084-04; Zanin E, 1997, J WILDLIFE DIS, V33, P632, DOI 10.7589/0090-3558-33.3.632; ZARNKE RL, 1989, J WILDLIFE DIS, V25, P568, DOI 10.7589/0090-3558-25.4.568; ZEMAN DH, 1993, J VET DIAGN INVEST, V5, P480	304	1	1	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	125 LONDON WALL, LONDON EC2Y 5AS, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							229	+		10.1016/B978-0-12-805306-5.00009-2			16	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300011					2019-10-28	
B	Terio, KA; McAloose, D; Mitchell, E		Terio, KA; McAloose, D; StLeger, J		Terio, Karen A.; McAloose, Denise; Mitchell (nee Lane), Emily			Felidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							CHEETAHS ACINONYX-JUBATUS; FELINE IMMUNODEFICIENCY VIRUS; CANINE-DISTEMPER VIRUS; KRUGER-NATIONAL-PARK; MYCOBACTERIUM-BOVIS INFECTION; BOBCATS LYNX-RUFUS; LION PANTHERA-LEO; GASTRIC SPIRAL BACTERIA; FREE-RANGING WILDLIFE; VITAMIN-A-DEFICIENCY		[Terio, Karen A.] Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA; [McAloose, Denise] Wildlife Conservat Soc, Bronx, NY USA; [Mitchell (nee Lane), Emily] Natl Zool Gardens South Africa, Pretoria, South Africa; [Mitchell (nee Lane), Emily] Univ Pretoria, Pretoria, South Africa	Terio, KA (reprint author), Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA.		Terio, Karen/AAC-5376-2019				ALEXANDER KA, 1994, AM J TROP MED HYG, V51, P568, DOI 10.4269/ajtmh.1994.51.568; APPEL MJG, 1994, J VET DIAGN INVEST, V6, P277, DOI 10.1177/104063879400600301; Aranaz A, 2004, J CLIN MICROBIOL, V42, P2602, DOI 10.1128/JCM.42.6.2602-2608.2004; Barnett KC, 2002, VET OPHTHALMOL, V5, P197, DOI 10.1046/j.1463-5224.2002.00219.x; Baron T, 1997, VET REC, V141, P270, DOI 10.1136/vr.141.11.270; Barr MC, 1997, VIROLOGY, V228, P84, DOI 10.1006/viro.1996.8358; Barron MG, 2004, ECOTOXICOLOGY, V13, P223, DOI 10.1023/B:ECTX.0000023567.42698.38; Bartsch R. C., 1975, J VET RES, V42, P43; Bengis RG, 1996, ONDERSTEPOORT J VET, V63, P15; Bergstrom J, 2006, AMYLOID, V13, P93, DOI 10.1080/13506120600722621; Bernard JM, 2015, VET PATHOL, V52, P369, DOI 10.1177/0300985814532822; Berry WL, 1997, J ZOO WILDLIFE MED, V28, P485; BJORK KE, J ZOO WILDL MED, V31, P56; Bolton LA, 1999, VET PATHOL, V36, P14, DOI 10.1354/vp.36-1-14; Bolton LA, 1999, J S AFR VET ASSOC, V70, P35; Bossart G. D., 1986, J ZOO WILDLIFE MED, V14, P73; BREUER W, 1993, BERL MUNCH TIERARZTL, V106, P47; Brglez J., 1976, Ippen, R.; Schroder, H.D. (Editors) Erkrankungen der Zootiere. Verhandlungsbericht des XVIII Internationalen Symposiums uber die Erkrankungen der Zootiere, 16-20 June, 1976, Innsbruck., P233; Briones V, 2000, EMERG INFECT DIS, V6, P189, DOI 10.3201/eid0602.000214; Brower AI, 2014, VET PATHOL, V51, P1013, DOI 10.1177/0300985813506917; BROWN EW, 1994, J VIROL, V68, P5953; Brown M, 2005, J WILDLIFE DIS, V41, P691, DOI 10.7589/0090-3558-41.4.691; Brown MA, 2008, EMERG INFECT DIS, V14, P252, DOI 10.3201/eid1402.070981; Bruning-Fann CS, 2001, J WILDLIFE DIS, V37, P58, DOI 10.7589/0090-3558-37.1.58; Bryan LK, 2015, JAVMA-J AM VET MED A, V247, P1117, DOI 10.2460/javma.247.10.1117; Buergelt CD, 2002, ANN NY ACAD SCI, V969, P350, DOI 10.1111/j.1749-6632.2002.tb04403.x; Bull ME, 2003, AM J VET RES, V64, P1293, DOI 10.2460/ajvr.2003.64.1293; Carpenter MA, 1996, J VIROL, V70, P6682; Carpenter MA, 1998, VIROLOGY, V251, P234, DOI 10.1006/viro.1998.9402; Chassy LM, 2002, VET PATHOL, V39, P379, DOI 10.1354/vp.39-3-379; CHAUVIER G., 1964, Annales de Parasitologie Humaine et Comparee, V39, P791; Cho HS, 2006, J VET DIAGN INVEST, V18, P312, DOI 10.1177/104063870601800318; Clarke C, 2016, J S AFR VET ASSOC, V87, DOI 10.4102/jsava.v87i1.1322; Cleaveland S, 2005, J WILDLIFE DIS, V41, P446, DOI 10.7589/0090-3558-41.2.446; Clyde VL, 1997, J ZOO WILDLIFE MED, V28, P148; Collett MG, 2000, J S AFR VET ASSOC, V71, P251; Corner S, 2017, VET PATHOL, V54, P269, DOI 10.1177/0300985816664791; Cousins DV, 2005, REV SCI TECH OIE, V24, P1039, DOI 10.20506/rst.24.3.1635; Craft ME, 2009, P ROY SOC B-BIOL SCI, V276, P1777, DOI 10.1098/rspb.2008.1636; Crossley B, 2012, EMERG INFECT DIS, V18, P315, DOI 10.3201/eid1802.111245; Cunningham MW, 2008, J WILDLIFE DIS, V44, P537, DOI 10.7589/0090-3558-44.3.537; Cunningham MW, 1999, J WILDLIFE DIS, V35, P519, DOI 10.7589/0090-3558-35.3.519; Cutler TJ, 2002, VET OPHTHALMOL, V5, P143, DOI 10.1046/j.1463-5224.2002.00237.x; Daoust PY, 2009, J WILDLIFE DIS, V45, P611, DOI 10.7589/0090-3558-45.3.611; de Lisle GW, 2002, REV SCI TECH OIE, V21, P317, DOI 10.20506/rst.21.2.1339; De Risio L, 2010, VET REC, V167, P534, DOI 10.1136/vr.c4802; Di Cesare A, 2016, PARASITOL RES, V115, P3731, DOI 10.1007/s00436-016-5134-y; Duarte A, 2012, VET MICROBIOL, V158, P400, DOI 10.1016/j.vetmic.2012.02.033; Duarte MD, 2009, J ZOO WILDLIFE MED, V40, P354, DOI 10.1638/2008-0015.1; Duvall SE, 2000, ECOTOX ENVIRON SAFE, V47, P298, DOI 10.1006/eesa.2000.1949; EATON KA, 1993, VET PATHOL, V30, P55, DOI 10.1177/030098589303000107; Eiden M, 2010, J GEN VIROL, V91, P2874, DOI 10.1099/vir.0.022103-0; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Esson D, 2001, VET OPHTHALMOL, V4, P159, DOI 10.1046/j.1463-5224.2001.00174.x; Eulenberger K., 1992, Erkrankungen der Zootiere, P7; EVERMANN JF, 1988, ARCH VIROL, V102, P155, DOI 10.1007/BF01310822; FACEMIRE CF, 1995, ENVIRON HEALTH PERSP, V103, P79, DOI 10.2307/3432416; Ferguson JA, 2011, J WILDLIFE DIS, V47, P140, DOI 10.7589/0090-3558-47.1.140; Ferreira SM, 2010, WILDLIFE RES, V37, P194, DOI 10.1071/WR09030; Filoni C, 2006, J WILDLIFE DIS, V42, P470, DOI 10.7589/0090-3558-42.2.470; Flacke GL, 2015, J ZOO WILDLIFE MED, V46, P641, DOI 10.1638/2014-0206.1; Franklin AD, 2016, J HERED, V107, P115, DOI 10.1093/jhered/esv089; Gallusova M, 2016, J PARASITOL, V102, P377, DOI 10.1645/15-881; Geret CP, 2011, ARCH VIROL, V156, P839, DOI 10.1007/s00705-011-0925-z; Gerhauser I, 2009, EUR J WILDLIFE RES, V55, P433, DOI 10.1007/s10344-009-0260-9; GERSHOFF SN, 1957, LAB INVEST, V6, P227; Gillin C. M., 2005, P AAZV AAWV AZA NAG, P251; GLENN BL, 1983, J AM VET MED ASSOC, V183, P1155; Gonzalez P, 2007, J PARASITOL, V93, P948, DOI 10.1645/GE-3519RN.1; Good KM, 2008, J WILDLIFE DIS, V44, P721, DOI 10.7589/0090-3558-44.3.721; GOSSELIN SJ, 1988, VET PATHOL, V25, P48, DOI 10.1177/030098588802500107; GRIPENBERG U, 1985, HEREDITAS, V103, P221, DOI 10.1111/j.1601-5223.1985.tb00505.x; Ha SD, 2016, J BIOL CHEM, V291, P8745, DOI 10.1074/jbc.M115.695809; Harrenstien LA, 1996, J ZOO WILDLIFE MED, V27, P468; Harrison TM, 2010, VET PATHOL, V47, P952, DOI 10.1177/0300985810375054; Harrison TM, 2007, J ZOO WILDLIFE MED, V38, P292, DOI 10.1638/1042-7260(2007)038[0292:SCEICE]2.0.CO;2; Harrison TM, 2014, J ZOO WILDLIFE MED, V45, P23, DOI 10.1638/2012-0069R2.1; Hasslinger M. A., 1982, Veterinary Medical Review, P220; He S, 2015, MICROBES INFECT, V17, P54, DOI 10.1016/j.micinf.2014.10.004; HEENEY JL, 1990, J VIROL, V64, P1964; Helman RG, 1998, J VET DIAGN INVEST, V10, P89, DOI 10.1177/104063879801000118; HINSHAW VS, 1981, INFECT IMMUN, V34, P354; Holt G., 1990, Norsk Veterinartidsskrift, V102, P427; HOOVER DL, 1994, INFECT IMMUN, V62, P4432; Hope K, 2006, ZOO BIOL, V25, P501, DOI 10.1002/zoo.20112; Hu TS, 2016, SCI REP-UK, V6, DOI 10.1038/srep25845; Hugh-Jones ME, 2002, REV SCI TECH OIE, V21, P359, DOI 10.20506/rst.21.2.1336; Illnait-Zaragozi MT, 2011, MYCOSES, V54, pE889, DOI 10.1111/j.1439-0507.2011.02046.x; Jauniaux TP, 2008, EMERG INFECT DIS, V14, P1496, DOI 10.3201/eid1409.080434; JESSUP DA, 1993, J ZOO WILDLIFE MED, V24, P73; Jimenez MA, 2008, VET IMMUNOL IMMUNOP, V121, P34, DOI 10.1016/j.vetimm.2007.07.018; Johnson KH, 1997, AMYLOID, V4, P171, DOI 10.3109/13506129709014381; JONES OLIVER G., 1953, VET REC, V65, P453; Joslin J. O., 2000, P AAZV IAAAM JOINT C, P155; JUNGE RE, 1991, J AM VET MED ASSOC, V198, P1057; Kadoi K, 1997, MICROBIOLOGICA, V20, P141; Kappeli U, 2009, J ZOO WILDLIFE MED, V40, P398, DOI 10.1638/2008-0120.1; Kazensky CA, 1998, J ZOO WILDLIFE MED, V29, P1; Keawcharoen J, 2004, EMERG INFECT DIS, V10, P2189, DOI 10.3201/eid1012.040759; Keet DF, 1996, ONDERSTEPOORT J VET, V63, P239; Kenny DE, 2002, J ZOO WILDLIFE MED, V33, P131; Ketz-Riley CJ, 2003, J ZOO WILDLIFE MED, V34, P239, DOI 10.1638/01-112; Kinsel MJ, 1998, J WILDLIFE DIS, V34, P317, DOI 10.7589/0090-3558-34.2.317; Kinsel MJ, 1998, J ZOO WILDLIFE MED, V29, P214; Kirberger RM, 2006, VET RADIOL ULTRASOUN, V47, P145, DOI 10.1111/j.1740-8261.2006.00121.x; Kirkwood JK, 1995, J ZOO WILDLIFE MED, V26, P577; Kolmstetter C, 2000, J ZOO WILDLIFE MED, V31, P15; Kuiken T, 2004, SCIENCE, V306, P241, DOI 10.1126/science.1102287; Landolfi JA, 2006, VET PATHOL, V43, P674, DOI 10.1354/vp.43-5-674; Lane EP, 2016, ONDERSTEPOORT J VET, V83, DOI 10.4102/ojvr.v83i1.1099; Lantos A, 2003, EMERG INFECT DIS, V9, P1462, DOI 10.3201/eid0911.030297; Lee JS, 2014, J VIROL, V88, P7727, DOI 10.1128/JVI.00473-14; Lembo T, 2011, EMERG INFECT DIS, V17, P387, DOI 10.3201/eid1703.101290; Lensink B.M., 1979, Zoologische Garten, V49, P121; Lepri E, 2013, J ZOO WILDLIFE MED, V44, P509, DOI 10.1638/2012-0221R1.1; Lester SJ, 2011, VET CLIN PATH, V40, P4, DOI 10.1111/j.1939-165X.2010.00281.x; Lezmi S, 2003, HISTOCHEM CELL BIOL, V119, P415, DOI 10.1007/s00418-003-0524-5; Lucena RB, 2011, PESQUI VET BRASIL, V31, P165, DOI 10.1590/S0100-736X2011000200012; Maas M, 2013, COMP IMMUNOL MICROB, V36, P269, DOI 10.1016/j.cimid.2012.10.010; Maas M, 2012, P ROY SOC B-BIOL SCI, V279, P4206, DOI 10.1098/rspb.2012.1503; Mandal D., 1985, P INT S DIS ZOO ANIM, P499; Mansfield KG, 2002, J WILDLIFE DIS, V38, P693, DOI 10.7589/0090-3558-38.4.693; Maratea KA, 2006, J VET DIAGN INVEST, V18, P608, DOI 10.1177/104063870601800617; Marker L, 2003, J WILDLIFE DIS, V39, P690, DOI 10.7589/0090-3558-39.3.690; Marshall E., 2012, P AM ASS ZOO VET, P244; Martin CL, 1997, VET COMP OPHTHALMOL, V7, P39; Martinez F, 2013, J ZOO WILDLIFE MED, V44, P845, DOI 10.1638/2011-0165R4.1; McAloose D, 2007, VET PATHOL, V44, P320, DOI 10.1354/vp.44-3-320; McCain S, 2008, J ZOO WILDLIFE MED, V39, P421, DOI 10.1638/2007-0157.1; McLean K., 2015, P ANN M AM ASS ZOO V; Meli ML, 2010, VET MICROBIOL, V146, P132, DOI 10.1016/j.vetmic.2010.04.024; Meli ML, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004744; Michel AL, 2009, VET MICROBIOL, V133, P335, DOI 10.1016/j.vetmic.2008.07.023; Miller M, 2015, J WILDLIFE DIS, V51, P493, DOI 10.7589/2014-07-170; MILLEREDGE MA, 1992, VET IMMUNOL IMMUNOP, V30, P261, DOI 10.1016/0165-2427(92)90143-E; Millward IR, 2005, J S AFR VET ASSOC, V76, P228; Mitchell EP, 2017, VET PATHOL, V54, P977, DOI 10.1177/0300985817728556; Morner T., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P1115; Morris PJ, 1996, J ZOO WILDLIFE MED, V27, P392; Munday JS, 2014, VET J, V199, P340, DOI 10.1016/j.tvjl.2013.11.025; Munson L, 2005, J WILDLIFE DIS, V41, P542, DOI 10.7589/0090-3558-41.3.542; Munson L, 2004, J WILDLIFE DIS, V40, P23, DOI 10.7589/0090-3558-40.1.23; Munson L, 2004, VET PATHOL, V41, P170, DOI 10.1354/vp.41-2-170; Munson L, 2002, VET PATHOL, V39, P419, DOI 10.1354/vp.39-4-419; MUNSON L, 1991, VET PATHOL, V28, P37, DOI 10.1177/030098589102800106; Munson L, 1999, J ZOO WILDLIFE MED, V30, P342; MUNSON L, 1993, ZOO BIOL, V12, P105, DOI 10.1002/zoo.1430120110; Munson L, 1995, VET PATHOL, V32, P578; Munson L., 1994, VET PATHOL, V31, P604; Munson Linda, 2010, P237; Munson L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002545; Munson Linda, 2007, Breast Dis, V28, P7; Mwanzia JM, 1995, P AAZV WDA AAWV JOIN, P95; Myers DL, 1997, CLIN DIAGN LAB IMMUN, V4, P180; Nagao Y, 2012, J VET MED SCI, V74, P699, DOI 10.1292/jvms.11-0509; Newman J, 2004, ARCH ENVIRON CON TOX, V48, P75, DOI 10.1007/s00244-003-0130-5; Nietfeld JC, 2002, J WILDLIFE DIS, V38, P607, DOI 10.7589/0090-3558-38.3.607; O'Halloran C, 2016, VET REC, V178, P145, DOI 10.1136/vr.i686; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; Orbell GMB, 2011, VET PATHOL, V48, P1176, DOI 10.1177/0300985810391111; Origgi FC, 2012, VET PATHOL, V49, P913, DOI 10.1177/0300985812436743; PANIKER CKJ, 1972, B WORLD HEALTH ORGAN, V47, P461; Papendick RE, 1997, VET PATHOL, V34, P549, DOI 10.1177/030098589703400602; PATTON S, 1986, J PARASITOL, V72, P517, DOI 10.2307/3281500; PEET RL, 1992, AUST VET J, V69, P171, DOI 10.1111/j.1751-0813.1992.tb07506.x; Pena L, 2006, COMP IMMUNOL MICROB, V29, P114, DOI 10.1016/j.cimid.2006.01.003; Penzhorn BL, 2006, VET PARASITOL, V138, P11, DOI 10.1016/j.vetpar.2006.01.036; Perez J, 2001, VET REC, V148, P414, DOI 10.1136/vr.148.13.414; Pettan-Brewer K. C., 1999, ZOO WILD ANIMAL MED, V4, P423; Picard J.A., 1998, P136; POLI A, 1995, J WILDLIFE DIS, V31, P70, DOI 10.7589/0090-3558-31.1.70; PORT CD, 1981, J COMP PATHOL, V91, P115, DOI 10.1016/0021-9975(81)90051-7; Rector A, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r57; RICKARD LG, 1992, J WILDLIFE DIS, V28, P130, DOI 10.7589/0090-3558-28.1.130; Rimmelzwaan GF, 2006, AM J PATHOL, V168, P176, DOI 10.2353/ajpath.2006.050466; Rivas AE, 2015, J ZOO WILDLIFE MED, V46, P141, DOI 10.1638/2013-0216R1.1; Robert N., 2009, IBERIAN LYNX EXSITU, P265; Roelke ME, 2006, J WILDLIFE DIS, V42, P234, DOI 10.7589/0090-3558-42.2.234; ROELKE ME, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P277; ROELKE ME, 1993, CURR BIOL, V3, P340, DOI 10.1016/0960-9822(93)90197-V; Roelke ME, 2009, VIROLOGY, V390, P1, DOI 10.1016/j.virol.2009.04.011; RoelkeParker ME, 1996, NATURE, V379, P441, DOI 10.1038/379441a0; Rotstein DS, 1999, J WILDLIFE DIS, V35, P613, DOI 10.7589/0090-3558-35.3.613; Rotstein DS, 1999, J ZOO WILDLIFE MED, V30, P281; Ryser-Degiorgis MP, 2002, J WILDLIFE DIS, V38, P228, DOI 10.7589/0090-3558-38.1.228; Sakai H, 2003, J ZOO WILDLIFE MED, V34, P302; Samuel W. M., 2008, PARASITIC DIS WILD M; Schaffer E., 1988, Tieraerztliche Praxis, V16, P87; SCHERBA G, 1988, ARCH VIROL, V100, P89, DOI 10.1007/BF01310910; Schmidbauer SM, 2007, VET REC, V161, P304, DOI 10.1136/vr.161.9.304; Schroder HD, 1998, J COMP PATHOL, V119, P67, DOI 10.1016/S0021-9975(98)80072-8; Schulman FY, 2003, J ZOO WILDLIFE MED, V34, P179; Seimon TA, 2013, MBIO, V4, DOI 10.1128/mBio.00410-13; Serizawa S, 2012, VET PATHOL, V49, P304, DOI 10.1177/0300985811410719; SETCHELL KDR, 1987, GASTROENTEROLOGY, V93, P225, DOI 10.1016/0016-5085(87)91006-7; Shamir MH, 2008, J ZOO WILDLIFE MED, V39, P455, DOI 10.1638/2006-0064.1; Siegal-Willott JL, 2005, J ZOO WILDLIFE MED, V36, P534, DOI 10.1638/03-123.1; SPENCER JA, 1992, ONDERSTEPOORT J VET, V59, P315; Steinel A, 2000, J GEN VIROL, V81, P345, DOI 10.1099/0022-1317-81-2-345; Stewart P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050623; SUNDBERG JP, VET PATHOLOGY, V37, P1; Sutherland-Smith M, 2004, J ZOO WILDLIFE MED, V35, P370, DOI 10.1638/03-106; Sykes JM, 2007, J ZOO WILDLIFE MED, V38, P252, DOI 10.1638/1042-7260(2007)038[0252:ATOTPT]2.0.CO;2; Tateno M, 2013, J WILDLIFE DIS, V49, P646, DOI 10.7589/2012-07-194; Terio K., 2014, P AM ASS ZOOL VET; Terio KA, 2008, VET PATHOL, V45, P393, DOI 10.1354/vp.45-3-393; Terio KA, 2012, VET PATHOL, V49, P824, DOI 10.1177/0300985811412620; Terio KA, 2005, J CLIN MICROBIOL, V43, P229, DOI 10.1128/JCM.43.1.229-234.2005; Terio KA, 2004, J WILDLIFE DIS, V40, P259, DOI 10.7589/0090-3558-40.2.259; Terio KA, 2013, MBIO, V4, DOI 10.1128/mBio.00702-13; Terrell SP, 2003, J ZOO WILDLIFE MED, V34, P380, DOI 10.1638/02-081; Thalwitzer S, 2010, CLIN VACCINE IMMUNOL, V17, P232, DOI 10.1128/CVI.00345-09; Thanawongnuwech R, 2005, EMERG INFECT DIS, V11, P699, DOI 10.3201/eid1105.050007; Tordiffe ASW, 2013, J S AFR VET ASSOC, V84, DOI 10.4102/jsava.v84i1.949; Traversa Maria Julia, 2009, Brazilian Journal of Veterinary Research and Animal Science, V46, P25; Trinkel M, 2011, J WILDLIFE DIS, V47, P494, DOI 10.7589/0090-3558-47.3.494; Troyer JL, 2011, VET IMMUNOL IMMUNOP, V143, P338, DOI 10.1016/j.vetimm.2011.06.013; Troyer JL, 2005, J VIROL, V79, P8282, DOI 10.1128/JVI.79.13.8282-8294.2005; Tubbesing U.H., 1997, P163; TURNBULL PCB, 1992, EPIDEMIOL INFECT, V108, P299, DOI 10.1017/S0950268800049773; Venter EH, 2003, J ZOO WILDLIFE MED, V34, P76; Veronesi F, 2016, TICKS TICK-BORNE DIS, V7, P853, DOI 10.1016/j.ttbdis.2016.04.003; Viana M, 2015, P NATL ACAD SCI USA, V112, P1464, DOI 10.1073/pnas.1411623112; Viljoen IM, 2015, VET MICROBIOL, V177, P252, DOI 10.1016/j.vetmic.2015.03.028; WACK RF, 1992, J ZOO WILDLIFE MED, V23, P442; Walzer C, 2003, J ZOO WILDLIFE MED, V34, P36; Walzer C, 1995, J ZOO WILDLIFE MED, V26, P430; Widmer CE, 2011, VECTOR-BORNE ZOONOT, V11, P1001, DOI 10.1089/vbz.2011.0619; Wild MA, 2006, J WILDLIFE DIS, V42, P646, DOI 10.7589/0090-3558-42.3.646; Witte CL, 2013, J ZOO WILDLIFE MED, V44, P634, DOI 10.1638/2012-0183R.1; Yilmaz R, 2015, KAFKAS UNIV VET FAK, V21, P441, DOI 10.9775/kvfd.2014.12607; Young E., 1972, Journal S Afr vet Ass, V43, P226; YOUNG E, 1972, Journal of the South African Veterinary Association, V43, P205; Yu CH, 2007, J VET DIAGN INVEST, V19, P709, DOI 10.1177/104063870701900617; Zhang BR, 2008, P NATL ACAD SCI USA, V105, P7263, DOI 10.1073/pnas.0800367105; Zhang B, 2008, J HERED, V99, P355, DOI 10.1093/jhered/esn015; Zumpt F., 1973, WILDL MANAG ASS, V3, P119; Zwart P., 1972, J SMALL ANIM PRACT, V13, P321	238	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							263	+		10.1016/B978-0-12-805306-5.00010-9			13	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300012					2019-10-28	
B	Williams, BH; Huntington, KAB; Miller, M		Terio, KA; McAloose, D; StLeger, J		Williams, Bruce H.; Huntington, Kathy A. Burek; Miller, Melissa			Mustelids	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							SOUTHERN SEA OTTERS; ENHYDRA-LUTRIS-NEREIS; CANINE-DISTEMPER VIRUS; SKUNK MEPHITIS-MEPHITIS; INFANTARIUS SUBSP COLI; TOXOPLASMA-GONDII; FARMED MINK; PUTORIUS-FURO; NECROTIZING ENCEPHALITIS; SPONTANEOUS AMYLOIDOSIS		[Williams, Bruce H.] Joint Pathol Ctr, Silver Spring, MD 20910 USA; [Huntington, Kathy A. Burek] Alaska Vet Pathol Serv, Eagle River, AK USA; [Miller, Melissa] Marine Wildlife Vet Care & Res Ctr, Santa Cruz, CA USA	Williams, BH (reprint author), Joint Pathol Ctr, Silver Spring, MD 20910 USA.						Allender MC, 2008, JAVMA-J AM VET MED A, V232, P742, DOI 10.2460/javma.232.5.742; Alterio N, 1996, NEW ZEAL J ZOOL, V23, P331, DOI 10.1080/03014223.1996.9518092; Anistoroaei R, 2013, ANIM GENET, V44, P178, DOI 10.1111/j.1365-2052.2012.02391.x; Arkush KD, 2003, INT J PARASITOL, V33, P1087, DOI 10.1016/S0020-7519(03)00181-4; Ballachey B. E., 2002, CARNIVORES 2002 MOUN; Barding Erin E., 2014, Journal of the Kentucky Academy of Science, V75, P94; BARKER IK, 1983, CAN J COMP MED, V47, P188; Bartlett G, 2016, J WILDLIFE DIS, V52, P1, DOI 10.7589/2015-02-048; Bartley PM, 2013, VET PARASITOL, V192, P279, DOI 10.1016/j.vetpar.2012.10.001; Benato L, 2014, J ZOO WILDLIFE MED, V45, P321, DOI 10.1638/2013-0172R1.1; Bielinska M, 2006, VET PATHOL, V43, P97, DOI 10.1354/vp.43-2-97; Blomstrom AL, 2010, J CLIN MICROBIOL, V48, P4392, DOI 10.1128/JCM.01040-10; BOUILLANT A, 1965, CAN J COMP MED VET S, V29, P183; Britton AP, 2010, EMERG INFECT DIS, V16, P1043, DOI 10.3201/eid1606.100352; Bronson E, 2007, J ZOO WILDLIFE MED, V38, P169, DOI 10.1638/1042-7260(2007)038[0169:MOCBFM]2.0.CO;2; Burek K. A., 2001, INFECT DIS WILD MAMM, P518; Burek-Huntington KA, 2014, J WILDLIFE DIS, V50, P389, DOI 10.7589/2013-11-288; Burek-Huntington KA, 2012, J WILDLIFE DIS, V48, P483, DOI 10.7589/0090-3558-48.2.483; Burns R, 2003, J WILDLIFE DIS, V39, P787, DOI 10.7589/0090-3558-39.4.787; Butterworth E. W., 1984, P HELMINTHOLOGICAL S, V48, P34; Byrom AE, 2015, NEW ZEAL VET J, V63, P42, DOI 10.1080/00480169.2014.981314; CARPENTER JW, 1976, J AM VET MED ASSOC, V169, P961; Carrasco SE, 2014, VECTOR-BORNE ZOONOT, V14, P831, DOI 10.1089/vbz.2014.1612; CAWTHORN RJ, 1976, CAN J ZOOL, V54, P313, DOI 10.1139/z76-035; Chalmers G, 2015, CAN J VET RES, V79, P129; Chang JC, 2015, J WILDLIFE DIS, V51, P923, DOI 10.7589/2015-04-090; CHARLTON KM, 1977, CAN J COMP MED, V41, P460; Conrad PA, 2005, INT J PARASITOL, V35, P1155, DOI 10.1016/j.ijpara.2005.07.002; Corn JL, 2005, APPL ENVIRON MICROB, V71, P6963, DOI 10.1128/AEM.71.11.6963-6967.2005; Correa P., 2018, REV BRASIL PARSITOL, V25, P407; Counihan KL, 2015, COMP IMMUNOL MICROB, V40, P7, DOI 10.1016/j.cimid.2015.03.002; Counihan-Edgar KL, 2012, J CLIN MICROBIOL, V50, P4131, DOI 10.1128/JCM.02581-12; Doroff AM, 2003, J MAMMAL, V84, P55, DOI 10.1644/1545-1542(2003)084<0055:SOPDIT>2.0.CO;2; Dubey JP, 2011, VET PARASITOL, V183, P156, DOI 10.1016/j.vetpar.2011.06.022; Dubey JP, 1996, J PARASITOL, V82, P172, DOI 10.2307/3284135; Dyer N. M., 1995, J VET DIAGN INVEST, V10, P111; Elhensheri M, 2012, J ZOO WILDLIFE MED, V43, P181, DOI 10.1638/2011-0090.1; ENGLUND L, 1986, ACTA VET SCAND, V27, P497; EVANS RH, 2002, CALIFORNIA J PARASIT, V88, P299; Ferroglio E, 2009, VET PARASITOL, V163, P164, DOI 10.1016/j.vetpar.2009.04.005; Ford T. M., 1961, IOWA STATE U VET, V24, P2; Fournier-Chambrillon C, 2014, J WILDLIFE DIS, V40, P688; FOX JG, 1990, GASTROENTEROLOGY, V99, P352, DOI 10.1016/0016-5085(90)91016-Y; Gabriel MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040163; Gagnon CA, 2011, J VET DIAGN INVEST, V23, P986, DOI 10.1177/1040638711418615; Garner MM, 2008, VET PATHOL, V45, P236, DOI 10.1354/vp.45-2-236; Garner MM, 2007, VET PATHOL, V44, P25, DOI 10.1354/vp.44-1-25; Garner MM, 2007, J ZOO WILDLIFE MED, V38, P32, DOI 10.1638/06-023.1; Gaydos JK, 2007, J PARASITOL, V93, P198, DOI 10.1645/GE-928R.1; Gerhold RW, 2005, J WILDLIFE DIS, V41, P224, DOI 10.7589/0090-3558-41.1.224; Gjeltema J, 2015, J ZOO WILDLIFE MED, V46, P120, DOI 10.1638/2014-0090R1.1; Goldstein T, 2009, EMERG INFECT DIS, V15, P925, DOI 10.3201/eid1506.090056; Gorham J. R., 1956, DIS PARASITES MINKS; Grove RA, 2003, J WILDLIFE DIS, V39, P914, DOI 10.7589/0090-3558-39.4.914; Guardabassi L, 2012, VET MICROBIOL, V159, P351, DOI 10.1016/j.vetmic.2012.04.004; HADLOW WJ, 1984, VET PATHOL, V21, P18, DOI 10.1177/030098588402100104; HADLOW WJ, 1985, VET PATHOL, V22, P206, DOI 10.1177/030098588502200303; HADLOW WJ, 1987, VET PATHOL, V24, P323, DOI 10.1177/030098588702400406; HADLOW WJ, 1981, VET PATHOL, V18, P599, DOI 10.1177/030098588101800504; HADLOW WJ, 1986, VET PATHOL, V23, P162, DOI 10.1177/030098588602300209; Hammer A. S., 2012, P 10 INT SCI C AN PR, P146; Hanni KD, 2003, J WILDLIFE DIS, V39, P837, DOI 10.7589/0090-3558-39.4.837; HEGREBERG GA, 1970, J INVEST DERMATOL, V54, P377, DOI 10.1111/1523-1747.ep12259079; HENRIKSEN P, 1988, J COMP PATHOL, V99, P101, DOI 10.1016/0021-9975(88)90109-0; Hinse D, 2011, SYST APPL MICROBIOL, V34, P52, DOI 10.1016/j.syapm.2010.11.010; Huckabone SE, 2015, J WILDLIFE DIS, V51, P295, DOI 10.7589/2014-06-143; HUNTER DB, 1991, CAN VET J, V32, P354; Imran M, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-493; JAKOB W, 1971, VET PATHOL, V8, P292, DOI 10.1177/030098587100800402; KARSTAD L, 1975, Journal of Wildlife Diseases, V11, P494; Kazacos KR, 2016, BAYLISASCARIS LARVA; Keller SM, 2012, J WILDLIFE DIS, V48, P1035, DOI 10.7589/2011-12-350; KIMBER KR, J ZOO WILDL MED, V31, P168; King DP, 2004, J WILDLIFE DIS, V40, P99, DOI 10.7589/0090-3558-40.1.99; Klopfleisch R, 2007, J COMP PATHOL, V137, P155, DOI 10.1016/j.jcpa.2007.06.001; Kreuder C, 2005, AM J VET RES, V66, P289, DOI 10.2460/ajvr.2005.66.289; Kubiski SV, 2016, VET PATHOL, V53, P674, DOI 10.1177/0300985815603430; Lair S, 2002, J ZOO WILDLIFE MED, V33, P204; LANCE M, 2004, WASHINGTON STATE REC; Lauckner G., 1985, DIS MARINE ANIMALS, V4, P644; Lee LM, 2016, EMERG INFECT DIS, V22, P707, DOI 10.3201/eid2204.151446; Lefebvre KA, 2016, HARMFUL ALGAE, V55, P13, DOI 10.1016/j.hal.2016.01.007; Li X, 1996, VET PATHOL, V33, P150, DOI 10.1177/030098589603300204; Li ZN, 2014, EMERG INFECT DIS, V20, P915, DOI 10.3201/eid2005.131890; Lindstrom M, 2004, J CLIN MICROBIOL, V42, P4718, DOI 10.1128/JCM.42.10.4718-4725.2004; LIPSCOMB TP, 1993, VET PATHOL, V30, P1; Lipsitz L, 2001, VET OPHTHALMOL, V4, P29, DOI 10.1046/j.1463-5224.2001.00115.x; MALATESTA D, 2014, ITALY VET ITALIA, V50, P199; Matsuda K, 2003, J ZOO WILDLIFE MED, V34, P200; Mayer KA, 2003, DIS AQUAT ORGAN, V53, P77, DOI 10.3354/dao053077; McDonald R. A., 2004, DIS PATHOGENS STOATS; Miller MA, 2008, INT J PARASITOL, V38, P1319, DOI 10.1016/j.ijpara.2008.02.005; Miller MA, 2002, INT J PARASITOL, V32, P997, DOI 10.1016/S0020-7519(02)00069-3; Miller MA, 2004, INT J PARASITOL, V34, P275, DOI 10.1016/j.ijpara.2003.12.008; Miller M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009057; Miller M, 2008, VET PARASITOL, V153, P12, DOI 10.1016/j.vetpar.2008.01.015; Moinet M, 2010, J WILDLIFE DIS, V46, P1141, DOI 10.7589/0090-3558-46.4.1141; Morera N, 2014, MYCOPATHOLOGIA, V178, P145, DOI 10.1007/s11046-014-9773-1; Mos L, 2003, VET REC, V152, P237, DOI 10.1136/vr.152.8.237; Needle DB, 2014, J COMP PATHOL, V151, P217, DOI [10.1016/j.jcpa.2014.01.017, 10.1016/j.jcpa.2014.04.017]; Newman SJ, 2006, VET PATHOL, V43, P865, DOI 10.1354/vp.43-6-865; Niemuth JN, 2014, J ZOO WILDLIFE MED, V45, P110, DOI 10.1638/2013-0135R2.1; Nikolova S, 2001, J VET MED B, V48, P203, DOI 10.1046/j.1439-0450.2001.00448.x; Nowak R., 1991, WALKERS MAMMALS WORL, V2, P1104; Nwaokorie EE, 2011, JAVMA-J AM VET MED A, V239, P1319, DOI 10.2460/javma.239.10.1319; Nyakatura K, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-12; Oakley MP, 2016, MAMM BIOL, V81, P189, DOI 10.1016/j.mambio.2015.11.004; OKADA HM, 1987, VET PATHOL, V24, P180, DOI 10.1177/030098588702400212; OTOOLE D, 1993, VET PATHOL, V30, P343, DOI 10.1177/030098589303000403; Overy DP, 2015, J VET DIAGN INVEST, V27, P621, DOI 10.1177/1040638715596036; Park NY, 2007, VET PATHOL, V44, P536, DOI 10.1354/vp.44-4-536; Pavlacik L, 2007, VET MED-CZECH, V52, P69, DOI 10.17221/2057-VETMED; Pedersen K, 2003, VET REC, V153, P264, DOI 10.1136/vr.153.9.264; Peterson RA, 2003, VET PATHOL, V40, P136, DOI 10.1354/vp.40-2-136; Petrini KR, 1999, J ZOO WILDLIFE MED, V30, P54; Piazza S, 2014, JAVMA-J AM VET MED A, V244, P1047, DOI 10.2460/javma.244.9.1047; Pollock Christal, 2012, Vet Clin North Am Exot Anim Pract, V15, P121, DOI 10.1016/j.cvex.2011.09.002; Poyart C, 2002, INT J SYST EVOL MICR, V52, P1247, DOI 10.1099/ijs.0.02044-0; Quinn JH, 2012, J WILDLIFE DIS, V48, P467, DOI 10.7589/0090-3558-48.2.467; Quiroga MI, 1997, DEUT TIERARZTL WOCH, V104, P147; RAUSCH R, 1953, ECOLOGY, V34, P584, DOI 10.2307/1929729; Roos A. M., 2013, PLOS ONE, V8; Root JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0070639; Salomonsen CM, 2013, CAN J VET RES, V77, P199; SANFORD SE, 1988, CAN VET J, V29, P298; Sato JJ, 2004, ZOOL SCI, V21, P111; Scaglione FE, 2013, RES VET SCI, V95, P569, DOI 10.1016/j.rvsc.2013.03.024; SCHULMAN FY, 1993, VET PATHOL, V30, P308, DOI 10.1177/030098589303000316; SCHWARTZ P, 1971, J COMP PATHOL, V81, P437, DOI 10.1016/0021-9975(71)90032-6; Serfass TL, 1995, J ZOO WILDLIFE MED, V26, P311; SEVILLE RS, 1995, J WILDLIFE DIS, V31, P529, DOI 10.7589/0090-3558-31.4.529; Shearer KE, 2014, CAN VET J, V55, P240; Shen ZL, 2017, DIS AQUAT ORGAN, V123, P1, DOI 10.3354/dao03082; Simpson VR, 2011, VET REC, V169, P49, DOI 10.1136/vr.d1929; Simpson VR, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0693-9; Siqueira JD, 2017, J WILDLIFE DIS, V53, P532, DOI 10.7589/2016-04-082; Sledge DG, 2010, VET PATHOL, V47, P751, DOI 10.1177/0300985810364514; Sledge DG, 2011, JAVMA-J AM VET MED A, V239, P1584, DOI 10.2460/javma.239.12.1584; SMITH DA, 1983, VET PATHOL, V20, P223, DOI 10.1177/030098588302000210; Stone WB, 1999, J WILDLIFE DIS, V35, P187, DOI 10.7589/0090-3558-35.2.187; STOWE HD, 1963, J NUTR, V81, P287, DOI 10.1093/jn/81.4.287; Tavernier P., 2012, DISTEMPER OUTBREAK B, P81; Ng TFF, 2015, J WILDLIFE DIS, V51, P446, DOI 10.7589/2014-06-152; Thomas Nancy J., 1996, Endangered Species Update, V13, P23; Tinker MT, 2016, MAR MAMMAL SCI, V32, P309, DOI 10.1111/mms.12261; Torres J, 2008, J HELMINTHOL, V82, P349, DOI 10.1017/S0022149X08046920; Tseng M, 2012, J WILDLIFE DIS, V48, P181, DOI 10.7589/0090-3558-48.1.181; Tuomi P., 1999, P 30 ANN INT ASS AQ, V30, P63; Williams B. H., 2017, FERRETS RABBITS RODE; Williams BH, 1996, VET PATHOL, V33, P437, DOI 10.1177/030098589603300412; WILLIAMS BH, 1994, VET PATHOL, V31, P260, DOI 10.1177/030098589403100218; Williams DL, 2004, VET REC, V155, P52, DOI 10.1136/vr.155.2.52; WILLIAMS ES, 1988, J WILDLIFE DIS, V24, P385, DOI 10.7589/0090-3558-24.3.385; WILLIAMS ES, 1991, J WILDLIFE DIS, V27, P441, DOI 10.7589/0090-3558-27.3.441; Wilson DJ, 2015, J VET DIAGN INVEST, V27, P470, DOI 10.1177/1040638715586438; Wise AG, 2009, VET PATHOL, V46, P985, DOI 10.1354/vp.08-VP-0315-S-FL; WOOLF A, 1985, J WILDLIFE DIS, V21, P441, DOI 10.7589/0090-3558-21.4.441; Zitzow LA, 2002, J VIROL, V76, P4420, DOI 10.1128/JVI.76.9.4420-4429.2002; Zoller M, 2008, EUR J WILDLIFE RES, V54, P15, DOI 10.1007/s10344-007-0101-7	159	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							287	+		10.1016/B978-0-12-805306-5.00011-0			11	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300013					2019-10-28	
B	Church, ME; Terio, KA; Keel, MK		Terio, KA; McAloose, D; StLeger, J		Church, Molly E.; Terio, Karen A.; Keel, M. Kevin			Procyonidae, Viverridae, Hyenidae, Herpestidae, Eupleridae, and Prionodontidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							CANINE-DISTEMPER VIRUS; MEERKATS SURICATA-SURICATTA; FREE-RANGING RACCOONS; MYCOBACTERIUM-BOVIS; CROCUTA-CROCUTA; SPOTTED HYENAS; TOXOPLASMA-GONDII; CELL CARCINOMA; ANTICOAGULANT RODENTICIDES; HEPATOCELLULAR-CARCINOMA		[Church, Molly E.] Univ Penn, Philadelphia, PA 19104 USA; [Terio, Karen A.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA; [Keel, M. Kevin] Univ Calif Davis, Davis, CA 95616 USA	Church, ME (reprint author), Univ Penn, Philadelphia, PA 19104 USA.		Terio, Karen/AAC-5376-2019				Adamovicz L, 2017, J ZOO WILDLIFE MED, V48, P544, DOI 10.1638/2016-0117R.1; Agnew DW, 1999, J ZOO WILDLIFE MED, V30, P431; Aihara N, 2009, J VET MED SCI, V71, P685, DOI 10.1292/jvms.71.685; Alexander K. A., 2016, MBIO, V7; Alexander KA, 2002, EMERG INFECT DIS, V8, P598, DOI 10.3201/eid0806.010358; Alexander KA, 2010, EMERG INFECT DIS, V16, P1296, DOI 10.3201/eid1608.100314; Allison AB, 2013, J VIROL, V87, P2342, DOI 10.1128/JVI.02428-12; Alvarado-Rybak M, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1808-7; ANDERSON GA, 1982, J AM VET MED ASSOC, V181, P1407; Anonis D. P., 1997, PERFUMER FLAVOURIST, V22, P44; [Anonymous], 2016, COMPL UN; Barker Ian K., 2001, P131, DOI 10.1002/9780470344880.ch6; Basso W, 2009, VET PARASITOL, V161, P201, DOI 10.1016/j.vetpar.2009.01.006; Bautista AC, 2014, J VET DIAGN INVEST, V26, P154, DOI 10.1177/1040638713510296; Beineke A, 2015, ONE HEALTH, V1, P49, DOI 10.1016/j.onehlt.2015.09.002; Berentsen AR, 2015, J WILDLIFE DIS, V51, P896, DOI 10.7589/2015-01-016; Bjornson AP, 1999, VET REC, V144, P421, DOI 10.1136/vr.144.15.421; Boadella M, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-7; Boonsri K, 2013, J ZOO WILDLIFE MED, V44, P740, DOI 10.1638/2012-0067R3.1; Brostoff T, 2014, J VIROL, V88, P12816, DOI 10.1128/JVI.01912-14; Bruns AC, 2017, J WILDLIFE DIS, V53, P19, DOI 10.7589/2015-11-318; Burger M, 2017, J S AFR VET ASSOC, V88, DOI 10.4102/jsava.v88i0.1428; Burroughs REJ, 2017, PARASITOL RES, V116, P685, DOI 10.1007/s00436-016-5334-5; Chan PKS, 2013, J THORAC DIS, V5, pS118, DOI 10.3978/j.issn.2072-1439.2013.06.19; Chandra AMS, 2000, J VET DIAGN INVEST, V12, P88, DOI 10.1177/104063870001200120; Childs-Sanford SE, 2005, J ZOO WILDLIFE MED, V36, P308, DOI 10.1638/02-096.1; Chittick E, 2001, J ZOO WILDLIFE MED, V32, P245; Christoffersen M. L., 2013, Zoologische Mededelingen (Leiden), V87, P1; Chu PY, 2012, ANIM BIOL, V62, P95, DOI 10.1163/157075611X616941; Chu PD, 2013, J ZOO WILDLIFE MED, V44, P769, DOI 10.1638/2012-0237R1.1; Church ME, 2016, VIROLOGY, V489, P292, DOI 10.1016/j.virol.2015.11.033; Church ME, 2016, J GEN VIROL, V97, P2939, DOI 10.1099/jgv.0.000594; Clothier KA, 2014, J VET DIAGN INVEST, V26, P297, DOI 10.1177/1040638714521207; Cooper TK, 2017, VET PATHOL, V54, P851, DOI 10.1177/0300985817709886; Dadone LI, 2014, J ZOO WILDLIFE MED, V45, P413, DOI 10.1638/2013-0158R.1; Daniels D., 2013, 2 GENERATION ANTICOA; Davidson W. R., 2006, FIELD MANUAL WILDLIF; Dawood K, 2012, J ANIM VET ADV, V11, P94; de Araujo JL, 2014, ACTA SCI VET, V42; Dechkajorn S, 2016, PARASITOL INT, V65, P58, DOI 10.1016/j.parint.2015.10.004; Del Rio L, 2014, PREV VET MED, V113, P430, DOI 10.1016/j.prevetmed.2013.12.001; Dela Cruz FN, 2013, EMERG INFECT DIS, V19, P77, DOI 10.3201/eid1901.121078; Demeter Z, 2009, VET REC, V164, P213, DOI 10.1136/vr.164.7.213; Drewe JA, 2009, J COMP PATHOL, V140, P12, DOI 10.1016/j.jcpa.2008.09.004; Drewe JA, 2011, PREV VET MED, V101, P113, DOI 10.1016/j.prevetmed.2011.05.006; Duarte MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059399; DUBEY JP, 1992, J AM VET MED ASSOC, V200, P534; Dubey JP, 2000, J PARASITOL, V86, P1299; Duncan C, 2012, ZOONOSES PUBLIC HLTH, V59, P29, DOI 10.1111/j.1863-2378.2011.01412.x; East ML, 2008, J WILDLIFE DIS, V44, P45, DOI 10.7589/0090-3558-44.1.45; EFFRON M, 1977, JNCI-J NATL CANCER I, V59, P185, DOI 10.1093/jnci/59.1.185; Eleni C, 2016, PARASITOL INT, V65, P333, DOI 10.1016/j.parint.2016.04.005; Enders AC, 2006, CELLS TISSUES ORGANS, V183, P141, DOI 10.1159/000095988; Eshar D, 2010, J ZOO WILDLIFE MED, V41, P342, DOI 10.1638/2009-0142R3.1; Ewer R. F., 1973, CARNIVORES, P62; Fitzgerald SD, 2004, J WILDLIFE DIS, V40, P347, DOI 10.7589/0090-3558-40.2.347; FLETCHER KC, 1985, J AM VET MED ASSOC, V187, P1263; Fournier-Chambrillon C, 2004, J WILDLIFE DIS, V40, P394, DOI 10.7589/0090-3558-40.3.394; Frantz AC, 2005, EUR J WILDLIFE RES, V51, P126, DOI 10.1007/s10344-005-0091-2; Gabriel MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040163; Ge XY, 2013, NATURE, V503, P535, DOI 10.1038/nature12711; Giannitti F, 2014, VET PATHOL, V51, P832, DOI 10.1177/0300985813502817; Goodnight AL, 2013, J ZOO WILDLIFE MED, V44, P1068, DOI 10.1638/2012-0153R1.1; Greene LK, 2016, SCI NAT-HEIDELBERG, V103, DOI 10.1007/s00114-016-1361-4; Greve J., 2017, J PARASITOL, V60, P52; Hahn NE, 2003, J AM VET MED ASSOC, V223, P1809, DOI 10.2460/javma.2003.223.1809; Hamir AN, 2008, VET PATHOL, V45, P949, DOI 10.1354/vp.45-6-949; Hamir AN, 2007, J VET DIAGN INVEST, V19, P680, DOI 10.1177/104063870701900610; Hamir AN, 2011, J VET DIAGN INVEST, V23, P873, DOI 10.1177/1040638711416851; Hamir AN, 2011, J AM ASSOC LAB ANIM, V50, P322; Hamir AN, 1996, J WILDLIFE DIS, V32, P670, DOI 10.7589/0090-3558-32.4.670; Hamir AN, 1996, J WILDLIFE DIS, V32, P674, DOI 10.7589/0090-3558-32.4.674; Hamir AN, 1998, J VET DIAGN INVEST, V10, P194, DOI 10.1177/104063879801000218; Hamir AN, 2002, J VET DIAGN INVEST, V14, P175, DOI 10.1177/104063870201400217; Hamir AN, 2001, CAN VET J, V42, P869; HAMIR AN, 1995, J VET DIAGN INVEST, V7, P413, DOI 10.1177/104063879500700325; HEIDT GA, 1969, AM MIDL NAT, V82, P280, DOI 10.2307/2423837; Hollamby S, 2004, VET REC, V154, P596, DOI 10.1136/vr.154.19.596; Honer OP, 2006, VET MICROBIOL, V115, P223, DOI 10.1016/j.vetmic.2005.12.018; Horai S, 2008, ENVIRON TOXICOL CHEM, V27, P1354, DOI [10.1897/07-370.1, 10.1897/07-370]; Howard L., 2007, P AAZV AAWV AZA NAG, V2007, P141; HUNTER KW, 1979, J MED ENTOMOL, V16, P547, DOI 10.1093/jmedent/16.6.547; Hur K, 1999, J COMP PATHOL, V121, P295, DOI 10.1053/jcpa.1999.0322; IKEDE B O, 1976, Journal of Wildlife Diseases, V12, P130; JuanSalles C, 1997, VET PATHOL, V34, P1; Junge RE, 2007, J ZOO WILDLIFE MED, V38, P18, DOI 10.1638/05-123.1; Kapil S, 2010, VET REC, V166, P24, DOI 10.1136/vr.b5587; Katale BZ, 2017, TRANSBOUND EMERG DIS, V64, P815, DOI 10.1111/tbed.12445; Klaphake E, 2005, J ZOO WILDLIFE MED, V36, P127, DOI 10.1638/03-084; Klinkowski-Clark Christine, 2010, Human-Wildlife Interactions, V4, P32; Knable A., 1964, Journal of Mammalogy, V45, P493; Koizumi N, 2009, J VET MED SCI, V71, P425, DOI 10.1292/jvms.71.425; Kubiski SV, 2016, VET PATHOL, V53, P674, DOI 10.1177/0300985815603430; Kurth A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006883; Laura Bongiovanni, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS62, DOI 10.12980/APJTB.4.2014C915; Lemberger KY, 2005, J PARASITOL, V91, P960, DOI 10.1645/GE-407R.1; Li WH, 2006, J VIROL, V80, P4211, DOI 10.1128/JVI.80.9.4211-4219.2006; LOMBARD LS, 1959, CANCER RES, V19, P127; LONG CA, 1988, J HERED, V79, P387, DOI 10.1093/oxfordjournals.jhered.a110534; Marrow JC, 2014, J ZOO WILDLIFE MED, V45, P134, DOI 10.1638/2013-0142R.1; McCain SL, 2010, J ZOO WILDLIFE MED, V41, P121, DOI 10.1638/2009-0155.1; MECH LD, 1966, J MAMMAL, V47, P128, DOI 10.2307/1378088; Millan J, 2008, SCI TOTAL ENVIRON, V399, P193, DOI 10.1016/j.scitotenv.2008.03.038; Millan J, 2015, VET QUART, V35, P43, DOI 10.1080/01652176.2014.987883; Millan J, 2009, VECTOR-BORNE ZOONOT, V9, P549, DOI 10.1089/vbz.2008.0081; Miller RS, 2013, EPIDEMIOL INFECT, V141, P1357, DOI 10.1017/S0950268813000976; Moinet M, 2010, J WILDLIFE DIS, V46, P1141, DOI 10.7589/0090-3558-46.4.1141; Monello RJ, 2009, J PARASITOL, V95, P56, DOI 10.1645/GE-1643.1; Montali R. J., 1980, COMP PATHOLOGY ZOO A; Nakamura S, 2015, J VET DIAGN INVEST, V27, P641, DOI 10.1177/1040638715596035; Naples LM, 2010, J ZOO WILDLIFE MED, V41, P275, DOI 10.1638/2009-0011R2.1; Nelson KG, 2013, J WILDLIFE DIS, V49, P627, DOI 10.7589/2011-09-262; Nicolier A, 2005, VET DERMATOL, V16, P420, DOI 10.1111/j.1365-3164.2005.00483.x; Ninomiya H, 2003, VET DERMATOL, V14, P339, DOI 10.1111/j.1365-3164.2003.00351.x; Oie KL, 1996, J VIROL, V70, P852; Olivieri L, 2015, J ZOO WILDLIFE MED, V46, P592, DOI 10.1638/2014-0152.1; Palgrave CJ, 2012, J COMP PATHOL, V146, P278, DOI 10.1016/j.jcpa.2011.06.001; Palmer MV, 2002, J WILDLIFE DIS, V38, P266, DOI 10.7589/0090-3558-38.2.266; Parsons SDC, 2013, EMERG INFECT DIS, V19, P2004, DOI 10.3201/eid1912.130268; Peirce MA, 2001, VET REC, V149, P561, DOI 10.1136/vr.149.18.561; Pinard CL, 2002, J WILDLIFE DIS, V38, P851, DOI 10.7589/0090-3558-38.4.851; Raizman EA, 2009, J WILDLIFE DIS, V45, P531, DOI 10.7589/0090-3558-45.2.531; Ramsay E., 2015, FOWLERS ZOO WILD ANI, V8; Rattner BA, 2014, ENVIRON SCI TECHNOL, V48, P8433, DOI 10.1021/es501740n; Renteria-Solis Z, 2014, MED VET ENTOMOL, V28, P98, DOI 10.1111/mve.12079; Richardson DJ, 2014, COMP PARASITOL, V81, P44, DOI 10.1654/4672.1; Richardson DJ, 2003, VECTOR-BORNE ZOONOT, V3, P187, DOI 10.1089/153036603322662174; RICHARDSON DJ, 1992, J PARASITOL, V78, P163, DOI 10.2307/3283710; Riley MC, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0445-7; Roberton SI, 2006, P ROY SOC B-BIOL SCI, V273, P1729, DOI 10.1098/rspb.2006.3549; Rupprecht Charles E., 2001, P3, DOI 10.1002/9780470344880.ch1; Sabeta CT, 2008, VET REC, V163, P580, DOI 10.1136/vr.163.19.580; SANDERSON GLEN C., 1960, AMER MIDLAND NAT, V64, P500, DOI 10.2307/2422679; Schmiedeknecht G, 2010, VET PATHOL, V47, P547, DOI 10.1177/0300985810363703; Schrenzel MD, 2011, EMERG INFECT DIS, V17, P747, DOI [10.3201/eid1704.101355, 10.3201/eid1706.101355]; Sedlak K, 2006, VET PARASITOL, V136, P223, DOI 10.1016/j.vetpar.2005.11.021; Seguel M, 2017, INT J PARASITOL-PAR, V6, P177, DOI 10.1016/j.ijppaw.2017.03.007; Singh BP, 2005, J VET DIAGN INVEST, V17, P623, DOI 10.1177/104063870501700621; Singleton CL, 2007, J ZOO WILDLIFE MED, V38, P488, DOI 10.1638/1042-7260(2007)38[488:DATOCT]2.0.CO;2; Speck S, 2008, VET MICROBIOL, V128, P148, DOI 10.1016/j.vetmic.2007.09.019; Stallknecht David E., 2001, P164; Stone WB, 1999, J WILDLIFE DIS, V35, P187, DOI 10.7589/0090-3558-35.2.187; Suzan G, 2005, J ZOO WILDLIFE MED, V36, P479, DOI 10.1638/04-078.1; Techangamsuwan S, 2015, VET PATHOL, V52, P724, DOI 10.1177/0300985814551580; Thompson KA, 2016, J ZOO WILDLIFE MED, V47, P1109, DOI 10.1638/2015-0285.1; Tokiwa T, 2014, PARASITOL INT, V63, P591, DOI 10.1016/j.parint.2014.03.003; Tolosa T, 2007, ANIM WELFARE, V16, P15; TURNBULL BG, 1986, SOMATOSENS MOT RES, V4, P43, DOI 10.3109/07367228609144597; van Helden PD, 2008, J WILDLIFE DIS, V44, P151, DOI 10.7589/0090-3558-44.1.151; VANDORP DA, 1973, RECL TRAV CHIM PAY B, V92, P915; Vapniarsky N, 2013, J COMP PATHOL, V149, P385, DOI 10.1016/j.jcpa.2013.01.011; Vellard J., 1931, B SOC ZOO FR, V56, P255; Voss RS, 2012, BIOL REV, V87, P822, DOI 10.1111/j.1469-185X.2012.00222.x; WADSWORTH PF, 1982, J ZOO ANIM MED, V13, P29, DOI 10.2307/20094559; Wang Fun-In, 2001, Proceedings of the National Science Council Republic of China Part B Life Sciences, V25, P193; Whithear K., 2001, INFECT DIS WILD MAMM, P414; Wicker LV, 2017, ZOONOSES PUBLIC HLTH, V64, P75, DOI 10.1111/zph.12290; Williams BM, 2014, PARASITOL RES, V113, P911, DOI 10.1007/s00436-013-3722-7; Williams Elizabeth S., 2001, P50; Witmer G, 2010, J WILDLIFE DIS, V46, P368, DOI 10.7589/0090-3558-46.2.368; WOJCINSKI ZW, 1986, J WILDLIFE DIS, V22, P55, DOI 10.7589/0090-3558-22.1.55; Xiao Y, 2008, J COMP PATHOL, V138, P171, DOI 10.1016/j.jcpa.2007.12.005; Yabsley MJ, 2002, J WILDLIFE DIS, V38, P75, DOI 10.7589/0090-3558-38.1.75; Youlatos D, 2003, J ZOOL, V259, P423, DOI 10.1017/S0952836903003431; Zhou Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174902	165	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							305	+		10.1016/B978-0-12-805306-5.00012-2			10	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300014					2019-10-28	
B	McAloose, D; Stalis, IH		Terio, KA; McAloose, D; StLeger, J		McAloose, Denise; Stalis, Ilse H.			Prosimians	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							WHITE RUFFED LEMURS; VARECIA-VARIEGATA-VARIEGATA; IRON-BINDING-CAPACITY; SLOW LORIS; ENCEPHALOMYOCARDITIS VIRUS; GASTROINTESTINAL PARASITES; GASTRIC PNEUMATOSIS; RINGTAILED LEMURS; BERENTY RESERVE; DENTAL DISEASE		[McAloose, Denise] Wildlife Conservat Soc, Bronx, NY 10460 USA; [Stalis, Ilse H.] San Diego Zoo Global, Inst Conservat Res, Dis Invest, San Diego, CA USA	McAloose, D (reprint author), Wildlife Conservat Soc, Bronx, NY 10460 USA.						Alexander AB, 2016, J ZOO WILDLIFE MED, V47, P141, DOI 10.1638/2015-0111.1; Alterman L, 1995, CREATURES OF THE DARK, P413; Ankel-Simons F, 2007, SENSE ORGANS VISCERA, P391; Ankel-Simons F, 2007, REPROD ORGANS REPROD, P521; Aswad A, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004332; Backues KA, 2001, J AM VET MED ASSOC, V218, P250, DOI 10.2460/javma.2001.218.250; Beltran WA, 2007, VET OPHTHALMOL, V10, P43, DOI 10.1111/j.1463-5224.2007.00491.x; BENIRSCHKE K, 1981, J MED PRIMATOL, V10, P38; BENIRSCHKE K, 1985, ADV VET SCI COMP MED, V30, P167; Beraldo P., 2008, PARASSITOLOGIA, V50, P172; Berrilli F, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-199; Blancou J, 1976, Rev Elev Med Vet Pays Trop, V29, P127; Bleier T, 2005, J ZOO WILDLIFE MED, V36, P342, DOI 10.1638/04-011.1; BORASKI EA, 1981, VET PATHOL, V18, P1; BRESNAHAN JF, 1984, J AM VET MED ASSOC, V185, P1354; BROCKMAN DK, 1987, ZOO BIOL, V6, P341, DOI 10.1002/zoo.1430060408; Bublitz DC, 2015, AM J PRIMATOL, V77, P330, DOI 10.1002/ajp.22348; BURKHOLDER PM, 1970, AM J PATHOL, V61, P437; BURKHOLDER PM, 1971, VIRCHOWS ARCH A, V354, P80, DOI 10.1007/BF00544109; BURTON M, 1986, J AM VET MED ASSOC, V189, P1209; Cabana F, 2015, ZOO BIOL, V34, P547, DOI 10.1002/zoo.21245; CALLE PP, 1986, J AM VET MED ASSOC, V189, P1212; CALLE PP, 1993, J ZOO WILDLIFE MED, V24, P459; Campbell GA, 1997, J ZOO WILDLIFE MED, V28, P204; Campbell JL, 2000, AM J PRIMATOL, V52, P133, DOI 10.1002/1098-2345(200011)52:3<133::AID-AJP2>3.0.CO;2-#; Canelli E, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-64; Canuti M., 2014, FRONT MICROBIOL, V5, P1; Carocci M, 2012, VIRULENCE, V3, P351, DOI 10.4161/viru.20573; CHANG J, 1980, J AM VET MED ASSOC, V177, P820; Charles-Smith LE, 2010, J ZOO WILDLIFE MED, V41, P438, DOI 10.1638/2009-0160.1; Clough D, 2010, J PARASITOL, V96, P245, DOI 10.1645/GE-2258.1; COULANGES P, 1979, B SOC PATHOL EXOT, V72, P272; Crawford G., 2006, BALD LEMUR SYNDROME, P332; Crawford G, 2015, AM J PRIMATOL, V77, P633, DOI 10.1002/ajp.22386; CROUNSE RG, 1962, NATURE, V194, P694, DOI 10.1038/194694b0; Cuozzo F, 2016, COMPANION DENT ANTHR, P540; Cuozzo Frank P., 2006, P67, DOI 10.1007/978-0-387-34586-4_4; De Liberato C, 2014, PARASITOL INT, V63, P695, DOI 10.1016/j.parint.2014.05.008; Drea CM, 2008, J MORPHOL, V269, P451, DOI 10.1002/jmor.10594; DREW ML, 1991, J ZOO WILDLIFE MED, V22, P494; DUBEY JP, 1985, J AM VET MED ASSOC, V187, P1272; Duval L, 2010, P NATL ACAD SCI USA, V107, P10561, DOI 10.1073/pnas.1005435107; Dyer NW, 1998, J VET DIAGN INVEST, V10, P362, DOI 10.1177/104063879801000410; Eisenberg T, 2015, ANTON LEEUW INT J G, V108, P1373, DOI 10.1007/s10482-015-0590-4; Evans C, 1995, CREATURES OF THE DARK, P393; Fuller G, 2014, ENDANGER SPECIES RES, V23, P205, DOI 10.3354/esr00568; Gaide N, 2015, J COMP PATHOL, V153, P231, DOI 10.1016/j.jcpa.2015.07.005; Gardiner CH, 2006, ATLAS METAZOAN PARAS; Garrett EC, 2013, ANAT REC, V296, P1881, DOI 10.1002/ar.22828; Gilardi KVK, 2014, EMERG INFECT DIS, V20, P1883, DOI 10.3201/eid2011.140075; Glenn KM, 2006, AM J PRIMATOL, V68, P369, DOI 10.1002/ajp.20231; GONZALES J, 1984, ZOO BIOL, V3, P255, DOI 10.1002/zoo.1430030308; Griner L.A., 1983, PATHOLOGY ZOO ANIMAL, P319; Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P420; Hall CA, 2007, J PARASITOL, V93, P93, DOI 10.1645/GE-936R.1; HELDSTAB A, 1981, J MED PRIMATOL, V10, P129; ISOUN T T, 1972, Journal of Wildlife Diseases, V8, P335; Martinez MAJ, 2015, VET PARASITOL, V210, P246, DOI 10.1016/j.vetpar.2015.04.010; Jolly A, 2009, AM J PRIMATOL, V71, P191, DOI 10.1002/ajp.20647; Junge Randall E., 2009, Veterinary Clinics of North America Exotic Animal Practice, V12, P339, DOI 10.1016/j.cvex.2009.01.011; JUNGE RE, 1994, J AM VET MED ASSOC, V205, P1024; KEMP G E, 1972, African Journal of Medical Sciences, V3, P177; KNEZEVIC AL, 1967, FOLIA PRIMATOL, V6, P153, DOI 10.1159/000155072; KORNEGAY RW, 1993, J ZOO WILDLIFE MED, V24, P196; Krane S, 2003, NATURWISSENSCHAFTEN, V90, P60, DOI 10.1007/s00114-002-0394-z; Kraska A, 2011, NEUROBIOL AGING, V32, P894, DOI 10.1016/j.neurobiolaging.2009.05.018; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kuznetsova E, 2012, VET DERMATOL, V23, P61, DOI 10.1111/j.1365-3164.2011.00989.x; LANDAU I, 1989, ANN PARASIT HUM COMP, V64, P171, DOI 10.1051/parasite/1989643171; LEPERS JP, 1989, ANN PARASIT HUM COMP, V64, P163, DOI 10.1051/parasite/1989643163; Luzon M, 2010, J ZOO WILDLIFE MED, V41, P327, DOI 10.1638/2009-0062R.1; Martin RD, 2005, PRIMATE VISUAL SYSTEM: A COMPARATIVE APPROACH, P1; Nekaris KAI, 2013, J VENOM ANIM TOXINS, V19, DOI 10.1186/1678-9199-19-21; Nemeth NM, 2013, J COMP PATHOL, V148, P283, DOI 10.1016/j.jcpa.2012.05.013; Niederwerder MC, 2013, J ZOO WILDLIFE MED, V44, P79, DOI 10.1638/1042-7260-44.1.79; Norton T., 2013, P AM ASS ZOO VET SAL, P50; PALOTAY JL, 1975, J AM VET MED ASSOC, V167, P615; Plesker R, 2006, AM J PRIMATOL, V68, P838, DOI 10.1002/ajp.20283; Plesker R, 2013, ZOO BIOL, V32, P571, DOI 10.1002/zoo.21072; Plesker R, 2012, J ZOO WILDLIFE MED, V43, P473, DOI 10.1638/2011-0084R1.1; POLLOCK JI, 1987, AM J PHYS ANTHROPOL, V73, P65, DOI 10.1002/ajpa.1330730106; Pye GW, 2000, J ZOO WILDLIFE MED, V31, P388; Rasambainarivo FT, 2013, J WILDLIFE DIS, V49, P741, DOI 10.7589/2012-10-264; Ratsimbazafy Jonah H., 2013, P387; Reddacliff LA, 1997, J ZOO WILDLIFE MED, V28, P153; Remick AK, 2009, VET PATHOL, V46, P746, DOI 10.1354/vp.08-VP-0154-R-FL; Rideout BA, 1997, VET PATHOL, V34, P15, DOI 10.1177/030098589703400103; Rietjens IMCM, 2005, MOL NUTR FOOD RES, V49, P131, DOI 10.1002/mnfr.200400078; ROTHSCHILD BM, 1992, AM J PHYS ANTHROPOL, V87, P341, DOI 10.1002/ajpa.1330870308; ROTHSCHILD BM, 1992, AM J PHYS ANTHROPOL, V88, P389, DOI 10.1002/ajpa.1330880310; Roy M, 2015, NEUROBIOL AGING, V36, P149, DOI 10.1016/j.neurobiolaging.2014.07.017; Schopler R., 2017, P AM ASS ZOO VET DAL, P55; Schwitzer C, 2009, ANAT HISTOL EMBRYOL, V38, P429, DOI 10.1111/j.1439-0264.2009.00964.x; Schwitzer C., 2013, LEMURS MADAGASCAR ST, P185; Smith TD, 2015, AM J PRIMATOL, V77, P229, DOI 10.1002/ajp.22326; Soligo C, 1999, J HUM EVOL, V36, P97, DOI 10.1006/jhev.1998.0263; SPELMAN LH, 1989, ZOO BIOL, V8, P239, DOI 10.1002/zoo.1430080305; Spencer JA, 2004, J PARASITOL, V90, P904, DOI 10.1645/GE-249R; STETTER MD, 1995, J ZOO WILDLIFE MED, V26, P155; Sutherland-Smith M, 2001, MANAGEMENT LORISES C, P60; van Helden PD, 2009, J S AFR VET ASSOC, V80, P210; Villers LM, 2008, AM J PRIMATOL, V70, P175, DOI 10.1002/ajp.20482; WELLS SK, 1989, J ZOO WILDLIFE MED, V20, P291; Williams C., 2002, P AM ASS ZOO VET, P359; Williams CV, 2008, JAVMA-J AM VET MED A, V232, P578, DOI 10.2460/javma.232.4.578; Williams CV, 2006, AM J PRIMATOL, V68, P477, DOI 10.1002/ajp.20237; Williams CV, 2002, EMERG INFECT DIS, V8, P1497, DOI 10.3201/eid0812.020085; WILLIAMS KJ, 2015, FOWLERS ZOO WILD ANI, P291; WORLEY M, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P173; Worley MB, 2002, J WILDLIFE DIS, V38, P258, DOI 10.7589/0090-3558-38.2.258; Yamashita N, 2010, AM J PRIMATOL, V72, P56, DOI 10.1002/ajp.20751; Zadrozny LM, 2010, VET PATHOL, V47, P306, DOI 10.1177/0300985809359380	112	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							323	+		10.1016/B978-0-12-805306-5.00013-4			41	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300015					2019-10-28	
B	Matz-Rensing, K; Lowenstine, LJ		Terio, KA; McAloose, D; StLeger, J		Maetz-Rensing, Kerstin; Lowenstine, Linda J.			New World and Old World Monkeys	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							MARMOSETS CALLITHRIX-JACCHUS; B-VIRUS-INFECTION; ECHINOCOCCUS-MULTILOCULARIS INFECTION; MACAQUES MACACA-NEMESTRINA; TAMARINS SAGUINUS-OEDIPUS; SIMIAN VARICELLA VIRUS; FATAL FASTING SYNDROME; RED-BELLIED TAMARINS; RHESUS-MONKEYS; COMMON MARMOSETS		[Maetz-Rensing, Kerstin] German Primate Ctr, Leibniz Inst Primate Res, Gottingen, Germany; [Lowenstine, Linda J.] Univ Calif Davis, Davis, CA 95616 USA	Matz-Rensing, K (reprint author), German Primate Ctr, Leibniz Inst Primate Res, Gottingen, Germany.						Adams JS, 2003, J CELL BIOCHEM, V88, P308, DOI 10.1002/jcb.10333; AMI Y, 1993, J VET MED SCI, V55, P7, DOI 10.1292/jvms.55.7; Andrade MCR, 2007, REV BRAS PARASITOL V, V16, P229, DOI 10.1590/S1984-29612007000400009; Ankel-Simons F, 2007, INTRO PRIMATE ANATOM; ARITA I, 1985, AM J TROP MED HYG, V34, P781, DOI 10.4269/ajtmh.1985.34.781; ARMITAGE GC, 1982, J PERIODONTAL RES, V17, P131, DOI 10.1111/j.1600-0765.1982.tb01139.x; Bacciarini LN, 2004, VET PATHOL, V41, P229, DOI 10.1354/vp.41-3-229; Bailey C, 2010, VET PATHOL, V47, P462, DOI 10.1177/0300985810363719; Baitchman EJ, 2006, J ZOO WILDLIFE MED, V37, P182, DOI 10.1638/05-062.1; BASKERVILLE M, 1983, LAB ANIM-UK, V17, P350, DOI 10.1258/002367783781062334; BASKIN GB, 1988, VET PATHOL, V25, P456, DOI 10.1177/030098588802500609; BASKIN GB, 1987, AM J PATHOL, V129, P345; BASKIN GB, 1995, J INFECT DIS, V172, P535, DOI 10.1093/infdis/172.2.535; Baxter JR, 2008, J AM ASSOC LAB ANIM, V47, P89; Baze WB, 2002, VET PATHOL, V39, P605, DOI 10.1354/vp.39-5-605; Beck AP, 2014, COMPARATIVE MED, V64, P148; BELLINI S, 1991, LAB ANIM SCI, V41, P509; BENNETT BT, 1980, LAB ANIM SCI, V30, P241; Bielli M, 1999, J ZOO WILDLIFE MED, V30, P532; BLANCHARD JL, 1986, VET PATHOL, V23, P425, DOI 10.1177/030098588602300412; BRACK M, 1981, VET PATHOL, V18, P45, DOI 10.1177/0300985881018s0605; Brack M., 1987, AGENTS TRANSMISSIBLE; BRADY PS, 1982, AM J VET RES, V43, P1489; Brammer DW, 1995, J MED PRIMATOL, V24, P231, DOI 10.1111/j.1600-0684.1995.tb00175.x; Brenner RM, 2012, REV ENDOCR METAB DIS, V13, P309, DOI 10.1007/s11154-012-9225-5; Brinton MA, 2015, VIRUS RES, V202, P112, DOI 10.1016/j.virusres.2014.11.024; BRONSON RT, 1982, LAB ANIM SCI, V32, P187; BRUESTLE ME, 1981, LAB ANIM SCI, V31, P292; Bushmitz M, 2009, J MED PRIMATOL, V38, P59, DOI 10.1111/j.1600-0684.2008.00303.x; BUTLER TM, 1991, LAB ANIM SCI, V41, P407; CALLE PP, 1993, J ZOO WILDLIFE MED, V24, P459; Campbell CJ, 2008, CAM S BIO EVOL ANTHR, V55, P266, DOI 10.1017/CBO9780511721915.010; Cann JA, 2010, VET PATHOL, V47, P713, DOI 10.1177/0300985810370011; Carme B, 2009, VET PARASITOL, V163, P132, DOI 10.1016/j.vetpar.2009.04.004; CASTLEMAN WL, 1980, J AM VET MED ASSOC, V177, P933; CHALIFOUX LV, 1981, J MED PRIMATOL, V10, P336; CHALIFOUX LV, 1981, GASTROENTEROLOGY, V80, P942; CHAPMAN WL, 1985, LAB ANIM SCI, V35, P491; Chaudhari UK, 2014, J AM ASSOC LAB ANIM, V53, P18; Chivers David J., 1994, P205; Cho YG, 2001, P NATL ACAD SCI USA, V98, P1224, DOI 10.1073/pnas.98.3.1224; Christe KL, 1999, CONTEMP TOP LAB ANIM, V38, P12; Chrousos G.P., 1986, Advances in Experimental Medicine and Biology, V196, P129; Chun RF, 2001, AM J PRIMATOL, V54, P107, DOI 10.1002/ajp.1016; Corte AC, 2007, MYCOPATHOLOGIA, V164, P225, DOI 10.1007/s11046-007-9059-y; COSTA EO, 1994, MYCOPATHOLOGIA, V125, P19, DOI 10.1007/BF01103970; Coulibaly C, 2004, LAB ANIM-UK, V38, P432, DOI 10.1258/0023677041958891; CUPP CJ, 1981, J MED PRIMATOL, V10, P110; David JM, 2009, J MED PRIMATOL, V38, P347, DOI 10.1111/j.1600-0684.2009.00362.x; de Boer B, 2009, J ACOUST SOC AM, V126, P3329, DOI 10.1121/1.3257544; de Rijk EPCT, 2008, TOXICOL PATHOL, V36, p108S, DOI 10.1177/0192623308326095; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Dietz HH, 1997, VET PARASITOL, V68, P299, DOI 10.1016/S0304-4017(96)01088-6; DOWNIE AW, 1974, J HYG-CAMBRIDGE, V72, P245, DOI 10.1017/S0022172400023445; DUBOIS A, 1994, GASTROENTEROLOGY, V106, P1405, DOI 10.1016/0016-5085(94)90392-1; Ehlers B, 2010, J GEN VIROL, V91, P630, DOI 10.1099/vir.0.017251-0; EISELE PH, 1992, LAB ANIM SCI, V42, P245; Eng C., 2002, P AAZV, P382; Engel GA, 2002, EMERG INFECT DIS, V8, P789, DOI 10.3201/eid0808.010467; Epiphanio S, 2003, J COMP PATHOL, V129, P196, DOI 10.1016/S0021-9975(03)00035-5; Fernandez KR, 2002, J CLIN MICROBIOL, V40, P1908, DOI 10.1128/JCM.40.6.1908-1912.2002; Fickenscher H, 2001, PHILOS T R SOC B, V356, P545, DOI 10.1098/rstb.2000.0780; FLURER C, 1983, LAB ANIM SCI, V33, P264; FLURER CI, 1987, J MED PRIMATOL, V16, P175; Fontani S, 2014, FOLIA PRIMATOL, V85, P109, DOI 10.1159/000360221; Fragaszy DM, 2016, AM J PRIMATOL, V78, P473, DOI 10.1002/ajp.22509; Fredriksson-Ahomaa M, 2007, VET MICROBIOL, V121, P363, DOI 10.1016/j.vetmic.2006.12.010; FUJIMOTO K, 1991, J MED PRIMATOL, V20, P42; Fuller PJ, 2004, TRENDS ENDOCRIN MET, V15, P296, DOI 10.1016/j.tem.2004.07.001; FURMAN DP, 1974, LAB ANIM SCI, V24, P622; Furuta T, 2001, EXP ANIM TOKYO, V50, P299, DOI 10.1538/expanim.50.299; Gao Y., 2014, MED IMAGING 2014 BIO; Garcia JL, 2005, VET PARASITOL, V133, P307, DOI 10.1016/j.vetpar.2005.06.004; Garcia MA, 2004, COMPARATIVE MED, V54, P578; Garcia MA, 2004, COMPARATIVE MED, V54, P86; Gebo D., 2014, COMP PRIMATE ANATOMY; GHANDOUR AM, 1995, ANN TROP MED PARASIT, V89, P313, DOI 10.1080/00034983.1995.11812958; GILBERT SG, 1987, J MED PRIMATOL, V16, P333; GILES RC, 1974, LAB ANIM SCI, V24, P610; GOODWIN WJ, 1987, LAB ANIM SCI, V37, P231; GRACZYK TK, 1995, J WILDLIFE DIS, V31, P75, DOI 10.7589/0090-3558-31.1.75; Gulani J, 2016, COMPARATIVE MED, V66, P150; Guscetti F, 2003, J MED PRIMATOL, V32, P111, DOI 10.1034/j.1600-0684.2003.00016.x; Guzman RE, 1999, TOXICOL PATHOL, V27, P672, DOI 10.1177/019262339902700609; HALL AS, 1967, J AM VET MED ASSOC, V151, P833; HARCOURT AH, 1994, P ROY SOC B-BIOL SCI, V255, P47, DOI 10.1098/rspb.1994.0007; Hatt JM, 2004, J ZOO WILDLIFE MED, V35, P387, DOI 10.1638/03-041; Heard DJ, 1997, J ZOO WILDLIFE MED, V28, P185; Helke KL, 2006, VET PATHOL, V43, P75, DOI 10.1354/vp.43-1-75; Hess J. C., 2002, AAZV ANN C P, V2002, P349; Hewitt G, 2002, FOLIA PRIMATOL, V73, P70, DOI 10.1159/000064786; HILLOOWALA RA, 1978, AM J PHYS ANTHROPOL, V49, P129, DOI 10.1002/ajpa.1330490119; HILLOOWALA RA, 1976, ACTA ANAT, V95, P260; Hobbs TR, 2003, COMPARATIVE MED, V53, P545; Holbrook MR, 2012, ANTIVIR RES, V96, P353, DOI 10.1016/j.antiviral.2012.10.005; Hsu MJ, 2000, AM J PRIMATOL, V52, P199, DOI 10.1002/1098-2345(200012)52:4<199::AID-AJP4>3.0.CO;2-2; Hubbard GB, 2002, J MED PRIMATOL, V31, P84, DOI 10.1034/j.1600-0684.2002.01020.x; HUBBARD GB, 1993, LAB ANIM SCI, V43, P301; Hufnagel D, 2015, SEMIN REPROD MED, V33, P333, DOI 10.1055/s-0035-1564609; Hukkanen RR, 2009, COMPARATIVE MED, V59, P482; HULL WB, 1970, LAB ANIM CARE, V20, P402; HUNT RD, 1970, J NATL CANCER I, V44, P447; Iwata T, 2005, MICROBIOL IMMUNOL, V49, P1; JACKSON RK, 1989, LAB ANIM SCI, V39, P425; Jahrling PB, 2004, P NATL ACAD SCI USA, V101, P15196, DOI 10.1073/pnas.0405954101; Jerman LF, 2015, BIOL REPROD, V92, DOI 10.1095/biolreprod.114.124313; Juan-Salles C, 1998, J ZOO WILDLIFE MED, V29, P55; Juan-Salles C, 2006, VET PATHOL, V43, P438, DOI 10.1354/vp.43-4-438; Juan-Salles C, 1998, J MED PRIMATOL, V27, P298, DOI 10.1111/j.1600-0684.1998.tb00079.x; Juan-Salles C, 2003, VET PATHOL, V40, P540, DOI 10.1354/vp.40-5-540; Juan-Salles C, 1997, J VET DIAGN INVEST, V9, P341, DOI 10.1177/104063879700900325; Kahnt K, 2002, VET PATHOL, V39, P42, DOI 10.1354/vp.39-1-42; Kalashnikova VA, 2002, B EXP BIOL MED+, V134, P299, DOI 10.1023/A:1021528122942; KATAKURA S, 1990, APMIS, V98, P313, DOI 10.1111/j.1699-0463.1990.tb01038.x; Kessler MJ, 2006, AM J PRIMATOL, V68, P725, DOI 10.1002/ajp.20262; King N., 1993, NONHUMAN PRIMATES, P226; Klein EC, 1999, J MED PRIMATOL, V28, P11, DOI 10.1111/j.1600-0684.1999.tb00084.x; Knauf S, 2012, VET PATHOL, V49, P292, DOI 10.1177/0300985811402839; Kobayashi R, 1999, EXP ANIM TOKYO, V48, P55, DOI 10.1538/expanim.48.55; Kock ND, 2003, VET REC, V152, P141, DOI 10.1136/vr.152.5.141; KORNEGAY RW, 1985, LAB ANIM SCI, V35, P400; Kuhn JH, 2016, ARCH VIROL, V161, P755, DOI 10.1007/s00705-015-2672-z; Kumar S, 2012, J MED PRIMATOL, V41, P266, DOI 10.1111/j.1600-0684.2012.00547.x; LACKNER AA, 1989, J MED PRIMATOL, V18, P195; Lafortune M, 2004, J ZOO WILDLIFE MED, V35, P549, DOI 10.1638/03-080; Leal SG, 2016, REV SOC BRAS MED TRO, V49, P29, DOI 10.1590/0037-8682-0363-2015; Lederer I, 2005, INT J INFECT DIS, V9, P290, DOI 10.1016/j.ijid.2004.11.003; Lefaux B, 2004, VET PATHOL, V41, P302, DOI 10.1354/vp.41-3-302-a; Leighty KA, 2004, FOLIA PRIMATOL, V75, P14, DOI 10.1159/000073425; Lerche Nicholas W., 2003, Toxicologic Pathology, V31, P103, DOI 10.1080/01926230390174977; LI SL, 1991, RES VIROLOGY, V142, P173, DOI 10.1016/0923-2516(91)90054-7; Lima AR, 2011, AN ACAD BRAS CIENC, V83, P1339, DOI 10.1590/S0001-37652011000400020; Lin PL, 2009, INFECT IMMUN, V77, P4631, DOI 10.1128/IAI.00592-09; LINE AS, 1992, LAB ANIM SCI, V42, P96; Liu CH, 2004, J VET MED SCI, V66, P1279, DOI 10.1292/jvms.66.1279; LIU SK, 1984, J AM VET MED ASSOC, V185, P1347; LOOMIS MR, 1981, J AM VET MED ASSOC, V179, P1236; Lowenstine L., 1993, MONOGRAPHS PATHOLOGY, P20; Lowenstine L., 1993, ILSI MONOGRAPHS PATH, P20; LOWENSTINE LJ, 1992, J MED PRIMATOL, V21, P1; LOWENSTINE LJ, 1988, J ZOO WILDLIFE MED, V19, P168, DOI 10.2307/20094885; Ludlage E, 2005, VET PATHOL, V42, P117, DOI 10.1354/vp.42-2-117; Ludlage E, 2003, COMPARATIVE MED, V53, P369; Luetjens CM, 2005, BIOL REV, V80, P475, DOI 10.1017/S1464793105006755; Luzon M, 2010, J ZOO WILDLIFE MED, V41, P327, DOI 10.1638/2009-0062R.1; Matz-Rensing K, 2007, VET PATHOL, V44, P327, DOI 10.1354/vp.44-3-327; Matz-Rensing K, 2015, J COMP PATHOL, V153, P81, DOI 10.1016/j.jcpa.2015.05.006; Matz-Rensing K, 2009, J MED PRIMATOL, V38, P328, DOI 10.1111/j.1600-0684.2009.00359.x; Mansfield KG, 1997, AM J PATHOL, V150, P1395; Mansfield KG, 2001, AM J PATHOL, V159, P693, DOI 10.1016/S0002-9440(10)61740-3; Mansfield KG, 2001, J INFECT DIS, V184, P803, DOI 10.1086/322990; Mansfield KG, 1997, J INFECT DIS, V175, P184, DOI 10.1093/infdis/175.1.184; MARKOVICS A, 1992, J COMP PATHOL, V106, P435, DOI 10.1016/0021-9975(92)90028-S; Marr-Belvin AK, 2008, VET PATHOL, V45, P914, DOI 10.1354/vp.45-6-914; Martina BEE, 2006, EMERG INFECT DIS, V12, P1005, DOI 10.3201/eid1206.051513; Matz-Rensing K, 2006, VET PATHOL, V43, P212, DOI 10.1354/vp.43-2-212; Matz-Rensing K, 2003, VET PATHOL, V40, P405, DOI 10.1354/vp.40-4-405; Rocha VCM, 2011, VECTOR-BORNE ZOONOT, V11, P593, DOI 10.1089/vbz.2010.0070; MEYERS WM, 1985, INT J LEPROSY, V53, P1; Miller AD, 2010, VET PATHOL, V47, P969, DOI 10.1177/0300985810369905; Miller GF, 1997, LAB ANIM SCI, V47, P138; Mittermeier RA, 2013, HDB MAMMALS WORLD PR; MONTALI RJ, 1995, AM J PATHOL, V147, P1441; Moraes IA, 2006, AM J PRIMATOL, V68, P1120, DOI 10.1002/ajp.20287; Moreno ES, 2015, MEM I OSWALDO CRUZ, V110, P865, DOI 10.1590/0074-02760150075; Morrisey J. K., 1994, P AM ASS ZOO VET PIT, P381; Mossman HW, 1973, COMP MORPHOLOGY MAMM; Nakamura S, 2010, J COMP PATHOL, V143, P150, DOI 10.1016/j.jcpa.2010.01.017; Nakamura S, 2009, J VET MED SCI, V71, P1657, DOI 10.1292/jvms.001657; Newman JD, 2009, BRAIN RES REV, V62, P1, DOI 10.1016/j.brainresrev.2009.09.001; NEWTON WM, 1971, LAB ANIM SCI, V21, P193; Oya C, 2008, LAB ANIM-UK, V42, P99, DOI 10.1258/la.2007.006031; Panarella ML, 2010, J AM ASSOC LAB ANIM, V49, P221; Pandrea I, 2009, CURR HIV RES, V7, P57, DOI 10.2174/157016209787048456; Pardo ID, 2012, TOXICOL PATHOL, V40, P624, DOI 10.1177/0192623311436180; Parsons SDC, 2009, J MED PRIMATOL, V38, P411, DOI 10.1111/j.1600-0684.2009.00367.x; PEROLAT P, 1992, AM J TROP MED HYG, V46, P538, DOI 10.4269/ajtmh.1992.46.538; Peters J. C., 1966, International zoo yearbook, V6, P274, DOI 10.1111/j.1748-1090.1966.tb01794.x; Pisharath HR, 2005, CONTEMP TOP LAB ANIM, V44, P35; Plesker Roland, 2009, Vietnamese Journal of Primatology, V1, P75; Plesker R, 2010, J MED PRIMATOL, V39, P129, DOI 10.1111/j.1600-0684.2010.00406.x; POLLACK M, 1983, J INFECT DIS, V147, P963, DOI 10.1093/infdis/147.5.963; POTKAY S, 1992, J MED PRIMATOL, V21, P189; RATTERREE MS, 1990, LAB ANIM SCI, V40, P165; RAWLINS RG, 1982, AM J PRIMATOL, V3, P23, DOI 10.1002/ajp.1350030103; Reimann KA, 2005, J VIROL, V79, P8878, DOI 10.1128/JVI.79.14.8878-8885.2005; Reme Thomas, 2009, J Occup Med Toxicol, V4, P29, DOI 10.1186/1745-6673-4-29; Reynolds PD, 1998, LAB ANIM SCI, V48, P364; Riede T, 2008, J ACOUST SOC AM, V124, P634, DOI 10.1121/1.2924125; Robertson BH, 2002, REV MED VIROL, V12, P133, DOI 10.1002/rmv.348; Rolland RM, 1997, LAB ANIM SCI, V47, P472; ROSENBERG DP, 1980, J AM VET MED ASSOC, V177, P818; ROUT WR, 1974, GASTROENTEROLOGY, V67, P59; Rubio CA, 2002, IN VIVO, V16, P191; Sa-nguanmoo P, 2010, PRIMATES, V51, P167, DOI 10.1007/s10329-009-0172-z; Salasia Siti Isrina Oktavia, 2004, J Vet Sci, V5, P263; Saleem KS., 2012, COMBINED MRI HISTOLO; Sallis ESV, 2003, J VET DIAGN INVEST, V15, P574, DOI 10.1177/104063870301500611; Sato C, 2005, J VET MED SCI, V67, P133, DOI 10.1292/jvms.67.133; Scammell J G, 2000, ILAR J, V41, P19; Scammell JG, 2001, GEN COMP ENDOCR, V124, P152, DOI 10.1006/gcen.2001.7696; Scheerer-Bernhard JU, 2015, ANIM REPROD SCI, V157, P44, DOI 10.1016/j.anireprosci.2015.03.014; SCHILLER CA, 1989, J ZOO WILDLIFE MED, V20, P322; Schiml PA, 1996, PHYSIOL BEHAV, V60, P1105, DOI 10.1016/0031-9384(96)00134-5; Schneider H, 2015, MOL PHYLOGENET EVOL, V82, P348, DOI 10.1016/j.ympev.2013.10.017; Schroeder C, 1999, NEPHROL DIAL TRANSPL, V14, P1875, DOI 10.1093/ndt/14.8.1875; SCHULMAN FY, 1993, VET PATHOL, V30, P491, DOI 10.1177/030098589303000601; SEO H, 1989, ENDOCRINOL JAPON, V36, P665; Setchell JM, 2010, CHEM SENSES, V35, P205, DOI 10.1093/chemse/bjp105; Shah Keerti V, 2012, F1000Res, V1, P61, DOI 10.12688/f1000research.1-61.v1; Siiteri P K, 1986, Adv Exp Med Biol, V196, P279; Simmons HA, 2011, ANTIOXID REDOX SIGN, V14, P221, DOI 10.1089/ars.2010.3311; Simmons J, 2012, AM COLL LAB, P105, DOI 10.1016/B978-0-12-381366-4.00002-X; Singh I, 2006, J MED PRIMATOL, V35, P352, DOI 10.1111/j.1600-0684.2006.00181.x; SLATTUM MM, 1989, LAB ANIM SCI, V39, P560; Smith KM, 2008, AM J PRIMATOL, V70, P629, DOI 10.1002/ajp.20538; Solnick JV, 2003, J CLIN MICROBIOL, V41, P5511, DOI 10.1128/JCM.41.12.5511-5516.2003; Springer DA, 2009, J ZOO WILDLIFE MED, V40, P95, DOI 10.1638/2008-0055.1; Stevens C. E., 1995, COMP PHYSL VERTEBRAT; Strait K, 2012, AM COLL LAB, P197, DOI 10.1016/B978-0-12-381366-4.00004-3; Sugiyama Y, 2011, PRIMATES, V52, P19, DOI 10.1007/s10329-010-0220-8; Swindler D.R, 1982, ATLAS PRIMATE GROSS; Szonyi B, 2011, VET J, V188, P237, DOI 10.1016/j.tvjl.2010.05.002; TAKASAKA M, 1988, JPN J MED SCI BIOL, V41, P1; Tappe D, 2007, AM J TROP MED HYG, V77, P504, DOI 10.4269/ajtmh.2007.77.504; Thompson SA, 2000, COMPARATIVE MED, V50, P649; Thomson JA, 1996, LAB ANIM SCI, V46, P275; TSAI CC, 1995, J MED PRIMATOL, V24, P43, DOI 10.1111/j.1600-0684.1995.tb00143.x; Tsubota K, 2009, VET PARASITOL, V161, P339, DOI 10.1016/j.vetpar.2009.01.024; Twenhafel NA, 2008, VET PATHOL, V45, P226, DOI 10.1354/vp.45-2-226; Urvater JA, 2000, IMMUNOGENETICS, V51, P314, DOI 10.1007/s002510050625; Valverde CR, 1998, INT J LEPROSY, V66, P140; VANDEWOUDE SJ, 1991, LAB ANIM SCI, V41, P401; Wagner JD, 2001, TOXICOL PATHOL, V29, P142, DOI 10.1080/019262301301418955; Walker ML, 2009, REPRODUCTION, V138, P793, DOI 10.1530/REP-08-0449; Ward JM, 2014, J AM ASSOC LAB ANIM, V53, P7; WELLER RE, 1990, J MED PRIMATOL, V19, P675; Windle CP, 1999, J MED PRIMATOL, V28, P73, DOI 10.1111/j.1600-0684.1999.tb00254.x; Wood JD, 1998, DIGEST DIS SCI, V43, P1443, DOI 10.1023/A:1018842210330; Yamauchi H, 2011, VET PATHOL, V48, pE1, DOI 10.1177/0300985810384408; Yanai T, 1999, VET PATHOL, V36, P471, DOI 10.1354/vp.36-5-471; Young L. A., 2001, P AM ASS ZOO VET INT; Ziegler TE, 2015, AM J PRIMATOL, V77, P801, DOI 10.1002/ajp.22403; Zinner Dietmar P., 2004, P71, DOI 10.1017/CBO9780511542459.007; Zoller M, 2012, J COMP PATHOL, V147, P381, DOI 10.1016/j.jcpa.2011.11.197; Zoeller M., 2008, Primate Report, V76, P63; Zondervan KT, 2004, HUM REPROD, V19, P448, DOI 10.1093/humrep/deh052; Zou SS, 2010, J MED PRIMATOL, V39, P417, DOI 10.1111/j.1600-0684.2010.00427.x	248	1	1	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							343	+		10.1016/B978-0-12-805306-5.00014-6			48	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300016					2019-10-28	
B	Lowenstine, LJ; McManamon, R; Terio, KA		Terio, KA; McAloose, D; StLeger, J		Lowenstine, Linda J.; McManamon, Rita; Terio, Karen A.			Apes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							GORILLA-GORILLA-GORILLA; WESTERN LOWLAND GORILLAS; CHIMPANZEE PAN-TROGLODYTES; AFRICAN GREAT APES; RESPIRATORY SYNCYTIAL VIRUS; HEPATITIS-B-VIRUS; HABITUATED MOUNTAIN GORILLAS; DEEP TROPHOBLAST INVASION; GOMBE NATIONAL-PARK; HUMAN METAPNEUMOVIRUS INFECTION		[Lowenstine, Linda J.] Univ Calif Davis, Davis, CA 95616 USA; [McManamon, Rita] Univ Georgia, Athens, GA 30602 USA; [Terio, Karen A.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA	Lowenstine, LJ (reprint author), Univ Calif Davis, Davis, CA 95616 USA.		Terio, Karen/AAC-5376-2019				Alvarez-Perez S, 2012, MED MYCOL, V50, P193, DOI 10.3109/13693786.2011.578155; Ancrenaz M, 2014, SCI REP-UK, V4, DOI 10.1038/srep04024; Andrade MCR, 2011, COMPARATIVE MED, V61, P457; ANDRLE M, 1979, CYTOGENET CELL GENET, V24, P1, DOI 10.1159/000131350; Ankel-Simons F, 2007, PRIMATE ANATOMY; Aryan HE, 2006, CLIN NEUROL NEUROSUR, V108, P205, DOI 10.1016/j.clineuro.2004.12.011; Ashbury AM, 2015, AM J PRIMATOL, V77, P1216, DOI 10.1002/ajp.22460; ASHLEY CR, 1978, LANCET, V2, P477; Atkins A, 2008, J ZOO WILDLIFE MED, V39, P638, DOI 10.1638/2007-0056.1; Avni-Magen N, 2008, J ZOO WILDLIFE MED, V39, P115, DOI 10.1638/2007-0018.1; Ayouba A, 2013, INFECT GENET EVOL, V18, P325, DOI 10.1016/j.meegid.2013.04.015; Baicharoen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109151; Baitchman EJ, 2006, J ZOO WILDLIFE MED, V37, P126, DOI 10.1638/05-064.1; Balolia KL, 2015, AM J PHYS ANTHROPOL, V156, P135, DOI 10.1002/ajpa.22633; BANISH LD, 1993, J AM VET MED ASSOC, V203, P126; Ben Salem N, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01101-16; Benirschke K, 1980, J Reprod Fertil Suppl, VSuppl 28, P139; Benirschke K., 2017, COMP PLACENTATION; BIENIASZ PD, 1995, VIROLOGY, V207, P217, DOI 10.1006/viro.1995.1068; Blinkova O, 2010, J GEN VIROL, V91, P74, DOI 10.1099/vir.0.015446-0; Bolter DR, 2012, AM J PHYS ANTHROPOL, V147, P629, DOI 10.1002/ajpa.22025; Bommineni YR, 2009, J MED PRIMATOL, V38, P247, DOI 10.1111/j.1600-0684.2009.00348.x; Bonvicino CR, 2014, WORLD J GASTROENTERO, V20, P7665, DOI 10.3748/wjg.v20.i24.7665; Borkowski R, 2000, J ZOO WILDLIFE MED, V31, P65; Boundenga L, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0622-6; Bradford CM, 2013, J ZOO WILDLIFE MED, V44, P1055, DOI 10.1638/2011-0206R1.1; Branche AR, 2015, DRUG AGING, V32, P261, DOI 10.1007/s40266-015-0258-9; Bratschi MW, 2015, LEPROSY REV, V86, P142; Brown K, 2017, MAMMAL REV, V47, P53, DOI 10.1111/mam.12079; Brown S, 2009, J MED PRIMATOL, V38, P137, DOI 10.1111/j.1600-0684.2008.00321.x; Brozova K, 2016, INFECT GENET EVOL, V37, P231, DOI 10.1016/j.meegid.2015.11.013; Buckley BJW, 2015, PRIMATES, V56, P293, DOI 10.1007/s10329-015-0487-x; Buitendijk H, 2014, VIRUSES-BASEL, V6, P1442, DOI 10.3390/v6031442; Calcedo R, 2016, HUM GENE THER CL DEV, V27, P79, DOI 10.1089/humc.2016.048; CALLE PP, 1993, J ZOO WILDLIFE MED, V24, P459; Canelli E, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-64; Canfield PJ, 1997, AUST VET J, V75, P97, DOI 10.1111/j.1751-0813.1997.tb14165.x; Capozzi O, 2012, GENOME RES, V22, P2520, DOI 10.1101/gr.138651.112; Carbone L, 2014, NATURE, V513, P195, DOI 10.1038/nature13679; Carocci M, 2012, VIRULENCE, V3, P351, DOI 10.4161/viru.20573; Carpenter NA, 2017, J ZOO WILDLIFE MED, V48, P224, DOI 10.1638/2015-0303.1; Carter AM, 2016, PLACENTA, V37, P65, DOI 10.1016/j.placenta.2015.11.005; CARTER AM, 2007, PLACENTA SA, V41, pS47; Carter AM, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0070; Carter AM, 2011, BEST PRACT RES CL OB, V25, P249, DOI 10.1016/j.bpobgyn.2010.10.010; Carter AM, 2011, REPRODUCTION, V141, P391, DOI 10.1530/REP-10-0530; Carville A, 2008, COMPARATIVE MED, V58, P57; Cervena B, 2017, PARASITOLOGY, V144, P1016, DOI 10.1017/S0031182017000221; Chaffee BK, 2016, VET PATHOL, V53, P425, DOI 10.1177/0300985815620654; Chatterjee Helen J., 2009, P13, DOI 10.1007/978-0-387-88604-6_2; Chi F, 2007, J BACTERIOL, V189, P6085, DOI 10.1128/JB.00468-07; Chilton J, 2016, VET PATHOL, V53, P417, DOI 10.1177/0300985815618435; Clarke E, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000073; Cloutier CT, 2015, AGE, V37, DOI 10.1007/s11357-015-9746-4; Cohen JI, 1996, J MED VIROL, V50, P289, DOI 10.1002/(SICI)1096-9071(199612)50:4<289::AID-JMV2>3.0.CO;2-4; Coscolla M, 2013, EMERG INFECT DIS, V19, P969, DOI 10.3201/eid1906.121012; Costello R, 2017, CLIN OTOLARYNGOL, V42, P144, DOI 10.1111/coa.12715; Cousins D., 1972, International Zoo Yearbook, V12, P211, DOI 10.1111/j.1748-1090.1972.tb02330.x; Cousins D., 1983, IZN (International Zoo News), V30, P5; Cousins D., 2008, GORILLA J, V37, P22; Cray J, 2014, J MORPHOL, V275, P342, DOI 10.1002/jmor.20218; Cray J, 2012, J MED PRIMATOL, V41, P356, DOI 10.1111/jmp.12018; Cray J, 2011, J ANAT, V218, P471, DOI 10.1111/j.1469-7580.2011.01358.x; Cray J, 2010, AM J PHYS ANTHROPOL, V143, P473, DOI 10.1002/ajpa.21367; Cray J, 2010, ANAT REC, V293, P1289, DOI 10.1002/ar.21167; CRELIN ES, 1988, YALE J BIOL MED, V61, P383; Crosley EJ, 2013, PLACENTA, V34, P127, DOI 10.1016/j.placenta.2012.12.001; Cummins L, 2016, J ZOO WILDLIFE MED, V47, P711; D'Amour DE, 2006, FOLIA PRIMATOL, V77, P212, DOI 10.1159/000091230; D'arc M, 2015, P NATL ACAD SCI USA, V112, pE1343, DOI 10.1073/pnas.1502022112; Dadakova E, 2018, ARCH VIROL, V163, P191, DOI 10.1007/s00705-017-3576-x; Dahl JF, 1999, J MED PRIMATOL, V28, P129, DOI 10.1111/j.1600-0684.1999.tb00260.x; DAVIS KJ, 1992, VET PATHOL, V29, P547, DOI 10.1177/030098589202900612; De Nys HM, 2015, AM J PRIMATOL, V77, P833, DOI 10.1002/ajp.22418; de Vries RD, 2012, CURR OPIN VIROL, V2, P248, DOI 10.1016/j.coviro.2012.03.005; Deblauwe I, 2008, AM J PHYS ANTHROPOL, V135, P42, DOI 10.1002/ajpa.20703; Dench R, 2015, J ZOO WILDLIFE MED, V46, P833, DOI 10.1638/2014-0220.1; DEPAOLI A, 1978, VET PATHOL, V15, P31, DOI 10.1177/030098587801500104; DeSilva J, 2006, J HUM EVOL, V51, P207, DOI 10.1016/j.jhevol.2006.05.006; Deuzing I, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-347; DICK EC, 1974, LAB ANIM SCI, V24, P177; DICK EC, 1968, AM J EPIDEMIOL, V88, P267, DOI 10.1093/oxfordjournals.aje.a120885; Dixson AF, 2012, PRIMATE SEXUALITY: COMPARATIVE STUDIES OF THE PROSIMIANS, MONKEYS, APES, AND HUMANS, 2ND EDITION, P1, DOI 10.1093/acprof:osobl/9780199544646.001.0001; DOLENSEK EP, 1977, J AM VET MED ASSOC, V171, P975; Dolezalova J, 2015, PARASITOLOGY, V142, P1278, DOI 10.1017/S003118201500058X; Dooley HM, 2015, AM J PRIMATOL, V77, P296, DOI 10.1002/ajp.22345; DORE M, 1985, CAN VET J, V26, P347; DOUGLAS JD, 1967, J AM VET MED ASSOC, V151, P901; DOUGLAS JD, 1970, LAB ANIM CARE, V20, P265; Dubuis E, 2003, VET REC, V152, P651, DOI 10.1136/vr.152.21.651; Duprez R, 2004, EMERG INFECT DIS, V10, P899, DOI 10.3201/eid1005.030964; EBERLE R, 1989, J CLIN MICROBIOL, V27, P1357; Ehlers B, 2010, J GEN VIROL, V91, P630, DOI 10.1099/vir.0.017251-0; ELLIS RA, 1962, AM J PHYS ANTHROPOL, V20, P79, DOI 10.1002/ajpa.1330200210; Ely JJ, 2006, AM J PHYS ANTHROPOL, V130, P96, DOI 10.1002/ajpa.20310; Ely JJ, 2005, AM J PRIMATOL, V67, P223, DOI 10.1002/ajp.20179; Ely JJ, 2013, ZOO BIOL, V32, P79, DOI 10.1002/zoo.21044; Emerson JA, 2013, VET QUART, V33, P191, DOI 10.1080/01652176.2013.880005; Essbauer S, 2010, VET MICROBIOL, V140, P229, DOI 10.1016/j.vetmic.2009.08.026; Etienne L, 2012, J VIROL, V86, P9760, DOI 10.1128/JVI.01186-12; Etienne L, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-4; Evans TS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04877-1; Evans TS, 2016, AM J PRIMATOL, V78, P1222, DOI 10.1002/ajp.22576; EYLES DE, 1964, AM J TROP MED HYG, V13, P248, DOI 10.4269/ajtmh.1964.13.248; Fain A., 1958, Revue de Zoologie et de Botanique Africaines, V58, P323; Fain A., 1957, Revue de Zoologie et de Botanique Africaines, V56, P234; FEINGOLD G, 1995, CONFERENCE ON CLOUD PHYSICS, P70; Fisher RE, 2000, ANAT REC, V261, P228, DOI 10.1002/1097-0185(20001215)261:6<228::AID-AR1005>3.0.CO;2-O; Flahou B, 2014, VET MICROBIOL, V174, P186, DOI 10.1016/j.vetmic.2014.08.032; Foitova I, 2008, RES VET SCI, V84, P232, DOI 10.1016/j.rvsc.2007.04.021; FOSTER JW, 1982, AM J PRIMATOL, V2, P121; Fujii-Hanamoto H, 2011, AM J PRIMATOL, V73, P570, DOI 10.1002/ajp.20930; Gagneux P, 2003, J BIOL CHEM, V278, P48245, DOI 10.1074/jbc.M309813200; Gamble Kathryn C., 2004, P565; Gibbs S, 2002, J ANAT, V200, P3, DOI 10.1046/j.0021-8782.2001.00001.x; Gibo D. L., 2014, COMP PRIMATE ANATOMY; Gilardi K., 2015, BEST PRACTICE GUIDEL; Gilardi KVK, 2014, EMERG INFECT DIS, V20, P1883, DOI 10.3201/eid2011.140075; Gillespie T. R., 2008, AM J PHYS ANTHR, P53; Gillespie TR, 2008, YEARB PHYS ANTHROPOL, V51, P53, DOI 10.1002/ajpa.20949; Gjeltema JL, 2016, JAVMA-J AM VET MED A, V248, P315, DOI 10.2460/javma.248.3.315; Goldberg TL, 2014, EMERG INFECT DIS, V20, P109, DOI 10.3201/eid2001.131191; Goldfinger JZ, 2014, J AM COLL CARDIOL, V64, P1725, DOI 10.1016/j.jacc.2014.08.025; Graczyk TK, 1999, J PARASITOL, V85, P1168, DOI 10.2307/3285682; Graczyk TK, 2001, PARASITOL RES, V87, P1024; Graham KJ, 2009, AUST VET J, V87, P66, DOI 10.1111/j.1751-0813.2008.00370.x; Gray WL, 2008, COMPARATIVE MED, V58, P22; Greenberg MJ, 1999, J ZOO WILDLIFE MED, V30, P256; Gregory WK, 1950, ANATOMY GORILLA STUD; Gresl TA, 2000, ZOO BIOL, V19, P193, DOI 10.1002/1098-2361(2000)19:3<193::AID-ZOO3>3.0.CO;2-M; Groenewoud MJ, 2010, J GEN VIROL, V91, P653, DOI 10.1099/vir.0.017673-0; Gross M, 2006, CYTOGENET GENOME RES, V112, P67, DOI 10.1159/000087515; GROVES MG, 1969, J INFECT DIS, V120, P605, DOI 10.1093/infdis/120.5.605; Grutzmacher KS, 2016, ECOHEALTH, V13, P499, DOI 10.1007/s10393-016-1144-6; Guatelli-Steinberg D, 2012, AM J PHYS ANTHROPOL, V148, P191, DOI 10.1002/ajpa.21619; Hahn A, 2014, J ZOO WILDLIFE MED, V45, P179, DOI 10.1638/2013-0118R1.1; Halbwax M, 2009, J MED PRIMATOL, V38, P171, DOI 10.1111/j.1600-0684.2009.00341.x; Hamad I, 2014, SCI REP-UK, V4, DOI 10.1038/srep04478; Hanamura S, 2008, PRIMATES, V49, P77, DOI 10.1007/s10329-007-0054-1; Hanley CS, 2006, J ZOO WILDLIFE MED, V37, P553, DOI 10.1638/06-036.1; Hanley PW, 2015, EMERG INFECT DIS, V21, P2158, DOI 10.3201/eid2112.142004; Hannibal DL, 2005, AM J PHYS ANTHROPOL, V127, P13, DOI 10.1002/ajpa.20141; HARCOURT AH, 1981, NATURE, V293, P55, DOI 10.1038/293055a0; Hardus ME, 2012, INT J PRIMATOL, V33, P287, DOI 10.1007/s10764-011-9574-z; Harrison ME, 2011, INT J PRIMATOL, V32, P531, DOI 10.1007/s10764-010-9487-2; Harvala H, 2014, J GEN VIROL, V95, P403, DOI 10.1099/vir.0.059048-0; Harvala H, 2012, EMERG INFECT DIS, V18, P283, DOI 10.3201/eid1802.111363; Hassell JM, 2017, AM J PRIMATOL, V79, DOI 10.1002/ajp.22686; HASTINGS BE, 1991, PROCEEDINGS : AMERICAN ASSOCIATION OF ZOO VETERINARIANS - ANNUAL MEETING 1991, P198; Hayakawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043277; HELDSTAB A, 1981, J MED PRIMATOL, V10, P129; Herd KE, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1843-3; HEUSCHELE WERNER P., 1960, JOUR AMER VET MED ASSOC, V136, P256; Hewitt S., 2005, Proceedings of the 7th Annual Symposium on Zoo Research, Twycross Zoo, Warwickshire, UK, 7-8th July 2005, P222; Hey J, 2010, MOL BIOL EVOL, V27, P921, DOI 10.1093/molbev/msp298; Hoffman K, 2007, ANN NY ACAD SCI, V1111, P404, DOI 10.1196/annals.1406.018; HOLLANDER CF, 1972, ORAL SURG ORAL MED O, V33, P220, DOI 10.1016/0030-4220(72)90391-X; HOOPES PJ, 1978, J AM VET MED ASSOC, V173, P1145; Hoppe E, 2015, MOL BIOL EVOL, V32, P2072, DOI 10.1093/molbev/msv090; Hrazdilova K, 2016, VIROLOGY, V487, P207, DOI 10.1016/j.virol.2015.10.016; Hu XD, 2016, MITOCHONDRIAL DNA A, V27, P1484, DOI 10.3109/19401736.2014.953103; HUBBARD GB, 1992, LAB ANIM SCI, V42, P233; HUBBARD GB, 1991, VET PATHOL, V28, P546, DOI 10.1177/030098589102800617; Hussain AI, 2003, VIROLOGY, V309, P248, DOI 10.1016/S0042-6822(03)00070-9; Hvilsom C, 2013, HEREDITY, V110, P586, DOI 10.1038/hdy.2013.9; Inogwabini BI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051112; Ishikawa MK, 2015, HISTOPATHOLOGY, V67, P836, DOI 10.1111/his.12716; IVERSON WO, 1978, J AM VET MED ASSOC, V173, P1134; JACOBS SC, 1984, PROSTATE, V5, P597, DOI 10.1002/pros.2990050605; JANSSEN DL, 1990, ZOO BIOL, V9, P123, DOI 10.1002/zoo.1430090206; Janssen Donald L., 1993, P334; Jean SM, 2012, COMPARATIVE MED, V62, P322; Jirku-Pomajbikova K, 2016, PARASITOLOGY, V143, P741, DOI 10.1017/S0031182016000263; JOHNSEN DO, 1971, J INFECT DIS, V123, P365, DOI 10.1093/infdis/123.4.365; JONES EE, 1984, J AM VET MED ASSOC, V185, P1351; Jones P, 2011, J MED PRIMATOL, V40, P157, DOI 10.1111/j.1600-0684.2010.00464.x; Junglen S, 2010, VIRUS RES, V150, P143, DOI 10.1016/j.virusres.2010.02.020; Jurmain R, 2000, J HUM EVOL, V39, P185, DOI 10.1006/jhev.2000.0413; JUSTINE JL, 1988, ANN PARASIT HUM COMP, V63, P420, DOI 10.1051/parasite/1988636420; Kading RC, 2013, J WILDLIFE DIS, V49, P587, DOI 10.7589/2012-08-212; Kalter S S, 1980, J Reprod Fertil Suppl, VSuppl 28, P149; KALTER SS, 1969, LAB ANIM CARE, V19, P63; Kalter SS, 1997, LAB ANIM SCI, V47, P461; KALTER SS, 1978, P SOC EXP BIOL MED, V159, P414; KALTER SS, 1967, AM J EPIDEMIOL, V86, P552, DOI 10.1093/oxfordjournals.aje.a120765; Kambale E. S, 2014, P AM ASS ZOO VET; Kanamori T, 2017, PRIMATES, V58, P225, DOI 10.1007/s10329-016-0584-5; Kapoor A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011948; KARR JF, 1995, CANCER RES, V55, P2455; Kaur T, 2008, AM J PRIMATOL, V70, P755, DOI 10.1002/ajp.20565; KAWAKAMI TG, 1980, INT J CANCER, V25, P641, DOI 10.1002/ijc.2910250514; KENNY DE, 1994, J ZOO WILDLIFE MED, V25, P561; Ketz-Riley CJ, 2009, J ZOO WILDLIFE MED, V40, P257, DOI 10.1638/2007-0170.1; Kik MJL, 2005, J ZOO WILDLIFE MED, V36, P131, DOI 10.1638/03-004; Kilbourn AM, 2003, J WILDLIFE DIS, V39, P73, DOI 10.7589/0090-3558-39.1.73; Kim SK, 2011, MOL BIOL EVOL, V28, P2211, DOI 10.1093/molbev/msr033; Klee SR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010986; Kondgen S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024236; Kondgen S, 2010, ECOHEALTH, V7, P332, DOI 10.1007/s10393-010-0340-z; Koppe Thomas, 1995, Okajimas Folia Anatomica Japonica, V72, P37; Koppe Thomas, 1996, Okajimas Folia Anatomica Japonica, V72, P297; Koppe Thomas, 1999, P77; KRAUSE WJ, 1975, ACTA ANAT, V93, P580; Krief S, 2008, J MED PRIMATOL, V37, P188, DOI 10.1111/j.1600-0684.2008.00285.x; Krishnamani R, 2000, ANIM BEHAV, V59, P899, DOI 10.1006/anbe.1999.1376; Kumar S, 2012, J MED PRIMATOL, V41, P266, DOI 10.1111/j.1600-0684.2012.00547.x; Kuze N, 2010, J PARASITOL, V96, P954, DOI 10.1645/GE-2379.1; Lacoste V, 2000, NATURE, V407, P151, DOI 10.1038/35025145; Lacoste V, 2001, GENOME RES, V11, P1511, DOI 10.1101/gr.158601; Lammey ML, 2008, COMPARATIVE MED, V58, P389; Landolfi JA, 2005, J VET DIAGN INVEST, V17, P369, DOI 10.1177/104063870501700412; Lankester F, 2008, J MED PRIMATOL, V37, P297, DOI 10.1111/j.1600-0684.2008.00287.x; Lankester F, 2010, J ZOO WILDLIFE MED, V41, P350, DOI 10.1638/2009-0190.1; Laurence H, 2017, J MED PRIMATOL, V46, P106, DOI 10.1111/jmp.12267; Lavergne A, 2014, J VIROL, V88, P13212, DOI 10.1128/JVI.01490-14; Lear TL, 2001, CYTOGENET CELL GENET, V95, P228, DOI 10.1159/000059350; Leendertz FH, 2006, AM J PRIMATOL, V68, P928, DOI 10.1002/ajp.20298; Leendertz FH, 2011, J VIROL, V85, P916, DOI 10.1128/JVI.01585-10; Leendertz FH, 2009, J GEN VIROL, V90, P2386, DOI 10.1099/vir.0.011866-0; LEIGH SR, 1994, AM J PHYS ANTHROPOL, V94, P499, DOI 10.1002/ajpa.1330940406; LEININGER JR, 1980, INT J LEPROSY, V48, P414; Lerche NW, 2008, ILAR J, V49, P170, DOI 10.1093/ilar.49.2.170; Leroy EM, 2004, J INFECT DIS, V190, P1895, DOI 10.1086/425421; Leroy EM, 2004, SCIENCE, V303, P387, DOI 10.1126/science.1092528; Less EH, 2014, ZOO BIOL, V33, P63, DOI 10.1002/zoo.21116; Lester SJ, 2011, VET CLIN PATH, V40, P4, DOI 10.1111/j.1939-165X.2010.00281.x; Levrero F, 2007, AM J PHYS ANTHROPOL, V132, P568, DOI 10.1002/ajpa.20560; Li YY, 2012, J VIROL, V86, P10776, DOI 10.1128/JVI.01498-12; Liu DX, 2012, J MED PRIMATOL, V41, P107, DOI 10.1111/j.1600-0684.2011.00529.x; Liu WM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000097; Locke DP, 2011, NATURE, V469, P529, DOI 10.1038/nature09687; Lonsdorf EV, 2006, AM J PRIMATOL, V68, P897, DOI 10.1002/ajp.20296; Lovell NC, 2000, PRIMATES, V41, P275, DOI 10.1007/BF02557597; Lowenstine L, 2008, P AM ASS ZOO VET, P40; Lowenstine LJ, 2016, VET PATHOL, V53, P250, DOI 10.1177/0300985815612154; Lowenstine L. J., 2003, TOXICOLOGIC PATHO S1, V31, P1; Lowenstine LJ, 2012, AM COLL LAB, P413, DOI 10.1016/B978-0-12-381366-4.00009-2; Lowenstine LJ, 2014, FOWLERS ZOO WILDLIFE, V8, P674; Luebcke E, 2006, J GEN VIROL, V87, P11, DOI 10.1099/vir.0.81606-0; Lycett SJ, 2011, P ROY SOC B-BIOL SCI, V278, P2091, DOI 10.1098/rspb.2010.2599; Madinda NF, 2015, MICROBIOL RESOUR ANN, V3, DOI 10.1128/genomeA.00888-15; Madinda NF, 2016, J VIROL, V90, P8531, DOI 10.1128/JVI.00247-16; Mahaney WC, 2016, ENVIRON GEOCHEM HLTH, V38, P51, DOI 10.1007/s10653-015-9678-z; Makanga B, 2016, P NATL ACAD SCI USA, V113, P5329, DOI 10.1073/pnas.1603008113; Manfreda Evelyn, 2006, Anatomical Record Part B:The New Anatomist, V289, P184, DOI 10.1002/ar.b.20113; MARTIN DP, 1983, J AM VET MED ASSOC, V183, P1185; Masters N, 2010, J ZOO WILDLIFE MED, V41, P713, DOI 10.1638/2009-0122.1; Matano S, 1997, AM J PHYS ANTHROPOL, V103, P173, DOI 10.1002/(SICI)1096-8644(199706)103:2<173::AID-AJPA4>3.0.CO;2-V; MCCLURE HM, 1969, SCIENCE, V165, P1010, DOI 10.1126/science.165.3897.1010; MCCLURE HM, 1980, LAB ANIM SCI, V30, P895; McManamon Rita, 2012, P408; McTighe MS, 2011, J AM ASSOC LAB ANIM, V50, P165; McVey D, 2013, VIROLOGY, V444, P119, DOI 10.1016/j.virol.2013.05.041; Meehan T. P., 1994, Proceedings American Association of Zoo Veterinarians and Association of Reptilian and Amphibian Veterinarians Annual Conference Pittsburgh, USA, 22-27, October, 1994., P216; MELNICK JL, 1953, J EXP MED, V97, P367, DOI 10.1084/jem.97.3.367; MEYERS WM, 1991, AM J TROP MED HYG, V44, P24, DOI 10.4269/ajtmh.1991.44.24; Mikkelsen TS, 2005, NATURE, V437, P69, DOI 10.1038/nature04072; Miller CL, 2006, J PARASITOL, V92, P406, DOI 10.1645/GE-653R.1; Miller CL, 1999, J ZOO WILDLIFE MED, V30, P262; Miller LJ, 2012, APPL ANIM BEHAV SCI, V141, P65, DOI 10.1016/j.applanim.2012.07.011; Mischnik A, 2014, MYCOSES, V57, P664, DOI 10.1111/myc.12215; Mitja O, 2013, LANCET, V381, P763, DOI 10.1016/S0140-6736(12)62130-8; Mombo IM, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00680-14; Mombo IM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169067; MONTAGNA W, 1963, AM J PHYS ANTHROPOL, V21, P189, DOI 10.1002/ajpa.1330210211; MONTAGNA W, 1972, AM ZOOL, V12, P109; Moore J, 2017, J HUM EVOL, V112, P30, DOI 10.1016/j.jhevol.2017.09.004; MORBECK ME, 1991, PRIMATES, V32, P77, DOI 10.1007/BF02381602; Morino L, 2011, FOLIA PRIMATOL, V81, P362, DOI 10.1159/000324303; Mossman H. W., 1973, COMP MORPHOLOGY MAMM, V100-116, P360; Mudakikwa A., 2001, MOUNTAIN GORILLAS 3, P341; Mugisha L, 2010, J MED PRIMATOL, V39, P71, DOI 10.1111/j.1600-0684.2009.00396.x; Muhangi D., 2008, THESIS MAKARERE U UG; Mun S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101195; Mundy NI, 1998, J ZOO WILDLIFE MED, V29, P261; MUNSON L, 1990, ZOO BIOL, V9, P99, DOI 10.1002/zoo.1430090204; MUNSON L, 1991, J MED PRIMATOL, V20, P265; Murphy HW, 2011, J ZOO WILDLIFE MED, V42, P572, DOI 10.1638/2010-0139.1; MYERS MG, 1987, J MED VIROL, V23, P317, DOI 10.1002/jmv.1890230403; MYERS RH, 1979, SCIENCE, V205, P308, DOI 10.1126/science.451603; Mynarova A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152771; NADLER RD, 1975, ANAT REC, V181, P791, DOI 10.1002/ar.1091810410; Nakauchi K, 1999, J VET MED SCI, V61, P63, DOI 10.1292/jvms.61.63; Nakikura S., 1992, PRIMATES, V33, P265; Nakikura S., 1993, PRIMATES, V34, P119; Nater A, 2017, CURR BIOL, V27, P3487, DOI 10.1016/j.cub.2017.09.047; Ngoubangoye B, 2016, INT J PARASITOL, V46, P737, DOI 10.1016/j.ijpara.2016.06.004; Nicol JTJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097030; Nielsen SCA, 2012, EMERG INFECT DIS, V18, P1163, DOI 10.3201/eid1807.111689; Niemuth JN, 2014, J MED PRIMATOL, V43, P276, DOI 10.1111/jmp.12114; Nishida Toshisada, 2007, Pan Africa News, V14, P5; Nishimura T, 2007, INT J PRIMATOL, V28, P483, DOI 10.1007/s10764-007-9127-7; Nizeyi JB, 2001, J WILDLIFE DIS, V37, P239, DOI 10.7589/0090-3558-37.2.239; Njouom R, 2010, INFECT GENET EVOL, V10, P790, DOI 10.1016/j.meegid.2010.05.002; Nkogue CN, 2016, VIRUS GENES, V52, P671, DOI 10.1007/s11262-016-1360-8; NRC Committee on Animal Nutrition, 2003, NUTR REQ NONH PRIM 2; Nunamaker EA, 2012, COMPARATIVE MED, V62, P131; Nunn CL, 1999, ANIM BEHAV, V58, P229, DOI 10.1006/anbe.1999.1159; Nurcahyo W, 2017, AM J PRIMATOL, V79, DOI 10.1002/ajp.22650; Nutter F. B., 2005, P WILDL DIS ASS ANN, V162, P276; Nutter F. B., 2005, P INT C WILDL DIS AS, P200; Nze-Nkogue C, 2017, INFECT GENET EVOL, V53, P30, DOI 10.1016/j.meegid.2017.05.004; Oelze VM, 2014, J HUM EVOL, V66, P95, DOI [10.1016/j.Thevol.2013.10.003, 10.1016/j.jhevol.2013.10.003]; OTCENASEK M, 1967, MYCOPATH MYCOL APPL, V31, P33, DOI 10.1007/BF02050282; Paixao TA, 2014, J MED PRIMATOL, V43, P118, DOI 10.1111/jmp.12094; Palacios G, 2011, EMERG INFECT DIS, V17, P711, DOI [10.3201/eid1704100883, 10.3201/eid1704.100883]; Paoli T, 2006, AM J PRIMATOL, V68, P333, DOI 10.1002/ajp.20228; Pardo ID, 2012, TOXICOL PATHOL, V40, P624, DOI 10.1177/0192623311436180; Parker CR, 2014, MOL CELL ENDOCRINOL, V387, P35, DOI 10.1016/j.mce.2014.02.010; Parker S, 2013, FUTURE VIROL, V8, P129, DOI 10.2217/FVL.12.130; PAZZAGLIA G, 1994, ACTA TROP, V57, P1, DOI 10.1016/0001-706X(94)90087-6; Peeters M, 2012, CLIN MICROBIOL INFEC, V18, P514, DOI 10.1111/j.1469-0691.2012.03843.x; Phakdeewirot P, 2006, J MED PRIMATOL, V35, P136, DOI 10.1111/j.1600-0684.2006.00156.x; Pijnenborg R, 2011, PLACENTA, V32, P586, DOI 10.1016/j.placenta.2011.05.007; Pijnenborg R, 2011, PLACENTA, V32, P400, DOI 10.1016/j.placenta.2011.02.009; Pomajbikova K, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002140; Pomajbikova K, 2010, J PARASITOL, V96, P1139, DOI 10.1645/GE-2433.1; Pomajbikova K, 2010, AM J PHYS ANTHROPOL, V142, P42, DOI 10.1002/ajpa.21191; POPPER H, 1980, VIRCHOWS ARCH A, V387, P91, DOI 10.1007/BF00428432; Porter BF, 2004, J MED PRIMATOL, V33, P38, DOI 10.1111/j.1600-0684.2003.00048.x; Prado-Martinez J, 2013, NATURE, V499, P471, DOI 10.1038/nature12228; Preuschoft H, 2002, Anthropol Anz, V60, P67; Prufer K, 2012, NATURE, V486, P527, DOI 10.1038/nature11128; Rae TC, 2000, J HUM EVOL, V38, P411, DOI 10.1006/jhev.1999.0357; RASMUSSEN AT, 1952, ANAT REC, V113, P325, DOI 10.1002/ar.1091130307; Reddacliff LA, 1997, J ZOO WILDLIFE MED, V28, P153; Reed DL, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-7; Rehmann P, 2003, J COMP PATHOL, V129, P85, DOI 10.1016/S0021-9975(02)00159-7; Reid MJC, 2006, EMERG INFECT DIS, V12, P1902; Reuter G, 2017, REV MED VIROL, V27, DOI 10.1002/rmv.1904; Rideout BA, 1997, VET PATHOL, V34, P15, DOI 10.1177/030098589703400103; Riede T, 2008, J ACOUST SOC AM, V124, P634, DOI 10.1121/1.2924125; Robertson BH, 2001, J VIRAL HEPATITIS, V8, P233, DOI 10.1046/j.1365-2893.2001.00295.x; Rothman JM, 2006, BIOL LETTERS, V2, P321, DOI 10.1098/rsbl.2006.0480; Rothman JM, 2014, J HUM EVOL, V71, P59, DOI 10.1016/j.jhevol.2014.02.016; Rothschild Bruce M, 2005, Curr Rheumatol Rep, V7, P173, DOI 10.1007/s11926-996-0036-0; Rubin S, 2015, J PATHOL, V235, P242, DOI 10.1002/path.4445; Rudicell RS, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001116; Russon AE, 2014, J HUM EVOL, V77, P50, DOI 10.1016/j.jhevol.2014.06.007; Sa-nguanmoo P, 2010, PRIMATES, V51, P167, DOI 10.1007/s10329-009-0172-z; Sadeuh-Mba SA, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003052; Saez H., 1975, Mykosen, V18, P519; SAGARTZ JW, 1974, J AM VET MED ASSOC, V165, P844; Sak B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109751; Sakamaki T, 2016, PRIMATES, V57, P295, DOI 10.1007/s10329-016-0529-z; Sakulwira K, 2002, BMC MICROBIOL, V2, DOI 10.1186/1471-2180-2-11; Sall AA, 2005, J GEN VIROL, V86, P333, DOI 10.1099/vir.0.80274-0; Scally A, 2012, NATURE, V483, P169, DOI 10.1038/nature10842; Schmidt DA, 2006, J ZOO WILDLIFE MED, V37, P292, DOI 10.1638/05-040.1; SCHMIDT RE, 1978, J MED PRIMATOL, V7, P274; SCHON MA, 1969, P NATL ACAD SCI USA, V63, P1174, DOI 10.1073/pnas.63.4.1174; Schovancova K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081374; SCHULMAN FY, 1995, J ZOO WILDLIFE MED, V26, P43; SCOTT GBD, 1980, J ANAT, V131, P549; SEIBOLD HR, 1970, LAB ANIM CARE, V20, P514; Seiler BM, 2009, J MED PRIMATOL, V38, P51, DOI 10.1111/j.1600-0684.2008.00307.x; Seimon TA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118543; Semendeferi K, 2000, J HUM EVOL, V38, P317, DOI 10.1006/jhev.1999.0381; Sharp CP, 2010, J VIROL, V84, P10289, DOI 10.1128/JVI.01304-10; Sheppard MN, 2011, PRACTICAL CARDIOVASCULAR PATHOLOGY, 2ND EDITION, P133; Sheppard MN, 2012, J CLIN PATHOL, V65, P484, DOI 10.1136/jclinpath-2011-200366; Siegal-Willott JL, 2015, J ZOO WILDLIFE MED, V46, P27, DOI 10.1638/2014-0034R.1; Skiadopoulos MH, 2002, VIROLOGY, V297, P153, DOI 10.1006/viro.2002.1416; Slater OM, 2014, EMERG INFECT DIS, V20, P2115, DOI 10.3201/eid2012.140408; Sleeman JM, 2000, J ZOO WILDLIFE MED, V31, P322; SMITH AW, 1983, SCIENCE, V221, P79, DOI 10.1126/science.6304880; SMITH AW, 1985, AM J VET RES, V46, P2197; Smith HF, 2009, J EVOLUTION BIOL, V22, P1984, DOI 10.1111/j.1420-9101.2009.01809.x; Snyder R.L., 1978, P33; SODARO CA, 1988, ZOO BIOL, V7, P173, DOI 10.1002/zoo.1430070211; Soike K. F., 1969, EXP MOL PATHOL, V14, P373; SOIKE KF, 1969, EXP MOL PATHOL, V11, P323, DOI 10.1016/0014-4800(69)90018-5; SOIKE KF, 1969, EXP MOL PATHOL, V11, P333, DOI 10.1016/0014-4800(69)90019-7; SOLLEVELD HA, 1984, LAB ANIM SCI, V34, P86; SOMA H, 1983, PLACENTA, V4, P279, DOI 10.1016/S0143-4004(83)80007-1; Spahr C., 2017, EPIDEMIOL INFECT, V23, P1; Spelman LH, 2013, J ZOO WILDLIFE MED, V44, P1027, DOI 10.1638/2013-0014R.1; Steele J, 2013, HUM BIOL, V85, P639, DOI 10.3378/027.085.0501; Steiner MS, 1999, J UROLOGY, V162, P1454, DOI 10.1016/S0022-5347(05)68340-1; Steinetz BG, 1996, J MED PRIMATOL, V25, P17, DOI 10.1111/j.1600-0684.1996.tb00188.x; Steinmetz H. A., 2011, FOWLERS ZOO WILD ANI, V7, P422; Stephens N, 2013, EPIDEMIOL INFECT, V141, P1488, DOI 10.1017/S095026881300068X; Stoddart D. M., 1998, HUM EVOL, V13, P73; Straus W. L., 1937, Journal of Mammalogy, V18, P501, DOI 10.2307/1374344; Strong VJ, 2016, J ZOO WILDLIFE MED, V47, P697; SUNDBERG JP, 1992, J VET DIAGN INVEST, V4, P70, DOI 10.1177/104063879200400115; Susic D, 2008, NAT CLIN PRACT CARD, V5, P104, DOI 10.1038/ncpcardio1091; Suzuki K, 2010, J CLIN MICROBIOL, V48, P3432, DOI 10.1128/JCM.00017-10; Swindler D.R, 1982, ATLAS PRIMATE GROSS; Szentiks CA, 2009, J MED PRIMATOL, V38, P236, DOI 10.1111/j.1600-0684.2009.00346.x; TENAZA RR, 1976, Z TIERPSYCHOL, V40, P37; Tennie C, 2014, J HUM EVOL, V71, P38, DOI 10.1016/j.jhevol.2014.02.015; Terio KA, 2018, AM J PRIMATOL, V80, DOI 10.1002/ajp.22572; Terio KA, 2011, J ZOO WILDLIFE MED, V42, P597, DOI 10.1638/2010-0237.1; THUNG SN, 1981, AM J PATHOL, V105, P328; TRUPKIEWICZ JG, 1995, J ZOO WILDLIFE MED, V26, P123; TSUCHIYA Y, 1970, JPN J MED SCI BIOL, V23, P71, DOI 10.7883/yoken1952.23.71; Unwin S, 2013, J ZOO WILDLIFE MED, V44, P105, DOI 10.1638/1042-7260-44.1.105; Van Brussel M, 1998, VIROLOGY, V243, P366, DOI 10.1006/viro.1998.9075; van der Linden M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008286; van Persie J, 2016, MICROBIOL RESOUR ANN, V4, DOI 10.1128/genomeA.01406-15; VANRANST M, 1991, J ORAL PATHOL MED, V20, P325; Varki NM, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0225; Verschoor EJ, 2004, J VIROL, V78, P12712, DOI 10.1128/JVI.78.22.12712-12716.2004; Verweij JJ, 2007, AM J TROP MED HYG, V77, P685, DOI 10.4269/ajtmh.2007.77.685; Videan EN, 2008, AM J PRIMATOL, V70, P327, DOI 10.1002/ajp.20494; Videan EN, 2007, ZOO BIOL, V26, P93, DOI 10.1002/zoo.20122; VILENSKY J A, 1978, Primates, V19, P363, DOI 10.1007/BF02382804; Vogel ER, 2012, BIOL LETTERS, V8, P333, DOI 10.1098/rsbl.2011.1040; Voisin JL, 2006, ANAT REC PART A, V288A, P944, DOI 10.1002/ar.a.20354; Walsh PD, 2003, NATURE, V422, P611, DOI 10.1038/nature01566; Walters M, 2017, MICROBIOL RESOUR ANN, V5, DOI 10.1128/genomeA.01715-16; Wang T, 2012, DIAGN HISTOPATHOL, V18, P461, DOI DOI 10.1016/J.MPDHP.2012.09.004; Warren KS, 1998, J MED PRIMATOL, V27, P33, DOI 10.1111/j.1600-0684.1998.tb00066.x; WATERS MFR, 1978, BRIT J EXP PATHOL, V59, P551; Wevers D, 2011, J VIROL, V85, P10774, DOI 10.1128/JVI.00810-11; WHITE RJ, 1972, J AM VET MED ASSOC, V161, P690; WHITTEN AJ, 1982, FOLIA PRIMATOL, V37, P177, DOI 10.1159/000156032; Whittier C. W., 2010, THESIS N CAROLINA ST; Wildman DE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024509; Williams JM, 2008, AM J PRIMATOL, V70, P766, DOI 10.1002/ajp.20573; Williams SA, 2015, EVOL ANTHROPOL, V24, P15, DOI 10.1002/evan.21437; Williams SA, 2012, J EXP ZOOL PART B, V318B, P134, DOI 10.1002/jezb.21451; WILSON P, 1984, LAB ANIM, V18, P383, DOI 10.1258/002367784780865351; Winkler LA, 1996, AM J PHYS ANTHROPOL, V99, P191; Wolf TM, 2016, ECOHEALTH, V13, P139, DOI 10.1007/s10393-015-1063-y; WRIGHT J, 1982, J MED PRIMATOL, V11, P67; Wyers M, 1999, J INFECT DIS, V179, pS54, DOI 10.1086/514300; Xue YL, 2015, SCIENCE, V348, P242, DOI 10.1126/science.aaa3952; Yaguchi Y, 2014, PARASITOL RES, V113, P4105, DOI 10.1007/s00436-014-4080-9; Yeo DSY, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-248; Yoshida T, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01262; Yu N, 2003, GENETICS, V164, P1511	433	0	0	3	3	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							375	+		10.1016/B978-0-12-805306-5.00015-8			62	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300017					2019-10-28	
B	Landolfi, JA; Terrell, SP		Terio, KA; McAloose, D; StLeger, J		Landolfi, Jennifer A.; Terrell, Scott P.			Proboscidae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							ELEPHANTS ELEPHAS-MAXIMUS; MYCOBACTERIUM-TUBERCULOSIS INFECTION; WILD AFRICAN ELEPHANT; ENCEPHALOMYOCARDITIS-VIRUS-INFECTION; ASIAN ELEPHANTS; ENDOTHELIOTROPIC HERPESVIRUSES; LOXODONTA-AFRICANA; CANCER RESISTANCE; DISEASE; ARTERIOSCLEROSIS		[Landolfi, Jennifer A.] Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA; [Terrell, Scott P.] Walt Disney Pk & Resorts, Orlando, FL USA	Landolfi, JA (reprint author), Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA.						Abegglen LM, 2015, JAMA-J AM MED ASSOC, V314, P1850, DOI 10.1001/jama.2015.13134; Agnew DW, 2004, VET PATHOL, V41, P179, DOI 10.1354/vp.41-2-179; ALLEN KB, 1974, J PARASITOL, V60, P952, DOI 10.2307/3278523; Atkins L, 2013, J ZOO WILDLIFE MED, V44, P136, DOI 10.1638/1042-7260-44.1.136; BASSON P A, 1971, Onderstepoort Journal of Veterinary Research, V38, P239; Bonar CJ, 2005, J ZOO WILDLIFE MED, V36, P719, DOI 10.1638/03-111.1; BROWN IRF, 1980, COMP BIOCHEM PHYS B, V65, P1, DOI 10.1016/0305-0491(80)90107-8; BROWN R J, 1973, Journal of Wildlife Diseases, V9, P227; Brown RE, 1997, RESP PHYSIOL, V109, P177, DOI 10.1016/S0034-5687(97)00038-8; Bryden H. B., 1996, SALISBURY MED B S, V87, P116; Casola C, 2016, JAMA-J AM MED ASSOC, V315, P1788, DOI 10.1001/jama.2016.0440; Chakraborty A., 1992, Indian Journal of Veterinary Pathology, V16, P98; CHAKRABORTY T, 1990, Indian Veterinary Medical Journal, V14, P213; Chandranaik BM, 2017, EMERG INFECT DIS, V23, P555, DOI 10.3201/eid2303.161439; Davis M, 2001, Appl Occup Environ Hyg, V16, P350, DOI 10.1080/104732201750154125; Denk D, 2012, VET REC, V171, P380, DOI 10.1136/vr.e6833; DILLMAN JS, 1970, J COMP PATHOL, V80, P81, DOI 10.1016/0021-9975(70)90034-4; Dumonceaux GA, 2011, J ZOO WILDLIFE MED, V42, P709, DOI 10.1638/2011-0040.1; Dumonceaux Genevieve A., 2006, P299, DOI 10.1002/9780470344484.ch22; Easwaran K. R., 2003, Zoos' Print Journal, V18, P1030; Ehlers B, 2001, J GEN VIROL, V82, P475, DOI 10.1099/0022-1317-82-3-475; ENGEL S, 1952, ACTA ANAT, V16, P308; ENGEL S, 1963, ACTA ANAT, V55, P105; Feldman M, 2013, VET QUART, V33, P28, DOI 10.1080/01652176.2013.772690; Fickel J, 2001, VET MICROBIOL, V82, P103, DOI 10.1016/S0378-1135(01)00363-7; Fowler M. E., 2006, BIOL MED SURG ELEPHA, P1331; Fowler ME, 2001, ELEPHANT'S FOOT, P3; Fowler Murray E., 2006, P271, DOI 10.1002/9780470344484.ch20; Fowler Murray E., 2006, P159, DOI 10.1002/9780470344484.ch12; Fraunfelder F, 2006, J ZOO WILDLIFE MED, V37, P424, DOI 10.1638/05-090.1; Garner MM, 2009, VET PATHOL, V46, P97, DOI 10.1354/vp.46-1-97; Gates C. Cormack, 2001, P396, DOI 10.1002/9780470344880.ch23; Grabarevic Z, 2013, J ZOO WILDLIFE MED, V44, P1049, DOI 10.1638/2011-0119R4.1; GRABER M, 1979, REV ELEV MED VET PAY, V32, P257, DOI 10.19182/remvt.8148; GROBLER DG, 1995, ONDERSTEPOORT J VET, V62, P97; Hedger R. S., 1981, INFECT DIS WILD MAMM; Hoby S, 2014, J ZOO WILDLIFE MED, V45, P406, DOI 10.1638/2013-0149R.1; HOWELL P G, 1973, Onderstepoort Journal of Veterinary Research, V40, P41; Isaza Ramiro, 2006, P291, DOI 10.1002/9780470344484.ch21; JACOBSON ER, 1986, J AM VET MED ASSOC, V189, P1075; JANSSEN DL, 1984, J AM VET MED ASSOC, V185, P1450; Jeffery J., 1999, Tropical Biomedicine, V16, P51; Keet DF, 1997, ONDERSTEPOORT J VET, V64, P25; KOCK ND, 1994, J WILDLIFE DIS, V30, P432, DOI 10.7589/0090-3558-30.3.432; Kretzschmar G., 1972, VEH INT S ERKR ZOO W, P197; Lamglait B, 2015, J ZOO WILDLIFE MED, V46, P393, DOI 10.1638/2014-0132R1.1; Landolfi JA, 2015, VET PATHOL, V52, P535, DOI 10.1177/0300985814548517; Landolfi JA, 2014, TUBERCULOSIS, V94, P374, DOI 10.1016/j.tube.2014.03.001; Landolfi JA, 2010, J ZOO WILDLIFE MED, V41, P445, DOI 10.1638/2009-0163.1; LEWIS JH, 1974, COMP BIOCHEM PHYSIOL, V49, P175, DOI 10.1016/0300-9629(74)90553-2; Lewis KD, 2010, ZOO BIOL, V29, P221, DOI 10.1002/zoo.20291; Liu CH, 2004, J VET DIAGN INVEST, V16, P421, DOI 10.1177/104063870401600508; Long SY, 2015, ILAR J, V56, P283, DOI 10.1093/ilar/ilv041; Lopes A., 2002, Garcia De Orta Serie de Zoologia, V24, P75; Luikart KA, 2005, J ZOO WILDLIFE MED, V36, P684, DOI 10.1638/04088.1; Maslow JN, 2015, VET PATHOL, V52, P437, DOI 10.1177/0300985814568357; Masters NJ, 2011, VET REC, V169, p209A, DOI 10.1136/vr.d4226; Mbise A. N., 1998, Bulletin of Animal Health and Production in Africa, V46, P95; MCCULLAGH K, 1967, LANCET, V2, P492; MCCULLAGH KG, 1972, ATHEROSCLEROSIS, V16, P307, DOI 10.1016/0021-9150(72)90080-9; MCCULLAGH KG, 1975, ATHEROSCLEROSIS, V21, P37, DOI 10.1016/0021-9150(75)90093-3; McCully R.M., 1971, Onderstepoort Journal of Veterinary Research, V38, P225; MCKINNEY B, 1970, J COMP PATHOL, V80, P275, DOI 10.1016/0021-9975(70)90095-2; Michalak K, 1998, EMERG INFECT DIS, V4, P283, DOI 10.3201/eid0402.980217; Mikota SK, 2001, J ZOO WILDLIFE MED, V32, P1; Mikota SK, 2011, TUBERCULOSIS, V91, P208, DOI 10.1016/j.tube.2011.02.007; Mikota Susan K., 2006, P253, DOI 10.1002/9780470344484.ch18; Mikota Susan K., 2006, P325, DOI 10.1002/9780470344484.ch25; Montali Richard J., 2006, P199, DOI 10.1002/9780470344484.ch14; Montali RJ, 2001, REV SCI TECH OIE, V20, P291, DOI 10.20506/rst.20.1.1268; Morner Torsten, 2001, P505; MUNSON L, 1986, J AM VET MED ASSOC, V189, P1190; Munson L, 1995, J ZOO WILDLIFE MED, V26, P353; Murata K., 2002, J ZOO WILDLIFE MED, V7, P154; Murphree R, 2011, EMERG INFECT DIS, V17, P366, DOI [10.3201/eid1703.101668, 10.3201/eid1703101668]; MUSTAFA AHM, 1984, VET REC, V114, P590, DOI 10.1136/vr.114.24.590; Obanda V, 2013, EPIDEMIOL INFECT, V141, P1476, DOI 10.1017/S0950268813000022; OSSENT P, 1990, VET PATHOL, V27, P131, DOI 10.1177/030098589002700212; Payeur JB, 2002, ANN NY ACAD SCI, V969, P256, DOI 10.1111/j.1749-6632.2002.tb04388.x; Pessier AP, 2016, JAMA-J AM MED ASSOC, V315, P1789, DOI 10.1001/jama.2016.0449; Pilaski J., 1991, VERHANDLUNGSBERICHT, P203; PYAKURAL S, 1976, VET REC, V99, P28, DOI 10.1136/vr.99.2.28; Raubenheimer E. J., 1989, J S AFR VET ASSOC, V60; Richman LK, 1999, SCIENCE, V283, P1171, DOI 10.1126/science.283.5405.1171; Richman LK, 2000, J WILDLIFE DIS, V36, P1, DOI 10.7589/0090-3558-36.1.1; RITCHIE BW, 1986, J AM VET MED ASSOC, V189, P1192; Robinson Anthony J., 2001, P179, DOI 10.1002/9780470344880.ch8; ROBINSON PT, 1977, VET MED SM ANIM CLIN, V72, P1638; Rutkowski C, 2001, ELEPHANT'S FOOT, P85; Sapundzhiev E, 2007, J VET MED A, V54, P499, DOI 10.1111/j.1439-0442.2007.00949.x; Schmitt Dennis, 2006, P347, DOI 10.1002/9780470344484.ch26; Schmitt DL, 2003, ZOO WILD ANIMAL MED, P541; SEAMAN JT, 1987, J WILDLIFE DIS, V23, P170, DOI 10.7589/0090-3558-23.1.170; Sharma D. K., 1994, Indian Journal of Veterinary Pathology, V18, P55; Shoshani Jeheskel, 2006, P3, DOI 10.1002/9780470344484.ch1; SILVA ID, 1993, J ZOO WILDLIFE MED, V24, P434; Simpson G, 2017, EMERG INFECT DIS, V23, P513, DOI 10.3201/eid2303.160726; SINGH KP, 1994, INDIAN J ANIM SCI, V64, P802; SMUTS MMS, 1993, ONDERSTEPOORT J VET, V60, P1; SMUTS MMS, 1994, ONDERSTEPOORT J VET, V61, P51; Soma H, 2013, PLACENTA, V34, pS17, DOI 10.1016/j.placenta.2012.11.021; SREEKUMAR KP, 1990, INDIAN J ANIM SCI, V60, P1061; Sripiboon S, 2013, J ZOO WILDLIFE MED, V44, P100, DOI 10.1638/1042-7260-44.1.100; Steenkamp Gerhard, 2003, Veterinary Clinics of North America Exotic Animal Practice, V6, P689, DOI 10.1016/S1094-9194(03)00035-5; Stevens H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077884; SUNDBERG JP, 1981, J AM VET MED ASSOC, V179, P1247; Thompson G. R., 2001, INFECT DIS WILD MAMM, P124; WELLS SK, 1989, J ZOO WILDLIFE MED, V20, P291; WERLE E, 1968, PATHOL VET, V5, P81, DOI 10.1177/030098586800500110; Wilkie GS, 2014, SCI REP-UK, V4, DOI 10.1038/srep06299; WINDSOR R S, 1972, Tropical Animal Health and Production, V4, P214, DOI 10.1007/BF02360113; ZACHARIAH A, 2013, J WILDLIFE DIS, V49, P383; Zachariah A, 2017, EMERG INFECT DIS, V23, P504, DOI 10.3201/eid2303.161741; Zlot A, 2016, MMWR-MORBID MORTAL W, V64, P1398, DOI 10.15585/mmwr.mm6452a2; Zong JC, 2016, J VIROL, V90, P3028, DOI 10.1128/JVI.02936-15	115	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							413	+		10.1016/B978-0-12-805306-5.00016-X			8	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300018					2019-10-28	
B	Duncan, M		Terio, KA; McAloose, D; StLeger, J		Duncan, Mary			Perissodactyls	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							RHINOCEROS DICEROS-BICORNIS; EQUINE HERPESVIRUS TYPE-1; IRON STORAGE DISEASE; BLACK RHINOCEROS; VITAMIN-E; MYCOBACTERIUM-BOVIS; TAPIRUS TERRESTRIS; HEMOLYTIC-ANEMIA; ZEBRA; INFECTION									Abou-Madi Noha, 1996, American Association of Zoo Veterinarians Annual Conference Proceedings, V1996, P421; Bauwens L, 1996, J ZOO WILDLIFE MED, V27, P271; Bertelsen MF, 2004, J ZOO WILDLIFE MED, V35, P245, DOI 10.1638/03-052; Beutler E, 2001, BLOOD CELL MOL DIS, V27, P342, DOI 10.1006/bcmd.2001.0386; Bishop GT, 2016, J ZOO WILDLIFE MED, V47, P855; Bonar CJ, 2006, J ZOO WILDLIFE MED, V37, P49, DOI 10.1638/03-032.1; Bryant B, 2012, J ZOO WILDLIFE MED, V43, P391, DOI 10.1638/2010-0161.1; Citino S., 2017, P AM ASS ZOO VET DAL, P105; CLAUSEN B, 1981, J WILDLIFE DIS, V17, P105, DOI 10.7589/0090-3558-17.1.105; Cozzuol MA, 2013, J MAMMAL, V94, P1331, DOI 10.1644/12-MAMM-A-169.1; Cray C, 2013, J ZOO WILDLIFE MED, V44, P1107, DOI 10.1638/2013-0033R.1; Da Silva MAO, 2011, J ZOO WILDLIFE MED, V42, P40, DOI 10.1638/2009-0247.1; Da Silveira AW, 2017, J WILDLIFE DIS, V53, P411, DOI 10.7589/2016-06-149; Dennis P, 1999, P AM ASS ZOO VET, V1999, P163; Dierenfeld ES, 1995, J ZOO WILDLIFE MED, V26, P220; DIERENFELD ES, 1988, J WILDLIFE DIS, V24, P547, DOI 10.7589/0090-3558-24.3.547; DILLEHAY DL, 1991, J ZOO WILDLIFE MED, V22, P237; Dorsey CL, 2010, J ZOO WILDLIFE MED, V41, P22, DOI 10.1638/2008-0188.1; DOUGLASS EM, 1980, J AM VET MED ASSOC, V177, P921; Espie IW, 2009, J WILDLIFE DIS, V45, P1187, DOI 10.7589/0090-3558-45.4.1187; Finnegan M., 1993, Proceedings of the American Association of Zoo Veterinarians, Saint Louis, 10-15 October 1993, P416; FLEMING J, 2003, P AM ASS ZOO VET MIN, P21; Gandolf AR, 2006, J ZOO WILDLIFE MED, V37, P387; Ganz T, 2012, J ZOO WILDLIFE MED, V43, pS19, DOI 10.1638/2011-0158.1; Goltenboth Reinhard, 1996, American Association of Zoo Veterinarians Annual Conference Proceedings, V1996, P18; Hawkins E, 2015, J WILDLIFE DIS, V51, P137, DOI 10.7589/2013-11-316; Helmick KE, 2012, J ZOO WILDLIFE MED, V43, P876, DOI 10.1638/2011-0174R.1; Hermes R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092595; Hernandez-Divers SM, 2005, J ZOO WILDLIFE MED, V36, P176, DOI 10.1638/04-004.1; Houszka M, 2014, J ZOO WILDLIFE MED, V45, P635, DOI 10.1638/2012-0213R5.1; Isaza R, 2000, J ZOO WILDLIFE MED, V31, P77; ISAZA R, J ZOO WILDL MED, V31, P77; Janssen D. L., 2003, ZOO WILD ANIMAL MED, P569; Janssen D. L., 2015, ZOO WILD ANIMAL MED, V8, P559; Janssen Donald L., 1999, P562; Janssen Donald L., 1996, American Association of Zoo Veterinarians Annual Conference Proceedings, V1996, P1; JESSUP DA, 1992, J ZOO WILDLIFE MED, V23, P401; Jurczynski K, 2011, J ZOO WILDLIFE MED, V42, P222, DOI 10.1638/2009-0207.1; Kenny DE, 1999, J ZOO WILDLIFE MED, V30, P383; Kenny DE, 1997, J ZOO WILDLIFE MED, V28, P307; Kenny DE, 1996, J ZOO WILDLIFE MED, V27, P259; KOCK MD, 1990, J ZOO WILDLIFE MED, V21, P283; KOCK N, 1991, J ZOO WILDLIFE MED, V22, P355; KOCK N, 1992, J ZOO WILDLIFE MED, V23, P230; KOCK ND, 1994, J ZOO WILDLIFE MED, V25, P270; KOCK ND, 1992, J ZOO WILDLIFE MED, V23, P409; Kock ND, 1996, J WILDLIFE DIS, V32, P367, DOI 10.7589/0090-3558-32.2.367; Kuehn G., 1986, P931; Lankau EW, 2012, EMERG INFECT DIS, V18, P1202, DOI 10.3201/eid1807.120081; Lankton JS, 2014, J ZOO WILDLIFE MED, V45, P708, DOI 10.1638/2013-0272R1.1; Lewis S, 2016, J ZOO WILDLIFE MED, V47, P876; LIU SK, 1983, J AM VET MED ASSOC, V183, P1266; Lohr CV, 2005, J ZOO WILDLIFE MED, V36, P74, DOI 10.1638/03-126; Love D, 2017, J ZOO WILDLIFE MED, V48, P466, DOI 10.1638/2016-0081R.1; LozanoAlarcon F, 1997, VET PATHOL, V34, P239, DOI 10.1177/030098589703400312; Marais HJ, 2011, J WILDLIFE DIS, V47, P917, DOI 10.7589/0090-3558-47.4.917; Marsh AE, 2000, J ZOO WILDLIFE MED, V31, P82; McCulloch B., 1969, International Zoo Yearbook, V9, P184, DOI 10.1111/j.1748-1090.1969.tb02681.x; Miller M, 2017, TRANSBOUND EMERG DIS, V64, P1071, DOI 10.1111/tbed.12489; Miller MA, 2015, ZOO WILD ANIMAL MED, V8, P538; Miller M, 2008, J ZOO WILDLIFE MED, V39, P56, DOI 10.1638/2007-0001.1; Miller MA, 2017, EMERG INFECT DIS, V23, P557, DOI 10.3201/eid2303.161622; Miller R. Eric, 1996, American Association of Zoo Veterinarians Annual Conference Proceedings, V1996, P22; Miller R. Eric, 1993, P455; MILLER RE, 1990, J ZOO WILDLIFE MED, V21, P192; MILLER RE, 1982, J AM VET MED ASSOC, V181, P1228; Miller RE, 2003, ZOO WILD ANIMAL MED, P558; Molenaar FM, 2016, J ZOO AQUAR RES, V4, P105; MONTALI RJ, 1985, J AM VET MED ASSOC, V187, P1248; MONTALI RJ, 1974, VET PATHOL, V11, P68, DOI 10.1177/030098587401100108; Munson L, 1998, VET PATHOL, V35, P31, DOI 10.1177/030098589803500103; Munson Linda, 1999, P551; Murakami PS, 2012, J ZOO WILDLIFE MED, V43, P872, DOI 10.1638/2010-0108R.1; Murphy MR, 1997, ZOO BIOL, V16, P427, DOI 10.1002/(SICI)1098-2361(1997)16:5<427::AID-ZOO5>3.0.CO;2-C; Murray S, 2000, J AM VET MED ASSOC, V216, P230, DOI 10.2460/javma.2000.216.230; Mutinda M, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-206; Neiffer DL, 2001, J ZOO WILDLIFE MED, V32, P476; Nelson L., 1986, P934; Nelson L., 1986, P926; Nelson L., 1986, ZOO WILD ANIMAL MED; Nowak RM, 1999, WALKERS MAMMALS WORL; Olias P, 2012, J COMP PATHOL, V147, P542, DOI 10.1016/j.jcpa.2012.07.005; Otiende MY, 2015, BMC VET RES, V11, DOI 10.1186/s12917-014-0316-2; Pagan O., 2009, International Zoo Yearbook, V43, P198, DOI 10.1111/j.1748-1090.2008.00072.x; Paglia D. E., 2000, P AM ASS ZOO VET, P124; Paglia DE, 2000, VET PATHOL, V37, P86, DOI 10.1354/vp.37-1-86; Paglia DE, 2012, J ZOO WILDLIFE MED, V43, pS92, DOI 10.1638/2011-0177.1; Paglia Donald E., 1992, American Association of Zoo Veterinarians Annual Proceedings, V1992, P217; Paglia Donald E., 1993, International Zoo Yearbook, V32, P20; PAPAS AM, 1991, J ZOO WILDLIFE MED, V22, P309; Pessier AP, 2004, J ZOO WILDLIFE MED, V35, P1, DOI 10.1638/03-039; Phillips Lyndsey G. Jr, 1999, P572; Radcliffe RW, 1998, J ZOO WILDLIFE MED, V29, P465; Ramsay Edward C., 1993, P459; Reese Kirk W., 1996, American Association of Zoo Veterinarians Annual Conference Proceedings, V1996, P425; Regnault S, 2013, J ZOO WILDLIFE MED, V44, P918, DOI 10.1638/2012-0277R1.1; Robert N, 2005, J ZOO WILDLIFE MED, V36, P273, DOI 10.1638/03-035.1; SCHMIDT RE, 1982, J ZOO ANIM MED, V13, P3, DOI 10.2307/20094554; Smith JE, 1995, J ZOO WILDLIFE MED, V26, P525; Sommanustweechai A, 2010, J ZOO WILDLIFE MED, V41, P165, DOI 10.1638/2009-0048.1; Suedmeyer K, 2006, J ZOO WILDLIFE MED, V37, P420; Takle GL, 2010, J ZOO WILDLIFE MED, V41, P545, DOI 10.1638/2009-0232.1; Terio KA, 2003, J ZOO WILDLIFE MED, V34, P339, DOI 10.1638/02-005; THAPA J, 2016, NEPAL EMERG INFECT D, V22, P570, DOI DOI 10.3201/EID2203.151929; Tjornelund KB, 2015, J ZOO WILDLIFE MED, V46, P363, DOI 10.1638/2013-0198R2.1; Vercammen F, 2017, OPEN VET J, V7, P100, DOI 10.4314/ovj.v7i2.4; von Houwald F., 2016, International Zoo Yearbook, V50, P215, DOI 10.1111/izy.12116; Wack RF, 1997, J ZOO WILDLIFE MED, V28, P285; Wallace RS, 2009, J ZOO WILDLIFE MED, V40, P365, DOI 10.1638/2008-0077.1; Walzer C., 2003, ZOO WILD ANIMAL MED, P578; Weber M, 1997, J ZOO WILDLIFE MED, V28, P105; Weber Martha, 1996, American Association of Zoo Veterinarians Annual Conference Proceedings, V1996, P34; Wilson M, 2010, J ZOO WILDLIFE MED, V41, P111, DOI 10.1638/2009-0128.1; WOLFF PL, 1986, J AM VET MED ASSOC, V189, P1185; YAMINI B, 1988, J WILDLIFE DIS, V24, P703, DOI 10.7589/0090-3558-24.4.703; Zimmerman D. M., 2015, FOWLERS ZOO WILD ANI, V8, P547	116	2	2	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							433	+		10.1016/B978-0-12-805306-5.00017-1			30	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300019					2019-10-28	
B	Higgins, D; Rose, K; Spratt, D		Terio, KA; McAloose, D; StLeger, J		Higgins, Damien; Rose, Karrie; Spratt, David			Monotremes and Marsupials	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							KANGAROOS MACROPUS-GIGANTEUS; KOALAS PHASCOLARCTOS-CINEREUS; EASTERN BARRED BANDICOOTS; NEOFORMANS VAR. GATTII; ECHINOCOCCUS-GRANULOSUS; TOXOPLASMA-GONDII; SARCOPTIC MANGE; SPONTANEOUS PROLIFERATIONS; AUSTRALIAN MARSUPIALS; DISEASE		[Higgins, Damien; Rose, Karrie] Univ Sydney, Sydney, NSW, Australia; [Rose, Karrie] Australian Registry Wildlife Hlth, Taronga Conservat Soc Australia, Mosman, NSW, Australia; [Spratt, David] CSIRO, Australian Natl Wildlife Collect, Canberra, ACT, Australia	Higgins, D (reprint author), Univ Sydney, Sydney, NSW, Australia.						ARUNDEL JH, 1979, AUST WILDLIFE RES, V6, P361, DOI 10.1071/WR9790361; ARUNDEL JH, 1990, AUST WILDLIFE RES, V17, P39; Arundel JH, 1977, BIOL MARSUPIALS, P141; Astudillo VG, 2015, J COMP PATHOL, V152, P283, DOI 10.1016/j.jcpa.2015.01.004; ATTWOOD H D, 1975, Journal of Wildlife Diseases, V11, P543; Attwood H. D., 1972, PATHOLOGY, V70, P50; Bacci B, 2014, AUST VET J, V92, P504, DOI 10.1111/avj.12272; BACKHOUSE TC, 1959, J PROTOZOOL, V6, P320, DOI 10.1111/j.1550-7408.1959.tb04377.x; BARKER IK, 1978, AUST J ZOOL, V26, P435, DOI 10.1071/ZO9780435; Bennett MD, 2008, VIROLOGY, V376, P173, DOI 10.1016/j.virol.2008.03.014; Bettiol SS, 2000, J WILDLIFE DIS, V36, P145, DOI 10.7589/0090-3558-36.1.145; BEVERIDGE I, 1984, Transactions of the Royal Society of South Australia, V108, P197; BEVERIDGE I, 1985, J WILDLIFE DIS, V21, P377, DOI 10.7589/0090-3558-21.4.377; BEVERIDGE I, 1978, INT J PARASITOL, V8, P379, DOI 10.1016/0020-7519(78)90036-X; BEVERIDGE I, 1979, J HELMINTHOL, V53, P229, DOI 10.1017/S0022149X00006015; BROWN AS, 1982, AUST VET J, V58, P8, DOI 10.1111/j.1751-0813.1982.tb00569.x; BROWN CC, 1988, J WILDLIFE DIS, V24, P214, DOI 10.7589/0090-3558-24.2.214; Buddle BM, 2000, DEV COMP IMMUNOL, V24, P517, DOI 10.1016/S0145-305X(00)00014-8; CANFIELD PJ, 1990, AUST VET J, V67, P342, DOI 10.1111/j.1751-0813.1990.tb07824.x; CANFIELD PJ, 1991, J COMP PATHOL, V105, P167, DOI 10.1016/S0021-9975(08)80072-2; CANFIELD PJ, 1989, AUST VET J, V66, P103, DOI 10.1111/j.1751-0813.1989.tb09758.x; CANFIELD PJ, 1990, J COMP PATHOL, V103, P147, DOI 10.1016/S0021-9975(08)80171-5; CANFIELD PJ, 1990, J COMP PATHOL, V103, P159, DOI 10.1016/S0021-9975(08)80172-7; CANFIELD PJ, 1990, J COMP PATHOL, V103, P135, DOI 10.1016/S0021-9975(08)80170-3; Carrick F. N., 1991, KOALAS RES MANAGEMEN, P65; Chand KK, 2016, SCI REP-UK, V6, DOI 10.1038/srep29446; Chappell KJ, 2017, J VIROL, V91, DOI 10.1128/JVI.01820-16; CHEAL PD, 1976, AUST J ZOOL, V24, P299, DOI 10.1071/ZO9760299; Clark P., 2004, HAEMATOLOGY AUSTR MA, P147; Connolly JH, 2000, J COMP PATHOL, V123, P36, DOI 10.1053/jcpa.2000.0384; Connolly JH, 1998, AUST VET J, V76, P819, DOI 10.1111/j.1751-0813.1998.tb12337.x; Cooper A, 2013, VECTOR-BORNE ZOONOT, V13, P12, DOI 10.1089/vbz.2011.0853; Cribb BW, 2000, J MED ENTOMOL, V37, P316, DOI 10.1603/0022-2585(2000)037[0316:OAMOFL]2.0.CO;2; Dawood Kaiser E., 2013, International Journal for Parasitology Parasites and Wildlife, V2, P54, DOI 10.1016/j.ijppaw.2012.12.001; Denner J, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-108; Dig D, 2008, ICSE'08 PROCEEDINGS OF THE THIRTIETH INTERNATIONAL CONFERENCE ON SOFTWARE ENGINEERING, P441, DOI 10.1145/1368088.1368148; Donahoe SL, 2015, INT J PARASITOL-PAR, V4, P268, DOI 10.1016/j.ijppaw.2015.02.002; Dougall AM, 2011, INT J PARASITOL, V41, P571, DOI 10.1016/j.ijpara.2010.12.008; DUDZINSKI ML, 1977, AUST WILDLIFE RES, V4, P219; Ellis AE, 2012, J ZOO WILDLIFE MED, V43, P367, DOI 10.1638/2011-0181.1; Elsheikha HM, 2003, VET PARASITOL, V115, P321, DOI 10.1016/S0304-4017(03)00221-8; Fancourt Bronwyn A., 2014, International Journal for Parasitology Parasites and Wildlife, V3, P102, DOI 10.1016/j.ijppaw.2014.05.001; Fowler M. F, 2001, BIOL MED SURG S AMER; Fyfe J, 2013, MICROBIOL AUST, V34, P189, DOI 10.1071/MA13066; Garcia ML, 2012, VET MEXICO, V43, P241; Giles J, 2016, VIROLOGY, V491, P20, DOI 10.1016/j.virol.2016.01.005; Hanger J., 2003, P ANN C AUSTR ASS VE, P19; Haynes JI, 2004, HISTOL HISTOPATHOL, V19, P777, DOI 10.14670/HH-19.777; Heatley J. Jill, 2009, Veterinary Clinics of North America Exotic Animal Practice, V12, P99, DOI 10.1016/j.cvex.2008.08.006; Higgins DP, 2005, J COMP PATHOL, V133, P164, DOI 10.1016/j.jcpa.2005.04.005; HOPE M, 1991, INT J PARASITOL, V21, P471, DOI 10.1016/0020-7519(91)90106-H; Hufschmid J, 2015, J COMP PATHOL, V153, P167, DOI 10.1016/j.jcpa.2015.06.002; Hufschmid J, 2011, ECOTOXICOLOGY, V20, P1378, DOI 10.1007/s10646-011-0695-0; Hufschmid J, 2010, AUST J ZOOL, V58, P250, DOI 10.1071/ZO10030; Jenkins DJ, 2006, PARASITOL INT, V55, pS203, DOI 10.1016/j.parint.2005.11.031; Jenkins DJ, 2003, AUST VET J, V81, P81, DOI 10.1111/j.1751-0813.2003.tb11440.x; Johnston SD, 2015, VET PATHOL, V52, P1254, DOI 10.1177/0300985815570069; Kagan RA, 2009, VET PATHOL, V46, P977, DOI 10.1354/vp.08-VP-0246-K-FL; KAKULAS BA, 1966, ANN NY ACAD SCI, V138, P90; Kierdorf U, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147427; Krockenberger MB, 2003, MED MYCOL, V41, P225, DOI 10.1080/369378031000137242; Krockenberger MB, 2002, MED MYCOL, V40, P273, DOI 10.1080/714031114; Kumaratilake L. M., 1982, Helminthological Abstracts, A, V51, P233; Ladds P.W., 2009, PATHOLOGY AUSTR NATI; Legione AR, 2017, J MED MICROBIOL, V66, P236, DOI 10.1099/jmm.0.000416; LENGHAUS C, 1990, MANAGEMENT AND CONSERVATION OF SMALL POPULATIONS, P89; Loh R, 2006, VET PATHOL, V43, P890, DOI 10.1354/vp.43-6-890; Ma GM, 2013, VET PARASITOL, V192, P158, DOI 10.1016/j.vetpar.2012.11.009; Macgregor JW, 2010, AUST VET J, V88, P190, DOI 10.1111/j.1751-0813.2010.00568.x; MACKERRAS M. JOSEPHINE, 1959, AUSTRALIAN JOUR ZOOL, V7, P105, DOI 10.1071/ZO9590105; Maher I. E, 2017, THESIS U SYDNEY AUST; Maher IE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163780; MARTIN RW, 1981, AUST WILDLIFE RES, V8, P275; McLelland DJ, 2005, AUST VET J, V83, P744, DOI 10.1111/j.1751-0813.2005.tb11585.x; MUNDAY B L, 1971, Journal of Wildlife Diseases, V7, P125; MUNDAY BL, 1983, J WILDLIFE DIS, V19, P132, DOI 10.7589/0090-3558-19.2.132; O'Donoghue Peter J., 2000, Memoirs of the Queensland Museum, V45, P1; Obendorf D.L., 1990, P193; OBENDORF DL, 1983, J WILDLIFE DIS, V19, P123, DOI 10.7589/0090-3558-19.2.123; Obendorf DL, 1996, J WILDLIFE DIS, V32, P623, DOI 10.7589/0090-3558-32.4.623; Paparini A, 2012, EXP PARASITOL, V131, P25, DOI 10.1016/j.exppara.2012.02.021; Parameswaran N, 2009, PARASITOLOGY, V136, P939, DOI 10.1017/S0031182009006453; Perrott MRF, 2000, NEW ZEAL VET J, V48, P9, DOI 10.1080/00480169.2000.36150; Pessier A. P., 1999, P AM ASS ZOO VET ANN, P139; Polkinghorne A, 2013, VET MICROBIOL, V165, P214, DOI 10.1016/j.vetmic.2013.02.026; Pye GW, 2013, J ZOO WILDLIFE MED, V44, P273, DOI 10.1638/2012-0031R1.1; Pye RJ, 2016, VET PATHOL, V53, P726, DOI 10.1177/0300985815616444; Pye RJ, 2016, P NATL ACAD SCI USA, V113, P374, DOI 10.1073/pnas.1519691113; Rose K, 2004, INT J PARASITOL, V34, P655, DOI 10.1016/j.ijpara.2004.03.001; Rose KA, 2012, AUST VET J, V90, P505, DOI 10.1111/j.1751-0813.2012.00993.x; Scheelings TF, 2015, AUST VET J, V93, P424, DOI 10.1111/avj.12378; Seymour AM, 2001, ANIM CONSERV, V4, P211, DOI 10.1017/S1367943001001251; Simmons G., 2011, THESIS U QUEENSLAND; Skerratt LF, 1998, AUST VET J, V76, P408, DOI 10.1111/j.1751-0813.1998.tb12389.x; Skerratt LF, 2003, J WILDLIFE DIS, V39, P179, DOI 10.7589/0090-3558-39.1.179; Skerratt LF, 2003, J WILDLIFE DIS, V39, P193, DOI 10.7589/0090-3558-39.1.193; SMALES LR, 1977, INT J PARASITOL, V7, P457, DOI 10.1016/0020-7519(77)90006-6; Smith DW, 2011, TRAVEL MED INFECT DI, V9, P113, DOI 10.1016/j.tmaid.2010.05.005; SPEARE R, 1985, AUST VET PRACT, V15, P11; SPEARE R, 1989, KANGAROOS, WALLABIES AND RAT-KANGAROOS, VOLS 1 AND 2, P705; Speight KN, 2013, AUST J ZOOL, V61, P366, DOI 10.1071/ZO13049; Speight KN, 2013, VET PATHOL, V50, P299, DOI 10.1177/0300985812456215; Spratt DM, 2015, INT J PARASITOL-PAR, V4, P178, DOI 10.1016/j.ijppaw.2015.02.006; Spratt DM, 2005, INT J PARASITOL, V35, P717, DOI 10.1016/j.ijpara.2005.01.014; SPRATT DM, 1981, AUST J EXP BIOL MED, V59, P713, DOI 10.1038/icb.1981.62; Stalder K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133807; STONE BF, 1989, EXP APPL ACAROL, V7, P59, DOI 10.1007/BF01200453; Tarlinton R, 2005, J GEN VIROL, V86, P783, DOI 10.1099/vir.0.80547-0; Thompson Craig K., 2014, International Journal for Parasitology Parasites and Wildlife, V3, P57, DOI 10.1016/j.ijppaw.2014.02.002; Tyndale-Biscoe CH, 1987, REPROD PHYSL MARSUPI; Vogelnest L, 2012, AUST VET J, V90, P143, DOI 10.1111/j.1751-0813.2011.00880.x; Vogelnest L., 1997, P WILDL DIS ASS AUST; Walton D. W, 1989, FAUNA AUSTR MAMMAL B, V1B; Waugh CA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00137-4; WHITTINGTON RJ, 1990, J WILDLIFE DIS, V26, P55, DOI 10.7589/0090-3558-26.1.55; WINTER H., 1958, AUSTRALIAN VET JOUR, V34, P118, DOI 10.1111/j.1751-0813.1958.tb08354.x; Woolford L, 2008, VET PATHOL, V45, P95, DOI 10.1354/vp.45-1-95; Worley M., 1993, Proceedings of the American Association of Zoo Veterinarians, Saint Louis, 10-15 October 1993, P181; Xu WQ, 2015, ANNU REV VIROL, V2, P119, DOI 10.1146/annurev-virology-100114-055056	119	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							455	+		10.1016/B978-0-12-805306-5.00018-3			8	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300020					2019-10-28	
B	Delaney, MA; Treuting, PM; Rothenburger, JL		Terio, KA; McAloose, D; StLeger, J		Delaney, Martha A.; Treuting, Piper M.; Rothenburger, Jamie L.			Lagomorpha	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							DOMESTIC RABBITS; LEPUS-EUROPAEUS; PET RABBITS; INFECTION; DISEASE; PATHOLOGY; TUMORS; VIRUS; MODEL		[Delaney, Martha A.; Treuting, Piper M.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Rothenburger, Jamie L.] Univ Guelph, Ontario Vet Coll, Guelph, ON, Canada	Delaney, MA (reprint author), Univ Washington, Sch Med, Seattle, WA 98195 USA.		Treuting, Piper M./AAB-2721-2019	Treuting, Piper M./0000-0002-1812-1519			Abrantes J, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-12; Adams MM, 2007, J VIROL, V81, P11084, DOI 10.1128/JVI.00423-07; Bergin IL, 2009, EMERG INFECT DIS, V15, P1955, DOI 10.3201/eid1512.090839; Bertagnoli S, 2015, REV SCI TECH OIE, V34, P549; Bock P, 2007, VET PATHOL, V44, P703, DOI 10.1354/vp.44-5-703; Botha M., 2014, Rabbit Genetics, V4, P7; Brown VR, 2015, J WILDLIFE DIS, V51, P564, DOI 10.7589/2015-02-030; CARLTON WW, 1977, VET PATHOL, V14, P29, DOI 10.1177/030098587701400104; CARMAN RJ, 1984, VET MICROBIOL, V9, P497, DOI 10.1016/0378-1135(84)90070-1; DiGiacomo R. F., 1994, BIOL LAB RABBIT, P178; FUCHS A, 1992, J COMP PATHOL, V107, P103, DOI 10.1016/0021-9975(92)90100-9; Gavier-Widen D., 1991, Revue Scientifique et Technique Office International des Epizooties, V10, P453; Hesselton R. M., 1998, AM J PATHOL, V133, P639; Hurst EW, 1933, J EXP MED, V58, P607, DOI 10.1084/jem.58.5.607; Irizarry-Rovira AR, 2008, VET PATHOL, V45, P73, DOI 10.1354/vp.45-1-73; Jin L, 2008, VET PATHOL, V45, P369, DOI 10.1354/vp.45-3-369; KORNBLATT AN, 1984, INFECT IMMUN, V46, P220; Lopushinsky T., 1967, B WILDLIFE DIS ASSOC, V3, P148; Lumeij JT, 2011, EUR J WILDLIFE RES, V57, P183, DOI 10.1007/s10344-010-0428-3; MADARAME H, 1990, J COMP PATHOL, V103, P351, DOI 10.1016/S0021-9975(08)80056-4; Madarame H, 2009, J VET MED SCI, V71, P987, DOI 10.1292/jvms.71.987; Marques RM, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-14; McIntosh MT, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-96; Muller K, 2009, JAVMA-J AM VET MED A, V235, P66, DOI 10.2460/javma.235.1.66; Muller W, 2007, VET MICROBIOL, V123, P225, DOI 10.1016/j.vetmic.2007.03.025; Ozkan O, 2011, VET PARASITOL, V179, P234, DOI 10.1016/j.vetpar.2011.02.007; PERCY DH, 1993, CAN VET J, V34, P95; PETRIC M, 1978, CAN J COMP MED, V42, P143; PROSE PH, 1971, AM J PATHOL, V64, P467; PULLEY LT, 1973, VET PATHOL, V10, P509, DOI 10.1177/030098587301000604; Rothenburger JL, 2015, J WILDLIFE DIS, V51, P503, DOI 10.7589/2014-06-159; Roy CJ, 2010, VIRUSES-BASEL, V2, P2096, DOI 10.3390/v2092096; Schoniger S, 2014, VET PATHOL, V51, P569, DOI 10.1177/0300985813497486; Schoondermark-van de Ven E, 2013, VET MICROBIOL, V166, P154, DOI 10.1016/j.vetmic.2013.05.028; STEWART FRED W., 1931, AMER JOUR CANCER, V15, P2013; Supuka P, 2014, VET MED-CZECH, V59, P95, DOI 10.17221/7319-VETMED; Thompson R, 2015, J ZOO WILDLIFE MED, V46, P560, DOI 10.1638/2015-0029.1; Velarde R, 2017, TRANSBOUND EMERG DIS, V64, P1750, DOI 10.1111/tbed.12562; von Bomhard W, 2007, VET PATHOL, V44, P579, DOI 10.1354/vp.44-5-579; Weiner CM, 2010, J VET DIAGN INVEST, V22, P451, DOI 10.1177/104063871002200321; White SD, 2002, SEMIN AVIAN EXOT PET, V11, P141, DOI 10.1053/saep.2002.123982; Wijesundera KK, 2013, J TOXICOL PATHOL, V26, P309, DOI 10.1293/tox.26.309; Wobeser G, 2009, CAN VET J, V50, P1251; Yu ZJ, 2014, VET MICROBIOL, V173, P132, DOI 10.1016/j.vetmic.2014.07.002	44	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							481	+		10.1016/B978-0-12-805306-5.00019-5			5	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300021					2019-10-28	
B	Delaney, MA; Treuting, PM; Rothenburger, JL		Terio, KA; McAloose, D; StLeger, J		Delaney, Martha A.; Treuting, Piper M.; Rothenburger, Jamie L.			Rodentia	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							SQUIRRELS SCIURUS-GRISEUS; WESTERN GRAY SQUIRRELS; RATS RATTUS-NORVEGICUS; NONPROLIFERATIVE LESIONS; NORWAY RATS; POLYOMAVIRUS INFECTION; FRANCISELLA-TULARENSIS; NOTOEDRIC MANGE; MARMOTA-MONAX; WOODCHUCK		[Delaney, Martha A.; Treuting, Piper M.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Rothenburger, Jamie L.] Univ Guelph, Ontario Vet Coll, Guelph, ON, Canada	Delaney, MA (reprint author), Univ Washington, Sch Med, Seattle, WA 98195 USA.		Treuting, Piper M./AAB-2721-2019	Treuting, Piper M./0000-0002-1812-1519			Anderson W.I., 1990, Veterinary Dermatology, V1, P177, DOI 10.1111/j.1365-3164.1990.tb00097.x; Anholt H, 2014, J WILDLIFE DIS, V50, P104, DOI 10.7589/2013-02-046; Baker DG, 1998, CLIN MICROBIOL REV, V11, P231, DOI 10.1128/CMR.11.2.231; Bangari DS, 2009, VET PATHOL, V46, P667, DOI 10.1354/vp.08-VP-0305-B-BC; Bangari DS, 2007, J VET DIAGN INVEST, V19, P705, DOI 10.1177/104063870701900616; Barthold S. W, 2016, PATHOLOGY LAB RODENT; Batista JS, 2010, PESQUISA VET BRASIL, V30, P497, DOI 10.1590/S0100-736X2010000600005; Bauer C, 2013, VET PARASITOL, V193, P404, DOI 10.1016/j.vetpar.2012.12.036; BENITZ KF, 1965, LAB ANIM CARE, V15, P281; Berliner A. L., 2007, P ANN M AM ASS ZOO V, P205; Berridge B. R., 2016, TOXICOL PATHOL, V29, P1; Boorman GA, 1996, MONOGRAPHS PATHOLOGY, P262; Boy SC, 2006, J COMP PATHOL, V135, P56, DOI 10.1016/j.jcpa.2006.03.002; Bruner RH, 2009, TOXICOL PATHOL, V37, P547, DOI 10.1177/0192623309335061; Campbell-Palmer R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130842; Carleton MD, 2005, MAMMAL SPECIES WORLD, P745; Carminato A, 2012, COMPARATIVE MED, V62, P279; Cavanagh R, 2002, J CLIN MICROBIOL, V40, P3281, DOI 10.1128/JCM.40.9.3281-3285.2002; Chanut F, 2013, TOXICOL PATHOL, V41, P1126, DOI 10.1177/0192623313478692; Cornish TE, 2001, J WILDLIFE DIS, V37, P630, DOI 10.7589/0090-3558-37.3.630; Cosgrove G E, 1968, Wildl Dis, V4, P54; Creasy D, 2012, TOXICOL PATHOL, V40, p40S, DOI 10.1177/0192623312454337; Cueto GR, 2000, J WILDLIFE DIS, V36, P97, DOI 10.7589/0090-3558-36.1.97; Cullen JM, 1996, HEPATOLOGY, V23, P1324, DOI 10.1053/jhep.1996.v23.pm0008675146; Cully JF, 2010, VECTOR-BORNE ZOONOT, V10, P7, DOI 10.1089/vbz.2009.0045; de Thoisy B, 2000, J PARASITOL, V86, P1035, DOI 10.1645/0022-3395(2000)086[1035:ASOHII]2.0.CO;2; Delaney MA, 2016, VET PATHOL, V53, P691, DOI 10.1177/0300985816630796; Delaney MA, 2016, VET PATHOL, V53, P493, DOI 10.1177/0300985815612557; Delaney MA, 2013, VET PATHOL, V50, P607, DOI 10.1177/0300985812471543; Dixon D, 2014, J TOXICOL PATHOL S, V27, P1; Dixon D, 2014, J TOXICOL PATHOL, V27, p1S, DOI 10.1293/tox.27.1S; DOBOSZYNSKA T, 1981, ACTA THERIOL, V26, P331, DOI 10.4098/AT.arch.81-27; Doi T, 2007, VET PATHOL, V44, P796, DOI 10.1354/vp.44-6-796; Easterbrook JD, 2008, LAB ANIM-UK, V42, P92, DOI 10.1258/la.2007.06015e; EATON GJ, 1978, AM J PATHOL, V90, P173; ERNST JV, 1968, J PARASITOL, V54, P545, DOI 10.2307/3277081; FOLEY GL, 1993, J ZOO WILDLIFE MED, V24, P475; Forzan MJ, 2004, J ZOO WILDLIFE MED, V35, P113, DOI 10.1638/03-031; Foster AP, 2002, VET REC, V151, P13, DOI 10.1136/vr.151.1.13; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; GARDNER SL, 1988, J PARASITOL, V74, P399, DOI 10.2307/3282045; GEISEL O, 1979, J WILDLIFE DIS, V15, P267, DOI 10.7589/0090-3558-15.2.267; Greaves P, 2013, J TOXICOL PATHOL, V26, p1S, DOI 10.1293/tox.26.1S; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P263, DOI 10.1016/B978-0-444-53856-7.00007-5; GREEN MN, 1963, NATURE, V197, P396, DOI 10.1038/197396a0; Guarner J, 2004, EMERG INFECT DIS, V10, P426, DOI 10.3201/eid1003.030878; Hamano T, 2014, J VET MED SCI, V76, P1301, DOI 10.1292/jvms.13-0395; Han BA, 2015, P NATL ACAD SCI USA, V112, P7039, DOI 10.1073/pnas.1501598112; Henderson KS, 2012, VET PATHOL, V49, P440, DOI 10.1177/0300985811432351; Hinney B, 2016, INT J PARASITOL-PAR, V5, P76, DOI 10.1016/j.ijppaw.2016.01.001; HITCHCOCK CR, 1952, JNCI-J NATL CANCER I, V12, P1345; Ilgun R, 2014, ANAT HISTOL EMBRYOL, V43, P474, DOI 10.1111/ahe.12098; Janovsky M, 2002, J WILDLIFE DIS, V38, P618, DOI 10.7589/0090-3558-38.3.618; Jara LF, 2005, J WILDLIFE DIS, V41, P431, DOI 10.7589/0090-3558-41.2.431; Kang BC, 2005, J VET MED SCI, V67, P353, DOI 10.1292/jvms.67.353; Kang BC, 2004, J VET MED SCI, V66, P1617, DOI 10.1292/jvms.66.1617; KENNEDY MJ, 1986, J WILDLIFE DIS, V22, P112, DOI 10.7589/0090-3558-22.1.112; KIRSCHSTEIN RL, 1958, CANCER RES, V18, P1340; Klein P. N., 2011, WCV CALL WILD C; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Krinke AL, 1994, PATHOBIOLOGY AGING R, V2, P109; Krinke GJ, 1996, PATHOBIOLOGY AGING M, V2, P139; Kurtz D. M., 2017, CLIN CHEM LAB ANIMAL; LANGHAM RF, 1990, J WILDLIFE DIS, V26, P295, DOI 10.7589/0090-3558-26.2.295; Losco PE, 1995, TOXICOL PATHOL, V23, P677, DOI 10.1177/019262339502300605; Mackie JT, 2001, AUST VET J, V79, P502, DOI 10.1111/j.1751-0813.2001.tb13026.x; MEASURES LN, 1983, J WILDLIFE DIS, V19, P219, DOI 10.7589/0090-3558-19.3.219; Meerburg BG, 2009, CRIT REV MICROBIOL, V35, P221, DOI 10.1080/10408410902989837; Meier C, 1998, CAN J ZOOL, V76, P1188, DOI 10.1139/cjz-76-6-1188; Miller AL, 2016, INT J PARASITOL-PAR, V5, P56, DOI 10.1016/j.ijppaw.2016.03.001; MORRISEY JK, 1996, SEMIN AVIAN EXOT PET, V5, P106; Muller DWH, 2009, VET PATHOL, V46, P656, DOI 10.1354/vp.08-VP-0107-W-FL; Nagy T, 2002, COMPARATIVE MED, V52, P152; Nelson DD, 2014, J VET DIAGN INVEST, V26, P312, DOI 10.1177/1040638713520541; Pearce L, 1916, J EXP MED, V23, P431, DOI 10.1084/jem.23.4.431; Pettan-Brewer C, 2011, PATHOBIOL AGING AGE, V1, DOI 10.3402/pba.v1i0.7202; Phalen D N, 2000, Vet Clin North Am Exot Anim Pract, V3, P513; Rafferty DP, 2000, J WILDLIFE DIS, V36, P636, DOI 10.7589/0090-3558-36.4.636; Ranck RS, 2008, VET PATHOL, V45, P388, DOI 10.1354/vp.45-3-388; RAUSCH RL, 1984, J PARASITOL, V70, P295, DOI 10.2307/3281880; Renne R, 2009, TOXICOL PATHOL, V37, p5S, DOI 10.1177/0192623309353423; Rossow H, 2014, VECTOR-BORNE ZOONOT, V14, P193, DOI 10.1089/vbz.2012.1255; ROTH L, 1986, J WILDLIFE DIS, V22, P533, DOI 10.7589/0090-3558-22.4.533; ROTH L, 1991, J WILDLIFE DIS, V27, P281, DOI 10.7589/0090-3558-27.2.281; ROTH L, 1985, VET PATHOL, V22, P338, DOI 10.1177/030098588502200407; Rothenburger JL, 2015, VET PATHOL, V52, P1210, DOI 10.1177/0300985815593123; Rothenburger JL, 2015, VET PATHOL, V52, P201, DOI 10.1177/0300985814528220; Rothenburger Jamie L., 2014, International Journal for Parasitology Parasites and Wildlife, V3, P95, DOI 10.1016/j.ijppaw.2014.04.003; Rothenburger JL, 2014, J WILDLIFE DIS, V50, P628, DOI 10.7589/2013-09-256; ROTHENBURGER JL, 2014, CANADA J WILDL DIS, V50, P628, DOI DOI 10.7589/2013-09-256; Rudmann D, 2012, TOXICOL PATHOL, V40, p7S, DOI 10.1177/0192623312454242; SILVEIRA FT, 1991, REV I MED TROP, V33, P18, DOI 10.1590/S0036-46651991000100004; Simmons JH, 2001, VET PATHOL, V38, P441, DOI 10.1354/vp.38-4-441; Simpson VR, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-229; Stannard HJ, 2017, VET MICROBIOL, V201, P201, DOI 10.1016/j.vetmic.2017.01.018; Stephenson Nicole, 2013, International Journal for Parasitology Parasites and Wildlife, V2, P266, DOI 10.1016/j.ijppaw.2013.09.004; Stevens CE, 1998, PHYSIOL REV, V78, P393; Strandberg J., 1996, MONOGRAPHS PATHOLOGY, P440; Suckow MA, 2012, AM COLL LAB, P1; Sura R, 2011, VET PATHOL, V48, P896, DOI 10.1177/0300985810377184; TAPPE JP, 1984, J AM VET MED ASSOC, V185, P1367; Taylor KR, 2017, J GERONTOL A-BIOL, V72, P38, DOI 10.1093/gerona/glw047; Terrell SP, 2002, J WILDLIFE DIS, V38, P305, DOI 10.7589/0090-3558-38.2.305; Thoolen B, 2012, J TOXICOL PATHOL, V25, P189, DOI 10.1293/tox.25.189; Tompkins DM, 2002, P ROY SOC B-BIOL SCI, V269, P529, DOI 10.1098/rspb.2001.1897; Treuting PM, 2017, COMP ANATOMY HISTOLO; Veiga-Parga T, 2016, J VET DIAGN INVEST, V28, P656, DOI 10.1177/1040638716665429; Wallau BR, 2000, J MORPHOL, V246, P228, DOI 10.1002/1097-4687(200012)246:3<228::AID-JMOR6>3.0.CO;2-G; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062; Wilcoxen Travis. E., 2015, Transactions of the Illinois State Academy of Science, V108, P27; Williams E. S., 1989, COMP ASPECTS TUMOR D, P214; Yang YR, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000518; Yarto-Jaromillo E, 2015, FOWLERS ZOO WILD ANI, V8, P384; Zimmerman DM, 2009, J ZOO WILDLIFE MED, V40, P551, DOI 10.1638/2009-0004.1	114	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							499	+		10.1016/B978-0-12-805306-5.00020-1			14	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300022					2019-10-28	
B	Agnew, D; Nofs, S; Delaney, MA; Rothenburger, JL		Terio, KA; McAloose, D; StLeger, J		Agnew, Dalen; Nofs, Sally; Delaney, Martha A.; Rothenburger, Jamie L.			Xenartha, Erinacoemorpha, Some Afrotheria, and Phloidota	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							HYRAX PROCAVIA-CAPENSIS; HEDGEHOGS ATELERIX-ALBIVENTRIS; PANCREATIC-ISLET FIBROSIS; ROCK HYRAX; RENAL-DISEASE; INFECTION; LEPROSY; VIRUS; CARCINOMA; ARMADILLO		[Agnew, Dalen] Michigan State Univ, Lansing, MI 48929 USA; [Nofs, Sally] Potter Pk Zoo, Lansing, MI USA; [Delaney, Martha A.] Univ Washington, Sch Med, Seattle, WA USA; [Rothenburger, Jamie L.] Univ Guelph, Ontario Vet Coll, Guelph, ON, Canada	Agnew, D (reprint author), Michigan State Univ, Lansing, MI 48929 USA.						Abegglen LM, 2015, JAMA-J AM MED ASSOC, V314, P1850, DOI 10.1001/jama.2015.13134; Adams LB, 2012, MEM I OSWALDO CRUZ, V107, P197, DOI 10.1590/S0074-02762012000900028; Agnew D. W., 2009, ANN C AM ASS ZOO VET; Aguilar R. F., 2002, ANN C P AM ASS ZOO V, P169; Aguilar RF, 2015, FOWLERS ZOO WILD ANI, V8, P355; Allison N, 2002, J COMP PATHOL, V126, P76, DOI 10.1053/jcpa.2001.0518; Aroch I, 2007, VET CLIN PATH, V36, P40, DOI 10.1111/j.1939-165X.2007.tb00180.x; Balamayooran G, 2015, CLIN DERMATOL, V33, P108, DOI [10.1016/j.clindermatol.2014.07.001, 10.1016/j.clindermato1.2014.07.001]; Bilyk O., 2011, EVALUATION NEOPLASIA, P6; BJORNHAG G, 1994, COMP BIOCHEM PHYS A, V109, P649, DOI 10.1016/0300-9629(94)90205-4; Brack M, 1998, J COMP PATHOL, V118, P301, DOI 10.1016/S0021-9975(07)80006-5; BRACK M, COMP MED, V50, P212; Britt J., 2006, CANINE DISTEMPER INF; Buss P. E., 2015, ZOO WILD ANIMAL MED, P514; Cardona-Castro N, 2009, LEPROSY REV, V80, P424; Carmona FD, 2008, J EXP ZOOL PART B, V310B, P259, DOI 10.1002/jez.b.21209; Clancy MM, 2013, J ZOO WILDLIFE MED, V44, P302, DOI 10.1638/2012-0115R1.1; Clauss M, 2012, J ZOO WILDLIFE MED, V43, pS6, DOI 10.1638/2011-0152.1; Coke RL, 2002, J ZOO WILDLIFE MED, V33, P272; Crawshaw GJ, 1996, J ZOO WILDLIFE MED, V27, P158; deMaar T. W., 1994, CHAGAS DIS AFRICAN H; El-Dakhly KM, 2013, PAK VET J, V33, P529; Elliott M. W., 1995, HISTOLOGIC VARIATION; FRYE FL, 1982, J ZOO ANIM MED, V13, P152, DOI 10.2307/20094609; Galeota JA, 2009, J VET DIAGN INVEST, V21, P531, DOI 10.1177/104063870902100418; Gamble KC, 2004, J ZOO WILDLIFE MED, V35, P361, DOI 10.1638/02-061; Garner M. M., 2000, CARDIOMYOPATHY CAPTI; Garner MM, 2004, J ZOO WILDLIFE MED, V35, P280, DOI 10.1638/02-078; GARNHAM PCC, 1951, J PARASITOL, V37, P528, DOI 10.2307/3273342; Graesser D, 2006, J EXOT PET MED, V15, P59, DOI 10.1053/j.jepm.2005.11.010; Griner L. A., 1983, PATHOLOGY ZOO ANIMAL; HARRISON L, 2012, CAUSES MORTALITY CAP, P209; Harrison TM, 2010, J ZOO WILDLIFE MED, V41, P152, DOI 10.1638/2008-0215.1; Howard L. L., 2007, LONG TERM MANAGEMENT, P210; IRVIN AD, 1973, J PARASITOL, V59, P203, DOI 10.2307/3278603; Johnson JG, 2015, J ZOO WILDLIFE MED, V46, P565, DOI 10.1638/2015-0008.1; Khoii MK, 2008, J ZOO WILDLIFE MED, V39, P392, DOI 10.1638/2007-0063.1; Kiupel M, 1999, J ZOO WILDLIFE MED, V30, P177; Kline S, 2015, J ZOO WILDLIFE MED, V46, P171, DOI 10.1638/2014-0003R2.1; Kruse TN, 2015, J ZOO WILDLIFE MED, V46, P798, DOI 10.1638/2014-0248.1; Lee BR, 2015, J ZOO WILDLIFE MED, V46, P333, DOI 10.1638/2013-0258R1.1; Lutze-Wallace C, 2006, CAN VET J, V47, P1011; Madarame H, 2014, VET MICROBIOL, V173, P136, DOI 10.1016/j.vetmic.2014.07.012; Marrow J. C., 2011, SUCCESSFUL RESOLUTIO, P169; Matas M, 2010, VET OPHTHALMOL, V13, P116, DOI 10.1111/j.1463-5224.2010.00803.x; MATSUYAMA M, 1982, JAP J CANC CLIN, V73, P115; MCLAUCHLAN JD, 1947, J HYG-CAMBRIDGE, V45, P474, DOI 10.1017/S0022172400014194; Mikaelian I, 2004, J ZOO WILDLIFE MED, V35, P216, DOI 10.1638/01-077; Moore T. A., 2001, RETROSPECTIVE STUDY; MORAN S, 1995, PESTIC SCI, V44, P305, DOI 10.1002/ps.2780440315; MORAN S, 1986, PHYTOPARASITICA, V14, P143, DOI 10.1007/BF02980900; Nakata M, 2011, J VET MED SCI, V73, P1333, DOI 10.1292/jvms.10-0341; Napier J. E., 2015, ZOO WILD ANIMAL MED, P532; Nofs S. A., 2017, J ANIM PHYSL ANIM NU; Nofs S, 2009, EMERG INFECT DIS, V15, P1081, DOI 10.3201/eid1507.081574; Olubayo R O, 1981, Bull Anim Health Prod Afr, V29, P263; oRaymond J. T., 2001, SPONTANEOUS TUMORS H, P326; Palmer AC, 1998, VET REC, V143, P550, DOI 10.1136/vr.143.20.550; Parsons S, 2008, TUBERCULOSIS, V88, P80, DOI 10.1016/j.tube.2007.08.012; PEAUROI JR, 1994, VET PATHOL, V31, P481, DOI 10.1177/030098589403100415; Pinto A. A, 2006, ANN NY ACAD SCI, V1026, P65; Raymond JT, 2009, J EXOT PET MED, V18, P220, DOI 10.1053/j.jepm.2009.06.007; Raymond JT, 1999, J ZOO WILDLIFE MED, V30, P273; RIEMANN H P, 1975, Journal of Wildlife Diseases, V11, P529; Salas E, 2014, J ZOO WILDLIFE MED, V45, P402, DOI 10.1638/2013-0137R2.1; Sanches AWD, 2013, J ZOO WILDLIFE MED, V44, P186, DOI 10.1638/1042-7260-44.1.186; SCHNUR LF, 1972, J HELMINTHOL, V46, P251, DOI 10.1017/S0022149X00024408; Schutt LK, 2010, J AM ASSOC LAB ANIM, V49, P638; Sharma R, 2015, EMERG INFECT DIS, V21, P2127, DOI 10.3201/eid2112.150501; STUART B P, 1977, Journal of Wildlife Diseases, V13, P240; Superina M., 2008, BIOL XENARTHA; Takle GL, 2010, J ZOO WILDLIFE MED, V41, P496, DOI 10.1638/2009-0108.1; Talmi-Frank D, 2010, AM J TROP MED HYG, V82, P814, DOI 10.4269/ajtmh.2010.09-0513; Tamam A. S, 2009, EUR J SCI RES, V32, P128; Teare J. A., 2009, DIETARY TAURINE SUPP; Thompson KA, 2017, J ZOO WILDLIFE MED, V48, P446, DOI 10.1638/2016-0039.1; Truman R, 2005, LEPROSY REV, V76, P198; Virmond M, 2015, CLIN DERMATOL, V33, P8, DOI 10.1016/j.clindermatol.2014.07.006; Weaver GV, 2013, J WILDLIFE DIS, V49, P759, DOI 10.7589/2012-11-276; Widen F, 1996, VET REC, V139, P237, DOI 10.1136/vr.139.10.237; Xia Hou-Jun, 2012, Zoological Research, V33, P55, DOI 10.3724/SP.J.1141.2012.01055; Yang C, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0256-x	82	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							517	+		10.1016/B978-0-12-805306-5.00021-3			17	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300023					2019-10-28	
B	St Leger, J; Raverty, S; Mena, A		Terio, KA; McAloose, D; StLeger, J		St Leger, Judy; Raverty, Stephen; Mena, Alexandria			Cetacea	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							BOTTLE-NOSED-DOLPHIN; RISK-ASSESSMENT PROJECT; ST-LAWRENCE ESTUARY; T-CELL LYMPHOMA; TURSIOPS-TRUNCATUS; STENELLA-COERULEOALBA; DELPHINUS-DELPHIS; KILLER WHALE; DELPHINAPTERUS-LEUCAS; MORBILLIVIRAL-DISEASE		[St Leger, Judy; Mena, Alexandria] SeaWorld Pk & Entertainment, San Diego, CA 92109 USA; [Raverty, Stephen] Anim Hlth Ctr, Abbotsford, BC, Canada	St Leger, J (reprint author), SeaWorld Pk & Entertainment, San Diego, CA 92109 USA.						Abdo W, 2012, J COMP PATHOL, V147, P94, DOI 10.1016/j.jcpa.2011.08.012; Aguilar A., 2009, BMC VET RES, V86, P143; Alonso-Farre Josep M., 2013, Journal of Marine Animals and their Ecology, V6, P11; Anthony SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068239; Arbelo M, 2014, J COMP PATHOL, V150, P336, DOI 10.1016/j.jcpa.2013.09.003; Arbelo M, 2013, DIS AQUAT ORGAN, V103, P87, DOI 10.3354/dao02558; Arbelo M, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-243; Arbelo M, 2010, DIS AQUAT ORGAN, V89, P261, DOI 10.3354/dao02208; Aznar F. J., 2002, MARINE MAMMALS BIOL, P385; Baily JL, 2013, J COMP PATHOL, V149, P514, DOI 10.1016/j.jcpa.2013.06.003; Barnett J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124315; Bellehumeur C, 2015, J WILDLIFE DIS, V51, P244, DOI 10.7589/2013-11-293; Benson KAS, 2006, J VIROL METHODS, V136, P261, DOI 10.1016/j.jviromet.2006.03.033; Birkun A, 1999, VET REC, V144, P85, DOI 10.1136/vr.144.4.85; Blanchard TW, 2001, J WILDLIFE DIS, V37, P297, DOI 10.7589/0090-3558-37.2.297; BOSSART GD, 1985, J AM VET MED ASSOC, V187, P1137; Bossart Gregory D., 2005, Aquatic Mammals, V31, P473, DOI 10.1578/AM.31.4.2005.473; Bossart GD, 2017, DIS AQUAT ORGAN, V125, P141, DOI 10.3354/dao03142; Bossart GD, 2010, VET MICROBIOL, V143, P160, DOI 10.1016/j.vetmic.2009.11.024; Bossart Gregory D., 2007, Aquatic Mammals, V33, P214, DOI 10.1578/AM.33.2.2007.214; Bowenkamp KE, 2001, J VET DIAGN INVEST, V13, P524, DOI 10.1177/104063870101300613; Buckle K, 2017, VET PATHOL, V54, P838, DOI 10.1177/0300985817707023; Clayton LA, 2012, J ZOO WILDLIFE MED, V43, P961, DOI 10.1638/2012-0110R.1; Colegrove KM, 2016, DIS AQUAT ORGAN, V119, P1, DOI 10.3354/dao02969; Colegrove KM, 2010, J WILDLIFE DIS, V46, P1300, DOI 10.7589/0090-3558-46.4.1300; Cowan D.F., 1986, P323; COWAN DF, 1995, VET PATHOL, V32, P311, DOI 10.1177/030098589503200314; Cox T. M., 2005, Journal of Cetacean Research and Management, V7, P177; Cozzi B, 2017, ANATOMY OF DOLPHINS: INSIGHTS INTO BODY STRUCTURE AND FUNCTION, pXV; Dailey M.D., 1985, P805; Davison NJ, 2014, J WILDLIFE DIS, V50, P431, DOI 10.7589/2013-02-047; de Graaf M, 2017, EMERG INFECT DIS, V23, P87, DOI 10.3201/eid2301.161081; Delaney MA, 2013, VET PATHOL, V50, P172, DOI 10.1177/0300985812446153; Di Guardo G, 2010, VET PATHOL, V47, P245, DOI 10.1177/0300985809358036; Di Guardo G, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00112; Di Guardo G, 2011, DIS AQUAT ORGAN, V95, P247, DOI 10.3354/dao02355; Diaz-Delgado J, 2017, DIS AQUAT ORGAN, V124, P247, DOI 10.3354/dao03124; Diaz-Delgado J, 2015, J COMP PATHOL, V153, P58, DOI 10.1016/j.jcpa.2015.04.004; Diaz-Delgado J, 2015, J COMP PATHOL, V152, P278, DOI 10.1016/j.jcpa.2014.12.016; Diaz-Delgado J, 2012, DIS AQUAT ORGAN, V101, P257, DOI 10.3354/dao02525; Diaz-Delgado J, 2015, J WILDLIFE DIS, V51, P538, DOI [10.7589/2015-08-199, 10.7589/2014-08-199]; Diaz-Delgado J, 2012, J VET MED SCI, V74, P1063, DOI 10.1292/jvms.11-0573; Dines JP, 2014, EVOLUTION, V68, P3296, DOI 10.1111/evo.12516; Dold C., 2001, FOWLERS ZOO WILD ANI, V7, P422; Duignan PJ, 1996, MAR MAMMAL SCI, V12, P499; Eissa Alaa Eldin, 2015, Journal of Fisheries and Aquatic Science, V10, P307, DOI 10.3923/jfas.2015.307.322; Estep JS, 2005, VET PATHOL, V42, P357, DOI 10.1354/vp.42-3-357; Ewing R, 2002, J WILDLIFE DIS, V38, P291, DOI 10.7589/0090-3558-38.2.291; Fauquier DA, 2017, ENDANGER SPECIES RES, V33, P211, DOI 10.3354/esr00772; Fenton H, 2017, DIS AQUAT ORGAN, V122, P171, DOI 10.3354/dao03080; Fernandez A, 2005, VET PATHOL, V42, P446, DOI 10.1354/vp.42-4-446; Fiorito CD, 2016, DIS AQUAT ORGAN, V121, P67, DOI 10.3354/dao03041; Foster G, 2011, J WILDLIFE DIS, V47, P206, DOI 10.7589/0090-3558-47.1.206; Garner M. M., 2002, J ZOO WILDLIFE MED, V33, P5; Geraci J. R., 1966, J AM VET MED ASSOC, V149, P90; GERACI JR, 1979, CAN J COMP MED, V43, P399; Gottschling M, 2011, MOL PHYLOGENET EVOL, V59, P34, DOI 10.1016/j.ympev.2010.12.013; Groch KR, 2014, EMERG INFECT DIS, V20, P511, DOI 10.3201/eid2003.131557; Groch KR, 2012, DIS AQUAT ORGAN, V101, P145, DOI 10.3354/dao02518; Gulland F. M. D., 2001, CRC HDB MARINE MAMMA; Guzman-Verri C, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00003; Haase JK, 2012, APPL ENVIRON MICROB, V78, P8829, DOI 10.1128/AEM.02310-12; Harms CA, 2004, J WILDLIFE DIS, V40, P588, DOI 10.7589/0090-3558-40.3.588; Harms CA, 2008, VET RES, V39, DOI 10.1051/vetres:2008036; Hart LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033081; Hayashi R, 2013, J MAR BIOL ASSOC UK, V93, P143, DOI 10.1017/S0025315412000847; Hernandez-Mora G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182644; Higgins R, 2000, CAN VET J, V41, P105; Hunt KE, 2014, CONSERV PHYSIOL, V2, DOI 10.1093/conphys/cou030; Isidoro-Ayza M, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0206-7; Jaber JR, 2005, J COMP PATHOL, V132, P242, DOI 10.1016/j.jcpa.2004.09.009; Jaber JR, 2004, VET PATHOL, V41, P147, DOI 10.1354/vp.41-2-147; Jepson PD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060953; Jepson PD, 2003, NATURE, V425, P575, DOI 10.1038/425575a; Kemper CM, 2016, ROY SOC OPEN SCI, V3, DOI 10.1098/rsos.160838; KENNEDY S, 1992, J ZOO WILDLIFE MED, V23, P374; Kidd SE, 2004, P NATL ACAD SCI USA, V101, P17258, DOI 10.1073/pnas.0402981101; Kinoshita R., 2008, MELIOIDOSIS MARINE M, P299; KUIKEN T, 1993, MAR POLLUT BULL, V26, P440, DOI 10.1016/0025-326X(93)90532-O; Ladds P.W., 2009, PATHOLOGY AUSTR NATI; Lair S, 1997, J WILDLIFE DIS, V33, P430, DOI 10.7589/0090-3558-33.3.430; Lair S., 2014, CAUSES MORTALITY STL; Lair S., 2014, DFO CAN SCI ADVIS SE, V14; LaMere SA, 2009, J VIROL, V83, P12956, DOI 10.1128/JVI.01354-09; Landsberg JH, 2002, REV FISH SCI, V10, P113, DOI 10.1080/20026491051695; Lavery TJ, 2009, MAR ENVIRON RES, V67, P1, DOI 10.1016/j.marenvres.2008.09.005; Leger JAS, 2009, VET PATHOL, V46, P299, DOI 10.1354/vp.46-2-299; Leger JS, 2011, EMERG INFECT DIS, V17, P1531, DOI 10.3201/eid1708.101979; Leone A, 2013, J ZOO WILDLIFE MED, V44, P744, DOI 10.1638/2012-0147R.1; LIPSCOMB TP, 1994, J WILDLIFE DIS, V30, P567, DOI 10.7589/0090-3558-30.4.567; Litz JA, 2014, DIS AQUAT ORGAN, V112, P161, DOI 10.3354/dao02807; Loch C, 2013, ARCH ORAL BIOL, V58, P134, DOI 10.1016/j.archoralbio.2012.08.002; March DT, 2016, AUST VET J, V94, P203, DOI 10.1111/avj.12449; MARTINEAU D, 1988, J COMP PATHOL, V98, P287, DOI 10.1016/0021-9975(88)90038-2; Martineau D, 2002, ENVIRON HEALTH PERSP, V110, P285, DOI 10.1289/ehp.02110285; Martinez-Levasseur LM, 2011, P ROY SOC B-BIOL SCI, V278, P1581, DOI 10.1098/rspb.2010.1903; Mazzariol S, 2012, BMC VET RES, V8, DOI 10.1186/1746-6148-8-20; McAloose D, 2016, DIS AQUAT ORGAN, V119, P17, DOI 10.3354/dao02986; Measures Lena M., 2001, P279, DOI 10.1002/9780470377000.ch10; Miclard J, 2006, J COMP PATHOL, V135, P254, DOI 10.1016/j.jcpa.2006.08.005; Mihindukulasuriya KA, 2008, J VIROL, V82, P5084, DOI 10.1128/JVI.02722-07; Villalba MCM, 2017, DIS AQUAT ORGAN, V123, P13, DOI 10.3354/dao03085; Moore MJ, 2009, VET PATHOL, V46, P536, DOI 10.1354/vp.08-VP-0065-M-FL; Moore MJ, 2013, DIS AQUAT ORGAN, V103, P229, DOI 10.3354/dao02566; Newman SJ, 2006, VET PATHOL, V43, P865, DOI 10.1354/vp.43-6-865; Nielsen O, 2001, J WILDLIFE DIS, V37, P820, DOI 10.7589/0090-3558-37.4.820; Nishina H, 2017, J VET MED SCI, V79, P1749, DOI 10.1292/jvms.17-0172; Nollens HH, 2008, VET MICROBIOL, V128, P231, DOI 10.1016/j.vetmic.2007.10.005; Nollens HH, 2009, VET MICROBIOL, V139, P170, DOI 10.1016/j.vetmic.2009.05.010; Nweeia MT, 2014, ANAT REC, V297, P599, DOI 10.1002/ar.22886; Ohishi K, 2006, MAR MAMMAL SCI, V22, P214, DOI 10.1111/j.1748-7692.2006.00016.x; Powell JWB, 2009, J WILDLIFE DIS, V45, P839, DOI 10.7589/0090-3558-45.3.839; Power E, 2002, VET REC, V150, P819; Profeta F, 2015, RES VET SCI, V101, P89, DOI 10.1016/j.rvsc.2015.06.008; Raga JA, 2008, EMERG INFECT DIS, V14, P471, DOI 10.3201/eid1403.071230; Read A. J., 2000, NMFSOPR15 NOAA US DE; Rehtanz M, 2006, J GEN VIROL, V87, P3559, DOI 10.1099/vir.0.82388-0; Rehtanz M, 2010, J WILDLIFE DIS, V46, P136, DOI 10.7589/0090-3558-46.1.136; Reidarson Thomas H., 1999, P478; Reidenberg JS, 2008, ANAT REC, V291, P1389, DOI 10.1002/ar.20792; Reif JS, 2017, DIS AQUAT ORGAN, V125, P155, DOI 10.3354/dao03143; Reynolds J. E., 1999, BIOL MARINE MAMMALS; Roe WD, 2013, VET PARASITOL, V192, P67, DOI 10.1016/j.vetpar.2012.11.001; Ross HM, 1996, P ROY SOC B-BIOL SCI, V263, P283, DOI 10.1098/rspb.1996.0043; Rotstein DS, 2007, VET REC, V160, P130, DOI 10.1136/vr.160.4.130; Rowles TK, 2011, MAR MAMMAL SCI, V27, P1, DOI 10.1111/j.1748-7692.2010.00393.x; Saliki JT, 2006, J WILDLIFE DIS, V42, P142, DOI 10.7589/0090-3558-42.1.142; Seibel H, 2012, DIS AQUAT ORGAN, V99, P79, DOI 10.3354/dao02449; Siebert U, 2010, J COMP PATHOL, V143, P179, DOI 10.1016/j.jcpa.2009.12.011; Siebert U, 2002, VET REC, V150, P273, DOI 10.1136/vr.150.9.273; Siegers JY, 2014, EMERG INFECT DIS, V20, P1081, DOI 10.3201/eid2006.131880; Sierra E, 2015, J WILDLIFE DIS, V51, P696, DOI 10.7589/2014-07-185; Simeone CA, 2018, VET OPHTHALMOL, V21, P298, DOI 10.1111/vop.12459; Simmonds M. P., 2012, J MAR BIOL, V2012, P8; Slijper EJ, 1979, WHALES; Smith CR, 2014, J UROLOGY, V192, P260, DOI 10.1016/j.juro.2014.01.008; SMOLAREK BKA, 2006, J VIROL METHODS, V136, P261, DOI DOI 10.1016/J.JVIR0MET.2006.03.033.PMID:16784784; Soto S, 2012, J COMP PATHOL, V146, P269, DOI 10.1016/j.jcpa.2011.04.002; Soto S, 2011, VET REC, V169, P102, DOI 10.1136/vr.d1686; Suarez-Santana CM, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0855-9; Taubenberger JK, 2000, EMERG INFECT DIS, V6, P42, DOI 10.3201/eid0601.000107; TAYLOR RF, 1973, FED PROC, V32, P822; Twiner MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042974; van Beurden S. J., 2017, ARCH VIROL, P1; Van Bressem MF, 2014, VIRUSES-BASEL, V6, P5145, DOI 10.3390/v6125145; Van Bressem MF, 2009, DIS AQUAT ORGAN, V85, P225, DOI 10.3354/dao02080; Van Bressem MF, 1999, DIS AQUAT ORGAN, V38, P53, DOI 10.3354/dao038053; Van Bressem MF, 2008, SC60DW8 INT WHAL COM; van Elk CE, 2009, J WILDLIFE DIS, V45, P895, DOI 10.7589/0090-3558-45.4.895; Venn-Watson S, 2008, EMERG INFECT DIS, V14, P397, DOI 10.3201/eid1403.071250; Venn-Watson S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126538; Venn-Watson S, 2012, J ZOO WILDLIFE MED, V43, pS35, DOI 10.1638/2011-0146.1; Venn-Watson S, 2012, DIS AQUAT ORGAN, V99, P237, DOI 10.3354/dao02471; Vilela R, 2016, EMERG INFECT DIS, V22, P2063, DOI 10.3201/eid2212.160860; West KL, 2013, MAR MAMMAL SCI, V29, P767, DOI 10.1111/j.1748-7692.2012.00616.x; Wohlsein P, 2007, EMERG INFECT DIS, V13, P1959, DOI 10.3201/eid1312.070309; Woo PCY, 2014, J VIROL, V88, P1318, DOI 10.1128/JVI.02351-13; Wright AK, 2018, BRAIN STRUCT FUNCT, V223, P1697, DOI 10.1007/s00429-017-1525-9; Wunschmann A, 2008, J ZOO WILDLIFE MED, V39, P412, DOI 10.1638/2007-0135.1	159	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							533	+		10.1016/B978-0-12-805306-5.00022-5			44	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300024					2019-10-28	
B	Colegrove, KM; Burek-Huntington, KA; Roe, W; Siebert, U		Terio, KA; McAloose, D; StLeger, J		Colegrove, Kathleen M.; Burek-Huntington, Kathy A.; Roe, Wendi; Siebert, Ursula			Pinnipediae	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							SEALS PHOCA-VITULINA; LIONS ZALOPHUS-CALIFORNIANUS; PACIFIC HARBOR SEALS; NORTHERN FUR SEALS; MYCOBACTERIUM-PINNIPEDII; CALLORHINUS-URSINUS; MIROUNGA-ANGUSTIROSTRIS; DISTEMPER VIRUS; MARINE MAMMALS; DOMOIC ACID		[Colegrove, Kathleen M.] Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA; [Burek-Huntington, Kathy A.] Alaska Vet Pathol Serv, Eagle River, AK USA; [Roe, Wendi] Massey Univ, Palmerston North, New Zealand; [Siebert, Ursula] Univ Vet Med Hannover, Hannover, Germany	Colegrove, KM (reprint author), Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA.						Anderson CE, 2015, J ZOO WILDLIFE MED, V46, P191, DOI 10.1638/2014-0048R2.1; Anthony SJ, 2012, MBIO, V3, DOI 10.1128/mBio.00166-12; Ayling RA, 2011, J WILDLIFE DIS, V47, P471, DOI 10.7589/0090-3558-47.2.471; Barbieri MM, 2016, DIS AQUAT ORGAN, V121, P85, DOI 10.3354/dao03047; Barbosa L, 2015, INT J PARASITOL, V45, P595, DOI 10.1016/j.ijpara.2015.02.013; Bastida R, 1999, J WILDLIFE DIS, V35, P796, DOI 10.7589/0090-3558-35.4.796; Beckmen KB, 1997, J WILDLIFE DIS, V33, P438, DOI 10.7589/0090-3558-33.3.438; Bergman A, 1985, FINNISH GAME RES, V44, P47; Bodewes R, 2015, EMERG INFECT DIS, V21, P720, DOI 10.3201/eid2104.141675; Bodewes R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079259; BORST GHA, 1986, J WILDLIFE DIS, V22, P1; BRITT JO, 1979, J AM VET MED ASSOC, V175, P921; Browning H. M., 2015, PHILOS TRANSAC B, V19; Brownlow A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156464; Buckles EL, 2007, VET MICROBIOL, V120, P1, DOI 10.1016/j.vetmic.2006.10.002; Burek KA, 2005, J WILDLIFE DIS, V41, P512, DOI 10.7589/0090-3558-41.3.512; Burek Kathy, 2001, P514; CALLAN RJ, 1995, J GEN VIROL, V76, P199, DOI 10.1099/0022-1317-76-1-199; Carlson-Bremer D, 2015, J WILDLIFE DIS, V51, P362, DOI 10.7589/2014-08-205; Carlson-Bremer DP, 2012, JAVMA-J AM VET MED A, V240, P324, DOI 10.2460/javma.240.3.324; Castinel A, 2007, VET MICROBIOL, V122, P178, DOI 10.1016/j.vetmic.2006.12.024; Colegrove KM, 2009, VET PATHOL, V46, P642, DOI 10.1354/vp.08-VP-0214-C-FL; Colegrove KM, 2009, J COMP PATHOL, V140, P105, DOI 10.1016/j.jcpa.2008.08.003; Colegrove K. M., 2018, CRC HDB MARINE MAMMA, P255; Colegrove Kathleen M., 2005, Aquatic Mammals, V31, P1, DOI 10.1578/AM.31.1.2005.1; Colegrove KM, 2011, J PARASITOL, V97, P868, DOI 10.1645/GE-2756.1; Colegrove KM, 2010, J VET DIAGN INVEST, V22, P628, DOI 10.1177/104063871002200422; Colegrove KM, 2009, ANAT REC, V292, P1801, DOI 10.1002/ar.21009; Colegrove KM, 2005, J WILDLIFE DIS, V41, P426, DOI 10.7589/0090-3558-41.2.426; Colitz CMH, 2010, VET OPHTHALMOL, V13, P47, DOI 10.1111/j.1463-5224.2010.00811.x; Colitz CMH, 2010, JAVMA-J AM VET MED A, V237, P429, DOI 10.2460/javma.237.4.429; Cousins DV, 2003, INT J SYST EVOL MICR, V53, P1305, DOI 10.1099/ijs.0.02401-0; Dagleish MP, 2013, J COMP PATHOL, V149, P119, DOI 10.1016/j.jcpa.2012.10.002; de Amorim DB, 2014, J WILDLIFE DIS, V50, P419, DOI 10.7589/2013-05-124; DEBOER GF, 1990, ARCH VIROL, V115, P47, DOI 10.1007/BF01310622; Del Piero F, 2006, VET PATHOL, V43, P58, DOI 10.1354/vp.43-1-58; DENISON DM, 1973, RESP PHYSIOL, V17, P1, DOI 10.1016/0034-5687(73)90105-9; Dennison S, 2007, J ZOO WILDLIFE MED, V38, P114, DOI 10.1638/05-121.1; Dennison SE, 2011, AQUAT MAMM, V37, P161, DOI 10.1578/AM.37.2.2011.161; Duignan PJ, 2014, VIRUSES-BASEL, V6, P5093, DOI 10.3390/v6125093; Duncan C, 2013, J WILDLIFE DIS, V49, P163, DOI 10.7589/2012-04-101; Duncan CG, 2014, J VET DIAGN INVEST, V26, P507, DOI 10.1177/1040638714532647; Fire SE, 2011, HARMFUL ALGAE, V10, P330, DOI 10.1016/j.hal.2010.12.001; Flower JE, 2014, J ZOO WILDLIFE MED, V45, P620, DOI 10.1638/2012-0218R1.1; FORSHAW D, 1991, J WILDLIFE DIS, V27, P288, DOI 10.7589/0090-3558-27.2.288; Foster G, 2007, INT J SYST EVOL MICR, V57, P2688, DOI 10.1099/ijs.0.65269-0; Gaffney P., 2008, P 39 ANN C INT ASS A, P10; Gaffney P. M., 2008, P 39 ANN C INT ASS A, P100; Garner MM, 1997, J VET DIAGN INVEST, V9, P298, DOI 10.1177/104063879700900311; GERACI JR, 1982, SCIENCE, V215, P1129; Gibson AK, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001142; Goldstein T, 2008, P ROY SOC B-BIOL SCI, V275, P267, DOI 10.1098/rspb.2007.1221; Goldstein T, 2006, MAR MAMMAL SCI, V22, P465, DOI 10.1111/j.1748-7692.2006.00025.x; Goldstein T, 2004, VET MICROBIOL, V103, P131, DOI 10.1016/j.vetmic.2004.06.017; Goldstein T, 2011, DIS AQUAT ORGAN, V94, P243, DOI 10.3354/dao02321; Goldstein T, 2003, J WILDLIFE DIS, V39, P487, DOI 10.7589/0090-3558-39.3.487; Goldstein T., 1999, Aquatic Mammals, V25, P43; Goldstein T, 2006, J WILDLIFE DIS, V42, P830, DOI 10.7589/0090-3558-42.4.830; Goldstein T, 2009, J WILDLIFE DIS, V45, P91, DOI 10.7589/0090-3558-45.1.91; GRACHEV MA, 1989, NATURE, V338, P209, DOI 10.1038/338209a0; Gray R, 2006, J ANAT, V209, P179, DOI 10.1111/j.1469-7580.2006.00591.x; Greig DJ, 2014, DIS AQUAT ORGAN, V111, P93, DOI 10.3354/dao02762; Gulland FMD, 1996, J WILDLIFE DIS, V32, P250, DOI 10.7589/0090-3558-32.2.250; Gulland FMD, 1996, J WILDLIFE DIS, V32, P572, DOI 10.7589/0090-3558-32.4.572; Gulland FMD, 1997, J WILDLIFE DIS, V33, P450, DOI 10.7589/0090-3558-33.3.450; Gulland FMD, 1997, MAR MAMMAL SCI, V13, P446, DOI 10.1111/j.1748-7692.1997.tb00651.x; Gulland FMD, 2012, JAVMA-J AM VET MED A, V241, P943, DOI 10.2460/javma.241.7.943; Haman K. H., 2013, P 44 ANN C INT ASS A; Harkonen T, 2006, DIS AQUAT ORGAN, V68, P115, DOI 10.3354/dao068115; Hart L., 2018, CRC HDB MARINE MAMMA, P285; Haulena M, 2006, J WILDLIFE DIS, V42, P40, DOI 10.7589/0090-3558-42.1.40; Hernandez-Orts JS, 2013, J HELMINTHOL, V87, P336, DOI 10.1017/S0022149X12000454; HINSHAW VS, 1984, J VIROL, V51, P863; Huckabone SE, 2015, J WILDLIFE DIS, V51, P295, DOI 10.7589/2014-06-143; Hueffer K, 2013, ACTA VET SCAND, V55, DOI 10.1186/1751-0147-55-2; Inoshima Y, 2013, VET MICROBIOL, V165, P455, DOI 10.1016/j.vetmic.2013.04.013; Jang S, 2010, VET MICROBIOL, V141, P174, DOI 10.1016/j.vetmic.2009.07.032; Jeffery B, 2004, FOOD CHEM TOXICOL, V42, P545, DOI 10.1016/j.fct.2003.11.010; Katz H, 2012, ISRN ZOOL, P1, DOI DOI 10.5402/2012/586079; Kennedy S, 1998, J COMP PATHOL, V119, P201, DOI 10.1016/S0021-9975(98)80045-5; Kersh GJ, 2012, J WILDLIFE DIS, V48, P201, DOI 10.7589/0090-3558-48.1.201; Kiers A, 2008, INT J TUBERC LUNG D, V12, P1469; Kik MJL, 2006, VET QUART, V28, P33, DOI 10.1080/01652176.2006.9695204; Kim JH, 2002, J VET DIAGN INVEST, V14, P260, DOI 10.1177/104063870201400315; Kriz P, 2011, VET MED-CZECH, V56, P307, DOI 10.17221/1549-VETMED; Lapointe JM, 1998, J PARASITOL, V84, P1184, DOI 10.2307/3284670; Lapointe JM, 1999, J VET DIAGN INVEST, V11, P541, DOI 10.1177/104063879901100612; Lefebvre KA, 2010, HARMFUL ALGAE, V9, P374, DOI 10.1016/j.hal.2010.01.007; Leger JAS, 2009, VET PATHOL, V46, P299, DOI 10.1354/vp.46-2-299; LING JK, 1970, Q REV BIOL, V45, P16, DOI 10.1086/406361; Lloyd-Smith JO, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-125; Loeffler SH, 2014, J WILDLIFE DIS, V50, P180, DOI 10.7589/2013-09-237; Ludes-Wehrmeister E, 2016, VET MICROBIOL, V183, P43, DOI 10.1016/j.vetmic.2015.11.017; Lynch M, 2011, J VET DIAGN INVEST, V23, P1123, DOI 10.1177/1040638711425699; Lyons ET, 2000, J PARASITOL, V86, P1348, DOI 10.2307/3285025; Lyons ET, 2011, PARASITOL RES, V109, P257, DOI 10.1007/s00436-011-2420-6; Mackereth GF, 2005, NEW ZEAL VET J, V53, P428, DOI 10.1080/00480169.2005.36588; Maness HTD, 2011, VET MICROBIOL, V149, P23, DOI 10.1016/j.vetmic.2010.09.035; McClenahan SD, 2009, J VIROL METHODS, V161, P12, DOI 10.1016/j.jviromet.2009.04.026; McHuron EA, 2013, HARMFUL ALGAE, V23, P28, DOI 10.1016/j.hal.2012.12.008; Measures L. N., 2018, CRC HDB MARINE MAMMA, P457; Measures Lena M., 2001, P279, DOI 10.1002/9780470377000.ch10; Miller MA, 2008, ZOO WILD ANIMAL MED, V6, P319; Minor C, 2013, J WILDLIFE DIS, V49, P441, DOI 10.7589/2012-09-226; Moeller RB, 2003, N P TOX ENV, P3; Moore MJ, 2009, VET PATHOL, V46, P536, DOI 10.1354/vp.08-VP-0065-M-FL; Moore MJ, 2013, DIS AQUAT ORGAN, V103, P229, DOI 10.3354/dao02566; Moser I, 2008, VET MICROBIOL, V127, P399, DOI 10.1016/j.vetmic.2007.08.028; Mulcahy D. M., 2018, CRC HDB MARINE MAMMA, P919; Nadler SA, 2013, INT J PARASITOL, V43, P1119, DOI 10.1016/j.ijpara.2013.08.006; Newman SJ, 2006, VET PATHOL, V43, P865, DOI 10.1354/vp.43-6-865; Nollens HH, 2006, VIROLOGY, V349, P316, DOI 10.1016/j.virol.2006.01.020; Nollens HH, 2010, DIS AQUAT ORGAN, V90, P113, DOI 10.3354/dao02190; Nollens HH, 2006, DIS AQUAT ORGAN, V69, P153, DOI 10.3354/dao069153; Nollens HH, 2006, J WILDLIFE DIS, V42, P23, DOI 10.7589/0090-3558-42.1.23; Nowak RM, 1999, WALKERS MAMMALS WORL, V1-2; Nymo IH, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-93; Osterhaus ADME, 2000, SCIENCE, V288, P1051, DOI 10.1126/science.288.5468.1051; Pollock CG, 2000, J ZOO WILDLIFE MED, V31, P374; Ponganis PJ, 2008, J EXP BIOL, V211, P3323, DOI 10.1242/jeb.018887; Ponganis PJ, 2009, ENCYCLOPEDIA OF MARINE MAMMALS, 2ND EDITION, P230; Prager KC, 2013, VET MICROBIOL, V164, P177, DOI 10.1016/j.vetmic.2013.01.032; Reidarson T. H., 2018, CRC HDB MARINE MAMMA, P377; Rivera R, 2012, VET MICROBIOL, V155, P257, DOI 10.1016/j.vetmic.2011.09.027; Roe WD, 2015, VET MICROBIOL, V176, P301, DOI 10.1016/j.vetmic.2015.01.019; Rommel SA, 2001, CRC HANDBOOK OF MARINE MAMMAL MEDICINE, SECOND EDITION, P129; Scholin CA, 2000, NATURE, V403, P80, DOI 10.1038/47481; Seguel M, 2017, VET PATHOL, V54, P846, DOI 10.1177/0300985817705172; Siebert U, 2007, J COMP PATHOL, V137, P47, DOI 10.1016/j.jcpa.2007.04.018; Siebert Ursula, 2010, NAMMCO Scientific Publications, V8, P265; Silvagni PA, 2005, VET PATHOL, V42, P184, DOI 10.1354/vp.42-2-184; Smith AW, 1998, EMERG INFECT DIS, V4, P13, DOI 10.3201/eid0401.980103; Spraker TR, 2007, J WILDLIFE DIS, V43, P179, DOI 10.7589/0090-3558-43.2.179; Spraker TR, 2010, J WILDLIFE DIS, V46, P450, DOI 10.7589/0090-3558-46.2.450; St Leger J. A., 2014, AQUAT MAMM, V40, P207; Stewardson CL, 1999, J ANAT, V195, P235, DOI 10.1046/j.1469-7580.1999.19520235.x; THOMPSON PJ, 1993, AM REV RESPIR DIS, V147, P164, DOI 10.1164/ajrccm/147.1.164; Thorel MF, 1998, VET RES, V29, P207; Thornton SM, 1998, J ZOO WILDLIFE MED, V29, P171; Trupkiewicz JG, 1997, J WILDLIFE DIS, V33, P220, DOI 10.7589/0090-3558-33.2.220; Vahlenkamp TW, 2006, BERL MUNCH TIERARZTL, V119, P123; van Bolhuis GH, 2007, VET REC, V160, P297, DOI 10.1136/vr.160.9.297; Vossen A, 2004, J CLIN MICROBIOL, V42, P469, DOI 10.1128/JCM.42.1.469-473.2004; Waltzek TB, 2012, ZOONOSES PUBLIC HLTH, V59, P521, DOI 10.1111/j.1863-2378.2012.01492.x; WEBSTER RG, 1981, VIROLOGY, V113, P712, DOI 10.1016/0042-6822(81)90200-2; Welsh T, 2014, J WILDLIFE DIS, V50, P405, DOI 10.7589/2013-03-079; WOHLSEIN P, 2003, TRANSBOUND EMERG DIS, V50, P145; Worthy GAJ, 2001, CRC HANDBOOK OF MARINE MAMMAL MEDICINE, SECOND EDITION, P791, DOI 10.1201/9781420041637.ch36; Zabka TS, 2009, VET PATHOL, V46, P105, DOI 10.1354/vp.46-1-105; Zabka T. S., 2005, P 36 ANN C INT ASS A; Zabka TS, 2006, J WILDLIFE DIS, V42, P651, DOI 10.7589/0090-3558-42.3.651; Zohari S, 2014, EUROSURVEILLANCE, V19, P2, DOI 10.2807/1560-7917.ES2014.19.46.20967	152	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							569	+		10.1016/B978-0-12-805306-5.00023-7			30	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300025					2019-10-28	
B	Owen, H; Flint, M; de Wit, M		Terio, KA; McAloose, D; StLeger, J		Owen, Helen; Flint, Mark; de Wit, Martine			Sirenia	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							DUGONGS DUGONG-DUGON; WEST-INDIAN MANATEE; TRICHECHUS-MANATUS; FLORIDA MANATEE; ANTILLEAN MANATEES; LYMPHOCYTE-PROLIFERATION; SERUM CHEMISTRY; WILD; LATIROSTRIS; QUEENSLAND		[Owen, Helen; Flint, Mark] Univ Queensland, Gatton, Qld, Australia; [Flint, Mark] Ohio State Univ, Columbus, OH 43210 USA; [de Wit, Martine] Florida Fish & Wildlife Conservat Commiss, St Petersburg, FL USA	Owen, H (reprint author), Univ Queensland, Gatton, Qld, Australia.						Adimey NM, 2014, MAR POLLUT BULL, V81, P103, DOI 10.1016/j.marpolbul.2014.02.008; Aragon-Martinez A, 2014, J WILDLIFE DIS, V50, P505, DOI 10.7589/2013-05-102; Barlas M. E., 2011, FLORIDA MANATEE COLD, P138; Beatty BL, 2012, ANAT REC, V295, P1504, DOI 10.1002/ar.22525; BECK C, 1988, J PARASITOL, V74, P628, DOI 10.2307/3282182; BECK CA, 1991, MAR POLLUT BULL, V22, P508, DOI 10.1016/0025-326X(91)90406-I; Beurgelt C. D., 1984, INT ASS AQUATIC ANIM, V1, P28; Bledsoe EL, 2006, MAR MAMMAL SCI, V22, P997, DOI 10.1111/j.1748-7692.2006.00053.x; BOEVER WJ, 1976, J AM VET MED ASSOC, V169, P927; Bonde R. K., 1983, PB83255273 NAT TECHN, P175; Bossart G.D., 2002, AQUAT MAMM, V29, P9, DOI DOI 10.1578/016754203101024031; Bossart GD, 2001, CRC HANDBOOK OF MARINE MAMMAL MEDICINE, SECOND EDITION, P383, DOI 10.1201/9781420041637.sec4; Bossart GD, 2001, CRC HANDBOOK OF MARINE MAMMAL MEDICINE, SECOND EDITION, P939; Bossart GD, 1999, J AM VET MED ASSOC, V214, P1178; Bossart GD, 2002, EXP MOL PATHOL, V72, P37, DOI 10.1006/exmp.2001.2407; Bossart GD, 1998, TOXICOL PATHOL, V26, P276, DOI 10.1177/019262339802600214; BOSSART GD, 2007, MICROBE, V2, P544; Bossart Gregory D., 2004, Aquatic Mammals, V30, P434, DOI 10.1578/AM.30.3.2004.434; BUERGELT CD, 1984, J AM VET MED ASSOC, V185, P1331; Campbell R.S.F., 1981, P176; Carter AM, 2008, REPROD FERT DEVELOP, V20, P537, DOI 10.1071/RD08009; Chansue N., 2006, P AS ZOO WILDL MED P, P56; COLARES EP, 1992, COMP BIOCHEM PHYS A, V103, P413, DOI 10.1016/0300-9629(92)90603-N; CONVERSE LJ, 1994, J ZOO WILDLIFE MED, V25, P423; Sidrim JJC, 2015, DIS AQUAT ORGAN, V113, P69, DOI 10.3354/dao02827; Cray C, 2013, J ZOO WILDLIFE MED, V44, P911, DOI 10.1638/2012-0270R.1; De Meirelles ACO, 2008, J MAR BIOL ASSOC UK, V88, P1133, DOI 10.1017/S0025315408000817; Dilbone R. P., 1965, J AM VET MED ASSOC, V147, P1095; DOMNING DP, 1991, MAR MAMMAL SCI, V7, P331, DOI 10.1111/j.1748-7692.1991.tb00111.x; Dona MG, 2011, J WILDLIFE DIS, V47, P673, DOI 10.7589/0090-3558-47.3.673; ELLIOTT H, 1981, J WILDLIFE DIS, V17, P203, DOI 10.7589/0090-3558-17.2.203; Enders AC, 2004, PLACENTA, V25, pS3, DOI 10.1016/j.placenta.2004.01.011; ENGEL S, 1962, ACTA ANAT, V48, P95; Eros C., 2007, PROCEDURES SALVAGE N, P98; Fire SE, 2015, MAR ECOL PROG SER, V526, P241, DOI 10.3354/meps11225; Flewelling LJ, 2005, NATURE, V435, P755, DOI 10.1038/nature435755a; Gerlach TJ, 2013, J ZOO WILDLIFE MED, V44, P295, DOI 10.1638/2012-0109R.1; Gerlach TJ, 2012, J WILDLIFE DIS, V48, P1102, DOI 10.7589/2011-12-344; Gillespie A, 2011, AUST VET J, V89, P276, DOI 10.1111/j.1751-0813.2011.00791.x; Hammer AS, 2005, J WILDLIFE DIS, V41, P834, DOI 10.7589/0090-3558-41.4.834; Harr K, 2006, J ZOO WILDLIFE MED, V37, P151, DOI 10.1638/05-023.1; Harr KE, 2011, J WILDLIFE DIS, V47, P1026, DOI 10.7589/0090-3558-47.4.1026; Harvey JW, 2007, J ZOO WILDLIFE MED, V38, P269, DOI 10.1638/1042-7260(2007)038[0269:CBIHMT]2.0.CO;2; Harvey JW, 2009, VET CLIN PATH, V38, P183, DOI 10.1111/j.1939-165X.2009.00113.x; HEINSOHN G E, 1974, Biological Conservation, V6, P143, DOI 10.1016/0006-3207(74)90026-3; Heinsohn GE, 1972, AUSTR BIOL CONSERV, V4, P205; HILL DA, 1989, ACTA ANAT, V135, P53; IUCN, VERS 2015 4 IUCN RED; Jefferson T. A., 1993, FAO SPECIES IDENTIFI, V320, P587; Keller M, 2008, J WILDLIFE DIS, V44, P707, DOI 10.7589/0090-3558-44.3.707; KENCHINGTON RA, 1972, J MAMMAL, V53, P884, DOI 10.2307/1379226; Kiehl A. R., 1994, Vet Clin Pathol, V23, P50; Landsberg JH, 2009, HARMFUL ALGAE, V8, P598, DOI 10.1016/j.hal.2008.11.010; Lanyon JM, 2015, VET CLIN PATH, V44, P234, DOI 10.1111/vcp.12249; Lanyon JM, 2012, J ZOO WILDLIFE MED, V43, P20, DOI 10.1638/2010-0178.1; Larkin ILV, 2007, ZOO BIOL, V26, P503, DOI 10.1002/zoo.20150; Lightsey JD, 2006, J ZOO WILDLIFE MED, V37, P262, DOI 10.1638/04-095.1; Marmontel M, 1996, MAR MAMMAL SCI, V12, P54, DOI 10.1111/j.1748-7692.1996.tb00305.x; Marsh H., 2011, ECOLOGY CONSERVATION, P263; MEDWAY W, 1982, J WILDLIFE DIS, V18, P229, DOI 10.7589/0090-3558-18.2.229; MITCHELL J, 1973, ZOOL J LINN SOC-LOND, V53, P1, DOI 10.1111/j.1096-3642.1973.tb01409.x; Moore DP, 2008, REV BIOL TROP, V56, P277; MORALES P, 1985, J AM VET MED ASSOC, V187, P1230; Naar J, 2002, ENVIRON HEALTH PERSP, V110, P179, DOI 10.1289/ehp.02110179; Nielsen KA, 2013, J ZOO WILDLIFE MED, V44, P35, DOI 10.1638/1042-7260-44.1.35; Odell D. K., 2003, WILD MAMMALS N AM, P855; OSHEA TJ, 1985, BIOL CONSERV, V33, P335, DOI 10.1016/0006-3207(85)90075-8; OSHEA TJ, 1985, J WILDLIFE MANAGE, V49, P1, DOI 10.2307/3801830; OSHEA TJ, 1991, MAR MAMMAL SCI, V7, P165, DOI 10.1111/j.1748-7692.1991.tb00563.x; Owen H, 2012, J WILDLIFE DIS, V48, P962, DOI 10.7589/2011-03-080; Owen HC, 2013, DIS AQUAT ORGAN, V103, P1, DOI 10.3354/dao02568; PREEN A, 1995, WILDLIFE RES, V22, P507, DOI 10.1071/WR9950507; Rector A, 2004, J VIROL, V78, P12698, DOI 10.1128/JVI.78.22.12698-12702.2004; Reep RL, 1998, MAR MAMMAL SCI, V14, P257, DOI 10.1111/j.1748-7692.1998.tb00715.x; REEP RL, 1990, BRAIN BEHAV EVOLUT, V35, P185, DOI 10.1159/000115866; Reynolds JE, 1996, ANAT REC, V245, P539, DOI 10.1002/(SICI)1097-0185(199607)245:3<539::AID-AR11>3.0.CO;2-Q; Rommel S, 2000, ANAT REC, V259, P41; Rommel SA, 2007, MAR MAMMAL SCI, V23, P110, DOI 10.1111/j.1748-7692.2006.00095.x; Runge M. C., 2017, 20175030 US GOEL SUR; Sato T, 2003, J ZOO WILDLIFE MED, V34, P184; Silva FMO, 2007, J VET MED A, V54, P119, DOI 10.1111/j.1439-0442.2007.00891.x; Smith LN, 2015, J ZOO WILDLIFE MED, V46, P895, DOI 10.1638/2014-0195.1; Sulzner K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044517; Tabuchi K., 1974, Bulletin Azabu vet Coll, VNo. 28, P127; TENNEY SM, 1958, AM HEART J, V56, P933, DOI 10.1016/0002-8703(58)90203-5; Varela-Lasheras I, 2011, EVODEVO, V2, DOI 10.1186/2041-9139-2-11; Vergara-Parente J. E., 2002, AQUAT MAMM, V29, P131; Walsh CJ, 2015, AQUAT TOXICOL, V161, P73, DOI 10.1016/j.aquatox.2015.01.019; Walsh CJ, 2005, VET IMMUNOL IMMUNOP, V103, P247, DOI 10.1016/j.vetimm.2004.09.026; Walsh M. T., 2014, FOWLERS ZOO WILD ANI, P450; WALSH MT, 1987, J WILDLIFE DIS, V23, P702, DOI 10.7589/0090-3558-23.4.702; Ward L. I., 2009, FWC FLORIDA MANATEE; WATSON AG, 1986, CLIN ORTHOP RELAT R, P294; Wellehan JFX, 2008, VET MICROBIOL, V127, P249, DOI 10.1016/j.vetmic.2007.08.024; Woods Rupert, 2008, P615; Woolford L, 2015, DIS AQUAT ORGAN, V113, P89, DOI 10.3354/dao02825; Woolford L, 2015, VET CLIN PATH, V44, P530, DOI 10.1111/vcp.12305	97	0	0	1	1	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							593	+		10.1016/B978-0-12-805306-5.00024-9			18	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300026					2019-10-28	
B	Farina, LL; Lankton, JS		Terio, KA; McAloose, D; StLeger, J		Farina, Lisa L.; Lankton, Julia S.			Chiroptera	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							WHITE-NOSE SYNDROME; BIG BROWN BATS; CENTRAL-NERVOUS-SYSTEM; IRON STORAGE DISEASE; INDIAN FLYING FOXES; FRUIT BATS; MYOTIS-LUCIFUGUS; RABIES VIRUS; MOLECULAR CHARACTERIZATION; ROUSETTUS-AEGYPTIACUS		[Farina, Lisa L.] Univ Florida, Gainesville, FL 32611 USA; [Lankton, Julia S.] US Geol Survey, Natl Wildlife Hlth Ctr, Madison, WI USA	Farina, LL (reprint author), Univ Florida, Gainesville, FL 32611 USA.						Aitken-Palmer C, 2012, VET REC, V170, DOI 10.1136/vr.100214; Akbar H, 2012, APPL ENVIRON MICROB, V78, P8122, DOI 10.1128/AEM.01791-12; Allendorf SD, 2012, VIRUS RES, V165, P119, DOI 10.1016/j.virusres.2012.01.011; ALTRINGHAM J. D., 1996, BATS BIOL BEHAV; Amaral TS, 2012, ACTA CHIROPTEROL, V14, P225, DOI 10.3161/150811012X654420; Amman BR, 2015, J WILDLIFE DIS, V51, P113, DOI 10.7589/2014-08-198; Ansari AA, 2014, J AUTOIMMUN, V55, P1, DOI 10.1016/j.jaut.2014.09.001; Ceballos NA, 2013, EMERG INFECT DIS, V19, P793, DOI 10.3201/eid1905.121071; Badwaik Nilima K., 2000, P221, DOI 10.1016/B978-012195670-7/50007-2; Baerwald EF, 2008, CURR BIOL, V18, pR695, DOI 10.1016/j.cub.2008.06.029; Ballmann AE, 2017, J WILDLIFE DIS, V53, P725, DOI 10.7589/2016-09-206; Bandouchova H, 2015, TRANSBOUND EMERG DIS, V62, P1, DOI 10.1111/tbed.12282; Banyard AC, 2014, VIRUSES-BASEL, V6, P2974, DOI 10.3390/v6082974; Banyard AC, 2011, ADV VIRUS RES, V79, P239, DOI 10.1016/B978-0-12-387040-7.00012-3; Barlow A, 2011, VET REC, V169, DOI 10.1136/vr.d7783; Barr JA, 2012, J GEN VIROL, V93, P2590, DOI 10.1099/vir.0.045385-0; Barrett J., 2005, WILDL DIS ASS INT C, P149; Barrett JL, 2002, AUST VET J, V80, P554, DOI 10.1111/j.1751-0813.2002.tb11039.x; Bello-Gutierrez J, 2010, J WILDLIFE DIS, V46, P1000, DOI 10.7589/0090-3558-46.3.1000; Ben-Hamo Miriam, 2012, P257; Berzunza-Cruz M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003438; BHIDE SA, 1980, MAMMALIA, V44, P571, DOI 10.1515/mamm.1980.44.4.571; Blehert DS, 2014, J WILDLIFE DIS, V50, P136, DOI 10.7589/2012-02-063; Blehert DS, 2009, SCIENCE, V323, P227, DOI 10.1126/science.1163874; BOJARSKI C, 1988, S AFR J ZOOL, V23, P155; BOTELLA P, 1995, FOLIA PARASIT, V42, P143; Brass D. A., 1994, RABIES BATS NATURAL; Brauburger K, 2012, VIRUSES-BASEL, V4, P1878, DOI 10.3390/v4101878; Brock AP, 2013, J VET DIAGN INVEST, V25, P433, DOI 10.1177/1040638713486645; Brook CE, 2015, TRENDS MICROBIOL, V23, P172, DOI 10.1016/j.tim.2014.12.004; Brook CE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003532; Brudenall DK, 2007, ANAT HISTOL EMBRYOL, V36, P382, DOI 10.1111/j.1439-0264.2007.00779.x; Brygoo E R, 1970, Bull Soc Pathol Exot Filiales, V63, P540; Buettner PG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073078; Burd EM, 2015, J CLIN MICROBIOL, V53, P4, DOI 10.1128/JCM.03115-14; Calisher CH, 2006, CLIN MICROBIOL REV, V19, P531, DOI 10.1128/CMR.00017-06; Sanches EMC, 2013, J MYCOL MED, V23, P47, DOI 10.1016/j.mycmed.2012.11.002; Chant K, 1998, EMERG INFECT DIS, V4, P273, DOI 10.3201/eid0402.980215; Chen LH, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau021; Childs-Sanford SE, 2009, J ZOO WILDLIFE MED, V40, P8, DOI 10.1638/2007-0033.1; Childs-Sanford SE, 2006, J COMP PATHOL, V134, P370, DOI 10.1016/j.jcpa.2006.01.004; Chua KB, 2007, P NATL ACAD SCI USA, V104, P11424, DOI 10.1073/pnas.0701372104; Chua KB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003803; Clark D. R., 1981, BATS ENV CONTAMINANT; Clark Donald R. Jr, 2001, P159; CLARK DR, 1981, J TOXICOL ENV HEALTH, V7, P925, DOI 10.1080/15287398109530035; Clark DR, 2001, ARCH ENVIRON CON TOX, V40, P537; Clayton BA, 2013, ZOONOSES PUBLIC HLTH, V60, P69, DOI 10.1111/j.1863-2378.2012.01501.x; Cogswell-Hawkinson A, 2012, J VIROL, V86, P5791, DOI 10.1128/JVI.00201-12; Concannon R, 2005, PARASITOLOGY, V131, P489, DOI 10.1017/S0031182005008097; Constantine D. G., 2009, BAT RABIES OTHER LYS; Constantine Denny G., 1993, P310; Cordeiro RD, 2012, EMERG INFECT DIS, V18, P668, DOI 10.3201/eid1804.111641; Courtin F, 2010, VET PATHOL, V47, P214, DOI 10.1177/0300985809358614; Crawshaw G., 1995, 1 C ZOO WILDL NUTR A; Crossland NA, 2016, J VET DIAGN INVEST, V28, P54, DOI 10.1177/1040638715614346; Cryan PM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-135; Cryan PM, 2009, J MAMMAL, V90, P1330, DOI 10.1644/09-MAMM-S-076R1.1; Dacheux L, 2009, EMERG INFECT DIS, V15, P280, DOI 10.3201/eid1502.080637; Davis A, 2012, VECTOR-BORNE ZOONOT, V12, P55, DOI 10.1089/vbz.2011.0674; Davis AD, 2007, J INFECT DIS, V195, P1144, DOI 10.1086/512616; Davis AD, 2013, J VIROL, V87, P9008, DOI 10.1128/JVI.03554-12; de Araujo JL, 2014, J WILDLIFE DIS, V50, P883, DOI 10.7589/2013-11-314; DEFREES S L, 1988, Mammalian Species, P1, DOI 10.2307/3504095; DeMarco JH, 2002, J ZOO WILDLIFE MED, V33, P147; Dennis GC, 2015, J WILDLIFE DIS, V51, P177, DOI 10.7589/2013-07-160; Dick CW, 2003, J MED ENTOMOL, V40, P813, DOI 10.1603/0022-2585-40.6.813; Dietrich M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005176; DIXIT VP, 1974, INDIAN J EXP BIOL, V12, P200; DOWNS WG, 1963, AM J TROP MED HYG, V12, P640, DOI 10.4269/ajtmh.1963.12.640; Drexler JF, 2014, ANTIVIR RES, V101, P45, DOI 10.1016/j.antiviral.2013.10.013; Drexler JF, 2011, EMERG INFECT DIS, V17, P449, DOI 10.3201/eid1703.100526; Duncan M, 1996, J ZOO WILDLIFE MED, V27, P325; Emerson GL, 2013, EMERG INFECT DIS, V19, P1002, DOI 10.3201/eid1906.121713; Evans NJ, 2009, EMERG INFECT DIS, V15, P1331, DOI 10.3201/eid1508.090475; Farina LL, 2005, J ZOO WILDLIFE MED, V36, P212, DOI 10.1638/03-115.1; Fenton M. B., 2014, BATS WORLD SCI MYSTE; Fleming Gregory J., 2001, P305; Formenty P, 1999, J INFECT DIS, V179, pS120, DOI 10.1086/514296; Francis JR, 2014, MED J AUSTRALIA, V201, P647, DOI 10.5694/mja13.00261; Frank C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095175; Freuing CM, 2015, VIRUS RES, V210, P42, DOI 10.1016/j.virusres.2015.07.009; Frick WF, 2010, SCIENCE, V329, P679, DOI 10.1126/science.1188594; Fuller NW, 2011, ECOHEALTH, V8, P154, DOI 10.1007/s10393-011-0705-y; Gadelha-Alves R, 2008, INT J MORPHOL, V26, P591, DOI 10.4067/S0717-95022008000300014; GARNHAM PCC, 1950, NATURE, V166, P155, DOI 10.1038/166155b0; GELUSO KN, 1976, SCIENCE, V194, P184, DOI 10.1126/science.959845; Gonzalez-Gonzalez AE, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-23; Gozalo AS, 2005, CONTEMP TOP LAB ANIM, V44, P49; GREEN R, 1975, NATURE, V254, P148, DOI 10.1038/254148a0; GREENHALL A M, 1983, Mammalian Species, P1, DOI 10.2307/3503895; GREER DL, 1981, AM J TROP MED HYG, V30, P653, DOI 10.4269/ajtmh.1981.30.653; Grodsky SM, 2011, J MAMMAL, V92, P917, DOI 10.1644/10-MAMM-A-404.1; Gruber AD, 1996, VET PATHOL, V33, P442, DOI 10.1177/030098589603300414; Gunawardena PS, 2016, EMERG INFECT DIS, V22, P1456, DOI 10.3201/eid2208.151986; GUPTA BHARAT B., 1967, MAMMALIA, V31, P313, DOI 10.1515/mamm.1967.31.2.313; Hajkova P, 2007, VET REC, V161, P139, DOI 10.1136/vr.161.4.139; Halpin K, 2011, AM J TROP MED HYG, V85, P946, DOI 10.4269/ajtmh.2011.10-0567; Hamerton A. E., 1931, Proceedings of the Zoological Society of London, V1931, P527; Handley C. O., 1991, DEMOGRAPHY NATURAL H, V511; HARIONO B, 1993, WILDLIFE RES, V20, P315, DOI 10.1071/WR9930315; Hasegawa H, 2012, J PARASITOL, V98, P995, DOI 10.1645/GE-2710.1; Hausmann J., 2015, 11 C ZOO WILDL NUTR; Heard D. J., 2003, ZOO WILD ANIMAL MED, P315; Heard Darryl J., 1999, P344; Heard DJ, 1996, J ZOO WILDLIFE MED, V27, P149; Heard DJ, 1995, J ZOO WILDLIFE MED, V26, P550; Hedenstrom A, 2015, J EXP BIOL, V218, P653, DOI 10.1242/jeb.031203; Helmick KE, 2004, J ZOO WILDLIFE MED, V35, P88, DOI 10.1638/01-083; Henson OW, 1970, BIOL BATS, VII, P57; Hernout BV, 2015, ENVIRON POLLUT, V206, P209, DOI 10.1016/j.envpol.2015.06.016; Hoenerhoff M, 2004, J VET DIAGN INVEST, V16, P590, DOI 10.1177/104063870401600619; HOLBROOK KA, 1978, J ANAT, V126, P21; Hooper P, 2001, MICROBES INFECT, V3, P315, DOI 10.1016/S1286-4579(01)01385-5; Hooper PT, 1999, AUST VET J, V77, P595, DOI 10.1111/j.1751-0813.1999.tb13198.x; Hoyt JR, 2016, EMERG INFECT DIS, V22, P140, DOI 10.3201/eid2201.151314; Hui DS, 2014, CURR OPIN PULM MED, V20, P233, DOI 10.1097/MCP.0000000000000046; HURLEY S, 1980, B ENVIRON CONTAM TOX, V25, P503, DOI 10.1007/BF01985562; Ikegami T, 2002, EXP ANIM TOKYO, V51, P447, DOI 10.1538/expanim.51.447; Jansen AM, 2015, ACTA TROP, V151, P1, DOI 10.1016/j.actatropica.2015.07.018; KALUNDA M, 1986, AM J TROP MED HYG, V35, P387, DOI 10.4269/ajtmh.1986.35.387; Karawita AC, 2017, J WILDLIFE DIS, V53, P414, DOI 10.7589/2016-07-170; Krutzsch P. H., 2000, REPROD BIOL BATS, P92; Ksiazek TG, 2011, VIRUS RES, V162, P173, DOI 10.1016/j.virusres.2011.09.026; Kurta A, 2007, ACTA CHIROPTEROL, V9, P495, DOI 10.3161/1733-5329(2007)9[495:TSAINW]2.0.CO;2; KUSEWITT DF, 1977, VET PARASITOL, V3, P365, DOI 10.1016/0304-4017(77)90022-X; Ladds P.W., 2009, PATHOLOGY AUSTR NATI; Landau I, 2012, PARASITE, V19, P137, DOI 10.1051/parasite/2012192137; Langwig KE, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.2335; Lankton JS, 2013, J ZOO WILDLIFE MED, V44, P124, DOI 10.1638/1042-7260-44.1.124; LAVOIPIERRE MM, 1968, PARASITOLOGY, V58, P515, DOI 10.1017/S0031182000028821; Leone AM, 2016, J ZOO WILDLIFE MED, V47, P45, DOI 10.1638/2015-0224.1; Leroy EM, 2005, NATURE, V438, P575, DOI 10.1038/438575a; Leroy EM, 2009, VECTOR-BORNE ZOONOT, V9, P723, DOI 10.1089/vbz.2008.0167; Li N, 2014, INT J MOL SCI, V15, P5193, DOI 10.3390/ijms15045193; Lilley TM, 2013, COMP BIOCHEM PHYS C, V157, P298, DOI 10.1016/j.cbpc.2013.01.003; Lorch JM, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00148-16; Lorch JM, 2015, J WILDLIFE DIS, V51, P36, DOI 10.7589/2014-05-134; Love RJ, 2001, AUST VET J, V79, P192, DOI 10.1111/j.1751-0813.2001.tb14578.x; Mackay IM, 2015, VIRUS RES, V202, P60, DOI 10.1016/j.virusres.2015.01.021; Mackie JT, 2013, AUST VET J, V91, P366, DOI 10.1111/avj.12082; Makanya AN, 2007, J ANAT, V211, P687, DOI 10.1111/j.1469-7580.2007.00817.x; MARINKELLE CJ, 1968, NATURE, V218, P487, DOI 10.1038/218487a0; Markotter W, 2006, EMERG INFECT DIS, V12, P504, DOI 10.3201/eid1203.051306; Markotter W, 2006, EMERG INFECT DIS, V12, P1913; Savani ESMM, 2010, VET PARASITOL, V168, P5, DOI 10.1016/j.vetpar.2009.10.019; Mascarelli PE, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-117; McAllister CT, 2009, J PARASITOL, V95, P991, DOI 10.1645/GE-1967.1; McKnight CA, 2006, J ZOO WILDLIFE MED, V37, P193, DOI 10.1638/05-101.1; McLelland DJ, 2013, J WILDLIFE DIS, V49, P1009, DOI 10.7589/2012-11-288; MCMURRAY DN, 1979, AM J TROP MED HYG, V28, P1036, DOI 10.4269/ajtmh.1979.28.1036; MEREDITH C D, 1971, South African Medical Journal, V45, P767; MEREDITH CD, 1981, LANCET, V1, P832; Meteyer CU, 2012, VIRULENCE, V3, P583, DOI 10.4161/viru.22330; Meteyer CU, 2011, J WILDLIFE DIS, V47, P618, DOI 10.7589/0090-3558-47.3.618; Meteyer CU, 2009, J VET DIAGN INVEST, V21, P411, DOI 10.1177/104063870902100401; METTLER F, 1975, VET PATHOL, V12, P118, DOI 10.1177/030098587501200204; Pinto CM, 2013, J PARASITOL, V99, P722, DOI 10.1645/12-18.1; Miia JV, 2015, ARCH VIROL, V160, P1489, DOI 10.1007/s00705-015-2424-0; Moras LM, 2013, ACTA PARASITOL, V58, P556, DOI 10.2478/s11686-013-0179-x; Muhldorfer K, 2013, ZOONOSES PUBLIC HLTH, V60, P93, DOI 10.1111/j.1863-2378.2012.01536.x; Muhldorfer K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029773; Muhldorfer K, 2011, BMC VET RES, V7, DOI 10.1186/1746-6148-7-61; Muhldorfer K, 2010, EMERG INFECT DIS, V16, P578, DOI 10.3201/eid1603.091035; Naidoo S, 2013, AFR ZOOL, V48, P39, DOI 10.3377/004.048.0111; Naidoo S, 2016, ENVIRON POLLUT, V208, P830, DOI 10.1016/j.envpol.2015.09.056; Naidoo S, 2015, ECOTOX ENVIRON SAFE, V114, P304, DOI 10.1016/j.ecoenv.2014.04.043; Nakamura S, 2013, J COMP PATHOL, V148, P410, DOI 10.1016/j.jcpa.2012.07.007; Napier JE, 2009, J ZOO WILDLIFE MED, V40, P437, DOI 10.1638/2007-0161.1; Nassar JM, 2008, ZOOLOGY, V111, P363, DOI 10.1016/j.zool.2007.10.006; Nathwani D, 2003, CLIN INFECT DIS, V37, P598, DOI 10.1086/376641; Neuweiler G, 2000, BIOL BATS; NGUYEN HT, 1987, LAB ANIM SCI, V37, P672; Nowak R. M., 1999, ORDER CHIROPTERA WAL, P253; O'Shea Thomas J., 2002, P237; O'Shea TJ, 2016, MAMMAL REV, V46, P175, DOI 10.1111/mam.12064; O'Shea TJ, 2001, ARCH ENVIRON CON TOX, V40, P112, DOI 10.1007/s002440010153; OKON EE, 1977, ACTA ZOOL-STOCKHOLM, V58, P83, DOI 10.1111/j.1463-6395.1977.tb00242.x; Olival KJ, 2014, VIRUSES-BASEL, V6, P1759, DOI 10.3390/v6041759; Olsson Annabelle, 2008, P465; Paweska JT, 2006, EMERG INFECT DIS, V12, P1965; PERRIN MR, 1992, Z SAUGETIERKD, V57, P257; Philbey AW, 2008, AUST VET J, V86, P449, DOI 10.1111/j.1751-0813.2008.00361.x; Philbey AW, 2007, AUST VET J, V85, P134, DOI 10.1111/j.1751-0813.2007.00131.x; Pikula J, 2012, J WILDLIFE DIS, V48, P207, DOI 10.7589/0090-3558-48.1.207; Prociv P., 1985, Australian Mammalogy, V8, P319; PROCIV P, 1983, Z PARASITENKD, V69, P773, DOI 10.1007/BF00927426; PROCIV P, 1990, J WILDLIFE DIS, V26, P532, DOI 10.7589/0090-3558-26.4.532; PYBUS MJ, 1986, J WILDLIFE DIS, V22, P449, DOI 10.7589/0090-3558-22.3.449; Quay W. B., 1970, P1; Raymond JT, 1997, J VET DIAGN INVEST, V9, P85, DOI 10.1177/104063879700900117; Reddacliff LA, 1999, AUST VET J, V77, P466, DOI 10.1111/j.1751-0813.1999.tb12095.x; Reeder DM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038920; Reichard JD, 2009, ACTA CHIROPTEROL, V11, P457, DOI 10.3161/150811009X485684; Reynolds HT, 2015, J WILDLIFE DIS, V51, P318, DOI 10.7589/2014-06-157; Rollins KE, 2012, VET PATHOL, V49, P362, DOI 10.1177/0300985812436745; Roque Andre Luiz R., 2014, International Journal for Parasitology Parasites and Wildlife, V3, P251, DOI 10.1016/j.ijppaw.2014.08.004; Rouquet P, 2005, EMERG INFECT DIS, V11, P283, DOI 10.3201/eid1102.040533; Sangster CR, 2012, AUST VET J, V90, P140, DOI 10.1111/j.1751-0813.2011.00868.x; Schaer J, 2013, P NATL ACAD SCI USA, V110, P17415, DOI 10.1073/pnas.1311016110; Schatz J, 2014, VET MICROBIOL, V169, P33, DOI 10.1016/j.vetmic.2013.12.004; Schatz J, 2013, ZOONOSES PUBLIC HLTH, V60, P22, DOI 10.1111/zph.12002; Schutt William A. Jr., 1998, Journal of Mammalian Evolution, V5, P1; Scott HH, 1926, P ZOOL SOC LOND, V1926, P231; Shapiro JT, 2013, ACTA TROP, V128, P171, DOI 10.1016/j.actatropica.2013.07.004; Shinwari MW, 2014, VET MICROBIOL, V173, P224, DOI 10.1016/j.vetmic.2014.07.029; Siegal-Willott J, 2007, J ZOO WILDLIFE MED, V38, P352, DOI 10.1638/1042-7260(2007)038[0352:MLIAEF]2.0.CO;2; Simmons JH, 2002, COMPARATIVE MED, V52, P97; Simpson VR, 2013, J VET DIAGN INVEST, V25, P551, DOI 10.1177/1040638713493780; Skerratt LF, 1998, J WILDLIFE DIS, V34, P355, DOI 10.7589/0090-3558-34.2.355; Smales LR, 2007, COMP PARASITOL, V74, P237, DOI 10.1654/4271.1; Snyder JM, 2015, COMPARATIVE MED, V65, P133; Stein LT, 2010, VET PATHOL, V47, P630, DOI 10.1177/0300985810370013; Stevens C. E., 1995, COMP PHYSL VERTEBRAT; Stringer E., 2013, 10 C ZOO WILDL NUTR; Strobel S, 2015, EUR J HISTOCHEM, V59, P107, DOI 10.4081/ejh.2015.2477; SUTTON RH, 1983, J WILDLIFE DIS, V19, P294, DOI 10.7589/0090-3558-19.3.294; SWANEPOEL R, 1993, ONDERSTEPOORT J VET, V60, P325; Swanepoel RE, 1999, ENVIRON POLLUT, V104, P169, DOI 10.1016/S0269-7491(98)00196-1; Swartz SM, 1996, J ZOOL, V239, P357, DOI 10.1111/j.1469-7998.1996.tb05455.x; Takahashi M, 2006, J MED ENTOMOL, V43, P128, DOI 10.1603/0022-2585(2006)043[0128:WFNATA]2.0.CO;2; Takami T, 2011, J CLIN BIOCHEM NUTR, V48, P103, DOI 10.3164/jcbn.10-76; Tandler B, 1996, J COMP PATHOL, V114, P1, DOI 10.1016/S0021-9975(96)80057-0; Taylor ML, 1999, AM J TROP MED HYG, V61, P914, DOI 10.4269/ajtmh.1999.61.914; TEDMAN RA, 1985, AUST J ZOOL, V33, P625, DOI 10.1071/ZO9850625; TESH RB, 1966, AM J TROP MED HYG, V15, P544, DOI 10.4269/ajtmh.1966.15.544; Tocidlowski M. E., 2003, ANN C AM ASS ZOO VET, P141; Turner GG, 2014, J WILDLIFE DIS, V50, P566, DOI 10.7589/2014-03-058; VANDERWESTHUYZEN J, 1983, J NUTR, V113, P531; Vaughan T. A., 1970, P97; Vaughan T. A., 2011, CHIROPTERA MAMMALOGY, P255; Verant Michelle L., 2014, BMC Physiology, V14, P10, DOI 10.1186/s12899-014-0010-4; Verant ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046280; Vogelnest L., 2015, BATS RADIOLOGY AUSTR, P187; Walton D. W, 1970, ABOUT BATS, P93; Wang W, 2013, J PARASITOL, V99, P1148, DOI 10.1645/13-322.1; Warnecke L, 2013, BIOL LETTERS, V9, DOI 10.1098/rsbl.2013.0177; WEBSTER WA, 1973, CAN J ZOOL, V51, P633, DOI 10.1139/z73-092; Welbergen JA, 2008, P ROY SOC B-BIOL SCI, V275, P419, DOI 10.1098/rspb.2007.1385; Wibbelt G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074105; Wild TF, 2009, PATHOL BIOL, V57, P188, DOI 10.1016/j.patbio.2008.04.006; Williams C. H., 2004, JOINT C AM ASS ZOO V, P299; Willis CKR, 2011, INTEGR COMP BIOL, V51, P364, DOI 10.1093/icb/icr076; Woller-Skar MM, 2015, AM MIDL NAT, V174, P331, DOI 10.1674/0003-0031-174.2.331; Wong K T, 2011, Patholog Res Int, V2011, P567248, DOI 10.4061/2011/567248; Wu ZQ, 2016, ISME J, V10, P609, DOI 10.1038/ismej.2015.138; Wunschmann A, 2010, J PARASITOL, V96, P178, DOI 10.1645/GE-2250.1; Yamanaka A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092777; Yates DE, 2014, ECOTOXICOLOGY, V23, P45, DOI 10.1007/s10646-013-1150-1; Zhang LB, 2009, ORYX, V43, P179, DOI 10.1017/S0030605309432022; Zhang YZ, 2014, VIRUS RES, V187, P15, DOI 10.1016/j.virusres.2013.12.035; Zocche JJ, 2010, ENVIRON RES, V110, P684, DOI 10.1016/j.envres.2010.06.003; ZOOK BC, 1970, J AM VET MED ASSOC, V157, P691; Zukal J, 2015, MAMM BIOL, V80, P220, DOI 10.1016/j.mambio.2015.01.001; Zukal J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097224	255	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							607	+		10.1016/B978-0-12-805306-5.00025-0			33	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300027					2019-10-28	
B	Smith, DA		Terio, KA; McAloose, D; StLeger, J		Smith, Dale A.			Palaeognathae: Apterygiformes, Casuariiformes, Rheiformes, Struthioniformes; Tinamiformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							EQUINE ENCEPHALOMYELITIS VIRUS; EMUS DROMAIUS-NOVAEHOLLANDIAE; BROWN KIWI; AVIAN INFLUENZA; HYPOPHOSPHATEMIC RICKETS; ENCEPHALITIS-VIRUS; REFERENCE VALUES; GUINEA-FOWL; NEW-ZEALAND; OSTRICHES		[Smith, Dale A.] Univ Guelph, Guelph, ON, Canada	Smith, DA (reprint author), Univ Guelph, Guelph, ON, Canada.						Abolnik C, 2016, AVIAN DIS, V60, P286, DOI 10.1637/11110-042815-Reg; aGill F. B., 2018, FOLIA ZOOL, DOI [10.14344/10C.ML.8.1, DOI 10.14344/10C.ML.8.1.BSALES]; Akkoc A, 2009, TURK J VET ANIM SCI, V33, P157; Allwright D., 1996, P27; Andreasen CB, 1997, VET CLIN PATH, V26, P165, DOI 10.1111/j.1939-165X.1997.tb00729.x; AYERS JR, 1994, J AM VET MED ASSOC, V205, P600; Baird GJ, 1997, VET REC, V140, P624, DOI 10.1136/vr.140.24.624; Banda ME, 2013, NEW ZEAL VET J, V61, P121, DOI 10.1080/00480169.2012.736130; BANG B G, 1971, Acta Anatomica, V79, P1; Barr AC, 1998, J VET DIAGN INVEST, V10, P77, DOI 10.1177/104063879801000113; Bello A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173873; BEZUIDENHOUT A, 1993, J S AFR VET ASSOC, V64, P159; Bezuidenhout AJ, 1999, OSTRICH: BIOLOGY, PRODUCTION AND HEALTH, P13; Biggs J. R., 2013, CAPTIVE MANAGEMENT G; Black PA, 2013, J AVIAN MED SURG, V27, P1; Blue-McLendon A., 2010, SCHALMS VET HEMATOLO, P987; Boardman W., 1998, KIW WORKSH P AUKL ZO, P61; BORST GHA, 1985, TIJDSCHR DIERGENEESK, V110, P536; BROWN TP, 1993, AVIAN DIS, V37, P602, DOI 10.2307/1591696; Button C., 1996, P35; Cabot J., 2012, HDB BIRDS WORLD, V1, P112; CAPUA I, 1994, AVIAN DIS, V38, P642, DOI 10.2307/1592092; Capua I, 2000, AVIAN PATHOL, V29, P643, DOI 10.1080/03079450020016913; Carreira V, 2011, J ZOO WILDLIFE MED, V42, P304, DOI 10.1638/2010-0146.1; Clark A. W. C., 2009, N Z J PARASITOL, V68, P175; Clark P, 2009, ATLAS CLIN AVIAN HEM; Clark W., 1981, INT C WILD LIF DIS A, P93; Cook, 2008, SURVEILLANCE, V24, P10; Cooper RG, 2007, AVIAN POULT BIOL REV, V18, P87, DOI 10.3184/147020607X270068; Cooper RG, 2007, NEW ZEAL VET J, V55, P130, DOI 10.1080/00480169.2007.36755; Cooper RG, 2007, TROP ANIM HEALTH PRO, V39, P439, DOI 10.1007/s11250-007-9044-y; Cowan D. F, 1968, VET PATHOL, V5, P51; Craig Thomas M., 1996, P115; Day JF, 1996, J AM MOSQUITO CONTR, V12, P429; Deeming D. C., 1999, SOURCES INFORM OSTRI; Dzoma BM, 2001, J AVIAN MED SURG, V15, P81, DOI 10.1647/1082-6742(2001)015[0081:YSRITO]2.0.CO;2; eAdby M. J, 1995, P JOINT C AM ASS ZOO, P428; FAUST BS, 1977, J ZOO ANIM MED, V8, P18; Ferreras MC, 2001, AVIAN DIS, V45, P251, DOI 10.2307/1593037; Foggin C. M, 1992, TOPAZ INTRO PRACTICA, P61; Folch A., 2012, HDB BIRDS WORLD, V1, P104; FOWLER ME, 1991, J ZOO WILDLIFE MED, V22, P204; Freitas Fagner Luiz da C., 2006, Revista Brasileira de Parasitologia Veterinaria, V15, P85; Fudge Alan M., 1996, P105; Garcia-Fernandez RA, 2000, VET REC, V146, P676, DOI 10.1136/vr.146.23.676; Gartrell BD, 2015, INT J PARASITOL-PAR, V4, P1, DOI 10.1016/j.ijppaw.2014.11.001; Gartrell BD, 2005, NEW ZEAL VET J, V53, P84, DOI 10.1080/00480169.2005.36474; Gough RE, 1997, VET REC, V140, P402, DOI 10.1136/vr.140.15.402; Griner L. A., 1983, PATHOLOGY ZOO ANIMAL; GRONE A, 1995, VET PATHOL, V32, P324; Guthrie A, 2016, JAVMA-J AM VET MED A, V249, P319, DOI 10.2460/javma.249.3.319; Ha HJ, 2013, NEW ZEAL VET J, V61, P49, DOI 10.1080/00480169.2012.700629; Hallam M. G., 1992, TOPAZ INTRO PRACTICA; Headley SA, 2005, VET REC, V156, P353, DOI 10.1136/vr.156.11.353; Heath Allen C. G., 2010, Tuhinga, P147; Hicks Karen D., 1993, P203; HILL FI, 1995, J MED VET MYCOL, V33, P305; Huchzermeyer F. W., 1998, DIS OSTRICHES OTHER; HUCHZERMEYER FW, 1993, J S AFR VET ASSOC, V64, P140; Jardine JE, 1997, AVIAN PATHOL, V26, P665, DOI 10.1080/03079459708419243; Jefferies R, 2008, J PARASITOL, V94, P557, DOI 10.1645/GE-1344.1; JEFFREY JS, 1994, AVIAN DIS, V38, P630, DOI 10.2307/1592090; Jensen J., 1992, HUSBANDRY MED MANAGE; Kang WH, 2006, IRISH VET J, V59, P148, DOI 10.1186/2046-0481-59-3-148; KINDER LL, 1995, AVIAN DIS, V39, P652, DOI 10.2307/1591824; KINSKY F C, 1971, Journal fuer Ornithologie, V112, P334, DOI 10.1007/BF01640692; Kummrow M. S., 2014, FOWLERS ZOO WILD ANI, V8, P75; Latch P., 2007, CASUARIUS CASUARIUS; LEVY A, 1990, AVIAN PATHOL, V19, P385, DOI 10.1080/03079459008418688; Mafuvadze Benford, 2007, Veterinarski Arhiv, V77, P427; Malik R, 2003, MED MYCOL, V41, P115, DOI 10.1080/714043906; MALKINSON M, 1995, CURR TOP MICROBIOL, V190, P31; Martins NRS, 2006, ARQ BRAS MED VET ZOO, V58, P291, DOI 10.1590/S0102-09352006000300001; McKenna P., 2010, WEBMEDCENTRAL PARASI, V1, P30; MCLELLAND J, 1989, J EXP ZOOL, P2; MERTINS JW, 1991, J WILDLIFE DIS, V27, P180, DOI 10.7589/0090-3558-27.1.180; Minnaar M., 1998, EMU FARMERS HDB, V2; Minnaar P., 1992, EMU FARMERS HDB; Mohammed B. R, 2015, RES J ANIM VET FISH, V3, P23; Momo C., 2007, BRAZ J VET SCI RES, V53, P227; Morgan KJ, 2017, PARASITOL RES, V116, P1433, DOI 10.1007/s00436-017-5414-1; Morgan KJ, 2012, PARASITOL RES, V111, P1689, DOI 10.1007/s00436-012-3008-5; Morgan K. J., 2008, KIWI 1 AID VET CARE; Morgan KJ, 2013, AVIAN PATHOL, V42, P137, DOI 10.1080/03079457.2013.776665; Moro M. E. G., 1994, Ars Veterinaria, V10, P50; Morrow CJ, 1997, VET REC, V140, P531, DOI 10.1136/vr.140.20.531; Mushi EZ, 2001, J S AFR VET ASSOC, V72, P46; Mushi EZ, 1998, ONDERSTEPOORT J VET, V65, P281; Neilsen A. M. W., 2017, AVIAN PATHOL, V47, P58; Ocal N, 2006, ACTA VET HUNG, V54, P213, DOI 10.1556/AVet.54.2006.2.8; ONDERKA DK, 1992, CAN VET J, V33, P547; Ornelas-Almeida MA, 2007, VET PARASITOL, V150, P374, DOI 10.1016/j.vetpar.2007.09.020; Palmieri C, 2015, VET PATHOL, V52, P160, DOI 10.1177/0300985814529314; PANIGRAHY B, 1995, AVIAN DIS, V39, P64, DOI 10.2307/1591983; Peirce MA, 2003, J NAT HIST, V37, P1797, DOI 10.1080/00222930110109082; PENRITH ML, 1994, ONDERSTEPOORT J VET, V61, P283; Perelman B., 1996, P47; Perelman Bension, 1995, Journal of Avian Medicine and Surgery, V9, P122; PHILBEY AW, 1991, AUST VET J, V68, P237, DOI 10.1111/j.1751-0813.1991.tb03215.x; Ponce-Gordo F, 2008, VET PARASITOL, V157, P41, DOI 10.1016/j.vetpar.2008.06.024; Prinzinger R, 2002, COMP BIOCHEM PHYS A, V131, P725, DOI 10.1016/S1095-6433(02)00010-7; Raines A. M., 1993, Proceedings of the Annual Conference of the Association of Avian Veterinarians, Nashville, 31 August-4 September 1993, P304; Randolph K, 1995, P ANN C ASS AV VET A, P5; RANDOLPH KD, 1994, J VET DIAGN INVEST, V6, P492, DOI 10.1177/104063879400600417; REECE RL, 1984, AUST VET J, V61, P403, DOI 10.1111/j.1751-0813.1984.tb07174.x; Reissig EC, 2001, AVIAN DIS, V45, P240, DOI 10.2307/1593035; Romer L, 1997, CASSOWARY HUSBANDRY; Marques MVR, 2012, J ZOO WILDLIFE MED, V43, P539, DOI 10.1638/2011-0262R1.1; Santos MMAB, 2005, Rev. Bras. Cienc. Avic., V7, P113, DOI 10.1590/S1516-635X2005000200008; Scataglini Alejandro, 2001, P65; Schutte K.H., 1973, South African Journal of Science, V69, P56; Shane S. M., 1996, RATITE MANAGEMENT ME; Shathele M. S., 2010, International Journal of Zoological Research, V6, P184, DOI 10.3923/ijzr.2009.80.85; Shivaprasad H.L., 1993, Proceedings Annual Conference Association of Avian Veterinarians, V1993, P282; Shivaprasad H. L, 1995, P ANN C ASS AV VET, P1; Silveira Luis Fabio, 2001, P72; SMITH BL, 1973, VET PATHOL, V10, P94, DOI 10.1177/030098587301000202; Sotiraki ST, 2001, VET REC, V148, P84, DOI 10.1136/vr.148.3.84; STOSKOPF MJ, 1982, J ZOO ANIM MED, V13, P160, DOI 10.2307/20094611; Teixeira CD, 2014, PARASITOL RES, V113, P3953, DOI 10.1007/s00436-014-4059-6; Tengelsen LA, 2001, J AM VET MED ASSOC, V218, P1469, DOI 10.2460/javma.2001.218.1469; THOMPSON EJ, 1978, NEW ZEAL VET J, V26, P167, DOI 10.1080/00480169.1978.34530; TOMIMURA T, 1970, JPN J VET SCI, V32, P25, DOI 10.1292/jvms1939.32.25; Travers C., 2015, BROWN KIWI APTERYX M; Tully T. N. J., 1998, VET CLINICS N AM FOO, V14; van Zyl N, 2014, THESIS MASSEY U PALM; VanDerHeyden N., 1992, Proceedings Annual Conference Association of Avian Veterinarians, V1992, P310; VANHOOSER SL, 1994, VET HUM TOXICOL, V36, P226; VEAZEY RS, 1994, VET PATHOL, V31, P109, DOI 10.1177/030098589403100115; Verstappen FALM, 2002, J WILDLIFE DIS, V38, P154, DOI 10.7589/0090-3558-38.1.154; Wang RJ, 2011, VET PARASITOL, V175, P151, DOI 10.1016/j.vetpar.2010.10.005; Woolcock PR, 2000, AVIAN DIS, V44, P737, DOI 10.2307/1593122; Yakimoff W. L., 1940, Annales de la Societe Belge de Medecine Tropicale, V20, P137	133	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							635	+		10.1016/B978-0-12-805306-5.00026-2			27	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300028					2019-10-28	
B	Stidworthy, MF; Denk, D		Terio, KA; McAloose, D; StLeger, J		Stidworthy, Mark F.; Denk, Daniela			Sphenisciformes, Gaviiformes, Podicipediformes, Procellariiformes, and Pelecaniformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							PENGUIN SPHENISCUS-HUMBOLDTI; CHLAMYDOPHILA-PSITTACI; BROWN PELICANS; COMMON LOONS; AVIAN POX; DISEASE; OUTBREAK; BIRDS; IDENTIFICATION; MORTALITY		[Stidworthy, Mark F.; Denk, Daniela] Int Zoo Vet Grp, Keighley, W Yorkshire, England	Stidworthy, MF (reprint author), Int Zoo Vet Grp, Keighley, W Yorkshire, England.						Adkesson MJ, 2007, J ZOO WILDLIFE MED, V38, P85, DOI 10.1638/06-004.1; Alley MR, 2017, J WILDLIFE DIS, V53, P102, DOI 10.7589/2015-07-195; Ardiles-Villegas K, 2011, AVIAN DIS, V55, P486, DOI 10.1637/9619-122010-ResNote.1; Bliss CD, 2015, VET OPHTHALMOL, V18, P86, DOI 10.1111/vop.12123; BLUS LJ, 1977, PESTIC MONIT J, V11, P40; Bradford C, 2008, J AVIAN MED SURG, V22, P331, DOI 10.1647/2007-059.1; Buckle KN, 2014, NEW ZEAL VET J, V62, P250, DOI 10.1080/00480169.2014.906332; Buckle KN, 2011, AVIAN PATHOL, V40, P371, DOI 10.1080/03079457.2011.586020; Clarke Judy R., 1993, Korean Journal of Polar Research, V4, P79; Denk D., 2016, JOINT EUR C ECVP ESV, P90; Duncan AE, 2014, J ZOO WILDLIFE MED, V45, P534, DOI 10.1638/2013-0207R1.1; Eulenberger K., 1995, P488; Greenwood AG, 2000, VET REC, V146, P172; Grilo ML, 2016, AVIAN PATHOL, V45, P393, DOI 10.1080/03079457.2016.1149145; Grimaldi WW, 2015, EMU, V115, P185, DOI 10.1071/MU14068; Herrmann B, 2006, EMERG INFECT DIS, V12, P330, DOI 10.3201/eid1202.050404; Herzke D, 2016, ENVIRON SCI TECHNOL, V50, P1924, DOI 10.1021/acs.est.5b04663; Hyatt MW, 2015, J ZOO WILDLIFE MED, V46, P880, DOI 10.1638/2015-0128.1; Ippen R., 1987, Verhandlungsbericht des Internationalen Symposiums uber die Erkrankungen der Zootiere, V29, P81; Jencek JE, 2012, J AVIAN MED SURG, V26, P225, DOI 10.1647/2010-046R1.1; Kane OJ, 2012, J WILDLIFE DIS, V48, P790, DOI 10.7589/0090-3558-48.3.790; KINCAID AL, 1988, J WILDLIFE DIS, V24, P173, DOI 10.7589/0090-3558-24.1.173; Kornetsky R, 2013, J WILDLIFE DIS, V49, P723, DOI 10.7589/2011-11-336; Krause KJ, 2015, J ZOO WILDLIFE MED, V46, P971, DOI 10.1638/2012-0205.1; Ladds P.W., 2009, PATHOLOGY AUSTR NATI; Landsberg J. H., 2007, ALGAL BIOTOXINS INFE, P431; Laughlin DS, 2016, J VET CARDIOL, V18, P290, DOI 10.1016/j.jvc.2016.04.001; Miller RE, 2015, FOWLERS ZOO WILD ANI; MUNDAY B L, 1971, Journal of Wildlife Diseases, V7, P126; NICHOLS DK, 1989, J ZOO WILDLIFE MED, V20, P57; NUTTALL PA, 1982, ARCH VIROL, V73, P1, DOI 10.1007/BF01341722; O'Connell KM, 2017, VET OPHTHALMOL, V20, P196, DOI 10.1111/vop.12389; Offerman K, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-463; Padilla L. R., 2014, FOWLERS ZOO WILD ANI, P89; Parsons NJ, 2015, DIS AQUAT ORGAN, V116, P149, DOI 10.3354/dao02907; Pauly Andreas, 2009, Zoologische Garten, V78, P141; Pesaro S, 2009, AVIAN PATHOL, V38, P229, DOI 10.1080/03079450902912176; Pfaff F, 2017, J GEN VIROL, V98, P89, DOI 10.1099/jgv.0.000698; Raidal SR, 2006, J AVIAN MED SURG, V20, P258, DOI 10.1647/1082-6742(2006)20[258:MILPEM]2.0.CO;2; REECE RL, 1992, AVIAN PATHOL, V21, P3, DOI 10.1080/03079459208418815; Reilly PN, 1975, BIOL PENGUINS, P161; Roberts AJ, 2014, WILSON J ORNITHOL, V126, P584, DOI 10.1676/13-192.1; Schmidt V, 2012, J AVIAN MED SURG, V26, P101, DOI 10.1647/2011-017.1; Schneider T., 2014, AZA PENGUIN TAXON AD; Seidel B., 1988, ZOOUND WILDTIERE, V30, P367; Sidor IF, 2003, J WILDLIFE DIS, V39, P306, DOI 10.7589/0090-3558-39.2.306; Simpson VR, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1214-1; Steele KE, 2000, VET PATHOL, V37, P208, DOI 10.1354/vp.37-3-208; Tuttle AD, 2005, JAVMA-J AM VET MED A, V226, P2059, DOI 10.2460/javma.2005.226.2059; Uhart M. M., 2017, BIRD CONSERV INT, P1; Watson M., 1883, REPORT ANATOMY SPHEN; White CL, 2015, J WILDLIFE DIS, V51, P101, DOI 10.7589/2014-05-132; WOBESER G, 1993, CAN VET J, V34, P353; Wunschmann A, 2006, VET PATHOL, V43, P1029, DOI 10.1354/vp.43-6-1029; Yonemaru K, 2004, AVIAN PATHOL, V33, P77, DOI 10.1080/03079450310001636327; Young LC, 2008, J FIELD ORNITHOL, V79, P93, DOI 10.1111/j.1557-9263.2008.00149.x	56	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							653	+		10.1016/B978-0-12-805306-5.00027-4			35	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300029					2019-10-28	
B	Buckles, EL		Terio, KA; McAloose, D; StLeger, J		Buckles, Elizabeth L.			Phoenicopteriformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							WEST NILE VIRUS; LESSER FLAMINGOS; IMMUNOHISTOCHEMICAL CHARACTERIZATION; RUBER; BIRDS; ANTIBODIES; CHILENSIS; FEATHERS; HEALTHY; ROSEUS		[Buckles, Elizabeth L.] Cornell Univ, Ithaca, NY 14850 USA	Buckles, EL (reprint author), Cornell Univ, Ithaca, NY 14850 USA.						Alonso-Andicoberry C, 2002, VET REC, V151, P706; Ancora S, 2008, ENVIRON RES, V107, P229, DOI 10.1016/j.envres.2008.02.004; Anthony SJ, 2014, ECOHEALTH, V11, P255, DOI 10.1007/s10393-014-0910-6; ARAI S, 1991, J COMP PATHOL, V104, P439, DOI 10.1016/S0021-9975(08)80154-5; Baitchman EJ, 2007, J ZOO WILDLIFE MED, V38, P337, DOI 10.1638/1042-7260(2007)038[0337:PTOMAT]2.0.CO;2; Bellehumeur C, 2015, J WILDLIFE DIS, V51, P244, DOI 10.7589/2013-11-293; Benato L, 2013, J ZOO WILDLIFE MED, V44, P245, DOI 10.1638/2011-0025R3.1; BRUSH AH, 1990, FASEB J, V4, P2969; Burger J, 2001, ENVIRON MONIT ASSESS, V69, P195, DOI 10.1023/A:1010710108434; Codd GA, 2003, VET REC, V152, P722; Coverdill CC, 2016, J VET DIAGN INVEST, V28, P219, DOI 10.1177/1040638716641157; Ferrell ST, 2007, J ZOO WILDLIFE MED, V38, P309, DOI 10.1638/1042-7260(2007)038[0309:FHIIMA]2.0.CO;2; Fowler M. E., 1986, ZOO WILD ANIMAL MED; Fowler M. E., 2001, BIOL MED SURG S AM W; Fowler M. E., 1978, ZOO WILD ANIMAL MED; Gobeli S, 2013, INT J SYST EVOL MICR, V63, P4046, DOI 10.1099/ijs.0.048546-0; Hammer S, 2007, J ZOO WILDLIFE MED, V38, P465, DOI 10.1638/06-035.1; HAWKEY C, 1984, AVIAN PATHOL, V13, P223, DOI 10.1080/03079458408418526; HAWKEY C, 1984, AVIAN PATHOL, V13, P163, DOI 10.1080/03079458408418521; Kock ND, 1999, J WILDLIFE DIS, V35, P297, DOI 10.7589/0090-3558-35.2.297; Krienitz L, 2003, FEMS MICROBIOL ECOL, V43, P141, DOI 10.1016/S0168-6496(02)00387-2; Metcalf JS, 2013, CHEMOSPHERE, V90, P835, DOI 10.1016/j.chemosphere.2012.09.094; Miller RE, 2015, FOWLERS ZOO WILD ANI; Mondal SP, 2008, AVIAN DIS, V52, P520, DOI 10.1637/8290-032008-RESNOTER; Poynton SL, 2000, J ZOO WILDLIFE MED, V31, P96; Shihmanter E, 1998, AVIAN DIS, V42, P829, DOI 10.2307/1592725; SILEO L, 1979, J WILDLIFE DIS, V15, P387, DOI 10.7589/0090-3558-15.3.387; SPANOGHE L, 1976, SABOURAUDIA, V14, P37; Thurber MI, 2014, J ZOO WILDLIFE MED, V45, P749, DOI 10.1638/2013-0284.1; Van Wettere AJ, 2013, J COMP PATHOL, V149, P434, DOI 10.1016/j.jcpa.2013.03.008; WADSWORTH PF, 1983, AVIAN PATHOL, V12, P321, DOI 10.1080/03079458308436174; Wyss F, 2015, VET PATHOL, V52, P1235, DOI 10.1177/0300985814568359; Wyss F, 2014, J ANIM PHYSIOL AN N, V98, P1102, DOI 10.1111/jpn.12184; Wyss F, 2013, SCHWEIZ ARCH TIERH, V155, P497, DOI 10.1024/0036-7281/a000499; Zeng BJ, 2008, MOL GENET METAB, V95, P59, DOI 10.1016/j.ymgme.2008.06.010; Zollinger TJ, 2005, J ZOO WILDLIFE MED, V36, P689, DOI 10.1638/04090.1; ZSCHIESCHE W, 1989, ACTA HISTOCHEM, V86, P45, DOI 10.1016/S0065-1281(89)80046-7	37	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							687	+		10.1016/B978-0-12-805306-5.00028-6			11	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300030					2019-10-28	
B	Fenton, H; McManamon, R; Howerth, EW		Terio, KA; McAloose, D; StLeger, J		Fenton, Heather; McManamon, Rita; Howerth, Elizabeth W.			Anseriformes, Ciconiiformes, Charadriiformes, and Gruiformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							DISSEMINATED VISCERAL COCCIDIOSIS; EIDERS SOMATERIA-MOLLISSIMA; CRANES GRUS-CANADENSIS; SWANS CYGNUS; VACUOLAR MYELINOPATHY; WHOOPING-CRANES; HISTOPATHOLOGICAL CHANGES; CRYPTOSPORIDIUM-BAILEYI; NEWCASTLE-DISEASE; VIRUS-INFECTION		[Fenton, Heather; McManamon, Rita; Howerth, Elizabeth W.] Univ Georgia, Athens, GA 30602 USA	Fenton, H (reprint author), Univ Georgia, Athens, GA 30602 USA.						Albers PH, 1996, J WILDLIFE DIS, V32, P468, DOI 10.7589/0090-3558-32.3.468; Allison AB, 2015, J VIROL, V89, P1389, DOI 10.1128/JVI.02019-14; Andersen Arthur A., 2007, P303, DOI 10.1002/9780470344668.ch15; ANDREASEN JK, 1987, ENVIRON TOXICOL CHEM, V6, P291, DOI 10.1002/etc.5620060406; ANKNEY CD, 1978, AUK, V95, P459; ASPLIN F. D., 1961, Veterinary Record, V73, P1215; Backues K. A., 2015, FOWLERS ZOO WILD ANI, P116; BAILEY R O, 1976, Wildlife Society Bulletin, V4, P26; Balseiro A, 2005, J WILDLIFE DIS, V41, P371, DOI 10.7589/0090-3558-41.2.371; Bartels T, 2002, VET PATHOL, V39, P396, DOI 10.1354/vp.39-3-396; Bartholomew JL, 2008, INT J PARASITOL, V38, P1199, DOI 10.1016/j.ijpara.2008.01.008; BARTLETT C M, 1984, Journal of Wildlife Diseases, V20, P289; BERGAN JF, 1994, J WILDLIFE DIS, V30, P351, DOI 10.7589/0090-3558-30.3.351; Bidin M, 2012, AVIAN PATHOL, V41, P91, DOI 10.1080/03079457.2011.642796; Bildfell RJ, 2013, J VET DIAGN INVEST, V25, P162, DOI 10.1177/1040638712472499; Birrenkott AH, 2004, J WILDLIFE DIS, V40, P485, DOI 10.7589/0090-3558-40.3.485; BLAIR D, 1979, J PARASITOL, V65, P982, DOI 10.2307/3280265; Bolette D. P., 1987, Veterinary Technician, V8, P19; Bollinger T. K., 1994, CAN COOP WILDL HLTH, V2, P7; Bossart GD, 1998, TOXICOL PATHOL, V26, P276, DOI 10.1177/019262339802600214; Brand C. J., 1987, US DEP INTERIOR FISH, V1, P127; Broman M, 2011, J ZOO WILDLIFE MED, V42, P766, DOI 10.1638/2011-0018.1; Bunyea H., 1926, N AM VET, V7, P47; BUTLER W. H., 1974, MYCOTOXINS, P1; Carmichael Wayne W, 2006, Saline Systems, V2, P5, DOI 10.1186/1746-1448-2-5; CARNAGHAN RB, 1965, NATURE, V208, P308, DOI 10.1038/208308a0; CAWTHORN RJ, 1980, CAN J ZOOL, V58, P1892, DOI 10.1139/z80-258; Cianciolo R. E., 2016, JUBB KENNEDY PALMERS, V2, P413; Clayton D.H., 2008, PARASITIC DIS WILD B, P515; CLEMENS ET, 1975, CORNELL VET, V65, P248; CLENCH MH, 1995, WILSON BULL, V107, P93; Converse Kathryn A., 2007, P360, DOI 10.1002/9780470344668.ch20; Cooper B. J., 2016, JUBB KENNEDY PALMERS, V1, P223; CORRIER DE, 1991, VET IMMUNOL IMMUNOP, V30, P73, DOI 10.1016/0165-2427(91)90010-A; Daoust Pierre-Yves, 2007, P270, DOI 10.1002/9780470344668.ch13; DAOUST PY, 1991, J WILDLIFE DIS, V27, P135, DOI 10.7589/0090-3558-27.1.135; Davies Ronald W., 2008, P501; Degernes LA, 2011, AVIAN PATHOL, V40, P103, DOI 10.1080/03079457.2010.541421; DEIN FJ, 1986, J AM VET MED ASSOC, V189, P1006; Delnatte P, 2013, AVIAN PATHOL, V42, P114, DOI 10.1080/03079457.2013.769669; DIAS JLC, 1994, AVIAN PATHOL, V23, P659, DOI 10.1080/03079459408419035; Docherty D.E., 1987, U S Fish and Wildlife Service Resource Publication, P129; DOCHERTY DE, 1994, AVIAN DIS, V38, P899, DOI 10.2307/1592132; Drew Mark L., 2007, P216, DOI 10.1002/9780470344668.ch11; DUFLOT A, 1995, HEPATOLOGY, V21, P1483, DOI 10.1016/0270-9139(95)90448-4; Duncan M, 2015, FOWLERS ZOO WILD ANI, V8, P667; Dusek RJ, 2004, J WILDLIFE DIS, V40, P682, DOI 10.7589/0090-3558-40.4.682; Echols MS, 2000, J AVIAN MED SURG, V14, P42; El-Dakhly K, 2012, J ZOO WILDLIFE MED, V43, P953, DOI 10.1638/2012-0070R.1; ENSLEY PK, 1978, J AM VET MED ASSOC, V173, P1246; Fach P, 1996, FEMS IMMUNOL MED MIC, V13, P279; Fagerholm Hans-Peter, 2008, P413; Fauquier DA, 2013, J WILDLIFE DIS, V49, P246, DOI 10.7589/2011-09-270; Fimreite N., 1971, 9 CAN WILDL SERV, P1; FINLEY MT, 1979, B ENVIRON CONTAM TOX, V21, P105, DOI 10.1007/BF01685396; Fischer JR, 2003, J WILDLIFE DIS, V39, P400, DOI 10.7589/0090-3558-39.2.400; Franciosa G, 1996, J CLIN MICROBIOL, V34, P882; FRANK A, 1986, SCI TOTAL ENVIRON, V54, P275, DOI 10.1016/0048-9697(86)90272-X; FRENCH RA, 1994, J ZOO WILDLIFE MED, V25, P403; Friend M., 1999, BIOL RESOURCES DIVIS; FRIEND M, 1999, FIELD MANUAL WILDLIF; Gamino V, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-39; Gardiner CH, 1999, ATLAS METAZOAN PARAS; Gentile J. H., 1971, MICROBIAL TOXINS, P27; Glowska E, 2015, SYST PARASITOL, V92, P73, DOI 10.1007/s11230-015-9580-1; Golvan Y.J., 1994, Research and Reviews in Parasitology, V54, P135; Gordus AG, 2002, J WILDLIFE DIS, V38, P124, DOI 10.7589/0090-3558-38.1.124; Gottdenker NL, 2003, J WILDLIFE DIS, V39, P702, DOI 10.7589/0090-3558-39.3.702; GOUGH RE, 1985, AVIAN PATHOL, V14, P227, DOI 10.1080/03079458508436224; Grenquist P., 1972, Suomen Riista, VNo. 24, P91; Guo JT, 1996, P NATL ACAD SCI USA, V93, P14548, DOI 10.1073/pnas.93.25.14548; Hallinger KK, 2010, AUK, V127, P156, DOI 10.1525/auk.2009.09058; Hansen Wallace R., 2007, P87, DOI 10.1002/9780470344668.ch4; HASHIMOTO Y, 1976, JPN J VET RES, V24, P65; HAYES MA, 1983, CAN J COMP MED, V47, P180; Henriksen P, 1997, TOXICON, V35, P901, DOI 10.1016/S0041-0101(96)00190-0; HILL EF, 1988, J WILDLIFE DIS, V24, P51, DOI 10.7589/0090-3558-24.1.51; Himsworth CG, 2009, AVIAN DIS, V53, P129, DOI 10.1637/8387-063008-Case.1; Hoerr F., 1997, DIS POULTRY, P951; Hollmen T, 2002, AVIAN DIS, V46, P478, DOI 10.1637/0005-2086(2002)046[0478:IACOAR]2.0.CO;2; Hollmen TE, 2003, J WILDLIFE DIS, V39, P114, DOI 10.7589/0090-3558-39.1.114; Horak P, 2005, PARASITE IMMUNOL, V27, P247, DOI 10.1111/j.1365-3024.2005.00776.x; Huffman Jane E., 2008, P246; HURST GA, 1979, J WILDLIFE DIS, V15, P395, DOI 10.7589/0090-3558-15.3.395; Isanhart JP, 2011, ARCH ENVIRON CON TOX, V61, P653, DOI 10.1007/s00244-011-9657-z; Jennings A. R., 1961, Bird Study, V8, P19; JENSEN WI, 1981, AVIAN DIS, V25, P184, DOI 10.2307/1589840; Jessup David A., 1996, P141; Johnsgard P.A, 1961, WILDFOWL, V12, P58; KALBE L., 1964, ARCH EXP VETERINAERMED, V18, P535; KARSTAD L, 1971, Journal of Wildlife Diseases, V7, P236; Karstad L, 1971, Conn Med, V35, P355; KENNEDY FA, 1995, J MED VET MYCOL, V33, P157; Kim Y, 2005, J PARASITOL, V91, P199, DOI 10.1645/GE-378R; Kinsella John M., 2008, P384; Kinsella John M., 2008, P376; KITTLER L, 1979, Z JAGDWISS, V24, P182; KOBAYASHI Y, 1992, J VET MED SCI, V54, P229, DOI 10.1292/jvms.54.229; Koci MD, 2002, AVIAN PATHOL, V31, P213, DOI 10.1080/03079450220136521; Kuiken T, 1999, J WILDLIFE DIS, V35, P331, DOI 10.7589/0090-3558-35.2.331; KUMMERFELD N, 1989, KLEINTIERPRAXIS, V34, P521; Landsberg Jan H., 2007, P431, DOI 10.1002/9780470344668.ch23; Leach S, 2008, J AVIAN MED SURG, V22, P315, DOI 10.1647/2007-017.1; Leighton Frederick A., 1993, Environmental Reviews, V1, P92; Levin II, 2012, J PARASITOL, V98, P847, DOI 10.1645/GE-3007.1; LIAT LB, 1980, J ZOOL, V190, P39; Little Susan E., 2008, P546; Liu N, 2014, VET MICROBIOL, V170, P39, DOI 10.1016/j.vetmic.2014.01.026; Lu AL, 2014, AVIAN PATHOL, V43, P325, DOI 10.1080/03079457.2014.931928; Luttrell Page, 2007, P317, DOI 10.1002/9780470344668.ch16; Maclean C, 2015, GLOB CULT SPORT, P155; Mascarenhas CS, 2009, NEOTROP ENTOMOL, V38, P695, DOI 10.1590/S1519-566X2009000500024; Mauldin E. A., 2016, JUBB KENNEDY PALMERS, V1, P581; McCain S., 2015, FOWLERS ZOO WILD ANI, P112; McDonald M. E., 1969, 125 US DEP INT; McKelvey R.W., 1981, Proceedings of the International Swan Symposium, P312; Meteyer CU, 1997, J VET DIAGN INVEST, V9, P269, DOI 10.1177/104063879700900308; MILLER RE, 1983, J AM VET MED ASSOC, V183, P1241; Millins C, 2010, J VET DIAGN INVEST, V22, P131, DOI 10.1177/104063871002200128; Murakami T, 2014, VET PATHOL, V51, P363, DOI 10.1177/0300985813511128; Muscatello G, 1998, AUST VET J, V76, P537, DOI 10.1111/j.1751-0813.1998.tb10209.x; Mutinelli F, 2006, AVIAN PATHOL, V35, P327, DOI 10.1080/03079450600821158; Nemeth NM, 2012, J ZOO WILDLIFE MED, V43, P412, DOI 10.1638/2011-0193.1; NISBET ICT, 1983, CONDOR, V85, P338, DOI 10.2307/1367071; Norton T. R., 2015, FOWLERS ZOO WILD ANI, P100; Novilla MN, 2004, AVIAN PATHOL, V33, P275, DOI 10.1080/0307945042000203371; Olsen GH, 1995, J ZOO WILDLIFE MED, V26, P569; ORTIZ NE, 1994, EPIDEMIOL INFECT, V112, P385, DOI 10.1017/S0950268800057794; Osweiler GD, 2000, VET CLIN N AM-FOOD A, V16, P511, DOI 10.1016/S0749-0720(15)30084-0; Pare Jean A., 2007, P194; PAVLASEK I, 1993, VET MED-CZECH, V38, P629; Peaker M., 1975, SALT GLANDS BIRDS RE, P1; PEIRCE MA, 1974, VET REC, V94, P493, DOI 10.1136/vr.94.21.493; Perrins C. M., 1991, Wildfowl, V42, P5; Popova Z. G., 1954, PATHOLOGICALMORPHOLO, P547; Poppenga RH, 2012, VETERINARY TOXICOLOGY: BASIC AND CLINICAL PRINCIPLES, 2ND EDITION, P856, DOI 10.1016/B978-0-12-385926-6.00099-5; PRIJONO WB, 1991, J WILDLIFE DIS, V27, P110, DOI 10.7589/0090-3558-27.1.110; Quist Charlotte F., 2007, P417, DOI 10.1002/9780470344668.ch22; RANDALL CJ, 1987, AVIAN PATHOL, V16, P479, DOI 10.1080/03079458708436397; Raymundo DL, 2012, J ZOO WILDLIFE MED, V43, P388, DOI 10.1638/2010-0084.1; Redig Patrick T., 1993, P178; Richardson Dennis J., 2008, P277; Riggert T. L., 1977, WILDLIFE MONOGR, V52, P3; RINGELMAN JK, 1992, J WILDLIFE MANAGE, V56, P317, DOI 10.2307/3808828; Rocke TE, 1998, J WILDLIFE DIS, V34, P744, DOI 10.7589/0090-3558-34.4.744; Rocke Tonie E., 2007, P377, DOI 10.1002/9780470344668.ch21; Roffe T.J., 1987, U S Fish and Wildlife Service Resource Publication, P95; ROFFE TJ, 1989, AVIAN DIS, V33, P451, DOI 10.2307/1591104; Samuel Michael D., 2007, P239, DOI 10.1002/9780470344668.ch12; SCHEUHAMMER AM, 1987, ENVIRON POLLUT, V46, P263, DOI 10.1016/0269-7491(87)90173-4; Schmidt G.D., 1985, P273; SCHMIDTNIELSON K, 1960, CIRCULATION, V21, P955, DOI 10.1161/01.CIR.21.5.955; SCHUH JCL, 1986, J AM VET MED ASSOC, V189, P993; Schulze C, 2012, BERL MUNCH TIERARZTL, V125, P428, DOI 10.2376/0005-9366-125-428; Shi SH, 2011, ARCH VIROL, V156, P405, DOI 10.1007/s00705-010-0866-y; SHLOSBERG A, 1975, Journal of Wildlife Diseases, V11, P534; Sileo L, 2003, AVIAN PATHOL, V32, P655, DOI 10.1080/03079450310001636246; Smith B. J., 1990, T N AM WILDL NAT RES, V55, P269; SMITH TK, 1992, J ANIM SCI, V70, P3989; Snow NJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150039; Sonnberg S, 2013, VIRUS RES, V178, P63, DOI 10.1016/j.virusres.2013.05.009; Spalding Marilyn G., 2008, P289; SPALDING MG, 1993, J WILDLIFE DIS, V29, P237, DOI 10.7589/0090-3558-29.2.237; Spalding MG, 1996, J WILDLIFE DIS, V32, P44, DOI 10.7589/0090-3558-32.1.44; Spalding MG, 1997, J PARASITOL, V83, P768, DOI 10.2307/3284263; Stalknecht David E., 2007, P108, DOI 10.1002/9780470344668.ch5; Steele KE, 2000, VET PATHOL, V37, P208, DOI 10.1354/vp.37-3-208; Sterner Mauritz C. III, 2008, P434; STROUD RK, 1982, J AM VET MED ASSOC, V181, P1389; SUGIMURA M, 1977, JPN J VET RES, V25, P7; Tanaka S, 2008, MED MOL MORPHOL, V41, P99, DOI 10.1007/s00795-008-0401-3; Thomas NJ, 1998, VET PATHOL, V35, P479, DOI 10.1177/030098589803500602; Tompkins D. M., 2008, PARASITIC DIS WILD B, P317; Valkiunas G, 2016, PARASITOL RES, V115, P2609, DOI 10.1007/s00436-016-5007-4; van Riper Charles III, 2007, P131, DOI 10.1002/9780470344668.ch6; VETESI F, 1976, ACTA VET ACAD SCI H, V26, P113; Walsh ME, 1996, ENVIRON TOXICOL CHEM, V15, P846, DOI 10.1002/etc.5620150605; Wehr E. E., 1971, P185; WIEMEYER SN, 1986, J WILDLIFE DIS, V22, P538, DOI 10.7589/0090-3558-22.4.538; Wilde SB, 2014, PHYTOTAXA, V181, P243, DOI 10.11646/phytotaxa.181.5.1; WildPro, 2016, WILDL INF NETW; WINDINGSTAD RM, 1989, J WILDLIFE DIS, V25, P38, DOI 10.7589/0090-3558-25.1.38; WINDINGSTAD RM, 1987, J WILDLIFE DIS, V23, P443, DOI 10.7589/0090-3558-23.3.443; WINDINGSTAD RM, 1980, AVIAN DIS, V24, P1044, DOI 10.2307/1589981; WOBESER G, 1992, J WILDLIFE DIS, V28, P215, DOI 10.7589/0090-3558-28.2.215; WOBESER G, 1987, J WILDLIFE DIS, V23, P341, DOI 10.7589/0090-3558-23.2.341; WOBESER G, 1987, J WILDLIFE DIS, V23, P127, DOI 10.7589/0090-3558-23.1.127; WOBESER G, 1993, CAN VET J, V34, P353; Wobeser G., 1997, DISEASES WILD WATERF; Wobeser GA, 1997, DIS WILD WATERFOWL; WOJCINSKI ZW, 1987, J WILDLIFE DIS, V23, P248, DOI 10.7589/0090-3558-23.2.248; Wolcott Mark J., 2007, P332, DOI 10.1002/9780470344668.ch17; WOOD LM, 1983, J PARASITOL, V69, P682, DOI 10.2307/3281141; WORK TM, 1993, J ZOO WILDLIFE MED, V24, P54; Wyss F, 2015, VET PATHOL, V52, P1235, DOI 10.1177/0300985814568359; Yabsley Michael J., 2008, P463; Young EA, 1998, J WILDLIFE DIS, V34, P625, DOI 10.7589/0090-3558-34.3.625; YU FL, 1988, CARCINOGENESIS, V9, P527, DOI 10.1093/carcin/9.4.527; Zachary J. F., 2012, PATHOLOGIC BASIS VET, P819; ZDZIARSKI JM, 1994, J ZOO WILDLIFE MED, V25, P438	200	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							697	+		10.1016/B978-0-12-805306-5.00029-8			11	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300031					2019-10-28	
B	Wunschmann, A; Armien, AG; Hofle, U; Kinne, J; Lowenstine, LJ; Shivaprasad, HL		Terio, KA; McAloose, D; StLeger, J		Wunschmann, Arno; Armien, Anibal G.; Hofle, Ursula; Kinne, Jorg; Lowenstine, Linda J.; Shivaprasad, H. L.			Birds of Prey	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							WEST-NILE-VIRUS; EAGLES HALIAEETUS-LEUCOCEPHALUS; GREAT HORNED OWLS; WILD BIRDS; NEWCASTLE-DISEASE; GENETIC-CHARACTERIZATION; ASPERGILLUS-FUMIGATUS; MYCOPLASMA-COROGYPSI; SCAVENGING BIRDS; BUBO-VIRGINIANUS		[Wunschmann, Arno; Armien, Anibal G.] Univ Minnesota, St Paul, MN 55108 USA; [Hofle, Ursula] Natl Game & Wildlife Res Inst, SaBio Hlth & Biotechnol Working Grp, Ciudad Real, Spain; [Kinne, Jorg] Cent Vet Res Lab, Dubai, U Arab Emirates; [Lowenstine, Linda J.] Univ Calif Davis, Davis, CA 95616 USA; [Shivaprasad, H. L.] Univ Calif Davis, Calif Anim Hlth & Food Safety Lab Syst Tulare Bra, Tulare, CA USA	Wunschmann, A (reprint author), Univ Minnesota, St Paul, MN 55108 USA.						Acosta I, 2010, VET J, V183, P234, DOI 10.1016/j.tvjl.2008.10.013; Albers PH, 2001, J TOXICOL ENV HEAL A, V63, P89, DOI 10.1080/15287390151126405; Martinez-Diaz RA, 2015, PARASITOL RES, V114, P101, DOI 10.1007/s00436-014-4165-5; Armien AG, 2013, VET PATHOL, V50, P182, DOI 10.1177/0300985812442690; Atkinson Carter T., 2008, P35; Barbon AR, 2010, J AVIAN MED SURG, V24, P222, DOI 10.1647/2008-041.1; Beaufrere H, 2007, J EXOT PET MED, V16, P55, DOI 10.1053/j.jepm.2006.11.011; Beernaert LA, 2010, AVIAN PATHOL, V39, P325, DOI 10.1080/03079457.2010.506210; Bertran K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032107; Bougiouklis PA, 2013, J COMP PATHOL, V148, P419, DOI 10.1016/j.jcpa.2012.09.005; BOWERMAN WW, 1994, B ENVIRON CONTAM TOX, V53, P450; Buchebner N, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-153; Bueno-Padilla I, 2012, VET OPHTHALMOL, V15, P271, DOI 10.1111/j.1463-5224.2011.00978.x; Burns RE, 2014, J VET DIAGN INVEST, V26, P695, DOI 10.1177/1040638714544499; BUYUKMIHCI NC, 1988, J WILDLIFE DIS, V24, P207, DOI 10.7589/0090-3558-24.2.207; Cabezon O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029549; Carpenter JW, 2003, J WILDLIFE DIS, V39, P96, DOI 10.7589/0090-3558-39.1.96; Carreno Ramon A., 2008, P326; Catanach TA, 2015, BIOL J LINN SOC, V114, P837, DOI 10.1111/bij.12453; CLAUSEN B, 1981, J WILDLIFE DIS, V17, P105, DOI 10.7589/0090-3558-17.1.105; Clayton D.H., 2008, PARASITIC DIS WILD B, P515; COLE RA, 1995, J WILDLIFE DIS, V31, P576, DOI 10.7589/0090-3558-31.4.576; Couper D, 2010, VET REC, V167, P258, DOI 10.1136/vr.c3608; Cruz-Martinez Luis, 2012, Human-Wildlife Interactions, V6, P94; Cuthbert R, 2007, BIOL LETTERS, V3, P90, DOI 10.1098/rsbl.2006.0554; Dean J, 2006, J VET DIAGN INVEST, V18, P282, DOI 10.1177/104063870601800310; Ducatez MF, 2007, EMERG INFECT DIS, V13, P611, DOI 10.3201/eid1304.061356; Edwards EE, 2017, J ZOO WILDLIFE MED, V48, P237, DOI 10.1638/2016-0123.1; Erdelyi K, 2007, VECTOR-BORNE ZOONOT, V7, P181, DOI 10.1089/vbz.2006.0586; Esperon F, 2013, PARASITOL INT, V62, P502, DOI 10.1016/j.parint.2013.07.005; Facon C, 2014, AVIAN DIS, V58, P176, DOI 10.1637/10555-041513-Case.1; Fagerholm Hans-Peter, 2008, P413; Feeney D., 2016, RES VET SCI, V105, P236; Fernie K, 2003, J TOXICOL ENV HEAL A, V66, P2089, DOI 10.1080/15287390390211270; Finkelstein ME, 2015, J WILDLIFE DIS, V51, P901, DOI 10.7589/2014-10-253; Forbes NA, 1997, J AVIAN MED SURG, V11, P110; Gyuranecz M, 2013, J VIROL, V87, P4938, DOI 10.1128/JVI.03183-12; Hafez Hafez Mohamed, 2010, Avian Dis, V54, P161, DOI 10.1637/9008-080309-Case.1; Hampel MR, 2009, AMYLOID, V16, P122, DOI 10.1080/13506120903090759; Harris MC, 2007, J ZOO WILDLIFE MED, V38, P62, DOI 10.1638/05-099.1; Heidenreich M, 1997, BIRDS PREY MED MANAG, P131; Helander B, 2009, SCI TOTAL ENVIRON, V407, P5555, DOI 10.1016/j.scitotenv.2009.07.027; Helander B., 1983, 1386 NAT SWED ENV PR; Holm L, 2006, ENVIRON TOXICOL CHEM, V25, P2787, DOI 10.1897/05-619R.1; Hunter D. Bruce, 1993, P54; Hunter DB, 1997, J WILDLIFE DIS, V33, P486, DOI 10.7589/0090-3558-33.3.486; Ip Hon S, 2014, PLoS Curr, V6, DOI 10.1371/currents.outbreaks.b0f031fc8db2a827d9da0f30f0766871; Ip HS, 2015, EMERG INFECT DIS, V21, P886, DOI 10.3201/eid2105.142020; James SB, 2000, J AVIAN MED SURG, V14, P268, DOI 10.1647/1082-6742(2000)014[0268:DATOHL]2.0.CO;2; Jankovsky JM, 2017, J WILDLIFE DIS, V53, P368, DOI 10.7589/2016-06-132; Jindal N, 2010, AVIAN PATHOL, V39, P441, DOI 10.1080/03079457.2010.517249; Johns JL, 2009, VET CLIN PATH, V38, P247, DOI 10.1111/j.1939-165X.2008.00091.x; Jung K, 2009, VET J, V179, P307, DOI 10.1016/j.tvjl.2007.09.004; Kelly Terra R, 2014, Vet Rec Open, V1, pe000028, DOI 10.1136/vropen-2014-000028; KIFF LF, 1979, CONDOR, V81, P166, DOI 10.2307/1367284; KINGSTON N, 1976, Journal of Wildlife Diseases, V12, P562; Korbel R.T., 2000, P179; Krone O, 2007, J HELMINTHOL, V81, P67, DOI 10.1017/S0022149X07214129; Krone O, 2006, AMBIO, V35, P98, DOI 10.1579/0044-7447(2006)35[98:MFHBAC]2.0.CO;2; Kurle CM, 2016, ENVIRON SCI TECHNOL, V50, P9114, DOI 10.1021/acs.est.6b01990; Kwon HI, 2011, VIRUS RES, V160, P305, DOI 10.1016/j.virusres.2011.07.003; Lierz M, 2008, AVIAN DIS, V52, P641, DOI 10.1637/8378-061608-Reg.1; Lierz M, 2008, J WILDLIFE DIS, V44, P845, DOI 10.7589/0090-3558-44.4.845; Lierz M, 1998, KLEINTIERPRAXIS, V43, P43; Lierz M, 2007, EMERG INFECT DIS, V13, P1667, DOI 10.3201/eid1311.070705; Lindsay DS, 1995, J PARASITOL, V81, P920, DOI 10.2307/3284041; Lloyd C, 2008, J AVIAN MED SURG, V22, P213, DOI 10.1647/2006-019.1; Locke Louis N., 1996, P108; Lopes H, 2007, AVIAN DIS, V51, P140, DOI 10.1637/0005-2086(2007)051[0140:CFLAVA]2.0.CO;2; Lublin A, 2001, AVIAN DIS, V45, P741, DOI 10.2307/1592921; Mayr SL, 2016, PARASITOL RES, V115, P3041, DOI 10.1007/s00436-016-5059-5; McRee AE, 2015, J AVIAN MED SURG, V29, P361; Mete A, 2014, EMERG INFECT DIS, V20, P1716, DOI 10.3201/eid2010.140504; Meteyer CU, 2005, J WILDLIFE DIS, V41, P707, DOI 10.7589/0090-3558-41.4.707; Mikaelian I, 1997, AVIAN DIS, V41, P738, DOI 10.2307/1592169; Molina-Lopez RA, 2011, VET REC, V168, DOI 10.1136/vr.c7123; Morishita TY, 1996, AVIAN DIS, V40, P908, DOI 10.2307/1592316; Muller K, 2007, J AVIAN MED SURG, V21, P103, DOI 10.1647/1082-6742(2007)21[103:POSIFW]2.0.CO;2; Muller MG, 2008, VET PARASITOL, V152, P67, DOI 10.1016/j.vetpar.2007.11.019; Murray M, 2008, J AVIAN MED SURG, V22, P41, DOI 10.1647/2007-012R.1; Naguib MM, 2015, J GEN VIROL, V96, P3212, DOI 10.1099/jgv.0.000274; Nemeth NM, 2009, J WILDLIFE DIS, V45, P817, DOI 10.7589/0090-3558-45.3.817; Nemeth NM, 2009, J ZOO WILDLIFE MED, V40, P51, DOI 10.1638/2007-0109.1; Oaks JL, 2005, J CLIN MICROBIOL, V43, P3414, DOI 10.1128/JCM.43.7.3414-3420.2005; Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317; Olias P, 2011, VET PARASITOL, V175, P230, DOI 10.1016/j.vetpar.2010.10.025; Papazahariadou MG, 2001, VET REC, V148, P54, DOI 10.1136/vr.148.2.54; PATTEE OH, 1981, J WILDLIFE MANAGE, V45, P806, DOI 10.2307/3808728; de la Lastra JMP, 2007, DEV COMP IMMUNOL, V31, P511, DOI 10.1016/j.dci.2006.08.003; Potier R, 2013, J ZOO WILDLIFE MED, V44, P549, DOI 10.1638/2011-0254R1.1; Raidal SR, 2000, AVIAN PATHOL, V29, P51, DOI 10.1080/03079450094289; Rattner BA, 2008, ENVIRON TOXICOL CHEM, V27, P2341, DOI 10.1897/08-123.1; REDIG PT, 1980, J WILDLIFE DIS, V16, P169, DOI 10.7589/0090-3558-16.2.169; Rideout BA, 2012, J WILDLIFE DIS, V48, P95, DOI 10.7589/0090-3558-48.1.95; Rose N, 2012, CAN VET J, V53, P265; Ruder MG, 2009, J WILDLIFE DIS, V45, P808, DOI 10.7589/0090-3558-45.3.808; Russell RE, 2014, WILDLIFE SOC B, V38, P697, DOI 10.1002/wsb.469; Rutz C, 2004, J ZOO WILDLIFE MED, V35, P97, DOI 10.1638/02-031.1; Sadar MJ, 2015, J AVIAN MED SURG, V29, P231, DOI 10.1647/2014-047; Sadar MJ, 2015, J ZOO WILDLIFE MED, V46, P150, DOI 10.1638/2013-0247R4.1; Saito K, 2009, AVIAN PATHOL, V38, P485, DOI 10.1080/03079450903349246; Samour J, 2014, J AVIAN MED SURG, V28, P1, DOI 10.1647/2011-041; Samour JH, 2005, J AVIAN MED SURG, V19, P294, DOI 10.1647/2004-028.1; Samour JH, 1996, VET REC, V139, P167, DOI 10.1136/vr.139.7.167; SAMOUR JH, 1995, VET REC, V136, P358, DOI 10.1136/vr.136.14.358; SAUMIER MD, 1988, CAN J ZOOL, V66, P1685, DOI 10.1139/z88-243; Schrenzel M, 2005, J CLIN MICROBIOL, V43, P3402, DOI 10.1128/JCM.43.7.3402-3413.2005; Seruca C, 2012, VET OPHTHALMOL, V15, P236, DOI 10.1111/j.1463-5224.2011.00976.x; Shrubsole-Cockwill AN, 2010, J AVIAN MED SURG, V24, P64, DOI 10.1647/2009-010R.1; Smith RN, 1998, AUK, V115, P368, DOI 10.2307/4089195; Smith Steven A., 1993, P99; Stone EG, 1999, J WILDLIFE DIS, V35, P137, DOI 10.7589/0090-3558-35.1.137; Tarello W, 2006, PARASITE, V13, P59, DOI 10.1051/parasite/2006131059; Tarello W, 2005, REV MED VET-TOULOUSE, V156, P11; Tell LA, 2004, J AVIAN MED SURG, V18, P30, DOI 10.1647/2003-007; Thomas NJ, 2002, J WILDLIFE DIS, V38, P187, DOI 10.7589/0090-3558-38.1.187; Thomas NJ, 1998, VET PATHOL, V35, P479, DOI 10.1177/030098589803500602; van den Brand JMA, 2015, VET RES, V46, DOI 10.1186/s13567-015-0148-5; Van Wettere AJ, 2013, VET PATHOL, V50, P291, DOI 10.1177/0300985812457791; Vaughan-Higgins R, 2013, VET REC, V173, DOI 10.1136/vr.101476; WARD F P, 1972, Journal of Wildlife Diseases, V8, P165; Wernery U, 1998, J VET MED B, V45, P577, DOI 10.1111/j.1439-0450.1998.tb00830.x; Wernery U., 2016, AVIAN MED, P442; WHEELDON EB, 1982, J AM VET MED ASSOC, V181, P1385; Wilde SB, 2014, PHYTOTAXA, V181, P243, DOI 10.11646/phytotaxa.181.5.1; Willette Michelle, 2009, Vet Clin North Am Exot Anim Pract, V12, P491, DOI 10.1016/j.cvex.2009.06.006; Wodak E, 2011, VET MICROBIOL, V149, P358, DOI 10.1016/j.vetmic.2010.12.012; Wong E., 1997, J ZOO WILDLIFE MED, V30, P584; Wunschmann A, 2017, VET PATHOL, V54, P277, DOI 10.1177/0300985816669404; Wunschmann A, 2014, J VET DIAGN INVEST, V26, P599, DOI 10.1177/1040638714539960; Wunschmann A, 2010, J VET DIAGN INVEST, V22, P282, DOI 10.1177/104063871002200222; Yabsley Michael J., 2008, P463; Zeiss CJ, 2006, J COMP PATHOL, V135, P243, DOI 10.1016/j.jcpa.2006.08.004; Ziegler U, 2015, VECTOR-BORNE ZOONOT, V15, P481, DOI 10.1089/vbz.2014.1746; Ziegler U, 2013, VET MICROBIOL, V161, P263, DOI 10.1016/j.vetmic.2012.07.041; Zsivanovits P, 2004, AVIAN PATHOL, V33, P599, DOI 10.1080/03079450400013113	136	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	125 LONDON WALL, LONDON EC2Y 5AS, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							723	+		10.1016/B978-0-12-805306-5.00030-4			10	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300032					2019-10-28	
B	Crespo, R; Franca, MS; Fenton, H; Shivaprasad, HL		Terio, KA; McAloose, D; StLeger, J		Crespo, Rocio; Franca, Monique S.; Fenton, Heather; Shivaprasad, H. L.			Galliformes and Columbiformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							TURKEYS MELEAGRIS-GALLOPAVO; EQUINE ENCEPHALITIS-VIRUS; DEEP PECTORAL MYOPATHY; LYMPHOPROLIFERATIVE DISEASE VIRUS; MARBLE SPLEEN DISEASE; HIGHLANDS J-VIRUS; WILD TURKEYS; MAREKS-DISEASE; INFECTIOUS LARYNGOTRACHEITIS; AVIAN PNEUMOVIRUS		[Crespo, Rocio] Washington State Univ, Puyallup, WA 98371 USA; [Franca, Monique S.] Univ Georgia, Poultry Diagnost & Res Ctr, Athens, GA 30602 USA; [Fenton, Heather] Univ Georgia, Athens, GA 30602 USA; [Shivaprasad, H. L.] Univ Calif Davis, Calif Anim Hlth & Food Safety Lab Syst Tulare Bra, Tulare, CA USA	Crespo, R (reprint author), Washington State Univ, Puyallup, WA 98371 USA.			Crespo, Rocio/0000-0002-6286-1004			Abadie J, 2001, AVIAN PATHOL, V30, P149, DOI 10.1080/03079450124811; Adang K.L., 2008, Research Journal of Parasitology, V3, P79; Aldous EW, 2004, AVIAN PATHOL, V33, P258, DOI 10.1080/0307945042000195768; Alger K, 2015, J ZOO WILDLIFE MED, V46, P806, DOI 10.1638/2015-0037.1; Allison AB, 2004, EMERG INFECT DIS, V10, P2252, DOI 10.3201/eid1012.040511; Allison AB, 2014, VIROLOGY, V450, P2, DOI 10.1016/j.virol.2013.11.037; Andersen AA, 2005, J VET DIAGN INVEST, V17, P479, DOI 10.1177/104063870501700514; Antonissen G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168205; ASRANI RK, 1993, MYCOPATHOLOGIA, V121, P83, DOI 10.1007/BF01103575; Atkinson R., 1998, P ASS AVIAN VET, P177; BAGUST TJ, 1986, AVIAN PATHOL, V15, P581, DOI 10.1080/03079458608436317; BENNETT GF, 1982, CAN J ZOOL, V60, P3105, DOI 10.1139/z82-394; BERGMANN V, 1980, MONATSH VETERINARMED, V35, P349; BIGLER WJ, 1976, AM J TROP MED HYG, V25, P884, DOI 10.4269/ajtmh.1976.25.884; Bonbon E., 2017, OIE LISTED DIS INFEC, P5; Boodhoo N, 2016, VET RES, V47, DOI 10.1186/s13567-016-0404-3; Boulianne M., 2013, AVIAN DIS MANUAL; Brugere-Picoux J., 2015, MANUAL POULTRY DIS; Burgess SC, 2001, VET PATHOL, V38, P129, DOI 10.1354/vp.38-2-129; BYGRAVE AC, 1973, VET REC, V92, P534, DOI 10.1136/vr.92.20.534; Cai Z, 2009, VET PATHOL, V46, P88, DOI 10.1354/vp.46-1-88; CARRASCO L, 1993, AVIAN DIS, V37, P923, DOI 10.2307/1592056; Catelli E, 1998, AVIAN PATHOL, V27, P632, DOI 10.1080/03079459808419395; Chandler F. W., 1989, COLOUR ATLAS TXB HIS; CHO BR, 1976, AVIAN DIS, V20, P714, DOI 10.2307/1589451; Converse Kathryn A., 2007, P360, DOI 10.1002/9780470344668.ch20; Cortes PL, 2006, J VET DIAGN INVEST, V18, P489, DOI 10.1177/104063870601800514; CRAWSHAW GJ, 1982, AVIAN DIS, V26, P397, DOI 10.2307/1590111; Cray C, 2009, AVIAN DIS, V53, P491, DOI 10.1637/8673-030209-Reg.1; Davidson W. R, 2003, NAT WILD TURKEY FED, V25, P1; DAVIDSON WR, 1989, J WILDLIFE DIS, V25, P534, DOI 10.7589/0090-3558-25.4.534; DAVIDSON WR, 1985, J WILDLIFE DIS, V21, P386, DOI 10.7589/0090-3558-21.4.386; Davison W. R., 1992, WILD TURKEY BIOL MAN, P101; DeRosa M, 1996, AVIAN DIS, V40, P865; Dhama Kuldeep, 2011, Vet Med Int, V2011, P712369, DOI 10.4061/2011/712369; Doufour-Zavala L., 2008, ISOLATION IDENTIFICA; Dvorska L, 2007, VET MICROBIOL, V119, P366, DOI 10.1016/j.vetmic.2006.09.010; Dyke GJ, 2003, ZOOL J LINN SOC-LOND, V137, P227, DOI 10.1046/j.1096-3642.2003.00048.x; ELEAZER TH, 1994, J VET DIAGN INVEST, V6, P98, DOI 10.1177/104063879400600118; Elsmo EJ, 2016, J WILDLIFE DIS, V52, P582, DOI 10.7589/2015-05-129; Engstrom BE, 2003, VET MICROBIOL, V94, P225, DOI 10.1016/S0378-1135(03)00106-8; Fernandez-Pinero J, 2014, J GEN VIROL, V95, P883, DOI 10.1099/vir.0.061465-0; FICKEN MD, 1993, AVIAN DIS, V37, P585, DOI 10.2307/1591693; Filippich LJ, 2004, SEMIN AVIAN EXOT PET, V13, P25, DOI 10.1053/S1055-937X(03)00055-0; FITZGERALD SD, 1992, AVIAN DIS, V36, P341, DOI 10.2307/1591509; FITZGERALD SD, 1989, J WILDLIFE DIS, V25, P455, DOI 10.7589/0090-3558-25.4.455; Fleischli MA, 2004, ARCH ENVIRON CON TOX, V46, P542, DOI 10.1007/s00244-003-3065-y; Fletcher O.J., 2008, AVIAN HISTOPATHOLOGY; Gailbreath KL, 2008, J WILDLIFE DIS, V44, P427, DOI 10.7589/0090-3558-44.2.427; Gamino V, 2012, VET RES, V43, DOI 10.1186/1297-9716-43-65; Gough RE, 2001, VET REC, V149, P312; Guillion G. W, 1957, AM MIDL NAT, V40, P414; Guo WN, 2016, SCI REP-UK, V6, DOI 10.1038/srep19638; GUY JS, 1993, AVIAN DIS, V37, P389, DOI 10.2307/1591663; GUY JS, 1992, AVIAN PATHOL, V21, P77, DOI 10.1080/03079459208418820; Haridy M, 2014, AVIAN DIS, V58, P383, DOI 10.1637/10775-011714-Reg.1; Harrach B., 2011, VIRUS TAXONOMY CLASS, P125, DOI DOI 10.1016/8978-0-12-384684-6.00009-4; Hayes L. E, 1992, J WILDLIFE DIS, V25, P262; Hellebuyck T, 2014, J AVIAN MED SURG, V28, P240, DOI 10.1647/2013-075; Hill AG, 2013, J ZOO WILDLIFE MED, V44, P990, DOI 10.1638/2012-0083R1.1; Hofle U, 2004, EUR J WILDLIFE RES, V50, P73, DOI 10.1007/s10344-004-0043-2; HUBBARD GB, 1983, J ZOO ANIM MED, V14, P33, DOI 10.2307/20094627; HURST GA, 1980, J WILDLIFE DIS, V16, P357, DOI 10.7589/0090-3558-16.3.357; Iadarola P, 1998, EXP LUNG RES, V24, P233; IANCONESCU M, 1976, AVIAN DIS, V20, P135, DOI 10.2307/1589481; Jia BB, 2008, ARCH VIROL, V153, P1821, DOI 10.1007/s00705-008-0193-8; Jirjis FF, 2004, AVIAN DIS, V48, P34, DOI 10.1637/7017; Jones RC, 2000, REV SCI TECH OIE, V19, P614, DOI 10.20506/rst.19.2.1237; JULIAN RJ, 1990, AVIAN PATHOL, V19, P643, DOI 10.1080/03079459008418720; Kaleta E.F., 1988, Developments in Veterinary Virology, V8, P197; Kaleta EF, 2003, AVIAN PATHOL, V32, P435, DOI 10.1080/03079450310001593613; Katz ME, 1996, AUST VET J, V74, P50, DOI 10.1111/j.1751-0813.1996.tb13735.x; KERNOHAN G., 1931, Journal of the American Veterinary Medical Association, V78, P553; Keyburn AL, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040026; KEYMER IF, 1984, AVIAN PATHOL, V13, P65, DOI 10.1080/03079458408418509; Kheirandish R., 2013, Global Veterinaria, V10, P140; KLEI T R, 1975, Journal of Wildlife Diseases, V11, P130; Klopfleisch R, 2006, VET PATHOL, V43, P463, DOI 10.1354/vp.43-4-463; Komarov A., 1960, Veterinary Record, V72, P257; Lane RS, 2006, J WILDLIFE DIS, V42, P759, DOI 10.7589/0090-3558-42.4.759; Levine N. D., 1959, Wildlife Dis, VNo 1, P1; Levine ND, 1980, NEMATODE PARASITES D; LITJENS JB, 1989, TIJDSCHR DIERGENEESK, V114, P719; LUTTRELL MP, 1991, J WILDLIFE DIS, V27, P74, DOI 10.7589/0090-3558-27.1.74; Marek A, 2014, VIROLOGY, V462, P107, DOI 10.1016/j.virol.2014.04.033; Marlier D, 2006, VET J, V172, P40, DOI 10.1016/j.tvjl.2005.02.026; Mayeda B., 1982, P AM ASS VET LAB DIA, P262; MCFERRAN JB, 1976, AVIAN DIS, V20, P519, DOI 10.2307/1589384; Moretti A, 2000, J VET MED B, V47, P433, DOI 10.1046/j.1439-0450.2000.00367.x; Morishita T. Y., 2007, Flynn's parasites of laboratory animals, P217, DOI 10.1002/9780470344552.ch10; Musher B, 2004, J CLIN MICROBIOL, V42, P5517, DOI 10.1128/JCM.42.12.5517-5522.2004; Neiman PE, 2006, ONCOGENE, V25, P6325, DOI 10.1038/sj.onc.1209646; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nishiyama N, 2015, IEEE MTTS INT MICROW, P143, DOI 10.1109/IMWS-BIO.2015.7303819; O'Meara D. C., 1971, Infectious and parasitic diseases of wild birds, P153; Oates David W., 2005, Transactions of the Nebraska Academy of Sciences, V30, P25; Ogawa A., 2001, Journal of the Japan Veterinary Medical Association, V54, P87; OIE, 2012, MAN DIAGN TESTS VACC, P555; Ossiboff RJ, 2015, VET PATHOL, V52, P716, DOI 10.1177/0300985814556186; Pantin-Jackwood MJ, 2008, AVIAN DIS, V52, P235, DOI 10.1637/8174-111507-Reg.1; PAUL PS, 1977, AM J VET RES, V38, P1653; Payne R., 2000, BIRDS WORLD BIOL, V532; Poppenga RH, 2005, J WILDLIFE DIS, V41, P218, DOI 10.7589/0090-3558-41.1.218; Portz C, 2008, VET MICROBIOL, V131, P57, DOI 10.1016/j.vetmic.2008.02.029; Qian DH, 2006, AM J VET RES, V67, P1575, DOI 10.2460/ajvr.67.9.1575; Rabsch W, 2002, INFECT IMMUN, V70, P2249, DOI 10.1128/IAI.70.5.2249-2255.2002; RANCK FM, 1965, AVIAN DIS, V9, P8, DOI 10.2307/1587788; Razin S., 1989, MYCOPLASMAS, P33; Reavill Drury R, 2004, Vet Clin North Am Exot Anim Pract, V7, P537, DOI 10.1016/j.cvex.2004.04.008; Redig P. T., 1998, Proceedings of the 19th Annual Conference on Avian Medicine and Surgery, Mid-Atlantic States Association of Avian Veterinarians, held in Lancaster, Pennsylvania, USA, 26-28 April, 1998., P172; REECE RL, 1992, AVIAN PATHOL, V21, P3, DOI 10.1080/03079459208418815; Richard J. L., 1983, AVIAN DIS, V8, P1; Robinson RA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012215; Saggese MD, 2008, AVIAN PATHOL, V37, P443, DOI 10.1080/03079450802210655; Sansano-Maestre J, 2009, AVIAN PATHOL, V38, P201, DOI 10.1080/03079450902912135; Sarabia J, 2008, AVIAN DIS, V52, P540, DOI 10.1637/8251-020508-Case.1; SASAKI T, 1991, J BACTERIOL, V173, P2398; Schmidt RE, 2002, J AVIAN MED SURG, V16, P111, DOI 10.1647/1082-6742(2002)016[0111:THIB]2.0.CO;2; SHANE SM, 1985, AVIAN DIS, V29, P822, DOI 10.2307/1590673; Shivaprasad HL, 2008, AVIAN DIS, V52, P353, DOI 10.1637/8032-062007-Case.1; SILLER WG, 1979, VET SCI COMMUN, V2, P331; SILLER WG, 1985, POULTRY SCI, V64, P1591, DOI 10.3382/ps.0641591; Soko&sp2 R., 2009, Zycie Weterynaryjne, V84, P407; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Stallknecht DE, 1998, PROCEEDINGS OF THE FORTH INTERNATIONAL SYMPOSIUM ON AVIAN INFLUENZA, P61; Stenzel TA, 2012, VET REC, V171, P562, DOI 10.1136/vr.100932; Stipkovits L, 2012, VET PATHOL, V49, P273, DOI 10.1177/0300985811415702; Suarez D. L., 2008, INFLUENZA VIRUS, P3; Swayne D. E., 2008, AVIAN INFLUENZA, P87; Swayne DE, 2013, DIS POULTRY; Swinnerton KJ, 2005, IBIS, V147, P772, DOI 10.1111/j.1474-919X.2005.00466.x; Thomas JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139266; Toplu N, 2004, AVIAN PATHOL, V33, P381, DOI 10.1080/0307945042000220570; Tripathy D. N., 2008, LAB MANUAL ISOLATION, P94; U. S. Geological Survey, 1990, FIELD MAN WILDL DIS; van Empel PCM, 1999, AVIAN PATHOL, V28, P217, DOI 10.1080/03079459994704; Vereecken M, 1998, AVIAN PATHOL, V27, P333, DOI 10.1080/03079459808419348; WADA Y, 1995, J VET MED SCI, V57, P531, DOI 10.1292/jvms.57.531; WADSWORTH PF, 1981, AVIAN PATHOL, V10, P499, DOI 10.1080/03079458108418500; WADSWORTH PF, 1979, AVIAN PATHOL, V8, P279, DOI 10.1080/03079457908418352; WAGES DP, 1993, AVIAN DIS, V37, P1163, DOI 10.2307/1591931; Welchman DD, 2002, VET REC, V150, P658, DOI 10.1136/vr.150.21.658; White PL, 2010, J CLIN MICROBIOL, V48, P1231, DOI 10.1128/JCM.01767-09; WIGHT PAL, 1979, AVIAN PATHOL, V8, P115, DOI 10.1080/03079457908418332; WITTER RL, 1974, AM J VET RES, V35, P1325; Woronecki P. P., 1992, 15 VERT PEST C U CAL; Wozniakowski GJ, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-52; Zhai SL, 2016, ARCH VIROL, V161, P2007, DOI 10.1007/s00705-016-2870-3; Zhang Z, 2006, J VET DIAGN INVEST, V18, P204, DOI 10.1177/104063870601800212; Zocevic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058741	150	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							747	+		10.1016/B978-0-12-805306-5.00031-6			31	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300033					2019-10-28	
B	Reavill, DR; Dorrestein, G		Terio, KA; McAloose, D; StLeger, J		Reavill, Drury R.; Dorrestein, Gerry			Psittacines, Coliiformes, Musophagiformes, Cuculiformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							BUDGERIGARS MELOPSITTACUS-UNDULATUS; PULMONARY INTERSTITIAL FIBROSIS; VITAMIN-A METABOLISM; AVIAN THYROID-GLAND; AMAZON PARROTS; YERSINIA-PSEUDOTUBERCULOSIS; MACRORHABDUS-ORNITHOGASTER; INTERNAL PAPILLOMATOSIS; FEATHER DISEASE; PET BIRDS		[Reavill, Drury R.] Zoo Exot Pathol Serv, Citrus Hts, CA 95610 USA; [Dorrestein, Gerry] Pathol Lab NOIVBD, Vessem, Netherlands	Reavill, DR (reprint author), Zoo Exot Pathol Serv, Citrus Hts, CA 95610 USA.						Ahmed B, 2017, TRANSBOUND EMERG DIS, V64, P167, DOI 10.1111/tbed.12358; Altman RB, 1997, AVIAN MED SURG; Amann O, 2007, AVIAN DIS, V51, P150, DOI 10.1637/0005-2086(2007)051[0150:CPIFIA]2.0.CO;2; [Anonymous], 1963, EIMERIAMUSOPHAGI; [Anonymous], 1967, COCCIDIA MUSOPHAGIFO; Balsamo G, 2017, J AVIAN MED SURG, V31, P262, DOI 10.1647/217-265; Barton CE, 2003, J AVIAN MED SURG, V17, P197, DOI 10.1647/2002-011; Beaufrere H, 2013, JAVMA-J AM VET MED A, V242, P1696, DOI 10.2460/javma.242.12.1696; BENKO M, 2005, VIRUS TAXONOMY, P213; Benskin CMH, 2009, BIOL REV, V84, P349, DOI 10.1111/j.1469-185X.2008.00076.x; BLOMHOFF R, 1991, PHYSIOL REV, V71, P951; Bostock J., 1855, NAT HIST; BOUGHTON DONALD C., 1938, OHIO JOUR SCI, V38, P149; BURGER WP, 1994, J S AFR VET ASSOC, V65, P113; Campbell TW, 1999, J AVIAN MED SURG, V13, P265; Canny CJ, 1999, J AVIAN MED SURG, V13, P279; COLLAR NJ, 1997, HDB BIRDS WORLD, V4, P280; Cork SC, 1999, AVIAN PATHOL, V28, P393, DOI 10.1080/03079459994669; Sidrim JJC, 2010, VET MICROBIOL, V145, P324, DOI 10.1016/j.vetmic.2010.04.006; Cray C, 2005, J AVIAN MED SURG, V19, P277, DOI 10.1647/2004-031.1; Cray C, 2009, J AVIAN MED SURG, V23, P125, DOI 10.1647/2007-041.1; D'Ambrosio DN, 2011, NUTRIENTS, V3, P63, DOI 10.3390/nu3010063; de Juana E, 2017, HDB BIRDS WORLD ALIV; de Kloet E, 2004, ARCH VIROL, V149, P2393, DOI 10.1007/s00705-004-0368-x; DORRESTEIN GM, 1985, AVIAN DIS, V29, P951, DOI 10.2307/1590448; Downs CT, 2000, AUK, V117, P791, DOI 10.1642/0004-8038(2000)117[0791:AANAOT]2.0.CO;2; Forshaw J. M., 1989, PARROTS WORLD; Fricke C, 2009, AVIAN DIS, V53, P466, DOI 10.1637/8521-111908-Case.1; Gancz Ady Y., 2010, Veterinary Clinics of North America Exotic Animal Practice, V13, P471, DOI 10.1016/j.cvex.2010.05.004; Garner MM, 2008, VET PATHOL, V45, P401, DOI 10.1354/vp.45-3-401; Garner MM, 2003, TAKE FLIGHT IN PITTSBURGH, PROCEEDINGS, P55; Gibbons PM, 2002, AVIAN DIS, V46, P1062, DOI 10.1637/0005-2086(2002)046[1062:IPWICA]2.0.CO;2; Greenacre C.B., 1993, Journal of the Association of Avian Veterinarians, V7, P19, DOI 10.2307/30134302; Gregonis L. M., 1997, HOHOKAM INDIANS TUCS; Gregory Christopher R., 1994, Journal of the Association of Avian Veterinarians, V8, P69; Habold C, 2004, SCAND J GASTROENTERO, V39, P531, DOI 10.1080/00365520410004514; Habold C, 2007, PFLUG ARCH EUR J PHY, V455, P323, DOI 10.1007/s00424-007-0289-0; HARGIS AM, 1989, J AM VET MED ASSOC, V194, P64; Harris D., 1999, EXOTIC DVM, V1, P13; HERMAN LH, 1969, VET MED SM ANIM CLIN, V64, P812; Hill G. E., 2006, BIRD COLORATION FUNC, P366; HOWARD BR, 1992, J AM VET MED ASSOC, V200, P1667; Kaiser G. W., 2010, INNER BIRD ANATOMY E, P188; Kajerova V, 2004, VET MED-CZECH, V49, P217, DOI 10.17221/5698-VETMED; Katohi H, 2010, J VET MED SCI, V72, P1099, DOI 10.1292/jvms.10-0022; King A. S., 1984, IRDS THEIR STRUCTURE, P23; Kistler AL, 2010, J VIROL, V84, P2176, DOI 10.1128/JVI.02191-09; Klasing KC, 1999, SEMIN AVIAN EXOT PET, V8, P42, DOI 10.1016/S1055-937X(99)80036-X; Koski MA, 2002, SEMIN AVIAN EXOT PET, V11, P105, DOI 10.1053/saep.2002.123981; Kutzer E., 1963, Archiv fuer Protistenkunde, V106, P569; Lanzarot P, 2013, MED MYCOL, V51, P888, DOI 10.3109/13693786.2013.813652; Larrhoven M. A., 1990, J ASS AVIAN VET, V4, P82; Leach Michael W., 1992, Seminars in Avian and Exotic Pet Medicine, V1, P52; Ledwon A, 2008, AVIAN PATHOL, V37, P59, DOI 10.1080/03079450701802255; Lee SY, 2011, APPL ENVIRON MICROB, V77, P8442, DOI 10.1128/AEM.05343-11; Legler M, 2008, DEUT TIERARZTL WOCH, V115, P461, DOI 10.2376/0341-6593-115-461; Levy MG, 2015, VET PARASITOL, V208, P169, DOI 10.1016/j.vetpar.2014.12.028; Lierz M, 2009, AVIAN PATHOL, V38, P491, DOI 10.1080/03079450903349238; Lightfoot Teresa L., 2008, Veterinary Clinics of North America Exotic Animal Practice, V11, P229, DOI 10.1016/j.cvex.2008.01.006; Loukopoulos P, 2014, J ZOO WILDLIFE MED, V45, P961, DOI 10.1638/2014-0080.1; LUMEIJ JT, 1985, VET QUART, V7, P133, DOI 10.1080/01652176.1985.9693969; LUMEIJ JT, 1990, AVIAN PATHOL, V19, P661, DOI 10.1080/03079459008418722; MCLELLAND J, 1989, J EXP ZOOL, P2; Merryman JI, 1998, J AVIAN MED SURG, V12, P238; Merryman JI, 1998, J AVIAN MED SURG, V12, P234; MINES JJ, 1979, INT J PARASITOL, V9, P371, DOI 10.1016/0020-7519(79)90088-2; NEUMANN U, 1983, AVIAN PATHOL, V12, P353, DOI 10.1080/03079458308436178; O'Malley B., 2005, CLIN ANATOMY PHYSL E, P97; OCHIAI K, 1993, VET PATHOL, V30, P522, DOI 10.1177/030098589303000605; OHMART RD, 1972, COMP BIOCHEM PHYSIOL, V43, P311, DOI 10.1016/0300-9629(72)90189-2; Ouyang N, 2009, AVIAN PATHOL, V38, P393, DOI 10.1080/03079450903191036; Palmieri C, 2013, J COMP PATHOL, V148, P126, DOI 10.1016/j.jcpa.2012.06.005; PELLERDY L, 1967, ACTA ZOOL ACAD SCI H, V13, P227; Phalen DN, 1996, J AM VET MED ASSOC, V209, P1435; Phalen DN, 1995, AVIAN DIS, V39, P897, DOI 10.2307/1592429; Platt SR, 1999, J AM VET MED ASSOC, V214, P1218; Powers L. V, 2006, P ANN C ASS AV VET, P101; Pulparampil N, 1998, J EUKARYOT MICROBIOL, V45, P651; Puschner B, 1999, J VET DIAGN INVEST, V11, P522, DOI 10.1177/104063879901100606; Pye GW, 1999, J AM VET MED ASSOC, V214, P1003; Raidal SR, 2015, AUST VET J, V93, P466, DOI 10.1111/avj.12388; RANDELL MG, 1981, J AM VET MED ASSOC, V179, P1277; Reavill D., 2011, P ANN C ASS AV VET, P265; Reavill D, 2004, P ANN C ASS AV VET, P335; Reavill D. R, 2004, 15 ANN MARD GRAS AV, P1; Reavill D. R, 1997, AV DERM PRACT S AM B, P29; Reavill D, 2007, PROCEEDINGS OF THE ASSOCIATION OF AVIAN VETERINARIANS 28TH ANNUAL CONFERENCE AND EXPO, P89; Reavill Drury R, 2004, Vet Clin North Am Exot Anim Pract, V7, P537, DOI 10.1016/j.cvex.2004.04.008; Reavill Drury R, 2010, Vet Clin North Am Exot Anim Pract, V13, P135, DOI 10.1016/j.cvex.2009.12.001; REECE RL, 1992, AVIAN PATHOL, V21, P3, DOI 10.1080/03079459208418815; Rich G, 1999, EXOT PET PRACT, V4, P25; Rimoldi G, 2013, J VET DIAGN INVEST, V25, P775, DOI 10.1177/1040638713502981; Ritchie B. W., 1991, Journal of the Association of Avian Veterinarians, V5, P147, DOI 10.2307/27671041; Ritchie B. W., 1989, Journal of the Association of Avian Veterinarians, V3, P143, DOI 10.2307/30143076; Roberts J., 2016, GROSS HISTOLOGIC DIA; Rosenthal KL, 2005, J VET DIAGN INVEST, V17, P239, DOI 10.1177/104063870501700304; Sak B, 2010, VET PARASITOL, V168, P196, DOI 10.1016/j.vetpar.2009.11.012; Sareyyupoglu B, 2008, AVIAN DIS, V52, P163, DOI 10.1637/8052-070507-Reg; Schmidt R. E., 2015, PATHOLOGY PET AVIARY; Schmidt RE, 2002, J AVIAN MED SURG, V16, P111, DOI 10.1647/1082-6742(2002)016[0111:THIB]2.0.CO;2; Schmidt V, 2008, AVIAN PATHOL, V37, P589, DOI 10.1080/03079450802428901; Schoemaker NJ, 2000, AVIAN DIS, V44, P470, DOI 10.2307/1592565; Shtrasburg S, 2005, VET PATHOL, V42, P132, DOI 10.1354/vp.42-2-132; Siegal-Willott JL, 2005, J AVIAN MED SURG, V19, P19, DOI 10.1647/2004-005; SILVA T, 1991, PSITTACULTURE BREEDI; Simova-Curd SA, 2010, AVIAN PATHOL, V39, P161, DOI 10.1080/03079451003716375; Snowden K, 2004, SEMIN AVIAN EXOT PET, V13, P94, DOI 10.1053/j.saep.2004.01.005; Speer B., 2015, PAC VET C 2015; Stamper A, 1998, J AVIAN MED SURG, V12, P108; Stanford M, 2007, VET REC, V161, P456, DOI 10.1136/vr.161.13.456; Stanford Michael, 2004, Exotic DVM, V6, P29; STOLTZ JH, 1992, VET HUM TOXICOL, V34, P420; Stoute ST, 2016, AVIAN DIS, V60, P82, DOI 10.1637/11269-090215-CaseR.1; Styles DK, 2005, AVIAN PATHOL, V34, P150, DOI 10.1080/03079450500059032; Styles DK, 2004, VIROLOGY, V325, P24, DOI 10.1016/j.virol.2004.04.033; Szymanska-Czerwinska M, 2016, VECTOR-BORNE ZOONOT, V16, P1, DOI 10.1089/vbz.2015.1839; Taylor M, 1991, J ASS AVIAN VET, V5, P71; Tell LA, 2001, REV SCI TECH OIE, V20, P180, DOI 10.20506/rst.20.1.1273; Thureen DR, 2006, J VIROL, V80, P7863, DOI 10.1128/JVI.00134-06; Tizard I, 2016, ANIM HEALTH RES REV, V17, P110, DOI 10.1017/S1466252316000189; To KKW, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003318; Tokita M, 2003, ZOOL SCI, V20, P749, DOI 10.2108/zsj.20.749; Tomaszewski EK, 2003, J VIROL, V77, P11260, DOI 10.1128/JVI.77.20.11260-11267.2003; Tomaszewski EK, 2003, INT J SYST EVOL MICR, V53, P1201, DOI 10.1099/ijs.0.02514-0; Tomaszewski EK, 2006, J VET DIAGN INVEST, V18, P536, DOI 10.1177/104063870601800603; Turner D., 1997, HDB BIRDS WORLD, V4, P480; Vasanjee SC, 2004, J AVIAN MED SURG, V18, P273; Verstappen FALM, 2005, J AVIAN MED SURG, V19, P138, DOI 10.1647/2002-029; Villar D, 2008, AVIAN DIS, V52, P187, DOI 10.1637/8104-090207-Case; Voigt A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035097; WADSWORTH PF, 1983, AVIAN PATHOL, V12, P321, DOI 10.1080/03079458308436174; WELLS RE, 1982, AM J VET RES, V43, P1243; West GD, 2001, J AVIAN MED SURG, V15, P297, DOI 10.1647/1082-6742(2001)015[0297:HISSOL]2.0.CO;2; Zandvliet MMJM, 2001, AVIAN PATHOL, V30, P517, DOI 10.1080/03079450120078716; Zehnder A., 2016, CURRENT THERAPY AVIA; Zimre-Grabensteiner E, 2011, PARASITOL INT, V60, P213, DOI 10.1016/j.parint.2011.02.003	136	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							775	+		10.1016/B978-0-12-805306-5.00032-8			10	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300034					2019-10-28	
B	Trupkiewicz, J; Garner, MM; Juan-Salles, C		Terio, KA; McAloose, D; StLeger, J		Trupkiewicz, John; Garner, Michael M.; Juan-Salles, Carles			Passeriformes, Caprimulgiformes, Coraciiformes, Piciformes, Bucerotiformes, and Apodiformes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							WEST-NILE-VIRUS; EQUINE ENCEPHALOMYELITIS VIRUS; FINCHES ERYTHRURA-GOULDIAE; AVIAN INFLUENZA-VIRUS; ATOXOPLASMA SPP.; WILD PASSERINES; YERSINIA-PSEUDOTUBERCULOSIS; MYCOPLASMAL CONJUNCTIVITIS; MOLECULAR CHARACTERIZATION; POLYOMAVIRUS INFECTION		[Trupkiewicz, John] Philadelphia Zoo, Philadelphia, PA 19104 USA; [Garner, Michael M.] Northwest ZooPath, Monroe, WA USA; [Juan-Salles, Carles] Noahs Path, Elche, Alicante, Spain	Trupkiewicz, J (reprint author), Philadelphia Zoo, Philadelphia, PA 19104 USA.						Adkesson MJ, 2005, J ZOO WILDLIFE MED, V36, P265, DOI 10.1638/03-091.1; Anderson K, 2013, J ZOO WILDLIFE MED, V44, P93, DOI 10.1638/1042-7260-44.1.93; Anderson R. C., 2000, NEMATODE PARASITES V; Antunes RG, 2008, AVIAN DIS, V52, P702, DOI 10.1637/8356-051208-Case.1; Arechiga-Ceballos N, 2015, REV SCI TECH OIE, V34, P491, DOI 10.20506/rst.34.2.2374; Ashraf U, 2015, VIRUSES-BASEL, V7, P219, DOI 10.3390/v7010219; Atkinson C. T., 2008, PARASITIC DIS WILD B; Atkinson CT, 2009, J AVIAN MED SURG, V23, P53, DOI 10.1647/2008-059.1; Atkinson CT, 1995, PARASITOLOGY, V111, pS59, DOI 10.1017/S003118200007582X; Baker PJ, 2005, MAMMAL REV, V35, P302, DOI 10.1111/j.1365-2907.2005.00071.x; BARTLETT C M, 1984, Journal of Wildlife Diseases, V20, P289; Bartlett Cheryl M., 2008, P439; Bennett MD, 2014, VET MICROBIOL, V168, P302, DOI 10.1016/j.vetmic.2013.11.026; Blancher P, 2013, AVIAN CONSERV ECOL, V8, DOI 10.5751/ACE-00557-080203; Breithaupt A, 2011, VET PATHOL, V48, P924, DOI 10.1177/0300985810386467; Bronson E, 2014, J WILDLIFE DIS, V50, P938, DOI 10.7589/2014-03-080; Brown RE, 1997, ENVIRON HEALTH PERSP, V105, P188, DOI 10.1289/ehp.97105188; Campbell TW, 2015, EXOTIC ANIMAL HEMATOLOGY AND CYTOLOGY, 4TH EDITION, P37; Carlisle MS, 2002, AUST VET J, V80, P41; CDC, 2012, MOSQ SPEC WHICH W NI; Circella E, 2017, J COMP PATHOL, V156, P436, DOI 10.1016/j.jcpa.2017.01.006; Cork SC, 1999, AVIAN PATHOL, V28, P393, DOI 10.1080/03079459994669; Cork SC, 2000, AVIAN PATHOL, V29, P7, DOI 10.1080/03079450094216; Cornelius EA, 2014, PHYSIOL BIOCHEM ZOOL, V87, P719, DOI 10.1086/677541; Cubas Z. S., 2002, Exotic DVM, V4, P27; Cushing TL, 2011, VET PATHOL, V48, P985, DOI 10.1177/0300985810391114; da Silva DC, 2010, PARASITOL RES, V107, P271, DOI 10.1007/s00436-010-1858-2; Dabert J, 2013, PARASITOL RES, V112, P2373, DOI 10.1007/s00436-013-3402-7; Dauphine N., 2009, P 4 INT PARTN FLIGHT, P205; Dhondt AA, 1998, J WILDLIFE DIS, V34, P265, DOI 10.7589/0090-3558-34.2.265; Dhondt AA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103553; DIERENFELD E, 1989, D S NUTR C, P101; Dierenfeld ES, 1994, J NUTR, V124, P2685; Docherty DE, 2004, EMERG INFECT DIS, V10, P907, DOI 10.3201/eid1005.030825; Donovan TA, 2008, J VET DIAGN INVEST, V20, P304, DOI 10.1177/104063870802000307; Edwards EE, 2017, J ZOO WILDLIFE MED, V48, P237, DOI 10.1638/2016-0123.1; EHRSAM H, 1985, SCHWEIZ ARCH TIERH, V127, P665; Elias R, 2008, VET PARASITOL, V158, P382, DOI 10.1016/j.vetpar.2008.09.016; Erickson W., 2004, POTENTIAL RISKS 9 RO, P225; Erickson WP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107491; Ferrell S., 2016, J ZOO WILDLIFE MED, V40, P543; Fessl B, 2006, PARASITOLOGY, V133, P739, DOI 10.1017/S0031182006001089; FOWLER ME, 2003, ZOO WILD ANIMAL MED; Franson JC, 1999, SEMIN AVIAN EXOT PET, V8, P3, DOI 10.1016/S1055-937X(99)80030-9; Frasca S, 1999, AVIAN DIS, V43, P616, DOI 10.2307/1592666; Frasca S, 1997, J WILDLIFE DIS, V33, P336, DOI 10.7589/0090-3558-33.2.336; French R., 1992, P AM ASS ZOO VET AM, P343; Fujimoto Y, 2015, AVIAN PATHOL, V44, P243, DOI 10.1080/03079457.2015.1043235; Fukui D, 2014, J WILDLIFE DIS, V50, P484, DOI 10.7589/2012-12-321; Gamble Kathryn C., 2012, P281; GARCIA F, 1984, COMP BIOCHEM PHYS A, V77, P651, DOI 10.1016/0300-9629(84)90179-8; Garner Michael M., 2006, P566; Garner MM, 2003, TAKE FLIGHT IN PITTSBURGH, PROCEEDINGS, P59; Gelis Stacey, 2006, Veterinary Clinics of North America Exotic Animal Practice, V9, P481, DOI 10.1016/j.cvex.2006.05.032; Gill H, 2008, PARASITOL RES, V103, P493, DOI 10.1007/s00436-008-0986-4; Grue CE, 1997, AM ZOOL, V37, P369; Guthrie A, 2016, JAVMA-J AM VET MED A, V249, P319, DOI 10.2460/javma.249.3.319; Halami MY, 2010, J GEN VIROL, V91, P3016, DOI 10.1099/vir.0.023549-0; Hasle G, 2009, ONDERSTEPOORT J VET, V76, P167; Heenemann K., 2015, GENOME ANNOUNC, V3, P3887; Hemmings NL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1870; HINDMARSH M, 1993, AUST VET J, V70, P451, DOI 10.1111/j.1751-0813.1993.tb00848.x; Hoekstra KA, 1998, J COMP PATHOL, V119, P419, DOI 10.1016/S0021-9975(98)80036-4; Hoop RK, 2002, AVIAN DIS, V46, P502, DOI 10.1637/0005-2086(2002)046[0502:MTIIAC]2.0.CO;2; Juan-Salles C., 2011, P 11 EAAV C 1 ECZM M, P159; Kanarek G, 2016, PARASITOL INT, V65, P447, DOI 10.1016/j.parint.2016.06.010; Keller LF, 1998, EVOLUTION, V52, P240, DOI 10.1111/j.1558-5646.1998.tb05157.x; Kinsella John M., 2008, P376; KLEM D, 1990, J FIELD ORNITHOL, V61, P115; Koop JAH, 2016, J APPL ECOL, V53, P511, DOI 10.1111/1365-2664.12575; Lafferty SL, 1999, AVIAN DIS, V43, P577, DOI 10.2307/1592659; LaPointe DA, 2012, ANN NY ACAD SCI, V1249, P211, DOI 10.1111/j.1749-6632.2011.06431.x; LaPointe DA, 2009, J WILDLIFE DIS, V45, P257, DOI 10.7589/0090-3558-45.2.257; LAW JM, 1993, AVIAN DIS, V37, P597, DOI 10.2307/1591695; Leclerc A, 2014, J ZOO WILDLIFE MED, V45, P577, DOI 10.1638/2013-0257R.1; Lewis LA, 2001, ARCH ENVIRON CON TOX, V41, P208; Ley DH, 1998, J WILDLIFE DIS, V34, P403, DOI 10.7589/0090-3558-34.2.403; Loss SR, 2014, CONDOR, V116, P8, DOI 10.1650/CONDOR-13-090.1; Lowenstine Linda J., 1999, P260; Lobo ML, 2006, APPL ENVIRON MICROB, V72, P7380, DOI 10.1128/AEM.01394-06; Mainez M., 2016, C ESP VET AVEPA GTA; Mainez M, 2015, J AVIAN MED SURG, V29, P46, DOI 10.1647/2013-066; MAINKA SA, 1994, J WILDLIFE DIS, V30, P254, DOI 10.7589/0090-3558-30.2.254; Manarolla G, 2009, VET MICROBIOL, V133, P323, DOI 10.1016/j.vetmic.2008.07.017; Marka A, 2013, INT J ENV RES PUB HE, V10, P6534, DOI 10.3390/ijerph10126534; Marton S., 2016, GENOME ANNOUNC, V4, P2014; Maslin WR, 2009, AVIAN DIS, V53, P473, DOI 10.1637/8557-121008-Case.1; Mather AE, 2016, APPL ENVIRON MICROB, V82, P6728, DOI 10.1128/AEM.01660-16; MCORIST S, 1982, AVIAN DIS, V26, P957, DOI 10.2307/1589887; METEYER CU, 1992, J ZOO WILDLIFE MED, V23, P222; Mikich Sandra Bos, 2001, P180; Mohr F, 2017, J ZOO WILDLIFE MED, V48, P1, DOI 10.1638/2016-0044.1; Nakamura S, 2016, J VET MED SCI, V78, P297, DOI 10.1292/jvms.15-0298; Niemuth J. N., 2013, CASE REP VET MED, V2013, P6; OSBORN D, 1979, ENVIRON POLLUT, V19, P145, DOI 10.1016/0013-9327(79)90145-9; Owen JC, 2013, AVIAN DIS, V57, P744, DOI 10.1637/10574-051513-Reg.1; Perkins LEL, 2003, VET PATHOL, V40, P14, DOI 10.1354/vp.40-1-14; Pfeiffer W, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173464; Projecto-Garcia J, 2013, P NATL ACAD SCI USA, V110, P20669, DOI 10.1073/pnas.1315456110; Proudfoot J., 2000, P AM ASS ZOO VET, P305; REECE RL, 1985, AUST VET J, V62, P426, DOI 10.1111/j.1751-0813.1985.tb14131.x; Refsum T, 2003, J WILDLIFE DIS, V39, P64, DOI 10.7589/0090-3558-39.1.64; Reid JM, 2007, P R SOC B, V274, P697, DOI 10.1098/rspb.2006.0092; Rettenmund CL, 2015, J VET DIAGN INVEST, V27, P382, DOI 10.1177/1040638715581677; Reza Kheirandish, 2013, Asian Pacific Journal of Tropical Biomedicine, V3, P182, DOI 10.1016/S2221-1691(13)60046-5; Riffkin G G, 1972, N Z Vet J, V20, P109, DOI 10.1080/00480169.1972.34026; Rosell J, 2016, VET PARASITOL, V219, P57, DOI 10.1016/j.vetpar.2016.01.022; Rossi G, 2003, AVIAN DIS, V47, P240, DOI 10.1637/0005-2086(2003)047[0240:SCTAWP]2.0.CO;2; Sanchez-Cordon PJ, 2007, J VET MED A, V54, P23, DOI 10.1111/j.1439-0442.2007.00909.x; Schmidt R., 2008, GASTROINTESTINAL SYS, P55; Schrenzel MD, 2005, J PARASITOL, V91, P635, DOI 10.1645/GE-3310; Shima A, 2003, ZOO WILD ANIMAL MED, P234; Shivaprasad HL, 2009, AVIAN PATHOL, V38, P311, DOI 10.1080/03079450903061643; Siegel RB, 2012, J ZOO WILDLIFE MED, V43, P421, DOI 10.1638/2011-0226.1; Siengsanan-Lamont J, 2011, VET MICROBIOL, V148, P213, DOI 10.1016/j.vetmic.2010.09.028; Slusher MJ, 2014, J WILDLIFE DIS, V50, P792, DOI 10.7589/2014-02-043; Smits JE, 2005, VET PATHOL, V42, P59, DOI 10.1354/vp.42-1-59; Snowden K, 2001, AVIAN PATHOL, V30, P251, DOI 10.1080/03079450120054500; Souza MJ, 2009, VET OPHTHALMOL, V12, P53, DOI 10.1111/j.1463-5224.2009.00674.x; Starck J. Matthias, 1998, Oxford Ornithology Series, V8, P3; SUAREZ RK, 1992, EXPERIENTIA, V48, P565, DOI 10.1007/BF01920240; SUAREZ RK, 1991, P NATL ACAD SCI USA, V88, P4870, DOI 10.1073/pnas.88.11.4870; Tell LA, 2001, REV SCI TECH OIE, V20, P180, DOI 10.20506/rst.20.1.1273; Thiel T, 2005, J WILDLIFE DIS, V41, P342, DOI 10.7589/0090-3558-41.2.342; TIDEMANN SC, 1992, J WILDLIFE DIS, V28, P80, DOI 10.7589/0090-3558-28.1.80; Trask AE, 2016, J ANIM ECOL, V85, P879, DOI 10.1111/1365-2656.12503; Travis EK, 2007, JAVMA-J AM VET MED A, V230, P1524, DOI 10.2460/javma.230.10.1524; Van Hemert C, 2013, VET PATHOL, V50, P500, DOI 10.1177/0300985812469637; Van Hemert C, 2016, J WILDLIFE DIS, V52, P927, DOI 10.7589/2016-02-034; VANRIPER C, 1986, ECOL MONOGR, V56, P327, DOI 10.2307/1942550; Vaughan JA, 2012, J MED ENTOMOL, V49, P1430, DOI 10.1603/ME12103; VICKERS MC, 1992, J AM VET MED ASSOC, V200, P1723; Vitali Simone D., 2006, Veterinary Clinics of North America Exotic Animal Practice, V9, P519, DOI 10.1016/j.cvex.2006.05.001; WARNER RE, 1968, CONDOR, V70, P101, DOI 10.2307/1365954; Weli SC, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-49; Wellehan JFX, 2003, J CLIN MICROBIOL, V41, P4054, DOI 10.1128/JCM.41.9.4054-4057.2003; WHEELDON EB, 1982, VET PATHOL, V19, P204, DOI 10.1177/030098588201900212; Work TM, 2000, J WILDLIFE DIS, V36, P205, DOI 10.7589/0090-3558-36.2.205; Zylberberg M, 2016, MBIO, V7, DOI 10.1128/mBio.00874-16	139	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							799	+		10.1016/B978-0-12-805306-5.00033-X			26	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300035					2019-10-28	
B	Rodriguez, CE; Duque, AMH; Steinberg, J; Woodburn, DB		Terio, KA; McAloose, D; StLeger, J		Rodriguez, Carlos E.; Henao Duque, Ana Maria; Steinberg, Jennifer; Woodburn, Daniel B.			Chelonia	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							LOGGERHEAD SEA-TURTLES; TORTOISES TESTUDO-HERMANNI; EASTERN BOX TURTLES; TISSUE ENZYME-ACTIVITIES; FREE-RANGING DESERT; INTRANUCLEAR COCCIDIOSIS; TRACHEMYS-SCRIPTA; CARETTA-CARETTA; PROTEIN ELECTROPHORESIS; PATHOLOGICAL FINDINGS		[Rodriguez, Carlos E.] Walt Disney Pk & Resorts, Orlando, FL 32830 USA; [Henao Duque, Ana Maria] Zoopath Vet Pathol Lab Cali Zoo, Cali, Colombia; [Steinberg, Jennifer] IDEXX Reference Labs, Glen Burnie, MD USA; [Woodburn, Daniel B.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA	Rodriguez, CE (reprint author), Walt Disney Pk & Resorts, Orlando, FL 32830 USA.						Abou-Madi N, 2003, VET CLIN PATH, V32, P61, DOI 10.1111/j.1939-165X.2003.tb00315.x; Allender MC, 2013, J COMP PATHOL, V149, P356, DOI 10.1016/j.jcpa.2013.01.007; Anderson ET, 2013, J ZOO WILDLIFE MED, V44, P62, DOI 10.1638/1042-7260-44.1.62; Andreani G, 2014, VET CLIN PATH, V43, P573, DOI 10.1111/vcp.12203; Ariel E, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-100; Bemis DA, 1999, J VET DIAGN INVEST, V11, P553, DOI 10.1177/104063879901100616; Bezjian M, 2013, VET CLIN PATH, V42, P368, DOI 10.1111/vcp.12061; Camacho M, 2013, JAVMA-J AM VET MED A, V242, P396, DOI 10.2460/javma.242.3.396; Campbell T. W., 2012, Veterinary hematology and clinical chemistry, P599; Campbell T. W., 2012, CLIN CHEM REPTILES, P599; Casal AB, 2009, VET CLIN PATH, V38, P213, DOI 10.1111/j.1939-165X.2008.00106.x; Chapman PA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149962; Chaudhry R, 2016, INDIAN J MED MICROBI, V34, P7, DOI 10.4103/0255-0857.174112; CHINEME CN, 1980, J WILDLIFE DIS, V16, P407, DOI 10.7589/0090-3558-16.3.407; Chinnadurai Sathya K, 2009, Vet Clin North Am Exot Anim Pract, V12, P583, DOI 10.1016/j.cvex.2009.06.008; Christopher MM, 1999, J WILDLIFE DIS, V35, P212, DOI 10.7589/0090-3558-35.2.212; Cordero-Tapia AA, 2004, J PARASITOL, V90, P645, DOI 10.1645/GE-165R; Craig L, 2016, JUBB KENNEDY PALMERS, P60; Cribb TH, 2017, INT J PARASITOL, V47, P61, DOI 10.1016/j.ijpara.2016.11.002; Cullen J. M., 2016, JUBB KENNEDY PALMERS, P273; Davenport J, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0592; De Voe R, 2004, J ZOO WILDLIFE MED, V35, P534, DOI 10.1638/03-037; Delgado C, 2011, J WILDLIFE DIS, V47, P523, DOI 10.7589/0090-3558-47.3.523; Di Girolamo Nicola, 2015, Veterinary Clinics of North America Exotic Animal Practice, V18, P507, DOI 10.1016/j.cvex.2015.04.008; Donnelly K, 2015, DIS AQUAT ORGAN, V113, P257, DOI 10.3354/dao02843; Drury SEN, 2001, VET REC, V148, P452, DOI 10.1136/vr.148.14.452; Duarte A, 2012, ARCH VIROL, V157, P1155, DOI 10.1007/s00705-012-1285-z; Duncan M, 2015, FOWLERS ZOO WILD ANI, V8, P667; Eatwell K, 2010, J SMALL ANIM PRACT, V51, P472, DOI 10.1111/j.1748-5827.2010.00963.x; Eatwell K, 2009, VET REC, V165, P82, DOI 10.1136/vetrec.165.3.82; Eydner M, 2017, VET PATHOL, V54, P704, DOI 10.1177/0300985817691579; Farkas SL, 2009, VET MICROBIOL, V138, P169, DOI 10.1016/j.vetmic.2009.03.016; Flanagan JP, 2015, FOWLERS ZOO WILD ANI, V8, P27; Flint M, 2015, ECOHEALTH, V12, P298, DOI 10.1007/s10393-014-0972-5; Flint M, 2009, J VET DIAGN INVEST, V21, P733, DOI 10.1177/104063870902100601; Fowler M.E., 1980, Contributions to Herpetology, V1, P227; Gandar F, 2015, J VIROL, V89, P11438, DOI 10.1128/JVI.01794-15; Garner MM, 2006, VET PATHOL, V43, P311, DOI 10.1354/vp.43-3-311; Gibbons Paul M., 2013, Veterinary Clinics of North America Exotic Animal Practice, V16, P303, DOI 10.1016/j.cvex.2013.02.004; Gicking John C., 2004, Journal of Herpetological Medicine and Surgery, V14, P13; Gimenez M, 2010, VET CLIN PATH, V39, P227, DOI 10.1111/j.1939-165X.2009.00204.x; Gonzales-Viera O, 2012, J COMP PATHOL, V147, P574, DOI 10.1016/j.jcpa.2012.03.005; GUEDES RMC, 2004, MED VET ZOOTECNIA, V56, P123; HARPER PAW, 1982, J WILDLIFE DIS, V18, P491, DOI 10.7589/0090-3558-18.4.491; Hedley J., 2012, COMPANION ANIMAL, V17, P52; Herbst LH, 2009, VIROLOGY, V383, P131, DOI 10.1016/j.virol.2008.09.022; Herbst LH, 1999, VET PATHOL, V36, P551, DOI 10.1354/vp.36-6-551; Hernandez JD, 2016, VET CLIN PATH, V45, P106, DOI 10.1111/vcp.12325; Hernandez-Divers SJ, 2001, J ZOO WILDLIFE MED, V32, P352; Homer BL, 1998, J WILDLIFE DIS, V34, P508, DOI 10.7589/0090-3558-34.3.508; Hunt K. E., 2016, CONSERV PHYSIOL, V1, P4; Innis C, 2009, J WILDLIFE DIS, V45, P594, DOI 10.7589/0090-3558-45.3.594; Innis CJ, 2007, J VET DIAGN INVEST, V19, P660, DOI 10.1177/104063870701900607; Irizarry Rovira A. R., 2006, HEMATOLOGY REPTILES, P1004; JACOBSON E, 1983, J AM VET MED ASSOC, V183, P1192; Jacobson ER, 2014, VET J, V201, P257, DOI 10.1016/j.tvjl.2014.05.039; Jacobson ER, 2012, J WILDLIFE DIS, V48, P1063, DOI 10.7589/2011-09-256; JACOBSON ER, 1994, J ZOO WILDLIFE MED, V25, P95; JACOBSON ER, 1994, J ZOO WILDLIFE MED, V25, P2; Jacobson ER, 2007, INFECT DIS PATHOLOGY; Johnson AJ, 2005, VET MICROBIOL, V111, P107, DOI 10.1016/j.vetmic.2005.09.008; Johnson AJ, 2008, J WILDLIFE DIS, V44, P851, DOI 10.7589/0090-3558-44.4.851; Jones K, 2016, VET J, V212, P48, DOI 10.1016/j.tvjl.2015.10.041; Joyner PH, 2006, J WILDLIFE DIS, V42, P859, DOI 10.7589/0090-3558-42.4.859; Jungwirth N, 2014, VET MICROBIOL, V170, P403, DOI 10.1016/j.vetmic.2014.02.029; Lewison RL, 2014, P NATL ACAD SCI USA, V111, P5271, DOI 10.1073/pnas.1318960111; Lombardini ED, 2013, J ZOO WILDLIFE MED, V44, P773, DOI 10.1638/2012-0238R3.1; Lopez-Olvera JR, 2003, J WILDLIFE DIS, V39, P830, DOI 10.7589/0090-3558-39.4.830; MacNeill AL, 2002, VET CLIN PATH, V31, P133, DOI 10.1111/j.1939-165X.2002.tb00293.x; Maddox C. W., 2016, ANN M AM COLL VET PA; Mader DR, 2006, REPTILE MED SURG; Manire CA, 2008, VET MICROBIOL, V130, P227, DOI 10.1016/j.vetmic.2008.01.013; McArthur S, 2004, MED SURG TORTOISES T; McGeoch DJ, 2005, J VIROL, V79, P725, DOI 10.1128/JVI.79.2.725-731.2005; Mihalca AD, 2015, VET PARASITOL, V213, P67, DOI 10.1016/j.vetpar.2015.03.024; Mitchell J, 2009, ANTIGONISH REV, P65; Mitchell MA, 2001, SEMIN AVIAN EXOT PET, V10, P25, DOI 10.1053/saep.2001.19798; Mitchell Mark A, 2012, Vet Clin North Am Exot Anim Pract, V15, P101, DOI 10.1016/j.cvex.2011.10.002; Murray M, 2009, J ZOO WILDLIFE MED, V40, P572, DOI 10.1638/2008-0125.1; Noyes Hillary, 2007, Journal of Herpetological Medicine and Surgery, V17, P100; Obst F. J., 2003, ENCY REPTILES AMPHIB; Obst F. J., 2003, ENCY REPTILES; Origgi FC, 2004, VET PATHOL, V41, P50, DOI 10.1354/vp.41-1-50; Origgi FC, 2001, J CLIN MICROBIOL, V39, P3156, DOI 10.1128/JCM.39.9.3156-3163.2001; Oros J, 1998, VET REC, V143, P508, DOI 10.1136/vr.143.18.508; Oros J, 2011, DIS AQUAT ORGAN, V95, P163, DOI 10.3354/dao02351; Oros J., 2011, NZ VET J, V52, P150; Osborne AC, 2010, JAVMA-J AM VET MED A, V237, P561, DOI 10.2460/javma.237.5.561; Ossiboff RJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122901; Petrosky KY, 2015, J ZOO WILDLIFE MED, V46, P637, DOI 10.1638/2015-0014.1; Phillips B.E., 2015, CASE REP VET MED, V2015, P1, DOI [10.1155/2015/604320, DOI 10.1155/2015/604320]; Plummer MV, 2009, HERPETOL CONSERV BIO, V4, P207; Prassack SL, 2001, J EXP BIOL, V204, P2185; Raphael B. L, 2003, ZOO WILD ANIMAL MED, P48; Reavill D. R, 2014, CURRENT THERAPY REPT, P13; Reavill Drury R., 2012, Veterinary Clinics of North America Exotic Animal Practice, V15, P25, DOI 10.1016/j.cvex.2011.10.001; Rivera S, 2009, J VET DIAGN INVEST, V21, P415, DOI 10.1177/104063870902100402; Sandmeier FC, 2009, BIOL CONSERV, V142, P1255, DOI 10.1016/j.biocon.2009.02.001; Santoro M, 2008, J COMP PATHOL, V138, P156, DOI 10.1016/j.jcpa.2007.11.004; Schumacher Juergen, 2003, Veterinary Clinics of North America Exotic Animal Practice, V6, P327, DOI 10.1016/S1094-9194(03)00013-6; Schumacher VL, 2012, J ZOO WILDLIFE MED, V43, P501, DOI 10.1638/2011-0228R.1; Scope A, 2013, RES VET SCI, V95, P59, DOI 10.1016/j.rvsc.2013.02.017; Sim RR, 2015, VET MICROBIOL, V175, P218, DOI 10.1016/j.vetmic.2014.11.029; Stacy BA, 2008, DIS AQUAT ORGAN, V80, P45, DOI 10.3354/dao01913; Stacy BA, 2008, VET MICROBIOL, V126, P63, DOI 10.1016/j.vetmic.2007.07.002; Stacy BA, 2010, DIS AQUAT ORGAN, V89, P237, DOI 10.3354/dao02195; Stchigel AM, 2013, PERSOONIA, V31, P86, DOI 10.3767/003158513X669698; Stringer EM, 2009, J ZOO WILDLIFE MED, V40, P160, DOI 10.1638/2008-0035.1; Teifke JP, 2000, VET PATHOL, V37, P377, DOI 10.1354/vp.37-5-377; Une Y, 2000, J VET MED SCI, V62, P905, DOI 10.1292/jvms.62.905; Van Dijk P. P., 2014, CHELON RES MONOGR, V5, P329, DOI [10.3854/CRM.5.000.CHECKLIST.V7.2014, DOI 10.3854/CRM.5.000.CHECKLIST.V7.2014]; Wellehan Jim, 2012, P254; Whiting SD, 2014, VET REC, V174, P608, DOI 10.1136/vr.101396; Wilkinson Roger, 2004, P141, DOI 10.1002/9780470698877.ch7; Williard A, 2015, BIOL LETTERS, V11, DOI 10.1098/rsbl.2015.0607; Work TM, 2004, DIS AQUAT ORGAN, V62, P163, DOI 10.3354/dao062163; Wyneken Jeanette, 2009, Veterinary Clinics of North America Exotic Animal Practice, V12, P51, DOI 10.1016/j.cvex.2008.08.001; Zaias J, 2006, VET CLIN PATH, V35, P321, DOI 10.1111/j.1939-165X.2006.tb00139.x; Zimmerman LM, 2013, J EXP BIOL, V216, P633, DOI 10.1242/jeb.078832	119	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							825	+		10.1016/B978-0-12-805306-5.00034-1			38	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300036					2019-10-28	
B	Conley, KJ; Shilton, CM		Terio, KA; McAloose, D; StLeger, J		Conley, Kenneth J.; Shilton, Catherine M.			Crocodilia	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							ALLIGATORS ALLIGATOR-MISSISSIPPIENSIS; WEST-NILE-VIRUS; AMERICAN ALLIGATORS; CROCODYLUS-NILOTICUS; FARMED CROCODILES; SKIN-LESIONS; GRANULOMATOUS PNEUMONIA; CHRYSOSPORIUM ANAMORPH; CAPTIVE CROCODILES; INFECTION		[Conley, Kenneth J.] Bronx Zoo, Wildlife Conservat Soc, Bronx, NY 10460 USA; [Shilton, Catherine M.] Northern Terr Dept Primary Ind & Resources, Darwin, NT, Australia	Conley, KJ (reprint author), Bronx Zoo, Wildlife Conservat Soc, Bronx, NY 10460 USA.						Adams L, 2001, J ZOO WILDLIFE MED, V32, P500; Afonso CL, 2006, J VIROL, V80, P4978, DOI 10.1128/JVI.80.10.4978-4991.2006; Ariel E, 1997, AUST VET J, V75, P831, DOI 10.1111/j.1751-0813.1997.tb15666.x; Ariel E, 1997, AUST VET J, V75, P247, DOI 10.1111/j.1751-0813.1997.tb10089.x; Austwick P.K.C., 1981, P193; Benedict S, 2016, MICROBIOL AUST, V37, P114, DOI 10.1071/MA16039; Bishop EJ, 2007, EPIDEMIOL INFECT, V135, P1248, DOI 10.1017/S0950268807008515; Brown DR, 2001, INT J SYST EVOL MICR, V51, P419, DOI 10.1099/00207713-51-2-419; Brown DR, 2001, J WILDLIFE DIS, V37, P671, DOI 10.7589/0090-3558-37.4.671; Buenviaje G., 2000, SKIN DIS FARMED CROC; BUENVIAJE GN, 1994, AUST VET J, V71, P165, DOI 10.1111/j.1751-0813.1994.tb03381.x; Buenviaje GN, 1997, AUST VET J, V75, P365, DOI 10.1111/j.1751-0813.1997.tb15720.x; Buenviaje GN, 1998, AUST VET J, V76, P357, DOI 10.1111/j.1751-0813.1998.tb12368.x; Camus AC, 2002, J AQUAT ANIM HEALTH, V14, P149, DOI 10.1577/1548-8667(2002)014<0149:PRASAM>2.0.CO;2; Camus AC, 1998, J WORLD AQUACULT SOC, V29, P370, DOI 10.1111/j.1749-7345.1998.tb00661.x; Cardoso AMC, 2013, VET PATHOL, V50, P582, DOI 10.1177/0300985812459337; Clippinger TL, 2000, J ZOO WILDLIFE MED, V31, P303; Cook R. A., 1989, P ANN M AM ASS ZOO V; DEAKINS DE, 1971, J PARASITOL, V57, P1197, DOI 10.2307/3277966; DIERENFELD ES, 1989, J ZOO WILDLIFE MED, V20, P3; Elsey RM, 2013, SOUTHEAST NAT, V12, pN31, DOI 10.1656/058.012.0420; Elsey Ruth M., 2013, Herpetological Review, V44, P503; Foggin C. M., 1987, WILDLIFE MANAGEMENT, P351; Foggin C. M, 1992, P 14 WORK M CROC SPE; FROMTLING RA, 1979, VET PATHOL, V16, P428; GARDINER CH, 1986, J WILDLIFE DIS, V22, P575, DOI 10.7589/0090-3558-22.4.575; Garner Michael M, 2004, Vet Clin North Am Exot Anim Pract, V7, P653, DOI 10.1016/j.cvex.2004.04.002; Grigg G. C., 1991, LUNG BIOL HLTH DIS, V56, P339; Gross K. L., 2000, SMALL ANIMAL CLIN NU, P21; Hall NH, 2011, J ZOO WILDLIFE MED, V42, P700, DOI 10.1638/2011-0027.1; Hammerton KM, 2003, ARCH ENVIRON CON TOX, V45, P390, DOI [10.1007/s00244-002-2054-x, 10.1007/s00244-003-0234-y]; Hill AG, 2016, AUST VET J, V94, P83, DOI 10.1111/avj.12404; Honeyfield DC, 2008, J WILDLIFE DIS, V44, P280, DOI 10.7589/0090-3558-44.2.280; HORNER RF, 1988, VET REC, V122, P459, DOI 10.1136/vr.122.19.459; HUBBARD GB, 1983, J ZOO ANIM MED, V14, P33, DOI 10.2307/20094627; Huchzermeyer FW, 2008, J S AFR VET ASSOC, V79, P99; Huchzermeyer FW, 2009, ONDERSTEPOORT J VET, V76, P311; Huchzermeyer F. W., 2000, P 15 WORK M CROC SPE; Huchzermeyer FW, 2002, REV SCI TECH OIE, V21, P265, DOI 10.20506/rst.21.2.1334; HUCHZERMEYER FW, 1994, J S AFR VET ASSOC, V65, P20; HUCHZERMEYER FW, 1991, J S AFR VET ASSOC, V62, P27; Huchzermeyer FW, 2003, CROCODILES BIOL HUSB; Hyndman TH, 2015, VET MICROBIOL, V181, P183, DOI 10.1016/j.vetmic.2015.09.013; Jackson O.F., 1981, P409; Jacobson E. R., 2007, INFECT DIS PATHOLOGY, P671; Jacobson Elliott R., 2007, P461; JACOBSON ER, 1984, J AM VET MED ASSOC, V185, P1421; JACOBSON ER, 1979, J AM VET MED ASSOC, V175, P937; Jacobson ER, 2005, J WILDLIFE DIS, V41, P96, DOI 10.7589/0090-3558-41.1.96; Jacobson ER, 2000, SEMIN AVIAN EXOT PET, V9, P94, DOI 10.1053/AX.2000.4621; JACOBSON ER, 1984, J ZOO ANIM MED, V15, P38, DOI 10.2307/20094678; Junker K, 2006, ONDERSTEPOORT J VET, V73, P27; Kik MJL, 2013, DIS AQUAT ORGAN, V107, P83, DOI 10.3354/dao02656; Kirchhoff H, 1997, INT J SYST BACTERIOL, V47, P742, DOI 10.1099/00207713-47-3-742; Ladds PW, 1996, AUST VET J, V74, P397, DOI 10.1111/j.1751-0813.1996.tb15456.x; LADDS PW, 1994, AUST VET J, V71, P300, DOI 10.1111/j.1751-0813.1994.tb03451.x; LADDS PW, 1990, AUST VET J, V67, P323, DOI 10.1111/j.1751-0813.1990.tb07815.x; Lance VA, 2006, COMP BIOCHEM PHYS C, V142, P30, DOI 10.1016/j.cbpc.2005.09.008; Lane EP, 2013, J ZOO WILDLIFE MED, V44, P899, DOI 10.1638/2012-0264R.1; LARSEN RE, 1983, J AM VET MED ASSOC, V183, P1202; Leitch DB, 2012, J EXP BIOL, V215, P4217, DOI 10.1242/jeb.076836; LEVINE ND, 1987, J WILDLIFE DIS, V23, P442, DOI 10.7589/0090-3558-23.3.442; Magnusson W. E., 2010, CROCODILES STATUS SU, P40; MCALLISTER CT, 1990, J PARASITOL, V76, P332, DOI 10.2307/3282660; McCowan C, 2004, AUST VET J, V82, P375, DOI 10.1111/j.1751-0813.2004.tb11109.x; Miller DL, 2003, EMERG INFECT DIS, V9, P794; MOHAN K, 1995, ONDERSTEPOORT J VET, V62, P45; Nevarez Javier G., 2005, Journal of Herpetological Medicine and Surgery, V15, P4; Nevarez JG, 2008, J ZOO WILDLIFE MED, V39, P562, DOI 10.1638/2007-0133.1; NOVAK SS, 1986, J WILDLIFE DIS, V22, P484, DOI 10.7589/0090-3558-22.4.484; Osipenko Y. V., 2005, P ANN M AM ASS ZOO V; Pare JA, 2008, J EXOT PET MED, V17, P285, DOI 10.1053/j.jepm.2008.07.005; Pare Jean A., 2007, P527; PERRY SF, 1988, J EXP BIOL, V134, P99; Putterill JF, 2006, J MORPHOL, V267, P924, DOI 10.1002/jmor.10448; Ramos MCC, 2002, AUST VET J, V80, P371, DOI 10.1111/j.1751-0813.2002.tb14792.x; Rao K. T., 1984, J BOMBAY NAT HIST SO, V81, P480; RILEY J, 1986, ADV PARASIT, V25, P45; Roh YS, 2011, J ZOO WILDLIFE MED, V42, P738, DOI 10.1638/2010-0234.1; Roh YS, 2010, J ZOO WILDLIFE MED, V41, P550, DOI 10.1638/2009-0237.1; Sanders RK, 2012, ANAT REC, V295, P699, DOI 10.1002/ar.22427; Sariya L, 2015, JPN J VET RES, V63, P5; Scheelings TF, 2015, J COMP PATHOL, V153, P352, DOI 10.1016/j.jcpa.2015.08.001; Schoeb TR, 2002, J WILDLIFE DIS, V38, P320, DOI 10.7589/0090-3558-38.2.320; Shilton CM, 2016, J VET DIAGN INVEST, V28, P279, DOI 10.1177/1040638716642268; Sigler L, 2013, J CLIN MICROBIOL, V51, P3338, DOI 10.1128/JCM.01465-13; Silberman M. S., 1977, P ANN M AM ASS ZOO V; Slany M, 2010, VET MED-CZECH, V55, P91, DOI 10.17221/26/2010-VETMED; Stevenson C, 2010, CROCODILES STATUS SU, P139; Tellez M, 2013, U CALIFORNIA PUBLICA, V136; Thomas AD, 2002, MED MYCOL, V40, P143, DOI 10.1080/714031088; Townsend H. M, 2008, THESIS; VANDERMERWE NJ, 1993, ONDERSTEPOORT J VET, V60, P219; Warner JK, 2016, ECOTOXICOLOGY, V25, P950, DOI 10.1007/s10646-016-1652-8; Webb GJW, 2010, CROCODILES STATUS SU, P99	95	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							855	+		10.1016/B978-0-12-805306-5.00035-3			20	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300037					2019-10-28	
B	Origgi, FC		Terio, KA; McAloose, D; StLeger, J		Origgi, Francesco C.			Lacertilia	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							DRAGONS POGONA-VITTICEPS; INLAND BEARDED DRAGON; IGUANA IGUANA-IGUANA; DEEP FUNGAL DERMATITIS; NEMATODES ASCAROPS SP; CHRYSOSPORIUM ANAMORPH; NANNIZZIOPSIS-VRIESII; GREEN IGUANA; DEVRIESEA-AGAMARUM; SP-NOV.		[Origgi, Francesco C.] Univ Bern, Ctr Fish & Wildlife Hlth FIWI, Bern, Switzerland	Origgi, FC (reprint author), Univ Bern, Ctr Fish & Wildlife Hlth FIWI, Bern, Switzerland.						Abarca ML, 2008, MED MYCOL, V46, P349, DOI 10.1080/13693780701851711; Abarca ML, 2011, MED MYCOL, V49, P319, DOI 10.3109/13693786.2011.556356; Abarca ML, 2009, VET DERMATOL, V20, P295, DOI 10.1111/j.1365-3164.2009.00736.x; Ahne W., 1991, P 2 INT S VIR LOW VE, P203; Al-Hashem MA, 2011, ECOTOX ENVIRON SAFE, V74, P1391, DOI 10.1016/j.ecoenv.2011.02.021; Al-Johany AM, 2009, ULTRASTRUCT PATHOL, V33, P39, DOI 10.1080/01913120902751312; Alibardi L, 2016, ANAT REC, V299, P461, DOI 10.1002/ar.23319; ALMEIDA WO, 2009, REVISTABRASLEIRA BIO, V69, P1183; de Matos APA, 2011, MICROSC MICROANAL, V17, P101, DOI 10.1017/S143192761009433X; Amaral MJ, 2012, ENVIRON TOXICOL CHEM, V31, P2345, DOI 10.1002/etc.1955; ANDERSON MP, 1976, VIRCHOWS ARCH B, V20, P169; ANDERSON MP, 1976, VIRCHOWS ARCH B, V21, P229; ANVER MR, 1976, LAB ANIM SCI, V26, P817; Ariel E, 1997, AUST VET J, V75, P247, DOI 10.1111/j.1751-0813.1997.tb10089.x; Ascher JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060977; AYALA SC, 1976, J PARASITOL, V62, P177, DOI 10.2307/3279261; Baird I. L., 1970, P193; Ball I, 2014, VET J, V202, P176, DOI 10.1016/j.tvjl.2014.07.027; Ball Inna, 2012, Journal of Herpetological Medicine and Surgery, V22, P12; Barten S, 2006, REPTILE MED SURG, P59, DOI DOI 10.1016/B0-72-169327-X/50010-9; Barten S. L., 2006, REPTILE MED SURG, P683; Barten S. L., 2006, REPTILE MED SURG, P862; Bauwens L, 2014, J ZOO AQUAR RES, V2, P88; Behncke H, 2013, VET REC, V173, P248, DOI 10.1136/vr.101545; Bicho RC, 2013, ECOTOXICOLOGY, V22, P156, DOI 10.1007/s10646-012-1012-2; BLAHAK S, 1995, VET RES, V26, P470; Blahak S., 1994, 2 WORLD C HERP AD AU, P29; Bodetti TJ, 2002, SYST APPL MICROBIOL, V25, P146, DOI 10.1078/0723-2020-00086; Bouma MJ, 2007, PARASITOL RES, V100, P949, DOI 10.1007/s00436-006-0379-5; Bowman MR, 2007, MED MYCOL, V45, P371, DOI 10.1080/13693780601188610; Boyer T. H., 2005, P 12 ANN M ASS REPT, P93; Brown DR, 2007, J ZOO WILDLIFE MED, V38, P348, DOI 10.1638/1042-7260(2007)038[0348:MIGIII]2.0.CO;2; Brown DR, 2006, INT J SYST EVOL MICR, V56, P761, DOI 10.1099/ijs.0.63852-0; Brown JD, 2004, J WILDLIFE DIS, V40, P704, DOI 10.7589/0090-3558-40.4.704; Buono S, 2007, COMP BIOCHEM PHYS C, V145, P306, DOI 10.1016/j.cbpc.2006.12.016; Burcham GN, 2011, JAVMA-J AM VET MED A, V239, P1305, DOI 10.2460/javma.239.10.1305; Cakici O, 2012, B ENVIRON CONTAM TOX, V88, P685, DOI 10.1007/s00128-012-0571-5; Cakici O, 2012, ENVIRON SCI POLLUT R, V19, P64, DOI 10.1007/s11356-011-0541-1; CANNON LRG, 1967, PARASITOLOGY, V57, P227, DOI 10.1017/S003118200007205X; Cardone A, 2008, ENVIRON RES, V108, P214, DOI 10.1016/j.envres.2008.07.011; Cardone A, 2015, ECOTOXICOLOGY, V24, P94, DOI 10.1007/s10646-014-1361-0; Cardone A, 2012, ECOTOXICOLOGY, V21, P512, DOI 10.1007/s10646-011-0812-0; Chia MY, 2009, VET PATHOL, V46, P673, DOI 10.1354/vp.08-VP-0224-P-CR; CHINEME CN, 1980, J WILDLIFE DIS, V16, P407, DOI 10.7589/0090-3558-16.3.407; Chung TH, 2014, J ZOO WILDLIFE MED, V45, P393, DOI 10.1638/2013-0076R2.1; Clancy MM, 2016, JAVMA-J AM VET MED A, V248, P1050, DOI 10.2460/javma.248.9.1050; CLARK HF, 1972, INFECT IMMUN, V5, P559; Coke R. L., 1998, P 5 ANN C ASS REPT A, P157; Coke RL, 1997, PROCEEDINGS OF THE FOURTH ANNUAL CONFERENCE OF THE ASSOCIATION OF REPTILIAN AND AMPHIBIAN VETERINARIANS, P25; Cooper J. E., 2006, REPTILE MED SURG, P196; COOPER JE, 1982, LAB ANIM, V16, P12, DOI 10.1258/002367782780908878; D'Agostino J. J., 2006, Journal of Herpetological Medicine and Surgery, V16, P27; Darevsky I.S., 1985, Biology of Reptilia, V15, P411; de Matos APA, 2002, INTERVIROLOGY, V45, P150, DOI 10.1159/000065868; Devloo R, 2011, VET MICROBIOL, V150, P297, DOI 10.1016/j.vetmic.2011.01.029; DILLEHAY DL, 1986, J AM VET MED ASSOC, V189, P1139; Divers SJ, 2000, SEMIN AVIAN EXOT PET, V9, P153, DOI 10.1053/ax.2000.7136; Doneley RJT, 2014, AUST VET J, V92, P41, DOI 10.1111/avj.12136; Doszpoly A, 2013, INFECT GENET EVOL, V17, P106, DOI 10.1016/j.meegid.2013.03.049; Drury SEN, 2002, VET REC, V151, P637, DOI 10.1136/vr.151.21.637; Ebani VV, 2012, RES VET SCI, V93, P1136, DOI 10.1016/j.rvsc.2012.05.006; Elschner MC, 2014, BMC VET RES, V10, DOI 10.1186/s12917-014-0283-7; Ezcurra MD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089165; Feldman SH, 2011, LAB ANIMAL, V40, P107, DOI 10.1038/laban0411-107; Ferguson GW, 1996, ZOO BIOL, V15, P279; Fitzgerald K. T., 2006, REPTILE MED SURG, P906; Fitzgerald SD, 1998, J VET DIAGN INVEST, V10, P179, DOI 10.1177/104063879801000211; FRYE FL, 1977, J AM VET MED ASSOC, V171, P882; FRYE FL, 1994, J ZOO WILDLIFE MED, V25, P167; Frye Fredric L., 1999, Proceedings of the Annual Conference of the Association of Reptilian and Amphibian Veterinarians, V6, P43; Gabor LJ, 2005, J VET DIAGN INVEST, V17, P71, DOI 10.1177/104063870501700115; Gardiner DW, 2009, J ZOO WILDLIFE MED, V40, P757, DOI 10.1638/2009-0007.1; Gardner BR, 2010, J S AFR VET ASSOC, V81, P121; Garner M. M., 2003, P ASS REPT AMPH VET, P50; Garner Michael M, 2004, Vet Clin North Am Exot Anim Pract, V7, P653, DOI 10.1016/j.cvex.2004.04.002; Garner MM, 1999, J ZOO WILDLIFE MED, V30, P443; Garvin SD, 2015, J MED ENTOMOL, V52, P873, DOI 10.1093/jme/tjv100; Goe AM, 2016, VET QUART, V36, P109, DOI 10.1080/01652176.2016.1153169; GOLDBERG SR, 1985, J WILDLIFE DIS, V21, P310, DOI 10.7589/0090-3558-21.3.310; GOLDBERG SR, 1988, J WILDLIFE DIS, V24, P568, DOI 10.7589/0090-3558-24.3.568; GOLDBERG SR, 1989, J WILDLIFE DIS, V25, P425, DOI 10.7589/0090-3558-25.3.425; GOLDBERG SR, 1994, J WILDLIFE DIS, V30, P274, DOI 10.7589/0090-3558-30.2.274; GOLDBERG SR, 1991, J WILDLIFE DIS, V27, P68, DOI 10.7589/0090-3558-27.1.68; GOLDBERG SR, 1989, J WILDLIFE DIS, V25, P630, DOI 10.7589/0090-3558-25.4.630; Gravendyck M, 1998, J WILDLIFE DIS, V34, P33, DOI 10.7589/0090-3558-34.1.33; Greek T. J., 2001, P ASS REPT AMPH VET, P161; Grigoryeva L.A., 2002, Parazitologiya (St. Petersburg), V36, P375; Grosset C, 2014, J VET DIAGN INVEST, V26, P354, DOI 10.1177/1040638714534851; Han JI, 2010, J EXOT PET MED, V19, P240, DOI 10.1053/j.jepm.2010.07.008; Hedley J, 2010, VET REC, V166, P464, DOI 10.1136/vr.b4816; Hellebuyck T, 2012, VET J, V193, P38, DOI 10.1016/j.tvjl.2012.02.001; Hellebuyck T, 2010, VET DERMATOL, V21, P429, DOI 10.1111/j.1365-3164.2010.00880.x; Hellebuyck T, 2009, VET MICROBIOL, V134, P267, DOI 10.1016/j.vetmic.2008.08.021; Hernandez-Divers Sonia M., 2003, Veterinary Clinics of North America Exotic Animal Practice, V6, P251, DOI 10.1016/S1094-9194(02)00028-2; Hoby S, 2010, J NUTR, V140, P1923, DOI 10.3945/jn.110.120998; Holz P., 2006, REPTILE MED SURG, P135; Hughes-Hanks JM, 2010, J VET DIAGN INVEST, V22, P295, DOI 10.1177/104063871002200224; Hyndman T, 2011, AUST VET J, V89, P232, DOI 10.1111/j.1751-0813.2011.00712.x; Hyndman TH, 2013, VET MICROBIOL, V165, P200, DOI 10.1016/j.vetmic.2013.04.002; Jacobson E. R., 1989, 3 C PATH REPT AMPH O, V3, P47; Jacobson E. R., 1991, DERMATOLOGY SMALL AN, P225; Jacobson Elliott R., 2007, P571; Jacobson Elliott R., 2007, P461; Jacobson Elliott R., 2007, P1; Jacobson Elliott R., 2007, P395, DOI 10.1201/9781420004038.ch9; JACOBSON ER, 1986, J ZOO WILDLIFE MED, V17, P149, DOI 10.2307/20094810; Jacobson ER, 1996, VET PATHOL, V33, P343, DOI 10.1177/030098589603300313; Jacobson ER, 1998, J ZOO WILDLIFE MED, V29, P315; JACOBSON ER, 1990, J WILDLIFE DIS, V26, P572, DOI 10.7589/0090-3558-26.4.572; Jacobson ER, 2001, J VET DIAGN INVEST, V13, P143, DOI 10.1177/104063870101300208; Janssen J, 2015, COMP BIOCHEM PHYS A, V189, P21, DOI 10.1016/j.cbpa.2015.07.002; Johnson RSP, 2011, AUST VET J, V89, P515, DOI 10.1111/j.1751-0813.2011.00851.x; JONES HI, 1995, J WILDLIFE DIS, V31, P299, DOI 10.7589/0090-3558-31.3.299; Jones YL, 2009, J ZOO WILDLIFE MED, V40, P576, DOI 10.1638/2008-0171.1; JULIAN AF, 1982, NEW ZEAL VET J, V30, P59, DOI 10.1080/00480169.1982.34880; Just F, 2001, J VET MED B, V48, P685, DOI 10.1046/j.1439-0450.2001.00495.x; KALVIG BA, 1991, J WILDLIFE DIS, V27, P551, DOI 10.7589/0090-3558-27.4.551; KANE KK, 1976, VET MED SM ANIM CLIN, V71, P183; Khosravi AR, 2012, J SMALL ANIM PRACT, V53, P286, DOI 10.1111/j.1748-5827.2011.01217.x; Kik MJL, 2011, VET PARASITOL, V175, P165, DOI 10.1016/j.vetpar.2010.10.002; Kim DY, 2002, J VET DIAGN INVEST, V14, P332, DOI 10.1177/104063870201400411; Kinsel MJ, 1997, J ZOO WILDLIFE MED, V28, P498; Kramer Marc H., 2006, Veterinary Clinics of North America Exotic Animal Practice, V9, P563, DOI 10.1016/j.cvex.2006.05.007; Kubiak M, 2013, VET REC, V172, P475, DOI 10.1136/vr.101087; Kummrow MS, 2010, J ZOO WILDLIFE MED, V41, P128, DOI 10.1638/2009-0175.1; Latney La'Toya V., 2013, Veterinary Clinics of North America Exotic Animal Practice, V16, P319, DOI 10.1016/j.cvex.2013.01.003; Le Souef AT, 2015, NEW ZEAL VET J, V63, P340, DOI 10.1080/00480169.2015.1063468; Literak L, 2010, J WILDLIFE DIS, V46, P257; Lloyd C, 2005, VET REC, V156, P578, DOI 10.1136/vr.156.18.578; lMacedo L. C., 2016, REVISTA; Loukopoulos P, 2007, J ZOO WILDLIFE MED, V38, P131, DOI 10.1638/2006-0018R.1; Lukac M, 2013, J ZOO WILDLIFE MED, V44, P430, DOI 10.1638/2012-0100R.1; Mader D. R., 2006, REPTILE MED SURG, V2, P841; Mader D. R., 2006, REPTILE MED SURG, V2, P135; Mans Christoph, 2014, Vet Clin North Am Exot Anim Pract, V17, P369, DOI 10.1016/j.cvex.2014.05.002; Marschang RE, 2009, VIRUS RES, V144, P272, DOI 10.1016/j.virusres.2009.05.011; Marschang RE, 2005, J ZOO WILDLIFE MED, V36, P295, DOI 10.1638/04-008.1; Marschang RE, 2002, J ZOO WILDLIFE MED, V33, P317; Martel A, 2006, VLAAMS DIERGEN TIJDS, V75, P306; Martel A, 2008, INT J SYST EVOL MICR, V58, P2206, DOI 10.1099/ijs.0.65478-0; Maxwell L. K., 2003, BIOL HUSBANDRY MED G, P1122; May M, 2007, FEMS MICROBIOL LETT, V274, P298, DOI 10.1111/j.1574-6968.2007.00847.x; MCALLISTER CT, 1995, J PARASITOL, V81, P281, DOI 10.2307/3283934; McCracken Helen E., 1994, University of Sydney Post Graduate Committee in Veterinary Science Proceedings, V233, P461; Mendyk RW, 2013, ZOO BIOL, V32, P152, DOI 10.1002/zoo.21043; Miller EA, 2001, CONTEMP TOP LAB ANIM, V40, P18; MINUCCI S, 1995, GEN COMP ENDOCR, V97, P273, DOI 10.1006/gcen.1995.1027; Molnar O, 2013, NATURWISSENSCHAFTEN, V100, P551, DOI 10.1007/s00114-013-1051-4; MONTALI RJ, 1975, J AM VET MED ASSOC, V167, P553; Moormann S, 2009, J COMP PATHOL, V141, P78, DOI 10.1016/j.jcpa.2009.03.002; Murray J. M., 2006, REPTILE MED SURG, P124; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; Origgi Francesco, 1999, Bulletin of the Association of Reptilian and Amphibian Veterinarians, V9, P9; Oros J, 1998, J WILDLIFE DIS, V34, P807, DOI 10.7589/0090-3558-34.4.807; Oros J, 2013, J COMP PATHOL, V149, P372, DOI 10.1016/j.jcpa.2012.11.245; Oros J, 1998, AVIAN DIS, V42, P818, DOI 10.2307/1592723; Paperna I., 2001, Parassitologia (Rome), V43, P91; Paperna I., 1989, S AFR J ZOOL, V24, P4; Papp T, 2009, VET MICROBIOL, V134, P233, DOI 10.1016/j.vetmic.2008.08.003; Pare JA, 2006, MED MYCOL, V44, P25, DOI 10.1080/13693780500165461; Pare JA, 1997, J ZOO WILDLIFE MED, V28, P443; Pare JA, 2006, REPTILE MED SURG, V2, P217; Pare Jean A., 2016, Journal of Herpetological Medicine and Surgery, V26, P46; Pare Jean A., 2007, P527; Pasmans F, 2005, VET MICROBIOL, V110, P285, DOI 10.1016/j.vetmic.2005.07.008; Pasmans F, 2008, VET J, V175, P53, DOI 10.1016/j.tvjl.2006.12.009; Pavlasek I, 2008, EXP PARASITOL, V118, P434, DOI 10.1016/j.exppara.2007.09.006; Perry Steven F., 1998, V19, P1; Pfaff M, 2015, BERL MUNCH TIERARZTL, V128, P39, DOI 10.2376/0005-9366-128-39; Pizzi R, 2009, VET REC, V164, P472, DOI 10.1136/vr.164.15.472; PUGSLEY SL, 1985, LAB ANIM, V19, P284, DOI 10.1258/002367785780887365; Quay W.B., 1979, P245; RAYNAUD A, 1976, CR ACAD SCI D NAT, V283, P845; Richter B, 2013, J COMP PATHOL, V148, P278, DOI 10.1016/j.jcpa.2012.05.009; Richter B, 2011, J VET DIAGN INVEST, V23, P430, DOI 10.1177/1040638711403415; Ritzman TB, 2012, ANAT REC, V295, P1596, DOI 10.1002/ar.22524; Rival F, 2015, VET OPHTHALMOL, V18, P71, DOI 10.1111/vop.12195; Rossier C, 2016, J ZOO WILDLIFE MED, V47, P280, DOI 10.1638/2014-0184.1; Rothschild BM, 1997, NATURE, V387, P357, DOI 10.1038/387357a0; Rothschild B, 2010, J HERPETOL, V44, P13, DOI 10.1670/08-243.1; Ryan T. P., 1992, B ASS REPT AMPH VET, V22, P7; SCHALL JJ, 1982, SCIENCE, V217, P1057, DOI 10.1126/science.7112113; Schall JJ, 1996, ADV PARASIT, V37, P255, DOI 10.1016/S0065-308X(08)60222-5; Schilliger L, 2010, J VET DIAGN INVEST, V22, P789, DOI 10.1177/104063871002200526; Schmidt V, 2012, VET MICROBIOL, V161, P145, DOI 10.1016/j.vetmic.2012.07.017; Schmidt-Ukaj S, 2014, VET DERMATOL, V25, P555, DOI 10.1111/vde.12146; Sigler L, 2013, J CLIN MICROBIOL, V51, P3338, DOI 10.1128/JCM.01465-13; Simbotwe M. P., 1983, J HERPETOL ASS AFR, V29; SIMMONS GC, 1972, AUST VET J, V48, P465, DOI 10.1111/j.1751-0813.1972.tb02285.x; Simoniello P, 2010, COMP BIOCHEM PHYS C, V151, P194, DOI 10.1016/j.cbpc.2009.10.005; Soldati G, 2004, VET PATHOL, V41, P388, DOI 10.1354/vp.41-4-388; Stacy BA, 2008, J ZOO WILDLIFE MED, V39, P161, DOI 10.1638/2007-0047R1.1; Stern AW, 2009, JAVMA-J AM VET MED A, V235, P669, DOI 10.2460/javma.235.6.669; Sting R, 2013, BERL MUNCH TIERARZTL, V126, P202, DOI 10.2376/0005-9366-126-202; Stohr AC, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-84; Sweet CR, 2009, JAVMA-J AM VET MED A, V234, P1259, DOI 10.2460/javma.234.10.1259; Szczepaniak KO, 2016, PARASITOL RES, V115, P681, DOI 10.1007/s00436-015-4787-2; Tamukai K, 2016, VET DERMATOL, V27, P99, DOI 10.1111/vde.12288; TELFORD SR, 1993, J WILDLIFE DIS, V29, P57, DOI 10.7589/0090-3558-29.1.57; Telford SR, 1998, INT J PARASITOL, V28, P475, DOI 10.1016/S0020-7519(97)00201-4; Terrell SP, 2003, J ZOO WILDLIFE MED, V34, P69; Toplon DE, 2013, VET PATHOL, V50, P585, DOI 10.1177/0300985812465324; Ugurtas Ismail Hakki, 2008, Journal of Biological & Environmental Sciences, V2, P11; Uhl EW, 2001, VET PATHOL, V38, P239, DOI 10.1354/vp.38-2-239; Underwood G., 1970, P1; WALLACH JD, 1966, J AM VET MED ASSOC, V149, P912; WATSON GL, 1993, J VET DIAGN INVEST, V5, P444, DOI 10.1177/104063879300500326; Wellehan James F.X., 2003, Journal of Herpetological Medicine and Surgery, V13, P15; Wellehan JFX, 2012, VET MICROBIOL, V158, P274, DOI 10.1016/j.vetmic.2012.02.020; Wellehan JFX, 2005, VET MICROBIOL, V105, P83, DOI 10.1016/j.vetmic.2004.10.012; Wellehan JFX, 2004, J VIROL, V78, P13366, DOI 10.1128/JVI.78.23.13366-13369.2004; Wellehan JFX, 2004, J ZOO WILDLIFE MED, V35, P50, DOI 10.1638/03-011; White SD, 2011, VET DERMATOL, V22, P150, DOI 10.1111/j.1365-3164.2010.00926.x; Wilkinson M, 2005, J ZOO WILDLIFE MED, V36, P724, DOI 10.1638/03-067.1; Wozniak EJ, 1996, INT J PARASITOL, V26, P141, DOI 10.1016/0020-7519(95)00110-7; Zehnder AM, 2014, EMERG INFECT DIS, V20, P304, DOI 10.3201/eid2002.131314; Zimmerman DM, 2009, J ZOO WILDLIFE MED, V40, P207, DOI 10.1638/2008-0030.1; ZWART P, 1964, PATHOL VET, V1, P542, DOI 10.1177/030098586400100607; ZWART P, 1964, VET PATHOL, V1, P542	219	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	125 LONDON WALL, LONDON EC2Y 5AS, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							871	+		10.1016/B978-0-12-805306-5.00036-5			34	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300038					2019-10-28	
B	Ossiboff, RJ		Terio, KA; McAloose, D; StLeger, J		Ossiboff, Robert J.			Serpentes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							INCLUSION-BODY DISEASE; HERPESVIRUS-LIKE INFECTION; EMERALD TREE BOA; BALL PYTHONS; CHLAMYDOPHILA-PNEUMONIAE; GASTRIC ADENOCARCINOMA; GOPHER SNAKE; IDENTIFICATION; RATTLESNAKE; REPTILES		[Ossiboff, Robert J.] Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA	Ossiboff, RJ (reprint author), Univ Illinois, Zool Pathol Program, Brookfield, IL 60513 USA.		Ossiboff, Robert/AAB-8732-2019	Ossiboff, Robert/0000-0001-6951-6070			Afonso CL, 2016, ARCH VIROL, V161, P2351, DOI 10.1007/s00705-016-2880-1; Alleman AR, 1999, AM J VET RES, V60, P507; Allender MC, 2011, EMERG INFECT DIS, V17, P2383, DOI 10.3201/eid1712.110240; Baron HR, 2014, AUST VET J, V92, P405, DOI 10.1111/avj.12233; Barrett R, 1970, P277; Bockman D. E., 1970, BIOL REPTILIA, V3, P111; Bodetti TJ, 2002, SYST APPL MICROBIOL, V25, P146, DOI 10.1078/0723-2020-00086; Bodewes R, 2013, J GEN VIROL, V94, P1206, DOI 10.1099/vir.0.051995-0; Bodewes R, 2014, J GEN VIROL, V95, P2480, DOI 10.1099/vir.0.068700-0; Bohm M, 2013, BIOL CONSERV, V157, P372, DOI 10.1016/j.biocon.2012.07.015; BROWNSTEIN DG, 1977, VET PATHOL, V14, P606, DOI 10.1177/030098587701400607; Caldwell MW, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6996; Campbell TW., 2014, CURRENT THERAPY REPT, P70; Catao-Dias JL, 1999, J COMP PATHOL, V120, P89, DOI 10.1053/jcpa.1998.0253; Chang L, 2016, VET J, V218, P13, DOI 10.1016/j.tvjl.2016.10.006; Chang LW, 2010, J EXOT PET MED, V19, P216, DOI 10.1053/j.jepm.2010.07.014; Clancy MM, 2016, JAVMA-J AM VET MED A, V248, P1050, DOI 10.2460/javma.248.9.1050; CLARK N B, 1970, P235; Comolli JR, 2015, J VET DIAGN INVEST, V27, P536, DOI 10.1177/1040638715590652; Da Silva MO, 2015, VET PATHOL, V52, P1220, DOI 10.1177/0300985815588605; DESTE L, 1993, CELL TISSUE RES, V273, P335, DOI 10.1007/BF00312836; Diethelm G, 1996, J AM VET MED ASSOC, V209, P786; Dietz J, 2016, J COMP PATHOL, V155, P76, DOI 10.1016/j.jcpa.2016.05.009; Drew ML, 1999, J ZOO WILDLIFE MED, V30, P151; Edmund A. G., 1969, BIOLOGY REPTILIA, V1, P117; EGAMI M I, 1988, Revista Brasileira de Biologia, V48, P155; Farrell A. P., 1998, V19, P375; Fitzgerald K. T., 2006, REPTILE MED SURG, P906; Fox H., 1977, P1; Gabe M., 1970, BIOL REPTILIA, V3, P263; Garner Michael M, 2004, Vet Clin North Am Exot Anim Pract, V7, P653, DOI 10.1016/j.cvex.2004.04.002; Gharzi Ahmad, 2013, Journal of Biological Sciences, V13, P372; Girling JE, 2002, J EXP ZOOL, V293, P141, DOI 10.1002/jez.10105; Gist DH, 2011, HORMONES AND REPRODUCTION OF VERTEBRATES, VOL 3: REPTILES, P117; Gregory CR, 1997, J ZOO WILDLIFE MED, V28, P198; HAUSER B, 1983, J COMP PATHOL, V93, P515, DOI 10.1016/0021-9975(83)90057-9; Hausmann JC, 2015, J COMP PATHOL, V152, P260, DOI 10.1016/j.jcpa.2014.12.005; HEARD D, 2004, BSAVA MANUAL REPTILE, P78; Heckers KO, 2012, J COMP PATHOL, V146, P258, DOI 10.1016/j.jcpa.2011.07.003; Hepojoki J, 2015, J VIROL, V89, P8657, DOI 10.1128/JVI.01112-15; Hernandez-Divers SJ, 2002, J AM VET MED ASSOC, V220, P1661, DOI 10.2460/javma.2002.220.1661; Hetzel U, 2013, J VIROL, V87, P10918, DOI 10.1128/JVI.01123-13; Hill RE, 2000, TOXICON, V38, P1663, DOI 10.1016/S0041-0101(00)00091-X; Hoffstetter R., 1969, P201; Hyatt AD, 2002, J WILDLIFE DIS, V38, P239, DOI 10.7589/0090-3558-38.2.239; Hyndman TH, 2013, VET MICROBIOL, V165, P200, DOI 10.1016/j.vetmic.2013.04.002; Hyndman TH, 2012, VET MICROBIOL, V161, P77, DOI 10.1016/j.vetmic.2012.07.030; Jacobson E, 2002, J VET DIAGN INVEST, V14, P487, DOI 10.1177/104063870201400607; Jacobson Elliott R., 2007, P571; Jacobson Elliott R., 2007, P461; Jacobson Elliott R., 2007, P1; Jacobson Elliott R., 2007, P395, DOI 10.1201/9781420004038.ch9; Jacobson ER, 2004, J VET DIAGN INVEST, V16, P153, DOI 10.1177/104063870401600211; JACOBSON ER, 1989, J ZOO WILDLIFE MED, V20, P364; JESSUP DA, 1980, J WILDLIFE DIS, V16, P419, DOI 10.7589/0090-3558-16.3.419; Johnsrude JD, 1997, VET PATHOL, V34, P235, DOI 10.1177/030098589703400311; Kaye Sarrah W., 2016, Journal of Herpetological Medicine and Surgery, V26, P26, DOI 10.5818/1529-9651-26.1-2.26; Klaphake Eric, 2005, Journal of Herpetological Medicine and Surgery, V15, P21; Kochva E., 1978, P43; Lamirande EW, 1999, VIRUS RES, V63, P135, DOI 10.1016/S0168-1702(99)00067-2; Landmann L., 1986, P150; Latimer KS, 1998, J ZOO WILDLIFE MED, V29, P344; Lucio-Forster A, 2015, COMP PARASITOL, V82, P115, DOI 10.1654/4732RR.1; Luppa H., 1977, P225; Lynn W. G., 1970, P201; Marschang RE, 2014, CURRENT THERAPY REPT, P32; MARTIN JC, 1994, J ZOO WILDLIFE MED, V25, P133; Mauldin G. N., 2006, REPTILE MED SURG, P299; MCNAMARA TS, 1994, J ZOO WILDLIFE MED, V25, P128; Miller M. R, 1970, P319; Mitchell Mark A, 2012, Vet Clin North Am Exot Anim Pract, V15, P101, DOI 10.1016/j.cvex.2011.10.002; Oros J, 2004, VET PATHOL, V41, P515, DOI 10.1354/vp.41-5-515; Pare JA, 2014, CURRENT THERAPY REPT, P53; Parsons T.S., 1977, P159; Penner JD, 1997, J COMP PATHOL, V117, P283, DOI 10.1016/S0021-9975(97)80024-2; Pereira ME, 2008, VET PATHOL, V45, P693, DOI 10.1354/vp.45-5-693; Preziosi R, 2007, VET J, V174, P669, DOI 10.1016/j.tvjl.2006.11.012; Pyron RA, 2011, MOL PHYLOGENET EVOL, V58, P329, DOI 10.1016/j.ympev.2010.11.006; Ramsay EC, 2002, J ZOO WILDLIFE MED, V33, P301; Reavill Drury R., 2012, Veterinary Clinics of North America Exotic Animal Practice, V15, P25, DOI 10.1016/j.cvex.2011.10.001; Rosenthal K. L., 2006, REPTILE MED SURG, P227; Saint Girons M. C., 1970, P73; Savitzky AH, 2008, J MORPHOL, V269, P935, DOI 10.1002/jmor.10629; Schaffner Fenton, 1998, V19, P485; Schumacher J, 1998, J VET DIAGN INVEST, V10, P101, DOI 10.1177/104063879801000121; Shoemaker M, 2016, JAVMA-J AM VET MED A, V248, P153, DOI 10.2460/javma.248.2.153; Sigler L, 2013, J CLIN MICROBIOL, V51, P3338, DOI 10.1128/JCM.01465-13; SIMPSON CF, 1979, J AM VET MED ASSOC, V175, P941; SMITH TG, 1994, J WILDLIFE DIS, V30, P169, DOI 10.7589/0090-3558-30.2.169; Stahl Scott J., 2002, Veterinary Clinics of North America Exotic Animal Practice, V5, P615, DOI 10.1016/S1094-9194(02)00017-8; Steeil JC, 2013, J ZOO WILDLIFE MED, V44, P144, DOI 10.1638/1042-7260-44.1.144; Stenglein MD, 2014, MBIO, V5, DOI 10.1128/mBio.01484-14; Stenglein MD, 2012, MBIO, V3, DOI 10.1128/mBio.00180-12; Strik Nicole I., 2007, P167, DOI 10.1201/9781420004038.ch3; Sykes JM, 2006, J ZOO WILDLIFE MED, V37, P11, DOI 10.1638/04-112.1; TAIRA K, 1981, ARCH HISTOL JAPON, V44, P373, DOI 10.1679/aohc1950.44.373; Tanaka Yasukazu, 1998, V19, P533; Thompson KA, 2015, J ZOO WILDLIFE MED, V46, P629, DOI 10.1638/2015-0028.1; TIMM KI, 1988, J MED VET MYCOL, V26, P101; Troiano JC, 1997, COMP HAEMATOL INT, V7, P109, DOI 10.1007/BF02652577; Tuttle Allison D., 2006, Journal of Herpetological Medicine and Surgery, V16, P140; Uccellini L, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-144; Underwood G., 1970, P1; Vidal N, 2007, CR BIOL, V330, P182, DOI 10.1016/j.crvi.2006.10.001; Wallach Van, 1998, V19, P93; Weinstein S. A., 2009, HDB VENOMS TOXINS RE, P76; Wellehan James F.X., 2005, Veterinary Clinics of North America Exotic Animal Practice, V8, P27, DOI 10.1016/j.cvex.2004.09.006; Wellehan JFX, 2004, J ZOO WILDLIFE MED, V35, P553, DOI 10.1638/03-099; Wozniak E, 2000, VET PATHOL, V37, P449, DOI 10.1354/vp.37-5-449; Wozniak E. J., 2000, Journal of Herpetological Medicine and Surgery, V10, P4	110	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							897	+		10.1016/B978-0-12-805306-5.00037-7			8	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300039					2019-10-28	
B	Pessier, AP		Terio, KA; McAloose, D; StLeger, J		Pessier, Allan P.			Amphibia	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							SYLVATICA LITHOBATES-SYLVATICUS; CUBAN TREE FROGS; BUFO-MARINUS; MOLECULAR CHARACTERIZATION; PATHOLOGICAL-CHANGES; TROMBICULID MITES; UNUSUAL MORTALITY; LEOPARD FROGS; CANE TOADS; INFECTION		[Pessier, Allan P.] Washington State Univ, Pullman, WA 99164 USA	Pessier, AP (reprint author), Washington State Univ, Pullman, WA 99164 USA.						Abdel-moneim A, 2015, J APPL TOXICOL, V35, P1228, DOI 10.1002/jat.3204; Andrews JM, 2015, J PARASITOL, V101, P275, DOI 10.1645/14-608.1; Antwis RE, 2009, COMP BIOCHEM PHYS A, V154, P184, DOI 10.1016/j.cbpa.2009.06.008; Archibald KE, 2015, J ZOO WILDLIFE MED, V46, P105, DOI 10.1638/2014-0086R1.1; Ballengee B, 2009, J EXP ZOOL PART B, V312B, P770, DOI 10.1002/jez.b.21296; Berger L, 2005, DIS AQUAT ORGAN, V68, P51, DOI 10.3354/dao068051; Berger L, 1999, J CLIN MICROBIOL, V37, P2378; Berger L, 2001, J HERPETOL, V35, P330, DOI 10.2307/1566126; Berger L, 2016, FUNGAL ECOL, V19, P89, DOI 10.1016/j.funeco.2015.09.007; Berger L, 2009, J WILDLIFE DIS, V45, P921, DOI 10.7589/0090-3558-45.4.921; Blumer C, 2007, VET PATHOL, V44, P144, DOI 10.1354/vp.44-2-144; Bollinger TK, 1999, J WILDLIFE DIS, V35, P413, DOI 10.7589/0090-3558-35.3.413; Borteiro C, 2015, J WILDLIFE DIS, V51, P530, DOI 10.7589/2014-06-149; Bowerman J, 2010, ECOLOGY, V91, P242, DOI 10.1890/08-1687.1; Brockes JP, 2005, SCIENCE, V310, P1919, DOI 10.1126/science.1115200; Brown DD, 2007, DEV BIOL, V306, P20, DOI 10.1016/j.ydbio.2007.03.021; Campbell CR, 2012, INT J BIOCHEM CELL B, V44, P431, DOI 10.1016/j.biocel.2011.12.002; CANNING EU, 1964, J PROTOZOOL, V11, P157, DOI 10.1111/j.1550-7408.1964.tb01738.x; Carey C, 1999, DEV COMP IMMUNOL, V23, P459, DOI 10.1016/S0145-305X(99)00028-2; CARLSON DL, 1994, J COMP PATHOL, V110, P349, DOI 10.1016/S0021-9975(08)80312-X; CARPENTER JL, 1986, VET PATHOL, V23, P337, DOI 10.1177/030098588602300320; Catenazzi A, 2015, ANNU REV ENV RESOUR, V40, P91, DOI 10.1146/annurev-environ-102014-021358; Cheng K, 2014, DIS AQUAT ORGAN, V111, P139, DOI 10.3354/dao02770; Clancy MM, 2015, J ZOO WILDLIFE MED, V46, P18, DOI 10.1638/2014-0171.1; Crawshaw G, 2014, ZOO BIOL, V33, P558, DOI 10.1002/zoo.21168; Creeper JH, 1998, AUST VET J, V76, P761, DOI 10.1111/j.1751-0813.1998.tb12312.x; Cunningham AA, 1996, PHILOS T ROY SOC B, V351, P1539, DOI 10.1098/rstb.1996.0140; CUNNINGHAM AA, 1993, VET REC, V133, P141, DOI 10.1136/vr.133.6.141; Davis AK, 2007, ECOHEALTH, V4, P310, DOI 10.1007/s10393-007-0115-3; Davis AK, 2010, PARASITOL RES, V107, P363, DOI 10.1007/s00436-010-1869-z; DiRenzo GV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093356; Duncan AE, 2004, J ZOO WILDLIFE MED, V35, P381, DOI 10.1638/03-048; Edwards JR, 2000, COMP BIOCHEM PHYS A, V125, P367, DOI 10.1016/S1095-6433(00)00168-9; Feldman SH, 2014, J AM ASSOC LAB ANIM, V53, P668; Felisbino SL, 1999, TISSUE CELL, V31, P301, DOI 10.1054/tice.1999.0036; Ferrie GM, 2014, ZOO BIOL, V33, P485, DOI 10.1002/zoo.21180; Forzan MJ, 2017, VET PATHOL, V54, P531, DOI 10.1177/0300985816684929; Forzan MJ, 2015, VET PATHOL, V52, P384, DOI 10.1177/0300985814535607; Forzan MJ, 2016, VET CLIN PATH, V45, P430, DOI 10.1111/vcp.12393; Gamble Kathryn C., 2005, Journal of Herpetological Medicine and Surgery, V15, P14; Garner M. M., 2005, P AM ASS ZOO VET AM, P274; Garner M. M., 2000, P ASS REPT AMPH VETE, P7; Gericota B, 2010, J ZOO WILDLIFE MED, V41, P242, DOI 10.1638/2009-0184R.1; GOODE RP, 1967, J EMBRYOL EXP MORPH, V18, P259; Grayfer L, 2016, DEV COMP IMMUNOL, V58, P60, DOI 10.1016/j.dci.2015.12.008; Green D. E., 2001, Amphibian medicine and captive husbandry, P335; Green DE, 2002, ANN NY ACAD SCI, V969, P323, DOI 10.1111/j.1749-6632.2002.tb04400.x; Green SL, 2003, COMPARATIVE MED, V53, P81; Green SL, 1999, J AM VET MED ASSOC, V214, P1833; Grosset C, 2014, J VET DIAGN INVEST, V26, P354, DOI 10.1177/1040638714534851; GRUIAGRAY J, 1992, J WILDLIFE DIS, V28, P34, DOI 10.7589/0090-3558-28.1.34; Hakvoort J. H. M., 1995, HERPETOPATHOLOGIA, P271; Han Manjong, 2005, Anatomical Record Part B:The New Anatomist, V287, P14, DOI 10.1002/ar.b.20082; Hartigan Ashlie, 2013, International Journal for Parasitology Parasites and Wildlife, V2, P62, DOI 10.1016/j.ijppaw.2012.12.002; Hecker M, 2006, REV ENVIRON CONTAM T, V187, P103, DOI 10.1007/0-387-32885-8_3; Holland MP, 2007, J ZOOL, V271, P455, DOI 10.1111/j.1469-7998.2006.00229.x; Imai DM, 2009, J VET DIAGN INVEST, V21, P568, DOI 10.1177/104063870902100427; Ip HS, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.94; Isidoro-Ayza M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10456-1; Jerrett IV, 2015, J COMP PATHOL, V152, P248, DOI 10.1016/j.jcpa.2014.12.007; Jirku M, 2007, PARASITOLOGY, V134, P1727, DOI 10.1017/S0031182007003241; Jirku M, 2008, FOLIA PARASIT, V55, P81, DOI 10.14411/fp.2008.011; Juopperi T, 2002, VET CLIN PATH, V31, P137, DOI 10.1111/j.1939-165X.2002.tb00294.x; Keel MK, 2010, J VET DIAGN INVEST, V22, P655, DOI 10.1177/104063871002200430; Kiryu Y, 2015, DIS AQUAT ORGAN, V113, P157, DOI 10.3354/dao02836; Koprivnikar J, 2012, ECOHEALTH, V9, P342, DOI 10.1007/s10393-012-0785-3; Kupferberg SJ, 2009, COPEIA, P529, DOI 10.1643/CH-08-011; Lannoo M, 2008, MALFORMED FROGS: THE COLLAPSE OF AQUATIC ECOSYSTEMS, P1; Loeffler IK, 2001, ANAT REC, V265, P228, DOI 10.1002/ar.10009; Lopez J, 2016, J ZOO WILDLIFE MED, V47, P1061, DOI 10.1638/2016-0037.1; Martel A, 2013, P NATL ACAD SCI USA, V110, P15325, DOI 10.1073/pnas.1307356110; Martel A, 2012, EMERG INFECT DIS, V18, P1020, DOI 10.3201/eid1806.111137; MCKINNELL RG, 1965, ANN NY ACAD SCI, V126, P85, DOI 10.1111/j.1749-6632.1965.tb14269.x; Mendez D, 2010, AUST VET J, V88, P328, DOI 10.1111/j.1751-0813.2010.00599.x; Meteyer C. U., 2000, USGSBRDBSR2000005; Mikaelian I, 2000, DIS AQUAT ORGAN, V40, P195, DOI 10.3354/dao040195; Miller DL, 2015, RANAVIRUSES LETHAL P, P171, DOI DOI 10.1007/978-3-319-13755-1_7; Miyata K, 2012, J TOXICOL PATHOL, V25, P1, DOI 10.1293/tox.25.1; Muhldorfer K, 2017, J APPL MICROBIOL, V122, P40, DOI 10.1111/jam.13326; Murphy BG, 2015, DIS AQUAT ORGAN, V114, P69, DOI 10.3354/dao02851; Mutschmann F, 2004, DIS AQUAT ORGAN, V60, P215, DOI 10.3354/dao060215; Origgi FC, 2017, VET PATHOL, V54, P686, DOI 10.1177/0300985817705176; PAPERNA I, 1995, DIS AQUAT ORGAN, V23, P7, DOI 10.3354/dao023007; Patterson-Kane JC, 2001, J ZOO WILDLIFE MED, V32, P106; Pereira CN, 2005, J CLIN MICROBIOL, V43, P192, DOI 10.1128/JCM.43.1.192-198.2005; Perpinan D, 2010, J WILDLIFE DIS, V46, P1185, DOI 10.7589/0090-3558-46.4.1185; Perpinan D, 2010, J WILDLIFE DIS, V46, P579, DOI 10.7589/0090-3558-46.2.579; Pessier AP, 2014, ZOO BIOL, V33, P516, DOI 10.1002/zoo.21166; Pessier AP, 2009, J EXOT PET MED, V18, P4, DOI 10.1053/j.jepm.2008.10.003; Pessier AP, 1999, J VET DIAGN INVEST, V11, P194, DOI 10.1177/104063879901100219; Pessier AP, 2003, SEMIN AVIAN EXOT PET, V12, P81, DOI 10.1053/saep.2003.127884; POYNTON SL, 1994, J ZOO WILDLIFE MED, V25, P29; Raffel TR, 2006, J PARASITOL, V92, P1256, DOI 10.1645/GE-808R1.1; Ramakrishnan L, 1997, INFECT IMMUN, V65, P767; Raymond JT, 2002, J VET DIAGN INVEST, V14, P501, DOI 10.1177/104063870201400610; Reeder NMM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033567; Robert J, 2009, DEV DYNAM, V238, P1249, DOI 10.1002/dvdy.21891; Rodriguez CE, 2014, ZOO BIOL, V33, P508, DOI 10.1002/zoo.21161; Rohr JR, 2008, NATURE, V455, P1235, DOI 10.1038/nature07281; Rozenblut B, 2005, J MORPHOL, V265, P304, DOI 10.1002/jmor.10344; Schadich E, 2010, COMPARATIVE MED, V60, P114; Scheid P, 2015, DIS AQUAT ORGAN, V115, P111, DOI 10.3354/dao02888; Shaw SD, 2012, J ZOO WILDLIFE MED, V43, P549, DOI 10.1638/2011-0276R1.1; Shilton CM, 2008, VET PATHOL, V45, P85, DOI 10.1354/vp.45-1-85; Shilton CM, 2001, J ZOO WILDLIFE MED, V32, P305; Sladky KK, 2000, J ZOO WILDLIFE MED, V31, P570; Speare R, 1997, J WILDLIFE DIS, V33, P105, DOI 10.7589/0090-3558-33.1.105; SPEARE R, 1991, J WILDLIFE DIS, V27, P457, DOI 10.7589/0090-3558-27.3.457; Stacy Brian A, 2004, Vet Clin North Am Exot Anim Pract, V7, P673, DOI 10.1016/j.cvex.2004.04.001; STENSAAS LJ, 1967, J PROTOZOOL, V14, P585, DOI 10.1111/j.1550-7408.1967.tb02045.x; Tapley B, 2015, ZOO BIOL, V34, P46, DOI 10.1002/zoo.21170; Taylor SK, 1999, J WILDLIFE DIS, V35, P70, DOI 10.7589/0090-3558-35.1.70; Tinsley RC, 2002, PARASITOLOGY, V125, P143, DOI 10.1017/S0031182002001993; Tokiwa T, 2015, DIS AQUAT ORGAN, V116, P199, DOI 10.3354/dao02936; VALENTINE BA, 1984, J AM VET MED ASSOC, V185, P1418; Wake DB, 2008, P NATL ACAD SCI USA, V105, P11466, DOI 10.1073/pnas.0801921105; White C. Leann, 2016, Herpetological Review, V47, P207	117	2	2	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	125 LONDON WALL, LONDON EC2Y 5AS, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							921	+		10.1016/B978-0-12-805306-5.00038-9			8	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300040					2019-10-28	
B	Frasca, S; Wolf, JC; Kinsel, MJ; Camus, AC; Lombardini, ED		Terio, KA; McAloose, D; StLeger, J		Frasca, Salvatore, Jr.; Wolf, Jeffrey C.; Kinsel, Michael J.; Camus, Alvin C.; Lombardini, Eric D.			Osteichthyes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							SALMON SALMO-SALAR; INFECTIOUS PANCREATIC NECROSIS; BACTERIAL GILL DISEASE; CANDIDATUS-PISCICHLAMYDIA SALMONIS; TROUT ONCORHYNCHUS-MYKISS; FLOUNDER PARALICHTHYS-OLIVACEUS; PLECOGLOSSUS-ALTIVELIS TEMMINCK; BASS DICENTRARCHUS-LABRAX; WALLEYE DERMAL SARCOMA; CARP CYPRINUS-CARPIO		[Frasca, Salvatore, Jr.] Univ Connecticut, Storrs, CT 06269 USA; [Wolf, Jeffrey C.] Expt Pathol Labs Inc, Sterling, VA USA; [Kinsel, Michael J.] Univ Illinois, Zool Pathol Program, Brookfield, IL USA; [Camus, Alvin C.] Univ Georgia, Athens, GA 30602 USA; [Lombardini, Eric D.] Publ Hlth Command Ft Dist Carson, Ft Carson, CO USA	Frasca, S (reprint author), Univ Connecticut, Storrs, CT 06269 USA.						Abayneh T, 2013, J APPL MICROBIOL, V114, P644, DOI 10.1111/jam.12080; Actis LA, 2011, FISH DISEASES AND DISORDERS, VOL 3: VIRAL, BACTERIAL AND FUNGAL INFECTIONS, 2ND EDITION, P570, DOI 10.1079/9781845935542.0570; Agnew W, 2007, VET MICROBIOL, V122, P1, DOI 10.1016/j.vetmic.2007.03.002; Al-Hussinee L, 2011, DIS AQUAT ORGAN, V93, P117, DOI 10.3354/dao02285; AMLACHER E, 1980, J FISH DIS, V3, P55, DOI 10.1111/j.1365-2761.1980.tb00184.x; Avendano-Herrera R, 2006, DIS AQUAT ORGAN, V71, P255, DOI 10.3354/dao071255; Bailey GS, 1996, ENVIRON HEALTH PERSP, V104, P5, DOI 10.2307/3432693; BAILEY GS, 1988, CARCINOGENESIS, V9, P1919, DOI 10.1093/carcin/9.11.1919; Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; BALL HJ, 1971, NATURE, V234, P417, DOI 10.1038/234417a0; Ball J. N., 1969, P1; Barriuso J, 2015, CLIN CANCER RES, V21, P969, DOI 10.1158/1078-0432.CCR-14-2921; Beaz-Hidalgo R, 2013, J FISH DIS, V36, P371, DOI 10.1111/jfd.12025; BERTHIAUME L, 1984, VIROLOGY, V135, P10, DOI 10.1016/0042-6822(84)90112-0; Birkbeck TH, 2011, J FISH DIS, V34, P173, DOI 10.1111/j.1365-2761.2010.01226.x; Blazer VS, 1999, J AQUAT ANIM HEALTH, V11, P340, DOI 10.1577/1548-8667(1999)011<0340:AAACOU>2.0.CO;2; BLOCK BA, 1987, NEWS PHYSIOL SCI, V2, P208; BOEREMA G.H., 1964, PERSOONIA, V3, P9; Bond C. E., 1996, GEN MORPHOLOGY, P15; Bone Q., 2008, BIOL FISHES; Boorman G, 2012, TOXICOL PATHOL, V40, P321, DOI 10.1177/0192623311427713; BOWSER P R, 1991, Journal of Aquatic Animal Health, V3, P147, DOI 10.1577/1548-8667(1991)003<0147:RODSIA>2.3.CO;2; BOWSER P R, 1990, Journal of Aquatic Animal Health, V2, P177, DOI 10.1577/1548-8667(1990)002<0177:POLLIB>2.3.CO;2; Bowser PR, 2012, J WILDLIFE DIS, V48, P795, DOI 10.7589/0090-3558-48.3.795; Bowser PR, 1999, J AQUAT ANIM HEALTH, V11, P158, DOI 10.1577/1548-8667(1999)011<0158:TOWDSA>2.0.CO;2; BOWSER PR, 1988, J WILDLIFE DIS, V24, P292, DOI 10.7589/0090-3558-24.2.292; BOWSER PR, 1991, DIS AQUAT ORGAN, V11, P117, DOI 10.3354/dao011117; Boylan SM, 2015, J FISH DIS, V38, P681, DOI 10.1111/jfd.12276; BRANSON EJ, 1991, J FISH DIS, V14, P147, DOI 10.1111/j.1365-2761.1991.tb00585.x; Bravo S., 1989, FHS AFS NEWSL, V17, P3; BRUNO DW, 1991, J APPL ICHTHYOL, V7, P238, DOI 10.1111/j.1439-0426.1991.tb00602.x; Bruno DW, 2004, AQUACULTURE, V235, P13, DOI 10.1016/j.aquaculture.2003.11.035; BRUNO DW, 1987, J FISH DIS, V10, P513, DOI 10.1111/j.1365-2761.1987.tb01104.x; Buchmann K, 2006, FISH DISEASES AND DISORDERS, VOL 1: PROTOZOAN AND METAZOAN INFECTIONS, 2ND EDITION, P297, DOI 10.1079/9780851990156.0297; BULLOCK AM, 1978, J ZOOL, V184, P423; Bunton TE, 1996, TOXICOL PATHOL, V24, P603, DOI 10.1177/019262339602400511; BURGESS PJ, 1995, FISH SHELLFISH IMMUN, V5, P459, DOI 10.1006/fsim.1995.0043; Burton TO, 2004, J AQUAT ANIM HEALTH, V16, P251, DOI 10.1577/H03-055.1; Campbell T. W., 2007, HEMATOLOGY FISH, P93; Camus A, 2013, DIS AQUAT ORGAN, V104, P13, DOI 10.3354/dao02586; Camus MS, 2011, VET CLIN PATH, V40, P549, DOI 10.1111/j.1939-165X.2011.00365.x; Canning EU, 2004, ADV PARASIT, V56, P43, DOI 10.1016/S0065-308X(03)56002-X; Caplan Jane, 2006, ENCY INDIAN DIASPORA, p[2, 10]; Cardoso EL, 1996, J FISH BIOL, V49, P778, DOI 10.1111/j.1095-8649.1996.tb00078.x; CAREY FG, 1971, AM ZOOL, V11, P137; Carmichael J W, 1966, Sabouraudia, V5, P120; CARUNCHO HJ, 1993, J SUBMICR CYTOL PATH, V25, P397; Cavin JM, 2012, J VET DIAGN INVEST, V24, P516, DOI 10.1177/1040638712440990; Chacko A. Jim, 1993, P373; Chen MF, 2000, DIS AQUAT ORGAN, V43, P117, DOI 10.3354/dao043117; Cheung P J, 1980, Ann N Y Acad Sci, V344, P336, DOI 10.1111/j.1749-6632.1980.tb33673.x; CHEUNG PJ, 1980, J FISH DIS, V3, P295, DOI 10.1111/j.1365-2761.1980.tb00400.x; CHILMONCZYK S, 1980, J RETICULOENDOTH SOC, V28, P327; Chinchar VG, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003850; Cipriano RC, 2011, FISH DISEASES AND DISORDERS, VOL 3: VIRAL, BACTERIAL AND FUNGAL INFECTIONS, 2ND EDITION, P424, DOI 10.1079/9781845935542.0424; Coffee LL, 2013, VET PATHOL, V50, P390, DOI 10.1177/0300985813480529; Coffee LL, 2013, VET PATHOL, V50, P483, DOI 10.1177/0300985812446149; Collier TK, 2014, FISH PHYSIOL, V33, P195, DOI 10.1016/B978-0-12-398254-4.00004-2; Colquhoun DJ, 2011, VET RES, V42, DOI 10.1186/1297-9716-42-47; COLT J, 1978, AQUACULTURE, V15, P353, DOI 10.1016/0044-8486(78)90081-9; Contador E, 2016, J FISH DIS, V39, P353, DOI 10.1111/jfd.12369; Courtney Lee A., 1996, Gulf Research Reports, V9, P211; Crane M, 2011, VIRUSES-BASEL, V3, P2025, DOI 10.3390/v3112025; Crockett Elizabeth L., 2006, P231; Crosbie PBB, 1999, DIS AQUAT ORGAN, V36, P213, DOI 10.3354/dao036213; CVITANICH JD, 1991, J FISH DIS, V14, P121, DOI 10.1111/j.1365-2761.1991.tb00584.x; Dalmo RA, 1997, J FISH DIS, V20, P241, DOI 10.1046/j.1365-2761.1997.00302.x; DANNEVIG BH, 1994, FISH SHELLFISH IMMUN, V4, P3, DOI 10.1006/fsim.1994.1002; Daugherty J, 1998, FUNGAL GENET BIOL, V24, P354, DOI 10.1006/fgbi.1998.1077; DAWE CJ, 1987, ENVIRON HEALTH PERSP, V71, P129, DOI 10.2307/3430420; de Hoog GS, 2011, PERSOONIA, V27, P46, DOI 10.3767/003158511X614258; Declercq AM, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-27; DEHOOG GS, 1993, ANTON LEEUW INT J G, V63, P105, DOI 10.1007/BF00872386; Dickerson HW, 2006, FISH DISEASES AND DISORDERS, VOL 1: PROTOZOAN AND METAZOAN INFECTIONS, 2ND EDITION, P116, DOI 10.1079/9780851990156.0116; Domenech A, 1996, J FISH DIS, V19, P33, DOI 10.1111/j.1365-2761.1996.tb00117.x; Downes JK, 2015, AQUACULT ENV INTERAC, V7, P239, DOI 10.3354/aei00150; Draghi A, 2004, J CLIN MICROBIOL, V42, P5286, DOI 10.1128/JCM.42.11.5286-5297.2004; Draghi A, 2010, DIS AQUAT ORGAN, V89, P39, DOI 10.3354/dao02171; DUNCAN IB, 1978, J FISH DIS, V1, P127, DOI 10.1111/j.1365-2761.1978.tb00012.x; DYKOVA I, 1980, J FISH DIS, V3, P265, DOI 10.1111/j.1365-2761.1980.tb00398.x; Dykova I, 1995, FISH DIS DISORDERS, V1, P149; Dykova I, 2010, FOLIA PARASIT, V57, P157, DOI 10.14411/fp.2010.021; Eldar A, 1999, DIS AQUAT ORGAN, V36, P227, DOI 10.3354/dao036227; ELLIS AE, 1977, J FISH BIOL, V11, P453, DOI 10.1111/j.1095-8649.1977.tb04140.x; Evans JJ, 2011, FISH DISEASES AND DISORDERS, VOL 3: VIRAL, BACTERIAL AND FUNGAL INFECTIONS, 2ND EDITION, P512, DOI 10.1079/9781845935542.0512; Faisal M, 2007, MYCOPATHOLOGIA, V163, P41, DOI 10.1007/s11046-006-0084-z; Faisal M, 2012, VIRUSES-BASEL, V4, P734, DOI 10.3390/v4050734; Faisal M, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-2; Faisal M, 2009, PARASITE VECTOR, V2, DOI 10.1186/1756-3305-2-45; Falk K, 1997, J VIROL, V71, P9016; FALKMER S, 1976, PROG EXP TUMOR RES, V20, P217; FANGE R, 1986, VET IMMUNOL IMMUNOP, V12, P153, DOI 10.1016/0165-2427(86)90119-4; Feist SW, 2015, MAR ENVIRON RES, V106, P42, DOI 10.1016/j.marenvres.2015.02.004; Ferguson D, 2006, INTELLIGENT AUTONOMOUS SYSTEMS 9, P65; FERGUSON H W, 1991, Journal of Aquatic Animal Health, V3, P118, DOI 10.1577/1548-8667(1991)003<0118:EPOBGD>2.3.CO;2; FERGUSON HW, 1992, J COMP PATHOL, V106, P255, DOI 10.1016/0021-9975(92)90054-X; FERGUSON HW, 1976, J COMP PATHOL, V86, P377, DOI 10.1016/0021-9975(76)90005-0; Ferraz E, 1998, DIS AQUAT ORGAN, V33, P43, DOI 10.3354/dao033043; FETCHO JR, 1991, BRAIN BEHAV EVOLUT, V37, P298, DOI 10.1159/000114367; FOURNIE JW, 1994, TOXICOL PATHOL, V22, P237, DOI 10.1177/019262339402200302; Fournie JW, 2005, TOXICOL PATHOL, V33, P540, DOI 10.1080/01926230500214509; Fournie JW, 1999, DIS AQUAT ORGAN, V38, P135, DOI 10.3354/dao038135; Frans I, 2011, J FISH DIS, V34, P643, DOI 10.1111/j.1365-2761.2011.01279.x; Fryer J. L., 2002, FISH HLTH SECTION NE, V30, P23; FRYER JL, 1992, INT J SYST BACTERIOL, V42, P120, DOI 10.1099/00207713-42-1-120; Fryer JL, 2003, J FISH DIS, V26, P251, DOI 10.1046/j.1365-2761.2003.00460.x; Gamperl A. K., 2014, PHYSL FISHES, P33; Gibson-Kueh S, 2003, J COMP PATHOL, V129, P111, DOI 10.1016/S0021-9975(03)00010-0; Gimenez-Conti I, 2001, MAR BIOTECHNOL, V3, pS100; Godoy MG, 2008, BMC VET RES, V4, DOI 10.1186/1746-6148-4-28; GOLDES SA, 1986, J FISH DIS, V9, P147, DOI 10.1111/j.1365-2761.1986.tb00996.x; Good C, 2015, J FISH DIS, V38, P409, DOI 10.1111/jfd.12249; Good CA, 2008, PREV VET MED, V83, P297, DOI 10.1016/j.prevetmed.2007.08.007; Greenwell M. G., 1998, P INT ASS AQ AN MED, P114; Greenwood MP, 2009, ENDOCRINOLOGY, V150, P3002, DOI 10.1210/en.2008-1758; Griffin MJ, 2016, J FISH DIS, V39, P947, DOI 10.1111/jfd.12431; Grim KC, 2009, VET PATHOL, V46, P622, DOI 10.1354/vp.08-VP-0150-W-FL; Grizzle JM, 1976, ANATOMY HISTOLOGY CH; Grizzle John M., 1995, Journal of Aquatic Animal Health, V7, P178, DOI 10.1577/1548-8667(1995)007<0178:RAIMTN>2.3.CO;2; Groff JM, 1996, J VET DIAGN INVEST, V8, P172, DOI 10.1177/104063879600800206; Groman D. B, 1982, AM FISHERIES SOC MON, V3; Guerreiro PM, 2007, AM J PHYSIOL-REG I, V292, pR679, DOI 10.1152/ajpregu.00480.2006; HAFEEZ MA, 1971, J MORPHOL, V134, P281, DOI 10.1002/jmor.1051340304; Haines AN, 2013, VET MICROBIOL, V166, P270, DOI 10.1016/j.vetmic.2013.05.002; Hanjavanit C, 2004, DIS AQUAT ORGAN, V61, P215, DOI 10.3354/dao061215; Hanson L, 2011, VIRUSES-BASEL, V3, P2160, DOI 10.3390/v3112160; HARADA T, 1991, J COMP PATHOL, V104, P187, DOI 10.1016/S0021-9975(08)80102-8; HATAI K, 1986, J FISH DIS, V9, P111, DOI 10.1111/j.1365-2761.1986.tb00989.x; Hawke JP, 2013, J AQUAT ANIM HEALTH, V25, P171, DOI 10.1080/08997659.2013.782226; HAWKE JP, 1979, J FISH RES BOARD CAN, V36, P1508, DOI 10.1139/f79-219; Hawkes J. W., 1983, RESOURCE PUBLICATION, V150, P8; Hendricks J.D., 1983, U S Fish and Wildlife Service Resource Publication, P97; Hickman C. P., 1969, P91; Hinton David E., 2001, P224; Hochwartner O, 2010, DIS AQUAT ORGAN, V89, P185, DOI 10.3354/dao02149; Hoffman G. L, 1999, PARASITES N AMERICAN, P46; HUGHES GM, 1984, FISH PHYSIOL, V10, P1; Hyatt MW, 2013, DIS AQUAT ORGAN, V107, P151, DOI 10.3354/dao02675; Jarp J, 1997, DIS AQUAT ORGAN, V28, P79, DOI 10.3354/dao028079; Jensen FB, 2003, COMP BIOCHEM PHYS A, V135, P9, DOI 10.1016/S1095-6433(02)00323-9; JOHNSON AK, 1993, FASEB J, V7, P678; Jung SJ, 2007, DIS AQUAT ORGAN, V73, P227, DOI 10.3354/dao073227; Kagan RA, 2010, VET PATHOL, V47, P553, DOI 10.1177/0300985809359600; Kane AS, 2007, EMERG INFECT DIS, V13, P329, DOI 10.3201/eid1302.060558; Karatas S, 2008, J FISH DIS, V31, P747, DOI 10.1111/j.1365-2761.2008.00948.x; Karlsen M, 2008, ENVIRON MICROBIOL, V10, P208, DOI 10.1111/j.1462-2920.2007.01445.x; Katharios P, 2011, J FISH DIS, V34, P459, DOI 10.1111/j.1365-2761.2011.01257.x; Keeling P, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000489; Keeling PJ, 2002, ANNU REV MICROBIOL, V56, P93, DOI 10.1146/annurev.micro.56.012302.160854; Keller M, 2011, J FISH DIS, V34, P635, DOI 10.1111/j.1365-2761.2011.01276.x; Kent M. L., 1997, Leukemia (Basingstoke), V11, P170; Kent ML, 2012, ILAR J, V53, P126, DOI 10.1093/ilar.53.2.126; Kent ML, 2001, J EUKARYOT MICROBIOL, V48, P395, DOI 10.1111/j.1550-7408.2001.tb00173.x; Kent ML, 2002, COMPARATIVE MED, V52, P354; Kern G, 2002, J EXP BIOL, V205, P2943; Khoo L, 1998, J FISH DIS, V21, P423, DOI 10.1046/j.1365-2761.1998.00118.x; Kibenge FSB, 2001, DIS AQUAT ORGAN, V45, P9, DOI 10.3354/dao045009; KIMURA I, 1983, J FISH DIS, V6, P195; Knusel R, 2007, VET PATHOL, V44, P237, DOI 10.1354/vp.44-2-237; Kondera E, 2011, FISH PHYSIOL BIOCHEM, V37, P355, DOI 10.1007/s10695-010-9432-5; Kranenbarg S, 2005, J EXP BIOL, V208, P3493, DOI 10.1242/jeb.01808; Kuperman BI, 1999, DIS AQUAT ORGAN, V39, P65, DOI 10.3354/dao039065; Kurahashi M, 2007, SYST APPL MICROBIOL, V30, P202, DOI 10.1016/j.syapm.2006.07.003; KUSUDA R, 1976, B JPN SOC SCI FISH, V42, P1345; Labrie L, 2008, DIS ASIAN AQUACULTUR, P297; Lall SP, 2010, FISH DISEASES AND DISORDERS, VOL 2: NON-INFECTIOUS DISORDERS, 2ND EDITION, P202, DOI 10.1079/9781845935535.0202; Lange M.A., 2000, Ontogenez, V31, P440; LANNAN C N, 1991, Journal of Aquatic Animal Health, V3, P229, DOI 10.1577/1548-8667(1991)003<0229:AFATFD>2.3.CO;2; LAWLER A R, 1977, Journal of Wildlife Diseases, V13, P307; LAWLER AR, 1980, GULF RES REP, V6, P403; Leatherland JF, 2001, FISH FISH, V2, P59, DOI 10.1046/j.1467-2979.2001.00035.x; LEATHERLAND JF, 1978, CANCER RES, V38, P3164; Leatherland John F., 2006, P267; Leibowitz MP, 2005, J FISH DIS, V28, P539, DOI 10.1111/j.1365-2761.2005.00658.x; LIM C, 1978, J NUTR, V108, P1137; Lin HT, 2005, J FISH BIOL, V66, P729, DOI 10.1111/j.0022-1112.2005.00635.x; Loch TP, 2015, J ADV RES, V6, P283, DOI 10.1016/j.jare.2014.10.009; Lom J, 1995, P229; Lom J, 2003, INT J PARASITOL, V33, P107, DOI 10.1016/S0020-7519(02)00252-7; Lom J., 1995, P97; Lom J, 2006, FOLIA PARASIT, V53, P1; Lom J., 1992, PROTOZOAN PARASITES, P1; Lombardini ED, 2014, VET PATHOL, V51, P1000, DOI 10.1177/0300985813511122; Lumsden John S., 2006, P169; Lumsden JS, 2003, J FISH DIS, V26, P393, DOI 10.1046/j.1365-2761.2003.00474.x; Lynn D. H., 2008, CILIATE TAXA INCLUDI, P339; Magi GE, 2013, J ZOO WILDLIFE MED, V44, P225, DOI 10.1638/1042-7260-44.1.225; MALINS DC, 1987, ENVIRON HEALTH PERSP, V71, P5, DOI 10.2307/3430408; Mandrioli L, 2014, J VET DIAGN INVEST, V26, P167, DOI 10.1177/1040638713515218; MASAHITO P, 1992, CANCER RES, V52, P2575; Matsche MA, 2012, J FISH DIS, V35, P873, DOI 10.1111/j.1365-2761.2012.01418.x; McAllister P.E., 1983, Bulletin of the European Association of Fish Pathologists, V3, P37; McArdle J. F., 1984, Bulletin of the European Association of Fish Pathologists, V4, P3; McBride M.J., 2014, PROKARYOTES OTHER MA, P643, DOI DOI 10.1007/978-3-642-38954-2; McDonald W. L., 1987, B EUR ASSOC FISH PAT, V35, P117; MCGINNIS MR, 1983, J AM ACAD DERMATOL, V8, P1, DOI 10.1016/S0190-9622(83)70001-0; MCKNIGHT IJ, 1976, BRIT VET J, V132, P76, DOI 10.1016/S0007-1935(17)34791-7; Mendoza L, 2002, ANNU REV MICROBIOL, V56, P315, DOI 10.1146/annurev.micro.56.012302.160950; Mendoza M, 2013, DIS AQUAT ORGAN, V106, P31, DOI 10.3354/dao02636; Menke AL, 2011, TOXICOL PATHOL, V39, P759, DOI 10.1177/0192623311409597; Mesbah M, 2016, VET RES FORUM, V7, P173; MEYER FP, 1973, PROG FISH CULT, V35, P74, DOI 10.1577/1548-8659(1973)35[74:BNFDON]2.0.CO;2; Mikalsen J, 2008, FEMS MICROBIOL LETT, V278, P43, DOI 10.1111/j.1574-6968.2007.00977.x; Mitchell SO, 2011, J FISH DIS, V34, P411, DOI 10.1111/j.1365-2761.2011.01251.x; Mitchell SO, 2013, DIS AQUAT ORGAN, V103, P35, DOI 10.3354/dao02563; Miwa S, 2004, DIS AQUAT ORGAN, V58, P165, DOI 10.3354/dao058165; Morris AL, 2011, J AQUAT ANIM HEALTH, V23, P92, DOI 10.1080/08997659.2011.574079; Mortensen S.H., 1990, Bulletin of the European Association of Fish Pathologists, V10, P42; MOSS ML, 1961, ACTA ANAT, V46, P343; Munday BL, 1997, DIS AQUAT ORGAN, V30, P17, DOI 10.3354/dao030017; Murchelano R. A., 1988, NOAATMNMFSFNEC61; Nelson J.S., 2016, FISHES WORLD, DOI [10.1002/9781119174844, DOI 10.1002/9781119174844]; Nerette P, 2005, J FISH DIS, V28, P101, DOI 10.1111/j.1365-2761.2005.00613.x; Netto LN, 2011, J FISH DIS, V34, P251, DOI 10.1111/j.1365-2761.2010.01220.x; NIEUWENHUYS R, 1982, AM ZOOL, V22, P287; Noga E. J., 2010, FISH DIS DIAGNOSIS T; Noga Edward J., 2006, P121; Noga EJ, 2006, FISH DISEASES AND DISORDERS, VOL 1: PROTOZOAN AND METAZOAN INFECTIONS, 2ND EDITION, P16, DOI 10.1079/9780851990156.0016; Nomoto R, 2004, J FISH DIS, V27, P679, DOI 10.1111/j.1365-2761.2004.00591.x; Nowak BF, 2006, J FISH DIS, V29, P573, DOI 10.1111/j.1365-2761.2006.00747.x; Nyaoke A, 2009, J VET DIAGN INVEST, V21, P69, DOI 10.1177/104063870902100111; Nylund A, 2002, BULL EUR ASSN FISH P, V22, P311; NYLUND A, 1994, DIS AQUAT ORGAN, V19, P95, DOI 10.3354/dao019095; Nylund S, 2015, ARCH MICROBIOL, V197, P17, DOI 10.1007/s00203-014-1038-3; O'Hagan Bradley J, 2006, Vet Clin North Am Exot Anim Pract, V9, P729; Ogawa M., 1961, Science Reports Tokyo Kyoiku Daigaku, V1OB, P61; OIE, 2003, DIAGN MAN AQ AN DIS, P74; OIE, 2016, MANUAL DIAGNOSTIC TE, P1; OKAMOTO N, 1985, Fish Pathology, V20, P273; OKIHIRO MS, 1993, CANCER RES, V53, P1761; OKIHIRO MS, 1988, VET PATHOL, V25, P422, DOI 10.1177/030098588802500604; OKIHIRO MS, 1989, DIS AQUAT ORGAN, V7, P79, DOI 10.3354/dao007079; Olson KR, 2002, J EXP ZOOL, V293, P214, DOI 10.1002/jez.10131; Olson KR, 1992, FISH PHYSIOL BIOCHEM, P135, DOI DOI 10.1016/S1546-5098(08)60010-2; Oryan A, 2015, FISH PATHOL, V50, P112; Ostrander GK, 2004, CANCER RES, V64, P8485, DOI 10.1158/0008-5472.CAN-04-2260; OTIS EJ, 1985, J WILDLIFE DIS, V21, P61, DOI 10.7589/0090-3558-21.1.61; Ozaka C, 2009, COPEIA, P609, DOI 10.1643/CP-08-131; PAPERNA I, 1977, AQUACULTURE, V10, P169, DOI 10.1016/0044-8486(77)90018-7; PAPERNA I, 1981, J FISH DIS, V4, P459, DOI 10.1111/j.1365-2761.1981.tb01159.x; PAPERNA I, 1980, J FISH DIS, V3, P363, DOI 10.1111/j.1365-2761.1980.tb00421.x; Paquette CE, 2013, ZEBRAFISH, V10, P228, DOI 10.1089/zeb.2012.0828; PARENTI LR, 1986, ZOOL J LINN SOC-LOND, V87, P37, DOI 10.1111/j.1096-3642.1986.tb01329.x; Paul TA, 2006, J VIROL, V80, P2941, DOI 10.1128/JVI.80.6.2941-2948.2006; Pereiro P, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00192; Perry SF, 1997, ANNU REV PHYSIOL, V59, P325, DOI 10.1146/annurev.physiol.59.1.325; Peterson TS, 2013, J COMP PATHOL, V148, P220, DOI 10.1016/j.jcpa.2012.05.015; PFEIFFER W, 1977, COPEIA, P653, DOI 10.2307/1443164; PFEIFFER W, 1962, BIOL REV, V37, P495, DOI 10.1111/j.1469-185X.1962.tb01333.x; Phillips AJ, 2008, TRENDS MICROBIOL, V16, P13, DOI 10.1016/j.tim.2007.10.013; Pickering A. D., 1982, 15 ANN REP YEAR END; PLUMB JA, 1974, T AM FISH SOC, V103, P358, DOI 10.1577/1548-8659(1974)103<358:SSFMFA>2.0.CO;2; Polkinghorne A, 2010, DIS AQUAT ORGAN, V91, P75, DOI 10.3354/dao02255; Poppe Trygve T., 2006, P141; Popper Arthur N., 1993, P99; Press CM, 1999, FISH SHELLFISH IMMUN, V9, P309, DOI 10.1006/fsim.1998.0181; PRITCHARD HN, 1968, J EXP ZOOL, V169, P371, DOI 10.1002/jez.1401690310; QUESADA J, 1990, J MORPHOL, V206, P273, DOI 10.1002/jmor.1052060304; RAO PDP, 1967, ACTA ANAT, V68, P379; Reichley SR, 2015, J VET DIAGN INVEST, V27, P130, DOI 10.1177/1040638714566672; REIMSCHUESSEL R, 1989, J COMP PATHOL, V101, P215, DOI 10.1016/0021-9975(89)90067-4; REIMSCHUESSEL R, 1990, TOXICOL PATHOL, V18, P32, DOI 10.1177/019262339001800105; Reimschuessel Renate, 2006, P91; Reite OB, 1997, FISH SHELLFISH IMMUN, V7, P567, DOI 10.1006/fsim.1997.0108; Reite OB, 2006, FISH SHELLFISH IMMUN, V20, P192, DOI 10.1016/j.fsi.2005.01.012; Revankar SG, 2010, CLIN MICROBIOL REV, V23, P884, DOI 10.1128/CMR.00019-10; Roberts R. J., 2012, FISH PATHOL, P383; Roberts R. J., 2012, FISH PATHOL, P17; Roberts R. J., 2012, FISH PATHOL, P1; Roberts RJ, 2005, J FISH DIS, V28, P383, DOI 10.1111/j.1365-2761.2005.00642.x; Rodriguez-Tovar LE, 2011, FISH SHELLFISH IMMUN, V30, P999, DOI 10.1016/j.fsi.2011.02.011; ROSE AS, 1989, J FISH DIS, V12, P573, DOI 10.1111/j.1365-2761.1989.tb00566.x; ROSS AJ, 1975, J FISH RES BOARD CAN, V32, P1648, DOI 10.1139/f75-193; Rovnak J, 2010, VIRUSES-BASEL, V2, P1984, DOI 10.3390/v2091984; Rowley A. F., 1998, VERTEBRATE BLOOD CEL, P29; Rozas M, 2014, J FISH DIS, V37, P163, DOI 10.1111/jfd.12211; RTLA, 2016, REG TUM LOW AN 1965; Ruane N., 2007, MARINE ENV HLTH SERI, V30, P48; Santacroce MP, 2008, REV FISH BIOL FISHER, V18, P99, DOI 10.1007/s11160-007-9064-8; SCHARTL A, 1995, CANCER RES, V55, P159; SCHLUMBERGER HG, 1956, CANCER RES, V16, P369; Schmidt-Posthaus H, 2012, ENVIRON MICROBIOL, V14, P2048, DOI 10.1111/j.1462-2920.2011.02670.x; Schonherz AA, 2013, J GEN VIROL, V94, P869, DOI 10.1099/vir.0.048223-0; Selvaraj G. S. D., 1973, J MARINE BIOL ASS IN, V15, P571; Seyedmousavi S, 2013, CLIN MICROBIOL REV, V26, P19, DOI 10.1128/CMR.00065-12; SHAHAROMHARRISON FM, 1990, AQUACULTURE, V86, P127, DOI 10.1016/0044-8486(90)90107-X; Sherrill J, 2004, J ZOO WILDLIFE MED, V35, P347, DOI 10.1638/03-025; Siddall ME, 1995, J PARASITOL, V81, P961, DOI 10.2307/3284049; Simeone CA, 2015, J ZOO WILDLIFE MED, V46, P431, DOI 10.1638/2014-0223R1.1; SIRE JY, 1990, CELL TISSUE RES, V260, P85, DOI 10.1007/BF00297493; Sirri R, 2015, J COMP PATHOL, V153, P190, DOI 10.1016/j.jcpa.2015.05.001; Sirri R, 2010, DIS AQUAT ORGAN, V92, P83, DOI 10.3354/dao02273; Sitja-Bobadilla A, 2008, PARASITE, V15, P420, DOI 10.1051/parasite/2008153420; Smail D.A., 2012, FISH PATHOL, V4th, P186; Small HJ, 2010, DIS AQUAT ORGAN, V88, P127, DOI 10.3354/dao02148; SMART GR, 1979, J FISH DIS, V2, P279, DOI 10.1111/j.1365-2761.1979.tb00170.x; Smith R.J.F., 1992, Reviews in Fish Biology and Fisheries, V2, P33, DOI 10.1007/BF00042916; Snow M, 2001, AQUACULTURE, V196, P47, DOI 10.1016/S0044-8486(00)00588-3; Song JY, 2009, DIS AQUAT ORGAN, V83, P133, DOI 10.3354/dao02017; Soto E, 2015, J AQUAT ANIM HEALTH, V27, P123, DOI 10.1080/08997659.2015.1032439; Soto E, 2012, J AQUAT ANIM HEALTH, V24, P81, DOI 10.1080/08997659.2012.675931; SPANGGAARD B, 1994, J FISH DIS, V17, P145, DOI 10.1111/j.1365-2761.1994.tb00207.x; SPATAFORA JW, 1995, J CLIN MICROBIOL, V33, P1322; Speare D. J., 2006, SYSTEMIC PATHOLOGY F, P291; Speare D. J., 2006, SYSTEMIC PATHOLOGY F, P243; Speare DJ, 2010, FISH DISEASES AND DISORDERS, VOL 2: NON-INFECTIOUS DISORDERS, 2ND EDITION, P342, DOI 10.1079/9781845935535.0342; Speare David J., 2006, P25; SPEARE DJ, 1991, J FISH DIS, V14, P21, DOI 10.1111/j.1365-2761.1991.tb00573.x; SPEARE DJ, 1989, CAN VET J, V30, P882; Spencer P, 2008, AQUAT TOXICOL, V90, P300, DOI 10.1016/j.aquatox.2008.08.017; Spitsbergen JM, 2013, VET PATHOL, V50, P418, DOI 10.1177/0300985813482949; Spitsbergen JM, 2012, ILAR J, V53, P114, DOI 10.1093/ilar.53.2.114; Sriwanayos P, 2013, DIS AQUAT ORGAN, V105, P1, DOI 10.3354/dao02594; Stamper MA, 2011, J AQUAT ANIM HEALTH, V23, P111, DOI 10.1080/08997659.2011.608608; Starliper CE, 2011, J ADV RES, V2, P97, DOI 10.1016/j.jare.2010.04.001; STEHR CM, 1990, TOXICOL PATHOL, V18, P362, DOI 10.1177/019262339001800302; Stolk A., 1953, Proceedings Acad Sci Amsterdam, V56C, P28; Stride MC, 2013, APPL ENVIRON MICROB, V79, P1590, DOI 10.1128/AEM.02899-12; Takei Y., 2006, PHYSL FISHES, P272; THOMPSON JC, 1964, J PROTOZOOL, V11, P378, DOI 10.1111/j.1550-7408.1964.tb01766.x; THOMPSON JS, 1990, CANCER RES, V50, pS5668; Todal JA, 2004, DIS AQUAT ORGAN, V58, P9, DOI 10.3354/dao058009; Toenshoff ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032696; TSUNEKI K, 1986, JPN J ICHTHYOL, V33, P27, DOI 10.1007/BF02905556; TSUNEKI K, 1986, J HIRNFORSCH, V27, P441; Tuan NA, 2002, AQUACULTURE, V212, P311, DOI 10.1016/S0044-8486(02)00021-2; Turnbull J. F., 1993, P40; Turnbull Jimmy, 2006, P289; Uribe M.C., 2014, SPERMATOGENESIS, V4, DOI DOI 10.4161/21565562.2014.983400; Van West Pieter, 2006, Mycologist, V20, P99, DOI 10.1016/j.mycol.2006.06.004; Vanden Bergh P, 2014, MICROB BIOTECHNOL, V7, P381, DOI 10.1111/1751-7915.12091; Vendrell D, 2006, COMP IMMUNOL MICROB, V29, P177, DOI 10.1016/j.cimid.2006.06.003; Vigliano FA, 2011, DIS AQUAT ORGAN, V96, P61, DOI 10.3354/dao02383; VOGELBEIN WK, 1994, TOXICOL PATHOL, V22, P248, DOI 10.1177/019262339402200303; Vogelbein WK, 1999, J FISH DIS, V22, P419, DOI 10.1046/j.1365-2761.1999.00192.x; WAKABAYASHI H, 1989, INT J SYST BACTERIOL, V39, P213, DOI 10.1099/00207713-39-3-213; WALKER R, 1969, NATL CANCER I MONOGR, P195; Weber ES, 2009, J VET DIAGN INVEST, V21, P306, DOI 10.1177/104063870902100302; White MR, 2004, VET PATHOL, V41, P72, DOI 10.1354/vp.41-1-72; Whitear M., 1986, BIOL INTEGUMENT, V2, P39; Whittington ID, 2012, FISH PARASITES: PATHOBIOLOGY AND PROTECTION, P225, DOI 10.1079/9781845938062.0225; Whittington RJ, 2010, J FISH DIS, V33, P95, DOI 10.1111/j.1365-2761.2009.01110.x; Wiklund T, 1998, DIS AQUAT ORGAN, V32, P49, DOI 10.3354/dao032049; Wiley M. L., 1970, B AM MUS NAT HIST, V143, P143; Willens S, 2004, J ZOO WILDLIFE MED, V35, P107, DOI 10.1638/02-085; Wilson JM, 2011, FISH PHYSIOL, V30, P1, DOI 10.1016/S1546-5098(10)03001-3; Wilson JM, 2002, J EXP ZOOL, V293, P192, DOI 10.1002/jez.10124; Wise DJ, 2008, J AQUAT ANIM HEALTH, V20, P39, DOI 10.1577/1-107-008.1; Wolf JC, 1999, DIS AQUAT ORGAN, V38, P191, DOI 10.3354/dao038191; Wolf JC, 2015, TOXICOL PATHOL, V43, P297, DOI 10.1177/0192623314540229; WOLF K, 1984, SCIENCE, V225, P1449, DOI 10.1126/science.225.4669.1449; WOLF K, 1966, SCIENCE, V151, P1004, DOI 10.1126/science.151.3713.1004; Wolke R. E., 1992, Annual Review of Fish Diseases, V2, P91, DOI 10.1016/0959-8030(92)90058-6; Won KM, 2010, FISHERIES SCI, V76, P991, DOI 10.1007/s12562-010-0287-6; Woo PTK, 2006, FISH DISEASES AND DISORDERS, VOL 1: PROTOZOAN AND METAZOAN INFECTIONS, 2ND EDITION, P46, DOI 10.1079/9780851990156.0046; WOOD EM, 1955, ARCH PATHOL, V60, P26; Wood J. W., 1974, DIS PACIFIC SALMON T, P82; Yakote M., 1982, ATLAS FISH HISTOLOGY, P64; Yanong RPE, 2004, JAVMA-J AM VET MED A, V224, P1644, DOI 10.2460/javma.2004.224.1644; Young ND, 2008, DIS AQUAT ORGAN, V78, P217, DOI 10.3354/dao01869; Zapata A, 2006, FISH SHELLFISH IMMUN, V20, P126, DOI 10.1016/j.fsi.2004.09.005; Zeng JS, 2007, J CLIN MICROBIOL, V45, P3713, DOI 10.1128/JCM.02012-06; Zychowski KE, 2013, TOXINS, V5, P1555, DOI 10.3390/toxins5091555	363	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							953	+		10.1016/B978-0-12-805306-5.00039-0			14	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300041					2019-10-28	
B	Stedman, NL; Garner, MM		Terio, KA; McAloose, D; StLeger, J		Stedman, Nancy L.; Garner, Michael M.			Chondrichthyes	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							CARCHARIAS-TAURUS RAFINESQUE; ELASMOBRANCH FISHES; NURSE SHARK; STINGRAY; CARCHARHINUS; INFECTION; DOGFISH; BLOOD; GULF; MENINGOENCEPHALITIS		[Stedman, Nancy L.] Busch Gardens Tampa, Tampa, FL 33612 USA; [Garner, Michael M.] Northwest ZooPath, Monroe, WA USA	Stedman, NL (reprint author), Busch Gardens Tampa, Tampa, FL 33612 USA.						Anderson ET, 2012, J FISH DIS, V35, P541, DOI 10.1111/j.1365-2761.2012.01367.x; Anderson PA, 2012, J ZOO WILDLIFE MED, V43, P750, DOI 10.1638/2011-0066R1.1; Benz GW, 2002, J PARASITOL, V88, P474; BIRD PM, 1981, FISH B-NOAA, V79, P376; Borucinska JD, 2012, J FISH DIS, V35, DOI 10.1111/j.1365-2761.2012.01405.x; Borucinska JD, 2011, J FISH DIS, V34, P149, DOI 10.1111/j.1365-2761.2010.01223.x; Borucinska JD, 2004, J FISH DIS, V27, P185, DOI 10.1111/j.1365-2761.2004.00532.x; BUNDGAARD M, 1991, CELL TISSUE RES, V265, P113, DOI 10.1007/BF00318145; Burgi H, 2001, THYROID, V11, P449, DOI 10.1089/105072501300176408; BURWASH FRANCES M., 1929, CONTR CANADIAN BIOL & FISH, V4, P117; Caira JN, 2014, J PARASITOL, V100, P373, DOI 10.1645/14-516.1; Camus A, 2013, DIS AQUAT ORGAN, V104, P13, DOI 10.3354/dao02586; Carlson JK, 2001, ENVIRON BIOL FISH, V61, P427, DOI 10.1023/A:1011641302048; Carroll SM, 2008, MOL BIOL EVOL, V25, P2643, DOI 10.1093/molbev/msn204; CHIBA A, 1986, ARCH HISTOL CYTOL, V49, P61, DOI 10.1679/aohc.49.61; CHIBA A, 1988, AM J ANAT, V183, P268, DOI 10.1002/aja.1001830309; Clarke EO, 2013, J ZOO WILDLIFE MED, V44, P470, DOI 10.1638/2012-0018R2.1; CREDILLE KM, 1993, J WILDLIFE DIS, V29, P502, DOI 10.7589/0090-3558-29.3.502; Crooks N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076887; CROW GL, 1991, ZOO BIOL, V10, P457, DOI 10.1002/zoo.1430100604; Crow GL, 2001, J AQUAT ANIM HEALTH, V13, P1, DOI 10.1577/1548-8667(2001)013<0001:HAOGIE>2.0.CO;2; De Boeck G, 2007, AQUAT TOXICOL, V84, P133, DOI 10.1016/j.aquatox.2007.04.012; Diamant A, 2010, DIS AQUAT ORGAN, V91, P137, DOI 10.3354/dao02256; Dulvy NK, 2014, ELIFE, V3, DOI 10.7554/eLife.00590; Dwivedi J, 2006, J TOXICOL ENV HEAL A, V69, P1311, DOI 10.1080/15287390500356800; Escobar-Sanchez O, 2014, J FISH BIOL, V85, P494, DOI 10.1111/jfb.12412; FANGE R, 1981, BIOL BULL, V160, P240, DOI 10.2307/1540884; Fernando N, 2015, MYCOSES, V58, P422, DOI 10.1111/myc.12342; Flewelling LJ, 2010, MAR BIOL, V157, P1937, DOI 10.1007/s00227-010-1463-z; GARCIAGARRIDO L, 1993, ARTERIOSCLER THROMB, V13, P876, DOI 10.1161/01.ATV.13.6.876; Garner MM, 2013, VET PATHOL, V50, P377, DOI 10.1177/0300985813482147; GRIMES DJ, 1985, J FISH DIS, V8, P173, DOI 10.1111/j.1365-2761.1985.tb01212.x; Jafarey YS, 2015, J ZOO WILDLIFE MED, V46, P382, DOI 10.1638/2014-0148R.1; Janse M, 2012, J FISH DIS, V35, P935, DOI 10.1111/j.1365-2761.2012.01444.x; JOHNSTON MRL, 1975, J PROTOZOOL, V22, P529, DOI 10.1111/j.1550-7408.1975.tb05225.x; KHAN RA, 1982, CAN J ZOOL, V60, P396, DOI 10.1139/z82-054; Knoff M, 2001, MEM I OSWALDO CRUZ, V96, P1095, DOI 10.1590/S0074-02762001000800012; KOBAYASHI K, 1981, CELL TISSUE RES, V215, P475; Koester DM, 2003, ANAT REC PART A, V273A, P648, DOI 10.1002/ar.a.10076; LEIBOVITZ L, 1985, J FISH DIS, V8, P273, DOI 10.1111/j.1365-2761.1985.tb00943.x; MacLean RA, 2006, DIS AQUAT ORGAN, V73, P83, DOI 10.3354/dao073083; Mandelman JW, 2009, J COMP PHYSIOL B, V179, P267, DOI 10.1007/s00360-008-0306-4; Manire CA, 2013, J FISH DIS, V36, P437, DOI 10.1111/j.1365-2761.2012.01435.x; MATTISSON A, 1986, BIOL BULL, V171, P660, DOI 10.2307/1541631; MENG QW, 1985, ACTA ZOOL SINICA, V31, P277; Mohan Peter J., 2004, P69; MOSER M, 1977, CAN J ZOOL, V55, P759, DOI 10.1139/z77-098; Mylniczenko N. D., 2003, AM ZOO AQ ASS ANN C; Mylniczenko N. D., 2012, AM ZOO AQ ASS ANN C; Mylniczenko ND, 2007, J AQUAT ANIM HEALTH, V19, P159, DOI 10.1577/H06-039.1; Ostrander GK, 2004, CANCER RES, V64, P8485, DOI 10.1158/0008-5472.CAN-04-2260; Pirarat N, 2016, DIS AQUAT ORGAN, V120, P195, DOI 10.3354/dao03028; Polkinghorne A, 2010, DIS AQUAT ORGAN, V91, P75, DOI 10.3354/dao02255; Preziosi R, 2006, J FISH DIS, V29, P49, DOI 10.1111/j.1365-2761.2005.00684.x; Rasmussen J. M., 1999, AM ZOO AQ ASS ANN C; Schaffer P, 2006, TOXICON, V47, P747, DOI 10.1016/j.toxicon.2006.01.030; Schaffer PA, 2013, VET PATHOL, V50, P412, DOI 10.1177/0300985812441033; Sims DW, 2000, NATURE, V404, P566, DOI 10.1038/35007149; Skomal GB, 2012, COMP BIOCHEM PHYS A, V162, P146, DOI 10.1016/j.cbpa.2011.10.002; Stamper MA, 1998, J AQUAT ANIM HEALTH, V10, P264, DOI 10.1577/1548-8667(1998)010<0264:ESIAWH>2.0.CO;2; Stidworthy MF, 2014, VET PATHOL, V51, P628, DOI 10.1177/0300985813492800; Tao Z, 2014, J AQUAT ANIM HEALTH, V26, P225, DOI 10.1080/08997659.2014.922513; Tate E.E., 2013, INT J COMP PSYCHOL, V26, P75; TESTER AL, 1972, PAC SCI, V26, P264; TORT L, 1987, COMP BIOCHEM PHYS C, V87, P349, DOI 10.1016/0742-8413(87)90020-X; Tuttle AD, 2008, J FISH DIS, V31, P311, DOI 10.1111/j.1365-2761.2007.00881.x; Waldoch JA, 2010, J ZOO WILDLIFE MED, V41, P729, DOI 10.1638/2010-0014.1; Worm B, 2013, MAR POLICY, V40, P194, DOI 10.1016/j.marpol.2012.12.034	68	0	0	1	1	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							1003	+		10.1016/B978-0-12-805306-5.00040-7			27	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300042					2019-10-28	
B	Newton, AL; Smolowitz, R		Terio, KA; McAloose, D; StLeger, J		Newton, Alisa L.; Smolowitz, Roxanna			Invertebrates	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter							EXPERIMENTAL WOUND REPAIR; BEE PARALYSIS VIRUS; CANDIDATUS XENOHALIOTIS CALIFORNIENSIS; AMPHIPOD PARASITES HYPERIIDAE; INFECTIOUS MYONECROSIS VIRUS; LOBSTER HOMARUS-AMERICANUS; IN-SITU HYBRIDIZATION; SPOT SYNDROME VIRUS; SEA-URCHIN DISEASE; BROWN RING DISEASE		[Newton, Alisa L.] Wildlife Conservat Soc, Bronx, NY 10460 USA; [Smolowitz, Roxanna] Roger Williams Univ, Bristol, RI 02809 USA	Newton, AL (reprint author), Wildlife Conservat Soc, Bronx, NY 10460 USA.						Aladaileh S, 2007, J INVERTEBR PATHOL, V96, P48, DOI 10.1016/j.jip.2007.02.011; Alker AP, 2001, HYDROBIOLOGIA, V460, P105, DOI 10.1023/A:1013145524136; Antonio DB, 2000, J INVERTEBR PATHOL, V75, P180, DOI 10.1006/jipa.1999.4906; Arala-Chaves M, 2000, AQUACULTURE, V191, P247, DOI 10.1016/S0044-8486(00)00430-0; ARMSTRONG DA, 1971, J INVERTEBR PATHOL, V17, P216, DOI 10.1016/0022-2011(71)90094-2; Arnold WR, 2010, ENVIRON TOXICOL CHEM, V29, P311, DOI 10.1002/etc.45; Aronstein K, 2013, MICROBIAL PATHOGENS, P402; Baker AC, 2016, DISEASES OF CORAL, P396; Barber BJ, 2004, AQUAT LIVING RESOUR, V17, P449, DOI 10.1051/alr:2004052; Bates AE, 2009, DIS AQUAT ORGAN, V86, P245, DOI 10.3354/dao02125; Baumgartner WA, 2009, DIS AQUAT ORGAN, V85, P15, DOI 10.3354/dao02051; Becker PT, 2008, J INVERTEBR PATHOL, V98, P136, DOI 10.1016/j.jip.2007.12.002; Behringer DC, 2011, DIS AQUAT ORGAN, V94, P153, DOI 10.3354/dao02326; Berzins I. K., 2012, INVERTEBRATE MED, P406; Bidla G, 2005, DEV COMP IMMUNOL, V29, P669, DOI 10.1016/j.dci.2004.11.007; Blanchard P, 2008, J INVERTEBR PATHOL, V97, P182, DOI 10.1016/j.jip.2007.07.003; Blanchard P, 2007, J VIROL METHODS, V141, P7, DOI 10.1016/j.jviromet.2006.11.021; Boettcher KJ, 2005, INT J SYST EVOL MICR, V55, P1531, DOI 10.1099/ijs.0.63620-0; Bottger SA, 2013, NORTHEAST NAT, V20, P430, DOI 10.1656/045.020.0308; Boletzky S., 1991, SEICHE CUTTLEFISH; Boonstra JL, 2015, J ZOO WILDLIFE MED, V46, P158, DOI 10.1638/2014-0087R.1; Bower Susan M., 1994, Annual Review of Fish Diseases, V4, P1, DOI 10.1016/0959-8030(94)90028-0; BOWSER PR, 1981, AQUACULTURE, V23, P11, DOI 10.1016/0044-8486(81)90003-X; Braverman H, 2012, J INVERTEBR PATHOL, V111, P90, DOI 10.1016/j.jip.2012.06.002; BROWN BE, 1995, MAR BIOL, V122, P655, DOI 10.1007/BF00350687; Brun NT, 1999, DIS AQUAT ORGAN, V37, P139, DOI 10.3354/dao037139; Burns JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021888; BURSEY CR, 1977, CAN J ZOOL, V55, P1158, DOI 10.1139/z77-150; Carballal MJ, 2001, J INVERTEBR PATHOL, V78, P87, DOI 10.1006/jipa.2001.5049; Carella F, 2009, J INVERTEBR PATHOL, V101, P154, DOI 10.1016/j.jip.2009.04.003; Carl M., 2008, ADV CORAL HUSBANDRY, V2, P31; Cawthorn RJ, 1996, DIS AQUAT ORGAN, V24, P143, DOI 10.3354/dao024143; Cepero A, 2015, PARASITOL RES, V114, P651, DOI 10.1007/s00436-014-4229-6; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Cerenius L, 2010, TRENDS BIOCHEM SCI, V35, P575, DOI 10.1016/j.tibs.2010.04.006; CHAPMAN G, 1958, BIOL REV, V33, P338, DOI 10.1111/j.1469-185X.1958.tb01260.x; Chistoserdov AY, 2012, J SHELLFISH RES, V31, P449, DOI 10.2983/035.031.0205; Chitty J. R., 2012, INVERTEBRATE MED; Cornman RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043562; COWDEN RR, 1968, J INVERTEBR PATHOL, V10, P151, DOI 10.1016/0022-2011(68)90275-9; Crane M., 2016, MAN DIAGN TESTS AQUA, P441; Crossley SMG, 2009, J ZOO WILDLIFE MED, V40, P174, DOI 10.1638/2008-0100.1; Crosson LM, 2014, DIS AQUAT ORGAN, V108, P261, DOI 10.3354/dao02713; da Silva PM, 2008, FISH SHELLFISH IMMUN, V24, P551, DOI 10.1016/j.fsi.2007.11.003; Darriba S, 2006, J INVERTEBR PATHOL, V93, P140, DOI 10.1016/j.jip.2006.06.009; de Graaf DC, 2006, LETT APPL MICROBIOL, V43, P583, DOI 10.1111/j.1472-765X.2006.02057.x; DESVOIGNE DM, 1968, J INVERTEBR PATHOL, V12, P53, DOI 10.1016/0022-2011(68)90243-7; DESVOIGNE DM, 1970, J INVERTEBR PATHOL, V15, P262, DOI 10.1016/0022-2011(70)90244-2; Domart-Coulon IJ, 2006, CORAL REEFS, V25, P531, DOI 10.1007/s00338-006-0133-6; Dombrowski Daniel, 2007, Veterinary Clinics of North America Exotic Animal Practice, V10, P621, DOI 10.1016/j.cvex.2007.01.005; Dubuffet A, 2013, APPL ENVIRON MICROB, V79, P385, DOI 10.1128/AEM.02699-12; DUNGAN ML, 1982, SCIENCE, V216, P989, DOI 10.1126/science.216.4549.989; Edgerton BF, 2002, AQUACULTURE, V206, P57, DOI 10.1016/S0044-8486(01)00865-1; Eisler R., 2007, EISLERS ENCY ENV HAZ, P161; Ellis JD, 2010, J APICULT RES, V49, P134, DOI 10.3896/IBRA.1.49.1.30; ELSTON RA, 1992, REV AQUAT SCI, V6, P405; Estevez J, 1996, DIS AQUAT ORGAN, V27, P227, DOI 10.3354/dao027227; FARLEY CA, 1969, NATL CANCER I MONOGR, P541; FARLEY CA, 1969, J NATL CANCER I, V43, P509; FERAL JP, 1988, J INVERTEBR PATHOL, V52, P380, DOI 10.1016/0022-2011(88)90049-3; Foelix R. F., 1996, BIOL SPIDERS; FONTAINE CT, 1973, J INVERTEBR PATHOL, V22, P23, DOI 10.1016/0022-2011(73)90005-0; Forsgren E, 2010, J INVERTEBR PATHOL, V103, pS5, DOI 10.1016/j.jip.2009.06.016; Franklin AM, 2012, BIOL LETTERS, V8, P754, DOI 10.1098/rsbl.2012.0556; Freeman KS, 2009, AM J VET RES, V70, P1087, DOI 10.2460/ajvr.70.9.1087; FRELIER PF, 1992, VET PATHOL, V29, P269, DOI 10.1177/030098589202900401; Friedman CS, 2007, J SHELLFISH RES, V26, P877, DOI 10.2983/0730-8000(2007)26[877:OAATTM]2.0.CO;2; Friedman CS, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00078; Friedman CS, 2005, DIS AQUAT ORGAN, V63, P33, DOI 10.3354/dao063033; FRIEDMAN CS, 1995, J INVERTEBR PATHOL, V66, P33, DOI 10.1006/jipa.1995.1057; Friedman CS, 2000, INT J SYST EVOL MICR, V50, P847, DOI 10.1099/00207713-50-2-847; Furuya H, 2004, J MORPHOL, V262, P629, DOI 10.1002/jmor.10265; Furuya H, 2003, ZOOL SCI, V20, P519, DOI 10.2108/zsj.20.519; Ganjoor M. A., 2015, FISH AQUAC J, V6, P136; GARDNER GR, 1995, J INVERTEBR PATHOL, V66, P111, DOI 10.1006/jipa.1995.1072; GARDNER GR, 1993, ADV FISH SC, P359; Genersch E, 2010, J INVERTEBR PATHOL, V103, pS10, DOI 10.1016/j.jip.2009.06.015; Gestal C, 2002, DIS AQUAT ORGAN, V50, P45, DOI 10.3354/dao050045; GILLES KW, 1986, DIS AQUAT ORGAN, V1, P105; Glenn RP, 2006, J CRUSTACEAN BIOL, V26, P639, DOI 10.1651/S-2754.1; GLYNN PW, 1985, DIS AQUAT ORGAN, V1, P29, DOI 10.3354/dao001029; Gonzalez R, 2014, J INVERTEBR PATHOL, V116, P13, DOI 10.1016/j.jip.2013.12.002; Grosell M, 2007, AQUAT TOXICOL, V84, P162, DOI 10.1016/j.aquatox.2007.03.026; Gudenkauf BM, 2014, J GEN VIROL, V95, P652, DOI 10.1099/vir.0.060780-0; Gustafson LL, 2005, DIS AQUAT ORGAN, V65, P167, DOI 10.3354/dao065167; Hameed ASS, 2012, INDIAN J VIROL, V23, P134, DOI 10.1007/s13337-012-0087-y; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hewson I, 2014, P NATL ACAD SCI USA, V111, P17278, DOI 10.1073/pnas.1416625111; HIBBITS J, 1983, J INVERTEBR PATHOL, V41, P51, DOI 10.1016/0022-2011(83)90235-5; Hooper C, 2007, AUST VET J, V85, P188, DOI 10.1111/j.1751-0813.2007.00155.x; Hopkin S. P., 1992, BIOL MILLIPEDES, P141; HUGUET G, 1992, J INVERTEBR PATHOL, V59, P11, DOI 10.1016/0022-2011(92)90105-D; Huguet G, 1999, J INVERTEBR PATHOL, V73, P15, DOI 10.1006/jipa.1998.4800; JANGOUX M, 1987, DIS AQUAT ORGAN, V2, P147; Jiravanichpaisal P, 2006, IMMUNOBIOLOGY, V211, P213, DOI 10.1016/j.imbio.2005.10.015; Johansson MW, 2000, AQUACULTURE, V191, P45, DOI 10.1016/S0044-8486(00)00418-X; JOHNSON PT, 1977, J INVERTEBR PATHOL, V29, P308, DOI 10.1016/S0022-2011(77)80036-0; Kanjanasopa D, 2015, AQUACULTURE, V443, P5, DOI 10.1016/j.aquaculture.2015.02.041; Kim K, 2006, DIS AQUAT ORGAN, V69, P95, DOI 10.3354/dao069095; Kohl WT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153670; Kumar V., 2015, ROBBINS COTRAN PATHO, P265; Kurtz J, 2006, TRENDS IMMUNOL, V27, P493, DOI 10.1016/j.it.2006.09.001; LaDouceur EEB, 2016, VET PATHOL, V53, P648, DOI 10.1177/0300985815603431; LaDouceur EEB, 2013, VET PATHOL, V50, P434, DOI 10.1177/0300985812461363; Larsen EH, 2014, COMPR PHYSIOL, V4, P405, DOI 10.1002/cphy.c130004; Lauckner G., 1983, P477; Leake L. D., 1975, COMP HISTOLOGY INTRO; Lightner DV, 2012, J INVERTEBR PATHOL, V110, P174, DOI 10.1016/j.jip.2012.03.006; Lightner D. V., 2006, MAN DIAGN TESTS AQUA, P18; LIGHTNER DV, 1977, J INVERTEBR PATHOL, V30, P298, DOI 10.1016/0022-2011(77)90137-9; LIGHTNER DV, 1987, J INVERTEBR PATHOL, V49, P188, DOI 10.1016/0022-2011(87)90159-5; Tran L, 2013, DIS AQUAT ORGAN, V105, P45, DOI 10.3354/dao02621; Longshaw M, 2011, J INVERTEBR PATHOL, V106, P54, DOI 10.1016/j.jip.2010.09.013; Loy JK, 1996, DIS AQUAT ORGAN, V25, P117, DOI 10.3354/dao025117; LOYA Y, 1984, HELGOLANDER MEERESUN, V37, P99, DOI 10.1007/BF01989297; MAES P, 1984, HELGOLANDER MEERESUN, V37, P217, DOI 10.1007/BF01989306; McCallum HI, 2004, TRENDS ECOL EVOL, V19, P585, DOI 10.1016/j.tree.2004.08.009; Menge B. A., 2016, PLOS ONE, V11, P1; MENTON DN, 1973, J MORPHOL, V141, P185, DOI 10.1002/jmor.1051410206; Meszaros A, 1999, J INVERTEBR PATHOL, V73, P321, DOI 10.1006/jipa.1999.4851; Metzger MJ, 2016, NATURE, V534, P705, DOI 10.1038/nature18599; MICHELSO.EH, 1972, J INVERTEBR PATHOL, V20, P264, DOI 10.1016/0022-2011(72)90154-1; Mill P. J., 1997, HDB PHYSL, P1009; Moltschaniwskyj NA, 2007, REV FISH BIOL FISHER, V17, P455, DOI 10.1007/s11160-007-9056-8; Moore JD, 2009, MAR BIOL, V156, P2325, DOI 10.1007/s00227-009-1260-8; Moore JD, 2001, DIS AQUAT ORGAN, V46, P147, DOI 10.3354/dao046147; Mullen TE, 2004, J AQUAT ANIM HEALTH, V16, P29, DOI 10.1577/H02-045.1; NEWMAN MW, 1973, J INVERTEBR PATHOL, V22, P329, DOI 10.1016/0022-2011(73)90159-6; Nibert ML, 2007, J GEN VIROL, V88, P1315, DOI 10.1099/vir.0.82681-0; Nonaka M, 2004, IMMUNOL REV, V198, P203, DOI 10.1111/j.0105-2896.2004.00118.x; Nunan LM, 2008, DIS AQUAT ORGAN, V80, P69, DOI 10.3354/dao01908; Odintsova NA, 2011, J EXP MAR BIOL ECOL, V407, P241, DOI 10.1016/j.jembe.2011.06.020; Oestmann DJ, 1997, CONTEMP TOP LAB ANIM, V36, P89; OIE, 2013, MAN DIAGN TESTS AQUA, V2013, P138; OIE, 2008, OIE TERR MAN, P395; Olivier V, 2008, J VIROL METHODS, V153, P232, DOI 10.1016/j.jviromet.2008.06.027; Ottaviani E, 2004, PROG MOLEC, V34, P1; Paillard C, 2004, AQUAT LIVING RESOUR, V17, P467, DOI 10.1051/alr:2004053; PAILLARD C, 1995, J INVERTEBR PATHOL, V65, P91, DOI 10.1006/jipa.1995.1015; Palmer CV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023992; PAULEY GB, 1967, J INVERTEBR PATHOL, V9, P298, DOI 10.1016/0022-2011(67)90064-X; PAULEY GB, 1969, J INVERTEBR PATHOL, V13, P241, DOI 10.1016/0022-2011(69)90215-8; PAULEY GB, 1967, J INVERTEBR PATHOL, V9, P459, DOI 10.1016/0022-2011(67)90124-3; PAULEY GB, 1968, J INVERTEBR PATHOL, V11, P398, DOI 10.1016/0022-2011(68)90189-4; Pernet F, 2015, AQUACULTURE, V445, P57, DOI 10.1016/j.aquaculture.2015.04.010; Peters E., 2012, INVERTEBRATE MED, P448; PETERS EC, 1986, JNCI-J NATL CANCER I, V76, P895; PETERS EC, 1994, DIS AQUAT ORGAN, V20, P59, DOI 10.3354/dao020059; POINAR GO, 1985, J ARACHNOL, V13, P121; POLGLASE JL, 1983, J ZOOL, V201, P185; Poulos BT, 2006, J GEN VIROL, V87, P987, DOI 10.1099/vir.0.81127-0; PUNZO F, 1983, COMP BIOCHEM PHYS A, V75, P647, DOI 10.1016/0300-9629(83)90435-8; REIMSCHUESSEL R, 1990, J INVERTEBR PATHOL, V55, P394, DOI 10.1016/0022-2011(90)90083-I; Renault T, 2014, APPL ENVIRON MICROB, V80, P5419, DOI 10.1128/AEM.00484-14; Reville C, 2005, J SHELLFISH RES, V24, P285; Ribiere M, 2010, J INVERTEBR PATHOL, V103, pS120, DOI 10.1016/j.jip.2009.06.013; RIDDLE WA, 1985, COMP BIOCHEM PHYS A, V80, P313, DOI 10.1016/0300-9629(85)90043-X; RIEGL B, 1995, J EXP MAR BIOL ECOL, V186, P259, DOI 10.1016/0022-0981(94)00164-9; Robert J, 2010, DEV COMP IMMUNOL, V34, P915, DOI 10.1016/j.dci.2010.05.011; ROBERTSON JD, 1953, J EXP BIOL, V30, P277; Robertson JD, 1939, J EXP BIOL, V16, P387; ROWLEY AF, 1978, J MORPHOL, V157, P181, DOI 10.1002/jmor.1051570206; Ruppert E.E., 2004, INVERTEBRATE ZOOLOGY; SCHARRER B, 1950, CANCER RES, V10, P403; SCHARTAU W, 1983, J COMP PHYSIOL, V152, P73, DOI 10.1007/BF00689730; Scimeca J. M., 2012, INVERTEBRATE MED, P129; Seeley KE, 2016, J ZOO WILDLIFE MED, V47, P271, DOI 10.1638/2014-0134.1; Sheppard BJ, 2008, DIS AQUAT ORGAN, V79, P229, DOI 10.3354/dao01888; Sherrill J, 2000, J ZOO WILDLIFE MED, V31, P523; Shields JD, 2013, J INVERTEBR PATHOL, V114, P245, DOI 10.1016/j.jip.2013.08.013; SHRESTHA R, 1986, J INVERTEBR PATHOL, V48, P1, DOI 10.1016/0022-2011(86)90137-0; Small HJ, 2012, J INVERTEBR PATHOL, V110, P234, DOI 10.1016/j.jip.2012.03.012; Smith GW, 1998, REV BIOL TROP, V46, P205; Smith SA, 2005, LAB ANIMAL, V34, P27, DOI 10.1038/laban0705-27; Smolowitz R, 2013, VET PATHOL, V50, P404, DOI 10.1177/0300985813480806; Smolowitz R, 1998, J INVERTEBR PATHOL, V71, P9, DOI 10.1006/jipa.1997.4706; Smolowitz R., 2005, BIOL BULL, V183, P99; SMOLOWITZ RM, 1992, BIOL BULL, V183, P99, DOI 10.2307/1542411; SMOLOWITZ RM, 1993, J INVERTEBR PATHOL, V62, P185, DOI 10.1006/jipa.1993.1094; SPARKS AK, 1973, J INVERTEBR PATHOL, V22, P203, DOI 10.1016/0022-2011(73)90135-3; SPARKS AK, 1972, INVERTEBRATE PATHOLO; Steers J., 2003, P AM ASS ZOO VET, P324; Stentiford GD, 2005, DIS AQUAT ORGAN, V66, P47, DOI 10.3354/dao066047; Stentiford GD, 2013, TRENDS PARASITOL, V29, P567, DOI 10.1016/j.pt.2013.08.005; Tang KFJ, 2012, DIS AQUAT ORGAN, V99, P179, DOI 10.3354/dao02470; Tascedda F, 2014, ISJ-INVERT SURVIV J, V11, P197; Tettamanti G, 2005, BIOL CELL, V97, P557; The World Organization for Animal Health, 2016, MAN DIAGN TESTS VACC; Uddin MJ, 2011, J SHELLFISH RES, V30, P875, DOI 10.2983/035.030.0328; vanEngelsdorp D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006481; Vargas-Angel B, 2006, P 10 INT COR REEF S, P1168; Walker AN, 2009, DIS AQUAT ORGAN, V85, P193, DOI 10.3354/dao02072; Walker CW, 2011, ADV MAR BIOL, V59, P1, DOI 10.1016/B978-0-12-385536-7.00001-7; Wang JT, 2016, ANIM FEED SCI TECH, V216, P225, DOI 10.1016/j.anifeedsci.2016.03.023; Widada J, 2004, DIS AQUAT ORGAN, V58, P83, DOI 10.3354/dao058083; Williams D L, 1999, Vet Clin North Am Exot Anim Pract, V2, P777; Woodley C. M., 2016, DIS CORAL; Work TM, 2016, VET PATHOL, V53, P153, DOI 10.1177/0300985815571669; Work TM, 2008, J EXP MAR BIOL ECOL, V362, P63, DOI 10.1016/j.jembe.2008.05.011; Work TM, 2008, DIS AQUAT ORGAN, V78, P255, DOI 10.3354/dao01881; World Organization for Animal Health, 2016, MANUAL DIAGNOSTIC TE, P1; World Organization for Animal Health, 2016, MAN DIAGN TESTS VACC, P1867; Zachariah TT, 2007, J ZOO WILDLIFE MED, V38, P245, DOI 10.1638/1042-7260(2007)038[0245:HBRRFW]2.0.CO;2	203	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							1019	+		10.1016/B978-0-12-805306-5.00041-9			10	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300043					2019-10-28	
B	McAloose, D; Chang, TY		Terio, KA; McAloose, D; StLeger, J		McAloose, Denise; Chang, Tylis Y.			Viral Families and Documented Diseases	PATHOLOGY OF WILDLIFE AND ZOO ANIMALS			English	Article; Book Chapter									[McAloose, Denise] Bronx Zoo, Wildlife Conservat Soc, Bronx, NY 10460 USA; [Chang, Tylis Y.] Zucker Sch Med, New Hyde Pk, NY USA	McAloose, D (reprint author), Bronx Zoo, Wildlife Conservat Soc, Bronx, NY 10460 USA.							0	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-809219-4; 978-0-12-805306-5				2018							1053	+		10.1016/B978-0-12-805306-5.00050-X			2	Pathology; Veterinary Sciences; Zoology	Pathology; Veterinary Sciences; Zoology	BN0EA	WOS:000472712300044					2019-10-28	
B	Mitchell, MG	Mitchell, MG			Mitchell, Maika G.	Mitchell, MG		Molecular Pathology Introduction and Research Review	MOLECULAR PATHOLOGY AND THE DYNAMICS OF DISEASE			English	Review; Book Chapter							HEPATITIS-C VIRUS; SPONTANEOUS CLEARANCE; GENETIC-VARIATION; OMICS; IL28B; PATHOGENESIS; RESPONSES; CELLS									ALBRECHT T, 1990, INTERVIROLOGY, V31, P68, DOI 10.1159/000150140; Cho W. C., 2007, BIOFORUM EUR, V11, P35; Cho WC, 2010, METHODS CANC DIAGNOS; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Coen Donald M., 1994, Trends in Microbiology, V2, P481, DOI 10.1016/0966-842X(94)90652-1; Day CL, 2002, J VIROL, V76, P12584, DOI 10.1128/JVI.76.24.12584-12595.2002; Doherty DG, 2000, IMMUNOL REV, V174, P5, DOI 10.1034/j.1600-0528.2002.017416.x; FIELDS BN, 1983, JAMA-J AM MED ASSOC, V250, P1754, DOI 10.1001/jama.250.13.1754; Finn WG, 2007, J MOL DIAGN, V9, P431, DOI 10.2353/jmoldx.2007.070023; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Grebely J, 2010, HEPATOLOGY, V52, P1216, DOI 10.1002/hep.23850; GRIEDER FB, 1995, VIROLOGY, V206, P994, DOI 10.1006/viro.1995.1022; Guidotti LG, 2006, ANNU REV PATHOL-MECH, V1, P23, DOI 10.1146/annurev.pathol.1.110304.100230; Hamacher M, 2008, PROTEOMICS, V8, P1116, DOI 10.1002/pmic.200890017; Keusch GT, 2006, AM J CLIN NUTR, V83, p520S; Lassen MG, 2010, J IMMUNOL, V184, P2693, DOI 10.4049/jimmunol.0901362; Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052; Nicholson JK, 2006, NATURE, V440, P992, DOI 10.1038/440992d; Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056; Shi FD, 2011, NAT REV IMMUNOL, V11, P658, DOI 10.1038/nri3065; SINGH IP, 1995, ANTIVIR RES, V27, P375, DOI 10.1016/0166-3542(95)00021-D; STRAYER DS, 1990, MICROB PATHOGENESIS, V9, P173, DOI 10.1016/0882-4010(90)90020-Q; Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463; Tillmann HL, 2010, GASTROENTEROLOGY, V139, P1586, DOI 10.1053/j.gastro.2010.07.005; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144; Wold William S. M., 1994, Trends in Microbiology, V2, P437, DOI 10.1016/0966-842X(94)90801-X	29	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-814611-8; 978-0-12-814610-1				2018							1	17		10.1016/B978-0-12-814610-1.00001-8			17	Pathology	Pathology	BM1RA	WOS:000460416000002					2019-10-28	
B	Mitchell, MG	Mitchell, MG			Mitchell, Maika G.	Mitchell, MG		Challenges in Molecular Pathology	MOLECULAR PATHOLOGY AND THE DYNAMICS OF DISEASE			English	Article; Book Chapter							EXTERNAL QUALITY ASSESSMENT; LUNG-CANCER; MUTATIONS; MELANOMA; THERAPY; PATIENT; GENES									Beadling C, 2011, J MOL DIAGN, V13, P504, DOI 10.1016/j.jmoldx.2011.04.003; Bellon E, 2011, ONCOLOGIST, V16, P467, DOI 10.1634/theoncologist.2010-0429; Blokx WAM, 2007, AM J SURG PATHOL, V31, P637, DOI 10.1097/PAS.0b013e318030718d; Bovee JVMG, 2010, VIRCHOWS ARCH, V456, P193, DOI 10.1007/s00428-009-0828-5; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dias SD, 2013, EUR J CANCER, V49, P1654, DOI 10.1016/j.ejca.2013.01.015; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Emile JF, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-472; Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002; Felsberg J., 2013, CLIN NEUROPATHOL, V32, P414; Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Geurts-Giele WRR, 2013, VIRCHOWS ARCH, V462, P249, DOI 10.1007/s00428-012-1346-4; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Lasota J, 2008, HISTOPATHOLOGY, V53, P245, DOI 10.1111/j.1365-2559.2008.02977.x; McCourt CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069604; Nowak Frederique, 2013, Am Soc Clin Oncol Educ Book, P332, DOI 10.1200/EdBook_AM.2013.33.332; Nowak F, 2012, NAT REV CLIN ONCOL, V9, P479, DOI 10.1038/nrclinonc.2012.42; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Raymaekers M, 2011, ACTA CLIN BELG, V66, P33, DOI 10.2143/ACB.66.1.2062511; Tops BBJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1015-5; Ulahannan D, 2013, BRIT J CANCER, V109, P827, DOI 10.1038/bjc.2013.416; van den Bent MJ, 2013, J NEURO-ONCOL, V112, P173, DOI 10.1007/s11060-013-1056-z; van der Sijp JRM, 2002, J CLIN ONCOL, V20, P1105, DOI 10.1200/JCO.20.4.1105; van Krieken JH, 2013, ANN ONCOL, V24, P1958, DOI 10.1093/annonc/mdt153; van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y; van Krieken JHJM, 2010, PROTEOM CLIN APPL, V4, P922, DOI 10.1002/prca.201000048; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096	29	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-814611-8; 978-0-12-814610-1				2018							19	54		10.1016/B978-0-12-814610-1.00002-X			36	Pathology	Pathology	BM1RA	WOS:000460416000003					2019-10-28	
B	Mitchell, MG	Mitchell, MG			Mitchell, Maika G.	Mitchell, MG		Review of Clinical Human Medical Genetics	MOLECULAR PATHOLOGY AND THE DYNAMICS OF DISEASE			English	Review; Book Chapter							BREAST-CANCER; EXPRESSION PATTERNS; RECURRENCE SCORE; DISTANT RECURRENCE; COMPLEMENTARY-DNA; CDNA MICROARRAY; PAM50 RISK; HYBRIDIZATION; IMPACT; IDENTIFICATION									Ahern TP, 2011, J NATL CANCER I, V103, P1558, DOI 10.1093/jnci/djr327; [Anonymous], 1996, NAT GENET, V14, P367, DOI [10.1038/ng1296-367, DOI 10.1038/NG1296-367]; Ashley EA, 2015, JAMA-J AM MED ASSOC, V313, P2119, DOI 10.1001/jama.2015.3595; AUGENLICHT LH, 1987, CANCER RES, V47, P6017; AUGENLICHT LH, 1991, P NATL ACAD SCI USA, V88, P3286, DOI 10.1073/pnas.88.8.3286; Nguyen B, 2012, ANN SURG ONCOL, V19, P3257, DOI 10.1245/s10434-012-2561-6; Blumencranz P, 2007, AM J SURG, V194, P426, DOI 10.1016/j.amjsurg.2007.07.008; Bubendorf L, 1999, J NATL CANCER I, V91, P1758, DOI 10.1093/jnci/91.20.1758; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cusumano PG, 2014, BREAST, V23, P423, DOI 10.1016/j.breast.2014.02.011; Debouck C, 1999, NAT GENET, V21, P48, DOI 10.1038/4475; DeRisi J, 1996, NAT GENET, V14, P457; Dowsett M, 2013, J CLIN ONCOL, V31, P2783, DOI 10.1200/JCO.2012.46.1558; DRMANAC R, 1992, ELECTROPHORESIS, V13, P566, DOI 10.1002/elps.11501301115; DRMANAC S, 1994, BIOTECHNIQUES, V17, P328; Drmanac S, 1996, GENOMICS, V37, P29, DOI 10.1006/geno.1996.0517; Exner R, 2014, BRIT J CANCER, V111, P837, DOI 10.1038/bjc.2014.339; Gnant M, 2014, ANN ONCOL, V25, P339, DOI 10.1093/annonc/mdt494; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gray JW, 2000, CARCINOGENESIS, V21, P443, DOI 10.1093/carcin/21.3.443; Handorf CR, 2013, AM J SURG PATHOL, V37, P1067, DOI 10.1097/PAS.0b013e31828309c4; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jaff S, 2015, LANCET, V385, P2448, DOI 10.1016/S0140-6736(15)61124-2; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Knezevic D, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-690; Kuhn K, 2004, GENOME RES, V14, P2347, DOI 10.1101/gr.2739104; Lo SS, 2010, J CLIN ONCOL, V28, P1671, DOI 10.1200/JCO.2008.20.2119; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; Maak M, 2013, ANN SURG, V257, P1053, DOI 10.1097/SLA.0b013e31827c1180; Mamounas EP, 2010, J CLIN ONCOL, V28, P1677, DOI 10.1200/JCO.2009.23.7610; Martin M, 2015, CURR MED RES OPIN, V31, P1129, DOI 10.1185/03007995.2015.1037730; Michael KL, 1998, ANAL CHEM, V70, P1242, DOI 10.1021/ac971343r; Mir KU, 2000, TRENDS GENET, V16, P63, DOI 10.1016/S0168-9525(99)01947-2; Moch H, 1999, AM J PATHOL, V154, P981, DOI 10.1016/S0002-9440(10)65349-7; Nystrom JS, 2012, ONCOTARGET, V3, P620; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips KA, 2006, NAT REV DRUG DISCOV, V5, P463, DOI 10.1038/nrd2033; Pillai R, 2011, J MOL DIAGN, V13, P48, DOI 10.1016/j.jmoldx.2010.11.001; Pollack JR, 1999, NAT GENET, V23, P41; Prat A, 2016, CLIN CANCER RES, V22, P560, DOI 10.1158/1078-0432.CCR-15-0630; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Schena M, 1996, P NATL ACAD SCI USA, V93, P10614, DOI 10.1073/pnas.93.20.10614; Sgroi DC, 1999, CANCER RES, V59, P5656; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; You YN, 2015, SURG ONCOL, V24, P61, DOI 10.1016/j.suronc.2015.02.001	47	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-814611-8; 978-0-12-814610-1				2018							55	76		10.1016/B978-0-12-814610-1.00003-1			22	Pathology	Pathology	BM1RA	WOS:000460416000004					2019-10-28	
B	Mitchell, MG	Mitchell, MG			Mitchell, Maika G.	Mitchell, MG		Molecular Medicine in Action	MOLECULAR PATHOLOGY AND THE DYNAMICS OF DISEASE			English	Article; Book Chapter																	0	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-814611-8; 978-0-12-814610-1				2018							77	149		10.1016/B978-0-12-814610-1.00004-3			73	Pathology	Pathology	BM1RA	WOS:000460416000005					2019-10-28	
B	Mitchell, MG	Mitchell, MG			Mitchell, Maika G.	Mitchell, MG		Mechanisms of Disease	MOLECULAR PATHOLOGY AND THE DYNAMICS OF DISEASE			English	Article; Book Chapter							HEPATITIS-C-VIRUS; NATURAL-KILLER-CELLS; COMPLEX CLASS-I; IMMUNOGLOBULIN-LIKE RECEPTORS; INFLUENZA-VIRUS; NK CELLS; HLA-C; INFECTED CELLS; IMMUNE-RESPONSES; INTERFERON-ALPHA									Abdul-Careem MF, 2012, J INFECT DIS, V206, P167, DOI 10.1093/infdis/jis340; Achdout H, 2003, J IMMUNOL, V171, P915, DOI 10.4049/jimmunol.171.2.915; Achdout H, 2008, J VIROL, V82, P8030, DOI 10.1128/JVI.00870-08; Achdout H, 2010, J VIROL, V84, P3993, DOI 10.1128/JVI.02289-09; Ahlenstiel G, 2008, J CLIN INVEST, V118, P1017, DOI 10.1172/JCI32400; Ahlenstiel G, 2010, GASTROENTEROLOGY, V138, P325, DOI 10.1053/j.gastro.2009.08.066; Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100; Alter G, 2011, NATURE, V476, P96, DOI 10.1038/nature10237; Alter G, 2011, J HEPATOL, V55, P278, DOI 10.1016/j.jhep.2010.11.030; Altfeld M, 2011, NAT REV IMMUNOL, V11, P176, DOI 10.1038/nri2935; Amadei B, 2010, GASTROENTEROLOGY, V138, P1536, DOI 10.1053/j.gastro.2010.01.006; Aranda-Romo S, 2012, IMMUNOGENETICS, V64, P653, DOI 10.1007/s00251-012-0623-3; Arase H, 2002, SCIENCE, V296, P1323, DOI 10.1126/science.1070884; Arnon TI, 2006, SEMIN CANCER BIOL, V16, P348, DOI 10.1016/j.semcancer.2006.07.005; Arnon TI, 2004, BLOOD, V103, P664, DOI 10.1182/blood-2003-05-1716; Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO;2-A; Asmal M, 2011, J VIROL, V85, P5465, DOI 10.1128/JVI.00313-11; Bashirova AA, 2011, ANNU REV IMMUNOL, V29, P295, DOI 10.1146/annurev-immunol-031210-101332; Beziat V, 2012, EUR J IMMUNOL, V42, P447, DOI 10.1002/eji.201141826; Bimber B, 2008, IMMUNOL RES, V40, P235, DOI 10.1007/s12026-007-8010-0; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BONAVITA MS, 1993, INT J TISSUE REACT, V15, P11; Bonorino P, 2009, J HEPATOL, V51, P458, DOI 10.1016/j.jhep.2009.05.030; Boulet S, 2008, AIDS, V22, P595, DOI 10.1097/QAD.0b013e3282f56b23; Brackenridge S, 2011, J VIROL, V85, P5415, DOI 10.1128/JVI.00238-11; Brainard DM, 2009, J VIROL, V83, P7305, DOI 10.1128/JVI.02207-08; Bubic I, 2004, J VIROL, V78, P7536, DOI 10.1128/JVI.78.14.7536-7544.2004; Bukh J, 2012, GASTROENTEROLOGY, V142, P1279, DOI 10.1053/j.gastro.2012.02.016; CALIGIURI MA, 1990, J EXP MED, V171, P1509, DOI 10.1084/jem.171.5.1509; Carneiro VL, 2010, LIVER INT, V30, P567, DOI 10.1111/j.1478-3231.2010.02212.x; Cerboni C, 2007, J GEN VIROL, V88, P242, DOI 10.1099/vir.0.82125-0; Cheent K, 2011, GUT, V60, P268, DOI 10.1136/gut.2010.212555; Choi EI, 2008, J VIROL, V82, P6758, DOI 10.1128/JVI.02277-07; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Colantonio AD, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001316; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Corado J, 1997, CLIN EXP IMMUNOL, V109, P451, DOI 10.1046/j.1365-2249.1997.4581355.x; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Crotta S, 2010, J HEPATOL, V52, P183, DOI 10.1016/j.jhep.2009.11.003; Daniels KA, 2001, J EXP MED, V194, P29, DOI 10.1084/jem.194.1.29; Day CL, 2002, J VIROL, V76, P12584, DOI 10.1128/JVI.76.24.12584-12595.2002; De Maria A, 2007, EUR J IMMUNOL, V37, P445, DOI 10.1002/eji.200635989; deHaas M, 1996, J IMMUNOL, V156, P2948; Denney L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010675; Desrosiers MP, 2005, NAT GENET, V37, P593, DOI 10.1038/ng1564; deVries E, 1996, BLOOD, V88, P3022, DOI 10.1182/blood.V88.8.3022.bloodjournal8883022; Doherty DG, 2000, IMMUNOL REV, V174, P5, DOI 10.1034/j.1600-0528.2002.017416.x; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; Dokun AO, 2001, NAT IMMUNOL, V2, P951, DOI 10.1038/ni714; Dong L, 2000, J INFECT DIS, V182, P391, DOI 10.1086/315727; Draghi M, 2007, J IMMUNOL, V178, P2688, DOI 10.4049/jimmunol.178.5.2688; Du N, 2010, J VIROL, V84, P7822, DOI 10.1128/JVI.00069-10; Dudek TE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003984; Duesberg U, 2001, J HEPATOL, V35, P650, DOI 10.1016/S0168-8278(01)00194-5; ENNIS FA, 1981, LANCET, V2, P891; Fadda L, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002805; Fadda L, 2011, J VIROL, V85, P5970, DOI 10.1128/JVI.00412-11; Fadda L, 2010, P NATL ACAD SCI USA, V107, P10160, DOI 10.1073/pnas.0913745107; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Flores-Villanueva PO, 2001, P NATL ACAD SCI USA, V98, P5140, DOI 10.1073/pnas.071548198; Fox A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031535; Gazit R, 2006, NAT IMMUNOL, V7, P517, DOI 10.1038/ni1322; Glasner A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036837; Golden-Mason L, 2008, GUT, V57, P1121, DOI 10.1136/gut.2007.130963; Golden-Mason L, 2004, CLIN EXP IMMUNOL, V138, P94, DOI 10.1111/j.1365-2249.2004.02586.x; Golden-Mason L, 2010, HEPATOLOGY, V52, P1581, DOI 10.1002/hep.23896; Grakoui A, 2003, SCIENCE, V302, P659, DOI 10.1126/science.1088774; Grebely J, 2010, HEPATOLOGY, V52, P1216, DOI 10.1002/hep.23850; Gregoire C, 2007, IMMUNOL REV, V220, P169, DOI 10.1111/j.1600-065X.2007.00563.x; Guidotti LG, 2001, ANNU REV IMMUNOL, V19, P65, DOI 10.1146/annurev.immunol.19.1.65; Guidotti LG, 2006, ANNU REV PATHOL-MECH, V1, P23, DOI 10.1146/annurev.pathol.1.110304.100230; Gunturi A, 2004, IMMUNOL RES, V30, P29, DOI 10.1385/IR:30:1:029; Guo HL, 2009, IMMUNOL CELL BIOL, V87, P579, DOI 10.1038/icb.2009.60; Guo XC, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-215; Hansasuta P, 2004, EUR J IMMUNOL, V34, P1673, DOI 10.1002/eji.200425089; Harrison RJ, 2010, CLIN EXP IMMUNOL, V161, P306, DOI 10.1111/j.1365-2249.2010.04169.x; HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785; Hayakawa Y, 2010, METHODS MOL BIOL, V612, P27, DOI 10.1007/978-1-60761-362-6_3; He XS, 2006, J VIROL, V80, P11756, DOI 10.1128/JVI.01460-06; Hellmann I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002436; Heltzer ML, 2009, J LEUKOCYTE BIOL, V85, P1036, DOI 10.1189/jlb.1108710; Herzer K, 2003, J VIROL, V77, P8299, DOI 10.1128/JVI.15.8299-8309.2003; Jawahar S, 1996, CLIN EXP IMMUNOL, V103, P408; Jegerlehner A, 2004, J IMMUNOL, V172, P5598, DOI 10.4049/jimmunol.172.9.5598; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Jinushi M, 2004, J IMMUNOL, V173, P6072, DOI 10.4049/jimmunol.173.10.6072; Jonsson AH, 2009, ADV IMMUNOL, V101, P27, DOI 10.1016/S0065-2776(08)01002-X; Jost S, 2012, MICROBES INFECT, V14, P904, DOI 10.1016/j.micinf.2012.05.001; Jost S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025060; Jost S, 2011, IMMUNOLOGY, V132, P516, DOI 10.1111/j.1365-2567.2010.03394.x; Katz G, 2004, J IMMUNOL, V173, P1819, DOI 10.4049/jimmunol.173.3.1819; Kenneson A, 2007, REV MED VIROL, V17, P253, DOI 10.1002/rmv.535; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Kielczewska A, 2009, J EXP MED, V206, P515, DOI 10.1084/jem.20080954; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Knapp S, 2010, HEPATOLOGY, V51, P1168, DOI 10.1002/hep.23477; Kramer B, 2012, HEPATOLOGY, V56, P1201, DOI 10.1002/hep.25804; Kulkarni S, 2011, NATURE, V472, P495, DOI 10.1038/nature09914; La D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029200; Lassen MG, 2010, J IMMUNOL, V184, P2693, DOI 10.4049/jimmunol.0901362; Lauer GM, 2002, J VIROL, V76, P6104, DOI 10.1128/JVI.76.12.6104-6113.2002; Lavanchy D, 2009, LIVER INT, V29, P74, DOI 10.1111/j.1478-3231.2008.01934.x; Liu BX, 2004, J GEN VIROL, V85, P423, DOI 10.1099/vir.0.19596-0; Long BR, 2008, CLIN VACCINE IMMUNOL, V15, P120, DOI 10.1128/CVI.00357-07; Lopez-Vazquez A, 2005, J INFECT DIS, V192, P162, DOI 10.1086/430351; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Mao HW, 2009, J VIROL, V83, P9215, DOI 10.1128/JVI.00805-09; Marangon AV, 2011, HUM IMMUNOL, V72, P1074, DOI 10.1016/j.humimm.2011.08.017; Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; McGeoch DJ, 2000, J VIROL, V74, P10401, DOI 10.1128/JVI.74.22.10401-10406.2000; Moesta AK, 2008, J IMMUNOL, V180, P3969, DOI 10.4049/jimmunol.180.6.3969; Mondelli MU, 2010, EUR J CLIN INVEST, V40, P851, DOI 10.1111/j.1365-2362.2010.02332.x; Morens DM, 2011, REV MED VIROL, V21, P262, DOI 10.1002/rmv.689; Morishima C, 2006, HEPATOLOGY, V43, P573, DOI 10.1002/hep.21073; Narni-Mancinelli E, 2012, SCIENCE, V335, P344, DOI 10.1126/science.1215621; Nattermann J, 2006, GUT, V55, P869, DOI 10.1136/gut.2005.076463; Nattermann J, 2005, AM J PATHOL, V166, P443, DOI 10.1016/S0002-9440(10)62267-5; Nogusa S, 2008, MECH AGEING DEV, V129, P223, DOI 10.1016/j.mad.2008.01.003; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Oliviero B, 2009, GASTROENTEROLOGY, V137, P1151, DOI 10.1053/j.gastro.2009.05.047; Orange JS, 2002, MICROBES INFECT, V4, P1545, DOI 10.1016/S1286-4579(02)00038-2; Owen RE, 2007, J VIROL, V81, P11170, DOI 10.1128/JVI.01217-07; Paladino N, 2007, TISSUE ANTIGENS, V69, P109, DOI 10.1111/j.1399-0039.2006.762_7.x; Par G, 2002, J HEPATOL, V37, P514, DOI 10.1016/S0168-8278(02)00218-0; Parsons MS, 2010, J INFECT DIS, V202, pS356, DOI 10.1086/655966; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Pegram HJ, 2011, IMMUNOL CELL BIOL, V89, P216, DOI 10.1038/icb.2010.78; Pelletier S, 2010, J HEPATOL, V53, P805, DOI 10.1016/j.jhep.2010.05.013; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Rauch A, 2007, TISSUE ANTIGENS, V69, P237, DOI 10.1111/j.1399-0039.2006.773_4.x; Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056; Ravet S, 2007, BLOOD, V109, P4296, DOI 10.1182/blood-2006-08-040238; REYNOLDS CW, 1981, J IMMUNOL, V127, P282; Romero V, 2008, MOL IMMUNOL, V45, P2429, DOI 10.1016/j.molimm.2008.01.002; Rosner C, 2011, J IMMUNOL, V186, P2156, DOI 10.4049/jimmunol.1002634; Schmitz JE, 1999, SCIENCE, V283, P857, DOI 10.1126/science.283.5403.857; Shi FD, 2011, NAT REV IMMUNOL, V11, P658, DOI 10.1038/nri3065; Stein-Streilein J, 1988, Reg Immunol, V1, P100; STEINSTREILEIN J, 1986, J IMMUNOL, V136, P1435; STEINSTREILEIN J, 1983, J IMMUNOL, V131, P2699; Stewart CA, 2005, P NATL ACAD SCI USA, V102, P13224, DOI 10.1073/pnas.0503594102; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Sun Y, 2011, J VIROL, V85, P6906, DOI 10.1128/JVI.00326-11; Thananchai H, 2009, AIDS, V23, P189, DOI 10.1097/QAD.0b013e32831fb55a; Thananchai H, 2007, J IMMUNOL, V178, P33, DOI 10.4049/jimmunol.178.1.33; Thomas DL, 2009, NATURE, V461, P798, DOI 10.1038/nature08463; Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237; Thompson WW, 2009, INFLUENZA OTHER RESP, V3, P37, DOI 10.1111/j.1750-2659.2009.00073.x; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Tillmann HL, 2010, GASTROENTEROLOGY, V139, P1586, DOI 10.1053/j.gastro.2010.07.005; Tseng CTK, 2002, J EXP MED, V195, P43, DOI 10.1084/jem.20011145; Ulsenheimer A, 2003, HEPATOLOGY, V37, P1189, DOI 10.1053/jhep.2003.50194; Valentine LE, 2008, TRENDS MICROBIOL, V16, P605, DOI 10.1016/j.tim.2008.08.010; Verbist KC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037539; Vidal-Castineira JR, 2010, J VIROL, V84, P475, DOI 10.1128/JVI.01285-09; Virgin HW, 2010, NATURE, V464, P224, DOI 10.1038/nature08898; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Wang SH, 2008, J VIRAL HEPATITIS, V15, P855, DOI 10.1111/j.1365-2893.2008.01014.x; Watkins DI, 2008, NAT MED, V14, P617, DOI 10.1038/nm.f.1759; Webster RL, 2005, IMMUNOLOGY, V115, P206, DOI 10.1111/j.1365-2567.2005.02147.x; Welsch C, 2012, GUT, V61, P36, DOI 10.1136/gutjnl-2012-302144; Wen CY, 2008, CELL MOL IMMUNOL, V5, P475, DOI 10.1038/cmi.2008.60; World Health Organization, 2009, INFL SEAS; Yawata M, 2008, BLOOD, V112, P2369, DOI 10.1182/blood-2008-03-143727; Yoon JC, 2009, HEPATOLOGY, V49, P12, DOI 10.1002/hep.22624; Zhang M, 2004, GLYCOBIOLOGY, V14, P1229, DOI 10.1093/glycob/cwh106; Zuniga J, 2009, MOL IMMUNOL, V46, P2723, DOI 10.1016/j.molimm.2009.05.014	172	0	0	0	0	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND			978-0-12-814611-8; 978-0-12-814610-1				2018							151	167		10.1016/B978-0-12-814610-1.00005-5			17	Pathology	Pathology	BM1RA	WOS:000460416000006					2019-10-28	
J	Erturk, N				Ertuerk, Nazile			Umbilical Cord Diameter at the Junction of the Body Wall in the Newborn. Is It a Biomarker for Congenital Umbilical Hernia?	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Birth weight; congenital umbilical cord hernia; umbilical cord circumference; umbilical cord diameter		Introduction: The aim is to obtain normal newborn umbilical cord diameters for use it in the evaluation of congenital umbilical hernia. Materials and methods: The umbilical cord diameter (UCD) at the abdominal wall, maternal age, birth weight, gestational age at birth, birth height, head, chest and abdominal circumferences, and the time of measurement after birth was noted. Results: Mean +/- standard deviation and median (minimum-maximum) values of the UCD were 9.9 +/- 1.9 mm, 10.0 (5-16 mm), respectively. There was a significance for a positive low correlation between birth height and UCD (p = .039, r = .143). No other birth parameter had a significant correlation with UCD. The gender of the newborn (p = .95) and the type of delivery (p = .056) did not affect UCD. Conclusion: These data may be used in determining the normality of UCD, which could be helpful in the evaluation of umbilical hernias.	[Ertuerk, Nazile] Mugla Sitki Kocman Univ, Dept Pediat Surg, Fac Med, Haluk Ozsoy Caddesi Mentese, TR-48000 Mugla, Turkey	Erturk, N (reprint author), Mugla Sitki Kocman Univ, Dept Pediat Surg, Fac Med, Haluk Ozsoy Caddesi Mentese, TR-48000 Mugla, Turkey.	erturknazile@gmail.com		Erturk, Nazile/0000-0001-9541-9741			ACHIRON R, 1995, ULTRASOUND OBST GYN, V6, P256, DOI 10.1046/j.1469-0705.1995.06040256.x; Billard C.M, 1839, AM J MED SCI, V25, P360; ChapmanSheath P, 1996, BRIT MED J, V313, P613; ENTE G, 1991, J ROY SOC HEALTH, V111, P138, DOI 10.1177/146642409111100406; Fahmy M, 2018, UMBILICUS AND UMBILICAL CORD, P199, DOI 10.1007/978-3-319-62383-2_32; Ghezzi F, 2001, ULTRASOUND OBST GYN, V18, P348, DOI 10.1046/j.0960-7692.2001.00507.x; Haas J, 2011, J ULTRAS MED, V30, P1629, DOI 10.7863/jum.2011.30.12.1629; Harder T, 2007, AM J EPIDEMIOL, V165, P849, DOI 10.1093/aje/kwk071; HILL LM, 1994, J CLIN ULTRASOUND, V22, P435, DOI 10.1002/jcu.1870220704; Ince E, 2017, HERNIA, V21, P449, DOI 10.1007/s10029-016-1544-0; Jaya D S, 1995, Indian Pediatr, V32, P1183; KLEIN MD, 1981, SURG GYNECOL OBSTET, V152, P805; Kosif R, 2010, MED B ZEYNEP KAMIL, V41, P129; MILLER ME, 1982, J PEDIATR-US, V101, P844, DOI 10.1016/S0022-3476(82)80344-2; MOESSINGER AC, 1982, PEDIATR RES, V16, P109, DOI 10.1203/00006450-198202000-00006; Nanaev AK, 1997, PLACENTA, V18, P53, DOI 10.1016/S0143-4004(97)90071-0; NOVACK AH, 1988, AM J DIS CHILD, V142, P220, DOI 10.1001/archpedi.1988.02150020122046; Pal Kamalesh, 2014, Afr J Paediatr Surg, V11, P74, DOI 10.4103/0189-6725.129241; PATEL D, 1989, AM J DIS CHILD, V143, P638, DOI 10.1001/archpedi.1989.02150180016002; Predanic M., 2005, ULTRASOUND REV OBSTE, V5, P105; SEASHORE J H, 1978, Clinics in Perinatology, V5, P61; Shen YL, 2004, CHEMPHYSCHEM, V5, P16, DOI 10.1002/cphc.200300942; SORNES T, 1989, ACTA OBSTET GYN SCAN, V68, P609, DOI 10.3109/00016348909013279; Varghese AS, 2017, ARCH DIS CHILDHOOD-E, V102, P19, DOI 10.1136/archdischild-2015-309030	24	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					223	230		10.1080/15513815.2018.1477886			8	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000001	30148418				2019-10-28	
J	Kittipornpechdee, N; Hanamornroongruang, S; Lekmak, D; Treetipsatit, J				Kittipornpechdee, Napaputch; Hanamornroongruang, Suchanan; Lekmak, Duanphen; Treetipsatit, Jitsupa			Fetal and Placental Pathology in Congenital Syphilis: A Comprehensive Study in Perinatal Autopsy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Congenital syphilis; intrauterine syphilis infection; fetal syphilis	TREPONEMA-PALLIDUM; SECONDARY SYPHILIS; STILLBORN INFANT	Introduction: At autopsy, without available serologic information, diagnosing congenital syphilis (CS) relies on identification of Treponema pallidum in tissues. Recognition of clues leading to detection of the organism is important. Materials and methods: Autopsy cases with CS were studied for fetal and placental abnormalities. Results: Twenty-one cases were recruited: 12/21 with identifiable T. pallidum and 9/21 with positive serology and characteristics of CS. 20/21 (95%) demonstrated >= 1 fetal abnormalities. Chronic stress involution of thymus was most common. Hydrops and hepatosplenomegaly were found in >50%. Metaphyseal abnormalities and organ inflammation were found in <30%. Mucocutaneous lesions were lacking. Placental abnormalities were identified in 20/21 (95%). Placentomegaly was most common. Amniotic fluid infection (AFI) was noted in >50%. Conclusion: Common findings in CS at autopsy include chronic stress involution of thymus, hydrops, and hepatosplenomegaly. Mucocutaneous lesions are uncommon. Common placental findings in fetal deaths due to CS include placentomegaly and AFI.	[Kittipornpechdee, Napaputch; Hanamornroongruang, Suchanan; Lekmak, Duanphen; Treetipsatit, Jitsupa] Mahidol Univ, Siriraj Hosp, Dept Pathol, Fac Med, 2 Prannok Rd, Bangkok 10700, Thailand	Treetipsatit, J (reprint author), Mahidol Univ, Siriraj Hosp, Dept Pathol, Fac Med, 2 Prannok Rd, Bangkok 10700, Thailand.	jitsupa.tre@mahidol.ac.th			Faculty of Medicine Siriraj Hospital, Mahidol University [(IO) R016031043]	The authors declare that they have no conflict of interest. This research project was supported by Faculty of Medicine Siriraj Hospital, Mahidol University [Grant Number (IO) R016031043].	Bartlett JH, 2013, BANCROFTS THEORY PRA, P299; Bell C, 2002, ARCH PATHOL LAB MED, V126, P484; Bembry W, 2018, CLIN PEDIATR, V57, P992, DOI 10.1177/0009922817738343; Benzick AE, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.1.e4; BRION LP, 1991, PEDIATRICS, V88, P1037; Buffet M, 2007, J INVEST DERMATOL, V127, P2345, DOI 10.1038/sj.jid.5700888; DAFFOS F, 1984, LANCET, V2, P1; Elston DM, 2015, HDB PRACTICAL IMMUNO, P641; Ernst LM, 2011, COLOR ATLAS FETAL NE, P241; Faye-Petersen OM, 2015, ADV ANAT PATHOL, V22, P71, DOI 10.1097/PAP.0000000000000060; George CR, 2015, KEELINGS FETAL NEONA, P219; Gersell DJ, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P999, DOI 10.1007/978-1-4419-0489-8_19; Gilbert-Barness E, 2014, HDB PEDIAT AUTOPSY P, P569; GREENBERG SB, 1992, RADIOLOGY, V182, P637, DOI 10.1148/radiology.182.3.1535873; Heller DS, 2015, ADV ANAT PATHOL, V22, P1, DOI 10.1097/PAP.0000000000000054; Hoang MP, 2004, J CUTAN PATHOL, V31, P595, DOI 10.1111/j.0303-6987.2004.00236.x; Hollier LM, 2001, OBSTET GYNECOL, V97, P947, DOI 10.1016/S0029-7844(01)01367-9; Kaschula RO, 2014, PEDIAT PERINATAL AUT, P329; KNOWLES S, 1989, J CLIN PATHOL, V42, P1157, DOI 10.1136/jcp.42.11.1157; McClure EM, 2010, CLIN OBSTET GYNECOL, V53, P635, DOI 10.1097/GRF.0b013e3181eb6620; NORGARD MV, 1995, INFECT IMMUN, V63, P1507; Phelps RG, 2000, INT J DERMATOL, V39, P609, DOI 10.1046/j.1365-4362.2000.00029.x; Qin JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102203; Rac MWF, 2017, AM J OBSTET GYNECOL, V216, P352, DOI 10.1016/j.ajog.2016.11.1052; Rac MWF, 2014, AM J OBSTET GYNECOL, V211, DOI 10.1016/j.ajog.2014.05.049; RILEY BS, 1992, J INFECT DIS, V165, P484, DOI 10.1093/infdis/165.3.484; Sangtawesin Varaporn, 2005, Journal of the Medical Association of Thailand, V88, P1519; SATIN AJ, 1992, J ULTRAS MED, V11, P49; Schwartz DA, 2017, ARCH GYNECOL OBSTET, V295, P1361, DOI 10.1007/s00404-017-4361-5; Sheffield JS, 2002, OBSTET GYNECOL, V100, P126, DOI 10.1016/S0029-7844(02)02010-0; Smith J, 1995, S AFR MED J, V85, P1232; SUGIURA H, 1988, ACTA PATHOL JAPON, V38, P1061; Taweevisit M, 2015, FETAL PEDIATR PATHOL, V34, P140, DOI 10.3109/15513815.2014.999391; Wang EA, 2018, PEDIATR DERMATOL, V35, pE110, DOI 10.1111/pde.13380; WENDEL GD, 1991, OBSTET GYNECOL, V78, P890; YOUNG SA, 1994, ARCH PATHOL LAB MED, V118, P44; Zou YR, 2017, AM J SURG PATHOL, V41, P1283, DOI 10.1097/PAS.0000000000000893	37	0	0	3	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					231	242		10.1080/15513815.2018.1485798			12	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000002	30207805				2019-10-28	
J	Chin, TF; Ibrahim, K; Thirunavakarasu, T; Azanan, MS; Oh, L; Lum, SH; Yap, TY; Ariffin, H				Chin, Tong Foh; Ibrahim, Kamariah; Thirunavakarasu, Tharshanadevasheri; Azanan, Mohamad Shafiq; Oh, Lixian; Lum, Su Han; Yap, Tsiao Yi; Ariffin, Hany			Nonclonal Chromosomal Aberrations in Childhood Leukemid Survivors	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Childhood leukemia survivors; karyotypic abnormalities; genomic instability	ACUTE LYMPHOBLASTIC-LEUKEMIA; CANCER; ANEUPLOIDY; MONOSOMY; RISK; INSTABILITY; CHILDREN	Background: Survivors of childhood cancer are at risk of developing a second malignancy. One possible mechanism for neoplastic transformation of cells is through induction of persistent genomic instability. This study aims to seek evidence of chromosomal instability in long-term childhood leukemia survivors (CLS) in one of the largest pediatric academic oncology centers in South East Asia. Methods: 50 asymptomatic (subjects have remained leukemia-free since treatment cessation) CLS and 50 healthy controls were recruited in this cross-sectional study. Of 50 CLS, 44 had acute lymphoblastic leukemia and 6 had acute myeloid leukemia. G-banded karyotyping was performed on unstimulated peripheral blood leukocytes of all subjects. Results: CLS had significantly higher occurrence of karyotypic abnormalities compared to controls. Five CLS harbored six nonclonal abnormalities (mostly aneuploidy) while none were found in controls. Conclusion: Subpopulations with nonclonal chromosomal aberrations were present in peripheral blood leukocytes of our cohort of childhood leukemia long-term survivors.	[Chin, Tong Foh; Thirunavakarasu, Tharshanadevasheri; Azanan, Mohamad Shafiq; Oh, Lixian; Lum, Su Han; Yap, Tsiao Yi; Ariffin, Hany] Univ Malaya, Dept Paediat, Fac Med, Kuala Lumpur, Malaysia; [Chin, Tong Foh; Thirunavakarasu, Tharshanadevasheri; Azanan, Mohamad Shafiq; Oh, Lixian; Ariffin, Hany] Univ Malaya, Dept Paediat, Med Ctr, Kuala Lumpur 59100, Malaysia; [Ibrahim, Kamariah] Univ Malaya, Dept Biomed Sci, Fac Med, Kuala Lumpur, Malaysia	Ariffin, H (reprint author), Univ Malaya, Dept Paediat, Med Ctr, Kuala Lumpur 59100, Malaysia.	hany@ummc.edu.my	Azanan, Mohamad Shafiq/N-9369-2016; Yi, Yap Tsiao/W-6510-2018; ARIFFIN, HANY/B-8590-2010	Chin, Tong Foh/0000-0001-5715-5183	Ministry of Higher Education, MalaysiaMinistry of Education, Malaysia [UMRG RP049-17HTM]; University of MalayaUniversiti Malaya [BK072-2016]	This work was supported by grants from the Ministry of Higher Education, Malaysia [UMRG RP049-17HTM] and University of Malaya [BK072-2016]	Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Ariyoshi K, 2016, MUTAT RES-FUND MOL M, V790, P19, DOI 10.1016/j.mrfmmm.2016.06.001; Durrbaum M, 2016, FEBS J, V283, P791, DOI 10.1111/febs.13591; Duesberg P, 2004, CELL CYCLE, V3, P823; Friedman DL, 2010, JNCI-J NATL CANCER I, V102, P1083, DOI 10.1093/jnci/djq238; Parra-Perez FAG, 2012, ONCOL LETT, V3, P445, DOI 10.3892/ol.2011.484; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Gramatges MM, 2014, CLIN CANCER RES, V20, P904, DOI 10.1158/1078-0432.CCR-13-2076; Hardy P, 2012, AM J MED GENET A, V158A, P2050, DOI 10.1002/ajmg.a.35462; Kovacevic Z, 2006, CARCINOGENESIS, V27, P2355, DOI 10.1093/carcin/bgl146; MAGNUSON T, 1982, J EMBRYOL EXP MORPH, V69, P223; Mody R, 2008, BLOOD, V111, P5515, DOI 10.1182/blood-2007-10-117150; Passerini V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10754; Pui CH, 2012, BLOOD, V120, P1165, DOI 10.1182/blood-2012-05-378943; Riemann K, 2004, CANCER GENET CYTOGEN, V150, P128, DOI 10.1016/j.cancergencyto.2003.10.013; ROBISON LL, 1982, CANCER RES, V42, P4289; Rossner P, 2005, ENVIRON HEALTH PERSP, V113, P517, DOI 10.1289/ehp.6925; SCHULER D, 1981, HUM GENET, V56, P339, DOI 10.1007/BF00274689; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Thorn CF, 2011, PHARMACOGENET GENOM, V21, P440, DOI 10.1097/FPC.0b013e32833ffb56; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Tucker JD, 1996, MUTAT RES-REV GENET, V365, P147, DOI 10.1016/S0165-1110(96)90018-4; van Jaarsveld RH, 2016, TRENDS CANCER, V2, P561, DOI 10.1016/j.trecan.2016.09.003; VIG BK, 1971, CANCER RES, V31, P32; WINQVIST R, 1995, CANCER RES, V55, P2660; Ye CJ, 2009, J CELL PHYSIOL, V219, P288, DOI 10.1002/jcp.21663; Yeoh AEJ, 2012, J CLIN ONCOL, V30, P2384, DOI 10.1200/JCO.2011.40.5936; Yoshihara T, 2005, BONE MARROW TRANSPL, V35, P587, DOI 10.1038/sj.bmt.1704860	29	2	2	2	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					243	253		10.1080/15513815.2018.1492054			11	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000003	30273079				2019-10-28	
J	Sharma, B; Kakkar, N; Aggarwal, N; Suri, V; Choudhary, N; Raina, A				Sharma, Bharti; Kakkar, Nandita; Aggarwal, Neelam; Suri, Vanita; Choudhary, Neelam; Raina, Ankit			Role of Autopsy in Elective Termination of Pregnancy for Fetal Anomaly (ETOPFA): A Study from a Tertiary Care Hospital in India	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Autopsy; ETOPFA; congenital anomaly; prenatal diagnosis		Objective: To evaluate the fetal anomalies in all the patients who underwent elective termination of pregnancy for fetal anomalies (ETOPFA) before 20 weeks of gestation and to compare prenatal diagnosis with final diagnosis made after autopsy. Methodology: Prospective study done in a tertiary care hospital in India over a period of two years which include 252 women who underwent ETOPFA. The prenatal diagnosis was compared with final diagnosis made after autopsy. Results: In 75.4% of cases autopsy findings were concordant with prenatal diagnosis where as in 21.6% of cases, additional findings were added. In 2.9 % of cases prenatal diagnosis was not confirmed by autopsy and found to be discordant. Conclusions: Autopsy plays an important role in completing the final diagnosis along with verification of prenatal diagnosis. To avoid discrepancy especially in cases of severe oligohydramnios, MRI or amnioinfusion could be offered for conformation of the diagnosis before offering ETOPFA.	[Sharma, Bharti; Aggarwal, Neelam; Suri, Vanita; Raina, Ankit] PGIMER Chandigarh, Dept Obstet & Gynaecol, Chandigarh 160012, India; [Kakkar, Nandita] PGIMER Chandigarh, Dept Histopathol, Chandigarh, India; [Choudhary, Neelam] PGIMER Chandigarh, Post Partum Unit, Chandigarh, India; [Raina, Ankit] Soc Appl Sci, New Delhi, India	Aggarwal, N (reprint author), PGIMER Chandigarh, Dept Obstet & Gynaecol, Chandigarh 160012, India.	drneelamaggarwal@gmail.com					[Anonymous], OMIM; Boyd PA, 2004, BRIT MED J, V328, P137, DOI 10.1136/bmj.37939.570104.EE; Curry CJ, 1992, PEDIATR CLIN N AM, V39, P36; Griffiths PD, 2005, LANCET, V365, P1271, DOI 10.1016/S0140-6736(05)74816-9; Griffiths PD, 2003, AM J NEURORADIOL, V24, P22; Radestad I, 1998, MIDWIFERY, V14, P111, DOI 10.1016/S0266-6138(98)90008-0; Royal College of Obstetricians and Gynaecologists, 2010, GREEN TOP GUID 55 LA; SALLER DN, 1995, JAMA-J AM MED ASSOC, V273, P663, DOI 10.1001/jama.273.8.663; Sankar VH, 2006, J PERINATOL, V26, P224, DOI 10.1038/sj.jp.7211482; Vikraman SK, 2017, EUR J OBSTET GYN R B, V212, P96, DOI 10.1016/j.ejogrb.2017.03.026; Votino C, 2018, ULTRASOUND OBST GYN, V52, P776, DOI 10.1002/uog.14642; WHO-March of Dimes, 2006, JOINT WHO MARCH DIM	12	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					254	262		10.1080/15513815.2018.1492655			9	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000004	30188228				2019-10-28	
J	Pani, E; Martin, A; Buccoliero, A; Ghionzoli, M; Messineo, A				Pani, Elisa; Martin, Alessandra; Buccoliero, Annamaria; Ghionzoli, Marco; Messineo, Antonio			Giant Ovarian Lymphangioma: Case Report and Review of the Literature	FETAL AND PEDIATRIC PATHOLOGY			English	Review						Ovarian lymphangioma; lymphatic system; pediatric age; abdominal distension; endothelial marker D-240	CYSTIC LYMPHANGIOMA	Introduction: Lymphangiomas are benign tumors/malformations, characterized by proliferation of the lymphatic vessels. They may arise anywhere, although the most common localizations are the head-neck region and the axilla. To date, only 21 cases of lymphangioma of the ovary in a 60-year literature survey have been reported. Case report: A 16-year-old female patient with long standing abdominal distension had 40 cm x 15 cm x 29 cm ovarian lymphangioma. Conclusions: Our case highlights that lymphangiomas can occur in the adolescent population and should be added to the differential diagnosis of ovarian masses in this age group.	[Ghionzoli, Marco] Univ Florence, Dept Pediat Surg, Viale Pieraccini 24, Florence, Italy; [Ghionzoli, Marco] Childrens Univ Hosp, Viale Pieraccini 24, Florence, Italy	Ghionzoli, M (reprint author), Univ Florence, Dept Pediat Surg, Viale Pieraccini 24, Florence, Italy.; Ghionzoli, M (reprint author), Childrens Univ Hosp, Viale Pieraccini 24, Florence, Italy.	marcoghionzoli@hotmail.com					Ahluwalia J, 2000, ACTA OBSTET GYN SCAN, V79, P894, DOI 10.1034/j.1600-0412.2000.079010894.x; Akyildiz E U, 2006, J BUON, V11, P91; ARISTIZABAL SA, 1977, LYMPHOLOGY, V10, P219; Bhavsar Tapan, 2010, World J Gastrointest Pathophysiol, V1, P171, DOI 10.4291/wjgp.v1.i5.171; BIENIASZ A, 1961, Ginekol Pol, V32, P667; Bonhomme A, 2001, CLIN RADIOL, V56, P156, DOI 10.1053/crad.2000.0162; Dowd CN, 1913, ANN SURG, V58, P112, DOI 10.1097/00000658-191307000-00012; Enzinger FM, 1988, SOFT TISSUE TUMORS, P614; Evans A, 1999, INT J GYNECOL PATHOL, V18, P87, DOI 10.1097/00004347-199901000-00014; FERRARI W, 1953, Rev Bras Cir, V25, P329; Goyal S, 2015, J OBSTET GYNAECOL, V35, P535, DOI 10.3109/01443615.2014.969210; Hauser H, 1997, EUR J SURG ONCOL, V23, P322, DOI 10.1016/S0748-7983(97)90777-0; Heinig J, 2002, EUR J OBSTET GYN R B, V103, P191, DOI 10.1016/S0301-2115(02)00044-1; Iwasa T, 2009, J OBSTET GYNAECOL RE, V35, P812, DOI 10.1111/j.1447-0756.2009.01016.x; Jain D, 2009, J OBSTET GYNAECOL, V29, P260, DOI 10.1080/01443610902755635; Jallouli Mohamed, 2011, J Pediatr Adolesc Gynecol, V24, pe9, DOI 10.1016/j.jpag.2010.08.008; Kearney CE, 2001, CLIN RADIOL, V56, P685, DOI 10.1053/crad.2000.0575; KHANNA S, 1978, INT SURG, V63, P104; Koening TR, 2001, AM J ROENTGENOL, V177, P1090, DOI 10.2214/ajr.177.5.1771090; Logani K B, 1997, J Indian Med Assoc, V95, P152; Naik Sejal Arunbhai, 2011, J Gynecol Endosc Surg, V2, P97, DOI 10.4103/0974-1216.114159; Palliez R, 1970, Bull Fed Soc Gynecol Obstet Lang Fr, V22, P51; Park C, 2005, J CLIN ULTRASOUND, V33, P421, DOI 10.1002/jcu.20151; Pillai S, 2013, INT J GYNECOL PATHOL, V32, P171, DOI 10.1097/PGP.0b013e31825b81fd; Radhouane A, 2016, EUR J OBSTET GYN R B, V203, P342, DOI 10.1016/j.ejogrb.2016.06.014; ROISMAN I, 1989, BRIT J SURG, V76, P485, DOI 10.1002/bjs.1800760519; Singer T, 2010, J MINIM INVAS GYN, V17, P97, DOI 10.1016/j.jmig.2009.09.005; Sinhasan SP, 2015, INDIAN J CANCER, V52, P380, DOI 10.4103/0019-509X.176730; Zhu JW, 2014, CUTIS, V93, P316	29	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					263	269		10.1080/15513815.2018.1502382			7	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000005	30188242				2019-10-28	
J	Soyer, T; Aydin, B; Orhan, D; Tanyel, FC				Soyer, Tutku; Aydin, Burca; Orhan, Diclehan; Tanyel, Feridun C.			Neuroencorine Tumor Arising within a Tailgut Cyst in an Adolesceni Boy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Neuroendocrine tumor; tailgut cyst; children	CARCINOID-TUMOR; CHILDREN	Introduction: Neuroendocrine tumors (NET) within tailgut cysts (TC) are usually seen in middle-aged females. A 14 year-old boy who underwent surgical excision of NET within TC is presented to discuss the clinical features, diagnosis and treatment options. Case report: A 14-year-old boy with rectal bleeding and constipation had a 5 x 4 cm mass detected upon rectal examination. The cystic mass was totally excised. The histopathological evaluation revealed a low-grade NET within mucularis layer of the cyst showing a positive immunhistochemical staining for cytokeratin and synaptophysin. Conclusion: Although, the malignant transition of TC is commonly observed in middle age females, males and children can also be affected. This is first report of a pediatric TC with malignant transformation. Total surgical excision of cysts is mandatory for local control of the disease and chemotherapy should be reserved for the patients who have positive surgical margins.	[Soyer, Tutku; Tanyel, Feridun C.] Hacettepe Univ, Fac Med, Pediat Surg, Ankara, Turkey; [Aydin, Burca] Hacettepe Univ, Fac Med, Pediat Oncol, Ankara, Turkey; [Orhan, Diclehan] Hacettepe Univ, Fac Med, Pediat Pathol, Ankara, Turkey	Soyer, T (reprint author), Hacettepe Univ, Fac Med, Dept Pediat Surg, TR-06100 Ankara, Turkey.	soyer.tutku@gmail.com					Abukar AA, 2014, CASE REP SURG, DOI 10.1155/2014/454502; Antao B, 2004, EUR J PEDIATR SURG, V14, P212, DOI 10.1055/s-2004-815872; Haider N, 2015, PEDIATR SURG INT, V31, P597, DOI 10.1007/s00383-015-3704-1; HJERMSTAD BM, 1988, AM J CLIN PATHOL, V89, P139, DOI 10.1093/ajcp/89.2.139; Kim JH, 2014, SCOT MED J, V59, pE14, DOI 10.1177/0036933013519029; Mathis KL, 2010, BRIT J SURG, V97, P575, DOI 10.1002/bjs.6915; Prasad AR, 2000, ARCH PATHOL LAB MED, V124, P725; Rafindadi AH, 1998, E AFR MED J, V75, P726; Raisolsadat SM, 2003, IRAN J PEDIATR, V23, P597; Redlich A, 2013, KLIN PADIATR, V225, P315, DOI 10.1055/s-0033-1355353; Song DE, 2004, ARCH PATHOL LAB MED, V128, P578; Sriganeshan V, 2006, ARCH PATHOL LAB MED, V130, P77; 김금래, 2008, [Journal of The Korean Radiological Society, 대한영상의학회지], V58, P177	13	1	1	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					270	275		10.1080/15513815.2018.1472355			6	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000006	29843558				2019-10-28	
J	Skillen, LA; Gates, D; Collins, JA; Saxena, N; Hurrell, D; McKenna, K; Morrison, PJ				Skillen, Laura A.; Gates, Damien; Collins, Julie-Ann; Saxena, Nivedita; Hurrell, Daniel; McKenna, Kevin; Morrison, Patrick J.			Aplasia Cutis Congenita with Ischemic Cortical Change and Normal Array Cytogenetic Analysis with a Fetus Papyraceus Twin	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Fetus papyraceus; array cytogenetic analysis; ischemic etiology	TRUNK	Background: Aplasia cutis congenita (ACC) is a heterogeneous condition that can be associated with fetus papyraceus. Few reports exist documenting genetic investigations in ACC or determining the etiology and recurrence risks. Objective: We present a Frieden group 5 ACC with fetus papyraceus along with molecular studies. Results: The newborn had multifocal aplasia cutis congenita involving the head, trunk, and limbs with cerebral ischemic changes demonstrated by imaging. The newborn had a monochorionic twin fetus papyraceus. The array cytogenetic analysis was normal. Conclusion: Supported by the ischemic cerebral damage, a monochorionic twin fetus papyraceus (monochorionic twins often have vascular anastomoses), and a normal cytogenetic array, this ACC with Frieden group 5 may have resulted from rapid but non-fatal exsanguination of the surviving twin into the dead twin. This type of ACC may have a low recurrence risk.	[Skillen, Laura A.; McKenna, Kevin] Belfast City Hosp, Dermatol, Belfast, Antrim, North Ireland; [Gates, Damien; Collins, Julie-Ann; Saxena, Nivedita] South Eastern Hlth & Social Care Trust, Paediat, Dundonald, North Ireland; [Hurrell, Daniel] Royal Victoria Hosp, Paediat Pathol, Belfast, Antrim, North Ireland; [Morrison, Patrick J.] Belfast City Hosp, Med Genet, Belfast BT9 7AB, Antrim, North Ireland	Morrison, PJ (reprint author), Belfast City Hosp, Med Genet, Belfast BT9 7AB, Antrim, North Ireland.	patrick.morrison@belfasttrust.hscni.net					Ahcan U, 2002, BRIT J PLAST SURG, V55, P530, DOI 10.1054/bjps.2002.3915; Amor DJ, 2000, AM J MED GENET, V93, P328, DOI 10.1002/1096-8628(20000814)93:4<328::AID-AJMG13>3.0.CO;2-0; Chan RK, 2012, J CRANIOFAC SURG, V23, P995, DOI 10.1097/SCS.0b013e31824e27ac; FRIEDEN IJ, 1986, J AM ACAD DERMATOL, V14, P646, DOI 10.1016/S0190-9622(86)70082-0; Kelly BJ, 2002, PEDIATR DERMATOL, V19, P326, DOI 10.1046/j.1525-1470.2002.00093.x; Klein RQ, 2011, PEDIATR DERMATOL, V28, P467, DOI 10.1111/j.1525-1470.2011.01314.x; Larralde M, 2006, DERMATOL PEDIAT LAT, V4, P190; Pieretti ML, 2015, PEDIATR DERMATOL, V32, P858, DOI 10.1111/pde.12651; Louise L, 2013, PEDIATR DERMATOL, V30, pE143, DOI 10.1111/pde.12096; Maccario S, 2009, EUR J DERMATOL, V19, P372, DOI 10.1684/ejd.2009.0681; Martinez-Regueira S, 2006, PEDIATR DERMATOL, V23, P528, DOI 10.1111/j.1525-1470.2006.00303.x; Pharoah POD, 2009, J PEDIATR-US, V155, P598, DOI 10.1016/j.jpeds.2009.04.040; Schaffer JV, 2008, J PEDIATR-US, V153, P860, DOI 10.1016/j.jpeds.2008.07.009; Snape KMG, 2009, AM J MED GENET A, V149A, P1860, DOI 10.1002/ajmg.a.32708; Sybert V P, 1985, Pediatr Dermatol, V3, P1, DOI 10.1111/j.1525-1470.1985.tb00478.x; Tempark T, 2012, INT J DERMATOL, V51, P1419, DOI 10.1111/j.1365-4632.2012.05545.x	16	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					276	281		10.1080/15513815.2018.1483453			6	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000007	30273087				2019-10-28	
J	Erenel, H; Ozel, A; Oztunc, F; Kizilkilic, O; Comunoglu, N; Uludag, S; Madazli, R				Erenel, Hakan; Ozel, Aysegul; Oztunc, Funda; Kizilkilic, Osman; Comunoglu, Nil; Uludag, Seyfettin; Madazli, Riza			Antenatal Diagnosis of Fetal Retinoid Syndrome at 20 Weeks of Gestation: A Case Report	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Embryopathy; isotretinoin; retinoic acid; syndrome; teratogen	ISOTRETINOIN; ACID; PREGNANCY; DELETION; TBX1	Introduction: Isotretinoin, a synthetic derivative of vitamin A, is one of the most potent human teratogens, and is mainly utilized for the treatment of severe recalcitrant nodular acne. Retinoic acid embryopathy is well defined in the literature. Case Report: The mother was referred for a fetal posterior fossa abnormality, first detected at 20 weeks of gestation. The mother used isotretinoin until 18 weeks gestation. Ultrasound examination revealed hypertelorism, cerebellar hypoplasia, vermian agenesis, truncus arteriosus, anotia, thymic aplasia, corpus callosum hypoplasia. An intrauterine diagnosis of fetal retinoid syndrome was confirmed by fetopsy after termination of pregnancy. Conclusion: The typical findings of fetal retinoid syndrome can be visualized with ultrasound in early second trimester.	[Erenel, Hakan; Ozel, Aysegul; Uludag, Seyfettin; Madazli, Riza] Istanbul Univ, Cerrahpasa Med Fac, Obstet & Gynecol Div Perinatol, Istanbul, Turkey; [Oztunc, Funda] Istanbul Univ, Div Pediat Cardiol, Dept Pediat, Cerrahpasa Med Fac, Istanbul, Turkey; [Kizilkilic, Osman] Istanbul Univ, Div Neuroradiol, Dept Radiol, Cerrahpasa Med Fac, Istanbul, Turkey; [Comunoglu, Nil] Istanbul Univ, Dept Pathol, Cerrahpasa Med Fac, Istanbul, Turkey	Erenel, H (reprint author), Istanbul Univ, Cerrahpasa Med Fac, Dept Obstet & Gynecol, Div Perinatal Med, Kocamustafapasa Cd 53, TR-34098 Fatih Istanbul, Turkey.	hakanerenel@yahoo.com		ERENEL, HAKAN/0000-0001-7583-5385			Botto LD, 2003, PEDIATRICS, V112, P101, DOI 10.1542/peds.112.1.101; Browne H, 2014, OBSTET GYNAECOL, V16, P7, DOI 10.1111/tog.12075; Choi JS, 2013, CAN MED ASSOC J, V185, P411, DOI 10.1503/cmaj.120729; COLLETT RW, 1949, SURG CLIN N AM, V29, P1245; Hardman JG, 2001, GOODMAN GILMANS PHAR, V48, P1781; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; Layton A, 2009, DERM-ENDOCRINOL, V1, P162, DOI 10.4161/derm.1.3.9364; Mukherjee S, 2006, CLIN INTERV AGING, V1, P327, DOI 10.2147/ciia.2006.1.4.327; Nau H, 2001, J AM ACAD DERMATOL, V45, pS183, DOI 10.1067/mjd.2001.113720; Okano J, 2008, DEV DYNAM, V237, P3059, DOI 10.1002/dvdy.21715; Robin NH, 2005, J PEDIATR-US, V147, P90, DOI 10.1016/j.jpeds.2005.03.007; Tsukada M, 2000, J INVEST DERMATOL, V115, P321, DOI 10.1046/j.1523-1747.2000.00066.x; VAHLQUIST A, 1987, Dermatologica (Basel), V175, P20; Zhang LF, 2006, INT J DEV BIOL, V50, P55, DOI 10.1387/ijdb.052036lz	14	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					282	286		10.1080/15513815.2018.1472354			5	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000008	29843537				2019-10-28	
J	Cho, HJ; Jung, EJ; Byun, JM; Jeong, DH; Lee, KB; Sung, MS; Kim, YN				Cho, Hwa Jin; Jung, Eun Jung; Byun, Jung Mi; Jeong, Dae Hoon; Lee, Kyung Bok; Sung, Moon Su; Kim, Young Nam			Thrombosed Fetal Dural Sinus Malformation: Correlation Between Prenatal Ultrasound and Autopsy Findings	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Cerebral sinovenous thrombosis; dural arteriovenous shunts; dural sinus thrombosis; dural sinus malformation; fetal autopsy	DIAGNOSIS	Introduction: Dural sinus malformations, which are characterized by massively dilated dural sinuses, are one of the etiologies of an intracranial fetal cystic mass. Thrombi within these dural sinus malformations can develop while in-utero, and can be visualized by ultrasound in fetal life. Definitive postnatal diagnosis requires an autopsy. Case Report: We report two thrombosed fetal dural sinus malformations which are prenatally suspected during the second trimester with ultrasonography and postnatally confirmed with autopsy. Conclusion: Prenatal ultrasound images and fetal autopsy findings can be useful to establish the prenatal diagnosis of thrombosed dural sinus malformation.	[Cho, Hwa Jin] Inje Univ, Pathol, Busan Paik Hosp, Busan, South Korea; [Jung, Eun Jung; Byun, Jung Mi; Jeong, Dae Hoon; Lee, Kyung Bok; Sung, Moon Su; Kim, Young Nam] Inje Univ, Busan Paik Hosp, Dept Obstet & Gynecol, Busan, South Korea; [Byun, Jung Mi; Jeong, Dae Hoon; Lee, Kyung Bok; Sung, Moon Su; Kim, Young Nam] Busan Paik Hosp, Paik Inst Clin Res, Busan, South Korea	Kim, YN (reprint author), Inje Univ, Busan Paik Hosp, Busan 614735, South Korea.	ob.youngnam@gmail.com					BALLESTER MJ, 1994, ACTA OBSTET GYN SCAN, V73, P592, DOI 10.3109/00016349409006280; Barbosa M, 2003, INTERV NEURORADIOL, V9, P407, DOI 10.1177/159101990300900413; Byrd SE, 2012, PEDIATR RADIOL, V42, P536, DOI 10.1007/s00247-011-2287-9; Delmas HL, 2008, ULTRASOUND OBST GYN, V32, P188, DOI 10.1002/uog.5348; Has R, 2013, J ULTRAS MED, V32, P2205, DOI 10.7863/ultra.32.12.2205; Monteagudo A, 2012, ULTRASONOGRAPHY PREN; Rossi A, 2006, PRENATAL DIAG, V26, P11, DOI 10.1002/pd.1347; Saracco P, 2009, THROMB RES, V123, P805, DOI 10.1016/j.thromres.2008.12.002; Spampinato MV, 2008, OBSTET GYNECOL, V111, P569, DOI 10.1097/01.AOG.0000289227.12531.03; Vielhaber H, 1998, EUR J PEDIATR, V157, P555, DOI 10.1007/s004310050877; Visentin A, 2001, ULTRASOUND OBST GYN, V17, P322, DOI 10.1046/j.1469-0705.2001.00372.x	11	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					287	295		10.1080/15513815.2018.1478473			9	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000009	30265815				2019-10-28	
J	Tan, AW; Leung, P; Patil, UP				Tan, April W.; Leung, Pablo; Patil, Uday P.			Tokyo-1 Mutation: Hereditary Spherocytosis in a Hispanic Newborn Presenting as Early Onset Severe Hyperbilirubinemia	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Spherocytosis; ankyrin gene mutation; ANK1; neonatal jaundice; severe hyperbilirubinemia; hemolytic anemia	NEONATAL HYPERBILIRUBINEMIA; DIAGNOSIS; ANKYRIN; MANAGEMENT; DEFICIENCY; SPECTRIN	Background: Hereditary spherocytosis in the Hispanic population does not often present with severe hyperbilirubinemia. Spectrin and band 3 mutations are most frequent in this population. Case report We present a Hispanic full-term female newborn with early onset significant hyperbilirubinemia without a history of familial hemolytic disorders. She was diagnosed with hereditary spherocytosis based on laboratory findings, including presence of spherocytes on a peripheral smear, and was later found by next-generation sequencing to have Tokyo-1 mutation, an ANK1 gene mutation, that was previously only reported in Japanese population. Conclusion: Our report adds to the currently limited literature of the genetic spectrum and characteristics of hereditary spherocytosis in the Hispanic population. The absence of a positive family history does not preclude hereditary spherocytosis as a differential for pathologic neonatal hyperbilirubinemia.	[Tan, April W.; Leung, Pablo; Patil, Uday P.] Icahn Sch Med Mt Sinai, Elmhurst Hosp Ctr, Dept Pediat, Elmhurst, NY 11373 USA	Tan, AW (reprint author), Icahn Sch Med Mt Sinai, Elmhurst Hosp Ctr, Dept Pediat, Elmhurst, NY 11373 USA.	aprilwj17@gmail.com					Bianchi P, 2012, HAEMATOL-HEMATOL J, V97, P516, DOI 10.3324/haematol.2011.052845; Bolton-Maggs PHB, 2012, BRIT J HAEMATOL, V156, P37, DOI 10.1111/j.1365-2141.2011.08921.x; Cheng Shao-Wen, 2012, Chang Gung Med J, V35, P148; Christensen RD, 2010, PEDIATRICS, V125, P120, DOI 10.1542/peds.2009-0864; Crisp RL, 2012, PEDIATR BLOOD CANCER, V59, P1299, DOI 10.1002/pbc.24157; Da Costa L, 2013, BLOOD REV, V27, P167, DOI 10.1016/j.blre.2013.04.003; Johnson L, 2009, J PERINATOL, V29, pS25, DOI 10.1038/jp.2008.211; Kar R, 2010, INT J LAB HEMATOL, V32, P8, DOI 10.1111/j.1751-553X.2008.01098.x; Kedar PS, 2003, CLIN LAB HAEMATOL, V25, P373, DOI 10.1046/j.0141-9854.2003.00557.x; Madlon-Kay DJ, 2001, ARCH PEDIAT ADOL MED, V155, P583, DOI 10.1001/archpedi.155.5.583; Maisels MJ, 2004, PEDIATRICS, V114, P297; Michaels LA, 1997, J PEDIATR-US, V130, P957, DOI 10.1016/S0022-3476(97)70283-X; Moyer VA, 2000, ARCH PEDIAT ADOL MED, V154, P391, DOI 10.1001/archpedi.154.4.391; Nakanishi H, 2001, INT J HEMATOL, V73, P54, DOI 10.1007/BF02981903; PEKRUN A, 1993, ANN HEMATOL, V67, P89, DOI 10.1007/BF01788132; Perrotta S, 2008, LANCET, V372, P1411, DOI 10.1016/S0140-6736(08)61588-3; Sanchez-Lopez JY, 2003, BLOOD CELL MOL DIS, V31, P357, DOI 10.1016/S1079-9796(03)00207-9; SAVVIDES P, 1993, BLOOD, V82, P2953; Sgro M, 2006, CAN MED ASSOC J, V175, P587, DOI 10.1503/cmaj.060328; Sheffield MJ, 2011, J PERINATOL, V31, P625, DOI 10.1038/jp.2010.212; Streichman S, 1998, AM J HEMATOL, V58, P206, DOI 10.1002/(SICI)1096-8652(199807)58:3<206::AID-AJH8>3.0.CO;2-V	21	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					296	300		10.1080/15513815.2018.1485797			5	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000010	30207817				2019-10-28	
J	Baris, Z; Ozcay, F; Usta, Y; Ozgun, G				Baris, Zeren; Ozcay, Figen; Usta, Yusuf; Ozgun, Gonca			Liver Cirrhosis in a Patient with Crigler Najjar Syndrome	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Crigler Najjar disease; cirrhosis; pathology	GILBERT	Introduction: Crigler Najjar (CN) disease is a genetic disorder which results in increased unconjugated bilirubin level. Liver parenchyma was previously considered structurally normal. Recent reports describe significant fibrosis in the liver parenchyma of patients with CN syndrome. Case report. We present a patient with persistent unconjugated hyperbilirubinemia, clinically diagnosed as CN-2, with a UGT1 A1 p. H39D (c.115C > G) (His -> Asp) mutation. She required hepatic transplantation at the age of 17.5 years for biliary cirrhosis. Explanted liver histopathology revealed regenerative cirrhotic nodules with dilated bile ducts filled with bile plugs. Conclusion: CN can develop significant hepatic fibrosis/cirrhosis requiring liver transplantation.	[Baris, Zeren] Baskent Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, TR-06419 Ankara, Turkey; [Ozcay, Figen; Usta, Yusuf] Mersin Univ, Fac Med, Dept Pediat Gastroentrol Hepatol & Nutr, Mersin, Turkey; [Ozgun, Gonca] Baskent Univ, Fac Med, Dept Pathol, Ankara, Turkey	Baris, Z (reprint author), Baskent Univ, Fac Med, Dept Pediat Gastroenterol Hepatol & Nutr, TR-06419 Ankara, Turkey.	zeren_baris@yahoo.com					Canu G, 2013, BLOOD CELL MOL DIS, V50, P273, DOI 10.1016/j.bcmd.2013.01.003; Costa E, 2006, BLOOD CELL MOL DIS, V36, P77, DOI 10.1016/j.bcmd.2005.10.006; CRIGLER JF, 1952, PEDIATRICS, V10, P169; Fata CR, 2017, PEDIATR DEVEL PATHOL, V20, P522, DOI 10.1177/1093526617697059; Kadakol A, 2000, HUM MUTAT, V16, P297, DOI 10.1002/1098-1004(200010)16:4<297::AID-HUMU2>3.0.CO;2-Z; Memon N, 2016, PEDIATR RES, V79, P378, DOI 10.1038/pr.2015.247; Mitchell E, 2018, J PEDIATR GASTR NUTR, V66, P588, DOI 10.1097/MPG.0000000000001843; Sun L, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008620; Wittenburg H, 2010, BEST PRACT RES CL GA, V24, P747, DOI 10.1016/j.bpg.2010.07.004	9	0	0	1	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					301	306		10.1080/15513815.2018.1492053			6	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000011	30260719				2019-10-28	
J	Nickavar, A; Rahbar, M				Nickavar, Azar; Rahbar, Mahtab			A Clinicopathologic Study of Children with Idiopathic Focal Segmental Glomerulosclerosis (vol 35, pg 159, 2016)	FETAL AND PEDIATRIC PATHOLOGY			English	Correction									[Nickavar, Azar] Iran Univ Med Sci, Ali Asghar Childrens Hosp, Dept Pediat Nephrol, Tehran, Iran; [Rahbar, Mahtab] Iran Univ Med Sci, Ali Asghar Childrens Hosp, Dept Pathol, Tehran, Iran	Nickavar, A (reprint author), Iran Univ Med Sci, Ali Asghar Childrens Hosp, Dept Pediat Nephrol, Tehran, Iran.						Nickavar A, 2016, FETAL PEDIATR PATHOL, V35, P159, DOI 10.3109/15513815.2016.1153177	1	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	4					307	307		10.1080/15513815.2018.1490490			1	Pathology; Pediatrics	Pathology; Pediatrics	HM9DC	WOS:000459782000012		Bronze			2019-10-28	
J	Poomarimuthu, M; Elango, S; Solomon, PR; Soundarapandian, S; Mariakuttikan, J				Poomarimuthu, Maheshkumar; Elango, Sivakumar; Solomon, Pravin Raj; Soundarapandian, Sambath; Mariakuttikan, Jayalakshmi			Lack of Association Between TNF-alpha, IFN-gamma, IL-10 Gene Polymorphisms and Rheumatic Heart Disease in South Indian Population	FETAL AND PEDIATRIC PATHOLOGY			English	Article						RHD; TNF-alpha; IFN-gamma; IL-10; polymorphism	NECROSIS-FACTOR-ALPHA; PROMOTER POLYMORPHISMS; CLINICAL-OUTCOMES; MOLECULAR MIMICRY; INTERLEUKIN-10; SUSCEPTIBILITY; FEVER; GENDER; TNF-ALPHA(-308); IL-10(-1082)	Background: Proinflammatory and anti-inflammatory cytokines play a crucial role in the development and maintenance of immune mediated inflammatory diseases including rheumatic heart disease (RHD). Polymorphisms in tumor necrosis factor (TNF)-alpha interferon (IFN)-gamma, and interleukin (IL)-10 genes influence the differential cytokine expression as well as the pathogenesis of various inflammatory and autoimmune diseases. Objective: The aim of the study is to investigate the association between TNF-alpha IFN-gamma, and IL-10 gene polymorphisms and RHD in South Indian population. Materials and Methods: TNF-alpha (-308, -238), IFN-gamma (+874), and IL-10 (-1082, -819, -592) gene polymorphisms were determined in 100 patients with RHD and 127 healthy siblings by PCR. Results: There was no significant difference in the genotype, allele, and haplotype frequencies of TNF-alpha, IFN-gamma and IL-10 polymorphisms between RHD patients and healthy siblings. Conclusion: The present study suggests that TNF-alpha, IFN-gamma, and IL-10 gene variants may not be associated with the development of RHD in South Indian population.	[Poomarimuthu, Maheshkumar; Mariakuttikan, Jayalakshmi] Madurai Kamaraj Univ, Sch Biol Sci, Dept Immunol, Madurai 625021, Tamil Nadu, India; [Elango, Sivakumar; Soundarapandian, Sambath] Govt Rajaji Hosp, Inst Child Hlth & Res Ctr, Madurai, Tamil Nadu, India; [Solomon, Pravin Raj] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur, Tamil Nadu, India	Mariakuttikan, J (reprint author), Madurai Kamaraj Univ, Sch Biol Sci, Dept Immunol, Madurai 625021, Tamil Nadu, India.	jayalakshmimk11@yahoo.com					Abdalla A.T., 2015, INT C COMM SIGN PROC, P1, DOI DOI 10.1109/ICCSPA.2015.7081281; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Berdeli A, 2006, SCAND J RHEUMATOL, V35, P44, DOI 10.1080/03009740510026760; Col-Araz N, 2012, EUR J PEDIATR, V171, P1103, DOI 10.1007/s00431-012-1689-5; Couper KN, 2008, J IMMUNOL, V180, P5771, DOI 10.4049/jimmunol.180.9.5771; Cunningham MW, 2014, INT REV IMMUNOL, V33, P314, DOI 10.3109/08830185.2014.917411; De Nardin E, 2009, IMMUNOL INVEST, V38, P198, DOI 10.1080/08820130902910526; Elahi MM, 2009, BBA-MOL BASIS DIS, V1792, P163, DOI 10.1016/j.bbadis.2009.01.007; Fae KC, 2006, J IMMUNOL, V176, P5662, DOI 10.4049/jimmunol.176.9.5662; Guilherme L, 2001, J AUTOIMMUN, V16, P363, DOI 10.1006/jaut.2000.0487; Guilherme L, 2006, AUTOIMMUNITY, V39, P31, DOI 10.1080/08916930500484674; Guilherme L, 2005, ANN NY ACAD SCI, V1051, P132, DOI 10.1196/annals.1361.054; Guilherme L, 2004, AM J PATHOL, V165, P1583, DOI 10.1016/S0002-9440(10)63415-3; Gupta R, 2009, IMMUNOL INVEST, V38, P240, DOI 10.1080/08820130902766563; Gupta U, 2016, IMMUNOL LETT, V174, P53, DOI 10.1016/j.imlet.2016.04.012; Hayek E, 2005, LANCET, V365, P507; Hernandez-Pacheco G, 2003, J AUTOIMMUN, V21, P59, DOI 10.1016/S0896-8411(03)00079-9; Iyer SS, 2012, CRIT REV IMMUNOL, V32, P23, DOI 10.1615/CritRevImmunol.v32.i1.30; Lee YH, 2016, LUPUS, V25, P710, DOI 10.1177/0961203315624557; Milicic A, 2000, GENES IMMUN, V1, P418, DOI 10.1038/sj.gene.6363701; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Mohamed AA, 2010, SAUDI MED J, V31, P644; Mullighan CG, 1999, GENES IMMUN, V1, P137, DOI 10.1038/sj.gene.6363653; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Nasuti JF, 2004, ANN THORAC SURG, V77, P532, DOI 10.1016/S0003-4975(03)01584-4; Nussinovitch U, 2012, AUTOIMMUN REV, V11, pA377, DOI 10.1016/j.autrev.2011.11.001; Paladino N, 2006, J VIROL, V80, P9144, DOI 10.1128/JVI.00339-06; Pravica V, 2000, HUM IMMUNOL, V61, P863, DOI 10.1016/S0198-8859(00)00167-1; Pravica V, 1999, EUR J IMMUNOGENET, V26, P1, DOI 10.1046/j.1365-2370.1999.00122.x; Ramasawmy R, 2007, MOL IMMUNOL, V44, P1873, DOI 10.1016/j.molimm.2006.10.001; Rehman S, 2013, CYTOKINE, V61, P527, DOI 10.1016/j.cyto.2012.10.020; Sallakci N, 2005, J AUTOIMMUN, V25, P150, DOI 10.1016/j.jaut.2005.05.005; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Settin A, 2007, PEDIATR CARDIOL, V28, P363, DOI 10.1007/s00246-006-0002-7; Tawfik E., 2010, EGYPT J MED HUM GENE, V11, P33; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Tedde A, 2008, SCAND J GASTROENTERO, V43, P712, DOI 10.1080/00365520701885507; Teker E, 2018, BIOCHEM GENET, V56, P225, DOI 10.1007/s10528-017-9839-0; Toor D, 2012, MICROBES INFECT, V14, P1111, DOI 10.1016/j.micinf.2012.07.003; Trifunovic J, 2015, BIOCHEM MEDICA, V25, P36, DOI 10.11613/BM.2015.004; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Yousry SM, 2016, CARDIOL YOUNG, V26, P1290, DOI 10.1017/S1047951115002413; Zheng RL, 2014, SCI REP-UK, V4, DOI 10.1038/srep04731	43	1	1	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					309	318		10.1080/15513815.2018.1494232			10	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200001	30247944				2019-10-28	
J	Oksuzoglu, A; Ustun, YE; Aktulay, A; Yoruk, O; Seckin, B; Danisman, N				Oksuzoglu, Aysegul; Ustun, Yaprak Engin; Aktulay, Ayla; Yoruk, Ozlem; Seckin, Berna; Danisman, Nuri			First and Second Trimester Biochemical Markers in Maternal Epilepsy: A Case-Control Study	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Epilepsy; estriol; hypothalamic-pituitaryadrenal axis; pregnancy; serum analytes	PREGNANCY OUTCOMES; SERUM MARKERS; WOMEN; ESTRIOL; RISK; COMPLICATIONS; ANEUPLOIDY	Background: Our aim is to investigate whether the maternal serum levels of first and second trimester serum analytes are altered in women with epilepsy in pregnancy. Methods: Maternal serum biochemical markers (estriol, alpha-fetoprotein [AFP], human chorionic gonadotrophin [hCG], free beta hCG, pregnancy-associated plasma protein-A) were compared in a series of 122 pregnant women with epilepsy and in a cohort of 122 normal pregnant women. The serum samples were obtained between 11-13 6/7 weeks and 16-18 weeks gestation. Results: Second trimester serum estriol levels, expressed as multiples of the median (MoM), in the epileptic group (1.55 +/- 0.77 MoM) were significantly higher than those in the control patients (1.13 +/- 0.40 MoM) (p < 0.001). Of the women with epilepsy, 66.3% (n = 81) were exposed to antiepileptic drugs. Conclusion: Our study revealed that otherwise uncomplicated pregnant epileptic women had higher second trimester (18-20 weeks of gestation) estriol levels compared to non-epileptic pregnant women.	[Oksuzoglu, Aysegul; Ustun, Yaprak Engin; Aktulay, Ayla; Yoruk, Ozlem; Seckin, Berna; Danisman, Nuri] Zekai Tahir Burak Womens Hlth Res & Educ Hosp, Dept Obstet & Gynecol, TR-06230 Ankara, Turkey	Oksuzoglu, A (reprint author), Zekai Tahir Burak Womens Hlth Res & Educ Hosp, Dept Obstet & Gynecol, TR-06230 Ankara, Turkey.	oksuzoglua@yahoo.com		Engin-Ustun, Yaprak/0000-0002-1011-3848			Borthen I, 2009, BJOG-INT J OBSTET GY, V116, P1736, DOI 10.1111/j.1471-0528.2009.02354.x; Chen YH, 2009, ARCH NEUROL-CHICAGO, V66, P979, DOI 10.1001/archneurol.2009.142; D'Alton M, 2005, SEMIN PERINATOL, V29, P240, DOI 10.1053/j.semperi.2005.06.006; Dugoff L, 2005, OBSTET GYNECOL, V106, P260, DOI 10.1097/01.AOG.0000172419.37410.eb; Dugoff L, 2010, OBSTET GYNECOL, V115, P1052, DOI 10.1097/AOG.0b013e3181da93da; Gagnon A, 2008, J OBSTET GYNAECOL CA, V30, P918, DOI 10.1016/S1701-2163(16)32973-5; Goodwin TM, 1999, AM J OBSTET GYNECOL, V180, pS208, DOI 10.1016/S0002-9378(99)70702-7; Graves JC, 2002, AM FAM PHYSICIAN, V65, P915; Harden CL, 2009, NEUROLOGY, V73, P133, DOI 10.1212/WNL.0b013e3181a6b312; Heine RP, 2000, OBSTET GYNECOL, V96, P490, DOI 10.1016/S0029-7844(00)01004-8; Korebrits C, 1998, J CLIN ENDOCR METAB, V83, P1585, DOI 10.1210/jc.83.5.1585; Meador K, 2008, EPILEPSY RES, V81, P1, DOI 10.1016/j.eplepsyres.2008.04.022; Newberger DS, 2000, AM FAM PHYSICIAN, V62, P825; Olsen RN, 2014, J MATERN-FETAL NEO M, V27, P376, DOI 10.3109/14767058.2013.815719; Pennell PB, 2006, EPILEPSIA, V47, P46, DOI 10.1111/j.1528-1167.2006.00660.x; Pennell PB, 2008, EPILEPSIA, V49, P43, DOI 10.1111/j.1528-1167.2008.01926.x; SIITERI PK, 1966, J CLIN ENDOCR METAB, V26, P751, DOI 10.1210/jcem-26-7-751; Turkcapar F, 2013, EUR REV MED PHARMACO, V17, P1820; Viinikainen K, 2006, EPILEPSIA, V47, P186, DOI 10.1111/j.1528-1167.2006.00386.x; Wood CE, 2013, CLIN OBSTET GYNECOL, V56, P610, DOI 10.1097/GRF.0b013e31829e5b15; Yaron Y, 1999, AM J OBSTET GYNECOL, V181, P968, DOI 10.1016/S0002-9378(99)70334-0	21	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					319	325		10.1080/15513815.2018.1502381			7	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200002	30247941				2019-10-28	
J	Baek, HS; Han, MH; Kim, YJ; Cho, MH				Baek, Hee Sun; Han, Man Hoon; Kim, Yong Jin; Cho, Min Hyun			Clinical Relevance of C4d Deposition in Pediatric Immunoglobulin A Nephropathy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						IgA nephropathy; C4d; mesangial proliferation; proteinuria; children	IGA NEPHROPATHY; OXFORD CLASSIFICATION; COMPLEMENT; ACTIVATION; ASSOCIATION; PROGRESSION; REJECTION	Introduction: Few studies have reported the association between the complement cascade and pediatric immunoglobulin A nephropathy (IgAN). This study aimed to investigate the association between C4d staining positivity and the clinical/histopathological characteristics of pediatric patients with IgAN. Methods: Children diagnosed with IgAN through renal biopsy were retrospectively reviewed. Renal biopsy specimens were stained using C4d immunohistochemistry. Results: Among the 56 patients, 31 (55.4%) showed positive mesangial or peripheral capillary C4d staining in glomeruli. Urine protein-to-creatinine ratio was significantly higher in C4d-positive patients (p = 0.001). The severity of mesangial proliferation according to the Haas and Oxford classification was positively associated with positive C4d staining (p < 0.001). Conclusion: Positive C4d staining was found to be significantly associated with the clinical/histopathological severity of IgAN.	[Baek, Hee Sun; Cho, Min Hyun] Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu 41944, South Korea; [Han, Man Hoon; Kim, Yong Jin] Kyungpook Natl Univ, Sch Med, Dept Pathol, Daegu, South Korea	Cho, MH (reprint author), Kyungpook Natl Univ, Sch Med, Dept Pediat, Daegu 41944, South Korea.	chomh@knu.ac.kr					Bartosik LP, 2001, AM J KIDNEY DIS, V38, P728, DOI 10.1053/ajkd.2001.27689; BOGERS WMJM, 1991, COMPLEMENT INFLAMMAT, V8, P347, DOI 10.1159/000463206; Cattran DC, 2009, KIDNEY INT, V76, P534, DOI 10.1038/ki.2009.243; Colvin RB, 2007, J AM SOC NEPHROL, V18, P1046, DOI 10.1681/ASN.2007010073; Coppo R, 2010, KIDNEY INT, V77, P921, DOI 10.1038/ki.2010.43; DAMICO G, 1986, Q J MED, V59, P363; Endo M, 1998, NEPHROL DIAL TRANSPL, V13, P1984, DOI 10.1093/ndt/13.8.1984; Espinosa M, 2014, CLIN J AM SOC NEPHRO, V9, P897, DOI 10.2215/CJN.09710913; Espinosa M, 2009, NEPHROL DIAL TRANSPL, V24, P886, DOI 10.1093/ndt/gfn563; Faria B, 2015, CLIN EXP IMMUNOL, V179, P354, DOI 10.1111/cei.12461; Fabiano RCG, 2017, PEDIATR NEPHROL, V32, P1211, DOI 10.1007/s00467-017-3610-y; Heybeli C, 2015, RENAL FAILURE, V37, P1464, DOI 10.3109/0886022X.2015.1077319; Maeng YI, 2013, INT J CLIN EXP PATHO, V6, P904; Maillard N, 2015, J AM SOC NEPHROL, V26, P1503, DOI 10.1681/ASN.2014101000; Racusen LC, 2004, TRANSPLANT P, V36, P768, DOI 10.1016/j.transproceed.2004.03.032; Radford MG, 1997, J AM SOC NEPHROL, V8, P199; Roberts ISD, 2009, KIDNEY INT, V76, P546, DOI 10.1038/ki.2009.168; Roos A, 2006, J AM SOC NEPHROL, V17, P1724, DOI 10.1681/ASN.2005090923; Schwartz GJ, 2009, J AM SOC NEPHROL, V20, P629, DOI 10.1681/ASN.2008030287; Suzuki H, 2011, J AM SOC NEPHROL, V22, P1795, DOI 10.1681/ASN.2011050464; WYATT RJ, 1988, AM J KIDNEY DIS, V12, P437, DOI 10.1016/S0272-6386(88)80042-8; WYATT RJ, 1993, CONTRIB NEPHROL, V104, P82; Wyatt RJ, 2013, NEW ENGL J MED, V368, P2402, DOI 10.1056/NEJMra1206793; 손진아, 2008, Korean Journal of Pediatrics, V51, P998; 이종국, 2008, Korean Journal of Pediatrics, V51, P33	25	1	1	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					326	336		10.1080/15513815.2018.1504841			11	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200003	30273085				2019-10-28	
J	Buonsenso, D; Sali, M; Pata, D; Masiello, E; Salerno, G; Ceccarelli, M; Delogu, G; Valentini, P				Buonsenso, Danilo; Sali, Michela; Pata, Davide; Masiello, Enrico; Salerno, Gilda; Ceccarelli, Manuela; Delogu, Giovanni; Valentini, Piero			Vitamin D Levels in Active TB, Latent TB, Non-TB Pneumonia and Healthy Children: A Prospective Observational Study	FETAL AND PEDIATRIC PATHOLOGY			English	Article						tuberculosis; vitamin D; pneumonia; latent TB infection	HIGH-DOSE VITAMIN-D-3; MYCOBACTERIUM-TUBERCULOSIS; D DEFICIENCY; DOUBLE-BLIND; PULMONARY TUBERCULOSIS; MACROPHAGES; INITIATION; D-3	Background: Growing evidence suggests that vitamin D deficiency might be implicated in the development of active tuberculosis (TB). We evaluated vitamin D levels In children with active TB compared to children with latent TB infection (LTBI), non-TB pneumonia (NTBP) and healthy controls to determine if there was a difference. Methods: In this prospective study, vitamin D levels were measured and compared between the four groups and adjusted for age, ethnicity, gender and season of sample collection. Results: Fifty-seven children were included: 24.6% active TB, 28.1% LTBI, 22.8% NPTB and 24.6% healthy controls. 36.8% of all children tested had an insufficient or deficient vitamin D level. Vitamin D level was significantly lower in active TB compared to other groups (p = 0.004). Conclusions: Our study showed a correlation between hypovitaminosis D and active pulmonary TB.	[Buonsenso, Danilo; Pata, Davide; Valentini, Piero] Fdn Policlin Univ A Gemelli, Dept Pediat, IRCCS, Rome, Italy; [Sali, Michela; Delogu, Giovanni] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Inst Microbiol, Rome, Italy; [Masiello, Enrico; Salerno, Gilda; Ceccarelli, Manuela] Univ Cattolica Sacro Cuore, A Gemelli Hosp, Dept Pediat, Rome, Italy	Buonsenso, D (reprint author), Fdn Policlin Univ A Gemelli, Dept Pediat, IRCCS, Rome, Italy.	danilobuonsenso@gmail.com	Ceccarelli, Manuela/G-6612-2018	Ceccarelli, Manuela/0000-0001-5987-3576; Buonsenso, Danilo/0000-0001-8567-2639			Balasubramanian V, 1996, J BACTERIOL, V178, P273, DOI 10.1128/jb.178.1.273-279.1996; Barry CE, 2009, NAT REV MICROBIOL, V7, P845, DOI 10.1038/nrmicro2236; Braegger C, 2013, J PEDIATR GASTR NUTR, V56, P692, DOI 10.1097/MPG.0b013e31828f3c05; Buonsenso D, 2012, PEDIATR INFECT DIS J, V31, P1022, DOI 10.1097/INF.0b013e3182615270; Cegielski P, 2015, LANCET INFECT DIS, V15, P489, DOI 10.1016/S1473-3099(15)70163-5; Chao MC, 2010, ANNU REV MICROBIOL, V64, P293, DOI 10.1146/annurev.micro.112408.134043; Coussens AK, 2009, IMMUNOLOGY, V127, P539, DOI 10.1111/j.1365-2567.2008.03024.x; Delogu G, 2013, MEDITERR J HEMATOL I, V5, DOI 10.4084/MJHID.2013.070; Fabri M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003045; Ford CB, 2011, NAT GENET, V43, P482, DOI 10.1038/ng.811; Ganmaa D, 2012, AM J CLIN NUTR, V96, P391, DOI 10.3945/ajcn.112.034967; Gengenbacher M, 2012, FEMS MICROBIOL REV, V36, P514, DOI 10.1111/j.1574-6976.2012.00331.x; Gibney KB, 2008, CLIN INFECT DIS, V46, P443, DOI 10.1086/525268; Gideon HP, 2011, IMMUNOL RES, V50, P202, DOI 10.1007/s12026-011-8229-7; Gray K, 2012, PEDIATR INFECT DIS J, V31, P521, DOI 10.1097/INF.0b013e3182456c55; Green M, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7505; Hmama Z, 2004, J CELL SCI, V117, P2131, DOI 10.1242/jcs.01072; Huang SJ, 2017, DRUG DES DEV THER, V11, P91, DOI 10.2147/DDDT.S79870; Khoo AL, 2011, CYTOKINE, V55, P294, DOI 10.1016/j.cyto.2011.04.016; Koh GCKW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057752; Lalvani A, 2010, BRIT MED BULL, V93, P69, DOI 10.1093/bmb/ldp039; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Lopez-Lopez N, 2014, MICROBES INFECT, V16, P755, DOI 10.1016/j.micinf.2014.06.010; Martineau AR, 2012, P NUTR SOC, V71, P84, DOI 10.1017/S0029665111003326; Martineau AR, 2011, LANCET, V377, P242, DOI 10.1016/S0140-6736(10)61889-2; Martineaua AR, 2011, P NATL ACAD SCI USA, V108, P19013, DOI 10.1073/pnas.1111825108; Mastala Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059017; Neyrolles O, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000043; Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247; Ottenhoff THM, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002607; Ralph AR, 2013, LANCET INFECT DIS, V13, P77, DOI 10.1016/S1473-3099(12)70275-X; ROOK GAW, 1986, IMMUNOLOGY, V59, P333; Sita-Lumsden A, 2007, THORAX, V62, P1003, DOI 10.1136/thx.2006.070060; Skerry C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039680; Talat N, 2010, EMERG INFECT DIS, V16, P853, DOI 10.3201/eid1605.091693; Tukvadze N, 2015, AM J CLIN NUTR, V102, P1059, DOI 10.3945/ajcn.115.113886; Urdahl KB, 2011, MUCOSAL IMMUNOL, V4, P288, DOI 10.1038/mi.2011.10; Valentini P, 2012, J PUBLIC HLTH, V9, P3; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002; Venturini E, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0652-7; Weiss G, 2015, IMMUNOL REV, V264, P182, DOI 10.1111/imr.12266; Williams B, 2008, PEDIATR INFECT DIS J, V27, P941, DOI 10.1097/INF.0b013e31817525df; Wingfield T, 2014, J INFECT DIS, V210, P774, DOI 10.1093/infdis/jiu121; Wolf AJ, 2008, J EXP MED, V205, P105, DOI 10.1084/jem.20071367; YANG SL, 1993, ARCH BIOCHEM BIOPHYS, V303, P98, DOI 10.1006/abbi.1993.1260	45	0	0	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					337	347		10.1080/15513815.2018.1509407			11	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200004	30260729				2019-10-28	
J	Gajardo, AIJ; von Dessauer, B; Molina, V; Vera, S; Libuy, M; Rodrigo, R				Gajardo, Abraham I. J.; von Dessauer, Bettina; Molina, Victor; Vera, Sergio; Libuy, Matias; Rodrigo, Ramon			Plasma Antioxidant Potential at Admission is Associated with Length of ICU Stay in Child with Sepsis: A Pilot Study	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Oxidative stress; sepsis; intensive care; pediatrics; biomarkers; length of stay	OXIDATIVE STRESS; SEPTIC SHOCK; VITAMIN-C; CAPACITY; MELATONIN	Objective: To assess the relationship between biomarkers of oxidative stress (OS) and the length of stay in intensive care units (LSICU) in septic children. Methods: Clinical parameters and biomarkers of OS were measured in 16 children admitted for sepsis in an intensive care unit. The associations between biomarkers of OS and the LSICU were assessed by linear correlation. Multiple linear regression models were constructed to adjust other variables. Results: The mean of LSICU was 7.13 +/- 4.17 days. LSICU was associated with the catalase activity (rho =0.56, p-value =0.024) and the ferric reducing ability of plasma (FRAP, r = 0.73, p-value =0.001). However, only FRAP at ICU admission was independently associated with LSICU, which rose 0.21 days for each 10 mu mol/l of increase in the FRAP level. Conclusion: We conclude for first time that FRAP level at ICU admission is independently associated with LSICU in pediatric patients.	[Gajardo, Abraham I. J.; Vera, Sergio; Libuy, Matias; Rodrigo, Ramon] Univ Chile, Fac Med, Inst Biomed Sci, Program Mol & Clin Pharmacol, Santiago, Chile; [von Dessauer, Bettina; Molina, Victor] Dr Roberto Rio Childrens Hosp, Pediat Intens Care Unit, Santiago, Chile	Rodrigo, R (reprint author), Univ Chile, Fac Med, Lab Oxidat Stress & Renal Pathophysiol, Program Mol & Clin Pharmacol, Av Independencia 1027, Santiago, Chile.	rrodrigo@med.uchile.cl			"Fondo Nacional de Investigacion Cientifica y Tecnologica" (FONDECYT grant, CONICYT, Ministry of Education, Government of Chile) [1070948]	This work was supported by "Fondo Nacional de Investigacion Cientifica y Tecnologica" (FONDECYT grant 1070948, CONICYT, Ministry of Education, Government of Chile).	Angstwurm MWA, 2007, CRIT CARE MED, V35, P118, DOI 10.1097/01.CCM.0000251124.83436.0E; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Berenholtz SM, 2002, J CRIT CARE, V17, P1, DOI 10.1053/jcrc.2002.33035; Cheng WE, 2007, INTENS CARE MED, V33, P1187, DOI 10.1007/s00134-007-0628-9; Chuang CC, 2006, CRIT CARE, V10, DOI 10.1186/cc4826; Cowley HC, 1996, CRIT CARE MED, V24, P1179, DOI 10.1097/00003246-199607000-00019; Crimi E, 2006, FREE RADICAL BIO MED, V40, P398, DOI 10.1016/j.freeradbiomed.2005.10.054; Crimi E, 2006, FREE RADICAL RES, V40, P665, DOI 10.1080/10715760600669612; Doise JM, 2008, FUND CLIN PHARMACOL, V22, P203, DOI 10.1111/j.1472-8206.2008.00573.x; Escames G, 2006, J PHARM PHARMACOL, V58, P1153, DOI 10.1211/jpp.58.9.0001; Gitto E, 2001, PEDIATR RES, V50, P756, DOI 10.1203/00006450-200112000-00021; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Hartman ME, 2013, PEDIATR CRIT CARE ME, V14, P686, DOI 10.1097/PCC.0b013e3182917fad; Jang JY, 2017, J CRIT CARE, V39, P131, DOI 10.1016/j.jcrc.2017.01.016; Kanter M, 2005, TOHOKU J EXP MED, V206, P155, DOI 10.1620/tjem.206.155; Karapetsa M, 2013, FOOD CHEM TOXICOL, V61, P106, DOI 10.1016/j.fct.2013.03.026; Kim JY, 2006, EUR J PHARMACOL, V534, P202, DOI 10.1016/j.ejphar.2006.01.015; Leteurtre S, 2003, LANCET, V362, P192, DOI 10.1016/S0140-6736(03)13908-6; Luce WA, 2007, CRIT CARE, V11, DOI 10.1186/cc6091; Moerer O, 2007, CRIT CARE, V11, DOI 10.1186/cc5952; Molina V., 2016, REDOX REP, P1; Namachivayam P, 2012, PEDIATR CRIT CARE ME, V13, P520, DOI 10.1097/PCC.0b013e31824fb989; Nathens AB, 2002, ANN SURG, V236, P814, DOI 10.1097/00000658-200212000-00014; Pascual C, 1998, CRIT CARE MED, V26, P705, DOI 10.1097/00003246-199804000-00019; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Ritter C, 2003, INTENS CARE MED, V29, P1782, DOI 10.1007/s00134-003-1789-9; Schell D, 2016, REPORT AUSTR NZ PEDI; Tsai KV, 2000, FREE RADICAL BIO MED, V28, P926, DOI 10.1016/S0891-5849(00)00180-5; van der Poll T, 1999, INFECT DIS CLIN N AM, V13, P413, DOI 10.1016/S0891-5520(05)70083-0; von Dessauer B, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.05.001; Watson RS, 2005, PEDIAT CRIT CARE, V6, P3	31	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					348	358		10.1080/15513815.2018.1517845			11	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200005	30339057				2019-10-28	
J	Ukazu, A; Ravikumar, S; Roche, N; Heller, DS				Ukazu, Adanna; Ravikumar, Sitara; Roche, Natalie; Heller, Debra S.			Are Short Umbilical Cords Seen in Pathology Really Short?	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Placenta; umbilical; cord; perinatal		Purpose: Short umbilical cords are associated with adverse perinatal outcomes. Clinicians may rely on measurements made by pathologists, which do not include portions of the cord remaining n the child or sent for blood gasses. Methods: This was a retrospective chart review of term placentas. Sequential cases from January through August 2017 were reviewed from the Pathology archive. Results: 198 placentas were recorded as either third trimester of mature, of which 146 were 37 or greater weeks of gestation. Of these 146, 142 had cords measuring less than 35 cm, the definition of short. Mean cord length was 19.6 cm. Of the 146 placentas, 50(34%) had had blood gases submitted. Conclusions: 34% of short cords by Pathology measurement had had blood gases sent. The fact that 142 out of 146 sequential placentas were recorded as "short" suggests an additional unmeasured loss of length due to cord attached to the infant. Pathology laboratory measurements should not be interpreted as truly short without clinical correlation.	[Ukazu, Adanna; Ravikumar, Sitara; Roche, Natalie; Heller, Debra S.] Rutgers New Jersey Med Sch, Dept Obstet Gynecol & Womens Hlth, Newark, NJ 07103 USA; [Heller, Debra S.] Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA	Heller, DS (reprint author), Rutgers New Jersey Med Sch, Dept Pathol UH E158, 185 South Orange Ave, Newark, NJ 07103 USA.	hellerds@njms.rutgers.edu					Adesina K T, 2014, East Afr Med J, V91, P274; Algreisi F, 2016, INT J REPROD CONTRAC, V5, P4228; Downey A, 2014, PEDIATR DEVEL PATHOL, V17, P327, DOI 10.2350/14-02-1437-OA.1; NAEYE RL, 1985, J PEDIATR-US, V107, P278, DOI 10.1016/S0022-3476(85)80149-9; Olaya-C M, 2015, J Neonatal Perinatal Med, V8, P251, DOI 10.3233/NPM-15915056; Olaya-C M, 2014, J Neonatal Perinatal Med, V7, P269, DOI 10.3233/NPM-14814023; Unmesh BN, 2012, J OBSTET GYN INDIA, V62, P520, DOI 10.1007/s13224-012-0194-0; Yamamoto Y, 2016, FETAL PEDIATR PATHOL, V35, P81, DOI 10.3109/15513815.2015.1122126	8	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					359	362		10.1080/15513815.2018.1517846			4	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200006	30339043				2019-10-28	
J	Soo-Kyeong, J; Lee, N; Bae, MH; Han, YM; Park, KH; Byun, SY				Soo-Kyeong, Jeon; Lee, Narae; Bae, Mi Hye; Han, Young Mi; Park, Kyung Hee; Byun, Shin Yun			Chylous Ascites in an Infant with Thanatophoric Dysplasia Type I with FGFR3 Mutation Surviviny Five Months	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Fibroblast growth factor receptor 3 (FGFR3) gene; dwarfism; chylous ascites; thanatophoric dysplasia	ABDOMINAL CIRCUMFERENCE; GROWTH; MALFORMATION; RATIO	Background: Thanatophoric dysplasia (TD) results from sporadic de novo mutations in the FGFR3 gene. Upon confirming intrauterine diagnosis of this perinatal disease, pregnancy termination is recommended. There is limited information on the natural history of longer-term survivors with type 1 TD. Case report A full-term neonate was confirmed via postnatal genetic testing to have type 1 TD. At 28 days, chylous ascites developed. Medium-chain triglyceride use improved the ascites. Cerebral ventriculomegaly worsened throughout life. Death due to respiratory failure occurred at age 5 months. Conclusion: The chylous ascites in this child with type 1 TD and survival past the neonatal stage suggests that type 1 TD may be accompanied by abnormalities of the lymphatic channels. Moreover, ventriculomegaly can be progressive.	[Soo-Kyeong, Jeon; Lee, Narae; Han, Young Mi; Byun, Shin Yun] Pusan Natl Univ, Dept Pediat, Childrens Hosp, Yangsan, South Korea; [Soo-Kyeong, Jeon; Lee, Narae; Bae, Mi Hye; Han, Young Mi; Park, Kyung Hee; Byun, Shin Yun] Pusan Natl Univ, Dept Pediat, Sch Med, Busan, South Korea; [Bae, Mi Hye; Park, Kyung Hee] Pusan Natl Univ, Dept Pediat, Sch Med, Yangsan, South Korea	Han, YM (reprint author), Pusan Natl Univ, Dept Pediat, Childrens Hosp, Sch Med, 20 Geumo Ro, Yangsan 50612, South Korea.	skybluehym@gmail.com		Byun, Shin Yun/0000-0002-9034-5533; Han, Young Mi/0000-0002-6120-0490			Fenton TR, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-59; Foldynova-Trantirkova S, 2012, HUM MUTAT, V33, P29, DOI 10.1002/humu.21636; GOUTIERES F, 1971, REV NEUROL-FRANCE, V125, P435; Hatzaki A, 2011, AM J MED GENET A, V155A, P2426, DOI 10.1002/ajmg.a.34189; Hevner RF, 2005, ACTA NEUROPATHOL, V110, P208, DOI 10.1007/s00401-005-1059-8; ISAACSON G, 1983, AM J DIS CHILD, V137, P896, DOI 10.1001/archpedi.1983.02140350070017; JOHNSON A, 1987, AM J OBSTET GYNECOL, V157, P764, DOI 10.1016/S0002-9378(87)80046-7; Langer L O Jr, 1987, Am J Med Genet Suppl, V3, P167; Maroteaux P, 1967, Presse Med, V75, P2519; Nakai K, 2010, BRIT J DERMATOL, V163, P656, DOI 10.1111/j.1365-2133.2010.09879.x; Nikkel SM, 2013, CLIN CASE REP, V1, P75, DOI 10.1002/ccr3.29; Noe Eun Jung, 2010, Korean J Pediatr, V53, P1022, DOI 10.3345/kjp.2010.53.12.1022; Osoba O, 2000, J Obstet Gynaecol, V20, P540; PARTINGT.MW, 1971, ARCH DIS CHILD, V46, P656, DOI 10.1136/adc.46.249.656; Rahemtullah A, 1997, AM J OBSTET GYNECOL, V177, P864, DOI 10.1016/S0002-9378(97)70284-9; ROUSSEAU F, 1995, NAT GENET, V10, P11, DOI 10.1038/ng0595-11; Sawai H, 1999, PRENATAL DIAG, V19, P21, DOI 10.1002/(SICI)1097-0223(199901)19:1<21::AID-PD457>3.0.CO;2-5; STENSVOLD K, 1986, CLIN GENET, V29, P157; Superti-Furga A, 2007, AM J MED GENET A, V143A, P1, DOI 10.1002/ajmg.a.31483; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; TONOKI H, 1987, CLIN GENET, V32, P415; Vogt C, 2013, PEDIATR DEVEL PATHOL, V16, P160, DOI 10.2350/12-09-1253-OA.1; Wilcox WR, 1998, AM J MED GENET, V78, P274, DOI 10.1002/(SICI)1096-8628(19980707)78:3<274::AID-AJMG14>3.0.CO;2-C; Wilkie AOM, 2005, CYTOKINE GROWTH F R, V16, P187, DOI 10.1016/j.cytogfr.2005.03.001; WONGMONGKOLRIT T, 1983, ARCH PATHOL LAB MED, V107, P132	25	0	0	1	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					363	371		10.1080/15513815.2018.1504843			9	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200007	30252581				2019-10-28	
J	Kapatia, G; Mitra, S; Gupta, K; Menon, P; Rao, KLN				Kapatia, Gargi; Mitra, Suvradeep; Gupta, Kirti; Menon, Prema; Rao, K. L. N.			Splenic Hemangiomatosis: An Uncommon Vascular Lesion in an Infant	FETAL AND PEDIATRIC PATHOLOGY			English	Article						splenic hemangiomatosis; pediatric tumor; infant	ISOLATED DIFFUSE HEMANGIOMATOSIS; SPLEEN	Background: Vascular tumors of spleen represent a wide spectrum of lesions, ranging from benign to highly aggressive neoplasms. Among the benign tumors, localized hemangiomas are the most frequently encountered. Splenic hemangiomatosis is seldom seen especially in the pediatric population with anecdotal cases described in the literature. Case report: We present of 6-month-old child presenting with abdominal distention. The resected spleen was totally replaced with a hemangiomatous lesion. There were no other hemangiomatous foci outside the spleen. Conclusions: Hemangiomatosis limited to the spleen can occur in a child, and the present case demonstrates its characteristic histological features.	[Kapatia, Gargi; Mitra, Suvradeep; Gupta, Kirti] Post Grad Inst Med Educ & Res, Dept Histopathol, 5th Floor,A Block,Sect 12, Chandigarh, India; [Menon, Prema; Rao, K. L. N.] Post Grad Inst Med Educ & Res, Dept Pediat Surg, Chandigarh, India	Gupta, K (reprint author), Post Grad Inst Med Educ & Res, Dept Histopathol, 5th Floor,A Block,Sect 12, Chandigarh, India.	kirtigupta10@yahoo.co.in					D'Antonio Antonio, 2002, Adv Clin Path, V6, P119; Dufau JP, 1999, HISTOPATHOLOGY, V35, P337; FALK S, 1991, AM J SURG PATHOL, V15, P1023, DOI 10.1097/00000478-199111000-00001; Langner C, 2001, PATHOLOGE, V22, P424, DOI 10.1007/s002920100491; MAEDA H, 1981, ACTA PATHOL JAPON, V31, P135; Nakano Y, 2015, J PEDIATR-US, V166, P1093, DOI 10.1016/j.jpeds.2014.12.033; RUCK P, 1994, PATHOL RES PRACT, V190, P708, DOI 10.1016/S0344-0338(11)80751-X; SCHMID C, 1991, HISTOPATHOLOGY, V18, P478, DOI 10.1111/j.1365-2559.1991.tb00884.x	8	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					372	376		10.1080/15513815.2018.1520372			5	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200008	30358467				2019-10-28	
J	Ghosh, M; Islam, N; Ghosh, A; Chaudhuri, PM; Saha, K; Chatterjee, U				Ghosh, Moupali; Islam, Nelofar; Ghosh, Arindam; Chaudhuri, Priyanka Maity; Saha, Koushik; Chatterjee, Uttara			Pleuropulmonary Blastoma Developing in a Case of Misinterpreted Congenital Pulmonary Airway Malformation: a Case Report	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Pleuropulmonary blastoma; pleuropulmonary blastoma type I; congenital pulmonary airway malformation	CYSTIC ADENOMATOID MALFORMATION; NEEDLE-ASPIRATION-CYTOLOGY; LUNG; RHABDOMYOSARCOMA; CLASSIFICATION; PATHOLOGY	Background: Pleuropulmonary blastoma (PPB) is a childhood malignancy known to be associated with congenital pulmonary airway malformation (CPAM). Case Report An 18 months boy presented with respiratory distress. Computed tomography (CT) scans revealed a large right-sided lung mass. Fine needle aspiration cytology (FNAC) showed sheets and clusters of small round to oval cells with scanty cytoplasm. The possibility of PPB was suggested. Trucut biopsy from the mass confirmed the diagnosis of PPB, of at least type II. The child had earlier been diagnosed as CPAM for which he had undergone lobectomy at six months, which on review was diagnosed as PPB I. Conclusion: We describe the cytological and histological findings of a case of PPBII/III evolving from a PPB I originally thought to be a CPAM type IV. This supports the theory that PPB I may progress to a more aggressive type II with time, and highlights the importance of the adequately treating the PPB I to prevent this transformation.	[Ghosh, Moupali; Islam, Nelofar; Chaudhuri, Priyanka Maity; Chatterjee, Uttara] Inst Post Grad Med Educ & Res, Dept Pathol, Kolkata, India; [Ghosh, Moupali; Islam, Nelofar; Chaudhuri, Priyanka Maity; Chatterjee, Uttara] SSKM Hosp, Kolkata, India; [Ghosh, Moupali; Islam, Nelofar; Chaudhuri, Priyanka Maity; Chatterjee, Uttara] SSKM, Kolkata, India; [Ghosh, Arindam; Saha, Koushik] NRSMCH, Dept Pediat Surg, Kolkata, India	Chatterjee, U (reprint author), Inst Post Grad Med Educ & Res, Dept Pathol, Kolkata, India.; Chatterjee, U (reprint author), SSKM Hosp, Kolkata, India.; Chatterjee, U (reprint author), SSKM, Kolkata, India.	uttarac1@gmail.com					Argani P, 2016, WHO CLASSIFICATION T; Cagle P, 2015, WHO CLASSIFICATION T; Cohen CM, 2014, ESSENTIALS SURG PEDI, P172; Das M, 2018, DIAGN CYTOPATHOL, V46, P175, DOI 10.1002/dc.23811; Dehner LP, 2015, PEDIATR DEVEL PATHOL, V18, P504, DOI 10.2350/15-10-1732-OA.1; Dehner LP, 2005, PEDIATR SURG INT, V21, P123, DOI 10.1007/s00383-004-1327-z; Dishop MK, 2008, ARCH PATHOL LAB MED, V132, P1079, DOI 10.1043/1543-2165(2008)132[1079:PAMLTI]2.0.CO;2; Drut R, 1998, DIAGN CYTOPATHOL, V19, P303; Gelven PL, 1997, DIAGN CYTOPATHOL, V16, P336, DOI 10.1002/(SICI)1097-0339(199704)16:4<336::AID-DC6>3.0.CO;2-B; Hill DA, 2004, AM J SURG PATHOL, V28, P554, DOI 10.1097/00000478-200404000-00017; Hill DA, 2008, AM J SURG PATHOL, V32, P282, DOI 10.1097/PAS.0b013e3181484165; KROUS HF, 1981, J PEDIATR SURG, V16, P506, DOI 10.1016/S0022-3468(81)80017-6; Langston Claire, 2003, Semin Pediatr Surg, V12, P17, DOI 10.1016/S1055-8586(03)70004-3; Libretti L, 2008, ANN THORAC SURG, V85, P658, DOI 10.1016/j.athoracsur.2007.08.012; MacSweeney F, 2003, AM J SURG PATHOL, V27, P1139, DOI 10.1097/00000478-200308000-00012; MANIVEL JC, 1988, CANCER, V62, P1516, DOI 10.1002/1097-0142(19881015)62:8<1516::AID-CNCR2820620812>3.0.CO;2-3; Messinger YH, 2015, CANCER-AM CANCER SOC, V121, P276, DOI 10.1002/cncr.29032; MURPHY JJ, 1992, J PEDIATR SURG, V27, P1364, DOI 10.1016/0022-3468(92)90299-M; Myers JL, 2018, ROSAI ACKERMANS SURG, P428; Nicol KK, 2000, ARCH PATHOL LAB MED, V124, P416; Ozcan C, 2001, J PEDIATR SURG, V36, P1062, DOI 10.1053/jpsu.2001.24747; Priest JR, 2009, PEDIATR PULM, V44, P14, DOI 10.1002/ppul.20917; Sengupta S, 2011, INDIAN J MED PAEDIAT, V32, P223, DOI 10.4103/0971-5851.95146; Shin BK, 2001, DIAGN CYTOPATHOL, V25, P397, DOI 10.1002/dc.10006; STOCKER JT, 1977, HUM PATHOL, V8, P155, DOI 10.1016/S0046-8177(77)80078-6; UEDA K, 1977, CANCER-AM CANCER SOC, V40, P383, DOI 10.1002/1097-0142(197707)40:1<383::AID-CNCR2820400154>3.0.CO;2-2; Wagh PK, 2015, J PATHOL, V236, P41, DOI 10.1002/path.4500	27	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	5					377	386		10.1080/15513815.2018.1520943			10	Pathology; Pediatrics	Pathology; Pediatrics	HM9JW	WOS:000459801200009	30358469				2019-10-28	
J	Munakata, S; Tomiyama, E; Takayama, H				Munakata, Satoru; Tomiyama, Eisuke; Takayama, Hitoshi			Case Report of Atypical Juxtaglomerular Cell Tumor	CASE REPORTS IN PATHOLOGY			English	Article								Juxtaglomerular cell tumor (JGCT) is a rare renal tumor, producing renin and behaving almost in a benign fashion. So far, only three cases have been reported as malignant. We report a rare case with atypical JGCT. A 74-year-old male was referred to our hospital due to hypertension, proteinuria, and hematuria. Abdominal CT revealed a mass measured in 9.7x7.0 cm in the lower portion of the right kidney. Right kidney was removed laparoscopically. Grossly, white to tan tumor with massive hemorrhage and necrosis occupied the lower portion of the right kidney. Microscopically, tumor grew in a solid fashion. Tumor cells were polygonal to ovoid cells with round nuclei and clear to eosinophilic cytoplasm. Mitosis was found in 5 per 10 HPF. Immunohistochemically, tumor cells were stained by vimentin and CD34. Some tumor cells were also positive for renin. Electron micrograph showed near rhomboid crystalline structure in the tumor cells. Because of massive necrosis and mitotic figures, diagnosis of atypical (potentially malignant) JGCT was rendered. Gene mutations for IDH1, PIK3CA, K-ras, N-ras, Braf, and EGFR were not found by MBP-QP system.	[Munakata, Satoru] Sakai City Hosp Org, Sakai City Med Ctr, Dept Pathol, Sakai, Osaka, Japan; [Tomiyama, Eisuke; Takayama, Hitoshi] Sakai City Hosp Org, Sakai City Med Ctr, Dept Urol, Sakai, Osaka, Japan	Munakata, S (reprint author), Sakai City Hosp Org, Sakai City Med Ctr, Dept Pathol, Sakai, Osaka, Japan.	munak-s@sakai-hospital.jp					Beaudoin J, 2008, NAT CLIN PRACT NEPHR, V4, P458, DOI 10.1038/ncpneph0890; Duan XZ, 2004, AM J SURG PATHOL, V28, P1098, DOI 10.1097/01.pas.0000126722.29212.a7; Elouazzani H, 2014, J CLIN IMAG SCI, V4, DOI 10.4103/2156-7514.135482; KIHARA I, 1968, ACTA PATHOL JAPON, V18, P197; Kuroda N, 2013, HUM PATHOL, V44, P47, DOI 10.1016/j.humpath.2012.04.006; Kuroda N, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-80; Nakashima Chiho, 2018, Oncotarget, V9, P25181, DOI 10.18632/oncotarget.25388; ROBERTSON PW, 1967, AM J MED, V43, P963, DOI 10.1016/0002-9343(67)90256-2; Sakata R, 2013, CASE REP PATHOL, DOI 10.1155/2013/973865; Shera Altaf H, 2011, J Indian Assoc Pediatr Surg, V16, P152, DOI 10.4103/0971-9261.86876; Wang F, 2017, J CLIN HYPERTENS, V19, P807, DOI 10.1111/jch.12997; Yang HY, 2016, ONCOL LETT, V11, P1418, DOI 10.3892/ol.2015.4041	12	1	1	1	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									6407360	10.1155/2018/6407360			5	Pathology	Pathology	GZ3VR	WOS:000449315900001	30473900	DOAJ Gold, Green Published			2019-10-28	
J	Lotowska, JM; Sobaniec-Lotowska, ME; Sobaniec, P; Lebensztejn, DM				Lotowska, Joanna M.; Sobaniec-Lotowska, Maria E.; Sobaniec, Piotr; Lebensztejn, Dariusz M.			LIVER SINUSOIDAL ENDOTHELIAL CELLS IN MORPHOGENESIS OF PEDIATRIC AUTOIMMUNE HEPATITIS. ULTRASTRUCTURAL CHARACTERISTICS - A NOVEL REPORT	POLISH JOURNAL OF PATHOLOGY			English	Review						liver sinusoidal endothelial cells; nonparenchymal hepatic cells; pediatric autoimmune hepatitis; pretreatment liver oligobiopsy material; ultrastructure	KUPFFER CELLS; FIBROSIS; CHILDREN; DIAGNOSIS; CIRRHOSIS; FEATURES; CRITERIA	The pathogenesis of autoimmune hepatitis (AIH) is poorly understood. Up to now, little is known of the involvement of liver sinusoidal endothelial cells (LSECs), accounting for approximately 40% of nonparenchymal hepatic cells, in AIH morphogenesis in pediatric patients. The study objective was ultrastructural analysis of LSECs from pretreatment biopsies of 19 children, aged 4-17 years (14 girls), with clinically and histologically diagnosed AIH. Our study is the first to describe alterations in LSECs, from swelling to necrosis, demonstrating their important role in the morphogenesis and progression of pediatric AIH. Frequently damage to LSECs coexisted with significantly activated Kupffer cells, fibrogenesis and fibrosis, but not cirrhosis, accompanied by the appearance of transitional hepatic stellate cells. Interestingly, even though in half of the AIH children the sinusoidal vessels were found to undergo transformation of discontinuous into continuous endothelium showing features of defenestration, the true basement membrane did not form underneath. The fact that the basement membrane is not formed, even when LSECs are markedly damaged, may seem to indicate some regenerative capacities of these cells and lesion reversibility.	[Lotowska, Joanna M.; Sobaniec-Lotowska, Maria E.] Med Univ Bialystok, Dept Med Pathomorphol, Waszyngtona 13, PL-15269 Bialystok, Poland; [Sobaniec, Piotr] Neuromaster Inst Neurophysiol, Bialystok, Poland; [Lebensztejn, Dariusz M.] Med Univ Bialystok, Dept Pediat Gastroenterol Hepatol Nutr & Allergol, Bialystok, Poland	Lotowska, JM (reprint author), Med Univ Bialystok, Dept Med Pathomorphol, Waszyngtona 13, PL-15269 Bialystok, Poland.	joannalotowska@gmail.com					Alvarez E, 1999, J HEPATOL, V31, P929, DOI 10.1016/S0168-8278(99)80297-9; BABBS C, 1990, HEPATOLOGY, V11, P723, DOI 10.1002/hep.1840110503; Braet F, 2012, MICRON, V43, P1252, DOI 10.1016/j.micron.2012.02.010; Braet F, 2009, LIVER INT, V29, P603, DOI 10.1111/j.1478-3231.2008.01836.x; Chazouilleres O, 2015, DIGEST DIS, V33, P181, DOI 10.1159/000440831; COUVELARD A, 1993, AM J PATHOL, V143, P738; de Boer YS, 2015, HISTOPATHOLOGY, V66, P351, DOI 10.1111/his.12558; DeLeve LD, 2015, HEPATOLOGY, V61, P1740, DOI 10.1002/hep.27376; Dohmen K, 2017, HEPATOL RES, V47, P1375, DOI 10.1111/hepr.12875; Fujiwara K, 2011, LIVER INT, V31, P1013, DOI 10.1111/j.1478-3231.2011.02524.x; Canh HN, 2017, J CLIN PATHOL, V70, P961, DOI 10.1136/jclinpath-2016-204271; Kage M, 2007, HEPATOL RES, V37, pS502, DOI 10.1111/j.1872-034X.2007.00234.x; Lammert C, 2017, CURR GASTROENTEROL R, V45, P723; Lebensztejn DM, 1998, MED SCI MONITOR, V4, P697; Lin R, 2016, MOL MED REP, V13, P3874, DOI 10.3892/mmr.2016.4998; Lotowska JM, 2014, WORLD J GASTROENTERO, V20, P4335, DOI 10.3748/wjg.v20.i15.4335; Lotowska JM, 2018, ADV MED SCI-POLAND, V63, P127, DOI 10.1016/j.advms.2017.09.002; Lotowska JM, 2017, DIGEST LIVER DIS, V49, P929, DOI 10.1016/j.dld.2017.04.001; Lotowska JM, 2017, GASTROENT RES PRACT, DOI 10.1155/2017/2721547; Lotowska JM, 2013, SCAND J GASTROENTERO, V48, P352, DOI 10.3109/00365521.2012.746390; Mehal WZ, 2001, GASTROENTEROLOGY, V120, P250, DOI 10.1053/gast.2001.20947; Mieli-Vergani G, 2009, SEMIN LIVER DIS, V29, P297, DOI 10.1055/s-0029-1233529; Mroczkowska-Juchkiewicz A, 2017, CENT EUR J IMMUNOL, V42, P107, DOI 10.5114/ceji.2017.67324; Muratori P, 2016, DIGEST LIVER DIS, V48, P1078, DOI 10.1016/j.dld.2016.06.018; Natarajan V, 2017, BIOMED RES INT, DOI 10.1155/2017/4097205; PETROVIC LM, 1989, HISTOPATHOLOGY, V14, P233, DOI 10.1111/j.1365-2559.1989.tb02142.x; Poisson J, 2017, J HEPATOL, V66, P212, DOI 10.1016/j.jhep.2016.07.009; Radhakrishnan KR, 2010, DIGEST LIVER DIS, V42, P724, DOI 10.1016/j.dld.2010.01.002; Soares JC, 2016, MINERVA GASTROENTERO, V62, P138; Sobaniec-Lotowska ME, 2011, ADV MED SCI-POLAND, V56, P172, DOI 10.2478/v10039-011-0037-8; Sobaniec-Lotowska ME, 2007, WORLD J GASTROENTERO, V13, P2918, DOI 10.3748/wjg.v13.i21.2918; Sogo T, 2018, HEPATOL RES, V48, P286, DOI 10.1111/hepr.12998; Sulkowska M, 2002, B VET I PULAWY, V46, P239; Tucker SM, 2015, AM J SURG PATHOL, V39, P772, DOI 10.1097/PAS.0000000000000395; Wang J, 2017, WORLD J GASTROENTERO, V23, P859, DOI 10.3748/wjg.v23.i5.859; Xu B, 2003, AM J PATHOL, V163, P1275, DOI 10.1016/S0002-9440(10)63487-6; Xu MX, 2017, BIOSCI TRENDS, V11, P163, DOI 10.5582/bst.2017.01007; Zhou WC, 2014, WORLD J GASTROENTERO, V20, P7312, DOI 10.3748/wjg.v20.i23.7312	38	0	0	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					327	334		10.5114/PJP.2018.81691			8	Pathology	Pathology	HK1SM	WOS:000457686800001	30786681	DOAJ Gold			2019-10-28	
J	Pehlivan, FS; Sivrikoz, ON; Dag, F; Kececi, SD; Sanal, SM				Pehlivan, Fatma S.; Sivrikoz, Oya N.; Dag, Filiz; Kececi, Steel D.; Sanal, Salahattin M.			DISTRIBUTION OF CXCR4 AND TUMOUR-INFILTRATING LYMPHOCYTES IN BREAST CANCER SUBTYPES; THEIR RELATIONSHIP WITH EACH OTHER, AXILLARY LYMPH NODE INVOLVEMENT, AND OTHER PROGNOSTIC INDICATORS	POLISH JOURNAL OF PATHOLOGY			English	Article						breast cancer; breast cancer subtype; CXCR4; tumour-infiltrating lymphocytes	EXPRESSION; CHEMOTHERAPY	We have investigated the distribution of chemokine receptor 4 (CXCR4) and CD8-positive, tumour-infiltrating T lymphocytes (CD8+ TILs) in breast cancer subtypes and explored the relationship between them and the well-established conventional prognostic markers, including axillary lymph node involvement. A total of 250 breast cancer patients were included in the study. The patients were separated into luminal A + B, HER2 enriched/overexpressed (HER2+), and triple-negative, on the basis of their staining characteristics, via conventional staining methods. Immunohistochemical (IHC) staining for CXCR4 and CD8+ TILs were performed on the archival tissues from each patient. With increasing intensity of CXCR4 staining, there was a higher incidence of lymph node metastasis (p < 0.01). Similarly, there was a positive correlation between the primary tumour size, HER2 + subtype, lymphovascular invasion, and axillary lymph node involvement. Dense lymphocytic infiltration was observed in HER2 + and triple-negative patients. No correlation between CD8+ TILs in all sites and breast cancer subtypes was discovered. A reverse correlation was discovered with CD8+ TILs stained only intratumorally and CXCR4 expression. In conclusion, lymph node involvement correlates with higher CXCR4 expression in all breast cancer subtypes. Conversely, no such correlation is found with CD8+ TILs.	[Pehlivan, Fatma S.; Sanal, Salahattin M.] Ozel Tinaztepe Hosp, Dept Pathol, Izmir, Turkey; [Sivrikoz, Oya N.] Frozen Private Pathol Lab, Dept Pathol, Izmir, Turkey; [Dag, Filiz] Izmir Metropolitan Municipal Esrefpasa Hosp, Dept Pathol, Izmir, Turkey; [Kececi, Steel D.; Sanal, Salahattin M.] Manisa Merkezefendi Govt Hosp, Dept Pathol, Manisa, Turkey; Ozel Tinaztepe Hosp, Dept Med Oncol, Izmir, Turkey	Sanal, SM (reprint author), Ozel Tinaztepe Hosp, Div Med Oncol, Ahmet Pristina Bulvari 203-27 Sk 12, TR-35160 Turkey, Turkey.	sanal_salahattin@yahoo.com					Adamkov M, 2010, NEOPLASMA, V57, P572, DOI 10.4149/neo_2010_06_572; Adams S, 2014, J CLIN ONCOL, V32, P2959, DOI 10.1200/JCO.2013.55.0491; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Bukholm IK, 2000, J PATHOL, V190, P15; Cabioglu N, 2005, CLIN CANCER RES, V11, P5686, DOI 10.1158/1078-0432.CCR-05-0014; Chu QD, 2011, SURGERY, V149, P193, DOI 10.1016/j.surg.2010.05.016; Denkert C, 2015, J CLIN ONCOL, V33, P983, DOI 10.1200/JCO.2014.58.1967; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Howland NK, 2013, J SURG RES, V185, P697, DOI 10.1016/j.jss.2013.06.048; Hwang JH, 2003, J CLIN ENDOCR METAB, V88, P408, DOI 10.1210/jc.2002-021381; Ibrahim EM, BREAST CANC RES TREA; Khedr RAG, 2016, J CANC SCI THER, V8, P7; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Liu YX, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-16; Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902; Macchetti Alexandre Henrique, 2006, Clinics, V61, P203, DOI 10.1590/S1807-59322006000300004; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Matkowski R, 2009, ANTICANCER RES, V29, P2445; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Park HS, 2016, J SURG ONCOL, V114, P17, DOI 10.1002/jso.24275; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Schrader AJ, 2002, BRIT J CANCER, V86, P1250, DOI 10.1038/sj/bjc/6600221; Sivrikoz ON, 2013, POL J PATHOL, V64, P253, DOI 10.5114/PJP.2013.39333; Vela M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00012; Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284; Yasuoka H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-340; Zhang S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3338-x; Zhang ZG, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-49; Zhao ZW, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0408-8	30	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					335	341		10.5114/PJP.2018.81692			7	Pathology	Pathology	HK1SM	WOS:000457686800002	30786682	DOAJ Gold			2019-10-28	
J	Bak, A; Junkiert-Czarnecka, A; Heise, M; Januchowska, D; Krzywinska, O; Haus, O				Bak, Aneta; Junkiert-Czarnecka, Anna; Heise, Marta; Januchowska, Daria; Krzywinska, Olga; Haus, Olga			SEARCHING FOR NEW BREAST CANCER-ASSOCIATED GENES. ABRAXAS1 GENE MUTATIONS IN THE GROUP OF BRCA1-NEGATIVE PATIENTS	POLISH JOURNAL OF PATHOLOGY			English	Article						breast cancer; ABRAXAS1 mutations; breast cancer predisposing genes	BRCA1; CCDC98; RAP80	In the present study, we analysed the association of mutations of a BRCA1-associated gene, ABRAXAS1, with the risk of development of breast cancer (BC) in BRCA1-negative women from North-Central Poland. A hundred women with consecutively diagnosed BC and 100 women belonging to the control group were screened for new mutations predisposing to breast cancer. The first step was a test carried out in order to find one of the three Polish founder mutations in the BRCA1 gene. In 96 BRCA1-negative patients two missense variants: c.422C>T and c.1042G >A as well as two intronic variants: IVS3-34G >A, IVS3-44T>C were detected in the ABRAXAS1 gene. The c.422C>T mutation was detected in one of 96 women diagnosed with breast cancer (1.04%); it was not associated with increased risk of disease in this group, compared to the controls (p = 0.49), but the odds ratio was 3.314; 95% CI: 0.122-75.352. IVS3-44T>C was found more frequently in the control group (15/93) than in the tested group (1/85), OR 0.062; 95% CI: 0.008-0.480, p = 0.007, which may suggest protective properties of this variant against tumorigenicity. The data obtained from the present study suggest the necessity for further research to be conducted on the ABRAXAS1 gene in relation to hereditary predisposition to breast cancer.	[Bak, Aneta; Junkiert-Czarnecka, Anna; Heise, Marta; Haus, Olga] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Fac Med, Dept Clin Genet, Bydgoszcz, Poland; [Januchowska, Daria; Krzywinska, Olga] Nicolaus Copernicus Univ Torun, Coll Med Bydgoszcz, Fac Med, Helisa Students Res Circle Med Genet,Dept Clin Ge, Bydgoszcz, Poland	Bak, A (reprint author), Nicolaus Copernicus Univ Torun, Dept Clin Genet, Coll Med Bydgoszcz, Curie Sklodowskiej 9, PL-85094 Bydgoszcz, Poland.	aneta.bak@cm.umk.pl	Bak, Aneta/H-4700-2014	Bak, Aneta/0000-0001-8879-2521	Collegium Medicum	We wish to thank all patients for participating in this investigation and Collegium Medicum for BIOTECH100 grant.	Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248; Castillo A, 2014, CELL REP, V8, P807, DOI 10.1016/j.celrep.2014.06.050; Choi Y, 2012, P ACM C BIOINF COMP, P414, DOI DOI 10.1145/2382936.2382989; Garehdaghchi Z, 2016, WSPOLCZESNA ONKOL, V20, P308, DOI 10.5114/wo.2016.61851; Gorski B, 2000, AM J HUM GENET, V66, P1963, DOI 10.1086/302922; Gorski B, 2005, BREAST CANCER RES TR, V92, P19, DOI 10.1007/s10549-005-1409-1; Gronwald J, 2017, CLIN GENETICS CANC 2, P85; Khabaz MN, 2014, POL J PATHOL, V65, P141, DOI 10.5114/PJP.2014.43964; Liu ZX, 2007, NAT STRUCT MOL BIOL, V14, P716, DOI 10.1038/nsmb1279; Lubinski J, 2012, INT J CANCER, V131, P229, DOI 10.1002/ijc.26369; Nagy Z, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005791; Nikkila J, 2009, ONCOGENE, V28, P1843, DOI 10.1038/onc.2009.33; Novak DJ, 2009, BREAST CANCER RES TR, V117, P453, DOI 10.1007/s10549-008-0134-y; Osorio A, 2009, BREAST CANCER RES TR, V113, P371, DOI 10.1007/s10549-008-9933-4; Renault AL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156820; Solyom S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003223; Tavtigian SV, 2006, J MED GENET, V43, P295, DOI 10.1136/jmg.2005.033878; Valcovici M, 2016, ARCH MED SCI, V12, P428, DOI 10.5114/aoms.2016.59270; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476	19	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					342	346		10.5114/PJP.2018.81693			5	Pathology	Pathology	HK1SM	WOS:000457686800003	30786683	DOAJ Gold			2019-10-28	
J	Hybiak, J; Domagala, P; Domagala, W				Hybiak, Jolanta; Domagala, Pawel; Domagala, Wenancjusz			BRCA1 AND PARP1 MRNA EXPRESSION DURING PROGRESSION FROM NORMAL BREAST TO DUCTAL CARCINOMA IN SITU AND INVASIVE BREAST CANCER: A LASER MICRODISSECTION STUDY	POLISH JOURNAL OF PATHOLOGY			English	Article						breast cancer; BRCA1; PARP1; laser microdissection; DCIS	GENOMIC INSTABILITY; HETEROGENEITY; PATHWAYS; LESIONS; GENES; GRADE	The contribution of DNA damage repair mechanisms to the progression of normal breast to ductal carcinoma in situ (DCIS) and invasive ductal carcinoma is largely unknown. The purpose of this report was to assess the mRNA expression levels of two important genes associated with DNA repair, BRCA1 and PARP1, in normal breast tissue, DCIS G1, G2 and G3, and co-existing adjacent invasive ductal carcinoma. BRCA1 and PARP1 mRNA expression was assessed in 32 ductal carcinomas in situ of the breast using a laser microdissection and pressure catapulting system and quantitative real-time PCR. The relative expression of BRCA1 mRNA was significantly increased in DCIS G2 and DCIS G3 relative to normal breast tissue (p = 0.02, p = 0.001, respectively). Significant differences in BRCA1 expression were observed between DCIS G1 and G2 (p = 0.02) and between DCIS G1 and G3 (p = 0.0007). No significant differences in BRCA1 expression were observed between normal breast tissue and DCIS G1 and between DCIS component and adjacent invasive ductal carcinoma. No significant differences in the relative expression of PARP1 mRNA were observed between groups. Increased BRCA1 mRNA expression (but not PARP1 mRNA) occurs early in the development of breast cancer, i.e. at the noninvasive (DCIS) stage, suggesting a demand for increased activity of a DNA double-strand break repair by homologous recombination. DCIS G1 and normal breast tissue share highly similar BRCA1 and PARP1 expression level. This finding supports the idea that DCIS G1 belongs to a separate family of precursor lesions with low malignant potential.	[Hybiak, Jolanta; Domagala, Pawel; Domagala, Wenancjusz] Pomeranian Med Univ, Dept Pathol, Unii Lubelskiej 1, PL-71252 Szczecin, Poland	Domagala, W (reprint author), Pomeranian Med Univ, Dept Pathol, Unii Lubelskiej 1, PL-71252 Szczecin, Poland.	wenek@pum.edu.pl					Abdel-Fatah TMA, 2008, AM J SURG PATHOL, V32, P513, DOI 10.1097/PAS.0b013e318161d1a5; Acland A, 2013, NUCLEIC ACIDS RES, V41, pD8, DOI 10.1093/nar/gks1189; Allred DC, 2008, CLIN CANCER RES, V14, P370, DOI 10.1158/1078-0432.CCR-07-1127; Balleine RL, 2008, CLIN CANCER RES, V14, P8244, DOI 10.1158/1078-0432.CCR-08-0939; Barnes NLP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e797; Bombonati A, 2011, J PATHOL, V223, P307, DOI 10.1002/path.2808; Castro NP, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2157; Chalabi N, 2004, EUR J CANCER, V40, P1768, DOI 10.1016/j.ejca.2004.03.028; Clark-Langone KM, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-279; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; de Kok JB, 2005, LAB INVEST, V85, P154, DOI 10.1038/labinvest.3700208; De Vos M, 2012, BIOCHEM PHARMACOL, V84, P137, DOI 10.1016/j.bcp.2012.03.018; Deng CX, 2000, ONCOGENE, V19, P1059, DOI 10.1038/sj.onc.1203269; Domagala P, 2011, BREAST CANCER RES TR, V127, P861, DOI 10.1007/s10549-011-1441-2; Egawa C, 2001, JPN J CANCER RES, V92, P624, DOI 10.1111/j.1349-7006.2001.tb01140.x; Ellsworth RE, 2007, ANN SURG ONCOL, V14, P3070, DOI 10.1245/s10434-007-9459-8; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Emery LA, 2009, AM J PATHOL, V175, P1292, DOI 10.2353/ajpath.2009.090115; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Goode EL, 2002, CANCER EPIDEM BIOMAR, V11, P1513; Heaphy CM, 2009, BREAST CANCER RES TR, V117, P17, DOI 10.1007/s10549-008-0165-4; Hernandez L, 2012, J PATHOL, V227, P42, DOI 10.1002/path.3990; Heselmeyer-Haddad K, 2012, AM J PATHOL, V181, P1807, DOI 10.1016/j.ajpath.2012.07.012; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105; Lubinski J, 2007, J BUON, V12, pS23; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Mallona I, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-404; Margeli M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009499; Masood S, 2011, ADV ANAT PATHOL, V18, P190, DOI 10.1097/PAP.0b013e31821698cc; Meeker AK, 2004, AM J PATHOL, V164, P925, DOI 10.1016/S0002-9440(10)63180-X; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Raymaekers M, 2009, J CLIN LAB ANAL, V23, P145, DOI 10.1002/jcla.20307; Schnitt S. J., 2012, WHO CLASSIFICATION T, P90; Schuetz CS, 2006, CANCER RES, V66, P5278, DOI 10.1158/0008-5472.CAN-05-4610; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Specht K, 2001, AM J PATHOL, V158, P419, DOI 10.1016/S0002-9440(10)63985-5; Thompson A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1983; To MD, 1998, AM J PATHOL, V153, P47, DOI 10.1016/S0002-9440(10)65544-7; van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Wapnir IL, 2011, J NATL CANCER I, V103, P478, DOI 10.1093/jnci/djr027	43	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					347	355		10.5114/PJP.2018.81694			9	Pathology	Pathology	HK1SM	WOS:000457686800004	30786684	DOAJ Gold			2019-10-28	
J	Kolenda, T; Kopczynska, M; Guglas, K; Teresiak, A; Blizniak, R; Lasinska, I; Mackiewicz, J; Lamperska, K				Kolenda, Tomasz; Kopczynska, Magda; Guglas, Kacper; Teresiak, Anna; Blizniak, Renata; Lasinska, Izabela; Mackiewicz, Jacek; Lamperska, Katarzyna			EGOT LNCRNA IN HEAD AND NECK SQUAMOUS CELL CARCINOMAS	POLISH JOURNAL OF PATHOLOGY			English	Article						eosinophil granule ontogeny transcript; lncRNA; head and neck cancers; biomarker	LONG NONCODING RNA; GENE-EXPRESSION	Head and neck squamous cell carcinomas (HNSCCs) are one of the most challenging cancers to cure. In this study, we focused on eosinophil granule ontogeny transcript (EGOT), a transcriptional regulator of granule protein expression during eosinophil development that has been previously associated with cancers. Expression levels of EGOT and other selected genes as well as clinical pathology data from HNSCC samples, were obtained from The Cancer Genome Atlas (TCGA) and analysed using GraphPad Prism 5. Our results indicated that the expression of EGOT is slightly down-regulated in HNSCC, depending on tumour grade and location, and is only up-regulated in grade 4 tumours and those located in the pharynx. EGOT expression levels were found to vary according to age, N-stage, grade, lymph node dissection and human papillomavirus (HPV) infection. Patients with higher levels of EGOT expression have longer disease-free survival and overall survival outcomes. Further analysis revealed that EGOT targets are associated with cell division, proliferation, protein modification, drug response and cell motility. Taken together, our findings suggest that the EGOT is involved in the progression of HSNCC and seems particularly associated with virus-related forms of HNSCC.	[Kolenda, Tomasz; Kopczynska, Magda; Guglas, Kacper; Teresiak, Anna; Blizniak, Renata; Lamperska, Katarzyna] Greater Poland Canc Ctr, Lab Canc Genet, Garbary 15, PL-61866 Poznan, Poland; [Kolenda, Tomasz; Kopczynska, Magda; Guglas, Kacper; Mackiewicz, Jacek] Poznan Univ Med Sci, Dept Canc Immunol, Chair Med Biotechnol, Poznan, Poland; [Kolenda, Tomasz; Guglas, Kacper] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Lasinska, Izabela] Poznan Univ Med Sci, Heliodor Swiecicki Clin Hosp, Dept Med & Expt Oncol, Poznan, Poland; [Mackiewicz, Jacek] Poznan Univ Med Sci, Dept Biol & Environm Sci, Poznan, Poland; [Mackiewicz, Jacek] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Poznan, Poland	Kolenda, T (reprint author), Greater Poland Canc Ctr, Lab Canc Genet, Garbary 15, PL-61866 Poznan, Poland.	kolenda.tomek@gmail.com			Greater Poland Cancer Centre [21/2015 (113), 13/2016 (128)]	This work was supported by Greater Poland Cancer Centre - grant no.: 21/2015 (113) and grant no.: 13/2016 (128).	Carnero E, 2016, EMBO REP, V17, P1013, DOI 10.15252/embr.201541763; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Cohen N, 2018, ORAL MAXIL SURG CLIN, V30, P381, DOI 10.1016/j.coms.2018.06.001; Dok R, 2016, CANCERS, V8, DOI 10.3390/cancers8040041; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garitano-Trojaola A, 2013, INT J MOL SCI, V14, P15386, DOI 10.3390/ijms140815386; Goedert L, 2016, ADV TUMOR VIROL, V2016, P1; Greco S, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0926-5; Guglas K, 2017, WSPOLCZESNA ONKOL, V21, P259, DOI 10.5114/wo.2017.72382; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jin L, 2017, MOL MED REP, V16, P7072, DOI 10.3892/mmr.2017.7470; Jou A, 2017, ONCOL RES TREAT, V40, P328, DOI 10.1159/000477127; Kolenda T, 2018, REP PRACT ONCOL RADI, V23, P143, DOI 10.1016/j.rpor.2018.01.004; Kolenda T, 2017, REP PRACT ONCOL RADI, V22, P378, DOI 10.1016/j.rpor.2017.07.001; Lamperska KM, 2016, CANCER BIOMARK, V16, P55, DOI 10.3233/CBM-150540; Lamperska KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180265; Lasniska I, 2019, ANTI-CANCER AGENT ME, V19, P290, DOI 10.2174/1871520618666180910092356; Peng W, 2019, PATHOL ONCOL RES, V25, P883, DOI 10.1007/s12253-017-0367-3; Rose Dominic, 2011, Frontiers in Genetics, V2, P69, DOI 10.3389/fgene.2011.00069; Terai G, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-015-2307-5; Tomar S, 2016, HEAD NECK-J SCI SPEC, V38, pE694, DOI 10.1002/hed.24072; Valadkhan S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00181; Wagner LA, 2007, BLOOD, V109, P5191, DOI 10.1182/blood-2006-06-027987; Wu Y, 2017, EXP THER MED, V14, P3817, DOI 10.3892/etm.2017.4949; Xu SP, 2015, TUMOR BIOL, V36, P9807, DOI 10.1007/s13277-015-3746-y; Zhang CX, 2018, BIOCHEM BIOPH RES CO, V503, P1186, DOI 10.1016/j.bbrc.2018.07.023	26	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					356	365		10.5114/PJP.2018.81695			10	Pathology	Pathology	HK1SM	WOS:000457686800005	30786685	DOAJ Gold			2019-10-28	
J	Nie, L; Zhou, XL; Peng, LJ; Fu, Y; Cheng, YQ; Huang, Q				Nie, Ling; Zhou, Xiaoli; Peng, Lijun; Fu, Yao; Cheng, Yuqing; Huang, Qin			HISTOLOGICAL HETEROGENEITY AND DISTRIBUTIONAL DIFFERENCE OF GASTRIC CARCINOSARCOMA: REPORT OF 4 CASES AND LITERATURE REVIEW	POLISH JOURNAL OF PATHOLOGY			English	Review						stomach; carcinosarcoma; gastric cardia; classification	GASTROESOPHAGEAL JUNCTION; CARCINOMA; STOMACH; DIFFERENTIATION; LIGHT; TUMOR; ADENOCARCINOMA; NEUROENDOCRINE; COMPONENT; BREAST	Carcinosarcoma is a rare malignant neoplasm, consisting of both epithelial and mesenchymal component. Primary gastric carcinosarcoma is rare and poorly understood. We reported clinicopathologic features of 4 cases and analysis of 76 cases published in the literature. Clinical symptoms were nonspecific with epigastric pain, weight loss, and melena, as the most common complaints. The prognosis of patients was dismal with high mortality. The tumor commonly occurred in the upper stomach in Chinese patients, whereas, it was more prevalent at the lower stomach in Japanese and other populations. The two malignant components of this rare cancer showed considerable histological heterogeneity with a wide range of differentiation. We propose that carcinosarcomas be divided in two main subtypes: conventional carcinosarcoma and carcinosarcoma, not-otherwise-specified (NOS). Such distinction may provide useful information for targeted treatment of various sarcomatous components of this tumor. Immunohistochemistry should be routinely applied in the diagnosis of this rare tumor.	[Nie, Ling; Fu, Yao] Nanjing Univ, Affiliated Drum Tower Hosp, Dept Pathol, Med Sch, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China; [Zhou, Xiaoli; Cheng, Yuqing] Nanjing Med Univ, Affiliated Changzhou Peoples Hosp 2, Dept Pathol, Changzhou, Jiangsu, Peoples R China; [Peng, Lijun] Nanjing Univ, Affiliated Nanjing Drum Tower Hosp, Dept Clin Lab, Med Sch, Nanjing, Jiangsu, Peoples R China; [Huang, Qin] Vet Affairs Boston Healthcare Syst, Dept Pathol & Lab Med, Boston, MA USA; [Huang, Qin] Harvard Med Sch, Boston, MA USA	Huang, Q (reprint author), Nanjing Univ, Affiliated Drum Tower Hosp, Dept Pathol, Med Sch, Zhongshan Rd 321, Nanjing 210008, Jiangsu, Peoples R China.	qinhuang2015@icloud.com		Fu, Yao/0000-0001-9864-1030			ARGANARAS E, 1963, GASTROENTEROLOGY, V44, P322; BANSAL M, 1982, CANCER, V50, P1876, DOI 10.1002/1097-0142(19821101)50:9<1876::AID-CNCR2820500937>3.0.CO;2-7; CHO KJ, 1990, APMIS, V98, P991, DOI 10.1111/j.1699-0463.1990.tb05025.x; Choi KW, 2013, J GASTRIC CANCER, V13, P69, DOI 10.5230/jgc.2013.13.1.69; Cirocchi R, 2012, ONCOL LETT, V4, P53, DOI 10.3892/ol.2012.699; Colquhoun A, 2015, GUT, V64, P1881, DOI 10.1136/gutjnl-2014-308915; CRUZ JJ, 1991, TUMORI, V77, P355; DUNDAS SAC, 1988, HISTOPATHOLOGY, V13, P347, DOI 10.1111/j.1365-2559.1988.tb02045.x; Fujiie M, 2016, SURG CASE REP, V2, DOI 10.1186/s40792-016-0176-z; Gohongi T, 2015, WORLD J GASTROENTERO, V21, P2830, DOI 10.3748/wjg.v21.i9.2830; Guo RJ, 2003, JIUJIANG MED J, V18, P210; HANADA M, 1985, ACTA PATHOL JAPON, V35, P951; Huang Q, 2007, INT J SURG PATHOL, V15, P38, DOI 10.1177/1066896906295998; Huang Q, 2011, HISTOPATHOLOGY, V59, P188, DOI 10.1111/j.1365-2559.2011.03924.x; Ikeda Y, 2007, GASTRIC CANCER, V10, P63, DOI 10.1007/s10120-006-0405-4; Inoue S, 1998, JAPANESE J GASTROENT, V31, P945; Jang SM, 2010, KOREAN J PATHOL, V44, P87, DOI 10.4132/KoreanJPathol.2010.44.1.87; [蒋娜 Jiang Na], 2016, [诊断病理学杂志, Chinese Journal of Diagnostic Pathology], V23, P662; Kayaselcuk Fazilet, 2002, Pathology & Oncology Research, V8, P275; Kernochan LE, 2009, J NATL COMPR CANC NE, V7, P550, DOI 10.6004/jnccn.2009.0037; KIDA Y, 1993, VIRCHOWS ARCH A, V423, P383, DOI 10.1007/BF01607151; Kikuyama R, 2009, ENDOSCOPY, V41, pE220, DOI 10.1055/s-0029-1214937; Kuroda N, 2006, APMIS, V114, P234, DOI 10.1111/j.1600-0463.2006.apm_328.x; Lakhani SREI, 2012, WHO CLASSIFICATION T; Lauwers G, 2010, WHO CLASSIFICATION T, P48; Li BL, 2015, CLIN NUCL MED, V40, pe506, DOI 10.1097/RLU.0000000000000928; Lien HC, 2004, J PATHOL, V204, P131, DOI 10.1002/path.1624; Maeda H, 2008, J AM COLL SURGEONS, V206, P306, DOI 10.1016/j.jamcollsurg.2007.06.306; Maeda O, 2014, INT CANCER CONF J, V3, P252, DOI 10.1007/s13691-014-0157-7; Maqsood S, 2016, ONCOL CLIN PRACT, V12, P105; Matsukuma S, 1997, PATHOL INT, V47, P73, DOI 10.1111/j.1440-1827.1997.tb04438.x; McCluggage WG, 2002, INT J GYNECOL CANCER, V12, P687, DOI 10.1046/j.1525-1438.2002.01151.x; 신해진, 2014, Korean Journal of Helicobacter Upper Gastrointestinal Research, V14, P121, DOI 10.7704/kjhugr.2014.14.2.121; Nakayama Y, 1997, PATHOL INT, V47, P557, DOI 10.1111/j.1440-1827.1997.tb04540.x; Nie Ling, 2017, ARCH PATHOL LAB MED, V141, pe11; Park MY, 2016, KOREAN J CLIN ONCOL, V12, P136; Randjelovic T, 2007, WORLD J GASTROENTERO, V13, P5533, DOI 10.3748/wjg.v13.i41.5533; Sano T, 2017, GASTRIC CANCER, V20, P217, DOI 10.1007/s10120-016-0601-9; Sato Y, 2001, HISTOPATHOLOGY, V39, P543, DOI 10.1046/j.1365-2559.2001.1301e.x; Selcukbiricik F, 2012, INT J SURG CASE REP, V3, P516, DOI 10.1016/j.ijscr.2012.07.001; SIEGAL A, 1988, HISTOPATHOLOGY, V13, P350, DOI 10.1111/j.1365-2559.1988.tb02046.x; Song SH, 1983, ACTA ACAD MED WANNAN, V2, P53; Song XL, 1991, BENGBU PHARM J, V9, P46; Su Q., 2001, HENAN J ONCOL, V14, P346; TANIMURA H, 1967, AM J SURG, V113, P702, DOI 10.1016/0002-9610(67)90325-X; Teixeira MR, 1998, GENE CHROMOSOME CANC, V22, P145, DOI 10.1002/(SICI)1098-2264(199806)22:2<145::AID-GCC9>3.3.CO;2-V; Teramachi K, 2003, PATHOL INT, V53, P552, DOI 10.1046/j.1440-1827.2003.01508.x; Thompson L, 1996, AM J SURG PATHOL, V20, P277, DOI 10.1097/00000478-199603000-00003; TOKUNAGA O, 1979, ACTA PATHOL JAPON, V29, P819; Tsuneyama K, 1999, PATHOL RES PRACT, V195, P93, DOI 10.1016/S0344-0338(99)80077-6; Villanacci V, 2006, DIGEST DIS SCI, V51, P1658, DOI 10.1007/s10620-005-9040-x; Virchow R., 1865, KRANKHAFTEN GESCHWUL, V2; Wang X, 2011, CELL, V145, P1023, DOI 10.1016/j.cell.2011.05.026; Xue CX, 2008, CHIN MODERN DOCT, V46, P145; Yamazaki K, 2003, VIRCHOWS ARCH, V442, P77, DOI 10.1007/s00428-002-0725-7; Yoshida H, 2012, WORLD J GASTROENTERO, V18, P4064, DOI 10.3748/wjg.v18.i30.4064; Zhao FX, 1994, CHIN J RADIOL, V3, P182; Zheng ZW, 2011, CHIN J GEN PRACT, V10, P278; 张丽, 2016, [中华病理学杂志, Chinese Journal of Pathology], V45, P130; 杨聪, 2012, [中华胸心血管外科杂志, Chinese Journal of Thoracic and Cardiovascular Surgery], V28, P445; 葛小刚, 2011, [中华普通外科杂志, Chinese Journal of General Surgery], V26, P521; 丁洪基, 2011, [临床与实验病理学杂志, Chinese Journal of Clinical and Experimental Pathology], V27, P96; 赵志清, 2008, [中国医学影像技术, Chinese Journal of Medical Imaging Technology], V24, P1305; 王志群, 2005, [中华医学杂志, National Medical Journal of China], V85, P1731; 吴越, 2007, [中华普通外科杂志, Chinese Journal of General Surgery], V22, P479	65	0	0	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					366	375		10.5114/PJP.2018.81696			10	Pathology	Pathology	HK1SM	WOS:000457686800006	30786686	DOAJ Gold			2019-10-28	
J	Al-Maghrabi, J; Mufti, S; Gomaa, W				Al-Maghrabi, Jaudah; Mufti, Shagufta; Gomaa, Wafaey			THE INCIDENCE OF RENAL CELL CARCINOMA ASSOCIATED WITH Xp11.2 TRANSLOCATION/TFE3 GENE FUSION IN SAUDI ADULT PATIENTS WITH RENAL CANCER: A RETROSPECTIVE TISSUE MICROARRAY ANALYSIS	POLISH JOURNAL OF PATHOLOGY			English	Article						renal cell carcinoma; translocation; Xp11.2; TFE3; immunohistochemistry	BREAK-APART FISH; SOFT PART SARCOMA; CLINICAL-EXPERIENCE; TFE3 REARRANGEMENT; AGGRESSIVE COURSE; ASSAY; VALIDATION; EXPRESSION; HETEROGENEITY; NEOPLASMS	Renal cell carcinoma (RCC) is the most common renal tumour. RCC with Xp11.2 translocation/TFE3 (transcription factor E3) gene fusions (Xp11.2 RCC) is positive for immunostain labelling by TFE3 antibody. This tumour is rarely described in adults. This study aims to evaluate the frequency of RCC with Xp11.2 in a subset of Saudi adult patients with RCC. 112 RCCs diagnosed in 1995-2016 were retrieved from the Department of Pathology at King Abdulaziz University and King and Faisal Specialist Hospital and Research Centre, Saudi Arabia. Tissue microarrays were constructed and TFE3 immunostaining was performed. TFE3 immunostaining was considered positive when diffuse strong nuclear immunostaining was detected. TFE3 immunostaining-positive tumours were confirmed by fluorescence in situ hybridisation. 4.5% of RCCs were shown to be Xp11.2 RCC by TFE3 immunostaining. TFE3-positive tumours have a papillary configuration, nested pattern, or both. Positive tumours show male predominance, more occurrences in middle age, high grade, and large-sized tumours with necrosis. Two tumours were FISH-positive. Xp11.2 RCC is rare in Saudi adult patients. Xp11.2 RCCs tend to be large sized and higher grade. TFE3 immunostaining should be considered in RCC that are histologically suggestive to confirm the diagnosis of Xp11.2.	[Al-Maghrabi, Jaudah; Mufti, Shagufta; Gomaa, Wafaey] King Abdulaziz Univ, Fac Med, Dept Pathol, POB 80205, Jeddah 21589, Saudi Arabia; [Al-Maghrabi, Jaudah] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Jeddah, Saudi Arabia; [Gomaa, Wafaey] Menia Univ, Fac Med, Dept Pathol, Al Minya, Egypt	Al-Maghrabi, J (reprint author), King Abdulaziz Univ, Fac Med, Dept Pathol, POB 80205, Jeddah 21589, Saudi Arabia.	jalmaghrabi@hotmail.com			National Plan for Science, Technology, and Innovation (MAARIFAH) - King Abdulaziz City for Science and Technology - the Kingdom of Saudi Arabia [11-BIO1524-03]; Science and Technology Unit, King Abdulaziz University	This project was funded by the National Plan for Science, Technology, and Innovation (MAARIFAH) - King Abdulaziz City for Science and Technology - the Kingdom of Saudi Arabia - award number (11-BIO1524-03). The authors also acknowledge with thanks the Science and Technology Unit, King Abdulaziz University for technical support.	Ahluwalia P., 2013, CASE REP UROL, V2013; Akhavein A, 2014, UROL CASE REP, V2, P75, DOI 10.1016/j.eucr.2014.02.003; Al-Eid H, 2010, CANC INCIDENCE REPOR; Argani P, 2005, CLIN LAB MED, V25, P363, DOI 10.1016/j.cll.2005.01.008; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Argani P, 2016, WHO CLASSIFICATION T, P33; Argani P, 2004, WHO CLASSIFICATION T, P37; Argani P, 2007, AM J SURG PATHOL, V31, P1149, DOI 10.1097/PAS.0b013e318031ffff; Argani P, 2006, AM J CLIN PATHOL, V126, P332, DOI 10.1309/EAEJTJGD5J4JB4F; Argani P, 2010, AM J SURG PATHOL, V34, P1395, DOI 10.1097/PAS.0b013e3181f17ac0; Armah HB, 2010, ARCH PATHOL LAB MED, V134, P124, DOI 10.1043/2008-0391-RSR.1; Camparo P, 2008, AM J SURG PATHOL, V32, P656, DOI 10.1097/PAS.0b013e3181609914; Chen XC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000873; DEJONG B, 1986, CANCER GENET CYTOGEN, V21, P165, DOI 10.1016/0165-4608(86)90042-7; Edge SB, 2010, AJCC CANC STAGING HD; Ellis CL, 2014, MODERN PATHOL, V27, P875, DOI 10.1038/modpathol.2013.208; Franzini A, 2007, UROL INT, V78, P179, DOI 10.1159/000098080; Green WM, 2013, AM J SURG PATHOL, V37, P1150, DOI 10.1097/PAS.0b013e31828a69ae; Haudebourg J, 2010, CANCER GENET CYTOGEN, V200, P75, DOI 10.1016/j.cancergencyto.2010.03.011; Hodge JC, 2014, MODERN PATHOL, V27, P113, DOI 10.1038/modpathol.2013.83; Hung CC, 2011, J CHIN MED ASSOC, V74, P500, DOI 10.1016/j.jcma.2011.09.005; Kallioniemi OP, 2001, HUM MOL GENET, V10, P657, DOI 10.1093/hmg/10.7.657; Kim SH, 2011, VIRCHOWS ARCH, V459, P299, DOI 10.1007/s00428-011-1127-5; Klatte T, 2012, AM J CLIN PATHOL, V137, P761, DOI 10.1309/AJCPQ6LLFMC4OXGC; Kuroda N, 2017, POL J PATHOL, V68, P66, DOI 10.5114/pjp.2017.67617; Kuroda N, 2011, MED MOL MORPHOL, V44, P46, DOI 10.1007/s00795-009-0478-3; Kuroda N, 2010, MED MOL MORPHOL, V43, P86, DOI 10.1007/s00795-008-0423-x; Lopez-Beltran A, 2006, EUR UROL, V49, P798, DOI 10.1016/j.eururo.2005.11.035; Macher-Goeppinger S, 2012, MODERN PATHOL, V25, P308, DOI 10.1038/modpathol.2011.169; Meyer PN, 2007, AM J CLIN PATHOL, V128, P70, DOI 10.1309/LR5G1VMXPY3G0CUK; Mosquera JM, 2011, DIAGN MOL PATHOL, V20, P129, DOI 10.1097/PDM.0b013e31820e9c67; Pflueger D, 2013, NEOPLASIA, V15, P1231, DOI 10.1593/neo.131544; Pradhan D, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0412-z; Qu Y, 2015, SCI REP, V6, P21677; Rao Q, 2013, AM J SURG PATHOL, V37, P804, DOI 10.1097/PAS.0b013e31827e17cb; Rao Q, 2012, AM J SURG PATHOL, V36, P1327, DOI 10.1097/PAS.0b013e31825aafb5; Salles Paulo G. O., 2005, Int. braz j urol., V31, P251, DOI 10.1590/S1677-55382005000300009; Su HH, 2014, KAOHSIUNG J MED SCI, V30, P402, DOI 10.1016/j.kjms.2014.03.003; Sudour-Bonnange H, 2014, PEDIATR BLOOD CANCER, V61, P1698, DOI 10.1002/pbc.25015; Sukov WR, 2012, AM J SURG PATHOL, V36, P663, DOI 10.1097/PAS.0b013e31824dd972; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1; Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099990; Wu A, 2008, HISTOPATHOLOGY, V53, P533, DOI 10.1111/j.1365-2559.2008.03151.x; Zhong MH, 2012, AM J SURG PATHOL, V36, P654, DOI 10.1097/PAS.0b013e31824f24a6; Zhong MH, 2010, AM J SURG PATHOL, V34, P757, DOI 10.1097/PAS.0b013e3181dd577e; Zou H, 2014, INT J CLIN EXP PATHO, V7, P236	47	0	0	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					376	383		10.5114/PJP.2018.81697			8	Pathology	Pathology	HK1SM	WOS:000457686800007	30786687	DOAJ Gold			2019-10-28	
J	Kuroda, N; Yorita, K; Sakamoto, K; Tsuji, K				Kuroda, Naoto; Yorita, Kenji; Sakamoto, Kei; Tsuji, Kazuya			VARIOUS PATTERNS OF ACUTE ALVEOLAR HAEMORRHAGE IN PATIENTS WITH MICROSCOPIC POLYANGIITIS: A CLINICOPATHOLOGICAL STUDY OF FOUR CASES	POLISH JOURNAL OF PATHOLOGY			English	Article						alveolar haemorrhage; microscopic polyangiitis	CYTOMEGALOVIRUS-INFECTION	It is well known that acute alveolar haemorrhage (AAH) is attributed to capillaritis in most cases with microscopic polyangiitis (MPA). In this article, we explore the cause of alveolar haemorrhage in MPA patients. In the present study, we extracted four autopsy cases of MPA with AAH. Patient's sex and age, cause of alveolar haemorrhage, therapy, follow-up duration, and cause of death were investigated. As a result, alveolar haemorrhage was caused by diffuse alveolar damage (DAD) due to candidiasis or influenza virus infection, haemorrhagic infarct due to aspergillosis, capillaritis due to MPA, vasculitis due to cytomegalovirus (CMV), and herpes simplex virus (HSV) infection. All patients received corticosteroid therapy, and one patient additionally underwent administration of cyclophosphamide. The duration of follow-up ranged from one to 26 months with a mean of eight months. All patients died of respiratory failure. In summary, clinicians and pathologists should recognise some causes of alveolar haemorrhage in MPA patients, which include DAD, haemorrhagic infarct, virus-associated vasculitis, or MPA-associated capillaritis.	[Kuroda, Naoto; Yorita, Kenji] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Japan; [Sakamoto, Kei; Tsuji, Kazuya] Kochi Red Cross Hosp, Dept Internal Med, Kochi, Japan	Kuroda, N (reprint author), Kochi Red Cross Hosp, Dept Pathol, Shin Honmachi 2-13-51, Kochi, Kochi 7808562, Japan.	kurochankochi@yahoo.co.jp					Cardinal-Fernandez P, 2017, ANN AM THORAC SOC, V14, P844, DOI 10.1513/AnnalsATS.201609-728PS; Engelmann I, 2011, TRANSPL INFECT DIS, V13, P259, DOI 10.1111/j.1399-3062.2010.00587.x; Isono M, 2011, CLIN EXP NEPHROL, V15, P294, DOI 10.1007/s10157-010-0394-9; Kimoto Y, 2014, INTERNAL MED, V53, P2821, DOI 10.2169/internalmedicine.53.2168; Lababidi Mohamad Hani, 2015, Proc (Bayl Univ Med Cent), V28, P469; Lara AR, 2010, CHEST, V137, P1164, DOI 10.1378/chest.08-2084; Meyer MF, 2000, RHEUMATOL INT, V20, P35, DOI 10.1007/s002960000063; Miyoshi I, 2005, INTERNAL MED, V44, P518, DOI 10.2169/internalmedicine.44.518; Nagarakanti S, 2018, IDCases, V11, P91, DOI 10.1016/j.idcr.2018.01.011; Pesci Alberto, 2007, Drugs R D, V8, P25, DOI 10.2165/00126839-200708010-00003; Takizawa Y, 2008, RHEUMATOLOGY, V47, P1373, DOI 10.1093/rheumatology/ken231; Tashiro H, 2016, CASE REPORTS RHEUMAT, V2016; Martinez-Martinez MU, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0651-y; Ward ND, 2014, CASE REP PATHOL, DOI 10.1155/2014/286030; Wilke L, 2014, JCR-J CLIN RHEUMATOL, V20, P179, DOI 10.1097/RHU.0000000000000108; Yoshida Masaharu, 2013, Ann Vasc Dis, V6, P9, DOI 10.3400/avd.ra.12.00092	16	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					384	387		10.5114/PJP.2018.81698			4	Pathology	Pathology	HK1SM	WOS:000457686800008	30786688	DOAJ Gold			2019-10-28	
J	Gabriel, A; Kukla, M; Adamek, B; Taboo, K; Banasik, G; Horyniecki, M; Halota, W				Gabriel, Andrzej; Kukla, Michal; Adamek, Brygida; Taboo, Kamil; Banasik, Grzegorz; Horyniecki, Maciej; Halota, Waldemar			STEATOSIS INFLUENCES HEPATOCYTES PROLIFERATIVE POTENTIAL IN CHRONIC HEPATITIS C PATIENTS	POLISH JOURNAL OF PATHOLOGY			English	Article						chronic hepatitis C; PCNA; nonalcoholic fatty liver disease; steatosis; hepatocyte ballooning	CELL NUCLEAR ANTIGEN; INSULIN-RESISTANCE; LIVER STEATOSIS; CORE; PCNA; ANGIOGENESIS; ASSOCIATION; EXPRESSION; PROTEINS; FIBROSIS	The study evaluates the influence of steatosis on hepatocytes proliferative potential, reflected by proliferating cell nuclear antigen (PCNA) expression in chronic hepatitis C (CHC) patients both in steatotic and non-steatotic areas of lobules. The liver histology was evaluated according to Kleiner's score. Nonalcoholic steatohepatitis (NASH) was also defined as the presence of lobular inflammation, hepatocyte ballooning and steatosis. Expression of PCNA was significantly in patients with definite NASH compared to those with simple steatosis, but not to those with borderline NASH. Advanced steatosis negatively influenced PCNA expression. NASH not only affects PCNA expression in staetotic, but also in non-steatotic lobule areas. Expression of PCNA could be an independent indicator of changes in hepatocyte metabolism in CHC patients. High NAS values and low PCNA expression may be a negative prognostic factor in predicting the further course of the disease.	[Gabriel, Andrzej] Med Univ Silesia, Sch Med Div Dent, Dept Histol & Embriol, Zabrze, Poland; [Kukla, Michal] Med Univ Silesia, Sch Med Katowice, Dept Gastroenterol & Hepatol, Katowice, Poland; [Adamek, Brygida] Med Univ Silesia, Fac Publ Hlth, Dept Basic Med Sci, Bytom, Poland; [Taboo, Kamil] Med Univ Silesia, Div Dent Zabrze, Dept Pathomorphol, Sch Med, Zabrze, Poland; [Banasik, Grzegorz; Horyniecki, Maciej] Med Univ Silesia, Div Dent Zabrze, Sch Med, Zabrze, Poland; [Halota, Waldemar] Nicolaus Copernicus Univ, Ludwig Rydygier Coll Med, Dept Infect Dis & Hepatol, Bydgoszcz, Poland	Kukla, M (reprint author), Med Univ Silesia, Dept Gastroenterol & Hepatol, Medykow 14, PL-40752 Katowice, Poland.	kuklamich@poczta.onet.pl		Kukla, Michal/0000-0002-7900-1094	Medical University of Silesia of Katowice [KNW-1-116/P/2/0]	This work was supported by grant of Medical University of Silesia of Katowice, no KNW-1-116/P/2/0.	AALTOMAA S, 1993, ANTICANCER RES, V13, P533; Chang ML, 2016, WORLD J GASTROENTERO, V22, P1461, DOI 10.3748/wjg.v22.i4.1461; Cheng Y, 2005, WORLD J GASTROENTERO, V11, P7591, DOI 10.3748/wjg.v11.i48.7591; De Biasio A, 2013, ADV PROTEIN CHEM STR, V91, P1, DOI 10.1016/B978-0-12-411637-5.00001-9; ELDRIDGE SR, 1993, ENVIRON HEALTH PERSP, V101, P211, DOI 10.2307/3431870; HAMADA M, 1995, J GASTROENTEROL, V30, P372, DOI 10.1007/BF02347514; Hu WT, 2013, BIOCHEM BIOPH RES CO, V435, P147, DOI 10.1016/j.bbrc.2013.04.059; Hui JM, 2003, GASTROENTEROLOGY, V125, P1695, DOI 10.1053/j.gastro.2003.08.032; Jurikova M, 2016, ACTA HISTOCHEM, V118, P544, DOI 10.1016/j.acthis.2016.05.002; Kao CC, 2016, CURR OPIN VIROL, V17, P66, DOI 10.1016/j.coviro.2016.01.009; Kleiner DE, 2005, HEPATOLOGY, V41, P1313, DOI 10.1002/hep.20701; Kukla M, 2015, CLIN EXP HEPATOL, V1, P17, DOI 10.5114/ceh.2015.51375; Kukla M, 2011, POL J PATHOL, V62, P218; Kukla M, 2010, POL J PATHOL, V61, P154; Masarone M, 2007, J VIRAL HEPATITIS, V14, P714, DOI 10.1111/j.1365-2893.2007.00861.x; Muzzi A, 2005, J HEPATOL, V42, P41, DOI 10.1016/j.jhep.2004.09.022; NAKAMURA T, 1993, HUM PATHOL, V24, P750, DOI 10.1016/0046-8177(93)90012-6; Negro F, 2006, WORLD J GASTROENTERO, V12, P6756, DOI 10.3748/wjg.v12.i42.6756; OJANGUREN I, 1993, HUM PATHOL, V24, P905, DOI 10.1016/0046-8177(93)90141-3; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Persico M, 2006, J VIRAL HEPATITIS, V13, P290, DOI 10.1111/j.1365-2893.2005.00667.x; Sanyal AJ, 2005, ALIMENT PHARM THERAP, V22, P48, DOI 10.1111/j.1365-2036.2005.02596.x; SCHEUER PJ, 1995, J HEPATOL, V22, P112, DOI 10.1016/0168-8278(95)80269-X; TERADA T, 1992, CANCER, V70, P591, DOI 10.1002/1097-0142(19920801)70:3<591::AID-CNCR2820700309>3.0.CO;2-7; Wang SC, 2014, TRENDS PHARMACOL SCI, V35, P178, DOI 10.1016/j.tips.2014.02.004; Wu Y, 2016, STEM CELLS, V34, P83, DOI 10.1002/stem.2209	26	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					388	394		10.5114/PJP.2018.78517			7	Pathology	Pathology	HK1SM	WOS:000457686800009	30786689	DOAJ Gold			2019-10-28	
J	Fus, LP; Pihowicz, P; Koperski, L; Marczewska, JM; Gornicka, B				Fus, Lukasz P.; Pihowicz, Pawel; Koperski, Lukasz; Marczewska, Janina M.; Gornicka, Barbara			HIF-1 alpha EXPRESSION IS INVERSELY ASSOCIATED WITH TUMOR STAGE, GRADE AND MICROVESSEL DENSITY IN UROTHELIAL BLADDER CARCINOMA	POLISH JOURNAL OF PATHOLOGY			English	Article						angiogenesis; hypoxia-inducible factor 1; microvessel density; urothelial bladder cancer	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RENAL-CELL CARCINOMA; MACROPHAGE INFILTRATION; UNFAVORABLE PROGNOSIS; FACTOR 1-ALPHA; BREAST-CANCER; LUNG-CANCER; ANGIOGENESIS; OVEREXPRESSION; CYCLOOXYGENASE-2	Urothelial bladder carcinoma (UBC) is the most common urinary tract malignancy. The most important histopathological factors affecting prognosis are cancer stage and grade. Studies show that microvessel density (MVD) reflecting angiogenesis is also associated with clinicopathological features and affects the outcome in UBC. One of the most important regulators of angiogenesis is hypoxia inducible factor 1 (HIF-1). Previous reports describing expression of the HIF-1 alpha subunit in UBC showed unclear and inconsistent results. Our study attempted do evaluate the association between HIF-1 alpha expression and tumor stage, grade, lymph nodes status and MVD in UBC. We performed immunohistochemical staining in 99 UBC cases, including 38 non-muscle invasive (NMIBC) and 61 muscle invasive tumors (MIBC). We observed inverse relationships between HIF-1 alpha immunoreactivity score (IRS) and tumor stage, grade and MVD. Significantly lower HIF-1 alpha IRS values were observed in MIBC and high grade cancers. We found a significant negative correlation between HIF-1 alpha IRS and MVD. These results suggest that HIF-1 alpha pathway is not involved in UBC growth and progression, and that angiogenesis in high grade MIBC is not regulated by HIF-1 alpha. Our findings contradict previous reports regarding HIF-1 alpha, MVD and UBC which shows the necessity of additional molecular studies in this field.	[Fus, Lukasz P.; Pihowicz, Pawel; Koperski, Lukasz; Marczewska, Janina M.; Gornicka, Barbara] Med Univ Warsaw, Dept Pathol, Pawinskiego 7, PL-02106 Warsaw, Poland	Fus, LP (reprint author), Med Univ Warsaw, Dept Pathol, Pawinskiego 7, PL-02106 Warsaw, Poland.	lukasz.fus@wum.edu.pl					Ajili F, 2012, ULTRASTRUCT PATHOL, V36, P336, DOI 10.3109/01913123.2012.672847; Amin MB, 2017, AJCC CANC STAGING MA; Benckert C, 2012, SURG TODAY, V42, P169, DOI 10.1007/s00595-011-0045-0; Canoglu Ali, 2004, International Urology and Nephrology, V36, P401, DOI 10.1007/s11255-004-8869-9; Chai CY, 2008, J CLIN PATHOL, V61, P658, DOI 10.1136/jcp.2007.050666; Chen WT, 2009, APMIS, V117, P176, DOI 10.1111/j.1600-0463.2008.00004.x; Cheng SH, 2014, INT J CLIN EXP PATHO, V7, P5855; Couvelard A, 2005, HISTOPATHOLOGY, V46, P668, DOI 10.1111/j.1365-2559.2005.02160.x; Deniz H, 2010, INT UROL NEPHROL, V42, P103, DOI 10.1007/s11255-009-9590-5; Ferlay J, 2013, GLOBOCAN 2012 V1 0 C; Fillies T, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-84; Fox SB, 2004, APMIS, V112, P413, DOI 10.1111/j.1600-0463.2004.apm11207-0803.x; Giatromanolaki A, 2001, BRIT J CANCER, V85, P881, DOI 10.1054/bjoc.2001.2018; Hasan J, 2002, BRIT J CANCER, V86, P1566, DOI 10.1038/sj/bjc/6600315; Huang J, 2004, CANCER BIOMARK, V14, P505; Inoue K, 2000, CLIN CANCER RES, V6, P4866; Ioachim E, 2006, UROL INT, V77, P255, DOI 10.1159/000094819; Kadota K, 2008, EUR J CANCER, V44, P1057, DOI 10.1016/j.ejca.2008.03.012; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kim SJ, 2005, LUNG CANCER, V49, P325, DOI 10.1016/j.lungcan.2005.03.036; Kitada T, 2003, HISTOPATHOLOGY, V43, P550, DOI 10.1111/j.1365-2559.2003.01733.x; Koukourakis MI, 2002, INT J RADIAT ONCOL, V53, P1192, DOI 10.1016/S0360-3016(02)02848-1; Koukourakis MI, 2001, CANCER RES, V61, P1830; Kronblad A, 2006, INT J CANCER, V118, P2609, DOI 10.1002/ijc.21676; Kuwai T, 2003, INT J CANCER, V105, P176, DOI 10.1002/ijc.11068; Lee JW, 2004, EXP MOL MED, V36, P1; Lidgren A, 2006, EUR UROL, V50, P1272, DOI 10.1016/j.eururo.2006.05.043; Mabjeesh NJ, 2007, HISTOL HISTOPATHOL, V22, P559, DOI 10.14670/HH-22.559; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI [10.1016/j.apsh.2015.05.007, 10.1016/j.apsb.2015.05.007]; Moch H, 2016, WHO CLASSIFICATION T, P81; Nadkarni NJ, 2013, CANCER LETT, V331, P99, DOI 10.1016/j.canlet.2012.12.016; Nakanishi K, 2005, CLIN CANCER RES, V11, P2583, DOI 10.1158/1078-0432.CCR-04-1685; Radomska-Lesniewska DM, 2017, CENT EUR J IMMUNOL, V42, P370, DOI 10.5114/ceji.2017.72804; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Saponaro C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053070; Semenza GL, 2008, IUBMB LIFE, V60, P591, DOI 10.1002/iub.93; Shirotake S, 2011, UROLOGY, V77, DOI 10.1016/j.urology.2010.11.002; Swinson DE, 2004, INT J CANC; Theodoropoulos VE, 2005, BJU INT, V95, P425, DOI 10.1111/j.1464-410X.2005.05314.x; Theodoropoulos VE, 2004, EUR UROL, V46, P200, DOI 10.1016/j.eururo.2004.04.008; Urano Naomi, 2006, Gastric Cancer, V9, P44, DOI 10.1007/s10120-005-0356-1; Uzzan B, 2004, CANCER RES, V64, P2941, DOI 10.1158/0008-5472.CAN-03-1957; Wang YBN, 2014, SCI WORLD J, DOI 10.1155/2014/102736; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Yoshimura H, 2004, CLIN CANCER RES, V10, P8554, DOI 10.1158/1078-0432.CCR-0946-03; Zhong H, 1999, CANCER RES, V59, P5830	46	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					395	404		10.5114/PJP.2018.81699			10	Pathology	Pathology	HK1SM	WOS:000457686800010	30786690	DOAJ Gold			2019-10-28	
J	Niebudek, K; Balcerczak, E; Mirowski, M; Zebrowska, M				Niebudek, Katarzyna; Balcerczak, Ewa; Mirowski, Marek; Zebrowska, Marta			ASSOCIATION OF ABCB1 T-129C POLYMORPHISM AND MULTIPLE MYELOMA RISK IN POLISH POPULATION	POLISH JOURNAL OF PATHOLOGY			English	Article						MDR1; ABCB1; P-gp; single-nucleotide polymorphism; plasma cell myeloma	SINGLE-NUCLEOTIDE POLYMORPHISMS; MDR1 GENE; HAPLOTYPES; TRANSPORTERS; FREQUENCIES; VARIANTS; SURVIVAL; LEUKEMIA; DISEASE; C3435T	The possible interaction between gene polymorphism and cancer risk development is a very interesting issue. The genetic variants of the ATP-binding cassette superfamily B member 1 (ABCB1) are known to be involved in developing cancer risk and individual differences in chemotherapeutic response. Polymorphisms may affect the reduction of the activity and/or expression of important protective cellular proteins. The increased exposure to toxic compounds, including carcinogens is associated with an increased risk of developing cancers. The present study was aimed to evaluate the possible effect of ABCB1 T-129C single nucleotide polymorphism in risk of cancer development in Polish patients diagnosed with multiple myeloma. 91 multiple myeloma patients and 94 healthy controls were enrolled in this case-control study. The ABCB1 T-129C genotypes were determined by polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). The distribution of particular genotypes between multiple myeloma patients and controls group was not significantly different for T-129C SNP (p = 0.4297). The studied polymorphism does not seem to affect the increased risk of multiple myeloma development.	[Niebudek, Katarzyna; Balcerczak, Ewa; Mirowski, Marek; Zebrowska, Marta] Med Univ Lodz, Lab Mol Diagnost & Pharmacogen, Muszynskiego 1, PL-90151 Lodz, Poland	Zebrowska, M (reprint author), Med Univ Lodz, Lab Mol Diagnost & Pharmacogen, Muszynskiego 1, PL-90151 Lodz, Poland.	marta.zebrowska@umed.lodz.pl	Niebudek, Katarzyna/W-7671-2019		Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz [503/3-015-02/503-31-001]	This study was supported by statutory funds of the Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz no. 503/3-015-02/503-31-001.	Au A, 2014, BIOMED PHARMACOTHER, V68, P343, DOI 10.1016/j.biopha.2014.01.009; Balcerczak E, 2010, INT J COLORECTAL DIS, V25, P1167, DOI 10.1007/s00384-010-0961-2; Chen CC, 2014, BIOMED RES INT, DOI 10.1155/2014/965729; Eslick R, 2013, AUST FAM PHYSICIAN, V42, P684; Fung KL, 2009, BBA-PROTEINS PROTEOM, V1794, P860, DOI 10.1016/j.bbapap.2009.02.014; Ghafouri H, 2016, TUMOR BIOL, V37, P7901, DOI 10.1007/s13277-015-4679-1; Hodges LM, 2011, PHARMACOGENET GENOM, V21, P152, DOI 10.1097/FPC.0b013e3283385a1c; Hu LL, 2013, LEUKEMIA LYMPHOMA, V54, P1188, DOI 10.3109/10428194.2012.736980; Jeannesson E, 2007, FUND CLIN PHARMACOL, V21, P411, DOI 10.1111/j.1472-8206.2007.00507.x; Jin SS, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000009428, 10.1097/md.0000000000009428]; Komoto C, 2006, DRUG METAB PHARMACOK, V21, P126, DOI 10.2133/dmpk.21.126; Kufelnicka-Babout M, 2008, MENOPAUSE REV, V7, P295; Landgren O, 2009, LEUKEMIA, V23, P1691, DOI 10.1038/leu.2009.134; Li HM, 2018, MOLECULES, V23, DOI 10.3390/molecules23030557; Li Y, 2014, NEUROSCI LETT, V566, P61, DOI 10.1016/j.neulet.2014.02.025; Liu H, 2016, BIOMED PHARMACOTHER, V80, P115, DOI 10.1016/j.biopha.2016.02.028; Llaudo I, 2013, TRANSPL INT, V26, P177, DOI 10.1111/tri.12018; Martino A, 2013, LEUKEMIA, V27, P1615, DOI 10.1038/leu.2013.146; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; Pongstaporn Wanida, 2015, Asian Pac J Cancer Prev, V16, P2839; Rajkumar SV, 2014, AM J HEMATOL, V89, P999, DOI 10.1002/ajh.23810; Ross DD, 2004, BEST PRACT RES CL HA, V17, P641, DOI 10.1016/j.beha.2004.08.014; Ryu HC, 2006, ARCH PHARM RES, V29, P1132, DOI 10.1007/BF02969304; Tan EK, 2004, NEUROSCI LETT, V372, P240, DOI 10.1016/j.neulet.2004.09.046; Wang J, 2014, MOL BIOL REP, V41, P2679, DOI 10.1007/s11033-014-3127-4; Wang Q, 2017, J BIOL REG HOMEOS AG, V31, P977; Wu HZ, 2015, BIOMED RES INT, DOI 10.1155/2015/279109; Xu J, 2018, J BIOL REG HOMEOS AG, V32, P327; Yin GL, 2016, TUMOR BIOL, V37, P9549, DOI 10.1007/s13277-015-4574-9; Zhai XW, 2012, ARCH MED SCI, V8, P659, DOI 10.5114/aoms.2012.30290; Zhang BB, 2013, EUR J CANCER CARE, V22, P617, DOI 10.1111/ecc.12067; Zhang YM, 2017, ARCH MED SCI, V13, P1335, DOI 10.5114/aoms.2017.71065; Zhao L, 2013, TUMOR BIOL, V34, P1949, DOI 10.1007/s13277-013-0740-0	33	0	0	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					405	409		10.5114/PJP.2018.81700			5	Pathology	Pathology	HK1SM	WOS:000457686800011	30786691	DOAJ Gold			2019-10-28	
J	Adamczyk, A; Biesaga, B; Klimek, M; Mucha-Malecka, A				Adamczyk, Agnieszka; Biesaga, Beata; Klimek, Malgorzata; Mucha-Malecka, Anna			COMET ASSAY IS NOT USEFUL TO PREDICT NORMAL TISSUE RESPONSE AFTER RADIOCHEMOTHERAPY IN CERVICAL AND LARYNX CANCER PATIENTS	POLISH JOURNAL OF PATHOLOGY			English	Article						comet assay; chemoradiosensitivity; cervix cancer patients; larynx cancer patients	DNA-REPAIR CAPACITY; PERIPHERAL-BLOOD LYMPHOCYTES; HEALTHY-INDIVIDUALS; RADIATION SENSITIVITY; SKIN REACTIONS; BREAST; RADIOTHERAPY; DAMAGE; RADIOSENSITIVITY; RADIOGENOMICS	Normal tissues reactions after radiotherapy vary considerably even between patients receiving the same treatment. The ability to predict the differences in radiosensitivity before radiotherapy would have important implication. Patients with squamous cell carcinoma of the: (i) cervix (38 patients) and (ii) larynx (19 patients) were studied. Control group consisted of 9 healthy women. To assess individual radiosensitivity/chemoradiosensitivity alkaline version of comet assay was performed using isolated peripheral blood lymphocytes from cancer patients and healthy donors. The level of endogenous (OGy), initial (immediately after 6Gy irradiation) and residual (after irradiation and 1h of repair) DNA damage was investigated. The mean value of endogenous damage was similar in control and cervical cancer (CCU) groups and significantly lower than in larynx cancer patients. Cancer patients showed slower DNA repair. For CCU and larynx patients, comet assay parameters were not helpful for unequivocal prediction of appearance of acute and late radiation reaction effects. Comet assay seems to be unable to predict normal tissue reaction after radiochemotherapy. Therefore, there is still need for developing predictive assays, however, due to complicated mechanism of chemoradiosensitivity, only assays assessing not one but many molecular pathways might gives us reliable score.	[Adamczyk, Agnieszka; Biesaga, Beata] Maria Sklodowska Curie Mem Canc Ctr, Dept Tumour Pathol, Garncarska 11, PL-31115 Krakow, Poland; [Adamczyk, Agnieszka; Biesaga, Beata; Klimek, Malgorzata; Mucha-Malecka, Anna] Inst Oncol, Krakow Branch, Garncarska 11, PL-31115 Krakow, Poland; [Klimek, Malgorzata] Maria Sklodowska Curie Mem Canc Ctr, Gynecol Dept, Krakow, Poland; [Mucha-Malecka, Anna] Maria Sklodowska Curie Mem Canc Ctr, Oncol Unit Dept, Krakow, Poland	Adamczyk, A (reprint author), Maria Sklodowska Curie Mem Canc Ctr, Dept Tumour Pathol, Garncarska 11, PL-31115 Krakow, Poland.; Adamczyk, A (reprint author), Inst Oncol, Krakow Branch, Garncarska 11, PL-31115 Krakow, Poland.	z5adamcz@cyfronet.pl			 [2 P05A 014 29]	Part of the study was supported by grant no. 2 P05A 014 29.	Alapetite C, 1999, INT J CANCER, V83, P83, DOI 10.1002/(SICI)1097-0215(19990924)83:1<83::AID-IJC16>3.0.CO;2-8; Andreassen CN, 2016, CANCER LETT, V382, P127, DOI 10.1016/j.canlet.2016.01.035; Andreassen CN, 2009, RADIOTHER ONCOL, V92, P299, DOI 10.1016/j.radonc.2009.06.015; Andreassen CN, 2002, RADIOTHER ONCOL, V64, P131, DOI 10.1016/S0167-8140(02)00154-8; Andreassen CN, 2005, ACTA ONCOL, V44, P801, DOI 10.1080/02841860500374513; Azqueta A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00288; Barnett GC, 2009, NAT REV CANCER, V9, P134, DOI 10.1038/nrc2587; Brendler-Schwaab S, 2005, MUTAGENESIS, V20, P245, DOI 10.1093/mutage/gei033; Buchynska L, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-765; Budach W, 1998, STRAHLENTHER ONKOL, V174, P20; Chua MLK, 2013, CLIN ONCOL-UK, V25, P610, DOI 10.1016/j.clon.2013.06.010; Collins A, 2014, MUTAT RES-REV MUTAT, V759, P27, DOI 10.1016/j.mrrev.2013.10.001; Cortes-Gutierrez EI, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/385245; Djuzenova CS, 2006, BRIT J CANCER, V94, P1194, DOI 10.1038/sj.bjc.6603005; Fernet M, 2008, CANCER RADIOTHER, V12, P614, DOI 10.1016/j.canrad.2008.07.013; Fikrova P, 2011, WIEN KLIN WOCHENSCHR, V123, P693, DOI 10.1007/s00508-011-0066-0; Gabelova A, 2008, NEOPLASMA, V55, P182; Hartley JM, 2011, METHODS MOL BIOL, V731, P309, DOI 10.1007/978-1-61779-080-5_25; Kerns SL, 2014, CANCER DISCOV, V4, P155, DOI 10.1158/2159-8290.CD-13-0197; Kopjar N, 2006, CLIN EXP MED, V6, P177, DOI 10.1007/s10238-006-0113-8; Liu JC, 2015, BIOMEDICINE-TAIWAN, V5, P11, DOI 10.7603/s40681-015-0002-0; McKenna DJ, 2008, MUTAGENESIS, V23, P183, DOI 10.1093/mutage/gem054; Muller WU, 2001, RADIAT ENVIRON BIOPH, V40, P83, DOI 10.1007/s004110000087; Nadin SB, 2006, CANCER LETT, V239, P84, DOI 10.1016/j.canlet.2005.07.025; Nascimento PA, 2001, BRAZ J MED BIOL RES, V34, P165, DOI 10.1590/S0100-879X2001000200003; Oppitz U, 1999, STRAHLENTHER ONKOL, V175, P341, DOI 10.1007/s000660050021; Oppitz U, 2002, INT J RADIAT BIOL, V78, P611, DOI 10.1080/09553000210126466; Padjas A, 2012, J CONTEMP BRACHYTHER, V4, P219, DOI 10.5114/jcb.2012.32556; Palyvoda O, 2003, ACTA BIOCHIM POL, V50, P181; Popanda O, 2003, INT J RADIAT ONCOL, V55, P1216, DOI 10.1016/S0360-3016(02)04415-2; Rajaee-Behbahani N, 2001, INT J CANCER, V95, P86, DOI 10.1002/1097-0215(20010320)95:2<86::AID-IJC1015>3.0.CO;2-B; Roberson JD, 2016, CURR OPIN PEDIATR, V28, P713, DOI 10.1097/MOP.0000000000000408; Rusin P, 2009, CELL BIOL INT, V33, P357, DOI 10.1016/j.cellbi.2009.01.007; Rzeszowska-Wolny J, 2008, INT J RADIAT BIOL, V84, P635, DOI 10.1080/09553000802087041; Shahidi M, 2007, CANCER LETT, V257, P263, DOI 10.1016/j.canlet.2007.08.002; Smith TR, 2003, CARCINOGENESIS, V24, P883, DOI 10.1093/carcin/bgg037; Sterpone S, 2010, MUTAT RES-FUND MOL M, V684, P43, DOI 10.1016/j.mrfmmm.2009.11.009; Turesson I, 1996, INT J RADIAT ONCOL, V36, P1065, DOI 10.1016/S0360-3016(96)00426-9; Twardella D, 2003, RADIOTHER ONCOL, V69, P145, DOI 10.1016/S0167-8140(03)00166-X; Wang WD, 2005, CLIN CANCER RES, V11, P5140, DOI 10.1158/1078-0432.CCR-04-2548	40	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					410	421		10.5114/PJP.2018.81230			12	Pathology	Pathology	HK1SM	WOS:000457686800012	30786692	DOAJ Gold			2019-10-28	
J	Felczak, P; Stepniak, I; Kowalski, P; Stepien, T; Wierzba-Bobrowicz, T				Felczak, Paulina; Stepniak, Iwona; Kowalski, Pawel; Stepien, Tomasz; Wierzba-Bobrowicz, Teresa			PATHOLOGY OF SKELETAL MUSCLE FIBRES AND SMALL BLOOD VESSELS IN MERRF SYNDROME: AN ULTRASTRUCTURAL STUDY	POLISH JOURNAL OF PATHOLOGY			English	Article						MERRF; A8344G mutation; abnormal mitochondria; ultrastructure; calcium precipitate	RAGGED-RED FIBERS; MITOCHONDRIAL DISEASE; PATHWAYS	Our studies concerned skeletal muscle biopsy specimens from a patient with clinically suspected MERRF syndrome, confirmed by genetic tests showing the presence of point mutation in the m.8344A> G in the tRNALys gene. Ultrastructurally, extensive damage of mitochondria in skeletal muscle fibres was observed, including the presence of two types of mitochondrial inclusions. Mild damage of mitochondria was revealed in small blood vessels and the presence of calcium deposits in the vascular walls were observed. The differences in mitochondrial damage may be related to different origin and expenditure of biologically useful energy in these cells.	[Felczak, Paulina; Stepien, Tomasz; Wierzba-Bobrowicz, Teresa] Inst Psychiat & Neurol, Dept Neuropathol, Sobieskiego 9, PL-02957 Warsaw, Poland; [Stepniak, Iwona] Inst Psychiat & Neurol, Dept Genet, Warsaw, Poland; [Kowalski, Pawel] Childrens Mem Hlth Inst, Lab Mol Genet, Warsaw, Poland	Felczak, P (reprint author), Inst Psychiat & Neurol, Dept Neuropathol, Sobieskiego 9, PL-02957 Warsaw, Poland.	felczak.p@wp.pl			Institute of Psychiatry and Neurology [POPC.02.03.01-00.0042/18];  [501-071-18021]	This work was supported by the statutory fund No. 501-071-18021 and by "Digital Brain -digital collection of the Institute of Psychiatry and Neurology" (Project No. POPC.02.03.01-00.0042/18). The authors are grateful to the First Polish Brain Bank in the Institute Psychiatry and Neurology, Warsaw, Poland.	ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Barohn RJ, 2014, NEUROL CLIN, V32, P569, DOI 10.1016/j.ncl.2014.04.008; Bowman MAH, 2012, TRENDS CARDIOVAS MED, V22, P93, DOI 10.1016/j.tcm.2012.07.002; Brewster LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032471; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Cheville NF, 2009, ULTRASTRUCT PATHOL, P797; Chinnery PF, 2014, GENEREVIEWS, P1993; Dias-Tosta E, 1988, Arq Neuropsiquiatr, V46, P143; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; FARRANTS GW, 1988, MUSCLE NERVE, V11, P45, DOI 10.1002/mus.880110109; Filosto M, 2007, BIOSCIENCE REP, V27, P23, DOI 10.1007/s10540-007-9034-3; Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x; Finsterer J, 2016, WORLD J CARDIOL, V8, P333, DOI 10.4330/wjc.v8.i5.333; FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; Houshmand M., 2011, NOVEL TREATMENT EPIL, P37; Kang HC, 2013, BRAIN DEV-JPN, V35, P757, DOI 10.1016/j.braindev.2013.01.006; Koopman WJH, 2016, EMBO MOL MED, V8, P311, DOI 10.15252/emmm.201506131; Leonard JV, 2000, LANCET, V355; Liu C C, 2001, Curr Rheumatol Rep, V3, P325, DOI 10.1007/s11926-001-0037-y; Longo N, 2003, NEUROL CLIN, V21, P817, DOI 10.1016/S0733-8619(03)00015-X; Lorenzoni PJ, 2014, ARQ NEURO-PSIQUIAT, V72, P803, DOI 10.1590/0004-282X20140124; Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93; Moghadam-Kia S, 2016, CLEV CLIN J MED, V83, P37, DOI 10.3949/ccjm.83a.14120; Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x; RIGGS JE, 1984, NEUROLOGY, V34, P48, DOI 10.1212/WNL.34.1.48; Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8; SCHWARTZKOPFF B, 1988, J AM COLL CARDIOL, V12, P1522, DOI 10.1016/S0735-1097(88)80020-2; Sena CM, 2013, BBA-MOL BASIS DIS, V1832, P2216, DOI 10.1016/j.bbadis.2013.08.006; Sirtoli R., 2015, WINNOWER, V24, P1; STADHOUDERS AM, 1987, J INHERIT METAB DIS, V10, P62, DOI 10.1007/BF01812848; Taglia I, 2015, NEUROL SCI, V36, P787, DOI 10.1007/s10072-015-2110-8; Tang X, 2014, FRONT PHYSIOL, V5, P1; TSAIRIS P, 1973, NEUROLOGY, V23, P408; Vincent AE, 2016, SCI REP, V6, P1; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259	37	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					422	431		10.5114/PJP.2018.80904			10	Pathology	Pathology	HK1SM	WOS:000457686800013	30786693	DOAJ Gold			2019-10-28	
J	Braun, M; Kuncman, W; Szumera-Cieckiewicz, A; Kosela-Paterczyk, H; Musial, J; Kupnicka, DJ; Rys, J; Kordek, R				Braun, Marcin; Kuncman, Wojciech; Szumera-Cieckiewicz, Anna; Kosela-Paterczyk, Hanna; Musial, Jacek; Kupnicka, Dorota-Jesionek; Rys, Janusz; Kordek, Radzislaw			QUIZ WHAT IS YOUR DIAGNOSIS?	POLISH JOURNAL OF PATHOLOGY			English	Editorial Material									[Braun, Marcin; Kuncman, Wojciech; Kupnicka, Dorota-Jesionek; Kordek, Radzislaw] Med Univ Lodz, Dept Pathol, Chair Oncol, Lodz, Poland; [Braun, Marcin] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Szumera-Cieckiewicz, Anna] Inst Hematol & Transfus Med, Dept Diagnost Hematol, Warsaw, Poland; [Szumera-Cieckiewicz, Anna] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Pathol & Lab Med, Warsaw, Poland; [Kosela-Paterczyk, Hanna] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland; [Musial, Jacek] Dept Pathomorphol Synevo, Lodz, Poland; [Rys, Janusz] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Dept Tumor Pathol, Krakow, Poland	Braun, M (reprint author), Med Univ Lodz, Dept Pathol, Chair Oncol, Lodz, Poland.; Braun, M (reprint author), Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.		Braun, Marcin/N-9235-2019; Szumera-Cieckiewicz, Anna/D-8391-2019	Braun, Marcin/0000-0003-3804-7042; Szumera-Cieckiewicz, Anna/0000-0001-5028-3422				0	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	4					435	436		10.5114/PJP.2018.81702			2	Pathology	Pathology	HK1SM	WOS:000457686800014	30786695	DOAJ Gold			2019-10-28	
J	Ramkumar, S				Ramkumar, Subramaniam			Rudimentary Meningocele of the Scalp: A Pitfall in the Diagnosis of Vascular Neoplasms	CASE REPORTS IN PATHOLOGY			English	Article							HAMARTOMA	We present a case of sequestrated meningocele in a 1-year-old girl, who presented with a 1x1cm occipital swelling since birth. CT brain revealed the soft tissue swelling to be extracranial. She underwent surgical excision of the specimen and the excised mass was sent for histopathological examination. The specimen consisted of skin and subcutaneous tissue measuring 2 x 1 x 1 cm. The entire tissue was paraffin processed. Multiple sections studied from the lesion showed an ill circumscribed locally infiltrative dermal lesion. The lesion was composed of whorled proliferations of meningothelial cells enclosing pseudovascular spaces. Immunohistochemically the lesion was positive for EMA, Desmin, and negative for endothelial markers. The present case was documented as a rare case of a rudimentary meningocele.	[Ramkumar, Subramaniam] Neuberg Diagnost Pvt Ltd, Neuberg Anand Reference Labs, Pathol, Elamakkara Rd, Cochin 682017, Kerala, India	Ramkumar, S (reprint author), Neuberg Diagnost Pvt Ltd, Neuberg Anand Reference Labs, Pathol, Elamakkara Rd, Cochin 682017, Kerala, India.	drramkumar@neubergdiagnostics.com		Ramkumar, Subramaniam/0000-0003-0137-6563			Ferran M, 2007, AM J DERMATOPATH, V29, P568, DOI 10.1097/DAD.0b013e31815710ed; LOPEZ DA, 1974, CANCER-AM CANCER SOC, V34, P728, DOI 10.1002/1097-0142(197409)34:3<728::AID-CNCR2820340332>3.0.CO;2-U; Miedema JR, 2012, ARCH PATHOL LAB MED, V136, P208, DOI 10.5858/arpa.2010-0505-RS; Mihara Yuko, 1997, Journal of Dermatology (Tokyo), V24, P606; Min L. I., 2011, EUROPEAN J DENT, V21; Ochiai Junichiro, 2016, Hiroshima Journal of Medical Sciences, V65, P9; SIBLEY DA, 1989, J CUTAN PATHOL, V16, P72, DOI 10.1111/j.1600-0560.1989.tb00014.x; STONE MS, 1994, ARCH DERMATOL, V130, P775, DOI 10.1001/archderm.130.6.775; SUSTER S, 1990, AM J SURG PATHOL, V14, P1, DOI 10.1097/00000478-199001000-00001	9	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									4847286	10.1155/2018/4847286			4	Pathology	Pathology	HH3YP	WOS:000455656700001	30687556	DOAJ Gold, Green Published			2019-10-28	
J	Wang, G; Yuan, R; Tucker, T; Gates, AB; Bellamy, CD; Hayes, MM				Wang, Gang; Yuan, Ren; Tucker, Tracy; Gates, Allan B.; Bellamy, Christopher D.; Hayes, Malcolm M.			Combined Papillary Renal Cell Carcinoma with Neuroendocrine Differentiation and Mucinous Tubular and Spindle Cell Carcinoma	CASE REPORTS IN PATHOLOGY			English	Article							KIDNEY; ELEMENTS	A unique case of combined papillary renal cell carcinoma (PRCC) and mucinous tubular and spindle cell carcinoma (MTSCC) presenting in a man aged 67 years is reported. The two separate components were distinct on morphological, immunohistochemical (IHC), and genetic grounds, while type 2 PRCC predominated. Three years after the initial diagnosis, the PRCC component metastasized to the lungs where it morphologically mimicked a pulmonary neuroendocrine tumor. Retrospectively focal neuroendocrine differentiation was demonstrated by IHC in the PRCC component of the primary neoplasm.	[Wang, Gang; Tucker, Tracy; Hayes, Malcolm M.] BC Canc Vancouver Ctr, Dept Pathol, Vancouver, BC, Canada; [Yuan, Ren] BC Canc Vancouver Ctr, Dept Radiol, Vancouver, BC, Canada; [Gates, Allan B.] Abbotsford Reg Hosp, Dept Pathol, Abbotsford, BC, Canada; [Bellamy, Christopher D.] North Isl Pathol, Comox, BC, Canada	Wang, G (reprint author), BC Canc Vancouver Ctr, Dept Pathol, Vancouver, BC, Canada.	gang.wang1@bccancer.bc.ca		Wang, Gang/0000-0002-0225-4173			Bressenot A, 2010, J CLIN PATHOL, V63, P174, DOI 10.1136/jcp.2009.070292; Corless CL, 1996, DIAGN MOL PATHOL, V5, P53, DOI 10.1097/00019606-199603000-00009; Cossu-Rocca P, 2006, MODERN PATHOL, V19, P488, DOI 10.1038/modpathol.3800565; Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb; Jung SJ, 2006, AM J CLIN PATHOL, V125, P99, DOI 10.1309/B9GUVP5Y8P3YQPEE; Kuroda N, 2011, PATHOL INT, V61, P552, DOI 10.1111/j.1440-1827.2011.02689.x; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Moch H, 2016, WHO CLASSIFICATION T; Mokhtar GA, 2015, UROL ANNALS, V7, P383, DOI 10.4103/0974-7796.158506; Paner GP, 2006, AM J SURG PATHOL, V30, P13, DOI 10.1097/01.pas.0000180443.94645.50; Parada DD, 2008, APMIS, V116, P859, DOI 10.1111/j.1600-0463.2008.01004.x; Peckova K, 2015, ANN DIAGN PATHOL, V19, P261, DOI 10.1016/j.anndiagpath.2015.05.001; Ronkainen H, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-28; THOENES W, 1986, PATHOL RES PRACT, V181, P125, DOI 10.1016/S0344-0338(86)80001-2	14	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8734823	10.1155/2018/8734823			5	Pathology	Pathology	HH5BA	WOS:000455739500001	30693127	DOAJ Gold, Green Published			2019-10-28	
J	Layfield, LJ; Pearson, L; Walker, BS; White, SK; Schmidt, RL				Layfield, Lester J.; Pearson, Lauren; Walker, Brandon S.; White, Sandra K.; Schmidt, Robert L.			Diagnostic Accuracy of Fine-Needle Aspiration Cytology for Discrimination of Squamous Cell Carcinoma from Adenocarcinoma in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis	ACTA CYTOLOGICA			English	Review						Non-small cell lung cancer; Fine-needle aspiration cytology; Sensitivity and specificity; Systematic review; Meta-analysis	SMALL BIOPSIES; INTERNATIONAL ASSOCIATION; P40; CYTOPATHOLOGY; DELTA-NP63; NAPSIN; P63; RELIABILITY; EXPRESSION; SOCIETY	Objective: To determine the accuracy with which morphology alone can distinguish adenocarcinoma and squamous cell carcinoma in non-small cell lung cancer. Methods: We performed a systematic review and meta-analysis. Three data bases (MEDLINE, EMBASE, Scopus) were searched for studies on the diagnostic accuracy of subtyping non-small cell lung cancer. Accuracy data was abstracted and synthesized using bivariate mixed effects logistic regression as implemented in the midas package in Stata 14. Heterogeneity was assessed using the Higgins I-2. Results: We included 17 studies (2,235 cases). Most studies had a low risk of bias. The pooled diagnostic accuracy for cytological diagnosis of adenocarcinoma resulted in a sensitivity of 63% (48-76%) and specificity of 95% (87-98%). The I-2 values were 93 and 88% for sensitivity and specificity, respectively. The pooled diagnostic accuracy for the cytological diagnosis of squamous cell carcinoma resulted in a sensitivity of 84% (79-88%) and a specificity of 90% (84-94%). The I-2 values were 69 and 86% for sensitivity and specificity, respectively. Conclusion: Accuracy varies widely by study and summary estimates do not provide a useful representation of accuracy. Squamous cell carcinoma was diagnosed more accurately than adenocarcinoma. (C) 2018 S. Karger AG, Basel	[Layfield, Lester J.] Univ Missouri, Dept Pathol & Anat Sci, One Hosp Dr,M263 Med Sci Bldg, Columbia, MO 65212 USA; [Pearson, Lauren; Walker, Brandon S.; White, Sandra K.; Schmidt, Robert L.] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Pearson, Lauren; Walker, Brandon S.; White, Sandra K.; Schmidt, Robert L.] Univ Utah, ARUP Labs, Salt Lake City, UT USA	Layfield, LJ (reprint author), Univ Missouri, Dept Pathol & Anat Sci, One Hosp Dr,M263 Med Sci Bldg, Columbia, MO 65212 USA.	layfieldl@health.missouri.edu					Biancosino C, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0510-6; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Chen J, 2015, J THORAC DIS, V7, P680, DOI 10.3978/j.issn.2072-1439.2015.04.27; Chuman Y, 1999, FEBS LETT, V462, P129, DOI 10.1016/S0014-5793(99)01493-3; Ebrahimi M, 2016, CANCER CYTOPATHOL, V124, P737, DOI 10.1002/cncy.21739; Edwards SL, 2000, J CLIN PATHOL, V53, P537, DOI 10.1136/jcp.53.7.537; Ettinger DS, 2017, J NATL COMPR CANC NE, V15, P504, DOI 10.6004/jnccn.2017.0050; Gurda GT, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0057-2; JOHNSTON WW, 1981, ACTA CYTOL, V25, P499; Johnston WW, 1997, COMPREHENSIVE CYTOPA, P361; Layfield LJ, 2016, DIAGN CYTOPATHOL, V44, P1000, DOI 10.1002/dc.23549; Lindeman NI, 2018, ARCH PATHOL LAB MED, V142, P321, DOI 10.5858/arpa.2017-0388-CP; LOVETT JV, 1988, AM J SURG, V156, P441, DOI 10.1016/S0002-9610(88)80523-3; MITCHELL ML, 1984, ACTA CYTOL, V28, P72; Moher D, 2016, LANCET, V387, P1573, DOI 10.1016/S0140-6736(15)00307-4; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Nandeesh BN, 2015, CLIN CANCER INVESTIG, V4, P637, DOI 10.4103/2278-0513.162250; National Institute for Health Research, PROSPERO INT PROSPEC; Nizzoli R, 2011, J THORAC ONCOL, V6, P489, DOI 10.1097/JTO.0b013e31820b86cb; Nonaka D, 2012, AM J SURG PATHOL, V36, P895, DOI 10.1097/PAS.0b013e3182498f2b; Okumura Y, 2016, J EPIDEMIOL, V26, P397, DOI 10.2188/jea.JE20160105; PAYNE CR, 1981, J CLIN PATHOL, V34, P773, DOI 10.1136/jcp.34.7.773; Pelosi G, 2012, J THORAC ONCOL, V7, P281, DOI 10.1097/JTO.0b013e31823815d3; Rekhtman N, 2011, MODERN PATHOL, V24, P1348, DOI 10.1038/modpathol.2011.92; Rekhtman N, 2011, J THORAC ONCOL, V6, P451, DOI 10.1097/JTO.0b013e31820517a3; Sakr L, 2012, LUNG CANCER, V75, P293, DOI 10.1016/j.lungcan.2011.09.001; Schmidt RL, 2015, ACTA OTORRINOLAR ESP, V66, P183, DOI 10.1016/j.otorri.2014.04.004; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; STROBEL SL, 1985, ACTA CYTOL, V29, P1047; SUPRUN H, 1980, ACTA CYTOL, V24, P494; Tatsumori T, 2014, APPL IMMUNOHISTO M M, V22, P377, DOI 10.1097/PAI.0b013e3182980544; THORNBURY JR, 1981, AM J ROENTGENOL, V136, P719; Tran L, 2016, APPL IMMUNOHISTO M M, V24, P648, DOI 10.1097/PAI.0000000000000235; Travis WD, 2013, ARCH PATHOL LAB MED, V137, P668, DOI 10.5858/arpa.2012-0263-RA; Ueno T, 2003, BRIT J CANCER, V88, P1229, DOI 10.1038/sj.bjc.6600879; Vazquez MF, 2007, CANCER CYTOPATHOL, V111, P252, DOI 10.1002/cncr.22767; Wallace WAH, 2011, EUR RESPIR J, V38, P911, DOI 10.1183/09031936.00176410; Wassermann K, 2004, J BRONCHOL, V11, P154; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010; Yilmaz A, 2001, Respirology, V6, P91, DOI 10.1046/j.1440-1843.2001.00313.x	41	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					318	326		10.1159/000493942			9	Pathology	Pathology	HF3VC	WOS:000454161600001	30380531				2019-10-28	
J	Ojha, SS; Jain, R; Meenai, FJ; Sawke, GK; Sawke, NG				Ojha, Sandeep S.; Jain, Rubal; Meenai, Farah Jalay; Sawke, Gopal Krishna; Sawke, Nilima Gopal			Role of Field Staining in the Cytological Assessment of Intraoperative Surgical Specimens	ACTA CYTOLOGICA			English	Article						Field staining; Intraoperative cytology; Cytology; Scrape smear	NERVOUS-SYSTEM LESIONS; SCRAPE CYTOLOGY; DIAGNOSIS; ASPIRATION; ADVANTAGES; TOUCH; SMEAR	Objective: To study the role of Field staining in scrape smears for intraoperative cytological (IOC) diagnosis. Specimens were assessed for categorizing among benign and malignant lesions, lymph node status, and adequacy of surgical cut margins as per specimen. Technique, adequacy, and quality were assessed along with comparison of cytological diagnosis with final histopathological diagnosis obtained on routine hematoxylin and eosin-stained slides. Study Design: A prospective observational study was conducted over a period of 1 year from November 2016 to October 2017 in the Department of Pathology of our Institute. Results: 50 cases were studied, and scrape smears were stained with Field stain. Results were satisfactory in terms of adequacy and attaining the objectives of the study. A diagnostic accuracy of 98% was observed with an average turnaround time of 5 min. A single case of low-grade glioma was found to be discordant. Conclusions: Use of Field staining for intraoper-ative cytological assessment of surgical specimens has 98% concordance with the final histopathological diagnosis and achieved the aim of the study. With its low costs, easy availability, short turnaround time, and simple technique, it will be helpful in IOC as an alternative to present techniques especially in financially constrained settings. (C) 2018 S. Karger AG, Basel	[Ojha, Sandeep S.; Jain, Rubal; Meenai, Farah Jalay; Sawke, Gopal Krishna; Sawke, Nilima Gopal] Chirayu Med Coll & Hosp, Dept Pathol, Bhopal, India	Sawke, NG (reprint author), A-152,Shahpura,1st Floor, Bhopal 462016, Madhya Pradesh, India.	drrubaljain@gmail.com					Abdelghany AM, 2015, OPEN J OBSTET GYNECO, V5, P28; Baker P, 2008, INT J GYNECOL PATHOL, V27, P353, DOI 10.1097/PGP.0b013e31815c24fe; Blumenfeld W, 1998, ACTA CYTOL, V42, P1414, DOI 10.1159/000332177; Chand P, 2016, J CYTOL, V33, P93, DOI 10.4103/0970-9371.182530; Chang M C, 1993, Zhonghua Yi Xue Za Zhi (Taipei), V51, P368; CHUNGE CN, 1989, ANN TROP MED PARASIT, V83, P361, DOI 10.1080/00034983.1989.11812358; Dudgeon LS, 1927, BRIT J SURG, V15, P250, DOI 10.1002/bjs.1800155810; Kolte SS, 2010, J CYTOL, V27, P86, DOI 10.4103/0970-9371.71871; KONTOZOGLOU TE, 1991, ACTA CYTOL, V35, P154; MAIR S, 1991, AM J CLIN PATHOL, V96, P8, DOI 10.1093/ajcp/96.1.8; Narang V, 2015, J CYTOL, V32, P153, DOI 10.4103/0970-9371.168835; Nishikawa S, 2015, AURIS NASUS LARYNX, V42, P463, DOI 10.1016/j.anl.2015.03.002; Ojima T, 2013, ONCOL REP, V30, P1067, DOI 10.3892/or.2013.2591; Ozsoy M, 2015, UROL ONCOL, V33, P67; Richard JZ, 1997, ARCH PATHOL LAB MED, V121, P559; Scucchi LF, 1997, ACTA CYTOL, V41, P1489; Shahid M, 2012, ACTA CYTOL, V56, P467, DOI 10.1159/000339394; Shidham V, 2000, DIAGN CYTOPATHOL, V23, P134, DOI 10.1002/1097-0339(200008)23:2<134::AID-DC14>3.0.CO;2-N; SHIDHAM VB, 1984, ACTA CYTOL, V28, P477; Stewart CJR, 2010, CANCER CYTOPATHOL, V118, P127, DOI 10.1002/cncy.20073; Vijayakumar A, 2013, J CLIN DIAGN RES, V7, P1047, DOI 10.7860/JCDR/2013/4853.3035; World Medical Association Declaration of Helsinki, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI [10.1001/jama.1997.03540350075038, DOI 10.1001/JAMA.1997.03540350075038]	22	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					327	332		10.1159/000489768			6	Pathology	Pathology	HF3VC	WOS:000454161600002	29940582				2019-10-28	
J	Rodriguez, EF; Chowsilpa, S; Maleki, Z				Rodriguez, Erika F.; Chowsilpa, Sayanan; Maleki, Zahra			Insulinoma-Associated Protein 1 Immunostain: A Diagnostic Tool for Pulmonary Small Cell Carcinoma in Cytology	ACTA CYTOLOGICA			English	Article						Insulinoma-associated protein 1; Neuroendocrine markers; CD56; Small cell lung carcinoma; Endobronchial ultrasound	NEUROENDOCRINE DIFFERENTIATION; LUNG NEOPLASMS; CANCER; MARKER; CD56	Objective: Cytology plays an important role in the diagnosis of small cell carcinoma (SCLC). Application of immunohistochemical (IHC) markers improves the accuracy and reproducibility of the diagnosis of SCLC. We report the application of insulinoma-associated protein 1 (INSM1) in the diagnosis of SCLC in cytology samples. Methods: Our pathology data system was searched for SCLC where INSM1 IHC was performed. Patients' demographics were recorded. Cytopathology specimens were reviewed. Results: A total of 32 cases were identified. INSM1 was positive in 31 (97%) cases. Twenty-seven cases showed a strong/diffuse pattern (84%). Four cases were focally/weak positive (13%). One case was negative (3%). the sensitivity of INSM1 for recognition of SCLC was 97%. CD56 was performed in SCLC. Twenty cases were strongly/diffusely positive (87%). One case was negative (4%). The sensitivity was 96%. Conclusion: INSM1 is positive in the majority of SCLC on cytology specimens and its sensitivity is similar to that of CD56 on SCLC. This has practical implications for the diagnosis of these tumors in cytology samples. (C) 2018 S. Karger AG, Basel	[Rodriguez, Erika F.; Chowsilpa, Sayanan; Maleki, Zahra] Johns Hopkins Univ Hosp, Div Cytopathol, Dept Pathol, Baltimore, MD 21287 USA; [Chowsilpa, Sayanan] Chiang Mai Univ, Dept Pathol, Fac Med, Chiang Mai, Thailand	Rodriguez, EF (reprint author), Johns Hopkins Univ, Dept Pathol, Carnegie Pathol 469, 600 N Wolfe St, Baltimore, MD 21287 USA.	erodri17@jhmi.edu					Doxtader EE, 2018, CANCER CYTOPATHOL, V126, P243, DOI 10.1002/cncy.21972; Fujino K, 2015, AM J PATHOL, V185, P3164, DOI 10.1016/j.ajpath.2015.08.018; Jia SQ, 2015, DEV BIOL, V408, P90, DOI 10.1016/j.ydbio.2015.10.009; LAN MS, 1993, CANCER RES, V53, P4169; Maleki Z, 2011, DIAGN CYTOPATHOL, V39, P159, DOI 10.1002/dc.21351; McColl K, 2017, ONCOTARGET, V8, P73745, DOI 10.18632/oncotarget.20572; Osipovich AB, 2014, DEVELOPMENT, V141, P2939, DOI 10.1242/dev.104810; Pedersen N, 2006, CANCER GENE THER, V13, P375, DOI 10.1038/sj.cgt.7700887; Robson T, 2003, J BIOMED BIOTECHNOL, P110, DOI 10.1155/S1110724303209074; Rooper LM, 2017, AM J SURG PATHOL, V41, P1561, DOI 10.1097/PAS.0000000000000916; Rosenbaum JN, 2015, AM J CLIN PATHOL, V144, P579, DOI 10.1309/AJCPGZWXXBSNL4VD; Thunnissen E, 2017, J THORAC ONCOL, V12, P334, DOI 10.1016/j.jtho.2016.12.004; Travis WD, 2015, WHO CLASSIFICATION T; Zheng G, 2013, ACTA CYTOL, V57, P281, DOI 10.1159/000346394	14	3	2	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					333	338		10.1159/000490091			6	Pathology	Pathology	HF3VC	WOS:000454161600003	29936498				2019-10-28	
J	Wei, SZ; Ehya, H				Wei, Shuanzeng; Ehya, Hormoz			Degenerated Keratinized Tumor Cells in Oropharyngeal Human Papilloma Virus-Associated Squamous Cell Carcinoma: A Pitfall in p16 Immunostaining of Fine-Needle Aspiration Specimens	ACTA CYTOLOGICA			English	Article						Human papilloma virus; Squamous cell carcinoma; Lymph node; p16; Fine-needle aspiration	NECK; HEAD; FEATURES; MARKER	Objective: High-risk human papilloma virus (HPV) testing should be performed on all patients with newly diagnosed oropharyngeal HPV-associated squamous cell carcinoma (OPHPVSCC), and p16 immunostaining can be used as a surrogate marker. Although in surgical pathology specimens p16 staining in > 70% of the tumor cells is considered a positive result, the interpretation in fine-needle aspiration (FNA) specimens has remained controversial. Study Design: FNA of neck lymph nodes and corresponding surgical specimens from 42 patients with OPHPVSCC were reviewed. Results: In FNA specimens, 38 cases (90.5%) had viable tumor cells, 32 (76.2%) had keratin debris, and 36 (85.7%) had degenerated keratinized tumor cells. Twenty-seven of 27 (100%) had positive p16 staining in > 70% of viable tumor cells, while the degenerated tumor cells were negative. Twenty of 24 (83.3%) primary OPHPVSCC exhibited focal degenerated keratinized tumor cells and/or keratin debris. Conclusions: This study showed that the majority of the OPHPVSCC metastases in lymph nodes had degenerated keratinized tumor cells and keratin debris. Many primary OPHPVSCC also demonstrated focal keratinization and/or degeneration. The degenerated tumor cells showed no immunoreactivity to p16. The same 70% cutoff used in histologic specimens should be applied in cytologic specimens, but only the viable tumor cells should be counted. (C) 2018 S. Karger AG, Basel	[Wei, Shuanzeng; Ehya, Hormoz] Fox Chase Canc Ctr, Dept Pathol, 333 Cottman Ave, Philadelphia, PA 19111 USA	Wei, SZ (reprint author), Fox Chase Canc Ctr, Dept Pathol, 333 Cottman Ave, Philadelphia, PA 19111 USA.	weishuanzeng@hotmail.com		Wei, Shuanzeng/0000-0002-0441-6973			Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Begum S, 2007, CLIN CANCER RES, V13, P1186, DOI 10.1158/1078-0432.CCR-06-1690; Bernadt CT, 2017, DIAGN CYTOPATHOL, V45, P221, DOI 10.1002/dc.23668; Bishop JA, 2015, SEMIN DIAGN PATHOL, V32, P344, DOI 10.1053/j.semdp.2015.02.013; Bishop JA, 2012, CANCER CYTOPATHOL, V120, P18, DOI 10.1002/cncy.20175; Chernock RD, 2009, HEAD NECK PATHOL, V3, P186, DOI 10.1007/s12105-009-0126-1; Chernock RD, 2012, HEAD NECK PATHOL, V6, pS41, DOI 10.1007/s12105-012-0373-4; El-Mofty SK, 2015, SEMIN DIAGN PATHOL, V32, P23, DOI 10.1053/j.semdp.2015.02.022; El-Mofty SK, 2008, HEAD NECK PATHOL, V2, P163, DOI 10.1007/s12105-008-0066-1; El-Naggar A, 2017, WHO CLASSIFICATION H; Guo M, 2014, CANCER CYTOPATHOL, V122, P96, DOI 10.1002/cncy.21375; Holmes BJ, 2015, ACTA CYTOL, V59, P97, DOI 10.1159/000375148; Jalaly JB, 2015, CANCER CYTOPATHOL, V123, P723, DOI 10.1002/cncy.21600; Jannapureddy S, 2010, DIAGN CYTOPATHOL, V38, P795, DOI 10.1002/dc.21293; Jarboe EA, 2012, DIAGN CYTOPATHOL, V40, P491, DOI 10.1002/dc.22837; Lewis JS, 2018, ARCH PATHOL LAB MED, V142, P559, DOI 10.5858/arpa.2017-0286-CP; Lewis JS, 2010, AM J SURG PATHOL, V34, P1088, DOI 10.1097/PAS.0b013e3181e84652; Mahajan A, 2016, HUM PATHOL, V51, P64, DOI 10.1016/j.humpath.2015.12.021; Maxwell JH, 2016, ANNU REV MED, V67, P91, DOI 10.1146/annurev-med-051914-021907; Mills AM, 2012, AM J SURG PATHOL, V36, P1158, DOI 10.1097/PAS.0b013e3182600eaa; Robinson M, 2012, HEAD NECK PATHOL, V6, pS83, DOI 10.1007/s12105-012-0370-7; Stevens TM, 2017, VIRCHOWS ARCH, V471, P295, DOI 10.1007/s00428-017-2118-y; Xu B, 2016, HUM PATHOL, V54, P193, DOI 10.1016/j.humpath.2016.04.002	23	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					339	345		10.1159/000490229			7	Pathology	Pathology	HF3VC	WOS:000454161600004	29966127				2019-10-28	
J	Nicola, M; Onorati, M; Lancia, M; Albertoni, M; Di Nuovo, F				Nicola, Marta; Onorati, Monica; Lancia, Mauro; Albertoni, Milena; Di Nuovo, Franca			Potential Difficulties in Cytological Approach of Basal Cell Adenoma of Salivary Glands: The Experience of a Single Institution	ACTA CYTOLOGICA			English	Article						Salivary gland; Basal cell adenoma; Fine needle aspiration cytology; Pitfalls	NEEDLE-ASPIRATION-CYTOLOGY; PAROTID-GLAND	Objective: Basal cell adenoma (BCA) is an uncommon benign epithelial neoplasm of salivary glands, which was first described by Kleinsasser and Klein in 1967 and which derives its name from the monomorphic basaloid appearance of tumor cells. This tumor represents 1-2% of all salivary gland epithelial tumors; the most common site of occurrence is the parotid gland. It usually arises in adults over 50 years of age with slight female prevalence. Study Design: We analyzed 5 cases of parotid lesions investigated by fine needle aspiration cytology at a single institution between 2002 and 2018. Results: Our series was composed by 3 women and 2 men with a mean age of 62 years. The most important cytological criteria we observed were cohesive sharp-angled clusters of regular basaloid cells, palisaded by p63-positive myoepithelial cells, and bordered by basement membrane-like hyaline membrane in the absence of a myxochondroid stroma. Overall features were consistent with the diagnosis of BCA. Conclusions: Our aim is to highlight the cytological features of these rare lesions improving the awareness of cytological pitfalls of salivary gland basaloid neoplasms. Moreover, the goal of this paper is to add to the literature 5 additional cases of these unusual tumors. (C) 2018 S. Karger AG, Basel	[Nicola, Marta; Onorati, Monica; Lancia, Mauro; Albertoni, Milena; Di Nuovo, Franca] ASST Rhodense, Garbagnate Milanese Hosp, Pathol Unit, Viale Forlanini 95, IT-20024 Garbagnate Milanese, Italy	Nicola, M (reprint author), ASST Rhodense, Garbagnate Milanese Hosp, Pathol Unit, Viale Forlanini 95, IT-20024 Garbagnate Milanese, Italy.	marta.nicola.ap@hotmail.it					Bhat Amoolya, 2015, J Oral Maxillofac Pathol, V19, P106, DOI 10.4103/0973-029X.157211; Daneshbod Y, 2009, ACTA CYTOL, V53, P53, DOI 10.1159/000325085; El-Naggar A, 2017, WHO CLASSIFICATION H; Faquin WC, 2008, ESSENT CYTOPATHOL, P1, DOI 10.1007/978-0-387-76623-2; Gupta N, 2011, DIAGN CYTOPATHOL, V39, P913, DOI 10.1002/dc.21576; Kanaujia SK, 2015, INDIAN J OTOLARYNGOL, V67, P430, DOI 10.1007/s12070-015-0865-0; Kawahara A, 2007, DIAGN CYTOPATHOL, V35, P85, DOI 10.1002/dc.20598; Kazakov DV, 2016, HEAD NECK PATHOL, V10, P125, DOI 10.1007/s12105-016-0705-x; Kleinsasser O, 1967, Arch Klin Exp Ohren Nasen Kehlkopfheilkd, V189, P302, DOI 10.1007/BF00455855; Lambade PN, 2015, J MAXILLOFAC ORAL SU, V14, P999, DOI 10.1007/s12663-014-0709-6; Lu JR, 2015, INT J CLIN EXP PATHO, V8, P2899; Nur MM, 2016, IRISH J MED SCI, V185, P711, DOI 10.1007/s11845-015-1352-z; Rajasenthil V, 2014, INDIAN J SURG, V76, P408, DOI 10.1007/s12262-013-1010-5; Schmitt AC, 2017, DIAGN CYTOPATHOL, V45, P1078, DOI 10.1002/dc.23820; Seethala RR, 2017, HEAD NECK PATHOL, V11, P55, DOI 10.1007/s12105-017-0795-0; Shetty Archana, 2016, J Oral Maxillofac Pathol, V20, P224, DOI 10.4103/0973-029X.185899; Vicandi B, 2012, CYTOPATHOLOGY, V23, P315, DOI 10.1111/j.1365-2303.2011.00899.x; Zurczyk M, 2014, DIAGN CYTOPATHOL, V43, P432	18	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					346	351		10.1159/000490692			6	Pathology	Pathology	HF3VC	WOS:000454161600005	30045010				2019-10-28	
J	Vallonthaiel, AG; Kaushal, S; Jangir, H; Rajendran, HK				Vallonthaiel, Archana George; Kaushal, Seema; Jangir, Hemlata; Rajendran, Hemanth Kumar			Application of the Milan System for Risk Stratification and Its Comparison with a Previous Reporting System of Parotid Gland Cytopathology in a Tertiary Care Centre	ACTA CYTOLOGICA			English	Article						Milan System for Reporting Salivary Gland Cytopathology; Parotid gland; Cytology; Risk stratification	FINE-NEEDLE-ASPIRATION; STANDARDIZED TERMINOLOGY; PAPANICOLAOU SOCIETY; FNA CYTOLOGY; NOMENCLATURE; DIAGNOSIS; LESIONS; BIOPSY; TUMORS	Objective: To compare the recently proposed Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) with the four-tiered reporting system (FTRS) followed at our institute. Methods: Parotid gland fine-needle aspirates reported over a period of 5 years were analysed. These aspirates had been placed into 4 categories according to the FTRS: unsatisfactory (UNS), no evidence of malignancy/negative (NEG), inconclusive for malignancy (INC), and diagnostic for malignancy/positive (POS). Aspirates with follow-up histopathology were then categorized according to the MSRSGC as follows: non-diagnostic, non-neoplastic, atypia of undetermined significance (AUS), neoplasm, suspicious for malignancy, and malignant. The risk of malignancy (ROM) was calculated. Results: A total of 893 parotid region aspirates were evaluated and histopathology was available for 190 cases (21%). ROM in MSRSGC groups, namely non-diagnostic, nonneoplastic, AUS, neoplasm, suspicious for malignant neoplasm, and malignant, was 44, 8, 0, 12, 81 and 100%, respectively. ROM in FTRS groups, namely UNS, NEG, INC, and POS, was 45, 13, 67 and 100%, respectively. Conclusions: MSRGC and FTRS are comparable with respect to the ROM across groups. Compared to FTRS, the further subcategorisation of the non-malignant group, the use of specific nomenclature, and the reproducibility of MSRGC provide proper risk stratification, thereby guiding better management and resulting in improved patient care. (C) 2018 S. Karger AG, Basel	[Vallonthaiel, Archana George; Kaushal, Seema; Jangir, Hemlata; Rajendran, Hemanth Kumar] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India	Kaushal, S (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	seema.dr@gmail.com					Ali NS, 2011, ISRN SURG, V2011, DOI DOI 10.5402/2011/721525.EPUB; Balakrishnan K, 2005, SURG-J R COLL SURG E, V3, P67, DOI 10.1016/S1479-666X(05)80064-2; Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830; Baloch ZW, 2017, DIAGN CYTOPATHOL, V45, P285, DOI 10.1002/dc.23601; Ersoz C, 2004, AEGEAN PATHOL J, V1, P51; Faquin WC, 2018, MILAN SYSTEM REPORTI; FRABLE MS, 1982, LARYNGOSCOPE, V92, P1414; Hartimath B, 2011, INDIAN J SURG, V73, P19, DOI 10.1007/s12262-010-0162-9; Layfield LJ, 2016, DIAGN CYTOPATHOL, V44, P399, DOI 10.1002/dc.23457; Layfield LJ, 2018, CYTOPATHOLOGY; Lussier C, 2000, CANCER CYTOPATHOL, V90, P350, DOI 10.1002/1097-0142(20001225)90:6<350::AID-CNCR5>3.3.CO;2-5; Mairembam P, 2016, CYTOPATHOLOGY, V27, P91, DOI 10.1111/cyt.12232; ODWYER P, 1986, CANCER, V57, P554, DOI 10.1002/1097-0142(19860201)57:3<554::AID-CNCR2820570325>3.0.CO;2-G; Piccioni LO, 2011, ACTA OTORHINOLARYNGO, V31, P1; Pitman MB, 2014, DIAGN CYTOPATHOL, V42, P338, DOI 10.1002/dc.23092; Rohilla M, 2017, CANCER CYTOPATHOL, V125, P767, DOI 10.1002/cncy.21900; Rosenthal DL, 2016, PARIS SYSTEM REPORTI, P5; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Thiryayi SA, 2018, CYTOPATHOLOGY; Wei SZ, 2017, DIAGN CYTOPATHOL, V45, P820, DOI 10.1002/dc.23716	20	3	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					352	359		10.1159/000492051			8	Pathology	Pathology	HF3VC	WOS:000454161600006	30223278				2019-10-28	
J	Ryu, A; Ashimura, J; Nakayama, T; Tamaki, Y; Nakatsuka, S; Tomita, Y				Ryu, Ayumi; Ashimura, Jyun-ichi; Nakayama, Takahiro; Tamaki, Yasuhiro; Nakatsuka, Shin-ichi; Tomita, Yasuhiko			Reliability of Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Expression on Breast Cancer Cells Stored in Cellprep (R) Vials	ACTA CYTOLOGICA			English	Article						ASCO/CAP guidelines; Estrogen receptor; Human epidermal growth factor receptor 2; Cellprep (R); Immunocytochemistry	LIQUID-BASED CYTOLOGY; PROGESTERONE-RECEPTOR; IMMUNOHISTOCHEMICAL DETECTION; HORMONE-RECEPTOR; HER2 EXPRESSION; NEEDLE-CORE; CARCINOMAS; IMPACT; BLOCK; IMMUNOCYTOCHEMISTRY	Objective: The aim of this study was to evaluate the reliability of estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) expression levels in Cellprep (R) (CP). Study Design: We evaluated the stability of immunocytochemistry (ICC) of ER and HER2 for primary or recurrent breast cancer samples rinsed in CP vials. Samples were prepared from CP vials stored for 1-30 or 160-240 days. ER and HER2 statuses were determined after 1-30 days (26 and 25 tests, respectively) or 160-240 days (15 and 18 tests, respectively) with the same protocols as immunohistochemistry (IHC), and were compared with the corresponding surgically resected specimens. Results: ER statuses according to CP samples showed perfect agreement (1-30 days: kappa, kappa = 1; 160-240 days: kappa = 1). HER2 statuses also showed good agreement (1-30 days: kappa = 0.79; 160-240 days: kappa = 0.64), although there were more equivocal HER2 cases in CP than in the surgically resected specimens. Conclusion: ER ICC in CP vials is reliable regardless of the preservation period. HER2 ICC in CP has more equivocal cases than HER2 IHC in surgically resected specimens. Both improvement of the immunostaining protocol and further validation study of in situ hybridization are indispensable for the practical application of ICC in CP. (C) 2018 S. Karger AG, Basel	[Ryu, Ayumi; Ashimura, Jyun-ichi; Nakatsuka, Shin-ichi; Tomita, Yasuhiko] Osaka Int Canc Inst, Dept Pathol & Cytol, Osaka, Japan; [Nakayama, Takahiro; Tamaki, Yasuhiro] Osaka Int Canc Inst, Dept Breast & Endocrine Surg, Osaka, Japan; [Tomita, Yasuhiko] Int Univ Hlth & Welf, Sch Med, Dept Pathol, Osaka, Japan	Ryu, A (reprint author), Osaka Int Canc Inst, Dept Pathol & Cytol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan.	ryuu-ay@mc.pref.osaka.jp					Allred DC, 1998, MODERN PATHOL, V11, P155; Amir E, 2012, J CLIN ONCOL, V30, P587, DOI 10.1200/JCO.2010.33.5232; Beatty BG, 2004, AM J CLIN PATHOL, V122, P246, DOI 10.1309/X8UP920UF4XM1C5C; Bedard YC, 2003, ACTA CYTOL, V47, P979, DOI 10.1159/000326671; Bianchi S, 2015, PATHOL ONCOL RES, V21, P477, DOI 10.1007/s12253-014-9852-0; Domanski AM, 2013, CYTOPATHOLOGY, V24, P21, DOI 10.1111/j.1365-2303.2012.00997.x; Gerhard R, 2014, ACTA CYTOL, V58, P533, DOI 10.1159/000362805; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hanley KZ, 2009, CANCER CYTOPATHOL, V117, P279, DOI 10.1002/cncy.20034; Kinsella MD, 2013, DIAGN CYTOPATHOL, V41, P192, DOI 10.1002/dc.21815; Knoepp SM, 2013, CANCER CYTOPATHOL, V121, P120, DOI 10.1002/cncy.21214; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Leung SW, 1999, AM J CLIN PATHOL, V112, P50; Marinsek ZP, 2013, CYTOPATHOLOGY, V24, P7, DOI 10.1111/cyt.12024; Nishimura R, 2016, DIAGN CYTOPATHOL, V44, P274, DOI 10.1002/dc.23433; Nishimura R, 2011, VIRCHOWS ARCH, V458, P153, DOI 10.1007/s00428-010-1025-2; Pegolo E, 2012, CANCER CYTOPATHOL, V120, P196, DOI 10.1002/cncy.20206; Saqi A, 2016, ARCH PATHOL LAB MED, V140, P1318, DOI 10.5858/arpa.2016-0125-RA; Sartelet H, 2005, J CLIN PATHOL, V58, P864, DOI 10.1136/jcp.2004.024224; Sauer T, 2010, CYTOJOURNAL, V7, DOI 10.4103/1742-6413.75665; Shabaik A, 2011, DIAGN CYTOPATHOL, V39, P328, DOI 10.1002/dc.21389; Shiino S, 2016, CLIN BREAST CANCER, V16, pE133, DOI 10.1016/j.clbc.2016.05.014; Son SM, 2012, KOREAN J PATHOL, V46, P68, DOI 10.4132/KoreanJPathol.2012.46.1.68; Tabbara SO, 1998, CANCER CYTOPATHOL, V84, P355, DOI 10.1002/(SICI)1097-0142(19981225)84:6<355::AID-CNCR7>3.0.CO;2-H; Thompson AM, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2771; Tong LC, 2011, AM J SURG PATHOL, V35, P545, DOI 10.1097/PAS.0b013e31820e6237; Vohra P, 2016, CANCER CYTOPATHOL, V124, P828, DOI 10.1002/cncy.21745; Williams SL, 2009, INT J CLIN EXP PATHO, V2, P476; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yamashita H, 2011, ANN ONCOL, V22, P1318, DOI 10.1093/annonc/mdq596; Yildiz-Aktas IZ, 2012, AM J CLIN PATHOL, V137, P691, DOI 10.1309/AJCPQRAG67GJRPMT; Zhang ZH, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000981	32	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					360	370		10.1159/000492501			11	Pathology	Pathology	HF3VC	WOS:000454161600007	30380525				2019-10-28	
J	Guleria, P; Phulware, R; Agarwal, S; Jain, D; Mathur, SR; Iyer, VK; Ballal, S; Bal, CS				Guleria, Prerna; Phulware, Ravi; Agarwal, Shipra; Jain, Deepali; Mathur, Sandeep R.; Iyer, Venkateswaran K.; Ballal, Sanjana; Bal, Chandrasekhar S.			Cytopathology of Solid Variant of Papillary Thyroid Carcinoma: Differential Diagnoses with other Thyroid Tumors	ACTA CYTOLOGICA			English	Article						Solid variant; Papillary thyroid carcinoma; Nuclear features; Cytohistological correlation; Bethesda category; Differential diagnoses	NEEDLE-ASPIRATION-CYTOLOGY; FEATURES; COMPONENT	D Objectives: Solid variant of papillary thyroid carcinoma (SVPTC) is rare, differing from classical PTC (cPTC) in architecture and outcome. We evaluated the cytomorphology of SVPTC cases to assess the feasibility of a preoperative diagnosis. Study Design: SVPTC cases were evaluated for architecture, nuclear features, and Bethesda category and were compared with noninvasive follicular thyroid neoplasm with papillary-like nuclear features/follicular variant of PTC (NIFTP/FVPTC), cPTC, and poorly differentiated thyroid carcinoma (PDTC). Results: Nine SVPTCs, 29 NIFTP/FVPTCs, 12 cPTCs, and 4 PDTCs were included. The predominant architecture in most SVPTCs was solid fragment, which is helpful in differentiating them from NIFTP/FVPTC (p < 0.001) and cPTC (p = 0.006) but not from PDTC. The presence of microfollicles led to misinterpretation as NIFTP/FVPTC/follicular neoplasm in 4 patients. All but 1 SVPTC showed diffuse nuclear features. Intranuclear pseudoinclusions (INIs) were seen in 67% of SVPTCs as compared to 83% of cPTCs, 14% of NIFTP/FVPTCs (p = 0.005), and none of PDTCs. SVPTC cases were commonly (78%) categorized as intermediate/suspicious. Conclusions: The presence of solid fragments and lack of true papillae are helpful in differentiating SVPTC from cPTC. Solid fragments, trabeculae, the extent of nuclear features, and INIs should be looked for in cases with prominent microfollicles for distinguishing SVPTC from NIFTP/FVPTC. None of the features were helpful in differentiating SVPTC from PDTC. (C) 2018 S. Karger AG, Basel	[Guleria, Prerna; Phulware, Ravi; Agarwal, Shipra; Jain, Deepali; Mathur, Sandeep R.; Iyer, Venkateswaran K.] All India Inst Med Sci, Dept Pathol, New Delhi 110029, India; [Ballal, Sanjana; Bal, Chandrasekhar S.] All India Inst Med Sci, Dept Nucl Med, New Delhi, India	Agarwal, S (reprint author), All India Inst Med Sci, Dept Pathol, New Delhi 110029, India.	drshipra0902@gmail.com		Guleria, Prerna/0000-0001-9608-7152			Abdul Rahman WF, 2013, BMJ CASE REP, V2013; Baloch Z, 2013, J CLIN PATHOL, V66, P733, DOI 10.1136/jclinpath-2013-201626; Bongiovanni M, 2009, CANCER CYTOPATHOL, V117, P185, DOI 10.1002/cncy.20023; CARCANGIU ML, 1985, CANCER, V55, P805, DOI 10.1002/1097-0142(19850215)55:4<805::AID-CNCR2820550419>3.0.CO;2-Z; Chang H, 2014, ANZ J SURG, V84, P380, DOI 10.1111/ans.12307; Chiosea S, 2009, ENDOCR PATHOL, V20, P122, DOI 10.1007/s12022-009-9073-3; Cibas ES, 2017, THYROID, V27, P1341, DOI 10.1089/thy.2017.0500; Damle N, 2011, INDIAN J NUCL MED, V26, P144, DOI [10.4103/0972-3919.106707, 10.4103/0972-3919.103997]; Giorgadze TA, 2015, CANCER CYTOPATHOL, V123, P71, DOI 10.1002/cncy.21504; Higuchi M, 2017, CYTOPATHOLOGY, V28, P268, DOI 10.1111/cyt.12399; LiVolsi VA, 2011, MODERN PATHOL, V24, pS1, DOI 10.1038/modpathol.2010.129; Mahajan S, 2018, CYTOPATHOLOGY, V29, P233, DOI 10.1111/cyt.12537; Nair M, 2001, DIAGN CYTOPATHOL, V24, P167, DOI 10.1002/1097-0339(200103)24:3<167::AID-DC1035>3.0.CO;2-3; Nguyen GK, 2006, DIAGN CYTOPATHOL, V34, P712, DOI 10.1002/dc.20492; Nikiforov YE, 2001, AM J SURG PATHOL, V25, P1478, DOI 10.1097/00000478-200112000-00002; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohashi R, 2017, DIAGN CYTOPATHOL, V45, P391, DOI 10.1002/dc.23679; Ohashi R, 2017, HISTOPATHOLOGY, V70, P775, DOI 10.1111/his.13132; Purkait S, 2016, CYTOPATHOLOGY, V27, P176, DOI 10.1111/cyt.12270; Renshaw AA, 2006, ARCH PATHOL LAB MED, V130, P148; Rosai JASJ, 2017, WHO CLASSIFICATION T, P81; Sak Serpil Dizbay, 2015, Turk Patoloji Derg, V31 Suppl 1, P34, DOI 10.5146/tjpath.2015.01313; Sebastian SO, 2000, ARCH SURG-CHICAGO, V135, P272, DOI 10.1001/archsurg.135.3.272; Troncone G, 2008, CYTOJOURNAL, V5, DOI 10.1186/1742-6413-5-2	24	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					371	379		10.1159/000493081			9	Pathology	Pathology	HF3VC	WOS:000454161600008	30253413				2019-10-28	
J	Gianella, P; Soccal, PM; Plojoux, J; Fresard, I; Pache, JC; Perneger, T; Gex, G				Gianella, Pietro; Soccal, Paola M.; Plojoux, Jerome; Fresard, Isabelle; Pache, Jean-Claude; Perneger, Thomas; Gex, Gregoire			Utility of Rapid On-Site Cytologic Evaluation during Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Malignant and Nonmalignant Disease	ACTA CYTOLOGICA			English	Article						Bronchoscopy; Endobronchial ultrasound; Transbronchial needle aspiration; Rapid on-site evaluation	LUNG-CANCER; DIAGNOSIS; TIME; TRIAL	Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is an accurate procedure to sample mediastinal tissue. Rapid on-site cytologic evaluation (ROSE) has been advocated to improve the performance of this procedure, but its benefit remains controversial. Our objective is to assess the utility of ROSE for EBUS-TBNA diagnostic accuracy among unselected patients. Methods: We prospectively collected data from all consecutive EBUS-TBNA procedures performed between 2008 and 2014. ROSE was introduced since 2011 in our daily practice. The accuracy of EBUS-TBNA with and without ROSE was compared in a univariate and multivariate model accounting for confounding factors. The impact of ROSE was then analyzed according to the etiology and size of the lesions. Results: Among 348 EBUS-TBNA procedures analyzed, 213 were performed with ROSE. The overall accuracy tended to be better with ROSE than without (90.6 vs. 84.4%; p = 0.082). After adjustment in a multivariate model, the benefit of ROSE still did not reach statistical significance (adjusted odds ratio 1.86; 95% confidence interval 0.79-4.41). Similar results were obtained in subgroups of patients with malignant disease or sarcoidosis. The size of the lesion did not influence the impact of ROSE on accuracy. Conclusions: ROSE was associated with a moderate increase in the accuracy of EBUS-TBNA, but the difference was not statistically significant. The same effect of ROSE was observed in malignant and nonmalignant lesions and this effect was not influenced by the lesion's size. (C) 2018 S. Karger AG, Basel	[Gianella, Pietro; Soccal, Paola M.; Plojoux, Jerome; Fresard, Isabelle; Gex, Gregoire] Geneva Univ Hosp, Dept Pulmonol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland; [Pache, Jean-Claude] Geneva Univ Hosp, Dept Clin Pathol, Geneva, Switzerland; [Perneger, Thomas] Geneva Univ Hosp, Div Clin Epidemiol, Geneva, Switzerland; [Gex, Gregoire] Hop Valais, Div Pulmonol, Sion, Switzerland	Gianella, P (reprint author), Geneva Univ Hosp, Dept Pulmonol, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.	pietro.gianella@eoc.ch					Alsharif M, 2008, AM J CLIN PATHOL, V130, P434, DOI 10.1309/BLLQF8KDHWW6MJNQ; Baram D, 2005, CHEST, V128, P869, DOI 10.1378/chest.128.2.869; Boyan W, 2003, J BRONCHOL, V10, P152; Chin R, 2002, AM J RESP CRIT CARE, V166, P377, DOI 10.1164/rccm.2106153; DAVENPORT RD, 1990, CHEST, V98, P59, DOI 10.1378/chest.98.1.59; Diacon AH, 2005, RESPIRATION, V72, P182, DOI 10.1159/000084050; Diette GB, 2000, CHEST, V117, P1186, DOI 10.1378/chest.117.4.1186; Gasparini S, 2005, RESPIRATION, V72, P129, DOI 10.1159/000084041; Griffin AC, 2011, CYTOJOURNAL, V8, DOI 10.4103/1742-6413.90081; Gu P, 2009, EUR J CANCER, V45, P1389, DOI 10.1016/j.ejca.2008.11.043; Guo HB, 2016, CANCER LETT, V371, P182, DOI 10.1016/j.canlet.2015.11.038; Herth FJF, 2006, THORAX, V61, P795, DOI 10.1136/thx.2005.047829; Joseph M, 2013, ANN THORAC SURG, V96, P403, DOI 10.1016/j.athoracsur.2013.04.003; Layfield LJ, 2001, CANCER CYTOPATHOL, V93, P319, DOI 10.1002/cncr.9046; Mondoni M, 2013, RESPIRATION, V86, P52, DOI 10.1159/000346998; Nakajima T, 2013, ANN THORAC SURG, V95, P1695, DOI 10.1016/j.athoracsur.2012.09.074; Oki M, 2013, RESPIRATION, V85, P486, DOI 10.1159/000346987; Plit ML, 2013, EUR RESPIR J, V42, P1302, DOI 10.1183/09031936.00128312; Schmidt RL, 2013, AM J CLIN PATHOL, V139, P300, DOI 10.1309/AJCPEGZMJKC42VUP; Trisolini R, 2015, CHEST, V148, P1430, DOI 10.1378/chest.15-0583; Trisolini R, 2011, CHEST, V139, P395, DOI 10.1378/chest.10-1521; van der Heijden EHFM, 2014, RESPIRATION, V88, P500, DOI 10.1159/000368857; Varela-Lema L, 2009, EUR RESPIR J, V33, P1156, DOI 10.1183/09031936.00097908; Vincent BD, 2008, ANN THORAC SURG, V85, P224, DOI 10.1016/j.athoracsur.2007.07.023; Yarmus L, 2011, J BRONCHOL INTERN PU, V18, P121, DOI 10.1097/LBR.0b013e31821707ee	25	2	3	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					380	385		10.1159/000493334			6	Pathology	Pathology	HF3VC	WOS:000454161600009	30244239				2019-10-28	
J	de Oliveira, GG; de Oliveira, JMDC; Eleuterio, RMN; Barbosa, RDC; de Almeida, PRC; Eleuterio, J				de Oliveira, Geilson Gomes; da Silva Costa de Oliveira, Judite Maria; Nunes Eleuterio, Renata Mirian; Carvalho Barbosa, Rita de Cassia; Carvalho de Almeida, Paulo Roberto; Eleuterio, Jose, Jr.			Atypical Squamous Cells: Cytopathological Findings and Correlation with HPV Genotype and Histopathology	ACTA CYTOLOGICA			English	Article						Uterine cervical neoplasm; Atypical squamous cells of the cervix; Papanicolaou test; Human papillomavirus	CERVICAL CYTOLOGY; FOLLOW-UP; INTRAEPITHELIAL LESIONS; ASC-US; MANAGEMENT; CANCER; CANNOT; PREVALENCE; INFECTION; DIAGNOSIS	Objective: We aimed to assess potential associations between atypical squamous cell (ASC) subgroups: ASC-US (undetermined significance) and ASC-H (cannot exclude highgrade squamous intraepithelial lesion), regarding cytomorphological features, high-risk (HR) human papillomavirus (HPV) testing, and histological outcomes in a sample of Brazilian women. Study Design: Cross-sectional study which evaluated 1,346 liquid-based cytologies between January 2010 and July 2016 with ASC results. ASC-US and ASC-H were analyzed for frequency, diagnostic criteria, and cytological findings and compared with HR-HPV tests and histological outcomes. Results: Enlarged nucleus was the most frequent ASC-US criterion, but alternative criteria were present in 20% of the total cases. No ASC-US criteria were associated with histological outcomes or HR-HPV positivity. Parakeratosis, corneal pearl, giant cells, and binucleation were strongly associated with ASC-US while hyperkeratosis was associated with high-grade squamous intraepithelial lesions (HSIL) or a superior outcome. HR-HPV was positive in 64.39% of ASC-US and 65.38% of ASC-H. HSIL or superior outcomes also occurred in 13.33% of ASC-US and 64.71% of ASC-H cases. Conclusion: Alternative criteria for ASC-US were relatively frequent. Reactive cellular changes suggestive of atypias were more abundant in ASC-US. Although ASC-H is associated with worse histological outcomes, no differences in HPV positivity were found in comparison to ASC-US. (C) 2018 S. Karger AG, Basel	[de Oliveira, Geilson Gomes; da Silva Costa de Oliveira, Judite Maria; Carvalho de Almeida, Paulo Roberto; Eleuterio, Jose, Jr.] Univ Fed Ceara, Dept Pathol, Rua Aluisio Borba,132,Casa 4, BR-60813730 Fortaleza, Ceara, Brazil; [Nunes Eleuterio, Renata Mirian] Univ Fed Ceara, Dept Pharm, Fortaleza, Ceara, Brazil; [Carvalho Barbosa, Rita de Cassia] Univ Fed Ceara, Dept Clin & Toxicol Anal, Fortaleza, Ceara, Brazil; [Eleuterio, Jose, Jr.] Univ Fed Ceara, Dept Motherhood & Child, Fortaleza, Ceara, Brazil	de Oliveira, GG (reprint author), Univ Fed Ceara, Dept Pathol, Rua Aluisio Borba,132,Casa 4, BR-60813730 Fortaleza, Ceara, Brazil.	geilson.ce@gmail.com					Barcelos A, 2011, INFECT DIS OBSTET GY, V2011; Bibbo M., 2014, COMPREHENSIVE CYTOPA; Boardman LA, 2008, OBSTET GYN CLIN N AM, V35, P599, DOI 10.1016/j.ogc.2008.09.001; Choi IH, 2011, KOREAN J PATHOL, V45, P612, DOI 10.4132/KoreanJPathol.2011.45.6.612; Cortes-Gutierrez EI, 2010, EUR J HISTOCHEM, V54, P189, DOI 10.4081/ejh.2010.e32; Cytryn A, 2009, SAO PAULO MED J, V127, P283, DOI 10.1590/S1516-31802009000500007; Discacciati MG, 2014, REV BRAS GINECOL OBS, V36, P192, DOI 10.1590/S0100-7203201400050002; Elfstrom KM, 2015, INT J CANCER, V136, P350, DOI 10.1002/ijc.28984; Etchebehere RM, 2016, REV BRAS GINECOL OBS, V38, P41, DOI 10.1055/s-0035-1570105; Fernandes F, 2012, REV BRAS CANCEROL, V58, P453; Gupta S, 2007, DIAGN CYTOPATHOL, V35, P677, DOI 10.1002/dc.20719; Husain RSA, 2015, ANN GLOB HEALTH, V81, P675, DOI 10.1016/j.aogh.2015.08.026; Jahic Mahira, 2016, Med Arch, V70, P296; Jordão Andréa Valderrama, 2003, J. Bras. Patol. Med. Lab., V39, P81, DOI 10.1590/S1676-24442003000100015; Karimi-Zarchi Mojgan, 2015, Int J Biomed Sci, V11, P173; Kietpeerakool C, 2014, ASIAN PAC J CANCER P, V15, P6489, DOI 10.7314/APJCP.2014.15.16.6489; Kir G, 2017, DIAGN CYTOPATHOL, V45, P297, DOI 10.1002/dc.23674; Koss L. G., 2006, KOSS DIAGNOSTIC CYTO; Krishnan K, 2016, DIAGN CYTOPATHOL, V44, P91, DOI 10.1002/dc.23391; Lee H, 2016, CANCER CYTOPATHOL, V124, P58, DOI 10.1002/cncy.21615; Lhee MJ, 2014, YONSEI MED J, V55, P331, DOI 10.3349/ymj.2014.55.2.331; Longatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801; Lopez-Alegria F, 2015, SAO PAULO MED J, V133, P480, DOI 10.1590/1516-3180.2014.9142511; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521; Nijhawan R, 2010, DIAGN CYTOPATHOL, V38, P645, DOI 10.1002/dc.21278; Preisler S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059765; Schiffman M, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.86; Schiffman M, 2015, GYNECOL ONCOL, V138, P573, DOI 10.1016/j.ygyno.2015.06.040; Selvaggi SM, 2013, DIAGN CYTOPATHOL, V41, P943, DOI 10.1002/dc.22982; Sherman ME, 2006, CANCER CYTOPATHOL, V108, P298, DOI 10.1002/cncr.21844; Srodon M, 2006, CANCER CYTOPATHOL, V108, P32, DOI 10.1002/cncr.21388; Tafurt-Cardona Yaliana, 2012, Rev. salud pública, V14, P53; Veijalainen O, 2015, ACTA OBSTET GYN SCAN, V94, P931, DOI 10.1111/aogs.12686; Wallace NA, 2014, J VIROL, V88, P6112, DOI 10.1128/JVI.03808-13; Washiya K, 2013, ACTA CYTOL, V57, P599, DOI 10.1159/000353802; Watson M, 2015, CANCER CAUSE CONTROL, V26, P759, DOI 10.1007/s10552-015-0549-9; Waxman AG, 2012, OBSTET GYNECOL, V120, P1465, DOI [10.1097/AOG.0b013e31827001d5, http://10.1097/AOG.0b013e31827001d5]; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Xiao GQ, 2009, AUST NZ J OBSTET GYN, V49, P302, DOI 10.1111/j.1479-828X.2009.00998.x; Xu L, 2016, CANCER CYTOPATHOL, V124, P261, DOI 10.1002/cncy.21661	41	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					386	392		10.1159/000489386			7	Pathology	Pathology	HF3VC	WOS:000454161600010	29898441				2019-10-28	
J	Leite, KRM; Silva, T; Naum, B; Canavez, F; Canavez, J; Pimenta, R; Reis, S; Camara-Lopes, LH				Moreira Leite, Katia Ramos; Silva, Thais; Naum, Bruna; Canavez, Flavio; Canavez, Juliana; Pimenta, Ruan; Reis, Sabrina; Camara-Lopes, Luiz Heraldo			Validation of a New Low-Cost, Methanol-Based Fixative for Cervical Cytology and Human Papillomavirus Detection	ACTA CYTOLOGICA			English	Article						Liquid-based cytology; ThinPrep; CellPreserv; Human papillomavirus; Cervical intraepithelial neoplasia	LIQUID-BASED CYTOLOGY; CONVENTIONAL CYTOLOGY; CANCER; POPULATION; SUREPATH	Objective: To test the performance of a new fixative for pap smear collection for liquid-based cervical cytology, CellPreserv (R) and compare it with the commercially available, PreservCyt (R) used in the diagnosis and detection of human papillomavirus (HPV). Methods: Seven hundred twenty five women participated in this study after signing an informed consent. The specimens were collected using a traditional device, agitated in PBS, and equally divided in both fixatives. The slides were prepared routinely, stained by Papanicolaou, examined blindly by 2 cytologists, and reviewed by one cytopathologist. To search for HPV, 1,000 mu L from each fixative was taken and processed by polymerase chain reaction. Results: Considering the adequacy of samples, both fixatives had similar results - 0.33 and 0.32% of the cases unsatisfactory for PreservCyt (R) and CellPreserv (R), respectively. Considering the 701 satisfactory cases and comparing the new fixative to the traditional fixative, there was 99.3% concordance between both. The results regarding the HPV detection was 100% concordant between the 2 fixatives. Conclusion: The new methanol-based fixative, CellPreserv (R), is cheaper and equally efficient for treating cervical cancer screening and for HPV detection, and can be safely used by the health system prevailing in low-income countries. (C) 2018 S. Karger AG, Basel	[Moreira Leite, Katia Ramos; Silva, Thais; Naum, Bruna; Canavez, Flavio; Canavez, Juliana; Pimenta, Ruan; Camara-Lopes, Luiz Heraldo] Lab Genoa LPCM, Sao Paulo, Brazil; [Moreira Leite, Katia Ramos; Pimenta, Ruan; Reis, Sabrina] Univ Sao Paulo, Fac Med, LIM 55, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil	Leite, KRM (reprint author), Univ Sao Paulo, Fac Med, LIM 55, Ave Dr Arnaldo 455, BR-01246903 Sao Paulo, Brazil.	katiaramos@usp.br	Pimenta, Ruan C/R-6169-2018; LEITE, KATIA RM/C-2055-2008	Pimenta, Ruan C/0000-0002-3423-5647; LEITE, KATIA RM/0000-0002-2615-7730			Albrow R, 2012, CANCER CYTOPATHOL, V120, P87, DOI 10.1002/cncy.20203; Beal CM, 2014, SALUD PUBLICA MEXICO, V56, P492; Beerman H, 2009, GYNECOL ONCOL, V112, P572, DOI 10.1016/j.ygyno.2008.12.012; Colgan TJ, 2004, CANCER CYTOPATHOL, V102, P362, DOI 10.1002/cncr.20656; Cox JT, 2009, J CLIN VIROL, V45, pS3, DOI 10.1016/S1386-6532(09)70002-2; Fremont-Smith M, 2004, CANCER CYTOPATHOL, V102, P269, DOI 10.1002/cncr.30599; Karnon J, 2004, HEALTH TECHNOL ASSES, V8, P1; Longatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801; Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521; Payne N, 2000, Health Technol Assess, V4, P1; Qu WM, 1997, J CLIN MICROBIOL, V35, P1304; ROZEMEIJER K, 2017, BMJ-BRIT MED J, V356, DOI DOI 10.1136/BMJ.J504; Rozemeijer K, 2016, CANCER CAUSE CONTROL, V27, P15, DOI 10.1007/s10552-015-0678-1; Siebers AG, 2009, JAMA-J AM MED ASSOC, V302, P1757, DOI 10.1001/jama.2009.1569; Simion N, 2014, ROM J MORPHOL EMBRYO, V55, P1331; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Weintraub J, 2000, DIAGN CYTOPATHOL, V22, P52, DOI 10.1002/(SICI)1097-0339(200001)22:1<52::AID-DC14>3.0.CO;2-#	17	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					393	396		10.1159/000489873			4	Pathology	Pathology	HF3VC	WOS:000454161600011	29913440				2019-10-28	
J	Lepe, M; Eklund, CM; Quddus, MR; Paquette, C				Lepe, Marcos; Eklund, Claire M.; Quddus, M. Ruhul; Paquette, Cherie			Atypical Glandular Cells: Interobserver Variability according to Clinical Management	ACTA CYTOLOGICA			English	Article						Papanicolaou test; Atypical glandular cells; Gynecology; Cytology; Interobserver variability	PAP TESTS; UNITED-STATES; FOLLOW-UP; IN-SITU; ADENOCARCINOMA; PREVENTION; DIAGNOSIS; LESIONS; CERVIX; SMEARS	Objective: The 2014 Bethesda System diagnostic criteria for atypical glandular cells (AGC) aids in classification of atypical cells in cervical cytology. There is limited literature regarding reproducibility and interobserver variability in the application of the 2014 AGC criteria. Our aim is to assess the interobserver variability of AGC with a focus on how diagnostic categories link with guideline-driven management. Study Design: Three observers re-reviewed 51 previously diagnosed AGC Papanicolaou tests. The diagnoses were categorized as follows: (1) according to guideline-specified management, and (2) as glandular vs. squamous lesions. The kappa statistic was used to evaluate interobserver agreement. Results: The interobserver variability per guideline management by weighted 2-observer kappa ranged from 0.009 to 0.530, with half of the interobserver pairings meeting the threshold for at least fair-moderate agreement. For categorization as glandular, squamous, or both, unweighted kappa yielded at best fair interobserver agreement (kappa = 0.250) in 1 pairing, with low kappa scores in the remainder of reviewer pairs (range 0.015-0.152). Conclusions: There is significant interobserver variability in the diagnosis of AGC. The AGC cases when divided by clinical management had fair-moderate interobserver agreement, suggesting that diagnostic variability likely has a real effect on patient care. This diagnostic uncertainty should be understood by cytologists and clinicians. (C) 2018 S. Karger AG, Basel	[Lepe, Marcos] Rhode Isl Hosp, Dept Pathol, Providence, RI 02902 USA; [Lepe, Marcos; Quddus, M. Ruhul; Paquette, Cherie] Brown Univ, Dept Pathol & Lab Med, Warren Alpert Med Sch, Providence, RI 02912 USA; [Lepe, Marcos; Eklund, Claire M.; Quddus, M. Ruhul; Paquette, Cherie] Women & Infants Hosp Rhode Isl, Dept Pathol & Lab Med, 101 Dudley St, Providence, RI 02905 USA	Paquette, C (reprint author), Women & Infants Hosp Rhode Isl, Dept Pathol & Lab Med, 101 Dudley St, Providence, RI 02905 USA.	CPaquette@wihri.org					[Anonymous], 2014, BETHESDA SYSTEM REPO; Chaump M, 2016, CYTOJOURNAL, V13, DOI 10.4103/1742-6413.196237; DeMay RM, 2012, ART SCI CYTOPATHOLOG; Derchain SFM, 2004, GYNECOL ONCOL, V95, P618, DOI 10.1016/j.ygyno.2004.08.033; Dhamne Sagar, 2016, J Am Soc Cytopathol, V5, P50, DOI 10.1016/j.jasc.2015.09.213; Howlader N, 1975, SEER CANC STAT REV; Jiang XZ, 2015, J LOW GENIT TRACT DI, V19, P194, DOI 10.1097/LGT.0000000000000105; Johnson JE, 1999, ACTA CYTOL, V43, P369, DOI 10.1159/000331083; Lee KR, 2002, AM J CLIN PATHOL, V117, P96; Miller RA, 2015, ARCH PATHOL LAB MED, V139, P1431, DOI 10.5858/arpa.2014-0633-OA; Nayar R, 2015, ACTA CYTOL, V59, P121, DOI 10.1159/000381842; Pimenta JM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-553; Pirog EC, 2014, MODERN PATHOL, V27, P1559, DOI 10.1038/modpathol.2014.55; Pradhan D, 2016, CANCER CYTOPATHOL, V124, P589, DOI 10.1002/cncy.21724; Raab SS, 1998, AM J CLIN PATHOL, V110, P653, DOI 10.1093/ajcp/110.5.653; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Saslow D, 2012, AM J CLIN PATHOL, V137, P516, DOI 10.1309/AJCPTGD94EVRSJCG; Schnatz PF, 2006, OBSTET GYNECOL, V107, P701, DOI 10.1097/01.AOG.0000202401.29145.68; Sherman ME, 2005, CANCER, V103, P1258, DOI 10.1002/cncr.20877; Simsir A, 2003, CANCER CYTOPATHOL, V99, P323, DOI 10.1002/cncr.11826; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; SOLOMON D, 1990, HUM PATHOL, V21, P704; Verdoodt F, 2016, INT J CANCER, V138, P303, DOI 10.1002/ijc.29424; Wang JR, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i276; Wentzensen N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv257; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Wood MD, 2007, DIAGN CYTOPATHOL, V35, P12, DOI 10.1002/dc.20589; Wright Thomas C Jr, 2007, J Low Genit Tract Dis, V11, P201, DOI 10.1097/LGT.0b013e3181585870; Zhao CQ, 2009, GYNECOL ONCOL, V114, P383, DOI 10.1016/j.ygyno.2009.05.019	29	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					397	404		10.1159/000489968			8	Pathology	Pathology	HF3VC	WOS:000454161600012	29969775				2019-10-28	
J	Komatsu, H; Oishi, T; Osaku, D; Sawada, M; Kudoh, A; Nonaka, M; Chikumi, J; Sato, S; Harada, T				Komatsu, Hiroaki; Oishi, Tetsuro; Osaku, Daiken; Sawada, Mayumi; Kudoh, Akiko; Nonaka, Michiko; Chikumi, Jun; Sato, Shinya; Harada, Tasuku			Significance of High-Risk Human Papillomavirus Testing for Atypical Glandular Cells on Cervical Cytology	ACTA CYTOLOGICA			English	Article						Atypical glandular cells; High-risk human papillomavirus; Human papillomavirus genotyping; Positive predictive value; Negative predictive value	ADENOCARCINOMA IN-SITU; SQUAMOUS-CELLS; WOMEN; MANAGEMENT; DIAGNOSIS; PREVALENCE; NEOPLASIA; SMEARS	Objectives: The aim of this study was to evaluate the diagnostic significance of high-risk human papillomavirus (hrHPV) testing for managing women with atypical glandular cells (AGC) and to explore the distribution of hrHPV genotypes. Methods: We analyzed cytologic and histopathologic diagnoses in patients referred to our institution due to AGC or atypical squamous cells of undetermined significance (ASC-US). All patients underwent hrHPV testing and genotyping, and positive (PPV) and negative predictive values (NPV) for cervical intraepithelial neoplasia (CIN) 2 or worse [ CIN2+/adenocarcinoma in situ (AIS)+] were calculated. Results: Among 41 cases previously diagnosed with AGC, 22 (53%) were classified as CIN2+ (2 squamous cell carcinomas), whereas only 2 were AIS or adenocarcinoma. Twenty-seven (65.8%) cases in the AGC group were hrHPV positive. The most frequent genotypes in both the ASC-US and AGC groups were HPV16 and HPV52. The PPV of hrHPV testing for CIN2+/AIS+ was significantly higher in the AGC than in the ASC-US group (74.1 vs. 35.0%; p = 0.0005). The NPV for CIN2+/AIS+ was significantly lower in the AGC than in the ASC-US group (74.4 vs. 100%; p = 0.0441). Conclusion: In patients with AGC, both glandular and squamous lesions must be monitored. hrHPV testing is useful for detecting CIN2+/AIS+ in AGC. (C) 2018 S. Karger AG, Basel	[Komatsu, Hiroaki; Oishi, Tetsuro; Osaku, Daiken; Sawada, Mayumi; Kudoh, Akiko; Nonaka, Michiko; Chikumi, Jun; Sato, Shinya; Harada, Tasuku] Tottori Univ, Dept Obstet & Gynecol, Sch Med, 36-1 Nishicho, Yonago, Tottori 6838504, Japan	Oishi, T (reprint author), Tottori Univ, Dept Obstet & Gynecol, Sch Med, 36-1 Nishicho, Yonago, Tottori 6838504, Japan.	tetsuro@med.tottori-u.ac.jp					Bergeron C, 2000, OBSTET GYNECOL, V95, P821, DOI 10.1016/S0029-7844(00)00795-X; Holl K, 2015, INT J CANCER, V137, P2858, DOI 10.1002/ijc.29651; Kim Sun-Suk, 2013, Obstet Gynecol Sci, V56, P76, DOI 10.5468/OGS.2013.56.2.76; Kinney W, 2003, ACTA CYTOL, V47, P167, DOI 10.1159/000326498; Liao SY, 2011, BRIT J CANCER, V104, P353, DOI 10.1038/sj.bjc.6606049; Lin CT, 2000, J REPROD MED, V45, P345; Manos MM, 1999, JAMA-J AM MED ASSOC, V281, P1605, DOI 10.1001/jama.281.17.1605; Massad LS, 2013, J LOW GENIT TRACT DI, V17, pS1, DOI 10.1097/LGT.0b013e318287d329; Mitchell H, 2004, ACTA CYTOL, V48, P595, DOI 10.1159/000326428; Namugenyi SB, 2013, J CLIN VIROL, V58, P432, DOI 10.1016/j.jcv.2013.08.006; Rabelo-Santos SH, 2008, CYTOPATHOLOGY, V19, P34, DOI 10.1111/j.1365-2303.2007.00466.x; Schiffman M, 2015, GYNECOL ONCOL, V138, P573, DOI 10.1016/j.ygyno.2015.06.040; Shlay JC, 2000, OBSTET GYNECOL, V96, P410, DOI 10.1016/S0029-7844(00)00907-8; Shoji T, 2014, CANCER INVEST, V32, P105, DOI 10.3109/07357907.2014.880453; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457; Solomon D, 2003, BETHESDA SYSTEM REPO, P128; Syrjanen K, 2004, ACTA CYTOL, V48, P591, DOI 10.1159/000326427; Verdoodt F, 2016, INT J CANCER, V138, P303, DOI 10.1002/ijc.29424; Westin MC, 2008, EUR J OBSTET GYN R B, V139, P79, DOI 10.1016/j.ejogrb.2007.08.017; Wright TC, 1998, AM J OBSTET GYNECOL, V178, P962, DOI 10.1016/S0002-9378(98)70531-9; Wright Thomas C Jr, 2007, J Low Genit Tract Dis, V11, P201, DOI 10.1097/LGT.0b013e3181585870; Zeferino LC, 2011, EUR J OBSTET GYN R B, V159, P160, DOI 10.1016/j.ejogrb.2011.05.023	23	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					405	410		10.1159/000490230			6	Pathology	Pathology	HF3VC	WOS:000454161600013	29990964				2019-10-28	
J	Edblad-Svensson, A; Silfverdal, L; Collberg, P; Tunon, K				Edblad-Svensson, Ann; Silfverdal, Lena; Collberg, Pia; Tunon, Katarina			High-Risk Types of Human Papilloma Virus DNA Testing in Women with False Negative Cytology	ACTA CYTOLOGICA			English	Article						Cervical screening; Cervical intraepithelial neoplasia; False negative cytology; Triage for colposcopy; Human papilloma virus; High-risk types of human papilloma virus DNA testing; Physician-collected sample; Self-collected sample	CERVICAL-CANCER; COLLECTED SPECIMENS; ACCURACY; SAMPLES; TRIAGE; OLDER; SMEAR; AGE	Objective: To determine whether high-risk types of human papilloma virus (hrHPV) DNA testing is reliable for selection patients in need of further investigation with colposcopy in women with increased risk of high-grade cervical lesions as a result of false negative cytology. The secondary objective was to compare the sensitivity of hrHPV testing on self-collected versus physician-collected samples for the detection of histological high-grade cervical intraepithelial neoplasia (CIN2+). Methods: Sixty-three patients identified with a missed abnormality following the re-evaluation of benign cervical cytology were included. A patient-collected and a physician-collected sample for HPV, colposcopy and cervical specimen collection for histology and cytology were performed. Results: The sensitivity of hrHPV testing of physician-collected samples for CIN2+ was 100% (95% CI 82.7-100), and the negative predictive value (NPV) was 100% (95% CI 93.3-100). The sensitivity of the self-sampling device to identify CIN2+ was 84.6% (95% CI 59.1-96.7), and the NPV was 94.4% (95% CI 83.4-98.8). The differences in the sensitivity and NPV between the 2 methods were non-significant. The agreement between the 2 methods regarding the HPV results was good, with a kappa value of 0.74 (95% CI 0.57-0.91). Conclusion: The current findings indicate that physician-collected samples for hrHPV DNA testing may be used as triage for the colposcopy of women with false negative cytology. (C) 2018 S. Karger AG, Basel	[Edblad-Svensson, Ann; Collberg, Pia] Umea Univ, Unit Obstet & Gynecol Ostersund, Dept Clin Sci Obstet & Gynecol, Ostersund, Sweden; [Silfverdal, Lena; Tunon, Katarina] Umea Univ, Dept Clin Sci Obstet & Gynecol, Umea, Sweden	Edblad-Svensson, A (reprint author), Umea Univ, Ostersund Hosp, Dept Obstet & Gynecol, SE-83183 Ostersund, Sweden.	ann.edblad-svensson@regionjh.se					Andrae B, 2011, GYNEKOLOGISK CELLPRO; Andrae B, 2008, J NATL CANCER I, V100, P622, DOI 10.1093/jnci/djn099; Arbyn M, 2011, ANN ONCOL, V22, P2675, DOI 10.1093/annonc/mdr015; Arbyn M, 2010, BJOG-INT J OBSTET GY, V117, P641, DOI 10.1111/j.1471-0528.2010.02521.x; Arbyn M, 2006, VACCINE, V24, P78, DOI 10.1016/j.vaccine.2006.05.117; Arbyn M, 2014, LANCET ONCOL, V15, P172, DOI 10.1016/S1470-2045(13)70570-9; Belinson JL, 2010, INT J CANCER, V127, P1151, DOI 10.1002/ijc.25144; Bosch FX, 2002, J CLIN PATHOL, V55, P244, DOI 10.1136/jcp.55.4.244; Brown LD, 2001, STAT SCI, V16, P101; Cormier K, 2014, AM J CLIN PATHOL, V141, P494, DOI 10.1309/AJCP98ENFCNOKVAE; Ferlay J, 2013, IARC CANCERBASE; Jentschke M, 2016, J CLIN VIROL, V82, P46, DOI 10.1016/j.jcv.2016.06.016; Koshiol J, 2008, AM J EPIDEMIOL, V168, P123, DOI 10.1093/aje/kwn036; Meijer CJLM, 2009, INT J CANCER, V124, P516, DOI 10.1002/ijc.24010; Petignat P, 2007, GYNECOL ONCOL, V105, P530, DOI 10.1016/j.ygyno.2007.01.023; Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7; Sanner K, 2009, BRIT J CANCER, V101, P871, DOI 10.1038/sj.bjc.6605194; Sherman ME, 2002, J NATL CANCER I, V94, P102, DOI 10.1093/jnci/94.2.102; Silfverdal L, 2011, THESIS; Snijders PJF, 2013, INT J CANCER, V132, P2223, DOI 10.1002/ijc.27790; Socialstyrelsen, SOS RAPP GYN CELLPR; Sparen P, 2013, GYNEKOLOGISK CELLPRO; Stenvall H, 2007, ACTA OBSTET GYN SCAN, V86, P16, DOI 10.1080/00016340601033667; Thrall MJ, 2010, AM J CLIN PATHOL, V133, P894, DOI 10.1309/AJCPAZV88VIFZSFD; Wikstrom I, 2011, BRIT J CANCER, V105, P337, DOI 10.1038/bjc.2011.236	25	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					411	417		10.1159/000490487			7	Pathology	Pathology	HF3VC	WOS:000454161600014	30007979				2019-10-28	
J	McHugh, KE; Reynolds, JP; Suarez, AA				McHugh, Kelsey E.; Reynolds, Jordan P.; Suarez, Adrian A.			Postmenopausal Squamous Atypia: Cytologic Features, Hybrid Capture 2 Tests and Contribution to the ASCUS Pool	ACTA CYTOLOGICA			English	Article						Pap test; Atypical squamous cells; Human papillomavirus; Hybrid Capture 2 hpv; Postmenopausal women; Atrophy	UNDETERMINED SIGNIFICANCE; CONSENSUS GUIDELINES; WOMEN; CELLS; AGE; PERIMENOPAUSAL; PREVALENCE; COLPOSCOPY; MANAGEMENT; RISK	Objective: Postmenopausal squamous atypia (PSA) mimics squamous intraepithelial lesion (SIL). We investigate the PSA contribution to the atypical squamous cells of undetermined significance (ASCUS) pool, its cytologic features and Hybrid Capture 2 (HC2) relative light unit/cutoff (RLU/CO) values. Study Design: 658 ASCUS Pap tests in women >= 55 years were reviewed to select those with koilocyte-like cells and/or atypical parakeratosis. Follow-up was positive when a biopsy showed SIL or carcinoma or a later HC2 test was positive. Results: Sixty-nine cases (10.5%) were selected. Forty-two (60.9%) were HC2 negative, and 27 (39.1%) were HC2 positive. Follow-up was available for 23 (54.7%) HC2-negative and 19 (70.3%) HC2-positive cases. No HC2-negative (0%) and 8 HC2-positive (42.1%) cases were positive on follow-up. Within cases negative on follow-up, 3 were PSA on biopsy. PSA was characterized by perinuclear halos, mild nuclear enlargement, smooth nuclear contours, and smooth chromatin. PSA-associated RLU/CO values were 0.25-2.95. Cases with SIL or carcinoma had RLU/CO values from 3.78 to 1,241.59. Conclusions: PSA contributes 0.5-2.3% to the ASCUS pool in women >= 55 years old. HC2 testing with RLU/CO of >= 1 may result in PSA occasionally testing positive. A different cutoff is not recommended but awareness of this caveat is important. (C) 2018 S. Karger AG, Basel	[McHugh, Kelsey E.; Suarez, Adrian A.] Ohio State Univ, Wexner Med Ctr, Dept Pathol, 460 West 10th Ave, Columbus, OH 43210 USA; [McHugh, Kelsey E.; Reynolds, Jordan P.] Cleveland Clin, Dept Lab Med, Cleveland, OH 44106 USA	Suarez, AA (reprint author), Ohio State Univ, Wexner Med Ctr, Dept Pathol, 460 West 10th Ave, Columbus, OH 43210 USA.	Adrian.Suarez@osumc.edu					Abati A, 1998, CANCER CYTOPATHOL, V84, P218, DOI 10.1002/(SICI)1097-0142(19980825)84:4<218::AID-CNCR6>3.0.CO;2-I; [Anonymous], 2004, HYBR CAPT 2 HIGH HPV; Castle PE, 2005, J INFECT DIS, V191, P1808, DOI 10.1086/428779; Cibas ES, 2005, AM J CLIN PATHOL, V124, P58, DOI 10.1309/23WU42WYHV8YAJYU; de Vries CE, 2012, DIAGN CYTOPATHOL, V40, P708, DOI 10.1002/dc.21710; Dunne EF, 2007, JAMA-J AM MED ASSOC, V297, P813, DOI 10.1001/jama.297.8.813; Elkins CT, 2013, AM J CLIN PATHOL, V139, P605, DOI 10.1309/AJCPARHTB40DTVFV; Franceschi S, 2006, INT J CANCER, V119, P2677, DOI 10.1002/ijc.22241; Jarboe EA, 2010, J LOW GENIT TRACT DI, V14, P174, DOI 10.1097/LGT.0b013e3181cd6d4b; Johnston EI, 2007, CANCER CYTOPATHOL, V111, P160, DOI 10.1002/cncr.22687; JOVANOVIC AS, 1995, MODERN PATHOL, V8, P408; Knoepp SM, 2010, CANCER CYTOPATHOL, V118, P209, DOI 10.1002/cncy.20093; Massad LS, 2013, OBSTET GYNECOL, V121, P829, DOI 10.1097/AOG.0b013e3182883a34; Rebolj M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2757; Richards A, 2015, J OBSTET GYNAECOL RE, V41, P440, DOI 10.1111/jog.12545; Ronco G, 2008, J NATL CANCER I, V100, P492, DOI 10.1093/jnci/djn065; Saad RS, 2006, DIAGN CYTOPATHOL, V34, P467, DOI 10.1002/dc.20475; Sargent A, 2010, J CLIN MICROBIOL, V48, P554, DOI 10.1128/JCM.00896-09; Sherman ME, 2002, J NATL CANCER I, V94, P102, DOI 10.1093/jnci/94.2.102; WIED GL, 1968, ACTA CYTOL, V12, P87; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120	22	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					418	422		10.1159/000490691			5	Pathology	Pathology	HF3VC	WOS:000454161600015	30045008				2019-10-28	
J	Fischer, G; Cormier, K				Fischer, Gabor; Cormier, Karen			Glandular Cell Abnormalities on SurePath Preparations: A Retrospective Review with Cytology-Histology Correlations	ACTA CYTOLOGICA			English	Review						Atypical glandular cells; SurePath; Cervical screening; Correlation	LIQUID-BASED CYTOLOGY; UNITED-STATES; UNDETERMINED SIGNIFICANCE; INCIDENCE TRENDS; CERVICAL SMEARS; FOLLOW-UP; PAP TEST; ADENOCARCINOMA; THINPREP; LESIONS	Objective: Detecting glandular lesions is challenging by all Pap test methodologies. As the availability of data on identifying glandular abnormalities by SurePath is scarce, we investigated the detection rates and the correlation with histology follow-up. Study Design: A total of 105,927 cases (SurePath and conventional) were searched for the diagnosis of atypical glandular cells or higher glandular abnormalities (AGC+) with the corresponding histologic diagnosis. The associations between the Pap test methods and diagnostic categories were assessed by chi(2) test. Results: Overall, 0.32% of SurePath (159/49,375) and 0.29% of conventional (164/56,552) cases showed AGC+ (p = 0.38). Histology confirmed significant abnormalities in 42 versus 53.5% of the cases, respectively (p = 0.064); 72.7% (SurePath) versus 65.2% (conventional) of these were glandular in nature (p = 0.37). The diagnosis of neoplasia (favored or definitive) showed malignancy on follow-up in 100% of SurePath cases (12/12). In contrast, 82.1% of these conventional cases disclosed premalignant or malignant lesions by histology (p = 0.12). Conclusions: AGC+ cases showed higher prevalence on SurePath preparations. Conventional cases had more abnormalities on follow-up, while glandular lesions represented a higher proportion of abnormal histologies following SurePath AGC+s. The positive predictive value of favored or definite neoplasia was higher in SurePath cases. Overall, these differences were not statistically significant. (C) 2018 S. Karger AG, Basel	[Fischer, Gabor; Cormier, Karen] Univ Manitoba, Dept Pathol, Diagnost Serv Manitoba Inc, Winnipeg, MB, Canada	Fischer, G (reprint author), Univ Manitoba, Dept Pathol, 409 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	gfischer@dsmanitoba.ca					Ajit D, 2013, ACTA CYTOL, V57, P45, DOI 10.1159/000342744; Ashfaq R, 1999, ACTA CYTOL, V43, P81, DOI 10.1159/000330872; Bai HW, 2000, DIAGN CYTOPATHOL, V23, P19, DOI 10.1002/1097-0339(200007)23:1<19::AID-DC4>3.0.CO;2-K; Bansal B, 2016, CYTOJOURNAL, V13, DOI 10.4103/1742-6413.177156; Belsley NA, 2008, DIAGN CYTOPATHOL, V36, P232, DOI 10.1002/dc.20782; Boyraz G, 2017, J CYTOL, V34, P203, DOI 10.4103/JOC.JOC_209_16; Bray F, 2005, CANCER EPIDEM BIOMAR, V14, P2191, DOI 10.1158/1055-9965.EPI-05-0231; Burnley C, 2011, DIAGN CYTOPATHOL, V39, P869, DOI 10.1002/dc.21471; Cangiarella JF, 2003, DIAGN CYTOPATHOL, V29, P271, DOI 10.1002/dc.10316; Cheung ANY, 2003, CANCER CYTOPATHOL, V99, P331, DOI 10.1002/cncr.11786; Chhieng DC, 2003, CLIN LAB MED, V23, P633, DOI 10.1016/S0272-2712(03)00057-X; Chin AB, 2000, AM J OBSTET GYNECOL, V182, P1278, DOI 10.1067/mob.2000.106537; Finall AI, 2009, CYTOPATHOLOGY, V20, P367, DOI 10.1111/j.1365-2303.2009.00714.x; Hecht JL, 2002, CANCER CYTOPATHOL, V96, P1; Lee KR, 2002, AM J CLIN PATHOL, V117, P96; Mathers ME, 2002, CYTOPATHOLOGY, V13, P83, DOI 10.1046/j.1365-2303.2002.00387.x; Nayar R., 2015, BETHESDA SYSTEM REPO, DOI [10.1007/978-3-319-11074-5, DOI 10.1007/978-3-319-11074-5]; Patel C, 2009, CYTOPATHOLOGY, V20, P380, DOI 10.1111/j.1365-2303.2008.00621.x; Schorge JO, 2002, CANCER CYTOPATHOL, V96, P338, DOI 10.1002/cncr.10761; Sharpless KE, 2005, OBSTET GYNECOL, V105, P494, DOI 10.1097/01.AOG.0000152350.10875.02; Sherman ME, 2005, CANCER, V103, P1258, DOI 10.1002/cncr.20877; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Tambouret R, 2016, GLANDULAR LESIONS UT; Thiryayi SA, 2010, CYTOPATHOLOGY, V21, P223, DOI 10.1111/j.1365-2303.2009.00695.x; Valdini A, 2001, J Am Board Fam Pract, V14, P172; Wang SS, 2004, CANCER-AM CANCER SOC, V100, P1035, DOI 10.1002/cncr.20064	26	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					423	429		10.1159/000493000			7	Pathology	Pathology	HF3VC	WOS:000454161600016	30244241				2019-10-28	
J	Kanda, H; Furuta, N; Takazawa, Y; Furuta, R; Ae, K; Sugiyama, Y; Ishikawa, Y				Kanda, Hiroaki; Furuta, Noriyuki; Takazawa, Yutaka; Furuta, Reiko; Ae, Keisuke; Sugiyama, Yuko; Ishikawa, Yuichi			Cytological Findings of Gastrointestinal Stromal Tumor-Derived Bone Metastasis	ACTA CYTOLOGICA			English	Article						Gastrointestinal stromal tumors; Metastasis; Bone; Cytomorphology	FINE-NEEDLE-ASPIRATION; PROGNOSTIC-FACTORS; DIAGNOSIS; IMATINIB	Objective: Procedures for diagnosing bone tumors should be rapid and minimally invasive. Thus, cytological examinations are more useful for such purposes than histological examinations. In order to identify cytomorphological findings that could be used to diagnose bone metastasis from gastrointestinal stromal tumors (GIST), previous cases were reviewed. Study Design: Cytological samples of 7 lesions from 4 patients with GIST-derived bone metastasis, which were obtained from 2001 to 2017 at the JFCR Cancer Institute Hospital, were reviewed. Results: The metastasis of GIST to the bone was clinically suspected before the cytological and histological examinations in all cases since they all involved other metastatic lesion(s), and characteristic osteolytic lesions were detected on radiological images. Although various cell shapes were encountered, spindle cell proliferation was seen in all cytological samples. No pleomorphism was apparent. Characteristic nuclear findings were observed. All of the cases could be diagnosed as GIST-derived bone metastasis. Conclusion: GIST-derived bone metastasis can be diagnosed by examining cytological samples. (C) 2018 S. Karger AG, Basel	[Kanda, Hiroaki; Takazawa, Yutaka; Furuta, Reiko; Ishikawa, Yuichi] JFCR, Canc Inst, Dept Pathol, Tokyo, Japan; [Kanda, Hiroaki; Furuta, Noriyuki; Takazawa, Yutaka; Furuta, Reiko; Sugiyama, Yuko; Ishikawa, Yuichi] JFCR, Canc Inst, Clinicopathol Ctr, Tokyo, Japan; [Furuta, Noriyuki; Ae, Keisuke] JFCR, Canc Inst, Sarcoma Ctr, Tokyo, Japan; [Furuta, Reiko] Kitasato Univ, Dept Med Lab Sci, Clin Cytol, Sagamihara, Kanagawa, Japan; [Kanda, Hiroaki] Saitama Canc Ctr, Dept Pathol, Saitama, Japan	Kanda, H (reprint author), Japanese Fdn Canc Res, Canc Inst, Dept Pathol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	hkanda-ind@umin.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Ministry of Health, Labor and Welfare, JapanMinistry of Health, Labour and Welfare, Japan; Foundation for the Promotion of Cancer Research in Japan	This study was partly supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan; the Ministry of Health, Labor and Welfare, Japan; and the Foundation for the Promotion of Cancer Research in Japan.	Barriere J, 2009, ONKOLOGIE, V32, P345, DOI 10.1159/000215712; Cheuk W, 2000, ACTA CYTOL, V44, P679, DOI 10.1159/000328547; DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008; Di Scioscio V, 2011, RARE TUMORS, V3, DOI 10.4081/rt.2011.e17; Feki J, 2012, CASE REP ONCOL MED, DOI 10.1155/2012/509845; Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545; Jati A, 2012, DIAGN INTERV RADIOL, V18, P391, DOI 10.4261/1305-3825.DIR.5179-11.1; Kanda H, 2015, CLIN J GASTROENTEROL, V8, P426, DOI 10.1007/s12328-015-0614-7; Kimura M, 2002, ACTA CYTOL, V46, P1170; Lee YS, 2014, J CANCER RES THER, V10, P763, DOI 10.4103/0973-1482.136030; Li SQ, 2001, ACTA CYTOL, V45, P9, DOI 10.1159/000327181; Manabe Jun, 2005, Int J Clin Oncol, V10, P103; Miettinen M, 2015, MODERN PATHOL, V8, P426; Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466; Sepe PS, 2009, GASTROINTEST ENDOSC, V70, P254, DOI 10.1016/j.gie.2008.11.038; Van Glabbeke M, 2005, J CLIN ONCOL, V23, P5795, DOI 10.1200/JCO.2005.11.601; Yoshida S, 2009, PATHOL INT, V59, P712, DOI 10.1111/j.1440-1827.2009.02433.x	17	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					430	435		10.1159/000492709			6	Pathology	Pathology	HF3VC	WOS:000454161600017	30253395				2019-10-28	
J	Rodriguez, EF; Chowsilpa, S; Maleki, Z				Rodriguez, Erika F.; Chowsilpa, Sayanan; Maleki, Zahra			The Differential Diagnosis in Nonlymphoproliferative Malignant Pleural Effusion Cytopathology and Its Correlation with Patients' Demographics	ACTA CYTOLOGICA			English	Article						Malignant pleural effusion; Exfoliative cytology; Pleural fluid; Ethnicity; Patients' demographics	LUNG-CARCINOMA; SPECIMENS; CYTOLOGY; SAMPLES	Background: We report our experience with malignant pleural effusion (MPE) and the impact of patients' demographics on the differential diagnosis at the primary site. Methods: After IRB approval, we searched our pathology database from January 2013 to January 2017 for patients with positive pleural effusions (PEs). Patients' demographics and clinical histories were noted. Results: 474 patients were identified (288 females [61%] and 186 males [39%]), ranging in age from 19 to 64 years old. Ethnicity was distributed as follows: Caucasian (n = 330, 70%), African American (n = 114, 24%) and Asian (n = 30, 6%). The most common primary sites were the lung (n = 180, 37%), followed by the breast (n = 81, 17%), and the gynecologic system (67, 13%). The lung was the most common primary for all ethnicities (n = 190, 40%). The second-most common primary site was the breast in African Americans and Caucasians and upper gastrointestinal (GI) tract in Asians. In 5 cases (1%), the primary tumor could not be determined. Conclusion: Cytology examination is a useful method to diagnose primary sites of PE. Pulmonary primary is the most common cause of effusion in all ethnicities. In African American and Caucasian patients, the breast was the second-most common site of MPE, while in Asian patients it was the upper GI tract. (C) 2018 S. Karger AG, Basel	[Rodriguez, Erika F.; Chowsilpa, Sayanan; Maleki, Zahra] Johns Hopkins Univ Hosp, Dept Pathol, Div Cytopathol, Baltimore, MD 21287 USA; [Chowsilpa, Sayanan] Chiang Mai Univ, Dept Pathol, Fac Med, Chiang Mai, Thailand	Rodriguez, EF (reprint author), Johns Hopkins Univ, Dept Pathol, Carnegie Pathol 469, 600 North Wolfe St, Baltimore, MD 21287 USA.	erodri17@jhmi.edu					Carter J, 2017, ANN AM THORAC SOC, V14, P1169, DOI 10.1513/AnnalsATS.201609-709OC; Hanley KZ, 2008, CANCER CYTOPATHOL, V114, P49, DOI 10.1002/cncr.23254; Hooper C, 2010, THORAX, V65, P4, DOI 10.1136/thx.2010.136978; HSU C, 1987, DIAGN CYTOPATHOL, V3, P8, DOI 10.1002/dc.2840030103; Husain AN, 2018, ARCH PATHOL LAB MED, V142, P89, DOI 10.5858/arpa.2017-0124-RA; JOHNSTON WW, 1985, CANCER, V56, P905, DOI 10.1002/1097-0142(19850815)56:4<905::AID-CNCR2820560435>3.0.CO;2-U; Pereira TC, 2006, ADV ANAT PATHOL, V13, P174, DOI 10.1097/00125480-200607000-00004; Perricone G, 2018, NEW ENGL J MED, V378, P1753, DOI 10.1056/NEJMc1803858; PRAKASH UBS, 1985, MAYO CLIN PROC, V60, P158, DOI 10.1016/S0025-6196(12)60212-2; Rekhtman N, 2011, J THORAC ONCOL, V6, P451, DOI 10.1097/JTO.0b013e31820517a3; Rex DK, 2017, GASTROENTEROLOGY, V153, P307, DOI 10.1053/j.gastro.2017.05.013; Rodriguez EF, 2017, ACTA CYTOL, V61, P214, DOI 10.1159/000477148; RODRIGUEZPANADERO F, 1989, EUR RESPIR J, V2, P366; Rooper LM, 2014, CANCER CYTOPATHOL, V122, P657, DOI 10.1002/cncy.21452; Rossi ED, 2015, CANCER CYTOPATHOL, V123, P258, DOI 10.1002/cncy.21518; Roy-Chowdhuri S, 2016, ARCH PATHOL LAB MED, V140, P1267, DOI 10.5858/arpa.2016-0091-SA; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Skov BG, 2017, APPL IMMUNOHISTO M M, V25, P453, DOI 10.1097/PAI.0000000000000540; Thapar M, 2009, J CYTOL, V26, P60, DOI 10.4103/0970-9371.55223; Tian SK, 2016, ARCH PATHOL LAB MED, V140, P1200, DOI 10.5858/arpa.2016-0108-RA	20	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					436	442		10.1159/000493336			7	Pathology	Pathology	HF3VC	WOS:000454161600018	30380527				2019-10-28	
J	Melis, C; Ballaux, F; Bourgain, C				Melis, Celine; Ballaux, Florence; Bourgain, Claire			Curious Residents of the Thyroid Gland: Two Case Reports of Colorectal Carcinoma Metastasis by Fine-Needle Aspiration Diagnosis	ACTA CYTOLOGICA			English	Article						Fine-needle aspiration; Thyroid; Tumour-to-tumour metastasis	COLON-CANCER; CELL VARIANT; IMMUNOCYTOCHEMISTRY; CYTOMORPHOLOGY	Background: The most frequent metastases to the thyroid originate in the kidney, lung or breast. Colorectal adenocarcinoma represents less than 4% of metastases to the thyroid gland. Solitary metastases of colorectal cancer with no other manifestation of disseminated cancer disease are exceedingly rare. Within the Bethesda Classification for Reporting Thyroid Cytopathology, metastases are included in Diagnostic Categories "Suspicious for Malignancy" and "Malignant." Cases: We present 2 cases of colorectal adenocarcinoma metastatic to the thyroid gland, diagnosed by fine-needle aspiration (FNA). One metastasis occurred in normal thyroid parenchyma; the other was a tumour-to-tumour metastasis into a follicular carcinoma of the thyroid. The latter is the first published tumour-to-tumour metastasis of a colorectal carcinoma in the thyroid from which both components were diagnosed by FNA. Conclusion: Diagnosing a metastasis to the thyroid is challenging. On FNA, a dual cell population should raise suspicion. Immunocytochemical and molecular analysis may be helpful. Clinical information is essential in guiding specific ancillary technique panels in scant cellular material. (C) 2018 S. Karger AG, Basel	[Melis, Celine; Bourgain, Claire] Univ Hosp Leuven, Dept Pathol, Herestr 49, BE-3000 Leuven, Belgium; [Ballaux, Florence; Bourgain, Claire] Imelda Hosp, Dept Pathol, Bonheiden, Belgium	Melis, C (reprint author), Univ Hosp Leuven, Dept Pathol, Herestr 49, BE-3000 Leuven, Belgium.	celine.melis1@gmail.com					Baloch ZW, 1999, ARCH PATHOL LAB MED, V123, P703; Bellevicine C, 2015, DIAGN CYTOPATHOL, V43, P585, DOI 10.1002/dc.23264; CAMPBELL LV, 1968, CANCER, V22, P635, DOI 10.1002/1097-0142(196809)22:3<635::AID-CNCR2820220320>3.0.CO;2-O; Cherk MH, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-122; Cozzolino I, 2010, DIAGN CYTOPATHOL, V38, P932, DOI 10.1002/dc.21346; Guan H, 2013, ACTA CYTOL, V57, P534, DOI 10.1159/000353823; Keranmu A, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1140-5; Layfield LJ, 2010, BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: DEFINITIONS, CRITERIA AND EXPLANATORY NOTES, P153, DOI 10.1007/978-0-387-87666-5_12; Nixon IJ, 2017, ANN SURG ONCOL, V24, P1533, DOI 10.1245/s10434-016-5683-4; Onorati M, 2015, PATHOLOGICA, V107, P192; Pusztaszeri M, 2015, CANCER CYTOPATHOL, V123, P19, DOI 10.1002/cncy.21494; Rottuntikarn W, 2017, CYTOPATHOLOGY, V28, P338, DOI 10.1111/cyt.12429; Stevens TM, 2011, PATHOLOG RES INT, V2011, P1; Witt Robert L, 2003, Del Med J, V75, P285; Yeo SJ, 2014, J KOREAN MED SCI, V29, P1432, DOI 10.3346/jkms.2014.29.10.1432	15	0	0	1	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					443	449		10.1159/000490367			7	Pathology	Pathology	HF3VC	WOS:000454161600019	30007959				2019-10-28	
J	Oliveira, RC; Schmitt, FC				Oliveira, Rui Caetano; Schmitt, Fernando C.			Stromal Cellular Fragments in Breast Fine Needle Aspirates: Think Outside of the Box	ACTA CYTOLOGICA			English	Article						Breast fine needle aspirates; Phyllodes tumour; Fibroadenoma; Cellular stroma; Mammary carcinoma with osteoclast-like giant cells	PHYLLODES TUMOR; GIANT-CELLS; MAMMARY-CARCINOMA; DISTINCTION; FIBROADENOMA	Background: The presence of highly cellular stromal fragments in breast fine needle aspirates (FNA) suggests some classical differential diagnoses such as cellular fibroadenoma, phyllodes tumour (PT), metaplastic carcinomas, and some mesenchymal/myoepithelial proliferations. The other components of the smears can help in the differential diagnosis, but the presence of a low-grade epithelial proliferation does not always represent a fibro-epithelial lesion as we demonstrate in these two cases. Cases: We discuss two cases of breast FNA, previously presented in a slide seminar at the 29th European Congress of Pathology in Amsterdam, where the common cytological finding was the presence of stromal cellular fragments together with an epithelial component. One case is a typical PT and the other is a case of a mammary carcinoma with osteoclast-like giant cells. Conclusion: Mammary carcinoma with osteoclast-like giant cells is an unusual type of breast carcinoma that should be included in the differential diagnosis of breast lesions containing cellular stroma. Since the associated carcinoma is usually low grade, careful evaluation for malignant cells on cytological smears is necessary for an accurate differential diagnosis with PT where the epithelial component is benign. (C) 2018 S. Karger AG, Basel	[Oliveira, Rui Caetano] Ctr Hosp & Univ Coimbra, Dept Pathol, Coimbra, Portugal; [Schmitt, Fernando C.] Univ Porto, Fac Med, Dept Pathol, Porto, Portugal; [Schmitt, Fernando C.] Univ Porto, I3S, Porto, Portugal; [Schmitt, Fernando C.] Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Porto, Portugal	Schmitt, FC (reprint author), Inst Mol Pathol & Immunol, Rua Julio Amaral de Carvalho 45, PT-4200135 Porto, Portugal.	fschmitt@ipatimup.pt	; Schmitt, Fernando/A-5270-2008	Schmitt, Fernando/0000-0003-1006-6946; Schmitt, Fernando/0000-0002-3711-8681			Bandyopadhyay R, 2010, J CYTOL, V27, P59, DOI 10.4103/0970-9371.70739; Cai GP, 2004, DIAGN CYTOPATHOL, V30, P396, DOI 10.1002/dc.20069; El Hag IA, 2010, CANCER CYTOPATHOL, V118, P33, DOI 10.1002/cncy.20057; Jacquet SF, 2010, CANCER CYTOPATHOL, V118, P468, DOI 10.1002/cncy.20112; Krishnamurthy S, 2000, CANCER CYTOPATHOL, V90, P342, DOI 10.1002/1097-0142(20001225)90:6<342::AID-CNCR4>3.3.CO;2-9; Maritz RM, 2017, ACTA CYTOL, V61, P418, DOI 10.1159/000477573; Ohashi R, 2018, ANN DIAGN PATHOL, V33, P1, DOI 10.1016/j.anndiagpath.2017.11.003; Perez-Alonso P, 2012, DIAGN CYTOPATHOL, V40, P148, DOI 10.1002/dc.21615; Shabb NS, 1997, ACTA CYTOL, V41, P1284; Tan PH, 2012, WHO CLASSIFICATION T; Tse G, 2013, FINE NEEDLE ASPIRATI, DOI [10.1007/978-3-642-35000-9, DOI 10.1007/978-3-642-35000-9]; Tse GMK, 2001, PATHOLOGY, V33, P153; World Medical Association Declaration of Helsinki, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI [10.1001/jama.1997.03540350075038, DOI 10.1001/JAMA.1997.03540350075038]	13	1	1	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					450	455		10.1159/000492566			6	Pathology	Pathology	HF3VC	WOS:000454161600020	30248671				2019-10-28	
J	Matsushita, M; Kuwamoto, S				Matsushita, Michiko; Kuwamoto, Satoshi			Cytologic Features of SMARCA4-Deficient Thoracic Sarcoma: A Case Report and Comparison with Other SWI/SNF Complex-Deficient Tumors	ACTA CYTOLOGICA			English	Article						SMARCA4-deficient thoracic sarcoma; Rhabdoid cells; SWI/SNF chromatin remodeling complexes; Immunocytochemistry	NEEDLE-ASPIRATION-CYTOLOGY; SMALL-CELL CARCINOMA; EPITHELIOID SARCOMA; RHABDOID TUMOR; OVARY; HYPERCALCEMIA; EXPRESSION; KIDNEY	Background: SMARCA4-deficient thoracic sarcoma is a recently proposed entity of soft tissue tumors associated with an extremely poor prognosis. Its cytologic features have not been well described in the literature yet. Case: A woman in her early 30s who presented with chest pain was found to have a tumor in the right chest wall. Cytologic smears revealed numerous atypical round-to-polygonal cells appearing singly or in loosely cohesive clusters. These cells had a well-defined cell border, scant-to-moderate cytoplasm, and enlarged vesicular nuclei with prominent nucleoli. In addition, some cells with eosinophilic globular intracytoplasmic inclusions and eccentrically located nuclei, consistent with rhabdoid cells, were observed. Immunocytochemically, the cells were at least focally positive for cytokeratin CAM5.2 and CD34 and showed a significantly reduced BRG1/SMARCA4 expression. The diagnosis was confirmed by histological, immunohistochemical, and genetic analysis of a metastatic lesion to the left axillary lymph node. Conclusion: Although the cytologic features of SMARCA4-deficient thoracic sarcoma are not fully unique, they are sufficiently characteristic to suspect this tumor in cases of supporting clinical and radiological features, which may promote additional immunological or molecular testing to establish a definitive diagnosis. (c) 2018 S. Karger AG, Basel	[Matsushita, Michiko] Tottori Univ, Fac Med, Sch Hlth Sci, Dept Pathobiol Sci & Technol, Yonago, Tottori, Japan; [Matsushita, Michiko; Kuwamoto, Satoshi] Tottori Univ, Div Mol Pathol, Fac Med, 86 Nishi Cho, Yonago, Tottori 6838503, Japan; [Kuwamoto, Satoshi] Tottori Univ Hosp, Dept Pathol, Yonago, Tottori, Japan	Kuwamoto, S (reprint author), Tottori Univ, Div Mol Pathol, Fac Med, 86 Nishi Cho, Yonago, Tottori 6838503, Japan.	s.quamoto@gmail.com					Barroca HMMT, 2003, ACTA CYTOL, V47, P1055; Cocker RS, 2004, ACTA CYTOL, V48, P836, DOI 10.1159/000326454; DHARAN M, 1993, ACTA CYTOL, V37, P61; Fuller CE, 2016, SEMIN DIAGN PATHOL, V33, P427, DOI 10.1053/j.semdp.2016.08.003; Gonzalez-Peramato P, 2001, DIAGN CYTOPATHOL, V25, P122, DOI 10.1002/dc.2018; Hasegawa T, 2001, MODERN PATHOL, V14, P655, DOI 10.1038/modpathol.3880368; Ikeda K, 2005, ACTA CYTOL, V49, P314, DOI 10.1159/000326155; Kuwamoto S, 2017, HUM PATHOL, V70, P92, DOI 10.1016/j.humpath.2017.05.024; Lae M, 2018, DIAGN CYTOPATHOL, V46, P365, DOI 10.1002/dc.23904; Le Loarer F, 2015, NAT GENET, V47, P1200, DOI 10.1038/ng.3399; Pendse AA, 2015, DIAGN CYTOPATHOL, V43, P859, DOI 10.1002/dc.23294; Rekhi B, 2016, DIAGN CYTOPATHOL, V44, P636, DOI 10.1002/dc.23494; Sauter JL, 2017, MODERN PATHOL, V30, P1422, DOI 10.1038/modpathol.2017.61; Schaefer IM, 2017, MODERN PATHOL, V30, P539, DOI 10.1038/modpathol.2016.230; SELVAGGI SM, 1994, DIAGN CYTOPATHOL, V11, P266, DOI 10.1002/dc.2840110314; Shah VI, 2016, HISTOPATHOLOGY, V69, P894, DOI 10.1111/his.13019; Shet T, 2009, J CLIN PATHOL, V62, P961, DOI 10.1136/jcp.2009.064659; Shintaku M, 2015, J JPN SOC CLIN CYTOL, V54, P164; Thomson TA, 2011, CANCER CYTOPATHOL, V119, P49, DOI 10.1002/cncy.20121; Trichia HJ, 2017, ACTA CYTOL, V61, P462, DOI 10.1159/000477487; Yoshida A, 2017, MODERN PATHOL, V30, P797, DOI 10.1038/modpathol.2017.11	21	2	2	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					456	462		10.1159/000493335			7	Pathology	Pathology	HF3VC	WOS:000454161600021	30286456				2019-10-28	
J	Xavier, JCC; Camilo, DJ; D'Avilla, SCGP; Mattar, NJ				Caldeira Xavier-Junior, Jose Candido; Camilo-Junior, Deolino Joao; Garcia Pires D'Avilla, Solange Correa; Mattar, Neivio Jose			One-Year Experience of Implementation of 100% Cervical Cytology Rapid Review	ACTA CYTOLOGICA			English	Letter									[Caldeira Xavier-Junior, Jose Candido; Camilo-Junior, Deolino Joao; Garcia Pires D'Avilla, Solange Correa; Mattar, Neivio Jose] Pathol Inst Aracatuba, Aracatuba, Brazil; [Caldeira Xavier-Junior, Jose Candido] Ctr Univ Catolico UniSALESIANO Auxilium, Sch Med, Aracatuba, Brazil; [Garcia Pires D'Avilla, Solange Correa] Sao Jose do Rio Preto Med Sch FAMERP, Sao Jose Do Rio Preto, Brazil	Xavier, JCC (reprint author), Pathol Inst Aracatuba, Private Clin, Floriano Peixoto St 808, BR-16015000 Aracatuba, SP, Brazil.	josecandidojr@yahoo.com.br		Xavier Jr, Jose Candido/0000-0003-0503-419X			[Anonymous], 2016, MAN QUAL MAN CYT LAB; da Silva Jose Alencar Gomes, 2017, EST 2018 CANC INC BR; Magalhaes JC, 2018, ACTA CYTOL, V62, P115, DOI 10.1159/000487426; Queiroz J, 2018, ACTA CYTOL, V62, P209, DOI 10.1159/000488872; Utagawa ML, 2008, ACTA CYTOL, V52, P439, DOI 10.1159/000325549	5	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	5-6					463	464		10.1159/000493337			2	Pathology	Pathology	HF3VC	WOS:000454161600022	30300889				2019-10-28	
J	Fujita, H; Tajiri, T; Machida, T; Itoh, H; Hiraiwa, S; Imai, M; Oda, S; Shimoda, M; Inomoto, C; Sugiyama, T; Nakamura, N				Fujita, Hirotaka; Tajiri, Takuma; Machida, Tomohisa; Itoh, Hitoshi; Hiraiwa, Shinichiro; Imai, Masaaki; Oda, Shinri; Shimoda, Masami; Inomoto, Chie; Sugiyama, Tomoko; Nakamura, Naoya			Vessel Morphologies of the Brain in Cytological Squash Preparations Are Useful for Intraoperative Diagnosis of High-Grade Astrocytomas	ACTA CYTOLOGICA			English	Article						Squash preparation; High-grade astrocytoma; Microvascular proliferation; Intraoperative diagnosis; Multibranched vessels	ENDOTHELIAL GROWTH-FACTOR; TUMOR GRADE; EXPRESSION; SURVIVAL; GLIOMAS	Objective: The aim of this study was to determine whether intraoperative cytological evaluation of squash preparations is of benefit for differentiating high-grade from low-grade astrocytomas. Methods: Squash preparations of 42 astrocytomas were classified histologically according to the World Health Organization (WHO) 2007 classification system as grade II (n = 12), grade III (n = 11), and grade IV (n = 19) and were divided into 2 groups, namely a low-grade group (grade II) and a high-grade group (grades III and IV). The focus was on morphological cell and vessel characteristics, namely nuclear atypia, chromatin pattern, nuclear enlargement, variation in nuclear size, the presence of nucleoli, mitosis, tumor necrosis, cell density, multibranched vessels, and vascular dilatation, and these characteristics were compared between the low-and high-grade groups. Results: Nuclear atypia, the presence of coarse chromatin, variations in nuclear size, and cell density = 200 per high-power field were significantly more prevalent in high-than in low-grade astrocytomas (p = 0.0407, p < 0.01, p < 0.01, and p < 0.01, respectively). Vessels with > 3 branches and a mean vessel diameter = 20 mu m were more prevalent in high-than in lowgrade astrocytomas (p < 0.01). Conclusion: Squash preparation cytology provides added benefit for the intraoperative identification of high-grade astrocytoma. (C) 2018 S. Karger AG, Basel.	[Fujita, Hirotaka; Machida, Tomohisa] Tokai Univ, Hachioji Hosp, Dept Lab Med, Tokyo, Japan; [Itoh, Hitoshi] Tokai Univ Hosp, Div Lab Med, Isehara, Kanagawa, Japan; [Tajiri, Takuma; Hiraiwa, Shinichiro; Sugiyama, Tomoko] Tokai Univ, Hachioji Hosp, Dept Diagnost Pathol, 1838 Ishikawa Cho, Hachioji, Tokyo 1920032, Japan; [Imai, Masaaki; Oda, Shinri; Shimoda, Masami] Tokai Univ, Hachioji Hosp, Dept Neurosurg, Tokyo, Japan; [Inomoto, Chie; Nakamura, Naoya] Tokai Univ, Sch Med, Dept Pathol, Isehara, Kanagawa, Japan	Tajiri, T (reprint author), Tokai Univ, Hachioji Hosp, Dept Diagnost Pathol, 1838 Ishikawa Cho, Hachioji, Tokyo 1920032, Japan.	takumatajiri1003@yahoo.co.jp		Shimoda, Masami/0000-0001-5758-739X			[Anonymous], 2015, JSCC ATL GUID CYT DI, P149; Brommeland T, 2003, ACTA NEUROL SCAND, V108, P153, DOI 10.1034/j.1600-0404.2003.00115.x; Chaudhry IH, 2001, HISTOPATHOLOGY, V39, P409, DOI 10.1046/j.1365-2559.2001.01230.x; DAUMASDUPORT C, 1988, CANCER-AM CANCER SOC, V62, P2152, DOI 10.1002/1097-0142(19881115)62:10<2152::AID-CNCR2820621015>3.0.CO;2-T; Folkerth R D, 1994, Neurosurg Clin N Am, V5, P1; Goel D, 2007, CYTOPATHOLOGY, V18, P300, DOI 10.1111/j.1365-2303.2007.00484.x; Inagawa H, 2007, ACTA CYTOL, V51, P900, DOI 10.1159/000325867; Iqbal M, 2006, ACTA CYTOL, V50, P608, DOI 10.1159/000326028; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Louis D, 2007, WHO CLASSIFICATION T; Louis DN, 2016, WHO CLASSIFICATION T; Mehdorn HM, 2011, ACTA NEUROCHIR SUPPL, V109, P103, DOI 10.1007/978-3-211-99651-5_16; Nakazato Y, 1993, TUMORS NERVOUS SYSTE, V23, P141; Sato S, 2011, CYTOPATHOLOGY, V22, P313, DOI 10.1111/j.1365-2303.2010.00807.x; Westphal M, 2003, NEURO-ONCOLOGY, V5, P79, DOI 10.1215/S1522851702000236; Yamazaki H, 2003, J JPN SOC CLIN CYTOL, V42, P405; Zhou YH, 2003, CLIN CANCER RES, V9, P3369	17	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					223	230		10.1159/000487701			8	Pathology	Pathology	GI8QT	WOS:000434790200009	29621779				2019-10-28	
J	Ferry, JA				Ferry, Judith A.			There Are No Magic Bullets in Hematopathology: Even Immunostains for CD20 and CD3 Can Get You Into Trouble	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						immunohistochemistry; CD20; CD3; plasmablastic lymphoma; HHV8+lymphoma; ALK plus large B-cell lymphoma; IgM plasma cell myeloma; CD20+T-cell lymphoma; T-antigen plus Hodgkin lymphoma	B-CELL LYMPHOMA; PRIMARY-EFFUSION-LYMPHOMA; SARCOMA-ASSOCIATED HERPESVIRUS; IGM MULTIPLE-MYELOMA; OF-THE-LITERATURE; NEGATIVE PLASMABLASTIC LYMPHOMA; KAPOSIS-SARCOMA; CLINICOPATHOLOGICAL FEATURES; ABERRANT EXPRESSION; ANTIGEN-EXPRESSION	Immunohistochemistry is a powerful tool for the diagnosis and subclassification of hematolymphoid neoplasms. However, the expression of certain markers is not always as expected, and unusual patterns of staining can lead to misdiagnosis. CD20 and CD3 are our most commonly used markers for identification of B cells and T cells, respectively, and they almost always yield reliable, specific staining. This discussion focuses on diagnostic pitfalls related to the use of immunohistochemistry for CD20 and CD3 in hematopathology, and specifically on diagnostic challenges that arise when (1) CD20 is not expressed in B-cell lymphomas, when (2) CD20 is expressed in plasma cell neoplasms and T-cell lymphomas, and when (3) CD3 is expressed in B-cell lymphomas and Hodgkin lymphoma.	[Ferry, Judith A.] Massachusetts Gen Hosp, James Homer Wright Pathol Labs, Boston, MA 02114 USA; [Ferry, Judith A.] Harvard Med Sch, Dept Pathol, Boston, MA USA	Ferry, JA (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.	jferry@partners.org					An G, 2013, LEUKEMIA RES, V37, P1251, DOI 10.1016/j.leukres.2013.06.020; Boulanger E, 2005, J CLIN ONCOL, V23, P4372, DOI 10.1200/JCO.2005.07.084; Carbone A, 2005, J CLIN PATHOL, V58, P1039, DOI 10.1136/jcp.2005.026542; Carbone A, 2005, BRIT J HAEMATOL, V130, P662, DOI 10.1111/j.1365-2141.2005.05613.x; Carbone A, 2005, J MOL DIAGN, V7, P17, DOI 10.1016/S1525-1578(10)60004-9; Castillo J, 2008, AM J HEMATOL, V83, P804, DOI 10.1002/ajh.21250; Castillo JJ, 2015, BLOOD, V125, P2323, DOI 10.1182/blood-2014-10-567479; Castillo JJ, 2012, CANCER-AM CANCER SOC, V118, P5270, DOI 10.1002/cncr.27551; Castillo JJ, 2011, CL LYMPH MYELOM LEUK, V11, P185, DOI [10.1016/j.dml.2011.03.008, 10.1016/j.clml.2011.03.008]; Cesarman E, 1997, SEMIN DIAGN PATHOL, V14, P54; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; Chadburn A, 2004, AM J SURG PATHOL, V28, P1401, DOI 10.1097/01.pas.0000138177.10829.5c; Chang CC, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-47; Chapman J, 2015, LEUKEMIA, V29, P2270, DOI 10.1038/leu.2015.109; Courville EL, 2014, AM J CLIN PATHOL, V142, P816, DOI 10.1309/AJCPULI3W6WUGGPY; Dawson Mark A, 2007, Haematologica, V92, pe11, DOI 10.3324/haematol.10933; Delecluse HJ, 1997, BLOOD, V89, P1413, DOI 10.1182/blood.V89.4.1413; Deloose STP, 2005, LEUKEMIA, V19, P851, DOI 10.1038/sj.leu.2403709; Delsol G, 2008, WHO CLASSIFICATION T, P254; Dojcinov SD, 2011, BLOOD, V117, P4726, DOI 10.1182/blood-2010-12-323238; Duman BB, 2012, MED ONCOL, V29, P1223, DOI 10.1007/s12032-011-9955-3; Ferry J, 1997, ATLAS LYMPHOID HYPER, P271; Hsi ED, 2011, AM J CLIN PATHOL, V136, P183, DOI 10.1309/AJCPV1I2QWKZKNJH; Isaacson PG, 2008, WHO CLASSIFICATION T, P258; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kim JE, 2009, LEUKEMIA LYMPHOMA, V50, P582, DOI 10.1080/10428190902789173; King RL, 2013, AM J CLIN PATHOL, V140, P519, DOI 10.1309/AJCP0N7IELYUNJGZ; Kitamura A, 2005, J CLIN EXP HEMATOP, V45, P45, DOI 10.3960/jslrt.45.45; Lazzi S, 2009, HUM PATHOL, V40, P1252, DOI 10.1016/j.humpath.2009.01.007; Liu F, 2012, HISTOPATHOLOGY, V61, P1183, DOI 10.1111/j.1365-2559.2012.04339.x; Liu JJ, 2011, LEUKEMIA RES, V35, P1571, DOI 10.1016/j.leukres.2011.06.023; Loghavi S, 2015, HISTOPATHOLOGY, V67, P225, DOI 10.1111/his.12640; Loghavi S, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0163-z; Maeshima AM, 2013, AM J SURG PATHOL, V37, P563, DOI 10.1097/PAS.0b013e3182759008; Martinez D, 2013, AM J SURG PATHOL, V37, P272, DOI 10.1097/PAS.0b013e31826cb1d1; Matsuda I, 2015, INT J CLIN EXP PATHO, V8, P9737; Mohrmann RL, 2000, MODERN PATHOL, V13, P1244, DOI 10.1038/modpathol.3880229; Montes-Moreno S, 2017, MODERN PATHOL, V30, P85, DOI 10.1038/modpathol.2016.162; Morscio J, 2014, AM J SURG PATHOL, V38, P875, DOI 10.1097/PAS.0000000000000234; Nakamaki T, 2012, EUR J HAEMATOL, V89, P350, DOI 10.1111/j.1600-0609.2012.01838.x; Oliveira JL, 2012, AM J SURG PATHOL, V36, P1364, DOI 10.1097/PAS.0b013e31825e63a9; Pan ZG, 2012, AM J SURG PATHOL, V36, P1129, DOI 10.1097/PAS.0b013e31825b38ec; Pan ZG, 2017, AM J SURG PATHOL, V41, P25, DOI 10.1097/PAS.0000000000000753; Pather S, 2013, ANN DIAGN PATHOL, V17, P80, DOI 10.1016/j.anndiagpath.2012.08.005; QUINTANILLAMARTINEZ L, 1994, AM J CLIN PATHOL, V102, P483, DOI 10.1093/ajcp/102.4.483; Rahemtullah A, 2008, AM J SURG PATHOL, V32, P1593, DOI 10.1097/PAS.0b013e31817d7452; Said J., 2008, WHO CLASSIFICATION T, P260; Said JW, 1996, BLOOD, V88, P3124, DOI 10.1182/blood.V88.8.3124.bloodjournal8883124; Schommers P, 2013, AIDS, V27, P842, DOI 10.1097/QAD.0b013e32835e069d; Seliem RM, 2006, APPL IMMUNOHISTO M M, V14, P18, DOI 10.1097/01.pai.0000145130.02931.74; Slack GW, 2011, ADV ANAT PATHOL, V18, P219, DOI 10.1097/PAP.0b013e3182169948; STEIN H, 2008, WHO CLASSIFICATION T, P256; Sun T, 2004, J CLIN PATHOL, V57, P442, DOI 10.1136/jcp.2003.011734; Taddesse-Heath L, 2010, MODERN PATHOL, V23, P991, DOI 10.1038/modpathol.2010.72; Tsutsumi Yutaka, 2016, J Med Case Rep, V10, P27, DOI 10.1186/s13256-016-0809-7; Tzankov A, 2005, MODERN PATHOL, V18, P1542, DOI 10.1038/modpathol.3800473; Vega F, 2005, MODERN PATHOL, V18, P806, DOI 10.1038/modpathol.3800355; Venkataraman G, 2013, BLOOD, V121, P1795, DOI 10.1182/blood-2012-06-439455; Wang E, 2010, INT J HEMATOL, V91, P509, DOI 10.1007/s12185-010-0501-4; Wang J, 2009, AM J SURG PATHOL, V33, P505, DOI 10.1097/PAS.0b013e318185d231; Willenbacher W, 2013, BRIT J HAEMATOL, V161, P902, DOI 10.1111/bjh.12313; Xu Z, 2014, ANN HEMATOL, V93, P1251, DOI 10.1007/s00277-013-1959-y; Yao X, 2001, MODERN PATHOL, V14, P105, DOI 10.1038/modpathol.3880265	63	1	1	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JAN	2018	25	1					14	23		10.1097/PAP.0000000000000174			10	Pathology	Pathology	FP9AX	WOS:000417940800002	28914619				2019-10-28	
J	Iczkowski, KA; Paner, GP; Van der Kwast, T				Iczkowski, Kenneth A.; Paner, Gladell P.; Van der Kwast, Theodorus			The New Realization About Cribriform Prostate Cancer	ADVANCES IN ANATOMIC PATHOLOGY			English	Review						cribriform; Gleason grading; prostate cancer; PTEN; morphology	GLEASON PATTERN 4; ULTRASOUND (TRUS)-GUIDED BIOPSIES; GRADE GROUP GG; INTRADUCTAL CARCINOMA; RADICAL PROSTATECTOMIES; INTRAEPITHELIAL NEOPLASIA; INTERNATIONAL-SOCIETY; PROLIFERATION INDEX; ACTIVE SURVEILLANCE; NEEDLE-BIOPSY	Data from the past 6 years have shown that the presence of any amount of cribriform (or more comprehensively, large acinar cribriform to papillary) pattern of invasive prostate cancer is associated with adverse pathologic features and leads to uniquely adverse outcomes. Sixteen papers and numerous abstracts have reached these conclusions concordantly. Not only does this justify removal of all cribriform cancer from Gleason grade 3, it shows that cribriform cancer has pathologic, outcome, and molecular features distinct from noncribriform Gleason grade 4. Suggestions for accommodating the presence of cribriform cancer into the 2014 Grade Group scheme are proposed.	[Iczkowski, Kenneth A.] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; [Paner, Gladell P.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA; [Van der Kwast, Theodorus] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada	Iczkowski, KA (reprint author), Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	kaiczkowski@mcw.edu					AMIN MB, 1994, ARCH PATHOL LAB MED, V118, P260; Billis A, 2017, MODERN PATHOL, V30, p215A; Choy B, 2017, MODERN PATHOL, V30, p217A; Choy B, 2017, MODERN PATHOL, V30, p218A; Choy B, 2016, AM J SURG PATHOL, V40, P1400, DOI 10.1097/PAS.0000000000000691; Choy B, 2016, MODERN PATHOL, V29, p222A; Chua ML, 2017, EUR UROL IN PRESS; Cole AI, 2016, J UROLOGY, V196, P405, DOI 10.1016/j.juro.2016.01.120; Danneman D, 2015, BJU INT, V115, P248, DOI 10.1111/bju.12671; Dong F, 2013, AM J SURG PATHOL, V37, P1855, DOI 10.1097/PAS.0b013e3182a02169; Egevad L, 1999, J UROL PATHOL, V10, P23; Elfandy H, 2017, MODERN PATHOL, V30, p222A; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Falzarano SM, 2017, MODERN PATHOL, V30, p224A; Flood TA, 2016, VIRCHOWS ARCH, V469, P313, DOI 10.1007/s00428-016-1981-2; Fu LY, 2016, MODERN PATHOL, V29, p230A; Haffner MC, 2016, J PATHOL, V238, P31, DOI 10.1002/path.4628; Harding-Jackson N, 2016, J UROLOGY, V196, P1076, DOI 10.1016/j.juro.2016.05.105; Hickman RA, 2017, AM J SURG PATHOL, V41, P550, DOI 10.1097/PAS.0000000000000794; Hogan K, 2016, MODERN PATHOL, V29, p239A; Hwang M, 2016, MODERN PATHOL, V29, p239A; ICZKOWSKI KA, 2014, PATHOL CASE REV, V19, P178; Iczkowski KA, 2014, ANN DIAGN PATHOL, V18, P333, DOI 10.1016/j.anndiagpath.2014.08.010; Iczkowski KA, 2011, AM J CLIN PATHOL, V136, P98, DOI 10.1309/AJCPZ7WBU9YXSJPE; Keefe DT, 2015, VIRCHOWS ARCH, V467, P437, DOI 10.1007/s00428-015-1809-5; Kir G, 2014, PATHOL RES PRACT, V210, P640, DOI 10.1016/j.prp.2014.06.002; Kryvenko ON, 2013, ARCH PATHOL LAB MED, V137, P610, DOI 10.5858/arpa.2012-0128-OA; Kweldam CF, 2016, EUR J CANCER, V66, P26, DOI 10.1016/j.ejca.2016.07.012; Kweldam CF, 2016, MODERN PATHOL, V29, P630, DOI 10.1038/modpathol.2016.49; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Li J, 2016, MODERN PATHOL, V29, p245A; Lotan TL, 2013, MODERN PATHOL, V26, P587, DOI 10.1038/modpathol.2012.201; Luo X, 2017, MODERN PATHOL, V30, p240A; McKenney JK, 2016, AM J SURG PATHOL, V40, P1439, DOI 10.1097/PAS.0000000000000736; O'Kelly F, 2014, WORLD J UROL, V32, P1067, DOI 10.1007/s00345-013-1184-2; Perlis N, 2017, J UROLOGY, V197, P75, DOI 10.1016/j.juro.2016.07.076; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Rhamy R K, 1972, Trans Am Assoc Genitourin Surg, V64, P61; Ronen S, 2017, HUM PATHOL IN PRESS; Ross HM, 2012, AM J SURG PATHOL, V36, P1346, DOI 10.1097/PAS.0b013e3182556dcd; Sarbay BC, 2014, PATHOL RES PRACT, V210, P554, DOI 10.1016/j.prp.2014.03.003; Sauter G, 2017, EUR UROL IN PRESS; Shah RB, 2010, AM J SURG PATHOL, V34, P470, DOI 10.1097/PAS.0b013e3181cfc44b; Siadat F, 2015, PROSTATE, V75, P1277, DOI 10.1002/pros.23009; Sowalsky AG, 2017, CLIN CANCER RES, V23, P3823, DOI 10.1158/1078-0432.CCR-16-2414; Tosoian J, 2017, NAT REV URO IN PRESS; Troncoso P, 2017, MODERN PATHOL, V30, p264A; Troncoso P, 2016, MODERN PATHOL, V29, p267A; Trudel D, 2014, EUR J CANCER, V50, P1610, DOI 10.1016/j.ejca.2014.03.009; Tsao CK, 2015, J UROLOGY, V194, P91, DOI 10.1016/j.juro.2015.01.078; Varma M, 2015, MODERN PATHOL, V28, p266A; Wang Y, 2017, MODERN PATHOL, V30, p266A	53	16	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1072-4109	1533-4031		ADV ANAT PATHOL	Adv. Anat. Pathol.	JAN	2018	25	1					31	37		10.1097/PAP.0000000000000168			7	Pathology	Pathology	FP9AX	WOS:000417940800004	28820750				2019-10-28	
J	Isaila, B; Ananthanarayanan, V; Pambuccian, SE				Isaila, Bogdan; Ananthanarayanan, Vijayalakshmi; Pambuccian, Stefan E.			Ciliated Muconodular Papillary Tumor of the Lung: A New Entity Formerly Regarded as a Well-Differentiated Adenocarcinoma	AJSP-REVIEWS AND REPORTS			English	Review						adenocarcinoma; ciliated muconodular papillary tumor; lung; metaplasia; mucinous neoplasms	MUTATIONS; SPECTRUM; BRAF; CMPT	Ciliated muconodular papillary tumor (CMPT) of the lung is a newly defined distinct entity in the spectrum of mucinous tumors of the peripheral lung. Previously regarded as a low-grade adenocarcinoma, CMPT is currently considered an indolent neoplasm with characteristic tubulopapillary, glandular, or papillary architecture showing tripartite morphology including basal cells, mucinous cells, and ciliated cells. The diagnosis can be made by identifying a tumor that shows proliferation of basal cells, mucinous cells, and ciliated cells without nuclear atypia or mitotic activity and demonstrating a continuous layer of p40/p63 or CK5/6 staining basal cells. These tumors were shown to harbor BRAF (V600E), EGFR (E746-T751/S752V), AKT1 (E17K), and rarely KRAS (G12C) mutations. The diagnosis of this entity may be particularly difficult on small biopsies, fine-needle aspirates, and frozen sections. The prognosis is excellent after limited resection. We present a case of CMPT incidentally identified in a lung explant with emphysema; review the clinical, histopathologic, and molecular features of CMPT and its differential diagnosis; and explore the controversial aspects regarding diagnosis, origin, and classification of these neoplasms.	[Isaila, Bogdan; Ananthanarayanan, Vijayalakshmi; Pambuccian, Stefan E.] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL USA	Isaila, B (reprint author), Loyola Univ Med Ctr, Dept Pathol, 2160 S First Ave, Maywood, IL 60153 USA.	bogdan.isaila@yahoo.com					Chang JC, 2017, LAB INVEST, V97, p473A; Chu HH, 2017, HUM PATHOL CASE REPO, V7, P8; Chuang HW, 2014, PATHOL INT, V64, P352, DOI 10.1111/pin.12179; Falk N, 2016, ADV ANAT PATHOL, V23, P13, DOI 10.1097/PAP.0000000000000099; Flieder DB, 1998, AM J SURG PATHOL, V22, P1328, DOI 10.1097/00000478-199811000-00003; Fukuoka J, 2005, AM J SURG PATHOL, V29, P948, DOI 10.1097/01.pas.0000168177.71405.ac; Gao ZH, 2005, AM J CLIN PATHOL, V124, P62, DOI 10.1309/52XXR6E6U0J2JX0F; Harada T, 2008, RESP MED CME, V1, P176; Hata Y, 2013, JPN J CLIN ONCOL, V43, P205, DOI 10.1093/jjco/hys218; Inamura K, 2011, PATHOL INT, V61, P252, DOI 10.1111/j.1440-1827.2011.02659.x; Ishikawa Y., 2002, PATHOL CLIN MED, V20, P964; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Kamata T, 2016, J THORAC ONCOL, V11, P261, DOI 10.1016/j.jtho.2015.10.021; Kamata T, 2015, AM J SURG PATHOL, V39, P753, DOI 10.1097/PAS.0000000000000414; Kim YK, 2015, HISTOPATHOLOGY, V67, P520, DOI 10.1111/his.12693; Klebe S, 2016, J CLIN PATHOL, V69, P136, DOI 10.1136/jclinpath-2015-203184; Kon T, 2016, PATHOL INT, V66, P633, DOI 10.1111/pin.12460; Lau KW, 2016, HUM PATHOL, V49, P22, DOI 10.1016/j.humpath.2015.09.038; Liu LP, 2016, AM J SURG PATHOL, V40, P1631, DOI 10.1097/PAS.0000000000000707; Nair AR, 2014, INT J SURG PATHOL, V22, P540, DOI 10.1177/1066896913510027; NAKAMURA S, 1992, ACTA PATHOL JAPON, V42, P745; Park WY, 2012, MODERN PATHOL, V25, P1265, DOI 10.1038/modpathol.2012.76; Sato S, 2010, INTERACT CARDIOV TH, V11, P685, DOI 10.1510/icvts.2009.229989; Sugase T, 2016, SURG CASE REP, V2, DOI 10.1186/s40792-016-0266-y; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Travis WD, 2015, WHO CLASSIFICATION T; Udo E, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-017-0651-2; Wang Z., 2017, ATMOS CHEM PHYS DISC, V2017, P1, DOI DOI 10.5194/ACP-2017-253; Zenali MJ, 2015, HUM PATHOL, V46, P836, DOI 10.1016/j.humpath.2014.10.032	29	0	0	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					30	37		10.1097/PCR.0000000000000224			8	Pathology	Pathology	GB8DA	WOS:000429304100007					2019-10-28	
J	Pant, M; Pehlivanoglu, B; Erbarut-Seven, I; Adsay, NV				Pant, Mamta; Pehlivanoglu, Burcin; Erbarut-Seven, Ipek; Adsay, N. Volkan			Intra-Ampullary Papillary-Tubular Neoplasm: An Update on the Ampullary Counterparts of Pancreatobiliary Intraductal Neoplasms	AJSP-REVIEWS AND REPORTS			English	Review						ampulla; ampullary carcinoma; intra-ampullary papillary-tubular neoplasm	PERIAMPULLARY ADENOCARCINOMAS; HISTOLOGIC TYPE; BILE-DUCTS; CARCINOMAS; CLASSIFICATION; VATER; SURVIVAL; BILIARY; DIFFERENTIATION; ASSOCIATION	Intra-ampullary papillary tubular neoplasms (IAPNs) are papillary or polypoid lesions that originate from and grow predominantly within the ampulla. They are fundamentally "adenoma-carcinoma sequence" and as such represent intra-ampullary counterparts of other tumoral intraepithelial neoplasms of the pancreatobiliary tract, namely, intraductal papillary mucinous neoplasms (of pancreas), intraductal papillary neoplasms (of bile ducts), intraductal tubulopapillary neoplasms (ITPNs) (of bile ducts and pancreas), and intracholecystic papillary tubular neoplasms (of gallbladder). Intra-ampullary papillary tubular neoplasm-associated invasive carcinoma is now recognized as a distinct subset among ampullary cancers in the College of American Pathologists synoptic reporting. Intra-ampullary papillary tubular neoplasms show a spectrum of neoplastic change from low grade to high grade. Most cases, however, are associated with high-grade dysplasia, and a significant proportion (similar to 75%), also with invasive carcinoma (usually small, often <1 cm). Unlike intraductal papillary mucinous neoplasms of the pancreas and intestinal-type adenomas of ampullary duodenum, IAPNs often display a mixture of cell lineages and chimeric appearance, but some cases are predominantly gastropancreatobiliary or intestinal type. Intra-ampullary papillary tubular neoplasms may exhibit papillary, tubular, or tubulopapillary growth patterns in variable amounts. They were recognized in the World Health Organization 2010 classification under 2 separate groups, intestinal adenoma versus noninvasive papillary neoplasms, but because of the overlap between these 2 groups, and also the presence of other patterns like tubulopapillary and gastric-lineage types, a unifying category of IAPN was created. They often get classified indiscriminately as "ampullary adenocarcinoma," although their biology and behavior are substantially different than other subsets of ampullary carcinomas. The size of invasive carcinoma ought to be reported separately, and T staging of the tumor is to be based on the invasive component. In conclusion, IAPN shows many analogies to intraductal neoplasia of the pancreatobiliary tract and intracholecystic tumors, but at the same time it forms a pathologically and biologically distinct entity among ampullary neoplasms.	[Adsay, N. Volkan] Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA; Marmara Univ Sch Med, Dept Pathol, Istanbul, Turkey	Adsay, NV (reprint author), Med Coll Wisconsin, Dept Pathol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	nadsay@mcw.edu	Adsay, Volkan/N-7130-2017	Adsay, Volkan/0000-0002-1308-3701			Abraham SC, 2003, HUM PATHOL, V34, P902, DOI 10.1016/S0046-8177(03)00337-X; Adsay NV, 2012, SEMIN DIAGN PATHOL, V29, P127, DOI 10.1053/j.semdp.2012.08.010; Adsay V., 2015, STERNBERGS DIAGNOSTI; Adsay V, 2014, GOLDBLUM SURG PATHOL; Adsay V, 2012, AM J SURG PATHOL, V36, P1592, DOI 10.1097/PAS.0b013e31826399d8; Adsay V, 2012, AM J SURG PATHOL, V36, P1279, DOI 10.1097/PAS.0b013e318262787c; Albores-Saavedra J, 2000, CANCER, V89, P508, DOI 10.1002/1097-0142(20000801)89:3<508::AID-CNCR5>3.0.CO;2-D; Albores-Saavedra J, 2010, WHO CLASSIFICATION T; Albores-Saavedra J, 2009, J SURG ONCOL, V100, P598, DOI 10.1002/jso.21374; Balci S, 2015, ANN SURG ONCOL, V22, P4392, DOI 10.1245/s10434-015-4499-y; Basturk O, 2017, MOD PATHOL; Basturk O, 2017, AM J SURG PATHOL, V41, P313, DOI 10.1097/PAS.0000000000000782; Bellizzi AM, 2009, AM J CLIN PATHOL, V132, P506, DOI 10.1309/AJCPUZWJ8WA2IHBG; Bronsert P, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-428; Chang DK, 2013, J CLIN ONCOL, V31, P1348, DOI 10.1200/JCO.2012.46.8868; Davis D, 2017, MODERN PATHOL, V30, P157; Estrella JS, 2011, AM J SURG PATHOL, V35, P563, DOI 10.1097/PAS.0b013e318211b3d2; He J, 2014, HPB, V16, P83, DOI 10.1111/hpb.12078; Hechtman JF, 2015, MODERN PATHOL, V28, P1123, DOI 10.1038/modpathol.2015.57; Khayyata S, 2005, MODERN PATHOL, V18, P1504, DOI 10.1038/modpathol.3800460; Klimstra DS, 2007, HISTOLOGY PATHOLOGIS; Kloppel G, 2013, BEST PRACT RES CL GA, V27, P285, DOI 10.1016/j.bpg.2013.04.002; Morini S, 2013, PANCREAS, V42, P60, DOI 10.1097/MPA.0b013e318258fda8; Muraki T, 2017, MODERN PATHOL, V30, p189A; Ohike N, 2010, AM J SURG PATHOL, V34, P1731, DOI 10.1097/PAS.0b013e3181f8ff05; Ohike N, 2010, AM J SURG PATHOL, V34, P1417, DOI 10.1097/PAS.0b013e3181f0b05a; Overman MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065144; Polydorides A, 2008, MODERN PATHOL, V21, p132A; Reid MD, 2016, MODERN PATHOL, V29, P1575, DOI 10.1038/modpathol.2016.124; Schiergens TS, 2015, SURGERY, V158, P151, DOI 10.1016/j.surg.2015.02.001; Schlitter AM, 2015, MODERN PATHOL, V28, P1249, DOI 10.1038/modpathol.2015.61; SESSA F, 1994, VIRCHOWS ARCH, V425, P357; Talamini MA, 1997, ANN SURG, V225, P590, DOI 10.1097/00000658-199705000-00015; Washington K, 2016, COLL AM PATHOLOGISTS, P1; Westgaard A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-5; Westgaard A, 2013, ANN SURG ONCOL, V20, P430, DOI 10.1245/s10434-012-2603-0; Williams JL, 2017, JAMA SURG, V152, P82, DOI 10.1001/jamasurg.2016.3466; Xue Y, 2017, AM J SURG PATHOL, V41, P865, DOI 10.1097/PAS.0000000000000863	38	0	0	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1082-9784	1533-4015		AJSP-REV REP	AJSP-Rev. Rep.	JAN-FEB	2018	23	1					38	43		10.1097/PCR.0000000000000229			6	Pathology	Pathology	GB8DA	WOS:000429304100008					2019-10-28	
J	Sun, QQ; Chen, ZX; He, P; Li, Y; Ding, XY; Huang, Y; Gu, H; Ni, X				Sun, Qianqian; Chen, Zixi; He, Ping; Li, Yuan; Ding, Xiaoying; Huang, Ying; Gu, Hang; Ni, Xin			Reduced Expression of Hydrogen Sulfide-Generating Enzymes Down-Regulates 15-Hydroxyprostaglandin Dehydrogenase in Chorion during Term and Preterm Labor	AMERICAN JOURNAL OF PATHOLOGY			English	Article							15-HYDROXY PROSTAGLANDIN DEHYDROGENASE; HUMAN FETAL MEMBRANES; HUMAN-PLACENTA; PARTURITION; PREGNANCY; LOCALIZATION; PURIFICATION; TROPHOBLASTS; MICRORNAS; INFECTION	Chorionic NAD-dependent 15-hydroxyprostaglandin dehydrogenase (PGDH) plays a pivotal role in controlling the amount of prostaglandins in the uterus and has been implicated in the process of labor. Prior studies identified hydrogen sulfide-generating enzymes cystathionine-beta-synthetase (CBS) and cystathionine-gamma-lyase (CSE) in fetal membranes. We investigated whether hydrogen sulfide is involved in the regulation of PGDH expression in the chorion during Labor. The chorionic tissues were obtained from pregnant women at preterm in Labor and at term in labor or not in Labor at term. Levels of CSE and CBS and hydrogen sulfide production rate were down-regulated in term in Labor and preterm in labor groups compared with not in labor at term group. The CBS level correlated to PGDH expression in the chorion. Hydrogen sulfide donor NaHS and precursor L-cysteine dose-dependently stimulated PGDH expression and activity in cultured chorionic trophoblasts. The effect of L-cysteine was blocked by CBS inhibitor and CBS siRNA but not by CSE inhibitor and CSE siRNA. Hydrogen sulfide treatment suppressed miR-26b and miR-199a expression in chorionic trophoblasts. miR-26b and miR-199a mimics blocked hydrogen sulfide upregulation of PGDH expression. Our results indicate that hydrogen sulfide plays pivotal roles in maintenance of PGDH expression in the chorion during human pregnancy. Reduced expression of hydrogen sulfide-generating enzymes contributes to an increased amount of prostaglandins in the uterus during Labor.	[Sun, Qianqian; Chen, Zixi; He, Ping; Ni, Xin] Second Mil Med Univ, Dept Physiol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China; [Sun, Qianqian; Li, Yuan; Gu, Hang] Changhai Hosp, Dept Gynecol & Obstet, 800 Xiangyin Rd, Shanghai 200433, Peoples R China; [Ding, Xiaoying; Huang, Ying] Matern & Child Hlth Hosp Pudong New Dist, Dept Gynecol & Obstet, Shanghai, Peoples R China	Ni, X (reprint author), Second Mil Med Univ, Dept Physiol, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.; Gu, H (reprint author), Changhai Hosp, Dept Gynecol & Obstet, 800 Xiangyin Rd, Shanghai 200433, Peoples R China.	guhh@sina.com; nixin@smmu.edu.cn			Major State Research and Development Program of China [2017YFC1001404]; Natural Science Foundation of ChinaNational Natural Science Foundation of China [81620108013, 813707341, 31371175]	Supported by Major State Research and Development Program of China grant 2017YFC1001404 (X.N.) and Natural Science Foundation of China grants 81620108013 (X.N.), 813707341 (X.N.), and 31371175 (H.P.).	Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X; Challis JRG, 1997, ANN NY ACAD SCI, V828, P254, DOI 10.1111/j.1749-6632.1997.tb48546.x; CHEUNG PYC, 1992, GYNECOL OBSTET INVES, V33, P142, DOI 10.1159/000294868; Cindrova-Davies T, 2013, AM J PATHOL, V182, P1448, DOI 10.1016/j.ajpath.2013.01.001; Gao L, 2007, ENDOCRINOLOGY, V148, P3645, DOI 10.1210/en.2006-1212; GERMAIN AM, 1994, J CLIN ENDOCR METAB, V78, P463, DOI 10.1210/jc.78.2.463; Gibb W, 1996, J ENDOCRINOL, V150, P497, DOI 10.1677/joe.0.1500497; He P, 2015, AM J PATHOL, V185, P1981, DOI 10.1016/j.ajpath.2015.03.021; Hu TX, 2017, PLACENTA, V52, P33, DOI 10.1016/j.placenta.2017.02.012; Hu TX, 2016, PLACENTA, V39, P101, DOI 10.1016/j.placenta.2016.01.019; Johnson RF, 2004, J CLIN ENDOCR METAB, V89, P5639, DOI 10.1210/jc.2004-0540; Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013; KLIMAN HJ, 1986, ENDOCRINOLOGY, V118, P1567, DOI 10.1210/endo-118-4-1567; Li Y, 2013, AM J PATHOL, V182, P1585, DOI 10.1016/j.ajpath.2013.01.033; Liu WN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152838; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUNDINSCHILLER S, 1990, PROSTAG LEUKOTR ESS, V39, P1, DOI 10.1016/0952-3278(90)90164-G; Mitchell MD, 2000, PROSTAG LEUKOTR ESS, V62, P1, DOI 10.1054/plef.1999.0117; Montenegro D, 2009, J PATHOL, V217, P113, DOI 10.1002/path.2463; NAGAI K, 1987, PROSTAG LEUKOTR ESS, V26, P123, DOI 10.1016/0262-1746(87)90107-7; Ning NN, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5107; Okita RT, 1996, CRIT REV BIOCHEM MOL, V31, P101, DOI 10.3109/10409239609106581; Olson DM, 2003, BEST PRACT RES CL OB, V17, P717, DOI 10.1016/S1521-6934(03)00069-5; Papapetropoulos A, 2009, P NATL ACAD SCI USA, V106, P21972, DOI 10.1073/pnas.0908047106; Patel FA, 2003, J CLIN ENDOCR METAB, V88, P2922, DOI 10.1210/jc.2002-021710; Patel P, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-10; SANGHA RK, 1994, J CLIN ENDOCR METAB, V78, P982, DOI 10.1210/jc.78.4.982; Skovgaard N, 2011, CURR PHARM BIOTECHNO, V12, P1385, DOI 10.2174/138920111798280956; TEIXEIRA FJ, 1994, J CLIN ENDOCR METAB, V78, P1396, DOI 10.1210/jc.78.6.1396; VanMeir CA, 1996, PLACENTA, V17, P291, DOI 10.1016/S0143-4004(96)90052-1; vanMeir CA, 1997, J CLIN ENDOCR METAB, V82, P969, DOI 10.1210/jc.82.3.969; Wallace JL, 2012, ANTIOXID REDOX SIGN, V17, P58, DOI 10.1089/ars.2011.4351; Xie ZZ, 2014, ANTIOXID REDOX SIGN, V21, P2531, DOI 10.1089/ars.2013.5604; You XJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023788; You XJ, 2017, REPRODUCTION, V153, P535, DOI 10.1530/REP-16-0549	35	0	0	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					63	71		10.1016/j.ajpath.2017.09.006			9	Pathology	Pathology	FQ8SS	WOS:000418634100009	29249255	Bronze			2019-10-28	
J	Yu, DF; Saini, Y; Chen, G; Ghio, AJ; Dang, H; Burns, KA; Wang, Y; Davis, RM; Randell, SH; Esther, CR; Paulsen, F; Boucher, RC				Yu, Dongfang; Saini, Yogesh; Chen, Gang; Ghio, Andrew J.; Dang, Hong; Burns, Kimberlie A.; Wang, Yang; Davis, Richard M.; Randell, Scott H.; Esther, Charles R., Jr.; Paulsen, Friedrich; Boucher, Richard C.			Loss of beta Epithelial Sodium Channel Function in Meibomian Glands Produces Pseudohypoaldosteronism 1-Like Ocular Disease in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DRY EYE DISEASE; INTERNATIONAL WORKSHOP; DYSFUNCTION REPORT; MOUSE MODEL; LACRIMAL GLAND; TEAR FILM; SUBCOMMITTEE; SURFACE; PREVALENCE; PROTEIN	Human subjects with pseudohypoaldosteronism-1 because of loss-of-function mutations in epithelial sodium channel (ENaC) subunits exhibit meibomian gland (MG) dysfunction. A conditional beta ENaC MG knockout (KO) mouse model was generated to elucidate the pathogenesis of absent ENaC function in the MG and associated ocular surface disease. beta ENaC MG KO mice exhibited a striking age-dependent, female-predominant MG dysfunction phenotype, with white toothpastelike secretions observed obstructing MG orifices at 7 weeks of age. There were compensatory increases in tear production but higher tear sodium and indexes of mucin concentration in beta ENaC MG KO mice. Histologically, MG acinar atrophy was observed with ductal enlargement and ductal epithelial hyperstratification. Inflammatory cell infiltration was observed in both MG and conjunctiva of beta ENaC MG KO mice. In older beta ENaC MG KO mice (5 to 11 months), significant ocular surface pathologies were noted, including corneal opacification, ulceration, neovascularization, and ectasia. Inflammation in MG and conjunctiva was confirmed by increased cytokine gene and protein expression and positive Ly-6B.2 immunostaining. Cell proliferation assays revealed lower proliferation rates of MG cells derived from beta ENaC MG KO than control mice, suggesting that beta ENaC plays a role in cell renewal of mouse MG. Loss of beta ENaC function resulted in MG disease and severe ocular surface damage that phenocopied aspects of human pseudohypoaldosteronism-1 MG disease and was sex dependent.	[Yu, Dongfang; Chen, Gang; Dang, Hong; Burns, Kimberlie A.; Wang, Yang; Randell, Scott H.; Boucher, Richard C.] Univ North Carolina Chapel Hill, Marsico Lung Inst, Univ North Carolina Cyst Fibrosis Res Ctr, Sch Med, 130 Mason Farm Rd,7008 Marsico Hall, Chapel Hill, NC 27599 USA; [Davis, Richard M.] Univ North Carolina Chapel Hill, Dept Ophthalmol, Chapel Hill, NC 27599 USA; [Esther, Charles R., Jr.] Univ North Carolina Chapel Hill, Dept Pediat, Chapel Hill, NC 27599 USA; [Yu, Dongfang] Wake Forest Sch Med, Dept Pathol, Winston Salem, NC USA; [Saini, Yogesh] Louisiana State Univ, Sch Vet Med, Dept Comparat Biomed Sci, Baton Rouge, LA 70803 USA; [Ghio, Andrew J.] Environm Protect Agcy, Natl Hlth & Environm Effects Res Lab, Chapel Hill, NC USA; [Paulsen, Friedrich] Friedrich Alexander Univ Erlangen Nurnberg, Dept Anat 2, Erlangen, Germany	Boucher, RC (reprint author), Univ North Carolina Chapel Hill, Marsico Lung Inst, Univ North Carolina Cyst Fibrosis Res Ctr, Sch Med, 130 Mason Farm Rd,7008 Marsico Hall, Chapel Hill, NC 27599 USA.	richard_boucher@med.unc.edu			NIH/National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [BOUCHER P01HL110873, P01HL108808, R01HL136961, R01HL116228, K23HL089708]; German Research Foundation DFGGerman Research Foundation (DFG) [PA738/9-2]	Supported by NIH/National Heart, Lung, and Blood Institute grants BOUCHER P01HL110873, P01HL108808, R01HL136961, R01HL116228, and K23HL089708; and German Research Foundation DFG grant PA738/9-2.	Ainsworth JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1018, DOI 10.1001/archopht.1996.01100140226025; Arita R, 2015, OPHTHALMOLOGY, V122, P925, DOI 10.1016/j.ophtha.2014.12.018; Baudouin C, 2016, BRIT J OPHTHALMOL, V100, P300, DOI 10.1136/bjophthalmol-2015-307415; Cui CY, 2005, AM J PATHOL, V167, P89, DOI 10.1016/S0002-9440(10)62956-2; Den S, 2006, CORNEA, V25, P651, DOI 10.1097/01.ico.0000227889.11500.6f; Dursun D, 2002, INVEST OPHTH VIS SCI, V43, P632; Eliwa MS, 2014, BMJ CASE REP, V2014; Enriquez-de-Salamanca A, 2010, MOL VIS, V16, P862; Esther Charles R Jr, 2017, Am J Physiol Lung Cell Mol Physiol, V312, pL398, DOI 10.1152/ajplung.00398.2016; Esther CR, 2009, AM J PHYSIOL-LUNG C, V296, pL987, DOI 10.1152/ajplung.90512.2008; Foulks Gary N, 2003, Ocul Surf, V1, P107; Garty H, 1997, PHYSIOL REV, V77, P359; GILBARD JP, 1989, OPHTHALMOLOGY, V96, P1180; Green-Church KB, 2011, INVEST OPHTH VIS SCI, V52, P1979, DOI 10.1167/iovs.10-6997d; Hampel U, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128096; Han SB, 2011, ARCH OPHTHALMOL-CHIC, V129, P633, DOI 10.1001/archophthalmol.2011.78; Jackson DC, 2016, INVEST OPHTH VIS SCI, V57, P4824, DOI 10.1167/iovs.16-19757; Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641; JESTER JV, 1982, INVEST OPHTH VIS SCI, V22, P660; Justet C, 2013, CELL TISSUE RES, V353, P53, DOI 10.1007/s00441-013-1635-5; Knop E, 2011, INVEST OPHTH VIS SCI, V52, P1938, DOI 10.1167/iovs.10-6997c; Krenzer KL, 2000, J CLIN ENDOCR METAB, V85, P4874, DOI 10.1210/jc.85.12.4874; Lin MH, 2013, J BIOL CHEM, V288, P3964, DOI 10.1074/jbc.M112.416990; Luo Lihui, 2005, Eye Contact Lens, V31, P186, DOI 10.1097/01.ICL.0000162759.79740.46; Merillat AM, 2009, AM J PHYSIOL-RENAL, V296, pF249, DOI 10.1152/ajprenal.00612.2007; Miyake H, 2016, INVEST OPHTH VIS SCI, V57, P3268, DOI 10.1167/iovs.16-19227; Nasir A, 2012, ARCH DIS CHILD-FETAL, V97, pF462, DOI 10.1136/archdischild-2011-301339; Nien CJ, 2011, ARCH OPHTHALMOL-CHIC, V129, P462, DOI 10.1001/archophthalmol.2011.69; Obata H, 2002, CORNEA, V21, pS70, DOI 10.1097/01.ICO.0000031084.62888.IE; Priebe M, 2006, J BIOMED MATER RES A, V78A, P399, DOI 10.1002/jbm.a.30779; Rocha EM, 2000, BRIT J OPHTHALMOL, V84, P76, DOI 10.1136/bjo.84.1.76; Rosas M, 2010, J LEUKOCYTE BIOL, V88, P169, DOI 10.1189/jlb.0809548; Schaumberg DA, 2003, AM J OPHTHALMOL, V136, P318, DOI 10.1016/S0002-9394(03)00218-6; Schaumberg DA, 2011, INVEST OPHTH VIS SCI, V52, P1994, DOI 10.1167/iovs.10-6997e; Schaumberg DA, 2009, ARCH OPHTHALMOL-CHIC, V127, P763, DOI 10.1001/archophthalmol.2009.103; Schirra F, 2006, EXP EYE RES, V83, P291, DOI 10.1016/j.exer.2005.11.026; Schirra F, 2006, CORNEA, V25, P438, DOI 10.1097/01.ico.0000183664.80004.44; Smith JA, 2007, OCUL SURF, V5, P93; Spelsberg H, 2004, EYE, V18, P729, DOI 10.1038/sj.eye.6701314; Stevenson W, 2012, ARCH OPHTHALMOL-CHIC, V130, P90, DOI 10.1001/archophthalmol.2011.364; Sullivan DA, 2009, MOL VIS, V15, P1553; Suprynowicz FA, 2012, P NATL ACAD SCI USA, V109, P20035, DOI 10.1073/pnas.1213241109; Tektas OY, 2012, ANN ANAT, V194, P436, DOI 10.1016/j.aanat.2012.07.004; Wang YC, 2016, AM J PATHOL, V186, P32, DOI 10.1016/j.ajpath.2015.09.019; Xu W, 2015, J INVEST DERMATOL, V135, P796, DOI 10.1038/jid.2014.477; Yagci A, 2014, INT OPHTHALMOL, V34, P1291, DOI 10.1007/s10792-014-9969-x; Yu DF, 2016, INVEST OPHTH VIS SCI, V57, P2328, DOI 10.1167/iovs.15-17945	47	2	2	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					95	110		10.1016/j.ajpath.2017.09.016			16	Pathology	Pathology	FQ8SS	WOS:000418634100012	29107074	Green Published			2019-10-28	
J	Bombelli, S; Meregalli, C; Scalia, C; Bovo, G; Torsello, B; De Marco, S; Cadamuro, M; Vigano, P; Strada, G; Cattoretti, G; Bianchi, C; Perego, RA				Bombelli, Silvia; Meregalli, Chiara; Scalia, Carla; Bovo, Giorgio; Torsello, Barbara; De Marco, Sofia; Cadamuro, Massimiliano; Vigano, Paolo; Strada, Guido; Cattoretti, Giorgio; Bianchi, Cristina; Perego, Roberto A.			Nephrosphere-Derived Cells Are Induced to Multilineage Differentiation when Cultured on Human Decellularized Kidney Scaffolds	AMERICAN JOURNAL OF PATHOLOGY			English	Article							EXTRACELLULAR-MATRIX SCAFFOLDS; RENAL PROGENITOR CELLS; STEM-CELLS; PORCINE KIDNEYS; TISSUE-SECTIONS; REGENERATION; IMPLANTATION; TRANSPLANTATION; GROWTH	In end-stage chronic kidney disease, the option of organ transplantation is Limited because of the scarce availability of kidneys. The combination of stem cell research, regenerative medicine, and tissue engineering seems a promising approach to produce new transplantable kidneys. Currently, the possibility to repopulate naturally obtained scaffolds with cells of different sources is advancing. Our aim was to test, for the first time, whether the nephrosphere (NS) cells, composed by renal stem/progenitor-Like cells, were able to repopulate different nephron portions of renal extracellular matrix scaffolds obtained after decellularization of human renal tissue slices. Our decellularization protocol enabled us to obtain a completely acellular renal scaffold while maintaining the extracellular matrix structure and composition in terms of collagen IV, laminin, and fibronectin. NS cells, cultured on decellularized renal scaffolds with basal medium, differentiated into proximal and distal tubules as well as endothelium, as highlighted by histology and by the specific expression of epithelial cytokeratin 8.18, proximal tubular CD10, distal tubular cytokeratin 7, and endothelial von Willebrand factor markers. Endothelial medium promoted the differentiation toward the endothelium, whereas epithelial medium promoted the differentiation toward the epithelium. NS cells seem to be a good tool for scaffold repopulation, paving the way for experimental investigations focused on whole-kidney reconstruction.	[Bombelli, Silvia; Meregalli, Chiara; Scalia, Carla; Torsello, Barbara; De Marco, Sofia; Cadamuro, Massimiliano; Cattoretti, Giorgio; Bianchi, Cristina; Perego, Roberto A.] Milano Bicocca Univ, Sch Med & Surg, Via Cadore 48, I-20900 Monza, Italy; [Bovo, Giorgio; Vigano, Paolo; Strada, Guido] Bassini Hosp, Urol Unit, Cinisello Balsamo, Italy; [Cattoretti, Giorgio] San Gerardo Hosp, Anatomopathol Unitt, Monza, Italy	Perego, RA (reprint author), Milano Bicocca Univ, Sch Med & Surg, Via Cadore 48, I-20900 Monza, Italy.	roberto.perego@unimib.it		Cattoretti, Giorgio/0000-0003-3799-3221; Cadamuro, Massimiliano/0000-0002-0899-7613	Ministero dell'Istruzione, dell'Universita e della RicercaMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [669373]; Milano-Bicocca University [0260, 0159]; Associazione Gianluca Strada Onlus [792010100-2]; Ministero dell'Istruzione, dell'Universita e della Ricerca Postdoctoral Fellowships; Ministero dell'Istruzione, dell'Universita e della Ricerca Ph.D. Fellowships	Supported by Ministero dell'Istruzione, dell'Universita e della Ricerca grant 669373 (R.A.P.); Milano-Bicocca University grants 0260 and 0159 (R.A.P.); Associazione Gianluca Strada Onlus grant 792010100-2 (R.A.P.); and Ministero dell'Istruzione, dell'Universita e della Ricerca Postdoctoral Fellowships (S.B. and M.C.) and Ph.D. Fellowships (C.M. and S.D.M.).	Bacci S, 2008, THROMB RES, V122, P657, DOI 10.1016/j.thromres.2008.04.013; Batchelder CA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143849; Bianchi C, 2010, AM J PATHOL, V176, P1660, DOI 10.2353/ajpath.2010.090402; Boi G, 2016, J HISTOCHEM CYTOCHEM, V64, P18, DOI 10.1369/0022155415616162; Bombelli S, 2013, STEM CELL RES, V11, P1163, DOI 10.1016/j.scr.2013.08.004; Bonandrini B, 2014, TISSUE ENG PT A, V20, P1486, DOI [10.1089/ten.tea.2013.0269, 10.1089/ten.TEA.2013.0269]; Bussolati B, 2015, NAT REV NEPHROL, V11, P695, DOI 10.1038/nrneph.2015.126; Buzhor E, 2011, TISSUE ENG PT A, V17, P2305, DOI [10.1089/ten.TEA.2010.0595, 10.1089/ten.tea.2010.0595]; Caralt M, 2015, AM J TRANSPLANT, V15, P64, DOI 10.1111/ajt.12999; Di Stefano V, 2016, AM J PATHOL, V186, P2473, DOI 10.1016/j.ajpath.2016.05.019; Du C, 2016, ADV HEALTHC MATER, V5, P2080, DOI 10.1002/adhm.201600120; Gendusa R, 2014, J HISTOCHEM CYTOCHEM, V62, P519, DOI 10.1369/0022155414536732; Guan Y, 2015, ONCOTARGET, V6, P36126, DOI 10.18632/oncotarget.5304; Jha V, 2013, LANCET, V382, P260, DOI 10.1016/S0140-6736(13)60687-X; Katari R, 2014, NEPHRON EXP NEPHROL, V126, P119, DOI 10.1159/000360684; Keller C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043584; Nakayama KH, 2010, TISSUE ENG PT A, V16, P2207, DOI 10.1089/ten.TEA.2009.0602; Nakayama KH, 2011, TISSUE ENG PT A, V17, P2891, DOI [10.1089/ten.tea.2010.0714, 10.1089/ten.TEA.2010.0714]; NOUWEN EJ, 1993, KIDNEY INT, V44, P147, DOI 10.1038/ki.1993.225; O'Neill JD, 2013, BIOMATERIALS, V34, P9830, DOI 10.1016/j.biomaterials.2013.09.022; Orlando G, 2013, BIOMATERIALS, V34, P5915, DOI 10.1016/j.biomaterials.2013.04.033; Orlando G, 2012, ANN SURG, V256, P363, DOI 10.1097/SLA.0b013e31825a02ab; Pavenstadt H, 2003, PHYSIOL REV, V83, P253, DOI 10.1152/physrev.00020.2002; Peloso A, 2015, TRANSPLANTATION, V99, P1807, DOI 10.1097/TP.0000000000000811; Peloso A, 2015, ORGANOGENESIS, V11, P58, DOI 10.1080/15476278.2015.1072661; Prozialeck Walter C, 2004, BMC Physiol, V4, P10, DOI 10.1186/1472-6793-4-10; Rinkevich Y, 2014, CELL REP, V7, P1270, DOI 10.1016/j.celrep.2014.04.018; Ross EA, 2012, ORGANOGENESIS, V8, P49, DOI 10.4161/org.20209; Ross EA, 2009, J AM SOC NEPHROL, V20, P2338, DOI 10.1681/ASN.2008111196; Sagrinati C, 2006, J AM SOC NEPHROL, V17, P2443, DOI 10.1681/ASN.2006010089; Scalia CR, 2016, APPL IMMUNOHISTO M M, V24, P436, DOI 10.1097/PAI.0000000000000203; Sciancalepore AG, 2016, BIOMATERIALS, V94, P57, DOI 10.1016/j.biomaterials.2016.03.042; Skinnider BE, 2005, AM J SURG PATHOL, V29, P747, DOI 10.1097/01.pas.0000163362.78475.63; Song JJ, 2013, NAT MED, V19, P646, DOI 10.1038/nm.3154; Sullivan DC, 2012, BIOMATERIALS, V33, P7756, DOI 10.1016/j.biomaterials.2012.07.023; Torsello B, 2016, J CELL SCI, V129, P2925, DOI 10.1242/jcs.183640; Wang YJ, 2015, XENOTRANSPLANTATION, V22, P48, DOI 10.1111/xen.12141; Yu YL, 2014, BIOMATERIALS, V35, P6822, DOI 10.1016/j.biomaterials.2014.04.074	38	7	7	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					184	195		10.1016/j.ajpath.2017.09.012			12	Pathology	Pathology	FQ8SS	WOS:000418634100019	29037855	Bronze			2019-10-28	
J	Knuuttila, M; Mehmood, A; Huhtaniemi, R; Yatkin, E; Hakkinen, MR; Oksala, R; Laajala, TD; Ryberg, H; Handelsman, DJ; Aittokallio, T; Auriola, S; Ohlsson, C; Laiho, A; Elo, LL; Sipila, P; Makela, SI; Poutanen, M				Knuuttila, Matias; Mehmood, Arfa; Huhtaniemi, Riikka; Yatkin, Emrah; Hakkinen, Merja R.; Oksala, Riikka; Laajala, Teemu D.; Ryberg, Henrik; Handelsman, David J.; Aittokallio, Tero; Auriola, Seppo; Ohlsson, Claes; Laiho, Asta; Elo, Laura L.; Sipila, Petra; Makela, Sari I.; Poutanen, Matti			Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer xenografts	AMERICAN JOURNAL OF PATHOLOGY			English	Article							SPLICE VARIANTS; IN-VIVO; DEPRIVATION THERAPY; MASS-SPECTROMETRY; GENE-EXPRESSION; C19 STEROIDS; TUMOR-GROWTH; PROGRESSION; TARGET; CELLS	The development of castration-resistant prostate cancer (CRPC) is associated with the activation of intratumoral androgen biosynthesis and an increase in androgen receptor (AR) expression. We recently demonstrated that, similarly to the clinical CRPC, orthotopically grown castration-resistant VCaP (CR-VCaP) xenografts express high levels of AR and retain intratumoral androgen concentrations similar to tumors grown in intact mice. Herein, we show that antiandrogen treatment (enzalutamide or ARN-509) significantly reduced (10-fold, P < 0.01) intratumoral testosterone and dihydrotestosterone concentrations in the CR-VCaP tumors, indicating that the reduction in intratumoral androgens is a novel mechanism by which antiandrogens mediate their effects in CRPC. Antiandrogen treatment also altered the expression of multiple enzymes potentially involved in steroid metabolism. Identical to clinical CRPC, the expression levels of the full-length AR (twofold, P < 0.05) and the AR splice variants 1 (threefold, P < 0.05) and 7 (threefold, P < 0.01) were further increased in the antiandrogen-treated tumors. Nonsignificant effects were observed in the expression of certain classic androgen-regulated genes, such as TMPRSS2 and KLK3, despite the low levels of testosterone and dihydrotestosterone. However, other genes recently identified to be highly sensitive to androgen-regulated AR action, such as NOV and ST6GalNAc1, were markedly altered, which indicated reduced androgen action. Taken together, the data indicate that, besides blocking AR, antiandrogens modify androgen signaling in CR-VCaP xenografts at multiple levels.	[Knuuttila, Matias; Huhtaniemi, Riikka; Yatkin, Emrah; Sipila, Petra; Poutanen, Matti] Univ Turku, Dept Physiol, Turku, Finland; [Knuuttila, Matias; Huhtaniemi, Riikka; Yatkin, Emrah; Laajala, Teemu D.; Aittokallio, Tero; Ohlsson, Claes; Elo, Laura L.; Sipila, Petra; Poutanen, Matti] Univ Turku, Turku Ctr Dis Modeling, Turku, Finland; [Laajala, Teemu D.; Aittokallio, Tero; Ohlsson, Claes; Elo, Laura L.; Makela, Sari I.] Univ Turku, Inst Biomed, Dept Math & Stat, Turku, Finland; [Makela, Sari I.] Univ Turku, Inst Biomed, Funct Foods Forum, Turku, Finland; [Mehmood, Arfa; Laiho, Asta] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Mehmood, Arfa; Laiho, Asta] Abo Akad Univ, Turku, Finland; [Huhtaniemi, Riikka; Ryberg, Henrik] Orion Pharma, R&D Oncol Rese, Turku, Finland; [Hakkinen, Merja R.; Auriola, Seppo] Univ Eastern Finland, Sch Pharm, Kuopio, Finland; [Laajala, Teemu D.; Aittokallio, Tero] Univ Helsinki, Inst Mol Med Finland, Helsinki, Finland; [Ohlsson, Claes; Poutanen, Matti] Gothenburg Univ, Sahlgrenska Acad, Ctr Bone & Arthrit Res, Gothenburg, Sweden; [Handelsman, David J.; Elo, Laura L.] Univ Sydney, ANZAC Res Inst, Concord, NSW, Australia	Poutanen, M (reprint author), Univ Turku, Inst Biomed, Dept Physiol, ICiinamyllynkatu 10, Turku 20520, Finland.	matti.poutanen@utu.fi	Poutanen, Matti/I-1700-2018; Elo, Laura/A-9449-2015; Aittokallio, Tero/B-6583-2009	Poutanen, Matti/0000-0002-8953-1734; Elo, Laura/0000-0001-5648-4532; Laajala, Teemu Daniel/0000-0002-7016-7354; Ryberg, Henrik/0000-0002-2652-6612; Handelsman, David/0000-0002-4200-7476; Sipila, Petra/0000-0001-8187-7143; Makela, Sari/0000-0002-8698-4076; Aittokallio, Tero/0000-0002-0886-9769; Ohlsson, Claes/0000-0002-9633-2805; Yatkin, Emrah/0000-0002-2597-6638	Academy of FinlandAcademy of Finland; Cancer Society of Finland; European Research CouncilEuropean Research Council (ERC); European UnionEuropean Union (EU); Juvenile Diabetes Research FoundationJuvenile Diabetes Research Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Finnish Cultural FoundationFinnish Cultural Foundation; Orion Pharma	Supported by a Academy of Finland grant (T.A., L.L.E., and M.P.), a Cancer Society of Finland grant (T.A. and M.P.), a European Research Council grant (L.L.E.), the European Union Horizon 2020 Research and Innovation Program (L.L.E.), a Juvenile Diabetes Research Foundation grant (L.L.E.), a Sigrid Juselius Foundation grant (L.L.E. and M.P.), the Finnish Cultural Foundation (M.K.), and an Orion Pharma grant (M.P.).	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bauman DR, 2006, MOL ENDOCRINOL, V20, P444, DOI 10.1210/me.2005-0287; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cai CM, 2011, ENDOCR-RELAT CANCER, V18, pR175, DOI 10.1530/ERC-10-0339; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cho E, 2014, ENDOCRINOLOGY, V155, P4124, DOI 10.1210/en.2014-1337; Chouinard S, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703370200; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Endo S, 2016, BIOCHEM BIOPH RES CO, V472, P231, DOI 10.1016/j.bbrc.2016.01.190; Gottlieb B, 2012, HUM MUTAT, V33, P887, DOI 10.1002/humu.22046; Grosse L, 2013, CANCER RES, V73, P6963, DOI 10.1158/0008-5472.CAN-13-1462; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Heidenreich A, 2014, EUR UROL, V65, P467, DOI 10.1016/j.eururo.2013.11.002; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Ishizaki F, 2013, SCI REP-UK, V3, DOI 10.1038/srep01528; Keski-Rahkonen P, 2011, J STEROID BIOCHEM, V127, P396, DOI 10.1016/j.jsbmb.2011.06.006; Knuuttila M, 2014, AM J PATHOL, V184, P2163, DOI 10.1016/j.ajpath.2014.04.010; Korenchuk S, 2001, IN VIVO, V15, P163; Laajala TD, 2016, SCI REP-UK, V6, DOI 10.1038/srep30723; Laajala TD, 2012, CLIN CANCER RES, V18, P4385, DOI 10.1158/1078-0432.CCR-11-3215; Levesque B, 1999, PHARMACOGENETICS, V9, P207; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Lu J, 2015, NAT REV UROL, V12, P137, DOI 10.1038/nrurol.2015.13; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; McNamara KM, 2010, J STEROID BIOCHEM, V121, P611, DOI 10.1016/j.jsbmb.2010.02.001; Mizokami A, 2004, CANCER RES, V64, P765, DOI 10.1158/0008-5472.CAN-03-0130; Moilanen AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12007; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Moore NL, 2012, MOL CELL ENDOCRINOL, V357, P60, DOI 10.1016/j.mce.2011.09.019; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Munkley J, 2015, ONCOTARGET, V6, P34358, DOI 10.18632/oncotarget.6024; Nilsson ME, 2015, ENDOCRINOLOGY, V156, P2492, DOI 10.1210/en.2014-1890; Page ST, 2006, J CLIN ENDOCR METAB, V91, P3850, DOI 10.1210/jc.2006-0968; Pretorius E, 2017, MOL CELL ENDOCRINOL, V441, P76, DOI 10.1016/j.mce.2016.08.014; Sayyid RK, 2017, CLIN CANCER RES, V23, P1974, DOI 10.1158/1078-0432.CCR-16-1790; Slovin SF, 2005, CLIN CANCER RES, V11, P8669, DOI 10.1158/1078-0432.CCR-05-1668; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Storbeck KH, 2013, MOL CELL ENDOCRINOL, V377, P135, DOI 10.1016/j.mce.2013.07.006; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wu L, 2014, ONCOGENE, V33, P504, DOI 10.1038/onc.2012.602; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhang AL, 2016, HORM CANCER-US, V7, P104, DOI 10.1007/s12672-016-0250-9; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970	49	3	3	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					216	228		10.1016/j.ajpath.2017.08.036			13	Pathology	Pathology	FQ8SS	WOS:000418634100022	29126837	Green Published, Bronze			2019-10-28	
J	Faulkner, S; Jobling, P; Rowe, CW; Oliveira, SMR; Roselli, S; Thorne, RF; Oldmeadow, C; Attia, J; Jiang, CC; Zhang, XD; Walker, MM; Hondermarck, H				Faulkner, Sam; Jobling, Philip; Rowe, Christopher W.; Oliveira, S. M. Rodrigues; Roselli, Severine; Thorne, Rick F.; Oldmeadow, Christopher; Attia, John; Jiang, Chen Chen; Zhang, Xu Dong; Walker, Marjorie M.; Hondermarck, Hubert			Neurotrophin Receptors TrkA, p75(NTR), and Sortilin Are Increased and Targetable in Thyroid Cancer	AMERICAN JOURNAL OF PATHOLOGY			English	Article							NERVE GROWTH-FACTOR; BREAST-CANCER; PANCREATIC-CANCER; CELLS; INVASION; PROGRESSION; KINASE; PAIN; PROLIFERATION; EXPRESSION	Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75(NTR), and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75(NTR) was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75(NTR), and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75(NTR), and sortilin as potential therapeutic targets in thyroid cancer.	Univ Newcastle, Sch Biomed Sci & Pharm, Life Sci Bldg, Callaghan, NSW 2308, Australia; [Faulkner, Sam; Jobling, Philip; Oliveira, S. M. Rodrigues; Roselli, Severine; Zhang, Xu Dong; Hondermarck, Hubert] Univ Newcastle, Fac Hlth & Med, Hunter Med Res Inst, Callaghan, NSW, Australia; [Faulkner, Sam; Jobling, Philip; Rowe, Christopher W.; Oliveira, S. M. Rodrigues; Roselli, Severine; Thorne, Rick F.; Oldmeadow, Christopher; Attia, John; Jiang, Chen Chen; Zhang, Xu Dong; Walker, Marjorie M.; Hondermarck, Hubert] Univ Newcastle, Sch Math & Phys Sci, Callaghan, NSW, Australia; [Oldmeadow, Christopher] Univ Newcastle, Fac Sci & Informat Technol, Callaghan, NSW, Australia; [Oldmeadow, Christopher] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia; [Rowe, Christopher W.; Attia, John; Walker, Marjorie M.] Univ Newcastle, Fac Hlth & Med, Callaghan, NSW, Australia; [Rowe, Christopher W.] John Hunter Hosp, Dept Endocrinol, Callaghan, NSW, Australia; [Walker, Marjorie M.] John Hunter Hosp, Dept Anat Pathol, Callaghan, NSW, Australia	Hondermarck, H (reprint author), Univ Newcastle, Sch Biomed Sci & Pharm, Life Sci Bldg, Callaghan, NSW 2308, Australia.	hubert.hondermarck@newcastle.edu.au	Attia, John/F-5376-2013	Attia, John/0000-0001-9800-1308; roselli, severine/0000-0001-7896-9127; Oldmeadow, Christopher/0000-0001-6104-1322; Rodrigues Oliveira, Sonia Marlene/0000-0002-0707-5203; Faulkner, Sam/0000-0002-4732-8252; Zhang, Xu Dong/0000-0001-9457-8003; Rowe, Christopher/0000-0002-9652-6562	University of Newcastle (Australia); Hunter Cancer Research Alliance	Supported by the University of Newcastle (Australia) and the Hunter Cancer Research Alliance.	Ahn HS, 2014, NEW ENGL J MED, V371, P1765, DOI 10.1056/NEJMp1409841; Akil H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025097; Bapat AA, 2011, NAT REV CANCER, V11, P695, DOI 10.1038/nrc3131; Bevan S, 2001, J CLIN ENDOCR METAB, V86, P3701, DOI 10.1210/jc.86.8.3701; Boilly B, 2017, CANCER CELL, V31, P342, DOI 10.1016/j.ccell.2017.02.005; Botta R, 2009, ENDOCRINOLOGY, V150, P509, DOI 10.1210/en.2008-0953; Bradshaw Ralph A., 2015, Advances in Biological Regulation, V58, P16, DOI 10.1016/j.jbior.2014.11.003; Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang DS, 2016, J PAIN RES, V9, P373, DOI 10.2147/JPR.S89061; Chiacchio S, 2008, MINERVA ENDOCRINOL, V33, P341; Chopin V, 2016, CELL MOL LIFE SCI, V73, P1859, DOI 10.1007/s00018-016-2156-7; Demir IE, 2016, BBA-REV CANCER, V1866, P37, DOI 10.1016/j.bbcan.2016.05.003; Demont Y, 2012, J BIOL CHEM, V287, P1923, DOI 10.1074/jbc.M110.211714; Dumont J, 2000, ENDOTEXT; Faulkner S, 2016, ONCOTARGET, V7, P28488, DOI 10.18632/oncotarget.8652; Festuccia C, 2007, INT J ONCOL, V30, P193; Hayakawa Y, 2017, CANCER CELL, V31, P21, DOI 10.1016/j.ccell.2016.11.005; Jin HF, 2007, NEOPLASIA, V9, P471, DOI 10.1593/neo.07175; Jobling P, 2015, CANCER RES, V75, P1777, DOI 10.1158/0008-5472.CAN-14-3180; Johnston ALM, 2007, PLOS BIOL, V5, P1723, DOI 10.1371/journal.pbio.0050212; Khwaja F, 2006, BIOCHEM BIOPH RES CO, V341, P1184, DOI 10.1016/j.bbrc.2006.01.073; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Lagadec C, 2009, ONCOGENE, V28, P1960, DOI 10.1038/onc.2009.61; Lam DK, 2016, PAIN MANAG, V6, P487, DOI 10.2217/pmt-2015-0003; Lei YF, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15130; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Miknyoczki SJ, 2002, CLIN CANCER RES, V8, P1924; Nykjaer A, 2004, NATURE, V427, P843, DOI 10.1038/nature02319; Nykjaer A, 2012, TRENDS NEUROSCI, V35, P261, DOI 10.1016/j.tins.2012.01.003; Palazzo E, 2012, J CELL PHYSIOL, V227, P1017, DOI 10.1002/jcp.22811; Pezet S, 2006, ANNU REV NEUROSCI, V29, P507, DOI 10.1146/annurev.neuro.29.051605.112929; Pundavela J, 2015, MOL ONCOL, V9, P1626, DOI 10.1016/j.molonc.2015.05.001; Ranganath R, 2015, CURR OPIN ENDOCRINOL, V22, P387, DOI 10.1097/MED.0000000000000189; Rocha AS, 2006, HUM PATHOL, V37, P562, DOI 10.1016/j.humpath.2005.12.016; Romon R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-157; Roselli S, 2015, ONCOTARGET, V6, P10473, DOI 10.18632/oncotarget.3401; Tanimoto R, 2015, ENDOCRINOLOGY, V156, P58, DOI 10.1210/en.2014-1590; Tomellini E, 2015, STEM CELLS, V33, P342, DOI 10.1002/stem.1849; Truzzi F, 2008, J INVEST DERMATOL, V128, P2031, DOI 10.1038/jid.2008.21; Vaishnavi A, 2015, CANCER DISCOV, V5, P25, DOI 10.1158/2159-8290.CD-14-0765; VANDERLAAN BFAM, 1995, THYROID, V5, P67, DOI 10.1089/thy.1995.5.67; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wilson CM, 2014, J CELL SCI, V127, P3983, DOI 10.1242/jcs.149336; Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438; Zhang Y, 2005, ONCOL REP, V14, P161	47	5	5	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					229	241		10.1016/j.ajpath.2017.09.008			13	Pathology	Pathology	FQ8SS	WOS:000418634100023	29037860	Bronze			2019-10-28	
J	Zhang, KQ; Keymeulen, S; Nelson, R; Tong, TR; Yuan, YC; Yun, XW; Liu, Z; Lopez, J; Raz, DJ; Kim, JY				Zhang, Keqiang; Keymeulen, Sawa; Nelson, Rebecca; Tong, Tommy R.; Yuan, Yate-Ching; Yun, Xinwei; Liu, Zheng; Lopez, Joshua; Raz, Dan J.; Kim, Jae Y.			Overexpression of Flap Endonuclease 1 Correlates with Enhanced Proliferation and Poor Prognosis of Non-Small-Cell Lung Cancer	AMERICAN JOURNAL OF PATHOLOGY			English	Article							FEN1 MUTANT MICE; DNA-REPAIR; OVARIAN-CANCER; HOMOLOGOUS RECOMBINATION; EXPRESSION ANALYSIS; GENE-EXPRESSION; PROSTATE-CANCER; GASTRIC-CANCER; MECHANISMS; BREAST	Flap endonuclease 1 (FEN1) plays a crucial role in both DNA replication and damage repair. In this study, FEN1 expression and its clinical-pathologic significance in non-small-cell lung cancer (NSCLC) was investigated. Quantitative RT-PCR and immunohistochemistry analysis identified that both FEN1 mRNA and protein were highly overexpressed in about 36% of 136 cancer tissues compared to adjacent tissues, in which FEN1 was generally undetectable. Notably, patients with FEN1-overexpressed cancers were prone to have poor differentiation and poor prognosis. A strong positive correlation between the levels of FEN1 and Ki-67 staining was identified in these NSCLC tissues (r = 0.485), suggesting overexpressed FEN1 conferred a proliferative advantage to NSCLC. Furthermore, knockdown of FEN1 resulted in G1/S or G2/M phase cell cycle arrest and suppressed in vitro cellular proliferation in NSCLC cancer cells. Consistently, a selective FEN1 inhibitor was shown to effectively inhibit cellular proliferation of NSCLC cells in a dose-dependent manner. Additionally, knockdown of FEN1 significantly attenuated homologous DNA repair efficiency and enhanced cytotoxic effects of cisplatin in NSCLC cells. Taken together, these findings have indicated that overexpressed FEN1 represents a prognostic biomarker and potential therapeutic target for NSCLC treatment, which warrants further study.	[Zhang, Keqiang; Keymeulen, Sawa; Yun, Xinwei; Lopez, Joshua; Raz, Dan J.; Kim, Jae Y.] City Hope Natl Med Ctr, Div Thorac Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Zhang, Keqiang; Keymeulen, Sawa; Yun, Xinwei; Lopez, Joshua; Raz, Dan J.; Kim, Jae Y.] City Hope Natl Med Ctr, Div Biostat, Duarte, CA 91010 USA; [Nelson, Rebecca] City Hope Natl Med Ctr, Dept Pathol, Duarte, CA 91010 USA; [Tong, Tommy R.] City Hope Natl Med Ctr, Bioinformat Core Facil, Duarte, CA 91010 USA; [Yuan, Yate-Ching] City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA	Zhang, KQ (reprint author), City Hope Natl Med Ctr, Div Thorac Surg, 1500 E Duarte Rd, Duarte, CA 91010 USA.	kzhang@coh.org; jaekim@coh.org	Zhang, Keqiang/P-7082-2019		V Foundation; NIH National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [5K12CA001727-20, P30CA33572]	Supported in part by the V Foundation (D.J.R.) and the NIH National Cancer Institute grants 5K12CA001727-20 (D.J.R.) and P30CA33572 (Bioinformatics, Pathology, and Analytical Cytometry Cores).	Abdel-Fatah TMA, 2014, MOL ONCOL, V8, P1326, DOI 10.1016/j.molonc.2014.04.009; Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Ba S, 2016, BIOORGAN MED CHEM, V24, P1988, DOI 10.1016/j.bmc.2016.03.025; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Christmann M, 2005, ONCOGENE, V24, P8304, DOI 10.1038/sj.onc.1208994; Christmann M, 2003, TOXICOLOGY, V193, P3, DOI 10.1016/S0300-483X(03)00287-7; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fojo T, 2001, J NATL CANCER I, V93, P1434, DOI 10.1093/jnci/93.19.1434; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; He LF, 2016, EBIOMEDICINE, V14, P32, DOI 10.1016/j.ebiom.2016.11.012; Henkels KM, 1997, CANCER RES, V57, P4488; Herrero AB, 2006, CANCER RES, V66, P8155, DOI 10.1158/0008-5472.CAN-06-0179; Johansson VM, 2008, CELL BIOL INT, V32, P1467, DOI 10.1016/j.cellbi.2008.08.018; Kikuchi K, 2005, MOL CELL BIOL, V25, P6948, DOI 10.1128/MCB.25.16.6948-6955.2005; Kim IS, 2000, BBA-MOL CELL RES, V1496, P333, DOI 10.1016/S0167-4889(00)00029-X; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Koberle B, 1997, INT J CANCER, V70, P551, DOI 10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G; Lam JS, 2006, BJU INT, V98, P445, DOI 10.1111/j.1464-410X.2006.06224.x; Larsen E, 2003, MOL CELL BIOL, V23, P5346, DOI 10.1128/MCB.23.15.5346-5353.2003; LaTulippe E, 2002, CANCER RES, V62, P4499; Liu L, 2012, CARCINOGENESIS, V33, P119, DOI 10.1093/carcin/bgr250; Martin B, 2004, BRIT J CANCER, V91, P2018, DOI 10.1038/sj.bjc.6602233; Matsuzaki Y, 2002, NUCLEIC ACIDS RES, V30, P3273, DOI 10.1093/nar/gkf440; Mocquet V, 2008, EMBO J, V27, P155, DOI 10.1038/sj.emboj.7601948; Nikolova T, 2009, ANTICANCER RES, V29, P2453; PARKER RJ, 1991, J CLIN INVEST, V87, P772, DOI 10.1172/JCI115080; Pearl LH, 2015, NAT REV CANCER, V15, P166, DOI 10.1038/nrc3891; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Shen BH, 2005, BIOESSAYS, V27, P717, DOI 10.1002/bies.20255; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Singh P, 2008, MOL CANCER RES, V6, P1710, DOI 10.1158/1541-7786.MCR-08-0269; van Pel DM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003254; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang J. Q., 2015, SCI WORLD J, V2015, P1, DOI DOI 10.1371/J0URNAL.P0NE.0124261; Wang KJ, 2014, INT J MOL MED, V33, P1268, DOI 10.3892/ijmm.2014.1682; Wu ZX, 2012, MUTAT RES-FUND MOL M, V731, P85, DOI 10.1016/j.mrfmmm.2011.11.009; Xu H, 2011, ONCOGENE, V30, P1072, DOI 10.1038/onc.2010.482; Yang M, 2009, HUM MUTAT, V30, P1320, DOI 10.1002/humu.21060; Zhang KQ, 2013, CANCER RES, V73, P1298, DOI 10.1158/0008-5472.CAN-12-2086; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zheng L, 2011, CELL RES, V21, P1052, DOI 10.1038/cr.2011.35; Zheng L, 2011, NUCLEIC ACIDS RES, V39, P781, DOI 10.1093/nar/gkq884	42	11	11	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2018	188	1					242	251		10.1016/j.ajpath.2017.09.011			10	Pathology	Pathology	FQ8SS	WOS:000418634100024	29037854	Green Published, Bronze			2019-10-28	
J	Kao, YC; Fletcher, CDM; Alaggio, R; Wexler, L; Zhang, L; Sung, YS; Orhan, D; Chang, WC; Swanson, D; Dickson, BC; Antonescu, CR				Kao, Yu-Chien; Fletcher, Christopher D. M.; Alaggio, Rita; Wexler, Leonard; Zhang, Lei; Sung, Yun-Shao; Orhan, Dicle; Chang, Wei-Chin; Swanson, David; Dickson, Brendan C.; Antonescu, Cristina R.			Recurrent BRAF Gene Fusions in a Subset of Pediatric Spindle Cell Sarcomas Expanding the Genetic Spectrum of Tumors With Overlapping Features With Infantile Fibrosarcoma	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						fibrosarcoma; infantile fibrosarcoma; BRAF; NTRK1; NTRK3; fusions	CONGENITAL MESOBLASTIC NEPHROMA; FIBROSARCOMA; ACTIVATION; THERAPY; TISSUE; RAF	Infantile fibrosarcomas (IFS) represent a distinct group of soft tissue tumors occurring in patients under 2 years of age and most commonly involving the extremities. Most IFS show recurrent ETV6-NTRK3 gene fusions, sensitivity to chemotherapy, and an overall favorable clinical outcome. However, outside these well-defined pathologic features, no studies have investigated IFS lacking ETV6-NTRK3 fusions, or tumors with the morphology resembling IFS in older children. This study was triggered by the identification of a novel SEPT7-BRAF fusion in an unclassified retroperitoneal spindle cell sarcoma in a 16-year-old female by targeted RNA sequencing. Fluorescence in situ hybridization screening of 9 additional tumors with similar phenotype and lacking ETV6-NTRK3 identified 4 additional cases with BRAF gene rearrangements in the pelvic cavity (n=2), paraspinal region (n=1), and thigh (n=1) of young children (0 to 3y old). Histologically, 4 cases including the index case shared a fascicular growth of packed monomorphic spindle cells, with uniform nuclei and fine chromatin, and a dilated branching vasculature; while the remaining case was composed of compact cellular sheets of short spindle to ovoid cells. In addition, a minor small blue round cell component was present in 1 case. Mitotic activity ranged from 1 to 9/10 high power fields. Immunohistochemical stains were nonspecific, with only focal smooth muscle actin staining demonstrated in 3 cases tested. Of the remaining 5 BRAF negative cases, further RNA sequencing identified 1 case with EML4-NTRK3 in an 1-year-old boy with a foot IFS, and a second case with TPM3-NTRK1 fusion in a 7-week-old infant with a retroperitoneal lesion. Our findings of recurrent BRAF gene rearrangements in tumors showing morphologic overlap with IFS expand the genetic spectrum of fusion-positive spindle cell sarcomas, to include unusual presentations, such as older children and adolescents and predilection for axial location, thereby opening new opportunities for kinase-targeted therapeutic intervention.	[Kao, Yu-Chien; Zhang, Lei; Sung, Yun-Shao; Antonescu, Cristina R.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Wexler, Leonard] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10065 USA; [Fletcher, Christopher D. M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA; [Alaggio, Rita] UPMC, Childrens Hosp, Dept Pathol, Pittsburgh, PA USA; [Orhan, Dicle] Hacettepe Univ, Dept Pathol, Ankara, Turkey; [Kao, Yu-Chien] Taipei Med Univ, Shuang Ho Hosp, Dept Pathol, Taipei, Taiwan; [Chang, Wei-Chin] MacKay Mem Hosp, Dept Pathol, Taipei, Taiwan; [Chang, Wei-Chin] MacKay Med Coll, Dept Pathol, New Taipei, Taiwan; [Chang, Wei-Chin] MacKay Med Nursing & Management Coll, Dept Pathol, New Taipei, Taiwan; [Swanson, David; Dickson, Brendan C.] Mt Sinai Hosp, Dept Pathol & Lab Med, Toronto, ON, Canada	Antonescu, CR (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	antonesc@mskcc.org	alaggio, rita/AAC-2348-2019	alaggio, rita/0000-0003-3915-3816	Kristen Ann Carr Foundation; Cycle for Survival;  [P50 CA140146-01];  [P30-CA008748]	Supported in parts by: P50 CA140146-01 (C.R.A.); P30-CA008748 (C.R.A.); Kristen Ann Carr Foundation (C.R.A.); Cycle for Survival (C.R.A.). The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Adem C, 2001, MODERN PATHOL, V14, P1246, DOI 10.1038/modpathol.3880469; Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Alaggio R, 2016, AM J SURG PATHOL, V40, P224, DOI 10.1097/PAS.0000000000000538; Argani P, 2000, MODERN PATHOL, V13, P29, DOI 10.1038/modpathol.3880006; Berrebi D, 2015, PEDIATR SURG INT, V31, P375, DOI 10.1007/s00383-015-3670-7; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; Cerveira N, 2011, BIOL CHEM, V392, P713, DOI 10.1515/BC.2011.072; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; CHUNG EB, 1976, CANCER, V38, P729, DOI 10.1002/1097-0142(197608)38:2<729::AID-CNCR2820380216>3.0.CO;2-Z; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Flucke U, 2017, GENE CHROMOSOME CANC, V56, P663, DOI 10.1002/gcc.22470; Gadd S, 2012, J PATHOL, V228, P119, DOI 10.1002/path.4010; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Kao YC, 2017, AM J SURG PATHOL, V41, P1456, DOI 10.1097/PAS.0000000000000899; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Nagasubramanian R, 2016, PEDIATR BLOOD CANCER, V63, P1468, DOI 10.1002/pbc.26026; Neubauer K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00003; Orbach D, 2010, J CLIN ONCOL, V28, P318, DOI 10.1200/JCO.2009.21.9972; Pavlick D, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26433; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Rubin BP, 1998, AM J PATHOL, V153, P1451, DOI 10.1016/S0002-9440(10)65732-X; SOULE EH, 1977, CANCER-AM CANCER SOC, V40, P1711, DOI 10.1002/1097-0142(197710)40:4<1711::AID-CNCR2820400447>3.0.CO;2-9; Subbiah V, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-8; Sulkowski JP, 2013, PEDIATR SURG INT, V29, P771, DOI 10.1007/s00383-013-3318-4; Suzuki Rikio, 2014, Leuk Res Rep, V3, P54, DOI 10.1016/j.lrr.2014.06.004; Tannenbaum-Dvir S, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000471; Wiesner T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4116; Wong V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv307	29	18	18	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					28	38		10.1097/PAS.0000000000000938			11	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200005	28877062	Green Accepted			2019-10-28	
J	Mukhopadhyay, S; Feldman, MD; Abels, E; Ashfaq, R; Beltaifa, S; Cacciabeve, NG; Cathro, HP; Cheng, L; Cooper, K; Dickey, GE; Gill, RM; Heaton, RP; Kerstens, R; Lindberg, GM; Malhotra, RK; Mandell, JW; Manlucu, ED; Mills, AM; Mills, SE; Moskaluk, CA; Nelis, M; Patil, DT; Przybycin, CG; Reynolds, JP; Rubin, BP; Saboorian, MH; Salicru, M; Samols, MA; Sturgis, CD; Turner, KO; Wick, MR; Yoon, JY; Zhao, P; Taylor, CR				Mukhopadhyay, Sanjay; Feldman, Michael D.; Abels, Esther; Ashfaq, Raheela; Beltaifa, Senda; Cacciabeve, Nicolas G.; Cathro, Helen P.; Cheng, Liang; Cooper, Kumarasen; Dickey, Glenn E.; Gill, Ryan M.; Heaton, Robert P., Jr.; Kerstens, Rene; Lindberg, Guy M.; Malhotra, Reenu K.; Mandell, James W.; Manlucu, Ellen D.; Mills, Anne M.; Mills, Stacey E.; Moskaluk, Christopher A.; Nelis, Mischa; Patil, Deepa T.; Przybycin, Christopher G.; Reynolds, Jordan P.; Rubin, Brian P.; Saboorian, Mohammad H.; Salicru, Mauricio; Samols, Mark A.; Sturgis, Charles D.; Turner, Kevin O.; Wick, Mark R.; Yoon, Ji Y.; Zhao, Po; Taylor, Clive R.			Whole Slide Imaging Versus Microscopy for Primary Diagnosis in Surgical Pathology A Multicenter Blinded Randomized Noninferiority Study of 1992 Cases (Pivotal Study)	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						whole slide imaging; microscopy; surgical pathology; digital imaging; pathology; primary diagnosis; noninferiority trial	DIGITAL PATHOLOGY; LIGHT-MICROSCOPY; PEDIATRIC PATHOLOGY; OPTICAL MICROSCOPY; ANATOMIC PATHOLOGY; NEEDLE BIOPSIES; BREAST-CANCER; GLASS SLIDES; VALIDATION; IMAGES	Most prior studies of primary diagnosis in surgical pathology using whole slide imaging (WSI) versus microscopy have focused on specific organ systems or included relatively few cases. The objective of this study was to demonstrate that WSI is noninferior to microscopy for primary diagnosis in surgical pathology. A blinded randomized noninferiority study was conducted across the entire range of surgical pathology cases (biopsies and resections, including hematoxylin and eosin, immunohistochemistry, and special stains) from 4 institutions using the original sign-out diagnosis (baseline diagnosis) as the reference standard. Cases were scanned, converted to WSI and randomized. Sixteen pathologists interpreted cases by microscopy or WSI, followed by a wash-out period of >= 4 weeks, after which cases were read by the same observers using the other modality. Major discordances were identified by an adjudication panel, and the differences between major discordance rates for both microscopy (against the reference standard) and WSI (against the reference standard) were calculated. A total of 1992 cases were included, resulting in 15,925 reads. The major discordance rate with the reference standard diagnosis was 4.9% for WSI and 4.6% for microscopy. The difference between major discordance rates for microscopy and WSI was 0.4% (95% confidence interval, -0.30% to 1.01%). The difference in major discordance rates for WSI and microscopy was highest in endocrine pathology (1.8%), neoplastic kidney pathology (1.5%), urinary bladder pathology (1.3%), and gynecologic pathology (1.2%). Detailed analysis of these cases revealed no instances where interpretation by WSI was consistently inaccurate compared with microscopy for multiple observers. We conclude that WSI is noninferior to microscopy for primary diagnosis in surgical pathology, including biopsies and resections stained with hematoxylin and eosin, immunohistochemistry and special stains. This conclusion is valid across a wide variety of organ systems and specimen types.	[Mukhopadhyay, Sanjay; Patil, Deepa T.; Przybycin, Christopher G.; Reynolds, Jordan P.; Rubin, Brian P.; Sturgis, Charles D.] Cleveland Clin, Dept Pathol, Cleveland, OH 44106 USA; [Feldman, Michael D.; Cooper, Kumarasen] Hosp Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA; [Abels, Esther; Kerstens, Rene; Nelis, Mischa] Philips Digital Pathol Solut, Best, Netherlands; [Ashfaq, Raheela; Lindberg, Guy M.; Malhotra, Reenu K.; Saboorian, Mohammad H.; Salicru, Mauricio; Turner, Kevin O.; Yoon, Ji Y.] Miraca Life Sci, Irving, TX USA; [Beltaifa, Senda; Cacciabeve, Nicolas G.; Dickey, Glenn E.; Heaton, Robert P., Jr.; Manlucu, Ellen D.; Samols, Mark A.; Zhao, Po] Adv Pathol Associates, Silver Spring, MD USA; [Cathro, Helen P.; Mandell, James W.; Mills, Anne M.; Mills, Stacey E.; Moskaluk, Christopher A.; Wick, Mark R.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN USA; [Gill, Ryan M.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Taylor, Clive R.] Univ Southern Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA	Taylor, CR (reprint author), Univ Southern Calif, Dept Pathol, Keck Sch Med, Pathol, HMR 311, Los Angeles, CA 90033 USA.	clive.taylor@med.usc.edu		Wick, Mark/0000-0002-6803-144X; Mukhopadhyay, Sanjay/0000-0001-9660-2599; Mills, Anne/0000-0002-2686-4857	Philips	Supported by Philips. E.A., R.K., and M.N. are employees of Philips. C.R.T. and M.D.F. are consultants to Philips for which they receive a personal remuneration. S.M., D.T.P., C.G.P., and C.D.S. received a personal remuneration for participating as readers in this study and have no other relationships with or financial interest in Philips. A.M.M., C.A.M., J.W.M., S.E.M., and H.P.C. report that they received compensation in the form of salary support from Philips for their participation in this study. All pathologists in the study completed a Financial Disclosure Form and Form FDA 3454. The remaining authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.	Al-Janabi S, 2014, J RENAL INJ PREV, V3, P91, DOI 10.12861/jrip.2014.26; Al-Janabi S, 2013, J CLIN PATHOL, V66, P218, DOI 10.1136/jclinpath-2012-201104; Al-Janabi S, 2012, J CLIN PATHOL, V65, P1107, DOI 10.1136/jclinpath-2012-200878; Al-Janabi S, 2012, HUM PATHOL, V43, P702, DOI 10.1016/j.humpath.2011.06.017; Al-Janabi S, 2012, J CLIN PATHOL, V65, P152, DOI 10.1136/jclinpath-2011-200277; Arnold MA, 2015, PEDIATR DEVEL PATHOL, V18, P109, DOI 10.2350/14-07-1523-OA.1; Ayad E, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-S1-S1; Bauer TW, 2014, ARCH PATHOL LAB MED, V138, P1459, DOI 10.5858/arpa.2013-0541-OA; Bauer TW, 2013, ARCH PATHOL LAB MED, V137, P518, DOI 10.5858/arpa.2011-0678-OA; Brunelli M, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-S1-S12; Buck Thomas P, 2014, J Pathol Inform, V5, P43, DOI 10.4103/2153-3539.145731; Campbell WS, 2014, HUM PATHOL, V45, P1713, DOI 10.1016/j.humpath.2014.04.007; Campbell WS, 2012, HUM PATHOL, V43, P1739, DOI 10.1016/j.humpath.2011.12.023; Cheng CL, 2016, J CLIN PATHOL, V69, P784, DOI 10.1136/jclinpath-2015-203600; Eccher A, 2016, HUM PATHOL, V47, P115, DOI 10.1016/j.humpath.2015.09.012; Elsheikh TM, 2008, AM J CLIN PATHOL, V130, P736, DOI 10.1309/AJCPKP2QUVN4RCCP; Fine JL, 2008, HUM PATHOL, V39, P564, DOI 10.1016/j.humpath.2007.08.007; Fonyad L, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-35; Fuller MY, 2016, ARCH PATHOL LAB MED, V140, P1273, DOI 10.5858/arpa.2016-0268-SA; Gage JC, 2013, HUM PATHOL, V44, P2542, DOI 10.1016/j.humpath.2013.06.015; Gilbertson JR, 2006, BMC CLIN PATHOL, V6, DOI 10.1186/1472-6890-6-4; Goacher E, 2017, ARCH PATHOL LAB MED, V141, P151, DOI 10.5858/arpa.2016-0025-RA; Hanna MG, 2015, J CLIN PATHOL, V68, P499, DOI 10.1136/jclinpath-2015-202914; Ho J, 2006, HUM PATHOL, V37, P322, DOI 10.1016/j.humpath.2005.11.005; Houghton JP, 2014, J CLIN PATHOL, V67, P1052, DOI 10.1136/jclinpath-2014-202491; Huisman A, 2010, HUM PATHOL, V41, P751, DOI 10.1016/j.humpath.2009.08.026; Hwang DH, 2014, ARCH PATHOL LAB MED, V138, P626, DOI 10.5858/arpa.2013-0179-OA; Jen KY, 2013, HUM PATHOL, V44, P888, DOI 10.1016/j.humpath.2012.08.015; Jones NC, 2015, ARCH PATHOL LAB MED, V139, P627, DOI 10.5858/arpa.2014-0133-OA; Jukic DM, 2011, ARCH PATHOL LAB MED, V135, P372, DOI 10.1043/2009-0678-OA.1; Kalinski T, 2008, AM J CLIN PATHOL, V130, P259, DOI 10.1309/QAM22Y85QCV5JM47; Kondo Y, 2012, PATHOL INT, V62, P592, DOI 10.1111/j.1440-1827.2012.02847.x; Krishnamurthy S, 2013, ARCH PATHOL LAB MED, V137, P1733, DOI 10.5858/arpa.2012-0437-OA; Loughrey MB, 2015, VIRCHOWS ARCH, V467, P137, DOI 10.1007/s00428-015-1780-1; McKenney JK, 2011, J UROLOGY, V186, P465, DOI 10.1016/j.juro.2011.03.115; Mills AM, 2017, AM J SURG P IN PRESS; Nassar A, 2011, APPL IMMUNOHISTO M M, V135, P19; Nassar A, 2011, AM J CLIN PATHOL, V135, P461, DOI 10.1309/AJCP4VFKA5FCMZNA; Nunes C, 2014, PATHOL RES PRACT, V210, P713, DOI 10.1016/j.prp.2014.06.031; Ordi J, 2015, J CLIN PATHOL, V68, P33, DOI 10.1136/jclinpath-2014-202524; Pagni F, 2011, ARCH PATHOL LAB MED, V135, P215, DOI 10.1043/1543-2165-135.2.215; Pantanowitz L, 2013, ARCH PATHOL LAB MED, V137, P1710, DOI 10.5858/arpa.2013-0093-CP; Pantanowitz Liron, 2012, J Pathol Inform, V3, P46, DOI 10.4103/2153-3539.104908; Raab SS, 2005, ARCH PATHOL LAB MED, V129, P459; Reyes Carolina, 2014, J Pathol Inform, V5, P5, DOI 10.4103/2153-3539.127814; Rodriguez-Urrego PA, 2011, HUM PATHOL, V42, P68, DOI 10.1016/j.humpath.2010.07.001; Shah KK, 2016, J AM ACAD DERMATOL, V75, P1229, DOI 10.1016/j.jaad.2016.08.024; Snead DRJ, 2016, HISTOPATHOLOGY, V68, P1063, DOI 10.1111/his.12879; Taylor CR, 2011, APPL IMMUNOHISTO M M, V19, P1491, DOI 10.1097/PAI.0b013e318229ffd6; Van der Kwast TH, 2010, AM J SURG PATHOL, V34, P169, DOI 10.1097/PAS.0b013e3181c7997b; van der Post RS, 2013, HISTOPATHOLOGY, V63, P114, DOI 10.1111/his.12131; Velez N, 2008, HUM PATHOL, V39, P1341, DOI 10.1016/j.humpath.2008.01.006; Weinstein RS, 2004, HUM PATHOL, V35, P1303, DOI 10.1016/j.humpath.2004.09.002; Wilbur DC, 2009, ARCH PATHOL LAB MED, V133, P1949, DOI 10.1043/1543-2165-133.12.1949	54	25	26	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					39	52		10.1097/PAS.0000000000000948			14	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200006	28961557	Green Published			2019-10-28	
J	Ryan, E; Khaw, YL; Creavin, B; Geraghty, R; Ryan, EJ; Gibbons, D; Hanly, A; Martin, ST; O'Connell, PR; Winter, DC; Sheahan, K				Ryan, Eanna; Khaw, Yi Ling; Creavin, Ben; Geraghty, Robert; Ryan, Elizabeth J.; Gibbons, David; Hanly, Ann; Martin, Sean T.; O'Connell, P. Ronan; Winter, Desmond C.; Sheahan, Kieran			Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						colorectal cancer; mismatch repair; microsatellite instability; Lynch syndrome; tumor budding; poorly differentiated clusters; prognostic histopathologic markers; immune checkpoint inhibition	EPITHELIAL-MESENCHYMAL TRANSITION; MICROSATELLITE-INSTABILITY STATUS; POORLY DIFFERENTIATED CLUSTERS; PROGNOSTIC-FACTOR; RECTAL-CANCER; COLON-CANCER; IMMUNE MICROENVIRONMENT; ADENOCARCINOMA; INTEROBSERVER; CARCINOMA	Mismatch repair deficient (dMMR) colorectal cancer (CRC) despite its association with poor histologic grade often has improved prognosis compared with MMR proficient CRC. Tumor budding and poorly differentiated clusters (PDCs) may predict metastatic potential of colorectal adenocarcinoma (CRC). In addition, their assessment may be more reproducible than the evaluation of other histopathologic parameters. Therefore, we wished to determine their potential as prognostic indicators in a cohort of dMMR CRC patients relative to histologic grade. We investigated the predictive value of conventional WHO grade, budding, PDC grade and other histopathologic parameters on the presence of lymph node metastasis (LNM) and clinical outcome in 238 dMMR CRCs. MMR status was determined by immunohistochemistry for the mismatch repair proteins hMLH1, hMSH2, hMSH6, and hPMS2. Tumor budding and PDCs were highly correlated (r=0.701; P<0.000). Both budding and PDC grade were associated with WHO grade, perineural invasion, lympho-vascular invasion, and extramural vascular invasion, and the presence of LNM in dMMR CRC (P<0.009). Independent predictors of LNM were PDC grade (odds ratio, 4.12; 95% confidence interval [CI], 1.69-10.04; P=0.011) and EMVI (odds ratio, 3.81; 95% CI, 1.56-9.19; P<0.000). Only pTstage (hazard ratio [HR], 4.11; 95% CI, 1.48-11.36; P=0.007) and tumor budding (HR, 2.99; 95% CI, 1.72-5.19; P<0.000) were independently associated with worse disease-free survival (DFS). If tumor budding was excluded from the model, PDC grade became significant for DFS (HR, 2.34; 95% CI, 1.34-4.09; P=0.003). WHO Grade does not independently correlate with clinical outcome in dMMR CRC. PDC grade and extramural vascular invasion are independent predictors of LNM. Tumor budding and pTstage are the best predictors of DFS. If tumor budding cannot be assessed, PDC grade may be used as a prognostic surrogate.	[Ryan, Eanna; Creavin, Ben; Hanly, Ann; Martin, Sean T.; O'Connell, P. Ronan; Winter, Desmond C.] St Vincents Univ Hosp, Dept Surg, Elm Pk, Ireland; [Khaw, Yi Ling; Geraghty, Robert; Gibbons, David; Sheahan, Kieran] St Vincents Univ Hosp, Dept Histopathol, Elm Pk, Ireland; [Ryan, Eanna; Creavin, Ben; Hanly, Ann; Martin, Sean T.; O'Connell, P. Ronan; Winter, Desmond C.; Sheahan, Kieran] St Vincents Univ Hosp, Ctr Colorectal Dis, Elm Pk, Ireland; [Ryan, Elizabeth J.; O'Connell, P. Ronan; Sheahan, Kieran] Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland	Ryan, E (reprint author), Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland.	eanna.ryan.1@gmail.com	Ryan, Elizabeth/H-9758-2019; Ryan, Eanna J./H-6829-2019	Ryan, Elizabeth/0000-0002-5137-1253; Ryan, Eanna J./0000-0003-2609-0836; Creavin, Ben/0000-0001-8209-4810; O'Connell, P. Ronan/0000-0002-1846-5629			Aaltonen LA, 2000, WHO CLASSIFICATION T, P103; Barresi V, 2014, HUM PATHOL, V45, P268, DOI 10.1016/j.humpath.2013.07.046; Chandler I, 2008, HISTOPATHOLOGY, V52, P494, DOI 10.1111/j.1365-2559.2008.02976.x; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Goldstein J, 2014, ANN ONCOL, V25, P1032, DOI 10.1093/annonc/mdu100; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hamiton SR, 2010, WHO CLASSIFICATION T, P131; HASE K, 1993, DIS COLON RECTUM, V36, P627, DOI 10.1007/BF02238588; Hayes BD, 2010, AM J SURG PATHOL, V34, P746, DOI 10.1097/PAS.0b013e3181da76b6; Jass JR, 2003, J CLIN PATHOL, V56, P69, DOI 10.1136/jcp.56.1.69; JASS JR, 1987, LANCET, V1, P1303; Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044; Kadota K, 2015, CHEST, V148, P711, DOI 10.1378/chest.14-3005; Karamitopoulou E, 2013, MODERN PATHOL, V26, P295, DOI 10.1038/modpathol.2012.155; Kevans D, 2011, INT J SURG PATHOL, V19, P751, DOI 10.1177/1066896911414566; Koelzer VH, 2015, VIRCHOWS ARCH, V466, P485, DOI 10.1007/s00428-015-1740-9; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863; Lugli A, 2009, BRIT J CANCER, V101, P1382, DOI 10.1038/sj.bjc.6605318; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Lugli A, 2011, HUM PATHOL, V42, P1833, DOI 10.1016/j.humpath.2011.02.010; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Mohan HM, 2016, EJSO-EUR J SURG ONC, V42, P1680, DOI 10.1016/j.ejso.2016.05.013; Moreira L, 2012, JAMA-J AM MED ASSOC, V308, P1555, DOI 10.1001/jama.2012.13088; Nordholm-Carstensen A, 2015, INT J CANCER, V137, P2139, DOI 10.1002/ijc.29585; Prall F, 2005, HISTOPATHOLOGY, V47, P17, DOI 10.1111/j.1365-2559.2005.02161.x; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Rosty C, 2014, HUM PATHOL, V45, P2077, DOI 10.1016/j.humpath.2014.06.020; Royal College of Surgeons in Ireland Clinical Guidelines Committee, 2002, COL CANC MAN CLIN GU, P2002; Ryan E, 2017, CRIT REV ONCOL HEMAT, V116, P38, DOI 10.1016/j.critrevonc.2017.05.006; Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825; Schemper M, 1996, CONTROL CLIN TRIALS, V17, P343, DOI 10.1016/0197-2456(96)00075-X; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x; Ueno H, 2004, ANN SURG, V240, P832, DOI 10.1097/01.sla.0000143243.81014.f2; Ueno H, 2002, CANCER, V94, P2882, DOI 10.1002/cncr.10551; Ueno H, 2014, J GASTROENTEROL, V49, P1314, DOI 10.1007/s00535-013-0881-3; Ueno H, 2012, AM J SURG PATHOL, V36, P193, DOI 10.1097/PAS.0b013e318235edee; Wang LM, 2009, AM J SURG PATHOL, V33, P134, DOI 10.1097/PAS.0b013e318184cd55; Ward R, 2001, GUT, V48, P821, DOI 10.1136/gut.48.6.821; Wright CL, 2003, AM J SURG PATHOL, V27, P1393, DOI 10.1097/00000478-200311000-00001; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007; Yang M, 2016, CANCER MED-US, V5, P1510, DOI 10.1002/cam4.740	44	5	8	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					60	68		10.1097/PAS.0000000000000931			9	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200008	29112018				2019-10-28	
J	Sayeed, S; Xing, DY; Jenkins, SM; Weisman, PS; Buehler, D; Warmke, L; Uram-Tuculescu, C; Bakkum-Gamez, JN; Howitt, BE; Cortese, C; Park, KJ; Schoolmeester, JK				Sayeed, Sadia; Xing, Deyin; Jenkins, Sarah M.; Weisman, Paul S.; Buehler, Darya; Warmke, Laura; Uram-Tuculescu, Cora; Bakkum-Gamez, Jamie N.; Howitt, Brooke E.; Cortese, Cherise; Park, Kay J.; Schoolmeester, J. Kenneth			Criteria for Risk Stratification of Vulvar and Vaginal Smooth Muscle Tumors An Evaluation of 71 Cases Comparing Proposed Classification Systems	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						smooth muscle tumor; leiomyosarcoma; leiomyoma; vulva; vagina	BENIGN NEOPLASM DISTINCT; OF-THE-LITERATURE; DERMATOFIBROSARCOMA PROTUBERANS; AGGRESSIVE ANGIOMYXOMA; IMMUNOHISTOCHEMICAL ANALYSIS; CELLULAR ANGIOFIBROMA; ANGIOMYOFIBROBLASTOMA; LEIOMYOMAS; VARIANT; UTERUS	Accurate risk stratification of smooth muscle tumors (SMTs) is essential for appropriate patient management. Yet, the rarity of SMTs of the vagina and vulva makes development of a prognostically meaningful classification system challenging. While 2 classification methods for vulvar SMTs and 1 for vaginal SMTs have been proposed, it is our experience that many pathologists tend to apply criteria for uterine SMTs when evaluating vulvovaginal tumors. We retrospectively reviewed a large cohort of vulvovaginal SMTs with clinical follow-up and evaluated which method most accurately classified tumors according to patient outcome. A total of 71 tumors, 53 vaginal (75%) and 18 vulvar (25%), from 71 patients were identified. All tumors were centrally examined for degree of cytologic atypia, morphology (spindled, epithelioid, myxoid), mitotic index per 10 high power fields, atypical mitotic figures, tumor cell necrosis, ischemic necrosis, tumor interface (circumscribed or infiltrative) and margin status. Clinical features were recorded for each patient. Follow-up was available for 63 patients (89%), and ranged from 1 to 234 months (median: 64 mo). While site-specific and uterine criteria showed equally excellent sensitivity in classifying smooth muscle neoplasms as leiomyosarcoma according to patient outcome, uterine criteria showed improved specificity relatively to site-specific methods in classifying tumors as nonsarcoma according to patient outcome. We recommend that uterine SMT criteria and nomenclature be adopted for evaluation and classification of vulvovaginal SMTs.	[Sayeed, Sadia; Schoolmeester, J. Kenneth] Mayo Clin, Dept Lab Med & Pathol, 200 First St, Rochester, MN 55905 USA; [Jenkins, Sarah M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; [Bakkum-Gamez, Jamie N.] Mayo Clin, Dept Obstet & Gynecol, Rochester, MN 55905 USA; [Xing, Deyin] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Weisman, Paul S.; Buehler, Darya] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; [Warmke, Laura; Uram-Tuculescu, Cora] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA; [Howitt, Brooke E.] Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA; [Cortese, Cherise] Mayo Clin, Dept Lab Med & Pathol, Jacksonville, FL 32224 USA; [Park, Kay J.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA	Schoolmeester, JK (reprint author), Mayo Clin, Dept Lab Med & Pathol, 200 First St, Rochester, MN 55905 USA.	schoolmeester.j@mayo.edu		Howitt, Brooke/0000-0002-0309-6680	NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA008748]		BELL SW, 1994, AM J SURG PATHOL, V18, P535, DOI 10.1097/00000478-199406000-00001; Calonje E, 1996, J CUTAN PATHOL, V23, P30, DOI 10.1111/j.1600-0560.1996.tb00774.x; Croce S, 2014, AM J SURG PATHOL, V38, P1330, DOI 10.1097/PAS.0000000000000249; Edelweiss M, 2010, AM J SURG PATHOL, V34, P393, DOI 10.1097/PAS.0b013e3181cf7fc1; Fletcher C, 2013, WHO CLASSIFICATION T; FLETCHER CDM, 1985, HISTOPATHOLOGY, V9, P921, DOI 10.1111/j.1365-2559.1985.tb02878.x; FLETCHER CDM, 1992, AM J SURG PATHOL, V16, P373, DOI 10.1097/00000478-199204000-00006; Ghorbani RP, 1999, INT J GYNECOL PATHOL, V18, P366, DOI 10.1097/00004347-199910000-00012; Ip PPC, 2009, AM J SURG PATHOL, V33, P992, DOI 10.1097/PAS.0b013e3181a02d1c; Iwasa Y, 2004, AM J SURG PATHOL, V28, P1426, DOI 10.1097/01.pas.0000138002.46650.95; Kurman RJ, 2014, WHO CLASSIFICATION T; Laskin WB, 1997, HUM PATHOL, V28, P1046, DOI 10.1016/S0046-8177(97)90058-7; Lerwill MF, 2004, AM J SURG PATHOL, V28, P1436, DOI 10.1097/01.pas.0000141393.99300.d0; Ly A, 2013, AM J SURG PATHOL, V37, P643, DOI 10.1097/PAS.0b013e3182893f36; Mills AM, 2013, AM J SURG PATHOL, V37, P634, DOI 10.1097/PAS.0b013e318287779c; Nielsen GP, 1996, AM J SURG PATHOL, V20, P779, DOI 10.1097/00000478-199607000-00001; Nucci MR, 1997, AM J SURG PATHOL, V21, P636, DOI 10.1097/00000478-199706000-00002; Romano RC, 2015, MODERN PATHOL, V28, P1033, DOI 10.1038/modpathol.2015.62; STEEPER TA, 1983, AM J SURG PATHOL, V7, P463, DOI 10.1097/00000478-198307000-00009; TAVASSOLI FA, 1979, OBSTET GYNECOL, V53, P213; TAVASSOLI FA, 1979, OBSTET GYNECOL, V53, P689; van Roggen JFG, 2005, VIRCHOWS ARCH, V446, P157, DOI 10.1007/s00428-004-1135-9; Vang R, 2002, AM J SURG PATHOL, V26, P1, DOI 10.1097/00000478-200201000-00001	23	1	1	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					84	94		10.1097/PAS.0000000000000920			11	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200011	28786880	Green Accepted			2019-10-28	
J	Quigley, B; Reid, MD; Pehlivanoglu, B; Squires, MH; Maithel, S; Xue, Y; Hyejeong, C; Akkas, G; Muraki, T; Kooby, DA; Sarmiento, JM; Cardona, K; Sekhar, A; Krasinskas, A; Adsay, V				Quigley, Brian; Reid, Michelle D.; Pehlivanoglu, Burcin; Squires, Malcolm H., III; Maithel, Shishir; Xue, Yue; Hyejeong, Choi; Akkas, Gizem; Muraki, Takashi; Kooby, David A.; Sarmiento, Juan M.; Cardona, Ken; Sekhar, Aarti; Krasinskas, Alyssa; Adsay, Volkan			Hepatobiliary Mucinous Cystic Neoplasms With Ovarian Type Stroma (So-Called "Hepatobiliary Cystadenoma/Cystadenocarcinoma") Clinicopathologic Analysis of 36 Cases Illustrates Rarity of Carcinomatous Change	AMERICAN JOURNAL OF SURGICAL PATHOLOGY			English	Article						mucinous cystic neoplasm; hepatobiliary cystadenoma; hepatobiliary cystadenocarcinoma; liver cyst; hepatic cyst	PANCREATIC INTRAEPITHELIAL NEOPLASIA; CLINICOPATHOLOGICAL FEATURES; CLASSIFICATION-SYSTEM; BILIARY CYSTADENOMA; PAPILLARY NEOPLASMS; PROGNOSIS; CYSTADENOCARCINOMA; CONSENSUS; LIVER; MANAGEMENT	The literature is highly conflicting on hepatobiliary mucinous cystic neoplasms (MCNs), aka "hepatobiliary cystadenoma/cystadenocarcinoma," largely because ovarian stroma (OS) was not a requirement until WHO-2010 and is not widely applied even today. In this study, MCNs (with OS) accounted for 24 of 229 (11%) resected hepatic cysts in one institution. Eight of the 32 (25%) cysts that had been originally designated as hepatobiliary cystadenoma/cystadenocarcinoma at the time of diagnosis proved not to have an OS during this review and were thus re-classified as non-MCN. In total, 36 MCNs (with OS) were analyzed24 from the institutional files and 12 consultation cases. All were women. Mean age was 51 (28 to 76 y). Mean size was 11 cm (5 to 23 cm). Most (91%) were intrahepatic and in the left lobe (72%). Preoperative imaging mentioned "neoplasm" in 14 (47%) and carcinoma was a differential in 6 (19%) but only 2 proved to have carcinoma. Microscopically, only 47% demonstrated diffuse OS (>75% of the cyst wall/lining); OS was often focal. The cyst lining was often composed of non-mucinous biliary epithelium, and this was predominant in 50% of the cases. Degenerative changes of variable amount were seen in most cases. In situ and invasive carcinoma was seen in only 2 cases (6%), both with small invasion (7 and 8 mm). Five cases had persistence/recurrence, 2 confirmed operatively (at 7 mo and 15 y). Of the 2 cases with carcinoma, one had "residual cyst or hematoma" by radiology at 4 months, and the other was without disease at 3 years. In conclusion, many cysts (25%) previously reported as hepatobiliary cystadenoma/cystadenocarcinoma are not MCNs. True MCNs are uncommon among resected hepatic cysts (11%), occur exclusively in females, are large, mostly intrahepatic and in the left lobe (72%). Invasive carcinomas are small and uncommon (6%) compared with their pancreatic counterpart (16%). Recurrences are not uncommon following incomplete excision.	[Quigley, Brian; Reid, Michelle D.; Pehlivanoglu, Burcin; Xue, Yue; Akkas, Gizem; Muraki, Takashi; Krasinskas, Alyssa] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; [Squires, Malcolm H., III; Maithel, Shishir; Kooby, David A.; Sarmiento, Juan M.; Cardona, Ken] Emory Univ, Sch Med, Dept Surg, Atlanta, GA 30322 USA; [Sekhar, Aarti] Emory Univ, Sch Med, Dept Radiol, Atlanta, GA 30322 USA; [Hyejeong, Choi] Ulsan Univ, Coll Med, Dept Pathol, Ulsan, South Korea; [Adsay, Volkan] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA	Adsay, V (reprint author), Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA.	nadsay@mcw.edu	Adsay, Volkan/N-7130-2017	Adsay, Volkan/0000-0002-1308-3701			Adsay NV, 1996, AM J SURG PATHOL, V20, P980, DOI 10.1097/00000478-199608000-00007; Adsay NV, 2010, PATHOLOGY GENETICS T, V1, P304; Adsay V, 2016, ANN SURG, V263, P162, DOI 10.1097/SLA.0000000000001173; Albores-Saavedra J, 2015, ANN DIAGN PATHOL, V19, P124, DOI 10.1016/j.anndiagpath.2015.03.001; Albores-Saavedra J, 2013, AM J CLIN PATHOL, V139, P599, DOI 10.1309/AJCPHSV7TV2WOJFE; Arnaoutakis DJ, 2015, ANN SURG, V261, P361, DOI 10.1097/SLA.0000000000000543; Basturk O, 2017, AM J SURG PATHOL, V41, P313, DOI 10.1097/PAS.0000000000000782; Basturk O, 2015, AM J SURG PATHOL, V39, P1730, DOI 10.1097/PAS.0000000000000533; Bosman FT, 2010, WHO CLASSIFICATION T; BUETOW PC, 1995, RADIOLOGY, V196, P805, DOI 10.1148/radiology.196.3.7644647; Crippa S, 2008, ANN SURG, V247, P571, DOI 10.1097/SLA.0b013e31811f4449; DEVANEY K, 1994, AM J SURG PATHOL, V18, P1078, DOI 10.1097/00000478-199411000-00002; Furukawa T, 2005, VIRCHOWS ARCH, V447, P794, DOI 10.1007/s00428-005-0039-7; Goh BKP, 2006, WORLD J SURG, V30, P2236, DOI 10.1007/s00268-006-0126-1; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; Hruban RH, 2007, TUMORS PANCREAS; Jang KT, 2015, AM J SURG PATHOL, V39, P179, DOI 10.1097/PAS.0000000000000357; Kloppel G, 2014, SEMIN DIAGN PATHOL, V31, P452, DOI 10.1053/j.semdp.2014.08.005; Krasinskas AM, 2017, AM J SURG PATHOL, V41, P121, DOI 10.1097/PAS.0000000000000750; Lewin M, 2006, EUR RADIOL, V16, P407, DOI 10.1007/s00330-005-2822-x; Lewis GH, 2013, AM J SURG PATHOL, V37, P601, DOI 10.1097/PAS.0b013e318273f3b0; Ohhashi K, 1982, PROG DIG ENDOSC, V20, P348; Reid MD, 2014, SEMIN DIAGN PATHOL, V31, P475, DOI 10.1053/j.semdp.2014.08.009; Rocha FG, 2012, HEPATOLOGY, V56, P1352, DOI 10.1002/hep.25786; Takano Y, 2015, CLIN J GASTROENTEROL, V8, P148, DOI 10.1007/s12328-015-0569-8; Thompson LDR, 1999, AM J SURG PATHOL, V23, P1, DOI 10.1097/00000478-199901000-00001; Wilentz RE, 1999, AM J SURG PATHOL, V23, P1320, DOI 10.1097/00000478-199911000-00002; Wilentz RE, 2000, SEMIN DIAGN PATHOL, V17, P31; Yamao K, 2011, PANCREAS, V40, P67, DOI 10.1097/MPA.0b013e3181f749d3; Zamboni G, 1999, AM J SURG PATHOL, V23, P410, DOI 10.1097/00000478-199904000-00005; Zen Y, 2007, MODERN PATHOL, V20, P701, DOI 10.1038/modpathol.3800788; Zen Y, 2014, HISTOPATHOLOGY, V65, P164, DOI 10.1111/his.12378; Zhelnin K, 2017, AM J SURG PATHOL, V41, P116, DOI 10.1097/PAS.0000000000000745	34	4	6	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0147-5185	1532-0979		AM J SURG PATHOL	Am. J. Surg. Pathol.	JAN	2018	42	1					95	102		10.1097/PAS.0000000000000963			8	Pathology; Surgery	Pathology; Surgery	FR0AB	WOS:000418722200012	29016404				2019-10-28	
S	Najor, NA	Galli, SJ	Abbas, AK; Aster, JC		Najor, Nicole A.	Galli, SJ		Desmosomes in Human Disease	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						desmosomal cadherins; armadillo proteins; plakin proteins; desmosomal diseases	AUTOSOMAL RECESSIVE HYPOTRICHOSIS; PEMPHIGUS-VULGARIS ANTIGEN; RIGHT-VENTRICULAR CARDIOMYOPATHY; RECURRENT INTRAGENIC DELETION; E-CADHERIN EXPRESSION; AMINO-ACID-SEQUENCE; PALMOPLANTAR KERATODERMA; DESMOGLEIN-4 GENE; SKIN FRAGILITY; WOOLLY HAIR	Tissue integrity is crucial for maintaining the homeostasis of living organisms. Abnormalities that affect sites of cell-cell contact can cause a variety of debilitating disorders. The desmosome is an essential cell-cell junctional protein complex in tissues that undergo stress, and it orchestrates intracellular signal transduction. Desmosome assembly and junctional integrity are required to maintain the overall homeostasis of a tissue, organ, and organism. This review discusses the desmosome and the human diseases associated with its disruption.	[Najor, Nicole A.] Univ Detroit Mercy, Dept Biol, Detroit, MI 48221 USA	Najor, NA (reprint author), Univ Detroit Mercy, Dept Biol, Detroit, MI 48221 USA.	najorn@udmercy.edu					Al-Amoudi A, 2008, BIOCHEM SOC T, V36, P181, DOI 10.1042/BST0360181; Al-Owain M, 2011, CLIN GENET, V80, P50, DOI 10.1111/j.1399-0004.2010.01518.x; Amagai M, 2000, NAT MED, V6, P1275; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 2003, J AM ACAD DERMATOL, V48, P244, DOI 10.1067/mjd.2003.7; AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Amagai M, 1996, Adv Dermatol, V11, P319; Amagai M, 1999, J DERMATOL SCI, V20, P92, DOI 10.1016/S0923-1811(99)00016-X; Amagai Masayuki, 2002, Keio Journal of Medicine, V51, P133; Amagai M, 2009, VET DERMATOL, V20, P308, DOI 10.1111/j.1365-3164.2009.00831.x; ANGST BD, 1990, J CELL SCI, V97, P247; Asimaki A, 2007, AM J HUM GENET, V81, P964, DOI 10.1086/521633; Awad MM, 2008, NAT CLIN PRACT CARD, V5, P258, DOI 10.1038/ncpcardio1182; Awad MM, 2006, AM J HUM GENET, V79, P136, DOI 10.1086/504393; Ayub M, 2009, AM J HUM GENET, V85, P515, DOI 10.1016/j.ajhg.2009.08.015; BEUTNER EH, 1964, P SOC EXP BIOL MED, V117, P505; Bizzozero G., 1905, OPERE SCI 1862 1896; Bolling MC, 2010, BRIT J DERMATOL, V162, P1388, DOI 10.1111/j.1365-2133.2010.09668.x; Bornslaeger EA, 1996, J CELL BIOL, V134, P985, DOI 10.1083/jcb.134.4.985; Bremnes RM, 2002, J CLIN ONCOL, V20, P2417, DOI 10.1200/JCO.2002.08.159; Brennan D, 2007, J CELL SCI, V120, P758, DOI 10.1242/jcs.03392; Brennan D, 2009, CELL ADHES MIGR, V3, P148, DOI 10.4161/cam.3.2.7539; Breuninger S, 2010, AM J PATHOL, V176, P2509, DOI 10.2353/ajpath.2010.090737; Broussard JA, 2015, CELL TISSUE RES, V360, P501, DOI 10.1007/s00441-015-2136-5; Bryant DM, 2004, TRENDS CELL BIOL, V14, P427, DOI 10.1016/j.tcb.2004.07.007; Burdett IDJ, 2002, EXP CELL RES, V276, P296, DOI 10.1006/excr.2002.5509; Cabral RM, 2010, J INVEST DERMATOL, V130, P1543, DOI 10.1038/jid.2010.7; Calkins Catharine C, 2007, J Invest Dermatol, V127 Suppl 3, pE2, DOI 10.1038/sj.skinbio.6250010; Carvajal-Huerta L, 1998, J AM ACAD DERMATOL, V39, P418, DOI 10.1016/S0190-9622(98)70317-2; Chan PT, 2010, BRIT J DERMATOL, V162, P1242, DOI 10.1111/j.1365-2133.2010.09696.x; Chen SN, 2014, CIRC RES, V114, P454, DOI 10.1161/CIRCRESAHA.114.302810; Chen YJ, 2007, ONCOGENE, V26, P467, DOI 10.1038/sj.onc.1209802; Chidgey M, 2001, J CELL BIOL, V155, P821, DOI 10.1083/jcb.200105009; Chitaev NA, 1997, J CELL BIOL, V138, P193, DOI 10.1083/jcb.138.1.193; Choi HJ, 2005, J MOL BIOL, V346, P367, DOI 10.1016/j.jmb.2004.11.048; Chun MGH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001120; Cirillo N, 2014, CELL COMMUN ADHES, V21, P85, DOI 10.3109/15419061.2013.863281; COLLINS JE, 1991, J CELL BIOL, V113, P381, DOI 10.1083/jcb.113.2.381; Delva E, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002543; Demirag GG, 2012, MED ONCOL, V29, P1518, DOI 10.1007/s12032-011-0071-1; Ding X, 1997, J INVEST DERMATOL, V109, P592, DOI 10.1111/1523-1747.ep12337524; Dua-Awereh MB, 2009, J DERMATOL SCI, V53, P192, DOI 10.1016/j.jdermsci.2008.11.005; Dusek RL, 2011, NAT REV CANCER, V11, P317, DOI 10.1038/nrc3051; Elias PM, 2001, J CELL BIOL, V153, P243, DOI 10.1083/jcb.153.2.243; Ersoy-Evans S, 2006, J AM ACAD DERMATOL, V55, P157, DOI 10.1016/j.jaad.2005.10.002; EYRE RW, 1988, J CLIN INVEST, V81, P807, DOI 10.1172/JCI113387; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Fidler LM, 2009, J CELL MOL MED, V13, P4219, DOI 10.1111/j.1582-4934.2008.00438.x; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Furukawa C, 2005, CANCER RES, V65, P7102, DOI 10.1158/0008-5472.CAN-04-1877; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Galoian K, 2015, MOL CLIN ONCOL, V3, P171, DOI 10.3892/mco.2014.445; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Gloushankova NA, 2003, CELL TISSUE RES, V314, P399, DOI 10.1007/s00441-003-0812-3; Godsel LM, 2010, MOL BIOL CELL, V21, P2844, DOI 10.1091/mbc.E10-02-0131; Godsel LM, 2005, J CELL BIOL, V171, P1045, DOI 10.1083/jcb.200510038; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Harmon RM, 2013, CELL COMMUN ADHES, V20, P171, DOI 10.3109/15419061.2013.855204; Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220; Harris TM, 2015, ARCH PATHOL LAB MED, V139, P494, DOI 10.5858/arpa.2014-0131-OA; Has C, 2015, BRIT J DERMATOL, V172, P257, DOI 10.1111/bjd.13247; HASHIMOTO T, 1990, J INVEST DERMATOL, V94, P327, DOI 10.1111/1523-1747.ep12874456; Hatzfeld M, 2014, CELL COMMUN ADHES, V21, P25, DOI 10.3109/15419061.2013.876017; Hershkovitz D, 2009, CLIN EXP DERMATOL, V34, P224, DOI 10.1111/j.1365-2230.2008.02733.x; Heuser A, 2006, AM J HUM GENET, V79, P1081, DOI 10.1086/509044; Holthofer B, 2007, INT REV CYTOL, V264, P65, DOI 10.1016/S0074-7696(07)64003-0; Hunt DM, 2001, EUR J HUM GENET, V9, P197, DOI 10.1038/sj.ejhg.5200605; Johnson JL, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015297; Jonkman MF, 2005, AM J HUM GENET, V77, P653, DOI 10.1086/496901; Kamekura R, 2014, ONCOGENE, V33, P4531, DOI 10.1038/onc.2013.442; Kaz AM, 2012, GENE CHROMOSOME CANC, V51, P384, DOI 10.1002/gcc.21923; Keith D, 1999, HUM MOL GENET, V8, P143, DOI 10.1093/hmg/8.1.143; Klessner JL, 2009, MOL BIOL CELL, V20, P328, DOI 10.1091/mbc.E08-04-0356; Kljuic A, 2003, EXP DERMATOL, V12, P523, DOI 10.1034/j.1600-0625.2003.00017.x; Kljuic A, 2003, CELL, V113, P249, DOI 10.1016/S0092-8674(03)00273-3; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kowalczyk AP, 2013, PROG MOL BIOL TRANSL, V116, P95, DOI 10.1016/B978-0-12-394311-8.00005-4; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; Kundu ST, 2008, INT J CANCER, V123, P2303, DOI 10.1002/ijc.23797; Kurzen H, 2003, J CUTAN PATHOL, V30, P621, DOI 10.1034/j.1600-0560.2003.00122.x; Lewis JE, 1997, J CELL BIOL, V136, P919, DOI 10.1083/jcb.136.4.919; Li JF, 2010, DERMAT RES PRACT, DOI 10.1155/2010/207835; Lombardi R, 2011, CIRC RES, V109, P1342, DOI 10.1161/CIRCRESAHA.111.255075; Lovgren ML, 2017, BRIT J DERMATOL, V176, P1345, DOI 10.1111/bjd.14973; Mahoney MG, 1999, J CLIN INVEST, V103, P461, DOI 10.1172/JCI5252; MARCUS FI, 1982, CIRCULATION, V65, P384, DOI 10.1161/01.CIR.65.2.384; MATHUR M, 1994, J BIOL CHEM, V269, P14075; Mazzarello P, 2001, NAT REV MOL CELL BIO, V2, P776, DOI 10.1038/35096085; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Merritt AJ, 2002, MOL CELL BIOL, V22, P5846, DOI 10.1128/MCB.22.16.5846-5858.2002; Moss C, 2004, J INVEST DERMATOL, V123, P607, DOI 10.1111/j.0022-202X.2004.23311.x; MUELLER H, 1983, J MOL BIOL, V163, P647, DOI 10.1016/0022-2836(83)90116-X; Najor NA, 2017, ELIFE IN PRESS; Nekrasova OE, 2013, J CELL BIOL, V201, P1085, DOI 10.1083/jcb.20110605705302013c; Neuber S, 2015, CELL TISSUE RES, V359, P799, DOI 10.1007/s00441-014-2063-x; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; Norgett EE, 2000, HUM MOL GENET, V9, P2761, DOI 10.1093/hmg/9.18.2761; Ohyama B, 2012, J INVEST DERMATOL, V132, P1158, DOI 10.1038/jid.2011.448; Papagerakis S, 2003, HUM PATHOL, V34, P565, DOI 10.1016/S0046-8177(03)00174-6; PARKER AE, 1991, J BIOL CHEM, V266, P10438; PASDAR M, 1989, J CELL BIOL, V109, P163, DOI 10.1083/jcb.109.1.163; PASDAR M, 1995, CELL MOTIL CYTOSKEL, V32, P258, DOI 10.1002/cm.970320403; Payne AS, 2004, CURR OPIN CELL BIOL, V16, P536, DOI 10.1016/j.ceb.2004.07.006; PENN EJ, 1987, J CELL BIOL, V105, P2327, DOI 10.1083/jcb.105.5.2327; Pigors M, 2011, HUM MOL GENET, V20, P1811, DOI 10.1093/hmg/ddr064; Pilichou K, 2006, CIRCULATION, V113, P1171, DOI 10.1161/CIRCULATIONAHA.105.583674; Protonotarios N, 2001, J AM ACAD DERMATOL, V44, P309, DOI 10.1067/mjd.2001.110648; Rafiq MA, 2004, J INVEST DERMATOL, V123, P247, DOI 10.1111/j.0022-202X.2004.22715.x; Rafique MA, 2003, EUR J HUM GENET, V11, P623, DOI 10.1038/sj.ejhg.5201005; Rakha EA, 2005, HISTOPATHOLOGY, V46, P685, DOI 10.1111/j.1365-2559.2005.02156.x; Rao B H, 1996, Indian Heart J, V48, P161; Resnik N, 2011, J BIOL CHEM, V286, P1499, DOI 10.1074/jbc.M110.189464; Rickman L, 1999, HUM MOL GENET, V8, P971, DOI 10.1093/hmg/8.6.971; ROH JY, 1995, J INVEST DERMATOL, V104, P720, DOI 10.1111/1523-1747.ep12606963; Samuelov L, 2013, NAT GENET, V45, P1244, DOI 10.1038/ng.2739; Schaffer JV, 2006, J INVEST DERMATOL, V126, P1286, DOI 10.1038/sj.jid.5700237; Sen-Chowdhry S, 2007, CIRCULATION, V115, P1710, DOI 10.1161/CIRCULATIONAHA.106.660241; Shimomura Y, 2006, J INVEST DERMATOL, V126, P1281, DOI 10.1038/sj.jid.5700113; SHORE EM, 1991, J BIOL CHEM, V266, P19672; Simpson MA, 2009, CARDIOLOGY, V113, P28, DOI 10.1159/000165696; Smith FJD, 2012, BRIT J DERMATOL, V166, P894, DOI 10.1111/j.1365-2133.2011.10664.x; Sobolik-Delmaire T, 2007, CELL COMMUN ADHES, V14, P99, DOI 10.1080/15419060701463082; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; Stahley SN, 2015, CELL TISSUE RES, V360, P439, DOI 10.1007/s00441-015-2155-2; Stanley JR, 2006, NEW ENGL J MED, V355, P1800, DOI 10.1056/NEJMra061111; STANLEY JR, 1982, J CLIN INVEST, V70, P281, DOI 10.1172/JCI110615; Syed SEH, 2002, BIOCHEM J, V362, P317, DOI 10.1042/0264-6021:3620317; Syrigos KN, 1995, INT J CANCER, V64, P367, DOI 10.1002/ijc.2910640603; Syrris P, 2006, AM J HUM GENET, V79, P978, DOI 10.1086/509122; Takahashi H, 2012, UROLOGY, V79, DOI 10.1016/j.urology.2011.08.049; Tanaka A, 2009, BRIT J DERMATOL, V160, P692, DOI 10.1111/j.1365-2133.2008.08900.x; TROYANOVSKY SM, 1994, J CELL BIOL, V127, P151, DOI 10.1083/jcb.127.1.151; TROYANOVSKY SM, 1994, P NATL ACAD SCI USA, V91, P10790, DOI 10.1073/pnas.91.23.10790; Tucker DK, 2014, J INVEST DERMATOL, V134, P1033, DOI 10.1038/jid.2013.401; Ullah A, 2015, CLIN EXP DERMATOL, V40, P78, DOI 10.1111/ced.12457; Uzumcu A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.032904; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Wajid M, 2007, J INVEST DERMATOL, V127, P1779, DOI 10.1038/sj.jid.5700791; Wang JM, 2015, INT J DERMATOL, V54, P1163, DOI 10.1111/ijd.12889; Waschke J, 2005, J CLIN INVEST, V115, P3157, DOI 10.1172/JCI23475; Waschke J, 2008, HISTOCHEM CELL BIOL, V130, P21, DOI 10.1007/s00418-008-0420-0; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; Whittock NV, 1999, J INVEST DERMATOL, V113, P940, DOI 10.1046/j.1523-1747.1999.00783.x; Whittock NV, 2002, J INVEST DERMATOL, V118, P232, DOI 10.1046/j.0022-202x.2001.01664.x; Wijnhoven BPL, 2005, J SURG ONCOL, V92, P116, DOI 10.1002/jso.20344; Wolf A, 2010, J CELL BIOL, V188, P463, DOI 10.1083/jcb.200908135; Wong MP, 2008, PATHOLOGY, V40, P611, DOI 10.1080/00313020802320614; Yang C, 2015, TUMOR BIOL, V36, P9567, DOI 10.1007/s13277-015-3628-3; Yang C, 2013, VIRCHOWS ARCH, V463, P379, DOI 10.1007/s00428-013-1452-y; Yang LL, 2012, CARCINOGENESIS, V33, P1863, DOI 10.1093/carcin/bgs226; Zheng Z, 1999, HUM PATHOL, V30, P458, DOI 10.1016/S0046-8177(99)90123-5	155	8	8	0	4	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						51	70		10.1146/annurev-pathol-020117-044030			20	Pathology	Pathology	BJ3ZK	WOS:000424631200003	29414250				2019-10-28	
S	Riggi, N; Aguet, M; Stamenkovic, I	Galli, SJ	Abbas, AK; Aster, JC		Riggi, Nicolo; Aguet, Michel; Stamenkovic, Ivan	Galli, SJ		Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						metastasis; mechanisms; stroma; dormancy; CTC; colonization	CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FOCAL ADHESION KINASE; BREAST-CANCER; STEM-CELLS; LUNG METASTASIS; EARLY DISSEMINATION; DISTANT METASTASIS; MYELOMA CELLS; E-CADHERIN	Metastases are responsible for the vast majority of cancer-related deaths, but, despite intense efforts to understand their underlying mechanisms with the goal of uncovering effective therapeutic targets, treatment of metastatic cancer has progressed minimally. In this review, we examine the biological programs currently proposed to be key drivers of metastasis. On the basis of evidence from a growing body of research, we discuss to what extent the cellular and molecular mechanisms that are suggested to underlie cancer cell dissemination are specific to the metastatic process, as opposed to representing natural primary tumor progression. Our review highlights the contrast between the abundance of insight gained into the events that constitute the metastatic cascade and the paucity of therapeutic options.	[Riggi, Nicolo; Aguet, Michel; Stamenkovic, Ivan] Univ Lausanne, Ctr Hosp Univ Vaudois, Expt Pathol Serv, CH-1005 Lausanne, Switzerland	Stamenkovic, I (reprint author), Univ Lausanne, Ctr Hosp Univ Vaudois, Expt Pathol Serv, CH-1005 Lausanne, Switzerland.	Ivan.Stamenkovic@chuv.ch					Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Affara Nesrine I., 2009, V539, P1, DOI 10.1007/978-1-60327-003-8_1; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Al-Mehdi AB, 2000, NAT MED, V6, P100, DOI 10.1038/71429; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Beck B, 2015, CELL STEM CELL, V16, P67, DOI 10.1016/j.stem.2014.12.002; Ben-Baruch A, 2008, CLIN EXP METASTAS, V25, P345, DOI 10.1007/s10585-007-9097-3; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Biancone L, 1996, J EXP MED, V183, P581, DOI 10.1084/jem.183.2.581; Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; Cedervall J, 2016, CANCER RES, V76, P4311, DOI 10.1158/0008-5472.CAN-15-3051; Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chang CC, 2013, CANCER RES, V73, P4147, DOI 10.1158/0008-5472.CAN-12-4085; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chung YC, 2016, EUR J CLIN INVEST, V46, P1002, DOI 10.1111/eci.12683; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Corey E, 2005, CANCER RES, V65, P1710, DOI 10.1158/0008-5472.CAN-04-2033; Corey E, 2003, CLIN CANCER RES, V9, P295; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44; Diaz-Lopez A, 2014, CANCER MANAG RES, V6, P205, DOI 10.2147/CMAR.S38156; Drasin DJ, 2015, CANCER RES, V75, P1908, DOI 10.1158/0008-5472.CAN-14-2394; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; FIDLER IJ, 1973, NATURE-NEW BIOL, V242, P148; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gong L, 2012, PATHOL ONCOL RES, V18, P989, DOI 10.1007/s12253-012-9531-y; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P3725, DOI 10.1073/pnas.1100446108; Hodgkinson CL, 2014, NAT MED, V20, P897, DOI 10.1038/nm.3600; Holien T, 2014, CYTOKINE GROWTH F R, V25, P343, DOI 10.1016/j.cytogfr.2014.04.009; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Huang RYJ, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.442; Huh SJ, 2010, CANCER RES, V70, P6071, DOI 10.1158/0008-5472.CAN-09-4442; Hwang WL, 2014, NAT CELL BIOL, V16, P268, DOI 10.1038/ncb2910; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Joosse SA, 2015, EMBO MOL MED, V7, P1, DOI 10.15252/emmm.201303698; Jordan NV, 2011, CELL CYCLE, V10, P2865, DOI 10.4161/cc.10.17.17188; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Karadag A, 2000, BRIT J HAEMATOL, V108, P383; Karrison TG, 1999, JNCI-J NATL CANCER I, V91, P80, DOI 10.1093/jnci/91.1.80; Khoo BL, 2015, ONCOTARGET, V6, P15578; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kohler S, 2010, BRIT J CANCER, V102, P602, DOI 10.1038/sj.bjc.6605492; Kopp HG, 2009, CANCER RES, V69, P7775, DOI 10.1158/0008-5472.CAN-09-2123; Kowanetz M, 2010, P NATL ACAD SCI USA, V107, P21248, DOI 10.1073/pnas.1015855107; KOZLOWSKI JM, 1984, J NATL CANCER I, V72, P913; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Labelle M, 2012, CANCER DISCOV, V2, P1091, DOI 10.1158/2159-8290.CD-12-0329; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lamouille S, 2013, CURR OPIN CELL BIOL, V25, P200, DOI 10.1016/j.ceb.2013.01.008; Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983; Li X, 2008, BLOOD, V112, P159, DOI 10.1182/blood-2007-11-124164; Liu YF, 2016, CANCER CELL, V30, P243, DOI 10.1016/j.ccell.2016.06.021; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Lovisa S, 2015, NAT MED, V21, P998, DOI 10.1038/nm.3902; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Maheswaran S, 2015, CANCER RES, V75, P2411, DOI 10.1158/0008-5472.CAN-15-0145; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Martin YD, 2015, CELL REP, V13, P2456, DOI 10.1016/j.celrep.2015.11.025; Mauti LA, 2011, J CLIN INVEST, V121, P2794, DOI 10.1172/JCI41936; Mayor R, 2016, NAT REV MOL CELL BIO, V17, P97, DOI 10.1038/nrm.2015.14; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI [10.1016/j.semedb.2015.02.010, 10.1016/j.semcdb.2015.02.010]; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Naxerova K, 2015, NAT REV CLIN ONCOL, V12, P258, DOI 10.1038/nrclinonc.2014.238; Nieto M. A., 2016, CELL, V166; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Ooi LL, 2010, CANCER RES, V70, P1835, DOI 10.1158/0008-5472.CAN-09-3194; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Palumbo JS, 2005, BLOOD, V105, P178, DOI 10.1182/blood-2004-06-2272; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Revenu C, 2009, CURR OPIN GENET DEV, V19, P338, DOI 10.1016/j.gde.2009.04.007; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792; Talmadge JE, 2007, CANCER RES, V67, P11471, DOI 10.1158/0008-5472.CAN-07-2496; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; TALMADGE JE, 1982, SCIENCE, V217, P361, DOI 10.1126/science.6953592; Teicher BA, 2010, CLIN CANCER RES, V16, P2927; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784; van 't Veer LJ, 2002, BREAST CANCER RES, V5, P57, DOI 10.1186/bcr562; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Veracini L, 2015, ONCOTARGET, V6, P7570, DOI 10.18632/oncotarget.3071; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Voon DCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070427; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Westcott JM, 2015, J CLIN INVEST, V125, P1927, DOI 10.1172/JCI77767; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Wu QD, 2001, AM J PHYSIOL-CELL PH, V280, pC814; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yakushiji Satomi, 2006, Int J Clin Oncol, V11, P421, DOI 10.1007/s10147-006-0599-9; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021; Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309; Yu Z, 2008, CLIN EXP METASTAS, V25, P559, DOI 10.1007/s10585-008-9172-4; Zhang LX, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005109; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064; Zheng Y, 2011, PROSTATE, V71, P1012, DOI 10.1002/pros.21316	150	15	15	4	18	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						117	140		10.1146/annurev-pathol-020117-044127			24	Pathology	Pathology	BJ3ZK	WOS:000424631200006	29068753				2019-10-28	
S	Giordano, TJ	Galli, SJ	Abbas, AK; Aster, JC		Giordano, Thomas J.	Galli, SJ		Genomic Hallmarks of Thyroid Neoplasia	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						cancer genome; thyroid cancer; mutation; papillary carcinoma; follicular carcinoma; anaplastic carcinoma	TERT PROMOTER MUTATIONS; TALL CELL VARIANT; ENCAPSULATED FOLLICULAR VARIANT; BRAF MUTATIONS; GENETIC ALTERATIONS; PAPILLARY CARCINOMA; FUSION ONCOGENES; RAS MUTATION; MOLECULAR CLASSIFICATION; PROGNOSTIC IMPLICATIONS	The genomic landscape of thyroid cancers that are derived from follicular cells has been substantially elucidated through the coordinated application of high-throughput genomic technologies. Here, I review the common genetic alterations across the spectrum of thyroid neoplasia and present the resulting model of thyroid cancer initiation and progression. This model illustrates the striking correlation between tumor differentiation and overall somatic mutational burden, which also likely explains the highly variable clinical behavior and outcome of patients with thyroid cancers. These advances are yielding critical insights into thyroid cancer pathogenesis, which are being leveraged for the development of new diagnostic tools, prognostic and predictive biomarkers, and novel therapeutic approaches.	[Giordano, Thomas J.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA; [Giordano, Thomas J.] Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA	Giordano, TJ (reprint author), Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Pathol, Ann Arbor, MI 48109 USA.; Giordano, TJ (reprint author), Univ Michigan, Sch Med, Ctr Comprehens Canc, Dept Internal Med, Ann Arbor, MI 48109 USA.	giordano@umich.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA046592]		Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b; Afkhami M, 2016, THYROID, V26, P242, DOI 10.1089/thy.2015.0227; Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Alexander EK, 2012, NEW ENGL J MED, V367, P705, DOI 10.1056/NEJMoa1203208; Berho M, 1997, HUM PATHOL, V28, P47, DOI 10.1016/S0046-8177(97)90278-1; Bishop JA, 2011, HUM PATHOL, V42, P1873, DOI 10.1016/j.humpath.2011.02.004; Brito JP, 2017, NAT REV ENDOCRINOL, V13, DOI 10.1038/nrendo.2016.224; Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625; Cameselle-Teijeiro J, 1999, MODERN PATHOL, V12, P400; CARCANGIU ML, 1989, AM J SURG PATHOL, V13, P1041, DOI 10.1097/00000478-198912000-00006; CARCANGIU ML, 1984, AM J SURG PATHOL, V8, P655, DOI 10.1097/00000478-198409000-00005; Chen JH, 2011, MODERN PATHOL, V24, P739, DOI 10.1038/modpathol.2011.2; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Chia WK, 2010, CANCER GENET CYTOGEN, V196, P7, DOI 10.1016/j.cancergencyto.2009.08.001; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies L, 2015, ENDOCR PRACT, V21, P686, DOI 10.4158/EP14466.DSCR; Dean DS, 2008, BEST PRACT RES CL EN, V22, P901, DOI 10.1016/j.beem.2008.09.019; Di Cristofaro J, 2006, HUM PATHOL, V37, P824, DOI 10.1016/j.humpath.2006.01.030; Donatini G, 2016, J ENDOCRINOL INVEST, V39, P153, DOI 10.1007/s40618-015-0356-x; Enewold L, 2009, CANCER EPIDEM BIOMAR, V18, P784, DOI 10.1158/1055-9965.EPI-08-0960; Esapa CT, 1999, CLIN ENDOCRINOL, V50, P529, DOI 10.1046/j.1365-2265.1999.00704.x; Esserman LJ, 2014, LANCET ONCOL, V15, pE234, DOI 10.1016/S1470-2045(13)70598-9; Fagin JA, 2016, NEW ENGL J MED, V375, P1054, DOI 10.1056/NEJMra1501993; Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010; Fredriksson NJ, 2014, NAT GENET, V46, P1258, DOI 10.1038/ng.3141; French CA, 2003, AM J PATHOL, V162, P1053, DOI 10.1016/S0002-9440(10)63902-8; Fugazzola L, 2006, ENDOCR-RELAT CANCER, V13, P455, DOI 10.1677/erc.1.01086; GAERTNER EM, 1995, AM J SURG PATHOL, V19, P940, DOI 10.1097/00000478-199508000-00010; Ganly I, 2014, THYROID, V24, P662, DOI 10.1089/thy.2013.0503; Ganly I, 2013, J CLIN ENDOCR METAB, V98, pE962, DOI 10.1210/jc.2012-3539; Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330; Gasparre G, 2007, P NATL ACAD SCI USA, V104, P9001, DOI 10.1073/pnas.0703056104; Ghossein R, 2008, THYROID, V18, P1179, DOI 10.1089/thy.2008.0164; Ghossein RA, 2007, THYROID, V17, P655, DOI 10.1089/thy.2007.0061; Giordano TJ, 2005, ONCOGENE, V24, P6646, DOI 10.1038/sj.onc.1208822; Giordano TJ, 2006, CLIN CANCER RES, V12, P1983, DOI 10.1158/1078-0432.CCR-05-2039; Greco A, 2010, MOL CELL ENDOCRINOL, V321, P44, DOI 10.1016/j.mce.2009.10.009; Halachmi N, 1998, GENE CHROMOSOME CANC, V23, P239, DOI 10.1002/(SICI)1098-2264(199811)23:3<239::AID-GCC5>3.0.CO;2-2; HARACH HR, 1994, HISTOPATHOLOGY, V25, P549, DOI 10.1111/j.1365-2559.1994.tb01374.x; Haugen BR, 2017, THYROID, V27, P481, DOI 10.1089/thy.2016.0628; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Hemmer S, 1998, BRIT J CANCER, V78, P1012, DOI 10.1038/bjc.1998.620; Hiltzik D, 2006, CANCER-AM CANCER SOC, V106, P1286, DOI 10.1002/cncr.21739; Howitt BE, 2015, HISTOPATHOLOGY, V67, P579, DOI 10.1111/his.12680; Vuong HG, 2016, CANCER MED-US, V5, P1883, DOI 10.1002/cam4.781; Hyman DM, 2017, CELL, V168, P584, DOI 10.1016/j.cell.2016.12.015; Iglesias ML, 2017, ARCH ENDOCRIN METAB, V61, P180, DOI 10.1590/2359-3997000000257; Jeong SH, 2015, J ENDOCRINOL INVEST, V38, P849, DOI 10.1007/s40618-015-0311-x; JOHNSON TL, 1988, AM J SURG PATHOL, V12, P22, DOI 10.1097/00000478-198801000-00003; Karunamurthy A, 2016, ENDOCR-RELAT CANCER, V23, P295, DOI 10.1530/ERC-16-0043; Kasaian K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1955-9; Kasaian K, 2015, J CLIN ENDOCR METAB, V100, pE611, DOI 10.1210/jc.2014-3622; Kelly LM, 2014, P NATL ACAD SCI USA, V111, P4233, DOI 10.1073/pnas.1321937111; Kimura ET, 2003, CANCER RES, V63, P1454; Kitahara CM, 2016, NAT REV ENDOCRINOL, V12, P646, DOI 10.1038/nrendo.2016.110; Klemke M, 2011, CANCER GENET-NY, V204, P334, DOI 10.1016/j.cancergen.2011.05.001; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Kumagai A, 2004, J CLIN ENDOCR METAB, V89, P4280, DOI 10.1210/jc.2004-0172; Kumar-Sinha C, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0252-1; Kunstman JW, 2015, HUM MOL GENET, V24, P2318, DOI 10.1093/hmg/ddu749; Kurelac I, 2015, AM J CANCER RES, V5, P1954; La Vecchia C, 2015, INT J CANCER, V136, P2187, DOI 10.1002/ijc.29251; Lam AKY, 2017, ENDOCR-RELAT CANCER, V24, pR109, DOI 10.1530/ERC-17-0014; Lancia I, 2016, J CLIN INVEST, V126, P1052, DOI 10.1172/JCI85271; Landa I, 2013, J CLIN ENDOCR METAB, V98, pE1562, DOI 10.1210/jc.2013-2383; Leeman-Neill RJ, 2014, CANCER-AM CANCER SOC, V120, P799, DOI 10.1002/cncr.28484; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lima J, 2004, J CLIN ENDOCR METAB, V89, P4267, DOI 10.1210/jc.2003-032224; Liu T, 2014, ONCOGENE, V33, P4978, DOI 10.1038/onc.2013.446; Liu XL, 2014, J CLIN ENDOCR METAB, V99, pE1130, DOI 10.1210/jc.2013-4048; Liu XL, 2013, ENDOCR-RELAT CANCER, V20, P603, DOI 10.1530/ERC-13-0210; Liu ZM, 2017, ONCOTARGET, V8, P6222, DOI 10.18632/oncotarget.14055; Liu Z, 2008, J CLIN ENDOCR METAB, V93, P3106, DOI 10.1210/jc.2008-0273; Lloyd RV, 2011, HEAD NECK PATHOL, V5, P51, DOI 10.1007/s12105-010-0236-9; Lubitz CC, 2014, THYROID, V24, P958, DOI 10.1089/thy.2013.0573; Lui WO, 2008, CANCER RES, V68, P7156, DOI 10.1158/0008-5472.CAN-08-1085; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Martin M, 2013, NAT GENET, V45, P933, DOI 10.1038/ng.2674; McFadden DG, 2014, J CLIN ENDOCR METAB, V99, pE2457, DOI 10.1210/jc.2014-2611; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Melo M, 2014, J CLIN ENDOCR METAB, V99, pE754, DOI 10.1210/jc.2013-3734; Mertens F, 2015, NAT REV CANCER, V15, P371, DOI 10.1038/nrc3947; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Miura D, 2003, THYROID, V13, P283, DOI 10.1089/105072503321582097; Moon S, 2017, THYROID, V27, P651, DOI 10.1089/thy.2016.0350; Nikiforov YE, 2001, AM J SURG PATHOL, V25, P1478, DOI 10.1097/00000478-200112000-00002; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nikiforov YE, 2015, THYROID, V25, P1217, DOI 10.1089/thy.2015.0305; Nikiforov YE, 2014, CANCER-AM CANCER SOC, V120, P3627, DOI 10.1002/cncr.29038; Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2004, CANCER LETT, V209, P1, DOI 10.1016/j.canlet.2003.12.004; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; OYAMA T, 1995, PATHOL INT, V45, P45, DOI 10.1111/j.1440-1827.1995.tb03378.x; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; PAPOTTI M, 1993, AM J SURG PATHOL, V17, P291, DOI 10.1097/00000478-199303000-00010; Parshad R, 2001, CRIT REV ONCOL HEMAT, V37, P87, DOI 10.1016/S1040-8428(00)00111-6; Paulson VA, 2017, THYROID, V27, P506, DOI 10.1089/thy.2016.0583; Penko K, 2005, THYROID, V15, P320, DOI 10.1089/thy.2005.15.320; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Pinto AE, 2008, ONCOL REP, V20, P913, DOI 10.3892/or_00000091; POLEEV A, 1992, DEVELOPMENT, V116, P611; Prasad ML, 2016, CANCER-AM CANCER SOC, V122, P1097, DOI 10.1002/cncr.29887; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Raman P, 2014, NAT REV ENDOCRINOL, V10, P616, DOI 10.1038/nrendo.2014.115; Ricarte JC, 2013, J CLIN INVEST, V123, P4935, DOI 10.1172/JCI69766; Ritterhouse LL, 2016, THYROID, V26, P794, DOI 10.1089/thy.2016.0101; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; Rogue L, 1998, GENE CHROMOSOME CANC, V21, P250; Romei C, 2016, NAT REV ENDOCRINOL, V12, P192, DOI 10.1038/nrendo.2016.11; Roque L, 2003, GENE CHROMOSOME CANC, V36, P292, DOI 10.1002/gcc.10146; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Rossi ED, 2017, ONCOTARGET, V8, P3746, DOI 10.18632/oncotarget.12564; Sadow Peter M, 2012, Front Endocrinol (Lausanne), V3, P77, DOI 10.3389/fendo.2012.00077; Sahin M, 2005, J CLIN ENDOCR METAB, V90, P463, DOI 10.1210/jc.2004-1203; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Shen XP, 2017, ENDOCR-RELAT CANCER, V24, P41, DOI 10.1530/ERC-16-0402; Soares P, 2003, ONCOGENE, V22, P4578, DOI 10.1038/sj.onc.1206706; SPIRES JR, 1988, ARCH OTOLARYNGOL, V114, P40; Tachibana K, 2008, PPAR RES, DOI 10.1155/2008/102737; Tallini G, 1999, LAB INVEST, V79, P547; Tallini G, 2011, ENDOCR PATHOL, V22, P190, DOI 10.1007/s12022-011-9176-5; Torregrossa L, 2016, J CLIN ENDOCR METAB, V101, P4413, DOI 10.1210/jc.2016-1775; Trovisco V, 2005, VIRCHOWS ARCH, V446, P589, DOI 10.1007/s00428-005-1236-0; Trovisco V, 2004, J PATHOL, V202, P247, DOI 10.1002/path.1511; Tufano RP, 2012, MEDICINE, V91, P274, DOI 10.1097/MD.0b013e31826a9c71; Valderrabano P, 2017, ENDOCR-RELAT CANCER, V24, P127, DOI 10.1530/ERC-16-0512; Vasko V, 2003, J CLIN ENDOCR METAB, V88, P2745, DOI 10.1210/jc.2002-021186; Cordioli MICV, 2017, THYROID, V27, P182, DOI 10.1089/thy.2016.0387; Vigneri R, 2015, CURR OPIN ONCOL, V27, P1, DOI 10.1097/CCO.0000000000000148; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Wada N, 2002, J CLIN ENDOCR METAB, V87, P4595, DOI 10.1210/jc.2002-020339; Wang N, 2014, CANCER-AM CANCER SOC, V120, P2965, DOI 10.1002/cncr.28800; Ward LS, 1998, J CLIN ENDOCR METAB, V83, P525, DOI 10.1210/jc.83.2.525; Wei SZ, 2015, ENDOCR PATHOL, V26, P365, DOI 10.1007/s12022-015-9403-6; Weir B, 2004, CANCER CELL, V6, P433, DOI 10.1016/j.ccr.2004.11.004; Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; Wylie D, 2016, J PATHOL CLIN RES, V2, P93, DOI 10.1002/cjp2.38; Xing MZ, 2010, THYROID, V20, P697, DOI 10.1089/thy.2010.1646; Xu B, 2015, ENDOCR PATHOL, V26, P191, DOI 10.1007/s12022-015-9376-5; Yang SP, 2016, ENDOCR-RELAT CANCER, V23, pR577, DOI 10.1530/ERC-16-0067; Yang X, 2017, J NUCL MED, V58, P258, DOI 10.2967/jnumed.116.180240; Yin DT, 2016, CLIN ENDOCRINOL, V85, P299, DOI 10.1111/cen.13017; Yip L, 2015, ANN SURG, V262, P519, DOI 10.1097/SLA.0000000000001420; Yoo SK, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006239; Zhang YX, 2017, ONCOTARGET, V8, P5761, DOI 10.18632/oncotarget.14050; Zhang Y, 2016, SKELET MUSCLE, V6, DOI 10.1186/s13395-016-0080-z; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	149	9	10	0	7	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						141	162		10.1146/annurev-pathol-121808-102139			22	Pathology	Pathology	BJ3ZK	WOS:000424631200007	29083981				2019-10-28	
S	Arab, JP; Arrese, M; Trauner, M	Galli, SJ	Abbas, AK; Aster, JC		Arab, Juan Pablo; Arrese, Marco; Trauner, Michael	Galli, SJ		Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						nonalcoholic fatty liver; steatosis; insulin resistance; cirrhosis; fibrosis; pathogenesis; nonalcoholic steatohepatitis; NAFLD; NASH	HEPATIC STELLATE CELLS; DE-NOVO LIPOGENESIS; PATTERN-RECOGNITION RECEPTORS; FREE-CHOLESTEROL ACCUMULATION; INSULIN-RESISTANCE; DOUBLE-BLIND; BILE-ACID; HEPATOCELLULAR-CARCINOMA; NATURAL-HISTORY; GENE-EXPRESSION	Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem worldwide and an important risk factor for both hepatic and cardiometabolic mortality. The rapidly increasing prevalence of this disease and of its aggressive form nonalcoholic steatohepatitis (NASH) will require novel therapeutic approaches based on a profound understanding of its pathogenesis to halt disease progression to advanced fibrosis or cirrhosis and cancer. The pathogenesis of NAFLD involves a complex interaction among environmental factors (i.e., Western diet), obesity, changes in microbiota, and predisposing genetic variants resulting in a disturbed lipid homeostasis and an excessive accumulation of triglycerides and other lipid species in hepatocytes. Insulin resistance is a central mechanism that leads to lipotoxicity, endoplasmic reticulum stress, disturbed autophagy, and, ultimately, hepatocyte injury and death that triggers hepatic inflammation, hepatic stellate cell activation, and progressive fibrogenesis, thus driving disease progression. In the present review, we summarize the currently available data on the pathogenesis of NAFLD, emphasizing the most recent advances. A better understanding of NAFLD/NASH pathogenesis is crucial for the design of new and efficient therapeutic interventions.	[Arab, Juan Pablo; Arrese, Marco] Pontificia Univ Catolica Chile, Escuela Med, Dept Gastroenterol, Santiago 8330077, Chile; [Arab, Juan Pablo] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA; [Arrese, Marco] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Ctr Envejecimiento & Regenerac CARE, Santiago 8331150, Chile; [Trauner, Michael] Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria	Trauner, M (reprint author), Med Univ Vienna, Dept Internal Med 3, Div Gastroenterol & Hepatol, A-1090 Vienna, Austria.	michael.trauner@meduniwien.ac.at	Arab, Juan Pablo/J-5674-2019	Arab, Juan Pablo/0000-0002-8561-396X			Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Angulo P, 2015, GASTROENTEROLOGY, V149, P389, DOI 10.1053/j.gastro.2015.04.043; Anstee QM, 2013, NAT REV GASTRO HEPAT, V10, P330, DOI 10.1038/nrgastro.2013.41; Anstee QM, 2010, J HEPATOL, V53, P542, DOI 10.1016/j.jhep.2010.03.016; Arab JP, 2017, HEPATOL INT; Arab JP, 2017, HEPATOLOGY, V65, P350, DOI 10.1002/hep.28709; Arab JP, 2016, ANN HEPATOL, V15, P721, DOI 10.5604/16652681.1212434; Argo CK, 2015, J HEPATOL, V62, P190, DOI 10.1016/j.jhep.2014.08.036; Argo CK, 2009, CLIN LIVER DIS, V13, P511, DOI 10.1016/j.cld.2009.07.005; Arguello G, 2015, BBA-MOL BASIS DIS, V1852, P1765, DOI 10.1016/j.bbadis.2015.05.015; Armstrong MJ, 2016, LANCET, V387, P679, DOI 10.1016/S0140-6736(15)00803-X; Arrese M, 2016, DIGEST DIS SCI, V61, P1294, DOI 10.1007/s10620-016-4049-x; Athyros VG, 2016, J HEPATOL, V64, P241, DOI 10.1016/j.jhep.2015.09.021; Awazawa M, 2009, BIOCHEM BIOPH RES CO, V382, P51, DOI 10.1016/j.bbrc.2009.02.131; Baeck C, 2014, HEPATOLOGY, V59, P1060, DOI 10.1002/hep.26783; Baeck C, 2012, GUT, V61, P416, DOI 10.1136/gutjnl-2011-300304; Barreyro FJ, 2015, LIVER INT, V35, P953, DOI 10.1111/liv.12570; Basantani MK, 2011, J LIPID RES, V52, P318, DOI 10.1194/jlr.M011205; Bates J, 2017, J HEPATOL, V66, pS430, DOI 10.1016/S0168-8278(17)31226-6; Bechmann LP, 2010, LIVER INT, V30, P850, DOI 10.1111/j.1478-3231.2010.02248.x; Bellanti F, 2017, FREE RADICAL BIO MED, V111, P173, DOI 10.1016/j.freeradbiomed.2017.01.023; Berk PD, 2008, HEPATOLOGY, V48, P1362, DOI 10.1002/hep.22632; Berlanga A, 2014, CLIN EXP GASTROENTER, V7, P221, DOI 10.2147/CEG.S62831; Beste LA, 2015, GASTROENTEROLOGY, V149, P1471, DOI 10.1053/j.gastro.2015.07.056; Biedermann L, 2015, EUR J PEDIATR, V174, P151, DOI 10.1007/s00431-014-2476-2; Bigorgne AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151063; Bluemel S, 2016, AM J PHYSIOL-GASTR L, V311, pG1018, DOI 10.1152/ajpgi.00245.2016; Boursier J, 2016, HEPATOLOGY, V63, P764, DOI 10.1002/hep.28356; Brandl K, 2017, CURR OPIN GASTROEN, V33, P128, DOI 10.1097/MOG.0000000000000349; Brunt EM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.80; Brunt EM, 2010, NAT REV GASTRO HEPAT, V7, P195, DOI 10.1038/nrgastro.2010.21; Bruschi FV, 2017, HEPATOLOGY, V65, P1875, DOI 10.1002/hep.29041; Budhu A, 2013, GASTROENTEROLOGY, V144, P1066, DOI 10.1053/j.gastro.2013.01.054; Buzzetti E, 2016, METABOLISM, V65, P1038, DOI 10.1016/j.metabol.2015.12.012; Cai CX, 2017, DIGEST DIS SCI, V62, P968; Caligiuri A, 2008, HEPATOLOGY, V47, P668, DOI 10.1002/hep.21995; Carr RM, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-015-0500-2; Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Charlton MR, 2011, GASTROENTEROLOGY, V141, P1249, DOI 10.1053/j.gastro.2011.06.061; Chen GY, 2010, NAT REV IMMUNOL, V10, P826, DOI 10.1038/nri2873; Cheung O, 2008, HEPATOLOGY, V48, P1810, DOI 10.1002/hep.22569; Crespo J, 2001, HEPATOLOGY, V34, P1158, DOI 10.1053/jhep.2001.29628; Crispe IN, 2009, ANNU REV IMMUNOL, V27, P147, DOI 10.1146/annurev.immunol.021908.132629; Cui J, 2016, J HEPATOL, V65, P369, DOI 10.1016/j.jhep.2016.04.021; Cusi K, 2016, ANN INTERN MED, V165, P305, DOI 10.7326/M15-1774; Cusi K, 2016, DIABETOLOGIA, V59, P1112, DOI 10.1007/s00125-016-3952-1; Czaja MJ, 2016, DIGEST DIS SCI, V61, P1304, DOI 10.1007/s10620-015-4025-x; D'Incao RB, 2017, OBES SURG, V27, P2151, DOI 10.1007/s11695-017-2627-4; de Mesquita FC, 2015, HEPATOLOGY, V62, p901A; DeMinicis S, 2014, HEPATOLOGY, V59, P1738, DOI 10.1002/hep.26695; Doege H, 2008, J BIOL CHEM, V283, P22186, DOI 10.1074/jbc.M803510200; Dongiovanni P, 2015, HEPATOLOGY, V61, P506, DOI 10.1002/hep.27490; Donnelly KL, 2005, J CLIN INVEST, V115, P1343, DOI 10.1172/JCI200523621; Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938; Dyson J, 2014, J HEPATOL, V60, P110, DOI 10.1016/j.jhep.2013.08.011; EASL, 2016, DIABETOLOGIA, V59, P1121, DOI [10.1007/s00125-016-3902-y, 10.1016/j.jhep.2015.11.004]; Feldstein AE, 2003, GASTROENTEROLOGY, V125, P437, DOI 10.1016/S0016-5085(03)00907-7; Ferrebee CB, 2015, ACTA PHARM SIN B, V5, P129, DOI 10.1016/j.apsb.2015.01.001; Flechtner-Mors Marion, 2014, BMC Res Notes, V7, P207, DOI 10.1186/1756-0500-7-207; Friedman SL, 2013, NAT REV GASTRO HEPAT, V10, P71, DOI 10.1038/nrgastro.2012.256; Fuchs CD, 2016, SEMIN LIVER DIS, V36, P69, DOI 10.1055/s-0036-1571296; Gao XL, 2016, HEPATOL RES, V46, P1226, DOI 10.1111/hepr.12671; Gautheron J, 2014, EMBO MOL MED, V6, P1062, DOI 10.15252/emmm.201403856; Goh GBB, 2016, DIGEST DIS SCI, V61, P1226, DOI 10.1007/s10620-016-4095-4; Greco D, 2008, AM J PHYSIOL-GASTR L, V294, pG1281, DOI 10.1152/ajpgi.00074.2008; Guo JS, 2010, FIBROGENESIS TISSUE, V3, DOI 10.1186/1755-1536-3-21; Handa P, 2016, AM J PHYSIOL-GASTR L, V310, pG117, DOI 10.1152/ajpgi.00246.2015; Hardy T, 2016, ANNU REV PATHOL-MECH, V11, P451, DOI 10.1146/annurev-pathol-012615-044224; Haslam DB, 2017, HEPATOLOGY, V65, P401, DOI 10.1002/hep.28864; Haukeland JW, 2006, J HEPATOL, V44, P1167, DOI 10.1016/j.jhep.2006.02.011; Henao-Mejia J, 2012, NATURE, V482, P179, DOI 10.1038/nature10809; Higashi T, 2017, ADV DRUG DELIVER REV, V121, P27, DOI 10.1016/j.addr.2017.05.007; Hirsova P, 2016, HEPATOLOGY, V64, P2219, DOI 10.1002/hep.28814; Hirsova P, 2016, J LIPID RES, V57, P1758, DOI 10.1194/jlr.R066357; Hirsova P, 2015, CELL MOL GASTROENTER, V1, P17, DOI 10.1016/j.jcmgh.2014.11.005; Hoki T, 2015, HEPATOLOGY, V62, P751, DOI 10.1002/hep.27774; Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034; Hubbard B, 2006, GASTROENTEROLOGY, V130, P1259, DOI 10.1053/j.gastro.2006.02.012; Ioannou GN, 2013, J LIPID RES, V54, P1326, DOI 10.1194/jlr.M034876; Jahn D, 2015, CYTOKINE GROWTH F R, V26, P625, DOI 10.1016/j.cytogfr.2015.07.016; Jiang CT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10166; Jiang JX, 2008, HEPATOLOGY, V48, P1497, DOI 10.1002/hep.22515; Jiang JX, 2013, HEPATOLOGY, V58, P1339, DOI 10.1002/hep.26491; Kalia HS, 2016, CLIN LIVER DIS, V20, P215, DOI 10.1016/j.cld.2015.10.005; Kawano Y, 2013, J GASTROENTEROL, V48, P434, DOI 10.1007/s00535-013-0758-5; Kim KH, 2013, NAT MED, V19, P83, DOI 10.1038/nm.3014; Kirpich IA, 2015, CLIN BIOCHEM, V48, P923, DOI 10.1016/j.clinbiochem.2015.06.023; Koliaki C, 2015, CELL METAB, V21, P739, DOI 10.1016/j.cmet.2015.04.004; Kowdley KV, 2012, HEPATOLOGY, V55, P77, DOI 10.1002/hep.24706; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Kozlitina J, 2014, NAT GENET, V46, P352, DOI 10.1038/ng.2901; Kumar H, 2011, INT REV IMMUNOL, V30, P16, DOI 10.3109/08830185.2010.529976; Kumashiro N, 2011, P NATL ACAD SCI USA, V108, P16381, DOI 10.1073/pnas.1113359108; Lambert JE, 2014, GASTROENTEROLOGY, V146, P726, DOI 10.1053/j.gastro.2013.11.049; Leclercq GRI, 2001, AM J PHYSIOL-GASTR L, V281, pG1135; Leclercq IA, 2002, J HEPATOL, V37, P206, DOI 10.1016/S0168-8278(02)00102-2; Lee YA, 2015, GUT, V64, P1337, DOI 10.1136/gutjnl-2014-306842corr1; Leung C, 2016, NAT REV GASTRO HEPAT, V13, P412, DOI 10.1038/nrgastro.2016.85; Li JZ, 2012, J CLIN INVEST, V122, P4130, DOI 10.1172/JCI65179; Li ZZ, 2009, J BIOL CHEM, V284, P5637, DOI 10.1074/jbc.M807616200; Liu YL, 2014, J HEPATOL, V61, P75, DOI 10.1016/j.jhep.2014.02.030; Liu YL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5309; Loomba R, 2016, HEPATOLOGY, V64, p1119A; Loomba R, 2015, HEPATOLOGY, V61, P1239, DOI 10.1002/hep.27647; Macdonald GA, 2001, J GASTROEN HEPATOL, V16, P599, DOI 10.1046/j.1440-1746.2001.02445.x; Malhi H, 2007, GUT, V56, P1124, DOI 10.1136/gut.2006.118059; Malhi H, 2011, J HEPATOL, V54, P795, DOI 10.1016/j.jhep.2010.11.005; Maliken BD, 2013, HEPATOLOGY, V57, P1806, DOI 10.1002/hep.26238; Mancina RM, 2015, J CLIN ENDOCR METAB, V100, pE821, DOI 10.1210/jc.2014-4464; Mandrekar P, 2009, J HEPATOL, V50, P1258, DOI 10.1016/j.jhep.2009.03.007; Mao JW, 2015, INT J CLIN EXP PATHO, V8, P3648; Marengo A, 2016, ANNU REV MED, V67, P103, DOI 10.1146/annurev-med-090514-013832; Marra F, 2014, CURR HEPATOL REP, V13, P142; Marra F, 2007, J HEPATOL, V46, P12, DOI 10.1016/j.jhep.2006.10.002; Martinez-Lopez N, 2015, ANNU REV NUTR, V35, P215, DOI 10.1146/annurev-nutr-071813-105336; Masaki T, 2004, HEPATOLOGY, V40, P177, DOI 10.1002/hep.20282; Mazuy C, 2015, CELL MOL LIFE SCI, V72, P1631, DOI 10.1007/s00018-014-1805-y; McClain CJ, 2007, HEPATOLOGY, V45, P1343, DOI 10.1002/hep.21788; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; McPherson S, 2015, J HEPATOL, V62, P1148, DOI 10.1016/j.jhep.2014.11.034; Mei S, 2011, J PHARMACOL EXP THER, V339, P487, DOI 10.1124/jpet.111.184341; Miele L, 2009, HEPATOLOGY, V49, P1877, DOI 10.1002/hep.22848; Mitro N, 2007, NATURE, V445, P219, DOI 10.1038/nature05449; Mittal S, 2016, CLIN GASTROENTEROL H, V14, P124, DOI 10.1016/j.cgh.2015.07.019; Miura K, 2010, GASTROENTEROLOGY, V139, P323, DOI 10.1053/j.gastro.2010.03.052; Montero J, 2008, CANCER RES, V68, P5246, DOI 10.1158/0008-5472.CAN-07-6161; Mridha AR, 2017, J HEPATOL, V66, P1037, DOI 10.1016/j.jhep.2017.01.022; Musso G, 2016, NAT REV DRUG DISCOV, V15, P249, DOI 10.1038/nrd.2015.3; Nazal L, 2010, OBES SURG, V20, P1400, DOI 10.1007/s11695-009-0051-0; Neuschwander-Tetri BA, 2015, LANCET, V385, P956, DOI 10.1016/S0140-6736(14)61933-4; Neuschwander-Tetri BA, 2010, HEPATOLOGY, V52, P774, DOI 10.1002/hep.23719; Nguyen P, 2008, J ANIM PHYSIOL AN N, V92, P272, DOI 10.1111/j.1439-0396.2007.00752.x; Oral EA, 2006, J CLIN ENDOCR METAB, V91, P621, DOI 10.1210/jc.2005-1220; Paradis V, 2001, HEPATOLOGY, V34, P738, DOI 10.1053/jhep.2001.28055; Park Pil-Hoon, 2015, Curr Pathobiol Rep, V3, P243; Perry RJ, 2015, SCIENCE, V347, P1253, DOI 10.1126/science.aaa0672; Petrasek J, 2011, GASTROENTEROLOGY, V140, P697, DOI 10.1053/j.gastro.2010.08.020; Petrasek J, 2010, GASTROENT RES PRACT, DOI 10.1155/2010/710381; Pirazzi C, 2012, J HEPATOL, V57, P1276, DOI 10.1016/j.jhep.2012.07.030; Piscaglia F, 2016, HEPATOLOGY, V63, P827, DOI 10.1002/hep.28368; Povero D, 2016, DIABETES METAB J, V40, P1, DOI 10.4093/dmj.2016.40.1.1; Puche JE, 2013, COMPR PHYSIOL, V3, P1473, DOI 10.1002/cphy.c120035; Puri P, 2008, GASTROENTEROLOGY, V134, P568, DOI 10.1053/j.gastro.2007.10.039; Rahman K, 2016, GASTROENTEROLOGY, V151, P733, DOI 10.1053/j.gastro.2016.06.022; Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765; Ramezani-Moghadam M, 2015, J BIOL CHEM, V290, P5533, DOI 10.1074/jbc.M114.598011; Ratziu V, 2016, GASTROENTEROLOGY, V150, P1147, DOI 10.1053/j.gastro.2016.01.038; Ratziu V, 2012, HEPATOLOGY, V55, P419, DOI 10.1002/hep.24747; Reddy JK, 2001, AM J PHYSIOL-GASTR L, V281, pG1333; Rogue A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018816; Romeo S, 2008, NAT GENET, V40, P1461, DOI 10.1038/ng.257; Saab S, 2016, CLIN GASTROENTEROL H, V14, P5, DOI 10.1016/j.cgh.2015.05.001; Sabio G, 2008, SCIENCE, V322, P1539, DOI 10.1126/science.1160794; Sanyal AJ, 2001, GASTROENTEROLOGY, V120, P1183, DOI 10.1053/gast.2001.23256; Sanyal AJ, 2016, HEPATOLOGY, V64, p1118A; Sanyal AJ, 2014, GASTROENTEROLOGY, V147, P377, DOI 10.1053/j.gastro.2014.04.046; Sanyal AJ, 2010, NEW ENGL J MED, V362, P1675, DOI 10.1056/NEJMoa0907929; Satapathy SK, 2015, SEMIN LIVER DIS, V35, P221, DOI 10.1055/s-0035-1562943; Saxena NK, 2015, TRENDS ENDOCRIN MET, V26, P153, DOI 10.1016/j.tem.2015.01.002; Schafer SL, 1998, J BIOL CHEM, V273, P2714, DOI 10.1074/jbc.273.5.2714; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Schneider KM, 2015, HEPATOLOGY, V62, P1405, DOI 10.1002/hep.27982; Schulze RJ, 2017, BBA-MOL CELL BIOL L, V1862, P1178, DOI 10.1016/j.bbalip.2017.06.008; Seki E, 2008, HEPATOLOGY, V48, P322, DOI 10.1002/hep.22306; Seki E, 2012, J PHYSIOL-LONDON, V590, P447, DOI 10.1113/jphysiol.2011.219691; Shields William W, 2009, Therap Adv Gastroenterol, V2, P157, DOI 10.1177/1756283X09105462; Shiffman M, 2015, J HEPATOL, V62, pS282, DOI 10.1016/S0168-8278(15)30191-4; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976; Siow W., 2016, Current Hepatology Reports, V15, P67, DOI 10.1007/s11901-016-0294-x; Smagris E, 2015, HEPATOLOGY, V61, P108, DOI 10.1002/hep.27242; Softic S, 2016, DIGEST DIS SCI, V61, P1282, DOI 10.1007/s10620-016-4054-0; Sookoian S, 2011, HEPATOLOGY, V53, P1883, DOI 10.1002/hep.24283; Sookoian S, 2009, J LIPID RES, V50, P2111, DOI 10.1194/jlr.P900013-JLR200; Spencer MD, 2011, GASTROENTEROLOGY, V140, P976, DOI 10.1053/j.gastro.2010.11.049; Staels B, 2013, HEPATOLOGY, V58, P1941, DOI 10.1002/hep.26461; Stefan N, 2013, NAT REV ENDOCRINOL, V9, P144, DOI 10.1038/nrendo.2012.258; Stiede K, 2017, HEPATOLOGY, V66, P324, DOI 10.1002/hep.29246; Sung KC, 2016, J HEPATOL, V65, P791, DOI 10.1016/j.jhep.2016.05.026; Szabo G, 2006, HEPATOLOGY, V44, P287, DOI 10.1002/hep.21308; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tang Y, 2011, CLIN EXP IMMUNOL, V166, P281, DOI 10.1111/j.1365-2249.2011.04471.x; Thomas C, 2009, CELL METAB, V10, P167, DOI 10.1016/j.cmet.2009.08.001; Tilg H, 2010, HEPATOLOGY, V52, P1836, DOI 10.1002/hep.24001; Tomita K, 2014, J HEPATOL, V61, P98, DOI 10.1016/j.jhep.2014.03.018; Tomita K, 2014, HEPATOLOGY, V59, P154, DOI 10.1002/hep.26604; Topping DL, 2001, PHYSIOL REV, V81, P1031; Trauner M, 2010, BBA-MOL CELL BIOL L, V1801, P299, DOI 10.1016/j.bbalip.2009.10.007; Trautwein C, 2015, J HEPATOL, V62, pS15, DOI 10.1016/j.jhep.2015.02.039; Trepo E, 2016, J HEPATOL, V65, P399, DOI 10.1016/j.jhep.2016.03.011; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Van Wagner LB, 2011, ANN HEPATOL, V10, P277, DOI 10.1016/S1665-2681(19)31539-X; Vanni E, 2015, SEMIN LIVER DIS, V35, P236, DOI 10.1055/s-0035-1562944; Vanni E, 2014, CLIN LIVER DIS, V18, P191, DOI 10.1016/j.cld.2013.09.001; Verstak B, 2009, J BIOL CHEM, V284, P24192, DOI 10.1074/jbc.M109.023044; Wang JH, 2009, GASTROENTEROLOGY, V137, P713, DOI 10.1053/j.gastro.2009.04.011; Watanabe M, 2004, J CLIN INVEST, V113, P1408, DOI 10.1172/JCI200421025; Wieckowska A, 2006, HEPATOLOGY, V44, P27, DOI 10.1002/hep.21223; Wieland A, 2015, ALIMENT PHARM THER, V42, P1051, DOI 10.1111/apt.13376; Williams CD, 2011, GASTROENTEROLOGY, V140, P124, DOI 10.1053/j.gastro.2010.09.038; Wong VWS, 2016, LANCET GASTROENTEROL, V1, P56, DOI 10.1016/S2468-1253(16)30011-5; Wree A, 2014, HEPATOLOGY, V59, P898, DOI 10.1002/hep.26592; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Xu CS, 2011, DIGEST DIS SCI, V56, P2299, DOI 10.1007/s10620-011-1599-9; Yamaguchi K, 2008, HEPATOLOGY, V47, P625, DOI 10.1002/hep.21988; Yamaguchi K, 2007, HEPATOLOGY, V45, P1366, DOI 10.1002/hep.21655; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yamauchi Toshimasa, 2003, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V3, P243, DOI 10.2174/1568008033340090; Ye DW, 2012, GUT, V61, P1058, DOI 10.1136/gutjnl-2011-300269; Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347; Younossi ZM, 2016, HEPATOLOGY, V64, P73, DOI 10.1002/hep.28431; Zein CO, 2011, HEPATOLOGY, V54, P1610, DOI 10.1002/hep.24544; Zhang YQ, 2006, P NATL ACAD SCI USA, V103, P1006, DOI 10.1073/pnas.0506982103	216	41	43	22	52	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						321	350		10.1146/annurev-pathol-020117-043617			30	Pathology	Pathology	BJ3ZK	WOS:000424631200013	29414249				2019-10-28	
S	Plog, BA; Nedergaard, M	Galli, SJ	Abbas, AK; Aster, JC		Plog, Benjamin A.; Nedergaard, Maiken	Galli, SJ		The Glymphatic System in Central Nervous System Health and Disease: Past, Present, and Future	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						glymphatic; cerebrospinal fluid; perivascular space; aquaporin-4; amyloid-beta; astrocyte	DEEP CERVICAL LYMPH; ACTIVATED ADENOSINE-TRIPHOSPHATASE; CEREBRAL INTERSTITIAL FLUID; BLOOD-BRAIN-BARRIER; CEREBROSPINAL-FLUID; GLUCOSE-TRANSPORTER; WATER PERMEABILITY; DIFFERENT REGIONS; BULK FLOW; IMPAIRMENT	The central nervous system (CNS) is unique in being the only organ system lacking lymphatic vessels to assist in the removal of interstitial metabolic waste products. Recent work has led to the discovery of the glymphatic system, a glial-dependent perivascular network that subserves a pseudolymphatic function in the brain. Within the glymphatic pathway, cerebrospinal fluid (CSF) enters the brain via periarterial spaces, passes into the interstitium via perivascular astrocytic aquaporin-4, and then drives the perivenous drainage of interstitial fluid (ISF) and its solute. Here, we review the role of the glymphatic pathway in CNS physiology, the factors known to regulate glymphatic flow, and the pathologic processes in which a breakdown of glymphatic CSF-ISF exchange has been implicated in disease initiation and progression. Important areas of future research, including manipulation of glymphatic activity aiming to improve waste clearance and therapeutic agent delivery, are also discussed.	[Plog, Benjamin A.; Nedergaard, Maiken] Univ Rochester, Med Ctr, Ctr Translat Neuromed, Dept Neurosurg, Rochester, NY 14642 USA; [Plog, Benjamin A.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA	Plog, BA (reprint author), Univ Rochester, Med Ctr, Ctr Translat Neuromed, Dept Neurosurg, Rochester, NY 14642 USA.; Plog, BA (reprint author), Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA.	benjamin_plog@urmc.rochester.edu; maiken_nedergaard@urmc.rochester.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG048769, RF1 AG057575]; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS100366, R01 NS078304]		Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Ball KK, 2010, J CEREBR BLOOD F MET, V30, P162, DOI 10.1038/jcbfm.2009.206; Blaumanis O R, 1990, Adv Neurol, V52, P385; BRADBURY MWB, 1983, J PHYSIOL-LONDON, V339, P519, DOI 10.1113/jphysiol.1983.sp014731; BRADBURY MWB, 1981, AM J PHYSIOL, V240, pF329; BRADBURY MWB, 1980, J PHYSIOL-LONDON, V299, P353, DOI 10.1113/jphysiol.1980.sp013129; BRIGHTMA.MW, 1969, J CELL BIOL, V40, P648, DOI 10.1083/jcb.40.3.648; Brightman M, 1992, PHYSL PHARM BLOOD BR, P1; Cserr H F, 1988, Ann N Y Acad Sci, V529, P9, DOI 10.1111/j.1749-6632.1988.tb51415.x; CSERR HF, 1974, EXP NEUROL, V45, P50, DOI 10.1016/0014-4886(74)90099-5; CSERR HF, 1981, AM J PHYSIOL, V240, pF319; CSERR HF, 1971, PHYSIOL REV, V51, P273; CSERR HF, 1977, EXP EYE RES, V25, P461, DOI 10.1016/S0014-4835(77)80041-9; Damkier HH, 2013, PHYSIOL REV, V93, P1847, DOI 10.1152/physrev.00004.2013; DOCZI T, 1982, NEUROSURGERY, V11, P402; FARRELL CL, 1992, J HISTOCHEM CYTOCHEM, V40, P193, DOI 10.1177/40.2.1552163; FISCHBARG J, 1989, P NATL ACAD SCI USA, V86, P8397, DOI 10.1073/pnas.86.21.8397; FISCHBARG J, 1990, P NATL ACAD SCI USA, V87, P3244, DOI 10.1073/pnas.87.8.3244; Gaberel T, 2014, STROKE, V45, P3092, DOI 10.1161/STROKEAHA.114.006617; Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108; HARIK SI, 1986, P NATL ACAD SCI USA, V83, P4067, DOI 10.1073/pnas.83.11.4067; Hladky SB, 2016, FLUIDS BARRIERS CNS, V13, DOI 10.1186/s12987-016-0040-3; Hladky SB, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-26; ICHIMURA T, 1991, BRAIN RES, V545, P103, DOI 10.1016/0006-8993(91)91275-6; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jessen NA, 2015, NEUROCHEM RES, V40, P2583, DOI 10.1007/s11064-015-1581-6; Jiang Q, 2017, J CEREBR BLOOD F MET, V37, P1326, DOI 10.1177/0271678X16654702; Johansson PA, 2005, CELL TISSUE RES, V322, P353, DOI 10.1007/s00441-005-1120-x; Johnston M., 2004, CEREBROSPINAL FLUID, V1, P2, DOI DOI 10.1186/1743-8454-1-2; KEEP RF, 1990, DEV BRAIN RES, V56, P47, DOI 10.1016/0165-3806(90)90163-S; Kiviniemi V, 2016, J CEREBR BLOOD F MET, V36, P1033, DOI 10.1177/0271678X15622047; Kratzer I, 2012, HISTOCHEM CELL BIOL, V138, P861, DOI 10.1007/s00418-012-1001-9; Kress BT, 2014, ANN NEUROL, V76, P845, DOI 10.1002/ana.24271; Krieg SM, 2015, J NEUROTRAUM, V32, P221, DOI 10.1089/neu.2013.3274; Lee HD, 2015, J NEUROSCI, V35, P11034, DOI 10.1523/JNEUROSCI.1625-15.2015; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lundgaard I, 2017, J CEREBR BLOOD F MET, V37, P2112, DOI 10.1177/0271678X16661202; Lundgaard I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7807; Maneshi MM, 2017, SCI REP-UK, V7, DOI 10.1038/srep39610; Mathieu E, 2013, FLUIDS BARRIERS CNS, V10, DOI 10.1186/2045-8118-10-35; MAXWELL DS, 1956, J BIOPHYS BIOCHEM CY, V2, P467, DOI 10.1083/jcb.2.4.467; Nagelhus EA, 2013, PHYSIOL REV, V93, P1543, DOI 10.1152/physrev.00011.2013; Nedergaard M, 2013, SCIENCE, V340, P1529, DOI 10.1126/science.1240514; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; OLDENDORF WH, 1977, ANN NEUROL, V1, P409, DOI 10.1002/ana.410010502; Oliver G, 2004, NAT REV IMMUNOL, V4, P35, DOI 10.1038/nri1258; Oshio K, 2004, FASEB J, V18, P76, DOI 10.1096/fj.04-1711fje; Oshio K, 2003, ACT NEUR S, V86, P525; Papadopoulos MC, 2013, NAT REV NEUROSCI, V14, P265, DOI 10.1038/nrn3468; Peng WG, 2016, NEUROBIOL DIS, V93, P215, DOI 10.1016/j.nbd.2016.05.015; POLLAY M, 1985, NEUROSURGERY, V17, P768, DOI 10.1227/00006123-198511000-00007; Praetorius J, 2007, PFLUG ARCH EUR J PHY, V454, P1, DOI 10.1007/s00424-006-0170-6; Praetorius J, 2006, AM J PHYSIOL-CELL PH, V291, pC59, DOI 10.1152/ajpcell.00433.2005; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; RAICHLE ME, 1978, BRAIN RES, V143, P191, DOI 10.1016/0006-8993(78)90766-7; Raper D, 2016, TRENDS NEUROSCI, V39, P581, DOI 10.1016/j.tins.2016.07.001; RASKIND MA, 1984, ARCH GEN PSYCHIAT, V41, P343; Rennels M L, 1990, Adv Neurol, V52, P431; RENNELS ML, 1985, BRAIN RES, V326, P47, DOI 10.1016/0006-8993(85)91383-6; Stokum JA, 2016, J CEREBR BLOOD F MET, V36, P513, DOI 10.1177/0271678X15617172; SZENTISTVANYI I, 1984, AM J PHYSIOL, V246, pF835; Thrane AS, 2014, TRENDS NEUROSCI, V37, P620, DOI 10.1016/j.tins.2014.08.010; Thrane VR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02582; Trevaskis NL, 2015, NAT REV DRUG DISCOV, V14, P781, DOI 10.1038/nrd4608; VATES TS, 1964, AM J PHYSIOL, V206, P1165; Vulchanova L, 2010, MOL PAIN, V6, DOI 10.1186/1744-8069-6-31; Wang MH, 2017, J NEUROSCI, V37, P2870, DOI 10.1523/JNEUROSCI.2112-16.2017; Weed LH, 1914, J MED RES, V31, P51; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; YAMADA S, 1991, AM J PHYSIOL, V261, pH1197; Yang LJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-107; Zarow C, 2003, ARCH NEUROL-CHICAGO, V60, P337, DOI 10.1001/archneur.60.3.337	76	82	84	12	43	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						379	394		10.1146/annurev-pathol-051217-111018			16	Pathology	Pathology	BJ3ZK	WOS:000424631200015	29195051	Green Accepted			2019-10-28	
S	Mittal, V	Galli, SJ	Abbas, AK; Aster, JC		Mittal, Vivek	Galli, SJ		Epithelial Mesenchymal Transition in Tumor Metastasis	ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13	Annual Review of Pathology-Mechanisms of Disease		English	Review; Book Chapter						epithelial mesenchymal transition; lineage tracing; therapy; resistance; cancer stem cells; miRNA; collective migration; metastasis	TRANSCRIPTION FACTOR SNAIL; SQUAMOUS-CELL CARCINOMA; TIME IMAGING REVEALS; BREAST-CANCER; MIR-200 FAMILY; STEM-CELLS; MICROENVIRONMENTAL REGULATION; EARLY DISSEMINATION; MASTER REGULATOR; REPRESSORS ZEB1	Metastasis is the major cause of cancer-related deaths; therefore, the prevention and treatment of metastasis are fundamental to improving clinical outcomes. Epithelial mesenchymal transition (EMT), an evolutionarily conserved developmental program, has been implicated in carcinogenesis and confers metastatic properties upon cancer cells by enhancing mobility, invasion, and resistance to apoptotic stimuli. Furthermore, EMT-derived tumor cells acquire stem cell properties and exhibit marked therapeutic resistance. Given these attributes, the complex biological process of EMThas been heralded as a key hallmark of carcinogenesis, and targetingEMTpathways constitutes an attractive strategy for cancer treatment. However, demonstrating the necessity of EMT for metastasis in vivo has been technically challenging, and recent efforts to demonstrate a functional contribution of EMT to metastasis have yielded unexpected results. Therefore, determining the functional role of EMT in metastasis remains an area of active investigation. Studies using improved lineage tracing systems, dynamic in vivo imaging, and clinically relevant in vivo models have the potential to uncover the direct link between EMT and metastasis. This review focuses primarily on recent advances in and emerging concepts of the biology of EMT in metastasis in vivo and discusses future directions in the context of novel diagnostic and therapeutic opportunities.	[Mittal, Vivek] Weill Cornell Med, Dept Cell & Dev Biol, Dept Cardiothorac Surg, New York, NY 10065 USA; [Mittal, Vivek] Weill Cornell Med, Neuberger Berman Fdn Lung Canc Ctr, New York, NY 10065 USA	Mittal, V (reprint author), Weill Cornell Med, Dept Cell & Dev Biol, Dept Cardiothorac Surg, New York, NY 10065 USA.; Mittal, V (reprint author), Weill Cornell Med, Neuberger Berman Fdn Lung Canc Ctr, New York, NY 10065 USA.	vim2010@med.cornell.edu					Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Alix-Panabieres C, 2017, J MOL MED, V95, P133, DOI 10.1007/s00109-016-1500-6; Alix-Panabieres C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258; Nieto MA, 2017, NAT CELL BIOL, V19, P416, DOI 10.1038/ncb3520; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Aparicio LA, 2015, CANCER LETT, V366, P1, DOI 10.1016/j.canlet.2015.06.007; Barriere G, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.10.04; Bastid J, 2012, CANCER METAST REV, V31, P277, DOI 10.1007/s10555-011-9344-6; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beerling E, 2016, CELL REP, V14, P2281, DOI 10.1016/j.celrep.2016.02.034; Bidard FC, 2014, LANCET ONCOL, V15, P406, DOI 10.1016/S1470-2045(14)70069-5; Bill R, 2015, FEBS LETT, V589, P1577, DOI 10.1016/j.febslet.2015.05.002; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Cheung KJ, 2016, SCIENCE, V352, P167, DOI 10.1126/science.aaf6546; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2014, CURR OPIN CELL BIOL, V30, P99, DOI 10.1016/j.ceb.2014.07.003; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Denecker G, 2014, CELL DEATH DIFFER, V21, P1250, DOI 10.1038/cdd.2014.44; Diaz-Lopez A, 2015, INT J CANCER, V136, pE62, DOI 10.1002/ijc.29177; Diepenbruck M, 2016, CURR OPIN CELL BIOL, V43, P7, DOI 10.1016/j.ceb.2016.06.002; Eckert MA, 2011, ONCOTARGET, V2, P562; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Fantozzi A, 2014, CANCER RES, V74, P1566, DOI 10.1158/0008-5472.CAN-13-1641; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gao DC, 2012, CANCER RES, V72, P1384, DOI 10.1158/0008-5472.CAN-11-2905; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Giampieri S, 2009, NAT CELL BIOL, V11, P1287, DOI 10.1038/ncb1973; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Grigore AD, 2016, J CLIN MED, V5, P51, DOI 10.3390/jcm5050051; Grosse-Wilde A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126522; Harney AS, 2015, CANCER DISCOV, V5, P932, DOI 10.1158/2159-8290.CD-15-0012; Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609; Hay ED, 1995, ACTA ANAT, V154, P8; Headley MB, 2016, NATURE, V531, P513, DOI 10.1038/nature16985; Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785; Huang RYJ, 2012, J CELL SCI, V125, P4417, DOI 10.1242/jcs.099697; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Jolly MK, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00155; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kasimir-Bauer S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3099; Khoo BL, 2015, ONCOTARGET, V6, P15578; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Ledford H, 2011, NATURE, V472, P273, DOI 10.1038/472273a; Li WY, 2016, TRENDS CANCER, V2, P65, DOI 10.1016/j.trecan.2016.01.001; Lim J, 2012, DEVELOPMENT, V139, P3471, DOI 10.1242/dev.071209; Lok C, 2014, NATURE, V509, P148, DOI 10.1038/509148a; Maheswaran S, 2015, NATURE, V527, P452, DOI 10.1038/nature16313; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcucci F, 2016, NAT REV DRUG DISCOV, V15, P311, DOI 10.1038/nrd.2015.13; Martin YD, 2015, CELL REP, V13, P2456, DOI 10.1016/j.celrep.2015.11.025; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Mego M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1548-7; Mego M, 2012, INT J CANCER, V130, P808, DOI 10.1002/ijc.26037; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Ni T, 2016, NAT CELL BIOL, V18, P1221, DOI 10.1038/ncb3425; NIETO MA, 1994, SCIENCE, V264, P835, DOI 10.1126/science.7513443; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44; Pantel K, 2009, NAT REV CLIN ONCOL, V6, P190, DOI 10.1038/nrclinonc.2009.23; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Patel AP, 2014, SCIENCE, V344, P1396, DOI 10.1126/science.1254257; Pattabiraman DR, 2016, COLD SH Q B, V81, P11, DOI 10.1101/sqb.2016.81.030957; Pignatelli J, 2016, SCI REP-UK, V6, DOI 10.1038/srep37874; Prall F, 2007, HISTOPATHOLOGY, V50, P151, DOI 10.1111/j.1365-2559.2006.02551.x; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prudkin L, 2009, MODERN PATHOL, V22, P668, DOI 10.1038/modpathol.2009.19; Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI [10.1038/nrd.2016246, 10.1038/nrd.2016.246]; Ruscetti M, 2015, CANCER RES, V75, P2749, DOI 10.1158/0008-5472.CAN-14-3476; Said NABM, 2011, CELLS TISSUES ORGANS, V193, P85, DOI 10.1159/000320360; Sampson VB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102041; Schliekelman MJ, 2015, CANCER RES, V75, P1789, DOI 10.1158/0008-5472.CAN-14-2535; Schmidt JM, 2015, CELL REP, V10, P131, DOI 10.1016/j.celrep.2014.12.032; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Shibue T, 2012, CANCER DISCOV, V2, P706, DOI 10.1158/2159-8290.CD-11-0239; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Soini Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-73; Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793; Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014; Stoletov K, 2010, J CELL SCI, V123, P2332, DOI 10.1242/jcs.069443; Sugino T, 2004, BMC MED, V2, DOI 10.1186/1741-7015-2-9; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Terry Stephane, 2015, Oncoscience, V2, P841; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020; Tran HD, 2014, CANCER RES, V74, P6330, DOI 10.1158/0008-5472.CAN-14-0923; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618; van Denderen BJW, 2013, NATURE, V493, P487, DOI 10.1038/493487a; van Nes JGH, 2012, BREAST CANCER RES TR, V133, P49, DOI 10.1007/s10549-011-1684-y; Vicovac L, 1996, ACTA ANAT, V156, P202; Viski C, 2016, CANCER RES, V76, P5313, DOI 10.1158/0008-5472.CAN-16-0932; Voon DCC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070427; Xue CS, 2003, CANCER RES, V63, P3386; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568; Yates C, 2012, ADV EXP MED BIOL, V720, P81, DOI 10.1007/978-1-4614-0254-1_7; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zhao Z, 2016, CANCER RES, V76, P2094, DOI 10.1158/0008-5472.CAN-15-2662; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	139	38	39	14	44	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1553-4006			ANNU REV PATHOL-MECH	Annu. Rev. Pathol.-Mech Dis.		2018	13						395	412		10.1146/annurev-pathol-020117-043854			18	Pathology	Pathology	BJ3ZK	WOS:000424631200016	29414248				2019-10-28	
J	Kenan, S; Kahn, L; Edelman, M; Redner, A; Kenan, S				Kenan, Shachar; Kahn, Leonard; Edelman, Morris; Redner, Arlene; Kenan, Samuel			Epiphyseal Primary Diffuse Large B-Cell Lymphoma of Bone	CASE REPORTS IN PATHOLOGY			English	Article							NON-HODGKINS-LYMPHOMA	Primary lymphoma of bone (PLB) confined to the epiphysis has only been described in four other patients. Due to the rarity of this entity, diagnosis has often been delayed, leading to mismanagement with adverse clinical consequences. We report a fifth case of primary epiphyseal lymphoma of bone located in the left distal medial femoral epiphysis of a 13-year-old boy. Radiographic and histologic features of PLB are discussed, along with a review of the literature and pitfalls of misdiagnosis. The patient initially presented with six months of progressive left knee pain with an associated loss of passive range of motion. Imaging revealed a mixed radiolucent lesion within the left distal medial femoral epiphysis with cortical breakthrough. A core biopsy was performed revealing a blue round cell tumor. Thanks to modern immunohistochemistry techniques, a diagnosis of primary lymphoma of bone was quickly made. The patient thus avoided further surgical intervention and received the appropriate treatment of chemotherapy, with subsequent rapid resolution of the lesion. This case highlights the necessity of including primary lymphoma of bone in all epiphyseal lesion differential diagnoses, especially in the pediatric patient population when aggressive radiographic features are present.	[Kenan, Shachar] Mem Sloan Kettering Canc Ctr, Dept Orthopaed, Orthopaed Oncol, 1275 York Ave, New York, NY 10021 USA; [Kahn, Leonard; Edelman, Morris] Zucker Hofstra North Shore Long Isl Jewish, Northwell Hlth Med Ctr, Dept Pathol, Musculoskeletal Pathol, New Hyde Pk, NY USA; [Redner, Arlene] Zucker Hofstra North Shore Long Isl Jewish, Northwell Hlth Med Ctr, Dept Pediat Hematol Oncol, New Hyde Pk, NY USA; [Kenan, Samuel] Zucker Hofstra North Shore Long Isl Jewish, Northwell Hlth Med Ctr, Dept Orthopaed, New Hyde Pk, NY USA	Kenan, S (reprint author), Mem Sloan Kettering Canc Ctr, Dept Orthopaed, Orthopaed Oncol, 1275 York Ave, New York, NY 10021 USA.	shachar.kenan@gmail.com		Kenan, Shachar/0000-0002-7292-0629			Alencar A, 2010, LEUKEMIA LYMPHOMA, V51, P39, DOI 10.3109/10428190903308007; Beal K, 2006, CANCER, V106, P2652, DOI 10.1002/cncr.21930; Cai L, 2012, INT J RADIAT ONCOL, V83, P284, DOI 10.1016/j.ijrobp.2011.06.1976; de Camargo OP, 2002, CLIN ORTHOP RELAT R, P271; Demircay E, 2013, CLIN ORTHOP RELAT R, V471, P2684, DOI 10.1007/s11999-013-2991-x; Fox MG, 2015, SKELETAL RADIOL, V44, P587, DOI 10.1007/s00256-014-2010-7; GIUDICI MAI, 1992, SKELETAL RADIOL, V21, P260; Hayase E, 2015, ACTA HAEMATOL-BASEL, V134, P80, DOI 10.1159/000375437; Hogendoorn P. C. W., 2013, WHO CLASSIFICATION T; Jawad MU, 2010, CANCER-AM CANCER SOC, V116, P871, DOI 10.1002/cncr.24828; Kitsoulis P, 2006, ANTICANCER RES, V26, P325; Messina C, 2015, CANCER TREAT REV, V41, P235, DOI 10.1016/j.ctrv.2015.02.001; Mounasamy V, 2006, SKELETAL RADIOL, V35, P619, DOI 10.1007/s00256-006-0087-3; Nouh MR, 2014, EUR J RADIOL, V83, P360, DOI 10.1016/j.ejrad.2013.10.012; Pilorge S, 2016, LEUKEMIA LYMPHOMA, V57, P2820, DOI 10.1080/10428194.2016.1177180; Scoccianti G, 2013, INT ORTHOP, V37, P2437, DOI 10.1007/s00264-013-2055-6; Suryanarayan K, 1999, J CLIN ONCOL, V17, P456, DOI 10.1200/JCO.1999.17.2.456; Swerdllow SH, 2008, WHO CLASSIFICATION T; Tao RD, 2015, INT J RADIAT ONCOL, V92, P122, DOI 10.1016/j.ijrobp.2015.01.014; Thawait SK, 2013, MAGN RESON IMAGING, V31, P418, DOI 10.1016/j.mri.2012.08.006; Wu HW, 2014, BRIT J HAEMATOL, V166, P60, DOI 10.1111/bjh.12841	21	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									4160925	10.1155/2018/4160925			7	Pathology	Pathology	HE1HD	WOS:000453020500001	30598851	DOAJ Gold, Green Published			2019-10-28	
J	Lee, CM; Moh, M; Sullivan, PS; Moatamed, NA				Lee, Christine M.; Moh, Michelle; Sullivan, Peggy S.; Moatamed, Neda A.			An Unusual Adenomatoid Tumor of Fimbria with Pronounced Psammoma Bodies in a BRCA Positive Patient as a Pitfall for Carcinoma on Frozen Section	CASE REPORTS IN PATHOLOGY			English	Article							GRADE SEROUS CARCINOMA; D2-40; DIFFERENTIATION; MESOTHELIOMA; EXPRESSION; DIAGNOSIS; UTILITY; OVARY	Background. BRCA gene mutations significantly increase the risk of breast and ovarian cancers where the lifetime risk of the ovarian cancer is about 40%. Therefore, manywomenwith suchmutations undergo prophylactic bilateralmastectomy and salpingooophorectomy. About 5-6% of these individuals display occult carcinomas in tubo-ovarian locations of which over 85% are tubal in origin. The objective of this case study was to emphasize emergence of benign lesionsmimicking cancer under these circumstances. Case Report. We present a case with positive BRCA1 mutation who underwent the prophylactic procedure where a small mass was identified in her fallopian tube. Our initial encounter with this tumor was during intraoperative consultation. The tumor was associatedwith extensive psammoma bodies arranged in closely packed small tubules, mimicking serous carcinoma. Frozen section limitations including artifact, time constraint, and lack of ancillary studies as well as the clinical history further complicated our diagnostic assessment, which was deferred. A diagnosis of adenomatoid tumor was rendered on permanent sections. Conclusion. It is important to be familiar with this morphologic presentation of adenomatoid tumor as it is a pitfall for carcinoma, particularly on frozen section, and inaccurate diagnosis could lead to further unnecessary extensive procedures.	[Lee, Christine M.; Moh, Michelle; Sullivan, Peggy S.; Moatamed, Neda A.] UCLA, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA	Moatamed, NA (reprint author), UCLA, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.	nmoatamed@mednet.ucla.edu		Moatamed, Neda/0000-0002-9986-8058			Arai E, 2006, J CUTAN PATHOL, V33, P492, DOI 10.1111/j.1600-0560.2006.00461.x; Boyd C, 2012, AM J SURG PATHOL, V36, P368, DOI 10.1097/PAS.0b013e31823732a9; Chu AY, 2005, MODERN PATHOL, V18, P105, DOI 10.1038/modpathol.3800259; Das DK, 2009, DIAGN CYTOPATHOL, V37, P534, DOI 10.1002/dc.21081; Fukunaga M, 2005, HISTOPATHOLOGY, V46, P396, DOI 10.1111/j.1365-2559.2005.02098.x; Hanada S, 2003, J OBSTET GYNAECOL RE, V29, P234, DOI 10.1046/j.1341-8076.2003.00102.x; Hes Ondrej, 2003, Ann Diagn Pathol, V7, P273, DOI 10.1016/S1092-9134(03)00085-6; Hyun TS, 2012, ACTA CYTOL, V56, P527, DOI 10.1159/000339586; Laury AR, 2010, AM J SURG PATHOL, V34, P627, DOI 10.1097/PAS.0b013e3181da7687; Meserve EEK, 2017, GYNECOL ONCOL, V146, P69, DOI 10.1016/j.ygyno.2017.04.015; Mhawech-Fauceglia P., 2018, APPL IMMUNOHISTOCHEM; Nebgen DR, 2018, GYNECOL ONCOL, V150, P79, DOI 10.1016/j.ygyno.2018.04.564; Oparka R, 2011, J CLIN PATHOL, V64, P313, DOI 10.1136/jcp.2010.086074; Phillips V, 2007, INT J GYNECOL PATHOL, V26, P16, DOI 10.1097/01.pgp.0000215303.24653.fc; QAZI FM, 1988, ARCH PATHOL LAB MED, V112, P564; Riboni F, 2010, ACTA CYTOL, V54, P311, DOI 10.1159/000325040; Sangoi AR, 2009, MODERN PATHOL, V22, P1228, DOI 10.1038/modpathol.2009.90; Seguin RE, 2000, J REPROD MED, V45, P526; Voutsadakis IA, 2016, CLIN MED INSIGHTS-ON, V10, P17, DOI 10.4137/CMO.S32813; Xing DY, 2018, HUM PATHOL, V72, P160, DOI 10.1016/j.humpath.2017.10.036; Zakhour M, 2016, GYNECOL ONCOL, V143, P231, DOI 10.1016/j.ygyno.2016.08.336	21	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8148147	10.1155/2018/8148147			5	Pathology	Pathology	HE2WN	WOS:000453211400001	30538879	DOAJ Gold, Green Published			2019-10-28	
J	Li, JJX; Lee, JHS; Chan, VTC; Yu, MY				Li, Joshua J. X.; Lee, Jacqueline H. S.; Chan, Vicky T. C.; Yu, Mei-yung			Uterine Carcinosarcoma with Alpha-Fetoprotein-Producing Hepatoid Component: A Case Report and Literature Review	CASE REPORTS IN PATHOLOGY			English	Review							OF-THE-LITERATURE; ADENOCARCINOMA; CORPUS; CARCINOMA; FEATURES	A 67-year-old woman presented with postmenopausal vaginal bleeding. Full body imaging demonstrated an intrauterine mass with deepmyometrial invasion but no nodal or othermetastatic disease. Uterine curettage was performed. Histologically, the tumor was an endometrioid adenocarcinoma with sarcomatous element and a hepatoid component, the latter was immunohistochemically positive for alpha-fetoprotein, HepPar-1, and arginase-1. The patient underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy. Serum alpha-fetoprotein level decreased from31896 ug/l preoperatively to 2063 ug/l postoperatively. Eight weeks later, a rise in serum alpha-fetoprotein was detected, and a biopsy-proven vaginal recurrence was diagnosed. Palliative chemotherapy led to tumor shrinkage and a concurrent decrease in the serum alpha-fetoprotein level. A rise in serum alpha-fetoprotein, refractory to second-line chemotherapy, was accompanied by subsequent development of ureteric obstruction, ascites, and radiological evidence of peritoneal metastases. This is an unusual case of uterine carcinosarcoma with an alpha-fetoprote-inproducing hepatoid adenocarcinoma component. Serumalpha-fetoprotein level corresponds to disease recurrence and progression.	[Li, Joshua J. X.; Yu, Mei-yung] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Lee, Jacqueline H. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Hong Kong, Peoples R China; [Chan, Vicky T. C.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China	Li, JJX (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.	jozhia@live.com					Armaghani Avan, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2014-206222; Chandan VS, 2016, HUM PATHOL, V55, P11, DOI 10.1016/j.humpath.2016.04.008; Ellouze S, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-103; Ferguson SE, 2007, AM J SURG PATHOL, V31, P1653, DOI 10.1097/PAS.0b013e3181161ba3; Haninger DM, 2014, MODERN PATHOL, V27, P535, DOI 10.1038/modpathol.2013.170; Hwang Jong Ha, 2011, Scott Med J, V56, P120, DOI 10.1258/smj.2011.011100; Inthasorn P, 2002, INT J GYNECOL CANCER, V12, P348, DOI 10.1046/j.1525-1438.2002.01117.x; ISHIKURA H, 1991, CANCER, V67, P3051, DOI 10.1002/1097-0142(19910615)67:12<3051::AID-CNCR2820671220>3.0.CO;2-C; Kawaguchi R, 2011, CASE REP ONCOL, V4, P358, DOI 10.1159/000330239; Lin CY, 2015, BIOMED J, V38, P65, DOI 10.4103/2319-4170.126860; Randolph LK, 2015, GYNECOL ONCOL REP, V13, P64, DOI 10.1016/j.gore.2015.06.006; Takahashi Y, 2003, PATHOL INT, V53, P323, DOI 10.1046/j.1440-1827.2003.01467.x; Takano M, 2003, GYNECOL ONCOL, V91, P444, DOI 10.1016/S0090-8258(03)00512-2; Ye MF, 2013, WORLD J GASTROENTERO, V19, P4437, DOI 10.3748/wjg.v19.i27.4437; Zhou R, 2015, ONCOL LETT, V9, P2126, DOI 10.3892/ol.2015.2979	15	0	0	1	3	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									UNSP 3972353	10.1155/2018/3972353			5	Pathology	Pathology	GK6XG	WOS:000436335500001	29992073	DOAJ Gold, Green Published			2019-10-28	
J	Roman, J; Palmer, MI; Palmer, CA; Johnson, NE; Butterfield, RJ				Roman, Joy; Palmer, Michael I.; Palmer, Cheryl A.; Johnson, Nicholas E.; Butterfield, Russell J.			Myopathy in the York Platelet Syndrome: An Underrecognized Complication	CASE REPORTS IN PATHOLOGY			English	Article								York Platelet Syndrome (YPS) is a calcium channelopathy caused by gain of function in STIM1, a gene which acts as a calcium sensor. It is characterized by platelet abnormalities and muscle weakness. Medical literature emphasizes the hematologic aspects of the cases with few data of the neuromuscular and neuropathologic evaluation. We present a patient with YPS whose myopathy was the most prominent aspect. She presented around 2 years of age with proximal weakness and easy bruisability. YPS was diagnosed in the infant at 16 months of age at the National Institutes of Health. Muscle biopsy demonstrated a severe chronic myopathy. Rimmed vacuoles and tubular aggregates were noted. Although YPS is rare, the combination of a congenital myopathy with thrombocytopenia may facilitate the diagnosis and enable further insights into the disease.	[Roman, Joy; Palmer, Michael I.; Palmer, Cheryl A.; Johnson, Nicholas E.] Univ Utah, Dept Pathol, Salt Lake City, UT 84103 USA; [Johnson, Nicholas E.; Butterfield, Russell J.] Univ Utah, Dept Neurol, Salt Lake City, UT USA; [Butterfield, Russell J.] Univ Utah, Dept Pediat, Salt Lake City, UT USA	Palmer, CA (reprint author), Univ Utah, Dept Pathol, Salt Lake City, UT 84103 USA.	cheryl.palmer@path.utah.edu		Palmer, Cheryl/0000-0001-6088-9161			[Anonymous], 2018, ONL MEND INH MAN OMI; Bohm J, 2013, AM J HUM GENET, V92, P271, DOI 10.1016/j.ajhg.2012.12.007; Markello T, 2015, MOL GENET METAB, V114, P474, DOI 10.1016/j.ymgme.2014.12.307; Singh AR, 2015, MOLEC GENET METAB RE, V2, P80, DOI 10.1016/j.ymgmr.2015.01.003; Stathopulos PB, 2008, CELL, V135, P110, DOI 10.1016/j.cell.2008.08.006; White JG, 2011, PLATELETS, V22, P117, DOI 10.3109/09537104.2010.524323	6	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5130143	10.1155/2018/5130143			3	Pathology	Pathology	GR7SI	WOS:000442894200001	30159190	DOAJ Gold, Green Published			2019-10-28	
J	Tie, J; Semira, C; Gibbs, P				Tie, Jeanne; Semira, Christine; Gibbs, Peter			Circulating tumor DNA as a biomarker to guide therapy in post-operative locally advanced rectal cancer: the best option?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Circulating tumor DNA; prognosis; biomarker; rectal cancer; colorectal cancer	ADJUVANT CHEMOTHERAPY; PREOPERATIVE CHEMORADIOTHERAPY; OPEN-LABEL; FLUOROURACIL; MULTICENTER; OXALIPLATIN; TRIAL		[Tie, Jeanne; Semira, Christine; Gibbs, Peter] Walter & Eliza Hall Inst Med Res, Div Syst Biol & Personalised Med, Melbourne, Vic, Australia; [Tie, Jeanne; Gibbs, Peter] Univ Melbourne, Fac Med Dent & Hlth Sci, Melbourne, Vic, Australia; [Tie, Jeanne; Gibbs, Peter] Western Hlth, Dept Med Oncol, Melbourne, Vic, Australia; [Tie, Jeanne; Gibbs, Peter] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia	Tie, J (reprint author), Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.	tie.j@wehi.edu.au					Allegra CJ, 2015, J NATL CANC I, V107; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Breugom AJ, 2015, LANCET ONCOL, V16, P200, DOI 10.1016/S1470-2045(14)71199-4; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021; Hong TS, 2015, J CLIN ONCOL, V33, P1878, DOI 10.1200/JCO.2015.60.8554; Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Petersen SH, 2012, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004078.PUB2; Rodel C, 2015, LANCET ONCOL, V16, P979, DOI 10.1016/S1470-2045(15)00159-X; Sausen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8686; Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177; Tie J, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3521; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219	16	2	2	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					1	3		10.1080/14737159.2018.1386558			3	Pathology	Pathology	FS9QO	WOS:000422753500001	28954554	Bronze			2019-10-28	
J	Klepser, DG; Klepser, ME				Klepser, Donald G.; Klepser, Michael E.			Point-of-care testing in the pharmacy: how is the field evolving?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Pharmacy; point of care testing; influenza; pharyngitis; collaborative practice agreement	COMMUNITY PHARMACIES; PROGRAM		[Klepser, Donald G.] Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE 68198 USA; [Klepser, Michael E.] Ferris State Univ, Coll Pharm, Big Rapids, MI USA	Klepser, DG (reprint author), Univ Nebraska Med Ctr, Coll Pharm, Omaha, NE 68198 USA.	dklepser@unmc.edu			Roche Diagnostics; NACDS Foundation	DG Klepser is a developer of NACDS POCT Certificate Program, has acted as a consultant for Force Diagnostics and Arkray Inc and discloses research support from Roche Diagnostics and NACDS Foundation. ME Klepser is a developer of NACDS POCT Certificate Program, has acted as a consultant for Force Diagnostics and Arkray Inc and discloses research support from Roche Diagnostics and NACDS Foundation. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.	Adams AJ, 2016, ANN PHARMACOTHER, V50, P778, DOI 10.1177/1060028016653608; [Anonymous], NACDS FAC TO FAC COM; [Anonymous], 2015, CDC NAT EARL SEAS FL; Balick R, 2017, PHARM TODAY, V23, P44; Darin KM, 2015, J AM PHARM ASSOC, V55, P81, DOI 10.1331/JAPhA.2015.14070; Darin KM, 2015, J AM PHARM ASSOC, V55, P67, DOI 10.1331/JAPhA.2015.14069; Deloitte, RET HLTH WELLN; Fleishman JA, 2012, JAIDS-J ACQ IMM DEF, V60, P249, DOI 10.1097/QAI.0b013e318258c696; Johnsen M., WALGREENS PARTNERS L; Klepser DG, 2017, RES SOC ADM IN PRESS, V4; Klepser DG, 2016, J AM PHARM ASSOC, V56, P323, DOI 10.1016/j.japh.2015.11.013; Klepser ME, 2016, RES SOC ADMIN PHARM, V12, P614, DOI 10.1016/j.sapharm.2015.09.006; Klepser ME, 2016, J AM PHARM ASSOC, V56, P14, DOI 10.1016/j.japh.2015.11.008	13	1	1	1	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					5	6		10.1080/14737159.2018.1392240			2	Pathology	Pathology	FS9QO	WOS:000422753500002	29034791				2019-10-28	
J	Postel, M; Roosen, A; Laurent-Puig, P; Taly, V; Wang-Renault, SF				Postel, Mathilde; Roosen, Alice; Laurent-Puig, Pierre; Taly, Valerie; Wang-Renault, Shu-Fang			Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Droplet-based digital PCR; NGS; circulating tumor DNA; early cancer diagnosis; mutation; DNA methylation; biomarker	CELL-FREE-DNA; GENE PROMOTER METHYLATION; PANCREATIC-CANCER; LUNG-CANCER; BREAST-CANCER; KRAS MUTATIONS; GASTRIC-CANCER; NUCLEIC-ACIDS; PLASMA DNA; QUANTITATIVE DETECTION	Introduction: Early detection of cancers through the analysis of ctDNA could have a significant impact on morbidity and mortality of cancer patients. However, using ctDNA for early cancer diagnosis is challenging partly due to the low amount of tumor DNA released in the circulation and its dilution within DNA originating from non-tumor cells. Development of new technologies such as droplet-based digital PCR (ddPCR) or optimized next generation sequencing (NGS) has greatly improved the sensitivity, specificity and precision for the detection of rare sequences. Areas covered: This paper will focus on the potential application of ddPCR and optimized NGS to detect ctDNA for detection of cancer recurrence and minimal residual disease as well as early diagnosis of cancer patients. Expert commentary: Compared to tumor tissue biopsies, blood-based ctDNA analyses are minimally invasive and accessible for regular follow-up of cancer patients. They are also described as a better picture of patients' pathology allowing to highlight both tumor heterogeneity and multiple tumor sites. After a brief introduction on the application of the follow-up of ctDNA using genetic or epigenetic biomarkers for prognosis and surveillance of cancer patients, potential perspectives of using ctDNA for early diagnosis of cancers will be presented.	[Postel, Mathilde; Roosen, Alice; Laurent-Puig, Pierre; Taly, Valerie; Wang-Renault, Shu-Fang] CNRS, INSERM, UMR S1147, SNC5014, Paris, France; [Postel, Mathilde; Roosen, Alice; Laurent-Puig, Pierre; Taly, Valerie; Wang-Renault, Shu-Fang] Paris Descartes Univ, Equipe Labellisee Ligue Natl Canc, Paris, France; [Laurent-Puig, Pierre] Hop Europeen Georges Pompidou, AP HP, Dept Biol, Paris, France	Taly, V; Wang-Renault, SF (reprint author), Univ Paris Sorbonne Cite, CNRS, INSERM, UMR S1147,Equipe Labellisee Ligue Canc,SNC 5014, Paris, France.	valerie.taly@parisdescartes.fr; shufang.renault@parisdescartes.fr	Laurent-Puig, Pierre/K-3641-2019; TALY, VALERIE/N-9766-2014	Laurent-Puig, Pierre/0000-0001-8475-5459; TALY, VALERIE/0000-0002-3116-8602	Ministere de l'Enseignement Superieur et de la Recherche; Universite Paris-Descartes; Centre National de la Recherche Scientifique (CNRS)Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM)Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National du Cancer (INCA)Institut National du Cancer (INCA) France [2009-1-RT-03-US-1, 2009-RT-03-UP5-1]; Association pour la recherche contre le cancer (ARC)Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR) [SL220100601375]; Agence Nationale de la Recherche (ANR Nanobiotechnologies)French National Research Agency (ANR) [ANR-10-NANO-0002-09]; SIRIC CARPEM; ligue nationale contre le cancer (LNCC, Program'Equipe labelisee LIGUE') [EL2016.LNCC/VaT]; Advanced Merieux Research Grant; canceropole funding [2011-1-LABEL-UP5-2]; SATT idF Innov [275]	This work was supported by the Ministere de l'Enseignement Superieur et de la Recherche, the Universite Paris-Descartes, the Centre National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), the Institut National du Cancer (INCA, no 2009-1-RT-03-US-1 and 2009-RT-03-UP5-1), the Association pour la recherche contre le cancer (ARC, no. SL220100601375), the Agence Nationale de la Recherche (ANR Nanobiotechnologies; no.ANR-10-NANO-0002-09), the SIRIC CARPEM, the ligue nationale contre le cancer (LNCC, Program'Equipe labelisee LIGUE'; no. EL2016.LNCC/VaT) and Advanced Merieux Research Grant (PLP and VT) and canceropole funding (no. 2011-1-LABEL-UP5-2) and SATT idF Innov (Grant no. 275). SF Wang-Renault receives salary from SATT idF Innov (Grant no. 275).	Akirav EM, 2011, P NATL ACAD SCI USA, V108, P19018, DOI 10.1073/pnas.1111008108; Allott EH, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0725-1; Andersen RF, 2016, CLIN CHIM ACTA, V458, P138, DOI 10.1016/j.cca.2016.05.007; ANKER P, 1975, CANCER RES, V35, P2375; [Anonymous], 2017, J CLIN ONCOL S, V35; [Anonymous], 2016, EP REC FDA APPR EPI; Beaver JA, 2014, CLIN CANCER RES, V20, P2643, DOI 10.1158/1078-0432.CCR-13-2933; Belinsky SA, 2005, CLIN CANCER RES, V11, P6505, DOI 10.1158/1078-0432.CCR-05-0625; Benesova L, 2013, ANAL BIOCHEM, V433, P227, DOI 10.1016/j.ab.2012.06.018; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bournet B, 2013, M S-MED SCI, V29, P991, DOI 10.1051/medsci/20132911015; Bronkhorst AJ, 2016, BBA-MOL CELL RES, V1863, P157, DOI 10.1016/j.bbamcr.2015.10.022; Bronkhorst AJ, 2015, CLIN CHIM ACTA, V450, P243, DOI 10.1016/j.cca.2015.08.028; Butt AN, 2008, ANN NY ACAD SCI, V1137, P236, DOI 10.1196/annals.1448.002; Caen O, 2015, M S-MED SCI, V31, P180, DOI 10.1051/medsci/20153102015; Caplan Lee, 2014, Front Public Health, V2, P87, DOI 10.3389/fpubh.2014.00087; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chae YK, 2017, MOL CANCER THER, V16, P1412, DOI 10.1158/1535-7163.MCT-17-0061; Chan KCA, 2005, CLIN CHEM, V51, P781, DOI 10.1373/clinchem.2004.046219; Chan TL, 2003, CANCER RES, V63, P4878; Chen H, 2010, EJSO-EUR J SURG ONC, V36, P657, DOI 10.1016/j.ejso.2010.05.014; Chen KZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep31985; CHETVERINA HV, 1993, NUCLEIC ACIDS RES, V21, P2349, DOI 10.1093/nar/21.10.2349; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Daniotti M, 2007, INT J CANCER, V120, P2439, DOI 10.1002/ijc.22598; Devonshire AS, 2014, ANAL BIOANAL CHEM, V406, P6499, DOI 10.1007/s00216-014-7835-3; Diaz EH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168153; Diaz IM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166354; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Diehl F, 2008, GASTROENTEROLOGY, V135, P489, DOI 10.1053/j.gastro.2008.05.039; Dressman D, 2003, P NATL ACAD SCI USA, V100, P8817, DOI 10.1073/pnas.1133470100; El Messaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022; Fan GW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171991; Fernandez-Cuesta L, 2016, EBIOMEDICINE, V10, P117, DOI 10.1016/j.ebiom.2016.06.032; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gao YH, 2017, ONCOTARGET, V8, P6330, DOI 10.18632/oncotarget.14064; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021; Garlan F, 2017, CLIN CANCER RES, V23, P5416, DOI 10.1158/1078-0432.CCR-16-3155; Garlan F, 2017, TARGET ONCOL, V12, P365, DOI 10.1007/s11523-017-0491-8; Garnis C, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-9; Garrigou S, 2016, CLIN CHEM, V62, P1129, DOI 10.1373/clinchem.2015.253609; Giannopoulou L, 2017, ONCOTARGET, V8, P21429, DOI 10.18632/oncotarget.15249; Gormally E, 2007, MUTAT RES-REV MUTAT, V635, P105, DOI 10.1016/j.mrrev.2006.11.002; Grizzle WE, 2011, CANCER BIOMARK, V9, P531, DOI 10.3233/CBM-2011-0183; Hamakawa T, 2015, BRIT J CANCER, V112, P352, DOI 10.1038/bjc.2014.609; Herceg Z, 2007, MOL ONCOL, V1, P26, DOI 10.1016/j.molonc.2007.01.004; HERREROSVILLANUEVA, 2016, ANN TRANSL MED, V4, DOI DOI 10.21037/ATM.2016.03.44; Hsu HS, 2007, CANCER-AM CANCER SOC, V110, P2019, DOI 10.1002/cncr.23001; Ibanez de Caceres I, 2004, CANCER RES, V64, P6476; Izumchenko E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9258; Jahr S, 2001, CANCER RES, V61, P1659; Jiang PY, 2016, TRENDS GENET, V32, P360, DOI 10.1016/j.tig.2016.03.009; Jiao L, 2007, PANCREAS, V34, P55, DOI 10.1097/01.mpa.0000246665.68869.d4; Jung M, 2003, CLIN CHEM, V49, P1028, DOI 10.1373/49.6.1028; Kang Q, 2016, CLIN BIOCHEM, V49, P1354, DOI 10.1016/j.clinbiochem.2016.03.012; Kelly BT, 2007, CHEM COMMUN, P1773, DOI 10.1039/b616252e; Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x; Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108; Kinugasa H, 2015, BRIT J CANCER, V112, P1652, DOI 10.1038/bjc.2015.129; Kisiel JB, 2015, CLIN CANCER RES, V21, P4473, DOI 10.1158/1078-0432.CCR-14-2469; Koukoura O, 2014, MOL MED REP, V10, P3, DOI 10.3892/mmr.2014.2221; Lam NYL, 2004, CLIN CHEM, V50, P256, DOI 10.1373/clinchem.2003.026013; Le Calvez-Kelm F, 2016, ONCOTARGET, V7, P78827, DOI 10.18632/oncotarget.12386; Leamon JH, 2003, ELECTROPHORESIS, V24, P3769, DOI 10.1002/elps.200305646; Lehmann-Werman R, 2016, P NATL ACAD SCI USA, V113, pE1826, DOI 10.1073/pnas.1519286113; Lennon AM, 2014, CANCER RES, V74, P3381, DOI 10.1158/0008-5472.CAN-14-0734; LEON SA, 1977, CANCER RES, V37, P646; Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; Madic J, 2016, Biomol Detect Quantif, V10, P34; MANDEL P, 1948, C R Seances Soc Biol Fil, V142, P241; McDermott GP, 2013, ANAL CHEM, V85, P11619, DOI 10.1021/ac403061n; Millholland JM, 2012, RES REP UROL, V4, P33, DOI 10.2147/RRU.S32736; Morrison T, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl639; Newman AM, 2016, NAT BIOTECHNOL, V34, P547, DOI 10.1038/nbt.3520; Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519; Lopez SO, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040484; Pan WY, 2015, CLIN CHEM, V61, P514, DOI 10.1373/clinchem.2014.235457; Pantel K, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002205; Pecuchet N, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002199; Pecuchet N, 2016, CLIN CHEM, V62, P1492, DOI 10.1373/clinchem.2016.258236; Pekin D, 2011, LAB CHIP, V11, P2156, DOI 10.1039/c1lc20128j; Perez-Toralla K, 2015, M S-MED SCI, V31, P84, DOI 10.1051/medsci/20153101017; Perkins G, 2017, ADV CLIN CHEM, V79, P43, DOI 10.1016/bs.acc.2016.10.001; Pietrasz D, 2017, CLIN CANCER RES, V23, P116, DOI 10.1158/1078-0432.CCR-16-0806; Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171; Qureshi SA, 2010, INT J SURG, V8, P194, DOI 10.1016/j.ijsu.2010.02.001; Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080; Remon J, 2013, TRANSL LUNG CANCER R, V2, P445, DOI 10.3978/j.issn.2218-6751.2013.10.14; Ruscito I, 2014, EUR J CANCER, V50, P2090, DOI 10.1016/j.ejca.2014.05.001; Sanmamed MF, 2015, CLIN CHEM, V61, P297, DOI 10.1373/clinchem.2014.230235; Scholer LV, 2017, CLIN CANC RES; Schrock A, 2017, CLIN CHEM; Shen F, 2010, ANAL CHEM, V82, P4606, DOI 10.1021/ac1007249; Shriner D, 2004, GENETICS, V167, P1573, DOI 10.1534/genetics.103.023382; Shu YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00520-1; Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14; Soh J, 2006, INT J CANCER, V119, P2353, DOI 10.1002/ijc.22190; Song LL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03321-8; Sorber L, 2017, J MOL DIAGN, V19, P162, DOI 10.1016/j.jmoldx.2016.09.009; Streck, 2014, CELL FREE DNA BCT IN; STROUN M, 1987, EUR J CANCER CLIN ON, V23, P707, DOI 10.1016/0277-5379(87)90266-5; STROUN M, 1989, ONCOLOGY, V46, P318; Suzawa K, 2017, ONCOL REP, V37, P3100, DOI 10.3892/or.2017.5567; Swarup V, 2007, FEBS LETT, V581, P795, DOI 10.1016/j.febslet.2007.01.051; Takai E, 2015, SCI REP-UK, V5, DOI 10.1038/srep18425; Takeshita T, 2015, CANCER SCI, V106, P1582, DOI 10.1111/cas.12813; Taly V, 2013, CLIN CHEM, V59, P1722, DOI 10.1373/clinchem.2013.206359; Taly V, 2012, TRENDS MOL MED, V18, P405, DOI 10.1016/j.molmed.2012.05.001; Thijssen MAMA, 2002, ANTICANCER RES, V22, P421; Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219; Tschandl P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069639; Uehiro N, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0788-z; Umetani N, 2006, ANN NY ACAD SCI, V1075, P299, DOI 10.1196/annals.1368.040; Underhill HR, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006162; Vogelstein B, 1999, P NATL ACAD SCI USA, V96, P9236, DOI 10.1073/pnas.96.16.9236; Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7; Wang YQ, 2013, J OBSTET GYNAECOL RE, V39, P549, DOI 10.1111/j.1447-0756.2012.01979.x; Wang YX, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8507; Wielscher M, 2015, EBIOMEDICINE, V2, P929, DOI 10.1016/j.ebiom.2015.06.025; Williams R, 2006, NAT METHODS, V3, P545, DOI 10.1038/NMETH896; World Health Organization, 2007, CANC CONTR EARL DET; Yamanishi Y, 2002, P NATL ACAD SCI USA, V99, P10025, DOI 10.1073/pnas.152333199; Zhang C, 2010, CHEM REV, V110, P4910, DOI 10.1021/cr900081z; Zhang YW, 2011, CANCER LETT, V303, P21, DOI 10.1016/j.canlet.2010.12.011; Zhong Q, 2011, LAB CHIP, V11, P2167, DOI 10.1039/c1lc20126c; Zhou JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159708; Zonta E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159094	130	10	11	0	28	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					7	17		10.1080/14737159.2018.1400384			11	Pathology	Pathology	FS9QO	WOS:000422753500003	29115895				2019-10-28	
J	Byrnes, SA; Weigl, BH				Byrnes, Samantha A.; Weigl, Bernhard H.			Selecting analytical biomarkers for diagnostic applications: a first principles approach	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Biomarker selection; clinical outcomes; diagnostic devices; test assessment criteria	DRIED BLOOD SPOTS; PLASMODIUM-FALCIPARUM; CHLAMYDIA-TRACHOMATIS; EMERGING TECHNOLOGIES; INFECTIOUS-DISEASES; MALARIA; ANTIGENS; ASSAY; PCR; QUANTIFICATION	Introduction: Biomarkers are objective indications of a medical state that can be measured accurately and reproducibly. Traditional biomarkers enable diagnosis of disease through detection of disease-specific molecules, disease-mediated molecular changes, or distinct physiological or anatomical signatures. Areas covered: This work provides a framework for selecting biomarkers that are most likely to provide useful information about a patient's disease state. Though the authors emphasize markers related to disease, this work is also applicable to biomarkers for monitoring physiological changes such as ovulation or pregnancy. Additionally, the scope was restricted to biomarkers that are amenable to analytical detection across a range of health care levels, including low resource settings. The authors describe trade-offs between biomarkers' sensitivity/specificity for a disease-causing agent, the complexity of detection, and how this knowledge can be applied to the development of diagnostic tests. This report also details additional assessment criteria for successful tests. Expert commentary: Biomarker selection should primarily be driven by an attempt to answer an explicit clinical question (preferably causative relationship of the biomarker to disease-state), and only then by test development expediency (ease of detection). This framework is useful for stakeholders from test developers to clinicians to identify the trade-offs for diagnostic biomarkers for any use case.	[Byrnes, Samantha A.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Byrnes, Samantha A.; Weigl, Bernhard H.] Intellectual Ventures Lab, Bellevue, WA 98007 USA	Byrnes, SA (reprint author), Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.; Byrnes, SA (reprint author), Intellectual Ventures Lab, Bellevue, WA 98007 USA.	sbyrnes@intven.com					Agarwal A, 2015, PHARMACOGN PERS MED, V8, P99, DOI 10.2147/PGPM.S49493; [Anonymous], 1978, MED LETT DRUGS THER, V20, P30; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bolad A, 2005, SCAND J IMMUNOL, V61, P380, DOI 10.1111/j.1365-3083.2005.01587.x; Chernesky M, 2003, SEX TRANSM DIS, V30, P345, DOI 10.1097/00007435-200304000-00014; Collet-Brose J, 2016, J IMMUNOL RES, DOI 10.1155/2016/5069678; Conroy AL, 2016, OPEN FORUM INFECT DI, V3, P1, DOI DOI 10.1093/0FID/0FW134; Cook RL, 2005, ANN INTERN MED, V142, P914, DOI 10.7326/0003-4819-142-11-200506070-00010; Coronell JAL, 2012, J PROTEOMICS, V76, P102, DOI 10.1016/j.jprot.2012.07.022; Cowan KJ, 2017, BIOANALYSIS, V9, P937, DOI 10.4155/bio-2017-0024; de la Cruz-Hernandez SI, 2013, AM J TROP MED HYG, V88, P446, DOI 10.4269/ajtmh.12-0023; Derda R., 2015, PLOS NEGLECT TROP D, V9, P1; DiClemente RJ, 2004, JAMA-J AM MED ASSOC, V292, P171, DOI 10.1001/jama.292.2.171; Dobano C, 2012, CLIN VACCINE IMMUNOL, V19, P157, DOI 10.1128/CVI.05523-11; Dondorp AM, 2005, PLOS MED, V2, P788, DOI 10.1371/journal.pmed.0020204; Duah NO, 2010, PARASITE IMMUNOL, V32, P125, DOI 10.1111/j.1365-3024.2009.01165.x; Ely S, 2009, TRANSL RES, V154, P303, DOI 10.1016/j.trsl.2009.08.001; Farrar D, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-317; Fischer SK, 2015, AAPS J, V17, P93, DOI 10.1208/s12248-014-9682-8; Fung ET, 2010, CLIN CHEM, V56, P327, DOI 10.1373/clinchem.2009.140855; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247; Goulart LR, 2010, CRIT REV IMMUNOL, V30, P201, DOI 10.1615/CritRevImmunol.v30.i2.70; Higgins T, 2013, ENDOCRINE, V43, P266, DOI 10.1007/s12020-012-9768-y; Ismail HA, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-425; Kreutz JE, 2011, ANAL CHEM, V83, P8158, DOI 10.1021/ac201658s; Kumar AA, 2015, ANGEW CHEM INT EDIT, V54, P5835, DOI 10.1002/anie.201411741; Laban NM, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0544-3; Leligdowicz A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175130; Limper M, 2010, J INFECTION, V60, P409, DOI 10.1016/j.jinf.2010.03.016; LONG GW, 1995, AM J TROP MED HYG, V52, P344, DOI 10.4269/ajtmh.1995.52.344; Loubiere S, 2010, CLIN MICROBIOL INFEC, V16, P1070, DOI 10.1111/j.1469-0691.2010.03280.x; Michel CEC, 2007, J CLIN MICROBIOL, V45, P1395, DOI 10.1128/JCM.00100-07; Oyola SO, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1641-7; Peeling RW, 2010, NAT REV MICROBIOL, pS2, DOI 10.1038/nrmicro1522; Ramutton T, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-276; Ray S, 2014, PROTEOM CLIN APPL, V8, P53, DOI 10.1002/prca.201300074; Rogier E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172139; Semiglazov VF, 2007, CANCER-AM CANCER SOC, V110, P244, DOI 10.1002/cncr.22789; Sherin K, 2014, AM FAM PHYSICIAN, V89, P265; Simon S, 2017, BIOANALYSIS, V9, P753, DOI 10.4155/bio-2017-0018; Storling J, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020072; Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177; Sugunendran H, 2001, SEX TRANSM INFECT, V77, P423, DOI 10.1136/sti.77.6.423; The Mayo Clinic C. Eosinophilia, 2017, MAYO CLIN C EOSINOPH, P1; Thompson M, 2016, IEEE J TRANSL ENG HE, P4; Tran TM, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-393; VanderMeide PH, 1996, BIOTHERAPY, V8, P243, DOI 10.1007/BF01877210; Vashist SK, 2015, TRENDS BIOTECHNOL, V33, P692, DOI 10.1016/j.tibtech.2015.09.001; Weigl BH, 2009, EXPERT REV MED DEVIC, V6, P461, DOI [10.1586/erd.09.31, 10.1586/ERD.09.31]; Wenk MR, 2006, EXPERT OPIN DRUG DIS, V1, P723, DOI 10.1517/17460441.1.7.723; Wihokhoen B, 2016, AM J TROP MED HYG, V94, P322, DOI 10.4269/ajtmh.15-0532; Yeung D, 2016, J IMMUNOL METHODS, V437, P53, DOI 10.1016/j.jim.2016.08.003; Zhao XM, 2015, CLIN CHEM, V61, P1343, DOI 10.1373/clinchem.2014.231712; Zhou QC, 2015, CLIN LAB, V61, P1589, DOI 10.7754/Clin.Lab.2015.150332	55	2	2	0	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					19	26		10.1080/14737159.2018.1412258			8	Pathology	Pathology	FS9QO	WOS:000422753500004	29200322				2019-10-28	
J	Choi, JJ; McCarthy, MW				Choi, Justin J.; McCarthy, Matthew W.			Novel applications for serum procalcitonin testing in clinical practice	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Antibiotic stewardship; acute kidney injury; cerebral hemorrhage; sepsis; cirrhosis; procalcitonin	C-REACTIVE PROTEIN; TUMOR-NECROSIS-FACTOR; COMMUNITY-ACQUIRED PNEUMONIA; CHRONIC KIDNEY-DISEASE; OBSTRUCTIVE PULMONARY-DISEASE; GUIDED ANTIBIOTIC-THERAPY; HEART-FAILURE; BACTERIAL-INFECTION; DIAGNOSTIC-VALUE; INFLAMMATION	Introduction: Procalcitonin has emerged as a reliable marker of acute bacterial infection in hospitalized patients and the assay has recently been incorporated into several clinical algorithms to reduce antimicrobial overuse, but its use in patients with end-organ dysfunction is controversial. Areas covered: In this review, the authors examine what is known about procalcitonin testing in patients with organ dysfunction, including those with end-stage renal disease, congestive heart failure, chronic obstructive pulmonary disease, and cirrhosis, and explore how the assay is now being used in the management of non-infectious diseases. Expert commentary: Procalcitonin holds tremendous promise to identify a diverse set of medical conditions beyond those associated with acute bacterial infection, including post-surgical anastomotic leaks, acute kidney injury, and complications after intracerebral hemorrhage. The authors review recent studies examining procalcitonin in these areas and explore how the assay might be used to guide diagnosis and prognosis of non-infectious diseases in the near future.	[Choi, Justin J.; McCarthy, Matthew W.] New York Presbyterian Hosp, Weill Cornell Med Coll, Div Gen Internal Med, 525 East 68th St,Box 331, New York, NY 10065 USA	McCarthy, MW (reprint author), New York Presbyterian Hosp, Weill Cornell Med Coll, Div Gen Internal Med, 525 East 68th St,Box 331, New York, NY 10065 USA.	mwm9004@med.cornell.edu			Thermofisher; BioMerieux	MW McCarthy has served as a paid consultant to Allergan. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. A reviewer on this manuscript has disclosed that their institution has received funding from Thermofisher and BioMerieux.	Anker SD, 1997, AM J CARDIOL, V79, P1426, DOI 10.1016/S0002-9149(97)00159-8; Bafadhel M, 2011, CHEST, V139, P1410, DOI 10.1378/chest.10-1747; Balog A, 2002, IMMUNOL LETT, V84, P199, DOI 10.1016/S0165-2478(02)00158-X; Becker KL, 2008, CRIT CARE MED, V36, P941, DOI 10.1097/CCM.0B013E318165BABB; Bota DP, 2005, J LAB CLIN MED, V146, P347, DOI 10.1016/j.lab.2005.08.005; Boucher BA, 2000, CRIT CARE MED, V28, P1224, DOI 10.1097/00003246-200004000-00056; Boulogne M, 2017, INT J CARDIOL, V226, P53, DOI 10.1016/j.ijcard.2016.10.038; Boursier G, 2016, CLIN LAB, V62, P435, DOI 10.7754/Clin.Lab.2015.150736; Bozkurt B, 1998, CIRCULATION, V97, P1382, DOI 10.1161/01.CIR.97.14.1382; Brocca A., 2017, SCAND J SURG; Caglar K, 2002, KIDNEY INT, V62, P1408, DOI 10.1111/j.1523-1755.2002.kid556.x; Canbay A, 2015, ACTA CARDIOL, V70, P473, DOI 10.2143/AC.70.4.3096896; Ceylan B, 2017, CLIN NEUROL NEUROSUR, V153, P43, DOI 10.1016/j.clineuro.2016.12.006; Chenevier-Gobeaux C, 2012, BIOMARKERS, V17, P477, DOI 10.3109/1354750X.2012.685953; Chirapongsathorn S, 2017, J GASTROEN HEPATOL, V21, P1543; Christ-Crain M, 2006, AM J RESP CRIT CARE, V174, P84, DOI 10.1164/rccm.200512-1922OC; Cohen J, 2016, J ROY COLL PHYS EDIN, V46, P263, DOI 10.4997/JRCPE.2016.413; Connert S, 2003, Z GASTROENTEROL, V41, P165, DOI 10.1055/s-2003-37314; Contou D, 2014, J INFECTION, V68, P105, DOI 10.1016/j.jinf.2013.10.003; Dahaba AA, 2003, INTENS CARE MED, V29, P579, DOI 10.1007/s00134-003-1664-8; DANDONA P, 1994, J CLIN ENDOCR METAB, V79, P1605, DOI 10.1210/jc.79.6.1605; Daubin C, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-157; Daubin C, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-145; Davidson RJ, 1997, AM J KIDNEY DIS S, V30, pSS15; Demissei BG, 2016, INT J CARDIOL, V204, P164, DOI 10.1016/j.ijcard.2015.11.141; Dominguez-Comesana Elias, 2014, Cir Cir, V82, P231; Dumea R, 2014, INT UROL NEPHROL, V46, P461, DOI 10.1007/s11255-013-0542-8; Eberhard OK, 1997, ARTHRITIS RHEUM, V40, P1250, DOI 10.1002/1529-0131(199707)40:7<1250::AID-ART9>3.0.CO;2-A; Elefsiniotis IS, 2006, EUR J GASTROEN HEPAT, V18, P525, DOI 10.1097/00042737-200605000-00012; Falsey AR, 2012, INT J CHRONIC OBSTR, V7, P127, DOI 10.2147/COPD.S29149; FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479; Fitzpatrick B, 2012, ISRN UROL, V2012; Gallego M, 2016, INT J CHRONIC OBSTR, V11, P2633, DOI 10.2147/COPD.S117129; Gilbert D, 2011, AM J RESP CRIT CARE, V184, P1210, DOI 10.1164/ajrccm.184.10.1210; Gilbert DN, 2010, J CLIN MICROBIOL, V48, P2325, DOI 10.1128/JCM.00655-10; Grace E, 2014, CLIN INFECT DIS, V59, P1761, DOI 10.1093/cid/ciu732; Guz G, 2006, PERITON DIALYSIS INT, V26, P240; HAEFFNERCAVAILLON N, 1993, KIDNEY INT, V43, pS139; Hayati Firdaus, 2017, Asian Pac J Cancer Prev, V18, P1821; He D, 2017, CELL MOL NEUROBIOL; HERBELIN A, 1990, KIDNEY INT, V37, P116, DOI 10.1038/ki.1990.16; Herget-Rosenthal S, 2005, SCAND J IMMUNOL, V61, P180, DOI 10.1111/j.0300-9475.2005.01545.x; Herget-Rosenthal S, 2001, NEPHROL DIAL TRANSPL, V16, P975, DOI 10.1093/ndt/16.5.975; Hoffmann U, 2003, AM J NEPHROL, V23, P442, DOI 10.1159/000074536; Hug A, 2011, NEUROCRIT CARE, V14, P416, DOI 10.1007/s12028-009-9325-6; Jeeha R, 2017, NEPHROLOGY, V54, P2111; Karakousis PC, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-89; Kherad O, 2010, CHEST, V138, P896, DOI 10.1378/chest.09-2225; Koutsounas I, 2015, WORLD J HEPATOL, V7, P2264, DOI 10.4254/wjh.v7.i20.2264; Kuse ER, 2000, CRIT CARE MED, V28, P555, DOI 10.1097/00003246-200002000-00044; Kutz A, 2014, BMC ANESTHESIOL, V14, DOI 10.1186/1471-2253-14-102; Kylanpaa-Back ML, 2001, CRIT CARE MED, V29, P63, DOI 10.1097/00003246-200101000-00016; Lai KN, 2010, NEPHRON CLIN PRACT, V116, pC11, DOI 10.1159/000314544; LAUDESHARP M, 1990, KIDNEY INT, V38, P1089, DOI 10.1038/ki.1990.317; Lavin-Gomez Bernardo A, 2011, Adv Perit Dial, V27, P33; Lazzarotto C, 2013, ANN HEPATOL, V12, P599; Lee WS, 2015, KOREAN J INTERN MED, V30, P198, DOI 10.3904/kjim.2015.30.2.198; Lesinska M, 2014, ADV MED SCI-POLAND, V59, P52, DOI 10.1016/j.advms.2013.07.006; Level C, 2001, NEPHROL DIAL TRANSPL, V16, P980, DOI 10.1093/ndt/16.5.980; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; Lin KH, 2014, DIAGN MICR INFEC DIS, V80, P72, DOI 10.1016/j.diagmicrobio.2014.03.029; Lindell RB, 2017, PEDIATR CRIT CARE ME, V18, P1114, DOI 10.1097/PCC.0000000000001338; Linscheid P, 2004, CRIT CARE MED, V32, P1715, DOI 10.1097/01.CCM.0000134404.63292.71; Linscheid P, 2003, ENDOCRINOLOGY, V144, P5578, DOI 10.1210/en.2003-0854; Liu H, 2017, CHINESE MED J-PEKING, V130, P1175, DOI 10.4103/0366-6999.205857; Loncar G, 2015, BIOMARK MED, V9, P651, DOI [10.2217/BMM.15.29, 10.2217/bmm.15.29]; LONNEMANN G, 1990, BLOOD PURIFICAT, V8, P214, DOI 10.1159/000169969; Lorton F, 2007, PEDIATR NEPHROL, V22, P430, DOI 10.1007/s00467-006-0304-2; Lu XL, 2013, NEPHROL DIAL TRANSPL, V28, P122, DOI 10.1093/ndt/gfs339; Maisel AS, 2012, NAT REV CARDIOL, V9, P478, DOI 10.1038/nrcardio.2012.60; Martinez FJ, 2007, CHEST, V131, P1, DOI 10.1378/chest.06-2567; Maruna P, 2000, PHYSIOL RES, V49, pS57; Meisner M, 2002, CLIN CHIM ACTA, V323, P17, DOI 10.1016/S0009-8981(02)00101-8; Miettinen KH, 2008, EUR J HEART FAIL, V10, P396, DOI 10.1016/j.ejheart.2008.02.008; Mollar A, 2014, INT J CARDIOL, V177, P532, DOI 10.1016/j.ijcard.2014.08.106; Montagnana M, 2009, SCAND J CLIN LAB INV, V69, P703, DOI 10.1080/00365510902993663; Moyer MW, 2012, NAT MED, V18, P999, DOI 10.1038/nm0712-999; Niebauer J, 1999, LANCET, V353, P1838, DOI 10.1016/S0140-6736(98)09286-1; Oberhoffer M, 1999, J CRIT CARE, V14, P29, DOI 10.1016/S0883-9441(99)90005-9; Oberhoffer M, 1999, J LAB CLIN MED, V134, P49, DOI 10.1016/S0022-2143(99)90053-7; Opatrna S, 2005, PERITON DIALYSIS INT, V25, P470; Oruc N, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-16; Page AE, 2015, MEDICINE, V94, pe2264; Page VJ, 2014, CRIT CARE, V18, DOI 10.1186/cc13712; Panichi V, 2000, KIDNEY INT, V58, pS96, DOI 10.1046/j.1523-1755.2000.07612.x; Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092; Villanueva MP, 2015, EUR J INTERN MED, V26, P42, DOI 10.1016/j.ejim.2014.12.009; Pilotto A, 2017, AGING CLIN EXP RES; Pouriki S, 2017, EUR J CLIN MICROBIOL; Povoa P, 2017, J CRIT CARE, V41, P91, DOI 10.1016/j.jcrc.2017.05.007; Rauchhaus M, 2000, CIRCULATION, V102, P3060; Reinhart K, 2017, JAMA INTERN MED, V177, P142, DOI 10.1001/jamainternmed.2016.7820; Reinhart K, 2011, CRIT CARE CLIN, V27, P253, DOI 10.1016/j.ccc.2011.01.002; Remskar M, 2002, WIEN KLIN WOCHENSCHR, V114, P205; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Rivers E, 2006, CRIT CARE, V10, DOI 10.1186/cc4973; Rivers EP, 2004, CRIT CARE MED, V32, P314, DOI 10.1097/01.CCM.0000104937.09370.53; Schmidt M, 2000, NEPHRON, V84, P187, DOI 10.1159/000045570; Schuetz P, 2011, EUR RESPIR J, V37, P384, DOI 10.1183/09031936.00035610; Schuetz P, 2017, LANCET INFECT DIS, V14, P865; Schuetz P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub3; Schuetz P, 2017, EXPERT REV MOL DIAGN, V17, P593, DOI 10.1080/14737159.2017.1324299; Schuetz P, 2016, INT J CARDIOL, V223, P390, DOI 10.1016/j.ijcard.2016.08.204; Schuetz P, 2014, INT J CARDIOL, V175, P464, DOI 10.1016/j.ijcard.2014.06.022; Schuetz P, 2010, VIRULENCE, V1, P88, DOI 10.4161/viru.1.2.10488; Schuetz P, 2010, EUR J CLIN INVEST, V40, P376, DOI 10.1111/j.1365-2362.2010.02259.x; Sinha M, 2011, INDIAN J ANAESTH, V55, P266, DOI 10.4103/0019-5049.82676; Sinning CR, 2011, CIRC J, V75, P1184, DOI 10.1253/circj.CJ-10-0638; Sitter T, 2002, J NEPHROL, V15, P297; Steinbach G, 2004, WIEN KLIN WOCHENSCHR, V116, P849, DOI 10.1007/s00508-004-0279-6; Thursz MR, 2015, NEW ENGL J MED, V373, P282, DOI 10.1056/NEJMc1506342; Travaglino F, 2014, AM J EMERG MED, V32, P334, DOI 10.1016/j.ajem.2013.12.045; Ulm L, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00153; Valent AM, 2017, AM J PERINAT, V34, P1212, DOI 10.1055/s-0037-1602418; van der Maas ME, 2017, OMICS, V21, P232, DOI 10.1089/omi.2016.0186; van Oers JAH, 2017, JAMA INTERN MED, V177, P142, DOI 10.1001/jamainternmed.2016.7814; Vasan RS, 2003, CIRCULATION, V107, P1486, DOI 10.1161/01.CIR.0000057810.48709.F6; Viallon A, 2000, INTENS CARE MED, V26, P1082, DOI 10.1007/s001340051321; Visvardis G, 2005, RENAL FAILURE, V27, P429, DOI 10.1081/JDI-200065200; Wang C, 2016, MOL NEUROBIOL, V53, P1509, DOI 10.1007/s12035-015-9112-7; Wolinski K, 2017, ENDOKRYNOL POL, V68, P434, DOI 10.5603/EP.a2017.0038	121	3	3	2	9	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					27	34		10.1080/14737159.2018.1407244			8	Pathology	Pathology	FS9QO	WOS:000422753500005	29148856				2019-10-28	
J	Mayo-de-Las-Casas, C; Ibanez, MG; Jordana-Ariza, N; Garcia-Pelaez, B; Balada-Bel, A; Villatoro, S; Malapelle, U; Karachaliou, N; Troncone, G; Rosell, R; Molina-Vila, MA				Mayo-de-Las-Casas, Clara; Garzon Ibanez, Monica; Jordana-Ariza, Nuria; Garcia-Pelaez, Beatriz; Balada-Bel, Ariadna; Villatoro, Sergio; Malapelle, Umberto; Karachaliou, Niki; Troncone, Giancarlo; Rosell, Rafael; Angel Molina-Vila, Miguel			An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Ctdna (circulating tumor DNA); cfDNA (circulating free DNA); biomarkers; acquired resistance; NSCLC (Non small cell lung cancer); liquid biopsy; NGS (next generation sequencing)	CIRCULATING TUMOR DNA; FACTOR RECEPTOR MUTATIONS; EGFR MUTATION; ACQUIRED-RESISTANCE; KRAS MUTATIONS; GENE-MUTATIONS; NSCLC PATIENTS; KINASE INHIBITORS; NUCLEIC-ACIDS; OPEN-LABEL	Introduction: Collection of tumor samples is not always feasible in non-small cell lung cancer (NSCLC) patients, and circulating free DNA (cfDNA) extracted from blood represents a viable alternative. Different sensitive platforms have been developed for genetic cfDNA testing, some of which are already in clinical use. However, several difficulties remain, particularly the lack of standardization of these methodologies. Areas covered: Here, the authors present a review of the literature to update the applicability of cfDNA for diagnosis and monitoring of NSCLC patients. Expert commentary: Detection of somatic alterations in cfDNA is already in use in clinical practice and provides valuable information for patient management. Monitoring baseline alterations and emergence of resistance mutations is one of the most important clinical applications and can be used to non-invasively track disease evolution. Today, different technologies are available for cfDNA analysis, including whole-genome or exome sequencing and targeted methods that focus on a selection of genes of interest in a specific disease. In the case of Next Generation Sequencing (NGS) approaches, in depth coverage of candidate mutation loci can be achieved by selecting a limited number of targeted genes.	[Mayo-de-Las-Casas, Clara; Garzon Ibanez, Monica; Jordana-Ariza, Nuria; Garcia-Pelaez, Beatriz; Balada-Bel, Ariadna; Villatoro, Sergio; Angel Molina-Vila, Miguel] Quiron Dexeus Univ Hosp, Pangaea Oncol, Barcelona, Spain; [Malapelle, Umberto; Troncone, Giancarlo] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy; [Karachaliou, Niki] Univ Hosp Sagrat Cor, Dr Rosell Oncol Inst, Barcelona, Spain; [Rosell, Rafael] Germans Trias i Pujol Hlth Sci Inst & Hosp, Catalan Inst Oncol, Canc Biol & Precis Med Program, Badalona, Spain	Molina-Vila, MA (reprint author), Quiron Dexeus Univ Hosp, Pangaea Oncol, Lab Oncol, External Consultat Bldg,Room 1-7, Barcelona 08028, Spain.	mamolina@panoncology.com		Malapelle, Umberto/0000-0003-3211-9957			Aguado C, 2016, TRANSL LUNG CANCER R, V5, P525, DOI 10.21037/tlcr.2016.09.02; Ai B, 2016, ONCOTARGET, V7, P44583, DOI 10.18632/oncotarget.10069; Bethune Gillian, 2010, J Thorac Dis, V2, P48; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Board RE, 2008, ANN NY ACAD SCI, V1137, P98, DOI 10.1196/annals.1448.020; Bordi P, 2017, CLIN LUNG CANCER, V18, P692, DOI 10.1016/j.cllc.2017.04.013; Bordi P, 2015, TRANSL LUNG CANCER R, V4, P584, DOI 10.3978/j.issn.2218-6751.2015.08.09; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01; Chic Nuria, 2017, J Thorac Oncol, V12, pe78, DOI 10.1016/j.jtho.2017.02.014; Choi JJ, 2005, IMMUNOLOGY, V115, P55, DOI 10.1111/j.1365-2567.2005.02130.x; Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011; Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554; Douillard JY, 2014, J THORAC ONCOL, V9, P1345, DOI 10.1097/JTO.0000000000000263; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; European Medicines Agency, SUMM PROD CHAR IR AN; Fan WW, 2011, CANCER RES, V71, P4494, DOI 10.1158/0008-5472.CAN-10-2668; Fang MY, 2014, J CANCER RES THER, V10, pC150, DOI 10.4103/0973-1482.145847; Federal Drug Administration, LIST CLEAR APPR COMP; Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001; Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726; Garzon M, 2016, TRANSL LUNG CANCER R, V5, P511, DOI 10.21037/tlcr.2016.10.14; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gonzalez-Cao M, 2015, MELANOMA RES, V25, P486, DOI 10.1097/CMR.0000000000000187; Goto K, 2012, J THORAC ONCOL, V7, P115, DOI 10.1097/JTO.0b013e3182307f98; Isozaki H, 2015, CANCERS, V7, P763, DOI 10.3390/cancers7020763; Janne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817; Janku F, 2016, CLIN CANCER RES, V22, P5400, DOI 10.1158/1078-0432.CCR-16-1769; Karachaliou N, 2015, JAMA ONCOL, V1, P149, DOI 10.1001/jamaoncol.2014.257; Karlovich C, 2016, CLIN CANCER RES, V22, P2386, DOI 10.1158/1078-0432.CCR-15-1260; Kim HR, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-50; Kimura H, 2006, CLIN CANCER RES, V12, P3915, DOI 10.1158/1078-0432.CCR-05-2324; Korpanty GJ, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00204; Leary RJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004742; Leary RJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000702; Lee HW, 2015, J CLIN ONCOL, V33; Lee JY, 2016, ONCOTARGET, V7, P6984, DOI 10.18632/oncotarget.6874; Lovly Christine M, 2017, Am Soc Clin Oncol Educ Book, V37, P607, DOI 10.14694/EDBK_176251; Luke JJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju214; Malapelle U, 2017, BRIT J CANCER, V116, P802, DOI 10.1038/bjc.2017.8; Marchetti A, 2015, J THORAC ONCOL, V10, P1437, DOI 10.1097/JTO.0000000000000643; de las Casas CM, 2016, TRANSL LUNG CANCER R, V5, P532, DOI 10.21037/tlcr.2016.10.04; Mayo-de-las-Casas C, 2017, ANN ONCOL, V28, P2248, DOI 10.1093/annonc/mdx288; Mohammed AA, 2017, J CANCER RES THER, V13, P9, DOI 10.4103/0973-1482.180605; Mok T, 2015, CLIN CANCER RES, V21, P3196, DOI 10.1158/1078-0432.CCR-14-2594; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Molina-Vila MA, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed.2016.00069; Molina-Vila MA, 2014, CLIN CANCER RES, V20, P4647, DOI 10.1158/1078-0432.CCR-13-2391; Morgensztern D, 2015, J THORAC ONCOL, V10, pS1, DOI 10.1097/JTO.0000000000000405; Morgillo F, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000060; Nilsson RJA, 2016, ONCOTARGET, V7, P1066, DOI 10.18632/oncotarget.6279; Nordgard O, 2012, DIAGN MOL PATHOL, V21, P9, DOI 10.1097/PDM.0b013e31821e59dc; Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162; Oxnard GR, 2014, CLIN CANCER RES, V20, P1698, DOI 10.1158/1078-0432.CCR-13-2482; Pan W, 2016, ONCOTARGET, V7, P8373, DOI 10.18632/oncotarget.7080; Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2; Punnoose EA, 2012, CLIN CANCER RES, V18, P2391, DOI 10.1158/1078-0432.CCR-11-3148; Reck M, 2014, ANN ONCOL, V25, P27, DOI 10.1093/annonc/mdu199; Reguart N, 2017, CLIN CHEM, V63, P751, DOI 10.1373/clinchem.2016.265314; Rosell R, 2016, LANCET, V387, P1354, DOI 10.1016/S0140-6736(15)01125-3; Rosell R, 2012, LANCET ONCOL, V13, P971, DOI 10.1016/S1470-2045(12)70369-8; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Sacher AG, 2016, JAMA ONCOL, V2, P1014, DOI 10.1001/jamaoncol.2016.0173; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Santarpia M, 2016, BIOMARK MED, V10, P417, DOI 10.2217/bmm.16.6; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Shaw AT, 2016, NEW ENGL J MED, V374, P54, DOI 10.1056/NEJMoa1508887; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Soh J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007464; Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]; Sorensen BS, 2014, CANCER-AM CANCER SOC, V120, P3896, DOI 10.1002/cncr.28964; Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9; Sundaresan TK, 2016, CLIN CANCER RES, V22, P1103, DOI 10.1158/1078-0432.CCR-15-1031; Tan DSW, 2014, INT J CANCER, V135, P1092, DOI 10.1002/ijc.28750; Thress KS, 2015, LUNG CANCER, V90, P509, DOI 10.1016/j.lungcan.2015.10.004; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Vallee A, 2013, LUNG CANCER, V82, P373, DOI 10.1016/j.lungcan.2013.08.014; VanderLaan PA, 2014, LUNG CANCER, V84, P39, DOI 10.1016/j.lungcan.2014.01.013; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Volik S, 2016, MOL CANCER RES, V14, P898, DOI 10.1158/1541-7786.MCR-16-0044; Wang Z, 2017, J THORAC ONCOL, V12, P1723, DOI 10.1016/j.jtho.2017.06.017; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yang M, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0468-1; Yang Y, 2017, ONCOTARGET, V8, P49773, DOI 10.18632/oncotarget.17937; Yu HA, 2015, JAMA ONCOL, V1, P981, DOI 10.1001/jamaoncol.2015.1066; Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	96	14	14	2	26	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					35	45		10.1080/14737159.2018.1407243			11	Pathology	Pathology	FS9QO	WOS:000422753500006	29172773				2019-10-28	
J	Howell, LS; Ireland, L; Park, BK; Goldring, CE				Howell, Lawrence S.; Ireland, Lucy; Park, B. Kevin; Goldring, Christopher E.			MiR-122 and other microRNAs as potential circulating biomarkers of drug-induced liver injury	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						MicroRNA; biomarker; DILI; hepatotoxicity; zonation; specificity; sensitivity	ALANINE AMINOTRANSFERASE; ALKALINE-PHOSPHATASE; PARTIAL-HEPATECTOMY; SAFETY BIOMARKERS; TIME-COURSE; RAT-LIVER; HYS LAW; EXPRESSION; SERUM; DISEASE	Introduction: Drug-induced liver injury (DILI) is a severe adverse drug reaction which is of major concern to patients, clinicians and the pharmaceutical industry. Accurate and rapid detection of DILI is important for patient stratification and treatment in the clinic and benefits preclinical drug design and risk assessment. MicroRNAs (miRNAs) offer a potential new and improved class of circulating biomarkers of DILI over the current gold standard biomarkers. Areas covered: This review highlights the shortcomings of the currently used panel of biomarkers and how miRNAs, primarily miR-122, show an improved level of specificity and sensitivity in the prediction of DILI. Furthermore, the use of miRNAs as potential markers of progression of DILI and specific zonated damage within the liver is discussed. Expert commentary: MiRNAs offer more sensitive and specific markers over the current biomarkers for DILI. Combinations of different miRNAs may be able to relay the location of DILI and the progression of disease. More studies using different hepatotoxins apart from acetaminophen will ultimately strengthen the case for the clinical introduction of miRNAs as biomarkers of DILI.	[Howell, Lawrence S.; Park, B. Kevin; Goldring, Christopher E.] Univ Liverpool, MRC Ctr Drug Safety Sci, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England; [Ireland, Lucy] Univ Liverpool, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England	Goldring, CE (reprint author), Univ Liverpool, MRC Ctr Drug Safety Sci, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	chrissy@liverpool.ac.uk			Medical Research CouncilMedical Research Council UK (MRC) [MR/L006758/1]	This paper was supported by the Medical Research Council (MR/L006758/1).	Alfirevic A, 2017, TRENDS PHARMACOL SCI, V38, P100, DOI 10.1016/j.tips.2016.11.003; Antoine DJ, 2014, TOXICOL RES-UK, V3, P75, DOI 10.1039/c3tx50077b; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bala S, 2012, HEPATOLOGY, V56, P1946, DOI 10.1002/hep.25873; Bandiera S, 2015, J HEPATOL, V62, P448, DOI 10.1016/j.jhep.2014.10.004; Bjornsson E, 2005, HEPATOLOGY, V42, P481, DOI 10.1002/hep.20800; Boix L, 2016, ONCOTARGET, V7, P71309, DOI 10.18632/oncotarget.11885; Campuzano S, 2014, ANAL BIOANAL CHEM, V406, P27, DOI 10.1007/s00216-013-7459-z; Castro RE, 2010, AM J PHYSIOL-GASTR L, V299, pG887, DOI 10.1152/ajpgi.00216.2010; Chalasani N, 2015, GASTROENTEROLOGY, V148, P1340, DOI 10.1053/j.gastro.2015.03.006; Chen MJ, 2015, J HEPATOL, V63, P503, DOI 10.1016/j.jhep.2015.04.016; Chen XY, 2016, MED SCI MONITOR, V22, P83, DOI 10.12659/MSM.896157; Church RJ, 2017, LIVER INT, V37, P1582, DOI 10.1111/liv.13441; Church RJ, 2016, TOXICOL SCI, V150, P3, DOI 10.1093/toxsci/kfv260; Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76; Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211; Dear JW, 2014, BRIT J CLIN PHARMACO, V77, P904, DOI 10.1111/bcp.12214; DUKES GE, 1984, ANN INTERN MED, V100, P646, DOI 10.7326/0003-4819-100-5-646; Esau C, 2006, CELL METAB, V3, P87, DOI 10.1016/j.cmet.2006.01.005; Farid WRR, 2012, LIVER TRANSPLANT, V18, P290, DOI 10.1002/lt.22438; Feng C, 2017, ANAL CHEM, V89, P6631, DOI 10.1021/acs.analchem.7b00850; Fontana RJ, 2014, GASTROENTEROLOGY, V147, P96, DOI 10.1053/j.gastro.2014.03.045; Fontana RJ, 2014, GASTROENTEROLOGY, V146, P914, DOI 10.1053/j.gastro.2013.12.032; Gatfield D, 2009, GENE DEV, V23, P1313, DOI 10.1101/gad.1781009; Giannini EG, 2005, CAN MED ASSOC J, V172, P367, DOI 10.1503/cmaj.1040752; Hornby RJ, 2014, EXPERT REV CLIN PHAR, V7, P349, DOI 10.1586/17512433.2014.904201; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Jaeschke H, 2015, DIGEST DIS, V33, P464, DOI 10.1159/000374090; Juskeviciute E, 2016, AM J PHYSIOL-GASTR L, V311, pG794, DOI 10.1152/ajpgi.00292.2016; Kim YK, 2016, P NATL ACAD SCI USA, V113, pE1881, DOI 10.1073/pnas.1602532113; KNOPP RH, 1993, ARCH INTERN MED, V153, P1321; Krauskopf J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177928; Kullak-Ublick GA, 2017, GUT, V66, P1154, DOI 10.1136/gutjnl-2016-313369; Lakehal F, 2001, CHEM RES TOXICOL, V14, P694, DOI 10.1021/tx0002435; Lewis PJS, 2011, HEPATOLOGY, V54, P1767, DOI 10.1002/hep.24538; Lindros KO, 1997, GEN PHARMACOL, V28, P191, DOI 10.1016/S0306-3623(96)00183-8; Longo DM, 2017, CLIN PHARMACOL THER, V102, P961, DOI 10.1002/cpt.711; Lopez-Riera M, 2017, FRONT PHARMACOL, V8, DOI [10.3389/fpahr.2017.00003, 10.3389/fphar.2017.00003]; Luna JM, 2015, CELL, V160, P1099, DOI 10.1016/j.cell.2015.02.025; Meunier J, 2013, GENOME RES, V23, P34, DOI 10.1101/gr.140269.112; Momen-Heravi F, 2015, SCI REP-UK, V5, DOI 10.1038/srep09991; Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520-014-0296-x; Nathwani RA, 2005, HEPATOLOGY, V41, P380, DOI 10.1002/hep.20548; Onakpoya IJ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0553-2; Padda MS, 2011, HEPATOLOGY, V53, P1377, DOI 10.1002/hep.24229; Park HK, 2016, J VET SCI, V17, P45, DOI 10.4142/jvs.2016.17.1.45; Pirola CJ, 2015, GUT, V64, P800, DOI 10.1136/gutjnl-2014-306996; Reau NS, 2008, CLIN LIVER DIS, V12, P203, DOI 10.1016/j.cld.2007.11.007; Regev A, 2014, GASTROENTEROLOGY, V147, P20, DOI 10.1053/j.gastro.2014.05.027; Robles-Diaz M, 2016, FRONT PHARMACOL; Robles-Diaz M, 2014, GASTROENTEROLOGY, V147, P109, DOI 10.1053/j.gastro.2014.03.050; Rockey DC, 2010, HEPATOLOGY, V51, P2117, DOI 10.1002/hep.23577; Roth RA, 2010, J PHARMACOL EXP THER, V332, P692, DOI 10.1124/jpet.109.162651; Russo MW, 2017, LIVER INT, V37, P757, DOI 10.1111/liv.13312; Sarac F, 2007, BIOTECHNOL BIOTEC EQ, V21, P194, DOI 10.1080/13102818.2007.10817444; Sekine S, 2009, J PATHOL, V219, P365, DOI 10.1002/path.2606; Singanayagam A, 2015, CURR OPIN CRIT CARE, V21, P134, DOI 10.1097/MCC.0000000000000187; Stutchfield BM, 2015, GASTROENTEROLOGY, V149, P1896, DOI 10.1053/j.gastro.2015.08.053; Tamai S, 2017, J TOXICOL SCI, V42, P73, DOI 10.2131/jts.42.73; Tavallaie R, 2015, WIRES NANOMED NANOBI, V7, P580, DOI 10.1002/wnan.1324; Thulin P, 2014, LIVER INT, V34, P367, DOI 10.1111/liv.12322; Vaca L, 2014, SENSORS-BASEL, V14, P9117, DOI 10.3390/s140509117; Vliegenthart ADB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15501; Vliegenthart ADB, 2017, BRIT J CLIN PHARMACO, V83, P2027, DOI 10.1111/bcp.13282; Vliegenthart ADB, 2014, ZEBRAFISH, V11, P219, DOI 10.1089/zeb.2013.0912; Wang J, 2016, J CELL PHYSIOL, V231, P25, DOI 10.1002/jcp.25056; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Ward J, 2014, P NATL ACAD SCI USA, V111, P12169, DOI 10.1073/pnas.1412608111; Woolbright BL, 2013, TOXICOL APPL PHARM, V273, P524, DOI 10.1016/j.taap.2013.09.023; Yamaura Y, 2014, TOXICOLOGY, V322, P89, DOI 10.1016/j.tox.2014.05.008; Yamaura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030250	71	7	8	1	9	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					47	54		10.1080/14737159.2018.1415145			8	Pathology	Pathology	FS9QO	WOS:000422753500007	29235390				2019-10-28	
J	Budd, E; Nalesso, G; Mobasheri, A				Budd, Emma; Nalesso, Giovanna; Mobasheri, Ali			Extracellular genomic biomarkers of osteoarthritis	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Osteoarthritis; extracellular; genomic biomarkers; body fluids; liquid biopsy; ncRNA; miRNA; cfDNA; mRNA; extracellular nucleic acid carriers	CELL-FREE DNA; BLOOD-BASED BIOMARKERS; FREE SERUM DNA; NONCODING RNAS; SYNOVIAL-FLUID; PERIPHERAL-BLOOD; KNEE OSTEOARTHRITIS; PROTEOMIC ANALYSIS; GENE-EXPRESSION; NUCLEIC-ACIDS	Introduction: Osteoarthritis (OA), a chronic, debilitating and degenerative disease of the joints, is the most common form of arthritis. The seriousness of this prevalent and chronic disease is often overlooked. Disease modifying OA drug development is hindered by the lack of soluble biomarkers to detect OA early. The objective of OA biomarker research is to identify early OA prior to the appearance of radiographic signs and the development of pain. Areas covered: This review has focused on extracellular genomic material that could serve as biomarkers of OA. Recent studies have examined the expression of extracellular genomic material such as miRNA, lncRNA, snoRNA, mRNA and cell-free DNA, which are aberrantly expressed in the body fluids of OA patients. Changes in genomic content of peripheral blood mononuclear cells in OA could also function as biomarkers of OA. Expert commentary: There is an unmet need for soluble biomarkers for detecting and then monitoring OA disease progression. Extracellular genomic material research may also reveal more about the underlying pathophysiology of OA. Minimally-invasive liquid biopsies such as synovial fluid and blood sampling of genomic material may be more sensitive over radiography in the detection, diagnosis and monitoring of OA in the future.	[Budd, Emma; Mobasheri, Ali] Univ Surrey, Sch Vet Med, D BOARD European Consortium Biomarker Discovery, Guildford, Surrey, England; [Budd, Emma; Nalesso, Giovanna; Mobasheri, Ali] Univ Surrey, Sch Vet Med, Fac Hlth & Med Sci, Dept Vet Preclin Sci, Guildford, Surrey, England; [Mobasheri, Ali] Queens Med Ctr, Arthritis Res UK Ctr Sport Exercise & Osteoarthri, Nottingham, England	Budd, E (reprint author), Univ Surrey, Sch Vet Med, Guildford GU2 7AL, Surrey, England.	e.budd@surrey.ac.uk	Mobasheri, Ali/D-5770-2011	Mobasheri, Ali/0000-0001-6261-1286; Nalesso, Giovanna/0000-0002-9424-3075	European Commission Framework 7 programme (EU FP7) [HEALTH.2012.2.4.5-2, 305815]; Innovative Medicines Initiative Joint Undertaking [115770]; European Union's Seventh Framework programmeEuropean Union (EU); EFPIA companies'	The research leading to these results was funded by the European Commission Framework 7 programme (EU FP7; HEALTH.2012.2.4.5-2, project number 305815; Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases). This project has also received partial support from the Innovative Medicines Initiative Joint Undertaking under grant agreement No. 115770, resources of which are composed of financial contribution from the European Union's Seventh Framework programme (FP7/2007-2013) and EFPIA companies' in-kind contribution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelal IT, 2016, EGYPT RHEUMATOL, V38, P295, DOI 10.1016/j.ejr.2016.06.005; Abels ER, 2016, CELL MOL NEUROBIOL, V36, P301, DOI 10.1007/s10571-016-0366-z; Agarwal A, 2015, PHARMACOGN PERS MED, V8, P99, DOI 10.2147/PGPM.S49493; Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Akhtar N, 2012, ANN RHEUM DIS, V71, P1073, DOI 10.1136/annrheumdis-2011-200519; ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Amort M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8030; [Anonymous], 2007, INT C HARM TECHN REQ; Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Arthritis Research UK, STAT OF MUSC HLTH 20; Attur M, 2011, ARTHRITIS RHEUM-US, V63, P1908, DOI 10.1002/art.30360; Balakrishnan L, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-6; Bay-Jensen AC, 2016, EBIOMEDICINE, V7, P4, DOI 10.1016/j.ebiom.2016.05.004; Beyer C, 2015, ANN RHEUM DIS, V74, DOI 10.1136/annrheumdis-2013-204698; Bloom RD, 2017, J AM SOC NEPHROL, V28, P2221, DOI 10.1681/ASN.2016091034; Cuadra VMB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097690; Budd E, 2017, SCI REP-UK, V7, DOI 10.1038/srep46704; Chan IS, 2011, ANNU REV GENOM HUM G, V12, P217, DOI 10.1146/annurev-genom-082410-101446; Chang CPY, 2003, CLIN CHIM ACTA, V327, P95, DOI 10.1016/S0009-8981(02)00337-6; Chang TJ, 2016, CELL PROLIFERAT, V49, P207, DOI 10.1111/cpr.12246; Chen WK, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12313; Cheng L, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.23743; Chi KR, 2016, NATURE, V538, P275, DOI 10.1038/538275a; Chu CR, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3845; Clutterbuck AL, 2011, J PROTEOMICS, V74, P704, DOI 10.1016/j.jprot.2011.02.017; Cross M, 2014, ANN RHEUM DIS, V73, P1323, DOI 10.1136/annrheumdis-2013-204763; Di Meo A, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0644-5; Diebel Kevin W, 2016, Biomark Insights, V11, P1, DOI 10.4137/BMI.S35904; Dirks RAM, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0284-4; Emans PJ, 2013, DEV INSIGHTS CARTILA; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Feingold KR, 2015, ENDOTEXT; Felekkis K, 2010, HIPPOKRATIA, V14, P236; Fernandez-Puente P, 2015, DISCOVERY BIOMARKERS; Fernandez-Puente P, 2011, J PROTEOME RES, V10, P5095, DOI 10.1021/pr200695p; Fleischhacker M, 2009, ENCY CANC, P695; Freedman JE, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11106; Fukuda I, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-36; Glyn-Jones S, 2015, LANCET, V386, P376, DOI 10.1016/S0140-6736(14)60802-3; Gobezie R, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2172; Gold B, 2015, J MOL DIAGN, V17, P209, DOI 10.1016/j.jmoldx.2015.02.001; Gornik I, 2009, CLIN BIOCHEM, V42, P38, DOI 10.1016/j.clinbiochem.2008.09.121; Greene J, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00038; Han MY, 2012, J INT MED RES, V40, P2243, DOI 10.1177/030006051204000622; Haseeb A, 2013, CLIN IMMUNOL, V146, P185, DOI 10.1016/j.clim.2012.12.011; Hashimoto T, 2017, INT J RHEUM DIS, V20, P722, DOI 10.1111/1756-185X.12959; Heidari B, 2011, CASP J INTERN MED, V2, P205; Henrotin Y, 2016, ANN PHYS REHABIL MED, V59, P145, DOI 10.1016/j.rehab.2016.03.004; Henrotin Y, 2012, ARTHRITIS RHEUM-US, V64, P2260, DOI 10.1002/art.34392; Hombach S, 2016, ADV EXP MED BIOL, V937, P3, DOI 10.1007/978-3-319-42059-2_1; Hunter DJ, 2008, RHEUM DIS CLIN N AM, V34, P623, DOI 10.1016/j.rdc.2008.05.004; Hunter DJ, 2013, FNIH OSTEOARTHRITIS; Hwang HS, 2015, INT J MOL SCI, V16, P26035, DOI 10.3390/ijms161125943; Ickinger C, 2014, S AFR FAM PRACT, V56, P102, DOI 10.1080/20786204.2014.10855346; Iwasaki YW, 2015, ANNU REV BIOCHEM, V84, P405, DOI 10.1146/annurev-biochem-060614-034258; Izzotti A, 2016, AM J CANCER RES, V6, P1461; Jeffries M, 2016, OSTEOARTHR CARTILAGE, V24, pS230, DOI 10.1016/j.joca.2016.01.444; Ji QB, 2016, J MOL MED, V94, P681, DOI 10.1007/s00109-016-1380-9; Kaikkonen MU, 2011, CARDIOVASC RES, V90, P430, DOI 10.1093/cvr/cvr097; KATO K, 1993, CYTOMETRY, V14, P384, DOI 10.1002/cyto.990140407; Kishore S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r45; Kleiveland CR, 2015, IMPACT FOOD BIOACTIV, DOI [10.1007/978-3-319-16104-4_15, DOI 10.1007/978-3-319-16104-4_15]; Kohn M, 2013, BIOMOLECULES, V3, P143, DOI 10.3390/biom3010143; Kolhe R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01905-y; Koncarevic S, 2014, INT J PROTEOMICS, V2014, P9; Kong RN, 2017, AM J TRANSL RES, V9, P2852; Korosty M, 2017, INT J GENOMICS, V2017, P7; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Laslett LL, 2016, CURR TREAT OPTIONS R, V2, P97; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; LEON SA, 1981, ARTHRITIS RHEUM, V24, P1142, DOI 10.1002/art.1780240905; Li LS, 2015, BIOMED PHARMACOTHER, V76, P94, DOI 10.1016/j.biopha.2015.10.014; Li LS, 2015, CURR PHARM DESIGN, V21, P5160, DOI 10.2174/1381612821666150909094712; Li YH, 2016, OSTEOARTHR CARTILAGE, V24, P1577, DOI 10.1016/j.joca.2016.04.019; Li ZF, 2016, MOL MED REP, V13, P2769, DOI 10.3892/mmr.2016.4878; Liao WX, 2015, INT J CLIN EXP PATHO, V8, P9975; Nguyen LT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030601; Lichtenstein AV, 2001, ANN NY ACAD SCI, V945, P239; LIVOLANT F, 1991, MOL CELL BIOL, V176, P117; Loeser RF, 2012, ARTHRITIS RHEUM-US, V64, P1697, DOI 10.1002/art.34453; Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913; Lourido L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00195-8; Luyten FP, 2012, KNEE SURG SPORT TR A, V20, P401, DOI 10.1007/s00167-011-1743-2; Ma XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169231; Makarova JA, 2016, PROG HISTOCHEM CYTO, V51, P33, DOI 10.1016/j.proghi.2016.06.001; Marshall KW, 2005, OSTEOARTHR CARTILAGE, V13, P861, DOI 10.1016/j.joca.2005.06.002; Marshall KW, 1996, J RHEUMATOL, V23, P582; Martens-Uzunova ES, 2013, CANCER LETT, V340, P201, DOI 10.1016/j.canlet.2012.11.058; Matera AG, 2014, NAT REV MOL CELL BIO, V15, P108, DOI 10.1038/nrm3742; Matsukawa T, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4164; Mattick JS, 2015, NAT STRUCT MOL BIOL, V22, P5, DOI 10.1038/nsmb.2942; McKiernan J, 2016, JAMA ONCOL, V2, P882, DOI 10.1001/jamaoncol.2016.0097; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Meng SJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0663-2; Mobasheri A, 2017, OSTEOARTHR CARTILAGE, V25, P199, DOI 10.1016/j.joca.2016.12.016; Mobasheri A, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0364-9; Mobasheri A, 2017, NAT REV RHEUMATOL, V13, P302, DOI 10.1038/nrrheum.2017.50; Mobasheri A, 2015, BIOMARKERS, V20, P513, DOI 10.3109/1354750X.2016.1140930; Moore PB, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003780; Mullany LE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154177; Murata K, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3013; Nakanishi K, 2016, WIRES RNA, V7, P637, DOI 10.1002/wrna.1356; Nassar W, 2016, AM J MOL BIOL, V06, P11; Okuhara A, 2012, MOD RHEUMATOL, V22, P446, DOI 10.1007/s10165-011-0536-2; Park SJ, 2013, OSTEOARTHR CARTILAGE, V21, P981, DOI 10.1016/j.joca.2013.04.012; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Patrushev LI, 2014, BIOCHEMISTRY-MOSCOW+, V79, P1442, DOI 10.1134/S0006297914130021; Patton JG, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27494; Peschansky VJ, 2014, EPIGENETICS-US, V9, P3, DOI 10.4161/epi.27473; Ponchel F, 2015, OSTEOARTHR CARTILAGE, V23, P1870, DOI 10.1016/j.joca.2015.06.018; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Ramos YFM, 2014, ANN RHEUM DIS, V73, P1844, DOI 10.1136/annrheumdis-2013-203405; Randau L, 2008, EMBO REP, V9, P623, DOI 10.1038/embor.2008.101; Review MT., 2015, 10 BREAKTHROUGH TECH; Ritter SY, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0456-6; Ritter SY, 2013, ARTHRITIS RHEUM-US, V65, P981, DOI 10.1002/art.37823; Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136; Ryd L, 2015, CARTILAGE, V6, P156, DOI 10.1177/1947603515586048; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Scott MS, 2011, BIOCHIMIE, V93, P1987, DOI 10.1016/j.biochi.2011.05.026; Sheridan C, 2016, NAT BIOTECHNOL, V34, P358, DOI 10.1038/nbt0416-359; Shi T, 2016, DIS MARKERS, DOI 10.1155/2016/9085195; Si Hai-bo, 2016, Chinese Medical Sciences Journal, V31, P207; Sokolove J, 2013, THER ADV MUSCULOSKEL, V5, P77, DOI 10.1177/1759720X12467868; Song J, 2015, BBA CLIN, V3, P79, DOI 10.1016/j.bbacli.2014.11.009; Song J, 2015, CLIN EXP MED, V15, P121, DOI 10.1007/s10238-013-0271-4; Song J, 2013, BIOCHEM BIOPH RES CO, V431, P210, DOI 10.1016/j.bbrc.2012.12.133; Sorrentino S, 2010, FEBS LETT, V584, P2194, DOI 10.1016/j.febslet.2010.04.018; Stadler PF, 2009, MOL BIOL EVOL, V26, P1975, DOI 10.1093/molbev/msp112; Starling RC, 2006, J HEART LUNG TRANSPL, V25, P1389, DOI 10.1016/j.healun.2006.10.002; Stastna M, 2012, PROTEOMICS, V12, P722, DOI 10.1002/pmic.201100346; Steinbusch MMF, 2017, SCI REP-UK, V7, DOI 10.1038/srep43558; Stepanov GA, 2015, BIOMED RES INT, DOI 10.1155/2015/206849; Strimbu K, 2010, CURR OPIN HIV AIDS, V5, P463, DOI 10.1097/COH.0b013e32833ed177; Swingler TE, 2012, ARTHRITIS RHEUM-US, V64, P1909, DOI 10.1002/art.34314; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tardif G, 2009, BMC MUSCULOSKEL DIS, V10, DOI 10.1186/1471-2474-10-148; Turchinovich A, 2012, TRENDS BIOCHEM SCI, V37, P460, DOI 10.1016/j.tibs.2012.08.003; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; Tzimagiorgis G, 2011, CANCER EPIDEMIOL, V35, P580, DOI 10.1016/j.canep.2011.02.016; Valadkhan S, 2013, ESSAYS BIOCHEM, V54, P79, DOI [10.1042/bse0540079, 10.1042/BSE0540079]; van der Vaart M, 2007, CLIN CHEM, V53, P2215, DOI 10.1373/clinchem.2007.092734; Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210; Wang GD, 2015, AM J TRANSL RES, V7, P2000; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang WT, 2016, SCI REP-UK, V6, DOI 10.1038/srep23343; Wang Z, 2015, P NATL ACAD SCI USA, V112, pE6293, DOI 10.1073/pnas.1505962112; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Weick EM, 2014, DEVELOPMENT, V141, P3458, DOI 10.1242/dev.094037; Winter J, 2011, RNA BIOL, V8, P1149, DOI 10.4161/rna.8.6.17665; Yamasaki K, 2009, ARTHRITIS RHEUM-US, V60, P1035, DOI 10.1002/art.24404; Yan YY, 2016, BIOMED RES INT, DOI 10.1155/2016/8079372; Zhang CP, 2016, GENE, V586, P248, DOI 10.1016/j.gene.2016.04.016; Zhang GL, 2016, CELL IMMUNOL, V302, P50, DOI 10.1016/j.cellimm.2016.01.007; Zhang L, 2012, OSTEOARTHR CARTILAGE, V20, P1631, DOI 10.1016/j.joca.2012.08.016	155	6	6	0	9	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					55	74		10.1080/14737159.2018.1415757			20	Pathology	Pathology	FS9QO	WOS:000422753500008	29235389	Green Accepted			2019-10-28	
J	Basile, K; Kok, J; Dwyer, DE				Basile, Kerri; Kok, Jen; Dwyer, Dominic E.			Point-of-care diagnostics for respiratory viral infections	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Point-of-care; respiratory viruses; diagnostics	A-AND-B; I INFLUENZA-A; NASOPHARYNGEAL FLOCKED SWABS; SYNCYTIAL VIRUS-INFECTION; SIMPLEXA(TM) FLU A/B; REAL-TIME PCR; RAPID DIAGNOSIS; ANTIGEN-DETECTION; FLUORESCENT IMMUNOASSAY; PERFORMANCE EVALUATION	Introduction: Successful treatment outcomes for viral respiratory tract infections presenting from primary health care to quaternary hospitals will only be achieved with rapid, sensitive and specific identification of pathogens to allow effective pathogen-specific antiviral therapy and infection control measures. Areas covered: This review aims to explore the different point-of-care tests currently available to diagnose viral respiratory tract infections, discuss the advantages and limitations of point-of-care testing, and provide insights into the future of point-of-care tests. The following databases were searched: Medline (January 1996 to 30 September 2017) and Embase (1988 to 30 September 2017), using the following keywords: 'point of care', 'respiratory virus', 'influenza', 'RSV', 'diagnostics', 'nucleic acid test' and 'PCR'. Expert commentary: Viral respiratory tract infections cause significant morbidity and mortality worldwide, and point-of-care tests are facilitating the rapid identification of the pathogen responsible given the similarities in clinical presentation.	[Basile, Kerri; Kok, Jen; Dwyer, Dominic E.] NSW Hlth Pathol, Inst Clin Pathol & Med Res, Ctr Infect Dis & Microbiol Lab Serv, Westmead, NSW, Australia; [Basile, Kerri; Kok, Jen; Dwyer, Dominic E.] Univ Sydney, Westmead Hosp, Marie Bashir Inst Emerging Infect & Biosecur, Westmead, NSW, Australia	Basile, K (reprint author), Westmead Hosp, NSW Hlth Pathol, Inst Clin Pathol & Med Res, Ctr Infect Dis & Microbiol Lab Serv, Westmead, NSW 2145, Australia.	kerri.basile@health.nsw.gov.au					Abu-Diab A, 2008, J CLIN MICROBIOL, V46, P2414, DOI 10.1128/JCM.00369-08; Al Johani S M, 2011, J Infect Public Health, V4, P7, DOI 10.1016/j.jiph.2010.10.004; [Anonymous], 228702016 ISO; [Anonymous], 2011, DATA COMPENDIUM; Baas C, 2013, EUROSURVEILLANCE, V18, P19; Bai GR, 2005, MICROBIOL IMMUNOL, V49, P1063, DOI 10.1111/j.1348-0421.2005.tb03703.x; Barenfanger J, 2000, J CLIN MICROBIOL, V38, P2824; Bates M, 2013, CURR OPIN PULM MED, V19, P229, DOI 10.1097/MCP.0b013e32835f4fe4; Bell JJ, 2014, J CLIN VIROL, V61, P113, DOI 10.1016/j.jcv.2014.05.020; Blyth CC, 2013, INFLUENZA OTHER RESP, V7, P168, DOI 10.1111/j.1750-2659.2012.00360.x; Blyth CC, 2011, METHODS MOL BIOL, V665, P415, DOI 10.1007/978-1-60761-817-1_22; Blyth CC, 2009, NEW ENGL J MED, V361, P2493, DOI 10.1056/NEJMc0909049; Bonner AB, 2003, PEDIATRICS, V112, P363, DOI 10.1542/peds.112.2.363; Branche AR, 2014, J CLIN MICROBIOL, V52, P3590, DOI 10.1128/JCM.01523-14; Brendish NJ, 2017, LANCET RESP MED, V5, P401, DOI [10.1016/S2213-2600(17)30120-0, 10.1016/s2213-2600(17)30120-0]; Britannica TEoE, POL CHAIN REACT; Bruning AH, 2017, FAM PRACT; Cao QQ, 2013, JOVE-J VIS EXP, DOI 10.3791/50325; Chan KH, 2008, J CLIN VIROL, V42, P65, DOI 10.1016/j.jcv.2007.12.003; Chan KH, 2017, ADV VIROL, DOI 10.1155/2017/1324276; Chapin KC, 2015, J CLIN MICROBIOL, V53, P706, DOI 10.1128/JCM.02783-14; Charles PGP, 2008, CURR OPIN PULM MED, V14, P176, DOI 10.1097/MCP.0b013e3282f7642f; Chartrand C, 2015, J CLIN MICROBIOL, V53, P3738, DOI 10.1128/JCM.01816-15; Chen L, 2015, EUR J MICROBIOL IMMU, V5, P236, DOI 10.1556/1886.2015.00046; Cohen DM, 2017, J CLIN MICROBIOL; De Witte E, 2012, EUR J CLIN MICROBIOL, V31, P761, DOI 10.1007/s10096-011-1372-1; DeByle C, 2012, J VIROL METHODS, V185, P89, DOI 10.1016/j.jviromet.2012.06.009; Druce J, 2012, J CLIN MICROBIOL, V50, P1064, DOI 10.1128/JCM.06551-11; Dwyer DE, 2006, MED J AUSTRALIA, V185, pS48; Falsey AR, 2007, ARCH INTERN MED, V167, P354, DOI 10.1001/archinte.167.4.ioi60207; Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1; Foo H, 2009, AUST PRESCR, V32, P64; Gakidou E, 2010, LANCET, V376, P959, DOI 10.1016/S0140-6736(10)61257-3; Gibson J, 2017, J CLIN VIROL, V95, P5, DOI 10.1016/j.jcv.2017.08.004; Gregson D, 2005, J CLIN MICROBIOL, V43, P5782, DOI 10.1128/JCM.43.11.5782-5783.2005; Hassan F, 2014, J CLIN MICROBIOL, V52, P906, DOI 10.1128/JCM.02484-13; Hazelton B, 2015, INFLUENZA OTHER RESP, V9, P151, DOI 10.1111/irv.12303; Hazelton B, 2015, J MED VIROL, V87, P35, DOI 10.1002/jmv.23976; Hernes SS, 2011, EUR J CLIN MICROBIOL, V30, P159, DOI 10.1007/s10096-010-1064-2; Iovine NM, 2014, CLIN INFECT DIS, V59, P605, DOI 10.1093/cid/ciu315; Ivaska L, 2013, J CLIN VIROL, V57, P136, DOI 10.1016/j.jcv.2013.02.011; Jang Jin Woo, 2015, J Clin Microbiol, V53, P684, DOI 10.1128/JCM.03324-14; Jennings LC, 2009, INFLUENZA OTHER RESP, V3, P91, DOI 10.1111/j.1750-2659.2009.00079.x; Jung BK, 2016, J MED VIROL, V88, P1720, DOI 10.1002/jmv.24522; Kanwar N, 2015, J CLIN VIROL, V65, P83, DOI 10.1016/j.jcv.2015.02.008; Khanom AB, 2011, J INFECTION, V62, P52, DOI 10.1016/j.jinf.2010.11.002; Kim YG, 2017, J CLIN MICROBIOL, V55, P226, DOI 10.1128/JCM.01704-16; Ko SY, 2013, J MED VIROL, V85, P2160, DOI 10.1002/jmv.23712; Kok J, 2010, J CLIN MICROBIOL, V48, P290, DOI 10.1128/JCM.01465-09; Landry ML, 2009, CLIN LAB MED, V29, P635, DOI 10.1016/j.cll.2009.07.003; Lee CK, 2012, J CLIN VIROL, V55, P239, DOI 10.1016/j.jcv.2012.07.008; Leonardi GP, 2015, J VIROL METHODS, V213, P131, DOI 10.1016/j.jviromet.2014.11.016; Leonardi GP, 2013, J VIROL METHODS, V189, P379, DOI 10.1016/j.jviromet.2013.02.008; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Low D, 2008, CLIN MICROBIOL INFEC, V14, P298, DOI 10.1111/j.1469-0691.2007.01910.x; MacIntyre CR, 2013, HEART, V99, P1843, DOI 10.1136/heartjnl-2013-304320; Mese S, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1811-9; Mills JM, 2011, J HOSP INFECT, V77, P248, DOI 10.1016/j.jhin.2010.11.019; Mitamura K, 2013, J VIROL METHODS, V194, P123, DOI 10.1016/j.jviromet.2013.08.018; Munywoki PK, 2011, J CLIN MICROBIOL, V49, P3365, DOI 10.1128/JCM.02231-10; Nelson RE, 2015, PEDIATR INFECT DIS J, V34, P577, DOI 10.1097/INF.0000000000000703; Newall AT, 2008, VACCINE, V26, P2135, DOI 10.1016/j.vaccine.2008.01.051; Nie SP, 2014, J CLIN MICROBIOL, V52, P3339, DOI 10.1128/JCM.01132-14; Nitsch-Osuch A, 2012, POSTEP HIG MED DOSW, V66, P752, DOI 10.5604/17322693.1015040; Peci A, 2014, J CLIN MICROBIOL, V52, P4309, DOI 10.1128/JCM.02024-14; Peters RM, 2017, J CLIN MICROBIOL, V55, P1032, DOI 10.1128/JCM.02433-16; Popowitch EB, 2015, J CLIN MICROBIOL, V53, P2720, DOI 10.1128/JCM.00972-15; Rath B, 2012, J CLIN VIROL, V55, P329, DOI 10.1016/j.jcv.2012.08.002; Sanbonmatsu-Gamez S, 2015, DIAGN MICR INFEC DIS, V83, P252, DOI 10.1016/j.diagmicrobio.2015.07.010; Selvaraju SB, 2014, DIAGN MICR INFEC DIS, V78, P232, DOI 10.1016/j.diagmicrobio.2013.11.016; Selvarangan R, 2008, DIAGN MICR INFEC DIS, V62, P157, DOI 10.1016/j.diagmicrobio.2008.05.005; Somerville LK, 2015, PATHOLOGY, V47, P243, DOI 10.1097/PAT.0000000000000240; Steensels D, 2017, J VIROL METHODS, V245, P61, DOI 10.1016/j.jviromet.2017.03.013; Stupica D, 2012, INFECTION, V40, P381, DOI 10.1007/s15010-012-0245-6; Svensson MJ, 2014, SCAND J INFECT DIS, V46, P825, DOI 10.3109/00365548.2014.946444; TILLETT HE, 1983, INT J EPIDEMIOL, V12, P344, DOI 10.1093/ije/12.3.344; To KK, 2017, EMERG MICROBES INFEC, V6, DOI 10.1038/emi.2017.35; Tuttle R, 2015, DIAGN MICR INFEC DIS, V81, P171, DOI 10.1016/j.diagmicrobio.2014.11.013; Uyeki TM, 2009, CLIN INFECT DIS, V48, pE89, DOI 10.1086/597828; Wolff BJ, 2017, J CLIN MICROBIOL, V55, P110, DOI 10.1128/JCM.01805-16; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579; Wu G, 2012, B WORLD HEALTH ORGAN, V90, P914, DOI 10.2471/BLT.12.102780; Xu GL, 2010, LAB CHIP, V10, P3103, DOI 10.1039/c005265e; Yoo Y, 2007, CLIN VACCINE IMMUNOL, V14, P1050, DOI 10.1128/CVI.00465-06	84	6	7	2	12	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					75	83		10.1080/14737159.2018.1419065			9	Pathology	Pathology	FS9QO	WOS:000422753500009	29251007				2019-10-28	
J	Arantes, LMRB; De Carvalho, AC; Melendez, ME; Carvalho, AL				Rebolho Batista Arantes, Lidia Maria; De Carvalho, Ana Carolina; Melendez, Matias Eliseo; Carvalho, Andre Lopes			Serum, plasma and saliva biomarkers for head and neck cancer	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						DNA methylation; head and neck cancer; lncRNA; microRNA; mRNA; plasma; protein expression; saliva; serum	SQUAMOUS-CELL CARCINOMA; GENE PROMOTER HYPERMETHYLATION; LYMPH-NODE METASTASIS; THROAT RINSING FLUID; LONG NONCODING RNA; ORAL-CANCER; NASOPHARYNGEAL CARCINOMA; CIRCULATING MICRORNAS; PROGNOSTIC-SIGNIFICANCE; PERIPHERAL-BLOOD	Introduction: Head and neck squamous cell carcinoma (HNSCC) encompasses tumors arising from several locations (oral and nasal cavities, paranasal sinuses, salivary glands, pharynx, and larynx) and currently stands as the sixth most common cancer worldwide. The most important risk factors identified so far are tobacco and alcohol consumption, and, for a subgroup of HNSCCs, infection with high-risk types of human papillomavirus (HPV). Despite several improvements in the treatment of these tumors in the last decades, overall survival rates have only improved marginally, mainly due to the advanced clinical stage at diagnosis and the high rates of treatment failure associated with this late diagnosis. Areas covered: This review will focus on the feasibility of evaluating molecular-based biomarkers (mRNA, microRNA, lncRNA, DNA methylation and protein expression) in body fluids (serum, plasma, and saliva) as markers for diagnosis, prognosis, and surveillance. Expert commentary: The potential use of those markers in the clinical setting would allow for early diagnosis, prediction of treatment response, improvement in treatment selection and provide disease monitoring for early detection of tumor recurrence. It can ultimately be translated into better survival rates and improved quality of life for HNSCC patients.	[Rebolho Batista Arantes, Lidia Maria; De Carvalho, Ana Carolina; Melendez, Matias Eliseo; Carvalho, Andre Lopes] Barretos Canc Hosp, Mol Oncol Res Ctr, Rua Antenor Duarte Villela,1331 Bairro Dr Paulo, BR-14784400 Barretos, SP, Brazil	Carvalho, AL (reprint author), Barretos Canc Hosp, Mol Oncol Res Ctr, Rua Antenor Duarte Villela,1331 Bairro Dr Paulo, BR-14784400 Barretos, SP, Brazil.	carvalhoal@gmail.com	Carvalho, Andre Lopes/S-7053-2016; de Carvalho, Ana Carolina/Q-4055-2019	Carvalho, Andre Lopes/0000-0001-7214-6402; de Carvalho, Ana Carolina/0000-0002-0114-7659	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2011/02864-7]; National Counsel of Technological and Scientific Development Scholarship (CNPq)	AL Carvalho has a National Counsel of Technological and Scientific Development Scholarship (CNPq). LMRB Arantes is recipient of scholarship from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP; grant number 2011/02864-7). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.	Abd-El-Fattah AA, 2013, CELL BIOCHEM BIOPHYS, V67, P875, DOI 10.1007/s12013-013-9575-y; Aggarwal S, 2015, CLIN CHIM ACTA, V442, P13, DOI 10.1016/j.cca.2014.12.038; Ahn SM, 2014, JAMA OTOLARYNGOL, V140, P846, DOI 10.1001/jamaoto.2014.1338; Allegra A, 2012, INT J ONCOL, V41, P1897, DOI 10.3892/ijo.2012.1647; Allegra E, 2014, J ORAL PATHOL MED, V43, P276, DOI 10.1111/jop.12129; Amerongen AVN, 2002, ORAL DIS, V8, P12, DOI 10.1034/j.1601-0825.2002.1o816.x; Arantes LMRB, 2014, ORAL ONCOL, V50, P587, DOI 10.1016/j.oraloncology.2014.02.015; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Blondal T, 2013, METHODS, V59, pS1, DOI 10.1016/j.ymeth.2012.09.015; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; Bu JQ, 2015, MED SCI MONITOR, V21, P2275, DOI 10.12659/MSM.893925; Buczko P, 2015, J PHYSIOL PHARMACOL, V66, P3; Camisasca DR, 2017, J PROTEOMICS, V151, P43, DOI 10.1016/j.jprot.2016.07.029; Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722; Chai RC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2217-1; Chai YD, 2016, HEAD NECK-J SCI SPEC, V38, P118, DOI 10.1002/hed.23870; Chakraborty C, 2016, TUMOR BIOL, V37, P5705, DOI 10.1007/s13277-016-4907-3; Chang HW, 2003, INT J CANCER, V105, P851, DOI 10.1002/ijc.11162; Chang HW, 2003, CLIN CANCER RES, V9, P1033; Chen YT, 2017, MOL CELL PROTEOMICS, V16, P799, DOI 10.1074/mcp.M116.064758; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Demokan S, 2010, INT J CANCER, V127, P2351, DOI 10.1002/ijc.25248; Denaro N, 2014, ANTICANCER RES, V34, P6887; Dreyer F, 2016, METHODS MOL BIOL, V1448, P201, DOI 10.1007/978-1-4939-3753-0_15; Duz MB, 2016, CELL ONCOL, V39, P187, DOI 10.1007/s13402-015-0259-z; Elashoff D, 2012, CANCER EPIDEM BIOMAR, V21, P664, DOI 10.1158/1055-9965.EPI-11-1093; Fayda M, 2016, TUMOR BIOL, V37, P3969, DOI 10.1007/s13277-015-4189-1; Federick A, 2013, INTRO GEN ORGANIC BI; Ferlazzo N, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040724; Frediani JN, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0525-3; Gaykalova DA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142148; Good DM, 2007, J PROTEOME RES, V6, P4549, DOI 10.1021/pr070529w; Guerrero-Preston R, 2011, CANCER PREV RES, V4, P1061, DOI 10.1158/1940-6207.CAPR-11-0006; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Holzinger D, 2017, INT J CANCER, V140, P2748, DOI 10.1002/ijc.30697; Hou B, 2015, CANCER BIOL THER, V16, P1042, DOI 10.1080/15384047.2015.1045692; Hsin CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113129; Hsu CM, 2012, TUMOR BIOL, V33, P1933, DOI 10.1007/s13277-012-0454-8; Jankowska Anna K, 2007, Wiad Lek, V60, P253; Jarai T, 2012, PATHOL ONCOL RES, V18, P623, DOI 10.1007/s12253-011-9486-4; Kaczor-Urbanowicz KE, 2017, J CELL MOL MED, V21, P640, DOI 10.1111/jcmm.13007; Kakurina GV, 2016, B EXP BIOL MED+, V160, P695, DOI 10.1007/s10517-016-3252-2; Kaufman E, 2002, CRIT REV ORAL BIOL M, V13, P197, DOI 10.1177/154411130201300209; Kawahara R, 2016, PROTEOMICS, V16, P159, DOI 10.1002/pmic.201500224; Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568; Krapfenbauer K, 2014, EPMA J, V5, DOI 10.1186/1878-5085-5-20; Kreimer AR, 2013, J CLIN ONCOL, V31, P2708, DOI 10.1200/JCO.2012.47.2738; Langevin SM, 2010, CARCINOGENESIS, V31, P864, DOI 10.1093/carcin/bgq051; Larrea E, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050627; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YH, 2009, AM J DENT, V22, P241; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li HP, 2013, ONCOTARGET, V4, P2154, DOI 10.18632/oncotarget.1367; Li SX, 2016, CANCER BIOMARK, V17, P377, DOI 10.3233/CBM-160651; Li Y, 2004, CLIN CANCER RES, V10, P8442, DOI 10.1158/1078-0432.CCR-04-1167; Li Y, 2012, MED ONCOL, V29, P1429, DOI 10.1007/s12032-011-0012-z; Lim AM, 2012, CLIN CANCER RES, V18, P301, DOI 10.1158/1078-0432.CCR-11-2295; Lim YK, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2785-0; Lim Y, 2016, BIOMARK MED, V10, P301, DOI 10.2217/bmm.16.2; Lin SC, 2010, ORAL ONCOL, V46, P204, DOI 10.1016/j.oraloncology.2009.12.005; Liu CJ, 2010, ORAL DIS, V16, P360, DOI 10.1111/j.1601-0825.2009.01646.x; Liu CJ, 2017, CLIN ORAL INVEST, V21, P1131, DOI 10.1007/s00784-016-1887-z; Liu CJ, 2013, ANN SURG ONCOL, V20, pS406, DOI 10.1245/s10434-012-2618-6; Liu CJ, 2012, HEAD NECK-J SCI SPEC, V34, P219, DOI 10.1002/hed.21713; Liu JY, 2012, ORAL ONCOL, V48, P569, DOI 10.1016/j.oraloncology.2012.01.021; Liu N, 2014, INT J CANCER, V134, P1359, DOI 10.1002/ijc.28468; Liu X, 2013, CANCER BIOL THER, V14, P1133, DOI 10.4161/cbt.26170; Lo Cicero L, 2015, PHYTOCHEMISTRY, V116, P69, DOI 10.1016/j.phytochem.2015.03.004; Carvalho AL, 2011, CLIN CANCER RES, V17, P4782, DOI 10.1158/1078-0432.CCR-11-0324; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu J, 2014, BRIT J CANCER, V110, P392, DOI 10.1038/bjc.2013.751; Lu YC, 2015, CLIN BIOCHEM, V48, P115, DOI 10.1016/j.clinbiochem.2014.11.020; Lu YC, 2012, CANCER PREV RES, V5, P665, DOI 10.1158/1940-6207.CAPR-11-0358; Ma HL, 2015, J ORAL PATHOL MED, V44, P193, DOI 10.1111/jop.12229; Marcu LG, 2009, J CANCER RES CLIN, V135, P1303, DOI 10.1007/s00432-009-0648-7; Michailidou E, 2016, CANCER EPIDEMIOL, V43, P112, DOI 10.1016/j.canep.2016.04.011; Mikkonen JJW, 2016, J PERIODONTAL RES, V51, P431, DOI 10.1111/jre.12327; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Momen-Heravi F, 2014, J DENT RES, V93, P86, DOI 10.1177/0022034514531018; Mydlarz WK, 2016, HEAD NECK-J SCI SPEC, V38, P9, DOI 10.1002/hed.23842; Nagata S, 2012, CANCER-AM CANCER SOC, V118, P4298, DOI 10.1002/cncr.27417; Nakahara Y, 2006, INT J ORAL MAX SURG, V35, P362, DOI 10.1016/j.ijom.2005.08.005; Ovchinnikov DA, 2012, TRANSL ONCOL, V5, P321, DOI 10.1593/tlo.12232; Park NJ, 2009, CLIN CANCER RES, V15, P5473, DOI 10.1158/1078-0432.CCR-09-0736; Patel BP, 2007, HEAD NECK-J SCI SPEC, V29, P564, DOI 10.1002/hed.20561; Pattani KM, 2010, CANCER PREV RES, V3, P1093, DOI 10.1158/1940-6207.CAPR-10-0115; Peng P, 2014, INT J ORAL MAX SURG, V43, P393, DOI 10.1016/j.ijom.2013.09.011; Pereira LHM, 2016, CANCER PREV RES, V9, P445, DOI 10.1158/1940-6207.CAPR-15-0200; Petrik D, 2006, J CLIN ONCOL, V24, P5291, DOI 10.1200/JCO.2006.06.8627; Pradhan-Palikhe P, 2010, ORAL ONCOL, V46, P514, DOI 10.1016/j.oraloncology.2010.03.002; Puttipanyalears C, 2013, ASIAN PAC J CANCER P, V14, P5495, DOI 10.7314/APJCP.2013.14.9.5495; Qiu MT, 2013, TUMOR BIOL, V34, P613, DOI 10.1007/s13277-013-0658-6; Qiu MT, 2015, CANCER EPIDEM BIOMAR, V24, P206, DOI 10.1158/1055-9965.EPI-14-0895; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Rettori MM, 2013, CARCINOGENESIS, V34, P20, DOI 10.1093/carcin/bgs311; Righini CA, 2007, CLIN CANCER RES, V13, P1179, DOI 10.1158/1078-0432.CCR-06-2027; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; Rogers E., 2011, BLOOD PHYSL CIRCULAT; Rosas SLB, 2001, CANCER RES, V61, P939; Salazar C, 2014, CELL ONCOL, V37, P331, DOI 10.1007/s13402-014-0188-2; Sanchez-Cespedes M, 2000, CANCER RES, V60, P892; Schafer CA, 2014, MONOGR ORAL SCI, V24, P88, DOI 10.1159/000358791; Schmidt H, 2016, EXPERT REV MOL DIAGN, V16, P165, DOI 10.1586/14737159.2016.1127758; Schrock A, 2017, CLIN CHEM, V63, P1288, DOI 10.1373/clinchem.2016.270207; Schussel J, 2013, CLIN CANCER RES, V19, P3268, DOI 10.1158/1078-0432.CCR-12-3496; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Selzer E, 2016, WIEN KLIN WOCHENSCHR, V128, P320, DOI 10.1007/s00508-016-0963-3; Severino P, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0102-4; Spielmann N, 2011, ORAL DIS, V17, P345, DOI 10.1111/j.1601-0825.2010.01773.x; Su CW, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002092; Summerer I, 2015, BRIT J CANCER, V113, P76, DOI 10.1038/bjc.2015.111; Summerer I, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-296; Sun LG, 2016, MED SCI MONITOR, V22, P289, DOI 10.12659/MSM.895683; Sun WY, 2012, CLIN CANCER RES, V18, P1082, DOI 10.1158/1078-0432.CCR-11-2392; Tang HK, 2013, MOL MED REP, V7, P761, DOI 10.3892/mmr.2012.1254; Tian WD, 2015, INT J CLIN EXP PATHO, V8, P9021; Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254; van Ginkel JH, 2017, PATHOBIOLOGY, V84, P115, DOI 10.1159/000452861; Vidotto A, 2010, CANCER BIOMARK, V8, P95, DOI 10.3233/CBM-2011-0205; Viet CT, 2008, CANCER EPIDEM BIOMAR, V17, P3603, DOI 10.1158/1055-9965.EPI-08-0507; Wang JL, 2016, YONSEI MED J, V57, P298, DOI 10.3349/ymj.2016.57.2.298; Wang JT, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0148-8; Wang SM, 2015, ONCOTARGET, V6, P35893, DOI 10.18632/oncotarget.5651; Wang XT, 2008, NATURE, V454, P126, DOI 10.1038/nature06992; Wang YX, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8507; Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484; Warawdekar UM, 2006, CLIN CHIM ACTA, V372, P83, DOI 10.1016/j.cca.2006.03.023; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Wei L, 2016, ACTA OTO-LARYNGOL, V136, P923, DOI 10.3109/00016489.2016.1165862; Wiklund ED, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027840; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Wong TS, 2004, CLIN CANCER RES, V10, P2401, DOI 10.1158/1078-0432.CCR-03-0139; Wong TS, 2003, EUR J CANCER, V39, P1881, DOI 10.1016/S0959-8049(03)00428-3; Wong TS, 2002, CLIN CANCER RES, V8, P433; Wu CC, 2015, PROTEOMICS, V15, P3394, DOI 10.1002/pmic.201500157; Wu JY, 2010, ORAL ONCOL, V46, P226, DOI 10.1016/j.oraloncology.2010.01.007; Wua BH, 2011, ORAL ONCOL, V47, P314, DOI 10.1016/j.oraloncology.2011.03.019; Xu HX, 2016, TUMOR BIOL, V37, P447, DOI 10.1007/s13277-015-3514-z; Yamashita T, 2016, CANCER MED-US, V5, P415, DOI 10.1002/cam4.600; Yang CC, 2011, J ORAL PATHOL MED, V40, P397, DOI 10.1111/j.1600-0714.2010.01003.x; Yao JJ, 2017, CANCER SCI, V108, P1640, DOI 10.1111/cas.13296; Yilmaz SS, 2015, LARYNGOSCOPE, V125, pE377, DOI 10.1002/lary.25332; Yu JS, 2016, P NATL ACAD SCI USA, V113, P11549, DOI 10.1073/pnas.1612368113; Zeng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046367; Zhang GH, 2015, INT J CANCER, V136, pE301, DOI 10.1002/ijc.29206	146	11	12	1	28	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	1					85	112		10.1080/14737159.2017.1404906			28	Pathology	Pathology	FS9QO	WOS:000422753500010	29134827				2019-10-28	
J	Maubon, D; Dard, C; Garnaud, C; Cornet, M				Maubon, Daniele; Dard, Celine; Garnaud, Cecile; Cornet, Muriel			Profile of GenMark's ePlex (R) blood culture identification fungal pathogen panel	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Fungemia; candidemia; invasive fungal infection; diagnosis; molecular diagnostic; blood culture; PCR; antifungal stewardship	YEAST TRAFFIC LIGHT; IONIZATION MASS-SPECTROMETRY; INFECTIOUS-DISEASES SOCIETY; ESCMID-ASTERISK GUIDELINE; POLYMERASE-CHAIN-REACTION; RAPID IDENTIFICATION; INVASIVE CANDIDIASIS; MULTIPLEX PCR; MULTICENTER EVALUATION; DIAGNOSTIC METHODS	Introduction: Fungemia presents high morbi-mortality and thus rapid microbiological diagnosis may contribute to appropriate patient management. In the last decade, kits based on molecular technologies have become available and health care institutes are increasingly facing critical investment choices. Although all these tools aim to achieve rapid fungal detection and species identification, they display different inherent characteristics.Areas covered: Considering technologies allowing detection and identification of fungal species in a sepsis context, the market proposes either tests on positive blood culture or tests on patient's whole blood. In this review, the authors describe and compare the ePlex (R) Blood Culture Identification Fungal Pathogen (BCID-FP) test, a fully automated one-step single-use cartridge assay that has been designed to detect identify frequent or rare but emerging, fungal species, from positive blood culture. A comparison with the competing kits is provided.Expert commentaries: The ePlex BCID-FP test provides a diversified and rather relevant panel. Its easy-to-use cartridges allow flexible use around the clock. Nevertheless, prospective clinical studies assessing the time-to-result benefit on antifungal stewardship and on hospital length of stay are not available yet. New tools aim to benefit clinicians and patients, but they should be accompanied by supervision of result interpretation and adaptation of antifungal stewardship.	[Maubon, Daniele; Garnaud, Cecile; Cornet, Muriel] Univ Grenoble Alpes, CNRS, Grenoble INP, Inst Engn, Grenoble, France; [Maubon, Daniele; Dard, Celine; Garnaud, Cecile; Cornet, Muriel] CHU Grenoble Alpes, Infect Agents Dept, Parasitol Mycol Lab, Grenoble, France	Maubon, D (reprint author), Univ Grenoble Alpes, CNRS, Grenoble INP, Inst Engn, Grenoble, France.; Maubon, D (reprint author), CHU Grenoble Alpes, Infect Agents Dept, Parasitol Mycol Lab, Grenoble, France.	DMaubon@chu-grenoble.fr	Cornet, Muriel/M-6563-2014	Cornet, Muriel/0000-0003-4155-3675			Afshari A, 2012, CRIT CARE, V16, DOI 10.1186/cc11202; Aittakorpi A, 2012, J CLIN MICROBIOL, V50, P3635, DOI 10.1128/JCM.01461-12; Altun O, 2013, J CLIN MICROBIOL, V51, P4130, DOI 10.1128/JCM.01835-13; Arvanitis M, 2014, CLIN MICROBIOL REV, V27, P490, DOI 10.1128/CMR.00091-13; Avni T, 2011, J CLIN MICROBIOL, V49, P665, DOI 10.1128/JCM.01602-10; Aydemir G, 2016, MIKROBIYOL BUL, V50, P293, DOI 10.5578/mb.22092; Babady NE, 2011, J CLIN MICROBIOL, V49, P3777, DOI 10.1128/JCM.01135-11; Bailly S, 2016, EUR J CLIN MICROBIOL, V35, P1023, DOI 10.1007/s10096-016-2633-9; Balada-Llasat JM, 2012, J CLIN MICROBIOL, V50, P492, DOI 10.1128/JCM.06375-11; Bassetti M, 2016, J ANTIMICROB CHEMOTH, V71, P13, DOI 10.1093/jac/dkw392; Beyda ND, 2013, J ANTIMICROB CHEMOTH, V68, P438, DOI 10.1093/jac/dks388; Bidart M, 2015, J CLIN MICROBIOL, V53, P1761, DOI 10.1128/JCM.03600-14; Bilir SP, 2015, FUTURE MICROBIOL, V10, P1133, DOI 10.2217/fmb.15.29; Bitar D, 2014, EMERG INFECT DIS, V20, P1149, DOI 10.3201/eid2007.140087; Bloos F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046003; Brealey D, 2014, CRIT CARE, V18; Briese T, 2015, MBIO, V6, DOI 10.1128/mBio.01491-15; Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Buchan BW, 2014, CLIN MICROBIOL REV, V27, P783, DOI 10.1128/CMR.00003-14; Clancy CJ, 2016, METHODS MOL BIOL, V1356, P215, DOI 10.1007/978-1-4939-3052-4_16; Clancy CJ, 2013, CLIN INFECT DIS, V56, P1284, DOI 10.1093/cid/cit006; Colombo AL, 2017, LANCET INFECT DIS, V17, pE344, DOI 10.1016/S1473-3099(17)30304-3; Cornely OA, 2012, CLIN MICROBIOL INFEC, V18, P19, DOI 10.1111/1469-0691.12039; Cuenca-Estrella M, 2012, CLIN MICROBIOL INFEC, V18, P9, DOI 10.1111/1469-0691.12038; Divakar K, 2012, 112 GEN M AM SOC MIC; Elges S, 2017, MYCOSES, V60, P781, DOI 10.1111/myc.12662; Farmakiotis D, 2017, INT J ANTIMICROB AG, V50, P318, DOI 10.1016/j.ijantimicag.2017.05.019; Fitting C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038916; Galiana A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177627; Gies F, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1722-9; Global Action Fund for Fungal Infections (GAFFI), 2015, IMPR OUTC PAT FUNG I; Gonzalez M, 2017, AM SOC MICR ASM MICR; Grumaz S, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0326-8; Gu ZM, 2012, MED MYCOL, V50, P259, DOI 10.3109/13693786.2011.600341; Guinea J, 2014, CLIN MICROBIOL INFEC, V20, P5, DOI 10.1111/1469-0691.12539; Hall L, 2012, J CLIN MICROBIOL, V50, P1446, DOI 10.1128/JCM.06148-11; Hogan D, 2017, 25 EUR C CLIN MICR I; Jordana-Lluch E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140865; Leading International Fungal Education (LIFE), 2017, BURD FUNG DIS NEW EV; Leon C, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1324-3; Leon C, 2014, INTENS CARE MED, V40, P808, DOI 10.1007/s00134-014-3281-0; Leong C, 2017, J CLIN MICROBIOL, V55, P1883, DOI 10.1128/JCM.00338-17; Lortholary O, 2014, INTENS CARE MED, V40, P1303, DOI 10.1007/s00134-014-3408-3; MacVane SH, 2016, J CLIN MICROBIOL, V54, P2455, DOI 10.1128/JCM.00996-16; Marschal M, 2017, J CLIN MICROBIOL, V55, P2116, DOI [10.1128/jcm.00181-17, 10.1128/JCM.00181-17]; Massire C, 2013, J CLIN MICROBIOL, V51, P959, DOI 10.1128/JCM.02621-12; Maubon D, 2010, J INFECTION, V61, P335, DOI 10.1016/j.jinf.2010.07.004; Metzgar D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158186; Meyer E, 2013, EUROSURVEILLANCE, DOI [10.2807/ese.18.24.20505-en, DOI 10.2807/ESE.18.24.20505-EN]; Minejima E, 2016, EXPERT REV ANTI-INFE, V14, P1065, DOI 10.1080/14787210.2016.1233814; Montravers P, 2011, CLIN MICROBIOL INFEC, V17, P1061, DOI 10.1111/j.1469-0691.2010.03360.x; Morio F, 2017, INT J ANTIMICROB AG, V50, P599, DOI 10.1016/j.ijantimicag.2017.05.012; Munoz P, 2011, CLIN MICROBIOL INFEC, V17, P1538, DOI 10.1111/j.1469-0691.2010.03338.x; Mylonakis E, 2015, CLIN INFECT DIS, V60, P892, DOI 10.1093/cid/ciu959; Neely LA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005377; Nelson RE, 2015, PEDIATR INFECT DIS J, V34, P577, DOI 10.1097/INF.0000000000000703; Nguyen MH, 2012, CLIN INFECT DIS, V54, P1240, DOI 10.1093/cid/cis200; Nieman AE, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1646-4; Nunes CZ, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-486; Pappas PG, 2016, CLIN INFECT DIS, V62, pE1, DOI 10.1093/cid/civ933; Pardo J, 2016, DIAGN MICR INFEC DIS, V84, P159, DOI 10.1016/j.diagmicrobio.2015.10.023; Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858; Perlin DS, 2017, LANCET INFECT DIS, V17, pE383, DOI 10.1016/S1473-3099(17)30316-X; Pfaller MA, 2004, J CLIN MICROBIOL, V42, P4419, DOI 10.1128/JCM.42.10.4419-4431.2004; Pfaller MA, 2016, FUTURE MICROBIOL, V11, P103, DOI 10.2217/fmb.15.111; Preuner S, 2013, Methods Mol Biol, V968, P119, DOI 10.1007/978-1-62703-257-5_9; Pryce TM, 2006, DIAGN MICR INFEC DIS, V54, P289, DOI 10.1016/j.diagmicrobio.2005.11.002; Puig-Asensio M, 2014, CRIT CARE MED, V42, P1423, DOI 10.1097/CCM.0000000000000221; Radic M, 2016, MED MYCOL, V54, P654, DOI 10.1093/mmy/myw012; Robbins N, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.FUNK-0002-2016; Schreckenberger PC, 2015, J CLIN MICROBIOL, V53, P3110, DOI 10.1128/JCM.00382-15; Selvarangan R, 2003, J CLIN MICROBIOL, V41, P5660, DOI 10.1128/JCM.41.12.5660-5664.2003; Shepard JR, 2008, J CLIN MICROBIOL, V46, P50, DOI 10.1128/JCM.01385-07; Simner PJ, 2013, J CLIN MICROBIOL, V51, P1699, DOI 10.1128/JCM.03282-12; Stevenson M, 2016, HEALTH TECHNOL ASSES, V20, P1, DOI 10.3310/hta20350; Stone NRH, 2013, J CLIN MICROBIOL, V51, P1301, DOI 10.1128/JCM.00028-13; Tissari P, 2010, LANCET, V375, P224, DOI 10.1016/S0140-6736(09)61569-5; Tissot F, 2013, AM J RESP CRIT CARE, V188, P1100, DOI 10.1164/rccm.201211-2069OC; Troger B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159821; Vallabhaneni S, 2015, OPEN FORUM INFECT DI, V2; White PL, 2014, J CLIN MICROBIOL, V52, P3536, DOI 10.1128/JCM.01135-14; Wilson DA, 2005, J CLIN MICROBIOL, V43, P2909, DOI 10.1128/JCM.43.6.2909-2912.2005; Yan YJ, 2011, J CLIN MICROBIOL, V49, P2528, DOI 10.1128/JCM.00339-11; Ziegler I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167883	84	5	5	1	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	2					119	132		10.1080/14737159.2018.1420476			14	Pathology	Pathology	FU3KC	WOS:000423748800002	29284316				2019-10-28	
J	Csaki, A; Stranik, O; Fritzsche, W				Csaki, Andrea; Stranik, Ondrej; Fritzsche, Wolfgang			Localized surface plasmon resonance based biosensing	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Localized surface plasmon resonance; plasmonic nanostructures; optical sensor; biosensor; sensitivity	ENHANCED RAMAN-SPECTROSCOPY; HYBRIDIZATION CHAIN-REACTION; LABEL-FREE DETECTION; SCATTERING SUBMICROSCOPIC PARTICLES; FUNCTIONALIZED GOLD NANOPARTICLES; INFRARED-ABSORPTION SPECTROSCOPY; REFRACTIVE-INDEX SENSITIVITY; SINGLE SILVER NANOPARTICLES; HIGHLY FLUORESCENT ANALOGS; RING-DOWN SPECTROSCOPY	Introduction: Bioanalytical sensing based on the principle of localized surface plasmon resonance experiences is currently an extremely rapid development. Novel sensors with new kinds of plasmonic transducers and innovative concepts for the signal development as well as read-out principles were identified. This review will give an overview of the development of this field.Areas covered: The focus is primarily on types of transducers by preparation or dimension, factors for optimal sensing concepts and the critical view of the usability of these devices as innovative sensors for bioanalytical applications.Expert commentary: Plasmonic sensor devices offer a high potential for future biosensing given that limiting factors such as long-time stability of the transducers, the required high sensitivity and the cost-efficient production are addressed. For higher sensitivity, the design of the sensor in shape and material has to be combined with optimal enhancement strategies. Plasmonic nanoparticles from bottom-up synthesis with a post-synthetic processing show a high potential for cost-efficient sensor production. Regarding the measurement principle, LSPRi offers a large potential for multiplex sensors and can provide a high-throughput as well as highly paralleled sensing. The main trends are expected towards optimal LSPR concepts which represent cost-efficient and robust point-of-care solutions, and the use of multiplexed devices for clinical applications.	[Csaki, Andrea; Stranik, Ondrej; Fritzsche, Wolfgang] Leibniz Inst Photon Technol IPHT, Dept Nanobiophoton, Jena, Germany	Csaki, A (reprint author), Leibniz Inst Photon Technol IPHT, Dept Nanobiophoton, Jena, Germany.	wolfgang.fritzsche@leibniz-ipht.de		Csaki, Andrea/0000-0002-2414-4100	BMBF GermanyFederal Ministry of Education & Research (BMBF) [JPI-Water Pilot FKZ 02WU1348A, INNO INDIGO FKZ 01DQ16003]; AIF Germany [ERA.Net RUS Plus FKZ KF2206925CR4]	The projects TRACE (JPI-Water Pilot FKZ 02WU1348A), RA-detect (INNO INDIGO FKZ 01DQ16003) supported by the BMBF Germany, and Exodiagnos (ERA.Net RUS Plus FKZ KF2206925CR4) supported by AIF Germany are gratefully acknowledged.	Abid JP, 2002, CHEM COMMUN, P792, DOI 10.1039/b200272h; Acimovic SS, 2014, NANO LETT, V14, P2636, DOI 10.1021/nl500574n; Adato R, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3154; Aherne D, 2008, ADV FUNCT MATER, V18, P2005, DOI 10.1002/adfm.200800233; Aherne D, 2010, ADV FUNCT MATER, V20, P1329, DOI 10.1002/adfm.200902030; Ahijado-Guzman R, 2014, NANO LETT, V14, P5528, DOI 10.1021/nl501865p; Altug H, 2014, LAT AM OPT PHOT C CA; Amatya VJ, 2016, INT J ONCOL, V48, P1599, DOI 10.3892/ijo.2016.3358; Anker JN, 2008, NAT MATER, V7, P442, DOI 10.1038/nmat2162; Aslan K, 2004, J FLUORESC, V14, P391, DOI 10.1023/B:JOFL.0000031820.17358.28; Aslan K, 2004, ANAL BIOCHEM, V330, P145, DOI 10.1016/j.ab.2004.03.032; Aslan K, 2004, J FLUORESC, V14, P401, DOI 10.1023/B:JOFL.0000031821.74706.ea; Austin LA, 2014, ARCH TOXICOL, V88, P1391, DOI 10.1007/s00204-014-1245-3; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Becker J, 2010, PLASMONICS, V5, P161, DOI 10.1007/s11468-010-9130-2; Bingham JM, 2009, J PHYS CHEM C, V113, P16839, DOI 10.1021/jp907377h; Brongersma ML, 2015, FARADAY DISCUSS, V178, P9, DOI 10.1039/c5fd90020d; Brongersma ML, 1999, MRS ONLINE P LIB ARC, V582; Burgin J, 2008, J PHYS CHEM C, V112, P19279, DOI 10.1021/jp807465p; Camara AR, 2013, OPT EXPRESS, V21, P27023, DOI 10.1364/OE.21.027023; Cardinal MF, 2010, J PHYS CHEM C, V114, P10417, DOI 10.1021/jp102519n; Cennamo N, 2013, SENSORS-BASEL, V13, P14676, DOI 10.3390/s131114676; Chang SS, 1999, LANGMUIR, V15, P701, DOI 10.1021/la980929l; Chen GQ, 2015, ANALYST, V140, P5400, DOI 10.1039/c5an00389j; Chen HJ, 2008, LANGMUIR, V24, P5233, DOI 10.1021/la800305j; Chen HJ, 2012, J PHYS CHEM C, V116, P14088, DOI 10.1021/jp303560s; Chen JJ, 2013, PLASMONICS, V8, P1627, DOI 10.1007/s11468-013-9580-4; Chen P, 2017, ACS SENSORS, V2, P235, DOI 10.1021/acssensors.6b00633; Chen PY, 2015, ACS NANO, V9, P4173, DOI 10.1021/acsnano.5b00396; Chen S, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/43/434015; Chen Y, 2007, NANO LETT, V7, P690, DOI 10.1021/nl062795z; Chou SY, 1996, J VAC SCI TECHNOL B, V14, P4129, DOI 10.1116/1.588605; CHUMANOV G, 1995, J PHYS CHEM-US, V99, P9466, DOI 10.1021/j100023a025; Chung T, 2011, SENSORS-BASEL, V11, P10907, DOI 10.3390/s111110907; Cinel NA, 2012, OPT EXPRESS, V20, P2587, DOI 10.1364/OE.20.002587; Colson P, 2013, J NANOMATER, V2013, P21, DOI DOI 10.1155/2013/948510; Costa MN, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/9/094006; Csaki A, 2015, ENG LIFE SCI, V15, P266, DOI 10.1002/elsc.201400075; Curry A, 2005, OPT EXPRESS, V13, P2668, DOI 10.1364/OPEX.13.002668; Dirks RM, 2004, P NATL ACAD SCI USA, V101, P15275, DOI 10.1073/pnas.0407024101; Dondapati SK, 2010, ACS NANO, V4, P6318, DOI 10.1021/nn100760f; Dong HF, 2015, ANAL CHEM, V87, P4334, DOI 10.1021/acs.analchem.5b00029; Doria G, 2012, SENSORS-BASEL, V12, P1657, DOI 10.3390/s120201657; Dover JE, 2009, J MICROBIOL METH, V78, P10, DOI 10.1016/j.mimet.2009.04.008; Dregely D, 2011, ACS NANO, V5, P8202, DOI 10.1021/nn202876k; Driskell JD, 2011, ANALYST, V136, P3083, DOI 10.1039/c1an15303j; Dutta S, 2016, RSC ADV, V6, P21871, DOI 10.1039/c6ra01113f; Eck D, 2001, LANGMUIR, V17, P957, DOI 10.1021/la001142+; El-Sayed MA, 2001, ACCOUNTS CHEM RES, V34, P257, DOI 10.1021/ar960016n; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; Endo T, 2006, ANAL CHEM, V78, P6465, DOI 10.1021/ac0608321; Englebienne P, 1998, ANALYST, V123, P1599, DOI 10.1039/a804010i; FANO U, 1961, PHYS REV, V124, P1866, DOI 10.1103/PhysRev.124.1866; Feuz L, 2012, NANO LETT, V12, P873, DOI 10.1021/nl203917e; Fong KE, 2013, NANOSCALE, V5, P12043, DOI 10.1039/c3nr02257a; Forestiere C, 2009, OPT EXPRESS, V17, P9648, DOI 10.1364/OE.17.009648; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; Fredriksson H, 2007, ADV MATER, V19, P4297, DOI 10.1002/adma.200700680; FRENS G, 1973, NATURE-PHYS SCI, V241, P20, DOI 10.1038/physci241020a0; Fu JX, 2009, SENSOR ACTUAT B-CHEM, V141, P276, DOI 10.1016/j.snb.2009.06.020; Galush WJ, 2009, NANO LETT, V9, P2077, DOI 10.1021/nl900513k; Garcia-Marin A, 2014, ANAL CHEM, V86, P4969, DOI 10.1021/ac5005212; Geddes CD, 2003, COMB CHEM HIGH T SCR, V6, P109, DOI 10.2174/1386207033329760; Gerion D, 2010, BIOPHARM INT, P1; Ghosh D, 2015, J LUMIN, V160, P223, DOI 10.1016/j.jlumin.2014.12.018; Gilb S, 2007, EUR PHYS J D, V45, P501, DOI 10.1140/epjd/e2007-00211-9; GIRARD C, 1991, J CHEM PHYS, V95, P2056, DOI 10.1063/1.461005; Gold L, 1997, P NATL ACAD SCI USA, V94, P59, DOI 10.1073/pnas.94.1.59; Govorov AO, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.125308; Griffin J, 2009, CHEM-EUR J, V15, P342, DOI 10.1002/chem.200801812; Grzelczak M, 2008, ADV FUNCT MATER, V18, P3780, DOI 10.1002/adfm.200800706; Guhlke M, 2016, PHYS CHEM CHEM PHYS, V18, P14228, DOI 10.1039/c6cp01625a; Guo LH, 2015, NANO TODAY, V10, P213, DOI 10.1016/j.nantod.2015.02.007; Guo LH, 2011, CHEM COMMUN, V47, P7125, DOI 10.1039/c1cc11865j; Guo ZR, 2010, J COLLOID INTERF SCI, V348, P29, DOI 10.1016/j.jcis.2010.04.013; Haes AJ, 2004, J PHYS CHEM B, V108, P109, DOI 10.1021/jp0361327; Haes AJ, 2005, J AM CHEM SOC, V127, P2264, DOI 10.1021/ja044087q; Haes AJ, 2002, J AM CHEM SOC, V124, P10596, DOI 10.1021/ja020393x; Halkare P, 2016, SPIE PHOTONICS EUROP, VIV; Hanarp P, 2003, J PHYS CHEM B, V107, P5768, DOI 10.1021/jp027562k; Hao E, 2004, J FLUORESC, V14, P331, DOI 10.1023/B:JOFL.0000031815.71450.74; He J, 2015, ANAL CHEM, V87, P11407, DOI 10.1021/acs.analchem.5b02870; He L, 2000, J AM CHEM SOC, V122, P9071, DOI 10.1021/ja001215b; Hobbs K, 2016, CHEM COMMUN, V52, P9785, DOI 10.1039/c6cc05260f; HOLLAND WR, 1983, PHYS REV B, V27, P7765, DOI 10.1103/PhysRevB.27.7765; Homola J, 1999, SENSOR ACTUAT B-CHEM, V54, P3, DOI 10.1016/S0925-4005(98)00321-9; Homola J, 2006, SURFACE PLASMON RESO, P251; Homola J, 2008, CHEM REV, V108, P462, DOI 10.1021/cr068107d; Huang CC, 2005, ANAL CHEM, V77, P5735, DOI 10.1021/ac050957q; Huang HW, 2012, ANAL CHIM ACTA, V755, P108, DOI 10.1016/j.aca.2012.10.020; Huang JS, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1143; Im H, 2015, EXPERT REV MOL DIAGN, V15, P725, DOI 10.1586/14737159.2015.1041378; Im H, 2014, NAT BIOTECHNOL, V32, P490, DOI 10.1038/nbt.2886; Inci F, 2013, ACS NANO, V7, P4733, DOI 10.1021/nn3036232; Indrasekara ASDS, 2014, NANOSCALE, V6, P8891, DOI 10.1039/c4nr02513j; Jackman JA, 2017, CHEM SOC REV, V46, P3615, DOI 10.1039/c6cs00494f; Jackman JA, 2014, LANGMUIR, V30, P9494, DOI 10.1021/la502431x; Jain PK, 2007, J PHYS CHEM C, V111, P17451, DOI 10.1021/jp0773177; Jakab A, 2011, ACS NANO, V5, P6880, DOI 10.1021/nn200877b; Jana NR, 2001, CHEM COMMUN, P617, DOI 10.1039/b100521i; Jana NR, 2005, SMALL, V1, P875, DOI 10.1002/smll.200500014; Jang SM, 2011, APPL OPTICS, V50, P2846, DOI 10.1364/AO.50.002846; Jatschka Jacqueline, 2016, Sensing and Bio-Sensing Research, V7, P62, DOI 10.1016/j.sbsr.2016.01.003; Jayabal S, 2015, ANALYST, V140, P2540, DOI 10.1039/c4an02330g; Jensen TR, 1999, J PHYS CHEM B, V103, P9846, DOI 10.1021/jp9926802; Jin HY, 2015, ACS APPL MATER INTER, V7, P12249, DOI 10.1021/acsami.5b02744; Joshi GK, 2015, ACS NANO, V9, P11075, DOI 10.1021/acsnano.5b04527; Joshi GK, 2014, NANO LETT, V14, P6955, DOI 10.1021/nl503220s; Joshi GK, 2012, J PHYS CHEM C, V116, P20990, DOI 10.1021/jp302674h; Joung HA, 2008, ANAL CHIM ACTA, V630, P168, DOI 10.1016/j.aca.2008.10.001; Jung LS, 1998, LANGMUIR, V14, P5636, DOI 10.1021/la971228b; Kang T, 2010, NANO LETT, V10, P1189, DOI 10.1021/nl1000086; Katyal J, 2013, J MOD OPTIC, V60, P1717, DOI 10.1080/09500340.2013.856483; Keunen R, 2016, NANOSCALE, V8, P2575, DOI 10.1039/c5nr08788k; Kharisov BI, 2008, RECENT PAT NANOTECH, V2, P190, DOI 10.2174/187221008786369651; Kim DK, 2011, ANAL CHEM, V83, P6215, DOI 10.1021/ac2007762; Kneipp K, 1998, PHYS REV E, V57, pR6281, DOI 10.1103/PhysRevE.57.R6281; KNEIPP K, 1984, CHEM PHYS LETT, V106, P498, DOI 10.1016/0009-2614(84)85370-1; Knight MW, 2014, ACS NANO, V8, P834, DOI 10.1021/nn405495q; KREIBIG U, 1970, Z PHYS, V231, P128, DOI 10.1007/BF01392504; KUME T, 1994, SUPERLATTICE MICROST, V15, P459, DOI 10.1006/spmi.1994.1087; Kvasnicka P, 2008, BIOINTERPHASES, V3, pFD4, DOI 10.1116/1.2994687; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai TS, 2017, SENSOR ACTUAT B-CHEM, V239, P9, DOI 10.1016/j.snb.2016.07.158; Lakowicz JR, 2008, ANALYST, V133, P1308, DOI 10.1039/b802918k; Lakowicz JR, 2001, ANAL BIOCHEM, V298, P1, DOI 10.1006/abio.2001.5377; Lakowicz JR, 2004, J FLUORESC, V14, P425, DOI 10.1023/B:JOFL.0000031824.48401.5c; LAKOWICZ JR, 2006, PRINCIPLES FLUORESCE, P841, DOI DOI 10.1007/978-0-387-46312-4_25; Langeluddecke L, 2015, APPL SPECTROSC, V69, P1357, DOI 10.1366/15-08014; Lazarides AA, 2000, J CHEM PHYS, V112, P2987, DOI 10.1063/1.480873; Lee JS, 2007, NANO LETT, V7, P2112, DOI 10.1021/nl071108g; Lee KS, 2006, J PHYS CHEM B, V110, P19220, DOI 10.1021/jp062536y; Leitgeb V, 2016, NANOSCALE, V8, P2974, DOI 10.1039/c5nr06401e; Lesniewski A, 2014, BIOCONJUGATE CHEM, V25, P644, DOI 10.1021/bc500035y; LEUVERING J H W, 1980, Journal of Immunoassay, V1, P77, DOI 10.1080/01971528008055777; Li JF, 2013, NAT PROTOC, V8, P52, DOI 10.1038/nprot.2012.141; Li JF, 2010, NATURE, V464, P392, DOI 10.1038/nature08907; Li JQ, 2015, ACS PHOTONICS, V2, P425, DOI 10.1021/ph5004779; Li M, 2015, ANALYST, V140, P386, DOI 10.1039/c4an01079e; Liu F, 2014, BIOSENS BIOELECTRON, V55, P141, DOI 10.1016/j.bios.2013.11.075; Liu GL, 2005, OPT EXPRESS, V13, P8520, DOI 10.1364/OPEX.13.008520; Liu JW, 2004, J FLUORESC, V14, P343, DOI 10.1023/B:JOFL.0000031816.06134.d3; Liu N, 2010, NANO LETT, V10, P2342, DOI 10.1021/nl9041033; Liu P, 2013, ANAL CHEM, V85, P7689, DOI 10.1021/ac4001157; Liu QT, 2015, TALANTA, V136, P114, DOI 10.1016/j.talanta.2014.12.020; Liu Y, 2016, MICROELECTRON ENG, V151, P7, DOI 10.1016/j.mee.2015.11.011; Liu ZD, 2009, ENVIRON SCI TECHNOL, V43, P5022, DOI 10.1021/es9001983; Lombardi A, 2016, NANO LETT, V16, P6311, DOI 10.1021/acs.nanolett.6b02680; Long YT, 2014, SPRBRIEF MOLEC SCI, P1, DOI 10.1007/978-3-642-54795-9; Lopez-Munoz GA, 2017, BIOSENS BIOELECTRON, V96, P260, DOI 10.1016/j.bios.2017.05.020; Losurdo M, 2012, J PHYS CHEM C, V116, P23004, DOI 10.1021/jp307936k; Lu YX, 2013, ANAL CHEM, V85, P6571, DOI 10.1021/ac4014594; Luk'yanchuk B, 2010, NAT MATER, V9, P707, DOI [10.1038/NMAT2810, 10.1038/nmat2810]; Lyon LA, 1998, ANAL CHEM, V70, P5177, DOI 10.1021/ac9809940; Mahmoud MA, 2010, J AM CHEM SOC, V132, P12704, DOI 10.1021/ja104532z; Maier SA, 2001, ADV MATER, V13, P1501, DOI 10.1002/1521-4095(200110)13:19<1501::AID-ADMA1501>3.0.CO;2-Z; Maiolo D, 2015, ANAL CHEM, V87, P4168, DOI 10.1021/ac504861d; Martinez AW, 2008, ANAL CHEM, V80, P3699, DOI 10.1021/ac800112r; Martinsson E, 2016, SMALL, V12, P330, DOI 10.1002/smll.201502449; Masson JF, 2017, ACS SENSORS, V2, P16, DOI 10.1021/acssensors.6b00763; Mayer KM, 2008, ACS NANO, V2, P687, DOI 10.1021/nn7003734; Mayer KM, 2011, CHEM REV, V111, P3828, DOI 10.1021/cr100313v; McFarland AD, 2003, NANO LETT, V3, P1057, DOI 10.1021/nl034372s; Meriaudeau F, 1998, APPL OPTICS, V37, P8030, DOI 10.1364/AO.37.008030; Miao J, 2016, SCI REP-UK, V6, DOI 10.1038/srep32219; Mie G, 1908, ANN PHYS-BERLIN, V25, P377; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Mock JJ, 2003, NANO LETT, V3, P485, DOI 10.1021/nl0340475; Mock JJ, 2002, J CHEM PHYS, V116, P6755, DOI 10.1063/1.1462610; Mock JJ, 2008, NANO LETT; Mohs AM, 2010, ANAL CHEM, V82, P9058, DOI 10.1021/ac102058k; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; Mulvaney P, 1996, LANGMUIR, V12, P788, DOI 10.1021/la9502711; MUNRO CH, 1995, LANGMUIR, V11, P3712, DOI 10.1021/la00010a021; Myers FB, 2008, LAB CHIP, V8, P2015, DOI 10.1039/b812343h; Nadgaran H, 2015, J APPL PHYS, V118, DOI 10.1063/1.4927266; Nam JM, 2004, J AM CHEM SOC, V126, P5932, DOI 10.1021/ja049384+; Nath N, 2004, J FLUORESC, V14, P377, DOI 10.1023/B:JOFL.0000031819.45448.dc; Nath N, 2002, ANAL CHEM, V74, P504, DOI 10.1021/ac015657x; Nazarenko I, 2012, EUR J CANCER, V48, pS165, DOI 10.1016/S0959-8049(12)71339-4; Neugebauer U, 2007, J PHYS CHEM A, V111, P2898, DOI 10.1021/jp0678397; Nie SM, 1997, SCIENCE, V275, P1102, DOI 10.1126/science.275.5303.1102; Nie XM, 2014, BIOSENS BIOELECTRON, V58, P314, DOI 10.1016/j.bios.2014.03.007; Niu LF, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4929579; Niu WX, 2009, J AM CHEM SOC, V131, P697, DOI 10.1021/ja804115r; Nusz GJ, 2008, ANAL CHEM, V80, P984, DOI 10.1021/ac7017348; Nusz GJ, 2009, ACS NANO, V3, P795, DOI 10.1021/nn8006465; Oh BR, 2016, ACS SENSORS, V1, P941, DOI 10.1021/acssensors.6b00240; Oh Y, 2014, BIOSENS BIOELECTRON, V51, P401, DOI 10.1016/j.bios.2013.08.008; Okamoto T, 2000, OPT LETT, V25, P372, DOI 10.1364/OL.25.000372; Oldenburg SJ, 1998, CHEM PHYS LETT, V288, P243, DOI 10.1016/S0009-2614(98)00277-2; Omidi M, 2015, EPL-EUROPHYS LETT, V109, DOI 10.1209/0295-5075/109/18005; Osawa M, 1997, B CHEM SOC JPN, V70, P2861, DOI 10.1246/bcsj.70.2861; Otte MA, 2010, ACS NANO, V4, P349, DOI 10.1021/nn901024e; Parab HJ, 2010, BIOSENS BIOELECTRON, V26, P667, DOI 10.1016/j.bios.2010.06.067; Park JH, 2015, BIOSENS BIOELECTRON, V73, P26, DOI 10.1016/j.bios.2015.05.043; Park JH, 2014, BIOSENS BIOELECTRON, V59, P321, DOI 10.1016/j.bios.2014.03.059; Park TJ, 2012, TALANTA, V89, P246, DOI 10.1016/j.talanta.2011.12.021; Petryayeva E, 2011, ANAL CHIM ACTA, V706, P8, DOI 10.1016/j.aca.2011.08.020; Piner RD, 1999, SCIENCE, V283, P661, DOI 10.1126/science.283.5402.661; Pipino ACR, 2004, J CHEM PHYS, V120, P1585, DOI 10.1063/1.1629279; Posthuma-Trumpie GA, 2009, ANAL BIOANAL CHEM, V393, P569, DOI 10.1007/s00216-008-2287-2; Prasad J, 2015, J PHYS CHEM C, V119, P5577, DOI 10.1021/jp510985n; Prikulis J, 2004, NANO LETT, V4, P1003, DOI 10.1021/nl0497171; Qiang WB, 2013, ANAL METHODS-UK, V5, P629, DOI 10.1039/c2ay26097b; Rampazzi S, 2016, IEEE T INSTRUM MEAS, V65, P317, DOI 10.1109/TIM.2015.2465691; Raschke G, 2003, NANO LETT, V3, P935, DOI 10.1021/nl034223+; Rosman C, 2013, NANO LETT, V13, P3243, DOI 10.1021/nl401354f; Ruemmele JA, 2013, ANAL CHEM, V85, P4560, DOI 10.1021/ac400192f; Sachan R, 2013, ADV MATER, V25, P2045, DOI 10.1002/adma.201204920; Sannomiya T, 2010, REV SCI INSTRUM, V81, DOI 10.1063/1.3405912; Schneider T, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1531-7; Schwartz T, 2011, PHYS REV LETT, V106, DOI 10.1103/PhysRevLett.106.196405; Sengupta A, 2006, ANAL BIOANAL CHEM, V386, P1379, DOI 10.1007/s00216-006-0711-z; Kumar PS, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/01/015606; Sepulveda B, 2009, NANO TODAY, V4, P244, DOI 10.1016/j.nantod.2009.04.001; Shen XB, 2013, NANO LETT, V13, P2128, DOI 10.1021/nl400538y; Sherry LJ, 2005, NANO LETT, V5, P2034, DOI 10.1021/nl0515753; Shopova SI, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3599584; Singh MP, 2010, J AM CHEM SOC, V132, P9383, DOI 10.1021/ja1022128; Soares L, 2014, ANALYST, V139, P4964, DOI 10.1039/c4an00810c; Sonnichsen C, 2005, NAT BIOTECHNOL, V23, P741, DOI 10.1038/nbt1100; Sonnichsen C, 2001, PLASMONS METAL NANOS, P134; Spadavecchia J, 2013, ANAL CHEM, V85, P3288, DOI 10.1021/ac3036316; Steinbruck A, 2006, PLASMONICS, V1, P79, DOI 10.1007/s11468-005-9000-5; Steinbruck A, 2008, J BIOPHOTONICS, V1, P104, DOI 10.1002/jbio.200810003; Steinbruck A, 2011, ANAL BIOANAL CHEM, V401, P1241, DOI 10.1007/s00216-011-5177-y; Stockle RM, 2000, CHEM PHYS LETT, V318, P131, DOI 10.1016/S0009-2614(99)01451-7; Stoltenburg R, 2007, BIOMOL ENG, V24, P381, DOI 10.1016/j.bioeng.2007.06.001; Storhoff JJ, 2000, J AM CHEM SOC, V122, P4640, DOI 10.1021/ja993825l; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Stranik O, 2005, SENSOR ACTUAT B-CHEM, V107, P148, DOI 10.1016/j.snb.2004.08.032; Sugawa K, 2015, ACS NANO, V9, P1895, DOI 10.1021/nn506800a; Sun XL, 2013, BIOSENS BIOELECTRON, V47, P318, DOI 10.1016/j.bios.2013.03.046; Sun YG, 2002, SCIENCE, V298, P2176, DOI 10.1126/science.1077229; Svedendahl M, 2009, NANO LETT, V9, P4428, DOI 10.1021/nl902721z; Swaim JD, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3669398; Tam F, 2004, J PHYS CHEM B, V108, P17290, DOI 10.1021/jp048499x; Tawil N, 2015, J PHYS CHEM C, V119, P14375, DOI 10.1021/acs.jpcc.5b02169; Tennant DM, 2011, COMPREHENSIVE NANOSCIENCE AND TECHNOLOGY, VOL 4: NANOFABRICATION AND DEVICES, P35; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thiele M, 2016, CHEM ENG J, V288, P432, DOI 10.1016/j.cej.2015.12.020; Thiele M, 2015, MATER TODAY-PROC, V2, P33, DOI 10.1016/j.matpr.2015.04.005; Thiele M, 2015, CHEM ENG TECHNOL, V38, P1131, DOI 10.1002/ceat.201400524; Tian LM, 2012, ANAL CHEM, V84, P9928, DOI 10.1021/ac302332g; Tokel O, 2014, CHEM REV, V114, P5728, DOI 10.1021/cr4000623; Toma M, 2014, PLASMONICS, V9, P765, DOI 10.1007/s11468-013-9657-0; Truong PL, 2011, LAB CHIP, V11, P2591, DOI 10.1039/c1lc20085b; Tseng TY, 2011, OPT EXPRESS, V19, P1291, DOI 10.1364/OE.19.001291; TURKEVICH J, 1951, DISCUSS FARADAY SOC, P55, DOI 10.1039/df9511100055; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Valdez J, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0167-z; Valsecchi C, 2016, ACS SENSORS, V1, P1103, DOI 10.1021/acssensors.6b00368; Verellen N, 2011, NANO LETT, V11, P391, DOI 10.1021/nl102991v; Vollmer F, 2012, NANOPHOTONICS-BERLIN, V1, P267, DOI 10.1515/nanoph-2012-0021; Wang DS, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16081175; Wang P, 2015, NANO LETT, V15, P7581, DOI 10.1021/acs.nanolett.5b03330; Wang T, 2006, J PHYS CHEM B, V110, P16930, DOI 10.1021/jp062486x; Wang XH, 2012, ANALYST, V137, P4267, DOI 10.1039/c2an35680e; Wang XH, 2010, BIOSENS BIOELECTRON, V26, P404, DOI 10.1016/j.bios.2010.07.121; Wilbur JL, 1996, NANOTECHNOLOGY, V7, P452, DOI 10.1088/0957-4484/7/4/028; Wu D, 2015, SENSOR ACTUAT B-CHEM, V221, P1433, DOI 10.1016/j.snb.2015.07.088; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G; Xia YS, 2013, ANAL CHEM, V85, P6241, DOI 10.1021/ac303591n; Xie XJ, 2012, ACCOUNTS CHEM RES, V45, P1511, DOI 10.1021/ar300044j; Xu XD, 2006, ADV FUNCT MATER, V16, P2170, DOI 10.1002/adfm.200500878; Yamamichi J, 2011, NANOMED-NANOTECHNOL, V7, P889, DOI 10.1016/j.nano.2011.02.002; Yang CT, 2016, ANAL CHEM, V88, P11924, DOI 10.1021/acs.analchem.6b03798; Yang JC, 2009, BIOSENS BIOELECTRON, V24, P2334, DOI 10.1016/j.bios.2008.12.011; Yanik AA, 2010, NANO LETT, V10, P4962, DOI 10.1021/nl103025u; Yguerabide J, 2001, J CELL BIOCHEM, V84, P71, DOI 10.1002/jcb.10077; Yguerabide J, 1998, ANAL BIOCHEM, V262, P137, DOI 10.1006/abio.1998.2759; Yguerabide J, 1998, ANAL BIOCHEM, V262, P157, DOI 10.1006/abio.1998.2760; Yonzon C, 2005, MRS P, V876; Yoo SM, 2016, TRENDS BIOTECHNOL, V34, P7, DOI 10.1016/j.tibtech.2015.09.012; Yoo SM, 2015, TALANTA, V132, P112, DOI 10.1016/j.talanta.2014.09.003; Yu WW, 2013, ANALYST, V138, P1020, DOI 10.1039/c2an36116g; Zeuner T, 2014, SENSOR ACTUAT B-CHEM, V195, P352, DOI 10.1016/j.snb.2013.12.091; Zhang M, 2012, ANALYST, V137, P601, DOI 10.1039/c1an15909g; Zhang QF, 2014, ACS APPL MATER INTER, V6, P17255, DOI 10.1021/am505245z; Zhang X, 2012, ACS NANO, V6, P9283, DOI 10.1021/nn303756a; Zhang XY, 2005, J AM CHEM SOC, V127, P4484, DOI 10.1021/ja0436623b0b; Zhao XH, 2015, BIOSENS BIOELECTRON, V74, P799, DOI 10.1016/j.bios.2015.07.022; Zhao YJ, 2016, TALANTA, V150, P81, DOI 10.1016/j.talanta.2015.09.013; Zhu SY, 2016, NANOTECHNOLOGY, V27, DOI 10.1088/0957-4484/27/29/295101; Zopf D, 2016, BIOSENS BIOELECTRON, V81, P287, DOI 10.1016/j.bios.2016.03.001	286	5	5	10	89	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	3					279	296		10.1080/14737159.2018.1440208			18	Pathology	Pathology	FY5ZM	WOS:000426918100007	29431525				2019-10-28	
J	Krausz, C; Cioppi, F; Riera-Escamilla, A				Krausz, Csilla; Cioppi, Francesca; Riera-Escamilla, Antoni			Testing for genetic contributions to infertility: potential clinical impact	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Male infertility; genetics; genes; spermatogenesis; Y chromosome; azoospermia; oligozooseprmia; exome	MULTIPLE MORPHOLOGICAL ABNORMALITIES; CONGENITAL BILATERAL ABSENCE; HUMAN Y-CHROMOSOME; ANDROGEN RECEPTOR GENE; CYSTIC-FIBROSIS GENE; SPERMATOGENIC FAILURE; KLINEFELTER SYNDROME; SPERM FLAGELLA; VAS-DEFERENS; TRUNCATING MUTATIONS	Introduction: Male infertility affects about 7% of the general male population, and it is a multifactorial, polygenic pathological condition. Known genetic factors, accounting for about 20-25% of male factor infertility, are present in each etiological category: i) hypothalamic-pituitary axis dysfunction; ii) quantitative and qualitative alterations of spermatogenesis; iii) ductal obstruction/dysfunction.Areas covered: All routinely available genetic tests are described. Indication for testing for chromosomal anomalies and Y chromosome microdeletions is based on sperm count (severe oligozoospermia/azoospermia). Mutation screening in candidate genes is indicated in specific semen/testis phenotypes. In about 40% of infertile patients, the aetiology remains unknown (idiopathic cases') and whole exome sequencing may reveal novel genetic causes.Expert commentary: Genetic testing is essential for its relevance in clinical decision-making. For instance, it helps to avoid unnecessary surgical or medical treatments and it may provide prediction for testicular sperm retrieval. The highest frequency of genetic anomalies is observed in severe spermatogenic impairment, which can be treated with in vitro fertilization (IVF). Given the risk of transmitting genetic disorders to the future offspring through IVF, the diagnosis of known and the discovery of novel genetic factors in idiopathic infertility is of outmost clinical importance.	[Krausz, Csilla; Cioppi, Francesca] Univ Florence, Dept Expt Clin & Biomed Sci Mario Serio, Sexual Med & Androl Unit, Viale Pieraccini 6, I-50139 Florence, Italy; [Riera-Escamilla, Antoni] Univ Autonoma Barcelona, Fundacio Puigvert, Androl Dept, IIB St Pau, Barcelona, Spain	Krausz, C (reprint author), Univ Florence, Dept Expt Clin & Biomed Sci Mario Serio, Sexual Med & Androl Unit, Viale Pieraccini 6, I-50139 Florence, Italy.	csilla.krausz@unifi.it	Riera-Escamilla, Antoni/W-3682-2019	RIERA-ESCAMILLA, ANTONI/0000-0002-4485-3094	Spanish Ministry of Health-Instituto Carlos IIIInstituto de Salud Carlos IIIMinistry of Health, Spain [FIS/FEDER PI14/01250, PI17/01822]; European Commission - Reproductive Biology Early Research Training (REPROTRAIN) [289880]	The study has been asupported in part by the Spanish Ministry of Health -Instituto Carlos III [grant number: FIS/FEDER PI14/01250; PI17/01822] to C Krausz and A Riera-Escamilla; European Commission - Reproductive Biology Early Research Training (REPROTRAIN, Project Number: 289880) to C Krausz and A Riera-Escamilla.	Adelman CA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000042; Aksglaede L, 2013, EUR J ENDOCRINOL, V168, pR67, DOI 10.1530/EJE-12-0934; Alasmari W, 2013, HUM REPROD, V28, P866, DOI 10.1093/humrep/des467; American College of Obstetricians and Gynecologists Committee on Genetics, 2011, Obstet Gynecol, V117, P1028, DOI 10.1097/AOG.0b013e31821922c2; Amiri-Yekta A, 2016, HUM REPROD, V31, P2872, DOI 10.1093/humrep/dew262; Arafat M, 2017, J MED GENET, V54, P633, DOI 10.1136/jmedgenet-2017-104514; Avenarius MR, 2009, AM J HUM GENET, V84, P505, DOI 10.1016/j.ajhg.2009.03.004; Avidan N, 2003, EUR J HUM GENET, V11, P497, DOI 10.1038/sj.ejhg.5200991; Ayhan O, 2014, J MED GENET, V51, P239, DOI 10.1136/jmedgenet-2013-102102; Baccetti B, 2005, HUM REPROD, V20, P2790, DOI 10.1093/humrep/dei126; Bashamboo A, 2016, SEX DEV, V10, P313, DOI 10.1159/000452637; Ben Khelifa M, 2014, AM J HUM GENET, V94, P95, DOI 10.1016/j.ajhg.2013.11.017; Ben Khelifa M, 2012, HUM REPROD, V27, P3337, DOI 10.1093/humrep/des296; Berthelsen GJ, 1981, DEV FUNCT REPROD ORG; Boehm U, 2015, NAT REV ENDOCRINOL, V11, P547, DOI 10.1038/nrendo.2015.112; Calogero AE, 2017, J ENDOCRINOL INVEST, V40, P705, DOI 10.1007/s40618-017-0619-9; CHEMES HE, 1987, FERTIL STERIL, V47, P310; Chemes HE, 2010, CELL TISSUE RES, V341, P349, DOI 10.1007/s00441-010-1007-3; Cheng H-B, 2014, ASIAN J ANDROL, V17, P513; Chianese C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097746; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Corona G, 2017, HUM REPROD UPDATE, V23, P265, DOI 10.1093/humupd/dmx008; Coutton C, 2015, HUM REPROD UPDATE, V21, P455, DOI 10.1093/humupd/dmv020; Cuppens H, 2004, INT J ANDROL, V27, P251, DOI 10.1111/j.1365-2605.2004.00485.x; Garza SAD, 2013, CURR OPIN OBSTET GYN, V25, P229, DOI 10.1097/GCO.0b013e32835faae5; Davis-Dao CA, 2007, J CLIN ENDOCR METAB, V92, P4319, DOI 10.1210/jc.2007-1110; de Meeus A, 1998, J MED GENET, V35, P594, DOI 10.1136/jmg.35.7.594; Dieterich K, 2007, NAT GENET, V39, P661, DOI 10.1038/ng2027; Du Q, 2014, BIOMED RES INT, DOI 10.1155/2014/689185; Dwyer AA, 2016, EUR J ENDOCRINOL, V174, pR267, DOI 10.1530/EJE-15-1033; Dwyer AA, 2015, BEST PRACT RES CL EN, V29, P91, DOI 10.1016/j.beem.2014.10.005; Eisenberg ML, 2015, J UROLOGY, V193, P1596, DOI 10.1016/j.juro.2014.11.080; Emery BR, 2004, FERTIL STERIL, V81, P686, DOI 10.1016/j.fertnstert.2003.07.025; Eskandari N, 2018, ANDROLOGIA, V50, DOI 10.1111/and.12843; Ferlin A, 2006, CLIN ENDOCRINOL, V65, P606, DOI 10.1111/j.1365-2265.2006.02635.x; Flannigan R, 2017, BEST PRACT RES CL OB, V44, P26, DOI 10.1016/j.bpobgyn.2017.05.002; Fullerton G, 2010, HUM REPROD, V25, P588, DOI 10.1093/humrep/dep431; Gambera L, 2010, FERTIL STERIL, V93, DOI 10.1016/j.fertnstert.2008.12.087; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; Gershoni M, 2017, GENET MED, V19, P998, DOI 10.1038/gim.2016.225; Gottlieb B, 2012, HUM MUTAT, V33, P887, DOI 10.1002/humu.22046; Greco E, 2013, HUM REPROD, V28, P1155, DOI 10.1093/humrep/det046; Hochstenbach R, 2000, Results Probl Cell Differ, V28, P271; Hoppman N, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-19; Jaruzelska J, 2001, J MED GENET, V38, P798, DOI 10.1136/jmg.38.11.798; Jensen TK, 2009, AM J EPIDEMIOL, V170, P559, DOI 10.1093/aje/kwp168; Jungwirth A, 2012, EUR UROL, V62, P324, DOI 10.1016/j.eururo.2012.04.048; Kamal A, 1999, HUM REPROD, V14, P2791, DOI 10.1093/humrep/14.11.2791; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Kherraf ZE, 2017, EMBO MOL MED, V9, P1132, DOI 10.15252/emmm.201607461; Knowles MR, 2016, CLIN CHEST MED, V37, P449, DOI 10.1016/j.ccm.2016.04.008; Krausz C, 2000, HUM REPROD, V15, P1431, DOI 10.1093/humrep/15.7.1431; Krausz C, 2017, HUM GENET, V136, P637, DOI 10.1007/s00439-017-1793-8; Krausz C, 2014, ANDROLOGY-US, V2, P5, DOI 10.1111/j.2047-2927.2013.00173.x; Krausz C, 2006, HUM MOL GENET, V15, P2673, DOI 10.1093/hmg/ddl198; Krausz C, 2015, REPRODUCTION, V150, pR159, DOI 10.1530/REP-15-0261; Krausz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044887; Krausz C, 2011, BEST PRACT RES CL EN, V25, P271, DOI 10.1016/j.beem.2010.08.006; Kuentz P, 2013, HUM REPROD, V28, P1054, DOI 10.1093/humrep/det005; Lange J, 2009, CELL, V138, P855, DOI 10.1016/j.cell.2009.07.042; Lao O, 2003, EUR J HUM GENET, V11, P385, DOI 10.1038/sj.ejhg.5200970; Larriba S, 2005, INT J ANDROL, V28, P284, DOI 10.1111/j.1365-2605.2005.00544.x; Latif T, 2017, AM J EPIDEMIOL, V186, P910, DOI 10.1093/aje/kwx067; Li L, 2017, ONCOTARGET, V8, P19914, DOI 10.18632/oncotarget.15251; Lo Giacco D, 2014, J MED GENET, V51, P340, DOI 10.1136/jmedgenet-2013-101988; Lo Giacco D, 2014, EUR J HUM GENET, V22, P754, DOI 10.1038/ejhg.2013.253; Lopes AM, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003349; Lotti F, 2015, HUM REPROD UPDATE, V21, P56, DOI 10.1093/humupd/dmu042; Lu CC, 2009, HUM MOL GENET, V18, P1122, DOI 10.1093/hmg/ddn427; Maduro MR, 2003, MOL HUM REPROD, V9, P61, DOI 10.1093/molehr/gag013; Maor-Sagie E, 2015, J ASSIST REPROD GEN, V32, P887, DOI 10.1007/s10815-015-0445-y; Mateu E, 2010, FERTIL STERIL, V94, P2874, DOI 10.1016/j.fertnstert.2010.06.046; McCallum TJ, 2001, HUM REPROD, V16, P282, DOI 10.1093/humrep/16.2.282; Mitchell MJ, 2017, CLIN GENET, V91, P208, DOI 10.1111/cge.12900; Mueller JL, 2013, NAT GENET, V45, P1083, DOI 10.1038/ng.2705; Nathanson KL, 2005, AM J HUM GENET, V77, P1034, DOI 10.1086/498455; NISTAL M, 1977, VIRCHOWS ARCH B, V26, P111; OATES RD, 1994, J ANDROL, V15, P1; Oates RD, 2002, HUM REPROD, V17, P2813, DOI 10.1093/humrep/17.11.2813; Obermann H, 2003, MOL REPROD DEV, V64, P13, DOI 10.1002/mrd.10220; Okutman O, 2017, J ASSIST REPROD GEN, V34, P683, DOI 10.1007/s10815-017-0900-z; Okutman O, 2015, HUM MOL GENET, V24, P5581, DOI 10.1093/hmg/ddv290; Patat O, 2016, AM J HUM GENET, V99, P437, DOI 10.1016/j.ajhg.2016.06.012; Patsalis PC, 2002, LANCET, V360, P1222, DOI 10.1016/S0140-6736(02)11248-7; Plotton I, 2015, J CLIN ENDOCR METAB, V100, P961, DOI 10.1210/jc.2014-3083; Porcu G, 2003, HUM REPROD, V18, P562, DOI 10.1093/humrep/deg121; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Rajender S, 2007, ASIAN J ANDROL, V9, P147, DOI 10.1111/j.1745-7262.2007.00250.x; Ramasamy R, 2015, FERTIL STERIL, V104, P286, DOI 10.1016/j.fertnstert.2015.04.001; Ray PF, 2017, CLIN GENET, V91, P217, DOI 10.1111/cge.12905; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; Repping S, 2002, AM J HUM GENET, V71, P906, DOI 10.1086/342928; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rohayem J, 2015, ANDROLOGY-US, V3, P868, DOI 10.1111/andr.12067; Salonia A, 2009, EUR UROL, V56, P1025, DOI 10.1016/j.eururo.2009.03.001; Sha YW, 2018, CLIN GENET, V93, P776, DOI 10.1111/cge.13140; Shang Y, 2017, ELIFE, V6, P1; Shen Y, 2017, BIOL REPROD, V96, P610, DOI 10.1093/biolre/iox006; SKAKKEBAEK NE, 1973, FERTIL STERIL, V24, P390; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Staessen C, 2003, HUM REPROD UPDATE, V9, P319, DOI 10.1093/humupd/dmg029; Stouffs K, 2005, HUM REPROD, V20, P1887, DOI 10.1093/humrep/deh847; Stouffs K, 2012, HUM REPROD, V27, P921, DOI 10.1093/humrep/der440; Takeuchi K, 2017, AURIS NASUS LARYNX, VS0385-8146, P30416; Tamburrino L, 2014, HUM REPROD, V29, P418, DOI 10.1093/humrep/det454; Tang SY, 2017, AM J HUM GENET, V100, P854, DOI 10.1016/j.ajhg.2017.04.012; Tenenbaum-Rakover Y, 2015, J MED GENET, V52, P391, DOI 10.1136/jmedgenet-2014-102921; TIEPOLO L, 1976, HUM GENET, V34, P119, DOI 10.1007/BF00278879; Tournaye H, 2017, LANCET DIABETES ENDO, V5, P544, DOI 10.1016/S2213-8587(16)30040-7; Tuttelmann F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019426; Tyler-Smith C, 2009, NEW ENGL J MED, V360, P925, DOI 10.1056/NEJMe0900301; vanderVen K, 1996, HUM REPROD, V11, P513, DOI 10.1093/HUMREP/11.3.513; Vetro A, 2011, J MED GENET, V48, P710, DOI 10.1136/jmedgenet-2011-100036; Vincent MC, 2002, J ANDROL, V23, P18, DOI 10.1002/j.1939-4640.2002.tb02597.x; Vogt PH, 1996, HUM MOL GENET, V5, P933, DOI 10.1093/hmg/5.7.933; Vorona E, 2007, J CLIN ENDOCR METAB, V92, P3458, DOI 10.1210/jc.2007-0447; Wambergue C, 2016, HUM REPROD, V31, P1164, DOI 10.1093/humrep/dew083; Wang X, 2017, CLIN GENET, V91, P313, DOI 10.1111/cge.12857; Westlander G, 2003, HUM REPROD, V18, P1286, DOI 10.1093/humrep/deg240; Yadav RP, 2014, MOL CELL ENDOCRINOL, V382, P498, DOI 10.1016/j.mce.2013.04.015; Yang B, 2017, ANDROLOGY-US, V5, P954, DOI 10.1111/andr.12407; Yang F, 2015, EMBO MOL MED, V7, P1198, DOI 10.15252/emmm.201404967; Yatsenko AN, 2015, NEW ENGL J MED, V372, P2097, DOI 10.1056/NEJMoa1406192; Yu JM, 2012, HUM REPROD, V27, P25, DOI 10.1093/humrep/der377; Zhang F, 2007, J MED GENET, V44, P437, DOI 10.1136/jmg.2007.049056; Zhang Y, 2007, J MED GENET, V44, P233, DOI 10.1136/jmg.2006.045765; Zhu FX, 2016, AM J HUM GENET, V99, P1405, DOI 10.1016/j.ajhg.2016.11.002	127	6	6	1	7	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					331	346		10.1080/14737159.2018.1453358			16	Pathology	Pathology	GD0SV	WOS:000430211800003	29540081				2019-10-28	
J	Ilijazi, D; Abufaraj, M; Hassler, MR; Ertl, IE; D'Andrea, D; Shariat, SF				Ilijazi, Dafina; Abufaraj, Mohammad; Hassler, Melanie R.; Ertl, Iris E.; D'Andrea, David; Shariat, Shahrokh F.			Waiting in the wings: the emerging role of molecular biomarkers in bladder cancer	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						BCG therapy; bladder cancer; molecular biomarker; neoadjuvant therapy; personalized medicine; predictive biomarker; prognostic biomarker	INVASIVE UROTHELIAL CARCINOMA; COPPER TRANSPORTER CTR1; DOSE-DENSE METHOTREXATE; T1 HIGH-GRADE; NEOADJUVANT CHEMOTHERAPY; FUNCTIONAL POLYMORPHISMS; SURVIVIN EXPRESSION; CELL-CARCINOMA; CYCLIN D1; CISPLATIN	Introduction: Bladder cancer (BCa) is the fifth most frequently diagnosed cancer worldwide and is, in fact, the most expensive cancer on a per-patient to treat basis. There is a critical need to implement new tests into clinical practice to improve the quality of clinical care, decrease unnecessary invasive therapies and ultimately save costs. Currently, no molecular or genetic biomarker has been widely integrated into daily clinical practice. However, major milestones have been achieved in our understanding of the molecular alterations in BCa that will provide the basis for integrating molecular and genetic biomarkers into clinical decision making to guide management. Clinical implementation of such novel molecular and genetic concepts is the cornerstone in an effort to usher the age of precision medicine into patient care.Areas covered: In this review, the authors discuss the emerging role of molecular biomarkers in patients receiving BCG immunotherapy as well as neoadjuvant and adjuvant chemotherapy in BCa.Expert commentary: Molecular predictive and prognostic biomarkers in BCa are promising diagnostic options that will pave the way for molecular-based personalized medicine.	[Ilijazi, Dafina; Abufaraj, Mohammad; Hassler, Melanie R.; Ertl, Iris E.; D'Andrea, David; Shariat, Shahrokh F.] Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria; [Abufaraj, Mohammad] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Amman, Jordan; [Shariat, Shahrokh F.] Karl Landsteiner Inst Urol & Androl, Vienna, Austria; [Shariat, Shahrokh F.] Univ Texas Southwestern Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Shariat, Shahrokh F.] New York Presbyterian Hosp, Dept Urol, Weill Cornell Med Coll, New York, NY USA	Shariat, SF (reprint author), Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	sfshariat@gmail.com	Abufaraj, Mohammad/I-2336-2019	Abufaraj, Mohammad/0000-0002-6603-6319; Shariat, Shahrokh/0000-0002-6627-6179			Abufaraj M, 2018, EUR UROL, V73, P543, DOI 10.1016/j.eururo.2017.09.030; Alvarez-Mugica M, 2013, EUR UROL, V63, P364, DOI 10.1016/j.eururo.2012.05.050; Aranda S, 2011, FASEB J, V25, P449, DOI 10.1096/fj.10-165837; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Ballman KV, 2015, J CLIN ONCOL, V33, P3968, DOI 10.1200/JCO.2015.63.3651; Baras AS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131245; Bensalah K, 2007, EUR UROL, V52, P1601, DOI 10.1016/j.eururo.2007.09.036; Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033; Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Choueiri TK, 2014, J CLIN ONCOL, V32, P1889, DOI 10.1200/JCO.2013.52.4785; de Martino M, 2014, CANCER BIOL THER, V15, P1239, DOI 10.4161/cbt.29687; DEBOER EC, 1991, CANCER IMMUNOL IMMUN, V33, P411, DOI 10.1007/BF01741603; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Fu C, 2016, HLA, V88, P275, DOI 10.1111/tan.12900; Groenendijk FH, 2016, EUR UROL, V69, P384, DOI 10.1016/j.eururo.2015.01.014; Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011; Hemdan T, 2015, J UROLOGY, V194, P1575, DOI 10.1016/j.juro.2015.06.085; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Jaiswal PK, 2012, MOL BIOL REP, V39, P5615, DOI 10.1007/s11033-011-1366-1; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Kamat AM, 2016, J CLIN ONCOL, V34, P1935, DOI 10.1200/JCO.2015.64.4070; Kamat AM, 2016, EUR UROL, V69, P197, DOI 10.1016/j.eururo.2015.06.023; Kamat AM, 2013, EUR UROL, V63, P4, DOI 10.1016/j.eururo.2012.09.057; Karakiewicz PI, 2006, EUR UROL, V50, P1254, DOI 10.1016/j.eururo.2006.06.010; Karam JA, 2007, UROLOGY, V70, P482, DOI 10.1016/j.urology.2007.05.009; Kawashima A, 2012, ONCOL LETT, V4, P15, DOI 10.3892/ol.2012.689; Kilari D, 2016, ANTICANCER RES, V36, P495; Kiss B, 2017, SCI REP-UK, V7, DOI 10.1038/srep42713; Kiss B, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2014.12.005; Klatte T, 2015, J UROLOGY, V194, P1456, DOI 10.1016/j.juro.2015.06.099; Kluth LA, 2015, EUR UROL, V68, P238, DOI 10.1016/j.eururo.2015.01.032; Lima L, 2013, BRIT J CANCER, V109, P2106, DOI 10.1038/bjc.2013.571; Lima L, 2014, UROL ONCOL-SEMIN ORI, V32, P1; Lima L, 2015, BJU INT, V116, P753, DOI 10.1111/bju.12844; Lima L, 2012, ADV UROL, DOI 10.1155/2012/232609; Liu D, 2016, JAMA ONCOL, V2, P1094, DOI 10.1001/jamaoncol.2016.1056; Malmstrom PU, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2017.03.010; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Margulis V, 2006, CLIN CANCER RES, V12, P7369, DOI 10.1158/1078-0432.CCR-06-1472; Margulis V, 2009, JNCI-J NATL CANCER I, V101, P114, DOI 10.1093/jnci/djn451; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; Mbeutcha A, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2016.05.013; McConkey DJ, 2016, EUR UROL, V69, P855, DOI 10.1016/j.eururo.2015.08.034; Mikeska T, 2012, EXPERT REV MOL DIAGN, V12, P473, DOI [10.1586/erm.12.45, 10.1586/ERM.12.45]; Miyake H, 1999, J UROLOGY, V162, P2176, DOI 10.1016/S0022-5347(05)68155-4; Moschini M, 2017, CLIN GENITOURIN CANC, V15, P67, DOI [10.1016/j.clgc.2016.06.002, 10.1016/j.clgc.2016.07.014]; Nomura S, 2015, BMC UROL, V15, DOI 10.1186/s12894-015-0040-7; Nomura S, 2013, BMC UROL, V13, DOI 10.1186/1471-2490-13-73; North S, 2014, J UROLOGY, V191, P35, DOI 10.1016/j.juro.2013.07.006; Nunez-Nateras R, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2013.06.008; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ozcan MF, 2013, UROL ONCOL-SEMIN ORI, V31, P1709, DOI 10.1016/j.urolonc.2012.06.014; Pichler R, 2017, CANCER IMMUNOL IMMUN, V66, P427, DOI 10.1007/s00262-016-1945-z; Pietzak EJ, 2017, EUR UROL, V72, P952, DOI 10.1016/j.eururo.2017.05.032; Plimack ER, 2015, EUR UROL, V68, P959, DOI 10.1016/j.eururo.2015.07.009; Redelman-Sidi G, 2014, NAT REV UROL, V11, P153, DOI 10.1038/nrurol.2014.15; Ren BM, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-55; Schiffmann J, 2016, CUAJ-CAN UROL ASSOC, V10, pE82, DOI 10.5489/cuaj.3292; Scott SN, 2017, CANCER CYTOPATHOL, V125, P416, DOI 10.1002/cncy.21847; Seiler R, 2017, EUR UROL, V72, P142, DOI [10.1016/j.eururo.2017.03.021, 10.1016/j.eururo.2017.03.030]; Seiler R, 2014, MODERN PATHOL, V27, P87, DOI 10.1038/modpathol.2013.125; Shariat SF, 2005, J UROLOGY, V173, P1518, DOI 10.1097/01.ju.0000154696.48217.75; Shariat SF, 2003, UROLOGY, V61, P1140, DOI 10.1016/S0090-4295(03)00236-X; Shariat SF, 2008, EUR UROL, V54, P41, DOI 10.1016/j.eururo.2008.01.004; Shariat SF, 2007, MODERN PATHOL, V20, P445, DOI 10.1038/modpathol.3800757; Shariat SF, 2007, CANCER-AM CANCER SOC, V109, P1106, DOI 10.1002/cncr.22521; Shariat SF, 2006, HUM PATHOL, V37, P1568, DOI 10.1016/j.humpath.2006.05.017; Shariat SF, 2017, LANCET ONCOL, V18, P271, DOI 10.1016/S1470-2045(17)30098-0; Shariat SF, 2010, J UROLOGY, V183, P68, DOI 10.1016/j.juro.2009.08.115; Shariat SF, 2009, CLIN CANCER RES, V15, P7012, DOI 10.1158/1078-0432.CCR-08-2554; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song IS, 2004, MOL CANCER THER, V3, P1543; Sun JM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-187; Svatek RS, 2014, EUR UROL, V66, P253, DOI 10.1016/j.eururo.2014.01.006; Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007; Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623; Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020; Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335; Xylinas E, 2013, BRIT J CANCER, V109, P1460, DOI 10.1038/bjc.2013.372; Xylinas E, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030037	84	3	3	2	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					347	356		10.1080/14737159.2018.1453808			10	Pathology	Pathology	GD0SV	WOS:000430211800004	29542328				2019-10-28	
J	Piro, G; Carbone, C; Santoro, R; Tortora, G; Melisi, D				Piro, Geny; Carbone, Carmine; Santoro, Raffaela; Tortora, Giampaolo; Melisi, Davide			Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Esophageal adenocarcinoma; esophago-gastric junction adenocarcinoma; gastric adenocarcinoma; predictive biomarker; neoadjuvant therapy	GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; TUMOR-INFILTRATING LYMPHOCYTES; ERCC1 GENE POLYMORPHISMS; PREOPERATIVE CHEMORADIOTHERAPY; PERIOPERATIVE CHEMOTHERAPY; GASTROESOPHAGEAL JUNCTION; MICROSATELLITE INSTABILITY; ALDEHYDE DEHYDROGENASE; GASTRIC-CANCER	Introduction: Esophageal and esophago-gastric junction (EGJ) adenocarcinomas remain a major health problem worldwide with a worryingly increasing incidence. Recent trials indicate survivals benefit for preoperative or perioperative chemoradiotherapy compared to surgery alone. Beside standard chemoradiotherapy regimens, new therapeutic approaches with targeted therapies have been proposed for the treatment of resectable disease. However, clinical outcomes remain extremely poor due to drug resistance phenomena. The failure of these approaches could be partially ascribed to their incorrect application in patients. Therefore, the identification of strong biomarkers for optimal patient management is urgently needed.Areas covered: This review aims to summarize and critically discuss the most relevant findings regarding predictive biomarker development for neoadjuvant treatment of resectable esophageal and esophago-gastric junction adenocarcinoma patients.Expert commentary: Optimizing the currently available therapeutic modalities through a more accurate selection of patients may avoid the use of ineffective and potentially toxic treatments. During the last decade, the advent of high-throughput -omics' technologies has set the basis for a new biomarker discovery approach from molecule by molecule' screening towards a large-scale systematic screening process with exponential increases in putative biomarkers, which often failed to provide adequate clinical validation.	[Piro, Geny; Carbone, Carmine; Santoro, Raffaela; Melisi, Davide] Univ Verona, Dept Med, Digest Mol Clin Oncol Res Unit, Verona, Italy; [Piro, Geny; Tortora, Giampaolo] Univ Verona, Dept Med, Lab Oncol & Mol Therapy, Verona, Italy; [Tortora, Giampaolo; Melisi, Davide] Azienda Osped Univ Integrata, Med Oncol Unit, Verona, Italy; [Piro, Geny; Carbone, Carmine; Santoro, Raffaela; Tortora, Giampaolo; Melisi, Davide] Azienda Osped Univ Integrata, Ctr Comprehens Canc, Verona, Italy	Melisi, D (reprint author), Univ Verona, Dept Med, Sect Med Oncol, Digest Mol Clin Oncol Res Unit, Piazzale LA Scuro 10, I-37134 Verona, Italy.	davide.melisi@univr.it	Piro, Geny/R-5563-2019; Melisi, Davide/K-7947-2016; Tortora, Giampaolo/AAA-1252-2019	Piro, Geny/0000-0003-3708-5397; Melisi, Davide/0000-0002-4031-7585; 	Associazione Italiana per la Ricerca sul Cancro (AIRC)Associazione Italiana per la Ricerca sul Cancro (AIRC) [19111, 18599]; University of VeronaMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR)	This paper was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC) under Investigator Grant (IG), No. 19111 to D Melisi; The Associazione Italiana per la Ricerca sul Cancro (AIRC) under Investigator Grant (IG), No. 18599 to G Tortora; The Basic Research Project 2015 through the University of Verona.	Aichler M, 2014, ONCOTARGET, V5, P6620, DOI 10.18632/oncotarget.2268; Ajani JA, 2014, MOL ONCOL, V8, P142, DOI 10.1016/j.molonc.2013.10.007; Alexander H R, 1995, Cancer J Sci Am, V1, P49; [Anonymous], 2017, NATURE, V541, P169, DOI DOI 10.1038/NATURE20805; Bain GH, 2014, BRIT J CANCER, V110, P1525, DOI 10.1038/bjc.2014.45; Bain GH, 2010, ONCOLOGIST, V15, P270, DOI 10.1634/theoncologist.2009-0293; Bang YJ, 2010, LANCET, V376, P1302; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Baykara M, 2015, J GASTROINTEST SURG, V19, P1565, DOI 10.1007/s11605-015-2888-y; Beardsmore DA, 2003, J GASTROINTEST SURG, V7, P77, DOI 10.1016/S1091-255X(02)00141-5; Boger C, 2016, ONCOTARGET, V7, P24269, DOI 10.18632/oncotarget.8169; Brabender J, 2004, ONCOGENE, V23, P4780, DOI 10.1038/sj.onc.1207663; Burtness Barbara, 2014, Am Soc Clin Oncol Educ Book, pe172, DOI 10.14694/EdBook_AM.2014.34.e172; Carbone C, 2018, INT J OBESITY, V42, P334, DOI 10.1038/ijo.2017.285; Carbone C, 2016, ANTI-CANCER DRUG, V27, P29, DOI 10.1097/CAD.0000000000000301; Carbone C, 2015, ONCOTARGET, V6, P13822, DOI 10.18632/oncotarget.2635; Carbone C, 2012, EXPERT OPIN THER TAR, V16, pS1, DOI 10.1517/14728222.2011.645806; Chen KY, 2017, MED SCI MONITOR, V23, P4619, DOI 10.12659/MSM.904154; Crumley ABC, 2011, ANN SURG ONCOL, V18, P2604, DOI 10.1245/s10434-011-1658-7; Cui HX, 2017, NAT REV ENDOCRINOL, V13, P338, DOI 10.1038/nrendo.2016.222; Cunningham D, 2017, LANCET ONCOL, V18, P357, DOI 10.1016/S1470-2045(17)30043-8; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; Dahlberg PS, 2004, ANN THORAC SURG, V77, P1008, DOI 10.1016/j.athoracsur.2003.09.051; Davies AR, 2014, J CLIN ONCOL, V32, P2983, DOI 10.1200/JCO.2014.55.9070; Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678; Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Edgren G, 2013, GUT, V62, P1406, DOI 10.1136/gutjnl-2012-302412; Fareed KR, 2009, GUT, V58, P127, DOI 10.1136/gut.2008.155861; Gaianigo N, 2017, CANCERS, V9, P9; Galipeau PC, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0520-y; Garofalo C, 2006, J CELL PHYSIOL, V207, P12, DOI 10.1002/jcp.20472; Gibson MK, 2003, CLIN CANCER RES, V9, P6461; Goode EF, 2016, J CLIN MED, V5, DOI 10.3390/jcm5100084; Gordon MA, 2013, ANN ONCOL, V24, P1754, DOI 10.1093/annonc/mdt106; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Heeren PAM, 2004, ANTICANCER RES, V24, P2579; HOFHEINZ R, 2014, J CLIN ONCOL S, V32; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Housa D, 2006, PHYSIOL RES, V55, P233; Howard JM, 2010, BRIT J SURG, V97, P1020, DOI 10.1002/bjs.7072; Izzo JG, 2006, J CLIN ONCOL, V24, P748, DOI 10.1200/JCO.2005.03.8810; Izzo JG, 2006, MOL CANCER THER, V5, P2844, DOI 10.1158/1535-7163.MCT-06-0351; Janjigian YY, 2012, ANN ONCOL, V23, P2656, DOI 10.1093/annonc/mds104; Jesinghaus M, 2017, ONCOTARGET, V8, P46756, DOI 10.18632/oncotarget.18606; Jin ZH, 2016, J GASTROINTEST ONCOL, V7, P771, DOI 10.21037/jgo.2016.08.06; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Joshi MBM, 2005, CLIN CANCER RES, V11, P2215; Kollmann D, 2017, ANN SURG ONCOL, V24, P2698, DOI 10.1245/s10434-017-5858-7; Koopman T, 2018, HISTOPATHOLOGY, V72, P191, DOI 10.1111/his.13322; Ku GY, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4025; Kurokawa Y, 2015, GASTRIC CANCER, V18, P691, DOI 10.1007/s10120-014-0430-7; Langer R, 2005, CLIN CANCER RES, V11, P7462, DOI 10.1158/1078-0432.CCR-05-0042; Langer R, 2007, AM J CLIN PATHOL, V128, P191, DOI 10.1309/1U6X4L9XFJLJV940; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928; Luthra R, 2006, J CLIN ONCOL, V24, P259, DOI 10.1200/JCO.2005.03.3688; Marx AH, 2010, HISTOPATHOLOGY, V57, P418, DOI 10.1111/j.1365-2559.2010.03643.x; Melisi D, 2007, EXPERT OPIN THER TAR, V11, P133, DOI 10.1517/14728222.11.2.133; Melisi D, 2013, CURR OPIN PHARMACOL, V13, P536, DOI 10.1016/j.coph.2013.06.012; Melisi D, 2011, J NATL CANCER I, V103, P1190, DOI 10.1093/jnci/djr243; Metzger R, 2012, J GASTROINTEST SURG, V16, P26, DOI 10.1007/s11605-011-1700-x; Miller CT, 2003, CLIN CANCER RES, V9, P4819; Mokdad AA, 2018, JAMA ONCOL, V4, P31, DOI 10.1001/jamaoncol.2017.2805; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3; Nebot-Bral L, 2017, EUR J CANCER, V84, P290, DOI 10.1016/j.ejca.2017.07.026; Noble F, 2016, CANCER IMMUNOL IMMUN, V65, P651, DOI 10.1007/s00262-016-1826-5; Nones K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6224; Noorani A, 2017, GENOME RES, V27, P902, DOI 10.1101/gr.214296.116; Ogino S, 2018, GUT; Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182; Okines AFC, 2013, ANN ONCOL, V24, P1253, DOI 10.1093/annonc/mds622; Oppedijk V, 2014, J CLIN ONCOL, V32, P385, DOI 10.1200/JCO.2013.51.2186; Pai R, 2005, BIOCHEM BIOPH RES CO, V331, P984, DOI 10.1016/j.bbrc.2005.03.236; Park SM, 2004, FEBS LETT, V566, P151, DOI 10.1016/j.feblset.2004.04.021; Peters JH, 2012, J GASTROINTEST SURG, V16, P34; Piro G, 2015, BRIT J CANCER, V113, P878, DOI 10.1038/bjc.2015.283; Piro G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1322242; Piro G, 2016, CLIN CANCER RES, V22, P6164, DOI 10.1158/1078-0432.CCR-16-0178; Ralph C, 2010, CLIN CANCER RES, V16, P1662, DOI 10.1158/1078-0432.CCR-09-2870; Ribeiro U, 1998, CANCER, V83, P7, DOI 10.1002/(SICI)1097-0142(19980701)83:1<7::AID-CNCR2>3.0.CO;2-R; Rivera F, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.e15269; Rodriguez-Torres M, 2016, CLIN EXP METASTAS, V33, P97, DOI 10.1007/s10585-015-9755-9; Sakurai H, 2012, TRENDS PHARMACOL SCI, V33, P522, DOI 10.1016/j.tips.2012.06.007; Schauer M, 2010, CLIN CANCER RES, V16, P330, DOI 10.1158/1078-0432.CCR-09-1673; Secrier M, 2016, NAT GENET, V48, P1131, DOI 10.1038/ng.3659; Shitara K, 2012, GASTRIC CANCER, V15, P137, DOI 10.1007/s10120-011-0083-8; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Smit JK, 2013, RADIOTHER ONCOL, V107, P434, DOI 10.1016/j.radonc.2013.03.027; Smyth E, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.17; Smyth EC, 2017, JAMA ONCOL, V3, P1197, DOI 10.1001/jamaoncol.2016.6762; Srinivasula SM, 2008, MOL CELL, V30, P123, DOI 10.1016/j.molcel.2008.03.008; Stein AV, 2017, PATHOLOGY, V49, P30, DOI 10.1016/j.pathol.2016.10.005; Sun ZJ, 2015, J CELL MOL MED, V19, P2691, DOI 10.1111/jcmm.12662; Tokunaga R, 2016, ONCOTARGET, V7, P19748, DOI 10.18632/oncotarget.7782; Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; VanSaun MN, 2013, CLIN CANCER RES, V19, P1926, DOI 10.1158/1078-0432.CCR-12-0930; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang KL, 2007, CANCER, V109, P658, DOI 10.1002/cncr.22445; Watson S, 2013, ANN ONCOL, V24, P3035, DOI 10.1093/annonc/mdt393; Yacoub L, 1997, MODERN PATHOL, V10, P105; Ychou M, 2011, J CLIN ONCOL, V29, P1715, DOI 10.1200/JCO.2010.33.0597; Zhang G, 2012, MOL MED REP, V6, P519, DOI 10.3892/mmr.2012.939; Zhuang ZN, 2016, CLIN CANCER RES, V22, P1432, DOI 10.1158/1078-0432.CCR-14-3382	107	1	1	1	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					357	370		10.1080/14737159.2018.1454312			14	Pathology	Pathology	GD0SV	WOS:000430211800005	29544370				2019-10-28	
J	Gous, N; Boeras, DI; Cheng, B; Takle, J; Cunningham, B; Peeling, RW				Gous, Natasha; Boeras, Debrah I.; Cheng, Ben; Takle, Jeff; Cunningham, Brad; Peeling, Rosanna W.			The impact of digital technologies on point-of-care diagnostics in resource-limited settings	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Digital technology; connected diagnostic system; health system strengthening; quality assurance; data governance	XPERT MTB/RIF; SOUTH-AFRICA; TUBERCULOSIS; HEALTH; IMPLEMENTATION; PERFORMANCE; SURVEILLANCE; ELIMINATION; ALGORITHMS; LESSONS	Introduction: Simple, rapid tests that can be used at the point-of-care (POC) can improve access to diagnostic services and overall patient management in resource-limited settings where laboratory infrastructure is limited. Implementation of POC tests places tremendous strain on already fragile health systems as the demand for training, supply management and quality assurance are amplified. Digital health has a major role to play in ensuring effective delivery and management of POC testing services.Area covered: The ability to digitise laboratory and POC platforms, including lateral flow rapid diagnostic test results, can standardize the interpretation of results and allows data to be linked to proficiency testing to ensure testing quality, reducing interpretation and transcription errors. Remote monitoring of POC instrument functionality and utilization through connectivity, allows programs to optimize instrument placement, algorithm adoption and supply management. Alerts can be built into the system to raise alarm at unusual trends such as outbreaks.Expert commentary: Digital technology has had a powerful impact on POC testing in resource limited settings. Technology, markets, and medical devices have matured to enable connected diagnostics to become a useful tool for epidemiology, patient care and tracking, research, and antimicrobial resistance and outbreak surveillance. However, to unlock this potential, digital tools must first add value at the point of patient care. The global health community need to propose models for protecting intellectual property to foster innovation and for safeguarding data confidentiality.	[Gous, Natasha; Cunningham, Brad] SystemOne LLC, Global Hlth Dept, Johannesburg, South Africa; [Boeras, Debrah I.] Global Hlth Impact Grp, Atlanta, GA USA; [Boeras, Debrah I.; Cheng, Ben] Int Diagnost Ctr, London, England; [Takle, Jeff] SystemOne LLC, Global Hlth Dept, Springfield, MA USA; [Peeling, Rosanna W.] London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London, England	Peeling, RW (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London, England.	Rosanna.peeling@lshtm.ac.uk			UK Engineering and Physical Sciences Research CouncilEngineering & Physical Sciences Research Council (EPSRC) [EP/K031953/1]	R Peeling would like to acknowledge funding from the UK Engineering and Physical Sciences Research Council, grant EP/K031953/1.	Alamo ST, 2012, TROP MED INT HEALTH, V17, P884, DOI 10.1111/j.1365-3156.2012.03003.x; Albert H, 2016, EUR RESPIR J, V48, P516, DOI 10.1183/13993003.00543-2016; Andre E, 2016, INT J TUBERC LUNG D, V20, P999, DOI 10.5588/ijtld.16.0015; Boeras DI, 2017, CURR OPIN HIV AIDS, V12, P171, DOI 10.1097/COH.0000000000000349; Buckeridge DL, 2008, J AM MED INFORM ASSN, V15, P760, DOI 10.1197/jamia.M2799; Cheng B, 2016, AFR J LAB MED, V5, DOI 10.4102/ajlm.v5i2.535; Clouse K, 2012, SAMJ S AFR MED J, V102, P805, DOI [10.7196/SAMJ.5851, 10.7196/samj.5851]; Cobelens F, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001358; Cohen GM, 2014, JAIDS-J ACQ IMM DEF, V67, pE88, DOI 10.1097/QAI.0000000000000309; Deloitte Centre for Health Solutions, 2015, CONN HLTH DIG TECHN; Dimagi and Global Solutions for Infectious Diseases, 2014, CAS STUD REP RAP DIA; DUGGAL R, 2018, BMJ-BRIT MED J, V360, DOI DOI 10.1136/BMJ.K6; Dye C, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0426; EU US Privacy Shield, PRIV SHIELD PROGR OV; Fionet: mobile diagnostics integrated with cloud information services, USAID MHEALTH COMPEN, V2, P62; Forsyth BWC, 2004, JAIDS-J ACQ IMM DEF, V35, P151, DOI 10.1097/00126334-200402010-00008; Futrell K, 2015, CISC VIS NETW IND GL; Glencross DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114727; Global Laboratory Initiative (GLI), 2016, QUICK GUID TB DIAGN; Global Laboratory Initiative (GLI), XPERT MTB RIF TRAIN; Granade TC, 2004, J CLIN VIROL, V30, P229, DOI 10.1016/j.jcv.2003.12.006; Habiyambere V, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002088; Jani IV, 2013, NEW ENGL J MED, V368, P2319, DOI 10.1056/NEJMsb1214197; Kehinde J, 2015, 46 UN C LUNG HLTH DE; Kelly GC, 2012, TRENDS PARASITOL, V28, P297, DOI 10.1016/j.pt.2012.04.002; Kostkova P, 2016, FRONT PUBLIC HEALTH, V4, DOI 10.3389/fpubh.2016.00007; Laksanasopin T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0056; Loveday M, 2008, INT J TUBERC LUNG D, V12, P1042; McGill University Health Centre foundation, 2016, HIVSMART APP; Mengesha E, 2017, 20 C UN AFR JUL 10 1; Morley C, 2017, MONITORING EVALUATIO; Mustapha G, 2015, SAARC J TUBERC LUNG, VXII, P1; Mwau M, 2016, AFR J LAB MED, V5, DOI 10.4102/ajlm.v5i2.439; Mwisongo A, 2016, AFR HEALTH SCI, V16, P646, DOI 10.4314/ahs.v16i3.2; Nicols JH, 1999, MANAGEMENT POINT CAR; Pathmanathan I, 2017, AFR J LAB MED, V6, DOI 10.4102/ajlm.v6i2.460; Peter T, 2017, J INT AIDS SOC, V20, P9, DOI 10.1002/jia2.25008; Prater VS, 2014, BIOMEDICAL HLTH INFO; Sadiq T, COMMUNICATION; Saito S, 2012, JAIDS-J ACQ IMM DEF, V61, P216, DOI 10.1097/QAI.0b013e3182638ec7; Scott LE, 2015, 46 WORLD C LUNG HLTH; Shaw Julie L V, 2016, Pract Lab Med, V4, P22, DOI 10.1016/j.plabm.2015.12.002; Shekalaghe S, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-141; Stavelin A, 2017, BIOCHEM MEDICA, V27, P81, DOI 10.11613/BM.2017.010; Stevens WS, 2017, JAIDS-J ACQ IMM DEF, V76, P65, DOI 10.1097/QAI.0000000000001456; Tafuma TA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088654; Tom-Aba D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131000; UNAIDS, 2014, 909090 UNAIDS; United Nations, 2016, SUST DEV AG; Van Gemert W, 2015, JOINT PARTNERS FORUM; van't Hoog AH, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-532; Wedderburn Catherine J, 2015, Int J Gynaecol Obstet, V130 Suppl 1, pS81, DOI 10.1016/j.ijgo.2015.04.006; Westcott L., 2015, NEWSWEEK; World Health Organization, 2017, M REP; Zarei M, 2017, TRAC-TREND ANAL CHEM, V91, P26, DOI 10.1016/j.trac.2017.04.001; Zhang HL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071803	56	5	5	0	9	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					385	397		10.1080/14737159.2018.1460205			13	Pathology	Pathology	GD0SV	WOS:000430211800007	29658382				2019-10-28	
J	Mariani, S; Bertero, L; Coppola, V; Saracco, G; Arezzo, A; Di Celle, PF; Metovic, J; Marchio, C; Cassoni, P				Mariani, Sara; Bertero, Luca; Coppola, Vittoria; Saracco, Giorgio; Arezzo, Alberto; Di Celle, Paola Francia; Metovic, Jasna; Marchio, Caterina; Cassoni, Paola			Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						UDG; mutational artefacts; PCR; liquid biopsy; sequencing; FFPE	METASTATIC COLORECTAL-CANCER; CIRCULATING TUMOR DNA; ANTI-EGFR THERAPY; RESOLUTION MELTING ANALYSIS; KRAS MUTATIONS; ENZYMATIC AMPLIFICATION; SEQUENCE ARTIFACTS; BRAF MUTATIONS; BREAST-CANCER; HETEROGENEITY	Background: Technical biases due to PCR artefacts could represent an insidious obstacle for mutational analysis and precision medicine. Methods: The authors report a retrospective analysis by fast COLD-PCR and sequencing of 31 suboptimal tumor DNA samples obtained from FFPE tissues and liquid biopsies. Results: In FFPE tumor tissues and plasma liquid biopsies of patients with lung and colorectal adenocarcinoma, we observed a significant rate of artefactual KRAS mutations, unveiled by repeated analysis following UDG pretreatment as well as by simple repetition without UDG pretreatment step, thus suggesting a DNA damage different from cytosine deamination. UDG pretreatment was not only unnecessary to contrast artefacts occurrence, but also hampered the efficiency of mutational screening, reducing the analytical sensitivity. Taken individually or considered together, the reduced DNA input per reaction and UDG pretreatment limited the detection of 'real' mutated alleles, decreasing PCR sensitivity enough to hamper distinction between artefactual and true subclonal mutations of KRAS. Conclusions: Careful validation of analytical sensitivities should always be carried out through standard controls, and strategies other than UDG pretreatment need to be identified to avoid both amplification of artefactual mutations and failure to identify real subclonal mutations.	[Mariani, Sara; Bertero, Luca; Coppola, Vittoria; Saracco, Giorgio; Metovic, Jasna; Marchio, Caterina; Cassoni, Paola] Univ Turin, Dept Med Sci, Turin, Italy; [Mariani, Sara; Bertero, Luca; Coppola, Vittoria; Di Celle, Paola Francia; Metovic, Jasna; Marchio, Caterina; Cassoni, Paola] Citta Salute & Sci Hosp, Pathol Unit, Turin, Italy; [Saracco, Giorgio] Citta Salute & Sci Hosp, Gastroenterol Unit, Turin, Italy; [Arezzo, Alberto] Univ Turin, Dept Surg Sci, Turin, Italy; [Arezzo, Alberto] Citta Salute & Sci Hosp, Surg Unit, Turin, Italy	Bertero, L (reprint author), Univ Turin, Dept Med Sci, Pathol Unit, Via Santena 7, I-10126 Turin, Italy.	luca.bertero@unito.it	Bertero, Luca/N-5357-2017	Bertero, Luca/0000-0001-9887-7668; Metovic, Jasna/0000-0002-9146-1747	Italian Ministry of UniversityMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [2015HAJH8E]; Rete Oncologica Piemonte e Valle d'Aosta	This work was supported by the Italian Ministry of University [ex-60% 2016-2017 to S Mariani and ex 60% 2016 and 2015HAJH8E to C Marchio] and by Rete Oncologica Piemonte e Valle d'Aosta (to P Cassoni).	Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Brastianos PK, 2015, CANCER DISCOV, V5, P1164, DOI 10.1158/2159-8290.CD-15-0369; Chen GL, 2014, MOL DIAGN THER, V18, P587, DOI 10.1007/s40291-014-0115-2; Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261; De Mattos-Arruda L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9839; Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789; Do HD, 2013, CLIN CHEM, V59, P1376, DOI 10.1373/clinchem.2012.202390; Do HD, 2012, ONCOTARGET, V3, P546; Dono M, 2012, MOL MED, V18, P1519, DOI 10.2119/molmed.2012.00175; Higgins MJ, 2012, CLIN CANCER RES, V18, P3462, DOI 10.1158/1078-0432.CCR-11-2696; Khoo BL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600274; Kim S, 2017, J MOL DIAGN, V19, P137, DOI 10.1016/j.jmoldx.2016.09.006; Kimura T, 2012, ONCOLOGY-BASEL, V82, P298, DOI 10.1159/000336792; Kockan C, 2017, BIOINFORMATICS, V33, P26, DOI 10.1093/bioinformatics/btw536; Lamy A, 2011, MODERN PATHOL, V24, P1090, DOI 10.1038/modpathol.2011.60; Laurent-Puig P, 2015, CLIN CANCER RES, V21, P1087, DOI 10.1158/1078-0432.CCR-14-0983; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Mancini I, 2010, J MOL DIAGN, V12, P705, DOI 10.2353/jmoldx.2010.100018; Marchio C, 2017, NEURO-ONCOLOGY, V19, P451, DOI 10.1093/neuonc/now244; Mariani S, 2017, BRIT J CANCER, V117, P358, DOI 10.1038/bjc.2017.170; Mariani S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121815; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137; Narayan A, 2012, CANCER RES, V72, P3492, DOI 10.1158/0008-5472.CAN-11-4037; Normanno N, 2015, ANN ONCOL, V26, P1710, DOI 10.1093/annonc/mdv176; PAABO S, 1990, J BIOL CHEM, V265, P4718; Perez-Baez W, 2017, MOL CELL PROBE, V35, P34, DOI 10.1016/j.mcp.2017.06.003; Phallen J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2415; Pierce KE, 2004, BIOTECHNIQUES, V36, P44, DOI 10.2144/04361BM04; Senft D, 2017, TRENDS MOL MED, V23, P874, DOI 10.1016/j.molmed.2017.08.003; Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14; Stiller M, 2006, P NATL ACAD SCI USA, V103, P13578, DOI 10.1073/pnas.0605327103; Thierry AR, 2014, NAT MED, V20, P430, DOI 10.1038/nm.3511; Tougeron D, 2013, ANN ONCOL, V24, P1267, DOI 10.1093/annonc/mds620; Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812; Venesio T, 2018, PATHOBIOLOGY, V85, P146, DOI 10.1159/000473882; Wei Q, 2017, ANN ONCOL, V28, P2135, DOI 10.1093/annonc/mdx278; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2; Wong SQ, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-23	41	1	1	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					467	475		10.1080/14737159.2018.1468254			9	Pathology	Pathology	GJ6FL	WOS:000435479400008	29676606				2019-10-28	
J	Srebniak, MI; Vogel, I; Van Opstal, D				Srebniak, Malgorzata I.; Vogel, Ida; Van Opstal, Diane			Is carriership of a balanced translocation or inversion an indication for non-invasive prenatal testing?	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						NIPT; invasive testing; indication; prenatal screening; balanced chromosome aberration carrier; prenatal	CELL-FREE DNA; MATERNAL PLASMA; SUBCHROMOSOMAL ABNORMALITIES; ANEUPLOIDIES; KARYOTYPES		[Srebniak, Malgorzata I.; Van Opstal, Diane] Erasmus MC, Dept Clin Genet, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands; [Vogel, Ida] Aarhus Univ Hosp, Dept Clin Genet, Aarhus, Denmark; [Vogel, Ida] Aarhus Univ Hosp, Ctr Prenatal Diagnost, Aarhus, Denmark; [Vogel, Ida] Aarhus Univ, Inst Biomed, Aarhus, Denmark	Srebniak, MI (reprint author), Erasmus MC, Dept Clin Genet, Wytemaweg 80, NL-3015 CN Rotterdam, Netherlands.	m.srebniak@erasmusmc.nl		Vogel, Ida/0000-0002-1125-0393			[Anonymous], 1994, Prenat Diagn, V14, P363; Chen SP, 2013, PRENATAL DIAG, V33, P584, DOI 10.1002/pd.4110; Evans M, 2015, AM J OBSTET GYNECOL, V212, pS403, DOI 10.1016/j.ajog.2014.10.1047; Fiorentino F, 2017, PRENATAL DIAG, V37, P593, DOI 10.1002/pd.5053; Gil MM, 2015, ULTRASOUND OBST GYN, V45, P249, DOI 10.1002/uog.14791; Li R, 2016, ULTRASOUND OBST GYN, V47, P53, DOI 10.1002/uog.14911; Lo KK, 2016, AM J HUM GENET, V98, P34, DOI 10.1016/j.ajhg.2015.11.016; Los FJ, 1998, PRENATAL DIAG, V18, P1023, DOI 10.1002/(SICI)1097-0223(1998100)18:10<1023::AID-PD402>3.0.CO;2-1; Oepkes D, 2016, PRENATAL DIAG, V36, P1083, DOI 10.1002/pd.4945; Pescia G, 2017, GENET MED, V19, P169, DOI 10.1038/gim.2016.72; Srinivasan A, 2013, AM J HUM GENET, V92, P167, DOI 10.1016/j.ajhg.2012.12.006; Straver R, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gkt992; van den Berg C, 2000, PRENATAL DIAG, V20, P956, DOI 10.1002/1097-0223(200012)20:12<956::AID-PD956>3.0.CO;2-Y; Van Opstal D, 2017, GENET MED; Yatsenko SA, 2015, GENET MED, V17, P836, DOI 10.1038/gim.2014.197; Zhao C, 2015, CLIN CHEM, V61, P608, DOI 10.1373/clinchem.2014.233312	16	0	0	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					477	479		10.1080/14737159.2018.1468255			3	Pathology	Pathology	GJ1IN	WOS:000435008800001	29676188	Bronze			2019-10-28	
J	Kavsak, PA; Andruchow, JE; McRae, AD; Worster, A				Kavsak, Peter A.; Andruchow, James E.; McRae, Andrew D.; Worster, Andrew			Profile of Roche's Elecsys Troponin T Gen 5 STAT blood test (a high-sensitivity cardiac troponin assay) for diagnosing myocardial infarction in the emergency department	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Acute coronary syndrome; acute myocardial infarction; cardiac troponin T 5th generation; emergency department; high-sensitivity cardiac troponin	METHODS INFLUENCE DERIVATION; UNIVERSAL SAMPLE BANK; RULE-OUT; 99TH PERCENTILE; CHEST-PAIN; POPULATION SELECTION; CANADIAN SOCIETY; HEART-FAILURE; AN UPDATE; I ASSAY	Introduction: The Elecsys Troponin T Gen 5 STAT test (distributed in the United States (US) by Roche Diagnostics, Indianapolis, IN) is the first high-sensitivity cardiac troponin test approved for use by the FDA in the US (2017).Areas covered: The test offers clinicians the opportunity for more rapid decision-making for diagnosing myocardial infarction (MI) in the emergency department (ED). The Troponin T Gen 5 STAT test (labeled as TNT-G5ST on the reagent pack) is similar to the Troponin T hs STAT (TNT-HSST) and Troponin T hs (TNT-HS) tests that have been available outside the US since 2009. Collectively, these tests can all be considered as high-sensitivity cardiac troponin T (hs-cTnT) assays.Expert commentary: Studies performed in the US and throughout the world using 0 and 3h blood draws for hs-cTnT testing in patients with possible MI have reliably achieved a sensitivity of >94% and negative predictive value of 99% for MI in the ED setting.	[Kavsak, Peter A.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Andruchow, James E.; McRae, Andrew D.] Univ Calgary, Dept Emergency Med, Calgary, AB, Canada; [Worster, Andrew] McMaster Univ, Div Emergency Med, Hamilton, ON, Canada	Kavsak, PA (reprint author), Juravinski Hosp & Canc Ctr, Dept Lab Med, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	kavsakp@mcmaster.ca	Kavsak, Pete/K-8089-2019				Ambavane A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191348; Andruchow JE, 2018, CAN J CARDIOL, V34, P98, DOI 10.1016/j.cjca.2017.11.012; Apple FS, 2015, CLIN BIOCHEM, V48, P201, DOI 10.1016/j.clinbiochem.2014.08.021; Apple FS, 2009, CLIN CHEM, V55, P1303, DOI 10.1373/clinchem.2009.128363; Bais R, 2010, CLIN CHEM, V56, P1357, DOI 10.1373/clinchem.2010.144139; Bandstein N, 2017, INT J CARDIOL, V240, P1, DOI 10.1016/j.ijcard.2017.04.028; Barth JH, 2014, CLIN CHIM ACTA, V432, P166, DOI 10.1016/j.cca.2013.10.023; Biener Moritz, 2013, Int J Cardiol, V167, P1134, DOI 10.1016/j.ijcard.2012.09.122; Bjurman C, 2017, CARDIOL J, V24, P612, DOI 10.5603/CJ.a2017.0079; Bjurman C, 2015, CLIN BIOCHEM, V48, P302, DOI 10.1016/j.clinbiochem.2015.01.008; Carlton EW, 2015, ANN EMERG MED, V66, P635, DOI 10.1016/j.annemergmed.2015.07.006; Chapman AR, 2017, JAMA-J AM MED ASSOC, V318, P1913, DOI 10.1001/jama.2017.17488; Collinson PO, 2012, CLIN CHEM, V58, P219, DOI 10.1373/clinchem.2011.171082; Crowder KR, 2015, AM J EMERG MED, V33, P1790, DOI 10.1016/j.ajem.2015.08.041; de Lemos JA, 2010, JAMA-J AM MED ASSOC, V304, P2503, DOI 10.1001/jama.2010.1768; deFilippi CR, 2010, JAMA-J AM MED ASSOC, V304, P2494, DOI 10.1001/jama.2010.1708; Devereaux PJ, 2017, JAMA-J AM MED ASSOC, V317, P1642, DOI 10.1001/jama.2017.4360; Dolci A, 2011, CLIN CHEM, V57, P1211, DOI 10.1373/clinchem.2011.164426; Eggers KM, 2016, CLIN BIOCHEM, V49, P1109, DOI 10.1016/j.clinbiochem.2016.08.012; Eggers KM, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2016.02.047; Estis J, 2018, CLIN CHEM, V64, P398, DOI 10.1373/clinchem.2017.276972; Florkowski C, 2010, CLIN CHEM, V56, P1195, DOI 10.1373/clinchem.2009.140863; Friden V, 2017, CLIN BIOCHEM, V50, P468, DOI 10.1016/j.clinbiochem.2017.02.007; Giannitsis E, 2010, CLIN CHEM, V56, P254, DOI 10.1373/clinchem.2009.132654; Gimenez MR, 2018, CIRCULATION, V137, P1867, DOI 10.1161/CIRCULATIONAHA.117.031940; Gore MO, 2016, CIRC-CARDIOVASC INTE, V9, DOI 10.1161/CIRCINTERVENTIONS.116.004031; Grimsey PFN, 2017, INT J PHARMACOKINET, V2, P247, DOI DOI 10.4155/IPK-2017-0013; Gunsolus IL, 2017, CLIN BIOCHEM, V50, P1073, DOI 10.1016/j.clinbiochem.2017.09.009; Herman DS, 2017, AM J CLIN PATHOL, V148, P281, DOI [10.1093/AJCP/AQX066, 10.1093/ajcp/aqx066]; Hickman PE, 2017, CLIN BIOCHEM, V50, P502, DOI 10.1016/j.clinbiochem.2017.02.022; Hickman PE, 2016, CLIN BIOCHEM, V49, P1105, DOI 10.1016/j.clinbiochem.2016.09.013; Katus H, 2017, EUR HEART J, V38, P3049, DOI 10.1093/eurheartj/ehx492; Kavsak PA, 2017, ANN CLIN BIOCHEM, V1; Kavsak PA, 2018, CLIN CHEM LAB MED, V56, P1176, DOI 10.1515/cclm-2017-1122; Kavsak PA, 2018, CAN J CARDIOL, V34, DOI 10.1016/j.cjca.2017.11.010; Kavsak PA, 2018, CLIN CHIM ACTA, V479, P166, DOI 10.1016/j.cca.2018.01.034; Kavsak PA, 2018, ANN CLIN BIOCHEM, V55, P500, DOI 10.1177/0004563217734883; Kavsak PA, 2017, CLIN CHIM ACTA, V475, P51, DOI 10.1016/j.cca.2017.10.006; Kavsak PA, 2017, CAN J CARDIOL, V33, P898, DOI 10.1016/j.cjca.2017.04.011; Kavsak PA, 2017, CLIN CHIM ACTA, V469, P69, DOI 10.1016/j.cca.2017.03.021; Kavsak Peter A, 2015, Pract Lab Med, V1, P28, DOI 10.1016/j.plabm.2015.02.001; Kavsak PA, 2016, CLIN CHEM, V62, P887, DOI 10.1373/clinchem.2016.255448; Kavsak PA, 2015, CLIN CHEM, V61, P1209, DOI 10.1373/clinchem.2015.243345; Kavsak PA, 2013, JAMA INTERN MED, V173, P477, DOI 10.1001/jamainternmed.2013.2270; Kavsak PA, 2013, CLIN CHEM, V59, P574, DOI 10.1373/clinchem.2012.197434; Kavsak PA, 2012, J AM COLL CARDIOL, V59, P1570, DOI 10.1016/j.jacc.2011.10.904; Kavsak PA, 2011, CLIN BIOCHEM, V44, P1273, DOI 10.1016/j.clinbiochem.2011.08.001; Kavsak PA, 2011, CLIN BIOCHEM, V44, P1021, DOI 10.1016/j.clinbiochem.2011.05.017; Kavsak PA, 2011, JAMA-J AM MED ASSOC, V305, P1196, DOI 10.1001/jama.2011.345; Kavsak PA, 2010, CLIN BIOCHEM, V43, P539, DOI 10.1016/j.clinbiochem.2009.12.014; Kavsak PA, 2009, CLIN CHEM, V55, P573, DOI 10.1373/clinchem.2008.116020; Koerbin G, 2013, CLIN BIOCHEM, V46, P1636, DOI 10.1016/j.clinbiochem.2013.08.004; Kufaishi H, 2016, ANN CLIN BIOCHEM, V53, P516, DOI 10.1177/0004563215613533; Lyon AW, 2017, CLIN CHEM, V63, P585, DOI 10.1373/clinchem.2016.265058; Mansour M, 2012, ANN CLIN BIOCHEM, V49, P101, DOI 10.1258/acb.2011.011204; McCord J, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003101; McQueen MJ, 2013, CLIN BIOCHEM, V46, P5, DOI 10.1016/j.clinbiochem.2012.10.003; McRae AD, 2017, ACAD EMERG MED, V24, P1267, DOI 10.1111/acem.13229; McRae AD, 2017, CAN J CARDIOL, V33, P1006, DOI 10.1016/j.cjca.2017.04.010; Mokhtari A, 2016, ANN EMERG MED, V68, P649, DOI 10.1016/j.annemergmed.2016.06.008; Mueller C, 2016, ANN EMERG MED, V68, P76, DOI 10.1016/j.annemergmed.2015.11.013; Mueller C, 2015, CLIN BIOCHEM, V48, P749, DOI 10.1016/j.clinbiochem.2015.07.005; Mueller-Hennessen M, 2017, CLIN CHEM, V63, P542, DOI 10.1373/clinchem.2016.258392; Nejatian A, 2017, J AM COLL CARDIOL, V69, P2622, DOI 10.1016/j.jacc.2017.03.586; Neumann JT, 2017, CLIN CHEM, V63, P394, DOI 10.1373/clinchem.2016.262659; Omland T, 2009, NEW ENGL J MED, V361, P2538, DOI 10.1056/NEJMoa0805299; Panteghini M, 2018, CLIN CHEM, V64, P621, DOI 10.1373/clinchem.2017.285577; Parikh CR, 2017, J AM SOC NEPHROL, V28, P3699, DOI 10.1681/ASN.2017010055; Parikh RH, 2015, CLIN CHEM, V61, P1524, DOI 10.1373/clinchem.2015.244160; Peacock WF, 2018, JAMA CARDIOL, V3, P104, DOI 10.1001/jamacardio.2017.4625; Pickering JW, 2017, ANN INTERN MED, V166, P715, DOI 10.7326/M16-2562; Pickering JW, 2016, CIRCULATION, V134, P1532, DOI 10.1161/CIRCULATIONAHA.116.022677; Pickering JW, 2016, HEART, V102, P1270, DOI 10.1136/heartjnl-2015-308505; Reichlin T, 2015, CAN MED ASSOC J, V187, pE243, DOI 10.1503/cmaj.141349; Reichlin T, 2015, AM J MED, V128, P369, DOI 10.1016/j.amjmed.2014.10.032; Reichlin T, 2012, ARCH INTERN MED, V172, P1211, DOI 10.1001/archinternmed.2012.3698; Roche Diagnostics Elecsys Troponin T Gen 5 STAT 2017 02, V 1 0 ENGL PACK INS; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Rubin J, 2016, CLIN BIOCHEM, V49, P657, DOI 10.1016/j.clinbiochem.2016.01.024; Rubini GM, 2016, JAMA CARDIOL, V1, P912, DOI DOI 10.1001/jamacardio.2016.2882; Saenger AK, 2011, CLIN CHIM ACTA, V412, P748, DOI 10.1016/j.cca.2010.12.034; Sandoval Y, 2017, AM J MED, V130; Sedaghat-Hamedani F, 2015, CLIN CHEM, V61, P1246, DOI 10.1373/clinchem.2015.240796; Seliger SL, 2017, CIRCULATION, V135, P1494, DOI 10.1161/CIRCULATIONAHA.116.025505; Shortt C, 2017, CLIN CHEM, V63, P593, DOI 10.1373/clinchem.2016.261776; Shortt C, 2017, CLIN CHEM, V63, P403, DOI 10.1373/clinchem.2016.261545; Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058; Thygesen K, 2012, EUR HEART J, V33, P2252, DOI 10.1093/eurheartj/ehs154; Trambas C, 2018, ANN CLIN BIOCHEM, V55, P205, DOI 10.1177/0004563217701777; Trupp RJ, 2018, CLIN BIOCHEM, V52, P173, DOI 10.1016/j.clinbiochem.2017.11.003; Twerenbold R, 2017, J AM COLL CARDIOL, V70, P996, DOI 10.1016/j.jacc.2017.07.718; Twerenbold R, 2016, EUR HEART J, V37, P3324, DOI 10.1093/eurheartj/ehw232; van der Linden N, 2017, CIRCULATION, V136, P1073, DOI 10.1161/CIRCULATIONAHA.117.029986; Vasikaran SD, 2012, CLIN BIOCHEM, V45, P513, DOI 10.1016/j.clinbiochem.2012.01.011; Wens SCA, 2016, CIRC-CARDIOVASC GENE, V9, P6, DOI 10.1161/CIRCGENETICS.115.001322; Wildi K, 2017, CLIN CHEM, V63, P1227, DOI 10.1373/clinchem.2016.268359; Wildi K, 2016, AM HEART J, V181, P16, DOI 10.1016/j.ahj.2016.07.013; Wu AHB, 2018, CLIN CHEM, V64, P645, DOI 10.1373/clinchem.2017.277186	98	2	2	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					481	489		10.1080/14737159.2018.1476141			9	Pathology	Pathology	GJ1IN	WOS:000435008800002	29756512				2019-10-28	
J	Yubero, D; Montero, R; Santos-Ocana, C; Salviati, L; Navas, P; Artuch, R				Yubero, Delia; Montero, Raquel; Santos-Ocana, Carlos; Salviati, Leonardo; Navas, Placido; Artuch, Rafael			Molecular diagnosis of coenzyme Q(10) deficiency: an update	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Coenzyme Q(10) deficiency syndromes; next generation sequencing; muscle biopsy; mitochondrial diseases; oxidative phosphorylation	CEREBELLAR-ATAXIA; OXIDATIVE STRESS; WHOLE-GENOME; MITOCHONDRIAL DYSFUNCTION; UBIQUINONE DEFICIENCY; COQ(10) BIOSYNTHESIS; NEPHROTIC SYNDROME; SULFIDE OXIDATION; INBORN-ERRORS; RENAL-DISEASE	Introduction: Coenzyme Q(10) (CoQ) deficiency syndromes comprise a growing number of genetic disorders. While primary CoQ deficiency syndromes are rare diseases, secondary deficiencies have been related to both genetic and environmental conditions, which are the main causes of biochemical CoQ deficiency. The diagnosis is the essential first step for planning future treatment strategies, as the potential treatability of CoQ deficiency is the most critical issue for the patients.Areas covered: While the quickest and most effective tool to define a CoQ-deficient status is its biochemical determination in biological fluids or tissues, this quantification does not provide a definite diagnosis of a CoQ-deficient status nor insight about the genetic etiology of the disease. The different laboratory tests to check for CoQ deficiency are evaluated in order to choose the best diagnostic pathway for the patient.Expert commentary: New insights are being discovered about the implication of new proteins in the intricate CoQ biosynthetic pathway. These insights reinforce the idea that next generation sequencing diagnostic strategies are the unique alternative in terms of rapid and accurate molecular diagnosis of CoQ deficiency.	[Yubero, Delia; Montero, Raquel; Artuch, Rafael] Inst Recerca St Joan Deu, Dept Genet & Clin Biochem, Barcelona, Spain; [Yubero, Delia; Montero, Raquel; Artuch, Rafael] CIBER Enfermedades Raras CIBERER, Barcelona, Spain; [Santos-Ocana, Carlos; Navas, Placido] Univ Pablo Olavide, Ctr Andaluz Biol Desarrollo, Seville, Spain; [Santos-Ocana, Carlos; Navas, Placido] CIBERER, Seville, Spain; [Salviati, Leonardo] Univ Padua, Dept Pediat, Clin Genet Unit, Padua, Italy	Artuch, R (reprint author), CIBER Enfermedades Raras CIBERER, Barcelona, Spain.; Artuch, R (reprint author), Inst Recerca St Joan Deu, Dept Clin Biochem, Barcelona, Spain.	rartuch@hsjdbcn.org	NAVAS, PLACIDO/R-5943-2019	NAVAS, PLACIDO/0000-0002-4115-7966	Secretaria de Estado de Investigacion, Desarrollo e iInnovacion (Plan Nacional de I+D+I); Instituto de Salud Carlos IIIInstituto de Salud Carlos III [PI17/00109]; European Regional Development Fund (FEDER)European Union (EU); CIBERER-ISCIIIInstituto de Salud Carlos III	This article was funded by 'Secretaria de Estado de Investigacion, Desarrollo e iInnovacion (Plan Nacional de I+D+I)' and 'Instituto de Salud Carlos III' [PI17/00109], the European Regional Development Fund (FEDER), and CIBERER-ISCIII.	Acosta MJ, 2016, BBA-BIOENERGETICS, V1857, P1079, DOI 10.1016/j.bbabio.2016.03.036; Aeby A, 2007, J INHERIT METAB DIS, V30, P827, DOI 10.1007/s10545-007-0612-0; Al-Shamsi A, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0474-3; Alcazar-Fabra M, 2016, BBA-BIOENERGETICS, V1857, P1073, DOI 10.1016/j.bbabio.2016.03.010; Andrich J, 2004, J NEURAL TRANSM-SUPP, P111; Artuch R, 2006, J NEUROL SCI, V246, P153, DOI 10.1016/j.jns.2006.01.021; Artuch R, 1999, AM J CLIN NUTR, V70, P892; Asencio C, 2016, EUR J HUM GENET, V24, P367, DOI 10.1038/ejhg.2015.112; Ashraf S, 2013, J CLIN INVEST, V123, P5179, DOI 10.1172/JCI69000; Balreira A, 2014, J NEUROL, V261, P2192, DOI 10.1007/s00415-014-7476-7; Barca E, 2016, CLIN GENET, V90, P156, DOI 10.1111/cge.12742; Barca E, 2016, J NEUROPATH EXP NEUR, V75, P663, DOI 10.1093/jnen/nlw037; Baruteau J, 2014, MITOCHONDRION, V17, P150, DOI 10.1016/j.mito.2014.07.001; Berberich AJ, 2018, CAN MED ASSOC J, V190, pE124, DOI 10.1503/cmaj.180076; BIANCHI GP, 1994, LIVER, V14, P138; Bujan N, 2014, J INHERIT METAB DIS, V37, P53, DOI 10.1007/s10545-013-9620-4; Rodriguez-Aguilera JC, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030027; Chamard L, 2016, EUR NEUROL, V75, P186, DOI 10.1159/000445109; Cooney RV, 2011, CANCER EPIDEM BIOMAR, V20, P1124, DOI 10.1158/1055-9965.EPI-10-1261; Cooper JM, 2008, EUR J NEUROL, V15, P1371, DOI 10.1111/j.1468-1331.2008.02318.x; Cotan D, 2011, FASEB J, V25, P2669, DOI 10.1096/fj.10-165340; Crane FL, 2007, MITOCHONDRION, V7, pS2, DOI 10.1016/j.mito.2007.02.011; DaRe JT, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-118; Degenhardt F, 2016, HUM MOL GENET, V25, P2881, DOI 10.1093/hmg/ddw134; Desbats MA, 2016, HUM MOL GENET, V25, P4256, DOI 10.1093/hmg/ddw257; Desbats MA, 2015, EUR J HUM GENET, V23, P1254, DOI 10.1038/ejhg.2014.277; Desbats MA, 2015, J INHERIT METAB DIS, V38, P145, DOI 10.1007/s10545-014-9749-9; Dinwiddie DL, 2013, GENOMICS, V102, P148, DOI 10.1016/j.ygeno.2013.04.013; Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833; Doimo M, 2014, MOL SYNDROMOL, V5, P156, DOI 10.1159/000362826; Duberley KEC, 2013, RAPID COMMUN MASS SP, V27, P924, DOI 10.1002/rcm.6529; Duncan AJ, 2005, CLIN CHEM, V51, P2380, DOI 10.1373/clinchem.2005.054643; Emma F, 2016, NAT REV NEPHROL, V12, P267, DOI 10.1038/nrneph.2015.214; Emmanuele V, 2012, ARCH NEUROL-CHICAGO, V69, P978, DOI 10.1001/archneurol.2012.206; Fazakerley DJ, 2018, ELIFE, V7, DOI 10.7554/eLife.32111; Floyd BJ, 2016, MOL CELL, V63, P621, DOI 10.1016/j.molcel.2016.06.033; Fragaki K, 2016, BIOL RES, V49, DOI 10.1186/s40659-015-0065-0; Freyer C, 2015, J MED GENET, V52, P779, DOI 10.1136/jmedgenet-2015-102986; Fu R, 2010, MOL GENET METAB, V101, P214, DOI 10.1016/j.ymgme.2010.06.018; GAFF CL, 2017, NPJ GENOM MED, V2, DOI DOI 10.1038/S41525-017-0017-4; Garone C, 2017, J CHILD NEUROL, V32, P246, DOI 10.1177/0883073816666221; Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054; Genova ML, 2011, BIOFACTORS, V37, P330, DOI 10.1002/biof.168; Haas D, 2009, J INHERIT METAB DIS, V32, P570, DOI 10.1007/s10545-009-1150-8; Haas D, 2008, BIOFACTORS, V32, P191, DOI 10.1002/biof.5520320123; Haas RH, 2007, MITOCHONDRION, V7, pS136, DOI 10.1016/j.mito.2007.03.008; Heeringa SF, 2011, J CLIN INVEST, V121, P2013, DOI 10.1172/JCI45693; HUBNER C, 1993, PEDIATR RES, V34, P129; LaDuca H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170843; Lohman DC, 2014, P NATL ACAD SCI USA, V111, pE4697, DOI 10.1073/pnas.1413128111; Lopez LC, 2014, MOL SYNDROMOL, V5, P163, DOI 10.1159/000360494; Lopez-Martin JM, 2007, HUM MOL GENET, V16, P1091, DOI 10.1093/hmg/ddm058; Luna-Sanchez M, 2017, EMBO MOL MED, V9, P78, DOI 10.15252/emmm.201606345; Luna-Sanchez M, 2015, EMBO MOL MED, V7, P670, DOI 10.15252/emmm.201404632; Malicdan MCV, 2018, HUM MUTAT, V39, P69, DOI 10.1002/humu.23345; Martinefski M, 2015, ANAL BIOANAL CHEM, V407, P5529, DOI 10.1007/s00216-015-8696-0; Matsuoka T, 1991, Neuromuscul Disord, V1, P443, DOI 10.1016/0960-8966(91)90007-F; Menke T, 2004, HORM RES, V61, P153, DOI 10.1159/000075670; Meyts I, 2016, J ALLERGY CLIN IMMUN, V138, P957, DOI 10.1016/j.jaci.2016.08.003; Miles MV, 2008, MITOCHONDRION, V8, P170, DOI 10.1016/j.mito.2008.01.003; Miles MV, 2007, MITOCHONDRION, V7, pS72, DOI 10.1016/j.mito.2007.02.012; Miyamae T, 2013, REDOX REP, V18, P12, DOI 10.1179/1351000212Y.0000000036; Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022; Molyneux SL, 2008, J AM COLL CARDIOL, V52, P1435, DOI 10.1016/j.jacc.2008.07.044; Montero R, 2005, BIOFACTORS, V25, P109, DOI 10.1002/biof.5520250112; Montero R, 2008, CLIN BIOCHEM, V41, P697, DOI 10.1016/j.clinbiochem.2008.03.007; Montero R, 2013, MITOCHONDRION, V13, P337, DOI 10.1016/j.mito.2013.04.001; Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582; Mortensen SA, 1998, HIGHLIGHTS UBIQUINON, P226; Nakagawa H, 2018, CANCER SCI, V109, P513, DOI 10.1111/cas.13505; Oudshoorn JH, 2006, J PEDIATR GASTR NUTR, V43, P646, DOI 10.1097/01.mpg.0000233193.77521.66; Park E., 2017, PEDIAT NEPHROL; Park E, 2017, AM J KIDNEY DIS, V70, P139, DOI 10.1053/j.ajkd.2016.10.040; Paul A, 2017, AM J HUM GENET, V101, P630, DOI 10.1016/j.ajhg.2017.09.007; Petersen BS, 2017, BMC GENET, V18, DOI 10.1186/s12863-017-0479-5; Pineda M, 2010, MOVEMENT DISORD, V25, P1262, DOI 10.1002/mds.23129; Quinzii CM, 2008, FASEB J, V22, P1874, DOI 10.1096/fj.07-100149; Quinzii CM, 2014, MOL SYNDROMOL, V5, P141, DOI 10.1159/000360490; Quinzii CM, 2013, FASEB J, V27, P612, DOI 10.1096/fj.12-209361; Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58; Rodriguez-Hernandez A, 2009, AUTOPHAGY, V5, P19, DOI 10.4161/auto.5.1.7174; Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014; Saiki R, 2008, AM J PHYSIOL-RENAL, V295, pF1535, DOI 10.1152/ajprenal.90445.2008; Salviati L, 1993, GENEREVIEWS; Sawyer SL, 2016, CLIN GENET, V89, P275, DOI 10.1111/cge.12654; Shen T, 2015, GENET RES, V97, DOI 10.1017/S0016672315000166; Shults CW, 1997, ANN NEUROL, V42, P261, DOI 10.1002/ana.410420221; Spiegel R, 2014, EUR J HUM GENET, V22, P902, DOI 10.1038/ejhg.2013.269; Stefely JA, 2017, TRENDS BIOCHEM SCI, V42, P824, DOI 10.1016/j.tibs.2017.06.008; Stefely JA, 2016, MOL CELL, V63, P608, DOI 10.1016/j.molcel.2016.06.030; Veling MT, 2017, MOL CELL, V68, P970, DOI 10.1016/j.molcel.2017.11.023; Villalba JM, 2000, ANTIOXID REDOX SIGN, V2, P213, DOI 10.1089/ars.2000.2.2-213; Wang Y, 2017, J CELL MOL MED, V21, P2329, DOI 10.1111/jcmm.13154; Watts GF, 1998, ATHEROSCLEROSIS, V141, P17, DOI 10.1016/S0021-9150(98)00170-1; Weber C, 1997, MOL ASPECTS MED, V18, pS251; Wong LJC, 2013, NEUROTHERAPEUTICS, V10, P262, DOI 10.1007/s13311-012-0170-5; Yubero D, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0008-1; Yubero D, 2016, JIMD REP, V25, P1, DOI 10.1007/8904_2015_421; Yubero D, 2016, MITOCHONDRION, V30, P51, DOI 10.1016/j.mito.2016.06.007; Yubero D, 2015, BIOFACTORS, V41, P424, DOI 10.1002/biof.1242; Yubero D, 2015, EXPERT REV MOL DIAGN, V15, P1049, DOI 10.1586/14737159.2015.1062727; ZIERZ S, 1989, J NEUROL, V236, P97, DOI 10.1007/BF00314404; Ziosi M, 2017, EMBO MOL MED, V9, P96, DOI 10.15252/emmm.201606356	103	0	0	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					491	498		10.1080/14737159.2018.1478290			8	Pathology	Pathology	GJ1IN	WOS:000435008800003	29781757				2019-10-28	
J	Lai, E; Pretta, A; Impera, V; Mariani, S; Giampieri, R; Casula, L; Pusceddu, V; Coni, P; Fanni, D; Puzzoni, M; Demurtas, L; Ziranu, P; Faa, G; Scartozzi, M				Lai, Eleonora; Pretta, Andrea; Impera, Valentino; Mariani, Stefano; Giampieri, Riccardo; Casula, Laura; Pusceddu, Valeria; Coni, Pierpaolo; Fanni, Daniela; Puzzoni, Marco; Demurtas, Laura; Ziranu, Pina; Faa, Gavino; Scartozzi, Mario			BRAF-mutant colorectal cancer, a different breed evolving	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						BRAF; colorectal cancer; prognostic value; predictive value; BRAF inhibitors	FOLFIRI PLUS CETUXIMAB; III COLON-CANCER; GENE MUTATION STATUS; ANTI-EGFR TREATMENT; KRAS WILD-TYPE; MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; MISMATCH REPAIR; V600E MUTATION; STAGE-II	Introduction: BRAF mutant colorectal cancer (BRAF MT CRC) is a unique category of colorectal tumour with peculiar molecular, pathological and clinical features and poor prognosis; despite recent research, BRAF mutation predictive value and standard treatment of BRAF MT CRC still have to be defined. In this review, we focused on this challenging topic.Areas covered: The potential use of BRAF mutational status among recent additional prognostic and predictive indicators and current treatment strategy in use in these patients is discussed. Moreover, implications and characteristics of new BRAF mutations other than BRAFV600E are analyzed. An in-deep outlook on the immediate future for clinical and translational research in this subgroup of patients is also presented, such as combination therapy with agents targeting the RAS/RAF/MEK/ERK pathway and standard chemotherapy in order to overcome resistance. We performed a research on Pubmed typing BRAF mutation', colorectal cancer', predictive and prognostic value', targeted therapy', BRAF inhibition'.Expert commentary: BRAFV600E mutation represents a strong, independent negative prognostic factor in II-III stage MSS CRC and mCRC. The best treatment still has to be identified; currently, in good performance status patients, an intensive-chemotherapy-combination remains the standard of care. Further investigations are warranted to explore new horizons to change BRAF MT mCRC outcomes.	[Lai, Eleonora; Pretta, Andrea; Impera, Valentino] Sapienza Univ Rome, Med Oncol, Rome, Italy; [Lai, Eleonora; Pretta, Andrea; Impera, Valentino; Mariani, Stefano; Casula, Laura; Pusceddu, Valeria; Puzzoni, Marco; Demurtas, Laura; Ziranu, Pina; Scartozzi, Mario] Univ Hosp, Med Oncol Unit, Cagliari, Italy; [Lai, Eleonora; Pretta, Andrea; Impera, Valentino; Mariani, Stefano; Casula, Laura; Pusceddu, Valeria; Puzzoni, Marco; Demurtas, Laura; Ziranu, Pina; Scartozzi, Mario] Univ Cagliari, Cagliari, Italy; [Giampieri, Riccardo] Univ Hosp, Med Oncol Unit, Ancona, Italy; [Giampieri, Riccardo] Univ Politecn Marche, Ancona, Italy; [Coni, Pierpaolo; Fanni, Daniela; Faa, Gavino] Univ Cagliari, Div Pathol, Dept Surg Sci, Ancona, Italy	Scartozzi, M (reprint author), Univ Hosp, Med Oncol Unit, Cagliari, Italy.; Scartozzi, M (reprint author), Univ Cagliari, Cagliari, Italy.	marioscartozzi@gmail.com		puzzoni, marco/0000-0001-5880-4309			Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35; Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518; Atreya CE, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.103; Bahrami A, 2018, J CELL PHYSIOL, V233, P2162, DOI 10.1002/jcp.25952; Baltruskeviciene Edita, 2016, Acta Med Litu, V23, P24, DOI 10.6001/actamedica.v23i1.3267; Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057; Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230; Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077; Cohen R, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0453-5; Corcoran RB, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw370.4; Corcoran RB, 2014, J CLIN ONCOL S, V32, P2765; Cremolini C, 2015, ANN ONCOL, V26, P2092, DOI 10.1093/annonc/mdv290; Cremolini C, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000241; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Demurtas L, 2017, BRIT J CANCER, V117, P315, DOI 10.1038/bjc.2017.178; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275; Durrant DE, 2018, BRIT J CANCER, V118, P3, DOI 10.1038/bjc.2017.399; Elez E, 2015, ANN ONCOL, V26, P2375; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Farina-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258; Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57; Gao XH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08413-z; Gavin PG, 2012, CLIN CANCER RES, V18, P6531, DOI 10.1158/1078-0432.CCR-12-0605; Giampieri R, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0501-5; Giampieri R, 2013, CRIT REV ONCOL HEMAT, V88, P272, DOI 10.1016/j.critrevonc.2013.05.008; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4; Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050; Hong SP, 2017, LIFE SCI, V183, P37, DOI 10.1016/j.lfs.2017.06.021; Huijberts S, 2017, ANN ONCOL          S, V28, pv158, DOI [10.1093/annonc/mdx393, DOI 10.1093/ANNONC/MDX393]; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394; Karapetis CS, 2014, CLIN CANCER RES, V20, P744, DOI 10.1158/1078-0432.CCR-13-0606; Kayhanian H, 2018, CLIN COLORECTAL CANC, V17, pE69, DOI 10.1016/j.clcc.2017.10.006; Koch C, 2015, DIGESTION, V91, P294, DOI 10.1159/000376573; Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534; Kopetz S, 2017, J CLIN ONCOL, V35; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Korphaisarn K, 2016, CANCER J, V22, P175, DOI 10.1097/PPO.0000000000000189; Le DT, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.195; Lech G, 2016, WORLD J GASTROENTERO, V22, P1745, DOI 10.3748/wjg.v22.i5.1745; Lo Nigro C, 2016, WORLD J GASTROENTERO, V22, P6944, DOI 10.3748/wjg.v22.i30.6944; Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173; Loupakis F, 2014, EUR J CANCER, V50, P57, DOI 10.1016/j.ejca.2013.08.024; Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177; Loupakis F, 2016, BRIT J CANCER, V114, P30, DOI 10.1038/bjc.2015.399; Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108; Masi G, 2010, LANCET ONCOL, V11, P845, DOI 10.1016/S1470-2045(10)70175-3; Modest DP, 2012, INT J CANCER, V131, P980, DOI 10.1002/ijc.26467; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakayama I, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2994-6; Overman MJ, 2016, ANN ONCOL, V27; Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054; Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.186; Preto A, 2008, J PATHOL, V214, P320, DOI 10.1002/path.2295; Price TJ, 2011, J CLIN ONCOL, V29, P2675, DOI 10.1200/JCO.2010.34.5520; PWirapati P, 2017, J CLIN ONCOL, V35, P3538; Renaud S, 2015, BRIT J CANCER, V112, P720, DOI 10.1038/bjc.2014.499; Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295; Roma C, 2016, CANCER BIOL THER, V17, P840, DOI 10.1080/15384047.2016.1195048; Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452; Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401; Saridaki Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084604; Scartozzi M, 2007, BRIT J CANCER, V97, P92, DOI 10.1038/sj.bjc.6603847; Scartozzi M, 2015, EXPERT REV MOL DIAGN, V15, P979, DOI 10.1586/14737159.2015.1047346; Scartozzi M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-71; Schmoll HJ, 2017, J CLIN ONCOL S, DOI [10.1200/JCO.2017.35.4_suppl.658, DOI 10.1200/JCO.2017.35.4_SUPPL.658]; Seligmann JF, 2017, ANN ONCOL, V28, P562, DOI 10.1093/annonc/mdw645; Seppala TT, 2015, BRIT J CANCER, V112, P1966, DOI 10.1038/bjc.2015.160; Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3; Shen YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081628; Shimada Y, 2017, ONCOTARGET, V8, P93567, DOI 10.18632/oncotarget.20510; Shinozaki E, 2017, BRIT J CANCER, V117, P1450, DOI 10.1038/bjc.2017.308; Sinicrope FA, 2016, CLIN GASTROENTEROL H, V14, P651, DOI 10.1016/j.cgh.2016.02.008; Sinicrope FA, 2013, J CLIN ONCOL, V31, P3664, DOI 10.1200/JCO.2013.48.9591; Stintzing S, 2017, EUR J CANCER, V79, P50, DOI 10.1016/j.ejca.2017.03.023; Stintzing S, 2013, EUR J CANCER, V49, pS8; Strickler JH, 2017, CANCER TREAT REV, V60, P109, DOI 10.1016/j.ctrv.2017.08.006; Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544; Taieb J, 2016, JAMA ONCOL, V2, P643, DOI 10.1001/jamaoncol.2015.5225; Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036; Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555; Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160; Tosi F, 2017, CLIN COLORECTAL CANC, V16, pE153, DOI 10.1016/j.clcc.2017.01.004; Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086; Tutuka CSA, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0684-x; van Brummelen EMJ, 2017, ONCOLOGIST, V22, P864, DOI 10.1634/theoncologist.2017-0031; Van Cutsem E, 2015, ANN ONCOL, V26, P2375; Van Cutsem E, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.627; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091; Van Geel R, 2014, J CLIN ONCOL, V32; van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795; Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332; Vogel A, 2017, CANCER TREAT REV, V59, P54, DOI 10.1016/j.ctrv.2017.04.007; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Wang Qi, 2014, Chinese Medical Sciences Journal, V29, P197; Wang XC, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0247-y; Xu Q, 2013, J DIGEST DIS, V14, P409, DOI 10.1111/1751-2980.12063; Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779; Yaeger R, 2014, CANCER-AM CANCER SOC, V120, P2316, DOI 10.1002/cncr.28729; Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941; Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291; Yuan ZX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065995	108	4	4	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					499	512		10.1080/14737159.2018.1470928			14	Pathology	Pathology	GJ1IN	WOS:000435008800004	29708446				2019-10-28	
J	Mora, C; Zonca, V; Riva, MA; Cattaneo, A				Mora, Cristina; Zonca, Valentina; Riva, Marco A.; Cattaneo, Annamaria			Blood biomarkers and treatment response in major depression	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						biomarkers; cytokines; epigenomics; major depressive disorder; pharmacogenomics	TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; SEROTONIN TRANSPORTER GENE; ANTIDEPRESSANT TREATMENT RESPONSE; REUPTAKE INHIBITOR RESPONSE; ENVIRONMENTAL RISK-FACTORS; MESSENGER-RNA LEVELS; NEUROTROPHIC FACTOR; PSYCHIATRIC-DISORDERS; DRUG RESPONSE	Introduction: Millions of people worldwide suffer from depression, but despite advances in pharmacological therapies, many patients do not experience symptomatic remission or treatment response, even after treatments with several medications. As such, there is an urgent need to identify biomarkers that can not only predict the treatment response but also allow a rational selection of optimal therapy for each patient.Areas covered: This review examines the recent findings, coming from different omic sciences,' in human blood-based biomarkers associated with antidepressant treatment response with particular attention on genetic/epigenetic and biochemical biomarkers. Specific emphasis will be placed on key molecules related to neuroplasticity and inflammation because of their involvement in the pathophysiology of depression and antidepressant response.Expert commentary: Biomarker identification is still an ongoing work. Indeed, to date, no biomarkers have sufficiently proven specificity, sensitivity, and reproducibility to be used in the clinical setting. However, omic' approaches hold great promise in identifying multiple features for predicting antidepressant response, making a personalized treatment strategy possible for each patient, and thereby assist with quick and efficacious responsiveness. It is thus necessary that future studies take an integrative approach that includes clinical assessment, environment influences, and molecular and biological biomarkers.	[Mora, Cristina; Zonca, Valentina; Cattaneo, Annamaria] IRCCS Fatebenefratelli S Giovanni di Dio, Biol Psychiat Unit, Brescia, Italy; [Zonca, Valentina; Riva, Marco A.] Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy; [Cattaneo, Annamaria] Kings Coll London, Stress Psychiat & Immunol Lab, Dept Psychol Med, Inst Psychiat, London, England	Riva, MA (reprint author), Univ Milan, Dept Pharmacol & Biomol Sci, Milan, Italy.	m.riva@unimi.it	Riva, Marco Andrea/N-7418-2017	Riva, Marco Andrea/0000-0002-1699-5060; Zonca, Valentina/0000-0002-6628-5999	Ministry of Health (Ricerca Corrente); Ministry of University and Research (PRIN)Ministero dell' Istruzione, dell' Universita e della Ricerca (MIUR) [2015SKN9YT]	This manuscript has been supported by Ministry of Health (Ricerca Corrente) and the Ministry of University and Research (PRIN grant number 2015SKN9YT).	Abo R, 2012, PHARMACOGENET GENOM, V22, P247, DOI 10.1097/FPC.0b013e32835001c9; Amare AT, 2017, EPMA J, V8, P211, DOI 10.1007/s13167-017-0112-8; American Psychiatric Association, 2013, DIAGN STAT MAN MENT; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Bahn S, 2013, REV PSIQ CLIN-BRAZIL, V40, P2, DOI 10.1590/S0101-60832012005000005; Baudry A, 2010, SCIENCE, V329, P1537, DOI 10.1126/science.1193692; Baune BT, 2010, BIOL PSYCHIAT, V67, P543, DOI 10.1016/j.biopsych.2009.11.004; Beger RD, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1094-6; Begni V, 2017, CLIN SCI, V131, P123, DOI 10.1042/CS20160009; Belzeaux R, 2018, J AFFECT DISORDERS, V233, P36, DOI 10.1016/j.jad.2017.08.087; Belzeaux R, 2017, CNS DRUGS, V31, P253, DOI 10.1007/s40263-017-0418-z; Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609; Bilello JA, 2016, BIOMARK MED, V10, P861, DOI 10.2217/bmm-2016-0076; Boks MP, 2012, EPIGENETICS-US, V7, P20, DOI 10.4161/epi.7.1.18688; Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Brunoni AR, 2014, EUR NEUROPSYCHOPHARM, V24, P1144, DOI 10.1016/j.euroneuro.2014.03.006; Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309; Cai SL, 2015, NEUROSCI BULL, V31, P61, DOI 10.1007/s12264-014-1486-4; Cattaneo A, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.214; Cattaneo A, 2013, NEUROPSYCHOPHARMACOL, V38, P377, DOI 10.1038/npp.2012.191; Cattaneo A, 2010, INT J NEUROPSYCHOPH, V13, P103, DOI 10.1017/S1461145709990812; Chen Ying, 2015, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V32, P801, DOI 10.3760/cma.j.issn.1003-9406.2015.06.010; Chen Z-Y, 2008, NOVART FDN SYMP, P188, DOI DOI 10.1002/9780470751251.CH14; Chen Zhe-Yu, 2008, Novartis Found Symp, V289, P180; Colle R, 2015, J AFFECT DISORDERS, V175, P233, DOI 10.1016/j.jad.2015.01.013; Csoka AB, 2009, MED HYPOTHESES, V73, P770, DOI 10.1016/j.mehy.2008.10.039; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; de Vos A, 2011, PHARMACOGENOMICS J, V11, P359, DOI 10.1038/tpj.2010.39; Desta Z, 2002, CLIN PHARMACOKINET, V41, P913, DOI 10.2165/00003088-200241120-00002; Domschke K, 2014, INT J NEUROPSYCHOPH, V17, P1167, DOI 10.1017/S146114571400039X; Dunlop BW, 2015, EXPERT REV CLIN PHAR, V8, P669, DOI 10.1586/17512433.2015.1075390; Dwivedi Y, 2016, PROG NEURO-PSYCHOPH, V64, P341, DOI 10.1016/j.pnpbp.2015.02.003; Eller T, 2008, PROG NEURO-PSYCHOPH, V32, P445, DOI 10.1016/j.pnpbp.2007.09.015; Enatescu VR, 2016, PSYCHIAT INVEST, V13, P549, DOI 10.4306/pi.2016.13.5.549; Fabbri C, 2013, AM J MED GENET B, V162, P487, DOI 10.1002/ajmg.b.32184; Fiori LM, 2017, INT J NEUROPSYCHOPH, V20, P619, DOI 10.1093/ijnp/pyx034; Flint J, 2014, NEURON, V81, P1214, DOI 10.1016/j.neuron.2014.02.033; Fradette C, 2004, BRIT J PHARMACOL, V141, P407, DOI 10.1038/sj.bjp.0705632; Fukuda T, 2000, EUR J CLIN PHARMACOL, V56, P175, DOI 10.1007/s002280050737; Gadad BS, 2018, J AFFECT DISORDERS, V233, P3, DOI 10.1016/j.jad.2017.07.001; Gassen NC, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac7695; Gressier F, 2015, AM J PSYCHIAT, V172, P909, DOI 10.1176/appi.ajp.2015.15010033; Gunes A, 2008, PHARMACOGENOMICS, V9, P625, DOI 10.2217/14622416.9.5.625; Gupta M, 2016, MOL PSYCHIATR, V21, P1717, DOI 10.1038/mp.2016.6; Gururajan A, 2016, NEUROSCI BIOBEHAV R, V64, P101, DOI 10.1016/j.neubiorev.2016.02.011; Haapakoski R, 2015, BRAIN BEHAV IMMUN, V49, P206, DOI 10.1016/j.bbi.2015.06.001; Hall-Flavin DK, 2013, PHARMACOGENET GENOM, V23, P535, DOI 10.1097/FPC.0b013e3283649b9a; Hannestad J, 2011, NEUROPSYCHOPHARMACOL, V36, P2452, DOI 10.1038/npp.2011.132; Harley J, 2010, J PSYCHOPHARMACOL, V24, P625, DOI 10.1177/0269881109102770; Hashimoto K, 2018, ADV CLIN CHEM, V84, P81, DOI 10.1016/bs.acc.2017.12.005; Hashimoto K, 2015, INT J MOL SCI, V16, P7796, DOI 10.3390/ijms16047796; He S, 2016, J PSYCHIATR RES, V78, P65, DOI 10.1016/j.jpsychires.2016.03.015; Hempstead Barbara L, 2015, Trans Am Clin Climatol Assoc, V126, P9; Hong W, 2014, NEUROREPORT, V25, P753, DOI 10.1097/WNR.0000000000000165; Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b; Hu YB, 2017, AUTISM RES, V10, P1184, DOI 10.1002/aur.1789; Iga J, 2007, PROG NEURO-PSYCHOPH, V31, P628, DOI 10.1016/j.pnpbp.2006.12.014; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Issler O, 2014, NEURON, V83, P344, DOI 10.1016/j.neuron.2014.05.042; Jeon SW, 2017, J NEUROIMMUNOL, V313, P92, DOI 10.1016/j.jneuroim.2017.10.016; Ji Y, 2011, CLIN PHARMACOL THER, V89, P97, DOI 10.1038/clpt.2010.250; Kaddurah-Daouk R, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2012.142; Kaddurah-Daouk R, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.22; Kaddurah-Daouk R, 2008, ANNU REV PHARMACOL, V48, P653, DOI 10.1146/annurev.pharmtox.48.113006.094715; Kang HJ, 2013, PROG NEURO-PSYCHOPH, V44, P23, DOI 10.1016/j.pnpbp.2013.01.006; Keers R, 2012, CURR PSYCHIAT REP, V14, P129, DOI 10.1007/s11920-011-0251-x; Kennedy SH, 2016, CAN J PSYCHIAT, V61, P540, DOI 10.1177/0706743716659417; Klengel T, 2015, NEURON, V86, P1343, DOI 10.1016/j.neuron.2015.05.036; Klengel T, 2013, INT J NEUROPSYCHOPH, V16, P701, DOI 10.1017/S1461145712001459; Kohler CA, 2017, ACTA PSYCHIAT SCAND, V135, P373, DOI 10.1111/acps.12698; Kohler C. A., 2017, MOL NEUROBIOL; Kovacs D, 2014, ANN GEN PSYCHIATR, V13, DOI 10.1186/1744-859X-13-17; Krystal JH, 2013, BIOL PSYCHIAT, V73, P1133, DOI 10.1016/j.biopsych.2013.03.026; Kubera N, 2001, J CLIN PSYCHOPHARM, V21, P199, DOI 10.1097/00004714-200104000-00012; Labermaier C, 2013, DIS MARKERS, P23, DOI 10.1155/2013/984845; Lam RW, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0785-x; Lanquillon S, 2000, NEUROPSYCHOPHARMACOL, V22, P370, DOI 10.1016/S0893-133X(99)00134-7; Launay JM, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.54; Leuchter AF, 2010, CURR PSYCHIAT REP, V12, P553, DOI 10.1007/s11920-010-0160-4; Leuchter AF, 2009, PSYCHIAT RES, V169, P124, DOI 10.1016/j.psychres.2009.06.004; Lisoway AJ, 2018, NEUROSCI LETT, V669, P14, DOI 10.1016/j.neulet.2016.12.071; Liu Y, 2012, J AFFECT DISORDERS, V139, P230, DOI 10.1016/j.jad.2011.08.003; Lopez JP, 2013, MOL PSYCHIATR, V18, P398, DOI 10.1038/mp.2012.38; Lopez JP, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15497; Lopez JP, 2014, NAT MED, V20, P764, DOI 10.1038/nm.3582; Luoni A, 2016, PHARMACOL THERAPEUT, V167, P13, DOI 10.1016/j.pharmthera.2016.07.006; Maciukiewicz M, 2015, PHARMACOGENOMICS, V16, P1919, DOI 10.2217/pgs.15.136; Maes M, 2001, HUM PSYCHOPHARM CLIN, V16, P95, DOI 10.1002/hup.191; Manoharan A, 2016, HUM PSYCHOPHARM CLIN, V31, P178, DOI 10.1002/hup.2525; Martino M, 2012, CURR NEUROPHARMACOL, V10, P97, DOI 10.2174/157015912800604542; Martocchia A, 2014, AGING CLIN EXP RES, V26, P461, DOI 10.1007/s40520-014-0194-2; Menke A, 2014, DIALOGUES CLIN NEURO, V16, P395; Mihara K, 2001, PHARMACOL TOXICOL, V88, P267, DOI 10.1034/j.1600-0773.2001.d01-115.x; Miller AH, 2017, PSYCHONEUROENDOCRINO, V84, P206, DOI 10.1016/j.psyneuen.2017.04.006; Miller AH, 2016, NAT REV IMMUNOL, V16, P22, DOI 10.1038/nri.2015.5; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Molendijk ML, 2014, MOL PSYCHIATR, V19, P791, DOI 10.1038/mp.2013.105; Murphy GM, 2013, PHARMACOGENET GENOM, V23, P301, DOI 10.1097/FPC.0b013e328360b175; Ng C, 2013, HUM PSYCHOPHARM CLIN, V28, P516, DOI 10.1002/hup.2340; Niitsu T, 2013, PROG NEURO-PSYCHOPH, V45, P183, DOI 10.1016/j.pnpbp.2013.05.011; Ninan PT, 2014, PROG NEURO-PSYCHOPH, V48, P86, DOI 10.1016/j.pnpbp.2013.09.016; Okada S, 2014, J PSYCHIATR RES, V53, P47, DOI 10.1016/j.jpsychires.2014.02.002; Ortiz R, 2015, J AFFECT DISORDERS, V172, P307, DOI 10.1016/j.jad.2014.09.015; Palma-Gudiel H, 2017, NEUROSCI BIOBEHAV R, V72, P190, DOI 10.1016/j.neubiorev.2016.11.011; Pandey GN, 2012, J PSYCHIATR RES, V46, P57, DOI 10.1016/j.jpsychires.2011.08.006; Papakostas GI, 2013, MOL PSYCHIATR, V18, P332, DOI 10.1038/mp.2011.166; Park H, 2013, NAT REV NEUROSCI, V14, P7, DOI 10.1038/nrn3379; Perez V, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1412-1; Polyakova M, 2015, J AFFECT DISORDERS, V174, P432, DOI 10.1016/j.jad.2014.11.044; Porcelli S, 2011, EXPERT OPIN DRUG MET, V7, P1101, DOI 10.1517/17425255.2011.597740; Powell TR, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.73; Powell TR, 2013, EUR NEUROPSYCHOPHARM, V23, P1105, DOI 10.1016/j.euroneuro.2012.09.009; Powell TR, 2013, J PSYCHOPHARMACOL, V27, P609, DOI 10.1177/0269881113490329; Qiu LF, 2015, ADV EXP MED BIOL, V888, P85, DOI 10.1007/978-3-319-22671-2_6; Quinones MP, 2009, NEUROBIOL DIS, V35, P165, DOI 10.1016/j.nbd.2009.02.019; Raison CL, 2013, JAMA PSYCHIAT, V70, P31, DOI 10.1001/2013.jamapsychiatry.4; Rajman M, 2017, DEVELOPMENT, V144, P2310, DOI 10.1242/dev.144337; Rotroff DM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.145; Sarginson JE, 2010, PHARMACOGENET GENOM, V20, P467, DOI 10.1097/FPC.0b013e32833b593a; Sasi M, 2017, PFLUG ARCH EUR J PHY, V469, P593, DOI 10.1007/s00424-017-1964-4; Sawamura K, 2004, EUR J CLIN PHARMACOL, V60, P553, DOI 10.1007/s00228-004-0792-6; Schatzberg AF, 2015, AM J PSYCHIAT, V172, P751, DOI 10.1176/appi.ajp.2015.14050680; Sen S, 2008, BIOL PSYCHIAT, V64, P527, DOI 10.1016/j.biopsych.2008.05.005; Serretti A, 2007, MOL PSYCHIATR, V12, P247, DOI 10.1038/sj.mp.4001926; Setoyama D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165267; Shen Xinhua, 2014, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V31, P196, DOI 10.3760/cma.j.issn.1003-9406.2014.02.015; Sim SC, 2006, CLIN PHARMACOL THER, V79, P103, DOI 10.1016/j.clpt.2005.10.002; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tadic A, 2014, MOL PSYCHIATR, V19, P281, DOI 10.1038/mp.2013.58; Tadic Andre, 2008, Neuropsychiatr Dis Treat, V4, P269; Tsao CW, 2006, PROG NEURO-PSYCHOPH, V30, P899, DOI 10.1016/j.pnpbp.2006.01.029; Tuglu C, 2003, PSYCHOPHARMACOLOGY, V170, P429, DOI 10.1007/s00213-003-1566-z; Ueda M, 2006, PROG NEURO-PSYCHOPH, V30, P486, DOI 10.1016/j.pnpbp.2005.11.007; Uher R, 2008, MOL PSYCHIATR, V13, P1070, DOI 10.1038/mp.2008.92; Uher R, 2014, AM J PSYCHIAT, V171, P1278, DOI 10.1176/appi.ajp.2014.14010094; Uher R, 2010, AM J PSYCHIAT, V167, P555, DOI 10.1176/appi.ajp.2009.09070932; Uhr M, 2008, NEURON, V57, P203, DOI 10.1016/j.neuron.2007.11.017; Ververs FFT, 2009, CLIN PHARMACOKINET, V48, P677, DOI 10.2165/11318050-000000000-00000; Vialou V, 2013, ANNU REV PHARMACOL, V53, P59, DOI 10.1146/annurev-pharmtox-010611-134540; Viswambharan V, 2017, BIOMARK MED, V11, P151, DOI 10.2217/bmm-2016-0242; Wankerl M, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.37; Wei CW, 2017, LIFE SCI, V188, P118, DOI 10.1016/j.lfs.2017.08.033; Wiedlocha M, 2018, PROG NEURO-PSYCHOPH, V80, P217, DOI 10.1016/j.pnpbp.2017.04.026; Williams LM, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.61; Winner JG, 2013, DISCOV MED, V16, P219; Yan TT, 2014, ASIA-PAC PSYCHIAT, V6, P241, DOI 10.1111/appy.12148; Yang JJ, 2015, BIOL PSYCHIAT, V77, pE19, DOI 10.1016/j.biopsych.2014.06.021; Yoon YR, 2000, CLIN PHARMACOL THER, V67, P567, DOI 10.1067/mcp.2000.106128; Yoshimura R, 2013, HUM PSYCHOPHARM CLIN, V28, P466, DOI 10.1002/hup.2333; Younger ST, 2011, NUCLEIC ACIDS RES, V39, P5682, DOI 10.1093/nar/gkr155; Younger WYY, 2003, NEUROPSYCHOPHARMACOL, V28, P1182, DOI 10.1038/sj.npp.1300172; Yuce-Artun N, 2016, INT J CLIN PHARM-NET, V38, P388, DOI 10.1007/s11096-016-0259-8; Zhou CJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172270; Zhu HJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068283; Zisook S, 2007, AM J PSYCHIAT, V164, P1539, DOI 10.1176/appi.ajp.2007.06101757	155	3	3	0	5	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					513	529		10.1080/14737159.2018.1470927			17	Pathology	Pathology	GJ1IN	WOS:000435008800005	29701114				2019-10-28	
J	Cheung, SW; Bi, WM				Cheung, Sau W.; Bi, Weimin			Novel applications of array comparative genomic hybridization in molecular diagnostics	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Exon-targeted array CGH; CMA in detecting AR disorders; CNV in human diseases; UPD; evolution of microarray	COPY NUMBER VARIATION; SEVERE DEVELOPMENTAL DELAY; CHROMOSOMAL MICROARRAY; CRITICAL REGION; COHEN-SYNDROME; DISEASE GENES; FISH ANALYSIS; HEARING-LOSS; DELETION; DNA	Introduction: In 2004, the implementation of array comparative genomic hybridization (array comparative genome hybridization [CGH]) into clinical practice marked a new milestone for genetic diagnosis. Array CGH and single-nucleotide polymorphism (SNP) arrays enable genome-wide detection of copy number changes in a high resolution, and therefore microarray has been recognized as the first-tier test for patients with intellectual disability or multiple congenital anomalies, and has also been applied prenatally for detection of clinically relevant copy number variations in the fetus.Area covered: In this review, the authors summarize the evolution of array CGH technology from their diagnostic laboratory, highlighting exonic SNP arrays developed in the past decade which detect small intragenic copy number changes as well as large DNA segments for the region of heterozygosity. The applications of array CGH to human diseases with different modes of inheritance with the emphasis on autosomal recessive disorders are discussed.Expert commentary: An exonic array is a powerful and most efficient clinical tool in detecting genome wide small copy number variants in both dominant and recessive disorders. However, whole-genome sequencing may become the single integrated platform for detection of copy number changes, single-nucleotide changes as well as balanced chromosomal rearrangements in the near future.	[Cheung, Sau W.; Bi, Weimin] Baylor Coll Med, Dept Mol & Human Genet, Baylor One Plaza, Houston, TX 77005 USA; [Bi, Weimin] Baylor Genet, Houston, TX USA	Cheung, SW (reprint author), Baylor Coll Med, Dept Mol & Human Genet, Baylor One Plaza, Houston, TX 77005 USA.	scheung@bcm.edu		Cheung, Sau W/0000-0002-3813-5256			Aguilera A, 2008, NAT REV GENET, V9, P204, DOI 10.1038/nrg2268; Albers CA, 2012, NAT GENET, V44, P435, DOI 10.1038/ng.1083; American College of Obstetricians and Gynecologists, 2013, OBSTET GYNECOL, V122, P1374; [Anonymous], 2016, Obstet Gynecol, V127, P979, DOI 10.1097/AOG.0000000000001439; [Anonymous], 2012, FERTIL STERIL, V98, P1103; Attard M, 1999, HUM MOL GENET, V8, P2507, DOI 10.1093/hmg/8.13.2507; Bolz H, 2004, HEARING RES, V188, P42, DOI 10.1016/S0378-5955(03)00346-0; Boone PM, 2013, GENOME RES, V23, P1383, DOI 10.1101/gr.156075.113; Boone PM, 2010, HUM MUTAT, V31, P1326, DOI 10.1002/humu.21360; Breman A, 2012, PRENATAL DIAG, V32, P351, DOI 10.1002/pd.3861; Buckley PG, 2002, HUM MOL GENET, V11, P3221, DOI 10.1093/hmg/11.25.3221; Cai WW, 2002, NAT BIOTECHNOL, V20, P393, DOI 10.1038/nbt0402-393; Callaway JLA, 2013, PRENATAL DIAG, V33, P1119, DOI 10.1002/pd.4209; Cheung SW, 2015, NEW ENGL J MED, V372, P1675, DOI 10.1056/NEJMc1412222; Chiu RWK, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.c7401; Dandouh EM, 2015, FERTIL STERIL, V104, P1503, DOI 10.1016/j.fertnstert.2015.08.038; del Gaudio D, 2006, GENET MED, V8, P784, DOI 10.1097/01.gim.0000250502.28516.3c; Dhar SU, 2010, AM J MED GENET A, V152A, P573, DOI 10.1002/ajmg.a.33253; Dittwald P, 2013, GENOME RES, V23, P1395, DOI 10.1101/gr.152454.112; Dong Z, 2017, GENET MED J AM COLL; Dong ZR, 2016, GENET MED, V18, P940, DOI 10.1038/gim.2015.199; Eldomery MK, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0412-6; Freeman JL, 2006, GENOME RES, V16, P949, DOI 10.1101/gr.3677206; Gambin T, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0472-7; Gillentine MA, 2017, AM J MED GENET A, V173, P2485, DOI 10.1002/ajmg.a.38328; Glessner JT, 2014, CIRC RES, V115, P884, DOI 10.1161/CIRCRESAHA.115.304458; Haraksingh RR, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3658-x; Haraksingh RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027859; Harrison V, 2011, AM J MED GENET A, V155A, P2826, DOI 10.1002/ajmg.a.34255; Hayes JL, 2013, GENOMICS, V102, P174, DOI 10.1016/j.ygeno.2013.04.006; Hehir-Kwa JY, 2015, EXPERT REV MOL DIAGN, V15, P1023, DOI 10.1586/14737159.2015.1053467; Hoppman N, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-19; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kang SHL, 2007, CLIN GENET, V72, P329, DOI 10.1111/j.1399-0004.2007.00876.x; Kearney HM, 2011, GENET MED, V13, P680, DOI 10.1097/GIM.0b013e3182217a3a; King DA, 2014, GENOME RES, V24, P673, DOI 10.1101/gr.160465.113; Koifman A, 2010, AM J MED GENET A, V152A, P1268, DOI 10.1002/ajmg.a.33319; Kolehmainen J, 2003, AM J HUM GENET, V72, P1359, DOI 10.1086/375454; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Ledbetter DH, 2007, AM J MED GENET C, V145C, P327, DOI 10.1002/ajmg.c.30149; Leduc MS, 2016, AM J MED GENET A, V170, P2206, DOI 10.1002/ajmg.a.37780; Lee C, 2007, NAT GENET, V39, pS48, DOI 10.1038/ng2092; Liang DS, 2014, J MOL DIAGN, V16, P519, DOI 10.1016/j.jmoldx.2014.05.002; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; Ligon AH, 1997, AM J HUM GENET, V61, P51, DOI 10.1086/513904; Liu PF, 2012, CURR OPIN GENET DEV, V22, P211, DOI 10.1016/j.gde.2012.02.012; Locke DP, 2004, J MED GENET, V41, P175, DOI 10.1136/jmg.2003.013813; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; Lu XY, 2008, PEDIATRICS, V122, P1310, DOI 10.1542/peds.2008-0297; Lupski JR, 2007, NAT GENET, V39, pS43, DOI 10.1038/ng2084; Lupski JR, 2005, PLOS GENET, V1, P627, DOI 10.1371/journal.pgen.0010049; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; Manning M, 2010, GENET MED, V12, P742, DOI 10.1097/GIM.0b013e3181f8baad; Mantripragada KK, 2003, J MOL MED-JMM, V81, P443, DOI 10.1007/s00109-003-0458-3; Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006; Moteki H, 2017, ACTA OTO-LARYNGOL, V137, P516, DOI 10.1080/00016489.2016.1252061; Okamoto Y, 2014, GENET MED, V16, P386, DOI 10.1038/gim.2013.155; Ou Z, 2008, GENET MED, V10, P278, DOI 10.1097/GIM.0b013e31816b4420; Papenhausen P, 2011, AM J MED GENET A, V155A, P757, DOI 10.1002/ajmg.a.33939; Petersen AK, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.10.005; Pfundt R, 2017, GENET MED, V19, P667, DOI 10.1038/gim.2016.163; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Ravnan JB, 2006, J MED GENET, V43, P478, DOI 10.1136/jmg.2005.036350; Reddy UM, 2012, NEW ENGL J MED, V367, P2185, DOI 10.1056/NEJMoa1201569; Reiter LT, 1998, AM J HUM GENET, V62, P1023, DOI 10.1086/301827; Retterer K, 2016, GENET MED, V18, P696, DOI [10.1038/gim.2014.160, 10.1038/gim.2015.148]; Rivera-Brugues N, 2011, J MED GENET, V48, P136, DOI 10.1136/jmg.2010.082206; Rodriguez-Paris J, 2009, BIOCHEM BIOPH RES CO, V389, P354, DOI 10.1016/j.bbrc.2009.08.152; Sahoo T, 2017, GENET MED, V19, P83, DOI 10.1038/gim.2016.69; Shao L, 2008, AM J MED GENET A, V146A, P2242, DOI 10.1002/ajmg.a.32399; Sharp AJ, 2006, NAT GENET, V38, P1038, DOI 10.1038/ng1862; Shiow LR, 2009, CLIN IMMUNOL, V131, P24, DOI 10.1016/j.clim.2008.11.002; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; Solomon NM, 2004, J MED GENET, V41, P669, DOI 10.1136/jmg.2003.016949; South ST, 2013, GENET MED, V15, P901, DOI 10.1038/gim.2013.129; Stankiewicz P, 2002, CURR OPIN GENET DEV, V12, P312, DOI 10.1016/S0959-437X(02)00304-0; Tammimies K, 2015, JAMA-J AM MED ASSOC, V314, P895, DOI 10.1001/jama.2015.10078; Tan RJ, 2014, HUM MUTAT, V35, P899, DOI 10.1002/humu.22537; Veltman JA, 2004, J MED GENET, V41, P425, DOI 10.1136/jmg.2004.018531; Veltman JA, 2003, AM J HUM GENET, V72, P1578, DOI 10.1086/375695; Veltman JA, 2002, AM J HUM GENET, V70, P1269, DOI 10.1086/340426; Vissers LELM, 2012, METHODS MOL BIOL, V838, P29, DOI 10.1007/978-1-61779-507-7_2; Vona B, 2015, CLIN GENET, V87, P49, DOI 10.1111/cge.12332; Wang H, 1993, GENEREVIEWS R; Wang J, 2016, GENET MED, V18, P513, DOI 10.1038/gim.2015.121; Wapner RJ, 2012, NEW ENGL J MED, V367, P2175, DOI 10.1056/NEJMoa1203382; Wiszniewska J, 2014, EUR J HUM GENET, V22, P79, DOI 10.1038/ejhg.2013.77; Wu N, 2015, NEW ENGL J MED, V372, P341, DOI 10.1056/NEJMoa1406829; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yatsenko AN, 2003, HUM MUTAT, V21, P636, DOI 10.1002/humu.10219; Yatsenko SA, 2009, J MOL DIAGN, V11, P226, DOI 10.2353/jmoldx.2009.080064; Zhang F, 2009, TRENDS GENET, V25, P298, DOI 10.1016/j.tig.2009.05.005	93	2	3	3	8	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					531	542		10.1080/14737159.2018.1479253			12	Pathology	Pathology	GJ1IN	WOS:000435008800006	29848116				2019-10-28	
J	Poole, S; Kidd, SP; Saeed, K				Poole, Stephen; Kidd, Stephen P.; Saeed, Kordo			A review of novel technologies and techniques associated with identification of bloodstream infection etiologies and rapid antimicrobial genotypic and quantitative phenotypic determination	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Blood stream infections; antimicrobial susceptibility; rapid diagnostics; PCR; Accelerate	DESORPTION IONIZATION-TIME; TOF MASS-SPECTROMETRY; RESISTANT STAPHYLOCOCCUS-AUREUS; COAGULASE-NEGATIVE STAPHYLOCOCCI; IN-SITU HYBRIDIZATION; DIFFERENTIAL GENE-EXPRESSION; 16S RIBOSOMAL-RNA; REAL-TIME; CULTURE IDENTIFICATION; MULTICENTER EVALUATION	Introduction: The antimicrobial aspect of management of patients with blood stream infections (BSI) and sepsis is time critical. In an era of increasing antimicrobial resistance, rapid detection and identification of bacteria with antimicrobial susceptibility is crucial to direct therapy early in the course of illness. Molecular techniques offer a potential solution to this.Areas covered: In the present review the authors have discussed a number of novel solutions utilizing a variety of molecular techniques for pathogen detection, identification and antimicrobial susceptibility. The review is not designed to be an exhaustive literature review covering all diagnostic solutions ever developed, instead the authors have focused on what they have had experience using, evaluating or currently view as new and exciting with potential to revolutionize BSI diagnosis.The authors searched PubMed (Medline) and Google Scholar with terms: BSI, Bacteraemia, Candidaemia, Diagnostics, AST, Rapid, AMR, Novel and Blood Culture. The authors attended recent clinical microbiology technology congresses.Expert commentary: There are multiple exciting novel technologies at differing stages of development with potential to revolutionize diagnosis of BSI. More work is needed as well as a standardized assessment of different platforms in order to better understand the clinical and financial impacts these will have in clinical microbiology laboratories.	[Poole, Stephen; Kidd, Stephen P.; Saeed, Kordo] Hampshire Hosp NHS Fdn Trust, Dept Microbiol, Basingstoke, Hants, England; [Poole, Stephen; Kidd, Stephen P.; Saeed, Kordo] Hampshire Hosp NHS Fdn Trust, Dept Microbiol, Winchester, Hants, England; [Saeed, Kordo] Univ Southampton, Sch Med, Southampton, Hants, England	Saeed, K (reprint author), Hampshire Hosp NHS Fdn Trust, Basingstoke, Hants, England.; Saeed, K (reprint author), Hampshire Hosp NHS Fdn Trust, Winchester, Hants, England.	kordosaeed@nhs.net		Poole, Stephen/0000-0002-6925-1399			Abdelhamed AM, 2015, J CLIN MICROBIOL, V53, P1672, DOI 10.1128/JCM.00549-15; Accelerate Diagnostics, MORPH CELL AN ACC PH; Afshari A, 2012, CRIT CARE, V16, DOI 10.1186/cc11202; Altun O, 2013, J CLIN MICROBIOL, V51, P4130, DOI 10.1128/JCM.01835-13; Arbefeville SS, 2011, J CLIN MICROBIOL, V49, P2996, DOI 10.1128/JCM.00046-11; Arroyo MA, 2017, J CLIN MICROBIOL, V55, P2708, DOI 10.1128/JCM.00692-17; Ashkenazi-Hoffnung L, 2018, EUR J CLIN MICROBIOL, V37, P1361, DOI 10.1007/s10096-018-3261-3; Baner J, 1998, NUCLEIC ACIDS RES, V26, P5073, DOI 10.1093/nar/26.22.5073; Banerjee R, 2015, CLIN INFECT DIS, V61, P1071, DOI 10.1093/cid/civ447; Beal Stacy G, 2015, Proc (Bayl Univ Med Cent), V28, P139; Beal SG, 2013, J CLIN MICROBIOL, V51, P3988, DOI 10.1128/JCM.01889-13; Belkum AV, 2016, MOL MICROBIOLOGY DIA, P92; Beutz M, 2003, CHEST, V123, P854, DOI 10.1378/chest.123.3.854; Blanc DS, 2011, J CLIN MICROBIOL, V49, P722, DOI 10.1128/JCM.01988-10; Blaschke AJ, 2013, DIAGN MICROBIOL INFE, V74, P349; Blaschke AJ, 2018, DIAGN MICROBIOL INFE, V74, P349; Buchan BW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001478; Buchan BW, 2012, J CLIN MICROBIOL, V50, P346, DOI 10.1128/JCM.05021-11; Carretto E, 2013, J CLIN MICROBIOL, V51, P131, DOI 10.1128/JCM.02103-12; Case RJ, 2007, APPL ENVIRON MICROB, V73, P278, DOI 10.1128/AEM.01177-06; Chapin K, 2003, J CLIN MICROBIOL, V41, P4324, DOI 10.1128/JCM.41.9.4324-4327.2003; Charnot-Katsikas A, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01166-17; Clancy CJ, 2018, CLIN INFECT DIS, P1095; Clancy CJ, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01909-17; Clark AE, 2013, CLIN MICROBIOL REV, V26, P547, DOI 10.1128/CMR.00072-12; Cohen JF, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012799; Croxatto A, 2012, FEMS MICROBIOL REV, V36, P380, DOI 10.1111/j.1574-6976.2011.00298.x; Culbreath K, 2015, OFID, V2, P1; Curtoni A, 2017, CURR MICROBIOL, V74, P97, DOI 10.1007/s00284-016-1161-2; Dahl F, 2004, P NATL ACAD SCI USA, V101, P4548, DOI 10.1073/pnas.0400834101; Dalpke AH, 2015, J CLIN MICROBIOL, V53, P3630, DOI 10.1128/JCM.01922-15; Davies J, 2012, J CLIN MICROBIOL, V50, P2056, DOI 10.1128/JCM.06773-11; Deck MK, 2012, J CLIN MICROBIOL, V50, P1994, DOI 10.1128/JCM.00225-12; Deck MK, 2018, DIAGN MICROBIOL INFE, V78, P338; Decuypere S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004470; Della-Latta P, 2011, J CLIN MICROBIOL, V49, P2259, DOI 10.1128/JCM.02250-10; DeMarco ML, 2013, CLIN LAB MED, V33, P611, DOI 10.1016/j.cll.2013.03.013; Deurenberg RH, 2017, J BIOTECHNOL, V243, P16, DOI 10.1016/j.jbiotec.2016.12.022; Dolch ME, 2012, J APPL MICROBIOL, V113, P1097, DOI 10.1111/j.1365-2672.2012.05414.x; Dolch ME, 2016, J BIOL RES-THESSALON, V23, DOI 10.1186/s40709-016-0040-0; Dryden M, 2017, INT J PHARM PRACT; Eckert DJ, 2010, EXPERT REV MOL DIAGN, V10, P399, DOI [10.1586/erm.10.24, 10.1586/ERM.10.24]; Faron ML, 2017, J CLIN MICROBIOL, V55, P3328, DOI 10.1128/JCM.00868-17; Fiori B, 2014, J CLIN MICROBIOL, V52, P3558, DOI 10.1128/JCM.01171-14; Forrest GN, 2006, J ANTIMICROB CHEMOTH, V58, P154, DOI 10.1093/jac/dkl146; Frolov AE, 2003, MOL BIOL+, V37, P486, DOI 10.1023/A:1025166706481; Frye AM, 2012, J CLIN MICROBIOL, V50, P127, DOI 10.1128/JCM.06169-11; Fuehrer HP, 2011, J CLIN MICROBIOL, V49, P1628, DOI 10.1128/JCM.01792-10; Galiana A., 2017, PLOS ONE, P1; Hamula CL, 2016, AM J CLIN PATHOL, V145, P858, DOI [10.1093/ajcp/aqw063, 10.1093/AJCP/AQW063]; Hardenbol P, 2003, NAT BIOTECHNOL, V21, P673, DOI 10.1038/nbt821; Hariu M, 2017, INFECT DRUG RESIST, V10, P115, DOI 10.2147/IDR.S132931; Hill JT, 2014, J CLIN MICROBIOL, V52, P3805, DOI 10.1128/JCM.01537-14; Holtzman C, 2011, J CLIN MICROBIOL, V49, P1581, DOI 10.1128/JCM.02461-10; Hrabak J, 2013, CLIN MICROBIOL REV, V26, P103, DOI 10.1128/CMR.00058-12; Huletsky A, 2004, J CLIN MICROBIOL, V42, P1875, DOI 10.1128/JCM.42.5.1875-1884.2004; Huttunen R, 2013, INT J INFECT DIS, V17, pE934, DOI 10.1016/j.ijid.2013.04.018; Idelevich EA, 2014, CLIN MICROBIOL INFEC, V20, P1001, DOI 10.1111/1469-0691.12640; Jordan JA, 2009, J CLIN MICROBIOL, V47, P368, DOI 10.1128/JCM.01991-08; Jung JS, 2016, J CLIN MICROBIOL, V54, P2820, DOI 10.1128/JCM.01131-16; Kaukonen KM, 2014, JAMA-J AM MED ASSOC, V311, P1308, DOI 10.1001/jama.2014.2637; Kerremans JJ, 2009, J CLIN MICROBIOL, V47, P3520, DOI 10.1128/JCM.01092-09; Kikuchi K, 2017, CAN J INFECT DIS MED, DOI 10.1155/2017/4896791; Kohlmann R, 2015, INT J MED MICROBIOL, V305, P469, DOI 10.1016/j.ijmm.2015.04.004; Konnerth Simone, 2014, BMC Res Notes, V7, P405, DOI 10.1186/1756-0500-7-405; Korber F, 2017, WIEN KLIN WOCHENSCHR, V129, P427, DOI 10.1007/s00508-017-1181-3; Kothari A, 2014, CLIN INFECT DIS, V59, P272, DOI 10.1093/cid/ciu292; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Ledeboer NA, 2015, J CLIN MICROBIOL, V53, P2460, DOI 10.1128/JCM.00581-15; Lee AWT, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00334; Lee J, 2017, ANN LAB MED, V37, P39, DOI 10.3343/alm.2017.37.1.39; Liesenfeld O, 2014, EUR J MICROBIOL IMMU, V4, P1, DOI 10.1556/EuJMI.4.2014.1.1; Lim SH, 2014, J CLIN MICROBIOL, V52, P592, DOI 10.1128/JCM.02377-13; Loonen AJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087315; Ly Tam, 2008, Ther Clin Risk Manag, V4, P637; MacVane SH, 2016, J CLIN MICROBIOL, V54, P2455, DOI 10.1128/JCM.00996-16; Marco D, 2016, EUR J PEDIATR, V175, P1107, DOI 10.1007/s00431-016-2745-3; Marschal M, 2017, J CLIN MICROBIOL, V55, P2116, DOI [10.1128/jcm.00181-17, 10.1128/JCM.00181-17]; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Maubon D, 2018, EXPERT REV MOL DIAGN, V18, P119, DOI 10.1080/14737159.2018.1420476; Maurer FP, 2017, INFECT DIS REP, V9, P18, DOI 10.4081/idr.2017.6839; Mejias A, 2014, J INFECTION, V68, pS94, DOI 10.1016/j.jinf.2013.09.018; Mestas J, 2014, J CLIN MICROBIOL, V52, P283, DOI 10.1128/JCM.02322-13; Mongelli G, 2015, J MED MICROBIOL, V64, P670, DOI 10.1099/jmm.0.000074; Moore MS, 2016, J CLIN MICROBIOL, V54, P99, DOI 10.1128/JCM.02394-15; Morck J, 2017, ASM; Morgenthaler NG, 2015, INT J MICROBIOL, V2015; NILSSON M, 1994, SCIENCE, V265, P2085, DOI 10.1126/science.7522346; Pan Q, 2018, J INFECTION, V77, P83, DOI 10.1016/j.jinf.2018.04.007; Pancholi P, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01329-17, 10.1128/JCM.01329-17]; Pantel A, 2018, J ANTIMICROB CHEMOTH; Paolucci M, 2014, J MICROBIOL METH, V104, P92, DOI 10.1016/j.mimet.2014.06.018; Papagiannitsis CC, 2015, J CLIN MICROBIOL, V53, P1731, DOI 10.1128/JCM.03094-14; Pasqualini L, 2012, J CLIN MICROBIOL, V50, P1285, DOI 10.1128/JCM.06793-11; Paul M, 2010, ANTIMICROB AGENTS CH, V54, P4851, DOI 10.1128/AAC.00627-10; Peralta G, 2007, J ANTIMICROB CHEMOTH, V60, P855, DOI 10.1093/jac/dkm279; Perlin DS, 2017, J INFECT DIS, V216, pS458, DOI 10.1093/infdis/jix121; Peters RPH, 2006, J CLIN MICROBIOL, V44, P119, DOI 10.1128/JCM.44.1.119-123.2006; Petersen A, 2013, CLIN MICROBIOL INFEC, V19, pE16, DOI 10.1111/1469-0691.12036; Public Health England, 2014, UK STAND MICROBIOL B, VB 37; Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996; Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477; Rees C, 2017, J BREATH RES; Revel AT, 2002, P NATL ACAD SCI USA, V99, P1562, DOI 10.1073/pnas.032667699; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Salimnia H, 2014, J CLIN MICROBIOL, V52, P3928, DOI 10.1128/JCM.01811-14; Salimnia H, 2016, J CLIN MICROBIOL, V54, P687, DOI 10.1128/JCM.01679-15; Scanvic A, 2011, PATHOL BIOL, V59, P67, DOI 10.1016/j.patbio.2010.07.016; Scotter JM, 2006, J MICROBIOL METH, V65, P628, DOI 10.1016/j.mimet.2005.09.016; Shrestha NK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173130; Sinha M, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00089-17; Sothoron C, 2015, J CLIN MICROBIOL, V53, P3627, DOI 10.1128/JCM.02161-15; Sparbier K, 2013, J CLIN MICROBIOL, V51, P3741, DOI 10.1128/JCM.01536-13; Spencer DH, 2011, AM J CLIN PATHOL, V136, P690, DOI 10.1309/AJCP07UGYOKBVVNC; Stone NRH, 2013, J CLIN MICROBIOL, V51, P1301, DOI 10.1128/JCM.00028-13; Tadros M, 2013, CAN J INFECT DIS MED, V24, P191, DOI 10.1155/2013/701093; Templier V, 2017, NATURE SCI REPORTS, P1; Tsalik EL, 2010, J CLIN MICROBIOL, V48, P26, DOI 10.1128/JCM.01447-09; UK Public Health England, 2014, BACTERIOLOGY B, VB 55, P1; van der Velden LB, 2011, J CLIN MICROBIOL, V49, P275, DOI 10.1128/JCM.00552-10; Vella A, 2013, J CLIN MICROBIOL, V51, P2964, DOI 10.1128/JCM.00903-13; Venturelli C, 2017, PLOS ONE, P1; Vincent JL, 2015, CRIT CARE MED, V43, P2283, DOI 10.1097/CCM.0000000000001249; Walker T, 2016, J CLIN MICROBIOL, V54, P1789, DOI 10.1128/JCM.00376-16; Warhurst G, 2015, HEALTH TECHNOL ASSES, V19, DOI 10.3310/hta19350; Weinbren M, 2016, BIOMED SCI, P194; Wiesner K, 2014, PROCEDIA ENGINEER, V87, P332, DOI 10.1016/j.proeng.2014.11.750; Wilson MR, 2014, NEW ENGL J MED, V370, P2408, DOI 10.1056/NEJMoa1401268; Wilson MR, 2018, JAMA NEUROL, pE1; Yapo-Kouadio C, 2018, MED MYCOL, P185; Yonetani S, 2016, INT J INFECT DIS, V52, P37, DOI 10.1016/j.ijid.2016.09.014; Zervou FN, 2017, METHODS MOL BIOL, V1508, P305, DOI 10.1007/978-1-4939-6515-1_18; Zheng XT, 2014, J CLIN MICROBIOL, V52, P4368, DOI 10.1128/JCM.02133-14; Ziegler I, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-155; Zimmerman JE, 2013, CRIT CARE, V17, DOI 10.1186/cc12695; Zweitzig DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078488; Zweitzig DR, 2013, J MOL DIAGN, V15, P319, DOI 10.1016/j.jmoldx.2012.12.004; Zweitzig DR, 2012, NUCLEIC ACIDS RES, V40, P1	139	7	8	1	16	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					543	555		10.1080/14737159.2018.1480369			13	Pathology	Pathology	GJ1IN	WOS:000435008800007	29790810				2019-10-28	
J	Lopez-Lopez, A; Lopez-Gonzalvez, A; Barker-Tejeda, TC; Barbas, C				Lopez-Lopez, Angeles; Lopez-Gonzalvez, Angeles; Clive Barker-Tejeda, Tomas; Barbas, Coral			A review of validated biomarkers obtained through metabolomics	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Metabolomics; validation; biomarkers; global profiling	SQUAMOUS-CELL CARCINOMA; MAJOR DEPRESSIVE DISORDER; SERUM METABOLOMICS; LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; POTENTIAL BIOMARKERS; EARLY-DIAGNOSIS; BLADDER-CANCER; TARGETED METABOLOMICS; METABOLITE BIOMARKER	Introduction: Studying changes in the whole set of small molecules, final products of biochemical reactions in living systems or metabolites, is extremely appealing because they represent the best approach to identifying what occurs in an organism when samples are collected. However, their usefulness as potential biomarkers is limited by discoveries obtained in small groups without proper validation or even confirmation of the chemical structure.Areas covered: During the past 5years, more than 900 papers have been published on metabolomics for biomarker discovery, but the numbers are much lower when some criteria of validation are applied. In total, 102 papers have been included in this review. The most frequent disease areas in which these markers have been discovered include the following: cancer, diabetes, and related diseases and neurodegenerative, cardiovascular, autoimmune, liver, and kidney diseases.Expert commentary: Metabolomics has been demonstrated as rapidly growing due to the improvements in instrumentation, mainly mass spectrometry, and data mining software. For application in the clinic, the results should be validated in different stages, from analytical validation to validation in independent sets of samples, using thousands of samples from different sources.	[Lopez-Lopez, Angeles; Lopez-Gonzalvez, Angeles; Clive Barker-Tejeda, Tomas; Barbas, Coral] Univ CEU San Pablo, Fac Farm, Ctr Metabol & Bioanal CEMBIO, Madrid, Spain	Barbas, C (reprint author), Univ CEU San Pablo, Fac Farm, Ctr Metabol & Bioanal CEMBIO, Madrid, Spain.	cbarbas@ceu.es	Lopez-Gonzalvez, Angeles/K-4361-2014; Barbas, Coral/K-3871-2014; Tejeda, Tomas Clive Barker/AAB-5863-2019	Lopez-Gonzalvez, Angeles/0000-0002-6363-7135; Barbas, Coral/0000-0003-4722-491X; Tejeda, Tomas Clive Barker/0000-0002-2942-5876	Spanish Ministerio de Economia y Competitividad	This article was funded by Spanish Ministerio de Economia y Competitividad.	Akita H, 2016, PANCREAS, V45, P1418, DOI 10.1097/MPA.0000000000000680; Alonso A, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0681-8; Bahado-Singh RO, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-017-1290-z; Ban GY, 2017, CLIN EXP ALLERGY, V47, P37, DOI 10.1111/cea.12797; Bansal N, 2013, J PROTEOME RES, V12, P5839, DOI 10.1021/pr400859w; Beger RD, 2013, METABOLITES, V3, P552, DOI 10.3390/metabo3030552; Botas A, 2015, INT REV NEUROBIOL, V122, P53, DOI 10.1016/bs.irn.2015.05.006; Carter TC, 2016, METABOLISM, V65, P1399, DOI 10.1016/j.metabol.2016.06.007; Casanova R, 2016, ALZHEIMERS DEMENT, V12, P815, DOI 10.1016/j.jalz.2015.12.008; Chan K.K.S., 2018, MOL NEUROBIOL, P1; Chen DY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168147; Chen JJ, 2015, J PROTEOME RES, V14, P3382, DOI 10.1021/acs.jproteome.5b00434; Chen R, 2018, J CHROMATOGR B, V1085, P54, DOI 10.1016/j.jchromb.2018.03.047; Chen Y, 2016, CLIN BIOCHEM, V49, P962, DOI 10.1016/j.clinbiochem.2016.05.016; Chen YN, 2016, ONCOTARGET, V7, P87496, DOI 10.18632/oncotarget.11754; Cobb J., 2014, J DIABETES SCI TECHN, V9, P69; Cobb J, 2016, DIABETES CARE, V39, P988, DOI 10.2337/dc15-2752; Cobb Jeff, 2013, J Diabetes Sci Technol, V7, P100; Crotti S, 2016, ANAL BIOANAL CHEM, V408, P6321, DOI 10.1007/s00216-016-9743-1; Cui S, 2017, JACC-CARDIOVASC INTE, V10, P1307, DOI 10.1016/j.jcin.2017.04.007; Cui Y, 2014, J NEUROPATH EXP NEUR, V73, P954, DOI 10.1097/NEN.0000000000000116; Dobbin KK, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0179-0; Drucker E, 2013, EPMA J, V4, DOI 10.1186/1878-5085-4-7; Dudzik D, 2018, J PHARMACEUT BIOMED, V147, P149, DOI 10.1016/j.jpba.2017.07.044; Esther CR, 2015, CHEST, V148, P507, DOI 10.1378/chest.14-1800; Farshidfar F, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3923-z; Fei H, 2016, BIOMED CHROMATOGR, V30, P1942, DOI 10.1002/bmc.3770; Fiandaca MS, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00237; Floegel A, 2013, DIABETES, V62, P639, DOI 10.2337/db12-0495; Fukutake N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132223; Gao R, 2015, SCI REP-UK, V5, DOI 10.1038/srep18175; Guo S, 2014, ANAL BIOANAL CHEM, V406, P4357, DOI 10.1007/s00216-014-7846-0; Havelund JF, 2017, METABOLITES, V7, DOI 10.3390/metabo7030042; Hirata Y, 2017, CLIN CHIM ACTA, V468, P98, DOI 10.1016/j.cca.2017.02.011; Huang Q, 2013, CANCER RES, V73, P4992, DOI 10.1158/0008-5472.CAN-13-0308; Izquierdo-Garcia JL, 2017, SHOCK; Jin X, 2014, ONCOTARGET, V5, P1635, DOI 10.18632/oncotarget.1744; Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25; Jung J, 2014, ANN SURG ONCOL, V21, pS736, DOI 10.1245/s10434-014-3886-0; Kobayashi T, 2013, CANCER EPIDEM BIOMAR, V22, P571, DOI 10.1158/1055-9965.EPI-12-1033; Kohashi M, 2014, J CROHNS COLITIS, V8, P1010, DOI 10.1016/j.crohns.2014.01.024; Konety BR, 2006, UROL ONCOL-SEMIN ORI, V24, P326, DOI 10.1016/j.urolonc.2005.11.023; Laborde CM, 2014, METABOLOMICS, V10, P414, DOI 10.1007/s11306-013-0595-9; Lam CW, 2014, CLIN CHIM ACTA, V436, P217, DOI 10.1016/j.cca.2014.05.014; Langley RJ, 2014, AM J RESP CRIT CARE, V190, P445, DOI 10.1164/rccm.201404-0624OC; Lee JE, 2016, J CHROMATOGR A, V1453, P105, DOI 10.1016/j.chroma.2016.05.058; Li YJ, 2014, J CHROMATOGR B, V966, P147, DOI 10.1016/j.jchromb.2014.04.047; Li YF, 2016, ANAL METHODS-UK, V8, P3284, DOI 10.1039/c6ay00127k; Liang Q, 2016, RSC ADV, V6, P11008, DOI 10.1039/c5ra25961d; Liang Q, 2016, MOL BIOSYST, V12, P334, DOI 10.1039/c5mb00572h; Liang Q, 2015, RSC ADV, V5, P102204, DOI 10.1039/c5ra19875e; Lima AR, 2016, TRANSL ONCOL, V9, P357, DOI 10.1016/j.tranon.2016.05.004; Lindahl A, 2017, METABOLOMICS, V13, DOI 10.1007/s11306-017-1199-6; Liu XY, 2015, J PROTEOME RES, V14, P2322, DOI 10.1021/acs.jproteome.5b00144; Lu YH, 2016, CANCER RES, V76, P2912, DOI 10.1158/0008-5472.CAN-15-3199; Luo P, 2018, HEPATOLOGY, V67, P662, DOI 10.1002/hep.29561; Maniscalco M, 2017, J ALLERGY CLIN IMMUN, V139, P1536, DOI 10.1016/j.jaci.2016.08.038; Mapstone M, 2014, NAT MED, V20, P415, DOI 10.1038/nm.3466; Mastrangelo A, 2016, INT J OBESITY, V40, P1494, DOI 10.1038/ijo.2016.92; Masucci GV, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0178-1; Mayerle J, 2018, GUT, V67, P128, DOI 10.1136/gutjnl-2016-312432; Menni C, 2013, DIABETES, V62, P4270, DOI 10.2337/db13-0570; Mueller-Hennessen M, 2017, CLIN CHEM, V63, P267, DOI 10.1373/clinchem.2016.257279; Naz S, 2014, J CHROMATOGR A, V1353, P99, DOI 10.1016/j.chroma.2014.04.071; Oresic M, 2016, EBIOMEDICINE, V12, P118, DOI 10.1016/j.ebiom.2016.07.015; Pan XL, 2016, EBIOMEDICINE, V3, P155, DOI 10.1016/j.ebiom.2015.11.039; Pasikanti KK, 2013, J PROTEOME RES, V12, P3865, DOI 10.1021/pr4000448; Peng F, 2018, J PHARMACEUT BIOMED, V154, P95, DOI 10.1016/j.jpba.2018.02.051; Pijls KE, 2016, SCI REP-UK, V6, DOI 10.1038/srep19903; Posada-Ayala M, 2014, KIDNEY INT, V85, P103, DOI 10.1038/ki.2013.328; Purroy F, 2016, EBIOMEDICINE, V14, P131, DOI 10.1016/j.ebiom.2016.11.010; Rindlisbacher B, 2018, J BREATH RES, V12, DOI 10.1088/1752-7163/aa840a; Ritchie SA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-416; Sanchez-Espiridion B, 2015, CLIN GASTROENTEROL H, V13, P1730, DOI 10.1016/j.cgh.2015.05.023; Shao YP, 2015, J PROTEOME RES, V14, P906, DOI 10.1021/pr500973d; Shen J, 2017, LUNG CANCER, V114, P70, DOI 10.1016/j.lungcan.2017.10.018; Shokry E, 2017, J PROTEOMICS, V159, P92, DOI 10.1016/j.jprot.2017.03.005; Srinivasan S, 2015, MBIO, V6, DOI 10.1128/mBio.00204-15; Tan GG, 2017, SCI REP-UK, V7, DOI 10.1038/srep46176; Tian YH, 2018, CLIN CANCER RES, V24, P2100, DOI 10.1158/1078-0432.CCR-17-2855; Tokushige K, 2013, J GASTROENTEROL, V48, P1392, DOI 10.1007/s00535-013-0766-5; Toledo JB, 2017, ALZHEIMERS DEMENT, V13, P965, DOI 10.1016/j.jalz.2017.01.020; Trezzi JP, 2017, MOVEMENT DISORD, V32, P1401, DOI 10.1002/mds.27132; Troisi J, 2018, J PROTEOME RES, V17, P804, DOI [10.1021/acs.jproteome.7b00503, 10.1021/acs.jproteome.7b00003]; Wagner JA, 2002, DIS MARKERS, V18, P41, DOI 10.1155/2002/929274; Wang JL, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-1050-5; Wang MQ, 2014, J PROTEOME RES, V13, P4131, DOI 10.1021/pr500517u; Wen CP, 2015, CLIN CANCER RES, V21, P193, DOI 10.1158/1078-0432.CCR-14-0748; Wikoff WR, 2015, J CLIN ONCOL, V33, P3880, DOI 10.1200/JCO.2015.61.7779; Wittmann BM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115870; Wurtz P, 2015, CIRCULATION, V131, P774, DOI 10.1161/CIRCULATIONAHA.114.013116; Xia JG, 2013, METABOLOMICS, V9, P280, DOI 10.1007/s11306-012-0482-9; Xiao H, 2017, PANCREATOLOGY, V17, P543, DOI 10.1016/j.pan.2017.04.015; Xu J, 2013, MOL CELL PROTEOMICS, V12, P1306, DOI 10.1074/mcp.M112.022830; Xu XJ, 2014, MOL BIOSYST, V10, P813, DOI 10.1039/c3mb70614a; Yang BY, 2018, CANCER SCI, V109, P777, DOI 10.1111/cas.13500; Yang QJ, 2018, J CACHEXIA SARCOPENI, V9, P71, DOI 10.1002/jcsm.12246; Ye GZ, 2014, J PROTEOME RES, V13, P1994, DOI 10.1021/pr4011298; Yin R, 2016, CANCER BIOMARK, V17, P259, DOI 10.3233/CBM-160638; Zeng J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16101; Zeng J, 2014, J PROTEOME RES, V13, P3420, DOI 10.1021/pr500390y; Zha HB, 2018, ANAL CHEM, V90, P4062, DOI 10.1021/acs.analchem.7b05318; Zhang W, 2016, OSTEOARTHR CARTILAGE, V24, P827, DOI 10.1016/j.joca.2015.12.004; Zhang W, 2015, CELL BIOCHEM BIOPHYS, V72, P661, DOI 10.1007/s12013-014-0472-9; Zhang WD, 2016, RHEUMATOLOGY, V55, P1566, DOI 10.1093/rheumatology/kew207; Zhang ZH, 2016, J PROTEOME RES, V15, P3802, DOI 10.1021/acs.jproteome.6b00583; Zhao H, 2016, ONCOTARGET, V7, P20486, DOI 10.18632/oncotarget.7974; Zhao XJ, 2014, J PROTEOME RES, V13, P1101, DOI 10.1021/pr401130w; Zheng P, 2013, METABOLOMICS, V9, P800, DOI 10.1007/s11306-013-0508-y; Zhou Y, 2016, ANAL BIOANAL CHEM, V408, P6741, DOI 10.1007/s00216-016-9797-0; Zmyslowska A, 2017, J PROTEOME RES, V16, P4000, DOI 10.1021/acs.jproteome.7b00401	111	13	13	6	32	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					557	575		10.1080/14737159.2018.1481391			19	Pathology	Pathology	GJ1IN	WOS:000435008800008	29808702				2019-10-28	
J	Rosset, C; Vairo, F; Bandeira, IC; Fonini, M; Netto, CBO; Ashton-Prolla, P				Rosset, Clevia; Vairo, Filippo; Bandeira, Isabel Cristina; Fonini, Maievi; Oliveira Netto, Cristina Brinckmann; Ashton-Prolla, Patricia			Clinical and molecular characterization of neurofibromatosis in southern Brazil	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Genotype-phenotype correlations; neurocutaneous syndromes; neurofibromatosis type 1; neurofibromatosis type 2; next-generation sequencing	GENOTYPE-PHENOTYPE CORRELATION; NF1 GENE; MUTATIONAL SPECTRUM; TYPE-1; VARIANTS; PRODUCT; GROWTH; DOMAIN; RAS	Objectives: Neurofibromatoses (type 1: NF1; type 2: NF2) are autosomal dominant tumor predisposition syndromes mostly caused by loss-of-function mutations in the tumor suppressor genes NF1 and NF2, respectively. Genotyping is important for correct diagnosis of these diseases. The authors aimed to characterize NF1 and NF2 variants in patients from Southern Brazil.Methods: Ninety-three unrelated probands with NF1 and 7 unrelated probands with NF2 features were recruited from an Oncogenetics center in Southern Brazil. Two next generation sequencing panels were customized to identify point mutations: NF1 (NF1, RNF135, and SUZ12 genes) and NF2 (NF2 and SMARCB1 genes). Large rearrangements were assessed by Multiplex Ligation-dependent Probe Amplification.Results: Sixty-eight heterozygous NF1 variants were identified in 75/93 probands (80%) and 3 heterozygous NF2 variants were identified in 3/7 probands (43%). In NF1, 59 (87%) variants were pathogenic (4 large rearrangements - 6%), 6 (9%) were likely pathogenic, 3 (4%) were variants of uncertain significance and 28 (41%) were novel. In NF2, all variants were pathogenic. No novel genotype-phenotype correlations were observed; however, previously described correlations were confirmed in our cohort.Conclusion: The clinical and molecular characterization of neurofibromatoses in different populations is very important to provide further insights into the pathogenesis of these diseases.	[Rosset, Clevia; Bandeira, Isabel Cristina; Fonini, Maievi; Ashton-Prolla, Patricia] Hosp Clin Porto Alegre, Lab Med Genom, Ctr Pesquisa Expt, Porto Alegre, RS, Brazil; [Rosset, Clevia; Bandeira, Isabel Cristina; Ashton-Prolla, Patricia] Univ Fed Rio Grande do Sul, Programa Posgrad Genet & Biol Mol, Porto Alegre, RS, Brazil; [Vairo, Filippo; Oliveira Netto, Cristina Brinckmann; Ashton-Prolla, Patricia] Hosp Clin Porto Alegre, Serv Genet Med, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil; [Ashton-Prolla, Patricia] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil	Ashton-Prolla, P (reprint author), Hosp Clin Porto Alegre, Serv Genet Med, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.	pprolla@hcpa.edu.br	Ashton-Prolla, Patricia/H-2927-2012		Fundo de Incentivo a Pesquisa (FIPE) of Hospital de Clinicas de Porto Alegre; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq); Instituto do Cancer Infantil (ICI)	This article was funded by Fundo de Incentivo a Pesquisa (FIPE) of Hospital de Clinicas de Porto Alegre, Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) and Instituto do Cancer Infantil (ICI).	Ablon J, 1996, SOC SCI MED, V42, P99, DOI 10.1016/0277-9536(95)00076-3; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; Baser ME, 2002, NEUROLOGY, V59, P1759, DOI 10.1212/01.WNL.0000035638.74084.F4; Bendl J, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003440; Boyanapalli M, 2006, BIOCHEM BIOPH RES CO, V340, P1200, DOI 10.1016/j.bbrc.2005.12.129; CAREY JC, 1986, ANN NY ACAD SCI, V486, P45, DOI 10.1111/j.1749-6632.1986.tb48061.x; Valero MC, 2011, J MOL DIAGN, V13, P113, DOI 10.1016/j.jmoldx.2010.09.002; Dasgupta B, 2003, J NEUROSCI, V23, P8949; de Souza JF, 2009, REV ASSOC MED BRAS, V55, P394, DOI 10.1590/S0104-42302009000400012; Evans DG, 2010, AM J MED GENET A, V152A, P327, DOI 10.1002/ajmg.a.33139; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; Ferner Rosalie E, 2010, Pract Neurol, V10, P82, DOI 10.1136/jnnp.2010.206532; Griffiths S, 2007, FAM CANCER, V6, P21, DOI 10.1007/s10689-006-9001-3; Jagadeesh KA, 2016, NAT GENET, V48, P1581, DOI 10.1038/ng.3703; Kehrer-Sawatzki H, 2012, NEUROFIBROMATOSIS TY, P187; Kehrer-Sawatzki H, 2017, HUM GENET, V136, P349, DOI 10.1007/s00439-017-1766-y; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Kluwe L, 2005, GENE CHROMOSOME CANC, V42, P384, DOI 10.1002/gcc.20138; Koczkowska M, 2018, AM J HUM GENET, V102, P69, DOI 10.1016/j.ajhg.2017.12.001; Larizza L, 2009, CURR MOL MED, V9, P634, DOI 10.2174/156652409788488801; Mangoura D, 2006, ONCOGENE, V25, P735, DOI 10.1038/sj.onc.1209113; Mattocks C, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011890; Messiaen L, 2008, NEUROFIBROMATOSES; Messiaen L, 2009, JAMA-J AM MED ASSOC, V302, P2111, DOI 10.1001/jama.2009.1663; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Morrison H, 2007, CANCER RES, V67, P520, DOI 10.1158/0008-5472.CAN-06-1608; Pasmant E, 2010, HUM MUTAT, V31, pE1506, DOI 10.1002/humu.21271; Pinna V, 2015, EUR J HUM GENET, V23, P1068, DOI 10.1038/ejhg.2014.243; Pros Eva, 2008, Hum Mutat, V29, pE173, DOI 10.1002/humu.20826; Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33; Reese MG, 1997, J COMPUT BIOL, V4, P311, DOI 10.1089/cmb.1997.4.311; Riccardi V, 1986, NEUROFIBROMATOSIS PH; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Sabbagh A, 2013, HUM MUTAT, V34, P1510, DOI 10.1002/humu.22392; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Seong MW, 2010, KOREAN J LAB MED, V30, P190, DOI 10.3343/kjlm.2010.30.2.190; Tonsgard James H, 2006, Semin Pediatr Neurol, V13, P2, DOI 10.1016/j.spen.2006.01.005; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; Trovo-Marqui AB, 2005, BRAZ J MED BIOL RES, V38, P1441, DOI 10.1590/S0100-879X2005000900020; Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781; Valero MC, 1997, HUM GENET, V99, P720, DOI 10.1007/s004390050438; van Minkelen R, 2014, CLIN GENET, V85, P318, DOI 10.1111/cge.12187; Yunoue S, 2003, J BIOL CHEM, V278, P26958, DOI 10.1074/jbc.M209413200	43	0	0	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	6					577	586		10.1080/14737159.2018.1468256			10	Pathology	Pathology	GJ1IN	WOS:000435008800009	29685074				2019-10-28	
J	Kost, GJ				Kost, Gerald J.			Molecular and point-of-care diagnostics for Ebola and new threats: National POCT policy and guidelines will stop epidemics	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Molecular and Point-of-Care Diagnostics; Ebola and New Threats; National POCT Policy and Guidelines; Epidemics	ANTIGEN RAPID TEST; BIOTHREAT-E TEST; VIRUS DISEASE; REAL-TIME; ISOTHERMAL AMPLIFICATION; HEMORRHAGIC-FEVER; EMERGING VIRUSES; PUBLIC-HEALTH; BLOOD-SAMPLES; SIERRA-LEONE	Introduction: US hospitals that admitted Ebola virus disease (EVD) patients mitigated risk by using point-or-care testing (POCT) for critical support in isolation units. Success proved unequivocally the need for POCT. Additionally, molecular diagnostics have been used to help stop new outbreaks, and even handheld diagnostic solutions are emerging.Areas covered: This update of Molecular detection and point-of-care testing in Ebola virus disease and other threats' [Expert Reviews 2015;15(10):1249-1255], assesses the impact of EVD epidemics, documents insights from recent reviews, summarizes evolving POC molecular technologies, presents General Accountability Office (GAO) recommendations, identifies the role of POC Coordinators, and casts a vision for national POCT policies and guidelines. Factual updating comprised summarizing EVD outbreaks including 2017-2018, analyzing reviews and evidence-based publications since the 2014-2016 epidemic, and tabulating published technical and molecular diagnostics. New graphics illustrate POC error mitigation/risk reduction, a framework for national POCT policy and guidelines, modular adaptations for country-specific solutions, and a logic diagram for future progress embedding artificial intelligence.Expert commentary: The USA is still not prepared for highly infectious diseases. Key is lack of community rapid response and resilience, which must be enhanced not via mechanisms distant, but instead by molecular diagnostics directly at critical points of need.	[Kost, Gerald J.] Univ Calif Davis, Sch Med, Point Of Care Ctr Teaching & Res POCT CTR, Davis, CA USA; [Kost, Gerald J.] Knowledge Optimizat, Davis, CA USA	Kost, GJ (reprint author), Univ Calif Davis, Davis Knowledge Optimizat, Sch Med, Point Of Care Ctr Teaching & Res POCT CTR, 506 Citadel Dr, Davis, CA 95616 USA.	gjkost@ucdavis.edu			Point-of-Care Testing Center for Teaching and Research (POCT.CTR(TM))	This work was supported by the Point-of-Care Testing Center for Teaching and Research (POCT center dot CTR (TM)) and by G.J. Kost, its Director.	Acquah C, 2016, CRIT REV BIOTECHNOL, V36, P1010, DOI 10.3109/07388551.2015.1083940; Ahrberg CD, 2016, ANAL CHEM, V88, P4803, DOI 10.1021/acs.analchem.6b00278; Baduge MSDSP, 2018, INT EMERG NURS, V38, P41, DOI 10.1016/j.ienj.2017.12.002; Balajee SA, 2016, HEALTH SECUR, V14, P424, DOI 10.1089/hs.2015.0062; Barocchi MA, 2015, PHILOS T R SOC B, V370, P1671; Bhadelia N, 2015, LANCET, V386, P833, DOI 10.1016/S0140-6736(15)61119-9; Boisen ML, 2015, J INFECT DIS, V212, pS359, DOI 10.1093/infdis/jiv353; Bradfute SB, 2012, VIRUSES-BASEL, V4, P1477, DOI 10.3390/v4091477; Brangel P, 2018, ACS NANO, V12, P63, DOI 10.1021/acsnano.7b07021; Brinkmann A, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006075; Broadhurst MJ, 2016, CLIN MICROBIOL REV, V29, P773, DOI 10.1128/CMR.00003-16; Broadhurst MJ, 2015, LANCET, V386, P867, DOI 10.1016/S0140-6736(15)61042-X; Cao J, 2017, LAB MED, V48, P188, DOI 10.1093/labmed/lmw072; Chan K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158502; Clark DJ, 2018, J CLIN VIROL, V103, P27, DOI 10.1016/j.jcv.2018.03.005; Cnops L, 2016, J INFECT DIS, V214, pS192, DOI 10.1093/infdis/jiw150; Coarsey CT, 2017, CRIT REV MICROBIOL, V43, P779, DOI [10.1080/1040841x.2017.1313814, 10.1080/1040841X.2017.1313814]; Cotte J, 2015, ANAESTH CRIT CARE PA, V34, P363, DOI 10.1016/j.accpm.2015.04.007; Cross Robert W, 2017, Methods Mol Biol, V1628, P363, DOI 10.1007/978-1-4939-7116-9_29; Cross RW, 2016, J INFECT DIS, V214, pS210, DOI 10.1093/infdis/jiw293; de La Vega MA, 2016, EXPERT REV ANTI-INFE, V14, P557, DOI 10.1080/14787210.2016.1176912; de Wit E, 2016, J INFECT DIS, V214, pS303, DOI 10.1093/infdis/jiw187; Dedkov VG, 2018, HEALTH SECUR, V16, P14, DOI 10.1089/hs.2017.0027; Dhama K, 2015, J INFECT DEV COUNTR, V9, P441, DOI 10.3855/jidc.6197; Diarra B, 2016, J INFECT DIS, V214, pS164, DOI 10.1093/infdis/jiw200; Donaldson H, 2018, INT J INFECT DIS, V12019712, P4; Du Y, 2017, ANGEW CHEM INT EDIT, V56, P992, DOI 10.1002/anie.201609108; Du Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep11039; Dubov A, 2016, ARCH PATHOL LAB MED, V140, P171, DOI 10.5858/arpa.2015-0134-RA; Emergency Use FDA, 2017, AUTH MED PROD REL AU; Fallah MP, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002227; FDA, 2017, EM US AUTH MED PROD; Feldmann H, 2003, NAT REV IMMUNOL, V3, P677, DOI 10.1038/nri1154; Flint M, 2015, J INFECT DIS, V212, pS350, DOI 10.1093/infdis/jiv361; GAO, 2016, EM FUND EB RESP US R; GAO, 2017, ANT FDA HAS ENC DEV; GAO, 2017, EM INF DIS ACT NEED; GAO, 2004, INF DIS PREP FED CHA; GAO, 2000, GLOB HLTH FRAM INF D; GAO, 2017, MED DEV CAP CHALL TE; GAO, 2017, RAP SIM DIAGN MULT H; Gardy JL, 2018, NAT REV GENET, V19, P9, DOI 10.1038/nrg.2017.88; Gay-Andrieu F, 2017, J CLIN VIROL, V92, P20, DOI 10.1016/j.jcv.2017.04.015; Geisbert TW, 2003, AM J PATHOL, V163, P2347, DOI 10.1016/S0002-9440(10)63591-2; Gilbert GL, 2015, PATHOLOGY, V47, P400, DOI 10.1097/PAT.0000000000000295; Gonzalez JP, 2018, MED SANTE TROP, V28, P12, DOI 10.1684/mst.2018.0751; Gonzalez VM, 2016, PHARMACEUTICALS, V9, DOI 10.3390/ph9040078; Grolla A, 2005, Bull Soc Pathol Exot, V98, P205; Grolla A, 2012, ZOONOSES PUBLIC HLTH, V59, P151, DOI 10.1111/j.1863-2378.2012.01477.x; Harmon JR, 2017, VIRAL IMMUNOL, V30, P671, DOI 10.1089/vim.2017.0088; Herstein JJ, 2017, J PUBLIC HLTH MANAGE; Hill CE, 2014, LABMEDICINE, V45, pE109, DOI 10.1309/LMTMW3VVN20HIFS; Ignatiev GM, 2000, IMMUNOL LETT, V71, P131, DOI 10.1016/S0165-2478(99)00169-8; Irenge LM, 2017, CLIN CHEM LAB MED, V55, P1881, DOI 10.1515/cclm-2016-0456; Jelden KC, 2016, J CLIN MICROBIOL, V54, P1031, DOI 10.1128/JCM.02905-15; Kager P A, 1998, Ned Tijdschr Geneeskd, V142, P448; Kaushik A, 2016, BIOSENS BIOELECTRON, V75, P254, DOI 10.1016/j.bios.2015.08.040; Kennedy SB, 2016, AFR J LAB MED, V5, DOI 10.4102/ajlm.v5i3.508; Kost GJ, 2016, PRACTICAL GUIDE TO GLOBAL POINT-OF-CARE TESTING, P291; Kost GJ, 2016, POINT CARE, V15, P43, DOI 10.1097/POC.0000000000000080; Kost GJ, 2015, EXPERT REV MOL DIAGN, V15, P1245, DOI 10.1586/14737159.2015.1079776; Kost Gerald J, 2015, Am J Disaster Med, V10, P121, DOI 10.5055/ajdm.2015.0196; Kost GJ, 2001, ARCH PATHOL LAB MED, V125, P1307; Kost GJ, 2017, WORLDLAB2017 INT C C; Kost GJ, 2015, GLOBAL POINT CARE ST, P595; Kost GJ, 2015, CLIN LAB INT, V39, P6; Kost GJ, 2015, GLOBAL POINT CARE ST; Krahling V, 2016, MED MICROBIOL IMMUN, V205, P173, DOI 10.1007/s00430-015-0438-6; Kurosaki Y, 2010, J CLIN MICROBIOL, V48, P2330, DOI 10.1128/JCM.01224-09; Lamontagne F, 2018, LANCET LONDON ENGLAN, V391, P700; Le AB, 2018, AM J INFECT CONTROL, V46, P246, DOI 10.1016/j.ajic.2017.09.024; LeBlanc JJ, 2016, ANN CLIN BIOCHEM, V53, P288, DOI 10.1177/0004563215581651; Levine AC, 2015, ANN EMERG MED, V66, P285, DOI 10.1016/j.annemergmed.2015.03.011; Liu J, 2016, J CLIN MICROBIOL, V54, P49, DOI 10.1128/JCM.02257-15; Logue CH, 2017, PHILOS T R SOC B, V372, P1721; Logue J, 2018, J VIROL METHODS, V255, P84, DOI 10.1016/j.jviromet.2018.02.018; Louie RFFW, 2015, GLOBAL POINT CARE ST, P293; Lowenthal J, 2016, J INFECT PUBLIC HEAL, V9, P236, DOI 10.1016/j.jiph.2016.04.007; Magro L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00758-9; Mann P, 2015, GLOBAL POINT CARE ST, P356; Mashamba-Thompson TP, 2018, BMC HEALTH SERV RES, V18, P1; McDowell A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193656; Moschos Sterghios A, 2015, Hell J Nucl Med, V18 Suppl 1, P144; Moschos SA, 2015, EXPERT REV MOL DIAGN, V15, P1237, DOI 10.1586/14737159.2015.1084228; Nakayama E, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00267; Nicholson-Roberts T, 2015, QJM-INT J MED, V108, P571, DOI 10.1093/qjmed/hcv092; Nouvellet P, 2015, NATURE, V528, pS109, DOI 10.1038/nature16041; O'Shea MK, 2015, CLIN INFECT DIS, V61, P795, DOI 10.1093/cid/civ399; Otter JA, 2015, J HOSP INFECT, V89, P229, DOI 10.1016/j.jhin.2015.02.004; Owen WE, 2015, CLIN CHIM ACTA, V446, P119, DOI 10.1016/j.cca.2015.03.044; Perkins MD, 2017, LANCET, V390, P2111, DOI 10.1016/S0140-6736(17)31224-2; Phan JC, 2016, J INFECT DIS, V214, pS222, DOI 10.1093/infdis/jiw251; Pollock NR, 2017, J CLIN MICROBIOL, V55, P1255, DOI [10.1128/jcm.00053-17, 10.1128/JCM.00053-17]; Racsa LD, 2016, CLIN INFECT DIS, V62, P214, DOI 10.1093/cid/civ792; Raftery P, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006135; Rieger T, 2016, J INFECT DIS, V214, pS243, DOI 10.1093/infdis/jiw246; Roca A, 2015, J ALLERGY CLIN IMMUN, V135, P856, DOI 10.1016/j.jaci.2015.02.015; Rosenstierne MW, 2016, J CLIN MICROBIOL, V54, P2521, DOI 10.1128/JCM.00346-16; Saijo Masayuki, 2015, Virus (Nagoya), V65, P89, DOI 10.2222/jsv.65.89; Schieffelin J, 2016, CLIN TRIALS, V13, P66, DOI 10.1177/1740774515621013; Semper AE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1001980; Shephard M, 2016, PRACTICAL GUIDE TO GLOBAL POINT-OF-CARE TESTING, P1; Shorten RJ, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004948; Shurtleff AC, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00108; Singh Bharti, 2016, J Pharm Pharm Sci, V19, P530, DOI 10.18433/J38C9N; Singh RK, 2017, VET QUART, V37, P98, DOI 10.1080/01652176.2017.1309474; Southern TR, 2015, J CLIN MICROBIOL, V53, P2956, DOI 10.1128/JCM.01317-15; Steele Keith E, 2007, US Army Med Dep J, P28; Storry JR, 2016, LAKARTIDNINGEN, P113; Strecker T, 2015, CLIN INFECT DIS, V61, P669, DOI 10.1093/cid/civ397; Stroher U, 2006, EXPERT OPIN INV DRUG, V15, P1523, DOI 10.1517/13543784.15.12.1523; Swaan CM, 2018, J PUBLIC HEALTH MAN, V24, P18, DOI 10.1097/PHH.0000000000000573; Titenko A. M., 2002, Zhurnal Mikrobiologii Epidemiologii i Immunobiologii, P116; Umubyeyi AN, 2016, PUBLIC HEALTH ACTION, V6, P32, DOI 10.5588/pha.15.0069; van Griensven J, 2016, EMERG INFECT DIS, V22, P2120, DOI 10.3201/eid2212.161136; van Vuren PJ, 2016, J CLIN MICROBIOL, V54, P359, DOI 10.1128/JCM.02724-15; VanSteelandt A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188047; Wadman MC, 2015, ANN EMERG MED, V66, P306, DOI 10.1016/j.annemergmed.2015.04.020; Wandtke T, 2015, VIRUSES-BASEL, V7, P751, DOI 10.3390/v7020751; Wang SQ, 2016, EXPERT REV MOL DIAGN, V16, P449, DOI 10.1586/14737159.2016.1142877; Weller SA, 2016, J CLIN MICROBIOL, V54, P114, DOI 10.1128/JCM.02287-15; Whitehouse CA, 2015, EXPERT REV MOL DIAGN, V15, P1231, DOI 10.1586/14737159.2015.1077117; WHO, 2016, GUID COR COMP INF PR; Wolfel R, 2015, EUROSURVEILLANCE, V20, P31, DOI 10.2807/1560-7917.ES.2015.20.44.30055; Woolhouse MEJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0191; Zantek ND, 2016, AM J CLIN PATHOL, V146, P378, DOI [10.1093/ajcp/aqw121, 10.1093/AJCP/AQW121]; Zhang Y, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005622	127	2	2	5	15	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					657	673		10.1080/14737159.2018.1491793			17	Pathology	Pathology	GP3EX	WOS:000440725900008	29933717				2019-10-28	
J	Mellis, R; Chandler, N; Chitty, LS				Mellis, Rhiannon; Chandler, Natalie; Chitty, Lyn S.			Next-generation sequencing and the impact on prenatal diagnosis	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Prenatal diagnosis; next-generation sequencing; noninvasive prenatal diagnosis; monogenic disorders; cell-free fetal DNA; single gene disorders; exome sequencing; fetal abnormalities	FREE FETAL DNA; SINGLE-GENE DISORDERS; CELL-FREE DNA; RELATIVE HAPLOTYPE DOSAGE; MATERNAL PLASMA; CYSTIC-FIBROSIS; DIAPHRAGMATIC-HERNIA; MOLECULAR-PATHOLOGY; MONOGENIC DISORDERS; INCIDENTAL FINDINGS	Introduction: The advent of affordable and rapid next-generation sequencing has been transformative for prenatal diagnosis. Sequencing of cell-free DNA in maternal plasma has enabled the development of not only a highly sensitive screening test for fetal aneuploidies, but now definitive noninvasive prenatal diagnosis for monogenic disorders at an early gestation. Sequencing of fetal exomes offers broad diagnostic capability for pregnancies with unexpected fetal anomalies, improving the yield and accuracy of diagnoses and allowing better counseling for parents. The challenge now is to translate these approaches into mainstream use in the clinic.Areas covered: Here, the authors review the current literature to describe the technologies available and how these have evolved. The opportunities and challenges at hand, including considerations for service delivery, counseling, and development of ethical guidelines, are discussed.Expert commentary: As technology continues to advance, future developments may be toward noninvasive fetal whole exome or whole genome sequencing and a universal method for noninvasive prenatal diagnosis without the need to sequence both parents or an affected proband. Expansion of cell-free fetal DNA analysis to include the transcriptome and the methylome is likely to yield clinical benefits for monitoring other pregnancy-related pathologies such as preeclampsia and intrauterine growth restriction.	[Mellis, Rhiannon; Chitty, Lyn S.] Great Ormond St NHS Fdn Trust, Genet & Genom Med, London, England; [Chandler, Natalie] Great Ormond St NHS Fdn Trust, North Thames NHS Reg Genet Serv, London, England; [Chitty, Lyn S.] UCL Great Ormond St Inst Child Hlth, Genet & Genom Med, London, England	Chitty, LS (reprint author), Great Ormond St NHS Fdn Trust, Great Ormond St, London, England.	l.chitty@ucl.ac.uk			NIHR Biomedical Research Centre at Great Ormond Street Hospital	LS Chitty is partially funded by the NIHR Biomedical Research Centre at Great Ormond Street Hospital. The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.	Abou Tayoun AN, 2018, PRENATAL DIAG, V38, P26, DOI 10.1002/pd.5038; Alberry M, 2007, PRENATAL DIAG, V27, P415, DOI 10.1002/pd.1700; Arzt W, 2011, PRENATAL DIAG, V31, P695, DOI 10.1002/pd.2810; Bayefsky MJ, 2016, PRENATAL DIAG, V36, P1250, DOI 10.1002/pd.4968; Best S, 2018, PRENATAL DIAG, V38, P10, DOI 10.1002/pd.5102; Beta J, 2018, MINERVA GINECOL, V70, P215, DOI 10.23736/S0026-4784.17.04178-8; Borry P, 2009, EUR J HUM GENET, V17, P711, DOI 10.1038/ejhg.2009.25; Breman AM, 2016, PRENATAL DIAG, V36, P1009, DOI 10.1002/pd.4924; Chandler N, 2018, GENET MED; Chen F, 2017, PRENATAL DIAG, V37, P1311, DOI 10.1002/pd.5186; Chitty L, 2017, PRENAT DIAGN S1, V37, P3; Chitty L. S., 2016, ULTRASOUND OBSTET S1, V48, P356, DOI [10.1002/uog.17084, DOI 10.1002/U0G.17084]; Chitty LS, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023085; Chitty LS, 2015, PRENATAL DIAG, V35, P656, DOI 10.1002/pd.4583; Chitty LS, 2013, PRENATAL DIAG, V33, P416, DOI 10.1002/pd.4066; Chiu EKL, 2018, PRENATAL DIAG, V38, P52, DOI 10.1002/pd.5207; Devaney SA, 2011, JAMA-J AM MED ASSOC, V306, P627, DOI 10.1001/jama.2011.1114; Drury S, 2015, PRENATAL DIAG, V35, P1010, DOI 10.1002/pd.4675; Gonzalez-Gonzalez MC, 2002, PRENATAL DIAG, V22, P946, DOI 10.1002/pd.439; Green RC, 2013, GENET MED, V15, P565, DOI 10.1038/gim.2013.73; Hartwig TS, 2017, PRENATAL DIAG, V37, P527, DOI 10.1002/pd.5049; Hayward J, 2018, SEMIN FETAL NEONAT M, V23, P94, DOI 10.1016/j.siny.2017.12.002; Henson M, 2018, PRENAT DIAGN, V38, P6, DOI [10.1002/pd.5195, DOI 10.1002/PD.5195]; Hill M, 2011, CLIN GENET, V80, P68, DOI 10.1111/j.1399-0004.2010.01533.x; Hill M, 2017, PRENATAL DIAG, V37, P1281, DOI 10.1002/pd.5182; Hill M, 2015, PRENATAL DIAG, V35, P950, DOI 10.1002/pd.4585; Hill M, 2014, J GENET COUNS, V23, P1012, DOI 10.1007/s10897-014-9725-4; Hill M, 2013, AM J MED GENET A, V161A, P1612, DOI 10.1002/ajmg.a.35972; Horn R, 2018, PRENATAL DIAG, V38, P20, DOI 10.1002/pd.5114; Hui WWI, 2017, CLIN CHEM, V63, P513, DOI 10.1373/clinchem.2016.268375; Hui WWI, 2016, CURR OPIN OBSTET GYN, V28, P105, DOI 10.1097/GCO.0000000000000252; Jani JC, 2009, ULTRASOUND OBST GYN, V34, P304, DOI 10.1002/uog.6450; Jenkins LA, 2018, PRENATAL DIAG, V38, P44, DOI 10.1002/pd.5197; Jiang PY, 2016, TRENDS GENET, V32, P360, DOI 10.1016/j.tig.2016.03.009; Kalynchuk EJ, 2015, PRENATAL DIAG, V35, P1030, DOI 10.1002/pd.4635; Kinnings SL, 2015, PRENATAL DIAG, V35, P816, DOI 10.1002/pd.4625; Kitzman JO, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004323; Lewis C, 2014, CLIN GENET, V85, P336, DOI 10.1111/cge.12179; Li Y, 2005, JAMA-J AM MED ASSOC, V293, P843, DOI 10.1001/jama.293.7.843; Lo YMD, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001720; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; Lun FMF, 2008, P NATL ACAD SCI USA, V105, P19920, DOI 10.1073/pnas.0810373105; Mesens T, 2013, GENET COUNSEL, V24, P367; Parks M, 2017, EUR J HUM GENET, V25, P416, DOI 10.1038/ejhg.2016.195; Parks M, 2016, PRENATAL DIAG, V36, P312, DOI 10.1002/pd.4781; Peffer ME, 2015, MOL ENDOCRINOL, V29, P658, DOI 10.1210/me.2015-1042; Perlado S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153258; Pfeifer I, 2016, PLACENTA, V37, P56, DOI 10.1016/j.placenta.2015.11.002; Quinlan-Jones E, 2017, PRENATAL DIAG, V37, P1225, DOI 10.1002/pd.5172; Quinlan-Jones E, 2016, PRENATAL DIAG, V36, P935, DOI 10.1002/pd.4916; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Ross LF, 2013, GENET MED, V15, P321, DOI [10.1038/gim.2013.39, 10.1038/gim.2012.176]; Sabatini LM, 2016, J MOL DIAGN, V18, P319, DOI 10.1016/j.jmoldx.2015.11.010; Schmidts M, 2013, J MED GENET, V50, P309, DOI 10.1136/jmedgenet-2012-101284; Seravalli V, 2017, PRENATAL DIAG, V37, P1046, DOI 10.1002/pd.5139; Shih DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016090; Skirton H, 2014, EUR J HUM GENET, V22, P580, DOI 10.1038/ejhg.2013.205; Sun K, 2018, PRENATAL DIAG, V38, P196, DOI 10.1002/pd.5214; Tardy-Guidollet V, 2014, J CLIN ENDOCR METAB, V99, P1180, DOI 10.1210/jc.2013-2895; Tsui NBY, 2011, BLOOD, V117, P3684, DOI 10.1182/blood-2010-10-310789; van der Schoot CE, 2017, CURR OPIN HEMATOL, V24, P544, DOI 10.1097/MOH.0000000000000379; Verhoef TI, 2016, PRENATAL DIAG, V36, P636, DOI 10.1002/pd.4832; Vestergaard EM, 2017, PRENATAL DIAG, V37, P1120, DOI 10.1002/pd.5150; Vora NL, 2017, GENET MED, V19, P1207, DOI 10.1038/gim.2017.33; Wang E, 2013, PRENATAL DIAG, V33, P662, DOI 10.1002/pd.4119; Wapner R, 2017, AM J OBSTET GYNECOL, V216, pS5; Westerfield L, 2014, J CLIN MED, V3, P1018, DOI 10.3390/jcm3031018; Westgren M, 2015, PRENATAL DIAG, V35, P827, DOI 10.1002/pd.4611; White HE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045073; Wilkie AOM, 2017, PRENATAL DIAG, V37, P946, DOI 10.1002/pd.5108; Xiong L, 2015, PRENATAL DIAG, V35, P258, DOI 10.1002/pd.4536; Yurkiewicz IR, 2014, OBSTET GYNECOL SURV, V69, P197, DOI 10.1097/01.ogx.0000446907.09890.ff; Zhang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054465; Zhang Y, 2017, INT J GYNECOL OBSTET, V139, P248, DOI 10.1002/ijgo.12269	74	2	3	1	13	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					689	699		10.1080/14737159.2018.1493924			11	Pathology	Pathology	GP3FD	WOS:000440726700002	29962246				2019-10-28	
J	Baptista, PV				Baptista, Pedro, V			Gold nanoprobe-based non-crosslinking hybridization for molecular diagnostics: an update	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Molecular diagnostics; gold nanoparticles; nanoprobes; non-cross-linking; nanodiagnostics; DNA; RNA; biodetection	NUCLEIC-ACID LNA; COLORIMETRIC DETECTION; DNA HYBRIDIZATION; NANOPARTICLES; AGGREGATION; ASSAY; RECOGNITION; RESONANCE; DYNAMICS; FUTURE	Introduction: An update on the uses and applications of the non-cross-linking (NCL) hybridization assay based on the spectral modulation of gold nanoparticles (AuNPs) are presented, emphasizing DNA arid RNA detection. Areas covered: Nanotechnology is strongly impacting the way we address diagnostics and therapeutics. In fact, nanoscale devices and particles have been used in a variety of platforms for improved biosensing and, more interestingly, for molecular diagnostics. AuNPs have been used in a great diversity of DNA and RNA detection strategies that are based on their nanoscale properties. Their unique optical properties have put them at the forefront of colorimetric sensing platforms. Among these, those relying on the NCL mechanism using DNA-modified AuNPs have shown remarkable versatility and simplicity for molecular detection of human pathogens, identification of single base alterations at the basis of human disease, gene expression, among others. Application of the NCL assay to molecular diagnostics will be discussed considering the challenges for validation and clinically relevant targets. Expert commentary: Integration of the NCL approach using AuNPs into chip biosensing platforms, projecting miniaturization and portability, will be addressed in terms of the future, i.e. clinical validation and translation to market.	[Baptista, Pedro, V] Univ NOVA Lisboa, Fac Ciencias & Tecnol, Dept Life Sci, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal	Baptista, PV (reprint author), Univ NOVA Lisboa, Fac Ciencias & Tecnol, Dept Life Sci, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.	pmvb@fct.unl.pt	Fernandes, Alexandra R/C-7465-2011; Baptista, Pedro/A-1237-2009; Baptista, Pedro/P-3182-2019	Fernandes, Alexandra R/0000-0003-2054-4438; Baptista, Pedro/0000-0001-5255-7095; Baptista, Pedro/0000-0001-5255-7095			Alves PU, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18725-9; [Anonymous], 2017, EM SENS TECHN TRANSF; Baptista P, 2005, J BIOTECHNOL, V119, P111, DOI 10.1016/j.jbiotec.2005.02.019; Baptista PV, 2006, CLIN CHEM, V52, P1433, DOI 10.1373/clinchem.2005.065391; Baptista PV, 2012, CLIN LAB MED, V32, P1, DOI 10.1016/j.cll.2011.09.001; Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2; Carlos FF, 2014, ANAL BIOCHEM, V12, P2; Carter JR, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-201; Cate DM, 2015, ANAL CHEM, V87, P19, DOI 10.1021/ac503968p; Conde J, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00048; Cordeiro M, 2016, DIAGNOSTICS, V6, DOI 10.3390/diagnostics6040043; Costa MN, 2014, NANOTECHNOLOGY, V25, DOI 10.1088/0957-4484/25/9/094006; Costa P, 2010, CLIN MICROBIOL INFEC, V16, P1464, DOI [10.1111/j.1469-0691.2009.03120.x, 10.1111/j.1469-0691.2010.03120.x]; Dincer C, 2017, TRENDS BIOTECHNOL, V35, P728, DOI 10.1016/j.tibtech.2017.03.013; Doria G, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/25/255101; Eustis S, 2006, CHEM SOC REV, V35, P209, DOI 10.1039/b514191e; Gambhir SS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3612; Gao ZF, 2015, BIOSENS BIOELECTRON, V65, P360, DOI 10.1016/j.bios.2014.10.061; Hermann T, 2000, SCIENCE, V287, P820, DOI 10.1126/science.287.5454.820; Hu B, 2017, ANAL BIOANAL CHEM, V409, P4819, DOI 10.1007/s00216-017-0425-4; Huang J, 2016, INT J NANOMED, V11, P5335, DOI 10.2147/IJN.S116288; Huckle D, 2015, EXPERT REV MOL DIAGN, V15, P815, DOI 10.1586/14737159.2015.1033405; Jain PK, 2008, ACCOUNTS CHEM RES, V41, P1578, DOI 10.1021/ar7002804; Jung YL, 2018, NANOSCALE, V10, P4339, DOI 10.1039/c7nr09542b; Kim TY, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8020081; Koo KM, 2017, LAB CHIP, V17, P3200, DOI 10.1039/c7lc00587c; Kumar-Sinha C, 2018, NAT BIOTECHNOL, V36, P46, DOI 10.1038/nbt.4017; Larguinho M, 2015, EXPERT REV MOL DIAGN, V15, P1355, DOI 10.1586/14737159.2015.1077704; Lei KF, 2013, RECENT PAT NANOTECH, V7, P81; Li SF, 2010, JALA-J LAB AUTOM, V15, P107, DOI 10.1016/j.jala.2009.11.001; Li S, 2017, ANAL BIOCHEM, V528, P47, DOI 10.1016/j.ab.2017.04.013; Li X, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.3687398; Liana DD, 2012, SENSORS-BASEL, V12, P11505, DOI 10.3390/s120911505; Link S, 2003, ANNU REV PHYS CHEM, V54, P331, DOI 10.1146/annurev.physchem.54.011002.103759; Lisowski P, 2013, CHROMATOGRAPHIA, V76, P1201, DOI 10.1007/s10337-013-2413-y; Ma Q, 2018, FOOD CHEM, V249, P98, DOI 10.1016/j.foodchem.2018.01.022; Mazumdar D, 2010, CHEM COMMUN, V46, P1416, DOI 10.1039/b917772h; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; Mollasalehi H, 2012, ANAL BIOCHEM, V425, P91, DOI 10.1016/j.ab.2012.03.008; Pal D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180919; Pande V, 2008, NUCLEIC ACIDS RES, V36, P1508, DOI 10.1093/nar/gkm1182; Pedrosa P, 1853, NANOMATERIALS, V2015; Pedrosa P, 2014, TUBERCULOSIS, V94, P332, DOI 10.1016/j.tube.2013.12.009; Peixoto de Almeida M, 2014, COMPREHENSIVE ANAL C, V66, P529; Sato K, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni007; Shakeel S, 2006, J CHEM TECHNOL BIOT, V81, P892, DOI 10.1002/jctb.1505; Storhoff JJ, 1998, J AM CHEM SOC, V120, P1959, DOI 10.1021/ja972332i; Rozenblum GT, 2016, EXPERT OPIN DRUG DIS, V11, P127, DOI 10.1517/17460441.2016.1126244; Veigas B, 2013, J NANOBIOTECHNOL, V11, DOI 10.1186/1477-3155-11-38; Veigas B, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/41/415101; Vinhas R, 2016, ANAL BIOANAL CHEM, V408, P5277, DOI 10.1007/s00216-016-9622-9; Viskari PJ, 2006, ELECTROPHORESIS, V27, P1797, DOI 10.1002/elps.200500565; Wang EC, 2014, INTEGR BIOL-UK, V6, P9, DOI 10.1039/c3ib40165k; Wang GQ, 2017, BIOCONJUGATE CHEM, V28, P270, DOI 10.1021/acs.bioconjchem.6b00410; Whitesides GM, 2006, NATURE, V442, P368, DOI 10.1038/nature05058; Wu JK, 2011, ANAL CHIM ACTA, V694, P115, DOI 10.1016/j.aca.2011.02.045; Yuan Y, 2011, BIOSENS BIOELECTRON, V26, P4245, DOI 10.1016/j.bios.2011.04.021	57	0	0	2	5	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	9					767	773		10.1080/14737159.2018.1503950			7	Pathology	Pathology	GR6IV	WOS:000442753800001	30037279				2019-10-28	
J	McGill, MR; Jaeschke, H				McGill, Mitchell R.; Jaeschke, Hartmut			Biomarkers of drug-induced liver injury: progress and utility in research, medicine, and regulation	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Hepatotoxicity; adverse drug reactions; idiosyncratic drug toxicity; acetaminophen	ACETAMINOPHEN-PROTEIN ADDUCTS; GLUTATHIONE S-TRANSFERASE; PRIMARY HUMAN HEPATOCYTES; INDUCED CELL-DEATH; ALANINE AMINOTRANSFERASE; INDUCED HEPATOTOXICITY; CIRCULATING MICRORNAS; UNITED-STATES; MITOCHONDRIAL DYSFUNCTION; OVERDOSE PATIENTS	Introduction: The difficulty of understanding and diagnosing drug-induced liver injury (DILI) has led to proliferation of serum and genetic biomarkers. Many applications of these biomarkers have been proposed, including investigation of mechanisms, prediction of DILI during early trials or before initiation of therapy in patients, and diagnosis of DILI during therapy. Areas covered: We review the definition and categories of DILI, describe recent developments in DILI biomarker development, and provide guidance for future directions in DILI biomarker research. Expert commentary: There are major obstacles to DILI biomarker development and implementation, including the low prevalence of idiosyncratic DILI (IDILI), weak associations of IDILI with genetic variants, and lack of specificity of many biomarkers for the liver. Certain serum biomarkers, like miR-122, may have clinical utility in early-presenting patients with either intrinsic or idiosyncratic DILI in the future, while others likely will not find use. Future research should focus on implementation of biomarkers to predict later injury and outcome in early presenters with intrinsic DILI, and on development of biomarkers of adaptation and repair in the liver that can be used to determine if a liver test abnormality is likely to be clinically significant in IDILI.	[McGill, Mitchell R.] Univ Arkansas Med Sci, Fay W Boozman Coll Publ Hlth, Dept Environm & Occupat Hlth, Little Rock, AR 72205 USA; [McGill, Mitchell R.] Univ Arkansas Med Sci, Coll Med, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; [Jaeschke, Hartmut] Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, 3901 Rainbow Blvd,MS 1018, Kansas City, KS 66160 USA	Jaeschke, H (reprint author), Univ Kansas, Med Ctr, Dept Pharmacol Toxicol & Therapeut, 3901 Rainbow Blvd,MS 1018, Kansas City, KS 66160 USA.	hjaeschke@kumc.edu		McGill, Mitchell/0000-0002-0401-0463	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01 DK102142]; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30 GM118247, P20 GM103549]		Alfirevic A, 2012, CLIN PHARMACOL THER, V92, P376, DOI 10.1038/clpt.2012.107; Andersson U, 2009, BIOMARKERS, V14, P572, DOI 10.3109/13547500903261354; Antoine DJ, 2013, HEPATOLOGY, V58, P777, DOI 10.1002/hep.26294; Arai M, 2006, SCAND J GASTROENTERO, V41, P102, DOI 10.1080/00365520510024061; Bajt ML, 2006, TOXICOL SCI, V94, P217, DOI 10.1093/toxsci/kfl077; Bajt ML, 2011, TOXICOL SCI, V122, P598, DOI 10.1093/toxsci/kfr116; Bala S, 2012, HEPATOLOGY, V56, P1946, DOI 10.1002/hep.25873; BANERJEE AK, 1988, HUM TOXICOL, V7, P561, DOI 10.1177/096032718800700608; Bartels S, 2008, CLIN TOXICOL, V46, P243, DOI 10.1080/15563650701447020; BECKETT GJ, 1985, GUT, V26, P26, DOI 10.1136/gut.26.1.26; BECKETT GJ, 1989, CLIN CHEM, V35, P2186; BERSON A, 1994, J HEPATOL, V20, P336, DOI 10.1016/S0168-8278(94)80004-9; Bhattacharyya S, 2014, BIOMARK MED, V8, P147, DOI 10.2217/bmm.13.150; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Bjornsson ES, 2013, GASTROENTEROLOGY, V144, P1419, DOI 10.1053/j.gastro.2013.02.006; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Budnitz DS, 2011, AM J PREV MED, V40, P585, DOI 10.1016/j.amepre.2011.02.026; Bunchorntavakul C, 2018, CLIN LIVER DIS, V22, P325, DOI 10.1016/j.cld.2018.01.007; Chalasani N, 2015, GASTROENTEROLOGY, V148, P1340, DOI 10.1053/j.gastro.2015.03.006; Chen CC, 2016, AM J THER, V23, pE260, DOI 10.1097/MJT.0000000000000149; Chen MJ, 2015, J HEPATOL, V63, P503, DOI 10.1016/j.jhep.2015.04.016; Chen MJ, 2013, HEPATOLOGY, V58, P388, DOI 10.1002/hep.26208; Cho T, 2017, CHEM RES TOXICOL, V30, P295, DOI 10.1021/acs.chemrestox.6b00357; Church RJ, 2019, HEPATOLOGY, V69, P760, DOI 10.1002/hep.29802; Court MH, 2017, J PHARMACOL EXP THER, V362, P431, DOI 10.1124/jpet.117.242107; Court MH, 2014, DRUG METAB DISPOS, V42, P28, DOI 10.1124/dmd.113.053546; Daly AK, 2007, GASTROENTEROLOGY, V132, P272, DOI 10.1053/j.gastro.2006.11.023; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Dart RC, 2006, CLIN TOXICOL, V44, P1, DOI 10.1080/15563650500394571; Dart RC, 2007, PHARMACOTHERAPY, V27, P1219, DOI 10.1592/phco.27.9.1219; Davern TJ, 2006, GASTROENTEROLOGY, V130, P687, DOI 10.1053/j.gastro.2006.01.033; Dear JW, 2018, LANCET GASTROENTEROL, V3, P104, DOI 10.1016/S2468-1253(17)30266-2; Dhupar R, 2011, SHOCK, V35, P293, DOI 10.1097/SHK.0b013e3181f6aab0; Donaldson PT, 2010, J HEPATOL, V53, P1049, DOI 10.1016/j.jhep.2010.05.033; Du K, 2015, EXPERT OPIN DRUG MET, V11, P1769, DOI 10.1517/17425255.2015.1071353; EADE OE, 1978, LANCET, V2, P1384; Esteban A, 1999, EUR J DRUG METAB PH, V24, P9, DOI 10.1007/BF03190005; Grecian R, 2012, BMJ CASE REP; Gujral JS, 2002, TOXICOL SCI, V67, P322, DOI 10.1093/toxsci/67.2.322; Haas DW, 2006, CLIN INFECT DIS, V43, P783, DOI 10.1086/507097; Han Derick, 2010, Handb Exp Pharmacol, P267, DOI 10.1007/978-3-642-00663-0_10; Hautekeete ML, 1999, GASTROENTEROLOGY, V117, P1181, DOI 10.1016/S0016-5085(99)70404-X; He Y, 2017, HEPATOLOGY, V66, P220, DOI 10.1002/hep.29153; Heard K, 2007, ALIMENT PHARM THERAP, V26, P283, DOI 10.1111/j.1365-2036.2007.03368.x; Heard K, 2016, BRIT J CLIN PHARMACO, V81, P562, DOI 10.1111/bcp.12831; Heard K, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-39; Heard KJ, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-20; Hirata K, 2008, PHARMACOGENOMICS J, V8, P29, DOI 10.1038/sj.tpj.6500442; Hu JT, 2016, TOXICOL SCI, V150, P204, DOI 10.1093/toxsci/kfv319; Huang YS, 2003, HEPATOLOGY, V37, P924, DOI 10.1053/jhep.2003.50144; Issa AM, 2007, CURR DRUG SAF, V2, P177, DOI 10.2174/157488607781668855; James LP, 2008, CLIN PHARMACOL THER, V84, P684, DOI 10.1038/clpt.2008.190; James L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131010; Kindmark A, 2008, PHARMACOGENOMICS J, V8, P186, DOI 10.1038/sj.tpj.6500458; Kohle C, 2003, BIOCHEM PHARMACOL, V65, P1521, DOI 10.1016/S0006-2952(03)00074-1; Kon K, 2004, HEPATOLOGY, V40, P1170, DOI 10.1002/hep.20437; Kowalec K, 2018, NAT GENET; Krauskopf J, 2015, TOXICOL SCI, V143, P268, DOI 10.1093/toxsci/kfu232; Kuffner EK, 2006, CURR MED RES OPIN, V22, P2137, DOI 10.1185/030079906X148346; Kuffner EK, 2001, ARCH INTERN MED, V161, P2247, DOI 10.1001/archinte.161.18.2247; Lammert C, 2008, HEPATOLOGY, V47, P2003, DOI 10.1002/hep.22272; Lammert C, 2010, HEPATOLOGY, V51, P615, DOI 10.1002/hep.23317; Lee KK, 2013, FREE RADICAL BIO MED, V65, P584, DOI 10.1016/j.freeradbiomed.2013.07.038; Lee VM, 2008, SEMIN LIVER DIS, V28, P142, DOI 10.1055/s-2008-1073114; Lee WM, 2012, BEST PRACT RES CL GA, V26, P3, DOI 10.1016/j.bpg.2012.01.014; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Lewis PJS, 2011, HEPATOLOGY, V54, P1767, DOI 10.1002/hep.24538; Li Jinze, 2010, Handb Exp Pharmacol, P493, DOI 10.1007/978-3-642-00663-0_18; LoGuidice A, 2011, HEPATOLOGY, V54, P969, DOI 10.1002/hep.24464; Lucena MI, 2011, GASTROENTEROLOGY, V141, P338, DOI 10.1053/j.gastro.2011.04.001; Luo LN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193824; Luo LN, 2014, TOXICOL SCI, V137, P12, DOI 10.1093/toxsci/kft221; Lutkewitte AJ, 2018, FOOD CHEM TOXICOL, V115, P273, DOI 10.1016/j.fct.2018.03.014; Major JM, 2016, PHARMACOEPIDEM DR S, V25, P590, DOI 10.1002/pds.3906; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Manthripragada AD, 2011, PHARMACOEPIDEM DR S, V20, P819, DOI 10.1002/pds.2090; Maria VAJ, 1997, GUT, V41, P534, DOI 10.1136/gut.41.4.534; Markova SM, 2013, CLIN PHARMACOL THER, V94, P678, DOI 10.1038/clpt.2013.143; Marques PE, 2012, HEPATOLOGY, V56, P1971, DOI 10.1002/hep.25801; Massart Julie, 2017, J Clin Transl Res, V3, P212, DOI 10.18053/jctres.03.2017S1.006; McGill MR, 2015, J CLIN MED, V4, P1063, DOI 10.3390/jcm4051063; McGill MR, 2014, HEPATOLOGY, V60, P1336, DOI 10.1002/hep.27265; McGill MR, 2014, BIOMARKERS, V19, P222, DOI 10.3109/1354750X.2014.897757; McGill MR, 2014, ARCH TOXICOL, V88, P391, DOI 10.1007/s00204-013-1118-1; McGill MR, 2013, PHARM RES-DORDR, V30, P2174, DOI 10.1007/s11095-013-1007-6; McGill MR, 2013, TOXICOL APPL PHARM, V269, P240, DOI 10.1016/j.taap.2013.03.026; McGill MR, 2012, TOXICOL APPL PHARM, V264, P387, DOI 10.1016/j.taap.2012.08.015; McGill MR, 2012, J CLIN INVEST, V122, P1574, DOI 10.1172/JCI59755; McGill MR, 2011, HEPATOLOGY, V53, P974, DOI 10.1002/hep.24132; Medina-Caliz I, 2016, J HEPATOL, V65, P532, DOI 10.1016/j.jhep.2016.05.003; Mikus M, 2017, LIVER INT, V37, P132, DOI 10.1111/liv.13174; Molleston JP, 2011, J PEDIATR GASTR NUTR, V53, P182, DOI 10.1097/MPG.0b013e31821d6cfd; Monshi MM, 2013, HEPATOLOGY, V57, P727, DOI 10.1002/hep.26077; Mosedale M, 2017, CLIN PHARMACOL THER, V101, P469, DOI 10.1002/cpt.564; Muldrew KL, 2002, DRUG METAB DISPOS, V30, P446, DOI 10.1124/dmd.30.4.446; NELSON RL, 1977, BIOCHEM GENET, V15, P87, DOI 10.1007/BF00484550; Nicoletti P, 2017, GASTROENTEROLOGY, V152, P1078, DOI 10.1053/j.gastro.2016.12.016; Nicoletti P, 2016, PHARMACOGENET GENOM, V26, P218, DOI 10.1097/FPC.0000000000000209; Nourjah P, 2006, PHARMACOEPIDEM DR S, V15, P398, DOI 10.1002/pds.1191; NYFORS A, 1976, ACTA DERM-VENEREOL, V56, P235; Onakpoya IJ, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0553-2; Ong MMK, 2007, TOXICOL SCI, V97, P205, DOI 10.1093/toxsci/kfl180; Phillips E, 2013, JAIDS-J ACQ IMM DEF, V62, pE55, DOI 10.1097/QAI.0b013e31827ca50f; Phillips EJ, 2013, AIDS, V27, P491, DOI 10.1097/QAD.0b013e32835ca9d5; Qi RQ, 2012, HEPATOLOGY, V55, P1640, DOI [10.1002/hep.25558, 10.1002/hep.25719]; Qin SZ, 2016, J PROTEOME RES, V15, P3724, DOI 10.1021/acs.jproteome.6b00547; RacineSamson L, 1996, HEPATOLOGY, V24, P104, DOI 10.1053/jhep.1996.v24.pm0008707247; Ramachandran A, 2013, HEPATOLOGY, V58, P2099, DOI 10.1002/hep.26547; Reddy KR, 2016, LIVER TRANSPLANT, V22, P505, DOI 10.1002/lt.24347; Rissin DM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179669; Rumack B, 2012, PHARMACOTHERAPY, V32, P784, DOI 10.1002/j.1875-9114.2012.01122.x; Russo MW, 2017, LIVER INT, V37, P757, DOI 10.1111/liv.13312; Saito C, 2010, HEPATOLOGY, V51, P246, DOI [10.1002/hep.2.3267, 10.1002/hep.23267]; Sato Y, 2004, TRANSPL P, V36, P2357, DOI 10.1016/j.transproceed.2004.07.006; Sato Y, 2004, TRANSPL P, V36, P2359, DOI 10.1016/j.transproceed.2004.07.007; Schiodt FV, 2006, LIVER TRANSPLANT, V12, P1776, DOI 10.1002/lt.20886; SCHMIDT ES, 1988, CLIN CHIM ACTA, V173, P43, DOI 10.1016/0009-8981(88)90356-7; Schmidt LE, 2005, HEPATOLOGY, V41, P26, DOI 10.1002/hep.20511; Schomaker S, 2013, TOXICOL SCI, V132, P276, DOI 10.1093/toxsci/kft009; Senior JR, 2008, HEPATOLOGY, V47, P1813, DOI 10.1002/hep.22332; Sharma M, 2012, MOL PHARMACOL, V82, P1001, DOI 10.1124/mol.112.079863; Sharma SK, 2002, AM J RESP CRIT CARE, V166, P916, DOI 10.1164/rccm.2108091; Sim E, 2008, TOXICOLOGY, V254, P170, DOI 10.1016/j.tox.2008.08.022; Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632; Slopianka M, 2017, TOXICOLOGY, V386, P1, DOI 10.1016/j.tox.2017.05.009; Solotke MT, 2018, EXPERT OPIN DRUG SAF, V17, P117, DOI 10.1080/14740338.2018.1415323; Spraggs CF, 2012, CLIN PHARMACOL THER, V91, P647, DOI 10.1038/clpt.2011.277; STRICKER BHC, 1988, HEPATOLOGY, V8, P599, DOI 10.1002/hep.1840080327; Uetrecht J, 2001, Curr Opin Drug Discov Devel, V4, P55; Uetrecht J, 2009, SEMIN LIVER DIS, V29, P383, DOI 10.1055/s-0029-1240007; Urban TJ, 2014, SEMIN LIVER DIS, V34, P123, DOI 10.1055/s-0034-1375954; Urban TJ, 2017, J HEPATOL, V67, P137, DOI 10.1016/j.jhep.2017.03.010; Vega M, 2017, DRUG SAFETY, V40, P783, DOI 10.1007/s40264-017-0547-9; Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031; Vitcheva V, 2012, CURR MED CHEM, V19, P5677, DOI 10.2174/092986712803988929; Vliegenthart ADB, 2017, BRIT J CLIN PHARMACO, V83, P2027, DOI 10.1111/bcp.13282; Walgren JL, 2005, CRIT REV TOXICOL, V35, P325, DOI 10.1080/10408440590935620; Wang GP, 2016, MOL BIOL REP, V43, P1371, DOI 10.1007/s11033-016-4071-2; Wang K, 2009, P NATL ACAD SCI USA, V106, P4402, DOI 10.1073/pnas.0813371106; Ward J, 2014, P NATL ACAD SCI USA, V111, P12169, DOI 10.1073/pnas.1412608111; Watkins PB, 2006, JAMA-J AM MED ASSOC, V296, P87, DOI 10.1001/jama.296.1.87; Weemhoff JL, 2017, LIVER INT, V37, P377, DOI 10.1111/liv.13202; Wen YK, 2015, INT J BIOL SCI, V11, P1236, DOI 10.7150/ijbs.12118; White KD, 2015, J ALLERGY CLIN IMMUN, V136, P219, DOI 10.1016/j.jaci.2015.05.050; Woolbright Benjamin L., 2017, Gene Expression, V17, P301, DOI 10.3727/105221617X15016197658871; Woolbright BL, 2014, TOXICOL SCI, V142, P436, DOI 10.1093/toxsci/kfu195; Xie YC, 2015, TOXICOL APPL PHARM, V289, P213, DOI 10.1016/j.taap.2015.09.022; Xie YC, 2015, XENOBIOTICA, V45, P921, DOI 10.3109/00498254.2015.1026426; Xie YC, 2014, TOXICOL APPL PHARM, V279, P266, DOI 10.1016/j.taap.2014.05.010; Xu CF, 2016, CLIN CANCER RES, V22, P1371, DOI 10.1158/1078-0432.CCR-15-2044; Yamazaki M, 2013, TOXICOL APPL PHARM, V268, P79, DOI 10.1016/j.taap.2013.01.018; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yang X, 2015, TOXICOL APPL PHARM, V284, P180, DOI 10.1016/j.taap.2015.02.013; Yimer G, 2012, PHARMACOGENOMICS J, V12, P499, DOI 10.1038/tpj.2011.34	155	3	3	0	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	9					797	807		10.1080/14737159.2018.1508998			11	Pathology	Pathology	GR6IV	WOS:000442753800004	30080986	Green Accepted			2019-10-28	
J	Gallinella, G				Gallinella, Giorgio			The clinical use of parvovirus B19 assays: recent advances	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Antibody detection; molecular diagnostic; parvovirus B19; qPCR assays; virus-host relationship	MASS-SPECTROMETRY ANALYSIS; BONE-MARROW BIOPSY; QUANTITATIVE PCR; IMMUNE-RESPONSE; LINEAR EPITOPES; STRUCTURAL PROTEINS; CUTANEOUS BIOPSIES; SERUM SAMPLES; BLOOD-DONORS; HUMAN VIROME	Introduction: Parvovirus B19 (B19V), a single-stranded DNA virus in the family Parvoviridae, is a human pathogenic virus, characterized by a selective but not exclusive tropism for erythroid progenitor cells. Widely diffuse, it is responsible for an ample range of clinical manifestations, whose characteristics and outcomes depend on the interplay between the viral properties and the physiological and immune status of the infected individuals. The complexity of virus-host relationship and the diversity of the clinical course of infection pose a diagnostic challenge that may require non-trivial solutions. Areas covered: The review includes an updated description of the course of B19V infection in its complexity and diversity of pathogenetic mechanisms, discusses the consequent requirements for different and appropriated diagnostic approaches, presents the main diagnostic techniques, more recent technical advancements, and their application to the diverse clinical situations. Expert commentary: The complex scenario of the infectious process and the diversity in possible pathogenetic mechanisms make necessary a multi-parametric approach for an accurate and informative laboratory diagnosis of B19V infection, combining as much as possible the molecular detection of viral components, mainly viral DNA, to commonly followed immunological detection of virus-specific antibodies and a critical assessment of laboratory findings.	[Gallinella, Giorgio] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy	Gallinella, G (reprint author), Univ Bologna, S Orsola Malpighi Hosp, Dept Pharm & Biotechnol, Microbiol, Via Massarenti 9, I-40138 Bologna, Italy.	giorgio.gallinella@unibo.it	Gallinella, Giorgio/H-6864-2017	Gallinella, Giorgio/0000-0003-1118-6341			Abrams S, 2015, BIOSTATISTICS, V16, P129, DOI 10.1093/biostatistics/kxu031; Adamson-Small LA, 2014, VIRUS RES, V190, P8, DOI 10.1016/j.virusres.2014.06.017; Bachelier K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176311; Barlinn R, 2017, J CLIN VIROL, V94, P57, DOI 10.1016/j.jcv.2017.07.010; Bascietto F, 2018, ULTRASOUND OBST GYN, V52, P569, DOI 10.1002/uog.19092; Baylis SA, 2012, VOX SANG, V102, P204, DOI 10.1111/j.1423-0410.2011.01541.x; Bock CT, 2014, WORLD J CARDIOL, V6, P183, DOI 10.4330/wjc.v6.i4.183; Bogdanovic G, 2016, BRIT J CANCER, V115, P1008, DOI 10.1038/bjc.2016.261; Bonjoch X, 2015, TRANSFUS MED HEMOTH, V42, P233, DOI 10.1159/000381979; Bonvicini F, 2009, BJOG-INT J OBSTET GY, V116, P813, DOI 10.1111/j.1471-0528.2009.02109.x; Bonvicini F, 2017, CURR OPIN VIROL, V27, P8, DOI 10.1016/j.coviro.2017.10.003; Bonvicini F, 2013, VIRUS RES, V178, P517, DOI 10.1016/j.virusres.2013.09.037; Bonvicini F, 2013, J CLIN MICROBIOL, V51, P3753, DOI 10.1128/JCM.01970-13; Bonvicini F, 2011, J CLIN MICROBIOL, V49, P3514, DOI 10.1128/JCM.00854-11; Bua G, 2017, FUTURE VIROL, V12, P549, DOI 10.2217/fvl-2017-0079; Bua G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148547; Corcoran C, 2010, J CLIN MICROBIOL, V48, P137, DOI 10.1128/JCM.00610-09; Cotmore SF, 2014, ARCH VIROL, V159, P1239, DOI 10.1007/s00705-013-1914-1; Crane J, 2014, J OBSTET GYNAECOL CA, V36, P1107, DOI 10.1016/S1701-2163(15)30390-X; De Cao E, 2014, BIOSTATISTICS, V15, P470, DOI 10.1093/biostatistics/kxu008; de Ory F, 2014, APMIS, V122, P223, DOI 10.1111/apm.12127; Eid AJ, 2013, AM J TRANSPLANT, V13, P201, DOI 10.1111/ajt.12111; Eis-Hubinger AM, 2014, TRANSFUSION, V54, P1682, DOI 10.1111/trf.12591; Gallinella G, 2003, J CLIN VIROL, V28, P1, DOI 10.1016/S1386-6532(03)00120-3; Gallinella G, 2003, J MED VIROL, V71, P135, DOI 10.1002/jmv.10452; Gallinella G, 2013, ISRN VIROL, DOI [10.5402/2013/898730, DOI 10.5402/2013/898730]; Ganaie SS, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00166; Ganaie SS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006370; Ganzel C, 2015, BLOOD, V125, P3351, DOI 10.1182/blood-2015-02-628008; Goeyvaerts N, 2011, BIOSTATISTICS, V12, P283, DOI 10.1093/biostatistics/kxq059; Greulich S, 2016, CLIN RES CARDIOL, V105, P37, DOI 10.1007/s00392-015-0884-6; Hellmund A, 2018, FETAL DIAGN THER, V43, P129, DOI 10.1159/000477208; Hubschen JM, 2009, J CLIN MICROBIOL, V47, P3735, DOI 10.1128/JCM.01201-09; Jain A, 2018, INFECT GENET EVOL, V57, P177, DOI 10.1016/j.meegid.2017.11.021; Jain A, 2016, J MED VIROL, V88, P1922, DOI 10.1002/jmv.24560; Janovitz T, 2017, VIROLOGY, V511, P40, DOI 10.1016/j.virol.2017.08.011; Juhl D, 2014, VOX SANG, V107, P226, DOI 10.1111/vox.12162; Juhl D, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00004; Kerr JR, 2016, J CLIN PATHOL, V69, P279, DOI 10.1136/jclinpath-2015-203455; Kerr JR, 2015, REV MED VIROL, V25, P224, DOI 10.1002/rmv.1839; Kerr S, 1999, J MED VIROL, V57, P179, DOI 10.1002/(SICI)1096-9071(199902)57:2<179::AID-JMV16>3.0.CO;2-T; Kuhl U, 2013, BASIC RES CARDIOL, V108, DOI 10.1007/s00395-013-0372-y; Lassen J, 2013, INT J EPIDEMIOL, V42, P1070, DOI 10.1093/ije/dyt117; Lecuit M, 2013, TRENDS MICROBIOL, V21, P510, DOI 10.1016/j.tim.2013.07.001; LeGoff J, 2013, J CLIN MICROBIOL, V51, P4186, DOI 10.1128/JCM.01978-13; LEISI R, 2016, VIRUSES-BASEL, V8, DOI DOI 10.3390/V8100265; Leisi R, 2013, J VIROL, V87, P13161, DOI 10.1128/JVI.02548-13; Leveque N, 2014, J CLIN MICROBIOL, V52, P212, DOI 10.1128/JCM.02270-13; Lindenburg ITM, 2014, FETAL DIAGN THER, V36, P263, DOI 10.1159/000362812; Lindenburg ITM, 2013, PRENATAL DIAG, V33, P815, DOI 10.1002/pd.4152; Luo Y, 2015, FUTURE VIROL, V10, P155, DOI 10.2217/FVL.14.103; Maisch B, 2013, HEART FAIL REV, V18, P761, DOI 10.1007/s10741-012-9362-7; Manaresi E, 2001, J MED VIROL, V64, P67, DOI 10.1002/jmv.1019; Manaresi E, 1999, J MED VIROL, V57, P174, DOI 10.1002/(SICI)1096-9071(199902)57:2<174::AID-JMV15>3.0.CO;2-0; Manaresi E, 2017, VIROLOGY, V508, P54, DOI 10.1016/j.virol.2017.05.006; Manaresi E, 2015, J VIROL METHODS, V223, P50, DOI 10.1016/j.jviromet.2015.07.013; Maple PAC, 2014, J CLIN MICROBIOL, V52, P947, DOI 10.1128/JCM.02613-13; Marano G, 2015, BLOOD TRANSFUS-ITALY, V13, P184, DOI 10.2450/2014.0174.14; Means RT, 2016, BLOOD, V128, P2504, DOI 10.1182/blood-2016-05-717140; Metzgar D, 2014, J CLIN VIROL, V59, P177, DOI 10.1016/j.jcv.2013.12.005; Mirasoli M, 2018, SENSOR ACTUAT B-CHEM, V262, P1024, DOI 10.1016/j.snb.2018.02.086; Mirasoli M, 2013, ANAL BIOANAL CHEM, V405, P1139, DOI 10.1007/s00216-012-6573-7; Molenaar-de Backer MWA, 2016, J CLIN VIROL, V84, P19, DOI 10.1016/j.jcv.2016.09.004; Molenaar-de Backer MWA, 2016, TRANSFUSION, V56, P440, DOI 10.1111/trf.13334; Molina KM, 2013, PEDIATR CARDIOL, V34, P390, DOI 10.1007/s00246-012-0468-4; Moustafa A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006292; Muller MM, 2013, VOX SANG, V104, P19, DOI 10.1111/j.1423-0410.2012.01635.x; Musiani M, 2000, J MED VIROL, V60, P347, DOI 10.1002/(SICI)1096-9071(200003)60:3<347::AID-JMV15>3.0.CO;2-T; Ngoi CN, 2016, J GEN VIROL, V97, P3359, DOI 10.1099/jgv.0.000644; Nguyen Y, 2013, J CLIN MICROBIOL, V51, P2288, DOI 10.1128/JCM.00820-13; Niccoli G, 2014, EUR J CLIN INVEST, V44, P209, DOI 10.1111/eci.12223; Ohrmalm L, 2013, BONE MARROW TRANSPL, V48, P1366, DOI 10.1038/bmt.2013.110; Ornoy A, 2017, BIRTH DEFECTS RES, V109, P311, DOI 10.1002/bdra.23588; Pan WY, 2017, CLIN CHEM, V63, P1695, DOI 10.1373/clinchem.2017.273888; Pankuweit S, 2013, HEART FAIL REV, V18, P683, DOI 10.1007/s10741-012-9357-4; Pankuweit S, 2013, HEART FAIL REV, V18, P329, DOI 10.1007/s10741-013-9375-x; Pisani G, 2016, VOX SANG, V111, P115, DOI 10.1111/vox.12403; Plentz A, 2013, J CLIN VIROL, V58, P443, DOI 10.1016/j.jcv.2013.07.007; Poliquin V, 2015, J OBSTET GYNAECOL CA, V37, P1118, DOI 10.1016/S1701-2163(16)30079-2; Porignaux R, 2013, J MED VIROL, V85, P1115, DOI 10.1002/jmv.23557; Puccetti C, 2012, PRENATAL DIAG, V32, P897, DOI 10.1002/pd.3930; Pyoria L, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14930; Qiu JM, 2017, CLIN MICROBIOL REV, V30, P43, DOI 10.1128/CMR.00040-16; Rahiala J, 2013, BONE MARROW TRANSPL, V48, P1308, DOI 10.1038/bmt.2013.63; Rascovan N, 2016, ANNU REV MICROBIOL, V70, P125, DOI 10.1146/annurev-micro-102215-095431; Reber U, 2017, J CLIN VIROL, V95, P10, DOI 10.1016/j.jcv.2017.07.017; Rogers HJ, 2015, BLOOD, V126, P1630, DOI 10.1182/blood-2015-07-656157; Sakata H, 2013, TRANSFUSION, V53, P2556, DOI 10.1111/j.1537-2995.2012.03949.x; Santonja C, 2017, BRIT J DERMATOL, V177, P1060, DOI 10.1111/bjd.15382; SODERLUND M, 1995, J INFECT DIS, V171, P710, DOI 10.1093/infdis/171.3.710; SODERLUND M, 1995, J INFECT DIS, V172, P1431, DOI 10.1093/infdis/172.6.1431; Soderlund-Venermo M, 2017, BRIT J DERMATOL, V177, P900, DOI 10.1111/bjd.15811; Somasekar S, 2017, CLIN INFECT DIS, V65, P1477, DOI 10.1093/cid/cix596; Stamenkovic GG, 2016, SCI REP-UK, V6, DOI 10.1038/srep35759; Takizawa K, 2013, TRANSFUSION, V53, P2545, DOI 10.1111/trf.12193; Thammasri K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067179; Toppinen M, 2015, SCI REP-UK, V5, DOI 10.1038/srep17226; Toppinen M, 2015, J VIROL METHODS, V218, P40, DOI 10.1016/j.jviromet.2015.03.006; Trosemeier JH, 2014, MICROBIOL RESOUR ANN, V2, DOI 10.1128/genomeA.00830-14; Tsitsikas DA, 2014, BLOOD REV, V28, P23, DOI 10.1016/j.blre.2013.12.002; Verdonschot J, 2016, EUR J HEART FAIL, V18, P1430, DOI 10.1002/ejhf.665; Virgin HW, 2014, CELL, V157, P142, DOI 10.1016/j.cell.2014.02.032; Wang YL, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-015-1194-3; Watt AP, 2013, J MED MICROBIOL, V62, P86, DOI 10.1099/jmm.0.046714-0; Weseslindtner L, 2017, J INFECT DIS, V215, P214, DOI 10.1093/infdis/jiw509; Wurdinger M, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9060149; Xu P, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006266; Yliharsila M, 2015, J VIROL METHODS, V222, P224, DOI 10.1016/j.jviromet.2015.05.012	108	2	2	0	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	9					821	832		10.1080/14737159.2018.1503537			12	Pathology	Pathology	GR6IV	WOS:000442753800006	30028234				2019-10-28	
J	Mertoglu, C; Gunay, M; Siranli, G; Kulhan, M; Gok, G; Erel, O				Mertoglu, Cuma; Gunay, Murat; Siranli, Gulsah; Kulhan, Mehmet; Gok, Gamze; Erel, Ozcan			The Effect of the 50 g Glucose Challenge Test on The Thiol/Disulfide Homeostasis in Pregnancy	FETAL AND PEDIATRIC PATHOLOGY			English	Article						50 g glucose challenge test; Thiol/disulfide homeostasis; Gestational diabetes mellitus; Oxidative stress; Oral glucose tolerance test	GESTATIONAL DIABETES-MELLITUS; THIOL-DISULFIDE HOMEOSTASIS; OXIDATIVE STRESS; TOLERANCE TEST; ANTIOXIDANT DEFENSES; INFLAMMATION; INGESTION; PLASMA; IMPACT; ASSAY	Aim: A 50 g glucose challenge test (GCT) is recommended for screening all pregnant women for gestational diabetes mellitus. In this study, the effect of GCT on the thiol/disulfide balance was investigated. Methods: One-hundred women that underwent a 50 g GCT at 24-28 weeks of gestation (63 positive and 37 negative results) were evaluated in terms of thiol/disulfide in serum samples at test hours 0 and 1. Results: Compared to the baseline values (hour 0), after the glucose load (hour 1), the thiol and native thiol/total thiol (p < 0.0001) of the GCT-positive women were reduced whereas the values of glucose, disulfide, disulfide/native thiol, disulfide/total thiol (p < 0.0001) and total thiol increased (p = 0.018). Conclusion: In GCT-positive pregnant individuals, the glucose load increases oxidative stress by changing the thiol/disulfide homeostasis. Such an effect is not observed in healthy pregnancies.	[Mertoglu, Cuma; Gunay, Murat; Siranli, Gulsah] Erzincan Univ, Dept Clin Biochem, Fac Med, Erzincan, Turkey; [Kulhan, Mehmet] Erzincan Univ, Dept Obstet & Gynecol, Fac Med, Erzincan, Turkey; [Gok, Gamze; Erel, Ozcan] Yildirim Beyazit Univ, Dept Clin Biochem, Fac Med, Ankara, Turkey	Mertoglu, C (reprint author), Erzincan Univ, Dept Clin Biochem, Mengucek Gazi Training & Res Hosp, Erzincan, Turkey.	drcumamert@hotmail.com	EREL, Ozcan/U-1008-2019; mertoglu, cuma/A-3506-2017	EREL, Ozcan/0000-0002-2996-3236; mertoglu, cuma/0000-0003-3497-4092			[Anonymous], 2011, Obstet Gynecol, V118, P751, DOI 10.1097/AOG.0b013e3182310cc3; Ates I, 2016, ENDOCRINE, V51, P47, DOI 10.1007/s12020-015-0784-6; Ates I, 2015, DIABETES RES CLIN PR, V110, P166, DOI 10.1016/j.diabres.2015.09.011; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; Ceriello A, 1998, EUR J CLIN INVEST, V28, P329; Cetin O, 2017, J MATERN 8 NEONATAL; Choi HJ, 2013, DIABETES RES CLIN PR, V99, pE27, DOI 10.1016/j.diabres.2012.01.005; Coustan DR, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.04.006; Cremers CM, 2013, J BIOL CHEM, V288, P26489, DOI 10.1074/jbc.R113.462929; Cundy T, 2014, BMJ-BRIT MED J, V1567, P1, DOI [10.1136/bmj.gl567, DOI 10.1136/BMJ.GL567]; Erel O, 2014, CLIN BIOCHEM, V47, P326, DOI 10.1016/j.clinbiochem.2014.09.026; Ergin M, 2015, J PERINATOL, V35, P788, DOI 10.1038/jp.2015.81; Erkenekli K, 2016, J OBSTET GYNAECOL RE, V42, P136, DOI 10.1111/jog.12860; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; Katar-Yildirim C, 2017, J MATERN-FETAL NEO M, V4, P1; Korkmaz V, 2016, J MATERN-FETAL NEO M, V29, P3848, DOI 10.3109/14767058.2016.1149561; Manning PJ, 2008, METABOLISM, V57, P1345, DOI 10.1016/j.metabol.2008.04.020; Meltzer SJ, 2010, BJOG-INT J OBSTET GY, V117, P407, DOI 10.1111/j.1471-0528.2009.02475.x; Nakanishi S, 2013, DIABETES METAB SYNDR, V6, P427, DOI 10.2147/DMSO.S53760; Ozler S, 2017, FETAL PEDIATR PATHOL, V36, P8, DOI 10.1080/15513815.2016.1223237; Ozler S, 2016, J MATERN-FETAL NEO M, V29, P3699, DOI 10.3109/14767058.2016.1141885; Sanhal CY, 2018, J MATERN-FETAL NEO M, V31, P1477, DOI 10.1080/14767058.2017.1319922; Siervo M, 2011, NUTR METAB CARDIOVAS, V21, P1, DOI 10.1016/j.numecd.2010.10.003; van Leeuwen M, 2012, BJOG-INT J OBSTET GY, V119, P393, DOI 10.1111/j.1471-0528.2011.03254.x; World Health Organization, 1999, DEF DIAGN CLASS DI 1	26	4	3	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					147	156		10.1080/15513815.2018.1453002			10	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500002	29694252				2019-10-28	
J	Inaguma, S; Lasota, J; Wang, ZF; Czapiewski, P; Langfort, R; Rys, J; Szpor, J; Waloszczyk, P; Okon, K; Biernat, W; Ikeda, H; Schrump, DS; Hassan, R; Miettinen, M				Inaguma, Shingo; Lasota, Jerzy; Wang, Zengfeng; Czapiewski, Piotr; Langfort, Renata; Rys, Janusz; Szpor, Joanna; Waloszczyk, Piotr; Okon, Krzysztof; Biernat, Wojciech; Ikeda, Hiroshi; Schrump, David S.; Hassan, Raffit; Miettinen, Markku			Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma	HUMAN PATHOLOGY			English	Article						ALCAM, activated leukocyte cell adhesion molecule (CD166); ALDH1A1, aldehyde dehydrogenase 1 A1 (ALDH1); MPM malignant pleural mesothelioma; PD-L1, programmed cell death ligand 1 (CD274); SALL4, spalt-like transcription factor 4	CELL-ADHESION MOLECULE; B7-H1 EXPRESSION; LUNG-CANCER; STEM-CELLS; CD6; IMMUNOSUPPRESSION; IMMUNORECEPTOR; PROLIFERATION; PROGRESSION; TOLERANCE	Diffuse malignant mesothelioma of the pleura is a highly aggressive tumor typically associated with short survival. ALCAM (CD166), a type 1 transmembrane protein, is a member of the immunoglobulin superfamily. In normal cells, ALCAM regulates physiological processes such as angiogenesis and immune response. In cancer, it is associated with neoplastic progression, including invasion, migration, and metastasis. Furthermore, ALCAM is considered one of the cancer stem cell markers such as ALDH1 (ALDH 1 A1) and SALL4. The PD-L1 (CD274)/PD-1 (PDCD1, CD279) pathway is crucial for the modulation of immune responses in normal cells. Nevertheless, pathologic activation of the PD-LI/PD-1 pathway participates in immune evasion by tumor cells. Many PD-L1 expressing tumor cells have been identified in different types of cancer, including malignant mesothelioma. In this study, 175 well-characterized primary diffuse pleural mesotheliomas, including the epithelioid (n = 148), biphasic (n = 15), and sarcomatoid (n = 12) histotypes, were evaluated immunohistochemically for cancer stem cell markers (ALCAM, ALDH1, and SALL4) and PD-L1 expression. Twenty-five percent of the mesotheliomas (43/175) expressed ALCAM, whereas ALDH1 and SALL4 positivity was seen in 1% to 2% of cases. Thirty-three percent of the analyzed tumors (57/175) contained PD-L1 positive cells. Overall survival was significantly decreased in the cohort of patients with ALCAM- or PD-L1-positive tumors (both P < .01). Furthermore, the multivariate Cox hazards regression analysis identified ALCAM and PD-L1 (both P < 0.01) as potential independent risk factors. Thus, a combination of these 2 markers might be useful for prognostication and planning the treatment of patients with malignant pleural mesothelioma. (C) 2017 Elsevier Inc. All rights reserved.	[Inaguma, Shingo; Lasota, Jerzy; Wang, Zengfeng; Miettinen, Markku] NCI, Lab Pathol, Bethesda, MD 20892 USA; [Inaguma, Shingo; Ikeda, Hiroshi] Aichi Med Univ, Sch Med, Dept Pathol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan; [Czapiewski, Piotr; Biernat, Wojciech] Med Univ Gdansk, Dept Pathomorphol, PL-80210 Gdansk, Poland; [Czapiewski, Piotr] Otto von Guericke Univ, Dept Pathol, D-39106 Magdeburg, Germany; [Langfort, Renata] Natl TB & Lung Dis Res Inst, Dept Pathol, PL-01138 Warsaw, Poland; [Rys, Janusz] Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Krakow Branch, Dept Tumor Pathol, PL-31115 Warsaw, Poland; [Szpor, Joanna; Okon, Krzysztof] Jagiellonian Univ, Dept Pathomorphol, PL-31007 Krakow, Poland; [Waloszczyk, Piotr] Zdunomed, Independent Lab Pathol, PL-70891 Szczecin, Poland; [Schrump, David S.; Hassan, Raffit] NCI, Thorac & GI Oncol Branch, Bethesda, MD 20892 USA	Inaguma, S (reprint author), Aichi Med Univ, Sch Med, Dept Pathol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.	inaguma@aichi-med-u.ac.jp	Okon, Krzysztof/D-1345-2011	Okon, Krzysztof/0000-0002-1921-5007	National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)	This work was supported as a part of the National Cancer Institute's Intramural Research Program.	Bloch O, 2013, CLIN CANCER RES, V19, P3165, DOI 10.1158/1078-0432.CCR-12-3314; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; BOWEN MA, 1995, J EXP MED, V181, P2213, DOI 10.1084/jem.181.6.2213; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Cedres S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121071; Cheng J, 2015, ONCOL REP, V34, P1923, DOI 10.3892/or.2015.4168; Curiel TJ, 2003, NAT MED, V9, P562, DOI 10.1038/nm863; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dong HD, 1999, NAT MED, V5, P1365; Fanoni D, 2011, IMMUNOL LETT, V134, P157, DOI 10.1016/j.imlet.2010.09.022; Fife BT, 2008, IMMUNOL REV, V224, P166, DOI 10.1111/j.1600-065X.2008.00662.x; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ikeda K, 2004, J BIOL CHEM, V279, P55315, DOI 10.1074/jbc.M407776200; Inaguma S, 2017, MODERN PATHOL, V30, P278, DOI 10.1038/modpathol.2016.185; Inaguma S, 2016, AM J SURG PATHOL, V40, P1133, DOI 10.1097/PAS.0000000000000653; Ishiguro F, 2012, J THORAC ONCOL, V7, P890, DOI 10.1097/JTO.0b013e31824af2db; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Kuang DM, 2009, J EXP MED, V206, P1327, DOI 10.1084/jem.20082173; Lunter PC, 2005, CANCER RES, V65, P8801, DOI 10.1158/0008-5472.CAN-05-0378; Ma LF, 2014, J BIOL CHEM, V289, P6921, DOI 10.1074/jbc.M113.524819; Mansfield AS, 2014, J THORAC ONCOL, V9, P1036, DOI 10.1097/JTO.0000000000000177; Miettinen M, 2014, AM J SURG PATHOL, V38, P410, DOI 10.1097/PAS.0000000000000116; Miettinen M, 2012, APPL IMMUNOHISTO M M, V20, P410, DOI 10.1097/PAI.0b013e318245c82f; Nelissen JMDT, 2000, MOL BIOL CELL, V11, P2057, DOI 10.1091/mbc.11.6.2057; Nishimura H, 2001, TRENDS IMMUNOL, V22, P265, DOI 10.1016/S1471-4906(01)01888-9; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Robinson BWS, 2005, NEW ENGL J MED, V353, P1591, DOI 10.1056/NEJMra050152; Swart GWM, 2002, EUR J CELL BIOL, V81, P313, DOI 10.1078/0171-9335-00256; Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993; Thies S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139312; van Kempen LCLT, 2000, AM J PATHOL, V156, P769, DOI 10.1016/S0002-9440(10)64943-7; van Kilsdonk JWJ, 2008, CANCER RES, V68, P3671, DOI 10.1158/0008-5472.CAN-07-5767; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; WHITNEY GS, 1995, J BIOL CHEM, V270, P18187, DOI 10.1074/jbc.270.31.18187; Zimmerman AW, 2006, BLOOD, V107, P3212, DOI 10.1182/blood-2005-09-3881	35	4	4	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						1	7		10.1016/j.humpath.2017.04.032			7	Pathology	Pathology	FS7TV	WOS:000422612600001	28811252	Green Accepted			2019-10-28	
J	Boland, JM; Maleszewski, JJ; Wampfler, JA; Voss, JS; Kipp, BR; Yang, P; Yi, ES				Boland, Jennifer M.; Maleszewski, Joseph J.; Wampfler, Jason A.; Voss, Jesse S.; Kipp, Benjamin R.; Yang, Ping; Yi, Eunhee S.			Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis	HUMAN PATHOLOGY			English	Article						Mucinous adenocarcinoma; Mutations; KRAS; STK11; Survival; Never smoker	LUNG ADENOCARCINOMA; BRONCHIOLOALVEOLAR CARCINOMAS; KRAS MUTATION; IN-SITU; EXPRESSION; FEATURES; EGFR; ASSOCIATION; PROGNOSIS; PATTERNS	Invasive mucinous adenocarcinoma is a variant of lung adenocarcinoma, which may be mixed with nonmucinous adenocarcinoma. KRAS mutations are common, but other clinical and genetic features are not clearly established. Lung adenocarcinomas (n = 760) with >= 5years of follow-up comprised 3 nonoverlapping cohorts for survival analysis. Mucinous tumors were evaluated with Ion AmpliSeq Cancer Hotspot Panel v2. Cases without detected mutations were tested for ALK and ROS1 and by OncoScan array. Fifty-seven invasive mucinous adenocarcinomas and 54 mixed mucinous/nonmucinous adenocarcinomas were identified. Mucinous tumors constituted 27 of 218 nonselected patients (12.4%), 23 of 268 never-smokers (8.6%), and 61 of 274 in a smokers cohort enriched for lepidic growth (22.3%). In the lepidic-enriched smokers, patients with mucinous tumors experienced worse overall survival (P = .006) and progression-free survival (P = .024), which persisted on multivariable analysis. No survival differences were observed in the other cohorts. KRAS mutations were common (76% of invasive mucinous adenocarcinomas, 68% of mixed mucinous/nonmucinous), and 38% of KRAS mutations occurred with other mutations, especially STK11. Six cases had potentially targetable mutations (3 ALK, 2 EGFR, 1 BRAE V600E). All ALK-rearranged tumors were mixed mucinous/nonmucinous. Four of 6 cases without hotspot mutations showed complex copy number/structural abnormalities. Pulmonary invasive mucinous adenocarcinomas and mixed nonmucinous/mucinous adenocarcinomas are clinically and genetically similar, except for a higher rate of ALK rearrangement in mixed tumors. Survival for mucinous tumors is similar to that for nonmucinous tumors in a nonselected cohort, although worse survival was seen in a cohort of smokers enriched for lepidic growth. (C) 2017 Elsevier Inc. All rights reserved.	[Boland, Jennifer M.; Maleszewski, Joseph J.; Voss, Jesse S.; Kipp, Benjamin R.; Yi, Eunhee S.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; [Wampfler, Jason A.; Yang, Ping] Mayo Clin, Dept Epidemiol, Rochester, MN 55905 USA	Boland, JM (reprint author), 200 First St SW, Rochester, MN 55905 USA.	Boland.jennifer@mayo.edu		Boland, Jennifer/0000-0002-2723-9586			BARSKY SH, 1994, CANCER-AM CANCER SOC, V73, P1163, DOI 10.1002/1097-0142(19940215)73:4<1163::AID-CNCR2820730407>3.0.CO;2-J; Boland JM, 2017, LUNG CANCER, V109, P14, DOI 10.1016/j.lungcan.2017.04.013; Boland JM, 2016, HUM PATHOL, V51, P41, DOI 10.1016/j.humpath.2015.12.010; Boland JM, 2014, AM J SURG PATHOL, V38, P1681, DOI 10.1097/PAS.0000000000000280; Cha YJ, 2016, PATHOLOGY, V48, P325, DOI 10.1016/j.pathol.2016.02.016; CLAYTON F, 1986, CANCER, V57, P1555, DOI 10.1002/1097-0142(19860415)57:8<1555::AID-CNCR2820570820>3.0.CO;2-N; Finberg KE, 2007, J MOL DIAGN, V9, P320, DOI 10.2353/jmoldx.2007.060182; Geles A, 2015, VIRCHOWS ARCH, V467, P675, DOI 10.1007/s00428-015-1852-2; Hata A, 2010, J THORAC ONCOL, V5, P1197, DOI 10.1097/JTO.0b013e3181e2a2bc; Hu HC, 2014, ONCOTARGETS THER, V7, P1423, DOI 10.2147/OTT.S58900; Hwang DH, 2016, J THORAC ONCOL, V11, P496, DOI 10.1016/j.jtho.2016.01.010; Ichinokawa H, 2011, PATHOL INT, V61, P423, DOI 10.1111/j.1440-1827.2011.02677.x; Kadota K, 2014, AM J SURG PATHOL, V38, P1118, DOI 10.1097/PAS.0000000000000246; Kadota K, 2014, AM J SURG PATHOL, V38, P448, DOI 10.1097/PAS.0000000000000134; Kakegawa S, 2011, CANCER-AM CANCER SOC, V117, P4257, DOI 10.1002/cncr.26010; Lau SK, 2002, MODERN PATHOL, V15, P538, DOI 10.1038/modpathol.3880560; Lee B, 2016, ONCOTARGET, V7, P23874, DOI 10.18632/oncotarget.8074; Lee HY, 2016, J THORAC ONCOL, V11, P1064, DOI 10.1016/j.jtho.2016.03.011; Luo JZ, 2016, J CANCER RES CLIN, V142, P1837, DOI 10.1007/s00432-016-2201-9; Maeshima A, 2002, VIRCHOWS ARCH, V440, P598, DOI 10.1007/s00428-002-0629-6; Mansuet-Lupo A, 2014, CHEST, V146, P633, DOI 10.1378/chest.13-2499; Marchetti A, 1996, J PATHOL, V179, P254, DOI 10.1002/(SICI)1096-9896(199607)179:3<254::AID-PATH589>3.0.CO;2-J; Nakaoku T, 2014, CLIN CANCER RES, V20, P3087, DOI 10.1158/1078-0432.CCR-14-0107; Popat N, 2012, CHEST, V141, P513, DOI 10.1378/chest.11-0956; Qu Y, 2016, TUMOR BIOL, V37, P887, DOI 10.1007/s13277-015-3869-1; Rossi G, 2004, AM J SURG PATHOL, V28, P442, DOI 10.1097/00000478-200404000-00003; Russell PA, 2011, J THORAC ONCOL, V6, P1496, DOI 10.1097/JTO.0b013e318221f701; Sakuma Y, 2007, AM J CLIN PATHOL, V128, P100, DOI 10.1309/WVXFGAFLAUX48DU6; Schabath MB, 2016, ONCOGENE, V35, P3209, DOI 10.1038/onc.2015.375; Shim HS, 2015, J THORAC ONCOL, V10, P1156, DOI 10.1097/JTO.0000000000000579; Travis WD, 2015, WHO CLASSIFICATION T; Wu J, 2013, AM J CLIN PATHOL, V139, P160, DOI 10.1309/AJCP62WJUAMSZCOM; Yang P, 2012, J THORAC ONCOL, V7, P90, DOI 10.1097/JTO.0b013e31823c5c32; Yatabe Y, 2004, J PATHOL, V203, P645, DOI 10.1002/path.1566; Yoshizawa A, 2013, J THORAC ONCOL, V8, P52, DOI 10.1097/JTO.0b013e3182769aa8	35	4	6	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						8	19		10.1016/j.humpath.2017.08.002			12	Pathology	Pathology	FS7TV	WOS:000422612600002	28823574				2019-10-28	
J	Wang, LS; Liu, ZB; Fisher, KW; Ren, F; Lv, JJ; Davidson, DD; Baldridge, LA; Du, X; Cheng, L				Wang, Lisha; Liu, Zebing; Fisher, Kurt W.; Ren, Fei; Lv, Jiaojie; Davidson, Darrell D.; Baldridge, Lee A.; Du, Xiang; Cheng, Liang			Prognostic value of programmed death ligand 1, p53, and Ki-67 in patients with advanced-stage colorectal cancer	HUMAN PATHOLOGY			English	Article						Colorectal cancer; Prognosis; Biomarkers; PD-L1; p53; Ki-67 labeling index	MISMATCH-REPAIR DEFICIENCY; COLON-CANCER; PREDICTIVE BIOMARKER; THYMIDYLATE SYNTHASE; ANTI-PD-L1 ANTIBODY; BREAST-CANCER; PD-1 BLOCKADE; BRAF MUTATION; INHIBITION; SURVIVAL	Current prognostic indicators are ineffective for identifying advanced-stage colorectal cancer (CRC) patients with high risk of recurrence after surgical resection. We investigated the prognostic value of p53, Ki-67, and programmed death ligand 1 (PD-L1) in 254 patients with stage II and III CRC. The expression of p53 was positive in 63% of cases. Up-regulation of p53 was associated with smaller tumor size (P = .001) and higher Ki-67 labeling index (LI) (P = .031). The tumor Ki-67 LI was high (>= 20%) in 197 (78%) of the patients. High Ki-67 LI was associated with higher TNM stage (P = .031), positive p53 expression (P = .031), and negative PD-L1 expression (P = .003). The 5-year relapse-free survivals (RFS) were 53% and 89%, respectively, for the p53-positive and Ki-67 LI-high patients and the p53-negative and Ki-67 LI-low patients (P < .001). In univariate analysis, negative p53 (P = .001), low Ki-67 LI (P = .006), low PD-L1 expression (P=.044), low TNM stage (P < .001), rectosigmoid location (P = .026), and small size (P = .013) were significantly related to RFS. In multivariate Cox regression analysis, positive p53 expression (hazard ratio [HR]: 2.48; 95% confidence interval: 1.34-4.59, P = .004), high Ki-67 LI (HR, 2.62; 95% CI, 1.12-6.14, P = .027) and high TNM stage (HR, 2.598; 95% CI, 1.55-4.37, P < .001,) were independent predictors of unfavorable prognosis. In summary, PD-L1, Ki-67, and p53 staining individually had significant prognostic value for patients with stage II and III CRC. Moreover, combining p53 H-score >= 35 and Ki-67 LI >= 20% identifies patients with poor clinical outcome. (C) 2017 Elsevier Inc. All rights reserved.	[Wang, Lisha; Ren, Fei; Lv, Jiaojie; Du, Xiang] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200032, Peoples R China; [Wang, Lisha; Ren, Fei; Lv, Jiaojie; Du, Xiang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Wang, Lisha] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Liu, Zebing] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pathol, Shanghai 200025, Peoples R China; [Fisher, Kurt W.; Davidson, Darrell D.; Baldridge, Lee A.; Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St, Indianapolis, IN 46202 USA	Du, X (reprint author), Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai 200032, Peoples R China.; Du, X (reprint author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.; Cheng, L (reprint author), Indiana Univ Sch Med, Dept Pathol & Lab Med, 350 West 11th St, Indianapolis, IN 46202 USA.	dx2008cn@163.com; liang_cheng@yahoo.com		Fisher, Kurt/0000-0002-8391-390X	Science and Technology Commission of Shanghai MunicipalityScience & Technology Commission of Shanghai Municipality (STCSM) [15495810300]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81071791, 81401963]	This study was supported by the grant from the Science and Technology Commission of Shanghai Municipality (15495810300), and the National Natural Science Foundation of China (81071791, 81401963).	Adsay V, 2012, AM J SURG PATHOL, V36, P1743, DOI 10.1097/PAS.0b013e318272ff77; Allegra CJ, 2002, J CLIN ONCOL, V20, P1735, DOI 10.1200/JCO.2002.07.080; Allegra CJ, 2003, J CLIN ONCOL, V21, P241, DOI 10.1200/JCO.2003.05.044; Andre T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Awad MM, 2015, J CLIN ONCOL, V33, P1993, DOI 10.1200/JCO.2015.61.4172; Bosman FT, 2010, WHO CLASSIFICATION T; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Christgen M, 2015, HUM PATHOL, V46, P1341, DOI 10.1016/j.humpath.2015.05.016; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Edge SB, 2010, AJCC CANC STAGING MA; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Ignatiadis M, 2016, JAMA ONCOL, V2, P217, DOI 10.1001/jamaoncol.2015.4377; Kirilovsky A, 2016, INT IMMUNOL, V28, P373, DOI 10.1093/intimm/dxw021; Kruschewski Martin, 2011, Cancers (Basel), V3, P1274, DOI 10.3390/cancers3011274; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418; Lugli A, 2008, MODERN PATHOL, V21, P1403, DOI 10.1038/modpathol.2008.117; Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226; Niedzwiecki D, 2016, J CLIN ONCOL, V34, P3047, DOI 10.1200/JCO.2015.65.4699; Ogino S, 2012, CLIN CANCER RES, V18, P890, DOI 10.1158/1078-0432.CCR-11-2246; Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983; Petersen S, 2001, DIS COLON RECTUM, V44, P322, DOI 10.1007/BF02234727; Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038; Prabhu VV, 2016, CANCER RES, V76, P1989, DOI 10.1158/0008-5472.CAN-14-2430; Russo A, 2005, J CLIN ONCOL, V23, P7518, DOI 10.1200/JCO.2005.00.471; Sarasqueta AF, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-277; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Siraj AK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-168; Wang L., 2016, AQUAC RES, V2016, P1, DOI DOI 10.1007/S11200-014-0975-2; Wang LS, 2015, MOL CARCINOGEN, V54, P900, DOI 10.1002/mc.22162; Yemelyanova A, 2011, MODERN PATHOL, V24, P1248, DOI 10.1038/modpathol.2011.85; Yu J, 2015, GUT, V64, P636, DOI 10.1136/gutjnl-2013-306620; Zlobec I, 2007, J CLIN PATHOL, V60, P1112, DOI 10.1136/jcp.2006.044537	36	6	7	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						20	29		10.1016/j.humpath.2017.07.014			10	Pathology	Pathology	FS7TV	WOS:000422612600003	28782638				2019-10-28	
J	Torrealba, JR; Fisher, S; Kanne, JP; Butt, YM; Glazer, C; Kershaw, C; Burguete, D; Gokaslan, T; Batra, K				Torrealba, Jose R.; Fisher, Stephen; Kanne, Jeffrey P.; Butt, Yasmeen M.; Glazer, Craig; Kershaw, Corey; Burguete, Daniel; Gokaslan, Tunc; Batra, Kiran			Pathology-radiology correlation of common and uncommon computed tomographic patterns of organizing pneumonia	HUMAN PATHOLOGY			English	Article						Organizing pneumonia (OP); Cryptogenic organizing pneumonia (COP); Acute fibrinous and organizing pneumonia (AFOP); Reverse halo sign; Chronic eosinophilic pneumonia (CEP); Alveolar proteinosis; Diffuse alveolar damage (DAD)	THIN-SECTION CT; IDIOPATHIC INTERSTITIAL PNEUMONIAS; DIFFUSE ALVEOLAR DAMAGE; BRONCHIOLITIS OBLITERANS; LUNG INJURY; DIFFERENTIAL-DIAGNOSIS; OPACITIES; SERIES; HRCT	Organizing pneumonia (OP) is a common pattern of lung injury that can be associated with a wide range of etiologies. Typical and not-so-typical imaging features of OP occur, as both common and rare lung pathologies can mimic the same imaging pattern as that of OP. This article will attempt to describe the difference between confusing terminologies that have been used in the past for OP and existence of primary versus secondary OP. The role Of a multidisciplinary approach as an essential component to correctly diagnose and effectively manage challenging cases of OP will be highlighted. Additionally, we will discuss the limitation of transbronchial and importance of open lung biopsy to make the correct diagnosis. One example of an emerging diagnosis in the spectrum of OP and diffuse alveolar damage is acute fibrinous and organizing pneumonia. Ultimately, the reader should feel comfortable recognizing the many variable presentations of OP and be able to participate knowledgeably in a multidisciplinary team after reading this article. OP is a disease entity with variable radiographic and distinct histological characteristics that requires a multidisciplinary approach to correctly diagnose cryptogenic OP. Classic radiologic findings of OP occur in as low as 60% of cases. Secondary causes include infections, neoplasms, inflammatory disorders, and iatrogenic. Acute fibrinous and organizing pneumonia can appear similarly, but miliary nodules are a clue to diagnosis. (C) 2017 Elsevier Inc. All rights reserved.	[Torrealba, Jose R.; Butt, Yasmeen M.; Gokaslan, Tunc] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, Dallas, TX 75235 USA; [Fisher, Stephen; Batra, Kiran] Univ Texas Southwestern Med Ctr Dallas, Dept Radiol, Dallas, TX 75235 USA; [Kanne, Jeffrey P.] Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA; [Glazer, Craig; Kershaw, Corey] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Dallas, TX 75235 USA; [Burguete, Daniel] Univ Texas Dallas, Med Sch, Dallas, TX 75390 USA	Torrealba, JR (reprint author), UT Southwestern Med Ctr, William P Clements Univ Hosp, Dept Pathol, 04-449,6201 Harry Hines Blvd, Dallas, TX 75390 USA.	jose.torrealba@utsouthwestern.edu		Fisher, Stephen/0000-0002-3812-0628			Akira M, 1998, AM J ROENTGENOL, V170, P291, DOI 10.2214/ajr.170.2.9456931; Al Ghanem S, 2008, ANN THORAC MED, V3, pS79; ALASALY K, 1995, MEDICINE, V74, P201, DOI 10.1097/00005792-199507000-00004; Beasley MB, 2002, ARCH PATHOL LAB MED, V126, P1064; Cazzato S, 2000, RESP MED, V94, P702, DOI 10.1053/rmed.2000.0805; Cordier JF, 2006, EUR RESPIR J, V28, P422, DOI 10.1183/09031936.06.00013505; CORDIER JF, 1989, CHEST, V96, P999, DOI 10.1378/chest.96.5.999; DOMINGO JA, 1993, CHEST, V103, P1621, DOI 10.1378/chest.103.5.1621; Elicker BM, 2016, RADIOL CLIN N AM, V54, P1119, DOI 10.1016/j.rcl.2016.05.006; GOSINK BB, 1973, AM J ROENTGENOL, V117, P816, DOI 10.2214/ajr.117.4.816; Gudmundsson G, 2006, THORAX, V61, P805, DOI 10.1136/thx.2006.059469; Johkoh T, 1999, RADIOLOGY, V211, P555, DOI 10.1148/radiology.211.2.r99ma01555; Johkoh T, 1999, J THORAC IMAG, V14, P172, DOI 10.1097/00005382-199907000-00003; King Jr TE, 2011, INTERSTITIAL LUNG DI, V5, P981; Kligerman SJ, 2013, RADIOGRAPHICS, V33, P1951, DOI 10.1148/rg.337130057; Lazor R, 2000, AM J RESP CRIT CARE, V162, P571, DOI 10.1164/ajrccm.162.2.9909015; Lee JS, 2003, J COMPUT ASSIST TOMO, V27, P260, DOI 10.1097/00004728-200303000-00027; LEE KS, 1994, AM J ROENTGENOL, V162, P543, DOI 10.2214/ajr.162.3.8109493; Marchiori E, 2016, ARCH BRONCONEUMOL, V52, P565, DOI 10.1016/j.arbres.2015.08.010; Marchiori E, 2014, AM J ROENTGENOL, V203, pW557, DOI 10.2214/AJR.14.12924; MULLER NL, 1995, RADIOLOGY, V196, P3; Murphy JM, 1999, EUR RADIOL, V9, P1813, DOI 10.1007/s003300050928; Oikonomou A, 2002, EUR RADIOL, V12, P1486, DOI 10.1007/s00330-001-1211-3; Poletti V, 1996, EUR RESPIR J, V9, P2513, DOI 10.1183/09031936.96.09122513; Polverosi R, 2006, RADIOL MED, V111, P202, DOI 10.1007/s11547-006-0021-8; Roberton BJ, 2011, EUR RADIOL, V21, P2244, DOI 10.1007/s00330-011-2191-6; Rossi SE, 2003, RADIOGRAPHICS, V23, P1509, DOI 10.1148/rg.236035101; SPITERI MA, 1992, LANCET, V340, P281, DOI 10.1016/0140-6736(92)92366-N; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Ujita M, 2004, RADIOLOGY, V232, P757, DOI 10.1148/radiol.2323031059	30	4	4	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						30	40		10.1016/j.humpath.2017.10.028			11	Pathology	Pathology	FS7TV	WOS:000422612600004	29122655				2019-10-28	
J	Peng, R; Chen, HJ; Yang, XT; Zhang, XL; Zhang, Z; He, X; Zhang, HY				Peng, Ran; Chen, Huijiao; Yang, Xuantao; Zhang, Xianliang; Zhang, Zhang; He, Xin; Zhang, Hongying			A novel sclerosing atypical lipomatous tumor/well-differentiated liposarcoma in a 7-year-old girl: report of a case with molecular confirmation	HUMAN PATHOLOGY			English	Article						Atypical lipomatous tumor/well-differentiated liposarcoma; Dedifferentiated liposarcoma; Pediatric sarcoma; 12q13-15 amplification; Molecular analysis	CHILDREN	Atypical lipomatous tumor (ALT)/well-differentiated liposarcoma (WDL)/dedifferentiated liposarcoma (DDL) is a common type of liposarcoma in late adulthood. However, pediatric ALT/WDL/DDL is extremely rare, and only 3 cases have been described in children younger than 10 years of age. Notably, none of these cases harbored MDM2 gene amplification. Here, we reported a sclerosing ALT/WDL in a 7-year-old Chinese girl. Histologically, in most areas, the neoplastic cells were embedded within the collagenous background, and typical lipogenic areas were inconspicuous throughout the sclerotic areas. In addition, scattered small foci of atypical osseous/chondrous elements were identified. Notably, a small typical lipoma-like ALT/WDL area was detected in the periphery of the mass. Immunohistochemically, all the neoplastic components demonstrated positivity for MDM2, CDK4, and p16. Fluorescence in situ hybridization revealed MDM2 gene amplification in all the tumor components. To the best of our knowledge, this is the first example of MDM2-amplified ALT/WDL in this age group. (C) 2017 Elsevier Inc. All rights reserved.	[Peng, Ran; Chen, Huijiao; Zhang, Xianliang; Zhang, Zhang; He, Xin; Zhang, Hongying] Sichuan Univ, West China Hosp, Dept Pathol, Guoxuexiang 37, Chengdu 610041, Sichuan, Peoples R China; [Yang, Xuantao] Kunming Univ Sci & Technol, Affiliated Hosp, Peoples Hosp Yunnan Prov 1, Dept Pathol, Kunming 650032, Yunnan, Peoples R China	Zhang, HY (reprint author), Sichuan Univ, West China Hosp, Dept Pathol, Guoxuexiang 37, Chengdu 610041, Sichuan, Peoples R China.	hy_zhang@scu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81472510, 81272944]	This work was supported by grants from the National Natural Science Foundation of China (grant nos. 81472510 and 81272944).	Alaggio R, 2009, AM J SURG PATHOL, V33, P645, DOI 10.1097/PAS.0b013e3181963c9c; Boland JM, 2012, AM J SURG PATHOL, V36, P1395, DOI 10.1097/PAS.0b013e3182562bc1; Chen M, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/1749-8090-9-119; Coffin CM, 1997, PEDIAT SOFT TISSUE T; Debelenko LV, 2010, PEDIATR DEVEL PATHOL, V13, P218, DOI 10.2350/09-08-0694-OA.1; DEITOS AP, 2013, WHO CLASSIFICATION T, V4, P33; Goldblum JR, 2013, LIPOSARCOMA ENZINGER, P484; Hahn HP, 2007, AM J SURG PATHOL, V31, P1868, DOI 10.1097/PAS.0b013e318093f925; Huh WW, 2011, PEDIATR BLOOD CANCER, V57, P1142, DOI 10.1002/pbc.23095; KAUFFMAN SL, 1959, CANCER, V12, P912, DOI 10.1002/1097-0142(195909/10)12:5<912::AID-CNCR2820120510>3.0.CO;2-G; Kuhnen C, 2002, VIRCHOWS ARCH, V441, P299, DOI 10.1007/s00428-002-0690-1; LAQUAGLIA MP, 1993, CANCER, V72, P3114, DOI 10.1002/1097-0142(19931115)72:10<3114::AID-CNCR2820721037>3.0.CO;2-I; Okamoto S, 2010, PATHOL RES PRACT, V206, P191, DOI 10.1016/j.prp.2009.05.005; Priyal G, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.147739; Rana V, 2017, OGH REPORTS, V6, P35; SHMOOKLER BM, 1983, CANCER-AM CANCER SOC, V52, P567, DOI 10.1002/1097-0142(19830801)52:3<567::AID-CNCR2820520332>3.0.CO;2-4	16	4	4	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						41	46		10.1016/j.humpath.2017.06.015			6	Pathology	Pathology	FS7TV	WOS:000422612600005	28705709				2019-10-28	
J	Udager, AM; Magers, MJ; Goerke, DM; Vinco, ML; Siddiqui, J; Cao, XH; Lucas, DR; Myers, JL; Chinnaiyan, AM; McHugh, JB; Giordano, TJ; Else, T; Mehra, R				Udager, Aaron M.; Magers, Martin J.; Goerke, Dayna M.; Vinco, Michelle L.; Siddiqui, Javed; Cao, Xuhong; Lucas, David R.; Myers, Jeffrey L.; Chinnaiyan, Arul M.; McHugh, Jonathan B.; Giordano, Thomas J.; Else, Tobias; Mehra, Rohit			The utility of SDHB and FH immunohistochemistry in patients evaluated for hereditary paraganglioma-pheochromocytoma syndromes	HUMAN PATHOLOGY			English	Article						Succinate dehydrogenase (SDHx); Fumarate hydratase (FH); Head and neck; Adrenal gland; Gernline	RENAL-CELL CARCINOMA; FUMARATE HYDRATASE FH; UTERINE LEIOMYOMAS; CUTANEOUS LEIOMYOMAS; MUTATIONS; GENETICS; AID; 2SC	A significant portion of paragangliomas (PGL) and pheochromocytomas (PCC) occur in patients with hereditary PGL/PCC syndromes, including those with germline mutations in succinate dehydrogenase (SDHx) subunit genes. Recently, germlinefumarate hydratase (FH) mutations have been identified in a subset of PGL/PCC, and patients with hereditary leiomyomatosis and renal cell carcinoma (HLRCC) may have an increased risk of developing PGL/PCC. SDHB immunohistochemistry (IHC) has previously been shown to be useful for identifying SDHx-deficient PGL/PCC, however, FH IHC has never been explored in these tumors. Thus, we characterized SDHB and FH IHC in a large cohort of PGL/PCC patients (n = 41) at our institution who were evaluated for hereditary PGL/PCC syndromes. Overall, there was strong, positive correlation between germline SDHx subunit gene mutation status and SDHB IHC status (re = 0.77; P <.0001), with high corresponding sensitivity, specificity, positive predictive value, and negative predictive value (95.0%, 81.8%, 82.6%, and 94.7%, respectively). Although SDHB loss by IHC was highly correlated with germline SDHx gene mutations, its utility in this population was dependent on clinicopathologic context: while all head and neck PGL patients with SDHB-deficient tumors had germline SDHx gene mutations, only a small subset (25.0%) of PCC patients with SDHB-deficient tumors harbored a germline SDHx gene mutation. Finally, although our cohort contained only one HLRCC patient, their tumor was FH-deficient by IHC, and all other PGL/PCC showed retained FH IHC. Thus, in the appropriate clinical setting, SDHB and FH IHC may be useful for identifying PGL/PCC patients for Medical Genetics evaluation. (C) 2017 Elsevier Inc. All rights reserved.	[Udager, Aaron M.; Magers, Martin J.; Goerke, Dayna M.; Vinco, Michelle L.; Lucas, David R.; Myers, Jeffrey L.; Chinnaiyan, Arul M.; McHugh, Jonathan B.; Giordano, Thomas J.; Mehra, Rohit] Univ Michigan, Dept Pathol, Med Sch, Room 2G332 UH,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA; [Siddiqui, Javed; Cao, Xuhong; Chinnaiyan, Arul M.; Else, Tobias; Mehra, Rohit] Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Chinnaiyan, Arul M.; Giordano, Thomas J.; Else, Tobias; Mehra, Rohit] Michigan Med, Comprehens Canc Ctr, Ann Arbor, MI USA; [Chinnaiyan, Arul M.] Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; [Giordano, Thomas J.] Univ Michigan, Dept Internal Med, Med Sch, Div Metab Endocrinol & Diabet, Ann Arbor, MI 48109 USA	Mehra, R (reprint author), Univ Michigan, Dept Pathol, Med Sch, Room 2G332 UH,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mrohit@med.umich.edu					Buelow B, 2016, AM J SURG PATHOL, V40, P982, DOI 10.1097/PAS.0000000000000626; Carter CS, 2017, AM J SURG PATHOL, V41, P801, DOI 10.1097/PAS.0000000000000840; Castelblanco E, 2013, ENDOCR PATHOL, V24, P199, DOI 10.1007/s12022-013-9269-4; Castro-Vega LJ, 2014, HUM MOL GENET, V23, P2440, DOI 10.1093/hmg/ddt639; Clark GR, 2014, J CLIN ENDOCR METAB, V99, pE2046, DOI 10.1210/jc.2014-1659; Gill AJ, 2010, HUM PATHOL, V41, P805, DOI 10.1016/j.humpath.2009.12.005; Giubellino A, 2015, AM J SURG PATHOL, V39, P1488, DOI 10.1097/PAS.0000000000000534; Harrison WJ, 2016, AM J SURG PATHOL, V40, P599, DOI 10.1097/PAS.0000000000000573; Jochmanova I, 2015, HORM CANCER-US, V6, P191, DOI 10.1007/s12672-015-0231-4; Joseph NM, 2015, AM J SURG PATHOL, V39, P1529, DOI 10.1097/PAS.0000000000000520; Koch CA, 2002, ANN NY ACAD SCI, V970, P11, DOI 10.1111/j.1749-6632.2002.tb04409.x; Korpershoek E, 2011, J CLIN ENDOCR METAB, V96, pE1472, DOI 10.1210/jc.2011-1043; Menara M, 2015, J CLIN ENDOCR METAB, V100, pE287, DOI 10.1210/jc.2014-1870; Miettinen M, 2016, AM J SURG PATHOL, V40, P1661, DOI 10.1097/PAS.0000000000000703; Milosevic D, 2010, CLIN BIOCHEM, V43, P700, DOI 10.1016/j.clinbiochem.2010.01.016; Muller M, 2017, CLIN GENET, V92, P606, DOI 10.1111/cge.13014; Pai R, 2014, APMIS, V122, P1130, DOI 10.1111/apm.12269; Papathomas TG, 2015, MODERN PATHOL, V28, P807, DOI 10.1038/modpathol.2015.41; Pillai S, 2016, CRIT REV ONCOL HEMAT, V100, P190, DOI 10.1016/j.critrevonc.2016.01.022; Santi R, 2017, ANTICANCER RES, V37, P805, DOI 10.21873/anticanres.11381; Schultz KAP, 2017, CLIN CANCER RES, V23, pE76, DOI 10.1158/1078-0432.CCR-17-0629; Smith SC, 2017, HISTOPATHOLOGY, V71, P42, DOI 10.1111/his.13183; Tischler AS, 2015, ENDOCR-RELAT CANCER, V22, pT123, DOI 10.1530/ERC-15-0261; Tischler AS, 2014, ENDOCR PATHOL, V25, P49, DOI 10.1007/s12022-013-9286-3; Trpkov K, 2016, AM J SURG PATHOL, V40, P865, DOI 10.1097/PAS.0000000000000617; Udager AM, 2014, AM J SURG PATHOL, V38, P567, DOI 10.1097/PAS.0000000000000127; Williams MD, 2017, HEAD NECK PATHOL, V11, P278, DOI 10.1007/s12105-017-0803-4	27	8	8	2	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						47	54		10.1016/j.humpath.2017.10.013			8	Pathology	Pathology	FS7TV	WOS:000422612600006	29079178				2019-10-28	
J	Brennan-Krohn, T; Yoon, E; Nishino, M; Kirby, JE; Riedel, S				Brennan-Krohn, Thea; Yoon, Edward; Nishino, Michiya; Kirby, James E.; Riedel, Stefan			Arthroconidia in lung tissue: an unusual histopathological finding in pulmonary coccidioidomycosis	HUMAN PATHOLOGY			English	Article						Coccidioides immitis; Coccidioidomycosis; Arthroconidia; Histopathology of endemic fungi; Coccidioides posadasii; Laboratory diagnosis of Coccidiodomycosis	IMMITIS; POSADASII; FORMS	Coccidioides immitis/posadasii presents in mycelial form with branching hyphae and arthroconidia when cultured in the laboratory. On histopathology, the presence of endospore-containing spherules is considered diagnostic of coccidioidomycosis. Here we report an unusual case of coccidioidomycosis with hyphae and arthroconidia in pulmonary tissue sections. A 49-year-old male patient with intermittently treated pulmonary coccidioidomycosis sought treatment for residual pulmonary complaints. A cavity in the left upper lobe was seen on computed tomographic scan. Due to minimal improvement of symptoms despite treatment with fluconazole, a left upper lobectomy was ultimately performed. Coccidioides minzmitis/posadasii was identified by culture and DNA probe from the lobectomy specimen. The histopathology showed a fibro-cavitary lesion, with arthroconidia and hyphal structures, but no typical endospore-forming spherules. While uncommon, C. immitis/posadasii may present with hyphae and arthroconidia on histopathology. Pathologists should be aware of this unusual presentation; culture remains the most reliable method for definitive diagnosis. (C) 2017 Elsevier Inc. All rights reserved.	[Brennan-Krohn, Thea; Yoon, Edward; Nishino, Michiya; Kirby, James E.; Riedel, Stefan] Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave, Boston, MA 02215 USA; [Brennan-Krohn, Thea] Boston Childrens Hosp, Div Infect Dis, Boston, MA 02215 USA; [Nishino, Michiya; Kirby, James E.; Riedel, Stefan] Harvard Med Sch, Boston, MA 02215 USA	Riedel, S (reprint author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Microbiol, 330 Brookline Ave,Yamins 309, Boston, MA 02215 USA.	sriedel@bidmc.harvard.edu	Kirby, James/K-4438-2019		Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health pediatric infectious diseases research training grant [T32HD055148]	Thea Brennan-Krohn was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the National Institutes of Health pediatric infectious diseases research training grant, T32HD055148.	Barnes HR, 1946, DIS CHEST, V12, P383; FEE HJ, 1977, J THORAC CARDIOV SUR, V74, P548; FIESE MJ, 1955, ANN INTERN MED, V43, P255, DOI 10.7326/0003-4819-43-2-255; Galgiani JN, 2005, CLIN INFECT DIS, V41, P1217, DOI 10.1086/496991; Garcia L. S, 2010, CLIN MICROBIOLOGY PR, V2; GREER SJ, 1949, DIS CHEST, V16, P336, DOI 10.1378/chest.16.3.336; Kaufman L, 1998, J CLIN MICROBIOL, V36, P3721; Larone DH, 2011, MED IMPORTANT FUNGI; Li RK, 2000, ANTIMICROB AGENTS CH, V44, P1734, DOI 10.1128/AAC.44.6.1734-1736.2000; McGinnis MR, 1997, ANTIMICROB AGENTS CH, V41, P1832, DOI 10.1128/AAC.41.8.1832; Nguyen C, 2013, CLIN MICROBIOL REV, V26, P505, DOI 10.1128/CMR.00005-13; PUCKETT TF, 1954, AM REV TUBERC PULM, V70, P320; PUTNAM JS, 1975, AM REV RESPIR DIS, V112, P733; Ramani R, 2007, MYCOPATHOLOGIA, V163, P315, DOI 10.1007/s11046-007-9018-7; Rohatgi PK, 1984, AM J MED, V76, P734; Saubolle MA, 2007, ANN NY ACAD SCI, V1111, P301, DOI 10.1196/annals.1406.049; SMITH AG, 1960, AM J CLIN PATHOL, V34, P477; Stockamp NW, 2016, INFECT DIS CLIN N AM, V30, P229, DOI 10.1016/j.idc.2015.10.008; Tintelnot K, 2007, MED MYCOL, V45, P385, DOI 10.1080/13693780701288070	19	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						55	59		10.1016/j.humpath.2017.07.013			5	Pathology	Pathology	FS7TV	WOS:000422612600007	28778515	Green Accepted			2019-10-28	
J	Arora, K; Miller, R; Mullick, S; Shen, S; Ayala, AG; Ro, JY				Arora, Komal; Miller, Ross; Mullick, Seema; Shen, Steven; Ayala, Alberto G.; Ro, Jae Y.			Renal collision tumor composed of oncocytoma and mucinous tubular and spindle cell carcinoma: case report of an unprecedented entity	HUMAN PATHOLOGY			English	Article						Collision tumor; Oncocytoma; Mucinous tubular and spindle cell carcinoma; First case report; Renal	IN-SITU HYBRIDIZATION; KIDNEY; FEATURES	Primary renal collision tumors composed of 2 histologically distinct components are rare with only isolated case reports in the medical literature. Oncocytoma is a benign renal neoplasm, which is thought to originate from distal tubular epithelial cells. Mucinous tubular and spindle cell carcinoma (MTSCC) of kidney is a rare, relatively recently described renal neoplasm that was first included in the 2004 World Health Organization renal cell carcinoma (RCC) classification as a distinct entity. Current studies suggest that the tumor originates from the proximal nephron, although it is still controversial. The presence of concurrent oncocytoma with conventional (clear cell) RCC, chromophobe RCC, and papillary RCC has been previously described. However, the association of oncocytoma with MTSCC has not yet been reported to our knowledge. Herein, we report the first case of a renal collision tumor composed of oncocytoma and MTSCC. (C) 2017 Elsevier Inc. All rights reserved.	[Arora, Komal; Miller, Ross; Mullick, Seema; Shen, Steven; Ayala, Alberto G.; Ro, Jae Y.] Cornell Univ, Weill Med Coll, Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA	Ro, JY (reprint author), Cornell Univ, Weill Med Coll, Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA.	jaero@houstonmethodist.org					Amin MB, 1998, AM J SURG PATHOL, V22, P510, DOI 10.1097/00000478-199804000-00021; Amin MB, 1997, AM J SURG PATHOL, V21, P1, DOI 10.1097/00000478-199701000-00001; Brandal P, 2006, MODERN PATHOL, V19, P186, DOI 10.1038/modpathol.3800499; Brown JA, 1996, J UROLOGY, V156, P31, DOI 10.1016/S0022-5347(01)65929-9; Bulimbasic S, 2009, HUM PATHOL, V40, P906, DOI 10.1016/j.humpath.2009.03.004; Burch-Smith R, 2014, CHIN J CANCER, V33, P351, DOI 10.5732/cjc.013.10155; Cossu-Rocca P, 2006, MODERN PATHOL, V19, P488, DOI 10.1038/modpathol.3800565; Eble J. N. S. G., 2004, WHO CLASSIFICATION T; Fine SW, 2006, AM J SURG PATHOL, V30, P1554, DOI 10.1097/01.pas.0000213271.15221.e3; Goyal R, 2015, AM J CLIN PATHOL, V144, P811, DOI 10.1309/AJCPQ0P1YHDBZUFL; Hes O, 2013, HISTOL HISTOPATHOL, V28, P1257, DOI 10.14670/HH-28.1257; Jain S, 2013, AM J SURG PATHOL, V37, P1824, DOI 10.1097/PAS.0000000000000108; Paner GP, 2007, ARCH PATHOL LAB MED, V131, P81; Paner GP, 2006, AM J SURG PATHOL, V30, P13, DOI 10.1097/01.pas.0000180443.94645.50; Rabbani F, 1998, J UROLOGY, V160, P1255, DOI 10.1016/S0022-5347(01)62510-2; Rakozy C, 2002, MODERN PATHOL, V15, P1162, DOI 10.1097/01.MP.0000031709.40712.46; Shen SS, 2007, ANN DIAGN PATHOL, V11, P13, DOI 10.1016/j.anndiagpath.2006.09.005; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Srigley JR, 2009, MODERN PATHOL, V22, pS2, DOI 10.1038/modpathol.2009.70; Wu XR, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-206; Yang G, 2010, J UROLOGY, V183, P738, DOI 10.1016/j.juro.2009.11.076	21	1	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						60	64		10.1016/j.humpath.2017.08.012			5	Pathology	Pathology	FS7TV	WOS:000422612600008	28843710				2019-10-28	
J	Espinosa, I; D'Angelo, E; Corominas, M; Gonzalez, A; Prat, J				Espinosa, Inigo; D'Angelo, Emanuela; Corominas, Marina; Gonzalez, Alan; Prat, Jaime			Mixed endometrial carcinomas with a "low-grade serous" like component: a clinicopathologic, immunohistochemical, and molecular genetic study	HUMAN PATHOLOGY			English	Article						Endometrial cancer; Mixed endometrial carcinoma; Serous carcinoma; Endometrioid carcinoma; Next-generation sequencing	MICROSATELLITE INSTABILITY; ADENOCARCINOMA; PATHOLOGY; CANCER; EXPRESSION; MUTATIONS; TARGETS; TUMOR	Recently, we reported 2 mixed endometrioid endometrial carcinomas with a "low-grade serous" like component, which does not fit into any of the 4 molecular groups described by The Cancer Genome Atlas. To understand the nature of these tumors, we have done an immunohistochemical and molecular genetic study of these 2 cases and added a third case. Immunoreactivity for p53, ER, Ki67, WTI, MLH1, PMS2, MSH2, and MSH6 was assessed. Targeted next-generation sequencing for somatic mutations, including genes commonly implicated in carcinogenesis including TP53, KRAS, and PIK3CA, and Sanger sequencing for PTEN and POLE were also performed. All patients were nulliparous and had morbid obesity. Their tumors showed a micropapillary component that resembled that of ovarian low-grade serous carcinoma and merged with villoglandular endometrioid carcinoma. The invasive tumor glands exhibited a microcystic, elongated, or fragmented pattern and contained psammoma bodies. Two tumors showed aberrant p53 expression, and all 3 were positive for ER. All showed KRAS mutations, and TP53 mutations were found in 2 cases. One patient developed peritoneal carcinomatosis, one patient is alive with disease, and another died of a brain tumor. The third patient, whose tumor was confined to the uterus (stage IA), is alive without evidence of disease, but she has been followed for only 6 months. Mixed endometrial carcinomas with a "low-grade" serous like component exhibit a morphologic spectrum of endometrioid and serous differentiation with microcystic, elongated, or fragmented features; ER expression; KRAS and TP53 mutations; and aggressive behavior. (C) 2017 Elsevier Inc. All rights reserved.	[Espinosa, Inigo; D'Angelo, Emanuela; Corominas, Marina; Gonzalez, Alan; Prat, Jaime] Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Inst Biomed Res IIB St Pau, Dept Pathol, Barcelona 08041, Spain	Prat, J (reprint author), Autonomous Univ Barcelona, Hosp Santa Creu & St Pau, Dept Pathol, Sant Quitin 87-89, Barcelona 08041, Spain.	jprat@santpau.cat			Department of Health, Spain; Fundacion AECC-Grupos Estables, Madrid, Spain;  [FIS PI16-00902];  [RTICC RD06/0020/0015]	This work was supported by grants FIS PI16-00902 and RTICC RD06/0020/0015, Department of Health, Spain, Fundacion AECC-Grupos Estables, Madrid, Spain.	Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Berg A, 2015, ONCOTARGET, V6, P1327, DOI 10.18632/oncotarget.2675; BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7; Busch EL, 2017, CANCER EPIDEM BIOMAR, V26, P727, DOI 10.1158/1055-9965.EPI-16-0821; Catasus L, 1998, HUM PATHOL, V29, P1160, DOI 10.1016/S0046-8177(98)90430-0; Catasus L, 2009, MODERN PATHOL, V22, P522, DOI 10.1038/modpathol.2009.5; Church DN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju402; Dedes KJ, 2011, NAT REV CLIN ONCOL, V8, P261, DOI 10.1038/nrclinonc.2010.216; Espinosa I, 2017, AM J SURG PATHOL, V41, P1121, DOI 10.1097/PAS.0000000000000873; Espinosa I, 2016, AM J SURG PATHOL, V40, P972, DOI 10.1097/PAS.0000000000000640; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Kim SS, 2016, INT J SURG PATHOL, V24, P153, DOI 10.1177/1066896915611489; Lagarda H, 2001, J PATHOL, V193, P193, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH769>3.0.CO;2-9; Lax S F, 1997, Verh Dtsch Ges Pathol, V81, P228; Llobet D, 2009, J CLIN PATHOL, V62, P777, DOI 10.1136/jcp.2008.056101; Matias-Guiu X, 2001, HUM PATHOL, V32, P569, DOI 10.1053/hupa.2001.25929; Matias-Guiu X, 2013, HISTOPATHOLOGY, V62, P111, DOI 10.1111/his.12053; Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6; Murray SK, 2003, INT J GYNECOL PATHOL, V22, P324, DOI 10.1097/01.pgp.0000092161.33490.a9; Parkash V, 1997, AM J SURG PATHOL, V21, P399, DOI 10.1097/00000478-199704000-00005; Pecorelli S, 2009, INT J GYNECOL OBSTET, V105, P103, DOI 10.1016/j.ijgo.2009.02.012; Peevey JF, 2017, ONCOTARGET, V8, P42548, DOI 10.18632/oncotarget.17209; Prat J, 2004, HUM PATHOL, V35, P649, DOI 10.1016/j.humpath.2004.02.007; Prat J, 2007, PATHOLOGY, V39, P72, DOI 10.1080/00313020601136153; Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Soslow RA, 2012, AM J SURG PATHOL, V36, P1771, DOI 10.1097/PAS.0b013e318273591a; Stewart CJR, 2009, MODERN PATHOL, V22, P725, DOI 10.1038/modpathol.2009.33; Yeramian A, 2013, ONCOGENE, V32, P403, DOI 10.1038/onc.2012.76; Zaino RJ, 2014, WHO CLASSIFICATION T, P125; Zhao SM, 2013, P NATL ACAD SCI USA, V110, P2916, DOI 10.1073/pnas.1222577110	31	0	0	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						65	73		10.1016/j.humpath.2017.10.016			9	Pathology	Pathology	FS7TV	WOS:000422612600009	29079180				2019-10-28	
J	Bychkov, A; Jung, CK				Bychkov, Andrey; Jung, Chan Kwon			Aberrant expression of CD20 in thyroid cancer and its ctinicopathologic significance	HUMAN PATHOLOGY			English	Article						Thyroid cancer; Papillary thyroid carcinoma; CD20; Immunohistochemistry; BRAF mutation	MONOCLONAL ANTI-CD20; PAPILLARY CARCINOMA; LYMPHOMA; RITUXIMAB; MUTATION; THERAPY; INFILTRATION; PROGNOSIS; DIAGNOSIS; CYTOLOGY	CD20 is the first-line diagnostic marker of B-cells, which serves as the target of the therapeutic monoclonal antibodies in B-cell lymphomas and leukemias. Recently, aberrant CD20 expression has been described in a small series of papillary thyroid carcinomas (PTCs). We aimed to evaluate CD20 immunoexpression and to perform clinicopathologic correlation in a large set of thyroid tumors, including a cohort of high-grade thyroid cancer. A total of 625 cases of thyroid tumor comprised tissue microarrays of 538 PTCs and 47 follicular adenomas, and whole-slide sections of 40 aggressive thyroid carcinomas (10 radioiodine-refractory PTCs and 8 poorly differentiated, 5 anaplastic, and 17 medullary thyroid carcinomas) were immunostained with anti-CD20 monoclonal antibody. BRAF(V600E) mutation was tested by direct sequencing in 478 cancers. Our study found that a small subset of PTCs (<10%, mainly of classic variant) exhibited aberrant membranous expression of CD20. These tumors displayed less aggressive histological features and had a lower prevalence of BRAF(V600E) mutation. We also discovered that CD20 expression was maintained in 6%-20% of aggressive thyroid cancers but not observed in follicular adenomas. All CD20-positive tumor cells were negative for CD79a and PAX5. Aberrant expression of CD20 by thyroid cancer cells may present a diagnostic pitfall in cytologic evaluation of thyroid and cervical masses. Residual expression of CD20 in aggressive cancers may offer promise for translational implications, which merits further experimental investigation. (C) 2017 Elsevier Inc. All rights reserved.	[Bychkov, Andrey] Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand; [Jung, Chan Kwon] Catholic Univ Korea, Coll Med, Dept Hosp Pathol, Seoul 06591, South Korea; [Jung, Chan Kwon] Catholic Univ Korea, Coll Med, Canc Res Inst, Seoul 06591, South Korea	Jung, CK (reprint author), Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Hosp Pathol, 222 Banpo Daero, Seoul 06591, South Korea.	ckjung@catholic.ac.kr	Bychkov, Andrey/N-1884-2019; Jung, Chan Kwon/C-7578-2014	Bychkov, Andrey/0000-0002-4203-5696; Jung, Chan Kwon/0000-0001-6843-3708	Basic Science Research Program through the National Research Foundation of Korea (Daejeon, Republic of Korea) - Ministry of Science, ICT, and Future Planning [NRF-2017RIDIA1B03029597]; Korean Health Technology R&D Project (Cheongju-si, Chungcheongbuk-do, Republic of Korea), Ministry of Health & Welfare, Republic of Korea [HI16C2013]; Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkom University, Bangkok, Thailand	This work was supported by a grant (NRF-2017RIDIA1B03029597) of Basic Science Research Program through the National Research Foundation of Korea (Daejeon, Republic of Korea) funded by the Ministry of Science, ICT, and Future Planning and a grant (HI16C2013) of the Korean Health Technology R&D Project (Cheongju-si, Chungcheongbuk-do, Republic of Korea), Ministry of Health & Welfare, Republic of Korea. A. B. was supported by the Rachadapisek Sompot Fund for Postdoctoral Fellowship, Chulalongkom University, Bangkok, Thailand.	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Bychkov A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05481-z; Bychkov A, 2017, MALAYS J PATHOL, V39, P95; Bychkov A, 2016, PATHOLOGY, V48, P425, DOI 10.1016/j.pathol.2016.04.002; Cardot-Bauters C, 2008, CLIN ENDOCRINOL, V69, P506, DOI 10.1111/j.1365-2265.2008.03230.x; CHILOSI M, 1992, AM J SURG PATHOL, V16, P988; Cho U, 2014, J KOREAN MED SCI, V29, P1054, DOI 10.3346/jkms.2014.29.8.1054; Chu PGG, 2006, AM J CLIN PATHOL, V126, P534, DOI 10.1309/3WG32YRAMQ7RB9D4; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Cunha LL, 2012, CLIN ENDOCRINOL, V77, P918, DOI 10.1111/j.1365-2265.2012.04482.x; Cunha LL, 2013, ENDOCR-RELAT CANCER, V20, P103, DOI 10.1530/ERC-12-0313; El Fassi D, 2006, EUR J ENDOCRINOL, V154, P623, DOI 10.1530/eje.1.02140; Fadda G, 2011, ACTA CYTOL, V55, P389, DOI 10.1159/000329029; Foran JM, 2001, BRIT J HAEMATOL, V114, P881, DOI 10.1046/j.1365-2141.2001.03019.x; Hainsworth JD, 2002, J CLIN ONCOL, V20, P4261, DOI 10.1200/JCO.2002.08.674; Kim Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174737; Lloyd RV, 2017, PATHOLOGY GENETICS T; Ludvikova M, 2001, HISTOPATHOLOGY, V39, P17, DOI 10.1046/j.1365-2559.2001.01154.x; Ogechukwu E., 2012, EPIGENETIC EVENTS SU; Ostrowski RA, 2015, NEURO-OPHTHALMOLOGY, V39, P109, DOI 10.3109/01658107.2015.1039140; Ozaki O, 1996, AM J SURG PATHOL, V20, P695, DOI 10.1097/00000478-199606000-00006; Sangalli G, 2001, CYTOPATHOLOGY, V12, P257, DOI 10.1046/j.1365-2303.2001.00338.x; Sasaki Y, 2017, PATHOL INT, V67, P350, DOI 10.1111/pin.12548; Song YS, 2015, ENDOCRINOL METAB, V30, P252, DOI 10.3803/EnM.2015.30.3.252; TEDDER TF, 1988, P NATL ACAD SCI USA, V85, P208, DOI 10.1073/pnas.85.1.208; Ugolini C, 2007, THYROID, V17, P389, DOI 10.1089/thy.2006.0306; Valerio L, 2017, CLIN ONCOL-UK, V29, P316, DOI 10.1016/j.clon.2017.02.009; Walsh S, 2013, ONCOLOGIST, V18, P994, DOI 10.1634/theoncologist.2013-0036; Wright CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034943; Xing MZ, 2013, JAMA-J AM MED ASSOC, V309, P1493, DOI 10.1001/jama.2013.3190; Zuccolo J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00195	31	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						74	83		10.1016/j.humpath.2017.10.015			10	Pathology	Pathology	FS7TV	WOS:000422612600010	29079175				2019-10-28	
J	Wang, DZ; Liu, P; Yao, L; Hao, YH; Zhu, RJ; Zhang, T; Tang, XB				Wang, Dai-Zhong; Liu, Ping; Yao, Li; Hao, Ying-Hua; Zhu, Rui-Juan; Zhang, Tao; Tang, Xian-Bin			Aberrant expression of thyroid transcription factor-1 in schwannomas	HUMAN PATHOLOGY			English	Article						Schwannoma; TTF-1; Immunohistochemistry; qPCR; mRNA; Transcriptional activation	LUNG ADENOCARCINOMA; TTF-1 EXPRESSION; CANCER; DIAGNOSIS; UPDATE; PATHOGENESIS; PROGRESSION; MECHANISMS; ONCOGENE; ORIGIN	Aberrant expression of thyroid transcription factor-1 (TTF-1) has been observed in tumors arising in locations other than thyroid gland, lung and ventral forebrain. However, TTF-1 expression in schwannomas has not yet been studied. Meanwhile, a few inconsistent changes in protein expression have been identified between schwannomas and other peripheral nerve sheath tumors. We evaluated TTF-1 expression in 161 schwannomas and 43 other peripheral nervous system lesions, including ganglioneuromas (n = 8), malignant peripheral nerve sheath tumors (MPNSTs) (n = 11), neurofibromas (n = 24), and traumatic neuromas (n = 9), using immunohistochemistry and verified it using quantitative real-time reverse-transcription polymerase chain reaction (qPCR) to explore TTF-1 expression in peripheral nervous system lesions. Formalinfixed paraffin-embedded (FFPE) tissues were obtained for both analyses. In this study, we observed nuclear TTF-1 staining in 109 (67.7%) schwannomas, including 102 of 131 (77.9%) conventional, 1 of 20 (5.0%) cellular and 6 of 10 (60.0%) plexiform schwannomas. Nuclear staining was not observed in normal peripheral nerves and non-schwannoma lesions. qPCR verified the aberrant expression and revealed a correlation between TTF-1 protein and mRNA levels (r = 0.633, P=.003). In conclusion, the data from our study show that TTF-1 is selectively expressed in the majority of schwannomas, particularly the conventional variants. Based on this observation, the TTF-1 protein and mRNA are specifically expressed in schwannomas. This highly aberrant expression of varying amounts of TTF-1 may provide new clues to reveal the pathogenesis of schwannoma. (C) 2017 Elsevier Inc. All rights reserved.	[Wang, Dai-Zhong; Liu, Ping; Yao, Li; Hao, Ying-Hua; Zhu, Rui-Juan; Tang, Xian-Bin] Hubei Univ Med, Taihe Hosp, Dept Pathol, 32 Ren Min South Rd, Shiyan 442000, Hubei, Peoples R China; [Zhang, Tao] Hubei Univ Med, Taihe Hosp, Dept Neurosurg, Shiyan 442000, Hubei, Peoples R China	Tang, XB (reprint author), Hubei Univ Med, Taihe Hosp, Dept Pathol, 32 Ren Min South Rd, Shiyan 442000, Hubei, Peoples R China.	taiheblk@126.com					Anagnostou VK, 2009, J CLIN ONCOL, V27, P271, DOI 10.1200/JCO.2008.17.0043; Bielle F, 2015, AM J SURG PATHOL, V39, P948, DOI 10.1097/PAS.0000000000000421; Carroll SL, 2012, ACTA NEUROPATHOL, V123, P321, DOI 10.1007/s00401-011-0928-6; CASADEI GP, 1995, CANCER, V75, P1109, DOI 10.1002/1097-0142(19950301)75:5<1109::AID-CNCR2820750510>3.0.CO;2-M; Comperat E, 2005, MODERN PATHOL, V18, P1371, DOI 10.1038/modpathol.3800422; David N, 2016, WHO CLASSIFICATION T; Evans DGR, 2005, BRIT J NEUROSURG, V19, P5, DOI 10.1080/02688690500081206; Fernandez LP, 2015, NAT REV ENDOCRINOL, V11, P29, DOI 10.1038/nrendo.2014.186; Galloway M, 2007, VIRCHOWS ARCH, V451, P109, DOI 10.1007/s00428-007-0432-5; Hang JF, 2017, MODERN PATHOL, V30, P318, DOI 10.1038/modpathol.2016.205; Hewer E, 2015, CLIN NEUROPATHOL, V34, P128, DOI 10.5414/NP300818; Hilton DA, 2014, BRAIN PATHOL, V24, P205, DOI 10.1111/bpa.12125; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416; Hulsebos TJM, 2014, ACTA NEUROPATHOL, V128, P439, DOI 10.1007/s00401-014-1281-3; Jessen KR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020487; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kleinschmidt-DeMasters BK, 2013, BRAIN PATHOL, V23, P495, DOI 10.1111/bpa.12068; Kristensen MH, 2011, APPL IMMUNOHISTO M M, V19, P437, DOI 10.1097/PAI.0b013e31820e6baf; Kwei KA, 2008, ONCOGENE, V27, P3635, DOI 10.1038/sj.onc.1211012; MacCollin M, 2005, NEUROLOGY, V64, P1838, DOI 10.1212/01.WNL.0000163982.78900.AD; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; Monk KR, 2015, GLIA, V63, P1376, DOI 10.1002/glia.22852; Mu D, 2013, J BIOL CHEM, V288, P24992, DOI 10.1074/jbc.R113.491647; Newbern JM, 2015, CURR TOP DEV BIOL, V111, P201, DOI 10.1016/bs.ctdb.2014.11.007; Ngan ESW, 2009, JNCI-J NATL CANCER I, V101, P162, DOI 10.1093/jnci/djn471; Ordonez NG, 2012, APPL IMMUNOHISTO M M, V20, P429, DOI 10.1097/PAI.0b013e31825439bc; Ordonez NG, 2003, AM J SURG PATHOL, V27, P1031, DOI 10.1097/00000478-200308000-00001; Piller Nicolas, 2013, BMC Res Notes, V6, P266, DOI 10.1186/1756-0500-6-266; Rodriguez FJ, 2012, ACTA NEUROPATHOL, V123, P295, DOI 10.1007/s00401-012-0954-z; Runkle EA, 2012, J BIOL CHEM, V287, P28790, DOI 10.1074/jbc.M112.367987; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sullivan PS, 2012, MODERN PATHOL, V25, P1140, DOI 10.1038/modpathol.2012.64; Walter RFH, 2013, PATHOL RES PRACT, V209, P784, DOI 10.1016/j.prp.2013.09.007; Wang JM, 2016, NEUROPATHOLOGY, V36, P432, DOI 10.1111/neup.12291; Weber R, 2014, BIOMED RES INT, DOI 10.1155/2014/198582; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wilkes D, 2005, LANCET ONCOL, V6, P501, DOI 10.1016/S1470-2045(05)70244-8; Winslow MM, 2011, NATURE, V473, P101, DOI 10.1038/nature09881; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yatabe Y, 2002, AM J SURG PATHOL, V26, P767, DOI 10.1097/00000478-200206000-00010	41	3	3	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						84	90		10.1016/j.humpath.2017.10.025			7	Pathology	Pathology	FS7TV	WOS:000422612600011	29104109				2019-10-28	
J	Panjwani, PK; Charu, V; DeLisser, M; Molina-Kirsch, H; Natkunam, Y; Zhao, SC				Panjwani, Poonam K.; Charu, Vivek; DeLisser, Monique; Molina-Kirsch, Hernan; Natkunam, Yasodha; Zhao, Shuchun			Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes	HUMAN PATHOLOGY			English	Article						PD-L1; PD-L2; Immune checkpoint; Hodgkin lymphoma; Non-Hodgkin lymphoma	B-CELL LYMPHOMA; HODGKIN LYMPHOMAS; T-CELLS; LYMPHOPROLIFERATIVE DISORDERS; CLASSICAL HODGKIN; CANCER; ACTIVATION; BLOCKADE; B7-H1; IMMUNITY	The success of immunotherapy using immune checkpoint blockade in solid tumors and in relapsed/refractory classical Hodgkin lymphoma and chronic lymphocytic leukemia holds promise for targeted therapy in hematologic malignancies. Because efficacy of immunomodulatory therapy is correlated with numbers of cells that express programmed death (PD-1) ligands, we evaluated the expression of PD-L1 and PD-L2 proteins using immunohistochemistry in more than 702 diagnostic lymphoma biopsies. In classical Hodgkin lymphoma, PD-L1 and PD-L2 were expressed in 82% and 41% of cases, respectively, and PD-L1 but not PD-L2 expression correlated with Epstein-Barr virus in tumor cells. PD-L1 staining was detected in 80% of anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, and follicular dendritic cell sarcoma; 75% of nodular lymphocyte predominant Hodgkin lymphoma; 53% of primary mediastinal large B-cell lymphoma; 39% of extranodal NIUT cell lymphoma; 26% of peripheral T-cell lymphoma; 10% of diffuse large B-cell lymphoma; and very rare examples of mantle, marginal zone, and small lymphocytic lymphomas. PD-L2 staining was present in 78% of primary mediastinal large B-cell lymphoma but in fewer cases in all other categories including 40% of follicular dendritic cell sarcoma and 7% of anaplastic large cell lymphoma. Our results confirm and extend prior studies of PD-L1 and provide new data of PD-L2 expression in lymphomas. The differential expression pattems in some tumor types and the expression of PD-L2 in the absence of PD-L1 raise the possibility of targeted therapy for additional subsets of patients with lymphoma. (C) 2017 Elsevier Inc. All rights reserved.	[Panjwani, Poonam K.] St Johns Med Coll & Hosp, Dept Pathol, Bangalore 560034, Karnataka, India; [Charu, Vivek; DeLisser, Monique; Natkunam, Yasodha; Zhao, Shuchun] Stanford Univ, Sch Med, Dept Pathol, L235,300 Pasteur Dr, Stanford, CA 94305 USA; [Molina-Kirsch, Hernan] Lab Patol Dr Molina Kirsch, Guatemala City, Guatemala	Zhao, SC (reprint author), Stanford Univ, Sch Med, Dept Pathol, L235,300 Pasteur Dr, Stanford, CA 94305 USA.	zshuchun@stanford.edu			World Pathology Foundation; Stanford UniversityStanford University; Sir Dorabji Tata Trust, Mumbai, India	Dr Panjwani thanks the World Pathology Foundation for the Gordon Signy Fellowship 2016 awarded for study at Stanford University and the Sir Dorabji Tata Trust, Mumbai, India, for a travel grant.	Anderson MW, 2012, AM J PATHOL, V181, P795, DOI 10.1016/j.ajpath.2012.05.015; Andorsky DJ, 2011, CLIN CANCER RES, V17, P4232, DOI 10.1158/1078-0432.CCR-10-2660; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Boussiotis VA, 2015, BLOOD, V126, P2171, DOI 10.1182/blood-2015-08-663997; Brown JA, 2003, J IMMUNOL, V170, P1257, DOI 10.4049/jimmunol.170.3.1257; Chen BJ, 2013, CLIN CANCER RES, V19, P3462, DOI 10.1158/1078-0432.CCR-13-0855; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; de Jong D, 2017, AM J CLIN PATHOL, V147, P153, DOI 10.1093/ajcp/aqw216; Ding W, 2017, BLOOD, V129, P3419, DOI 10.1182/blood-2017-02-765685; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Dorfman DM, 2006, AM J SURG PATHOL, V30, P802, DOI 10.1097/01.pas.0000209855.28282.ce; Gatalica Z, 2014, CANCER EPIDEM BIOMAR, V23, P2965, DOI 10.1158/1055-9965.EPI-14-0654; Green MR, 2012, CLIN CANCER RES, V18, P1611, DOI 10.1158/1078-0432.CCR-11-1942; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Han LJ, 2014, ONCOL LETT, V8, P1461, DOI 10.3892/ol.2014.2356; Ishida M, 2002, IMMUNOL LETT, V84, P57, DOI 10.1016/S0165-2478(02)00142-6; Kiyasu J, 2015, BLOOD, V126, P2193, DOI 10.1182/blood-2015-02-629600; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Mahoney KM, 2015, CANCER IMMUNOL RES, V3, P1308, DOI 10.1158/2326-6066.CIR-15-0116; Marzec M, 2008, P NATL ACAD SCI USA, V105, P20852, DOI 10.1073/pnas.0810958105; Messal N, 2011, MOL IMMUNOL, V48, P2214, DOI 10.1016/j.molimm.2011.06.436; Rehman JA, 2017, MODERN PATHOL, V30, P340, DOI 10.1038/modpathol.2016.186; Rimm DL, 2017, JAMA ONCOL, V3, P1051, DOI 10.1001/jamaoncol.2017.0013; Rosenwald A, 2003, J EXP MED, V198, P851, DOI 10.1084/jem.20031074; Shi M, 2014, AM J SURG PATHOL, V38, P1715, DOI 10.1097/PAS.0000000000000297; Stevens WBC, 2017, HAEMATOLOGICA, V102, P1413, DOI 10.3324/haematol.2017.165415; Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Wilcox RA, 2009, BLOOD, V114, P2149, DOI 10.1182/blood-2009-04-216671; Xerri L, 2008, HUM PATHOL, V39, P1050, DOI 10.1016/j.humpath.2007.11.012; Xu J, 2016, AM J SURG PATHOL, V40, P443, DOI 10.1097/PAS.0000000000000590; Yamamoto R, 2008, BLOOD, V111, P3220, DOI 10.1182/blood-2007-05-085159; Zappasodi R, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00448; Zhang Y, 2006, P NATL ACAD SCI USA, V103, P11695, DOI 10.1073/pnas.0601347103	35	14	15	1	7	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						91	99		10.1016/j.humpath.2017.10.029			9	Pathology	Pathology	FS7TV	WOS:000422612600012	29122656				2019-10-28	
J	Hurabielle, C; Sbidian, E; Beltraminelli, H; Bouchindhomme, B; Chassagne-Clement, C; Balme, B; Bossard, C; Delfau-Larue, MH; Wolkenstein, P; Chosidow, O; Cordonnier, C; Toma, A; Pautas, C; Ortonne, N				Hurabielle, Charlotte; Sbidian, Emilie; Beltraminelli, Helmut; Bouchindhomme, Brigitte; Chassagne-Clement, Catherine; Balme, Brigitte; Bossard, Celine; Delfau-Larue, Marie-Helene; Wolkenstein, Pierre; Chosidow, Olivier; Cordonnier, Catherine; Toma, Andrea; Pautas, Cecile; Ortonne, Nicolas			Eruption of lymphocyte recovery with atypical lymphocytes mimicking a primary cutaneous T-cell lymphoma: a series of 12 patients	HUMAN PATHOLOGY			English	Article						Eruption of lymphocyte recovery; Pseudolymphoma; CD30+lymphoproliferative disorder; Cutaneous T-cell lymphoma; Maculopapular rash	LYMPHOPROLIFERATIVE DISORDERS; FOLLOW-UP; CHEMOTHERAPY; DIAGNOSIS; FEATURES; SKIN	Eruption of lymphocyte recovery (ELR) may occur during bone marrow aplasia after chemotherapies. We reviewed the clinical and pathologic features of 12 patients (male-female ratio, 7:5; median age, 61 years) with an atypical ELR histologically mimicking a primary cutaneous T-cell lymphoma such as Sezary syndrome or CD30+ T-cell lymphoproliferative disorder. All the patients displayed an erythematous maculopapular eruption on the trunk and the limbs associated with fever. All but one had received a poly chemotherapy for an acute myeloid leukemia (n = 10) or a urothelial carcinoma (n = 1) before the occurrence of the skin eruption. One had an autoimmune lymphoproliferative syndrome causing chronic agranulocytosis requiring granulocyte colony-stimulating factor injection. In all patients, the skin eruption was associated with a slight increase of white blood cell count followed by bone marrow recovery within the next weeks. All skin biopsies showed a dermal perivascular lymphocytic infiltrate containing atypical medium- to large-sized CD3+, CD4+ and CD8+, CD25+, ICOS+, PDI- lymphocytes with a strong CD30 expression in most instances (n = 10), suggesting the recruitment of strongly activated T cells in the skin. In 6 patients, a diagnosis of CD30+ lymphoproliferative disorder or Sezary syndrome was proposed or suspected histopathologically, and only the clinical context allowed the diagnosis of ELR with a peculiar presentation with atypical lymphocytes. We describe a series of patients with an unusual form of ELR characterized by the presence of atypical activated T cells in the skin. On a practical ground, pathologists should be aware of this distinctive and misleading presentation. (C) 2017 Elsevier Inc. All rights reserved.	[Hurabielle, Charlotte; Sbidian, Emilie; Wolkenstein, Pierre; Chosidow, Olivier] Hop Henri Mondor, AP HP, Dept Dermatol, F-94220 Creteil, France; [Beltraminelli, Helmut] Univ Bern, Inselspital, Bern Univ Hosp, Dept Dermatol, CH-3010 Bern, Switzerland; [Bouchindhomme, Brigitte] Lille Univ Hosp, Dept Pathol, F-59000 Lille, France; [Chassagne-Clement, Catherine] Ctr Leon Berard, Dept Pathol, F-69008 Lyon, France; [Balme, Brigitte] Lyon Sud Univ Hosp, Dept Pathol, F-69310 Pierre Benite, France; [Bossard, Celine] Nantes Univ Hosp, Dept Pathol, F-44093 Nantes 1, France; [Delfau-Larue, Marie-Helene] Henri Mondor Hosp, AP HP, Dept Biol Hematol, F-94220 Creteil, France; [Delfau-Larue, Marie-Helene; Ortonne, Nicolas] Henri Mondor Hosp, AP HP, INSERM, U955,Team 9, F-94220 Creteil, France; [Cordonnier, Catherine; Toma, Andrea; Pautas, Cecile] Henri Mondor Hosp, AP HP, Dept Hematol, F-94220 Creteil, France; [Ortonne, Nicolas] Henri Mondor Hosp, AP HP, Dept Pathol, F-94220 Creteil, France	Ortonne, N (reprint author), Henri Mondor Hosp, AP HP, INSERM, U955,Team 9, F-94220 Creteil, France.	nicolas.ortonne@aphp.fr		Ortonne, Nicolas/0000-0003-0111-7422; Wolkenstein, Pierre/0000-0001-8194-457X			Ahmed I, 1998, MAYO CLIN PROC, V73, P239, DOI 10.4065/73.3.239; Alley E, 2002, CURR OPIN ONCOL, V14, P212, DOI 10.1097/00001622-200203000-00012; BAUER DJ, 1993, ARCH DERMATOL, V129, P855, DOI 10.1001/archderm.129.7.855; Bekkenk MW, 2000, BLOOD, V95, P3653; Bircher AJ, 2012, CURR PROBL DERMATOL, V43, P150, DOI 10.1159/000335483; Castano E, 2002, J CUTAN PATHOL, V29, P579, DOI 10.1034/j.1600-0560.2002.291002.x; Cepeda LT, 2003, AM J SURG PATHOL, V27, P912, DOI 10.1097/00000478-200307000-00006; Cetkovska P, 2002, J EUR ACAD DERMATOL, V16, P481, DOI 10.1046/j.1468-3083.2002.00395.x; Delfau-Larue MH, 1998, J PATHOL, V184, P185; GIBNEY MD, 1995, J CUTAN PATHOL, V22, P472, DOI 10.1111/j.1600-0560.1995.tb00765.x; Hayashi T, 2015, BLOOD TRANSFUS-ITALY, V13, P380, DOI 10.2450/2015.0275-14; Hirayama F, 2013, BRIT J HAEMATOL, V160, P434, DOI 10.1111/bjh.12150; Horn T, 1996, J CUTAN PATHOL, V23, P242, DOI 10.1111/j.1600-0560.1996.tb01473.x; HORN TD, 1989, ARCH DERMATOL, V125, P1512, DOI 10.1001/archderm.125.11.1512; HORN TD, 1994, J CUTAN PATHOL, V21, P385, DOI 10.1111/j.1600-0560.1994.tb00277.x; Li X, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010432.pub2; Macgrogan G, 1996, AM J CLIN PATHOL, V105, P440; Nellen RGL, 2008, INT J DERMATOL, V47, P32, DOI 10.1111/j.1365-4632.2008.03956.x; Ortonne N, 2015, BRIT J DERMATOL, V173, P50, DOI 10.1111/bjd.13683; PAULLI M, 1995, J CLIN ONCOL, V13, P1343, DOI 10.1200/JCO.1995.13.6.1343; Payne AS, 2006, SEMIN ONCOL, V33, P86, DOI 10.1053/j.seminoncol.2005.11.004; Ruben BS, 2015, J AM ACAD DERMATOL, V73, P821, DOI 10.1016/j.jaad.2015.07.010; Sanborn RE, 2008, DERMATOL CLIN, V26, P103, DOI 10.1016/j.det.2007.08.006; Vergier B, 1998, AM J SURG PATHOL, V22, P1192, DOI 10.1097/00000478-199810000-00004; WALKER IR, 1985, ARCH DERMATOL, V121, P1240, DOI 10.1001/archderm.1985.01660100020006; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; Wright LG, 2006, ONCOL NURS FORUM, V33, P1095, DOI 10.1188/06.ONF.1095-1103	27	2	2	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						100	108		10.1016/j.humpath.2017.10.018			9	Pathology	Pathology	FS7TV	WOS:000422612600013	29107664				2019-10-28	
J	Lloyd, IE; Ahmed, F; Revelo, MP; Khalighi, MA				Lloyd, Isaac E.; Ahmed, Faris; Revelo, Monica P.; Khalighi, Mazdak A.			De novo immune complex deposition in kidney allografts: a series of 32 patients	HUMAN PATHOLOGY			English	Article						Kidney transplant; Glomerulonephritis; Rejection; Immune complex deposition; Kidney Biopsy	ANTIBODY-MEDIATED REJECTION; C VIRUS-INFECTION; OF-THE-LITERATURE; RENAL-ALLOGRAFT; MEMBRANOUS NEPHROPATHY; GLOMERULONEPHRITIS; RECURRENT; TRANSPLANTATION; CLASSIFICATION; RECIPIENTS	Immune complex deposition in kidney allografts can include both recurrent and de novo processes. Recurrent glomerulonephritis is a well-recognized phenomenon and has been shown to be a common cause of allograft failure. De novo immune complex mediated disease remains relatively poorly characterized, likely owing to the less frequent use of immunofluorescence and electron microscopy in the transplant setting. We performed a retrospective review of kidney allograft biopsies showing glomerular immune complex deposition. Cases with de novo deposits were identified and further organized into two groups depending on whether the immune complex deposition could be clinically and/or histologically classified. Thirtytwo patients with de novo immune complex deposition were identified over a 7-year period. A broad range of immune complex mediated injuries were observed, the majority (63%) of which could be readily classified either clinically or histologically. These included cases of membranous glomerulonephropathy, IgA nephropathy, infection-related glomerulonephritis and glomerulonephritis related to an underlying autoimmune process. A smaller subset of patients (37%) demonstrated immune complex deposition that was difficult to histologically or clinically classify. These patients typically showed mild mesangial immune complex deposition with co-dominant IgG and IgM staining by immunofluorescence microscopy. The presence of concurrent antibody-mediated rejection and donor-specific antibody positivity was significantly higher in the unclassifiable group. The significance of these deposits and their possible relationship to allograft rejection deserves further investigation. (C) 2017 Elsevier Inc. All rights reserved.	[Lloyd, Isaac E.; Revelo, Monica P.; Khalighi, Mazdak A.] Univ Utah, Dept Pathol, Salt Lake City, UT 84112 USA; [Ahmed, Faris] Univ Utah, Div Nephrol, Salt Lake City, UT 84312 USA	Khalighi, MA (reprint author), Huntsman Canc Hosp, 1950 Circle Hope Dr RM N3100, Salt Lake City, UT 84124 USA.	Mazdak.Khalighi@hsc.utah.edu					Briganti EM, 2002, NEW ENGL J MED, V347, P103, DOI 10.1056/NEJMoa013036; Cosio FG, 2017, KIDNEY INT, V91, P304, DOI 10.1016/j.kint.2016.08.030; Cruzado JM, 2001, AM J TRANSPLANT, V1, P171, DOI 10.1034/j.1600-6143.2001.001002171.x; Giannico GA, 2015, HUM PATHOL, V46, P1521, DOI 10.1016/j.humpath.2015.06.012; Gough J, 2005, ARCH PATHOL LAB MED, V129, P231; Grau V, 2016, TRANSPLANTATION, V100, P1004, DOI 10.1097/TP.0000000000001068; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Hariharan S, 1998, AM J KIDNEY DIS, V31, P928, DOI 10.1053/ajkd.1998.v31.pm9631835; Honda K, 2011, CLIN TRANSPLANT, V25, P191, DOI 10.1111/j.1399-0012.2010.01213.x; Ivanyi B, 2008, NAT CLIN PRACT NEPHR, V4, P446, DOI 10.1038/ncpneph0854; Kearney N, 2011, TRANSPL P, V43, P3743, DOI 10.1016/j.transproceed.2011.10.042; Loupy A, 2017, AM J TRANSPLANT, V17, P28, DOI 10.1111/ajt.14107; Mengel M, 2012, AM J TRANSPLANT, V12, P563, DOI 10.1111/j.1600-6143.2011.03926.x; MONGA G, 1993, MODERN PATHOL, V6, P249; Moroni G, 2004, AM J TRANSPLANT, V4, P132, DOI 10.1046/j.1600-6135.2003.00283.x; Ozdemir BH, 2006, TRANSPL P, V38, P492, DOI 10.1016/j.transproceed.2005.12.109; Patel K, 2013, TRANSPL P, V45, P3424, DOI 10.1016/j.transproceed.2013.05.011; Plumb TJ, 2006, TRANSPLANTATION, V82, P1224, DOI 10.1097/01.tp.0000232327.09757.7b; Ponticelli C, 2012, TRANSPL INT, V25, P1205, DOI 10.1111/j.1432-2277.2012.01548.x; Requiao-Moura LR, 2007, CLIN TRANSPLANT, V21, P363, DOI 10.1111/j.1399-0012.2007.00650.x; Said SM, 2010, MODERN PATHOL, V23, P1080, DOI 10.1038/modpathol.2010.92; SOLEZ K, 1993, KIDNEY INT, V44, P411, DOI 10.1038/ki.1993.259	22	1	1	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						109	116		10.1016/j.humpath.2017.10.012			8	Pathology	Pathology	FS7TV	WOS:000422612600014	29079181				2019-10-28	
J	Carter, MD; Gaston, D; Huang, WY; Greer, WL; Pasternak, S; Ly, TY; Walsh, NM				Carter, Michael D.; Gaston, Dan; Huang, Weei-Yuarn; Greer, Wenda L.; Pasternak, Sylvia; Thai Yen Ly; Walsh, Noreen M.			Genetic profiles of different subsets of Merkel. cell carcinoma show links between combined and pure MCPyV-negative tumors	HUMAN PATHOLOGY			English	Article						Merkel cell carcinoma; SNP microarray; Copy number aberrations; Next-generation sequencing; TP53; RBI	COMPARATIVE GENOMIC HYBRIDIZATION; MUTATIONAL LANDSCAPE; ARRAY-CGH; POLYOMAVIRUS; CANCER; EXPRESSION; P53	Tumorigenesis in Merkel cell carcinoma (MCC) is driven by (1) clonal integration of the Merkel cell polyomavirus (MCPyV) in neoplastic cells and/or (2) genetic damage by ultraviolet (UV) light. A higher mutational burden, a UV-mutational signature, and many mutations in the TP53 and RBI genes characterize the virus-negative subset. MCPyV-negative MCCs include combined (often squamous and neuroendocrine) and pure (neuroendocrine) tumors. Because a combined morphology could elude detection microscopically, we sought a genetic link between combined and pure virus-negative tumors. From a global cohort of 46 cases, 9 pure MCPyV-positive, 9 pure MCPyV-negative, and 10 combined MCPyV-negative MCCs were studied by genome-wide microarray in search of copy number aberrations. The entire cohort (n = 46) was evaluated by next-generation sequencing for mutations in selected tumor suppressor genes and oncogenes. More copy number aberrations and a greater fraction of the genome were changed in combined and pure MCPyV-negative tumors relative to MCPyV-positive cases (P < .01 for all comparisons). No difference in these parameters was found between the 2 MCPyV-negative groups. Copy number loss of RBI or an inactivating RBI mutation (either or both) was common in combined (8/10, 80%) and pure (7/9, 78%) MCPyV-negative tumors but not MCPyV-positive cases (1/9, 11%). A similar trend was seen for TP53 (combined [2/10, 20%] and pure virus-negative tumors [5/9, 56%] showed gene copy number loss or mutations contrasted with pure virus-positive cases [0/9, 0%]). The shared genetic profiles of combined and pure MCPyV-negative tumors link these subsets and separate them from MCPyV-positive tumors. (C) 2017 Elsevier Inc. All rights reserved.	[Carter, Michael D.; Gaston, Dan; Huang, Weei-Yuarn; Greer, Wenda L.; Pasternak, Sylvia; Thai Yen Ly; Walsh, Noreen M.] Nova Scotia Hlth Author Cent Zone, Queen Elizabeth II Hlth Sci Ctr, DPLM, Halifax, NS B3H 1V8, Canada; [Carter, Michael D.; Gaston, Dan; Huang, Weei-Yuarn; Greer, Wenda L.; Pasternak, Sylvia; Thai Yen Ly; Walsh, Noreen M.] Dalhousie Univ, Dept Pathol, Halifax, NS B3H 1V8, Canada; [Walsh, Noreen M.] Dalhousie Univ, Dept Med, Halifax, NS B3H 1V8, Canada; [Carter, Michael D.] Michigan Med Dept Pathol, Traverwood 2,2910 Huron Pkwy Suite C, Ann Arbor, MI 48105 USA	Carter, MD (reprint author), Queen Elizabeth 2 Hlth Sci Ctr, Div Anat Pathol, Mackenzie Bldg,5788 Univ Ave,Seventh Floor, Halifax, NS B3H 1V8, Canada.; Carter, MD (reprint author), Dalhousie Univ, Mackenzie Bldg,5788 Univ Ave,Seventh Floor, Halifax, NS B3H 1V8, Canada.; Carter, MD (reprint author), Michigan Med Dept Pathol, Traverwood 2,2910 Huron Pkwy Suite C, Ann Arbor, MI 48105 USA.	carter.mike@gmail.com			Nova Scotia Health Authority Research Fund; DPLM Fund for Molecular Pathology housed at the QE II Foundation, Halifax, Nova Scotia, Canada	The study was supported by research grants from the Nova Scotia Health Authority Research Fund and the DPLM Fund for Molecular Pathology housed at the QE II Foundation, Halifax, Nova Scotia, Canada.	Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393; Ardakani NM, 2017, PATHOLOGY, V49, P285, DOI 10.1016/j.pathol.2016.11.008; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Feng HC, 2008, SCIENCE, V319, P1096, DOI 10.1126/science.1152586; Fleming KE, 2014, HUM PATHOL, V45, P952, DOI 10.1016/j.humpath.2013.12.008; Foster JM, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0079-z; Gaston D., 2016, NSHA NGS ANAL PIPELI; Goh G, 2016, ONCOTARGET, V7, P3393, DOI 10.18632/oncotarget.6494; Harms PW, 2016, MODERN PATHOL, V29, P240, DOI 10.1038/modpathol.2015.154; Harms PW, 2015, CANCER RES, V75, P3720, DOI 10.1158/0008-5472.CAN-15-0702; Hesbacher S, 2016, ONCOTARGET, V7, P32956, DOI 10.18632/oncotarget.8793; Kanska J, 2016, GYNECOL ONCOL, V143, P152, DOI 10.1016/j.ygyno.2016.07.111; Lai JH, 2015, HUM PATHOL, V46, P1290, DOI 10.1016/j.humpath.2015.05.008; Larramendy ML, 2004, MODERN PATHOL, V17, P561, DOI 10.1038/modpathol.3800091; Ly TY, 2012, HUM PATHOL, V43, P557, DOI 10.1016/j.humpath.2011.06.005; MacDonald JR, 2014, NUCLEIC ACIDS RES, V42, pD986, DOI 10.1093/nar/gkt958; Massacesi C, 2016, ONCOTARGETS THER, V9, P203, DOI 10.2147/OTT.S89967; Moshiri AS, 2017, J INVEST DERMATOL, V137, P819, DOI 10.1016/j.jid.2016.10.028; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Paulson KG, 2009, J INVEST DERMATOL, V129, P1547, DOI 10.1038/jid.2008.365; Pulitzer MP, 2015, MODERN PATHOL, V28, P1023, DOI 10.1038/modpathol.2015.60; Shihab HA, 2015, BIOINFORMATICS, V31, P1536, DOI 10.1093/bioinformatics/btv009; Sihto H, 2009, JNCI-J NATL CANCER I, V101, P938, DOI 10.1093/jnci/djp139; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Walsh NMG, 2001, HUM PATHOL, V32, P680, DOI 10.1053/hupa.2001.25904; Walsh NM, 2016, HUM PATHOL, V52, P190, DOI 10.1016/j.humpath.2016.02.002; Wang L, 2013, J MOL DIAGN, V15, P581, DOI 10.1016/j.jmoldx.2013.04.001; Wang Y, 2012, CANCER GENET-NY, V205, P341, DOI 10.1016/j.cancergen.2012.06.005; Wong SQ, 2015, CANCER RES, V75, P5228, DOI 10.1158/0008-5472.CAN-15-1877; Woods Robbie Sr, 2014, World J Clin Cases, V2, P172, DOI 10.12998/wjcc.v2.i6.172	30	11	11	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						117	125		10.1016/j.humpath.2017.10.014			9	Pathology	Pathology	FS7TV	WOS:000422612600015	29079179				2019-10-28	
J	Pradhan, D; Schoedel, K; McGough, RL; Ranganathan, S; Rao, UNM				Pradhan, Dinesh; Schoedel, Karen; McGough, Richard L.; Ranganathan, Sarangarajan; Rao, Uma N. M.			Pseudomyogenic hemangioendothelioma of skin, bone and soft tissue-a clinicopathological, immunohistochemical, and fluorescence in situ hybridization study	HUMAN PATHOLOGY			English	Article						Pseudomyogenic hemangioendothelioma; t(7;19); FISH; Bone; Soft tissue; Skin	SARCOMA-LIKE HEMANGIOENDOTHELIOMA; FIBROMA-LIKE VARIANT; EPITHELIOID SARCOMA; MYC AMPLIFICATION; INDOLENT BEHAVIOR; TUMOR; FOSB; EXPRESSION; ANGIOSARCOMA; NEOPLASM	Pseudomyogenic hemangioendothelioma (PHE) is an uncommon neoplasm with propensity for local recurrence. The tumor mimics epithelioid hemangioendothelioma and epithelioid sarcoma, representing a possible diagnostic pitfall. We investigated the clinicopathological, immunohistochemical, and fluorescence in situ hybridization features of PHEs. Eight cases of PHE were retrieved from our pathology archives. The clinical and outcome information was available in 6 patients. In 6 cases, the tumors were located in the lower limb, whereas the upper limb was involved in 2 cases. Three patients had exclusively bone involvement, and 2 patients had cutaneous tumor only. The tumor was multifocal in 5 cases, of which 2 patients had simultaneous bone and soft tissue involvement. Immunohistochemical stains revealed all tumors to be positive for AE1/AE3 (8/8), ERG (7/7), and FLI-1 (7/7) with preserved INI1 (7/7) expression. Most of the tumors were variably positive for CD31 (7/8), CAMS.2 (2/3), and SMA (4/6). t(7;19)(q22;q13) fusion pattern was detected in 3 cases (5 tumors) with cutaneous and multifocal PHE. In 3 cases, a translocation pattern was detected in a few nuclei but did not meet our laboratory cutoff value. MYC amplification was not detected in any of the 5 cases examined, aiding in ruling out the possibility of angiosarcoma. Four patients underwent excision, and 2 with multifocal tumor required below-knee amputation. Six patients with outcome information were alive and free of disease after a median follow-up of 35 months. We conclude that ancillary techniques can be helpful in differentiating this unusual indolent tumor from potentially aggressive epithelioid hemangioendothelioma, epithelioid sarcoma, and epithelioid angiosarcoma. Long-term follow-up is warranted. (C) 2017 Elsevier Inc. All rights reserved.	[Pradhan, Dinesh; Schoedel, Karen; Ranganathan, Sarangarajan; Rao, Uma N. M.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15232 USA; [McGough, Richard L.] Univ Pittsburgh, Med Ctr, Dept Orthoped Surg, Pittsburgh, PA 15232 USA	Rao, UNM (reprint author), UPMC Shadyside, Dept Pathol, WG2-9,5230 Ctr Ave, Pittsburgh, PA 15232 USA.	raounm@upmc.edu	Pradhan, Dinesh/I-7764-2013	Pradhan, Dinesh/0000-0001-8591-1601			Amary MF, 2013, SKELETAL RADIOL, V42, P947, DOI 10.1007/s00256-013-1577-8; Billings SD, 2003, AM J SURG PATHOL, V27, P48, DOI 10.1097/00000478-200301000-00006; Declerck PJ, 2013, SEMIN THROMB HEMOST, V39, P356, DOI 10.1055/s-0033-1334487; ENZINGER FM, 1970, CANCER-AM CANCER SOC, V26, P1029, DOI 10.1002/1097-0142(197011)26:5<1029::AID-CNCR2820260510>3.0.CO;2-R; Fisher C, 2006, ADV ANAT PATHOL, V13, P114, DOI 10.1097/00125480-200605000-00002; Fletcher C, 2013, WHO CLASSIFICATION T; FLETCHER CDM, 1991, AM J SURG PATHOL, V15, P915, DOI 10.1097/00000478-199110000-00001; Friel NA, 2014, J CANC THER, V5, P363; Gabor KM, 2017, PEDIAT BLOOD CANC; Hornick JL, 2008, MODERN PATHOL, V21, p13A; Hornick JL, 2011, AM J SURG PATHOL, V35, P190, DOI 10.1097/PAS.0b013e3181ff0901; Hornick JL, 2009, AM J SURG PATHOL, V33, P542, DOI 10.1097/PAS.0b013e3181882c54; Hung YP, 2017, AM J SURG PATHOL, V41, P596, DOI 10.1097/PAS.0000000000000795; Ide YH, 2015, PATHOL RES PRACT, V211, P415, DOI 10.1016/j.prp.2015.02.003; Inyang A, 2016, AM J SURG PATHOL, V40, P587, DOI 10.1097/PAS.0000000000000613; Italiano A, 2012, GENE CHROMOSOME CANC, V51, P569, DOI 10.1002/gcc.21943; Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050; Ju HS, 2010, CANCER-AM CANCER SOC, V116, P4248, DOI 10.1002/cncr.25213; Karakasli A, 2014, J ORTHOP, V11, P197, DOI 10.1016/j.jor.2014.06.019; Kaul A, 2014, P UCLA HEALTHC, V18; McGinity M, 2013, EUR SPINE J, V22, pS506, DOI 10.1007/s00586-013-2727-3; Mentzel T, 1997, AM J SURG PATHOL, V21, P363, DOI 10.1097/00000478-199704000-00001; Miettinen M, 1999, HUM PATHOL, V30, P934, DOI 10.1016/S0046-8177(99)90247-2; MIRRA JM, 1992, CANCER-AM CANCER SOC, V69, P1382, DOI 10.1002/1097-0142(19920315)69:6<1382::AID-CNCR2820690614>3.0.CO;2-Y; Ozeki M, 2017, J PEDIAT HEMATOL ONC, V39, pE328, DOI 10.1097/MPH.0000000000000778; Ramachandran A, 2011, AM J PATHOL, V179, P2977, DOI 10.1016/j.ajpath.2011.08.034; Requena L, 2013, JAMA DERMATOL, V149, P459, DOI 10.1001/jamadermatol.2013.3190; Righi A, 2015, SKELETAL RADIOL, V44, P727, DOI 10.1007/s00256-014-2024-1; Shah AR, 2015, SKELETAL RADIOL, V44, P1381, DOI 10.1007/s00256-015-2168-7; Sheng WQ, 2012, HISTOPATHOLOGY, V61, P1219, DOI 10.1111/j.1365-2559.2012.04347.x; Sheng WQ, 2013, AM J DERMATOPATH, V35, P597, DOI 10.1097/DAD.0b013e31827c8051; Shon W, 2014, MODERN PATHOL, V27, P509, DOI 10.1038/modpathol.2013.163; Stuart LN, 2013, J CUTAN PATHOL, V40, P909, DOI 10.1111/cup.12196; Sugita S, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0530-2; Takayama Y, 2016, CANCER RES, V76, P3285, DOI 10.1158/0008-5472.CAN-15-1796; Tan S H, 2001, Australas J Dermatol, V42, P139, DOI 10.1046/j.1440-0960.2001.00499.x; Trombetta D, 2011, CANCER GENET-NY, V204, P211, DOI 10.1016/j.cancergen.2011.01.002; Walther C, 2014, J PATHOL, V232, P534, DOI 10.1002/path.4322; Zasadil LM, 2013, SEMIN CELL DEV BIOL, V24, P370, DOI 10.1016/j.semcdb.2013.02.001	39	6	7	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						126	134		10.1016/j.humpath.2017.10.023			9	Pathology	Pathology	FS7TV	WOS:000422612600016	29104110				2019-10-28	
J	Wang, GH; Zhao, CM; Huang, Y; Wang, W; Zhang, S; Wang, XD				Wang, Gui-Hua; Zhao, Chun-Mei; Huang, Ying; Wang, Wei; Zhang, Shu; Wang, Xudong			BRCA1 and BRCA2 expression patterns and prognostic significance in digestive system cancers	HUMAN PATHOLOGY			English	Article						BRCA1; BRCA2; Cancer; Digestive system; Immunohistochemistry	SPORADIC BREAST CARCINOMAS; EPITHELIAL OVARIAN-CARCINOMA; GYNECOLOGIC-ONCOLOGY-GROUP; CELL LUNG-CANCER; HIGH-GRADE; PROTEIN EXPRESSION; DNA-DAMAGE; SURVIVAL; REPAIR; IMMUNOHISTOCHEMISTRY	The role of BRCA1 and BRCA2 genes is mainly to maintain genome integrity in response to DNA damage through different mechanisms. Deregulation of BRCA1 and BRCA2 is associated with the development of tumor and altered sensitivity to chemotherapeutic agents. In this study, we determined protein expression of BRCA I and BRCA2 in 4 digestive system cancers (gastric cancer, colorectal cancer, hepatocellular carcinoma, and pancreatic cancer) by immunohistochemistry on tissue microarrays. A total of 1546 samples of 4 types of cancer tissues, their matched adjacent nontumor tissues, and corresponding benign tissues were studied, respectively. Immunohistochemistry expression patterns of the 2 proteins and their correlation with patients' clinical parameters and overall survival were analyzed. The results showed that low expression of cytoplasmic BRCA1 and BRCA2 was commonly associated with advanced tumor lymph node metastasis stage, whereas high expression of nuclear BRCA I was generally correlated with advanced tumor stages in these cancers. High expression of cytoplasmic BRCA1 and BRCA2 had significantly favorable overall survival in digestive system cancers; in contrast, BRCA1 nuclear expression usually predicted poor outcomes. We conclude that BRCA1 and BRCA2 could be used as clinicopathological biomarkers to evaluate the prognosis of digestive system cancers. (C) 2017 Elsevier Inc. All rights reserved.	[Wang, Gui-Hua; Zhao, Chun-Mei; Huang, Ying; Wang, Xudong] Nantong Univ, Sch Publ Hlth, Affiliated Hosp, Dept Tissue Bank,Dept Lab Med, Nantong 226001, Jiangsu, Peoples R China; [Wang, Wei; Zhang, Shu] Nantong Univ, Affiliated Hosp, Dept Pathol, Nantong 226001, Jiangsu, Peoples R China	Wang, XD (reprint author), Nantong Univ, Affiliated Hosp, Dept Clin Lab Ctr, 20 Xisi Rd, Nantong City 226001, Jiangsu, Peoples R China.	wangxudong88@hotmail.com			Elite Program of Affiliated Hospital of Nantong University; 226 Talent Training Program of Nantong City, Nantong, Jiangsu, PRC; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81702086]	This study was supported by research grants from the Elite Program of Affiliated Hospital of Nantong University, the 226 Talent Training Program of Nantong City, Nantong, Jiangsu, PRC, and the National Natural Science Foundation of China (81702086).	Alkam Y, 2013, HISTOPATHOLOGY, V63, P713, DOI 10.1111/his.12220; Carser JE, 2011, GYNECOL ONCOL, V123, P492, DOI 10.1016/j.ygyno.2011.08.017; Chen WJ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0423-5; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Coene E, 1997, NAT GENET, V16, P122, DOI 10.1038/ng0697-122; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Garg K, 2013, AM J SURG PATHOL, V37, P138, DOI 10.1097/PAS.0b013e31826cabbd; Grabsch H, 2006, CLIN CANCER RES, V12, P1494, DOI 10.1158/1078-0432.CCR-05-2105; Henderson BR, 2005, BIOESSAYS, V27, P884, DOI 10.1002/bies.20277; Hjortkjaer M, 2017, INT J GYNECOL PATHOL, V36, P180, DOI 10.1097/PGP.0000000000000310; Huang JF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12991; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; Jiang JH, 2011, CANCER RES, V71, P5546, DOI 10.1158/0008-5472.CAN-10-3423; Kim SH, 2016, HISTOPATHOLOGY, V68, P673, DOI 10.1111/his.12809; Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112; Lambie H, 2003, J PATHOL, V200, P207, DOI 10.1002/path.1348; Lesnock JL, 2013, BRIT J CANCER, V108, P1231, DOI 10.1038/bjc.2013.70; Lu CL, 2015, ONCOTARGET, V6, P24912, DOI 10.18632/oncotarget.4701; Meisel JL, 2014, ANN ONCOL, V25, P2372, DOI 10.1093/annonc/mdu461; Mylona E, 2014, PATHOL RES PRACT, V210, P533, DOI 10.1016/j.prp.2014.05.009; Oliveira-Costa Joao Paulo, 2014, Oncoscience, V1, P383; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Sun RW, 2014, ONCOTARGET, V5, P12398, DOI 10.18632/oncotarget.2643; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Thike AA, 2016, HISTOPATHOLOGY, V68, P702, DOI 10.1111/his.12801; Thrall M, 2006, INT J GYNECOL CANCER, V16, P166, DOI 10.1111/j.1525-1438.2006.00504.x; Wang TB, 2014, GENET MOL RES, V13, P3704, DOI 10.4238/2014.May.9.15; Weberpals JI, 2011, ANN ONCOL, V22, P2403, DOI 10.1093/annonc/mdq770; Wilson CA, 1999, NAT GENET, V21, P236; Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284; Yang F, 2011, MODERN PATHOL, V24, P836, DOI 10.1038/modpathol.2011.44; Yang QF, 2001, CANCER-AM CANCER SOC, V92, P54, DOI 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x	34	6	6	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						135	144		10.1016/j.humpath.2017.10.032			10	Pathology	Pathology	FS7TV	WOS:000422612600017	29126833				2019-10-28	
J	Mamoori, A; Wahab, R; Islam, F; Lee, K; Vider, J; Lu, CT; Gopalan, V; Lam, AKY				Mamoori, Afraa; Wahab, Riajul; Islam, Farhadul; Lee, Katherine; Vider, Jelena; Lu, Cu-Tai; Gopalan, Vinod; Lam, Alfred King-yin			Clinical and biological significance of miR-193a-3p targeted KRAS in colorectal cancer pathogenesis	HUMAN PATHOLOGY			English	Article						miR-193a-3p; Colorectal cancer; Tumor suppressor; Apoptosis; Proliferation	EPITHELIAL-MESENCHYMAL TRANSITION; LYMPH-NODE METASTASIS; TUMOR-SUPPRESSOR; CLINICOPATHOLOGICAL SIGNIFICANCE; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; DOWN-REGULATION; BREAST-CANCER; LUNG-CANCER; STEM-CELLS	This study was to investigate the expression pattern, mechanisms and clinicopathological implications of miR-193a-3p in colorectal cancer. Fresh-frozen tissues from 70 matched colorectal adenocarciomas and the adjacent non-neoplastic mucosae were prospectively collected. Two colorectal cancer cell lines (SW480 and SW48) and a non-neoplastic colon cell line (FHC) were also used. The expression levels of miR193a-3p in the cells and tissues were measured by quantitative real-time polymerase chain reaction. The expression of KRAS protein as a predicted downstream target for miR-193a was studied by immunohistochemistry. Restoration of the miR-193a level in the cell lines by permanent transfection was achieved and multiple functional and immunological assays were performed to analyze the functions of miR-193a in vitro. Down-regulation of miR-193a-3p was noted in 70% of the colorectal cancer tissues when compared to non-neoplastic colorectal tissues. In addition, down-regulation of miR-193a was significantly correlated with carcinoma of early stages (P < .05). Significant inverse correlation between miR-193a-3p and its target KRAS protein was determined (P < .05). Overexpression of miR-193a in colon cancer cells resulted in reduced cell proliferation, increased apoptosis, induced significant changes in cell cycle events and decreased the expression of epithelial-mesenchymal transition marker TWIST. This study confirms the tumor suppressor roles of miR-193a-3p, its downstream target affinity to KRAS and clinical significance in patients with colorectal adenocarcinoma. (C) 2017 Elsevier Inc. All rights reserved.	[Mamoori, Afraa; Wahab, Riajul; Islam, Farhadul; Lee, Katherine; Gopalan, Vinod; Lam, Alfred King-yin] Griffith Univ, Menzies Hlth Inst Queensland, Sch Med, Canc Mol Pathol, Gold Coast, Qld 4222, Australia; [Mamoori, Afraa] Univ Babylon, Coll Med, Dept Pathol & Forens Med, Hillah 51002, Iraq; [Islam, Farhadul] Univ Rajshahi, Dept Biochem & Mol Biol, Rajshahi 6205, Bangladesh; [Vider, Jelena; Gopalan, Vinod] Griffith Univ, Menzies Hlth Inst Queensland, Sch Med Sci, Gold Coast, Qld 4222, Australia; [Lu, Cu-Tai] Gold Coast Hosp, Dept Surg, Gold Coast, Qld 4215, Australia; [Lam, Alfred King-yin] Gold Coast Hosp, Pathol Queensland, Gold Coast, Qld 4215, Australia	Gopalan, V (reprint author), Griffith Univ, Sch Med & Med Sci, Gold Coast Campus, Gold Coast, Qld 4222, Australia.; Lam, AKY (reprint author), Griffith Med Sch, Pathol, Gold Coast Campus, Gold Coast, Qld 4222, Australia.	v.gopalan@griffith.edu.au; a.lam@griffith.edu.au	Lam, Alfred/C-1652-2008; Vider, Jelena/B-9663-2011	Lam, Alfred/0000-0003-2771-564X; Vider, Jelena/0000-0003-1696-9812; Lee, Katherine Ting-Wei/0000-0003-2068-7762			Amin M, 2017, AJCC CANC STAGING MA, P251; Campbell CJV, 2010, BLOOD, V116, P1433, DOI 10.1182/blood-2009-12-258095; Chen JJ, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0450-8; Ebrahimi F, 2015, EXP CELL RES, V339, P333, DOI 10.1016/j.yexcr.2015.10.004; Fan XJ, 2013, HUM PATHOL, V44, P173, DOI 10.1016/j.humpath.2012.03.029; Gao XN, 2011, ONCOGENE, V30, P3416, DOI 10.1038/onc.2011.62; Gopalan V, 2015, EXP CELL RES, V330, P423, DOI 10.1016/j.yexcr.2014.08.006; Gopalan V, 2014, MOL CARCINOGEN, V53, pE36, DOI 10.1002/mc.21993; Hamilton SR, 2010, WHO CLASSIFICATION T, P134; Hansen TF, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0254-6; Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450; Iliopoulos D, 2011, CANCER RES, V71, P5144, DOI 10.1158/0008-5472.CAN-11-0425; Islam F, 2017, EXP CELL RES, V357, P260, DOI 10.1016/j.yexcr.2017.05.021; Khoo CP, 2017, SCI REP-UK, V7, DOI 10.1038/srep44137; Kim HS, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2141-4; Kwon JE, 2013, APOPTOSIS, V18, P896, DOI 10.1007/s10495-013-0841-7; Lam LT, 2010, MOL CANCER THER, V9, P2943, DOI 10.1158/1535-7163.MCT-10-0427; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Li M, 2009, WORLD J SURG, V33, P667, DOI 10.1007/s00268-008-9836-x; Liang HW, 2015, J BIOL CHEM, V290, P926, DOI 10.1074/jbc.M114.621409; Lin MS, 2017, ONCOL LETT, V14, P1061, DOI 10.3892/ol.2017.6266; Lv L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.367; Ma KL, 2012, J BIOL CHEM, V287, P5639, DOI 10.1074/jbc.M111.291229; Mamoori A, 2016, BIOL CELL, V108, P51, DOI 10.1111/boc.201500062; McCubrey JA, 2012, ONCOTARGET, V3, P954; Pillai MM, 2014, BREAST CANCER RES TR, V146, P85, DOI 10.1007/s10549-014-3004-9; Qiao B, 2012, BIOL CELL, V104, P476, DOI 10.1111/boc.201100077; Ren FH, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0227-8; Salvi A, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-162; Seviour EG, 2017, ONCOGENE, V36, P1339, DOI 10.1038/onc.2016.308; Teng Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14448; Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100; Ung L, 2014, CLIN TRANSL ONCOL, V16, P425, DOI 10.1007/s12094-013-1154-6; Vesuna F, 2009, NEOPLASIA, V11, P1318, DOI 10.1593/neo.91084; Walter BA, 2013, J CANCER, V4, P350, DOI 10.7150/jca.6394; Williams M, 2015, ONCOTARGET, V6, P23480, DOI 10.18632/oncotarget.4346; Worthley Daniel L, 2010, Clin Biochem Rev, V31, P31; Yang XF, 2014, CHINESE J CANCER RES, V26, P331, DOI 10.3978/j.issn.1000-9604.2014.06.11; Yong FL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-280; Yu XF, 2011, WORLD J GASTROENTERO, V17, P4711, DOI 10.3748/wjg.v17.i42.4711; Zaravinos A, 2015, J ONCOL, V2015, DOI DOI 10.1155/2015/865816; Zhang P, 2014, WORLD J GASTROENTERO, V20, P12241, DOI 10.3748/wjg.v20.i34.12241	42	8	8	2	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						145	156		10.1016/j.humpath.2017.10.024			12	Pathology	Pathology	FS7TV	WOS:000422612600018	29104111				2019-10-28	
J	Minato, H; Kobayashi, E; Nakada, S; Kurose, N; Tanaka, M; Tanaka, Y; Suzuki, S; Tanioka, F; Saikawa, Y; Miwa, T; Nojima, T				Minato, Hiroshi; Kobayashi, Eriko; Nakada, Satoko; Kurose, Nozomu; Tanaka, Mio; Tanaka, Yukichi; Suzuki, Shioto; Tanioka, Fumihiko; Saikawa, Yutaka; Miwa, Takaki; Nojima, Takayuki			Sinonasal NUT carcinoma: clinicopathological and cytogenetic analysis with autopsy findings	HUMAN PATHOLOGY			English	Article						NUT carcinoma; Sinonasal tumor; BRD4-NUT; Fluorescence in situ hybridization; Autopsy; Mesenchymal differentiation	MIDLINE CARCINOMA; EWING SARCOMA; BRD-NUT; DIFFERENTIATION; TUMORS; TRACT; MYC; REARRANGEMENT; ONCOPROTEIN; EXPRESSION	Nuclear protein in testis (NUT) carcinoma is a rare malignant neoplasm with an undifferentiated morphology. Its diagnosis is often difficult, especially as the sinonasal tract gives rise to many tumors with undifferentiated morphologies. Not many cases of sinonasal NUT carcinomas have been reported, and its clinicopathological features have not been sufficiently clarified. In this study, we performed a clinicopathological study of 4 patients with sinonasal NUT carcinoma, including wide-ranging immunohistochemical tests and cytogenetic analyses using fluorescence in situ hybridization and DNA sequencing. Autopsy findings were obtained from 2 patients. Patients' ages ranged from 9 months to 66 years (median, 37 years). Three cases involved the nasal cavity; of these, 2 also involved the ethmoid sinus. One case only involved the frontal sinus. Histologically, all cases revealed undifferentiated small round cell morphology and necrosis with indistinct cell borders, vesicular chromatin, and distinct nucleoli. All patients received chemoradiotherapy; 3 died of disease 10 to 15 months after their diagnoses, while one was lost to follow-up. The 2 autopsied patients showed multiorgan metastases; interestingly, one showed cartilaginous differentiation in a metastatic lesion. Immunohistochemically, all cases were diffusely positive for NUT, p63, and Myc, and were focal for p40. The cells variably expressed epithelial markers, and CD34 was positive in one patient. Cytogenetically, all showed BRD4-NUT fusion genes, but one had a different breakpoint in each exon. Finally, a literature review indicated that sinonasal NUT carcinoma tends to involve frontal and ethmoidal sinuses more frequently than other sinonasal cancers. (C) 2017 Elsevier Inc. All rights reserved.	[Minato, Hiroshi; Kobayashi, Eriko; Nakada, Satoko; Kurose, Nozomu; Nojima, Takayuki] Kanazawa Med Univ, Dept Pathol & Lab Med, Kanazawa, Ishikawa 9200293, Japan; [Minato, Hiroshi] Ishikawa Prefectural Cent Hosp, Dept Diagnost Pathol, Kanazawa, Ishikawa 9208201, Japan; [Kobayashi, Eriko] Univ Fukui, Fac Med Sci, Dept Pathol Sci, Div Tumor Pathol, Fukui 9101104, Japan; [Tanaka, Mio; Tanaka, Yukichi] Kanagawa Childrens Med Ctr, Dept Pathol, Yokohama, Kanagawa 2320066, Japan; [Suzuki, Shioto; Tanioka, Fumihiko] Iwata City Hosp, Div Pathol, Shizuoka 4388550, Japan; [Saikawa, Yutaka] Kanazawa Med Univ, Dept Pediat, Kanazawa, Ishikawa 9200293, Japan; [Miwa, Takaki] Kanazawa Med Univ, Dept Otorhinolatyngol, Kanazawa, Ishikawa 9200293, Japan; [Nojima, Takayuki] Kanazawa Univ, Sch Med, Dept Orthoped, Kanazawa, Ishikawa 9200934, Japan	Minato, H (reprint author), Ishikawa Prefectural Cent Hosp, Dept Diagnost Pathol, Kanazawa, Ishikawa 9208201, Japan.	hminato@ipch.jp					Agaimy A, 2017, AM J SURG PATHOL, V41, P458, DOI 10.1097/PAS.0000000000000797; Alekseyenko AA, 2017, P NATL ACAD SCI USA, V114, pE4184, DOI 10.1073/pnas.1702086114; Alekseyenko AA, 2015, GENE DEV, V29, P1507, DOI 10.1101/gad.267583.115; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Bellizzi AM, 2009, CANCER CYTOPATHOL, V117, P508, DOI 10.1002/cncy.20044; Bishop JA, 2016, HEAD NECK PATHOL, V10, P23, DOI 10.1007/s12105-016-0688-7; Bishop JA, 2015, AM J SURG PATHOL, V39, P1267, DOI 10.1097/PAS.0000000000000460; Bishop JA, 2014, AM J SURG PATHOL, V38, P1282, DOI 10.1097/PAS.0000000000000285; Bishop JA, 2012, AM J SURG PATHOL, V36, P1216, DOI 10.1097/PAS.0b013e318254ce54; Chau NG, 2016, CANCER-AM CANCER SOC, V122, P3632, DOI 10.1002/cncr.30242; Chisholm KM, 2015, AM J SURG PATHOL, V39, P294, DOI 10.1097/PAS.0000000000000365; den Bakker MA, 2009, AM J SURG PATHOL, V33, P1253, DOI 10.1097/PAS.0b013e3181abe120; Dutta R, 2015, LARYNGOSCOPE, V125, P2491, DOI 10.1002/lary.25465; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2003, CANCER RES, V63, P304; French CA, 2015, WHO CLASSIFICATION T, P229; French CA, 2017, WHO CLASSIFICATION H, P20; French CA, 2014, CANCER DISCOV, V4, P928, DOI 10.1158/2159-8290.CD-14-0014; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; French CA, 2010, CANCER GENET CYTOGEN, V203, P16, DOI 10.1016/j.cancergencyto.2010.06.007; Grayson AR, 2014, ONCOGENE, V33, P1736, DOI 10.1038/onc.2013.126; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Hung YP, 2016, MODERN PATHOL, V29, P370, DOI 10.1038/modpathol.2016.31; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; KUBONISHI I, 1991, CANCER RES, V51, P3327; McCuiston A, 2017, HEAD NECK PATHOL; Nakada S, 2015, BRAIN TUMOR PATHOL, V32, P268, DOI 10.1007/s10014-015-0220-x; Stathis A, 2016, CANCER DISCOV, V6, P492, DOI 10.1158/2159-8290.CD-15-1335; Stimweiss A, 2015, ONCOGENE, V4; Suzuki S, 2015, PATHOL RES PRACT, V211, P404, DOI 10.1016/j.prp.2014.10.013; Suzuki S, 2014, PATHOL RES PRACT, V210, P383, DOI 10.1016/j.prp.2014.01.013; Thompson-Wicking K, 2013, ONCOGENE, V32, P4664, DOI 10.1038/onc.2012.487; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; VOLM M, 1994, CLIN EXP METASTAS, V12, P329, DOI 10.1007/BF01753840; Yoshida A, 2012, AM J SURG PATHOL, V36, P993, DOI 10.1097/PAS.0b013e31824ee43c	35	0	0	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						157	165		10.1016/j.humpath.2017.10.011			9	Pathology	Pathology	FS7TV	WOS:000422612600019	29079177				2019-10-28	
J	Gurzu, S; Banias, L; Kovacs, Z; Jung, J				Gurzu, Simona; Banias, Laura; Kovacs, Zsolt; Jung, Ioan			Epithelial-mesenchymal transition of tumor budding in colorectal cancer: the mystery of CD44-positive stromal cells	HUMAN PATHOLOGY			English	Letter									[Gurzu, Simona; Kovacs, Zsolt; Jung, Ioan] Univ Med & Pharm, Dept Pathol, Targu Mures 540139, Romania; [Gurzu, Simona] Clin Cty Emergency Hosp, Targu Mures 540139, Romania; [Banias, Laura] Clin Cty Emergency Hosp, Dept Pathol, Targu Mures 540139, Romania; [Kovacs, Zsolt] Univ Med & Pharm, Dept Biochem, Targu Mures 540139, Romania; [Kovacs, Zsolt] Clin Cty Emergency Hosp, Dept Genet, Targu Mures 540139, Romania	Gurzu, S (reprint author), Univ Med & Pharm, Dept Pathol, Targu Mures 540139, Romania.; Gurzu, S (reprint author), Clin Cty Emergency Hosp, Targu Mures 540139, Romania.	simonagurzu@yahoo.com	Kovacs, Zsolt/P-2666-2017	Kovacs, Zsolt/0000-0002-1038-7769; gurzu, simona/0000-0003-3968-5118	University of Medicine and Pharmacy of Tirgu-Mures, Romania [275/2017]	This work was partially sustained by the University of Medicine and Pharmacy of Tirgu-Mures, Romania, research project frame 275/2017.	Gurzu S, 2016, WORLD J GASTROENTERO, V22, P6764, DOI 10.3748/wjg.v22.i30.6764; Yamada N, 2017, HUM PATHOL, V60, P151, DOI 10.1016/j.humpath.2016.10.007	2	4	5	1	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	JAN	2018	71						168	169		10.1016/j.humpath.2017.07.019			2	Pathology	Pathology	FS7TV	WOS:000422612600023	28899739				2019-10-28	
J	Sungu, N; Dogan, HT; Kilicarslan, A; Kilic, M; Polat, S; Tokac, M; Akbaba, S; Parlak, O; Balci, S; Ogut, B; Cakir, B				Sungu, Nuran; Dogan, Hayriye Tatli; Kilicarslan, Aydan; Kilic, Mehmet; Polat, Sefika; Tokac, Mehmet; Akbaba, Soner; Parlak, Omer; Balci, Serdar; Ogut, Betul; Cakir, Bekir			Role of calcium-sensing receptor, Galectin-3, Cyclin D1, and Ki-67 immunohistochemistry to favor in the diagnosis of parathyroid carcinoma	INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY			English	Article						Atypical parathyroid adenoma; calcium-sensing receptor; parathyroid adenoma; parathyroid carcinoma	EXPRESSION; PARAFIBROMIN; CANCER; RETINOBLASTOMA; NEOPLASMS; ADENOMAS; MARKERS; BENIGN	Background: As histopathological findings of parathyroid carcinoma are not certain, the diagnosis of tumors with degenerative changes may be difficult. In these cases, immunohistochemical markers are beneficial. We aimed to research the acceptability of calcium-sensing receptor (CaSR), Galactin-3, Cyclin D1, and Ki-67 as helpful markers in parathyroid tumors in cases which are difficult to diagnose. Materials and Methods: Those cases who had been diagnosed with atypical parathyroid adenoma and parathyroid carcinoma between 2010 and 2015 were reevaluated. Immunohistochemical markers were applied to this cases. Results: About 21 cases were parathyroid adenoma, 14 were atypical adenoma, and 10 cases were parathyroid carcinoma. According to the immunohistochemical results, global loss of CaSR staining was seen in 50% (5/10) of the patients with carcinoma while there was no loss of staining in those with parathyroid adenoma (P = 0,001). Global loss of CaSR staining was found in only one out of 14 cases with atypical adenoma. The expression of Galactin-3 was found to be positive in 40% (4/10) of carcinoma cases, 71.4% (10/14) of those with atypical adenoma, and 14.3% (3/21) of those with adenoma (P = 0,002). Cyclin D1 expression was determined to be positive in 70% (7/10) of patients with carcinoma, 71.4% (10/14) of atypical adenoma cases, and 23.8% (5/21) of those with adenoma. The Ki-67 proliferation index was seen to be above 5% in 50% (5/10) of carcinoma cases and 35,7% (5/14) of those with atypical adenoma. Conclusion: In these studies, it has been emphasized that the global loss of CaSR staining was used as a negative marker in the diagnosis of carcinoma. In this study, we have also confirmed that the global loss of CaSR staining is a useful marker to determine potential increased malignancy.	[Sungu, Nuran; Dogan, Hayriye Tatli; Kilicarslan, Aydan; Balci, Serdar] Ankara Yildirim Beyazit Univ, Ataturk Educ & Res Hosp, Fac Med, Dept Pathol, Ankara, Turkey; [Kilic, Mehmet; Akbaba, Soner; Parlak, Omer] Ankara Yildirim Beyazit Univ, Ataturk Educ & Res Hosp, Fac Med, Dept Gen Surg, Ankara, Turkey; [Polat, Sefika; Cakir, Bekir] Ankara Yildirim Beyazit Univ, Ataturk Educ & Res Hosp, Fac Med, Dept Endocrinol & Metab, Ankara, Turkey; [Ogut, Betul] Gazi Univ, Fac Med, Dept Pathol, Ankara, Turkey; [Tokac, Mehmet] Yeni Yuzyil Univ, Gaziosmanpasa Hosp, Dept Gen Surg, Istanbul, Turkey	Sungu, N (reprint author), Ankara Yildirim Beyazit Univ, Dept Pathol, TR-006800 Ankara, Turkey.	nuransungu@gmail.com	BALCI, Serdar/B-6401-2011	BALCI, Serdar/0000-0002-7852-3851			Al-Sharaky DR, 2016, J CLIN DIAGN RES, V10, pEC6, DOI 10.7860/JCDR/2016/18375.7430; Bergero N, 2005, HUM PATHOL, V36, P908, DOI 10.1016/j.humpath.2005.06.020; Brennan SC, 2013, BBA-MOL CELL RES, V1833, P1732, DOI 10.1016/j.bbamcr.2012.12.011; Cetani F, 2007, EUR J ENDOCRINOL, V156, P547, DOI 10.1530/EJE-06-0720; Delellis R.A., 2004, WHO CLASSIFICATION T, V96, P124; Erovic BM, 2012, ENDOCR PATHOL, V23, P221, DOI 10.1007/s12022-012-9222-y; Farnebo F, 1999, WORLD J SURG, V23, P68, DOI 10.1007/s002689900567; Fernandez-Ranvier GG, 2009, CANCER-AM CANCER SOC, V115, P334, DOI 10.1002/cncr.24037; Grimelius L, 2004, WHO CLASSIFICATION T, P128; Haven CJ, 2004, J PATHOL, V202, P86, DOI 10.1002/path.1489; Kumari N, 2016, ENDOCR PATHOL, V27, P87, DOI 10.1007/s12022-016-9426-7; LLOYD RV, 1995, ENDOCR PATHOL, V6, P279, DOI 10.1007/BF02738728; Tennakoon S, 2016, BBA-MOL CELL RES, V1863, P1398, DOI 10.1016/j.bbamcr.2015.11.017; Truran PP, 2014, WORLD J SURG, V38, P2845, DOI 10.1007/s00268-014-2700-2; Vasef MA, 1999, MODERN PATHOL, V12, P412; Witteveen JE, 2011, MODERN PATHOL, V24, P688, DOI 10.1038/modpathol.2010.236; Zhang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103482	17	2	2	0	4	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	0377-4929	0974-5130		INDIAN J PATHOL MICR	Indian J. Pathol. Microbiol.	JAN-MAR	2018	61	1					22	26		10.4103/IJPM.IJPM_85_17			5	Pathology	Pathology	GA6JJ	WOS:000428438900004	29567879	DOAJ Gold			2019-10-28	
J	Hwang, S; Ko, Y; Park, D; Yoon, C				Hwang, Sungho; Ko, Yeji; Park, Donguk; Yoon, Chungsik			Seasonality in airborne bacterial, fungal, and (1 -> 3)-beta-D-glucan concentrations in two indoor laboratory animal rooms	JOURNAL OF CLINICAL PATHOLOGY			English	Article							ENVIRONMENTS; HEALTH; AIR; BIOAEROSOLS; EXPOSURE; OUTDOOR; WORKERS; TAIWAN	Aims The purpose of this study was to assess the temporal changes in the concentrations of bioaerosols in a laboratory mouse room (LMR) and laboratory rabbit room (LRR), and to determine environmental factors associated with the culturable bacteria, fungi and (1 -> 3)-beta-D-glucan concentrations. Method The concentrations of culturable airborne bacteria, fungi and (1 -> 3)-beta-D-glucan in the LMR and LRR were sampled once a month from March 2011 to February 2012. A single-stage viable cascade impactor was used to sample bacteria and fungi, while a two-stage cyclone bioaerosol sampler was used to collect airborne (1 -> 3)-beta-D-glucan. Results The culturable bacterial concentrations in the LMR showed a gradual increase during the summer. The culturable fungal concentrations showed similar seasonal patterns of change in the LMR and LRR with a noticeable increase during the summer. The (1 -> 3)-beta-D-glucan concentrations were highest during the warmer spring and summer months. Relative humidity (RH) was the environmental factor most associated with the concentrations of culturable bacteria and fungi. The overall airborne microbe concentrations were significantly higher in the LRR than in the LMR. Conclusions Airborne microbe concentrations in the LMR and LRR varied greatly depending on season, and these changes were affected by environmental factors.	[Hwang, Sungho] Natl Canc Ctr, Natl Canc Control Inst, Ilsan, South Korea; [Ko, Yeji] Korea Workers Compensat & Welf Serv, Seoul, South Korea; [Park, Donguk] Korea Natl Open Univ, Dept Environm Hlth, Ulsan, South Korea; [Yoon, Chungsik] Seoul Natl Univ, Inst Hlth & Environm, Grad Sch Publ Hlth, Seoul, South Korea; [Yoon, Chungsik] Seoul Natl Univ, Dept Environm Hlth Sci, Grad Sch Publ Hlth, 1,Gwanak Ro, Seoul 08826, South Korea	Yoon, C (reprint author), Seoul Natl Univ, Dept Environm Hlth Sci, Grad Sch Publ Hlth, 1,Gwanak Ro, Seoul 08826, South Korea.	csyoon@snu.ac.kr			National Research Foundation of Korean (NRF) - Ministry of Science, ICT & Future Planning [2015R1C1A1A02037363]	This research was supported by the Basic Science Research Programme through the National Research Foundation of Korean (NRF) funded by the Ministry of Science, ICT & Future Planning (2015R1C1A1A02037363).	ARUNDEL AV, 1986, ENVIRON HEALTH PERSP, V65, P351, DOI 10.2307/3430203; AYERST G, 1969, J STORED PROD RES, V5, P127, DOI 10.1016/0022-474X(69)90055-1; Bartlett KH, 2004, J OCCUP ENVIRON HYG, V1, P639, DOI 10.1080/15459620490497744; Bioaerosol sampling (Indoor Air) NIOSH Manual of Analytical Methods (NMAM), 1998, 0800 NMAM; BURGE H, 1990, J ALLERGY CLIN IMMUN, V86, P687, DOI 10.1016/S0091-6749(05)80170-8; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; BURGE HA, 1979, LAB ANIM, V13, P333, DOI 10.1258/002367779780943189; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; Chang CW, 2001, APPL ENVIRON MICROB, V67, P155, DOI 10.1128/AEM.67.1.155-161.2001; Douwes J, 2005, INDOOR AIR, V15, P160, DOI 10.1111/j.1600-0668.2005.00333.x; Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032; Gorny RL, 1999, ANN AGR ENV MED, V6, P105; Goyal R, 2013, AIR QUAL ATMOS HLTH, V6, P747, DOI 10.1007/s11869-013-0212-0; Haig CW, 2016, J HOSP INFECT, V93, P242, DOI 10.1016/j.jhin.2016.03.017; Hwang SH, 2017, APPL ECOL ENV RES, V15, P321, DOI 10.15666/aeer/1501_321333; Hwang SH, 2011, CHEMOSPHERE, V85, P135, DOI 10.1016/j.chemosphere.2011.06.024; Hwang SH, 2011, J CLIN PATHOL, V64, P261, DOI 10.1136/jcp.2010.084764; Jang JH, 2009, ANN ALLERG ASTHMA IM, V102, P373, DOI 10.1016/S1081-1206(10)60507-8; Kaliste E, 2002, LAB ANIM-UK, V36, P43, DOI 10.1258/0023677021911759; Lavine BK, 2012, MICROCHEM J, V103, P37, DOI 10.1016/j.microc.2012.01.002; Lugauskas A, 2004, ANN AGR ENV MED, V11, P19; Mentese S, 2009, CLEAN-SOIL AIR WATER, V37, P487, DOI 10.1002/clen.200800220; National Research Council, 2010, GUIDE CARE USE LAB A; Pastuszka JS, 2000, ATMOS ENVIRON, V34, P3833, DOI 10.1016/S1352-2310(99)00527-0; PITT JI, 1983, J APPL BACTERIOL, V54, P109, DOI 10.1111/j.1365-2672.1983.tb01307.x; Smith KR, 2008, AIR QUAL ATMOS HLTH, V1, P17, DOI 10.1007/s11869-008-0010-2; Stone B.A., 1992, CHEM BIOL 1 3 BETA G; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; Tang JW, 2009, J R SOC INTERFACE, V6, pS737, DOI 10.1098/rsif.2009.0227.focus; Tsai MY, 2009, SCI TOTAL ENVIRON, V407, P1536, DOI 10.1016/j.scitotenv.2008.10.029; World Health Organization, 2009, WHO GUID IND AIR QUA; Wu PC, 2005, INDOOR AIR, V15, P19, DOI 10.1111/j.1600-0668.2004.00313.x	32	1	1	3	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					59	66		10.1136/jclinpath-2017-204377			8	Pathology	Pathology	FP8TS	WOS:000417919600011	28667192				2019-10-28	
J	Liu, DY; Gan, RC; Zhang, WD; Wang, W; Saiyin, HG; Zeng, WJ; Liu, GY				Liu, Danyang; Gan, Rongchang; Zhang, Weidi; Wang, Wei; Saiyin, Hexige; Zeng, Wenjiao; Liu, Guoyuan			Autopsy interrogation of emergency medicine dispute cases: how often are clinical diagnoses incorrect?	JOURNAL OF CLINICAL PATHOLOGY			English	Article							SUDDEN UNEXPECTED DEATH; AORTIC DISSECTION; ERRORS; REPAIR; RATES; ERAS	Aims Emergency medicine is a 'high risk' specialty. Some diseases develop suddenly and progress rapidly, and sudden unexpected deaths in the emergency department (ED) may cause medical disputes. We aimed to assess discrepancies between antemortem clinical diagnoses and postmortem autopsy findings concerning emergency medicine dispute cases and to figure out the most common major missed diagnoses. Methods Clinical files and autopsy reports were retrospectively analysed and interpreted. Discrepancies between clinical diagnoses and autopsy diagnoses were evaluated using modified Goldman classification as major and minor discrepancy. The difference between diagnosis groups was compared with Pearson chi(2) test. Results Of the 117 cases included in this study, 71 of cases (58 class I and 13 class II diagnostic errors) were revealed as major discrepancies (60.7%). The most common major diagnoses were cardiovascular diseases (54 cases), followed by pulmonary diseases, infectious diseases and so on. The difference of major discrepancy between the diagnoses groups was significant (p<0.001). Aortic dissection and myocardial infarction were the most common cause of death (15 cases for each disease) and the most common missed class I diagnoses (80% and 66.7% for each), higher than the average 49.6% of all class I errors of the study patients. Conclusions High major disparities between clinical diagnoses and postmortem examinations exist in emergency medical disputes cases; acute aortic dissection and myocardial infarction are the most frequently major missed diagnoses that ED clinicians should pay special attention to in practice. This study reaffirmed the necessity and usefulness of autopsy in auditing death in EDs.	[Liu, Danyang; Zhang, Weidi; Wang, Wei; Zeng, Wenjiao; Liu, Guoyuan] Fudan Univ, Dept Pathol, Sch Basic Med Sci, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China; [Liu, Danyang] Fudan Univ, Dept Pathol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Gan, Rongchang] Shanghai Minhang Dist Cent Hosp, Judicial Authenticat Inst, Shanghai, Peoples R China; [Saiyin, Hexige] Fudan Univ, State Key Lab Genet Engn, Shanghai, Peoples R China	Liu, GY (reprint author), Fudan Univ, Dept Pathol, Sch Basic Med Sci, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.	gyliu@fudan.edu.cn	Liu, Guoyuan/P-8026-2019	Saiyin, Hexige/0000-0003-2993-6817	Natural Science Foundation of ChinaNational Natural Science Foundation of China [NSFC 31671461, NSFC 31301162]	This work was supported by the Natural Science Foundation of China (NSFC 31671461, NSFC 31301162).	BARENDREGT WB, 1992, BRIT J SURG, V79, P1297, DOI 10.1002/bjs.1800791218; BATTLE RM, 1987, JAMA-J AM MED ASSOC, V258, P339, DOI 10.1001/jama.258.3.339; Costache Mariana, 2014, Maedica (Buchar), V9, P261; Custer JW, 2015, PEDIATR CRIT CARE ME, V16, P29, DOI 10.1097/PCC.0000000000000274; Czerny M, 2016, CURR OPIN CARDIOL, V31, P606, DOI 10.1097/HCO.0000000000000330; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; Ifteni P, 2014, SCHIZOPHR RES, V155, P72, DOI 10.1016/j.schres.2014.03.011; Jayawardena S, 2007, AM J MED SCI, V334, P87, DOI 10.1097/MAJ.0b013e31812f53d6; Mussa FF, 2016, JAMA-J AM MED ASSOC, V316, P754, DOI 10.1001/jama.2016.10026; O'Connor AE, 2002, ACAD EMERG MED, V9, P957; Shah A, 2016, ANN CARDIOTHORAC SUR, V5, P389, DOI 10.21037/acs.2016.07.08; Shojania KG, 2003, JAMA-J AM MED ASSOC, V289, P2849, DOI 10.1001/jama.289.21.2849; Sonderegger-Iseli K, 2000, LANCET, V355, P2027, DOI 10.1016/S0140-6736(00)02349-7; Steward DJ, 2013, PEDIATR ANESTH, V23, P1101, DOI 10.1111/pan.12231; WHITEHOUSE SR, 1994, PEDIATR EMERG CARE, V10, P72, DOI 10.1097/00006565-199404000-00002; Winters B, 2012, BMJ QUAL SAF, V21, P894, DOI 10.1136/bmjqs-2012-000803; Wood MJ, 2001, ARCH PATHOL LAB MED, V125, P924; Zhu MH, 2011, CHINESE MED J-PEKING, V124, P3403, DOI 10.3760/cma.j.issn.0366-6999.2011.20.035	18	1	1	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					67	71		10.1136/jclinpath-2017-204484			5	Pathology	Pathology	FP8TS	WOS:000417919600012	28735302				2019-10-28	
J	Franca, JA; de Sousa, SF; Moreira, RG; Bernardes, VF; Guimaraes, LM; Santos, JN; Diniz, MG; Gomez, RS; Gomes, CC				Franca, Josiane Alves; de Sousa, Silvia Ferreira; Moreira, Rennan Garcias; Bernardes, Vanessa Fatima; Guimaraes, Leticia Martins; Santos, Jean Nunes; Diniz, Marina Goncalves; Gomez, Ricardo Santiago; Gomes, Carolina Cavalieri			Sporadic granular cell tumours lack recurrent mutations in PTPN11, PTEN and other cancer-related genes	JOURNAL OF CLINICAL PATHOLOGY			English	Letter							NOONAN SYNDROME; CHILD		[Franca, Josiane Alves; Bernardes, Vanessa Fatima; Gomes, Carolina Cavalieri] Univ Fed Minas Gerais, Biol Sci Inst, Dept Pathol, BR-31270901 Belo Horizonte, MG, Brazil; [de Sousa, Silvia Ferreira] UFS, Dept Dent, Hlth & Biol Sci Inst, Aracaju, Brazil; [Moreira, Rennan Garcias] Univ Fed Minas Gerais, Genom Lab, Biol Sci Inst, Belo Horizonte, MG, Brazil; [Guimaraes, Leticia Martins; Diniz, Marina Goncalves; Gomez, Ricardo Santiago] Univ Fed Minas Gerais, Dept Oral Surg & Pathol, Sch Dent, Belo Horizonte, MG, Brazil; [Santos, Jean Nunes] Univ Fed Bahia, Sch Dent, Dept Oral Pathol, Salvador, BA, Brazil	Gomes, CC (reprint author), Univ Fed Minas Gerais, Biol Sci Inst, Dept Pathol, BR-31270901 Belo Horizonte, MG, Brazil.	carolinacgomes@ufmg.br	Gomez, Ricardo Santiago/G-1976-2012; Franca, Josiane/V-5039-2019; DE SOUSA, SILVIA/M-5721-2015; Gomes, Carolilna/D-1807-2018	Gomez, Ricardo Santiago/0000-0001-8770-8009; Franca, Josiane/0000-0002-6005-783X; DE SOUSA, SILVIA/0000-0001-7820-4749; santos, jean/0000-0001-7225-5879	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/BrazilNational Council for Scientific and Technological Development (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)/BrazilCAPES; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)/BrazilMinas Gerais State Research Foundation (FAPEMIG)	This study was funded by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)/Brazil, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)/Brazil, and Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)/Brazil.	Bamps S, 2013, EUR J PEDIATR SURG, V23, P257, DOI 10.1055/s-0032-1322537; Gomes CC, 2013, OR SURG OR MED OR PA, V115, P249, DOI 10.1016/j.oooo.2012.11.011; Marchese C, 2003, AM J MED GENET A, V120A, P286, DOI 10.1002/ajmg.a.20179; Park SH, 2017, J DERMATOL; Ramaswamy PV, 2010, PEDIATR DERMATOL, V27, P209, DOI 10.1111/j.1525-1470.2010.01111.x; Schrader KA, 2009, CLIN GENET, V75, P185, DOI 10.1111/j.1399-0004.2008.01100.x; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Vered M, 2009, J ORAL PATHOL MED, V38, P150, DOI 10.1111/j.1600-0714.2008.00725.x	8	1	1	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0021-9746	1472-4146		J CLIN PATHOL	J. Clin. Pathol.	JAN	2018	71	1					93	94		10.1136/jclinpath-2017-204849			2	Pathology	Pathology	FP8TS	WOS:000417919600019	29097601				2019-10-28	
J	Palmieri, C; Story, M; Lean, FZX; Akter, SH; Grieco, V; De Marzo, AM				Palmieri, C.; Story, M.; Lean, F. Z. X.; Akter, S. H.; Grieco, V.; De Marzo, A. M.			Diagnostic Utility of Cytokeratin-5 for the Identification of Proliferative Inflammatory Atrophy in the Canine Prostate	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						cytokeratin 5; dog; proliferative inflammatory atrophy; prostate	INTRAEPITHELIAL-NEOPLASIA; INTERMEDIATE CELLS; CANCER; EPITHELIUM; EXPRESSION; PATTERNS; LESIONS	Proliferative inflammatory atrophy (PIA), which is comprised of highly proliferative but atrophic prostate epithelial cells in association with chronic inflammation, is considered a risk lesion for prostate cancer in men, while its role in canine prostate carcinogenesis is still unknown. We evaluated the value of immunohistochemical labelling for the basal cell marker cytokeratin-5 (CK5) in identifying PTA lesions in 87 samples of formalin-fixed and paraffin wax-embedded canine prostate. Canine PIA showed cytological features identical to the human counterpart and in most cases was associated with chronic lymphoplasmacytic inflammation. PIA lesions were identified in a higher number of CK5-labelled slides (43 out of 87) compared with slides stained by haematoxylin and eosin (HE) (24 out of 87). This lesion was frequently present in normal, hyperplastic and neoplastic canine prostates, although it was underestimated on evaluation of HE-stained slides. Therefore, CK5 can be considered a useful basal cell marker with high sensitivity and specificity for PIA. (C) 2017 Elsevier Ltd. All rights reserved.	[Palmieri, C.; Story, M.; Lean, F. Z. X.; Akter, S. H.] Univ Queensland, Sch Vet Sci, Gatton Campus, Gatton, Qld, Australia; [Akter, S. H.] Bangladesh Agr Univ, Dept Anat & Histol, Fac Vet Sci, Mymensing, Bangladesh; [Grieco, V.] Univ Milan, Dept Vet Sci & Publ Hlth, Via Celoria 10, Milan, Italy; [De Marzo, A. M.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Johns Hopkins Sch Med, Dept Pathol, Baltimore, MD USA; [De Marzo, A. M.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Johns Hopkins Sch Med, Dept Urol, Baltimore, MD USA; [De Marzo, A. M.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Johns Hopkins Sch Med, Dept Oncol, Baltimore, MD USA; [De Marzo, A. M.] Brady Urol Res Inst, Baltimore, MD USA	Palmieri, C (reprint author), Univ Queensland, Sch Vet Sci, Gatton Campus, Gatton, Qld, Australia.	c.palmieri@uq.edu.au	Story, Michelle M/I-4731-2017; GRIECO, VALERIA/J-3663-2017	Story, Michelle M/0000-0002-8084-5446; GRIECO, VALERIA/0000-0002-9445-4235; De Marzo, Angelo/0000-0003-4847-5307	John and Mary Kibble Trust	This work was supported by the John and Mary Kibble Trust. The current affiliation of F. Z. X. Lean is CSIRO Australian Animal Health Laboratory, 3219 East Geelong, Australia.	Abrahams NA, 2003, AM J CLIN PATHOL, V120, P368, DOI 10.1309/3YNLXCR33817JLTR; Akter SH, 2015, VET PATHOL, V52, P1027, DOI 10.1177/0300985815574008; De Marzo AM, 1998, J UROLOGY, V160, P2381, DOI 10.1016/S0022-5347(01)62196-7; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; De Marzo AM, 2010, NAT REV UROL, V7, P650, DOI 10.1038/nrurol.2010.188; Fonseca-Alves CE, 2013, MICROSC RES TECHNIQ, V76, P1250, DOI 10.1002/jemt.22292; Green R, 1999, AM J SURG PATHOL, V22, P1215; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; Nakayama M, 2003, AM J PATHOL, V163, P923, DOI 10.1016/S0002-9440(10)63452-9; Palmieri C, 2014, RES VET SCI, V97, P568, DOI 10.1016/j.rvsc.2014.11.006; Palmieri C, 2014, J COMP PATHOL, V150, P373; Perletti G, 2010, MOL MED REP, V3, P3, DOI 10.3892/mmr_00000211; Putzi MJ, 2000, UROLOGY, V56, P828, DOI 10.1016/S0090-4295(00)00776-7; Rodrigues M M P, 2013, Pak J Biol Sci, V16, P1324; Trpkov K, 2009, AM J CLIN PATHOL, V132, P211, DOI 10.1309/AJCPGFJP83IXZEUR; Valdman A, 2008, CURR CLIN ONCOL, P1, DOI 10.1007/978-1-60327-079-3_1; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; van Leenders GJLH, 2003, AM J PATHOL, V162, P1529, DOI 10.1016/S0002-9440(10)64286-1; Wang WZ, 2009, PROSTATE, V69, P1378, DOI 10.1002/pros.20992	19	2	3	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					1	5		10.1016/j.jcpa.2017.10.172			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300001	29422309				2019-10-28	
J	Henker, LC; Bianchi, RM; Vargas, TP; de Oliveira, EC; Driemeier, D; Pavarini, SP				Henker, L. C.; Bianchi, R. M.; Vargas, T. P.; de Oliveira, E. C.; Driemeier, D.; Pavarini, S. P.			Multifocal Spinal Cord Nephroblastoma in a Dog	JOURNAL OF COMPARATIVE PATHOLOGY			English	Article						dog; immunohistochemistry; spinal cord; Wilms tumour	WILMS-TUMOR GENE; IMMUNOHISTOCHEMICAL DEMONSTRATION; CANINE NEUROEPITHELIOMA; METASTASIS; EXPRESSION	A 1-year-old male American pit bull terrier was presented with a history of proprioceptive deficits and mild lameness of the right hindlimb, which progressed after 5 months to paraparesis, culminating in tetraparesis after 2 weeks. Necropsy findings were limited to the spinal cord and consisted of multiple, intradural, extramedullary, slightly red masses which produced segmental areas of medullary swelling located in the cervical intumescence, thoracolumbar column, sacral segment and cauda equina. Histological evaluation revealed a tumour, composed of epithelial, stromal and blastemal cells, with structures resembling tubules, acini and embryonic glomeruli. Immunohistochemical labelling for vimentin, cytokeratin and S100 was positive for the stromal, epithelial and blastemal cells, respectively. A final diagnosis of multifocal spinal cord nephroblastoma was established. This is the first report of such a tumour showing concomitant involvement of the cervicothoracic, thoracolumbar, sacral and cauda equina areas of the spinal cord. (C) 2017 Elsevier Ltd. All rights reserved.	[Henker, L. C.; Bianchi, R. M.; Vargas, T. P.; Driemeier, D.; Pavarini, S. P.] Univ Fed Rio Grande do Sul, Dept Vet Pathol, Av Bento Goncalves,9090 Pr 42505, Porto Alegre, RS, Brazil; [de Oliveira, E. C.] Univ Caxias Do Sul, Rua Francisco Getulio Vargas 1130, Caxias Do Sul, Brazil	Henker, LC (reprint author), Univ Fed Rio Grande do Sul, Dept Vet Pathol, Av Bento Goncalves,9090 Pr 42505, Porto Alegre, RS, Brazil.	henkerluan@hotmail.com	Driemeier, David/H-3461-2012	Driemeier, David/0000-0003-3766-0654; Bianchi, Ronaldo/0000-0001-9187-486X			BAUMGARTNER W, 1987, VET PATHOL, V24, P500, DOI 10.1177/030098588702400605; Bianchi MV, 2017, SEMIN-CIENC AGRAR, V38, P305, DOI 10.5433/1679-0359.2017v38n1p305; BOYLE R, 1980, POSTGRAD MED J, V56, P149, DOI 10.1136/pgmj.56.653.149; Brewer DM, 2011, JAVMA-J AM VET MED A, V238, P618, DOI 10.2460/javma.238.5.618; Bridges CH, 1984, P 35 ANN M AM COLL V, P97; Candle C, 2016, JUBB KENNEDY PALMERS, V1, P263; De Lorenzi D, 2007, VET CLIN PATH, V36, P200, DOI 10.1111/j.1939-165X.2007.tb00210.x; Grieco V, 2006, J COMP PATHOL, V134, P143, DOI 10.1016/j.jcpa.2005.09.003; Grossman SA, 1999, CANCER TREAT REV, V25, P103, DOI 10.1053/ctrv.1999.0119; Higgins RI, 2016, TUMORS DOMESTIC ANIM, P863; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; Liebel FX, 2011, VET SURG, V40, P244, DOI 10.1111/j.1532-950X.2010.00789.x; MADOW L, 1951, AMA ARCH NEUROL PSY, V65, P161, DOI 10.1001/archneurpsyc.1951.02320020033003; Meuten DJ, 2016, TUMORS DOMESTIC ANIM, P646; Nakade T, 2006, J VET MED SCI, V68, P1383, DOI 10.1292/jvms.68.1383; Pearson GR, 1997, J COMP PATHOL, V116, P321, DOI 10.1016/S0021-9975(97)80006-0; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; SHARMA PM, 1992, CANCER RES, V52, P6407; SUMMERS BA, 1988, ACTA NEUROPATHOL, V75, P402, DOI 10.1007/BF00687794; Terrell SP, 2000, VET PATHOL, V37, P94, DOI 10.1354/vp.37-1-94	20	0	0	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9975	1532-3129		J COMP PATHOL	J. Comp. Pathol.	JAN	2018	158	1					12	16		10.1016/j.jcpa.2017.10.176			5	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FX6VV	WOS:000426226300003	29422310				2019-10-28	
J	Roy, S; Coldren, C; Karunamurthy, A; Kip, NS; Klee, EW; Lincoln, SE; Leon, A; Pullambhatla, M; Temple-Smolkin, RL; Voelkerding, KV; Wang, C; Carter, AB				Roy, Somak; Coldren, Christopher; Karunamurthy, Arivarasan; Kip, Nefize S.; Klee, Eric W.; Lincoln, Stephen E.; Leon, Annette; Pullambhatla, Mrudula; Temple-Smolkin, Robyn L.; Voelkerding, Karl V.; Wang, Chen; Carter, Alexis B.			Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines A Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							CONSENSUS-RECOMMENDATION; CLINICAL VALIDATION; COPY NUMBER; VARIANTS; IMPLEMENTATION; ONCOLOGY; MUTATION; CONTAMINATION; PERFORMANCE; CHALLENGES	Bioinformatics pipelines are an integral component of next-generation sequencing (NGS). Processing raw sequence data to detect genomic alterations has significant impact on disease management and patient care. Because of the lack of published guidance, there is currently a high degree of variability in how members of the global molecular genetics and pathology community establish and validate bioinformatics pipelines. Improperly developed, validated, and/or monitored pipelines may generate inaccurate results that may have negative consequences for patient care. To address this unmet need, the Association of Molecular Pathology, with organizational representation from the College of American Pathologists and the American Medical Informatics Association, has developed a set of 17 best practice consensus recommendations for the validation of clinical NGS bioinformatics pipelines. Recommendations include practical guidance for laboratories regarding NGS bioinformatics pipeline design, development, and operation, with additional emphasis on the role of a properly trained and qualified molecular professional to achieve optimal NGS testing quality.	[Roy, Somak; Coldren, Christopher; Karunamurthy, Arivarasan; Kip, Nefize S.; Klee, Eric W.; Lincoln, Stephen E.; Leon, Annette; Voelkerding, Karl V.; Wang, Chen; Carter, Alexis B.] Clin Practice Comm, Next Generat Sequencing Bioinformat Pipeline Valid, Bethesda, MD USA; [Pullambhatla, Mrudula; Temple-Smolkin, Robyn L.] Assoc Mol Pathol, Bethesda, MD USA; [Roy, Somak; Karunamurthy, Arivarasan] Univ Pittsburgh, Med Ctr, Div Mol & Genom Pathol, 3477 Euler Way,Room 7028, Pittsburgh, PA 15213 USA; [Coldren, Christopher] PathGroup, Nashville, TN USA; [Kip, Nefize S.] Mt Sinai Hosp, Icahn Sch Med, Genet & Genom Ctr, New York, NY 10029 USA; [Kip, Nefize S.] Sema4 Lab, Branford, CT USA; [Klee, Eric W.; Wang, Chen] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA; [Lincoln, Stephen E.] Invitae, San Francisco, CA USA; [Leon, Annette] Color Genom Inc, Burlingame, CA USA; [Voelkerding, Karl V.] ARUP Labs, Salt Lake City, UT USA; [Carter, Alexis B.] Childrens Healthcare Atlanta, Dept Pathol & Lab Med, Atlanta, GA USA	Roy, S (reprint author), Univ Pittsburgh, Med Ctr, Div Mol & Genom Pathol, 3477 Euler Way,Room 7028, Pittsburgh, PA 15213 USA.	roys@upmc.edu	Carter, Alexis Byrne/D-7843-2011; Wang, Chen/B-3244-2011	Carter, Alexis Byrne/0000-0002-0171-2216; Wang, Chen/0000-0003-2638-3081	Association for Molecular Pathology	Supported by the Association for Molecular Pathology.	[Anonymous], 2008, US PROT EV QUAL TEST; Au CH, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0456-8; Chong HK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097408; Choudhary A, 2014, BMC MED GENOMICS, V7, DOI 10.1186/s12920-014-0062-0; CLSI, 2008, EP12 A2 US PROT EV Q; CLSI, 2014, MM09 A2 NUCL AC SEQ; Cock PJA, 2010, NUCLEIC ACIDS RES, V38, P1767, DOI 10.1093/nar/gkp1137; Cottrell CE, 2014, J MOL DIAGN, V16, P89, DOI 10.1016/j.jmoldx.2013.10.002; Cucoranu Ioan C, 2013, J Pathol Inform, V4, P4, DOI 10.4103/2153-3539.108542; Davies KD, 2016, J MOL DIAGN, V18, P572, DOI 10.1016/j.jmoldx.2016.03.002; Davis JC, 2005, CELL PRESERV TECHNOL, V3, P54; den Dunnen JT, 2016, HUM MUTAT, V37, P564, DOI 10.1002/humu.22981; Duncavage EJ, 2016, ARCH PATHOL LAB MED, V140, P1085, DOI 10.5858/arpa.2016-0194-CP; Escalona M, 2016, NAT REV GENET, V17, P459, DOI 10.1038/nrg.2016.57; Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696; Griffith M, 2015, CELL SYST, V1, P210, DOI 10.1016/j.cels.2015.08.015; Huang ZC, 2016, GENOME RES, V26, P1687, DOI 10.1101/gr.206870.116; Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Joseph L, 2016, J MOL DIAGN, V18, P605, DOI 10.1016/j.jmoldx.2016.05.007; Jun G, 2012, AM J HUM GENET, V91, P839, DOI 10.1016/j.ajhg.2012.09.004; Kanagal-Shamanna R, 2014, MODERN PATHOL, V27, P314, DOI 10.1038/modpathol.2013.122; Li AR, 2008, J MOL DIAGN, V10, P242, DOI 10.2353/jmoldx.2008.070178; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002; Li MK, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-5-r34; Lin MT, 2014, AM J CLIN PATHOL, V141, P856, DOI 10.1309/AJCPMWGWGO34EGOD; Linderman MD, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-20; Luscombe NM, 2001, METHOD INFORM MED, V40, P346; Manning C. D., 2008, INTRO INFORM RETRIEV; Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626; Ong M, 2014, BRIT J CANCER, V111, P828, DOI 10.1038/bjc.2014.350; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Quail MA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-110; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Roy S, 2016, ARCH PATHOL LAB MED, V140, P958, DOI 10.5858/arpa.2015-0507-RA; Sakai K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121891; Schrijver I, 2015, J MOL DIAGN, V17, P335, DOI 10.1016/j.jmoldx.2015.03.001; Sehn JK, 2015, AM J CLIN PATHOL, V144, P667, DOI 10.1309/AJCPR88WDJJLDMBN; Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003; Spencer DH, 2014, J MOL DIAGN, V16, P75, DOI 10.1016/j.jmoldx.2013.09.003; Spencer DH, 2013, J MOL DIAGN, V15, P623, DOI 10.1016/j.jmoldx.2013.05.004; Spencer DH, 2013, J MOL DIAGN, V15, P81, DOI 10.1016/j.jmoldx.2012.08.001; Sutton LA, 2015, HAEMATOLOGICA, V100, P370, DOI 10.3324/haematol.2014.109777; Tan A, 2015, BIOINFORMATICS, V31, P2202, DOI 10.1093/bioinformatics/btv112; Thorvaldsdottir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017; Van Deusen B, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.5251.5251; Yohe SL, 2015, ARCH PATHOL LAB MED, V139, P1400, DOI 10.5858/arpa.2014-0568-CP	46	47	48	3	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					4	27		10.1016/j.jmoldx.2017.11.003			24	Pathology	Pathology	FR2DY	WOS:000418878400002	29154853	Bronze			2019-10-28	
J	Hata, T; Dal Molin, M; McGregor-Das, A; Song, TJ; Wolfgang, C; Eshleman, JR; Hruban, RH; Goggins, M				Hata, Tatsuo; Dal Molin, Marco; McGregor-Das, Anne; Song, Tae Jun; Wolfgang, Christopher; Eshleman, James R.; Hruban, Ralph H.; Goggins, Michael			Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							INTERNATIONAL-CONSENSUS-GUIDELINES; INTRAEPITHELIAL NEOPLASIA; MANAGEMENT; DYSFUNCTION; INITIATION; LENGTH; CLASSIFICATION; ABNORMALITIES; CHROMOSOMES; COMBINATION	Telomere end-to-end fusions are an important source of chromosomal instability that arise in cells with critically shortened telomeres. We developed a nested real-time quantitative PCR method for telomere fusion detection in pancreatic ductal adenocarcinomas, intraductal papillary mucinous neoplasms (IPMNs), and IPMN cyst fluids. Ninety-one pancreatic cancer cell lines and xenograft samples, 93 IPMNs, and 93 surgically aspirated IPMN cyst fluid samples were analyzed. The association between telomere shortening, telomerase activity, and telomere fusion detection was evaluated. Telomere fusions were detected in 56 of 91 pancreatic cancers (61.5%). Telomere fusion-positive cell lines had significantly shorter telomere lengths than fusion-negative lines (P = 0.003). Telomere fusions were undetectable in normal pancreas or IPMNs with low-grade dysplasia (0.0%) and were detected in IPMN with high-grade dysplasia (HGD; 48.0%) (P< 0.001). In IPMN cyst fluids, telomere fusions were more frequent in IPMNs with HGD (26.9%) or associated invasive cancer (42.9%) than IPMN with intermediate-grade dysplasia (15.4%) or low-grade dysplasia (0%) (P = 0.025). Telomerase activity levels were higher in cyst fluids with fusions than in those without (P = 0.0414). Cyst fluid telomere fusion status was an independent predictor of HGD/invasive cancer by multivariate analysis (odds ratio, 6.23; 95% CI, 1.61-28.0). Telomere fusions are detected in later stages of IPMN progression and can serve as a marker for predicting the presence of HGD and/or invasive cancer.	[Hata, Tatsuo; Dal Molin, Marco; McGregor-Das, Anne; Song, Tae Jun; Eshleman, James R.; Hruban, Ralph H.; Goggins, Michael] Johns Hopkins Univ, Dept Pathol, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Wolfgang, Christopher] Johns Hopkins Univ, Sch Med, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Eshleman, James R.; Hruban, Ralph H.; Goggins, Michael] Johns Hopkins Univ, Dept Oncol, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA; [Goggins, Michael] Johns Hopkins Univ, Dept Med, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21205 USA	Goggins, M (reprint author), Johns Hopkins Med Inst, Dept Pathol, CRB2 351,1550 Orleans St, Baltimore, MD 21231 USA.	mgoggins@jhmi.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01CA210170, CA62924, R01CA176828]; Rolfe Pancreatic Cancer Foundation	Supported by NIH grants U01CA210170, CA62924, and R01CA176828 (M.G.), Susan Wojcicki and Dennis Troper, and the Rolfe Pancreatic Cancer Foundation (M.G.).	Amato E, 2014, J PATHOL, V233, P217, DOI 10.1002/path.4344; Amin MB, 2017, AJCC CANC STAGING MA; BROWN WRA, 1990, CELL, V63, P119, DOI 10.1016/0092-8674(90)90293-N; Brugge WR, 2004, GASTROENTEROLOGY, V126, P1330, DOI 10.1053/j.gastro.2004.02.013; Canto MI, 2013, GUT, V62, P339, DOI 10.1136/gutjnl-2012-303108; Capper R, 2007, GENE DEV, V21, P2495, DOI 10.1101/gad.439107; Cawthon RM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkn1027; Crippa S, 2017, GUT, V66, P495, DOI 10.1136/gutjnl-2015-310162; Cui YF, 2012, CLIN CANCER RES, V18, P6519, DOI 10.1158/1078-0432.CCR-12-0827; de Lange T, 2009, SCIENCE, V326, P948, DOI 10.1126/science.1170633; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Griffin CA, 2007, CYTOGENET GENOME RES, V118, P148, DOI 10.1159/000108295; Hashimoto Y, 2008, J GASTROINTEST SURG, V12, P17, DOI 10.1007/s11605-007-0383-9; Hata T, 2016, CLIN CANCER RES, V22, P5141, DOI 10.1158/1078-0432.CCR-16-0311; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Hong SM, 2011, MODERN PATHOL, V24, P256, DOI 10.1038/modpathol.2010.181; Hruban RH, 2004, AM J SURG PATHOL, V28, P977, DOI 10.1097/01.pas.0000126675.59108.80; IJDO JW, 1991, P NATL ACAD SCI USA, V88, P9051, DOI 10.1073/pnas.88.20.9051; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Lee KM, 2005, LAB INVEST, V85, P1003, DOI 10.1038/labinvest.3700298; Lee M, 2014, NUCLEIC ACIDS RES, V42, P1733, DOI 10.1093/nar/gkt1117; Letsolo BT, 2010, NUCLEIC ACIDS RES, V38, P1841, DOI 10.1093/nar/gkp1183; Li A, 2010, CANCER BIOL THER, V9, P321, DOI 10.4161/cbt.9.4.10750; Lin TT, 2010, BLOOD, V116, P1899, DOI 10.1182/blood-2010-02-272104; Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171; Maker AV, 2011, CLIN CANCER RES, V17, P1502, DOI 10.1158/1078-0432.CCR-10-1561; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; Masica DL, 2017, J AM MED INFORM ASSN, V24, P145, DOI 10.1093/jamia/ocw069; Matthaei H, 2012, CLIN CANCER RES, V18, P4713, DOI 10.1158/1078-0432.CCR-12-0035; Meeker AK, 2004, CLIN CANCER RES, V10, P3317, DOI 10.1158/1078-0432.CCR-0984-03; Meeker AK, 2004, AM J PATHOL, V164, P925, DOI 10.1016/S0002-9440(10)63180-X; Mukewar S, 2017, GUT, V66, P1811, DOI 10.1136/gutjnl-2016-311615; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Ridtitid W, 2016, GASTROINTEST ENDOSC, V84, P436, DOI 10.1016/j.gie.2016.02.008; Roger L, 2013, JNCI-J NATL CANCER I, V105, P1202, DOI 10.1093/jnci/djt191; Sahora K, 2013, ANN SURG, V258, P466, DOI 10.1097/SLA.0b013e3182a18f48; Schmidt CM, 2008, J GASTROINTEST SURG, V12, P243, DOI 10.1007/s11605-007-0404-8; Schmidt CM, 2007, ANN SURG, V246, P644, DOI 10.1097/SLA.0b013e318155a7b6; Springer S, 2015, GASTROENTEROLOGY, V149, P1501, DOI 10.1053/j.gastro.2015.07.041; Stohr BA, 2010, MOL CELL, V39, P307, DOI 10.1016/j.molcel.2010.06.020; Tan MC, 2015, J AM COLL SURGEONS, V220, P845, DOI 10.1016/j.jamcollsurg.2014.11.029; Tanaka H, 2014, NEOPLASIA, V16, P814, DOI 10.1016/j.neo.2014.08.009; Tanaka H, 2012, P NATL ACAD SCI USA, V109, P14098, DOI 10.1073/pnas.1120062109; Tanaka M, 2012, PANCREATOLOGY, V12, P183, DOI 10.1016/j.pan.2012.04.004; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; Vasen H, 2016, J CLIN ONCOL, V34, P2010, DOI 10.1200/JCO.2015.64.0730; Yamada S, 2016, SURGERY, V159, P878, DOI 10.1016/j.surg.2015.08.042; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	50	2	2	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					46	55		10.1016/j.jmoldx.2017.09.006			10	Pathology	Pathology	FR2DY	WOS:000418878400006	29229290	Bronze, Green Published			2019-10-28	
J	Zhuo, R; Parsons, BD; Lee, BE; Drews, SJ; Chui, LD; Louie, M; Crago, B; Freedman, SB; Ali, S; Pang, XL				Zhuo, Ran; Parsons, Brendon D.; Lee, Bonita E.; Drews, Steven J.; Chui, Linda; Louie, Marie; Crago, Bryanne; Freedman, Stephen B.; Ali, Samina; Pang, Xiaoli			Identification of Enteric Viruses in Oral Swabs from Children with Acute Gastroenteritis	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Article							GASTROINTESTINAL PATHOGEN PANEL; EPIDEMIOLOGY; INFECTIONS; NOROVIRUS; ASSAY	Stool is the diagnostic specimen of choice to identify enteropathogens in pediatric gastroenteritis. However, stool collection is challenging and its diagnostic characteristics in patients with isolated vomiting are unknown. Therefore, we evaluated if oral swabs are a suitable alternative specimen to stools. In total, 738 oral swabs and 577 stool specimens were collected from 738 children with vomiting and/or diarrhea. All specimens were tested by a laboratory-developed quantitative RT-PCR Gastroenteritis Virus Panel; 150 oral swabs and 577 stool specimens were tested by the commercial gastroenteritis pathogen panel. The Gastroenteritis Virus Panel identified adenovirus (n = 38), norovirus (n = 21), and rotavirus (n = 16) commonly in oral swabs. In stool specimens, rotavirus (n = 139), norovirus (n = 86), and adenovirus (n = 69) were detected commonly. Compared with stooL specimens, the specificity of oral swabs was 99% (95% CI, 96%-100%); the sensitivity of oral swabs was 18% (95% CI, 14%-22%) for the detection of enteric viruses. The Gastrointestinal Pathogen Panel identified enteric bacteria and parasites in stooL but not in oral swabs. Given the lower sensitivity of oral swabs, stool remains a preferable specimen to detect enteric viruses. However, with their high specificity, oral swabs can be considered as a suitable specimen if stool specimens are unavailable. Nevertheless, negative oral swabs require a confirmative test of stool specimens.	[Zhuo, Ran; Parsons, Brendon D.; Drews, Steven J.; Chui, Linda; Pang, Xiaoli] Univ Alberta, Dept Lab Med & Pathol, Edmonton, AB, Canada; [Lee, Bonita E.; Ali, Samina] Univ Alberta, Dept Pediat, Edmonton, AB, Canada; [Ali, Samina] Univ Alberta, Women & Childrens Hlth Res Inst, Edmonton, AB, Canada; [Drews, Steven J.; Chui, Linda; Pang, Xiaoli] Alberta Hlth Serv, Prov Lab Publ Hlth, Edmonton, AB, Canada; [Louie, Marie; Crago, Bryanne] Alberta Hlth Serv, Prov Lab Publ Hlth, Calgary, AB, Canada; [Louie, Marie; Crago, Bryanne] Univ Calgary, Cumming Sch Med, Dept Immunol & Infect Dis, Alberta Childrens Hosp,Res Inst, Calgary, AB, Canada; [Louie, Marie; Crago, Bryanne] Univ Calgary, Cumming Sch Med, Dept Pathol & Lab Med, Alberta Childrens Hosp,Res Inst, Calgary, AB, Canada; [Freedman, Stephen B.] Univ Calgary, Cumming Sch Med, Sect Pediat Emergency Med, Alberta Childrens Hosp,Res Inst, Calgary, AB, Canada; [Freedman, Stephen B.] Univ Calgary, Cumming Sch Med, Sect Gastroenterol, Alberta Childrens Hosp,Res Inst, Calgary, AB, Canada	Pang, XL (reprint author), Univ Alberta Hosp, Prov Lab Publ Hlth, WMC 1B1-22,8440-112 St, Edmonton, AB T6G 2J2, Canada.	xiao-li.pang@ahs.ca	Freedman, Stephen/H-9102-2012	Freedman, Stephen/0000-0003-2319-6192; Ali, Samina/0000-0002-0595-364X	Alberta Provincial Pediatric EnTeric Infection TEam; Alberta Innovates Collaborative Research and Innovation Opportunity [20140161]; Alberta Childrenamp;apos;s Hospital Research Institute (Calgary, Alberta, Canada); Women and Childrenapos;s Health Research Institute (Edmonton, Alberta, Canada); Alberta Children's Hospital Foundation; Alberta Children's Hospital Foundation Professorship in Child Health and Wellness	Supported by the Alberta Provincial Pediatric EnTeric Infection TEam, which is funded by Alberta Innovates Collaborative Research and Innovation Opportunity grant 20140161, the Alberta Children's Hospital Research Institute (Calgary, Alberta, Canada), and the Women and Children's Health Research Institute (Edmonton, Alberta, Canada). The Pediatric Emergency Medicine Research Associate Program is supported by a grant from the Alberta Children's Hospital Foundation. In-kind support to enable the conduct of this study was provided by Calgary Laboratory Services, Provincial Laboratory Alberta, Luminex Corporation, and Copan Italia. Supported by the Alberta Children's Hospital Foundation Professorship in Child Health and Wellness (S.B.F.).	Baron EJ, 2013, CLIN INFECT DIS, V57, pE22, DOI 10.1093/cid/cit278; CAUL EO, 1994, LANCET, V343, P1240, DOI 10.1016/S0140-6736(94)92146-6; Claas EC, 2013, J MICROBIOL BIOTECHN, V23, P1041, DOI 10.4014/jmb.1212.12042; Daley P, 2006, J CLIN MICROBIOL, V44, P2265, DOI 10.1128/JCM.02055-05; Deng JK, 2015, DIAGN MICR INFEC DIS, V83, P325, DOI 10.1016/j.diagmicrobio.2015.07.024; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; Freedman SB, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0407-7; Goldfarb DM, 2014, J CLIN MICROBIOL, V52, P3922, DOI 10.1128/JCM.01894-14; GREENBERG HB, 1979, LANCET, V1, P55; Hall AJ, 2011, EMERG INFECT DIS, V17, P1381, DOI 10.3201/eid1708.101533; Karst SM, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004626; Kirby A, 2011, J CLIN VIROL, V51, P86, DOI 10.1016/j.jcv.2011.02.007; Kirby A, 2010, J CLIN VIROL, V48, P285, DOI 10.1016/j.jcv.2010.05.009; Klein EJ, 2006, CLIN INFECT DIS, V43, P807, DOI 10.1086/507335; Pang XLL, 2014, J MED VIROL, V86, P1594, DOI 10.1002/jmv.23851; SCHMITZ H, 1983, AM J EPIDEMIOL, V117, P455, DOI 10.1093/oxfordjournals.aje.a113563; Tabain I, 2012, PEDIATR INFECT DIS J, V31, P680, DOI 10.1097/INF.0b013e318256605e; Tan M, 2005, TRENDS MICROBIOL, V13, P285, DOI 10.1016/j.tim.2005.04.004; Wong S, 2008, J MED VIROL, V80, P856, DOI 10.1002/jmv.21136	19	2	2	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					56	62		10.1016/j.jmoldx.2017.09.003			7	Pathology	Pathology	FR2DY	WOS:000418878400007	29056575	Bronze			2019-10-28	
J	Li, MM; Datto, M; Duncavage, EJ; Kulkarni, S; Lindeman, NI; Roy, S; Tsimberidou, AM; Vnencak-Jones, CL; Wolff, DJ; Younes, A; Nikiforova, MN				Li, Marilyn M.; Datto, Michael; Duncavage, Eric J.; Kulkarni, Shashikant; Lindeman, Neal I.; Roy, Somak; Tsimberidou, Apostolia M.; Vnencak-Jones, Cindy L.; Wolff, Daynna J.; Younes, Anas; Nikiforova, Marina N.			Identification of Germline Variants in Tumor Genomic Sequencing Analysis Reply	JOURNAL OF MOLECULAR DIAGNOSTICS			English	Letter							FOR-MOLECULAR-PATHOLOGY; GUIDELINES; ONCOLOGY		[Li, Marilyn M.; Datto, Michael; Duncavage, Eric J.; Kulkarni, Shashikant; Lindeman, Neal I.; Roy, Somak; Tsimberidou, Apostolia M.; Vnencak-Jones, Cindy L.; Wolff, Daynna J.; Younes, Anas; Nikiforova, Marina N.] Assoc Mol Pathol, Clin Practice Comm, Interpretat Sequence Variants Somat Condit Workin, Bethesda, MD USA; [Li, Marilyn M.] Univ Penn, Perelman Sch Med, Childrens Hosp Philadelphia, Dept Pathol & Lab Med,Div Genom Diagnost, 3615 Civ Ctr Blvd,ARC 716i, Philadelphia, PA 19104 USA; [Datto, Michael] Duke Univ, Sch Med, Durham, NC USA; [Duncavage, Eric J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA; [Kulkarni, Shashikant] Baylor Genet, Houston, TX USA; [Lindeman, Neal I.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Roy, Somak; Nikiforova, Marina N.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Tsimberidou, Apostolia M.] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA; [Vnencak-Jones, Cindy L.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Wolff, Daynna J.] Med Univ South Carolina, Dept Pathol & Lab Med, Charleston, SC USA; [Younes, Anas] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Li, MM (reprint author), Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Pathol & Lab Med, 3615 Civ Ctr Blvd,ARC 716i, Philadelphia, PA 19104 USA.	lim5@email.chop.edu		Tsimberidou, Apostolia M./0000-0003-2713-233X; Nikiforova, Marina Nikolaevna/0000-0001-9976-9378	Foundation Medicine; EMD SeronoMerck Serono; Baxalta; BayerBayer AG; Onyx	E.J.D. is the Medical Director for Cofactor Genomics and claims ownership in P&V Licensing, LLC; A.Y. is a consultant for Foundation Medicine; A.M.T. received research funding from Foundation Medicine, EMD Serono, Baxalta, Bayer, and Onyx.	Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011; Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002	2	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1525-1578	1943-7811		J MOL DIAGN	J. Mol. Diagn.	JAN	2018	20	1					125	126		10.1016/j.jmoldx.2017.11.002			2	Pathology	Pathology	FR2DY	WOS:000418878400014	29249244	Green Published			2019-10-28	
J	Armstrong, D; Wildman, DE				Armstrong, Don; Wildman, Derek E.			Extracellular Vesicles and the Promise of Continuous Liquid Biopsies	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Review						Exosomes; Microvesicles; Extracellular vesicles; Cell-free RNA; Liquid biopsy	DENSITY-GRADIENT SEPARATION; PLACENTA-DERIVED EXOSOMES; PROTEOMIC ANALYSIS; MEMBRANE MICROPARTICLES; MULTIVESICULAR BODIES; ACTIVATED PLATELETS; FAS LIGAND; CELLS; MICROVESICLES; MICRORNA	The rapid and accurate diagnosis of patients with minimally invasive procedures was once only found in science fiction. However, the discovery of extracellular vesicles (EVs) and their near ubiquity in body fluids, coupled with the advent of inexpensive next generation sequencing techniques and EV purification protocols, promises to make science fiction a reality. Purifying and sequencing the RNA content of EV from routine blood draws and urine samples are likely to enable pathologists and physicians to diagnose and track the progress of diseases in many inaccessible tissues in the near future. Here we present the evolutionary background of EV, summarize the biology of EV formation and cargo selection, and discuss the current barriers to making continuous liquid biopsies through the use of EV a science reality.	[Armstrong, Don; Wildman, Derek E.] Univ Illinois, Carl R Woese Inst Genom Biol, Urbana, IL USA; [Wildman, Derek E.] Univ Illinois, Dept Mol & Integrat Physiol, 1206 W Gregory Dr MC-195, Urbana, IL 61801 USA	Wildman, DE (reprint author), Univ Illinois, Dept Mol & Integrat Physiol, 1206 W Gregory Dr MC-195, Urbana, IL 61801 USA.	wildmand@illinois.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1R21ES027878-01]	We would like to thank the insightful comments of Priyadarshini Pantham and Monica Uddin on drafts of this manuscript. This work was funded in part by the National Institutes of Health 1R21ES027878-01 grant to DEW.	Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703; Admyre C, 2007, J IMMUNOL, V179, P1969, DOI 10.4049/jimmunol.179.3.1969; Albuquerque PC, 2008, CELL MICROBIOL, V10, P1695, DOI 10.1111/j.1462-5822.2008.01160.x; Aldick T, 2009, MOL MICROBIOL, V71, P1496, DOI 10.1111/j.1365-2958.2009.06618.x; An QL, 2007, PLANT SIGNAL BEHAV, V2, P4, DOI 10.1111/j.1469-8137.2006.01844.x; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Asaga S, 2011, CLIN CHEM, V57, P84, DOI 10.1373/clinchem.2010.151845; Bard MP, 2004, AM J RESP CELL MOL, V31, P114, DOI 10.1165/rcmb.2003-0238OC; Batagov AO, 2013, BIOL DIRECT, V8, DOI 10.1186/1745-6150-8-12; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Buck AH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6488; Chavez-Munoz C, 2008, J CELL BIOCHEM, V104, P2165, DOI 10.1002/jcb.21774; Cheng L, 2014, KIDNEY INT, V86, P433, DOI 10.1038/ki.2013.502; Chikina M, 2015, BIOINFORMATICS, V31, P1584, DOI 10.1093/bioinformatics/btv015; Choi DS, 2015, MASS SPECTROM REV, V34, P474, DOI 10.1002/mas.21420; Coakley G, 2015, TRENDS PARASITOL, V31, P477, DOI [10.1016/j.pt.2015.05.009, 10.1016/j.pt.2015.06.009]; Coleman BM, 2015, SEMIN CELL DEV BIOL, V40, P89, DOI 10.1016/j.semcdb.2015.02.007; Collino F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011803; Avila-Calderon ED, 2015, ARCH MICROBIOL, V197, P1, DOI 10.1007/s00203-014-1042-7; Deatherage BL, 2012, INFECT IMMUN, V80, P1948, DOI 10.1128/IAI.06014-11; del Conde I, 2005, BLOOD, V106, P1604, DOI 10.1182/blood-2004-03-1095; Del Tatto M, 2011, EXP HEMATOL, V39, P1072, DOI 10.1016/j.exphem.2011.08.008; Deregibus MC, 2007, BLOOD, V110, P2440, DOI 10.1182/blood-2007-03-078709; Dutta S, 2004, MICROBIOL IMMUNOL, V48, P965, DOI 10.1111/j.1348-0421.2004.tb03626.x; Ellen AF, 2011, J BACTERIOL, V193, P4380, DOI 10.1128/JB.05028-11; Ellen AF, 2010, ARCHAEA, DOI 10.1155/2010/608243; Fesler A, 2014, MOL DIAGN THER, V18, P303, DOI 10.1007/s40291-014-0089-0; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gardiner C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026313; Gerlach JQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074801; Gibbings DJ, 2009, NAT CELL BIOL, V11, P1143, DOI 10.1038/ncb1929; Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009; Greening DW, 2015, METHODS MOL BIOL, V1295, P179, DOI 10.1007/978-1-4939-2550-6_15; HARDING C, 1983, J CELL BIOL, V97, P329, DOI 10.1083/jcb.97.2.329; Haurat MF, 2015, BIOL CHEM, V396, P95, DOI 10.1515/hsz-2014-0183; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; Hessvik NP, 2012, BBA-GENE REGUL MECH, V1819, P1154, DOI 10.1016/j.bbagrm.2012.08.016; Hood JL, 2017, SEMIN CELL DEV BIOL, V67, P29, DOI 10.1016/j.semcdb.2016.12.002; Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Kalra H, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001450; Keller S, 2007, KIDNEY INT, V72, P1095, DOI 10.1038/sj.ki.5002486; Kesimer M, 2009, FASEB J, V23, P1858, DOI 10.1096/fj.08-119131; Kibria G, 2016, SCI REP-UK, V6, DOI 10.1038/srep36502; Kim DK, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20384; Knight M, 1998, BRIT J OBSTET GYNAEC, V105, P632, DOI 10.1111/j.1471-0528.1998.tb10178.x; Kriebel PW, 2008, J CELL BIOL, V183, P949, DOI 10.1083/jcb.200808105; Lai FW, 2015, J LEUKOCYTE BIOL, V97, P237, DOI 10.1189/jlb.3RU0513-292RR; Lavialle F, 2009, INT J PHARMACEUT, V380, P206, DOI 10.1016/j.ijpharm.2009.06.039; Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087; Leung KF, 2008, TRAFFIC, V9, P1698, DOI 10.1111/j.1600-0854.2008.00797.x; Li M, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0502; Lo Cicero A, 2015, CURR OPIN CELL BIOL, V35, P69, DOI 10.1016/j.ceb.2015.04.013; Lopez-Verrilli MA, 2013, BIOL RES, V46, P5, DOI 10.4067/S0716-97602013000100001; Lykke-Andersen S, 2009, J CELL SCI, V122, P1487, DOI 10.1242/jcs.047399; Maas SLN, 2017, TRENDS CELL BIOL, V27, P172, DOI 10.1016/j.tcb.2016.11.003; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Mallat Z, 1999, CIRCULATION, V99, P348, DOI 10.1161/01.CIR.99.3.348; Mangeot PE, 2011, MOL THER, V19, P1656, DOI 10.1038/mt.2011.138; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; Matsumura T, 2015, BRIT J CANCER, V113, P275, DOI 10.1038/bjc.2015.201; Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581; Michael A, 2010, ORAL DIS, V16, P34, DOI 10.1111/j.1601-0825.2009.01604.x; Miguet L, 2006, PROTEOMICS, V6, P153, DOI 10.1002/pmic.200500133; Mincheva-Nilsson L, 2014, AM J REPROD IMMUNOL, V72, P440, DOI 10.1111/aji.12311; Mitchell MD, 2015, AM J OBSTET GYNECOL, V213, pS173, DOI 10.1016/j.ajog.2015.07.001; Morelli AE, 2004, BLOOD, V104, P3257, DOI 10.1182/blood-2004-03-0824; Ogawa Y, 2008, BIOL PHARM BULL, V31, P1059, DOI 10.1248/bpb.31.1059; Ostrowski EA, 2015, CURR BIOL, V25, P1661, DOI 10.1016/j.cub.2015.04.059; Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Regente M, 2009, FEBS LETT, V583, P3363, DOI 10.1016/j.febslet.2009.09.041; Saadatpour L, 2016, CANCER GENE THER, V23, P415, DOI 10.1038/cgt.2016.48; Sabapatha A, 2006, AM J REPROD IMMUNOL, V56, P345, DOI 10.1111/j.1600-0897.2006.00435.x; Salomon C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00175; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Skriner K, 2006, ARTHRITIS RHEUM, V54, P3809, DOI 10.1002/art.22276; Smith ZJ, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.28533; Stamer WD, 2011, J PROTEOMICS, V74, P796, DOI 10.1016/j.jprot.2011.02.024; Stenqvist AC, 2013, J IMMUNOL, V191, P5515, DOI 10.4049/jimmunol.1301885; Sullivan R, 2005, BLOOD CELL MOL DIS, V35, P1, DOI 10.1016/j.bcmd.2005.03.005; Tauro BJ, 2012, METHODS, V56, P293, DOI 10.1016/j.ymeth.2012.01.002; Thimon V, 2008, HUM REPROD, V23, P1698, DOI 10.1093/humrep/den181; Tu HH, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1600675; Urbanelli Lorena, 2015, Recent Pat CNS Drug Discov, V10, P10; Utleg AG, 2003, PROSTATE, V56, P150, DOI 10.1002/pros.10255; Vella LJ, 2008, VET IMMUNOL IMMUNOP, V124, P385, DOI 10.1016/j.vetimm.2008.04.002; Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2; Whitford W., 2015, GENET ENG BIOTECHNOL, V35, P34, DOI DOI 10.1089/gen.35.16.15; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x; Yang M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-117; Yuan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004722	93	20	20	0	4	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					1	8		10.4132/jptm.2017.05.21			8	Pathology	Pathology	FS7VE	WOS:000422616200001	29370511	DOAJ Gold, Green Published			2019-10-28	
J	Kim, SI; Lee, Y; Won, JK; Park, CK; Choi, SH; Park, SH				Kim, Seong-Ik; Lee, Yujin; Won, Jae-Kyung; Park, Chul-Kee; Choi, Seung Hong; Park, Sung-Hye			Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Oligoastrocytoma; Glioblastoma with oligodendroglioma component; WHO classification; Genetics; Integrated diagnosis	ANAPLASTIC OLIGODENDROGLIOMA; ASTROCYTIC TUMORS; IDH2 MUTATIONS; GLIOMAS; ATRX; GLIOBLASTOMA; PROGNOSIS; SURVIVAL; CANCER	Background: Mixed gliomas, such as oligoastrocytomas (OA), anaplastic oligoastrocytomas, and glioblastomas (GBMs) with an oligodendroglial component (GBMO) are defined as tumors composed of a mixture of two distinct neoplastic cell types, astrocytic and oligodendroglial. Recently, mutations ATRX and TP53, and codeletion of 1p/19q are shown to be genetic hallmarks of astrocytic and oligodendroglial tumors, respectively. Subsequent molecular analyses of mixed gliomas preferred the reclassification to either oligodendroglioma or astrocytoma. This study was designed to apply genetically integrated diagnostic criteria to mixed gliomas and determine usefulness and prognostic value of new classification in Korean patients. Methods: Fifty-eight cases of mixed OAs and GBMOs were retrieved from the pathology archives of Seoul National University Hospital from 2004 to 2015. Reclassification was performed according to genetic and immunohistochemical properties. Clinicopathological characteristics of each subgroup were evaluated. Overall survival was assessed and compared between subgroups. Results: We could reclassify all mixed OAs and GBMOs into either astrocytic or oligodendroglial tumors. Notably, 29 GBMOs could be reclassified into 11 cases of GBM, IDH-mutant, 16 cases of GBM, IDH-wildtype, and two cases of anaplastic oligodendroglioma, IDH mutant. Overall survival was significantly different among these new groups (p < .001). Overall survival and progression-free survival were statistically better in gliomas with IDH mutation, ATRX mutation, no microscopic necrosis, and young patient age (cut off, 45 years old). Conclusions: Our results strongly suggest that a genetically integrated diagnosis of glioma better reflects prognosis than former morphology-based methods.	[Kim, Seong-Ik; Lee, Yujin; Won, Jae-Kyung; Park, Sung-Hye] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Lee, Yujin; Park, Chul-Kee] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea; [Choi, Seung Hong] Seoul Natl Univ, Coll Med, Dept Radiol, Seoul, South Korea; [Park, Sung-Hye] Seoul Natl Univ, Coll Med, Neurosicence Inst, Seoul, South Korea	Park, SH (reprint author), Seoul Natl Univ, Coll Med, Neurosicence Inst, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea.	shparknp@snu.ac.kr	Park, Chul-Kee/O-7842-2019; Park, Chul-Kee/J-5499-2012	Park, Chul-Kee/0000-0002-2350-9876; Won, Jae-Kyung/0000-0003-1459-8093	Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI14C1277]	This study was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number : HI14C1277).	Grisold W, 2009, ACTA NEUROL SCAND, V119, P1, DOI 10.1111/j.1600-0404.2008.01059.x; Haberler C, 2014, CLIN NEUROPATHOL, V33, P108, DOI 10.5414/NP300758; Houillier C, 2010, NEUROLOGY, V75, P1560, DOI 10.1212/WNL.0b013e3181f96282; Jiang HH, 2013, NEURO-ONCOLOGY, V15, P775, DOI 10.1093/neuonc/not027; Killela PJ, 2014, ONCOTARGET, V5, P1452, DOI 10.18632/oncotarget.1505; Kros JM, 2007, J NEUROPATH EXP NEUR, V66, P545, DOI 10.1097/01.jnen.0000263869.84188.72; Labussiere M, 2010, NEUROLOGY, V74, P1886, DOI 10.1212/WNL.0b013e3181e1cf3a; Liu XY, 2012, ACTA NEUROPATHOL, V124, P615, DOI 10.1007/s00401-012-1031-3; Louis DN, 2014, BRAIN PATHOL, V24, P429, DOI 10.1111/bpa.12171; LOUIS DN, 1993, J NEUROPATH EXP NEUR, V52, P31, DOI 10.1097/00005072-199301000-00005; Louis DN, 2016, WHO CLASSIFICATION T; Love S., 2015, GREENFIELDS NEUROPAT; Myung JK, 2014, TRANSL ONCOL, V7, P712, DOI 10.1016/j.tranon.2014.10.002; Ohgaki H., 2013, DIFFUSE LOW GRADE GL, P61; Okamoto Y, 2004, ACTA NEUROPATHOL, V108, P49, DOI 10.1007/s00401-004-0861-z; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Sahm F, 2014, ACTA NEUROPATHOL, V128, P551, DOI 10.1007/s00401-014-1326-7; Tortosa A, 2003, CANCER, V97, P1063, DOI 10.1002/cncr.11120; van den Bent MJ, 2013, J CLIN ONCOL, V31, P344, DOI 10.1200/JCO.2012.43.2229; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710	20	2	2	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					28	36		10.4132/jptm.2017.09.25			9	Pathology	Pathology	FS7VE	WOS:000422616200005	28958143	DOAJ Gold, Green Published			2019-10-28	
J	Park, SY; Kim, SI; Kim, H; Lee, Y; Park, SH				Park, Sun-Young; Kim, Seong Ik; Kim, Hannah .; Lee, Yoojin; Park, Sung-Hye			An Autopsy Case of Epstein-Barr Virus-Associated Diffuse Large B-Cell Lymphoma of the Central Nervous System in an Immunocompromised Host	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Autopsy; Central nervous system; Lymphoma; Epstein-Barr virus; Immunocompromised host		Lymphomas arising in the central nervous system (CNS) of immunocompromised hosts are most commonly non-Hodgkin's lymphomas and are highly associated with Epstein-Barr virus (EBV). Here we report an autopsy case of EBV-associated CNS diffuse large B-cell lymphoma (DLBCL) in a host suffering from systemic lupus erythematosus who underwent immunosuppressive therapy. After autopsy, EBV-associated CNS DLBCL as well as pulmonary mixed aspergillosis and Pneumocystis jirovecii pneumonia were added to the cause of clinical manifestations of complicated pneumonia and cerebral hemorrhage in this immunocompromised patient. In conclusion, complex disease processes were revealed by autopsy in this case, indicating that the clinicopathological correlations observed through autopsy can improve our understanding of disease progression and contribute to the management of similar patients in the future.	[Park, Sun-Young; Kim, Seong Ik; Kim, Hannah .; Lee, Yoojin; Park, Sung-Hye] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea	Park, SH (reprint author), Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Pathol, 103 Daehak Ro, Seoul 03080, South Korea.	shparknp@snu.ac.kr					Bayraktar S, 2011, J NEURO-ONCOL, V101, P257, DOI 10.1007/s11060-010-0252-3; Bibas M, 2009, MEDITERR J HEMATOL I, V1, DOI 10.4084/MJHID.2009.032; Campo E, 2011, BLOOD, V117, P5019, DOI 10.1182/blood-2011-01-293050; Doucet S, 2013, CURR TREAT OPTION ON, V14, P185, DOI 10.1007/s11864-013-0227-7; El Jamal S, 2014, BRAIN TUMOR PATHOL, V31, P265, DOI 10.1007/s10014-013-0173-x; Fraser E, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.02.01; Hunt KE, 2008, ARCH PATHOL LAB MED, V132, P118, DOI 10.1043/1543-2165(2008)132[118:DLBL]2.0.CO;2; Mahmoud HM, 2011, HEMATOL REP, V3, P80, DOI 10.4081/hr.2011.e26; Phillips EH, 2014, CURR HEMATOL MALIG R, V9, P243, DOI 10.1007/s11899-014-0217-2; Romero M, 2016, DIAGN CYTOPATHOL, V44, P61, DOI 10.1002/dc.23374; Roschewski M, 2012, BEST PRACT RES CL HA, V25, P75, DOI 10.1016/j.beha.2012.01.005; Sabatini E, 2010, PATHOLOGICA, V102, P83; Sugita Y, 2016, NEUROPATHOLOGY, V36, P313, DOI 10.1111/neup.12276; Tun HW, 2008, BLOOD, V111, P3200, DOI 10.1182/blood-2007-10-119099	14	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					51	55		10.4132/jptm.2017.01.23			5	Pathology	Pathology	FS7VE	WOS:000422616200008	28774170	DOAJ Gold, Green Published			2019-10-28	
J	Choi, J; Kim, SH				Choi, Jiwoon; Kim, Se Hoon			Liquid-Based Cytology of the Cerebrospinal Fluid in a Case of Cryptococcal Meningitis	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article						Cryptococcus neoformans; Cerebrospinal fluid; Liquid-based cytology	NEOFORMANS; SPUTUM	Cryptococcus neoformans is the most common microorganism found in cerebrospinal fluid (CSF) cytology and causes life-threatening infections in immunocompromised hosts. Although its cytomorphologic features in conventional smear cytology have been well described, those in liquid-based cytology have rarely been. A 73-year-old woman with diffuse large B-cell lymphoma presented with mental confusion and a spiking fever. To rule out infectious conditions, CSF examination was performed. A cytology slide that was prepared using the ThinPrep method showed numerous spherical yeast-form organisms with diameters of 4-11 mu m and thick capsules. Occasional asymmetrical, narrow-based budding but no true hyphae or pseudohyphae were observed. Gomori methenamine silver staining was positive. Cryptococcosis was confirmed in blood and CSF through the cryptococcal antigen test and culture. Liquid-based cytology allows for a clean background and additional slides for ancillary testing, facilitating the detection of microorganisms in CSF specimens, particularly when the number of organisms is small.	[Choi, Jiwoon] Yonsei Univ, Wonju Coll Med, Dept Pathol, Wonju, South Korea; [Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, 50-1 Yonsei Ro, Seoul 03722, South Korea	Kim, SH (reprint author), Yonsei Univ, Coll Med, Dept Pathol, 50-1 Yonsei Ro, Seoul 03722, South Korea.	paxco@yuhs.ac		Kim, Se Hoon/0000-0001-7516-7372			Dixit A, 2009, INTERDISCIP PERSPECT, V2009, DOI DOI 10.1155/2009/840452; Kanazawa M, 2008, ACTA CYTOL, V52, P266, DOI 10.1159/000325499; Kobayashi TK, 2003, ACTA CYTOL, V47, P103; KWONCHUNG KJ, 1982, J CLIN MICROBIOL, V15, P535; LEVITZ SM, 1991, REV INFECT DIS, V13, P1163; Powers CN, 1998, CLIN MICROBIOL REV, V11, P341, DOI 10.1128/CMR.11.2.341; Prayson RA, 1998, ARCH PATHOL LAB MED, V122, P47; SAIGO P, 1977, AM J CLIN PATHOL, V67, P141; Sharma S, 2017, CYTOPATHOLOGY, V28, P177, DOI 10.1111/cyt.12409; WALTS AE, 1992, DIAGN CYTOPATHOL, V8, P394, DOI 10.1002/dc.2840080420; Williamson JD, 1996, ACTA CYTOL, V40, P363, DOI 10.1159/000333769	11	2	2	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					61	63		10.4132/jptm.2017.06.13			3	Pathology	Pathology	FS7VE	WOS:000422616200010	29069886	DOAJ Gold, Green Published			2019-10-28	
J	Kang, Y; Chae, YS; Kim, CH; Lee, Y; Kim, DS; Yu, YD; Kim, JY				Kang, Youngjin; Chae, Yang-Seok; Kim, Chul Hwan; Lee, Youngseok; Kim, Dong-Sik; Yu, Young-Dong; Kim, Joo Young			Hyalinizing Cholecystitis and Associated Carcinoma: A Case Report	JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE			English	Article							PORCELAIN GALLBLADDER; ULTRASOUND; FEATURES	Hyalinizing cholecystitis (HC) is a recently described rare variant of chronic cholecystitis that is characterized by replacement of the normal structures of the entire gallbladder wall with diffuse and dense hyaline sclerosis.(1) Some cases of cholecystitis are associated with variable degrees of calcification. Porcelain gallbladder (PG) is an extensively calcific example that is a vaguely and radiologically defined entity whose pathologic correlation has not been identified.(2-4) PG is subclassified into "complete porcelain," showing extensive dystrophic calcifications that form an intramural continuous band involving more than 80% of the gallbladder wall, and "incomplete porcelain," which lacks these findings.(2,5-7) Although HC is rare and found in only approximately 1.6% of cholecystectomy specimens, it is more commonly accompanied by carcinomas with more aggressive clinical behavior compared to usual gallbladder carcinomas.(1) However, preoperative diagnosis of HC-related carcinoma is challenging, because the wall is thinner than that of typical chronic cholecystitis or usual carcinomas, and discrete masses are not formed. There has been only one case report of HC, which was accompanied by immunoglobulin G4-related disease,(8) since Patel et al.(1) first described the entity in a retrospective case series. We present a case of HC and associated carcinoma masquerading as primary biliary cancer.	[Kang, Youngjin; Chae, Yang-Seok; Kim, Chul Hwan; Lee, Youngseok; Kim, Joo Young] Korea Univ, Coll Med, Anam Hosp, Dept Pathol, 73 Inchon Ro, Seoul 02841, South Korea; [Kim, Dong-Sik; Yu, Young-Dong] Korea Univ, Coll Med, Anam Hosp, Dept Surg, Seoul, South Korea	Kim, JY (reprint author), Korea Univ, Coll Med, Anam Hosp, Dept Pathol, 73 Inchon Ro, Seoul 02841, South Korea.	lepetit80@hanmail.net					Gupta RK, 2015, HUM PATHOL, V46, P625, DOI 10.1016/j.humpath.2014.12.015; KANE RA, 1984, RADIOLOGY, V152, P137, DOI 10.1148/radiology.152.1.6729103; OCHSNER SF, 1963, AMER J ROENTGENOL RA, V89, P847; Patel S, 2011, AM J SURG PATHOL, V35, P1104, DOI 10.1097/PAS.0b013e31822179cc; SHIMIZU M, 1989, J CLIN GASTROENTEROL, V11, P471; Stephen AE, 2001, SURGERY, V129, P699, DOI 10.1067/msy.2001.113888; Towfigh S, 2001, AM SURGEON, V67, P7; WEINER PL, 1975, AM J GASTROENTEROL, V64, P224	8	0	0	0	0	KOREAN SOC PATHOLOGISTS	SEOUL	1209 GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, 03186, SOUTH KOREA	2383-7837	2383-7845		J PATHOL TRANSL MED	J. Pathol. Transl. Med.	JAN	2018	52	1					64	66		10.4132/jptm.2016.11.04			3	Pathology	Pathology	FS7VE	WOS:000422616200011	28372345	DOAJ Gold, Green Published			2019-10-28	
J	Kemmochi, Y; Ohta, T; Motohashi, Y; Kaneshige, A; Katsumi, S; Kakimoto, K; Yasui, Y; Anagawa-Nakamura, A; Toyoda, K; Taniai-Riya, E; Takahashi, A; Shoda, T; Yamada, T				Kemmochi, Yusuke; Ohta, Takeshi; Motohashi, Yu; Kaneshige, Akihiro; Katsumi, Sohei; Kakimoto, Kochi; Yasui, Yuzo; Anagawa-Nakamura, Akiko; Toyoda, Kaoru; Taniai-Riya, Eriko; Takahashi, Akemi; Shoda, Toshiyuki; Yamada, Takahisa			Pathophysiological analyses of skeletal muscle in obese type 2 diabetes SDT fatty rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						diabetes; sarcopenia; SDT fatty rat; skeletal muscle	PROTEIN-DEGRADATION; INSULIN-RESISTANCE; SARCOPENIA FACTS; CLINICAL IMPACT; IN-VITRO; PREVALENCE; MECHANISMS; DIAGNOSIS; NUMBERS; GLUCOSE	Sarcopenia is the age-related decrease of muscle mass and function. Diabetes and obesity are known to be risk factors that exacerbate sarcopenia, but the underlying mechanism of diabetes-related sarcopenia is still unknown. Obese type 2 diabetes SDT fatty rats show early onset of severe diabetes and there have been no reports on the characteristics of their skeletal muscle. Therefore, pathophysiological analyses were performed for the skeletal muscle in these rats. Diabetic male SDT fatty rats were sacrificed at 8, 16, 24, 32 and 40 weeks of age. Age-matched Sprague Dawley (SD) rats were used as the normal control. In addition to biological blood parameters, the soleus and the extensor digitorum longus muscles were examined for muscle weight, histopathology, and protein synthesis and degradation. Muscle grip strength was also examined. These results revealed that the muscle weights of the SDT fatty rats were significantly decreased from 16 weeks of age. The mean cross-sectional area of muscle fibers in the SDT fatty rats decreased from 24 weeks of age. Increased intramyocellular lipid accumulation, identified by immunohistochemistry for adipophilin and TEM, was observed in the SDT fatty rats from 8 weeks of age. Plasma insulin-like growth factor (IGF)-1 levels and muscle strength in the SDT fatty rats decreased at 24 weeks of age and thereafter. These pathophysiological findings have been reported both in sarcopenia in aged humans and in patients with diabetes. In conclusion, the SDT fatty rat was considered to be a useful model for analysis of diabetes-related sarcopenia.	[Kemmochi, Yusuke; Kakimoto, Kochi; Yasui, Yuzo; Anagawa-Nakamura, Akiko; Toyoda, Kaoru; Taniai-Riya, Eriko; Takahashi, Akemi; Shoda, Toshiyuki] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Toxicol Res Labs, 23 Naganuki, Hadano, Kanagawa 2570024, Japan; [Ohta, Takeshi; Motohashi, Yu; Kaneshige, Akihiro; Katsumi, Sohei] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Biol & Res Labs, 1-1 Murasaki Cho, Takatsuki, Osaka 5691125, Japan; [Yamada, Takahisa] Niigata Univ, Dept Agrobiol, Fac Agr, Nishi Ku, 2-8050 Igarashi, Niigata, Niigata 9502181, Japan	Kemmochi, Y (reprint author), Japan Tobacco Inc, Cent Pharmaceut Res Inst, Toxicol Res Labs, 23 Naganuki, Hadano, Kanagawa 2570024, Japan.	Yusuke.kemmochi@jt.com		Ohta, Takeshi/0000-0002-9573-3455			Ali S, 2014, GERONTOLOGY, V60, P294, DOI 10.1159/000356760; Alway SE, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00246; Argiles JM, 1999, J NUTR BIOCHEM, V10, P244, DOI 10.1016/S0955-2863(98)00098-9; Aughsteen AA, 2006, J PANCREAS, V7, P382; Basualto-Alarcon C, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00217; Benbassat CA, 1997, J CLIN ENDOCR METAB, V82, P1484, DOI 10.1210/jc.82.5.1484; Buford TW, 2010, AGEING RES REV, V9, P369, DOI 10.1016/j.arr.2010.04.004; Cawthon PM, 2007, J AM GERIATR SOC, V55, P1216, DOI 10.1111/j.1532-5415.2007.01259.x; Cederholm T, 2000, CLIN PHYSIOL, V20, P354, DOI 10.1046/j.1365-2281.2000.00269.x; Cleasby ME, 2016, J ENDOCRINOL, V229, pR67, DOI 10.1530/JOE-15-0533; Conte M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073709; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Gumucio JP, 2013, ENDOCRINE, V43, P12, DOI 10.1007/s12020-012-9751-7; Han HJ, 2006, CLIN EXP PHARMACOL P, V33, P1172, DOI 10.1111/j.1440-1681.2006.04495.x; HICKEY MS, 1995, AM J PHYSIOL-ENDOC M, V268, pE453; Kalyani RR, 2014, LANCET DIABETES ENDO, V2, P819, DOI 10.1016/S2213-8587(14)70034-8; Katsuda Y, 2014, EXP ANIM TOKYO, V63, P121, DOI 10.1538/expanim.63.121; Kemmochi Y, 2013, J DIABETES RES, DOI 10.1155/2013/948257; Kemp JG, 2009, INT J OBESITY, V33, P831, DOI 10.1038/ijo.2009.100; Kim Min Sun, 2015, Ann Pediatr Endocrinol Metab, V20, P69, DOI 10.6065/apem.2015.20.2.69; Kim Tae Nyun, 2013, J Bone Metab, V20, P1, DOI 10.11005/jbm.2013.20.1.1; Long YC, 2011, MOL CELL BIOL, V31, P430, DOI 10.1128/MCB.00983-10; Maekawa T, 2017, J PHARMACOL TOX MET, V88, P160, DOI 10.1016/j.vascn.2017.09.257; Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5; Masuyama T, 2005, EXP ANIM TOKYO, V54, P13, DOI 10.1538/expanim.54.13; Matsui K, 2008, EXP ANIM TOKYO, V57, P111, DOI 10.1538/expanim.57.111; Meyer O A, 1979, Neurobehav Toxicol, V1, P233; Morley JE, 2014, J CACHEXIA SARCOPENI, V5, P253, DOI 10.1007/s13539-014-0161-y; Morley JE, 2012, FAM PRACT, V29, pi44, DOI 10.1093/fampra/cmr063; Newman AB, 2003, J AM GERIATR SOC, V51, P1602, DOI 10.1046/j.1532-5415.2003.51534.x; Ohta T, 2014, J DIABETES RES, DOI 10.1155/2014/841957; Ozaki K, 2001, ACTA NEUROPATHOL, V102, P264; Pani G, 2016, J CLIN MOL ENDOCRINO, V1, P29; Park SW, 2007, DIABETES CARE, V30, P1507, DOI 10.2337/dc06-2537; Pepato MT, 1996, AM J PHYSIOL-ENDOC M, V271, pE340; Schiaffino S, 2011, PHYSIOL REV, V91, P1447, DOI 10.1152/physrev.00031.2010; Sitnick M, 2009, J PHYSIOL-LONDON, V587, P5753, DOI 10.1113/jphysiol.2009.180174; Sugimoto Ken, 2014, Clin Calcium, V24, P1479, DOI CliCa141014791486; von Haehling S, 2010, J CACHEXIA SARCOPENI, V1, P129, DOI 10.1007/s13539-010-0014-2; Wang XN, 2006, ENDOCRINOLOGY, V147, P4160, DOI 10.1210/en.2006-0251	40	3	3	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					113	123		10.1293/tox.2017-0064			11	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200004	29750000	Green Published, Bronze			2019-10-28	
J	Tsuchiya, Y; Sakai, H; Hirata, A; Yanai, T				Tsuchiya, Yuya; Sakai, Hiroki; Hirata, Akihiro; Yanai, Tokuma			Brazilian green propolis suppresses acetaminophen-induced hepatocellular necrosis by modulating inflammation-related factors in rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						acetaminophen; antioxidative enzyme; Brazilian green propolis; chemokine; cytokine; hepatocellular necrosis	INDUCED LIVER-INJURY; NF-KAPPA-B; INDUCED HEPATOTOXICITY; CARBON-TETRACHLORIDE; NATURAL-PRODUCTS; CELL-DEATH; MICE; PARACETAMOL; MECHANISMS; TOXICITY	Propolis is a resin-like material produced by honey bees from bud exudates and sap of plants and their own secretions. An ethanol extract of Brazilian green propolis (EEBGP) contains prenylated phenylpropanoids and flavonoids and has antioxidative and anti-inflammatory effects. Acetaminophen (N-acetyl-p-aminophenol; APAP) is a typical hepatotoxic drug, and APAP-treated rats are widely used as a model of drug-induced liver injury. Oxidative stress and inflammatory reactions cause APAP-induced hepatocellular necrosis and are also related to expansion of the lesion. In the present study, we investigated the preventive effects of EEBGP on APAP-induced hepatocellular necrosis in rats and the protective mechanism including the expression of antioxidative enzyme genes and inflammation-related genes. A histological analysis revealed that administration 0.3% EEBGP in the diet for seven days reduced centrilobular hepatocellular necrosis with inflammatory cell infiltration induced by oral administration of APAP (800 mg/kg) and significantly reduced the area of necrosis. EEBGP administration did not significantly change the mRNA expression levels of antioxidant enzyme genes in the liver of APAP-treated rats but decreased the mRNA expression of cytokines including Il10 and Il1b, with a significant difference in Il10 expression. In addition, the decrease in the mRNA levels of the Il1b and Il10 genes significantly correlated with the decrease in the percentage of hepatocellular necrosis. These findings suggest that EEBGP could suppress APAP-induced hepatocellular necrosis by modulating cytokine expression.	[Tsuchiya, Yuya] API Co Ltd, Nagaragawa Res Ctr, 692-3 Nagara, Gifu, Gifu 5020071, Japan; [Tsuchiya, Yuya; Sakai, Hiroki; Yanai, Tokuma] Gifu Univ, Dept Vet Med, Lab Vet Pathol, 1-1 Yanagido, Gifu, Gifu 5011193, Japan; [Hirata, Akihiro] Gifu Univ, Life Sci Res Ctr, Div Anim Expt, 1-1 Yanagido, Gifu, Gifu 5011194, Japan	Yanai, T (reprint author), Gifu Univ, Dept Vet Med, Lab Vet Pathol, 1-1 Yanagido, Gifu, Gifu 5011193, Japan.	yanai@gifu-u.ac.jp					Ajith TA, 2007, FOOD CHEM TOXICOL, V45, P2267, DOI 10.1016/j.fct.2007.06.001; ALBERT KS, 1974, J PHARMACOKINET BIOP, V2, P381, DOI 10.1007/BF01071309; Bantel H, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00079; BLAZKA ME, 1995, TOXICOL APPL PHARM, V133, P43, DOI 10.1006/taap.1995.1125; Bourdi M, 2002, HEPATOLOGY, V35, P289, DOI 10.1053/jhep.2002.30956; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Chen X, 2009, WORLD J GASTROENTERO, V15, P1829, DOI 10.3748/wjg.15.1829; CLEMENTS JA, 1984, BRIT J CLIN PHARMACO, V18, P481, DOI 10.1111/j.1365-2125.1984.tb02495.x; Cover C, 2006, TOXICOL APPL PHARM, V216, P98, DOI 10.1016/j.taap.2006.04.010; CUMMINGS AJ, 1967, BRIT J PHARM CHEMOTH, V29, P150, DOI 10.1111/j.1476-5381.1967.tb01948.x; Duffield JS, 2005, J CLIN INVEST, V115, P56, DOI 10.1172/JCI200522675; Glasgow SC, 2007, AM J PHYSIOL-LUNG C, V293, pL491, DOI 10.1152/ajplung.00009.2007; Hanawa N, 2008, J BIOL CHEM, V283, P13565, DOI 10.1074/jbc.M708916200; Harata D, 2018, J TOXICOL PATHOL, V31, P89, DOI 10.1293/tox.2017-0044; Huebener P, 2015, J CLIN INVEST, V125, P539, DOI 10.1172/JCI76887; Imaeda AB, 2009, J CLIN INVEST, V119, P305, DOI 10.1172/JCI35958; Izuta H, 2009, BIOL PHARM BULL, V32, P1947, DOI 10.1248/bpb.32.1947; Jaeschke H, 2006, TOXICOL SCI, V89, P31, DOI 10.1093/toxsci/kfi336; Jaeschke H, 2003, TOXICOL LETT, V144, P279, DOI 10.1016/S0378-4274(03)00239-X; Jaeschke Hartmut, 2018, React Oxyg Species (Apex), V5, P145; Jaeschke H, 2013, FOOD CHEM TOXICOL, V55, P279, DOI 10.1016/j.fct.2012.12.063; Jaeschke H, 2011, LIFE SCI, V88, P737, DOI 10.1016/j.lfs.2011.01.025; Jamshidzadeh A, 2008, FOOD CHEM TOXICOL, V46, P3612, DOI 10.1016/j.fct.2008.09.006; Kanno S, 2016, BIOL PHARM BULL, V39, P440, DOI 10.1248/bpb.b15-00734; Lee KJ, 2008, TOXICOLOGY, V248, P18, DOI 10.1016/j.tox.2008.03.009; Lei XG, 2006, BIOCHEM J, V399, P455, DOI 10.1042/BJ20060784; Maher JJ, 2009, J CLIN INVEST, V119, P246, DOI 10.1172/JCI38178; Martin-Murphy BV, 2010, TOXICOL LETT, V192, P387, DOI 10.1016/j.toxlet.2009.11.016; Matsunaga N, 2004, J PHARMACOL EXP THER, V311, P594, DOI 10.1124/jpet.104.069062; Mossanen JC, 2016, HEPATOLOGY, V64, P1667, DOI 10.1002/hep.28682; Muriel P, 2009, J APPL TOXICOL, V29, P91, DOI 10.1002/jat.1393; Nakajima Y, 2009, BMC COMPLEM ALTERN M, V9, DOI 10.1186/1472-6882-9-4; Nakamura T, 2013, EVID-BASED COMPL ALT, DOI 10.1155/2013/302720; Nakamura T, 2012, PHYTOTHER RES, V26, P1482, DOI 10.1002/ptr.4601; Ray SD, 1999, ARCH BIOCHEM BIOPHYS, V369, P42, DOI 10.1006/abbi.1999.1333; Rumack BH, 2004, HEPATOLOGY, V40, P10, DOI 10.1002/hep.20300; Salatino A, 2011, NAT PROD REP, V28, P925, DOI 10.1039/c0np00072h; Seo KW, 2003, PHYTOTHER RES, V17, P250, DOI 10.1002/ptr.1120; Sforcin JM, 2016, PHYTOTHER RES, V30, P894, DOI 10.1002/ptr.5605; Sforcin JM, 2011, J ETHNOPHARMACOL, V133, P253, DOI 10.1016/j.jep.2010.10.032; Szabo G, 2012, J HEPATOL, V57, P642, DOI 10.1016/j.jhep.2012.03.035; Wang K, 2015, J FUNCT FOODS, V19, P464, DOI 10.1016/j.jff.2015.09.009; Yemitan OK, 2006, PHYTOTHER RES, V20, P997, DOI 10.1002/ptr.1957; Yoshikawa Y, 2009, TOXICOLOGY, V264, P89, DOI 10.1016/j.tox.2009.07.017; Zhai Y, 2011, AM J TRANSPLANT, V11, P1563, DOI 10.1111/j.1600-6143.2011.03579.x; Zhang JL, 2016, PHARM BIOL, V54, P2220, DOI 10.3109/13880209.2016.1151444	46	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					275	282		10.1293/tox.2018-0027			8	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900006	30393431	Green Published, Bronze			2019-10-28	
J	Siegel, G; Regelman, D; Maronpot, R; Rosenstock, M; Hayashi, S; Nyska, A				Siegel, Gabriel; Regelman, Dan; Maronpot, Robert; Rosenstock, Moti; Hayashi, Shim-mo; Nyska, Abraham			Utilizing novel telepathology system in preclinical studies and peer review	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						telepathology; toxicology; toxicologic pathology	PATHOLOGY	The demand for board certified toxicologic pathologists and expansion of IT capabilities has resulted in an increase of "virtual" and "distance" pathology (telepathology), and a need for greater flexibility in real time consultations. Newly developed microscope-integrated telepathology systems enable geographically remote stakeholders to view the live histopathology slide as seen by the microscope user. Simultaneous online viewing, annotation, and dialog between pathologists and study experts facilitates good science and economic benefits by enabling more timely and informed clinical decisions.	[Siegel, Gabriel; Regelman, Dan] Augmentiqs, LIAD Bldg,POB 10,Techelet St,Teradion Business Pk, IL-2017400 Jerusalem, Israel; [Maronpot, Robert] Maronpot Consulting LLC, 1612 Medfield Rd, Raleigh, NC 27607 USA; [Rosenstock, Moti] Nonclin Safety Consultancy, LEA, IL-38812 Talmei Elazar, Israel; [Hayashi, Shim-mo] FFI Inc, Global Sci & Regulatory Affairs, San Ei Gen, 1-1-11 Sanwa Cho, Toyonaka, Osaka 5618588, Japan; [Nyska, Abraham] Tel Aviv Univ, Sackler Sch Med, POB 39040, IL-6997801 Tel Aviv, Israel; [Nyska, Abraham] Toxicol Pathol, Haharuv 18,POB 184, IL-36576 Timrat, Israel	Nyska, A (reprint author), Tel Aviv Univ, Sackler Sch Med, POB 39040, IL-6997801 Tel Aviv, Israel.; Nyska, A (reprint author), Toxicol Pathol, Haharuv 18,POB 184, IL-36576 Timrat, Israel.	anyska@bezeqint.net					Cesta MF, 2014, TOXICOL PATHOL, V42, P458, DOI 10.1177/0192623313517304; Crissman JW, 2004, TOXICOL PATHOL, V32, P126, DOI 10.1080/01926230490268756; Ettlin RA, 2013, TOXICOL PATHOL, V41, P689, DOI 10.1177/0192623312466192; Hanna MG, 2015, J CLIN PATHOL, V68, P499, DOI 10.1136/jclinpath-2015-202914; Morton D, 2010, TOXICOL PATHOL, V38, P1118, DOI 10.1177/0192623310383991; Siegel G, 2017, TOXICOL PATHOL, V45, P1039, DOI 10.1177/0192623317743722	6	1	1	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					315	319		10.1293/tox.2018-0032			5	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900011	30393436	Green Published, Bronze			2019-10-28	
J	Seethala, RR; Baloch, ZW; Barletta, JA; Khanafshar, E; Mete, O; Sadow, PM; LiVolsi, VA; Nikiforov, YE; Tallini, G; Thompson, LDR				Seethala, Raja R.; Baloch, Zubair W.; Barletta, Justine A.; Khanafshar, Elham; Mete, Ozgur; Sadow, Peter M.; LiVolsi, Virginia A.; Nikiforov, Yuri E.; Tallini, Giovanni; Thompson, Lester D. R.			Noninvasive follicular thyroid neoplasm with papillary-like nuclear features: a review for pathologists	MODERN PATHOLOGY			English	Review							FINE-NEEDLE-ASPIRATION; ASSOCIATION GUIDELINES; RISK STRATIFICATION; OBSERVER VARIATION; PATTERNED LESIONS; VASCULAR INVASION; BRAF V600E; TASK-FORCE; CARCINOMA; VARIANT	The rising incidence of papillary thyroid carcinoma is linked in part to inclusion of noninvasive follicular variant of papillary thyroid carcinoma. Despite its designation as carcinoma, noninvasive follicular variant of papillary thyroid carcinoma appears to be exceptionally indolent, often over treated by current treatment practices. Additionally, criteria for diagnosis have historically been subjective and challenging. Recently, an international multidisciplinary collaborative group performed a clinicopathologic survey of such cases with extended follow-up and concluded based on the outcome data that a revision in nomenclature was warranted, proposing 'Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP).' This monograph is a synopsis and guide for pathologists on NIFTP and focuses on histologic features, including inclusion and exclusion criteria used to define NIFTP, as well as grossing guidelines, reporting practices, and potential diagnostic limitations.	[Seethala, Raja R.; Baloch, Zubair W.; Barletta, Justine A.; Khanafshar, Elham; Mete, Ozgur; Sadow, Peter M.; LiVolsi, Virginia A.; Nikiforov, Yuri E.; Tallini, Giovanni; Thompson, Lester D. R.] Univ Pittsburgh, Med Ctr, Dept Pathol, A614-X Presbyterian Univ Hosp,200 Lothrop St, Pittsburgh, PA 15217 USA	Seethala, RR (reprint author), Univ Pittsburgh, Med Ctr, Dept Pathol, A614-X Presbyterian Univ Hosp,200 Lothrop St, Pittsburgh, PA 15217 USA.	seethalarr@upmc.edu	Thompson, Lester D. R./J-8404-2016; Sadow, Peter/E-7691-2015	Thompson, Lester D. R./0000-0003-3714-1432; Sadow, Peter/0000-0003-1036-6367			Ali SZ, 2011, ACTA CYTOL, V55, P4, DOI 10.1159/000322365; Baloch ZW, 2007, J CLIN PATHOL, V60, P244, DOI 10.1136/jcp.2006.038604; Baloch ZW, 2016, CANCER CYTOPATHOL, V124, P616, DOI 10.1002/cncy.21744; Baloch ZW, 2002, AM J CLIN PATHOL, V117, P143; Baloch ZW, 2000, MODERN PATHOL, V13, P861, DOI 10.1038/modpathol.3880153; Bongiovanni M, 2014, INT J SURG PATHOL, V22, P749, DOI 10.1177/1066896914531814; Chan JKC, 2002, AM J CLIN PATHOL, V117, P16; CHEN KTK, 1977, AM J SURG PATHOL, V1, P123, DOI 10.1097/00000478-197706000-00003; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Davies L, 2006, JAMA-J AM MED ASSOC, V295, P2164, DOI 10.1001/jama.295.18.2164; DeLellis RA, 2004, PATHOLOGY GENETICS T, P57; Elsheikh TM, 2008, AM J CLIN PATHOL, V130, P736, DOI 10.1309/AJCPKP2QUVN4RCCP; Esserman LJ, 2014, LANCET ONCOL, V15, pE234, DOI 10.1016/S1470-2045(13)70598-9; Ganly I, 2015, HUM PATHOL, V46, P657, DOI 10.1016/j.humpath.2015.01.010; Gucer H, 2016, ENDOCR PATHOL, V27, P224, DOI 10.1007/s12022-016-9433-8; Haugen BR, 2017, THYROID, V27, P481, DOI 10.1089/thy.2016.0628; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; HAZARD JB, 1954, AMA ARCH PATHOL, V58, P554; Hiltzik D, 2006, CANCER-AM CANCER SOC, V106, P1286, DOI 10.1002/cncr.21739; Hirokawa M, 2002, AM J SURG PATHOL, V26, P1508, DOI 10.1097/00000478-200211000-00014; Hodak S, 2016, THYROID, V26, P869, DOI 10.1089/thy.2016.0205; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Howitt BE, 2015, HISTOPATHOLOGY, V67, P579, DOI 10.1111/his.12680; Hunt JL, 2002, AM J CLIN PATHOL, V118, P602; Ito Y, 2008, ENDOCR J, V55, P889, DOI 10.1507/endocrj.K08E-116; Jiang XY, 2017, CANCER CYTOPATHOL, V125, P293, DOI 10.1002/cncy.21829; Jiang XY, 2016, CANCER CYTOPATHOL, V124, P893, DOI 10.1002/cncy.21802; JOHANNESSEN JV, 1980, LAB INVEST, V43, P287; Johnson S, 2016, NIFTP ADDENDUM RCPAT; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Kakudo K, 2015, J BASIC CLIN MED, V4, P2; Kakudo K, 2012, ENDOCR J, V59, P1; LANG W, 1980, VIRCHOWS ARCH A, V385, P125, DOI 10.1007/BF00427399; Lee SE, 2017, THYROID, V27, P802, DOI 10.1089/thy.2016.0547; Lindsay S., 1960, CARCINOMA THYROID GL; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Liu ZY, 2011, CANCER SCI, V102, P288, DOI 10.1111/j.1349-7006.2010.01769.x; LIVOLSI VA, 1994, PATHOL ANNU, V29, P99; Lloyd RV, 2004, AM J SURG PATHOL, V28, P1336, DOI 10.1097/01.pas.0000135519.34847.f6; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Meissn W, 1969, TUMOURS THYROID GLAN, P70; Mete O, 2011, MODERN PATHOL, V24, P1545, DOI 10.1038/modpathol.2011.119; Niemeier LA, 2012, CANCER-AM CANCER SOC, V118, P2069, DOI 10.1002/cncr.26425; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Nikiforov YE, 2014, CANCER-AM CANCER SOC, V120, P3627, DOI 10.1002/cncr.29038; Papotti M, 2005, MODERN PATHOL, V18, P541, DOI 10.1038/modpathol.3800321; Perez-Montiel MD, 2008, HUM PATHOL, V39, P1080, DOI 10.1016/j.humpath.2007.12.001; Piana S, 2010, AM J SURG PATHOL, V34, P868, DOI 10.1097/PAS.0b013e3181dbee07; Renshaw AA, 2002, AM J CLIN PATHOL, V117, P19; Rivera M, 2010, MODERN PATHOL, V23, P1191, DOI 10.1038/modpathol.2010.112; ROSAI J, 1983, AM J SURG PATHOL, V7, P809, DOI 10.1097/00000478-198307080-00010; Rosai J, 1993, ATLAS TUMOR PATHOL, P65; Rosario PW, 2014, CLIN ENDOCRINOL, V81, P630, DOI 10.1111/cen.12387; Routhier CA, 2013, HUM PATHOL, V44, P2563, DOI 10.1016/j.humpath.2013.06.018; Seethala RR, 2013, PROTOCOL EXAMINATION; Strickland KC, 2016, THYROID, V26, P1466, DOI 10.1089/thy.2016.0280; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Thompson LDR, 2001, CANCER-AM CANCER SOC, V91, P505, DOI 10.1002/1097-0142(20010201)91:3<505::AID-CNCR1029>3.0.CO;2-6; Thompson LDR, 2016, MODERN PATHOL, V29, P698, DOI 10.1038/modpathol.2016.65; Vanzati A, 2013, ARCH PATHOL LAB MED, V137, P1707, DOI 10.5858/arpa.2013-0255-LE; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Wallander M, 2010, APPL IMMUNOHISTO M M, V18, P231, DOI 10.1097/PAI.0b013e3181c61cdd; Widder S, 2008, SURGERY, V144, P80, DOI 10.1016/j.surg.2007.11.014; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; YAMASHINA M, 1992, AM J SURG PATHOL, V16, P392, DOI 10.1097/00000478-199204000-00008	65	27	27	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					39	55		10.1038/modpathol.2017.130			17	Pathology	Pathology	FS4MK	WOS:000419766500003	29052599				2019-10-28	
J	Lavigne, M; Menet, E; Tille, JC; Lae, M; Fuhrmann, L; Bonneau, C; Deniziaut, G; Melaabi, S; Ng, CCK; Marchio, C; Rouzier, R; Bieche, I; Vincent-Salomon, A				Lavigne, Marion; Menet, Emmanuelle; Tille, Jean-Christophe; Lae, Marick; Fuhrmann, Laetitia; Bonneau, Claire; Deniziaut, Gabrielle; Melaabi, Samia; Ng, Charlotte C. K.; Marchio, Caterina; Rouzier, Roman; Bieche, Ivan; Vincent-Salomon, Anne			Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast	MODERN PATHOLOGY			English	Article							SMALL-CELL CARCINOMA; TERM-FOLLOW-UP; ENDOCRINE DIFFERENTIATION; MAMMARY-CARCINOMA; CANCER; EXPRESSION; FEATURES; REVEALS; IMPACT; PIK3CA	Neuroendocrine breast carcinomas represent a rare subtype of breast cancer. Their definition, prevalence, and prognosis remain controversial in the literature. The 2012 WHO classification of breast cancer categorizes neuroendocrine carcinomas into three morphologically distinct subtypes: well-differentiated neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas, and invasive breast carcinomas with neuroendocrine differentiation. We aimed to gain insight into the clinical, morphologic, phenotypic, and molecular features of 47 neuroendocrine breast carcinomas. Targeted next-generation sequencing by an AmpliSeq 22 cancer gene hotspot panel and the Prosigna assay were performed on 42/47 and 35/47 cases, respectively. Average age at diagnosis was 69 years. All tumors were estrogen receptor-positive and the large majority expressed progesterone receptor (89%), GATA3 (98%), FOXA1 (96%), and CK8/18 (98%). There was an almost equal distribution of luminal A (52%) and B (48%) carcinomas. Almost half of the cohort (49%) displayed a high risk of recurrence score with the Prosigna test. Patients with a neuroendocrine carcinoma had a shorter disease-free survival compared with those affected by carcinomas of no special type matched for age, size, grade, and estrogen receptor status. No significant differences were observed in terms of overall survival. Stratification of neuroendocrine carcinomas using the 2012 WHO criteria did not reveal statistically significant differences among the distinct categories (well-differentiated neuroendocrine tumors, poorly differentiated neuroendocrine carcinomas, and invasive breast carcinomas with neuroendocrine differentiation), in terms of either progressionfree or overall survival. Our targeted sequencing analysis found three cases (7%) harboring a PIK3CA mutation, and in three other cases (7%) TP53 mutations were detected. This study showed that neuroendocrine breast carcinoma is a distinct subtype of luminal carcinoma with a low rate of PIK3CA mutations and with an aggressive clinical behavior. An accurate identification of neuroendocrine differentiation may be useful to better tailor patient adjuvant therapy within luminal carcinomas.	[Lavigne, Marion; Lae, Marick; Fuhrmann, Laetitia; Deniziaut, Gabrielle; Melaabi, Samia; Bieche, Ivan; Vincent-Salomon, Anne] Paris Sci Lettres Res Univ, Inst Curie, Pathol Genet Immunol Dept, Paris, France; [Menet, Emmanuelle] Versailles St Quentin Univ, Inst Curie, Pathol Genet Immunol, St Cloud, France; [Tille, Jean-Christophe] Geneva Univ Hosp, Fac Med, Div Clin Pathol, Geneva, Switzerland; [Bonneau, Claire; Rouzier, Roman] Versailles St Quentin Univ, Inst Curie, Surg Dept, St Cloud, France; [Ng, Charlotte C. K.] Univ Hosp Basel, Inst Pathol, Dept Biomed, Basel, Switzerland; [Marchio, Caterina] Univ Turin, Dept Med Sci, Turin, Italy; [Vincent-Salomon, Anne] PSL Res Univ, INSERM U934, Inst Curie, Paris, France	Vincent-Salomon, A (reprint author), Paris Sci Lettres Res Univ, Inst Curie, INSERM U934, Pathol Genet Immunol Dept, F-75248 Paris, France.	anne.salomon@curie.fr	Rouzier, Roman/G-2953-2018; Bieche, Ivan/O-7399-2017	Rouzier, Roman/0000-0002-8167-6808; Bieche, Ivan/0000-0002-2430-5429; claire, bonneau/0000-0001-6251-286X; Ng, Charlotte K Y/0000-0002-6100-0026	Italian Ministry of UniversityMinistero dell' Istruzione, dell' Universita e della Ricerca (MIUR)	CM is supported by the Italian Ministry of University (ex-60% 2014 and 2015). We thank Eliane Padoy and Myriam Chaillou for their help in retrieving the tumor blocks.	Agnese PAD, 2000, SEMIN DIAGN PATHOL, V17, P149; Ang D, 2014, DIAGN MOL PATHOL, V23, P97; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bogina G, 2016, HISTOPATHOLOGY, V68, P422, DOI 10.1111/his.12766; Brambilla E, 2000, SEMIN DIAGN PATHOL, V17, P138; Bussolati G, 2012, WHO CLASSIFICATION T, P62; CAPELLA C, 1990, ULTRASTRUCT PATHOL, V14, P321, DOI 10.3109/01913129009032247; Cizkova M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3113; Cloyd JM, 2014, BREAST CANCER RES TR, V148, P637, DOI 10.1007/s10549-014-3207-0; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Ellis IO, 2003, PATHOLOGY GENETICS T, P32; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; FEYRTER F, 1963, Frankf Z Pathol, V73, P24; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hisamatsu Y, 2012, ANN SURG ONCOL, V19, P1145, DOI 10.1245/s10434-011-2094-4; Kalinsky K, 2009, CLIN CANCER RES, V15, P5049, DOI 10.1158/1078-0432.CCR-09-0632; Kehr EL, 2012, HUM PATHOL, V43, P2207, DOI 10.1016/j.humpath.2012.03.012; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kwon SY, 2014, HISTOPATHOLOGY, V64, P647, DOI 10.1111/his.12306; Makretsov N, 2003, HUM PATHOL, V34, P1001, DOI 10.1053/S0046-8177(03)00411-8; MALUF HM, 1994, VIRCHOWS ARCH, V425, P449; MALUF HM, 1995, AM J SURG PATHOL, V19, P1237, DOI 10.1097/00000478-199511000-00003; Marchio C, 2017, J PATHOL, V241, P405, DOI 10.1002/path.4837; Miremadi A, 2002, HISTOPATHOLOGY, V40, P215, DOI 10.1046/j.1365-2559.2002.01336.x; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11908; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Rekhtman N, 2016, CLIN CANCER RES, V22, P3618, DOI 10.1158/1078-0432.CCR-15-2946; Righi L, 2010, SEMIN DIAGN PATHOL, V27, P69, DOI 10.1053/j.semdp.2009.12.003; Rovera Francesca, 2013, Int J Surg, V11 Suppl 1, pS79, DOI 10.1016/S1743-9191(13)60023-0; Rovera Francesca, 2008, Int J Surg, V6 Suppl 1, pS113, DOI 10.1016/j.ijsu.2008.12.007; Sapino A, 2001, MODERN PATHOL, V14, P768, DOI 10.1038/modpathol.3880387; Shin SJ, 2000, AM J SURG PATHOL, V24, P1231, DOI 10.1097/00000478-200009000-00006; Simbolo M, 2017, J PATHOL, V241, P488, DOI 10.1002/path.4853; Tang F, 2011, HISTOPATHOLOGY, V59, P106, DOI 10.1111/j.1365-2559.2011.03880.x; van Krimpen C, 2004, BREAST, V13, P329, DOI 10.1016/j.breast.2003.11.008; Wang J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-147; Weigelt B, 2008, J PATHOL, V216, P141, DOI 10.1002/path.2407; Weigelt B, 2009, MODERN PATHOL, V22, P1401, DOI 10.1038/modpathol.2009.112; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; WOODARD BH, 1981, CANCER, V47, P1823, DOI 10.1002/1097-0142(19810401)47:7<1823::AID-CNCR2820470717>3.0.CO;2-2; Yoon YS, 2014, CLIN IMAG, V38, P734, DOI 10.1016/j.clinimag.2014.05.009; Zhang Y, 2013, NEOPLASMA, V60, P215, DOI 10.4149/neo_2013_029	43	5	5	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					68	82		10.1038/modpathol.2017.107			15	Pathology	Pathology	FS4MK	WOS:000419766500006	28884749	Bronze			2019-10-28	
J	Maehara, R; Fujikura, K; Takeuchi, K; Akita, M; Abe-Suzuki, S; Karbanova, J; Corbeil, D; Itoh, T; Kakeji, Y; Zen, Y				Maehara, Ritsuko; Fujikura, Kohei; Takeuchi, Kengo; Akita, Masayuki; Abe-Suzuki, Shiho; Karbanova, Jana; Corbeil, Denis; Itoh, Tomoo; Kakeji, Yoshihiro; Zen, Yoh			SOX2-silenced squamous cell carcinoma: a highly malignant form of esophageal cancer with SOX2 promoter hypermethylation	MODERN PATHOLOGY			English	Article							AMPLIFICATION; GENE; LUNG; GROWTH; TARGET; CD133	This study originally aimed to investigate whether the overexpression of SOX2 is associated with the poor prognosis of patients with squamous cell carcinoma of the esophagus. However, we unexpectedly found that esophageal squamous cell carcinomas completely lacking SOX2 expression showed distinct pathologic features and highly aggressive clinical courses. The study cohort consisted of 113 consecutive patients with esophageal squamous cell carcinoma who underwent surgical resection without neoadjuvant therapy. Immunostaining on tissue microarrays and whole sections revealed that 8/113 (7%) cases were entirely negative for this transcriptional factor. SOX2-negative cancers were histologically less differentiated (P= 0.002) and showed higher pT and pStages (P= 0.003 and 0.007, respectively) than SOX2-positive cases. A remarkable finding was widespread lymphatic infiltration distant from the primary invasive focus, which was observed in 4 SOX2-negative cancers (50%), but none of the SOX2-positive cases. All separate dysplastic lesions observed in SOX2-negative cases were also SOX2-negative. The negative expression of SOX2 appeared to be an independent poor prognostic factor (OR= 7.05, 95% CI= 1.27-39.0). No mutations were identified in the coding or non-coding regions of SOX2. Fluorescent in situ hybridization did not show any copy-number variations in this gene. Since the SOX2 promoter contains an extensive CpG island, SOX2-negative cases underwent methylation-specific PCR, which disclosed promoter hypermethylation in all cases. In conclusion, SOX2-silenced squamous cell carcinomas of the esophagus appear to be a minor, but distinct form of malignancy characterized by extensive lymphatic invasion, a poor prognosis, and potential association with multiple SOX2-negative neoplastic lesions. The hypermethylation of the promoter region is seemingly a critical epigenetic event leading to SOX2 silencing.	[Maehara, Ritsuko; Fujikura, Kohei; Akita, Masayuki; Abe-Suzuki, Shiho; Itoh, Tomoo; Zen, Yoh] Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Hyogo 6500017, Japan; [Maehara, Ritsuko; Kakeji, Yoshihiro] Kobe Univ, Grad Sch Med, Dept Gastrointestinal Surg, Kobe, Hyogo, Japan; [Takeuchi, Kengo] Japanese Fdn Canc Res, Canc Inst, Div Pathol, Tokyo, Japan; [Takeuchi, Kengo] Japanese Fdn Canc Res, Canc Inst, Pathol Project Mol Targets, Tokyo, Japan; [Karbanova, Jana; Corbeil, Denis] Tech Univ Dresden, Tissue Engn Labs BIOTEC, Dresden, Germany	Zen, Y (reprint author), Kobe Univ, Grad Sch Med, Dept Diagnost Pathol, Kobe, Hyogo 6500017, Japan.	yohzen@med.kobe-u.ac.jp	Corbeil, Denis/L-2340-2019; Corbeil, Denis/A-6519-2010	Corbeil, Denis/0000-0003-1181-3659; Fujikura, Kohei/0000-0002-0520-733X; Karbanova, Jana/0000-0001-7687-0983			Alonso MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026740; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Brcic L, 2012, AM J CLIN PATHOL, V138, P712, DOI 10.1309/AJCP05TTWQTWNLTN; Chen YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071140; Chuang WY, 2015, INT J CLIN EXP PATHO, V8, P9248; Fong HL, 2008, STEM CELLS, V26, P1931, DOI 10.1634/stemcells.2007-1002; Gen Y, 2013, CANCER SCI, V104, P810, DOI 10.1111/cas.12155; Gen Y, 2010, CANCER GENET CYTOGEN, V202, P82, DOI 10.1016/j.cancergencyto.2010.01.023; Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086; Honing J, 2014, ANN SURG ONCOL, V21, pS657, DOI 10.1245/s10434-014-3763-x; Jia XP, 2011, J MOL CELL BIOL, V3, P230, DOI 10.1093/jmcb/mjr002; Karbanova J, 2008, J HISTOCHEM CYTOCHEM, V56, P977, DOI 10.1369/jhc.2008.951897; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li ASM, 2008, REPROD SCI, V15, P735, DOI 10.1177/1933719108322433; Li J, 2013, CANCER LETT, V329, P84, DOI 10.1016/j.canlet.2012.10.019; Maier S, 2011, HUM PATHOL, V42, P1078, DOI 10.1016/j.humpath.2010.11.010; Otsubo T, 2008, BRIT J CANCER, V98, P824, DOI 10.1038/sj.bjc.6604193; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Pennathur A, 2009, ANN THORAC SURG, V87, P1048, DOI 10.1016/j.athoracsur.2008.12.060; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Sobin LH, 2010, TNM CLASSIFICATION M; Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176; Velcheti V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061427; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Wilbertz T, 2011, MODERN PATHOL, V24, P944, DOI 10.1038/modpathol.2011.49; Wong OGW, 2010, OBSTET GYNECOL INT, DOI 10.1155/2010/682504	26	5	6	2	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					83	92		10.1038/modpathol.2017.112			10	Pathology	Pathology	FS4MK	WOS:000419766500007	28862264				2019-10-28	
J	Wang, L; Basturk, O; Wang, JJ; Benayed, R; Middha, S; Zehir, A; Linkov, I; Rao, M; Aryeequaye, R; Cao, L; Chmielecki, J; Ross, J; Stephens, PJ; Adsay, V; Askan, G; Balci, S; Klimstra, DS				Wang, Lu; Basturk, Olca; Wang, Jiajing; Benayed, Ryma; Middha, Sumit; Zehir, Ahmet; Linkov, Irina; Rao, Mamta; Aryeequaye, Ruth; Cao, Long; Chmielecki, Juliann; Ross, Jeffrey; Stephens, Philip J.; Adsay, Volkan; Askan, Gokce; Balci, Serdar; Klimstra, David S.			A FISH assay efficiently screens for BRAF gene rearrangements in pancreatic acinar-type neoplasms	MODERN PATHOLOGY			English	Article							CELL CARCINOMA; FUSIONS; CANCER; LIVER; ASTROCYTOMAS; ACTIVATION; PATHWAY	Approximately 1-2% of pancreatic neoplasms are acinar cell carcinomas. Recently, BRAF gene rearrangements were identified in over 20% of acinar-type neoplasms, which included both pure acinar cell carcinomas and mixed carcinomas with acinar differentiation, using next-generation sequencing-based platforms, providing a potential therapeutic target for patients with these neoplasms. Thus, it is clinically important to develop a rapid, cost-and material-efficient assay to screen for BRAF gene fusions in pancreatic acinar-type neoplasms. We developed a dual color, break-apart FISH assay to detect BRAF gene rearrangements in these neoplasms and evaluated its performance in comparison to next-generation sequencing-based studies. A blinded BRAF rearrangement FISH investigation was performed on 31 acinar-type neoplasms that had been studied previously by next-generation sequencing-based analysis as well as on 18 additional acinar-type neoplasms that were accrued over the past 2 years. In total, BRAF fusions were identified in 12/49 (24%) acinar-type neoplasms by FISH. BRAF fusion partners were uncovered by using targeted next-generation sequencing studies in 11 FISH-positive cases that had sufficient material for next-generation sequencing studies. SND1 was the most frequent fusion partner involved in BRAF-fusion acinar-type neoplasms (50%), followed by HERPUD1 (18%). No BRAF fusions were identified by next-generation sequencing in any of the FISH-negative cases investigated. FISH analysis showed that BRAF rearrangements were diffusely present across tumor-rich areas in BRAF-fusion acinar-type neoplasms, which is consistent with an oncogenic driver alteration pattern. Thus, we demonstrated that, in comparison to targeted next-generation sequencing-based technologies, the FISH assay is highly sensitive and specific as well as time- and cost-efficient in the detection of BRAF fusions in acinar-type neoplasms. The FISH assay can be easily implemented in diagnostic settings to identify acinar-type neoplasms patients potentially suitable for targeted therapy to inhibit MAPK pathway activity.	[Wang, Lu; Basturk, Olca; Wang, Jiajing; Benayed, Ryma; Middha, Sumit; Zehir, Ahmet; Linkov, Irina; Rao, Mamta; Aryeequaye, Ruth; Cao, Long; Askan, Gokce; Klimstra, David S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA; [Chmielecki, Juliann; Ross, Jeffrey; Stephens, Philip J.] Fdn Med, Dept Pathol, Cambridge, MA USA; [Ross, Jeffrey] Albany Med Coll, Dept Pathol, Albany, NY 12208 USA; [Adsay, Volkan; Balci, Serdar] Emory Univ, Dept Pathol, Atlanta, GA 30322 USA	Klimstra, DS (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	klimstrd@mskcc.org	Adsay, Volkan/N-7130-2017; Basturk, Olca/N-7214-2017; BALCI, Serdar/B-6401-2011; Wang, Lu/N-8128-2018	Adsay, Volkan/0000-0002-1308-3701; Basturk, Olca/0000-0003-2747-1366; BALCI, Serdar/0000-0002-7852-3851; Wang, Lu/0000-0002-0073-0666; Middha, Sumit/0000-0003-4135-6268	Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute [P30CA008748]	Research reported in this publication was supported in part by the Cancer Center Support Grant of the National Institutes of Health/National Cancer Institute under award number P30CA008748. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Agaimy A, 2011, MODERN PATHOL, V24, P1620, DOI 10.1038/modpathol.2011.127; Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006; Chmielecki J, 2014, CANCER DISCOV, V4, P1398, DOI 10.1158/2159-8290.CD-14-0617; Ciampi R, 2005, J CLIN INVEST, V115, P94, DOI 10.1172/JCI200523237; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Furukawa T, 2015, SCI REP-UK, V5, DOI 10.1038/srep08829; Hruban RH, 2007, AFIP ATLAS TUMOR PAT, P191; Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Klimstra DS, 2016, SEMIN DIAGN PATHOL, V33, P307, DOI 10.1053/j.semdp.2016.05.009; Lee NV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039653; Palanisamy N, 2010, NAT MED, V16, P793, DOI 10.1038/nm.2166; Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825; Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110; Wildgruber M, 2013, ROFO-FORTSCHR RONTG, V185, P572, DOI 10.1055/s-0032-1330711; Wood LD, 2014, SEMIN DIAGN PATHOL, V31, P491, DOI 10.1053/j.semdp.2014.08.003; Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729; Zundler S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2184-6	18	0	0	0	0	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					132	140		10.1038/modpathol.2017.106			9	Pathology	Pathology	FS4MK	WOS:000419766500012	28884748	Bronze			2019-10-28	
J	Rossi, S; Gasparotto, D; Cacciatore, M; Sbaraglia, M; Mondello, A; Polano, M; Mandolesi, A; Gronchi, A; Reuss, DE; von Deimling, A; Maestro, R; Dei Tos, AP				Rossi, Sabrina; Gasparotto, Daniela; Cacciatore, Matilde; Sbaraglia, Marta; Mondello, Alessia; Polano, Maurizio; Mandolesi, Alessandra; Gronchi, Alessandro; Reuss, David E.; von Deimling, Andreas; Maestro, Roberta; Dei Tos, Angelo Paolo			Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs	MODERN PATHOLOGY			English	Article							GASTROINTESTINAL STROMAL TUMORS; NERVE SHEATH TUMORS; SUCCINATE-DEHYDROGENASE; ASTROCYTIC TUMORS; MUTATIONS; TYPE-1; SUPPRESSOR; EXPRESSION; GENE; IMMUNOHISTOCHEMISTRY	An increasing body of evidence supports the involvement of NF1 mutations, constitutional or somatic, in the pathogenesis of gastrointestinal stromal tumors (GISTs). Due to the large size of the NF1 locus, the existence of multiple pseudogenes and the wide spectrum of mechanisms of gene inactivation, the analysis of NF1 gene status is still challenging for most laboratories. Here we sought to assess the efficacy of a recently developed neurofibromin-specific antibody (NFC) in detecting NF1-inactivated GISTs. NFC reactivity was analyzed in a series of 98 GISTs. Of these, 29 were 'NF1-associated' (17 with ascertained NF1 mutations and 12 arising in the context of clinically diagnosed Neurofibromatosis type 1 syndrome and thus considered bona fine NF1 inactivated); 38 were 'NF1-unrelated' (either wild-type or carrying non-pathogenic variants of NF1). Thirty-one additional GISTs with no available information on NF1 gene status or with NF1 gene variants of uncertain pathogenic significance were also included in the analysis. Cases were scored as NFC negative when, in the presence of NFC positive internal controls, no cytoplasmic staining was detected in the neoplastic cells. NFC immunoreactivity was lost in 24/29 (83%) NF1-associated GISTs as opposed to only 2/38 (5%) NF1-unrelated GISTs (P = 3e-11). NFC staining loss significantly correlated (P = 0.007) with the presence of biallelic NF1 inactivation, due essentially to large deletions or truncating mutations. NFC reactivity was instead retained in two cases in which the NF1 alteration was heterozygous and in one case where the pathogenic NF1 variant, although homo/hemizygous, was a missense mutation predicted not to affect neurofibromin half-life. Overall this study provides evidence that NFC is a valuable tool for identifying NF1-inactivated GISTs, thus serving as a surrogate for molecular analysis.	[Rossi, Sabrina; Cacciatore, Matilde; Sbaraglia, Marta; Dei Tos, Angelo Paolo] Treviso Gen Hosp, Dept Pathol & Mol Genet, I-31100 Treviso, Italy; [Gasparotto, Daniela; Mondello, Alessia; Polano, Maurizio; Maestro, Roberta] CRO Aviano Natl Canc Inst, Oncogenet & Funct Oncogen Unit, Via Gallini 2, I-33081 Aviano, Italy; [Mandolesi, Alessandra] Osped Riuniti Ancona, Dept Internal Med, Ancona, Italy; [Gronchi, Alessandro] Fdn IRCCS Ist Nazl Tumori Milano, Dept Surg, Milan, Italy; [Reuss, David E.; von Deimling, Andreas] Heidelberg Univ, Inst Pathol, Dept Neuropathol, Heidelberg, Germany; [Reuss, David E.; von Deimling, Andreas] German Canc Res Ctr, Clin Cooperat Unit Neuropathol, German Canc Consortium DKTK, Heidelberg, Germany; [Dei Tos, Angelo Paolo] Univ Padua, Dept Med, Sch Med, Padua, Italy	Dei Tos, AP (reprint author), Treviso Gen Hosp, Dept Pathol & Mol Genet, I-31100 Treviso, Italy.; Maestro, R (reprint author), CRO Aviano Natl Canc Inst, Oncogenet & Funct Oncogen Unit, Via Gallini 2, I-33081 Aviano, Italy.	maestro@cro.it; angelopaolo.deitos@aulss2.veneto.it	Gronchi, Alessandro/O-6589-2016; von Deimling, Andreas/F-7774-2013; Gasparotto, Daniela/Y-2351-2019; Maestro, Roberta/P-9748-2019	Gronchi, Alessandro/0000-0002-4703-3534; von Deimling, Andreas/0000-0002-5863-540X; Gasparotto, Daniela/0000-0003-0914-1654; Maestro, Roberta/0000-0002-6642-5592; DEI TOS, ANGELO/0000-0002-1228-8940	CRO; Italian Ministry of HealthMinistry of Health, Italy [RF-2011-02348953]	This work was supported by a CRO Intramural Grant and by the Italian Ministry of Health (RF-2011-02348953). We are grateful to M. Mafra, P. Iuzzolino, A. Rizzo for their support and suggestions.	Agaimy A, 2012, INT J CLIN EXP PATHO, V5, P852; Andersson J, 2005, AM J SURG PATHOL, V29, P1170, DOI 10.1097/01.pas.0000159775.77912.15; Boikos SA, 2016, JAMA ONCOL, V2, P922, DOI 10.1001/jamaoncol.2016.0256; Brenca M, 2016, J PATHOL, V238, P543, DOI 10.1002/path.4677; Chan JKC, 2013, INT J SURG PATHOL, V21, P455, DOI 10.1177/1066896913502529; Corless CL, 2014, MODERN PATHOL, V27, pS1, DOI 10.1038/modpathol.2013.173; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DASTON MM, 1992, DEV DYNAM, V195, P216, DOI 10.1002/aja.1001950307; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Doyle LA, 2014, HISTOPATHOLOGY, V64, P53, DOI 10.1111/his.12302; Doyle LA, 2012, HISTOPATHOLOGY, V61, P801, DOI 10.1111/j.1365-2559.2012.04300.x; Gasparotto D, 2017, CLIN CANCER RES, V23, P273, DOI 10.1158/1078-0432.CCR-16-0152; Hechtman JF, 2015, GENE CHROMOSOME CANC, V54, P177, DOI 10.1002/gcc.22230; Hollstein PE, 2013, CANCER DISCOV, V3, P880, DOI 10.1158/2159-8290.CD-13-0146; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Laycock-van Spyk Sebastian, 2011, Human Genomics, V5, P623; Liu XY, 2012, ACTA NEUROPATHOL, V124, P615, DOI 10.1007/s00401-012-1031-3; McGillicuddy LT, 2009, CANCER CELL, V16, P44, DOI 10.1016/j.ccr.2009.05.009; Miettinen M, 2006, AM J SURG PATHOL, V30, P90, DOI 10.1097/01.pas.0000176433.81079.bd; Mussi C, 2008, CLIN CANCER RES, V14, P4550, DOI 10.1158/1078-0432.CCR-08-0086; Paschou M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046773; Patil DT, 2015, AM J CLIN PATHOL, V144, P782, DOI 10.1309/AJCPRK3V2EIIUPQZ; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Reuss DE, 2014, ACTA NEUROPATHOL, V127, P565, DOI 10.1007/s00401-014-1246-6; Ritterhouse LL, 2015, SEMIN DIAGN PATHOL, V32, P400, DOI 10.1053/j.semdp.2015.02.010; Rohrich M, 2016, ACTA NEUROPATHOL, V131, P877, DOI 10.1007/s00401-016-1540-6; Rossi S, 2016, ONCOTARGET, V7, P30109, DOI [10.18632/oncotarget.8798, 10.18632/oncotarget.8768]; Rossi S, 2010, AM J SURG PATHOL, V34, P1480, DOI 10.1097/PAS.0b013e3181ef7431; Shi E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1075-6; Wagner AJ, 2013, MODERN PATHOL, V26, P289, DOI 10.1038/modpathol.2012.153; Wiestler B, 2013, ACTA NEUROPATHOL, V126, P443, DOI 10.1007/s00401-013-1156-z	31	1	1	0	2	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31	1					160	168		10.1038/modpathol.2017.105			9	Pathology	Pathology	FS4MK	WOS:000419766500015	28862263				2019-10-28	
J	Epstein, JI				Epstein, Jonathan, I			Prostate cancer grading: a decade after the 2005 modified system	MODERN PATHOLOGY			English	Article							GLEASON PATTERN 5; ISUP CONSENSUS-CONFERENCE; EXTERNAL-BEAM RADIATION; 2014 INTERNATIONAL SOCIETY; DISEASE-SPECIFIC DEATH; NEEDLE-CORE BIOPSY; RADICAL PROSTATECTOMY; MUCINOUS ADENOCARCINOMA; PROGNOSTIC-SIGNIFICANCE; GROUPING SYSTEM	This review article will cover the evolution of grading of prostate cancer from the original Gleason system in the 1960-1970s to a more patient-centric grading system proposed in 2013 from a group at Johns Hopkins Hospital, validated in 2014 by a large multi-institutional study, and subsequently accepted by the World Health Organization (WHO), College of American Pathology (CAP), and the AJCC TNM system. Covered topics include: (1) historical background; (2) 2005 and 2014 International Society of Urological Pathology Grading Conferences; (3) Description of Gleason patterns; (4) new approaches to display Gleason grades; (5) grading variants and variations of acinar adenocarcinoma; (6) reporting rules for Gleason grading reporting secondary patterns of higher grade when present to a limited extent; (7) reporting secondary patterns of lower grade when present to a limited extent; (8) reporting percentage pattern 4; (9) general applications of the Gleason grading system; (10) needle biopsy with different cores showing different grades; (11) radical prostatectomy specimens with separate tumor nodules; and (12) a new grading system for prostate cancer.	[Epstein, Jonathan, I] Johns Hopkins Med Inst, Dept Pathol, 401N Broadway St,Weinberg Bldg,Room 2242, Baltimore, MD 21231 USA; [Epstein, Jonathan, I] Johns Hopkins Med Inst, Dept Urol, Baltimore, MD 21231 USA; [Epstein, Jonathan, I] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD 21231 USA	Epstein, JI (reprint author), Johns Hopkins Med Inst, Dept Pathol, 401N Broadway St,Weinberg Bldg,Room 2242, Baltimore, MD 21231 USA.	jepstein@jhmi.edu					Adam M, 2014, J UROLOGY, V192, P97, DOI 10.1016/j.juro.2014.01.029; Al-Hussain TO, 2012, UROLOGY, V79, P178, DOI 10.1016/j.urology.2011.08.060; Amin A, 2011, J UROLOGY, V186, P1286, DOI 10.1016/j.juro.2011.05.075; Bailar J C 3rd, 1966, Cancer Chemother Rep, V50, P129; Baisden BL, 1999, AM J SURG PATHOL, V23, P918, DOI 10.1097/00000478-199908000-00009; Baras AS, 2017, HUM PATHOL, V63, P27, DOI 10.1016/j.humpath.2016.12.008; Berman DM, 2014, UROL CLIN N AM, V41, P339, DOI 10.1016/j.ucl.2014.01.006; Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86; Bill-Axelson A, 2014, NEW ENGL J MED, V370, P932, DOI 10.1056/NEJMoa1311593; Brinker DA, 1999, AM J SURG PATHOL, V23, P1471, DOI 10.1097/00000478-199912000-00004; Chabner BA, 2012, ONCOLOGIST, V17, P149, DOI 10.1634/theoncologist.2012-0004; Chan TY, 2000, UROLOGY, V56, P823, DOI 10.1016/S0090-4295(00)00753-6; Chen RC, 2016, J CLIN ONCOL, V34, P2182, DOI 10.1200/JCO.2015.65.7759; Choy B, 2016, AM J SURG PATHOL, V40, P1400, DOI 10.1097/PAS.0000000000000691; COHEN MB, 1994, AM J CLIN PATHOL, V101, P250, DOI 10.1093/ajcp/101.3.250; Cole AI, 2016, J UROLOGY, V196, P405, DOI 10.1016/j.juro.2016.01.120; D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969; Deng FM, 2016, EUR UROL, V70, P248, DOI 10.1016/j.eururo.2015.10.026; Djaladat H, 2017, PROSTATE, V77, P743, DOI 10.1002/pros.23306; Egevad L, 2016, EUR UROL, V69, P599, DOI 10.1016/j.eururo.2015.11.008; Eifler JB, 2013, BJU INT, V111, P22, DOI 10.1111/j.1464-410X.2012.11324.x; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Epstein JI, 2000, AM J SURG PATHOL, V24, P477, DOI 10.1097/00000478-200004000-00001; EPSTEIN JI, 1985, AM J SURG PATHOL, V9, P299, DOI 10.1097/00000478-198504000-00006; Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001; Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Epstein JI, 2016, AM J SURG PATHOL, V40, P137, DOI 10.1097/PAS.0000000000000563; Epstein JI, 2016, EUR UROL, V69, P428, DOI 10.1016/j.eururo.2015.06.046; Epstein JI, 2012, EUR UROL, V61, P1019, DOI 10.1016/j.eururo.2012.01.050; Esserman LJ, 2014, LANCET ONCOL, V15, pE234, DOI 10.1016/S1470-2045(13)70598-9; Fajardo DA, 2011, AM J SURG PATHOL, V35, P1706, DOI 10.1097/PAS.0b013e318228571d; Fine SW, 2008, J UROLOGY, V179, P1335, DOI 10.1016/j.juro.2007.11.057; Flood TA, 2016, VIRCHOWS ARCH, V469, P313, DOI 10.1007/s00428-016-1981-2; Gandaglia G, 2017, UROL ONCOL, V35, pe7; Gleason D F, 1977, UROLOGIC PATHOLOGY P, P171; HALL GS, 1992, AM J SURG PATHOL, V16, P315, DOI 10.1097/00000478-199204000-00001; Harding-Jackson N, 2016, J UROLOGY, V196, P1076, DOI 10.1016/j.juro.2016.05.105; Hashine K, 2011, JPN J CLIN ONCOL, V41, P571, DOI 10.1093/jjco/hyq250; Hattab EM, 2006, J UROLOGY, V175, P1695, DOI 10.1016/S0022-5347(05)00998-5; He JM, 2017, EUR UROL, V71, P760, DOI 10.1016/j.eururo.2016.11.031; Hernandez DJ, 2008, UROLOGY, V72, P172, DOI 10.1016/j.urology.2007.10.055; Humphrey PA, 1998, AM J SURG PATHOL, V22, P1239, DOI 10.1097/00000478-199810000-00009; Iczkowski KA, 2011, AM J CLIN PATHOL, V136, P98, DOI 10.1309/AJCPZ7WBU9YXSJPE; Isbarn H, 2009, EUR UROL, V55, P394, DOI 10.1016/j.eururo.2008.08.015; Kooby DA, 2004, ANN SURG ONCOL, V11, P78, DOI 10.1245/ASO.2004.03.058; Kunju LP, 2009, HUM PATHOL, V40, P558, DOI 10.1016/j.humpath.2008.07.020; Kunz GM, 2003, HUM PATHOL, V34, P911, DOI 10.1016/S0046-8177(03)00338-1; Kuroiwa K, 2009, J CLIN PATHOL, V62, P260, DOI 10.1136/jcp.2008.060632; Kweldam CF, 2015, BJU INT, V116, P230, DOI 10.1111/bju.12879; Kweldam CF, 2015, MODERN PATHOL, V28, P457, DOI 10.1038/modpathol.2014.116; Lane BR, 2006, UROLOGY, V68, P825, DOI 10.1016/j.urology.2006.04.028; Latour M, 2008, AM J SURG PATHOL, V32, P1532, DOI 10.1097/PAS.0b013e318169e8fd; Leapman MS, 2017, EUR UROL, V71, P750, DOI 10.1016/j.eururo.2016.11.032; Levi AW, 2000, AM J SURG PATHOL, V24, P1039, DOI 10.1097/00000478-200008000-00001; Loeb S, 2016, EUR UROL, V70, P1083, DOI 10.1016/j.eururo.2016.05.039; Loeb S, 2016, EUR UROL, V69, P1135, DOI 10.1016/j.eururo.2015.11.036; Lotan TL, 2009, HUM PATHOL, V40, P471, DOI 10.1016/j.humpath.2008.10.002; Lucca I, 2015, UROL ONCOL, V33; Mahal BA, 2016, BJU INT, V118, P95, DOI 10.1111/bju.13239; Huynh MA, 2016, EUR UROL, V69, P976, DOI 10.1016/j.eururo.2015.08.054; Makarov DV, 2002, J UROLOGY, V167, P2440, DOI 10.1016/S0022-5347(05)65000-8; Mathieu R, 2017, PROSTATE CANCER P D, V20, P197, DOI 10.1038/pcan.2016.66; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; Mellinger G T, 1977, Recent Results Cancer Res, P61; Miyamoto H, 2009, HUM PATHOL, V40, P1693, DOI 10.1016/j.humpath.2009.05.001; Moch H, 2016, WHO CLASSIFICATION T; Morash C, 2015, CUAJ-CAN UROL ASSOC, V9, P171, DOI 10.5489/cuaj.2806; Nelson RS, 1996, AM J SURG PATHOL, V20, P419, DOI 10.1097/00000478-199604000-00004; Netto GJ, 2012, ARCH PATHOL LAB MED, V136, P372, DOI 10.5858/arpa.2011-0471-RA; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Ohori M, 2004, J UROLOGY, V171, P1844, DOI 10.1097/01.ju.0000121693.05077.3d; Osunkoya AO, 2008, AM J SURG PATHOL, V32, P468, DOI 10.1097/PAS.0b013e3181589f72; Pan CC, 2000, AM J SURG PATHOL, V24, P563, DOI 10.1097/00000478-200004000-00011; Park HK, 2006, UROLOGY, V67, P110, DOI 10.1016/j.urology.2005.07.018; Pierorazio PM, 2013, BJU INT, V111, P753, DOI 10.1111/j.1464-410X.2012.11611.x; Pompe RS, 2017, PROSTATE, V77, P686, DOI 10.1002/pros.23316; Poulos CK, 2005, MODERN PATHOL, V18, P228, DOI 10.1038/modpathol.3800302; Resnick MJ, 2013, NEW ENGL J MED, V368, P436, DOI 10.1056/NEJMoa1209978; RO JY, 1990, HUM PATHOL, V21, P593, DOI 10.1016/S0046-8177(96)90004-0; Ross HM, 2012, AM J SURG PATHOL, V36, P1346, DOI 10.1097/PAS.0b013e3182556dcd; Sabolch A, 2011, INT J RADIAT ONCOL, V81, pE351, DOI 10.1016/j.ijrobp.2011.01.063; Sadimin ET, 2016, AM J SURG PATHOL, V40, P1686, DOI 10.1097/PAS.0000000000000714; Samaratunga H, 2015, PATHOLOGY, V47, P515, DOI 10.1097/PAT.0000000000000315; Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029; Sehdev AES, 2001, HUM PATHOL, V32, P494, DOI 10.1053/hupa.2001.24322; Sim HG, 2008, J UROLOGY, V179, P1775, DOI 10.1016/j.juro.2008.01.016; Spratt DE, 2016, PROSTATE CANCER P D, V19, P292, DOI 10.1038/pcan.2016.18; Stenmark MH, 2011, INT J RADIAT ONCOL, V81, pE335, DOI 10.1016/j.ijrobp.2011.04.037; Stock RG, 2006, INT J RADIAT ONCOL, V64, P810, DOI 10.1016/j.ijrobp.2005.09.005; Stone NN, 2011, J UROLOGY, V185, P495, DOI 10.1016/j.juro.2010.09.099; Sylvester JE, 2011, INT J RADIAT ONCOL, V81, P376, DOI 10.1016/j.ijrobp.2010.05.042; Tavora F, 2008, AM J SURG PATHOL, V32, P1060, DOI 10.1097/PAS.0b013e318160edaf; Thurtle D, 2016, BRIT J CANCER, V115, P1285, DOI 10.1038/bjc.2016.353; Tolonen TT, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-21; Trock BJ, 2009, J UROLOGY, V182, P1364, DOI 10.1016/j.juro.2009.06.048; Trudel D, 2014, EUR J CANCER, V50, P1610, DOI 10.1016/j.ejca.2014.03.009; Turker P, 2013, UROL ONCOL-SEMIN ORI, V31, P93, DOI 10.1016/j.urolonc.2010.10.009; van Oort IM, 2005, EUR UROL, V48, P572, DOI 10.1016/j.eururo.2005.06.003; Wang W, 2008, AM J SURG PATHOL, V32, P65, DOI 10.1097/PAS.0b013e318058a96b; Whittemore DE, 2008, J UROLOGY, V179, P516, DOI 10.1016/j.juro.2007.09.085; Wilt TJ, 2012, NEW ENGL J MED, V367, P203, DOI 10.1056/NEJMoa1113162; Yeong J, 2017, J CLIN PATHOL, V70, P745, DOI 10.1136/jclinpath-2016-204276; Zhao J, 2009, AM J SURG PATHOL, V33, P583, DOI 10.1097/PAS.0b013e31818a5c6c; Zumsteg ZS, 2013, EUR UROL, V64, P895, DOI 10.1016/j.eururo.2013.03.033	105	12	12	1	5	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S47	S63		10.1038/modpathol.2017.133			17	Pathology	Pathology	FW3PC	WOS:000425219700004	29297487				2019-10-28	
J	Zhou, M				Zhou, Ming			High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate	MODERN PATHOLOGY			English	Article							ATYPICAL CRIBRIFORM LESIONS; CLINICAL-SIGNIFICANCE; NEEDLE-BIOPSY; ADENOCARCINOMA; DIAGNOSIS; PROPOSAL; PATTERNS; FEATURES; CANCER; PTEN	Many prostate lesions have 'large gland' morphology with gland size similar to or larger than benign glands, complex glandular architecture including papillary, cribriform, and solid, and significant cytological atypia in glandular epithelium with nucleomegaly, prominent nucleoli, or anisonucleosis. The most common and clinically important lesions with 'large gland' morphology include high-grade prostatic intraepithelial neoplasia (HGPIN), PIN-like carcinoma, ductal adenocarcinoma, and intraductal carcinoma. These lesions have diverse clinical significance and management implications. HGPIN refers to proliferation of glandular epithelium that displays severe cytological atypia within the confines of prostatic ducts and acini. A HGPIN diagnosis in biopsies connotes similar to 25% risk of detection of cancer in repeat biopsies. It has been accepted as the main precursor lesion to invasive carcinoma. PIN-like carcinoma is a variant of acinar carcinoma that is morphologically reminiscent of HGPIN and is composed of large cancer glands lined with pseudostratified epithelium. Its clinical outcome is similar to that of usual acinar carcinomas and is graded as Gleason score 3+3= 6. Ductal adenocarcinoma comprises large glands lined with tall columnar and pseudostratified epithelium. It is more aggressive than acinar carcinomas and is associated with higher stage disease and greater risk of PSA recurrence and mortality. Intraductal carcinoma is an intraglandular/ductal neoplastic proliferation of glandular epithelial cells that results in marked expansion of glandular architecture and nuclear atypia that often exceeds that in invasive carcinomas. In majority of cases, it is thought to represent retrograde extension of invasive carcinoma into pre-existing ducts and acini. Rarely it may represent a peculiar form of carcinoma with predilection for intraductal location. It is considered an adverse pathological feature and is seen almost always in high-grade and volume carcinoma and harbingers worse clinical outcomes. This article reviews 'new' information on the clinical and pathological features of HGPIN, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma, and focuses morphological features that aid the differential diagnosis.	[Zhou, Ming] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA	Zhou, M (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Ming.Zhou@utsouthwestern.edu					Aydin H, 2010, BJU INT, V105, P476, DOI 10.1111/j.1464-410X.2009.08812.x; BOSTWICK DG, 1993, HUM PATHOL, V24, P298, DOI 10.1016/0046-8177(93)90041-E; Cohen RJ, 2007, ARCH PATHOL LAB MED, V131, P1103; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; De Marzo AM, 2016, CANCER PREV RES, V9, P648, DOI 10.1158/1940-6207.CAPR-15-0431; DUBE VE, 1973, CANCER, V32, P402, DOI 10.1002/1097-0142(197308)32:2<402::AID-CNCR2820320218>3.0.CO;2-Q; Epstein JI, 2006, J UROLOGY, V175, P820, DOI 10.1016/S0022-5347(05)00337-X; Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530; Guo CC, 2006, MODERN PATHOL, V19, P1528, DOI 10.1038/modpathol.3800702; Haffner MC, 2016, J PATHOL, V238, P31, DOI 10.1002/path.4628; Hameed O, 2006, MODERN PATHOL, V19, P899, DOI 10.1038/modpathol.3800601; Han B, 2010, AM J SURG PATHOL, V34, P478, DOI 10.1097/PAS.0b013e3181d6827b; Herawi M, 2006, J UROLOGY, V175, P121, DOI 10.1016/S0022-5347(05)00064-9; Hickman RA, 2017, AM J SURG PATHOL, V41, P550, DOI 10.1097/PAS.0000000000000794; Jang WS, 2017, J UROLOGY, V197, P1048, DOI 10.1016/j.juro.2016.11.104; Lotan TL, 2013, MODERN PATHOL, V26, P587, DOI 10.1038/modpathol.2012.201; Lotan TL, 2009, MODERN PATHOL, V22, P359, DOI 10.1038/modpathol.2008.236; McNeal JE, 1996, AM J SURG PATHOL, V20, P802, DOI 10.1097/00000478-199607000-00003; MELICOW MM, 1971, J UROLOGY, V106, P892, DOI 10.1016/S0022-5347(17)61430-7; Moch H, 2016, WHO CLASSIFICATION T; Montironi R, 2011, BJU INT, V108, P1394, DOI [10.1111/j.1464-410X.2011.010413.x, 10.1111/j.1464-410X.2011.10413.x]; Morais CL, 2015, AM J SURG PATHOL, V39, P169, DOI 10.1097/PAS.0000000000000348; National Comprehensive Cancer Network, 2017, NCCN CLIN GUID ONC P; Robinson B, 2012, ARCH PATHOL LAB MED, V136, P418, DOI 10.5858/arpa.2011-0519-RA; Robinson BD, 2010, J UROLOGY, V184, P1328, DOI 10.1016/j.juro.2010.06.017; Seipel AH, 2017, HUM PATHOL; Seipel AH, 2014, VIRCHOWS ARCH, V465, P559, DOI 10.1007/s00428-014-1636-0; Seipel AH, 2014, HISTOPATHOLOGY, V65, P216, DOI 10.1111/his.12382; Seipel AH, 2013, VIRCHOWS ARCH, V462, P429, DOI 10.1007/s00428-013-1385-5; Shah R. B., 2012, PROSTATE BIOPSY INTE; Shah RB, 2017, HISTOPATHOLOGY, V71, P693, DOI 10.1111/his.13273; Shah RB, 2012, ADV ANAT PATHOL, V19, P270, DOI 10.1097/PAP.0b013e31825c6c0e; Shah RB, 2010, AM J SURG PATHOL, V34, P470, DOI 10.1097/PAS.0b013e3181cfc44b; Tavora F, 2008, AM J SURG PATHOL, V32, P1060, DOI 10.1097/PAS.0b013e318160edaf; Watts K, 2013, HISTOPATHOLOGY, V63, P574, DOI 10.1111/his.12198	35	7	8	0	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0893-3952	1530-0285		MODERN PATHOL	Mod. Pathol.	JAN	2018	31			1			S71	S79		10.1038/modpathol.2017.138			9	Pathology	Pathology	FW3PC	WOS:000425219700006	29297491				2019-10-28	
J	Ikeda, J; Tanaka, H; Ishikawa, K; Sakakita, H; Ikehara, Y; Hori, M				Ikeda, Jun-ichiro; Tanaka, Hiromasa; Ishikawa, Kenji; Sakakita, Hajime; Ikehara, Yuzuru; Hori, Masaru			Plasma-activated medium (PAM) kills human cancer-initiating cells	PATHOLOGY INTERNATIONAL			English	Article						aldehyde dehydrogenase; cancer-initiating cells; endometrioid carcinoma; gastric cancer; non-thermal plasma; plasma-activated medium	ATMOSPHERIC-PRESSURE PLASMA; STEM-CELLS; ALDEHYDE DEHYDROGENASE; MARKER; OXYGEN; INHIBITION; PREDICTOR; GROWTH; BLOOD; LINE	Medical non-thermal plasma (NTP) treatments for various types of cancers have been reported. Cells with tumorigenic potential (cancer-initiating cells; CICs) are few in number in many types of tumors. CICs efficiently eliminate anti-cancer chemicals and exhibit high-level aldehyde dehydrogenase (ALDH) activity. We previously examined the effects of direct irradiation via NTP on cancer cells; even though we targeted CICs expressing high levels of ALDH, such treatment affected both non-CICs and CICs. Recent studies have shown that plasma-activated medium (PAM) (culture medium irradiated by NTP) selectively induces apoptotic death of cancer but not normal cells. Therefore, we explored the anti-cancer effects of PAM on CICs among endometrioid carcinoma and gastric cancer cells. PAM reduced the viability of cells expressing both low and high levels of ALDH. Combined PAM/cisplatin appeared to kill cancer cells more efficiently than did PAM or cisplatin alone. In a mouse tumor xenograft model, PAM exerted an anti-cancer effect on CICs. Thus, our results suggest that PAM effectively kills both non-CICs and CICs, as does NTP. Therefore, PAM may be a useful new anti-cancer therapy, targeting various cancer cells including CICs.	[Ikeda, Jun-ichiro] Osaka Univ, Grad Sch Med, Dept Pathol, Yamada Oka 2-2, Suita, Osaka 5650871, Japan; [Tanaka, Hiromasa; Ishikawa, Kenji; Hori, Masaru] Nagoya Univ, Inst Innovat Future Soc, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648603, Japan; [Sakakita, Hajime] Natl Inst Adv Ind Sci & Technol, Energy Technol Res Inst, Tsukuba Cent 2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan; [Ikehara, Yuzuru] Natl Inst Adv Ind Sci & Technol, Mol Med Team, Res Ctr Med Glycosci, Tsukuba Cent 2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan; [Ikehara, Yuzuru] Chiba Univ, Dept Tumor Pathol, Grad Sch Med, Chiba 1070052, Japan	Ikeda, J (reprint author), Osaka Univ, Grad Sch Med, Dept Pathol, Yamada Oka 2-2, Suita, Osaka 5650871, Japan.	jikeda@molpath.med.osaka-u.ac.jp	Ishikawa, Kenji/M-3570-2019; Ikehara, yuzuru/L-7696-2018; SAKAKITA, HAJIME/L-1510-2018; Ikehara, yuzuru/R-2239-2019; Ishikawa, Kenji/I-6758-2014	Ishikawa, Kenji/0000-0002-8288-6620; Ikehara, yuzuru/0000-0002-1915-9172; SAKAKITA, HAJIME/0000-0001-8728-252X; Ikehara, yuzuru/0000-0002-1915-9172; Ishikawa, Kenji/0000-0002-8288-6620	Ministry of Education, Culture, Sports, Science and Technology, JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT) [15H00894, 16K08649]	The authors thank Ms. Yoko Tsuruta, Ms. Etsuko Maeno, Ms. Takako Sawamura, and Ms. Megumi Nihei for their technical assistance. This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (#15H00894, #16K08649).	Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Fridman G, 2008, PLASMA PROCESS POLYM, V5, P503, DOI 10.1002/ppap.200700154; Gibson AR, 2014, PLASMA PROCESS POLYM, V11, P1142, DOI 10.1002/ppap.201400111; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Goodell MA, 2002, CYTOTHERAPY, V4, P507, DOI 10.1080/146532402761624638; Ikeda J., 2014, PLASMA MED, V4, P49; Ikeda J, 2015, PLASMA PROCESS POLYM, V12, P1370, DOI 10.1002/ppap.201500097; Ikeda JI, 2012, LAB INVEST, V92, P606, DOI 10.1038/labinvest.2012.4; Ikehara Y, 2013, J PHOTOPOLYM SCI TEC, V26, P555; Iseki S, 2012, APPL PHYS LETT, V100, DOI 10.1063/1.3694928; Jiang F, 2009, MOL CANCER RES, V7, P330, DOI 10.1158/1541-7786.MCR-08-0393; Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270; Kalghati S., 2011, PLASMA MED, V1, P249, DOI DOI 10.1615/PlasmaMed.2012004184; Kim CH, 2010, J BIOTECHNOL, V150, P530, DOI 10.1016/j.jbiotec.2010.10.003; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kong MG, 2009, NEW J PHYS, V11, DOI 10.1088/1367-2630/11/11/115012; Kurake N, 2016, ARCH BIOCHEM BIOPHYS, V605, P102, DOI 10.1016/j.abb.2016.01.011; Kvinlaug BT, 2007, EXPERT OPIN THER TAR, V11, P915, DOI 10.1517/14728222.11.7.915; Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127; Ma I, 2011, STEM CELL REV REP, V7, P292, DOI 10.1007/s12015-010-9208-4; Meyer-Siegler KL, 2006, J IMMUNOL, V177, P8730, DOI 10.4049/jimmunol.177.12.8730; Miyamoto K, 2016, ARCH BIOCHEM BIOPHYS, V605, P95, DOI 10.1016/j.abb.2016.03.023; Mochizuki Y, 2004, CLIN EXP METASTAS, V21, P39, DOI 10.1023/B:CLIN.0000017181.01474.35; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; OKAZAKI S, 1993, J PHYS D APPL PHYS, V26, P889, DOI 10.1088/0022-3727/26/5/025; Rahadiani N, 2011, CANCER SCI, V102, P903, DOI 10.1111/j.1349-7006.2011.01864.x; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Sakakita Hajime, 2010, Plasma and Fusion Research, V5, DOI 10.1585/pfr.5.S2117; Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010; Tanaka H, 2011, PLASMA MED, V1, P265, DOI DOI 10.1615/PLASMAMED.2012006275; Tanaka H, 2015, CLIN PLASMA MED, V3, P72, DOI 10.1016/j.cpme.2015.09.001; Tanaka H, 2015, PHYS PLASMAS, V22, DOI 10.1063/1.4933402; Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576	36	12	12	5	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1320-5463	1440-1827		PATHOL INT	Pathol. Int.	JAN	2018	68	1					23	30		10.1111/pin.12617			8	Pathology	Pathology	FR5JQ	WOS:000419103200004	29235204				2019-10-28	
J	Helmo, FR; Lopes, AMM; Carneiro, ACDM; Campos, CG; Silva, PB; Monteiro, MLGD; Rocha, LP; dos Reis, MA; Etchebehere, RM; Machado, JR; Correa, RRM				Helmo, Fernanda Rodrigues; Moed Lopes, Angela Maria; Dias Maciel Carneiro, Anna Cecilia; Campos, Carolina Guissoni; Silva, Polyana Barbosa; Goncalves dos Reis Monteiro, Maria Luiza; Rocha, Laura Penna; dos Reis, Marlene Antonia; Etchebehere, Renata Margarida; Machado, Juliana Reis; Miranda Correa, Rosana Rosa			Angiogenic and antiangiogenic factors in preeclampsia	PATHOLOGY RESEARCH AND PRACTICE			English	Review						Preeclampsia; Endothelial dysfunction; Soluble fms-like-tyrosine-kinase receptor; Soluble endoglin; Angiogenisis	ENDOTHELIAL GROWTH-FACTOR; LATE-ONSET PREECLAMPSIA; ENDOPLASMIC-RETICULUM STRESS; CARDIOVASCULAR-DISEASE RISK; UTERINE ARTERY DOPPLER; NATURAL-KILLER-CELLS; SOLUBLE ENDOGLIN; TYROSINE KINASE-1; INDUCED APOPTOSIS; ADVERSE OUTCOMES	Background: Pre-eclampsia is a multifactorial hypertensive disorder that is triggered by placental insufficiency and that accounts for up to 15% of maternal deaths. In normal pregnancies, this process depends on the balance between the expression of angiogenic factors and antiangiogenic factors, which are responsible for remodeling the spiral arteries, as well as for neoangiogenesis and fetal development. Purpose: The aim of this review is to discuss the main scientific findings regarding the role of angiogenic and antiangiogenic factors in the etiopathogenesis of preeclampsia. Methods: An extensive research was conducted in the Pubmed database in search of scientific manuscripts discussing potential associations between angiogenic and antiangiogenic factors and preeclampsia. Ninety-one papers were included in this review. Results: There is an increased expression of soluble fms-like tyrosine kinase receptor and soluble endoglin in preeclampsia, as well as reduced placental expression of vascular endothelial growth factor and placental growth factor. Systemic hypertension, proteinuria and kidney injury such as enlargement and glomerular fibrin deposit, capillary occlusion due to edema, and hypertrophy of endocapillary cells are some of these changes. The complex etiopathogenesis of preeclampsia instigates research of different biomarkers that allow for the early diagnosis of this entity, such as vascular endothelial growth factor, placental growth factor, soluble fms-like tyrosine kinase receptor, soluble endoglin, placental glycoprotein pregnancy-associated plasma protein-A and protein 13. Conclusion: Even though it is possible to establish an efficient and effective diagnostic tool, three key principles must be observed in the management of preeclampsia: prevention, early screening and treatment.	[Helmo, Fernanda Rodrigues; Goncalves dos Reis Monteiro, Maria Luiza; Rocha, Laura Penna; dos Reis, Marlene Antonia; Machado, Juliana Reis; Miranda Correa, Rosana Rosa] Univ Fed Triangulo Mineiro, Inst Biol & Nat Sci, Discipline Gen Pathol, Rua Frei Paulino 30, BR-38025180 Uberaba, MG, Brazil; [Moed Lopes, Angela Maria; Campos, Carolina Guissoni; Silva, Polyana Barbosa] Univ Fed Triangulo Mineiro, Oncol Res Inst, Uberaba, MG, Brazil; [Dias Maciel Carneiro, Anna Cecilia] Univ Fed Triangulo Mineiro, Inst Biol & Nat Sci, Discipline Histol, Uberaba, MG, Brazil; [Etchebehere, Renata Margarida] Univ Fed Triangulo Mineiro, Clin Hosp, Surg Pathol Serv, Uberaba, MG, Brazil; [Machado, Juliana Reis] Univ Fed Goias, Inst Trop Pathol & Publ Hlth, Dept Gen Pathol, Goiania, Go, Brazil	Correa, RRM (reprint author), Univ Fed Triangulo Mineiro, Inst Biol & Nat Sci, Discipline Gen Pathol, Rua Frei Paulino 30, BR-38025180 Uberaba, MG, Brazil.	rosana.correa@uftm.edu.br			Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)National Council for Scientific and Technological Development (CNPq) [470029/20110]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)CAPES [PNPD-02604/094]; Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)Minas Gerais State Research Foundation (FAPEMIG) [CDS-APQ-02135-14]; Fundacao de Ensino e Pesquisa de Uberaba (FUNEPU) [CDS-922/2009]	This study was funded by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) (grant number 470029/20110), Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (grant number PNPD-02604/094), Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) (grant number CDS-APQ-02135-14), and Fundacao de Ensino e Pesquisa de Uberaba (FUNEPU) (grant number CDS-922/2009). All them from Brazil.	Aggarwal P. K., 2012, AM J PATHOL, V180, P888; Ahmed A, 2011, THROMB RES, V127, pS72, DOI 10.1016/S0049-3848(11)70020-2; Altman O., 2002, LANCET, V359, P1877; American College of Obstetricians and Gynecologists (ACOG) Task Force on Hypertension in Pregnancy, 2013, HYPERTENSION PREGNAN; Anderson UD, 2012, PLACENTA, V33, pS42, DOI 10.1016/j.placenta.2011.11.021; Bellamy L, 2007, BMJ-BRIT MED J, V335, P974, DOI 10.1136/bmj.39335.385301.BE; Borzychowski AM, 2006, SEMIN FETAL NEONAT M, V11, P309, DOI 10.1016/j.siny.2006.04.001; Brasil DATASUS, 2015, MORT NASC VIV OB MAT; Breetveld NM, 2015, BJOG-INT J OBSTET GY, V122, P1092, DOI 10.1111/1471-0528.13057; Burton GJ, 2011, PREGNANCY HYPERTENS, V1, P72, DOI 10.1016/j.preghy.2010.12.002; Cardenas-Mondragon MG, 2014, ARCH MED RES, V45, P561, DOI 10.1016/j.arcmed.2014.10.004; Cartwright JE, 2017, J REPROD IMMUNOL, V119, P81, DOI 10.1016/j.jri.2016.09.002; Cerdeira AS, 2012, COLD SPRING HARB PER, V2; Chaiworapongsa T, 2004, AM J OBSTET GYNECOL, V190, P1541, DOI 10.1016/j.ajog.2004.03.043; Chaiworapongsa T, 2014, NAT REV NEPHROL, V10, P466, DOI 10.1038/nrneph.2014.102; Chaiworapongsa T, 2013, AM J OBSTET GYNECOL, V208, DOI 10.1016/j.ajog.2013.01.016; Charnock-Jones DS, 2016, J REPROD IMMUNOL, V114, P81, DOI 10.1016/j.jri.2015.07.004; Cindrova-Davies T, 2011, CARDIOVASC RES, V89, P671, DOI 10.1093/cvr/cvq346; Costantine MM, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.038; Crispi F, 2006, AM J OBSTET GYNECOL, V195, P201, DOI 10.1016/j.ajog.2006.01.014; Du L, 2017, J HUM HYPERTENS, V31, P49, DOI 10.1038/jhh.2016.17; Duley L., 2000, COCHRANE DB SYST REV; Duley L, 2009, SEMIN PERINATOL, V33, P130, DOI 10.1053/j.semperi.2009.02.010; Egbor M, 2006, BJOG-INT J OBSTET GY, V113, P580, DOI 10.1111/j.1471-0528.2006.00882.x; Eiland E, 2012, J PREGNANCY, DOI 10.1155/2012/586578; Elsheikh A, 2001, ARCH GYNECOL OBSTET, V264, P182, DOI 10.1007/s004040000104; English FA, 2015, INTEGR BLOOD PRESS C, V8, P7, DOI 10.2147/IBPC.S50641; Erez O, 2008, J MATERN-FETAL NEO M, V21, P279, DOI 10.1080/14767050802034545; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fraser R, 2015, J REPROD IMMUNOL, V110, P54, DOI 10.1016/j.jri.2015.04.003; Fu JH, 2015, TAIWAN J OBSTET GYNE, V54, P19, DOI 10.1016/j.tjog.2014.11.002; Fujita D, 2010, J ENDOCRINOL, V206, P131, DOI 10.1677/JOE-10-0027; Ghosh SK, 2012, ARCH GYNECOL OBSTET, V285, P417, DOI 10.1007/s00404-011-1960-4; Goel A, 2013, CURR OPIN NEPHROL HY, V22, P643, DOI 10.1097/MNH.0b013e328365ad98; Govender L, 2012, CARDIOVASC J AFR, V23, P153, DOI 10.5830/CVJA-2012-003; Gupta S, 2005, OBSTET GYNECOL SURV, V60, P807, DOI 10.1097/01.ogx.0000193879.79268.59; Haggerty CL, 2012, PREGNANCY HYPERTENS, V2, P158, DOI 10.1016/j.preghy.2012.01.005; Hong R, 2007, MATERN CHILD HLTH J, V11, P199, DOI 10.1007/s10995-006-0147-2; Hung Tai-Ho, 2006, Taiwan J Obstet Gynecol, V45, P189; Hunkapiller NM, 2011, DEVELOPMENT, V138, P2987, DOI 10.1242/dev.066589; Jardim LL, 2015, CLIN CHIM ACTA, V447, P34, DOI 10.1016/j.cca.2015.05.004; Kaitu'u-Lino TJ, 2012, AM J PATHOL, V180, P888, DOI 10.1016/j.ajpath.2011.11.014; Khan F, 2005, HYPERTENSION, V46, P1123, DOI 10.1161/01.HYP.0000186328.90667.95; Kharfi A, 2003, CLIN BIOCHEM, V36, P323, DOI 10.1016/S0009-9120(03)00060-2; Kim SC, 2012, J OBSTET GYNAECOL RE, V38, P665, DOI 10.1111/j.1447-0756.2011.01773.x; Kulkarni AV, 2010, HYPERTENS RES, V33, P561, DOI 10.1038/hr.2010.31; Kusanovic JP, 2009, J MATERN-FETAL NEO M, V22, P1021, DOI 10.3109/14767050902994754; Lam C, 2005, HYPERTENSION, V46, P1077, DOI 10.1161/01.HYP.0000187899.34379.b0; Laresgoiti-Servitje E, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.099861; Lash GE, 2006, FASEB J, V20, P2512, DOI 10.1096/fj.06-6616com; Leanos-Miranda A, 2013, HYPERTENSION, V61, P1118, DOI 10.1161/HYPERTENSIONAHA.111.00754; LERNER AB, 1960, J BIOL CHEM, V235, P1992; Levine RJ, 2006, NEW ENGL J MED, V355, P992, DOI 10.1056/NEJMoa055352; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; Lindheimer M. D., 2013, CLIN REV, V31, P8; Llurba E, 2015, FETAL DIAGN THER, V37, P81, DOI 10.1159/000368605; Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004; Maynard SE, 2005, PEDIATR RES, V57, p1R, DOI 10.1203/01.PDR.0000159567.85157.B7; Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189; Maynard SE, 2011, SEMIN NEPHROL, V31, P33, DOI 10.1016/j.semnephrol.2010.10.004; McGinnis R, 2017, NAT GENET, V49, P1255, DOI 10.1038/ng.3895; Moffett A, 2007, PLACENTA, V28, pS51, DOI 10.1016/j.placenta.2006.11.008; Moffett A, 2009, HUM REPROD, V24, P2048, DOI 10.1093/humrep/dep216; Molvarec A, 2010, HYPERTENS RES, V33, P892, DOI 10.1038/hr.2010.92; Nogueira TC, 2011, ENDOCRINOLOGY, V152, P1253, DOI 10.1210/en.2010-1088; Odibo AO, 2011, PLACENTA, V32, P598, DOI 10.1016/j.placenta.2011.05.006; Palei AC, 2013, ACTA PHYSIOL, V208, P224, DOI 10.1111/apha.12106; Parrish MR, 2010, AM J HYPERTENS, V23, P911, DOI 10.1038/ajh.2010.70; Perucci LO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097632; PIJNENBORG R, 1983, PLACENTA, V4, P397, DOI 10.1016/S0143-4004(83)80043-5; Powers RW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013263; Pramatirta Akhmad Yogi, 2015, BMC Res Notes, V8, P208, DOI 10.1186/s13104-015-1186-9; Pratt A, 2015, ANGIOGENESIS, V18, P115, DOI 10.1007/s10456-014-9452-3; Purwosunu Y, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.06.079; Ramma W, 2012, ANGIOGENESIS, V15, P333, DOI 10.1007/s10456-012-9261-5; Rana S, 2007, HYPERTENSION, V50, P137, DOI 10.1161/HYPERTENSIONAHA.107.087700; Rana S, 2012, CIRCULATION, V125, P911, DOI 10.1161/CIRCULATIONAHA.111.054361; Reddy A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004453; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Rigourd V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003905; Riise HKR, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.004158; Romero R, 2008, J MATERN-FETAL NEO M, V21, P9, DOI 10.1080/14767050701830480; Saxena AR, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-85; Schaarschmidt W, 2013, J PERINAT MED, V41, P511, DOI 10.1515/jpm-2012-0248; Schmidt M, 2008, HYPERTENS PREGNANCY, V27, P131, DOI 10.1080/10641950701885170; Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012; Sibai B, 2005, LANCET, V365, P785, DOI 10.1016/S0140-6736(05)17987-2; Silasi M, 2010, OBSTET GYN CLIN N AM, V37, P239, DOI 10.1016/j.ogc.2010.02.013; Sircar M, 2015, CURR OPIN NEPHROL HY, V24, P131, DOI 10.1097/MNH.0000000000000105; Soto E, 2012, J MATERN-FETAL NEO M, V25, P498, DOI 10.3109/14767058.2011.591461; Stepan H, 2007, HYPERTENSION, V49, P818, DOI 10.1161/01.HYP.0000258404.21552.a3; Stepan H, 2008, AM J OBSTET GYNECOL, V198, DOI 10.1016/j.ajog.2007.08.052; Strevens H, 2003, BJOG-INT J OBSTET GY, V110, P831, DOI 10.1111/j.1471-0528.2003.02162.x; Stubert J, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-292; Tanbe Alain F, 2010, Curr Bioact Compd, V6, P60; Thadhani R, 2016, J AM SOC NEPHROL, V27, P903, DOI 10.1681/ASN.2015020157; Torry DS, 1998, AM J OBSTET GYNECOL, V179, P1539, DOI 10.1016/S0002-9378(98)70021-3; Unal ER, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.05.022; Vaisbuch E, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.08.049; Valbuena-Diez AC, 2012, CIRCULATION, V126, P2612, DOI 10.1161/CIRCULATIONAHA.112.101261; Vatten LJ, 2007, AM J OBSTET GYNECOL, V196, P239, DOI 10.1016/j.ajog.2006.10.909; Vatten LJ, 2012, ACTA OBSTET GYN SCAN, V91, P1388, DOI 10.1111/j.1600-0412.2012.01516.x; Veerbeek JHW, 2015, HYPERTENSION, V65, P600, DOI 10.1161/HYPERTENSIONAHA.114.04850; Venkatesha S, 2006, NAT MED, V12, P642, DOI 10.1038/nm1429; Walker LO, 2010, JOGNN-J OBST GYN NEO, V39, P328, DOI 10.1111/j.1552-6909.2010.01144.x; Wallace AE, 2014, HUM REPROD, V29, P652, DOI 10.1093/humrep/deu017; Wallace AE, 2015, J LEUKOCYTE BIOL, V97, P79, DOI 10.1189/jlb.2A0614-282R; Walsh SW, 1998, SEMIN REPROD ENDOCR, V16, P93, DOI 10.1055/s-2007-1016256; Wang A, 2009, PHYSIOLOGY, V24, P147, DOI 10.1152/physiol.00043.2008; Zeisler H, 2016, NEW ENGL J MED, V374, P13, DOI 10.1056/NEJMoa1414838	110	7	8	0	3	ELSEVIER GMBH	MUNICH	HACKERBRUCKE 6, 80335 MUNICH, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					7	14		10.1016/j.prp.2017.10.021			8	Pathology	Pathology	GB5EN	WOS:000429086000002	29174227				2019-10-28	
J	Schwab, DE; Lepski, G; Borchers, C; Trautrnann, K; Paulsen, F; Schittenhelm, J				Schwab, David Emanuel; Lepski, Guilherme; Borchers, Christian; Trautrnann, Katrin; Paulsen, Frank; Schittenhelm, Jens			Immunohistochemical comparative analysis of GFAP, MAP-2, NOGO - A, OLIG-2 and WT-1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value	PATHOLOGY RESEARCH AND PRACTICE			English	Article						Glioma; GFAP; MAP-2; NOGG - A; OLIG-2; WT-1, Astrocytoma; Oligodendroglioma; Ependymoma; Tissue microarrays	MICROTUBULE-ASSOCIATED PROTEIN-2; CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTORS; OLIGODENDROGLIAL TUMORS; GRADE GLIOMA; BRAIN-TUMORS; A EXPRESSION; WT1 PROTEIN; GENE WT1; GLIOBLASTOMA	Immunohistochemistry is routinely used in differential diagnosis of tumours of the central nervous system (CNS). The latest 2016 WHO 2016 revision now includes molecular data such as IDH mutation and 1p/19q codeletion thus restructuring glioma classification. Direct comparative information between commonly used immunohistochemical markers for glial tumours GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 concerning quality and quantity of expression and their relation to the new molecular markers are lacking. We therefore compared the immunohistochemical staining results of all five antibodies in 34 oligodendrogliomas, 106 ependymomas and 423 astrocytic tumours. GFAP expression was reduced in cases with higher WHO grade, oligodendroglial differentiation and in IDH wildtype diffuse astrocytomas. By contrast MAP - 2 expression was significantly increased in diffuse astrocytomas with IDH mutation, while NOGO - A expression was not associated with any molecular marker. WT - 1 expression was significantly decreased in tumours with IDH mutation and ATRX loss. OLIG - 2 was increased in IDH-mutant grade II astrocytomas and in cases with higher proliferation rate. In univariate survival analysis high WT - 1 expression was significantly associated with worse outcome in diffuse astrocytic tumours (log rank p < 0.0001; n = 211; median time: 280 days vs 562 days). None of the markers was prognostic in multivariate survival analysis. Among the evaluated markers MAP - 2, OLIG - 2 and WT - 1 showed the best potential to separate between glioma entities and can be recommended for a standardized immunohistochemical panel.	[Schwab, David Emanuel; Trautrnann, Katrin; Schittenhelm, Jens] Eberhard Karls Univ Tuebingen, Univ Hosp Tuebingen, Inst Pathol & Neuropathol, Dept Neuropathol, D-72076 Tubingen, Germany; [Schwab, David Emanuel; Trautrnann, Katrin; Paulsen, Frank; Schittenhelm, Jens] Comprehens Canc Ctr Tuebingen Stuttgart, D-72076 Tubingen, Germany; [Paulsen, Frank] Eberhard Karls Univ Tuebingen, Univ Hosp Tuebingen, Dept Radiat Oncol, D-72076 Tubingen, Germany; [Borchers, Christian] Univ Tubingen, Dept Neurol, Tubingen, Germany; [Borchers, Christian] Univ Tubingen, Hertie Inst Clin Brain Res, Tubingen, Germany; [Lepski, Guilherme] Eberhard Karls Univ Tuebingen, Univ Hosp Tuebingen, Dept Neurosurg, D-72076 Tubingen, Germany; [Borchers, Christian] Nordwestkliniken Sanderbusch, Dept Neurol, D-26452 Sande, Germany	Schittenhelm, J (reprint author), Univ Hosp Tuebingen, Inst Pathol & Neuropathol, Dept Neuropathol, Calwerstr 3, D-72076 Tubingen, Germany.	jens.schittenhelm@med.uni-tuebingen.de	Lepski, Guilherme/V-6905-2019; Lepski, G/E-1508-2012	Lepski, G/0000-0002-9030-4192			Aguirre-Cruz L, 2004, J NEURO-ONCOL, V67, P265, DOI 10.1023/B:NEON.0000024190.56750.81; Aldape K, 2000, CANCER-AM CANCER SOC, V88, P2342, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X; Allmendinger O, 2012, HUM PATHOL, V43, P1289, DOI 10.1016/j.humpath.2011.10.007; Blumcke I, 2004, ACTA NEUROPATHOL, V108, P89, DOI 10.1007/s00401-004-0873-8; Blumcke I, 2001, J NEUROPATH EXP NEUR, V60, P984; Bourne TD, 2010, BRAIN PATHOL, V20, P1090, DOI 10.1111/j.1750-3639.2010.00415.x; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Coons SW, 1997, CANCER, V79, P1381, DOI 10.1002/(SICI)1097-0142(19970401)79:7<1381::AID-CNCR16>3.0.CO;2-W; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; FIGARELLABRANGER D, 1991, ACTA NEUROPATHOL, V82, P208, DOI 10.1007/BF00294447; Graham N. J., 2006, ADAMS GRAHAMS INTRO; GULLOTTA F, 1985, PATHOL RES PRACT, V180, P54, DOI 10.1016/S0344-0338(85)80075-3; Hashiba T, 2007, NEUROL MED-CHIR, V47, P165, DOI 10.2176/nmc.47.165; Jung TY, 2011, NEUROPATHOLOGY, V31, P11, DOI 10.1111/j.1440-1789.2010.01118.x; KENNEDY PGE, 1987, NEUROPATH APPL NEURO, V13, P327, DOI 10.1111/j.1365-2990.1987.tb00190.x; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kuhlmann T, 2008, AM J SURG PATHOL, V32, P1444, DOI 10.1097/PAS.0b013e31817ce978; Leu S, 2013, NEURO-ONCOLOGY, V15, P469, DOI 10.1093/neuonc/nos317; Ligon KL, 2004, J NEUROPATH EXP NEUR, V63, P499, DOI 10.1093/jnen/63.5.499; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Love D. L. Seth, 2008, GREENFIELDS NEUROPAT; Lu QR, 2001, P NATL ACAD SCI USA, V98, P10851, DOI 10.1073/pnas.181340798; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Martin H., 1986, SZYMAS IMPORTANCE IM, V132, P209; Marucci G, 2012, HUM PATHOL, V43, P374, DOI 10.1016/j.humpath.2011.05.007; Menke AL, 1998, INT REV CYTOL, V181, P151, DOI 10.1016/S0074-7696(08)60418-0; Mokhtari K, 2005, NEUROPATH APPL NEURO, V31, P62, DOI 10.1111/j.1365-2990.2004.00612.x; Nakahara Yukiko, 2004, Brain Tumor Pathol, V21, P113, DOI 10.1007/BF02482185; Oji Y, 2004, CANCER SCI, V95, P822, DOI 10.1111/j.1349-7006.2004.tb02188.x; Otero JJ, 2011, J NEURO-ONCOL, V104, P423, DOI 10.1007/s11060-010-0509-x; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pritchard-Jones K, 1999, PEDIATR NEPHROL, V13, P620; Rauscher J, 2014, J CLIN PATHOL, V67, P556, DOI 10.1136/jclinpath-2013-202114; Reifenberger C. V. P., 2016, WHO CLASSIFICATION T, P60; Reuss DE, 2015, ACTA NEUROPATHOL, V129, P133, DOI 10.1007/s00401-014-1370-3; Rousseau A, 2006, J NEUROPATH EXP NEUR, V65, P1149, DOI 10.1097/01.jnen.0000248543.90304.2b; Rushing EJ, 2010, INT J SURG PATHOL, V18, P255, DOI 10.1177/1066896909338596; Sahm F, 2017, LANCET ONCOL, V18, P682, DOI 10.1016/S1470-2045(17)30155-9; SARKAR C, 1988, CANCER, V61, P1862, DOI 10.1002/1097-0142(19880501)61:9<1862::AID-CNCR2820610923>3.0.CO;2-X; Schafer S., 2017, NEUROPATHOL APPL NEU; Schittenhelm J, 2009, NEUROPATH APPL NEURO, V35, P69, DOI 10.1111/j.1365-2990.2008.00957.x; Schittenhelm J., 2011, ADV BIOL IMAGING THE; Schittenhelm J, 2008, BRAIN PATHOL, V18, P344, DOI 10.1111/j.1750-3639.2008.00127.x; SCOTT CB, 1995, CANCER, V76, P307, DOI 10.1002/1097-0142(19950715)76:2<307::AID-CNCR2820760222>3.0.CO;2-L; Shafit-Zagardo B, 2000, GLIA, V29, P233, DOI 10.1002/(SICI)1098-1136(20000201)29:3<233::AID-GLIA5>3.3.CO;2-L; Skalli O, 2013, HUM PATHOL, V44, P2081, DOI 10.1016/j.humpath.2013.03.013; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Suzuki SO, 2002, J NEUROPATH EXP NEUR, V61, P403, DOI 10.1093/jnen/61.5.403; Wegner M, 2001, MICROSC RES TECHNIQ, V52, P746, DOI 10.1002/jemt.1059; Xiong Nan-Xiang, 2007, Neurosci Bull, V23, P41, DOI 10.1007/s12264-007-0006-1; Yokoo H, 2004, AM J PATHOL, V164, P1717, DOI 10.1016/S0002-9440(10)63730-3; Yu SX, 2012, J NEUROPATH EXP NEUR, V71, P665, DOI 10.1097/NEN.0b013e31825d6585; Zhou Q, 2000, NEURON, V25, P331, DOI 10.1016/S0896-6273(00)80898-3	54	3	3	0	4	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0344-0338			PATHOL RES PRACT	Pathol. Res. Pract.	JAN	2018	214	1					15	24		10.1016/j.prp.2017.12.009			10	Pathology	Pathology	GB5EN	WOS:000429086000003	29258767				2019-10-28	
J	Davis, JL; Lockwood, CM; Albert, CM; Tsuchiya, K; Hawkins, DS; Rudzinski, ER				Davis, Jessica L.; Lockwood, Christina M.; Albert, Catherine M.; Tsuchiya, Karen; Hawkins, Douglas S.; Rudzinski, Erin R.			Infantile NTRK-associated Mesenchymal Tumors	PEDIATRIC AND DEVELOPMENTAL PATHOLOGY			English	Article						infantile; fibrosarcoma; NTRK1; NTRK3; TRK; soft tissue tumor	ETV6-NTRK3 GENE FUSION; SOFT-TISSUE TUMORS; DERMATOFIBROSARCOMA PROTUBERANS; MOLECULAR-DETECTION; FIBROSARCOMA; REARRANGEMENTS; CARCINOMA; ONCOGENES; INFANCY; SENSITIVITY	Pediatric fibroblastic/myofibroblastic lesions are a relatively common group of tumors with varying morphologies, for which the molecular mechanisms are becoming increasingly well characterized. Congenital infantile fibrosarcoma (CIFS), perhaps the most well studied of these lesions is characterized by a recurrent ETV6-NTRK3 gene fusion. However, a notable subset of locally aggressive congenital/infantile soft tissue lesions with similar morphologic features to CIFS, have not to-date, shown evidence of any canonical molecular aberration. We describe 6 patients with mesenchymal tumors composed of infiltrative fibroblastic/myofibroblastic tumor cells and showing a morphologic spectrum of features much analogous to that previously described in CIFS but without ETV6 fusion transcripts. These tumors lacked a uniform immunoprofile, but showed variable expression of CD34, S100, smooth muscle actin, and CD30. All patients first developed a mass in infancy (<= 2 months of age). Using next-generation DNA sequencing, TMP3-NTRK1 fusions were identified in 4 cases, an LMNA-NTRK1 fusion in one case, and a variant EML4-NTRK3 fusion in one case. Similar to infantile fibrosarcoma, these tumors were locally aggressive (with local recurrences if incompletely excised) and rarely metastasized (lung metastases in one patient). Proper identification of these tumors including investigation for NTRK family gene rearrangements is essential for diagnostic accuracy, as well as for clinical management decisions. Given the morbidity associated with radical resection of large soft tissue tumors, children with unresectable, recurrent, and/or metastatic disease may benefit from treatment with NTRK targeted therapies.	[Davis, Jessica L.] Univ Calif San Francisco, Dept Pathol & Lab Med, 1825 4th St,M2384 Box 4066, San Francisco, CA 94158 USA; [Davis, Jessica L.; Tsuchiya, Karen; Rudzinski, Erin R.] Seattle Childrens Hosp, Dept Pathol, Seattle, WA USA; [Lockwood, Christina M.; Tsuchiya, Karen] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Albert, Catherine M.; Hawkins, Douglas S.] Univ Washington, Seattle Childrens Hosp, Div Pediat Hematol Oncol, Seattle, WA 98195 USA; [Albert, Catherine M.; Hawkins, Douglas S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA	Davis, JL (reprint author), Univ Calif San Francisco, Dept Pathol & Lab Med, 1825 4th St,M2384 Box 4066, San Francisco, CA 94158 USA.	Jessica.Davis@ucsf.edu		Lockwood, Christina/0000-0001-9036-7604			Agaram NP, 2016, AM J SURG PATHOL, V40, P1407, DOI 10.1097/PAS.0000000000000675; Alaggio R, 2006, AM J SURG PATHOL, V30, P388; Alaggio R, 2008, PEDIATR DEVEL PATHOL, V11, P355, DOI 10.2350/07-09-0355.1; Ardini E, 2014, MOL ONCOL, V8, P1495, DOI 10.1016/j.molonc.2014.06.001; Bourgeois JM, 2000, AM J SURG PATHOL, V24, P937, DOI 10.1097/00000478-200007000-00005; BUTTI MG, 1995, GENOMICS, V28, P15, DOI 10.1006/geno.1995.1100; Calonje E, 1996, J CUTAN PATHOL, V23, P30, DOI 10.1111/j.1600-0560.1996.tb00774.x; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; COFFIN C M, 1991, Pediatric Pathology, V11, P569; COFFIN C M, 1990, Pediatric Pathology, V10, P509; Coffin CM, 2012, PEDIATR DEVEL PATHOL, V15, P127, DOI 10.2350/10-12-0944-PB.1; COFFIN CM, 1994, PEDIATR PATHOL, V14, P133, DOI 10.3109/15513819409022033; Coffin CM, 2001, PEDIAT PATHOLOGY, P1163; Creancier L, 2015, CANCER LETT, V365, P107, DOI 10.1016/j.canlet.2015.05.013; Doebele RC, 2015, CANCER DISCOV, V5, P1049, DOI 10.1158/2159-8290.CD-15-0443; Fan X., 2014, CURR PROTOC BIOINFOR, V45, DOI [10.1002/0471250953.bi1506s45, DOI 10.1002/0471250953.BI1506S45]; Fetsch JF, 2000, AM J SURG PATHOL, V24, P1491, DOI 10.1097/00000478-200011000-00004; Fletcher C, 2013, WHO CLASSIFICATION T; Greco A, 1996, ONCOGENE, V13, P2463; GRECO A, 1993, GENOMICS, V18, P397, DOI 10.1006/geno.1993.1482; Haller F, 2016, J PATHOL, V238, P700, DOI 10.1002/path.4701; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Lih CJ, 2015, JNCI-J NATL CANCER I, V108, P1; Llombart B, 2009, HISTOPATHOLOGY, V54, P860, DOI 10.1111/j.1365-2559.2009.03310.x; MANDAHL N, 1989, CANCER GENET CYTOGEN, V40, P137, DOI 10.1016/0165-4608(89)90156-8; Mandahl N, 2009, CANC CYTOGENETICS, P683; Nagasubramanian R, 2016, PEDIATR BLOOD CANCER, V63, P1468, DOI 10.1002/pbc.26026; Orbach D, 2016, EUR J CANCER, V57, P1, DOI 10.1016/j.ejca.2015.12.028; Pavlick D, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26433; Pierotti MA, 2006, CANCER LETT, V232, P90, DOI 10.1016/j.canlet.2005.07.043; Prasad ML, 2016, CANCER-AM CANCER SOC, V122, P1097, DOI 10.1002/cncr.29887; Pritchard CC, 2014, J MOL DIAGN, V16, P56, DOI 10.1016/j.jmoldx.2013.08.004; Pritchard CC, 2012, J MOL DIAGN, V14, P357, DOI 10.1016/j.jmoldx.2012.03.002; PULCIANI S, 1982, NATURE, V300, P539, DOI 10.1038/300539a0; Reimann JDR, 2007, AM J SURG PATHOL, V31, P1371, DOI 10.1097/PAS.0b013e31802ff7e7; Saab ST, 2014, AM J SURG PATHOL, V38, P394, DOI 10.1097/PAS.0000000000000104; Sandberg AA, 2002, CANCER GENET CYTOGEN, V132, P1, DOI 10.1016/S0165-4608(01)00528-3; Sartore-Bianchi A, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv306; Sheng WQ, 2001, AM J CLIN PATHOL, V115, P348; Skapek SX, 2007, J CLIN ONCOL, V25, P501, DOI 10.1200/JCO.2006.08.2966; Tannenbaum-Dvir S, 2015, CSH MOL CASE STUD, V1, DOI 10.1101/mcs.a000471; Tatematsu T, 2014, MOL CLIN ONCOL, V2, P725, DOI 10.3892/mco.2014.318; Tognon C, 2002, CANCER CELL, V2, P367, DOI 10.1016/S1535-6108(02)00180-0; Urano M, 2015, HUM PATHOL, V46, P94, DOI 10.1016/j.humpath.2014.09.012; Vaishnavi A, 2015, CANCER DISCOV, V5, P25, DOI 10.1158/2159-8290.CD-14-0765; Wang JM, 2011, NAT METHODS, V8, P652, DOI [10.1038/NMETH.1628, 10.1038/nmeth.1628]; Wong V, 2015, JNCI-J NATL CANCER I, V108, P1; Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394	49	21	22	2	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1093-5266	1615-5742		PEDIATR DEVEL PATHOL	Pediatr. Dev. Pathol.	JAN-FEB	2018	21	1					68	78		10.1177/1093526617712639			11	Pathology; Pediatrics	Pathology; Pediatrics	FU1PW	WOS:000423622900007	28683589				2019-10-28	
J	Szumera-Cieckiewicz, A; Rymkiewicz, G; Lewicz, BG; Jesionek-Kupnicka, D; Gruchala, A; Ziarkiewicz-Wroblewska, B; Galazka, K; Reszec, J; Borg, K; Prochorec-Sobieszek, M				Szumera-Cieckiewicz, Anna; Rymkiewicz, Grzegorz; Lewicz, Beata Gryga; Jesionek-Kupnicka, Dorota; Gruchala, Andrzej; Ziarkiewicz-Wroblewska, Bogna; Galazka, Krystyna; Reszec, Joanna; Borg, Katarzyna; Prochorec-Sobieszek, Monika			COMPREHENSIVE HISTOPATHOLOGICAL DIAGNOSTICS OF AGGRESSIVE B-CELL LYMPHOMAS BASED ON THE UPDATED CR ITERIA OF THE WORLD HEALTH ORGANISATION'S 2017 CLASSIFICATION	POLISH JOURNAL OF PATHOLOGY			English	Review						aggressive B-cell lymphomas; high grade B-cell lymphomas; Burkitt-like lymphoma; 11q aberration	NON-HODGKINS-LYMPHOMA; OF-ORIGIN CLASSIFICATION; BURKITT-LYMPHOMA; PLASMABLASTIC LYMPHOMA; MYC-REARRANGEMENTS; PROGNOSTIC IMPACT; GENE-EXPRESSION; POOR-PROGNOSIS; RITUXIMAB; NEOPLASMS	Revision of the fourth edition of the World Health Organisation (WHO) Classification of Haematopoietic and Lymphatic Tissues, which was published in 2017, introduced important changes updating the biology, pathology, genetics, and clinical presentation of aggressive B-cell lymphomas. High grade B-cell lymphomas (HGBLs) replaced B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, the new provisional entity Burkitt-like lymphoma with 11q aberration was identified, and some categories were upgraded, e.g. EBV-positive diffuse large B-cell lymphoma, not otherwise specified. Still the histopathological diagnostics is based on morphology and immunoprofile, but to define the HGBLs evaluation of MYC, BCL2, and BCL6 gene statuses is required. According to the presented WHO criteria, in the comprehensive histopathological diagnostics of aggressive B-cell lymphomas a highly specialised diagnostic team including a pathologist, a molecular biologist, a geneticist, a haematologist, and immunophenotyping technicians is needed.	[Szumera-Cieckiewicz, Anna; Borg, Katarzyna; Prochorec-Sobieszek, Monika] Inst Haematol & Transfus Med, Dept Diagnost Haematol, I Gandhi 14, PL-02776 Warsaw, Poland; [Szumera-Cieckiewicz, Anna; Rymkiewicz, Grzegorz; Prochorec-Sobieszek, Monika] Maria Sklodowska Curie Inst, Oncol Ctr, Dept Pathol & Lab Diagnost, Warsaw, Poland; [Lewicz, Beata Gryga] Maria Sklodowska Curie Inst, Oncol Ctr, Cytogenet Lab, Warsaw, Poland; [Jesionek-Kupnicka, Dorota] Med Univ Lodz, Chair Oncol, Dept Pathol, Lodz, Poland; [Gruchala, Andrzej] Maria Sklodowska Curie Mem Inst Oncol, Ctr Oncol, Dept Tumor Pathol, Cracow Branch, Krakow, Poland; [Ziarkiewicz-Wroblewska, Bogna] Med Univ, Dept Pathol, Warsaw, Poland; [Galazka, Krystyna] Jagiellonian Univ, Med Coll, Fac Med, Dept Pathomorphol, Krakow, Poland; [Reszec, Joanna] Med Univ Bialystok, Dept Med Pathomorphol, Bialystok, Poland	Szumera-Cieckiewicz, A (reprint author), Inst Haematol & Transfus Med, Dept Diagnost Haematol, I Gandhi 14, PL-02776 Warsaw, Poland.	szumann@gmail.com	Borg, Katarzyna/Y-3782-2018; Reszec, Joanna/T-7207-2018; Rymkiewicz, Grzegorz/AAB-7301-2019; Szumera-Cieckiewicz, Anna/D-8391-2019	Borg, Katarzyna/0000-0003-4831-735X; Reszec, Joanna/0000-0002-0169-0897; Szumera-Cieckiewicz, Anna/0000-0001-5028-3422; Gruchala, Andrzej/0000-0001-9412-1329	Operational Programme Innovative Economy [POIG.02.03.00-14-111/13]	This work has been implemented using the Project infrastructure POIG.02.03.00-14-111/13 funded by Operational Programme Innovative Economy 2007-2013, Priority II. R&D Infrastructure, Measure 2.3. Investments connected with development of IT infrastructure of Science.	Aukema SM, 2014, HAEMATOLOGICA, V99, P726, DOI 10.3324/haematol.2013.091827; Boerma EG, 2009, LEUKEMIA, V23, P225, DOI 10.1038/leu.2008.281; Camicia R, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0474-2; Campo E, 2015, BLOOD, V126, P2439, DOI 10.1182/blood-2015-10-671362; Cascione L, 2018, BRIT J HAEMATOL, V182, P453, DOI 10.1111/bjh.14817; Castillo J, 2008, AM J HEMATOL, V83, P804, DOI 10.1002/ajh.21250; Castillo JJ, 2016, AM J HEMATOL, V91, P529, DOI 10.1002/ajh.24370; Chan WC, 1997, BLOOD, V89, P3909; Cheah CY, 2015, BRIT J HAEMATOL, V168, P784, DOI 10.1111/bjh.13276; Chen AI, 2017, LEUKEMIA LYMPHOMA, DOI [10.1080/10428194.2017, DOI 10.1080/10428194.2017]; Chiappella A, 2017, EXPERT REV HEMATOL, V10, P697, DOI 10.1080/17474086.2017.1350164; Choi WWL, 2009, CLIN CANCER RES, V15, P5494, DOI 10.1158/1078-0432.CCR-09-0113; Colomo L, 2004, AM J SURG PATHOL, V28, P736, DOI 10.1097/01.pas.0000126781.87158.e3; Copie-Bergman C, 2015, BLOOD, V126, P2466, DOI 10.1182/blood-2015-05-647602; Deckert M, 2014, HEMATOL ONCOL, V32, P57, DOI 10.1002/hon.2087; Deckert M, 2014, ACTA NEUROPATHOL, V127, P175, DOI 10.1007/s00401-013-1202-x; Goodman A, 2017, NAT REV CLIN ONCOL, V14, P203, DOI 10.1038/nrclinonc.2016.168; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Grygalewicz B, 2018, AM J CLIN PATHOL, V149, P17, DOI [10.1093/AJCP/AQX139, 10.1093/ajcp/aqx139]; Harmon CM, 2016, ARCH PATHOL LAB MED, V140, P1074, DOI 10.5858/arpa.2016-0232-RA; Hoelzer D, 2014, BLOOD, V124, P3870, DOI 10.1182/blood-2014-03-563627; Hong J, 2011, LEUKEMIA LYMPHOMA, V52, P1904, DOI 10.3109/10428194.2011.588761; Hwang HS, 2014, AM J SURG PATHOL, V38, P1046, DOI 10.1097/PAS.0000000000000211; Jaffe ES, 2017, HEMATOPATHOLOGY E BO; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Klapper W, 2008, LEUKEMIA, V22, P2226, DOI 10.1038/leu.2008.230; Landsburg DJ, 2016, BRIT J HAEMATOL, V175, P631, DOI 10.1111/bjh.14282; Li SY, 2018, PATHOLOGY, V50, P74, DOI 10.1016/j.pathol.2017.09.006; Liu JJ, 2011, LEUKEMIA RES, V35, P1571, DOI 10.1016/j.leukres.2011.06.023; Martelli M, 2015, EXPERT REV HEMATOL, V8, P173, DOI 10.1586/17474086.2015.994604; Moore EM, 2017, AM J SURG PATHOL, V41, P1155, DOI 10.1097/PAS.0000000000000818; Nyman H, 2009, MODERN PATHOL, V22, P1094, DOI 10.1038/modpathol.2009.73; Otto C, 2016, GENE CHROMOSOME CANC, V55, P932, DOI 10.1002/gcc.22391; Pasqualucci L, 2015, SEMIN HEMATOL, V52, P67, DOI 10.1053/j.seminhematol.2015.01.005; Patrick LB, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-015-0483-8; Pedersen MO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186983; Pienkowska-Grela B, 2011, MED ONCOL, V28, P1589, DOI 10.1007/s12032-010-9614-0; Quesada AE, 2017, MODERN PATHOL, V30, P1688, DOI 10.1038/modpathol.2017.93; Reagan PM, 2017, HEMATOL-AM SOC HEMAT, P295, DOI 10.1182/asheducation-2017.1.295; Roschewski M, 2014, NAT REV CLIN ONCOL, V11, P12, DOI 10.1038/nrclinonc.2013.197; Roy SG, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6040046; Rymkiewicz G, 2018, MODERN PATHOL, DOI [10.1038/modpathol.2017.186, DOI 10.1038/MODPATH0L.2017.186]; Salaverria I, 2014, BLOOD, V123, P1187, DOI 10.1182/blood-2013-06-507996; Schmidt-Hansen M, 2017, LEUKEMIA LYMPHOMA, V58, P2403, DOI 10.1080/10428194.2017.1287364; Schneider C, 2011, SEMIN DIAGN PATHOL, V28, P167, DOI 10.1053/j.semdp.2011.04.001; Sjo LD, 2007, EUR J HAEMATOL, V79, P501, DOI 10.1111/j.1600-0609.2007.00976.x; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Staiger AM, 2017, J CLIN ONCOL, V35, P2515, DOI 10.1200/JCO.2016.70.3660; Swerdlow SH, 2017, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2014, HEMATOL-AM SOC HEMAT, P90, DOI 10.1182/asheducation-2014.1.90; Szczepanowski M, 2017, BRIT J HAEMATOL, V179, P116, DOI 10.1111/bjh.14812; Szumera-Cieckiewicz A, 2014, INT J CLIN EXP PATHO, V7, P3280; Taylor J, 2017, BLOOD, V130, P410, DOI 10.1182/blood-2017-02-734541; THANGAVELU M, 1990, GENE CHROMOSOME CANC, V2, P147, DOI 10.1002/gcc.2870020211; Turakhia SK, 2014, AM J CLIN PATHOL, V142, P339, DOI 10.1309/AJCPBWVHTF7RRSA4; Wu D, 2010, AM J CLIN PATHOL, V134, P258, DOI 10.1309/AJCP7YLDTJPLCE5F; Ye Q, 2016, ONCOTARGET, V7, P2401, DOI 10.18632/oncotarget.6262; Yoon N, 2017, ONCOTARGET, V8, P22014, DOI 10.18632/oncotarget.15782; Yu L, 2017, BLOOD REV, V31, P77, DOI 10.1016/j.blre.2016.10.001; Zajdel M, 2015, TUMOR BIOL, V36, P5377, DOI 10.1007/s13277-015-3203-y; Zeng DF, 2019, AM J CLIN ONCOL-CANC, V42, P304, DOI 10.1097/COC.0000000000000427	62	0	0	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					1	19		10.5114/pjp.2018.75332			19	Pathology	Pathology	GH0LS	WOS:000433094500001	29895122	DOAJ Gold			2019-10-28	
J	Natkaniec, M; Dworak, J; Hankus, J; Sanak, M; Pedziwiatr, M; Major, P; Licholai, S; Budzynski, A				Natkaniec, Michal; Dworak, Jadwiga; Hankus, Jerzy; Sanak, Marek; Pedziwiatr, Michal; Major, Piotr; Licholai, Sabina; Budzynski, Andrzej			INFLUENCE OF TNF-alpha PROMOTER VARIABILITY ON STAGE AND GRADE IN INDIVIDUALS WITH COLORECTAL CANCER	POLISH JOURNAL OF PATHOLOGY			English	Article						colorectal cancer; TNF-alpha; promoter; SNP; stage; grade	TUMOR-NECROSIS-FACTOR; POLYMORPHISM; EXPRESSION; RISK; PROGRESSION; POPULATION; CARCINOMA	Carcinogenesis is a multistep process in which inflammation plays an important role. Tumour necrosis factor a (TNF-alpha) is a cytokine that plays a major role in inflammation. Activity of the TNF cytokine family could influence progression of colorectal cancer (CRC). The aim of the study was to establish an association between TNF-alpha promoter variability and stage/grade in individuals with sporadic CRC. The study included 152 CRC patients and 107 healthy volunteers. Four single nucleotide polymorphisms (rs361525, rs1800629, rs1799724, and rs1799964) located at the promoter of TNFA gene were genotyped using commercially available TaqMan allelic discrimination assays by real-time PCR. CRC stage was described on the basis of preoperative imaging studies and postoperative histopathological report. The grade was described on the basis postoperative pathological examination of the specimen. In the case of rs361525, there was a statistically significant association with M-score (p = 0.0209). Rs361525 has significant association with tumour grade (p = 0.0260). We failed to demonstrate significant association between the other 3 SNPs and cancer grade. Rs361525 potentially could be under consideration when the survival rate and prognosis is assessed.	[Natkaniec, Michal; Dworak, Jadwiga; Pedziwiatr, Michal; Major, Piotr; Budzynski, Andrzej] Jagiellonian Univ, Dept Gen Surg 2, Kopernika 21, PL-31501 Krakow, Poland; [Hankus, Jerzy] Jagiellonian Univ, Dept Patomorphol, Krakow, Poland; [Sanak, Marek; Licholai, Sabina] Jagiellonian Univ, Dept Internal Med 2, Krakow, Poland	Natkaniec, M (reprint author), Jagiellonian Univ, Dept Gen Surg 2, Kopernika 21, PL-31501 Krakow, Poland.	michal.natkaniec@uj.edu.pl	Pedziwiatr, Michal/B-1594-2016	Pedziwiatr, Michal/0000-0001-9073-2667			Al Obeed OA, 2014, WORLD J GASTROENTERO, V20, P18390, DOI 10.3748/wjg.v20.i48.18390; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Balkwill F, 2006, CANCER METAST REV, V25, P409, DOI 10.1007/s10555-006-9005-3; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Csiszar A, 2004, PATHOL ONCOL RES, V10, P109, DOI 10.1007/BF02893465; Edge SB, 2010, AJCC CANC STAGING HD; Guo XF, 2013, WORLD J GASTROENTERO, V19, P9461, DOI 10.3748/wjg.v19.i48.9461; Hamadien MA, 2016, TUMOR BIOL, V37, P5529, DOI 10.1007/s13277-015-4421-z; Korobeinikova E, 2015, BMC GENET, V16, DOI 10.1186/s12863-015-0234-8; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; Lewandowska M, 2016, POL J PATHOL, V67, P13, DOI 10.5114/PJP.2015.59222; Li MQ, 2011, GENET TEST MOL BIOMA, V15, P743, DOI 10.1089/gtmb.2011.0068; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Marszalek A, 2012, POL J PATHOL, V63, P221, DOI 10.5114/PJP.2012.32768; Min L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085187; Rattray Nicholas J W, 2017, Curr Pharmacol Rep, V3, P114, DOI 10.1007/s40495-017-0088-z; Sousa H, 2014, TUMOR BIOL, V35, P2561, DOI 10.1007/s13277-013-1337-3; Stanilov N, 2014, BIOTECHNOL BIOTEC EQ, V28, P911, DOI 10.1080/13102818.2014.965047; Szlosarek P, 2006, EUR J CANCER, V42, P745, DOI 10.1016/j.ejca.2006.01.012; Theodoropoulos G, 2006, WORLD J GASTROENTERO, V12, P5037, DOI 10.3748/wjg.v12.i31.5037; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Waters JP, 2013, J PATHOL, V230, P241, DOI 10.1002/path.4188; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Zhang K, 2016, ARCH MED SCI, V12, P68, DOI 10.5114/aoms.2016.57581; Zhou C, 2008, BREAST CANCER RES, V10, P101	26	1	1	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					150	156		10.5114/PJP.2018.76698			7	Pathology	Pathology	GM4PM	WOS:000438104000007	30351862	DOAJ Gold			2019-10-28	
J	Elfeky, M; Harb, O; Gertallah, L				Elfeky, Mariem; Harb, Ola; Gertallah, Loay			Panel of Villin, Pro-Ex-C, Estrogen Receptor and Progesterone Receptor Expressions Could Help in Differentiation Between Endocervical and Endometrioid Adenocarcinoma	TURKISH JOURNAL OF PATHOLOGY			English	Article						Endocervical adenocarcinoma; Endometrioid adenocarcinoma; Immunohistochemistry; Villin; Pro-Ex-C; ER; PR	HUMAN-PAPILLOMAVIRUS DNA; CERVICAL ADENOCARCINOMA; IMMUNOHISTOCHEMICAL ANALYSIS; CLASSIFICATION-SYSTEM; P16 IMMUNOREACTIVITY; UTERINE CERVIX; CANCER; MARKER; DISTINCTION; PROTEIN	Objective: Endocervical and endometrioid adenocarcinoma have marked overlapping features and the differentiation between them is important for their accurate management. Villin is an actin-binding protein which has an important role in the maintenance of microvilli in epithelial cells and epithelial cell-specific anti-apoptotic protein processes. Pro-Ex-C is a marker for higher-risk human papilloma virus (HPV) which targets the cell cycle proteins causing their overexpression. The aim of the study was to clarify the diagnostic and predictive role of villin, Pro-Ex-C, estrogen receptor (ER) and progesterone receptor (PR) expression in endocervical and endometrioid adenocarcinoma. Material and Method: We evaluated villin, Pro-Ex-C, ER and PR expressions in 15 cases of endocervical adenocarcinoma and 30 cases of endometrioid adenocarcinoma. We analyzed the diagnostic and predictive role of that panel in both carcinoma subtypes. Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated. Results: Positive villin and Pro-Ex-C expressions were positively correlated with the presence and pattern of cervical stromal invasion (p<0.05). ER was positive in all cases of endometrioid adenocarcinoma. PR was detected in most cases of endometrioid adenocarcinoma. The differences of villin, Pro-Ex-C, ER and PR expression in endocervical and endometrioid adenocarcinoma was statistically significant (p<0.05). This methodology for distinguishing endocervical and endometrioid adenocarcinoma had a sensitivity of 100%, a specificity of 100% and a significant prognostic and predictive role. Conclusion: In conclusion, villin, Pro-Ex-C, ER and PR expressions have diagnostic and predictive roles in endocervical and endometrioid adenocarcinoma	[Elfeky, Mariem; Harb, Ola] Zagazig Univ, Fac Med, Dept Pathol, Zagazig, Egypt; [Gertallah, Loay] Zagazig Univ, Fac Med, Dept Gen Surg, Zagazig, Egypt	Harb, O (reprint author), Zagazig Univ, Fac Med, Dept Pathol, Zagazig, Egypt.	olaharb2015@gmail.com		Harb, Ola/0000-0002-4396-3101			Al-Maghrabi J, 2013, ISRN GASTROENTEROL, V2013; Aximu D, 2009, INT J GYNECOL PATHOL, V28, P114, DOI 10.1097/PGP.0b013e3181895573; Badr RE, 2008, AM J SURG PATHOL, V32A, P899, DOI 10.1097/PAS.0b013e31815bbb69; Brown CA, 2012, J ONCOL, DOI 10.1155/2012/289315; Conesa-Zamora P, 2009, J CLIN PATHOL, V62, P159, DOI 10.1136/jcp.2008.061408; De Vivar AD, 2013, INT J GYNECOL PATHOL, V32, P592, DOI 10.1097/PGP.0b013e31829952c6; Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043; Esheba GE, 2013, J EGYPT NATL CANCER, V25, P87, DOI 10.1016/j.jnci.2013.01.005; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Fletcher AH, 2011, J LOW GENIT TRACT DI, V15, P6, DOI 10.1097/LGT.0b013e3181f0b4b7; Guo M, 2011, AM J CLIN PATHOL, V135, P212, DOI 10.1309/AJCP1LLX8QMDXHHO; Hoffman BL, 2012, WILLIAMS GYNECOLOGY, P817; Houghton O, 2010, HISTOPATHOLOGY, V57, P342, DOI 10.1111/j.1365-2559.2010.03632.x; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Kamoi S, 2002, INT J GYNECOL PATHOL, V21, P217, DOI 10.1097/00004347-200207000-00003; Khoury T, 2006, BMC CLIN PATHOL, V6, DOI 10.1186/1472-6890-6-1; Khurana S, 2008, FEBS LETT, V582, P2128, DOI 10.1016/j.febslet.2008.02.040; Kong CS, 2010, AM J SURG PATHOL, V34, P915, DOI 10.1097/PAS.0b013e3181e3291e; KONISHI I, 1991, CANCER-AM CANCER SOC, V68, P1340, DOI 10.1002/1097-0142(19910915)68:6<1340::AID-CNCR2820680626>3.0.CO;2-Q; Kurman RJ, 2014, WHO CLASSIFICATION T; Lewin SN, 2010, OBSTET GYNECOL, V116, P1141, DOI 10.1097/AOG.0b013e3181f39849; Lhocine N, 2015, CELL HOST MICROBE, V17, P164, DOI 10.1016/j.chom.2014.12.003; Liang J, 2007, INT J GYNECOL PATHOL, V26, P71, DOI 10.1097/01.pgp.0000225851.97739.9f; McCluggage WG, 2003, INT J GYNECOL PATHOL, V22, P231, DOI 10.1097/01.PGP.0000055172.04957.2F; MOLL R, 1987, VIRCHOWS ARCH B, V54, P155, DOI 10.1007/BF02899208; Nakamura E, 2009, CANCER BIOL THER, V8, P1146, DOI 10.4161/cbt.8.12.8477; Park KJ, 2011, AM J SURG PATHOL, V35, P633, DOI 10.1097/PAS.0b013e31821534b9; Patnaik S, 2016, MOL BIOL CELL, V27, P535, DOI 10.1091/mbc.E15-06-0453; Pirog EC, 2000, AM J PATHOL, V157, P1055, DOI 10.1016/S0002-9440(10)64619-6; Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402; Salim EI, 2009, ASIAN PAC J CANCER P, V10, P3; Semczuk A, 2000, ONCOL REP, V7, P905; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Socolov D, 2016, MED-SURG J, V120, P355; Wang YH, 2008, J BIOL CHEM, V283, P9454, DOI 10.1074/jbc.M707962200; WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre), HUM PAP REL CANC EG; Xi LQ, 2006, CLIN CHEM, V52, P520, DOI 10.1373/clinchem.2005.062844; Yemelyanova A, 2009, AM J SURG PATHOL, V33, P914, DOI 10.1097/PAS.0b013e3181971fdd; Yu HY, 2013, TUMOR BIOL, V34, P3981, DOI 10.1007/s13277-013-0986-6; Zhao J, 2015, TUMOR BIOL, V36, P1299, DOI 10.1007/s13277-014-2761-8	40	0	0	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					29	40		10.5146/tjpath.2017.01399			12	Pathology	Pathology	GH2RY	WOS:000433250700003	28832070	DOAJ Gold			2019-10-28	
J	Esendagli, G; Akarca, FG; Balci, S; Argon, A; Sengiz Erhan, S; Turhan, N; Ince Zengin, N; Hallac Keser, S; Celik, B; Bulut, T; Abdullazade, S; Erden, E; Savas, B; Bostan, T; Sagol, O; Aysal Agalar, A; Kepil, N; Karslioglu, Y; Gunal, A; Markoc, F; Saka, B; Ozgun, G; Ozdamar, SO; Bahadir, B; Kaymaz, E; Isik, E; Ayhan, S; Tuncel, D; Ozguven Yilmaz, B; Celik, S; Karabacak, T; Erbarut Seven, I; Ataizi Celikel, C; Gucin, Z; Ekinci, O; Akyol, G				Esendagli, Guldal; Akarca, F. Goknur; Balci, Serdar; Argon, Asuman; Sengiz Erhan, Selma; Turhan, Nesrin; Ince Zengin, Neslihan; Hallac Keser, Sevinc; Celik, Betul; Bulut, Tangul; Abdullazade, Samir; Erden, Esra; Savas, Berna; Bostan, Temmuz; Sagol, Ozgul; Aysal Agalar, Anil; Kepil, Nuray; Karslioglu, Yildirim; Gunal, Armagan; Markoc, Fatma; Saka, Burcu; Ozgun, Gonca; Ozdamar, Sukru Oguz; Bahadir, Burak; Kaymaz, Esin; Isik, Emre; Ayhan, Semin; Tuncel, Deniz; Ozguven Yilmaz, Banu; Celik, Sevinc; Karabacak, Tuba; Erbarut Seven, Ipek; Ataizi Celikel, Cigdem; Gucin, Zuhal; Ekinci, Ozgur; Akyol, Gulen			A Retrospective Evaluation of the Epithelial Changes/Lesions and Neoplasms of the Gallbladder in Turkey and a Review of the Existing Sampling Methods: A Multicentre Study	TURKISH JOURNAL OF PATHOLOGY			English	Review						Gallbladder; Cholecystectomy; Dysplasia; Neoplasia; Sampling	LAPAROSCOPIC CHOLECYSTECTOMY; PRECURSOR LESIONS; POLYPOID LESIONS; GALL-BLADDER; CARCINOMA; DYSPLASIA	Objective: As there is continuing disagreement among the observers on the differential diagnosis between the epithelial changes/lesions and neoplasms of the gallbladder, this multicentre study was planned in order to assess the rate of the epithelial gallbladder lesions in Turkey and to propose microscopy and macroscopy protocols. Material and Method: With the participation of 22 institutions around Turkey that were included in the Hepato-Pancreato-Biliary Study Group, 89,324 cholecystectomy specimens sampled from 2003 to 2016 were retrospectively evaluated. The numbers of adenocarcinomas, dysplasias, intracholecystic neoplasms/adenomas, intestinal metaplasias and reactive atypia were identified with the review of pathology reports and the regional and countrywide incidence rates were presented in percentages. Results: Epithelial changes/lesions were reported in 6% of cholecystectomy materials. Of these epithelial lesions, 7% were reported as adenocarcinoma, 0.9% as high-grade dysplasia, 4% as low-grade dysplasia, 7.8% as reactive/regenerative atypia, 1.7% as neoplastic polyp, and 15.6% as intestinal metaplasia. The remaining lesions (63%) primarily included non-neoplastic polypoids/hyperplastic lesions and antral/pyloric metaplasia. There were also differences between pathology laboratories. Conclusion: The major causes of the difference in reporting these epithelial changes/lesions and neoplasms include the differences related to the institute's oncological surgery frequency, sampling protocols, geographical dissimilarities, and differences in the diagnoses/interpretations of the pathologists. It seems that the diagnosis may change if new sections are taken from the specimen when any epithelial abnormality is seen during microscopic examination of the cholecystectomy materials.	[Esendagli, Guldal; Akarca, F. Goknur; Ekinci, Ozgur; Akyol, Gulen] Gazi Univ, Sch Med, Dept Med Pathol, Ankara, Turkey; [Balci, Serdar] Ankara Univ, Yildirim Beyazit Sch Med, Dept Med Pathol, Ankara, Turkey; [Argon, Asuman] Izmir Bozyaka Training & Res Hosp, Dept Pathol, Izmir, Turkey; [Sengiz Erhan, Selma] Okmeydani Training & Res Hosp, Dept Pathol, Istanbul, Turkey; [Turhan, Nesrin; Ince Zengin, Neslihan] Turkiye Yuksek Ihtisas Training & Res Hosp, Ankara, Turkey; [Hallac Keser, Sevinc] Dr Lutfi Kirdar Training & Res Hosp, Istanbul, Turkey; [Celik, Betul; Bulut, Tangul] Univ Hlth Sci, Dept Med Pathol, Antalya Training & Res Hosp, Antalya, Turkey; [Abdullazade, Samir] Izmir Tepecik Training & Res Hosp, Dept Pathol, Izmir, Turkey; [Erden, Esra; Savas, Berna; Bostan, Temmuz] Ankara Univ, Sch Med, Dept Med Pathol, Ankara, Turkey; [Sagol, Ozgul; Aysal Agalar, Anil] Dokuz Eylul Univ, Sch Med, Izmir, Turkey; [Kepil, Nuray] Istanbul Univ, Cerrahpasa Med Sch, Istanbul, Turkey; [Karslioglu, Yildirim; Gunal, Armagan] Gulhane Training & Res Hosp, Dept Pathol, Ankara, Turkey; [Markoc, Fatma] Dr Abdurrahman Yurtaslan Ankara Onkol Training &, Dept Pathol, Ankara, Turkey; [Saka, Burcu] Istanbul Univ, Medipol Sch Med, Dept Pathol, Istanbul, Turkey; [Ozgun, Gonca] Baskent Univ, Sch Med, Dept Med Pathol, Ankara, Turkey; [Ozdamar, Sukru Oguz; Bahadir, Burak; Kaymaz, Esin; Isik, Emre] Bulent Ecevit Univ, Sch Med, Dept Med Pathol, Zonguldak, Turkey; [Ayhan, Semin] Celal Bayar Univ, Sch Med, Manisa, Turkey; [Tuncel, Deniz; Ozguven Yilmaz, Banu] Sisli Hamidiye Etfal Training & Res Hosp, Dept Pathol, Istanbul, Turkey; [Celik, Sevinc] Bozok Univ, Sch Med, Dept Med Pathol, Yozgat, Turkey; [Karabacak, Tuba] Mersin Univ, Sch Med, Mersin, Turkey; [Erbarut Seven, Ipek; Ataizi Celikel, Cigdem] Marmara Univ, Sch Med, Pendik Training & Res Hosp, Dept Pathol, Istanbul, Turkey; [Gucin, Zuhal] Bezmialem Fdn Univ, Sch Med, Dept Med Pathol, Istanbul, Turkey	Esendagli, G (reprint author), Univ Gazi, Dept Med Pathol, Sch Med, Ankara, Turkey.	drguldal@yahoo.com	Karslioglu, Yildirim/Q-1442-2019; Ozdamar, Sukru O/J-2209-2016; BALCI, Serdar/B-6401-2011; Abdullazade, Samir/H-2455-2011	BALCI, Serdar/0000-0002-7852-3851; Abdullazade, Samir/0000-0002-9119-8301			Abraham S., 2002, SURG PATHOLOGY DISSE, P82; Adsay NV, 2015, STERNBERGS DIAGNOSTI, P1770; Adsay V, 2016, MODERN PATHOL, V29, p438A; Adsay V, 2013, AM J CLIN PATHOL, V140, P278, DOI 10.1309/AJCPUJPGQIZ6DC6A; Albores-Saavedra J, 2015, AFIP ATLAS TUMOR PAT, P31; Albores-Saavedra J, 2000, ATLAS TUMOR PATHOLOG, V27; Albores-Saavedra J, 2011, AM J CLIN PATHOL, V135, P637, DOI 10.1309/AJCPFRKCFEDLV03Y; ALBORESSAAVEDRA J, 1980, CANCER, V45, P919, DOI 10.1002/1097-0142(19800301)45:5<919::AID-CNCR2820450514>3.0.CO;2-4; ALBORESSAAVEDRA J, 1993, PATHOL ANNU, V28, P145; Allen DC, 2013, HISTOPATHOLOGY SPECI, P95; Aloia TA, 2015, HPB, V17, P681, DOI 10.1111/hpb.12444; Argon A, 22 UL PAT K SOZL BIL; Bahadir B, 2007, AKAD GASTROENTEROLOJ, V6, P25; BIVINS BA, 1975, SOUTHERN MED J, V68, P297, DOI 10.1097/00007611-197503000-00009; Bolat F, 2007, TURK J PATHOL, V23, P137; DUARTE I, 1993, CANCER-AM CANCER SOC, V72, P1878, DOI 10.1002/1097-0142(19930915)72:6<1878::AID-CNCR2820720615>3.0.CO;2-2; Dursun N, 2014, MODERN PATHOL, V27, p173A; Federasyonu Patoloji Dernekleri, 2013, SAFRA KESESI VE SAFR; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Hartman D, 2013, AM J CLIN PATHOL, V139, P830, DOI 10.1309/AJCP90LNQAKHZQBQ; KIJIMA H, 1989, ACTA PATHOL JAPON, V39, P235; Koca SB, 2011, 21 UL PAT K 16 20 KA; KOZUKA S, 1982, CANCER, V50, P2226, DOI 10.1002/1097-0142(19821115)50:10<2226::AID-CNCR2820501043>3.0.CO;2-3; Mazlum M, 2011, TURK J PATHOL, V27, P23, DOI 10.5146/tjpath.2010.01042; OJEDA VJ, 1985, PATHOLOGY, V17, P451, DOI 10.3109/00313028509105499; Patel K, 2014, MODERN PATHOL, V27, p452A; Patel K, 2016, WORLD J GASTRO SURG, V8, P685, DOI 10.4240/wjgs.v8.i10.685; Raziel A, 2015, ISR MED ASSOC J, V17, P703; Renshaw AA, 2012, AM J CLIN PATHOL, V138, P374, DOI 10.1309/AJCPB0ZTXXIF6MOF; Rosai J., 2011, ROSAI ACKERMANS SURG, V2, P2601; Sasatomi E, 2000, J Hepatobiliary Pancreat Surg, V7, P556, DOI 10.1007/s005340070004; Talreja Vikash, 2016, Surg Res Pract, V2016, P9319147, DOI 10.1155/2016/9319147; Tantia O, 2009, SURG ENDOSC, V23, P2041, DOI 10.1007/s00464-008-9950-8; Tuncel D, 2015, CUKUROVA MED J, V40, P452; Utsumi Masashi, 2017, BMC Res Notes, V10, P56, DOI 10.1186/s13104-017-2387-1; Wrenn SM, 2017, SURG ENDOSC, V31, P586, DOI 10.1007/s00464-016-5002-y; YAMAGIWA H, 1989, JPN J CANCER RES, V80, P238, DOI 10.1111/j.1349-7006.1989.tb02299.x; Yamamoto H, 2005, J HEPATO-BILIARY-PAN, V12, P391, DOI 10.1007/s00534-005-0996-x; Yildirim M, 2005, MEAND MED DENT J, V6, P27	39	1	1	1	2	FEDERATION TURKISH PATHOLOGY SOC	ANKARA	YILDIZEVLER MAH RABINDRANATH TAGORE CAD 29-5 CANKAYA, ANKARA, 00000, TURKEY	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					41	48		10.5146/tjpath.2017.01404			8	Pathology	Pathology	GH2RY	WOS:000433250700004	28984336	DOAJ Gold			2019-10-28	
J	Diehl, L; Meyerholz, DK; Day, MJ; Affolter, VK				Diehl, Lauri; Meyerholz, David K.; Day, Michael J.; Affolter, Verena K.			Pathology and Pathogenesis of Immune-Mediated Diseases of Animals	VETERINARY PATHOLOGY			English	Editorial Material							MODELS		[Diehl, Lauri] Genentech Inc, San Francisco, CA USA; [Meyerholz, David K.] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA; [Day, Michael J.] Univ Bristol, Bristol, Avon, England; [Affolter, Verena K.] Univ Calif Davis, Sch Vet Med, Davis, CA 95616 USA	Meyerholz, DK (reprint author), Univ Iowa, Dept Pathol, Carver Coll Med, Med Res Ctr 145, Iowa City, IA 52242 USA.	david-meyerholz@uiowa.edu	Meyerholz, David/J-8131-2019	Meyerholz, David/0000-0003-1552-3253	NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30 DK054759]		Aleman M, 2008, NEUROMUSCULAR DISORD, V18, P277, DOI 10.1016/j.nmd.2008.01.001; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Cadena AM, 2017, NAT REV IMMUNOL, V17, P691, DOI 10.1038/nri.2017.69; Carstens PO, 2014, CLIN EXP IMMUNOL, V175, P349, DOI 10.1111/cei.12194; Cooper CJ, 2018, VET PATHOL, V55, P159, DOI 10.1177/0300985817720983; Durward-Akhurst SA, 2018, VET PATHOL, V55, P68, DOI 10.1177/0300985816688755; Evans J, 2004, J VET INTERN MED, V18, P679, DOI 10.1892/0891-6640(2004)18<679:CIMACR>2.0.CO;2; Ferrari CR, 2018, VET PATHOL, V55, P144, DOI 10.1177/0300985817741729; Friedenberg SG, 2018, VET PATHOL, V55, P177, DOI 10.1177/0300985816684914; Goulet S, 2018, VET PATHOL, V55, P108, DOI 10.1177/0300985816688746; Jeffery U, 2018, VET PATHOL, V55, P116, DOI 10.1177/0300985817699860; Lassmann H, 2017, ACTA NEUROPATHOL, V133, P223, DOI 10.1007/s00401-016-1631-4; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Martinot AJ, 2018, VET PATHOL, V55, P14, DOI 10.1177/0300985817705177; Matsumoto I, 2018, VET PATHOL, V55, P98, DOI 10.1177/0300985817690212; Meyerholz DK, 2018, VET PATHOL, V55, P42, DOI 10.1177/0300985817726117; Ohfuji S, 2018, VET PATHOL, V55, P182, DOI 10.1177/0300985817736115; Palmer MV, 2018, VET PATHOL, V55, P8, DOI 10.1177/0300985817712795; Pasolini MP, 2018, VET PATHOL, V55, P133, DOI 10.1177/0300985817716262; Richter KR, 2018, VET PATHOL, V55, P53, DOI 10.1177/0300985817725388; Rosa FB, 2018, VET PATHOL, V55, P124, DOI 10.1177/0300985817738316; Sagar S, 2015, EUR J PHARMACOL, V759, P272, DOI 10.1016/j.ejphar.2015.03.037; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Stimmer L, 2018, VET PATHOL, V55, P27, DOI 10.1177/0300985817712794; van der Worp HB, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000245; Vogel P, 2018, VET PATHOL, V55, P76, DOI 10.1177/0300985817705174; Yamada N, 2018, VET PATHOL, V55, P173, DOI 10.1177/0300985817712556	27	1	1	0	2	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		5	7		10.1177/0300985817739091			3	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300001	29254471				2019-10-28	
J	Meyerholz, DK; Sieren, JC; Beck, AP; Flaherty, HA				Meyerholz, David K.; Sieren, Jessica C.; Beck, Amanda P.; Flaherty, Heather A.			Approaches to Evaluate Lung Inflammation in Translational Research	VETERINARY PATHOLOGY			English	Review						airways; animal models of human disease; cytology; imaging; immunology; inflammation; lung; mice; morphometry; pathology; respiratory	POSITRON-EMISSION-TOMOGRAPHY; SYNCYTIAL VIRUS-INFECTION; NITRIC-OXIDE SYNTHASE; SURFACTANT PROTEIN D; BRONCHOALVEOLAR LAVAGE; CYSTIC-FIBROSIS; MOUSE MODEL; LONGITUDINAL CHARACTERIZATION; PULMONARY INFLAMMATION; MACROPHAGE ACTIVATION	Inflammation is a common feature in several types of lung disease and is a frequent end point to validate lung disease models, evaluate genetic or environmental impact on disease severity, or test the efficacy of new therapies. Questions relevant to a study should be defined during experimental design and techniques selected to specifically address these scientific queries. In this review, the authors focus primarily on the breadth of techniques to evaluate lung inflammation that have both clinical and preclinical applications. Stratification of approaches to assess lung inflammation can diminish weaknesses inherent to each technique, provide data validation, and increase the reproducibility of a study. Specialized techniques (eg, imaging, pathology) often require experienced personnel to collect, evaluate, and interpret the data; these experts should be active contributors to the research team through reporting of the data. Scoring of tissue lesions is a useful method to transform observational pathologic data into semiquantitative or quantitative data for statistical analysis and enhanced rigor. Each technique to evaluate lung inflammation has advantages and limitations; understanding these parameters can help identify approaches that best complement one another to increase the rigor and translational significance of data.	[Meyerholz, David K.] Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, 500 Newton Rd,1165ML, Iowa City, IA 52242 USA; [Sieren, Jessica C.] Univ Iowa, Dept Radiol, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Sieren, Jessica C.] Univ Iowa, Dept Biomed Engn, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; [Beck, Amanda P.] Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; [Flaherty, Heather A.] Iowa State Univ, Dept Vet Pathol, Ames, IA USA	Meyerholz, DK (reprint author), Univ Iowa, Dept Pathol, Roy J & Lucille A Carver Coll Med, 500 Newton Rd,1165ML, Iowa City, IA 52242 USA.	david-meyerholz@uiowa.edu	Meyerholz, David/J-8131-2019	Meyerholz, David/0000-0003-1552-3253; Sieren, Jessica/0000-0002-1109-7886	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HL051670, P01 HL091842, P30 DK054759, R01 HL112986]; Cystic Fibrosis Foundation Research and Development Program	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the National Institutes of Health (P01 HL051670, P01 HL091842, P30 DK054759, and R01 HL112986) and the Cystic Fibrosis Foundation Research and Development Program.	Abdulla S, 2014, EUR J NUCL MED MOL I, V41, P350, DOI 10.1007/s00259-013-2579-4; Adissu HA, 2014, DIS MODEL MECH, V7, P515, DOI 10.1242/dmm.015263; Aeffner F, ARCH PATHOL LAB MED; Amin R, 2012, RADIOLOGY, V264, P868, DOI 10.1148/radiol.12111873; Antonucci TC, 2015, RES HUM DEV, V12, P342, DOI 10.1080/15427609.2015.1068035; Anzola LK, 2015, Q J NUCL MED MOL IM, V59, P197; Bartlett JA, 2016, AM J RESP CRIT CARE, V194, P845, DOI 10.1164/rccm.201510-2112OC; Begley CG, 2012, NATURE, V483, P531, DOI 10.1038/483531a; Beigelman-Aubry C, 2012, Diagn Interv Imaging, V93, P431, DOI 10.1016/j.diii.2012.04.021; Bertram CA, 2017, VET PATHOL, V54, P756, DOI 10.1177/0300985817709888; Biederer J, 2012, INSIGHTS IMAGING, V3, P355, DOI 10.1007/s13244-011-0146-8; Biederer J, 2012, INSIGHTS IMAGING, V3, P373, DOI 10.1007/s13244-011-0142-z; Bont L, 1999, EUR RESPIR J, V14, P144, DOI 10.1034/j.1399-3003.1999.14a24.x; Borish L, 2016, ANN ALLERG ASTHMA IM, V117, P108, DOI 10.1016/j.anai.2016.04.022; Bosson JA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081816; Braber S, 2010, AM J PHYSIOL-LUNG C, V299, pL843, DOI 10.1152/ajplung.00192.2010; Branchfield K, 2016, SCIENCE, V351, P707, DOI 10.1126/science.aad7969; Brayton CF, 2012, VET PATHOL, V49, P85, DOI 10.1177/0300985811430696; Brehm M, 2015, MED PHYS, V42, P1948, DOI 10.1118/1.4916083; Brown DL, 2017, VET PATHOL, V54, P358, DOI 10.1177/0300985817695781; Buckles EL, 2017, NECROPSY GUIDE DOGS, P69; Bustin Stephen A, 2016, Biomol Detect Quantif, V7, pA1, DOI 10.1016/j.bdq.2015.11.002; Bustin SA, 2013, NAT METHODS, V10, P1063, DOI 10.1038/nmeth.2697; Casadevall A, 2016, MBIO, V7; Changani K, 2013, CLIN SCI, V125, P555, DOI 10.1042/CS20130086; Chen DL, 2006, MOL PHARMACEUT, V3, P488, DOI 10.1021/mp060050w; Chen DL, 2006, AM J RESP CRIT CARE, V173, P1363, DOI 10.1164/rccm.200506-934OC; Cohen TS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad9922; Cooper TK, 2017, VET PATHOL, V54, P178, DOI 10.1177/0300985816658102; Cray C, 2009, COMPARATIVE MED, V59, P517; Czernik C, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-164; Darzynkiewicz Z, 2001, SEMIN HEMATOL, V38, P179, DOI 10.1053/shem.2001.21929; Daubeuf Francois, 2012, Curr Protoc Mouse Biol, V2, P167, DOI 10.1002/9780470942390.mo110201; Donnenberg Albert D., 2008, P181, DOI 10.1201/9781420003710.ch6; Duan YL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-4; Dunstan RW, 2011, TOXICOL PATHOL, V39, P988, DOI 10.1177/0192623311419163; Eichinger M, 2012, EUR J RADIOL, V81, P1321, DOI 10.1016/j.ejrad.2011.02.045; Finke MD, 2013, TOP COMPANION ANIM M, V28, P97, DOI 10.1053/j.tcam.2013.06.003; Fulton RB, 2010, J IMMUNOL, V185, P2382, DOI 10.4049/jimmunol.1000423; George CLS, 2008, INFECT IMMUN, V76, P380, DOI 10.1128/IAI.01043-07; Gibson-Corley KN, 2013, VET PATHOL, V50, P1007, DOI 10.1177/0300985813485099; Grecchi E, 2016, MOL IMAGING BIOL, V18, P143, DOI 10.1007/s11307-015-0871-3; Guo XL, 2012, PHYS MED BIOL, V57, P257, DOI 10.1088/0031-9155/57/1/257; Hammond E, 2016, TOXICOL PATHOL, V44, P373, DOI 10.1177/0192623315622303; Harris RS, 2011, J NUCL MED, V52, P1713, DOI 10.2967/jnumed.110.086355; Hartwig W, 2002, CRIT CARE MED, V30, P2075, DOI 10.1097/01.CCM.0000020985.14851.06; HELMERS RA, 1989, J APPL PHYSIOL, V67, P1443; HENDERSON AJW, 1994, ARCH DIS CHILD, V70, P167, DOI 10.1136/adc.70.3.167; Hofman P, 2016, VIRCHOWS ARCH, V469, P601, DOI 10.1007/s00428-016-2004-z; Johnson Paula D, 2002, ILAR J, V43, P202; JONES HA, 1994, AM J RESP CRIT CARE, V149, P1635, DOI 10.1164/ajrccm.149.6.7516252; Kamata T, 2017, BLOOD, V130, P514, DOI 10.1182/blood-2017-02-770149; Karimi R, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-23; Keijsers RGM, 2013, EUR RESPIR J, V41, P743, DOI 10.1183/09031936.00088612; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; King JM, 2014, NECROPSY BOOK GUIDE; Klesney-Tait J, 2013, J CLIN INVEST, V123, P138, DOI 10.1172/JCI64181; Knudsen L, 2015, AM J PHYSIOL-LUNG C, V309, pL959, DOI 10.1152/ajplung.00017.2015; Knudson CJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004757; Kwon BI, 2013, AM J RESP CRIT CARE, V188, P577, DOI 10.1164/rccm.201302-0295OC; Ladiges W, 2013, PATHOBIOL AGING AGE, P3, DOI DOI 10.3402/PBA.V3I0.22451; Landolfi JA, 2015, VET PATHOL, V52, P535, DOI 10.1177/0300985814548517; Lazic T, 2007, ALCOHOL, V41, P347, DOI 10.1016/j.alcohol.2007.07.006; Liebler JM, 2016, AM J PHYSIOL-LUNG C, V310, pL114, DOI 10.1152/ajplung.00337.2015; Liu Y, 2013, CLIN REV ALLERG IMMU, V45, P314, DOI 10.1007/s12016-013-8398-3; Luciw PA, 2011, AM J PHYSIOL-LUNG C, V301, pL731, DOI 10.1152/ajplung.00120.2011; Malaviya R, 2015, TOXICOL SCI, V144, P27, DOI 10.1093/toxsci/kfu255; McInnes EF, 2011, BACKGROUND LESIONS I, P93; Medeiros AI, 2015, BIOMED RES INT, DOI 10.1155/2015/409309; Mesnil C, 2016, J CLIN INVEST, V126, P3279, DOI 10.1172/JCI85664; Meyerholz DK, 2016, NATURE, V532, P177, DOI 10.1038/532177c; Miller GW, 2014, NMR BIOMED, V27, P1542, DOI 10.1002/nbm.3156; Mori H, 2015, TOXICOL PATHOL, V43, P883, DOI 10.1177/0192623315587593; Morton J, 2017, PATHOBIOL AGING AGE, V7; Moses WW, 2011, NUCL INSTRUM METH A, V648, pS236, DOI 10.1016/j.nima.2010.11.092; Mukhopadhyay S, 2012, MODERN PATHOL, V25, pS43, DOI 10.1038/modpathol.2011.153; Musch G, 2007, ANESTHESIOLOGY, V106, P723, DOI 10.1097/01.anes.0000264748.86145.ac; Namati E, 2006, PHYS MED BIOL, V51, P6061, DOI 10.1088/0031-9155/51/23/008; Nehmeh SA, 2008, SEMIN NUCL MED, V38, P167, DOI 10.1053/j.semnuclmed.2008.01.002; Okada S, 2013, CYTOKINE, V63, P194, DOI 10.1016/j.cyto.2013.04.035; Olivier AK, 2012, J HISTOTECHNOL, V35, P63, DOI 10.1179/2046023612Y.0000000003; Petruzzi N, 2009, SEMIN NUCL MED, V39, P115, DOI 10.1053/j.semnuclmed.2008.10.005; Radaelli E, 2016, VET PATHOL, V53, P477, DOI 10.1177/0300985815608673; Radhakrishnan D, 2014, PEDIATRICS, V134, P135, DOI 10.1542/peds.2013-1911; Raju B, 2008, TUBERCULOSIS, V88, P39, DOI 10.1016/j.tube.2007.07.003; Rodrigues MR, 2002, BIOCHEM BIOPH RES CO, V292, P869, DOI 10.1006/bbrc.2002.6724; Rodriguez F, 2004, J COMP PATHOL, V130, P306, DOI 10.1016/j.jcpa.2003.12.008; Rollins KE, 2012, VET PATHOL, V49, P362, DOI 10.1177/0300985812436745; Russell WMS, 1959, PRINCIPLES OF HUMANE; Schuster DP, 2003, EXP LUNG RES, V29, P45, DOI 10.1080/01902140303760; Scudamore CL, 2016, J PATHOL, V238, P359, DOI 10.1002/path.4642; Scudamore Cheryl L, 2014, Curr Protoc Mouse Biol, V4, P1, DOI 10.1002/9780470942390.mo130200; Shackelford C, 2002, TOXICOL PATHOL, V30, P93, DOI 10.1080/01926230252824761; Shah VS, 2016, SCIENCE, V351, P503, DOI 10.1126/science.aad5589; Srinivasan M, 2002, AM J PATHOL, V161, P1961, DOI 10.1016/S0002-9440(10)64472-0; Stoltz DA, 2015, NEW ENGL J MED, V372, P1574, DOI 10.1056/NEJMc1502191; Stoltz DA, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000928; Strenge KS, 2015, LABMEDICINE, V46, P4, DOI 10.1309/LMLJHG4E2UZKD7RG; Strobel K, 2012, MAGN RESON MED, V68, P1924, DOI 10.1002/mrm.24180; Suarez CS, 2012, COMP ANATOMY HISTOLO, P121; Torrano V, 2016, CURR OPIN PHARMACOL, V29, P47, DOI 10.1016/j.coph.2016.06.003; Treuting PM, 2016, VET PATHOL, V53, P244, DOI 10.1177/0300985815620629; TYLER WS, 1983, AM REV RESPIR DIS, V128, pS32; Ubags NDJ, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.82101; Vande Velde G, 2016, DIS MODEL MECH, V9, P91, DOI 10.1242/dmm.020321; Vaneker M, 2007, ANESTHESIOLOGY, V107, P419, DOI 10.1097/01.anes.0000278908.22686.01; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Vidal S, 2012, IMMUNOBIOLOGY, V217, P692, DOI 10.1016/j.imbio.2011.11.008; Vrolyk V, 2017, VET PATHOL, V54, P129, DOI 10.1177/0300985816646432; Ward JM, 2016, VET PATHOL, V53, P229, DOI 10.1177/0300985815612151; Weiss KA, 2011, J IMMUNOL, V187, P3145, DOI 10.4049/jimmunol.1100764; Weissleder R, 2016, SCI TRANSL MED, V8, pps16; Whittle C, 2014, DIAGNOSTIC IMAGING OF INFECTIONS AND INFLAMMATORY DISEASES: A MULTIDISCIPLINARY APPROACH, P75; Wilson SJ, 2013, J TOXICOL ENV HEAL A, V76, P176, DOI 10.1080/15287394.2013.752323; Wu CX, 2013, THERANOSTICS, V3, P448, DOI 10.7150/thno.6592; Young LR, 2006, J IMMUNOL, V176, P4361, DOI 10.4049/jimmunol.176.7.4361; Zeiss CJ, 2012, VET PATHOL, V49, P24, DOI 10.1177/0300985811417247; Zhao T, 2016, AM J PATHOL, V186, P2183, DOI 10.1016/j.ajpath.2016.04.014; Zhou ZH, 2005, AM J PHYSIOL-LUNG C, V289, pL760, DOI 10.1152/ajplung.00146.2005	119	6	6	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		42	52		10.1177/0300985817726117			11	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300006	28812529	Bronze, Green Accepted			2019-10-28	
J	Goulet, S; Blais, MC				Goulet, S.; Blais, M. C.			Characterization of Anti-Dal Alloantibodies Following Sensitization of Two Dal-Negative Dogs	VETERINARY PATHOLOGY			English	Article						agglutination; blood type; crossmatch; dog erythrocyte antigen; transfusion	HEMOLYTIC TRANSFUSION REACTIONS; VITRO BIOTINYLATION TECHNIQUE; BLOOD-CELL SURVIVAL; IN-VITRO; GEL COLUMN; SYSTEMS; ANTIBODIES; MEDICINE; ANIMALS	Since its discovery, the immunogenicity of the Dal blood type has not been further investigated. The aim of this study was to better characterize anti-Dal alloantibodies produced following sensitization of Dal-negative dogs, notably their rate of appearance, the agglutination titer over time, and their immunoglobulin class. A secondary objective was to obtain polyclonal anti-Dal alloantibodies to increase the availability of Dal blood typing. Of 100 healthy laboratory Beagles tested, 2 Dal-negative dogs were identified as recipients. Ten healthy Dal-positive dogs were investigated as potential blood donors. All dogs were extensively blood typed for DEA 1, 3, 4, 5, and 7, as well as for Dal. Then, the recipients were transfused uneventfully with 10 ml/kg of Dal-positive but otherwise compatible packed red blood cells. Posttransfusion blood samples were collected routinely over a minimum of 1 year. Using a gel column technology, anti-Dal alloantibodies were detected as early as 4 days posttransfusion and remained detectable 2 years posttransfusion, with maximum agglutination titers reached at 1 and 2 months posttransfusion. The immunoglobulin class was IgG. The immunogenicity and clinical significance of the Dal blood type were confirmed. The results support the recommendations that previously transfused dogs be crossmatched starting 4 days posttransfusion and for the animal's lifetime. The polyclonal anti-Dal antibodies produced will allow blood typing of a significant number of dogs, especially transfused dogs facing blood incompatibilities and canine blood donors.	[Goulet, S.; Blais, M. C.] Univ Montreal, Fac Med Vet, Dept Clin Sci, 1500 Ave Vet, St Hyacinthe, PQ J2S 2M2, Canada	Blais, MC (reprint author), Univ Montreal, Fac Med Vet, Dept Clin Sci, 1500 Ave Vet, St Hyacinthe, PQ J2S 2M2, Canada.	mc.blais@umontreal.ca			Association des Medecins Veterinaires du Quebec	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Association des Medecins Veterinaires du Quebec.	Abrams-Ogg A., 2000, MANUAL CANINE FELINE, P263; Acierno MM, 2014, J VET INTERN MED, V28, P592, DOI 10.1111/jvim.12321; Blais MC, 2007, J VET INTERN MED, V21, P281, DOI 10.1892/0891-6640(2007)21[281:CDBTAR]2.0.CO;2; Boysen SR, 2015, CLIN VET ADVISOR DOG, P1132; Bruce JA, 2015, J VET EMERG CRIT CAR, V25, P620, DOI 10.1111/vec.12327; CALLAN MB, 1995, J VET INTERN MED, V9, P277, DOI 10.1111/j.1939-1676.1995.tb01080.x; CHRISTIAN RM, 1951, BLOOD, V6, P142, DOI 10.1182/blood.V6.2.142.142; CHRISTIAN RM, 1951, J IMMUNOL, V66, P37; Couto CG, 2003, SMALL ANIMAL INTERNA, P1156; EJIMA H, 1986, JPN J VET SCI, V48, P363; Friday J, 2008, AM ASS BLOOD BANKS T; Gibson G., 2007, BSAVA manual of canine and feline emergency and critical care, P215; Gibson G, 2012, BSAVA MANUAL CANINE, P289; GIGER U, 1995, J AM VET MED ASSOC, V206, P1358; Goulet S, 2014, ACVIM FORUM; Harmening DM, 2012, MODERN BLOOD BANKING, P293; Hohenhaus AE, 2004, TRANSFUS MED REV, V18, P117, DOI 10.1016/j.tmrv.2003.12.003; Hohenhaus AE., 2010, TXB VET INTERNAL MED, P537; Kessler RJ, 2010, VET CLIN PATH, V39, P306, DOI 10.1111/j.1939-165X.2010.00249.x; Korell J, 2011, J PHARMACOKINET PHAR, V38, P787, DOI 10.1007/s10928-011-9220-6; Korell J, 2011, J THEOR BIOL, V291, P88, DOI 10.1016/j.jtbi.2011.09.016; Lanevschi A, 2001, CAN VET J, V42, P447; McDevitt RI, 2011, J VET EMERG CRIT CAR, V21, P209, DOI 10.1111/j.1476-4431.2011.00634.x; Melzer KJ, 2003, J VET INTERN MED, V17, P931, DOI 10.1892/0891-6640(2003)017<0931:AHTRDT>2.3.CO;2; Mock DM, 2014, TRANSFUS MED REV, V28, P114, DOI 10.1016/j.tmrv.2014.03.003; Novinger MS, 1996, AM J VET RES, V57, P739; Ottenberg R, 1913, J MED RES, V28, P141; PANZER S, 1987, LANCET, V1, P474; Patterson J, 2011, J VET INTERN MED, V25, P927, DOI 10.1111/j.1939-1676.2011.0737.x; Seth M, 2012, AM J VET RES, V73, P213, DOI 10.2460/ajvr.73.2.213; SWISHER SN, 1962, ANN NY ACAD SCI, V97, P15; SWISHER SN, 1961, PHYSIOL REV, V41, P495; Tocci LJ, 2010, VET CLIN N AM-SMALL, V40, P485, DOI 10.1016/j.cvsm.2010.02.005; VRIESENDORP HM, 1976, TRANSPL P, V8, P289; Wardrop KJ, 1998, AM J VET RES, V59, P397; Weisbach V, 1999, TRANSFUSION, V39, P1045, DOI 10.1046/j.1537-2995.1999.39101045.x; YOUNG LE, 1949, BLOOD, V4, P1218, DOI 10.1182/blood.V4.11.1218.1218; YOUNG LE, 1952, AM J VET RES, V13, P207; YUILE CL, 1949, BLOOD, V4, P1232, DOI 10.1182/blood.V4.11.1232.1232	39	3	3	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		108	115		10.1177/0300985816688746			8	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300011	28129096				2019-10-28	
J	Rosa, FB; Older, CE; Meason-Smith, C; Suchodolski, JS; Lingsweiler, S; Mansell, JE; Hoffmann, AR				Rosa, Fabio B.; Older, Caitlin E.; Meason-Smith, Courtney; Suchodolski, Jan S.; Lingsweiler, Sonia; Mansell, Joanne E.; Hoffmann, Aline Rodrigues			Analysis of Bacterial and Fungal Nucleic Acid in Canine Sterile Granulomatous and Pyogranulomatous Dermatitis and Panniculitis	VETERINARY PATHOLOGY			English	Article						canine; skin; sterile; pyogranulomatous; granulomatous; dermatitis; Sterile granuloma and pyogranuloma syndrome	SKIN MICROBIOME; PYOGRANULOMA/GRANULOMA SYNDROME; CUTANEOUS LEISHMANIASIS; ATOPIC-DERMATITIS; DIVERSITY; CONTAMINATION; COMMUNITIES; DISEASE; IMPACT; TEXAS	Next generation sequencing (NGS) studies are revealing a diverse microbiota on the skin of dogs. The skin microbiota of canine sterile granulomatous and pyogranulomatous dermatitis (SGPD) has yet to be investigated using NGS techniques. NGS targeting the 16S rRNA and ITS-1 region of bacterial and fungal DNA, respectively, were used to investigate if bacterial and fungal DNA were associated with skin lesions in cases of canine SGPD. The study included 20 formalin-fixed paraffin-embedded (FFPE) skin samples and 12 fresh samples from SGPD-affected dogs, and 10 FFPE and 10 fresh samples from healthy dogs. DNA was extracted from deep dermis and panniculus, and microbial DNA was amplified using primers targeting the bacterial 16S rRNA V1-V3 and fungal ITS-1 regions. The amplified DNA was utilized for NGS on an Illumina MiSeq instrument. The sequences were processed using QIIME. No differences in fungal or bacterial alpha diversity were observed between the SGPD and control samples. Beta diversity analysis demonstrated differences in the bacterial communities between SGPD and control, but not in the fungal communities. Compared to controls, the family Erysipelotrichaceae and genus Staphylococcus were significantly more abundant in the SGPD FFPE samples, and genus Corynebacterium were more abundant in fresh samples. The bacteria found to be more abundant in SGPD are common inhabitants of skin surfaces, and likely secondary contaminants in SGPD cases. This study provides additional evidence that SGPD lesions are likely sterile.	[Rosa, Fabio B.; Older, Caitlin E.; Meason-Smith, Courtney; Mansell, Joanne E.; Hoffmann, Aline Rodrigues] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA; [Suchodolski, Jan S.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Small Anim Clin Sci, College Stn, TX USA; [Lingsweiler, Sonia] Texas A&M Vet Med Diagnost Labs, College Stn, TX USA	Hoffmann, AR (reprint author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.	arodrigues@cvm.tamu.edu		Smith, Courtney/0000-0002-5189-2702; Older, Caitlin/0000-0001-7007-5815	Coordination for the Improvement of Higher Education Personnel CAPES-BrazilCAPES [99999.006281/2015-00]	Fabio B. Rosa's visitor scholar fellowship was supported by the Coordination for the Improvement of Higher Education Personnel CAPES-Brazil, project no. 99999.006281/2015-00.	BARNES JC, 1993, J AM VET MED ASSOC, V202, P416; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bradley CW, 2016, J INVEST DERMATOL, V136, P1182, DOI 10.1016/j.jid.2016.01.023; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cornegliani L, 2005, VET DERMATOL, V16, P233, DOI 10.1111/j.1365-3164.2005.00425.x; Cornegliani L, 2015, VET DERMATOL, V26, P186, DOI 10.1111/vde.12208; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Findley K, 2013, NATURE, V498, P367, DOI 10.1038/nature12171; Grice EA, 2008, GENOME RES, V18, P1043, DOI 10.1101/gr.075549.107; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; HARVEY RG, 1995, VET DERMATOL, V6, P79, DOI 10.1111/j.1365-3164.1995.tb00047.x; Kawarai S, 2014, J AM ANIM HOSP ASSOC, V50, P278, DOI 10.5326/JAAHA-MS-6009; Kong HH, 2012, J INVEST DERMATOL, V132, P933, DOI 10.1038/jid.2011.417; Kong HDH, 2011, TRENDS MOL MED, V17, P320, DOI 10.1016/j.molmed.2011.01.013; Lazarevic V, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0689-4; Lozupone C, 2005, APPL ENVIRON MICROB, V71, P8228, DOI 10.1128/AEM.71.12.8228-8235.2005; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Meason-Smith C, 2017, VET DERMATOL, V28, P71, DOI 10.1111/vde.12373; Meason-Smith C, 2015, FEMS MICROBIOL ECOL, V91, DOI 10.1093/femsec/fiv139; Meisel JS, 2016, J INVEST DERMATOL, V136, P947, DOI 10.1016/j.jid.2016.01.016; Nakatsuji T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2441; Petersen CA, 2009, TOP COMPANION ANIM M, V24, P182, DOI 10.1053/j.tcam.2009.06.006; Pierezan F, 2016, VET DERMATOL, V27, P332, DOI 10.1111/vde.12366; Rodrigues-Hoffman A, 2014, PLOS ONE, V9; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Santoro D, 2008, J SMALL ANIM PRACT, V49, P552, DOI [10.1111/j.1748-5827.2008.00638x, 10.1111/j.1748-5827.2008.00638.x]; Santoro D, 2008, CAN VET J, V49, P1204; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; SELLON RK, 1993, J VET INTERN MED, V7, P16, DOI 10.1111/j.1939-1676.1993.tb03163.x; Suchodolski JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051907; Torres SMF, 1999, VET CLIN N AM-SMALL, V29, P1311, DOI 10.1016/S0195-5616(99)50129-0; Trainor KE, 2010, VET PATHOL, V47, P1076, DOI 10.1177/0300985810382094; Vazquez-Baeza Y, 2013, GIGASCIENCE, V2, DOI 10.1186/2047-217X-2-16; Weese JS, 2013, VET DERMATOL, V24, P137, DOI 10.1111/j.1365-3164.2012.01076.x; Weiss S, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0564-2; Werner JJ, 2012, ISME J, V6, P94, DOI 10.1038/ismej.2011.82	36	2	2	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	JAN	2018	55	1			SI		124	132		10.1177/0300985817738316			9	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	FQ4DR	WOS:000418308300013	29145794				2019-10-28	
J	Assarzadegan, N; Montgomery, E; Anders, RA				Assarzadegan, Naziheh; Montgomery, Elizabeth; Anders, Robert A.			Immune checkpoint inhibitor colitis: the flip side of the wonder drugs	VIRCHOWS ARCHIV			English	Review						Colitis; Immune checkpoint inhibitors; PD-L1	GASTROINTESTINAL-TRACT; CANCER-IMMUNOTHERAPY; ADVANCED MELANOMA; ADVERSE EVENTS; THERAPY; IPILIMUMAB; BLOCKADE; TOXICITIES; IDELALISIB; INJURY	Immune checkpoint inhibitors block the co-inhibitory receptors on T cells to activate their cytotoxic immune function and are rapidly being explored for the treatment of various advanced-stage malignancies. These novel drugs have already significantly increased survival rates. The first available immune checkpoint inhibitors were cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors (such as ipilimumab), followed by programmed cell death protein 1 (PD-1) and programmed cell death protein ligand 1 (PD-L1) inhibitors (such as pembrolizumab and nivolumab). Anti-PD-1 and anti-PD-L1 therapies have demonstrated better efficacy and tolerability and less severe adverse effects compared to anti-CTLA-4 agents. Idelalisib, a PI3K delta isoform inhibitor, is another immunotherapeutic agent that is often classified separately and is currently used in treatment of chronic lymphocytic leukemia and non-Hodgkin lymphomas. Despite successful therapeutic responses, immune-related adverse events have been reported with the use of these agents. The gastrointestinal side effects, particularly diarrhea, are among the most commonly reported symptoms. The histologic features of immune checkpoint inhibitor-associated colitis show a spectrum of patterns of injury among various drug classes. There is significant overlap between immune checkpoint inhibitor-associated colitis and other colitides, making the differential diagnosis difficult-especially in the absence of clinical history. The histopathology data on immune checkpoint inhibitor-associated colitis are limited. Here we review clinical features as well as various histologic patterns of colitis associated with these groups of medications.	[Assarzadegan, Naziheh] Univ Florida, Gainesville, FL USA; [Montgomery, Elizabeth; Anders, Robert A.] Johns Hopkins Med Inst, Baltimore, MD 21205 USA	Assarzadegan, N (reprint author), Univ Florida, Gainesville, FL USA.	nassarzadegan@ufl.edu					Andrade RJ, 2005, GASTROENTEROLOGY, V129, P512, DOI 10.1053/j.gastro.2005.05.006; Arnold CA, 2015, ATLAS GASTROINTESTIN; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Baroudjian B, 2016, MELANOMA RES, V26, P308, DOI 10.1097/CMR.0000000000000252; Bavi P, 2017, HISTOPATHOLOGY, V71, P494, DOI 10.1111/his.13224; Beck KE, 2006, J CLIN ONCOL, V24, P2283, DOI 10.1200/JCO.2005.04.5716; Chen JH, 2017, AM J SURG PATHOL, V41, P643, DOI 10.1097/PAS.0000000000000829; Dolan DE, 2014, CANCER CONTROL, V21, P231, DOI 10.1177/107327481402100308; FAY AP, 2016, EXPERT REV QUAL LIFE, V1, P89, DOI DOI 10.1080/23809000.2016.1142827; Fecher LA, 2013, ONCOLOGIST, V18, P733, DOI 10.1634/theoncologist.2012-0483; Furman RR, 2014, NEW ENGL J MED, V370, P997, DOI 10.1056/NEJMoa1315226; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gonzalez RS, 2017, HISTOPATHOLOGY, V70, P223, DOI 10.1111/his.13068; Gupta A, 2015, ALIMENT PHARM THER, V42, P406, DOI 10.1111/apt.13281; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hofmann L, 2016, EUR J CANCER, V60, P190, DOI 10.1016/j.ejca.2016.02.025; Hude I, 2017, HAEMATOLOGICA, V102, P30, DOI 10.3324/haematol.2016.150656; Johnson DB, 2016, JAMA ONCOL, V2, P234, DOI 10.1001/jamaoncol.2015.4368; Johnston RL, 2009, DIGEST DIS SCI, V54, P2538, DOI 10.1007/s10620-008-0641-z; Korman AJ, 2006, ADV IMMUNOL, V90, P297, DOI 10.1016/S0065-2776(06)90008-X; Kyi C, 2014, FEBS LETT, V588, P368, DOI 10.1016/j.febslet.2013.10.015; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Linardou H, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.07.10; Lord JD, 2010, DIGEST DIS SCI, V55, P1396, DOI 10.1007/s10620-009-0839-8; Louie CY, 2015, AM J SURG PATHOL, V39, P1653, DOI 10.1097/PAS.0000000000000525; Marginean EC, 2016, ARCH PATHOL LAB MED, V140, P748, DOI 10.5858/arpa.2015-0451-RA; McDermott DF, 2013, CANCER MED-US, V2, P662, DOI 10.1002/cam4.106; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Mitchell KA, 2013, J CLIN GASTROENTEROL, V47, P781, DOI 10.1097/MCG.0b013e31828f1d51; Naidoo J, 2016, ANN ONCOL, V27, P1362, DOI 10.1093/annonc/mdw141; Oble DA, 2008, AM J SURG PATHOL, V32, P1130, DOI 10.1097/PAS.0b013e31817150e3; Topalian SL, 2016, NAT REV CANCER, V16, P275, DOI 10.1038/nrc.2016.36; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Verschuren EC, 2016, CLIN GASTROENTEROL H, V14, P836, DOI 10.1016/j.cgh.2015.12.028; Vieth M, 2017, VIRCHOWS ARCH, V470, P245, DOI 10.1007/s00428-017-2077-3; Villadolid J, 2015, TRANSL LUNG CANCER R, V4, P560, DOI 10.3978/j.issn.2218-6751.2015.06.06; Weber JS, 2015, J CLIN ONCOL, V33, P2092, DOI 10.1200/JCO.2014.60.0379; Weber JS, 2013, CANCER-AM CANCER SOC, V119, P1675, DOI 10.1002/cncr.27969; Weidner AS, 2015, AM J SURG PATHOL, V39, P1661, DOI 10.1097/PAS.0000000000000522; West NR, 2015, CANCER CELL, V28, P687, DOI 10.1016/j.ccell.2015.11.010; Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1	41	12	12	0	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0945-6317	1432-2307		VIRCHOWS ARCH	Virchows Arch.	JAN	2018	472	1					125	133		10.1007/s00428-017-2267-z			9	Pathology	Pathology	FZ3FX	WOS:000427473200011	29143108				2019-10-28	
J	Starzynska-Kubicka, A; Perkowska-Ptasinska, A; Gornicka, B				Starzynska-Kubicka, Aleksandra; Perkowska-Ptasinska, Agnieszka; Gornicka, Barbara			MEMBRANOUS GLOMERULONEPHRITIS - A COMM ON, UNSPECIFIC PATTERN OF GLOMERULAR INJURY	POLISH JOURNAL OF PATHOLOGY			English	Review						membranous glomerulonephritis; membranous nephropathy; PLAR-related MN	PASSIVE HEYMANN NEPHRITIS; IGG SUBCLASS DEPOSITS; DOMAIN-CONTAINING 7A; HEPATITIS-B VIRUS; LONG-TERM; PHOSPHOLIPASE-A2 RECEPTOR; ANTI-PLA2R ANTIBODIES; BINDING LECTIN; RENAL BIOPSY; RISK-FACTOR	Membranous nephropathy (MN) is a chronic form of glomerulonephritis, associated with the presence of immune complexes beneath the podocytes on the sub-epithelial region of glomerular capillaries. MN is not a disease entity but one of rela-tively common patterns of glomerular injury that may be a manifestation of primary renal autoimmunological reaction or may evolve as a phenomenon secondary to wide spectrum of systemic processes.	[Starzynska-Kubicka, Aleksandra; Gornicka, Barbara] Med Univ Warsaw, Dept Pathol, Warsaw, Poland; [Perkowska-Ptasinska, Agnieszka] Med Univ Warsaw, Dept Transplantol Nephrol & Internal Dis, Warsaw, Poland	Perkowska-Ptasinska, A (reprint author), Warsaw Med Univ, Dept Transplantol Nephrol & Internal Dis, Nowogrodzka 59, PL-02006 Warsaw, Poland.	aggape@poczta.onet.pl		Starzynska-Kubicka, Aleksandra/0000-0001-7874-7751			ABE S, 1986, J CLIN PATHOL, V39, P1193, DOI 10.1136/jcp.39.11.1193; Alfaadhel T, 2015, KIDNEY DIS-BASEL, V1, P126, DOI 10.1159/000437287; Aline-Fardin A, 2009, TRANSPL P, V41, P669, DOI 10.1016/j.transproceed.2009.01.042; Alnasrallah B, 2017, INT J NEPHROL, DOI 10.1155/2017/8409829; Araujo SD, 2015, BRAZ J INFECT DIS, V19, P442, DOI 10.1016/j.bjid.2015.03.003; Bally S, 2016, J AM SOC NEPHROL, V27, P3539, DOI 10.1681/ASN.2015101155; Bantis C, 2006, AM J NEPHROL, V26, P12, DOI 10.1159/000090706; Barbour SJ, 2012, KIDNEY INT, V81, P190, DOI 10.1038/ki.2011.312; Beck LH, 2011, J AM SOC NEPHROL, V22, P1543, DOI 10.1681/ASN.2010111125; Beck LH, 2009, NEW ENGL J MED, V361, P11, DOI 10.1056/NEJMoa0810457; Bohana-Kashtan O, 2004, MOL IMMUNOL, V41, P583, DOI 10.1016/j.molimm.2004.04.007; BORDER WA, 1982, J CLIN INVEST, V69, P451, DOI 10.1172/JCI110469; Cattran D, 2017, NEPHROL DIAL TRANSPL, V32, P22, DOI 10.1093/ndt/gfw404; Cattran DC, 2017, KIDNEY INT, V91, P566, DOI 10.1016/j.kint.2016.09.048; Cattran DC, 1997, KIDNEY INT, V51, P901, DOI 10.1038/ki.1997.127; Chen SY, 2011, CLIN CHIM ACTA, V412, P1899, DOI 10.1016/j.cca.2011.06.020; Choi IJ, 2001, YONSEI MED J, V42, P247, DOI 10.3349/ymj.2001.42.2.247; Churg J, 1973, Perspect Nephrol Hypertens, V1 Pt 1, P443; Cosio FG, 2017, KIDNEY INT, V91, P304, DOI 10.1016/j.kint.2016.08.030; Cunningham PN, 2005, J AM SOC NEPHROL, V16, P1214, DOI 10.1681/ASN.2005010096; Dai HZ, 2015, SCI REP-UK, V5, DOI 10.1038/srep08803; Debiec H, 2004, LANCET, V364, P1252, DOI 10.1016/S0140-6736(04)17142-0; Debiec H, 2003, J AM SOC NEPHROL, V14, pS27, DOI 10.1097/01.ASN.0000067649.64849.75; Debiec H, 2002, NEW ENGL J MED, V346, P2053, DOI 10.1056/NEJMoa012895; Debiec H, 2011, NEW ENGL J MED, V364, P2101, DOI 10.1056/NEJMoa1013792; DONADIO JV, 1977, MEDICINE, V56, P527, DOI 10.1097/00005792-197711000-00007; du Buf-Vereijken PWG, 2004, NEPHROL DIAL TRANSPL, V19, P2036, DOI 10.1093/ndt/gfh312; Du Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104936; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; Golgert WA, 2008, CLIN J AM SOC NEPHRO, V3, P800, DOI 10.2215/CJN.04050907; Gu QH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003786; HALL CL, 1988, BRIT MED J, V296, P1083, DOI 10.1136/bmj.296.6629.1083; Hanko JB, 2009, NEPHROL DIAL TRANSPL, V24, P3050, DOI 10.1093/ndt/gfp254; Hara S, 2015, VIRCHOWS ARCH, V467, P87, DOI 10.1007/s00428-015-1754-3; Hiramatsu R, 2016, HUM PATHOL, V50, P187, DOI 10.1016/j.humpath.2015.12.005; HOGAN SL, 1995, AM J KIDNEY DIS, V25, P862, DOI 10.1016/0272-6386(95)90568-5; Hoxha E, 2014, J AM SOC NEPHROL, V25, P1357, DOI 10.1681/ASN.2013040430; Iwakura T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138841; JONES DB, 1957, AM J PATHOL, V33, P313; Kearney N, 2011, TRANSPL P, V43, P3743, DOI 10.1016/j.transproceed.2011.10.042; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group, 2012, KDIG CLIN PRACT GUID; KOYAMA A, 1986, IMMUNOLOGY, V58, P529; Koyama A, 1999, NEPHRON, V82, P205; Kuroki A, 2002, INTERNAL MED, V41, P936, DOI 10.2169/internalmedicine.41.936; LAI KN, 1991, NEW ENGL J MED, V324, P1457, DOI 10.1056/NEJM199105233242103; Larsen CP, 2016, MODERN PATHOL, V29, P421, DOI 10.1038/modpathol.2016.32; Larsen CP, 2014, KIDNEY INT, V86, P154, DOI 10.1038/ki.2013.548; LEE JC, 1966, ANN INTERN MED, V64, P41, DOI 10.7326/0003-4819-64-1-41; Leeaphorn N, 2014, AM J NEPHROL, V40, P29, DOI 10.1159/000364782; LEENAERTS PL, 1995, KIDNEY INT, V47, P1604, DOI 10.1038/ki.1995.224; Lefaucheur C, 2006, KIDNEY INT, V70, P1510, DOI 10.1038/sj.ki.5001790; Lhotta K, 1999, NEPHROL DIAL TRANSPL, V14, P881, DOI 10.1093/ndt/14.4.881; Lonnbro-Widgren J, 2015, CLIN KIDNEY J, V8, P433, DOI 10.1093/ckj/sfv049; Lv JC, 2013, J AM SOC NEPHROL, V24, P1323, DOI 10.1681/ASN.2012080771; Ma LJ, 2009, FRONT BIOSCI-LANDMRK, V14, P2028, DOI 10.2741/3361; Maixnerova D, 2015, J NEPHROL, V28, P39, DOI 10.1007/s40620-014-0090-z; Makino H, 2002, Mod Rheumatol, V12, P148, DOI 10.3109/s101650200025; Mariani LH, 2018, NEPHROL DIAL TRANSPL, V33, P310, DOI 10.1093/ndt/gfw443; McGrogan A, 2011, NEPHROL DIAL TRANSPL, V26, P414, DOI 10.1093/ndt/gfq665; MELLORS RC, 1957, J EXP MED, V106, P191, DOI 10.1084/jem.106.2.191; Mirza MK, 2014, NEPHROL DIAL TRANSPL, V29, P2343, DOI 10.1093/ndt/gfu333; Morita M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116700; Muller-Deile J, 2017, KIDNEY INT, V92, P836, DOI 10.1016/j.kint.2017.03.005; Murtas C, 2016, J NEPHROL, V29, P469, DOI 10.1007/s40620-016-0268-7; Nangaku M, 2005, J AM SOC NEPHROL, V16, P1195, DOI 10.1681/ASN.2004121098; Nawaz FA, 2013, AM J KIDNEY DIS, V62, P1012, DOI 10.1053/j.ajkd.2013.03.045; Nosaka H, 2009, J NEPHROL, V22, P484; Ohtani H, 2004, NEPHROL DIAL TRANSPL, V19, P574, DOI 10.1093/ndt/gfg616; Ozkok A, 2014, WORLD J GASTROENTERO, V20, P7544, DOI 10.3748/wjg.v20.i24.7544; Pani A, 2016, J NEPHROL, V29, P143, DOI 10.1007/s40620-015-0234-9; Paraskevakou H, 2000, PATHOL RES PRACT, V196, P141, DOI 10.1016/S0344-0338(00)80093-X; Perkowska-Ptasinska A, 2017, NEPHROL DIAL TRANSPL, V32, P209, DOI 10.1093/ndt/gfw365; Perkowska-Ptasinska A, 2016, BMC NEPHROL, V17, DOI 10.1186/s12882-016-0410-8; Pippias M, 2016, TRANSPLANTATION, V100, P1955, DOI 10.1097/TP.0000000000000962; Polanco N, 2010, J AM SOC NEPHROL, V21, P697, DOI 10.1681/ASN.2009080861; PONTICELLI C, 1986, KIDNEY INT, V29, P927, DOI 10.1038/ki.1986.88; Ponticelli C, 2012, TRANSPL INT, V25, P1205, DOI 10.1111/j.1432-2277.2012.01548.x; Qu Z, 2012, NEPHROL DIAL TRANSPL, V27, P1931, DOI 10.1093/ndt/gfr534; Ramachandran R, 2016, NEPHROL DIAL TRANSPL, V31, P1486, DOI 10.1093/ndt/gfv399; Reiser J, 2004, J CLIN INVEST, V113, P1390, DOI 10.1172/JCI200420402; Ruggenenti P, 2008, CLIN J AM SOC NEPHRO, V3, P1652, DOI 10.2215/CJN.01730408; Saran AM, 2003, KIDNEY INT, V64, P2072, DOI 10.1046/j.1523-1755.2003.00305.x; Scharpe J, 2005, ACTA CLIN BELG, V60, P86, DOI 10.1179/acb.2005.016; Segawa Y, 2010, PEDIATR NEPHROL, V25, P1091, DOI 10.1007/s00467-009-1439-8; Sim JJ, 2016, AM J KIDNEY DIS, V68, P533, DOI 10.1053/j.ajkd.2016.03.416; Spicer ST, 2007, J IMMUNOL, V179, P172, DOI 10.4049/jimmunol.179.1.172; Sprangers B, 2012, AM J NEPHROL, V36, P78, DOI 10.1159/000339628; Stanescu HC, 2011, NEW ENGL J MED, V364, P616, DOI 10.1056/NEJMoa1009742; Stehle T, 2015, NEPHROL DIAL TRANSPL, V30, P1047, DOI 10.1093/ndt/gfv080; Svobodova B, 2013, NEPHROL DIAL TRANSPL, V28, P1839, DOI 10.1093/ndt/gfs439; Tegla CA, 2011, IMMUNOL RES, V51, P45, DOI 10.1007/s12026-011-8239-5; Timmermans SAMEG, 2015, AM J NEPHROL, V42, P70, DOI 10.1159/000437236; Tomas NM, 2016, J CLIN INVEST, V126, P2519, DOI 10.1172/JCI85265; Tomas NM, 2014, NEW ENGL J MED, V371, P2277, DOI 10.1056/NEJMoa1409354; Tsuboi N, 2011, NEPHROL DIAL TRANSPL, V26, P3555, DOI 10.1093/ndt/gfr399; van de Logt AE, 2016, EXPERT REV CLIN PHAR, V9, P1463, DOI 10.1080/17512433.2016.1225497; van den Brand JAJG, 2014, J AM SOC NEPHROL, V25, P150, DOI 10.1681/ASN.2013020185; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Vivarelli M, 2015, KIDNEY INT, V87, P602, DOI 10.1038/ki.2014.381; Wen JQ, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004809; Xie QH, 2015, AM J NEPHROL, V41, P345, DOI 10.1159/000431331; Yang Y, 2016, IMMUNOL RES, V64, P919, DOI 10.1007/s12026-016-8790-1; Yokoyama H, 2012, CLIN EXP NEPHROL, V16, P557, DOI 10.1007/s10157-012-0593-7	103	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					209	218		10.5114/pjp.2018.79540			10	Pathology	Pathology	HA9TL	WOS:000450649700002	30509047	DOAJ Gold			2019-10-28	
J	Sambri, A; Richi, A; Tuzzato, G; Donati, D; Bianchi, G				Sambri, Andrea; Richi, Alberto; Tuzzato, Gianmarco; Donati, Davide; Bianchi, Giuseppe			LOW-GRADE FIBROMYXOID SARCOMA OF THE EXTREMITIES: A CLINICOPATHOLOGIC STUDY OF 24 CASES AND REVIEW OF THE LITERATURE	POLISH JOURNAL OF PATHOLOGY			English	Article						low-grade fibromyxoid sarcoma; Evans tumour; survival	SCLEROSING EPITHELIOID FIBROSARCOMA; SPINDLE-CELL TUMOR; GIANT ROSETTES; EVANS TUMOR; TRANSLOCATION; GENE; FUSION	Low-grade fibromyxoid sarcoma (LGFMS) and hybrid sclerosing epithelioid fibrosarcoma (SEF)/LGFMS have a low potential for recurrence (10%) and metastasis (5%) but they are notorious for late occurring metastases. The aim of this study was to evaluate the outcome of LGFMS and review similar cases reported in the literature. We retrospectively evaluated 24 LGFMS operated at a single Institution. All cases were histologically revised. Mean age was 34 years (range, 8 to 74). Two cases presented areas of SEF (hybrid tumours). Three patients presented with metastasis at diagnosis. A strong cytoplasmic staining for MUC4 antibody was found in the majority of neoplastic cells. RT-PCR was feasible in 6 cases and it detected the presence of FUS-CREB3L2 fusion gene chimeric transcript. Mean follow-up was 44 months (range, 6 to 217). Two patients developed lung metastasis after 9 and 26 months respectively. Low-grade fibromyxoid sarcoma has a various histopathologic spectrum with few cases of LGFMS that share histopathologic resemblance with SEF, thereby reinforcing a possibility of a link within these two. It is of paramount importance an accurate and extensive sampling and examination of the whole specimen, in order to identify higher risk patients.	[Sambri, Andrea; Richi, Alberto; Tuzzato, Gianmarco; Donati, Davide; Bianchi, Giuseppe] Rizzoli Orthoped Inst, Via Pupilli 1, I-40136 Bologna, Italy	Sambri, A (reprint author), Rizzoli Orthoped Inst, Via Pupilli 1, I-40136 Bologna, Italy.	andrea_sambri@libero.it	Righi, Alberto/J-6028-2016	Righi, Alberto/0000-0002-1074-0155			Antonescu CR, 2001, AM J SURG PATHOL, V25, P699, DOI 10.1097/00000478-200106000-00001; Arnaoutoglou C, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749-799X-5-49; Bajpai J, 2014, ONCOL LETT, V7, P1308, DOI 10.3892/ol.2014.1888; Billings SD, 2005, AM J SURG PATHOL, V29, P204, DOI 10.1097/01.pas.0000146014.22624.8e; Doyle LA, 2012, AM J SURG PATHOL, V36, P1444, DOI 10.1097/PAS.0b013e3182562bf8; ENNEKING WF, 1980, CLIN ORTHOP RELAT R, P106; Evans HL, 2011, AM J SURG PATHOL, V35, P1450, DOI 10.1097/PAS.0b013e31822b3687; Folpe AL, 2000, AM J SURG PATHOL, V24, P1353, DOI 10.1097/00000478-200010000-00004; GOODLAD JR, 1995, HISTOPATHOLOGY, V26, P229, DOI 10.1111/j.1365-2559.1995.tb01436.x; Guillou L, 2007, AM J SURG PATHOL, V31, P1387, DOI 10.1097/PAS.0b013e3180321959; Hisaoka M, 2012, PATHOL RES PRACT, V208, P557, DOI 10.1016/j.prp.2012.06.002; Indap S, 2014, INDIAN J PLAST SURG, V47, P259, DOI 10.4103/0970-0358.138973; Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050; Kurisaki-Arakawa A, 2014, INT J SURG CASE REP, V5, P1123, DOI 10.1016/j.ijscr.2014.09.034; Kurisaki-Arakawa A, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0163-2; Lane KL, 1997, AM J SURG PATHOL, V21, P1481, DOI 10.1097/00000478-199712000-00011; Le Cesne A, 2012, EUR J CANCER, V48, P3036, DOI 10.1016/j.ejca.2012.05.012; Lee BJ, 2009, CLIN ORTHOP SURG, V1, P240, DOI 10.4055/cios.2009.1.4.240; Maretty-Nielsen Katja, 2013, Sarcoma, P256280, DOI 10.1155/2013/256280; MEISKINDBLOM JM, 1995, AM J SURG PATHOL, V19, P979, DOI 10.1097/00000478-199509000-00001; Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230; Mohamed M, 2017, ANN DIAGN PATHOL, V28, P60, DOI 10.1016/j.anndiagpath.2017.04.001; Papp S, 2015, VIRCHOWS ARCH, V466, P223, DOI 10.1007/s00428-014-1684-5; Reid R, 2003, AM J SURG PATHOL, V27, P1229, DOI 10.1097/00000478-200309000-00006; Rekhi B, 2011, ANN DIAGN PATHOL, V15, P303, DOI 10.1016/j.anndiagpath.2011.02.005; Righi A, 2015, VIRCHOWS ARCH, V467, P339, DOI 10.1007/s00428-015-1810-z; Sambri A, 2016, EJSO-EUR J SURG ONC, V42, P1042, DOI 10.1016/j.ejso.2016.05.015; Tay TKY, 2018, PATHOLOGY, V50, P348, DOI 10.1016/j.pathol.2017.09.022	28	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					219	225		10.5114/PJP.2018.79541			7	Pathology	Pathology	HA9TL	WOS:000450649700003	30509048	DOAJ Gold			2019-10-28	
J	Chen, H; Tan, W; Tu, YB; Liu, HZ				Chen Heng; Tan Wei; Tu Yingbing; Liu Hanzhong			CLINICOPATHOLOGICAL CHARACTERISTICS OF BREAST SEBACEOUS ADENOCARCINOMA	POLISH JOURNAL OF PATHOLOGY			English	Article						sebaceous carcinoma of the breast; clinical; pathology	OF-THE-LITERATURE; CARCINOMA	Two middle-aged females presented with a mass located in the lateral quadrant of the breast. Both patients received modified radical surgery for breast cancer, radiotherapy, and chemotherapy and have been living without evidence of disease for more than one year. Under the microscope, we observed that the tumour cells were organised in a solid nest-like or leafy distribution and comprised sebaceous gland cells and oval or fusiform cells. The differences between the two cases are as follows: First, the mass in the first case had a mixed echo pattern on ultrasound, whereas that in the second case had a hypoechoic pattern. Pathology revealed the presence of irregular cysts in the first case, which was consistent with the ultrasound features, and microscopy revealed the presence of necrosis in the tumour. Second, the first case was strongly positive for HER-2 expression, but the second case was negative. In contrast, the second case was positive for ER expression, whereas the first case was negative. Third, the second patient had two axillary lymph node metastases, whereas the first patient had none. We analysed the obtained data to derive the following conclusions: breast sebaceous carcinoma typically occurs in middle-aged women. Under the microscope, two types of cells can be observed in a solid nest-like or leafy distribution. One cell population consists of sebaceous gland-like tumour cells, which are mostly located in the centre of the lobules or cell nests. These represent a more differentiated cell type and are rich in vacuolar cytoplasm. The other cell population consists of smaller oval or fusiform non-vacuolar cells, mostly located at the periphery of the lobules or cell nests. These cells are usually undifferentiated and are thus difficult to distinguish from typical ductal carcinoma cells. Breast sebaceous carcinoma has a high rate of positive expression of ER, PR, p53, and EMA and a low rate of positive expression of HER-2 and GCDFP-15. Primary breast sebaceous cancer has the following diagnostic characteristics: sebaceous differentiation in at least 50% of cells in the absence of any evidence of originating in the cutaneous adnexa; features, such as ductal carcinoma differentiation, lobular carcinoma differentiation, and others, which can be found in primary breast sebaceous cancer, distinct from those in skin sebaceous adenocarcinorna; and a typical transitional structure between the cancer tissue and ductal epithelium. Breast sebaceous carcinoma should be distinguished from skin sebaceous adenocarcinoma, lipid-rich carcinoma, apocrine carcinoma, and glycogen-rich clear cell carcinoma, among others. Furthermore, this is a hormone receptor-dependent type of breast cancer that requires comprehensive treatment. Thus, after extensive analysis, we conclude that breast sebaceous carcinoma has low invasiveness and good prognosis.	[Chen Heng; Tan Wei] Wuhan Univ Sci & Technol Hosp, Wuhan, Hubei, Peoples R China; [Tu Yingbing; Liu Hanzhong] Xiaogan City Ctr Hosp, Xiaogan, Peoples R China	Tan, W (reprint author), Wuhan Univ Sci & Technol, 2 Huangjiahu West Rd, Wuhan 457, Hubei, Peoples R China.						Chen J, 2005, LIN CHUANG YU SHI YA, V20, P273; Eusebi V, 2012, WHO CLASSIFICATION T, P71; Fasanella S, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-S1-S7; Gao RL, 2013, XIAN DAI ZHONG LIU Y, V21, P1257; Hisaoka M, 2006, VIRCHOWS ARCH, V449, P484, DOI 10.1007/s00428-006-0264-8; Mazzella FM, 1995, PATHOLOGY, V27, P280, DOI 10.1080/00313029500169123; Moinfar F, 2007, ESSENTIALS DIAGNOSTI, P232; Murakami A, 2009, PATHOL INT, V59, P188, DOI 10.1111/j.1440-1827.2009.02349.x; Numoto S, 2007, JPN J DIAGN PATHOL, V24, P58; PRESCOTT RJ, 1992, HISTOPATHOLOGY, V21, P181, DOI 10.1111/j.1365-2559.1992.tb00371.x; Qiu ZY, 2016, LIN CHUANG YU SHI YA, V32, P599; Ramljak V, 2010, COLLEGIUM ANTROPOL, V34, P201; Svajdler M, 2015, POL J PATHOL, V66, P142, DOI 10.5114/PJP.2015.53010; Tavassoli FA, 1999, PATHOLOGY BREAST, P555; VANBOGAERT LJ, 1977, VIRCHOWS ARCH A, V375, P345; Varga Z, 2000, PATHOL INT, V50, P63, DOI 10.1046/j.1440-1827.2000.01003.x; Yamamoto Y, 2017, SURG CASE REP, V3, DOI 10.1186/s40792-017-0312-4; Zhang JN, 2001, ZHONG LIU YAN JIU YU, V13, P312; Zuo Z, 2017, LIN CHUANG YU SHI YA, V33, P453	19	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					226	233		10.5114/PJP.2018.79542			8	Pathology	Pathology	HA9TL	WOS:000450649700004	30509049	DOAJ Gold			2019-10-28	
J	Elzamy, S; Abd Allah, MS; Kandeel, W				Elzamy, Shaimaa; Abd Allah, M. S.; Kandeel, Wael			THE PROGNOSTIC SIGNIFICANCE OF ANDROGEN RECEPTOR AND beta-CATENIN IMMUNOHISTOCHEMICAL EXPRESSION IN UROTHELIAL CARCINOMA WITH AND WITHOUT DETRUSOR MUSCLE INVASION FROM AN EGYPTIAN INSTITUTION	POLISH JOURNAL OF PATHOLOGY			English	Article						androgen receptors; beta-catenin; non-detrusor muscle invasive urothelial carcinoma; detrusor muscle invasive urothelial carcinoma	TRANSITIONAL-CELL-CARCINOMA; STEROID-HORMONE RECEPTORS; BLADDER-CANCER; ESTROGEN-RECEPTORS; PROSTATE-CANCER; E-CADHERIN; PROGRESSION; EXCESS	Androgen receptor (AR) activation plays an important role in the promotion and progression of urothelial tumorigenesis. Also, dysregulation of the Wnt/beta-catenin signaling pathway has also been linked to bladder cancer growth. However, cross talk between the two pathways in remains unclear in bladder cancer. This study investigated the prognostic significance of AR and beta-catenin expression and their relationship to different clinic-pathological parameters, recurrence free and progression free survival. 106 urothelial carcinoma cases were used to study the immunohistochemical expression of AR and beta-catenin. Log-Rank test to compare survival between groups. Androgen receptor positivity was in 37 (34.9%) cases. Both aberrant beta-catenin and AR positivity were associated with higher tumor grade (p = 0.033 and p = 0.037 respectively) and muscle invasion (p = 0.007 and p = 0.039 respectively). Aberrant beta-catenin only showed statistically significant association with tumor diameter (p = 0.036), tumor stage (p = 0.038), LN metastasis (p = 0.001), tumor recurrence (p = 0.026) and tumor progression (p = 0.01). Cases with aberrant beta-catenin showed higher AR positivity (p = 0.018). Our study highlighted important information about the link between Wnt/beta-catenin and AR pathway during the progression of transitional urothelial carcinoma with aberrant beta-catenin could be used as a prognostic marker	[Elzamy, Shaimaa; Abd Allah, M. S.] Benha Univ, Fac Med, Pathol Dept, Banha, Egypt; [Kandeel, Wael] Benha Univ, Fac Med, Urol Dept, Banha, Egypt	Elzamy, S (reprint author), Benha Univ, Fac Med, Pathol Dept, Banha, Egypt.	shaimaa.nagy1@gmail.com					Bakry OA, 2014, ULTRASTRUCT PATHOL, V38, P344, DOI 10.3109/01913123.2014.911788; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Birtle AJ, 2004, HISTOPATHOLOGY, V45, P98, DOI 10.1111/j.1365-2559.2004.01841.x; Boorjian S, 2004, UROLOGY, V64, P383, DOI 10.1016/j.urology.2004.03.025; Boorjian SA, 2009, ENDOCR-RELAT CANCER, V16, P123, DOI 10.1677/ERC-08-0124; BOORMAN GA, 1977, AM J PATHOL, V88, P251; Botelho MC, 2011, VIRULENCE, V2, P267, DOI 10.4161/viru.2.4.16734; Chen FH, 2003, J UROLOGY, V170, P2009, DOI 10.1097/01.ju.0000092238.15685.10; del Muro XG, 2000, EUR J CANCER, V36, P357; DEWINTER JAR, 1991, J HISTOCHEM CYTOCHEM, V39, P927, DOI 10.1177/39.7.1865110; El-Sharkawi F, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0072-4; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Goebell PJ, 2010, UROL ONCOL-SEMIN ORI, V28, P409, DOI 10.1016/j.urolonc.2010.04.003; HARTGE P, 1990, J NATL CANCER I, V82, P1636, DOI 10.1093/jnci/82.20.1636; Hemelt M, 2009, INT J CANCER, V124, P412, DOI 10.1002/ijc.23856; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Hu XK, 2011, INT J UROL, V18, P630, DOI 10.1111/j.1442-2042.2011.02793.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI 10.3322/caac.20115; Jung SJ, 2013, WORLD J MENS HEALTH, V31, P36, DOI 10.5534/wjmh.2013.31.1.36; Kashiwagi E, 2016, CANCER BIOL THER, V17, P1188, DOI 10.1080/15384047.2016.1235667; Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758; Li Y, 2012, JPN J CLIN ONCOL, V42, P569, DOI 10.1093/jjco/hys072; Mashhadi R, 2014, UROL J, V11, P1968; McCahy PJ, 1997, BRIT J UROL, V79, P91, DOI 10.1046/j.1464-410X.1997.30119.x; Mir C, 2011, BJU INT, V108, P24, DOI 10.1111/j.1464-410X.2010.09834.x; Miyamoto H, 2004, PROSTATE, V61, P332, DOI 10.1002/pros.20115; Miyamoto H, 2007, J NATL CANCER I, V99, P558, DOI 10.1093/jnci/djk113; Miyamoto H, 2012, BJU INT, V109, P1716, DOI 10.1111/j.1464-410X.2011.10706.x; Miyamoto H, 2010, PATHOL INT, V60, P1, DOI 10.1111/j.1440-1827.2009.02477.x; Miyazaki J, 2017, INT J UROL, V24, P730, DOI 10.1111/iju.13376; NORONHA RFX, 1986, UROLOGY, V28, P401, DOI 10.1016/0090-4295(86)90073-7; OKAJIMA E, 1975, UROL RES, V3, P73; Rahman M, 2004, CLIN CANCER RES, V10, P2208, DOI 10.1158/1078-0432.CCR-0746-3; Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-4; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Syrigos KN, 1998, J UROLOGY, V160, P1889, DOI 10.1016/S0022-5347(01)62438-8; Tuygun C, 2011, UROL ONCOL-SEMIN ORI, V29, P43, DOI 10.1016/j.urolonc.2009.01.033; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; Vale N, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692247; Wang G, 2008, CANCER RES, V68, P9918, DOI 10.1158/0008-5472.CAN-08-1718; Zhuang YH, 1997, HISTOPATHOLOGY, V30, P556, DOI 10.1046/j.1365-2559.1997.5610801.x	42	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					234	242		10.5114/PJP.2018.79543			9	Pathology	Pathology	HA9TL	WOS:000450649700005	30509050	DOAJ Gold			2019-10-28	
J	Mahmoud, SAM; Amer, HW; Mohamed, SI				Mahmoud, Sarah Ahmed Mohamed; Amer, Hatem Wael; Mohamed, Sally Ibrahim			PRIMARY AMELOBLASTIC CARCINOMA: LITERATURE REVIEW WITH CASE SERIES	POLISH JOURNAL OF PATHOLOGY			English	Review						ameloblastic carcinoma; case series; primary type; review	EXPRESSION; MAXILLA; REGIONS; KI-67	Ameloblastic carcinoma (AC) is an extremely rare malignant odontogenic tumour arising from odontogenic epithelium. It was classified into primary type and secondary type. A previous study revealed that primary ameloblastic carcinoma cases were associated with more favourable prognosis than secondary cases. The aim of the present work was: to report the clinical, histopathological, immunohistochemical, and ploidy status, and therapeutic details of four cases of primary AC, and to review the literature with regard to clinical, follow-up, prognosis, histopathological, and immunohistochemical information of primary AC. The Medline database was searched using the term ameloblastic carcinoma and primary type. The review of English literature revealed that primary ameloblastic carcinoma favours the posterior mandible with profound male predilection and appears as an ill-defined radiolucency. Metastasis and invasion are more likely to occur in maxillary cases. The treatment of choice is wide surgical resection with or without cervical lymph node dissection. Adjuvant postoperative radiotherapy is beneficial in incomplete resection cases and advanced soft tissue invasion. The most specific diagnostic methods of AC, as concluded from review, are a-SMA in epithelial cells in conjunction with Ki-67 index value and SPF more than 11.5%.	[Mahmoud, Sarah Ahmed Mohamed; Amer, Hatem Wael; Mohamed, Sally Ibrahim] Cairo Univ, Fac Dent, Oral & Maxillofacial Pathol Dept, Giza 11222, Egypt	Mahmoud, SAM (reprint author), Cairo Univ, Fac Dent, Oral & Maxillofacial Pathol Dept, Giza 11222, Egypt.	sarah.badawy@dentistry.cu.edu.eg	Ahmed, Sarah/V-8813-2019				Ansari HA, 2015, INDIAN J PATHOL MICR, V58, P513, DOI 10.4103/0377-4929.168856; Bello IO, 2009, ORAL ONCOL, V45, P760, DOI 10.1016/j.oraloncology.2008.11.011; Bologna-Molina R, 2013, MED ORAL PATOL ORAL, V18, pE174, DOI 10.4317/medoral.18573; Franca DCC, 2012, ONCOL LETT, V4, P1297, DOI 10.3892/ol.2012.937; Carreon-Burciaga RG, 2015, DIS MARKERS, DOI 10.1155/2015/683087; Casaroto AR, 2012, ANTICANCER RES, V32, P1515; Chaisuparat R, 2012, HISTOPATHOLOGY, V61, P107, DOI 10.1111/j.1365-2559.2012.04200.x; da Silva AD, 2016, OR SURG OR MED OR PA, V121, P396, DOI 10.1016/j.oooo.2015.11.011; Fitzpatrick SG, 2015, ORAL SURG ORAL MED O, V119, P241; Garcia-Munoz A, 2015, ARCH ORAL BIOL, V60, P799, DOI 10.1016/j.archoralbio.2015.02.017; Garcia-Munoz A, 2014, J ORAL MAXIL SURG, V72, P1183, DOI 10.1016/j.joms.2013.11.029; Grewal HK, 2014, J CLIN DIAGN RES, V8, P17; Horvath A, 2012, ROM J MORPHOL EMBRYO, V53, P179; Jaitley S, 2013, INDIAN J CANCER, V50, DOI 10.4103/0019-509X.112316; Kallianpur S, 2014, J ORAL MEXILLO FAC P, V18, P96; Kamath KP, 2010, HEAD NECK PATHOL, V4, P157, DOI 10.1007/s12105-010-0173-7; Kar Indu Bhusan, 2014, Ann Maxillofac Surg, V4, P70, DOI 10.4103/2231-0746.133070; Khojasteh A, 2013, J ORAL MAXIL SURG, V71, P62, DOI 10.1016/j.joms.2012.04.033; Kiresur MA, 2017, J CLIN DIAGN RES, V11, pZD25, DOI 10.7860/JCDR/2017/23818.9205; Koca T, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-157; Kodati S, 2016, J CLIN DIAGN RES, V10, pZD23, DOI 10.7860/JCDR/2016/21100.8697; Kumaran PS, 2014, J PHARM BIOALLIED SC, V6, P208, DOI 10.4103/0975-7406.137473; Lei Y, 2014, OR SURG OR MED OR PA, V117, P608, DOI 10.1016/j.oooo.2014.01.017; Li J, 2014, ONCOL LETT, V8, P914, DOI 10.3892/ol.2014.2230; Mahmoud SAM, 2017, ARCH ORAL BIOL, V78, P94, DOI 10.1016/j.archoralbio.2017.02.015; Maya R, 2012, Indian J Dent Res, V23, P15, DOI 10.4103/0970-9290.99031; Prasanna Md, 2014, J Oral Maxillofac Pathol, V18, pS45, DOI 10.4103/0973-029X.141345; Roy Swati, 2013, J Oral Maxillofac Res, V4, pe4, DOI 10.5037/jomr.2013.4104; Safadi RA, 2016, OR SURG OR MED OR PA, V121, P402, DOI 10.1016/j.oooo.2015.11.015; Takahashi Y, 2016, J ORAL MAXIL SURG, V74, P302, DOI 10.1016/j.joms.2015.07.015; Uzawa N, 2015, ONCOL LETT, V9, P459, DOI 10.3892/ol.2014.2654; Zwahlen RA, 2003, J ORAL MAXIL SURG, V61, P731, DOI 10.1053/joms.2003.50146	32	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					243	253		10.5114/pjp.2018.79544			11	Pathology	Pathology	HA9TL	WOS:000450649700006	30509051	DOAJ Gold			2019-10-28	
J	Piccaluga, PP; Paolini, S; Navari, M; Etebari, M; Visani, G; Ascani, S				Piccaluga, Pier P.; Paolini, Stefania; Navari, Mohsen; Etebari, Maryam; Visani, Giuseppe; Ascani, Stefano			INCREASED ANGIOGENESIS SEEMS TO CORRELATE WITH INFERIOR OVERALL SURVIVAL IN MYELOID SARCOMA PATIENTS	POLISH JOURNAL OF PATHOLOGY			English	Article						myeloid sarcoma; angiogenesis; micro-vessel density; immunohistochemistry; anti-angiogenic therapy	ACUTE MYELOGENOUS LEUKEMIA; BONE-MARROW ANGIOGENESIS; MYELODYSPLASTIC SYNDROMES; MULTIPLE-MYELOMA; ANTIANGIOGENIC ACTIVITY; SIGNALING PATHWAYS; COMPLETE REMISSION; THALIDOMIDE; MYELOFIBROSIS; LENALIDOMIDE	Myeloid sarcomas (MS) are tumors composed by myeloid elements and developing outside bone marrow. The prognosis is overall poor, only stem cell transplantation being consistently reposted as a potentially curative approach. In this study we explored whether microvessel density, a biomarker of angiogenesis, might be relevant in MS. We studied 60 MS, 24 acute myeloid leukemia, 5 normal bone marrow samples and 2 cases of extramedullary hemopoiesis in patients without evidence of hematological malignancy. We used immunohistochernistry (anti-CD34) to identify and quantify micro-vessel density (MVD) and micro-vessel grading (MVG). We found that MS had significantly higher MVD and MVG than normal bone marrow (p = 0.0002 and p < 0.001, respectively). We then found that cases with rnonocytic morphology had significantly higher MVD than myelo-monocytic and blastic ones (p = 0.005), while no differences were recorded based on extramedullary site. Finally, we found that higher MVD and higher MVG were associated with inferior outcome in terms of overall survival in multivariate analysis (p = 0.05 and p = 0.02, respectively), when censoring for stem cell transplantation was undertaken. In conclusion, we documented for the first time that increased angiogenesis is characteristic of MS and correlates with survival, suggesting that anti-angiogenic approaches might deserve a clinical evaluation in this setting.	[Piccaluga, Pier P.; Paolini, Stefania; Etebari, Maryam] Bologna Univ, Dept Expt Diagnost & Special Med, Sch Med, I-40138 Bologna, Italy; [Navari, Mohsen] Torbat Heydariyeh Univ Med Sci, Res Ctr Adv Technol Med, Torbat Heydariyeh, Iran; [Visani, Giuseppe] AORMN, Hematol & Hematopoiet Stem Cell Transplant Ctr, Pesaro, Italy; [Ascani, Stefano] Univ Perugia, S Maria Hosp, Pathol Serv, Terni, Italy	Piccaluga, PP (reprint author), Bologna Univ, Dept Expt Diagnost & Special Med, Sch Med, I-40138 Bologna, Italy.	pierpaolo.piccaluga@unibo.it		Piccaluga, Pier Paolo/0000-0002-9432-0595			Arber DA, 2008, WHO CLASSIFICATION T, P130; Barosi G, 2001, BRIT J HAEMATOL, V114, P78, DOI 10.1046/j.1365-2141.2001.02918.x; Barr P, 2007, LEUKEMIA LYMPHOMA, V48, P1940, DOI 10.1080/10428190701573208; BYRD JC, 1994, CANCER, V73, P2107, DOI 10.1002/1097-0142(19940415)73:8<2107::AID-CNCR2820730815>3.0.CO;2-W; Canepa L, 2001, BRIT J HAEMATOL, V115, P313, DOI 10.1046/j.1365-2141.2001.03072.x; Cao YH, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003149; COX DR, 1972, J R STAT SOC B, V34, P187; Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498; Dias S, 2002, BLOOD, V99, P2532, DOI 10.1182/blood.V99.7.2532; Falini B, 2007, LEUKEMIA, V21, P1566, DOI 10.1038/sj.leu.2404699; Fehniger TA, 2009, BLOOD, V113, P1002, DOI 10.1182/blood-2008-04-152678; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Ghannadan M, 2003, AM J CLIN PATHOL, V119, P663, DOI 10.1309/331QX7AXKWFJFKXM; GIMBRONE MA, 1972, J EXP MED, V136, P261, DOI 10.1084/jem.136.2.261; Grimwade D, 2010, BLOOD, V116, P354, DOI 10.1182/blood-2009-11-254441; Heimburg S, 1999, ANTICANCER RES, V19, P2527; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Karp JE, 2004, CLIN CANCER RES, V10, P3577, DOI 10.1158/1078-0432.CCR-03-0627; Lancet JE, 2007, LEUKEMIA, V21, P586, DOI 10.1038/sj.leu.2404526; Li Z, 2015, LEUKEMIA, V29, P2113, DOI 10.1038/leu.2015.81; List A, 2005, NEW ENGL J MED, V352, P549, DOI 10.1056/NEJMoa041668; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mesa RA, 2000, BLOOD, V96, P3374; Mesa RA, 2010, AM J HEMATOL, V85, P129, DOI 10.1002/ajh.21598; Meyer SC, 2014, LANCET ONCOL, V15, pE382, DOI 10.1016/S1470-2045(14)70008-7; Mirza MK, 2014, LEUKEMIA RES, V38, P1091, DOI 10.1016/j.leukres.2014.05.004; Movassaghian M, 2015, LEUKEMIA LYMPHOMA, V56, P1698, DOI 10.3109/10428194.2014.963080; Padro T, 2000, BLOOD, V95, P2637, DOI 10.1182/blood.V95.8.2637.008k07_2637_2644; Peker D, 2014, INT J HEMATOL, V100, P457, DOI 10.1007/s12185-014-1659-y; Piccaluga PP, 2007, HISTOPATHOLOGY, V50, P802, DOI 10.1111/j.1365-2559.2007.02645.x; Piccaluga Pier Paolo, 2002, Haematologica, V87, pELT18; Piccaluga PP, 2002, LEUKEMIA, V16, P1609, DOI 10.1038/sj.leu.2402596; Pileri S, 2017, WHO CLASSIFICATION T, P140; Pileri SA, 2007, LEUKEMIA, V21, P340, DOI 10.1038/sj.leu.2404491; Pileri SA, 1997, J PATHOL, V183, P116; Pozzato G, 2001, HAEMATOLOGICA, V86, P772; Pruneri G, 2002, BRIT J HAEMATOL, V118, P817, DOI 10.1046/j.1365-2141.2002.03654.x; Pruneri G, 1999, BRIT J CANCER, V81, P1398, DOI 10.1038/sj.bjc.6693515; Pruneri G, 2003, BRIT J HAEMATOL, V120, P695, DOI 10.1046/j.1365-2141.2003.04133.x; QUINTANILLAMARTINEZ L, 1995, AM J CLIN PATHOL, V104, P431; Quintas-Cardama A, 2009, J CLIN ONCOL, V27, P4760, DOI 10.1200/JCO.2009.22.6548; Raanani P, 2007, ANN ONCOL, V18, P7, DOI 10.1093/annonc/mdl129; Raza A, 2008, CANCER, V113, P1596, DOI 10.1002/cncr.23789; Reichert F, 2005, EUR J HAEMATOL, V75, P41, DOI 10.1111/j.1600-0609.2005.00436.x; Ribatti D, 1996, EUR J HAEMATOL, V56, P45; Santos SCR, 2004, BLOOD, V103, P3883, DOI 10.1182/BLOOD-2003-05-1634; Steins MB, 2002, BLOOD, V99, P834, DOI 10.1182/blood.V99.3.834; Tefferi A, 2009, J CLIN ONCOL, V27, P4563, DOI 10.1200/JCO.2008.21.7356; Vacca A, 1999, BLOOD, V93, P3064; VACCA A, 1994, BRIT J HAEMATOL, V87, P503, DOI 10.1111/j.1365-2141.1994.tb08304.x; Visani G, 2014, LEUKEMIA, V28, P967, DOI 10.1038/leu.2014.31; Walter RB, 2015, LEUKEMIA, V29, P2104, DOI 10.1038/leu.2015.76; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Went P, 2006, J CLIN ONCOL, V24, P2472, DOI 10.1200/JCO.2005.03.6327	54	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					254	265		10.5114/PJP.2018.79545			12	Pathology	Pathology	HA9TL	WOS:000450649700007	30509052	DOAJ Gold			2019-10-28	
J	Shahmohamady, P; Eidi, A; Mortazavi, P; Panahi, N; Minai-Tehrani, D				Shahmohamady, Pouneh; Eidi, Akram; Mortazavi, Pejman; Panahi, Negar; Minai-Tehrani, Dariush			EFFECT OF SINAPIC ACID ON MEMORY DEFICITS AND NEURONAL DEGENERATION INDUCED BY INTRACEREBROVENTRICULAR ADMINISTRATION OF STREPTOZOTOCIN IN RATS	POLISH JOURNAL OF PATHOLOGY			English	Article						sinapic acid; streptozotocin; Alzheimer's disease; rat	SPORADIC ALZHEIMERS-DISEASE; MYOCARDIAL INFARCTED RATS; NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; COGNITIVE IMPAIRMENT; LIPID-PEROXIDATION; GLUCOSE-METABOLISM; DIABETOGENIC DRUG; ENERGY-METABOLISM; INDUCED DEMENTIA	The present study aimed to elucidate the neuroprotective effect of sinapic acid on intracerebroventricular streptozotocin (ICV-STZ) induced neuronal loss and memory impairment. To test this hypothesis, male Wistar rats were randomly divided into 11 groups: normal control, sham-operated control, sinapic acid (2.5, 5, 10, and 20 mg/kg bw intragastrically, daily) alone, Alzheimer control rats (ICV-STZ, 3 mg/kg bw), sinapic acid (2.5, 5, 10, and 20 mg/kg bw intragastrically, daily) together with STZ, and the treatment was performed accordingly. After 28 days of ICV-STZ administration, the animals were assessed for cognitive performance using passive avoidance test and then sacrificed for biochemical and histopathological examinations. Sinapic acid was found to be effective in improving antioxidant status and preventing memory loss in Alzheimer rats. Moreover, TNF-alpha level in the hippocampus was significantly decreased by sinapic acid. Also, administration of sinapic acid significantly increased the levels of antioxidant enzymes and decreased malondialdehyde level in the hippocampus. Histopathological examination showed that sinapic acid reduced cell loss in the cerebral cortex and hippocampus in Alzheimer's rats. The present study suggests that sinapic acid is effective in the prevention of memory loss and improvement of oxidative stress and might be beneficial in the treatment of Alzheimer's disease.	[Shahmohamady, Pouneh; Eidi, Akram] Islamic Azad Univ, Dept Biol, Sci & Res Branch, Tehran 16535, Iran; [Mortazavi, Pejman] Islamic Azad Univ, Dept Pathol, Sci & Res Branch, Fac Specialized Vet Sci, Tehran, Iran; [Panahi, Negar] Islamic Azad Univ, Dept Basic Sci, Sci & Res Branch, Fac Specialized Vet Sci, Tehran, Iran; [Minai-Tehrani, Dariush] Shahid Beheshti Univ, Fac Sci & Biotechnol, Tehran, Iran	Eidi, A (reprint author), Islamic Azad Univ, Dept Biol, Sci & Res Branch, Tehran 16535, Iran.	akram_eidi@yahoo.com	panahi, negar/V-6352-2017	panahi, negar/0000-0003-2261-3388			AEBI H, 1984, METHOD ENZYMOL, V105, P121; Agrawal R, 2011, EUR NEUROPSYCHOPHARM, V21, P261, DOI 10.1016/j.euroneuro.2010.11.009; Agrawal R, 2009, NEUROPHARMACOLOGY, V56, P779, DOI 10.1016/j.neuropharm.2009.01.005; Ahmad M, 2005, J NEUROCHEM, V93, P94, DOI 10.1111/j.1471-4159.2005.03000.x; Alasalvar C, 2006, J AGR FOOD CHEM, V54, P4826, DOI 10.1021/jf0601259; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Arendt T, 2001, NEUROSCIENCE, V102, P723, DOI 10.1016/S0306-4522(00)00516-9; Arsenijevic D, 2001, EUR CYTOKINE NETW, V12, P518; Awasthi H, 2010, LIFE SCI, V86, P87, DOI 10.1016/j.lfs.2009.11.007; Barber MS, 2000, PHYTOCHEMISTRY, V54, P53, DOI 10.1016/S0031-9422(00)00038-8; Deak T, 2003, BRAIN RES, V972, P53, DOI 10.1016/S0006-8993(03)02485-5; Elcioglu HK, 2015, ACTA HISTOCHEM, V117, P176, DOI 10.1016/j.acthis.2014.12.002; Engels C, 2012, EUR FOOD RES TECHNOL, V234, P535, DOI 10.1007/s00217-012-1669-z; Fernandez-Botran R, 2011, BRAIN BEHAV IMMUN, V25, P314, DOI 10.1016/j.bbi.2010.09.023; Frankola KA, 2011, CNS NEUROL DISORD-DR, V10, P391; Galano A, 2011, PHYS CHEM CHEM PHYS, V13, P11199, DOI 10.1039/c1cp20722a; Gaspar A, 2010, J AGR FOOD CHEM, V58, P11273, DOI 10.1021/jf103075r; Ghaznavi R, 2007, ARCH TOXICOL, V81, P453, DOI 10.1007/s00204-006-0157-2; HALLIWELL B, 1993, AM J CLIN NUTR, V57, P715; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; HOYER S, 1991, J NEURAL TRANSM-PARK, V3, P1, DOI 10.1007/BF02251132; Hoyer S, 2004, ADV EXP MED BIOL, V541, P135; Hoyer S, 2004, EUR J PHARMACOL, V490, P115, DOI 10.1016/j.ejphar.2004.02.049; Hoyer S, 1999, ANN NY ACAD SCI, V893, P301, DOI 10.1111/j.1749-6632.1999.tb07842.x; Hudson EA, 2000, CANCER EPIDEM BIOMAR, V9, P1163; Ishrat T, 2006, BEHAV BRAIN RES, V171, P9, DOI 10.1016/j.bbr.2006.03.009; Ishrat T, 2009, EUR NEUROPSYCHOPHARM, V19, P636, DOI 10.1016/j.euroneuro.2009.02.002; Johnson ML, 2008, POULTRY SCI, V87, P958, DOI 10.3382/ps.2007-00349; Kamat PK, 2012, LIFE SCI, V90, P713, DOI 10.1016/j.lfs.2012.03.012; Kamat PK, 2014, NEUROCHEM INT, V76, P32, DOI 10.1016/j.neuint.2014.06.012; Kanchana G., 2011, GLOBAL J PHARM, V2011, P33; Karakida F, 2007, BIOL PHARM BULL, V30, P514, DOI 10.1248/bpb.30.514; Kim DH, 2010, NEUROPHARMACOLOGY, V59, P20, DOI 10.1016/j.neuropharm.2010.03.012; Labak M, 2010, ACTA NEUROCHIR SUPPL, V106, P177, DOI 10.1007/978-3-211-98811-4_32; Lannert H, 1998, BEHAV NEUROSCI, V112, P1199, DOI 10.1037/0735-7044.112.5.1199; Lee HE, 2012, PHARMACOL BIOCHEM BE, V103, P260, DOI 10.1016/j.pbb.2012.08.015; Lenard L, 2002, ACTA BIOL HUNG, V53, P95, DOI 10.1556/ABiol.53.2002.1-2.11; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Mahmoud AM, 2014, EXCLI J, V13, P98; Misra S, 2011, EUR J PHARMACOL, V659, P177, DOI 10.1016/j.ejphar.2011.03.026; Nayagam A. A. J., 2011, Journal of Pharmacy Research, V4, P1073; NITSCH R, 1991, NEUROSCI LETT, V128, P199, DOI 10.1016/0304-3940(91)90260-Z; NOWAK H, 1992, FETT WISS TECHNOL, V94, P149, DOI 10.1002/lipi.19920940406; Ott A, 1999, NEUROLOGY, V53, P1937, DOI 10.1212/WNL.53.9.1937; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; Pari L, 2011, CHEM-BIOL INTERACT, V194, P40, DOI 10.1016/j.cbi.2011.08.004; Pathan AR, 2006, LIFE SCI, V79, P2209, DOI 10.1016/j.lfs.2006.07.018; Petursdottir AL, 2007, NEUROBIOL AGING, V28, P1170, DOI 10.1016/j.neurobiolaging.2006.05.033; PLASCHKE K, 1993, INT J DEV NEUROSCI, V11, P477, DOI 10.1016/0736-5748(93)90021-5; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Qin LY, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-10; Raghavendra V, 2001, FREE RADICAL BIO MED, V30, P595, DOI 10.1016/S0891-5849(00)00447-0; Rai S, 2013, J NEUROIMMUNOL, V254, P1, DOI 10.1016/j.jneuroim.2012.08.008; Roy SJ, 2013, EUR J PHARMACOL, V699, P213, DOI 10.1016/j.ejphar.2012.11.012; Roy SJ, 2012, FOOD CHEM TOXICOL, V50, P3984, DOI 10.1016/j.fct.2012.08.017; Salkovic-Petrisic M, 2013, J NEURAL TRANSM, V120, P233, DOI 10.1007/s00702-012-0877-9; Sharma M, 2003, EUR NEUROPSYCHOPHARM, V13, P241, DOI 10.1016/S0924-977X(03)00008-7; Sharma M, 2001, LIFE SCI, V68, P1021, DOI 10.1016/S0024-3205(00)01005-5; Shoham S, 2003, EXP NEUROL, V184, P1043, DOI 10.1016/j.expneurol.2003.08.015; Silambarasan T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115682; Silambarasan T, 2015, BIOCHEM BIOPH RES CO, V456, P853, DOI 10.1016/j.bbrc.2014.12.022; Sun XL, 2007, BIOL PHARM BULL, V30, P1727, DOI 10.1248/bpb.30.1727; SUN Y, 1988, CLIN CHEM, V34, P497; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Teixeira J, 2013, BIOMED RES INT, DOI 10.1155/2013/251754; Tesaki S, 1998, BIOSCI BIOTECH BIOCH, V62, P998, DOI 10.1271/bbb.62.998; Victor VM, 2003, PHYSIOL RES, V52, P789; Wang XK, 2005, MOL BRAIN RES, V140, P120, DOI 10.1016/j.molbrainres.2005.07.018; Wei PH, 2015, NEUROSCI LETT, V604, P161, DOI 10.1016/j.neulet.2015.08.008; Wickens AP, 2001, RESP PHYSIOL, V128, P379, DOI 10.1016/S0034-5687(01)00313-9; Wilde GJC, 1997, J NEUROCHEM, V69, P883; Williams TI, 2006, NEUROBIOL AGING, V27, P1094, DOI 10.1016/j.neurobiolaging.2005.06.004; Yoon BH, 2007, LIFE SCI, V81, P234, DOI 10.1016/j.lfs.2007.05.007; Yun KJ, 2008, J AGR FOOD CHEM, V56, P10265, DOI 10.1021/jf802095g; Zou YN, 2002, J AGR FOOD CHEM, V50, P5884, DOI 10.1021/jf020496z	75	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					266	277		10.5114/PJP.2018.79546			12	Pathology	Pathology	HA9TL	WOS:000450649700008	30509053	DOAJ Gold			2019-10-28	
J	Wisniewski, P; Glogowski, M; Olszewski, W				Wisniewski, Piotr; Glogowski, Maciej; Olszewski, Wlodzimierz			ASSESSMENT OF DIAGNOSTIC VALUE OF CYTOLOGICAL EXAMINATION IN LUNG CARCINOMA IN OWN MATERIAL OBTAINED BY EBUS AND EUS METHODS	POLISH JOURNAL OF PATHOLOGY			English	Article						lung carcinoma; EBUS-TBNA; EUSB-FNA; cytopathology	TRANSBRONCHIAL NEEDLE ASPIRATION; MUTATION ANALYSIS; SPECIMENS; CANCER; ADENOCARCINOMA; CLASSIFICATION	The aim of the study was the evaluation of the efficiency of cytological examination of the material obtained by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and endoscopic ultrasound bronchoscope-guided fine needle aspiration (EUSB-FNA) methods in the diagnosis of lung carcinoma. The usefulness was also assessed of the material obtained in that way for inimuno cytochemical and molecular tests in the diagnosis of non-small cell lung carcinoma. The material included cytological preparations obtained by EBUS and EUS methods. It was demonstrated that the technique made it possible to obtain diagnostic material from 94% of patients. A retrospective thorough analysis of those cases was the basis for the discussion of diagnostic difficulties.	[Wisniewski, Piotr; Olszewski, Wlodzimierz] Inst Warsaw, Div Pathol & Lab Diagnost, Ctr Oncol, Warsaw, Poland; [Glogowski, Maciej] Inst Warsaw, Dept Lung & Chest Tumours, Ctr Oncol, Warsaw, Poland	Wisniewski, P (reprint author), Inst Roentgena 5, Div Pathol & Lab Diagnost, Ctr Oncol, PL-02781 Warsaw, Poland.	piotr.patolog@gmail.com		Glogowski, Maciej/0000-0002-0850-0566; Glogowski, Michal Piotr/0000-0003-2571-1151			Alsharif M, 2008, AM J CLIN PATHOL, V130, P434, DOI 10.1309/BLLQF8KDHWW6MJNQ; Billah S, 2011, CANCER CYTOPATHOL, V119, P111, DOI 10.1002/cncy.20151; Boldrini L, 2007, J THORAC ONCOL, V2, P1086, DOI 10.1097/JTO.0b013e31815ba1fa; Cai GP, 2013, CANCER CYTOPATHOL, V121, P500, DOI 10.1002/cncy.21288; Choi YR, 2013, KOREAN J INTERN MED, V28, P660, DOI 10.3904/kjim.2013.28.6.660; Dabbs DJ, 2006, DIAGNOSTIC IMMUNOHIS; Feller-Kopman D, 2009, CANCER CYTOPATHOL, V117, P482, DOI 10.1002/cncy.20049; Herth FJF, 2006, THORAX, V61, P795, DOI 10.1136/thx.2005.047829; Izumo T, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0268-3; Jiang JH, 2014, J THORAC DIS, V6, P416, DOI 10.3978/j.issn.2072-1439.2014.03.22; Khode R, 2013, CANCER CYTOPATHOL, V121, P361, DOI 10.1002/cncy.21273; Koss LG, 1992, ASPIRATION BIOPSY CY, P288; Kramer H, 2006, CANCER CYTOPATHOL, V108, P206, DOI 10.1002/cncr.21914; Langfort R., 2016, ONKOLOGIA DYPLOMIE, V2, P42; Langfort R, 2011, PNEUMONOL ALERGOL PO, V80, P172; Langfort R, 2010, POL J PATHOL, V61, pS1; Li AR, 2008, J MOL DIAGN, V10, P242, DOI 10.2353/jmoldx.2008.070178; Navani N, 2012, AM J RESP CRIT CARE, V185, P1316, DOI 10.1164/rccm.201202-0294OC; Nayak A, 2012, DIAGN CYTOPATHOL, V40, P128, DOI 10.1002/dc.21517; Patelli M, 2002, ANN THORAC SURG, V73, P407, DOI 10.1016/S0003-4975(01)03447-6; Santos GD, 2011, CANCER CYTOPATHOL, V119, P80, DOI 10.1002/cncy.20150; Travis WD, 2015, J THORAC ONCOL, V10, P1240, DOI 10.1097/JTO.0000000000000663; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; van Boerdonk RAA, 2013, J THORAC ONCOL, V8, P711, DOI 10.1097/JTO.0b013e3182897c14	24	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					278	284		10.5114/PJP.2018.79547			7	Pathology	Pathology	HA9TL	WOS:000450649700009	30509054	DOAJ Gold			2019-10-28	
J	Bodzek, M; Blecharz, P; Rys, J; Szatkowski, W; Jasiowka, M; Majchrzak, P; Halaszka, K; Kruczak, A; Lackowska, B				Bodzek, Maciej; Blecharz, Pawel; Rys, Janusz; Szatkowski, Wiktor; Jasiowka, Marek; Majchrzak, Pawel; Halaszka, Krzysztof; Kruczak, Anna; Lackowska, Bozena			MOLECULAR PROGNOSTIC FACTORS IN EARLY-STAGE CERVICAL ADENOCARCINOMA	POLISH JOURNAL OF PATHOLOGY			English	Article						cervical adenocarcinoma; flow cytometry; prognosis	SQUAMOUS-CELL CARCINOMA; UTERINE CERVIX; UNITED-STATES; YOUNG-WOMEN; IN-SITU; CYTOMETRY; MORTALITY	Within the past years the proportion of cervical adenocarcinomas has increased, however, there is a shortage of data regarding immunohistochemical and molecular features and their prognostic relevance in early-stage cervical adenocarcinoma (esCAC). Aim of the present study was to evaluate molecular prognostic factors in esCAC patients treated with primary surgery. Analyses of surgical specimens in 59 patients with esCAC were performed on fixed paraffin-embedded sections of tumour tissue. Tumour tissue sections were routinely stained with hematoxylin and eosin followed by microscopic examination. Immunohistochemical analyses (IHC) were performed on paraffin-embedded section. Flow cytometry (FCM) analysis of paraffin-embedded tumor tissue was performed using flow cytometer FACSCalibur equipped with argon laser. DNA histogram analysis was performed with ModFit application. Treatment effectiveness was evaluated using overall 5-year survival. Survival probability was estimated using the Kaplan-Meier method. Overall survival rate estimated using Kaplan-Meier method was 74.6%. Among the IHC and FCM features univariate analysis showed statistical significance of nm23-H1 gene expression and total S-phase fraction <= 11.9% (S-TOT). In multivariate analysis LVSI and parametrial involvement had significant, negative impact on survival (HR = 8.04, p < 0.003 and HR = 4.03, p < 0.017, respectively). However, none of the tested IHC and FCM features had any influence on overall 5-year survival.	[Bodzek, Maciej] Prov Hosp Chrzanow, Dept Obstet & Gynecol, Chrzanow, Poland; [Blecharz, Pawel; Szatkowski, Wiktor; Jasiowka, Marek] Maria Sklodowska Curie Mem Canc Ctr, Gynecol Oncol Dept, Garncarska 11, PL-31115 Krakow, Poland; [Blecharz, Pawel; Rys, Janusz; Szatkowski, Wiktor; Jasiowka, Marek; Majchrzak, Pawel; Halaszka, Krzysztof; Kruczak, Anna; Lackowska, Bozena] Inst Oncol, Krakow Branch, Garncarska 11, PL-31115 Krakow, Poland; [Rys, Janusz; Majchrzak, Pawel; Halaszka, Krzysztof; Kruczak, Anna; Lackowska, Bozena] Maria Sklodowska Curie Mem Canc Ctr, Dept Tumour Pathol, Krakow, Poland	Szatkowski, W (reprint author), Maria Sklodowska Curie Mem Canc Ctr, Gynecol Oncol Dept, Garncarska 11, PL-31115 Krakow, Poland.; Szatkowski, W (reprint author), Inst Oncol, Krakow Branch, Garncarska 11, PL-31115 Krakow, Poland.	vigor27@wp.pl					ANTONCULVER H, 1992, AM J OBSTET GYNECOL, V166, P1507, DOI 10.1016/0002-9378(92)91627-M; COX DR, 1972, J R STAT SOC B, V34, P187; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; HOPKINS MP, 1991, OBSTET GYNECOL, V77, P912; HOPKINS MP, 1990, GYNECOL ONCOL, V36, P7, DOI 10.1016/0090-8258(90)90100-Y; Huang Y, 1997, Zhonghua Fu Chan Ke Za Zhi, V32, P718; IVERSEN T, 1979, BRIT J OBSTET GYNAEC, V86, P593, DOI 10.1111/j.1471-0528.1979.tb10819.x; Kaku T, 1997, GYNECOL ONCOL, V65, P281, DOI 10.1006/gyno.1997.4652; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASPAR HG, 1993, OBSTET GYNECOL, V81, P296; Kristensen GB, 1996, GYNECOL ONCOL, V61, P378, DOI 10.1006/gyno.1996.0160; Kurman RJ, 2014, WHO CLASSIFICATION T; MANDAI M, 1995, BRIT J CANCER, V72, P691, DOI 10.1038/bjc.1995.395; MATSUKUMA K, 1989, GYNECOL ONCOL, V35, P38, DOI 10.1016/0090-8258(89)90007-3; McHale MT, 2001, OBSTET GYNECOL, V98, P726, DOI 10.1016/S0029-7844(01)01544-7; NIEMINEN P, 1995, OBSTET GYNECOL, V85, P1017, DOI 10.1016/0029-7844(95)00063-W; PETERS RK, 1986, JNCI-J NATL CANCER I, V76, P423; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PLATZ CE, 1995, CANCER, V75, P270, DOI 10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D; QIZILBASH AH, 1975, AM J CLIN PATHOL, V64, P155; ROLLASON TP, 1989, INT J GYNECOL PATHOL, V8, P230, DOI 10.1097/00004347-198909000-00006; Schorge JO, 1999, OBSTET GYNECOL, V93, P219, DOI 10.1016/S0029-7844(98)00371-8; SCHWARTZ SM, 1986, AM J EPIDEMIOL, V124, P1045, DOI 10.1093/oxfordjournals.aje.a114474; SHANKEY TV, 1993, CYTOMETRY, V14, P472, DOI 10.1002/cyto.990140503; Sherman ME, 2005, CANCER, V103, P1258, DOI 10.1002/cncr.20877; Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826; Wright C, 1994, BLAUSTEINS PATHOLOGY, P279	27	0	0	0	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					285	291		10.5114/PJP.2018.79548			7	Pathology	Pathology	HA9TL	WOS:000450649700010	30509055	DOAJ Gold			2019-10-28	
J	Pronicki, M; Piekutowska-Abramczuk, D; Rokicki, D; Iwanicka-Pronicka, K; Grajkowska, W				Pronicki, Maciej; Piekutowska-Abramczuk, Dorota; Rokicki, Dariusz; Iwanicka-Pronicka, Katarzyna; Grajkowska, Wieslawa			HISTOPATHOLOGICAL LIVER FINDINGS IN PATIENTS WITH HEPATOCEREBRAL MITOCHONDRIAL DEPLETION SYNDROME WITH DEFINED MOLECULAR BASIS	POLISH JOURNAL OF PATHOLOGY			English	Article						mitochondrial DNA depletion; liver failure; POLG1; DGUOK; MPV17	ALPERS-HUTTENLOCHER SYNDROME; DNA DEPLETION; DEGENERATION	Mitochondrial DNA depletion consisting of the systemic reduction of mtDNA copy number in cells may have a heterogenous genetic basis, resulting from a pathogenic change in the nuclear genes involved in mtDNA synthesis. The mode of inheritance is autosomal recessive. Severe hepatocerebral disease represents one of many different clinical forms of so-called mitochondrial depletion syndrome (MDS). We present the liver histopathology of 13 children who eventually died in the course of hepatocerebral MDS confirmed molecularly, harbouring mutations of DGUOK, MPV17, and POLG genes. Material comprising eight autopsy and five liver biopsy specimens showed a moderately reproducible pattern of parenchymal damage, which we consider potentially helpful in the differential diagnosis and planning of the diagnostic investigation in families of children who died due to early-onset acute liver failure and encephalopathy.	[Pronicki, Maciej; Grajkowska, Wieslawa] Childrens Mem Hlth Inst, Dept Pathol, Aleja Dzieci Polskich 20, PL-04730 Warsaw, Poland; [Piekutowska-Abramczuk, Dorota; Iwanicka-Pronicka, Katarzyna] Childrens Mem Hlth Inst, Dept Genet, Warsaw, Poland; [Rokicki, Dariusz] Childrens Mem Hlth Inst, Dept Paediat Nutr & Metab Disorders, Warsaw, Poland; [Iwanicka-Pronicka, Katarzyna] Childrens Mem Hlth Inst, Dept Audiol & Phoniatr, Warsaw, Poland	Grajkowska, W (reprint author), Childrens Mem Hlth Inst, Dept Pathol, Aleja Dzieci Polskich 20, PL-04730 Warsaw, Poland.	w.grajkowska@ipczd.pl		Piekutowska-Abramczuk, Dorota/0000-0002-9786-3704; Pronicki, Maciej/0000-0002-5589-0456; Grajkowska, Wieslawa/0000-0001-8318-5781	Polish National Science Centre [N 2857/B/P01/2010/39, 2012/05/B/NZ2/01627]	This study was partially supported by grants from the Polish National Science Centre No. N 2857/B/P01/2010/39, 2012/05/B/NZ2/01627.	BATTS KP, 1995, AM J SURG PATHOL, V19, P1409, DOI 10.1097/00000478-199512000-00007; El-Hattab A.W., 1993, GENEREVIEWS; HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402; HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009; MORAES CT, 1991, AM J HUM GENET, V48, P492; Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X; Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079; Piekutowska-Abramczuk D, 2014, CLIN GENET, V85, P573, DOI 10.1111/cge.12228; Piekutowska-Abramczuk D, 2016, STANDARDY MEDYCZNE P, V13, P869; Pronicka E, 2011, MED SCI MONITOR, V17, pCR203, DOI 10.12659/MSM.881716; Pronicka E, 2011, J APPL GENET, V52, P61, DOI 10.1007/s13353-010-0008-y	11	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					292	298		10.5114/PJP.2018.79549			7	Pathology	Pathology	HA9TL	WOS:000450649700011	30509056	DOAJ Gold			2019-10-28	
J	Szablowska-Gadomska, I; Ducher, M; Orzechowska, M; Boguslawska-Duch, J; Kowalska, M; Polawska, H; Malecki, M				Szablowska-Gadomska, Ilona; Ducher, Magdalena; Orzechowska, Magdalena; Boguslawska-Duch, Joanna; Kowalska, Magdalena; Polawska, Helena; Malecki, Maciej			PERITONEAL FLUID STIMULATES NEOPLASTIC TRANSFORMATION OF NORMAL HEK 293 CELLS BY HIGH EXPRESSION OF PLURIPOTENT GENES	POLISH JOURNAL OF PATHOLOGY			English	Article						microenvironment; ascites; ovarian cancer; endometrial cancer; pluripotency	OVARIAN-CANCER CELLS; HYPOXIA-INDUCIBLE FACTORS; E-CADHERIN; STEM-CELLS; IN-VITRO; SPHEROID FORMATION; PROLIFERATION; MIGRATION; INVASION; REPRESSION	Gynecological cancers constitute a serious problem in the world. Their advanced stages are often characterized by the accumulation of ascites, which leads to spreading of cancer cells outside their primary focus. Despite progress in the treatment, prognoses are still not satisfactory. The main causes of these failures are chemoresistance, metastases and recurrences of the disease, which is influenced by, among others, the microenvironment of cancer cells. This study investigated the effect of the microenvironment, which create ascites derived from patients with ovarian and endornetrial cancer to non-gynecological HEK 293 cells. The effect of the gynecological cancer microenvironment on HEK 293 cells behaviour was analysed using RT-PCR, qRT-PCR, Western blotting and functional analysis (invasion assays, hanging drop) methods. Our results suggest that the key genes for the development of cancer can be regulated by epigenetic and hypoxiainducible factor in dependent manner. It was observed that in vitro microenvironment, which is created by cells originating from patients with gynecological cancer (ovarian cancer, endometrial cancer) is able to generate changes in HEK 293 cells by itself.	[Szablowska-Gadomska, Ilona; Ducher, Magdalena; Orzechowska, Magdalena; Boguslawska-Duch, Joanna; Polawska, Helena; Malecki, Maciej] Med Univ Warsaw, Dept Appl Pharm, Banacha 1, PL-02097 Warsaw, Poland; [Kowalska, Magdalena] Mem Canc Ctr & Inst Oncol, Dept Gynecol Oncol, Warsaw, Poland	Ducher, M (reprint author), Med Univ Warsaw, Dept Appl Pharm, Banacha 1, PL-02097 Warsaw, Poland.	mducher@wum.edu.pl			National Centre for Research and Develoment [1/233624/4/NCBR/2014]	This work was partially supported by a grant from the National Centre for Research and Develoment (Strategmed 1/233624/4/NCBR/2014).	Adamaki M, 2012, PEDIAT THERAPEUT S1, pS1; Ahmed N, 2005, BRIT J CANCER, V92, P1475, DOI 10.1038/sj.bjc.6602495; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Darai E, 1997, HUM PATHOL, V28, P922, DOI 10.1016/S0046-8177(97)90007-1; Dong LL, 2012, ACTA PHARMACOL SIN, V33, P817, DOI 10.1038/aps.2012.30; Dovey OM, 2010, P NATL ACAD SCI USA, V107, P8242, DOI 10.1073/pnas.1000478107; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Flate E, 2014, INT J ONCOL, V45, P1401, DOI 10.3892/ijo.2014.2553; Forristal CE, 2010, REPRODUCTION, V139, P85, DOI 10.1530/REP-09-0300; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Gawrychowski K, 2014, DIS MARKERS, DOI 10.1155/2014/683757; Gerhauser C, 2013, TOP CURR CHEM, V329, P73, DOI 10.1007/128_2012_360; Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x; Haan C, 2007, J IMMUNOL METHODS, V318, P11, DOI 10.1016/j.jim.2006.07.027; Hayashi A, 2010, INT J CANCER, V127, P1332, DOI 10.1002/ijc.25151; Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262; Jin Ke Long, 2008, J Gynecol Oncol, V19, P185, DOI 10.3802/jgo.2008.19.3.185; Jing SW, 2013, DIS ESOPHAGUS, V26, P75, DOI 10.1111/j.1442-2050.2011.01321.x; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Kelly RDW, 2013, BIOCHEM SOC T, V41, P741, DOI 10.1042/BST20130010; Kramer N, 2013, MUTAT RES-REV MUTAT, V752, P10, DOI 10.1016/j.mrrev.2012.08.001; Lau MT, 2011, ONCOGENE, V30, P2753, DOI 10.1038/onc.2011.6; Lin Ruei-Zhen, 2008, Biotechnology Journal, V3, P1172, DOI 10.1002/biot.200700228; Matte I, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-288; Murphy SK, 2012, FUTURE ONCOL, V8, P151, DOI [10.2217/FON.11.152, 10.2217/fon.11.152]; Nieborowska-Skorska M, 2006, CANCER RES, V66, P4108, DOI 10.1158/0008-5472.CAN-05-1584; Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Puiffe ML, 2007, NEOPLASIA, V9, P820, DOI 10.1593/neo.07472; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Shi WJ, 2006, J BIOL CHEM, V281, P23319, DOI 10.1074/jbc.M601811200; Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188; Soncin S, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-78; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Yoshihara K, 2009, CANCER SCI, V100, P1421, DOI 10.1111/j.1349-7006.2009.01204.x; Zhang X, 2013, ONCOGENE, V32, P2249, DOI 10.1038/onc.2012.237; Zhang ZB, 2013, INT J ONCOL, V43, P1194, DOI 10.3892/ijo.2013.2054	40	1	1	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					299	310		10.5114/PJP.2018.79550			12	Pathology	Pathology	HA9TL	WOS:000450649700012	30509057	DOAJ Gold			2019-10-28	
J	Stolnicu, S; Bauer, O; Naznean, A; Podoleanu, C; Georgescu, R				Stolnicu, Simona; Bauer, Orsolya; Naznean, Adrian; Podoleanu, Cristian; Georgescu, Rares			ER-/PR plus SUBSET OF INVASIVE BREAST CARCINOMA (IBC): A DISTINCT PHENOTYPE WITH GOOD PROGNOSIS	POLISH JOURNAL OF PATHOLOGY			English	Article						breast pathology; breast cancer; immunohistochemistry; hormone receptors; management	EXPRESSION; CANCERS	The expression of the estrogen (ER) and progesterone (PR) receptors in IBC patients represents a well-know prognostic and predictive factor. The existence of ER-/PR+ as a distinct phenotype, however, is controversial as well as is its prognostic significance. The aim of the study was to assess the incidence and prognosis in patients with ER-/PR+ IBC. One hundred and twelve patients with IBC were analyzed regarding ER/PR profile and survival. GraphPad prism 6 for Windows and Kaplan Mayer curve were used to determine overall survival (OS) and disease-free survival (DFS), with p < 0.05 as statistically significant. Of the 112 IBC patients, 75% were ER+/PR-, 16.07% were ER-/PR-, 7.14% were ER+/PR- and only 1.78% were ER-/PR+. OS was 100% in the ER-/PR+ group and 91.6% in the ER+/PR+ group. The lowest OS was found in the ER-I PR- group (72.2%), while OS was 100% in ER-/PR+ group. Regarding DFS, there were no statistically significant differences in the four groups (p = 0.11), although the highest DFS was found in the ER-/PR+ group (100%). ER-/PR+ tumors were associated with younger age (p = 0.72), smaller tumor diameter (p = 0.27), absence of lymph node metastases, and HER2 overexpression. Our results suggest that ER-/PR+ cases represent the rarest phenotype in IBC cases but its association with the best OS and DFS in other ER/PR phenotypes indicates an independent predictive value of PR for treatment considerations.	[Stolnicu, Simona] Univ Med & Pharm Tirgu Mures, Dept Pathol, Targu Mures, Romania; [Bauer, Orsolya; Georgescu, Rares] Univ Med & Pharm Tirgu Mures, Dept Surg, Targu Mures, Romania; [Naznean, Adrian] Univ Med & Pharm Tirgu Mures, Dept Foreign Languages, Targu Mures, Romania; [Podoleanu, Cristian] Univ Med & Pharm Tirgu Mures, Dept Cardiol, Targu Mures, Romania	Naznean, A (reprint author), Univ Med & Pharm Tirgu Mures, Dept Foreign Languages, Targu Mures, Romania.	adinaznean@yahoo.com		Stolnicu, Simona/0000-0002-4459-7019			Ahmed SS, 2017, J CLIN PATHOL, V70, P320, DOI 10.1136/jclinpath-2016-203847; Chan M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132449; Cserni G, 2011, PATHOL ONCOL RES, V17, P663, DOI 10.1007/s12253-011-9366-y; Hefti MM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3462; Itoh M, 2014, BREAST CANCER RES TR, V143, P403, DOI 10.1007/s10549-013-2763-z; National Comprehensive Cancer Networ (NCCN), 2017, BREAST CANC; Schroth W, 2016, BREAST CANCER RES TR, V155, P85, DOI 10.1007/s10549-015-3651-5; Shen TS, 2015, HUM PATHOL, V46, P1776, DOI 10.1016/j.humpath.2015.07.019	8	0	0	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					311	313		10.5114/PJP.2018.79551			3	Pathology	Pathology	HA9TL	WOS:000450649700013	30509058	DOAJ Gold			2019-10-28	
J	Rudzki, Z; Lovell, R; Miller, B; Murthy, V; Paneesha, S; Pratt, G; Smith, N				Rudzki, Zbigniew; Lovell, Richard; Miller, Ben; Murthy, Vidhya; Paneesha, Shankara; Pratt, Guy; Smith, Neil			FATAL SYSTEMIC ANGIOMATOSIS WITH WIDESPREAD SCLEROTIC SKELETAL CHANGES, DIAGNOSED WITH THE AID OF A BONE MARROW BIOPSY: THE LYMPHATICS ENTER THE BONE MARROW	POLISH JOURNAL OF PATHOLOGY			English	Article						angiomatosis; angiogenesis; bone marrow; trephine bone marrow biopsy	GENERALIZED LYMPHANGIOMATOSIS; CYSTIC ANGIOMATOSIS; INVOLVEMENT; CELLS; MRI	A 56-year-old female presented with popliteal venous thrombosis, splenomegaly, and sclerotic bone lesions. Bone marrow biopsy showed fibrosis, proliferation of abnormal blood vessels and lymphatics, bone remodelling, and no significant changes in haematopoietic elements. Following a relatively indolent initial clinical course, one year later she rapidly deteriorated and died of respiratory failure associated with widespread disease. Ingrowth of podoplanin+ lymphatics mixed with CD34+/podoplanin- blood vessels into the bone marrow is a new finding and may be a unique feature of this disease.	[Rudzki, Zbigniew] Univ Hosp Birmingham NHS Fdn Trust, Dept Histopathol, Birmingham, W Midlands, England; [Lovell, Richard; Murthy, Vidhya; Paneesha, Shankara; Pratt, Guy; Smith, Neil] Univ Hosp Birmingham NHS Fdn Trust, Dept Haematol, Birmingham, W Midlands, England; [Miller, Ben] Univ Hosp Birmingham NHS Fdn Trust, Dept Radiol, Birmingham, W Midlands, England	Rudzki, Z (reprint author), Birmingham Heartlands Hosp, Dept Histopathol, Birmingham B9 5SS, W Midlands, England.	zbigniew.rudzki@heartofengland.nhs.uk					Aviv RI, 2001, CLIN RADIOL, V56, P184, DOI 10.1053/crad.2000.0606; DEVANEY K, 1994, J BONE JOINT SURG AM, V76A, P878, DOI 10.2106/00004623-199406000-00012; Faber DL, 2015, ISR MED ASSOC J, V17, P785; Forstner R, 1998, SKELETAL RADIOL, V27, P445, DOI 10.1007/s002560050415; Kwag E, 2013, CLIN IMAG, V37, P723, DOI 10.1016/j.clinimag.2012.12.003; Marcucci G, 2013, CALCIFIED TISSUE INT, V93, P462, DOI 10.1007/s00223-013-9761-3; MUNKA V., 1965, FOLIA MORPHOL [PRAGUE], V13, P404; Naresh KN, 2006, J CLIN PATHOL, V59, P903, DOI 10.1136/jcp.2004.020610; Nikolaou VS, 2014, WORLD J ORTHOP, V5, P694, DOI 10.5312/wjo.v5.i5.694; Religa P, 2005, BLOOD, V106, P4184, DOI 10.1182/blood-2005-01-0226; Renjen P, 2014, SKELETAL RADIOL, V43, P1633, DOI 10.1007/s00256-014-1935-1; Soler R, 1996, EUR J RADIOL, V22, P149, DOI 10.1016/0720-048X(95)00733-7; Tawada M, 2014, ONCOL REP, V32, P2359, DOI 10.3892/or.2014.3499; Vanhoenacker FM, 2003, EUR RADIOL, V13, pL35, DOI 10.1007/s00330-002-1805-4	14	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					314	318		10.5114/PJP.2018.79552			5	Pathology	Pathology	HA9TL	WOS:000450649700014	30509059	DOAJ Gold			2019-10-28	
J	Tjalma, WAA				Tjalma, Wiebren A. A.			THE HEALTH OUTCOME AND THE COSTS OF PRIMARY HPV TESTING WITH DUAL-STAIN CYTOLOGY TRIAGE IN CERVICAL CANCER SCREENING	POLISH JOURNAL OF PATHOLOGY			English	Letter							BELGIUM		[Tjalma, Wiebren A. A.] Univ Antwerp, Antwerp Univ Hosp, Dept Obstet & Gynaecol, Multidisciplinary Breast Clin,Gynaecol Oncol Unit, Antwerp, Belgium	Tjalma, WAA (reprint author), Antwerp Univ Hosp, Unit Gynecol Oncol, Multidisciplinary Breast Clin, Wilrijkstr 10, B-2650 Edegem, Belgium.	Wiebren.Tjalma@uza.be					Celewicz A, 2018, POL J PATHOL, V69, P42, DOI 10.5114/pjp.2018.75335; Tjalma WAA, 2014, EUR J GYNAECOL ONCOL, V35, P211; Tjalma WAA, 2017, EUR J OBSTET GYN R B, V212, P171, DOI 10.1016/j.ejogrb.2017.01.010; Tjalma WAA, 2017, EUR J OBSTET GYN R B, V210, P275, DOI 10.1016/j.ejogrb.2017.01.009	4	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					319	320		10.5114/pjp.2018.79553			2	Pathology	Pathology	HA9TL	WOS:000450649700015	30509060	DOAJ Gold			2019-10-28	
J	Hattori, Y; Sentani, K; Matsuoka, N; Nakayama, H; Hattori, T; Kudo, Y; Yasui, W				Hattori, Yui; Sentani, Kazuihro; Matsuoka, Naoki; Nakayama, Hirofumi; Hattori, Takuya; Kudo, Yoshiki; Yasui, Wataru			INTRAMURAL FLORID CYSTIC ENDOSALPINGIOSIS OF THE UTERUS AFTER MENOPAUSE	POLISH JOURNAL OF PATHOLOGY			English	Article						florid cystic endosalpingiosis; endosalpingiosis; after menopause; gynecological pathology; immunohistochemistry		Endosalpingiosis is a benign condition characterized by the presence of tubal epithelium outside the fallopian tube and the absence of endometrial stroma. Florid cystic endosalpingiosis is a very rare form of endosalpingiosis that presents as a tumor-like lesion. We report the case of a 67-year-old woman who presented with a cystic lesion of the uterus. Macroscopically, a cut section revealed a multicystic, whitish mass in the myometrium of the fundus. Histologically, the lesion consisted of numerous variably sized glands that were lined with a single or stratified layer of ciliated columnar cells similar to tubal epithelium.	[Hattori, Yui; Sentani, Kazuihro; Hattori, Takuya; Yasui, Wataru] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Pathol, Hiroshima, Japan; [Matsuoka, Naoki; Kudo, Yoshiki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Obstet & Gynecol, Hiroshima, Japan; [Nakayama, Hirofumi] JR Hiroshima Hosp, Pathol & Lab Med, Hiroshima, Japan	Sentani, K (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	kzsentani@hiroshima-u.ac.jp					Batt RE, 2013, REPROD SCI, V20, P1030, DOI 10.1177/1933719112472736; Cil AP, 2008, ULTRASOUND OBST GYN, V32, P106, DOI 10.1002/uog.5346; Clement PB, 1999, AM J SURG PATHOL, V23, P166, DOI 10.1097/00000478-199902000-00005; Heatley MK, 2001, J CLIN PATHOL, V54, P399, DOI 10.1136/jcp.54.5.399; Hesseling MH, 2000, J AM ASSOC GYN LAP, V7, P215, DOI 10.1016/S1074-3804(00)80043-2; Im S, 2015, TAIWAN J OBSTET GYNE, V54, P75, DOI 10.1016/j.tjog.2014.11.011; Kajo K, 2007, HISTOPATHOLOGY, V51, P709, DOI 10.1111/j.1365-2559.2007.02827.x; Kajo K, 2005, PATHOL RES PRACT, V201, P527, DOI 10.1016/j.prp.2005.04.010; McCoubrey A, 2005, J CLIN PATHOL, V58, P1221, DOI 10.1136/jcp.2005.027946; Prentice L, 2012, FERTIL STERIL, V98, P942, DOI 10.1016/j.fertnstert.2012.06.039; Vang R, 2013, HISTOPATHOLOGY, V62, P44, DOI 10.1111/his.12046; ZINSSER KR, 1982, AM J SURG PATHOL, V6, P109, DOI 10.1097/00000478-198203000-00003	12	0	0	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					321	324		10.5114/PJP.2018.79554			4	Pathology	Pathology	HA9TL	WOS:000450649700016	30509061	DOAJ Gold			2019-10-28	
J	Chang, IW; Gule, MF				Chang, I-Wei; Gule, Mpendulo Felix			Quiz WHAT IS YOUR DIAGNOSIS?	POLISH JOURNAL OF PATHOLOGY			English	Article									[Chang, I-Wei] Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan; [Chang, I-Wei] Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei, Taiwan; [Gule, Mpendulo Felix] Mbabane Govt Hosp, Mbabane, Swaziland	Chang, IW (reprint author), Taipei Med Univ Hosp, Dept Pathol, Taipei, Taiwan.; Chang, IW (reprint author), Taipei Med Univ, Coll Med, Sch Med, Dept Pathol, Taipei, Taiwan.							0	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	3					325	326		10.5114/PJP.2018.79555			2	Pathology	Pathology	HA9TL	WOS:000450649700017	30509062	DOAJ Gold			2019-10-28	
J	Alsaqobi, A; Al-Brahim, N				Alsaqobi, Ameerah; Al-Brahim, Nabeel			Osseous Metaplasia of the Cervix: A Rare Transformation Can Mimic a Tumor-Literature Review	CASE REPORTS IN PATHOLOGY			English	Review							HETEROTOPIC OSSIFICATION; MANAGEMENT	Background. The transformation of nonosseous soft tissue into bone is known as osseous metaplasia (OM). This condition most commonly affects the musculoskeletal and central nervous systems and it is a well-known phenomenon in different soft tissue organs. Rarely, OM can affect the uterus, which can extend into the cervix. OM affecting the cervix alone is a more rare condition that has multiple different clinical presentations. The presentation can be similar to that of a tumor in extremely rare cases. Case Summary. A 23-year-old nulligravida was complaining of irregular vaginal bleeding for one-month duration. Speculum examination revealed a foul-smelling bloody purulent discharge, tender cervix, and a brownish growth located at the posterior cervical lip. A punch biopsy of the growth was performed. Histological examination of the tissue revealed multiple bone fragments with necrosis and an inflammatory exudate. Because of the unusual findings, a repeat biopsy was performed. The biopsy yielded the same findings, which confirmed the diagnosis of osseous metaplasia of the cervix. Conclusion. Although osseous metaplasia is a known phenomenon in different soft tissues, it is extremely rare in the uterine cervix and can mimic malignancy. Therefore, clinicians should be aware of it.	[Alsaqobi, Ameerah] Kuwait Univ, Safat, Kuwait; [Al-Brahim, Nabeel] Farwaniya Hosp, Dept Pathol, Farwaniya, Kuwait	Alsaqobi, A (reprint author), Kuwait Univ, Safat, Kuwait.	metalcoreftw@live.com					Al-Daraji WI, 2005, J CLIN PATHOL, V58, P220, DOI 10.1136/jcp.2004.020685; Bedaiwy MA, 2001, OBSTET GYNECOL, V98, P968, DOI 10.1016/S0029-7844(01)01486-7; BHATIA NN, 1982, OBSTET GYNECOL, V60, P256; Cayuela E, 2009, FERTIL STERIL, V91, DOI 10.1016/j.fertnstert.2008.12.026; Cholok D, 2018, BONE, V109, P12, DOI 10.1016/j.bone.2017.09.019; Chun JS, 2013, ONCOL LETT, V6, P977, DOI 10.3892/ol.2013.1475; Cicinelli E, 2005, J MINIM INVAS GYN, V12, P159, DOI 10.1016/j.jmig.2005.01.006; Coccia ME, 1996, ULTRASOUND OBST GYN, V8, P134, DOI 10.1046/j.1469-0705.1996.08020134.x; Czerwionka-Szaflarska G. B. Mieczyslawa, 2004, AM J CASE REPORTS, V5, P313; Elkattan E, 2015, J TURK-GER GYNECOL A, V16, P58, DOI 10.5152/jtgga.2015.68466; Giannella L, 2014, J LOW GENIT TRACT DI, V18, pE19, DOI 10.1097/LGT.0b013e3182914eef; Grayzel DM, 1939, ARCH INTERN MED, V64, P136, DOI 10.1001/archinte.1939.00190010146012; Haschek WM, 2010, FUNDAMENTALS OF TOXICOLOGIC PATHOLOGY, 2ND EDITION, P1; King TC, 2007, ELSEVIERS INTEGRATED; Lattin GE, 2014, RADIOGRAPHICS, V34, P805, DOI 10.1148/rg.343130127; Mandato VD, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.01.028; Marrazzo JM, 2002, OBSTET GYNECOL, V100, P579, DOI 10.1016/S0029-7844(02)02140-3; Patil SB, 2013, ANN MED HEALTH SCI R, V3, pS10, DOI 10.4103/2141-9248.121209; Polat I., 2011, FERTIL STERIL, V95, P2434; Ranganathan K, 2015, J BONE JOINT SURG AM, V97A, P1101, DOI 10.2106/JBJS.N.01056; Sabatini L, 2001, BRIT J OBSTET GYNAEC, V108, P333, DOI 10.1111/j.1471-0528.2001.00062.x; Shehab D, 2002, J NUCL MED, V43, P346; Singh Prem, 2011, J Hum Reprod Sci, V4, P56, DOI 10.4103/0974-1208.82363; SMITH CML, 1983, PARAPLEGIA, V21, P380, DOI 10.1038/sc.1983.62; Umashankar T, 2010, J Hum Reprod Sci, V3, P102, DOI 10.4103/0974-1208.69329	25	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1392975	10.1155/2018/1392975			4	Pathology	Pathology	HA0XP	WOS:000449935600001	30515339	DOAJ Gold, Green Published			2019-10-28	
J	Amer, SM; Ukudeyeva, A; Pine, HS; Campbell, GA; Clement, CG				Amer, Samir M.; Ukudeyeva, Aijan; Pine, Harold S.; Campbell, Gerald A.; Clement, Cecilia G.			Plexiform Schwannoma of the Tongue in a Pediatric Patient with Neurofibromatosis Type 2: A Case Report and Review of Literature	CASE REPORTS IN PATHOLOGY			English	Review							BENIGN; BASE	Introduction. Plexiform schwannoma is a rare variant of schwannoma that accounts for only 5% of all schwannomas. Herein, we present a rare case of plexiform schwannoma of the tongue in a pediatric patient with neurofibromatosis type 2 (NF2). Case Presentation. A 13-year-old female presented with a growing left-sided tongue mass. The patient has a past medical history of NF2. The tongue mass was excised and histopathological examination revealed a spindle cell tumor with multinodular growth pattern, with Verocay bodies' formation. Tumor cells were strongly positive for S-100 protein and negative for smooth muscle actin (SMA), and EMA highlighted perineural fibroblasts surrounding tumor nodules. These findings were diagnostic of plexiform schwannoma. Conclusion. Plexiform schwannoma of the tongue is an extremely rare tumor seen in patients with NF2. Clinical examination and histopathological evaluation are important for diagnosis of plexiform schwannoma.	[Amer, Samir M.; Ukudeyeva, Aijan; Campbell, Gerald A.; Clement, Cecilia G.] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Pine, Harold S.] Univ Texas Med Branch, Dept Otolaryngol, Galveston, TX 77555 USA	Clement, CG (reprint author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.	cgclemen@utmb.edu					Agaram NP, 2005, AM J SURG PATHOL, V29, P1042; Ali S., 2014, OPEN J STOMATOLOGY, V04, P174; Andreadis D, 2011, HEAD NECK PATHOL, V5, P302, DOI 10.1007/s12105-011-0251-5; Berg JC, 2008, HUM PATHOL, V39, P633, DOI 10.1016/j.humpath.2007.10.029; Carlson ML, 2016, J NEUROL SURG REP, V77, pE106, DOI 10.1055/s-0036-1584603; Cohen M, 2009, EUR ARCH OTO-RHINO-L, V266, P1823, DOI 10.1007/s00405-008-0907-2; Cokelaere K, 2000, INT J SURG PATHOL, V8, P353, DOI 10.1177/106689690000800419; de Bree R, 2000, EUR ARCH OTO-RHINO-L, V257, P283, DOI 10.1007/s004050050241; Enoz Murat, 2006, J Cancer Res Ther, V2, P76; GEIST JR, 1992, ORAL SURG ORAL MED O, V73, P376, DOI 10.1016/0030-4220(92)90139-H; Hirose T, 1997, MODERN PATHOL, V10, P1075; Iida A, 2003, SURG TODAY, V33, P940, DOI 10.1007/s00595-003-2610-7; Jouhilahti EM, 2012, CLIN ORAL INVEST, V16, P551, DOI 10.1007/s00784-011-0519-x; Kanazawa H., 2018, ORAL MAXILLOFACIAL S, V4, P68; Karaca CT, 2010, AM J OTOLARYNG, V31, P46, DOI 10.1016/j.amjoto.2008.09.010; Ko JY, 2009, ANN DERMATOL, V21, P402, DOI 10.5021/ad.2009.21.4.402; Kohyama S, 2011, J BRACHIAL PLEX PERI, V6, DOI 10.1186/1749-7221-6-9; Lee E., 2017, MAXILLOFACIAL PLASTI, V39; Li XN, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-342; Lira RB, 2013, ACTA OTORHINOLARYNGO, V33, P137; Lobo I, 2009, J EUR ACAD DERMATOL, V23, P616, DOI 10.1111/j.1468-3083.2008.03057.x; Luksic L, 2011, J CRANIO MAXILL SURG, V39, P441, DOI 10.1016/j.jcms.2010.10.004; Neville B. W., 2009, SOFT TISSUE TUMORS O, P526; Nisa Lluis, 2011, CASE REPORTS OTOLARY, V2011; Nonaka D, 2008, J CUTAN PATHOL, V35, P1014, DOI 10.1111/j.1600-0560.2007.00953.x; Piatelli A, 1984, Acta Stomatol Belg, V81, P213; Sawhney R, 2008, AM J OTOLARYNG, V29, P119, DOI 10.1016/j.amjoto.2006.08.003; WRIGHT BA, 1980, ORAL SURG ORAL MED O, V49, P509, DOI 10.1016/0030-4220(80)90075-4	28	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									9814591	10.1155/2018/9814591			4	Pathology	Pathology	GY6OI	WOS:000448708600001	30410810	DOAJ Gold, Green Published			2019-10-28	
J	Mirchia, K; Naous, R				Mirchia, Kanish; Naous, Rana			Nasal Chondromesenchymal Hamartoma: Rare Case Report in an Elderly Patient and Brief Review of Literature	CASE REPORTS IN PATHOLOGY			English	Review							CHILDREN; INFANCY	Hamartomas are considered a mixture of nonneoplastic tissue, which may be indigenous to a different location in the body. As such, they may be epithelial, mesenchymal, or mixed. In the sinonasal region, the following hamartomatous lesions are considered to lie on a spectrum and include respiratory epithelial adenomatoid hamartoma (REAH), chondro-osseous respiratory epithelial adenomatoid hamartoma (COREAH), and nasal chondromesenchymal hamartoma (NCMH). To our knowledge, less than 50 cases of sinonasal hamartomas have been reported in the English literature so far with NCMH being very rare and primarily a tumor in infancy, with only 2 cases reported in individuals older than 16 years of age. We report a highly unusual case of a NCMH in the right maxillary sinus of a 70-year-old female.	[Mirchia, Kanish; Naous, Rana] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	Mirchia, K (reprint author), SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA.	mirchiak@upstate.edu					Alrawi M, 2003, INT J PEDIATR OTORHI, V67, P669, DOI 10.1016/S0165-5876(03)00067-3; Avci Hakan, 2016, Kulak Burun Bogaz Ihtis Derg, V26, P300, DOI 10.5606/kbbihtisas.2016.70852; Cho YC, 2013, J ORAL MAXIL SURG, V71, P72, DOI 10.1016/j.joms.2012.03.020; El Behery R, 2012, PEDIATR DEVEL PATHOL, V15, P249, DOI 10.2350/11-11-1121-CR.1; Finitsis S, 2009, CARDIOVASC INTER RAD, V32, P593, DOI 10.1007/s00270-008-9458-6; Hill DA, 2009, SCIENCE, V325, P965, DOI 10.1126/science.1174334; Hsueh C, 2001, ARCH PATHOL LAB MED, V125, P400; Johnson C, 2007, PEDIATR RADIOL, V37, P101, DOI 10.1007/s00247-006-0352-6; Kato K, 1999, PATHOL INT, V49, P731, DOI 10.1046/j.1440-1827.1999.00933.x; Kim B, 2004, PEDIATR NEUROSURG, V40, P136, DOI 10.1159/000079857; Kim JE, 2009, KOREAN J RADIOL, V10, P416, DOI 10.3348/kjr.2009.10.4.416; Lee CH, 2015, INT J CLIN EXP PATHO, V8, P9643; Li GY, 2013, CAN J OPHTHALMOL, V48, pE22, DOI 10.1016/j.jcjo.2012.10.007; Low SE, 2006, HISTOPATHOLOGY, V49, P321, DOI 10.1111/j.1365-2559.2006.02431.x; Mason KA, 2015, J OTOLARYNGOL-HEAD N, V44, DOI 10.1186/s40463-015-0077-3; McDermott MB, 1998, AM J SURG PATHOL, V22, P425, DOI 10.1097/00000478-199804000-00006; Moon SH, 2014, CAN J OPHTHALMOL, V49, pE30, DOI 10.1016/j.jcjo.2013.11.011; Nakaya M, 2017, EUR ANN OTORHINOLARY, V134, P423, DOI 10.1016/j.anorl.2016.05.014; Norman ES, 2004, PEDIATR DEVEL PATHOL, V7, P517, DOI 10.1007/s10024-004-1003-2; Obidan AA, 2014, SAUDI MED J, V35, P876; Ozolek JA, 2005, ARCH PATHOL LAB MED, V129, P1444; Priest JR, 2010, INT J PEDIATR OTORHI, V74, P1240, DOI 10.1016/j.ijporl.2010.07.022; Sharif M, 2013, MOD PHYS LETT A, V28, DOI 10.1142/S0217732313501800; Shet T, 2004, INT J PEDIATR OTORHI, V68, P359, DOI 10.1016/j.ijporl.2003.10.014; Silkiss RZ, 2007, OPHTHAL PLAST RECONS, V23, P243, DOI 10.1097/IOP.0b013e31803eaa0d; Unal A, 2016, TURKISH J PEDIATR, V58, P208; Uzomefuna V., 2012, BMJ CASE REPORTS; Wu JT, 2014, WORLD J SURG ONCOL, V12, DOI [10.1186/1477-7819-12-407, 10.1186/1477-7819-12-257]	28	0	0	2	2	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5971786	10.1155/2018/5971786			7	Pathology	Pathology	GY6OH	WOS:000448708500001	30405930	DOAJ Gold, Green Published			2019-10-28	
J	Naous, R				Naous, Rana			TLE1 Positive Clear Cell Sarcoma of the Kidney: A Case Report and Review of the Literature	CASE REPORTS IN PATHOLOGY			English	Review							DIAGNOSTIC IMMUNOHISTOCHEMICAL MARKER; CYCLIN D1 IMMUNOREACTIVITY; BCOR-CCNB3 GENE FUSION; PEDIATRIC RENAL TUMORS; SYNOVIAL SARCOMA; EXPRESSION; BCOR; ABNORMALITIES	Clear cell sarcoma of the kidney (CCSK) is an uncommon malignant tumor of uncertain histogenesis that occurs most commonly in childhood. Histologically, CCSK can mimic myxoid variant of synovial sarcoma (SS); however, the double positivity for CD99 and TLE1 in SS helps in excluding CCSK. Herein, we report a rare case of CCSK arising in the left kidney of a 3-year-old girl. The mass grossly measured 9.5 cm in maximum dimension and histologically showed the classic arborizing fibrovascular septae and background myxoid matrix that is usually seen in CCSK. The tumor however was double positive for CD99 and TLE1 which made it difficult to discriminate it from the myxoid variant of SS based on histopathological examination and immunophenotype alone, and genetic analysis for SYT gene rearrangement was required to reach a definitive diagnosis. Although there have been previous case reports of CCSK with positive expression of CD99 and negative TLE1, to our knowledge, this is the first case of CCSK expressing both CD99 and TLE1.	[Naous, Rana] SUNY Upstate Med Univ, Dept Pathol, 750 East Adams St, Syracuse, NY 13210 USA	Naous, R (reprint author), SUNY Upstate Med Univ, Dept Pathol, 750 East Adams St, Syracuse, NY 13210 USA.	naousr@upstate.edu					Argani P, 2000, AM J SURG PATHOL, V24, P4, DOI 10.1097/00000478-200001000-00002; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Aw SJ, 2015, PEDIATR DEVEL PATHOL, V18, P297, DOI 10.2350/14-12-1581-OA.1; Balarezo FS, 2001, ADV ANAT PATHOL, V8, P98, DOI 10.1097/00125480-200103000-00006; Gooskens SLM, 2012, EUR J CANCER, V48, P2219, DOI 10.1016/j.ejca.2012.04.009; He L, 2001, Zhonghua Bing Li Xue Za Zhi, V30, P422; Hirose Masahito, 2015, BMC Res Notes, V8, P129, DOI 10.1186/s13104-015-1100-5; Huang CC, 2006, PEDIATR BLOOD CANCER, V46, P728, DOI 10.1002/pbc.20773; Humphrey PA, 2016, WHO CLASSIFICATION T; Jagdis A, 2009, AM J SURG PATHOL, V33, P1743, DOI 10.1097/PAS.0b013e3181b7ed36; Kao YC, 2016, AM J SURG PATHOL, V40, P1670, DOI 10.1097/PAS.0000000000000697; Kosemehmetoglu K, 2009, MODERN PATHOL, V22, P872, DOI 10.1038/modpathol.2009.47; Kural A. R., 2006, BMC UROLOGY, V6; Matsuyama A, 2017, AM J SURG PATHOL, V41, P1713, DOI 10.1097/PAS.0000000000000934; Mirkovic J, 2015, HISTOPATHOLOGY, V67, P306, DOI 10.1111/his.12641; Nag D, 2014, J CANCER RES THER, V10, P1104, DOI 10.4103/0973-1482.146106; Namaoui RY, 2010, PROG UROL, V20, P465, DOI 10.1016/j.purol.2009.09.038; Rekhi B, 2012, INDIAN J MED RES, V136, P766; Sebire NJ, 2009, HISTOPATHOLOGY, V54, P516, DOI 10.1111/j.1365-2559.2008.03110.x; SOTELOAVILA C, 1985, HUM PATHOL, V16, P1219, DOI 10.1016/S0046-8177(85)80034-4; Terry J, 2007, AM J SURG PATHOL, V31, P240, DOI 10.1097/01.pas.0000213330.71745.39; Valente AL, 2013, APPL IMMUNOHISTO M M, V21, P408, DOI 10.1097/PAI.0b013e318279f9ee; Wong MK, 2018, HISTOPATHOLOGY, V72, P320, DOI 10.1111/his.13366; Xu X. W., 2016, MODERN HLTH PRESERVA, V4, P40	24	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									3462096	10.1155/2018/3462096			5	Pathology	Pathology	GY6OF	WOS:000448708200001	30410809	DOAJ Gold, Green Published			2019-10-28	
J	Ferlosio, A; Di Prete, M; Rossi, P; Campione, E; Orlandi, A				Ferlosio, Amedeo; Di Prete, Monia; Rossi, Piero; Campione, Elena; Orlandi, Augusto			Bednar Tumour Occurring after Malignant Melanoma Excision	CASE REPORTS IN PATHOLOGY			English	Article							PIGMENTED DERMATOFIBROSARCOMA PROTUBERANS; MULTIDIRECTIONAL DIFFERENTIATION; CELL; PATHOLOGY; UPDATE	We report the case of a seventy-four-year-old man with a slow-growing 2 cm mass on the back that arose near the surgical scar of previously excised melanoma, invasive to a Breslow depth of 3 mm. Preoperative clinical diagnosis was "in-transit" melanoma metastasis. After surgical excision, histopathologic examination revealed a dermal nodular proliferation of spindle cells arranged in storiform pattern, with mild pleomorphism, infiltrating around appendages and into the subcutaneous tissue. Immunohistochemical investigation documented diffuse positivity for CD34 and vimentin of spindle cells. Scattered dendritic cells, containing dark pigment in varying proportion and positive for S100, Melan-A and HMB-45, were also observed. A final diagnosis of Bednar tumour was formulated. Subsequently, the patient developed numerous metastases from the primary melanoma and died after 18 months. Bednar tumour is a rare pigmented variant of dermatofibrosarcoma protuberans of intermediate malignant potential. The presence of pigmented cells in Bednar tumour requires careful differential diagnosis with malignant or benign pigmented skin tumours. The clinical history of a Bednar tumour developing close to the scar of a previous melanoma gives the opportunity of a critical and intriguing discussion about the potential origin of pigmented cells in this rare variant of dermatofibrosarcoma protuberans.	[Ferlosio, Amedeo; Di Prete, Monia; Orlandi, Augusto] Univ Roma Tor Vergata, Anat Pathol, Viale Oxford 81, I-00133 Rome, Italy; [Rossi, Piero] Univ Roma Tor Vergata, Surg, Viale Oxford 81, I-00133 Rome, Italy; [Campione, Elena] Univ Roma Tor Vergata, Dermatol, Viale Oxford 81, I-00133 Rome, Italy	Orlandi, A (reprint author), Univ Roma Tor Vergata, Anat Pathol, Viale Oxford 81, I-00133 Rome, Italy.	orlandi@uniroma2.it		Campione, Elena/0000-0001-7447-6798			Abbott JJ, 2006, AM J SURG PATHOL, V30, P436, DOI 10.1097/00000478-200604000-00002; BEDNAR B, 1957, CANCER, V10, P368, DOI 10.1002/1097-0142(195703/04)10:2<368::AID-CNCR2820100218>3.0.CO;2-3; DELELLIS RA, 1984, J HISTOCHEM CYTOCHEM, V32, P899, DOI 10.1177/32.8.6146648; DING J, 1990, ACTA PATHOL JAPON, V40, P744; DUPREE WB, 1985, AM J SURG PATHOL, V9, P630, DOI 10.1097/00000478-198509000-00002; Fukunaga M, 1997, MODERN PATHOL, V10, P443; Goncharuk V, 2003, J CUTAN PATHOL, V30, P147, DOI 10.1034/j.1600-0560.2003.00030.x; Jha P, 2007, ANN DIAGN PATHOL, V11, P81, DOI 10.1016/j.anndiagpath.2006.12.010; Kagoura M, 1999, EUR J DERMATOL, V9, P366; Llombart B, 2013, SEMIN DIAGN PATHOL, V30, P13, DOI 10.1053/j.semdp.2012.01.002; Marcus JR, 1998, J PEDIATR SURG, V33, P1811, DOI 10.1016/S0022-3468(98)90292-5; Maurichi A, 2010, ANN SURG, V252, P1052, DOI 10.1097/SLA.0b013e3181efc23c; NAKAMURA T, 1987, AM J DERMATOPATH, V9, P18, DOI 10.1097/00000372-198702000-00005; Orlandi A, 1998, J CUTAN PATHOL, V25, P386, DOI 10.1111/j.1600-0560.1998.tb01763.x; REED RJ, 1983, AM J DERMATOPATH, V5, P385, DOI 10.1097/00000372-198308000-00011; Reha J, 2016, SURG CLIN N AM, V96, P1031, DOI 10.1016/j.suc.2016.05.006; Sellami Rym, 2012, Tunis Med, V90, P185; Thway K, 2016, ANN DIAGN PATHOL, V25, P64, DOI 10.1016/j.anndiagpath.2016.09.013; Thway K, 2014, ANN DIAGN PATHOL, V18, P369, DOI 10.1016/j.anndiagpath.2014.09.002; Weissinger SE, 2014, MODERN PATHOL, V27, P524, DOI 10.1038/modpathol.2013.162; ZELGER BW, 1995, HISTOPATHOLOGY, V26, P519, DOI 10.1111/j.1365-2559.1995.tb00270.x	21	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									7694272	10.1155/2018/7694272			5	Pathology	Pathology	GX2HH	WOS:000447539200001	30364040	DOAJ Gold, Green Published			2019-10-28	
J	Picken, MM; Bova, D; Pins, MR; Quek, ML				Picken, Maria M.; Bova, Davide; Pins, Michael R.; Quek, Marcus L.			Mixed Epithelial and Stromal Tumor of the Kidney with Extension into Inferior Vena Cava: Case Report and Discussion of Adult Biphasic Cystic Renal Lesions and the Significance of Vascular Involvement	CASE REPORTS IN PATHOLOGY			English	Article							OF-THE-LITERATURE; NEPHROMA; FEATURES; ENTITY; DIFFERENTIATION; ANGIOMYOLIPOMA; SPECTRUM; NEOPLASM; DISTINCT; VARIANT	Mixed epithelial and stromal tumor (MEST) is a biphasic adult renal lesion composed of solid and cystic areas containing spindle cell stroma and epithelium that lines the tubules and cystic spaces. While most MEST lesions are benign, rare cases with malignant morphology and biology have been reported. We present a case of mixed epithelial and stromal tumor of the kidney (MEST) with extension into the inferior vena cava in a young adult male. We discuss the differential diagnosis of MEST in the context of other biphasic cystic renal lesions and the significance of vascular involvement in the setting of an otherwise benign tumor morphology.	[Picken, Maria M.] Loyola Univ, Med Ctr, Dept Pathol, Chicago, IL 60611 USA; [Bova, Davide] Loyola Univ, Med Ctr, Dept Radiol, Chicago, IL 60611 USA; [Pins, Michael R.] Advocate Lutheran Gen Hosp, Dept Pathol, Park Ridge, IL USA; [Quek, Marcus L.] Loyola Univ, Med Ctr, Dept Urol, Chicago, IL 60611 USA	Picken, MM (reprint author), Loyola Univ, Med Ctr, Dept Pathol, Chicago, IL 60611 USA.	mpicken@lumc.edu		Picken, Maria/0000-0002-8065-6178			Adsay NV, 2000, AM J SURG PATHOL, V24, P958, DOI 10.1097/00000478-200007000-00007; Antic T, 2006, ARCH PATHOL LAB MED, V130, P80; Antic T, 2006, AJSP-REV REP, V11, P173, DOI 10.1097/01.pcr.0000227462.98588.47; Argani P, 2000, AM J SURG PATHOL, V24, P1087, DOI 10.1097/00000478-200008000-00006; Arriola AGP, 2018, INT J SURG PATHOL, V26, P56, DOI 10.1177/1066896917720032; Cacciamani G., 2017, APPL IMMUNOHISTOCHEM; Calio A, 2016, AM J SURG PATHOL, V40, P1538, DOI 10.1097/PAS.0000000000000733; Chu PGG, 2009, VIRCHOWS ARCH, V455, P389, DOI 10.1007/s00428-009-0831-x; Colombo P, 2008, UROLOGY, V71, DOI 10.1016/j.urology.2007.09.057; Farias JA, 2016, UROL ANNALS, V8, P114, DOI 10.4103/0974-7796.171493; Fine SW, 2006, AM J SURG PATHOL, V30, P593, DOI 10.1097/01.pas.0000194298.19839.b4; Hara N, 2005, PATHOL INT, V55, P670, DOI 10.1111/j.1440-1827.2005.01888.x; Hes O, 2008, VIRCHOWS ARCH, V452, P285, DOI 10.1007/s00428-007-0564-7; Jung SJ, 2008, HUM PATHOL, V39, P463, DOI 10.1016/j.humpath.2007.08.008; Kum JBJ, 2011, AM J SURG PATHOL, V35, P1114, DOI 10.1097/PAS.0b013e3182233fb6; Kuroda N, 2008, APMIS, V116, P1013, DOI 10.1111/j.1600-0463.2008.01063.x; LeRoy MA, 2016, ARCH PATHOL LAB MED, V140, P594, DOI 10.5858/arpa.2015-0170-RS; Li YJ, 2017, AM J SURG PATHOL, V41, P472, DOI 10.1097/PAS.0000000000000816; Li Z., 2017, HISTOL HISTOPATHOL, V2017; Michal M, 2004, VIRCHOWS ARCH, V445, P359, DOI 10.1007/s00428-004-1060-y; Michal M, 1998, PATHOL RES PRACT, V194, P445, DOI 10.1016/S0344-0338(98)80038-1; Michal M, 2016, WHO CLASSIFICATION T, P70; Montironi R, 2008, EUR UROL, V54, P1237, DOI 10.1016/j.eururo.2007.10.040; Mudaliar KM, 2014, INT J SURG PATHOL, V22, P266, DOI 10.1177/1066896913488823; Pierson CR, 2001, HUM PATHOL, V32, P513, DOI 10.1053/hupa.2001.24323; Smith NE, 2015, HUM PATHOL, V46, P894, DOI 10.1016/j.humpath.2015.02.003; Sountoulides P., 2013, CAN TAX J, V6, P23; Sukov WR, 2007, HUM PATHOL, V38, P1432, DOI 10.1016/j.humpath.2007.03.022; Sun BL, 2015, INT J SURG PATHOL, V23, P238, DOI 10.1177/1066896914563391; Suzuki T, 2013, INT J UROL, V20, P448, DOI 10.1111/j.1442-2042.2012.03155.x; Svec A, 2001, VIRCHOWS ARCH, V439, P700, DOI 10.1007/s004280100518; Teklali Y, 2010, J PEDIATR UROL, V6, P320, DOI 10.1016/j.jpurol.2009.10.010; Turbiner J, 2007, AM J SURG PATHOL, V31, P489, DOI 10.1097/PAS.0b013e31802bdd56; Vanecek T, 2017, APPL IMMUNOHISTO M M, V25, P117, DOI 10.1097/PAI.0000000000000262; Xie WL, 2017, HISTOL HISTOPATHOL, V32, P361, DOI 10.14670/HH-11-800; Yang Y, 2005, VIRCHOWS ARCH, V447, P669, DOI 10.1007/s00428-005-1269-4; Yap YS, 2004, LANCET ONCOL, V5, P747, DOI 10.1016/S1470-2045(04)01651-1; Zhang C, 2017, J X-RAY SCI TECHNOL, V25, P831, DOI 10.3233/XST-16245; Zhou M, 2009, AM J SURG PATHOL, V33, P72, DOI 10.1097/PAS.0b013e3181852105; Zou L, 2014, INT J CLIN EXP PATHO, V7, P2658	40	1	1	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8234295	10.1155/2018/8234295			6	Pathology	Pathology	GX2HJ	WOS:000447539400001	30364101	DOAJ Gold, Green Published			2019-10-28	
J	Maronpot, RR; Hobbs, CA; Hayashi, S				Maronpot, Robert R.; Hobbs, Cheryl A.; Hayashi, Shim-mo			Role of pathology peer review in interpretation of the comet assay	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						4,5-epoxydec-2(trans)-enal; perillaldehyde; comet assay; pathology peer review; global harmonization		When a comet assay, an increasingly popular in vivo genotoxicity test, shows a positive test result, interpretation of that response requires ruling out any confounding tissue site toxicity. Since the comet assay typically uses only two or three daily doses of test agent, precursor tissue changes indicative of toxicity may be easily overlooked. Using case examples for two flavoring agents, perillaldehyde and 4,5-epoxydec-2(trans)-enal, we highlight the role of pathology peer review in verifying precursor tissue changes indicative of tissue site toxicity, thereby increasing confidence in final interpretation of comet assay results. Given global deliberation regarding safety assessment of compounds entering the marketplace, we recommend consideration of pathology peer review for equivocal and positive comet assays so that interpretations are universally consistent.	[Maronpot, Robert R.] Maronpot Consulting LLC, 1612 Medfield Rd, Raleigh, NC 27607 USA; [Hobbs, Cheryl A.] Integrated Lab Syst Inc, POB 13501, Res Triangle Pk, NC 27709 USA; [Hobbs, Cheryl A.] JFFMA, Chuo Ku, Sankei Nihonbashi Bldg 6th Floor, Tokyo 1030023, Japan; [Hayashi, Shim-mo] San Ei Gen FFI Inc, Global Sci & Regulatory Affairs, 1-1-11 Sanwa Cho, Toyonaka, Osaka 5618588, Japan	Maronpot, RR (reprint author), Maronpot Consulting LLC, 1612 Medfield Rd, Raleigh, NC 27607 USA.	maronpot@gmail.com					Beevers C., 2016, FINAL REPORT 4 5 EPO; Beevers C., 2014, FINAL REPORT P MENTH; Burdock GA, 2010, FENAROLIS HDB FLAVOR; Burlinson B, 2007, MUTAT RES-GEN TOX EN, V627, P31, DOI 10.1016/j.mrgentox.2006.08.011; Cohen SM, 2016, FOOD CHEM TOXICOL, V98, P201, DOI 10.1016/j.fct.2016.10.020; EFSA, 2015, EFSA J, V13, DOI 10.2903/j.efsa.2015.4191; EFSA CEF Panel (EFSA Panel on Food Contact Materials Enzymes Flavourings and Processing Aids), 2013, EFSA J, V11, P3151, DOI [DOI 10.2903/J.EFSA.2013.3151, 10.2903/j.efsa.2013.3151]; EFSA Scientific Opinion on Flavouring Group Evaluation, 2017, EFSA J, V15, P4847, DOI DOI 10.2903/J.EFSA.2017.4847; European Food Safety Authority, 2012, EFSA J, V10, DOI 10.2903/j.efsa.2012.2977; Hobbs CA, 2016, FOOD CHEM TOXICOL, V97, P232, DOI 10.1016/j.fct.2016.08.029; JECFA, 2003, WHO FOOD ADD SER; JECFA, 2006, WHO FOOD ADDIT SER, V56, P1; JECFA Evaluation of certain food additives, 2009, WHO TECHN REP SER, V952, P1; Konishi Y, 2014, TOXICOL PATHOL, V42, P949, DOI 10.1177/0192623313495603; Lorenzo Y, 2013, MUTAGENESIS, V28, P427, DOI 10.1093/mutage/get018; Mann PC, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P551, DOI 10.1016/B978-0-12-415759-0.00017-0; Morton D, 2010, TOXICOL PATHOL, V38, P1118, DOI 10.1177/0192623310383991; OECD, 2014, OECD TEST 474 MAMM E; OECD, 2016, IN VIVO MAMMALIAN AL, V489; OSER BL, 1978, FOOD TECHNOL-CHICAGO, V32, P60; Tice RR, 2000, ENVIRON MOL MUTAGEN, V35, P206, DOI 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J; Uno Y, 2015, MUTAT RES-GEN TOX EN, V786, P45, DOI 10.1016/j.mrgentox.2015.04.010	22	1	1	0	2	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					155	161		10.1293/tox.2018-0019			7	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400001	30093784	Green Published, Bronze			2019-10-28	
J	Ying, JTX; Yokohira, M; Nakano-Narusawa, Y; Yamakawa, K; Hashimoto, N; Imaida, K				Ying, Jane Tey Xin; Yokohira, Masanao; Nakano-Narusawa, Yuko; Yamakawa, Keiko; Hashimoto, Nozomi; Imaida, Katsumi			gamma H2AX is immunohistochemically detectable until 7 days after exposure of N-bis (2-hydroxypropyl) nitrosamine (DHPN) in rat lung carcinogenesis	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						gamma H2AX; rat; DHPN; lung; carcinogenesis; double-strand break	DOUBLE-STRAND BREAKS; DNA; MARKER; H2AX	It is known that gamma H2AX, which is formed when there is a double-strand break in DNA, can act as a sensitive marker of genomic instability. In this experiment, the time-course manner of the expression of gamma H2AX in the lung was examined in the early phase after treatment with a lung carcinogen, N-bis (2-hydroxypropyl) nitrosamine (DHPN). The expression of gamma H2AX is expected to be one of the useful markers for lung carcinogenesis in early stages. Rats were separated into 10 groups of 5 rats. The DHPN groups were administered 0.1% DHPN in drinking tap water for two weeks, while the control group received drinking tap water. At 0, 1, 3, 7, and 14 days after finishing DHPN treatment, one group each from the DHPN and control groups was sacrificed. The removed lung tissues were examined for immunostaining of gamma H2AX and PCNA, and positive cells were counted. The gamma H2AX levels of the DHPN-treated groups were found to be increased significantly at 0, 1, 3, and 7 days (4.4 +/- 1.4, 5.1 +/- 2.7, 3.3 +/- 1.0, and 4.1 +/- 1.3%, respectively), and they dropped significantly on day 14 (1.1 +/- 0.4%). The experiment showed that the gamma H2AX-positive score could be effectively measured for up to 7 days after exposure, as a significance difference was observed between the treated group and the control group. It can be deduced that gamma H2AX is an effective marker for DHPN-induced double-strand breaks in pulmonary epithelial cells.	[Ying, Jane Tey Xin; Yokohira, Masanao; Nakano-Narusawa, Yuko; Yamakawa, Keiko; Hashimoto, Nozomi; Imaida, Katsumi] Kagawa Univ, Dept Pathol & Host Def, Oncopathol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan; [Ying, Jane Tey Xin] Univ Brunei Darussalam, Inst Hlth Sci, Pengiran Anak Puteri Rashidah Saadatul Bolkiah, Jalan Tungku Link, BE-1410 Gadong, Brunei	Yokohira, M; Imaida, K (reprint author), Kagawa Univ, Dept Pathol & Host Def, Oncopathol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	yokohira@med.kagawa-u.ac.jp; imaida@med.kagawa-u.ac.jp			Ministry of Health, Labour and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan	This work was supported in part by Grants-in-Aid for chemical risk research from the Ministry of Health, Labour and Welfare (MHLW) of Japan.	Aplan PD, 2006, TRENDS GENET, V22, P46, DOI 10.1016/j.tig.2005.10.002; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gisselsson D., 2001, ATLAS GENET CYTOGENE, V5, P236; Ibuki Y, 2015, TOXICOL IN VITRO, V29, P1831, DOI 10.1016/j.tiv.2015.07.023; Karaolanis G., 2017, TUMOUR BIOL, V39; KONISHI Y, 1980, EXP PATHOL-JENA, V18, P136, DOI 10.1016/S0014-4908(80)80063-9; Leng JP, 2017, ANAL CHEM, V89, P9124, DOI 10.1021/acs.analchem.7b01857; Matthaios D, 2012, ONCOTARGETS THER, V5, P309, DOI 10.2147/OTT.S36995; Negritto M, 2010, NAT ED, V3, P26; OGATA K, 1987, METHOD ENZYMOL, V150, P147; Ozaki T, 2015, CANC RES FRONTIERS, V1, P48; Reddy D, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0330-x; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Takahashi A, 2005, CANCER LETT, V229, P171, DOI 10.1016/j.canlet.2005.07.016; Tanaka T, 2007, CYTOM PART A, V71A, P648, DOI 10.1002/cyto.a.20426; Torre Lindsey A, 2016, Adv Exp Med Biol, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Toyoda T, 2015, TOXICOL SCI, V148, P400, DOI 10.1093/toxsci/kfv192; Toyoda T, 2013, J TOXICOL PATHOL, V26, P215, DOI 10.1293/tox.26.215; Turinetto V, 2015, NUCLEIC ACIDS RES, V43, P2489, DOI 10.1093/nar/gkv061; Yamakawa K, 2010, MOL MED REP, V3, P141, DOI 10.3892/mmr_00000231; Yokohira M, 2014, EXP TOXICOL PATHOL, V66, P117, DOI 10.1016/j.etp.2013.11.002; Yokohira M, 2009, J TOXICOL PATHOL, V22, P71, DOI 10.1293/tox.22.71	23	1	1	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					163	168		10.1293/tox.2017-0066			6	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400002	30093785	Green Published, Bronze			2019-10-28	
J	Tsuchiya, T; Kijima, A; Ishii, Y; Takasu, S; Yokoo, Y; Nishikawa, A; Yanai, T; Umemura, T				Tsuchiya, Takuma; Kijima, Aki; Ishii, Yuji; Takasu, Shinji; Yokoo, Yuh; Nishikawa, Akiyoshi; Yanai, Tokuma; Umemura, Takashi			Role of oxidative stress in the chemical structure-related genotoxicity of nitrofurantoin in Nrf2-deficient gpt delta mice	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						nitrofurantoin; NRF2; oxidative stress; in vivo mutagenicity; kidney	ENVIRONMENTAL-POLLUTANT; NRF2; CARCINOGENESIS; DNA; GENES; PENTACHLOROPHENOL; HEPATOTOXICITY; CYTOTOXICITY; MECHANISMS; PREVENTION	Despite its antimicrobial activity, nitrofurantoin (NFT) is a renal carcinogen in rats. Oxidative stress induced by reduction of the nitro group of NFT may contribute to its genotoxicity. This is supported by our recent results indicating that the structure of the nitrofuran plays a key role in NFT-induced genotoxicity, and oxidative DNA damage is involved in renal carcinogenesis. Nuclear factor erythroid 2-related factor 2 (NRF2) regulates cellular responses to oxidative stress. To clarify the role of oxidative stress in the chemical structure-related genotoxic mechanism of NFT, we performed reporter gene mutation assays for NFT and 5-nitro-2-furaldehyde (NFA) using Nrf2-proficient and Nrf2-deficient gpt delta mice. NFT administration for 13 weeks resulted in a significant increase in 8-hydroxydeoxyguanosine (8-OHdG; a marker of oxidative stress) and gpt mutant frequency only in the kidneys of Nrf2(-/-) mice. The mutation spectrum, characterized by increased substitutions at guanine bases, suggested that oxidative stress is involved in NFT-induced genotoxicity. However, NFA did not increase the mutation frequency in the kidneys, despite the increased 8-OHdG in NFA-treated Nrf2(-/-) mice. Thus, it is unlikely that oxidative stress is involved in the genotoxic mechanism of NFA. These results imply that nitro reduction plays a key role in the genotoxicity of NFT, but the lack of a role of oxidative stress in the genotoxicity of NFA indicates a potential role of side chain interactions in oxidative stress caused by nitro reduction. These findings provide a basis for the development of safe nitrofurans.	[Tsuchiya, Takuma; Kijima, Aki; Ishii, Yuji; Takasu, Shinji; Yokoo, Yuh; Nishikawa, Akiyoshi; Umemura, Takashi] Natl Inst Hlth Sci, Div Pathol, Kawasaki Ku, 3-25-26 Tonomachi, Kawasaki, Kanagawa 2109501, Japan; [Tsuchiya, Takuma; Yanai, Tokuma] Gifu Univ, United Grad Sch Vet Sci, Pathogenet Vet Sci, 1-1 Yanagido, Gifu, Gifu 5011193, Japan; [Umemura, Takashi] Yamazaki Gakuen Univ, Dept Anim Nursing, 4-7-2 Minamiosawa, Hachioji, Tokyo 1920364, Japan	Umemura, T (reprint author), Natl Inst Hlth Sci, Div Pathol, Kawasaki Ku, 3-25-26 Tonomachi, Kawasaki, Kanagawa 2109501, Japan.; Umemura, T (reprint author), Yamazaki Gakuen Univ, Dept Anim Nursing, 4-7-2 Minamiosawa, Hachioji, Tokyo 1920364, Japan.	umemura@nihs.go.jp					[Anonymous], 1990, IARC Monogr Eval Carcinog Risks Hum, V50, P211; [Anonymous], 1989, NATL TOXICOL PROGRAM, V341, P1; Bartel LC, 2009, FOOD CHEM TOXICOL, V47, P140, DOI 10.1016/j.fct.2008.09.069; Boelsterli UA, 2006, CURR DRUG METAB, V7, P715, DOI 10.2174/138920006778520606; Chung MC, 2011, CURR PHARM DESIGN, V17, P3515; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Fleck LE, 2014, ANTIMICROB AGENTS CH, V58, P1410, DOI 10.1128/AAC.02136-13; Hu XM, 2006, MOL CELL BIOL, V26, P940, DOI 10.1128/MCB.26.3.940-954.2006; IARC Working Group on the Evaluation of the Carcino-genic Risk to Humans Nitrofural (nitrofurazone), 1990, IARC MON EV CARC RIS, V50, P195; IARC Working Group on the Evaluation of the Carcinogenic Risk to Humans Furaltadone, 1974, IARC MONOGRAPHS EVAL, V7, P161; IARC Working Group on the Evaluation of the Carcinogenic Risk to Humans Furazolidone, 1983, IARC MON EV CARC RIS, V31; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Kanki K, 2008, TOXICOL PATHOL, V36, P353, DOI 10.1177/0192623307311401; Kijima A, 2015, TOXICOLOGY, V331, P125, DOI 10.1016/j.tox.2015.03.003; Kitamura Y, 2007, CANCER SCI, V98, P19, DOI 10.1111/j.1349-7006.2006.00352.x; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Matsushita K, 2015, EXP TOXICOL PATHOL, V67, P31, DOI 10.1016/j.etp.2014.09.006; Nakabeppu Y, 2014, INT J MOL SCI, V15, P12543, DOI 10.3390/ijms150712543; Nohmi T, 2005, MUTAT RES-FUND MOL M, V591, P60, DOI 10.1016/j.mrfmmm.2005.03.033; Nohmi T, 2000, MUTAT RES-FUND MOL M, V455, P191, DOI 10.1016/S0027-5107(00)00077-4; ROSSI L, 1988, BIOCHEM PHARMACOL, V37, P3109, DOI 10.1016/0006-2952(88)90308-5; STREETER AJ, 1988, PHARMACEUT RES, V5, P434, DOI 10.1023/A:1015988401601; SUNTRES ZE, 1992, BIOCHEM PHARMACOL, V43, P1127, DOI 10.1016/0006-2952(92)90621-O; Tasaki M, 2014, EXP TOXICOL PATHOL, V66, P19, DOI 10.1016/j.etp.2013.07.003; TOUATI E, 1993, MUTAGENESIS, V8, P149, DOI 10.1093/mutage/8.2.149; Umemura T, 2006, TOXICOL SCI, V90, P111, DOI 10.1093/toxsci/kfj076; Umemura T, 2003, CARCINOGENESIS, V24, P1105, DOI 10.1093/carcin/bgg053; Umemura T, 2006, CANCER SCI, V97, P829, DOI 10.1111/j.1349-7006.2006.00248.x; Wang Y, 2008, FREE RADICAL BIO MED, V44, P1169, DOI 10.1016/j.freeradbiomed.2007.12.013; Yokoo Y, 2016, CANCER MED-US, V5, P1228, DOI 10.1002/cam4.672; Zorzi RR, 2014, BIOORGAN MED CHEM, V22, P2844, DOI 10.1016/j.bmc.2014.03.044	32	3	3	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					169	178		10.1293/tox.2018-0014			10	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400003	30093786	Green Published, Bronze			2019-10-28	
J	Tsuchiya, T; Kijima, A; Ishii, Y; Takasu, S; Yokoo, Y; Nishikawa, A; Yanai, T; Umemura, T				Tsuchiya, Takuma; Kijima, Aki; Ishii, Yuji; Takasu, Shinji; Yokoo, Yuh; Nishikawa, Akiyoshi; Yanai, Tokuma; Umemura, Takashi			Mechanisms of oxidative stress-induced in vivo mutagenicity by potassium bromate and nitrofurantoin	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						bromates; nitrofurantoin; NF-E2-related factor 2; DNA damage; mutagens; kidney	DNA-DAMAGE; CELL-PROLIFERATION; ENVIRONMENTAL-POLLUTANT; RENAL CARCINOGEN; FOOD-ADDITIVES; F344 RATS; NRF2; MICE; INITIATION; KIDNEYS	Oxidative stress is well known as a key factor of chemical carcinogenesis. However, the actual role of oxidative stress in carcinogenesis, such as oxidative stress-related in vivo mutagenicity, remains unclear. It has been reported that 8-hydroxydeoxyguanosine (8-OHdG), an oxidized DNA lesion, might contribute to chemical carcinogenesis. Potassium bromate (KBrO3) and nitrofurantoin (NFT) are known as renal carcinogens in rats. Our previous studies showed an increase in mutant frequencies accompanied by an increased level of 8-OHdG in the kidneys of rodents following KBrO3 or NFT exposure. Furthermore, KBrO3 and NFT induced different types of gene mutations. Thus, in the present study, we performed reporter gene mutation assays and 8-OHdG measurements following KBrO3 or NFT exposure using Nrf2-proficient and Nrf2-deficient mice to clarify the relationship between KBrO3(-) or NFT-induced oxidative stress and subsequent genotoxicity. Administration of 1,500 ppm of KBrO3 in drinking water resulted in an increase in deletion mutations accompanied by an increase in 8-OHdG level, and administration of 2,500 ppm of NFT in diet induced an increase in guanine base substitution mutations without elevation of the 8-OHdG level in Nrf2-deficient mice. These results demonstrated that the formation of 8-OHdG, which resulted from the oxidizing potential of KBrO3, was directly involved in the increase in deletion mutations, although factors related to oxidative stress other than 8-OHdG might be crucial for NFT-induced guanine base substitution mutations. The present study provides new insight into oxidative stress-related in vivo mutagenicity.	[Tsuchiya, Takuma; Kijima, Aki; Ishii, Yuji; Takasu, Shinji; Yokoo, Yuh; Nishikawa, Akiyoshi; Umemura, Takashi] Natl Inst Hlth Sci, Div Pathol, Kawasaki Ku, 3-25-26 Tonomachi, Kawasaki, Kanagawa 2109501, Japan; [Tsuchiya, Takuma; Yanai, Tokuma] Gifu Univ, United Grad Sch Vet Sci, Pathogenet Vet Sci, 1-1 Yanagido, Gifu, Gifu 5011193, Japan; [Umemura, Takashi] Yamazaki Gakuen Univ, Dept Anim Nursing, 4-7-2 Minamiosawa, Hachioji, Tokyo 1920364, Japan	Umemura, T (reprint author), Natl Inst Hlth Sci, Div Pathol, Kawasaki Ku, 3-25-26 Tonomachi, Kawasaki, Kanagawa 2109501, Japan.; Umemura, T (reprint author), Yamazaki Gakuen Univ, Dept Anim Nursing, 4-7-2 Minamiosawa, Hachioji, Tokyo 1920364, Japan.	umemura@nihs.go.jp					BALLMAIER D, 1995, CARCINOGENESIS, V16, P335, DOI 10.1093/carcin/16.2.335; Bartel LC, 2009, FOOD CHEM TOXICOL, V47, P140, DOI 10.1016/j.fct.2008.09.069; Boelsterli UA, 2006, CURR DRUG METAB, V7, P715, DOI 10.2174/138920006778520606; Chung MC, 2011, CURR PHARM DESIGN, V17, P3515; Di Minno A, 2016, ANTIOXID REDOX SIGN, V24, P548, DOI 10.1089/ars.2015.6508; French JE, 1989, TOXICOLOGY CARCINOGE; HAYASHI M, 1988, FOOD CHEM TOXICOL, V26, P487, DOI 10.1016/0278-6915(88)90001-4; IARC Working Group on the Evaluation of the Carcinogenic Risk to Humans Nitrofurantoin, 1990, IARC MON EV CARC RIS, V50, P211; Il'yasova D, 2012, CLIN CHIM ACTA, V413, P1446, DOI 10.1016/j.cca.2012.06.012; ISHIDATE M, 1984, FOOD CHEM TOXICOL, V22, P623, DOI 10.1016/0278-6915(84)90271-0; Ishidate M Jr, 1980, Arch Toxicol Suppl, V4, P41; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Kanki K, 2008, TOXICOL PATHOL, V36, P353, DOI 10.1177/0192623307311401; KASAI H, 1987, CARCINOGENESIS, V8, P1959, DOI 10.1093/carcin/8.12.1959; Kasai H, 1991, OXIDATIVE STRESS OXI, P99; Kijima A, 2015, TOXICOLOGY, V331, P125, DOI 10.1016/j.tox.2015.03.003; Kitamura Y, 2007, CANCER SCI, V98, P19, DOI 10.1111/j.1349-7006.2006.00352.x; Klaunig JE, 1998, ENVIRON HEALTH PERSP, V106, P289, DOI 10.2307/3433929; KUROKAWA Y, 1990, ENVIRON HEALTH PERSP, V87, P309, DOI 10.2307/3431039; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Luan Y, 2007, MUTAT RES-FUND MOL M, V619, P113, DOI 10.1016/j.mrfmmm.2007.02.029; Matsushita K, 2015, EXP TOXICOL PATHOL, V67, P31, DOI 10.1016/j.etp.2014.09.006; MICHAELS ML, 1991, NUCLEIC ACIDS RES, V19, P3629, DOI 10.1093/nar/19.13.3629; Murata M, 2001, CHEM RES TOXICOL, V14, P678, DOI 10.1021/tx000209q; Murata M, 2013, CHEM RES TOXICOL, V26, P1455, DOI 10.1021/tx400182n; Nakabeppu Y, 2014, INT J MOL SCI, V15, P12543, DOI 10.3390/ijms150712543; Nohmi T, 2005, MUTAT RES-FUND MOL M, V591, P60, DOI 10.1016/j.mrfmmm.2005.03.033; Nohmi T, 2000, MUTAT RES-FUND MOL M, V455, P191, DOI 10.1016/S0027-5107(00)00077-4; Okazaki K, 2006, CANCER SCI, V97, P175, DOI 10.1111/j.1349-7006.2006.00162.x; Rundhaug Joyce E, 2010, Cancers (Basel), V2, P436, DOI 10.3390/cancers2020436; Saha SK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071544; Tasaki M, 2014, EXP TOXICOL PATHOL, V66, P19, DOI 10.1016/j.etp.2013.07.003; Tsuchiya T, 2018, J TOXICOL PATHOL, V31, P169, DOI 10.1293/tox.2018-0014; Umemura T, 2006, TOXICOL SCI, V90, P111, DOI 10.1093/toxsci/kfj076; Umemura T, 2004, CANCER SCI, V95, P393, DOI 10.1111/j.1349-7006.2004.tb03221.x; Umemura T, 2003, CARCINOGENESIS, V24, P1105, DOI 10.1093/carcin/bgg053; Umemura T, 2000, ARCH TOXICOL, V74, P54, DOI 10.1007/s002040050652; UMEMURA T, 1993, J CANCER RES CLIN, V119, P463, DOI 10.1007/BF01215926; Umemura T, 2006, CANCER SCI, V97, P829, DOI 10.1111/j.1349-7006.2006.00248.x; Yokoo Y, 2016, CANCER MED-US, V5, P1228, DOI 10.1002/cam4.672	41	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					179	188		10.1293/tox.2018-0024			10	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400004	30093787	Green Published, Bronze			2019-10-28	
J	Eguchi, A; Inohana, M; Nakamura, M; Nagahara, R; Itahashi, M; Nakajima, K; Yoshida, T; Shibutani, M				Eguchi, Ayumi; Inohana, Mari; Nakamura, Misato; Nagahara, Rei; Itahashi, Megu; Nakajima, Kota; Yoshida, Toshinori; Shibutani, Makoto			A case of rapid recurrence of apocrine ductal carcinoma originating from the oral scent gland of a Richardson's ground squirrel (Urocitellus richardsonii)	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						apocrine ductal carcinoma; oral scent gland; Richardson's ground squirrels; metastasis; recurrence	SPERMOPHILUS-RICHARDSONII; HEPATOCELLULAR-CARCINOMA; ADENOCARCINOMA; METASTASIS; INFECTION; MYC	A 3-year-old female Richardson's ground squirrel developed a subcutaneous mass at the left oral angle. Seven days after removal of the mass, the mass recurred and metastasized to the cervical lymph node. Histologically, the primary mass was subdivided by fibrous trabeculae into various-sized neoplastic cell lobules showing a solid growth pattern with frequent mitoses and sometimes forming intracytoplasmic lumina. Large to medium-sized lobules formed a central cyst plugged by comedo necrosis. Neoplastic cells showed infiltrative subcutaneous growth. In the recurrent tumor, tubular structures lacking apparent apocrine secretion appeared within the solid growth portion. Neutrophil infiltration was evident within the tubules and intracytoplasmic lumina. Neoplastic cells were diffusely immunopositive for AE1/AE3 pan-cytokeratin (CK) in all lobules and focally positive for CAM5.2 CK in the lobules forming a central cyst and/or tubular structures, but they entirely lacked positivity for the periodic acid Schiff reaction. Ki-67-positive proliferating neoplastic cells were higher in numbers with the recurrent tumor than with the primary tumor. In addition, phosphorylated c-MYC immunoreactivity was observed in neoplastic cell nuclei, distinctly at the portion of invasive growth. Thus, the present case was diagnosed as apocrine ductal carcinoma originating from the oral scent gland, which typically shows highly aggressive biological behavior.	[Eguchi, Ayumi; Inohana, Mari; Nakamura, Misato; Nagahara, Rei; Nakajima, Kota; Yoshida, Toshinori; Shibutani, Makoto] Tokyo Univ Agr & Technol, Lab Vet Pathol, Div Anim Life Sci, Inst Agr, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan; [Itahashi, Megu] New Histo Sci Lab Co Ltd, Div Pathol, 2-979-2 Kurosawa, Ome, Tokyo 1980005, Japan; [Nakajima, Kota] Gifu Univ, United Grad Sch Vet Sci, Pathogenet Vet Sci, 1-1 Yanagido, Gifu, Gifu 5011193, Japan; [Shibutani, Makoto] Tokyo Univ Agr & Technol, Inst Global Innovat Res, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan	Shibutani, M (reprint author), Tokyo Univ Agr & Technol, Lab Vet Pathol, Div Anim Life Sci, Inst Agr, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.; Shibutani, M (reprint author), Tokyo Univ Agr & Technol, Inst Global Innovat Res, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	mshibuta@cc.tuat.ac.jp	Yoshida, Toshinori/B-7255-2015; Shibutani, Makoto/C-2510-2013				Carminato A, 2012, COMPARATIVE MED, V62, P279; Deutschland M, 2011, VET REC, V169, P636, DOI 10.1136/vr.100380; Goldschmidt M. H., 2017, Tumors in domestic animals, P88; Gross TL, 2005, SKIN DISEASES OF THE DOG AND CAT: CLINICAL AND HISTOPATHOLOGIC DIAGNOSIS, 2ND EDITION, P665; He XJ, 2009, J VET DIAGN INVEST, V21, P156, DOI 10.1177/104063870902100128; Helgen KM, 2009, J MAMMAL, V90, P270, DOI 10.1644/07-MAMM-A-309.1; KIVETT VK, 1976, CAN J ZOOL, V54, P1294, DOI 10.1139/z76-147; KIVETT VK, 1978, CAN J ZOOL, V56, P374, DOI 10.1139/z78-054; Lagios MD, 1996, J CELL BIOCHEM, P108; Lin QS, 2014, CANCER LETT, V350, P15, DOI 10.1016/j.canlet.2014.04.017; LUSCHER B, 1992, J CELL BIOL, V118, P775, DOI 10.1083/jcb.118.4.775; MINUK GY, 1986, LIVER, V6, P350; MYKYTOWYCZ R, 1974, J INVEST DERMATOL, V62, P124, DOI 10.1111/1523-1747.ep12676776; Rafferty JP, 2011, BRITANNICA GUIDE PRE, P86; SIMPSON RHW, 1991, HISTOPATHOLOGY, V18, P229, DOI 10.1111/j.1365-2559.1991.tb00830.x; TENNANT BC, 1991, HEPATOLOGY, V13, P1215, DOI 10.1016/0270-9139(91)92493-R; Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776; Yamate J, 2007, EXP ANIM TOKYO, V56, P379, DOI 10.1538/expanim.56.379; Yoshida GJ, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0393-y	19	1	1	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					189	193		10.1293/tox.2017-0071			5	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400005	30093788	Bronze, Green Published			2019-10-28	
J	Castiglioni, V; Radaelli, E				Castiglioni, Vittoria; Radaelli, Enrico			Spontaneous pulmonary co-metastasis of hepatoblastoma arising within a hepatocellular carcinoma in an aged C57BL/6J mouse	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						hepatoblastoma; immunohistochemistry; mouse; pathogenesis; pulmonary metastases	B6C3F1 MICE; COLLISION; CATENIN; TUMORS	Murine hepatoblastoma (HB) is a rare spontaneous tumor with controversial histogenesis. It mainly occurs in aged males, frequently in close association with preexisting hepatocellular neoplasms. The present work describes a spontaneous HB arising within a hepatocellular carcinoma (HCC) in a 22-month-old male C57BL/6J mouse. The mouse also developed pulmonary co-metastases with either tumor components physically associated within the same metastatic foci. Microscopically, the HB consisted of a densely cellular neoplastic growth composed of palisades and perivascular pseudorosettes of poorly differentiated primitive cells, with a scant amount of cytoplasm, elongated hyperchromatic nuclei, and a high mitotic rate, whereas the hepatocellular carcinoma was composed of solid areas of neoplastic hepatocytes. Both in primary tumors and their metastases, beta-catenin immunohistochemistry revealed a strong nucleocytoplasmic signal in HB cells, while neoplastic hepatocytes displayed a delicate membranous staining pattern. These findings suggest that the Wnt/beta-catenin oncogenic pathway is upregulated in murine HB but not in the co-existing HCC, thus providing some insights into their divergent pathogenesis. Coexisting murine HB and HCC have been demonstrated to be completely distinct entities including origin, mutational landscape, and molecular profile. In this context, they might be regarded as collision tumors because of their intimate association, unique histologic features, and distinct immunohistochemical patterns. Nevertheless, the nature of their coevolution and progression to a co-metastatic phenotype reflects a close interdependence and support the overall idea that HB's origin and progression might be promoted by not otherwise specified paracrine stimuli provided by the concurrent hepatocellular tumor (the so called "interaction theory").	[Castiglioni, Vittoria] IDEXX Labs Italia Srl, Via Guglielmo Silva 36, I-20149 Milan, Italy; [Radaelli, Enrico] Univ Penn, Sch Vet Med, Dept Pathobiol, Comparat Pathol Core, 3900 Delancey St, Philadelphia, PA 19104 USA; [Radaelli, Enrico] VIB Ctr Biol Dis, Herestr 49, B-3000 Leuven, Belgium; [Radaelli, Enrico] Katholieke Univ Leuven, Ctr Human Genet, Herestr 49, B-3000 Leuven, Belgium	Castiglioni, V (reprint author), IDEXX Labs Italia Srl, Via Guglielmo Silva 36, I-20149 Milan, Italy.	vittoria-castiglioni@idexx.com					Anna CH, 2000, CANCER RES, V60, P2864; Ano N, 2011, VET PATHOL, V48, P1020, DOI 10.1177/0300985810390017; Beeler-Marfisi J, 2010, J VET DIAGN INVEST, V22, P174, DOI 10.1177/104063871002200202; Bhusari S, 2015, TOXICOL PATHOL, V43, P1114, DOI 10.1177/0192623315599853; Cairo S, 2008, CANCER CELL, V14, P471, DOI 10.1016/j.ccr.2008.11.002; Cantile C, 2001, EQUINE VET J, V33, P214; Castiglioni V, 2013, J TOXICOL PATHOL, V26, P423, DOI 10.1293/tox.2013-0021; CHHABRA RS, 1992, FUND APPL TOXICOL, V18, P405, DOI 10.1016/0272-0590(92)90139-9; Cruz RJ, 2013, SURGERY, V153, P150, DOI 10.1016/j.surg.2012.11.006; Cullen J. M., 2017, Tumors in domestic animals, P602; de Leval L, 2002, VIRCHOWS ARCH, V441, P462, DOI 10.1007/s00428-002-0707-9; Herzog C E, 2000, Oncologist, V5, P445, DOI 10.1634/theoncologist.5-6-445; LACK EE, 1982, AM J SURG PATHOL, V6, P693, DOI 10.1097/00000478-198212000-00001; Lennox TJ, 2000, J AM VET MED ASSOC, V216, P718, DOI 10.2460/javma.2000.216.718; MANKTELO.BW, 1965, J PATHOL BACTERIOL, V89, P711, DOI 10.1002/path.1700890231; Miteva M, 2009, AM J DERMATOPATH, V31, P599, DOI 10.1097/DAD.0b013e3181a88116; Murthaiah P, 2009, ANTICANCER RES, V29, P1495; Shiga A, 1997, J VET MED SCI, V59, P1167, DOI 10.1292/jvms.59.1167; Spector LG, 2012, PEDIATR BLOOD CANCER, V59, P776, DOI 10.1002/pbc.24215; Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499; Turusov VS, 2002, TOXICOL PATHOL, V30, P580, DOI 10.1080/01926230290105802; von Schweinitz D, 2012, SEMIN PEDIATR SURG, V21, P21, DOI 10.1053/j.sempedsurg.2011.10.011; Watt BC, 2001, CAN VET J, V42, P872	23	1	1	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					195	199		10.1293/tox.2017-0067			5	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400006	30093789	Bronze, Green Published			2019-10-28	
J	Miki, M; Ohishi, N; Nakamura, E; Furumi, A; Mizuhashi, F				Miki, Masayo; Ohishi, Norio; Nakamura, Eiko; Furumi, Akane; Mizuhashi, Fukutaro			Improved fixation of the whole bodies of fish by a double-fixation method with formalin solution and Bouin's fluid or Davidson's fluid	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						fish; fixative; double fixation; 20% formalin; Bouin's fluid; histopathology	LIVER; TOOL; PATHOGENESIS; CADMIUM; GILLS	To prevent fixation defects or artifacts in the whole bodies of fish caused by conventional fixatives, such as formalin solution, Bouin's fluid (BF), and Davidson's fluid (DF), the optimal fixatives and fixing method were examined. An improved method of fixing the whole bodies of fish was examined that makes use of a combination of 20% formalin and BF or DF. The fixatives were examined with four representative tissues, i.e., the gill, liver, intestinal tract, and kidney, to evaluate end points including the appearance of degraded tissues and artifacts caused by each fixative, overall morphological clarity of nuclei, staining intensity, and integrity of the other tissues. The best results were obtained when the fresh whole bodies were initially fixed in 20% formalin (primary fixation) at 4 degrees C for 1 h and subsequently fixed in BF for 5 h at 4 degrees C (secondary fixation). Therefore, the current findings led the authors to conclude that the combination of primary fixation with 20% formalin at 4 degrees C for 1 h and secondary fixation with BF at 4 degrees C for 5 h was suitable for fixation of the whole bodies of fish.	[Miki, Masayo; Ohishi, Norio; Nakamura, Eiko; Furumi, Akane; Mizuhashi, Fukutaro] Public Interest Inc Fdn, Biosafety Res Ctr, 582-2 Shioshinden, Iwata, Shizuoka 4371213, Japan	Miki, M (reprint author), Public Interest Inc Fdn, Biosafety Res Ctr, 582-2 Shioshinden, Iwata, Shizuoka 4371213, Japan.	m-miki@anpyo.co.jp					Aghamirkarimi S, 2017, GLOB J ENVIRON SCI M, V3, P323, DOI 10.22034/gjesm.2017.03.03.009; Annabi A, 2011, INT J ENVIRON RES, V5, P745; COUCH JA, 1991, TOXICOL PATHOL, V19, P237, DOI 10.1177/019262339101900306; Doaa MM, 2013, J LIFE SCI BIOMEDICI, V3, P256; Flores-Lopes F, 2011, BRAZ J BIOL, V71, P179, DOI 10.1590/S1519-69842011000100026; Fukuda T., 2008, THEORY PATHOLOGICAL; George J, 2016, PEERJ, V4, DOI 10.7717/peerj.1943; Hadi A. A., 2012, International Journal of Pharmacy and Life Sciences (IJPLS), V3, P2071; Heiden TCK, 2007, TOXICOL APPL PHARM, V225, P70, DOI 10.1016/j.taap.2007.07.009; Huiting L N, 2015, Austin J Pharmacol Ther, V3, P1069; ISHIKAWA T, 1979, J TOXICOL ENV HEALTH, V5, P537, DOI 10.1080/15287397909529765; Miwa S., 2017, SAMPLING METHODS HIS; Pikarsky E, 2004, J VIROL, V78, P9544, DOI 10.1128/JVI.78.17.9544-9551.2004; Saoud I. P., 2014, Journal of Aquaculture Research and Development, V5, P263; SPEILBERG L, 1993, DIS AQUAT ORGAN, V17, P47, DOI 10.3354/dao017047; Strzyzewska E, 2016, VET MED-CZECH, V61, P123, DOI 10.17221/8763-VETMED; Younis EM, 2013, PAK J ZOOL, V45, P833	17	0	0	0	2	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					201	206		10.1293/tox.2018-0001			6	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400007	30093790	Green Published, Bronze			2019-10-28	
J	Matsuyama, S; Karim, MR; Izawa, T; Kuwamura, M; Yamate, J				Matsuyama, Satoshi; Karim, Mohammad Rabiul; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji			Immunohistochemical analyses of the kinetics and distribution of macrophages in the developing rat kidney	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						developing kidney; immunohistochemistry; macrophages; rats	GROWTH; HETEROGENEITY; PHAGOCYTES; FIBROSIS; LESIONS; INJURY; REPAIR; EMBRYO; CSF-1	Macrophages are required during kidney development and appear in the initiation and propagation of renal injury. To establish baseline data, we analyzed the kinetics of the macrophage with different immunophenotypes in the developing rat kidney (fetus at 18 and 20 days, neonate at 1-21 days, and adult at 7-weeks old). Macrophages reacting to CD68, CD163, and MHC class II were identified in the cortex and medulla of the developing rat kidney. CD68(+) macrophages appeared in the fetal kidney as early as fetal day 18, and the number increased gradually in the neonatal kidney, whereas MHC class II+ and CD163(+) macrophages first appeared on neonatal days 4 and 8, respectively. Apoptotic bodies were seen in the fetal kidney and early stages of the neonatal kidney (days 1-4), and simultaneously CD68(+) macrophages appeared, indicating that CD68(+) macrophages may have roles in phagocytosis of apoptotic bodies and contribute to renal tissue maturation. Colony stimulating factor 1 and insulin growth factor 1 mRNAs were increased in the late stage of renal development (neonatal day 12 or later), and simultaneously CD163(+) and MHC class II+ cells appeared, suggesting that these cells may be a source of these growth factors and participate in renal tissue modeling. Generally, the CD163(+) and MHC class II+ cell number was much smaller than that of CD68(+) cells in the developing neonatal kidney. Therefore, the obtained findings provide valuable information on the participation of macrophages in the developing rat kidney. This information may be useful for evaluation of renal toxicity when macrophages are involved in the development of renal injury.	[Matsuyama, Satoshi; Karim, Mohammad Rabiul; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, 1-58 Rinku Ourai Kita, Izumisano, Osaka 5988531, Japan	Yamate, J (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, 1-58 Rinku Ourai Kita, Izumisano, Osaka 5988531, Japan.	yamate@vet.osakafu-u.ac.jp			JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26292152]; Platform Project for Supporting Drug Discovery and Life Science Research from AMED [JP18am0101123]; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care (The 31st International Student Grant)	This work was supported partly by the JSPS KAKENHI Grant Numbers 26292152 (to Yamate), by the Platform Project for Supporting Drug Discovery and Life Science Research (Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS) from AMED under Grant Number JP18am0101123, and by the Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care (The 31st International Student Grant to Karim).	Alikhan MA, 2011, AM J PATHOL, V179, P1243, DOI 10.1016/j.ajpath.2011.05.037; Anders HJ, 2011, KIDNEY INT, V80, P915, DOI 10.1038/ki.2011.217; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Golbar HM, 2012, EXP TOXICOL PATHOL, V64, P1, DOI 10.1016/j.etp.2010.05.011; Gow DJ, 2010, J LEUKOCYTE BIOL, V88, P475, DOI 10.1189/jlb.0310158; Hammerman MR, 1999, NEPHROL DIAL TRANSPL, V14, P1853, DOI 10.1093/ndt/14.8.1853; Henson PM, 2006, TRENDS IMMUNOL, V27, P244, DOI 10.1016/j.it.2006.03.005; Ide M, 2005, J COMP PATHOL, V133, P92, DOI 10.1016/j.jcpa.2005.01.011; Jones CV, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-41; Minto AWM, 2003, AM J PATHOL, V163, P2033, DOI 10.1016/S0002-9440(10)63561-4; Ovchinnikov DA, 2008, GENESIS, V46, P447, DOI 10.1002/dvg.20417; Penaloza C, 2006, HISTOCHEM CELL BIOL, V126, P149, DOI 10.1007/s00418-006-0214-1; Polfliet MMJ, 2006, IMMUNOBIOLOGY, V211, P419, DOI 10.1016/j.imbio.2006.05.015; Williams TM, 2010, SEMIN NEPHROL, V30, P255, DOI 10.1016/j.semnephrol.2010.03.011; Yamate J, 2005, TOXICOL PATHOL, V33, P207, DOI 10.1080/01926230490523978; Yamate J., 2016, FOOD SAFETY, V3, P61; Zhang MZ, 2012, J CLIN INVEST, V122, P4519, DOI 10.1172/JCI60363	18	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					209	+		10.1293/tox.2018-0002			6	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400008	30093791	Bronze, Green Published			2019-10-28	
J	Yamazaki, M; Yabuki, N; Suzuki, Y; Ito, M; Ikeda, A; Natori, O; Suzuki, M; Kato, A				Yamazaki, Masaki; Yabuki, Nami; Suzuki, Yasunori; Ito, Mayumi; Ikeda, Asuka; Natori, Osamu; Suzuki, Masami; Kato, Atsuhiko			PAXgene-fixed paraffin-embedded sample is applicable to laser capture microdissection with well-balanced RNA quality and tissue morphology	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						PAXgene; RNA quality; morphology; laser capture microdissection; RNA-Seq	NUCLEIC-ACIDS; FIXATION; FORMALIN; PRESERVATION; INTEGRITY; IMMUNOHISTOCHEMISTRY; TECHNOLOGY; PROTEIN; SYSTEM	Assessing how gene expression analysis by RNA sequencing (RNA-Seq) correlates to a unique morphology is increasingly necessary, and laser capture microdissection (LCM) is a critical research tool for discovering the genes responsible in a region of interest (ROI). Because RNA-Seq requires high-quality RNA, a sample preparation procedure that can preserve morphology and give the required quality of RNA is essential. A PAXgene (R)-fixed paraffin-embedded (XFPE) block can satisfy the need for high-quality RNA, but there are few reports on adapting the method for LCM, such as how small an ROI is analyzable by RNA-Seq. In this study, we confirmed the morphology and preservation of RNA in XFPE and then assessed the relationship between the size of pieces cut by LCM and their RNA quality. In XFPE, the morphology was similar to that in alcohol-based fixed samples, the quality of the RNA extracted from a whole sample was excellent, that is equivalent to that of a fresh frozen sample, and the quality was maintained over one year later. Three sizes of pieces large (25,000 mu m(2)), medium (5,000 mu m(2)), and small (1,000 mu m(2)) were cut by LCM so that the total areas of the sections cut per size were the same. RNA quality was found to be best preserved when tissue was cut into pieces of over 5,000 mu m(2). In summary, XFPE exhibits good morphology and excellent preservation of RNA quality. Furthermore, it can be a good tool when used with LCM and RNA-Seq, giving well-balanced RNA quality and tissue morphology in the ROI.	[Yamazaki, Masaki; Yabuki, Nami; Suzuki, Masami; Kato, Atsuhiko] Chugai Pharmaceut Co Ltd, Div Res, 1-135 Komakado, Gotemba, Shizuoka 4128513, Japan; [Yabuki, Nami; Suzuki, Yasunori; Ito, Mayumi; Natori, Osamu; Suzuki, Masami] Forerunner Pharma Res Co Ltd, Yokohama Bio Ind Ctr, Tsurumi Ku, 1-6 Suehiro Cho, Yokohama, Kanagawa, Japan; [Ikeda, Asuka] Chugai Res Inst Med Sci Inc, 1-135 Komakado, Gotemba, Shizuoka 4128513, Japan	Yamazaki, M (reprint author), Chugai Pharmaceut Co Ltd, Div Res, 1-135 Komakado, Gotemba, Shizuoka 4128513, Japan.	yamazakimsk@chugai-pharm.co.jp	Yamazaki, Masaki/V-6997-2019	Yamazaki, Masaki/0000-0002-2079-0084; Suzuki, Yasunori/0000-0001-9361-4172			Baldelli E, 2015, PROTEOM CLIN APPL, V9, P928, DOI 10.1002/prca.201400056; Belloni B, 2013, J CLIN PATHOL, V66, P124, DOI 10.1136/jclinpath-2012-200983; Castro NP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153270; Cox ML, 2006, EXP MOL PATHOL, V80, P183, DOI 10.1016/j.yexmp.2005.10.002; Dotti I, 2010, DIAGN MOL PATHOL, V19, P112, DOI 10.1097/PDM.0b013e3181b520f8; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; Ergin B, 2010, J PROTEOME RES, V9, P5188, DOI 10.1021/pr100664e; Erickson HS, 2009, NAT PROTOC, V4, P902, DOI 10.1038/nprot.2009.61; Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85; Espina V, 2007, EXPERT REV MOL DIAGN, V7, P647, DOI 10.1586/14737159.7.5.647; Furukawa S, 2017, J TOXICOL PATHOL, V30, P79, DOI 10.1293/tox.2016-0047; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Groelz D, 2013, EXP MOL PATHOL, V94, P188, DOI 10.1016/j.yexmp.2012.07.002; Gundisch S, 2014, VIRCHOWS ARCH, V465, P509, DOI 10.1007/s00428-014-1624-4; Gundisch S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060638; Jacquet R, 2005, ANAL BIOCHEM, V337, P22, DOI 10.1016/j.ab.2004.09.033; Kap M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027704; Kukurba Kimberly R, 2015, Cold Spring Harb Protoc, V2015, P951, DOI 10.1101/pdb.top084970; Ledford H, 2008, NATURE, V455, P847, DOI 10.1038/455847a; Li S, 2014, NAT BIOTECHNOL, V32, P888, DOI 10.1038/nbt.3000; Liu Y, 2017, CURR EYE RES, V42, P104, DOI 10.3109/02713683.2016.1146777; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Mardis ER, 2013, ANNU REV ANAL CHEM, V6, P287, DOI 10.1146/annurev-anchem-062012-092628; Mathieson W, 2016, AM J CLIN PATHOL, V146, P25, DOI 10.1093/ajcp/aqw023; Milcheva R, 2013, ACTA HISTOCHEM, V115, P279, DOI 10.1016/j.acthis.2012.08.002; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Oetjen J, 2013, J PROTEOMICS, V90, P52, DOI 10.1016/j.jprot.2013.03.013; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Staff S, 2013, J CLIN PATHOL, V66, P807, DOI 10.1136/jclinpath-2012-201283; Suzuki Masami, 2002, J Toxicol Sci, V27, P165, DOI 10.2131/jts.27.165; Viertler C, 2012, J MOL DIAGN, V14, P458, DOI 10.1016/j.jmoldx.2012.05.002; Wang SY, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-163; Watanabe T, 2015, J TOXICOL PATHOL, V28, P41, DOI 10.1293/tox.28.2014-0045	33	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					213	220		10.1293/tox.2017-0049			8	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400009	30093792	Bronze, Green Published			2019-10-28	
J	Kashimura, A; Tanaka, K; Sato, H; Kaji, H; Tanaka, M				Kashimura, Akane; Tanaka, Kouji; Sato, Hiroko; Kaji, Hidefumi; Tanaka, Masaharu			Imaging mass spectrometry for toxicity assessment: a useful technique to confirm drug distribution in histologically confirmed lesions	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						imaging mass spectrometry; toxicity assessment; histological examination; amiodarone; desethylamiodarone; phosphatidylcholine	INDUCED PHOSPHOLIPIDOSIS; AMIODARONE; TOXICOLOGY; RATS	To evaluate the usefulness of imaging mass spectrometry (IMS) technology for assessing drug toxicity, we analyzed animal tissues in an amiodarone (AMD)-induced phospholipidosis model by IMS and confirmed the relationship between the distribution of AMD, its metabolites, and representative phospholipids (phosphatidylcholine, PC) and histological changes. AMD was administered to rats for 7 days at 150 mg/kg/day. The lung, spleen, and mesenteric lymph node were histologically examined and analyzed using IMS. The detection intensities of AMD, its metabolites, and typical PCs were higher in regions infiltrated by foamy macrophages compared with normal areas. This tendency was common in all three organs analyzed in this study. For the spleen, signals for AMD, its metabolites, and typical PCs were significantly more intense in the marginal zone, where foamy macrophages and vacuolated lymphocytes are abundant, than in the other areas. These results indicate that AMD, its metabolites, and PCs accumulate together in foamy or vacuolated cells, which is consistent with the mechanism of AMD-induced phospholipidosis. They also indicate that IMS is a useful technique for evaluating the distribution of drugs and biological components in the elucidation of toxicity mechanisms.	[Kashimura, Akane; Sato, Hiroko; Tanaka, Masaharu] Mitsubishi Tanabe Pharma Corp, Innovat Res Div, Safety Res Labs, Sohya Ku, 2-2-50 Kawagishi, Toda, Saitama 3358505, Japan; [Tanaka, Kouji] Mitsubishi Tanabe Pharma Corp, Innovat Res Div, DMPK Res Labs, Sohya Ku, 2-2-50 Kawagishi, Toda, Saitama 3358505, Japan; [Kaji, Hidefumi] LSI Medience Corp, Adv Med Business Dev Dept, Drug Dev Serv Segment, Chiyoda Ku, 1-13-4 Uchikanda, Tokyo 1018517, Japan	Kashimura, A (reprint author), Mitsubishi Tanabe Pharma Corp, Innovat Res Div, Safety Res Labs, Sohya Ku, 2-2-50 Kawagishi, Toda, Saitama 3358505, Japan.; Tanaka, K (reprint author), Mitsubishi Tanabe Pharma Corp, Innovat Res Div, DMPK Res Labs, Sohya Ku, 2-2-50 Kawagishi, Toda, Saitama 3358505, Japan.	kashimura.akane@ma.mt-pharma.co.jp; tanaka.kouji@ma.mt-pharma.co.jp					ADAMS PC, 1985, CIRCULATION, V72, P1064, DOI 10.1161/01.CIR.72.5.1064; Baronas ET, 2007, TOXICOL APPL PHARM, V218, P72, DOI 10.1016/j.taap.2006.10.015; Bruinen AL, 2016, J AM SOC MASS SPECTR, V27, P117, DOI 10.1007/s13361-015-1254-3; Groseclose MR, 2015, J AM SOC MASS SPECTR, V26, P887, DOI 10.1007/s13361-015-1103-4; Halliwell WH, 1997, TOXICOL PATHOL, V25, P53, DOI 10.1177/019262339702500111; KANNAN R, 1991, FUND APPL TOXICOL, V16, P103, DOI 10.1016/0272-0590(91)90139-U; Karlsson O, 2017, ARCH TOXICOL, V91, P2283, DOI 10.1007/s00204-016-1905-6; Maronpot RR, 2017, TOXICOL PATHOL, V45, P444, DOI 10.1177/0192623317710014; McDonnell LA, 2007, MASS SPECTROM REV, V26, P606, DOI 10.1002/mas.20124; Mortuza GB, 2003, BBA-MOL CELL BIOL L, V1631, P136, DOI 10.1016/S1388-1981(02)00361-X; Nonoyama T, 2008, J TOXICOL PATHOL, V21, P9, DOI 10.1293/tox.21.9; Norris JL, 2013, CHEM REV, V113, P2309, DOI 10.1021/cr3004295; Sanoh S, 2017, J TOXICOL SCI, V42, P589, DOI 10.2131/jts.42.589; Sato H, 2016, 32 ANN M JAP SOC TOX; Stoeckli M, 2001, NAT MED, V7, P493, DOI 10.1038/86573	15	1	1	1	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3					221	227		10.1293/tox.2018-0006			7	Pathology; Toxicology	Pathology; Toxicology	GW4NF	WOS:000446891400010	30093793	Bronze, Green Published			2019-10-28	
J	Kolesnyk, YM; Kamyshnyi, OM; Gavrilenko, MA				Kolesnyk, Yu. M.; Kamyshnyi, O. M.; Gavrilenko, M. A.			Changes in the expression of mRNA TLR2 and 4 type, nuclear factor kB and pro-inflammatory cytokines IL-1 beta and IL-17A in the epithelium of the oral cavity in children with special needs	PATHOLOGIA			Russian	Article						child; disabled persons; gingivitis; cytocine receptor; IL-1 beta; IL-17A		Objective: to assess the relative level of mRNA of proinflammatory cytokines IL-1 beta and IL-17A, toll-like receptors 2 and 4 types and the transcription factor NF-KB in the epithelium of the oral cavity in children with diseases of the central nervous system, blood system, respiratory organs, and in children with mental disorders. Object and methods: the molecular-genetic study by polymerase chain reaction with reverse transcription real-time (RT-PCR) mRNA expression of the genes TLR2, TLR4, NF-KB, IL-1 beta and IL-17A in the epithelium of the oral cavity in 93 children with disabilities and 25 children with chronic catarrhal gingivitis without associated pathology in age from 12 to 15 years. Results. In children with special needs there is the rise of transcription activity of membrane TLR2 and TLR4 in all study groups except the group of children with mental disorders. Activation of pattern recognition receptors naturally causes transcriptional induction of the gene NF-KB and regulated by it the proinflammatory cytokines IL-1 beta and IL-17A by the buccal epithelium: expression levels of mRNA of IL-1 beta and IL-17A in children with central nervous system diseases were increased by 8.9 and 7.7 times (P < 0.05), respectively, in children with mental diseases the level of IL-17A was increased by 2.2 times (P < 0.05) in comparison with the control, in children with respiratory diseases and diseases of the blood system the expression of IL-1 beta was increased by 6.5 and 2.9 times (P < 0.05), respectively, IL-17A -3.8 and 3 times (P < 0.05) as compared to control. Conclusions: discovered in the work transcriptional induction of the genes TLR2 and TLR4 and subsequent activation of Nf-kB and production of proinflammatory cytokines IL-1 beta and IL-17A d is one of the mechanisms that explains the more severe course of periodontitis in children with disabilities as compared to patients with periodontitis and without comorbidities.	[Kolesnyk, Yu. M.] Zaporizhzhia State Med Univ, Zaporizhia, Ukraine; [Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Dept Microbiol Virol & Immunol, Zaporizhia, Ukraine; [Gavrilenko, M. A.] Zaporizhzhia State Med Univ, Dept Therapeut Orthoped & Pediat Dent, Zaporizhia, Ukraine	Kolesnyk, YM (reprint author), Zaporizhzhia State Med Univ, Zaporizhia, Ukraine.	zpstomat@ukr.net					[Anonymous], TITLE ERROR; Beklen A, 2014, BIOTECH HISTOCHEM, V89, P505, DOI 10.3109/10520295.2014.903299; Belstrom D, 2017, J ORAL MICROBIOL, V9, DOI 10.1080/20002297.2017.1364101; Cheng WC, 2014, J CLIN PERIODONTOL, V41, P541, DOI 10.1111/jcpe.12238; Chitrapriya Muthugounder Nalanaswamy, 2015, J Indian Soc Periodontol, V19, P14, DOI 10.4103/0972-124X.145798; D'Souza RS, 2013, J CLIN DIAGN RES, V7, P2780, DOI 10.7860/JCDR/2013/6745.3745; Dolasia K, 2018, INT REV IMMUNOL, V37, P3, DOI 10.1080/08830185.2017.1397656; Ebersole JL, 2017, PERIODONTOL 2000, V75, P52, DOI 10.1111/prd.12222; Gavrilenko M. A., 2015, SOVREMENNAYA STOMATO, V2, P28; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Ilango P, 2016, J CLIN DIAGN RES, V10, pZC86, DOI [10.7860/JCDR/2016/18353.8027, 10.7860/JCDR/2016/18.53.8027]; Kamasaki Y, 2016, PEDIATR INT, V58, P484, DOI 10.1111/ped.12829; Kinane D. F., 2017, NAT REV DIS PRIMERS, V3, P17; Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38; Leifer CA, 2016, J LEUKOCYTE BIOL, V100, P927, DOI 10.1189/jlb.2MR0316-117RR; Manger D, 2017, BRIT DENT J, V222, P527, DOI 10.1038/sj.bdj.2017.315; McClure R, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00386; Mendes V, 2018, J DENT, V69, P32, DOI 10.1016/j.jdent.2017.11.011; Papadopoulos G, 2013, J IMMUNOL, V190, P1148, DOI 10.4049/jimmunol.1202511; Rashkova M., 2010, ORAL HLTH DENT MANAG, V9, P148; Sasai M, 2013, INT REV IMMUNOL, V32, P116, DOI 10.3109/08830185.2013.774391; Visekruna A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/239368; Wara-aswapati N, 2013, J PERIODONTOL, V84, P1010, DOI 10.1902/jop.2012.120362	23	0	0	1	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					4	9		10.14739/2310-1237.2018.1.129332			6	Pathology	Pathology	GU7AL	WOS:000445470500001		DOAJ Gold			2019-10-28	
J	Bukina, YV; Varynskyi, BO; Voitovich, AV; Koval, GD; Kaplaushenko, AG; Kamyshnyi, OM				Bukina, Yu. V.; Varynskyi, B. O.; Voitovich, A. V.; Koval, G. D.; Kaplaushenko, A. G.; Kamyshnyi, O. M.			The definition of neutrophil extracellular traps and the concentration of short-chain fatty acids in salmonella-induced inflammation of the intestine against the background of vancomycin and Bacteroides fragilis	PATHOLOGIA			English	Article						microbiome; salmonella; bacteroides; neutrophil traps; short chain fatty acids; chromatography-mass spectrometry; immunofluorescence	COUPLED RECEPTOR 43; MICROBIAL METABOLITES; MONONUCLEAR-CELLS; CANDIDA-ALBICANS; INNATE IMMUNITY; NETOSIS; RECRUITMENT; ACTIVATION; INHIBITION; INFECTION	The aim is to study the features of the formation of neutrophil extracellular traps in the blood and gut-associated lymphoid tissue with salmonella-induced inflammation against the background of the administration of vancomycin and B. fragilis, and to determine the concentration of short-chain fatty acids in the luminal microflora of rats by means of chromatography-mass spectrometry. Methods. Studies were carried out on quantitative counting of Sytox(+)-neutrophiles and NETs in scrapings of the mucous membrane of the ileum of the intestine and in blood by the method of immunofluorescence microscopy, and also by determination of the concentration of SCFA in the luminal microflora of rats by chromatography-mass spectrometry. Results. The introduction of vancomycin contributed to an increase in the number of Sytox(+)-cells in scrapings of the intestinal mucosa and in the blood by 55 % and 2.5 times (group II). With the combined administration of vancomycin and S. enteritidis (III group), S. typhimurium (IV group), the mean Sytox(+)-cell counts in mucosal scrapings increased by 30 % and 2.4 times, and in the blood by 30 % (group IV), there was also a decrease in the number of NETs by 40 % (group IV). The introduction of B. fragilis against the background of pretreatment with vancomycin and infection with salmonella showed a decrease of Sytox+-cells in the scrapings of the intestinal mucosa by 43 % and 53 %, and in the blood by 46 % and 58 % (V and VI groups), and the number of NETs in scrapings from the intestinal mucosa and in the blood significantly increased by 43 % and 40 % (V group), and by 2.3 and 2.0 times (group VI). When infecting the rats with S. typhimurium against the background of pretreatment with vancomycin and the introduction of B. fragilis, the concentration of acetate in the samples increased by 2 times; propionate -6 times and butyrate -3 times. Conclusions. The introduction of B. fragilis in the infection of S. enteritidis and S. typhimurium against the background of vancomycin pretreatment leads to decrease in the number of Sytox+-cells in scrapings from the intestinal mucosa and in the blood, but induces the generation of NETs, and also causes an increase in the concentration of SCFA in the luminal microflora of rats, which helps to reduce salmonella-induced inflammation and restore the integrity of the intestinal epithelium.	[Bukina, Yu. V.; Voitovich, A. V.; Kamyshnyi, O. M.] Zaporizhzhia State Med Univ, Dept Microbiol Virol & Immunol, Zaporizhia, Ukraine; [Varynskyi, B. O.; Kaplaushenko, A. G.] Zaporizhzhia State Med Univ, Dept Phys & Colloidal Chem, Zaporizhia, Ukraine; [Koval, G. D.] HSEE Bukovinian State Med Univ, Chernovtsy, Ukraine; [Koval, G. D.] Bukovinian State Med Univ, HSEE Ukraine, Dept Clin Immunol Allergol & Endocrinol, Chernovtsy, Ukraine	Bukina, YV (reprint author), Zaporizhzhia State Med Univ, Dept Microbiol Virol & Immunol, Zaporizhia, Ukraine.	lingvus25@gmail.com	Kaplaushenko, Andrii/X-6060-2019; Voitovych, Oleksandr/AAC-2925-2019	Kaplaushenko, Andrii/0000-0003-3704-5539; Voitovych, Oleksandr/0000-0001-6460-9649			Al-Khafaji AB, 2016, MOL MED, V22, P621, DOI 10.2119/molmed.2016.00054; Andrade-Oliveira V, 2015, J DIABETES RES, DOI 10.1155/2015/681612; Aoyama M, 2010, NUTRITION, V26, P653, DOI 10.1016/j.nut.2009.07.006; Arazna M, 2013, RESP PHYSIOL NEUROBI, V187, P74, DOI 10.1016/j.resp.2013.03.002; BRANITZKIHEINEMANN, 2016, FRONT IMMUNOL, V7, DOI DOI 10.3389/FIMMU.2016.00518; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bukina Yu. V., 2017, PATHOLOGIA, V14, P12, DOI [10.14739/2310-1237.2017.1.97504, DOI 10.14739/2310-1237.2017.1.97504]; Byrd AS, 2013, J IMMUNOL, V190, P4136, DOI 10.4049/jimmunol.1202671; Carestia A, 2016, J LEUKOCYTE BIOL, V99, P153, DOI 10.1189/jlb.3A0415-161R; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Correa RO, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12720; Correa RO, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.17; Dazbrowska D, 2016, SCAND J IMMUNOL, V84, P317, DOI 10.1111/sji.12494; de Buhr N, 2016, J IMMUNOL RES, DOI 10.1155/2016/4604713; Delgado-Rizo V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00081; Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112; Dubois AV, 2012, AM J RESP CELL MOL, V47, P80, DOI 10.1165/rcmb.2011-0380OC; Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Grinberg N, 2008, INFECT IMMUN, V76, P2802, DOI 10.1128/IAI.00051-08; Ibarra JA, 2009, CELL MICROBIOL, V11, P1579, DOI 10.1111/j.1462-5822.2009.01368.x; Jagtap AG, 2004, J ETHNOPHARMACOL, V90, P195, DOI 10.1016/j.jep.2003.09.042; Kaplan MJ, 2012, J IMMUNOL, V189, P2689, DOI 10.4049/jimmunol.1201719; Kim M, 2016, CELL HOST MICROBE, V20, P202, DOI 10.1016/j.chom.2016.07.001; Konstantinidis T, 2016, ANTIMICROB AGENTS CH, V60, P1040, DOI 10.1128/AAC.02063-15; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lewis HD, 2015, NAT CHEM BIOL, V11, P189, DOI 10.1038/nchembio.1735; Li PX, 2010, J EXP MED, V207, P1853, DOI 10.1084/jem.20100239; Loginov V. A., 2014, EXPT CLIN GASTROENTE, V12, P30; Marcos V, 2010, NAT MED, V16, P1018, DOI 10.1038/nm.2209; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Masuda S, 2016, CLIN CHIM ACTA, V459, P89, DOI 10.1016/j.cca.2016.05.029; Masui R, 2013, INFLAMM BOWEL DIS, V19, P2848, DOI 10.1097/01.MIB.0000435444.14860.ea; Mills SW, 2006, AM J VET RES, V67, P1901, DOI 10.2460/ajvr.67.11.1901; Mishiro T, 2013, LAB INVEST, V93, P834, DOI 10.1038/labinvest.2013.70; Neeli I, 2008, J IMMUNOL, V180, P1895, DOI 10.4049/jimmunol.180.3.1895; Pacello F, 2008, BBA-GEN SUBJECTS, V1780, P226, DOI 10.1016/j.bbagen.2007.12.001; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052; Pieterse E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00484; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Pluznick JL, 2014, GUT MICROBES, V5, P202, DOI 10.4161/gmic.27492; Remijsen Q, 2011, CELL DEATH DIFFER, V18, P581, DOI 10.1038/cdd.2011.1; Rodrigues HG, 2016, EUR J PHARMACOL, V785, P50, DOI 10.1016/j.ejphar.2015.03.098; Sina C, 2009, J IMMUNOL, V183, P7514, DOI 10.4049/jimmunol.0900063; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sorensen OE, 2016, J CLIN INVEST, V126, P1612, DOI 10.1172/JCI84538; Tedelind S, 2007, WORLD J GASTROENTERO, V13, P2826; Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x; Urban CF, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000639; Usami M, 2008, NUTR RES, V28, P321, DOI 10.1016/j.nutres.2008.02.012; Vinolo MAR, 2011, NUTRIENTS, V3, P858, DOI 10.3390/nu3100858; Vinolo MAR, 2011, J NUTR BIOCHEM, V22, P849, DOI 10.1016/j.jnutbio.2010.07.009; Vinolo MAR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021205; von Kockritz-Blickwede M, 2009, J MOL MED, V87, P775, DOI 10.1007/s00109-009-0481-0; Yipp BG, 2013, BLOOD, V122, P2784, DOI 10.1182/blood-2013-04-457671; Yipp BG, 2012, NAT MED, V18, P1386, DOI 10.1038/nm.2847; Yousefi S, 2009, CELL DEATH DIFFER, V16, P1438, DOI 10.1038/cdd.2009.96	58	0	0	7	8	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					10	17		10.14739/2310-1237.2018.1.128847			8	Pathology	Pathology	GU7AL	WOS:000445470500002		DOAJ Gold			2019-10-28	
J	Tumanskiy, VA; Fen, SV				Tumanskiy, V. A.; Fen, S. V.			Ductular reaction or hepatic reparative complex: immunohistochemical features in liver cirrhosis in patients with chronic hepatitis	PATHOLOGIA			Russian	Article						steatohepatitis; liver cirrhosis; biopsy	PROGENITOR CELLS; BILIARY TREE; STEM-CELLS; HEPATOCYTES; FIBROSIS; DIFFERENTIATION; DISEASE; REPAIR; RISE	Until recently, a discussion about the mechanisms of development and the biological role of the ductular reaction, which develops in patients with chronic liver diseases continues among hepatologists and pathomorphologists. Purpose of the study. To characterize the pathomorphological features and significance of the ductular response in liver cirrhosis in patients with chronic non-alcoholic, alcoholic and viral hepatitis in hepatobioptats with the use of immunohistochemical (IHC) techniques. Material and methods of investigation. Histological, histochemical and IHC study of the ductular liver reaction in liver biopsies of 52 patients aged 24 to 66 years with cirrhosis of the liver on the background of non-alcoholic steatohepatitis (13 patients), and alcoholic steatohepatitis (13 patients) and on the background of chronic viral hepatitis C (10 patients, 26-47 years), as well as those suffering from severe biliostasis (8 patients) and focal nodular liver hyperplasia (8 patients). Results. The ductular reaction can be detected in the active phase with maximum manifestations in patients with liver cirrhosis on the background of chronic hepatitis, it may have an average or weak degree of severity; in a significant number of patients, the effects of the ductular reaction of the liver are revealed. Cellular chains and groups of cells with the immunophenotype of the progenitor cells of the liver appear in the active phase of the ductular reaction at the periphery of the hepatic lobules in the projection of the Goering canals, in the fibrotically altered portal tracts, in the subcapsular zone of the liver and in the thickened fibrosis septa (c-kit CD117+, CD34+, CD56+ CK7-, CK19-, Hepar-) without presence of figures of mitosis or increased level of expression of Ki-67 in them. In small ductules localized in the projection of the Goering canals, single cells with the expression of c-kit CD 117+, CD44 Std./HCAM+, CD34+, CD56+, expressing the markers of biliary (CK7+, CK19+) and hepatocyte (Hepar+, alpha-fetoprotein+) differentiation are revealed. Cellular chains and ductules in the intermediate zones of the hepatic lobules are represented by cells of biphasic differentiation: biliary (CK7+, CK19+), hepatocyte (Hepar+) differentiation and intermediate hepatobiliary CK7+ cells. Hepatocyte differentiation of progenitor cells in lobules of the liver is facilitated by local expression of laminin by perisinusoidal stellate cells. New pseudolobes arise in the active phase of the ductular reaction in the lobes with perisinusoidal pericellular fibrosis from disorderly located large hepatocytes without linear perisinusoid spaces and centrolobular veins, with the presence of "intermediate" SC7+ hepatocytes on the periphery. One-two-row chains and ductules from SC7+ and CK19+ cells dominate in the fibro-altered portal tracts, septa and the subcapsular zone of the liver among the collagen fibers of I, III, IV type and the processes of alpha-SMA+ myofibroblasts, and small short chains from Hepar+ and alpha- fetoprotein-cells. When the severity of micronodular liver cirrhosis increases, when the area of hepatic lobules and pseudotypes becomes equal to or less than the area of the surrounding fibrosis, there is a parallel increase in the number of Ki-67+ cells in portal-lobular ductules and chains, as well as the number of Ki-67+ hepatocytes in hepatic lobules and pseudolobes. The long-term consequences of the ductular reaction in liver cirrhosis reflect the presence of the different number of bile-free ductules with CK7 + epithelium in the fibrous tissue of portal tracts, septa and under the liver capsule. In the lobules of the liver with perisinusoidal pericellular fibrosis, fuzzy outlines of hepatocyte hyperplasia without ordered sinusoids and liver-celled beams are found.	[Tumanskiy, V. A.; Fen, S. V.] Zaporizhzhia State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine; [Tumanskiy, V. A.] Human Clin Pathol Inst, Zaporizhia, Ukraine	Tumanskiy, VA (reprint author), Zaporizhzhia State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine.; Tumanskiy, VA (reprint author), Human Clin Pathol Inst, Zaporizhia, Ukraine.	Alchimik1989@gmail.com	Tumanskiy, Valeriy/R-8880-2017	Tumanskiy, Valeriy/0000-0001-8267-2350			Alwahsh SM, 2018, CELL MOL LIFE SCI, V75, P1307, DOI 10.1007/s00018-017-2713-8; Burt AD, 2012, MACSWEENS PATHOLOGY; Cadamuro M., 2015, J LIVER CLIN RES, V2, P1017; Cameron K, 2015, STEM CELL REP, V5, P1250, DOI 10.1016/j.stemcr.2015.10.016; Cardinale V, 2011, HEPATOLOGY, V54, P2159, DOI 10.1002/hep.24590; Carpino G, 2013, INT J MOL SCI, V14, P20112, DOI 10.3390/ijms141020112; Fabris L, 2017, AM J PHYSIOL-GASTR L, V313, pG102, DOI 10.1152/ajpgi.00452.2016; Font-Burgada J, 2015, CELL, V162, P766, DOI 10.1016/j.cell.2015.07.026; Gavrilyuk OM, 2014, PATHOLOGIA, P41; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Huch M, 2015, CELL, V160, P299, DOI 10.1016/j.cell.2014.11.050; Hung TM, 2015, AM J PATHOL, V185, P2454, DOI 10.1016/j.ajpath.2015.05.010; Kanninen LK, 2016, BIOMATERIALS, V103, P86, DOI 10.1016/j.biomaterials.2016.06.054; Kaur S, 2015, AM J PATHOL, V185, P2342, DOI 10.1016/j.ajpath.2015.06.004; Kholodenko IV, 2017, BIOMED RES INT, DOI 10.1155/2017/8910821; Kim KH, 2015, J CLIN INVEST, V125, P1886, DOI 10.1172/JCI79327; Mak K.M., 2017, FASEB, V31; Mak KM, 2017, ANAT REC, V300, P1371, DOI 10.1002/ar.23567; Morell C. M., 2014, DIMET PHD PROGRAM TR, P1; Nakanuma Y., 2012, MACSWEENS PATHOLOGY, P491; Nobili V, 2012, HEPATOLOGY, V56, P2142, DOI 10.1002/hep.25742; Roskams TA, 2004, HEPATOLOGY, V39, P1739, DOI 10.1002/hep.20130; Schaub JR, 2014, CELL REP, V8, P933, DOI 10.1016/j.celrep.2014.07.003; Strazzabosco M, 2014, HEPATOLOGY, V60, P1469, DOI 10.1002/hep.27291; Strazzabosco M, 2013, J HEPATOL, V58, P181, DOI 10.1016/j.jhep.2012.08.006; Strazzabosco M, 2012, J HEPATOL, V56, P1159, DOI 10.1016/j.jhep.2011.09.022; Tanimizu N, 2016, STEM CELLS, V34, P2889, DOI 10.1002/stem.2457; Wang Y, 2017, JOVE-J VIS EXP, DOI 10.3791/55355; Williams MJ, 2014, GASTROENTEROLOGY, V146, P349, DOI 10.1053/j.gastro.2013.11.034; Yanger K, 2014, CELL STEM CELL, V15, P340, DOI 10.1016/j.stem.2014.06.003; Zhao L, 2018, MODERN PATHOL, V31, P150, DOI 10.1038/modpathol.2017.115	31	0	0	2	7	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					18	28		10.14739/2310-1237.2018.1.129316			11	Pathology	Pathology	GU7AL	WOS:000445470500003		DOAJ Gold			2019-10-28	
J	Loskutova, TO				Loskutova, T. O.			Polymorphism of genes of hemostasis system, endothelial dysfunction and regulation of blood pressure in pregnant woman with preeclampsia and fetal growth retardation	PATHOLOGIA			Russian	Article						pre-eclampsia; pregnancy complications; fetal growth retardation; genetic polymorphism; risk factors	HYPERTENSION	Objective. To study the distribution and effect of blood clotting, endothelial dysfunction, and blood pressure regulator gene polymorphisms on the development of fetal growth retardation in women with preeclampsia (PE). Materials and methods. A prospective cohort study that included 36 women with PE and FGR and 97 with PE without FGR was conducted. A determinations of genes polymorphisms in factor V Leiden 1691 G -> A (FVL), prothrombin 20210 G -> A, plasminogen activator inhibitor 1 type 675 5G / 4G (PAI-1), fibrinogen beta 455 G -> A, paraoxonasae 1 192 Q -> R (PON-1), methylentetrahydrofolatereductase 677 C -> T (MTHFR), angiotensinogen II 235 M -> T (AGT II) were performed. Results. It was found that the early onset of preeclampsia (up to 34 weeks), the duration of hypertension more than 4 weeks increase the relative risk of developing FGR in PE by 3.77 (95 % CI 1.85-7.66) and by 2.1 (95 % DI 1.2-3.6) times respectively. The severity of PE increases the risk of FGR almost by 2 times (RR = 1.98, 95 % CI 1.07-3.69). It was found that the frequency of abnormal polymorphisms was equally high between groups (80.5 % vs. 68.0 %). It was revealed that two or more abnormal polymorphisms were observed more often in pregnant women with PE and FGR (OR = 2.17, 95 % CI 1.26-3.72, P < 0.01). Conclusions. Pre-eclampsia is independently associated with the development of FGR. Our findings do not indicate that there are associations between studied maternal polymorphisms and an increased risk of intrauterine growth restriction in pregnant woman with preeclampsia.	[Loskutova, T. O.] Minist Hlth Ukraine, State Inst Dnipropetrovsk Med Acad, Dept Obstet & Gynecol, Dnipro, Ukraine	Loskutova, TO (reprint author), Minist Hlth Ukraine, State Inst Dnipropetrovsk Med Acad, Dept Obstet & Gynecol, Dnipro, Ukraine.	Loskutovata@gmail.com	Loskutova, Tetiana/F-3002-2017	Loskutova, Tetiana/0000-0002-9844-5520			Gathiram P, 2016, CARDIOVASC J AFR, V27, P71, DOI 10.5830/CVJA-2016-009; [ХОДЖАЕВА Зульфия Сагдуллаевна KHODZHAEVA Z.S.], 2013, [Акушерство и гинекология, Akusherstvo i ginekologiya], P4; Roberts JM, 2013, OBSTET GYNECOL, V122, P1122, DOI 10.1097/01.AOG.0000437382.03963.88; Simcox LE, 2015, INT J MOL SCI, V16, P28418, DOI 10.3390/ijms161226104; Tranquilli AL, 2013, PREGNANCY HYPERTENS, V3, P44, DOI [10.1016/j.preghy.2013.04.006, 10.1016/j.preghy.2012.11.001]; Vdovychenko Yu.P., 2017, ZATRYMKA ROSTU PLODA	6	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					29	33		10.14739/2310-1237.2018.1.127709			5	Pathology	Pathology	GU7AL	WOS:000445470500004		DOAJ Gold			2019-10-28	
J	Shelestova, LP; Radchenko, NM				Shelestova, L. P.; Radchenko, N. M.			The course of pregnancy and its result in women who have diffuse non-toxic goiter	PATHOLOGIA			English	Article						goiter; pregnancy; parturition; obstetric labor complications	CHINA	Aim-to study the peculiarities of the pregnancy course and its result with women who have diffuse non-toxic goiter. Materials and methods. The course of pregnancy and its result in 75 women with diffuse non-toxic goiter and in 75 women without thyroid pathology has been studied. The amount of thyroid-stimulating hormone (TSH), free triiodothyronine (FT3) and free thyroxin (FT4) was defined in blood serum, the concentration of iodine-in urine. Results. The pregnancy in women who have diffuse non-toxic goiter goes with mild iodine deficiency (median 66.0 mu g/l), an increase in TSH, a decrease in thyroid hormones and an integral thyroid index, compared with pregnant women without pathology of the thyroid gland. In 78.7 % (95 % CI 68.1-86.4 %) of women with diffuse non-toxic goiter, the thyroid gland enlargement is first detected during pregnancy. In 32.0 % (95 % CI 22.5-43.2 %) of women with diffuse nontoxic goiter in the second half of pregnancy subclinical hypothyroidism is developed. The presence of diffuse non-toxic goiter in the pregnant in comparison with the women without thyroid pathology increases the possibility of spontaneous abortion (OR 4.2; 95 % CI 2.0-8.9), iron-deficiency anemia (OR 2.3; 95 % CI 1.1-4.8), preeclampsia (OR 2.7; 95 % CI 1.2-6.2), placental dysfunction (OR 6.3; 95 % CI 3.1-12.8), fetal growth retardation (OR 5.6; 95% CI 1.2-26.6), premature labor (OR 5.6; 95 % CI 1.2-26.6), untimely outpouring of amniotic fluid (OR 2.2; 95 % CI 1.1-4.4), labor abnormalities (OR 2.8; 95 % CI 1.2-7.0). Conclusions. In women with diffuse non-toxic goiter the likelihood of complications increases during pregnancy and childbirth, which points to the need to develop therapeutic and preventive measures aimed at their reduction.	[Shelestova, L. P.; Radchenko, N. M.] Donetsk Natl Med Univ, Dept Obstet & Gynecol, Lyman, Ukraine	Shelestova, LP (reprint author), Donetsk Natl Med Univ, Dept Obstet & Gynecol, Lyman, Ukraine.	larysa.shelestova@gmail.com					BRUNN J, 1981, DEUT MED WOCHENSCHR, V106, P1338, DOI 10.1055/s-2008-1070506; Kaminskyj O. V., 2017, MIZHNARODNYI ENDOKRY, V13, P152, DOI [10.22141/2224-0721.13.2.2017.100605, DOI 10.22141/2224-0721.13.2.2017.100605]; Liu HX, 2014, THYROID, V24, P1642, DOI 10.1089/thy.2014.0029; Mao GM, 2015, ASIA PAC J CLIN NUTR, V24, P234, DOI 10.6133/apjcn.2015.24.2.08; Nazarenko G. I., 2000, KLIN OCENKA REZULTAT; Romanenko T. G., 2015, ZDOROVE ZHENSHHINY, V2, P8; Savel'eva G. M., 2015, AKUSHERSTVO NACL RUK; Shi XG, 2015, J CLIN ENDOCR METAB, V100, P1630, DOI 10.1210/jc.2014-3704; Wang KL, 2017, BMC ENDOCR DISORD, V17, DOI 10.1186/s12902-017-0162-x	9	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					34	37		10.14739/2310-1237.2018.1.129187			4	Pathology	Pathology	GU7AL	WOS:000445470500005		DOAJ Gold			2019-10-28	
J	Vorontsova, LL; Dub, MI; Kovalenko, VA				Vorontsova, L. L.; Dub, M. I.; Kovalenko, V. A.			Condition of a cellular link of innate immunity in infertile men against the background of toxocariasis invasion	PATHOLOGIA			Russian	Article						innate immunity; toxocariasis; male infertility		Aim. Investigating the role of various factors in the development of pathospermia, such as: the presence of toxocariasis invasion, the level of DNA fragmentation of sperm, indices of the cellular link of innate immunity, could complement existing methods and will allow the determination of the share of influence of each factor on the ultrastructure of spermatozoa for a more in-depth understanding of the pathogenesis of violations of male reproductive function. That is why the aim of our research was to study the peculiarities of disorders of the cellular link of innate immunity in men with infertility against the background of toxocariasis invasion. Materials and methods. 89 men aged from 20 to 45 years, which were divided into 5 groups, were examined. The first (control) group consisted of 12 fertile men; the second group (comparison group)-27 infertile patients with normal level of DNA fragmentation of sperm and without antibodies to toxocariasis; the third group-20 infertile men with normal level of DNA fragmentation of sperm and presence of antibodies to toxocariasis. The fourth and fifth groups included 15 infertile men with high levels of DNA fragmentation of sperm and the presence and absence of antibodies to toxocariasis respectively. A comprehensive research was conducted for all the men that included determination of sperm DNA fragmentation, presence of toxocariasis invasion and the study of the state of the cellular link of innate immunity as well as assessment of the degree of immune system disorders. Results. The incompleteness of phagocytosis in neutrophilic and monocytic elements was observed in all studied groups, in the second and fifth groups with the preservation of the functional-metabolic reserve and the depletion of it in the third and fourth groups. The results of the assessment of the degree of immune system disorders have shown that most immunologically compromised are the groups without the presence of toxocariasis invasion, in which there was an immune failure of 2-3 degree. In groups with the presence of toxocariasis, on the contrary, changes from activation to immune failure of 2 degree (due to the growth of absorbing capacity of monocytes) were determined, which may be due to the presence of toxocariasis invasion, which, in turn, obviously causes the activation of the monocytic link. Conclusions. The state of the cellular link of innate immunity in infertile men is characterized by incompleteness of phagocytosis of both neutrophilic and monocytic elements. The presence of toxocariasis invasion in this contingent of patients, in turn, introduces certain changes to the phagocytic system, which manifests itself as an increase in absorbing capacity of monocytes, which are key immune factors in the protection against helminths.	[Vorontsova, L. L.] Minist Hlth Ukraine, State Estab Zaporizhzha Med Acad Post Grad Educ, Dept Clin Lab Diagnost, Kiev, Ukraine; [Dub, M. I.; Kovalenko, V. A.] Minist Hlth Ukraine, State Estab Zaporizhzha Med Acad Post Grad Educ, Kiev, Ukraine	Vorontsova, LL (reprint author), Minist Hlth Ukraine, State Estab Zaporizhzha Med Acad Post Grad Educ, Dept Clin Lab Diagnost, Kiev, Ukraine.	zmapo32@gmail.com; dub.maryana@gmail.com	Vorontsova, Lolita/X-6045-2019	Kovalenko, Victoria/0000-0003-2385-8547			Adamenko G. P., 2004, MED NOVOSTI, V2, P31; Bekish V., 1999, VOPROSY EKSPERIMENTA, P70; Bekish V. Ya., 2004, SOSTOYANIE GENOMA VL; [БОЖЕДОМОВ Владимир Александрович BOZHEDOMOV V.A.], 2013, [Акушерство и гинекология, Akusherstvo i ginekologiya], P68; Castillo J, 2015, ASIAN J ANDROL, V17, P601, DOI 10.4103/1008-682X.153302; Centola GM, 2014, UROL CLIN N AM, V41, P163, DOI 10.1016/j.ucl.2013.08.007; Coakley G, 2017, CELL REP, V19, P1545, DOI 10.1016/j.celrep.2017.05.001; Farhi J, 2011, ISR MED ASSOC J, V13, P51; Frimel G. N., 1984, IMMUNOLOGICHESKIE ME; [Гришина Е.А. Grishina E.A.], 2016, [Российский паразитологический журнал, Russian Journal of Parasitology, Rossiiskii parazitologicheskii zhurnal], V36, P202; Jugwirth A., 2015, GUIDELINES MALE INFE; Kreider T, 2007, CURR OPIN IMMUNOL, V19, P448, DOI 10.1016/j.coi.2007.07.002; Macpherson CNL, 2013, INT J PARASITOL, V43, P999, DOI 10.1016/j.ijpara.2013.07.004; Makepeace BL, 2012, CURR MED CHEM, V19, P1567; Narcissov R. P., 1964, LAB WORK, V3, P150; Natcheva L. V., 2012, ROSSIJSKIJ PARAZITOL, V3, P80; Nordkap L., 2012, UGESKRIFT LAEGER, V41, P2444; Novikov P. D., 2007, IMMUNOPATOLOGIYA ALL, V2, P65; Povoroznyuk M. V., 2015, MED ASPEKTY ZDOROVYA, V2, P63; Savelyeva N. N., 2016, VESTNIK VITEBSKOGO G, V15, P80; Shubich M. G., 1974, CYTOLOGY, V10, P1321; Stybel V., 2014, NAUKOVYI VISNYK LNUV, V16, P330; Tarasova M. N., 2007, IMM UR P 6 C IMM UR, V1, P165; Usachova O. V., 2013, ZBIRNYK NAUKOVYKH PR, V3, P304; Viksman M. E., 1979, SPOSOB OCENKI FUNKCI; Vismont F. I., 2006, VOSPALENIE PATOFIZIO; Zemskov A. M., 2011, RUKOVODSTVO KLIN IMM	27	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					38	44		10.14739/2310-1237.2018.1.129328			7	Pathology	Pathology	GU7AL	WOS:000445470500006		DOAJ Gold			2019-10-28	
J	Riabokon, YY; Tumanskiy, VA; Riabokon, EV				Riabokon, Yu. Yu.; Tumanskiy, V. A.; Riabokon, E. V.			The interaction of morphological changes in the liver with the development of extrahepatic manifestations in patients with chronic hepatitis C	PATHOLOGIA			English	Article						chronic hepatitis C; immunohisto-chemistry; extrahepatic manifestations	VIRUS-INFECTION; CRYOGLOBULINEMIA; FIBROSIS	The purpose of the work was to analyze the connections of morphological changes in the liver with the manifestation of clinical signs of extrahepatic manifestations in patients with CHC. Material and methods. The study included 86 patients with CHC. The correlation analysis of expressiveness degree of liver fibrosis and histological activity depending on the presence of clinical signs of extrahepatic manifestations of disease and changes of autoimmune parameters was carried out. Results. It was found that the incidence of mixed cryoglobulins in the blood of patients with CHC had a dependence on the degree of fibrosis of the liver. In the presence of liver fibrosis F 3-4 mixed cryoglobulins were found in 94.2 % versus 64.7 % of patients with stages of liver fibrosis F 12 (P < 0.01). In patients with stages of liver fibrosis F 3-4, the quantitative content of mixed cryoglobulins, RF-IgM and CIC was higher than those of patients with stages of liver fibrosis F 1-2. In patients with fibrosis in the liver F 3-4 cryoglobulinema incidence of vasculitis with formation of Meltzer's triad was higher than in patients with liver fibrosis F 1-2 (19.2 % versus 2.9 %, P < 0.05). Content of mixed cryoglobulins correlated with the degree of fibrosis of the liver (r= + 0.49, P < 0.01). A factor A3 was more often detected in patients with stage F 3-4, compared with patients with stage F 1-2 of fibrosis (81.5 % versus 19,2 %, P < 0.01). Conclusions. CHC patients with liver fibrosis F 3-4 are characterized with more frequent appearance of mixed cryoglobulins, higher content of RF-IgM and CIC in serum than in patients with liver fibrosis F 1-2. This explains the higher frequency of clinical manifestations of extrahepatic manifestations of immunocomplex genesis in patients with F 3-4 fibrosis. Histological activity of A3 in patients with CHC is most often combined with fibrosis of the liver F 3-4, which causes a high frequency of cryoglobulinemic vasculitis development in these patients.	[Riabokon, Yu. Yu.] Zaporizhzhia State Med Univ, Dept Children Infect Dis, Zaporizhia, Ukraine; [Tumanskiy, V. A.] Zaporizhzhia State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine; [Tumanskiy, V. A.] Human Clin Pathol Inst, Zaporizhia, Ukraine; [Riabokon, E. V.] Zaporizhzhia State Med Univ, Dept Infect Dis, Zaporizhia, Ukraine	Riabokon, YY (reprint author), Zaporizhzhia State Med Univ, Dept Children Infect Dis, Zaporizhia, Ukraine.	RyabokonZSMU@gmail.com	Tumanskiy, Valeriy/R-8880-2017; Riabokon, Yurii/Z-3191-2019	Riabokon, Yurii/0000-0002-2273-8511; Tumanskiy, Valeriy/0000-0001-8267-2350			Agnello V, 1997, HEPATOLOGY, V26, P1375; Allison RD, 2015, J HEPATOL, V63, P822, DOI 10.1016/j.jhep.2015.04.021; Atta AM, 2010, MICROB PATHOGENESIS, V48, P53, DOI 10.1016/j.micpath.2009.12.002; Cacoub P, 2016, THER ADV INFECT DIS, V3, P3, DOI 10.1177/2049936115585942; Andrade LJD, 2011, BRAZ J INFECT DIS, V15, P66, DOI 10.1590/S1413-86702011000100012; [Дунаева Н.В. Dunaeva N.V.], 2016, [Журнал инфектологии, Zhurnal infektologii], V8, P40; Gragnani L, 2016, HEPATOLOGY, V64, P1473, DOI 10.1002/hep.28753; Milovanova S.Yu, 2014, MANAKH KLIN MED, V30, P46; Milovanova S.Yu, 2013, THESIS; Negro F, 2015, GASTROENTEROLOGY, V149, P1345, DOI 10.1053/j.gastro.2015.08.035; Pawlotsky JM, 2015, J HEPATOL, V63, P199, DOI 10.1016/j.jhep.2015.03.025; Roccatello D, 2017, ONCOTARGET, V8, P41764, DOI 10.18632/oncotarget.16986; Saadoun D, 2006, HEPATOLOGY, V43, P1337, DOI 10.1002/hep.21190; Yang DH, 2014, WORLD J GASTROENTERO, V20, P2962, DOI 10.3748/wjg.v20.i11.2962	14	0	0	2	5	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					45	48		10.14739/2310-1237.2018.1.129194			4	Pathology	Pathology	GU7AL	WOS:000445470500007		DOAJ Gold			2019-10-28	
J	Shyshkin, MA				Shyshkin, M. A.			Molecular-immunohistochemical characteristics of proliferation and apoptosis of tumor cells in colorectal adenocarcinoma	PATHOLOGIA			Russian	Article						colorectal cancer; immunohisto-chemistry; K-RAS gene	CANCER CELLS; MUTATIONS	Aim-to study the features of K-RAS transcriptional activity gene, Ki-67 and TP53 mRNA genes expression levels in comparison with the immunohistochemical expression levels of Ki-67, p53 proteins and caspase-3 encoded by them in colorectal adenocarcinoma (CRA) with its progression from the I to the IV stage. Materials and methods. Parallel immunohistochemical and molecular-genetic, pathohistological studies of operational material of CRA from 40 patients (4 study groups-I, II, III, IV stages of the disease according to pTNM classification-10 cases in each group) with diagnosis of colorectal adenocarcinoma, and also sectional material of 10 fragments of distal colonic wall with normal histological structure were conducted. Results. In comparison with unchanged mucosa of distal colon, CRA is characterized by the increased K-RAS gene and Ki-67 gene activity. As CRA progresses from the I to IV stages, there is an increase in the transcriptional activity of the K-RAS gene and a decrease in the transcriptional activity of the Ki-67 gene in the study groups. The tumor cells are characterized by the medium level of expression of Ki-67, which is the marker of cellular proliferation, herewith the reverse correlation between the Ki-67 expression level and the tumor invasion level is present. CRA is characterized by the increased TP53 gene transcriptional activity with the tendency to elevation, which happens during the progression of the tumor from the I to the IV stage and correlates with the increased K-RAS gene transcriptional activity. CRA is also characterized by the medium p53 expression level and the low level of caspase-3 expression, which is the marker of apoptotic degradation process, which happens in the presence of the reverse correlation between the increased K-RAS gene transcriptional activity and the low level of apoptosis of the tumor cells. Conclusions. The K-RAS and TP53 genes transcriptional activity increases, but the Ki-67 gene transcriptional activity decreases during the process of CRA progression from the I to the IV stage. The inverse correlation between the level of transcription activity of the K-RAS, TP53 genes and apoptosis of tumor cells of the colorectal adenocarcinoma was determined. The decline of proliferation level of the tumor cells, that is observed during the process of CRA progression from the I to the IV stage, is mediated by the signal pathways, which don't have connection with RAS-protein.	[Shyshkin, M. A.] Zaporizhzh State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine	Shyshkin, MA (reprint author), Zaporizhzh State Med Univ, Dept Pathol Anat & Forens Med, Zaporizhia, Ukraine.	Shishkin.stomat@gmail.com					Arvelo F, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.520; Bardaji HR, 2018, EUR J CELL BIOL, V97, P279, DOI 10.1016/j.ejcb.2018.04.004; Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116; Coulson Ryanne, 2015, J Adv Pract Oncol, V6, P470; Du L, 2017, ONCOTARGET, V8, P22175, DOI 10.18632/oncotarget.14549; Fedorenko Z. P., 2017, B NATSIONALNOHO KANT, V18; Hegazy A., 2014, ACAD J CANC RES, V7, P168, DOI [DOI 10.5829/ID0SI.AJCR.2014.7.3.1111, 10.5829/idosi.ajcr.2014.7.3.1111]; Kwak MS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007882; Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84; Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP; Loree JM, 2017, THER ADV MED ONCOL, V9, P551, DOI 10.1177/1758834017714997; Margetis N, 2017, IN VIVO, V31, P527, DOI 10.21873/invivo.11091; Melling N, 2016, J CLIN PATHOL, V69, P209, DOI 10.1136/jclinpath-2015-202985; Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448; Shyshkin MA, 2016, PATHOLOGIA, P65, DOI 10.14739/2310-1237.2016.3.87497; Sobin LH, 2009, INT UNION CANC UICC; Temraz S, 2015, INT J MOL SCI, V16, P22976, DOI 10.3390/ijms160922976; Thomas J, 2015, INT J MOL SCI, V16, P28063, DOI 10.3390/ijms161226080; Tumanskyi V. O., 2015, [Patent, Patent of Ukraine], Patent No. 99314; Uhlen Mathias, 2015, HUMAN PROTEIN ATLAS; van Helden EJ, 2017, CANCER METAST REV, V36, P395, DOI 10.1007/s10555-017-9668-y; Wang Y, 2016, ONCOTARGET, V7, P32854, DOI 10.18632/oncotarget.9056; Xiao RL, 2015, BIOMED PHARMACOTHER, V74, P138, DOI 10.1016/j.biopha.2015.08.006; Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030	24	1	1	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					49	56		10.14739/2310-1237.2018.1.129447			8	Pathology	Pathology	GU7AL	WOS:000445470500008		DOAJ Gold			2019-10-28	
J	Yaremenko, LM; Grabovoy, AN; Bidna, LP; Shepelev, SY; Grusha, MM				Yaremenko, L. M.; Grabovoy, A. N.; Bidna, L. P.; Shepelev, S. Ye.; Grusha, M. M.			Expression of NF-L protein in the sensorimotor cortex during the modeling of transient ischemia against the background of sensitization by brain antigen and immunocorrection of the changes	PATHOLOGIA			Russian	Article						ischemia; NF-L-protein (NFP-L); central nervous system sensitization; immunomodulation	STROKE	Aim. To study the levels of NFP-L protein expression in the sensorimotor cortex of rats in the simulation of transient ischemia against the background of sensitization by the brain antigen and immunocorrection of the resulting changes by imunofan. Materials and methods. The study was conducted on 185 male mature white rats from Wistar line weighted 260-290 g, in which the damage of the brain was modulated. The brain for study was taken on the 1st, 3rd, 10th, 30th and 90th days after the start of the experiment. The histological, immunehistochemical, morphometric and statistical methods were used. Results. Observations have shown that sensitization with the brain antigen causes diffuse degenerative changes in the cerebral cortex and a decrease in NFP-L expression. This background leads to an increase in the severity of brain damage in acute circulatory disturbances compared with when no sensitization was performed. After transient ischemic attack, the recovery period was significantly less than in the absence of sensitization, rounded corpuscles with a relatively high level of expression of NFP-L, which we qualified as nerve growth flasks (cones). This allows us to say that sensitization by the brain antigen delays the regeneration of nerve fibers, which is an important component of compensatory-recovery processes in the cerebral cortex after ischemic attack. Imunofan under the conditions of modeling of combined immune-vascular lesions of the brain had protective properties and reduced the severity of the decrease in NFP-L expression. We attribute these effects of imunofan, especially in the recovery period after brain damage in the first place, to its immunomodulatory effect which is confirmed by comparing the dynamics of the restoration of NFP-L expression in the affected and contralateral hemispheres, where the latter experienced immune damage in the absence of ischemia. Conclusions. Sensitization by the brain antigen leads to diffuse degenerative changes in the cerebral cortex, which are accompanied by a decrease in the expression of NFP-L. Previous sensitization by brain antigen in acute impairment of cerebral circulation leads to increased severity of brain damage and decreased expression of NFP-L, slows and changes the dynamics of its recovery. The effect of immunophan use is to reduce changes in NFP-L expression in the sensorimotor cortex caused by both sensitization with the brain antigen and in combination with transient impairment of cerebral blood flow.	[Yaremenko, L. M.; Bidna, L. P.] Bogomolets Natl Med Univ, Dept Histol & Embryol, Kiev, Ukraine; [Grabovoy, A. N.] Ukrainian Natl Canc Inst, Res Dept Cytopathol & Pathol Anat, Kiev, Ukraine; [Shepelev, S. Ye.; Grusha, M. M.] Bogomolets Natl Med Univ, Dept Biol, Kiev, Ukraine	Yaremenko, LM (reprint author), Bogomolets Natl Med Univ, Dept Histol & Embryol, Kiev, Ukraine.	L.yaremenko03@gmail.com	Grabovoy, Alexandr/R-1421-2017; Yaremenko, Lilia/AAB-3783-2019	Grabovoy, Alexandr/0000-0001-5705-9909; Yaremenko, Lilia/0000-0001-7076-467X			Hartig W, 2016, J CHEM NEUROANAT, V78, P140, DOI 10.1016/j.jchemneu.2016.09.004; Hrabovyi O. M., 2008, Patent, Patent No. 36843; Lebedev VV, 2006, B EXP BIOL MED+, V142, P693, DOI 10.1007/s10517-006-0453-0; Liesz A, 2011, BRAIN, V134, P704, DOI 10.1093/brain/awr008; Miro-Mur F, 2016, NEUROTHERAPEUTICS, V13, P719, DOI 10.1007/s13311-016-0469-8; Park MG, 2018, NEUROL SCI, V39, P243, DOI 10.1007/s10072-017-3163-7; Ueno Y, 2012, STROKE, V43, P2221, DOI 10.1161/STROKEAHA.111.646224; Vickers JC, 2016, BRAIN RES BULL, V126, P324, DOI 10.1016/j.brainresbull.2016.07.012; Yaremenko LM, 2016, NEUROPHYSIOLOGY+, V48, P111, DOI 10.1007/s11062-016-9576-8; Zozulia A.I., 2014, UKRAINSKYI MED CHASO, V5, P112	10	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					57	61		10.14739/2310-1237.2018.1.129443			5	Pathology	Pathology	GU7AL	WOS:000445470500009		DOAJ Gold			2019-10-28	
J	Mukvich, OM; Zadorozhnaja, TD; Lavrenchuk, OV; Archakova, TN				Mukvich, O. M.; Zadorozhnaja, T. D.; Lavrenchuk, O. V.; Archakova, T. N.			Pathological and morphological properties of chronic gastroduodenitis in children with connective tissue dysplasia	PATHOLOGIA			Russian	Article						connective tissue dysplasia; diseases gastritis; hypertrophic; children		Predictive chronic gastroduodenitis (CGD) treating in children is bound to genetically controlled collagen synthesis underpinning the connective tissue dysplasia (CTD). Collagen metabolic disorder affects morphological changes of mucosal-cellular barrier determining clinically-aided reparation processes. Morphologic assessment enables personalized approaches to handle inflammatory processes in upper gastro-intestinal tract (GIT) associated with extracellular matrix disorders. Aim: examining patho-morphologic properties of gastric and duodenal mucosa in children with CGD associated with CTD. Materials and methods. Morphologic examination of endoscopic biopsies in 63 children, 11-17 years old. Samples were processed by hematoxylin eosin section staining. The influence of dysplasia and patient's response to standard therapy on morphological changes were assessed using odd ratio statistics, confidence limits, and p-values. Results. Dependency of morphological changes versus the CTD degree and patient response to standard therapy: foci of fibrosis OR = 7 and 5.25, eosin infiltration OR = 3.684 and 3.667, dystrophic epithelium changes OR = 2.344 and 3.023, change in glands architectonics OR = 3.684 and 3.279, respectively. Biopsy samples from patients with CTD and weak therapy response feature dense lymphocyte-plasmocyte infiltration of gland epithelium and lamina propria (81.3 %), pronounced diffuse edema (68.8 %), and uneven gland localization with changed architectonics and dystrophically modified epithelium (62.5 %). 78.6 % not therapy-responsive children without DCT have morphologically pronounced CGD whereas irresponsiveness in children with the associated pathology isn't strongly connected with CGD morphology. Conclusion. Gastric and duodenal mucosa inflammation in children with expressed CTD features are characterized with lympho-histological infiltration of lamina propria and surface gland epithelium, increased edema, dystrophic changes of gland epithelium, and spread fibrosis loci indicating high risk of early chronicity and atrophic process formation. The account of clinical CTD conditions affecting pathogenic mucosal processes stipulates adequate CGD development assessment.	[Mukvich, O. M.] NAMS Ukraine, SI Inst Pediat Obstet & Gynaecol, Kiev, Ukraine; [Zadorozhnaja, T. D.] NAMS Ukraine, Kiev, Ukraine; [Zadorozhnaja, T. D.; Archakova, T. N.] NAMS Ukraine, SI Inst Pediat Obstet & Gynaecol, Lab Pathomorphol, Kiev, Ukraine; [Lavrenchuk, O. V.] Ctr Primary Med & Sanit Hlth 1, Publ Nonprofit Enterprise, Kiev, Ukraine	Lavrenchuk, OV (reprint author), Ctr Primary Med & Sanit Hlth 1, Publ Nonprofit Enterprise, Kiev, Ukraine.	ov.lavrenchuk@gmail.com					Abbakumova L. N., 2006, KLIN FORMY DISPLAZII; Barinov E. F., 2013, UKRAIINSKII ZH KHIRU, V4, P96; Chen QR, 2017, FOOD FUNCT, V8, P1144, DOI [10.1039/c6fo01347c, 10.1039/C6FO01347C]; Glanz S., 1998, MEDIKO BIOLOGICHESKA; Kankova N. U., 2012, PRAKTICHESKAYA MED, V6, P86; Marushko Yu. V, 2014, ZDOROVE REBENKA, V4, P7; Mukvich E. N., 2016, VOPROSY ORG INF ZDRA, V5, P234; Nakaz MOZ Ukrainy, PRO ZATV UN PROT MED; Nechaeva G. I., 2010, EKSP I KLIN GASTROEN, V6, P66; Nesterenko Z. V., 2012, B SUSTAVY POZVONOCHN, V1, P17; Polivanova T. V., 2014, MEZHUNARODNYI ZH PRI, V9, P82; Sazanova N. Ye, 2009, SIBIRSKIJ MED ZH, V24, P24	12	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					62	67		10.14739/2310-1237.2018.1.128818			6	Pathology	Pathology	GU7AL	WOS:000445470500010		DOAJ Gold			2019-10-28	
J	Protsiuk, TL; Herasymova, YV; Protsiuk, LO; Surkova, NM				Protsiuk, T. L.; Herasymova, Ye. V.; Protsiuk, L. O.; Surkova, N. M.			The course of bronchial asthma associated with metabolic syndrome in children with different phenotypes depending on vitamin D-3 level	PATHOLOGIA			English	Article						asthma; metabolic syndrome; children; vitamin D3		Objective: to establish specific features of BA course in children with various phenotypes on the background of metabolic syndrome, depending on serum vitamin D-3 level. Subjects and methods. 106 children with BA participated in the study. 42 patients had BA associated with metabolic syndrome (MS), and 64 had BA with no MS. By the phenotype 61 (57.5 %) of patients had allergen-induced (allergic) asthma and 45 (42.5 %)-virus-induced (non-allergic) BA. The control group consisted of 44 children (the patients with MS and those without MS and BA), average age 15.5 +/- 1.3 years. All the patients underwent a unified complex of diagnostic investigations: general physical examination, measurement of waist circumference and body mass index (BMI), clinical blood test, spirometry, lipid profile. Weight categories (normal weight, excess weight and obesity) were determined by percentiles (P) of BMI variation series with regard to age, as indicated in WHO recommendations. Serum 25(OH) D levels were determined by enzyme immunoassay. Vitamin D level >= 20 ng/ml was considered sufficient, 11-20 ng/ml-insufficient, <= 10 ng/ml-deficient. General and specific serum IgE levels were determined by enzyme immunoassay. The data obtained were processed with Statistica 8 program, P values of less than 0.05 were considered to indicate statistical significance. Results. In the group of patients with vitamin D-3 level below 20 ng/ml, 19.5 % had controlled BA and 41.3 %-uncontrolled BA, while among the children with vitamin D-3 level over 20 ng/ml, 30.4 % had controlled BA and 8.6 %-uncontrolled BA (chi(2) = 9.12, P < 0.05). Mean value of vitamin D-3 concentration in the control group was significantly higher than in the patients with BA associated with MS and BA without MS (P < 0.05). The relationship between OW, obesity and atopy was confirmed by high serum level of sIgE antibodies in those weight categories. High sIgE levels to allergens from the pollen of meadow grass, weeds and trees, animal epithelium, household dust mite, food and fungal allergens were determined much more frequently in the children with OW and obesity than in those with NW. In the patients with BA associated with MS and vitamin D-3 level below 20 ng/ml, FEV1 and FVLC values appeared to be significantly lower as compared to those with vitamin D-3 level over 20 ng/ml (P = 0.002). Inverse relationship between the most important parameters of external respiration function and BMI was established: VLC (r(xy) =-0.45, P = 0.002), FVLC (r(xy) =-0.52, P = 0.001), FEV1 (r(xy) =-0.78, P = 0.001), respectively. Conclusions. The severity of BA as well as the degree of its control in the patients with different phenotypes was found to be influenced by both the presence of MS and vitamin D-3 level. Therefore, vitamin D deficiency can be one of the risk factors of BA and MS development, and can affect the severity of both BA and MS course. Vitamin D-3 deficiency and the presence of MS greatly influence FEV1, FVLC, PEF values, decreasing the indices of external respiration in children and leading to more severe obstruction.	[Protsiuk, T. L.; Herasymova, Ye. V.] Natl Pirogov Mem Med Univ, Dept Pediat 1, Vinnytsia, Ukraine; [Protsiuk, L. O.] Natl Pirogov Mem Med Univ, Dept Hyg & Ecol, Vinnytsia, Ukraine; [Surkova, N. M.] Vinnytsia Reg Childrens Clin Hosp, Vinnytsia, Ukraine	Protsiuk, TL (reprint author), Natl Pirogov Mem Med Univ, Dept Pediat 1, Vinnytsia, Ukraine.	rossata@ukr.net					Farzan Sherry, 2013, J Allergy (Cairo), V2013, P602908, DOI 10.1155/2013/602908; Forno E, 2017, CURR OPIN ALLERGY CL, V17, P123, DOI 10.1097/ACI.0000000000000339; Guillot X, 2010, JOINT BONE SPINE, V77, P552, DOI 10.1016/j.jbspin.2010.09.018; Haines ST, 2012, PHARMACOTHERAPY, V32, P354, DOI 10.1002/phar.1037; Lautenbacher LA, 2016, PEDIATR PULM, V51, P1276, DOI 10.1002/ppul.23485; Neyestani TR, 2012, J CLIN ENDOCR METAB, V97, P2005, DOI 10.1210/jc.2011-3465; Schatz M, 2014, J ALLER CL IMM-PRACT, V2, P645, DOI 10.1016/j.jaip.2014.09.004	7	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					68	72		10.14739/2310-1237.2018.1.129321			5	Pathology	Pathology	GU7AL	WOS:000445470500011		DOAJ Gold			2019-10-28	
J	Gaida, IM; Badyuk, MI; Sushko, YI				Gaida, I. M.; Badyuk, M. I.; Sushko, Yu. I.			Peculiarities of structure and current of modern combat trauma among servicemen of the Armed Forces of Ukraine	PATHOLOGIA			Russian	Article						wounds; war-related injuries; injury severity score; rehabilitation		The aim. To investigate the level and structure of combat trauma among servicemen of the Armed Forces of Ukraine in conditions of military operations. Materials and methods. The results of the analysis of the structure and character of the modern combat trauma in 954 soldiers - participants of the anti-terrorist operation, who were treated in the Military Medical Clinical Center of the Western Region (MMCC of the WR), are presented. Results. It was found that the largest proportion among the injuries is injury of extremities - 52 % (496 wounded). In most of the wounded - 583 (61 %) - the state at the time of admission to the MMCC of the WR was rated as of mild severity. 94 wounded (10 %) received treatment in severe condition. In 277 wounded (29 %) state at the time of admission was assessed as of average severity. The longest treatment period was observed in patients with severe injuries - it was 36.6 days on the average. Duration of treatment in patients with injury of moderate severity was 21.8 days. In case of mild injury the duration of treatment for patients was 24.2 days. 6 (0.6 %) patients of the total number of treated patients (954 persons) died. These lethal consequences were caused by serious injuries: a mine-explosive injury of a severe degree (2 patients), a combined gunshot wound (3 patients), a gunshot wound of the head (1 patient). 604 patients (63.3 %) returned to military service without treatment without changing the category of suitability; 344 (36.1 %) patients are considered unsuitable for military service. Conclusions. Summarizing the results obtained, we can say that in the structure of wounds the greatest part was wound of extremities - 52 %. Among these the upper extremities were injured in 41.12 %, wounds of the lower extremities were 58.8 %. Modern combat trauma requires a long period of treatment and rehabilitation, which in the case of serious injuries is 36.6 days on the average. Treatment of modern combat trauma cannot be separated from rehabilitation measures. Therefore, treatment and rehabilitation of servicemen is a topical issue that today faces not only military but also civilian medicine and social protection services.	[Gaida, I. M.; Sushko, Yu. I.] Mil Med Clin Ctr Western Reg, Lvov, Ukraine; [Badyuk, M. I.] Ukrainian Mil Med Acad, Lvov, Ukraine; [Badyuk, M. I.] Ukrainian Mil Med Acad, Med Support Org Armed Forces, Lvov, Ukraine	Gaida, IM (reprint author), Mil Med Clin Ctr Western Reg, Lvov, Ukraine.	vmkczr@ukr.net					Badiuk M. I., 2016, UKRAINA ZDOROVIA NAT, V4, P13; Bilyi V.Ya., 2016, MEDYCHNE ZABEZPECHEN, P60; Guriev S., 2014, EKSTRENA MEDYTSYNA N, V4, P3; Korol S. O, 2015, TRAVMA, V16, P11; Maydanyuk V. P., 2015, P SCI PRACT C KYIV H; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270	6	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					73	76		10.14739/2310-1237.2018.1.129329			4	Pathology	Pathology	GU7AL	WOS:000445470500012		DOAJ Gold			2019-10-28	
J	Raznatovska, OM; Khlystun, VM				Raznatovska, O. M.; Khlystun, V. M.			Diagnosis of respiratory epithelial clearance abnormality in patients suffering from chemo-resistant pulmonary tuberculosis with comorbidity of bronchial mucosa	PATHOLOGIA			English	Article						bronchoscopy; trachea bronchial tree mucosa; chemoresistance tuberculosis; mucociliary transport system		Respiratory epithelial clearance timely and early disorder diagnosis in patients suffering from chemo-resistant pulmonary tuberculosis (CRPTB) concomitant pathology of the bronchial mucosa is an actual problem of modern phthisiology, the solution of which will allow the timely application of rational correction, which will increase the effectiveness of this category treatment among patients. Objective is to investigate the nature and features of respiratory epithelial clearance disorders among patients suffering from CRPTB with comorbidity of the bronchi mucous membrane by using the developed method of these disorders diagnosis. Materials and methods. The respiratory epithelial clearance state diagnosis was carried out among 133 patients with CRPTB at the beginning of the intensive phase of antimycobacterial therapy during fibrobronchoscopy, provided there is a concomitant specific pathology of the mucous membrane (including its combination with non-specific endobronchitis). Average age of patients was 36.5 +/- 1.1 years old. There were 89 (66.9 %) men and 44 (33.1 %) women. The tracheobronchial tree diagnostic fibrobronchoscopy with further study of the respiratory epithelial clearance condition among patients suffering from CRPTB was carried out by V. M. Khlystun at Phthisiology and Pulmonology Department of Zaporizhzhia State Medical University in CI Zaporizhzhia Regional Antituberculous Clinical Dispensary. Criteria of patients including into the research: existence of resistance of tuberculosis mycobacteria to anti-mycobacterial drugs in patients with new and repeated cases of tuberculosis, existence of pathology of the mucosa of bronchi confirmed during fiberoptic bronchoscopy. Serious associated diseases (HIV infection/AIDS, diabetes mellitus, etc.) were criteria of exception. The condition of bronchial mucosa was studied under narcotic anaesthesia by fiberoptic bronchoscopes of Olympus (Japan). Pathology of a bronchial tree was described according to classification by M. V. Shesterina, A. N. Kalyuk (1975). Results of the research are processed by modern methods of the analysis using the personal computer with the statistical package Statistica (R) for Windows 6.0 license program (StatSoft Inc., No. AXXR712 D833214FAN5). Results. There were respiratory epithelial clearance disturbances in 94.7 %, which predominate with the 1st and 2nd stages of mucociliary inefficiency (51.1 % and 37.6 %). There was mucociliary inefficiency dependence on the bronchi mucous membrane pathology nature: the incidence of respiratory epithelial clearance in patients with concomitant bronchial tuberculosis in combination with the nonspecific purulent endobronchitis is 2.4 times higher than in those with concomitant bronchial tuberculosis only (70.7 % vs 29.3 %). The association of nonspecific purulent endobronchitis with concomitant bronchial tuberculosis leads to an increase in the mucociliary inefficiency degree of severity, due to its diffuse localization, where it is diagnosed more often than in the limited one, thus, mucociliary inefficiency of the 2nd stage of severity (64.9 % vs 24.6 %, is 2.6 times more (64.9 % vs 24.6 %) and 4.6 times more in the 3rd stage (16.2 % vs 3.5 %). Conclusions. The proposed method for the diagnosis of mucociliary inefficiency disorders among patients suffering from CRPTB with bronchial mucosa concomitant pathology allows to diagnose mucociliary inefficiency and mucociliary inefficiency dependence on the bronchi mucous membrane pathology nature.	[Raznatovska, O. M.] Zaporizhzhia State Med Univ, Zaporizhia, Ukraine; [Raznatovska, O. M.; Khlystun, V. M.] Zaporizhzhia State Med Univ, Dept Phthisiol & Pulmonol, Zaporizhia, Ukraine	Raznatovska, OM (reprint author), Zaporizhzhia State Med Univ, Zaporizhia, Ukraine.; Raznatovska, OM (reprint author), Zaporizhzhia State Med Univ, Dept Phthisiol & Pulmonol, Zaporizhia, Ukraine.	raxnatovskaya@gmail.com	Raznatovskaya, Elen E.N./O-1298-2016	Raznatovskaya, Elen E.N./0000-0003-2252-9063			Chuchalin A. G., 1988, PROBLEMY TUBERKULEZA, V8, P13; Kobylyanskij V. I., 2008, MUKOCILYARNAYA SISTE; Mall MA, 2008, J AEROSOL MED PULM D, V21, P13, DOI 10.1089/jamp.2007.0659; Novikov Yu. K, 2007, RUSSKIJ MED ZH, V5, P357; Pertseva T. A., 2005, UKRAINSKYI PULMONOLO, V4, P69; Zakharova G. P., 2010, MUKOCILYARNAYA SISTE; Zavalii M. A., 2014, RYNOLOHIIA, V1, P38	7	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					77	80		10.14739/2310-1237.2018.1.128632			4	Pathology	Pathology	GU7AL	WOS:000445470500013		DOAJ Gold			2019-10-28	
J	Garmash, OV; Gubina-Vakulyk, GI				Garmash, O. V.; Gubina-Vakulyk, G. I.			Morphofunctional status of parotid salivary glands in three-month-old rats with experimentally induced fetal macrosomia	PATHOLOGIA			Russian	Article						fetal macrosomia; animal experiments; glands; parotid salivary glands		The paper aims at studying the features of postnatal morphogenesis of parotid salivary glands acinar tissue in three-month-old rats which were born with experimentally induced fetal macrosomia. The aim of the study is to examine experimentally the features of postnatal morphogenesis of salivary glands in three-month-old rats born with macrosomia. Materials and methods. Somatometric data of the animals were examined at birth and after the experiment, which induced macrosomia of rat fetus with four different ways (high-calorie diet for young pregnant female specimens, high-calorie diet for mature pregnant female specimens, high-calorie diet and hypokinesia condition for young pregnant female specimens, increased placental-fetal blood supply on the background of normal living conditions for young pregnant female specimens). To make the morphological analysis we used the tissues of parotid glands of three-month-old rats. We examined absolute and relative values of salivary gland mass. Beside the histological tests we used Gallocianin-chrome alum technique to detect DNA and RNA, and PAS-reaction to detect glycoproteins. Using computer images we measured the squares of serocytes, evaluated the content of DNA in the cell nucleus, the content of RNA in cytoplasm and glycoproteins in saliva in ducts and gaps of acini. Results. When rats reached the age of three months macrosomia-induced specimens with stimulated intrauterine growth (group Aks) had a tendency to increase their average body weight while macrosomia-induced descendants of rats in the group 3 (high-calorie died and "soft" hypokinesia (group Y+Hk+cal) had a tendency to decrease their body mass. And macrosomia-induced descendants of rats in the group 1 (high-calorie diet during pregnancy, Y+cal group) and decsendants in group 2 (high-calorie diet for mature rats during pregnancy, M+cal group) had somatometric data similar to the control-group. The relative mass of parotid glands of three-month-old rats which were born with macrosomia appeared to be increased in all the groups, but top values were observed in groups Y+cal and Y+Hk+cal. Rats with macrosomia from the group Aks by the age of three month had salivary glands with hypoplasia of serocytes which were morphofunctionally more active and had signs of proteins and glycoproteins hypoproduction. Rats with macrosomia in the Y+cal group by the age of three months had the amount of serocytes commensurate to the data of the control group but serocytes were more morphofunctionally active and had signs of glycoproteins hyperprodution. Rats in the M+cal group at the age of three months had serocytes hyperplasia, but their mophofunctional condition was similar to the control group. And macrosomia-induced rats in the Y+Hk+cal group had signs of the increase of morphofunctional activity of serocytes and hyperproduction of glycoproteins. Conclusion. It has been found that specimens which were born with macrosomia at the age of three months showed changes in morphofunctional state of parotid salivary glands parenchyma and, therefore, changes in the salivary composition in ducts and gaps of acini.	[Garmash, O. V.] Kharkiv Natl Med Univ, Therapeut Dent Dept, Kharkov, Ukraine; [Gubina-Vakulyk, G. I.] Kharkiv Natl Med Univ, Pathol Anat Dept, Kharkov, Ukraine	Garmash, OV (reprint author), Kharkiv Natl Med Univ, Therapeut Dent Dept, Kharkov, Ukraine.	o.v.garmash@gmail.com					Garmash O, 2017, Georgian Med News, P14; Garmash O. V., 2013, SVIT MEDYTSYNY TA BI, V3, P89; Godfrey KM, 2011, SEMIN REPROD MED, V29, P257, DOI 10.1055/s-0031-1275518; Hermann GM, 2010, NEONATOLOGY, V98, P238, DOI 10.1159/000285629; Julihn A., 2014, Dentistry Journal, V2, P118, DOI 10.3390/dj2040118; Khomenko L. O., 2007, P C STOM ZDOR DIT UK, P11; Khuraseva A. B., 2010, MIZHNARODNYI ENDOKRY, V8, P106; Merkulov G. A, 1969, KURS PATOGISTOLOGICH; Pearse AG, 1960, HISTOCHEMISTRY THEOR; Sarkisov D. S, 1996, MIKROSKOPICHESKAYA T; [Сорокина А.В. Sorokina A.V.], 2013, [Российский вестник акушера-гинеколога, Rossiiskii vestnik akushera-ginekologa], V13, P86; Yokomichi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133872	12	1	1	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					81	87		10.14739/2310-1237.2018.1.129324			7	Pathology	Pathology	GU7AL	WOS:000445470500014		DOAJ Gold			2019-10-28	
J	Kuznietsov, AA				Kuznietsov, A. A.			Development of multivariate models for the verification of short-term vital and functional prognosis in patients with hemorrhagic hemispheric stroke in the onset of the disease	PATHOLOGIA			English	Article						cerebral hemorrhage; X-Ray tomography; inflammation; mortality; prognosis	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; TO-LYMPHOCYTE RATIO; MONOCYTE COUNT; CASE-FATALITY; NEUTROPHIL; MORTALITY; LEUKOCYTOSIS; RECRUITMENT	The main purpose of the study was to develop multivariate models for the verification of short-term vital and functional prognosis in patients with hemorrhagic hemispheric stroke in the onset of the disease. Materials and methods. A prospective, cohort, comparative study was conducted in 203 patients with spontaneous supratentorial intracerebral hemorrhage (SSICH) (121 men and 82 women, mean age 65.1 +/- 0.8 years), who were hospitalized within the first 12 hours since the onset of the disease and received conservative therapy. National Institute of Health Stroke Scale (NIHSS) score, Glasgow Coma Scale score, Full Outline of UnResponsiveness Scale score, intracerebral hemorrhage volume, displacement of the septum pellucidum and pineal gland, white blood cell count (WBCC), neutrophil count, lymphocyte count, monocyte count, neutrophil-to-lymphocyte ratio (NLR) were detected upon admission to the hospital. The functional outcome (FO) of the acute period of the disease was assessed on the 21st day in accordance with the modified Rankin Scale (mRS), whereas > 3 points on this scale were considered as an unfavourable FO, <= 3 points were considered as a favourable FO. Binary logistic regression method and ROC-analysis were used for the elaboration of prediction criteria. Results of research. Lethal outcome (12.3 %), unfavourable FO (37.5 %) and favourable FO (51.2 %) were registered in the structure of acute period outcomes of the disease. In accordance with the data of multivariate regression analysis it was determined that admission NIHSS score > 16 (Se = 68.0 %, Sp = 93.3 %), septum pellucidum displacement > 3 mm (Se = 84.0 %, Sp = 74.2 %) and admission WBCC > 8 600 cells/mu L (Se = 84.0 %, Sp = 62.4 %) are independently associated with an increased risk of the lethal outcome of the acute period of SSICH by 12.8 (12.8-26.8) (P < 0.0001), 10.7 (3.8-29.8) (P < 0.0001) and 6.9 (2.4-19.3) (P = 0.0003) times respectively. Admission NIHSS score > 9 (Se = 90.5 %, Sp = 66.3 %), septum pellucidum displacement >= 1 mm (Se = 71.6 %, Sp = 71.2 %) and ANLR > 2.92 (Se = 86.5 %, Sp = 36.5 %) were independently associated with an increased risk of the unfavourable FO of the acute period of SSICH by 4.9 (2.9-8.3) (P < 0.0001), 2.9 (2.6-3.3) (P < 0.0001) and 2.4 (2.1-2.7) (P < 0.0001) times respectively. Conclusions. Multivariate models for lethal outcome prognosis (AUC = 0.94 (0.89-0.97), P < 0.01) and unfavourable functional outcome of SSICH prediction (AUC = 0.88 (0.83-0.93), P < 0.01) were elaborated, which take into consideration the combination of clinical, neuroimaging data and the severity of inflammatory activation in the onset of the disease. Informativeness of elaborated multivariate models, which integrated independent predictors, statistically exceeds informativeness of separate predictors usage in verification of the vital and functional prognosis of SSICH acute period outcome.	[Kuznietsov, A. A.] Zaporizhzh State Med Univ, Dept Nervous Dis, Zaporizhia, Ukraine	Kuznietsov, AA (reprint author), Zaporizhzh State Med Univ, Dept Nervous Dis, Zaporizhia, Ukraine.	titus3.05@gmail.com	Kuznietsov, Anton/AAA-5158-2019	Kuznietsov, Anton/0000-0002-6118-9682			Adeoye O, 2014, J STROKE CEREBROVASC, V23, pE107, DOI 10.1016/j.jstrokecerebrovasdis.2013.09.006; Agnihotri S, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-160; Askenase MH, 2016, SEMIN NEUROL, V36, P288, DOI 10.1055/s-0036-1582132; Behrouz R, 2015, NEUROCRIT CARE, V23, P370, DOI 10.1007/s12028-015-0128-7; Giede-Jeppe A, 2017, CEREBROVASC DIS, V44, P26, DOI 10.1159/000468996; Hammond MD, 2014, STROKE, V45, P2485, DOI 10.1161/STROKEAHA.114.005551; Hammond MD, 2014, J NEUROSCI, V34, P3901, DOI 10.1523/JNEUROSCI.4070-13.2014; Hammond MD, 2012, TRANSL STROKE RES, V3, pS125, DOI 10.1007/s12975-012-0174-9; Keep RF, 2012, LANCET NEUROL, V11, P720, DOI 10.1016/S1474-4422(12)70104-7; Lattanzi S, 2017, ONCOTARGET, V8, P57489, DOI 10.18632/oncotarget.15423; Mattishent K, 2015, J CLIN NEUROL, V11, P339, DOI 10.3988/jcn.2015.11.4.339; Morotti A, 2016, STROKE, V47, P1473, DOI 10.1161/STROKEAHA.116.013176; Mracsko E, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00388; Mracsko E, 2014, STROKE, V45, P2107, DOI 10.1161/STROKEAHA.114.005801; Spina S, 2018, MINERVA ANESTESIOL, V84, P572, DOI 10.23736/S0375-9393.17.12225-X; Sun W, 2012, J CLIN NEUROSCI, V19, P1096, DOI 10.1016/j.jocn.2011.11.020; Tao CY, 2017, BIOMARK MED, V11, P33, DOI 10.2217/bmm-2016-0187; Walsh KB, 2015, STROKE, V46, P2302, DOI 10.1161/STROKEAHA.115.009880; Wang F, 2016, J STROKE CEREBROVASC, V25, P182, DOI 10.1016/j.jstrokecerebrovasdis.2015.09.013; Zhang J, 2017, ONCOTARGET, V8, P77752, DOI 10.18632/oncotarget.20776	20	0	0	0	0	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					88	94		10.14739/2310-1237.2018.1.128488			7	Pathology	Pathology	GU7AL	WOS:000445470500015		DOAJ Gold			2019-10-28	
J	Klimenko, VM; Syvolap, DV				Klimenko, V. M.; Syvolap, D. V.			Predictors of prolongation of the hospital stay in patients with cholecystolithiasis after laparoscopic surgical interventions on the gallbladder	PATHOLOGIA			Russian	Article						cholecystolithiasis; laparoscopic cholecystectomy; laparoscopic cholecystolythomy; prognosis	CHOLECYSTECTOMY; SURGERY	The purpose of the study is to identify predictors associated with prolongation of the period of hospital stay more than 48 hours in patients with cholecystolithiasis after laparoscopic surgery on the gallbladder (laparoscopic cholecystectomy and cholecystolithotomy). Material and methods. The one-center open prospective study involved 136 patients with cholecystolithiasis. The average age of the patients was 48.9 +/- 12.6 years (from 22 to 78 years), 79.41 %-women. Laparoscopic cholecystectomy was performed in 103 patients, of which 53 patients had 4-port laparoscopic cholecystectomy (4PLC) and 50 patients-single-incision laparoscopic cholecystectomy (SILC). Laparoscopic cholecystolithotomy (LCLT) was performed in 33 patients. Groups of patients were comparable by age. The baseline indices of laboratory general-clinical and biochemical blood tests, ultrasound scan of the hepato-biliary system, the duration of surgical intervention and the duration of stay in the hospital were evaluated. Predictors were determined using binary logistic regression. Results. The average duration of laparoscopic cholecystolithotomy was 61.06 +/- 13.27 minutes, which was significantly longer than the duration of laparoscopic four-port cholecystectomy (42.83 +/- 16.97 minutes, P = 0.001) and single-port cholecystectomy (36.60 +/- 14.37 minutes, P = 0.001). The average duration of SILC (36.60 +/- 14.37 minutes) was significantly shorter than the mean duration of 4PLC (42.83 +/- 16.97 minutes), (P = 0.039). The average stay in hospital after surgery (4PLC, SILC and LCLT) did not exceed 4.2 days, and the shortest period of postoperative hospital stay was in patients with the LCLT group, although the difference did not reach the limit of statistical probability. Most of the studied parameters, including anthropometric (body weight, height, body mass index, age, gender), had no probable effect on the duration of staying in hospital after surgery. The excess of fibrinogen in the blood serum from the baseline of over 2.2 g/L in patients with cholecystolithiasis increases the risk of delay in the hospital more than 48 hours after the intervention by 20 times (95 % CI 2.97-136.61; P = 0.002). The decrease of the hemoglobin level < 135 g/L in the preoperative period was associated with an increase of odds ratio of prolonging the stay of patients in the hospital for more than 72 hours by 2.48 times (95 % CI 1.16-5.29), and the absence of an increase in body temperature on the first day after the operation on the gallbladder reduced the odds ratio of stay in the hospital by 66 % (VS = 0.34; 95 % DI 0.1661-0.6885; P = 0.0028). Conclusions. The influence of the type of laparoscopic intervention (SILC, 4PLC, LCLT) on the duration of postoperative stay of patients with cholecystolithiasis has not been established. The predictor of staying in the hospital for more than 48 hours after operation in patients with cholecystolithiasis was the preoperative level of fibrinogen above 2.2 g/l. The level of hemoglobin before the surgery on the gallbladder less than 135 g/l increases the risk of prolonged postoperative stay of patients for more than 72 hours by 2.48 times, and the absence of increased body temperature on the first day after the operation reduces the risk of delay in the hospital for more than three days by 66 %.	[Klimenko, V. M.] Zaporizhzhia State Med Univ, Zaporizhia, Ukraine; [Klimenko, V. M.] Zaporizhzhia State Med Univ, Fac Surg, Zaporizhia, Ukraine; [Syvolap, D. V.] Zaporizhzhia State Med Univ, Dept Fac Surg, Zaporizhia, Ukraine	Syvolap, DV (reprint author), Zaporizhzhia State Med Univ, Dept Fac Surg, Zaporizhia, Ukraine.	syvolap89@gmail.com					Cheng SP, 2008, SURG ENDOSC, V22, P1283, DOI 10.1007/s00464-007-9610-4; Gurusamy K, 2008, BRIT J SURG, V95, P161, DOI 10.1002/bjs.6105; Howard DPJ, 2011, BRIT J SURG, V98, P139; Issa ME, 2005, SURG LAPARO ENDO PER, V15, P90, DOI 10.1097/01.sle.0000160287.93535.a6; Morimoto Y, 2015, ASIAN J ENDOSC SURG, V8, P289, DOI 10.1111/ases.12183; Sato N, 2014, HPB, V16, P177, DOI 10.1111/hpb.12100; Tran TT, 2014, SURGERY, V156, P20, DOI 10.1016/j.surg.2014.03.024; Uchiyama K, 2002, SURG ENDOSC, V16, P1594, DOI 10.1007/s00464-002-9018-0	8	0	0	1	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					95	100		10.14739/2310-1237.2018.1.129440			6	Pathology	Pathology	GU7AL	WOS:000445470500016		DOAJ Gold			2019-10-28	
J	Stepanov, YM; Kosynska, SV; Pavlenko, OV				Stepanov, Yu. M.; Kosynska, S. V.; Pavlenko, O. V.			Management of patients with autoimmune liver diseases on the basis of the latest EASL recommendations and our own experience	PATHOLOGIA			Russian	Article						autoimmune hepatitis; primary biliary cirrhosis; cholangitis; disease attributes; diagnosis; treatment	PRIMARY BILIARY CHOLANGITIS; PRIMARY SCLEROSING CHOLANGITIS; HEPATITIS; DIAGNOSIS; CIRRHOSIS; PROGNOSIS; COHORT	Autoimmune hepatitis (AIH), primary biliary cirrhosis/cholangitis (PBC), primary sclerosing cholangitis (PSC) and autoimmune cholangiopaties are the autoimmune liver diseases. These diseases are rare and remain under-explored, therefore difficult for understanding and conducting even by specialists. Aim. To provide a comprehensively modern view of autoimmune liver diseases and their features. It is important to clearly distinguish AIG, PBH, and PSC between each other. Epidemiological data indicate low prevalence of these diseases, but its growth is noted. Most of the patients are young and middle age, prevalence of the AIH and PBC is higher in women, for PSC-in men. Etiologic factors remain unknown; the role of viral-bacterial, toxic, drugs that change the immune system with forming of autoantibodies is examined. Genetic factors also may play role in pathogenesis of these diseases. Diagnostics of autoimmune liver diseases are based on specific signs. AIH can proceed as acute or chronic hepatitis, cirrhosis or fulminant hepatic-cellular insufficiency, but also can be asymptomatic for a long time. For PBC and PSC, the clinic of cholestasis is characterized by skin itch, jaundice, skin changes. In later stages, a picture of cirrhosis develops. Hepatic tests in patients with AIH are characterized by predominance of cytolysis that can reach high values, and for PBC and PSC-cholestasis with high alkaline phosphatase and GGTP. Diagnostics with specific markers of autoimmune liver diseases are crucial for our country. AIH is characterized by detection of ANA, SMA, anti-LKM, anti-SLA, anti-LP anti-LC1, ASGP-R, and increased level of IgG. A highly specific PBC marker is AMA-M2, while p-ANCA can be determined in PSC. Among the visualizing methods of the hepatobiliary system, MRCP was identified as an accurate method for evaluating the duct system in PSC and liver elastography for evaluating the degree of fibrosis. Treatment of autoimmune liver diseases, according to the latest EASL recommendations, includes immunosuppressive therapy with hormones, azathioprine, other cytostatics, UDCA. Since the data of evidence-based medicine are limited, it is believed that an expert opinion can be crucial for the treatment of such patients. Clinical examples showing the features of management of autoimmune liver diseases are given in this article. Conclusions. Diagnosis and treatment of autoimmune liver diseases are a complex process. In this case, the latest modern recommendations can considerably help, at the same time, the clinical experience of the doctor and the patient's individual data still matter	[Stepanov, Yu. M.] Natl Acad Med Sci Ukraine, Inst Gastroenterol, Dnipro, Ukraine; [Stepanov, Yu. M.; Kosynska, S. V.] Natl Acad Med Sci Ukraine, Inst Gastroenterol, State Inst, Dnipro, Ukraine; [Pavlenko, O. V.] Odesa Natl Med Univ, Dept Infect Dis, Odessa, Ukraine	Stepanov, YM (reprint author), Natl Acad Med Sci Ukraine, Inst Gastroenterol, Dnipro, Ukraine.; Stepanov, YM (reprint author), Natl Acad Med Sci Ukraine, Inst Gastroenterol, State Inst, Dnipro, Ukraine.	stepanovgastro@i.ua; kosinskay@gmail.com					Beuers U, 2015, J HEPATOL, V63, P1285, DOI 10.1016/j.jhep.2015.06.031; Borssen AD, 2017, SCAND J GASTROENTERO, V52, P1022, DOI 10.1080/00365521.2017.1335772; Corrigan M, 2015, DIGEST DIS, V33, P102, DOI 10.1159/000440755; Czaja AJ, 2017, DIGEST DIS SCI, V62, P2277, DOI 10.1007/s10620-017-4675-y; Czaja AJ, 2016, GUT LIVER, V10, P177, DOI 10.5009/gnl15352; De Lemos-Bonotto M, 2018, EUR J GASTROEN HEPAT, V30, P212, DOI 10.1097/MEG.0000000000001019; Eaton JE, 2013, GASTROENTEROLOGY, V145, P521, DOI 10.1053/j.gastro.2013.06.052; Floreani A, 2015, DIGEST LIVER DIS, V47, P432, DOI 10.1016/j.dld.2015.02.002; Gatselis NK, 2015, WORLD J GASTROENTERO, V21, P60, DOI 10.3748/wjg.v21.i1.60; Hirschfield GM, 2017, J HEPATOL, V67, P145, DOI 10.1016/j.jhep.2017.03.022; Jhaveri MA, 2017, THER CLIN RISK MANAG, V13, P1053, DOI 10.2147/TCRM.S113052; Kim BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182391; Lapierre P, 2015, J IMMUNOL RES, DOI 10.1155/2015/479703; Liang HF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007116; Liberal R, 2017, ALIMENT PHARM THER, V45, P723, DOI 10.1111/apt.13907; Licata A, 2014, DIGEST LIVER DIS, V46, P1116, DOI 10.1016/j.dld.2014.08.040; Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030; Manns MP, 2015, J HEPATOL, V62, pS100, DOI 10.1016/j.jhep.2015.03.005; Molleston JP, 2013, J PEDIATR GASTR NUTR, V56, P304, DOI 10.1097/MPG.0b013e3182774cae; Muratori P, 2015, ALIMENT PHARM THER, V41, P1281, DOI 10.1111/apt.13210; Poupon R, 2015, DIGEST DIS, V33, P115, DOI 10.1159/000440758; Singh S, 2013, CLIN GASTROENTEROL H, V11, P898, DOI 10.1016/j.cgh.2013.02.016; Tanaka A, 2018, EXP BIOL MED, V243, P184, DOI 10.1177/1535370217748893; van Buuren HR, 2015, DIGEST DIS, V33, P118, DOI 10.1159/000440759; Vergani D, 2013, SEMIN IMMUNOPATHOL, V35, P73, DOI 10.1007/s00281-012-0328-6; Vierling JM, 2015, CLIN GASTROENTEROL H, V13, P2088, DOI 10.1016/j.cgh.2015.08.012	26	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					101	108		10.14739/2310-1237.2018.1.127703			8	Pathology	Pathology	GU7AL	WOS:000445470500017		DOAJ Gold			2019-10-28	
J	Romaniuk, AM; Gyryavenko, NI; Lyndin, MS; Sikora, VV; Piddubnyi, AM				Romaniuk, A. M.; Gyryavenko, N. I.; Lyndin, M. S.; Sikora, V. V.; Piddubnyi, A. M.			YY The case of synchronous fallopian tube and endometrium cancer. Clinical observation	PATHOLOGIA			English	Article						adenocarcinoma; Fallopian tube; prognosis	CARCINOMA; DIAGNOSIS	Background. The problems of pre-operative cancer diagnosis of the fallopian tube are associated with a rare occurrence of this disease. More rarely, there is a combination of the fallopian tube cancer and other gynecological tumors. Clinical observation of the fallopian tube cancer and endometrial cancer in postmenopausal woman is presented, which demonstrates the difficulty of the pre-operative diagnostics of these pathologies combination. Case presentation. We described a case of uterine tube cancer in Ukrainian woman (77 years), which had been combined with adenocarcinoma of an endometrium. Conclusion. Primary fallopian tubes carcinoma is a rare disease with an insufficiently studied etiology. The clinical manifestations are not always present in full. Diagnosis in pre-operative period is very hard to establish. Only the qualitative morphological investigation allows establishing the primary lesion of the fallopian tube. Introducing immunohistochemical investigations in practice serves as additional methods for correct diseases diagnostic, which allow more fully characterizing the prognosis and suggesting appropriate treatment of the patients.	[Romaniuk, A. M.] Sumy State Univ, Sumy, Ukraine; [Romaniuk, A. M.; Gyryavenko, N. I.; Lyndin, M. S.; Sikora, V. V.; Piddubnyi, A. M.] Sumy State Univ, Pathol Dept, Sumy, Ukraine	Romaniuk, AM (reprint author), Sumy State Univ, Sumy, Ukraine.; Romaniuk, AM (reprint author), Sumy State Univ, Pathol Dept, Sumy, Ukraine.	pathomorph@gmail.com; n.gyryavenko@med.sumdu.edu.ua	Romaniuk, Anatolii/I-3241-2017	Romaniuk, Anatolii/0000-0003-2560-1382			Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Benoit MF, 2006, INT J GYNECOL CANCER, V16, P29, DOI 10.1111/j.1525-1438.2006.00292.x; Colgan TJ, 2003, INT J GYNECOL PATHOL, V22, P109, DOI 10.1097/01.PGP.0000055049.78118.63; Deffieux X, 2005, Gynecol Obstet Fertil, V33, P23, DOI 10.1016/j.gyobfe.2004.11.008; Nordin A J, 1994, Obstet Gynecol Surv, V49, P349, DOI 10.1097/00006254-199405000-00026; Oliveira Carolina, 2013, J Med Case Rep, V7, P252, DOI 10.1186/1752-1947-7-252; Pectasides D, 2009, GYNECOL ONCOL, V115, P97, DOI 10.1016/j.ygyno.2009.06.025; Pectasides D, 2006, ONCOLOGIST, V11, P902, DOI 10.1634/theoncologist.11-8-902; ROSENBLATT KA, 1989, GYNECOL ONCOL, V35, P236, DOI 10.1016/0090-8258(89)90051-6; Tavassoli FA, 2003, PATHOLOGY GENETICS T; Tong SY, 2008, EUR J OBSTET GYN R B, V136, P78, DOI 10.1016/j.ejogrb.2006.09.010; Yuen JHF, 2002, J ULTRAS MED, V21, P1171, DOI 10.7863/jum.2002.21.10.1171	12	0	0	1	2	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					109	113		10.14739/2310-1237.2018.1.129192			5	Pathology	Pathology	GU7AL	WOS:000445470500018		DOAJ Gold			2019-10-28	
J	Lomeiko, OO; Kolesnyk, YM; Avramenko, NV				Lomeiko, O. O.; Kolesnyk, Yu. M.; Avramenko, N. V.			Male infertility in a large industrial city: the role of chemical, physical and emotional factors	PATHOLOGIA			Russian	Review						male infertility; reactive oxygen species; spermogram; hazardous chemical; radiation; life stress	ENDOCRINE-DISRUPTING CHEMICALS; REPRODUCTIVE HEALTH; SPERMATOGENESIS; SPERM; EXPOSURE; FERTILIZATION; FERTILITY; STRESS; SEMEN; RISK	The problem of infertile marriages has worsened recently in the world. Today there are 60.0 to 80.0 million infertile couples, in 40.0% of cases married couples are infertile due to a man's fault. The aim of the work is to analyze specialized scientific literature for generalization of data on modern views on etiology and pathogenesis of male infertility in urbanization. Materials and methods. Available scientific sources over the past five years, devoted to the mechanisms of male infertility in urbanization are studied by the methods of overview, system and content analysis. The data of the world statistics are presented and the data of modern researches devoted to the influence of chemical, physical and emotional factors on the parameters of male infertility are analyzed. It is accentuated on active forms of oxygen and parameters that reflect the morphological and functional state of spermatozoa, as well as the problems of male infertility that need to be addressed. A number of other factors affecting male infertility have been analyzed, in particular: food factors in urbanization, the role of chemical compounds in the anthropogenic environment, the importance of emotional factors and the risk caused by physical factors. Conclusions. It has been confirmed that external conditions have a serious impact on the development of reproductive system disorders in men, although their causes and structure are still unclear, are controversial despite a convincing list of factors that interfere with spermatogenesis. Based on the sources studied, it can be argued that there is no single model of oppression of the male reproductive function that can explain pathogenetic changes in various components of the reproductive apparatus, depending on the direction and strength of the adverse factor. The creation of such a model will make it possible to approach the issue of prevention of reproductive disorders in a context of various external factors. To study the relationship between stress and the development of secondary infertility and subfertility in men, it is necessary to study further the patterns obtained on the basis of clinical-laboratory, statistical and epidemiological studies.	[Lomeiko, O. O.; Avramenko, N. V.] Zaporizhzhia State Med Univ, Dept Obstet Gynecol & Reprod Med FPE, Zaporizhia, Ukraine; [Kolesnyk, Yu. M.] Zaporizhzhia State Med Univ, Dept Pathol Physiol, Zaporizhia, Ukraine	Lomeiko, OO (reprint author), Zaporizhzhia State Med Univ, Dept Obstet Gynecol & Reprod Med FPE, Zaporizhia, Ukraine.	elena.bogomaz1009@gmail.com	Avramenko, Nataliia/AAB-8139-2019	Avramenko, Nataliia/0000-0003-4403-2920			Agarwal A, 2008, HDB CHEMILUMINESCENT, P195; Agarwal A, 2016, THER ADV UROL, V8, P302, DOI 10.1177/1756287216652779; Al-Damegh M. A., 2014, Open Journal of Animal Sciences, V4, P70, DOI 10.4236/ojas.2014.42010; Asadi N, 2017, J CLIN DIAGN RES, V11, DOI 10.7860/JCDR/2017/23927.9886; Avramenko NV, 2013, ZAPOROZHYE MED J, P54; Balise VD, 2016, FERTIL STERIL, V106, P795, DOI 10.1016/j.fertnstert.2016.07.1099; Baranov V. S., 2007, ZH AKUSH ZHEN BOL, V1, P3; Barazani Y, 2014, UROL CLIN N AM, V41, P55, DOI 10.1016/j.ucl.2013.08.017; Belolyubskaya D. S., 2015, VESTNIK SEVERO VOSTO, V1, P48; Carre J, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0291-8; Chistiakova N V, 2011, Genetika, V47, P1013; Den Hond E, 2015, ENVIRON INT, V84, P154, DOI 10.1016/j.envint.2015.07.017; [Дергилев А.А. Dergilev A.A.], 2012, [Радиация и риск (Бюллетень Национального радиационно-эпидемиологического регистра), Radiation and Risk, Radiatsiya i risk (Byulleten' Natsional'nogo radiatsionno-epidemiologicheskogo registra)], V21, P39; Esteves SC, 2014, INT BRAZ J UROL, V40, P443, DOI 10.1590/S1677-5538.IBJU.2014.04.02; Fujii J, 2011, ASIAN J ANDROL, V13, P420, DOI 10.1038/aja.2011.10; Fukunaga H, 2017, INT J RADIAT BIOL, V93, P1291, DOI 10.1080/09553002.2017.1355579; Gandhi J, 2017, ZYGOTE, V25, P103, DOI 10.1017/S0967199417000028; Glybochko P. V., 2011, SECHENOVSKIJ VESTNIK, V3-4, P4; Hlyakina O. V., 2011, VESTNIK TAMBOVSKOGO, V16, P356; Hsu PC, 2016, CHEMOSPHERE, V165, P294, DOI 10.1016/j.chemosphere.2016.09.035; Hyshiktuev B. S., 2010, KLIN LAB DIAGNOSTIKA, V7, P27; Inhorn MC, 2015, HUM REPROD UPDATE, V21, P411, DOI 10.1093/humupd/dmv016; Jenardhanana P, 2016, SEMIN CELL DEV BIOL, V59, P126, DOI 10.1016/j.semcdb.2016.03.024; Juarez-Rojas L, 2017, ACTA HISTOCHEM, V119, P284, DOI 10.1016/j.acthis.2017.02.004; Kolesnikova L I, 2015, Vestn Ross Akad Med Nauk, P579, DOI 10.15690/vramn.v70.i5.1445; Latif T, 2017, AM J EPIDEMIOL, V186, P910, DOI 10.1093/aje/kwx067; Madeen EP, 2017, REV ENVIRON HEALTH, V32, P73, DOI 10.1515/reveh-2016-0045; Majzoub A, 2017, INDIAN J UROL, V33, P207, DOI 10.4103/iju.IJU_15_17; Mamina V. P., 2013, USPEKHI SOVREMENNOGO, V11, P50; Mascarenhas MN, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001356; McCartney PR, 2010, MCN-AM J MATERN-CHIL, V35, P173, DOI 10.1097/NMC.0b013e3181d8036b; Minguez-Alarcon L, 2016, FERTIL STERIL, V106, P864, DOI 10.1016/j.fertnstert.2016.07.1118; Najafi TF, 2015, IRAN RED CRESCENT ME, V17, DOI 10.5812/ircmj.17(4)2015.26930; Nargund VH, 2015, NAT REV UROL, V12, P372, DOI 10.1038/nrurol.2015.112; Nikolaev A. A., 2014, ASTRAKHANSKIJ MED ZH, V9, P23; Noorimotlagh Z, 2017, ENVIRON SCI POLLUT R, V24, P3298, DOI 10.1007/s11356-016-7960-y; Punab M, 2017, HUM REPROD, V32, P18, DOI 10.1093/humrep/dew284; Radchenko O. R., 2012, PRAKTICHESKAYA MED, V2, P218; Sengupta P, 2017, AM J MENS HEALTH, V11, P1279, DOI 10.1177/1557988316643383; Sidorkiewicz I, 2017, TOXICOL IND HEALTH, V33, P601, DOI 10.1177/0748233717695160; Szkodziak P, 2016, ANN AGR ENV MED, V23, P227, DOI 10.5604/12321966.1203881; Tavares RS, 2016, REPRODUCTION, V151, pR1, DOI 10.1530/REP-15-0355; Tiktinskij O. L., 2010, ANDROLOGIYA; Tremellen K, 2008, HUM REPROD UPDATE, V14, P243, DOI 10.1093/humupd/dmn004; Tymchenko O. I., 2014, MEDYCHNI PERSPEKTYVY, V19, P105; Vecoli C, 2016, ENVIRON SCI POLLUT R, V23, P23339, DOI 10.1007/s11356-016-7728-4; Verkuijlen J, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011034.pub2; Wang XF, 2016, SCI TOTAL ENVIRON, V571, P307, DOI 10.1016/j.scitotenv.2016.07.169; Yang P, 2017, INT J HYG ENVIR HEAL, V220, P1340, DOI 10.1016/j.ijheh.2017.09.004; Ying LY, 2016, J ASSIST REPROD GEN, V33, P689, DOI 10.1007/s10815-016-0690-8	50	0	0	0	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					114	121		10.14739/2310-1237.2018.1.129334			8	Pathology	Pathology	GU7AL	WOS:000445470500019		DOAJ Gold			2019-10-28	
J	Voloshyna, IM				Voloshyna, I. M.			Management of table salt consumption in hypertensive patients (review)	PATHOLOGIA			Russian	Review						arterial hypertension; table salt; blood pressure; potassium; sodium	REDUCE SODIUM-INTAKE; DIETARY-SODIUM; INTERVENTIONS; RISK; EXPERIENCE; MORTALITY; HEALTH	Purpose. The review is aimed to light the current evidence data about the effectiveness of dietary interventions on reducing table salt consumption and discussing the appropriateness of dietary recommendations prescribed by physicians to hypertensive patients. Materials and methods. The analysis of the specialized scientific literature over the past 10 years, cited by the systems of Google Scholar, Web of Science, Scopus considering the results of at least 20 randomized international clinical trials with more than 300.000 participants regarding table salt consumption, hypertension risk and cardiovascular outcomes has been done. Results. The average consumption of kitchen salt in Ukraine as well as all worldwide is excessive and associated with high cardiovascular mortality rates. The strategic approaches of dietary intervention management in reduction of table salt consumption Ukraine are outlined. Conclusions. The compliance of hypertensive patients to low-sodium diet is considered as highly effective and cost-effective non-pharmacological antihypertensive treatment but requires doctors and related professionals to provide the detailed explanation of this diet to patients.	[Voloshyna, I. M.] Zaporizhzhia State Med Univ, Dept Family Med Therapy Cardiol & Neurol FPE, Zaporizhia, Ukraine	Voloshyna, IM (reprint author), Zaporizhzhia State Med Univ, Dept Family Med Therapy Cardiol & Neurol FPE, Zaporizhia, Ukraine.	phd.voloshyna@gmail.com					Amer M, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006671; Aronow WS, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.08.06; Campbell NRC, 2016, J CLIN HYPERTENS, V18, P1082, DOI 10.1111/jch.12894; Campbell NRC, 2015, J CLIN HYPERTENS, V17, P247, DOI 10.1111/jch.12442; Chang HY, 2006, AM J CLIN NUTR, V83, P1289; Charlton K. E., 2015, Current Nutrition Reports, V4, P279, DOI 10.1007/s13668-015-0138-2; Choi Hoon Young, 2015, Electrolyte Blood Press, V13, P7, DOI 10.5049/EBP.2015.13.1.7; Choi SE, 2016, MED DECIS MAKING, V36, P72, DOI 10.1177/0272989X15583846; Cogswell ME, 2016, NEW ENGL J MED, V375, P580, DOI 10.1056/NEJMsb1607161; Cook NR, 2007, BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; Graudal NA, 2012, AM J HYPERTENS, V25, P1, DOI 10.1038/ajh.2011.210; Gu DF, 2013, HYPERTENSION, V62, P499, DOI 10.1161/HYPERTENSIONAHA.113.01034; He FJ, 2009, J HUM HYPERTENS, V23, P363, DOI 10.1038/jhh.2008.144; He FJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1325; Imaizumi Y, 2016, J CLIN HYPERTENS, V18, P315, DOI 10.1111/jch.12668; Jackson SL, 2016, AM J PREV MED, V50, P30, DOI 10.1016/j.amepre.2015.04.034; Jousilahti P, 2016, GLOB HEART, V11, P207, DOI 10.1016/j.gheart.2016.04.004; Kim Hyun, 2016, Prev Med Rep, V4, P525; Kornatskyi V. M, 2014, KHVOROBY SYSTEMY KRO; Lashkul Z. V., 2014, SUCHASNI MEDYCHNI TE, V2, P134; Mente A, 2016, LANCET, V388, P465, DOI 10.1016/S0140-6736(16)30467-6; Micha R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175149; Mozaffarian D, 2014, NEW ENGL J MED, V371, P624, DOI 10.1056/NEJMoa1304127; Santos JA, 2017, J CLIN HYPERTENS, V19, P439, DOI 10.1111/jch.12971; Strazzullo P, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4567; Voloshyna I. M., 2016, ARTERIAL NAYA GIPERT, V5, P47, DOI [10.22141/2224-1485.5.49.2016.83864, DOI 10.22141/2224-1485.5.49.2016.83864]; Wang GJ, 2011, J HYPERTENS, V29, P1693, DOI 10.1097/HJH.0b013e328349ba18; WHO: World Health Organization, 2013, GLOB BRIEF HYP SIL K; Zoccali C, 2016, NEPHROL DIAL TRANSPL, V31, P1405, DOI 10.1093/ndt/gfw277	29	0	0	1	1	ZAPORIZHZHYA STATE MEDICAL UNIV	ZAPORIZHZHYA	PR-KT MAYAKOVSKOGO, 26, ZAPORIZHZHYA, 69035, UKRAINE	2306-8027	2310-1237		PATHOLOGIA	Pathologia	JAN-APR	2018		1					122	126		10.14739/2310-1237.2018.1.127715			5	Pathology	Pathology	GU7AL	WOS:000445470500020		DOAJ Gold			2019-10-28	
J	Enomoto, M				Enomoto, Makoto			Dr. Eisei Ishikawa (deceased) In Memoriam	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Biographical-Item																ISHIKAWA E, PUBLICATION LIST	1	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					229	230		10.1293/tox.2018M1			2	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900001		Bronze			2019-10-28	
J	Yokohira, M; Yamakawa, K; Nakano-Narusawa, Y; Hashimoto, N; Kanie, S; Yoshida, S; Imaida, K				Yokohira, Masanao; Yamakawa, Keiko; Nakano-Narusawa, Yuko; Hashimoto, Nozomi; Kanie, Shohei; Yoshida, Shota; Imaida, Katsumi			Characteristics of surfactant proteins in tumorigenic and inflammatory lung lesions in rodents	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						lungs; surfactant protein; napsin A; ambroxol hydrochloride; hyperplasia	F344 MALE RATS; INTRATRACHEAL INSTILLATION; ALVEOLAR MACROPHAGES; FINE PARTICLES; BRONCHIOLOALVEOLAR HYPERPLASIA; PULMONARY ADENOCARCINOMA; NAPSIN-A; EXPRESSION; BIOASSAY; TOXICITY	Surfactant proteins (SPs) are essential for the proper structure and respiratory function of the lungs. There are four subtypes of SPs: SP-A, SP-B, SP-C, and SP-D. The expectorant drug ambroxol hydrochloride is clinically used to stimulate pulmonary surfactant and airway serous secretion. In addition, previous studies showed that ambroxol regulated SP production and attenuated pulmonary inflammation, with ambroxol hydrochloride being found to suppress quartz-induced lung inflammation via stimulation of pulmonary surfactant and airway serous secretion. In this study, we investigated the expression of SP-A, SP-B, SP-C, and SP-D in neoplastic and inflammatory lung lesions in rodents, as well as their possible application as potential markers for diagnostic purposes. SP-B and SP-C showed strong expression in lung hyperplasia and adenoma, whereas SP-A and SP-D were expressed in the mucus or exudates of inflammatory alveoli. Rodent tumorigenic hyperplasic tissues induced by various carcinogens were positive for napsin A, an aspartic proteinase involved in the maturation of SP-B; this indicated a focal increase in type II pneumocytes in the lungs. Therefore, high expression of napsin A in the alveolar walls may serve as a useful marker for prediction of the tumorigenic potential of lung hyperplasia in rodents.	[Yokohira, Masanao; Yamakawa, Keiko; Nakano-Narusawa, Yuko; Hashimoto, Nozomi; Kanie, Shohei; Yoshida, Shota; Imaida, Katsumi] Kagawa Univ, Oncopathol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan	Yokohira, M; Imaida, K (reprint author), Kagawa Univ, Oncopathol, Fac Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	yokohira@med.kagawa-u.ac.jp; imaida@med.kagawa-u.ac.jp			Ministry of Health, Labour and Welfare (MHLW) of JapanMinistry of Health, Labour and Welfare, Japan	Not applicable. This work was supported in part by Grants-in-Aid for Chemical Risk Research from the Ministry of Health, Labour and Welfare (MHLW) of Japan.	Al-Gahtany Mubarak, 2003, Hormones (Athens), V2, P149; Archer F, 2007, AM J RESP CELL MOL, V36, P534, DOI 10.1165/rcmb.2006-0285OC; BENSON SC, 1986, ENVIRON RES, V41, P61, DOI 10.1016/S0013-9351(86)80168-2; Bishop JA, 2010, HUM PATHOL, V41, P20, DOI 10.1016/j.humpath.2009.06.014; Casals C, 2012, BBA-BIOMEMBRANES, V1818, P2550, DOI 10.1016/j.bbamem.2012.05.024; Gao XW, 2011, ARCH MED SCI, V7, P405, DOI 10.5114/aoms.2011.23403; Gary AB, 1990, PATHOLOGY FISCHER RA, P350; Guttentag S, 2003, AM J RESP CELL MOL, V28, P69, DOI 10.1165/rcmb.2002-0111OC; Hasegawa Y, 2017, J BIOL CHEM, V292, P18565, DOI 10.1074/jbc.M117.800771; Houtmeyers E, 1999, EUR RESPIR J, V14, P452, DOI 10.1034/j.1399-3003.1999.14b35.x; Jakel A, 2013, FRONT BIOSCI-LANDMRK, V18, P1129, DOI 10.2741/4168; Jang YY, 2003, PHARMACOL TOXICOL, V92, P173, DOI 10.1034/j.1600-0773.2003.920407.x; Kadivar M, 2013, APPL IMMUNOHISTO M M, V21, P191, DOI 10.1097/PAI.0b013e3182612643; Kanie S, 2017, J TOXICOL PATHOL, V30, P153, DOI 10.1293/tox.2016-0050; Kassie F, 2007, CANCER RES, V67, P6502, DOI 10.1158/0008-5472.CAN-06-4438; Khoor A, 1999, HUM PATHOL, V30, P695, DOI 10.1016/S0046-8177(99)90096-5; Kumar V, 2004, PATHOLOGIC BASIS DIS, P6; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; LINDEN M, 1993, AM REV RESPIR DIS, V148, P1226, DOI 10.1164/ajrccm/148.5.1226; Masai K, 2013, APPL IMMUNOHISTO M M, V21, P292, DOI 10.1097/PAI.0b013e31826fd4f3; Miles PR, 1999, AM J PHYSIOL-LUNG C, V276, pL186; Minutti CM, 2016, J IMMUNOL, V197, P590, DOI 10.4049/jimmunol.1501032; Mitsuhashi A, 2013, AM J PATHOL, V182, P1843, DOI 10.1016/j.ajpath.2013.01.030; Moliva JI, 2014, AGE, V36, P1187, DOI 10.1007/s11357-014-9633-4; Nagahama F, 1981, YAKURI TO CHIRYO, V9, P2091; Nagaoka S, 1981, YAKURI TO CHIRYO, V9, P1845; Olmeda B, 2014, J PROTEOMICS, V101, P179, DOI 10.1016/j.jprot.2014.02.019; OREILLY MA, 1989, AM J PHYSIOL, V257, pL385; Perak RB, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-165; Perez-Gil J, 1998, BBA-MOL BASIS DIS, V1408, P203, DOI 10.1016/S0925-4439(98)00068-4; Perez-Gil J, 2010, PHYSIOLOGY, V25, P132, DOI 10.1152/physiol.00006.2010; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341, DOI 10.1164/ajrccm.156.2.9611013; Sin DD, 2013, J CLIN ONCOL, V31, P4536, DOI 10.1200/JCO.2013.50.6105; Stoll LM, 2010, CANCER CYTOPATHOL, V118, P441, DOI 10.1002/cncy.20108; Tjoe-Nij E, 2003, AM J IND MED, V43, P574, DOI 10.1002/ajim.10229; Tokieda K, 1999, PEDIATR RES, V46, P708, DOI 10.1203/00006450-199912000-00012; Um SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083881; van Berlo D, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-13; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; Whitsett JA, 2002, NEW ENGL J MED, V347, P2141, DOI 10.1056/NEJMra022387; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; Xu JG, 2014, ARCH TOXICOL, V88, P65, DOI 10.1007/s00204-013-1086-5; Yokohira M, 2005, J TOXICOL PATHOL, V18, P13; Yokohira M, 2007, EXP TOXICOL PATHOL, V58, P211, DOI 10.1016/j.etp.2006.10.001; Yokohira M, 2017, EXP TOXICOL PATHOL, V69, P637, DOI 10.1016/j.etp.2017.06.001; Yokohira M, 2014, J TOXICOL PATHOL, V27, P175, DOI [10.1293/tox.27.2014-0020, 10.1293/tox.2014-0020]; Yokohira M, 2014, EXP TOXICOL PATHOL, V66, P117, DOI 10.1016/j.etp.2013.11.002; Yokohira M, 2009, J TOXICOL PATHOL, V22, P1, DOI 10.1293/tox.22.1; Yokohira M, 2009, J TOXICOL PATHOL, V22, P71, DOI 10.1293/tox.22.71; Yokohira M, 2008, TOXICOL PATHOL, V36, P620, DOI 10.1177/0192623308318214; Zhi QM, 2011, INTERNAL MED, V50, P1879, DOI 10.2169/internalmedicine.50.5407	51	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					231	240		10.1293/tox.2018-0025			10	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900002	30393427	Bronze, Green Published			2019-10-28	
J	Aniya, Y				Aniya, Yoko			Development of bioresources in Okinawa: understanding the multiple targeted actions of antioxidant phytochemicals	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Review						antioxidant; phytochemicals; multitargeted action; stress adaptive response; xenohormesis	NF-KAPPA-B; ACTIVATED PROTEIN-KINASE; MALE F344 RATS; OXIDATIVE STRESS; HEPATOPROTECTIVE ACTIONS; MEDICINAL HERB; NUTRITIONAL ANTIOXIDANTS; TRANSCRIPTION FACTORS; TERMINALIA-CATAPPA; SIGNALING PATHWAYS	In research to develop healthy foods or preventive medicines from edible and medicinal herbs in Okinawa, we focused on the antioxidant activities of those bioresources. We first confirmed that the herbal antioxidant activities of such herbs increased upon ultraviolet irradiation treatment. This observation explains the high antioxidant activity of Okinawan vegetables, which grow under exposure to stronger ultraviolet light compared with those in other prefectures in Japan. Antidiabetic, hepatoprotective, cancer preventive, and cardioprotective actions were clarified using herbal extracts, and quercetin, chlorogenic acid, and gallic acid derivatives were isolated as antioxidant components from the herbs. Dimerumic acid was also isolated from the mold Monascus anka. All these antioxidants showed strong radical scavenging activities in vitro and beneficial effects in animal models. However, the concentrations of these compounds used in vivo seemed to be too low to have a physiologically important antioxidant effect based on their radical scavenging activities in vitro. Therefore, I performed a literature survey of antioxidant activities in vivo. Accumulating evidence has emerged that antioxidant phytochemicals show not only radical scavenging activities in vitro but also pleiotropic actions in vivo. The multitargeted, beneficial effects of antioxidant phytochemicals can be rationally explained using the xenohormesis concept, in which phytochemicals are the products of plant evolutionary adaptation to stress in plants, and their ability to induce a stress-adaptive response has been evolutionarily conserved in animals.	[Aniya, Yoko] Univ Ryukyus, Senbaru 1, Nishihara, Okinawa 9030213, Japan	Aniya, Y (reprint author), Univ Ryukyus, Senbaru 1, Nishihara, Okinawa 9030213, Japan.	aniyayoko@at.au-hikari.ne.jp					Aniya Y, 2000, FREE RADICAL BIO MED, V28, P999, DOI 10.1016/S0891-5849(00)00188-X; Aniya Y, 2005, BIOL PHARM BULL, V28, P19, DOI 10.1248/bpb.28.19; Aniya Y, 2000, BIOL PHARM BULL, V23, P309; Baby B, 2016, DRUG DES DEV THER, V10, P3109, DOI 10.2147/DDDT.S118423; Baell JB, 2016, J NAT PROD, V79, P616, DOI 10.1021/acs.jnatprod.5b00947; Banerjee B, 2016, FRONT PHARMACOL, V7, DOI [10.3389/fphar.2016.002415, 10.3389/fphar.2016.00245]; Barrajon-Catalan E, 2014, ADV EXP MED BIOL, V824, P141, DOI 10.1007/978-3-319-07320-0_11; Beyfuss K, 2018, REDOX REP, V23, P100, DOI 10.1080/13510002.2017.1416773; Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613; Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93; Calabrese V, 2012, BBA-MOL BASIS DIS, V1822, P753, DOI 10.1016/j.bbadis.2011.11.002; Chung SW, 2010, ARCH BIOCHEM BIOPHYS, V501, P79, DOI 10.1016/j.abb.2010.05.003; Dahlin JL, 2015, J MED CHEM, V58, P2091, DOI 10.1021/jm5019093; Devi NS, 2017, BIOCHEM BIOPH RES CO, V484, P467, DOI 10.1016/j.bbrc.2017.01.046; Forman HJ, 2014, FREE RADICAL BIO MED, V66, P24, DOI 10.1016/j.freeradbiomed.2013.05.045; Gameiro I, 2017, SCI REP-UK, V7, DOI 10.1038/srep45701; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Goszcz K, 2017, BRIT J PHARMACOL, V174, P1209, DOI 10.1111/bph.13708; Halliwell B, FREE RADICALS BIOL M; Han DD, 2017, ONCOTARGET, V8, P14680, DOI 10.18632/oncotarget.14747; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hooper PL, 2010, CELL STRESS CHAPERON, V15, P761, DOI 10.1007/s12192-010-0206-x; Howitz KT, 2008, CELL, V133, P387, DOI 10.1016/j.cell.2008.04.019; Ingolfsson HI, 2014, ACS CHEM BIOL, V9, P1788, DOI 10.1021/cb500086e; Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861; Kalyanaraman B, 2013, REDOX BIOL, V1, P244, DOI 10.1016/j.redox.2013.01.014; Kang KA, 2010, INT J MOL SCI, V11, P4348, DOI 10.3390/ijms11114348; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Katsuoka F, 2005, MOL CELL BIOL, V25, P8044, DOI 10.1128/MCB.25.18.8044-8051.2005; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kerimi A, 2017, ANTIOXID REDOX SIGNA; Kim JE, 2010, CELL SIGNAL, V22, P1645, DOI 10.1016/j.cellsig.2010.06.004; Kinoshita S, 2007, PHYTOMEDICINE, V14, P755, DOI 10.1016/j.phymed.2006.12.012; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee J, 2014, PHARMACOL REV, V66, P815, DOI 10.1124/pr.113.007757; Leonov A, 2015, MOLECULES, V20, P6544, DOI 10.3390/molecules20046544; Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011; Lv HM, 2017, REDOX BIOL, V12, P311, DOI 10.1016/j.redox.2017.03.001; Mansuri ML, 2014, GENES NUTR, V9, DOI 10.1007/s12263-014-0400-z; Mattison JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14063; Mattson MP, 2008, AGEING RES REV, V7, P1, DOI 10.1016/j.arr.2007.08.007; Matzinger M, 2017, BIOTECHNOL ADV; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Mo CF, 2014, ANTIOXID REDOX SIGN, V20, P574, DOI 10.1089/ars.2012.5116; Morioka T, 2005, EUR J CANCER PREV, V14, P101, DOI 10.1097/00008469-200504000-00005; Morioka T, 2004, CANCER LETT, V205, P133, DOI 10.1016/j.canlet.2003.10.002; Nelson KM, 2017, J MED CHEM, V60, P1620, DOI 10.1021/acs.jmedchem.6b00975; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan H, 2017, J BIOL CHEM, V292, P6452, DOI 10.1074/jbc.R116.771915; Pan MH, 2000, BIOCHEM PHARMACOL, V60, P1665, DOI 10.1016/S0006-2952(00)00489-5; Park SE, 2011, BRIT J PHARMACOL, V164, P1008, DOI 10.1111/j.1476-5381.2011.01389.x; Pazoki-Toroudi H, 2016, AGEING RES REV, V31, P55, DOI 10.1016/j.arr.2016.07.004; Rojo AI, 2012, FREE RADICAL BIO MED, V52, P473, DOI 10.1016/j.freeradbiomed.2011.11.003; Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005; Schroeter H, 2007, J NEUROCHEM, V101, P1596, DOI 10.1111/j.1471-4159.2006.04434.x; Seo EJ, 2018, PHARMACOL RES, V129, P262, DOI 10.1016/j.phrs.2017.11.030; Si HW, 2014, J NUTR BIOCHEM, V25, P581, DOI 10.1016/j.jnutbio.2014.02.001; Sies H, 2015, REDOX BIOL, V4, P180, DOI 10.1016/j.redox.2015.01.002; Sinclair DA, 2014, ANNU REV PHARMACOL, V54, P363, DOI 10.1146/annurev-pharmtox-010611-134657; Speciale A, 2011, CURR MOL MED, V11, P770, DOI 10.2174/156652411798062395; Stefanson AL, 2014, NUTRIENTS, V6, P3777, DOI 10.3390/nu6093777; Surh YJ, 2005, J NUTR, V135, p2993S, DOI 10.1093/jn/135.12.2993S; Surh YJ, 2008, PLANTA MED, V74, P1526, DOI 10.1055/s-0028-1088302; Suvarna V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00916; Taira J, 2002, BIOCHEM PHARMACOL, V63, P1019, DOI 10.1016/S0006-2952(01)00923-6; Tanigawa S, 2007, FREE RADICAL BIO MED, V42, P1690, DOI 10.1016/j.freeradbiomed.2007.02.017; Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Williamson G, 2017, BIOCHEM PHARMACOL, V139, P24, DOI 10.1016/j.bcp.2017.03.012; Wrighton KH, 2011, NAT REV MOL CELL BIO, V12, P206, DOI 10.1038/nrm3081; Yagasaki K, 2014, NUTR AGING, V2, P35; Yamashiro S, 2003, PHARMACOLOGY, V67, P128, DOI 10.1159/000067799; Zhang YJ, 2015, MOLECULES, V20, P21138, DOI 10.3390/molecules201219753; Zhu MZ, 2010, CELL MOL IMMUNOL, V7, P89, DOI 10.1038/cmi.2009.112; Zimmermann K, 2015, FREE RADICAL BIO MED, V88, P417, DOI 10.1016/j.freeradbiomed.2015.03.030	76	0	0	1	2	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					241	253		10.1293/tox.2018-0041			13	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900003	30393428	Green Published, Bronze			2019-10-28	
J	Yoshida, S; Yokohira, M; Yamakawa, K; Nakano-Narusawa, Y; Kanie, S; Hashimoto, N; Imaida, K				Yoshida, Shota; Yokohira, Masanao; Yamakawa, Keiko; Nakano-Narusawa, Yuko; Kanie, Shohei; Hashimoto, Nozomi; Imaida, Katsumi			Effects of the expectorant drug ambroxol hydrochloride on chemically induced lung inflammatory and neoplastic lesions in rodents	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						ambroxol hydrochloride; lung carcinogenesis; lung inflammation; DHPN; NNK; TISMO	POTASSIUM OCTATITANATE FIBERS; MESOTHELIAL CELL REACTIONS; FEMALE A/J MICE; F344 RATS; SURFACTANT PROTEINS; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE NNK; INTRATRACHEAL INSTILLATION; FINE PARTICLES; MOUSE LUNG; TOXICITY	Ambroxol hydrochloride (AH) is an expectorant drug used to stimulate pulmonary surfactant and serous airway secretion. Surfactant proteins (SPs) are essential for maintaining respiratory structure and function, although SP expression has also been reported in lung inflammatory and proliferative lesions. To determine whether AH exerts modulatory effects on these lung lesions, we examined its effects on pleural thickening induced by intrathoracic administration of dipotassium titanate (TISMO) in A/JJmsSlc (A/J) mice. We also analyzed the modulatory effects of AH on neoplastic lung lesions induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in A/J mice and by N-nitrosobis (2-hydroxypropyl) amine (DHPN) in F344/DuCrlCrj (F344) rats. A/J mice treated with TISMO showed decreased body weight, increased white blood cell (WBC) counts, and pleural thickening caused by pleuritis and poor general condition. However, A/J mice treated with TISMO + 120 ppm showed significant recovery of body weight and WBC counts to the same levels as those of A/J mice not treated with TISMO, although no significant differences were observed in histopathological changes including the immunohistopathological expression of IL-1 beta in the lung and maximum pleural thickness regardless of AH treatment. In the NNK and DHPN experiments, no significant differences in body weight, hematology, plasma biochemistry, and histopathological changes were associated with AH concentration. These results suggest that AH potentially exerts anti-inflammatory effects but does not have a direct suppressive effect on lung tumorigenesis in rodents.	[Yoshida, Shota; Yokohira, Masanao; Yamakawa, Keiko; Nakano-Narusawa, Yuko; Hashimoto, Nozomi; Imaida, Katsumi] Kagawa Univ, Fac Med, Dept Pathol & Host Def, Oncopathol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan; [Yoshida, Shota; Kanie, Shohei] TAIHO Pharmaceut Co Ltd, Discovery & Preclin Res Div, Toxicol Lab, 224-2 Ebisuno, Kawaguchi, Tokushima 7710194, Japan	Imaida, K (reprint author), Kagawa Univ, Fac Med, Dept Pathol & Host Def, Oncopathol, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan.	imaida@med.kagawa-u.ac.jp			Taiho Pharmaceutical Co., Ltd.	iKatsumi Imaida has received research funding from Taiho Pharmaceutical Co., Ltd.	Akopyan G, 2006, INT J ONCOL, V29, P745; BELINSKY SA, 1992, CANCER RES, V52, P3164; Chen RJ, 2011, J ONCOL, DOI 10.1155/2011/654931; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Fukuyama Y, 1997, BRIT J CANCER, V75, P1125, DOI 10.1038/bjc.1997.194; Furusu A, 1997, J AM SOC NEPHROL, V8, P730; Gao XW, 2011, ARCH MED SCI, V7, P405, DOI 10.5114/aoms.2011.23403; Hosoe H, 1998, J PHARMACOL TOXICOL, V40, P165, DOI 10.1016/S1056-8719(98)00053-7; Houtmeyers E, 1999, EUR RESPIR J, V14, P452, DOI 10.1034/j.1399-3003.1999.14b35.x; Igarashi M, 2009, J TOXICOL SCI, V34, P163, DOI 10.2131/jts.34.163; Jang YY, 2003, PHARMACOL TOXICOL, V92, P173, DOI 10.1034/j.1600-0773.2003.920407.x; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; Kanie S, 2017, J TOXICOL PATHOL, V30, P153, DOI 10.1293/tox.2016-0050; Kitahashi T, 2008, CANCER SCI, V99, P241, DOI 10.1111/j.1349-7006.2008.00680.x; Nagahama F, 1981, YAKURI TO CHIRYO, V9, P2091; Perez-Gil J, 1998, BBA-MOL BASIS DIS, V1408, P203, DOI 10.1016/S0925-4439(98)00068-4; PETERSON LA, 1991, CANCER RES, V51, P5557; Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111; Ren YC, 2009, J PHARM SCI-US, V98, P1797, DOI 10.1002/jps.21529; Renne R, 2009, TOXICOL PATHOL, V37, p5S, DOI 10.1177/0192623309353423; RONAI ZA, 1993, CARCINOGENESIS, V14, P2419, DOI 10.1093/carcin/14.11.2419; Seifart C, 2005, TOXICOL APPL PHARM, V203, P27, DOI 10.1016/j.taap.2004.07.015; Toyokuni S, 2009, JPN J LUNG CANC, V49, P362; Tsutsumi H., 2002, WATANABE NAKANES IMM, P335; Yamakawa K, 2010, MOL MED REP, V3, P141, DOI 10.3892/mmr_00000231; Yokohira M, 2008, EXP TOXICOL PATHOL, V60, P469, DOI 10.1016/j.etp.2008.05.007; Yokohira M, 2007, EXP TOXICOL PATHOL, V58, P211, DOI 10.1016/j.etp.2006.10.001; Yokohira M, 2016, CANCER SCI, V107, P1047, DOI 10.1111/cas.12944; Yokohira M, 2015, INT J TOXICOL, V34, P325, DOI 10.1177/1091581815587744; Yokohira M, 2014, J TOXICOL PATHOL, V27, P175, DOI [10.1293/tox.27.2014-0020, 10.1293/tox.2014-0020]; Yokohira M, 2010, ONCOL LETT, V1, P589, DOI 10.3892/ol_00000104; Yokohira M, 2009, J TOXICOL PATHOL, V22, P1, DOI 10.1293/tox.22.1; Zhi QM, 2011, INTERNAL MED, V50, P1879, DOI 10.2169/internalmedicine.50.5407	33	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					255	265		10.1293/tox.2018-0012			11	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900004	30393429	Bronze, Green Published			2019-10-28	
J	Tsuchiya, Y; Sakai, H; Hirata, A; Yanai, T				Tsuchiya, Yuya; Sakai, Hiroki; Hirata, Akihiro; Yanai, Tokuma			Effects of food restriction on the expression of genes related to acetaminophen-induced liver toxicity in rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						acetaminophen; hepatotoxicity; food restriction; cytochrome P450 2E1; glutathione	CALORIC RESTRICTION; DIETARY RESTRICTION; CARBON-TETRACHLORIDE; OXIDATIVE STRESS; FISCHER-344 RATS; NATURAL-PRODUCTS; HEPATOTOXICITY; GLUTATHIONE; METABOLISM; INJURY	It is well known that fasting substantially affects the metabolism of drugs and chemicals. Food restriction also affects drug kinetics, such as absorption, metabolism, and excretion, and therefore, it can potentially modulate the onset of chemical toxicity or drug-induced adverse reactions. In the present study, the expression of drug-metabolizing enzyme genes and total glutathione content in the liver, which are related to toxicity induced by overdose of the hepatotoxic drug acetaminophen (N-acetyl-p-aminophenol; APAP), were examined in rats reared under different feeding conditions: ad libitum feeding, 16-h fasting, and food restriction (fed 70% of the average intake of ad libitum feeding for 10 days) conditions. The rats under food restriction conditions as well as fasted rats showed significantly higher expression of Cyp2e1, the gene encoding the enzyme that metabolizes APAP to its toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI). They also had lower levels of liver total glutathione, which detoxifies NAPQI. In contrast, the gene expression of UDP-glucuronosyltransferase 1A6 (Ugt1a6), sulfotransferase 1A1 (Sultlal), and glutathione S-transferase M1 (Gstml) was not affected by food restriction or fasting. When APAP was administered (800 mg/kg), histopathological changes were not observed in rats fed ad libitum, while hepatocellular necrosis was observed in most of the rats treated with APAP after fasting or food restriction. Taken together, these results suggest that not only fasting but also food restriction exacerbate APAP-induced acute liver injury, probably by the induction of CYP2E1 and the reduction of liver glutathione contents, in rodents.	[Tsuchiya, Yuya] API Co Ltd, Nagaragawa Res Ctr, 692-3 Nagara, Gifu, Gifu 5020071, Japan; [Tsuchiya, Yuya; Sakai, Hiroki; Yanai, Tokuma] Gifu Univ, Dept Vet Med, Lab Vet Pathol, 1-1 Yanagido, Gifu, Gifu 5011193, Japan; [Hirata, Akihiro] Gifu Univ, Life Sci Res Ctr, Div Anim Expt, 1-1 Yanagido, Gifu, Gifu 5011193, Japan	Yanai, T (reprint author), Gifu Univ, Dept Vet Med, Lab Vet Pathol, 1-1 Yanagido, Gifu, Gifu 5011193, Japan.	yanai@gifu-u.ac.jp					ALBERT KS, 1974, J PHARMACOKINET BIOP, V2, P381, DOI 10.1007/BF01071309; ALBRECHT R, 1992, TOXICOL LETT, V63, P91, DOI 10.1016/0378-4274(92)90111-V; Bantel H, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00079; BELANGER PM, 1991, DRUG METAB DISPOS, V19, P241; Brown BL, 1995, TOXICOL LETT, V81, P39, DOI 10.1016/0378-4274(95)03407-2; Bruckner JV, 2002, J PHARMACOL EXP THER, V300, P273, DOI 10.1124/jpet.300.1.273; CHOU MW, 1993, MECH AGEING DEV, V70, P23, DOI 10.1016/0047-6374(93)90056-W; CLEMENTS JA, 1984, BRIT J CLIN PHARMACO, V18, P481, DOI 10.1111/j.1365-2125.1984.tb02495.x; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; CUMMINGS AJ, 1967, BRIT J PHARM CHEMOTH, V29, P150, DOI 10.1111/j.1476-5381.1967.tb01948.x; DAHLIN DC, 1984, P NATL ACAD SCI-BIOL, V81, P1327, DOI 10.1073/pnas.81.5.1327; Fok WC, 2013, J GERONTOL A-BIOL, V68, P108, DOI 10.1093/gerona/gls127; Gonzalez FJ, 2007, DRUG METAB DISPOS, V35, P1, DOI 10.1124/dmd.106.012492; Gonzalez-Jasso E, 2003, TOXICOL LETT, V144, P55, DOI 10.1016/S0378-4274(02)00337-5; Harris RZ, 2003, CLIN PHARMACOKINET, V42, P1071, DOI 10.2165/00003088-200342130-00001; HIGASHI T, 1977, J BIOCHEM-TOKYO, V82, P117, DOI 10.1093/oxfordjournals.jbchem.a131659; Hodgman MJ, 2012, CRIT CARE CLIN, V28, P499, DOI 10.1016/j.ccc.2012.07.006; Jaeschke H, 2006, TOXICOL SCI, V89, P31, DOI 10.1093/toxsci/kfi336; Jaeschke H, 2013, FOOD CHEM TOXICOL, V55, P279, DOI 10.1016/j.fct.2012.12.063; Jaeschke H, 2011, LIFE SCI, V88, P737, DOI 10.1016/j.lfs.2011.01.025; Kondo K, 2012, J TOXICOL SCI, V37, P911, DOI 10.2131/jts.37.911; Lee IH, 2008, P NATL ACAD SCI USA, V105, P3374, DOI 10.1073/pnas.0712145105; Lee WM, 2008, HEPATOLOGY, V47, P1401, DOI 10.1002/hep.22177; Lopez-Lluch G, 2016, J PHYSIOL-LONDON, V594, P2043, DOI 10.1113/JP270543; Mahoney LB, 2006, LIPIDS HEALTH DIS, V5, DOI 10.1186/1476-511X-5-13; MILLER KW, 1984, ARCH BIOCHEM BIOPHYS, V229, P483, DOI 10.1016/0003-9861(84)90179-6; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Mladenovic D, 2013, ENVIRON TOXICOL PHAR, V36, P296, DOI 10.1016/j.etap.2013.04.002; Mohammadi M, 2014, SCI WORLD J, DOI 10.1155/2014/821524; Ning YC, 2013, MECH AGEING DEV, V134, P570, DOI 10.1016/j.mad.2013.11.006; PESSAYRE D, 1979, GASTROENTEROLOGY, V77, P264; Qin LQ, 2007, TOHOKU J EXP MED, V212, P379, DOI 10.1620/tjem.212.379; Renaud HJ, 2016, DRUG METAB DISPOS, V44, P366, DOI 10.1124/dmd.115.064766; Rui LY, 2014, COMPR PHYSIOL, V4, P177, DOI 10.1002/cphy.c130024; Rumack BH, 2004, HEPATOLOGY, V40, P10, DOI 10.1002/hep.20300; Sabate M, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-80; Salminen A, 2008, BIOESSAYS, V30, P939, DOI 10.1002/bies.20799; SENDELBACH LE, 1990, TOXICOL APPL PHARM, V102, P259, DOI 10.1016/0041-008X(90)90025-P; Speakman JR, 2011, MOL ASPECTS MED, V32, P159, DOI 10.1016/j.mam.2011.07.001; Stankovic M, 2013, GEN PHYSIOL BIOPHYS, V32, P277, DOI 10.4149/gpb_2013027; Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405; STRUBELT O, 1981, TOXICOL APPL PHARM, V60, P66, DOI 10.1016/0041-008X(81)90136-8; TATEISHI N, 1977, J NUTR, V107, P51; WHITCOMB DC, 1994, JAMA-J AM MED ASSOC, V272, P1845, DOI 10.1001/jama.272.23.1845; XIA EN, 1995, J NUTR, V125, P195	45	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					267	274		10.1293/tox.2018-0009			8	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900005	30393430	Bronze, Green Published			2019-10-28	
J	Saito, T; Toriniwa, Y; Ishii, Y; Uemura, A; Miyajima, K; Uno, K; Shirai, Y; Nakae, D; Ohta, T				Saito, Tomoyuki; Toriniwa, Yasufumi; Ishii, Yukihito; Uemura, Atsuhiro; Miyajima, Katsuhiro; Uno, Kinuko; Shirai, Yuki; Nakae, Dai; Ohta, Takeshi			Hepatic lesions induced by feeding Western diets to Zucker fatty rats, an insulin-resistant model	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						hepatic lesion; insulin resistance; nonalcoholic steatohepatitis; Western diet; Zucker fatty rat	LIVER-DISEASE; NONALCOHOLIC STEATOHEPATITIS; ACCUMULATION; STEATOSIS; OBESITY; MICE; TRIGLYCERIDE; PATHOGENESIS; CHOLESTEROL; EXPRESSION	Metabolic diseases including nonalcoholic steatohepatitis develop due to various environmental factors. In particular, the westernization of food is closely related to the development of these diseases. In this study, we investigated pathophysiological changes in the livers of Zucker fatty (ZF) rats induced by feeding Western diets. Male ZF rats were fed a sucrose/fat/cholesterol-enriched diet (Western diet, WD) or standard diet (SD) for 18 weeks, from 7 to 25 weeks of age. Body weight, food intake, and biochemical parameters were periodically measured, histopathological analyses were performed at 25 weeks, and mRNA expression in the liver was determined. ZF rats fed the WD (ZF-WD rats) developed obesity, hyperinsulinemia, hyperglycemia, and hyperlipidemia, and their alanine aminotransferase and aspartate aminotransferase levels increased compared with those of ZF rats fed the SD (ZF-SD rats). Hepatic lesions including fibrosis and necrosis were observed in the ZF-WD rats at 25 weeks; however, fibrosis and necrosis were not observed in the ZF-SD rats. Oxidative stress markers also increased in the livers of ZF-WD rats. Hepatic mRNA expression related to inflammation and fibrosis increased in the ZF-WD rats; however, mRNA expression related to lipid synthesis decreased. Microsomal triglyceride transfer protein mRNA levels in the ZF-WD rats also decreased. In Zucker lean rats fed the WD, similar changes were observed in the liver; however, the hepatic changes were not serious compared with ZF-WD rats. In conclusion, hepatic lesions, such as inflammation, fibrosis, and necrosis, were observed in the ZF-WD rats. The sucrose/fat/cholesterol-enriched diet induced significant lipotoxicity in the livers of animals in this insulin-resistant model.	[Saito, Tomoyuki; Toriniwa, Yasufumi; Ishii, Yukihito; Uemura, Atsuhiro; Miyajima, Katsuhiro; Ohta, Takeshi] Japan Tobacco Inc, Cent Pharmaceut Res Inst, 1-1 Murasaki Cho, Takatsuki, Osaka 5691125, Japan; [Miyajima, Katsuhiro; Uno, Kinuko; Shirai, Yuki; Nakae, Dai] Tokyo Univ Agr, Fac Appl Biosci, Setagaya Ku, 1-1-1 Sakuragaoka, Tokyo 1568502, Japan	Ohta, T (reprint author), Japan Tobacco Inc, Cent Pharmaceut Res Inst, 1-1 Murasaki Cho, Takatsuki, Osaka 5691125, Japan.	takeshi.ohta@jt.com		Ohta, Takeshi/0000-0002-9573-3455			Altinbas A, 2015, MINERVA GASTROENTERO, V61, P159; Asgharpour A, 2016, J HEPATOL, V65, P579, DOI 10.1016/j.jhep.2016.05.005; Asrih M, 2015, MOL CELL ENDOCRINOL, V418, P55, DOI 10.1016/j.mce.2015.02.018; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Caprio S, 2017, GASTROENTEROLOGY, V152, P1638, DOI 10.1053/j.gastro.2016.12.051; de Alwis NMW, 2008, J HEPATOL, V48, pS104, DOI 10.1016/j.jhep.2008.01.009; Ertle J, 2011, INT J CANCER, V128, P2436, DOI 10.1002/ijc.25797; Ge FX, 2010, AM J PHYSIOL-GASTR L, V299, pG855, DOI 10.1152/ajpgi.00434.2009; Halford JCG, 2010, NAT REV ENDOCRINOL, V6, P255, DOI 10.1038/nrendo.2010.19; Han H, 2017, OXID MED CELL LONGEV, DOI 10.1155/2017/3256241; Higuchi N, 2011, EXP THER MED, V2, P1077, DOI 10.3892/etm.2011.328; Hockings PD, 2003, DIABETES OBES METAB, V5, P234, DOI 10.1046/j.1463-1326.2003.00268.x; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Ingawale DK, 2014, ENVIRON TOXICOL PHAR, V37, P118, DOI 10.1016/j.etap.2013.08.015; Lin MJ, 2014, DRUG SAFETY, V37, P213, DOI 10.1007/s40264-014-0147-x; Contreras-Zentella ML, 2016, OXID MED CELL LONGEV, DOI 10.1155/2016/3529149; Malik SM, 2009, CLIN GASTROENTEROL H, V7, P800, DOI 10.1016/j.cgh.2009.02.025; Prentice AM, 1996, INT J OBESITY, V20, pS18; Ran JM, 2004, AM J PHYSIOL-ENDOC M, V287, pE227, DOI 10.1152/ajpendo.00090.2004; Rinella ME, 2008, J LIPID RES, V49, P1068, DOI 10.1194/jlr.M800042-JLR200; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Savard C, 2013, HEPATOLOGY, V57, P81, DOI 10.1002/hep.25789; Schierwagen R, 2015, SCI REP-UK, V5, DOI 10.1038/srep12931; Stein CJ, 2004, J CLIN ENDOCR METAB, V89, P2522, DOI 10.1210/jc.2004-0288; Takaki A, 2013, INT J MOL SCI, V14, P20704, DOI 10.3390/ijms141020704; Tan Y, 2017, WORLD J GASTROENTERO, V23, P3805, DOI 10.3748/wjg.v23.i21.3805; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	28	2	3	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					283	291		10.1293/tox.2018-0016			9	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900007	30393432	Bronze, Green Published			2019-10-28	
J	Nakano, K; Nishizawa, T; Komura, D; Fujii, E; Monnai, M; Kato, A; Funahashi, S; Ishikawa, S; Suzuki, M				Nakano, Kiyotaka; Nishizawa, Takashi; Komura, Daisuke; Fujii, Etsuko; Monnai, Makoto; Kato, Atsuhiko; Funahashi, Shin-ichi; Ishikawa, Shumpei; Suzuki, Masami			Difference in morphology and interactome profiles between orthotopic and subcutaneous gastric cancer xenograft models	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						ubcutaneous; orthotopic; CASTIN; interactome; microenvironment	BREAST-CANCER; MOUSE MODEL; EXPRESSION; METASTASIS; CONTRAST; BEHAVIOR; RNA	In xenograft models, orthotopic (ORT) engraftment is thought to provide a different tumor microenvironment compared with subcutaneous (SC) engraftment. We attempted to characterize the biological difference between OE19 (adenocarcinoma of the gastroesophageal junction) SC and ORT models by pathological analysis and CASTIN (CAncer-STromal INteractome) analysis, which is a novel method developed to analyze the tumor-stroma interactome framework. In SC models, SCID mice were inoculated subcutaneously with OE19 cells, and tumor tissues were sampled at 3 weeks. In ORT models, SCID mice were inoculated under the serosal membrane of the stomach wall, and tumor tissues were sampled at 3 and 6 weeks after engraftment. Results from the two models were then compared. Histopathologically, the SC tumors were well circumscribed from the adjacent tissue, with scant stroma and the formation of large ductal structures. In contrast, the ORT tumors were less circumscribed, with small ductal structures invading into abundant stroma. Then we compared the transcriptome profiles of human tumor cells with the mouse stromal cells of each model by species-specific RNA sequencing. With CASTIN analysis, we successfully identified several interactions that are known to affect the tumor microenvironment as being selectively enhanced in the ORT model. In conclusion, pathological analysis and CASTIN analysis revealed that ORT models of OE19 cells have a more invasive character and enhanced interaction with stromal cells compared with SC models.	[Nakano, Kiyotaka; Nishizawa, Takashi; Fujii, Etsuko; Funahashi, Shin-ichi; Suzuki, Masami] Univ Tokyo, Forerunner Pharma Res Co Ltd, Komaba Open Lab, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan; [Komura, Daisuke; Ishikawa, Shumpei] Tokyo Med & Dent Univ, Med Res Inst, Dept Genom Pathol, Tokyo 1138510, Japan; [Fujii, Etsuko; Kato, Atsuhiko] Chugai Pharmaceut Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan; [Monnai, Makoto] Chugai Res Inst Med Sci Co Ltd, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan	Nakano, K; Suzuki, M (reprint author), Univ Tokyo, Forerunner Pharma Res Co Ltd, Komaba Open Lab, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	nakanokyt@chugai-pharm.co.jp; suzukimsm@chugai-pharm.co.jp					Bainer R, 2016, SCI REP-UK, V6, DOI 10.1038/srep39240; Bibby MC, 2004, EUR J CANCER, V40, P852, DOI 10.1016/j.ejca.2003.11.021; Dai L, 2015, EXP THER MED, V10, P1033, DOI 10.3892/etm.2015.2642; Du Q, 2014, ASIAN PAC J CANCER P, V15, P3747, DOI 10.7314/APJCP.2014.15.8.3747; FIDLER IJ, 1994, CANCER METAST REV, V13, P209, DOI 10.1007/BF00689637; Fung AS, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1091-6; FURUKAWA T, 1993, INT J CANCER, V53, P608, DOI 10.1002/ijc.2910530414; Hiroshima Y, 2015, ANTICANCER RES, V35, P697; Hoover M, 2017, ONCOTARGET, V8, P5885, DOI 10.18632/oncotarget.11809; Hu GL, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714624; Igarashi K, 2017, CELL CYCLE, V16, P91, DOI 10.1080/15384101.2016.1252885; Killion JJ, 1998, CANCER METAST REV, V17, P279, DOI 10.1023/A:1006140513233; Komura D, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3207-z; Li J, 2015, INT J MOL MED, V36, P1451, DOI 10.3892/ijmm.2015.2390; Loi M, 2011, INT J DEV BIOL, V55, P547, DOI 10.1387/ijdb.103230ml; Makalowski W, 1996, GENOME RES, V6, P846, DOI 10.1101/gr.6.9.846; Rockett JC, 1997, BRIT J CANCER, V75, P258, DOI 10.1038/bjc.1997.42; Rosano L, 2013, NAT REV CANCER, V13, P637, DOI 10.1038/nrc3546; See ALP, 2014, CURR CANCER DRUG TAR, V14, P294, DOI 10.2174/1568009614666140305222328; Smith JP, 2017, CELL MOL GASTROENTER, V4, P75, DOI 10.1016/j.jcmgh.2017.03.004; Song C, 2016, INT J RADIAT ONCOL, V95, P1022, DOI 10.1016/j.ijrobp.2016.01.064; Wells JE, 2015, INT J CANCER, V137, P504, DOI 10.1002/ijc.28972; Zhan BH, 2017, ONCOTARGET, V8, P61264, DOI 10.18632/oncotarget.18057; Zhang Y, 2016, J CELL BIOCHEM, V117, P2546, DOI 10.1002/jcb.25547; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	25	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					293	300		10.1293/tox.2018-0020			8	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900008	30393433	Bronze, Green Published			2019-10-28	
J	Mitori, H; Izawa, T; Kuwamura, M; Matsumoto, M; Yamate, J				Mitori, Hikaru; Izawa, Takeshi; Kuwamura, Mitsuru; Matsumoto, Masahiro; Yamate, Jyoji			Gene expression profile in retinal excitotoxicity induced by L-glutamate in neonatal rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						gene expression profile; L-glutamate; neonatal rat; apoptosis; retinal excitotoxicity	GANGLION-CELLS; GLAUCOMA; NMDA; HYPOTHESIS; RECEPTORS; APOPTOSIS; ISCHEMIA; PROTEIN	In neonatal rats, glutamate could induce retinal thinning depending on the development stage, and the severity peaked at treatment on postnatal day (PND) 8. To elucidate the molecular mechanism of retinal thinning induced by L-glutamate in neonatal rats, we investigated the time-course gene expression profile in the developing retina in addition to initial histopathological changes. Histopathologically, apoptotic cells in the inner retina were observed at 6 hours after treatment on PNDs 4, 6 and 8, and inflammatory cell infiltration was noted at 24 hours. Comprehensive gene expression analysis conducted on PNDs 4 and 8 indicated that cell death/ proliferation- and inflammation-related genes were upregulated and that neuron development- and neurotransmitter-related genes were downregulated. Furthermore, quantitative RT-PCR analysis of apoptosis- and inflammation-related genes performed on PNDs 4, 6, 8, 10 and 12 showed that the time-course changes of the gene expression ratios of Gadd45b and Ccl3 seemed to be related to histopathological changes of the retina induced by L-glutamate. These results revealed that the association of initial histopathological changes with the gene expression profile in the retina induced by L-glutamate and that Gadd45b and Ccl3 are considered to participate in retinal thinning induced by L-glutamate in neonatal rats.	[Mitori, Hikaru; Matsumoto, Masahiro] Astellas Pharma Inc, Drug Safety Res Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan; [Mitori, Hikaru; Izawa, Takeshi; Kuwamura, Mitsuru; Yamate, Jyoji] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, Rinku Ourai Kita 1-58, Izumisano, Osaka 5988531, Japan	Mitori, H (reprint author), Astellas Pharma Inc, Drug Safety Res Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan.; Mitori, H (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Lab Vet Pathol, Rinku Ourai Kita 1-58, Izumisano, Osaka 5988531, Japan.	hikaru.mitori@astellas.com					Chidlow G, 2003, BRAIN RES, V963, P298, DOI 10.1016/S0006-8993(02)04052-0; Denes V, 2011, NEUROCHEM RES, V36, P1464, DOI 10.1007/s11064-011-0472-8; Donello JE, 2001, J PHARMACOL EXP THER, V296, P216; Gilliland CT, 2013, J BIOL CHEM, V288, P32194, DOI 10.1074/jbc.M113.503797; Grunert U, 2002, J COMP NEUROL, V447, P138, DOI 10.1002/cne.10220; Guerin MB, 2011, CLIN EXP OPHTHALMOL, V39, P243, DOI 10.1111/j.1442-9071.2011.02496.x; Hare WA, 2009, INVEST OPHTH VIS SCI, V50, P2940, DOI 10.1167/iovs.08-2103; KANNO C, 1991, CELL STRUCT FUNCT, V16, P399, DOI 10.1247/csf.16.399; Kiagiadaki F, 2010, NEUROPHARMACOLOGY, V58, P297, DOI 10.1016/j.neuropharm.2009.06.028; Kido N, 2000, BRAIN RES, V884, P59, DOI 10.1016/S0006-8993(00)02887-0; Kitano S, 1996, EXP EYE RES, V63, P105, DOI 10.1006/exer.1996.0096; Lam TT, 1999, INVEST OPHTH VIS SCI, V40, P2391; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Martin KRG, 2002, INVEST OPHTH VIS SCI, V43, P2236; MASSEY SC, 1990, J NEUROPHYSIOL, V63, P16; Mitori H, 2016, TOXICOL PATHOL, V44, P1137, DOI 10.1177/0192623316676424; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; Sakamoto K, 2009, EXP EYE RES, V88, P974, DOI 10.1016/j.exer.2008.12.011; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Salvador JM, 2013, ADV EXP MED BIOL, V793, P1, DOI 10.1007/978-1-4614-8289-5_1; Sone K, 2018, BIOL PHARM BULL, V41, P657, DOI 10.1248/bpb.b17-01032; Strong M, 1996, NEUROLOGY, V47, pS26; Sullivan RKP, 2006, INVEST OPHTH VIS SCI, V47, P3853, DOI 10.1167/iovs.06-0231; Zhou X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.82; ZUCKER CL, 1994, J NEURAL TRANSP PLAS, V5, P17, DOI 10.1155/NP.1994.17	25	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					301	306		10.1293/tox.2018-0026			6	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900009	30393434	Bronze, Green Published			2019-10-28	
J	Tochinai, R; Komatsu, K; Murakami, J; Nagata, Y; Ando, M; Hata, C; Suzuki, T; Kado, S; Kobayashi, T; Kuwahara, M				Tochinai, Ryota; Komatsu, Kayoko; Murakami, Junta; Nagata, Yuriko; Ando, Minoru; Hata, Chie; Suzuki, Tomo; Kado, Shoichi; Kobayashi, Toshihide; Kuwahara, Masayoshi			Histopathological and functional changes in a single-dose model of combretastatin A4 disodium phosphate-induced myocardial damage in rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						combretastatin A4; fosbretabulin; cardiotoxicity; echocardiography; cardiac necrosis; microtubule	VASCULAR-TARGETING AGENT; ADVANCED CANCER; A-4 PHOSPHATE; PHASE-I; TOXICITY; LESIONS	Cardiotoxicity is a concern in the development of microtubule-disassembling agents (MDAs) as vascular-disrupting agents of tumors. This study investigated cardiotoxicity in rats induced by a single-dose of combretastatin A4 disodium phosphate (CA4DP), an MDA and discussed the use of this rat model in nonclinical studies of MDAs. First, CA4DP (120 mg/kg) was administered to rats intravenously, and cardiac histopathology and blood biomarkers were examined after 0.5, 24, and 72 h. Next, CA4DP (120 mg/kg) was administered to rats intravenously, and the electrocardiography and echocardiography results were analyzed. The results showed that at 0.5 h after dosing, plasma creatine kinase (CK), CK-muscle/brain (CK-MB), and fatty acid binding protein 3 levels increased. At 24 h, lactate dehydrogenase (LDH)-1, CK, and CK-MB levels increased, and multifocal vacuolar degeneration of myocardial cells was observed in the apical inner layer. At 72 h, LDH-1 levels were increased, and multifocal myocardial necrosis was observed in the interventricular septum and inner layer of the apex of left ventricular wall. Furthermore, at 0.5 h, heart rate (HR), ejection fraction (EF), and cardiac output (CO) decreased. At 24 h, CO decreased. Finally, at 72 h, HR, EF, and CO decreased, and depression of the T-wave amplitude was observed. In conclusion, myocardial injury, bradycardia, and depressed cardiac function were induced in rats by a single-dose of CA4DP. The lesion distribution and electrocardiographic features suggested that myocardial injury was induced by ischemia. These findings are similar to MDA-induced cardiotoxicity in humans, and this rat model will prove useful in studies of the cardiotoxicity in humans.	[Tochinai, Ryota; Komatsu, Kayoko; Murakami, Junta; Nagata, Yuriko; Ando, Minoru; Hata, Chie; Suzuki, Tomo; Kado, Shoichi; Kobayashi, Toshihide] Yakult Honsha Co Ltd, Yakult Cent Inst, 5-11 Izumi, Kunitachi, Tokyo 1868650, Japan; [Tochinai, Ryota; Kuwahara, Masayoshi] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathophysiol & Anim Hlth, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan	Tochinai, R (reprint author), Yakult Honsha Co Ltd, Yakult Cent Inst, 5-11 Izumi, Kunitachi, Tokyo 1868650, Japan.; Tochinai, R (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathophysiol & Anim Hlth, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	ar-tochinai@g.ecc.u-tokyo.ac.jp					Berridge BR, 2016, J TOXICOL PATHOL, V29, p1S, DOI [10.1293/tox.2016-I001, 10.1293/tox.29.3S-1]; Bhakta Shyam, 2009, Clin Cardiol, V32, pE80, DOI 10.1002/clc.20685; Cooney MM, 2004, CLIN CANCER RES, V10, P96, DOI 10.1158/1078-0432.CCR-0364-3; Dark GG, 1997, CANCER RES, V57, P1829; Dowlati A, 2002, CANCER RES, V62, P3408; PETTIT GR, 1982, CAN J CHEM, V60, P1374, DOI 10.1139/v82-202; Subbiah IM, 2011, ONCOLOGIST, V16, P1120, DOI 10.1634/theoncologist.2010-0432; Tochinai R, 2016, J TOXICOL PATHOL, V29, P163, DOI 10.1293/tox.2016-0012; Tochinai R, 2014, J TOXICOL PATHOL, V27, P223, DOI [10.1293/tox.2014-0013, 10.1293/tox.27.2014-0013]; Tochinai R, 2013, EXP TOXICOL PATHOL, V65, P737, DOI 10.1016/j.etp.2012.09.008; Tonomura Y, 2012, TOXICOLOGY, V302, P179, DOI 10.1016/j.tox.2012.07.012; Tozer GM, 1999, CANCER RES, V59, P1626; Wittstein IS, 2005, NEW ENGL J MED, V352, P539, DOI 10.1056/NEJMoa043046	13	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	4					307	313		10.1293/tox.2018-0023			7	Pathology; Toxicology	Pathology; Toxicology	GW4NI	WOS:000446891900010	30393435	Bronze, Green Published			2019-10-28	
J	Katerji, R; Hudson, CA				Katerji, Roula; Hudson, Chad A.			Concurrent Polycythemia of Undetermined Etiology an Smouldering Plasma Cell Myeloma	CASE REPORTS IN PATHOLOGY			English	Article							POEMS SYNDROME; MULTIPLE-MYELOMA; TEMPI SYNDROME; ERYTHROCYTOSIS; MUTATION; DIAGNOSIS	The combination of polycythemia and plasma cell myeloma occurring concurrently is very rare and few cases have been reported in the literature. Further, the vast majority of these cases are cases of polycythemia vera and myeloma. Here, we present a case of polycythemia of undetermined etiology and myeloma. The patient is a 48-year-old Caucasian male who was originally diagnosed with polycythemia of undetermined etiology. Twelve years later, when a bone marrow biopsy was performed in an attempt to determine the etiology of the polycythemia, findings diagnostic of plasma cell myeloma were discovered. Subsequent scrum studies were also consistent with a plasma cell neoplasm, while evaluation for end-organ damage was negative. A battery of genetic and biochemical tests ruled out various congenital polycythemias, leading to a final diagnosis of polycythemia of undetermined etiology and smouldering plasma cell myeloma. This case highlights that while being unusual, polycythemia and plasma cell myeloma can occur concurrently, and, in this report, we discuss both entities and potential mechanisms of the pathophysiology of the concurrent presentation.	[Katerji, Roula; Hudson, Chad A.] Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14627 USA	Katerji, R (reprint author), Univ Rochester, Dept Pathol & Lab Med, Rochester, NY 14627 USA.	roula_katerji@urmc.rochester.edu		Katerji, Roula/0000-0003-2156-9442			Dispenzieri A, 2003, BLOOD, V101, P2496, DOI 10.1182/blood-2002-07-2299; Dispenzieri A, 2017, AM J HEMATOL, V92, P814, DOI 10.1002/ajh.24802; FINK L, 1993, AM J HEMATOL, V44, P196, DOI 10.1002/ajh.2830440311; Gherardi RK, 1996, BLOOD, V87, P1458, DOI 10.1182/blood.V87.4.1458.bloodjournal8741458; Hutchison E. J., 2016, BMJ CASE REPORTS, V2016; Langabeer SE, 2015, J CLIN DIAGN RES, V9, pEL01, DOI 10.7860/JCDR/2015/16407.6934; Lee SG, 2011, ACTA HAEMATOL-BASEL, V126, P169, DOI 10.1159/000328996; Ludwig Heinz, 2004, Clin Adv Hematol Oncol, V2, P233; Miasnikova GY, 2011, HAEMATOL-HEMATOL J, V96, P1371, DOI 10.3324/haematol.2011.045609; Michels TC, 2017, AM FAM PHYSICIAN, V95, P373; Rosado FG, 2015, MODERN PATHOL, V28, P367, DOI 10.1038/modpathol.2014.117; Scarlato M, 2005, BRAIN, V128, P1911, DOI 10.1093/brain/awh519; Swerdlow SH, 2017, WHO CLASSIFICATION T; Sykes DB, 2011, NEW ENGL J MED, V365, P475, DOI 10.1056/NEJMc1106670	14	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8781721	10.1155/2018/8781721			5	Pathology	Pathology	GV5ZW	WOS:000446186900001	30305975	DOAJ Gold, Green Published			2019-10-28	
J	Thinesen, MT; de Muckadell, OBS; Detlefsen, S				Thinesen, Malene Theilmann; de Muckadell, Ove B. Schaffalitzky; Detlefsen, Sonke			IgG4-Related Sclerosing Cholangitis Involving the Intrahepatic Bile Ducts Diagnosed with Liver Biopsy	CASE REPORTS IN PATHOLOGY			English	Article							IMMUNOGLOBULIN G4-ASSOCIATED CHOLANGITIS; AUTOIMMUNE PANCREATITIS; PLASMA-CELLS; G4-RELATED DISEASE; CHOLANGIOCARCINOMA; ASSOCIATION; MALIGNANCIES; PSEUDOTUMOR; FEATURES; PROFILE	IgG4-related disease is characterized by lymphoplasmacytic inflammation and fibrosis, often leading to mass-forming lesions in different organs. When IgG4-related disease affects the bile ducts, it is called IgG4-related sclerosing cholangitis. A 74-year-old male complained of dysphagia and abdominal pain. Endoscopic retrograde cholangiography and magnetic resonance cholangiography revealed bile duct changes suspicious of a bile duct carcinoma or cholangitis. Liver biopsy showed storiform fibrosis, lymphoplasmacytic infiltration, obliterative phlebitis, and a portal-based inflammatory nodule with expansion of a portal tract. Hot spots revealed 339 IgG4-positive cells per high power field (HPF) and an IgG4/IgG ratio of 72%. Eight months earlier, an inguinal lymph node had been removed, showing expanded interfollicular zones and increased plasma cells. Hot spots revealed 593 IgG4-positive cells and an IgG4/IgG ratio of 92%. The serum IgG4 of the patient was elevated nearly 10 times upper limit of normal. The diagnosis of IgG4-related sclerosing cholangitis associated with IgG4-related lymphadenopathy was made. There was good response to treatment with prednisolone and azathioprine. The differentiation of IgG4-related sclerosing cholangitis from primary sclerosing cholangitis and bile duct carcinoma is often difficult. Liver biopsy only rarely contributes to this setting, but we describe and report in detail a case where liver biopsy showed a portal-based inflammatory nodule with the characteristic features of this disease.	[Thinesen, Malene Theilmann; Detlefsen, Sonke] Odense Univ Hosp, Dept Pathol, Odense, Denmark; [de Muckadell, Ove B. Schaffalitzky] Odense Univ Hosp, Dept Gastroenterol, Odense, Denmark	Detlefsen, S (reprint author), Odense Univ Hosp, Dept Pathol, Odense, Denmark.	sonke.detlefsen@rsyd.dk					Ahn SS, 2017, INT J RHEUM DIS, V20, P1028, DOI 10.1111/1756-185X.13093; Anan R, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008710; Asano J, 2015, J RHEUMATOL, V42, P2135, DOI 10.3899/jrheum.150436; BARTHOLOMEW LG, 1963, NEW ENGL J MED, V269, P8, DOI 10.1056/NEJM196307042690102; Boonstra K, 2014, HEPATOLOGY, V59, P1954, DOI 10.1002/hep.26977; Chen JH, 2017, GASTROENTEROL CLIN N, V46, P195, DOI 10.1016/j.gtc.2017.01.001; Cheuk W, 2012, SEMIN DIAGN PATHOL, V29, P226, DOI 10.1053/j.semdp.2012.07.001; Colafrancesco S, 2015, BEST PRACT RES CL RH, V29, P810, DOI 10.1016/j.berh.2016.02.005; COMINGS DE, 1967, ANN INTERN MED, V66, P884, DOI 10.7326/0003-4819-66-5-884; Deshpande V, 2015, ARCH PATHOL LAB MED, V139, P742, DOI 10.5858/arpa.2014-0181-RA; Deshpande V, 2012, MODERN PATHOL, V25, P1181, DOI 10.1038/modpathol.2012.72; Deshpande V, 2009, MODERN PATHOL, V22, P1287, DOI 10.1038/modpathol.2009.94; Detlefsen S, 2018, VIRCHOWS ARCH, V472, P545, DOI 10.1007/s00428-017-2275-z; Detlefsen S, 2015, PANCREAS, V44, P845, DOI 10.1097/MPA.0000000000000312; Detlefsen S, 2013, HISTOL HISTOPATHOL, V28, P565, DOI 10.14670/HH-28.565; Detlefsen S, 2012, PANCREATOLOGY, V12, P276, DOI 10.1016/j.pan.2012.03.055; Detlefsen S, 2009, SCAND J GASTROENTERO, V44, P1391, DOI 10.3109/00365520903358881; Ghazale A, 2008, GASTROENTEROLOGY, V134, P706, DOI 10.1053/j.gastro.2007.12.009; Grimm KE, 2012, MODERN PATHOL, V25, P480, DOI 10.1038/modpathol.2011.177; Hirano K, 2014, INTERNAL MED, V53, P171, DOI 10.2169/internalmedicine.53.1342; Kalaitzakis E, 2011, CLIN GASTROENTEROL H, V9; Kimura Y, 2012, HUM PATHOL, V43, P2149, DOI 10.1016/j.humpath.2012.03.001; Lee JJ, 2017, ABDOM RADIOL, V42, P2898, DOI 10.1007/s00261-017-1328-8; Liang L, 2015, WORLD J CLIN CASES, V3, P650, DOI 10.12998/wjcc.v3.i7.650; Naitoh I, 2011, J GASTROENTEROL, V46, P269, DOI 10.1007/s00535-010-0319-0; Nakazawa T, 2013, WORLD J GASTROENTERO, V19, P7661, DOI 10.3748/wjg.v19.i43.7661; Ohara H, 2012, J HEPATO-BIL-PAN SCI, V19, P536, DOI 10.1007/s00534-012-0521-y; Ohno Y, 2018, CLIN J GASTROENTEROL, V11, P62, DOI 10.1007/s12328-017-0787-3; Oseini AM, 2011, HEPATOLOGY, V54, P940, DOI 10.1002/hep.24487; Shimosegawa T, 2011, PANCREAS, V40, P352, DOI 10.1097/MPA.0b013e3182142fd2; Siddiqi I. N., 2011, J HEMATOP, V4, P207, DOI DOI 10.1007/S12308-011-0117-5; Tabata T, 2013, GUT LIVER, V7, P234, DOI 10.5009/gnl.2013.7.2.234; Tan LM, 2018, SCAND J GASTROENTERO, V53, P206, DOI 10.1080/00365521.2017.1416159; Umemura T, 2007, HEPATOLOGY, V46, P463, DOI 10.1002/hep.21700; Yamamoto M, 2012, MOD RHEUMATOL, V22, P414, DOI 10.1007/s10165-011-0520-x; Zen Y, 2007, MODERN PATHOL, V20, P884, DOI 10.1038/modpathol.3800836	36	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2309293	10.1155/2018/2309293			7	Pathology	Pathology	GV5ZV	WOS:000446186800001	30305974	DOAJ Gold, Green Published			2019-10-28	
J	Behling, F; Schittenhelm, J				Behling, Felix; Schittenhelm, Jens			Tissue microarrays - translational biomarker research in the fast lane	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Tissue microarray; TMA; tumor marker; translational research	CONSTRUCTION; GUIDELINES; SAMPLES; CANCER		[Behling, Felix] Eberhard Karls Univ Tubingen, Dept Neurosurg, Tubingen, Germany; [Behling, Felix; Schittenhelm, Jens] Eberhard Karls Univ Tuebingen, Univ Hosp Tuebingen, Comprehens Canc Ctr Tuebingen Stuttgart, Ctr CNS Tumors, Tubingen, Germany; [Schittenhelm, Jens] Eberhard Karls Univ Tubingen, Dept Neuropathol, Tubingen, Germany	Schittenhelm, J (reprint author), Eberhard Karls Univ Tuebingen, Univ Hosp Tuebingen, Dept Neuropathol, Calwerstr 3, Tubingen, Germany.	jens.schittenhelm@med.uni-tuebingen.de					Albanghali M, 2016, HISTOPATHOLOGY, V68, P323, DOI 10.1111/his.12802; BATTIFORA H, 1986, LAB INVEST, V55, P244; Behling F, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0506-2; Deng FM, 2013, J CLIN PATHOL, V66, P627, DOI 10.1136/jclinpath-2012-201171; Garranzo-Asensio Maria, 2018, Oncotarget, V9, P10847, DOI 10.18632/oncotarget.24303; Giltnane JM, 2008, ARCH PATHOL LAB MED, V132, P1635, DOI 10.1043/1543-2165(2008)132[1635:COQIWC]2.0.CO;2; Ilyas M, 2013, HISTOPATHOLOGY, V62, P827, DOI 10.1111/his.12118; Jonczyk Rebecca, 2016, Microarrays (Basel), V5, DOI 10.3390/microarrays5020011; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; LeBaron MJ, 2005, NAT METHODS, V2, P511, DOI 10.1038/NMETH772; Rimm DL, 2011, J CLIN ONCOL, V29, P2282, DOI 10.1200/JCO.2010.33.2023; Simon R., 2001, TISSUE MICROARRAYS M, V1; Thul PJ, 2018, PROTEIN SCI, V27, P233, DOI 10.1002/pro.3307; Vogel Ulrich, 2014, Microarrays (Basel), V3, P103, DOI 10.3390/microarrays3020103; WAN WH, 1987, J IMMUNOL METHODS, V103, P121; Wang HM, 2002, BRAIN PATHOL, V12, P95	16	0	0	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					833	835		10.1080/14737159.2018.1522252			3	Pathology	Pathology	GV6IZ	WOS:000446213900001	30198797				2019-10-28	
J	Franzmann, EJ; Donovan, MJ				Franzmann, Elizabeth J.; Donovan, Michael J.			Effective early detection of oral cancer using a simple and inexpensive point of care device in oral rinses	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						CD44; early detection; oral cancer; point-of-care; saliva; total protein	SQUAMOUS-CELL CARCINOMA; POTENTIALLY MALIGNANT DISORDERS; OROPHARYNGEAL CANCER; HUMAN-PAPILLOMAVIRUS; TOLUIDINE BLUE; SOLUBLE CD44; HEAD; DIAGNOSIS; LESIONS; SALIVA	Introduction: Head and neck cancer remains a challenging disease that is increasing in incidence with the majority of patients diagnosed at an advanced stage where 5-year survival is approximately 50%. Current approaches including oral-brush biopsies, fluorescence-based technologies, and salivary molecular profiling have demonstrated some success; however, cost, ease of use, and accuracy remain limiting factors. Areas covered: This is a profile of a novel, easy to use oral rinse point-of-care (POC) test to aid in the diagnosis of oral and oropharyngeal cancer. Background science related to the challenge of oral and oropharyngeal cancer and natural history of diagnostic aids for this disease are provided. Results of studies performed for validation of a POC and laboratory test are also discussed. Expert commentary: The POC test has been validated through a case : control clinical study and a prospective European trial, using version 1.0 (v1.0), which have demonstrated consistent performance including a > 90% negative predictive value, with a sensitivity of 80%. The assay was designed to identify malignant lesions in the oral cavity and oropharynx by improving upon standard clinical assessment.	[Franzmann, Elizabeth J.] Univ Miami, Miller Sch Med, Dept Otolaryngol, Sylvester Med Off Bldg,1121 NW 14th St, Miami, FL 33136 USA; [Donovan, Michael J.] Icahn Sch Med Mt Sinai, Dept Pathol, New York, NY 10029 USA	Franzmann, EJ (reprint author), Univ Miami, Miller Sch Med, Dept Otolaryngol, Sylvester Med Off Bldg,1121 NW 14th St, Miami, FL 33136 USA.	elizabeth.franzmann@vigilantbiosciences.com			Vigilant Biosciences, University of Miami [NCI R01CA118584, NCI RO3 CA107828, 4BB-20 Bankhead-Coley, 10BG-02 Bankhead-Coley]	This paper is funded by Vigilant Biosciences, University of Miami, [NCI R01CA118584, NCI RO3 CA107828, 4BB-20 Bankhead-Coley, and 10BG-02 Bankhead-Coley]	Acharya S, 2015, J ORAL PATHOL MED, V44, P252, DOI 10.1111/jop.12231; Adami GR, 2017, ORAL ONCOL, V69, P62, DOI 10.1016/j.oraloncology.2017.04.001; Allegra E, 2012, J CANC SCI THER, V4, P330; Alsarraf AH, 2018, J ORAL PATHOL MED, V47, P104, DOI 10.1111/jop.12660; American Cancer Society, 2018, CANC FACTS FIG 2018; American Head & Neck Society, AHNS RESP USPSTF OR; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; [Anonymous], ORAL CANC; [Anonymous], AB THE USPSTF; [Anonymous], OR CANC SCREEN; Bhatia A, 2015, J CLIN ONCOL, V33, P3243, DOI 10.1200/JCO.2015.61.2358; Bregman JA, 2016, TODAYS FDA, V28, P35; Bregman Jonathan A, 2016, Todays FDA, V28, P32; Brisam M, 2016, ONCOL REP, V35, P1979, DOI 10.3892/or.2016.4600; BROCKLEHURST P, 2013, COCHRANE DB SYST REV, V11, DOI DOI 10.1002/14651858.CD004150.PUB4; Carvalho AL, 2008, CLIN CANCER RES, V14, P97, DOI 10.1158/1078-0432.CCR-07-0722; Centers for Disease Control and Prevention, 2017, OR DENT HLTH; Cheng YSL, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-3; Chhabra N, 2015, J MAXILLOFAC ORAL SU, V14, P188, DOI 10.1007/s12663-014-0660-6; Chi AC, 2015, CA-CANCER J CLIN, V65, P401, DOI 10.3322/caac.21293; Cuddy KK, 2015, J CAN DENT ASSOC, V81; Dasari S, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0139-9; Donovan MJ, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3266; Donovan MJ, 2018, DENTISTRY, V8, P94; El-Naggar AK, 2001, J MOL DIAGN, V3, P164, DOI 10.1016/S1525-1578(10)60668-X; Elashoff D, 2012, CANCER EPIDEM BIOMAR, V21, P664, DOI 10.1158/1055-9965.EPI-11-1093; Epstein JB, 2008, CAN FAM PHYSICIAN, V54, P870; Epstein JB, 2012, J AM DENT ASSOC, V143, P1332, DOI 10.14219/jada.archive.2012.0096; Fakhry C, 2013, ORAL ONCOL, V49, P863, DOI 10.1016/j.oraloncology.2013.06.002; Fedele S, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-5; Franzmann EJ, 2005, CANCER EPIDEM BIOMAR, V14, P735, DOI 10.1158/1055-9965.EPI-04-0546; Franzmann EJ, 2007, CANCER EPIDEM BIOMAR, V16, P1348, DOI 10.1158/1055-9965.EPI-06-0011; Franzmann EJ, 2012, HEAD NECK-J SCI SPEC, V34, P687, DOI 10.1002/hed.21810; Grau JJ, 2016, ONCOLOGY-BASEL, V90, P267, DOI 10.1159/000445118; Gray L, 2002, J CANCER EDUC, V17, P191; Guneri P, 2010, ORAL ONCOL, V46, pE2, DOI 10.1016/j.oraloncology.2009.10.006; Guneri P, 2011, INT J ORAL MAX SURG, V40, P155, DOI 10.1016/j.ijom.2010.10.022; Guneri P, 2014, ORAL ONCOL, V50, P1131, DOI 10.1016/j.oraloncology.2014.09.005; He BC, 2016, ACTA OTO-LARYNGOL, V136, P1074, DOI 10.1080/00016489.2016.1185539; Herbella FAM, 2015, WORLD J GASTROENTERO, V21, P815, DOI 10.3748/wjg.v21.i3.815; Hirvikoski P, 1999, VIRCHOWS ARCH, V434, P37, DOI 10.1007/s004280050302; Hung KF, 2016, ORAL ONCOL, V53, P42, DOI 10.1016/j.oraloncology.2015.11.017; Ioachim E, 1999, HISTOL HISTOPATHOL, V14, P1113, DOI 10.14670/HH-14.1113; Javaid Mohammad A, 2016, J Oral Biol Craniofac Res, V6, P66, DOI 10.1016/j.jobcr.2015.08.006; Kaczor-Urbanowicz KE, 2017, J CELL MOL MED, V21, P640, DOI 10.1111/jcmm.13007; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kamarajan P, 2013, CANCER MED-US, V2, P793, DOI 10.1002/cam4.147; LARSSON A, 1991, J ORAL PATHOL MED, V20, P258, DOI 10.1111/j.1600-0714.1991.tb00924.x; Lim K, 2003, BRIT DENT J, V194, P497, DOI 10.1038/sj.bdj.4810069; Lingen MW, 2008, ORAL ONCOL, V44, P10, DOI 10.1016/j.oraloncology.2007.06.011; Lingen MW, 2017, J AM DENT ASSOC, V148, P712, DOI 10.1016/j.adaj.2017.07.032; Lydiatt WM, 2017, CA-CANCER J CLIN, V67, P122, DOI 10.3322/caac.21389; Macey R, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010276.pub2; MATHEW B, 1995, BRIT J CANCER, V71, P397, DOI 10.1038/bjc.1995.81; Osazuwa-Peters N, 2016, J CANCER RES CLIN, V142, P521, DOI 10.1007/s00432-015-2061-8; Patton LL, 2008, J AM DENT ASSOC, V139, P896, DOI 10.14219/jada.archive.2008.0276; Pereira LHM, 2016, CANCER PREV RES, V9, P445, DOI 10.1158/1940-6207.CAPR-15-0200; Pereira LHM, 2011, CANCER BIOMARK, V10, P241, DOI 10.3233/CBM-2012-0252; Perez A, 2013, ORAL ONCOL, V49, P306, DOI 10.1016/j.oraloncology.2012.11.009; Peterson CE, 2016, J CANCER RES CLIN, V142, P1715, DOI 10.1007/s00432-016-2182-8; PINDBORG JJ, 1977, ORAL SURG ORAL MED O, V43, P383, DOI 10.1016/0030-4220(77)90325-5; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Ralhan R, 1998, CLIN CANCER RES, V4, P2147; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sethi S, 2009, DIAGN MOL PATHOL, V18, P81, DOI 10.1097/PDM.0b013e3181804b82; Shield KD, 2017, CA-CANCER J CLIN, V67, P51, DOI 10.3322/caac.21384; Shpitzer T, 2009, BRIT J CANCER, V101, P1194, DOI 10.1038/sj.bjc.6605290; Shulman JD, 2004, J AM DENT ASSOC, V135, P1279, DOI 10.14219/jada.archive.2004.0403; Simkin M, 2012, EPIGENOMICS-UK, V4, P343, DOI [10.2217/epi.12.24, 10.2217/EPI.12.24]; STEVENS VJ, 1995, AM J PUBLIC HEALTH, V85, P231, DOI 10.2105/AJPH.85.2.231; Stewart BW, 2014, WORLD CANC REPORT 20; Vu A, 2016, ORAL DIS, V22, P383, DOI 10.1111/odi.12430; Wang QH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06802; Warnakulasuriya S, 2007, J ORAL PATHOL MED, V36, P575, DOI 10.1111/j.1600-0714.2007.00582.x; Warnakulasuriya S, 2014, ORAL MED PATHOLOGY G, P300; Wei F, 2009, CLIN CANCER RES, V15, P4446, DOI 10.1158/1078-0432.CCR-09-0050; Zhong LP, 2005, INT J ORAL MAX SURG, V34, P566, DOI 10.1016/j.ijom.2004.10.007	78	0	0	2	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					837	844		10.1080/14737159.2018.1523008			8	Pathology	Pathology	GV6IZ	WOS:000446213900002	30221559				2019-10-28	
J	Dadwal, SS; Kontoyiannis, DP				Dadwal, Sanjeet S.; Kontoyiannis, Dimitrios P.			Recent advances in the molecular diagnosis of mucormycosis	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Molecular diagnosis; mucormycosis; biomarkers; early diagnosis; mycology	FLIGHT MASS-SPECTROMETRY; DESORPTION IONIZATION-TIME; BRONCHOALVEOLAR LAVAGE SAMPLES; MALDI-TOF MS; PCR ASSAY; IMMUNOCOMPROMISED PATIENTS; HEMATOLOGIC MALIGNANCIES; CEREBRAL MUCORMYCOSIS; RHIZOPUS-MICROSPORUS; CEREBROSPINAL-FLUID	Introduction: Fungal infection burden related to Mucorales has been on the rise with significant associated morbidity and mortality. The major obstacle in the management has been lack of a non-invasive rapid and a reliable diagnostic test. Developing a culture-independent biomarker for the early diagnosis of mucormycosis is a major unmet need in modern mycology. Several approaches have been developed, such as immunohistochemistry (IHC) that can confirm the histopathologic diagnosis of the invasive mold infection, polymerase chain reaction (PCR) on formalin-fixed paraffin-embedded (FFPE) or fresh tissue, body fluids such as bronchoalveolar fluid (BAL), and detection directly from serum/blood. Serologic tests, matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF/MS), metabolomics and metagenomic shotgun sequencing are other evolving technologies. Area covered: In this review paper, we report the current status of the molecular diagnostics in the diagnosis of mucormycosis: serologic tests, IHC, PCR, protein-based with MALDI-TOF, metabolomics and metagenomic sequencing. Expert commentary: This review will conclude with an expert commentary on the potential uses/challenges of the currently available tests and the future of molecular diagnostics for mucormycosis.	[Dadwal, Sanjeet S.] City Hope Natl Med Ctr, Div Infect Dis, 1500 E Duarte Rd, Duarte, CA 91010 USA; [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Houston, TX 77030 USA	Kontoyiannis, DP (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Infect Dis Infect Control & Employee Hlth, Unit 1406, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dkontoyi@mdanderson.org					Alanio A, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.01.017; Alanio A, 2017, MED MYCOL, V55, P56, DOI 10.1093/mmy/myw080; Angebault C, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw128; Balajee SA, 2009, J CLIN MICROBIOL, V47, P877, DOI 10.1128/JCM.01685-08; Balajee SA, 2006, EUKARYOT CELL, V5, P1705, DOI 10.1128/EC.00162-06; Baldin C, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.00746-18; Baldin C, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006408; Becker PT, 2014, MED MYCOL, V52, P826, DOI 10.1093/mmy/myu064; Bengel D, 2007, EUR J NEUROL, V14, P1067, DOI 10.1111/j.1468-1331.2007.01878.x; Bernal-Martinez L, 2013, CLIN MICROBIOL INFEC, V19, pE1, DOI 10.1111/j.1469-0691.2012.03976.x; Bezdicek M, 2016, MED MYCOL, V54, P714, DOI 10.1093/mmy/myw032; Bialek R, 2005, J CLIN PATHOL, V58, P1180, DOI 10.1136/jcp.2004.024703; Burnham-Marusich AR, 2018, MSPHERE, V3, DOI [10.1128/mSphere.00094-18, 10.1128/msphere.00094-18]; Caillot Denis, 2016, Open Forum Infect Dis, V3, pofw190, DOI 10.1093/ofid/ofw190; Cassagne C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028425; Chamilos G, 2008, CLIN INFECT DIS, V47, P503, DOI 10.1086/590004; Chamilos G, 2006, HAEMATOL-HEMATOL J, V91, P986; Cornely OA, 2014, CLIN MICROBIOL INFEC, V20, P5, DOI 10.1111/1469-0691.12371; Dannaoui E, 2017, INT J ANTIMICROB AG, V50, P617, DOI 10.1016/j.ijantimicag.2017.08.010; Dannaoui E, 2009, CLIN MICROBIOL INFEC, V15, P66, DOI 10.1111/j.1469-0691.2009.02983.x; De Pauw B, 2008, CLIN INFECT DIS, V46, P1813, DOI 10.1086/588660; Desnos-Ollivier M, 2014, J CLIN MICROBIOL, V52, P2196, DOI 10.1128/JCM.00039-14; Dolatabadi S, 2014, MYCOSES, V57, P67, DOI 10.1111/myc.12245; Dolatabadi S, 2015, J MED MICROBIOL, V64, P694, DOI 10.1099/jmm.0.000091; Drogari-Apiranthitou M, 2016, PATHOL RES PRACT, V212, P393, DOI 10.1016/j.prp.2016.02.010; Giebel R, 2010, ADV APPL MICROBIOL, V71, P149, DOI 10.1016/S0065-2164(10)71006-6; Gomez CA, 2017, CLIN INFECT DIS, V65, P2035, DOI 10.1093/cid/cix728; Hammond SP, 2011, J CLIN MICROBIOL, V49, P2151, DOI 10.1128/JCM.00256-11; Hata DJ, 2008, J CLIN MICROBIOL, V46, P2353, DOI 10.1128/JCM.02331-07; Hofman V, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-1; Huang YF, 2017, J MED MICROBIOL, V66, P328, DOI 10.1099/jmm.0.000435; Huffnagle GB, 2013, TRENDS MICROBIOL, V21, P334, DOI 10.1016/j.tim.2013.04.002; Ibrahim AS, 2005, ANTIMICROB AGENTS CH, V49, P721, DOI 10.1128/AAC.49.2.721-727.2005; Ibrahim AS, 2006, MOLECULAR PRINCIPLES OF FUNGAL PATHOGENESIS, P429; Ino K, 2017, INTERNAL MED, V56, P707, DOI 10.2169/internalmedicine.56.7647; Jung J, 2015, Clin Microbiol Infect, V21, DOI 10.1016/j.cmi.2015.03.019; Jung J, 2015, CLIN INFECT DIS, V61, P1664, DOI 10.1093/cid/civ660; Kasai M, 2008, J CLIN MICROBIOL, V46, P3690, DOI 10.1128/JCM.00917-08; Kontoyiannis DP, 2007, AM J CLIN PATHOL, V127, P208, DOI 10.1309/7KU5XWURYM0151YN; Kontoyiannis DP, 2016, OPEN FORUM INFECT DI, V3, DOI [10.1093/ofid/ofw209, DOI 10.1093/OFID/OFW209]; Koshy S, 2017, OPEN FORUM INFECT DI, V4, P553; Lau A, 2007, J CLIN MICROBIOL, V45, P380, DOI 10.1128/JCM.01862-06; Legrand M, 2016, CLIN INFECT DIS, V63, P1312, DOI 10.1093/cid/ciw563; Lengerova M, 2014, J CLIN MICROBIOL, V52, P2824, DOI 10.1128/JCM.00637-14; Liu MX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23611-z; Magira EE, 2018, MYCOSES, P1; Marvin LF, 2003, CLIN CHIM ACTA, V337, P11, DOI 10.1016/j.cccn.2003.08.008; McCarthy MW, 2016, EXPERT REV MOL DIAGN, V16, P1025, DOI 10.1080/14737159.2016.1219253; Mendoza L, 2014, COLD SPRING HARB PER, V5; Millon L, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.12.006; Millon L, 2013, CLIN INFECT DIS, V56, pE95, DOI 10.1093/cid/cit094; Neofytos D, 2009, CLIN INFECT DIS, V48, P265, DOI 10.1086/595846; Orne C, 2018, 28 ECCMID; Patel R, 2015, CLIN CHEM, V61, P100, DOI 10.1373/clinchem.2014.221770; Petraitis V, 2013, MED MYCOL, V51, P72, DOI 10.3109/13693786.2012.690107; Pongas GN, 2009, CLIN MICROBIOL INFEC, V15, P93, DOI 10.1111/j.1469-0691.2009.02988.x; Ribes JA, 2000, CLIN MICROBIOL REV, V13, P236, DOI 10.1128/CMR.13.2.236-301.2000; Rickerts V, 2006, EUR J CLIN MICROBIOL, V25, P8, DOI 10.1007/s10096-005-0078-7; Roden MM, 2005, CLIN INFECT DIS, V41, P634, DOI 10.1086/432579; Salehi E, 2016, J CLIN MICROBIOL, V54, P2798, DOI 10.1128/JCM.01185-16; Schrodl W, 2012, J CLIN MICROBIOL, V50, P419, DOI 10.1128/JCM.01070-11; Shah AA, 2013, AM J CLIN PATHOL, V139, P55, DOI 10.1309/AJCPO8VTSK3HRNUT; Shelburne SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139851; Shigemura T, 2014, INT J INFECT DIS, V29, P200, DOI 10.1016/j.ijid.2014.10.019; Shokouhi S, 2016, Curr Med Mycol, V2, P46, DOI 10.18869/acadpub.cmm.2.4.46; Springer J, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01655-17; Springer J, 2016, J MED MICROBIOL, V65, P1414, DOI 10.1099/jmm.0.000375; Springer J, 2017, METHODS MOL BIOL, V1508, P267, DOI 10.1007/978-1-4939-6515-1_15; Sunagawa K, 2013, JPN J INFECT DIS, V66, P345, DOI 10.7883/yoken.66.345; Walsh TJ, 2014, MYCOSES, V57, P2, DOI 10.1111/myc.12249; Walsh TJ, 2012, CLIN INFECT DIS, V54, pS55, DOI 10.1093/cid/cir868; Walther G, 2013, PERSOONIA, V30, P11, DOI 10.3767/003158513X665070; Woo PCY, 2010, J CLIN MICROBIOL, V48, P208, DOI 10.1128/JCM.01750-09; Zaman K, 2017, J MED MICROBIOL, V66, P1124, DOI 10.1099/jmm.0.000560	74	3	3	0	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					845	854		10.1080/14737159.2018.1522250			10	Pathology	Pathology	GV6IZ	WOS:000446213900003	30203997				2019-10-28	
J	Brusius-Facchin, AC; Malaga, DR; Leistner-Segal, S; Giugliani, R				Brusius-Facchin, Ana Carolina; Malaga, Diana Rojas; Leistner-Segal, Sandra; Giugliani, Roberto			Recent advances in molecular testing to improve early diagnosis in children with mucopolysaccharidoses	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Molecular genetic testing; lysosomal storage disorders; mucopolysaccharidoses; next generation sequencing; mutation identification	ENZYME REPLACEMENT THERAPY; LYSOSOMAL STORAGE DISORDERS; COMPARATIVE GENOMIC HYBRIDIZATION; SYNDROME TYPE-C; SANFILIPPO-SYNDROME; MUTATIONAL ANALYSIS; SEVERE PHENOTYPE; READ-THROUGH; IDS GENE; ATTENUATED PHENOTYPE	Introduction: The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders with high phenotypic and genotypic heterogeneity, making precise diagnosis challenging. Although enzyme activity assay is considered the gold standard for the diagnosis of these disorders, molecular testing can greatly refine this task. New methods for rapid detection of variants are useful to reduce the 'diagnostic odyssey' faced by patients and their family, to lead to appropriate genetic counseling and to select the most appropriate therapy for each case. Areas covered: We review and discuss the advantages, disadvantages and limitations of the modern technologies in the field of molecular diagnosis of MPS, presenting our own experience. Expert commentary: While current molecular genetics testing for MPS mostly relies on PCR and Sanger sequencing, promising alternative techniques have emerged over the last few years, and its application into routine clinical practice is gaining momentum.	[Brusius-Facchin, Ana Carolina; Malaga, Diana Rojas; Leistner-Segal, Sandra; Giugliani, Roberto] HCPA, Med Genet Serv, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil; [Malaga, Diana Rojas; Giugliani, Roberto] Univ Fed Rio Grande do Sul, Postgrad Program Genet & Mol Biol, Porto Alegre, RS, Brazil; [Leistner-Segal, Sandra; Giugliani, Roberto] Univ Fed Rio Grande do Sul, Postgrad Program Med Sci, Porto Alegre, RS, Brazil; [Giugliani, Roberto] Univ Fed Rio Grande do Sul, Dept Genet, Porto Alegre, RS, Brazil	Giugliani, R (reprint author), HCPA, Med Genet Serv, Rua Ramiro Barcelos 2350, BR-90035903 Porto Alegre, RS, Brazil.	rgiugliani@hcpa.edu.br	Leistner-Segal, Sandra/M-3199-2019; Giugliani, Roberto/G-4790-2015	Leistner-Segal, Sandra/0000-0003-3792-6168; Giugliani, Roberto/0000-0001-9655-3686			Adam M, GENEREVIEWSR PUBMED; Al Kaissi A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004561; Al-Jasmi FA, 2012, J INHERIT METAB DIS, V10, P1, DOI DOI 10.1007/8904_; Aldenhoven M, 2015, BLOOD, V125, P2164, DOI 10.1182/blood-2014-11-608075; Amartino H, 2014, MOLEC GENET METAB RE, V1, P401, DOI 10.1016/j.ymgmr.2014.08.006; Applegarth DA, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.1.e10; Ashton-Prolla P, 2015, J COMMUN GENET, V6, P275, DOI 10.1007/s12687-015-0238-0; Atceken N, 2016, TURK J MED SCI, V46, P404, DOI 10.3906/sag-1411-160; Barba M, 2014, VIRUSES-BASEL, V6, P106, DOI 10.3390/v6010106; Bartolomeo R, 2013, J INHERIT METAB DIS, V36, P363, DOI 10.1007/s10545-012-9521-y; Beesley CE, 2000, J MED GENET, V37, P704, DOI 10.1136/jmg.37.9.704; Berger-Plantinga EG, 2004, J NEUROL, V251, P479, DOI 10.1007/s00415-004-0368-5; Bochernitsan AN, 2018, META GENE, V16, P77, DOI 10.1016/j.mgene.2018.01.008; BONDESON ML, 1995, EUR J HUM GENET, V3, P219; BONDESON ML, 1995, HUM MOL GENET, V4, P615, DOI 10.1093/hmg/4.4.615; Bravo H, 2017, MOL GENET METAB REP, V12, P92, DOI 10.1016/j.ymgmr.2017.06.006; Breen Catherine, 2016, Hum Genome Var, V3, P16031; Brusius-Facchin AC, 2014, MOL GENET METAB, V111, P133, DOI 10.1016/j.ymgme.2013.08.011; Brusius-Facchin AC, 2013, GENE, V526, P150, DOI 10.1016/j.gene.2013.05.007; Brusius-Facchin AC, 2012, AM J MED GENET A, V158A, P1055, DOI 10.1002/ajmg.a.35271; Caciotti A, 2015, HUM MUTAT, V36, P357, DOI 10.1002/humu.22751; Canals I, 2011, CLIN GENET, V80, P367, DOI 10.1111/j.1399-0004.2010.01525.x; Catarzi S, 2012, MOL GENET METAB, V105, P438, DOI 10.1016/j.ymgme.2011.11.196; Champion KJ, 2010, MOL GENET METAB, V100, P51, DOI 10.1016/j.ymgme.2010.01.004; Chiong MAD, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-016-0558-0; Claes KBM, 2014, METHODS MOL BIOL, V1167, P303, DOI 10.1007/978-1-4939-0835-6_21; Clarke LA, 2017, J PEDIATR-US, V182, P363, DOI 10.1016/j.jpeds.2016.11.036; Clarke Lorne A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000550; Costa-Motta FM, 2011, MOL GENET METAB, V104, P603, DOI 10.1016/j.ymgme.2011.09.017; Coutinho MF, 2008, CLIN GENET, V74, P194, DOI 10.1111/j.1399-0004.2008.01040.x; de Ru MH, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-55; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Di Fruscio G, 2015, AUTOPHAGY, V11, P928, DOI 10.1080/15548627.2015.1043077; Di Natale P, 1998, HUM MUTAT, V11, P313, DOI 10.1002/(SICI)1098-1004(1998)11:4<313::AID-HUMU9>3.3.CO;2-G; Di Natale P, 2003, CLIN GENET, V63, P314, DOI 10.1034/j.1399-0004.2003.00053.x; Dursun A, 2017, CLIN DYSMORPHOL, V26, P1, DOI 10.1097/MCD.0000000000000149; Eldering E, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng153; Fedele Anthony Olind, 2007, Hum Mutat, V28, P523, DOI 10.1002/humu.9488; Feldhammer M, 2009, HUM MUTAT, V30, P918, DOI 10.1002/humu.20986; Fernandez-Marmiesse A, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-59; Filocamo Mirella, 2011, Human Genomics, V5, P156; Gaber KR, 2015, EGYPT J MED HUM GENE, V16, P159; Gabrielli O, 2005, AM J MED GENET A, V133A, P85, DOI 10.1002/ajmg.a.30552; Gallegos-Arreola MP, 2000, ARCH MED RES, V31, P505, DOI 10.1016/S0188-4409(00)00104-1; Galvis J, 2015, JIMD REP, V19, P101, DOI 10.1007/8904_2014_376; Ghosh A, 2016, MOL GENET METAB, V117, P373, DOI 10.1016/j.ymgme.2016.01.011; Giugliani R, 2017, GENET MOL BIOL, V40, P31, DOI [10.1590/1678-4685-GMB-2016-0268, 10.1590/1678-4685-gmb-2016-0268]; Grada A, 2013, J INVEST DERMATOL, V133, pE1, DOI 10.1038/jid.2013.248; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hein LK, 2004, J MOL BIOL, V338, P453, DOI 10.1016/j.jmb.2004.03.012; Hu J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077940; Navarrete-Martinez JI, 2017, MOL GENET METAB, V121, P16, DOI 10.1016/j.ymgme.2017.03.001; Ittiwut C, 2017, GENET TEST MOL BIOMA, V21, P58, DOI 10.1089/gtmb.2016.0221; Jurecka A, 2012, MOL GENET METAB, V105, P237, DOI 10.1016/j.ymgme.2011.11.003; Jurecka A, 2012, AM J MED GENET A, V158A, P450, DOI 10.1002/ajmg.a.34415; Kamei M, 2014, JIMD REP, V13, P139, DOI 10.1007/8904_2013_270; Karageorgos L, 2007, HUM MUTAT, V28, P897, DOI 10.1002/humu.20534; Kato Z, 1997, HUM GENET, V101, P97, DOI 10.1007/s004390050594; Kingma SDK, 2015, BEST PRACT RES CL EN, V29, P145, DOI 10.1016/j.beem.2014.08.004; Kondo H, 2017, HUM MOL GENET, V26, P173, DOI 10.1093/hmg/ddw377; Lehman TJA, 2011, RHEUMATOLOGY, V50, pV41, DOI 10.1093/rheumatology/ker390; Leistner-Segal S, 2014, CLIN BIOMED RES, V34; Lualdi S, 2006, BBA-MOL BASIS DIS, V1762, P478, DOI 10.1016/j.bbadis.2006.01.003; Lualdi S, 2005, HUM MUTAT, V25, P491, DOI 10.1002/humu.20165; Mangas M, 2008, CLIN GENET, V73, P251, DOI 10.1111/j.1399-0004.2007.00951.x; Marloes M, 2010, NAT PUBL GR, V7, P3133; Meikle PJ, 1999, JAMA-J AM MED ASSOC, V281, P249, DOI 10.1001/jama.281.3.249; Miyazaki T, 2002, J NEUROL NEUROSUR PS, V73, P777, DOI 10.1136/jnnp.73.6.777; Muenzer J, 2004, J PEDIATR-US, V144, pS27, DOI 10.1016/j.jpeds.2004.01.052; Muenzer J, 2014, MOL GENET METAB, V111, P63, DOI 10.1016/j.ymgme.2013.11.015; Neufeld EF, 2014, ONLINE METABOLIC MOL; Nikkel SM, 2014, CLIN GENET, V86, P172, DOI 10.1111/cge.12236; Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127; Ouesleti S, 2017, WORLD J PEDIATR, V13, P374, DOI 10.1007/s12519-017-0005-x; Paschke E, 2001, HUM GENET, V109, P159, DOI 10.1007/s004390100570; Pasqualim G, 2015, CLIN GENET, V88, P376, DOI 10.1111/cge.12507; Pena-Gomar IM, 2016, MOL GENET METAB, V117, pS92, DOI 10.1016/j.ymgme.2015.12.397; Pinto R, 2004, EUR J HUM GENET, V12, P87, DOI 10.1038/sj.ejhg.5201044; PIRAUD M, 1993, CLIN CHIM ACTA, V221, P171, DOI 10.1016/0009-8981(93)90031-X; Poe MD, 2014, ANN NEUROL, V76, P747, DOI 10.1002/ana.24246; Poorthuis BJ, HUM GENET, V105, P151; Poupetova H, 2010, J INHERIT METAB DIS, V33, P387, DOI 10.1007/s10545-010-9093-7; Rehm HL, 2013, NAT REV GENET, V14, P295, DOI 10.1038/nrg3463; Richards CS, 2008, GENET MED, V10, P294, DOI 10.1097/GIM.0b013e31816b5cae; Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003; Ruijter GJG, 2008, MOL GENET METAB, V93, P104, DOI 10.1016/j.ymgme.2007.09.011; Saito S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163964; Saito S, 2012, J HUM GENET, V57, P280, DOI 10.1038/jhg.2012.6; Sandberg S, 2008, MOL GENET METAB, V93, pS34, DOI 10.1016/j.ymgme.2007.10.091; Santos S, 2014, CIENC SAUDE COLETIVA, V19, P559, DOI 10.1590/1413-81232014192.00182013; Scarpa M, 1993, MUCOPOLYSACCHARIDOSI; Schielen PCJI, 2017, INT J NEONATAL SCREE, V3, P2; Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056; Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890; Scott Hamish S., 1992, Human Mutation, V1, P103, DOI 10.1002/humu.1380010204; Selmer KK, 2012, EUR J HUM GENET, V20, P58, DOI 10.1038/ejhg.2011.126; Sim NL, 2012, NUCLEIC ACIDS RES, V40, pW452, DOI 10.1093/nar/gks539; Tajima G, 2013, MOL GENET METAB, V108, P172, DOI 10.1016/j.ymgme.2012.12.010; Tayeh MK, 2009, GENET MED, V11, P232, DOI 10.1097/GIM.0b013e318195e191; Timms KM, 2018, 30 KB DNA SEQUENE RE; TOMATSU S, 1995, AM J HUM GENET, V57, P556; Valayannopoulos V, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-5; Valencia CA, 2012, J MOL DIAGN, V14, P233, DOI 10.1016/j.jmoldx.2012.01.009; VERVOORT R, 1995, AM J HUM GENET, V57, P798; Vieira T, 2008, AM J MED GENET A, V146A, P1741, DOI 10.1002/ajmg.a.32320; Vijay S, 2005, ACTA PAEDIATR, V94, P872, DOI 10.1080/08035250510031584; Vrijenhoek T, 2015, EUR J HUM GENET, V23, P1142, DOI 10.1038/ejhg.2014.279; Wang J, 2012, MOL GENET METAB, V106, P221, DOI 10.1016/j.ymgme.2012.03.005; Wei XM, 2011, CLIN CHIM ACTA, V412, P2340, DOI 10.1016/j.cca.2011.08.031; Weller M, 2012, AM J HUM BIOL, V24, P835, DOI 10.1002/ajhb.22328; Wijburg FA, 2013, ACTA PAEDIATR, V102, P462, DOI 10.1111/apa.12169; Wilcox WR, 2004, J PEDIATR-US, V144, pS3, DOI 10.1016/j.jpeds.2004.01.049; Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721; Wraith JE, 2007, PEDIATRICS, V120, pE37, DOI 10.1542/peds.2006-2156; Yamada N, 1998, HUM MUTAT, V11, P202, DOI 10.1002/(SICI)1098-1004(1998)11:3<202::AID-HUMU4>3.3.CO;2-0; Zanetti A, 2014, JIMD REP, V17, P13, DOI 10.1007/8904_2014_317; Zeng QW, 2017, J PEDIATR ENDOCR MET, V30, P463, DOI 10.1515/jpem-2016-0333; Zhang HN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022874	118	0	1	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					855	866		10.1080/14737159.2018.1523722			12	Pathology	Pathology	GV6IZ	WOS:000446213900004	30222014				2019-10-28	
J	Zhang, H; Zeng, Z; Mukherjee, A; Shen, B				Zhang, Hu; Zeng, Zhen; Mukherjee, Arjudeb; Shen, Bo			Molecular diagnosis and classification of inflammatory bowel disease	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Ulcerative colitis; crohn's disease; marker; molecular diagnosis; differential diagnosis; disease activity; clinical phenotype; response to therapy	GENOME-WIDE ASSOCIATION; C-REACTIVE PROTEIN; ANTI-GLYCAN ANTIBODIES; ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES; SACCHAROMYCES-CEREVISIAE ANTIBODIES; STIMULATING FACTOR AUTOANTIBODIES; ERYTHROCYTE SEDIMENTATION-RATE; ACTIVE ULCERATIVE-COLITIS; POUCH-ANAL ANASTOMOSIS; B-ASSOCIATED LIPOCALIN	Introduction: Traditional diagnosis and classification of inflammatory bowel diseases (IBDs) have been based on clinical evaluation, laboratory testing, endoscopy, imaging, and histological examinations. With the advancement of medical technology, an increasing number of molecular surrogates are playing a key role in diagnosis, differential diagnosis, assessment of disease activity, prediction of clinical course, and therapeutic response of IBD. Areas covered: The authors review roles of both existing and emerging surrogates including genetic, serological, histologic, and fecal markers in diagnosis and classification of IBD. Comparisons in advantages and disadvantages of different markers have also been discussed. In addition, this review underscores controversial and unclear aspects which need further study. Expert commentary: IBD is characteristic of chronicity, relapse-remission and destructiveness. It is of great importance for clinicians to make an accurate diagnosis and classification. Current and new molecular markers perform well with acceptable sensitivity and specificity. The use of molecular markers in clinical practice needs to be further explored and then generalized. More work is warranted to identify novel useful markers and elucidate how to apply them together with current markers in clinical settings.	[Zhang, Hu; Zeng, Zhen] Sichuan Univ, West China Hosp, Ctr Inflammatory Bowel Dis, Chengdu, Sichuan, Peoples R China; [Zhang, Hu; Zeng, Zhen] Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Sichuan, Peoples R China; [Mukherjee, Arjudeb] Sichuan Univ, West China Sch Med, Chengdu, Sichuan, Peoples R China; [Shen, Bo] Cleveland Clin Fdn, Digest Dis & Surg Inst, Ctr Inflammatory Bowel Dis, 9500 Euclid Ave, Cleveland, OH 44195 USA	Zhang, H (reprint author), Sichuan Univ, West China Hosp, Ctr Inflammatory Bowel Dis, Chengdu, Sichuan, Peoples R China.; Zhang, H (reprint author), Sichuan Univ, West China Hosp, Dept Gastroenterol, Chengdu, Sichuan, Peoples R China.; Shen, B (reprint author), Cleveland Clin Fdn, Digest Dis & Surg Inst, Ctr Inflammatory Bowel Dis, 9500 Euclid Ave, Cleveland, OH 44195 USA.	zhanghu@scu.edu.cn; shenb@ccf.org			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81570502]	The work was supported by National Natural Science Foundation of China [No. 81570502].	Adler J, 2011, AM J GASTROENTEROL, V106, P699, DOI 10.1038/ajg.2011.19; Ahmad T, 2002, GASTROENTEROLOGY, V122, P854, DOI 10.1053/gast.2002.32413; Allen PB, 2017, THER ADV GASTROENTER, V10, P865, DOI 10.1177/1756283X17732720; ANDUS T, 1993, DIGEST DIS SCI, V38, P1638, DOI 10.1007/BF01303172; Annahazi A, 2013, INFLAMM BOWEL DIS, V19, P316, DOI 10.1002/ibd.22996; Ardesia M, 2015, BIOMED RES INT, V2015, P1; Arijs I, 2009, GUT, V58, P1612, DOI 10.1136/gut.2009.178665; Arsenescu R, 2008, MUCOSAL IMMUNOL, V1, P399, DOI 10.1038/mi.2008.32; Atreya R, 2014, NAT MED, V20, P313, DOI 10.1038/nm.3462; Atreya R, 2011, GASTROENTEROLOGY, V141, P2026, DOI 10.1053/j.gastro.2011.08.032; Baldassano RN, 2007, CLIN GASTROENTEROL H, V5, P972, DOI 10.1016/j.cgh.2007.04.024; Bank S, 2014, PHARMACOGENOMICS J, V14, P526, DOI 10.1038/tpj.2014.19; Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175; Beaudoin M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003723; BERLIN R, 1973, ACTA MED SCAND, V194, P371; Bian Z, 2011, J PATHOL, V225, P544, DOI 10.1002/path.2907; Bogdanos DP, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-102; Bonneau J, 2015, AUTOIMMUN REV, V14, P231, DOI 10.1016/j.autrev.2014.11.004; Boon GJAM, 2015, WORLD J GASTROENTERO, V21, P11469, DOI 10.3748/wjg.v21.i40.11469; Boschetti G, 2015, INFLAMM BOWEL DIS, V21, P331, DOI 10.1097/MIB.0000000000000273; Bruno MEC, 2015, DIGEST DIS SCI, V60, P2976, DOI 10.1007/s10620-015-3700-2; Buderus S, 2004, DIGEST DIS SCI, V49, P1036, DOI 10.1023/B:DDAS.0000034568.69407.47; Buning C, 2007, ALIMENT PHARM THERAP, V26, P1025, DOI 10.1111/j.1365-2036.2007.03446.x; Chung-Faye G, 2007, INFLAMM BOWEL DIS, V13, P1374, DOI 10.1002/ibd.20214; Chung-Faye G, 2011, GASTROENTEROLOGY, V140, pS421; Cleynen I, 2016, LANCET, V387, P156, DOI 10.1016/S0140-6736(15)00465-1; Cleynen I, 2013, GUT, V62, P1556, DOI 10.1136/gutjnl-2011-300777; Cornillie F, 2014, GUT, V63, P1721, DOI 10.1136/gutjnl-2012-304094; Coskun M, 2013, WORLD J GASTROENTERO, V19, P4289, DOI 10.3748/wjg.v19.i27.4289; Coukos JA, 2012, DIGEST DIS SCI, V57, P1544, DOI 10.1007/s10620-012-2050-6; Cuthbert AP, 2002, GASTROENTEROLOGY, V122, P867, DOI 10.1053/gast.2002.32415; Dabritz J, 2013, AM J GASTROENTEROL, V108, P1901, DOI 10.1038/ajg.2013.360; Day AS, 2013, DIS MARKERS, DOI 10.1155/2013/873582; de Bruyn M, 2015, J CROHNS COLITIS, V9, P1079, DOI 10.1093/ecco-jcc/jjv148; de Bruyn M, 2014, INFLAMM BOWEL DIS, V20, P1198, DOI 10.1097/MIB.0000000000000068; de Lange KM, 2017, NAT GENET, V49, P256, DOI 10.1038/ng.3760; Dendrou CA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1974; Dotan I, 2006, GASTROENTEROLOGY, V131, P366, DOI 10.1053/j.gastro.2006.04.030; Dotan N, 2006, LUPUS, V15, P442, DOI 10.1191/0961203306lu2331oa; Dubinsky M, 2015, GASTROENTEROLOGY, V149, P1265, DOI 10.1053/j.gastro.2015.08.006; Dubinsky MC, 2010, INFLAMM BOWEL DIS, V16, P1357, DOI 10.1002/ibd.21174; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; El-Matary W, 2011, DIGEST DIS SCI, V56, P825, DOI 10.1007/s10620-010-1380-5; Ellinghaus D, 2013, GASTROENTEROLOGY, V145, P339, DOI 10.1053/j.gastro.2013.04.040; FAGAN EA, 1982, EUR J CLIN INVEST, V12, P351, DOI 10.1111/j.1365-2362.1982.tb02244.x; Farmer M, 2000, AM J GASTROENTEROL, V95, P3184; Fasseu M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013160; Ferrante M, 2007, GUT, V56, P1394, DOI 10.1136/gut.2006.108043; Fisher SA, 2008, NAT GENET, V40, P710, DOI 10.1038/ng.145; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Fu Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02835-5; Gazouli Maria, 2013, J Crohns Colitis, V7, pe461, DOI 10.1016/j.crohns.2013.02.021; Gevers D, 2014, CELL HOST MICROBE, V15, P382, DOI 10.1016/j.chom.2014.02.005; Glas J, 2008, AM J GASTROENTEROL, V103, P682, DOI 10.1111/j.1572-0241.2007.01694.x; Ham M, 2014, INFLAMM BOWEL DIS, V20, P856, DOI 10.1097/MIB.0000000000000016; Hamilton AL, 2017, J GASTROEN HEPATOL, V32, P1195, DOI 10.1111/jgh.13677; Hampe J, 2002, LANCET, V359, P1661, DOI 10.1016/S0140-6736(02)08590-2; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Han XN, 2009, GASTROENTEROLOGY, V136, P1261, DOI 10.1053/j.gastro.2008.12.046; HARRIES AD, 1985, GUT, V26, P1197, DOI 10.1136/gut.26.11.1197; He C, 2017, GASTROENTEROLOGY, V152, P1434, DOI 10.1053/j.gastro.2017.01.049; HEISTO H, 1969, SCAND J HAEMATOL, V6, P427; Henckaerts L, 2011, INFLAMM BOWEL DIS, V17, P1392, DOI 10.1002/ibd.21486; Hisabe T, 2003, J GASTROENTEROL, V38, P121, DOI 10.1007/s005350300020; Hlavaty T, 2007, INFLAMM BOWEL DIS, V13, P372, DOI 10.1002/ibd.20024; Ho GT, 2009, AM J GASTROENTEROL, V104, P673, DOI 10.1038/ajg.2008.119; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Hui T, 2005, DIS COLON RECTUM, V48, P1254, DOI 10.1007/s10350-005-0013-0; Iborra M, 2013, CLIN EXP IMMUNOL, V173, P250, DOI 10.1111/cei.12104; Johnson MW, 2008, EUR J GASTROEN HEPAT, V20, P174, DOI 10.1097/MEG.0b013e3282f1c9a7; Joossens S, 2006, GUT, V55, P1667, DOI 10.1136/gut.2005.089623; Jurgens M, 2010, AM J GASTROENTEROL, V105, P1811, DOI 10.1038/ajg.2010.95; Kaiser T, 2007, GUT, V56, P1706, DOI 10.1136/gut.2006.113431; Kakuta Y, 2006, GUT, V55, P1527, DOI 10.1136/gut.2006.100297; Kalla R, 2016, AM J GASTROENTEROL, V111, P1796, DOI 10.1038/ajg.2016.342; Kane SV, 2003, AM J GASTROENTEROL, V98, P1309, DOI 10.1016/S0002-9270(03)00232-6; Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kini GP, 2014, NEW ZEAL MED J, V127, P51; Koder S, 2015, PHARMACOGENOMICS, V16, P191, DOI 10.2217/pgs.14.172; Kolho KL, 2015, AM J GASTROENTEROL, V110, P921, DOI 10.1038/ajg.2015.149; Koutroubakis IE, 2001, AM J GASTROENTEROL, V96, P449; Lacruz-Guzman D, 2013, EUR J CLIN PHARMACOL, V69, P431, DOI 10.1007/s00228-012-1389-0; Landers CJ, 2002, GASTROENTEROLOGY, V123, P689, DOI 10.1053/gast.2002.35379; Langhorst J, 2008, AM J GASTROENTEROL, V103, P162, DOI 10.1111/j.1572-0241.2007.01556.x; Langhorst J, 2016, J CROHNS COLITIS, V10, P786, DOI 10.1093/ecco-jcc/jjw044; Lawrance IC, 2004, AM J GASTROENTEROL, V99, P2186, DOI 10.1111/j.1572-0241.2004.40486.x; Lee KM, 2013, J GASTROEN HEPATOL, V28, P1829, DOI 10.1111/jgh.12324; Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lewis JD, 2011, GASTROENTEROLOGY, V140, P1817, DOI 10.1053/j.gastro.2010.11.058; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359; Lopez RN, 2017, J GASTROEN HEPATOL, V32, P577, DOI 10.1111/jgh.13611; Lu XC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080602; Luo Y, 2017, NAT GENET, V49, P186, DOI 10.1038/ng.3761; MAIN J, 1988, BRIT MED J, V297, P1105, DOI 10.1136/bmj.297.6656.1105; MASSON PL, 1969, J EXP MED, V130, P643, DOI 10.1084/jem.130.3.643; Mathew CG, 2004, HUM MOL GENET, V13, pR161, DOI 10.1093/hmg/ddh079; Matsukura H, 2008, ALIMENT PHARM THERAP, V27, P765, DOI 10.1111/j.1365-2036.2008.03630.x; MAZLAM MZ, 1992, GUT, V33, P773, DOI 10.1136/gut.33.6.773; Mei L, 2006, GASTROENTEROLOGY, V130, P1078, DOI 10.1053/j.gastro.2006.02.013; Melmed GY, 2008, DIS COLON RECTUM, V51, P100, DOI 10.1007/s10350-007-9158-3; Menees SB, 2015, AM J GASTROENTEROL, V110, P444, DOI 10.1038/ajg.2015.6; Meuwis M-A, 2013, J Crohns Colitis, V7, pe678, DOI 10.1016/j.crohns.2013.06.008; Meuwis MA, 2008, CLIN BIOCHEM, V41, P960, DOI 10.1016/j.clinbiochem.2008.04.021; Meuwis MA, 2007, BIOCHEM PHARMACOL, V73, P1422, DOI 10.1016/j.bcp.2006.12.019; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mitsuyama K, 2016, WORLD J GASTROENTERO, V22, P1304, DOI 10.3748/wjg.v22.i3.1304; Mooiweer E, 2015, J CROHNS COLITIS, V9, P50, DOI 10.1093/ecco-jcc/jju003; Morgan XC, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r79; Mosli MH, 2015, AM J GASTROENTEROL, V110, P802, DOI 10.1038/ajg.2015.120; Mow WS, 2004, GASTROENTEROLOGY, V126, P414, DOI 10.1053/j.gastro.2003.11.015; Naser SA, 2012, WORLD J GASTROENTERO, V18, P412, DOI 10.3748/wjg.v18.i5.412; Newman B, 2004, AM J GASTROENTEROL, V99, P306, DOI 10.1111/j.1572-0241.2004.04038.x; Ng WK, 2016, INTEST RES, V14, P111, DOI 10.5217/ir.2016.14.2.111; Oikonomou KA, 2012, J GASTROENTEROL, V47, P519, DOI 10.1007/s00535-011-0516-5; Oussalah A, 2010, AM J GASTROENTEROL, V105, P2617, DOI 10.1038/ajg.2010.345; Paul S, 2015, J CROHNS COLITIS, V9, P445, DOI 10.1093/ecco-jcc/jjv063; Peck BCE, 2015, INFLAMM BOWEL DIS, V21, P2178, DOI 10.1097/MIB.0000000000000478; Peng TJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178008; Plevy S, 2013, INFLAMM BOWEL DIS, V19, P1139, DOI 10.1097/MIB.0b013e318280b19e; Prideaux L, 2012, INFLAMM BOWEL DIS, V18, P1340, DOI 10.1002/ibd.21903; Quinton JF, 1998, GUT, V42, P788, DOI 10.1136/gut.42.6.788; Reese GE, 2006, AM J GASTROENTEROL, V101, P2410, DOI 10.1111/j.1572-0241.2006.00840.x; Reinisch W, 2012, ALIMENT PHARM THER, V35, P568, DOI 10.1111/j.1365-2036.2011.04987.x; Ricanek P, 2011, SCAND J GASTROENTERO, V46, P1081, DOI 10.3109/00365521.2011.584897; Rismo R, 2012, SCAND J GASTROENTERO, V47, P538, DOI 10.3109/00365521.2012.667146; Rivas MA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12869; Roggenbuck D, 2011, CLIN CHIM ACTA, V412, P718, DOI 10.1016/j.cca.2010.12.029; Roseth AG, 1997, DIGESTION, V58, P176, DOI 10.1159/000201441; ROSETH AG, 1992, SCAND J GASTROENTERO, V27, P793, DOI 10.3109/00365529209011186; Roseth AG, 2004, SCAND J GASTROENTERO, V39, P1017, DOI 10.1080/00365520410007971; Ruemmele FM, 1998, GASTROENTEROLOGY, V115, P822, DOI 10.1016/S0016-5085(98)70252-5; RUMP JA, 1990, IMMUNOBIOLOGY, V181, P406, DOI 10.1016/S0171-2985(11)80509-7; Sadeghian M, 2016, NUTRITION, V32, P505, DOI 10.1016/j.nut.2015.11.008; Sasaki MM, 2016, INFLAMM BOWEL DIS, V22, P20, DOI 10.1097/MIB.0000000000000610; Satsangi J, 2006, GUT, V55, P749, DOI 10.1136/gut.2005.082909; Schaefer JS, 2015, BMC IMMUNOL, V16, DOI 10.1186/s12865-015-0069-0; Schmidt C, 2007, INFLAMM BOWEL DIS, V13, P65, DOI 10.1002/ibd.20012; Schoepfer AM, 2010, AM J GASTROENTEROL, V105, P162, DOI 10.1038/ajg.2009.545; Schoepfer AM, 2009, INFLAMM BOWEL DIS, V15, P1358, DOI 10.1002/ibd.20892; Selvaggi F, 2014, INFLAMM BOWEL DIS, V20, P1296, DOI 10.1097/MIB.0000000000000026; Sennikov SV, 2002, J GASTROENTEROL, V37, P1048, DOI 10.1007/s005350200176; Seow CH, 2009, AM J GASTROENTEROL, V104, P1426, DOI 10.1038/ajg.2009.79; Sidhu R, 2010, ALIMENT PHARM THER, V31, P1365, DOI 10.1111/j.1365-2036.2010.04306.x; Sidler MA, 2008, INFLAMM BOWEL DIS, V14, P359, DOI 10.1002/ibd.20336; Siegel CA, 2016, ALIMENT PHARM THER, V43, P262, DOI 10.1111/apt.13460; Silberer H, 2005, CLIN LAB, V51, P117; Singh S, 2013, ALIMENT PHARM THER, V37, P867, DOI 10.1111/apt.12274; Sipponen T, 2008, ALIMENT PHARM THER, V28, P1221, DOI 10.1111/j.1365-2036.2008.03835.x; Sipponen T, 2008, INFLAMM BOWEL DIS, V14, P1392, DOI 10.1002/ibd.20490; Sipponen T, 2008, INFLAMM BOWEL DIS, V14, P40, DOI 10.1002/ibd.20312; Smids C, 2017, SCAND J GASTROENTERO, V52, P1104, DOI 10.1080/00365521.2017.1344875; Somma V, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/683824; Sugi K, 1996, AM J GASTROENTEROL, V91, P927; Takagi T, 2010, J GASTROEN HEPATOL, V25, pS129, DOI 10.1111/j.1440-1746.2009.06216.x; Takashima S, 2015, AM J GASTROENTEROL, V110, P873, DOI 10.1038/ajg.2015.66; Targan SR, 2005, GASTROENTEROLOGY, V128, P2020, DOI 10.1053/j.gastro.2005.03.046; Taylor KD, 2001, GASTROENTEROLOGY, V120, P1347, DOI 10.1053/gast.2001.23966; Thia KT, 2010, GASTROENTEROLOGY, V139, P1147, DOI 10.1053/j.gastro.2010.06.070; Thorsvik S, 2017, J GASTROEN HEPATOL, V32, P128, DOI 10.1111/jgh.13598; Tibble J, 2000, GUT, V47, P506, DOI 10.1136/gut.47.4.506; TOMCSIK J, 1965, PATHOL MICROBIOL, V28, P38, DOI 10.1159/000161609; Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608; Turner D, 2010, GUT, V59, P1207, DOI 10.1136/gut.2010.211755; Tyler AD, 2013, GUT, V62, P1433, DOI 10.1136/gutjnl-2011-301957; Ulitsky A, 2011, JPEN-PARENTER ENTER, V35, P308, DOI 10.1177/0148607110381267; van Rheenen PF, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3369; van Schaik FDM, 2013, GUT, V62, P683, DOI 10.1136/gutjnl-2012-302717; Vasiliauskas EA, 1996, GASTROENTEROLOGY, V110, P1810, DOI 10.1053/gast.1996.v110.pm8964407; Vermeire S, 2002, GASTROENTEROLOGY, V123, P106, DOI 10.1053/gast.2002.34172; Viennois E, 2015, INFLAMM BOWEL DIS, V21, P2467, DOI 10.1097/MIB.0000000000000444; von Roon AC, 2007, AM J GASTROENTEROL, V102, P803, DOI 10.1111/j.1572-0241.2007.01126.x; Wang Y, 2015, INT J CLIN EXP PATHO, V8, P12319; Wang YZ, 2018, J CROHNS COLITIS, V12, P337, DOI 10.1093/ecco-jcc/jjx153; Weissman SM, 2018, PRECISION CLIN MED, V1, P1, DOI DOI 10.1093/pcmedi/pby001; Wu F, 2008, GASTROENTEROLOGY, V135, P1624, DOI 10.1053/j.gastro.2008.07.068; Wu F, 2011, INFLAMM BOWEL DIS, V17, P241, DOI 10.1002/ibd.21450; Yamamoto-Furusho JK, 2010, COLORECTAL DIS, V12, P1231, DOI 10.1111/j.1463-1318.2009.02025.x; Yamamoto-Furusho JK, 2003, HUM IMMUNOL, V64, P119, DOI 10.1016/S0198-8859(02)00772-3; Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379; Yamazaki K, 2007, J HUM GENET, V52, P575, DOI 10.1007/s10038-007-0156-z; Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193; Yau YY, 2017, MOL CELL PROTEOMICS, V16, P1244, DOI 10.1074/mcp.M116.066506; Zampeli Evanthia, 2014, World J Gastrointest Pathophysiol, V5, P293, DOI 10.4291/wjgp.v5.i3.293; Zhao Xiao-dan, 2011, Zhonghua Nei Ke Za Zhi, V50, P935; Zholudev A, 2004, AM J GASTROENTEROL, V99, P2235, DOI 10.1111/j.1572-0241.2004.40369.x; Zhou YL, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00188-17	190	1	1	1	7	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					867	886		10.1080/14737159.2018.1516549			20	Pathology	Pathology	GV6IZ	WOS:000446213900005	30152711				2019-10-28	
J	Timmerman, C; Taveras, LR; Huerta, S				Timmerman, Corey; Taveras, Luis R.; Huerta, Sergio			Clinical and molecular diagnosis of pathologic complete response in rectal cancer: an update	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Neoadjuvant chemotherapy; rectal cancer; clinical complete response; tumor regression grade; pathologic complete response	PREDICTING COMPLETE RESPONSE; COEFFICIENT HISTOGRAM ANALYSIS; R90-01 RANDOMIZED-TRIAL; TUMOR-REGRESSION GRADE; WAIT-AND-SEE; NEOADJUVANT CHEMORADIOTHERAPY; PREOPERATIVE CHEMORADIOTHERAPY; CHEMORADIATION THERAPY; LOCAL EXCISION; NONOPERATIVE MANAGEMENT	Introduction: The standard of care for locally advanced rectal cancer includes neoadjuvant chemoradiation with subsequent total mesorectal excision. This approach has shown various degrees of response to neoadjuvant chemoradiation (ranging from complete response to further tumor growth), which have substantial prognostic and therapeutic implications. A total regression of the tumor is a predictor of superior oncologic outcomes compared with partial responders and non-responders. Further, this concept has opened the possibility of nonoperative strategies for complete responders and explains the widespread research interest in finding clinical, radiographic, pathologic, and biochemical parameters that allow for identification of these patients. Areas covered: The present review evaluates the most recent efforts in the literature to identify predictors of patients likely to achieve a complete response following neoadjuvant treatment for the management of rectal cancer. This includes clinical predictors of pathologic complete response such as tumor location, size, and stage, molecular predictors such as tumor biology and microRNA, serum biomarkers such as carcinoembryogenic antigen and nomograms. Expert commentary: There has been significant progress in our ability to predict pathological complete response. However, more high-quality research is still needed to use this concept to confidently dictate clinical management.	[Timmerman, Corey; Taveras, Luis R.; Huerta, Sergio] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [Huerta, Sergio] VA North Texas Healthcare Syst, Dallas, TX USA	Huerta, S (reprint author), Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA.	Sergio.Huerta@UTSouthwestern.edu	; Huerta, Sergio/G-3699-2013	Taveras, Luis/0000-0002-5770-3773; Huerta, Sergio/0000-0001-7720-419X			Adell G, 1999, RADIOTHER ONCOL, V51, P169, DOI 10.1016/S0167-8140(99)00041-9; Agostini M, 2015, CANCER BIOL THER, V16, P1160, DOI 10.1080/15384047.2015.1046652; Al-Sukhni E, 2016, ANN SURG ONCOL, V23, P1177, DOI 10.1245/s10434-015-5017-y; Battersby NJ, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2085-2; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Bhoday J, 2016, DIS COLON RECTUM, V59, P925, DOI 10.1097/DCR.0000000000000667; Bitterman DS, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00286; Bonnen M, 2004, INT J RADIAT ONCOL, V60, P1098, DOI 10.1016/j.ijrobp.2004.04.062; Brettingham-Moore KH, 2011, CLIN CANCER RES, V17, P3039, DOI 10.1158/1078-0432.CCR-10-2915; Buijsen J, 2014, RADIOTHER ONCOL, V111, P237, DOI 10.1016/j.radonc.2014.03.006; Carpinetti P, 2015, ONCOTARGET, V6, P38360, DOI 10.18632/oncotarget.5256; Charara M, 2004, ANTICANCER RES, V24, P3161; Chen M-B, 2012, PLOS ONE, V7; Chen Y-G, 2016, PLOS ONE, V11; Chen ZB, 2011, J AM COLL SURGEONS, V212, P1008, DOI 10.1016/j.jamcollsurg.2011.02.024; Chidambaram V, 2017, ABDOM RADIOL, V42, P1310, DOI 10.1007/s00261-016-1010-6; Choi MH, 2016, J MAGN RESON IMAGING, V44, P212, DOI 10.1002/jmri.25117; Clancy C, 2013, SURG ONCOL, V22, P105, DOI 10.1016/j.suronc.2013.02.001; Clarke TL, 2017, ANN ROY COLL SURG, V99, P373, DOI 10.1308/rcsann.2017.0030; Conde-Muino R, 2015, BIOMED RES INT, DOI 10.1155/2015/921435; Cotte E, 2016, INT J RADIAT ONCOL, V94, P544, DOI 10.1016/j.ijrobp.2015.10.061; Cunningham HB, 2018, CURR COLORECT CANC R, V14, P31, DOI 10.1007/s11888-018-0400-2; Curvo-Semedo L, 2011, RADIOLOGY, V260, P734, DOI 10.1148/radiol.11102467; Dalton RSJ, 2012, COLORECTAL DIS, V14, P567, DOI 10.1111/j.1463-1318.2011.02752.x; De Felice F, 2017, EJSO-EUR J SURG ONC, V43, P1324, DOI 10.1016/j.ejso.2017.03.010; dos Anjos DA, 2016, DIS COLON RECTUM, V59, P805, DOI 10.1097/DCR.0000000000000655; Dou X, 2015, CANCER BIOMARK, V15, P181, DOI 10.3233/CBM-140452; Dou X, 2013, ASIAN PAC J CANCER P, V14, P3881, DOI 10.7314/APJCP.2013.14.6.3881; Flanagan L, 2015, RADIAT ONCOL, V10, DOI 10.1186/s13014-015-0437-1; Francesca D, 2016, ONCOTARGET, V7, P33374, DOI 10.18632/oncotarget.8133; Francois Y, 1999, J CLIN ONCOL, V17, P2396, DOI 10.1200/JCO.1999.17.8.2396; Ghadimi BM, 2005, J CLIN ONCOL, V23, P1826, DOI 10.1200/JCO.2005.00.406; Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI 10.1093/annonc/mdx224; Glynne-Jones R, 2013, CANCER RADIOTHER, V17, P675, DOI 10.1016/j.canrad.2013.06.043; Gollub MJ, 2017, EUR RADIOL, V27, P1605, DOI 10.1007/s00330-016-4493-1; Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32; Han YD, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001971; Hawkins AT, 2016, CURR TREAT OPTION ON, V17, DOI 10.1007/s11864-016-0398-0; Heo J, 2016, CANCER RES TREAT, V48, P232, DOI 10.4143/crt.2014.351; Hiotis SP, 2002, J AM COLL SURGEONS, V194, P131, DOI 10.1016/S1072-7515(01)01159-0; Hu-Lieskovan S, 2011, CLIN CANCER RES, V17, P5161, DOI 10.1158/1078-0432.CCR-10-2666; Huerta S, 2013, SURGERY, V154, P143, DOI 10.1016/j.surg.2013.03.012; Huerta S, 2010, DIGEST LIVER DIS, V42, P679, DOI 10.1016/j.dld.2010.02.003; Huerta S, 2009, EXPERT REV MOL DIAGN, V9, P469, DOI 10.1586/ERM.09.26; Hughes R, 2006, INT J COLORECTAL DIS, V21, P11, DOI 10.1007/s00384-005-0749-y; Huh JW, 2014, ANN SURG, V259, P508, DOI 10.1097/SLA.0b013e31829b3916; Huntington CR, 2016, ANN SURG ONCOL, V23, P877, DOI 10.1245/s10434-015-4927-z; Hur H, 2014, DIS COLON RECTUM, V57, P592, DOI 10.1097/DCR.0000000000000109; Intven M, 2015, J MAGN RESON IMAGING, V41, P1646, DOI 10.1002/jmri.24718; Janjan NA, 1999, INT J RADIAT ONCOL, V44, P1027, DOI 10.1016/S0360-3016(99)00099-1; Jwa E, 2014, BRIT J CANCER, V111, P249, DOI 10.1038/bjc.2014.256; Kim IJ, 2007, DIS COLON RECTUM, V50, P1342, DOI 10.1007/s10350-007-277-7; Kitayama J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-64; Kitayama J, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-47; Komuro Y, 2002, CANCER-AM CANCER SOC, V95, P1199, DOI 10.1002/cncr.10807; Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x; Kuremsky JG, 2009, INT J RADIAT ONCOL, V74, P673, DOI 10.1016/j.ijrobp.2009.03.003; Lambregts DMJ, 2011, ANN SURG ONCOL, V18, P2224, DOI 10.1245/s10434-011-1607-5; Lee SY, 2015, ONCOLOGY-BASEL, V89, P311, DOI 10.1159/000439279; Lefevre JH, 2016, J CLIN ONCOL, V34, P3773, DOI 10.1200/JCO.2016.67.6049; Li J, 2016, ONCOTARGET, V7, P44857, DOI 10.18632/oncotarget.8622; Li J, 2015, ONCOTARGET, V6, P42354, DOI 10.18632/oncotarget.6093; Li N, 2017, GASTROINTEST ENDOSC, V85, P669, DOI 10.1016/j.gie.2016.06.042; Lim SG, 2016, WORLD J SURG, V40, P3029, DOI 10.1007/s00268-016-3661-4; Lopes-Ramos C, 2015, CANCER GENET-NY, V208, P319, DOI 10.1016/j.cancergen.2015.03.010; Lopes-Ramos CM, 2014, BMC MED GENOMICS, V7, DOI 10.1186/s12920-014-0068-7; Lorimer PD, 2017, ANN SURG ONCOL, V24, P2095, DOI 10.1245/s10434-017-5873-8; Maas M, 2011, J CLIN ONCOL, V29, P4633, DOI 10.1200/JCO.2011.37.7176; MOHIUDDIN M, 1994, INT J RADIAT ONCOL, V30, P845, DOI 10.1016/0360-3016(94)90359-X; Molinari C, 2013, J CELL PHYSIOL, V228, P2343, DOI 10.1002/jcp.24405; Monson JRT, 2013, DIS COLON RECTUM, V56, P535, DOI 10.1097/DCR.0b013e31828cb66c; Garcia VM, 2011, COLORECTAL DIS, V13, P989, DOI 10.1111/j.1463-1318.2010.02386.x; Nagata T, 2011, ANTICANCER RES, V31, P495; Nam TK, 2010, ONCOL LETT, V1, P23, DOI 10.3892/ol_00000004; Nehls O, 1999, CANCER, V85, P2541, DOI 10.1002/(SICI)1097-0142(19990615)85:12<2541::AID-CNCR8>3.3.CO;2-O; Neuman HB, 2009, DIS COLON RECTUM, V52, P863, DOI 10.1007/DCR.0b013e31819eefba; Nie K, 2016, CLIN CANCER RES, V22, P5256, DOI 10.1158/1078-0432.CCR-15-2997; Onaitis MW, 2001, ANN SURG ONCOL, V8, P801, DOI 10.1007/s10434-001-0801-2; Panagiotopoulou IG, 2015, INT SURG, V100, P968, DOI 10.9738/INTSURG-D-14-00192.1; Patel PM, 2015, EXPERT REV MOL DIAGN, V15, P1505, DOI 10.1586/14737159.2015.1091728; Patel SV, 2016, J SURG ONCOL, V114, P637, DOI 10.1002/jso.24358; Peng JH, 2016, CLINICS, V71, P449, DOI 10.6061/clinics/2016(08)07; Perez RO, 2014, TECH COLOPROCTOL, V18, P699, DOI 10.1007/s10151-013-1113-9; Perez RO, 2009, DIS COLON RECTUM, V52, P1137, DOI 10.1007/DCR.0b013e31819ef76b; Pettit C, 2017, INT J ONCOL, V51, P393, DOI 10.3892/ijo.2017.4045; Probst CP, 2015, J AM COLL SURGEONS, V221, P430, DOI 10.1016/j.jamcollsurg.2015.04.010; Pucciarelli S, 2012, ANN SURG ONCOL, V19, P3089, DOI 10.1245/s10434-012-2272-z; Ramzan Z, 2014, WORLD J GASTRO ONCOL, V6, P194, DOI 10.4251/wjgo.v6.i7.194; Reerink O, 2004, ANTICANCER RES, V24, P1217; Restivo A, 2013, ANN SURG ONCOL, V20, P864, DOI 10.1245/s10434-012-2669-8; Rimkus C, 2008, CLIN GASTROENTEROL H, V6, P53, DOI 10.1016/j.cgh.2007.10.022; Russo Andrea L, 2014, J Gastrointest Cancer, V45, P34, DOI 10.1007/s12029-013-9546-y; Juliao GPS, 2017, SURG CLIN N AM, V97, P587, DOI 10.1016/j.suc.2017.01.008; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Scarpati GD, 2012, INT J RADIAT ONCOL, V83, P1113, DOI 10.1016/j.ijrobp.2011.09.030; Schell SR, 2002, J AM COLL SURGEONS, V194, P584, DOI 10.1016/S1072-7515(02)01128-6; Senetta R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123759; Shin JS, 2012, PATHOLOGY, V44, P209, DOI 10.1097/PAT.0b013e3283511cd5; Siddiqui Ali A, 2006, Int Semin Surg Oncol, V3, P36, DOI 10.1186/1477-7800-3-36; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Sloothaak DAM, 2013, BRIT J SURG, V100, P933, DOI 10.1002/bjs.9112; Smith FM, 2015, DIS COLON RECTUM, V58, P159, DOI 10.1097/DCR.0000000000000281; Smith RK, 2015, INT J COLORECTAL DIS, V30, P769, DOI 10.1007/s00384-015-2165-2; Someya M, 2006, CARCINOGENESIS, V27, P117, DOI 10.1093/carcin/bgi175; Sprenger T, 2013, CANCER-AM CANCER SOC, V119, P26, DOI 10.1002/cncr.27703; Sun W, 2013, COLORECTAL DIS, V15, pE231, DOI 10.1111/codi.12165; Sun YW, 2017, ONCOTARGET, V8, P67732, DOI 10.18632/oncotarget.18821; Sun Yanwu, 2014, Zhonghua Wei Chang Wai Ke Za Zhi, V17, P556; Taveras LR, 2018, CURR COLORECT CANC R, V14, P56, DOI 10.1007/s11888-018-0401-1; Tawfik B, 2016, ANTI-CANCER DRUG, V27, P879, DOI 10.1097/CAD.0000000000000411; van Stiphout RGPM, 2011, RADIOTHER ONCOL, V98, P126, DOI 10.1016/j.radonc.2010.12.002; Watanabe T, 2006, CANCER RES, V66, P3370, DOI 10.1158/0008-5472.CAN-05-3834; Wolthuis AM, 2012, ANN SURG ONCOL, V19, P2833, DOI 10.1245/s10434-012-2327-1; Xiao Yi, 2015, Zhonghua Wei Chang Wai Ke Za Zhi, V18, P474; Yang TJ, 2015, J GASTROINTEST ONCOL, V6, P241, DOI 10.3978/j.issn.2078-6891.2014.110; Yasuda Koji, 2012, J Gastrointest Cancer, V43, P236, DOI 10.1007/s12029-011-9268-y; Zeng WG, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0033-7; Zitt M, 2006, DIS COLON RECTUM, V49, P1484, DOI 10.1007/s10350-006-0673-4; Zorcolo L, 2012, ANN SURG ONCOL, V19, P2822, DOI 10.1245/s10434-011-2209-y	119	1	1	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					887	896		10.1080/14737159.2018.1514258			10	Pathology	Pathology	GV6IZ	WOS:000446213900006	30124091				2019-10-28	
J	Tinhofer, I; Staudte, S				Tinhofer, Ingeborg; Staudte, Stephanie			Circulating tumor cells as biomarkers in head and neck cancer: recent advances and future outlook	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Liquid biopsy; biomarker; personalized treatment; head neck cancer; circulating tumor cells	METASTATIC BREAST-CANCER; LOCALLY ADVANCED HEAD; PERIPHERAL-BLOOD; MOLECULAR CHARACTERIZATION; EPITHELIAL-CELLS; CARCINOMA; SURVIVAL; EXPRESSION; PROGRESSION; ENRICHMENT	Introduction: Assessment of circulating tumor cells (CTCs) in peripheral blood from solid cancer patients including head and neck squamous cell carcinoma (HNSCC) has proven useful for detection of subclinical disease that otherwise remains invisible for current staging techniques. Based on large cohort studies, diagnostic tests for enumeration of CTCs have been developed, which can be used for tumor staging, prognosis, treatment monitoring, and post-treatment surveillance. Areas covered: Here, we briefly summarize the history of CTC discovery. We review the current evidence of a diagnostic potential of CTCs in HNSCC. We present recent technical advancements in the tools for enrichment, detection, and molecular characterization of CTCs. We also discuss potential clinical applications of CTC detection for personalized treatment strategies. Expert commentary: Recent technical advances in the platforms for enrichment, detection, and comprehensive molecular characterization of CTC represent a great opportunity to improve our understanding in the biology of CTCs and will allow to expand the clinical utility of CTCs in HNSCC. Especially, HNSCC patients with recurrent/metastatic disease associated dismal prognosis and little improvement in treatment outcome over the past decade might benefit in the future from incorporation of CTC assays in clinical management.	[Tinhofer, Ingeborg; Staudte, Stephanie] Charite, Dept Radiooncol & Radiotherapy, Berlin, Germany; [Tinhofer, Ingeborg; Staudte, Stephanie] Free Univ Berlin, Berlin, Germany; [Tinhofer, Ingeborg; Staudte, Stephanie] Humboldt Univ, Berlin, Germany; [Tinhofer, Ingeborg; Staudte, Stephanie] Berlin Inst Hlth, Berlin, Germany; [Tinhofer, Ingeborg; Staudte, Stephanie] German Canc Res Ctr, Heidelberg, Germany; [Tinhofer, Ingeborg; Staudte, Stephanie] German Canc Consortium DKTK, Partner Site Berlin, Berlin, Germany	Tinhofer, I (reprint author), Charite Univ Med Berlin, Res Lab, Dept Radiooncol & Radiotherapy, Translat Radiat Oncol, Charitepl 1, D-10117 Berlin, Germany.	ingeborg.tinhofer@charite.de					Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Alix-Panabieres C, 2014, NAT REV CANCER, V14, P623, DOI 10.1038/nrc3820; Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378; Ang KK, 2002, CANCER RES, V62, P7350; Ashworth T. R., 1869, AUST MED J, V14, P146; ATIYAH RA, 1986, OTOLARYNG HEAD NECK, V94, P278, DOI 10.1177/019459988609400303; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Balasubramanian P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042048; Bauman JE, 2017, CANCER-AM CANCER SOC, V123, P1259, DOI 10.1002/cncr.30449; Bilkenroth U, 2001, INT J CANCER, V92, P577, DOI 10.1002/ijc.1217; Bozec A, 2013, EUR ARCH OTO-RHINO-L, V270, P2745, DOI 10.1007/s00405-013-2399-y; Braig F, 2016, ONCOTARGET, V7, P42988, DOI 10.18632/oncotarget.8943; Bredemeier M, 2017, CLIN CHEM, V63, P1585, DOI 10.1373/clinchem.2016.269605; Buglione M, 2012, EUR J CANCER, V48, P3019, DOI 10.1016/j.ejca.2012.05.007; BUTLER TP, 1975, CANCER RES, V35, P512; Campton DE, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1383-x; Cann GM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049144; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923; COLE WH, 1954, JAMA-J AM MED ASSOC, V155, P1549, DOI 10.1001/jama.1954.03690360001001; Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766; Danila DC, 2011, CANCER J, V17, P438, DOI 10.1097/PPO.0b013e31823e69ac; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; De Luca F, 2016, ONCOTARGET, V7, P26107, DOI 10.18632/oncotarget.8431; Deng G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-456; Dent BM, 2016, INT J CANCER, V138, P206, DOI 10.1002/ijc.29680; DRYE JC, 1962, ANN SURG, V155, P733, DOI 10.1097/00000658-196205000-00012; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; Gazzaniga P, 2014, INT J CANCER, V135, P1978, DOI 10.1002/ijc.28830; Gorges TM, 2016, CLIN CANCER RES, V22, P2197, DOI 10.1158/1078-0432.CCR-15-1416; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Govers T, 2018, J UROL; Grisanti S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103918; Grobe A, 2014, CLIN CANCER RES, V20, P425, DOI 10.1158/1078-0432.CCR-13-1101; Grunwald V, 2015, ANN ONCOL, V26, P561, DOI 10.1093/annonc/mdu571; He S, 2013, J LARYNGOL OTOL, V127, P788, DOI 10.1017/S0022215113001412; Hong X, 2018, P NATL ACAD SCI USA, V115, P2467, DOI 10.1073/pnas.1719264115; Hristozova T, 2011, ANN ONCOL, V22, P1878, DOI 10.1093/annonc/mdr130; Hristozova T, 2012, CYTOM PART A, V81A, P489, DOI 10.1002/cyto.a.22041; Hsieh JCH, 2015, HEAD NECK-J SCI SPEC, V37, P1448, DOI 10.1002/hed.23779; Ignatiadis M, 2015, CLIN CANCER RES, V21, P4786, DOI 10.1158/1078-0432.CCR-14-1190; Inhestern J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132901; Jatana KR, 2016, HEAD NECK-J SCI SPEC, V38, P1799, DOI 10.1002/hed.24519; Jatana KR, 2010, ARCH OTOLARYNGOL, V136, P1274, DOI 10.1001/archoto.2010.223; Kallergi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2149; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kulasinghe A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19117-9; Kulasinghe A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3316-3; Kulasinghe A, 2015, INT J CANCER, V136, P2515, DOI 10.1002/ijc.29108; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Li J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1200778; LONG L, 1960, ARCH SURG-CHICAGO, V80, P639; Lu NN, 2015, ACS APPL MATER INTER, V7, P8817, DOI 10.1021/acsami.5b01397; Michiels S, 2009, LANCET ONCOL, V10, P341, DOI 10.1016/S1470-2045(09)70023-3; Nichols AC, 2012, HEAD NECK-J SCI SPEC, V34, P1440, DOI 10.1002/hed.21941; Nicolazzo C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31726; Oliveira-Costa JP, 2015, ONCOTARGET, V6, P20902, DOI 10.18632/oncotarget.3939; Ozkumur E, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005616; Pajonk F, 2001, RADIOTHER ONCOL, V59, P213, DOI 10.1016/S0167-8140(00)00315-7; Partridge M, 2003, CLIN CANCER RES, V9, P5287; Pignon JP, 2009, RADIOTHER ONCOL, V92, P4, DOI 10.1016/j.radonc.2009.04.014; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Sequist LV, 2009, J THORAC ONCOL, V4, P281, DOI 10.1097/JTO.0b013e3181989565; Smerage JB, 2014, J CLIN ONCOL, V32, P3483, DOI 10.1200/JCO.2014.56.2561; Soulieres D, 2017, LANCET ONCOL, V18, P323, DOI 10.1016/S1470-2045(17)30064-5; Strati A, 2017, ANN ONCOL, V28, P1923, DOI 10.1093/annonc/mdx206; Talasaz AH, 2009, P NATL ACAD SCI USA, V106, P3970, DOI 10.1073/pnas.0813188106; TAYLOR FW, 1958, SURGERY, V44, P453; Thiele JA, 2017, ANNU REV PATHOL-MECH, V12, P419, DOI 10.1146/annurev-pathol-052016-100256; Tinhofer I, 2014, ANN ONCOL, V25, P2042, DOI 10.1093/annonc/mdu271; Tinhofer I, 2012, INT J RADIAT ONCOL, V83, pE685, DOI 10.1016/j.ijrobp.2012.02.009; Ulrich H, 2014, CYTOM PART A, V85, P201, DOI 10.1002/cyto.a.22441; Vilalta M, 2014, CELL REP, V8, P401, DOI 10.1016/j.celrep.2014.06.011; Wang ST, 2011, ANGEW CHEM INT EDIT, V50, P3084, DOI 10.1002/anie.201005853; Wang ZD, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0579-x	76	1	1	2	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					897	906		10.1080/14737159.2018.1522251			10	Pathology	Pathology	GV6IZ	WOS:000446213900007	30199647				2019-10-28	
J	Hehir-Kwa, JY; Tops, BBJ; Kemmeren, P				Hehir-Kwa, Jayne Y.; Tops, Bastiaan B. J.; Kemmeren, Patrick			The clinical implementation of copy number detection in the age of next-generation sequencing	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Structural variation; long read; somatic; copy number variation; detection	STRUCTURAL VARIATION ANALYSIS; SINGLE-MOLECULE; WHOLE-GENOME; CANCER GENOME; NEURODEVELOPMENTAL DISEASE; COMPUTATIONAL METHODS; CONGENITAL-ANOMALIES; VARIATION DISCOVERY; COLORECTAL CANCERS; NANOCHANNEL ARRAYS	Introduction: The role of copy number variants (CNVs) in disease is now well established. In parallel NGS technologies, such as long-read technologies, there is continual development and data analysis methods continue to be refined. Clinical exome sequencing data is now a reality for many diagnostic laboratories in both congenital genetics and oncology. This provides the ability to detect and report both SNVs and structural variants, including CNVs, using a single assay for a wide range of patient cohorts. Areas covered: Currently, whole-genome sequencing is mainly restricted to research applications and clinical utility studies. Furthermore, detecting the full-size spectrum of CNVs as well as somatic events remains difficult for both exome and whole-genome sequencing. As a result, the full extent of genomic variants in an individual's genome is still largely unknown. Recently, new sequencing technologies have been introduced which maintain the long-range genomic context, aiding the detection of CNVs and structural variants. Expert commentary: The development of long-read sequencing promises to resolve many CNV and SV detection issues but is yet to become established. The current challenge for clinical CNV detection is how to fully exploit all the data which is generated by high throughput sequencing technologies.	[Hehir-Kwa, Jayne Y.; Tops, Bastiaan B. J.; Kemmeren, Patrick] Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands	Hehir-Kwa, JY (reprint author), Princess Maxima Ctr Pediat Oncol, Heidelberglaan 25, NL-3584 CS Utrecht, Netherlands.	j.y.hehirkwa@prinsesmaximacentrum.nl	Tops, Bastiaan/L-4697-2015	Tops, Bastiaan/0000-0002-1699-8210	Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO) [91616015]	This paper is funded by the The Netherlands Organization for Scientific Research (NWO) grant number 91616015.	Abyzov A, 2012, NATURE, V492, P438, DOI 10.1038/nature11629; Abyzov A, 2011, GENOME RES, V21, P974, DOI 10.1101/gr.114876.110; Amarasinghe KC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-732; Ardui S, 2018, NUCLEIC ACIDS RES, V46, P2159, DOI [10.1093/narlgkx066, 10.1093/nar/gky066]; Babadi M, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3580; Benjamini Y, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks001; Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670; Bonberg N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-854; Bragin E, 2014, NUCLEIC ACIDS RES, V42, pD993, DOI 10.1093/nar/gkt937; Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203; Chaisson M. J, 2018, BIORXIV, DOI [10.1101/193144, DOI 10.1101/193144]; Chaisson MJ, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-238; Chaisson MJP, 2015, NATURE, V517, P608, DOI 10.1038/nature13907; Coe BP, 2012, CURR OPIN NEUROBIOL, V22, P829, DOI 10.1016/j.conb.2012.04.007; Coe BP, 2012, AM J MED GENET C, V160C, P118, DOI 10.1002/ajmg.c.31327; Cooper GM, 2011, NAT GENET, V43, P838, DOI 10.1038/ng.909; Dashnow H, 2018, DETECTING TANDEM REP, V19, P121; de Ligt J, 2013, HUM MUTAT, V34, P1439, DOI 10.1002/humu.22387; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Despierre E, 2014, GYNECOL ONCOL, V135, P415, DOI 10.1016/j.ygyno.2014.09.014; Dolzhenko E, 2017, GENOME RES, V27, P1895, DOI 10.1101/gr.225672.117; El-Metwally S, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003345; Ellingford JM, 2018, J MED GENET, V55, P114, DOI 10.1136/jmedgenet-2017-104791; Elyanow R, 2018, BIOINFORMATICS, V34, P353, DOI 10.1093/bioinformatics/btx712; English AC, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-180; English AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041444; Fan X, 2017, GENOME RES, V27, P793, DOI 10.1101/gr.214767.116; Faust GG, 2012, BIOINFORMATICS, V28, P2417, DOI 10.1093/bioinformatics/bts456; Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121; Fransson S, 2016, INT J ONCOL, V48, P1103, DOI 10.3892/ijo.2016.3349; Fromer M, 2012, AM J HUM GENET, V91, P597, DOI 10.1016/j.ajhg.2012.08.005; Garcia S, 2017, LINKED READ SEQUENCI, DOI [10.1101/231662, DOI 10.1101/231662]; Girirajan S, 2013, AM J HUM GENET, V92, P221, DOI 10.1016/j.ajhg.2012.12.016; Glessner JT, 2014, CIRC RES, V115, P884, DOI 10.1161/CIRCRESAHA.115.304458; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Goodwin S, 2015, GENOME RES, V25, P1750, DOI 10.1101/gr.191395.115; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Grobner SN, 2018, NATURE, V559, pE10, DOI 10.1038/s41586-018-0167-2; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Herve B, 2015, EUR J MED GENET, V58, P346, DOI 10.1016/j.ejmg.2015.04.005; Hochstenbach R, 2009, EUR J MED GENET, V52, P161, DOI 10.1016/j.ejmg.2009.03.015; Horpaopan S, 2015, INT J CANCER, V136, pE578, DOI 10.1002/ijc.29215; Hu LW, 2018, J GENET GENOMICS, V45, P3, DOI 10.1016/j.jgg.2018.01.001; Huang MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091944; Huddleston J, 2014, GENOME RES, V24, P688, DOI 10.1101/gr.168450.113; Jain M, 2018, NAT BIOTECHNOL, V36, P338, DOI 10.1038/nbt.4060; Juhlin CC, 2015, J CLIN ENDOCR METAB, V100, pE493, DOI 10.1210/jc.2014-3282; Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280; Krumm N, 2012, GENOME RES, V22, P1525, DOI 10.1101/gr.138115.112; Kuiper RP, 2010, CURR OPIN GENET DEV, V20, P282, DOI 10.1016/j.gde.2010.03.005; Lam ET, 2012, NAT BIOTECHNOL, V30, P771, DOI 10.1038/nbt.2303; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Larson NB, 2013, BIOINFORMATICS, V29, P1888, DOI 10.1093/bioinformatics/btt293; Laurie S, 2016, HUM MUTAT, V37, P1263, DOI 10.1002/humu.23114; Laver T, 2015, Biomol Detect Quantif, V3, P1; Layer RM, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-6-r84; Leary RJ, 2008, P NATL ACAD SCI USA, V105, P16224, DOI 10.1073/pnas.0808041105; Liang L, 2016, ONCOGENE, V35, P1475, DOI 10.1038/onc.2015.209; Lin Y, 2016, P NATL ACAD SCI USA, V113, pE8396, DOI 10.1073/pnas.1604560113; Liu BA, 2015, ONCOTARGET, V6, P5477, DOI 10.18632/oncotarget.3491; Liu BA, 2013, ONCOTARGET, V4, P1868, DOI 10.18632/oncotarget.1537; Love MI, 2011, STAT APPL GENET MOL, V10, DOI 10.2202/1544-6115.1732; Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795; Magi A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r120; Mak ACY, 2016, GENETICS, V202, P351, DOI 10.1534/genetics.115.183483; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Marks P, 2017, BIORXIV, DOI [10.1101/230946, DOI 10.1101/230946]; McConnell MJ, 2013, SCIENCE, V342, P632, DOI 10.1126/science.1243472; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mefford HC., 2014, CURR GENET MED REP, V2, P162, DOI DOI 10.1007/S40142-014-0046-6; Merker JD, 2018, GENET MED, V20, P159, DOI 10.1038/gim.2017.86; Meynert AM, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-247; Miller DT, 2010, AM J HUM GENET, V86, P749, DOI 10.1016/j.ajhg.2010.04.006; Mortreux J, 2018, EUR J HUM GENET, V26, P143, DOI 10.1038/s41431-017-0018-x; Mostovoy Y, 2016, NAT METHODS, V13, P587, DOI [10.1038/nmeth.3865, 10.1038/NMETH.3865]; Nakano K, 2017, HUM CELL, V30, P149, DOI 10.1007/s13577-017-0168-8; Nam JY, 2016, BRIEF BIOINFORM, V17, P185, DOI 10.1093/bib/bbv055; Nathan N, 2017, DERMATOL CLIN, V35, P51, DOI 10.1016/j.det.2016.07.001; Northcott PA, 2014, NATURE, V511, P428, DOI 10.1038/nature13379; Nouhaud FX, 2018, CLIN GENITOURIN CANC, V16, pE795, DOI 10.1016/j.clgc.2018.02.013; O'Huallachain M, 2012, P NATL ACAD SCI USA, V109, P18018, DOI 10.1073/pnas.1213736109; Oesper L, 2014, BIOINFORMATICS, V30, P3532, DOI 10.1093/bioinformatics/btu651; Orange JS, 2011, J ALLERGY CLIN IMMUN, V127, P1360, DOI 10.1016/j.jaci.2011.02.039; Pajusalu S, 2018, IDENTIFYING LONG IND, DOI [10. 1101/244756, DOI 10.1101/244756]; Pendleton M, 2015, NAT METHODS, V12, P780, DOI [10.1038/NMETH.3454, 10.1038/nmeth.3454]; Pfundt R, 2017, GENET MED, V19, P667, DOI 10.1038/gim.2016.163; Plagnol V, 2012, BIOINFORMATICS, V28, P2747, DOI 10.1093/bioinformatics/bts526; Pollard MO, 2018, HUM MOL GENET, V27, pR234, DOI 10.1093/hmg/ddy177; Pritchard CC, 2013, GENET MED, V15, P1004, DOI 10.1038/gim.2013.51; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Retterer K, 2016, GENET MED, V18, P696, DOI [10.1038/gim.2014.160, 10.1038/gim.2015.148]; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Riester M, 2016, SOURCE CODE BIOL MED, V11, DOI 10.1186/s13029-016-0060-z; Ritz A, 2014, BIOINFORMATICS, V30, P3458, DOI 10.1093/bioinformatics/btu714; Ritz A, 2010, BIOINFORMATICS, V26, P1291, DOI 10.1093/bioinformatics/btq153; Roller E, 2016, BIOINFORMATICS, V32, P2375, DOI 10.1093/bioinformatics/btw163; Sagoo GS, 2009, GENET MED, V11, P139, DOI 10.1097/GIM.0b013e318194ee8f; Salo-Mullen EE, 2014, FAM CANCER, V13, P459, DOI 10.1007/s10689-014-9709-4; Sanders AD, 2016, GENOME RES, V26, P1575, DOI 10.1101/gr.201160.115; Sathirapongsasuti JF, 2011, BIOINFORMATICS, V27, P2648, DOI 10.1093/bioinformatics/btr462; Schatz MC, 2010, GENOME RES, V20, P1165, DOI 10.1101/gr.101360.109; Schneider VA, 2017, GENOME RES, V27, P849, DOI 10.1101/gr.213611.116; Schwarze K, 2018, GENET MED, V20, P1122, DOI 10.1038/gim.2017.247; Sedlazeck FJ, 2018, NAT METHODS, V15, P461, DOI 10.1038/s41592-018-0001-7; Sedlazeck FJ, 2018, NAT REV GENET, V19, P329, DOI 10.1038/s41576-018-0003-4; Shearer AE, 2014, GENOME MED, V6, DOI 10.1186/gm554; Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520; Silveira SM, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0181-x; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Stamouli S, 2018, TWIN RES HUM GENET, V21, P1, DOI 10.1017/thg.2017.69; Stancu MC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01343-4; Su XP, 2012, BIOINFORMATICS, V28, P2265, DOI 10.1093/bioinformatics/bts365; Tan RJ, 2014, HUM MUTAT, V35, P899, DOI 10.1002/humu.22537; Tankard RM, 2018, DETECTING TANDEM REP, DOI [10. 1101/157792, DOI 10.1101/157792]; Trost B, 2018, AM J HUM GENET, V102, P142, DOI 10.1016/j.ajhg.2017.12.007; Tsuchida N, 2018, CLIN GENET, V93, P577, DOI 10.1111/cge.13144; Turner TR, 2018, HLA, V91, P88, DOI 10.1111/tan.13184; Valentijn LJ, 2015, NAT GENET, V47, P1411, DOI 10.1038/ng.3438; Wittler R, 2015, BIOINFORMATICS, V31, P2947, DOI 10.1093/bioinformatics/btv304; Xu HT, 2015, J CANCER, V6, P247, DOI 10.7150/jca.10747; Yadav VK, 2015, BRIEF BIOINFORM, V16, P232, DOI 10.1093/bib/bbu002; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zare F, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1705-x; Zhao M, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-S11-S1; Zheng GXY, 2016, NAT BIOTECHNOL, V34, P303, DOI 10.1038/nbt.3432; Zook JM, 2014, NAT BIOTECHNOL, V32, P246, DOI 10.1038/nbt.2835	127	0	0	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	10					907	915		10.1080/14737159.2018.1523723			9	Pathology	Pathology	GV6IZ	WOS:000446213900008	30221560				2019-10-28	
J	Villatoro, TM; Mardekian, SK				Villatoro, Tatiana M.; Mardekian, Stacey K.			Two Cases of Sinonasal Non-Intestinal-Type Adenocarcinoma with Squamoid Morules Expressing Nuclear beta-Catenin and CDX2: A Curious Morphologic Finding Supported by Molecular Analysis	CASE REPORTS IN PATHOLOGY			English	Article							MUTATIONS; SUBSET; TUMORS; DIFFERENTIATION; ENDOMETRIAL; CARCINOMAS; PATHWAY; MARKER	Sinonasal non-intestinal-type adenocarcinoma (non-ITAC) is a rare, morphologically diverse neoplasm of the head and neck. Squamoid morular metaplasia has recently been reported as an occasional finding in non-ITAC. Interestingly, these squamoid morules often show aberrant expression of CDX2 as well as nuclear expression of beta-catenin, similar to other tumors that show this type of metaplasia, but the underlying mechanism responsible for this finding is not completely understood. We present two cases of low-grade non-ITAC with squamoid morules coexpressing CDX2 and nuclear beta-catenin by immunohistochemistry, both of which were found to harbor a mutation in CTNNB1, the gene encoding beta-catenin. This finding provides support that an alteration in the beta-catenin pathway, including mutations in the beta-catenin gene itself, is responsible for this recently described morphologic phenomenon in non-ITAC.	[Villatoro, Tatiana M.; Mardekian, Stacey K.] Thomas Jefferson Univ Hosp, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Mardekian, SK (reprint author), Thomas Jefferson Univ Hosp, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA.	stacey.mardekian@jefferson.edu		Gargano, Stacey/0000-0002-2780-1866; Mardekian, Stacey/0000-0001-6430-1847			Andreasen S, 2018, AM J SURG PATHOL, V42, P985, DOI 10.1097/PAS.0000000000001069; Andreasen S, 2017, AM J SURG PATHOL, V41, P1552, DOI 10.1097/PAS.0000000000000912; El-Naggar A, 2017, WHO CLASSIFICATION H; Franchi A, 2014, PATHOL ONCOL RES, V20, P571, DOI 10.1007/s12253-013-9730-1; Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105; Houghton O, 2008, HISTOPATHOLOGY, V53, P156, DOI 10.1111/j.1365-2559.2008.03083.x; Kennedy MT, 2004, J CLIN PATHOL, V57, P932, DOI 10.1136/jcp.2004.016964; Lasota J, 2015, MODERN PATHOL, V28, P715, DOI 10.1038/modpathol.2014.161; Li MK, 2004, ADV ANAT PATHOL, V11, P101, DOI 10.1097/00125480-200403000-00004; Makishi S, 2006, J CLIN PATHOL, V59, P95, DOI 10.1136/jcp.2005.026237; Purgina B, 2015, HEAD NECK PATHOL, V9, P436, DOI 10.1007/s12105-015-0615-3; Saegusa M, 2001, J PATHOL, V194, P59, DOI 10.1002/path.856; Sekine S, 2003, J PATHOL, V200, P214, DOI 10.1002/path.1352; Shang H, 2015, CANCER-AM CANCER SOC, V121, P4088, DOI 10.1002/cncr.29564; Skalova A, 2018, AM J SURG PATHOL, V42, P234, DOI 10.1097/PAS.0000000000000972; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; Wani Y, 2008, HUM PATHOL, V39, P1072, DOI 10.1016/j.humpath.2007.07.019; Yom SS, 2005, MODERN PATHOL, V18, P315, DOI 10.1038/modpathol.3800315	18	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8741017	10.1155/2018/8741017			6	Pathology	Pathology	GU8SX	WOS:000445613700001	30302299	DOAJ Gold, Green Published			2019-10-28	
J	Filotico, M; Moretti, V; Floccari, F; D'Amuri, A				Filotico, Marcello; Moretti, Valentina; Floccari, Federica; D'Amuri, Alessandro			Very Rare Liver Neoplasm: Lymphoepithelioma-Like (LEL) Hepatocellular Carcinoma	CASE REPORTS IN PATHOLOGY			English	Article							INFILTRATION; CHOLANGIOCARCINOMA	A case of lymphoepithelioma-like (LEL) hepatobiliary carcinoma is reported. To date, only 89 cases of this rare neoplasm have been reported, with both hepatocellular and cholangiocellular histotype. The case reported here could be classified as LEL mixed hepatobiliary carcinoma (Hepato-Cholangio), a histotype not reported so far in the LEL variant.	[Filotico, Marcello; Moretti, Valentina; D'Amuri, Alessandro] Card G Panico Hosp, Anat Pathol Unit, Tricase, LE, Italy; [Floccari, Federica] Camillo De Lellis Hosp, Clin Pathol Unit, Manfredonia, FG, Italy	D'Amuri, A (reprint author), Card G Panico Hosp, Anat Pathol Unit, Tricase, LE, Italy.	a.damuri@inwind.it					Bosman FT, 2010, WHO CLASSIFICATION T; Henderson-Jackson E, 2010, INT J CLIN EXP PATHO, V3, P736; Hsu HC, 1996, HUM PATHOL, V27, P848, DOI 10.1016/S0046-8177(96)90460-8; Kim H, 2004, J HEPATOL, V40, P298, DOI 10.1016/j.jhep.2003.10.023; Labgaa I, 2017, AM J PATHOL, V187, P1438, DOI 10.1016/j.ajpath.2017.02.022; Park HS, 2009, PATHOL RES PRACT, V205, P648, DOI 10.1016/j.prp.2009.01.001; Patel KR, 2014, ARCH PATHOL LAB MED, V138, P1193, DOI 10.5858/arpa.2013-0371-OA; Roncalli M, 2010, DIGEST LIVER DIS, V42, pS228, DOI 10.1016/S1590-8658(10)60510-5; Saxena R., 2017, PRACTICAL HEPATIC PA; Shirabe K, 1995, HEPATO-GASTROENTEROL, V42, P996; Solinas A, 2015, WORLD J GASTROENTERO, V21, P3472, DOI 10.3748/wjg.v21.i12.3472; Wada Y, 1998, HEPATOLOGY, V27, P407, DOI 10.1002/hep.510270214	12	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2651716	10.1155/2018/2651716			7	Pathology	Pathology	GT9UI	WOS:000444891500001	30258661	DOAJ Gold, Green Published			2019-10-28	
J	Catteau, X; Anaf, V; Noel, JC				Catteau, Xavier; Anaf, Vincent; Noel, Jean-Christophe			Adenolipoleiomyoma Polyp of the Uterus: A Case Report and Review of the Literature	CASE REPORTS IN PATHOLOGY			English	Review							UTERINE ADENOLIPOLEIOMYOMA	Adenolipoleiomyoma is a very rare lesion of the uterus. Only four cases were reported. We describe one case of adenolipoleiomyoma presenting as a polyp in a postmenopausal woman with menorrhagia. Adenolipoleiomyoma is a very rare lesion and the histogenesis remains unclear. We discuss the origin and the differential diagnosis of this lesion.	[Catteau, Xavier] CUREPATH, Rue Borfilet 12A, B-6040 Jumet, Belgium; [Catteau, Xavier; Noel, Jean-Christophe] Univ Libre Bruxelles, Erasme Univ Hosp, Pathol Dept, CP 610,Route Lennik 808, B-1070 Brussels, Belgium; [Anaf, Vincent] Univ Libre Bruxelles, Erasme Univ Hosp, Gynaecol Dept, CP 610,Route Lennik 808, B-1070 Brussels, Belgium	Catteau, X (reprint author), CUREPATH, Rue Borfilet 12A, B-6040 Jumet, Belgium.; Catteau, X (reprint author), Univ Libre Bruxelles, Erasme Univ Hosp, Pathol Dept, CP 610,Route Lennik 808, B-1070 Brussels, Belgium.	xavier.catteau06@gmail.com					Furuhashi M, 2000, ARCH GYNECOL OBSTET, V263, P198, DOI 10.1007/s004040050283; Ilhan R, 2001, PATHOL INT, V51, P305, DOI 10.1046/j.1440-1827.2001.01194.x; McCluggage WG, 2000, INT J GYNECOL PATHOL, V19, P183, DOI 10.1097/00004347-200004000-00015; PAYNE F, 1992, HISTOPATHOLOGY, V20, P357, DOI 10.1111/j.1365-2559.1992.tb00995.x; Selvarajan S., 2017, PATHOLOGY, V49, pS125; Shaco-Levy R, 2008, INT J GYNECOL PATHOL, V27, P252, DOI 10.1097/PGP.0b013e3181569a37; Tahlan A, 2006, INT J GYNECOL PATHOL, V25, P361, DOI 10.1097/01.pgp.0000209570.08716.b3	7	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5704382	10.1155/2018/5704382			4	Pathology	Pathology	GT9UL	WOS:000444891900001	30258662	DOAJ Gold, Green Published			2019-10-28	
J	Febres-Aldana, CA; Min, J; Rafols, M; Willis, I; Alexis, J				Febres-Aldana, Christopher A.; Min, Jin; Rafols, Marc; Willis, Irvin; Alexis, John			Liposarcoma in the Inguinal Canal: Challenges in Preoperative Diagnosis and Importance of Routine Pathological Examination of "Hernia Sacs"	CASE REPORTS IN PATHOLOGY			English	Article							RETROPERITONEAL LIPOSARCOMA	Liposarcoma is the most common histologic subtype of soft tissue sarcoma in the retroperitoneum. The distinction of primary cord liposarcomas, which arise in and are confined to the inguinal canal, from inguinoscrotal extension of a retroperitoneal tumor is mandatory. Both can be found incidentally in inguinal hernia sac specimens. Preoperative diagnosis is essential for adequate surgery with clear margins. We present a clinicopathological correlation of two men with slowly growing right para-testicular masses diagnosed as inguinal hernias. Pathological examination revealed well-differentiated lipoma-like liposarcoma and well-differentiated liposarcoma mixed type (lipoma-like and sclerosing types), respectively. The first tumor was considered a primary cord liposarcoma with no recurrence on follow-up. The second tumor showed an unusual growth pattern of discontinuous nodules that gave the false impression of complete resection. This growth pattern may explain why inguinal liposarcomas have a high recurrence rate despite apparently negative surgical margins. A follow-up CT scan exposed a fatty tumor in the retroperitoneum of the second patient. Careful interpretation of imaging studies in patients with fatty inguinal masses is mandatory to rule out a retroperitoneal or intraperitoneal component. Although the two cases herein discussed represent less than 0.1% of the total inguinal hernia sacs examined over the past five years in our pathology department, we recommend routine examination of all "mass-containing" hernia sacs as missing the diagnosis of liposarcoma can lead to substantial morbidity and mortality.	[Febres-Aldana, Christopher A.; Alexis, John] Mt Sinai Med Ctr, Arkadi M Rywlin MD Dept Pathol & Lab Med, Miami Beach, FL 33140 USA; [Min, Jin] Nova Southeastern Univ, KC Patel Coll Osteopath Med, Davie, FL USA; [Rafols, Marc; Willis, Irvin] Mt Sinai Med Ctr, Dept Surg, Miami Beach, FL 33140 USA	Febres-Aldana, CA (reprint author), Mt Sinai Med Ctr, Arkadi M Rywlin MD Dept Pathol & Lab Med, Miami Beach, FL 33140 USA.	chrisfeb.2009@gmail.com		/0000-0002-4754-1344			Chalouhy C, 2017, MOL CLIN ONCOL, V6, P438, DOI 10.3892/mco.2017.1157; Dalal KM, 2008, J SURG ONCOL, V97, P298, DOI 10.1002/jso.20975; Dalal KM, 2006, ANN SURG, V244, P381, DOI 10.1097/01.sla.0000234795.98607.00; Di Gregorio M, 2017, CASE REP ONCOL, V10, P136, DOI 10.1159/000455900; Li FB, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-18; Montgomery E, 1999, J SURG ONCOL, V71, P50, DOI 10.1002/(SICI)1096-9098(199905)71:1<50::AID-JSO10>3.0.CO;2-T; Noguchi H, 2001, ACTA MED OKAYAMA, V55, P51; Parray F. Q., CASE REPORTS UROLOGY, V2011; Rhu J, 2017, CAN J SURG, V60, P399, DOI 10.1503/cjs.005917; Wang T, 2013, J CLIN PATHOL, V66, P1084, DOI 10.1136/jclinpath-2013-201734	10	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5929626	10.1155/2018/5929626			4	Pathology	Pathology	GT9UM	WOS:000444892000001	30258663	DOAJ Gold, Green Published			2019-10-28	
J	Hero, E; Carey, M; Hero, I; Shaaban, AM				Hero, Emily; Carey, Martyn; Hero, Isabelle; Shaaban, Abeer M.			Bilateral Neurofibromas of the Nipple-Areolar Complex: A Case Report and Approach to Diagnosis	CASE REPORTS IN PATHOLOGY			English	Article							SPINDLE-CELL LESIONS; BREAST-LESIONS; TUMORS; CARCINOMA; BENIGN	Neurofibromatosis type 1 is an autosomal dominant condition which can manifest as multiple neurofibromas within subcutaneous tissue. Neurofibromas of the breast are rare and most often encountered on the nipple-areolar complexes. A 33-year-old woman presented with large, bilateral, fleshy, skin tags of the nipple-areolar complexes. She underwent bilateral diagnostic excision of the lesions and macroscopically, both nipple specimens displaying polypoid lesions. Histological examination showed bilateral neurofibromas comprising skin with underlying dermal proliferation of bland spindle shaped cells with wavy nuclei. Immunohistochemistry confirmed the spindle cell proliferation to be neural in origin; positive for S100 and neurofilament and negative for cytokeratins. This was associated with florid smooth muscle proliferation. This case demonstrates a rare presentation of nipple-areolar neurofibroma occurring within the skin and nipple parenchyma. Our report considers the differential diagnoses of spindle cell proliferation within the dermis and subcutis of the breast and also other deeper breast spindle cell lesions that may involve the nipple. It aims to provide an approach to diagnosing these lesions examining the literature surrounding breast neurofibromas.	[Hero, Emily] Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England; [Carey, Martyn; Hero, Isabelle; Shaaban, Abeer M.] Queen Elizabeth Hosp Birmingham, Dept Cellular Pathol, Birmingham, W Midlands, England	Hero, E (reprint author), Univ Hosp Coventry & Warwickshire NHS Trust, Coventry, W Midlands, England.	emilyhero@doctors.org.uk		Shaaban, Abeer/0000-0001-5784-8705			Al-Nafussi A, 1999, HISTOPATHOLOGY, V35, P1; Bongiorno M. R., 2010, J MED CASE REPORTS, V4; Brogi E, 2004, SEMIN DIAGN PATHOL, V21, P57, DOI 10.1053/j.semdp.2003.10.007; Dhingra Kajal Kiran, 2007, World J Surg Oncol, V5, P142, DOI 10.1186/1477-7819-5-142; Jeyaretna Deva S, 2007, World J Surg Oncol, V5, P23, DOI 10.1186/1477-7819-5-23; Magro Gaetano, 2018, Surg Pathol Clin, V11, P91, DOI 10.1016/j.path.2017.09.005; Miettinen MM, 2017, HUM PATHOL, V67, P1, DOI 10.1016/j.humpath.2017.05.010; Moriya T, 2009, PATHOLOGY, V41, P68, DOI 10.1080/00313020802563544; Nonnis R, 2012, CLIN BREAST CANCER, V12, P147, DOI 10.1016/j.clbc.2012.01.011; Parikh Yasha, 2016, Radiol Case Rep, V11, P129, DOI 10.1016/j.radcr.2016.05.011; Rakha EA, 2016, HISTOPATHOLOGY, V68, P45, DOI 10.1111/his.12861; Rakha EA, 2016, HISTOPATHOLOGY, V68, P33, DOI 10.1111/his.12865; Sneige N, 2001, AM J SURG PATHOL, V25, P1009, DOI 10.1097/00000478-200108000-00004; Spyropoulou GA, 2015, J EUR ACAD DERMATOL, V29, P7, DOI 10.1111/jdv.12623	14	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									6702561	10.1155/2018/6702561			5	Pathology	Pathology	GT9UQ	WOS:000444892600001	30271648	DOAJ Gold, Green Published			2019-10-28	
J	Pearson, L; Taatjes, DJ; von Turkovich, M; King, BJ; Zenali, M				Pearson, Lauren; Taatjes, Douglas J.; von Turkovich, Michele; King, Benjamin J.; Zenali, Maryam			A Composite Renal Tumor with Dual Differentiation, Chromophobe and Collecting Duct Carcinoma	CASE REPORTS IN PATHOLOGY			English	Article							CELL CARCINOMA	Chromophobe carcinoma constitutes a small subset of all renal carcinomas. Within this category, rare tumors with divergent differentiation have been recognized. Herein, we report a rare case of composite chromophobe and collecting duct carcinoma and describe its pathologic and clinical features.	[Pearson, Lauren; Taatjes, Douglas J.; von Turkovich, Michele; Zenali, Maryam] Univ Vermont, Dept Pathol & Lab Med, Med Ctr, Burlington, VT 05405 USA; [Taatjes, Douglas J.; von Turkovich, Michele] Univ Vermont, Microscopy Imaging Ctr, Larner Coll Med, Burlington, VT 05405 USA; [King, Benjamin J.] Univ Vermont, Dept Urol, Med Ctr, Burlington, VT 05405 USA	Zenali, M (reprint author), Univ Vermont, Dept Pathol & Lab Med, Med Ctr, Burlington, VT 05405 USA.	maryam.zenali@uvmhealth.org					Becker F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078137; Burch-Smith R, 2014, CHIN J CANCER, V33, P351, DOI 10.5732/cjc.013.10155; Gira FA, 2010, INT J SURG PATHOL, V18, P419, DOI 10.1177/1066896908329414; Gong Y, 2003, ARCH PATHOL LAB MED, V127, P38; Hes O., 1999, CESK PATOL, V35, P9; Kawano N, 2005, PATHOL INT, V55, P360, DOI 10.1111/j.1440-1827.2005.01837.x; Klatte T, 2008, UROL ONCOL-SEMIN ORI, V26, P604, DOI 10.1016/j.urolonc.2007.07.015; Lindgren V, 2004, ARCH PATHOL LAB MED, V128, P1274; Matei DV, 2005, ANTICANCER RES, V25, P579; Nagashima Y, 2000, PATHOL INT, V50, P872, DOI 10.1046/j.1440-1827.2000.01131.x; Parada D., 2006, ARCHIVOS ESPANOLES U, V59; Petersson F, 2010, INT J CLIN EXP PATHO, V3, P534; Przybycin CG, 2011, AM J SURG PATHOL, V35, P962, DOI 10.1097/PAS.0b013e31821a455d; Shannon BA, 2003, PATHOLOGY, V35, P228, DOI 10.1080/0031302031000123209; Sharma R., 2015, J CANCER RES THER, V11, P1135; THOENES W, 1985, VIRCHOWS ARCH B, V48, P207, DOI 10.1007/BF02890129; Truong LD, 2011, ARCH PATHOL LAB MED, V135, P92, DOI 10.1043/2010-0478-RAR.1	17	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2410920	10.1155/2018/2410920			6	Pathology	Pathology	GT3DS	WOS:000444381100001	30228921	DOAJ Gold, Green Published			2019-10-28	
J	Yamada, R; Horiguchi, S; Onishi, T; Motoi, T; Hishima, T				Yamada, Rin; Horiguchi, Shin-ichiro; Onishi, Tomoko; Motoi, Toru; Hishima, Tsunekazu			Early Gastric Cancer with Purely Enteroblastic Differentiation and No Conventional Adenocarcinoma Component	CASE REPORTS IN PATHOLOGY			English	Article							ALPHA-FETOPROTEIN; CLINICOPATHOLOGICAL FEATURES; IMMUNOHISTOCHEMICAL ANALYSES; STOMACH; CARCINOMA	Gastric carcinoma with enteroblastic differentiation (GCED) is a rare variant of gastric carcinoma, and a part of GCED produces alpha-fetoprotein. GCED is characterized by cells with clear cytoplasm and a tubulopapillary and solid growth pattern resembling those in the primitive gut. GCED is typically overlaid by a conventional adenocarcinoma (CA) component, implying that CA in the mucosa differentiates into GCED during tumor invasion and proliferation. We present the case of a 73-year-old woman with a 10-mm superficial elevated lesion and a slight central depression at the anterior wall of the lower gastric body. Endoscopic submucosal dissection revealed tumor cells having clear cytoplasm and severely atypical nuclei characteristic of GCED. The growth pattern was predominantly solid and trabecular but included submucosal layer invasion and limited tubular growth. Atrophic pyloric mucosa without intestinal metaplasia surrounded the tumor. Immunohistochemically, the tumor cells were positive for AFP, GPC3, and SALL4. The present patient showed a purely enteroblastic differentiation without a CA component despite the presence of early cancer, indicating that few cases of GCED may arise de novo in the gastric mucosa. GCED is more aggressive compared with CA; therefore, pathologists should be aware that GCED without CA can appear in biopsy specimens of early cancer while making an accurate diagnosis.	[Yamada, Rin; Horiguchi, Shin-ichiro; Motoi, Toru; Hishima, Tsunekazu] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan; [Onishi, Tomoko] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Gastroenterol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan	Yamada, R (reprint author), Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Pathol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.	r.yamada82@gmail.com	Yamada, Rin/L-2928-2019	Yamada, Rin/0000-0001-9161-1429			Akazawa Y, 2018, HUM PATHOL, V78, P79, DOI 10.1016/j.humpath.2018.04.022; CHANG YC, 1992, AM J GASTROENTEROL, V87, P321; Fujii H, 2003, J CLIN PATHOL, V56, P942, DOI 10.1136/jcp.56.12.942; ISHIKURA H, 1986, CANCER, V58, P119, DOI 10.1002/1097-0142(19860701)58:1<119::AID-CNCR2820580121>3.0.CO;2-U; Kanai Masashi, 2005, Int J Gastrointest Cancer, V35, P77, DOI 10.1385/IJGC:35:1:077; Kinjo T, 2012, AM J SURG PATHOL, V36, P56, DOI 10.1097/PAS.0b013e31823aafec; KODAMA T, 1981, CANCER, V48, P1647, DOI 10.1002/1097-0142(19811001)48:7<1647::AID-CNCR2820480729>3.0.CO;2-V; Li XD, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-246; Matsumoto K, 2016, WORLD J GASTROENTERO, V22, P8203, DOI 10.3748/wjg.v22.i36.8203; MATSUNOU H, 1994, CANCER, V73, P534, DOI 10.1002/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X; MOTOYAMA T, 1993, ACTA PATHOL JAPON, V43, P654; Murakami T, 2016, GASTRIC CANCER, V19, P498, DOI 10.1007/s10120-015-0497-9; NAGAI E, 1993, CANCER, V72, P1827, DOI 10.1002/1097-0142(19930915)72:6<1827::AID-CNCR2820720606>3.0.CO;2-8; OOI A, 1990, CANCER-AM CANCER SOC, V65, P1741, DOI 10.1002/1097-0142(19900415)65:8<1741::AID-CNCR2820650814>3.0.CO;2-3; Yamabuki Takumi, 2014, Case Rep Gastroenterol, V8, P1, DOI 10.1159/000358046	15	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									3620293	10.1155/2018/3620293			5	Pathology	Pathology	GT3DU	WOS:000444381300001	30228922	DOAJ Gold, Green Published			2019-10-28	
J	Nelem-Colturato, CB; Cury, PM; Pereira, TM; Cosso, IS; Pivato, K; Volpato, LER; Borges, AH				Nelem-Colturato, Carla Bento; Cury, Patricia Maluf; Pereira, Thiago Machado; Cosso, Isabelle Silva; Pivato, Kellin; Ricci Volpato, Luiz Evaristo; Borges, Alvaro Henrique			Sextuple Tumors in Head and Neck Area: Evidence of Field Cancerization	CASE REPORTS IN PATHOLOGY			English	Article							SQUAMOUS-CELL CARCINOMA; TRIPLE CANCERS	Background. Field cancerization is a phenomenon in which prolonged exposure to carcinogens induces changes throughout the epithelium leaving the field ready for the appearance of premalignant or malignant lesions. These alterations can promote the development of multiple carcinomas and explain the appearance of recurrences and second primary tumors. The objective of this study was to report the case of a patient who developed six oral cavity tumors in five years of treatment and, also, demonstrate the immunohistochemical changes for p53 and Ki-67, routinely used to assess dysplasic regions. Case Report. When altered, p53 and Ki-67 suggest the presence of field cancers, an area with genetically altered cells, presenting a high risk of developing premalignant and malignant lesions. This phenomenon explains the recurrence of malignant neoplasms after tumor resections. Conclusion. In addition, early identification of potentially malignant lesions in cases of second primary tumors is essential for effective treatment and patient survival, which usually have an unwelcoming prognosis.	[Nelem-Colturato, Carla Bento] Univ Fed Acre, Hlth & Sports Sci Ctr, Rio Branco, Acre, Brazil; [Cury, Patricia Maluf] Ceres Coll Sch Med FACERES, Dept Pathol, Sao Paulo, Brazil; [Pereira, Thiago Machado; Cosso, Isabelle Silva; Pivato, Kellin; Ricci Volpato, Luiz Evaristo; Borges, Alvaro Henrique] Univ Cuiaba, Dept Oral Sci, Cuiaba, Mato Grosso, Brazil	Borges, AH (reprint author), Univ Cuiaba, Dept Oral Sci, Cuiaba, Mato Grosso, Brazil.	alvarohborges@gmail.com	Volpato, Luiz/I-2933-2019	Volpato, Luiz/0000-0002-2969-1963			Birajdar Smita Shrishail, 2014, J Oral Maxillofac Pathol, V18, P169, DOI 10.4103/0973-029X.140729; Clark DJ, 2017, ORAL MAXIL SURG CLIN, V29, P245, DOI 10.1016/j.coms.2017.03.002; Curado MP, 2013, CURR OPIN ONCOL, V25, P229, DOI 10.1097/CCO.0b013e32835ff48c; Gao XL, 2017, ONCOTARGETS THER, V10, P5219, DOI 10.2147/OTT.S140854; Gissi DB, 2015, OPEN DENT J, V9, P41, DOI 10.2174/1874210601509010041; Hedberg ML, 2016, J CLIN INVEST, V126, P169, DOI 10.1172/JCI82066; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; MartinGranizo R, 1997, J CRANIO MAXILL SURG, V25, P153, DOI 10.1016/S1010-5182(97)80007-8; Priante AVM, 2011, CURR ONCOL REP, V13, P132, DOI 10.1007/s11912-010-0147-7; Mohan M., 2014, ONCOLOGY REV, V8; Monti-Hughes A, 2015, PERIODONTOL 2000, V67, P292, DOI 10.1111/prd.12066; Nemeth Z, 2002, NEOPLASMA, V49, P412; Reddy VM, 2012, INDIAN J CANCER, V49, P27, DOI 10.4103/0019-509X.98913; Rivera C, 2014, ONCOL LETT, V8, P7, DOI 10.3892/ol.2014.2103; Simple M, 2015, ORAL ONCOL, V51, P643, DOI 10.1016/j.oraloncology.2015.04.006; Singh PK, 2015, CANCER BIOMARK, V15, P125, DOI 10.3233/CBM-140444; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Viswanathan Vidya, 2015, J Int Oral Health, V7, P40	18	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8428395	10.1155/2018/8428395			4	Pathology	Pathology	GR7SJ	WOS:000442894300001	30186652	DOAJ Gold, Green Published			2019-10-28	
J	Gaipa, G; Buracchi, C; Biondi, A				Gaipa, Giuseppe; Buracchi, Chiara; Biondi, A.			Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Acute Leukemia; flow cytometry; minimal residual disease	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; STEM-CELL TRANSPLANTATION; CHILDRENS ONCOLOGY GROUP; PRECURSOR-B-ALL; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE; REMISSION INDUCTION THERAPY; BONE-MARROW-TRANSPLANTATION; INTERNATIONAL EXPERT PANEL; POLYMERASE-CHAIN-REACTION	Introduction: Flow cytometric quantification of minimal residual disease (MRD) in acute leukemia (AL) represents an indispensable tool to guide modern therapeutic protocols toward a precision medicine approach, being a powerful predictor of the overall response to treatment. This review covers the most challenging aspects and developments of this method, aiming at supporting further its implementation in clinical practices. Area covered: Flow cytometric MRD is based on the discrimination of leukemia cells from their physiological counterparts by the recognition of the leukemia-associated immunophenotypes. Technical and standardization advances along the last decades have been implemented allowing flow cytometric MRD to consolidate its role in modern therapeutic protocols for ALs. However, gaps in sensitivity and data interpretation are still present together with the need for further optimization of MRD-based clinical protocols. In this review, we critically analyze and discuss the most relevant and representative contributions in the field by accurate selection of the literature available in PubMed. Expert commentary: Further research in flow cytometric MRD can bring this technology toward wider and consistent applications in multiple acute leukemia settings rendering this tool a future golden standard and providing clinicians with more reliable and accurate tools for clinical decisions.	[Gaipa, Giuseppe; Buracchi, Chiara; Biondi, A.] Univ Milano Bicocca, Dept Pediat, Fdn Tettamanti, Ctr Ric M Tettamanti, Monza, Italy; [Biondi, A.] Univ Milano Bicocca, Dept Pediat, Osped San Gerardo, Fdn MBBM, Monza, Italy	Gaipa, G (reprint author), Fdn Tettamanti, Ctr Ric M Tettamanti, Monza, Italy.	g.gaipa@hsgerardo.org			Comitato Maria Letizia Verga; Fondazione Alessandro Maria Zancan (GrandeAle) ONLUS; Investigator Grant 2017 Associazione Italiana per la Ricerca sul Cancro (AIRC) [20564]; AIRC Special Program Molecular Clinical Oncology-5 per mile 2018 [21147]	This article was funded by Charities: Comitato Maria Letizia Verga; Fondazione Alessandro Maria Zancan (GrandeAle) ONLUS. Grants: Investigator Grant 2017 Associazione Italiana per la Ricerca sul Cancro (AIRC; project number 20564 to A.B.); AIRC Special Program Molecular Clinical Oncology-5 per mile 2018 (project number 21147 to A.B.)	Adriaansen H J, 1990, Haematol Blood Transfus, V33, P41; Al-Mawali A, 2009, AM J CLIN PATHOL, V131, P16, DOI 10.1309/AJCP5TSD3DZXFLCX; Annino L, 2002, BLOOD, V99, P863, DOI 10.1182/blood.V99.3.863; Arroz M, 2016, CYTOM PART B-CLIN CY, V90, P31, DOI 10.1002/cyto.b.21228; Bader P, 2002, LEUKEMIA, V16, P1668, DOI 10.1038/sj.leu.2402552; Bahia DMM, 2001, HAEMATOLOGICA, V86, P801; Basso G, 2009, J CLIN ONCOL, V27, P5168, DOI 10.1200/JCO.2008.20.8934; Borowitz MJ, 2008, BLOOD, V111, P5477, DOI 10.1182/blood-2008-01-132837; Borowitz MJ, 2015, BLOOD, V126, P964, DOI 10.1182/blood-2015-03-633685; BRADSTOCK KF, 1981, LEUKEMIA RES, V5, P301, DOI 10.1016/0145-2126(81)90002-3; BRADSTOCK KF, 1986, AM J HEMATOL, V23, P43, DOI 10.1002/ajh.2830230107; Bruggemann M, 2017, BLOOD ADV, V1, P2456, DOI 10.1182/bloodadvances.2017009845; Buccisano F, 2017, CURR HEMATOL MALIG R, V12, P547, DOI 10.1007/s11899-017-0420-z; Buldini B, 2017, BRIT J HAEMATOL, V177, P116, DOI 10.1111/bjh.14523; Campana D, 2003, BRIT J HAEMATOL, V121, P823, DOI 10.1046/j.1365-2141.2003.04393.x; Campana D, 1999, CYTOMETRY, V38, P139, DOI 10.1002/(SICI)1097-0320(19990815)38:4<139::AID-CYTO1>3.0.CO;2-H; CAMPANA D, 1990, BLOOD, V76, P163; Campana D, 2017, BLOOD, V129, P1913, DOI [10.1182/blood-2016-12725804, 10.1182/blood-2016-12-725804]; Cazzaniga G, 2011, BRIT J HAEMATOL, V155, P45, DOI 10.1111/j.1365-2141.2011.08795.x; Chen JS, 2001, BLOOD, V97, P2115, DOI 10.1182/blood.V97.7.2115; Cherian S, 2018, CYTOM PART B-CLIN CY, V94, P112, DOI 10.1002/cyto.b.21482; Chiaretti S, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.073; Ciudad J, 1999, BRIT J HAEMATOL, V104, P695, DOI 10.1046/j.1365-2141.1999.01236.x; Ciudad J, 1998, HAEMATOLOGICA, V83, P1069; Ciudad J, 1998, J CLIN ONCOL, V16, P3774, DOI 10.1200/JCO.1998.16.12.3774; Costa ES, 2010, LEUKEMIA, V24, P1927, DOI 10.1038/leu.2010.160; Coustan-Smith E, 2000, BLOOD, V96, P2691; Coustan-Smith E, 2004, LEUKEMIA, V18, P499, DOI 10.1038/sj.leu.2403283; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; Coustan-Smith E, 2013, CURR OPIN HEMATOL, V20, P86, DOI 10.1097/MOH.0b013e32835dd90a; Coustan-Smith E, 2011, BLOOD, V117, P6267, DOI 10.1182/blood-2010-12-324004; Coustan-Smith E, 2010, BEST PRACT RES CL HA, V23, P347, DOI 10.1016/j.beha.2010.07.007; Creutzig U, 2005, LEUKEMIA, V19, P2030, DOI 10.1038/sj.leu.2403920; Creutzig U, 2012, BLOOD, V120, P3187, DOI 10.1182/blood-2012-03-362608; Del Principe MI, 2016, MEDITERR J HEMATOL I, V8, DOI 10.4084/MJHID.2016.052; DiGiuseppe JA, 2009, CYTOM PART B-CLIN CY, V76B, P150, DOI 10.1002/cyto.b.20440; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Dworzak MN, 2008, CYTOM PART B-CLIN CY, V74B, P331, DOI 10.1002/cyto.b.20430; Dworzak MN, 2002, BLOOD, V99, P1952, DOI 10.1182/blood.V99.6.1952; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Dworzak MN, 1998, EXP HEMATOL, V26, P305; Dworzak MN, 1998, BLOOD, V92, P3203, DOI 10.1182/blood.V92.9.3203.421k34_3203_3209; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; Dworzak MN, 1997, LEUKEMIA, V11, P1266, DOI 10.1038/sj.leu.2400732; Elorza I, 2010, HAEMATOL-HEMATOL J, V95, P936, DOI 10.3324/haematol.2009.010843; Eveillard M, 2017, HEMATOL ONCOL, V35, P237, DOI 10.1002/hon.2263; Farahat N, 1998, BRIT J HAEMATOL, V101, P158, DOI 10.1046/j.1365-2141.1998.00675.x; Freeman SD, 2013, J CLIN ONCOL, V31, P4123, DOI 10.1200/JCO.2013.49.1753; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Gaipa G, 2005, LEUKEMIA, V19, P49, DOI 10.1038/sj.leu.2403559; Gaipa G, 2012, HAEMATOL-HEMATOL J, V97, P1586, DOI 10.3324/haematol.2011.060426; Gaipa G, 2013, CYTOM PART B-CLIN CY, V84, P359, DOI 10.1002/cyto.b.21101; Gaynon PS, 1997, CANCER-AM CANCER SOC, V80, P1717, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1717::AID-CNCR4>3.0.CO;2-B; GAYNOR J, 1988, J CLIN ONCOL, V6, P1014, DOI 10.1200/JCO.1988.6.6.1014; Griesinger F, 1999, BRIT J HAEMATOL, V105, P241, DOI 10.1046/j.1365-2141.1999.01300.x; Grimwade D, 2016, BLOOD, V127, P29, DOI 10.1182/blood-2015-07-604496; HOELZER D, 1988, BLOOD, V71, P123; Holowiecki J, 2008, BRIT J HAEMATOL, V142, P227, DOI 10.1111/j.1365-2141.2008.07185.x; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; HURWITZ CA, 1988, BLOOD, V72, P299; HURWITZ CA, 1992, LEUKEMIA, V6, P233; Irving J, 2009, HAEMATOL-HEMATOL J, V94, P870, DOI 10.3324/haematol.2008.000414; Jabbour E, 2017, CANCER-AM CANCER SOC, V123, P294, DOI 10.1002/cncr.30264; Jacoby E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12320; Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108; JANOSSY G, 1979, J IMMUNOL, V123, P1525; JANOSSY G, 1980, BLOOD, V56, P430; Kalina T, 2012, LEUKEMIA, V26, P1986, DOI 10.1038/leu.2012.122; Karawajew L, 2015, HAEMATOLOGICA, V100, P935, DOI 10.3324/haematol.2014.116707; Kern W, 2004, BLOOD, V104, P3078, DOI 10.1182/blood-2004-03-1036; Kern W, 2003, BLOOD, V101, P64, DOI 10.1182/blood-2002-02-0532; Knechtli CJC, 1998, BLOOD, V92, P4072, DOI 10.1182/blood.V92.11.4072.423k33_4072_4079; Krampera M, 2003, BRIT J HAEMATOL, V120, P74, DOI 10.1046/j.1365-2141.2003.03974.x; Leung W, 2011, BLOOD, V118, P223, DOI 10.1182/blood-2011-01-333070; Loken MR, 2012, BLOOD, V120, P1581, DOI 10.1182/blood-2012-02-408336; Lucio P, 1999, LEUKEMIA, V13, P419, DOI 10.1038/sj.leu.2401279; Lucio P, 2001, LEUKEMIA, V15, P1185, DOI 10.1038/sj.leu.2402150; Maurillo L, 2008, J CLIN ONCOL, V26, P4944, DOI 10.1200/JCO.2007.15.9814; McKenna RW, 2001, BLOOD, V98, P2498, DOI 10.1182/blood.V98.8.2498; Mejstrikova E, 2017, BLOOD CANCER J, V7, DOI 10.1038/s41408-017-0023-x; Mo XD, 2017, BRIT J HAEMATOL, V179, P184, DOI 10.1111/bjh.14778; Motwani J, 2009, BRIT J HAEMATOL, V144, P133, DOI 10.1111/j.1365-2141.2008.07410.x; Muzzafar T, 2009, AM J CLIN PATHOL, V132, P692, DOI 10.1309/AJCP02RPVOKTNWEC; Norkin M, 2017, BLOOD CANCER J, V7, DOI 10.1038/s41408-017-0007-x; Olaru D, 2008, CYTOM PART B-CLIN CY, V74B, P17, DOI 10.1002/cyto.b.20371; ORFAO A, 1994, LEUKEMIA LYMPHOMA, V13, P87, DOI 10.3109/10428199409052682; Ossenkoppele GJ, 2011, BRIT J HAEMATOL, V153, P421, DOI 10.1111/j.1365-2141.2011.08595.x; Parker C, 2010, LANCET, V376, P2009, DOI 10.1016/S0140-6736(10)62002-8; Pemmaraju N, 2017, AM J HEMATOL, V92, P279, DOI 10.1002/ajh.24629; Pession A, 2013, BLOOD, V122, P170, DOI 10.1182/blood-2013-03-491621; Pui CH, 2001, LANCET ONCOL, V2, P597, DOI 10.1016/S1470-2045(01)00516-2; Pui CH, 2006, NEW ENGL J MED, V354, P166, DOI 10.1056/NEJMra052603; Pui CH, 2015, LANCET ONCOL, V16, P465, DOI 10.1016/S1470-2045(15)70082-3; Pulte D, 2009, BLOOD, V113, P1408, DOI 10.1182/blood-2008-06-164863; Raetz EA, 2008, J CLIN ONCOL, V26, P3971, DOI 10.1200/JCO.2008.16.1414; Ravandi F, 2016, BRIT J HAEMATOL, V172, P392, DOI 10.1111/bjh.13834; READING CL, 1993, BLOOD, V81, P3083; Rhein P, 2010, BLOOD, V115, P3763, DOI 10.1182/blood-2009-10-247585; Rimsza LM, 2000, AM J CLIN PATHOL, V114, P66; Rubnitz JE, 2010, LANCET ONCOL, V11, P543, DOI 10.1016/S1470-2045(10)70090-5; Ruella M, 2016, COMPUT STRUCT BIOTEC, V14, P357, DOI 10.1016/j.csbj.2016.09.003; Ruella M, 2016, CURR HEMATOL MALIG R, V11, P368, DOI 10.1007/s11899-016-0336-z; Ruella M, 2015, EXPERT OPIN BIOL TH, V15, P761, DOI 10.1517/14712598.2015.1009888; SAELAND S, 1991, BLOOD, V78, P2229; SAELAND S, 1992, EXP HEMATOL, V20, P24; San Miguel JF, 2001, BLOOD, V98, P1746, DOI 10.1182/blood.V98.6.1746; Schrappe M, 1996, J CLIN ONCOL, V14, P2403, DOI 10.1200/JCO.1996.14.8.2403; Schuurhuis GJ, 2018, BLOOD, V131, P1275, DOI 10.1182/blood-2017-09-801498; Sedek Lukasz, 2018, J Immunol Methods, DOI 10.1016/j.jim.2018.03.005; SMITH RG, 1989, BLOOD, V74, P312; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; SYRJALA M, 1994, LEUKEMIA, V8, P1564; Tembhare PR, 2018, CYTOM PART B-CLIN CY, V94, P100, DOI 10.1002/cyto.b.21486; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P70; Terwijn M, 2013, J CLIN ONCOL, V31, P3889, DOI 10.1200/JCO.2012.45.9628; Theunissen P, 2017, BLOOD, V129, P347, DOI 10.1182/blood-2016-07-726307; UCKUN FM, 1990, BLOOD, V76, P1908; van der Velden VHJ, 2001, LEUKEMIA, V15, P1485, DOI 10.1038/sj.leu.2402198; van Dongen JJM, 2012, LEUKEMIA, V26, P1908, DOI 10.1038/leu.2012.120; van Dongen JJM, 2015, BLOOD, V125, P3996, DOI 10.1182/blood-2015-03-580027; van Lochem EG, 2000, LEUKEMIA, V14, P688, DOI 10.1038/sj.leu.2401749; van Rhenen A, 2007, LEUKEMIA, V21, P1700, DOI 10.1038/sj.leu.2404754; van Rhenen A, 2007, BLOOD, V110, P2659, DOI 10.1182/blood-2007-03-083048; van Wering ER, 2000, BRIT J HAEMATOL, V110, P139, DOI 10.1046/j.1365-2141.2000.02143.x; VANDONGEN JJM, 1992, LEUKEMIA, V6, P47; Varella-Garcia M, 2001, LEUKEMIA, V15, P1408, DOI 10.1038/sj.leu.2402219; Veltroni M, 2003, HAEMATOLOGICA, V88, P1245; Venditti A, 2003, LEUKEMIA, V17, P2178, DOI 10.1038/sj.leu.2403138; Voskova D, 2007, LEUKEMIA LYMPHOMA, V48, P80, DOI 10.1080/10428190600886164; Walter RB, 2011, J CLIN ONCOL, V29, P1190, DOI 10.1200/JCO.2010.31.8121; Walter RB, 2010, J CLIN ONCOL, V28, P1766, DOI 10.1200/JCO.2009.25.1066; Wells DA, 1998, AM J CLIN PATHOL, V110, P84; Wood BL, 2007, CLIN LAB MED, V27, P551, DOI 10.1016/j.cll.2007.05.006; Wood BL, 2016, CYTOM PART B-CLIN CY, V90, P47, DOI 10.1002/cyto.b.21239; Zeijlemaker W, 2016, LEUKEMIA, V30, P439, DOI 10.1038/leu.2015.252; Zeijlemaker W, 2014, CYTOM PART B-CLIN CY, V86, P3, DOI 10.1002/cyto.b.21134; Zeleznikova T, 2006, NEOPLASMA, V53, P500; Zhou Y, 2016, LEUKEMIA, V30, P1456, DOI 10.1038/leu.2016.46	138	0	0	1	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	9					775	787		10.1080/14737159.2018.1504680			13	Pathology	Pathology	GR6IV	WOS:000442753800002	30047795				2019-10-28	
J	Gous, N; Takle, J; Oppenheimer, A; Schooley, A				Gous, Natasha; Takle, Jeff; Oppenheimer, Aaron; Schooley, Alan			Racing for results: lessons learnt in improving the efficiency of HIV viral load and early infant diagnosis result delivery from laboratory to clinic	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Digital reporting; early infant diagnosis; eHealth; HIV; laboratory; mHealth; result delivery	SCALE-UP; TIME	Introduction: In pursuit of the 90-90-90 goals, emphasis has been placed on accelerating centralized-laboratory HIV viral load testing of a population that is largely rural and decentralized. Successful outcome requires effective specimen transport, laboratory testing, and results delivery. This paper focuses on the methods currently employed for results delivery. New innovations in this area are yielding mixed results; we analyze different approaches and estimate the impact of each on achieving the third '90.' Areas covered: Strategies employing electronic or mobile health platforms, such as online portals, SMS, and SMS printers are showing potential to deliver results in significantly improved turnaround times but are not without challenges. Also, merely delivering a result to the clinic is not sufficient; results need to be actioned to ensure improved patient linkage and retention. Innovative solutions that not only support real-time reporting but monitor receipt of results and address infrastructure constraints faced by limited-resource settings are discussed. Expert commentary: There is tremendous opportunity to inform better patient care and directly contribute to '90-90-90' progress by developing digital systems for result delivery. Besides infrastructure and technical challenges, systems should address the entire cascade of care from initial diagnosis to monitoring treatment response.	[Gous, Natasha] SystemOne, Dept Global Hlth, Johannesburg, South Africa; [Takle, Jeff; Oppenheimer, Aaron] SystemOne, Dept Global Hlth, Springfield, MA USA; [Schooley, Alan] EQUIP Malawi, Partners Hope Med Ctr, Lilongwe, Malawi; [Schooley, Alan] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA; [Schooley, Alan] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA	Gous, N (reprint author), SystemOne, Constantia Off Pk, Johannesburg, South Africa.	ngous@systemone.id					Asamoah-Odei E, 2011, AFRICAN HLTH MONITOR, V14, P46; AVERT [Internet], 2018, HIV AIDS E SO AFR RE; Baruah A, 2014, J CLIN DIAGN RES, V8, pCC1, DOI 10.7860/JCDR/2014/10150.5285; Berrie L, 2014, SO AFR HIV CLIN SOC; Bianchi F, 2017, SAT SESS IAS PAR FRA; Bourne DE, 2009, AIDS, V23, P101, DOI 10.1097/QAD.0b013e32831c54bd; Clinton Health Access Initiative, 2016, AIDS C JUL 18 22 DUR; DisaLab [Internet], MOD WHAT SOFTW MOD D; Dryden-Peterson S, 2015, PLOS ONE, V10, P2; Engel N, 2015, TROP MED INT HEALTH, V20, P493, DOI 10.1111/tmi.12450; Garises V, 2017, UNPAN WORKSH JOH S A; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Goswami B, 2010, INDIAN J CLIN BIOCHE, V25, P376, DOI 10.1007/s12291-010-0056-4; Gous N, 2018, CROI BOST US MARCH 4; Hall CS, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.25606; Hao WR, 2015, COMPUT METH PROG BIO, V118, P77, DOI 10.1016/j.cmpb.2014.10.005; Hawkins R, 2012, ANN LAB MED, V32, P5, DOI 10.3343/alm.2012.32.1.5; Jo Y, 2014, PLOS ONE, V9, P7; Kandulu J, 2016, AIDS C DUR S AFR JUL; Kayumba K, 2016, PEDIATR INFECT DIS J, V35, P767, DOI 10.1097/INF.0000000000001153; Kiyaga C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078609; Lecher S, 2016, MMWR-MORBID MORTAL W, V65, P1332, DOI 10.15585/mmwr.mm6547a2; Manumbu S, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001897; Minchella PA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173009; Nhavoto JA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176051; Plebani M, 2010, ANN CLIN BIOCHEM, V47, P101, DOI 10.1258/acb.2009.009222; Preanalytic VP., 1990, LAB MED, V21, P448; Roberts T, 2016, CLIN INFECT DIS, V62, P1043, DOI 10.1093/cid/ciw001; Rodrigues R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007574; Stevens W, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0173-7; Sukums F, 2014, GLOBAL HEALTH ACTION, V7, P1, DOI 10.3402/gha.v7.24534; Sutcliffe CG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087028; Uddin J, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0502-9; UNAIDS, 2017, END AIDS PROGR 90 90; UNICEF [Internet], 2012, PROJ MWAN RAPIDSMS; Vojnov L, 2017, JAIDS-J ACQ IMM DEF, V76, P522, DOI [10.1097/qai.0000000000001526, 10.1097/QAI.0000000000001526]; Wexler C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181005; WHO, 2016, CONS GUID US ANT DRU; World Health Organization, 2016, GLOB DIFF EHEALTH MA; World Health Organization, 2016, TDR NEWS ITEM INT RI	40	1	1	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	9					789	795		10.1080/14737159.2018.1503951			7	Pathology	Pathology	GR6IV	WOS:000442753800003	30033823				2019-10-28	
J	DiPardo, BJ; Winograd, P; Court, CM; Tomlinson, JS				DiPardo, Benjamin J.; Winograd, Paul; Court, Colin M.; Tomlinson, James S.			Pancreatic cancer circulating tumor cells: applications for personalized oncology	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Biomarker; circulating tumor cells; liquid biopsy; pancreatic cancer; personalized medicine	RESISTANT PROSTATE-CANCER; EX-VIVO CULTURE; PROGNOSTIC-SIGNIFICANCE; PERIPHERAL-BLOOD; CARCINOMA PATIENTS; CLINICAL-TRIALS; ORGANOID MODELS; LUNG-CANCER; RT-PCR; ADENOCARCINOMA	Introduction: Pancreatic cancer (PC) is a highly lethal disease, in part because of early metastasis, late diagnosis, and limited treatment options. Circulating tumor cells (CTCs) are cancer cells that have achieved the metastatic step of intravasation, and are thus a unique source of biomarkers with potential applications in the staging, prognostication, and treatment of PC. Areas covered: This review describes the use of CTCs in PC, including isolation methods, the significance of CTC enumeration, and studies examining phenotypic and molecular characteristics of CTCs. We also speculate on future directions for PC CTC research such as single-cell analysis and CTC culture. Expert commentary: CTCs represent a potential unique serial source of cancer tissue via a convenient and minimally invasive blood draw. Recent development of isolation methods that allow for the release of viable CTCs with unaltered molecular characteristics has set the stage for single-cell analysis and ex vivo culture. Although there is significant potential for CTCs as a biomarker to impact PC from diagnosis to therapy, there still remain a number of challenges to the routine implementation of CTCs in the clinical management of PC.	[DiPardo, Benjamin J.; Winograd, Paul; Court, Colin M.; Tomlinson, James S.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA; [DiPardo, Benjamin J.; Winograd, Paul; Court, Colin M.; Tomlinson, James S.] Greater Los Angeles Vet Hlth Adm, Dept Surg, Los Angeles, CA USA	DiPardo, BJ (reprint author), Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.	bdipardo@mednet.ucla.edu		Court, Colin/0000-0002-9357-8957			Aberle MR, 2018, BRIT J SURG, V105, pE48, DOI 10.1002/bjs.10726; Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Alix-Panabieres C, 2005, J IMMUNOL METHODS, V299, P177, DOI 10.1016/j.jim.2005.02.007; Alix-Panabieres C, 2014, NAT REV CANCER, V14, P623, DOI 10.1038/nrc3820; Allen PJ, 2017, ANN SURG, V265, P185, DOI 10.1097/SLA.0000000000001763; Ameri K, 2010, BRIT J CANCER, V102, P561, DOI 10.1038/sj.bjc.6605491; Ankeny JS, 2016, BRIT J CANCER, V114, P1367, DOI 10.1038/bjc.2016.121; Ashworth T. R., 1869, AUST MED J, V14, P146; Baslan T, 2017, NAT REV CANCER, V17, P557, DOI 10.1038/nrc.2017.58; Bhagwat N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23217-5; Bidard FC, 2013, ANN ONCOL, V24, P2057, DOI 10.1093/annonc/mdt176; Bidard F.C., 2018, J NATL CANC I; Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021; Broutier L, 2016, NAT PROTOC, V11, P1724, DOI 10.1038/nprot.2016.097; Brychta N, 2017, ONCOTARGET, V8, P86143, DOI 10.18632/oncotarget.21026; Carter L, 2017, NAT MED, V23, P114, DOI 10.1038/nm.4239; Court CM, 2018, ANN SURG ONCOL, V25, P1000, DOI 10.1245/s10434-017-6290-8; Court CM, 2016, J MOL DIAGN, V18, P688, DOI 10.1016/j.jmoldx.2016.03.006; Court CM, 2015, EXPERT REV MOL DIAGN, V15, P1491, DOI 10.1586/14737159.2015.1091311; de Albuquerque A, 2012, ONCOLOGY-BASEL, V82, P3, DOI 10.1159/000335479; Dotan E, 2016, PANCREAS, V45, P1131, DOI 10.1097/MPA.0000000000000619; Effenberger K.E., 2018, CLIN CANC RES; Es HA, 2018, TRENDS BIOTECHNOL, V36, P358, DOI 10.1016/j.tibtech.2017.12.005; Fischer JC, 2013, P NATL ACAD SCI USA, V110, P16580, DOI 10.1073/pnas.1313594110; Friedlander TW, 2014, INT J CANCER, V134, P2284, DOI 10.1002/ijc.28561; Gemenetzis G, 2018, AM SURG ASS 138 ANN; Gupta V, 2012, BIOMICROFLUIDICS, V6, DOI 10.1063/1.4731647; Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014; Hall CS, 2016, J AM COLL SURGEONS, V223, P20, DOI 10.1016/j.jamcollsurg.2016.02.021; Heller G, 2018, J CLIN ONCOL, V36, P572, DOI 10.1200/JCO.2017.75.2998; Hoffmann K, 2007, WORLD J GASTROENTERO, V13, P257, DOI 10.3748/wjg.v13.i2.257; Hou YC, 2014, CANCER-AM CANCER SOC, V120, P2766, DOI 10.1002/cncr.28774; Ilie M, 2018, CLIN CHEM LAB MED, V56, P980, DOI 10.1515/cclm-2017-0764; Ilie M, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.11; Jan YJ, 2018, ADV DRUG DELIVER REV, V125, P78, DOI 10.1016/j.addr.2018.03.006; Karabacak NM, 2014, NAT PROTOC, V9, P694, DOI 10.1038/nprot.2014.044; Khoja L, 2012, BRIT J CANCER, V106, P508, DOI 10.1038/bjc.2011.545; Khoo BL, 2018, NAT PROTOC, V13, P34, DOI 10.1038/nprot.2017.125; Khoo BL, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600274; Khoo BL, 2015, ONCOTARGET, V6, P15578; Krantz BA, 2018, CLIN CANCER RES, V24, P2241, DOI 10.1158/1078-0432.CCR-16-3169; Krebs MG, 2011, J CLIN ONCOL, V29, P1556, DOI 10.1200/JCO.2010.28.7045; Kulemann B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04601-z; Kurihara T, 2008, J HEPATO-BILIARY-PAN, V15, P189, DOI 10.1007/s00534-007-1250-5; Li M, 2014, BIOMED RES INT, DOI 10.1155/2014/981261; Luk AWS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051047; Maheswaran S, 2015, CANCER RES, V75, P2411, DOI 10.1158/0008-5472.CAN-15-0145; Massague J, 2016, NATURE, V529, P298, DOI 10.1038/nature17038; Mataki Y, 2004, CLIN CANCER RES, V10, P3807, DOI 10.1158/1078-0432.CCR-03-0130; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Mokdad AA, 2017, J CLIN ONCOL, V35, P515, DOI 10.1200/JCO.2016.68.5081; Noone AM, 2018, SEER CANC STAT REV 1; Okubo K, 2017, EJSO-EUR J SURG ONC, V43, P1050, DOI 10.1016/j.ejso.2017.01.241; Poruk KE, 2017, CLIN CANCER RES, V23, P2681, DOI 10.1158/1078-0432.CCR-16-1467; Poruk KE, 2016, ANN SURG, V264, P1073, DOI 10.1097/SLA.0000000000001600; Qin JB, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-23; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Salvianti F, 2017, EXPERT REV MOL DIAGN, V17, P975, DOI 10.1080/14737159.2017.1381561; Saucedo-Zeni N, 2012, INT J ONCOL, V41, P1241, DOI 10.3892/ijo.2012.1557; Sefrioui D, 2017, BRIT J CANCER, V117, P1017, DOI 10.1038/bjc.2017.250; Sergeant G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-47; Sharma S, 2018, BIOTECHNOL ADV, V36, P1063, DOI 10.1016/j.biotechadv.2018.03.007; Sho S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3447-6; Sho SN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170897; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Soeth E, 2005, J CANCER RES CLIN, V131, P669, DOI 10.1007/s00432-005-0008-1; Stefansson S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2330-1; Stephenson D, 2017, ONCOTARGET, V8, P107223, DOI 10.18632/oncotarget.19928; Uchikura K, 2002, ANN SURG ONCOL, V9, P364, DOI 10.1245/aso.2002.9.4.364; Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774; Vona G, 2000, AM J PATHOL, V156, P57, DOI 10.1016/S0002-9440(10)64706-2; Wong MCS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45846; Xu TJ, 2017, ONCOTARGET, V8, P62524, DOI 10.18632/oncotarget.19122; Yan WT, 2017, SCI REP-UK, V7, DOI 10.1038/srep43464; Yermilov I, 2009, ANN SURG ONCOL, V16, P554, DOI 10.1245/s10434-008-0178-6; Yu KH, 2014, CLIN CANCER RES, V20, P5281, DOI 10.1158/1078-0432.CCR-14-0531; Yu M, 2014, SCIENCE, V345, P216, DOI 10.1126/science.1253533; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zhang LX, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005109; Zhang YJ, 2015, INT J CANCER, V136, P1228, DOI 10.1002/ijc.29070; Zhang Z, 2014, ONCOTARGET, V5, P12383, DOI 10.18632/oncotarget.2592; Zhou JH, 2011, J SURG RES, V171, P631, DOI 10.1016/j.jss.2010.05.007	85	4	4	1	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	9					809	820		10.1080/14737159.2018.1511429			12	Pathology	Pathology	GR6IV	WOS:000442753800005	30099926				2019-10-28	
J	Cagli, F; Uysal, G; Oz, L; Akkaya, H; Aksoy, H; Karakilic, EU; Acmaz, G				Cagli, Fulya; Uysal, Gulsum; Oz, Leyla; Akkaya, Hatice; Aksoy, Huseyin; Karakilic, Eda Ulku; Acmaz, Gokhan			Serum Galectin 7 is Not Useful to Predict Abortion in the First Trimester	FETAL AND PEDIATRIC PATHOLOGY			English	Article						galectin-7; pregnancy; threatened abortion; prognosis; lectins	ENDOMETRIUM; PREGNANCIES; EXPRESSION; INTERFACE	Objective: Galectins are animal lectins that bind to surface glycoproteins expressed at the fetal-maternal interface. The aim of this prospective case-control study was to investigate the possible relationship between levels of maternal serum galectin-7 and threatened abortion (TA) and to determine whether serum galectin-7 had any prognostic value. Methods: This prospective study was conducted between August 2014 and February 2015. Included in the study were 31 consecutive pregnant women who were hospitalized for TA between 6 and 14 weeks of gestation and 33 healthy gestational age matched pregnant women without any symptoms of miscarriage. Serum galectin-7 levels were measured via ELISA. Results: The mean serum galectin-7 levels of the two groups were not significantly different (31 TA patients: 2.84 + 0.43 pg/mL, 33 controls: 2.785 +/- 0.32 pg/mL, p = 0.543). Six pregnancies in the TA group resulted in abortion (19.4%). Conclusion: Serum galectin-7 was not useful for predicting prognosis in TA.	[Cagli, Fulya; Aksoy, Huseyin; Karakilic, Eda Ulku; Acmaz, Gokhan] Univ Hlth Sci Training & Res Hosp, Dept Obstet & Gynecol, Kayseri, Turkey; [Uysal, Gulsum] Adana City Res & Educ Hosp, Adana, Turkey; [Oz, Leyla] Univ Hlth Sci Training & Res Hosp, Dept Biochem, Kayseri, Turkey; [Akkaya, Hatice] Zekai Tahir Burak Womens Hlth Training & Res Hosp, Dept Obstet & Gynecol, Ankara, Turkey	Uysal, G (reprint author), Adana City Res & Educ Hosp, Adana, Turkey.	gulsumaykut@yahoo.com	Akkaya, Hatice/S-5660-2018	Akkaya, Hatice/0000-0002-9613-1712			Aksoy H., 2015, Turkiye Klinikleri Jinekoloji Obstetrik, V25, P92, DOI 10.5336/gynobstet.2014-42689; Ball RH, 1996, AM J OBSTET GYNECOL, V174, P996, DOI 10.1016/S0002-9378(96)70339-3; Cowans NJ, 2008, PRENATAL DIAG, V28, P121, DOI 10.1002/pd.1921; de La Rochebrochard E, 2002, HUM REPROD, V17, P1649, DOI 10.1093/humrep/17.6.1649; Hanita O, 2012, Malays J Pathol, V34, P41; Jeschke U, 2013, PLACENTA, V34, P863, DOI 10.1016/j.placenta.2013.07.005; Kaur Manpreet, 2016, Asian Pac J Cancer Prev, V17, P455; Knofler M, 2010, INT J DEV BIOL, V54, P269, DOI 10.1387/ijdb.082769mk; Menkhorst E, 2014, PLACENTA, V35, P281, DOI 10.1016/j.placenta.2014.01.009; Menkhorst EM, 2014, PLACENTA, V35, P195, DOI 10.1016/j.placenta.2014.01.004; Phipps MG, 2000, OBSTET GYNECOL, V95, P227, DOI 10.1016/S0029-7844(99)00480-9; Schulz H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061230; Siriwachirachai T, 2011, THAI J OBSTET GYNAEC, V19, P97; Than NG, 2012, TRENDS ENDOCRIN MET, V23, P23, DOI 10.1016/j.tem.2011.09.003; Tirado-Gonzalez I, 2013, MOL HUM REPROD, V19, P43, DOI 10.1093/molehr/gas043; Unverdorben L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050644; von Wolff M, 2005, MOL HUM REPROD, V11, P189, DOI 10.1093/molehr/gah144	17	1	1	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					141	146		10.1080/15513815.2018.1453001			6	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500001	29693486				2019-10-28	
J	Nakajima, J; Tsutsumi, N; Nara, S; Ishii, H; Suganami, Y; Sunohara, D; Kawashima, H				Nakajima, Junya; Tsutsumi, Norito; Nara, Shonosuke; Ishii, Hiroki; Suganami, Yusuke; Sunohara, Daisuke; Kawashima, Hisashi			Correlations of Enzyme Levels at Birth in Stressed Neonates with Short-Term Outcomes	FETAL AND PEDIATRIC PATHOLOGY			English	Article						enzyme; mechanical ventilation; perinatal asphyxia	ASPHYXIA; ENCEPHALOPATHY; NEWBORNS; DYNAMICS; HYPOXIA; INJURY	Introduction: Multi-organ injury causes leakage of several intracellular enzymes into the circulation. We evaluated the correlation between the serum-leaked intracellular enzyme levels at the beginning of treatment and the outcome in perinatally stressed neonates. Materials and methods: We retrospectively studied neonates whose 1 minute Apgar score was < 7.We collected initial venous blood sample data, including aspartate transaminase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH), and creatine kinase (CK) levels, and correlated these with patient short-term outcomes. Results: Of 60 neonates, nine patients were treated with therapeutic hypothermia, and 32 needed mechanical ventilation. The therapeutic hypothermia group showed significantly larger base deficit, and higher lactate, AST, ALT, LDH, and CK (all p < 0.01). The duration of mechanical ventilation significantly correlated with AST, ALT, LDH, and CK levels (all p < 0.01). Conclusion: Initial enzyme levels are useful for predicting the duration of mechanical ventilation in stressed neonates.	[Nakajima, Junya; Tsutsumi, Norito; Nara, Shonosuke; Ishii, Hiroki; Suganami, Yusuke; Sunohara, Daisuke; Kawashima, Hisashi] Tokyo Med Univ, Dept Pediat, Shinjuku Ku, Tokyo, Japan; [Nakajima, Junya] Kameda Med Ctr, Dept Neonatol, Higashi Cho, Kamogawa City, Chiba, Japan	Nakajima, J (reprint author), 929 Higashi Cho, Chiba, Chiba 2968602, Japan.	ob13po@hotmail.co.jp					Ahearne Caroline E, 2016, World J Clin Pediatr, V5, P67, DOI 10.5409/wjcp.v5.i1.67; Association JN, 2007, MANUAL NEONATAL INTE; Chhavi N, 2014, PEDIATR GASTROENTERO, V17, P162, DOI 10.5223/pghn.2014.17.3.162; Choudhary M, 2015, CLIN MED INSIGHTS-PE, V9, P1, DOI 10.4137/CMPed.S21426; Hankins GDV, 2002, OBSTET GYNECOL, V99, P688, DOI 10.1016/S0029-7844(02)01959-2; Jensen A, 1999, EUR J OBSTET GYN R B, V84, P155, DOI 10.1016/S0301-2115(98)00325-X; Karlsson M, 2006, ACTA PAEDIATR, V95, P1405, DOI 10.1080/08035250600693488; LACKMANN GM, 1993, ENZYME PROTEIN, V47, P160, DOI 10.1159/000468672; OMOKHODION SI, 1991, EUR HEART J, V12, P980; Ozkiraz S, 2013, J MATERN-FETAL NEO M, V26, P1245, DOI 10.3109/14767058.2013.776532; Pappas A, 2016, CLIN PERINATOL, V43, P559, DOI 10.1016/j.clp.2016.04.012; Reis DJ, 1997, ANN NY ACAD SCI, V835, P168, DOI 10.1111/j.1749-6632.1997.tb48628.x; Takenouchi T, 2012, BRAIN DEV-JPN, V34, P165, DOI 10.1016/j.braindev.2011.06.009; Watterberg KL, 2015, PEDIATRICS, V136, P819, DOI 10.1542/peds.2015-2651	14	0	0	2	2	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					157	165		10.1080/15513815.2018.1458928			9	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500003	29737915				2019-10-28	
J	Eros, FR; Simonyi, A; Tidrenczel, Z; Szabo, I; Rigo, J; Beke, A				Eros, Fanni Rebeka; Simonyi, Atene; Tidrenczel, Zsolt; Szabo, Istvan; Rigo, Janos, Jr.; Beke, Artur			Efficacy of Prenatal Ultrasound in Craniospinal Malformations According to Fetopathological and Postnatal Neonatological, Pathological Results	FETAL AND PEDIATRIC PATHOLOGY			English	Article						44/290 patients; craniospinal malformations; fetopathological and pathological examinations; prenatal ultrasound	CENTRAL-NERVOUS-SYSTEM; NEURAL-TUBE DEFECTS; FETAL MALFORMATIONS; ROUTINE ULTRASOUND; EARLY-PREGNANCY; DIAGNOSIS; ANOMALIES; FETUSES; TRIAL	Objective: Our objective is to examine the effectiveness of prenatal ultrasound diagnosis of craniospinal malformations compared to postnatal neonatological and pathological findings. Methods: Over a 7-year period, we preformed approximately 82500 prenatal ultrasounds of 26.827 pregnancies. We detected 290 fetuses with 351 craniospinal malformations. Results: Craniospinal abnormalities were found as a part of multiplex malformations in 84/290 cases: in 47/84 cases (55.95%) there was complete concurrence between prenatal and postnatal results. In 15/290 fetuses the craniospinal malformation was associated with chromosomal abnormalities. In 9/15 (60%) of these fetuses, malformations were fully diagnosed with ultrasound. Isolated craniospinal malformations occurred in 191/290 cases, in 162/191 (84.82%) the results of prenatal ultrasonography and postnatal or post abortion examinations showed complete concurrence. In addition to the 290 fetuses with craniospinal malformations, there were an additional 17 who were thought by ultrasound to have a craniospinal malformation, which could not be documented after birth (false positives). Conclusions: Prenatal ultrasound accurately diagnosed 218/290 (75,17%) craniospinal abnormalities, and partially defined the abnormalities in 9.66%, failed to detect abnormalities in 15.17%, with an approximate 0.06% false detection rate.	[Eros, Fanni Rebeka; Simonyi, Atene; Tidrenczel, Zsolt; Szabo, Istvan; Rigo, Janos, Jr.; Beke, Artur] Semmelweis Univ, Dept Obstet & Gynecol 1, Baross U 27, H-1088 Budapest, Hungary; [Tidrenczel, Zsolt] Med Ctr Hungarian Def Forces, Dept Obstet & Gynecol, Budapest, Hungary	Beke, A (reprint author), Semmelweis Univ, Dept Obstet & Gynecol 1, Baross U 27, H-1088 Budapest, Hungary.	beke.artur@noil.sote.hu	MedHabil, Artur Beke MD PhD/A-9482-2008	MedHabil, Artur Beke MD PhD/0000-0002-6826-7751			Barros ML, 2012, BRAS, V45, P309; Boyd PA, 2011, BIRTH DEFECTS RES A, V91, pS2, DOI 10.1002/bdra.20780; Cameron M, 2009, PRENATAL DIAG, V29, P402, DOI 10.1002/pd.2250; Copp AJ, 2013, LANCET NEUROL, V12, P799, DOI 10.1016/S1474-4422(13)70110-8; CRANE JP, 1994, AM J OBSTET GYNECOL, V171, P392, DOI 10.1016/S0002-9378(94)70040-0; D'Addario V, 2012, SEMIN FETAL NEONAT M, V17, P310, DOI 10.1016/j.siny.2012.06.007; De Keersmaecker B, 2011, FACTS VIEWS VIS OBGY, V3, P135; Fadda GM, 2009, EUR J OBSTET GYN R B, V144, P110, DOI 10.1016/j.ejogrb.2009.02.045; Garne E, 2010, EUR J PAEDIATR NEURO, V14, P150, DOI 10.1016/j.ejpn.2009.03.005; Gelber SE, 2017, J PERINAT MED, V45, P167, DOI 10.1515/jpm-2016-0220; Grandjean H, 1999, AM J OBSTET GYNECOL, V181, P446, DOI 10.1016/S0002-9378(99)70577-6; Isaksen CV, 1998, ULTRASOUND OBST GYN, V11, P246, DOI 10.1046/j.1469-0705.1998.11040246.x; LEVI S, 1991, ULTRASOUND OBST GYN, V1, P102, DOI 10.1046/j.1469-0705.1991.01020102.x; Levi S, 2002, PRENATAL DIAG, V22, P285, DOI 10.1002/pd.306; Rossi AC, 2017, EUR J OBSTET GYN R B, V210, P201, DOI 10.1016/j.ejogrb.2016.12.024; RUTLEDGE JC, 1986, PRENATAL DIAG, V6, P51, DOI 10.1002/pd.1970060108; Saltvedt S, 2006, BJOG-INT J OBSTET GY, V113, P664, DOI 10.1111/j.1471-0528.2006.00953.x; Taipale P, 2003, OBSTET GYNECOL, V101, P273, DOI 10.1016/S0029-7844(02)02590-5; VanDorsten JP, 1998, AM J OBSTET GYNECOL, V178, P742, DOI 10.1016/S0002-9378(98)70484-3; Whitlow BJ, 1999, BRIT J OBSTET GYNAEC, V106, P929, DOI 10.1111/j.1471-0528.1999.tb08432.x	20	1	1	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					166	176		10.1080/15513815.2018.1461282			11	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500004	29737917				2019-10-28	
J	Beksac, MS; Beksac, AT; Buyukeren, M; Tanacan, A; Bektas, H; Gucer, S				Beksac, M. Sinan; Beksac, Alp Tuna; Buyukeren, Melek; Tanacan, Atakan; Bektas, Hatice; Gucer, Safak			Are Congenital Urinary Tract Abnormalities Linked to Maternal Methylenetetrahydrofolate Reductase Polymorphisms in Fetuses of Intentionally Terminated Pregnancies with Oligo- or Anhydramnios ?	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Anhydramnios; methylenetetrahydrofolate reductase polymorphisms; oligohydramnios; renal anomalies	AMNIOTIC-FLUID VOLUME; A SINGLE-CENTER; HEART-DEFECTS; RENAL ORIGIN; RISK-FACTOR; MTHFR; OLIGOHYDRAMNIOS; HYPERHOMOCYSTEINEMIA; METAANALYSIS; ASSOCIATION	Objective: We aimed to evaluate fetuses of terminated pregnancies with oligo-or anhydramnios (OAH) to further investigate the association between maternal methylenetetrahydrofolate reductase (MTHFR) polymorphisms and fetal urinary tract malformations. Materials and Methods: This retrospective study included 16 pregnancies with OAH (with normal fetal karyotype) that were intentionally terminated before 22nd gestational week. Fetal autopsy was performed in all cases. We evaluated cases for presence of DNA methylation pathway-related gene polymorphisms. Results: We demonstrated that renal abnormalities and disorders exist in 75% of the cases. Pulmonary system anomalies and single umbilical artery were the most frequently observed associated abnormalities. Polymorphisms with known reduced MTHFR activity were found in 81.8% (9/11) of the cases.Association between urinary system abnormalities and polymorphisms with known reduced MTHFR activity was observed in 88.8% (8/9) of the cases. Conclusion: Physicians should keep in mind that polymorphisms with known reduced MTHFR activity may be associated with urinary tract abnormalities and OAH.	[Beksac, M. Sinan; Tanacan, Atakan] Hacettepe Univ, Dept Obstet & Gynecol, Div Perinatol, Ankara, Turkey; [Beksac, Alp Tuna] Hacettepe Univ, Dept Urol, Ankara, Turkey; [Buyukeren, Melek] Hacettepe Univ, Dept Pediat, Div Neonatol, Ankara, Turkey; [Bektas, Hatice] Hacettepe Univ, Dept Pediat, Ankara, Turkey; [Gucer, Safak] Hacettepe Univ, Dept Pediat, Div Pediat Pathol, Ankara, Turkey	Tanacan, A (reprint author), Hacettepe Univ Hosp, Ankara, Turkey.	atakantanacan@yahoo.com					Ashwal E, 2014, ARCH GYNECOL OBSTET, V290, P875, DOI 10.1007/s00404-014-3292-7; Beksac M. Sinan, 2007, Archives of Gynecology and Obstetrics, V276, P547, DOI 10.1007/s00404-007-0367-8; Beloosesky R, OLIGOHYDRAMNIOS; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; BRACE RA, 1989, AM J OBSTET GYNECOL, V161, P382, DOI 10.1016/0002-9378(89)90527-9; Brace RA, 1997, CLIN OBSTET GYNECOL, V40, P280, DOI 10.1097/00003081-199706000-00005; Chaudhary R, 2017, INT J REPROD CONTRAC, V6, P2401, DOI [10.18203/2320-1770.ijrcog20172320, DOI 10.18203/2320-1770.IJRCOG20172320]; Cleves MA, 2011, PAEDIATR PERINAT EP, V25, P124, DOI 10.1111/j.1365-3016.2010.01160.x; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; Gadd R L, 1966, J Obstet Gynaecol Br Commonw, V73, P11, DOI 10.1111/j.1471-0528.1966.tb05114.x; Goyette P, 1998, MAMM GENOME, V9, P652, DOI 10.1007/s003359900838; Grijseels EWM, 2011, PRENATAL DIAG, V31, P1039, DOI 10.1002/pd.2827; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Kaur A, 2016, J GENET, V95, P505, DOI 10.1007/s12041-016-0657-7; Kemper MJ, 2007, EUR J PEDIATR, V166, P393, DOI 10.1007/s00431-006-0368-9; Khatun T, 2017, MED PHOENIX, V1, P23, DOI [10.3126/medphoenix.v1i1.17885, DOI 10.3126/MEDPHOENIX.V1I1.17885]; LI DK, 1995, EPIDEMIOLOGY, V6, P212, DOI 10.1097/00001648-199505000-00004; Locatelli A, 2004, J Matern Fetal Neonatal Med, V15, P233, DOI 10.1080/14767050410001668671; Magann EF, 2000, AM J OBSTET GYNECOL, V182, P1581, DOI 10.1067/mob.2000.107325; Mehler K, 2011, NEPHROL DIAL TRANSPL, V26, P3514, DOI 10.1093/ndt/gfr046; Melcer Y, 2017, PRENATAL DIAG, V37, P215, DOI 10.1002/pd.4988; MERCER LJ, 1984, AM J OBSTET GYNECOL, V149, P355, DOI 10.1016/0002-9378(84)90237-0; ozek A, 2016, GYNECOL OBSTET REPRO, V19, P36; Rabie N, 2017, ULTRASOUND OBST GYN, V49, P442, DOI 10.1002/uog.15929; Rozen R, 1997, THROMB HAEMOSTASIS, V78, P523; RUTHERFORD SE, 1987, OBSTET GYNECOL, V70, P353; Spiro JE, 2015, ARCH GYNECOL OBSTET, V292, P327, DOI 10.1007/s00404-015-3648-7; Turgal M, 2013, J OBSTET GYNAECOL, V33, P904, DOI 10.3109/01443615.2013.838547; van Beynum IM, 2007, QJM-INT J MED, V100, P743, DOI 10.1093/qjmed/hcm094; van Beynum IM, 2006, EUR HEART J, V27, P981, DOI 10.1093/eurheartj/ehi815; Verldeij-Hagoort A, 2007, AM J MED GENET A, V143A, P952, DOI 10.1002/ajmg.a.31684; Vikraman SK, 2017, EUR J OBSTET GYN R B, V212, P96, DOI 10.1016/j.ejogrb.2017.03.026; Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714; Zhang ZQ, 2016, MOL BIOL REP, V43, P1147, DOI 10.1007/s11033-016-4047-2	34	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					177	183		10.1080/15513815.2018.1461283			7	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500005	29737941				2019-10-28	
J	Gonzalez, C; Serrano, MG; Lopez, CB; Garcia-Riano, T; Calero, VB; Perea, RM; Mogollon, BR; Rojas, AQ; Climent, AG; Valenciano, FC				Gonzalez, Cristina; Gutierrez Serrano, Miriam; Barbancho Lopez, Carmen; Garcia-Riano, Taida; Barea Calero, Vanesa; Moreno Perea, Rebeca; Rodriguez Mogollon, Begona; Queipo Rojas, Amelia; Garcia Climent, Ana; Cava Valenciano, Fernando			CGH Array and Karyotype as Complementary Tools in Prenatal Diagnosis: Prenatal Diagnosis of a 4q Derivative Chromosome from Maternal 4q;11q Translocation	FETAL AND PEDIATRIC PATHOLOGY			English	Article						array; translocation; derivative chromosome; prenatal diagnosis	REARRANGEMENTS; DELETIONS; ANOMALIES	Background: There is controversy whether chromosomal microarray (CMA) can replace karyotyping in prenatal diagnosis. Chromosomal microarray may detect more clinically significant chromosomal imbalances than karyotyping in a shorter time but does not detect inversions, triploidies or low mosaicisms. Case report: Amniocentesis was performed in the late second trimester based on ultrasound abnormalities. A CMA, obtained at 10 days, demonstrated a terminal deletion in 4q34.3q352 and a duplication in 11q21-q25. The karyotype results, obtained 1 week later, showed a derivative chromosome 4 inherited from a maternal balanced 4;11 translocation. Conclusion: CMA and karyotype were complementary in this case, together permitting a more accurate diagnosis and genetic counseling than if only one method was used.	[Gonzalez, Cristina; Gutierrez Serrano, Miriam; Barea Calero, Vanesa; Moreno Perea, Rebeca; Rodriguez Mogollon, Begona; Queipo Rojas, Amelia] Hosp Univ Infanta Sofia, Genet Dept, Madrid, Spain; [Barbancho Lopez, Carmen; Garcia-Riano, Taida] Hosp Univ Infanta Sofia, Gynecol & Obstret Dept, Madrid, Spain; [Garcia Climent, Ana] CIALAB, Genet, Calle Cristo Paz, Alicante, Spain; [Cava Valenciano, Fernando] Hosp Univ Infanta Sofia, Clin Lab, Madrid, Spain	Gonzalez, C (reprint author), Hosp Infanta Sofia, Genet Dept, Avda Europa 34, Madrid 28702, Spain.	cgonzalezggen@yahoo.es					Baptista J, 2008, AM J HUM GENET, V82, P927, DOI 10.1016/j.ajhg.2008.02.012; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; De Gregori M, 2007, J MED GENET, V44, P750, DOI 10.1136/jmg.2007.052787; de Wit MC, 2014, ULTRASOUND OBST GYN, V43, P139, DOI 10.1002/uog.12575; Hillman SC, 2011, ULTRASOUND OBST GYN, V37, P6, DOI 10.1002/uog.7754; Kan ASY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087988; Lee CN, 2012, BJOG-INT J OBSTET GY, V119, P614, DOI 10.1111/j.1471-0528.2012.03279.x; Manolakos E, 2013, MOL CYTOGENET, V6, DOI 10.1186/1755-8166-6-47; Miny Peter, 2013, Microarrays (Basel), V2, P304, DOI 10.3390/microarrays2040304; PIHKO H, 1981, HUM GENET, V58, P129, DOI 10.1007/BF00278696; Rankin J, 2005, ARCH DIS CHILD-FETAL, V90, pF374, DOI 10.1136/adc.2003.047902; Robson SC, 2017, NIHR J LIB; Rossi AC, 2013, OBSTET GYNECOL, V122, P1160, DOI 10.1097/AOG.0000000000000015; Wapner RJ, 2012, NEW ENGL J MED, V367, P2175, DOI 10.1056/NEJMoa1203382; WARBURTON D, 1991, AM J HUM GENET, V49, P995	15	2	2	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					184	190		10.1080/15513815.2018.1467518			7	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500006	29771170				2019-10-28	
J	Pinar, MH; Gibbins, K; He, M; Kostadinov, S; Silver, R				Pinar, M. Halit; Gibbins, Karen; He, Mai; Kostadinov, Stefan; Silver, Robert			Early Pregnancy Losses: Review of Nomenclature, Histopathology, and Possible Etiologies	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Early pregnancy loss; nomenclature; miscarriage; histopathology	GESTATIONAL TROPHOBLASTIC DISEASE; SPONTANEOUS-ABORTION; PLACENTAL PATHOLOGY; SPIRAL ARTERIES; PARVOVIRUS B19; MISCARRIAGE; FETAL; ULTRASOUND; DIAGNOSIS; CYTOMEGALOVIRUS	Miscarriage is a frequent complication of human pregnancy: similar to 50% to 70% of spontaneous conceptions are lost prior to the second trimester. Etiology of miscarriage includes genetic abnormalities, infections, immunological and implantation disorders, uterine and endocrine abnormalities, and lifestyle factors. Given such variability, knowledge regarding causes, pathophysiological mechanisms, and morphologies of primary early pregnancy loss has significant gaps; often, pregnancy losses remain unexplained. Pathologic evaluation of miscarriage tissue is an untapped source of knowledge. Although miscarriage specimens comprise a significant part of pathologists' workload, information reported from these specimens is typically of minimal clinical utility for delineating etiology or predicting recurrence risk. Standardized terminology is available, though not universally used. We reintroduce the terminology and review new information about early pregnancy losses and their morphologies. Current clinical terminology is inconsistent, hampering research progress. This review is a resource for diagnostic pathologists studying this complex problem.	[Pinar, M. Halit] Brown Univ, Warren Alpert Med Sch, Perinatal & Pediat Pathol, Providence, RI 02905 USA; [Gibbins, Karen] Univ Utah Hosp, Div Maternal & Fetal Med, Obstet & Gynecol, Salt Lake City, UT USA; [He, Mai] Washington Univ, Sch Med, Pathol & Lab Med, Div Pediat Pathol, St Louis, MO USA; [Kostadinov, Stefan] Brown Univ, Women & Infants Hosp, Div Perinatal & Pediat Pathol, Pathol & Lab Med,Warren Alpert Med Sch, Providence, RI 02905 USA; [Silver, Robert] Univ Utah Hosp, Div Maternal Fetal Med, Obstet & Gynecol, Salt Lake City, UT USA	Pinar, MH (reprint author), Brown Univ, Warren Alpert Med Sch, Div Perinatal & Pediat Pathol, 101 Dudley St, Providence, RI 02905 USA.	halit.pinar@gmail.com		Pinar, MD, Halit/0000-0001-6426-4302			[Anonymous], 2001, ACOG PRACT B MAN REC; Avagliano L, 2011, J CLIN PATHOL, V64, P1064, DOI 10.1136/jclinpath-2011-200092; Boyd TK, 2000, HUM PATHOL, V31, P1389, DOI 10.1016/S0046-8177(00)80009-X; Branch DW, 2010, NEW ENGL J MED, V363, P1740, DOI 10.1056/NEJMcp1005330; Brosens JJ, 2002, AM J OBSTET GYNECOL, V187, P1416, DOI 10.1067/mob.2002.127305; Carr DH, 1975, PATHOL ANNU, V10, P931; Cartwright JE, 2010, REPRODUCTION, V140, P803, DOI 10.1530/REP-10-0294; Casikar I, 2012, AUST NZ J OBSTET GYN, V52, P597, DOI 10.1111/ajo.12022; Chan YY, 2011, ULTRASOUND OBST GYN, V38, P371, DOI 10.1002/uog.10056; Charnock-Jones DS, 2000, BEST PRACT RES CL OB, V14, P953, DOI 10.1053/beog.2000.0137; Conway DA, 2011, FERTIL STERIL, V95, P503, DOI 10.1016/j.fertnstert.2010.09.019; Craven CM, 2002, AM J OBSTET GYNECOL, V186, P291, DOI 10.1067/mob.2002.119717; DEBRAEKELEER M, 1990, HUM REPROD, V5, P519, DOI 10.1093/oxfordjournals.humrep.a137135; Dekel N, 2010, AM J REPROD IMMUNOL, V63, P17, DOI 10.1111/j.1600-0897.2009.00792.x; Doubilet PM, 2014, ULTRASOUND Q, V30, P3, DOI 10.1097/RUQ.0000000000000060; Doubilet PM, 2013, NEW ENGL J MED, V369, P1443, DOI 10.1056/NEJMra1302417; Dukhovny S, 2009, CURR OPIN ENDOCRINOL, V16, P451, DOI 10.1097/MED.0b013e328332b808; Ernst LM, 2013, ARCH PATHOL LAB MED, V137, P326, DOI 10.5858/arpa.2012-0090-RA; Farquharson RG, 2005, HUM REPROD, V20, P3008, DOI 10.1093/humrep/dei167; Filges I, 2015, PRENATAL DIAG, V35, P1005, DOI 10.1002/pd.4464; Garcia-Enguidanos A, 2002, EUR J OBSTET GYN R B, V102, P111, DOI 10.1016/S0301-2115(01)00613-3; GENEST DR, 1995, HUM PATHOL, V26, P201, DOI 10.1016/0046-8177(95)90038-1; Goddijn M, 2000, BEST PRACT RES CL OB, V14, P855, DOI 10.1053/beog.2000.0124; Golubovsky MD, 2003, HUM REPROD, V18, P236, DOI 10.1093/humrep/deg060; Greenwold N, 2002, HUM REPROD, V17, P452, DOI 10.1093/humrep/17.2.452; Grinschgl I, 2013, VIRCHOWS ARCH, V462, P175, DOI 10.1007/s00428-012-1350-8; Guarner J, 2000, EMERG INFECT DIS, V6, P487, DOI 10.3201/eid0605.000507; Hardy K, 2015, TRANSL PEDIATR, V4, P189, DOI 10.3978/j.issn.2224-4336.2015.03.05; Hoffner L, 2012, CANCER GENET-NY, V205, P63, DOI 10.1016/j.cancergen.2012.01.004; Horn LC, 2006, EUR J OBSTET GYN R B, V128, P10, DOI 10.1016/j.ejogrb.2006.01.024; HouwertaEuroDe Jong MH, 1990, BRIT J OBSTET GYNAEC, V97, P5335; Hui P, 2005, ADV ANAT PATHOL, V12, P116, DOI 10.1097/01.pap.0000163960.11107.73; HUSTIN J, 1990, PLACENTA, V11, P477, DOI 10.1016/S0143-4004(05)80193-6; Jaslow CR, 2014, OBSTET GYN CLIN N AM, V41, P57, DOI 10.1016/j.ogc.2013.10.002; Jauniaux E, 2005, ULTRASOUND OBST GYN, V25, P613, DOI 10.1002/uog.1892; Jauniaux E, 2005, PLACENTA, V26, P114, DOI 10.1016/j.placenta.2004.05.011; Jenderny J, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-38; Jeve Y, 2011, ULTRASOUND OBST GYN, V38, P489, DOI 10.1002/uog.10108; Jindal P, 2007, HUM REPROD, V22, P313, DOI 10.1093/humrep/de1128; Jurkovic D, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f3676; Kalousek DK, 1996, J MED GENET, V33, P529, DOI 10.1136/jmg.33.7.529; Kohut KG, 1997, AM J REPROD IMMUNOL, V37, P257; Lapinsky SE, 2013, CRIT CARE CLIN, V29, P509, DOI 10.1016/j.ccc.2013.03.006; Larsen EC, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-154; Lathi RB, 2007, J ASSIST REPROD GEN, V24, P521, DOI 10.1007/s10815-007-9166-1; Lathi RB, 2011, SEMIN REPROD MED, V29, P463, DOI 10.1055/s-0031-1293200; Lee KA, 2013, PLACENTA, V34, P432, DOI 10.1016/j.placenta.2013.02.003; Levy B, 2014, OBSTET GYNECOL, V124, P202, DOI 10.1097/AOG.0000000000000325; Lurain JR, 2010, AM J OBSTET GYNECOL, V203, P531, DOI 10.1016/j.ajog.2010.06.073; Lyall F, 2005, PLACENTA, V26, pS31, DOI 10.1016/j.placenta.2005.02.010; Massalska D, 2017, J OBSTET GYNAECOL RE, V43, P23, DOI 10.1111/jog.13179; Musizzano Y, 2010, VIRCHOWS ARCH, V456, P543, DOI 10.1007/s00428-010-0883-y; Nguyen NMP, 2014, CURR OBSTET GYNECOL, V3, P55, DOI 10.1007/s13669-013-0076-1; Norwitz ER, 2001, NEW ENGL J MED, V345, P1400, DOI 10.1056/NEJMra000763; NOVAK RW, 1990, PATHOL ANNU, V25, P297; Nuovo GJ, 2005, DIAGN MOL PATHOL, V14, P152, DOI 10.1097/01.pas.0000176769.18423.37; Pandya PP, 1996, ULTRASOUND OBST GYN, V7, P170, DOI 10.1046/j.1469-0705.1996.07030170.x; Papaioannou GI, 2011, HUM REPROD, V26, P1685, DOI 10.1093/humrep/der130; Redline RW, 1998, MODERN PATHOL, V11, P762; Royal College of Obstetricians and Gynaecologists, 2006, MAN EARL PREGN LOSS; Sahoo T, 2017, GENET MED, V19, P83, DOI 10.1038/gim.2016.69; Sebire NJ, 2008, J CLIN PATHOL, V61, P1276, DOI 10.1136/jcp.2008.055251; Sierra S, 2006, SEMIN REPROD MED, V24, P17, DOI 10.1055/s-2006-931797; Silver RM, 2011, OBSTET GYNECOL, V118, P1402, DOI 10.1097/AOG.0b013e3182392977; Spinillo A, 2014, EARLY HUM DEV, V90, pS7, DOI 10.1016/S0378-3782(14)70003-9; Stephenson MD, 2002, HUM REPROD, V17, P446, DOI 10.1093/humrep/17.2.446; Syridou G, 2008, J MED VIROL, V80, P1776, DOI 10.1002/jmv.21293; SZULMAN AE, 1991, ARCH PATHOL LAB MED, V115, P696; Twig G, 2012, J AUTOIMMUN, V38, pJ275, DOI 10.1016/j.jaut.2011.11.014; van den Berg MM, 2012, BIOCHIM BIOPHYS ACTA, V1822, P19519; Wohlfahrt J, 2000, EPIDEMIOLOGY, V11, P92, DOI 10.1097/00001648-200001000-00021; Zhou Y, 1998, J REPROD IMMUNOL, V39, P197, DOI 10.1016/S0165-0378(98)00022-9; Zhou Y, 2015, J MED VIROL, V87, P1749, DOI 10.1002/jmv.24218; Zlopasa G, 2007, INT J GYNECOL OBSTET, V98, P129, DOI 10.1016/j.ijgo.2007.04.022	74	3	3	2	3	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					191	209		10.1080/15513815.2018.1455775			19	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500007	29737906				2019-10-28	
J	Sun, LL; Hickey, CA; Harris, BR; Maluf, HM; He, M				Sun, Lulu; Hickey, Christina A.; Harris, Brendan R.; Maluf, Horacio M.; He, Mai			Pediatric Sloughing Esophagitis: A Case Report and Discussion	FETAL AND PEDIATRIC PATHOLOGY			English	Article						endoscopy; esophagitis; gastroenterology; pediatrics	DISSECANS SUPERFICIALIS; PARAKERATOSIS; FEATURES	Background: Sloughing esophagitis is an uncommon entity with an unclear pathogenesis characterized by desquamating sheets of squamous mucosa. It has been associated with bullous dermatologic disorders, other autoimmune diseases and has been most commonly reported in elderly, debilitated individuals on multiple medications. Case report: We report sloughing esophagitis in a previously healthy 17 year-old girl. While the initial trigger of her esophagitis is unclear, she improved with proton pump inhibitor therapy and swallowed fluticasone, with complete resolution after 6 months. Conclusions: Sloughing esophagitis can occur in the pediatric population. We discuss the presentation, differential diagnosis,and treatment of sloughing esophagitis in adolescents.	[Sun, Lulu; Hickey, Christina A.; Harris, Brendan R.; Maluf, Horacio M.; He, Mai] Washington Univ, Sch Med, Dept Pathol & Immunol, 425 S Euclid Ave,Box 8118, St Louis, MO 63110 USA	He, M (reprint author), Washington Univ, Sch Med, Dept Pathol & Immunol, 425 S Euclid Ave,Box 8118, St Louis, MO 63110 USA.	maihe@wustl.edu					Akhondi Hossein, 2014, Int J Biomed Sci, V10, P282; ASHWORTH MT, 1991, HISTOPATHOLOGY, V19, P303, DOI 10.1111/j.1365-2559.1991.tb00044.x; Carmack SW, 2009, AM J SURG PATHOL, V33, P1789, DOI 10.1097/PAS.0b013e3181b7ce21; Dumas-Campagna Myriam, 2014, J Clin Med Res, V6, P295, DOI 10.14740/jocmr1845w; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Guerra M-AR, 2015, ADV PEDIAT RES, V2; Hage-Nassar G, 2003, GASTROINTEST ENDOSC, V57, P140, DOI 10.1067/mge.2003.42; Hart PA, 2015, DIGEST DIS SCI, V60, P2049, DOI 10.1007/s10620-015-3590-3; Hokama A, 2010, WORLD J GASTRO ENDOS, V2, P252, DOI 10.4253/wjge.v2.i7.252; Kayhan B, 2011, ENDOSCOPY, V43, pE231, DOI 10.1055/s-0030-1256285; Mutalib M, 2013, J PEDIATR GASTR NUTR, V57, pE33, DOI 10.1097/MPG.0b013e31825a2286; Purdy JK, 2012, MODERN PATHOL, V25, P767, DOI 10.1038/modpathol.2011.204; Tu CH, 2007, ENDOSCOPY, V39, pE119, DOI 10.1055/s-2006-945173	13	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					210	215		10.1080/15513815.2018.1469702			6	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500008	29781748				2019-10-28	
J	Tonni, G; Grisolia, G; Zampriolo, P; Araujo, E; Ruano, R				Tonni, Gabriele; Grisolia, Gianpaolo; Zampriolo, Paolo; Araujo Junior, Edward; Ruano, Rodrigo			Early Prenatal Diagnosis of Blakes' Pouch Cyst by 2D/3D Ultrasound with Cristal and Realistic Vue Application	FETAL AND PEDIATRIC PATHOLOGY			English	Article						first trimester; Blake's pouch cyst; 2D/3D ultrasound; cristal Vue; realistic Vue; prenatal diagnosis	POSTERIOR MEMBRANOUS AREA; INTRACRANIAL TRANSLUCENCY; FOSSA; 4TH-VENTRICLE; ABNORMALITIES; ANATOMY	Introduction: Blake's pouch cyst (BPC) represents an abnormal development of the posterior membranous area of the fetal brain. Material and Methods: Two- and three-dimensional ultrasound with Cristal and Realistic Vue were used to characterized the early prenatal diagnosis. Results: At 9 weeks and 5 days a ballooning in the posterior fossa and resulting in an enlarged intracranial translucency (IT) was detected by 3D ultrasound using Cristal Vue in "inversion" mode and Cristal plus Realistic Vue. In addition, an increased nuchal translucency (7 mm) due to septated cystic hygroma (SCHy) was an associated finding. Hydrops fetalis ensued and a chorionic villus sampling at 12 weeks revealed a 45,X monosomy with persisting BPC. Follow up scan were planned fortnightly. A spontaneous miscarriage occurred at 16 weeks. Conclusion: Three-dimensional ultrasound with Cristal and Realistic Vue aided the prenatal diagnosis of BPC in the first trimester.	[Tonni, Gabriele] AUSL Reggio Emilia, Dept Obstet & Gynecol, Ist Ric Carattere Clin Sci, Reggio Emilia, Italy; [Grisolia, Gianpaolo; Zampriolo, Paolo] Carlo Poma Hosp, Dept Obstet & Gynecol, Azienda Socio Sanitaria Terr Mantova, Mantua, Italy; [Araujo Junior, Edward] Fed Univ Sao Paulo UNIFESP, Paulista Sch Med, Sao Paulo, Brazil; [Ruano, Rodrigo] Mayo Clin Minnesota, Div Maternal Fetal Med, Rochester, MN USA	Tonni, G (reprint author), Via G Amendola 2, I-42122 Reggio Emilia, Italy.	Tonni.Gabriele@ausl.re.it	Junior, Edward Araujo/E-1228-2012	Junior, Edward Araujo/0000-0002-6145-2532			Babcook CJ, 1996, AM J ROENTGENOL, V166, P427, DOI 10.2214/ajr.166.2.8553961; Blake JA, 1900, J COMP NEUROL, V10, P79, DOI 10.1002/cne.910100104; Bretelle F, 2002, ULTRASOUND OBST GYN, V20, P400, DOI 10.1046/j.1469-0705.2002.00813.x; Carroll SGM, 2000, ULTRASOUND OBST GYN, V16, P149, DOI 10.1046/j.1469-0705.2000.00199.x; Chaoui R, 2010, ULTRASOUND OBST GYN, V35, P133, DOI 10.1002/uog.7552; Contro E, 2014, ULTRASOUND OBST GYN, V43, P154, DOI 10.1002/uog.13227; Guibaud L, 2006, ULTRASOUND OBST GYN, V27, P477, DOI 10.1002/uog.2777; Lafouge A, 2012, ULTRASOUND OBST GYN, V40, P479, DOI 10.1002/uog.11099; Martinez-Ten P, 2018, ULTRASOUND OBST GYN, V51, P199, DOI 10.1002/uog.17445; Paladini D, 2012, ULTRASOUND OBST GYN, V39, P279, DOI 10.1002/uog.10138; Pires P, 2017, J ULTRAS MED, V36, P1963, DOI 10.1002/jum.14224; TortoriDonati P, 1996, CHILD NERV SYST, V12, P303, DOI 10.1007/BF00301017; Volpe P, 2012, ULTRASOUND OBST GYN, V39, P632, DOI 10.1002/uog.11101; Wuest A, 2017, ACTA OBSTET GYN SCAN, V96, P837, DOI 10.1111/aogs.13131	14	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	3					216	221		10.1080/15513815.2018.1467519			6	Pathology; Pediatrics	Pathology; Pediatrics	GQ4KK	WOS:000441640500009	29781742				2019-10-28	
J	Al-Hajeili, M; Alqassa, M; Alomran, A; Batarfi, B; Basunaid, B; Alshail, R; Alaydarous, S; Bokhary, R; Mosli, M				Al-Hajeili, Marwan; Alqassa, Maryam; Alomran, Astabraq; Batarfi, Bashaer; Basunaid, Bashaer; Alshail, Reem; Alaydarous, Shahad; Bokhary, Rana; Mosli, Mahmoud			The Diagnostic Accuracy of Cytology for the Diagnosis of Hepatobiliary and Pancreatic Cancers	ACTA CYTOLOGICA			English	Article						Hepatobiliary cancer; Biliary cytology; Pancreatic cytology histopathology; Diagnostic accuracy	BILIARY BRUSH CYTOLOGY; DUCT STRICTURES; EXPERIENCE; STENOSIS; LESIONS; YIELD; ERCP	Objective: Although cytology testing is considered a valuable method to diagnose tumors that are difficult to access such as hepato-biliary-pancreatic (HBP) malignancies, its diagnostic accuracy remains unclear. We therefore aimed to investigate the diagnostic accuracy of cytology testing for HBP tumors. Study Design: We performed a retrospective study of all cytology samples that were used to confirm radiologically detected HBP tumors between 2002 and 2016. The cytology techniques used in our center included fine needle aspiration (FNA), brush cytology, and aspiration of bile. Sensitivity, specificity, positive and negative predictive values, and likelihood ratios were calculated in comparison to histological confirmation. Results: From a total of 133 medical records, we calculated an overall sensitivity of 76%, specificity of 74%, a negative likelihood ratio of 0.30, and a positive likelihood ratio of 2.9. Cytology was more accurate in diagnosing lesions of the liver (sensitivity 79%, specificity 57%) and biliary tree (sensitivity 100%, specificity 50%) compared to pancreatic (sensitivity 60%, specificity 83%) and gallbladder lesions (sensitivity 50%, specificity 85%). Cytology was more accurate in detecting primary cancers (sensitivity 77%, specificity 73%) when compared to metastatic cancers (sensitivity 73%, specificity 100%). FNA was the most frequently used cytological technique to diagnose HBP lesions (sensitivity 78.8%). Conclusion: Cytological testing is efficient in diagnosing HBP cancers, especially for hepatobiliary tumors. Given its relative simplicity, cost-effectiveness, and paucity of alternative diagnostic methods, cytology should still be considered as a first-line tool for diagnosing HBP malignancies. (c) 2018 S. Karger AG, Basel	[Al-Hajeili, Marwan; Mosli, Mahmoud] King Abdulaziz Univ, Dept Med, Jeddah, Saudi Arabia; [Alqassa, Maryam; Alomran, Astabraq; Batarfi, Bashaer; Basunaid, Bashaer; Alshail, Reem; Alaydarous, Shahad] King Abdulaziz Univ, Fac Med, Abdullah Bin Nafea St, Jeddah 21333, Saudi Arabia; [Bokhary, Rana] King Abdulaziz Univ, Dept Pathol, Jeddah, Saudi Arabia	Alaydarous, S (reprint author), King Abdulaziz Univ, Fac Med, Abdullah Bin Nafea St, Jeddah 21333, Saudi Arabia.	shahad.alaydarous@gmail.com					Almadouj A, 2013, CANC INCIDENCE REPOR; Brugge W, 2014, DIAGN CYTOPATHOL, V42, P333, DOI 10.1002/dc.23096; Fogel EL, 1999, ENDOSCOPY, V31, P758, DOI 10.1055/s-1999-147; Fritcher EGB, 2011, AM J CLIN PATHOL, V136, P442, DOI 10.1309/AJCPDULIOEOTUZ5H; Harewood G, 2004, GASTROINTEST ENDOSC, V59, pAB99; Howlader N, 1975, SEER CANC STAT REV; Kocjan G, 1997, DIAGN CYTOPATHOL, V16, P358, DOI 10.1002/(SICI)1097-0339(199704)16:4<358::AID-DC11>3.0.CO;2-J; KURZAWINSKI TR, 1993, HEPATOLOGY, V18, P1399, DOI 10.1016/0270-9139(93)90230-K; Kuzu U, 2015, GASTROENT RES PRACT, V2015, P1; LEE JG, 1995, AM J GASTROENTEROL, V90, P722; Logrono R, 2000, ARCH PATHOL LAB MED, V124, P387; Mahmoudi N, 2008, WORLD J GASTROENTERO, V14, P569, DOI 10.3748/wjg.14.569; Parsi MA, 2011, PANCREAS, V40, P52, DOI 10.1097/MPA.0b013e3181f3aa96; PONCHON T, 1995, GASTROINTEST ENDOSC, V42, P565, DOI 10.1016/S0016-5107(95)70012-9; Soyuer I, 2010, TURK J MED SCI, V40, P807, DOI 10.3906/sag-0901-19; Stewart CJR, 2001, J CLIN PATHOL, V54, P449, DOI 10.1136/jcp.54.6.449; Stoos-Veic T, 2010, COLLEGIUM ANTROPOL, V34, P139; Lopez-Jurado RT, 2009, REV ESP ENFERM DIG, V101, P385, DOI 10.4321/s1130-01082009000600003; Weilert F, 2014, GASTROINTEST ENDOSC, V80, P97, DOI 10.1016/j.gie.2013.12.031; Westenend PJ, 2001, CANCER CYTOPATHOL, V93, P146, DOI 10.1002/cncr.9021	20	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000489549			6	Pathology	Pathology	GP3UW	WOS:000440780900011	29898439				2019-10-28	
J	Allison, DB; Sharma, R; Cowan, ML; VandenBussche, CJ				Allison, Derek B.; Sharma, Rajni; Cowan, Morgan L.; VandenBussche, Christopher J.			Evaluation of Sienna Cancer Diagnostics hTERT Antibody on 500 Consecutive Urinary Tract Specimens	ACTA CYTOLOGICA			English	Article						Urine cytology; Urinary tract; Telomerase; Ancillary test	TERT PROMOTER MUTATIONS; HOPKINS HOSPITAL TEMPLATE; BLADDER-CANCER; TELOMERASE ACTIVITY; UROTHELIAL CARCINOMA; HIGH PREVALENCE; CELL CARCINOMA; PARIS SYSTEM; CYTOLOGY; TERMINOLOGY	Objectives: Telomerase activity can be detected in up to 90% of urothelial carcinomas (UC). Telomerase activity can also be detected in urinary tract cytology (UTC) specimens and indicate an increased risk of UC. We evaluated the performance of a commercially available antibody that putatively binds the telomerase reverse transcriptase (hTERT) subunit on 500 UTC specimens. Study Design: Unstained Cytospin (TM) preparations were created from residual urine specimens and were stained using the anti-hTERT antibody (SCDA7). Two algorithms were developed for concatenating the hTERT result and cytologic diagnosis: a "no indeterminates algorithm," in which a negative cytology and positive hTERT result are considered positive, and a "high-specificity algorithm," in which a negative cytology and positive hTERT result are considered indeterminate (and thus negative for comparison to the gold standard). Results: The "no indeterminates algorithm" and "high-specificity algorithm" yielded a sensitivity of 60.6 and 52.1%, a specificity of 70.4 and 90.7%, a positive predictive value of 39.1 and 63.8%, and a negative predictive value of 85.0 and 85.8%, respectively. Conclusions: A positive hTERT result may identify a subset of patients with an increased risk of high-grade UC (HGUC) who may otherwise not be closely followed, while a negative hTERT immunocytochemistry result is associated with a reduction in risk for HGUC. (c) 2018 The Author(s) Published by S. Karger AG, Basel	[Allison, Derek B.; Sharma, Rajni; Cowan, Morgan L.; VandenBussche, Christopher J.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA; [VandenBussche, Christopher J.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA	VandenBussche, CJ (reprint author), Johns Hopkins Univ Hosp, Dept Pathol, Carnegie 406,600 N Wolfe St, Baltimore, MD 21287 USA.	cjvand@jhmi.edu			Sienna Cancer Diagnostics	The materials and laboratory technologist time required for this study were funded by a research grant awarded to the Johns Hopkins University School of Medicine by Sienna Cancer Diagnostics.	Avritscher EBC, 2006, UROLOGY, V68, P549, DOI 10.1016/j.urology.2006.03.062; Barkan GA, 2016, ACTA CYTOL, V60, P185, DOI 10.1159/000446270; Bubendorf L, 2001, AM J CLIN PATHOL, V116, P79; Chen CH, 2011, J FORMOS MED ASSOC, V110, P275, DOI 10.1016/S0929-6646(11)60043-0; Cowan M, 2016, MODERN PATHOL, V29, P511, DOI 10.1038/modpathol.2016.53; Cowan ML, 2016, HUM PATHOL, V53, P8, DOI 10.1016/j.humpath.2016.02.009; HENEY NM, 1983, J UROLOGY, V130, P1083, DOI 10.1016/S0022-5347(17)51695-X; Kamata S, 1996, BRIT J UROL, V78, P704, DOI 10.1046/j.1464-410X.1996.01957.x; Khalbuss Walid, 2006, Cytojournal, V3, P18, DOI 10.1186/1742-6413-3-18; Kinde I, 2013, CANCER RES, V73, P7162, DOI 10.1158/0008-5472.CAN-13-2498; Lin Y, 1996, CLIN CANCER RES, V2, P929; McCroskey Z, 2015, AM J CLIN PATHOL, V144, P902, DOI 10.1309/AJCPE1O9YKMRSQKG; Miyanaga N, 1997, EUR UROL, V31, P163; Nguyen D, 2016, VIRCHOWS ARCH, V469, P427, DOI 10.1007/s00428-016-2001-2; Owens CL, 2013, CANCER CYTOPATHOL, V121, P9, DOI 10.1002/cncy.21253; Rosenthal DL, 2013, CANCER CYTOPATHOL, V121, P15, DOI 10.1002/cncy.21255; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Sullivan PS, 2010, AM J TRANSL RES, V2, P412; VandenBussche CJ, 2016, CYTOPATHOLOGY, V27, P153, DOI 10.1111/cyt.12345; VandenBussche CJ, 2013, CANCER CYTOPATHOL, V121, P21, DOI 10.1002/cncy.21254; Yoshida K, 1997, CANCER, V79, P362, DOI 10.1002/(SICI)1097-0142(19970115)79:2<362::AID-CNCR20>3.0.CO;2-Y; Zhang ML, 2016, CANCER CYTOPATHOL, V124, P552, DOI 10.1002/cncy.21716; Zheng XY, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0047-7	23	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000489181			9	Pathology	Pathology	GP3UW	WOS:000440780900010	29874657	Other Gold, Green Published			2019-10-28	
J	del Arco, CD; Acenero, MJF				Diaz del Arco, Cristina; Fernandez Acenero, M. Jesus			Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features: Can Cytology Face the Challenge of Diagnosis in the Light of the New Classification?	ACTA CYTOLOGICA			English	Article						Thyroid; Fine needle aspiration cytology; Noninvasive follicular thyroid neoplasm; Papillary-like nuclear features; Papillary thyroid carcinoma; Cytology	FINE-NEEDLE-ASPIRATION; VARIANT; CARCINOMA; CANCER; IMPACT; NIFTP; NOMENCLATURE; ASSOCIATION; NODULES	Objectives: To assess the cytological findings of noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP), conventional papillary thyroid carcinomas (CPTC), and invasive follicular variants of papillary thyroid carcinomas (IFV-PTC) to determine if there are cytological differences between groups. Study Design: We have reviewed all thyroid fine-needle aspiration cytology samples diagnosed between 2000 and 2017. We have included all NIFTP cases (n = 6) and randomly selected cases of C-PTC (n = 14) and IFV-PTC (n = 8). Results: Comparing NIFTP and C-PTC cases, NIFTP cases showed significantly less papillary or pseudopapillary architecture, more bidimensional groups and microfollicles, and less tridimensionality, giant cells, and nuclear folds. We observed a trend towards significance for smear cellularity and amount of cytoplasm. Presence of nuclear folds was the only significant difference between NIFTP and IFV-PTC cases. The differences between groups in percent papillary or pseudopapillary architecture, cellularity, and tridimensionality showed a trend towards significance. Amount of colloid, dirty background, pleomorphism or atypia, nuclear pseudoinclusions, type of chromatin, and nucleolus were not significant. Conclusions: No cytopathological feature can differentiate between invasive and encapsulated IFV-PTC. In accordance with the recently accepted category, PTC smears with cells arranged in a predominantly follicular architecture should be reported as Bethesda IV category with descriptive terms to avoid false-positive cases. (c) 2018 S. Karger AG, Basel	[Diaz del Arco, Cristina; Fernandez Acenero, M. Jesus] Hosp Clin San Carlos, Dept Surg Pathol, Calle Prof Martin Lagos S-N, ES-28040 Madrid, Spain	del Arco, CD (reprint author), Hosp Clin San Carlos, Dept Surg Pathol, Calle Prof Martin Lagos S-N, ES-28040 Madrid, Spain.	crisdelarco@gmail.com		Fernandez-Acenerp/0000-0002-2439-3553			Armstrong MJ, 2014, THYROID, V24, P1369, DOI 10.1089/thy.2014.0067; Baloch ZW, 2017, ENDOCR PRACT, V23, P1150, DOI 10.4158/EP171940.DSCR; Bizzarro T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132939; Borrelli N, 2017, MODERN PATHOL, V30, P39, DOI [10.1038/nnodpathol.2016.157, 10.1038/modpathol.2016.157]; Brandler TC, 2018, DIAGN CYTOPATHOL, V46, P139, DOI 10.1002/dc.23863; Cho U, 2017, MODERN PATHOL, V30, P810, DOI 10.1038/modpathol.2017.9; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Fu GD, 2017, EBIOMEDICINE, V18, P50, DOI 10.1016/j.ebiom.2017.03.031; Haugen BR, 2017, THYROID, V27, P481, DOI 10.1089/thy.2016.0628; Hung YP, 2018, HISTOPATHOLOGY, V72, P53, DOI 10.1111/his.13363; Hwang TS, 2015, BIOMED RES INT, DOI 10.1155/2015/697068; Ibrahim AA, 2016, AM J CLIN PATHOL, V146, P373, DOI [10.1093/AJCP/AQW126, 10.1093/ajcp/aqw126]; Jang EK, 2015, CLIN ENDOCRINOL, V83, P968, DOI 10.1111/cen.12674; Jug R, 2017, PATHOLOG RES INT, V2017, P1; Jug R, 2017, PATHOLOG RES INT, V2017; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Mainthia R, 2018, SURGERY, V163, P60, DOI 10.1016/j.surg.2017.04.037; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Nikiforov YE, 2016, JAMA ONCOL, V2, P1023, DOI 10.1001/jamaoncol.2016.0386; Rosario PW, 2017, CLIN ENDOCRINOL, V87, P635, DOI 10.1111/cen.13317; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Wartofsky L, 2016, J TRANSL INTERN MED, V4, P55, DOI 10.1515/jtim-2016-0023; Xu B, 2017, THYROID, V27, P512, DOI 10.1089/thy.2016.0649; Yang GCH, 2018, ULTRASONOGRAPHY, V37, P157, DOI 10.14366/usg.17045; Yang GCH, 2017, DIAGN CYTOPATHOL, V45, P533, DOI 10.1002/dc.23709; Yang GCH, 2013, ACTA CYTOL, V57, P26, DOI 10.1159/000342986; Zhao LN, 2017, CANCER CYTOPATHOL, V125, P323, DOI 10.1002/cncy.21839	28	5	5	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000488579			8	Pathology	Pathology	GP3UW	WOS:000440780900005	29723867				2019-10-28	
J	Acenero, MJF; Vazquez, M; Esteban, JM; Diego, GG; del Arco, CD				Fernandez Acenero, M. Jesus; Vazquez, M.; Esteban, J. M.; Garcia Diego, Guillermo; Diaz del Arco, Cristina			Influence of the Histopathological Features of the Lesion on the Diagnostic Yield of Fine-Needle Aspiration Cytology of Pancreatic Solid Lesions	ACTA CYTOLOGICA			English	Article						Pancreatic lesions; Fine-needle aspiration cytology; Pancreatic adenocarcinoma; Diagnostic yield; Histopathologic factors	CARCINOMA; CANCER; BIOPSY	Objective: The rate of pancreatic lesions has increased in recent decades due to the widespread use of advanced imaging techniques. Nowadays, a significant proportion of cases are incidentally discovered in asymptomatic patients and cytology is an important tool for the diagnosis and multidisciplinary management of these cases. Study Design: In this study we retrospectively review the experience with pancreatic fine-needle aspiration cytology in the last 17 years at a single large tertiary hospital in Madrid, Spain. Results: Our results indicate that more than 60% of pancreatic malignant lesions are cytologically confirmed before surgery and 30% of the patients are asymptomatic. Despite this, we have noted that the total number of malignant lesions surgically resected in our hospital has basically remained unchanged over the years, because incidental diagnosis is not always synonymous with resectability and a substantial number of patients are already metastatic at the time of diagnosis. Our series also shows an increase in the number of neuroendocrine tumors, which now represent almost 20% of all cytological diagnoses at our hospital. The sensitivity in our series is 70% and the false negative rate remains 30%, despite sample quality control by experienced cytologists and standardized technical conditions. Fibrosis and necrosis are the 2 features of the primary tumor that significantly and negatively influence the accuracy of cytologic diagnosis. Conclusion: We herein report our experience with cytologic diagnosis of pancreatic lesions in a single tertiary hospital. Our results confirm that cytology is a safe, reliable, and important tool for pancreatic lesion diagnosis and management. (c) 2018 S. Karger AG, Basel	[Vazquez, M.; Esteban, J. M.] Hosp Clin Univ San Carlos, Dept Surg Pathol, Cytol Unit, Madrid, Spain; [Fernandez Acenero, M. Jesus; Garcia Diego, Guillermo; Diaz del Arco, Cristina] Hosp Clin Univ San Carlos, Dept Endoscopy, Endoscop Ultrasonog Unit, Madrid, Spain	Acenero, MJF (reprint author), Hosp Clin Univ San Carlos, Dept Surg Pathol, Avda Prof Martin Lagos S-N, E-28040 Madrid, Spain.	mgg10167@gmail.com		Fernandez-Acenerp/0000-0002-2439-3553			Bhatia P, 2008, ACTA CYTOL, V52, P523, DOI 10.1159/000325592; Chang YR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005535; Cohen S, 2018, SURG CLIN N AM, V98, P13, DOI 10.1016/j.suc.2017.09.002; Cote GA, 2017, AM J EPIDEMIOL, V186, P944, DOI 10.1093/aje/kwx168; Frampas E, 2016, DIAGN INTERV IMAG, V97, P1207, DOI 10.1016/j.diii.2016.07.008; Fritscher-Ravens A, 2002, AM J GASTROENTEROL, V97, P2768; Frozanpor F, 2010, J PANCREAS, V11, P439; Gupta P, 2017, APMIS, V125, P16, DOI 10.1111/apm.12627; GUPTA RK, 1995, DIAGN CYTOPATHOL, V13, P120, DOI 10.1002/dc.2840130207; Hawes R H, 1995, Gastrointest Endosc Clin N Am, V5, P61; Ilic M, 2016, WORLD J GASTROENTERO, V22, P9694, DOI 10.3748/wjg.v22.i44.9694; Lin CY, 2017, SAUDI J GASTROENTERO, V23, P241, DOI 10.4103/sjg.SJG_199_17; Lozano MD, 1998, ACTA CYTOL, V42, P1451, DOI 10.1159/000332185; Mosteiro L, 2014, ANAL QUANT CYTOPATHO, V36, P9; Noh DH, 2018, SCAND J GASTROENTERO, V53, P94, DOI 10.1080/00365521.2017.1390597; O'Connell AM, 2008, J MED IMAG RADIAT ON, V52, P231, DOI 10.1111/j.1440-1673.2008.01952.x; Qureshi A, 2013, JCPSP-J COLL PHYSICI, V23, P484, DOI 07.2013/JCPSP.484486; Schneider AR, 2015, ENDOSC INT OPEN, V3, pE134, DOI 10.1055/s-0034-1390886; Sharma C, 2011, WORLD J GASTROENTERO, V17, P867, DOI 10.3748/wjg.v17.i7.867; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332	20	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000488383			6	Pathology	Pathology	GP3UW	WOS:000440780900004	29705811				2019-10-28	
J	Heo, I; Kwak, HJ; Nah, EH; Cho, S; Kim, S; Cho, HI				Heo, Ilyeong; Kwak, Hyoung-Jung; Nah, Eun-Hee; Cho, Seon; Kim, Suyoung; Cho, Han-Ik			Evaluation of the LC-1000 Flow Cytometry Screening System for Cervical Cancer Screening in Routine Health Checkups	ACTA CYTOLOGICA			English	Article						Flow cytometry; Cervical cancer screening; Liquid-based cytology	BETHESDA SYSTEM; CYTOLOGY; SMEARS	Objective: This study evaluated the performance of a flow cytometry system (LC-1000) in screening cervical precancerous lesions at routine health checkups. Study design: In total, 928 health examinees were enrolled at 16 health promotion centers in 13 Korean cities between 2016 and 2017. All participants underwent liquid-based cervical cytology and flow cytometry testing to determine the cell proliferation index (CPIx). Results: The positivity rate of the LC-1000 system increased with the severity of the cervical cytology findings (p for trend <0.001). When low-grade squamous intraepithelial lesion (LSIL) or higher (including LSIL, high-grade squamous intraepithelial lesion [HSIL], and atypical squamous cells without excluding HSIL [ASC-H]) was defined as gold-standard positivity, the sensitivity, specificity, PPV, and NPV of LC-1000 were 75.3% (95% confidence interval [CI], 66.8-83.7), 58.5% (95% CI, 55.2-61.9), 18.1% (95% CI, 14.5-21.8), and 95.1% [95% CI, 93.2-97.0], respectively. The median CPIx increased significantly from normal cytology to HSIL (p < 0.001). The median CPIx was higher in high-risk human papillomavirus (HR-HPV)-positive cases than in HR-HPV-negative cases (0.23 vs. 0.17, p < 0.001), while it did not differ between HR-HPV-positive and HR-HPV-negative cases with normal cytology findings (0.16 vs. 0.16, p = 0.700). Conclusion: The LC-1000 system is potentially useful for screening cervical precancer and cancer, especially when excluding normal or ASC of undetermined significance cases in routinely screened populations. (c) 2018 S. Karger AG, Basel	[Heo, Ilyeong; Kwak, Hyoung-Jung; Cho, Han-Ik] Korea Assoc Hlth Promot, MEDIcheck LAB, Chongju, South Korea; [Nah, Eun-Hee; Cho, Seon; Kim, Suyoung] Korea Assoc Hlth Promot, Hlth Promot Res Inst, Seoul, South Korea	Nah, EH (reprint author), Assoc Hlth Promot, Hlth Promot Res Inst, 350 Hwagokro, Seoul 07653, South Korea.	cellonah@hanmail.net			Sysmex Corporation, Kobe, Japan	This study was supported by Sysmex Corporation, Kobe, Japan.	Baba A. I., 2007, COMP ONCOLOGY; Bollmann R, 2001, CANCER CYTOPATHOL, V93, P222, DOI 10.1002/cncr.9033.abs; Burd E. M., 2014, Clinical Microbiology Newsletter, V36, P95, DOI 10.1016/j.clinmicnews.2014.06.001; Carcopino X, 2011, J MED VIROL, V83, P637, DOI 10.1002/jmv.22022; Han XT, 2015, GYNECOL ONCOL, V139, P52, DOI 10.1016/j.ygyno.2015.07.102; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; KIMMIG R, 1995, J CANCER RES CLIN, V121, P107, DOI 10.1007/BF01202222; Koshiol J, 2008, AM J EPIDEMIOL, V168, P123, DOI 10.1093/aje/kwn036; Lorenzato M, 2002, AM J CLIN PATHOL, V118, P708; Mishra Sridhar, 2017, Asian Pac J Cancer Prev, V18, P1595; Monsonego J, 2001, BRIT J CANCER, V84, P360, DOI 10.1054/bjoc.2000.1588; Morisaki H., 2014, CYTOMETRY RES, V24, P41; Saslow D, 2012, AM J CLIN PATHOL, V137, P516, DOI 10.1309/AJCPTGD94EVRSJCG; Shirasuna K., 2015, EUR PATENT APPL, P1, Patent No. EP2860263A1; Soler ME, 2000, PRIM CARE UPDATE OB, V7, P118; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Tong H, 2009, CLIN CANCER RES, V15, P6438, DOI 10.1158/1078-0432.CCR-09-1689; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262	18	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000489079			9	Pathology	Pathology	GP3UW	WOS:000440780900007	29843120				2019-10-28	
J	Krogerus, L; Kholova, I				Krogerus, Leena; Kholova, Ivana			Cell Block in Cytological Diagnostics: Review of Preparatory Techniques	ACTA CYTOLOGICA			English	Review						Cell block; Cytology technique; Cytology	FINE-NEEDLE-ASPIRATION; ATYPICAL GLANDULAR CELLS; DIFFERENTIAL-DIAGNOSIS; CYTOPATHOLOGY; SPECIMENS; BIOPSIES; IMMUNOCYTOCHEMISTRY; THROMBOPLASTIN; CELLULARITY; EXPERIENCE	Objective: The cell block (CB) technique refers to the processing of sediments, blood clots, or grossly visible tissue fragments from cytological specimens into paraffin blocks that can be cut and stained by the same methods used for histopathology. The technique brings additional tissue architectural information. CB can be used for ancillary techniques such as immunocytochemistry and molecular techniques. Study Design: We reviewed the literature on the various preparatory techniques of CBs. Results: There is a wide range of preparatory techniques for CBs and no golden standard for CBs exists: tens of methods are used in various institutions. The majority of the methods are modified in house techniques with a few commercially available kits. The techniques most commonly used are the plasma/thrombin method, the agar method, and commercially available Histogel- and Cellient CB-methods. Dissatisfaction with the cellular yield of the CBs is common. Conclusions: In the CBs, the cytological material is preserved for future use, which is a tremendous advantage in the era of targeted therapy and biobanking. The CB is thus central to the future of cytology: more can be done with less material and with less invasiveness to the patient. (C) 2018 S. Karger AG, Basel	[Krogerus, Leena] Jorvi Hosp, Dept Pathol, HUSLAB, Espoo, Finland; [Kholova, Ivana] Tampere Univ Hosp, Dept Pathol, Fimlab Labs, POB 66, FI-33101 Tampere, Finland; [Kholova, Ivana] Univ Tampere, Fac Med & Life Sci, Dept Pathol, Tampere, Finland	Kholova, I (reprint author), Tampere Univ Hosp, Dept Pathol, Fimlab Labs, POB 66, FI-33101 Tampere, Finland.	ivana.kholova@sll.fimnet.fi					Bahrenberg LPH, 1896, CLEVELAND MED GAZ, V11, P274; Balassanian R, 2016, CANCER CYTOPATHOL, V124, P508, DOI 10.1002/cncy.21722; Baloch ZW, 1999, DIAGN CYTOPATHOL, V20, P389, DOI 10.1002/(SICI)1097-0339(199906)20:6<389::AID-DC14>3.0.CO;2-S; Bhatia P, 2008, ACTA CYTOL, V52, P329, DOI 10.1159/000325516; BIRGE RF, 1948, AM J CLIN PATHOL, V18, P754; BUSSOLATI G, 1982, J CLIN PATHOL, V35, P574, DOI 10.1136/jcp.35.5.574; CHAPMAN CB, 1947, NEW ENGL J MED, V237, P215, DOI 10.1056/NEJM194708142370702; Collins BT, 2015, CANCER CYTOPATHOL, V123, P540, DOI 10.1002/cncy.21573; Crapanzano JP, 2014, CYTOJOURNAL, V11, DOI 10.4103/1742-6413.129187; De Girolami E, 1977, Pathol Annu, V12 Pt 2, P91; De Girolami E, 1977, Pathol Annu, V12 Pt 1, P251; Desai KM, 2018, ACTA CYTOL, V62, P39, DOI 10.1159/000484195; Diaz-Rosario LA, 2000, CANCER CYTOPATHOL, V90, P265, DOI 10.1002/1097-0142(20001025)90:5<265::AID-CNCR1>3.0.CO;2-Q; DOMAGALA WM, 1990, ACTA CYTOL, V34, P291; FAHEY C, 1993, LAB MED, V24, P94, DOI 10.1093/labmed/24.2.94; Field AS, 2017, ACTA CYTOL, V61, P3, DOI 10.1159/000450880; Fischer AH, 2006, MODERN PATHOL, V19, P57; Gorman BK, 2012, ACTA CYTOL, V56, P289, DOI 10.1159/000337436; He QL, 2012, CELL TISSUE RES, V350, P395, DOI 10.1007/s00441-012-1467-8; Hecht SA, 2013, PATHOL LAB MED INT, V5, P1, DOI 10.2147/PLMI.S37555; Henwood AF, 2014, CYTOPATHOLOGY, V25, P412, DOI 10.1111/cyt.12129; Herbert A, 2014, CYTOPATHOLOGY, V25, P351, DOI 10.1111/cyt.12222; Jain D, 2014, CYTOPATHOLOGY, V25, P356, DOI 10.1111/cyt.12174; Leiman G, 2013, CANCER CYTOPATHOL, V121, P109, DOI 10.1002/cncy.21284; Kaneko C, 2010, DIAGN CYTOPATHOL, V38, P652, DOI 10.1002/dc.21280; KARNAUCHOW PN, 1982, J CLIN PATHOL, V35, P688, DOI 10.1136/jcp.35.6.688; Kerstens HMJ, 2000, J HISTOCHEM CYTOCHEM, V48, P709, DOI 10.1177/002215540004800515; Khan S, 2012, J CYTOL, V29, P177, DOI 10.4103/0970-9371.101167; Koss LG, 2006, KOSS DIAGNOSTIC CYTO, P1590; KROGERUS LA, 1988, ACTA CYTOL, V32, P585; Kruger AM, 2014, CYTOPATHOLOGY, V25, P381, DOI 10.1111/cyt.12216; Kubik MJ, 2015, DIAGN CYTOPATHOL, V43, P773, DOI 10.1002/dc.23300; Kulkarni MB, 2009, DIAGN CYTOPATHOL, V37, P86, DOI 10.1002/dc.20963; Kulkarni MB, 2000, CYTOPATHOLOGY, V11, P179, DOI 10.1046/j.1365-2303.2000.00249.x; La Fortune KA, 2017, CANCER CYTOPATHOL, V125, P267, DOI 10.1002/cncy.21814; Lindsey KG, 2016, CANCER CYTOPATHOL, V124, P885, DOI 10.1002/cncy.21795; Mandelbaum FS., 1917, J LAB CLIN MED, V2, P580; Mansy SS, 2006, ULTRASTRUCT PATHOL, V30, P379, DOI 10.1080/01913120600854269; Martins D, 2014, CYTOPATHOLOGY, V25, P225, DOI 10.1111/cyt.12158; Mayall F, 2003, J CLIN PATHOL, V56, P728, DOI 10.1136/jcp.56.10.728; Mayall F, 2010, J CLIN PATHOL, V63, P837, DOI 10.1136/jcp.2010.078410; Nathan NA, 2000, AM J CLIN PATHOL, V114, P599, DOI 10.1309/G035-P2MM-D1TM-T5QE; Noda Y, 2010, J GASTROENTEROL, V45, P868, DOI 10.1007/s00535-010-0217-5; Prendeville S, 2014, CYTOPATHOLOGY, V25, P372, DOI 10.1111/cyt.12159; Rekhtman N, 2018, ARCH PATHOL LAB MED, V142, P529, DOI 10.5858/arpa.2017-0030-OA; RICHARDSON HL, 1955, CANCER, V8, P948, DOI 10.1002/1097-0142(1955)8:5<948::AID-CNCR2820080515>3.0.CO;2-M; Roy-Chowdhuri S, 2016, ARCH PATHOL LAB MED, V140, P1191, DOI 10.5858/arpa.2016-0117-RA; Shi Y, 2018, CANCER CYTOPATHOL, V126, P190, DOI 10.1002/cncy.21950; Skov BG, 2017, APPL IMMUNOHISTO M M, V25, P453, DOI 10.1097/PAI.0000000000000540; Smedts F, 2010, ACTA CYTOL, V54, P587, DOI 10.1159/000325182; van Hemel BM, 2013, DIAGN CYTOPATHOL, V41, P734, DOI 10.1002/dc.22963; Varsegi GM, 2009, JOVE-J VIS EXP, V29, P1316; Xing W, 2014, CANCER CYTOPATHOL, V122, P8, DOI 10.1002/cncy.21343; Yang GCH, 1998, ACTA CYTOL, V42, P703, DOI 10.1159/000331830; Yung RCW, 2012, CANCER CYTOPATHOL, V120, P185, DOI 10.1002/cncy.20199; Zhao J, 2014, ACTA CYTOL, V58, P182, DOI 10.1159/000357658; ZITO FA, 1995, ACTA CYTOL, V39, P93	57	4	4	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000489769			7	Pathology	Pathology	GP3UW	WOS:000440780900001	29909418				2019-10-28	
J	Lee, YJ; Kim, DW; Jung, SJ; Baek, HJ				Lee, Yoo Jin; Kim, Dong Wook; Jung, Soo Jin; Baek, Hye Jin			Factors that Influence Sample Adequacy in Liquid-Based Cytology after Ultrasonography-Guided Fine-Needle Aspiration of Thyroid Nodules: A Single-Center Study	ACTA CYTOLOGICA			English	Article						Thyroid nodule; Fine-needle aspiration; Liquid-based cytology; Adequacy; Cellularity	SCIENCE CONFERENCE; BIOPSY; FNA; EXPERIENCE; SYNOPSIS; CRITERIA; STATE; SIZE	Objective: The factors that influence the acquisition of adequate samples during liquid-based cytology (LBC) remain unclear. This study aimed to identify factors that affect cytological adequacy in LBC after ultrasonography (US)-guided fine-needle aspiration (US-FNA) of thyroid nodules. Study Design: From January 2017 to May 2017, a single radiologist performed US-FNA to diagnose 112 thyroid nodules in 112 consecutive patients. Based on US findings after US-FNA, the size, location, position, composition, calcification, and vascularity of each nodule, as well as the US-based diagnosis, were investigated by the same radiologist. Blinded to US information, a single cytopathologist investigated cytological adequacy, cytological cellularity, and Bethesda category. Results: Of the 112 thyroid nodules, cytological adequacy was achieved in 91.1% (102/112). Thyroid nodules with sizes >= 20 mm or those that were predominantly cystic showed a high-er rate of cytological inadequacy (p < 0.05). Thyroid nodule location, position, calcification status, and vascularity did not influence cytological adequacy, nor did US-based diagnosis (p > 0.05). Nodule composition or calcification significantly influenced cytological cellularity (p < 0.05), whereas nodule size, location, position, vascularity, and US-based diagnosis did not (p > 0.05). Conclusions: Most investigated factors did not influence cytological adequacy or cellularity. (c) 2018 S. Karger AG, Basel	[Lee, Yoo Jin; Kim, Dong Wook] Inje Univ, Coll Med, Busan Paik Hosp, Dept Radiol, 75 Bokji Ro, Busan 47392, South Korea; [Jung, Soo Jin] Inje Univ, Coll Med, Busan Paik Hosp, Dept Pathol, Busan, South Korea; [Baek, Hye Jin] Gyeongsang Natl Univ, Changwon Hosp, Sch Med, Dept Radiol, Chang Won, South Korea	Kim, DW (reprint author), Inje Univ, Coll Med, Busan Paik Hosp, Dept Radiol, 75 Bokji Ro, Busan 47392, South Korea.	dwultra@nate.com	; Kim, Dong Wook/I-7600-2015	Baek, Hye Jin/0000-0001-7349-2841; Kim, Dong Wook/0000-0002-9826-1326	Inje University Busan Paik Hospital	This work was supported by a 2017 Inje University Busan Paik Hospital research grant.	Abraham TM, 2011, THYROID, V21, P237, DOI 10.1089/thy.2010.0211; Arul P, 2016, J CYTOL, V33, P177, DOI 10.4103/0970-9371.190446; Baloch ZW, 2008, DIAGN CYTOPATHOL, V36, P425, DOI 10.1002/dc.20830; Caruso D, 1991, ENDOCRINOLOGIST, V1, P194; Chang H, 2013, APMIS, V121, P139, DOI 10.1111/j.1600-0463.2012.02944.x; Chow LS, 2001, THYROID, V11, P1147, DOI 10.1089/10507250152740993; Cibas ES, 2009, THYROID, V19, P1159, DOI 10.1089/thy.2009.0274; de Koster EJ, 2016, ACTA CYTOL, V60, P39, DOI 10.1159/000444917; Degirmenci B, 2007, CLIN RADIOL, V62, P798, DOI 10.1016/j.crad.2007.01.024; Fadda G, 2011, ACTA CYTOL, V55, P389, DOI 10.1159/000329029; Geers C, 2011, CANCER CYTOPATHOL, V119, P58, DOI 10.1002/cncy.20125; GHARIB H, 1993, ANN INTERN MED, V118, P282, DOI 10.7326/0003-4819-118-4-199302150-00007; Kim DW, 2012, AM J NEURORADIOL, V33, P1144, DOI 10.3174/ajnr.A2923; Kim DW, 2012, DIAGN CYTOPATHOL, V40, pE48, DOI 10.1002/dc.21669; Kim DW, 2009, THYROID, V19, P27, DOI 10.1089/thy.2008.0106; Lee YJ, 2013, ENDOCRINE, V44, P696, DOI 10.1007/s12020-013-9906-1; Naim C, 2013, CAN ASSOC RADIOL J, V64, P220, DOI 10.1016/j.carj.2012.03.003; Pitman MB, 2008, DIAGN CYTOPATHOL, V36, P407, DOI 10.1002/dc.20829; Vivero M, 2017, CANCER CYTOPATHOL, V125, P534, DOI 10.1002/cncy.21858; Zhu WJ, 2007, DIAGN CYTOPATHOL, V35, P183, DOI 10.1002/dc.20552	20	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000486442			6	Pathology	Pathology	GP3UW	WOS:000440780900003	29393083				2019-10-28	
J	Misra, JS; Srivastava, AN; Gupta, HP				Misra, Jata S.; Srivastava, Anand N.; Gupta, Hem P.			Results of Cervical Cancer Screening in the Rural Population of Lucknow West, India, through a Camp Approach	ACTA CYTOLOGICA			English	Article						Rural cervical cancer screening; Squamous intraepithelial lesions of the cervix; Risk factors; Sexually transmitted diseases	COMMUNITY; CYTOLOGY; WOMEN	Objective: Cytological screening was carried out in rural women of Lucknow West, India, through a camp approach to detect cervical cancer in its preinvasive phase and to see whether the primitive living conditions in the villages have any effect on the incidence of precancer and carcinoma of the cervix and the associated predisposing factors of cervical carcinogenesis. Study Design: During a span of 4 years (May 2013 to March 2017), a total of 135 camps were organized under the auspice of Era's Lucknow Medical College and Hospital (Lucknow, India). Only 4,269 (31.2%) out of 13,500 women who were motivated and counseled attended the camp and 2,369 (55.1%) of them underwent a Pap smear examination. Results: The incidence of squamous intraepithelial lesions of the cervix (SIL) was found to be very high (18.2%) in the 2,369 women who were screened, but the majority of them were of a low grade. The SIL incidence was very high for all predisposing factors like gynaecological symptoms, age, and clinical lesions of the cervix. However, the SIL rate showed a rise with increasing parity. Candida albicans was more common in rural women (4.7%) than Trichomonas vaginalis (1.1%), and a low incidence of viral sexually transmitted diseases (STD) was seen. Conclusions: Organizing camps in the villages through proper counseling and motivation may help in the screening of larger numbers of women for early detection of cervical cancer, the adequate treatment of which will check the progression of the disease and thus minimize the incidence of carcinoma of the cervix and its associated mortality in the rural population of India. (c) 2018 S. Karger AG, Basel	[Misra, Jata S.] Eras Lucknow Med Coll & Hosp, Dept Pathol, Hardoi Rd, Lucknow 226003, Uttar Pradesh, India; Eras Lucknow Med Coll & Hosp, Dept Obstet & Gynaecol, Lucknow, Uttar Pradesh, India	Misra, JS (reprint author), Eras Lucknow Med Coll & Hosp, Dept Pathol, Hardoi Rd, Lucknow 226003, Uttar Pradesh, India.	jata_misra@yahoo.com			Intramural Research Project of Era's Lucknow Medical College and Hospital, Lucknow, India	This work was carried out with funding from the Intramural Research Project of Era's Lucknow Medical College and Hospital, Lucknow, India.	Aggarwal P, 2010, INT J GYNECOL CANCER, V20, P862, DOI 10.1111/IGC.0b013e3181e02f77; Ambedkar RKV, 2015, CLIN CANC INVESTIG, V4, P147; [Anonymous], 1993, ACTA CYTOL, V57, P115; Arora BB, 2014, J SEX TRANSM DIS, V2014; Bukhari MH, 2012, J CYTOL, V29, P20, DOI 10.4103/0970-9371.93213; Dasgupta S, 2012, ARCH GYNECOL OBSTET, V285, P1731, DOI 10.1007/s00404-012-2228-3; Deodhar K, 2012, INT J CANCER, V131, pE954, DOI 10.1002/ijc.27633; Ganesan S, 2015, ASIA-PAC J ONCOL NU, V2, P42, DOI 10.4103/2347-5625.146223; Khasnabish S, 2017, J EVID BASED MED HLT, V4, P2936; Labni S, 2014, EUR J OBSET GYNAECOL, V76, P75; Nene B M, 1994, Indian J Cancer, V31, P34; Nikumbh DB, 2012, INT J HLTH SCI RES, V1, P125; Rajput N, 2013, J EVOL MED DENT SCI-, V2, P7923, DOI 10.14260/jemds/1396; Rawat K, 2016, INT J REPROD CONTRAC, V50, P3186; Satyanarayana L, 2014, INDIAN J CANCER, V51, P124, DOI 10.4103/0019-509X.138172; Sharma Pragya, 2010, Indian J Community Med, V35, P86, DOI 10.4103/0970-0218.62576; Srivastava M, 2011, PRAVARA MED REV, V3, P04; Verma A, 2017, MIDDLE EAST FERTIL S, V22, P39, DOI 10.1016/j.mefs.2016.09.002	18	1	1	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000489078			6	Pathology	Pathology	GP3UW	WOS:000440780900006	29898440				2019-10-28	
J	Nishimura, R; Murata, Y; Mori, K; Yamashiro, K; Kuraoka, K; Ichihara, S; Taguchi, K; Suzuki, H; Ito, M; Yamashita, N				Nishimura, Rieko; Murata, Yuya; Mori, Kiyoshi; Yamashiro, Katsushige; Kuraoka, Kazuya; Ichihara, Shu; Taguchi, Kenichi; Suzuki, Hiroyoshi; Ito, Masahiro; Yamashita, Natsumi			Evaluation of the HER2 and Hormone Receptor Status in Metastatic Breast Cancer Using Cell Blocks: A Multi-Institutional Study	ACTA CYTOLOGICA			English	Article						Cytology; Breast cancer metastases; Hormone receptors; HER2; Cell block	PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; RECOMMENDATIONS; PATHOLOGISTS; CARCINOMAS; EXPRESSION; SPECIMENS; ER	Objective: We explore the problems associated with the cell block (CB) method for receptor analysis in breast cancer metastases and propose a method for reporting the results. Study Design: Nine institutions used the CB method for the analysis of hormone receptors (HRs) and HER2 (human epidermal growth factor receptor 2) protein in cytological specimens of breast cancer metastases in routine practice. The stained slides were independently evaluated by 8 pathologists. Dual in situ hybridization assay was performed in cases of discordant results for HER2 protein. Based on the results, we propose a method for receptor scoring in the CB method. Results: Of 61 specimens, 57 contained tumor cells. Two or more pathologists disagreed on the results for the estrogen receptor, progesterone receptor, and HER2 protein in 3 (5.3%), 13 (22.8%), and 19 (33.3%) cases, respectively. The discrepant results for the HRs were attributed to the presence of a few positive cells or faintly stained cells. The high interobserver discordance rate for HER2 protein was explained by interobserver differences in the scoring criteria. Conclusion: The use of categorical scoring into positive and negative is recommended for evaluating the HR expressions. Use of strict criteria for HER2 protein 2+ and 3+ cases is recommended, as HER2-positive cases should not be missed. (c) 2018 The Author(s) Published by S. Karger AG, Basel	[Nishimura, Rieko] Shikoku Canc Ctr, Dept Clin Lab, Matsuyama, Ehime, Japan; [Murata, Yuya] Tokyo Med Ctr, Dept Pathol, Tokyo, Japan; [Mori, Kiyoshi] Osaka Natl Hosp, Dept Pathol, Osaka, Japan; [Yamashiro, Katsushige] Hokkaido Canc Ctr, Div Pathol, Sapporo, Hokkaido, Japan; [Kuraoka, Kazuya] Kure Med Ctr, Dept Diagnost Pathol, Kure, Japan; [Kuraoka, Kazuya] Chugoku Canc Ctr, Kure, Japan; [Nishimura, Rieko; Ichihara, Shu] Nagoya Med Ctr, Dept Pathol, Nagoya, Aichi, Japan; [Taguchi, Kenichi] Kyushu Canc Ctr, Dept Pathol, Fukuoka, Fukuoka, Japan; [Suzuki, Hiroyoshi] Sendai Med Ctr, Dept Pathol & Lab Med, Sendai, Miyagi, Japan; [Ito, Masahiro] Nagasaki Med Ctr, Clin Res Ctr, Omura, Japan; [Yamashita, Natsumi] Shikoku Canc Ctr, Clin Res Ctr, Sect Canc Prevent & Epidemiol, Div Clin Biostat, Matsuyama, Ehime, Japan	Nishimura, R (reprint author), Natl Hosp Org, Nagoya Med Ctr, Dept Pathol, Naka Ku, 4-1-1 Sannomaru, Nagoya, Aichi 4600001, Japan.	rnishimura-path@umin.ac.jp	Ichihara, Shu/L-2371-2019	Ichihara, Shu/0000-0001-6596-5725	National Hospital Organization [H26-NHO Gan Ippan-02, H29-NHO Gan Ippan-02]	This study was supported by a Grant-in Aid for Clinical Research from the National Hospital Organization (H26-NHO Gan Ippan-02 and H29-NHO Gan Ippan-02). We thank the other members of the research group sponsored by the grant.	Cohen DA, 2012, AM J CLIN PATHOL, V138, P796, DOI 10.1309/AJCP6DKRND5CKVDD; Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529; Hsu CY, 2002, AM J CLIN PATHOL, V118, P693; Kumar KS, 2012, CYTOPATHOLOGY, V23, P181, DOI 10.1111/j.1365-2303.2011.00853.x; Monaco SE, 2013, DIAGN CYTOPATHOL, V41, P308, DOI 10.1002/dc.21841; Nishimura R, 2016, BREAST CANCER-TOKYO, V23, P917, DOI 10.1007/s12282-015-0664-1; Nishimura R, 2016, DIAGN CYTOPATHOL, V44, P274, DOI 10.1002/dc.23433; Reisenbichler ES, 2013, AM J CLIN PATHOL, V140, P487, DOI 10.1309/AJCP1RF9FUIZRDPI; Tsuda H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-534; Vohra P, 2016, CANCER CYTOPATHOL, V124, P828, DOI 10.1002/cncy.21745; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	11	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000488382			7	Pathology	Pathology	GP3UW	WOS:000440780900008	29763896	Other Gold, Green Published			2019-10-28	
J	Pearson, L; Factor, RE; White, SK; Walker, BS; Layfield, LJ; Schmidt, RL				Pearson, Lauren; Factor, Rachel E.; White, Sandra K.; Walker, Brandon S.; Layfield, Lester J.; Schmidt, Robert L.			Rapid On-Site Evaluation of Fine-Needle Aspiration by Non-Cytopathologists: A Systematic Review and Meta-Analysis of Diagnostic Accuracy Studies for Adequacy Assessment	ACTA CYTOLOGICA			English	Review						Biopsy; Fine-needle aspiration; Adequacy; Accuracy; Meta-analysis; Systematic review; Cytopathology	SPECIMEN ADEQUACY; COST-EFFECTIVENESS; ONSITE EVALUATION; CYTOLOGY; CYTOTECHNOLOGIST; ENDOSONOGRAPHERS; PULMONOLOGIST; SCIENTISTS; BIOPSY; PASSES	Objective: Rapid on-site evaluation (ROSE) has been shown to improve adequacy rates and reduce needle passes. ROSE is often performed by cytopathologists who have limited availability and may be costlier than alternatives. Several recent studies examined the use of alternative evaluators (AEs) for ROSE. A summary of this information could help inform guidelines regarding the use of AEs. The objective was to assess the accuracy of AEs compared to cytopathologists in assessing the adequacy of specimens during ROSE. Study Design: This was a systematic review and meta-analysis. Reporting and study quality were assessed using the STARD guidelines and QUADAS-2. All steps were performed independently by two evaluators. Summary estimates were obtained using the hierarchal method in Stata v14. Heterogeneity was evaluated using Higgins' I-2 statistic. Results: The systematic review identified 13 studies that were included in the meta-analysis. Summary estimates of sensitivity and specificity for AEs were 97% (95% CI: 92-99%) and 83% (95% CI: 68-92%). There was wide variation in accuracy statistics between studies (I-2 = 0.99). Conclusions: AEs sometimes have accuracy that is close to cytopathologists. However, there is wide variability between studies, so it is not possible to provide a broad guideline regarding the use of AEs. (C) 2018 S. Karger AG, Basel	[Pearson, Lauren; Factor, Rachel E.; White, Sandra K.; Walker, Brandon S.; Schmidt, Robert L.] Univ Utah, Dept Pathol, 50 N Med Dr East,Suite 1100, Salt Lake City, UT 84112 USA; [Pearson, Lauren; Factor, Rachel E.; White, Sandra K.; Walker, Brandon S.; Schmidt, Robert L.] Univ Utah, ARUP Labs, Salt Lake City, UT USA; [Layfield, Lester J.] Univ Missouri, Dept Pathol & Lab Med, Columbia, MO USA	Schmidt, RL (reprint author), Univ Utah, Dept Pathol, 50 N Med Dr East,Suite 1100, Salt Lake City, UT 84112 USA.	Robert.schmidt@hsc.utah.edu					Ahmed A, 2014, ACTA CYTOL, V58, P367, DOI 10.1159/000364853; American Society of Cytopathology, ASC RAP SIT EV ROS P; Bonifazi M, 2014, CHEST, V145, P60, DOI 10.1378/chest.13-0756; Bossuyt PM, 2016, ANN TRANSL MED, V4, DOI 10.3978/j.issn.2305-5839.2016.02.06; Burlingame OO, 2012, CANCER CYTOPATHOL, V120, P177, DOI 10.1002/cncy.20184; Choi SH, 2011, CLIN ENDOCRINOL, V74, P776, DOI 10.1111/j.1365-2265.2011.04011.x; Collins JA, 2013, KOREAN J PATHOL, V47, P405, DOI 10.4132/KoreanJPathol.2013.47.5.405; De Fiori E, 2010, RADIOL MED, V115, P612, DOI 10.1007/s11547-010-0528-x; Eedes CR, 2004, AM J CLIN PATHOL, V121, P64, DOI 10.1309/XLNDTE289WAQYK0Y; Harada R, 2014, SCAND J GASTROENTERO, V49, P1119, DOI 10.3109/00365521.2014.915051; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Layfield LJ, 2001, CANCER CYTOPATHOL, V93, P319, DOI 10.1002/cncr.9046; Marotti Jonathan D, 2015, J Am Soc Cytopathol, V4, P160, DOI 10.1016/j.jasc.2015.01.004; Medford ARL, 2011, CHEST, V140, P559, DOI 10.1378/chest.11-0508; Meena N, 2016, CANCER CYTOPATHOL, V124, P279, DOI 10.1002/cncy.21637; Mehotra S, 2014, MODERN PATHOL, V27, p112A; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Olson MT, 2012, ACTA CYTOL, V56, P340, DOI 10.1159/000338646; Olson MT, 2012, AM J CLIN PATHOL, V138, P90, DOI 10.1309/AJCP84AXSRABZCTZ; Petrone MC, 2012, DIGEST LIVER DIS, V44, P311, DOI 10.1016/j.dld.2011.12.001; Robitschek J, 2010, OTOLARYNG HEAD NECK, V142, P306, DOI 10.1016/j.otohns.2009.11.011; Rossi ED, 2010, CYTOPATHOLOGY, V21, P97, DOI 10.1111/j.1365-2303.2009.00659.x; Savoy AD, 2007, GASTROINTEST ENDOSC, V65, P953, DOI 10.1016/j.gie.2006.11.014; Schacht MJ, 2016, CYTOPATHOLOGY, V27, P344, DOI 10.1111/cyt.12338; Schmidt RL, 2015, CYTOPATHOLOGY, V26, P217, DOI 10.1111/cyt.12163; Schmidt RL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135466; Schmidt RL, 2013, DIGEST DIS SCI, V58, P3280, DOI 10.1007/s10620-013-2750-6; Schmidt RL, 2013, DIGEST DIS SCI, V58, P872, DOI 10.1007/s10620-012-2411-1; Schmidt RL, 2013, AM J CLIN PATHOL, V139, P336, DOI 10.1309/AJCPEAKR4MO2GQBO; Schmidt RL, 2013, AM J CLIN PATHOL, V139, P300, DOI 10.1309/AJCPEGZMJKC42VUP; Schmidt RL, 2012, AM J CLIN PATHOL, V138, P823, DOI 10.1309/AJCP8BYTCFI0XJZU; Shield PW, 2014, CYTOPATHOLOGY, V25, P322, DOI 10.1111/cyt.12157; Siegfried N, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003362.pub2; Tamura T, 2017, CLIN ENDOSC, V50, P372, DOI 10.5946/ce.2016.083; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; Wotruba AL, 2011, DIAGN CYTOPATHOL, V39, P896, DOI 10.1002/dc.21487; Zanocco K, 2013, ANN SURG ONCOL, V20, P2462, DOI 10.1245/s10434-013-2954-1	37	1	2	0	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000489550			9	Pathology	Pathology	GP3UW	WOS:000440780900002	29874653				2019-10-28	
J	Zhai, J				Zhai, Jing			UroVysion Multi-Target Fluorescence in situ Hybridization Assay for the Detection of Malignant Bile Duct Brushing Specimens: A Comparison with Routine Cytology	ACTA CYTOLOGICA			English	Article						Bile duct brushing cytology; Fluorescence in situ hybridization; Bile duct stricture	COMPARATIVE GENOMIC HYBRIDIZATION; PRIMARY SCLEROSING CHOLANGITIS; OF-THE-LITERATURE; PANCREATICOBILIARY STRICTURES; CHROMOSOMAL ALTERATIONS; BILIARY-TRACT; CANCER; SENSITIVITY; DIAGNOSIS; PANCREAS	Objective: Routine bile duct brushing cytology is an important diagnostic tool in the evaluation of bile duct stricture. The purpose of this study was to evaluate the performance of the UroVysion fluorescence in situ hybridization (FISH) assay for the detection of malignant bile duct brushing specimens. Study Design: Thirty-five bile duct brushing specimens were included in the study. The FISH assay utilized the commercially available UroVysion probes. The indeterminate cytology results were considered as negative for statistical analysis. Results: Twenty-two of 35 patients were diagnosed as having malignancy based on tissue diagnosis or clinical progression of disease by image assessment. The sensitivity of routine cytology and FISH for the detection of malignancy was 14% (3/22) and 55% (12/22), respectively (p = 0.003). The specificity of routine cytology and FISH was 100% (13/13) and 62% (8/13), respectively (p = 0.025). The false-positive rate for routine cytology and FISH was 0% (0/13) and 38% (5/13), respectively. Conclusions: Our study shows that FISH is significantly more sensitive than routine cytology for the detection of malignancy in bile duct brushing specimens. However, in our study, the specificity of FISH was poor compared to the excellent specificity of routine cytology. The compromised specificity of FISH may limit its utility in the detection of malignant bile duct brushing specimens. (c) 2018 S. Karger AG, Basel	[Zhai, Jing] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, 8700 Beverly Blvd,S Tower Suite 8707, Los Angeles, CA 90048 USA	Zhai, J (reprint author), Cedars Sinai Med Ctr, Dept Pathol & Lab Med, 8700 Beverly Blvd,S Tower Suite 8707, Los Angeles, CA 90048 USA.	zhaij@cshs.org			Department of Pathology, Washington University	I would like to thank Julie Branson and Diane Robirds, Department of Pathology, Washington University, for their excellent technical support with the FISH assay, and Kay Kasal, CT (ASCP), Department of Pathology, Washington University, for her help with the Cytospin preparations. Elizabeth Zhang provided assistance with proofreading and editing. This research is supported by the Department of Pathology, Washington University.	Burnett AS, 2014, J SURG RES, V190, P535, DOI 10.1016/j.jss.2014.04.014; Burnett AS, 2013, J SURG RES, V184, P304, DOI 10.1016/j.jss.2013.06.028; Chadwick BE, 2012, DIAGN CYTOPATHOL, V40, P536, DOI 10.1002/dc.22839; Chaiteerakij R, 2016, GASTROINTEST ENDOSC, V83, P1228, DOI 10.1016/j.gie.2015.11.037; DeHaan RD, 2007, HUM PATHOL, V38, P491, DOI 10.1016/j.humpath.2006.09.004; Fritcher EGB, 2014, CYTOPATHOLOGY, V25, P288, DOI 10.1111/cyt.12170; Fritcher EGB, 2015, GASTROENTEROLOGY, V149, P1813, DOI 10.1053/j.gastro.2015.08.046; Fritcher EGB, 2011, AM J CLIN PATHOL, V136, P442, DOI 10.1309/AJCPDULIOEOTUZ5H; Fritcher EGB, 2009, GASTROENTEROLOGY, V136, P2180, DOI 10.1053/j.gastro.2009.02.040; Griffin CA, 2007, CYTOGENET GENOME RES, V118, P148, DOI 10.1159/000108295; Halling KC, 2007, HUM PATHOL, V38, P1137, DOI 10.1016/j.humpath.2007.04.015; Kipp BR, 2013, CANCER CYTOPATHOL, V121, P610, DOI 10.1002/cncy.21303; Kipp BR, 2004, AM J GASTROENTEROL, V99, P1675, DOI 10.1111/j.1572-0241.2004.30281.x; Layfield LJ, 2014, DIAGN CYTOPATHOL, V42, P351, DOI 10.1002/dc.23093; Levy MJ, 2008, AM J GASTROENTEROL, V103, P1263, DOI 10.1111/j.1572-0241.2007.01776.x; Luna LEM, 2006, GASTROENTEROLOGY, V131, P1064, DOI 10.1053/j.gastro.2006.08.021; Mahlamaki EH, 2002, GENE CHROMOSOME CANC, V35, P353, DOI 10.1002/gcc.10122; Njei B, 2016, ALIMENT PHARM THER, V44, P1139, DOI 10.1111/apt.13817; Schleger C, 2000, J PATHOL, V191, P27, DOI 10.1002/(SICI)1096-9896(200005)191:1<27::AID-PATH582>3.0.CO;2-J; Shiraishi K, 2001, ONCOLOGY-BASEL, V60, P151, DOI 10.1159/000055313; Sonavane SK, 2014, CURR PROBL DIAGN RAD, V43, P14, DOI 10.1067/j.cpradiol.2013.10.002; Vasilieva LE, 2013, HUM PATHOL, V44, P2173, DOI 10.1016/j.humpath.2013.04.012; Vlajnic T, 2014, CANCER CYTOPATHOL, V122, P627, DOI 10.1002/cncy.21429; Wu X, 2017, CLIN LAB, V63, P407, DOI 10.7754/Clin.Lab.2016.160801	24	0	0	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	4								10.1159/000488636			7	Pathology	Pathology	GP3UW	WOS:000440780900009	29734171				2019-10-28	
J	Mavreli, D; Papantoniou, N; Kolialexi, A				Mavreli, Danai; Papantoniou, Nikolas; Kolialexi, Aggeliki			miRNAs in pregnancy-related complications: an update	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						miRNAs; circulating miRNAs; pregnancy complications; biomarkers; prenatal screening	MICRORNA EXPRESSION; PREECLAMPSIA; HYPERTENSION; C19MC		[Mavreli, Danai; Kolialexi, Aggeliki] Univ Athens, Sch Med, Dept Obstet & Gynecol 3, Athens, Greece; [Mavreli, Danai; Papantoniou, Nikolas; Kolialexi, Aggeliki] Univ Athens, Sch Med, Dept Med Genet, Athens, Greece	Kolialexi, A (reprint author), Aghia Sofia Childrens Hosp, Dept Med Genet, Athens 11527, Greece.	akolial@med.uoa.gr					Akehurst C, 2015, J HYPERTENS, V33, P2068, DOI 10.1097/HJH.0000000000000656; Anton L, 2013, AM J PATHOL, V183, P1437, DOI 10.1016/j.ajpath.2013.07.021; Biro O, 2017, PREGNANCY HYPERTENS, V10, P207, DOI 10.1016/j.preghy.2017.09.002; Biro O, 2017, HYPERTENS PREGNANCY, V36, P90, DOI 10.1080/10641955.2016.1239736; Gunel T, 2011, GENET MOL RES, V10, P4034, DOI 10.4238/2011.November.8.5; Hromadnikova I, 2017, MOL MED REP, V16, P3849, DOI 10.3892/mmr.2017.7067; Hromadnikova I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171756; Jairajpuri DS, 2017, GENE, V627, P543, DOI 10.1016/j.gene.2017.07.010; Luo RC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19588; Luque A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04882; Lycoudi A, 2015, EXPERT REV MOL DIAGN, V15, P999, DOI 10.1586/14737159.2015.1053468; Munaut C, 2016, BIOMED REP, V5, P686, DOI 10.3892/br.2016.779; Noguer-Dance M, 2010, HUM MOL GENET, V19, P3566, DOI 10.1093/hmg/ddq272; Pheiffer C, 2018, MOL DIAGN THER, V22, P345, DOI 10.1007/s40291-018-0325-0; Sadovsky Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a023036; Tsai PY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071570; Ura B, 2014, TAIWAN J OBSTET GYNE, V53, P232, DOI 10.1016/j.tjog.2014.03.001; Wallis AB, 2008, AM J HYPERTENS, V21, P521, DOI 10.1038/ajh.2008.20; Wander PL, 2017, DIABETES RES CLIN PR, V132, P1, DOI 10.1016/j.diabres.2017.07.024; Zhang YG, 2017, CLIN EXP HYPERTENS, V39, P108, DOI 10.1080/10641963.2016.1210619; Zhao CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021768; Zhu YN, 2015, INT J GYNECOL OBSTET, V130, P49, DOI 10.1016/j.ijgo.2015.01.010	22	0	1	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					587	589		10.1080/14737159.2018.1480939			3	Pathology	Pathology	GP3EX	WOS:000440725900001	29806507	Bronze			2019-10-28	
J	Bevilacqua, E; Resta, S; Carlin, A; Kang, X; Sanchez, TC; de Marchin, J; Jani, JC				Bevilacqua, Elisa; Resta, Serena; Carlin, Andrew; Kang, Xin; Sanchez, Teresa Cos; de Marchin, Jerome; Jani, Jacques C.			Profile of women choosing the Harmony (R) Prenatal Test	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Cell-free DNA; patient's profile; technology transfer; fetal fraction; trisomy	CELL-FREE DNA; CLINICAL-LABORATORY-EXPERIENCE; FETAL WEIGHT ESTIMATION; MATERNAL PLASMA; TRISOMIES 21; CHROMOSOMAL ANEUPLOIDIES; DUTCH LABORATORIES; BLOOD; ULTRASOUND; DIAGNOSIS	Introduction: The Harmony (R) Prenatal Test, a noninvasive cell-free DNA (cfDNA) method for major trisomies has been available since January 2013 at our unit, and tests were sent to the Ariosa Clinical Laboratory Improvement Amendments (CLIA) laboratory in California. From July 2017 onward, prenatal cfDNA has been reimbursed in Belgium for all pregnancies; however, since then samples are sent to a local laboratory. Little data are available on patient's profile and choices toward cfDNA and on the performance of local technology transfer centers.Areas covered: The profiles and choices of women regarding this test were evaluated. Further, the performance of cfDNA at the local laboratory was compared to the one in California. Our results showed that women from the Netherlands, as compared to Belgium, were more likely to undergo cfDNA testing for maternal request and would be less likely to undergo karyotyping if cfDNA were unavailable, therefore are better candidates for cfDNA testing, when this is used as first-line screening.Expert commentary: Our findings highlight the importance of conducting these types of studies, before decisions about clinical implementation are made by national governments and ministries of health.	[Bevilacqua, Elisa; Resta, Serena; Carlin, Andrew; Kang, Xin; Sanchez, Teresa Cos; Jani, Jacques C.] Univ Libre Bruxelles, Univ Hosp Brugmann, Dept Obstet & Gynecol, Brussels, Belgium; [de Marchin, Jerome] Citadelle Hosp, Labocita, Liege, Belgium	Jani, JC (reprint author), Univ Hosp Brugmann, Dept Obstet & Gynecol, Pl A Van Gehuchten 4, B-1020 Brussels, Belgium.	jacques.jani@chu-brugmann.be		Bevilacqua, Elisa/0000-0002-9791-9552	Fetal Medicine Foundation Belgium; Brugmann Foundation	The Fetal Medicine Foundation Belgium and the Brugmann Foundation partly funded this study; however, these funding agencies had no role in the study design, data gathering, data analysis, data interpretation, or writing of the report.	Ashoor G, 2013, ULTRASOUND OBST GYN, V41, P21, DOI 10.1002/uog.12299; Barrett AN, 2017, SINGAP MED J, V58, P298, DOI 10.11622/smedj.2016114; Benachi A, 2015, OBSTET GYNECOL, V125, P1330, DOI 10.1097/AOG.0000000000000874; Benn P, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2016.01.003; Bevilacqua E, 2016, ULTRASOUND OBST GYN, V47, P124, DOI 10.1002/uog.14938; Bevilacqua E, 2015, ULTRASOUND OBST GYN, V45, P61, DOI 10.1002/uog.14690; Bevilacqua E, 2018, FETAL DIAGN THER, V44, P98, DOI 10.1159/000479507; Bevilacqua E, 2019, FETAL DIAGN THER, V45, P302, DOI 10.1159/000489124; Bianchi DW, 2015, OBSTET GYNECOL, V125, P375, DOI 10.1097/AOG.0000000000000637; Bianchi DW, 2014, NEW ENGL J MED, V370, P799, DOI 10.1056/NEJMoa1311037; Bianchi DW, 2012, OBSTET GYNECOL, V119, P890, DOI 10.1097/AOG.0b013e31824fb482; Chen A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173669; Chen EZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021791; Chitty LS, 2018, PRENATAL DIAG, V38, P160, DOI 10.1002/pd.5216; Chiu RWK, 2008, P NATL ACAD SCI USA, V105, P20458, DOI 10.1073/pnas.0810641105; Costa JM, 2018, GENET MED, V20, P1346, DOI 10.1038/gim.2018.4; Dahl F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22606-0; Dan S, 2012, PRENATAL DIAG, V32, P1225, DOI 10.1002/pd.4002; Ehrich M, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.12.060; Ellison CK, 2016, CLIN CHEM, V62, P1621, DOI 10.1373/clinchem.2016.260034; Evans MI, 2018, PRENATAL DIAG, V38, P243, DOI 10.1002/pd.5226; Fan HC, 2008, P NATL ACAD SCI USA, V105, P16266, DOI 10.1073/pnas.0808319105; Farrell R, 2015, PRENATAL DIAG, V35, P748, DOI 10.1002/pd.4599; Futch T, 2013, PRENATAL DIAG, V33, P569, DOI 10.1002/pd.4123; Garite TJ, 2017, AM J PERINAT, V34, P1430, DOI 10.1055/s-0037-1603992; Gil MM, 2017, ULTRASOUND OBST GYN, V50, P302, DOI 10.1002/uog.17484; Gil MM, 2016, ULTRASOUND OBST GYN, V47, P45, DOI 10.1002/uog.15783; Gil MM, 2015, ULTRASOUND OBST GYN, V45, P67, DOI 10.1002/uog.14683; Herrera CA, 2017, AM J OBSTET GYNECOL, V217, DOI 10.1016/j.ajog.2017.05.027; Hofmann W, 2013, PRENAT DIAGN S1, V33, P27; Jani J, 2015, ULTRASOUND OBST GYN, V46, P515, DOI 10.1002/uog.15733; Juneau K, 2014, FETAL DIAGN THER, V36, P282, DOI 10.1159/000367626; Kacem Y, 2013, RADIOLOGY, V267, P902, DOI 10.1148/radiol.12121374; Kadji C, 2018, ULTRASOUND OBST GYN, V52, P250, DOI 10.1002/uog.17523; Kadji C, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2017.10.009; Kadji C, 2017, FETAL DIAGN THER, V42, P181, DOI 10.1159/000453356; Kadji C, 2017, FETAL DIAGN THER, V41, P307, DOI 10.1159/000448950; Kou KO, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0636-7; Lau TK, 2012, J MATERN-FETAL NEO M, V25, P1856, DOI 10.3109/14767058.2012.678442; Lau TK, 2012, J MATERN-FETAL NEO M, V25, P1370, DOI 10.3109/14767058.2011.635730; Le Conte G, 2018, ULTRASOUND OBST GYN, V52, P318, DOI 10.1002/uog.18838; Livergood MC, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2017.01.011; Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0; McCullough RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109173; Nicolaides KH, 2013, PRENATAL DIAG, V33, P575, DOI 10.1002/pd.4103; Nicolaides KH, 2014, FETAL DIAGN THER, V35, P212, DOI 10.1159/000355655; Nicolaides KH, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.08.033; Norton ME, 2017, AM J OBSTET GYNECOL, V216, pB2, DOI 10.1016/j.ajog.2017.01.005; Norton ME, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.05.021; Norton ME, 2015, NEW ENGL J MED, V372, P1589, DOI 10.1056/NEJMoa1407349; Norton ME, 2016, AM J OBSTET GYNECOL, V215; Norton ME, 2016, AM J OBSTET GYNECOL, V214, pe1; Oepkes D, 2016, PRENATAL DIAG, V36, P1083, DOI 10.1002/pd.4945; Palomaki GE, 2016, AM J OBSTET GYNECOL, V215; Palomaki GE, 2012, GENET MED, V14, P296, DOI 10.1038/gim.2011.73; Palomaki GE, 2011, GENET MED, V13, P913, DOI 10.1097/GIM.0b013e3182368a0e; Quezada MS, 2015, ULTRASOUND OBST GYN, V45, P36, DOI 10.1002/uog.14664; Rolnik DL, 2017, NEW ENGL J MED, V377, P613, DOI 10.1056/NEJMoa1704559; Schmid M, 2017, FETAL DIAGN THER; Scibetta EW, 2017, PRENATAL DIAG, V37, P1291, DOI 10.1002/pd.5146; Sehnert AJ, 2011, CLIN CHEM, V57, P1042, DOI 10.1373/clinchem.2011.165910; Shani H, 2016, AM J OBSTET GYNECOL, V214, DOI 10.1016/j.ajog.2015.12.025; Song YJ, 2013, PRENATAL DIAG, V33, P700, DOI 10.1002/pd.4160; Sparks AB, 2012, AM J OBSTET GYNECOL, V206, DOI 10.1016/j.ajog.2012.01.030; Sparks AB, 2012, PRENATAL DIAG, V32, P3, DOI 10.1002/pd.2922; Stumm M, 2012, PRENATAL DIAG, V32, P569, DOI 10.1002/pd.3862; Valderramos SG, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.06.039; van Schendel RV, 2016, PRENATAL DIAG, V36, P1091, DOI 10.1002/pd.4941; Wright D, 2018, AM J OBSTET GYNECOL, V218, DOI 10.1016/j.ajog.2018.02.014; Yao H, 2014, ULTRASOUND OBST GYN, V44, P17, DOI 10.1002/uog.13361; Yaron Y, 2015, OBSTET GYNECOL, V126, P1095, DOI 10.1097/AOG.0000000000001091; Zhang H, 2015, ULTRASOUND OBST GYN, V45, P530, DOI 10.1002/uog.14792	72	0	0	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					591	599		10.1080/14737159.2018.1489242			9	Pathology	Pathology	GP3EX	WOS:000440725900002	29911931				2019-10-28	
J	Greninger, AL				Greninger, Alexander L.			The challenge of diagnostic metagenomics	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Metagenomics; clinical metagenomics; mNGS; next-generation sequencing; utilization management; clinical microbiology; Luddite	BALAMUTHIA-MANDRILLARIS ENCEPHALITIS; BLOOD CULTURE CONTAMINATION; VIRUS 3 INFECTIONS; REAL-TIME; UNITED-STATES; EMERGENCY-DEPARTMENT; CLINICAL-SAMPLES; GENOME; IDENTIFICATION; OUTBREAK	Introduction: Diagnostic metagenomics and its associated trail of publications are spreading across the world. Multiple clinical labs in the United States, Europe, and Asia have gone to considerable lengths to optimize and validate a range of protocols for agnostically detecting viral, bacterial, fungal, and eukaryotic parasite nucleic acid across a range of patient specimens to aid in diagnosis for particularly recalcitrant cases. Others see a role for diagnostic metagenomics as a frontline diagnostic to replace other microbiological testing.Areas covered: There are considerable barriers to adoption for diagnostic metagenomics, including analytical sensitivity, interpretation, actionability, turnaround time, antimicrobial susceptibility, clinical utility, laboratory workflow, trial comparators, cost, and reimbursement.Expert commentary: Metagenomics is unlikely to become one test to rule them all' any time soon, not least because it is not indicative of historical infection like some of the highest volume tests in the clinical virology lab, viral serologies. The high cost and low marginal utility compared to standard of care' diagnostics have forced metagenomics to be mostly used for last-ditch cases. However, waiting for such patients to declare themselves as being diagnostically challenging in turn likely lessens the diagnostic yield and actionability of the information. Significant reductions in the cost of metagenomic sequencing are required for it to move up in the diagnostic pipeline. This review covers these associated obstacles of metagenomics, arguing for a parsimonious role in last-ditch diagnostics and awaiting the answer of many outstanding questions regarding its adoption.	[Greninger, Alexander L.] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA	Greninger, AL (reprint author), Univ Washington, Dept Lab Med, Seattle, WA 98195 USA.	agrening@uw.edu		Greninger, Alexander/0000-0002-7443-0527			Abril MK, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw144; Allander T, 2005, P NATL ACAD SCI USA, V102, P12891, DOI 10.1073/pnas.0504666102; Allander T, 2001, P NATL ACAD SCI USA, V98, P11609, DOI 10.1073/pnas.211424698; [Anonymous], PALM REL DRAFT COV D; Bajema KL, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx174; Balogh EP, 2015, DIAGN TEAM MEMB TASK; Bateman AC, 2017, CLIN CHEM, V63, P761, DOI 10.1373/clinchem.2016.265512; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; Bender JM, 2018, CURR OPIN PEDIATR, V30, P125, DOI 10.1097/MOP.0000000000000577; Briese T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000455; Brown JR, 2018, J INFECTION, V76, P225, DOI 10.1016/j.jinf.2017.12.014; Chai JH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194648; Chiu CY, 2010, J VIROL, V84, P4407, DOI 10.1128/JVI.02536-09; Chiu CY, 2008, P NATL ACAD SCI USA, V105, P14124, DOI 10.1073/pnas.0805968105; Chiu CY, 2017, EMERG INFECT DIS, V23, P1694, DOI 10.3201/eid2310.161986; Christiansen MT, 2017, CLIN MICROBIOL INFEC, V23, DOI 10.1016/j.cmi.2016.09.018; College of American Pathologists, 2015, CAP TODAY; Depledge DP, 2016, J INFECT DIS, V214, P1399, DOI 10.1093/infdis/jiw398; Duff S, 2018, FUTURE MICROBIOL; Edgerton D, 2011, NATURE, V471, P27, DOI 10.1038/471027a; Finkbeiner SR, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000011; Flygare S, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0969-1; Forbes JD, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01069; Gander RM, 2009, J CLIN MICROBIOL, V47, P1021, DOI 10.1128/JCM.02162-08; Garcia E, 2017, LAB MED, V48, P113, DOI 10.1093/labmed/lmx031; Gardy JL, 2011, NEW ENGL J MED, V364, P730, DOI 10.1056/NEJMoa1003176; Garner M, MAN REG ISS GET FDA; Graf EH, 2016, J CLIN MICROBIOL, V54, P1000, DOI 10.1128/JCM.03060-15; Green DA, 2016, J CLIN MICROBIOL, V54, P2950, DOI 10.1128/JCM.01579-16; GRENINGER AL, 2009, VIROL J, V6; Greninger AL, 2018, VIRUS RES, V244, P218, DOI 10.1016/j.virusres.2017.10.014; Greninger AL, 2017, J PEDIAT INF DIS SOC, V6, P168, DOI 10.1093/jpids/pix019; Greninger AL, 2017, J CLIN MICROBIOL, V55, P177, DOI 10.1128/JCM.01881-16; Greninger AL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0235-2; Greninger AL, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0220-9; Greninger AL, 2015, LANCET INFECT DIS, V15, P671, DOI 10.1016/S1473-3099(15)70093-9; Greninger AL, 2012, J VIROL, V86, P3605, DOI 10.1128/JVI.06778-11; Greninger AL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013381; Hall KK, 2006, CLIN MICROBIOL REV, V19, P788, DOI 10.1128/CMR.00062-05; Holtz LR, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-159; HOLTZ LR, 2009, VIROL J, V6; Houldcroft CJ, 2017, NAT REV MICROBIOL, V15, P183, DOI 10.1038/nrmicro.2016.182; Houldcroft CJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01317; Illumina, EFF IND MIS MULT DOW; Jajosky RP, 2018, HUM PATHOL, V73, P26, DOI 10.1016/j.humpath.2017.11.014; Kapoor A, 2009, J GEN VIROL, V90, P2965, DOI 10.1099/vir.0.014449-0; Kapoor A, 2008, P NATL ACAD SCI USA, V105, P20482, DOI 10.1073/pnas.0807979105; Koehler JW, 2017, MICROBIOL RESOUR ANN, V5, DOI [10.1128/genomeA.00240-17, 10.1128/genomea.00240-17]; Kothari A, 2017, J CLIN VIROL, V92, P53, DOI 10.1016/j.jcv.2017.05.010; Kowarsky M, 2017, P NATL ACAD SCI USA, V114, P9623, DOI 10.1073/pnas.1707009114; Kozyreva VK, 2017, J CLIN MICROBIOL, V55, P2502, DOI 10.1128/JCM.00361-17; Kozyreva VK, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00344-16; KROLL MH, 1994, CLIN CHEM, V40, P1996; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Langelier C, 2018, AM J RESP CRIT CARE, V197, P524, DOI 10.1164/rccm.201706-1097LE; Leber AL, 2016, J CLIN MICROBIOL, V54, P2251, DOI 10.1128/JCM.00730-16; Li LL, 2009, J VIROL, V83, P12002, DOI 10.1128/JVI.01241-09; Meyers L, 2017, BIORXIV; Mongkolrattanothai K, 2017, J PEDIATR INFECT DIS, V6, P393, DOI 10.1093/jpids/piw066; Naccache SN, 2014, GENOME RES, V24, P1180, DOI 10.1101/gr.171934.113; Naccache SN, 2013, J VIROL, V87, P11966, DOI 10.1128/JVI.02323-13; Paisse S, 2016, TRANSFUSION, V56, P1138, DOI 10.1111/trf.13477; Palacios G, 2008, NEW ENGL J MED, V358, P991, DOI 10.1056/NEJMoa073785; Quan TP, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01480-17; Plebani M, 2010, ANN CLIN BIOCHEM, V47, P101, DOI 10.1258/acb.2009.009222; Quick J, 2016, NATURE, V530, P228, DOI 10.1038/nature16996; Robboy SJ, 2013, ARCH PATHOL LAB MED, V137, P1723, DOI 10.5858/arpa.2013-0200-OA; Ruppe E, 2017, ANTIBIOTICS-BASEL, V6, DOI 10.3390/antibiotics6040030; Ruppe E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07546-5; Saporta-Keating SR, 2018, J PEDIAT INFECT DIS; Schlaberg R, 2017, ARCH PATHOL LAB MED, V141, P776, DOI 10.5858/arpa.2016-0539-RA; Sedlak RH, 2017, J CLIN MICROBIOL, V55, P442, DOI 10.1128/JCM.01970-16; Sedlak RH, 2016, SCI REP-UK, V6, DOI 10.1038/srep20064; Self WH, 2013, ACAD EMERG MED, V20, P89, DOI 10.1111/acem.12057; Shean RC, 2018, VIRUS EVOL, V4, DOI 10.1093/ve/vey005; Simner PJ, 2018, CLIN INFECT DIS, V66, P778, DOI 10.1093/cid/cix881; Stalnikowicz R, 2001, Eur J Emerg Med, V8, P93; Tunkel AR, 2008, CLIN INFECT DIS, V47, P303, DOI 10.1086/589747; UCSF Infectious Diseases Management Program, PED GUID CNS INF MEN; van der Heijden YF, 2011, INFECT CONT HOSP EP, V32, P623, DOI 10.1086/660096; Westblade LF, 2015, J CLIN MICROBIOL, V53, P2349, DOI 10.1128/JCM.00187-15; Wilson MR, 2015, ANN NEUROL, V78, P722, DOI 10.1002/ana.24499; Wilson MR, 2017, BIORXIV; Yozwiak NL, 2015, NATURE, V518, P477, DOI 10.1038/518477a; Yu GX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049449	85	9	9	0	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					605	615		10.1080/14737159.2018.1487292			11	Pathology	Pathology	GP3EX	WOS:000440725900004	29898605				2019-10-28	
J	Hogan, CA; Caya, C; Papenburg, J				Hogan, Catherine A.; Caya, Chelsea; Papenburg, Jesse			Rapid and simple molecular tests for the detection of respiratory syncytial virus: a review	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Diagnosis; molecular diagnostic techniques; point-of-care systems; respiratory syncytial virus; rapid nucleic acid amplification	PNEUMONIA REQUIRING HOSPITALIZATION; HUMAN METAPNEUMOVIRUS; YOUNG-CHILDREN; PATHOGEN PANEL; UNITED-STATES; INFLUENZA-A; INFECTION; ASSAY; DIAGNOSIS; COMMUNITY	Introduction: Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections. The clinical manifestations of RSV are indistinguishable from other etiologies of acute respiratory infection. Therefore, accurate and timely laboratory testing is needed to impact clinical management.There are now multiple rapid, low-complexity, commercially available assays for RSV. These tests present significant performance advantages compared to older antigen detection tests. Accurate and rapid diagnosis of RSV has the potential for enabling timely cessation of unnecessary antibiotics and implementation of good infection control practices. Furthermore, a recently approved RSV diagnostic assay can reduce the test turnaround time to 13min or less.Areas covered: The authors aim to review the importance of rapid and accurate testing for RSV and will describe the available molecular RSV diagnostic assays approved for use at the point-of-care.Expert commentary: Further independent evaluations are needed to confirm that the accuracy of the low-complexity assays is indeed similar to reverse transcriptase polymerase chain reaction across the age spectrum, and in immunosuppressed hosts. In the future, the challenge will be to achieve a balance between increasingly sophisticated multiplex diagnostic platforms and tests that are sufficiently simple to be used at the point-of-care.	[Hogan, Catherine A.] McGill Univ, Hlth Ctr, Dept Microbiol, Div Infect Dis, Montreal, PQ, Canada; [Hogan, Catherine A.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA USA; [Hogan, Catherine A.] Stanford Univ, Med Ctr, Clin Microbiol Lab, Palo Alto, CA 94304 USA; [Caya, Chelsea] McGill Univ, Hlth Ctr, Res Inst, Infect Dis & Immun Global Hlth Program, Montreal, PQ, Canada; [Papenburg, Jesse] McGill Univ, Hlth Ctr, Dept Microbiol, Div Pediat Infect Dis, Montreal, PQ, Canada; [Papenburg, Jesse] McGill Univ, Hlth Ctr, Dept Pediat, Div Pediat Infect Dis, Montreal, PQ, Canada	Papenburg, J (reprint author), McGill Univ, Hlth Ctr, Montreal Childrens Hosp, Room E05-1905,1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada.	Jesse.papenburg@mail.mcgill.ca	Papenburg, Jesse/I-7847-2019	Papenburg, Jesse/0000-0003-4232-871X			Adcock PM, 1997, PEDIATR INFECT DIS J, V16, P842, DOI 10.1097/00006454-199709000-00005; Alby K, 2013, J CLIN MICROBIOL, V51, P352, DOI 10.1128/JCM.02504-12; [Anonymous], 2012, RSV RESPI STRIP PACK; [Anonymous], VER RESP VIR NUCL AC; [Anonymous], 2016, AL RSV; [Anonymous], 2017, COB INFL AB RSV NUCL; [Anonymous], 2017, XPERT XPRESS FLURSV; [Anonymous], XPERT FLURSV XC; [Anonymous], 2015, PROD PROFLU ASS INST; [Anonymous], 2016, BD VER SYST RAP DET; [Anonymous], 2015, SIMPL FLU AB RSV DIR; [Anonymous], 2015, BINAXNOW RSV CARD; [Anonymous], 2009, QUID SOF RSV FIA PAC; Barenfanger J, 2000, J CLIN MICROBIOL, V38, P2824; Beckmann C, 2016, J MED VIROL, V88, P1319, DOI 10.1002/jmv.24492; BEEM M, 1960, NEW ENGL J MED, V263, P523, DOI 10.1056/NEJM196009152631101; Branche AR, 2015, DRUG AGING, V32, P261, DOI 10.1007/s40266-015-0258-9; Byington CL, 2002, ARCH PEDIAT ADOL MED, V156, P1230, DOI 10.1001/archpedi.156.12.1230; Chartrand C, 2015, J CLIN MICROBIOL, V53, P3738, DOI 10.1128/JCM.01816-15; Chen JHK, 2016, J CLIN MICROBIOL, V54, P1820, DOI 10.1128/JCM.00517-16; Cohen DM, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01237-17; DeVincenzo JP, 2015, NEW ENGL J MED, V373, P2048, DOI 10.1056/NEJMoa1413275; Donaldson GC, 2006, CLIN INFECT DIS, V42, P677, DOI 10.1086/500208; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Falsey AR, 2000, CLIN MICROBIOL REV, V13, P371, DOI 10.1128/CMR.13.3.371-384.2000; Ferronato AE, 2012, CLINICS, V67, P1001, DOI 10.6061/clinics/2012(09)03; Gibson J, 2017, J CLIN VIROL, V95, P5, DOI 10.1016/j.jcv.2017.08.004; Guerrero MD, COMPARISON LUMINEXTM; Hall CB, 2009, NEW ENGL J MED, V360, P588, DOI 10.1056/NEJMoa0804877; Hassan F, 2018, J CLIN MICROBIOL, V56, P3; Haynes AK, 2014, MMWR-MORBID MORTAL W, V63, P1133; Huzly D, 2016, ARCH VIROL, V161, P2417, DOI 10.1007/s00705-016-2930-8; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI 10.1056/NEJMoa1500245; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Kim HK, 2013, J CLIN MICROBIOL, V51, P1137, DOI 10.1128/JCM.02958-12; KRASINSKI K, 1990, J PEDIATR-US, V116, P894, DOI 10.1016/S0022-3476(05)80646-8; Loeffelholz MJ, 2011, J CLIN MICROBIOL, V49, P4083, DOI 10.1128/JCM.05010-11; MADGE P, 1992, LANCET, V340, P1079, DOI 10.1016/0140-6736(92)93088-5; Maffey AF, 2010, PEDIATR PULM, V45, P619, DOI 10.1002/ppul.21236; Mahony JB, 2009, J CLIN MICROBIOL, V47, P2812, DOI 10.1128/JCM.00556-09; Mazur N, 2015, LANCET RESP MED, V3, P888, DOI 10.1016/S2213-2600(15)00255-6; Meissner HC, 2016, NEW ENGL J MED, V374, P62, DOI 10.1056/NEJMra1413456; Mills JM, 2011, J HOSP INFECT, V77, P248, DOI 10.1016/j.jhin.2010.11.019; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; National Center for Immunization and Respiratory Diseases (NCIRD)Division of Viral Diseases, CDC RESP SYNCYT VIR; Papenburg J, 2013, J PEDIATR-US, V163, P911, DOI 10.1016/j.jpeds.2013.03.067; Papenburg J, 2012, J INFECT DIS, V206, P178, DOI 10.1093/infdis/jis333; Papenburg J, 2012, EMERG INFECT DIS, V18, P120, DOI 10.3201/eid1801.110515; Papenburg J, 2010, REV MED VIROL, V20, P245, DOI 10.1002/rmv.651; Peters RM, 2017, J CLIN MICROBIOL, V55, P1032, DOI 10.1128/JCM.02433-16; Popowitch EB, 2015, J CLIN MICROBIOL, V53, P2720, DOI 10.1128/JCM.00972-15; Popowitch EB, 2013, J CLIN MICROBIOL, V51, P1528, DOI 10.1128/JCM.03368-12; Purcell K, 2002, ARCH PEDIAT ADOL MED, V156, P322, DOI 10.1001/archpedi.156.4.322; Ralston SL, 2014, PEDIATRICS, V134, pE1474, DOI 10.1542/peds.2014-2742; Revill P, 2018, LANCET INFECT DIS, V18, P11, DOI 10.1016/S1473-3099(17)30593-5; Rogers BB, 2015, ARCH PATHOL LAB MED, V139, P636, DOI 10.5858/arpa.2014-0257-OA; Salez N, 2015, DIAGN MICR INFEC DIS, V81, P256, DOI 10.1016/j.diagmicrobio.2015.01.008; Samson L, 1999, Paediatr Child Health, V4, P195; Sato M, 2005, J CLIN MICROBIOL, V43, P36, DOI 10.1128/JCM.43.1.36-40.2005; Scheltema NM, 2017, LANCET GLOB HEALTH, V5, pE984, DOI 10.1016/S2214-109X(17)30344-3; Schnee SV, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2855-1; Shi T, 2017, LANCET, V390, P946, DOI [10.1016/S0140-6736(17)30938-8, 10.1016/s0140-6736(17)30938-8]; Simoes EAF, 2015, J INFECT DIS, V211, pS1, DOI 10.1093/infdis/jiu828; Sullender WM, 2000, CLIN MICROBIOL REV, V13, P1; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579; Zambon MC, 2001, LANCET, V358, P1410, DOI 10.1016/S0140-6736(01)06528-X; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	67	2	2	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					617	629		10.1080/14737159.2018.1487293			13	Pathology	Pathology	GP3EX	WOS:000440725900005	29890085				2019-10-28	
J	Diaz-Decaro, JD; Green, NM; Godwin, HA				Diaz-Decaro, John D.; Green, Nicole M.; Godwin, Hilary A.			Critical evaluation of FDA-approved respiratory multiplex assays for public health surveillance	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Multiplex respiratory assays; surveillance; respiratory pathogens; sensitivity; specificity; diagnostic odds ratio; ROC curves; Youden Index	VIRAL-PANEL; VIRUS-INFECTIONS; SYNCYTIAL VIRUS; INFLUENZA-VIRUS; FILMARRAY RP; XTAG RVP; LIKELIHOOD RATIOS; PREDICTIVE VALUES; ENTEROVIRUS D68; PATHOGEN PANEL	Introduction: Clinical management and identification of respiratory diseases has become more rapid and increasingly specific due to widespread use of PCR(polymerase chain reaction) multiplex technologies. Although significantly improving clinical diagnosis, multiplexed PCR assays could have a greater impact on local and global disease surveillance. The authors wish to propose methods of evaluating respiratory multiplex assays to maximize diagnostic yields specifically for surveillance efforts.Areas covered: The authors review multiplexed assays and critically assess what barriers have limited these assays for disease surveillance and how these barriers might be addressed. The manuscript focuses specifically on the case study of using multiplexed assays for surveillance of respiratory pathogens. The authors also provide a method of validation of specific surveillance measures.Expert commentary: Current commercially available respiratory multiplex PCR assays are widely used for clinical diagnosis; however, specific barriers have limited their use for surveillance. Key barriers include differences in testing phase requirements and diagnostic performance evaluation. In this work the authors clarify phase testing requirements and introduce unique diagnostic performance measures that simplify the use of these assays on a per target basis for disease surveillance.	[Diaz-Decaro, John D.; Green, Nicole M.] Los Angeles Cty Publ Hlth Labs, Res & Training Unit, Downey, CA USA; [Diaz-Decaro, John D.; Godwin, Hilary A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Environm Hlth Sci, Los Angeles, CA USA	Diaz-Decaro, JD (reprint author), 12750 Erickson Ave, Downey, CA 90242 USA.	jdiazdecaro@gmail.com					Aanensen DM, 2016, MBIO, V7, DOI 10.1128/mBio.00444-16; Akobeng AK, 2007, ACTA PAEDIATR, V96, P338, DOI 10.1111/j.1651-2227.2006.00180.x; Aliabadi N, 2016, EMERG INFECT DIS, V22, P1387, DOI 10.3201/eid2208.151949; Babady NE, 2012, J CLIN MICROBIOL, V50, P2282, DOI 10.1128/JCM.06186-11; Brenner H, 1997, STAT MED, V16, P981, DOI 10.1002/(SICI)1097-0258(19970515)16:9<981::AID-SIM510>3.0.CO;2-N; Byington CL, 2015, CLIN INFECT DIS, V61, P1217, DOI 10.1093/cid/civ486; Carrico JA, 2013, EUROSURVEILLANCE, V18, P1; CDC, HEALTHC ASS INF TRAC; CDC, ENT D68; CDC, RSV CENS REG TRENDS; Chen JHK, 2016, J CLIN MICROBIOL, V54, P1820, DOI 10.1128/JCM.00517-16; Coleman CM, 2014, J VIROL, V88, P5209, DOI 10.1128/JVI.03488-13; Costa LF, 2014, PEDIATRICS, V133, pE312, DOI 10.1542/peds.2013-2216; Dallman TJ, 2015, EPIDEMIOL INFECT, V143, P1672, DOI 10.1017/S0950268814002696; Dundas NE, 2011, J MOL DIAGN, V13, P175, DOI 10.1016/j.jmoldx.2010.09.003; Esposito S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030297; Faden H, 2005, J PEDIATR-US, V146, P523, DOI 10.1016/j.jpeds.2004.11.032; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Feighner JP, 1987, ISSUES DIAGNOSTIC RE; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; French CE, 2016, INFLUENZA OTHER RESP, V10, P268, DOI 10.1111/irv.12379; Ghebremedhin B, 2014, EUR J MICROBIOL IMMU, V4, P26, DOI 10.1556/EuJMI.4.2014.1.2; Ginocchio CC, 2009, J CLIN MICROBIOL, V47, P2347, DOI 10.1128/JCM.01027-09; Glas AS, 2003, J CLIN EPIDEMIOL, V56, P1129, DOI 10.1016/S0895-4356(03)00177-X; Graf EH, 2016, J CLIN MICROBIOL, V54, P1000, DOI 10.1128/JCM.03060-15; Halling KC, 2012, ARCH PATHOL LAB MED, V136, P11, DOI 10.5858/arpa.2011-0212-ED; Hayden FG, 2011, J INFECT DIS, V203, P6, DOI 10.1093/infdis/jiq012; Hwang SM, 2015, J CLIN LAB ANAL, V29, P116, DOI 10.1002/jcla.21738; Idrovo AJ, 2011, ENVIRON HEALTH PERSP, V119, pA332, DOI 10.1289/ehp.1103768; Jacob JT, 2013, MMWR-MORBID MORTAL W, V62, P165; Jannetto PJ, 2010, J CLIN MICROBIOL, V48, P3997, DOI 10.1128/JCM.01118-10; Jansen RR, 2011, J CLIN MICROBIOL, V49, P2631, DOI 10.1128/JCM.02094-10; Koser CU, 2014, TRENDS GENET, V30, P401, DOI 10.1016/j.tig.2014.07.003; Koser CU, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002824; Lau LLH, 2010, J INFECT DIS, V201, P1509, DOI 10.1086/652241; Lee CK, 2017, ANN LAB MED, V37, P267, DOI 10.3343/alm.2017.37.3.267; Lieberman D, 2006, J CLIN MICROBIOL, V44, P525, DOI 10.1128/JCM.44.2.525-528.2006; Mahony J, 2007, J CLIN MICROBIOL, V45, P2965, DOI 10.1128/JCM.02436-06; Mahony JB, 2009, J CLIN MICROBIOL, V47, P2812, DOI 10.1128/JCM.00556-09; Marchand-Austin A, 2009, EMERG INFECT DIS, V15, P2001, DOI 10.3201/eid1512.091022; McAllister SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118529; McGinnis J, 2016, J CLIN VIROL, V79, P44, DOI 10.1016/j.jcv.2016.03.005; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276; Moons KGM, 1997, EPIDEMIOLOGY, V8, P12, DOI 10.1097/00001648-199701000-00002; National Foundation for Infectious Diseases, RESP SYNC VIR OLD AD; Pabbaraju K, 2008, J CLIN MICROBIOL, V46, P3056, DOI 10.1128/JCM.00878-08; Parikh R, 2009, INDIAN J OPHTHALMOL, V57, P217, DOI 10.4103/0301-4738.49397; Pierce VM, 2012, J CLIN MICROBIOL, V50, P3458, DOI 10.1128/JCM.01384-12; Popowitch EB, 2013, J CLIN MICROBIOL, V51, P1528, DOI 10.1128/JCM.03368-12; Poritz MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026047; Rand KH, 2011, J CLIN MICROBIOL, V49, P2449, DOI 10.1128/JCM.02582-10; Rodriguez JP, 2017, FRONT PHYS-LAUSANNE, V5, DOI 10.3389/fphy.2017.00046; Ruggiero P, 2014, J CLIN MICROBIOL, V52, P288, DOI 10.1128/JCM.02787-13; Ruopp MD, 2008, BIOMETRICAL J, V50, P419, DOI 10.1002/bimj.200710415; Scott MK, 2016, EMERG INFECT DIS, V22, P1044, DOI 10.3201/eid2206.151898; Shibib DR, 2016, J CLIN MICROBIOL, V54, P457, DOI 10.1128/JCM.02339-15; Sim J, 2005, PHYS THER, V85, P257; Simundic Ana-Maria, 2009, EJIFCC, V19, P203; Song Cho G, 2013, J CLIN MICROBIOL, V51, P979; Song E, 2016, J CLIN MICROBIOL, V54, P1479, DOI 10.1128/JCM.00143-16; Struelens MJ, 2013, EUROSURVEILLANCE, V18, P3; Su S, 2016, INFLUENZA OTHER RESP, V10, P86, DOI 10.1111/irv.12355; Subramony A, 2016, J PEDIATR-US, V173, P196, DOI 10.1016/j.jpeds.2016.02.050; WHO, CHILDR ENV HLTH INV; Wong KK, 2013, PEDIATRICS, V132, P796, DOI 10.1542/peds.2013-1493; Xu M, 2013, AM J CLIN PATHOL, V139, P118, DOI 10.1309/AJCPH7X3NLYZPHBW; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3; Zhou XH, 2009, STAT METHODS DIAGNOS, P23; Zoll J, 2015, J CLIN VIROL, V66, P6, DOI 10.1016/j.jcv.2015.02.010	69	1	1	0	0	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					631	643		10.1080/14737159.2018.1487294			13	Pathology	Pathology	GP3EX	WOS:000440725900006	29886764				2019-10-28	
J	Cimadamore, A; Gasparrini, S; Santoni, M; Cheng, L; Lopez-Beltran, A; Battelli, N; Massari, F; Giunchi, F; Fiorentino, M; Scarpelli, M; Montironi, R				Cimadamore, Alessia; Gasparrini, Silvia; Santoni, Matteo; Cheng, Liang; Lopez-Beltran, Antonio; Battelli, Nicola; Massari, Francesco; Giunchi, Francesca; Fiorentino, Michelangelo; Scarpelli, Marina; Montironi, Rodolfo			Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Biomarkers; genomic assays; risk assessment; renal cell carcinoma; prostate cancer; urothelial cancer	RENAL-CELL CARCINOMA; COMPREHENSIVE MOLECULAR CHARACTERIZATION; IMPROVE RISK STRATIFICATION; GENE-EXPRESSION ASSAY; HIGH-GRADE; RADICAL PROSTATECTOMY; INDEPENDENT PREDICTOR; ANDROGEN DEPRIVATION; PROGNOSTIC MARKER; ADVERSE OUTCOMES	Introduction: Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases.Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses. In urothelial carcinoma, there is great interest in the possibility of distinguishing the basal vs. luminal subtypes and to acquire deeper insight into the tumor biology through examining exosomes in urine and biomarkers in the serum. In prostate cancer, single gene expression and multiple gene expression classifiers are reviewed as a tool to distinguish indolent vs. aggressive disease.Expert commentary: The genomic information along with the application of ancillary techniques allow the definition of a neoplasia not only by its morphology but also by its biological signature. This continuous increase in knowledge will result in a better comprehension of oncogenesis, development of targeted therapies and optimizing decision-making processes related to patient care	[Cimadamore, Alessia; Gasparrini, Silvia; Scarpelli, Marina; Montironi, Rodolfo] Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, Italy; [Santoni, Matteo; Battelli, Nicola] Macerata Hosp, Oncol Unit, Macerata, Italy; [Cheng, Liang] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA; [Lopez-Beltran, Antonio] Fac Med, Dept Pathol & Surg, Cordoba, Spain; [Massari, Francesco] St Orsola Marcello Malpighi Hosp, Div Oncol, Bologna, Italy; [Giunchi, Francesca; Fiorentino, Michelangelo] St Orsola Marcello Malpighi Hosp, Lab Oncol Mol Pathol, Bologna, Italy	Montironi, R (reprint author), Polytech Univ Marche Reg, United Hosp, Sch Med, Pathol Anat, Via Conca 71, I-60126 Ancona, Italy.	r.montironi@univpm.it	Massari, Francesco/K-7239-2016	Massari, Francesco/0000-0001-6476-6871; CIMADAMORE, ALESSIA/0000-0001-5981-3514			Ahearn TU, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv346; Bacher R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0927-y; Baumgart S, 2017, ONCOTARGET, V8, P58278, DOI 10.18632/oncotarget.17619; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Brooks JD, 2016, PROSTATE, V76, P1409, DOI 10.1002/pros.23225; Bussemakers MJG, 1999, CANCER RES, V59, P5975; Carmon KS, 2008, MOL CANCER RES, V6, P1017, DOI 10.1158/1541-7786.MCR-08-0039; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Choi W, 2014, NAT REV UROL, V11, P400, DOI 10.1038/nrurol.2014.129; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Cimadamore A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00305; Cooperberg MR, 2013, J CLIN ONCOL, V31, P1428, DOI 10.1200/JCO.2012.46.4396; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Cullen J, 2015, EUR UROL, V68, P123, DOI 10.1016/j.eururo.2014.11.030; Dadhania V, 2016, EBIOMEDICINE, V12, P105, DOI 10.1016/j.ebiom.2016.08.036; Descazeaud A, 2006, PROSTATE, V66, P1037, DOI 10.1002/pros.20405; Donovan M, 2015, EUR J CANCER, V51, pS503, DOI 10.1016/S0959-8049(16)31395-8; Duex JE, 2018, MOL CANCER RES, V16, P69, DOI 10.1158/1541-7786.MCR-17-0260; Escudier B, 2016, ANN ONCOL, V27, pv58, DOI 10.1093/annonc/mdw328; Ferraldeschi R, 2015, EUR UROL, V67, P795, DOI 10.1016/j.eururo.2014.10.027; Flavin R, 2011, J PATHOL, V223, P283, DOI 10.1002/path.2809; Foersch S, 2017, ONCOTARGET, V8, P78545, DOI 10.18632/oncotarget.20827; Fossati N, 2015, EUR UROL, V68, P132, DOI 10.1016/j.eururo.2014.07.034; Franzen CA, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.21; Gibney GT, 2013, ANN ONCOL, V24, P343, DOI 10.1093/annonc/mds463; Giskeodegard GF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062375; Habuchi T, 2005, UROLOGY, V66, P64, DOI 10.1016/j.urology.2005.08.065; Hakimi AA, 2016, CANCER-AM CANCER SOC, V122, P402, DOI 10.1002/cncr.29765; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; Hakimi AA, 2013, EUR UROL, V63, P848, DOI 10.1016/j.eururo.2012.09.005; Horvath LG, 2004, CLIN CANCER RES, V10, P615, DOI 10.1158/1078-0432.CCR-0707-03; Hussain M, 2006, J CLIN ONCOL, V24, P3984, DOI 10.1200/JCO.2006.06.4246; Irshad S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006408; Itsumi M, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/284581; Jain S, 2018, ANN ONCOL, V29, P215, DOI 10.1093/annonc/mdx637; Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6; Kang HW, 2017, ONCOL LETT, V14, P2468, DOI 10.3892/ol.2017.6408; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Kim WJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-3; Kirk JS, 2015, ONCOTARGET, V6, P3136, DOI 10.18632/oncotarget.3077; Klein EA, 2016, UROLOGY, V90, P148, DOI 10.1016/j.urology.2016.01.012; Klein EA, 2015, EUR UROL, V67, P778, DOI 10.1016/j.eururo.2014.10.036; Klein EA, 2014, EUR UROL, V66, P550, DOI 10.1016/j.eururo.2014.05.004; Krebs Matthew G, 2010, Ther Adv Med Oncol, V2, P351, DOI 10.1177/1758834010378414; Kruck S, 2013, INT J MOL SCI, V14, P10944, DOI 10.3390/ijms140610944; Labbe DP, 2017, CLIN CANCER RES, V23, P7072, DOI 10.1158/1078-0432.CCR-17-0413; Leivo MZ, 2016, PATHOLOGY, V48, P543, DOI 10.1016/j.pathol.2016.05.008; Linehan WM, 2016, NEW ENGL J MED, V374, P135, DOI 10.1056/NEJMoa1505917; Liou LS, 2006, UROLOGY, V67, P25, DOI 10.1016/j.urology.2006.01.034; Loeb S, 2014, EUR UROL, V65, P1046, DOI 10.1016/j.eururo.2013.12.062; Lu J, 2017, ONCOTARGET, V8, P21461, DOI 10.18632/oncotarget.15591; Macher-Goeppinger S, 2013, ONCOL REP, V30, P2245, DOI 10.3892/or.2013.2698; Massard C, 2016, J CLIN ONCOL, V34, P3119, DOI 10.1200/JCO.2016.67.9761; Matsumoto K, 2008, UROLOGY, V72, P444, DOI 10.1016/j.urology.2007.11.128; McKiernan J, 2016, JAMA ONCOL, V2, P882, DOI 10.1001/jamaoncol.2016.0097; Merola R, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0127-8; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Mo F, 2018, EUR UROL, V73, P524, DOI 10.1016/j.eururo.2017.02.038; Mortensen MM, 2015, SCI REP-UK, V5, DOI 10.1038/srep16018; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Na R, 2017, EUR UROL, V71, P740, DOI 10.1016/j.eururo.2016.11.033; Parekh DJ, 2015, EUR UROL, V68, P464, DOI 10.1016/j.eururo.2014.10.021; Peng Y, 2017, ONCOTARGET, V8, P14089, DOI 10.18632/oncotarget.12923; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Piva F, 2015, EXPERT REV MOL DIAGN, V15, P1201, DOI 10.1586/14737159.2015.1068122; Plimack ER, 2015, J CLIN ONCOL S, V33; Powles T, 2016, EUR UROL, V69, P450, DOI 10.1016/j.eururo.2015.08.035; Prensner JR, 2014, LANCET ONCOL, V15, P1469, DOI 10.1016/S1470-2045(14)71113-1; Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rosenberg JE, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.104; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sahoo Debashis, 2018, Oncotarget, V9, P6550, DOI 10.18632/oncotarget.23973; Sandsmark E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14622-3; Scelo G, 2016, ANN ONCOL, V27, P1382, DOI 10.1093/annonc/mdw186; Schutz FAB, 2013, LANCET ONCOL, V14, P81, DOI 10.1016/S1470-2045(12)70517-X; Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z; Severi G, 2014, CANCER MED-US, V3, P1266, DOI 10.1002/cam4.281; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith BA, 2015, P NATL ACAD SCI USA, V112, pE6544, DOI 10.1073/pnas.1518007112; Soave A, 2017, ONCOTARGET, V8, P56398, DOI 10.18632/oncotarget.17657; Stopsack KH, 2017, CARCINOGENESIS, V38, P806, DOI 10.1093/carcin/bgx058; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsourlakis MC, 2013, HUM PATHOL, V44, P1789, DOI 10.1016/j.humpath.2013.01.022; Tsumura Hideyasu, 2015, Asian Pac J Cancer Prev, V16, P1539; Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Van Neste L, 2016, EUR UROL, V70, P740, DOI 10.1016/j.eururo.2016.04.012; Wang Z, 2018, CLIN EXP MED, V18, P165, DOI 10.1007/s10238-018-0488-3; Wilczak W, 2017, CARCINOGENESIS, V38, P19, DOI 10.1093/carcin/bgw116; Yao R, 2007, HISTOL HISTOPATHOL, V22, P1025, DOI 10.14670/HH-22.1025; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zhao SG, 2017, JAMA ONCOL, V3, P1663, DOI 10.1001/jamaoncol.2017.0751	95	4	4	2	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					645	655		10.1080/14737159.2018.1490179			11	Pathology	Pathology	GP3EX	WOS:000440725900007	29912582				2019-10-28	
J	Romano, A; Parrinello, NL; La Cava, P; Tibullo, D; Giallongo, C; Camiolo, G; Puglisi, F; Parisi, M; Pirosa, MC; Martino, E; Conticello, C; Palumbo, GA; Di Raimondo, F				Romano, Alessandra; Parrinello, Nunziatina Laura; La Cava, Piera; Tibullo, Daniele; Giallongo, Cesarina; Camiolo, Giuseppina; Puglisi, Fabrizio; Parisi, Marina; Pirosa, Maria Cristina; Martino, Enrica; Conticello, Concetta; Palumbo, Giuseppe Alberto; Di Raimondo, Francesco			PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Btz; PMN-MDSC; arginase; nor-NOHA; refractoriness; multiple myeloma	TUMOR-BEARING MICE; SUPPRESSOR-CELLS; MULTIPLE-MYELOMA; ARSENIC TRIOXIDE; ASCORBIC-ACID; T-LYMPHOCYTES; BONE-MARROW; BORTEZOMIB; INHIBITION; CYCLOPHOSPHAMIDE	Objectives: Despite improvement in overall response due to the introduction of the first-in-class proteasome inhibitor bortezomib (btz), multiple myeloma (MM) is still an incurable disease due to the immune-suppressive bone marrow (BM) environment. Thus, the authors aimed to identify the role of CD11b(+)CD15(+)CD14(-)HLA-DR- granulocytic-like myeloid-derived suppressor cells (PMN-MDSC) in MM patients treated up-front with novel agents.Methods: In MM cell lines and primary cells derived by patients affected by MGUS and MM, we investigated sensitivity to bortezomib and lenalidomide in presence of Arg-1 and PMN-MDSC.Results: The authors found that PMN-MDSC and their function through increased arginase-1 (Arg-1) are associated with MM progression. When the authors assessed cell viability of the human myeloma cell lines MM1.s, OPM2 and U266 treated with 5-20nM btz for 24h in PMN-MDSC conditioned media, they disclosed that amount of Arg-1 and Arg-1 inhibition could affect btz sensitivity in-vitro.PMN-MDSC and Arg-1 were increased in peripheral blood of newly diagnosed MM patients compared to healthy subjects. PMN-MDSC and arginase were reduced after exposure to lenalidomide-based regimen but increased after btz-based treatment.Conclusion: In MM, Arg-1 is mainly expressed by PMN-MDSC. PMN-MDSC and Arg-1 are reduced in vivo after lenalidomide but not bortezomib treatment.	[Romano, Alessandra; Parrinello, Nunziatina Laura; La Cava, Piera; Tibullo, Daniele; Giallongo, Cesarina; Camiolo, Giuseppina; Puglisi, Fabrizio; Parisi, Marina; Pirosa, Maria Cristina; Martino, Enrica; Conticello, Concetta; Palumbo, Giuseppe Alberto; Di Raimondo, Francesco] Univ Catania, Hematol Sect, Dept Med & Surg Specialties, Catania, Italy	Di Raimondo, F (reprint author), Univ Catania, Hematol Sect, Dept Med & Surg Specialties, Catania, Italy.	romano.alessandra@hsr.it	Palumbo, Giuseppe/W-7072-2019; TIBULLO, Daniele/AAC-1276-2019; ROMANO, ALESSANDRA/I-9201-2012	Palumbo, Giuseppe/0000-0003-1859-6319; TIBULLO, Daniele/0000-0002-4416-8556; ROMANO, ALESSANDRA/0000-0002-6333-4433; Giallongo, Cesarina/0000-0002-7667-6088	2017 Brian D. Novis Research Award by the International Myeloma Foundation; Fondazione VeronesiFondazione Umberto Veronesi; SIES (Societa Italiana Ematologia Sperimentale; Collegio Ghislieri; Italian Ministry of HealthMinistry of Health, Italy [RF 10/PE-2011-02350147]	This work was supported by a 2017 Brian D. Novis Research Award by the International Myeloma Foundation (A Romano), and by grants from Fondazione Veronesi (A Romano), SIES (Societa Italiana Ematologia Sperimentale, A Romano), Collegio Ghislieri (A Romano) and the Italian Ministry of Health (RF 10/PE-2011-02350147, F Di Raimondo, A Romano, NL Parrinello, D Tibullo).	Alizadeh D, 2014, CANCER RES, V74, P104, DOI 10.1158/0008-5472.CAN-13-1545; Badros A, 2017, BLOOD, V130, P1189, DOI 10.1182/blood-2017-03-775122; Brimnes MK, 2010, SCAND J IMMUNOL, V72, P540, DOI 10.1111/j.1365-3083.2010.02463.x; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Bryant C, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.34; Buglio D, 2010, BRIT J HAEMATOL, V151, P387, DOI 10.1111/j.1365-2141.2010.08342.x; Campbell RA, 2007, BRIT J HAEMATOL, V138, P467, DOI 10.1111/j.1365-2141.2007.06675.x; Canestraro M, 2010, CANCER GENET CYTOGEN, V199, P110, DOI 10.1016/j.cancergencyto.2010.02.010; Castella B, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1047580; Dolcetti L, 2010, CURR PROTOC IMMUNOL; Feldmeyer N, 2012, INT IMMUNOL, V24, P303, DOI 10.1093/intimm/dxs004; Georgakis GV, 2006, CLIN CANCER RES, V12, P584, DOI 10.1158/1078-0432.CCR-05-1194; Giallongo C., 2016, ONCOTARGET, DOI 10.18632/oncotarget.7969.; Giallongo C, 2015, CLIN LYMPHOMA MYELOM, V15, pe211; Gorgun GT, 2013, BLOOD, V121, P2975, DOI 10.1182/blood-2012-08-448548; Hock BD, 2012, IMMUNOLOGY, V137, P249, DOI 10.1111/imm.12004; Jemal A, 2017, JNCI-J NATL CANCER I, V109, P110; Kumazoe M, 2013, J CLIN INVEST, V123, P787, DOI 10.1172/JCI64768; Liu P, 2010, J IMMUNOTHER, V33, P53, DOI 10.1097/CJI.0b013e3181b56af4; Malek E, 2016, BLOOD REV, V30, P341, DOI 10.1016/j.blre.2016.04.002; Mandruzzato S, 2016, CANCER IMMUNOL IMMUN, V65, P161, DOI 10.1007/s00262-015-1782-5; Mocellin S, 2004, CLIN CANCER RES, V10, P6879, DOI 10.1158/1078-0432.CCR-04-0791; Noonan K. A., 2014, CANC IMMUNOL RES; Noonan K, 2013, BLOOD, V122; Park E, 2010, J DRUGS DERMATOL, V9, P330; Ramachandran IR, 2016, CANCER LETT, V371, P117, DOI 10.1016/j.canlet.2015.10.040; Rodriguez PC, 2003, J IMMUNOL, V171, P1232, DOI 10.4049/jimmunol.171.3.1232; Romano A, 2013, ANN ONCOL, V24, P1038, DOI 10.1093/annonc/mds531; Romano A, 2014, EUR J HAEMATOL, V93, P207, DOI 10.1111/ejh.12325; Romano A, 2013, IMMUNOTHERAPY-UK, V5, P327, DOI [10.2217/IMT.13.14, 10.2217/imt.13.14]; Serafini P, 2006, J EXP MED, V203, P2691, DOI 10.1084/jem.20061104; Sharma M, 2012, CANCER-AM CANCER SOC, V118, P2507, DOI 10.1002/cncr.26517; Sistigu A, 2011, SEMIN IMMUNOPATHOL, V33, P369, DOI 10.1007/s00281-011-0245-0; Van Valckenborgh E, 2012, LEUKEMIA, V26, P2424, DOI 10.1038/leu.2012.113; Wei Q, 2006, J BIOL CHEM, V281, P21652, DOI 10.1074/jbc.M602105200; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Youn JI, 2012, J LEUKOCYTE BIOL, V91, P167, DOI 10.1189/jlb.0311177; Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014	38	3	3	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	7					675	683		10.1080/14737159.2018.1470929			9	Pathology	Pathology	GP3EX	WOS:000440725900009	29707981				2019-10-28	
J	Buppasiri, P; Kleebkaow, P; Tharanon, C; Aue-aungkul, A; Kietpeerakool, C				Buppasiri, Pranom; Kleebkaow, Pilaiwan; Tharanon, Chantip; Aue-aungkul, Apiwat; Kietpeerakool, Chumnan			Clear Cell Carcinoma Arising in Vulvar Endometriosis	CASE REPORTS IN PATHOLOGY			English	Article							BILATERAL SALPINGO-OOPHORECTOMY; TOTAL ABDOMINAL HYSTERECTOMY; INGUINAL ENDOMETRIOSIS; REPLACEMENT THERAPY; ADENOCARCINOMA; OVARIAN; COLON	We report a case of vulvar clear cell adenocarcinoma in a woman presenting with a lump and pain in the right side of the labia majora. Three years prior to this visit, she underwent a total abdominal hysterectomy with bilateral salpingooophorectomy and excision of a labial mass. Pathological examination revealed adenomyosis and multiple leiomyomas in the uterus, endometriotic cysts in both ovaries, and foci of atypical endometriosis in the labial mass. The results of an incision biopsy performed before referral indicted only apocrine hidrocystoma. Physical examination revealed a hard mass at the right labia majora extending to the right groin. The mass seemed to be in continuity with the pubic symphysis that would require pubic bone excision and reconstruction with flap surgery to achieve complete resection. However, the patient refused such extensive surgery. Based on previous diagnosis of vulvar endometriosis, she had been treated with GnRH agonists and depot medroxyprogesterone acetate. However, the mass developed into an ulcer and increased in size. A second biopsy of the mass was undertaken, and the pathological diagnosis was clear cell carcinoma with coexisting atypical endometriosis. Computed tomography of the abdominopelvic region showed an ulcerative mass at the right labia majora and nodal metastasis at the external iliac and inguinal regions. Systemic chemotherapy was administered. The growth of the tumors stabilized during the first two cycles of chemotherapy but rapidly progressed thereafter. At 17 months after her initial presentation, the patient passed away due to the progression of the disease.	[Buppasiri, Pranom; Kleebkaow, Pilaiwan; Tharanon, Chantip; Aue-aungkul, Apiwat; Kietpeerakool, Chumnan] Khon Kaen Univ, Dept Obstet & Gynaecol, Fac Med, Khon Kaen, Thailand	Kietpeerakool, C (reprint author), Khon Kaen Univ, Dept Obstet & Gynaecol, Fac Med, Khon Kaen, Thailand.	kiet_ji@hotmail.com		Kietpeerakool, chumnan/0000-0002-9544-9462			Abu MAE, 1997, EUR J GYNAECOL ONCOL, V18, P482; Abu Saadeh F., 2014, BMJ CASE REPORTS; Al-Talib A, 2008, SAUDI MED J, V29, P1044; CANDIANI GB, 1991, OBSTET GYNECOL, V78, P191; Debus G, 2001, ACTA OBSTET GYN SCAN, V80, P589, DOI 10.1034/j.1600-0412.2001.080006589.x; Fruscio R, 2008, J OBSTET GYNAECOL RE, V34, P706, DOI 10.1111/j.1447-0756.2008.00911.x; Hagiwara Y, 2007, AUSTRALAS RADIOL, V51, P91, DOI 10.1111/j.1440-1673.2006.01667.x; Jones KD, 2002, GYNECOL ONCOL, V86, P220, DOI 10.1006/gyno.2002.6643; Kawate S, 2005, JPN J CLIN ONCOL, V35, P154, DOI 10.1093/jjco/hyi037; Kleebkaow P., 2017, CASE REPORTS PATHOLO, V2017; Kurman RJ, 2016, AM J PATHOL, V186, P733, DOI 10.1016/j.ajpath.2015.11.011; Licheri S, 2005, Hernia, V9, P294, DOI 10.1007/s10029-004-0314-6; Machairiotis N, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-194; Matalliotakis M, 2017, EUR J OBSTET GYN R B, V217, P34, DOI 10.1016/j.ejogrb.2017.08.019; Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6; Nomura S, 2006, ACTA OBSTET GYN SCAN, V85, P1019, DOI 10.1080/00016340600609103; Pectasides D, 2006, ONCOLOGIST, V11, P1089, DOI 10.1634/theoncologist.11-10-1089; Prabhu R., 2013, BMJ CASE REPORTS; Stern RC, 2001, INT J GYNECOL PATHOL, V20, P133, DOI 10.1097/00004347-200104000-00004; Zhao CQ, 2011, J CANCER, V2, P94, DOI 10.7150/jca.2.107	20	1	1	0	3	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									4263104	10.1155/2018/4263104			5	Pathology	Pathology	GP5MJ	WOS:000440917200001	30147978	DOAJ Gold, Green Published			2019-10-28	
J	Burris, A; Hixson, C; Smith, N				Burris, Ashley; Hixson, Caleb; Smith, Nathaniel			Frozen Section Diagnostic Pitfalls of Sertoli-Leydig Cell Tumor with Heterologous Elements	CASE REPORTS IN PATHOLOGY			English	Article							CORD-STROMAL TUMORS; OVARY	A woman in her sixth decade presented with several months of abdominal cramping, decreased appetite, bloating, and increased constipation. Radiologic imaging revealed a 28 cm, multilocular, heterogeneous cystic neoplasm involving the right adnexa. An intraoperative frozen section showed mucinous glandular epithelium, with and without foci of goblet cells, embedded in apparent ovarian Aroma. The findings were concerning at least borderline mucinous cystadenoma with possible invasion. Subsequent surgical management and staging were performed. Permanent sections showed a moderately to poorly differentiated Sertoli-Leydig cell tumor (SLCT) with retiform foci and heterologous elements. The discrepancy between frozen and permanent sections was attributable to solely sampling a focus of heterologous elements during intraoperative consultation. The rarity of SLCT and even rarer presence of both heterologous and retiform elements make this concerning frozen section diagnostic pitfall.	[Burris, Ashley; Smith, Nathaniel] Brooke Army Med Ctr, San Antonio, TX 78234 USA; [Hixson, Caleb] Tripler Army Med Ctr, Honolulu, HI 96859 USA	Burris, A (reprint author), Brooke Army Med Ctr, San Antonio, TX 78234 USA.	ashley.m.burris.mil@mail.mil					Abu-Zaid A, 2013, CASE REP OBSTET GYNE, V2013, P1; Dhanya CSR, 2014, J CLIN DIAGN RES, V8, P127, DOI 10.7860/JCDR/2014/7000.4099; Kanade U. S., 2014, J CLIN DIAGNOSTIC RE, V8; Franzin CMO, 2006, J ULTRAS MED, V25, P1327, DOI 10.7863/jum.2006.25.10.1327; Mooney EE, 1999, HUM PATHOL, V30, P611, DOI 10.1016/S0046-8177(99)90083-7; Mooney EE, 2002, HISTOPATHOLOGY, V41, P110, DOI 10.1046/j.1365-2559.2002.01426.x; Nogales FF, 2009, HISTOPATHOLOGY, V54, P471, DOI 10.1111/j.1365-2559.2009.03244.x; Rabban JT, 2013, HISTOPATHOLOGY, V62, P71, DOI 10.1111/his.12052; Young RH, 2001, SEMIN DIAGN PATHOL, V18, P161; Young RH, 2005, MODERN PATHOL, V18, pS81, DOI 10.1038/modpathol.3800311; ZALOUDEK C, 1984, AM J SURG PATHOL, V8, P405, DOI 10.1097/00000478-198406000-00001	11	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5151082	10.1155/2018/5151082			4	Pathology	Pathology	GP5MM	WOS:000440917500001	30147979	DOAJ Gold, Green Published			2019-10-28	
J	Irwin, T; Snow, AR; Orton, TS; Elliott, C				Irwin, Trent; Snow, Alexandria R.; Orton, Taylor S.; Elliott, Christie			Endoscopic, Ultrasonographic, and Histologic Descriptions of Dextranomer/Hyaluronic Acid in a Case of Fecal Incontinence	CASE REPORTS IN PATHOLOGY			English	Article							FOREIGN-BODY GRANULOMA; VESICOURETERAL REFLUX; HYALURONIC-ACID; URETERAL CALCULI; INJECTION; COPOLYMER	Objective. To present a case of fecal incontinence treated with dextranomer/hyaluronic acid (Solesta (R)) injections, which later caused clinical confusion and avoidable interventions. 'I he endoscopic, ultrasonographic, and histologic appearances of dextranomer/hyaluronic acid will also be reported. Case Presentation. A middle-aged Hispanic male who failed conservative management of his fecal incontinence was injected with dextranomer/hyaluronic acid in an attempt to alleviate symptoms. An unrelated screening colonoscopy was performed soon after, revealing a submucosal rectal lesion. Flexible sigmoidoscopy and endoscopic rectal ultrasound with FNA were scheduled for patient for further evaluation. An unknown foreign material was noted under microscopy and, upon attaining additional history, the gastroenterologist uncovered the patient's recent injections of dextranomer/hyaluronic acid. Conclusion. Dextranomer/hyaluronic acid for the treatment of fecal incontinence has become more common in recent years. Though the imaging and histologic appearance of this gel-like material is seen in other areas of medicine, equivalent descriptions are limited in the anorectal region. To curb misdiagnoses and prevent unnecessary interventions, it is important to expound on the endoscopic, imaging, and histopathologic features of this tissue-bulking agent in the setting of fecal incontinence and to encourage communication, proper documentation, and easy accessibility to patient health information by all medical staff.	[Irwin, Trent; Snow, Alexandria R.; Orton, Taylor S.; Elliott, Christie] Univ Nevada, Reno Sch Med, 1664 North Virginia St, Reno, NV 89557 USA	Irwin, T (reprint author), Univ Nevada, Reno Sch Med, 1664 North Virginia St, Reno, NV 89557 USA.	trent.irwin@msn.com		Irwin, Trent/0000-0002-0493-7410			Alavi K, 2015, J GASTROINTEST SURG, V19, P1910, DOI 10.1007/s11605-015-2905-1; Alkan M, 2007, PEDIATR SURG INT, V23, P183, DOI 10.1007/s00383-006-1818-1; Alshehri A, 2014, J PEDIATR SURG, V49, P1353, DOI 10.1016/j.jpedsurg.2014.02.088; Arena S, 2009, J UROLOGY, V181, P2695, DOI 10.1016/j.juro.2009.02.059; Clark ATD, 2010, UROLOGY, V75, P1178, DOI 10.1016/j.urology.2009.06.007; DeCaro JJ, 2012, OBSTET GYNECOL, V119, P476, DOI 10.1097/AOG.0b013e31824118d9; FDA, 2011, FDA SUMM SAF EFF DAT; Hallen L, 2001, LARYNGOSCOPE, V111, P1063, DOI 10.1097/00005537-200106000-00025; Kaiser AM, 2014, SURG ENDOSC, V28, P2277, DOI 10.1007/s00464-014-3464-3; Kim JW, 2014, UROLITHIASIS, V42, P561, DOI 10.1007/s00240-014-0709-5; Massone C, 2009, AM J DERMATOPATH, V31, P197, DOI 10.1097/DAD.0b013e318194816d; Nelson CP, 2008, PEDIATR RADIOL, V38, P104, DOI 10.1007/s00247-007-0613-z; Ng KS, 2015, DIS COLON RECTUM, V58, P1194, DOI 10.1097/DCR.0000000000000514; Noe H Norman, 2008, J Pediatr Urol, V4, P88, DOI 10.1016/j.jpurol.2007.02.005; Papafragkakis H, 2014, WORLD J GASTRO ENDOS, V6, P324, DOI 10.4253/wjge.v6.i7.324; Peck Brandon W, 2017, Mayo Clin Proc Innov Qual Outcomes, V1, P176, DOI 10.1016/j.mayocpiqo.2017.06.003; Routh JC, 2007, J UROLOGY, V178, P1707, DOI 10.1016/j.juro.2007.03.165; Stenberg A, 2003, J UROLOGY, V169, P1109, DOI 10.1097/01.ju.0000053013.49676.89; Yang JH, 2012, INT J DERMATOL, V51, P1517, DOI 10.1111/j.1365-4632.2010.04795.x	19	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5873094	10.1155/2018/5873094			5	Pathology	Pathology	GP5MP	WOS:000440917800001	30147980	DOAJ Gold, Green Published			2019-10-28	
J	Pritzker, K				Pritzker, Kenneth			Biomarker imprecision in precision medicine	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Biomarker; oncology; precision medicine; theranostics; genomics; diagnostics; personalized medicine	BREAST; HEALTH		[Pritzker, Kenneth] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Pritzker, K (reprint author), Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada.	k.pritzker@utoronto.ca					a NRCUCoAFfD, 2011, DIS NFFDANTO PREC ME; Aronson SJ, 2015, NATURE, V526, P336, DOI 10.1038/nature15816; Awuah B, 2011, ANN SURG ONCOL, V18, P957, DOI 10.1245/s10434-010-1422-4; Bilski J, 2017, MEDIAT INFLAMM, DOI 10.1155/2017/9074601; Brunoni AR, 2018, PROG NEURO-PSYCHOPH, V86, P211, DOI 10.1016/j.pnpbp.2018.06.003; Cascorbi I, 2018, CLIN PHARMACOL THER, V103, P732, DOI 10.1002/cpt.1052; Janssens JP, 2006, EUR J CANCER PREV, V15, P471, DOI 10.1097/CEJ.0b013e3280126b77; Ji Y, 2018, EXPERT REV MOL DIAGN, V18, P411, DOI 10.1080/14737159.2018.1461561; Khoury T, 2018, AM J CLIN PATHOL, V149, P275, DOI [10.1093/AJCP/AQX164, 10.1093/ajcp/aqx164]; Kimmelman J, 2018, NAT REV CLIN ONCOL, V15, P341, DOI 10.1038/s41571-018-0016-0; Kogan JN, 2018, AM J MANAG CARE, V24, P177; Mariani S, 2018, EXPERT REV MOL DIAGN, V18, P467, DOI 10.1080/14737159.2018.1468254; Marks KM, 2018, BRIT J SURG, V105, pE99, DOI 10.1002/bjs.10756; Mazzarella L, 2018, ECANCERMEDICALSCIENC, V12, DOI 10.3332/ecancer.2018.817; McKenna MT, 2018, TRANSL ONCOL, V11, P732, DOI 10.1016/j.tranon.2018.03.009; Mentis AFA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00067; Ogino S, 2018, LANCET, V391, P2084, DOI 10.1016/S0140-6736(18)30953-X; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Parlato M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708483; Peer D, 2014, CANCER LETT, V352, P2, DOI 10.1016/j.canlet.2014.04.011; Pritzker Kenneth Ph, 2012, Expert Opin Med Diagn, V6, P39, DOI 10.1517/17530059.2012.634797; Pritzker KPH, 2002, CLIN CHEM, V48, P1147; Rodriguez H, 2018, CELL, V173, P533, DOI 10.1016/j.cell.2018.04.008; Stausberg Jurgen, 2018, Stud Health Technol Inform, V247, P566; Tsui FWL, 2014, ANN RHEUM DIS, V73, P1873, DOI 10.1136/annrheumdis-2013-203630; Wallin A, 2017, BMC NEUROL, V17, DOI 10.1186/s12883-017-0877-3	26	0	0	1	9	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					685	687		10.1080/14737159.2018.1493379			3	Pathology	Pathology	GP3FD	WOS:000440726700001	29939098	Bronze			2019-10-28	
J	Millington, D; Norton, S; Singh, R; Sista, R; Srinivasan, V; Pamula, V				Millington, David; Norton, Scott; Singh, Raj; Sista, Rama; Srinivasan, Vijay; Pamula, Vamsee			Digital microfluidics comes of age: high-throughput screening to bedside diagnostic testing for genetic disorders in newborns	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Digital microfluidics; lysosomal storage disorders; newborn screening; dried blood spots; near patient testing; hyperbilirubinemia; hypoglycemia	DRIED BLOOD SPOTS; TANDEM MASS-SPECTROMETRY; LYSOSOMAL STORAGE DISORDERS; HUNTER-SYNDROME; INBORN-ERRORS; POMPE-DISEASE; FILTER-PAPER; HURLER DISEASES; MULTIPLEX ASSAY; PLATFORM	Introduction: Digital microfluidics (DMF) is an emerging technology with the appropriate metrics for application to newborn and high-risk screening for inherited metabolic disease and other conditions that benefit from early treatment.Areas covered: This review traces the development of electrowetting-based DMF technology toward the fulfillment of its promise to provide an inexpensive platform to conduct enzymatic assays and targeted biomarker assays at the bedside. The high-throughput DMF platform, referred to as SEEKER (R), was recently authorized by the United States Food and Drug Administration to screen newborns for four lysosomal storage disorders (LSDs) and is deployed in newborn screening programs in the United States. The development of reagents and methods for LSD screening and results from screening centers are reviewed. Preliminary results from a more compact DMF device, to perform disease-specific test panels from small volumes of blood, are also reviewed. Literature for this review was sourced using principal author and subject searches in PubMed.Expert commentary: Newborn screening is a vital and highly successful public health program. DMF technology adds value to the current testing platforms that will benefit apparently healthy newborns with underlying genetic disorders and infants at-risk for conditions that present with symptoms in the newborn period.	[Millington, David] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Norton, Scott; Singh, Raj; Sista, Rama; Srinivasan, Vijay; Pamula, Vamsee] Baebies Inc, Durham, NC USA	Millington, D (reprint author), Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.	david.millington@duke.edu			NIH - National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HHSN268201000001C, R43HL125484]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R44HD057713, R44HD072853, R44HD092154]; National Institute on Deafness and Other Communication DisordersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R44DC012967]	This paper was funded by NIH - National Heart, Lung, and Blood Institute (HHSN268201000001C and R43HL125484); National Institute of Child Health and Human Development (R44HD057713, R44HD072853, and R44HD092154); and National Institute on Deafness and Other Communication Disorders (R44DC012967).	Abdelgawad M, 2008, LAB CHIP, V8, P672, DOI 10.1039/b801516c; [Anonymous], 1989, B WORLD HEALTH ORGAN, V67, P601; [Anonymous], 2013, ILL ACQ ADV LIQ LOG; Bhutani VK, 2015, PEDIATRICS, V136, pE1268, DOI 10.1542/peds.2015-2122; Burton B, 2012, MOL GENET METAB, V105, pS23, DOI 10.1016/j.ymgme.2011.11.038; Chamoles NA, 2004, CLIN CHIM ACTA, V347, P97, DOI 10.1016/j.cccn.2004.04.009; Chamoles NA, 2001, CLIN CHEM, V47, P780; Chamoles NA, 2001, CLIN CHIM ACTA, V308, P195, DOI 10.1016/S0009-8981(01)00478-8; Chien YH, 2008, PEDIATRICS, V122, pE39, DOI 10.1542/peds.2007-2222; Chien YH, 2013, PEDIATR NEONATOL, V54, P219, DOI 10.1016/j.pedneo.2013.03.009; Chien YH, 2009, PEDIATRICS, V124, pE1116, DOI 10.1542/peds.2008-3667; Choi K, 2012, ANNU REV ANAL CHEM, V5, P413, DOI 10.1146/annurev-anchem-062011-143028; Chopra S, 2017, PED AC SOC ANN M MAY; Coelho B, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17071495; Cotten CM, 2018, PED AC SOC ANN M MAY; Emani S, 2018, LAB MED, V49, P47, DOI 10.1093/labmed/lmx067; Emani S, 2012, BLOOD COAGUL FIBRIN, V23, P760, DOI 10.1097/MBC.0b013e328358e982; Fan SK, 2011, LAB CHIP, V11, P343, DOI [10.1039/c0lc00178c, 10.1039/c01c00178c]; Gelb MH, 2017, MOL GENET METAB REP, V12, P80, DOI 10.1016/j.ymgmr.2017.05.004; Giugliani R, 2015, EXPERT OPIN ORPHAN D, V3, P141, DOI 10.1517/21678707.2015.999666; Graham C, 2013, CLIN BIOCHEM, V46, P1889, DOI 10.1016/j.clinbiochem.2013.09.003; Hall PL, 2014, GENET MED, V16, P889, DOI 10.1038/gim.2014.62; Health Resources and Services Administration Advisory Committee on Heritable Disorders in Newborns and Children , 2018, REC UN SCREEN PAN; Hong J, 2015, SCI REP-UK, V5, DOI 10.1038/srep10685; Hopkins P, 2017, COMMUNICATION   0406; Hopkins PV, 2018, JAMA PEDIATR, V172, P696, DOI 10.1001/jamapediatrics.2018.0263; Hopkins PV, 2015, J PEDIATR-US, V166, P172, DOI 10.1016/j.jpeds.2014.09.023; Jebrail MJ, 2012, LAB CHIP, V12, P2452, DOI 10.1039/c2lc40318h; Kayyem JF, 2016, United States patent, Patent No. [US 20160129437A1, 20160129437]; Kirby AE, 2013, ANAL CHEM, V85, P6178, DOI 10.1021/ac401150q; Kokalj T, 2015, NEW BIOTECHNOL, V32, P485, DOI 10.1016/j.nbt.2015.03.007; Krivit W, 1998, NEW ENGL J MED, V338, P1119, DOI 10.1056/NEJM199804163381605; Li YJ, 2004, CLIN CHEM, V50, P1785, DOI 10.1373/clinchem.2004.035907; Li YJ, 2004, CLIN CHEM, V50, P638, DOI 10.1373/clinchem.2003.028381; Marsden D, 2010, CLIN CHEM, V56, P1071, DOI 10.1373/clinchem.2009.141622; Millington DS, 2017, MOL GENET METAB REP, V12, P98, DOI 10.1016/j.ymgmr.2017.06.008; Millington DS, 2017, MOL GENET METAB REP, V11, P72, DOI 10.1016/j.ymgmr.2017.04.009; Millington DS, 2010, SEMIN PERINATOL, V34, P163, DOI 10.1053/j.semperi.2009.12.008; MILLINGTON DS, 1990, J INHERIT METAB DIS, V13, P321, DOI 10.1007/BF01799385; Nelson L, 2015, INT CONG CMV C 5 ANN; Ng R, 2017, HOT TOP NEON DEC 3 5; Ng R, 2018, PED AC SOC ANN M MAY; Nuffer M, 2016, INT SOC NEON SCREEN; Oemardien LF, 2011, MOL GENET METAB, V102, P44, DOI 10.1016/j.ymgme.2010.09.008; Orsini JJ, 2012, CLIN CHIM ACTA, V413, P1270, DOI 10.1016/j.cca.2012.04.012; Paik P, 2003, LAB CHIP, V3, P253, DOI 10.1039/b307628h; Paik PY, 2008, IEEE T VLSI SYST, V16, P432, DOI 10.1109/TVLSI.2007.915434; Peake RWA, 2016, CLIN CHEM, V62, P1430, DOI 10.1373/clinchem.2016.258459; Pitt James J, 2010, Clin Biochem Rev, V31, P57; Pollack M.G., 2003, P 7 INT C MIN CHEM B, P619; Pollack MG, 2002, LAB CHIP, V2, P96, DOI 10.1039/b110474h; Pollack MG, 2011, EXPERT REV MOL DIAGN, V11, P393, DOI [10.1586/erm.11.22, 10.1586/ERM.11.22]; Rashed MS, 1997, CLIN CHEM, V43, P1129; Ries M, 2017, J INHERIT METAB DIS, V40, P343, DOI 10.1007/s10545-017-0032-8; Schell WA, 2012, EUR J CLIN MICROBIOL, V31, P2237, DOI 10.1007/s10096-012-1561-6; Schulze A, 2003, PEDIATRICS, V111, P1399, DOI 10.1542/peds.111.6.1399; Singh R, 2018, WORLD S LYS DIS 14 A; Sista R, 2011, CLIN CHIM ACTA, V412, P1895, DOI 10.1016/j.cca.2011.06.015; Sista R, 2008, LAB CHIP, V8, P2091, DOI 10.1039/b814922d; Sista RS, 2013, CLIN CHIM ACTA, V424, P12, DOI 10.1016/j.cca.2013.05.001; Sista RS, 2013, MOL GENET METAB, V109, P218, DOI 10.1016/j.ymgme.2013.03.010; Sista RS, 2011, CLIN CHEM, V57, P1444, DOI 10.1373/clinchem.2011.163139; Srinivasan V, 2004, ANAL CHIM ACTA, V507, P145, DOI 10.1016/j.aca.2003.12.030; Tolun AA, 2012, MOL GENET METAB, V105, P519, DOI 10.1016/j.ymgme.2011.12.011; US Food & Drug Administration 510k K163636 Silver Spring (MD): US Food & Drug Administration, 2017, US FOOD DRUG ADM 510; Voznyi YV, 2001, J INHERIT METAB DIS, V24, P675, DOI 10.1023/A:1012763026526; Wang D, 2005, CLIN CHEM, V51, P898, DOI 10.1373/clinchem.2004.047167; WASTELL H, 1984, ANAL BIOCHEM, V140, P69, DOI 10.1016/0003-2697(84)90134-9; Wilcken B, 2008, PATHOLOGY, V40, P104, DOI 10.1080/00313020701813743; Wulff-Burchfield E, 2010, DIAGN MICR INFEC DIS, V67, P22, DOI 10.1016/j.diagmicrobio.2009.12.020; Yang H., 2005, ASME 2005 INT MECH E, DOI [10.1115/IMECE2005-80744, DOI 10.1115/IMECE2005-80744]; Zhou H, 2011, J PEDIATR-US, V159, P7, DOI 10.1016/j.jpeds.2011.02.026	72	6	6	2	13	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					701	712		10.1080/14737159.2018.1495076			12	Pathology	Pathology	GP3FD	WOS:000440726700003	30004274	Green Accepted			2019-10-28	
J	Kotha, S; Neong, S; Patel, K				Kotha, Sreelakshmi; Neong, ShuetFong; Patel, Keyur			Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Antigen assay; biomarkers; hepatitis B; hepatitis C; hepatocellular carcinoma; molecular diagnostics; viral hepatitis	B SURFACE-ANTIGEN; C VIRUS-INFECTION; CORE-RELATED ANTIGEN; NUCLEOS(T)IDE ANALOG THERAPY; CLINICAL-PRACTICE GUIDELINES; NATURAL-HISTORY; HYALURONIC-ACID; LIVER FIBROSIS; A VIRUS; COMPENSATED CIRRHOSIS	Introduction: Chronic liver disease due to viral hepatitis continues to be a major global health concern. Timely diagnosis and treatment will prevent cirrhosis, risk of hepatocellular carcinoma (HCC), and requirement for liver transplantation. Numerous serum biomarkers are available for viral hepatitis that are helpful in diagnosis, measuring severity, progression of disease, evaluating the best therapeutic options, and monitoring antiviral treatment response. Determining the clinical use of available diagnostic tests can be challenging for the health care provider.Areas covered: This review article attempts to summarize the established and emerging serological markers for diagnosis and managing viral hepatitis. The literature search was performed in February 2018 and included MEDLINE and Embase databases for recent relevant literature on biomarkers for viral hepatitis.Expert Commentary: Despite the discovery of several candidate biomarkers, translating these to clinical practice in viral hepatitis and HCC remains challenging. While limited availability of the new biomarkers in prevalent geographic areas and significant cost remain major obstacles, there have been exciting developments in this field. Understanding the detection limits and sensitivity of these markers and translating them into clinical use is important in management of viral hepatitis and complications of liver disease such as cirrhosis and hepatocellular cancer.	[Kotha, Sreelakshmi; Neong, ShuetFong; Patel, Keyur] Toronto Gen Hosp, Dept Hepatol, Toronto, ON, Canada	Kotha, S (reprint author), Toronto Gen Hosp, Dept Hepatol, Toronto, ON, Canada.	sreelakshmi_kotha@yahoo.com					Aggarwal R., 2010, GLOBAL PREVALENCE HE; Akinyemiju T, 2017, JAMA ONCOL, V3, P1683, DOI 10.1001/jamaoncol.2017.3055; ANGARANO G, 1985, DIAGN MICR INFEC DIS, V3, P521, DOI 10.1016/S0732-8893(85)80009-2; [Anonymous], 2018, ALIMENT PHARM THER, V47, P43; Aspinall EJ, 2011, OCCUP MED-OXFORD, V61, P531, DOI 10.1093/occmed/kqr136; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Baranova A, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-91; Bendall R, 2010, J MED VIROL, V82, P799, DOI 10.1002/jmv.21656; Benvegnu L, 2004, GUT, V53, P744, DOI 10.1136/gut.2003.020263; BERGSTRAND CG, 1956, SCAND J CLIN LAB INV, V8, P174, DOI 10.3109/00365515609049266; Biasiolo A, 2015, WORLD J CLIN INFECT, V5, P59; Blach S, 2017, LANCET GASTROENTEROL, V2, P161, DOI 10.1016/S2468-1253(16)30181-9; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Butcher A, 2014, J CLIN VIROL, V60, P336, DOI 10.1016/j.jcv.2014.04.018; Cao JY, 2009, HEPATOL INT, V3, P356, DOI 10.1007/s12072-008-9116-8; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; Chan HLY, 2007, CLIN GASTROENTEROL H, V5, P1462, DOI 10.1016/j.cgh.2007.09.005; Chen CJ, 2009, HEPATOLOGY, V49, pS72, DOI 10.1002/hep.22884; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Cheng JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087011; Chevaliez S, 2009, LIVER INT, V29, P9, DOI 10.1111/j.1478-3231.2008.01926.x; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cornberg M, 2017, J HEPATOL, V66, P398, DOI 10.1016/j.jhep.2016.08.009; Dai MY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140067; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Fan R, 2016, GUT, V65, P313, DOI 10.1136/gutjnl-2014-308546; Fattovich G, 2002, AM J GASTROENTEROL, V97, P2886; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; FEINSTONE SM, 1973, SCIENCE, V182, P1026, DOI 10.1126/science.182.4116.1026; Fourati S, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25058; Fytili P, 2007, J CLIN VIROL, V39, P308, DOI 10.1016/j.jcv.2007.05.007; Ghany MG, 2009, HEPATOLOGY, V49, P1335, DOI 10.1002/hep.22759; Giannini E, 2003, ARCH INTERN MED, V163, P218, DOI 10.1001/archinte.163.2.218; Gressner OA, 2007, J CELL MOL MED, V11, P1031, DOI 10.1111/j.1582-4934.2007.00092.x; Gripenberg M, 2018, INT J INFECT DIS, V68, P13, DOI 10.1016/j.ijid.2017.12.021; Hees Van, 2016, WJG, V22, P8271; HENNING KJ, 1995, AM J MED, V99, P132, DOI 10.1016/S0002-9343(99)80132-6; Honda M, 2016, J INFECT DIS, V213, P1096, DOI 10.1093/infdis/jiv572; Hoofnagle JH, 2012, NEW ENGL J MED, V367, P1237, DOI 10.1056/NEJMra1204512; Hosaka T, 2010, LIVER INT, V30, P1461, DOI 10.1111/j.1478-3231.2010.02344.x; Hughes SA, 2011, LANCET, V378, P73, DOI 10.1016/S0140-6736(10)61931-9; HURNI WM, 1993, ANN NY ACAD SCI, V694, P289, DOI 10.1111/j.1749-6632.1993.tb18367.x; Hyun KA, 2016, ANALYST, V141, P382, DOI 10.1039/c5an01762a; Imbert-Bismut F, 2001, LANCET, V357, P1069, DOI 10.1016/S0140-6736(00)04258-6; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; Iqbal K, 2015, CLIN INFECT DIS, V61, P584, DOI 10.1093/cid/civ332; JACOBSON SK, 1995, CLIN DIAGN VIROL, V3, P173, DOI 10.1016/0928-0197(94)00033-Q; KAO HW, 1984, HEPATOLOGY, V4, P933, DOI 10.1002/hep.1840040525; Khan H, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofw252; Kimura T, 2002, J CLIN MICROBIOL, V40, P439, DOI 10.1128/JCM.40.2.439-445.2002; KRUGMAN S, 1967, J AMER MED ASSOC, V200, P365, DOI 10.1001/jama.200.5.365; Kumada T, 2013, J HEPATOL, V58, P427, DOI 10.1016/j.jhep.2012.10.025; Lang K, 2009, J HEPATOL, V50, P89, DOI 10.1016/j.jhep.2008.07.029; Lee JM, 2011, HEPATOLOGY, V53, P1486, DOI 10.1002/hep.24221; Leerapun A, 2007, CLIN GASTROENTEROL H, V5, P394, DOI 10.1016/j.cgh.2006.12.005; Leino T, 1997, SCAND J INFECT DIS, V29, P213, DOI 10.3109/00365549709019029; Lemon SM, 2018, J HEPATOL, V68, P167, DOI 10.1016/j.jhep.2017.08.034; Li A, 2010, CLIN VACCINE IMMUNOL, V17, P464, DOI 10.1128/CVI.00457-09; Li D, 2001, CLIN CHIM ACTA, V313, P15, DOI 10.1016/S0009-8981(01)00644-1; Lin CL, 2013, J FORMOS MED ASSOC, V112, P302, DOI 10.1016/j.jfma.2013.02.001; Lin SM, 1999, HEPATOLOGY, V29, P971, DOI 10.1002/hep.510290312; Lingala S, 2015, GASTROENTEROL CLIN N, V44, P717, DOI 10.1016/j.gtc.2015.07.003; Liu B, 2015, MOL MED REP, V12, P105, DOI 10.3892/mmr.2015.3386; Llovet JM, 2012, J HEPATOL, V56, P908, DOI 10.1016/j.jhep.2011.12.001; MAGNIUS LO, 1972, J IMMUNOL, V109, P1017; Martinot-Peignoux M, 2014, LIVER INT, V34, P97, DOI 10.1111/liv.12403; Mengshol JA, 2007, NAT CLIN PRACT GASTR, V4, P622, DOI 10.1038/ncpgasthep0961; Myers RP, 2003, J HEPATOL, V39, P222, DOI 10.1016/S0168-8278(03)00171-5; Nainan OV, 2006, CLIN MICROBIOL REV, V19, P63, DOI 10.1128/CMR.19.1.63-79.2006; NALIN DR, 1993, J HEPATOL, V18, pS51, DOI 10.1016/S0168-8278(05)80379-4; Nguyen T, 2010, J HEPATOL, V52, P508, DOI 10.1016/j.jhep.2010.01.007; Omata M, 2017, HEPATOL INT, V11, P317, DOI 10.1007/s12072-017-9799-9; Omata M, 2010, HEPATOL INT, V4, P439, DOI 10.1007/s12072-010-9165-7; Patel K, 2003, J GASTROEN HEPATOL, V18, P253, DOI 10.1046/j.1440-1746.2003.02930.x; PERRILLO R, 1993, HEPATOLOGY, V18, P1306, DOI 10.1002/hep.1840180604; Perz JF, 2006, J HEPATOL, V45, P529, DOI 10.1016/j.jhep.2006.05.013; Plevris JN, 2000, EUR J GASTROEN HEPAT, V12, P1121, DOI 10.1097/00042737-200012100-00009; Raimondo G, 2008, J HEPATOL, V49, P652, DOI 10.1016/j.jhep.2008.07.014; Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6; RIZZETTO M, 1977, GUT, V18, P997, DOI 10.1136/gut.18.12.997; Saitou Y, 2005, WORLD J GASTROENTERO, V11, P476, DOI 10.3748/wjg.v11.i4.476; Sanvisens A, 2009, J VIRAL HEPATITIS, V16, P513, DOI 10.1111/j.1365-2893.2009.01103.x; Sarrazin C, 2015, J VIROL METHODS, V214, P29, DOI 10.1016/j.jviromet.2014.11.027; Sebastiani G, 2006, WORLD J GASTROENTERO, V12, P3682, DOI 10.3748/wjg.v12.i23.3682; Sebastiani G, 2014, WORLD J GASTROENTERO, V20, P11033, DOI 10.3748/wjg.v20.i32.11033; Seeff LB, 2001, HEPATOLOGY, V33, P455, DOI 10.1053/jhep.2001.21905; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; SEREGNI E, 1995, ANTICANCER RES, V15, P1491; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Sodek J, 2000, CRIT REV ORAL BIOL M, V11, P279, DOI 10.1177/10454411000110030101; Song G, 2016, J MED VIROL, V89, P463; STEFFEN R, 1994, JAMA-J AM MED ASSOC, V272, P885, DOI 10.1001/jama.272.11.885; Stuver S, 2008, TXB CANC EPIDEMIOLOG; Suzuki F, 2009, J MED VIROL, V81, P27, DOI 10.1002/jmv.21339; Tada T, 2016, J HEPATOL, V65, P48, DOI 10.1016/j.jhep.2016.03.013; Tanaka E, 2006, LIVER INT, V26, P90, DOI 10.1111/j.1478-3231.2005.01200.x; Taneja S, PROTEOME SCI; Thomas HC, 2007, J HEPATOL, V47, P588, DOI 10.1016/j.jhep.2007.07.017; Thompson AJV, 2010, HEPATOLOGY, V51, P1933, DOI 10.1002/hep.23571; Tillmann HL, 2014, WORLD J GASTROENTERO, V20, P6701, DOI 10.3748/wjg.v20.i22.6701; TONAMI N, 1975, CANCER, V36, P466, DOI 10.1002/1097-0142(197508)36:2<466::AID-CNCR2820360224>3.0.CO;2-U; Tseng TC, 2011, GASTROENTEROLOGY, V141, P517, DOI 10.1053/j.gastro.2011.04.046; Valva P, 2016, WORLD J GASTROENTERO, V22, P1367, DOI 10.3748/wjg.v22.i4.1367; Valva P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023218; van Bommel F, 2015, HEPATOLOGY, V61, P66, DOI 10.1002/hep.27381; Waidely E, 2016, ANALYST, V141, P36, DOI 10.1039/c5an01884f; Waldenstrom J, 2013, SCAND J INFECT DIS, V45, P796, DOI 10.3109/00365548.2013.797601; Wang CS, 2005, WORLD J GASTROENTERO, V11, P6115, DOI 10.3748/wjg.v11.i39.6115; Wang J, 2016, J HEPATOL, V65, P700, DOI 10.1016/j.jhep.2016.05.029; Wedemeyer H, 2010, NAT REV GASTRO HEPAT, V7, P31, DOI 10.1038/nrgastro.2009.205; WHO, 2012, WKLY EPIDEMIOL REC, V87, P261; Witjes CDM, 2013, HEPATOL INT, V7, P59, DOI 10.1007/s12072-012-9374-3; Wong DKH, 2007, J CLIN MICROBIOL, V45, P3942, DOI 10.1128/JCM.00366-07; Wong VS, 1998, J VIRAL HEPATITIS, V5, P187, DOI 10.1046/j.1365-2893.1998.00100.x; Yang HI, 2002, NEW ENGL J MED, V347, P168, DOI 10.1056/NEJMoa013215; Yuan Q, 2013, GUT, V62, P182, DOI 10.1136/gutjnl-2012-302656; Zachou K, 2010, LIVER INT, V30, P430, DOI 10.1111/j.1478-3231.2009.02140.x; Zhu WW, 2013, CLIN CANCER RES, V19, P3944, DOI 10.1158/1078-0432.CCR-12-3363	119	1	1	0	5	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					713	722		10.1080/14737159.2018.1496020			10	Pathology	Pathology	GP3FD	WOS:000440726700004	30019978				2019-10-28	
J	Lydon, EC; Ko, ER; Tsalik, EL				Lydon, Emily C.; Ko, Emily R.; Tsalik, Ephraim L.			The host response as a tool for infectious disease diagnosis and management	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Communicable diseases; host-pathogen interactions; metabolome; molecular diagnostics; proteome; respiratory tract infection; Sepsis; transcriptome	EMERGENCY-DEPARTMENT PATIENTS; GENE-EXPRESSION ANALYSIS; EARLY LACTATE CLEARANCE; EBOLA-VIRUS DISEASE; C-REACTIVE PROTEIN; SEPTIC SHOCK; SEVERE SEPSIS; SERUM PROCALCITONIN; DISCRIMINATING BACTERIAL; METHYLATION DATABASE	Introduction: A century of advances in infectious disease diagnosis and treatment changed the face of medicine. However, challenges continue to develop including multi-drug resistance, globalization that increases pandemic risks, and high mortality from severe infections. These challenges can be mitigated through improved diagnostics, and over the past decade, there has been a particular focus on the host response. Since this article was originally published in 2015, there have been significant developments in the field of host response diagnostics, warranting this updated review.Areas Covered: This review begins by discussing developments in single biomarkers and pauci-analyte biomarker panels. It then delves into omics, an area where there has been truly exciting progress. Specifically, progress has been made in sepsis diagnosis and prognosis; differentiating viral, bacterial, and fungal pathogen classes; pre-symptomatic diagnosis; and understanding disease-specific diagnostic challenges in tuberculosis, Lyme disease, and Ebola.Expert Commentary: As omics have become faster, more precise, and less expensive, the door has been opened for academic, industry, and government efforts to develop host-based infectious disease classifiers. While there are still obstacles to overcome, the chasm separating these scientific advances from the patient's bedside is shrinking.	[Lydon, Emily C.] Duke Univ, Sch Med, Durham, NC USA; [Ko, Emily R.; Tsalik, Ephraim L.] Duke Univ, Dept Med, Duke Ctr Appl Genom & Precis Med, DUMC 102359, Durham, NC 27710 USA; [Ko, Emily R.] Duke Univ, Dept Med, Duke Reg Hosp, Durham, NC USA; [Tsalik, Ephraim L.] Duke Univ, Dept Med, Div Infect Dis & Int Hlth, Durham, NC USA; [Tsalik, Ephraim L.] Durham Vet Affairs Hlth Care Syst, Emergency Med Serv, Durham, NC USA	Tsalik, EL (reprint author), Duke Univ, Dept Med, Duke Ctr Appl Genom & Precis Med, DUMC 102359, Durham, NC 27710 USA.	e.t@duke.edu		Tsalik, Ephraim/0000-0002-6417-2042			Aberg KA, 2014, JAMA PSYCHIAT, V71, P255, DOI 10.1001/jamapsychiatry.2013.3730; Adly AAM, 2014, CYTOKINE, V65, P184, DOI 10.1016/j.cyto.2013.11.004; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; [Anonymous], 2017, BUSSINESSWIRE   0430; Arnold RC, 2009, SHOCK, V32, P35, DOI 10.1097/SHK.0b013e3181971d47; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Attar BM, 2014, WORLD J GASTROENTERO, V20, P2374, DOI 10.3748/wjg.v20.i9.2374; Baginsky S, 2010, PLANT PHYSIOL, V152, P402, DOI 10.1104/pp.109.150433; Bhattacharya S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06738-3; Boulos M, 2003, CRIT CARE MED, V31, P353, DOI 10.1097/01.CCM.0000050074.82486.B2; Bouquet J, 2016, MBIO, V7, DOI 10.1128/mBio.00100-16; Broadhurst MJ, 2015, LANCET, V386, P867, DOI 10.1016/S0140-6736(15)61042-X; Brodska H, 2018, CLIN CHEM LAB MED, V56, P658, DOI 10.1515/cclm-2017-0839; Bryan CP, 1931, PAPYRUS EBERS; Burke TW, 2017, EBIOMEDICINE, V17, P172, DOI 10.1016/j.ebiom.2017.02.015; Cairns C B, 2001, Curr Opin Crit Care, V7, P437, DOI 10.1097/00075198-200112000-00011; Cao C, 2018, ACCOUNTS CHEM RES, V51, P331, DOI 10.1021/acs.accounts.7b00143; Carsin H, 1997, BURNS, V23, P218, DOI 10.1016/S0305-4179(96)00124-6; Carvalho CM, 2008, J AM STAT ASSOC, V103, P1438, DOI 10.1198/016214508000000869; Chen L, 2017, MMWR-MORBID MORTAL W, V66, P33, DOI 10.15585/mmwr.mm6601a7; Chen MH, 2011, IEEE T BIO-MED ENG, V58, P468, DOI 10.1109/TBME.2010.2059702; Ching TS, 2008, INT J NANOMED, V3, P211; Covolo L, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4378; Cox FEG, 2002, CLIN MICROBIOL REV, V15, P595, DOI 10.1128/CMR.15.4.595-612.2002; Crespo-Leiro MG, 2016, EUR HEART J, V37, P2591, DOI 10.1093/eurheartj/ehv682; Dano Ibrahim Dan, 2016, Pak J Biol Sci, V19, P185, DOI 10.3923/pjbs.2016.185.190; Davenport EE, 2016, LANCET RESP MED, V4, P259, DOI 10.1016/S2213-2600(16)00046-1; Davenport EE, 2015, J MOL MED, V93, P105, DOI 10.1007/s00109-014-1212-8; Davis BH, 2006, ARCH PATHOL LAB MED, V130, P654; De Groote MA, 2017, J CLIN MICROBIOL, V55, P3057, DOI [10.1128/jcm.00467-17, 10.1128/JCM.00467-17]; de Monerri NCS, 2014, AM J PATHOL, V184, P897, DOI 10.1016/j.ajpath.2013.12.022; De Tymowski C, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1738-6; Debiane L, 2014, CRIT CARE MED, V42, P2500, DOI 10.1097/CCM.0000000000000526; Delgado-Morales R, 2017, MOL PSYCHIATR, V22, P485, DOI 10.1038/mp.2016.242; Dix A, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00171; Donnelly JP, 2014, ANTIMICROB AGENTS CH, V58, P1451, DOI 10.1128/AAC.02039-13; du Preez I, 2017, BIOMARK MED, V11, P179, DOI 10.2217/bmm-2016-0287; Eden E, 2016, J INFECTION, V73, P177, DOI 10.1016/j.jinf.2016.05.002; Eisfeld AJ, 2017, CELL HOST MICROBE, V22, P817, DOI 10.1016/j.chom.2017.10.011; Finfer S, 2004, INTENS CARE MED, V30, P589, DOI 10.1007/s00134-004-2157-0; Fleming-Dutra KE, 2016, JAMA-J AM MED ASSOC, V315, P1864, DOI 10.1001/jama.2016.4151; Freund Y, 2012, BIOMARKERS, V17, P590, DOI 10.3109/1354750X.2012.704645; Garalde DR, 2018, NAT METHODS, V15, P201, DOI [10.1038/NMETH.4577, 10.1038/nmeth.4577]; GARDLUND B, 1995, J INFECT DIS, V172, P296, DOI 10.1093/infdis/172.1.296; Giudice G, 2019, BRIEF BIOINFORM, V20, P767, DOI 10.1093/bib/bbx141; Goncalves SM, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02362; Gowda G A Nagana, 2014, Methods Mol Biol, V1198, P3, DOI 10.1007/978-1-4939-1258-2_1; Grace E, 2014, CLIN INFECT DIS, V16, P2014; Gygi SP, 1999, MOL CELL BIOL, V19, P1720; Hanna WJ, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1095-2; Haran JP, 2013, AM J EMERG MED, V31, P816, DOI 10.1016/j.ajem.2013.01.030; Harris LN, 2016, J CLIN ONCOL, V34, P1134, DOI 10.1200/JCO.2015.65.2289; [Health TCfDaR SeptiCYTE FDA], 2017, 510 K PREMARKET NOTI; Herberg JA, 2016, JAMA-J AM MED ASSOC, V316, P835, DOI 10.1001/jama.2016.11236; Hsueh EC, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0520-1; Huang HB, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0338-6; Huttunen R, 2011, J INTERN MED, V270, P32, DOI 10.1111/j.1365-2796.2011.02363.x; Jedynak M, 2018, ARCH IMMUNOL THER EX, V66, P299, DOI 10.1007/s00005-017-0499-x; Khatri K, 2017, ANAL CHEM, V89, P6645, DOI 10.1021/acs.analchem.7b00875; Khine AASA, 2017, ASM MICR NEW ORL; Kloos RT, 2017, MOL IMAGING RADIONUC, V26, P36, DOI 10.4274/2017.26.suppl.05; Koster-Brouwer ME, 2018, CRIT CARE MED, V46, P368, DOI 10.1097/CCM.0000000000002735; Landry ML, 2016, CLIN VACCINE IMMUNOL, V23, P540, DOI 10.1128/CVI.00211-16; Langley RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005893; Levenson VV, 2010, EXPERT REV MOL DIAGN, V10, P481, DOI 10.1586/ERM.10.17; Li H, 2017, J MASS SPECTROM, V52, P319, DOI 10.1002/jms.3932; Liu B, 2013, CRIT CARE, V17, DOI 10.1186/cc13070; Liu ML, 2011, ONCOL LETT, V2, P583, DOI 10.3892/ol.2011.300; Liu V, 2014, JAMA-J AM MED ASSOC, V312, P90, DOI 10.1001/jama.2014.5804; Liu X, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1137-3; Livaditi O, 2006, CYTOKINE, V36, P283, DOI 10.1016/j.cyto.2007.02.007; Loebe M, 2000, INTENS CARE MED, V26, pS193, DOI 10.1007/BF02900737; Lowe R, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005457; Lv J, 2012, NUCLEIC ACIDS RES, V40, pD1030, DOI 10.1093/nar/gkr1169; Lytkin NI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020662; Mahajan P, 2016, JAMA-J AM MED ASSOC, V316, P846, DOI 10.1001/jama.2016.9207; Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036; Manjili MH, 2012, FUTURE ONCOL, V8, P703, DOI [10.2217/fon.12.57, 10.2217/FON.12.57]; Marinov GK, 2017, BRIEF FUNCT GENOMICS, V16, P326, DOI 10.1093/bfgp/elw043; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Martin NJ, 2013, J AM SOC MASS SPECTR, V24, P1242, DOI 10.1007/s13361-013-0658-1; Masson S, 2014, CRIT CARE, V18, DOI 10.1186/cc13183; McClain MT, 2016, OPEN FORUM INFECT DI, V3, DOI 10.1093/ofid/ofw007; McHugh L, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001916; Mikkelsen ME, 2009, CRIT CARE MED, V37, P1670, DOI 10.1097/CCM.0b013e31819fcf68; Mimoz O, 1998, INTENS CARE MED, V24, P185, DOI 10.1007/s001340050543; Molins CR, 2015, CLIN INFECT DIS, V60, P1767, DOI 10.1093/cid/civ185; Montgomery JLNJ, 2017, ASM MICR 2017 NEW OR; Moyer MW, 2012, NAT MED, V18, P999, DOI 10.1038/nm0712-999; Muller B, 2001, J CLIN ENDOCR METAB, V86, P396, DOI 10.1210/jc.86.1.396; Nagata J, 2008, EUR J VASC ENDOVASC, V35, P694, DOI 10.1016/j.ejvs.2007.11.014; Nguyen HB, 2004, CRIT CARE MED, V32, P1637, DOI 10.1097/01.CCM.0000132904.35713.A7; Nylen ES, 1997, CRIT CARE MED, V25, P1362, DOI 10.1097/00003246-199708000-00024; Oved K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120012; Pankla R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r127; Park JM, 2015, SCI REP-UK, V5, DOI 10.1038/srep18189; Raman G, 2013, AHRQ TECHNOLOGY ASSE; Ramirez LA, 2014, J LEUKOCYTE BIOL, V96, P1055, DOI 10.1189/jlb.3A0414-232RR; Ravetti CG, 2015, J CRIT CARE, V30, DOI 10.1016/j.jcrc.2014.12.002; Rhodes A, 2017, INTENS CARE MED, V43, P304, DOI 10.1007/s00134-017-4683-6; Saini S, 2016, CELL ONCOL, V39, P97, DOI 10.1007/s13402-016-0268-6; Sandquist M, 2014, EXPERT REV CLIN IMMU, V10, P1349, DOI 10.1586/1744666X.2014.949675; Sargentini V, 2017, J BIOL REG HOMEOS AG, V31, P1147; Schierenbeck F, 2014, CRIT CARE, V18, DOI 10.1186/cc13808; Schuetz P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007498.pub3; Scicluna BP, 2015, AM J RESP CRIT CARE, V192, P826, DOI 10.1164/rccm.201502-0355OC; Scire CA, 2006, CLIN EXP RHEUMATOL, V24, P123; Self WH, 2017, J CLIN MED, V6, DOI 10.3390/jcm6100094; Serrano-Gomez S, 2017, J INTENSIVE CARE MED, DOI 10.1177/0885066617732284; Shapiro NI, 2009, CRIT CARE MED, V37, P96, DOI 10.1097/CCM.0b013e318192fd9d; Sharma Sanjiv, 2017, Sens Biosensing Res, V13, P104, DOI 10.1016/j.sbsr.2016.10.004; Shehab N, 2016, JAMA-J AM MED ASSOC, V316, P2115, DOI 10.1001/jama.2016.16201; Soloski MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093243; Steere AC, 2008, CLIN INFECT DIS, V47, P188, DOI 10.1086/589242; Suarez NM, 2015, J INFECT DIS, V29, P2015; Suberviola B, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13542; Sundararajan V, 2005, CRIT CARE MED, V33, P71, DOI 10.1097/01.CCM.0000150027.98160.80; Sweeney TE, 2018, CRIT CARE MED, V46, P915, DOI 10.1097/CCM.0000000000003084; Sweeney TE, 2017, CRIT CARE MED, V45, P1, DOI 10.1097/CCM.0000000000002021; Tian Q, 2004, MOL CELL PROTEOMICS, V3, P960, DOI 10.1074/mcp.M400055-MCP200; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; Trzeciak S, 2007, INTENS CARE MED, V33, P970, DOI 10.1007/s00134-007-0563-9; Trzeciak S, 2007, ANN EMERG MED, V49, P88, DOI 10.1016/j.annemergmed.2006.08.021; Tsalik EL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6873; Tsalik EL, 2014, GENOME MED, V6, DOI 10.1186/s13073-014-0111-5; Ulla M, 2013, CRIT CARE, V17, DOI 10.1186/cc12847; van Engelen TSR, 2018, CRIT CARE CLIN, V34, P139, DOI 10.1016/j.ccc.2017.08.010; van Houten CB, 2017, LANCET INFECT DIS, V17, P431, DOI 10.1016/S1473-3099(16)30519-9; van Laar R, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-25; van Oort PM, 2018, J BREATH RES, V12, DOI 10.1088/1752-7163/aaa499; Vargas Jose, 2013, PLoS Curr, V5, DOI 10.1371/currents.eogt.0f04f6081905998fa92b99593478aeab; WAAGE A, 1989, J EXP MED, V169, P333, DOI 10.1084/jem.169.1.333; Wacker C, 2013, LANCET INFECT DIS, V13, P426, DOI 10.1016/S1473-3099(12)70323-7; Wang J, 2016, J CELL PHYSIOL, V231, P25, DOI 10.1002/jcp.25056; Waugh T R, 1923, Can Med Assoc J, V13, P604; WHO, 2011, GLOB TUB CONTR WORLD; Wong HR, 2018, CRIT CARE MED, V46, pe242, DOI 10.1097/CCM.0000000000002932; Wong HR, 2016, CRIT CARE MED, V44, P2010, DOI 10.1097/CCM.0000000000001852; Wong HR, 2014, CRIT CARE MED, V42, P781, DOI 10.1097/CCM.0000000000000106; Wong HR, 2012, CRIT CARE, V16, DOI 10.1186/cc11652; Wong HR, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-34; Woods CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052198; World Health Organization, 2018, EB VIR DIS FACT SHEE; Wu YC, 2013, J COMPUT GRAPH STAT, V22, P379, DOI 10.1080/10618600.2012.680823; Xiong YC, 2017, NUCLEIC ACIDS RES, V45, pD888, DOI 10.1093/nar/gkw1123; Zak DE, 2016, LANCET, V387, P2312, DOI 10.1016/S0140-6736(15)01316-1; Zhou MY, 2016, MOL MED REP, V13, P4620, DOI 10.3892/mmr.2016.5097; Zimmerman JJ, 2017, CRIT CARE MED, V45, pE418, DOI 10.1097/CCM.0000000000002100	148	1	1	1	10	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					723	738		10.1080/14737159.2018.1493378			16	Pathology	Pathology	GP3FD	WOS:000440726700005	29939801				2019-10-28	
J	Janssen, KJH; Dirks, JAMC; Dukers-Muijrers, NHTM; Hoebe, CJPA; Wolffs, PFG				Janssen, Kevin J. H.; Dirks, Jeanne A. M. C.; Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.; Wolffs, Petra F. G.			Review of Chlamydia trachomatis viability methods: assessing the clinical diagnostic impact of NAAT positive results	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Chlamydia trachomatis; viability; viability-PCR; messenger-RNA; culture; test of cure; anorectal chlamydia; post-treatment positivity; molecular diagnostics	REAL-TIME PCR; NEISSERIA-GONORRHOEAE INFECTIONS; ACID AMPLIFICATION TESTS; PHARYNGEAL CHLAMYDIA; DEVELOPMENTAL CYCLE; ETHIDIUM MONOAZIDE; GENITAL-INFECTION; MULTICENTER EVALUATION; RECTAL CHLAMYDIA; GENE-EXPRESSION	Introduction: Chlamydia trachomatis (chlamydia) is the most commonly diagnosed bacterial sexually transmitted infection (STI) worldwide. The advancement of molecular techniques has made chlamydia diagnostics infinitely easier. However, molecular techniques lack the information on chlamydia viability. Where in routine diagnostics the detection of chlamydia DNA or RNA might suffice, in other patient scenarios, information on the viability of chlamydia might be essential.Areas covered: In this review, the authors discuss the specific strengths and limitations of currently available methods to evaluate chlamydia viability: conventional cell culture, messenger RNA (mRNA) detection and viability-PCR (V-PCR).PubMed and Google Scholar were searched with the following terms: Chlamydia trachomatis, Treatment failure, Anal chlamydia, Microbial viability, Culture, Viability-PCR, Messenger RNA, and Molecular diagnosticsExpert commentary: Several techniques are currently available to determine chlamydia viability and thus the clinical relevance of a positive test result in clinical samples. Depending on the underlying research question, all three discussed techniques have their merits when testing for viability. However, mRNA methods show the most promise in determining the presence of a true infection, in case the chlamydia reticulate body can be specifically detected. Further research is needed to understand how to best apply viability testing in current chlamydia diagnostics.	[Janssen, Kevin J. H.; Dirks, Jeanne A. M. C.; Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.; Wolffs, Petra F. G.] Maastricht Univ, Med Ctr MUMC, Care & Publ Hlth Res Inst CAPHRI, Dept Med Microbiol, NL-6202 AZ Maastricht, Netherlands; [Dukers-Muijrers, Nicole H. T. M.; Hoebe, Christian J. P. A.] South Limburg Publ Hlth Serv, Dept Sexual Hlth Infect Dis & Environm Hlth, Heerlen, Netherlands	Wolffs, PFG (reprint author), Maastricht Univ, Med Ctr MUMC, Care & Publ Hlth Res Inst CAPHRI, Dept Med Microbiol, NL-6202 AZ Maastricht, Netherlands.	p.wolffs@mumc.nl	Dukers-Muijrers, Nicole/M-7178-2014	Wolffs, Petra/0000-0002-5326-3985			Yanez MA, 2011, J MICROBIOL METH, V85, P124, DOI 10.1016/j.mimet.2011.02.004; BARNES RC, 1989, CLIN MICROBIOL REV, V2, P119; Belland RJ, 2003, P NATL ACAD SCI USA, V100, P8478, DOI 10.1073/pnas.1331135100; BENES S, 1982, J CLIN MICROBIOL, V16, P847; Bennett J.E., 2015, MANDELL DOUGLAS BENN; Bogosian G, 2001, EMBO REP, V2, P770, DOI 10.1093/embo-reports/kve182; Cangelosi GA, 2014, APPL ENVIRON MICROB, V80, P5884, DOI 10.1128/AEM.01763-14; Cenciarini-Borde C, 2009, FUTURE MICROBIOL, V4, P45, DOI 10.2217/17460913.4.1.45; Chandra NL, 2018, SEX TRANSM INFECT, V94, P320, DOI 10.1136/sextrans-2017-053161; COFFMAN GL, 1982, J BIOL CHEM, V257, P13205; Delgado-Viscogliosi P, 2009, APPL ENVIRON MICROB, V75, P3502, DOI 10.1128/AEM.02878-08; Dewart CM, 2018, SEX TRANSM DIS, V45, P287, DOI 10.1097/OLQ.0000000000000754; Ding A, 2014, INT J STD AIDS, V25, P587, DOI 10.1177/0956462413515637; Dirks JAMC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145693; Dreses-Werringloer U, 2000, ANTIMICROB AGENTS CH, V44, P3288, DOI 10.1128/AAC.44.12.3288-3297.2000; Dubbink JH, 2016, J CLIN MICROBIOL, V54, P200, DOI 10.1128/JCM.02848-15; Dukers-Muijrers NHTM, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1721-x; Dukers-Muijrers NHTM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1280-6; Dukers-Muijrers NHTM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081236; Dukers-Muijrers NHTM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034108; Elizaquivel P, 2014, J APPL MICROBIOL, V116, P1, DOI 10.1111/jam.12365; Elwell C, 2016, NAT REV MICROBIOL, V14, P385, DOI 10.1038/nrmicro.2016.30; EVANS RT, 1983, BRIT MED BULL, V39, P181, DOI 10.1093/oxfordjournals.bmb.a071813; Ferreira R, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00364; Gaydos CA, 2004, J CLIN MICROBIOL, V42, P3041, DOI 10.1128/JCM.42.7.3041-3045.2004; Gaydos CA, 2003, J CLIN MICROBIOL, V41, P304, DOI 10.1128/JCM.41.1.304-309.2003; Geisler WM, 2010, J INFECT DIS, V201, pS104, DOI 10.1086/652402; GORDON FB, 1969, J INFECT DIS, V120, P451, DOI 10.1093/infdis/120.4.451; Hein I, 2006, J MICROBIOL METH, V66, P538, DOI 10.1016/j.mimet.2006.02.008; Hellyer TJ, 1999, J CLIN MICROBIOL, V37, P290; Hoebe CJPA, 2006, SEX TRANSM DIS, V33, P491, DOI 10.1097/01.olq.0000204619.87066.28; Inoue H, 2015, MICROBES ENVIRON, V30, P108, DOI 10.1264/jsme2.ME14115; Janssen KJH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165920; Keer JT, 2003, J MICROBIOL METH, V53, P175, DOI 10.1016/S0167-7012(03)00025-3; Laalami S, 2014, CELL MOL LIFE SCI, V71, P1799, DOI 10.1007/s00018-013-1472-4; Lanjouw E, 2016, INT J STD AIDS, V27, P333, DOI 10.1177/0956462415618837; Lau A, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-016-2125-7; Meyer T, 2016, MICROORGANISMS, V4, DOI 10.3390/microorganisms4030025; Molano M, 2005, J INFECT DIS, V191, P907, DOI 10.1086/428287; Moncada J, 2009, J CLIN MICROBIOL, V47, P1657, DOI 10.1128/JCM.02269-08; Moreno L, 2015, INT J FOOD MICROBIOL, V201, P1, DOI 10.1016/j.ijfoodmicro.2015.02.012; Morre SA, 2002, INT J STD AIDS, V13, P12, DOI 10.1258/095646202762226092; Mpiga P, 2006, INT J ANTIMICROB AG, V27, P316, DOI 10.1016/j.ijantimicag.2005.11.010; Musil K, 2016, INT J STD AIDS, V27, P526, DOI 10.1177/0956462415586317; Newman L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143304; Nicholson TL, 2003, J BACTERIOL, V185, P3179, DOI 10.1128/JB.185.10.3179-3189.2003; Nocker A, 2006, J MICROBIOL METH, V67, P310, DOI 10.1016/j.mimet.2006.04.015; Nogva HK, 2003, BIOTECHNIQUES, V34, P804, DOI 10.2144/03344rr02; Nwokolo NC, 2016, INT J STD AIDS, V27, P251, DOI 10.1177/0956462415615443; Peters RPH, 2014, SEX TRANSM DIS, V41, P564, DOI 10.1097/OLQ.0000000000000175; Peuchant O, 2011, J MED MICROBIOL, V60, P508, DOI 10.1099/jmm.0.023887-0; Pitt R, 2018, J ANTIMICROB CHEMOTH, V73, P680, DOI 10.1093/jac/dkx454; Rank RG, 2014, INFECT IMMUN, V82, P1362, DOI 10.1128/IAI.01244-13; Renault CA, 2011, SEX HEALTH, V8, P69, DOI 10.1071/SH10030; RIPA KT, 1977, J CLIN MICROBIOL, V6, P328; Roges GB, 2008, DIAGN MICR INFEC DIS, V62, P133, DOI 10.1016/j.diagmicrobio.2008.06.011; ROTA TR, 1973, APPL MICROBIOL, V26, P560; Rudi K, 2005, LETT APPL MICROBIOL, V40, P301, DOI 10.1111/j.1472-765X.2005.01672.x; Rudi K, 2005, APPL ENVIRON MICROB, V71, P1018, DOI 10.1128/AEM.71.2.1018-1024.2005; Scidmore Marci A, 2005, Curr Protoc Microbiol, VChapter 11, DOI 10.1002/9780471729259.mc11a01s00; Shao LL, 2016, J CLIN LAB ANAL, V30, P697, DOI 10.1002/jcla.21924; Shaw EI, 2000, MOL MICROBIOL, V37, P913, DOI 10.1046/j.1365-2958.2000.02057.x; Storm M, 2005, J MICROBIOL METH, V61, P361, DOI 10.1016/j.mimet.2004.12.015; THEJLS H, 1994, GENITOURIN MED, V70, P300; van den Broek IVF, 2014, OBSTET GYNECOL INT, V2014, P1; van der Helm JJ, 2009, SEX TRANSM DIS, V36, P493, DOI 10.1097/OLQ.0b013e3181a44b8c; Van der Pol B, 2000, J CLIN MICROBIOL, V38, P1105; van der Pol B, 2001, J CLIN MICROBIOL, V39, P1008, DOI 10.1128/JCM.39.3.1008-1016.2001; van Dommelen L, 2011, SEX TRANSM DIS, V38, P533, DOI 10.1097/OLQ.0b013e318205e435; van Liere GAFS, 2017, CLIN INFECT DIS, V64, P1705, DOI 10.1093/cid/cix243; van Liere GAFS, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-274; van Liere GAFS, 2013, SEX TRANSM DIS, V40, P285, DOI 10.1097/OLQ.0b013e31828098f8; van Rooijen MS, 2015, SEX TRANSM INFECT, V91, P157, DOI 10.1136/sextrans-2014-051633; VanGuilder HD, 2008, BIOTECHNIQUES, V44, P619, DOI 10.2144/000112776; Versteeg B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185295; Vodstrcil LA, 2015, J INFECT DIS, V211, P1628, DOI 10.1093/infdis/jiu670; Wang L, 2009, J APPL MICROBIOL, V107, P1719, DOI 10.1111/j.1365-2672.2009.04358.x; Wang SS, 2006, J MICROBIOL METH, V64, P1, DOI 10.1016/j.mimet.2005.04.023; Witkin SS, 2017, CLIN VACCINE IMMUNOL, V24, DOI [10.1128/CVI.00203-17, 10.1128/cvi.00203-17]; Workowski KA, 2015, MMWR RECOMM REP, V64, P1; Wyrick PB, 2010, J INFECT DIS, V201, pS88, DOI 10.1086/652394; Yamamoto S, 2016, CELL STRUCT FUNCT, V41, P137, DOI 10.1247/csf.16014; Yamamoto S, 2015, SCI REP-UK, V5, DOI 10.1038/srep08505; Yeruva L, 2013, PATHOG DIS, V68, P88, DOI 10.1111/2049-632X.12052	84	1	1	1	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					739	747		10.1080/14737159.2018.1498785			9	Pathology	Pathology	GP3FD	WOS:000440726700006	29987959				2019-10-28	
J	Rutanga, JP; Van Puyvelde, S; Heroes, AS; Muvunyi, CM; Jacobs, J; Deborggraeve, S				Rutanga, Jean Pierre; Van Puyvelde, Sandra; Heroes, Anne-Sophie; Muvunyi, Claude Mambo; Jacobs, Jan; Deborggraeve, Stijn			16S metagenomics for diagnosis of bloodstream infections: opportunities and pitfalls	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Bacterial bloodstream infections; molecular diagnosis; sepsis; 16S metagenomics; 16S rRNA gene	RIBOSOMAL-RNA GENE; POLYMERASE-CHAIN-REACTION; MICROBIOTA PROFILES; NANOPORE SEQUENCER; NEONATAL SEPSIS; SOLID MEDIUM; BACTERIAL; IDENTIFICATION; TIME; PCR	Introduction: Bacterial bloodstream infections (BSI) form a large public health threat worldwide. Current routine diagnosis is based on blood culture (BC) but this technique suffers from limited sensitivity. Molecular diagnostic tools have been developed for identification of bacteria in the blood of BSI patients. 16S metagenomics is an open-ended technique that can detect simultaneously all bacteria in a given sample based on PCR amplification of the 16S ribosomal RNA gene (rDNA) followed by sequencing of the PCR amplicons and taxonomic labeling of the sequence reads at genus or species level.Areas covered: Here we review the studies that have used 16S metagenomics for the identification of bacteria in human blood samples. We also discuss the potential added value of 16S metagenomics in the diagnosis of BSI, challenges as well as future directions for implementation in clinical settings.Expert commentary: 16S metagenomics has the potential to complement conventional BC; however, the technique currently suffers from several technical limitations jeopardizing implementation in routine clinical microbiology laboratories. Further studies are required to assess the cost-efficiency and clinical impact of 16S metagenomics in comparison to BC which remains the gold standard diagnostic method for BSI.	[Rutanga, Jean Pierre] Univ Rwanda, Coll Sci & Technol, Kigali, Rwanda; [Rutanga, Jean Pierre; Van Puyvelde, Sandra; Deborggraeve, Stijn] Inst Trop Med, Dept Biomed Sci, Antwerp, Belgium; [Van Puyvelde, Sandra] Wellcome Trust Sanger Inst, Hinxton, England; [Rutanga, Jean Pierre; Heroes, Anne-Sophie; Jacobs, Jan] Katholieke Univ Leuven, Dept Microbiol & Immunol, Leuven, Belgium; [Heroes, Anne-Sophie; Jacobs, Jan] Inst Trop Med, Dept Clin Sci, Antwerp, Belgium; [Muvunyi, Claude Mambo] Univ Rwanda, Coll Med & Hlth Sci, Kigali, Rwanda	Deborggraeve, S (reprint author), Inst Trop Med Antwerp, Dept Biomed Sci, Natl Str 155, B-2000 Antwerp, Belgium.	sdeborggraeve@itg.be	Rutanga, Jean Pierre/S-2543-2018	Rutanga, Jean Pierre/0000-0002-5273-6170	InBev-Baillet Latour (IBL) Fund for the Bacterial Infections in the Tropics (BIT) research cluster at the Institute of Tropical Medicine (ITM), Antwerp, Belgium; Department of Economy, Science and Innovation in Flanders (EWI funding ITM Antwerp)	This work was financially supported by the InBev-Baillet Latour (IBL) Fund for the Bacterial Infections in the Tropics (BIT) research cluster at the Institute of Tropical Medicine (ITM), Antwerp, Belgium, and the Department of Economy, Science and Innovation in Flanders (EWI funding ITM Antwerp).	Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107000-00002; Balvociute M, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3501-4; Balzan S, 2007, J GASTROEN HEPATOL, V22, P464, DOI 10.1111/j.1440-1746.2007.04933.x; Benitez-Paez A, 2016, GIGASCIENCE, V5, DOI 10.1186/s13742-016-0111-z; Benson DA, 2015, NUCLEIC ACIDS RES, V43, pD30, DOI 10.1093/nar/gku1216; Blottiere HM, 2013, CURR OPIN MICROBIOL, V16, P232, DOI 10.1016/j.mib.2013.06.006; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Chang SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054564; Chen T, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq013; Damgaard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120826; Decuypere S, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004470; El Gawhary S, 2016, J TROP PEDIATRICS, V62, P75, DOI 10.1093/tropej/fmv066; Faria MMP, 2015, BMC MICROBIOL, V15, DOI 10.1186/s12866-015-0557-7; Frickmann H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135923; Gebert S, 2008, J INFECTION, V57, P307, DOI 10.1016/j.jinf.2008.07.013; Gyarmati P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135756; Heather JM, 2016, GENOMICS, V107, P1, DOI 10.1016/j.ygeno.2015.11.003; Huse SM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000255; Idelevich EA, 2014, CLIN MICROBIOL INFEC, V20, P1001, DOI 10.1111/1469-0691.12640; Jervis-Bardy J, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0083-8; Jordan JA, 2005, J MOL DIAGN, V7, P575, DOI 10.1016/S1525-1578(10)60590-9; Jordan JA, 2005, J MOL DIAGN, V7, P105, DOI 10.1016/S1525-1578(10)60015-3; Jorgensen JH, 2009, CLIN INFECT DIS, V49, P1749, DOI 10.1086/647952; Kilianski A, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0051-z; Kim NH, 2011, ANN INTERN MED, V154, P145, DOI 10.7326/0003-4819-154-3-201102010-00003; Kirn TJ, 2013, CLIN MICROBIOL INFEC, V19, P513, DOI 10.1111/1469-0691.12180; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Kodama Y, 2015, NUCLEIC ACIDS RES, V43, pD18, DOI 10.1093/nar/gku1120; Kohlmann R, 2015, INT J MED MICROBIOL, V305, P469, DOI 10.1016/j.ijmm.2015.04.004; Kommedal O, 2012, J CLIN MICROBIOL, V50, P1289, DOI 10.1128/JCM.06269-11; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lebovitz E, 2013, MOL DIAGN THER, V17, P221, DOI 10.1007/s40291-013-0037-4; Lecuit M, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00025; Lelouvier B, 2016, HEPATOLOGY, V64, P2015, DOI 10.1002/hep.28829; Liesenfeld O, 2014, EUR J MICROBIOL IMMU, V4, P1, DOI 10.1556/EuJMI.4.2014.1.1; Loonen AJM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072349; Ludwig W, 2004, NUCLEIC ACIDS RES, V32, P1363, DOI 10.1093/nar/gkh293; Mancini N, 2010, CLIN MICROBIOL REV, V23, P235, DOI 10.1128/CMR.00043-09; McCann CD, 2015, DIAGN MICR INFEC DIS, V81, P158, DOI 10.1016/j.diagmicrobio.2014.11.014; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Moore MS, 2016, J CLIN MICROBIOL, V54, P99, DOI 10.1128/JCM.02394-15; Moriyama K, 2008, MICROBIOL IMMUNOL, V52, P375, DOI 10.1111/j.1348-0421.2008.00048.x; Mount David W, 2007, CSH Protoc, V2007, DOI 10.1101/pdb.top17; Muhl H, 2010, DIAGN MICR INFEC DIS, V66, P41, DOI 10.1016/j.diagmicrobio.2008.07.011; Nikkari S, 2001, J CLIN MICROBIOL, V39, P1956, DOI 10.1128/JCM.39.5.1956-1959.2001; Noyes NR, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0361-8; Ombelet S, 2018, LANCET INFECT DIS, pii; Opota O, 2015, CLIN MICROBIOL INFEC, V21, P323, DOI 10.1016/j.cmi.2015.02.005; Paisse S, 2016, TRANSFUSION, V56, P1138, DOI 10.1111/trf.13477; Paolucci M, 2010, INT J ANTIMICROB AG, V36, pS6, DOI 10.1016/j.ijantimicag.2010.11.010; Parahitiyawa NB, 2009, CLIN MICROBIOL REV, V22, P46, DOI 10.1128/CMR.00028-08; Pearson WR, 2016, CURR PROTOC BIOINFOR, V53, P3; Pei AY, 2010, APPL ENVIRON MICROB, V76, P3886, DOI 10.1128/AEM.02953-09; Perriere G, 1996, BIOCHIMIE, V78, P364, DOI 10.1016/0300-9084(96)84768-7; Petti CA, 2005, J CLIN MICROBIOL, V43, P6123, DOI 10.1128/JCM.43.12.6123-6125.2005; Salter SJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915-014-0087-z; Schabereiter-Gurtner C, 2008, J APPL MICROBIOL, V104, P1228, DOI 10.1111/j.1365-2672.2007.03648.x; SEDMAN PC, 1994, GASTROENTEROLOGY, V107, P643, DOI 10.1016/0016-5085(94)90110-4; Seymour CW, 2012, AM J RESP CRIT CARE, V186, P1264, DOI 10.1164/rccm.201204-0713OC; Stoesser G, 2002, NUCLEIC ACIDS RES, V30, P21, DOI 10.1093/nar/30.1.21; Stokkou S, 2015, EUR J MICROBIOL IMMU, V5, P103, DOI [10.1556/EuJMI-D-15-00005, 10.1556/EUJMI-D-15-00005]; Tacconelli E, 2018, LANCET INFECT DIS, V18, P318, DOI [10.1016/S1473-3099(17)30753-3, 10.1016/s1473-3099(17)30753-3]; Tang YW, 1998, J CLIN MICROBIOL, V36, P3674; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tseng CH, 2014, INT J MOL SCI, V15, P8878, DOI 10.3390/ijms15058878; Vincent JL, 2013, LANCET, V381, P774, DOI 10.1016/S0140-6736(12)61815-7; Vondracek M, 2011, J INFECTION, V62, P472, DOI 10.1016/j.jinf.2011.04.010; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang WL, 2015, WORLD J GASTROENTERO, V21, P803, DOI 10.3748/wjg.v21.i3.803; Wellinghausen N, 2009, J CLIN MICROBIOL, V47, P2759, DOI 10.1128/JCM.00567-09; Wilairatana P, 1997, CLIN INFECT DIS, V24, P430; Woo PCY, 2003, J CLIN MICROBIOL, V41, P1996, DOI 10.1128/JCM.41.5.1996-2001.2003; Yilmaz P, 2014, NUCLEIC ACIDS RES, V42, pD643, DOI 10.1093/nar/gkt1209; Zucol F, 2006, J CLIN MICROBIOL, V44, P2750, DOI 10.1128/JCM.00112-06	75	1	1	2	6	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					749	759		10.1080/14737159.2018.1498786			11	Pathology	Pathology	GP3FD	WOS:000440726700007	29985081				2019-10-28	
J	Bao, WX; He, FP; Yu, LH; Gao, J; Meng, FX; Ding, YH; Zou, H; Luo, BY				Bao, Wangxiao; He, Fangping; Yu, Lihua; Gao, Jian; Meng, Fanxia; Ding, Yahui; Zou, Hai; Luo, Benyan			Complement cascade on severe traumatic brain injury patients at the chronic unconscious stage: implication for pathogenesis	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Complement cascade; chronic disorders of consciousness; severe traumatic brain injury; iTRAQ; proteomics; plasma	PROTEOMICS; PATHOPHYSIOLOGY; RECOVERY; SYSTEM	Background: Patients who awake from severely traumatic brain injury (TBI) may remain unconscious for many years. Although behavioral assessment and functional imaging are currently used as diagnostic tools, the molecular basis underlying chronic condition has yet to be explored.Method: Plasma samples were obtained at 3 time points (1, 3 and 6months) from 18 patients with chronic disorders of consciousness who survived severe TBI, and 6 healthy volunteers. A coupled isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomics approach was used to screen differentially expressed proteins (DEPs) between patients and controls. Potential molecular mechanisms were further discussed through bioinformatics analyses.Result: In total, 300 plasma proteins <1% false discovery rates were identified and 32 proteins were consistently altered between patients and controls. Biological pathway analysis revealed that the DEPs were predominantly involved in complement cascade.Conclusions: This study discussed potential mechanisms of complement cascade underlying chronic stage in severe TBI.	[Bao, Wangxiao; He, Fangping; Meng, Fanxia; Luo, Benyan] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurol,Collaborat Innovat Ctr Brain Sci, Hangzhou, Zhejiang, Peoples R China; [Yu, Lihua] Zhejiang Prov Peoples Hosp, Dept Neurol, Hangzhou, Zhejiang, Peoples R China; [Gao, Jian] Hangzhou Hosp Zhejiang CAPR, Dept Rehabil, Hangzhou, Zhejiang, Peoples R China; [Ding, Yahui; Zou, Hai] Zhejiang Prov Peoples Hosp, Affiliated Hosp 1, Dept Neurol, Hangzhou, Zhejiang, Peoples R China; [Yu, Lihua; Ding, Yahui; Zou, Hai] Hangzhou Med Coll, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China	Luo, BY (reprint author), Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Neurol,Collaborat Innovat Ctr Brain Sci, Hangzhou, Zhejiang, Peoples R China.; Ding, YH; Zou, H (reprint author), Zhejiang Prov Peoples Hosp, Dept Cardiol, Hangzhou, Zhejiang, Peoples R China.	dyh@zjheart.com; haire1993@163.com; luobenyan@zju.edu.cn			Science and Technology Plan of Zhejiang Province [2017C03011]	This work was supported by grants from the Science and Technology Plan of Zhejiang Province (2017C03011).	Anada RP, 2018, ELECTROPHORESIS, V39, P2308, DOI 10.1002/elps.201700407; Babikian T, 2018, J NEUROTRAUM, V35, P1637, DOI 10.1089/neu.2017.5366; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bernat JL, 2006, LANCET, V367, P1181, DOI 10.1016/S0140-6736(06)68508-5; Bodien YG, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00688; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brennan FH, 2016, SEMIN IMMUNOL, V28, P292, DOI 10.1016/j.smim.2016.03.015; Brennan FH, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-137; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Gao WM, 2014, PEDIATR RES, V76, P280, DOI 10.1038/pr.2014.86; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Hammad A, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1066-z; Harboe M, 2004, CLIN EXP IMMUNOL, V138, P439, DOI 10.1111/j.1365-2249.2004.02627.x; Hardwick J, 2008, ISBT SCI SER, V3, P148, DOI 10.1111/j.1751-2824.2008.00195.x; Lizhnyak PN, 2015, EXPERT REV PROTEOMIC, V12, P75, DOI 10.1586/14789450.2015.1000869; Longhi L, 2014, CRIT CARE MED, V42, P1910, DOI 10.1097/CCM.0000000000000399; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Nguyen HX, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-26; Omenn GS, 2014, BBA-PROTEINS PROTEOM, V1844, P866, DOI 10.1016/j.bbapap.2013.10.016; Osthoff M, 2017, J NEUROTRAUM, V34, P2560, DOI 10.1089/neu.2016.4941; Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Ruet A, 2018, J NEUROTRAUM, V35, P1552, DOI 10.1089/neu.2017.5242; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Thelin EP, 2018, BEHAV BRAIN RES, V340, P71, DOI 10.1016/j.bbr.2016.08.058; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Zhang P, 2016, J PROTEOMICS, V133, P93, DOI 10.1016/j.jprot.2015.12.014	30	2	3	0	3	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	8					761	766		10.1080/14737159.2018.1471985			6	Pathology	Pathology	GP3FD	WOS:000440726700008	29718755				2019-10-28	
J	Ching, D; Leslie, C				Ching, Daniel; Leslie, Connull			Atypical Features Resembling Poorly Differentiated Thyroid Carcinoma Presenting Entirely within a Follicular Adenoma	CASE REPORTS IN PATHOLOGY			English	Article							HIGH-GRADE FEATURES; TURIN PROPOSAL	Poorly differentiated thyroid carcinoma (PDTC) is rare and is usually widely invasive at presentation. Here we present an unusual case with a component meeting diagnostic criteria for PDTC by Turin consensus proposal arising within a follicular adenoma. A 44-year-old female was foundto have an incidental right thyroid nodule that was suggestive of follicular neoplasm on FNA. Histological examination of hemithyroidectomy revealed an 11 mm focus with insular growth pattern, alteration in cell morphology, and high mitotic count meeting criteria for PDTC. In addition there were several regions showing trabecular architecture with increased mitotic activity but not meeting criteria for PDTC. The literature for such cases is sparse but suggests much better prognosis than conventional invasive PDTC, although a biological potential for aggressive behaviour may be possible.	[Ching, Daniel; Leslie, Connull] QEII Med Ctr, Dept Anat Pathol, PathWest, Nedlands, WA, Australia	Ching, D (reprint author), QEII Med Ctr, Dept Anat Pathol, PathWest, Nedlands, WA, Australia.	danielching.lh@gmail.com					Bongiovanni M, 2014, INT J SURG PATHOL, V22, P749, DOI 10.1177/1066896914531814; CARCANGIU ML, 1984, AM J SURG PATHOL, V8, P655, DOI 10.1097/00000478-198409000-00005; Decaussin M, 2002, AM J SURG PATHOL, V26, P1007, DOI 10.1097/01.PAS.0000021229.30983.23; Dettmer M, 2011, AM J SURG PATHOL, V35, P1866, DOI 10.1097/PAS.0b013e31822cf962; Gnemmi V, 2014, HISTOPATHOLOGY, V64, P263, DOI 10.1111/his.12246; Hiltzik D, 2006, CANCER-AM CANCER SOC, V106, P1286, DOI 10.1002/cncr.21739; Ibrahimpasic T, 2014, J CLIN ENDOCR METAB, V99, P1245, DOI 10.1210/jc.2013-3842; Lloyd RV, 2017, WHO CLASSIFICATION T; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/mpath.2008.10; Rivera M, 2010, HUM PATHOL, V41, P172, DOI 10.1016/j.humpath.2009.08.011; Volante M, 2007, AM J SURG PATHOL, V31, P1256, DOI 10.1097/PAS.0b013e3180309e6a	11	1	1	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									7290343	10.1155/2018/7290343			4	Pathology	Pathology	GP0RT	WOS:000440518900001	30112239	DOAJ Gold, Green Published			2019-10-28	
J	Mass, J; Talmon, G				Mass, Jirong (Betty); Talmon, Geoffrey			Undifferentiated Pleomorphic Sarcoma of Liver: Case Report and Review of the Literature	CASE REPORTS IN PATHOLOGY			English	Review							MALIGNANT FIBROUS HISTIOCYTOMA; SOFT-TISSUE TUMORS; CLASSIFICATION; PATHWAY; MFH	Undifferentiated pleomorphic sarcoma (UPS), previously known as malignant fibrous histiocytoma (MFH), is rarely reported in the liver as a primary site. We report a case of a previously healthy 56-year-old male, who presented with abdominal pain and jaundice. The patient was originally diagnosed with cholecystitis, treated with cholecystectomy, which was complicated by abdominal abscess. One week following discharge, the patient was readmitted with fever, chills, and leukocytosis. Computed tomography (CT) guided liver biopsies demonstrated an epithelioid to spindle cell neoplasm with markedly atypical nuclei and prominent necrosis infiltrating between hepatocytes. Immunohistochemical studies were negative for epithelial, melanocytic, and hematolymphoid differentiation. Positron emission tomography (PET) was performed, which showed a single markedly hypermetabolic central hepatic mass (14 x 8.5 x 8.5 cm) with likely central necrosis, consistent with primary malignancy. The patient was treated with one cycle of chemotherapy (doxorubicin and ifosfamide), refusing additional cycle due to medication side effects. The patient subsequently succumbed to complications associated with the malignancy and died within 19 days of diagnosis.	[Mass, Jirong (Betty); Talmon, Geoffrey] Univ Nebraska Med Ctr, Omaha, NE 68198 USA	Talmon, G (reprint author), Univ Nebraska Med Ctr, Omaha, NE 68198 USA.	gtalmon@unmc.edu					ALBERTIFLOR JJ, 1985, GASTROENTEROLOGY, V89, P890, DOI 10.1016/0016-5085(85)90588-8; Becerikli M, 2014, ANTICANCER RES, V34, P7119; Boxberg M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1389366; Brooks JSJ, 2015, J SURG ONCOL, V111, P513, DOI 10.1002/jso.23853; Caldeira A, 2010, REV ESP ENFERM DIG, V102, P146, DOI 10.4321/s1130-01082010000200013; Cipriani NA, 2014, HUM PATHOL, V45, P1504, DOI 10.1016/j.humpath.2014.03.002; Derre J, 2001, LAB INVEST, V81, P211, DOI 10.1038/labinvest.3780229; Dodd RD, 2016, CANCER-AM CANCER SOC, V122, P17, DOI 10.1002/cncr.29730; Fletcher CDM, 2006, HISTOPATHOLOGY, V48, P3, DOI 10.1111/j.1365-2559.2005.02284.x; Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050; Kelleher Fergal C, 2013, Cancers (Basel), V5, P218, DOI 10.3390/cancers5010218; Kikuta K, 2015, BBA-PROTEINS PROTEOM, V1854, P696, DOI 10.1016/j.bbapap.2014.08.012; Konstantinopoulos PA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009747; Kresse SH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015378; Larramendy ML, 2008, CANCER GENET CYTOGEN, V187, P1, DOI 10.1016/j.cancergencyto.2008.06.005; Liu Y., 2018, CLIN NUCL MED, V6; Matushansky I, 2009, EXPERT REV ANTICANC, V9, P1135, DOI 10.1586/ERA.09.76; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nascimento AF, 2008, J SURG ONCOL, V97, P330, DOI 10.1002/jso.20972; Nishio J, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-153; OBRIEN JE, 1964, CANCER, V17, P1445, DOI 10.1002/1097-0142(196411)17:11<1445::AID-CNCR2820171112>3.0.CO;2-G; Roland CL, 2016, ANN SURG ONCOL, V23, P2220, DOI 10.1245/s10434-016-5115-5; Rosenberg AE, 2013, CURR OPIN ONCOL, V25, P571, DOI 10.1097/01.cco.0000432522.16734.2d; Ruping K, 2014, J CANCER RES CLIN, V140, P1315, DOI 10.1007/s00432-014-1700-9; Serrano C, 2016, CANCER-AM CANCER SOC, V122, P99, DOI 10.1002/cncr.29733; Tong YF, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007110; Tos APD, 2006, HISTOPATHOLOGY, V48, P51, DOI 10.1111/j.1365-2559.2005.02289.x; Weiss SW, 2014, ENZINGER WEISSS SOFT; Wong P, 2015, ONCOTARGET, V6, P39127, DOI 10.18632/oncotarget.3926; Wushou A, 2015, ONCOTARGET, V6, P41875, DOI 10.18632/oncotarget.6174; Yao DB, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-2; Ye SA, 2018, CANCER RES, V78, P2705, DOI 10.1158/0008-5472.CAN-17-4052	32	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8031253	10.1155/2018/8031253			5	Pathology	Pathology	GP0RV	WOS:000440519100001	30105111	DOAJ Gold, Green Published			2019-10-28	
J	Mathew, MR; Ramdas, A; Kurian, SS; Kuruvilla, L; Singh, N				Mathew, Manju Rachel; Ramdas, Anita; Kurian, Susy S.; Kuruvilla, Linu; Singh, Neelima			A Rare Malignant Transformation of an Ovarian Cystic Teratoma: A Case Report	CASE REPORTS IN PATHOLOGY			English	Article							UROTHELIAL CARCINOMA; CELL CARCINOMA; UROPLAKIN III	Mature cystic teratoma (MCT) is the commonest germ cell neoplasm of the ovary but malignant transformation is a rare occurrence (1-2%). Of these malignancies documented in literature the commonest are squamous cell carcinoma and adenocarcinoma. Urothelial carcinomas arising in an MCT are a rare occurrence and only 7 cases have been reported in literature. We report a case of an MCT which was complicated by the presence of urothelial carcinoma confirmed on histopathological examination.	[Mathew, Manju Rachel; Ramdas, Anita; Kurian, Susy S.] Pondicherry Inst Med Sci, Dept Pathol, Kalapet 605014, Puducherry, India; [Kuruvilla, Linu] Pondicherry Inst Med Sci, Dept Radiodiag, Kalapet 605014, Puducherry, India; [Singh, Neelima] Pondicherry Inst Med Sci, Dept Obstet & Gynecol, Kalapet 605014, Puducherry, India	Mathew, MR (reprint author), Pondicherry Inst Med Sci, Dept Pathol, Kalapet 605014, Puducherry, India.	manjumathew36@hotmail.com					Al-Rayyan ES, 2009, SAUDI MED J, V30, P524; Chuang HY, 2015, TAIWAN J OBSTET GYNE, V54, P442, DOI 10.1016/j.tjog.2015.06.003; Dasgupta S, 2015, CLIN CANCER INVESTIG, V4, P534, DOI 10.4103/2278-0513.159781; Kido A, 1999, AM J ROENTGENOL, V172, P445, DOI 10.2214/ajr.172.2.9930800; Kikkawa F, 1998, CANCER, V82, P2249, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2249::AID-CNCR21>3.0.CO;2-T; Kurman RJ, 2014, WHO CLASSIFICATION T; Lee HH, 1999, KOREAN J OBSTET GYNE, V42, p[1123, 1123]; Lee OJ, 2010, KOREAN J PATHOL, V44, P666, DOI 10.4132/KoreanJPathol.2010.44.6.666; Li W, 2014, AM J CLIN PATHOL, V142, P864, DOI 10.1309/AJCP1J0JPJBPSUXF; Movahedi-Lankarani S., 2017, PROTOCOL EXAMINATION; Rosai J, 2011, ROSAI ACKERMANS SURG, P1553; Smith SC, 2014, HISTOPATHOLOGY, V65, P132, DOI 10.1111/his.12360; STAMP GWH, 1983, BRIT J OBSTET GYNAEC, V90, P671, DOI 10.1111/j.1471-0528.1983.tb09289.x; Yamaguchi K, 2008, ONCOL REP, V19, P705	14	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									UNSP 6892783	10.1155/2018/6892783			4	Pathology	Pathology	GO2RL	WOS:000439824200001	30112238	DOAJ Gold, Green Published			2019-10-28	
J	Al-Zahid, S; Wright, T; Reece, P				Al-Zahid, Saif; Wright, Tanwen; Reece, Philip			Laryngeal Inflammatory Pseudotumour Secondary to Mycobacterium kansasii	CASE REPORTS IN PATHOLOGY			English	Article							SPINDLE-CELL PSEUDOTUMOR; MYOFIBROBLASTIC TUMOR; INFECTION; PATIENT	Background. Inflammatory pseudotumours(IPT)are rare benign tumours characterised by spindle-shaped histiocyte proliferation often mimicking a soft tissue sarcoma. They can occur in different parts of the body and various aetiological factors have been proposed. To our knowledge this is the first case report of IPT of the larynx caused by mycobacterial disease. Case Report. We report a case of IPT of the larynx in an immunocompromised 81-year-old lady presenting with stridor and dysphagia with known disseminated Mycobacterium kansasii of the lungs. Conclusion. This case demonstrates both the clinical and histological difficulties in making the diagnosis of IPT. A high index of suspicion is needed, and the importance of a multidisciplinary approach in the work-up, diagnosis, and management is highlighted.	[Al-Zahid, Saif] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England; [Wright, Tanwen] Torbay Hosp, Dept Histopathol, Torquay, England; [Reece, Philip] Torbay Hosp, Dept Otolaryngol, Torquay, England	Al-Zahid, S (reprint author), Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.	saif.alzahid@gmail.com					Alhumaid H, 2011, INT J HEALTH SCI-IJH, V5, P187; Boylan K. E., 2018, INT J SURG PATHOLOGY; Dava CJ, 2012, ECANCERMEDICALSCIENC, V6, DOI 10.3332/ecancer.2012.273; Evans AJ, 1996, THORAX, V51, P1243, DOI 10.1136/thx.51.12.1243; Hanna SJ, 2005, INT J PEDIATR OTORHI, V69, P1253, DOI 10.1016/j.ijporl.2005.02.023; Haworth CS, 2017, THORAX, V72, DOI 10.1136/thoraxjnl-2017-210927; Ilyas S, 2011, HEAD NECK PATHOL, V5, P296, DOI 10.1007/s12105-011-0248-0; Kansara S, 2016, NEURORADIOL J, V29, P440, DOI 10.1177/1971400916665377; Kapoor V., 2018, BMJ CASE REPORTS; King YA, 2017, J DERMATOL, V44, P1396, DOI 10.1111/1346-8138.13973; Lemoine M, 2015, AM J TRANSPLANT, V15, P3255, DOI 10.1111/ajt.13433; Logani S, 1999, AM J SURG PATHOL, V23, P656, DOI 10.1097/00000478-199906000-00004; MANNI JJ, 1992, EUR ARCH OTO-RHINO-L, V249, P16, DOI 10.1007/BF00175664; Patnana M, 2012, AM J ROENTGENOL, V198, pW217, DOI 10.2214/AJR.11.7288; Phowthongkum P, 2008, INT J INFECT DIS, V12, P421, DOI 10.1016/j.ijid.2007.11.010; Ramotar H, 2016, J LARYNGOL OTOL, V130, P107, DOI 10.1017/S0022215115002868; SEKOSAN M, 1994, AM J SURG PATHOL, V18, P1065, DOI 10.1097/00000478-199410000-00010; WENIG BM, 1995, CANCER-AM CANCER SOC, V76, P2217, DOI 10.1002/1097-0142(19951201)76:11<2217::AID-CNCR2820761107>3.0.CO;2-N; Yeh I, 2011, AM J DERMATOPATH, V33, pE66, DOI 10.1097/DAD.0b013e3182120ae3; Zitsch RP, 2007, OTOLARYNG HEAD NECK, V136, P139, DOI 10.1016/j.otohns.2005.11.044	20	0	0	1	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									UNSP 9356243	10.1155/2018/9356243			5	Pathology	Pathology	GO2RQ	WOS:000439824700001	30105112	DOAJ Gold, Green Published			2019-10-28	
J	Brandli-Baiocco, A; Balme, E; Bruder, M; Chandra, S; Hellmann, J; Hoenerhoff, MJ; Kambara, T; Landes, C; Lenz, B; Mense, M; Rittinghausen, S; Satoh, H; Schorsch, F; Seeliger, F; Tanaka, T; Tsuchitani, M; Wojcinski, Z; Rosol, TJ				Brandli-Baiocco, Annamaria; Balme, Emmanuelle; Bruder, Marc; Chandra, Sundeep; Hellmann, Juergen; Hoenerhoff, Mark J.; Kambara, Takahito; Landes, Christian; Lenz, Barbara; Mense, Mark; Rittinghausen, Susanne; Satoh, Hiroshi; Schorsch, Frederic; Seeliger, Frank; Tanaka, Takuji; Tsuchitani, Minoru; Wojcinski, Zbigniew; Rosol, Thomas J.			Nonproliferative and Proliferative Lesions of the Rat and Mouse Endocrine System	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						diagnostic pathology; nomenclature; pituitary; pituicytes; hypophysis; pineal; pinealocytes; thyroid; follicular cells; C cells; chief cells; adrenal; cortical cells; medullary cells; pancreas; islets; islets of Langerhans; parathyroid	ISLET-CELL TUMORS; PINEAL-GLAND; PARATHYROID-GLAND; PANCREATIC-ISLETS; TRANSGENIC MICE; ADRENAL-MEDULLA; THYROID-GLAND; BRAIN-TUMORS; SPONTANEOUS GANGLIONEUROMA; NONNEOPLASTIC LESIONS	The INHAND (International Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice) Project (www. toxpath.org/inhand.asp) is a joint initiative among the Societies of Toxicological Pathology from Europe (ESTP), Great Britain (BSTP), Japan (JSTP) and North America (STP) to develop an internationally accepted nomenclature for proliferative and nonproliferative lesions in laboratory animals. The purpose of this publication is to provide a standardized nomenclature for classifying microscopic lesions observed in the endocrine organs (pituitary gland, pineal gland, thyroid gland, parathyroid glands, adrenal glands and pancreatic islets) of laboratory rats and mice, with color photomicrographs illustrating examples of the lesions. The standardized nomenclature presented in this document is also available electronically on the internet (http://www.goreni.org/). Sources of material included histopathology databases from government, academia, and industrial laboratories throughout the world. Content includes spontaneous and aging lesions as well as lesions induced by exposure to test materials. A widely accepted and utilized international harmonization of nomenclature for endocrine lesions in laboratory animals will decrease confusion among regulatory and scientific research organizations in different countries and provide a common language to increase and enrich international exchanges of information among toxicologists and pathologists.	[Brandli-Baiocco, Annamaria; Landes, Christian; Lenz, Barbara] Roche Innovat Ctr, Roche Pharma Res & Early Dev, Pharmaceut Sci, Basel, Switzerland; [Balme, Emmanuelle] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Bruder, Marc] Compugen Inc, Nonclin Safety, San Francisco, CA USA; [Chandra, Sundeep] BioMarin Pharmaceut Inc, San Rafael, CA USA; [Hellmann, Juergen] Merck KGaA, D-64293 Darmstadt, Germany; [Hoenerhoff, Mark J.] Univ Michigan, Sch Med, Unit Lab Anim Med, In Vivo Anim Core, Ann Arbor, MI USA; [Kambara, Takahito] AbbVie, Preclin Safety, N Chicago, IL USA; [Mense, Mark] Covance, Chantilly, VA USA; [Rittinghausen, Susanne] Fraunhofer ITEM, Dept Pathol, Hannover, Germany; [Satoh, Hiroshi] Iwate Univ, Fac Agr, Morioka, Iwate, Japan; [Schorsch, Frederic] Bayer CropSci, Sophia Antipolis, France; [Seeliger, Frank] AstraZeneca Pathol Drug Safety & Metab, IMED Biotech Unit, Gothenburg, Sweden; [Tanaka, Takuji] Tohkai Cytopathol Inst, Canc Res & Prevent, Gifu, Japan; [Tsuchitani, Minoru] LSI Med Corp, Nonclin Res Ctr, Ibaraki, Japan; [Wojcinski, Zbigniew] Toxicol & Pathol Consulting LLC, Ann Arbor, MI USA; [Rosol, Thomas J.] Ohio Univ, Dept Biomed Sci, 1 Ohio Univ, Athens, OH 45701 USA	Rosol, TJ (reprint author), Ohio Univ, Dept Biomed Sci, 1 Ohio Univ, Athens, OH 45701 USA.	rosolt@ohio.edu					Abe M, 2012, J TOXICOL PATHOL, V25, P11, DOI 10.1293/tox.25.11; Ackermann MR, 2012, PATHOLOGIC BASIS VET, P51; Adeghate E, 2010, EXP CLIN ENDOCR DIAB, V118, P699, DOI 10.1055/s-0030-1253395; AGUZZI A, 1990, New Biologist, V2, P533; Aigelsreiter A, 2007, PATHOBIOLOGY, V74, P145, DOI 10.1159/000103374; ALLEN DJ, 1982, AGE, V5, P119, DOI 10.1007/BF02431274; Alonso G, 2003, EUR J NEUROSCI, V18, P1889, DOI 10.1046/j.1460-9568.2003.02927.x; ALTENAHR E, 1974, VIRCHOWS ARCH A, V363, P333, DOI 10.1007/BF00447844; ALZUBAIDY AJ, 1984, LAB ANIM, V18, P224, DOI 10.1258/002367784780958295; Anderson MP, 1978, PATHOLOGY LAB ANIMAL, P424; Apps JR, 2017, BRAIN PATHOL, V27, P364, DOI 10.1111/bpa.12501; Armocida AD, 1994, J TOXICOL PATHOL, V7, P87; Asamoto M, 2001, TOXICOL PATHOL, V29, P363, DOI 10.1080/019262301316905327; ATTIA MA, 1985, ARCH TOXICOL, V57, P77, DOI 10.1007/BF00343114; Bartels T, 2016, TOXICOL PATHOL, V44, P931, DOI 10.1177/0192623316665721; BELLONI AS, 1989, J ANAT, V165, P107; Bertolino P, 2003, CANCER RES, V63, P4836; BOMHARD E, 1993, EXP TOXICOL PATHOL, V45, P269; Boorman GA, 1996, MONOGRAPHS PATHOLOGY, P262; Boorman GA, 1990, ATLAS TUMOR PATHOL, P222; Boorman GA, 1999, PATHOLOGY MOUSE REFE, P185; Bosse R, 1997, NEURON, V19, P127, DOI 10.1016/S0896-6273(00)80353-0; Botts S, 1994, IARC SCI PUBL, P1; Botts S, 1991, GUIDES TOXICOLOGIC P, P1; Brandao Rafael Augusto Castro Santiago, 2010, Surg Neurol Int, V1, P79, DOI 10.4103/2152-7806.73802; Burek JD, 1978, PATHOLOGY AGING RAT, P38; CALVO J, 1984, J ANAT, V138, P45; Capella C, 2004, WHO CLASSIFICATION T, P205; Capen C C, 1975, Adv Vet Sci Comp Med, V19, P249; Capen C C, 1993, Monogr Pathol, P1; Capen CC, 1997, TOXICOL PATHOL, V25, P39, DOI 10.1177/019262339702500109; CAPEN CC, 1989, TOXICOL PATHOL, V17, P333, DOI 10.1177/019262338901700210; CAPEN CC, 1989, TOXICOL PATHOL, V17, P266, DOI 10.1177/019262338901700205; Capen CC, 1996, MONOGRAPHS PATHOLOGY, P3; Capen CC, 1990, ATLAS TUMOR PATHOL, P368; Capen CC, 2001, INT CLASSIFICATION R, P269; Carlton WW, 1996, MONOGRAPHS PATHOLOGY, P109; Chamanza R, 2010, TOXICOL PATHOL, V38, P642, DOI 10.1177/0192623310368981; Chandra S, 2013, TOXICOL PATHOL, P655; Chou FC, 2013, J DIABETES RES, DOI 10.1155/2013/138412; COCA S, 1992, CLIN NEUROPATHOL, V11, P298; Crabtree JS, 2003, MOL CELL BIOL, V23, P6075, DOI 10.1128/MCB.23.17.6075-6085.2003; Crabtree JS, 2001, P NATL ACAD SCI USA, V98, P1118, DOI 10.1073/pnas.98.3.1118; CRISSMAN JW, 1991, VET PATHOL, V28, P354, DOI 10.1177/030098589102800502; DIEHL BJM, 1978, CELL TISSUE RES, V195, P359; DILL RE, 1963, ACTA ANAT, V54, P310; DILLBERGER JE, 1994, TOXICOL PATHOL, V22, P48, DOI 10.1177/019262339402200107; Doi T., 2004, J TOXICOL PATHOL, V17, P197; DUNN TB, 1970, JNCI-J NATL CANCER I, V44, P1323; Duprat P, 1990, PATHOLOGY TUMOURS LA, V1, P573; Ehses JA, 2007, DIABETES, V56, P2356, DOI 10.2337/db06-1650; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Elmore SA, 2016, TOXICOL PATHOL, V44, P173, DOI 10.1177/0192623315625859; Elmore SA, 2013, TOXICOL PATHOL, V41, P151, DOI 10.1177/0192623312467102; Engeland WC, 1999, AM J PHYSIOL-REG I, V276, pR1374; Everds NE, 2013, TOXICOL PATHOL, V41, P560, DOI 10.1177/0192623312466452; Faccini JM, 1990, MOUSE HISTOPATHOLOGY, P169; Figarella-Branger D, 2002, ACTA NEUROPATHOL, V104, P313, DOI 10.1007/s00401-002-0557-1; FITZGERA.JE, 1974, J NATL CANCER I, V52, P265, DOI 10.1093/jnci/52.1.265; FITZGERALD JE, 1971, LAB ANIM SCI, V21, P581; FRASER H, 1986, FOOD CHEM TOXICOL, V24, P105, DOI 10.1016/0278-6915(86)90344-3; FRITH CH, 1991, TOXICOL PATHOL, V19, P123, DOI 10.1177/019262339101900206; FRITH CH, 1984, J GERONTOL, V39, P7, DOI 10.1093/geronj/39.1.7; Frith CH, 1988, COLOR ATLAS NEOPLAST, P7; Frith CH, 1994, PATHOLOGY TUMOURS LA, V2, P595; Frith CH, 1996, MONOGRAPHS PATHOLOGY, P333; Frith CH, 1996, MONOGRAPHS PATHOLOGY, P361; Frith CH, 2000, GUIDES TOXICOLOGIC P, P1; Frith CH, 1996, ENDOCRINE SYSTEM, P386; Furukawa S, 1999, J VET MED SCI, V61, P41, DOI 10.1292/jvms.61.41; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; GLAISTER J R, 1977, Laboratory Animals (London), V11, P35, DOI 10.1258/002367777780959238; Goodman DG, 1996, MONOGRAPHS PATHOLOGY, P464; Gopinath C, 2014, ATLAS TOXICOLOGICAL, P169; GOTZ W, 1992, ACTA NEUROPATHOL, V83, P308; Greaves P., 2012, HISTOPATHOLOGY PRECL, P740; Greaves P., 2012, HISTOPATHOLOGY PRECL, P727; Greaves P, 1992, RAT HISTOPATHOLOGY G, P222; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P1, DOI 10.1016/B978-0-444-53856-7.00001-4; Gunther T, 2000, NATURE, V406, P199, DOI 10.1038/35018111; Hamlin II MH, 1990, PATHOLOGY FISCHER RA, P501; Hardisty J. F., 1990, PATHOLOGY FISCHER RA, P519; Hardisty JF, 1999, PATHOLOGY MOUSE, P537; Harvey PW, 2010, J APPL TOXICOL, V30, P617, DOI 10.1002/jat.1569; Heath JE, 1998, TOXICOL PATHOL, V26, P294, DOI 10.1177/019262339802600217; Heath JE, 1996, MONOGRAPHY PATHOLOGY, P448; HEIDER K, 1986, VET PATHOL, V23, P522, DOI 10.1177/030098588602300427; Hershkovitz L, 2007, ENDOCRINOLOGY, V148, P976, DOI 10.1210/en.2006-1100; Hill GD, 2003, ENDOCR PATHOL, V14, P81, DOI 10.1385/EP:14:1:81; Hirato J, 2001, J NEURO-ONCOL, V54, P239, DOI 10.1023/A:1012721723387; Hoenerhoff MJ, NTP NONNEOPLASTIC LE, P1; HOPPENER JWM, 1994, J CELL BIOCHEM, V55, P39, DOI 10.1002/jcb.240550006; HOSOKAWA S, 1993, TOXICOL PATHOL, V21, P283, DOI 10.1177/019262339302100303; HUGGINS C, 1961, J EXP MED, V114, P741, DOI 10.1084/jem.114.5.741; HUMBERT W, 1995, J PINEAL RES, V18, P32, DOI 10.1111/j.1600-079X.1995.tb00137.x; Imaoka M, 2007, TOXICOL PATHOL, V35, P388, DOI 10.1080/01926230701230304; Imaoka M, 2009, TOXICOL PATHOL, V37, P218, DOI 10.1177/0192623308329283; Imazawa T, 2001, TOXICOL PATHOL, V29, P320, DOI 10.1080/019262301316905273; Inoue S, 1996, LAB INVEST, V74, P670; Iwata H, 2000, TOXICOL PATHOL, V28, P568, DOI 10.1177/019262330002800410; JAMESON JL, 1992, AM J PATHOL, V140, P75; JANAT MF, 1987, EXP BIOL, V46, P217; JOHNSON KH, 1992, LAB INVEST, V66, P522; Jokinen MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; JONES IC, 1952, PROC R SOC SER B-BIO, V139, P398, DOI 10.1098/rspb.1952.0020; Jones TC, 1997, VET PATHOL, P1223; Jouvet A, 2006, RUSSELL RUBINSTEINS, P413; KALTER H, 1968, TERATOLOGY, V1, P193, DOI 10.1002/tera.1420010208; Kamino K, 1996, MONOGRAPHS PATHOLOGY, P350; KANNO J, 1992, TOXICOL PATHOL, V20, P226, DOI 10.1177/019262339202000209; KANNO J, 1994, TOXICOL PATHOL, V22, P23, DOI 10.1177/019262339402200104; Karbe E, 1996, MONOGRAPHS PATHOLOGY, P114; Kaspareit J, 1999, EXP TOXICOL PATHOL, V51, P105, DOI 10.1016/S0940-2993(99)80079-7; KASPAREITRITTINGHAUSEN J, 1990, J COMP PATHOL, V102, P421, DOI 10.1016/S0021-9975(08)80163-6; KASPAREITRITTINGHAUSEN J, 1989, VET PATHOL, V26, P195, DOI 10.1177/030098588902600302; Kittel B, 1996, MONOGRAPHS PATHOLOGY, P328; Kiupel M, 2008, HISTOLOGICAL CLASSIF, P38; Koestner A, 1996, MONOGRAPHS PATHOLOGY, P205; Koivisto C, 2012, TOXICOL PATHOL, V40, P751, DOI 10.1177/0192623312441407; Kokoshima H, 2014, TOXICOL PATHOL, V42, P565, DOI 10.1177/0192623313491858; KORF HW, 1990, J NEUROPATH EXP NEUR, V49, P424, DOI 10.1097/00005072-199007000-00006; KRINKE G, 1985, J COMP PATHOL, V95, P175, DOI 10.1016/0021-9975(85)90004-0; Krinke GJ, 2000, TOXICOL PATHOL, V28, P178, DOI 10.1177/019262330002800123; Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150; KRSTIC R, 1972, Z ZELLFORSCH MIK ANA, V128, P227, DOI 10.1007/BF00306900; KUCHELMEISTER K, 1994, ACTA NEUROPATHOL, V88, P448; Kumar V, 2010, ROBBINS COTRAN PATHO, P79; Laast VA, 2014, TOXICOL PATHOL, V42, P823, DOI 10.1177/0192623313502258; Landes C, 1996, MONOGRAPHS PATHOLOGY, P481; Laroque P, 1997, PATHOLOGY NEOPLASIA, P129; LEE AK, 1982, LAB INVEST, V47, P595; Leiter EH, 1996, PATHOBIOLOGY AGING M, P153; Levin S, 1999, TOXICOL PATHOL, V27, P484, DOI 10.1177/019262339902700419; LEWIS DJ, 1982, J COMP PATHOL, V92, P337, DOI 10.1016/0021-9975(82)90093-7; Libutti SK, 2003, CANCER RES, V63, P8022; Liebelt AG, 1994, PATHOLOGY TUMOURS LA, V2, P527; Lloyd RV, 1990, PATHOLOGY TUMOURS LA, V1, P499; Lloyd RV, 2004, PATHOLOGY GENETICS T, P169; Longeart LE, 1996, MONOGRAPHS PATHOLOGY, P421; Longnecker D. S., 1990, PATHOLOGY TUMORS LAB, VI, P241; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; MACKENZIE WF, 1990, PATHOLOGY FISCHER RA, P485; MAEKAWA A, 1984, GANN, V75, P784; Mahler JF, 1999, PATHOLOGY MOUSE REFE, P491; MAITA K, 1988, TOXICOL PATHOL, V16, P340, DOI 10.1177/019262338801600305; MAJEED SK, 1993, ARZNEIMITTEL-FORSCH, V43-1, P170; MAJEED SK, 1986, J COMP PATHOL, V96, P575, DOI 10.1016/0021-9975(86)90078-2; Majka JA, 1990, GUIDES TOXICOLOGIC P, P1; Maronpot RR, 2010, TOXICOL PATHOL, V38, P776, DOI 10.1177/0192623310373778; Martin-Lacave I, 2002, CELL TISSUE RES, V309, P361, DOI 10.1007/s00441-002-0599-7; Martinez MJ, 2001, VET PATHOL, V38, P470, DOI 10.1354/vp.38-4-470; MCCOMB DJ, 1985, J SUBMICR CYTOL PATH, V17, P517; McInnes EF, 2012, BACKGROUND LESIONS L, P17; Mense MG, 2018, BOORMANS PATHOLOGY R, P1; MOLENAAR WM, 1990, EXP NEUROL, V108, P1, DOI 10.1016/0014-4886(90)90001-9; Moroki T, 2015, J TOXICOL PATHOL, V28, P171, DOI [10.1293/tox.28.2015-0012, 10.1293/tox.2015-0012]; Moroki T, 2013, IN VIVO, V27, P465; Murthy ASK, 1990, ATLAS TUMOR PATHOL, P323; MURUGAIYAN P, 1995, GLIA, V15, P65, DOI 10.1002/glia.440150108; NAESER P, 1975, ACTA PATH MICRO IM A, VA 83, P120; Napalkov NP, 1990, PATHOLOGY TUMOURS LA, V1, P539; Neville AM, 1982, HUMAN ADRENAL CORTEX, P290; Nugent DA, 2008, TOXICOL PATHOL, V36, P529, DOI 10.1177/0192623308318209; Nyska A, 1999, PATHOLOGY MOUSE, P509; OHSHIMA M, 1986, CANCER RES, V46, P877; Oishi Y, 1992, J TOXICOL PATHOL, V5, P223; Okazaki Y, 1997, J VET MED SCI, V59, P833, DOI 10.1292/jvms.59.833; Osamura RY, 1996, MONOGRAPHS PATHOLOGY, P66; Pace V, 2003, VET PATHOL, V40, P203, DOI 10.1354/vp.40-2-203; Pace V, 2002, TOXICOL PATHOL, V30, P492, DOI 10.1080/01926230290105668; Pace V, 1997, VET PATHOL, V34, P146, DOI 10.1177/030098589703400207; Pace V, 2001, ACTA NEUROPATHOL, V101, P277; Parker GA, 1996, ENDOCRINE SYSTEM, P394; Patterson DR, 1995, GUIDES TOXICOLOGIC P, P1; Pilling AM, 2007, TOXICOL PATHOL, V35, P348, DOI 10.1080/01926230701230270; PRICE SC, 1988, TOXICOL LETT, V40, P37, DOI 10.1016/0378-4274(88)90181-6; PROSENC N, 1994, ANN NY ACAD SCI, V719, P64, DOI 10.1111/j.1749-6632.1994.tb56820.x; Quintanar-Stephano A, 2001, ENDOCR PATHOL, V12, P63, DOI 10.1385/EP:12:1:63; RAORUPANAGUDI S, 1992, VET PATHOL, V29, P278, DOI 10.1177/030098589202900402; REAVEN EP, 1981, J CLIN INVEST, V68, P75, DOI 10.1172/JCI110256; REBUFFAT P, 1992, CELL TISSUE RES, V270, P265, DOI 10.1007/BF00328012; REHM S, 1985, Z VERSUCHSTIERKD, V27, P249; REZNIK G, 1980, VET PATHOL, V17, P614, DOI 10.1177/030098588001700510; Reznik G, 1996, MONOGRAPHS PATHOLOGY, P427; Riley M. G. I., 1990, PATHOLOGY FISCHER RA, P545; Riley MGI, 1990, GUIDES TOXICOLOGIC P, P1; Robbins SL, 2010, ROBBINS COTRAN PATHO, P3; ROE FJC, 1995, FOOD CHEM TOXICOL, V33, pS1, DOI 10.1016/0278-6915(94)00139-F; Rosol TJ, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P2391, DOI 10.1016/B978-0-12-415759-0.00058-3; Rosol TJ, 2013, TOXICOL PATHOL, V41, P303, DOI 10.1177/0192623312472402; ROSOL TJ, 1989, TOXICOL PATHOL, V17, P346, DOI 10.1177/019262338901700211; ROSOL TJ, 1986, LAB INVEST, V54, P679; Rosol TJ, 2001, TOXICOL PATHOL, V29, P41, DOI 10.1080/019262301301418847; Rubinstein LJ, 1972, ATLAS TUMOR PATHOL 6, P279; RUSSFIELD A B, 1967, P391; Sakai Y, 2000, ANAT REC, V259, P60; Sandusky GE, 1996, MONOGRAPHS PATHOLOGY, P287; Sass B., 1996, MONOGRAPHS PATHOLOGY, P391; Satoh H, 2000, TOXICOL PATHOL, V28, P836, DOI 10.1177/019262330002800612; SCHACHNER M, 1984, CELL TISSUE RES, V237, P245, DOI 10.1007/BF00217142; SCHAETTI P, 1995, EXP TOXICOL PATHOL, V47, P129, DOI 10.1016/S0940-2993(11)80299-X; Seely JC, 1990, PATHOLOGY FISCHER RA, P537; SELYE H, 1950, AM J PATHOL, V26, P211; Shimoi A, 2001, J TOXICOL PATHOL, V14, P253; Shirai M, 2012, TOXICOL PATHOL, V40, P807, DOI 10.1177/0192623312441401; Solomon A, 1999, AM J PATHOL, V154, P1267, DOI 10.1016/S0002-9440(10)65378-3; Son WC, 2004, TOXICOL LETT, V153, P213, DOI 10.1016/j.toxlet.2004.03.024; SPENCER AJ, 1986, VET PATHOL, V23, P11, DOI 10.1177/030098588602300102; Steiner DJ, 2010, ISLETS, V2, P135, DOI 10.4161/isl.2.3.11815; Strandberg JD, 1996, MONOGRAPHS PATHOLOGY, P444; STROMBERG PC, 1983, VET PATHOL, V20, P291, DOI 10.1177/030098588302000305; TAJIMA K, 1985, TOXICOL APPL PHARM, V81, P393, DOI 10.1016/0041-008X(85)90410-7; TAKAOKA M, 1994, J VET MED SCI, V56, P989, DOI 10.1292/jvms.56.989; Tekeli S, 1997, TOXICOL PATHOL, V25, P516, DOI 10.1177/019262339702500515; Teta M, 2005, DIABETES, V54, P2557, DOI 10.2337/diabetes.54.9.2557; THEURING F, 1990, ONCOGENE, V5, P225; Tischler A.S., 1994, PATHOBIOLOGY AGING R, V2, P245; TISCHLER AS, 1990, LAB INVEST, V63, P44; Tischler AS, 1996, MONOGRAPHS PATHOLOGY, P405; Tischler AS, 1992, HISTOLOGY PATHOLOGIS, P363; TODD GC, 1986, VET PATHOL, V23, P110, DOI 10.1177/030098588602300202; Tomonari Y, 2012, J TOXICOL PATHOL, V25, P287, DOI 10.1293/tox.25.287; Treumann S, 2015, TOXICOL PATHOL, V43, P838, DOI 10.1177/0192623315572700; Tucker MJ, 1997, DIS WISTAR RAT, P193; UNGER PD, 1990, ARCH PATHOL LAB MED, V114, P892; VANZWIETEN MJ, 1983, AM J PATHOL, V110, P219; VAZQUEZ R, 1987, ACTA ANAT, V128, P171; Venalis A, 2005, AMYLOID AMYLOIDOSIS, P231; Vogel Hannes, 2003, Ann Diagn Pathol, V7, P387, DOI 10.1016/j.anndiagpath.2003.09.007; Walker V E, 1994, IARC Sci Publ, P731; Wallace MJ, 1999, NAT GENET, V21, P334; Ward J M, 1986, Adv Exp Med Biol, V206, P529; WARD JM, 1979, J NATL CANCER I, V62, P1067; WARD JM, 1979, J NATL CANCER I, V63, P849, DOI 10.1093/jnci/63.3.849; WARD JM, 1980, VET PATHOL, V17, P678, DOI 10.1177/030098588001700604; WARREN S, 1966, ARCH PATHOL, V82, P115; Weber K, 2009, J TOXICOL PATHOL, V22, P247, DOI 10.1293/tox.22.247; Wei XY, 2009, NEUROSCI LETT, V465, P27, DOI 10.1016/j.neulet.2009.06.059; WILD P, 1995, MICROSC RES TECHNIQ, V32, P120, DOI 10.1002/jemt.1070320207; Wong WPS, 2008, DIABETES, V57, P2737, DOI 10.2337/db06-1755; WRIGHT JA, 1990, J COMP PATHOL, V102, P475, DOI 10.1016/S0021-9975(08)80168-5; Yamakawa S, 1995, J TOXICOL PATHOL, V8, P117; YAMAMOTO O, 1991, J VET MED SCI, V53, P527, DOI 10.1292/jvms.53.527; Yamaoka T, 1998, J CLIN INVEST, V102, P294, DOI 10.1172/JCI2769; Yamazaki M, 2009, J TOXICOL PATHOL, V22, P133, DOI 10.1293/tox.22.133; Yarrington JT, 1996, PATHOBIOLOGY AGING M, P125; Yarrington JT, 1992, PATHOBIOLOGY AGING R, P227; Yasui Y, 2008, J TOXICOL PATHOL, V21, P105, DOI 10.1293/tox.21.105; Yasui Y, 2009, TOXICOL PATHOL, V37, P343, DOI 10.1177/0192623309333786; Yasuno H, 2013, J TOXICOL PATHOL, V26, P209, DOI 10.1293/tox.26.209; Yoshizawa K, 2010, TOXICOL PATHOL, V38, P1037, DOI 10.1177/0192623310382560; Zabka TS, 2011, TOXICOL PATHOL, V39, P664, DOI 10.1177/0192623311406934; ZWICKER GM, 1993, TOXICOL PATHOL, V21, P502, DOI 10.1177/019262339302100509	253	3	3	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3		S			1S	95S		10.1293/tox.31.1S			95	Pathology; Toxicology	Pathology; Toxicology	GN6AB	WOS:000439151200001	30158740	Bronze, Green Published			2019-10-28	
J	Ramos, MF; Baker, J; Atzpodien, EA; Bach, U; Brassard, J; Cartwright, J; Farman, C; Fishman, C; Jacobsen, M; Junker-Walker, U; Kuper, F; Moreno, MCR; Rittinghausen, S; Schafer, K; Tanaka, K; Teixeira, L; Yoshizawa, K; Zhang, H				Ramos, Meg Ferrell; Baker, Julia; Atzpodien, Elke-Astrid; Bach, Ute; Brassard, Jacqueline; Cartwright, James; Farman, Cynthia; Fishman, Cindy; Jacobsen, Matt; Junker-Walker, Ursula; Kuper, Frieke; Moreno, Maria Cecilia Rey; Rittinghausen, Susanne; Schafer, Ken; Tanaka, Kohji; Teixeira, Leandro; Yoshizawa, Katsuhiko; Zhang, Hui			Nonproliferative and Proliferative Lesions of the Rat and Mouse Special Sense Organs (Ocular eye and glands], Olfactory and Otic)	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article							SPRAGUE-DAWLEY-RATS; GRUENEBERG GANGLION NEURONS; RETINAL-PIGMENT EPITHELIUM; HARDERIAN-GLAND; VOMERONASAL ORGAN; IMMUNE PRIVILEGE; NASAL CAVITY; IN-VIVO; MORPHOLOGICAL DEFECTS; POSTNATAL-DEVELOPMENT		[Ramos, Meg Ferrell] AbbVie Inc, 1 North Waukegan Rd, N Chicago, IL 60064 USA; [Baker, Julia] Charles River Labs Inc, Frederick, MD USA; [Atzpodien, Elke-Astrid] F Hoffman La Roche Ltd, Basel, Switzerland; [Bach, Ute] Bayer AG, Wuppertal, Germany; [Cartwright, James; Jacobsen, Matt] AstraZeneca, Cambridge, England; [Farman, Cynthia] Farman Pathol, Reno, NV USA; [Fishman, Cindy] GlaxoSmithKline, King Of Prussia, PA USA; [Junker-Walker, Ursula] Novartis, Basel, Switzerland; [Kuper, Frieke] Netherlands Org Appl Sci Res TNO, Zeist, Netherlands; [Moreno, Maria Cecilia Rey] BASF SE, Ludwigshafen, Germany; [Rittinghausen, Susanne] Fraunhofer Inst Toxicol & Aerosol Res, Hannover, Germany; [Schafer, Ken] Vet Path Serv Inc, Mason, OH USA; [Tanaka, Kohji] Nippon Boehringer Ingelheim, Tokyo, Japan; [Teixeira, Leandro] Univ Wisconsin, Madison, WI 53706 USA; [Yoshizawa, Katsuhiko] Mukogawa Womens Univ, Osaka, Hyogo, Japan	Ramos, MF (reprint author), AbbVie Inc, 1 North Waukegan Rd, N Chicago, IL 60064 USA.	margaret.ramos@abbvie.com					Ackermann LJ, 1998, GUIDES TOXICOLOGIC P; ADAMS DR, 1992, MICROSC RES TECHNIQ, V23, P86, DOI 10.1002/jemt.1070230108; Adams ET, 2011, TOXICOL PATHOL, V39, P240, DOI 10.1177/0192623310391680; Agardh CD, 1997, J DIABETES COMPLICAT, V11, P158, DOI 10.1016/S1056-8727(96)00049-9; Albert DM, 2010, ARCH OPHTHALMOL-CHIC, V128, P212, DOI 10.1001/archophthalmol.2009.395; Anderson MG, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-1; Atsumi I., 2013, ANIM EYE RES, V32, P35; BALAZS EA, 1964, EXP EYE RES, V3, P57, DOI 10.1016/S0014-4835(64)80008-7; Bancroft JD, 2002, THEORY PRACTICE HIST, P258; Barrios AW, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00063; Barskey D., 2006, DUANES OPHTHALOMOLOG, P1; BIHUN CGD, 1995, VET PATHOL, V32, P1; Bishop PN., 2014, VITREOUS HLTH DIS, P3, DOI DOI 10.1007/978-1-4939-1086-1; Bobu C, 2008, VISION RES, V48, P424, DOI 10.1016/j.visres.2007.08.011; BOK D, 1993, J CELL SCI, P189; Boorman GA, 1990, PATHOLOGY FISCHER RA, P295; Botts S, 1999, PATHOLOGY MOUSE, P49; Boulton M., 1988, RETINAL PIGMENT EPIT, P68; Bourne WM, 2003, EYE, V17, P912, DOI 10.1038/sj.eye.6700559; Boycott B, 1999, INVEST OPHTH VIS SCI, V40, P1313; Brann JH, 2010, J NEUROSCI, V30, P15686, DOI 10.1523/JNEUROSCI.4316-10.2010; Brechbuhl J, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00087; Bredow L, 2014, MOL VIS, V20, P683; BREIPOHL W, 1989, CHEM SENSES, V14, P649, DOI 10.1093/chemse/14.5.649; Brinker T, 1997, ACTA NEUROPATHOL, V94, P493, DOI 10.1007/s004010050738; Brown D V, 1974, Trans Am Ophthalmol Soc, V72, P404; BUCKLEY LA, 1985, FUND APPL TOXICOL, V5, P341, DOI 10.1016/0272-0590(85)90082-X; BUTLER WH, 1987, TOXICOL PATHOL, V15, P143, DOI 10.1177/019262338701500203; CAINE R, 1975, INVEST OPHTH VISUAL, V14, P359; Carlton WW, 1991, MONOGRAPHS PATHOLOGY, P33; Cavallotti D, 2001, OPHTHALMOLOGICA, V215, P366, DOI 10.1159/000050887; CHANDRA M, 1993, LAB ANIM SCI, V43, P500; CHIQUOINE AD, 1958, ANAT REC, V132, P569, DOI 10.1002/ar.1091320406; Chiu T., 1991, MONOGRAPHS PATHOLOGY; Choi SO, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138076; CHUNG EH, 1992, INVEST OPHTH VIS SCI, V33, P2199; Coca-Prados Miguel, 2014, J Glaucoma, V23, pS36, DOI 10.1097/IJG.0000000000000107; Collinson JM, 2000, DEVELOPMENT, V127, P945; Corps KN, 2010, TOXICOL PATHOL, V38, P429, DOI 10.1177/0192623310364026; Cowan CM, 2002, MICROSC RES TECHNIQ, V58, P204, DOI 10.1002/jemt.10150; Crafoord S, 2014, VITREOUS HLTH DIS, P13; Cursiefen C, 2006, P NATL ACAD SCI USA, V103, P11405, DOI 10.1073/pnas.0506112103; CURTIS M. R., 1931, AMER JOUR CANCER, V15, P67; DAMICO DJ, 1984, INVEST OPHTH VIS SCI, V25, P564; Dawes LJ, 2014, DEV BIOL, V385, P291, DOI 10.1016/j.ydbio.2013.10.030; de la Rosa-Prieto C, 2010, DEV NEUROBIOL, V70, P961, DOI 10.1002/dneu.20838; De La Rosa-Prieto C, 2009, J COMP NEUROL, V517, P723, DOI 10.1002/cne.22188; Denlinger JL, 2014, VITREOUS HLTH DIS, P13; Doving KB, 1998, J EXP BIOL, V201, P2913; Dungworth DL, 1992, IARC SCI PUBL, V122, P1; Dungworth DL, 2001, INT CLASSIFICATION R, P87; Ebneter A, 2012, CLIN EXP OPHTHALMOL, V40, P626, DOI 10.1111/j.1442-9071.2011.02741.x; Eiben R, 1989, Lens Eye Toxic Res, V6, P269; Elmore SA, 2016, TOXICOL PATHOL, V44, P173, DOI 10.1177/0192623315625859; Elwell MR, 1990, IARC SCI PUBL, V99, P79; Ernst H, 1991, MONOGRAPHS PATHOLOGY, P44; Everitt JF, 1991, MONOGRAPHS PATHOLOGY, P40; Fernandez JRR, 2013, VET OPHTHALMOL, V16, P94, DOI 10.1111/vop.12070; Ferrara D, J EXP ZOOL A, V301, P297; Fielden MR, 2015, TOXICOL PATHOL, V43, P581, DOI 10.1177/0192623314553804; FIGGE FHJ, 1957, P SOC EXP BIOL MED, V96, P437; Finger TE, 2003, P NATL ACAD SCI USA, V100, P8981, DOI 10.1073/pnas.1531172100; FINGER TE, 1990, J COMP NEUROL, V294, P293, DOI 10.1002/cne.902940212; FITZGERA.JE, 1974, J NATL CANCER I, V52, P265, DOI 10.1093/jnci/52.1.265; Fleischer J, 2006, J NEUROCHEM, V98, P543, DOI 10.1111/j.1471-4159.2006.03894.x; Fleischer J, 2010, HISTOL HISTOPATHOL, V25, P909, DOI 10.14670/HH-25.909; FOSTER H L, 1958, J Am Vet Med Assoc, V133, P201; FOX DA, 1988, EXP EYE RES, V46, P613, DOI 10.1016/S0014-4835(88)80017-4; French DD, 2008, RETINA-J RET VIT DIS, V28, P889, DOI 10.1097/IAE.0b013e31816576ef; Frith CH, 1988, COLOR ATLAS NEO PLAS; Fuss SH, 2005, EUR J NEUROSCI, V22, P2649, DOI 10.1111/j.1460-9568.2005.04468.x; GAAFAR KM, 1995, ARZNEIMITTEL-FORSCH, V45-2, P1231; GARTNER S, 1981, OPHTHALMOLOGY, V88, P1307; GASKELL BA, 1990, ENVIRON HEALTH PERSP, V85, P275, DOI 10.2307/3430689; Geiss V, 1999, PATHOLOGY MOUSE, P471; GETCHELL ML, 1995, CELL TISSUE RES, V280, P139; Gopinath C, 1987, ATLAS EXPT TOXICOLOG; Grant Maxie M, 2007, JUBB KENNEDY PALMERS, V287-295, P454; Greaves P., 2000, HISTOPATHOLOGY PRECL, P823; Greaves P, 2013, J TOXICOL PATHOL, V26, p1S, DOI 10.1293/tox.26.1S; GREGORY MH, 1970, J PATHOL, V102, P139, DOI 10.1002/path.1711020304; Grierson I, 2000, EYE, V14, P492, DOI 10.1038/eye.2000.136; GROSS EA, 1987, TOXICOL APPL PHARM, V90, P359, DOI 10.1016/0041-008X(87)90129-3; Grubb BR, 2007, AM J PHYSIOL-CELL PH, V293, pC574, DOI 10.1152/ajpcell.00106.2007; Gruebbel MM, 2014, SPECIAL SENSES SYSTE; GRUNEBERG H, 1973, Z ANAT ENTWICKLUNGS, V140, P39, DOI 10.1007/BF00520716; Guillamon A, 1997, BRAIN RES BULL, V44, P377, DOI 10.1016/S0361-9230(97)00217-7; Gulbransen BD, 2008, J NEUROPHYSIOL, V99, P2929, DOI 10.1152/jn.00066.2008; Gutman DA, 2013, BRAIN STRUCT FUNCT, V218, P527, DOI 10.1007/s00429-012-0413-6; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Halfter W, 2014, VITREOUS HLTH DIS, P165, DOI DOI 10.1007/978-1-4939-1086-1; Halpern M, 2003, PROG NEUROBIOL, V70, P245, DOI 10.1016/S0301-0082(03)00103-5; Hardisty JF, 1999, TOXICOL PATHOL, V27, P618, DOI 10.1177/019262339902700602; HARKEMA JR, 1990, ENVIRON HEALTH PERSP, V85, P231, DOI 10.2307/3430686; HARKEMA JR, 1991, TOXICOL PATHOL, V19, P321, DOI 10.1177/0192623391019004-102; Harkema JR, 1996, MONOGRAPHS PATHOLOGY, P3; Haschek-Hock WM, 2004, HDB TOXICOLOGIC PATH, P761; Hassell JR, 2010, EXP EYE RES, V91, P326, DOI 10.1016/j.exer.2010.06.021; Hebel R, 1986, ANATOMY EMBRYOLOGY L, P218; Hebel R, 1976, ANATOMY LABORATORY R; Henriksson JT, 2009, INVEST OPHTH VIS SCI, V50, P3648, DOI 10.1167/iovs.08-2941; Herbert RA, 1999, PATHOLOGY MOUSE REFE, P259; HEYWOOD R, 1973, Laboratory Animals (London), V7, P19, DOI 10.1258/002367773781005914; Hockwin O, 1992, MANUAL OCULOTOXICITY; Hogan MJ, 1962, OPHTHALMIC PATHOLOGY, P58; Hottendorf GH., 1991, MONOGRAPHS PATHOLOGY, P156; Huard JMT, 1998, J COMP NEUROL, V400, P469; HUBERT MF, 1994, LAB ANIM SCI, V44, P561; HUGHES BA, 1998, RETINAL PIGMENT EPIT, P103; HUGHES WF, 1974, AM J PATHOL, V77, P237; Ibrahim KE, 2014, EXP TOXICOL PATHOL, V66, P89, DOI 10.1016/j.etp.2013.11.004; IVANINA TA, 1983, GRAEF ARCH CLIN EXP, V220, P32, DOI 10.1007/BF02307013; JENSEN RK, 1987, FUND APPL TOXICOL, V8, P217, DOI 10.1016/0272-0590(87)90120-5; Jeon CJ, 1998, J NEUROSCI, V18, P8936; JESTER JV, 1981, INVEST OPHTH VIS SCI, V20, P537; Jia CP, 2003, BRAIN RES, V977, P261, DOI 10.1016/S0006-8993(03)02693-3; Joshi M, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/192582; Jun AS, 2006, EXP EYE RES, V83, P890, DOI 10.1016/j.exer.2006.03.025; Kai K, 2006, TOXICOL PATHOL, V34, P223, DOI 10.1080/01926230600695557; Kalatzis V, 2007, PEDIATR RES, V62, P156, DOI 10.1203/PDR.0b013e31809fda89; Kang N, 2009, EUR J NEUROSCI, V29, P624, DOI 10.1111/j.1460-9568.2009.06638.x; Katahashi Tatsuaki, 1997, Auris Nasus Larynx, V24, P271, DOI 10.1016/S0385-8146(96)00036-3; Kaufmann W, 2012, TOXICOL PATHOL, V40, P87, DOI 10.1177/0192623312439125; Kingston ZS, 2014, VITREOUS HLTH DIS, P95; Kita T, 2014, VITREOUS HLTH DIS, P151, DOI DOI 10.1007/978-1-4939-1086-1; Kitagaki M, 2003, LAB ANIM-UK, V37, P249, DOI 10.1258/002367703766453100; Kittel B, 2004, EXP TOXICOL PATHOL, V55, P413, DOI 10.1078/0940-2993-00349; Kowalczuk L, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.2.3; Kreutzberg GW, 1997, GREENFIELDS NEUROPAT, V1, P85; Krinke AL, 1994, PATHOBIOLOGY AGING R, V2, P109; Krinke G, 2001, INT CLASSIFICATION R, P347; Krinke GJ, 1996, PATHOBIOLOGY AGING M, V2, P139; Krinke GK., 1991, MONOGRAPHS PATHOLOGY, P137; KUNO H, 1991, J VET MED SCI, V53, P607, DOI 10.1292/jvms.53.607; LAI YL, 1982, EXP EYE RES, V34, P219, DOI 10.1016/0014-4835(82)90056-2; LAI YL, 1980, INVEST OPHTH VIS SCI, V19, P849; LAPHAM LW, 1964, J NEUROPATH EXP NEUR, V23, P156; LEE KP, 1991, ARCH TOXICOL, V65, P292, DOI 10.1007/BF01968963; Lei YA, 2011, INVEST OPHTH VIS SCI, V52, P1865, DOI 10.1167/iovs.10-6019; Leininger JR, 1996, PATHOBIOLOGY AGING M, V1, P247; Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015; Levin S, 1999, TOXICOL PATHOL, V27, P484, DOI 10.1177/019262339902700419; Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402; Lewis JL, 1994, INHAL TOXICOL S, V6, P422; Liu CY, 2009, J COMP NEUROL, V516, P36, DOI 10.1002/cne.22096; Los LI, 2008, EYE, V22, P1223, DOI 10.1038/eye.2008.39; LUTJENDRECOLL E, 1972, A GRAEF ARCH KLIN EX, V183, P267, DOI 10.1007/BF00496154; Ma M, 2010, NEUROBIOLOGY OLFACTI; Ma MH, 2003, J NEUROSCI, V23, P317; Ma MH, 2007, CRIT REV BIOCHEM MOL, V42, P463, DOI 10.1080/10409230701693359; MACHEMER R, 1975, AM J OPHTHALMOL, V80, P1; Mamasuew K, 2008, EUR J NEUROSCI, V28, P1775, DOI 10.1111/j.1460-9568.2008.06465.x; Mamasuew K, 2011, CHEM SENSES, V36, P271, DOI 10.1093/chemse/bjq124; Verdaguer JM, 2006, LAB ANIMAL, V35, P40, DOI 10.1038/laban1106-40; MARKERT CL, 1956, GENETICS, V41, P429; Marmor MF., 1998, RETINAL PIGMENT EPIT, P3; MARONPOT RR, 1990, ENVIRON HEALTH PERSP, V85, P331, DOI 10.2307/3430693; MARSHALL DA, 1986, BRAIN RES, V366, P329, DOI 10.1016/0006-8993(86)91312-0; Martinez-Marcos A, 2000, J NEUROBIOL, V44, P423, DOI 10.1002/1097-4695(20000915)44:4<423::AID-NEU5>3.0.CO;2-H; Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877; Masli S, 2011, METHODS MOL BIOL, V677, P449, DOI 10.1007/978-1-60761-869-0_28; MASSOF RW, 1972, VISION RES, V12, P793, DOI 10.1016/0042-6989(72)90005-3; MATSUMURA M, 1986, OPHTHALMIC RES, V18, P47, DOI 10.1159/000265414; Matsuoka M, 2002, BRAIN RES, V946, P52, DOI 10.1016/S0006-8993(02)02823-8; Maurer JK, 1998, TOXICOL PATHOL, V26, P217, DOI 10.1177/019262339802600205; Maurer JK, 1996, TOXICOL PATHOL, V24, P403, DOI 10.1177/019262339602400403; MCCRACKEN JS, 1976, AM J PATHOL, V85, P167; MCGINN MD, 1982, ACTA OTO-LARYNGOL, V93, P61, DOI 10.3109/00016488209130853; McKay JS, 1998, NEUROPATH APPL NEURO, V24, P498; MCMARTIN DN, 1992, TOXICOL PATHOL, V20, P212, DOI 10.1177/019262339202000208; McMartin DN, 1997, GUIDES TOXICOLOGIC P; Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199; Mecklenburg L, 2013, J TOXICOL PATHOL, V26, p27S, DOI 10.1293/tox.26.27S; Mehta S, 2014, VITREOUS HLTH DIS, P395, DOI DOI 10.1007/978-1-4939-1086-1; Miyazaki M, 2001, J NUTR, V131, P2260; Mohr U, 1994, IARC PUBLICATION, V122, P34; MONTICELLO TM, 1990, ENVIRON HEALTH PERSP, V85, P249, DOI 10.2307/3430688; Morgan KT, 1996, MONOGRAPHS PATHOLOGY, P28; MORRISON JC, 1995, INVEST OPHTH VIS SCI, V36, P751; Morrison JC, 1999, INVEST OPHTH VIS SCI, V40, P1702; Mucignat-Caretta C, 2010, J COMP PHYSIOL A, V196, P767, DOI 10.1007/s00359-010-0555-z; Mudry MCD, 2013, TOXICOL PATHOL, V41, P813, DOI 10.1177/0192623312469308; Nagai N, 2011, SPONTANEOUS CNV NOVE; National Toxicology Program, 2010, Natl Toxicol Program Tech Rep Ser, P7; Nunez-Parra A, 2011, MOL CELL NEUROSCI, V47, P274, DOI 10.1016/j.mcn.2011.05.003; Nyska A, 2005, TOXICOL PATHOL, V33, P371, DOI 10.1080/01926230590930209; Oikawa T, 2001, J VET MED SCI, V63, P759, DOI 10.1292/jvms.63.759; Owen RA, 1991, MONOGRAPHS PATHOLOGY, P47; Palczewski K, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15502; PAULINI K, 1975, BEITR PATHOL, V156, P65, DOI 10.1016/S0005-8165(75)80086-2; PAYNE AP, 1994, J ANAT, V185, P1; Peichl L, 2005, ANAT REC PART A, V287A, P1001, DOI 10.1002/ar.a.20262; PERASALO R, 1974, ACTA OPHTHALMOL, P94; PERCY DH, 1989, VET PATHOL, V26, P238, DOI 10.1177/030098588902600308; POULSOM R, 1988, GRAEF ARCH CLIN EXP, V226, P31, DOI 10.1007/BF02172713; Pow DV, 2008, INVEST OPHTH VIS SCI, V49, P2790, DOI 10.1167/iovs.08-1757; Protti DA, 2005, J NEUROPHYSIOL, V93, P3479, DOI 10.1152/jn.00839.2004; Quantock AJ, 2008, DEV DYNAM, V237, P2607, DOI 10.1002/dvdy.21579; Ramos MF, 2017, COMPREHENSIVE GUIDE TO TOXICOLOGY IN NONCLINICAL DRUG DEVELOPMENT, 2ND EDITION, P757, DOI 10.1016/B978-0-12-803620-4.00029-3; Ramos M, 2011, FUNDAMENTAL NEUROPATHOLOGY FOR PATHOLOGISTS AND TOXICOLOGISTS: PRINCIPLES AND TECHNIQUES, P385; REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8; Render JA, 2013, TOXICOL PATHOL, P931; Renne R, 2009, TOXICOL PATHOL, V37, p5S, DOI 10.1177/0192623309353423; Restrepo D, 2004, HORM BEHAV, V46, P247, DOI 10.1016/j.yhbeh.2004.02.009; Reuber MD, 1976, TOXICOL PATHOL, V4, P5; Reynaud J, 2012, INVEST OPHTH VIS SCI, V53, P2951, DOI 10.1167/iovs.11-9274; Riordan-Eva P., 2011, VAUGHAN ASHBURYS GEN; Riviere S, 2009, NATURE, V459, P574, DOI 10.1038/nature08029; Robinson DA, 2003, TOXICOL PATHOL, V31, P340, DOI 10.1080/01926230390204388; ROE FJC, 1963, NATURE, V199, P1201, DOI 10.1038/1991201a0; Rohen J W, 1968, Albrecht Von Graefes Arch Klin Exp Ophthalmol, V175, P143, DOI 10.1007/BF02385060; Roppolo D, 2006, EUR J NEUROSCI, V23, P2887, DOI 10.1111/j.1460-9568.2006.04818.x; Rosolen SG, 2008, EXP TOXICOL PATHOL, V60, P17, DOI 10.1016/j.etp.2007.11.012; RUBIN LF, 1982, LAB ANIM SCI, V32, P64; Rubin LF, 1986, ANIM EYE RES, V5, P15; Rubin LF., 1974, ATLAS VET OPHTHALMOS; Rudmann D, 2012, TOXICOL PATHOL, V40, p7S, DOI 10.1177/0192623312454242; Ruggeri M, 2007, INVEST OPHTH VIS SCI, V48, P1808, DOI 10.1167/iovs.06-0815; Saidi T, 2011, GRAEF ARCH CLIN EXP, V249, P1029, DOI 10.1007/s00417-011-1641-9; Sakamoto T, 2011, RETINA-J RET VIT DIS, V31, P222, DOI 10.1097/IAE.0b013e3181facfa9; Sam Z, 2006, ENVIRON HEALTH PERSP, V114, P1099, DOI 10.1289/ehp.8854; Samuelson DA., 2007, VET OPHTHALMOLOGY, P62; SASHIMA M, 1989, ACTA ANAT, V135, P303; Saunders LZ, 1975, OPHTHALMIC PATHOLOGY, P122; Schafer K. A., 2013, ASSESSING OCULAR TOX, P159; Schafer K. A., 2013, ASSESSING OCULAR TOX, P219; Schafer KA, 2013, HASCHEK ROUSSEAUXS H; Schmid A, 2010, J NEUROSCI, V30, P7563, DOI 10.1523/JNEUROSCI.0608-10.2010; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schoevers E. J., 1994, Journal of Environmental Pathology Toxicology and Oncology, V13, P49; Schulz D, 2003, VISION RES, V43, P723, DOI 10.1016/S0042-6989(03)00005-1; Schwob James E., 2002, Anatomical Record, V269, P33, DOI 10.1002/ar.10047; SEBAG J, 1992, EYE, V6, P541, DOI 10.1038/eye.1992.119; Sebag J, 1989, VITREOUS STRUCTURE F; Secker GA, 2009, STEMBOOK; Senoh H, 2014, J TOXICOL PATHOL, V27, P139, DOI 10.1293/tox.2013-0066; Sha O., 2006, Neuroembryology and Aging, V4, P183, DOI 10.1159/000118928; Shi YR, 2013, INVEST OPHTH VIS SCI, V54, P7163, DOI 10.1167/iovs.13-12687; Shi YR, 2013, INVEST OPHTH VIS SCI, V54, P2504, DOI 10.1167/iovs.13-11619; Shibuya K, 1999, BIOL REFERENCE DATA, P60; Silvotti L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024462; Smith PM, 2006, BRAIN PATHOL, V16, P99, DOI 10.1111/j.1750-3639.2006.00001.x; Smith R. S., 2002, SYSTEMATIC EVALUATIO; SMITH RS, 1994, LAB ANIM SCI, V44, P551; Smith RS, 2002, RES METH MUT M SER, P111; Smith RS, 1996, INVEST OPHTH VIS SCI, V37, P397; Smith RS, 1996, PATHOBIOLOGY AGING M, V2, P139; Smith RS, 2002, SYSTEMATIC EVALUATIO, P3; Song JY, 2014, DEV BIOL, V386, P281, DOI 10.1016/j.ydbio.2013.12.037; Sonoda KH, 2005, IMMUNOLOGY, V116, P390, DOI 10.1111/j.1365-2567.2005.02239.x; Soucy ER, 2009, NAT NEUROSCI, V12, P210, DOI 10.1038/nn.2262; SPIT BJ, 1993, CELL TISSUE RES, V274, P329, DOI 10.1007/BF00318751; St Clair MGB, 1992, PATHOBIOLOGY AGING R, P111; Stahl A, 2010, INVEST OPHTH VIS SCI, V51, P2813, DOI 10.1167/iovs.10-5176; STEINBACH E, 1980, J LARYNGOL OTOL, V94, P269, DOI 10.1017/S0022215100088782; Stewart H. L., 1979, PATHOLOGY TUMOURS LA, V1, P251; Storan MJ, 2006, J COMP NEUROL, V494, P834, DOI 10.1002/cne.20858; Streilein JW, 2003, NAT REV IMMUNOL, V3, P879, DOI 10.1038/nri1224; Su CY, 2009, CELL, V139, P45, DOI 10.1016/j.cell.2009.09.015; Suzukawa K, 2011, J COMP NEUROL, V519, P2154, DOI 10.1002/cne.22611; Suzuki Y, 1998, ANN NY ACAD SCI, V855, P252, DOI 10.1111/j.1749-6632.1998.tb10577.x; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Tanaka K, 1996, TOXICOL PATHOL, V24, P639, DOI 10.1177/019262339602400516; TANAKA K, 1994, LAB ANIM SCI, V44, P71; Tanaka K, 1995, J TOXICOL PATHOL, V8, P161; Tanaka K, 1993, J TOXICOL PATHOL, V6, P205; TARADACH C, 1984, CRC CR REV TOXICOL, V12, P121, DOI 10.3109/10408448409023759; TARADACH C, 1981, LAB ANIM, V15, P285, DOI 10.1258/002367781780893759; Taylor AW, 2009, EYE, V23, P1885, DOI 10.1038/eye.2008.382; Taylor AW, 2010, OCUL IMMUNOL INFLAMM, V18, P488, DOI 10.3109/09273948.2010.525730; Teixeira LBC, 2013, HASCHEK ROUSSEAUXS H, P2135; Teixeira L, 2013, HASCHEK AND ROUSSEAUX'S HANDBOOK OF TOXICOLOGIC PATHOLOGY, VOL 1-3, 3RD EDITION, P2095, DOI 10.1016/B978-0-12-415759-0.00053-4; Tian HK, 2004, J NEUROSCI, V24, P8383, DOI 10.1523/JNEUROSCI.2222-04.2004; Tizzano M, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-3; Toyran S, 2005, BRIT J OPHTHALMOL, V89, P885, DOI 10.1136/bjo.2004.056374; Ueda J, 1998, JPN J OPHTHALMOL, V42, P337, DOI 10.1016/S0021-5155(98)00026-4; URAIH LC, 1990, ENVIRON HEALTH PERSP, V85, P187, DOI 10.2307/3430683; Van Winkle TJ., 1991, MONOGRAPHS PATHOLOGY, P21; Wagner JG, 2009, TOXICOL PATHOL, V37, P481, DOI 10.1177/0192623309335630; Ward JM, 2001, AM J PATHOL, V158, P323, DOI 10.1016/S0002-9440(10)63972-7; WASSLE H, 1991, PHYSIOL REV, V71, P447; Weiler E, 2005, CHEM SENSES, V30, pI127, DOI 10.1093/chemse/bjh147; Weiler E, 2003, CHEM SENSES, V28, P581, DOI 10.1093/chemse/bjg047; Weisse I., 1993, PATHOGIOLOGY AGING R, V2, P65; WESTWOOD FR, 1991, TOXICOL PATHOL, V19, P214, DOI 10.1177/019262339101900303; Wilkerson CL, 1996, ARCH OPHTHALMOL-CHIC, V114, P437, DOI 10.1001/archopht.1996.01100130433014; Williams D., 2007, EUR J COMPANION ANIM, V17, P242; Williams DL, 2002, VET OPHTHALMOL, V5, P183, DOI 10.1046/j.1463-5224.2002.00251.x; Wine JJ, 2007, AM J PHYSIOL-CELL PH, V293, pC537, DOI 10.1152/ajpcell.00183.2007; WORST JGF, 1992, DOC OPHTHALMOL, V82, P169, DOI 10.1007/BF00157007; Woutersen RA, 2010, TARG ORG T, P272; Yokosuka M, 2012, EXP ANIM TOKYO, V61, P13, DOI 10.1538/expanim.61.13; YOSHITOMI K, 1994, VET PATHOL, V31, P254, DOI 10.1177/030098589403100216; YOSHITOMI K, 1991, VET PATHOL, V28, P403, DOI 10.1177/030098589102800508; YOSHITOMI K, 1991, VET PATHOL, V28, P79, DOI 10.1177/030098589102800111; YOSHITOMI K, 1991, VET PATHOL, V28, P457, DOI 10.1177/030098589102800601; Yoshitomi K, 1990, PATHOLOGY FISCHER RA, P239; YOUNG C, 1974, Laboratory Animals (London), V8, P21, DOI 10.1258/002367774780943797; Zabka TS, 2015, TOXICOL SCI, V144, P163, DOI 10.1093/toxsci/kfu268; Zampighi GA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023753; Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598; Zhao F, 2013, RETINA-J RET VIT DIS, V33, P77, DOI 10.1097/IAE.0b013e3182602087; Zieske JD, 2004, INT J DEV BIOL, V48, P903, DOI 10.1387/ijdb.041860jz	303	1	1	1	2	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	3		S			97S	214S		10.1293/tox.31.97S			118	Pathology; Toxicology	Pathology; Toxicology	GN6AB	WOS:000439151200002	30158741	Bronze, Green Published			2019-10-28	
J	Kuroda, N; Sugawara, E; Kusano, H; Yuba, Y; Yorita, K; Takeuchi, K				Kuroda, Naoto; Sugawara, Emiko; Kusano, Hironori; Yuba, Yoshiaki; Yorita, Kenji; Takeuchi, Kengo			A REVIEW OF ALK-REARRANGED RENAL CELL CARCINOMAS WITH A FOCUS ON CLINICAL AND PATHOBIOLOGICAL ASPECTS	POLISH JOURNAL OF PATHOLOGY			English	Review						ALK; renal cell carcinoma; pathology; review	MUCONODULAR PAPILLARY TUMOR; LARGE SERIES; FUSION GENE; LUNG; IMMUNOHISTOCHEMISTRY; LYMPHOMA; CHILDREN; KINASE; CLASSIFICATION; IDENTIFICATION	ALK-rearranged renal cell carcinoma (ALK-RCC) has been recently proposed and incorporated into the recent World Health Organisation Classification of renal tumours as a provisional entity. In this article, we review ALK-RCC with a focus on clinical and pathobiological aspects. Seventeen cases have been described to date. ALK-RCC accounts for less than 1% of all renal tumours. The age of patients ranges from 6 to 61 years with a mean age of 29.6 years. Grossly, the tumour forms were ill-demarcated or well demarcated solid mass in the renal medulla. Histologically, RCC with VCL-ALK translocation resembles renal medullary carcinoma and mutinous cribriform pattern, signet-ring cell pattern and solid rhabdoid pattern are often observed in RCC with non-VCL-ALK fusion. Immunohistochemically, ALK protein diffusely expresses and TFE3 is often expressed. ALK gene can fuse to VCL, TPM3, EML4, HOOK] or STRN gene. A break-apart fluorescence in situ hybridisation study is clinically available for the practice of definite diagnosis. ALK inhibitor therapy will provide great benefit for patients with advanced stage of ALK-RCC in the near future.	[Kuroda, Naoto; Yorita, Kenji] Kochi Red Cross Hosp, Dept Diagnost Pathol, Shin Honmachi 2-13-51, Kochi, Kochi 7808562, Japan; [Sugawara, Emiko] Tokyo Med & Dent Univ Hosp, Devis Diagnost Pathol, Tokyo, Japan; [Kusano, Hironori] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka, Japan; [Yuba, Yoshiaki] Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Pathol, Osaka, Japan; [Takeuchi, Kengo] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo, Japan	Kuroda, N (reprint author), Kochi Red Cross Hosp, Dept Diagnost Pathol, Shin Honmachi 2-13-51, Kochi, Kochi 7808562, Japan.	kurochankcohi@yahoo.co.jp			Life Fund of Kochi Shimbun and Kochi Broadcast 2012	This study was approved by the Ethical Committee (no. 144) of Kochi Red Cross Hospital and was partly supported by Grant-in-Aid from Life Fund of Kochi Shimbun and Kochi Broadcast 2012.	Buraczewska A, 2016, WSPOLCZESNA ONKOL, V20, P481, DOI 10.5114/wo.2016.65609; Cajaiba MM, 2016, GENE CHROMOSOME CANC, V55, P814, DOI 10.1002/gcc.22382; Cajaiba MM, 2016, GENE CHROMOSOME CANC, V55, P442, DOI 10.1002/gcc.22346; Chen YB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13131; Chou A, 2015, AM J SURG PATHOL, V39, P652, DOI 10.1097/PAS.0000000000000368; Debelenko LV, 2011, MODERN PATHOL, V24, P430, DOI 10.1038/modpathol.2010.213; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; Ferician O, 2016, POL J PATHOL, V67, P46, DOI 10.5114/PJP.2016.59477; Hodge JC, 2013, MODERN PATHOL, V26, P604, DOI 10.1038/modpathol.2012.144; Jeanneau M, 2016, PATHOL RES PRACT, V212, P1064, DOI 10.1016/j.prp.2016.07.015; Jin Y, 2017, PATHOL INT, V67, P171, DOI 10.1111/pin.12512; Kuroda N, 2005, HISTOL HISTOPATHOL, V20, P221, DOI 10.14670/HH-20.221; Kuroda N, 2003, HISTOL HISTOPATHOL, V18, P487, DOI 10.14670/HH-18.487; Kuroda N, 2002, HISTOL HISTOPATHOL, V17, P1329, DOI 10.14670/HH-17.1329; Kuroda N, 2016, DIAGN HISTOPATHOL, V22, P47; Kuroda N, 2017, POL J PATHOL, V68, P66, DOI 10.5114/pjp.2017.67617; Kuroda N, 2016, POL J PATHOL, V67, P3, DOI 10.5114/PJP.2016.59227; Kuroda N, 2013, PATHOL INT, V63, P381, DOI 10.1111/pin.12080; Kuroda N, 2012, HISTOL HISTOPATHOL, V27, P133, DOI 10.14670/HH-27.133; Kusano H, 2016, AM J SURG PATHOL, V40, P761, DOI 10.1097/PAS.0000000000000610; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee C, 2013, KOREAN J PATHOL, V47, P452, DOI 10.4132/KoreanJPathol.2013.47.5.452; Liu QY, 2013, AM J SURG PATHOL, V37, P368, DOI 10.1097/PAS.0b013e3182770406; Marino-Enriquez A, 2011, GENE CHROMOSOME CANC, V50, P146, DOI 10.1002/gcc.20839; Moch H, 2016, WHO CLASSIFICATION T; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Perot G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087170; Rao Q, 2016, CHINESE J CANCER RES, V28, P29, DOI 10.3978/j.issn.1000-9604.2016.01.03; Ryan C, 2014, VIRCHOWS ARCH, V464, P241, DOI 10.1007/s00428-013-1520-3; Smith NE, 2014, AM J SURG PATHOL, V38, P858, DOI 10.1097/PAS.0000000000000179; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1; Sugawara E, 2012, CANCER-AM CANCER SOC, V118, P4427, DOI 10.1002/cncr.27391; Sukov WR, 2012, MODERN PATHOL, V25, P1516, DOI 10.1038/modpathol.2012.107; Taguchi R, 2017, PATHOL INT, V67, P99, DOI 10.1111/pin.12504; Thorner PS, 2016, PATHOL RES PRACT, V212, P937, DOI 10.1016/j.prp.2016.07.004; Udager AM, 2016, ARCH PATHOL LAB MED, V140, P1026, DOI 10.5858/arpa.2016-0218-RA; Yoshida A, 2011, AM J SURG PATHOL, V35, P1226, DOI 10.1097/PAS.0b013e3182233e06; YOSHIDA MA, 1986, CANCER RES, V46, P2139	39	1	1	0	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					109	113		10.5114/PJP.2018.76693			5	Pathology	Pathology	GM4PM	WOS:000438104000001	30351856	DOAJ Gold			2019-10-28	
J	Dzikowski, A; Szarek, J; Gulda, D; Babinska, I; Felsmann, MZ; Poplawski, K; Szynaka, B				Dzikowski, Andrzej; Szarek, Jozef; Gulda, Dominika; Babinska, Izabella; Felsmann, Mariusz Zbigniew; Poplawski, Krystian; Szynaka, Beata			WHERE ARE WE WITH POLISH PATHOLOGY AT THE TURN OF THE CENTURIES IN THE LIGHT OF THE CONGRESSES OF THE POLISH SOCIETY OF PATHOLOGISTS?	POLISH JOURNAL OF PATHOLOGY			English	Article						pathology; Polish Society of Pathologists; congresses in Poland	CANCER STATISTICS; MODELS	The aim of this study is to depict the current and past research directions in Polish pathology at the turn of the centuries. The analysis was based on the abstracts of the congresses of the Polish Society of Pathologists organized in 1992-2016 and concerned 1,824 presentations. It has been proven that oncology (1,090 presentations, 59.76%) was the most commonly discussed topic and dominated the dispute. Organ pathology was the area of research covered with over 1/4 of all papers (464 presentations, 25.44%), while subsequent topics played a marginal role: varia (86 presentations, 4.71%), infectious and parasitic diseases (84 presentations, 4.61%) and toxicopathology (56 presentations, 3.07%). A special, multidisciplinary category of veterinary pathology was particularized (44 presentations, 2.41%). Positive trend was revealed for oncology, while a downward one for the organ pathology, toxicopathology as well as pathology of infectious and parasitic diseases.	[Dzikowski, Andrzej; Szarek, Jozef; Babinska, Izabella; Poplawski, Krystian] Univ Warmia & Mazury, Dept Pathophysiol Forens Vet Med & Adm, Michala Oczapowskiego 13, PL-10719 Olsztyn, Poland; [Gulda, Dominika] Univ Sci & Technol Bydgoszcz, Dept Sheep Goat & Bearing Anim Breeding, Bydgoszcz, Poland; [Felsmann, Mariusz Zbigniew] Nicolaus Copernicus Univ Torun, Ctr Vet Sci, Torun, Poland; [Szynaka, Beata] Med Univ Bialystok, Dept Med Pathomorphol, Bialystok, Poland	Dzikowski, A (reprint author), Univ Warmia & Mazury, Dept Pathophysiol Forens Vet Med & Adm, Michala Oczapowskiego 13, PL-10719 Olsztyn, Poland.	andrzej.dzikowski@uwm.edu.pl	Szynaka, Beata/U-3316-2018	Szynaka, Beata/0000-0003-2640-7792			[Anonymous], 1992, POL J PATHOL, V43, P97; [Anonymous], 2001, POL J PATHOL, V52, P65; [Anonymous], 1998, POL J PATHOL, V49, P187; [Anonymous], 1995, POL J PATHOL, V46, P91; [Anonymous], 2013, POL J PATHOL S, V64, P1; [Anonymous], 2007, POL J PATHOL, V58, P107; [Anonymous], 2011, POL J PATHOL S, V62, P1; [Anonymous], 2004, POL J PATHOL, V55, P4; Bagi Cedo M, 2010, Cancers (Basel), V2, P1441, DOI 10.3390/cancers2031441; Berns A, 2013, MOL ONCOL, V7, P143, DOI 10.1016/j.molonc.2013.02.014; Botha JL, 2003, EUR J CANCER, V39, P1718, DOI 10.1016/S0959-8049(03)00118-7; Cekanova M, 2014, DRUG DES DEV THER, V8, P1911, DOI 10.2147/DDDT.S49584; Dzikowski A, 2017, POL J PATHOL, V68, P252, DOI [10.5114/PJP.2017.71533, 10.5114/pjp.2017.71533]; Gabriel A, 2014, MED SCI MONITOR, V20, P1510, DOI 10.12659/MSM.890762; Kobuszewska-Faryna M, 1995, PATOMORFOLOGIA WCZOR, V1, P15; Mataraza JM, 2016, BJU INT, V118, P506, DOI 10.1111/bju.13518; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; Ruggeri BA, 2014, BIOCHEM PHARMACOL, V87, P150, DOI 10.1016/j.bcp.2013.06.020; Santos NP, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695923; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; StatSoft Inc., 2017, EL STAT TXB; Streszczenia XX Jubileuszowego Zjazdu Polskiego Towarzystwa Patologow, 2016, POL J PATHOL S1, V67, P1; Vizcaino AP, 1998, INT J CANCER, V75, P536, DOI 10.1002/(SICI)1097-0215(19980209)75:4<536::AID-IJC8>3.3.CO;2-E	23	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					114	117		10.5114/PJP.2018.76694			4	Pathology	Pathology	GM4PM	WOS:000438104000002	30351857	DOAJ Gold			2019-10-28	
J	Gulczynski, J; Paluchowski, P; Halasz, J; Szarszewski, A; Bukowski, M; Izycka-Swieszewska, E				Gulczynski, Jacek; Paluchowski, Piotr; Halasz, Jacek; Szarszewski, Adam; Bukowski, Marek; Izycka-Swieszewska, Ewa			AN INSIGHT INTO THE HISTORY OF ANATOMOPATHOLOGICAL MUSEUMS. PART 2	POLISH JOURNAL OF PATHOLOGY			English	Article						pathology; museum; history; collections; preservation; ceroplastics	ANATOMY; MODELS; COLLECTIONS; PATHOLOGY; LOUIS	The second part of the comprehensive work concerning pathology museums and collections presents their history since the 19th century. The evolution and specialisation of museums, depending on the attitude of their creators and geographic localization, have been analysed. The changing aspects of obtaining the exhibits and how they were preserved, presented, and stored are also a part of this work. The methods of human organ fixation reached excellence in the 19th century, but the rarity of some pathologies urged the scientists to recreate them artificially in models for didactic purposes. In the 19th and 20th centuries one could observe the flourishing development with a plateau and then decline from the second part of the 20th century to the reorientation of the museums that took place in Europe and North America. The history of anatomopathological museums is connected with ethical problems related to acquisition of exhibits in previous centuries and especially during World War II. The changing purpose of the collections, as well as their unclear future and the impact on the visitors, are evident. For the last 50 years, many museums have been closing completely, but some collections have been digitalised and are still in permanent use. The uniqueness of old specimens with certain diseases, often long gone and not observed anymore, makes them important in many aspects nowadays. Pathology museums are themselves relics of the past, being at the same time tangible proof of ways of development in medicine, but also a way of preservation of human knowledge in a special type of relation with the human body.	[Gulczynski, Jacek; Izycka-Swieszewska, Ewa] Med Univ Gdansk, Dept Pathol & Neuropathol, Gdansk, Poland; [Paluchowski, Piotr; Halasz, Jacek; Szarszewski, Adam] Med Univ Gdansk, Dept Hist & Philosophy Med Sci, Tuwima 15, PL-80210 Gdansk, Poland; [Bukowski, Marek] Museum Med Univ Gdansk, Gdansk, Poland; [Izycka-Swieszewska, Ewa] COPERNICUS, Dept Pathomorphol, Gdansk, Poland	Paluchowski, P (reprint author), Med Univ Gdansk, Dept Hist & Philosophy Med Sci, Tuwima 15, PL-80210 Gdansk, Poland.	p.paluchowski@gumed.edu.pl	Szarszewski, Adam/U-7952-2018	Szarszewski, Adam/0000-0002-8913-2784; Halasz, Jacek/0000-0003-1976-8207; Paluchowski, Piotr/0000-0002-6525-3821			Altmann HW, 1992, VERH DTSCH GES PATHO, V76, P45; [Anonymous], 1926, BULLETIN, VIX; Baker JA, 2011, AM SURGEON, V77, P662; Barnes Joseph K., 1870, MED SURG HIST WAR RE; Bauer Axel W, 2003, Neuere Med Wiss Quellen Stud, V6, P41; Buttner S., 2003, NEUE DTSCH BIOGRAPHI, V21, P627; Campbell M, 2004, AUST NZ J OBSTET GYN, V44, P488, DOI 10.1111/j.1479-828X.2004.00335.x; Ciranni Rosalba, 2004, Med Secoli, V16, P31; Cocks MM, 2014, J HIST COLLECT, V26, P229, DOI 10.1093/jhc/fht036; Cooke RA, 2010, VIRCHOWS ARCH, V457, P513, DOI 10.1007/s00428-010-0983-8; Cornwall J, 2014, EUR J ANAT, V18, P209; Dallenbach-Hellweg G, 1999, INT J GYNECOL PATHOL, V18, P281, DOI 10.1097/00004347-199907000-00016; de Saint-Maur PP, 2012, VIRCHOWS ARCH, V460, P109, DOI 10.1007/s00428-011-1162-2; Di Matteo B, 2015, CLIN ORTHOP RELAT R, V473, P783, DOI 10.1007/s11999-014-3909-y; Durakiewicz M, 2006, ACTA ANGIOL, V12, P187; Ellis H, 2008, BRIT J HOSP MED, V69, P471, DOI 10.12968/hmed.2008.69.8.30745; Geiges ML, 2009, J AM ACAD DERMATOL, V60, P980, DOI 10.1016/j.jaad.2008.07.021; Gryglewski Ryszard W, 2015, Przegl Lek, V72, P707; Hermes da Fonseca L, 2006, VERFUHRERISCHE LEICH; Holzmann A, 1929, VIRCHOWS ARCH A, V272, P531, DOI 10.1007/BF02070853; Hughes J T, 2007, J Med Biogr, V15, P116; Katner W., 1966, NEUE DTSCH BIOGRAPHI, V7, P13; Keppie L, 2007, W HUNTER HUNTERIAN M; Klee E., 2005, AUSCHWITZ MED 3 RZES; Korf H- W, 2004, HESSISCHES ARZTEBLAT, V3, P132; Kortner UHJ, 2007, KOMMERZIALISIERUNG M, P83; Kozuszek W., 2007, ROZWOJ ANATOMII PATO, P108; Krietsch P, 1986, Zentralbl Allg Pathol, V131, P145; Krietsch P, 1996, PATHOLOGISCH ANATOMI; Lakhani SR, 2012, PATHOLOGY S1, V44; Malinowski A., 2010, MUZEA ANATOMICZNE AN; Markov D, 2010, Akush Ginekol (Sofiia), V49, P56; Matyssek Angela, 2002, R VIRCHOW PATHOLOGIS; Mendis D, 2003, J Med Biogr, V11, P212; Morciniec P., 2009, BIOETYKA PERSONALIST; Murphey MD, 2012, RADIOLOGY, V262, P623, DOI 10.1148/radiol.11111357; Musial Agata, 2016, Folia Med Cracov, V56, P31; Nesi Gabriella, 2013, Med Secoli, V25, P295; Ohne Schnalke T., 2007, ACTA HISTORICA LEOP, V48, P217; Olry R, 2000, J INT SOC PLASTINATI, V15, P30; Pagel JL, 1905, ALLGEMEINE DTSCH BIO, V50, P293; Paluchowski P, 2016, POL J PATHOL, V67, P207, DOI [10.5114/PJP.2016.63771, 10.5114/pjp.2016.63771]; Sabat Daniel, 2004, Polish Journal of Pathology, V55, P75; Schnalke T, 2010, 2 BLICK BESONDERE OB, P238; SOLENTE G, 1983, AM J DERMATOPATH, V5, P483; Toomsalu Maie, 2011, Papers on Anthropology University of Tartu, V20, P11; van den Tweel JG, 2010, VIRCHOWS ARCH, V457, P3, DOI 10.1007/s00428-010-0934-4	47	1	1	1	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					118	127		10.5114/PJP.2018.76695			10	Pathology	Pathology	GM4PM	WOS:000438104000003	30351858	DOAJ Gold			2019-10-28	
J	Kuroda, N; Yorita, K				Kuroda, Naoto; Yorita, Kenji			CLINICOPATHOLOGIC STUDY OF 10 CASES OF GASTRIC ADENOCARCINOMA WITH HEPATOID OR ENTEROBLASTIC DIFFERENTIATION	POLISH JOURNAL OF PATHOLOGY			English	Article						stomach; hepatoid; enteroblastic; clinicopathological study; differentiation; adenocarcinoma	HEPATOCELLULAR-CARCINOMA; STOMACH; CANCER; FEATURES	Gastric adenocarcinoma with hepatoid or enteroblastic differentiation (GAHED), known also as AFP-producing carcinoma, is a rare neoplasm. Ten cases with GAHED and 209 cases without GAHED were selected. Clinicopathological features of GAHED were investigated. The disease-free survival (DFS) of the GAHED group was compared with that of the non-GAHED group. Grossly, the tumours consisted of two early types and eight advanced types. Histologically, all tumours were composed of various proportions of tubular, cribriform, papillary, solid, and/or trabecular growth patterns of clear to slightly eosinophilic tumour cells. Hyaline globules were observed in all tumours. AFP and Hep-Par1 were immunoreactive in all tumours. In fluorescence in situ hybridisation of HER2 gene/chromosome 17, the amplification of HER2 gene was observed in two cases that showed positive reaction for HER2 protein. Clinical follow-up was available in nine cases. Regarding the clinical outcome, 3 and 6 patients were alive without disease and alive with disease, respectively. In a statistical analysis, the DFS of the GAHED group was significantly worse than that of the non-GAHED group. GAHED is morphologically characterised by various growth patterns of clear to slightly eosinophilic tumour cells and intracytoplasmic possession of hyaline globules. This tumour may have the potential to behave in an aggressive clinical fashion.	[Kuroda, Naoto; Yorita, Kenji] Kochi Red Cross Hosp, Dept Diagnost Pathol, Kochi, Kochi, Japan	Kuroda, N (reprint author), Kochi Red Cross Hosp, Dept Pathol, Shin Honmachi 2-13-51, Kochi, Kochi 7808562, Japan.	kurochankochi@yahoo.co.jp					DELORIMIER A, 1993, CANCER, V71, P293, DOI 10.1002/1097-0142(19930115)71:2<293::AID-CNCR2820710204>3.0.CO;2-O; Deng YJ, 2016, WSPOLCZESNA ONKOL, V20, P311, DOI 10.5114/wo.2016.61852; Galvez-Munoz Elisa, 2009, Int Semin Surg Oncol, V6, P13, DOI 10.1186/1477-7800-6-13; Hwang SW, 2012, BASIC APPL PATHOL, V5, P22; Ishikura H, 1997, HISTOPATHOLOGY, V31, P47, DOI 10.1046/j.1365-2559.1997.5740812.x; ISHIKURA H, 1985, CANCER-AM CANCER SOC, V56, P840, DOI 10.1002/1097-0142(19850815)56:4<840::AID-CNCR2820560423>3.0.CO;2-E; ISHIKURA H, 1986, CANCER, V58, P119, DOI 10.1002/1097-0142(19860701)58:1<119::AID-CNCR2820580121>3.0.CO;2-U; Kinjo T, 2012, AM J SURG PATHOL, V36, P56, DOI 10.1097/PAS.0b013e31823aafec; Kishimoto Takashi, 2000, Medical Electron Microscopy, V33, P57, DOI 10.1007/s007950070002; Matsumoto K, 2016, WORLD J GASTROENTERO, V22, P8203, DOI 10.3748/wjg.v22.i36.8203; MATSUNOU H, 1994, CANCER, V73, P534, DOI 10.1002/1097-0142(19940201)73:3<534::AID-CNCR2820730307>3.0.CO;2-X; MOTOYAMA T, 1993, ACTA PATHOL JAPON, V43, P654; Murakami T, 2016, GASTRIC CANCER, V19, P498, DOI 10.1007/s10120-015-0497-9; Roberts CC, 1997, MAYO CLIN PROC, V72, P1154, DOI 10.4065/72.12.1154; Su JS, 2013, WORLD J GASTROENTERO, V19, P321, DOI 10.3748/wjg.v19.i3.321; Ushiku T, 2010, AM J SURG PATHOL, V34, P533, DOI 10.1097/PAS.0b013e3181d1dcdd; Yang JL, 2014, GASTROENT RES PRACT, DOI 10.1155/2014/140587	17	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					128	135		10.5114/PJP.2018.76696			8	Pathology	Pathology	GM4PM	WOS:000438104000004	30351859	DOAJ Gold			2019-10-28	
J	Jovanovic, MP; Mihaljevic, B; Jovanovic, P; Jelicic, J; Martinovic, VC; Jovanovic, J; Fekete, MD; Cekerevac, M; Bojanic, N				Jovanovic, Maja Perunicic; Mihaljevic, Biljana; Jovanovic, Petar; Jelicic, Jelena; Martinovic, Vesna Cemerikic; Jovanovic, Jelica; Fekete, Marija Dencic; Cekerevac, Milica; Bojanic, Nebojsa			CLINICOPATHOLOGICAL AND FLUORESCENCE IN SITU HIBRIDISATION ANALYSIS OF PRIMARY TESTICULAR DIFFUSE LARGE B -CELL LYMPHOMA: A SINGLE-CENTRE CASE SERIES	POLISH JOURNAL OF PATHOLOGY			English	Article						primary testicular lymphoma; diffuse large B cell lymphoma	RITUXIMAB PLUS CYCLOPHOSPHAMIDE; MYC STATUS; EXPRESSION; FEATURES; TISSUE; BCL2; CLASSIFICATION; VINCRISTINE; DOXORUBICIN; PREDNISONE	Primary testicular diffuse large B-cell lymphoma (PT-DLBCL) represents a rare and aggressive extranodal non-Hodgkin's lymphoma (NHL) with some specific features that differ from other NHLs. Formalin fixed, paraffin wax embedded (FFPE) samples of 21 PT-DLBCLs and 30 comparative patients with DLBCL were analysed. All PT-DLBCL patients were treated with rituximab-containing regimens, intrathecal prophylaxis (10 patients), and irradiation of the contralateral testis (9 patients). FFPE samples were additionally analysed by immunohistochemistry (Bcl-2, c-Myc protein expression) and fluorescence in situ hybridisation (FISH) (BCL2 and MYC). The patients with PT-DLBCL (median age 48.5 years), had low frequency of B symptoms (28.6%) and were often diagnosed in I and II Ann Arbor clinical stage (66.0%). The majority of PT-DLBCL (80.9%) had a non-germinal centre B-cell-like immunophenotype. Immunohistochemical staining showed increased c-Myc protein expression in the PT-DLBCL group compared to the control group (p = 0.016). MYC rearrangement was detected in 1 of 14 (7.0%), and MYC amplification in 3 of 14 (21.0%) patients. One of the 14 cases (7.0%) in the PT-DLBCL group showed BCL2 rearrangement, and four of 14 (28.05%) cases showed BCL2 amplification. Complete remission (CR) was achieved in 75.0% of PT-DLBCL patients who had superior survival compared to those who did not achieve CR (median 48 vs. 21 months, p = 0.012). Patients with PT-DLBCL express some immunohistochemical, biological, and clinical features that might differentiate them from nodal and extranodal DLBCL patients, indicating the need for a more personalised treatment approach.	[Jovanovic, Maja Perunicic; Cekerevac, Milica] Clin Ctr Serbia, Dept Pathol, Belgrade, Serbia; [Mihaljevic, Biljana; Jelicic, Jelena; Jovanovic, Jelica; Fekete, Marija Dencic] Clin Ctr Serbia, Clin Haematol, Belgrade, Serbia; [Mihaljevic, Biljana; Bojanic, Nebojsa] Univ Belgrade, Fac Med, Belgrade, Serbia; [Jovanovic, Petar] Univ Pristina Serbian, Fac Med, Kosovo, Serbia; [Martinovic, Vesna Cemerikic] Beo Lab, Belgrade, Serbia; [Bojanic, Nebojsa] Clin Ctr Serbia, Urol Clin, Belgrade, Serbia	Jovanovic, MP (reprint author), KosteTodorovica 2 Str, Belgrade 11000, Serbia.	majaperunicicjovanovic@yahoo.com					Bernasconi B, 2014, LEUKEMIA LYMPHOMA, V55, P1410, DOI 10.3109/10428194.2013.834055; Booman M, 2006, J PATHOL, V210, P163, DOI 10.1002/path.2033; Chapuy B, 2016, BLOOD, V127, P869, DOI 10.1182/blood-2015-10-673236; Cheah CY, 2014, BLOOD, V123, P486, DOI 10.1182/blood-2013-10-530659; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Chin SF, 2003, J CLIN PATHOL-MOL PA, V56, P275, DOI 10.1136/mp.56.5.275; Deng L, 2016, LEUKEMIA, V30, P361, DOI 10.1038/leu.2015.237; Fonseca R, 2000, CANCER, V88, P154, DOI 10.1002/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2-T; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Gundrum JD, 2009, J CLIN ONCOL, V27, P5227, DOI 10.1200/JCO.2009.22.5896; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Horn H, 2013, BLOOD, V121, P2253, DOI 10.1182/blood-2012-06-435842; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Karube K, 2015, SEMIN HEMATOL, V52, P97, DOI 10.1053/j.seminhematol.2015.01.009; Kridel R, 2017, BRIT J HAEMATOL, V176, P210, DOI 10.1111/bjh.14392; Menter T, 2014, HEMATOL ONCOL, V32, P72, DOI 10.1002/hon.2090; Schmitz N, 2016, HEMATOL ONCOL CLIN N, V30, P1277, DOI 10.1016/j.hoc.2016.07.008; Scott DW, 2014, BLOOD, V123, P1214, DOI 10.1182/blood-2013-11-536433; SHIPP MA, 1993, NEW ENGL J MED, V329, P987; Stein H, 2008, WHO CLASSIFICATION T; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2014, HEMATOL-AM SOC HEMAT, P90, DOI 10.1182/asheducation-2014.1.90; Twa DDW, 2018, BLOOD REV, V32, P249, DOI 10.1016/j.blre.2017.12.001; Twa DDW, 2015, J PATHOL, V236, P136, DOI 10.1002/path.4522; Vaidya R, 2014, ANN ONCOL, V25, P2124, DOI 10.1093/annonc/mdu109; Visco C, 2013, HAEMATOLOGICA, V98, P255, DOI 10.3324/haematol.2012.066209; Wang XJ, 2015, AM J SURG PATHOL, V39, P1250, DOI 10.1097/PAS.0000000000000433; Zucca E, 2003, J CLIN ONCOL, V21, P20, DOI 10.1200/JCO.2003.11.141	28	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					136	142		10.5114/PJP.2018.76697			7	Pathology	Pathology	GM4PM	WOS:000438104000005	30351860	DOAJ Gold			2019-10-28	
J	Kilicarslan, A; Dogan, HT; Sungu, N; Dogan, M; Yalcin, A; Dede, DS				Kilicarslan, Aydan; Dogan, Hayriye Tatli; Sungu, Nuran; Dogan, Mehmet; Yalcin, Abdussamet; Dede, Didem Sener			ASSOCIATION BETWEEN HER2/NEU STATUS IN COLORECTAL CARCINOMA AND CLINICOPATHOLOGICAL FEATURES: A RETROSPECTIVE STUDY USING WHOLE - TISSUE SECTIONS	POLISH JOURNAL OF PATHOLOGY			English	Article						colorectal cancer; Her2/neu; immunohistochemistry; in situ hybridization	PROGNOSTIC VALUE; BREAST-CANCER; HER-2/NEU OVEREXPRESSION; GENE AMPLIFICATION; OVER-EXPRESSION; COLON-CANCER; C-ERBB-2; PROTEIN; IMMUNOHISTOCHEMISTRY; METAANALYSIS	The human epidermal growth factor receptor 2 (Her2/neu) signal pathway plays a significant role in the occurance of various solid tumor types. The rate of Her2/neu in colorectal carcinoma (CRC) is not clearly elucidated. In this study, we discuss the association between Her2/neu overexpression and clinicopathological parameters in CRC. Her2/neu immunohistochemical (IHC) staining was performed on whole sections of formalin fixed paraffin embedded tumor tissues of 100 CRC resections. Cases with score 3+ and score 2+ expressions were further evaluated by silver in-situ hybridization (ISH) for the existence of Her2/neu gene amplification. Her2/neu membranous overexpression was observed in 12 of the 100 cases (6 cases with a score 3+ and 6 cases with a score 2+) and 6 of these were heterogenous. There were 10 cases with Her2/neu amplification (6/6 score 3+, 4/6 score 2 +). Strong cytoplasmic staining was observed in 5 cases. Membranous scores were either 3+ or 2+ in 3 of these 5 cases. Moreover, there was Her2/neu amplification in 2 of these 3 cases. Her2/neu amplification status and overexpression was not related to clinicopathological parameters and overall survival. More clear results can be obtained from studies with Her2/neu IHC and ISH test on whole sections.	[Kilicarslan, Aydan; Dogan, Hayriye Tatli; Sungu, Nuran] Yildirim Beyazit Univ, Dept Pathol, Eskisehir Yolu,Lodumlu Mevkii 2, Ankara, Turkey; [Dogan, Mehmet] Dr Abdurrahman Yurtaslan Oncol Educ & Res Hosp, Dept Pathol, Ankara, Turkey; [Yalcin, Abdussamet] Yildirim Beyazit Univ, Dept Surg, Ankara, Turkey; [Dede, Didem Sener] Yildirim Beyazit Univ, Dept Oncol, Ankara, Turkey	Kilicarslan, A (reprint author), Yildirim Beyazit Univ, Dept Pathol, Eskisehir Yolu,Lodumlu Mevkii 2, Ankara, Turkey.	dr.kilicaydan@gmail.com	Dogan, Mehmet/A-6890-2015	Dogan, Mehmet/0000-0001-8806-0400			Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Bang YJ, 2010, LANCET, V376, P1302; Bernhard H, 2002, ENDOCR-RELAT CANCER, V9, P33, DOI 10.1677/erc.0.0090033; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Blok EJ, 2013, CLIN MED INSIGHTS-ON, V7, P41, DOI 10.4137/CMO.S10811; Ciardiello F, 2011, CANCER DISCOV, V1, P472, DOI 10.1158/2159-8290.CD-11-0261; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Demirbas Sezai, 2006, Turk J Gastroenterol, V17, P13; Drecoll E, 2014, INT J COLORECTAL DIS, V29, P663, DOI 10.1007/s00384-014-1857-3; Dursun Ayse, 2001, Pathology and Oncology Research, V7, P24; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fuchs EM, 2014, INT J CANCER, V135, P224, DOI 10.1002/ijc.28660; Gutierrez C, 2011, ARCH PATHOL LAB MED, V135, P55, DOI 10.1043/2010-0454-RAR.1; Half E, 2004, INT J CANCER, V108, P540, DOI 10.1002/ijc.11599; Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483; Ieni A, 2015, DIS MARKERS, DOI 10.1155/2015/234851; Josef R, 2012, MODERN PATHOLOGY, V25, P637; Kavanagh DO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1; Kim JY, 2004, APPL IMMUNOHISTO M M, V12, P67; Kountourakis P, 2006, CANCER J, V12, P229, DOI 10.1097/00130404-200605000-00012; Kruszewski WJ, 2010, DIS MARKERS, V29, P207, DOI 10.3233/DMA-2010-0742; Lee AHS, 2014, J CLIN PATHOL, V67, P573, DOI 10.1136/jclinpath-2013-201978; Li QG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-277; Lim SW, 2013, CELL ONCOL, V36, P311, DOI 10.1007/s13402-013-0136-6; Long TH, 2015, AM J CLIN PATHOL, V144, P253, DOI 10.1309/AJCP3Q9WFOQTKUVV; Marx AH, 2010, HUM PATHOL, V41, P1577, DOI 10.1016/j.humpath.2010.02.018; McIntire M, 2012, ARCH PATHOL LAB MED, V136, P496, DOI 10.5858/arpa.2011-0167-RA; Molina R, 1998, BREAST CANCER RES TR, V51, P109, DOI 10.1023/A:1005734429304; Nathanson DR, 2003, INT J CANCER, V105, P796, DOI 10.1002/ijc.11137; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Park DI, 2007, INT J COLORECTAL DIS, V22, P491, DOI 10.1007/s00384-006-0192-8; Pyo JS, 2016, INT J BIOL MARKER, V31, pE389, DOI 10.5301/jbm.5000208; Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645; Rossi HA, 2002, CANCER J, V8, P268, DOI 10.1097/00130404-200205000-00011; Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9; Simon R, 2001, J NATL CANCER I, V93, P1141, DOI 10.1093/jnci/93.15.1141; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Song ZJ, 2014, INT J CLIN EXP PATHO, V7, P4454; Tavangar S, 2005, MED SCI MONITOR, V11, pCR123; Tong LC, 2011, AM J SURG PATHOL, V35, P545, DOI 10.1097/PAS.0b013e31820e6237; Tu JH, 2015, EXP THER MED, V9, P17, DOI 10.3892/etm.2014.2063; Uner A, 2005, EXP ONCOL, V27, P225; Wu SW, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0380-3; Wu SW, 2014, TUMOR BIOL, V35, P10799, DOI 10.1007/s13277-014-2376-0	44	0	0	0	3	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					143	149		10.5114/PJP.2018.75671			7	Pathology	Pathology	GM4PM	WOS:000438104000006	30351861	DOAJ Gold			2019-10-28	
J	Kucukzeybek, BB; Bayoglu, IV; Kucukzeybek, Y; Yildiz, Y; Oflazoglu, U; Atahan, MK; Taskaynatan, H; Alacacioglu, A; Yigit, S; Tarhan, MO				Kucukzeybek, Betul Bolat; Bayoglu, Ibrahim V.; Kucukzeybek, Yuksel; Yildiz, Yasar; Oflazoglu, Utku; Atahan, Murat K.; Taskaynatan, Halil; Alacacioglu, Ahmet; Yigit, Seyran; Tarhan, Mustafa O.			PROGNOSTIC SIGNIFICANCE OF ANDROGEN RECEPTOR EXPRESSION IN HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER	POLISH JOURNAL OF PATHOLOGY			English	Article						breast cancer; triple-negative; HER2-positive; prognosis; androgen receptor	MOLECULAR SUBTYPES; ESTROGEN; SURVIVAL; FEATURES; PATTERNS; GROWTH	Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are more aggressive than other subtypes of breast cancer. Due to the limited number of treatment alternatives and the absence of target receptors in TNBC, and because of progression in the HER2-positive group despite targeted treatments, new treatment targets and therapeutic combinations are required. In this context, the present study aims to evaluate the prognostic importance of immunohistochemical androgen receptor (AR) expression in HER2-positive breast cancer and TNBC subtypes. AR nuclear staining density was evaluated immunohistochemically. A total of 111 operated patients with breast cancer were included in the study; 44 (39.6%) belonged to the HER2-positive breast cancer subgroup and 67 (60.4%) belonged to the TNBC subgroup. AR expression was 34.3% and 79.5% in TNBC and HER2-positive groups, respectively. The 5-year overall survival (OS) was 76% and 58% for the group with an AR-expression > 7.5% and AR-expression < 7.5%, respectively, in the TNBC subgroup (p = 0.042). In the HER2-positive patient group, the subgroups characterised by an AR-expression > 7.5% and AR-expression < 7.5% had 5-year OS rates of 57.6% and 63.5%, respectively (p = 0.91). Including the assessment of AR expression in the routine pathological examination will contribute to our understanding of the relevance of AR in the biology and prognosis of breast cancer.	[Kucukzeybek, Betul Bolat; Yigit, Seyran] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, TR-35360 Izmir, Turkey; [Bayoglu, Ibrahim V.; Kucukzeybek, Yuksel; Yildiz, Yasar; Oflazoglu, Utku; Taskaynatan, Halil; Alacacioglu, Ahmet] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey; [Atahan, Murat K.] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Gen Surg, Izmir, Turkey; [Tarhan, Mustafa O.] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Prevent Oncol, Izmir, Turkey	Kucukzeybek, BB (reprint author), Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, TR-35360 Izmir, Turkey.	bbkzeybek@yahoo.com					Aleskandarany MA, 2016, BREAST CANCER RES TR, V159, P215, DOI 10.1007/s10549-016-3934-5; Arce-Salinas C, 2016, J CLIN ONCOL, V34, pE21, DOI 10.1200/JCO.2013.49.8899; Barton VN, 2015, MOL CANCER THER, V14, P769, DOI 10.1158/1535-7163.MCT-14-0926; Bonnefoi H, 2016, ANN ONCOL, V27, P812, DOI 10.1093/annonc/mdw067; Chia KM, 2011, NEOPLASIA, V13, P154, DOI 10.1593/neo.101324; Choi JE, 2015, ANN SURG ONCOL, V22, P82, DOI 10.1245/s10434-014-3984-z; Collins LC, 2011, MODERN PATHOL, V24, P924, DOI 10.1038/modpathol.2011.54; Cuenca-Lopez MD, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-302; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Doane AS, 2006, ONCOGENE, V25, P3994, DOI 10.1038/sj.onc.1209415; Foradori CD, 2008, FRONT NEUROENDOCRIN, V29, P169, DOI 10.1016/j.yfrne.2007.10.005; Gasparini P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088525; Gucalp A, 2013, CLIN CANCER RES, V19, P5505, DOI 10.1158/1078-0432.CCR-12-3327; He JH, 2012, MED ONCOL, V29, P406, DOI 10.1007/s12032-011-9832-0; Hu R, 2011, CLIN CANCER RES, V17, P1867, DOI 10.1158/1078-0432.CCR-10-2021; Jezequel P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0550-y; Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9; Lehmann BD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157368; Lehmann BD, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0406-x; Lin NU, 2012, CANCER-AM CANCER SOC, V118, P5463, DOI 10.1002/cncr.27581; Loibl S, 2011, BREAST CANCER RES TR, V130, P477, DOI 10.1007/s10549-011-1715-8; Luo Xiang, 2010, Chin J Cancer, V29, P585; Macedo LF, 2006, CANCER RES, V66, P7775, DOI 10.1158/0008-5472.CAN-05-3984; McGhan LJ, 2014, ANN SURG ONCOL, V21, P361, DOI 10.1245/s10434-013-3260-7; McNamara KM, 2013, J STEROID BIOCHEM, V133, P66, DOI 10.1016/j.jsbmb.2012.08.007; Mehta J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120622; Mrklic I, 2013, ACTA HISTOCHEM, V115, P344, DOI 10.1016/j.acthis.2012.09.006; Ni M, 2013, GENE DEV, V27, P734, DOI 10.1101/gad.209569.112; Niemeier LA, 2010, MODERN PATHOL, V23, P205, DOI 10.1038/modpathol.2009.159; Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510; Perez EA, 2014, J CLIN ONCOL, V32, P3744, DOI 10.1200/JCO.2014.55.5730; Perez-Rodriguez G, 2015, WSPOLCZESNA ONKOL, V19, P462, DOI 10.5114/wo.2015.56652; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Peters AA, 2009, CANCER RES, V69, P6131, DOI 10.1158/0008-5472.CAN-09-0452; Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397; Qi JP, 2012, BREAST CANCER-BASIC, V6, P1, DOI 10.4137/BCBCR.S8323; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; Sas-Korczynska B, 2015, POL J PATHOL, V66, P347, DOI 10.5114/PJP.2015.57065; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Tang DB, 2012, MED ONCOL, V29, P526, DOI 10.1007/s12032-011-9948-2; Toth-Fejel SE, 2004, ARCH SURG-CHICAGO, V139, P50, DOI 10.1001/archsurg.139.1.50; Traina TA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.1003; Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207; Vera-Badillo FE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt319; Yu KD, 2013, CLIN CANCER RES, V19, P2723, DOI 10.1158/1078-0432.CCR-12-2986; Zhu X, 1999, MOL CELL ENDOCRINOL, V152, P199, DOI 10.1016/S0303-7207(99)00031-3	47	0	1	1	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					157	168		10.5114/PJP.2018.76699			12	Pathology	Pathology	GM4PM	WOS:000438104000008	30351863	DOAJ Gold			2019-10-28	
J	Glajcar, A; Szpor, J; Tyrak, KE; Streb, J; Hodorowicz-Zaniewska, D; Okon, K				Glajcar, Anna; Szpor, Joanna; Tyrak, Katarzyna Ewa; Streb, Joanna; Hodorowicz-Zaniewska, Diana; Okon, Krzysztof			LYMPHOID ENVIRONMENT IN MOLECULAR SUBTYPES OF BREAST CANCER	POLISH JOURNAL OF PATHOLOGY			English	Article						breast cancer; T-lymphocytes; B-lymphocytes; natural killer cells; tumour microenvironment	TUMOR-INFILTRATING LYMPHOCYTES; INTERNATIONAL EXPERT CONSENSUS; T-CELLS; NK CELLS; B-CELLS; PROGNOSTIC-SIGNIFICANCE; DUCTAL CARCINOMA; PRIMARY THERAPY; METASTASIS; EXPRESSION	Recently, a large body of evidence has shown that the microenvironment of invasive breast carcinoma affects its development and the patient's outcome, and vice versa - cancer cells express factors that modulate tumour milieu in terms of its composition and function. We performed an immunohistochemical (IHC) staining of 108 formalin-fixed, paraffin-embedded (FFPE) tissue samples to investigate the relationships between T-cell, B-cell, and NK-cell infiltrate, invasive breast carcinomas molecular subtypes, and other prognostic indicators. The main findings of our study were as follows: the significantly higher infiltrate of the analysed immune cell subsets in triple-negative (TNBC), HER2-positive, non-luminal and luminal B/HER2+ breast carcinomas than in luminal A cancers; their higher densities in poorly differentiated lesions; correlations between lymphoid cells and the expression of hormonal receptors, HER2 receptor status, and marker of cancer proliferation. Furthermore, we observed T-cell numbers to be associated with greater tumour diameter. In summary, the results of our study indicate associations between tumoural lymphoid infiltration and the unfavourable intrinsic subtypes as well as other detrimental prognostic factors in invasive breast carcinomas.	[Glajcar, Anna; Szpor, Joanna; Okon, Krzysztof] Jagiellonian Univ, Coll Med, Chair & Dept Pathomorphol, Grzegorzecka 16, PL-31531 Krakow, Poland; [Tyrak, Katarzyna Ewa] Jagiellonian Univ, Coll Med, Fac Med, Chair Internal Med 2, Krakow, Poland; [Streb, Joanna] Jagiellonian Univ, Coll Med, Dept Oncol, Krakow, Poland; [Hodorowicz-Zaniewska, Diana] Jagiellonian Univ, Coll Med, Chair Gen Ontol & Gastrointestinal Surg 1, Krakow, Poland	Okon, K (reprint author), Jagiellonian Univ, Coll Med, Chair & Dept Pathomorphol, Grzegorzecka 16, PL-31531 Krakow, Poland.	k.okon@uj.edu.pl	Okon, Krzysztof/D-1345-2011	Okon, Krzysztof/0000-0002-1921-5007	Jagiellonian University [K/DSC/003589]	The study was approved by the Jagiellonian University Committee of Bioethics (consent number: 122.6120.149.2016). The study was supported by Jagiellonian University grant K/DSC/003589. Preliminary results from the present study were previously published at the 7th Jagiellonian University Medical College Doctoral Students' Conference (Krakow, 27th May 2017).	Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870; Ahn SG, 2015, J PATHOL TRANSL MED, V49, P355, DOI 10.4132/jptm.2015.07.29; Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Ascierto ML, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-145; Beckermann KE, 2017, CYTOKINE GROWTH F R, V35, P7, DOI 10.1016/j.cytogfr.2017.04.003; Beckhove P, 2004, J CLIN INVEST, V114, P67, DOI 10.1172/JC1200420278; Carvalho MI, 2014, BIOMED RES INT, DOI 10.1155/2014/130894; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Cimino-Mathews A, 2013, HUM PATHOL, V44, P2055, DOI 10.1016/j.humpath.2013.03.010; Coates AS, 2015, ANN ONCOL, V26, P1533, DOI 10.1093/annonc/mdv221; Coronella JA, 2002, J IMMUNOL, V169, P1829, DOI 10.4049/jimmunol.169.4.1829; Coronella-Wood JA, 2003, CANCER IMMUNOL IMMUN, V52, P715, DOI 10.1007/s00262-003-0409-4; de la Cruz-Merino L, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/785317; Dong DD, 2012, HUM IMMUNOL, V73, P998, DOI 10.1016/j.humimm.2012.07.321; Eiro N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052796; Engels CC, 2014, BRIT J CANCER, V111, P532, DOI 10.1038/bjc.2014.338; Esposito A, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.518; Fu ZX, 2013, ACTA ONCOL, V52, P1760, DOI 10.3109/0284186X.2012.760847; Gillgrass A, 2014, J IMMUNOL, V193, P6184, DOI 10.4049/jimmunol.1303175; Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393; Glajcar A, 2017, VIRCHOWS ARCH, V470, P505, DOI 10.1007/s00428-017-2103-5; Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303; Helal TEA, 2013, INDIAN J PATHOL MICR, V56, P89, DOI 10.4103/0377-4929.118676; Hussein MR, 2006, J CLIN PATHOL, V59, P972, DOI 10.1136/jcp.2005.031252; Kim JH, 2013, CAN J VET RES, V77, P142; Kim JY, 2017, VIRCHOWS ARCH, V470, P381, DOI 10.1007/s00428-017-2083-5; Kmieciak M, 2011, J IMMUNOL, V187, P708, DOI 10.4049/jimmunol.1100502; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Loi S, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24720; LORENZEN J, 1991, BRIT J CANCER, V64, P457, DOI 10.1038/bjc.1991.331; Mahmoud SMA, 2012, BREAST CANCER RES TR, V132, P545, DOI 10.1007/s10549-011-1620-1; Mamessier E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26688; Matsumoto H, 2015, J CLIN PATHOL, V68, P506, DOI 10.1136/jclinpath-2015-202944; Melichar B, 2014, ANTICANCER RES, V34, P1115; Mittal D, 2014, CURR OPIN IMMUNOL, V27, P16, DOI 10.1016/j.coi.2014.01.004; Mohammed ZMA, 2013, BRIT J CANCER, V109, P1676, DOI 10.1038/bjc.2013.493; Morita M, 2016, J CLIN PATHOL, V69, P890, DOI 10.1136/jclinpath-2015-203506; Nagalla S, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r34; Nzula S, 2003, CANCER RES, V63, P3275; Olkhanud PB, 2011, CANCER RES, V71, P3505, DOI 10.1158/0008-5472.CAN-10-4316; Owen Jennifer L, 2004, Breast Dis, V20, P145; Pavoni E, 2007, BMC BIOTECHNOL, V7, DOI 10.1186/1472-6750-7-70; Poschke I, 2012, INT J CANCER, V131, P1611, DOI 10.1002/ijc.27410; Rathore AS, 2013, INDIAN J CANCER, V50, P239, DOI 10.4103/0019-509X.118744; Renner K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00248; Roberti MP, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00375; Roncati L, 2016, PATHOL ONCOL RES, V22, P449, DOI 10.1007/s12253-015-0024-7; Salgado R, 2015, ANN ONCOL, V26, P259, DOI 10.1093/annonc/mdu450; Santoiemma PP, 2016, GYNECOL ONCOL, V143, P120, DOI 10.1016/j.ygyno.2016.07.105; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Toss A, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0560-9; Tsang JYS, 2014, BREAST CANCER RES TR, V143, P1, DOI 10.1007/s10549-013-2781-x; Vgenopoulou S, 2003, BREAST, V12, P172, DOI 10.1016/S0960-9776(03)00004-3; Wakatsuki K, 2013, ONCOL REP, V29, P1756, DOI 10.3892/or.2013.2302; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yajima R, 2016, BREAST CANCER-TOKYO, V23, P668, DOI 10.1007/s12282-015-0622-y; Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013; Zhang ZG, 2017, CANCER LETT, V393, P1, DOI 10.1016/j.canlet.2017.02.008	58	1	1	0	3	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					169	181		10.5114/PJP.2018.76700			13	Pathology	Pathology	GM4PM	WOS:000438104000009	30351864	DOAJ Gold			2019-10-28	
J	Zerbino, D; Volos, LI				Zerbino, Dmytro; Volos, Liliya I.			PROFESSOR ANDREW OBRZUT THE FIRST HEAD OF THE PATHOLOGICAL ANATOMY DEPARTMENT (1896-1910) OF THE MEDICAL FACULTY OF JAN CASIMIR UNIVERSITY IN LVIV	POLISH JOURNAL OF PATHOLOGY			English	Biographical-Item									[Zerbino, Dmytro; Volos, Liliya I.] Lviv Natl Med Univ, Dept Pathol Anat, Pekarska St 69, UA-79000 Lvov, Ukraine	Zerbino, D (reprint author), Lviv Natl Med Univ, Dept Pathol Anat, Pekarska St 69, UA-79000 Lvov, Ukraine.; Zerbino, D (reprint author), Lviv Natl Med Univ, Museum Human Dis, Pekarska St 69, UA-79000 Lvov, Ukraine.	dmytro.zerbino@gmail.com	Zerbino, Dmytro/G-2972-2019	Zerbino, Dmytro/0000-0002-2771-5044			ZERBINO D, PUBLICATION LIST	1	0	0	1	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					182	184		10.5114/PJP.2018.76701			3	Pathology	Pathology	GM4PM	WOS:000438104000010	30351865	DOAJ Gold			2019-10-28	
J	Stolnicu, S; Giurgi, A; Bauer, O; Chiriac, A; Podoleanu, C; Georgescu, R				Stolnicu, Simona; Giurgi, Alexandra; Bauer, Orsolya; Chiriac, Anca; Podoleanu, Cristian; Georgescu, Rares			ENCAPSULATED PAPILLARY BREAST CARCINOMA IN A MALE PATIENT IN ASSOCIATION WITH MICRODEPOSITS OF CARCINOMA CELLS IN THE NEEDLE TRACK AND SENTINEL LYMPH NODE TREATED CONSERVATIVELY	POLISH JOURNAL OF PATHOLOGY			English	Article						encapsulated papillary carcinoma; breast; male; displaced cells	OF-THE-LITERATURE; CANCER; BIOPSY; EPITHELIUM; RECURRENCE	We present an encapsulated papillary breast carcinoma in a male patient, in association with microdeposits of carcinoma cells within the needle track, in the lymphatic spaces of the breast parenchyma and subcapsular sinus of two sentinel lymph nodes in which conservative treatment has been recommended. Both in females and males, papillary tumours and particularly encapsulated papillary breast carcinoma can be associated with microdeposits mechanically displaced, which have to be differentiated from true invasion and metastases and treated conservatively.	[Stolnicu, Simona; Giurgi, Alexandra] Univ Med & Pharm Tirgu Mures, Dept Pathol, Targu Mures, Romania; [Stolnicu, Simona; Giurgi, Alexandra] Histopat Invest Lab Tirgu Mures, Targu Mures, Romania; [Bauer, Orsolya; Georgescu, Rares] Univ Med & Pharm Tirgu Mures, Dept Surg, Targu Mures, Romania; [Chiriac, Anca] Nicolina Med Ctr, Dept Dermatol, Iasi, Romania; [Chiriac, Anca] Apollonia Univ, Iasi, Romania; [Chiriac, Anca] Romanian Acad, P Poni Res Inst, Iasi, Romania; [Podoleanu, Cristian] Univ Med & Pharm Tirgu Mures, Dept Internal Med, Gheorghe Marinescu St 38, Targu Mures 540139, Romania	Podoleanu, C (reprint author), Univ Med & Pharm Tirgu Mures, Dept Internal Med, Gheorghe Marinescu St 38, Targu Mures 540139, Romania.	podoleanu@me.com	; Chiriac, Anca/L-6829-2013	Stolnicu, Simona/0000-0002-4459-7019; Chiriac, Anca/0000-0002-0989-4931			Burga AM, 2006, VIRCHOWS ARCH, V449, P507, DOI 10.1007/s00428-006-0305-3; Carter BA, 2000, AM J CLIN PATHOL, V113, P259; Chen AM, 2002, RADIOLOGY, V225, P707, DOI 10.1148/radiol.2253011698; Douglas-Jones AG, 2002, J CLIN PATHOL, V55, P780, DOI 10.1136/jcp.55.10.780; Giuliano AE, 2016, ANN SURG, V264, P413, DOI 10.1097/SLA.0000000000001863; HELLER KS, 1978, ANN SURG, V188, P60, DOI 10.1097/00000658-197807000-00010; Hussain A, 2012, IRISH J MED SCI, V181, P329, DOI 10.1007/s11845-009-0372-y; Imoto S, 1998, JPN J CLIN ONCOL, V28, P517, DOI 10.1093/jjco/28.8.517; NORRIS HJ, 1969, CANCER, V23, P1428, DOI 10.1002/1097-0142(196906)23:6<1428::AID-CNCR2820230626>3.0.CO;2-4; Olu-Eddo A N, 2008, Niger Postgrad Med J, V15, P270; Pant I, 2009, J CANC RES THER, V5, P216, DOI 10.4103/0973-1482.57132; Romics Laszlo Jr, 2009, J Med Case Rep, V3, P13, DOI 10.1186/1752-1947-3-13; Stolnicu S, 2017, APPL IMMUNOHISTO M M, V25, pE18, DOI 10.1097/PAI.0000000000000376; VISFELDT J, 1973, CANCER-AM CANCER SOC, V32, P985, DOI 10.1002/1097-0142(197310)32:4<985::AID-CNCR2820320433>3.0.CO;2-0; Wolff M, 1981, PROGR SURGICAL PATHO, VIII, P77	15	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					185	188		10.5114/PJP.2018.76702			4	Pathology	Pathology	GM4PM	WOS:000438104000011	30351866	DOAJ Gold			2019-10-28	
J	Gaetano, M; Giuseppe, A; Saveria, S; Ragusa, R; Alberto, R; Enrico, O				Gaetano, Magro; Giuseppe, Angelico; Saveria, Spadola; Ragusa, Rosalia; Alberto, Righi; Enrico, Orvieto			FIBROMA OF THE BREAST: A RARE TUMOUR IN THE SPECTRUM OF THE BENIGN SPINDLE CELL TUMOURS OF THE MAMMARY STROMA	POLISH JOURNAL OF PATHOLOGY			English	Article						breast; mammary stroma; fibroma; benign spindle cell tumour; 13q14 deletion	MYOFIBROBLASTOMA; LIPOMA; EMPHASIS	Benign spindle cell tumours of the mammary stroma comprises different lesions that show a variable degree of fibroblastic/myofibroblastic differentiation. We herein report a previously under-recognised hypocellular fibrocollagenous tumour of the breast, for which the term "fibroma" is proposed. The tumour was composed of CD34-positive bland-looking spindle cells embedded in an abundant hyalinised stroma. Fluorescence in situ hybridisation (FISH) showed 13q14 deletion in most neoplastic cells, a chromosomal alteration typically found in mammary myofibroblastoma. Based on morphological, immunohistochemical, and cytogenetic features, we suggest that fibroma belongs to the group of the benign spindle cell tumours of the mammary stroma.	[Gaetano, Magro; Saveria, Spadola] Univ Catania, Anat Pathol, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy; [Giuseppe, Angelico] Univ Messina, Dept Human Pathol Adult & Dev Age Gaetano Barresi, Sect Anat Pathol, Messina, Italy; [Ragusa, Rosalia] Univ Hosp G Rodolico Catania, Med Staff Hosp Direct, Catania, Italy; [Alberto, Righi] Rizzoli Inst, Dept Pathol, Bologna, Italy; [Enrico, Orvieto] UOC Anat Pathol Osped Rovigo ULSS5 Polesana, Dept Serv Diag & Therapy, Rovigo, RO, Italy	Gaetano, M (reprint author), Univ Catania, Anat Pathol, Dept Med & Surg Sci & Adv Technol GF Ingrassia, Via S Sofia 87, I-95123 Catania, Italy.	g.magro@unict.it	Ragusa, Rosalia/R-9599-2017	Ragusa, Rosalia/0000-0002-0964-3438; Angelico, Giuseppe/0000-0003-4808-2052; Spadola, Saveria/0000-0003-0387-5921			BEGIN LR, 1991, ULTRASTRUCT PATHOL, V15, P613, DOI 10.3109/01913129109023191; BOGER A, 1984, PATHOL RES PRACT, V178, P395; CHAN KW, 1984, PATHOLOGY, V16, P331, DOI 10.3109/00313028409068546; DAMIANI S, 1994, VIRCHOWS ARCH, V425, P89; Devouassoux-Shisheboran M, 2000, ARCH PATHOL LAB MED, V124, P276; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; Falconieri Giovanni, 2004, Ann Diagn Pathol, V8, P121, DOI 10.1016/j.anndiagpath.2004.03.002; Fritchie KJ, 2012, AM J CLIN PATHOL, V137, P963, DOI 10.1309/AJCPQEG6YNN6CNAL; Halpert B, 1933, AM J PATHOL, V9, P905; Magro G, 2002, VIRCHOWS ARCH, V440, P249, DOI 10.1007/s00428-001-0572-y; Magro G, 1998, Ann Diagn Pathol, V2, P306, DOI 10.1016/S1092-9134(98)80023-3; Magro G, 2000, HISTOPATHOLOGY, V37, P189, DOI 10.1046/j.1365-2559.2000.00985-3.x; Magro G., 2002, Pathologica (Genoa), V94, P238, DOI 10.1007/s102420200039; Magro G, 2001, PATHOL RES PRACT, V197, P453, DOI 10.1078/0344-0338-00112; Magro G, 2008, ARCH PATHOL LAB MED, V132, P1813, DOI 10.1043/1543-2165-132.11.1813; Magro Gaetano, 2018, Surg Pathol Clin, V11, P91, DOI 10.1016/j.path.2017.09.005; Magro G, 2016, PATHOL RES PRACT, V212, P463, DOI 10.1016/j.prp.2015.12.013; Magro G, 2016, HISTOL HISTOPATHOL, V31, P1, DOI 10:14670; Magro G, 2012, HUM PATHOL, V43, P1887, DOI 10.1016/j.humpath.2012.01.015; Magro M, 2012, WHO CLASSIFICATION T, P130; Meguerditchian AN, 2008, BREAST J, V14, P287, DOI 10.1111/j.1524-4741.2008.00588.x; Mulvany NJ, 1999, PATHOLOGY, V31, P288, DOI 10.1080/003130299105188; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rosen PP, 2009, ROSENS BREAST PATHOL; Smith DN, 1996, ACTA RADIOL, V37, P893; TOKER C, 1981, CANCER, V48, P1615, DOI 10.1002/1097-0142(19811001)48:7<1615::AID-CNCR2820480724>3.0.CO;2-I; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137	27	0	0	0	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					189	194		10.5114/PJP.2018.76703			6	Pathology	Pathology	GM4PM	WOS:000438104000012	30351867	DOAJ Gold			2019-10-28	
J	Hamza, A; Khawar, S; Ibrar, W; Sakhi, R; Fathallah, L				Hamza, Ameer; Khawar, Sidrah; Ibrar, Warda; Sakhi, Ramen; Fathallah, Lamia			DEDIFFERENTIATED ENDOMETRIAL CARCINOMA: AN ONGOING DIAGNOSTIC DILEMMA	POLISH JOURNAL OF PATHOLOGY			English	Article						dedifferentiated endometrial carcinoma; endometrial carcinoma; endometrioid carcinoma undifferentiated carcinoma; immunohistochemistry	UNDIFFERENTIATED CARCINOMA; PROTEIN EXPRESSION; ADRENAL METASTASIS; ADENOCARCINOMA; UTERUS; CANCER	Tumours of uterine corpus are the most common gynaecological malignancies. The clinicopathological features of most of these tumours are well understood; however, dedifferentiated endometrial carcinoma still requires a lot of research to establish adequate management guidelines. The entity was first described in 2006 and is an aggressive tumour with poor prognosis. We present two cases of this tumour with a literature review, emphasising morphologic and immunohistochemical features that may help in the differential diagnosis.	[Hamza, Ameer; Khawar, Sidrah; Ibrar, Warda; Sakhi, Ramen; Fathallah, Lamia] St John Hosp & Med Ctr, Dept Pathol, 22101 Moross Rd, Detroit, MI 48236 USA	Hamza, A (reprint author), St John Hosp & Med Ctr, Dept Pathol, 22101 Moross Rd, Detroit, MI 48236 USA.	ameerhamza7@hotmail.com					Altrabulsi B, 2005, AM J SURG PATHOL, V29, P1316, DOI 10.1097/01.pas.0000171003.72352.9a; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Berretta R, 2013, INT J CLIN EXP PATHO, V6, P1652; Garg K, 2009, AM J SURG PATHOL, V33, P925, DOI 10.1097/PAS.0b013e318197a046; Han J, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-016-1093-0; Hoang LN, 2016, HISTOPATHOLOGY, V69, P560, DOI 10.1111/his.12989; Karnezis AN, 2016, MODERN PATHOL, V29, P302, DOI 10.1038/modpathol.2015.155; Li ZB, 2016, APPL IMMUNOHISTO M M, V24, P562, DOI 10.1097/PAI.0000000000000232; Mouka V, 2016, J OBSTET GYNAECOL, V36, P881, DOI 10.1080/01443615.2016.1188275; Onder S, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006248; Ramalingam P, 2016, INT J GYNECOL PATHOL, V35, P410, DOI 10.1097/PGP.0000000000000248; SAKURAGI N, 1994, GYNECOL ONCOL, V53, P183, DOI 10.1006/gyno.1994.1113; Shen Y, 2012, INT J CLIN EXP PATHO, V5, P77; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Silva EG, 2006, INT J GYNECOL PATHOL, V25, P52, DOI 10.1097/01.pgp.0000183048.22588.18; Silva EG, 2007, PATHOLOGY, V39, P134, DOI 10.1080/00313020601159494; Stewart CJR, 2015, HUM PATHOL, V46, P1514, DOI 10.1016/j.humpath.2015.06.011; Stewart CJR, 2015, PATHOLOGY, V47, P439, DOI 10.1097/PAT.0000000000000270; Strehl JD, 2015, ANN DIAGN PATHOL, V19, P198, DOI 10.1016/j.anndiagpath.2015.04.001; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41	20	0	0	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					195	199		10.5114/PJP.2018.76704			5	Pathology	Pathology	GM4PM	WOS:000438104000013	30351868	DOAJ Gold			2019-10-28	
J	Oruba, Z; Kaczmarzyk, T; Urbanczyk, K; Jurczyszyn, A; Fornagiel, S; Galazka, K; Bednarczyk, A; Chomyszyn-Gajewska, M				Oruba, Zuzanna; Kaczmarzyk, Tomasz; Urbanczyk, Katarzyna; Jurczyszyn, Artur; Fornagiel, Szymon; Galazka, Krystyna; Bednarczyk, Anna; Chomyszyn-Gajewska, Maria			INTRAORAL MANIFESTATION OF SYSTEMIC AL AMYLOIDOSIS WITH UNIQUE MICROSCOPIC PRESENTATION OF INTRACELLULAR AMYLOID DEPOSITION IN STRIATED MUSCLES	POLISH JOURNAL OF PATHOLOGY			English	Editorial Material						AL amyloidosis; amyloid; multiple myeloma; macroglossia; oral manifestation	MYOPATHY; INVOLVEMENT; FEATURES; HEAD; NECK	We report the history of a 59-year old patient with systemic AL amyloidosis of intraoral manifestation. The patient first presented with complaints about dysphagia and remarkable enlargement of the tongue with highly reduced mobility, as well as bilateral submucosal thickenings on the cheeks. Histopathological examination of the incisional biopsy of the buccal mucosa and underlying tissues revealed AL amyloidosis. The microscopic presentation was, however, unique, as the amyloid deposits were present intracellularly in the striated muscles. The subsequent bone marrow biopsy confirmed the diagnosis of primary amyloidosis/multiple myeloma associated amyloidosis.	[Oruba, Zuzanna; Chomyszyn-Gajewska, Maria] Jagiellonian Univ, Coll Med, Fac Med, Chair Periodontol & Oral Med, Krakow, Poland; [Kaczmarzyk, Tomasz; Bednarczyk, Anna] Jagiellonian Univ, Coll Med, Fac Med, Chair Oral Surg, Krakow, Poland; [Urbanczyk, Katarzyna; Galazka, Krystyna] Jagiellonian Univ, Coll Med, Fac Med, Chair Pathomorphol, Krakow, Poland; [Jurczyszyn, Artur; Fornagiel, Szymon] Jagiellonian Univ, Coll Med, Fac Med, Chair & Clin Hematol, Krakow, Poland	Oruba, Z (reprint author), Jagiellonian Univ, Coll Med, Chair Periodontol & Oral Med, Montelupich 4, PL-31155 Krakow, Poland.	zuzanna.oruba@uj.edu.pl					Chapin JE, 2005, MUSCLE NERVE, V31, P266, DOI 10.1002/mus.20169; Cohen AD, 2010, HEMATOL-AM SOC HEMAT, P287, DOI 10.1182/asheducation-2010.1.287; Elad S, 2010, AMYLOID, V17, P27, DOI 10.3109/13506121003619351; Gouvea AF, 2012, J ORAL PATHOL MED, V41, P178, DOI 10.1111/j.1600-0714.2011.01073.x; KYLE RA, 1975, MEDICINE, V54, P271; Matsuo FS, 2016, CLIN ORAL INVEST, V20, P1913, DOI 10.1007/s00784-015-1649-3; Nandapalan V, 1998, HEAD NECK-J SCI SPEC, V20, P73; Prashantha DK, 2010, ANN INDIAN ACAD NEUR, V13, P142, DOI 10.4103/0972-2327.64642; Prayson RA, 1998, HUM PATHOL, V29, P463, DOI 10.1016/S0046-8177(98)90061-2; Rocken C, 2003, VIRCHOWS ARCH, V443, P3, DOI 10.1007/s00428-003-0834-y; Sipe JD, 2016, AMYLOID, V23, P209, DOI 10.1080/13506129.2016.1257986; Spuler S, 1998, ANN NEUROL, V43, P719, DOI 10.1002/ana.410430606; Tuomaala H, 2009, NEUROL INT, V1, P24, DOI 10.4081/ni.2009.e7; van der Waal RIF, 2002, ORAL SURG ORAL MED O, V94, P444, DOI 10.1067/moe.2002.126342	14	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	2					200	204		10.5114/PJP.2018.76705			5	Pathology	Pathology	GM4PM	WOS:000438104000014	30351869	DOAJ Gold			2019-10-28	
J	Hanson, KF; Birinyi, P; Walker, R; Raptis, C; Chernock, R; Coppens, J; Schwetye, KE				Hanson, Katie Fox; Birinyi, Paul; Walker, Ronald; Raptis, Constantine; Chernock, Rebecca; Coppens, Jeroen; Schwetye, Katherine E.			Melanoma Mimicking Malignant Peripheral Nerve Sheath Tumor with Spread to the Cerebellopontine Angle: Utility of Next-Generation Sequencing in Diagnosis	CASE REPORTS IN PATHOLOGY			English	Article							DESMOPLASTIC MELANOMA; MUTATIONS; NF1; MANAGEMENT	Cutaneous spindle cell malignancy is associated with a broad differential diagnosis, particularly in the absence of a known primary melanocytic lesion. We present an unusually challenging patient who presented with clinical symptoms involving cranial nerves VII and VIII and a parotid-region mass, which was S100-positive while lacking in melanocytic pigment and markers. Over a year after resection of the parotid mass, both a cutaneous primary lentigo maligna melanoma and a metastatic CP angle melanoma were diagnosed in the same patient, prompting reconsideration of the diagnosis in the original parotid-region mass. Next-generation sequencing of a panel of cancer-associated genes demonstrated 19 identical, clinically significant mutations as well as a high tumor mutation burden in both the parotid-region and CP angle tumors, indicating a metastatic relationship between the two and a melanocytic identity of the parotid-region tumor.	[Hanson, Katie Fox; Schwetye, Katherine E.] St Louis Univ, Sch Med, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA; [Birinyi, Paul] Univ Tennessee, Hlth Sci Ctr, Dept Neurosurg, Semmes Murphey Clin, Knoxville, TN 37996 USA; [Walker, Ronald] St Louis Univ, Sch Med, Dept Otolaryngol, 1402 S Grand Blvd, St Louis, MO 63104 USA; [Raptis, Constantine] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, 660 S Euclid Ave, St Louis, MO 63110 USA; [Chernock, Rebecca] Washington Univ, Sch Med, Dept Pathol & Immunol, 660 S Euclid Ave, St Louis, MO 63110 USA; [Coppens, Jeroen] St Louis Univ, Sch Med, Dept Neurosurg, 1402 S Grand Blvd, St Louis, MO 63104 USA	Schwetye, KE (reprint author), St Louis Univ, Sch Med, Dept Pathol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	schwetyeke@slu.edu					Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Barnett SL, 2011, J NEUROSURG, V115, P273, DOI 10.3171/2011.4.JNS10913; Bastian BC, 2014, ANNU REV PATHOL-MECH, V9, P239, DOI 10.1146/annurev-pathol-012513-104658; Brackmann DE, 2007, OTOL NEUROTOL, V28, P529, DOI 10.1097/mao.0b013e3180383694; Cirenajwis H, 2017, MOL ONCOL, V11, P438, DOI 10.1002/1878-0261.12050; Gerganov VM, 2008, J NEUROSURG, V108, P803, DOI 10.3171/JNS/2008/108/4/0803; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Holzel M, 2016, CANCER RES, V76, P251, DOI 10.1158/0008-5472.CAN-15-1090; Jackson CR, 2016, J CUTAN PATHOL, V43, P1220, DOI 10.1111/cup.12834; Kiuru M, 2014, AM J SURG PATHOL, V38, P864, DOI 10.1097/PAS.0000000000000201; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Linos K., 2015, DERMATOLOGY ONLINE J, V21; Longo C, 2016, DERMATOL CLIN, V34, P411, DOI 10.1016/j.det.2016.05.004; Machado I, 2017, J CUTAN PATHOL, V44, P632, DOI 10.1111/cup.12949; Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398; Nissan MH, 2014, CANCER RES, V74, P2340, DOI 10.1158/0008-5472.CAN-13-2625; Shain AH, 2015, NAT GENET, V47, P1194, DOI 10.1038/ng.3382; Shin TM, 2017, J AM ACAD DERMATOL, V76, P714, DOI 10.1016/j.jaad.2016.11.048; Wiesner T, 2015, AM J SURG PATHOL, V39, P1357, DOI 10.1097/PAS.0000000000000451	19	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									9410465	10.1155/2018/9410465			6	Pathology	Pathology	GM4GE	WOS:000438073400001	30050716	DOAJ Gold, Green Published			2019-10-28	
J	Jagannathan, G; Uppal, G; Judy, K; Curtis, MT				Jagannathan, Geetha; Uppal, Guldeep; Judy, Kevin; Curtis, Mark T.			Cerebral Amyloidoma Resulting from Central Nervous System Lymphoplasmacytic Lymphoma: A Case Report and Literature Review	CASE REPORTS IN PATHOLOGY			English	Article							MARGINAL ZONE LYMPHOMA; INVOLVEMENT	Cerebral amyloidomas are rare cerebral mass lesions often associated with significant morbidity. Cerebral amyloid accumulation can be the result of a number of disease states and it is crucial for proper patient care to identify the pathogenic process leading to amyloidoma formation. Low grade clonal B-cell processes are one cause of cerebral amyloidomas. We report a case of an 87-year-old woman who presented with a lymphoplasmacytic lymphoma associated cerebral amyloidoma complicated by cerebral hemorrhage, discuss the proper workup of this disease entity, and present a review of the literature on this topic.	[Jagannathan, Geetha; Uppal, Guldeep; Curtis, Mark T.] Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA; [Judy, Kevin] Thomas Jefferson Univ Hosp, Dept Neurosurg, Philadelphia, PA 19107 USA	Curtis, MT (reprint author), Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA.	mark.curtis@jefferson.edu		curtis, mark/0000-0003-0198-7583			Abbi Kamal K S, 2013, Hematol Oncol Stem Cell Ther, V6, P76, DOI 10.1016/j.hemonc.2013.06.002; Ayanambakkam A., 2017, CLIN LYMPHOMA MYELOM, V18; Aziz M., 2014, BMJ CASE REPORTS, V2014; Hess K, 2018, BRAIN PATHOL, V28, P234, DOI 10.1111/bpa.12493; Hunter Z, 2011, BLOOD, V118, P200; Karadurmus N, 2013, CANCER RES TREAT, V45, P234, DOI 10.4143/crt.2013.45.3.234; Labro H, 2009, J AM OSTEOPATH ASSOC, V109, P372; Lehman NL, 2002, J NEUROSURG, V96, P368, DOI 10.3171/jns.2002.96.2.0368; Pace AA, 2015, J NEUROL SCI, V359, P404, DOI 10.1016/j.jns.2015.09.372; Schroder R, 1999, VIRCHOWS ARCH, V434, P551, DOI 10.1007/s004280050383; Shiels MS, 2016, BRIT J HAEMATOL, V174, P417, DOI 10.1111/bjh.14073; Skardelly M, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-107; Tu PH, 2005, J CLIN ONCOL, V23, P5718, DOI 10.1200/JCO.2005.17.624; VIGUSHIN DM, 1994, J NEUROL NEUROSUR PS, V57, P751, DOI 10.1136/jnnp.57.6.751; Yan CR, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004627	15	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5083234	10.1155/2018/5083234			6	Pathology	Pathology	GM4FV	WOS:000438072100001	30046502	DOAJ Gold, Green Published			2019-10-28	
J	Marquez, CP; Zhang, HY; Goodrum, J; Sreshta, JN; Afrouzian, M				Marquez, Christopher P.; Zhang, Haiyan; Goodrum, Jason; Sreshta, J. Nicholas; Afrouzian, Marjan			Florid Proliferation of Hyalinized Vessels in a Spermatic Cord STAT6 Positive Solitary Fibrous Tumor and Its Potential Clinical Implications	CASE REPORTS IN PATHOLOGY			English	Article							NAB2-STAT6 GENE FUSIONS; DEDIFFERENTIATED LIPOSARCOMA; CELLULAR ANGIOFIBROMA; HEMANGIOPERICYTOMA; DIFFERENTIATION; EXPRESSION; TESTIS; LINES	A solitary fibrous tumor (SFT) arising in the paratesticular region is a rare event. Typically most SFTs present as a lung mass and have a characteristic microscopic appearance. Although uncommon, SFTs may present at just about any anatomical site. Here we present a case of a SFT arising along the right spermatic cord, with histologic features mimicking a cellular angiofibroma. We describe the diagnostic immunohistochemical markers useful for arriving at its diagnosis. We also summarize our current understanding of the structural and molecular features that make up SFTs and discuss how these features may help us better understand the pathophysiology of pluripotent mesenchymal stem cell differentiation.	[Marquez, Christopher P.; Zhang, Haiyan; Afrouzian, Marjan] Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA; [Goodrum, Jason; Sreshta, J. Nicholas] Univ Texas Med Branch, Dept Surg, Div Urol, Galveston, TX 77555 USA	Afrouzian, M (reprint author), Univ Texas Med Branch, Dept Pathol, Galveston, TX 77555 USA.	maafrouz@utmb.edu					Arrabal-Polo MA, 2009, SAUDI MED J, V30, P569; Barazani Y, 2012, CUAJ-CAN UROL ASSOC, V6, pE131, DOI 10.5489/cuaj.11092; Bongiovanni M, 2002, J PATHOL, V198, P252, DOI 10.1002/path.1195; Dei Tos AP, 2013, WHO CLASSIFICATION T, P37; Demicco EG, 2015, AM J CLIN PATHOL, V143, P672, DOI 10.1309/AJCPN25NJTOUNPNF; Doyle LA, 2014, MODERN PATHOL, V27, P1231, DOI 10.1038/modpathol.2013.247; Doyle LA, 2014, MODERN PATHOL, V27, P390, DOI 10.1038/modpathol.2013.164; FISHER C, 1994, BRIT J UROL, V74, P798, DOI 10.1111/j.1464-410X.1994.tb07131.x; Fletcher CDM, 2015, WHO CLASSIFICATION T, P178; Fletcher CDM, 2013, WHO CLASSIFICATION T, P80; Flucke U, 2011, MODERN PATHOL, V24, P82, DOI 10.1038/modpathol.2010.170; Gold JS, 2002, CANCER, V94, P1057, DOI 10.1002/cncr.10328; Goldblum J. R., 2013, ENZINGER WEISSS SOFT, P969; Gutierrez-Diaz Ceballos Maria Esther, 2011, Cir Cir, V79, P417; Han YA, 2015, INT J CLIN EXP PATHO, V8, P13166; Honeck P, 2008, AKTUEL UROL, V39, P305, DOI 10.1055/s-2008-1038162; Hu SB, 2015, EXP THER MED, V9, P55, DOI 10.3892/etm.2014.2066; Huang SC, 2016, CANCER MED-US, V5, P159, DOI 10.1002/cam4.572; Ide F, 2005, VIRCHOWS ARCH, V446, P646, DOI 10.1007/s00428-005-1261-z; Ilica A. T., 2008, EUROPEAN J RADIOLOGY, V67, P25; Iwasa Y, 2004, AM J SURG PATHOL, V28, P1426, DOI 10.1097/01.pas.0000138002.46650.95; Jones MA, 1997, AM J SURG PATHOL, V21, P296, DOI 10.1097/00000478-199703000-00005; Kryvenko ON, 2015, AM J SURG PATHOL, V39, P1219, DOI 10.1097/PAS.0000000000000426; Lee GE, 2011, J ULTRAS MED, V30, P279, DOI 10.7863/jum.2011.30.2.279; Li H, 2003, ONCOGENE, V22, P1501, DOI 10.1038/sj.onc.1206223; Moreno A. J. Marquez, 2001, ARCH ESP UROL, V54; Parikh B. J., 2012, GUJARAT MED J, V67, P126; Robinson DR, 2013, NAT GENET, V45, P180, DOI 10.1038/ng.2509; Rodriguez-Gil Y, 2009, ULTRASTRUCT PATHOL, V33, P274, DOI 10.3109/01913120903352177; Shim J. W., 1999, KOREAN J PATHOL, V33, P295; Topsakal K., 2011, TURKIYE KLIN J UROLO, V2, P33; Torrelles Marta Garcia, 2006, Archivos Espanoles de Urologia, V59, P186; Tsili AC, 2005, BRIT J RADIOL, V78, P565, DOI 10.1259/bjr/31560902; Varela Rodolfo, 2010, Archivos Espanoles de Urologia, V63, P816; Xambre L, 2003, Actas Urol Esp, V27, P832; Yoshida A, 2014, AM J SURG PATHOL, V38, P552, DOI 10.1097/PAS.0000000000000137; Zhao XY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008854; Zhou YH, 2015, INT J CLIN EXP PATHO, V8, P3358	38	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									7462032	10.1155/2018/7462032			6	Pathology	Pathology	GM4GC	WOS:000438073200001	30050715	DOAJ Gold, Green Published			2019-10-28	
J	Azzakhmam, M; Kessab, A; Malihy, A; Rouas, L; Lamalmi, N				Azzakhmam, Mustapha; Kessab, Amine; Malihy, Abderrahmane; Rouas, Lamiae; Lamalmi, Najat			Intracardiac Teratoma in an Infant: Report of a New Case and Literature Review	CASE REPORTS IN PATHOLOGY			English	Review							OF-THE-LITERATURE; CARDIAC TUMORS; HEART	Primitive intracardiac tumours are rare, especially in childhood, and are often discovered on autopsy. The intracardiac teratoma is the rarest intracardiac tumours of childhood. Herein, we report the case of an 11-month-old infant, which featured recurrent bronchoalveolitis since the age of 3 months, with a thoracic deformation. Physical examination did found discrete respiratory distress signs. Chest radiography showed large mediastinal enlargement. The computed tomography showed a solid cystic-cloisonned mass with fat and central calcification highly suggestive of an intracardiac teratoma. A radical surgical excision was made and the histological examination found a well circumscribed tumour containing elements of the three germ layers confirming the diagnosis of mature well-differentiated teratoma, with no need of immunohistochemical support.	[Azzakhmam, Mustapha; Kessab, Amine] Mil Hosp Rabat, Dept Pathol, Rabat, Morocco; [Malihy, Abderrahmane; Rouas, Lamiae; Lamalmi, Najat] Pediat Hosp Rabat, Dept Pathol, Rabat, Morocco	Azzakhmam, M (reprint author), Mil Hosp Rabat, Dept Pathol, Rabat, Morocco.	mustapha_azzak@hotmail.com					ALI SZ, 1994, PEDIATR PATHOL, V14, P913, DOI 10.3109/15513819409037687; Barnes A. R., 1934, AM HEART J, V52, P561; CABANAS VY, 1973, ARCH PATHOL, V96, P399; Campagne G, 1998, EUR J OBSTET GYN R B, V80, P105, DOI 10.1016/S0301-2115(98)00066-9; Columbus M. R., 1562, DE RE ANATOMICA, V482; COSTAS C, 1986, PEDIATR CARDIOL, V7, P179, DOI 10.1007/BF02424995; COX JN, 1983, VIRCHOWS ARCH A, V402, P163, DOI 10.1007/BF00695058; De Chatel A, 1933, FRANKFURT Z CASE PAT, V44; FAROOKI ZQ, 1988, CLIN CARDIOL, V11, P642, DOI 10.1002/clc.4960110910; Geipel A, 2001, ULTRASOUND OBST GYN, V17, P17, DOI 10.1046/j.1469-0705.2001.00314.x; Isaacs Jr H, 2004, PEDIAT CARDIOL, V25; LAZARUS KH, 1989, AM J PEDIAT HEMATOL, V11, P343; MAURER ER, 1952, J THORAC SURG, V23, P479; Niewiadomska-Jarosik K, 2010, PRENATAL DIAG, V30, P882, DOI 10.1002/pd.2586; PRICHARD RW, 1951, AMA ARCH PATHOL, V51, P98; SWALWELL CI, 1993, ARCH PATHOL LAB MED, V117, P739; VANDERHAUWAERT LG, 1971, BRIT HEART J, V33, P125; WILLIAMS GE, 1961, J PATHOL BACTERIOL, V82, P281, DOI 10.1002/path.1700820206; Yuan SM, 2017, PEDIATR NEONATOL, V58, P205, DOI 10.1016/j.pedneo.2016.07.004	19	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									6805234	10.1155/2018/6805234			6	Pathology	Pathology	GK6XI	WOS:000436335800001	29984028	DOAJ Gold, Green Published			2019-10-28	
J	Reddi, DM; Scherpelz, KP; Lerma, A; Shriki, J; Virgin, J				Reddi, Deepti M.; Scherpelz, Kathryn P.; Lerma, Angelica; Shriki, Jabi; Virgin, Jeffrey			Rapidly Growing Pancreatic Adenocarcinoma Presenting as an Irreducible Umbilical Hernia	CASE REPORTS IN PATHOLOGY			English	Article							TUMOR	Hernia sacs are a common anatomic pathology specimen, which rarely contain malignancy. We present a case of rapidly growing pancreatic adenocarcinoma, which initially presented as metastasis to an umbilical hernia sac. The patient was a 55-year-old male with a two-year history of umbilical hernia. Two months prior to herniorrhaphy, the hernia became painful and the patient experienced nausea and weight loss. The gross examination did not reveal distinct lesions. Microscopically, the hernia sac was diffusely infiltrated by moderately differentiated adenocarcinoma, which was positive for CK7 and pancylokeratin and negative for TTF-1, CK20, PSA, and CDX2. Clinical laboratory tests found elevated levels of CA 19-9 and CEA. Computed tomography scan with intravenous contrast showed a 5 cm ill-defined and hypoattenuating mass involving the pancreatic tail and body, as well as numerous ill-defined lesions in the liver and peritoneal carcinomatosis. The patient had an earlier noncontrast computed tomography scan four months prior to the surgery, which did not detect any lesions in the abdomen. This case highlights the importance of intravenous contrast with computed tomography for the evaluation of pancreatic lesions and also emphasizes the importance of thorough histologic evaluation of hernia sacs for the detection of occult malignancy.	[Reddi, Deepti M.; Scherpelz, Kathryn P.; Lerma, Angelica] Univ Washington, Med Ctr, Dept Pathol, 1959 NE Pacific St,Box 356100,Room NE110, Seattle, WA 98195 USA; [Reddi, Deepti M.; Virgin, Jeffrey] Vet Affairs Puget Sound Hlth Care Syst, Dept Pathol, 1660 S Columbian Way, Seattle, WA 98108 USA; [Shriki, Jabi] Vet Affairs Puget Sound Hlth Care Syst, Dept Radiol, 1660 S Columbian Way, Seattle, WA 98108 USA	Reddi, DM (reprint author), Univ Washington, Med Ctr, Dept Pathol, 1959 NE Pacific St,Box 356100,Room NE110, Seattle, WA 98195 USA.	dreddi@uw.edu					Adamu IW, 2010, PATHOL LAB MED INT, V2, P127; BARON BW, 1988, GYNECOL ONCOL, V30, P71, DOI 10.1016/0090-8258(88)90048-0; Bender E., 2001, INTERNET J SURG, V3; Chesley PM, 2015, AM J SURG, V209, P783, DOI 10.1016/j.amjsurg.2014.12.019; College of American Pathologists, 2009, SURG SPEC BE SUMB PA; Dabbas Natalie, 2011, JRSM Short Rep, V2, P5, DOI 10.1258/shorts.2010.010071; Droeser RA, 2014, J CLIN ONCOL, V32, pE3, DOI 10.1200/JCO.2012.45.3092; Durai R, 2010, ANZ J SURG, V80, P377, DOI 10.1111/j.1445-2197.2010.05288.x; Karabulut Z, 2009, J KOREAN MED SCI, V24, P539, DOI 10.3346/jkms.2009.24.3.539; Kenig Jakub, 2014, Pol Przegl Chir, V86, P189, DOI 10.2478/pjs-2014-0034; Klauss M, 2013, EUR J RADIOL, V82, P208, DOI 10.1016/j.ejrad.2012.09.012; MILLAR R C, 1975, Journal of Surgical Oncology, V7, P493, DOI 10.1002/jso.2930070609; Sams Valerie G, 2010, Am Surg, V76, pE144; Singh V. K., 2014, BMJ CASE REPORTS; Tsuruya K, 2013, WORLD J GASTRO ENDOS, V5, P407, DOI 10.4253/wjge.v5.i8.407; Urbano FL, 2001, HOSP PHYS, V37, P33; Varga-Szabo D, 2016, INT J SURG CASE REP, V19, P134, DOI 10.1016/j.ijscr.2015.12.022; Wang T, 2013, J CLIN PATHOL, V66, P1084, DOI 10.1136/jclinpath-2013-201734; Yoon SH, 2011, RADIOLOGY, V259, P442, DOI 10.1148/radiol.11101133	19	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1784548	10.1155/2018/1784548			4	Pathology	Pathology	GK6XH	WOS:000436335700001	30009070	DOAJ Gold, Green Published			2019-10-28	
J	Jimenez, AR; Rolon, MDR; Eyzaguirre, E; Clement, C				Jimenez, Antonio R.; Rolon, Maria del Mar Rivera; Eyzaguirre, Eduardo; Clement, Cecilia			Vaginal Bleeding as Initial Presentation of an Aggressive Renal Cell Carcinoma: A Case Report and Review of the Literature	CASE REPORTS IN PATHOLOGY			English	Article							METASTASIS	Introduction. Renal cell carcinoma is the third most common urogenital cancer. In some patients, it can metastasize to distant organs. Metastasis to the vagina is extremely rare. Case Presentation. A 54-year-old female with unremarkable history presented to the clinic with a chief complaint of vaginal bleeding. Further examination identified a pedunculated mass on the vaginal wall. Histologic examination revealed a metastatic clear cell renal cell carcinoma. Radiological studies then revealed a left renal mass and bilateral adrenal masses. The patient underwent a nephrectomy, adrenalectomy, and resection of the vaginal mass. The mass in the vagina has since recurred. Conclusion. We report the first known case of vaginal metastasis as initial presentation of a renal cell carcinoma with rhabdoid features. Postmenopausal women with renal cell carcinoma who present with vaginal bleeding should undergo a thorough inspection of the vaginal wall for the potential of metastatic neoplasms.	[Jimenez, Antonio R.; Rolon, Maria del Mar Rivera; Eyzaguirre, Eduardo; Clement, Cecilia] Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77550 USA	Clement, C (reprint author), Univ Texas Med Branch, Dept Pathol, 301 Univ Blvd, Galveston, TX 77550 USA.	cgclemen@utmb.edu					Allard JE, 2004, GYNECOL ONCOL, V92, P970, DOI 10.1016/j.ygyno.2003.11.046; Benbrahim Z, 2013, PAN AFR MED J, V14, DOI 10.11604/pamj.2013.14.62.838; Cairns P, 2011, CANCER BIOMARK, V9, P461, DOI 10.3233/CBM-2011-0176; DeRoche T, 2008, AM J CLIN PATHOL, V130, P560, DOI 10.1309/YR7P42XUVQHPHDWL; Fadare O., 2018, INT J GYNECOLOGICAL, P1; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; OVESEN H, 1990, SCAND J UROL NEPHROL, V24, P237, DOI 10.3109/00365599009180868; Przybycin CG, 2014, AM J SURG PATHOL, V38, P1260, DOI 10.1097/PAS.0000000000000251; Singh K, 2016, INT J GYNECOL PATHOL, V35, P419, DOI 10.1097/PGP.0000000000000253; SOGANI PC, 1979, J UROLOGY, V121, P95, DOI 10.1016/S0022-5347(17)56678-1; Sun DQ, 2013, CHINESE MED J-PEKING, V126, P1793, DOI 10.3760/cmaj.issn.0366-6999.20130118	11	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2109279	10.1155/2018/2109279			4	Pathology	Pathology	GK1AY	WOS:000435846000001	29967708	DOAJ Gold, Green Published			2019-10-28	
J	Watanabe, J; Yamada, S; Sasaguri, Y; Inagaki, M; Iwagaki, H				Watanabe, Jiro; Yamada, Sohsuke; Sasaguri, Yasuyuki; Inagaki, Masaru; Iwagaki, Hiromi			Two Surgical Cases of Combined Hepatocellular-Cholangiocarcinoma, Intermediate-Cell Subtype: Potentially Characteristic Gross Features	CASE REPORTS IN PATHOLOGY			English	Editorial Material							CLINICOPATHOLOGICAL SIGNIFICANCE	We herein reported two rare surgical cases of primary combined hepatocellular-cholangiocellular carcinoma, intermediate-cell subtype (CHC-INT), showing potentially characteristic and specific gross findings on their cut surface: both CHC-INTs demonstrated poorly demarcated and expansive and/or infiltrative hepatic nodules in lobulated margins, appearing clearly whitish in color. We were finally able to accurately diagnose the current lesions after thorough analyses including an appropriate and wide panel of immunohistochemical antibodies. Despite that, all pathologists should be aware that the potentially characteristic gross features of primary CHC-INT might also be one of the powerful supplementary tools for reaching its correct, conclusive diagnosis.	[Watanabe, Jiro; Yamada, Sohsuke; Sasaguri, Yasuyuki] Fukuyama Med Ctr, Natl Hosp Org, Lab Pathol, Fukuyama, Hiroshima, Japan; [Yamada, Sohsuke] Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Uchinada, Kanazawa, Ishikawa 9200293, Japan; [Sasaguri, Yasuyuki] Fukuoka Tokushukai Hosp, Pathol Lab, Fukuoka, Fukuoka, Japan; [Inagaki, Masaru; Iwagaki, Hiromi] Fukuyama Med Ctr, Natl Hosp Org, Dept Surg, Fukuyama, Hiroshima, Japan	Yamada, S (reprint author), Fukuyama Med Ctr, Natl Hosp Org, Lab Pathol, Fukuyama, Hiroshima, Japan.; Yamada, S (reprint author), Kanazawa Med Univ, Dept Pathol & Lab Med, 1-1 Uchinada, Kanazawa, Ishikawa 9200293, Japan.	sohsuke@kanazawa-med.ac.jp		Yamada, Sohsuke/0000-0002-4071-2657	National Hospital Organization, Fukuyama Medical Center, Fukuyama, Japan	This work received fund from the National Hospital Organization, Fukuyama Medical Center, Fukuyama, Japan. The authors would like to thank Dr. and Associate Professor Jun Akiba, Department of Pathology, Kurume University School of Medicine, Kurume, Japan, for his constructive and helpful suggestions/comments and correct diagnoses.	Akiba J, 2016, J CLIN PATHOL, V69, P846, DOI 10.1136/jclinpath-2015-203491; Akiba J, 2013, AM J SURG PATHOL, V37, P496, DOI 10.1097/PAS.0b013e31827332b0; ALLEN RA, 1949, AM J PATHOL, V25, P647; Sasaki M, 2017, HISTOPATHOLOGY, V70, P423, DOI 10.1111/his.13084; Sasaki M, 2015, LIVER INT, V35, P1024, DOI 10.1111/liv.12563; Taguchi J, 1996, J GASTROEN HEPATOL, V11, P758, DOI 10.1111/j.1440-1746.1996.tb00327.x; Theise N. D., 2010, WHO CLASSIFICATION T	7	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8423939	10.1155/2018/8423939			4	Pathology	Pathology	GK1BB	WOS:000435846300001	29967709	DOAJ Gold, Green Published			2019-10-28	
J	Wald, NJ				Wald, Nicholas J.			Prenatal reflex DNA screening for trisomy 21, 18 and 13	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Prenatal screening; reflex DNA screening; NIPT; Down syndrome; trisomy 21; trisomy 18; trisomy 13			[Wald, Nicholas J.] Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England	Wald, NJ (reprint author), Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med & Dent, Charterhouse Sq, London EC1M 6BQ, England.	n.j.wald@qmul.ac.uk					Bestwick JP, 2016, J MED SCREEN, V23, P171, DOI 10.1177/0969141315617982; Chitty LS, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3426; Gil MM, 2015, ULTRASOUND OBST GYN, V45, P249, DOI 10.1002/uog.14791; Wald NJ, 2018, GENET MED, V20, P825, DOI 10.1038/gim.2017.188; Wald NJ, 2015, J MED SCREEN, V22, P168, DOI 10.1177/0969141315581005; Wald NJ, 1984, ANTENATAL NEONATAL S, p[ii, 3]	6	3	3	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					399	401		10.1080/14737159.2018.1462703			3	Pathology	Pathology	GJ6FL	WOS:000435479400001	29633889				2019-10-28	
J	Wang, HM; Deng, JK; Tang, YW				Wang, Hongmei; Deng, Jikui; Tang, Yi-Wei			Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Article						Influenza viruses A and B; isothermal nucleic acid amplification technology; nasal swabs; nasopharyngeal swabs; nicking enzyme amplification reaction; rapid molecular diagnosis	RESPIRATORY SYNCYTIAL VIRUS; XPERT FLU/RSV XC; RAPID DETECTION; DIAGNOSTIC-ACCURACY; HOSPITALIZED-PATIENTS; CLINICAL-EVALUATION; CHAIN-REACTION; DOUBLE-BLIND; AMPLIFICATION; PERFORMANCE	Introduction: The Alere i Influenza A & B assay incorporates the Nicking Enzyme Amplification Reaction technique on the Alere i instrument to detect and differentiate influenza virus (Flu) A and B nucleic acids in specific specimens. Areas covered: The Alere i Influenza A & B assay was cleared by the US Food and Drug Administration for use with nasal swabs (NS) and nasopharyngeal swabs, either directly or in viral transport medium. Notably, direct use on NS was the first ever CLIA-waived nucleic acid-based test. Previously published evaluations have reported sensitivities and specificities of 55.2-100% and 62.5-100% for Flu A and 45.2-100% and 53.6-100% for Flu B, respectively. Expert commentary: The Alere i Influenza A & B assay provides a rapid and simple platform for detection and differentiation of Flu A and B. Efforts are expected to further improve sensitivity and user-friendliness for effective and widespread use in the true point-of-care setting.	[Wang, Hongmei; Deng, Jikui] Shenzhen Children Hosp, Div Infect Dis, Shenzhen, Peoples R China; [Wang, Hongmei; Tang, Yi-Wei] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA; [Wang, Hongmei; Tang, Yi-Wei] Mem Sloan Kettering Canc Ctr, Dept Internal Med, 1275 York Ave, New York, NY 10021 USA; [Tang, Yi-Wei] Cornell Univ, Dept Pathol & Lab Med, Weill Med Coll, New York, NY 10021 USA	Deng, JK (reprint author), Shenzhen Children Hosp, Div Infect Dis, Shenzhen, Peoples R China.; Tang, YW (reprint author), Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA.; Tang, YW (reprint author), Mem Sloan Kettering Canc Ctr, Dept Internal Med, 1275 York Ave, New York, NY 10021 USA.; Tang, YW (reprint author), Cornell Univ, Dept Pathol & Lab Med, Weill Med Coll, New York, NY 10021 USA.	jikui.deng@yahoo.com; tangy@mskcc.org			Memorial Sloan Kettering Cancer Center; Alere Scarborough [SK2013-0262]; NIH/NCI Cancer Center Support Grant [P30 (CA008748)]	The study was supported in part by a research agreement between the Memorial Sloan Kettering Cancer Center and Alere Scarborough (SK2013-0262) and by an NIH/NCI Cancer Center Support Grant P30 (CA008748).	Beigel JH, 2017, LANCET INFECT DIS, V17, P1255, DOI 10.1016/S1473-3099(17)30476-0; Bell JJ, 2014, J CLIN MICROBIOL, V52, P3992, DOI 10.1128/JCM.01639-14; Bell J, 2014, J CLIN VIROL, V61, P81, DOI 10.1016/j.jcv.2014.06.001; Berry GJ, 2018, J CLIN MICROBIOL, V56, DOI [10.1128/jcm.01310-17, 10.1128/JCM.01310-17]; Busson L, 2017, DIAGN MICR INFEC DIS, V87, P238, DOI 10.1016/j.diagmicrobio.2016.11.015; Hurtado JC, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-0775-5; Carman WF, 2000, BRIT MED J, V321, P736, DOI 10.1136/bmj.321.7263.736; Chiarella FC, 2016, J MED MICROBIOL, V65, P456, DOI 10.1099/jmm.0.000249; Chapin KC, 2015, J CLIN MICROBIOL, V53, P706, DOI 10.1128/JCM.02783-14; Chen J, 2018, DIAGN MICR INFEC DIS, V90, P177, DOI 10.1016/j.diagmicrobio.2017.11.010; Cohen DM, 2017, J CLIN MICROBIOL; Davis S, 2017, J HOSP INFECT, V97, P301, DOI 10.1016/j.jhin.2017.05.017; Deng Jikui, 2013, Virologica Sinica, V28, P97, DOI 10.1007/s12250-013-3312-y; Doll MK, 2017, J ANTIMICROB CHEMOTH, V72, P2990, DOI 10.1093/jac/dkx271; Hazelton B, 2015, INFLUENZA OTHER RESP, V9, P151, DOI 10.1111/irv.12303; Huang HS, 2017, CLIN MICROBIOL INFEC, V2, P30643; Huang SC, 2017, ANAL CHEM, V89, P5777, DOI 10.1021/acs.analchem.6b04801; Iuliano AD, 2017, LANCET, V14, P33292; Jokela P, 2015, J CLIN VIROL, V70, P72, DOI 10.1016/j.jcv.2015.07.294; Ling LF, 2018, J CLIN MICROBIOL, V56, DOI 10.1128/JCM.01691-17; Linnes JC, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0057-z; Loens K, 2006, J CLIN MICROBIOL, V44, P166, DOI 10.1128/JCM.44.1.166-171.2006; Marty FM, 2017, LANCET RESP MED, V5, P135, DOI 10.1016/S2213-2600(16)30435-0; Merckx J, 2017, ANN INTERN MED, V167, P394, DOI 10.7326/M17-0848; Nguyen Van JC, 2016, DIAGN MICROBIOL INFE, V85, P19, DOI DOI 10.1016/j.diagmicrobio.2015.11.012; Nie SP, 2014, J CLIN MICROBIOL, V52, P3339, DOI 10.1128/JCM.01132-14; Nolte FS, 2016, J CLIN MICROBIOL, V54, P2763, DOI 10.1128/JCM.01586-16; O'Leary MF, J CLIN MICROBIOL; Otto CC, 2017, JOVE-J VIS EXP, DOI 10.3791/54312; Paules C, 2017, LANCET, V390, P697, DOI 10.1016/S0140-6736(17)30129-0; Peaper DR, 2014, CLIN LAB MED, V34, P365, DOI 10.1016/j.cll.2014.02.009; Peters RM, 2017, J CLIN MICROBIOL, V55, P1032, DOI 10.1128/JCM.02433-16; Poehling KA, 2006, ARCH PEDIAT ADOL MED, V160, P713, DOI 10.1001/archpedi.160.7.713; Poon LLM, 2005, J CLIN MICROBIOL, V43, P427, DOI 10.1128/JCM.43.1.427-430.2005; Popowitch EB, 2015, J CLIN MICROBIOL, V53, P2720, DOI 10.1128/JCM.00972-15; Riazzo C, 2017, ENFERM INFEC MICR CL, V35, P438, DOI 10.1016/j.eimc.2015.10.006; Schnee SV, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2855-1; Sikkema RS, 2016, EUROSURVEILLANCE, V21, P44; Stramer SL, 2012, J INFECT DIS, V205, P886, DOI 10.1093/infdis/jir863; Tang YW, 2016, J CLIN MICROBIOL, V54, P1912, DOI 10.1128/JCM.00482-16; Tang YW, 2013, J CLIN MICROBIOL, V51, P40, DOI 10.1128/JCM.01978-12; Trabattoni E., 2017, AM J EMERG MED; Uyeki TM, 2017, LANCET, V389, P2172, DOI 10.1016/S0140-6736(17)31274-6; Wahrenbrock MG, 2016, J CLIN MICROBIOL, V54, P1902, DOI 10.1128/JCM.00084-16; Yoon J, 2017, J VIROL METHODS, V243, P15, DOI 10.1016/j.jviromet.2017.01.013; Young S, 2017, J CLIN VIROL, V94, P86, DOI 10.1016/j.jcv.2017.07.012; Yu YY, 2015, BIOSENS BIOELECTRON, V64, P566, DOI 10.1016/j.bios.2014.09.080	47	1	1	2	5	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					403	409		10.1080/14737159.2018.1466703			7	Pathology	Pathology	GJ6FL	WOS:000435479400002	29688086	Green Accepted			2019-10-28	
J	Ji, Y; Si, Y; McMillin, GA; Lyon, E				Ji, Yuan; Si, Yue; McMillin, Gwendolyn A.; Lyon, Elaine			Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Pharmacogenomics; pharmacogenetics; PGx; genomic medicine; precision medicine; HLA-B*5701; CYP2D6; next generation sequencing; NGS	IMPLEMENTATION CONSORTIUM GUIDELINES; REUPTAKE INHIBITOR RESPONSE; GENOME-WIDE ASSOCIATIONS; HLA-B GENOTYPE; FUNCTIONAL GENOMICS; DRUG RESPONSE; PERSONALIZED MEDICINE; RESEARCH NETWORK; METHYLTRANSFERASE PHARMACOGENOMICS; ABACAVIR HYPERSENSITIVITY	Introduction: The rapid development and dramatic decrease in cost of sequencing techniques have ushered the implementation of genomic testing in patient care. Next generation DNA sequencing (NGS) techniques have been used increasingly in clinical laboratories to scan the whole or part of the human genome in order to facilitate diagnosis and/or prognostics of genetic disease. Despite many hurdles and debates, pharmacogenomics (PGx) is believed to be an area of genomic medicine where precision medicine could have immediate impact in the near future. Areas covered: This review focuses on lessons learned through early attempts of clinically implementing PGx testing; the challenges and opportunities that PGx testing brings to precision medicine in the era of NGS. Expert commentary: Replacing targeted analysis approach with NGS for PGx testing is neither technically feasible nor necessary currently due to several technical limitations and uncertainty involved in interpreting variants of uncertain significance for PGx variants. However, reporting PGx variants out of clinical whole exome or whole genome sequencing (WES/WGS) might represent additional benefits for patients who are tested by WES/WGS.	Univ Utah, Sch Med, ARUP Labs, Salt Lake City, UT 84108 USA; Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84108 USA	Lyon, E (reprint author), Univ Utah, Sch Med, Mol Genet & Genom, ARUP Labs,Dept Pathol, 500 Chipeta Way, Salt Lake City, UT 84108 USA.	lyone@aruplab.com					Abo R, 2012, PHARMACOGENET GENOM, V22, P247, DOI 10.1097/FPC.0b013e32835001c9; Ajay SS, 2011, GENOME RES, V21, P1498, DOI 10.1101/gr.123638.111; Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Arnaout R, 2013, CLIN CHEM, V59, P649, DOI 10.1373/clinchem.2012.199455; Bakker E, 2006, CLIN CHEM, V52, P557, DOI 10.1373/clinchem.2005.066068; Bank PCD, 2018, PHARMACOGENOMICS, V19, P311, DOI 10.2217/pgs-2017-0175; Belkadi A, 2015, P NATL ACAD SCI USA, V112, P5473, DOI 10.1073/pnas.1418631112; Bielinski SJ, 2014, MAYO CLIN PROC, V89, P25, DOI 10.1016/j.mayocp.2013.10.021; Black JL, 2012, DRUG METAB DISPOS, V40, P111, DOI 10.1124/dmd.111.040832; Brothers CH, 2008, ANN PHARMACOTHER, V42, P1519, DOI [10.1345/aph.1K522b, 10.1345/aph.1K522c]; Caraballo PJ, 2017, GENET MED, V19, P421, DOI 10.1038/gim.2016.120; Caudle KE, 2017, GENET MED, V19, P215, DOI 10.1038/gim.2016.87; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/NMETH.1363, 10.1038/nmeth.1363]; Chidambaran V, 2012, CURR CLIN PHARMACOL, V7, P78, DOI 10.2174/157488412800228866; Claes KBM, 2014, METHODS MOL BIOL, V1167, P303, DOI 10.1007/978-1-4939-0835-6_21; Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975; Clarke TK, 2013, ADDICT BIOL, V18, P702, DOI 10.1111/j.1369-1600.2011.00346.x; Collins FS, 2013, NEW ENGL J MED, V369, P2369, DOI 10.1056/NEJMp1314561; Coonrod EM, 2012, CLIN CHEM LAB MED, V50, P1161, DOI 10.1515/cclm-2011-0841; Cressman AM, 2012, CLIN PHARMACOL THER, V92, P669, DOI 10.1038/clpt.2012.179; Crews KR, 2014, CLIN PHARMACOL THER, V95, P376, DOI 10.1038/clpt.2013.254; Crews KR, 2012, CLIN PHARMACOL THER, V92, P467, DOI 10.1038/clpt.2012.120; Crews KR, 2012, CLIN PHARMACOL THER, V91, P321, DOI 10.1038/clpt.2011.287; Danzer M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-221; Dean L, 2017, MED GENETICS SUMMARI; Ehrenberg PK, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-864; Erlich RL, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-42; Faruki H, 2013, CLIN PHARMACOL THER, V94, P189, DOI 10.1038/clpt.2013.61; Foster RH, 1998, DRUGS, V55, P729, DOI 10.2165/00003495-199855050-00018; Fromer M, 2012, AM J HUM GENET, V91, P597, DOI 10.1016/j.ajhg.2012.08.005; Gabriel C, 2014, TISSUE ANTIGENS, V83, P65, DOI 10.1111/tan.12298; Gaedigk A, 2013, INT REV PSYCHIATR, V25, P534, DOI 10.3109/09540261.2013.825581; Giacomini KM, 2007, CLIN PHARMACOL THER, V81, P328, DOI 10.1038/sj.clpt.6100087; Gillis NK, 2014, CLIN PHARMACOL THER, V95, P269, DOI 10.1038/clpt.2013.214; Godman B, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-179; Hajj A, 2013, PHARMACOGENOMICS, V14, P575, DOI [10.2217/PGS.13.13, 10.2217/pgs.13.13]; Hall FS, 2013, PHARMACOL THERAPEUT, V140, P267, DOI 10.1016/j.pharmthera.2013.07.006; Hoffman JM, 2014, AM J MED GENET C, V166, P45, DOI 10.1002/ajmg.c.31391; Hosomichi K, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-355; Hughes DA, 2004, PHARMACOGENETICS, V14, P335, DOI 10.1097/00008571-200406000-00002; Ingelman-Sundberg M, 2005, PHARMACOGENOMICS J, V5, P6, DOI 10.1038/sj.tpj.6500285; Jannetto PJ, 2010, GENOME MED, V2, DOI 10.1186/gm187; Ji Y, 2005, J NEUROCHEM, V95, P1766, DOI 10.1111/j.1471-4159.2005.03453.x; Ji Y, 2013, PHARMACOGENOMICS J, V13, P456, DOI 10.1038/tpj.2012.32; Ji Y, 2012, PHARMACOGENOMICS J, V12, P78, DOI 10.1038/tpj.2010.69; Ji Y, 2011, CLIN PHARMACOL THER, V89, P97, DOI 10.1038/clpt.2010.250; Ji Y, 2008, CANCER RES, V68, P5997, DOI 10.1158/0008-5472.CAN-08-0043; Ji Y, 2007, J PHARMACOL EXP THER, V322, P529, DOI 10.1124/jpet.107.122895; Ji Y, 2016, J MOL DIAGN, V18, P438, DOI 10.1016/j.jmoldx.2016.01.003; Ji Y, 2014, BRIT J CLIN PHARMACO, V78, P373, DOI 10.1111/bcp.12348; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; Jones B, 2012, NAT REV GENET, V13, P450, DOI 10.1038/nrg3267; Just KS, 2017, EUR J CLIN PHARMACOL, V73, P1247, DOI 10.1007/s00228-017-2292-5; Kadalayil L, 2015, BRIEF BIOINFORM, V16, P380, DOI 10.1093/bib/bbu027; Kalia SS, 2017, GENET MED, V19, P249, DOI 10.1038/gim.2016.190; KIMURA S, 1989, AM J HUM GENET, V45, P889; Koren G, 2006, LANCET, V368, P704, DOI 10.1016/S0140-6736(06)69255-6; Kramer WE, 2009, PHARMACOGENET GENOM, V19, P813, DOI 10.1097/FPC.0b013e3283317b95; Lee H, 2014, JAMA-J AM MED ASSOC, V312, P1880, DOI 10.1001/jama.2014.14604; Leeder JS, 2014, PHARMACOGENOMICS, V15, P1055, DOI [10.2217/PGS.14.27, 10.2217/pgs.14.27]; Linder MW, 1997, CLIN CHEM, V43, P254; Liu M, 2014, MOL ENDOCRINOL, V28, P1740, DOI 10.1210/me.2014-1147; Lyon E, 2012, GENET MED, V14, P990, DOI 10.1038/gim.2012.108; Madadi P, 2009, CLIN PHARMACOL THER, V85, P31, DOI 10.1038/clpt.2008.157; Madadi P, 2009, CAN FAM PHYSICIAN, V55, P1077; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P568, DOI 10.1056/NEJMoa0706135; Mamanova L, 2010, NAT METHODS, V7, P111, DOI 10.1038/nmeth.1419; Manolio TA, 2013, GENET MED, V15, P258, DOI 10.1038/gim.2012.157; Margulies M, 2005, NATURE, V437, P376, DOI 10.1038/nature03959; Martin MA, 2014, CLIN PHARMACOL THER, V95, P499, DOI 10.1038/clpt.2014.38; Martin MA, 2012, CLIN PHARMACOL THER, V91, P734, DOI 10.1038/clpt.2011.355; Meyer UA, 2004, NAT REV GENET, V5, P669, DOI 10.1038/nrg1428; Motsinger-Reif AA, 2013, PHARMACOGENET GENOM, V23, P383, DOI 10.1097/FPC.0b013e32833d7b45; Niklas N, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-176; O'Donnell PH, 2012, CLIN PHARMACOL THER, V92, P446, DOI 10.1038/clpt.2012.117; O'Donnell PH, 2014, AM J MED GENET C, V166, P68, DOI 10.1002/ajmg.c.31385; Ober U, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002685; Pratt VM, 2018, J MOL DIAGN, V20, P269, DOI 10.1016/j.jmoldx.2018.01.011; Ratain MJ, 2013, CLIN PHARMACOL THER, V94, P184, DOI 10.1038/clpt.2013.66; Relling MV, 2011, CLIN PHARMACOL THER, V89, P464, DOI 10.1038/clpt.2010.279; Saag M, 2008, CLIN INFECT DIS, V46, P1111, DOI 10.1086/529382; Schackman BR, 2008, AIDS, V22, P2025, DOI 10.1097/QAD.0b013e3283103ce6; Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486; Shuldiner AR, 2013, CLIN PHARMACOL THER, V94, P207, DOI 10.1038/clpt.2013.59; Squassina A, 2010, PHARMACOGENOMICS, V11, P1149, DOI 10.2217/PGS.10.97; Stamer UM, 2010, PHARMACOGENOMICS, V11, P843, DOI 10.2217/PGS.10.47; Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34; Thorn Caroline F, 2013, Methods Mol Biol, V1015, P311, DOI 10.1007/978-1-62703-435-7_20; Torkamani A, 2011, GENOMICS, V98, P233, DOI 10.1016/j.ygeno.2011.07.006; Van Driest SL, 2014, CLIN PHARMACOL THER, V95, P423, DOI 10.1038/clpt.2013.229; Veenstra DL, 2013, GENET MED, V15, P14, DOI 10.1038/gim.2012.106; Wadelius M, 2011, GENOME MED, V3, DOI 10.1186/gm294; Wang B, 2009, DRUG METAB REV, V41, P573, DOI [10.3109/03602530903118729, 10.1080/03602530903118729]; Wang H, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-109; Wang LW, 2011, NEW ENGL J MED, V364, P1144, DOI 10.1056/NEJMra1010600; Weinshilboum R, 2003, NEW ENGL J MED, V348, P529, DOI 10.1056/NEJMra020021; Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601; Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007	100	5	5	1	8	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					411	421		10.1080/14737159.2018.1461561			11	Pathology	Pathology	GJ6FL	WOS:000435479400003	29634383				2019-10-28	
J	Clausen, FB				Clausen, Frederik Banch			Lessons learned from the implementation of non-invasive fetal RHD screening	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Fetal RHD screening; cell-free fetal DNA; HDFN; antenatal prophylaxis; noninvasive prenatal testing	CELL-FREE DNA; NEGATIVE PREGNANT-WOMEN; ANTI-D PROPHYLAXIS; RHESUS D STATUS; REAL-TIME PCR; MATERNAL PLASMA; HEMOLYTIC-DISEASE; PRENATAL-DIAGNOSIS; ANTENATAL PROPHYLAXIS; 1ST TRIMESTER	Introduction: In the fight against hemolytic disease of the fetus and newborn, pregnant RhD negative women are offered antenatal and postnatal anti-D immunoglobulin prophylaxis to prevent the development of antibodies against the fetal D antigen. Antenatal prophylaxis has traditionally been provided to all D negative pregnant women, as the fetal RhD type remains unknown until birth. With noninvasive prenatal testing of cell-free DNA, predicting the fetal RhD type has become highly feasible based on analysis of the fetal RHD gene. Fetal RHD screening can guide targeted antenatal prophylaxis, treating only women who carry an RhD positive fetus, thereby avoiding the unnecessary treatment of approximately 40% of the RhD negative women. Areas covered: Areas covered are the current clinical practice, performance, and challenges of fetal RHD screening, and relevant issues for its implementation. Expert commentary: Fetal RHD screening is highly accurate, with sensitivities of 99.9%, as reported from clinical programs. From gestational week 10, sensitivities are approximately 99%. Despite challenges in assay design, low levels of cell-free fetal DNA in the maternal plasma, and concerns regarding implementation and medical necessity, the clinical experience with fetal RHD screening and targeted prophylaxis has generated encouraging results, and its future widespread use is expected.	[Clausen, Frederik Banch] Copenhagen Univ Hosp, Dept Clin Immunol, Lab Blood Genet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark	Clausen, FB (reprint author), Copenhagen Univ Hosp, Dept Clin Immunol, Lab Blood Genet, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	frederik.banch.clausen@rh.regionh.dk					Akolekar R, 2011, FETAL DIAGN THER, V29, P301, DOI 10.1159/000322959; Amaral DRT, 2011, J CLIN LAB ANAL, V25, P100, DOI 10.1002/jcla.20440; Angert RM, 2003, CLIN CHEM, V49, P195, DOI 10.1373/49.1.195; Barra GB, 2015, CLIN BIOCHEM, V48, P976, DOI 10.1016/j.clinbiochem.2015.02.014; Barrett AN, 2014, PRENATAL DIAG, V34, P1283, DOI 10.1002/pd.4468; Benachi A, 2012, EUR J OBSTET GYN R B, V162, P28, DOI 10.1016/j.ejogrb.2012.02.001; Bills VL, 2014, TRANSFUS APHER SCI, V50, P148, DOI 10.1016/j.transci.2014.02.005; BOWMAN JM, 1978, CAN MED ASSOC J, V118, P627; BOWMAN JM, 1978, CAN MED ASSOC J, V118, P623; Bronkhorst AJ, 2015, CLIN CHIM ACTA, V450, P243, DOI 10.1016/j.cca.2015.08.028; Canick JA, 2013, PRENATAL DIAG, V33, P667, DOI 10.1002/pd.4126; Cardo L, 2010, CLIN CHEM LAB MED, V48, P1121, DOI 10.1515/CCLM.2010.234; Chan KCA, 2006, CLIN CHEM, V52, P2211, DOI 10.1373/clinchem.2006.074997; Chitty LS, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5243; Clausen FB, 2014, PRENATAL DIAG, V34, P1000, DOI 10.1002/pd.4419; Clausen FB, 2017, BLOOD TRANSFUS, V5, P1; Clausen FB, 2007, PRENATAL DIAG, V27, P6, DOI 10.1002/pd.1605; Clausen FB, 2015, APMIS, V123, P731, DOI 10.1111/apm.12405; Clausen FB, 2014, TRANSFUS APHER SCI, V50, P154, DOI 10.1016/j.transci.2014.02.008; Clausen FB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076990; Clausen FB, 2012, TRANSFUSION, V52, P752, DOI 10.1111/j.1537-2995.2011.03362.x; Clausen FB, 2011, FETAL DIAGN THER, V29, P155, DOI 10.1159/000321347; CROWTHER CA, 2000, COCHRANE DB SYST REV, V2; Damkjaer MB, 2012, VOX SANG, V103, P145, DOI 10.1111/j.1423-0410.2012.01602.x; Daniels G, 2018, VOX SANG, V113, pE26, DOI 10.1111/vox.12615; Daniels G, 2018, VOX SANG, V113, P198, DOI 10.1111/vox.12616; Daniels G, 2004, VOX SANG, V87, P225, DOI 10.1111/j.1423-0410.2004.00569.x; Daniels G, 2011, VOX SANG, V101, P327, DOI 10.1111/j.1423-0410.2011.01540.x; Daniels G, 1997, LANCET, V350, P862, DOI 10.1016/S0140-6736(05)62031-4; Daniels G., 2013, HUMAN BLOOD GROUPS; Daniels G, 2013, BRIT J HAEMATOL, V161, P461, DOI 10.1111/bjh.12275; Daniels G, 2009, HUM GENET, V126, P729, DOI 10.1007/s00439-009-0738-2; Daniels G, 2009, PRENATAL DIAG, V29, P101, DOI 10.1002/pd.2172; de Haas M, 2015, VOX SANG, V109, P99, DOI 10.1111/vox.12265; de Haas M, 2014, TRANSFUSION MED, V24, P1, DOI 10.1111/tme.12099; de Haas M, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5789; Doescher A, 2013, TRANSFUSION, V53, P353, DOI 10.1111/j.1537-2995.2012.03738.x; Dziegiel MH, 2012, ISBT SCI SER, V7, P160, DOI DOI 10.1111/J.1751-2824.2012.01562.X; El Messaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022; Finning K, 2008, BRIT MED J, V336, P816, DOI 10.1136/bmj.39518.463206.25; Finning KM, 2002, TRANSFUSION, V42, P1079, DOI 10.1046/j.1537-2995.2002.00165.x; Flegel WA, 2007, J OBSTET GYNAECOL CA, V29, P746, DOI 10.1016/S1701-2163(16)32606-8; Goodspeed TA, 2013, TRENDS BIOTECHNOL, V31, P7, DOI 10.1016/j.tibtech.2012.09.001; Gordon LG, 2017, PRENATAL DIAG, V37, P1245, DOI 10.1002/pd.5176; Grill S, 2009, ARCH GYNECOL OBSTET, V279, P533, DOI 10.1007/s00404-008-0774-5; Grootkerk-Tax MGHM, 2006, TRANSFUSION, V46, P2142, DOI 10.1111/j.1537-2995.2006.01044.x; Haimila K, 2017, ACTA OBSTET GYN SCAN, V96, P1228, DOI 10.1111/aogs.13191; Hawk AF, 2013, OBSTET GYNECOL, V122, P579, DOI 10.1097/AOG.0b013e31829f8814; Hirose TG, 2007, J OBSTET GYNAECOL, V27, P545, DOI 10.1080/01443610701469941; Hyland CA, 2017, PATHOLOGY, V49, P757, DOI 10.1016/j.pathol.2017.08.010; Hyland CA, 2009, MED J AUSTRALIA, V191, P21, DOI 10.5694/j.1326-5377.2009.tb02668.x; Javadi A, 2016, VOX SANG, V111, P246; Johnson JA, 2017, J OBSTET GYNAECOL CA, V39, P366, DOI 10.1016/j.jogc.2016.12.006; Kacker S, 2015, TRANSFUSION, V55, P2095, DOI 10.1111/trf.13074; Kent J, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-87; Kjaer M, 2018, ACTA OBSTET GYN SCAN, V97, P766, DOI 10.1111/aogs.13320; Koby L, 2012, J OBSTET GYNAECOL CA, V34, P429, DOI 10.1016/S1701-2163(16)35239-2; Koelewijn JM, 2008, TRANSFUSION, V48, P1721, DOI 10.1111/j.1537-2995.2008.01742.x; Kolialexi A, 2012, EUR J OBSTET GYN R B, V161, P34, DOI 10.1016/j.ejogrb.2011.12.025; Legler TJ, 2007, PRENATAL DIAG, V27, P824, DOI 10.1002/pd.1783; Legler TJ, 2009, TRANSFUS MED HEMOTH, V36, P189, DOI 10.1159/000216580; Li Y, 2010, PRENATAL DIAG, V30, P1010, DOI 10.1002/pd.2598; Liumbruno GM, 2010, BLOOD TRANSFUS-ITALY, V8, P8, DOI 10.2450/2009.0108-09; Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205; Lui YYN, 2002, CLIN CHEM LAB MED, V40, P962, DOI 10.1515/CCLM.2002.169; Brajovich MEL, 2012, TRANSFUSION, V52, P389, DOI 10.1111/j.1537-2995.2011.03297.x; Ma KK, 2016, J MATERN-FETAL NEO M, V29, P1866, DOI 10.3109/14767058.2015.1066773; Maddocks DG, 2009, BIOCHEM SOC T, V37, P460, DOI 10.1042/BST0370460; Manzanares S, 2014, FETAL DIAGN THER, V35, P7, DOI 10.1159/000356078; Martin FO, 2013, TRANSFUS APHER SCI, V48, P113, DOI 10.1016/j.transci.2012.09.004; Masala M, 2015, PRENATAL DIAG, V35, P506, DOI 10.1002/pd.4489; Moise KJ, 2013, PRENATAL DIAG, V33, P95, DOI 10.1002/pd.4018; Moise KJ, 2016, OBSTET GYNECOL, V128, P1340, DOI 10.1097/AOG.0000000000001741; Mota M, 2012, J CLIN LAB ANAL, V26, P104, DOI 10.1002/jcla.21489; Muller SP, 2008, TRANSFUSION, V48, P2292, DOI 10.1111/j.1537-2995.2008.01843.x; Muller SP, 2011, PRENATAL DIAG, V31, P1300, DOI 10.1002/pd.2889; National Institute for Health and Care Excellence (NICE), 2016, HIGH THROUGHP NON PR; Neovius M, 2016, BJOG-INT J OBSTET GY, V123, P1337, DOI 10.1111/1471-0528.13801; Oxenford K, 2013, PRENATAL DIAG, V33, P688, DOI 10.1002/pd.4135; Picchiassi E, 2015, TRANSFUS MED HEMOTH, V42, P22, DOI 10.1159/000370233; Repiska G, 2012, CLIN CHEM LAB MED, V8, P1; Rieneck K, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a023093; Sandler SG, 2017, OBSTET GYNECOL, V130, P633, DOI 10.1097/AOG.0000000000002190; Scheffer PG, 2011, CURR OPIN HEMATOL, V18, P467, DOI 10.1097/MOH.0b013e32834bab2d; Schmidt LC, 2014, GENET MOL RES, V13, P799, DOI 10.4238/2014.February.7.1; Shih DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016090; Sillence KA, 2015, CLIN CHEM, V61, P1399, DOI 10.1373/clinchem.2015.239137; Singleton BK, 2000, BLOOD, V95, P12; Soothill PW, 2015, BJOG-INT J OBSTET GY, V122, P1682, DOI 10.1111/1471-0528.13055; Stegmann TC, 2016, BRIT J HAEMATOL, V173, P469, DOI 10.1111/bjh.13960; Svobodova I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142572; Szczepura A, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-5; Teitelbaum L, 2015, ULTRASOUND OBST GYN, V45, P84, DOI 10.1002/uog.14723; Thurik FF, 2015, PRENATAL DIAG, V35, P754, DOI 10.1002/pd.4600; Thurik FF, 2016, TRANSFUSION, V56, P2122, DOI 10.1111/trf.13669; Tiblad E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070984; Boggione CT, 2017, BLOOD TRANSFUS-ITALY, V15, P66, DOI 10.2450/2016.0228-15; Boggione CT, 2014, TRANSFUSION, V54, P2456, DOI 10.1111/trf.12691; Turner RM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030711; Tynan JA, 2011, AM J OBSTET GYNECOL, V204, DOI 10.1016/j.ajog.2010.09.028; Urbaniak SJ, 1998, BRIT J OBSTET GYNAEC, V105, P11, DOI 10.1111/j.1471-0528.1998.tb10286.x; Urbaniak SJ, 2000, BLOOD REV, V14, P44, DOI 10.1054/blre.1999.0123; van der Schoot CE, 2017, CURR OPIN HEMATOL, V24, P544, DOI 10.1097/MOH.0000000000000379; van der Schoot CE, 2003, TRANSFUS MED REV, V17, P31, DOI 10.1053/tmrv.2003.50001; Van Sandt VST, 2015, TRANSFUSION, V55, P1411, DOI 10.1111/trf.12947; Vivanti A, 2016, AM J OBSTET GYNECOL, V215, DOI 10.1016/j.ajog.2016.06.054; Wagner F F, 2004, Immunohematology, V20, P23; Wagner FF, 2013, TRANSFUS MED HEMOTH, V40, P172, DOI 10.1159/000351604; Wang E, 2013, PRENATAL DIAG, V33, P662, DOI 10.1002/pd.4119; Wang XD, 2009, EUR J CLIN INVEST, V39, P607, DOI 10.1111/j.1365-2362.2009.02148.x; Westhoff CM, 2007, SEMIN HEMATOL, V44, P42, DOI 10.1053/j.seminhematol.2006.09.010; White HE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045073; Wienzek-Lischka S, 2015, TRANSFUSION, V55, P1538, DOI 10.1111/trf.13102; Wikman AT, 2012, OBSTET GYNECOL, V120, P227, DOI 10.1097/AOG.0b013e31825d33d9; Wong D, 2013, CLIN BIOCHEM, V46, P1099, DOI 10.1016/j.clinbiochem.2013.04.023; Xiong YL, 2017, PRENATAL DIAG, V37, P311, DOI 10.1002/pd.5006; Zejskova L, 2010, EXP MOL PATHOL, V89, P241, DOI 10.1016/j.yexmp.2010.09.002; Zhou L, 2005, AM J OBSTET GYNECOL, V193, P1966, DOI 10.1016/j.ajog.2005.04.052; Zhu YJ, 2014, J MATERN-FETAL NEO M, V27, P1839, DOI 10.3109/14767058.2014.882306; Ziza KC, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22052	120	1	2	0	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					423	431		10.1080/14737159.2018.1461562			9	Pathology	Pathology	GJ6FL	WOS:000435479400004	29616835				2019-10-28	
J	Tsang, HF; Chan, LWC; Tong, JCH; Wong, HT; Lai, CKC; Au, TCC; Chan, AKC; Ng, LPW; Cho, WCS; Wong, SCC				Tsang, Hin-Fung; Chan, Lawrence Wing-Chi; Tong, Jennifer Chiu-Hung; Wong, Heong-Ting; Lai, Christopher Koon-Chi; Au, Thomas Chi-Chuen; Chan, Amanda Kit-Ching; Ng, Lawrence Po-Wah; Cho, William Chi-Shing; Wong, Sze-Chuen Cesar			Implementation and new insights in molecular diagnostics for HIV infection	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Acquired immunodeficiency syndrome; AIDS; human immunodeficiency virus; HIV detection; molecular diagnostics	NUCLEIC-ACID AMPLIFICATION; REAL-TIME; IMMUNO-PCR; RNA; TRANSCRIPTION; TRANSMISSION; ASSAYS; CELLS; DNA	Introduction: Acquired immunodeficiency syndrome(AIDS) is a kind of acquired disease that breaks down the immune system. Human immunodeficiency virus (HIV) is the causative agent of AIDS. By the end of 2016, there were 36.7 million people living with HIV worldwide. Early diagnosis can alert infected individuals to risk behaviors in order to control HIV transmission. Infected individuals are also benefited from proper treatment and management upon early diagnosis. Thanks to the public awareness of the disease, the annual increase of new HIV infections has been slowly declining over the past decades. The advent of molecular diagnostics has allowed early detection and better management of HIV infected patients. Areas covered: In this review, the authors summarized and discussed the current and future technologies in molecular diagnosis as well as the biomarkers developed for HIV infection. Expert Commentary: A simple and rapid detection of viral load is important for patients and doctors to monitor HIV progression and antiretroviral treatment efficiency. In the near future, it is expected that new technologies such as digital PCR and CRISPR-based technology will play more important role in HIV detection and patient management.	[Tsang, Hin-Fung; Chan, Lawrence Wing-Chi; Wong, Sze-Chuen Cesar] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China; [Tong, Jennifer Chiu-Hung] Tung Wah Coll, Sch Med & Hlth Sci, Kowloon, Hong Kong, Peoples R China; [Wong, Heong-Ting] Kiang Wu Hosp, Dept Pathol, Macau, Peoples R China; [Lai, Christopher Koon-Chi; Chan, Amanda Kit-Ching; Ng, Lawrence Po-Wah; Wong, Sze-Chuen Cesar] Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China; [Au, Thomas Chi-Chuen; Wong, Sze-Chuen Cesar] Chinese Univ Hong Kong, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Hong Kong Canc Inst, Shatin, Hong Kong, Peoples R China; [Au, Thomas Chi-Chuen; Wong, Sze-Chuen Cesar] Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China; [Cho, William Chi-Shing] Queen Elizabeth Hosp, Dept Clin Oncol, Kowloon, Hong Kong, Peoples R China	Wong, SCC (reprint author), Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Kowloon, Hong Kong, Peoples R China.; Wong, SCC (reprint author), Queen Elizabeth Hosp, Dept Pathol, Kowloon, Hong Kong, Peoples R China.; Wong, SCC (reprint author), Chinese Univ Hong Kong, State Key Lab Oncol South China, Sir YK Pao Ctr Canc, Dept Clin Oncol,Hong Kong Canc Inst, Shatin, Hong Kong, Peoples R China.; Wong, SCC (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.	cesar.wong@polyu.edu.hk					Barletta JM, 2004, AM J CLIN PATHOL, V122, P20, DOI 10.1309/529T2WDNEB6X8VUN; Branson BM, 2012, J INFECT DIS, V205, P521, DOI 10.1093/infdis/jir793; Buonaguro L, 2007, J VIROL, V81, P10209, DOI 10.1128/JVI.00872-07; Elisa FL, 2011, PLOS ONE, V6; Eriksson S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003174; Eshleman SH, 2009, JAIDS-J ACQ IMM DEF, V52, P121, DOI 10.1097/QAI.0b013e3181ab61e1; Esseghaier C, 2013, BIOSENS BIOELECTRON, V41, P335, DOI 10.1016/j.bios.2012.08.049; Ferrer M, 2016, NUCLEIC ACIDS RES, V44, P7922, DOI 10.1093/nar/gkw511; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Garland FC, 1996, ANN EPIDEMIOL, V6, P341, DOI 10.1016/S1047-2797(96)00053-1; Gerasimov JY, 2010, CHEM COMMUN, V46, P395, DOI 10.1039/b919070h; Gootenberg JS, 2017, SCIENCE, V356, P438, DOI 10.1126/science.aam9321; Gueudin M, 2007, JAIDS-J ACQ IMM DEF, V44, P500, DOI 10.1097/QAI.0b013e31803260df; Gueudin M, 2012, J CLIN MICROBIOL, V50, P831, DOI 10.1128/JCM.05669-11; Hollingsworth TD, 2008, J INFECT DIS, V198, P687, DOI 10.1086/590501; Jangam SR, 2013, BIOSENS BIOELECTRON, V42, P69, DOI 10.1016/j.bios.2012.10.024; Kheiri F, 2011, BIOSENS BIOELECTRON, V26, P4457, DOI 10.1016/j.bios.2011.05.002; Kosaka PM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171899; Mahmoud KA, 2008, ACS NANO, V2, P1051, DOI 10.1021/nn8000774; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Mallal S, 2008, NEW ENGL J MED, V358, P6; MNneil SE, 2005, J LEUKOCYTE BIOL, V78, P585, DOI 10.1189/jlb.0205074; Morley Alexander A, 2014, Biomol Detect Quantif, V1, P1; Oliveira D, 2010, ACCREDIT QUAL ASSUR, V15, P89, DOI 10.1007/s00769-009-0598-4; Owen SM, 2008, J CLIN MICROBIOL, V46, P1588, DOI 10.1128/JCM.02196-07; Patel P, 2010, ARCH INTERN MED, V170, P66, DOI 10.1001/archinternmed.2009.445; Pilcher CD, 2002, JAMA-J AM MED ASSOC, V288, P216, DOI 10.1001/jama.288.2.216; Pinkerton SD, 2007, AIDS, V21, P1625, DOI 10.1097/QAD.0b013e32826fb6a6; Plantin J, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-017-0385-y; Porichis F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6641; Prabhu VS, 2009, AIDS, V23, P1792, DOI 10.1097/QAD.0b013e32832e7d04; Qiao YC, 2017, AIDS RES HUM RETROV, V33, P898, DOI [10.1089/aid.2017.0017, 10.1089/AID.2017.0017]; Quinn TC, 2000, AIDS, V14, P2751, DOI 10.1097/00002030-200012010-00015; Rohrman BA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045611; Rosi NL, 2005, CHEM REV, V105, P1547, DOI 10.1021/cr030067f; SANO T, 1992, SCIENCE, V258, P120, DOI 10.1126/science.1439758; Sara ML, 2017, PLOS ONE, V12; Schito ML, 2010, J INFECT DIS, V201, pS1, DOI 10.1086/650394; Schlatzer D, 2017, ANAL CHEM, V89, P5325, DOI 10.1021/acs.analchem.6b05070; Sedlak RH, 2012, DIAGN MICROBIOL INFE, V75, P1; Shen F, 2011, J AM CHEM SOC, V133, P17705, DOI 10.1021/ja2060116; Strain MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055943; Tang SX, 2010, J INFECT DIS, V201, pS59, DOI 10.1086/650386; Tiwari RP, 2013, J IMMUNOL METHODS, V387, P157, DOI 10.1016/j.jim.2012.10.009; Tsai CT, 2018, P NATL ACAD SCI USA, V115, P1250, DOI 10.1073/pnas.1711004115; Vyboh K, 2012, JOVE-J VIS EXP, V63, P4002; Wang JH, 2013, BIOSENS BIOELECTRON, V41, P484, DOI 10.1016/j.bios.2012.09.011; Wang K, 2017, BIOSENS BIOELECTRON, V87, P116, DOI 10.1016/j.bios.2016.08.017; Wang SQ, 2010, BIOTECHNOL ADV, V28, P770, DOI 10.1016/j.biotechadv.2010.06.004; Wesolowski LG, 2011, J CLIN VIROL, V52, pS45, DOI 10.1016/j.jcv.2011.09.026; Wilburn KM, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0289-2; Wong YK, 2017, EXPERT REV PRECIS ME, V2, P177, DOI 10.1080/23808993.2017.1347482; Zhang DD, 2010, BIOSENS BIOELECTRON, V25, P1088, DOI 10.1016/j.bios.2009.09.032; Zhang HQ, 2007, ANALYST, V132, P724, DOI 10.1039/b704256f	54	1	1	1	4	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					433	441		10.1080/14737159.2018.1464393			9	Pathology	Pathology	GJ6FL	WOS:000435479400005	29641941				2019-10-28	
J	Maas, M; Walz, S; Stuhler, V; Aufderklamm, S; Rausch, S; Bedke, J; Stenzl, A; Todenhofer, T				Maas, Moritz; Walz, Simon; Stuehler, Viktoria; Aufderklamm, Stefan; Rausch, Steffen; Bedke, Jens; Stenzl, Arnulf; Todenhoefer, Tilman			Molecular markers in disease detection and follow-up of patients with non-muscle invasive bladder cancer	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Molecular urine markers; non-muscle invasive bladder cancer; disease detection; follow-up; cell-free DNA	IN-SITU HYBRIDIZATION; TRANSITIONAL-CELL CARCINOMA; VOIDED URINE CYTOLOGY; NUCLEAR-MATRIX PROTEIN; COMPLEMENT FACTOR-H; UROTHELIAL CARCINOMA; TUMOR-MARKERS; BTA STAT; COST-EFFECTIVENESS; CYFRA 21-1	Introduction: Diagnosis and surveillance of non-muscle invasive bladder cancer (NMIBC) is mainly based on endoscopic bladder evaluation and urine cytology. Several assays for determining additional molecular markers (urine-, tissue-or blood-based) have been developed in recent years but have not been included in clinical guidelines so far. Areas covered: This review gives an update on different molecular markers in the urine and evaluates their role in patients with NMIBC in disease detection and surveillance. Moreover, the potential of recent approaches such as DNA methylation assays, multi-panel RNA gene expression assays and cell-free DNA analysis is assessed. Expert commentary: Most studies on various molecular urine markers have mainly focused on a potential replacement of cystoscopy. New developments in high throughput technologies and urine markers may offer further advantages as they may represent a non-invasive approach for molecular characterization of the disease. This opens new options for individualized surveillance strategies and may help to choose the best therapeutic option. The implementation of these technologies in well-designed clinical trials is essential to further promote the use of urine diagnostics in the management of patients with NMIBC.	[Maas, Moritz; Walz, Simon; Stuehler, Viktoria; Aufderklamm, Stefan; Rausch, Steffen; Bedke, Jens; Stenzl, Arnulf; Todenhoefer, Tilman] Univ Hosp Tuebingen, Dept Urolo Gy, Tubingen, Germany	Stenzl, A (reprint author), Univ Hosp Tuebingen, Dept Urol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	urologie@med.uni-tuebingen.de		Bedke, Jens/0000-0003-2778-3108			ABBASCIANO V, 1995, CANCER DETECT PREV, V19, P331; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; [Anonymous], 2013, EUR UROL, V63, P4; Babjuk M, 2002, EUR UROL, V41, P34, DOI 10.1016/S0302-2838(01)00015-X; Barkan GA, 2016, ACTA CYTOL, V60, P185, DOI 10.1159/000446270; Bensalah K, 2007, EUR UROL, V52, P1601, DOI 10.1016/j.eururo.2007.09.036; Bergen HR, 2003, DIS MARKERS, V19, P239; Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094; Beukers W, 2017, J UROLOGY, V197, P1410, DOI 10.1016/j.juro.2016.12.096; Bhat A, 2016, BLADDER CANCER, V2, P65, DOI 10.3233/BLC-150024; Birkenkamp-Demtroder K, 2018, EUR UROL, V73, P535, DOI 10.1016/j.eururo.2017.09.011; Birkenkamp-Demtroder K, 2016, EUR UROL, V70, P75, DOI 10.1016/j.eururo.2016.01.007; Blick CGT, 2012, BJU INT, V110, P84, DOI 10.1111/j.1464-410X.2011.10664.x; Bohm M, 2014, UROL ONCOL-SEMIN ORI, V32, P383, DOI 10.1016/j.urolonc.2013.11.002; Boman H, 2002, J UROLOGY, V167, P80, DOI 10.1016/S0022-5347(05)65387-6; Bubendorf L, 2004, METH MOLEC MED, V97, P117; Cai QL, 2015, ONCOTARGET, V6, P37509, DOI 10.18632/oncotarget.6061; Carpinito GA, 1996, J UROLOGY, V156, P1280, DOI 10.1016/S0022-5347(01)65569-1; Cha EK, 2012, EUR UROL, V61, P185, DOI 10.1016/j.eururo.2011.08.073; Chang SS, 2017, J UROLOGY, V198, P552, DOI 10.1016/j.juro.2017.04.086; Chen CL, 2013, J PROTEOMICS, V85, P28, DOI 10.1016/j.jprot.2013.04.024; Chen L, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201700117; Chen YT, 2010, J PROTEOME RES, V9, P5803, DOI 10.1021/pr100576x; Choi W, 2014, NAT REV UROL, V11, P400, DOI 10.1038/nrurol.2014.129; Chou R, 2015, ANN INTERN MED, V163, P922, DOI 10.7326/M15-0997; Chou R, 2010, ANN INTERN MED, V153, P461, DOI 10.7326/0003-4819-153-7-201010050-00009; Christensen E, 2017, EUR UROL, V71, P961, DOI 10.1016/j.eururo.2016.12.016; Comploj E, 2013, CANCER CYTOPATHOL, V121, P392, DOI 10.1002/cncy.21287; Conconi Donatella, 2018, Methods Mol Biol, V1655, P3, DOI 10.1007/978-1-4939-7234-0_1; Deininger S, 2018, DIAGN CYTOPATHOL, V46, P111, DOI 10.1002/dc.23857; Dimashkieh H, 2013, CANCER CYTOPATHOL, V121, P591, DOI 10.1002/cncy.21327; Eissa S, 2002, J UROLOGY, V168, P465, DOI 10.1016/S0022-5347(05)64659-9; Frantzi M, 2017, BLADDER CANCER, V3, P1, DOI 10.3233/BLC-160073; Frantzi M, 2016, ONCOTARGET, V7, P70750, DOI 10.18632/oncotarget.12218; Frantzi M, 2016, CLIN CANCER RES, V22, P4077, DOI 10.1158/1078-0432.CCR-15-2715; Frantzi M, 2013, J PROTEOME RES, V12, P3969, DOI 10.1021/pr400255h; Getzenberg RH, 1996, CANCER RES, V56, P1690; Giannopoulos A, 2000, UROLOGY, V55, P871, DOI 10.1016/S0090-4295(00)00489-1; Giberti C, 2010, BIOMED ENVIRON SCI, V23, P300, DOI 10.1016/S0895-3988(10)60067-0; Glas AS, 2003, J UROLOGY, V169, P1975, DOI 10.1097/01.ju.0000067461.30468.6d; Gofrit ON, 2008, UROL ONCOL-SEMIN ORI, V26, P246, DOI 10.1016/j.urolonc.2007.02.011; Greene Kirsten L, 2006, Rev Urol, V8, P190; Grubmuller B, 2016, MINI-REV MED CHEM, V16, P1444, DOI 10.2174/1389557515666150909141404; Hajdinjak T, 2008, UROL ONCOL-SEMIN ORI, V26, P646, DOI 10.1016/j.urolonc.2007.06.002; Halling KC, 2002, J UROLOGY, V167, P2001, DOI 10.1016/S0022-5347(05)65072-0; Hood L, 2011, NAT REV CLIN ONCOL, V8, P184, DOI 10.1038/nrclinonc.2010.227; Horie S, 2014, CLIN EXP NEPHROL, V18, P679, DOI 10.1007/s10157-014-1001-2; Huang YL, 2015, TUMOR BIOL, V36, P3137, DOI 10.1007/s13277-015-3352-z; Hussain SA, 2017, INT J ONCOL, V50, P1147, DOI 10.3892/ijo.2017.3893; Irani J, 1999, EUR UROL, V35, P89, DOI 10.1159/000019824; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kamat AM, 2017, EUR UROL; Kamat AM, 2016, BJU INT, V117, P754, DOI 10.1111/bju.13186; Kamat AM, 2012, J UROLOGY, V187, P862, DOI 10.1016/j.juro.2011.10.144; Kinders R, 1998, CLIN CANCER RES, V4, P2511; Kohler CU, 2014, BIOCHEM BIOPH RES CO, V448, P467, DOI 10.1016/j.bbrc.2014.04.137; Konety BR, 2000, CLIN CANCER RES, V6, P2618; Konety BR, 2000, J UROLOGY, V164, P634, DOI 10.1016/S0022-5347(05)67269-2; Konety BR, 2001, J UROLOGY, V165, P600, DOI 10.1097/00005392-200102000-00081; Ku JH, 2012, BJU INT, V110, P630, DOI 10.1111/j.1464-410X.2011.10884.x; Kuziora M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11538; Latosinska A, 2018, PROTEOM CLIN APPL, V12, DOI 10.1002/prca.201700074; Lei T, 2013, CLIN GENITOURIN CANC, V11, P56, DOI 10.1016/j.clgc.2012.06.003; Leyh H, 1999, EUR UROL, V35, P52, DOI 10.1159/000019819; Li CY, 2014, BIOCHEM BIOPH RES CO, V446, P1047, DOI 10.1016/j.bbrc.2014.03.053; Li HJ, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-21; Linden M, 2012, PROTEOMICS, V12, P135, DOI 10.1002/pmic.201000810; Lokeshwar VB, 2005, UROLOGY, V66, P35, DOI 10.1016/j.urology.2005.08.064; Lokeshwar VB, 2001, J UROLOGY, V165, P1067, DOI 10.1016/S0022-5347(05)66428-2; Lotan Y, 2003, UROLOGY, V61, P109, DOI 10.1016/S0090-4295(02)02136-2; Lotan Y, 2002, J UROLOGY, V167, P75, DOI 10.1016/S0022-5347(05)65386-4; Lotan Y, 2008, J UROLOGY, V179, P2164, DOI 10.1016/j.juro.2008.01.105; Lotan Y, 2008, WORLD J UROL, V26, P13, DOI 10.1007/s00345-007-0223-2; Lotan Y, 2009, CANCER, V115, P4096, DOI 10.1002/cncr.24463; Margulis V, 2008, WORLD J UROL, V26, P59, DOI 10.1007/s00345-007-0219-y; Mengual L, 2014, J UROLOGY, V191, P261, DOI 10.1016/j.juro.2013.06.083; Mischinger J, 2017, J CANCER RES CLIN, V143, P677, DOI 10.1007/s00432-016-2310-5; Moonen PMJ, 2007, EUR UROL, V51, P1275, DOI 10.1016/j.eururo.2006.10.044; Morgan TM, 2011, CURR OPIN ONCOL, V23, P275, DOI 10.1097/CCO.0b013e3283446a11; Moris D, 2018, CANCER GENOM PROTEOM, V15, P153, DOI 10.21873/cgp.20073; Mowatt G, 2010, HEALTH TECHNOL ASSES, V14, P1, DOI 10.3310/hta14040; Nasuti JF, 1999, DIAGN CYTOPATHOL, V21, P27, DOI 10.1002/(SICI)1097-0339(199907)21:1<27::AID-DC8>3.3.CO;2-#; Nisman B, 2002, CANCER, V94, P2914, DOI 10.1002/cncr.10565; Odisho AY, 2013, EUR UROL, V63, P936, DOI 10.1016/j.eururo.2012.04.019; Pesch B, 2011, BJU INT, V108, P546, DOI 10.1111/j.1464-410X.2010.09971.x; Pichler R, 2018, BJU INT, V121, P29, DOI 10.1111/bju.14019; Pode D, 1999, J UROLOGY, V161, P443, DOI 10.1016/S0022-5347(01)61918-9; Poulakis V, 2001, BJU INT, V88, P692, DOI 10.1046/j.1464-410X.2001.02355.x; Reid MD, 2012, INT J CLIN EXP PATHO, V5, P882; Reid-Nicholson MD, 2009, MODERN PATHOL, V22, P119, DOI 10.1038/modpathol.2008.179; Ribal MJ, 2016, EUR J CANCER, V54, P131, DOI 10.1016/j.ejca.2015.11.003; Riethdorf S, 2017, TRANSL ANDROL UROL, V6, P1090, DOI 10.21037/tau.2017.09.16; Ritter R, 2014, UROL ONCOL-SEMIN ORI, V32, P337, DOI 10.1016/j.urolonc.2013.09.024; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Sanchez-Carbayo M, 1999, UROLOGY, V54, P656, DOI 10.1016/S0090-4295(99)00195-8; Sanchez-Carbayo M, 1999, J UROLOGY, V162, P1951, DOI 10.1016/S0022-5347(05)68076-7; Schlomer BJ, 2010, J UROLOGY, V183, P62, DOI 10.1016/j.juro.2009.08.157; Schmidt J, 2016, J CANCER RES CLIN, V142, P401, DOI 10.1007/s00432-015-2037-8; Schmitz-Drager BJ, 2008, UROLOGE, V47, P190, DOI 10.1007/s00120-007-1598-9; Schmitz-Drager BJ, 2008, WORLD J UROL, V26, P31, DOI 10.1007/s00345-007-0228-x; Schmitz-Drager B, 2008, BJU INT, V101, P455, DOI 10.1111/j.1464-410X.2007.07287.x; Schmitz-Drager BJ, 2016, UROL ONCOL-SEMIN ORI, V34, P437, DOI 10.1016/j.urolonc.2016.05.030; Schmitz-Drager BJ, 2015, UROL INT, V94, P1, DOI 10.1159/000369357; Schmitz-Drager C, 2016, UROL ONCOL-SEMIN ORI, V34, P452, DOI 10.1016/j.urolonc.2016.06.001; Schroeder GL, 2004, J UROLOGY, V172, P1123, DOI 10.1097/01.ju.0000134347.14643.ab; Schultz IJ, 2006, CLIN CHIM ACTA, V368, P20, DOI 10.1016/j.cca.2005.12.036; Seiler R, 2017, EUR UROL, V72, P142, DOI [10.1016/j.eururo.2017.03.021, 10.1016/j.eururo.2017.03.030]; Senol S, 2015, BOSNIAN J BASIC MED, V15, P7, DOI 10.17305/bjbms.2015.556; Shariat SF, 2004, J UROLOGY, V171, P626, DOI 10.1097/01.ju.0000107826.78479.90; Shariat SF, 2010, UROL ONCOL-SEMIN ORI, V28, P389, DOI 10.1016/j.urolonc.2010.02.011; Shariat Shahrokh F, 2008, Rev Urol, V10, P120; Sharma S, 1999, J UROLOGY, V162, P53, DOI 10.1097/00005392-199907000-00014; Sharp JD, 2002, FRONT BIOSCI-LANDMRK, V7, pE36, DOI 10.2741/sharp; Skacel M, 2003, J UROLOGY, V169, P2101, DOI 10.1097/01.ju.0000066842.45464.cc; Stahlberg A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw224; Steiner H, 2008, BJU INT, V102, P291, DOI 10.1111/j.1464-410X.2008.07596.x; Sullivan PS, 2009, CANCER CYTOPATHOL, V117, P167, DOI 10.1002/cncy.20026; Theodorescu D, 2006, LANCET ONCOL, V7, P230, DOI 10.1016/S1470-2045(06); Todenhofer T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1089-0; Todenhofer T, 2013, CANCER CYTOPATHOL, V121, P252, DOI 10.1002/cncy.21247; Todenhofer T, 2013, J CANCER RES CLIN, V139, P49, DOI 10.1007/s00432-012-1297-9; Todenhofer T, 2012, UROLOGY, V79, P620, DOI 10.1016/j.urology.2011.10.067; Tritschler S, 2010, UROLOGY, V76, P677, DOI 10.1016/j.urology.2010.01.083; Tyan YC, 2011, RAPID COMMUN MASS SP, V25, P2851, DOI 10.1002/rcm.5169; van der Aa MNM, 2010, J UROLOGY, V183, P76, DOI 10.1016/j.juro.2009.08.150; van der Aa MNM, 2009, EUR UROL, V55, P659, DOI 10.1016/j.eururo.2008.05.001; van Kessel KEM, 2017, J UROLOGY, V197, P590, DOI 10.1016/j.juro.2016.09.118; van Kessel KEM, 2016, J UROLOGY, V195, P601, DOI 10.1016/j.juro.2015.08.085; van Rhijn BWG, 2005, EUR UROL, V47, P736, DOI 10.1016/j.eururo.2005.03.014; Van Valenberg FJP, 2017, EUR UROL SUPPL, V16, P190; Villicana P, 2009, BIOMARK MED, V3, P265, DOI 10.2217/BMM.09.23; Wallace E, 2018, J UROLOGY, V199, P655, DOI 10.1016/j.juro.2017.09.141; Ward DG, 2017, TRANSL ANDROL UROL, V6, P331, DOI 10.21037/tau.2017.03.08; Weichenhan D, 2013, HUM MOL GENET, V22, pR1, DOI 10.1093/hmg/ddt348; Wild PJ, 2009, CANCER EPIDEM BIOMAR, V18, P1798, DOI 10.1158/1055-9965.EPI-09-0099; Wollin T, 2009, CUAJ-CAN UROL ASSOC, V3, P77; Yang N, 2011, CLIN CANCER RES, V17, P3349, DOI 10.1158/1078-0432.CCR-10-3121; Ye F, 2014, AM J CLIN EXP UROL, V2, P1; Yerlikaya G, 2014, EUR J OBSTET GYN R B, V173, P101, DOI 10.1016/j.ejogrb.2013.11.007; Yoder BJ, 2007, AM J CLIN PATHOL, V127, P295, DOI 10.1309/ADJL7E810U1H42BJ; Yoo JH, 2010, CANCER GENET CYTOGEN, V198, P107, DOI 10.1016/j.cancergencyto.2009.12.017; Yossepowitch O, 2007, J UROLOGY, V177, P1277, DOI 10.1016/j.juro.2006.11.066; Youssef RF, 2012, UROL ONCOL-SEMIN ORI, V30, P273, DOI 10.1016/j.urolonc.2010.02.012; Zellweger T, 2006, INT J CANCER, V119, P1660, DOI 10.1002/ijc.21704; Zoidakis J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009449	145	3	3	1	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					443	455		10.1080/14737159.2018.1469979			13	Pathology	Pathology	GJ6FL	WOS:000435479400006	29707982				2019-10-28	
J	Yin, S; Ma, ZF				Yin, Shuang; Ma, Zhanfang			Electrochemical immunoassay for tumor markers based on hydrogels	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Electrochemical immunosensor; good biocompatibility; hydrogel; rapid electron transfer; stimuli-responsive; tailored functionality; tumour markers	CONDUCTING POLYMER-HYDROGEL; ONE-STEP SYNTHESIS; GOLD NANOPARTICLES; CARBON NANOTUBES; SENSING PLATFORM; METAL-IONS; CANCER; GRAPHENE; POLYANILINE; OXIDE	Introduction: Hydrogel-based electrochemical immunoassays exhibit a large surface-to-volume ratio, excellent biocompatibility, unique stimuli-responsive behavior, high permeability and hydrophilicity and, thus, have shown great potential in the sensitive and accurate detection of tumor markers. Electrochemical immunosensing techniques for tumor markers based on hydrogels have greatly progressed in recent years. Areas covered: In this review, the authors describe the recent advances of hydrogel-based electrochemical immunosensing interface of tumor markers based on the different functions of hydrogels including conductive, catalytic, redox, stimuli-responsive and antifouling hydrogels. Expert commentary: Hydrogels have been successfully employed in electrochemical immunoassay of tumor markers, which is accountable to their unique properties. For further exploitation of hydrogel-based electrochemical biosensors, more variety of hydrogels need be fabricated with improved functionality.	[Yin, Shuang; Ma, Zhanfang] Capital Normal Univ, Dept Chem, Beijing 100048, Peoples R China	Ma, ZF (reprint author), Capital Normal Univ, Dept Chem, Beijing 100048, Peoples R China.	mazhanfang@cnu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [21673143, 21273153]; Natural Science Foundation of Beijing MunicipalityBeijing Natural Science Foundation [2172016, 2132008]; High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan [IDHT20180517]; Project of the Construction of Scientific Research Base by the Beijing Municipal Education Commission	This research was financed by grants from the National Natural Science Foundation of China [21673143, 21273153], Natural Science Foundation of Beijing Municipality [2172016, 2132008], High-level Teachers in Beijing Municipal Universities in the Period of 13th Five-year Plan [IDHT20180517] and the Project of the Construction of Scientific Research Base by the Beijing Municipal Education Commission.	Amani J, 2018, ANAL BIOCHEM, V548, P53, DOI 10.1016/j.ab.2018.02.024; Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989; Atta AM, 2012, J APPL POLYM SCI, V123, P2500, DOI 10.1002/app.34798; Chen SH, 2009, ELECTROCHIM ACTA, V54, P7242, DOI 10.1016/j.electacta.2009.07.035; Chen X, 2014, BIOSENS BIOELECTRON, V55, P343, DOI 10.1016/j.bios.2013.12.037; Cui HF, 2009, BIOSENS BIOELECTRON, V24, P1723, DOI 10.1016/j.bios.2008.09.002; Cui M, 2017, ACS SENSORS, V2, P490, DOI 10.1021/acssensors.7b00103; Guibal E, 2014, J MATER SCI, V49, P5505, DOI 10.1007/s10853-014-8301-5; Guo SJ, 2009, SMALL, V5, P1869, DOI 10.1002/smll.200900190; Han JM, 2013, BIOSENS BIOELECTRON, V47, P243, DOI 10.1016/j.bios.2013.03.032; Han QZ, 2018, BIOSENS BIOELECTRON, V99, P493, DOI 10.1016/j.bios.2017.08.034; Hasanzadeh M, 2014, TRAC-TREND ANAL CHEM, V62, P11, DOI 10.1016/j.trac.2014.06.011; He JA, 2011, MACROMOLECULES, V44, P2245, DOI 10.1021/ma1029532; He SJ, 2015, BIOSENS BIOELECTRON, V68, P462, DOI 10.1016/j.bios.2015.01.018; Hoa LT, 2015, SENSOR ACTUAT B-CHEM, V210, P618, DOI 10.1016/j.snb.2015.01.020; Hou Y, 2013, SENSOR ACTUAT B-CHEM, V182, P605, DOI 10.1016/j.snb.2013.03.067; Huang JS, 2008, ADV FUNCT MATER, V18, P441, DOI 10.1002/adfm.200700729; Huang KJ, 2010, ANAL BIOANAL CHEM, V397, P3553, DOI 10.1007/s00216-010-3868-4; Huang YX, 2015, ANAL METHODS-UK, V7, P411, DOI 10.1039/c4ay02640c; Hui N, 2017, ACS APPL MATER INTER, V9, P2914, DOI 10.1021/acsami.6b11682; Jia HY, 2017, MICROCHIM ACTA, V184, P3747, DOI 10.1007/s00604-017-2407-9; Jung IY, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601475; Kim E, 2016, ADV HEALTHC MATER, V5, P2595, DOI 10.1002/adhm.201600516; Kim MC, 2016, ACS APPL MATER INTER, V8, P34317, DOI 10.1021/acsami.6b10471; Labib M, 2016, CHEM REV, V116, P9001, DOI 10.1021/acs.chemrev.6b00220; Lai GS, 2011, ANAL CHEM, V83, P2726, DOI 10.1021/ac103283p; Li LL, 2015, NANO LETT, V15, P1146, DOI 10.1021/nl504217p; Li N, 2008, BIOPROC BIOSYST ENG, V31, P551, DOI 10.1007/s00449-008-0201-0; Li WX, 2017, SENSOR ACTUAT B-CHEM, V248, P545, DOI 10.1016/j.snb.2017.04.021; Li X., 2016, BIOSENS BIOELECTRON, V89, P1020; Li XJ, 2017, BIOSENS BIOELECTRON, V96, P113, DOI 10.1016/j.bios.2017.04.050; Li YR, 2017, MICROCHIM ACTA, V184, P2767, DOI 10.1007/s00604-017-2303-3; Lira LM, 2005, ELECTROCHEM COMMUN, V7, P717, DOI 10.1016/j.elecom.2005.04.027; Liu N, 2014, J MATER CHEM B, V2, P3292, DOI 10.1039/c3tb21699c; Liu N, 2013, BIOSENS BIOELECTRON, V48, P33, DOI 10.1016/j.bios.2013.03.080; Liu XG, 2011, J ELECTROANAL CHEM, V654, P72, DOI 10.1016/j.jelechem.2011.01.024; Lu XB, 2006, BIOMATERIALS, V27, P5740, DOI 10.1016/j.biomaterials.2006.07.026; Luo XL, 2013, CHEM SOC REV, V42, P5944, DOI 10.1039/c3cs60077g; Ma ZF, 2015, EXPERT REV MOL DIAGN, V15, P1075, DOI 10.1586/14737159.2015.1052798; Majkic-Singh N, 2011, J MED BIOCHEM, V30, P186, DOI 10.2478/v10011-011-0029-z; Mateescu A, 2012, MEMBRANES, V2, DOI 10.3390/membranes2010040; Mendes PM, 2008, CHEM SOC REV, V37, P2512, DOI 10.1039/b714635n; Nikpour M, 1999, SYNTHETIC MET, V99, P121, DOI 10.1016/S0379-6779(98)01486-6; Pan LJ, 2012, P NATL ACAD SCI USA, V109, P9287, DOI 10.1073/pnas.1202636109; Ren JA, 2010, EXPERT REV MOL DIAGN, V10, P787, DOI [10.1586/erm.10.39, 10.1586/ERM.10.39]; Richter A, 2008, SENSORS-BASEL, V8, P561, DOI 10.3390/s8010561; Riedel T, 2013, LANGMUIR, V29, P3388, DOI 10.1021/la304886r; Rong QF, 2016, BIOSENS BIOELECTRON, V75, P148, DOI 10.1016/j.bios.2015.08.041; Sankiewicz A, 2016, ANAL BIOANAL CHEM, V408, P5269, DOI 10.1007/s00216-016-9621-x; Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913; Shan J, 2017, MICROCHIM ACTA, V184, P969, DOI 10.1007/s00604-017-2146-y; Shan J, 2016, MICROCHIM ACTA, V183, P2889, DOI 10.1007/s00604-016-1941-1; Shan J, 2016, SENSOR ACTUAT B-CHEM, V237, P666, DOI 10.1016/j.snb.2016.06.151; Shi WT, 2011, BIOSENS BIOELECTRON, V26, P3068, DOI 10.1016/j.bios.2010.11.048; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332; Song HS, 2017, BIOSENS BIOELECTRON, V89, P187, DOI 10.1016/j.bios.2016.03.045; Song YJ, 2010, ADV MATER, V22, P2206, DOI 10.1002/adma.200903783; Suginta W, 2013, CHEM REV, V113, P5458, DOI 10.1021/cr300325r; Sui XF, 2013, J MATER CHEM B, V1, P1658, DOI 10.1039/c3tb00209h; Sun ZF, 2013, J AM CHEM SOC, V135, P13379, DOI 10.1021/ja403345p; Sun ZH, 2015, ANAL CHIM ACTA, V899, P91, DOI 10.1016/j.aca.2015.09.057; Tang DP, 2006, ANAL CHIM ACTA, V564, P158, DOI 10.1016/j.aca.2006.01.094; Tang LH, 2012, ANAL CHEM, V84, P4711, DOI 10.1021/ac203274k; Tang YQ, 2017, J MATER CHEM B, V5, P2989, DOI 10.1039/c6tb03222b; Tang ZX, 2017, BIOSENS BIOELECTRON, V91, P299, DOI 10.1016/j.bios.2016.12.049; Tavakoli J, 2017, POLYMERS-BASEL, V9, DOI 10.3390/polym9080364; Tokarev I, 2009, SOFT MATTER, V5, P511, DOI 10.1039/b813827c; Tothill IE, 2009, SEMIN CELL DEV BIOL, V20, P55, DOI 10.1016/j.semcdb.2009.01.015; Wang B, 2017, INT J ELECTROCHEM SC, V12, P7607, DOI 10.20964/2017.08.05; Wang HQ, 2017, SENSOR ACTUAT B-CHEM, V254, P642; Wang HQ, 2017, MICROCHIM ACTA, V184, P3247, DOI 10.1007/s00604-017-2287-z; Wang HQ, 2017, BIOELECTROCHEMISTRY, V114, P48, DOI 10.1016/j.bioelechem.2016.12.006; Wang LY, 2016, ELECTROANAL, V28, P1692, DOI 10.1002/elan.201600122; Wang LY, 2016, ANAL CHIM ACTA, V911, P108, DOI 10.1016/j.aca.2016.01.016; Wang LY, 2015, J MATER CHEM B, V3, P2867, DOI 10.1039/c5tb00001g; Wang R, 2018, BIOSENS BIOELECTRON, V102, P276, DOI 10.1016/j.bios.2017.11.041; Wang XP, 2017, BIOSENS BIOELECTRON, V96, P239, DOI 10.1016/j.bios.2017.04.052; Wang ZF, 2015, BIOSENS BIOELECTRON, V70, P98, DOI 10.1016/j.bios.2015.03.015; Wang ZF, 2014, BIOSENS BIOELECTRON, V53, P324, DOI 10.1016/j.bios.2013.10.009; Wei H, 2008, ANAL CHEM, V80, P2250, DOI 10.1021/ac702203f; Wu D, 2016, SCI REP-UK, V6, DOI 10.1038/srep20511; Wu FH, 2008, ELECTROCHIM ACTA, V53, P8238, DOI 10.1016/j.electacta.2008.06.031; Wu LN, 2006, ELECTROCHIM ACTA, V51, P1208, DOI 10.1016/j.electacta.2005.06.011; Xiong YT, 2018, APPL SURF SCI, V427, P1152, DOI 10.1016/j.apsusc.2017.08.150; Xu T, 2014, BIOSENS BIOELECTRON, V56, P174, DOI 10.1016/j.bios.2014.01.006; Yin S, 2018, ANAL BIOANAL CHEM, V410, P1279, DOI 10.1007/s00216-017-0767-y; Zangar RC, 2006, EXPERT REV PROTEOMIC, V3, P37, DOI 10.1586/14789450.3.1.37; Zeng K, 2017, MICROCHIM ACTA, V184, P2637, DOI 10.1007/s00604-017-2276-2; Zhai DY, 2013, ACS NANO, V7, P3540, DOI [10.1021/nn4004132d, 10.1021/nn400482d]; Zhang ZY, 2014, ACS APPL MATER INTER, V6, P21035, DOI 10.1021/am505911h; Zhao FL, 2015, NANOMATERIALS-BASEL, V5, P2054, DOI 10.3390/nano5042054; Zhao LH, 2016, SENSOR ACTUAT B-CHEM, V241, P849; Zhao LH, 2018, ANAL CHIM ACTA, V997, P60, DOI 10.1016/j.aca.2017.10.017; Zhao Y, 2013, ENERG ENVIRON SCI, V6, P2856, DOI 10.1039/c3ee40997j; Zheng Y, 2017, MICROCHIM ACTA, V184, P4269, DOI 10.1007/s00604-017-2470-2; Zhou M, 2013, BIOSENS BIOELECTRON, V49, P243, DOI 10.1016/j.bios.2013.05.036; Zhuo Y, 2008, BIOMATERIALS, V29, P1501, DOI 10.1016/j.biomaterials.2007.12.007	97	0	0	13	47	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	5					457	465		10.1080/14737159.2018.1472579			9	Pathology	Pathology	GJ6FL	WOS:000435479400007	29722573				2019-10-28	
J	Rossi, ED; Baloch, ZW; Pusztaszeri, M; Faquin, WC				Rossi, Esther Diana; Baloch, Zubair W.; Pusztaszeri, Marc; Faquin, William C.			The Milan System for Reporting Salivary Gland Cytopathology (MSRSGC): An ASC-IAC-Sponsored System for Reporting Salivary Gland Fine-Needle Aspiration	ACTA CYTOLOGICA			English	Article						Fine-needle aspiration; Salivary gland; Benign lesions; Standardized reporting; Malignant lesions	INTERINSTITUTIONAL VARIABILITY; CLASSIFICATION SCHEME; DIAGNOSTIC-ACCURACY; RISK STRATIFICATION; CYTOLOGY; LESIONS; SPECIMENS; BIOPSY; METAANALYSIS; MALIGNANCY	The diagnostic role of salivary gland fine-needle aspiration (SG-FNA) is well established in the preoperative evaluation of patients with salivary gland lesions. At present, most salivary SG-FNA specimens are diagnosed based on conventional diagnostic criteria. However, there exists a lack of uniform reporting for these specimens to guide the clinical management of patients. This void motivated a group of experienced cytopathologists to spearhead the development of a uniform reporting system. This international panel, under the sponsorship of the American Society of Cytopathology (ASC) and the International Academy of Cytology (IAC),gathered in September 2015 at the European Congress of Cytology, held in Milan, Italy, to propose the "Milan System for Reporting Salivary Gland Cytopathology" (MSRSGC). This effort sparked the interest of many and brought forth an agreement to develop an evidence-based tiered classification consisting of 6 diagnostic categories. It is hoped that this standard reporting system will enhance the overall effectiveness of SG-FNA reporting across institutions, with the ultimate result being better communication and improved patient care. (C) 2018 S. Karger AG, Basel.	[Rossi, Esther Diana] Univ Cattolica Sacro Cuore, Agostino Gemelli Sch Med, Div Anat Pathol & Histol, Rome, Italy; [Baloch, Zubair W.] Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Pusztaszeri, Marc] Jewish Gen Hosp, Div Pathol, Montreal, PQ, Canada; [Pusztaszeri, Marc] McGill Univ, Montreal, PQ, Canada; [Faquin, William C.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA	Rossi, ED (reprint author), Univ Cattolica Sacro Cuore, Agostino Gemelli Sch Med, Div Anat Pathol & Histol, Largo Francesco Vito 1, IT-00168 Rome, Italy.	esther.rossi@policlinicogemelli.it		Rossi, Esther/0000-0003-3819-4229			Ahn S, 2013, ACTA CYTOL, V57, P567, DOI 10.1159/000354958; Bajwa MS, 2016, HEAD NECK-J SCI SPEC, V38, P1596, DOI 10.1002/hed.24482; Bajwa MS, 2014, BRIT J ORAL MAX SURG, V52, P99, DOI 10.1016/j.bjoms.2013.11.006; Baloch ZW, 2017, DIAGN CYTOPATHOL, V45, P285, DOI 10.1002/dc.23601; Bishop Pitman M, 2015, CRITERIA EXPLANATORY; Cibas ES, 2017, BETHESDA SYSTEM REPO; Colella G, 2010, J ORAL MAXIL SURG, V68, P2146, DOI 10.1016/j.joms.2009.09.064; Faquin W, 2017, ASC B JASC, V6, P1; Foo WC, 2016, CANCER CYTOPATHOL, V124, P397, DOI 10.1002/cncy.21693; Griffith CC, 2017, ARCH PATHOL LAB MED, V141, P381, DOI 10.5858/arpa.2016-0259-SA; Griffith CC, 2015, AM J CLIN PATHOL, V143, P839, DOI 10.1309/AJCPMII6OSD2HSJA; Hughes JH, 2005, ARCH PATHOL LAB MED, V129, P26; Jo VY, 2016, AM J SURG PATHOL, V40, P1143, DOI 10.1097/PAS.0000000000000669; Liu CC, 2016, OTOLARYNG HEAD NECK, V154, P9, DOI 10.1177/0194599815607841; Maleki Z, 2018, CANCER CYTOPATHOL, V126, P94, DOI 10.1002/cncy.21939; Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521; Pusztaszeri M, 2014, SEMIN DIAGN PATHOL, V2570, P115; Pusztaszeri MP, 2014, CANCER CYTOPATHOL, V122, P257, DOI 10.1002/cncy.21381; Rohilla M, 2017, CANCER CYTOPATHOL, V125, P767, DOI 10.1002/cncy.21900; Rosenberg D, 2016, STUD POLIT, P1, DOI 10.1007/978-3-319-40118-8_1; Rossi ED, 2017, CANCER CYTOPATHOL, V125, P757, DOI 10.1002/cncy.21898; Rossi ED, 2016, CANCER CYTOPATHOL, V124, P388, DOI 10.1002/cncy.21710; Schmidt RL, 2014, ARCH PATHOL LAB MED, V138, P88, DOI 10.5858/arpa.2013-0036-OA; Schmidt RL, 2011, AM J CLIN PATHOL, V136, P516, DOI [10.1309/AJCP5LTO4RVOOAIT, 10.1309/AJCP5LTQ4RVOQAIT]; Song IH, 2015, J PATHOL TRANSL MED, V49, P136, DOI 10.4132/jptm.2015.01.03; Tyagi R, 2015, DIAGN CYTOPATHOL, V43, P495, DOI 10.1002/dc.23255; Wang H, 2017, DIAGN CYTOPATHOL, V45, P1088, DOI 10.1002/dc.23826; Wang H, 2015, ARCH PATHOL LAB MED, V139, P1491, DOI 10.5858/arpa.2015-0222-RA; Wei SZ, 2017, DIAGN CYTOPATHOL, V45, P820, DOI 10.1002/dc.23716	29	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					157	165		10.1159/000488969			9	Pathology	Pathology	GI8QT	WOS:000434790200001					2019-10-28	
J	Malhone, C; Longatto, A; Filassi, JR				Malhone, Carolina; Longatto-Filho, Adhemar; Filassi, Jose Roberto			Is Human Papilloma Virus Associated with Breast Cancer? A Review of the Molecular Evidence	ACTA CYTOLOGICA			English	Review						Human papillomavirus; Breast cytology; Beast cytopathology; Breast pathology; Cytopathology oncology	MAMMARY-TUMOR-VIRUS; EPSTEIN-BARR-VIRUS; SQUAMOUS-CELL CARCINOMA; POLYMERASE CHAIN-REACTION; NO EVIDENCE; VIRAL ETIOLOGY; DNA; RISK; SEQUENCES; WOMEN	Background: Although the association of human papillomavirus (HPV) with many cancers is well established, the involvement of HPV in breast cancer remains controversial. The purpose of this study is to perform a comprehensive review of the results and methods used to demonstrate that HPV markers are present in human breast cancer, and how well these studies fulfil the criteria for proving the viral etiology of a cancer. Study Design: We conducted a search for molecular studies published until November 2016 that relate human breast cancer to HPV. Results: Forty-three original molecular studies were found, some of which compared cases to nonneoplastic controls. Some investigations did not identify HPV in mammary tissue, but others identified it with different frequencies of positivity, varying between 1.2 and 86%. In most case-control studies (21/24 studies), positivity in cases was found to be higher than in controls, but odds ratios and confidence intervals were not reported. Conclusion: The results are controversial. However, they arouse a great interest in the potential participation of HPV in breast carcinogenesis, but rather as an essential cause-effect participant, at least as a co-participant in some cases. The circumstance of HPV positivity in breast cancer can be criticized, but the elements that clearly demonstrate it in a number of cases are also relevant. (C) 2018 S. Karger AG, Basel.	[Malhone, Carolina; Filassi, Jose Roberto] Univ Sao Paulo, Sch Med, Canc Inst Sao Paulo, Breast Div, Sao Paulo, Brazil; [Longatto-Filho, Adhemar] Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest LIM 14, Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil; [Longatto-Filho, Adhemar] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Hlth Sci, PT Govt Associate Lab ICVS 3Bs, Braga, Portugal; [Longatto-Filho, Adhemar] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, Brazil	Longatto, A (reprint author), Univ Sao Paulo, Sch Med, Dept Pathol, Lab Med Invest LIM 14, Dr Arnaldo 455, BR-01246903 Sao Paulo, SP, Brazil.	longatto16@hotmail.com	longatto-filho, adhemar/D-7039-2013; Longatto-Filho, Adhemar/N-3397-2019	longatto-filho, adhemar/0000-0002-5779-9752; Longatto-Filho, Adhemar/0000-0002-5779-9752			Abhyankar SH, 1998, BONE MARROW TRANSPL, V21, P295, DOI 10.1038/sj.bmt.1701070; Ahangar-Oskouee M, 2014, ASIAN PAC J CANCER P, V15, P4061, DOI 10.7314/APJCP.2014.15.9.4061; Akil N, 2008, BRIT J CANCER, V99, P404, DOI 10.1038/sj.bjc.6604503; Ali SHM, 2014, E MEDITERR HEALTH J, V20, P372; AXEL R, 1972, NATURE, V235, P32, DOI 10.1038/235032a0; Baltzell K, 2012, CANCER-AM CANCER SOC, V118, P1212, DOI 10.1002/cncr.26389; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; Beaulieu BL, 2002, CLIN VIROLOGY, P483; Bittner JJ, 1943, CANCER RES, V2, P710; Bonnez W, 2002, CLIN VIROLOGY, P583; BRATTHAUER GL, 1992, PATHOL RES PRACT, V188, P384, DOI 10.1016/S0344-0338(11)81229-X; de Leon DC, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-26; Chang P, 2012, MED ONCOL, V29, P521, DOI 10.1007/s12032-011-9945-5; CHATTOPADHYAY J, 1984, GANN, V75, P342; Choi YL, 2007, TUMOR BIOL, V28, P327, DOI 10.1159/000124238; Czerwenka K, 1996, BREAST CANCER RES TR, V41, P51, DOI 10.1007/BF01807036; Damin APS, 2004, BREAST CANCER RES TR, V84, P131, DOI 10.1023/B:BREA.0000018411.89667.0d; de Cremoux P, 2008, BREAST CANCER RES TR, V109, P55, DOI 10.1007/s10549-007-9626-4; de Villiers EM, 2005, BREAST CANCER RES, V7, pR1, DOI 10.1186/bcr940; DILONARDO A, 1992, BREAST CANCER RES TR, V21, P95, DOI 10.1007/BF01836955; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Evans Alfred S., 1990, Annals of Epidemiology, V1, P71; Fakhry C, 2008, JNCI-J NATL CANCER I, V100, P261, DOI 10.1093/jnci/djn011; Frega A, 2012, EUR J GYNAECOL ONCOL, V33, P164; Fu L, 2015, J MED VIROL, V87, P1034, DOI 10.1002/jmv.24142; FURMANSKI P, 1974, JNCI-J NATL CANCER I, V52, P975, DOI 10.1093/jnci/52.3.975; Gillio-Tos A, 2007, PATHOLOGY, V39, P345, DOI 10.1080/00313020701329757; Glaser SL, 2004, CANCER EPIDEM BIOMAR, V13, P688; Glenn WK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048788; Gopalkrishna V, 1996, BREAST CANCER RES TR, V39, P197, DOI 10.1007/BF01806186; Gumus M, 2006, J EXP CLIN CANC RES, V25, P515; Hachana M, 2010, BREAST, V19, P541, DOI 10.1016/j.breast.2010.05.007; He Q, 2009, MOL BIOL REP, V36, P807, DOI 10.1007/s11033-008-9249-9; Hedau S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-27; Heng B, 2009, BRIT J CANCER, V101, P1345, DOI 10.1038/sj.bjc.6605282; HENLE G, 1966, J BACTERIOL, V91, P1248; Hennig EM, 1999, BREAST CANCER RES TR, V53, P121, DOI 10.1023/A:1006162609420; Higgins CD, 2007, J INFECT DIS, V195, P474, DOI 10.1086/510854; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hobbs CGL, 2006, CLIN OTOLARYNGOL, V31, P259, DOI 10.1111/j.1749-4486.2006.01246.x; Hortobagyi Gabriel N, 2005, Clin Breast Cancer, V6, P391, DOI 10.3816/CBC.2005.n.043; Joshi D, 2012, BREAST CANCER RES TR, V135, P1, DOI 10.1007/s10549-011-1921-4; Kan CY, 2005, BRIT J CANCER, V93, P946, DOI 10.1038/sj.bjc.6602778; KEYDAR I, 1984, P NATL ACAD SCI-BIOL, V81, P4188, DOI 10.1073/pnas.81.13.4188; Khan NA, 2008, BRIT J CANCER, V99, P408, DOI 10.1038/sj.bjc.6604502; Kroupis C, 2006, CLIN BIOCHEM, V39, P727, DOI 10.1016/j.clinbiochem.2006.03.005; LABRECQUE LG, 1995, CANCER RES, V55, P39; Lassen P, 2009, J CLIN ONCOL, V27, P1992, DOI 10.1200/JCO.2008.20.2853; Lawson James S., 2009, V471, P421, DOI 10.1007/978-1-59745-416-2_21; Lawson JS, 2006, FUTURE MICROBIOL, V1, P33, DOI 10.2217/17460913.1.1.33; Lawson JS, 2001, BREAST CANCER RES, V3, P81, DOI 10.1186/bcr275; LEMINEN A, 1991, AM J CLIN PATHOL, V95, P647, DOI 10.1093/ajcp/95.5.647; LESPAGNARD L, 1995, AM J CLIN PATHOL, V103, P449; Li J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136050; Li T, 2002, CANCER-AM CANCER SOC, V95, P2571, DOI 10.1002/cncr.11008; Liang WL, 2013, J MED VIROL, V85, P2087, DOI 10.1002/jmv.23703; Licitra L, 2006, J CLIN ONCOL, V24, P5630, DOI 10.1200/JCO.2005.04.6136; Lindel K, 2007, BREAST, V16, P172, DOI 10.1016/j.breast.2006.09.001; LITVINOV SV, 1987, B EXP BIOL MED+, V103, P379, DOI 10.1007/BF00840569; Liu Y, 2001, J HUMAN VIROL, V4, P329; Longworth MS, 2004, MICROBIOL MOL BIOL R, V68, P362, DOI 10.1128/MMBR.68.2.362-372.2004; Mant C, 2004, REV MED VIROL, V14, P169, DOI 10.1002/rmv.427; Mant C, 2004, INTERVIROLOGY, V47, P2, DOI 10.1159/000076636; Manzouri Leila, 2014, Adv Biomed Res, V3, P75, DOI 10.4103/2277-9175.125873; MAY FEB, 1983, NUCLEIC ACIDS RES, V11, P4127, DOI 10.1093/nar/11.12.4127; MCGRATH CM, 1971, J NATL CANCER I, V47, P455; Mendizabal-Ruiz AP, 2009, BREAST CANCER RES TR, V114, P189, DOI 10.1007/s10549-008-9989-1; MESATEJADA R, 1978, P NATL ACAD SCI USA, V75, P1529, DOI 10.1073/pnas.75.3.1529; MOORE DH, 1971, NATURE, V229, P611, DOI 10.1038/229611a0; Moore PS, 2010, NAT REV CANCER, V10, P878, DOI 10.1038/nrc2961; Morris BJ, 2005, CLIN CHEM LAB MED, V43, P1171, DOI 10.1515/CCLM.2005.203; Mou X, 2011, J INT MED RES, V39, P1636, DOI 10.1177/147323001103900506; Peng JP, 2014, J CLIN VIROL, V61, P255, DOI 10.1016/j.jcv.2014.07.010; Petrelli F, 2014, HEAD NECK-J SCI SPEC, V36, P750, DOI 10.1002/hed.23351; SASCO AJ, 1993, INT J CANCER, V53, P538, DOI 10.1002/ijc.2910530403; SCHLOM J, 1971, NATURE, V231, P97, DOI 10.1038/231097a0; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Sigaroodi A, 2012, SCI WORLD J, P1, DOI 10.1100/2012/837191; Silva RG, 2011, BREAST CANCER RES TR, V125, P261, DOI 10.1007/s10549-010-1129-z; SUSSER M, 1991, AM J EPIDEMIOL, V133, P635, DOI 10.1093/oxfordjournals.aje.a115939; Tsai JH, 2005, J MED VIROL, V75, P276, DOI 10.1002/jmv.20267; VAIDYA AB, 1974, NATURE, V249, P565, DOI 10.1038/249565a0; Vernet-Tomas M, 2015, ANTICANCER RES, V35, P851; WANG Y, 1995, CANCER RES, V55, P5173; Weinberger PM, 2004, CLIN CANCER RES, V10, P5684, DOI 10.1158/1078-0432.CCR-04-0448; Widschwendter A, 2004, J CLIN VIROL, V31, P292, DOI 10.1016/j.jcv.2004.06.009; WREDE D, 1992, BRIT J CANCER, V65, P891, DOI 10.1038/bjc.1992.186; Yu Y, 2000, Breast Cancer, V7, P33, DOI 10.1007/BF02967185; Yu YY, 1999, ANTICANCER RES, V19, P5057	89	1	1	1	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					166	177		10.1159/000487700			12	Pathology	Pathology	GI8QT	WOS:000434790200002	29694946				2019-10-28	
J	Sood, R; Tyagi, R; Selhi, PK; Kaur, G; Kaur, H; Singh, A				Sood, Ridhi; Tyagi, Ruchita; Selhi, Pavneet Kaur; Kaur, Gursheen; Kaur, Harpreet; Singh, Akashdeep			Role of FNA and Special Stains in Rapid Cytopathological Diagnosis of Pulmonary Nocardiosis	ACTA CYTOLOGICA			English	Article						FNAC; Nocardia; Ziehl-Neelsen stain; Reticulin	INFECTION	Background: Nocardia, a gram-positive aerobic bacillus of the Actinomycetales family, is a significant opportunistic pathogen in immunocompromised individuals. Clinical and radiological features of pulmonary nocardiosis are nonspecific and can be misdiagnosed as tuberculosis, pneumocystis, staphylococcal or fungal infections, or as malignancy. Aspiration cytology with special stains is a quick and effective approach for accurate diagnosis. Materials and Methods: We present 7 cases of pulmonary nocardiosis, admitted to the pathology department in a tertiary-care hospital in Punjab. Clinical findings, immune status, laboratory tests, chest radiographs, and computed tomography scans were reviewed. Cytologically, special stains like 1% Ziehl-Neelsen (ZN), 20% ZN, periodic acid-Schiff (PAS), Grocott methenamine silver (GMS), and reticulin stains were studied along with May-Grunwald Giemsa, Papanicolaou, and hematoxylin and eosin. Results: All the patients were immunocompromised. The radiological changes were nonspecific. Cytomorphology showed acute and chronic inflammatory infiltrates with necrosis. None of the cases showed well-defined granulomas. GMS, modified 1% ZN and, Gordon and Sweet reticulin stains highlighted the delicate filamentous bacteria in all cases. PAS and 20% ZN stain for tuberculous bacilli were uniformly negative. Conclusion: FNAC can provide a quick and accurate diagnosis of nocardiosis and thereby facilitate timely medical management. (C) 2018 S. Karger AG, Basel.	[Sood, Ridhi] Rajiv Gandhi Canc Inst, Dept Oncopathol, New Delhi, India; [Tyagi, Ruchita; Selhi, Pavneet Kaur; Kaur, Harpreet] Dayanand Med Coll & Hosp, Dept Pathol, Ludhiana, Punjab, India; [Kaur, Gursheen] Banaras Hindu Univ, Inst Med Sci, Dept Cardiol, Varanasi, Uttar Pradesh, India; [Singh, Akashdeep] Dayanand Med Coll & Hosp, Dept Chest & Pulm Med, Ludhiana, Punjab, India	Tyagi, R (reprint author), Dayanand Med Coll & Hosp, Ludhiana 141001, Punjab, India.	ruchitatyagi@gmail.com					Ambrosioni J, 2010, INFECTION, V38, P89, DOI 10.1007/s15010-009-9193-9; Corti Marcelo E., 2003, International Journal of Infectious Diseases, V7, P243, DOI 10.1016/S1201-9712(03)90102-0; Hannaman MJ, 2013, MED CLIN N AM, V97, P1139, DOI 10.1016/j.mcna.2013.06.002; Hui CH, 2003, RESP MED, V97, P709, DOI 10.1053/rmed.2003.1505; Kumar R, 2008, INDIAN J MED MICROBI, V26, P380; Leong KP, 2000, J RHEUMATOL, V27, P1306; Martinez R, 2008, CURR OPIN PULM MED, V14, P219, DOI 10.1097/MCP.0b013e3282f85dd3; Mathur S, 2005, ACTA CYTOL, V49, P567, DOI 10.1159/000326207; McHugh KE, 2017, DIAGN CYTOPATHOL, V45, P1105, DOI 10.1002/dc.23816; POLLOCK PG, 1978, ACTA CYTOL, V22, P575; Powers CN, 1998, CLIN MICROBIOL REV, V11, P341, DOI 10.1128/CMR.11.2.341; Sharma S, 2016, DIAGN CYTOPATHOL, V44, P347, DOI 10.1002/dc.23429; Shivaprakash MR, 2007, MYCOPATHOLOGIA, V163, P267, DOI 10.1007/s11046-007-9011-1; Torres OH, 2000, EUR J CLIN MICROBIOL, V19, P205, DOI 10.1007/s100960050460; Woods GL, 1996, CLIN MICROBIOL REV, V9, P382, DOI 10.1128/CMR.9.3.382; Yang MF, 2014, EXP THER MED, V8, P25, DOI 10.3892/etm.2014.1715	16	2	2	1	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					178	182		10.1159/000488134			5	Pathology	Pathology	GI8QT	WOS:000434790200003	29669313				2019-10-28	
J	Bas, Y				Bas, Yilmaz			Cytological Findings of Malignant and Benign Head and Neck Masses in Somalia	ACTA CYTOLOGICA			English	Article						Fine-needle aspiration; Head and neck masses; Tumor metastasis; Infectious diseases; Somalia	NEEDLE-ASPIRATION BIOPSY; DIAGNOSIS; CANCER	Objective: There are no up-to-date records on head and neck masses (HNMs) in Somalia. This cytological study is the first to demonstrate the benefits and findings of fine- needle aspiration cytology in evaluating HNMs in the adult population of Somalia. Study Design: A total of 116 aspiration samples were taken from different levels of the neck region, except for the thyroid. Cases were classified as salivary gland, lymph node, or soft tissue/cystic lesions. They were classified according to age, gender, and cytological diagnosis. Results: Patients included 54 (46.6%) males and 62 (53.4%) females, with a mean age of 40.6 years. Seventy-two patients (62.1%) had benign lesions, while 44 (37.9%) had malignant lesions. Necrotizing granulomatous lymphadenitis (n = 51, 70.8% of the benign findings) and lymph node metastasis of squamous cell carcinoma (n = 13, 29.5% of the malignant findings) were the most frequent findings. Conclusion: Fineneedle aspiration is a useful procedure in the diagnosis of neck masses. It is a cheap and easy guiding method for diagnosing granulomatous lymphadenitis and advanced-stage metastatic cancers, which are common in this country. (C) 2018 S. Karger AG, Basel.	[Bas, Yilmaz] Hitit Univ, Erol Olcok Educ & Res Hosp, Dept Pathol, TR-19200 Corum, Turkey; [Bas, Yilmaz] Somali Mogadishu Turkey Educ & Res Hosp, Dept Pathol, Mogadishu, Somalia	Bas, Y (reprint author), Hitit Univ, Erol Olcok Educ & Res Hosp, Dept Pathol, TR-19200 Corum, Turkey.	yilbas@yahho.com		Bas, Yilmaz/0000-0002-4229-8568			Adoga AA, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-9; Bas Y, 2017, SEMIN ONCOL, V44, P178, DOI 10.1053/j.seminoncol.2017.10.007; Bayazit YA, 2004, ORL-J OTO-RHIN-LARYN, V66, P275, DOI 10.1159/000081125; dos Santos APC, 2011, BRAZ ORAL RES, V25, P186, DOI 10.1590/S1806-83242011000200015; Chen JQ, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-110; El Hag IA, 2003, ACTA CYTOL, V47, P387, DOI 10.1159/000326538; Fathallah L, 2006, OTOLARYNG HEAD NECK, V134, P302, DOI 10.1016/j.otohns.2005.10.020; Goret CC, 2015, INT J CLIN EXP PATHO, V8, P8709; Iacob A, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004448; Mabedi C, 2014, MALAWI MED J, V26, P16; Mackenzie K, 2016, J LARYNGOL OTOL, V130, pS170, DOI 10.1017/S0022215116000591; Olu-eddo AN, 2011, PAN AFR MED J, V10; Parkin DM, 2014, CANCER EPIDEM BIOMAR, V23, P953, DOI 10.1158/1055-9965.EPI-14-0281; Reddy DL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130148; Rives P, 2016, EUR ANN OTORHINOLARY, V133, P107, DOI 10.1016/j.anorl.2016.02.001; Roland N, 2016, J LARYNGOL OTOL, V130, pS53, DOI 10.1017/S002221511600044X; Salwan J, 2014, ANN GLOB HEALTH, V80, P115, DOI 10.1016/j.aogh.2014.04.010; SCHELKUN PM, 1991, J ORAL MAXIL SURG, V49, P262, DOI 10.1016/0278-2391(91)90216-9; Sindani I, 2013, EMERG INFECT DIS, V19, P478, DOI 10.3201/eid1903.121287; Weiler Z, 2000, J ORAL MAXIL SURG, V58, P477, DOI 10.1016/S0278-2391(00)90004-1; WHO, 2017, GLOB TUB CONTR WHO R; Wright CA, 2009, INT J TUBERC LUNG D, V13, P1467; Xu D, 2014, INT J CLIN EXP PATHO, V7, P5165	23	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					183	192		10.1159/000488021			10	Pathology	Pathology	GI8QT	WOS:000434790200004	29642058				2019-10-28	
J	del Arco, CD; Acenero, MJF				Diaz del Arco, Cristina; Fernandez Acenero, M. Jesus			Preoperative Diagnosis of Neoplastic or Malignant Hurthle Cell Lesions: A Chimera?	ACTA CYTOLOGICA			English	Article						Hurthle cell; Oncocytic; Carcinoma; Fine-needle aspiration cytology; Thyroid	FINE-NEEDLE-ASPIRATION; BETHESDA SYSTEM; PREDICTIVE FACTORS; THYROID-CARCINOMA; INCREASED RISK; LESION/NEOPLASM; MANAGEMENT; MUTATIONS; FEATURES; BIOPSY	Objective: We aimed to review all cytological specimens with Hurthle cells (HC) diagnosed in our institution, identify cytological features related to neoplastic (adenoma or carcinoma) and malignant histology, and discuss the role of clinicopathological findings and clinical management in these cases. Study Design: We included 359 thyroid fine-needle aspiration cytology cases in our study. We reviewed the clinical and cytological features of surgical cases and correlated them with histological diagnosis. We also reviewed the literature on this issue. Results: We found a significant association between neoplasia and highly cellular smears, the absence of colloid, the presence of microfollicles, large-cell dysplasia, prominent nucleoli or macronucleoli, coarse chromatin, nuclear grooves and inclusions, nuclear irregularity, and pleomorphism. The absence of colloid, high cellularity, >25% of isolated HC, the presence of tridimensional groups, transgressing vessels, nuclear irregularity, prominent nucleoli or macronucleoli, coarse chromatin, hyperchromatism, pleomorphism, and diffuse large-cell dysplasia were features significantly associated with malignancy. Conclusions: No cytological feature alone can predict histological outcome, but all findings related to a neoplastic or malignant histology must be assessed. Individualized management protocols should be developed in each institution. (C) 2018 S. Karger AG, Basel.	[Diaz del Arco, Cristina; Fernandez Acenero, M. Jesus] Hosp Clin San Carlos, Dept Surg Pathol, C Prof Martin Lagos S-N, ES-28040 Madrid, Spain	del Arco, CD (reprint author), Hosp Clin San Carlos, Dept Surg Pathol, C Prof Martin Lagos S-N, ES-28040 Madrid, Spain.	crisdelarco@gmail.com		Fernandez-Acenerp/0000-0002-2439-3553			Alaedeen DI, 2005, SURGERY, V138, P650, DOI 10.1016/j.surg.2005.06.047; Arduc A, 2015, CLIN ENDOCRINOL, V83, P405, DOI 10.1111/cen.12628; Auger M, 2014, CANCER CYTOPATHOL, V122, P241, DOI 10.1002/cncy.21391; Cacchi C, 2015, INT J ENDOCRINOL, DOI 10.1155/2015/276854; Canberk S, 2013, CYTOJOURNAL, V10, DOI 10.4103/1742-6413.106686; Cibas ES, 2017, THYROID, V27, P1341, DOI 10.1089/thy.2017.0500; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Donatini G, 2016, J ENDOCRINOL INVEST, V39, P153, DOI 10.1007/s40618-015-0356-x; Elliott DD, 2006, CANCER CYTOPATHOL, V108, P102, DOI 10.1002/cncr.21716; Ganly I, 2013, J CLIN ENDOCR METAB, V98, pE962, DOI 10.1210/jc.2012-3539; Giorgadze T, 2004, DIAGN CYTOPATHOL, V31, P307, DOI 10.1002/dc.20132; Haigh PI, 2005, SURGERY, V138, P1152, DOI 10.1016/j.surg.2005.08.034; Kasaian K, 2015, J CLIN ENDOCR METAB, V100, pE611, DOI 10.1210/jc.2014-3622; Kroeker T, 2014, THYROID DISORD THER, V3, P2; Lee KH, 2013, INT J SURG, V11, P898, DOI 10.1016/j.ijsu.2013.07.010; Lloyd RV, 2017, WHO CLASSIFICATION T; MCIVOR NP, 1993, HEAD NECK-J SCI SPEC, V15, P335, DOI 10.1002/hed.2880150411; Mckee S, 2014, ACTA CYTOL, V58, P235, DOI 10.1159/000361073; Melck A, 2006, AM J SURG, V191, P593, DOI 10.1016/j.amjsurg.2006.02.007; Monaco M, 2014, EUR THYROID J, V3, P211, DOI 10.1159/000367989; Parikh PP, 2013, J SURG RES, V184, P247, DOI 10.1016/j.jss.2013.03.005; Petric R, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-282; Pisanu A, 2010, WORLD J SURG, V34, P836, DOI 10.1007/s00268-009-0357-z; Pu RT, 2006, DIAGN CYTOPATHOL, V34, P330, DOI 10.1002/dc.20440; Renshaw AA, 2002, CANCER CYTOPATHOL, V96, P261, DOI 10.1002/cncr.10797; Renshaw AA, 2016, CANCER CYTOPATHOL, V124, P729, DOI 10.1002/cncy.21741; Roh MH, 2011, AM J CLIN PATHOL, V135, P139, DOI 10.1309/AJCP0RW2WMDUAKGK; Rossi ED, 2013, EUR J ENDOCRINOL, V169, P649, DOI 10.1530/EJE-13-0431; Samulski TD, 2013, HISTOPATHOLOGY, V63, P568, DOI 10.1111/his.12206; Seethala RR, 2018, MODERN PATHOL, V31, P39, DOI 10.1038/modpathol.2017.130; Shawky M, 2016, INDIAN J SURG, V78, P41, DOI 10.1007/s12262-015-1381-x; Sippel RS, 2008, WORLD J SURG, V32, P702, DOI 10.1007/s00268-007-9416-5; Straccia P, 2015, CANCER CYTOPATHOL, V123, P713, DOI 10.1002/cncy.21605; Strazisar B, 2010, J SURG ONCOL, V101, P582, DOI 10.1002/jso.21526; Troncone G, 2009, CANCER CYTOPATHOL, V117, P522, DOI 10.1002/cncy.20050; Wei SZ, 2015, ENDOCR PATHOL, V26, P365, DOI 10.1007/s12022-015-9403-6; Wu HHJ, 2008, DIAGN CYTOPATHOL, V36, P149, DOI 10.1002/dc.20750; Yang GCH, 2013, CYTOPATHOLOGY, V24, P185, DOI 10.1111/j.1365-2303.2012.00988.x; Yang YJ, 2001, ARCH PATHOL LAB MED, V125, P1031; Yazgan A, 2014, CYTOPATHOLOGY, V25, P185, DOI 10.1111/cyt.12093; Yazgan A, 2016, J CYTOL, V33, P214, DOI 10.4103/0970-9371.190447; Zivic R, 2016, J BUON, V21, P1496	42	5	5	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					193	203		10.1159/000488441			11	Pathology	Pathology	GI8QT	WOS:000434790200005	29723867				2019-10-28	
J	Gupta, V; Bhake, A				Gupta, Vivek; Bhake, Arvind			Reactive Lymphoid Hyperplasia or Tubercular Lymphadenitis: Can Real-Time PCR on Fine-Needle Aspirates Help Physicians in Concluding the Diagnosis?	ACTA CYTOLOGICA			English	Article						Reactive lymphoid hyperplasia; Tubercular lymphadenitis; Real-time PCR; Fine-needle aspirates; Clinical diagnosis	MYCOBACTERIUM-TUBERCULOSIS; INSERTION-SEQUENCE; LYMPHADENOPATHY; CULTURE	Background: Enlarged lymph nodes in adult patients often present a diagnostic challenge. In the absence of granuloma or necrosis, the cytology/tissue findings are misleading and relate the enlarged lymph nodes to reactive lymphoid hyperplasia (RLH), because granuloma formation is an immunological response that usually takes 14-100 days to develop. This study assesses the role of real-time (RT)-PCR in the diagnosis of the Mycobacterium complex (MTBC) in lymph node aspirates compared with culture in cases of RLH. Methods: A cross-sectional study was conducted on 112 patients, aged 15-74 years, with a diagnosis of RLH on cytology. RTPCR for MTBC detection and culture on Lowenstein-Jensen medium for tubercular bacilli was done on lymph node aspirates. Comparative values with reference to culture were calculated. The chi(2) value, positive predictive value (PPV), negative predictive value (NPV), and likelihood ratios (LR) were calculated. Results: Out of 112 RLH cases, 35 (31%) were positive on both RT-PCR and culture. RT- PCR was positive in 43 cases and culture was positive in 44 cases. The chi(2) test was found to be highly significant. PPV, NPV, positive LR, and negative LR were 81.4%, 87%, 6.76, and 0.23, respectively. Conclusion: RT- PCR for MTBC proves to be useful in arriving at a conclusive diagnosis in patients with a cytological diagnosis of RLH. (C) 2018 S. Karger AG, Basel.	[Gupta, Vivek; Bhake, Arvind] Jawaharlal Nehru Med Coll, Datta Meghe Inst Med Sci, Dept Pathol, Wardha 442001, India	Gupta, V (reprint author), Jawaharlal Nehru Med Coll, Datta Meghe Inst Med Sci, Dept Pathol, Wardha 442001, India.	dr_vivek_gupta@yahoo.com	GUPTA, VIVEK/D-6916-2016	GUPTA, VIVEK/0000-0002-7830-4616	International Society of Infectious Diseases, USA	We gratefully acknowledge all the consultant and laboratory staff of Jawaharlal Nehru Medical College, Wardha, India, for their support in data collection. This research work was supported by a grant from the International Society of Infectious Diseases, USA.	Aljafari AS, 2004, CYTOPATHOLOGY, V15, P44, DOI 10.1111/j.1365-2303.2003.00119.x; Alonso H, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-422; Bales CE, 2006, KOSS DIAGNOSTIC CYTO, P1570; Capuano SV, 2003, INFECT IMMUN, V71, P5831, DOI 10.1128/IAI.71.10.5831-5844.2003; Central TB Division, 2009, REV NAT TB CONTR PRO, P13; Chien HP, 2000, INT J TUBERC LUNG D, V4, P866; Churukian CJ, 2008, THEORY PRACTICE HIST, P247; Cortez-Herrera E, 2008, BRAZ ARCH BIOL TECHN, V51, P685, DOI 10.1590/S1516-89132008000400006; Derese Y, 2012, J INFECT DEV COUNTR, V6, P53, DOI 10.3855/jidc.2050; Green M. R., 2012, MOL CLONING LAB MANU, P64; Gupta Vivek, 2017, Indian J Tuberc, V64, P314, DOI 10.1016/j.ijtb.2016.11.014; Gupta V, 2017, ACTA CYTOL, V61, P173, DOI 10.1159/000475832; Makeshkumar V, 2014, INDIAN J MED RES, V139, P161; Mittal P, 2011, DIAGN CYTOPATHOL, V39, P822, DOI 10.1002/dc.21472; Pahwa R, 2005, J MED MICROBIOL, V54, P873, DOI 10.1099/jmm.0.45904-0; Pierce KE, 2004, BIOTECHNIQUES, V36, P44, DOI 10.2144/04361BM04; Purohit MR, 2009, INT J INFECT DIS, V13, P600, DOI 10.1016/j.ijid.2008.06.046; Reed JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03930-3; Simon A.K., 2015, P R SOC B, V282, P2014; VANSOOLINGEN D, 1991, J CLIN MICROBIOL, V29, P2578	20	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					204	208		10.1159/000488871			5	Pathology	Pathology	GI8QT	WOS:000434790200006	29763927				2019-10-28	
J	Queiroz, J; Eleuterio, J; Cobucci, RN; Crispim, JCD; Giraldo, PC; Goncalves, AK				Queiroz Filho, Jose; Eleuterio, Jose, Jr.; Cobucci, Ricardo Ney; de Oliveira Crispim, Janaina Cristiana; Giraldo, Paulo Cesar; Goncalves, Ana Katherine			Does 100% Rapid Review Improve Cervical Cancer Screening?	ACTA CYTOLOGICA			English	Review						Quality control; Diagnosis; Accuracy; Cytology	INTERNAL QUALITY-CONTROL; CYTOLOGY; SMEARS; TIME	Objective: The aim of this work was to evaluate 100% rapid review (100% RR) as a useful tool to detect false negative (FN) results. Study Design: A sample of 8,677 swabs was investigated; the unsatisfactory and negative results were referred to 100% RR, concordant results were taken as the final diagnosis, while the discordant results were debated in a consensus meeting to reach a conclusion. The positive results were examined by 2 cytologists. The data were entered into SAS statistical software, and the agreement of the 100% RR results with the final diagnosis was tested with the weighted kappa statistic. Results: There was a significant increase in unsatisfactory results from 348 to 1,927, and of positive results from 174 to 349. On the other hand, there was a substantial decrease in negative results from 8,155 to 6,401. Assessing the relative risk of FN results in smears that were not referred to quality control (100% RR) revealed the following results: atypical squamous cells of undetermined significance (ASC-US), 2.93; low-grade squamous intraepithelial lesion (LSIL), 2.72; high-grade squamous intraepithelial lesion/atypical squamous cells - cannot exclude HSIL (HSIL/ASC-H), 2.25. Evaluating by age group, a higher risk for LSIL (4.90) and ASC- US (3.85) was observed in patients aged under 25 years, whereas patients between 25 and 64 years and those over 64 years presented a higher risk for HSIL and ASC-H: 2.46 and 2.75, respectively. Conclusion: 100% RR is an effective screening tool for FN results in countries where molecular tests for DNA-HPV and prophylactic vaccines are not available in cervical cancer screening programs. (C) 2018 S. Karger AG, Basel.	[Queiroz Filho, Jose; Goncalves, Ana Katherine] Univ Fed Rio Grande do Norte, BR-59161610 Natal, RN, Brazil; [Eleuterio, Jose, Jr.; Goncalves, Ana Katherine] Univ Fed Ceara, Fac Med, Dept Child & Motherhood, Fortaleza, Ceara, Brazil; [Cobucci, Ricardo Ney; Goncalves, Ana Katherine] Univ Fed Rio Grande do Norte, Fac Med, Dept Gynecol & Obstet, Natal, RN, Brazil; [de Oliveira Crispim, Janaina Cristiana] Univ Fed Rio Grande do Norte, Sch Pharm, Dept Clin Anal, Natal, RN, Brazil; [Giraldo, Paulo Cesar] Univ Estadual Campinas, Fac Med, Dept Gynecol & Obstet, Campinas, SP, Brazil	Queiroz, J (reprint author), Univ Fed Rio Grande do Norte, BR-59161610 Natal, RN, Brazil.	josqfilho@gmail.com	Eleuterio, Jose/K-5027-2019; Cobucci, Ricardo Ney Oliveira/E-2907-2015	Eleuterio, Jose/0000-0003-4617-7269; Cobucci, Ricardo Ney Oliveira/0000-0002-0184-2061			Alwahaibi NY, 2015, E MEDITERR HEALTH J, V21, P579, DOI 10.26719/2015.21.8.579; Amaral RG, 2008, REV BRAS GINECOL OBS, V30, P556, DOI 10.1590/S0100-72032008001100005; Branca M, 2015, ACTA CYTOL, V59, P361, DOI 10.1159/000441515; Derchain S, 2016, REV BRAS GINECOL OBS, V38, P161, DOI 10.1055/s-0036-1582399; Tavares SBD, 2014, ACTA CYTOL, V58, P439, DOI 10.1159/000368041; Elmajjaoui S, 2016, BMC WOMENS HEALTH, V16, DOI 10.1186/s12905-016-0342-2; Franco R, 2006, REV BRAS GINECOL OBS, V28, P479; Gullo CE, 2012, EINSTEIN-SAO PAULO, V10, P86, DOI 10.1590/S1679-45082012000100018; Longatto A, 2010, ACTA CYTOL, V54, P654, DOI 10.1159/000325196; Manrique EJC, 2011, CYTOPATHOLOGY, V22, P195, DOI 10.1111/j.1365-2303.2010.00776.x; Mathew A, 2009, ASIAN PAC J CANCER P, V10, P645; Ministerio da Saude (Brasil) Instituto Nacional do Cancer Jose de Alencar Gomes da Silva; Coordenacao de Prevencao e Vigilancia Di-visao de Deteccao Precoce e Apoio a Orga-nizacao de Rede, 2016, MAN GEST QUAL LAB CI; Mirzamani N, 2017, DIAGN CYTOPATHOL, V45, P873, DOI 10.1002/dc.23783; Tavares SBN, 2011, CANCER CYTOPATHOL, V119, P367, DOI 10.1002/cncy.20190; Pilozo BQCH, 2017, REV ARGENT MICROBIOL; Queiroz J, 2017, ACTA CYTOL, V61, P207, DOI 10.1159/000475833; Rosa M, 2013, DIAGN CYTOPATHOL, V41, P588, DOI 10.1002/dc.22904; Samson KK, 2016, CANCER EPIDEMIOL, V44, P154, DOI 10.1016/j.canep.2016.08.014; Sood N, 2009, INDIAN J PATHOL MICR, V52, P495, DOI 10.4103/0377-4929.56134; Sorbye SW, 2017, BMC CLIN PATHOL, V17, DOI 10.1186/s12907-017-0058-8; Vaccarella S, 2017, INT J CANCER, V141, P1997, DOI 10.1002/ijc.30901	21	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					209	214		10.1159/000488872			6	Pathology	Pathology	GI8QT	WOS:000434790200007	29788025				2019-10-28	
J	Chaithra, GV; Saha, D; Yadav, R; Adiga, DS; Lobo, FD; Ghosh, A; Kini, J				Chaithra, G., V; Saha, Debarshi; Yadav, Richa; Adiga, Deepa S.; Lobo, Flore D.; Ghosh, Apurv; Kini, Jyoti			The Role of Crush Cytology in the Diagnosis of Large-Intestine Lesions with Correlation on Histopathology	ACTA CYTOLOGICA			English	Article						Colonic adenocarcinoma; Adenoma; Ulcerative colitis; Crush cytology	COLORECTAL-CANCER; TRENDS; RATES	Objective: To study the efficacy of colonoscopic crush cytology as a convenient and near-accurate method to evaluate colonic neoplasms. Study Design: Retrospective and crosssectional. The original cytologic diagnoses were correlated with a histology report on 100 cases sent to the cytology laboratory over 2 years. Results: Of the 100 cases, 25 were nonmalignant. Of the 75 malignant lesions, 72 could be identified as positive for malignancy on cytology. The falsepositives consisted of 6 adenomas and 1 case of ulcerative colitis. Thus, sensitivity and specificity of cytology are 96 and 63.2%, respectively. Of the 6 adenomas diagnosed as malignant, 4 showed high-grade dysplasia, and the other 2 showed superficial ulceration with low-grade dysplasia on histopathology. The ulcerative colitis case showed widespread ulcers and regenerative/reparative features on biopsy. The 3 adenocarcinomas diagnosed s benign on cytology showed an occasional malignant cell with thickened nuclear borders and prominent central nucleoli. Conclusions: With careful attention to the cytomorphology, coupled with good clinical and endoscopic correlation, crush cytology of the large intestine is a reliable diagnostic tool. It categorizes lesions as malignant and benign with a high sensitivity, positive predictive value, and negative predictive value. Adenomas and reparative/regenerative changes seen in inflammatory bowel disease are major pitfalls in the cytology diagnosis of malignancy that may be averted by informing the endoscopic findings and clinical history. Cytology diagnosis saves time and gives proper feedback to the gastroenterologist. (C) 2018 S. Karger AG, Basel.	[Chaithra, G., V; Saha, Debarshi; Yadav, Richa; Adiga, Deepa S.; Lobo, Flore D.; Ghosh, Apurv; Kini, Jyoti] Manipal Univ, Kasturba Med Coll, Pathol, Light House Hill Rd, Mangalore 575001, Karnataka, India	Saha, D (reprint author), Manipal Univ, Kasturba Med Coll, Pathol, Light House Hill Rd, Mangalore 575001, Karnataka, India.	devrishi2006@gmail.com		KINI, JYOTI/0000-0002-3351-9517			Bibbo M, 2015, COMPREHENSIVE CYTOPA, P59; Bosman FT, WHO CLASSIFICATION T; Brouwer R, 2009, DIS COLON RECTUM, V52, P598, DOI 10.1007/DCR.0b013e3181a0ad44; Conrad R, 2012, J GASTROINTEST ONCOL, V3, P285, DOI 10.3978/j.issn.2078-6891.2012.023; Cooper HS, 2015, STERNBERGS DIAGNOSTI, P1522; Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760; Fenoglio-Preiser CM, 2008, GASTROINTESTINAL PAT, P899; Greenson JK, 2009, SURG PATHOLOGY GI TR, V355-394; Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437; Rana S, 2015, MULTITARGETED APPROA, P217; Rosai J, 2011, ROSAI ACKERMANS SURG, P731; WINAWER SJ, 1976, CANCER, V37, P440, DOI 10.1002/1097-0142(197601)37:1+<440::AID-CNCR2820370708>3.0.CO;2-T; WINAWER SJ, 1978, CANCER, V42, P2849, DOI 10.1002/1097-0142(197812)42:6<2849::AID-CNCR2820420646>3.0.CO;2-U; Yu GH, 2001, DIAGN CYTOPATHOL, V24, P364, DOI 10.1002/dc.1079	14	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					215	222		10.1159/000487628			8	Pathology	Pathology	GI8QT	WOS:000434790200008	29617680				2019-10-28	
J	Savant, D; Adler, M; Kahn, L; Cocker, R				Savant, Deepika; Adler, Michael; Kahn, Leonard; Cocker, Rubina			Amyloidoma of Stomach: A Case Report	ACTA CYTOLOGICA			English	Article						Amyloidoma; Stomach; Fine needle aspiration cytology	DIAGNOSIS	Objective: Amyloidomas are tumor-like deposits of amyloid. Amyloidoma of the gastrointestinal tract is rare. To the best of our knowledge, this is the first instance of diagnosis of an amyloidoma in the gastrointestinal tract by fine needle aspiration (FNA). Study Design: We report a case of a 64-year-old male with a history of ulcerative colitis and primary sclerosing cholangitis who was incidentally found to have a mass in the stomach wall. Results: Initially thought to be gastrointestinal stromal tumor, FNA demonstrated the lesion to be amyloidoma with a prominent giant cell reaction. This was further confirmed by mass spectrometry. This is the only case report of diagnosis of a gastric amyloidoma by FNA. Conclusion: The presence of a florid giant cell reaction in the absence of ulceration or an inflammatory or neoplastic lesion should alert the pathologist to the possibility of an amyloidoma. This is the only case report of diagnosis of a gastric amyloidoma by FNA. (C) 2018 S. Karger AG, Basel.	[Savant, Deepika; Kahn, Leonard; Cocker, Rubina] Hofstra Northwell Sch Med, Dept Pathol, New Hyde Pk, NY USA; [Adler, Michael] Hofstra Northwell Sch Med, Dept Med, New Hyde Pk, NY USA	Savant, D (reprint author), Hofstra Northwell Sch Med, Dept Anat Pathol, 6 Ohio Dr, New Hyde Pk, NY 11040 USA.	dsavant@northwell.edu					CLOFT HJ, 1995, AM J NEURORADIOL, V16, P1152; DASTUR KJ, 1980, GASTROINTEST RADIOL, V5, P17, DOI 10.1007/BF01888593; Dhakal M, 2013, J DIG ENDOSC, V4, P78, DOI 10.4103/0976-5042.129974; Garg M, 2015, ONCOL GASTROENTEROL, V4, P1; Grunes D, 2015, CYTOJOURNAL, V12, DOI 10.4103/1742-6413.161602; Kapoor R, 2014, LUNG INDIA, V31, P404, DOI 10.4103/0970-2113.142151; Manucha V, 2003, DIAGN CYTOPATHOL, V29, P160, DOI 10.1002/dc.10239; Oyasiji Tolutope, 2009, Cases J, V2, P9100, DOI 10.1186/1757-1626-2-9100; Poulios C, 2013, CASE REP PATHOL, DOI 10.1155/2013/240758; Saindane AM, 2005, AM J ROENTGENOL, V185, P1187, DOI 10.2214/AJR.04.1134; Verhoeven F, 2014, CASE REP RHEUMATOL, V2014; Zheng LD, 2009, J ZHEJIANG UNIV-SC B, V10, P237, DOI 10.1631/jzus.B0820172	12	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					231	233		10.1159/000488133			3	Pathology	Pathology	GI8QT	WOS:000434790200010	29694947				2019-10-28	
J	Kassaby, SS; Preiszner, J; Youngberg, GA				Kassaby, Sarah S.; Preiszner, Johanna; Youngberg, George A.			Optimizing the Use of a Voided Urine Cytology Specimen as Control Material for Anti-BK Virus Immunohistochemical Staining	ACTA CYTOLOGICA			English	Letter									[Kassaby, Sarah S.; Preiszner, Johanna; Youngberg, George A.] East Tennessee State Univ, Dept Pathol, POB 70568, Johnson City, TN 37614 USA	Kassaby, SS (reprint author), East Tennessee State Univ, Dept Pathol, POB 70568, Johnson City, TN 37614 USA.	kassaby@etsu.edu					Adam B, 2014, AM J TRANSPLANT, V14, P2137, DOI 10.1111/ajt.12794; Elshenawy Y, 2012, MODERN PATHOL, V25, p398A; Masutani K, 2014, NEPHROLOGY, V19, P11, DOI 10.1111/nep.12254	3	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	3					234	236		10.1159/000487792			3	Pathology	Pathology	GI8QT	WOS:000434790200011	29642056				2019-10-28	
J	Snak, Y; Dwianingsih, EK; Sumpono, ASB; Panji, R; Rahman, A; Ghozali, A; Amr, SS				Snak, Yosinta; Dwianingsih, Ery Kus; Sumpono, Auliya Suluk Brilliant; Panji, Rovi; Rahman, Afif; Ghozali, Ahmad; Amr, Samir S.			Mediastinal Ectopic Pancreas with Abundant Endocrine Cells Coexisting with Mediastinal Cyst and Thymic Hyperplasia	CASE REPORTS IN PATHOLOGY			English	Article							OF-THE-LITERATURE; ANTERIOR MEDIASTINUM; TISSUE	Mediastinal ectopic pancreas is a rare condition with only 28 cases reported in the literature. Here we report a 21-year-old female patient who presented with dyspnea and intermittent severe chest pain of 7 years' duration. Computerized tomography scan (CT-scan) of the chest revealed a mediastinal cyst. The cyst was resected and it demonstrated on histopathological examination the presence of pancreatic tissue with increased number of islets of Langerhans, coexistent with mediastinal cyst and thymic hyperplasia. We made a review of all previously reported cases of this entity.	[Snak, Yosinta; Dwianingsih, Ery Kus; Sumpono, Auliya Suluk Brilliant; Panji, Rovi; Ghozali, Ahmad] Univ Gadjah Mada, Fac Med, Dept Anat Pathol, Yogyakarta, Indonesia; [Rahman, Afif] Univ Gadjah Mada, Fac Med, Dept Radiol, Yogyakarta, Indonesia; [Amr, Samir S.] King Fahad Specialist Hosp, Dept Pathol & Lab Med, Dammam, Saudi Arabia	Amr, SS (reprint author), King Fahad Specialist Hosp, Dept Pathol & Lab Med, Dammam, Saudi Arabia.	samir.amr48@gmail.com		Amr, Samir/0000-0001-8752-0647; Snak, Yosinta/0000-0003-0577-2758			Agrawal T., 2015, ENDOCRINE PATHOLOGY; Al-Salam S, 2006, VIRCHOWS ARCH, V448, P661, DOI 10.1007/s00428-006-0159-8; Arslan S, 2014, TURK GOGUS KALP DAMA, V22, P192, DOI 10.5606/tgkdc.dergisi.2014.5697; Byun Chun Sung, 2012, Korean J Thorac Cardiovasc Surg, V45, P131, DOI 10.5090/kjtcs.2012.45.2.131; Cagirici U, 2001, EUR J CARDIO-THORAC, V19, P514, DOI 10.1016/S1010-7940(01)00606-6; CARR MJT, 1977, THORAX, V32, P512, DOI 10.1136/thx.32.4.512; Chen ZH, 2009, KOREAN J RADIOL, V10, P527, DOI 10.3348/kjr.2009.10.5.527; Ehricht A, 2009, ZBL CHIR, V134, P178, DOI 10.1055/s-2008-1076882; Fayoumi S, 2010, ANN THORAC SURG, V90, pE25, DOI 10.1016/j.athoracsur.2010.05.059; Gong N., 1997, CHIN J THORAC CARDIO, P308; Kim YJ, 2011, KOREAN J RADIOL, V12, P376, DOI 10.3348/kjr.2011.12.3.376; Koh HM, 2015, INT J SURG PATHOL, V23, P585, DOI 10.1177/1066896915596810; Li WW, 2016, CLIN RESPIR J, V10, P125, DOI 10.1111/crj.12176; PerezOrdonez B, 1996, MODERN PATHOL, V9, P210; Rokach A, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-176; Romain PS, 2012, ANN DIAGN PATHOL, V16, P494, DOI 10.1016/j.anndiagpath.2011.04.005; Sentis MI, 2004, ARCH BRONCONEUMOL, V40, P185; SHILLITOE AJ, 1957, J THORAC SURG, V34, P810; Stella Franco, 2011, J Med Case Rep, V5, P238, DOI 10.1186/1752-1947-5-238; SUDA K, 1984, ARCH PATHOL LAB MED, V108, P835; Szabados S, 2012, J CARDIOTHORAC SURG, V7, DOI 10.1186/1749-8090-7-22; Takemura M, 2011, J CARDIOTHORAC SURG, V6, DOI 10.1186/1749-8090-6-118; Tamura Y, 2005, GEN THORAC CARDIOVAS, V53, P498; VONSCHWEINITZ D, 1990, Z KINDERCHIR, V45, P249; Wang W, 2007, J THORAC IMAG, V22, P256, DOI 10.1097/01.rti.0000213587.44719.a7; Wu J., 1998, CHIN J THORAC CARDIO, V14, P214; Wu L, 2015, ANN THORAC SURG, V100, P2368, DOI 10.1016/j.athoracsur.2015.08.064; Zhang LZ, 2014, ONCOL LETT, V7, P1053, DOI 10.3892/ol.2014.1840	28	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8270516	10.1155/2018/8270516			6	Pathology	Pathology	GI9CN	WOS:000434822600001	29977637	DOAJ Gold, Green Published			2019-10-28	
J	Tynski, Z; Chiang, W; Barrett, A				Tynski, Zofia; Chiang, Way; Barrett, Albert			An Inguinal Perivascular Epithelioid Cell Tumor Metastatic to the Orbit	CASE REPORTS IN PATHOLOGY			English	Article							PECOMAS; LESIONS; SUGAR	Malignant PEComas are rare mesenchymal neoplasms. These tumors harbor distinct myomelanocytic phenotype. The PEComa family of tumors includes lymphangioleiomyomatosis, angiomyolipoma, clear cell sugar tumor of the lung, and myomelanocytic tumor of the falciparum ligament/ligamentum teres. PEComas have no known normal cell counterpart. Majority of PEComas are benign and occur predominantly in the middle-age women. These tumors are commonly encountered in the uterus. Herein, we report a 20-year-old woman with a left inguinal mass metastatic to orbit, brain, lumbar spine, and skin at presentation. To our knowledge, this is the first case of metastatic PEComa to the orbit. This is the third case of primary PEComa of the inguinal area.	[Tynski, Zofia] Clarion Hosp, Dept Pathol, Clarion, PA 16214 USA; [Chiang, Way] Clarion Hosp, Dept Family Med, Clarion, PA 16214 USA; [Barrett, Albert] Clarion Hosp, Dept Radiol, Clarion, PA 16214 USA	Tynski, Z (reprint author), Clarion Hosp, Dept Pathol, Clarion, PA 16214 USA.	ztynski@clarionhospital.org		Tynski, Zofia/0000-0001-7105-408X	Lake Erie College ofOsteopathicMedicine (LECOM); Lake Erie Consortium for Osteopathic Medical Training (LECOMT)	The authors are indebted to Drs. John Goldblum, Steven Billings, and Fadi Abdul Karim who were consulted at Cleveland Clinic. This work is supported by the Lake Erie College ofOsteopathicMedicine (LECOM) and the Lake Erie Consortium for Osteopathic Medical Training (LECOMT).	Armah H., 2009, ARCH PATHOLOGY LAB, V133; Bleeker Jonathan S., 2012, Sarcoma, P541626, DOI 10.1155/2012/541626; BONETTI F, 1992, AM J SURG PATHOL, V16, P307, DOI 10.1097/00000478-199203000-00013; Conlon N, 2015, J CLIN PATHOL, V68, P418, DOI 10.1136/jclinpath-2015-202945; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Folpe AL, 2002, PATHOLOGY GENETICS T, P221; Folpe AL, 2010, HUM PATHOL, V41, P1, DOI 10.1016/j.humpath.2009.05.011; Guo TH, 2011, GENE CHROMOSOME CANC, V50, P25, DOI 10.1002/gcc.20827; Hyrcza MD, 2017, ENDOCR PATHOL, V28, P22, DOI 10.1007/s12022-016-9434-7; Martignoni G, 2008, VIRCHOWS ARCH, V452, P119, DOI 10.1007/s00428-007-0509-1; Selvaggi F, 2011, BMC SURG, V11, DOI 10.1186/1471-2482-11-3; Tynski Z., 2017, HUMAN PATHOLOGY CASE, V10, P5; Wang T, 2013, PATHOL RES PRACT, V209, P593, DOI 10.1016/j.prp.2013.06.003; Zamboni G, 1996, AM J SURG PATHOL, V20, P722, DOI 10.1097/00000478-199606000-00010; Zhao LN, 2014, ARCH PATHOL LAB MED, V138, P1238, DOI 10.5858/arpa.2013-0092-CR	15	0	1	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5749421	10.1155/2018/5749421			5	Pathology	Pathology	GI9CH	WOS:000434822000001	30002939	DOAJ Gold, Green Published			2019-10-28	
J	Liu, CY; Tsai, HC				Liu, Chih-Yi; Tsai, Hui-Chih			Comparison of Diagnostic Cytomorphology of Natural Killer/T-Cell Lymphoma (Nasal Type) in Conventional Smears, Liquid-Based Preparations, and Histopathology	CASE REPORTS IN PATHOLOGY			English	Article							FINE-NEEDLE-ASPIRATION; EPSTEIN-BARR-VIRUS; T-CELL; CYTOLOGY; PATHOLOGY; TAIWAN	Natural killer (NK)/T-cell lymphoma is formally referred to as extranodal NK/T-cell lymphoma, nasal type (ENKTCL), in the 2008 and 2016 World Health Organization (WHO) classifications. NK/T-cell lymphoma, nasal type, is a rare but clinically important lymphoid neoplasm. It is the predominant type of extranodal lymphoma associated with the Epstein-Barr virus (EBV). NK/T-cell lymphoma is marked by a wide cytomorphological spectrum. The cytological findings may be so subtle that NK/T-cell lymphoma could possibly be easily overlooked. Here, we report a case of NK/T-cell lymphoma involving the sinonasal region with lymph node involvement. Fine needle aspiration of the neck lymph node and punch biopsy of the nasal mucosa were performed. The diagnosis of NK/T-cell lymphoma was confirmed based on pathological and immunohistochemical analyses, as well as in situ hybridization for EBV-encoded mRNA (EBER). The present case report underlines the importance of prompt clinicopathological assessment in suspected cases. The comparison of cytomorphologic features of NK/T-cell lymphoma in various specimens is presented.	[Liu, Chih-Yi; Tsai, Hui-Chih] Sijhih Cathay Gen Hosp, Div Pathol, New Taipei, Taiwan; [Liu, Chih-Yi] Fu Jen Catholic Univ, Coll Med, New Taipei, Taiwan	Liu, CY (reprint author), Sijhih Cathay Gen Hosp, Div Pathol, New Taipei, Taiwan.; Liu, CY (reprint author), Fu Jen Catholic Univ, Coll Med, New Taipei, Taiwan.	cyl1124@gmail.com		Liu, Chih Yi/0000-0002-3996-8452			Chen L, 2018, CYTOPATHOLOGY, V29, P10, DOI 10.1111/cyt.12449; Chuang SS, 2014, PATHOLOGY, V46, P581, DOI 10.1097/PAT.0000000000000161; Crane GM, 2016, SEMIN DIAGN PATHOL, V33, P71, DOI 10.1053/j.semdp.2015.09.008; Dunning KK, 2009, DIAGN CYTOPATHOL, V37, P686, DOI 10.1002/dc.21077; Ham MF, 2010, INT J HEMATOL, V92, P681, DOI 10.1007/s12185-010-0738-y; Jhuang JY, 2015, HUM PATHOL, V46, P313, DOI 10.1016/j.humpath.2014.11.008; Jimenez-Heffernan JA, 2002, DIAGN CYTOPATHOL, V27, P371, DOI 10.1002/dc.10185; Kishimoto K, 2007, DIAGN CYTOPATHOL, V35, P125, DOI 10.1002/dc.20604; Kuo TT, 2004, INT J SURG PATHOL, V12, P375, DOI 10.1177/106689690401200410; Li SY, 2013, AM J SURG PATHOL, V37, P14, DOI 10.1097/PAS.0b013e31826731b5; Loo CKC, 2002, ACTA CYTOL, V46, P877; Nava VE, 2005, ADV ANAT PATHOL, V12, P27, DOI 10.1097/01.pap.0000151318.34752.80; Ng WK, 2003, ACTA CYTOL, V47, P1063, DOI 10.1159/000326648; Omori M, 2016, DIAGN CYTOPATHOL, V44, P430, DOI 10.1002/dc.23439; Siddiqui MT, 2009, DIAGN CYTOPATHOL, V37, P220, DOI 10.1002/dc.21045; Suzuki R, 2008, HEMATOL ONCOL, V26, P66, DOI 10.1002/hon.847; Swerdlow SH, 2014, AM J SURG PATHOL, V38, pE60, DOI 10.1097/PAS.0000000000000295; Wright CA, 1998, DIAGN CYTOPATHOL, V19, P9, DOI 10.1002/(SICI)1097-0339(199807)19:1<9::AID-DC3>3.3.CO;2-C	18	1	1	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									6264810	10.1155/2018/6264810			7	Pathology	Pathology	GH4YK	WOS:000433420700001	29888018	DOAJ Gold, Green Published			2019-10-28	
J	Dziuba, I; Kurzawa, P; Dopierala, M; Larque, AB; Ewicz-Lewandowska, DJ				Dziuba, Ireneusz; Kurzawa, Pawel; Dopierala, Michal; Larque, Ana B.; Ewicz-Lewandowska, Danuta Januszki			RHABDOMYOSARCOMA IN CHILDREN - CURR ENT PATHOLOGIC AND MOLECULAR CLASSIFICATION	POLISH JOURNAL OF PATHOLOGY			English	Review						rhabdomyosarcoma; children; pathologic and molecular classification	SOFT-TISSUE SARCOMAS; ONCOLOGY GROUP; PEDIATRIC RHABDOMYOSARCOMA; ALVEOLAR RHABDOMYOSARCOMA; SPINDLE-CELL; TUMORS; CANCER; EXPRESSION; EXPERIENCE; DIAGNOSIS	The last 25 years have brought significant progress in the treatment of sarcomas in children, especially rhabdomyosarcoma (RMS). Nevertheless, treatment failure in some patients results from considerable biological heterogeneity noted in these tumours. RMS, the most common malignant soft tissue neoplasm in children, includes two main subtypes: embryonal (ERMS) and alveolar (ARMS). Due to greater aggressiveness and worse prognosis of ARMS in comparison to ERMS, discrimination between different rhabdomyosarcoma subtypes is of crucial clinical importance. This paper presents the current histological classification of RMS, up-to-date immunohistochemical and biological research regarding RMS, and its associated clinical and prognostic significance.	[Dziuba, Ireneusz; Kurzawa, Pawel] Poznan Univ Med Sci, Univ Hosp Lords Transfigurat, Pathol Dept, Poznan, Poland; [Dziuba, Ireneusz] Pomeranian Med Univ, Szczecin, Poland; [Kurzawa, Pawel; Dopierala, Michal] Poznan Univ Med Sci, Clin Pathol Dept, Poznan, Poland; [Dopierala, Michal; Ewicz-Lewandowska, Danuta Januszki] Poznan Univ Med Sci, Dept Paediat Oncol Haematol & Transplantol, Poznan, Poland; [Larque, Ana B.] Massachusetts Gen Hosp, Pathol Dept, Boston, MA 02114 USA; [Ewicz-Lewandowska, Danuta Januszki] Med Diagnost Dept, Poznan, Poland	Dziuba, I (reprint author), Univ Hosp Lords Transfigurat, Pathol Dept, Szamarzewskiego 82-84, PL-60569 Poznan, Poland.	mmid@wp.pl	Dziuba, Ireneusz/M-1947-2018	Larque Daza, Ana Belen/0000-0002-1492-2116			Alexandrescu S, 2017, PEDIATR DEVEL PATHOL, V20, P105, DOI 10.1177/1093526616683881; Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Barr FG, 1997, J PEDIAT HEMATOL ONC, V19, P483, DOI 10.1097/00043426-199711000-00001; Bennicelli JL, 1999, ONCOGENE, V18, P4348, DOI 10.1038/sj.onc.1202812; Bishop JA, 2015, HEAD NECK PATHOL, V9, P507, DOI 10.1007/s12105-015-0624-2; Carroll SJ, 2013, ARCH PATHOL LAB MED, V137, P1155, DOI 10.5858/arpa.2012-0465-RS; Coindre JM, 2006, ARCH PATHOL LAB MED, V130, P1448; Dagher R, 1999, Oncologist, V4, P34; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; El Demellawy D, 2017, PATHOLOGY, V49, P238, DOI 10.1016/j.pathol.2016.12.345; Fletcher CDM, 2013, WHO CLASSIFICATION T, P125; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Hawkins DS, 2014, CURR OPIN PEDIATR, V26, P50, DOI 10.1097/MOP.0000000000000041; Homma T, 2017, NEUROPATHOLOGY, V37, P227, DOI 10.1111/neup.12346; Hornick JL, 2013, BIOL POTENTIAL GRADI, P7; Hostein I, 2004, CANCER-AM CANCER SOC, V101, P2817, DOI 10.1002/cncr.20711; Jain S, 2010, INT J CLIN EXP PATHO, V3, P416; Knapke Sara, 2012, Am Soc Clin Oncol Educ Book, P576, DOI 10.14694/EdBook_AM.2012.32.576; KODET R, 1991, CANCER-AM CANCER SOC, V67, P2907, DOI 10.1002/1097-0142(19910601)67:11<2907::AID-CNCR2820671133>3.0.CO;2-B; Koscielniak Ewa, 2002, Paediatr Drugs, V4, P21, DOI 10.2165/00148581-200204010-00003; Leuschner I, 2003, PEDIATR DEVEL PATHOL, V6, P128, DOI 10.1007/s10024-001-0097-z; Lindberg Matthew R., 2017, DIAGNOSTIC PATHOLOGY, p[10, 372]; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Morotti RA, 2006, AM J SURG PATHOL, V30, P962, DOI 10.1097/00000478-200608000-00005; Parham DM, 2006, ARCH PATHOL LAB MED, V130, P1454; Parham DM, 2013, ADV ANAT PATHOL, V20, P387, DOI 10.1097/PAP.0b013e3182a92d0d; Rekhi B, 2016, MODERN PATHOL, V29, P1532, DOI 10.1038/modpathol.2016.144; Rudzinski ER, 2015, ARCH PATHOL LAB MED, V139, P1281, DOI 10.5858/arpa.2014-0475-OA; Rudzinski Erin R, 2013, Am Soc Clin Oncol Educ Book, P425, DOI 10.1200/EdBook_AM.2013.33.425; SCRABLE H, 1989, GENE CHROMOSOME CANC, V1, P23, DOI 10.1002/gcc.2870010106; Slominski A, 1999, ARCH PATHOL LAB MED, V123, P1246; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Tarnowski M, 2014, POSTEP HIG MED DOSW, V68, P258, DOI 10.5604/17322693.1093219; Villani A, 2011, LANCET ONCOL, V12, P559, DOI 10.1016/S1470-2045(11)70119-X; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934	36	4	4	0	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					20	32		10.5114/pjp.2018.75333			13	Pathology	Pathology	GH0LS	WOS:000433094500002	29895123	DOAJ Gold			2019-10-28	
J	Pluta, P; Jesionek-Kupnicka, D; Kubicka-Wolkowska, J; Pluta, A; Brzozowski, K; Potemski, P; Piekarski, J; Kordek, R; Jeziorski, A				Pluta, Piotr; Jesionek-Kupnicka, Dorota; Kubicka-Wolkowska, Joanna; Pluta, Agnieszka; Brzozowski, Kamil; Potemski, Piotr; Piekarski, Janusz; Kordek, Radzislaw; Jeziorski, Arkadiusz			SMAC PROTEIN EXPRESS ION AS A POTENT FAVORABLE PROGNOS TIC FACTOR IN LOC ALLY ADVANCED BREAST CANCER	POLISH JOURNAL OF PATHOLOGY			English	Article						locally advanced breast cancer; chemotherapy; SMAC protein	IMMUNOHISTOCHEMICAL ANALYSIS; CHEMOTHERAPY; THERAPEUTICS; ACTIVATION; FEATURES	Preoperative systemic therapy including neoadjuvant chemotherapy (NCT) is standard treatment in locally advanced breast cancer (LABC), the aim of which is to enable a radical surgery and to reduce the risk of local and distant recurrence. It has been established that NCT in LABC may effectively induce apoptosis. The study objective was to assess the role of a proapoptotic second mitochondria-derived activator of apoptosis (SMAC) in LABC. The study group comprised 56 patients with advanced non-metastatic breast cancer (stage IIB -node positive and III), who received NCT followed by surgery and adjuvant treatment. Expression of SMAC protein was analysed using the immunohistochemistry technique in core biopsies sampled from the patients' breasts before NCT and in surgical specimens collected after completion of NCT. Expression of SMAC was significantly higher in the breast cancer specimens after NCT (p < 0.01). High expression of SMAC in the core biopsy before NCT correlated with a pathological complete remission (pCR, p < 0.01). The patients with a high expression of SMAC in the surgical specimens after NCT had longer DFS. Our study proves a potential role of SMAC expression in LABC as a novel favourable prognostic factor in LABC for pCR and disease-free survival (DFS).	[Pluta, Piotr] Copernicus Mem Hosp, Dept Surg Oncol 1, Breast Canc Unit, Lodz, Poland; [Jesionek-Kupnicka, Dorota; Kordek, Radzislaw] Med Univ Lodz, Dept Canc Pathol, Lodz, Poland; [Kubicka-Wolkowska, Joanna; Potemski, Piotr] Med Univ Lodz, Copernicus Mem Hosp, Dept Gen Oncol, Lodz, Poland; [Pluta, Agnieszka; Brzozowski, Kamil] Med Univ Lodz, Copernicus Mem Hosp, Dept Hematol, Lodz, Poland; [Piekarski, Janusz; Jeziorski, Arkadiusz] Med Univ Lodz, Copernicus Mem Hosp, Dept Surg Oncol 2, Lodz, Poland	Pluta, P (reprint author), Copernicus Mem Hosp, Dept Surg Oncol 1, Pabianicka 62, PL-93513 Lodz, Poland.	drpiotrpluta@gmail.com	Brzozowski, Kamil/K-6903-2018		Medical University of Lodz [503/1-034-01/503-06-100]	This work was partly funded by the Medical University of Lodz (Grant No. 503/1-034-01/503-06-100).	Allred DC, 1998, MODERN PATHOL, V11, P155; Bai LC, 2014, PHARMACOL THERAPEUT, V144, P82, DOI 10.1016/j.pharmthera.2014.05.007; Bai LC, 2014, ANNU REV MED, V65, P139, DOI 10.1146/annurev-med-010713-141310; Benetatos CA, 2014, MOL CANCER THER, V13, P867, DOI 10.1158/1535-7163.MCT-13-0798; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Cohen J., 1988, STAT POWER ANAL BEHA; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Erbes T, 2016, CLIN BREAST CANCER, V16, pE119, DOI 10.1016/j.clbc.2016.02.018; Fandy TE, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-60; Greene FL, 2009, TNM CLASSIFICATION M, P181; Jin GS, 2016, MOL MED REP, V13, P359, DOI 10.3892/mmr.2015.4542; Kolacinska A, 2015, ONCOL LETT, V10, P1079, DOI 10.3892/ol.2015.3321; Krzakowski M, 2013, ZALECENIA POSTEPOWAN, P246; Li D, 2007, CANCER BIOL THER, V6, P1442; Lv QX, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122095; Montagna E, 2010, BREAST CANCER RES TR, V124, P689, DOI 10.1007/s10549-010-1027-4; Moulder S, 2010, WOMENS HEALTH, V6, P821, DOI 10.2217/WHE.10.60; National Comprehensive Cancer Network (NCCN), 2019, NCCN CLIN PRACT GUID; Newman LA, 2009, SEMIN RADIAT ONCOL, V19, P195, DOI 10.1016/j.semradonc.2009.05.003; Palma G, 2015, ONCOTARGET, V6, P26560, DOI 10.18632/oncotarget.5306; Perrone F, 2006, CLIN CANCER RES, V12, P6643, DOI 10.1158/1078-0432.CCR-06-1759; Pluta A, 2010, LEUKEMIA RES, V34, P1308, DOI 10.1016/j.leukres.2009.11.030; Pluta P, 2011, NEOPLASMA, V58, P430, DOI 10.4149/neo_2011_05_430; Verhagen AM, 2002, APOPTOSIS, V7, P163, DOI 10.1023/A:1014318615955; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984; Yoo NJ, 2003, APMIS, V111, P382, DOI 10.1034/j.1600-0463.2003.t01-1-1110202.x; Zhao YC, 2014, MOL MED REP, V9, P614, DOI 10.3892/mmr.2013.1842	28	0	0	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					33	41		10.5114/pjp.2018.75334			9	Pathology	Pathology	GH0LS	WOS:000433094500003	29895124	DOAJ Gold			2019-10-28	
J	Celewicz, A; Celewicz, M; Wezowska, M; Chudecka-Glaz, A; Menkiszak, J; Urasinska, E				Celewicz, Aleksander; Celewicz, Marta; Wezowska, Malgorzata; Chudecka-Glaz, Anita; Menkiszak, Janusz; Urasinska, Elzbieta			CLINICAL EFFICACY OF P16/KI-67 DUAL-STAINED CERVICAL CYTOLOGY IN SECO NDARY PREVENTION OF CERVICAL CANCER	POLISH JOURNAL OF PATHOLOGY			English	Article						cervical cancer; pap smear; cytology; p16/Ki-67; dual-stained cytology; HPV	NEOPLASIA; PERFORMANCE; COLPOSCOPY; PRECURSORS	Cervical cancer is the third most common malignant neoplasm in women worldwide. HPV infection is the necessary factor for the cancer to develop. HPV DNA can be integrated into the genome of squamous epithelium and cause transcription of the viral oncoproteins and development of invasive cancer within 15-20 years. We assessed ICC co-expression of p16/Ki-67 proteins in smears collected from the uterine cervix and the association between p16/Ki-67 co-expression and cytologic and histologic results. Samples were collected from 93 women using liquid based cytology (LBC). Two microscopic slides were prepared: for Papanicolaou staining and ICC staining. Biopsy samples were collected from 43 women. Diagnosis of CIN 2+ was the endpoint of the study. p16/Ki-67 positive cells were found in women with: 1) a cytology result of ASC-US (3.59%), LSIL (2.22%), ASC-H (21.92%), HSIL (33.18%), SCC (72.22%) or NILM (3.44%); 2) a histopathologic result of CIN 1 (2.13%), CIN 2 (19.93%), CIN 3 (23.22%), SCC (69.72%) or normal histology (7.58%). p16/Ki-67 dual staining can increase the efficiency of screening methods and indicate women in whom further diagnostic procedures are required or those with extremely low risk of cancer. Sparing protocols will have a significant role in women of reproductive age.	[Celewicz, Aleksander; Wezowska, Malgorzata; Chudecka-Glaz, Anita; Menkiszak, Janusz] Pomeranian Med Univ, Dept Gynecol Surg & Gynecol Oncol Adults & Adoles, Al Powstancow Wielkopolskich 72, PL-71111 Szczecin, Poland; [Celewicz, Aleksander; Urasinska, Elzbieta] Pomeranian Med Univ, Dept Pathol, Szczecin, Poland; [Celewicz, Marta] Pomeranian Med Univ, Dept Obstet & Gynecol, Szczecin, Poland	Celewicz, A (reprint author), Pomeranian Med Univ, Dept Gynecol Surg & Gynecol Oncol Adults & Adoles, Al Powstancow Wielkopolskich 72, PL-71111 Szczecin, Poland.	katklgin@pum.edu.pl	Menkiszak, Janusz JM/I-4036-2014; Chudecka-Glaz, Anita/A-5813-2015	Menkiszak, Janusz JM/0000-0001-8279-7196; Chudecka-Glaz, Anita/0000-0003-2784-7968			Beaudenon S, 2008, BMC BIOCHEM, V9, DOI 10.1186/1471-2091-9-S1-S4; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Ferlay J, 2013, GLOBOCAN 2012 V1 0; Fujii T, 2015, INT J CLIN ONCOL, V20, P134, DOI 10.1007/s10147-014-0688-0; Harper DM, 2008, THERAPY, V5, P313; Ikenberg H, 2013, JNCI-J NATL CANCER I, V105, P1550, DOI 10.1093/jnci/djt235; Kumar V, 2005, ROBBINS BASIC PATHOL; Lee W H, 1989, Princess Takamatsu Symp, V20, P159; Negri G, 2004, VIRCHOWS ARCH, V445, P616, DOI 10.1007/s00428-004-1127-9; Peto J, 2004, BRIT J CANCER, V91, P942, DOI 10.1038/sj.bjc.6602049; Rokita W., 2011, ANALIZA WARTOSCI DIA; Saslow D, 2012, J LOW GENIT TRACT DI, V16, P175, DOI 10.1097/LGT.0b013e31824ca9d5; Schmidt D, 2011, CANCER CYTOPATHOL, V119, P158, DOI 10.1002/cncy.20140; Stoler MH, 2000, INT J GYNECOL PATHOL, V19, P16, DOI 10.1097/00004347-200001000-00004; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; Wentzensen N, 2014, CANCER CYTOPATHOL, V122, P914, DOI 10.1002/cncy.21473; Wentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270	17	2	2	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					42	47		10.5114/pjp.2018.75335			6	Pathology	Pathology	GH0LS	WOS:000433094500004	29895125	DOAJ Gold			2019-10-28	
J	Kovari, B; Kocsis, L; Varga, E; Cserni, G				Kovari, Bence; Kocsis, Lajos; Varga, Erika; Cserni, Gobor			EXPRESSION OF GROWTH HORMONE-RELEASING HORMONE RECEPTORS IN APOCRINE ADNEXAL TUMOURS AND APOCRINE GLANDS OF THE SKIN	POLISH JOURNAL OF PATHOLOGY			English	Article						skin adnexal tumours; sweat gland; apocrine gland; growth hormone-releasing hormone receptor; immunohistochemistry	BREAST CARCINOMAS; GHRH; CANCERS	Encouraged by our previous finding of growth hormone-releasing hormone receptor (GHRH-R) expression in metaplastic and neoplastic apocrine breast epithelium, we examined a small series of skin adnexal tumours with various degrees of apocrine (oxyphilic) differentiation, as well as normal axillary and anogenital apocrine sweat glands, for the expression of GHRH-R. Sections of formalin-fixed paraffin-embedded tissue blocks were immunostained for gross cystic disease fluid protein-15 (GCDFP-15) and androgen receptor (AR), to prove apocrine differentiation and correlate it with areas of GHRH-R expression. All but one of 19 tumours with apocrine epithelium and all five benign apocrine glands stained with both anti-GHRH-R antibodies used, each labelling a different domain of the receptor. Non-apocrine areas of the tumours and four eccrine tumours without oxyphilic features did not stain, but most sebaceous glands and some eccrine glands were labelled. Our data suggest that anti-GHRH-R antibodies highlight apocrine differentiation at extramammary sites also. Although GHRH-R seems to have a sensitivity comparable to classic apocrine markers such as AR and GCDFP-15, it seems to be inferior in specificity. The GHRH-R labelling of apocrine glands and neoplastic epithelium might also interfere with the emerging anti-GHRH targeted treatment of some malignancies acting on these receptors.	[Kovari, Bence; Cserni, Gobor] Univ Szeged, Inst Pathol, Allomas U 1, H-6720 Szeged, Hungary; [Kocsis, Lajos; Cserni, Gobor] Bacs Kiskun Cty Teaching Hosp, Dept Pathol, Kecskemet, Hungary; [Varga, Erika] Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary	Kovari, B (reprint author), Univ Szeged, Inst Pathol, Allomas U 1, H-6720 Szeged, Hungary.	kovari.bence.p@gmail.com		Cserni, Gabor/0000-0003-1344-7744	National Research, Development, and Innovation Office [GI-NOP-2.3.2-15-2016-00020]	This work was supported by National Research, Development, and Innovation Office grant number: GI-NOP-2.3.2-15-2016-00020.	Barabutis N, 2008, BRIT J CANCER, V98, P1790, DOI 10.1038/sj.bjc.6604386; Kahan Z, 1999, J CLIN ENDOCR METAB, V84, P582, DOI 10.1210/jc.84.2.582; Kazakov D, 2012, CUTANEOUS ADNEXAL TU, P1; Kovari B, 2017, HUM PATHOL, V64, P164, DOI 10.1016/j.humpath.2017.03.026; Kovari B, 2014, APMIS, V122, P824, DOI 10.1111/apm.12224; Perez Roberto, 2014, Oncoscience, V1, P665; Seitz S, 2013, ONCOL REP, V30, P413, DOI 10.3892/or.2013.2435; Vranic S, 2013, HISTOL HISTOPATHOL, V28, P1393, DOI 10.14670/HH-28.1393	8	0	0	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					48	52		10.5114/pjp.2018.75336			5	Pathology	Pathology	GH0LS	WOS:000433094500005	29895126	DOAJ Gold, Green Accepted			2019-10-28	
J	Nechifor-Boila, A; Decaussin-Petrucci, M; Varga-Ilyes, A; Chinezu, L; Carasca, C; Borda, A				Nechifor-Boila, Adela; Decaussin-Petrucci, Myriam; Varga-Ilyes, Agota; Chinezu, Laura; Carasca, Cosmin; Borda, Angela			ANGIOINVASION AS A FACTOR FOR PREDICTING AGGRESSIVE OUTCOME IN PRIMARY THYROID ANGIOSARCOMA: THREE CASE REPORTS AND LITERATURE REVIEW	POLISH JOURNAL OF PATHOLOGY			English	Review						thyroid; angiosarcoma; primary; angioinvasion; prognostic	OF-THE-LITERATURE; FINE-NEEDLE-ASPIRATION; NON-ALPINE REGION; EPITHELIOID ANGIOSARCOMA; GLAND; HEMANGIOSARCOMA; CARCINOMA; DIAGNOSIS; SARCOMA; GOITER	We report three primary thyroid angiosarcoma (PTA) cases revealing distinctive morphological features. A systematic literature review completed our analysis to evaluate the most important morphological factors for predicting prognosis in PTAs. Three rare PTA cases were analysed. In addition, we identified 46 previously reported PTAs with available follow-up data to compare morphological features related to prognosis between patients with a favourable versus aggressive outcome. The three PTAs displayed considerable architectural heterogeneity: case 1 presented a well circumscribed tumour, extensively necrotic, with only a few highly pleomorphic vascular proliferation; cases 2 and 3 both exhibited plump epithelioid cells forming rudimentary vascular spaces or solid sheets. Case 3 also presented angioinvasion. Cases 1 and 2 were alive and disease-free at 40 and 73 months following diagnosis, respectively, whereas case 3 died within 14 months. Other significant prognostic factors were highlighted by our review and literature data analysis: increased tumour size (p = 0.042), extrathyroidal extension (p = 0.009), and distant metastases at diagnosis (p = 0.001). Although regarded as highly aggressive, PTA can also be characterised by an unusual favourable outcome. For the first time we highlight the importance of reporting angioinvasion, in cases of PTA, as a possible adverse prognostic factor.	[Nechifor-Boila, Adela; Chinezu, Laura; Carasca, Cosmin; Borda, Angela] Univ Med & Pharm Tirgu Mures, Dept Histol, Targu Mures, Romania; [Nechifor-Boila, Adela] Tirgu Mures Cty Hosp, Dept Pathol, Targu Mures, Romania; [Decaussin-Petrucci, Myriam] Univ Lyon, Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Pathol, Lyon, France; [Varga-Ilyes, Agota; Borda, Angela] Tirgu Mures Emergency Cty Hosp, Dept Pathol, Targu Mures, Romania	Decaussin-Petrucci, M (reprint author), Univ Lyon 1, Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Pathol, F-69495 Lyon, France.	myriam.decaussin-petrucci@chu-lyon.fr					Altinay S, 2014, ONCOL LETT, V8, P2117, DOI 10.3892/ol.2014.2470; Astl J, 2000, NEUROENDOCRINOL LETT, V21, P213; Bayir O, 2016, INT J SURG CASE REP, V19, P92, DOI 10.1016/j.ijscr.2015.12.028; Binesh F, 2011, BMJ CASE REP, V2011; CHAN YF, 1986, CANCER, V57, P2381, DOI 10.1002/1097-0142(19860615)57:12<2381::AID-CNCR2820571224>3.0.CO;2-Q; Collini P, 2016, VIRCHOWS ARCH, V469, P223, DOI 10.1007/s00428-016-1964-3; Couto J, 2014, INT J ENDOCRINOL MET, V12, DOI 10.5812/ijem.15806; Cutlan RT, 2000, EXP MOL PATHOL, V69, P159, DOI 10.1006/exmp.2000.2323; Das P, 2007, CANCER-AM CANCER SOC, V109, P2323, DOI 10.1002/cncr.22680; Del Rio Paolo, 2007, Chir Ital, V59, P747; DeLellis RA, 2004, PATHOLOGY GENETICS T, P57; EUSEBI V, 1990, AM J SURG PATHOL, V14, P737, DOI 10.1097/00000478-199008000-00004; Fulciniti F, 2008, ACTA CYTOL, V52, P612, DOI 10.1159/000325607; Goh Seng Geok Nicholas, 2003, Arch Pathol Lab Med, V127, pE70; Gouveia P, 2013, INT J SURG CASE REP, V4, P524, DOI 10.1016/j.ijscr.2013.02.005; Hart J, 2011, ARCH PATHOL LAB MED, V135, P268, DOI 10.1043/1543-2165-135.2.268; Innaro N, 2013, CASE REP ONCOL MED, DOI 10.1155/2013/901246; Isa NM, 2009, DIAGN CYTOPATHOL, V37, P427, DOI 10.1002/dc.21065; Italiano A, 2012, CANCER-AM CANCER SOC, V118, P5878, DOI 10.1002/cncr.27614; Kalitova P, 2009, EUR ARCH OTO-RHINO-L, V266, P903, DOI 10.1007/s00405-008-0820-8; Kaur A, 2013, ENDOCR PATHOL, V24, P156, DOI 10.1007/s12022-013-9253-z; Kefeli M, 2014, ENDOCR PATHOL, V25, P350, DOI 10.1007/s12022-013-9243-1; Kim NR, 2003, J KOREAN MED SCI, V18, P908, DOI 10.3346/jkms.2003.18.6.908; LAMOVEC J, 1994, ARCH PATHOL LAB MED, V118, P642; Lin O, 2002, ACTA CYTOL, V46, P767, DOI 10.1159/000326994; Maiorana A, 1996, VIRCHOWS ARCH, V429, P131; MILLS SE, 1994, AM J CLIN PATHOL, V102, P322, DOI 10.1093/ajcp/102.3.322; Moon SY, 2016, INTERNAL MED, V55, P1165, DOI 10.2169/internalmedicine.55.5447; Papotti M, 2008, ENDOCR PATHOL, V19, P175, DOI 10.1007/s12022-008-9039-x; Petronella P, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-73; Prather J, 2014, JAMA OTOLARYNGOL, V140, P469, DOI 10.1001/jamaoto.2014.95; Proces S, 1998, J ENDOCRINOL INVEST, V21, P67, DOI 10.1007/BF03347289; Rotellini M, 2015, ENDOCR PATHOL, V26, P152, DOI 10.1007/s12022-015-9372-9; Ryska A, 2004, HISTOPATHOLOGY, V44, P40, DOI 10.1111/j.1365-2559.2004.01772.x; SAPINO A, 1995, HISTOPATHOLOGY, V26, P457; Surov A, 2015, ANTICANCER RES, V35, P5185; TANDA F, 1988, HUM PATHOL, V19, P742, DOI 10.1016/S0046-8177(88)80183-7; Yilmazlar T, 2005, ENDOCR J, V52, P57, DOI 10.1507/endocrj.52.57	38	1	1	0	1	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					53	61		10.5114/pjp.2018.75337			9	Pathology	Pathology	GH0LS	WOS:000433094500006	29895127	DOAJ Gold			2019-10-28	
J	Wlodek, J; Pituch-Noworolska, A				Wlodek, Joanna; Pituch-Noworolska, Anna			THE INFLUENCE OF FIBRONECTIN ON PROLIFERATION AND APOPTO SIS OF ACUTE LYMPHOBLASTIC LEUKAEMIA CELLS IN VITRO	POLISH JOURNAL OF PATHOLOGY			English	Article						acute lymphoblastic leukaemia; proliferation; apoptosis; fibronectin; collagen	MYELOID-LEUKEMIA; BONE-MARROW	The extracellular matrix (ECM) is a dynamic environment involved in the regulation of haematopoiesis. A crucial role of this structure is the promotion of proliferation, maturation, and differentiation of haematopoietic stem cells (HSC), and adhesion and migration of HSC in bone marrow. In the present study the effect of ECM proteins (fibronectin, collagens, laminin, thrombospondin, and vitronectin) on proliferation and apoptosis of acute lymphoblastic leukaemia cells isolated from acute lymphoblastic leukaemia (ALL) patients (in vitro) was assessed. The leukaemia cells were obtained as interphase on Ficoll/Isopaque (Pancoll human, PAN-Biotech) density gradient and, after washing, counted in a chamber. Subsequently, cells were used for culture and apoptosis assay. Presence of fibronectin, collagen type IV, and laminin was associated with inhibition of lymphoblastic leukaemia cell proliferation. Analysis of the culture of lymphoblastic leukaemia cells in the presence of ECM showed fibronectin as the most active protein.	[Wlodek, Joanna] Jagiellonian Univ, Med Coll, Dept Clin Immunol, Doctoral Programme Med Sci, Krakow, Poland; [Pituch-Noworolska, Anna] Jagiellonian Univ, Med Coll, Dept Clin Immunol, Wielicka 265, PL-30663 Krakow, Poland	Wlodek, J (reprint author), Jagiellonian Univ, Med Coll, Dept Clin Immunol, Wielicka 265, PL-30663 Krakow, Poland.	joanna.wlodek91@gmail.com					Chiarini F, 2016, BBA-MOL CELL RES, V1863, P449, DOI 10.1016/j.bbamcr.2015.08.015; Choi JS, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1600455; Dutta A, 2010, INT J CLIN EXP PATHO, V3, P288; Dworzak MN, 2018, CYTOM PART B-CLIN CY, V94, P82, DOI 10.1002/cyto.b.21518; Favreau AJ, 2014, CANCER MED-US, V3, P265, DOI 10.1002/cam4.203; Lazar-Karsten P, 2011, VOX SANG, V101, P65, DOI 10.1111/j.1423-0410.2010.01453.x; Sangaletti S, 2017, CANCER IMMUNOL IMMUN, V66, P1059, DOI 10.1007/s00262-017-2014-y; Shin JW, 2016, P NATL ACAD SCI USA, V113, P12126, DOI 10.1073/pnas.1611338113; Song KD, 2016, HUM CELL, V29, P53, DOI 10.1007/s13577-016-0134-x; Zollinger AJ, 2017, MATRIX BIOL, V60-61, P27, DOI 10.1016/j.matbio.2016.07.011	10	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					62	66		10.5114/pjp.2018.75338			5	Pathology	Pathology	GH0LS	WOS:000433094500007	29895128	DOAJ Gold			2019-10-28	
J	Stasikowska-Kanicka, O; Wagrowska-Danilewicz, M; Kulicka, P; Danilewicz, M				Stasikowska-Kanicka, Olga; Wagrowska-Danilewicz, Malgorzata; Kulicka, Paulina; Danilewicz, Marian			OVEREXPRESSION OF ADAM10 IN ORAL SQUAMO US CELL CARCINOM A WITH METASTASES	POLISH JOURNAL OF PATHOLOGY			English	Article						ADAM10; microvessels density; oral cancer; oral leukoplakia	HEPATOCELLULAR-CARCINOMA; CANCER PROGRESSION; METALLOPROTEASE 10; BREAST-CANCER; LUNG-CANCER; IN-VITRO; DISINTEGRIN; EXPRESSION; FAMILY; ANGIOGENESIS	ADAMs (a disintegrin and metalloproteinase) are important mediators of cell signalling events, which play a role in the pathogenesis and progression of cancers. Immunohistochemical method was used to examine the immunoexpression of ADAM10 and microvessel density in 80 cases of oral squamous cell carcinoma (OSCC): without metastases - OSCC M(-) (n = 38), and with metastases - OSCC M(+) (n = 42), in 24 cases of oral leukoplakia (OLK), (15 cases with low-grade dysplasia - OLK-LG, and 9 cases with high-grade dysplasia - OLK-HG), and 19 controls. The immunoexpression of ADAM10 and the mean number of vessels were significantly increased in both groups of OSCC in comparison to both groups of OLK and controls. Moreover, the immunoexpression of ADAM10 and microvessel density were significantly increased in the OSCC M(+) group in comparison to the OSCC M(-) group. No statistically significant differences were found between immunoexpression of ADAM10 and microvessels density in the OLK-LG, OLK-HG, and control cases. In conclusion, the present study revealed overexpression of ADAM10 in OSCCs, especially in OSCC with metastasis. These findings suggest that ADAM10 could potentially contribute to metastases of oral cancer. Although, our findings suggest that ADAM10 may be involved in angiogenesis of OSCC, further studies are required to determine the role of ADAM10 in this process.	[Stasikowska-Kanicka, Olga; Wagrowska-Danilewicz, Malgorzata; Kulicka, Paulina] Med Univ Lodz, Dept Nephropathol, Czechoslowacka 8-10, PL-92216 Lodz, Poland; [Danilewicz, Marian] Med Univ Lodz, Dept Pathomorphol, Lodz, Poland	Stasikowska-Kanicka, O (reprint author), Med Univ Lodz, Dept Nephropathol, Czechoslowacka 8-10, PL-92216 Lodz, Poland.	olga.stasikowska@umed.lodz.pl			Medical University of Lodz [503/6-038-01/503-61-002]	This work was supported by a grant from the Medical University of Lodz 503/6-038-01/503-61-002.	Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Barnes L, 2005, PATHOLOGY GENETICS H, P168; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Caltabiano R, 2016, PATHOL RES PRACT, V212, P980, DOI 10.1016/j.prp.2016.08.003; Caolo V, 2015, ANGIOGENESIS, V18, P13, DOI 10.1007/s10456-014-9443-4; Donners MPC, 2010, ARTERIOSCL THROM VAS, V30, P2188, DOI 10.1161/ATVBAHA.110.213124; Edwards DR, 2008, MOL ASPECTS MED, V29, P258, DOI 10.1016/j.mam.2008.08.001; Ferlay J, 2013, GLOBOCAN 2012 V1 0; Fu L, 2014, TUMOR BIOL, V35, P9263, DOI 10.1007/s13277-014-2201-9; Gaida MM, 2010, INT J MOL MED, V26, P281, DOI 10.3892/ijmm_00000463; Guo JL, 2012, ONCOL REP, V28, P1709, DOI 10.3892/or.2012.2003; Huxley-Jones J, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-63; Kauttu T, 2017, CLIN TRANSL ONCOL, V19, P58, DOI 10.1007/s12094-016-1503-3; Klein T, 2011, J PROTEOME RES, V10, P17, DOI 10.1021/pr100556z; Lee SB, 2010, J INVEST DERMATOL, V130, P763, DOI 10.1038/jid.2009.335; Lendeckel U, 2005, J CANCER RES CLIN, V131, P41, DOI 10.1007/s00432-004-0619-y; Liu SY, 2015, MOL MED REP, V11, P597, DOI 10.3892/mmr.2014.2652; Mullooly M, 2015, BRIT J CANCER, V113, P945, DOI 10.1038/bjc.2015.288; Nakamura T, 2004, EUKARYOT CELL, V3, P27, DOI 10.1128/EC.3.1.27-39.2004; Napier SS, 2008, J ORAL PATHOL MED, V37, P1, DOI 10.1111/j.1600-0714.2007.00579.x; Saftig P, 2011, EUR J CELL BIOL, V90, P527, DOI 10.1016/j.ejcb.2010.11.005; Schulz B, 2008, CIRC RES, V102, P1192, DOI 10.1161/CIRCRESAHA.107.169805; Seals DF, 2003, GENE DEV, V17, P7, DOI 10.1101/gad.1039703; Shaw RJ, 2011, PERIODONTOL 2000, V57, P89, DOI 10.1111/j.1600-0757.2011.00392.x; Wang YY, 2011, J SURG ONCOL, V103, P116, DOI 10.1002/jso.21781; Wu K, 2011, MED ONCOL, V28, P475, DOI 10.1007/s12032-010-9481-8; Zhang W, 2014, ONCOL REP, V32, P1913, DOI 10.3892/or.2014.3418; Zhang W, 2014, J INT MED RES, V42, P611, DOI 10.1177/0300060513505500; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	29	2	2	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					67	72		10.5114/pjp.2018.75339			6	Pathology	Pathology	GH0LS	WOS:000433094500008	29895129	DOAJ Gold			2019-10-28	
J	Avadanei, ER; Giusca, SE; Ura, LN; Caruntu, ID				Avadanei, Elena-Roxana; Giusca, Simona-Eliza; Ura, Lucian Neg; Caruntu, Irina-Draga			SINGLE NUCLEOTIDE POLYMORPHISMS OF XRCC3 GENE IN HEPATOCELLULAR CARCINOMA - RELATIONSHIP WITH CLINICOPATHOLOGICAL FEATURES	POLISH JOURNAL OF PATHOLOGY			English	Article						XRCC3 gene; single nucleotide polymorphism; hepatocellular carcinoma; tumour grade; survival	DNA-REPAIR GENE; STRAND BREAK REPAIR; CHINESE POPULATION; THR241MET POLYMORPHISM; HOMOLOGOUS RECOMBINATION; CANCER SUSCEPTIBILITY; GUANGXI POPULATION; COLORECTAL-CANCER; BLADDER-CANCER; RISK-FACTORS	Recent studies support the involvement of XRCC3 gene polymorphisms in carcinogenesis. Our study focuses on the identification of polymorphic variants of XRCC3 in hepatocellular carcinoma (HCC) and an analysis of the relationship between these polymorphic variants and clinicopathological (including the genotype specific risk) and survival characteristics. Fifty cases of HCC were genotyped using molecular biology techniques for Thr241Met, rs861539 (c. 722C>T) and 5'-UTR, rs1799796 (c. 562-14A>G) polymorphisms. Statistical analysis was based on chi(2), Fisher's, logistic regression (odd ratio - OR), and log-rank tests. Statistically significant differences were shown only for rs1799796 A>G and tumour grade, between wild type (AA) and heterozygote (AG) genotypes, and wild type (AA) and heterozygote & homozygote (AG & GG) genotypes. The logistic regression analysis found an OR of rs1799796 polymorphism occurrence in HCC related to tumour grade. The statistical analysis revealed, for the rs861539 C>T polymorphism, a better survival only for the homozygote genotype (TT) compared to the heterozygote (CT), and for rs1799796 A>G polymorphism, a longer survival for the wild type (AA) compared to heterozygote (AG) and to heterozygote & homozygote (AG & GG) genotypes, respectively. Our results suggest that XRCC3 gene SNPs could influence the tumour aggressiveness expressed by tumour grade.	[Avadanei, Elena-Roxana; Giusca, Simona-Eliza; Ura, Lucian Neg; Caruntu, Irina-Draga] Grigore T Popa Univ Med & Pharm, Dept Morphofunct Sci 1, 16 Univ St, Iasi 700115, Romania	Caruntu, ID (reprint author), Grigore T Popa Univ Med & Pharm, Dept Morphofunct Sci 1, 16 Univ St, Iasi 700115, Romania.	irinadragacaruntu@gmail.com			European Social FundEuropean Social Fund (ESF) [POSDRU/88/1.5/S/78702]; Romanian Government	POSDRU/88/1.5/S/78702 project, financed by the European Social Fund and the Romanian Government	Akkiz H, 2014, ANN HEPATOL, V13, P788, DOI 10.1016/S1665-2681(19)30981-0; Ali AM, 2016, BIOMED RES INT, DOI 10.1155/2016/8721052; Au WW, 2003, ENVIRON HEALTH PERSP, V111, P1843, DOI 10.1289/ehp.6632; Avadanei R, 2015, VIRCHOWS ARCH, V467, pS227; Azoicai Alice Nicoleta, 2010, Rev Med Chir Soc Med Nat Iasi, V114, P731; Bishop DK, 1998, J BIOL CHEM, V273, P21482, DOI 10.1074/jbc.273.34.21482; Bowen GD, 2012, J EXP MED, V11, P1709; Bradbury PA, 2009, PHARMACOGENET GENOM, V19, P613, DOI 10.1097/FPC.0b013e32832f3010; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Brenneman MA, 2000, MUTAT RES-DNA REPAIR, V459, P89, DOI 10.1016/S0921-8777(00)00002-1; Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6; Cahill D, 2006, FRONT BIOSCI-LANDMRK, V11, P1958, DOI 10.2741/1938; Duan CY, 2013, TUMOR BIOL, V34, P2827, DOI 10.1007/s13277-013-0841-9; Economopoulos KP, 2010, BREAST CANCER RES TR, V121, P439, DOI 10.1007/s10549-009-0562-3; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Fang F, 2011, MED ONCOL, V28, P999, DOI 10.1007/s12032-010-9591-3; Gheorghe L, 2010, J GASTROINTEST LIVER, V19, P373; Guo LY, 2012, ASIAN PAC J CANCER P, V13, P4423, DOI 10.7314/APJCP.2012.13.9.4423; Hahne SJM, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-181; Han SZ, 2006, EUR J HUM GENET, V14, P1136, DOI 10.1038/sj.ejhg.5201681; Han XC, 2012, HEPATO-GASTROENTEROL, V59, P2285, DOI 10.5754/hge12096; Huang JY, 2015, GENET MOL RES, V14, P10569, DOI 10.4238/2015.September.8.18; Iancu LS, 2000, REV MED CHIRSOC MED, V104, P113; Ji RB, 2015, GENET MOL RES, V14, P15988, DOI 10.4238/2015.December.7.11; Jiang Z, 2010, INT J COLORECTAL DIS, V25, P169, DOI 10.1007/s00384-009-0817-9; Kuschel B, 2002, HUM MOL GENET, V11, P1399, DOI 10.1093/hmg/11.12.1399; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Liu CB, 2013, TUMOR BIOL, V34, P2249, DOI 10.1007/s13277-013-0765-4; Liu QH, 1998, CURR BIOL, V8, P1300, DOI 10.1016/S0960-9822(07)00560-X; Liu R, 2007, J TOXICOL ENV HEAL A, V70, P956, DOI 10.1080/15287390701290725; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Long XD, 2008, ANN EPIDEMIOL, V18, P572, DOI 10.1016/j.annepidem.2008.03.003; Long Xi-dai, 2008, Zhonghua Yixue Yichuanxue Zazhi, V25, P268; Luo HC, 2014, TUMOR BIOL, V35, P3415, DOI 10.1007/s13277-013-1451-2; Mandal RK, 2012, INDIAN J MED RES, V135, P64, DOI 10.4103/0971-5916.93426; Matullo G, 2001, INT J CANCER, V92, P562, DOI 10.1002/ijc.1228; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Montalto G, 2002, ANN NY ACAD SCI, V963, P13, DOI 10.1111/j.1749-6632.2002.tb04090.x; Niwa Y, 2005, GYNECOL ONCOL, V99, P43, DOI 10.1016/j.ygyno.2005.05.018; Noureddin M, 2015, CLIN LIVER DIS, V19, P361, DOI 10.1016/j.cld.2015.01.012; Preda CM, 2018, LIVER INT, V38, P602, DOI 10.1111/liv.13550; Qiu LX, 2010, BREAST CANCER RES TR, V122, P489, DOI 10.1007/s10549-009-0726-1; Romanowicz-Makowska H, 2012, POL J PATHOL, V63, P121; Ronen A, 2001, ENVIRON MOL MUTAGEN, V37, P241, DOI 10.1002/em.1033; Schild D, 2000, J BIOL CHEM, V275, P16443, DOI 10.1074/jbc.M001473200; Shen MR, 1998, CANCER RES, V58, P604; Slyskova J, 2012, MUTAGENESIS, V27, P225, DOI 10.1093/mutage/ger088; Smith TR, 2003, CANCER LETT, V190, P183, DOI 10.1016/S0304-3835(02)00595-5; Sun HM, 2010, CANCER SCI, V101, P1777, DOI 10.1111/j.1349-7006.2010.01608.x; TEBBS RS, 1995, P NATL ACAD SCI USA, V92, P6354, DOI 10.1073/pnas.92.14.6354; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Verslype C, 2012, ANN ONCOL, V23, P41, DOI 10.1093/annonc/mds225; Winsey SL, 2000, CANCER RES, V60, P5612; Wu D, 2013, TUMOR BIOL, V34, P3865, DOI 10.1007/s13277-013-0973-y; Yan L, 2009, DIS ESOPHAGUS, V22, P396, DOI 10.1111/j.1442-2050.2008.00912.x; Yan L, 2016, CELL PHYSIOL BIOCHEM, V38, P1075, DOI 10.1159/000443058; Yin JY, 2012, GENE, V503, P118, DOI 10.1016/j.gene.2012.04.072; Yuan CZ, 2014, BIOMED RES INT, DOI 10.1155/2014/648137; Zhao Y, 2012, ASIAN PAC J CANCER P, V13, P665, DOI 10.7314/APJCP.2012.13.1.665; Zhou KK, 2009, INT J CANCER, V124, P2948, DOI 10.1002/ijc.24307	60	2	2	0	3	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					73	81		10.5114/pjp.2018.75340			9	Pathology	Pathology	GH0LS	WOS:000433094500009	29895130	DOAJ Gold			2019-10-28	
J	Val-Bernal, JF; Hermana, S; Gomez-Roman, JJ				Fernando Val-Bernal, J.; Hermana, Sandra; Gomez-Roman, Jose-Javier			INCIDENTAL, LOW-FAT VARIANT OF SPINDLE CELL LIPOMA: A NOVEL TUMOUR OF THE SMALL INTESTINE	POLISH JOURNAL OF PATHOLOGY			English	Article						small intestine; gastrointestinal tract; spindle cell lipoma; dendritic fibromyxolipoma; immunohistochemistry	EXPRESSION	A woman underwent surgical intervention for a carcinoma of the ovary. In the intervention, a submucosal nodule of the ileum was found. Pathological study revealed a spindle cell lipoma (SCL). This case revealed the presence of CD34-positive spindle and stellate cells with dendritic cytoplasmic prolongations, a feature shared with dendritic fibromyxolipoma. Fluorescence in in situ hybridisation analysis showed 13q14 heterozygous deletion. Spindle cell lipoma of the small intestine has not been previously reported. Spindle cell lipoma, although rare, should be included among the benign mesenchymal lesions of the small intestine. This report extends the range of locations in which this tumour is found to arise.	[Fernando Val-Bernal, J.] Univ Cantabria, Anat Pathol Unit, Avda Cardenal Herrera Oria S-N, ES-39011 Santander, Spain; [Hermana, Sandra; Gomez-Roman, Jose-Javier] Univ Cantabria, Med & Surg Sci Dept, Pathol Unit, Santander, Spain; [Hermana, Sandra; Gomez-Roman, Jose-Javier] IDIVAL Res Inst, Santander, Spain	Val-Bernal, JF (reprint author), Univ Cantabria, Anat Pathol Unit, Avda Cardenal Herrera Oria S-N, ES-39011 Santander, Spain.	apavbj@humv.es		Gomez-Roman, Jose Javier/0000-0002-2849-9435			ACKERMAN NB, 1975, SURG GYNECOL OBSTET, V141, P565; AlAbdulsalam A, 2016, CASE REP PATHOL, DOI 10.1155/2016/7289017; Bancroft LW, 2003, AM J ROENTGENOL, V181, P1251, DOI 10.2214/ajr.181.5.1811251; Billings SD, 2007, AM J DERMATOPATH, V29, P437, DOI 10.1097/DAD.0b013e31813735df; Chen BJ, 2012, AM J SURG PATHOL, V36, P1119, DOI 10.1097/PAS.0b013e31825d532d; ENZINGER FM, 1975, CANCER, V36, P1852, DOI 10.1002/1097-0142(197511)36:5<1852::AID-CNCR2820360542>3.0.CO;2-U; Gaskin CM, 2004, AM J ROENTGENOL, V182, P733, DOI 10.2214/ajr.182.3.1820733; Genchellac H, 2008, J COMPUT ASSIST TOMO, V32, P841, DOI 10.1097/RCT.0b013e318159a4b5; Kopacova M, 2013, GASTROENT RES PRACT, DOI 10.1155/2013/702536; Pascal RR, 1990, ATLAS TUMOR PATHOL, V27, P501; ROBB JA, 1982, HUM PATHOL, V13, P1052, DOI 10.1016/S0046-8177(82)80101-9; Suster S, 1998, Ann Diagn Pathol, V2, P111, DOI 10.1016/S1092-9134(98)80047-6; Tardio J, 2004, VIRCHOWS ARCH, V445, P354, DOI 10.1007/s00428-004-1085-2; Weisberg T, 1955, AM J CLIN PATHOL, V25, P272; WILSON JM, 1975, ANN SURG, V181, P247; Wong YP, 2014, PATHOL INT, V64, P346, DOI 10.1111/pin.12176; Zhang XJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-157	17	1	1	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					82	86		10.5114/pjp.2018.75341			5	Pathology	Pathology	GH0LS	WOS:000433094500010	29895131	DOAJ Gold			2019-10-28	
J	Nemejcova, K; Hajkova, N; Ticha, I; Bartu, M; Dolinska, D; Kalist, V; Dundr, P				Nemejcova, Kristyna; Hajkova, Nikola; Ticha, Ivana; Bartu, Michaela; Dolinska, Dagmar; Kalist, Vladimir; Dundr, Pavel			LYMPHOEPITHELIOMA-LIKE CARCINOMA OF THE ENDOMETRIUM: CASE REPORT OF A RARE TUMOUR WITH COMPREHENSIVE IMMUNOHISTOCHEMICAL AND MOLECULAR ANALYSIS	POLISH JOURNAL OF PATHOLOGY			English	Article						serous carcinoma; lymphoepithelial carcinoma; lymphoepithelioma-like carcinoma; endometrium	EPSTEIN-BARR-VIRUS; GASTRIC-CARCINOMA; URINARY-BLADDER; UTERINE CERVIX; ASSOCIATION; VARIANT	We are reporting a case of endometrial lymphoepithelioma-like carcinoma (LELC) in a 63-year-old female. Microscopically, the tumor consisted of groups of tumor cells surrounded by dense lymphoplasmacytic infiltrate. Immunohistochemically, the tumour cells were positive for cytokeratins AE1/AE3, EMA, PAX8, p16, and estrogen receptors. Protein p53 showed an aberrant type of expression. Molecular genetic analysis revealed mutations in the TP53 and PIKP53CA genes. Based on our results, we believe that the tumor represents an unusual morphological variant of endometrial serous carcinoma. To the best of our knowledge, only six cases of LELC arising in endometrium have been reported in literature to date.	[Nemejcova, Kristyna; Hajkova, Nikola; Ticha, Ivana; Bartu, Michaela; Dundr, Pavel] Charles Univ Prague, Fac Med 1, Inst Pathol, Studnickova 2, Prague 12800 2, Czech Republic; [Nemejcova, Kristyna; Hajkova, Nikola; Ticha, Ivana; Bartu, Michaela; Dundr, Pavel] Gen Univ Hosp Prague, Studnickova 2, Prague 12800 2, Czech Republic; [Dolinska, Dagmar] Bata Reg Hosp Zlin, Dept Pathol, Zlin, Czech Republic; [Kalist, Vladimir] Bata Reg Hosp Zlin, Dept Gynecol & Obstet, Zlin, Czech Republic	Nemejcova, K (reprint author), Charles Univ Prague, Fac Med 1, Inst Pathol, Studnickova 2, Prague 12800 2, Czech Republic.; Nemejcova, K (reprint author), Gen Univ Hosp Prague, Studnickova 2, Prague 12800 2, Czech Republic.	kristyna.nemejcova@vfn.cz	Nemejcova, Kristyna/C-7373-2017; Hajkova, Nikola/H-2844-2017; Ticha, Ivana/D-7033-2017	Nemejcova, Kristyna/0000-0001-9340-9320; Hajkova, Nikola/0000-0002-1683-7783; Ticha, Ivana/0000-0002-8451-4222	Ministry of Health, Czech RepublicMinistry of Health, Czech RepublicCzech Republic Government [64165, AZV 17-28404A]; Charles University [Q28/LF1, UNCE204065, SVV 260367]; OPPK (Research Laboratory of Tumor Diseases) [CZ.2.16/3.1.00/24509]	This work was supported by the Ministry of Health, Czech Republic (Conceptual development of research organisation 64165, General University Hospital in Prague and Project AZV 17-28404A), by Charles University (Project Progres Q28/LF1, UNCE204065, and SVV 260367), and by OPPK (Research Laboratory of Tumor Diseases, CZ.2.16/3.1.00/24509).	Abouelfad Dalia M, 2017, Asian Pac J Cancer Prev, V18, P1737; Ahn Hyein, 2014, Korean J Pathol, V48, P458, DOI 10.4132/KoreanJPathol.2014.48.6.458; Ambrosio MR, 2010, PATHOLOGICA, V102, P57; Bosmuller H, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-4; Chao A, 2009, INT J GYNECOL PATHOL, V28, P279, DOI 10.1097/PGP.0b013e31818fb0a9; Chen PCH, 2002, J PATHOL, V197, P684, DOI 10.1002/path.1141; Dundr P, 2003, PATHOL RES PRACT, V199, P559, DOI 10.1078/0344-0338-00462; Ewing J, 1929, AM J PATHOL, V5, P99; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Haga K, 2007, INT J UROL, V14, P851, DOI 10.1111/j.1442-2042.2007.01846.x; Herath CHP, 2008, ARCH PATHOL LAB MED, V132, P706, DOI 10.1043/1543-2165(2008)132[706:EVLGC]2.0.CO;2; Hoang LN, 2013, AM J SURG PATHOL, V37, P1421, DOI 10.1097/PAS.0b013e31828c63ed; Hussein YR, 2016, INT J GYNECOL PATHOL, V35, P16, DOI 10.1097/PGP.0000000000000212; Hussein YR, 2015, MODERN PATHOL, V28, P505, DOI 10.1038/modpathol.2014.143; Jafarian AH, 2013, INDIAN J PATHOL MICR, V56, P359, DOI 10.4103/0377-4929.125290; Jones H, 2014, INT J GYNECOL PATHOL, V33, P64, DOI 10.1097/PGP.0b013e318276310b; Ramos MFKP, 2017, J SURG RES, V210, P159, DOI 10.1016/j.jss.2016.11.012; Lee S, 2007, ARCH PATHOL LAB MED, V131, P1715; Makannavar JH, 2015, INDIA J SURG ONCOL, V6, P130, DOI 10.1007/s13193-015-0405-0; McCluggage WG, 2001, J CLIN PATHOL, V54, P964, DOI 10.1136/jcp.54.12.964; Rahimi S, 2007, INT J GYNECOL CANCER, V17, P532, DOI 10.1111/j.1525-1438.2007.00793.x; Tafe LJ, 2010, MODERN PATHOL, V23, P781, DOI 10.1038/modpathol.2010.41; Tseng CJ, 1997, CANCER, V80, P91, DOI 10.1002/(SICI)1097-0142(19970701)80:1<91::AID-CNCR12>3.0.CO;2-A; Vargas MP, 1998, INT J GYNECOL PATHOL, V17, P272, DOI 10.1097/00004347-199807000-00013; Yang AW, 2017, BMC UROL, V17, DOI 10.1186/s12894-017-0224-4; Zhao W, 2014, INT J CLIN EXP PATHO, V7, P7951	26	0	0	0	3	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					87	92		10.5114/pjp.2018.75342			6	Pathology	Pathology	GH0LS	WOS:000433094500011	29895132	DOAJ Gold			2019-10-28	
J	Stolnicu, S; Giurgi, A; Naznean, A; Podoleanu, C; Chiriac, A				Stolnicu, Simona; Giurgi, Alexandra; Naznean, Adrian; Podoleanu, Cristian; Chiriac, Anca			KELOIDAL-LIKE LOCAL RECURRENCE AFTER INFILTRATING ADENOSQUAMOUS BREAST CARCINOMA WITH STROMAL-OVERGROWTH MIMICK ING A BENIGN SKIN LESION	POLISH JOURNAL OF PATHOLOGY			English	Article						adenosquamous carcinoma; recurrence; stromal overgrowth		We present a very rare case of an adenosquamous infiltrating breast carcinoma with sarcomatous stromal overgrowth of hypocellular collagenised type, which subsequently developed local recurrence, mistaken for a benign skin lesion due to bland keloid-like morphological appearance. All the histological, immunohistochemical, and clinical features must be taken into consideration when distinguishing between a benign skin lesion and a local recurrence of a rare subtype of breast carcinoma.	[Stolnicu, Simona] Histopat Invest Lab, Targu Mures, Romania; [Stolnicu, Simona; Giurgi, Alexandra] Univ Med & Pharm Tirgu Mures, Dept Pathol, Targu Mures, Romania; [Naznean, Adrian] Univ Med & Pharm Tirgu Mures, Foreign Language Dept, Targu Mures, Romania; [Podoleanu, Cristian] Univ Med & Pharm Tirgu Mures, Dept Internal Med, Targu Mures, Romania; [Chiriac, Anca] Nicolina Med Ctr, Dept Dermatol, Iasi, Romania; [Chiriac, Anca] Apollonia Univ Iasi, Dept Dermatophysiol, Iasi, Romania; [Chiriac, Anca] Romanian Acad, P Poni Res Inst, Iasi, Romania	Podoleanu, C (reprint author), Univ Med & Pharm Targu Mures Romania, Gheorghe Marinescu St 38, Targu Mures 540139, Romania.	podoleanu@me.com	Chiriac, Anca/L-6829-2013	Chiriac, Anca/0000-0002-0989-4931; Stolnicu, Simona/0000-0002-4459-7019			Friedlander ML, 2014, INT J GYNECOL CAN S3, V24, pS78; Kinkor Z, 2005, Ceska Gynekol, V70, P211; Kurman RJ, 2014, WHO CLASSIFICATION T, P150; Lakhani SREI, 2012, WHO CLASSIFICATION T; Stolnicu S, 2016, INT J GYNECOL PATHOL, V35, P147, DOI 10.1097/PGP.0000000000000231; Wu RI, 2014, INT J GYNECOL PATHOL, V33, P573, DOI 10.1097/PGP.0000000000000100	6	0	0	0	2	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					93	97		10.5114/pjp.2018.75343			5	Pathology	Pathology	GH0LS	WOS:000433094500012	29895133	DOAJ Gold			2019-10-28	
J	Koufopoulos, N; Syrios, J; Papanikolaou, A; Misitzis, I; Kapatou, KA; Dimas, D; Khaldi, L				Koufopoulos, Nektarios; Syrios, John; Papanikolaou, Asimina; Misitzis, Ioannis; Kapatou, Kasiani A.; Dimas, Dionysis; Khaldi, Lubna			LYMPHOEPITHELIOMA-LIKE BREAST CARCINOMA	POLISH JOURNAL OF PATHOLOGY			English	Article						lymphoepithelioma-like carcinoma; breast cancer; lymphoepithelioma; Epstein-Barr virus; HPV	EPSTEIN-BARR-VIRUS; OF-THE-LITERATURE; HUMAN-PAPILLOMA-VIRUS; SALIVARY-GLAND; LOBULAR CARCINOMA; CANCER; ASSOCIATION; LYMPHOMA; ESKIMOS	Nasopharyngeal lymphoepithelioma is an undifferentiated carcinoma in a dominated lymphoplasma-histiocyte stroma. Lymphoepithelioma-like carcinoma of the breast is the mammary counterpart of the lymphoepithelioma of the nasopharynx and is characterised by proliferation of poorly differentiated malignant cells within a prominent lymphoid infiltrate. It is a very rare primary carcinoma of the breast first reported in 1994 by Kumar and Kumar. Fewer than 40 cases have been reported in the English literature. In this manuscript a case of lymphoepithelioma-like carcinoma of the breast in a 57-year-old patient is reported along with a literature review on this rare entity.	[Koufopoulos, Nektarios; Khaldi, Lubna] St Savvas Anticanc Hosp, Dept Pathol, 13 Parnasidos St, Athens 12136, Greece; [Syrios, John] St Savvas Anticanc Hosp, Oncol Dept 2, Athens, Greece; [Papanikolaou, Asimina] Evangelismos Gen Hosp, Dept Hematopathol, Athens, Greece; [Misitzis, Ioannis; Dimas, Dionysis] St Savvas Anticanc Hosp, Breast Surg Clin 1, Athens, Greece; [Kapatou, Kasiani A.] Gen Hosp Volos, Dept Pathol, Volos, Greece	Koufopoulos, N (reprint author), St Savvas Anticanc Hosp, Dept Pathol, 13 Parnasidos St, Athens 12136, Greece.	koufonektar@yahoo.com	Koufopoulos, Nektarios/R-2973-2017	Koufopoulos, Nektarios/0000-0001-9502-7916			Abdou AG, 2015, DIAGN CYTOPATHOL, V43, P210, DOI 10.1002/dc.23141; Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; Andryk J, 1996, AM J OTOLARYNG, V17, P61, DOI 10.1016/S0196-0709(96)90046-0; Blasi MA, 2011, EUR J OPHTHALMOL, V21, P320, DOI 10.5301/EJO.2010.6102; Bloching M, 2000, EUR ARCH OTO-RHINO-L, V257, P399, DOI 10.1007/s004050000237; Cristina S, 2000, VIRCHOWS ARCH, V437, P198, DOI 10.1007/s004280000204; Dadmanesh F, 2001, HISTOPATHOLOGY, V38, P54, DOI 10.1046/j.1365-2559.2001.01055.x; Dinniwell R, 2012, CURR ONCOL, V19, pE177, DOI 10.3747/co.19.926; HAMILTONDUTOIT SJ, 1991, HUM PATHOL, V22, P811, DOI 10.1016/0046-8177(91)90210-G; Herath CHP, 2008, ARCH PATHOL LAB MED, V132, P706, DOI 10.1043/1543-2165(2008)132[706:EVLGC]2.0.CO;2; Herrera-Goepfert R, 2016, J CLIN CASE REP, V3, P1102; Ho JC, 2006, RESPIROLOGY, V11, P539, DOI 10.1111/j.1440-1843.2006.00910.x; IEZZONI JC, 1995, AM J CLIN PATHOL, V103, P308, DOI 10.1093/ajcp/103.3.308; Ilvan S, 2004, BREAST, V13, P522, DOI 10.1016/j.breast.2004.06.010; Jansari TR, 2015, ANN PATHOL LAB MED, V2, pC235; Jeong AK, 2010, J ULTRAS MED, V29, P485, DOI 10.7863/jum.2010.29.3.485; Kalita LK, 2015, INT J MED RES HEALTH, V4, P702, DOI 10.5958/2319-5886.2015.00133.2; Kaul R, 2009, J CANCER RES THER, V5, P300, DOI 10.4103/0973-1482.59916; Kon S, 2001, PATHOL RES PRACT, V197, P577, DOI 10.1078/0344-0338-00130; KRISHNAMURTHY S, 1987, HUM PATHOL, V18, P986, DOI 10.1016/S0046-8177(87)80214-9; Kucukzeybek BB, 2013, TURK J HEMATOL, V30, P275, DOI 10.4274/Tjh.2011.0034; Kulka J, 2008, HUM PATHOL, V39, P298, DOI 10.1016/j.humpath.2007.08.006; KUMAR S, 1994, MODERN PATHOL, V7, P129; Kurose A, 2005, VIRCHOWS ARCH, V447, P653, DOI 10.1007/s00428-004-1195-x; Lakhani SR, 2012, CARCINOMAS MEDULLARY, P46; Lee W, 2011, CASE REP ONCOL, V4, P68, DOI 10.1159/000324485; McCluggage WG, 2001, J CLIN PATHOL, V54, P964, DOI 10.1136/jcp.54.12.964; Naidoo F, 2001, ARCH PATHOL LAB MED, V125, P669; Nankin Nils L, 2015, Radiol Case Rep, V10, P963, DOI 10.2484/rcr.v10i1.963; Nemolato S, 2008, WORLD J GASTROENTERO, V14, P4694, DOI 10.3748/wjg.14.4694; Nicolato A, 2001, SURG NEUROL, V55, P232, DOI 10.1016/S0090-3019(01)00361-5; Nio Y, 2012, ANTICANCER RES, V32, P1435; Niu Weiwei, 2003, J Low Genit Tract Dis, V7, P184, DOI 10.1097/00128360-200307000-00005; O'Sullivan-Mejia E, 2009, BREAST J, V15, P658, DOI 10.1111/j.1524-4741.2009.00840.x; Ohtani H, 2015, PATHOL INT, V65, P644, DOI 10.1111/pin.12355; Pestereli HE, 2002, APMIS, V110, P447, DOI 10.1034/j.1600-0463.2002.100602.x; Porcaro Antonio B., 2003, International Urology and Nephrology, V35, P99, DOI 10.1023/A:1025981106561; Regaud C, 1921, REV LARYNG, V42, P369; Ribassin-Majed L, 2017, J CLIN ONCOL, V35, P498, DOI 10.1200/JCO.2016.67.4119; RIDOLFI RL, 1977, CANCER, V40, P1365, DOI 10.1002/1097-0142(197710)40:4<1365::AID-CNCR2820400402>3.0.CO;2-N; SAEMUNDSEN AK, 1982, BRIT J CANCER, V46, P721, DOI 10.1038/bjc.1982.264; Saleh R, 2005, BREAST J, V11, P353, DOI 10.1111/j.1075-122X.2005.21577.x; Sanati Souzan, 2004, Ann Diagn Pathol, V8, P309, DOI 10.1016/j.anndiagpath.2004.07.012; Satyanarayana S, 2002, Indian J Cancer, V39, P112; SAW D, 1986, HUM PATHOL, V17, P914, DOI 10.1016/S0046-8177(86)80641-4; Schmincke A, 1921, BEITR PATHOL ANAT AL, V68, P161; Shek TWH, 1996, HUM PATHOL, V27, P851, DOI 10.1016/S0046-8177(96)90461-X; Shet T, 2016, ANN DIAGN PATHOL, V25, P42, DOI 10.1016/j.anndiagpath.2016.05.006; Slukvin Igor I, 2003, J Low Genit Tract Dis, V7, P136, DOI 10.1097/00128360-200304000-00010; Suzuki I, 2014, WORLD J CLIN ONCOL, V5, P1107, DOI 10.5306/wjco.v5.i5.1107; Tamas EF, 2007, MODERN PATHOL, V20, P828, DOI 10.1038/modpathol.3800823; Terai A, 2005, UROLOGY, V66, P110913, DOI 10.1016/j.urology.2005.05.038; Top OE, 2014, J BREAST HEALTH, V10, P177, DOI 10.5152/tjbh.2014.1675; Trihia H, 2012, ACTA CYTOL, V56, P85, DOI 10.1159/000330677; Welch PQ, 2011, ORAL SURG ORAL MED O, V111, P78, DOI 10.1016/j.tripleo.2010.05.075; Yamada T, 1999, SURG TODAY, V29, P542, DOI 10.1007/BF02482349	56	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					98	104		10.5114/pjp.2018.75344			7	Pathology	Pathology	GH0LS	WOS:000433094500013	29895134	DOAJ Gold			2019-10-28	
J	Miyagawa, T; Saigusa, R; Sato, S				Miyagawa, Takuya; Saigusa, Ryosuke; Sato, Shinichi			QUIZ CORRECT ANSWER TO THE QUIZ. CHECK YOUR DIAGNOSIS A TICK BITE-INDUCED SKIN LESION	POLISH JOURNAL OF PATHOLOGY			English	Editorial Material									[Miyagawa, Takuya; Saigusa, Ryosuke; Sato, Shinichi] Univ Tokyo, Grad Sch Med, Dept Dermatol, Tokyo, Japan	Saigusa, R (reprint author), Univ Tokyo, Grad Sch Med, Dept Dermatol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	saigusar-der@h.u-tokyo.ac.jp						0	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					105	106		10.5114/pjp.2017.73934			2	Pathology	Pathology	GH0LS	WOS:000433094500014		DOAJ Gold			2019-10-28	
J	Oruba, Z; Kaczmarzyk, T; Urbanczyk, K; Jurczyszyn, A; Fornagiel, S; Galazka, K; Bednarczyk, A; Chomyszyn-Gajewska, M				Oruba, Zuzanna; Kaczmarzyk, Tomasz; Urbanczyk, Katarzyna; Jurczyszyn, Artur; Fornagiel, Szymon; Galazka, Krystyna; Bednarczyk, Anna; Chomyszyn-Gajewska, Maria			QUIZ WHAT IS YOUR DIAGNOSIS?	POLISH JOURNAL OF PATHOLOGY			English	Editorial Material									[Oruba, Zuzanna; Chomyszyn-Gajewska, Maria] Jagiellonian Univ, Chair Periodontol & Oral Med, Fac Med, Med Coll, Krakow, Poland; [Kaczmarzyk, Tomasz; Bednarczyk, Anna] Jagiellonian Univ, Chair Oral Surg, Fac Med, Med Coll, Krakow, Poland; [Urbanczyk, Katarzyna; Galazka, Krystyna] Jagiellonian Univ, Chair Pathomorphol, Fac Med, Med Coll, Krakow, Poland; [Jurczyszyn, Artur; Fornagiel, Szymon] Jagiellonian Univ, Chair & Clin Hematol, Fac Med, Med Coll, Krakow, Poland	Oruba, Z (reprint author), Jagiellonian Univ, Chair Periodontol & Oral Med, Fac Med, Med Coll, Krakow, Poland.							0	0	0	0	0	VESALIUS UNIV MEDICAL PUBL	CRACOW	WISLISKO 1, CRACOW, 00000, POLAND	1233-9687			POL J PATHOL	Pol. J. Pathol.		2018	69	1					107	107		10.5114/pjp.2018.75637			1	Pathology	Pathology	GH0LS	WOS:000433094500015		DOAJ Gold			2019-10-28	
J	Soluk-Tekkesin, M; Wright, JM				Soluk-Tekkesin, Merva; Wright, John M.			The World Health Organization Classification of Odontogenic Lesions: A Summary of the Changes of the 2017 (4th) Edition	TURKISH JOURNAL OF PATHOLOGY			English	Review						WHO classification; Odontogenic cysts; Odontogenic tumors; Update; Odontogenic keratocyst	OF-THE-LITERATURE; GHOST CELL TUMOR; AMELOBLAST-ASSOCIATED PROTEIN; CLINICOPATHOLOGICAL ANALYSIS; UNICYSTIC AMELOBLASTOMA; PARADENTAL CYST; CARCINOMA; FIBROMA; MUTATIONS; EXPRESSION	The 4th edition of the World Health Organization (WHO) Classification of Head and Neck Tumors was published in January 2017. The edition serves to provide an updated classification scheme, and extended genetic and molecular data that are useful as diagnostic tools for the lesions of the head and neck region. This review focuses on the most current update of odontogenic cysts and tumors based on the 2017 WHO edition. The updated classification has some important differences from the 3rd edition (2005), including a new classification of odontogenic cysts, 'reclassified' odontogenic tumors, and some new entities.	[Soluk-Tekkesin, Merva] Istanbul Univ, Inst Oncol, Dept Tumor Pathol, Istanbul, Turkey; [Wright, John M.] Texas A&M Univ, Sch Dent, Dept Diagnost Sci, Dallas, TX USA	Soluk-Tekkesin, M (reprint author), Istanbul Univ, Inst Oncol, Dept Tumor Pathol, Istanbul, Turkey.	msoluk@istanbul.edu.tr					ALLEN CM, 1992, ORAL SURG ORAL MED O, V73, P62, DOI 10.1016/0030-4220(92)90156-K; Antonescu CR, 2011, GENE CHROMOSOME CANC, V50, P559, DOI 10.1002/gcc.20881; Barnes L, 2005, WHO CLASSIFICATION T, P283; Bilodeau EA, 2013, AM J SURG PATHOL, V37, P1001, DOI 10.1097/PAS.0b013e31828a6727; Bilodeau EA, 2011, HEAD NECK PATHOL, V5, P101, DOI 10.1007/s12105-011-0244-4; Bodner L, 2011, J ORAL PATHOL MED, V40, P733, DOI 10.1111/j.1600-0714.2011.01058.x; Bologna-Molina R, 2013, MED ORAL PATOL ORAL, V18, pE174, DOI 10.4317/medoral.18573; Bose P, 2015, ORAL ONCOL, V51, pE71, DOI 10.1016/j.oraloncology.2015.06.013; Brown Noah A, 2015, Biomark Cancer, V7, P19, DOI 10.4137/BIC.S29329; Brown NA, 2014, CLIN CANCER RES, V20, P5517, DOI 10.1158/1078-0432.CCR-14-1069; Brunner P, 2015, ORAL ONCOL, V51, pE77, DOI 10.1016/j.oraloncology.2015.07.010; Buchner A, 2016, J ORAL MAXIL SURG, V74, P307, DOI 10.1016/j.joms.2015.08.001; Buchner A, 2013, OR SURG OR MED OR PA, V116, P598, DOI 10.1016/j.oooo.2013.06.039; Buchner A, 2013, HEAD NECK PATHOL, V7, P54, DOI 10.1007/s12105-012-0397-9; Chen Y, 2005, J ORAL PATHOL MED, V34, P588, DOI 10.1111/j.1600-0714.2005.00361.x; Chikosi R, 2011, J ORAL MAXIL SURG, V69, P1501, DOI 10.1016/j.joms.2010.05.071; COLMENERO C, 1990, J CRANIO MAXILL SURG, V18, P215, DOI 10.1016/S1010-5182(05)80414-7; Crivelini MM, 2012, J ORAL PATHOL MED, V41, P272, DOI 10.1111/j.1600-0714.2011.01079.x; CROWLEY TE, 1992, J ORAL MAXIL SURG, V50, P22, DOI 10.1016/0278-2391(92)90187-5; da Silva WG, 2014, OR SURG OR MED OR PA, V117, P626, DOI 10.1016/j.oooo.2014.01.021; Del Corso G, 2015, ORAL MAXILLOFAC SURG, V19, P85, DOI 10.1007/s10006-014-0465-2; DeLair D, 2007, ORAL SURG ORAL MED O, V103, P516, DOI 10.1016/j.tripleo.2006.02.025; Diniz MG, 2015, TUMOR BIOL, V36, P5649, DOI 10.1007/s13277-015-3238-0; Dunlap CL, 1999, SEMIN DIAGN PATHOL, V16, P293; El-Mofty SK, 2014, HEAD NECK PATHOL, V8, P432, DOI 10.1007/s12105-014-0590-0; Fowler CB, 2011, HEAD NECK PATHOL, V5, P364, DOI 10.1007/s12105-011-0298-3; Galvao CF, 2012, J ORAL PATHOL MED, V41, P389, DOI 10.1111/j.1600-0714.2011.01115.x; Harnet JC, 2013, J ORAL MAXIL SURG, V71, P706, DOI 10.1016/j.joms.2012.10.006; Hertog D, 2012, MED ORAL PATOL ORAL, V17, pE76, DOI 10.4317/medoral.18006; Irie T, 2010, PATHOL INT, V60, P694, DOI 10.1111/j.1440-1827.2010.02583.x; Karathanasi V, 2013, J ORAL PATHOL MED, V42, P415, DOI 10.1111/jop.12016; Koutlas IG, 2008, AM J SURG PATHOL, V32, P1613, DOI 10.1097/PAS.0b013e31817a8a58; KRAMER IRH, 1992, CANCER-AM CANCER SOC, V70, P2988, DOI 10.1002/1097-0142(19921215)70:12<2988::AID-CNCR2820701242>3.0.CO;2-V; Kurppa KJ, 2014, J PATHOL, V232, P492, DOI 10.1002/path.4317; Lai J, 2012, J ORAL MAXIL SURG, V70, P2007, DOI 10.1016/j.joms.2011.09.012; Ledesma-Montes C, 2008, J ORAL PATHOL MED, V37, P302, DOI 10.1111/j.1600-0714.2007.00623.x; Lei Y, 2014, OR SURG OR MED OR PA, V117, P608, DOI 10.1016/j.oooo.2014.01.017; LEIDER AS, 1989, ORAL SURG ORAL MED O, V68, P175, DOI 10.1016/0030-4220(89)90189-8; Li TJ, 1998, ARCH PATHOL LAB MED, V122, P371; Martin L, 2015, DIAGNOSTIC HISTOPATH, V21, P359; Maruyama S, 2015, OR SURG OR MED OR PA, V120, P227, DOI 10.1016/j.oooo.2015.04.001; Moro A, 2016, ONCOL LETT, V12, P4339, DOI 10.3892/ol.2016.5272; Mosqueda-Taylor A, 2002, ORAL ONCOL, V38, P800, DOI 10.1016/S1368-8375(02)00046-5; Mosqueda-Taylor A, 2014, HISTOPATHOLOGY, V65, P606, DOI 10.1111/his.12451; Murphy CL, 2008, AMYLOID, V15, P89, DOI 10.1080/13506120802005965; Pavelic B, 2001, J ORAL PATHOL MED, V30, P569, DOI 10.1034/j.1600-0714.2001.300911.x; Peacock ZS, 2010, ORAL ONCOL, V46, P387, DOI 10.1016/j.oraloncology.2010.02.023; Pereira NB, 2016, J ORAL PATHOL MED, V45, P780, DOI 10.1111/jop.12443; Philipsen HP, 1997, ORAL ONCOL, V33, P86, DOI 10.1016/S0964-1955(96)00067-X; Philipsen HP, 2004, J ORAL PATHOL MED, V33, P147, DOI 10.1111/j.0904-2512.2004.00139.x; Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P651, DOI 10.1016/j.joms.2003.08.029; Rizzitelli A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117789; Shao Z, 2013, J CRANIOFAC SURG, V24, P1840, DOI 10.1097/SCS.0b013e318275eb4b; Shear M, 2007, CYSTS ORAL MAXILLOFA; SHINODA T, 1992, ACTA CYTOL, V36, P132; Siar CH, 2010, EUR J MED RES, V15, P180, DOI 10.1186/2047-783X-15-4-180; Slater LJ, 2016, J ORAL MAXIL SURG, V74, P547, DOI 10.1016/j.joms.2015.08.019; Smullin SE, 2008, ORAL SURG ORAL MED O, V105, P37, DOI 10.1016/j.tripleo.2007.04.012; Solomon A, 2003, J LAB CLIN MED, V142, P348, DOI 10.1016/S0022-2143(03)00149-5; Sun G, 2009, INT J ORAL MAX SURG, V38, P1179, DOI 10.1016/j.ijom.2009.06.016; Sun ZJ, 2009, ORAL ONCOL, V45, P752, DOI 10.1016/j.oraloncology.2009.01.016; Sweeney RT, 2014, NAT GENET, V46, P722, DOI 10.1038/ng.2986; Tan SH, 2014, OR SURG OR MED OR PA, V118, pE119, DOI 10.1016/j.oooo.2014.02.010; Tekkesin MS, 2012, HEAD NECK-J SCI SPEC, V34, P852, DOI 10.1002/hed.21820; Tilson MP, 2014, HEAD NECK PATHOL, V8, P59, DOI 10.1007/s12105-013-0475-7; Van Heerden WFP, 2017, WHO CLASSIFICATION H, P205; Wakolbinger R, 2016, CLIN ORAL INVEST, V20, P15, DOI 10.1007/s00784-015-1552-y; Wenguang X, 2016, PLOS ONE, V11; Williams MD, 2007, ORAL SURG ORAL MED O, V104, P72, DOI 10.1016/j.tripleo.2006.07.013; WRIGHT JM, 1981, ORAL SURG ORAL MED O, V51, P609, DOI 10.1016/S0030-4220(81)80011-4; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Wright JM, 2014, HEAD NECK PATHOL, V8, P373, DOI 10.1007/s12105-014-0585-x; Yancoskie AE, 2014, OR SURG OR MED OR PA, V118, pE115, DOI 10.1016/j.oooo.2014.02.004	73	10	10	0	4	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					1	18		10.5146/tjpath.2017.01410			18	Pathology	Pathology	GH2RY	WOS:000433250700001	28984343	DOAJ Gold			2019-10-28	
J	Ileri, AB; Koseoglu, RD; Markoc, F; Etikan, I; Atilgan, D; Deresoy, FA				Ileri, Ayse Burcu; Koseoglu, Resit Dogan; Markoc, Fatma; Etikan, Ilker; Atilgan, Dogan; Deresoy, Faik Alev			Immunohistochemical Analysis of the Extrinsic Apoptosis Process in the Non-Neoplastic and Neoplastic Prostate	TURKISH JOURNAL OF PATHOLOGY			English	Article						Prostate; Carcinogenesis; Fas; FasL; DcR1; FLIP	TRAIL-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; CANCER IN-VITRO; FAS LIGAND; DIFFERENTIAL EXPRESSION; INACTIVATING MUTATIONS; MEDIATED APOPTOSIS; BREAST-CANCER; CELLS; DEATH	Objective: Deviations in the apoptotic process have been demonstrated in prostate carcinogenesis. We aimed to evaluate especially the process of extrinsic apoptosis in the spectrum of neoplastic lesions of the prostate epithelium so as to reveal the variations in the apoptotic process. Material and Method: The study included 20 benign prostatic hyperplasia, 8 high-grade prostatic intraepithelial neoplasia and 82 prostatic carcinoma patients. Immunohistochemistry was performed on sections obtained from materials of suprapubic prostatectomy, tru-cut biopsy, transurethral resection and radical prostatectomy. While Fas and FasL were evaluated in glandular and stromal areas, DcR1 and FLIP were evaluated in only glandular areas. Intensity and extent of immunostaining for Fas and FasL antibodies were separately scored and both scores were summarized. The total score of >= 4 both for Fas and FasL, expressions of FLIP and DcR1determined in more than 5% of glandular areas were accepted as positive. Results: Glandular FasL positivity was observed in 63.8 and 20% of the cases with prostatic carcinoma and benign prostatic hyperplasia, respectively (p=0.001). The loss of stromal Fas expression in PCa was obvious (p<0.001). FLIP positivity was more frequently seen in high-grade prostatic intraepithelial neoplasia and PCa. Conclusion: In prostatic carcinoma, decreased stromal Fas expression, contrary to higher glandular FasL positivity, supports the assertion that sensitivity of epithelial and stromal cells to apoptosis and their protective pathways against apoptosis undergo alterations. Increased FLIP expressions in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma can also be interpreted accordingly.	[Ileri, Ayse Burcu; Koseoglu, Resit Dogan; Markoc, Fatma; Deresoy, Faik Alev] Gaziosmanpasa Univ, Dept Pathol, Sch Med, Tokat, Turkey; [Etikan, Ilker] Near East Univ, Sch Med, Dept Biostat, Mersin 10, Lefkosa, North Cyprus, Turkey; [Atilgan, Dogan] Gaziosmanpasa Univ, Dept Urol, Sch Med, Tokat, Turkey	Koseoglu, RD (reprint author), Gaziosmanpasa Univ, Dept Pathol, Sch Med, Tokat, Turkey.	residdogan@hotmail.com			Gaziosmanpasa University Scientific Research Projects CommitteeGaziosmanpasa University [2010/01]	This study was supported by Gaziosmanpasa University Scientific Research Projects Committee (Project No: 2010/01).	Anees M, 2011, CANCER-AM CANCER SOC, V117, P1172, DOI 10.1002/cncr.25504; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bavik C, 2006, CANCER RES, V66, P794, DOI 10.1158/0008-5472.CAN-05-1716; Begley L, 2006, GENE CHROMOSOME CANC, V45, P136, DOI 10.1002/gcc.20274; Cunha GR, 2003, INT J CANCER, V107, P1, DOI 10.1002/ijc.11335; Dean JP, 2008, BRIT J CANCER, V98, P245, DOI 10.1038/sj.bjc.6604087; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Higaki K, 1996, AM J PATHOL, V149, P429; Hughes SJ, 1997, CANCER RES, V57, P5571; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang JZ, 2002, CANCER, V95, P296, DOI 10.1002/cncr.10674; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; Kim SY, 2009, APMIS, V117, P28, DOI 10.1111/j.1600-0463.2008.00012.x; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Lee SH, 2003, APMIS, V111, P309, DOI 10.1034/j.1600-0463.2003.1110203.x; Lee SH, 1999, J PATHOL, V188, P207; LEITHAUSER F, 1993, LAB INVEST, V69, P415; Liu WY, 1998, CLIN CANCER RES, V4, P1803; Mawji IA, 2007, J NATL CANCER I, V99, P811, DOI 10.1093/jnci/djk182; Mullauer L, 2000, J PATHOL, V190, P20, DOI 10.1002/(SICI)1096-9896(200001)190:1<20::AID-PATH497>3.0.CO;2-S; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Nambu Y, 1998, J CLIN INVEST, V101, P1102, DOI 10.1172/JCI1692; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nimmanapalli R, 2001, CANCER RES, V61, P759; Risbridger GP, 2008, ENDOCRINOLOGY, V149, P4303, DOI 10.1210/en.2008-0465; Ryu BK, 2001, J PATHOL, V194, P15, DOI 10.1002/path.835; Sanlioglu AD, 2006, CANCER GENE THER, V13, P21, DOI 10.1038/sj.cgt.7700877; Sanlioglu AD, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-54; Sanlioglu AD, 2007, J UROLOGY, V177, P359, DOI 10.1016/j.juro.2006.08.087; Santourlidis S, 2001, MOL CARCINOGEN, V32, P36, DOI 10.1002/mc.1062; Sasaki Y, 1998, BRIT J UROL, V81, P852; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Shankar S, 2004, PROSTATE, V61, P35, DOI 10.1002/pros.20069; Shankar S, 2005, PROSTATE, V62, P165, DOI 10.1002/pros.20126; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shimada K, 2006, CARCINOGENESIS, V27, P1349, DOI 10.1093/carcin/bgi380; Shin MS, 1999, AM J PATHOL, V154, P1785, DOI 10.1016/S0002-9440(10)65434-X; Shin MS, 2002, BLOOD, V99, P4094, DOI 10.1182/blood.V99.11.4094; Sridhar S, 2001, CANCER RES, V61, P7179; Thomas RK, 2002, AM J PATHOL, V160, P1521, DOI 10.1016/S0002-9440(10)62578-3; Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	45	1	1	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					19	28		10.5146/tjpath.2017.01409			10	Pathology	Pathology	GH2RY	WOS:000433250700002	28984341	DOAJ Gold			2019-10-28	
J	Sargolzaei, S; Taghavi, N; Poursafar, F				Sargolzaei, Soudabeh; Taghavi, Nasim; Poursafar, Farzaneh			Are CD68 and Factor VIII-RA Expression Different in Central and Peripheral Giant Cell Granuloma of Jaw: An Immunohistochemical Comparative Study	TURKISH JOURNAL OF PATHOLOGY			English	Article						Giant cell granuloma; CD68; Factor VIII-RA; Jaw	LESIONS; BEHAVIOR; OSTEOCLASTS	Objective: Central giant cell granuloma and peripheral giant cell granuloma of the jaw and oral cavity are identical in histopathologic features, although they are different in pathogenesis and clinical behavior. The aim of present study was to compare CD 68 and factor VIII related antigen (VIII-RA) immunoreactivity in central giant cell granuloma and peripheral giant cell granuloma to determine the biologic nature and clinical behavior of these lesions which may lead to a better or new treatment modality. Material and Method: CD68 and factor VIII-RA expression were examined immunohistochemically in 22 cases of central giant cell granuloma (10 aggressive and 12 non-aggressive) and 19 cases of peripheral giant cell granuloma. The Kruskal-Wallis test followed by the Dunn test was used for data analysis. Results: CD68 expression was observed in approximately 100% of multinucleated giant cells and 50% of mononuclear cells. Overexpression of factor VIII-RA in the endothelial cells of capillary like vessels in the periphery of the lesions was prominent. A statistical significant difference for CD68 intensity score in mononuclear cells among three groups (P=0.016) was observed. Indeed, factor VIII-RA intensity score in the endothelial cells of central giant cell granuloma and peripheral giant cell granuloma showed significant difference (P=0.004). Conclusion: These findings support the histiocyte/macrophage nature of multinucleated giant cells and mononuclear cells. Overexpression and high intensity score of CD68 in mononuclear cells and the high intensity score of factor VIII-RA in endothelial cells represent less aggressive behavior in central giant cell granuloma.	[Sargolzaei, Soudabeh; Taghavi, Nasim; Poursafar, Farzaneh] Shahid Beheshti Univ Med Sci, Sch Dent, Dept Oral Pathol, Tehran, Iran	Taghavi, N (reprint author), Shahid Beheshti Univ Med Sci, Sch Dent, Dept Oral Pathol, Tehran, Iran.	nasim.taghavi@yahoo.com		taghavi ghasemian, NASIM/0000-0002-0334-9385; Sargolzaei, Soudabeh/0000-0002-6452-4909	Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran [12846]	This research is extracted from undergraduate thesis by Dr. Poursafar, which was successfully completed under the supervision of Dr. Sargolzaei and Dr. Taghavi, Department of Oral Pathology, Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran, which was supported by research deputy of Dental School, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Code number 12846).	Amaral FR, 2011, TUMOR BIOL, V32, P997, DOI 10.1007/s13277-011-0201-6; Aragao MD, 2007, J APPL ORAL SCI, V15, P310, DOI 10.1590/S1678-77572007000400013; Badawi Manal A, 2015, Open Access Maced J Med Sci, V3, P209, DOI 10.3889/oamjms.2015.044; Baud'huin M, 2009, J BIOL CHEM, V284, P31704, DOI 10.1074/jbc.M109.030312; BONETTI F, 1990, ORAL SURG ORAL MED O, V70, P471, DOI 10.1016/0030-4220(90)90213-C; Carvalho Y R, 1995, Oral Dis, V1, P20; Castro WH, 1998, BRIT J ORAL MAX SURG, V36, P301, DOI 10.1016/S0266-4356(98)90715-X; Dewsnup NC, 2008, J ORAL MAXIL SURG, V66, P928, DOI 10.1016/j.joms.2008.01.033; Fanourakis G, 2010, J ORAL PATHOL MED, V39, P687, DOI 10.1111/j.1600-0714.2010.00924.x; FLANAGAN AM, 1988, CANCER, V62, P1139, DOI 10.1002/1097-0142(19880915)62:6<1139::AID-CNCR2820620617>3.0.CO;2-8; Florez-Moreno GA, 2008, ORAL SURG ORAL MED O, V105, P625, DOI 10.1016/j.tripleo.2007.08.032; HOLNESS CL, 1993, BLOOD, V81, P1607; Tobon-Arroyave SI, 2010, ORAL SURG ORAL MED O, V110, P755, DOI 10.1016/j.tripleo.2010.06.024; Ivkovic-Kapicl Tatjana, 2006, Vojnosanit Pregl, V63, P635, DOI 10.2298/VSP0607635I; LIM L, 1995, ORAL SURG ORAL MED O, V79, P190, DOI 10.1016/S1079-2104(05)80281-1; Liu B, 2003, J ORAL PATHOL MED, V32, P367, DOI 10.1034/j.1600-0714.2003.00126.x; Matos FR, 2011, J ORAL PATHOL MED, V40, P338, DOI 10.1111/j.1600-0714.2010.00993.x; Neville BW, 2009, ORAL MAXILLOFACIAL P, P507; Papanicolaou P, 2012, MED ORAL PATOL ORAL, V17, pE56, DOI 10.4317/medoral.17205; Peacock ZS, 2012, J ORAL MAXIL SURG, V70, P1860, DOI 10.1016/j.joms.2011.08.020; REGEZI JA, 1987, CANCER, V59, P64, DOI 10.1002/1097-0142(19870101)59:1<64::AID-CNCR2820590116>3.0.CO;2-Q; Sarode SC, 2014, J ORAL PATHOL MED, V43, P459, DOI 10.1111/jop.12119; Schutz P, 2010, J ORAL MAXIL SURG, V68, P2537, DOI 10.1016/j.joms.2009.06.042; Souza PEA, 2000, ORAL DIS, V6, P35; Susarla SM, 2009, J ORAL MAXIL SURG, V67, P951, DOI 10.1016/j.joms.2008.12.045; Syrio NFL, 2011, MED ORAL PATOL ORAL, V16, pE488, DOI 10.4317/medoral.16.e488; Tobon-Arroyave SI, 2005, ORAL ONCOL, V41, P480, DOI 10.1016/j.oraloncology.2004.11.006; Torabinia N, 2011, J ORAL PATHOL MED, V40, P334, DOI 10.1111/j.1600-0714.2010.00944.x; Vered M, 2006, J ORAL PATHOL MED, V35, P613, DOI 10.1111/j.1600-0714.2006.00477.x; Vered M, 2007, J ORAL PATHOL MED, V36, P495, DOI 10.1111/j.1600-0714.2007.00541.x; Vk Varsha, 2014, J Oral Maxillofac Pathol, V18, P341, DOI 10.4103/0973-029X.151310	31	1	1	0	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					49	56		10.5146/tjpath.2017.01401			8	Pathology	Pathology	GH2RY	WOS:000433250700005	28832079	DOAJ Gold			2019-10-28	
J	Gandhi, P; Khare, R				Gandhi, Puneet; Khare, Richa			A Unique Immunofluorescence Protocol to Detect Protein Expression in Vascular Tissues: Tacking a Long Standing Pathological Hitch	TURKISH JOURNAL OF PATHOLOGY			English	Article						Autofluorescence; Immunofluorescence; Immunohistochemistry; Signal intensity	REDUCES AUTOFLUORESCENCE; BRAIN SECTIONS; IMMUNOHISTOCHEMISTRY; HTERT	Objective: Autofluorescence induced interference is one of the major drawbacks in immunofluorescence analysis of formalin-fixed paraffin-embedded tissues, as it decreases the signal-to-noise ratio of specific labeling. Apart from aldehyde-fixation induced artifacts; collagen and elastin, red blood cells and endogenous fluorescent pigment lipofuscin are prime sources of autofluorescence in vascular and aging tissues. We describe herein, an optimized indirect-immunofluorescence method for archival formalin-fixed paraffin-embedded tissues tissues and cryo sections, using a combination of 3-reagents in a specific order, to achieve optimal fluorescence signals and imaging. Material and Method: Human telomerase reverse transcriptase, a protein implicated as a proliferation marker, was chosen relevant to its expression in solid tumors along with 3 other intracellular proteins exhibiting nuclear and/or cytoplasmic expression. Staining was performed on 10 glioma tissue sections along with 5 of their cryo sections, 5 sections each of hepatocellular, lung, papillary-thyroid and renal cell carcinoma, with 10 non-malignant brain tissue samples serving as control. Specimens were imaged using epifluorescence microscopy, followed by software-based quantification of fluorescence signals for statistical analysis and validation. Results: We observed that the combined application of sodium-borohydride followed by crystal violet before antigen retrieval and a Sudan black B treatment after secondary antibody application proved to be most efficacious for masking autofluorescence/non-specific background in vascular tissues. Conclusion: This unique trio-methodology provides quantifiable observations with maximized fluorescence signal intensity of the target protein for longer retention time of the signal even after prolonged storage. The results can be extrapolated to other human tissues for different protein targets.	[Gandhi, Puneet; Khare, Richa] Bhopal Mem Hosp & Res Ctr, Dept Res, Bhopal 38, India	Gandhi, P (reprint author), Bhopal Mem Hosp & Res Ctr, Dept Res, Bhopal 38, India.	puneetgandhi67@yahoo.com			M.P. Biotech Council, M.P. [249];  [IEC/21/Res/11]	The authors are thankful to M.P. Biotech Council, M.P. (project no. 249) for financial assistance and BMHRC for infrastructural facilities. The present study is part of approved project IEC/21/Res/11. The authors kindly acknowledge Dr. Nitin Garg and Dr. Sandeep K Sorte, Dept. of Neurosurgery for referral of glioma cases. The authors are also thankful to Ms. Kavita Niraj for assistance in literature survey and standardization of protocol, to Dr. Hunni Gulwani and staff of Histopathology, Dept. of Pathology, for providing tissue sections.	Billinton N, 2001, ANAL BIOCHEM, V291, P175, DOI 10.1006/abio.2000.5006; Boenisch T., 2001, HDB IMMUNOHISTOCHEMI, P34; Buchynska L., 2008, Experimental Oncology, V30, P327; Casella GTB, 2004, J NEUROSCI METH, V139, P1, DOI 10.1016/j.jneumeth.2004.04.008; Chen X, 2010, N AM J MED SCI, V2, P241, DOI 10.4297/najms.2010.2241; Croce AC, 2014, EUR J HISTOCHEM, V58, P320, DOI 10.4081/ejh.2014.2461; Diez-Fraile A, 2012, APPL IMMUNOCYTOCHEMI, P29; Gasser EMS, 2006, NAT PROTOC, V1, P1887, DOI 10.1038/nprot.2006.265; Glass G, 2009, J HISTOCHEM CYTOCHEM, V57, P899, DOI 10.1369/jhc.2009.953612; Guan GG, 2015, ONCOL LETT, V9, P1567, DOI 10.3892/ol.2015.2926; Jie Chen, 2015, J CYTOL HISTOL, VS3; Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008; Kanjimura J, 2016, J HISTOCHEM CYTOCHEM, V64, P112; KONG J, 1995, CYTOMETRY, V20, P86, DOI 10.1002/cyto.990200113; Kumar BS, 2015, INDIAN J BIOCHEM BIO, V52, P107; Li J, 2013, MOL MED REP, V7, P1409, DOI 10.3892/mmr.2013.1376; Lu MH, 2012, ONCOL REP, V28, P1945, DOI 10.3892/or.2012.2036; Nybo K, 2012, BIOTECHNIQUES, V52, P351, DOI [10.2144/000113870, 10.2144/000113872]; Oliveira VC, 2010, HISTOL HISTOPATHOL, V25, P1017, DOI 10.14670/HH-25.1017; Perse M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059638; Ramos-Vara JA, 2014, VET PATHOL, V51, P42, DOI 10.1177/0300985813505879; Rizzardi AE, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-42; Robertson D, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-13; Spitzer N, 2011, J NEUROSCI METH, V197, P48, DOI 10.1016/j.jneumeth.2011.01.029; Sun Y, 2011, ARCH PATHOL LAB MED, V135, P1335, DOI 10.5858/arpa.2010-0549-OA; Viegas MS, 2007, EUR J HISTOCHEM, V51, P59	26	1	1	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					57	65		10.5146/tjpath.2017.01405			9	Pathology	Pathology	GH2RY	WOS:000433250700006	28984339	DOAJ Gold			2019-10-28	
J	Cavit, A; Ozcanli, H; Sancmis, M; Ocak, GA; Gurer, EI				Cavit, Ali; Ozcanli, Haluk; Sancmis, Mesut; Ocak, Guzide Ayse; Gurer, Elif Inanc			Tumorous Conditions of the Hand: A Retrospective Review of 402 Cases	TURKISH JOURNAL OF PATHOLOGY			English	Review						Hand; Neoplasms; Bone; Soft tissue; Metastasis	SOFT-TISSUE; WRIST; LESIONS; MASSES	Objective: Knowledge concerning treatment and care of hand lesions is often based on small case series, case reports and a few large general case series. The aim of this study is to present our experience with hand tumors' and tumor-like lesions' incidence, age range and localizations. Material and Method: Between 2006-2016, 402 patients operated and histopathologically diagnosed with bone and soft tissue tumorous conditions of the hand were evaluated retrospectively. Results: Three hundred sixty one out of 402 cases (89.8%) were soft tissue tumors and 41 cases (10.2%) were osseous tumors of the hand. A total of 10 malignant tumors (2.5%) were encountered in the hand. The average age of the patients was 41.9 years (ranged from 1 to 83 years). Among 361 soft tissue tumors, only 6 cases (1.6%) were malignant and they were squamous cell tumors (n=5) and synovial sarcoma (n=1). The most common soft tissue pathology was ganglion cyst (n=125). The most common bone tumor was enchondroma, diagnosed in 26 patients (6.4% of all patients). Primary malignant bone tumors were extremely rare in the hand; one osteosarcoma and one chondrosarcoma were reported. Metastatic tumors to the hand were seen in two patients; and they were lung carcinoma and chondrosarcoma metastasis. Conclusion: Up-date knowledge and a thorough understanding of the nature and demographic characteristics of the tumorous conditions of the hand are crucial for accurate diagnosis and appropriate treatment.	[Cavit, Ali; Ozcanli, Haluk] Akdeniz Univ, Fac Med, Dept Orthopaed & Traumatol, Antalya, Turkey; [Sancmis, Mesut] Manavgat State Hosp, Antalya, Turkey; [Ocak, Guzide Ayse; Gurer, Elif Inanc] Akdeniz Univ, Dept Pathol, Fac Med, Antalya, Turkey	Cavit, A (reprint author), Akdeniz Univ, Fac Med, Dept Orthopaed & Traumatol, Antalya, Turkey.	alicavit@hotmail.com					Adams Erin L, 2012, Eplasty, V12, pe50; Athanesian E., 2011, GREENS OPERATIVE HAN, P2141; Blei Francine, 2002, Curr Probl Pediatr Adolesc Health Care, V32, P72, DOI 10.1067/mps.2002.125533; BRIEN EW, 1995, J BONE JOINT SURG AM, V77A, P564, DOI 10.2106/00004623-199504000-00009; Campanacci M, 1999, BONE SOFT TISSUE TUM; Canavese F, 2008, J PEDIATR ORTHOPED, V28, P381, DOI 10.1097/BPO.0b013e318168d1a7; Capelastegui A, 1999, SKELETAL RADIOL, V28, P498, DOI 10.1007/s002560050553; De Schepper Arthur M, 2007, Top Magn Reson Imaging, V18, P431, DOI 10.1097/rmr.0b013e3181652220; Farzan M, 2013, ARCH BONE JT SURG-AB, V1; FINN MC, 1983, J PEDIATR SURG, V18, P894; Garcia J, 2001, EUR RADIOL, V11, P1470, DOI 10.1007/s003300000751; Henderson M, 2014, PLAST RECONSTR SURG, V133, p814E, DOI 10.1097/PRS.0000000000000178; Henderson MM, 2014, PLAST RECONSTR SURG, V133, p154E, DOI 10.1097/01.prs.0000436854.09656.05; Hsu CS, 2007, LANCET ONCOL, V8, P157, DOI 10.1016/S1470-2045(07)70035-9; Khaled W, 2015, DIAGN INTERV IMAG, V96, P1238, DOI 10.1016/j.diii.2015.10.005; KRANSDORF MJ, 1993, RADIOGRAPHICS, V13, P853, DOI 10.1148/radiographics.13.4.8356273; Lanzinger WD, 2013, J HAND SURG-AM, V38A, P154, DOI 10.1016/j.jhsa.2012.11.001; Nahra ME, 2004, HAND CLIN, V20, P249, DOI 10.1016/j.hcl.2004.03.015; Ogose A, 1997, CANCER, V80, P50, DOI 10.1002/(SICI)1097-0142(19970701)80:1<50::AID-CNCR7>3.3.CO;2-R; Ozcanli Haluk, 2005, Acta Orthop Traumatol Turc, V39, P445; PALMIERI TJ, 1987, HAND CLIN, V3, P225; Saglik Y, 2013, EKLEM HAST CERRAHISI, V24, P149, DOI 10.5606/ehc.2013.33; Simon MJK, 2014, BMC MUSCULOSKEL DIS, V15, DOI 10.1186/1471-2474-15-182; Sobanko JF, 2007, DERMATOL SURG, V33, P651, DOI 10.1111/j.1524-4725.2007.33140.x; Tang P, 2002, CLIN ORTHOP RELAT R, P205; Thornburg L E, 1999, J Am Acad Orthop Surg, V7, P231; UNNI KK, 1996, DAHLINS BONE TUMORS; Upton J, 1999, J HAND SURG-AM, V24A, P1019, DOI 10.1053/jhsu.1999.1019; Williams J, 2010, J HAND SURG-AM, V35A, P451, DOI 10.1016/j.jhsa.2009.12.004	29	3	3	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					66	72		10.5146/tjpath.2017.01413			7	Pathology	Pathology	GH2RY	WOS:000433250700007	28984347	DOAJ Gold			2019-10-28	
J	Romaniuk, A; Lyndin, M; Lyndina, Y; Sikora, V; Hrintsova, N; Timakova, O; Gudymenko, O; Gladchenko, O				Romaniuk, Anatolii; Lyndin, Mykola; Lyndina, Yulia; Sikora, Vladyslav; Hrintsova, Natalia; Timakova, Olena; Gudymenko, Olena; Gladchenko, Oksana			Changes in the Hematopoietic System and Blood Under the Influence of Heavy Metal Salts Can Be Reduced with Vitamin E	TURKISH JOURNAL OF PATHOLOGY			English	Article						Heavy metal salts; Vitamin E; Hematopoietic system; Bone marrow	BONE-MARROW; MECHANISMS	Objective: The aim of our work was to study the blood parameters and bone marrow morphological changes in rats exposed to increased amounts of heavy metal salts and the effect of vitamin E. Material and Method: Investigation of bone marrow structural features and blood parameters was performed in sexually mature Wistar male rats (n=84). Results: Exposure to increased amounts of heavy metal salts led to the inhibition of erythropoiesis and leukopoiesis, as well as a synchronized increase in the number of megakaryocytes which was clearly reflected in the blood: the number of erythrocytes, leukocytes and Hb decreased, and the number of platelets increased. These changes in the blood and bone marrow were less pronounced when vitamin E was used as an adjuster. Conclusion: When increased amounts of HMS enter the rats' bodies, suppression of erythropoiesis and leukocytopoiesis occurs while thrombocytopoiesis increases. These changes depend on the period of intake of heavy metal salts. The adjustment of vitamin E reduces the severity of the cytotoxic effect of heavy metals and improves readaptation in the recovery period.	[Romaniuk, Anatolii; Lyndin, Mykola; Lyndina, Yulia; Sikora, Vladyslav; Hrintsova, Natalia; Timakova, Olena; Gudymenko, Olena; Gladchenko, Oksana] Sumy State Univ, Dept Pathol, Sumy, Ukraine	Romaniuk, A (reprint author), Sumy State Univ, Dept Pathol, Sumy, Ukraine.	pathomorph@gmail.com	Romaniuk, Anatolii/I-3241-2017	Romaniuk, Anatolii/0000-0003-2560-1382; Lyndina, Yulia/0000-0002-2132-0965			CLINE J M, 1985, Toxicologic Pathology, V13, P349; Frenkel M. A., 2007, Klinicheskaya Laboratornaya Diagnostika, P44; Gornicka M, 2016, ADV CLIN EXP MED, V25, P673, DOI 10.17219/acem/62922; Hounkpatin ASY, 2013, AFRICAN J BIOTECHNOL, V12, P3731, DOI DOI 10.5897/AJB12.2669; Iavicoli I, 2009, J TOXICOL ENV HEAL B, V12, P206, DOI 10.1080/10937400902902062; Jaishankar Monisha, 2014, Interdiscip Toxicol, V7, P60, DOI 10.2478/intox-2014-0009; Koloskov AV, 2012, TRANSFUSIOLOGY, V13, P359; Kuzenko Y, 2014, OSTEOLOGICKY B, V1, P23; Lucas EA, 2006, J MED FOOD, V9, P77, DOI 10.1089/jmf.2006.9.77; Romaniuk A, 2016, INTERV MED APPL SCI, V8, DOI 10.1556/1646.8.2016.3.3; Romaniuk A, 2015, INTERV MED APPL SCI, V7, P49, DOI 10.1556/1646.7.2015.2.1; Sabath E, 2012, NEFROLOGIA, V32, P279, DOI 10.3265/Nefrologia.pre2012.Jan.10928; Saljooghi AS, 2012, J CLIN TOXICOL, V3, P1; Schulze H, 2005, J THROMB HAEMOST, V3, P1717, DOI 10.1111/j.1538-7836.2005.01426.x; Travlos GS, 2006, TOXICOL PATHOL, V34, P566, DOI 10.1080/01926230600964706; Yakovtsova AF, 2007, COMP CLIN PATHOL, V16, P131	16	0	0	1	1	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					73	81		10.5146/tjpath.2017.01412			9	Pathology	Pathology	GH2RY	WOS:000433250700008	28984345	DOAJ Gold			2019-10-28	
J	Celik, H; Kefeli, M; Cetinkaya, M; Yildiz, L				Celik, Handan; Kefeli, Mehmet; Cetinkaya, Mehmet; Yildiz, Levent			Perivascular Epithelioid Cell Tumor (PEComa) of the Uterine Cervix in a Patient with Tuberous Sclerosis Complex: A Literature Review	TURKISH JOURNAL OF PATHOLOGY			English	Review						Perivascular epithelioid cell neoplasm; Uterine cervical neoplasm; Tuberous sclerosis	SMOOTH-MUSCLE TUMORS; UTERUS; ANGIOMYOLIPOMA; FAMILY	Perivascular epithelioid cell tumors (PEComa) are a rare type of mesenchymal tumor arising from perivascular epithelial cells. These tumor cells are a co-expression of both melanocytic and myogenic antigens, such as HMB 45 and smooth muscle actin, and at least in some patients, are located around vessels. PEComas has been reported at various sites, including visceral organs, soft tissue, the prostate gland and broad ligaments. In the female reproductive system, the uterine corpus is the most common site of involvement. Some cases are related to tuberous sclerosis complex. Cervical PEComa with tuberous sclerosis complex is presented in the case of a 41 year-old and the literature is reviewed. There have been only eight cases of cervical PEComas and only one other case associated with tuberous sclerosis complex reported to date.	[Celik, Handan; Cetinkaya, Mehmet] Ondokuz Mayis Univ, Fac Med, Dept Obstet & Gynecol, Samsun, Turkey; [Kefeli, Mehmet; Yildiz, Levent] Ondokuz Mayis Univ, Fac Med, Dept Pathol, Samsun, Turkey	Kefeli, M (reprint author), Ondokuz Mayis Univ, Fac Med, Dept Pathol, Samsun, Turkey.	mehmetkefeli@gmail.com					Azad Najamul Sahar, 2006, JPMA Journal of the Pakistan Medical Association, V56, P83; BONETTI F, 1994, PATHOLOGY, V26, P230, DOI 10.1080/00313029400169561; Bradshaw MJ, 2010, RARE TUMORS, V2, P161, DOI 10.4081/rt.2010.e56; Fadare Oluwole, 2004, World J Surg Oncol, V2, P35, DOI 10.1186/1477-7819-2-35; Folpe AL, 2005, AM J SURG PATHOL, V29, P1558, DOI 10.1097/01.pas.0000173232.22117.37; Folpe AL, 2000, AM J SURG PATHOL, V24, P1239, DOI 10.1097/00000478-200009000-00007; Folpe AL, 2002, PATHOLOGY GENETICS T, P221; Fukunaga M, 2005, INT J GYNECOL PATHOL, V24, P341, DOI 10.1097/01.pgp.0000168515.83557.89; Martignoni G, 2008, VIRCHOWS ARCH, V452, P119, DOI 10.1007/s00428-007-0509-1; Natella V, 2014, PATHOL RES PRACT, V210, P186, DOI 10.1016/j.prp.2013.10.003; PEA M, 1991, PATHOLOGY, V23, P185, DOI 10.3109/00313029109063563; Schoolmeester JK, 2014, AM J SURG PATHOL, V38, P176, DOI 10.1097/PAS.0000000000000133; Toledo G, 2008, ARCH PATHOL LAB MED, V132, P595, DOI 10.1043/1543-2165(2008)132[595:SMTOTU]2.0.CO;2; Vang R, 2002, AM J SURG PATHOL, V26, P1, DOI 10.1097/00000478-200201000-00001; Wang Y, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-23; Yamamoto E, 2010, RARE TUMORS, V2, P72, DOI 10.4081/rt.2010.e26	16	1	1	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					82	86		10.5146/tjpath.2014.01274			5	Pathology	Pathology	GH2RY	WOS:000433250700009	25110244	DOAJ Gold			2019-10-28	
J	Kini, JR; Kini, H; Rau, A; Kamath, J; Kini, A				Kini, Jyoti R.; Kini, Hema; Rau, Aarathi; Kamath, Jagannath; Kini, Anand			Lipofibromatous Hamartoma of the Median Nerve in Association with or without Macrodactyly	TURKISH JOURNAL OF PATHOLOGY			English	Article						Carpal tunnel syndrome; Median nerve; Hamartoma	FIBROLIPOMATOUS HAMARTOMA; DIAGNOSIS; HAND	Lipofibromatous hamartoma is a rare tumour-like condition involving the peripheral nerves, particularly the median nerve. It commonly affects the volar aspect of the hands, wrists and forearms of young adults. Most patients present either early with macrodactyly or later with a forearm mass lesion or symptoms consistent with compressive neuropathy of the involved nerve. The clinical and histomorphological findings of five patients with lipofibromatous hamartoma of the median nerve are analysed. The presentation, pathological features and differential diagnosis of neural lipofibromas are discussed along with a brief review of the literature. Of the five cases of lipofibromatous hamartoma, all were seen to involve the median nerve, occurring in four women and one man. Three of these cases had associated macrodactyly which was congenital in two and was seen from childhood in one. Microscopic examination showed fibrofatty tissue surrounding and infiltrating along the epineurium and perineurium. The nerve bundles were splayed apart by the infiltrating adipose tissue. Neural fibrolipomatous hamartoma is a benign condition. Most respond to conservative management with surgical exploration, biopsy and carpal tunnel release to decompress the nerve. Correct diagnosis of this uncommon lesion is important as surgical excision of the lesion may lead to loss of neurological function.	[Kini, Jyoti R.; Kini, Hema; Rau, Aarathi] Manipal Univ, Kasturba Med Coll, Dept Pathol, Mangalore 575001, Karnataka, India; [Kamath, Jagannath] Manipal Univ, Kasturba Med Coll, Dept Orthopaed, Mangalore, Karnataka, India; [Kini, Anand] Manipal Univ, Kasturba Med Coll, Dept Plast Surg, Mangalore, Karnataka, India	Kini, JR (reprint author), Manipal Univ, Kasturba Med Coll, Dept Pathol, Mangalore 575001, Karnataka, India.	kinijyoti@gmail.com		KINI, JYOTI/0000-0002-3351-9517			AMADIO PC, 1988, J HAND SURG-AM, V13A, P67, DOI 10.1016/0363-5023(88)90203-1; Berry MG, 1999, J ROY SOC MED, V92, P408, DOI 10.1177/014107689909200808; BERTI E, 1994, HISTOPATHOLOGY, V24, P391, DOI 10.1111/j.1365-2559.1994.tb00543.x; Bisceglia M, 2007, ADV ANAT PATHOL, V14, P46, DOI 10.1097/PAP.0b013e31802f04b7; Canga A, 1998, J NEUROSURG, V89, P683, DOI 10.3171/jns.1998.89.4.0683; Cui Q, 2008, AM J ORTHOP, V37, P146; GOULDESBROUGH DR, 1989, J BONE JOINT SURG BR, V71, P331; HOUPT P, 1989, J HAND SURG-AM, V14A, P706, DOI 10.1016/0363-5023(89)90195-0; JACOB RA, 1989, J HAND SURG-AM, V14A, P704, DOI 10.1016/0363-5023(89)90194-9; JOHNSON RJ, 1969, J BONE JOINT SURG AM, VA 51, P984, DOI 10.2106/00004623-196951050-00016; Mason M, 1953, J BONE JOINT SURG AM, V35, P273; MIKHAIL IK, 1964, J BONE JOINT SURG BR, V46, P726; PATEL ME, 1979, J BONE JOINT SURG AM, V61, P393, DOI 10.2106/00004623-197961030-00014; Razzaghi A, 2005, CAN J SURG, V48, P394; SILVERMAN TA, 1985, AM J SURG PATHOL, V9, P7, DOI 10.1097/00000478-198501000-00004; Ulrich D, 2009, ARCH ORTHOP TRAUM SU, V129, P1219, DOI 10.1007/s00402-008-0695-6; WARHOLD LG, 1993, J HAND SURG-AM, V18A, P1032, DOI 10.1016/0363-5023(93)90398-M; YEOMAN PM, 1964, J BONE JOINT SURG BR, V46, P737	18	5	5	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					87	91		10.5146/tjpath.2014.01282			5	Pathology	Pathology	GH2RY	WOS:000433250700010	25371022	DOAJ Gold			2019-10-28	
J	Onder, E; Arikok, AT; Turkoglu, E; Alper, M				Onder, Evrim; Arikok, Ata Turker; Turkoglu, Erhan; Alper, Murat			Lhermitte-Duclos Disease: A Rare Lesion with Variable Presentations and Obscure Histopathology	TURKISH JOURNAL OF PATHOLOGY			English	Article						Lhermitte-Duclos; Cerebellum; Histopathology	DYSPLASTIC GANGLIOCYTOMA; PATHWAY	Since Lhermitte-Duclos is a quite rare disorder with both neoplastic and hamartomatous features, clinical and pathological diagnosis can sometimes be challenging. For the pathologist it is of extreme importance to be aware of variable clinical and histopathological presentations of such a rare lesion particularly to differentiate it from the low-grade glial and neuronal tumors. We present four cases of Lhermitte-Duclos in a histopathological perspective. Although enlargement of the internal granular layer of the cerebellum is a consistent finding in our cases, morphological severity was highly variable and in some cases the enlargement was insignificant. Frozen sections of one case did not reveal diagnostic findings. The vacuolar change observed in the paraffin sections was obscure in the frozen. Pathological diagnosis of Lhermitte-Duclos disease can be extremely difficult in the absence of proper clinical information and the pathologist should be watchful for any irregularity in the internal granular layer in evaluating the cerebellar tissue which is otherwise normal.	[Onder, Evrim; Arikok, Ata Turker; Alper, Murat] Ankara Diskapi Yildirim Beyazit Res & Training Ho, Dept Pathol, Ankara, Turkey; [Turkoglu, Erhan] Ankara Diskapi Yildirim Beyazit Res & Training Ho, Dept Neurosurg, Ankara, Turkey	Onder, E (reprint author), Ankara Diskapi Yildirim Beyazit Egitim & Arastirm, Patol Bolumu, Ankara, Turkey.	evrimin@yahoo.com					Abel TW, 2005, J NEUROPATH EXP NEUR, V64, P341, DOI 10.1093/jnen/64.4.341; Bozbuga M, 2010, NEUROL INDIA, V58, P309, DOI 10.4103/0028-3886.63799; Capone MA, 2003, NEUROPEDIATRICS, V34, P30; Douglas-Akinwande AC, 2009, CLIN NEUROL NEUROSUR, V111, P536, DOI 10.1016/j.clineuro.2009.01.008; Lhermitte J, 1920, B ASSOC FR ETUD CANC, V9, P99; Louis D, 2007, WHO CLASSIFICATION T; Nowak DA, 2001, CLIN NEUROL NEUROSUR, V103, P105, DOI 10.1016/S0303-8467(01)00124-X; Nowak DA, 2002, ACTA NEUROL SCAND, V105, P137, DOI 10.1034/j.1600-0404.2002.1r127.x; Robinson Shenandoah, 2006, Neurosurg Focus, V20, pE6; Savardekar A, 2012, NEUROL INDIA, V60, P555, DOI 10.4103/0028-3886.103225; Thomas B, 2007, NEURORADIOLOGY, V49, P733, DOI 10.1007/s00234-007-0241-1; Wei G, 2012, MOL CLIN ONCOL, V2, P415; Zhou XP, 2003, AM J HUM GENET, V73, P1191, DOI 10.1086/379382	13	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					92	99		10.5146/tjpath.2014.01283			8	Pathology	Pathology	GH2RY	WOS:000433250700011	25371023	DOAJ Gold			2019-10-28	
J	Toru, HS; Cobankent Aytekin, E; Sanhal, CY; Yakut, S; Cetin, Z; Mendilcioglu, II; Pestereli, HE				Toru, Havva Serap; Cobankent Aytekin, Esra; Sanhal, Cem Yasar; Yakut, Sezin; Cetin, Zafer; Mendilcioglu, Ibrahim Inanc; Pestereli, Hadice Elif			We can Diagnose it if we Consider it. Diagnostic Pitfall for Placenta: Placental Mesenchymal Dysplasia	TURKISH JOURNAL OF PATHOLOGY			English	Article						Placental mesenchymal dysplasia; Molar pregnancy; Diagnostic errors	BECKWITH-WIEDEMANN SYNDROME; PARTIAL HYDATIDIFORM MOLE; DIPLOID DNA-CONTENT; TWIN PREGNANCY; MALFORMATION; HYPERPLASIA; HYDROPS	Placental mesenchymal dysplasia is an increasingly recognizable abnormality. Early cases have been confused with partial hydatidiform mole. Placental mesenchymal dysplasia is probably under-diagnosed because of being an unfamiliar clinical entity and also mistaken for gestational trophoblastic disease due to the similar sonographic findings of two entities. In this report, we describe the clinical, gross, and histopathological findings of placental mesenchymal dysplasia in two cases. The 33-week-preterm baby of a 26-year-old woman with cardiovascular disease and 342 gram placenta and the 19-week fetus with trisomy 21 of a 40 year-old woman were terminated. Macroscopically thick-walled vessels and microscopically hydropic villous with peripherally localized thick-walled vessels without trophoblastic cell proliferation were observed in both cases. These two cases represent a rare placental anomaly that is benign but it is challenging to distinguish placental mesenchymal dysplasia from an incomplete mole. Placental mesenchymal dysplasia should be included in the differential diagnosis of sonographic findings that show a normal appearing fetus and a placenta with cystic lesions. Placental mesenchymal dysplasia is associated with pregnancy-related hypertension. In conclusion, the most important point is "you can diagnose it if you consider it".	[Toru, Havva Serap; Cobankent Aytekin, Esra; Pestereli, Hadice Elif] Akdeniz Univ, Sch Med, Dept Pathol, Antalya, Turkey; [Sanhal, Cem Yasar; Mendilcioglu, Ibrahim Inanc] Akdeniz Univ, Sch Med, Dept Obstet & Gynecol, Antalya, Turkey; [Yakut, Sezin] Akdeniz Univ, Sch Med, Dept Med Biol & Genet, Antalya, Turkey; [Cetin, Zafer] SANKO Univ, Sch Med, Dept Med Biol, Gaziantep, Turkey	Toru, HS (reprint author), Akdeniz Univ, Tip Fak Hastanesi, Patol Anabilim Dali, Antalya, Turkey.	serap_toru@yahoo.com					Benirschke K, 2012, PATHOLOGY HUMAN PLAC; Chan YF, 2003, AUST NZ J OBSTET GYN, V43, P475, DOI 10.1046/j.0004-8666.2003.00130.x; Chew SH, 2000, HUM PATHOL, V31, P914, DOI 10.1053/hupa.2000.9085; Cohen MC, 2005, PRENATAL DIAG, V25, P187, DOI 10.1002/pd.1103; Gibson BR, 2004, PLACENTA, V25, P671, DOI 10.1016/j.placenta.2003.12.008; Gizzo S, 2012, ARCH GYNECOL OBSTET, V286, P15, DOI 10.1007/s00404-012-2232-7; Heazell AEP, 2009, PLACENTA, V30, P654, DOI 10.1016/j.placenta.2009.04.004; HOJBERG KE, 1994, PATHOL RES PRACT, V190, P808, DOI 10.1016/S0344-0338(11)80429-2; Kaiser-Rogers KA, 2006, J MED GENET, V43, P187, DOI 10.1136/jmg.2005.033571; LAGE JM, 1991, HUM PATHOL, V22, P591, DOI 10.1016/0046-8177(91)90237-J; Matsui H, 2003, PATHOL INT, V53, P810, DOI 10.1046/j.1440-1827.2003.01550.x; MOSCOSO G, 1991, PATHOL RES PRACT, V187, P324; Nayeri UA, 2013, ULTRASOUND OBST GYN, V41, P366, DOI 10.1002/uog.12359; Ohyama M, 2000, PATHOL INT, V50, P759, DOI 10.1046/j.1440-1827.2000.01100.x; Parveen Z, 2007, ARCH PATHOL LAB MED, V131, P131; PRIDMORE BR, 1994, AM J PERINAT, V11, P14, DOI 10.1055/s-2007-994525; Reichert RA., 2012, DIAGNOSTIC GYNECOLOG; Robertson M, 2007, J ULTRAS MED, V26, P689, DOI 10.7863/jum.2007.26.5.689; SANDER CM, 1993, PEDIATR PATHOL, V13, P621; Surti U, 2005, PRENATAL DIAG, V25, P1048, DOI 10.1002/pd.1255; TAKAYAMA M, 1986, GYNECOL OBSTET INVES, V22, P165, DOI 10.1159/000298909; Woo GW, 2011, AM J OBSTET GYNECOL, V205, pE3, DOI 10.1016/j.ajog.2011.08.019; Zeng X, 2012, ACTA OBSTET GYN SCAN, V91, P754, DOI 10.1111/j.1600-0412.2012.01397.x; Zhang P, 2000, J Perinatol, V20, P63	24	1	1	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					100	103		10.5146/tjpath.2015.01301			4	Pathology	Pathology	GH2RY	WOS:000433250700012	28272653	DOAJ Gold			2019-10-28	
J	Askan, G; Bagci, P; Hameed, M; Basturk, O				Askan, Gokce; Bagci, Pelin; Hameed, Meera; Basturk, Olca			Dedifferentiated Liposarcoma of the Gastroesophageal Junction	TURKISH JOURNAL OF PATHOLOGY			English	Article						Gastrointestinal neoplasms; Gastroesophageal junction; Dedifferentiated liposarcoma	REAL-TIME PCR; GIANT LIPOSARCOMA; STOMACH; DIAGNOSIS; AMPLIFICATION; ESOPHAGUS; SUBTYPE; SARCOMA; MDM2	Liposarcoma is one of the most common sarcomas in adults, but very rarely presents as a primary in the upper gastrointestinal system. Herein, we present a 71-year-old male patient who underwent wedge excision biopsy twice and then fine needle aspiration and total gastrectomy for a recurrent gastroeosophageal junction mass. In microscopic sections, both well-differentiated and dedifferentiated components were seen. Tumor cells were positive for MDM2, CDK4 and negative for CD117, DOG1, CD34, SMA, Desmin, S-100, HMB45, SOX10, AE1/AE3, CAM5.2, CK18. Fluorescence in situ hybridization (FISH) was performed and MDM2 gene (12q15) amplification was detected. According to these findings, a diagnosis of dedifferentiated liposarcoma was supported. We believe this is the first reported case of dedifferentiated liposarcoma of the gastroesophageal junction.	[Askan, Gokce; Bagci, Pelin] Marmara Univ, Fac Med, Dept Pathol, Istanbul, Turkey; [Hameed, Meera; Basturk, Olca] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA	Basturk, O (reprint author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10065 USA.	basturko@mskcc.org	Basturk, Olca/N-7214-2017	Basturk, Olca/0000-0003-2747-1366			Binh MBN, 2005, AM J SURG PATHOL, V29, P1340, DOI 10.1097/01.pas.0000170343.09562.39; Bostanoglu A, 2013, TURK J GASTROENTEROL, V24, P167, DOI 10.4318/tjg.2013.0510; Choi YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-239; Dalal KM, 2006, ANN SURG, V244, P381, DOI 10.1097/01.sla.0000234795.98607.00; Dei Tos AP, 2013, WHO CLASSIFICATION T, P37; EVANS HL, 1979, AM J SURG PATHOL, V3, P507, DOI 10.1097/00000478-197912000-00004; Ferrozzi F, 2000, J COMPUT ASSIST TOMO, V24, P854, DOI 10.1097/00004728-200011000-00006; Ferrozzi F, 2000, Radiol Med, V100, P343; Goldblum JR, 2014, ENZINGER WEISSS SOFT, P500; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; HOHF RP, 1955, ANN SURG, V142, P1029, DOI 10.1097/00000658-195512000-00024; Hostein I, 2004, J PATHOL, V202, P95, DOI 10.1002/path.1495; LAKY D, 1986, PATHOL RES PRACT, V181, P112; LopezNegrete L, 1997, ABDOM IMAGING, V22, P373, DOI 10.1007/s002619900213; Michiels A, 2007, ACTA CHIR BELG, V107, P468, DOI 10.1080/00015458.2007.11680102; Neuville A, 2013, AM J SURG PATHOL, V37, P1259, DOI 10.1097/PAS.0b013e31828f51b9; Okabayashi T, 2013, INTERNAL MED, V52, P2753, DOI 10.2169/internalmedicine.52.1230; Radaelli S, 2014, EXPERT REV ANTICANC, V14, P689, DOI 10.1586/14737140.2014.885840; Singer S, 2003, ANN SURG, V238, P358, DOI 10.1097/01.sla.0000086542.11899.38; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Smith MA, 2010, ANN THORAC SURG, V89, P610, DOI 10.1016/j.athoracsur.2009.06.094; Sui XZ, 2011, EUR J CARDIO-THORAC, V40, P1253, DOI 10.1016/j.ejcts.2011.02.006; Takahashi Y, 2009, DIAGN THER ENDOSC, V2009; Torres-Mora J, 2012, CASE REP GASTROINTES, DOI 10.1155/2012/141693; Watkin Emmanuel, 2011, J Gastrointest Cancer, V42, P65, DOI 10.1007/s12029-010-9174-8	25	0	0	0	2	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					104	107		10.5146/tjpath.2014.01297			4	Pathology	Pathology	GH2RY	WOS:000433250700013	25690861	DOAJ Gold			2019-10-28	
J	Chander, RV; Jayaganesh, P; Sekhar, G; Chitra, S				Chander, R. Vimal; Jayaganesh, P.; Sekhar, Ganthimathy; Chitra, S.			Multiple Pigmented Seborrheic Keratosis with Sebaceous Differentiation - A Case Report	TURKISH JOURNAL OF PATHOLOGY			English	Article						Seborrheic keratosis; Sebaceous differentiation; Differential diagnosis	TRANSFORMATION; SEBOMATRICOMA; EPITHELIOMA; NEOPLASMS	Seborrheic keratosis is a benign lesion that is common in the trunk and head and neck regions. It shows a considerable variety of histological appearances leading to different variants. The presence of sebaceous differentiation in seborrheic keratosis is very rare and can histologically mimic benign and malignant tumors with sebaceous differentiation. We present a case of a 65-year-old male presenting with multiple nodules over the right and left sides of neck and the right preauricular region, histopathological examination of which revealed multiple pigmented seborrheic keratoses with sebaceous differentiation. This case is reported for its rare sebaceous differentiation and multiplicity along with the importance of differentiating it from a variety of benign to malignant neoplasms showing sebaceous differentiation.	[Chander, R. Vimal; Jayaganesh, P.; Sekhar, Ganthimathy; Chitra, S.] Saveetha Med Coll & Hosp, Dept Pathol, Chennai, Tamil Nadu, India	Chander, RV (reprint author), Saveetha Med Coll, Dept Pathol, Madras 602105, Tamil Nadu, India.	rvimalchander@gmail.com		SEKHAR, GANTHIMATHY/0000-0002-5690-1321			Betti R, 2001, AM J DERMATOPATH, V23, P58, DOI 10.1097/00000372-200102000-00010; Bhuiyan ZH, 2007, ORION MED J, V26, P441; Hafner C, 2008, J DTSCH DERMATOL GES, V6, P664, DOI 10.1111/j.1610-0387.2008.06788.x; JAKOBIEC FA, 1988, OPHTHALMOLOGY, V95, P1543; Lee MJ, 2003, YONSEI MED J, V44, P347, DOI 10.3349/ymj.2003.44.2.347; Lee NH, 2000, AM J DERMATOPATH, V22, P261, DOI 10.1097/00000372-200006000-00010; Misago N, 2002, AM J DERMATOPATH, V24, P294, DOI 10.1097/01.DAD.0000021434.76177.A0; Rajabi P, 2012, J RES MED SCI, V17, P217; RAO BK, 1994, J DERMATOL SURG ONC, V20, P761, DOI 10.1111/j.1524-4725.1994.tb03201.x; Requena L, 1998, AM J DERMATOPATH, V20, P383, DOI 10.1097/00000372-199808000-00011; Requena L, 2006, J CUTAN PATHOL, V33, P42, DOI 10.1111/j.1600-0560.2006.00528.x; Safa G, 2011, CASE REP ONCOL, V4, P175, DOI 10.1159/000327363; Venegas AF, 2012, REV MED CHILE, V140, P1585, DOI 10.4067/S0034-98872012001200010; Yoon NY, 2013, ANN DERMATOL, V25, P512, DOI 10.5021/ad.2013.25.4.512; YUS ES, 1995, AM J DERMATOPATH, V17, P213, DOI 10.1097/00000372-199506000-00001; Zhang Ru-Zhi, 2011, Indian J Dermatol, V56, P432, DOI 10.4103/0019-5154.84754	16	0	0	0	0	DE GRUYTER POLAND SP ZOO	WARSAW	BOGUMILA ZUGA 32A STR., 01-811 WARSAW, POLAND	1018-5615	1309-5730		TURK J PATHOL	Turk. J. Pathol.	JAN	2018	34	1					108	111		10.5146/tjpath.2015.01304			4	Pathology	Pathology	GH2RY	WOS:000433250700014	28272654	DOAJ Gold			2019-10-28	
J	Bhutada, E; Pyragius, T; Petersen, SG; Niemann, F; Matsika, A				Bhutada, Ekta; Pyragius, Timothy; Petersen, Scott G.; Niemann, Frans; Matsika, Admire			Perinatal Lethal Gaucher Disease due to RecNcil Recombinant Mutation in the GBA Gene Presenting with Hydrops Fetalis and Severe Congenital Anemia	CASE REPORTS IN PATHOLOGY			English	Article								A 35-year-old woman presented at 27-week gestation with hypertension and pedal edema. Antenatal scan showed hydrops fetalis and growth restriction. Cordocentesis showed severe fetal anemia. This was treated with multiple in utero blood transfusions with no clinically significant improvement and intrauterine death occurred at 28 weeks. Perinatal autopsy confirmed severe hydrops with hepatosplenomegaly and visceral effusions. Microscopic examination of the reticuloendothelial organs showed widespread infiltration by large-mono-and multinucleate histiocytic cells with fibrillary appearance ("Gaucher cells"). DNA-extracted from fetal tissue was submitted for analysis by next generation sequencing which revealed homozygosity for the RecNcil mutation in the GBA gene. Both parents were found to be heterozygous for the variant. The case report highlights a severe form of Gaucher disease with histopathological and molecular confirmation that presents with hydrops fetalis and severe refractory anemia. It also emphasizes the importance of perinatal autopsy coupled with exome sequencing in confirming syndromic diagnosis in the modern area.	[Bhutada, Ekta; Niemann, Frans; Matsika, Admire] Mater Hlth Serv, Mater Pathol, South Brisbane, Qld, Australia; [Bhutada, Ekta; Niemann, Frans; Matsika, Admire] Univ Queensland, Dept Biomed Sci, Fac Med, Brisbane, Qld, Australia; [Pyragius, Timothy] SA Pathol, Genet & Mol Pathol, Natl Referral Lab, Adelaide, SA, Australia; [Petersen, Scott G.] Mater Hlth Serv, Ctr Maternal Fetal Med, South Brisbane, Qld, Australia	Bhutada, E (reprint author), Mater Hlth Serv, Mater Pathol, South Brisbane, Qld, Australia.; Bhutada, E (reprint author), Univ Queensland, Dept Biomed Sci, Fac Med, Brisbane, Qld, Australia.	ekta.mundhara@gmail.com		Matsika, Admire/0000-0002-4418-7394			Armes JE, 2018, PEDIATR DEVEL PATHOL, V21, P54, DOI 10.1177/1093526617715528; BenHamida E, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.110.7052; Fuller M, 2006, FABRY DIS PERSPECTIV; Gupta N, 2011, BLOOD CELL MOL DIS, V46, P75, DOI 10.1016/j.bcmd.2010.08.012; Mignot C, 2003, AM J MED GENET A, V120A, P338, DOI 10.1002/ajmg.a.20117; Sorop-Florea M, 2017, ROM J MORPHOL EMBRYO, V58, P323; Weiss K, 2015, MOL GENET METAB, V114, P110, DOI 10.1016/j.ymgme.2014.11.008	7	1	1	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2549451	10.1155/2018/2549451			4	Pathology	Pathology	GH0GK	WOS:000433080300001	29854527	DOAJ Gold, Green Published			2019-10-28	
J	Santos, HBD; de Morais, EF; Moreira, DGL; Neto, LFD; Gomes, PP; Freitas, RD				de Pontes Santos, Hellen Bandeira; de Morais, Everton Freitas; Lambert Moreira, Deborah Gondim; de Almeida Neto, Luis Ferreira; Gomes, Petrus Pereira; Freitas, Roseana de Almeida			Calcifying Odontogenic Cyst with Extensive Areas of Dentinoid: Uncommon Case Report and Update of Main Findings	CASE REPORTS IN PATHOLOGY			English	Article							TUMOR; PROFILE	The calcifying odontogenic cyst (COC) is a benign odontogenic cyst that occurs in the gnathic bones. This cyst is part of a spectrum of lesions characterized by odontogenic epithelium containing "ghost cells," which may undergo calcification. Areas of an eosinophilic matrix material compatible dentinoid also may present adjacent to the epithelial component. However, these areas of dentinoid commonly do not appear so abundant in COCs. In this study, we report a case of intraosseous COC with extensive areas of dentinoid and perform an update regarding the clinical, radiographical, histopathological, and differential diagnosis, treatment, and prognosis of this cystic lesion.	[de Pontes Santos, Hellen Bandeira; de Morais, Everton Freitas; Lambert Moreira, Deborah Gondim; Freitas, Roseana de Almeida] Univ Fed Rio Grande do Norte, Postgrad Program Oral Pathol, Natal, RN, Brazil; [de Almeida Neto, Luis Ferreira; Gomes, Petrus Pereira] Univ Fed Rio Grande do Norte, Oral & Maxillofacial Surg Residence, Natal, RN, Brazil	Santos, HBD (reprint author), Univ Fed Rio Grande do Norte, Postgrad Program Oral Pathol, Natal, RN, Brazil.	hellenbps@hotmail.com	Santos, Hellen HPBS/C-4565-2019	Santos, Hellen HPBS/0000-0002-6596-5220			BUCHNER A, 1991, J ORAL MAXIL SURG, V49, P330, DOI 10.1016/0278-2391(91)90365-S; de Souza LB, 2010, MED ORAL PATOL ORAL, V15, pE583, DOI 10.4317/medoral.15.e583; El-Naggar A. K., 2017, ORG CLASSIFICATION H; Fregnani ER, 2003, J ORAL PATHOL MED, V32, P163, DOI 10.1034/j.1600-0714.2003.00070.x; GORLIN R J, 1962, Oral Surg Oral Med Oral Pathol, V15, P1235, DOI 10.1016/0030-4220(62)90159-7; Irani Soussan, 2017, J Contemp Dent Pract, V18, P688; Johnson NR, 2013, OR SURG OR MED OR PA, V115, P515, DOI 10.1016/j.oooo.2013.01.016; Kler Shikha, 2009, J Oral Maxillofac Pathol, V13, P27, DOI 10.4103/0973-029X.48753; Ledesma-Montes C, 2008, J ORAL PATHOL MED, V37, P302, DOI 10.1111/j.1600-0714.2007.00623.x; Lucchese A, 2011, ULTRASTRUCT PATHOL, V35, P146, DOI 10.3109/01913123.2010.548111; Mokhtari S., 2013, CASE REP PATHOL, V2013; Sheikh J, 2017, J ORAL MAXIL SURG, V75, P750, DOI 10.1016/j.joms.2016.10.013; Tarakji B, 2015, WSPOLCZESNA ONKOL, V19, P184, DOI 10.5114/wo.2015.52654; Urs AB, 2016, OR SURG OR MED OR PA, V121, pE32, DOI 10.1016/j.oooo.2015.06.033; Utumi ER, 2012, EINSTEIN-SAO PAULO, V10, P366, DOI 10.1590/S1679-45082012000300019; Wright JM, 2017, HEAD NECK PATHOL, V11, P68, DOI 10.1007/s12105-017-0794-1; Yoshida M, 2001, J ORAL PATHOL MED, V30, P582, DOI 10.1034/j.1600-0714.2001.301002.x; Zornosa X, 2010, HEAD NECK PATHOL, V4, P292, DOI 10.1007/s12105-010-0197-z	18	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8323215	10.1155/2018/8323215			4	Pathology	Pathology	GH0GN	WOS:000433080600001	29862107	DOAJ Gold, Green Published			2019-10-28	
J	Zhang, X; Findeis-Hosey, JJ				Zhang, Xin; Findeis-Hosey, Jennifer J.			Dystrophic Adipocytes Mimicking Metastatic Signet Ring Cell Adenocarcinoma: A Diagnostic Pitfall in a Cachectic Patient	CASE REPORTS IN PATHOLOGY			English	Article							CANCER CACHEXIA; ADIPOSE-TISSUE; CARCINOMA; ATROPHY	Cachexia is a debilitating condition and complex syndrome commonly associated with a variety of chronic diseases. It is caused by metabolic dysregulation and characterized by profound loss of adipose tissue and skeletal muscles. While pathological changes of cachectic conditions on adipose tissue have been studied and documented in tumor-bearing animal models, similar morphological changes in human surgical specimens are rare. Here we report a case of a cachectic patient with pancreatic adenocarcinoma whose adipocytes underwent dramatic lipodystrophy mimicking signet ring cell adenocarcinoma. The patient had presented with a large bowel obstruction, a mass extending between the pancreas and colon, and radiographic concern for carcinomatosis. A moderately differentiated adenocarcinoma was identified invading externally into the colon, with extensive signet ring-like cells throughout the specimen, including those adjacent to the colon and lymph nodes and around nerves. These signet ring-like cells were round with variably clear to eosinophilic cytoplasm and a peripherally displaced round to oval nucleus. Immunohistochemical staining demonstrated that these signet ring-like cells were negative for AE1/AE3, CD138, or Kreyberg staining, while they were positive for S-100 staining, confirming these as dystrophic adipocytes. Here we examine dystrophic adipocytes in a cachetic patient, examining the differential diagnosis and potential ancillary studies.	[Zhang, Xin; Findeis-Hosey, Jennifer J.] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, POB 626,601 Elmwood Ave, Rochester, NY 14642 USA	Findeis-Hosey, JJ (reprint author), Univ Rochester, Med Ctr, Dept Pathol & Lab Med, POB 626,601 Elmwood Ave, Rochester, NY 14642 USA.	Jennifer_Findeis-Hosey@urmc.rochester.edu					Agustsson T, 2007, CANCER RES, V67, P5531, DOI 10.1158/0008-5472.CAN-06-4585; ALGUACILGARCIA A, 1986, AM J SURG PATHOL, V10, P795, DOI 10.1097/00000478-198611000-00007; Alves MJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3178-8; Batista ML, 2013, CYTOKINE, V61, P532, DOI 10.1016/j.cyto.2012.10.023; Batista ML, 2016, J CACHEXIA SARCOPENI, V7, P37, DOI 10.1002/jcsm.12037; Bing C, 2006, BRIT J CANCER, V95, P1028, DOI 10.1038/sj.bjc.6603360; Bing C, 2009, P NUTR SOC, V68, P385, DOI 10.1017/S0029665109990267; De Petris G, 1998, AM J SURG PATHOL, V22, P545, DOI 10.1097/00000478-199805000-00004; DRUDE RB, 1982, J CLIN GASTROENTEROL, V4, P217, DOI 10.1097/00004836-198206000-00005; Houghton Oisin, 2006, Ulster Med J, V75, P93; Khan O, 2017, INT J SURG PATHOL, V25, P168, DOI 10.1177/1066896916664988; Lortscher David N, 2012, Dermatol Online J, V18, P3; Pena Gil Patrus, 2014, Int J Surg Pathol, V22, P241, DOI 10.1177/1066896913492848; Tisdale MJ, 2002, NAT REV CANCER, V2, P862, DOI 10.1038/nrg927; Trivedi A, 2013, ARCH PATHOL LAB MED, V137, P284, DOI 10.5858/arpa.2011-0386-CR; Vajpeyi R., 2013, DIAGNOSTIC HISTOPATH, V19, P457; Wang K, 2003, AM J SURG PATHOL, V27, P1429, DOI 10.1097/00000478-200311000-00004	17	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									9027870	10.1155/2018/9027870			4	Pathology	Pathology	GH0IL	WOS:000433085600001	29854530	DOAJ Gold, Green Published			2019-10-28	
J	Xie, L; Deng, Y; Yuan, YM; Tan, X; Liu, LJ; Li, NN; Deng, CF; Liu, HM; Dai, L				Xie, Liang; Deng, Ying; Yuan, Yumei; Tan, Xiong; Liu, Lijun; Li, Nana; Deng, Changfei; Liu, Hanmin; Dai, Li			Association of SNP rs1867277 in FOXE1 Gene and Cleft Lip with or without Cleft Palate in a Han Chinese Population	FETAL AND PEDIATRIC PATHOLOGY			English	Article						association study; cleft lip with or without cleft palate; family based; FOXE1	OROFACIAL CLEFTS; RISK; PREGNANCY; VARIANTS; PROMOTER; LINKAGE; BIRTH	Background: The genetic factors causing cleft lip with or without cleft palate (CL +/- P) are still unclear. The SNPs in FOXE1 gene were associated with CL +/- P. However, the results have been inconsistent. Objective: We explored the associations of four SNPs in FOXE1 gene and CL +/- P by a family based study. Materials and Methods:128 children with CL +/- P and their parents were recruited. rs3758249 and rs1867277 were genotyped by high-resolution melting curve (HRM) method, whereas rs1443434 and rs907577 were genotyped by Sequenom MassARRAY (R) method. The software PLINK, FBAT and FAMHAP were used for analyzing data. Results: rs1867277 was associated with CL +/- P (P-m = 0.0395). The patients were divided into two subgroups, individuals with cleft lip only and persons with cleft lip and palate. There were no associations in subgroup analyses. Conclusion: We confirmed the association of FOXE1 gene and CL +/- P by a family based study. For the first time, rs1867277 was significantly associated with CL +/- P.	[Xie, Liang; Liu, Hanmin] Sichuan Univ, West China Univ Hosp 2, Dept Pediat Resp, Chengdu, Sichuan, Peoples R China; [Xie, Liang; Liu, Lijun; Liu, Hanmin; Dai, Li] Sichuan Univ, West China Univ Hosp 2, West China Inst Women & Childrens Hlth, Vasc Remodeling & Dev Defects Res Unit, Chengdu, Sichuan, Peoples R China; [Xie, Liang; Deng, Ying; Liu, Lijun; Li, Nana; Deng, Changfei; Liu, Hanmin; Dai, Li] Sichuan Univ, West China Univ Hosp 2, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Sichuan, Peoples R China; [Deng, Ying; Li, Nana; Deng, Changfei; Dai, Li] Sichuan Univ, West China Univ Hosp 2, Natl Ctr Birth Defect Monitoring, 20,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China; [Deng, Ying; Li, Nana; Dai, Li] Sichuan Univ, West China Inst Women & Childrens Hlth, Lab Mol Epidemiol Birth Defect, Chengdu, Sichuan, Peoples R China; [Yuan, Yumei; Tan, Xiong] Hengyang Matern & Child Healthcare Hosp, Hengyang, Hunan, Peoples R China	Dai, L (reprint author), Sichuan Univ, West China Univ Hosp 2, Natl Ctr Birth Defect Monitoring, 20,Sect 3,South Renmin Rd, Chengdu 610041, Sichuan, Peoples R China.	daili@scu.edu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81072375]; National Basic Research Program of ChinaNational Basic Research Program of China [2007CB511905]	National Natural Science Foundation of China (81072375). National Basic Research Program of China (2007CB511905).	Acs N, 2005, BIRTH DEFECTS RES A, V73, P989, DOI 10.1002/bdra.20195; Becker T, 2004, AM J HUM GENET, V75, P561, DOI 10.1086/424390; Christensen K, 2004, BRIT MED J, V328, P1405, DOI 10.1136/bmj.38106.559120.7C; CIVITAREALE D, 1989, EMBO J, V8, P2537, DOI 10.1002/j.1460-2075.1989.tb08391.x; Cuesta I, 2007, MOL CELL BIOL, V27, P7302, DOI 10.1128/MCB.00758-07; De Felice M, 1998, NAT GENET, V19, P395; Fernandez LP, 2015, NAT REV ENDOCRINOL, V11, P29, DOI 10.1038/nrendo.2014.186; Hernandez-Diaz S, 2000, NEW ENGL J MED, V343, P1608, DOI 10.1056/NEJM200011303432204; Honein MA, 2007, EPIDEMIOLOGY, V18, P226, DOI 10.1097/01.ede.0000254430.61294.c0; Johnson CY, 2008, INT J EPIDEMIOL, V37, P1041, DOI 10.1093/ije/dyn098; Landa I, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000637; LITTLE J, 1986, SEMIN PERINATOL, V10, P50; Liu K, 2015, BRIT J ORAL MAX SURG, V53, P705, DOI 10.1016/j.bjoms.2015.05.021; Ludwig KU, 2014, J DENT RES, V93, P376, DOI 10.1177/0022034514523987; Lunetta KL, 2000, AM J HUM GENET, V66, P605, DOI 10.1086/302782; Marazita ML, 2004, AM J HUM GENET, V75, P161, DOI 10.1086/422475; Moreno LM, 2009, HUM MOL GENET, V18, P4879, DOI 10.1093/hmg/ddp444; Mossey PA, 2003, GLOBAL REGISTRY DATA; Mossey PA, 2009, LANCET, V374, P1773, DOI 10.1016/S0140-6736(09)60695-4; Mostowska A, 2010, BIRTH DEFECTS RES A, V88, P538, DOI 10.1002/bdra.20687; Ngai CW, 2005, J MATERN-FETAL NEO M, V17, P203, DOI 10.1080/14767050500072854; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Yin X, 2016, ORAL DIS, V22, P274, DOI 10.1111/odi.12435	23	1	1	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					89	94		10.1080/15513815.2018.1424278			6	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100001	29509083				2019-10-28	
J	Sharma, K; Aziz, M; Afroz, N; Ehsan, A				Sharma, Kashmi; Aziz, Mehar; Afroz, Nishat; Ehsan, Aaliya			Profile of Non-Hematological Pediatric Tumors: A Clinicopathological Study at a Tertiary Health Care Centre	FETAL AND PEDIATRIC PATHOLOGY			English	Article						pediatric tumors; childhood cancer; clinicopathological; benign; malignant; solid tumors	CHILDHOOD-CANCER; RISK-FACTORS; NEUROBLASTOMA; INDIA; DIAGNOSIS; SPECTRUM	Background: Tumors in pediatric age group are biologically different from tumors in adults and emerging as a significant contributor to morbidity/mortality in children. Objectives: This study evaluated the epidemiological profile of pediatric solid tumors in 0-18 years of age over a period of 5 years in a general hospital in India. Results: A total of 510 cases of tumors were included, which accounted for 5.1% of the total tumor burden of the hospital. Benign tumors were more common than malignant tumors. Most common age group affected was 14-18 years. Among benign tumors, vascular tumors were the most common, while malignant bone tumors outnumbered all other malignant tumors. Neuroblastomas comprised only 0.9% of our malignancies. Conclusion: Our study provides an insight into the patterns of childhood tumors for which exists little literature in India. With lack of a dedicated pediatric cancer registry from India, tracking of the diverse histological spectrum of tumors is difficult.	[Sharma, Kashmi] Subharti Med Coll, Dept Pathol, Meerut, Uttar Pradesh, India; [Aziz, Mehar; Afroz, Nishat; Ehsan, Aaliya] Aligarh Muslim Univ, Dept Pathol, Fac Med, Aligarh, Uttar Pradesh, India	Sharma, K (reprint author), Subharti Med Coll, NH-58 Delhi Haridwar Bypass Rd, Meerut 250001, Uttar Pradesh, India.	sharmakashmi@gmail.com		Sharma, Kashmi/0000-0003-2508-4098			[Anonymous], 2013, 3 SOURC REP POP BAS; Arora R. S., 2009, Indian Journal of Cancer, V46, P264, DOI 10.4103/0019-509X.55546; Banerjee C K, 1986, Indian J Pediatr, V53, P93, DOI 10.1007/BF02787078; Beckwith J. Bruce, 1994, P1741; Bock K, 2005, J ULTRAS MED, V24, P1347, DOI 10.7863/jum.2005.24.10.1347; Daniels JL, 2001, EPIDEMIOLOGY, V12, P20, DOI 10.1097/00001648-200101000-00005; Das J, 2010, NATL J COMMUNITY MED, V3, P91; Eyre R, 2009, BRIT J CANCER, V100, P188, DOI 10.1038/sj.bjc.6604837; Fathi Afshin, 2015, Asian Pac J Cancer Prev, V16, P5459; Ferlay JB, 2004, GLOBOCAN 2002 CANC I; Hamrick SEG, 2001, PAEDIATR PERINAT EP, V15, P328, DOI 10.1046/j.1365-3016.2001.0376a.x; Harmon BE, 2011, INDIAN J PATHOL MICR, V54, P514, DOI 10.4103/0377-4929.85084; Jabeen S, 2010, J DHAKA MED COLL, V19, P33; Jain A, 2011, NEUROL INDIA, V59, P208, DOI 10.4103/0028-3886.79142; Jan M, 2015, J K PRACTITIONER, V20, P12; Kaatsch P, 2010, CANCER TREAT REV, V36, P277, DOI 10.1016/j.ctrv.2010.02.003; Kediya AS, 2015, IJRRMS, V5, P1; KRAMER S, 1987, JNCI-J NATL CANCER I, V78, P797; Kusumakumary P, 2000, Indian Pediatr, V37, P1234; Lee CK, 1966, JKCRA, V1, P75; Madhavan J, 2008, J PEDIAT OPHTH STRAB, V45, P22, DOI 10.3928/01913913-20080101-16; Maitra A, 2010, ROBBINS COTRAN PATHO, P447; Marina NM, 1996, NELSON TXB PEDIAT, V2, P1471; McCall EE, 2005, CANCER CAUSE CONTROL, V16, P743, DOI 10.1007/s10552-005-1229-y; Mondal SK, 2013, INDIAN J MED PAEDIAT, V34, P242, DOI 10.4103/0971-5851.125235; Ocheni S, 2005, J CLIN ONCOL, V34, P371; Parham DM, 2006, ARCH PATHOL LAB MED, V130, P1454; Parkin DM, 1998, IARC SCI PUBLICATION, VII; Pattnaik N, 2012, J CLIN DIAGN RES, V6, P674; Punia RS, 2014, INDIAN J MED PAEDIAT, V35, P170, DOI 10.4103/0971-5851.138995; Rathi K R, 2007, Indian J Pathol Microbiol, V50, P754; Satyanarayana L, 2014, INDIAN PEDIATR, V51, P218, DOI 10.1007/s13312-014-0377-0; Schuz J, 2001, J CLIN EPIDEMIOL, V54, P702, DOI 10.1016/S0895-4356(00)00339-5; Sharma Sonal, 2004, Indian Journal of Pediatrics, V71, P501, DOI 10.1007/BF02724289; Steliarova-Foucher E, 2005, CANCER-AM CANCER SOC, V103, P1457, DOI 10.1002/cncr.20910; Ueno T, 2004, RADIOGRAPHICS, V24, P387, DOI 10.1148/rg.242035082	36	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					95	101		10.1080/15513815.2018.1424276			7	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100002	29608111				2019-10-28	
J	Almarzooqi, S; Quadri, A; Albawardi, A				Almarzooqi, Saeeda; Quadri, Asif; Albawardi, Alia			Gallbladder Polyps in Metachromatic Leukodystrophy	FETAL AND PEDIATRIC PATHOLOGY			English	Review						metachromatic leukodystrophy; gallbladder papillomatosis	ABNORMALITIES; INVOLVEMENT; SULFATIDE; DIAGNOSIS	Background: Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease, caused by a deficiency of arylsulfatase A, and leads to demyelination of the nervous system. A putative association between MLD and gallbladder pathology including malignancy is documented in the medical literature. Case report: A 10-year-old boy with MLD was found to have a papillary growth within a cystically dilated gallbladder. The lesion was confirmed to be papillomatosis/polyp with focal intestinal metaplasia. Dysplasia was not identified. Conclusion: MLD may be associated with a spectrum of gallbladder pathology including neoplastic conditions. Pathologists and clinicians should be aware of this association/risk. The patient may be offered regular ultrasound screening of the gallbladder.	[Almarzooqi, Saeeda; Albawardi, Alia] UAE Univ, Coll Med & Hlth Sci, Pathol Dept, POB 17666, Al Ain, U Arab Emirates; [Quadri, Asif] Tawam Hosp, Pathol Dept, Al Ain, U Arab Emirates	Albawardi, A (reprint author), UAE Univ, Coll Med & Hlth Sci, Pathol Dept, POB 17666, Al Ain, U Arab Emirates.	alia.albawardi@uaeu.ac.ae					Adsay NV, 2015, STERNBERGS DIAGNOSTI, P1784; AUSTIN J, 1968, ARCH NEUROL-CHICAGO, V18, P225, DOI 10.1001/archneur.1968.00470330015001; AUSTIN JH, 1960, NEUROLOGY, V10, P470, DOI 10.1212/WNL.10.5.470; BURGESS JH, 1985, ARCH PATHOL LAB MED, V109, P79; Inoue Natsumi, 2016, Pediatr Neurol, V64, pe3, DOI 10.1016/j.pediatrneurol.2016.08.006; Kim J, 2017, J SURG RES, V208, P187, DOI 10.1016/j.jss.2016.08.081; Kim TS, 1996, J ULTRAS MED, V15, P821; McFadden K, 2015, PEDIATR DEVEL PATHOL, V18, P228, DOI 10.2350/14-09-1551-CR.1; Mehrotra AK, 2009, VISIBLE HUMAN J ENDO, V8; Pasquini P, 2009, WORLD J GASTROENTERO, V15, P2287, DOI 10.3748/wjg.15.2287; Pawel BR, 2014, PATHOLOGY PEDIAT GAS, P323; Rodriguez-Waitkus PM, 2011, ULTRASTRUCT PATHOL, V35, P271, DOI 10.3109/01913123.2011.620730; Russo P, 2014, PATHOLOGY PEDIAT GAS, P412; Shah S, 2013, PEDIATR NEUROL, V49, P68, DOI 10.1016/j.pediatrneurol.2013.03.019; SIEGEL EG, 1992, DIGESTION, V51, P121, DOI 10.1159/000200886; Simanovsky N, 1998, PEDIATR RADIOL, V28, P706, DOI 10.1007/s002470050446; Takahashi T, 2012, J LIPID RES, V53, P1437, DOI 10.1194/jlr.R026682; van Rappard DF, 2016, NEUROLOGY, V87, P103, DOI 10.1212/WNL.0000000000002811; Yavuz H, 2011, J CHILD NEUROL, V26, P117, DOI 10.1177/0883073810378166	19	3	3	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					102	108		10.1080/15513815.2018.1424277			7	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100003	29494779				2019-10-28	
J	Korgali, EU; Yavuz, A; Simsek, CEC; Guney, C; Kurtulgan, HK; Baser, B; Atalar, MH; Ozer, H; Egilmez, HR				Korgali, Elif Unver; Yavuz, Amine; Simsek, Cemile Ece Caglar; Guney, Cengiz; Kurtulgan, Hande Kucuk; Baser, Burak; Atalar, Mehmet Haydar; Ozer, Hatice; Egilmez, Hatice Reyhan			Megacystis Microcolon Intestinal Hypoperistalsis Syndrome in Which a Different De Novo Actg2 Mutation was Detected: A Case Report	FETAL AND PEDIATRIC PATHOLOGY			English	Article						ACTG2 gene mutation; megacystis microcolon intestinal hypoperiltastis syndrome; newborn	OF-THE-LITERATURE; SMOOTH-MUSCLE; SYNDROME MMIHS; VARIANTS; DISEASE; ACTIN; OBSTRUCTION; MYOPATHY	Introduction: Megacystis microcolon intestinal hypoperistalsis syndrome (MMIHS) is characterized by bladder distension without urinary tract obstruction, decreased or absent intestinal peristalsis and microcolon. Although the definitive cause remains unknown, changes in the ACTG2 gene are thought to be responsible for the intestinal and bladder hypoperistalsis. Case report. This female newborn with MMIHS had a c.532C > A /p.Arg178Ser heterozygous de novo mutation detected in the ACTG2 gene. Normal immature ganglion cells, normal calretinin punctate positivity, maintence of smooth muscle actin immunoreactivity, and decreased numbers of interstitial cells of Cajal(ICCs) were detected. Conclusion: This previously unreported c.532C >A /p.Arg178Ser heterozygous de novo mutation in the ACTG2 gene may lead to a severe form of MMIHS.	[Korgali, Elif Unver; Yavuz, Amine; Simsek, Cemile Ece Caglar] Cumhuriyet Univ, Fac Med, Dept Pediat, TR-58100 Sivas, Turkey; [Guney, Cengiz] Cumhuriyet Univ, Dept Pediat Surg, Sivas, Turkey; [Kurtulgan, Hande Kucuk; Baser, Burak] Cumhuriyet Univ, Fac Med, Dept Med Genet, Sivas, Turkey; [Atalar, Mehmet Haydar] Cumhuriyet Univ, Fac Med, Dept Radiol, Sivas, Turkey; [Ozer, Hatice; Egilmez, Hatice Reyhan] Cumhuriyet Univ, Fac Med, Dept Pathol, Sivas, Turkey	Korgali, EU (reprint author), Cumhuriyet Univ, Fac Med, Dept Pediat, TR-58100 Sivas, Turkey.	elfkorgali@hotmail.com	Guney, Cengiz/Y-4620-2019	Guney, Cengiz/0000-0001-9052-741X			BERDON WE, 1976, AM J ROENTGENOL, V126, P957, DOI 10.2214/ajr.126.5.957; Friedmacher F, 2013, PEDIATR SURG INT, V29, P855, DOI 10.1007/s00383-013-3351-3; Gosemann JH, 2011, PEDIATR SURG INT, V27, P1041, DOI 10.1007/s00383-011-2954-9; Halim D, 2016, HUM MOL GENET, V25, P571, DOI 10.1093/hmg/ddv497; Kohler M, 2004, EUR J PEDIATR SURG, V14, P362, DOI 10.1055/s-2004-821208; Lee S, 2016, JPEN-PARENTER ENTER, V40, P437, DOI 10.1177/0148607114567200; Lopez-Munoz E, 2013, J PEDIATR UROL, V9, pE12, DOI 10.1016/j.jpurol.2012.05.017; Mantan M, 2011, Indian J Nephrol, V21, P212, DOI 10.4103/0971-4065.78075; Mc Laughlin D, 2013, PEDIATR SURG INT, V29, P947, DOI 10.1007/s00383-013-3357-x; O' Donnell AM, 2008, PEDIATR SURG INT, V24, P1191, DOI 10.1007/s00383-008-2235-4; Okada Mari, 2016, BMC Res Notes, V9, P196, DOI 10.1186/s13104-016-1997-3; Piotrowska AP, 2003, J PEDIATR SURG, V38, P749, DOI 10.1016/S0022-3468(03)00002-2; Puri Prem, 2005, Semin Pediatr Surg, V14, P58, DOI 10.1053/j.sempedsurg.2004.10.026; Puri P, 2012, SEMIN PEDIATR SURG, V21, P310, DOI 10.1053/j.sempedsurg.2012.07.005; Rolle U, 2002, PEDIATR SURG INT, V18, P2, DOI 10.1007/s003830200001; Sipponen T, 2009, J CLIN GASTROENTEROL, V43, P437, DOI 10.1097/MCG.0b013e31817d3f84; Thorson W, 2014, HUM GENET, V133, P737, DOI 10.1007/s00439-013-1406-0; Tuzovic L, 2015, FETAL DIAGN THER, V38, P296, DOI 10.1159/000381638; Wangler MF, 2015, GENEREVIEWS, P1993; Wangler MF, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004258; Wymer KM, 2016, J PEDIATR SURG, V51, P1565, DOI 10.1016/j.jpedsurg.2016.06.011	21	2	2	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					109	116		10.1080/15513815.2018.1445149			8	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100004	29608093				2019-10-28	
J	Caporalini, C; Moscardi, S; Tamburini, A; Pierossi, N; Di Maurizio, M; Buccoliero, AM				Caporalini, Chiara; Moscardi, Selene; Tamburini, Angela; Pierossi, Nicola; Di Maurizio, Marco; Buccoliero, Anna Maria			Inflammatory Myofibroblastic Tumor of the Tongue. Report of a Pediatric Case and Review of the Literature	FETAL AND PEDIATRIC PATHOLOGY			English	Review						Inflammatory myofibroblastic tumor; tongue; child; ALK-1; IMT	LYMPHOMA KINASE ALK; IMMUNOHISTOCHEMICAL FEATURES; PSEUDOTUMOR; EXPRESSION; P53	Background: Inflammatory myofibroblastic tumor (IMT) is an uncommon mesenchymal lesion composed of myofibroblastic and fibroblastic spindle cells, accompanied by inflammatory infiltration. IMT may occur in the tongue. Five cases have been previously reported at this site. Case Report: An inflammatory myofibroblastic tumor arose in the tongue of a 10 month old infant, confirmed by anaplastic lymphoma kinase (ALK) immunohistochemical staining and the clinical response to the tyrosine kinase inhibitor. Conclusions: IMT can occur in the tongue. This report highlights the differential diagnosis of IMT. ALK staining is both a helpful diagnostic marker and a predictive marker for targeted therapy in this tumor type.	[Caporalini, Chiara; Moscardi, Selene; Buccoliero, Anna Maria] A Meyer Childrens Univ Hosp, Pathol Unit, Florence, Italy; [Tamburini, Angela] A Meyer Childrens Univ Hosp, Hematol Oncol Serv, Florence, Italy; [Pierossi, Nicola] A Meyer Childrens Univ Hosp, Otolaryngol Unit, Florence, Italy; [Di Maurizio, Marco] A Meyer Childrens Univ Hosp, Pediat Radiol Unit, Florence, Italy	Caporalini, C (reprint author), A Meyer Childrens Univ Hosp, V le Pieraccini 24, I-50139 Florence, Italy.	chiaracaporalini@gmail.com		di maurizio, marco/0000-0002-4266-0918			Alassiri AH, 2016, AM J SURG PATHOL, V40, P1051, DOI 10.1097/PAS.0000000000000677; Bridge JA, 2001, AM J PATHOL, V159, P411, DOI 10.1016/S0002-9440(10)61711-7; Brooks JK, 2005, ORAL SURG ORAL MED O, V99, P716, DOI 10.1016/j.tripleo.2004.11.023; Buccoliero AM, 2014, PATHOL RES PRACT, V210, P1152, DOI 10.1016/j.prp.2014.03.011; Butrynski JE, 2010, NEW ENGL J MED, V363, P1727, DOI 10.1056/NEJMoa1007056; Chennouf A, 2017, CUREUS, V9, DOI 10.7759/cureus.1068; Chun YS, 2005, PEDIATR BLOOD CANCER, V45, P796, DOI 10.1002/pbc.20294; Coffin CM, 2007, AM J SURG PATHOL, V31, P509, DOI 10.1097/01.pas.0000213393.57322.c7; COFFIN CM, 1995, AM J SURG PATHOL, V19, P859, DOI 10.1097/00000478-199508000-00001; Coffin CM, 2002, PATHOLOGY GENETICS T, P91; Corao DA, 2009, PEDIATR DEVEL PATHOL, V12, P275, DOI 10.2350/08-03-0434.1; Gleizal A, 2007, BRIT J ORAL MAX SURG, V45, P423, DOI 10.1016/j.bjoms.2006.01.005; Ide F, 2000, ORAL ONCOL, V36, P300, DOI 10.1016/S1368-8375(99)00091-3; Jiang YH, 2009, J INT MED RES, V37, P867, DOI 10.1177/147323000903700332; Lourenco SV, 2014, DERMATOL ONLINE J, V18, P6; Lovly CM, 2014, CANCER DISCOV, V4, P889, DOI 10.1158/2159-8290.CD-14-0377; Minoo P, 2012, INT J CLIN EXP PATHO, V5, P397; Palaskar S, 2011, CONTEMP CLIN DENT, V2, P274, DOI 10.4103/0976-237X.91787; Pankaj C, 2001, ORAL DIS, V7, P315, DOI 10.1034/j.1601-0825.2001.00696.x; Saab ST, 2011, MODERN PATHOL, V24, P606, DOI 10.1038/modpathol.2010.226; Sukov WR, 2007, MODERN PATHOL, V20, P592, DOI 10.1038/modpathol.3800776; Swain RS, 2008, HUM PATHOL, V39, P410, DOI 10.1016/j.humpath.2007.07.012; Tothova Z, 2012, CURR OPIN ONCOL, V24, P409, DOI 10.1097/CCO.0b013e328354c155; Yucel Ekici N, 2013, CASE REP OTOLARYNGOL, V2013, P787	24	1	2	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					117	125		10.1080/15513815.2017.1385667			9	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100005	29336647				2019-10-28	
J	Lang, A; Dehner, LP				Lang, Adam; Dehner, Louis P.			Delayed Metastasis of Clear Cell Sarcoma of Kidney to Bladder After 7 Disease-Free Years	FETAL AND PEDIATRIC PATHOLOGY			English	Article						Clear cell sarcoma of kidney; bladder; delayed metastasis; Cyclin D1; inflammatory myofibroblastic tumor; rhabdomyosarcoma	CHILDHOOD-CANCER SURVIVOR; INTERNAL TANDEM DUPLICATION; TUMOR STUDY-GROUP; 5-YEAR SURVIVORS; LATE RECURRENCE; LATE MORTALITY; CYCLIN D1; BCOR; CARCINOMA; FUSIONS	Introduction: Clear cell sarcoma of the kidney (CCSK) is childhood neoplasm with its own distinctive pattern of metastasis and may appear after a disease free interval of 5 years or more. Materials and Methods: Histopathology and immunohistochemistry were available from the radical nephrectomy and the later partial cystectomy, which was performed after a seven disease-free interval. Results: The pathologic features of the primary tumor were those of a classic CCSK with a monotypic pattern of uniform rounded to ovoid tumor cells with a background network of delicate blood vessels. By contrast, the bladder recurrence had a myxoid hypocellular appearance (one of the known variant patterns of CCSK). Both tumors displayed immunopositivity for Cyclin-D1 and CD117 with a less intense reaction in the bladder metastasis. Conclusions: This case demonstrates that CCSK has the potential to metastasize after a prolonged disease-free interval and may have deceptively bland histopathologic features.	[Lang, Adam; Dehner, Louis P.] Washington Univ, Med Ctr, St Louis Childrens Hosp, Lauren V Ackerman Lab Surg Pathol,Barnes Jewish H, St Louis, MO 63110 USA	Dehner, LP (reprint author), Washington Univ, Med Ctr, Dept Immunol & Pathol, 660 So Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	dehner@path.wustl.edu					Argani P, 2000, AM J SURG PATHOL, V24, P4, DOI 10.1097/00000478-200001000-00002; Argani P, 2015, STERNBERGS DIAGNOSTI, P2034; Argani P, 2017, AM J SURG PATHOL, V41, P1702, DOI 10.1097/PAS.0000000000000926; Armstrong GT, 2010, J CLIN ONCOL, V28, P1224, DOI 10.1200/JCO.2009.24.4608; Armstrong GT, 2009, J CLIN ONCOL, V27, P2328, DOI 10.1200/JCO.2008.21.1425; Astolfi A, 2015, ONCOTARGET, V6, P40934, DOI 10.18632/oncotarget.5882; Aw SJ, 2015, PEDIATR DEVEL PATHOL, V18, P297, DOI 10.2350/14-12-1581-OA.1; Cimatti M, 2004, TUMORI J, V90, P342; Cutcliffe C, 2005, CLIN CANCER RES, V11, P7986, DOI 10.1158/1078-0432.CCR-05-1354; Fernandez CV, 2016, PRINCIPLES PRACTICE, P766; FLORINE BL, 1988, ORAL SURG ORAL MED O, V65, P567, DOI 10.1016/0030-4220(88)90139-9; Friedman DL, 2010, JNCI-J NATL CANCER I, V102, P1083, DOI 10.1093/jnci/djq238; Furtwangler R, 2013, EUR J CANCER, V49, P3497, DOI 10.1016/j.ejca.2013.06.036; Gomis R. R., 2016, MOL ONCOL; Gooskens SL, 2014, BRIT J CANCER, V111, P227, DOI 10.1038/bjc.2014.291; Gooskens SLM, 2012, EUR J CANCER, V48, P2219, DOI 10.1016/j.ejca.2012.04.009; Gooskens SL, 2016, GENE CHROMOSOME CANC, V55, P549, DOI 10.1002/gcc.22353; Hertel NT, 2003, ACTA PAEDIATR, V92, P439; Huppmann AR, 2011, PEDIATR DEVEL PATHOL, V14, P438, DOI 10.2350/11-01-0958-OA.1; Jones C, 2007, J CLIN PATHOL, V60, P1226, DOI 10.1136/jcp.2007.046441; Kao YC, 2016, AM J SURG PATHOL, V40, P1009, DOI 10.1097/PAS.0000000000000629; Kenny C, 2016, J PATHOL, V238, P617, DOI 10.1002/path.4693; Kitajima Kumiko, 2010, Case Rep Gastroenterol, V4, P93; Kusumakumary P, 1997, MED PEDIATR ONCOL, V28, P355, DOI 10.1002/(SICI)1096-911X(199705)28:5<355::AID-MPO5>3.3.CO;2-I; Laverdiere C, 2009, J NATL CANCER I, V101, P1131, DOI 10.1093/jnci/djp230; Lee SY, 2012, KOREAN J UROL, V53, P288, DOI 10.4111/kju.2012.53.4.288; Magro G, 2017, HUM PATHOL, V60, P58, DOI 10.1016/j.humpath.2016.07.038; Mattke AC, 2009, PEDIATR BLOOD CANCER, V52, P772, DOI 10.1002/pbc.21906; Mertens AC, 2007, PEDIATR BLOOD CANCER, V48, P723, DOI 10.1002/pbc.21114; Mirkovic J, 2015, HISTOPATHOLOGY, V67, P306, DOI 10.1111/his.12641; Norkin M, 2011, LEUKEMIA RES, V35, P139, DOI 10.1016/j.leukres.2010.09.016; Parikh SH, 1998, J PEDIAT HEMATOL ONC, V20, P165, DOI 10.1097/00043426-199803000-00016; Robison LL, 2014, NAT REV CANCER, V14, P61, DOI 10.1038/nrc3634; Roy A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9891; Santiago T, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26602; Santiago T, 2017, MODERN PATHOL, V30, P884, DOI 10.1038/modpathol.2017.12; Schroder H, 2016, CLIN EPIDEMIOL, V8, P461, DOI 10.2147/CLEP.S99508; Sturm D, 2016, CELL, V164, P1060, DOI 10.1016/j.cell.2016.01.015; Terracini B, 2013, EPIDEMIOL PREV, V37, P1; Vujanic GM, 2009, DIAGN HISTOPATHOL, V15, P501, DOI DOI 10.1016/J.MPDHP.2009.08.002; Wasilewski-Masker K, 2009, J NATL CANCER I, V101, P1709, DOI 10.1093/jnci/djp417; Wong MK, 2017, HISTOPATHOLOGY, DOI 10.111/his.13366	42	0	1	0	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					126	133		10.1080/15513815.2018.1435757			8	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100006	29509095				2019-10-28	
J	Tonni, G; Ruano, R; Sa, R; Peixoto, FM; Lopes, J; Werner, H				Tonni, Gabriele; Ruano, Rodrigo; Sa, Renato; Peixoto Filho, Fernando Maia; Lopes, Jorge; Werner, Heron			3D Virtual Broncoscopy before FETO Procedure in a Fetus with Severe, isolated Left Congenital Diaphragmatic Hernia	FETAL AND PEDIATRIC PATHOLOGY			English	Article						congenital diaphragmatic hernia; fetal MRI; FETO; fetal surgery; 3D virtual reality	FETOSCOPIC TRACHEAL OCCLUSION; ULTRASOUND	Introduction: Congenital diaphragmatic hernia (CDH) is a life-threatening event in severe forms and fetuses affected may benefit from in utero treatment by fetoscopic endotracheal occlusion (FETO). Materials and Methods: Application of 3D virtual bronchoscopy in a case of severe, isolated, left CDH before performing FETO procedure at 27 week's gestation is reported. Results: The 3D virtual imaging of the fetal trachea was technically useful in planning the real FETO procedure. FETO successfully promoted fetal lung growth by decreasing the herniation of abdominal organs into the thorax and decreasing the risk of pulmonary hypoplasia. Ultrasound calculation of lung to head ratio (LHR) and fetal-MRI were used to assess lung development following FETO procedure. Conclusion: 3D virtual fetal reality enabled the fetal surgeon to review and navigate on demand inside the upper airway, reducing the risk of unexpected intervention complications.	[Tonni, Gabriele] AUSL Reggio Emilia, Obstet & Gynceol, Guastalla, Italy; [Ruano, Rodrigo] Mayo Clin, Obstet & Gynecol, Maternal Fetal Med, Rochester, MN USA; [Sa, Renato] Univ Fed Fluminense Niteroi, Obstet & Gynecol, Rio De Janeiro, Brazil; [Peixoto Filho, Fernando Maia] Inst Fernandes Figueira Fiocruz, Fetal Med, Rio De Janeiro, Brazil; [Lopes, Jorge] Pontificia Univ Catolica Rio de Janeiro, Rio De Janeiro, Brazil; [Werner, Heron] CDPI, Radiol, Rio De Janeiro, Brazil	Tonni, G (reprint author), Via Amendola, I-142100 Reggio Emilia, Italy.	Tonni.Gabriele@ausl.re.it	Werner, Heron/W-1578-2019; PEIXOTO-FILHO, FERNANDO MAIA/J-8848-2015	PEIXOTO-FILHO, FERNANDO MAIA/0000-0001-8521-6393			Peralta CFA, 2011, REV BRAS GINECOL OBS, V33, P381, DOI 10.1590/S0100-72032011001200002; Araujo E, 2017, EUR J PEDIATR SURG, V27, P297, DOI 10.1055/s-0036-1587331; Belfort MA, 2017, OBSTET GYNECOL, V129, P20, DOI 10.1097/AOG.0000000000001749; Boloker J, 2002, J PEDIATR SURG, V37, P357, DOI 10.1053/jpsu.2002.30834; Deprest J, 2004, ULTRASOUND OBST GYN, V24, P594, DOI 10.1002/uog.1772; Deprest J, 2004, ULTRASOUND OBST GYN, V24, P121, DOI 10.1002/uog.1711; Le LD, 2012, J PEDIATR SURG, V47, P57, DOI 10.1016/j.jpedsurg.2011.10.020; Ruano R, 2015, ULTRASOUND OBST GYN, V45, P566, DOI 10.1002/uog.13420; Ruano R, 2012, ULTRASOUND OBST GYN, V39, P20, DOI 10.1002/uog.10142; Ruano R, 2012, OBSTET GYNECOL, V119, P93, DOI 10.1097/AOG.0b013e31823d3aea; Tonni G, 2010, FETAL PEDIATR PATHOL, V29, P69, DOI 10.3109/15513811003615005; Werner H, 2016, CONGENIT ANOM, V56, P46, DOI 10.1111/cga.12131; Werner H, 2015, MED ULTRASON, V17, P252, DOI 10.11152/mu.2013.2066.172.tert; Werner H, 2015, REV BRAS GINECOL OBS, V37, P149, DOI 10.1590/SO100-720320150005250	14	2	2	1	1	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					134	139		10.1080/15513815.2018.1445148			6	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100007	29608113				2019-10-28	
J	Han, M; Afshar, Y; Chon, AH; Scibetta, E; Rao, R; Chmait, RH				Han, Michelle; Afshar, Yalda; Chon, Andrew H.; Scibetta, Emily; Rao, Rashmi; Chmait, Ramen H.			Pseudoamniotic Band Syndrome Post Fetal Thoracoamniotic Shunting for Bilateral Hydrothorax (vol 36, pg 311, 2017)	FETAL AND PEDIATRIC PATHOLOGY			English	Correction																Han M, 2017, FETAL PEDIATR PATHOL, V36, P311, DOI 10.1080/15513815.2017.1313915	1	0	0	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1551-3815	1551-3823		FETAL PEDIATR PATHOL	Fetal Pediatr. Pathol.		2018	37	2					140	140		10.1080/15513815.2018.1459797			1	Pathology; Pediatrics	Pathology; Pediatrics	GF7PA	WOS:000432159100008					2019-10-28	
J	Bienfait, L; D'Haene, N; Catteau, X; Noel, JC				Bienfait, Lucie; D'Haene, Nicky; Catteau, Xavier; Noel, Jean-Christophe			PIK3CA and p53 Mutations by Next Generation Sequencing in Lymphoepithelioma-Like Carcinoma of the Endometrium	CASE REPORTS IN PATHOLOGY			English	Article							EPSTEIN-BARR-VIRUS; CANCER; CERVIX; OVARY; NECK; HEAD	Lymphoepithelioma-like carcinoma of the endometriumis a very rare variant of endometrial carcinoma characterized by syncytial nests of pleomorphic epithelial cells and heavy infiltration of the stroma by lymphocytes (in particular CD8 cytotoxic T-lymphocytes) and plasma cells. Until now, only five cases have been characterized in this location. This report describes the clinicopathological and the molecular features of this unusual tumor. In particular, using the next generation sequencing (NGS) technique, we have demonstrated that this tumor could be associated with PIK3CA and p53 gene mutations. These data have not been reported to date and suggest that lymphoepithelioma-like carcinoma of the endometrium shares common molecular features with high grade endometrioid and serous-like endometrial carcinoma which are associated with poor outcome. Nevertheless, in endometrial lymphoepithelioma-like carcinoma, the alterations on cell cycle, apoptosis, and/or senescence secondary to p53 mutations could potentially be counterbalanced by the antitumoral response induced by CD8 cytotoxic T-lymphocytes numerous in these tumors.	[Bienfait, Lucie; D'Haene, Nicky; Catteau, Xavier; Noel, Jean-Christophe] Free Univ Brussels ULB, Erasme Univ Hosp Curepath, Dept Pathol, Brussels, Belgium	Noel, JC (reprint author), Free Univ Brussels ULB, Erasme Univ Hosp Curepath, Dept Pathol, Brussels, Belgium.	jean-christophe.noel@erasme.ulb.ac.be					AMBINDER RF, 1994, HUM PATHOL, V25, P602, DOI 10.1016/0046-8177(94)90227-5; Ambrosio MR, 2010, PATHOLOGICA, V102, P57; Ambrosio MR, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-115; Ambrosio MR, 2011, INT J SURG PATHOL, V19, P514, DOI 10.1177/1066896909354336; Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005; Bosmuller H, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-4; Brun JL, 2010, INT J GYNECOL PATHOL, V29, P427, DOI 10.1097/PGP.0b013e3181db69da; Castro FA, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1281-5; Catteau X, 2016, MOL CLIN ONCOL, V5, P372, DOI 10.3892/mco.2016.975; Catteau X, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-499; D'Haene N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138245; de Cremoux P, 1999, J NATL CANCER I, V91, P641, DOI 10.1093/jnci/91.7.641; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Goebel E. A., 2017, VIRCHOWS ARCH, P1; Jones H, 2014, INT J GYNECOL PATHOL, V33, P64, DOI 10.1097/PGP.0b013e318276310b; Makannavar JH, 2015, INDIA J SURG ONCOL, V6, P130, DOI 10.1007/s13193-015-0405-0; McCluggage WG, 2001, J CLIN PATHOL, V54, P964, DOI 10.1136/jcp.54.12.964; Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6; Noel JCR, 2001, HUM PATHOL, V32, P135, DOI 10.1053/hupa.2001.20901; Pascual-Garcia M, 2016, HUM PATHOL, V56, P180, DOI 10.1016/j.humpath.2016.05.025; PHILLOTT AD, 2017, INDIAN OCEAN TUR JUL, P1; Rahimi S, 2007, INT J GYNECOL CANCER, V17, P532, DOI 10.1111/j.1525-1438.2007.00793.x; Saylam K, 2002, ACTA OBSTET GYN SCAN, V81, P564; Vargas MP, 1998, INT J GYNECOL PATHOL, V17, P272, DOI 10.1097/00004347-199807000-00013; Vierkoetter KR, 2016, INT J GYNECOL CANCER, V26, P228, DOI 10.1097/IGC.0000000000000606; Welch PQ, 2011, ORAL SURG ORAL MED O, V111, P78, DOI 10.1016/j.tripleo.2010.05.075; Wenig BM, 2015, SEMIN DIAGN PATHOL, V32, P74, DOI 10.1053/j.semdp.2014.12.004; Yun Hyun Sil, 2017, Obstet Gynecol Sci, V60, P118, DOI 10.5468/ogs.2017.60.1.118	28	1	1	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5894589	10.1155/2018/5894589			5	Pathology	Pathology	GF6IP	WOS:000432070800001	29854528	DOAJ Gold, Green Published			2019-10-28	
J	Erinanc, H; Turk, E				Erinanc, Hilal; Turk, Emin			The Rare Benign Lesion That Mimics a Malignant Tumor in Breast Parenchyma: Nodular Fasciitis of the Breast	CASE REPORTS IN PATHOLOGY			English	Article								We herein report the clinical and pathological findings of a rare case of nodular fasciitis in the breast parenchyma of a 48-year-old female. Because of potentially malignant findings on ultrasonography and during clinical examination, the patient underwent an excisional biopsy. Histologically, the lesion was composed of spindle to round shaped cells arranged in short bundles in a storiform pattern. Immunohistochemically, the cells were positive for vimentin and SMA and negative for desmin, S100, and CD34. Based on these morphological and immunohistochemical features, a diagnosis of nodular fasciitis was made. We emphasize that nodular fasciitis of the breast may showclinical features and imaging findings similar to those of breast cancer. The histopathologic diagnosis of nodular fasciitis can also be challenging. The purpose of this case report is to highlight the characteristics and the differential diagnosis of this rare neoplasm.	[Erinanc, Hilal] Baskent Univ, Konya Uygulama & Arastirma Hastanesi, Med Fac, Pathol Dept, Selcuklu, Konya, Turkey; [Turk, Emin] Baskent Univ, Konya Uygulama & Arastirma Hastanesi, Med Fac, Surg Dept, Selcuklu, Konya, Turkey	Erinanc, H (reprint author), Baskent Univ, Konya Uygulama & Arastirma Hastanesi, Med Fac, Pathol Dept, Selcuklu, Konya, Turkey.	hilalerinanc@yahoo.com					Brown V, 2005, BREAST, V14, P384, DOI 10.1016/j.breast.2004.09.014; Dahlstrom J, 2001, Australas Radiol, V45, P67, DOI 10.1046/j.1440-1673.2001.00879.x; Goldblum J. R., 2014, BENIGN FIBROBLASTIK; Graham BS, 1999, J AM ACAD DERMATOL, V40, P490, DOI 10.1016/S0190-9622(99)70506-2; Hayashi Hironori, 2007, Breast Cancer, V14, P337, DOI 10.2325/jbcs.14.337; Hayashi Satoshi, 2017, J Med Case Rep, V11, P57, DOI 10.1186/s13256-017-1219-1; Maly B, 2001, ACTA CYTOL, V45, P794, DOI 10.1159/000328308; Melinda F. L., 2014, BENIGN MESENCHYMAL N; Paliogiannis P, 2016, BREAST CARE, V11, P270, DOI 10.1159/000448185; Sinn HP, 2013, BREAST CARE, V8, P149, DOI 10.1159/000350774; Squillaci S, 2007, INT J SURG PATHOL, V15, P69, DOI 10.1177/1066896906295999; Tulbah Asma, 2003, Breast J, V9, P223, DOI 10.1046/j.1524-4741.2003.09318.x; Velagaleti GVN, 2003, CANCER GENET CYTOGEN, V141, P160, DOI 10.1016/S0165-4608(02)00725-2; Yanagisawa A, 2008, J CRANIOFAC SURG, V19, P1167, DOI 10.1097/SCS.0b013e318176ac1a	14	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1612587	10.1155/2018/1612587			3	Pathology	Pathology	GF6IJ	WOS:000432070200001	29854526	DOAJ Gold, Green Published			2019-10-28	
J	Murshid, AA; Al-Maghraby, HQ				Murshid, Areen Abdulelah; Al-Maghraby, Hatim Q.			Subsequent Development of Desmoid Tumor after a Resected Gastrointestinal Stromal Tumor	CASE REPORTS IN PATHOLOGY			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; INTRAABDOMINAL FIBROMATOSIS; IMATINIB; MIMICKING; MUTATIONS; DISEASE; GIST	Desmoid tumors (deep fibromatosis) of the mesentery are rare mesenchymal tumors. They are often misdiagnosed, especially with a previous history of resection for gastrointestinal stromal tumor (GIST). Immunohistochemistry can help differentiate between these two tumors. In this article, we present a case we had encountered: a Desmoid tumor developing in a patient with a history of GIST 3 years ago. It is the first case of GIST with subsequent development of Desmoid tumor to be reported in Saudi Arabia. We discuss the two entities of Desmoid tumor and GIST by comparing their definitions, clinical presentations, histological features, immunohistochemistry stains, molecular pathogenesis, prognosis, and treatment. We also discuss the relationship between GIST and the subsequent development of Desmoid tumors and compare our case with case reports in literature.	[Murshid, Areen Abdulelah] King Abdulaziz Univ Hosp, Dept Pathol, Jeddah, Saudi Arabia; [Al-Maghraby, Hatim Q.] King Saud Bin Abdulaziz Univ Hlth Sci, Dept Pathol & Lab Med, Jeddah, Saudi Arabia	Al-Maghraby, HQ (reprint author), King Saud Bin Abdulaziz Univ Hlth Sci, Dept Pathol & Lab Med, Jeddah, Saudi Arabia.	drpathology@gmail.com		AlMaghrabi, Hatim/0000-0002-0074-2245			Agaram NP, 2008, GENE CHROMOSOME CANC, V47, P853, DOI 10.1002/gcc.20589; BURKE AP, 1990, AM J SURG PATHOL, V14, P335, DOI 10.1097/00000478-199004000-00004; BURKE MAP, 1990, ARCH PATHOL LAB MED, V114, P832; Colombo P, 2005, WORLD J GASTROENTERO, V11, P5226; Dumont AG, 2012, ANN ONCOL, V23, P1335, DOI 10.1093/annonc/mdr442; Ferreira SS, 2010, INT J SURG, V8, P314, DOI 10.1016/j.ijsu.2010.03.008; Folli F, 2006, DIABETES CARE, V29, P2178, DOI 10.2337/dc06-0984; Heinrich MC, 2006, J CLIN ONCOL, V24, P1195, DOI 10.1200/JCO.2005.04.0717; Ishizuka M, 2006, TOHOKU J EXP MED, V210, P189, DOI 10.1620/tjem.210.189; Jiang DX, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-125; Khan M, 2010, RARE TUMORS, V2, P91, DOI 10.4081/rt.2010.e33; Kotiligam D, 2008, HISTOL HISTOPATHOL, V23, P117, DOI 10.14670/HH-23.117; Lazar AJF, 2008, AM J PATHOL, V173, P1518, DOI 10.2353/ajpath.2008.080475; Lee CK, 2009, WORLD J SURG ONCOL, V7, DOI 10.1186/1477-7819-7-8; Miettinen M, 2011, AM J SURG PATHOL, V35, P1712, DOI 10.1097/PAS.0b013e3182260752; Patel SR, 2006, J CLIN ONCOL, V24, P11, DOI 10.1200/JCO.2005.03.6566; PENNA C, 1993, SURG GYNECOL OBSTET, V177, P263; Pinheiro LV, 2014, INT J SURG CASE REP, V5, P370, DOI 10.1016/j.ijscr.2014.04.018; Ravi V., 2016, DESMOID TUMORS EPIDE; Robinson William A, 2012, Cancers (Basel), V4, P184, DOI 10.3390/cancers4010184; Rosai J., 2016, INT J SURG PATHOL, V11, P177; Soravia C, 2000, DIS COLON RECTUM, V43, P363, DOI 10.1007/BF02258303; Yantiss RK, 2000, AM J SURG PATHOL, V24, P947, DOI 10.1097/00000478-200007000-00006	23	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1082956	10.1155/2018/1082956			5	Pathology	Pathology	GF6IF	WOS:000432069800001	29854525	DOAJ Gold, Green Published			2019-10-28	
J	Puvabanditsin, S; Burger, R; Puthenpura, V; Walzer, L; Madubuko, A; Minerowicz, C; Mehta, R				Puvabanditsin, Surasak; Burger, Robin; Puthenpura, Vidya; Walzer, Lauren; Madubuko, Adaora; Minerowicz, Christine; Mehta, Rajeev			A Giant Gastroschisis Associated with Pulmonary Hypoplasia and Spinal Anomaly: A Case Report and a Literature Review	CASE REPORTS IN PATHOLOGY			English	Review							ABDOMINAL-WALL DEFECTS	Gastroschisis most often occurs as an isolated anomaly and extragastrointestinal associations are rare. Most commonly, the anomalies associated with gastroschisis are cardiac and central nervous system abnormalities. Respiratory insufficiency has sometimes been reported in association with giant abdominal wall defects. Poor outcomes and prolonged ventilator support have been reported in giant gastroschisis and omphalocele, especially if associated with herniation of the majority of the liver. We report a case of a large gastroschisis that was associated with a kyphoscoliosis and pulmonary hypoplasia.	[Puvabanditsin, Surasak; Puthenpura, Vidya; Walzer, Lauren; Madubuko, Adaora; Mehta, Rajeev] Rutgers Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08854 USA; [Burger, Robin; Minerowicz, Christine] Rutgers Robert Wood Johnson Med Sch, Dept Pathol, New Brunswick, NJ USA	Puvabanditsin, S (reprint author), Rutgers Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08854 USA.	surasak1@aol.com					ARGYLE J C, 1989, Pediatric Pathology, V9, P43; Baerg J, 2003, J PEDIATR SURG, V38, P771, DOI 10.1016/S0022-3468(03)00008-3; Barisic I, 2001, ULTRASOUND OBST GYN, V18, P309, DOI 10.1046/j.0960-7692.2001.00534.x; Byron-Scott R, 1998, PAEDIATR PERINAT EP, V12, P136, DOI 10.1046/j.1365-3016.1998.00090.x; Chen XK, 2007, HUM REPROD, V22, P1730, DOI 10.1093/humrep/dem043; Christison-Lagay ER, 2011, SEMIN FETAL NEONAT M, V16, P164, DOI 10.1016/j.siny.2011.02.003; Corey KM, 2014, EARLY HUM DEV, V90, P421, DOI 10.1016/j.earlhumdev.2014.05.006; Curry JI, 2000, BRIT J OBSTET GYNAEC, V107, P1339, DOI 10.1111/j.1471-0528.2000.tb11645.x; Danzer E, 2012, FETAL DIAGN THER, V31, P248, DOI 10.1159/000334284; Feldkamp ML, 2007, AM J MED GENET A, V143A, P639, DOI 10.1002/ajmg.a.31578; Fratelli N, 2007, ULTRASOUND OBST GYN, V30, P266, DOI 10.1002/uog.4086; Frolov P, 2010, PEDIATR SURG INT, V26, P1135, DOI 10.1007/s00383-010-2701-7; Kazaura MR, 2004, AM J EPIDEMIOL, V159, P358, DOI 10.1093/aje/kwh051; Pakdaman R, 2015, RADIOGRAPHICS, V35, P636, DOI 10.1148/rg.352140104; Panitch HB, 2015, PAEDIATR RESPIR REV, V16, P11, DOI 10.1016/j.prrv.2014.10.004; Prendergast M, 2011, BJOG-INT J OBSTET GY, V118, P608, DOI 10.1111/j.1471-0528.2010.02841.x	16	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									8378769	10.1155/2018/8378769			4	Pathology	Pathology	GF6IT	WOS:000432071200001	29854529	DOAJ Gold, Green Published			2019-10-28	
J	Baumgartner, E; Ullman, D; Jones, JA; Fasciano, D; Atherton, DS; Pavlidakey, P; Peker, D				Baumgartner, Erin; Ullman, David; Jones, Jeffrey Adam; Fasciano, Danielle; Atherton, Daniel S.; Pavlidakey, Peter; Peker, Deniz			Postradiation Histiocytic Sarcoma in the Setting of Muir-Torre Syndrome	CASE REPORTS IN PATHOLOGY			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; HEREDITARY; MSH6	Hereditary nonpolyposis colorectal carcinoma (HNPCC) is an autosomal dominant genetic disorder characterized by a predisposition towards colorectal carcinoma and other extracolonic neoplasms. Histiocytic sarcoma (HS) is a very rare hematologic neoplasm characterized by a malignant proliferation of cells with histiocytic differentiation. We present the case of a 62-year-old male with previous diagnosis of MTS who presented with metastatic colorectal adenocarcinoma, bilateral papillary renal cell carcinoma, and a new squamous cell carcinoma of the scalp, treated with resection and adjuvant radiation therapy. After reconstructive surgery for his scalp resection, the patient developed a persistent nonhealing skin defect. A punch biopsy of this nonhealing skin defect and subsequent immunohistochemistry revealed neoplastic histiocytic cells restricted to the epidermis and underlying dermis. The diagnosis of cutaneous histiocytic sarcoma was then rendered. Histiocytic sarcoma is an exceptionally rare malignancy. Consequently, there is no universally agreed upon management protocol for this malignancy. The patient was admitted to hospice and treated with palliative radiation. This case demonstrates the need for awareness of the risk of secondary malignancies in cancer patients in order to facilitate early surgical intervention and optimal treatment.	[Baumgartner, Erin; Ullman, David; Jones, Jeffrey Adam; Fasciano, Danielle; Atherton, Daniel S.; Peker, Deniz] UAB, Dept Pathol, Birmingham, AL 35294 USA; [Pavlidakey, Peter] UAB, Dept Dermatol, Birmingham, AL USA	Ullman, D (reprint author), UAB, Dept Pathol, Birmingham, AL 35294 USA.	diullman@uabmc.edu					Bandipalliam P, 2005, FAM CANCER, V4, P323, DOI 10.1007/s10689-005-8351-6; Caldes T., 2004, ONCOLOGY REPORTS; Godley LA, 2008, SEMIN ONCOL, V35, P418, DOI 10.1053/j.seminoncol.2008.04.012; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; LYNCH HT, 1985, CANCER, V56, P934, DOI 10.1002/1097-0142(19850815)56:4<934::AID-CNCR2820560439>3.0.CO;2-I; Mahalingam M, 2017, AM J DERMATOPATH, V39, P239, DOI 10.1097/DAD.0000000000000633; Ramsoekh D, 2009, HERED CANCER CLIN PR, V7, DOI 10.1186/1897-4287-7-17; Sijmons R, 2000, GENE CHROMOSOME CANC, V29, P353, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1042>3.0.CO;2-T; Takahashi E, 2013, J CLIN EXP HEMATOP, V53, P1; Trevisan F, 2013, AN BRAS DERMATOL, V88, P807, DOI 10.1590/abd1806-4841.20132070; Wells K, 2017, SURG CLIN N AM, V97, P605, DOI 10.1016/j.suc.2017.01.009; Wu WN, 2013, HUM PATHOL, V44, P1177, DOI 10.1016/j.humpath.2012.11.002; Yozu M, 2013, VIRCHOWS ARCH, V462, P355, DOI 10.1007/s00428-012-1369-x	13	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5947870	10.1155/2018/5947870			4	Pathology	Pathology	GE9OA	WOS:000431557800001	29850341	DOAJ Gold, Green Published			2019-10-28	
J	Salimian, KJ; Fazeli, R; Zheng, G; Ettinger, D; Maleki, Z				Salimian, Kevan J.; Fazeli, Roghayeh; Zheng, Gang; Ettinger, David; Maleki, Zahra			V600E BRAF versus Non-V600E BRAF Mutated Lung Adenocarcinomas: Cytomorphology, Histology, Coexistence of Other Driver Mutations and Patient Characteristics	ACTA CYTOLOGICA			English	Article						BRAF; Lung adenocarcinoma; Cytology; Next-generation sequencing; Fine-needle aspiration	CLINICAL CHARACTERISTICS; CANCER; MELANOMA; INHIBITION; FEATURES; CHEMOTHERAPY; CRIZOTINIB; THERAPY	Objectives: We analyzed the morphologic features and clinical characteristics of lung adenocarcinomas (ACAs) harboring mutated BRAF. Study Design: A review of the histology/cytology of BRAF-mutated lung ACAs was performed at the Johns Hopkins Hospital from January 1, 2013, to January 1, 2015. Patient demographics, clinical history, and ACA morphology were assessed. Results: Thirty-six cases were identified with a median age of 66 years (range 44-87), 58% (21/36) were female, and 94% (34/36) were current or former smokers. In total, 28% (10/36) had a BRAF-V600E mutation. Concurrent mutations were identified in KRAS in 4 cases (11%), PIK3CA in 2 cases (6%), and AKT1 in 2 cases (6%). No cases tested for ALK rearrangement were positive. The tumor grading varied from well to poorly differentiated, and the architecture assumed various patterns, including papillary, micropapillary, solid/cribriform, lepidic, and acinar. Of the cases with immunostains, 90% (18/20) were TTF-1 positive, 88% (14/16) were napsin-A positive, and 100% (8/8) were P63 negative. Conclusion: Mutated-BRAF lung ACA arose on average in the seventh decade of life in patients who were current or former smokers and was infrequently found in combination with other common lung ACA driver mutations. The actionable V600E mutation was present in <30% of cases, more commonly in females. The histologic grade and architecture of these tumors varied significantly. (C) 2018 S. Karger AG, Basel	[Salimian, Kevan J.; Zheng, Gang; Maleki, Zahra] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA; [Ettinger, David] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA; [Fazeli, Roghayeh] Boston Univ, Dept Pathol, Boston, MA 02215 USA	Maleki, Z (reprint author), Dept Pathol, Div Cytol, 600 N Wolfe St,Pathol 412C, Baltimore, MD 21287 USA.	zmaleki1@jhmi.edu		Zheng, Gang/0000-0003-0276-9430			Brose MS, 2002, CANCER RES, V62, P6997; Cardarella S, 2013, CLIN CANCER RES, V19, P4532, DOI 10.1158/1078-0432.CCR-13-0657; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Gerber DE, 2010, CANCER CELL, V18, P548, DOI 10.1016/j.ccr.2010.11.033; Kinno T, 2014, ANN ONCOL, V25, P138, DOI 10.1093/annonc/mdt495; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Litvak AM, 2014, J THORAC ONCOL, V9, P1669, DOI 10.1097/JTO.0000000000000344; Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Myall Nathaniel J, 2016, Clin Lung Cancer, V17, pe17, DOI 10.1016/j.cllc.2015.12.001; Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Shaw AT, 2011, LANCET ONCOL, V12, P1004, DOI 10.1016/S1470-2045(11)70232-7; Shea M, 2016, THER ADV RESPIR DIS, V10, P113, DOI 10.1177/1753465815617871; Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221; Wong DJL, 2016, CANCER TREAT RES, V167, P251, DOI 10.1007/978-3-319-22539-5_10; Zheng G, 2016, CANCER CYTOPATHOL, V124, P744, DOI 10.1002/cncy.21743; Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y	19	1	1	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					79	84		10.1159/000485497			6	Pathology	Pathology	GE3QY	WOS:000431129100001	29320776				2019-10-28	
J	Erivwo, P; Ghosh, C				Erivwo, Polycarp; Ghosh, Chandrani			Atypia of Undetermined Significance in Thyroid Fine-Needle Aspirations: Follow-Up and Outcome Experience in Newfoundland, Canada	ACTA CYTOLOGICA			English	Article						Atypia of undetermined significance; Fine-needle aspiration; The Bethesda System; Thyroid cytopathology; Malignancy rate; AUS diagnosis rate	BETHESDA SYSTEM; NODULES; MALIGNANCY; CATEGORY; SOLITARY; TERMINOLOGY; PREVALENCE; LESIONS; BENIGN; STATE	Introduction: The rates of atypia of undetermined significance (AUS) by fine-needle aspiration (FNA) and malignant outcomes have been estimated at <7% and 5-15%, respectively. Initial AUS diagnosis is followed up clinically with serial ultrasounds, repeat FNA, molecular testing, or direct surgery. We investigated the incidence, follow-up modalities, and final outcomes of AUS in Newfoundland. Methods: All cases of AUS diagnosed at the Eastern Health Cytology Laboratory between 1 January 2010 and 31 December 2013 were identified. Electronic medical records were examined for follow-up modalities and final histologic diagnosis. The final outcomes were reported as benign, malignant, or undetermined. Results: Out of 3,285 thyroid FNAs, 181 (5.5%) were AUS. Fifty-seven (31.5%) had repeat FNA diagnosed as benign (38.6%), AUS (29.8%), or suspicious/malignant (8.8%). Eighty-four (46.4%) had surgery after the first AUS diagnosis, 39 (46.4%) of which were malignant. Twenty-four patients (13.3%) were followed up by serial ultrasound only, 2 (1.1%) by molecular testing, and 1 (0.6%) died of unrelated disease. Thirteen (7.2%) had no follow-up record. Our malignancy rate (MR) was 29.8%. Conclusion: The MR in our population was higher than the rate proposed by The Bethesda System for Reporting Thyroid Cytopathology. Repeat FNA can reduce the rate of unnecessary surgeries, but practice guidelines should consider individual and institutional circumstances. The ratio MR: ADR (AUS diagnostic rate) may be a better indicator of performance. (C) 2018 S. Karger AG, Basel	[Erivwo, Polycarp] Mem Univ, Lab Med Program, Discipline Anat Pathol, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada; [Erivwo, Polycarp] Eastern Hlth, Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada	Erivwo, P (reprint author), Mem Univ, Lab Med Program, Discipline Anat Pathol, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.; Erivwo, P (reprint author), Eastern Hlth, Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.	perivwo@yahoo.com					Akhtar I, 2013, J AM SOC CYTOPATHOL, V2, pS47; Asanuma K, 2001, EUR J SURG, V167, P102; Baloch ZW, 2010, BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: DEFINITIONS, CRITERIA AND EXPLANATORY NOTES, P1, DOI 10.1007/978-0-387-87666-5_1; Boelaert K, 2006, J CLIN ENDOCR METAB, V91, P4295, DOI 10.1210/jc.2006-0527; Cibas ES, 2009, AM J CLIN PATHOL, V132, P658, DOI 10.1309/AJCPPHLWMI3JV4LA; Fazeli R, 2015, ACTA CYTOL, V59, P225, DOI 10.1159/000379738; Frates MC, 2006, J CLIN ENDOCR METAB, V91, P3411, DOI 10.1210/jc.2006-0690; Harvey AM, 2013, ARCH PATHOL LAB MED, V137, P1664, DOI 10.5858/arpa.2012-0366-OA; Ho AS, 2014, THYROID, V24, P832, DOI 10.1089/thy.2013.0317; HUNG W, 1992, J PEDIATR SURG, V27, P1407, DOI 10.1016/0022-3468(92)90187-C; Iskandar ME, 2015, SURGERY, V157, P510, DOI 10.1016/j.surg.2014.10.004; Jo VY, 2010, AM J CLIN PATHOL, V134, P450, DOI 10.1309/AJCP5N4MTHPAFXFB; Kamran SC, 2013, J CLIN ENDOCR METAB, V98, P564, DOI 10.1210/jc.2012-2968; Krane JF, 2012, CANCER CYTOPATHOL, V120, P111, DOI 10.1002/cncy.20192; KUMA K, 1992, WORLD J SURG, V16, P583, DOI 10.1007/BF02067327; Layfield LJ, 2008, DIAGN CYTOPATHOL, V36, P442, DOI 10.1002/dc.20832; Layfield LJ, 2009, DIAGN CYTOPATHOL, V37, P710, DOI 10.1002/dc.21093; Mondal SK, 2013, J CYTOL, V30, P94, DOI 10.4103/0970-9371.112650; Moon WJ, 2008, RADIOLOGY, V247, P762, DOI 10.1148/radiol.2473070944; Nayar R, 2009, CANCER CYTOPATHOL, V117, P195, DOI 10.1002/cncy.20029; Ozluk Y, 2011, INT J SURG PATHOL, V19, P761, DOI 10.1177/1066896911415667; Renshaw AA, 2010, CANCER CYTOPATHOL, V118, P186, DOI 10.1002/cncy.20091; Shi Y, 2009, CANCER CYTOPATHOL, V117, P298, DOI 10.1002/cncy.20039; Theoharis CGA, 2009, THYROID, V19, P1215, DOI 10.1089/thy.2009.0155; VanderLaan PA, 2011, AM J CLIN PATHOL, V135, P770, DOI 10.1309/AJCP4P2GCCDNHFMY; Witt B, 2012, J AM SOC CYTOPATHOL, V1, pS67; Witt BL, 2013, THYROID, V23, P428, DOI 10.1089/thy.2012.0211	27	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					85	92		10.1159/000486779			8	Pathology	Pathology	GE3QY	WOS:000431129100002	29486467				2019-10-28	
J	Suzuki, A; Hirokawa, M; Ito, A; Takada, N; Higuchi, M; Hayashi, T; Kuma, S; Miyauchi, A				Suzuki, Ayana; Hirokawa, Mitsuyoshi; Ito, Aki; Takada, Nami; Higuchi, Miyoko; Hayashi, Toshitetsu; Kuma, Seiji; Miyauchi, Akira			Identification of Cytological Features Distinguishing Mucosa-Associated Lymphoid Tissue Lymphoma from Reactive Lymphoid Proliferation Using Thyroid Liquid-Based Cytology	ACTA CYTOLOGICA			English	Article						Thyroid; Lymphoma; Mucosa-associated lymphoid tissue; Liquid-based cytology; Hashimoto thyroiditis	NEEDLE-ASPIRATION-CYTOLOGY; CONVENTIONAL SMEARS; RISK-FACTOR; EXPERIENCE; SPECIMENS; THINPREP; SAMPLES	Objective: To identify cytological differences between mucosa-associated lymphoid tissue lymphoma (MALT-L) and nonneoplastic lymphocytes using thyroid liquid-based cytology (LBC). Study Design: We observed LBC and conventional specimens from 35 MALT-L cases, 3 diffuse large B-cell cell lymphoma (DLBCL) cases, and 44 prominent nonneoplastic lymphocytic infiltration cases. Results: In MALT-L cases, the incidence of lymphoglandular bodies in the LBC specimens was lower than that in the conventional specimens (p < 0.001). Moreover, the nuclear sizes in LBC specimens were larger than those in conventional specimens. In 62.9% of the MALT-L and all DLBCL specimens, large nuclei were present in >10% of the lymphoid cells in LBC specimens. Two cases with prominent nonneoplastic lymphocytic infiltration also exhibited these findings. In LBC specimens, swollen naked nuclei with less punctate chromatin patterns and thin nuclear margins were observed in 92.1% of lymphoma and 20.5% of prominent nonneoplastic lymphocytic infiltration. Elongated nuclei were significantly more apparent in thyroid lymphoma than in prominent nonneoplastic lymphocytic infiltration (p < 0.001), with a significantly higher incidence in LBC specimens than in conventional specimens (p < 0.001). Conclusions: Lymphoglandular bodies are not reliable markers for lymphoma diagnosis using LBC specimens. Large, swollen naked, and elongated nuclei are useful in distinguishing thyroid lymphoma from nonneoplastic lymphocytes in LBC specimens. (C) 2018 The Author(s) Published by S. Karger AG, Basel	[Suzuki, Ayana; Ito, Aki; Takada, Nami; Higuchi, Miyoko] Kuma Hosp, Dept Clin Lab, Kobe, Hyogo, Japan; [Hirokawa, Mitsuyoshi; Hayashi, Toshitetsu; Kuma, Seiji] Kuma Hosp, Dept Diagnost Pathol & Cytol, Kobe, Hyogo, Japan; [Miyauchi, Akira] Kuma Hosp, Dept Surg, Kobe, Hyogo, Japan	Suzuki, A (reprint author), Kuma Hosp, Dept Clin Lab, Chuo Ku, 8-2-35 Shimoyamate Dori, Kobe, Hyogo 6500011, Japan.	suzuki01@kuma-h.or.jp					Abraham LK, 2014, INT SURG J, V1, P53; Alzouebi M, 2012, INT J ONCOL, V40, P2075, DOI 10.3892/ijo.2012.1387; AOZASA K, 1990, ACTA PATHOL JAPON, V40, P459; Chan JK, 2007, DIAGNOSTIC HISTOPATH, V2, P1197; DeMay RM, 2012, ART SCI CYTOPATHOLOG, V2, P929; Fischer AH, 2013, ARCH PATHOL LAB MED, V137, P26, DOI 10.5858/arpa.2012-0009-CP; Ford L, 2002, OTOLARYNG HEAD NECK, V126, P554, DOI 10.1067/mhn.2002.124704; Gatter KC, 2001, PATHOLOGY GENETICS T, P171; Hirokawa M, 2016, THYROID FNA CYTOLOGY, P125; Hirokawa M, 2017, ENDOCR J, V64, P859, DOI 10.1507/endocrj.EJ17-0111; Jung CK, 2008, ACTA CYTOL, V52, P313, DOI 10.1159/000325513; KATO I, 1985, JPN J CANCER RES, V76, P1085; Layfield LJ, 2010, BETHESDA SYSTEM FOR REPORTING THYROID CYTOPATHOLOGY: DEFINITIONS, CRITERIA AND EXPLANATORY NOTES, P153, DOI 10.1007/978-0-387-87666-5_12; Mygdakos N, 2009, ROM J MORPHOL EMBRYO, V50, P245; Rossi ED, 2010, CYTOPATHOLOGY, V21, P97, DOI 10.1111/j.1365-2303.2009.00659.x; Sangalli G, 2001, CYTOPATHOLOGY, V12, P257, DOI 10.1046/j.1365-2303.2001.00338.x; Stein SA, 2013, J CLIN ENDOCR METAB, V98, P3131, DOI 10.1210/jc.2013-1428; Suzuki A, 2016, DIAGN CYTOPATHOL, V44, P659, DOI 10.1002/dc.23500; Suzuki A, 2015, DIAGN CYTOPATHOL, V43, P108, DOI 10.1002/dc.23191; Thompson LDR, 2009, DIAGNOSTIC PATHOLOGY, P333; Walsh S, 2013, ONCOLOGIST, V18, P994, DOI 10.1634/theoncologist.2013-0036	21	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					93	98		10.1159/000487502			6	Pathology	Pathology	GE3QY	WOS:000431129100003	29597203	Green Published, Other Gold			2019-10-28	
J	Rammeh, S; Romdhane, E; Toumi, AA; Houcine, Y; Lahiani, R; Sassi, A; Mardassi, H; Ben Salah, M; Ferjaoui, M				Rammeh, Soumaya; Romdhane, Emna; Toumi, Amira Arfaoui; Houcine, Yoldez; Lahiani, Rym; Sassi, Asma; Mardassi, Helmi; Ben Salah, Mamia; Ferjaoui, Mohamed			Efficacy of Fine-Needle Aspiration Cytology in the Diagnosis of Tuberculous Cervical Lymphadenitis	ACTA CYTOLOGICA			English	Article						Culture; Fine-needle aspiration cytology; Lymph node; Tuberculosis; Ziehl-Neelsen stain	LYMPHADENOPATHY; PCR	Objective: This study assesses the role of fine-needle aspiration cytology (FNAC) in the diagnosis of tuberculous lymphadenitis (TL) in comparison with histology and bacteriology findings. Study Design: We undertook a descriptive retrospective study of 937 FNAC specimens from 851 patients with cervical lymph nodes. The FNAC findings were then compared to histopathology and bacteriology. Results: Of the 937 aspirates, the cytopathological diagnoses consisted of 426 (55.9%) TL, 185 (24.3%) reactive lymphoid hyperplasia, 18 (2.3%) suppurative inflammation, 78 (10.2%) malignant metastatic tumor, and 54 (7%) lymphoma. Of the 426 TL cases, 171 were diagnosed by FNAC combined with bacteriological examination. In this group, 22 cases were found to be positive on Ziehl-Neelsen stain and 16 by culture. A histopathology report was available for 62 cases. Compared to histopathology, the overall diagnostic sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of FNAC in the diagnosis of cervical TL were, respectively, 96.77, 100, 100, and 96.67%. When comparing bacteriology to histopathology, these values were 97.44, 100, 100, and 91.67%. Conclusion: Our study shows that FNAC is a sensitive and specific tool for the diagnosis of cervical TL. (C) 2018 S. Karger AG, Basel	[Rammeh, Soumaya; Romdhane, Emna; Toumi, Amira Arfaoui; Houcine, Yoldez; Sassi, Asma] Univ Tunis El Manar, Charles Nicolle Hosp, Fac Med, Dept Pathol, Tunis 1006, Tunisia; [Lahiani, Rym; Ben Salah, Mamia; Ferjaoui, Mohamed] Univ Tunis El Manar, Charles Nicolle Hosp, Fac Med, Dept ENT, Tunis, Tunisia; [Mardassi, Helmi] Univ Tunis El Manar, Inst Pasteur Tunis, Lab Mol Microbiol Vaccinol & Biotechnol Dev, Tunis, Tunisia	Rammeh, S (reprint author), Univ Tunis El Manar, Charles Nicolle Hosp, Fac Med, Dept Pathol, Tunis 1006, Tunisia.	rammehs@yahoo.fr	Houcine, Yoldez/AAA-1287-2019	Rammeh, Soumaya/0000-0003-0366-4630			Abdissa K, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0720-z; Abebe G, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-504; BEM C, 1993, AIDS, V7, P1221, DOI 10.1097/00002030-199309000-00011; Bhaskar M, 2015, J DENT MED SCI, V14, P57; Biadglegne F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081918; Datta S, 2015, CLIN INFECT DIS, V60, P1186, DOI 10.1093/cid/ciu1153; Dilip KD, 2000, CYTOLOGY, V13, P628; Ellison E, 1999, ACTA CYTOL, V43, P153, DOI 10.1159/000330969; Gunvanti BR, 2014, INT J MED PHARM SCI, V4, P1; Gupta V, 2018, ACTA CYTOL, V62, P4, DOI 10.1159/000480064; Gupta V, 2017, ACTA CYTOL, V61, P173, DOI 10.1159/000475832; Mistry Y, 2012, NJMR, V2, P77; Mittal P, 2011, DIAGN CYTOPATHOL, V39, P822, DOI 10.1002/dc.21472; Muyanja D, 2015, AFR HEALTH SCI, V15, P107, DOI 10.4314/ahs.v15i1.15; Namad T, 2014, PAN AFR MED J, V19, DOI 10.11604/pamj.2014.19.156.4948; Namouchi A, 2008, J MED MICROBIOL, V57, P864, DOI 10.1099/jmm.0.47483-0; Neyrolles O, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000199; Patel J. M., 2015, International Journal of Medical Science and Public Health, V4, P400; Rammeh S, 2014, REV STOMATOL CHIR, V115, P85, DOI 10.1016/j.revsto.2014.02.002; Ramzy I, 1985, Diagn Cytopathol, V1, P39, DOI 10.1002/dc.2840010110; Rathod GB, 2015, IAIM, V2, P20; Sarwar A, 2004, INT J PATH, V2, P85; Shankar EM, 2007, J MED MICROBIOL, V56, P1709, DOI 10.1099/jmm.0.47497-0; Sharma S, 2017, J MED SCI CLIN RES, V5, P22176; Shykhon M, 2004, J LARYNGOL OTOL, V118, P294, DOI 10.1258/002221504323012058; Tadele A, 2014, BMC INFECT DIS, V14, DOI 10.1186/s12879-014-0585-1; Vimal S, 2016, INT J MED RES REV, V4, P1466; Zhou J, 2016, BRIT J BIOMED SCI, V73, P28, DOI 10.1080/09674845.2016.1144947	28	1	2	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					99	103		10.1159/000487503			5	Pathology	Pathology	GE3QY	WOS:000431129100004	29587250				2019-10-28	
J	Prigenzi, KCK; Heinke, T; Salim, RC; Focchi, GRD				Kabbach Prigenzi, Karla Calaca; Heinke, Thais; Salim, Rafael Calil; de Azevedo Focchi, Gustavo Rubino			Dual p16 and Ki-67 Expression in Liquid-Based Cervical Cytological Samples Compared to Pap Cytology Findings, Biopsies, and HPV Testing in Cervical Cancer Screening: A Diagnostic Accuracy Study	ACTA CYTOLOGICA			English	Article						Cervical intraepithelial neoplasia; Uterine cervical neoplasms; Uterine cervical dysplasia; Immunocytochemistry; Papanicolaou test; Cytological techniques; Cyclin-dependent kinase inhibitor p16; Genes; Ki-67 antigen; Diagnostic techniques	HUMAN-PAPILLOMAVIRUS; STAINED CYTOLOGY; POSITIVE WOMEN; FOLLOW-UP; INTRAEPITHELIAL NEOPLASIA; PAPANICOLAOU TEST; COLPOSCOPY; TRIAGE; ABNORMALITIES; RISK	Objective: Our objective was to verify the sensitivity and specificity of dual immunocytochemistry staining for p16 and Ki-67 in liquid-based samples (the "dual" assay) for cervical lesion screening, compared to biopsy findings and human papillomavirus (HPV) DNA molecular detection. Study Design: Sensitivity, specificity, and positive (PPV) and negative (NPV) predictive values for the "dual immunocytochemistry assay" were calculated and compared to histopathological results and to high-risk HPV DNA detection in adult women or teenagers submitted to cervical cancer screening. Results: A total of 151 women were included. The majority (96.2%) of those with negative dual assay results had lower biopsy grades (p < 0.001). Women with cytology results suggestive of cervical cancer had positive dual immunocytochemistry assay results more frequently (p < 0.001), and these positive results were also significantly associated with biopsy findings (p < 0.001) and with high-risk genotype HPV infection (p = 0.007). Specificity and PPV for the dual assay were 0.972 (0.855-0.999) and 0.800 (0.284-0.995), respectively, and 1.000 (0.590-1.000) and 1.000 (0.631-1.000) for HPV detection. Conclusions: The dual immunocytochemistry assay had high specificity and PPV. It reveals a persistent HPV infection, avoiding the need for new tissue collections for biopsies or hybrid capture. (C) 2018 S. Karger AG, Basel	[Kabbach Prigenzi, Karla Calaca; Heinke, Thais; Salim, Rafael Calil; de Azevedo Focchi, Gustavo Rubino] Univ Fed Sao Paulo Unifesp, Pathol Dept, Sao Paulo, Brazil; [Heinke, Thais; de Azevedo Focchi, Gustavo Rubino] SalomaoZoppi Diagnost Lab, Sao Paulo, Brazil	Heinke, T (reprint author), Univ Fed Sao Paulo, Pathol Dept, Rua Botucatu 740,Terreo Vila Clementino, BR-04023062 Sao Paulo, SP, Brazil.	thaish1978@gmail.com		FOCCHI, GUSTAVO/0000-0002-5978-0879	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)CAPES	This study received a grant from CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior).	Allia E, 2015, CANCER CYTOPATHOL, V123, P212, DOI 10.1002/cncy.21511; Baak JPA, 2006, J CLIN PATHOL, V59, P1017, DOI 10.1136/jcp.2005.027839; Bergeron C, 2015, CANCER CYTOPATHOL, V123, P373, DOI 10.1002/cncy.21542; Buban Tamas, 2009, Orvosi Hetilap, V150, P1059, DOI 10.1556/OH.2009.28638; Cox JT, 2003, AM J OBSTET GYNECOL, V188, P1406, DOI 10.1067/mob.2003.461; Darragh TM, 2012, ARCH PATHOL LAB MED, V136, P1266, DOI 10.5858/arpa.LGT200570; Dijkstra MG, 2014, CANCER EPIDEM BIOMAR, V23, P55, DOI 10.1158/1055-9965.EPI-13-0173; Dona MG, 2012, GYNECOL ONCOL, V126, P198, DOI 10.1016/j.ygyno.2012.05.004; Durzynska J, 2017, MUTAT RES-REV MUTAT, V772, P36, DOI 10.1016/j.mrrev.2016.09.006; Edgerton N, 2013, DIAGN CYTOPATHOL, V41, P35, DOI 10.1002/dc.21757; Ghittoni R, 2010, VIRUS GENES, V40, P1, DOI 10.1007/s11262-009-0412-8; Gustinucci D, 2016, AM J CLIN PATHOL, V145, P35, DOI [10.1093/AJCP/AQV019, 10.1093/ajcp/aqv019]; Holladay EB, 2002, RISK MANAGEMENT CYTO; Ikenberg H, 2013, JNCI-J NATL CANCER I, V105, P1550, DOI 10.1093/jnci/djt235; Kisser A, 2015, BJOG-INT J OBSTET GY, V122, P64, DOI 10.1111/1471-0528.13076; Loghavi S, 2013, DIAGN CYTOPATHOL, V41, P582, DOI 10.1002/dc.22900; Longatto A, 2005, INT J GYNECOL PATHOL, V24, P118, DOI 10.1097/01.RCT.0000157092.44680.25; Mitchell MF, 1998, OBSTET GYNECOL, V91, P626, DOI 10.1016/S0029-7844(98)00006-4; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; Ordi J, 2014, CANCER CYTOPATHOL, V122, P227, DOI 10.1002/cncy.21366; Petry KU, 2011, GYNECOL ONCOL, V121, P505, DOI 10.1016/j.ygyno.2011.02.033; Pinto AP, 2012, ACTA CYTOL, V56, P109, DOI 10.1159/000335065; Possati-Resende JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134445; Rijkaart DC, 2012, INT J CANCER, V130, P602, DOI 10.1002/ijc.26056; Rodriguez AC, 2008, JNCI-J NATL CANCER I, V100, P513, DOI 10.1093/jnci/djn044; Roelens J, 2012, CANCER CYTOPATHOL, V120, P294, DOI 10.1002/cncy.21205; Rossi P, 2015, PATHOLOGICA, V107, P185; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; Schiffman M, 2010, OBSTET GYNECOL, V116, P177, DOI 10.1097/AOG.0b013e3181e4629f; Schmidt D, 2011, CANCER CYTOPATHOL, V119, P158, DOI 10.1002/cncy.20140; Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457; Stoler MH, 2011, AM J CLIN PATHOL, V135, P468, DOI 10.1309/AJCPZ5JY6FCVNMOT; Toll AD, 2014, DIAGN CYTOPATHOL, V42, P576, DOI 10.1002/dc.23076; Uijterwaal MH, 2014, BRIT J CANCER, V110, P1579, DOI 10.1038/bjc.2014.34; Uijterwaal MH, 2015, INT J CANCER, V136, P2361, DOI 10.1002/ijc.29290; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F; Walker JL, 2006, AM J OBSTET GYNECOL, V195, P341, DOI 10.1016/j.ajog.2006.02.047; Wentzensen N, 2007, DIS MARKERS, V23, P315, DOI 10.1155/2007/678793; Wentzensen N, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv257; Wentzensen N, 2014, CANCER CYTOPATHOL, V122, P914, DOI 10.1002/cncy.21473; Wentzensen N, 2012, CLIN CANCER RES, V18, P4154, DOI 10.1158/1078-0432.CCR-12-0270; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 2017, GYNECOL ONCOL, V144, P51, DOI 10.1016/j.ygyno.2016.10.031; Yoshida T, 2011, ACTA CYTOL, V55, P413, DOI 10.1159/000331047; Yu LL, 2016, ONCOTARGET, V7, P64810, DOI 10.18632/oncotarget.11705	45	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					104	114		10.1159/000487504			11	Pathology	Pathology	GE3QY	WOS:000431129100005	29566392				2019-10-28	
J	Magalhaes, JC; Azara, CZS; Tavares, SBD; Manrique, EJC; Amaral, RG				Magalhaes, Juliana Cristina; Silveira Azara, Cinara Zago; do Nascimento Tavares, Sulene Brito; Claudio Manrique, Edna Joana; Amaral, Rita Goreti			Impact of Implementing 100% Rapid Review as a Quality Control Tool in Cervical Cytology	ACTA CYTOLOGICA			English	Review						Cervical cancer; Cervical smears; Screening; Quality control	GYNECOLOGIC CYTOLOGY; PERFORMANCE; PROGRAM	Objective: We aimed to evaluate the impact of implementing 100% rapid review (100% RR) as a quality control tool in cervical smear cytology. Design: A cross-sectional study was conducted in which cytology findings, false-negative results, and quality indicators were evaluated. The variables were analyzed in 2004, the year in which 100% RR was implemented, and again in 2013, i.e., 10 years on. Results: Detection of atypical squamous cells of undetermined significance (ASCUS) increased from 0.90% in 2004 to 2.47% in 2013 by routine screening. Detection of atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H) increased from 13.33% in 2004 to 36.27% in 2013 by 100% RR. Detection of high-grade squamous intraepithelial lesion (HSIL) increased from 0.64% in 2004 to 4.29% in 2013 by routine screening, and increased from 0% in 2004 to 19.61% in 2013 by 100% RR. There was a significant increase (p = 0.00001) in the identification of false-negative results of ASCUS, low-grade squamous intraepithelial lesion, ASC-H, HSIL, and atypical glandular cells. All quality indicators had increased in 2013 when compared to 2004 results. Conclusions: Ten years after the implementation of the 100% RR method, improvements were found in the detection of atypia and precursor lesions and in quality indicators. (C) 2018 S. Karger AG, Basel	[Magalhaes, Juliana Cristina; Silveira Azara, Cinara Zago; do Nascimento Tavares, Sulene Brito; Amaral, Rita Goreti] Univ Fed Goias, Sch Pharm, Rua 240,Esquina Com 5a,Ave S-N,Setor Leste Univ, BR-74605170 Goiania, Go, Brazil; [Claudio Manrique, Edna Joana] Pontifical Catholic Univ Goias, Goiania, Go, Brazil	Amaral, RG (reprint author), Univ Fed Goias, Sch Pharm, Rua 240,Esquina Com 5a,Ave S-N,Setor Leste Univ, BR-74605170 Goiania, Go, Brazil.	ritagoreti26@gmail.com			Coordination for the Improvement of Higher Education Personnel (CAPES)CAPES	This study was supported by the Coordination for the Improvement of Higher Education Personnel (CAPES).	Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945; Amaral AF, 2014, REV BRAS GINECOL OBS, V36, P182, DOI 10.1590/S0100-7203201400040004; Araujo Jr Mario Lucio C., 2015, J. Bras. Patol. Med. Lab., V51, P102, DOI 10.5935/1676-2444.20150018; Auger M, 2011, CANCER CYTOPATHOL, V119, P357, DOI 10.1002/cncy.20189; Brasil. Ministerio da Saude, 2015, SIST INF CANC COL UT; Brasil. Ministerio da Saude; Instituto Nacio- nal do C~ncer Jose Alencar Gomes da Silva; Coordenacao de Prevencao e Vigilancia, 2016, DIV DET PREC AP ORG; Catteau X., 2014, ISRN OBSTET GYNECOL, V2014; Chebib I, 2013, CANCER CYTOPATHOL, V121, P638, DOI 10.1002/cncy.21328; Currens HS, 2012, AM J CLIN PATHOL, V137, P150, DOI 10.1309/AJCP6LW4SYBTISOW; Davey DD, 2004, ARCH PATHOL LAB MED, V128, P1224; Ferreira TXAM, 2013, REV APS, V16, P75; Gupta N, 2013, CYTOPATHOLOGY, V24, P39, DOI 10.1111/j.1365-2303.2012.00992.x; Karimi-Zarchi Mojgan, 2013, Int J Biomed Sci, V9, P205; Montemor EBL, 2007, DIAGN CYTOPATHOL, V35, P57, DOI 10.1002/dc.20405; Manrique EJC, 2006, CYTOPATHOLOGY, V17, P116, DOI 10.1111/j.1365-2303.2006.00368.x; Manrique EJC, 2011, CYTOPATHOLOGY, V22, P195, DOI 10.1111/j.1365-2303.2010.00776.x; Nygard JF, 2002, J MED SCREEN, V9, P86, DOI 10.1136/jms.9.2.86; Rao AS, 2015, INT J MANUF MATER ME, V5, P1, DOI 10.4018/ijmmme.2015010101; Renshaw AA, 2011, DIAGN CYTOPATHOL, V39, P832, DOI 10.1002/dc.21541; Sundstrom K, 2017, AM J OBSTET GYNECOL, V216, DOI 10.1016/j.ajog.2016.07.042; Utagawa ML, 2008, ACTA CYTOL, V52, P439, DOI 10.1159/000325549; Walavalkar Vighnesh, 2015, J Am Soc Cytopathol, V4, P190, DOI 10.1016/j.jasc.2014.11.006; Wilbur CD, 2015, BETHESDA SYSTEM REPO; Zola P, 2007, INT J GYNECOL CANCER, V17, P1186, DOI 10.1111/j.1525-1438.2007.00943.x	24	1	1	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					115	120		10.1159/000487426			6	Pathology	Pathology	GE3QY	WOS:000431129100006	29597202				2019-10-28	
J	Pandey, P; Agarwal, S; Ralli, M; Dixit, A; Singh, D				Pandey, Pinki; Agarwal, Savita; Ralli, Megha; Dixit, Alok; Singh, Dheerendra			Oral Brush Liquid-Based Cytology: A Study of Concordance between a Cytotechnologist and a Cytopathologist	ACTA CYTOLOGICA			English	Article						Liquid-based cytology; Oral cytology; Oral cancer; Erythroplakia; Leukoplakia	COMPUTER-ASSISTED ANALYSIS; FINE-NEEDLE-ASPIRATION; HUMAN-PAPILLOMAVIRUS; EPITHELIAL DYSPLASIA; OROPHARYNGEAL CANCER; CERVICAL CYTOLOGY; LESIONS; CARCINOMA; DIAGNOSIS; QUALITY	Objective: Oral cancer accounts for almost 40% of all cancers in the Indian subcontinent. Techniques like oral scrape cytology are helpful in early diagnosis of premalignant lesion and thus prevention of malignant transformation. The purpose of this study is to evaluate the performance of cytotechnologists in assessing the adequacy and preliminary diagnostic accuracy of oral brush liquid-based cytology. Study Design: 110 oral brush liquid-based cytology smears were prospectively screened by a cytotechnologist for adequacy assessment, and a preliminary diagnosis was recorded. Smears were subsequently studied by the reporting cytopathologist for the final diagnosis. The performance of the cytotechnologist in the assessment of adequacy and the preliminary diagnosis were compared with the final interpretation rendered by the cytopathologist. Results: There was no significant difference in adequacy assessment between both observers, and good concordance was observed in the identification of frankly malignant lesions; however, in premalignant cases, complete agreement in all the cases was not observed. Maximum numbers of discrepant cases were seen in high-grade squamous intraepithelial lesions, 4/17 were downgraded to low-grade squamous intraepithelial lesions and 2/17 to negative for intraepithelial lesion or malignancy, respectively. Conclusion: Trained cytotechnologists are capable of assessing the adequacy and identifying the malignancy in oral brush liquid-based cytology smears, and hence there is potential for them to perform initial screening of such cases. (C) 2018 S. Karger AG, Basel	[Pandey, Pinki; Agarwal, Savita; Ralli, Megha; Singh, Dheerendra] Uttar Pradesh Univ Med Sci, Dept Pathol, Type 5,B 301,New Campus, Saifai 206130, Etawah, India; [Dixit, Alok] Uttar Pradesh Univ Med Sci, Dept Clin Pharmacol, Saifai, India	Pandey, P (reprint author), Uttar Pradesh Univ Med Sci, Dept Pathol, Type 5,B 301,New Campus, Saifai 206130, Etawah, India.	pnkdxt@yahoo.co.in					ABBEY LM, 1995, ORAL SURG ORAL MED O, V80, P188, DOI 10.1016/S1079-2104(05)80201-X; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Barnes L, 2005, WHO CLASSIFICATION T; BOON ME, 1986, ACTA CYTOL, V30, P264; Brothwell DJ, 2003, COMMUNITY DENT ORAL, V31, P300; Cibas ES, 2001, AM J CLIN PATHOL, V115, P512; Driemel Oliver, 2007, J Dtsch Dermatol Ges, V5, P1095, DOI 10.1111/j.1610-0387.2007.06397.x; Kaugars G E, 1998, J Cancer Educ, V13, P85; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Kuyama K, 2013, OJST, V3, P215; LESTRANGE P, 1989, ORAL SURG ORAL MED O, V67, P282, DOI 10.1016/0030-4220(89)90355-1; Lindquist D, 2007, MOL ONCOL, V1, P350, DOI 10.1016/j.molonc.2007.08.005; Marur S, 2010, LANCET ONCOL, V11, P781, DOI 10.1016/S1470-2045(10)70017-6; Mehrotra R, 2008, ORAL SURG ORAL MED O, V106, P246, DOI 10.1016/j.tripleo.2008.02.030; Mehrotra R, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-11; MONTGOMERY PW, 1951, J DENT RES, V30, P308, DOI 10.1177/00220345510300030201; Nasman A, 2009, INT J CANCER, V125, P362, DOI 10.1002/ijc.24339; Neville BW, 2002, CA-CANCER J CLIN, V52, P195, DOI 10.3322/canjclin.52.4.195; OGDEN GR, 1989, BRIT J ORAL MAX SURG, V27, P224, DOI 10.1016/0266-4356(89)90149-6; Olson MT, 2013, ACTA CYTOL, V57, P550, DOI 10.1159/000354079; Olson MT, 2012, AM J CLIN PATHOL, V138, P90, DOI 10.1309/AJCP84AXSRABZCTZ; Sadiq H, 2015, INT J ADV HLTH SCI, V1, P20; SCHER RL, 1988, CANCER, V62, P2602, DOI 10.1002/1097-0142(19881215)62:12<2602::AID-CNCR2820621225>3.0.CO;2-9; Sciubba JJ, 1999, J AM DENT ASSOC, V130, P1445, DOI 10.14219/jada.archive.1999.0055; Shah SS, 2016, CANCERS, V8, DOI 10.3390/cancers8090085; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; Speight PM, 2007, HEAD NECK PATHOL, V1, P61, DOI 10.1007/s12105-007-0014-5; Warnakulasuriya S, 2009, ORAL ONCOL, V45, P309, DOI 10.1016/j.oraloncology.2008.06.002	28	1	1	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					121	129		10.1159/000486661			9	Pathology	Pathology	GE3QY	WOS:000431129100007	29402796				2019-10-28	
J	Nam, AS; Giorgadze, T; Tam, W; Chadburn, A				Nam, Anna S.; Giorgadze, Tamara; Tam, Wayne; Chadburn, Amy			Assessment of the Utility of Cytology and Flow Cytometry of Cerebrospinal Fluid Samples in Clinical Practice	ACTA CYTOLOGICA			English	Article						Cytology; Flow cytometry; Cerebrospinal fluid; Lymphoma; Leukemia; Leptomeningeal disease	MALIGNANT HEMATOPOIETIC-CELLS; OCCULT LEPTOMENINGEAL DISEASE; LYMPHOMAS; SENSITIVITY; MENINGITIS; DIAGNOSIS; TOOL; CSF	Objectives: We sought to assess the utility and limitations of both flow cytometry (FC) and cytology for the analysis of cerebrospinal fluid (CSF) in a practical clinical setting. Methods: A total of 393 consecutive CSF samples from 171 patients submitted for both cytomorphologic and FC assessments were analyzed. Results: Both FC and cytology findings were negative for malignancy in 315/393 samples (80%), and either positive (POS) or suspicious/atypical (SUSP/AT) in 7% of samples. This resulted in high agreement between FC and cytology (87%). Minor discrepancies were present in 4% of the cases. In 28 samples, an abnormal population was detected by FC but not by cytology. Conclusions: FC and cytology are important complementary methods for analyzing CSF samples. In cases where cytology is SUSP/AT and FC is inconclusive or negative, additional specimens should be submitted for immunostaining, cytogenetics, and/or molecular studies. (C) 2018 S. Karger AG, Basel	[Nam, Anna S.; Tam, Wayne; Chadburn, Amy] Weill Cornell Med, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA; [Giorgadze, Tamara] Med Coll Wisconsin, Dept Pathol & Lab Med, Milwaukee, WI 53226 USA	Nam, AS (reprint author), Weill Cornell Med, Dept Pathol & Lab Med, 1300 York Ave, New York, NY 10065 USA.	shn9035@nyp.org					Ahluwalia MS, 2012, CANCER-AM CANCER SOC, V118, P1747, DOI 10.1002/cncr.26335; Armitage JO, 1998, J CLIN ONCOL, V16, P2780, DOI 10.1200/JCO.1998.16.8.2780; Bromberg JEC, 2007, NEUROLOGY, V68, P1674, DOI 10.1212/01.wnl.0000261909.28915.83; Craig FE, 2011, AM J CLIN PATHOL, V135, P22, DOI 10.1309/AJCPANA7ER1ABMZI; Di Noto R, 2008, LEUKEMIA RES, V32, P1196, DOI 10.1016/j.leukres.2007.12.016; Finn WG, 1998, AM J CLIN PATHOL, V110, P341, DOI 10.1093/ajcp/110.3.341; French CA, 2000, DIAGN CYTOPATHOL, V23, P369, DOI 10.1002/1097-0339(200012)23:6<369::AID-DC1>3.0.CO;2-3; Glantz MJ, 1998, CANCER, V82, P733, DOI 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z; GLASS JP, 1979, NEUROLOGY, V29, P1369, DOI 10.1212/WNL.29.10.1369; Hegde U, 2005, BLOOD, V105, P496, DOI 10.1182/blood-2004-05-1982; Langerak AW, 2012, LEUKEMIA, V26, P2159, DOI 10.1038/leu.2012.246; Nuckel H, 2006, CLIN LAB HAEMATOL, V28, P22, DOI 10.1111/j.1365-2257.2006.00741.x; Quijano S, 2009, J CLIN ONCOL, V27, P1462, DOI 10.1200/JCO.2008.17.7089; Roma AA, 2002, DIAGN CYTOPATHOL, V27, P271, DOI 10.1002/dc.10190; SCHIFF D, 1993, ARCH INTERN MED, V153, P389, DOI 10.1001/archinte.153.3.389; Schinstine M, 2006, CANCER CYTOPATHOL, V108, P157, DOI 10.1002/cncr.21915; Urbanits S, 2002, CLIN CHIM ACTA, V317, P101, DOI 10.1016/S0009-8981(01)00771-9; WASSERSTROM WR, 1982, CANCER, V49, P759, DOI 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0.CO;2-7	18	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					130	136		10.1159/000487070			7	Pathology	Pathology	GE3QY	WOS:000431129100008	29510385				2019-10-28	
J	Margari, N; Giovannopoulos, I; Pouliakis, A; Mastorakis, E; Gouloumi, AR; Panayiotides, IG; Karakitsos, P				Margari, Niki; Giovannopoulos, Ilias; Pouliakis, Abraham; Mastorakis, Emmanouil; Gouloumi, Alina Roxani; Panayiotides, Ioannis G.; Karakitsos, Petros			Application of Immunocytochemistry on Cell Block Sections for the Investigation of Thyroid Lesions	ACTA CYTOLOGICA			English	Article						Thyroid cytology; Liquid-based cytology; Immunocytochemistry; Cell block; Statistics; Classification and regression trees; Cytokeratin 19; Galectin 3; HBME-1	FINE-NEEDLE-ASPIRATION; ARTIFICIAL NEURAL-NETWORKS; LIQUID-BASED CYTOLOGY; DIAGNOSTIC-ACCURACY; MANAGEMENT GUIDELINES; DECISION-SUPPORT; CYTOKERATIN 19; CARCINOMA; NODULES; HBME-1	Objective: To investigate the potential of Classification and Regression Trees (CARTs) for the diagnosis of thyroid lesions based on cell block immunocytochemistry and cytological outcome. Study Design: A total of 956 histologically confirmed cases (673 benign and 283 malignant) from patients with thyroid nodules were prepared via liquid-based cytology and evaluated; 4 additional slides were stained for cytokeratin 19 (CK-19), galectin 3 (Gal-3), Hector Battifora mesothelial cell 1 (HBME-1), and thyroglobulin. On the basis of immunocytochemistry and the cytological diagnosis, a CART algorithm was constructed and used for evaluation. Results: The major important factors contributing to the diagnostic CART model were: cytological outcome, CK-19, Gal-3, and HBME-1. The sensitivity and specificity of the cytological diagnosis were 96.27% and 88.26%, respectively (cut-off: category 3 of The Bethesda System [TBS-3]). The introduction of immunocytochemistry and the CART model increased the sensitivity and specificity to 98.88% and 99.11%, respectively. CK-19 presented the best performance for discriminating papillary thyroid carcinomas, followed by HBME-1 and Gal-3. In the TBS-2 cases, CK-19 and, subsequently, Gal-3 were important immunocytochemistry markers. Ultimately, CK-19 and HBME-1 on TBS-5 or TBS-6 cases demonstrated the best results. Conclusions: The hierarchical structure of the CART model provides a diagnostic algorithm linked with the risk of malignancy at every step of the procedure. It also provides guidance on the use of ancillary examinations as it goes by simple, human understandable rules. (C) 2018 S. Karger AG, Basel	[Margari, Niki; Pouliakis, Abraham; Gouloumi, Alina Roxani; Panayiotides, Ioannis G.] Univ Athens, Attikon Univ Hosp, Sch Med, Dept Pathol 2, Iraklion, Greece; [Karakitsos, Petros] Univ Athens, Attikon Univ Hosp, Sch Med, Dept Cytopathol, Iraklion, Greece; [Giovannopoulos, Ilias] Laiko Hosp, Dept Internal Med 1, Diabet Mellitus & Metab Dis Unit, Unit Endocrinol, Athens, Greece; [Mastorakis, Emmanouil] Venizeleio Gen Hosp, Dept Cytopathol, Iraklion, Greece	Margari, N (reprint author), Attikon Univ Hosp, Dept Pathol 2, 1 Rimini St, GR-12462 Athens, Greece.	nikimarg@gmail.com		Margari, Niki/0000-0003-4975-8616			Akalin A, 2008, DIAGN CYTOPATHOL, V36, P523, DOI 10.1002/dc.20846; Ali SZ, 2010, BETHESDA SYSTEM REPO; Bartolazzi A, 2001, LANCET, V357, P1644, DOI 10.1016/S0140-6736(00)04817-0; Bartolazzi A, 2008, LANCET ONCOL, V9, P543, DOI 10.1016/S1470-2045(08)70132-3; Bonzanini M, 2008, ACTA CYTOL, V52, P541, DOI 10.1159/000325595; Breiman L., 1984, CLASSIFICATION REGRE; Cheung CC, 2001, MODERN PATHOL, V14, P338, DOI 10.1038/modpathol.3880312; Cibas ES, 2008, CANCER CYTOPATHOL, V114, P71, DOI 10.1002/cncr.23343; Cochand-Priollet B, 2011, THYROID, V21, P1067, DOI 10.1089/thy.2011.0014; Dabbs D. J., 2010, DIAGNOSTIC IMMUNOHIS; de Cristo AP, 2016, ARCH ENDOCRIN METAB, V60, P367, DOI 10.1590/2359-3997000000180; de Micco C, 2008, BRIT J CANCER, V98, P818, DOI 10.1038/sj.bjc.6604194; Dean DS, 2008, BEST PRACT RES CL EN, V22, P901, DOI 10.1016/j.beem.2008.09.019; Dunderovic D, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0428-4; DYTCH HE, 1990, ANAL QUANT CYTOL, V12, P379; Fang Qingquan, 2015, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V50, P668; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Horton M, 2016, DIAGN CYTOPATHOL, V44, P737, DOI 10.1002/dc.23522; Inohara H, 1999, CANCER, V85, P2475, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO;2-1; Khurana KK, 2003, ARCH PATHOL LAB MED, V127, P579; Kontzoglou K, 2005, J SURG ONCOL, V89, P75, DOI 10.1002/jso.20190; Kouniavsky G, 2012, J SURG ONCOL, V105, P438, DOI 10.1002/jso.21935; Lacoste-Collin L, 2014, CYTOPATHOLOGY, V25, P160, DOI 10.1111/cyt.12128; Lisboa PJ, 2006, NEURAL NETWORKS, V19, P408, DOI 10.1016/j.neunet.2005.10.007; Lubitz Carrie C, 2005, Adv Surg, V39, P355, DOI 10.1016/j.yasu.2005.04.009; Mastorakis E, 2014, CYTOPATHOLOGY, V25, P120, DOI 10.1111/cyt.12062; Miccoli P, 2006, ANZ J SURG, V76, P123, DOI 10.1111/j.1445-2197.2006.03667.x; Miettinen M, 1996, VIRCHOWS ARCH, V429, P213; Nasser SM, 2000, CANCER CYTOPATHOL, V90, P307, DOI 10.1002/1097-0142(20001025)90:5<307::AID-CNCR7>3.0.CO;2-N; Ohta M, 2015, PATHOL INT, V65, P119, DOI 10.1111/pin.12252; Orlandi F, 1998, CANCER RES, V58, P3015; Papini E, 2002, J CLIN ENDOCR METAB, V87, P1941, DOI 10.1210/jc.87.5.1941; Pouliakis A, 2016, BIOMED ENG COMPUT BI, V7, P1, DOI 10.4137/BECB.S31601; Raggio E, 2010, J ENDOCRINOL INVEST, V33, P378, DOI 10.3275/6444; RAPHAEL SJ, 1994, MODERN PATHOL, V7, P295; Sack MT, 1997, MODERN PATHOL, V10, P668; Saggiorato E, 2005, ENDOCR-RELAT CANCER, V12, P305, DOI 10.1677/erc.1.00944; Saleh HA, 2009, CYTOJOURNAL, V6, DOI 10.4103/1742-6413.55894; Sciacchitano S, 2016, ENDOCRINE, V54, P139, DOI 10.1007/s12020-015-0774-8; Sidawy MK, 1997, CANCER CYTOPATHOL, V81, P253, DOI 10.1002/(SICI)1097-0142(19970825)81:4<253::AID-CNCR7>3.0.CO;2-Q; Stamataki M, 2008, CYTOPATHOLOGY, V19, P11, DOI 10.1111/j.1365-2303.2007.00512.x	41	3	3	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					137	144		10.1159/000485824			8	Pathology	Pathology	GE3QY	WOS:000431129100009	29339640				2019-10-28	
J	Ojha, SS; Jain, R; Meenai, F; Nilkanthe, R; Haritwal, A				Ojha, Sandeep S.; Jain, Rubal; Meenai, Farah; Nilkanthe, Ramrao; Haritwal, Amit			Cytomorphological Findings of Follicular Dendritic Cell Sarcoma on Fine-Needle Aspiration Cytology	ACTA CYTOLOGICA			English	Article						Fine-needle aspiration cytology; Follicular dendritic cell sarcoma; Lymph node	TUMOR; LIVER	Background: Follicular dendritic cell sarcoma (FDCS) is a rare neoplasm arising from follicular dendritic cells of germinal centers. The most common site of origin is lymph nodes and it may mimic a variety of tumors at that location, including carcinomas and sarcomas. Diagnosis is frequently missed on cytology as there are very few case reports describing the cytological characteristics of the lesion. Even on histology, a high degree of suspicion is required for an appropriate diagnosis. Case: A 60-year-old male presented with a gradually increasing left submandibular mass that had been present for 3 months. Fine-needle aspiration cytology (FNAC) was performed, showing many clusters as well as scattered epithelioid cells with spindled to oval nuclei, nuclear pleomorphism, grooves, inclusions, and uniformly dispersed mature lymphocytes throughout the smears. The diagnosis of FDCS was suspected and was confirmed on histopathology and immunohistochemistry. Conclusion: FNAC can be a cheap, easy, and helpful tool in obtaining a diagnosis of FDCS as there are few characteristic cytological features that are better recognized than histology. (C) 2017 S. Karger AG, Basel	[Ojha, Sandeep S.; Jain, Rubal; Meenai, Farah; Nilkanthe, Ramrao; Haritwal, Amit] Chirayu Med Coll & Hosp, Dept Pathol, Bhopal 462030, India	Ojha, SS (reprint author), Chirayu Med Coll & Hosp, Dept Pathol, Bhopal 462030, India.	drsandy0582@gmail.com					Chan JKC, 1997, CANCER, V79, P294; Chan JKC, 2008, WHO CLASSIFICATION T, P363; Chang K, 2011, HEMATOPATHOLOGY, P829; Czapla A, 2017, DIAGN CYTOPATHOL, V45, P322, DOI 10.1002/dc.23664; Fan YS, 2007, ACTA CYTOL, V51, P642, DOI 10.1159/000325817; Granados R, 2008, DIAGN CYTOPATHOL, V36, P42, DOI 10.1002/dc.20744; Imai Y, 1996, PATHOL INT, V46, P807, DOI 10.1111/j.1440-1827.1996.tb03555.x; Mohanty SK, 2003, DIAGN CYTOPATHOL, V29, P368, DOI 10.1002/dc.10392; MONDA L, 1986, AM J PATHOL, V122, P562; PerezOrdonez B, 1996, AM J SURG PATHOL, V20, P944, DOI 10.1097/00000478-199608000-00003; Ren RL, 2005, DIAGN CYTOPATHOL, V32, P38, DOI 10.1002/dc.20151; Vicandi B, 2000, ACTA CYTOL, V44, P1106, DOI 10.1159/000328607; Wu A, 2016, ARCH PATHOL LAB MED, V140, P186, DOI 10.5858/arpa.2014-0374-RS; Yang GCH, 2006, ACTA CYTOL, V50, P534, DOI 10.1159/000326009	14	0	0	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					145	150		10.1159/000485789			6	Pathology	Pathology	GE3QY	WOS:000431129100010	29275417				2019-10-28	
J	Jimenez-Heffernan, JA; Adrados, M; Munoz-Hernandez, P; Fernandez-Rico, P; Ballesteros-Garcia, AI; Fraga, J				Jimenez-Heffernan, Jose A.; Adrados, Magdalena; Munoz-Hernandez, Patricia; Fernandez-Rico, Paloma; Ballesteros-Garcia, Ana I.; Fraga, Javier			Cytologic Features of Malignant Melanoma with Osteoclast-Like Giant Cells	ACTA CYTOLOGICA			English	Article						Cytology; Fine needle aspiration; Malignant melanoma; Osteoclast-like giant cells	TRANSCRIPTION FACTOR; TUMOR; BONE; EXPRESSION; CARCINOMA	Background: Malignant melanoma showing numerous osteoclast-like giant cells (OGCs) is an uncommon morphologic phenomenon, rarely mentioned in the cytologic literature. The few reported cases seem to have an aggressive clinical behavior. Although most findings support monocyte/macrophage differentiation, the exact nature of OGCs is not clear. Case: A 57-year-old woman presented with an inguinal lymphadenopathy. Sixteen years before, cutaneous malignant melanoma of the lower limb had been excised. Needle aspiration revealed abundant neoplastic single cells as well as numerous multinucleated OGCs. Occasional neoplastic giant cells were also present. Nuclei of OGCs were monomorphic with oval morphology and were smaller than those of melanoma cells. The immunophenotype of OGCs (S100-, HMB45-, Melan-A-, SOX10-, Ki67-, CD163-, BRAF-, CD68+, MiTF+, p16+) was the expected for reactive OGCs of mono-cyte/macrophage origin. The tumor has shown an aggressive behavior with further metastases to the axillary lymph nodes and oral cavity. Conclusion: Numerous OGCs are a rare and relevant finding in malignant melanoma. Their presence should not induce confusion with other tumors rich in osteoclastic cells. Since a relevant number of OGCs in melanoma may mean a more aggressive behavior, and patients may benefit from specific treatments, their presence should be mentioned in the pathologic report. (C) 2018 S. Karger AG, Basel	[Jimenez-Heffernan, Jose A.; Adrados, Magdalena; Munoz-Hernandez, Patricia; Fernandez-Rico, Paloma; Fraga, Javier] Univ Hosp La Princesa, Dept Pathol, Madrid, Spain; [Ballesteros-Garcia, Ana I.] Univ Hosp La Princesa, Dept Oncol, Madrid, Spain; [Jimenez-Heffernan, Jose A.; Fraga, Javier] Labco Pathol, Madrid, Spain	Jimenez-Heffernan, JA (reprint author), Hosp Univ La Princesa, Dept Anat Patol, Diego Leon 62, ES-28006 Madrid, Spain.	jjheffernan@yahoo.com	Adrados, Magdalena/H-8123-2015	Adrados, Magdalena/0000-0003-3317-670X			Al-Brahim N, 2005, AM J DERMATOPATH, V27, P126, DOI 10.1097/00000372-200504000-00007; Albores-Saavedra J, 2006, AM J SURG PATHOL, V30, P495, DOI 10.1097/00000478-200604000-00010; Aoki J, 1996, AM J ROENTGENOL, V166, P145, DOI 10.2214/ajr.166.1.8571864; Baydar D, 2006, MODERN PATHOL, V19, P161, DOI 10.1038/modpathol.3800521; Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078-0432.CCR-12-0578; Choi JW, 2011, PATHOBIOLOGY, V78, P233, DOI 10.1159/000327359; Clevenger J, 2014, CANCER CYTOPATHOL, V122, P779, DOI 10.1002/cncy.21458; DAROCA PJ, 1990, HUM PATHOL, V21, P978, DOI 10.1016/0046-8177(90)90183-6; DENTON KJ, 1992, HISTOPATHOLOGY, V20, P179, DOI 10.1111/j.1365-2559.1992.tb00951.x; Goel G, 2011, J CANCER RES THER, V7, P336, DOI 10.4103/0973-1482.86998; Houang M, 2015, AM J DERMATOPATH, V37, P299; Li X, 2017, AM J DERMATOPATHOL; Maggiani F, 2011, J CLIN PATHOL, V64, P701, DOI 10.1136/jcp.2011.090852; Seethala RR, 2004, MODERN PATHOL, V17, P1491, DOI 10.1038/modpathol.3800211; Vicandi B, 2004, CYTOPATHOLOGY, V15, P321, DOI 10.1111/j.1365-2303.2004.00166.x; Wasserman JK, 2015, INT J SURG PATHOL, V23, P478, DOI 10.1177/1066896915592016	16	2	2	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					151	154		10.1159/000486027			4	Pathology	Pathology	GE3QY	WOS:000431129100011	29332062				2019-10-28	
J	Schmitt, FC				Schmitt, Fernando C.			Lymph Node FNC - Cytopathology of Lymph Nodes and Extranodal Lymphoproliferative Processes	ACTA CYTOLOGICA			English	Book Review									[Schmitt, Fernando C.] Univ Porto, Med Fac, Dept Pathol, Porto, Portugal; [Schmitt, Fernando C.] IPATIMUP, Mol Pathol, Porto, Portugal; [Schmitt, Fernando C.] Int Acad Cytol, Freiburg, Germany	Schmitt, FC (reprint author), Univ Porto, Med Fac, Dept Pathol, Porto, Portugal.; Schmitt, FC (reprint author), IPATIMUP, Mol Pathol, Porto, Portugal.; Schmitt, FC (reprint author), Int Acad Cytol, Freiburg, Germany.						ZEPPA P, 2018, LYMPH NODE FNC CYTOP	1	0	0	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5547	1938-2650		ACTA CYTOL	Acta Cytol.		2018	62	2					155	155		10.1159/000487449			1	Pathology	Pathology	GE3QY	WOS:000431129100012					2019-10-28	
J	Shekarkhar, G; Soleimanpour, H; Jafari, SH; Zamani, F				Shekarkhar, Golsa; Soleimanpour, Hossein; Jafari, Seyed Hamed; Zamani, Fatemeh			Sebaceous Lymphadenoma of Parotid: Imaging, Cytological, and Histological Findings in Detail	CASE REPORTS IN PATHOLOGY			English	Article							GLAND; TUMORS	Sebaceous lymphadenomas are rare and account for less than 1% of primary salivary gland tumors. These rare tumors are mostly found inmen older than 50 years. The clinicopathological features of these tumors are poorly understood and no definite causative factor has been reported for them till now. They are not often diagnosed prior to surgery, which could be due to their rarity and lack of enough preop radiological and cytological findings. Few case reports have been published in literature about their pathogenesis and accompanying malignant lesions. The cytological and imaging findings have been dealt with in some articles. Here we describe the histologic, cytologic, and radiologic findings of sebaceous lymphadenomas of parotid gland, all together, and discuss their differential diagnoses in various diagnostic methods.	[Shekarkhar, Golsa] Shiraz Univ Med Sci, Pathol Dept, Shiraz 7134845794, Iran; [Soleimanpour, Hossein] Daneshbod Lab, Shiraz, Iran; [Jafari, Seyed Hamed; Zamani, Fatemeh] Shiraz Univ Med Sci, Shiraz, Iran	Shekarkhar, G (reprint author), Shiraz Univ Med Sci, Pathol Dept, Shiraz 7134845794, Iran.	g.shekarkhar@gmail.com					Croitoru Claudia M, 2003, Ann Diagn Pathol, V7, P236, DOI 10.1016/S1092-9134(03)00052-2; GNEPP DR, 1984, CANCER-AM CANCER SOC, V53, P2155, DOI 10.1002/1097-0142(19840515)53:10<2155::AID-CNCR2820531026>3.0.CO;2-F; Hayashi D, 2007, Acta Otorhinolaryngol Ital, V27, P144; Jin GQ, 2011, EUR RADIOL, V21, P1692, DOI 10.1007/s00330-011-2101-y; Majeed M, 2008, DENTOMAXILLOFAC RAD, V37, P300, DOI 10.1259/dmfr/72624194; Seethala RR, 2012, MODERN PATHOL, V25, P26, DOI 10.1038/modpathol.2011.135; Tartaglione T, 2015, ACTA OTORHINOLARYNGO, V35, P314, DOI 10.14639/0392-100X-693	7	0	0	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									2915907	10.1155/2018/2915907			4	Pathology	Pathology	GE4SF	WOS:000431206300001	29850339	DOAJ Gold, Green Published			2019-10-28	
J	Harata, D; Tsuchiya, Y; Miyoshi, T; Yanai, T; Suzuki, K; Murakami, T				Harata, Daichi; Tsuchiya, Yuya; Miyoshi, Tomoyuki; Yanai, Tokuma; Suzuki, Kazuhiko; Murakami, Tomoaki			Inhibitory effect of propolis on the development of AA amyloidosis	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						AA amyloidosis; antioxidant; propolis	OXIDATIVE STRESS; CURCUMIN; TRANSMISSION	In the several types of amyloidoses, participation of oxidative stresses in the pathogenesis and the effect of antioxidants on amyloidosis have been reported. Meanwhile, the relationship between oxidative stresses and pathogenesis of amyloid A (AA) amyloidosis is still unclear. In this study, we used an antioxidant, Brazilian propolis, to investigate the inhibitory effects on AA amyloidosis. The results showed that AA deposition was inhibited by administration of propolis. Increased expression of antioxidant markers was detected in molecular biological examinations of mice treated with propolis. Although serum amyloid A (SAA) levels were strongly correlated with the immunoreactive area of AA deposits in the control group, the correlation was weaker in the propolis-treated groups. In addition, there were no changes in SAA levels between the control group and the propolis-treated groups. The results indicate that propolis, an antioxidant, may induce inhibitory effects against AA amyloidosis.	[Harata, Daichi; Miyoshi, Tomoyuki; Suzuki, Kazuhiko; Murakami, Tomoaki] Tokyo Univ Agr & Technol, Cooperat Dept Vet Med, Lab Vet Toxicol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan; [Tsuchiya, Yuya] API Co Ltd, Nagaragawa Res Ctr, 692-3 Nagara, Gifu, Gifu 5020071, Japan; [Tsuchiya, Yuya; Yanai, Tokuma] Gifu Univ, Dept Vet Med, Lab Vet Pathol, 1-1 Yanagido, Gifu, Gifu 5011193, Japan	Murakami, T (reprint author), Tokyo Univ Agr & Technol, Cooperat Dept Vet Med, Lab Vet Toxicol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	mrkmt@cc.tuat.ac.jp	Suzuki, Kazuhiko/C-8348-2013; Murakami, Tomoaki/D-4654-2015	Suzuki, Kazuhiko/0000-0001-6047-8127; Murakami, Tomoaki/0000-0002-5706-7842	JSPS KAKENHIMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [16H05027, 17K17702]	This work was supported by JSPS KAKENHI Grant Numbers 16H05027 and 17K17702.	Ando Y, 1997, BIOCHEM BIOPH RES CO, V232, P497, DOI 10.1006/bbrc.1996.5997; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; Jesudason EP, 2008, MOL CELL BIOCHEM, V311, P145, DOI 10.1007/s11010-008-9705-9; Kamata K, 2014, AMYLOID, V21, P191, DOI 10.3109/13506129.2014.937857; Lim GP, 2001, J NEUROSCI, V21, P8370; Liu R, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-105; Lundmark K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079104; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Macedo B, 2010, PHARMACOL RES, V62, P514, DOI 10.1016/j.phrs.2010.08.001; Miyamae Y, 2011, CYTOTECHNOLOGY, V63, P191, DOI 10.1007/s10616-011-9341-1; Murakami T, 2014, VET PATHOL, V51, P363, DOI 10.1177/0300985813511128; Murakami T, 2015, VIRUS RES, V207, P76, DOI 10.1016/j.virusres.2014.12.019; Nakajima Y, 2009, PHYTOTHER RES, V23, P1431, DOI 10.1002/ptr.2797; Obici L, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13580; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; de Asua DR, 2014, CLIN EPIDEMIOL, V6, P369, DOI 10.2147/CLEP.S39981; Shtrasburg S, 2012, AUTOIMMUN REV, V12, P18, DOI 10.1016/j.autrev.2012.07.017; Silva MR, 2016, SCI REP-UK, V6, DOI 10.1038/srep32288; Silva-Carvalho R, 2015, EVID-BASED COMPL ALT, DOI 10.1155/2015/206439; Watanabe K, 2015, VET PATHOL, V52, P505, DOI 10.1177/0300985814556154; Zhang C, 2010, J BIOL CHEM, V285, P28472, DOI 10.1074/jbc.M110.133520; Zhang JL, 2016, PHARM BIOL, V54, P2220, DOI 10.3109/13880209.2016.1151444	22	1	1	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					89	93		10.1293/tox.2017-0044			5	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200001	29749997	Bronze, Green Published			2019-10-28	
J	Kumabe, S; Sato, J; Tomonari, Y; Takahashi, M; Inoue, K; Yoshida, M; Doi, T; Wako, Y; Tsuchitani, M				Kumabe, Shino; Sato, Junko; Tomonari, Yuki; Takahashi, Miwa; Inoue, Kaoru; Yoshida, Midori; Doi, Takuya; Wako, Yumi; Tsuchitani, Minoru			Morphological and immunohistochemical diversity of endometrial stromal sarcoma in rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						endometrial stromal sarcoma; rat; S-100; ER alpha; immunohistochemistry	TUMORS; CELLS; EXPRESSION; CD10	To clarify the histopathological characteristics of rat endometrial stromal sarcoma (ESS), we morphologically reviewed 12 malignant uterine tumors protruding into the lumen in previous rat carcinogenicity studies. The 12 cases were classified into the following 6 types based on their morphological features: spindle cell and collagen rich type, pleomorphic/spindle cell and compact type, decidual alteration type, histiocytic and multinucleated giant cell mixture type, Antoni A-type schwannoma type, and Antoni B-type schwannoma type. Immunohistochemically, tumor cells in all cases exhibited focal or diffuse positive reactions for vimentin, and 11 of the 12 cases were positive for S-100. Interestingly, 9 cases were positive for desmin or alpha SMA, indicating tumor cells expressing smooth muscle properties. Both Antoni A-and B-type schwannoma types showed low reactions for both muscle markers. Positive results for estrogen receptor a in the 11 cases suggested that they were derived from endometrial stromal cells. On the basis of their immunohistochemical profiles, they were considered to be derived from endometrial stromal cells while they showed morphological variation. The detection of a basement membrane surrounding tumor cells might not be a definitive indicator for differential diagnosis of ESS from malignant schwannoma. In conclusion, ESS could exhibit wide morphological and immunohistochemical variation including features of schwannoma or smooth muscle tumor.	[Kumabe, Shino; Sato, Junko; Tomonari, Yuki; Doi, Takuya; Wako, Yumi; Tsuchitani, Minoru] LSI Medience Corp, Nonclin Res Ctr, Dept Pathol, 14-1 Sunayama, Kamisu, Ibaraki 3140255, Japan; [Takahashi, Miwa] Astellas Pharma Inc, Drug Safety Res Labs, 21 Miyukigaoka, Tsukuba, Ibaraki 3058585, Japan; [Inoue, Kaoru; Yoshida, Midori] Food Safety Commiss Japan, Minato Ku, 5-2-20 Akasaka, Tokyo 1076122, Japan	Sato, J (reprint author), LSI Medience Corp, Nonclin Res Ctr, Dept Pathol, 14-1 Sunayama, Kamisu, Ibaraki 3140255, Japan.	Satou.Junko@ms.medience.co.jp					Amant F, 2003, GYNECOL ONCOL, V90, P37, DOI 10.1016/S0090-8258(03)00207-5; Bernard CZ, 1987, MONOGRAPHS PATHOLOGY, P72; Chu PG, 2001, MODERN PATHOL, V14, P465, DOI 10.1038/modpathol.3880335; Dixon D, GUIDES TOXICOLOGIC P; Dixon D, 2014, J TOXICOL PATHOL, V27, p1S, DOI 10.1293/tox.27.1S; FABER M, 1986, AM J PATHOL, V124, P384; Goodman DO, 1987, MONOGRAPHS PATHOLOGY, P70; GREAVES MF, 1983, BLOOD, V61, P628; GREAVES MF, 1975, CLIN IMMUNOL IMMUNOP, V4, P67, DOI 10.1016/0090-1229(75)90041-0; Greaves P, 2012, HISTOPATHOLOGY OF PRECLINICAL TOXICITY STUDIES: INTERPRETATION AND RELEVANCE IN DRUG SAFETY EVALUATION, 4TH EDITION, P667, DOI 10.1016/B978-0-444-53856-7.00012-9; Kim Yu-Hoon, 1996, Journal of Korean Medical Science, V11, P88; Leininger JR, 1990, PATHOLOGY FISCHER RA, P455; MAITA K, 1987, Journal of Toxicological Sciences, V12, P111; McCluggage WG, 2001, HISTOPATHOLOGY, V39, P273, DOI 10.1046/j.1365-2559.2001.01215.x; Nephew KP, 2000, BIOL REPROD, V62, P168, DOI 10.1095/biolreprod62.1.168; Park JY, 2013, HISTOPATHOLOGY, V63, P833, DOI 10.1111/his.12232; Picut CA, 2009, TOXICOL PATHOL, V37, P474, DOI 10.1177/0192623309335632; Xue WC, 2011, BEST PRACT RES CL OB, V25, P719, DOI 10.1016/j.bpobgyn.2011.07.004; Yilmaz A, 2002, AM J SURG PATHOL, V26, P1142, DOI 10.1097/01.PAS.0000022569.53433.DF; Yoshizawa K, 2013, J TOXICOL PATHOL, V26, P61, DOI 10.1293/tox.26.61; Zhu XQ, 2004, GYNECOL ONCOL, V92, P71, DOI 10.1016/j.ygyno.2003.08.038	21	0	0	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					95	103		10.1293/tox.2017-0056			9	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200002	29749998	Bronze, Green Published			2019-10-28	
J	Yamamoto, A; Harano, S; Shinya, N; Nagano, A; Miyatsu, Y; Sawabe, K; Matsumura, T; Ato, M; Takahashi, M; Taki, H; Hifumi, T				Yamamoto, Akihiko; Harano, Satomi; Shinya, Noriko; Nagano, Ayataka; Miyatsu, Yoshinobu; Sawabe, Kyouko; Matsumura, Takayuki; Ato, Manabu; Takahashi, Motohide; Taki, Hisashi; Hifumi, Toru			Freeze-dried equine-derived redback spider antivenom: a local irritation study by intramuscular injection in rabbits and a repeated-dose toxicity study in rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						freeze-dried redback spider antivenom; equine polyclonal antibody; local irritation study; repeated-dose toxicity study	BITES	The redback spider (Latrodectus hasseltii) is nonindigenous to Japan but has now spread throughout the country. Bites to humans are rare but can be fatal. We prepared freeze-dried redback spider antivenom for therapeutic use against bites in Japan by immunization of horse plasma. This study included two nonclinical tests of the antivenom: a local irritation study involving a single intramuscular administration to rabbits (with injections of physiological saline and an existing freeze-dried diphtheria antitoxin as control and comparison substances, respectively) and a 2-week repeated intermittent intravenous-dose toxicity study in rats. The irritation study showed the antivenom's irritancy to be comparable with that of the saline and the existing antitoxin preparations under the test conditions. In a repeated-dose toxicity study, no toxicity change was found in male or female rats, and the no-observed-adverse-effect level (NOAEL) was judged to be a dose volume of 20 mL/kg (1082 units/kg antivenom activity) in both male and female rats. In addition, there was no toxicological difference between proteinaceous diphtheria antitoxin and redback spider antivenom prepared to have the same protein content and the same additive composition. Based on these findings, we will further advance our research towards clinical application of the redback spider antivenom. This research was supported by the Research Program on Emerging and Re-emerging Infectious Disease of the Japan Agency for Medical Research and Development.	[Yamamoto, Akihiko] Natl Inst Infect Dis, Div Biosafety Control & Res, 4-7-1 Gakuen, Musashimurayama, Tokyo 2080011, Japan; [Harano, Satomi; Shinya, Noriko; Nagano, Ayataka; Miyatsu, Yoshinobu] Chemoserotherapeut Res Inst KAKETSUKEN, Kita Ku, 1-6-1 Okubo, Kumamoto, Kumamoto 8608568, Japan; [Sawabe, Kyouko] Natl Inst Infect Dis, Dept Med Entomol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan; [Matsumura, Takayuki; Ato, Manabu] Natl Inst Infect Dis, Dept Immunol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan; [Takahashi, Motohide] Pharmaceut & Med Devices Agcy, Chiyoda Ku, 3-3-2 Kasumigaseki, Tokyo 1000013, Japan; [Taki, Hisashi] Minist Hlth Labour & Welf, Tokyo 1008916, Japan; [Hifumi, Toru] Kagawa Univ Hosp, Ctr Emergency Med, 1750-1 Ikenobe, Miki, Kagawa 7610793, Japan	Yamamoto, A (reprint author), Natl Inst Infect Dis, Div Biosafety Control & Res, 4-7-1 Gakuen, Musashimurayama, Tokyo 2080011, Japan.	yama-aki@nih.go.jp	Ato, Manabu/K-6452-2019		Research Program on Emerging and Re-emerging Infectious Disease of the Japan Agency for Medical Research and Development (AMED)Japan Agency for Medical Research and Development (AMED)	This research was supported by the Research Program on Emerging and Re-emerging Infectious Disease of the Japan Agency for Medical Research and Development (AMED).	[Anonymous], 2014, ABC NEWS; [Anonymous], 2004, MINIMUM REQUIREMENTS; [Anonymous], 2010, WHO GUIDELINES PRODU; Aya Kumei YY, 2011, JPN J DERMATOL, V121, P1881; Bartlett MS, 1937, PROC R SOC LON SER-A, V160, P0268, DOI 10.1098/rspa.1937.0109; Braitberg G, 2009, AUST FAM PHYSICIAN, V38, P862; Chippaux JP, 1992, HDB NATURAL TOXINS, V5, P529; Chotwiwatthanakun C, 2001, TOXICON, V39, P1487, DOI 10.1016/S0041-0101(01)00108-8; de Silva HA, 2016, BRIT J CLIN PHARMACO, V81, P446, DOI 10.1111/bcp.12739; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; DUNNETT CW, 1964, BIOMETRICS, V20, P482, DOI 10.2307/2528490; Frazier KS, 2012, TOXICOL PATHOL, V40, P14, DOI 10.1177/0192623312438736; GOODGOLD A L, 1955, Urol Int, V1, P225; Graudins A, 2001, ANN EMERG MED, V37, P154, DOI 10.1067/mem.2001.113033; Hard GC, 2008, TOXICOL PATHOL, V36, P1014, DOI 10.1177/0192623308327413; Hifumi T, 2015, J INTENSIVE CARE, V3, DOI 10.1186/s40560-014-0070-3; Isbister GK, 2007, INTERN MED J, V37, P820, DOI 10.1111/j.1445-5994.2007.01513.x; Khomvilai S, 2007, WHO CONS M RAB ENV N; LLEWELYN MB, 1992, BMJ-BRIT MED J, V305, P1269, DOI 10.1136/bmj.305.6864.1269; Mori S, 2017, JJID, V70, P625; Peter G, 2007, HISTOPATHOLOGY PRECL, P600; Ryan NM, 2016, CLIN TOXICOL, V54, P27, DOI 10.3109/15563650.2015.1101771; WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.1093/biomet/34.1-2.28; WIENER S, 1961, MED J AUSTRALIA, V2, P41, DOI 10.5694/j.1326-5377.1961.tb82565.x; WILCOXON F, 1945, BIOMETRICS BULL, V1, P80, DOI 10.2307/3001968	25	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					105	112		10.1293/tox.2017-0053			8	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200003	29749999	Green Published, Bronze			2019-10-28	
J	Ozaki, K; Terayama, Y; Matsuura, T; Narama, I				Ozaki, Kiyokazu; Terayama, Yui; Matsuura, Tetsuro; Narama, Isao			Effect of combined dyslipidemia and hyperglycemia on diabetic peripheral neuropathy in alloxan-induced diabetic WBN/Kob rats	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						diabetes; dyslipidemia; neuropathy; rat	MOTOR NEUROPATHY; METABOLIC SYNDROME; MOUSE MODELS; RISK-FACTORS; OBESITY; HYPERLIPIDEMIA; HYPERTENSION; PROGRESSION	Clinical and experimental research have suggested that dyslipidemia aggravates diabetic peripheral neuropathy (DPN). However, whether dyslipidemia is a risk factor for DPN remains unclear. To investigate the effect of dyslipidemia on DPN, morphological features of peripheral nerves were analyzed in diabetic rats treated with a high-fat diet (HFD). Male rats were divided into four groups: nondiabetic rats (N), alloxan-induced diabetic rats (AL), diabetic rats treated with an HFD (AH), and nondiabetic rats treated with an HFD (HF). Combined hyperglycemia and dyslipidemia (AH group) induced a significant increase in plasma triglyceride and cholesterol levels. In addition, the combined effects contributed to a reduction in myelin size and a reduction in myelin thickness as indicated on sensory sural nerve histograms. There was also a reduction in the size of motor nerve axons when compared with the effects of hyperglycemia or dyslipidemia alone. However, the sensory nerve conduction velocity in the AH group was slightly but not significantly lower than those in the HF and AL groups. These results suggest that combined hyperglycemia and dyslipidemia induced mild peripheral motor and sensory nerve lesions, without significantly affecting sensory nerve conduction velocity.	[Ozaki, Kiyokazu; Terayama, Yui; Matsuura, Tetsuro; Narama, Isao] Setsunan Univ, Fac Pharmaceut Sci, Pathol Lab, 45-1 Nagaotohge Cho, Hirakata, Osaka 5730101, Japan	Ozaki, K (reprint author), Setsunan Univ, Fac Pharmaceut Sci, Pathol Lab, 45-1 Nagaotohge Cho, Hirakata, Osaka 5730101, Japan.	ozaki@pharm.setsunan.ac.jp					Christianson JA, 2007, NEUROSCIENCE, V145, P303, DOI 10.1016/j.neuroscience.2006.11.064; De Visser A, 2014, NEUROBIOL DIS, V62, P18, DOI 10.1016/j.nbd.2013.07.019; Drel VR, 2006, DIABETES, V55, P3335, DOI 10.2337/db06-0885; Gregory JA, 2012, ACTA NEUROPATHOL, V124, P561, DOI 10.1007/s00401-012-1012-6; Guilford BL, 2011, EXP DIABETES RES, DOI 10.1155/2011/848307; Hinder LM, 2013, EXP NEUROL, V239, P102, DOI 10.1016/j.expneurol.2012.10.002; Johnson MS, 2008, PAIN, V140, P35, DOI 10.1016/j.pain.2008.07.007; Lauria G, 2005, EUR J NEUROL, V12, P747, DOI 10.1111/j.1468-1331.2005.01260.x; Low PA, 2005, JOSLINS DIABETES MEL, P839; NARAMA I, 1989, ACTA NEUROPATHOL, V79, P52, DOI 10.1007/BF00308958; Nowicki M, 2012, J NEUROSCI RES, V90, P122, DOI 10.1002/jnr.22728; Obrosova IG, 2007, DIABETES, V56, P2598, DOI 10.2337/db06-1176; Oltman CL, 2005, AM J PHYSIOL-ENDOC M, V289, pE113, DOI 10.1152/ajpendo.00594.2004; Ozaki K, 1996, ACTA NEUROPATHOL, V92, P603, DOI 10.1007/s004010050567; Ozaki K, 2016, J TOXICOL PATHOL, V29, P1, DOI 10.1293/tox.2015-0033; Ozaki K, 2013, J VET MED SCI, V75, P1323, DOI 10.1292/jvms.13-0184; Ozaki K, 2010, COMPARATIVE MED, V60, P282; POWELL H, 1977, NEUROLOGY, V27, P60, DOI 10.1212/WNL.27.1.60; Smith AG, 2013, J DIABETES COMPLICAT, V27, P436, DOI 10.1016/j.jdiacomp.2013.04.003; Smith AG, 2006, J NEUROL SCI, V242, P9, DOI 10.1016/j.jns.2005.11.020; Steinmetz A, 2008, DIABETES-METAB RES, V24, P286, DOI 10.1002/dmrr.806; Tesfaye S, 2005, NEW ENGL J MED, V352, P341, DOI 10.1056/NEJMoa032782; Vincent AM, 2009, J PERIPHER NERV SYST, V14, P257, DOI 10.1111/j.1529-8027.2009.00237.x; Vincent AM, 2009, DIABETES, V58, P2376, DOI 10.2337/db09-0047; Wiggin TD, 2009, DIABETES, V58, P1634, DOI 10.2337/db08-1771; YAGIHASHI S, 1979, TOHOKU J EXP MED, V127, P35, DOI 10.1620/tjem.127.35; YAGIHASHI S, 1993, LAB INVEST, V68, P296	27	4	4	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					125	133		10.1293/tox.2017-0063			9	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200005	29750001	Bronze, Green Published			2019-10-28	
J	Katoh, Y; Ito, T; Shimada, Y; Ohnuma-Koyama, A; Takahashi, N; Okazaki, Y; Shiga, A; Kuwahara, M; Yoshida, T; Harada, T				Katoh, Yoshitaka; Ito, Tsuyoshi; Shimada, Yuko; Ohnuma-Koyama, Aya; Takahashi, Naofumi; Okazaki, Yoshimasa; Shiga, Atsushi; Kuwahara, Maki; Yoshida, Toshinori; Harada, Takanori			Spontaneous malignant myoid thymoma in an aged female Fischer 344 rat	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						Fischer rat; malignant myoid thymoma; epithelial; rhabdomyosarcomatous	THYMUS; CELLS; DIFFERENTIATION	A whitish mass approximately 30 mm in diameter was noted in the anterior mediastinum of a 67-week-old female Fischer 344 rat. Histopathologically, two types of tumor cells were identified on the basis of morphologic features: epithelial tumor cells with a tubular or cord-like growth pattern and rhabdomyosarcomatous tumor cells characterized by the presence of cross-striations. Immunohistochemically, the epithelial tumor cells reacted positively for cytokeratin AE1/AE3, and some reacted positively for p63, which is expressed in normal thymic epithelial cells. The rhabdomyosarcomatous tumor cells stained positively for desmin, sarcomeric actin, and S-100 protein, which coincides with the stainability of normal thymic myoid cells. Since the tumor was also found to have malignant features such as high proliferative activity, cytologic atypia, and necrotic behavior, it was diagnosed as a malignant myoid thymoma. We believe that this is the first case report of such a tumor in a rodent.	[Katoh, Yoshitaka; Ito, Tsuyoshi; Shimada, Yuko; Ohnuma-Koyama, Aya; Takahashi, Naofumi; Okazaki, Yoshimasa; Shiga, Atsushi; Kuwahara, Maki; Harada, Takanori] Inst Environm Toxicol, 4321 Uchimoriya Machi, Joso, Ibaraki 3030043, Japan; [Yoshida, Toshinori] Tokyo Univ Agr & Technol, Lab Vet Pathol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan	Katoh, Y (reprint author), Inst Environm Toxicol, 4321 Uchimoriya Machi, Joso, Ibaraki 3030043, Japan.	y.katoh@iet.or.jp	Yoshida, Toshinori/B-7255-2015				BELETSKAYA L V, 1977, Arkhiv Anatomii Gistologii i Embriologii, V72, P5; Bodi I, 2015, CELL TISSUE RES, V359, P489, DOI 10.1007/s00441-014-2027-1; Bornemann A, 1996, Verh Dtsch Ges Pathol, V80, P322; Dotto J, 2007, AM J CLIN PATHOL, V127, P415, DOI 10.1309/2GAYKPDDM85P2VEW; Furukawa S, 2017, J TOXICOL PATHOL, V30, P79, DOI 10.1293/tox.2016-0047; Irifune T, 2004, ARCH HISTOL CYTOL, V67, P149, DOI 10.1679/aohc.67.149; ITO T, 1969, Archivum Histologicum Japonicum, V30, P207; Marx A, 2015, J THORAC ONCOL, V10, P1383, DOI 10.1097/JTO.0000000000000654; MORAN CA, 1993, AM J SURG PATHOL, V17, P633, DOI 10.1097/00000478-199306000-00012; MURAKAMI S, 1984, ACTA PATHOL JAPON, V34, P1375; Oka T, 2000, CELL TISSUE RES, V300, P119, DOI 10.1007/s004419900174; Pearse G, 2006, TOXICOL PATHOL, V34, P515, DOI 10.1080/01926230600978458; Pearse G, 2006, TOXICOL PATHOL, V34, P504, DOI 10.1080/01926230600865549; SAAD AH, 1992, THYMUS, V20, P135; Shimosato Y, 1997, ATLAS TUMOR PATHOL, P40; SPARN HG, 1994, DIFFERENTIATION, V56, P191, DOI 10.1046/j.1432-0436.1994.5630191.x; The Japanese Association for Laboratory Animal Science, 1987, EXP ANIM, V36, P285; ZOLTOWSKA A, 1991, THYMUS, V17, P237	18	1	1	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					135	139		10.1293/tox.2017-0045			5	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200006	29750002	Green Published, Bronze			2019-10-28	
J	Naito, T; Saito, T; Higuchi, T; Inomata, A; Hayashi, T; Shimada, Y; Yamauchi-Ohguchi, A; Kenmochi, S; Kakinuma, C; Yao, T				Naito, Tomoharu; Saito, Tsuyoshi; Higuchi, Tamami; Inomata, Akira; Hayashi, Takuo; Shimada, Yasuhiro; Yamauchi-Ohguchi, Atsuko; Kenmochi, Sayaka; Kakinuma, Chihaya; Yao, Takashi			Dedifferentiated retroperitoneal liposarcoma spontaneously occurring in an aged SD rat	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						liposarcoma; lipoblasts; SD rat; spontaneous	CLINICOPATHOLOGICAL ANALYSIS; DIFFERENTIATED LIPOSARCOMA; SOFT-TISSUE; METASTASIS	Liposarcoma is a rare neoplasm in rats and is characterized by the presence of lipoblasts containing multiple cytoplasmic vacuoles. We encountered a rare type of liposarcoma in a male SD (Crj:CD(SD) IGS) rat during a long-term study to gather background data. At necropsy at 105 weeks of age, there was a large amount of fatty tissue covering the mesentery, pancreas, and retroperitoneum; a white nodule in the right kidney; and paleness of the liver. Microscopically, the tumor had a well-differentiated component and dedifferentiated high-grade component. Immunohistochemical and electron microscopic examinations revealed that the pleomorphic tumor cells retained the characteristics of lipoblasts. Distant or disseminated metastasis was also confirmed in various organs. A liposarcoma with these histological features is extremely rare in rats, and this is the first report of a highly metastatic dedifferentiated type of liposarcoma originating from the abdominal fat tissue in a rat.	[Naito, Tomoharu; Saito, Tsuyoshi; Hayashi, Takuo; Shimada, Yasuhiro; Kakinuma, Chihaya; Yao, Takashi] Juntendo Univ, Sch Med, Dept Human Pathol, Bunkyo Ku, 1-1-19 Hongo, Tokyo 1130033, Japan; [Naito, Tomoharu; Higuchi, Tamami; Inomata, Akira; Shimada, Yasuhiro; Yamauchi-Ohguchi, Atsuko; Kenmochi, Sayaka; Kakinuma, Chihaya] FujiFilm Corp, Pharmaceut & Healthcare Res Labs, Res & Dev Management Headquarters, 577 Ushizima, Kaisei, Kanagawa 2588577, Japan; [Higuchi, Tamami] Gunma Univ, Grad Sch Med, Dept Oncol Clin Dev, 3-39-22 Showa Machi, Maebashi, Gunma 3718511, Japan	Naito, T (reprint author), Juntendo Univ, Sch Med, Dept Human Pathol, Bunkyo Ku, 1-1-19 Hongo, Tokyo 1130033, Japan.; Naito, T (reprint author), FujiFilm Corp, Pharmaceut & Healthcare Res Labs, Res & Dev Management Headquarters, 577 Ushizima, Kaisei, Kanagawa 2588577, Japan.	t-naito@jundendo.ac.jp		Higuchi, Tamami/0000-0002-6049-3666			Angiero F, 2006, ANTICANCER RES, V26, P4857; [Anonymous], 1989, Monogr Am Assoc Ment Retard, P1; Coindre JM, 2010, VIRCHOWS ARCH, V456, P167, DOI 10.1007/s00428-009-0815-x; Dalal KM, 2006, ANN SURG, V244, P381, DOI 10.1097/01.sla.0000234795.98607.00; Greaves P, 2013, J TOXICOL PATHOL, V26, p1S, DOI 10.1293/tox.26.1S; Hallin M, 2016, INT J SURG PATHOL, V24, P620, DOI 10.1177/1066896916653213; Hardisty JF, 2007, TOXICOL PATHOL, V35, P928, DOI 10.1080/01926230701748156; Hasegawa T, 2000, HUM PATHOL, V31, P717, DOI 10.1053/hupa.2000.8222; HASHIMOTO H, 1984, VIRCHOWS ARCH A, V405, P1, DOI 10.1007/BF00694921; Henricks WH, 1997, AM J SURG PATHOL, V21, P271, DOI 10.1097/00000478-199703000-00002; Horiguchi Akio, 2002, Nihon Hinyokika Gakkai Zasshi, V93, P491; Huang HY, 2005, MODERN PATHOL, V18, P976, DOI 10.1038/modpathol.3800381; Jo VY, 2014, PATHOLOGY, V46, P95, DOI 10.1097/PAT.0000000000000050; Kammerer-Jacquet SF, 2017, HUM PATHOL, V59, P34, DOI 10.1016/j.humpath.2016.08.009; Kim ES, 2010, CANCER RES TREAT, V42, P57, DOI 10.4143/crt.2010.42.1.57; KIM YI, 1987, CANCER, V60, P2785, DOI 10.1002/1097-0142(19871201)60:11<2785::AID-CNCR2820601131>3.0.CO;2-O; Matthyssens LE, 2015, FRONT SURG, V2, DOI 10.3389/fsurg.2015.00004; MCCORMICK D, 1994, AM J SURG PATHOL, V18, P1213, DOI 10.1097/00000478-199412000-00004; MINATO Y, 1986, JPN J VET SCI, V48, P429; Miura K, 1982, J JAPANESE PRACTICAL, V43, P150; Parakh RS, 2010, INDIAN J PATHOL MICR, V53, P353, DOI 10.4103/0377-4929.64347; Snarska J, 2009, WSPOLCZESNA ONKOL, V13, P334; Tirumani SH, 2015, EJSO-EUR J SURG ONC, V41, P899, DOI 10.1016/j.ejso.2015.01.012; Weiss S W, 1996, Monogr Pathol, V38, P207	24	0	0	0	2	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					141	146		10.1293/tox.2017-0055			6	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200007	29750003	Green Published, Bronze			2019-10-28	
J	Shirai, N; Evans, MG				Shirai, Norimitsu; Evans, Mark G.			Testicular microlithiasis in a clinically healthy cynomolgus monkey (Macaca fascicularis)	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						testis; microlithiasis; monkey	PULMONARY ALVEOLAR MICROLITHIASIS; PREVALENCE; TUMOR	The present article describes an occurrence of testicular microlithiasis in a cynomolgus monkey from a routine regulatory toxicology study. The monkey was from a negative control group. Microscopically, the lesion was characterized by multiple extracellular mineralized calculi within seminiferous tubular epithelia of both testes without any tissue reaction or abnormal condition such as cryptorchidism, testicular neoplasm, or hypogonadism. The present case is remarkable in that there is a paucity of reports on spontaneous testicular microlithiasis in nonhuman primates. It is hoped that this case report will help to facilitate the differentiation of spontaneous changes from induced changes in nonhuman primate toxicology studies that are designed to use limited numbers of animals.	[Shirai, Norimitsu] Pfizer Inc, Drug Safety Res & Dev, Eastern Point Rd,Off B274-1706D, Groton, CT 06340 USA; [Evans, Mark G.] Pfizer Inc, Drug Safety Res & Dev, Sci Ctr Dr, San Diego, CA 92121 USA	Shirai, N (reprint author), Pfizer Inc, Drug Safety Res & Dev, Eastern Point Rd,Off B274-1706D, Groton, CT 06340 USA.	norimitsu.shirai@pfizer.com					Bennett HF, 2001, RADIOLOGY, V218, P359, DOI 10.1148/radiology.218.2.r01fe25359; BERTHELSEN JG, 1981, SCAND J UROL NEPHROL, V15, P165, DOI 10.3109/00365598109179596; BRIX AE, 1994, VET PATHOL, V31, P382, DOI 10.1177/030098589403100314; Cast JEI, 2000, AM J ROENTGENOL, V175, P1703, DOI 10.2214/ajr.175.6.1751703; Cinone M, 2006, VET PATHOL, V43, P818; Corut A, 2006, AM J HUM GENET, V79, P650, DOI 10.1086/508263; Costabile RA, 2007, CURR OPIN UROL, V17, P419, DOI 10.1097/MOU.0b013e3282f0ffea; Derogee M, 2001, UROLOGY, V57, P1133, DOI 10.1016/S0090-4295(01)00957-8; DOHERTY FJ, 1987, J ULTRAS MED, V6, P389, DOI 10.7863/jum.1987.6.7.389; Fuller G. N., 1992, HISTOLOGY PATHOLOGIS, P145; Gartner LP, 2000, COLOR ATLAS HISTOLOG, P360; Hoei-Hansen CE, 2005, ASIAN J ANDROL, V7, P445, DOI 10.1111/j.1745-7262.2005.00020.x; Lofrano-Porto A, 2007, NEW ENGL J MED, V357, P897, DOI 10.1056/NEJMoa071999; MADARAME H, 1989, VET PATHOL, V26, P333, DOI 10.1177/030098588902600408; McKentee K., 1990, ANATOMY CONGENITAL A, P224; Miller RL, 1996, J CLIN ULTRASOUND, V24, P197, DOI 10.1002/(SICI)1097-0096(199605)24:4<197::AID-JCU6>3.0.CO;2-A; Parra BL, 1996, UROLOGY, V48, P797, DOI 10.1016/S0090-4295(96)00304-4; PRIEBE CJ, 1970, PEDIATRICS, V46, P785; Sato J, 2012, J TOXICOL PATHOL, V25, P63, DOI 10.1293/tox.25.63; Scott GBD, 1992, COMP PRIMATE PATHOLO, P28; Starost MF, 2002, VET PATHOL, V39, P390, DOI 10.1354/vp.39-3-390; VEGNITALLURI M, 1980, J UROLOGY, V124, P105, DOI 10.1016/S0022-5347(17)55318-5	22	1	1	0	0	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					147	150		10.1293/tox.2017-0065			4	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200008	29750004	Bronze, Green Published			2019-10-28	
J	Iwata, M; Yamamoto, W; Shimomoto, T; Okada, Y; Oosawa, S; Miura, D; Hara, Y				Iwata, Munetaka; Yamamoto, Wataru; Shimomoto, Takasumi; Okada, Yuki; Oosawa, Satomi; Miura, Daishiro; Hara, Yasushi			Persistence of vertebral growth plate cartilage in aged cynomolgus monkeys	JOURNAL OF TOXICOLOGIC PATHOLOGY			English	Article						cynomolgus monkey; growth plate; histology; spine; vertebra	LABORATORY-ANIMALS; END-PLATES; BONE MASS; MACAQUES; MODELS	Growth plates at each end of vertebral bodies play a pivotal role in longitudinal spinal growth. Epiphyseal closures are formed in adult humans. Although monkeys are frequently employed in bone and disc research, the age of epiphyseal closure has not been well documented. In this study, histological analyses of lumbar vertebral end plates and the surrounding tissue were performed in 11 normal cynomolgus monkeys aged approximately 9 to 15 years, and unclosed growth plate cartilage was detected in all the end plates. The data from this study constitute the first documentation of persistent vertebral growth plate cartilage in cynomolgus monkeys. The persistence of growth plate cartilage in cynomolgus monkeys approximately 15 years of age or younger, which differs from the complete epiphyseal closure exhibited in adult humans, may affect the biomechanical behavior of the spine. This is an important factor to consider in extrapolating the results of spine and intervertebral disc research using cynomolgus monkeys to adult humans.	[Iwata, Munetaka] Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Ctr Vet Med, 1-58 Rinku Oraikita, Izumisano, Osaka 5988531, Japan; [Iwata, Munetaka; Hara, Yasushi] Nippon Vet & Life Sci Univ, Sch Vet Med, Div Vet Surg, 1-7-1 Kyonancho, Musashino, Tokyo 1808602, Japan; [Yamamoto, Wataru; Shimomoto, Takasumi; Okada, Yuki; Oosawa, Satomi; Miura, Daishiro] Teijin Pharma Ltd, Toxicol Res Dept, Teijin Inst Biomed Res, 4-3-2 Asahigaoka, Hino, Tokyo 1918512, Japan	Iwata, M (reprint author), Osaka Prefecture Univ, Grad Sch Life & Environm Sci, Ctr Vet Med, 1-58 Rinku Oraikita, Izumisano, Osaka 5988531, Japan.; Iwata, M (reprint author), Nippon Vet & Life Sci Univ, Sch Vet Med, Div Vet Surg, 1-7-1 Kyonancho, Musashino, Tokyo 1808602, Japan.	s3bam2002@yahoo.co.jp					Alini M, 2008, EUR SPINE J, V17, P2, DOI 10.1007/s00586-007-0414-y; Bagi CM, 2011, COMPARATIVE MED, V61, P76; BERNICK S, 1982, SPINE, V7, P97, DOI 10.1097/00007632-198203000-00002; Bogduk N, 2005, CLIN ANATOMY LUMBAR; CARLTON WW, 1995, THOMSONS SPECIAL VET; CARPENTER E B, 1961, Clin Orthop, V21, P49; Chen Y, 2000, EXP ANIM TOKYO, V49, P163, DOI 10.1538/expanim.49.163; Iwamoto J, 2009, YONSEI MED J, V50, P358, DOI 10.3349/ymj.2009.50.3.358; JAYO MJ, 1994, CALCIFIED TISSUE INT, V54, P231, DOI 10.1007/BF00301684; Jerome CP, 2001, BONE, V29, P1, DOI 10.1016/S8756-3282(01)00477-X; Kajiura K, 2001, SPINE, V26, P2208, DOI 10.1097/00007632-200110150-00010; Kilborn SH, 2002, CONTEMP TOP LAB ANIM, V41, P21; Longo G, 2006, EUR SPINE J, V15, P1845, DOI 10.1007/s00586-005-0035-2; Maxie MG, 2007, JUBB KENNEDY PALMERS, V1; Nakai M, 2001, AM J PHYS ANTHROPOL, V116, P59, DOI 10.1002/ajpa.1102; REVEL M, 1992, CLIN ORTHOP RELAT R, P303; SHIMIZU T, 1991, EXP ANIM TOKYO, V40, P215, DOI 10.1538/expanim1978.40.2_215; Turner A. Simon, 2001, European Cells & Materials, V1, P66; Zhang YJ, 2014, SPINE, V39, pE312, DOI 10.1097/BRS.0000000000000174	19	0	0	0	1	JAPANESE SOC TOXICOLOGIC PATHOLOGY	TOKYO	DEPT ACAD SOC, MEDICAL TRIBUNE INC, ITALIAN CULTURAL INST BLDG 8F 2-1-30, KUDAN MINAMI, CHIYODA, TOKYO, 102-0074, JAPAN	0914-9198	1881-915X		J TOXICOL PATHOL	J. Toxicol. Pathol.		2018	31	2					151	154		10.1293/tox.2017-0041			4	Pathology; Toxicology	Pathology; Toxicology	GE5FI	WOS:000431244200009	29750005	Bronze, Green Published			2019-10-28	
J	Jorgensen, JT				Jorgensen, Jan Trost			When biomarkers define a drug indication	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Editorial Material						Companion diagnostics; drug-diagnostic codevelopment; dMMR; MIS-H; pembrolizumab; personalized medicine; precision medicine; tropomyosin receptor kinase inhibitor	MISMATCH-REPAIR DEFICIENCY; PD-1 BLOCKADE; MICROSATELLITE INSTABILITY; CANCER; TUMORS		[Jorgensen, Jan Trost] Dx Rx Inst, Baunevaenget 76, DK-3480 Fredensborg, Denmark	Jorgensen, JT (reprint author), Dx Rx Inst, Baunevaenget 76, DK-3480 Fredensborg, Denmark.	jan.trost@dx-rx.dk					Amatu A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000023; Au TH, 2017, J GASTROINTEST ONCOL, V8, P387, DOI 10.21037/jgo.2017.01.04; Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI 10.1053/j.gastro.2009.12.064; Chen W, 2017, DIAGN PATHOL, V12, P1, DOI 10.1186/s13000-017-0613-8; Copija A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010107; Dolgin E, 2017, NAT BIOTECHNOL, V35, P694, DOI 10.1038/nbt0817-694; Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678; Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309; Jorgensen JT, 2016, EXPERT REV MOL DIAGN, V16, P807, DOI 10.1080/14737159.2016.1199962; Jorgensen JT, 2015, TRENDS MOL MED, V21, P405, DOI 10.1016/j.molmed.2015.05.003; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968; Richman S, 2015, INT J ONCOL, V47, P1189, DOI 10.3892/ijo.2015.3119; U. S. Food and Drug Administration, 2014, GUID IND FOOD DRUG A; US FDA, 2017, PRESCR INF KEYTR PEM; US FDA, LIST CLEAR APPR COMP; US FDA, 2017, SUMM SAF EFF DAT ONC; Woodcock J, 2017, NEW ENGL J MED, V377, P62, DOI 10.1056/NEJMra1510062	19	4	4	0	1	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					315	317		10.1080/14737159.2018.1428090			3	Pathology	Pathology	GD0SV	WOS:000430211800001	29333885	Bronze			2019-10-28	
J	Sanchez, E; Tanenbaum, EJ; Patil, S; Li, MJ; Soof, CM; Vidisheva, A; Waterman, GN; Hekmati, T; Tang, G; Wang, CS; Chen, HM; Berenson, J				Sanchez, Eric; Tanenbaum, Edward J.; Patil, Saurabh; Li, Mingjie; Soof, Camilia M.; Vidisheva, Aleksandra; Waterman, Gabriel N.; Hekmati, Tara; Tang, George; Wang, Cathy S.; Chen, Haiming; Berenson, James			The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						B-cell activating factor; B-cell maturation antigen; chronic lymphocytic leukemia; immune deficiency; multiple myeloma; Waldenstrom's macroglobulinemia	NECROSIS-FACTOR FAMILY; CHRONIC LYMPHOCYTIC-LEUKEMIA; MULTIPLE-MYELOMA; BISPECIFIC ANTIBODY; BAFF-R; BCMA; SURVIVAL; APRIL; RECEPTOR; GROWTH	Introduction: B-cell maturation antigen (BCMA) is a cell membrane bound tumor necrosis factor receptor family member that is expressed exclusively on late stage normal and malignant B-cells and plasma cells. Addition of two of its ligands, B-cell activating factor and a proliferation inducting ligand, to normal B-cells cause B-cell proliferation and antibody production. Serum BCMA is elevated among patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and is a prognostic and monitoring tool for these patients. The first anti-BCMA antibody (Ab) was developed in 2007. Recently, biotech and pharmaceutical companies have created various forms of BCMA-directed Abs (naked Abs, Ab drug conjugates, and bispecific Abs) and cellular therapies (chimeric antigen receptor T-cells) with promising clinical results.Areas covered: This BCMA review encompasses full-text publications of original research articles and abstracts presented at hematology/oncology meetings.Expert commentary: The limited preclinical and ongoing clinical studies published to date evaluating BCMA-directed therapies have shown great promise. It has also been demonstrated that BCMA is solubilized and elevated in the blood of MM, Waldenstrom's macroglobulinemia and CLL patients, and is also responsible for the immune deficiency in MM. Reducing circulating levels may improve the efficacy of these treatments.	[Sanchez, Eric; Tanenbaum, Edward J.; Patil, Saurabh; Li, Mingjie; Soof, Camilia M.; Hekmati, Tara; Tang, George; Wang, Cathy S.; Chen, Haiming; Berenson, James] IMBCR, West Hollywood, CA 90069 USA; [Vidisheva, Aleksandra] Univ Arizona, Coll Med Tucson, Tucson, AZ USA; [Waterman, Gabriel N.] Univ Southern Calif Los Angeles, Keck Sch Med, Los Angeles, CA USA	Berenson, J (reprint author), IMBCR, West Hollywood, CA 90069 USA.	jberenson@imbcr.org					Alyanakian MA, 2004, AM J HEMATOL, V75, P246, DOI 10.1002/ajh.20007; Anderson CL, 2006, TRENDS IMMUNOL, V27, P343, DOI 10.1016/j.it.2006.05.004; Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025; Berdeja JG, 2017, 53 AM SOC CLIN ONC A; BRODER S, 1975, NEW ENGL J MED, V293, P887, DOI 10.1056/NEJM197510302931801; Bujarski S, 2017, MYEL BIOL PATH EXCL; Carpenter RO, 2013, CLIN CANCER RES, V19, P2048, DOI 10.1158/1078-0432.CCR-12-2422; Chen H, 2016, 58 ASH ANN M EXP DEC; Chiu A, 2007, BLOOD, V109, P729, DOI 10.1182/blood-2006-04-015958; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; CONE L, 1964, J CLIN INVEST, V43, P2241, DOI 10.1172/JCI105098; Dittrich T, 2017, BLOOD, V130, P632, DOI 10.1182/blood-2017-02-767475; FAHEY JL, 1963, AM J MED, V35, P698, DOI 10.1016/0002-9343(63)90140-2; Fan F, 2017, 53 AM SOC CLIN ONC A; Ghermezi M, 2017, HAEMATOLOGICA, V102, P785, DOI 10.3324/haematol.2016.150896; Gross JA, 2000, NATURE, V404, P995, DOI 10.1038/35010115; Hallek M, 1996, LEUKEMIA LYMPHOMA, V22, P439, DOI 10.3109/10428199609054782; Hamblin TJ, 1999, BLOOD, V94, P1848; Hipp S, 2017, LEUKEMIA, V31, P1743, DOI 10.1038/leu.2016.388; Jagannath S, 2007, CLIN LYMPHOMA MYELOM, V7, P518, DOI 10.3816/CLM.2007.n.036; Kastritis E, 2014, LEUKEMIA, V28, P2075, DOI 10.1038/leu.2014.110; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; LAABI Y, 1992, EMBO J, V11, P3897, DOI 10.1002/j.1460-2075.1992.tb05482.x; LAABI Y, 1994, NUCLEIC ACIDS RES, V22, P1147, DOI 10.1093/nar/22.7.1147; Laurent SA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8333; Mackay F, 2002, NAT REV IMMUNOL, V2, P465, DOI 10.1038/nri844; Maglione PJ, 2016, GEN DYSR IMM IMM MED; Mariani G, 1990, FC RECEPTORS ACTION, P94; Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Moreno L, 2016, 58 ASH ANN M EXP DEC; Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood-2003-06-2043; Pelletier M, 2003, J BIOL CHEM, V278, P33127, DOI 10.1074/jbc.M305754200; PERRI RT, 1981, AM J MED, V71, P935, DOI 10.1016/0002-9343(81)90303-X; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Ramadoss NS, 2015, J AM CHEM SOC, V137, P5288, DOI 10.1021/jacs.5b01876; Rennert P, 2000, J EXP MED, V192, P1677, DOI 10.1084/jem.192.11.1677; Ryan MC, 2007, MOL CANCER THER, V6, P3009, DOI 10.1158/1535-7163.MCT-07-0464; Samy E, 2017, INT REV IMMUNOL, V36, P3, DOI 10.1080/08830185.2016.1276903; Sanchez E, 2016, CLIN CANCER RES, V22, P3383, DOI 10.1158/1078-0432.CCR-15-2224; Sanchez E, 2012, BRIT J HAEMATOL, V158, P727, DOI 10.1111/j.1365-2141.2012.09241.x; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Schneider P, 2001, J EXP MED, V194, P1691, DOI 10.1084/jem.194.11.1691; Seckinger A, 2017, CANCER CELL, V31, P396, DOI 10.1016/j.ccell.2017.02.002; Shu HB, 2000, P NATL ACAD SCI USA, V97, P9156, DOI 10.1073/pnas.160213497; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Sun C, 2017, LYMPH BIOL NONG STUD; Tai YT, 2016, BLOOD, V127, P3225, DOI 10.1182/blood-2016-01-691162; Tai YT, 2014, BLOOD, V123, P3128, DOI 10.1182/blood-2013-10-535088; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; Trudel S, 2017, MYEL THER EXCL TRANS; Udd KA, 2015, 57 ASH ANN M EXP DEC; Udd KA, 2017, 16 INT MYEL WORKSH M; Vardanyan S, 2015, 57 ASH ANN M EXP DEC; Yan MH, 2000, NAT IMMUNOL, V1, P37	55	2	2	0	6	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					319	329		10.1080/14737159.2018.1448269			11	Pathology	Pathology	GD0SV	WOS:000430211800002	29504446				2019-10-28	
J	Cao, HY; You, D; Lan, Z; Ye, H; Hou, MM; Xi, MR				Cao, Hanyu; You, Di; Lan, Zhu; Ye, Hui; Hou, Minmin; Xi, Mingrong			Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies	EXPERT REVIEW OF MOLECULAR DIAGNOSTICS			English	Review						Human epididymis protein 4; ovarian cancer; prognosis; survival; recurrence	EPIDIDYMIS PROTEIN 4; PREDICT OPTIMAL CYTOREDUCTION; NEWCASTLE-OTTAWA SCALE; NEOADJUVANT CHEMOTHERAPY; DIAGNOSTIC PERFORMANCE; MALIGNANCY ALGORITHM; ROMA ALGORITHM; CA125; CARCINOMA; BIOMARKER	Introduction: Ovarian cancer (OC) is one of the leading causes of cancer-related death in women. Accumulating evidence showed an evolving role of HE4 in monitoring the progression and prognosis of OC but without a comprehensive analysis for prognosis and survival data.Areas covered: The present meta-analysis aims to explore the association of HE4 with survival and the clinicopathological features of OC patients. PubMed, Embase, Web of Science and the China National Knowledge Infrastructure (CNKI) were searched for relevant studies regarding the role of both serum and tissue HE4 expression in ovarian cancer.Expert commentary: HE4 has been proposed as the most promising biomarker that may complement the CA125 expression and has been approved by the FDA in monitoring the follow-up and relapse of OC patients. Our results are in accordance with the most recent evidence suggesting its important role in the prognostic surveillance of OC and a better performance in the early prediction of OC recurrence than CA125.	[Cao, Hanyu; You, Di; Ye, Hui; Hou, Minmin; Xi, Mingrong] Sichuan Univ, West China Univ Hosp 2, Dept Gynecol & Obstet, 20 Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China; [Lan, Zhu] Minist Educ, Key Lab Birth Defects & Related Dis Women & Child, Chengdu, Sichuan, Peoples R China; [Hou, Minmin] Univ Elect Sci & Technol China, Terahertz Sci & Technol Key Lab Sichuan Prov, Chengdu, Sichuan, Peoples R China	Hou, MM; Xi, MR (reprint author), Sichuan Univ, West China Univ Hosp 2, Dept Gynecol & Obstet, 20 Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.	mayvenhou@126.com; xmrjzz@126.com			Terahertz Science and Technology Key Laboratory of Sichuan Province [SCTHZ2017002]; National Science Foundation of ChinaNational Natural Science Foundation of China [61741511]	The study was supported by the Terahertz Science and Technology Key Laboratory of Sichuan Province (grant number SCTHZ2017002) and the National Science Foundation of China (grant number 61741511).	Anastasi E, 2010, TUMOR BIOL, V31, P113, DOI 10.1007/s13277-009-0015-y; Anderson KS, 2010, CANCER EPIDEM BIOMAR, V19, P859, DOI 10.1158/1055-9965.EPI-09-0880; Angioli R, 2014, TUMOR BIOL, V35, P7009, DOI 10.1007/s13277-014-1836-x; Angioli R, 2013, GYNECOL ONCOL, V128, P579, DOI 10.1016/j.ygyno.2012.11.040; Bai J, 2015, CHIN J OBSTET GYNECO, V4, P458; Bandiera E, 2011, CANCER EPIDEM BIOMAR, V20, P2496, DOI 10.1158/1055-9965.EPI-11-0635; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bi YL, 2013, CHINA MED HERALD, V10, P58; Braicu EI, 2014, ANN SURG ONCOL, V21, P955, DOI 10.1245/s10434-013-3347-1; Buys SS, 2011, JAMA-J AM MED ASSOC, V305, P2295, DOI 10.1001/jama.2011.766; Chen S, 2012, LABELED IMMUNOASSAYS, V19, P6; Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024; Chen ZB, 2014, LAB MED CHIN, V11, P749; Dayyani F, 2016, INT J GYNECOL CANCER, V26, P1586, DOI 10.1097/IGC.0000000000000804; Devan SM, 2013, ASIAN PAC J CANCER P, V14, P4545, DOI 10.7314/APJCP.2013.14.8.4545; Dong HM, 2014, CHIN J HLTH LAB TEC, V24, P1590; Drapkin R, 2005, CANCER RES, V65, P2162, DOI 10.1158/0008-5472.CAN-04-3924; Egger M, 1998, BMJ-BRIT MED J, V316, P61, DOI 10.1136/bmj.316.7124.61; Gan L, 2016, CHIN J HUM SEXUALITY, V25, P50; Gao H, 2016, CHIN J FRONT MED SCI, V8, P83; Georgakopoulos P, 2012, INT J GYNECOL PATHOL, V31, P517, DOI 10.1097/PGP.0b013e31824fe269; Granato T, 2015, CLIN CHIM ACTA, V446, P147, DOI 10.1016/j.cca.2015.03.047; Guo YD, 2015, TUMOR BIOL, V36, P2457, DOI 10.1007/s13277-014-2858-0; Hamed EO, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-11; Hao YM, 2017, INT J LAB MED, V38, P981; Hartling L, 2013, J CLIN EPIDEMIOL, V66, P982, DOI 10.1016/j.jclinepi.2013.03.003; He SQ, 2016, J MATH MED, V29, P1607; He XL, 2017, J CHIN PRACT DIAGN T, V31, P245; Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7; Hellstrom I, 2003, CANCER RES, V63, P3695; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hou CY, 2016, PRACT J CANC, V31, P1379; Hu SS, 2012, CHINA CANC, V21, P638; Hu XD, 2017, SHANDONG MED J, V57, P58; Huang LJ, 2015, WORLD LATEST MED INF, V15, P12; Huang LY, 2013, CHIN J CLIN ONCOL RE, V20, P816; Huang SY, 2011, HEBEI MED, V17, P443; Jia MM, 2017, ONCOTARGET, V8, P9660, DOI 10.18632/oncotarget.14173; Jiang JH, 2015, INT J CLIN EXP MED, V8, P21303; Kalapotharakos G, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-20; Karlsen MA, 2016, APMIS, V124, P1038, DOI 10.1111/apm.12625; Kobel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232; Kong SY, 2012, ANN SURG ONCOL, V19, P1707, DOI 10.1245/s10434-011-1943-5; Leandersson P, 2016, ANTICANCER RES, V36, P957; Lee S, 2017, J OBSTET GYNAECOL RE, V43, P220, DOI 10.1111/jog.13181; Li K, 2016, SHANDONG MED J, V56, P79; Li Kai, 2012, Chinese Journal of Biologicals, V25, P99; Li RQ, 2015, CHIN MED ENG, V10, P47; Li WJ, 2017, J HENAN MED COLL, V29, P211; Li XQ, 2017, INT J LAB MED, V38, P1138; Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349; Moore RG, 2014, SCI REP-UK, V4, DOI 10.1038/srep03574; Moore RG, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.03.043; Mou YP, 2016, INT J LAB MED, V37, P2805; Nassir M, 2016, TUMOR BIOL, V37, P3009, DOI 10.1007/s13277-015-4031-9; Orsaria M, 2016, CANCER BIOMARK, V17, P479, DOI 10.3233/CBM-160665; Paek J, 2011, EUR J OBSTET GYN R B, V158, P338, DOI 10.1016/j.ejogrb.2011.05.021; Pallin DJ, 2010, INTENS CARE MED, V36, P1268, DOI 10.1007/s00134-010-1880-y; Pan QW, 2016, ONCOL PROG, V14, P526; Plotti F, 2012, TUMOR BIOL, V33, P2117, DOI 10.1007/s13277-012-0471-7; Qiu J, 2011, J RADIOIMMUNOLOGY, V24, P125; Qiu Zhenhua WM, 2014, INT J LAB MED, V35, P1984; Ren HY, 2014, CHINA HLTH IND, V21, P177; Ribeiro JR, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0240-0; Rodriguez N, 2012, GYNECOL ONCOL, V125, P362, DOI 10.1016/j.ygyno.2012.02.006; Rosen DG, 2005, GYNECOL ONCOL, V99, P267, DOI 10.1016/j.ygyno.2005.06.040; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8; Sandri MT, 2013, GYNECOL ONCOL, V128, P233, DOI 10.1016/j.ygyno.2012.11.026; Scaletta G, 2017, EXPERT REV ANTICANC, V17, P827, DOI 10.1080/14737140.2017.1360138; Shen HM, 2014, J XINXIANG MED U, V31, P922; [申颖 Shen Ying], 2016, [现代妇产科进展, Current Advances In Obstetrics and Gynecology], V25, P495; Shi SF, 2014, J WANNAN MED COLL, V33, P402; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Song XC, 2012, PRACT J PRACT J, V28, P2380; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Steffensen KD, 2012, INT J GYNECOL CANCER, V22, P1474, DOI 10.1097/IGC.0b013e3182681cfd; Steffensen KD, 2011, INT J GYNECOL CANCER, V21, P1040, DOI 10.1097/IGC.0b013e31821e052e; Su HW, 2014, J MED RES, V43, P71; Su SG, 2015, PRACT J CANC, V30, P636; Su T, 2011, SHANGDONG MED, V51, P62; Tang ZJ, 2011, CHIN J CLIN OBSTET G, V12, P364; Tian F, 2014, LAB MED, V7, P697; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Trudel D, 2012, GYNECOL ONCOL, V127, P511, DOI 10.1016/j.ygyno.2012.09.003; Vallius T, 2014, TUMOR BIOL, V35, P12389, DOI 10.1007/s13277-014-2553-1; Wang DD, 2012, PRACT J CANC, V27, P578; Wang JW, 2014, TUMOR BIOL, V35, P6127, DOI 10.1007/s13277-014-1811-6; Wang L, 2016, J MED FORUM, V37, P164; Wang YC, 2012, MOD ONCOL, V4, P785; Wang YK, 2015, MED RECAPITULATE, V21, P1700; Wang ZQ, 2014, PRACT J CANC, V4, P412; Wu HJ, 2015, CHINA MED PHARM, V5, P123; Wu XM, 2014, J NANCHANG U MED SCI, V54, P51; Xie YM, 2014, MED J W CHINA, V26, P576; Xu FL, 2013, CHIN J CLINICIANS, V7, P2407; Xu K, 2015, CHIN J CLIN OBSTET G, V30, P3725; Xu LJ, 2016, J HAINAN MED U, V22, P503; Xu Y, 2016, CLIN BIOCHEM, V49, P32, DOI 10.1016/j.clinbiochem.2015.07.029; Xue W, 2016, LAB MED CLIN, V13, P73; [杨辰 Yang Chen], 2010, [苏州大学学报. 医学版, Suzhou University Journal of Medical Science], V30, P795; Yang HC, 2016, BMU J, V39, P9; Yin YY, 2014, J MED RES, V43, P132; Yu YA, 2016, CHIN J CLIN OBSTET G, V5, P391; Yuan Y, 2012, J XINXIANG MED COLL, V29, P850; Yuping F, 2010, LABELED IMMUNOASSAYS, V17, P368; Zhang CY, 2012, JOURNAL OF RADIOIMMU, V25, P406; Zhang M., 2016, SCI REP, V6, P1; Zhang SM, 2015, CHINA MODERN DOCTOR, V53, P112; Zhang YJ, 2013, MATERN CHILD HLTH J, V28, P2290, DOI DOI 10.7620/ZGFYBJ.J.ISSN.1001-4411.2013.28.38; Zhao H, 2013, J TAISHAN MED COLL, V33, P893; Zhen S, 2014, MOL CLIN ONCOL, V2, P559, DOI 10.3892/mco.2014.279; Zheng L-E, 2013, CHINA MED PHARM, V3, P23; Zheng LE, 2016, OPEN MED-WARSAW, V11, P125, DOI 10.1515/med-2016-0024; Zhong H, 2017, CLIN CHIM ACTA, V470, P109, DOI 10.1016/j.cca.2017.05.007; Zhou Z, 2015, MED J COMMUNICATIONS, V29, P117; [朱凤琴 Zhu Fengqin], 2014, [临床与实验病理学杂志, Chinese Journal of Clinical and Experimental Pathology], V30, P1131; Zhu LC, 2016, ONCOTARGET, V7, P729, DOI 10.18632/oncotarget.6327; Zhu P, 2017, J HAINAN MED U, V23, P1120; Zhu WL, 2014, SICHUAN MED J, V35, P1223; Zhu YF, 2012, ASIAN PAC J TROP MED, V5, P925, DOI 10.1016/S1995-7645(12)60175-8; Zhuang HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068994; 刘玉嵚, 2016, [中国老年学杂志, Chinese Journal of Gerontology], V36, P4242; 杨丽萍, 2014, [中国老年学杂志, Chinese Journal of Gerontology], V34, P7083	123	2	2	4	5	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	1473-7159	1744-8352		EXPERT REV MOL DIAGN	Expert Rev. Mol. Diagn.		2018	18	4					371	383		10.1080/14737159.2018.1457436			13	Pathology	Pathology	GD0SV	WOS:000430211800006	29569984				2019-10-28	
J	Cheah, PL; Looi, LM; Horton, S				Cheah, Phaik-Leng; Looi, Lai Meng; Horton, Susan			Cost Analysis of Operating an Anatomic Pathology Laboratory in a Middle-Income Country	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Economic evaluation; Global health; Malaysia; Cost	WORKFLOW; WORKLOAD; TOOL	Objective: To examine the cost of operating an anatomic pathology laboratory in a teaching hospital in Malaysia. Once the cost is determined, compare it with the costs of operating other laboratories in the same hospital, and operating anatomic pathology laboratories in other countries. Methods: Cost and workload data were obtained from hospital records for 2015. Time allocation of staff between laboratory testing and other activities was determined using assumptions from published workload studies. Results: The laboratory received 20,093 cases for testing in 2015, and total expenditures were US $1.20 million, ie, $61.97 per case. The anatomic pathology laboratory accounted for 5.2% of the laboratory budget at the hospital, compared to 64.3% for the clinical laboratory and 30.5% for the microbiology laboratory. We provide comparisons to a similar laboratory in the United States. Conclusions: Anatomic pathology is more costly than other hospital laboratories due to the labor-intensive work, but is essential, particularly for cancer diagnoses and treatment.	[Cheah, Phaik-Leng; Looi, Lai Meng] Univ Malaya, Dept Pathol, Kuala Lumpur, Malaysia; [Horton, Susan] Univ Waterloo, Sch Publ Hlth & Hlth Syst, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada	Horton, S (reprint author), Univ Waterloo, Sch Publ Hlth & Hlth Syst, 200 Univ Ave West, Waterloo, ON N2L 3G1, Canada.	sehorton@uwaterloo.ca	Looi, Lai Meng/A-3382-2009; Looi, Lai Meng/AAB-9403-2019	Looi, Lai Meng/0000-0001-8325-0117; Horton, Susan/0000-0002-9243-4767			[Anonymous], 2015, U MAL MED CTR ANN RE; Charuruks Navapun, 2004, J Med Assoc Thai, V87, P955; Chua HT, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-S1-S7; Connolly J. L., 2003, ROLE SURG PATHOLOGIS; Department of Health, 2008, REP 2 PHAS REV NHS P; Fleming KA, 2017, AM J CLIN PATHOL, V147, P15, DOI [10.1093/AJCP/AQW143, 10.1093/ajcp/aqw143]; Gopal S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070361; Grimm EE, 2009, ARCH PATHOL LAB MED, V133, P601, DOI 10.1043/1543-2165-133.4.601; Gujral S, 2010, INDIAN J PATHOL MICR, V53, P68, DOI 10.4103/0377-4929.59187; Kohl SK, 2011, ARCH PATHOL LAB MED, V135, P728, DOI 10.1043/2010-0288-CP.1; Malaysia Department of Standards, 2011, STR 2 1 SPEC TECHN R; Maung RTA, 2005, AM J CLIN PATHOL, V123, P45, DOI 10.1309/23NYGNB2HFNNW4V8; Muirhead D, 2010, ARCH PATHOL LAB MED, V134, P1164, DOI 10.1043/2000-0401-OA.1; Resar RK, 2006, HEALTH SERV RES, V41, P1677, DOI 10.1111/j.1475-6773.2006.00571.x; Su BG, 2016, CLIN CHEM LAB MED, V54, P1753, DOI 10.1515/cclm-2016-0193	15	1	1	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					1	7		10.1093/AJCP/AQX088			7	Pathology	Pathology	GC0FL	WOS:000429452200001	29267843				2019-10-28	
J	Su, CL; Jia, SS; Liu, HG				Su, Caili; Jia, Shuangshuang; Liu, Honggang			Immunolocalization of CD163+Tumor-Associated Macrophages and Symmetric Proliferation of Ki-67 as Biomarkers to Differentiate New Different Grades of Laryngeal Dysplasia	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Tumor-associated macrophages; Laryngeal dysplasia; Ki-67; Tumor biomarker; 2017 WHO classification	TUMOR-ASSOCIATED MACROPHAGES; SQUAMOUS-CELL CARCINOMA; MALIGNANT-TRANSFORMATION; PRECANCEROUS LESIONS; PREMALIGNANT LESIONS; PATTERN LOSS; MICROENVIRONMENT; ADENOCARCINOMA; CLASSIFICATION; POLARIZATION	Objectives: To evaluate CD163+ tumor-associated macrophages (TAMs), Ki-67, and cyclin D1 to differentiate laryngeal dysplasia in the 2017 World Health Organization classification. Methods: Immunohistochemistry for CD163, Ki-67, and cyclin D1 was performed using paraffin-embedded specimens. CD163+ TAMs infiltrating the epithelium were estimated. Ki-67 and cyclin D1 were evaluated in four parts of the epithelium-basal, parabasal, middle third, and upper third layers. Results: In total, 133 specimens were analyzed, including low-grade dysplasia (n = 31), high-grade dysplasia (n = 49), carcinoma in situ (n = 23), and normal mucosa (n = 30). CD163+ TAMs infiltrating the epithelium were significantly higher in high-grade dysplasia than in low-grade dysplasia. In the basal layer, Ki-67+ and cyclin D1+ cells were overexpressed in high-grade dysplasia (P < .0001). The area under the curve was 0.958 for Ki-67 and 0.909 for CD163+ TAMs (P < .0001). Conclusions: CD163+ TAMs infiltrating the epithelium and Ki-67 overexpression in the basal layer may serve as biomarkers to differentiate low-grade dysplasia from high-grade dysplasia of the larynx. A symmetric proliferative pattern was observed during laryngeal carcinogenesis following Ki-67 overexpression.	[Su, Caili; Jia, Shuangshuang; Liu, Honggang] Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Head & Neck Mol Diagnost Pathol, Dept Pathol, Dongjiaominxiang St, Beijing 100730, Peoples R China	Liu, HG (reprint author), Capital Med Univ, Beijing Tongren Hosp, Beijing Key Lab Head & Neck Mol Diagnost Pathol, Dept Pathol, Dongjiaominxiang St, Beijing 100730, Peoples R China.	liuhg1125@163.com	Bridgewater, John/J-5957-2018		Capital Health Research and Development of Special Foundation [2014-2-2053]	This work was supported by the Capital Health Research and Development of Special Foundation (No. 2014-2-2053).	Bierie B, 2010, CYTOKINE GROWTH F R, V21, P49, DOI 10.1016/j.cytogfr.2009.11.008; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Fleskens S, 2009, HEAD NECK ONCOL, V1, DOI 10.1186/1758-3284-1-11; Fleskens SAJHM, 2011, MODERN PATHOL, V24, P892, DOI 10.1038/modpathol.2011.50; Fujii T, 2013, PATHOBIOLOGY, V80, P119, DOI 10.1159/000342396; Gale N, 2017, HEAD NECK PATHOL, V11, P23, DOI 10.1007/s12105-017-0788-z; Gale N, 2014, HISTOPATHOLOGY, V65, P456, DOI 10.1111/his.12427; Garcia NG, 2016, J EUR ACAD DERMATOL, V30, P1315, DOI 10.1111/jdv.13671; Gonzalez-Moles MA, 2014, J ORAL PATHOL MED, V43, P507, DOI 10.1111/jop.12164; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Jiang XF, 2013, J OBSTET GYNAECOL RE, V39, P855, DOI 10.1111/j.1447-0756.2012.02036.x; Lin Jia-Ying, 2011, Chin J Cancer, V30, P280; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mori K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1587-0; Pettersen JS, 2011, J INVEST DERMATOL, V131, P1322, DOI [10.1038/jid.2011.9, 10.103/jid.2011.9]; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Preethi Penubolu Lakshmi, 2014, J Indian Soc Periodontol, V18, P161, DOI 10.4103/0972-124X.131315; ROLAND NJ, 1994, CLIN OTOLARYNGOL, V19, P13, DOI 10.1111/j.1365-2273.1994.tb01140.x; Wei L, 2016, ACTA OTO-LARYNGOL, V136, P923, DOI 10.3109/00016489.2016.1165862; Zhang BC, 2011, CLINICS, V66, P1879, DOI 10.1590/S1807-59322011001100006; Zhang HK, 2012, ACTA OTO-LARYNGOL, V132, P325, DOI 10.3109/00016489.2011.642812; Zhao HX, 2014, TOXICOL APPL PHARM, V279, P311, DOI 10.1016/j.taap.2014.07.001; Zidar N, 1996, J LARYNGOL OTOL, V110, P440, DOI 10.1017/S0022215100133924	24	1	1	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					8	16		10.1093/AJCP/AQX107			9	Pathology	Pathology	GC0FL	WOS:000429452200002	29228085				2019-10-28	
J	Grygalewicz, B; Woroniecka, R; Rymkiewicz, G; Rygier, J; Borkowska, K; Kotyl, A; Blachnio, K; Bystydzienski, Z; Nowakowska, B; Pienkowska-Grela, B				Grygalewicz, Beata; Woroniecka, Renata; Rymkiewicz, Grzegorz; Rygier, Jolanta; Borkowska, Klaudia; Kotyl, Aleksandra; Blachnio, Katarzyna; Bystydzienski, Zbigniew; Nowakowska, Beata; Pienkowska-Grela, Barbara			The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						11q-gain/loss; Burkitt-like lymphoma with 11q aberration; KMT2A; MYC; High-grade B-cell lymphoma	UNIPARENTAL DISOMY; PATHOGENESIS; DIAGNOSIS; REGIONS; PATTERN; SUBSET; CANCER; ETS1	Objectives: The latest revision of lymphoma's World Health Organization classification describes the new provisional entity "Burkitt-like lymphoma with 11q aberration" (BLL, 11q) as lacking MYC rearrangement, but harboring the specific11q-gain/loss aberration. We report genetic characteristics of 11 lymphoma cases with this aberration. Methods: Classical cytogenetics, fluorescence in situ hybridization (FISH), and single nucleotide polymorphism/array comparative genomic hybridization. Results: The 11q aberrations were described as duplication, inversion, and deletion. Array comparative genomic hybridization showed two types of duplication: bigger than 50 megabase pairs (Mbp) and smaller than 20 Mbp, which were associated with bulky tumor larger than 20 cm and amplification of the 11q23.3 region, including KMT2A. Six cases revealed a normal FISH status of MYC and were diagnosed as BLL, 11q. Five cases showed MYC rearrangement and were diagnosed as Burkitt lymphoma (BL) or high-grade B-cell lymphoma, not otherwise specified (HGBL, NOS). Conclusions: The 11q-gain/loss is not specific for BLL, 11q, but occurs recurrently in MYC-positive BL and MYC-positive HGBL.	[Grygalewicz, Beata; Woroniecka, Renata; Rymkiewicz, Grzegorz; Rygier, Jolanta; Borkowska, Klaudia; Kotyl, Aleksandra; Pienkowska-Grela, Barbara] Maria Sklodowska Curie Inst Oncol Ctr, Cytogenet Lab, 15B Wawelska St, PL-02034 Warsaw, Poland; [Rymkiewicz, Grzegorz; Blachnio, Katarzyna; Bystydzienski, Zbigniew] Maria Sklodowska Curie Inst Oncol Ctr, Flow Cytometry Lab, Pathol & Lab Diagnost Dept, Warsaw, Poland; [Nowakowska, Beata] Mother & Child Inst, Dept Med Genet, Warsaw, Poland	Grygalewicz, B (reprint author), Maria Sklodowska Curie Inst Oncol Ctr, Cytogenet Lab, 15B Wawelska St, PL-02034 Warsaw, Poland.	bgrygal@coi.pl	Rymkiewicz, Grzegorz/AAB-7301-2019				Bonetti P, 2013, BLOOD, V122, P2233, DOI 10.1182/blood-2013-01-475772; Ferreiro JF, 2015, HAEMATOLOGICA, V100, pE275, DOI 10.3324/haematol.2015.124305; Gondek LP, 2008, BLOOD, V111, P1534, DOI 10.1182/blood-2007-05-092304; Grygalewicz B, 2016, MOL CYTOGENET, V9, DOI 10.1186/s13039-015-0212-x; Havelange V, 2016, CANCER GENET-NY, V209, P117, DOI 10.1016/j.cancergen.2015.12.005; Hermetz KE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004139; Makishima H, 2011, CLIN CANCER RES, V17, P3913, DOI 10.1158/1078-0432.CCR-10-2900; McGowan-Jordan J, 2016, ISCN 2016 INT SYSTEM; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Nielaender I, 2006, LEUKEMIA, V20, P904, DOI 10.1038/sj.leu.2404173; O'Shea D, 2009, BLOOD, V113, P2298, DOI 10.1182/blood-2008-08-174953; Pienkowska-Grela B, 2011, MED ONCOL, V28, P1589, DOI 10.1007/s12032-010-9614-0; Rymkiewicz G, 2015, 57 ANN M AM SOC HEM; Salaverria I, 2014, BLOOD, V123, P1187, DOI 10.1182/blood-2013-06-507996; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Sund KL, 2013, GENET MED, V15, P70, DOI 10.1038/gim.2012.94; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Testoni M, 2015, LEUKEMIA LYMPHOMA, V56, P1975, DOI 10.3109/10428194.2014.981670; Zajdel M, 2015, TUMOR BIOL, V36, P5377, DOI 10.1007/s13277-015-3203-y; Zhang XK, 2008, J IMMUNOL, V181, P1644, DOI 10.4049/jimmunol.181.3.1644	20	5	5	2	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					17	28		10.1093/AJCP/AQX139			12	Pathology	Pathology	GC0FL	WOS:000429452200003	29272887	Bronze, Green Published			2019-10-28	
J	O'Brien, JJ; Cooke, RK; Ebrahim-Nejad, AA; Hunt, JM; Fontaine, MJ				O'Brien, Jennifer J.; Cooke, Rhonda K.; Ebrahim-Nejad, Ali A.; Hunt, Janice M.; Fontaine, Magali J.			Algorithm to Manage Inconclusive RBC Antibodies by Reflex Manual Testing	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Transfusion medicine; Red blood cell; Antibody identification; Inconclusive antibody	RED-CELL ALLOANTIBODIES; SOLID-PHASE; IDENTIFICATION	Objectives: Inconclusive RBC antibody identification (ABID) may delay RBC crossmatch. An increased number of inconclusive ABID was observed, and an algorithm was developed to improve ABID efficiency. Methods: RBC antibody screen (AS) and ABID were initially performed using solid-phase RBC adherence assay (SPRCA) and manual tube method. A retrospective analysis of AS and ABID results was performed pre- and postalgorithm implementation. Results: The number of inconclusive ABID results decreased from 26 to six per month pre- and postimplementation, respectively. SPRCA became the primary AS method, and manual tube became the gold standard for ABID. SPRCA was used for ABID upon reference specialist secondary review and allowed identification of 30 specific RBC antibodies, for which no patients developed signs or symptoms of a hemolytic transfusion reaction. Conclusions: RBC reference workflow using SPRCA and manual tube methods for AS and ABID decreases "inconclusive" ABID without adverse events.	[O'Brien, Jennifer J.; Cooke, Rhonda K.; Fontaine, Magali J.] Univ Maryland, Sch Med, Dept Pathol & Lab Med, 22 S Greene St,N2W40, Baltimore, MD 21201 USA; [Ebrahim-Nejad, Ali A.; Hunt, Janice M.] Univ Maryland, Med Ctr, Dept Pathol & Lab Med, Baltimore, MD 21201 USA	O'Brien, JJ (reprint author), Univ Maryland, Sch Med, Dept Pathol & Lab Med, 22 S Greene St,N2W40, Baltimore, MD 21201 USA.	jenniferobrien@umm.edu					Bunker ML, 2001, TRANSFUSION, V41, P621, DOI 10.1046/j.1537-2995.2001.41050621.x; Callahan DL, 2000, TRANSFUSION, V40, p113S; Casina T S, 2006, Immunohematology, V22, P196; Ebrahim A, 2014, TRANSFUSION, V54, p177A; Finck R H, 2011, Immunohematology, V27, P1; Garratty G, 2003, TRANSFUSION, V43, P844, DOI 10.1046/j.1537-2995.2003.00492.x; ISSITT PD, 1993, TRANSFUSION, V33, P284, DOI 10.1046/j.1537-2995.1993.33493242634.x; Liu C, 2014, AABB ANN M CTTXPO, p175A; Liu C, 2013, TRANSFUSION, V53, P931, DOI 10.1111/trf.12070; Tormey CA, 2013, TRANSFUSION, V53, P926, DOI 10.1111/trf.12147; Weisbach V, 2006, TRANSFUSION MED, V16, P276, DOI 10.1111/j.1365-3148.2006.00674.x; Yamada C, 2008, TRANSFUSION, V48, P1693, DOI 10.1111/j.1537-2995.2008.01736.x	12	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					29	34		10.1093/AJCP/AQX109			6	Pathology	Pathology	GC0FL	WOS:000429452200004	29272886	Bronze			2019-10-28	
J	Gultawatvichai, P; Tavares, MF; DiQuattro, PJ; Cheves, TC; Sweeney, JD				Gultawatvichai, Patan; Tavares, Maria F.; DiQuattro, Pamela J.; Cheves, Tracey C.; Sweeney, Joseph D.			Hemolysis in In-Date RBC Concentrates	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						RBCs; In vitro hemolysis	RED-BLOOD-CELLS; PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; TRANSFUSED BLOOD; STORAGE TIME; RESTRICTIVE TRANSFUSION; TISSUE OXYGENATION; NITRIC-OXIDE; MORTALITY; AGE; DURATION	Objectives: Hemolysis is one of the most prominent changes that occur during the liquid storage of RBCs in additive solution (AS), but most studies have measured hemolysis only on day 42. Methods: Prestorage leukoreduced RBCs in AS-1 and AS-3 were studied, one group on day 42 and a second group between day 0 and day 40. Each product was sampled for direct measurement of supernatant hemoglobin and hematocrit. Results: Ninety day 42 and 218 day 7 to day 39 RBCs showed a mean +/- SD supernatant hemoglobin of 75 +/- 100 vs 25.5 +/- 16 mg/dL respectively (P < .01). Supernatant hemoglobin correlated weakly with storage age (r = 0.2, P < .01) but more strongly with hematocrit (r = 0.4, P < .01). Conclusions: There are minimal differences in supernatant hemoglobin until the final days of liquid storage when some high hematocrit RBCs show excessive hemolysis.	[Gultawatvichai, Patan; Tavares, Maria F.; DiQuattro, Pamela J.; Cheves, Tracey C.; Sweeney, Joseph D.] Roger Williams Hosp, 825 Chalkstone Ave, Providence, RI 02908 USA	Sweeney, JD (reprint author), Roger Williams Hosp, 825 Chalkstone Ave, Providence, RI 02908 USA.	transfusionmed@gmail.com					Alexander PE, 2016, BLOOD, V127, P400, DOI 10.1182/blood-2015-09-670950; Ataga KI, 2007, BRIT J HAEMATOL, V139, P3, DOI 10.1111/j.1365-2141.2007.06740.x; Atzil S, 2008, ANESTHESIOLOGY, V109, P989, DOI 10.1097/ALN.0b013e31818ddb72; Balla J, 2005, MOL NUTR FOOD RES, V49, P1030, DOI 10.1002/mnfr.200500076; Basran S, 2006, ANESTH ANALG, V103, P15, DOI 10.1213/01.ane.0000221167.58135.3d; Belcher JD, 2014, BLOOD, V123, P377, DOI 10.1182/blood-2013-04-495887; Belcher JD, 2010, ANTIOXID REDOX SIGN, V12, P233, DOI 10.1089/ars.2009.2822; Belpulsi D, 2017, BLOOD TRANSFUS-ITALY, V15, P112, DOI 10.2450/2017.0328-16; Biffl WL, 2001, J TRAUMA, V50, P426, DOI 10.1097/00005373-200103000-00005; BLAKNEY GB, 1975, CLIN BIOCHEM, V8, P96, DOI 10.1016/S0009-9120(75)91005-X; Bullen JJ, 2005, FEMS IMMUNOL MED MIC, V43, P325, DOI 10.1016/j.femsim.2004.11.010; Carson JL, 2011, NEW ENGL J MED, V365, P2453, DOI 10.1056/NEJMoa1012452; Carson JL, 1998, TRANSFUSION, V38, P522, DOI 10.1046/j.1537-2995.1998.38698326331.x; Chatterjee S, 2013, JAMA INTERN MED, V173, P132, DOI 10.1001/2013.jamainternmed.1001; D'Alessandro A, 2015, VOX SANG, V108, P131, DOI 10.1111/vox.12193; D'Alessandro A, 2015, TRANSFUSION, V55, P205, DOI 10.1111/trf.12804; de Watering LV, 2006, TRANSFUSION, V46, P1712, DOI 10.1111/j.1537-2995.00958.x; Dhabangi A, 2015, JAMA-J AM MED ASSOC, V314, P2514, DOI 10.1001/jama.2015.13977; Donadee C, 2011, CIRCULATION, V124, P465, DOI 10.1161/CIRCULATIONAHA.110.008698; Edgren G, 2010, TRANSFUSION, V50, P1185, DOI 10.1111/j.1537-2995.2010.02583.x; Eikelboom JW, 2010, AM HEART J, V159, P737, DOI 10.1016/j.ahj.2009.12.045; Fergusson DA, 2012, JAMA-J AM MED ASSOC, V308, P1443, DOI 10.1001/2012.jama.11953; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Foss NB, 2009, TRANSFUSION, V49, P227, DOI 10.1111/j.1537-2995.2008.01967.x; Goel R, 2016, TRANSFUSION, V56, P1690, DOI 10.1111/trf.13559; GREENWALT TJ, 1991, VOX SANG, V61, P14, DOI 10.1111/j.1423-0410.1991.tb00920.x; HEATON W A L, 1992, Transfusion Medicine Reviews, V6, P153, DOI 10.1016/S0887-7963(92)70166-7; Heaton WA, 2009, TRANSFUSION, V49, P2551, DOI 10.1111/j.1537-2995.2009.02495.x; Hebert PC, 2005, ANESTH ANALG, V100, P1433, DOI 10.1213/01.ANE.0000148690.48803.27; Heddle NM, 2016, NEW ENGL J MED, V375, P1937, DOI 10.1056/NEJMoa1609014; Heddle NM, 2015, TRANSFUSION, V55, P364, DOI 10.1111/trf.12861; Hendrick A M, 2003, Hematology, V8, P53, DOI 10.1080/1024533021000059474; Hess JR, 2014, VOX SANG, V107, P1, DOI 10.1111/vox.12130; Hess JR, 2010, TRANSFUS APHER SCI, V43, P51, DOI 10.1016/j.transci.2010.05.009; Hess JR, 2009, TRANSFUSION, V49, P2599, DOI 10.1111/j.1537-2995.2009.02275.x; Hess JR, 2002, TRANSFUS MED REV, V16, P283, DOI 10.1053/tmrv.2002.35213; Holst LB, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1354; Kanias T, 2012, TRANSFUSION, V52, P1388, DOI 10.1111/j.1537-2995.2012.03748.x; Koch CG, 2013, ANN THORAC SURG, V96, P1894, DOI 10.1016/j.athoracsur.2013.05.116; Koch CG, 2008, NEW ENGL J MED, V358, P1229, DOI 10.1056/NEJMoa070403; Lacroix J, 2015, NEW ENGL J MED, V372, P1410, DOI 10.1056/NEJMoa1500704; Larsen R, 2010, SCI TRANSL MED, V51, P1; Leal- Noval SR, 2008, CRIT CARE MED, V36, P1209; Liu C, 2014, REDOX BIOL, V2, P211, DOI 10.1016/j.redox.2013.12.014; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Middelburg RA, 2013, TRANSFUS MED REV, V27, P36, DOI 10.1016/j.tmrv.2012.06.002; Mou SS, 2004, NEW ENGL J MED, V351, P1635, DOI 10.1056/NEJMoa041065; Mynster T, 2000, SCAND J GASTROENTERO, V35, P212; Nahra R, 2008, CHEST, V134, p48003S; Offner PJ, 2002, ARCH SURG-CHICAGO, V137, P711, DOI 10.1001/archsurg.137.6.711; Pereira A, 2013, TRANSFUSION, V53, P34, DOI 10.1111/j.1537-2995.2012.03656.x; Purdy FR, 1997, CAN J ANAESTH, V44, P1256, DOI 10.1007/BF03012772; Rohde JM, 2014, JAMA-J AM MED ASSOC, V311, P1317, DOI 10.1001/jama.2014.2726; Setty BNY, 2008, J THROMB HAEMOST, V6, P2202, DOI 10.1111/j.1538-7836.2008.03177.x; Sherwood MW, 2014, JAMA-J AM MED ASSOC, V311, P836, DOI 10.1001/jama.2014.980; SILLIMAN CC, 1994, J LAB CLIN MED, V124, P684; Silva G, 2009, J BIOL CHEM, V284, P29582, DOI 10.1074/jbc.M109.045344; So-Osman C, 2010, VOX SANG, V98, P56, DOI 10.1111/j.1423-0410.2009.01225.x; Stein PD, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2006.08.015; Steiner ME, 2015, NEW ENGL J MED, V372, P1419, DOI 10.1056/NEJMoa1414219; SWEENEY JD, 1995, TRANSFUSION, V35, P131, DOI 10.1046/j.1537-2995.1995.35295125735.x; Sweeney J, 2009, TRANSFUSION, V49, P1569, DOI 10.1111/j.1537-2995.2009.02196.x; Taher A, 2006, THROMB HAEMOSTASIS, V96, P488, DOI 10.1160/TH06-05-0267; Vamvakas EC, 2000, TRANSFUSION, V40, P101, DOI 10.1046/j.1537-2995.2000.40010101.x; Van 't Erve TJ, 2015, TRANSFUSION, V55, P1178, DOI 10.1111/trf.12992; Walsh TS, 2004, CRIT CARE MED, V32, P364, DOI 10.1097/01.CCM.0000108878.23703.E0; Weinberg JA, 2008, J TRAUMA, V65, P279, DOI 10.1097/TA.0b013e31817c9687; Weiskopf RB, 2006, ANESTHESIOLOGY, V104, P911, DOI 10.1097/00000542-200605000-00005; Willekens FLA, 2005, BLOOD, V105, P2141, DOI 10.1182/blood-2004-04-1578; Yap CH, 2008, ANN THORAC SURG, V86, P554, DOI 10.1016/j.athoracsur.2008.04.040; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1; Ziakas PD, 2007, J THROMB HAEMOST, V5, P642, DOI 10.1111/j.1538-7836.2007.02379.x; Ziakas PD, 2008, CURR VASC PHARMACOL, V6, P347, DOI 10.2174/157016108785909742	73	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					35	41		10.1093/AJCP/AQX120			7	Pathology	Pathology	GC0FL	WOS:000429452200005	29267842	Bronze			2019-10-28	
J	Cassidy, DP; Vega, F; Chapman, JR				Cassidy, Daniel P.; Vega, Francisco; Chapman, Jennifer R.			Epstein-Barr Virus-Positive Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue in the Posttransplant Setting	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Epstein-Barr virus; Posttransplant lymphoproliferative disorder; Extranodal marginal zone lymphoma; Bronchial-associated lymphoid tissue	COMMON VARIABLE IMMUNODEFICIENCY; LYMPHOPROLIFERATIVE DISORDERS; RHEUMATOID-ARTHRITIS; METHOTREXATE THERAPY; TRANSPLANT PATIENT; MALT LYMPHOMA; B-CELL; IMMUNOSUPPRESSION; CLASSIFICATION; REGRESSION	Objectives: Posttransplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of hematolymphoid proliferations arising in the context of chronic immunosuppression. The common and indolent B-cell lymphomas, including extranodal marginal zone lymphomas (ENMZLs) of mucosa-associated lymphoid tissue (MALT), are excluded from the category of PTLD in the current World Health Organization classification. Methods: We report a case of Epstein-Barr virus (EBV)-positive bronchial-associated lymphoid tissue (BALT) lymphoma involving the lungs of a transplant patient. Results: Aside from history of cardiac transplant, young patient age, and EBV positivity, the histopathologic findings were indistinguishable from usual BALT lymphoma. Conclusions: We review the literature of ENMZL occurring in immunocompromised patients and present this case for consideration that this specific entity is a PTLD. We believe that additional studies might lend strength to the hypothesis that this particular group of EBV-positive, posttransplant ENMZLs merits classification and management as PTLDs.	[Cassidy, Daniel P.; Vega, Francisco; Chapman, Jennifer R.] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Pathol & Lab Med, Div Hematopathol, Miami, FL USA; [Vega, Francisco] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol, Dept Med, Miami, FL USA; Jackson Mem Hosp, Miami, FL 33136 USA	Chapman, JR (reprint author), Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematopathol, Dept Pathol, 1400 NW 12th Ave,Suite 4046, Miami, FL 33136 USA.; Chapman, JR (reprint author), Univ Miami Hosp, Jackson Mem Hosp, 1400 NW 12th Ave,Suite 4046, Miami, FL 33136 USA.	jchapman@med.miami.edu					Aghamohammadi A, 2006, LEUKEMIA LYMPHOMA, V47, P343, DOI 10.1080/10428190500285285; Ashrafi Farzaneh, 2015, Int J Hematol Oncol Stem Cell Res, V9, P26; Bates WD, 2003, J CLIN PATHOL, V56, P439, DOI 10.1136/jcp.56.6.439; Bennett JA, 2015, J PEDIAT HEMATOL ONC, V37, pE114, DOI 10.1097/MPH.0b013e31829f3496; Boulanger E, 2008, BRIT J HAEMATOL, V140, P470, DOI 10.1111/j.1365-2141.2007.06939.x; Caillard S, 2006, AM J TRANSPLANT, V6, P2735, DOI 10.1111/j.1600-6143.2006.01540.x; Carbone A, 2008, ONCOLOGIST, V13, P577, DOI 10.1634/theoncologist.2008-0036; Chadburn A, 1998, CANCER, V82, P1978; de Jong D, 2017, AM J CLIN PATHOL, V147, P153, DOI 10.1093/ajcp/aqw216; Desar IME, 2006, NETH J MED, V64, P136; FERRY JA, 1989, MODERN PATHOL, V2, P583; FRANK D, 1995, BLOOD, V85, P1396, DOI 10.1182/blood.V85.5.1396.bloodjournal8551396; Gibson SE, 2011, AM J SURG PATHOL, V35, P807, DOI 10.1097/PAS.0b013e3182190999; Harris NL, 1997, SEMIN DIAGN PATHOL, V14, P8; Hsi ED, 2000, AM J SURG PATHOL, V24, P100, DOI 10.1097/00000478-200001000-00012; KAMEL OW, 1993, NEW ENGL J MED, V328, P1317, DOI 10.1056/NEJM199305063281806; Lasmar EP, 2009, TRANSPL P, V41, P959, DOI 10.1016/j.transproceed.2009.02.003; LONES MA, 1995, HUM PATHOL, V26, P525, DOI 10.1016/0046-8177(95)90248-1; Mackrides N, 2017, MODERN PATHOL, V30, P519, DOI 10.1038/modpathol.2016.214; NALESNIK MA, 1988, AM J PATHOL, V133, P173; Nassif S, 2013, PEDIATR TRANSPLANT, V17, pE141, DOI 10.1111/petr.12111; Oertel SHK, 2005, AM J TRANSPLANT, V5, P2901, DOI 10.1111/j.1600-6143.2005.01098.x; Paul C, 1997, ARCH DERMATOL, V133, P867, DOI 10.1001/archderm.133.7.867; Gibert MP, 2015, EUR J PEDIATR, V174, P1069, DOI 10.1007/s00431-015-2508-6; Pongpruttipan T, 2012, J PEDIATR-US, V161, P954, DOI 10.1016/j.jpeds.2012.07.003; Salloum E, 1996, J CLIN ONCOL, V14, P1943, DOI 10.1200/JCO.1996.14.6.1943; Sammassimo S, 2016, HEMATOL ONCOL, V34, P177, DOI 10.1002/hon.2243; STARZL TE, 1984, LANCET, V1, P583; Swerdlow SH, 2008, WHO CLASSIFICATION T, p[214, 347]; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Thorley-Lawson DA, 2004, NEW ENGL J MED, V350, P1328, DOI 10.1056/NEJMra032015; Verma S, 2005, J CUTAN PATHOL, V32, P474, DOI 10.1111/j.0303-6987.2005.00363.x; Webber S A, 1999, Pediatr Transplant, V3, P95; Webber SA, 2006, LANCET, V367, P233, DOI 10.1016/S0140-6736(06)67933-6; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604	35	3	3	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					42	49		10.1093/AJCP/AQX134			8	Pathology	Pathology	GC0FL	WOS:000429452200006	29228090				2019-10-28	
J	Lau, RP; Paulsen, JD; Brandler, TC; Liu, CZ; Simsir, A; Zhou, F				Lau, Ryan P.; Paulsen, John D.; Brandler, Tamar C.; Liu, Cheng Z.; Simsir, Aylin; Zhou, Fang			Impact of the Reclassification of "Noninvasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma" to "Noninvasive Follicular Thyroid Neoplasm With Papillary-Like Nuclear Features" on the Bethesda System for Reporting Thyroid Cytopathology	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Thyroid; Bethesda; Cytology; Fine-needle aspiration; Risk of malignancy; Encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC); Noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP)	FINE-NEEDLE-ASPIRATION; CANCER; METAANALYSIS; MALIGNANCY; RISK; DIAGNOSIS; NODULES	Objectives: Noninvasive encapsulated follicular variant of papillary thyroid carcinoma (NEFVPTC) was recently reclassified as noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). Excluding "carcinoma" from the new terminology shifted NIFTP out of the malignant category and altered Bethesda System for Reporting Thyroid Cytopathology (BSRTC) rates of malignancy (ROMs) on thyroid fine-needle aspiration (FNA). Because of potential effects on management guidelines, we examined our ROM data. Methods: In total, 750 thyroid FNAs with surgical resections from January 2013 to June 2016 were reviewed (including 87 NIFTPs). ROM was recorded for each BSRTC category: classifying NEFVPTC/NIFTP as "malignant" and reclassifying NEFVPTC/NIFTP as "nonmalignant." Results: ROM changes were as follows: nondiagnostic (ND), no change; benign, 5.5% to 2.5%; atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS), 42.3% to 22.3%; follicular neoplasm/suspicious for follicular neoplasm (FN/SFN), 48.7% to 17.9%; suspicious for malignancy (SFM), 93.6% to 61.7%; and positive for malignancy, 100% to 97%. Conclusions: Decreased ROM was seen in most BSRTC categories, most significantly in AUS/FLUS, FN/SFN, and SFM categories.	[Lau, Ryan P.; Paulsen, John D.; Brandler, Tamar C.; Liu, Cheng Z.; Simsir, Aylin; Zhou, Fang] NYU, Sch Med, Dept Pathol, New York, NY USA	Zhou, F (reprint author), NYU, Sch Med, Dept Pathol, NYU Langone Med Ctr, 560 1st Ave,TH383, New York, NY 10016 USA.	fang.zhou@nyu.edu		Liu, Cheng/0000-0002-2219-1018; Lau, Ryan/0000-0003-2155-0346			Ali SZ, 2010, BETHESDA SYSTEM REPO; Baloch Z, 2002, AM J CLIN PATHOL, V118, P603; Baloch ZW, 2010, ENDOCR PRACT, V16, P952, DOI 10.4158/EP10060.OR; Bongiovanni M, 2012, ACTA CYTOL, V56, P333, DOI 10.1159/000339959; Brandler TC, 2017, CANCER CYTOPATHOL, V125, P378, DOI 10.1002/cncy.21848; Canberk S, 2016, ACTA CYTOL, V60, P198, DOI 10.1159/000447990; Davies L, 2010, ARCH OTOLARYNGOL, V136, P440, DOI 10.1001/archoto.2010.55; Faquin WC, 2016, CANCER CYTOPATHOL, V124, P181, DOI 10.1002/cncy.21631; Gupta S, 2012, ARCH OTOLARYNGOL, V138, P227, DOI 10.1001/archoto.2011.1466; Haugen BR, 2016, THYROID, V26, P1, DOI 10.1089/thy.2015.0020; Howitt BE, 2015, AM J CLIN PATHOL, V144, P850, DOI 10.1309/AJCPEIE12POICULI; Jung CK, 2014, J CLIN ENDOCR METAB, V99, pE276, DOI 10.1210/jc.2013-2503; Layfield LJ, 2017, ACTA CYTOL, V61, P187, DOI 10.1159/000469654; Liu J, 2006, CANCER-AM CANCER SOC, V107, P1255, DOI 10.1002/cncr.22138; Maletta F, 2016, HUM PATHOL, V54, P134, DOI 10.1016/j.humpath.2016.03.014; Nikiforov YE, 2016, JAMA ONCOL, V2, P1098, DOI 10.1001/jamaoncol.2016.2205; Otto KJ, 2010, HEAD NECK-J SCI SPEC, V32, P1629, DOI 10.1002/hed.21373; Pusztaszeri M, 2016, ACTA CYTOL, V60, P399, DOI 10.1159/000451020; Rivera M, 2009, THYROID, V19, P119, DOI 10.1089/thy.2008.0303; Sheffield BS, 2014, EXPERT REV ENDOCRINO, V9, P97, DOI 10.1586/17446651.2014.887435; Strickland KC, 2015, THYROID, V25, P987, DOI 10.1089/thy.2014.0612; Vivero M, 2013, THYROID, V23, P273, DOI 10.1089/thy.2012.0369; Vollmer RT, 2014, AM J CLIN PATHOL, V141, P128, DOI 10.1309/AJCP9TBSMWZVYPRR	23	10	10	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					50	54		10.1093/AJCP/AQX136			5	Pathology	Pathology	GC0FL	WOS:000429452200007	29272354	Bronze			2019-10-28	
J	Wu, B; Ingersoll, K; Jug, R; Yang, LH; Luedke, C; Lo, A; Su, P; Liu, X; Rehder, C; Gong, J; Lu, CM; Wang, ED				Wu, Bin; Ingersoll, Kimberly; Jug, Rachel; Yang, Lian-he; Luedke, Catherine; Lo, Amanda; Su, Pu; Liu, Xin; Rehder, Catherine; Gong, Jerald; Lu, Chuanyi Mark; Wang, Endi			Myeloid Neoplasms Following Solid Organ Transplantation Clinicopathologic Studies of 23 Cases	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Myeloid neoplasm; Acute myeloid leukemia; Myelodysplastic syndrome; Solid organ transplant; Cytogenetics	MYCOPHENOLATE-MOFETIL; MYELODYSPLASTIC SYNDROMES; ACUTE-LEUKEMIA; LIVER-TRANSPLANTATION; RENAL-TRANSPLANTATION; CANCER-RISK; RECIPIENTS; IMMUNOSUPPRESSION; CLASSIFICATION; EPIDEMIOLOGY	Objectives: Myeloid neoplasms (MNs) after solid organ transplant are rare, and their clinicopathologic features have not been well characterized. Methods: We retrospectively analyzed 23 such cases. Results: The ages ranged from 2 to 76 years, with a median of 59 years at the diagnosis. The median interval between the transplant and diagnosis was 56 months (range, 8-384 months). The transplanted organs included liver in five, kidney in six, lung in five, heart in six, and heart/lung in one case(s). The types of MN included acute myeloid leukemia (AML) in 12, myelodysplastic syndrome (MDS) in five, chronic myelogenous leukemia (CML) in four, and myeloproliferative neoplasms (MPNs) in two cases. Cytogenetics demonstrated clonal abnormalities in 18 (78.3%) cases, including unbalanced changes in 10 (55.6%), Philadelphia chromosome in four (22.2%), and other balanced aberrations in four (22.2%) cases. Thirteen (56.5%) patients died, with an estimated median survival of 9 months. With disease stratification, AML and MDS have short median survivals (3.5 and 7 months, respectively), with an initial precipitous decline of the survival curve. Conclusions: Posttransplant MNs have a latency period between that seen in AML/MDS related to alkylators and that associated with topoisomerase II inhibitors. The cytogenetic profile suggests a mutagenic effect on leukemogenesis. The clinical outcome for AML/MDS is dismal, with death occurring at an early phase of treatment.	[Wu, Bin] China Med Univ, Shengjing Hosp, Dept Med, Div Hematol, Shenyang, Liaoning, Peoples R China; [Wu, Bin; Ingersoll, Kimberly; Jug, Rachel; Yang, Lian-he; Luedke, Catherine; Lo, Amanda; Su, Pu; Liu, Xin; Rehder, Catherine; Wang, Endi] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Gong, Jerald] Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Lu, Chuanyi Mark] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA	Wang, ED (reprint author), Duke Hosp South, Dept Pathol, DUMC Box 3712,M-345 Davison Bldg, Durham, NC 27710 USA.	endi.wang@duke.edu					Adami J, 2003, BRIT J CANCER, V89, P1221, DOI 10.1038/sj.bjc.6601219; [Anonymous], 2013, Am J Transplant, V13 Suppl 1, P8, DOI 10.1111/ajt.12018; Arber DA, 2017, WHO CLASSIFICATION T, P16; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Byun JM, 2016, ANN HEMATOL, V95, P1223, DOI 10.1007/s00277-016-2691-1; Camos M, 2004, TRANSPLANTATION, V77, P311, DOI 10.1097/01.TP.0000102549.40531.13; Cho YU, 2008, ANN HEMATOL, V87, P513, DOI 10.1007/s00277-008-0458-z; Doti CA, 2001, TRANSPLANTATION, V72, P1643, DOI 10.1097/00007890-200111270-00011; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Engels EA, 2011, JAMA-J AM MED ASSOC, V306, P1891, DOI 10.1001/jama.2011.1592; Ertz-Archambault N, 2017, JAMA ONCOL, V3, P936, DOI 10.1001/jamaoncol.2016.6435; Fulton B, 1996, DRUGS, V51, P278, DOI 10.2165/00003495-199651020-00007; Gale RP, 2012, LEUKEMIA, V26, P422, DOI 10.1038/leu.2011.224; Grulich AE, 2007, LANCET, V370, P59, DOI 10.1016/S0140-6736(07)61050-2; HO WKW, 1994, LANCET, V343, P1298, DOI 10.1016/S0140-6736(94)92189-X; Huebner G, 2000, TRANSPLANTATION, V70, P688, DOI 10.1097/00007890-200008270-00026; Jiang N, 2009, LEUKEMIA RES, V33, P1349, DOI 10.1016/j.leukres.2009.03.035; Jung SW, 2011, LEUKEMIA RES, V35, P735, DOI 10.1016/j.leukres.2010.11.009; Kourelis Taxiarchis V, 2012, Conn Med, V76, P151; Kwon O, 2013, TRANSPL P, V45, P1487, DOI 10.1016/j.transproceed.2013.02.046; le Coutre P, 2010, EUR J HAEMATOL, V84, P26, DOI 10.1111/j.1600-0609.2009.01357.x; Mauritzson N, 2002, LEUKEMIA, V16, P2366, DOI 10.1038/sj.leu.2402713; Medeiros BC, 2015, HAEMATOLOGICA, V100, P331, DOI 10.3324/haematol.2014.117267; Menes M, 2007, LEUKEMIA RES, V31, P59, DOI 10.1016/j.leukres.2006.05.010; Mohamedali AM, 2015, LEUKEMIA, V29, P1928, DOI 10.1038/leu.2015.110; Morscio J, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/150835; Morton LM, 2014, LEUKEMIA, V28, P2317, DOI 10.1038/leu.2014.132; Nakazawa S, 2014, TRANSPL P, V46, P411, DOI 10.1016/j.transproceed.2013.12.038; Oberender C, 2014, CASE REP HEMATOL, DOI 10.1155/2014/890438; Offman J, 2004, BLOOD, V104, P822, DOI 10.1182/blood-2003-11-3938; Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192; PENN I, 1991, TRANSPLANT P, V23, P1771; Petrara MR, 2015, CANCER LETT, V369, P37, DOI 10.1016/j.canlet.2015.08.007; Piselli P, 2014, BEST PRACT RES CL OB, V28, P1251, DOI 10.1016/j.bpobgyn.2014.08.007; Quinlan SC, 2010, CANCER EPIDEM BIOMAR, V19, P1229, DOI 10.1158/1055-9965.EPI-09-1220; RANSOM JT, 1995, THER DRUG MONIT, V17, P681, DOI 10.1097/00007691-199512000-00023; Rashidi A, 2016, ANN HEMATOL, V95, P169, DOI 10.1007/s00277-015-2524-7; Rashidi A, 2014, EUR J HAEMATOL, V92, P459, DOI 10.1111/ejh.12288; Vardiman JW, 2017, WHO CLASSIFICATION T, P153; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Wong TN, 2015, NATURE, V518, P552, DOI 10.1038/nature13968	41	1	1	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					55	66		10.1093/AJCP/AQX133			12	Pathology	Pathology	GC0FL	WOS:000429452200008	29228125				2019-10-28	
J	Harrison, G; Hemmerich, A; Guy, C; Perkinson, K; Fleming, D; McCall, S; Cardona, D; Zhang, XF				Harrison, Grant; Hemmerich, Amanda; Guy, Cynthia; Perkinson, Kathryn; Fleming, Debra; McCall, Shannon; Cardona, Diana; Zhang, Xuefeng			Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Solid-pseudopapillary neoplasm; SOX11; TFE3	BETA-CATENIN; TRANSCRIPTION FACTORS; TUMOR; EXPRESSION; MUTATIONS; DIAGNOSIS; PATHWAYS; FAMILY; CANCER; CYSTS	Objectives: To characterize the expression of SOX11 and TFE3 proteins in solid-pseudopapillary neoplasms (SPNs) and their histologic mimickers. Methods: Immunohistochemistry for SOX11, TFE3, and ss-catenin was performed on 31 cases of surgically resected SPNs. Neuroendocrine tumors, acinar cell carcinomas, and pancreatoblastomas served as controls. Results: Nuclear immunoreactivity for SOX11 was detected in all SPNs and five of 31 control tumors. Nuclear immunoreactivity for TFE3 was detected in 30 SPNs and three control tumors. Nuclear immunoreactivity for ss-catenin was detected in all SPNs and four control tumors. The combination of three markers as immunohistochemical panels resulted in optimal sensitivity and specificity. Conclusions: Both SOX11 and TFE3 were overexpressed in SPNs and may be involved in the pathogenesis. Clinically, SOX11 and TFE3 can be potentially used as diagnostic markers in distinguishing indeterminate SPNs from their histologic mimickers.	[Harrison, Grant; Hemmerich, Amanda; Guy, Cynthia; Perkinson, Kathryn; Fleming, Debra; McCall, Shannon; Cardona, Diana; Zhang, Xuefeng] Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA	Zhang, XF (reprint author), Duke Univ, Med Ctr, Dept Pathol, Box 3712, Durham, NC 27710 USA.	xuefeng.zhang@duke.edu		McCall, Shannon/0000-0003-3957-061X			Abraham SC, 2002, AM J PATHOL, V160, P1361, DOI 10.1016/S0002-9440(10)62563-1; Albores-Saavedra J, 2006, AM J SURG PATHOL, V30, P1237, DOI 10.1097/01.pas.0000209849.97787.e0; Argani P, 2003, AM J SURG PATHOL, V27, P750, DOI 10.1097/00000478-200306000-00005; Bea S, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0598-1; Bernard P, 2010, INT J BIOCHEM CELL B, V42, P400, DOI 10.1016/j.biocel.2009.10.017; Bosman FT, 2010, WHO CLASSIF TUMOURS, V3, P417; Castillo SD, 2012, EXPERT OPIN THER TAR, V16, P903, DOI 10.1517/14728222.2012.709239; Cho JH, 2008, GASTROENTEROLOGY, V134, pA699; El-Bahrawy MA, 2008, AM J SURG PATHOL, V32, P1, DOI 10.1097/PAS.0b013e31813e0676; Fitzgibbons PL, 2014, ARCH PATHOL LAB MED, V138, P1432, DOI 10.5858/arpa.2013-0610-CP; Huang SC, 2012, ANN SURG ONCOL, V19, pS438, DOI 10.1245/s10434-011-1930-x; Julian LM, 2017, CURR OPIN GENET DEV, V46, P24, DOI 10.1016/j.gde.2017.06.005; La Rosa S, 2012, AM J SURG PATHOL, V36, P1782, DOI 10.1097/PAS.0b013e318263209d; Li PP, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0718-3; Moradi A, 2017, J CELL PHYSIOL, V232, P3221, DOI 10.1002/jcp.25802; Ohara Y, 2016, WORLD J GASTROENTERO, V22, P8596, DOI 10.3748/wjg.v22.i38.8596; Park M, 2014, MODERN PATHOL, V27, P580, DOI 10.1038/modpathol.2013.154; Ploper D, 2015, PHARMACOL RES, V99, P36, DOI 10.1016/j.phrs.2015.04.006; Singhi AD, 2014, MODERN PATHOL, V27, P1355, DOI 10.1038/modpathol.2014.40; Springer S, 2015, GASTROENTEROLOGY, V149, P1501, DOI 10.1053/j.gastro.2015.07.041; Tanaka Y, 2001, CANCER RES, V61, P8401; Terris B, 2014, SEMIN DIAGN PATHOL, V31, P484, DOI 10.1053/j.semdp.2014.08.010; Thu KL, 2014, ONCOGENE, V33, P279, DOI 10.1038/onc.2012.595; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yin CY, 2017, SEMIN CELL DEV BIOL, V63, P68, DOI 10.1016/j.semcdb.2016.08.015; Zhao TS, 2016, CANCER LETT, V375, P100, DOI 10.1016/j.canlet.2016.02.044	26	3	3	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					67	75		10.1093/AJCP/AQX142			9	Pathology	Pathology	GC0FL	WOS:000429452200009	29272888	Bronze			2019-10-28	
J	Shih, AW; Crowther, MA; Jamula, E; El-Sharkawy, R; Brown, M; Paterson, G; Lui, M; Don-Wauchope, AC				Shih, Andrew W.; Crowther, Mark A.; Jamula, Erin; El-Sharkawy, Rami; Brown, Mark; Paterson, Georgina; Lui, Michelle; Don-Wauchope, Andrew C.			Assessment of the Measurement Error in Cyclosporine Levels Drawn Between Peripheral and Central Sources	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Bone marrow transplantation; Blood sampling; Central venous catheters; Cyclosporine; Preanalytical error; Therapeutic drug monitoring	CENTRAL VENOUS CATHETERS; GUIDELINES	Objectives: Cyclosporine is often monitored by drug levels drawn through central venous catheters (CVCs), which may be falsely elevated due to reversible drug adsorption onto the catheter. Therefore, we assessed the correlation between cyclosporine levels drawn peripherally and through CVCs. Methods: Bone marrow transplantation patients had a weekly collection of both peripheral and CVC draws from dual-lumen catheters simultaneously to assess cyclosporine levels after research ethics approval. Our primary outcome was the proportion of paired samples that were incongruent-defined as the mean of the CVC level being greater than 2 standard deviations from the peripheral level mean. Results: After approaching 27 eligible patients, 20 patients (77.8%) provided samples. Of 53 paired samples, seven were incongruent (13.2%). Peripheral and CVC levels correlated (r = 0.91) and agreed well. Conclusion: Despite potential for preanalytical error due to adsorption, cyclosporine infusion and monitoring via CVCs produce results similar to monitoring via peripheral blood draws.	[Shih, Andrew W.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada; [Shih, Andrew W.; Jamula, Erin] McMaster Univ, McMaster Ctr Transfus Res, Hamilton, ON, Canada; [Crowther, Mark A.; Don-Wauchope, Andrew C.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Crowther, Mark A.; Don-Wauchope, Andrew C.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [El-Sharkawy, Rami; Brown, Mark; Paterson, Georgina; Lui, Michelle] Juravinski Canc Ctr, Dept Pharm, Hamilton, ON, Canada	Shih, AW (reprint author), Vancouver Gen Hosp, Dept Pathol, JPP1,Rm 1553,855 W 12th Ave, Vancouver, BC V5Z 1M9, Canada.	andrew.shih@medportal.ca	Don-Wauchope, Andrew/L-6586-2019	Don-Wauchope, Andrew/0000-0003-2116-2423	Department of Pathology and Molecular Medicine; Hematology Trainee Quality Improvement Award Program from the Canadian Hematology Educators Committee	We acknowledge the Department of Pathology and Molecular Medicine and the Hematology Trainee Quality Improvement Award Program from the Canadian Hematology Educators Committee for their financial support in this project. We also thank the staff at the Bone Marrow Transplantation Program for helping us perform this initiative, the laboratory staff at the Juravinski Hospital who provided the sample handling, and Liz Feeney who built the laboratory information system adjustments to accommodate the study. Finally, we thank the patients and their families involved in this study and recognize their contribution in furthering the safety of other patients undergoing transplantation.	Bishop L, 2007, INT J LAB HEMATOL, V29, P261, DOI 10.1111/j.1751-553X.2007.00931.x; Braunholtz DA, 2001, J CLIN EPIDEMIOL, V54, P217, DOI 10.1016/S0895-4356(00)00305-X; Hacker C, 2014, CLIN CHIM ACTA, V433, P62, DOI 10.1016/j.cca.2014.02.031; Holt DW, 2002, THER DRUG MONIT, V24, P59, DOI 10.1097/00007691-200202000-00011; Huitema ADR, 1999, THER DRUG MONIT, V21, P102, DOI 10.1097/00007691-199902000-00016; Kontny NE, 2011, THER DRUG MONIT, V33, P766, DOI 10.1097/FTD.0b013e31823aa8ab; McBeth Cheryl L, 2004, Pediatr Nurs, V30, P200; O'Grady NP, 2011, AM J INFECT CONTROL, V39, pS1, DOI 10.1016/j.ajic.2011.01.003; Park S, 2016, ONCOTARGET, V7, P59892, DOI 10.18632/oncotarget.10988; Rogosheske JR, 2014, BONE MARROW TRANSPL, V49, P122, DOI 10.1038/bmt.2013.139; SHAEFER MS, 1993, TRANSPLANTATION, V56, P475; Trevillian P, 2007, NEPHROLOGY, V12, pS57, DOI 10.1111/j.1440-1797.2007.00730.x; Wright DFB, 2010, BRIT J CLIN PHARMACO, V70, P769, DOI 10.1111/j.1365-2125.2010.03749.x	13	0	0	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					76	81		10.1093/AJCP/AQX145			6	Pathology	Pathology	GC0FL	WOS:000429452200010	29272889				2019-10-28	
J	Gunsolus, IL; Love, SA; Kohl, LP; Schmidt, M; Apple, FS				Gunsolus, Ian L.; Love, Sara A.; Kohl, Louis P.; Schmidt, Martin; Apple, Fred S.			Low pO(2) Contributes to Potential Error in Oxygen Saturation Calculations Using a Point-of-Care Assay	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Oxygen saturation; Point-of-care testing; iSTAT	EQUATIONS; BLOOD	Objectives: The present study addressed the accuracy of calculated oxygen saturation (sO(2)) using point-of-care (POC) testing compared with measured values on a blood gas analyzer. Methods: In total, 3,323 sO(2) values were measured in 1,180 patients using a CO-oximeter (ABL 800 Flex; Radiometer, Copenhagen, Denmark). Measured parameters were then used to calculate an expected sO(2) for the POC method (Abbott i-STAT; Abbott POC, Princeton, NJ). Cases in which calculated sO(2) differed from measured sO(2) by 10% or more were analyzed. Results: Of the 3,323 comparisons performed, 260 (8%) showed discrepancies (+/- >= 10%) between measured and calculated sO(2) values. Ninety-four of discrepant measurements (245 of 260) occurred when pO(2) was less than 50 mm Hg. pH and bicarbonate distributions shifted to lower values in discrepant vs nondiscrepant cases. Conclusions: Our results suggest that the likelihood of discrepant sO(2) is 27% among patients with pO(2) less than 50 mm Hg. Direct measurement of sO(2) by CO-oximetry is strongly suggested in this clinical scenario.	[Gunsolus, Ian L.; Love, Sara A.; Schmidt, Martin; Apple, Fred S.] Hennepin Cty Med Ctr, Dept Lab Med & Pathol, Minneapolis, MN 55415 USA; [Kohl, Louis P.] Hennepin Cty Med Ctr, Dept Med, Div Cardiol, Minneapolis, MN 55415 USA; [Love, Sara A.; Apple, Fred S.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	Apple, FS (reprint author), Hennepin Cty Med Ctr, Clin Labs P4, 701 Pk Ave, Minneapolis, MN 55415 USA.	apple004@umn.edu					BREUER HWM, 1989, INTENS CARE MED, V15, P385; Clinical and Laboratory Standards Institute (CLSI), CA46A2 CLSI; GOTHGEN IH, 1990, SCAND J CLIN LAB INV, V50, P87, DOI 10.3109/00365519009087495; Hess D, 1984, RESP CARE, V29, P1001; JOHNSON PA, 1993, ANAESTH INTENS CARE, V21, P72, DOI 10.1177/0310057X9302100117; KOKHOLM G, 1990, SCAND J CLIN LAB INV, V50, P75, DOI 10.3109/00365519009087494; MYBURGH JA, 1992, ANAESTH INTENS CARE, V20, P460, DOI 10.1177/0310057X9202000411; NIERMAN DM, 1994, J CLIN MONITOR, V10, P39, DOI 10.1007/BF01651465; Nijland R, 1995, Acta Anaesthesiol Scand Suppl, V107, P49; Porath M, 2001, CLIN CHIM ACTA, V307, P151, DOI 10.1016/S0009-8981(01)00447-8; SEVERINGHAUS JW, 1979, J APPL PHYSIOL, V46, P599; Woda RP, 1996, J APPL PHYSIOL, V80, P559	12	0	0	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					82	86		10.1093/AJCP/AQX152			5	Pathology	Pathology	GC0FL	WOS:000429452200011	29228083				2019-10-28	
J	Schmidt, AE; Henrichs, KF; Kirkley, SA; Refaai, MA; Blumberg, N				Schmidt, Amy E.; Henrichs, Kelly F.; Kirkley, Scott A.; Refaai, Majed A.; Blumberg, Neil			Prophylactic Preprocedure Platelet Transfusion Is Associated With Increased Risk of Thrombosis and Mortality	AMERICAN JOURNAL OF CLINICAL PATHOLOGY			English	Article						Platelet transfusion; Thrombocytopenia; Thrombosis; Invasive procedure; Transfusion complications	CARDIAC-SURGERY; BYPASS SURGERY; THROMBOCYTOPENIA; COMPLICATIONS; HEMOSTASIS; GUIDELINES; OUTCOMES; PLASMA; STROKE	Objectives: We evaluated thrombosis and mortality rates of hospitalized patients receiving prophylactic platelet transfusion prior to an invasive procedure. Methods: Patient age and underlying medical condition(s), preprocedure and postprocedure platelet counts, type of procedure, number of platelet products transfused, and any complications were recorded on every prophylactic platelet given prior to an invasive procedure. Results: A total of 376 prophylactic transfusion recipients were identified. Nineteen (5%) thrombotic events were identified and 60 (16%) deaths occurred within 30 days of the preprocedure platelet transfusion. Most deaths were due to infection, sepsis, or organ failure, and none were due to bleeding or thrombosis. Conclusions: Preprocedure platelet transfusion is associated with an increased risk of thrombosis and 30-day mortality. Whether these findings are due to higher incidences of comorbidities and confounding or to cause and effect is not determinable from these data. This study highlights an association between prophylactic platelet transfusion and thrombosis and poor outcome, including death.	[Schmidt, Amy E.; Henrichs, Kelly F.; Kirkley, Scott A.; Refaai, Majed A.; Blumberg, Neil] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA	Schmidt, AE (reprint author), Univ Rochester, Med Ctr, 601 Elmwood Ave,Box 608, Rochester, NY 14642 USA.	Amy_Schmidt@urmc.rochester.edu					Baharoglu MI, 2016, LANCET, V387, P2605, DOI 10.1016/S0140-6736(16)30392-0; Bilgin YM, 2011, TRANSFUSION, V51, P2603, DOI 10.1111/j.1537-2995.2011.03200.x; Chowdhury P, 2004, BRIT J HAEMATOL, V125, P69, DOI 10.1111/j.1365-2141.2004.04868.x; Cornet Alexander D, 2007, J Invasive Cardiol, V19, pE297; de Boer MT, 2008, ANESTH ANALG, V106, P32, DOI 10.1213/01.ane.0000289638.26666.ed; Dzik Walter H, 2004, Curr Hematol Rep, V3, P324; Heit JA, 2000, ARCH INTERN MED, V160, P809, DOI 10.1001/archinte.160.6.809; Karkouti K, 2006, CAN J ANAESTH, V53, P279, DOI 10.1007/BF03022216; Khorana AA, 2008, ARCH INTERN MED, V168, P2377, DOI 10.1001/archinte.168.21.2377; Khorana AA, 2009, J CLIN ONCOL, V27, P4839, DOI 10.1200/JCO.2009.22.3271; Kremke M, 2015, EUR J CARDIO-THORAC, V48, pe102, DOI 10.1093/ejcts/ezv297; Kyaw Tun J, 2015, BRIT J RADIOL, V88; Mangano DT, 2002, NEW ENGL J MED, V347, P1309, DOI 10.1056/NEJMoa020798; McGrath T, 2008, ANN THORAC SURG, V86, P543, DOI 10.1016/j.athoracsur.2008.04.051; MCVAY PA, 1991, TRANSFUSION, V31, P164, DOI 10.1046/j.1537-2995.1991.31291142949.x; Mikkola R, 2012, BLOOD TRANSFUS-ITALY, V10, P490, DOI 10.2450/2012.0119-11; Nandagopal L, 2016, TRANSFUSION, V56, P344, DOI 10.1111/trf.13348; Nuti SV, 1999, MED CARE; Patel IJ, 2012, J VASC INTERV RADIOL, V23, P727, DOI 10.1016/j.jvir.2012.02.012; Segal JB, 2005, TRANSFUSION, V45, P1413, DOI 10.1111/j.1537-2995.2005.00546.x; Shin HS, 2012, KOREAN CIRC J, V42, P54, DOI 10.4070/kcj.2012.42.1.54; Spiess BD, 2004, TRANSFUSION, V44, P1143, DOI 10.1111/j.1537-2995.2004.03322.x; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Warner MA, 2017, TRANSFUSION, V57, P890, DOI 10.1111/trf.13996; Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401; Zakko L, 2017, CLIN GASTROENTEROL H, V15, P46, DOI 10.1016/j.cgh.2016.07.017	26	5	5	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9173	1943-7722		AM J CLIN PATHOL	Am. J. Clin. Pathol.	JAN	2018	149	1					87	94		10.1093/AJCP/AQX151			8	Pathology	Pathology	GC0FL	WOS:000429452200012	29228089				2019-10-28	
J	Boukhechba, M; Kadiri, H; El Khannoussi, B				Boukhechba, M.; Kadiri, H.; El Khannoussi, B.			Invasive Lobular Carcinoma of the Breast with Extracellular Mucin: Case Report of a New Variant of Lobular Carcinoma of the Breast	CASE REPORTS IN PATHOLOGY			English	Article								Invasive carcinoma of no special type (NST) or ductal carcinoma is the largest group of invasive breast cancers. Invasive lobular carcinoma (ILC) is the second most common histological type; it comprises 5%-15% of all invasive breast cancers. Historically, lobular neoplasia and invasive lobular carcinoma may produce intracellular mucin that pushes the nucleus to one side, creating the characteristic signet ring cell morphology. The extracellular mucin secretion is essentially described in mucinous breast carcinoma. Mucinous differentiation can be seen in small areas of NST carcinoma, but recently a few cases of invasive lobular carcinoma with extracellular mucin are reported in the literature. It is important for pathologists to recognize this new entity because it mimics a NST carcinoma, as such a diagnosis may require a different approach in clinical management and surveillance. We report a new case of ILC with extracellular mucin and a review of the literature.	[Boukhechba, M.; Kadiri, H.; El Khannoussi, B.] Natl Inst Oncol, Dept Pathol, Rabat, Morocco	Boukhechba, M (reprint author), Natl Inst Oncol, Dept Pathol, Rabat, Morocco.	mohammed.boukhechba@gmail.com					Bari VB, 2015, J CLIN DIAGN RES, V9, pED5, DOI [10.7860/JCDR/2015/13220.5765, 10.7860/JCD/2015/13220.5765]; Cserni G, 2017, VIRCHOWS ARCH, V471, P3, DOI 10.1007/s00428-017-2147-6; Macias GSG, 2016, INT J SURG CASE REP, V25, P33, DOI 10.1016/j.ijscr.2016.05.056; Haltas H, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-91; Lal P, 2005, AM J CLIN PATHOL, V123, P541, DOI 10.1309/YMJ3A83TB39MRUT9; Rosa M, 2009, PATHOL INT, V59, P405, DOI 10.1111/j.1440-1827.2009.02385.x; Rosen P. P., 2009, ROSENS BREAST PATHOL, P690; Tan PH, 2015, HISTOPATHOLOGY, V66, P761, DOI 10.1111/his.12463; Yu J, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-36	9	2	2	0	1	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									5362951	10.1155/2018/5362951			3	Pathology	Pathology	GD2FZ	WOS:000430316800001	29850340	DOAJ Gold, Green Published			2019-10-28	
J	Perez, D; Naous, R				Perez, Diandra; Naous, Rana			A Rare Case of Clear Cell Carcinoma, Mullerian Type in the Renal Pelvis of a 21-Year-Old Woman	CASE REPORTS IN PATHOLOGY			English	Article							ADENOCARCINOMA; CANCER; TUMORS	Clear Cell Carcinomas of Mullerian origin are extremely rare within the upper urinary system. Their morphology is identical to that of the Clear Cell Carcinomas of the female genital tract. When they arise in the urinary tract, it is thought to be due to ectopic Mullerian embryogenesis. Here, we present a case of a 21-year-old woman with a Clear Cell Carcinoma, Mullerian type, arising from the renal pelvis. Histologically, it consisted of tubulopapillary architecture with associated foamy macrophages and a mucinous background. The neoplastic cells exhibited variably sized round nuclei with prominent nucleoli, eosinophilic to vacuolated cytoplasm with occasional intracytoplasmic mucin vacuoles, and a hobnail appearance. Immunohistochemical stains showed that the neoplastic cells were positive for Pax-8, p53, CK7, HMWK 903, and INI-1 and focally positive for p504s (AMACR). The neoplastic cells were negative for GATA-3, CK5/CK6, p63, CK20, and CDX-2 immunostains, ruling out urothelial or enteric phenotype. Additional immunostains performed by an outside institution showed that the neoplastic cells were positive for HNF-1 beta. The overall morphology and immunophenotype were consistent with Clear Cell Carcinoma of Mullerian origin arising from the renal pelvis. Follow-up revealed no metastasis or other tumor sites, supporting that this was the primary location.	[Perez, Diandra; Naous, Rana] SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA	Naous, R (reprint author), SUNY Upstate Med Univ, Dept Pathol, Syracuse, NY 13210 USA.	naousr@upstate.edu					Amin MB, 2002, AM J SURG PATHOL, V26, P281, DOI 10.1097/00000478-200203000-00001; Klaassen Z, 2014, UROLOGY, V84, P997, DOI 10.1016/j.urology.2014.06.042; Kongkarnka S., 2013, CHINA J, P1; Laronda MM, 2012, DIFFERENTIATION, V84, P252, DOI 10.1016/j.diff.2012.05.004; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Liu KW, 2013, POL J PATHOL, V64, P308, DOI 10.5114/PJP.2013.30341; Menko FH, 2014, FAM CANCER, V13, P637, DOI 10.1007/s10689-014-9735-2; Miller EM, 2016, GYNECOL ONCOL REP, V18, P8, DOI 10.1016/j.gore.2016.08.005; Moch H., 2016, WHO CLASSIFICATION T, V8; Oliva E, 2002, AM J SURG PATHOL, V26, P190, DOI 10.1097/00000478-200202000-00005; Shih CM, 2010, J CHIN MED ASSOC, V73, P40, DOI 10.1016/S1726-4901(10)70020-4; Signorile PG, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-49; Smith NE, 2014, AM J SURG PATHOL, V38, P858, DOI 10.1097/PAS.0000000000000179; Sukov WR, 2012, MODERN PATHOL, V25, P1516, DOI 10.1038/modpathol.2012.107; Williamson SR, 2015, MODERN PATHOL, V28, P80, DOI 10.1038/modpathol.2014.86	15	0	0	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	2090-6781	2090-679X		CASE REP PATHOL	Case Rep. Pathol.		2018									1521598	10.1155/2018/1521598			5	Pathology	Pathology	GD2FX	WOS:000430316600001	29805829	DOAJ Gold, Green Published			2019-10-28	
